FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Kasstan, B
AF Kasstan, Ben
TI Vaccines and vitriol: an anthropological commentary on vaccine
   hesitancy, decision-making and interventionism among religious
   minorities
SO ANTHROPOLOGY & MEDICINE
LA English
DT Article; Early Access
DE COVID-19; preparedness; public health relations; religious minorities;
   vaccine hesitancy
ID IMMUNIZATION; COVERAGE; REFUSAL
AB This commentary addresses the issue of vaccine hesitancy and decision-making among religious minority groups in high-income country settings. Recent measles outbreaks have been attributed to lower-level vaccination coverage among religious minorities, which has inspired targeted as well as wholesale public health interventions and legislation in a range of jurisdictions. The commentary takes the case of self-protective ethnic and religious minority groups, especially Haredi or 'ultra-Orthodox' Jews in the United Kingdom, to address two key aims. First, this commentary flags how damaging representations of religious minorities in recent measles outbreaks can be avoided by better understanding inner processes of vaccine decision-making and acceptance, which can, in turn, help to address hesitancy sustainably and trustfully. Second, the commentary advocates for addressing vaccine hesitancy as part of a broader re-visioning of public health relations with minority groups. This commentary calls on public health services to improve confidence in childhood vaccinations rather than resorting to compulsory (and coercive) vaccination policies in order to address lower-level vaccination coverage. The commentary signposts how essential it is to carefully navigate relationships with minority groups amidst the new forms of public health preparedness that will emerge from the 2020 Coronavirus pandemic (COVID-19).
C1 [Kasstan, Ben] Hebrew Univ Jerusalem, Dept Sociol & Anthropol, Jerusalem, Israel.
RP Kasstan, B (corresponding author), Hebrew Univ Jerusalem, Dept Sociol & Anthropol, Jerusalem, Israel.
EM ben.kasstan@mail.huji.ac.il
FU Wellcome TrustWellcome Trust [101955/Z/13/Z]
FX I submitted research evidence conducted as part of a three-year
   (2013-2016) anthropological study into maternity care and child health
   among Haredi Jews in England, funded by The Wellcome Trust (grant code:
   101955/Z/13/Z). I specifically cautioned against introducing any
   compulsory or coercive vaccination policy. The recommendations I
   submitted to the AllParty Parliamentary Group on Vaccinations for All
   have been included in this Commentary to raise further debate in the
   anthropological and medical community on policy engagement vis-a-vis
   childhood vaccinations in religious groups.
CR All-Party Parliamentary Group on Vaccinations for All, 2019, CALL WRITT EV
   [Anonymous], 2019, GUARDIAN
   Casiday RE, 2007, SOC SCI MED, V65, P1059, DOI 10.1016/j.socscimed.2007.04.023
   Chantler T, 2019, APPL HEALTH ECON HEA, V17, P265, DOI 10.1007/s40258-019-00460-z
   Coleman-Brueckheimer K, 2009, SOC SCI MED, V68, P323, DOI 10.1016/j.socscimed.2008.10.003
   Durkin Erin, 2019, GUARDIAN
   Henderson L, 2008, J ROY SOC MED, V101, P244, DOI 10.1258/jrsm.2008.070363
   Hill HA, 2019, MMWR-MORBID MORTAL W, V68, P913, DOI 10.15585/mmwr.mm6841e2
   Jackson C, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4178-y
   Kasstan B., 2019, MAKING BODIES KOSHER
   Kasstan B., 2020, HAARETZ
   Kaufman SR, 2010, ETHOS, V38, P8, DOI 10.1111/j.1548-1352.2009.01079.x
   Kettunen C, 2017, AM J INFECT CONTROL, V45, P630, DOI 10.1016/j.ajic.2017.01.032
   Leach M, 2007, VACCINE ANXIETIES GL
   Letley L, 2018, VACCINE, V36, P4687, DOI 10.1016/j.vaccine.2018.06.028
   Markel H., 1999, QUARANTINE E EUROPEA
   NHS Digital., 2018, CHILDH VACC COV STAT
   Organization WH, 2019, 10 THREATS GLOB HLTH
   Parents Educating and Advocating for Children's Health, 2017, VACC SAF HDB
   Poltorak M, 2005, SOC SCI MED, V61, P709, DOI 10.1016/j.socscimed.2004.12.014
   Public Health England, 2016, TAIL IMM PROGR CHAR
   Public Health England, 2019, MEASL ENGL
   Reich JA, 2014, GENDER SOC, V28, P679, DOI 10.1177/0891243214532711
   Silverberg R, 2019, AM J MED, V132, P1005, DOI 10.1016/j.amjmed.2019.04.041
   Sobo EJ, 2015, MED ANTHROPOL Q, V29, P381, DOI 10.1111/maq.12214
   Staetsky L. D., 2015, STRICTLY ORTHODOX RI
   Taragin-Zeller L, 2020, ANTHROPOL EDUC QUART, DOI 10.1111/aeq.12358
   Warraich HJ, 2009, EMERG INFECT DIS, V15, P978, DOI 10.3201/eid1506.090087
   Wineberg J., 2016, SALFORD JEWISH COMMU
   Younis T, 2020, SOCIOL HEALTH ILL, V42, P610, DOI 10.1111/1467-9566.13047
NR 30
TC 0
Z9 0
U1 5
U2 5
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1364-8470
EI 1469-2910
J9 ANTHROPOL MED
JI Anthropol. Med.
DI 10.1080/13648470.2020.1825618
EA NOV 2020
PG 9
WC Anthropology; Public, Environmental & Occupational Health; Social
   Sciences, Biomedical
SC Anthropology; Public, Environmental & Occupational Health; Biomedical
   Social Sciences
GA OQ4ZW
UT WOS:000588794500001
PM 33183060
DA 2021-01-01
ER

PT J
AU Gallicano, GI
   Casey, JL
   Fu, JY
   Mahapatra, S
AF Ian Gallicano, G.
   Casey, John L.
   Fu, Jiayu
   Mahapatra, Samiksha
TI Molecular targeting of vulnerable RNA sequences in SARS CoV-2:
   identifying clinical feasibility
SO GENE THERAPY
LA English
DT Article; Early Access
ID NONCODING RNAS; FAMILY; REVEALS; MIRNAS
AB Covid-19 (SARS CoV-2) has become a deadly, world-wide pandemic. Although most who are infected survive, complications from the virus can be pronounced and long-lasting. To date, of all the respiratory viruses including influenza and coronaviruses, only influenza has had a drug (i.e., Tamiflu) specifically targeted to treat and prevent infection. As a result, additional agents that specifically target viral production and are clinically feasible are needed to alleviate respiratory viral infections. The idea of using a miRNA/siRNA molecular approach for treating various diseases was postulated over a decade ago; however, only within the past few years has it become feasible. One technological advancement has been the molecular linkage of lipophilic moieties to mi/siRNAs in order to bypass the need for enveloping these inhibitory RNAs in lipid-based transfection reagents, which could irritate the airway if inhaled. Here we show that siRNAs and miRNAs inhibit SARS CoV-2 spike protein production in a dose-dependent manner in both HEK293 cells and a primary human airway tracheal cell line. We also show that this inhibition is equally robust using a clinically relevant siRNA that does not need to be prepped with a transfection reagent.
C1 [Ian Gallicano, G.; Fu, Jiayu; Mahapatra, Samiksha] Georgetown Univ, Med Ctr, Dept Biochem & Mol & Cellular Biol, Washington, DC 20057 USA.
   [Casey, John L.] Georgetown Univ, Med Ctr, Dept Microbiol, 3900 Reservoir Rd NW, Washington, DC 20057 USA.
RP Gallicano, GI (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol & Cellular Biol, Washington, DC 20057 USA.
EM gig@georgetown.edu
FU Covid-19 Pilot Project Award from Georgetown University Medical Center
FX We need to thank Dr Nady Golestaneh for use of her EVOS AMG inverted
   microscope and secondary antibody reagents. We also thank Vaughn
   Gallicano for acquiring immunofluorescence images used for data
   gathering and publication. We also thank to Olympia Hatzilambrou for
   assisting in off-target identification. This work was funded by a
   Covid-19 Pilot Project Award from Georgetown University Medical Center.
CR Adams BD, 2017, J CLIN INVEST, V127, P761, DOI 10.1172/JCI84424
   Badodi S, 2015, CELL CYCLE, V14, P1517, DOI 10.1080/15384101.2015.1026519
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Foshay Kara M, 2007, Curr Stem Cell Res Ther, V2, P264, DOI 10.2174/157488807782793781
   Foshay KM, 2009, DEV BIOL, V326, P431, DOI 10.1016/j.ydbio.2008.11.016
   Ghosh S, 2020, EXCLI J, V19, P528, DOI 10.17179/excli2020-1328
   Lal A, 2009, MOL CELL, V35, P610, DOI 10.1016/j.molcel.2009.08.020
   Larabee SM, 2015, STEM CELLS DEV, V24, P354, DOI 10.1089/scd.2014.0051
   Matsui M, 2017, NAT REV DRUG DISCOV, V16, P167, DOI 10.1038/nrd.2016.117
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Pfister EL, 2017, MOL THER-NUCL ACIDS, V7, P324, DOI 10.1016/j.omtn.2017.04.011
   Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246
   Shi Ting, 2020, J Infect Dis, V222, pS563, DOI 10.1093/infdis/jiy662
   Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019
   Wang J, 2012, STEM CELLS DEV, V21, P1524, DOI 10.1089/scd.2011.0350
   Wu W, 2013, BRIT J CANCER, V108, P653, DOI 10.1038/bjc.2012.587
   Zhang Z, 2018, MECH DEVELOP, V150, P10, DOI 10.1016/j.mod.2018.02.002
   Zhu WY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087780
NR 18
TC 0
Z9 0
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0969-7128
EI 1476-5462
J9 GENE THER
JI Gene Ther.
DI 10.1038/s41434-020-00210-0
EA NOV 2020
PG 8
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Research & Experimental Medicine
GA OQ5UF
UT WOS:000588847500001
PM 33184504
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Scarpioni, R
   Ricardi, M
   Manini, A
   Chiappini, P
   Ballocchi, L
   Albertazzi, V
   Deamicis, S
   Melfa, L
   Rocca, C
   Valsania, T
   Blanco, V
   Fenocchio, C
AF Scarpioni, Roberto
   Ricardi, Marco
   Manini, Alessandra
   Chiappini, Paola
   Ballocchi, Laura
   Albertazzi, Vittorio
   DeAmicis, Sara
   Melfa, Luigi
   Rocca, Chiara
   Valsania, Teresa
   Blanco, Valentina
   Fenocchio, Chiara
TI What can a home hemodialysis program offer to patients in a nursing home
   setting? A case series and feasibility analysis
SO HEMODIALYSIS INTERNATIONAL
LA English
DT Article; Early Access
DE Home hemodialysis; nursing home; chronic kidney disease; dialysis;
   feasibility; COVID&#8208; 19
ID QUALITY-OF-LIFE; DIALYSIS; HEALTH; IMPACT
AB Introduction Over the last decades, the number of elderly patients on dialysis has rapidly grown on account of increased life expectancy, improved care and reduced mortality rate. Therefore, cooperation between geriatricians and nephrologists has become mandatory for co-managing kidney disease in these patients. Based on renewed interest in home hemodialysis (HHD), elderly patients may benefit from not being transported from their home for therapy.
   Methods Here, we report our experience with HHD involving three elderly patients who were followed-up over a 15-months period in a nursing home.
   Findings Our experience demonstrates that hospitalization abruptly dropped from 40 days to zero days, the need for erythropoietin stimulating agents (ESAs) diminished, transportation-related costs for home treatments decreased, and quality of life (QoL) improved. This was confirmed by a questionnaire administered to our patients at the start and again after 6 months of HHD which evaluated the Physical Health Component Score (PCS) and the Mental Health Component Score (MCS).
   Discussion Home hemodialysis may represent an important way to improve social, mental, and physical recovery, while also eliminating the cost of transportation and the discomfort of abandoning their "homes" and daily habits. Home hemodialysis is an effective alternative to in-center HD or peritoneal dialysis (PD) that should be offered to elderly patients when a home caregiver is not available, nonetheless, nursing assistance is required. Moreover, HHD allows patients to stay at home, thereby avoiding several weekly trips to the dialysis center, and may be useful in reducing infections, especially in times of the COVID-19 pandemic, as demonstrated by our experience.
C1 [Scarpioni, Roberto; Ricardi, Marco; Manini, Alessandra; Chiappini, Paola; Albertazzi, Vittorio; DeAmicis, Sara; Melfa, Luigi; Rocca, Chiara; Valsania, Teresa; Blanco, Valentina; Fenocchio, Chiara] ASL Hosp Guglielmo da Saliceto, Dept Nephrol & Dialysis, Via Taverna 49, I-29121 Piacenza, Italy.
   [Ballocchi, Laura] ASL Hosp Guglielmo da Saliceto, Dept Mental Hlth Psychiat, Piacenza, Italy.
RP Scarpioni, R (corresponding author), ASL Hosp Guglielmo da Saliceto, Dept Nephrol & Dialysis, Via Taverna 49, I-29121 Piacenza, Italy.
EM r.scarpioni@ausl.pc.it
OI Scarpioni, Roberto/0000-0003-1809-0596
CR [Anonymous], 2010, SIN RIDT
   Apolone G, 2005, QUESTIONARIO STATO S
   Aydede SK, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-118
   Brown EA, 2010, NEPHROL DIAL TRANSPL, V25, P3755, DOI 10.1093/ndt/gfq212
   Coresh J, 2003, AM J KIDNEY DIS, V41, P1, DOI 10.1053/ajkd.2003.50007
   Cornelis T, 2014, NEPHROL DIAL TRANSPL, V29, P2327, DOI 10.1093/ndt/gfu260
   Cornelis T, 2013, KIDNEY INT, V83, P967, DOI 10.1038/ki.2013.17
   Derrett S, 2010, NEPHROLOGY, V15, P464, DOI 10.1111/j.1440-1797.2010.01286.x
   Finkelstein FO, 2012, NAT REV NEPHROL, V8, P718, DOI 10.1038/nrneph.2012.238
   Garofalo C, 2019, J NEPHROL, V32, P823, DOI 10.1007/s40620-018-00577-9
   Gedney N, 2018, SEMIN NEPHROL, V38, P426, DOI 10.1016/j.semnephrol.2018.05.012
   Liu FX, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-161
   Miller BW, 2018, BLOOD PURIFICAT, V45, P224, DOI 10.1159/000485159
   Oliver MJ, 2007, KIDNEY INT, V71, P673, DOI 10.1038/sj.ki.5002107
   Piccoli GB, 2018, J NEPHROL, V31, P627, DOI 10.1007/s40620-018-0519-x
   Rioux JP, 2010, CLIN NEPHROL, V74, P167
   Santoro A, 2019, J NEPHROL, V32, P417, DOI 10.1007/s40620-018-00570-2
   Scarpioni R, 2020, G ITAL NEFROL, V37, P1
   Scarpioni R, 2020, J NEPHROL, V33, P1123, DOI 10.1007/s40620-020-00822-0
   van Eps CL, 2010, HEMODIAL INT, V14, P29, DOI 10.1111/j.1542-4758.2009.00419.x
   Walker RC, 2017, CLINICOECONOMIC OUTC, V9, P149, DOI 10.2147/CEOR.S69340
   Weisbord SD, 2016, SEMIN DIALYSIS, V29, P158, DOI 10.1111/sdi.12464
NR 22
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1492-7535
EI 1542-4758
J9 HEMODIAL INT
JI Hemodial. Int.
DI 10.1111/hdi.12904
EA NOV 2020
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA OQ2LA
UT WOS:000588619800001
PM 33184982
DA 2021-01-01
ER

PT J
AU Sharma, A
   Vora, J
   Patel, D
   Sinha, S
   Jha, PC
   Shrivastava, N
AF Sharma, Abhilasha
   Vora, Jaykant
   Patel, Dhaval
   Sinha, Sonam
   Jha, Prakash C.
   Shrivastava, Neeta
TI Identification of natural inhibitors against prime targets of SARS-CoV-2
   using molecular docking, molecular dynamics simulation and MM-PBSA
   approaches
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; phyto-compounds; molecular docking; SARS-CoV-2; molecular
   dynamics; MM-PBSA
ID DEPENDENT RNA-POLYMERASE; DRUG DISCOVERY; CORONAVIRUSES; POTENTIALS;
   REMDESIVIR; TRIPHALA; GROMACS
AB The recently emerged COVID-19 has been declared a pandemic by the World Health Organization as to date; no therapeutic drug/vaccine is available for the treatment. Due to the lack of time and the urgency to contain the pandemic, computational screening appears to be the best tool to find a therapeutic solution. Accumulated evidence suggests that many phyto-compounds possess anti-viral activity. Therefore, we identified possible phyto-compounds that could be developed and used for COVID-19 treatment. In particular, molecular docking was used to prioritize the possible active phyto-compounds against two key targets namely RNA dependent RNA polymerase (RdRp) and main protease (M-pro) of SARS-CoV-2. In this study, an antiviral drug- Remdesivir (RdRp inhibitor) and Darunavir (M-pro inhibitor) are used as reference drugs. This study revealed that phyto-molecules- Mulberroside-A/C/E/F, Emblicanin A, Nimbolide, and Punigluconin showed high binding affinity against RdRp while Andrographolides, Mulberrosides, Anolignans, Chebulic acid, Mimusopic acid, and Punigluconin showed better binding affinity against M-pro as compared with the reference drug. Furthermore, ADME profiles validated the drug-likeness properties of prioritized phyto-compounds. Besides, to assess the stability, MD simulations studies were performed along with reference inhibitors for M-pro (Darunavir) and RdRp (Remdesivir). Binding free energy calculations (MM-PBSA) revealed the estimated value (Delta G) of M-pro_Darunavir; M-pro_Mulberroside E; RdRp_Remdesivir and RdRp_Emblicanin A were -111.62 +/- 6.788, -141.443 +/- 9.313, 30.782 +/- 5.85 and -89.424 +/- 3.130 kJmol(-1), respectively. Taken together, the study revealed the potential of these phyto-compounds as inhibitors of RdRp and M-pro inhibitor that could be further validated against SARS-CoV-2 for clinical benefits.
   Communicated by Ramaswamy H. Sarma
C1 [Sharma, Abhilasha; Vora, Jaykant; Sinha, Sonam; Shrivastava, Neeta] BV Patel Pharmaceut Educ & Res Dev PERD Ctr, Ahmadabad, Gujarat, India.
   [Sharma, Abhilasha; Vora, Jaykant; Sinha, Sonam] Gujarat Univ, Dept Life Sci, Ahmadabad, Gujarat, India.
   [Patel, Dhaval] Indian Inst Adv Res, Koba Inst Area, Dept Biol Sci & Biotechnol, Gandhinagar, Gujarat, India.
   [Jha, Prakash C.] Cent Univ Gujarat, Sch Appl Mat Sci, Gandhinagar, India.
RP Shrivastava, N (corresponding author), BV Patel Pharmaceut Educ & Res Dev PERD Ctr, Ahmadabad, Gujarat, India.
EM neetas@perdcentre.com
RI Jha, Prakash/I-5341-2017; patel, dhaval/M-4265-2018
OI Jha, Prakash/0000-0002-1709-511X; patel, dhaval/0000-0002-1811-2057
CR Al-Tawfiq JA, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101615
   Belapurkar P, 2014, INDIAN J PHARM SCI, V76, P467
   Ben-Shabat S, 2020, DRUG DELIV TRANSL RE, V10, P354, DOI 10.1007/s13346-019-00691-6
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Berry M, 2015, VIRUSES-BASEL, V7, P6642, DOI 10.3390/v7122963
   Campagnola G, 2011, ANTIVIR RES, V91, P241, DOI 10.1016/j.antiviral.2011.06.006
   Chan EWC, 2016, CHIN J NAT MEDICINES, V14, P17, DOI 10.3724/SP.J.1009.2016.00017
   Chandel V., 2020, CHEM BIOL LETT, V7, P166, DOI DOI 10.20944/PREPRINTS202003.0349.V1
   Cragg GM, 2001, PHARM BIOL, V39, P8, DOI 10.1076/phbi.39.s1.8.0009
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978-1-4939-2269-7_19
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Daura X, 1999, ANGEW CHEM INT EDIT, V38, P236, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<236::AID-ANIE236>3.3.CO;2-D
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   ENMOZHI SK, 2020, J BIOMOL STRUCT 0504, DOI DOI https://doi.org/10.1080/07391102.2020.1760136
   Sousa da Silva Alan W, 2012, BMC Res Notes, V5, P367, DOI [10.1186/1756-0500-5-185, 10.1186/1756-0500-5-367]
   Furuta Y, 2013, ANTIVIR RES, V100, P446, DOI 10.1016/j.antiviral.2013.09.015
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Kalita P, 2020, MICROB PATHOGENESIS, V145, DOI 10.1016/j.micpath.2020.104236
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI https://doi.org/10.1080/07391102.2020.1753577
   Koulgi S, 2020, RSC ADV, V10, P26792, DOI 10.1039/d0ra04743k
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Lim HS, 2009, ANTIMICROB AGENTS CH, V53, P1468, DOI 10.1128/AAC.00339-08
   Lindorff-Larsen K, 2010, PROTEINS, V78, P1950, DOI 10.1002/prot.22711
   LIU JN, 2017, SCI REP UK, V7
   Liu X, 2020, J GENET GENOMICS, V47, P119, DOI 10.1016/j.jgg.2020.02.001
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Manhas A, 2019, J CELL BIOCHEM, V120, P14531, DOI 10.1002/jcb.28714
   Mathur S, 2017, BIOMED REP, V6, P612, DOI 10.3892/br.2017.909
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Naithani R, 2008, MINI-REV MED CHEM, V8, P1106, DOI 10.2174/138955708785909943
   NISAR MF, 2018, MOLECULES, V23, DOI DOI https://doi.org/10.3390/molecules23102567
   OBOYLE NM, 2011, J CHEMINFORMATICS, V3, DOI DOI https://doi.org/10.1186/1758-2946-3-33
   Padhi A., 2020, DOES ARBIDOL INHIBIT, DOI [10.26434/chemrxiv.12464576.v1, DOI 10.26434/CHEMRXIV.12464576.V1]
   Padhi A. K., 2020, BIORXIV, DOI [10.1101/2020.05.19.104042, DOI 10.1101/2020.05.19.104042]
   Pagadala Nataraj S, 2017, Biophys Rev, V9, P91, DOI 10.1007/s12551-016-0247-1
   PARRINELLO M, 1980, PHYS REV LETT, V45, P1196, DOI 10.1103/PhysRevLett.45.1196
   Patel B, 2018, BBA-PROTEINS PROTEOM, V1866, P426, DOI 10.1016/j.bbapap.2017.12.002
   Patel D., 2020, BIORXIV, DOI [10.1101/2020.03.31.017541, DOI 10.1101/2020.03.31.017541]
   Patel P, 2018, INT J BIOL MACROMOL, V114, P666, DOI 10.1016/j.ijbiomac.2018.03.152
   Patel P, 2017, J MOL GRAPH MODEL, V77, P295, DOI 10.1016/j.jmgm.2017.09.004
   Peterson CT, 2017, J ALTERN COMPLEM MED, V23, P607, DOI 10.1089/acm.2017.0083
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   RAPPE AK, 1992, J AM CHEM SOC, V114, P10024, DOI 10.1021/ja00051a040
   Rofaani E, 2015, HAYATI J BIOSCI, V22, P67, DOI 10.4308/hjb.22.2.67
   Salehi B, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051459
   Seeliger D, 2010, J COMPUT AID MOL DES, V24, P417, DOI 10.1007/s10822-010-9352-6
   Sinha S, 2019, INT J BIOL MACROMOL, V140, P454, DOI 10.1016/j.ijbiomac.2019.08.061
   Sliwoski G, 2014, PHARMACOL REV, V66, P334, DOI 10.1124/pr.112.007336
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Sun HY, 2018, PHYS CHEM CHEM PHYS, V20, P14450, DOI 10.1039/c7cp07623a
   Udeinya IJ, 2004, T ROY SOC TROP MED H, V98, P435, DOI 10.1016/j.trstmh.2003.10.016
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Vora J, 2020, CURR HIV RES, V18, P132, DOI 10.2174/1570162X18666200129112509
   Vora J, 2020, J BIOMOL STRUCT DYN, V38, P1726, DOI 10.1080/07391102.2019.1615002
   Vora Jaykant, 2019, J Biomol Struct Dyn, V37, P131, DOI 10.1080/07391102.2017.1420489
   Wang CH, 2016, J COMPUT CHEM, V37, P2436, DOI 10.1002/jcc.24467
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Zhang DK, 2010, INFECT GENET EVOL, V10, P84, DOI 10.1016/j.meegid.2009.10.006
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou JW, 2019, FASEB J, V33, P14575, DOI 10.1096/fj.201901624RR
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 71
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1846624
EA NOV 2020
PG 16
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OQ5JM
UT WOS:000588819500001
PM 33183178
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Deebak, BD
   Al-Turjman, F
   Nayyar, A
AF Deebak, B. D.
   Al-Turjman, Fadi
   Nayyar, Anand
TI Chaotic-map based authenticated security framework with privacy
   preservation for remote point-of-care
SO MULTIMEDIA TOOLS AND APPLICATIONS
LA English
DT Article; Early Access
DE Remote point-of-care; Authentication; And key agreement; Security and
   privacy; Chaotic-map; Real-or-random
ID KEY AGREEMENT SCHEME; USER AUTHENTICATION; MUTUAL AUTHENTICATION;
   PASSWORD AUTHENTICATION; PROTOCOL; CRYPTANALYSIS; INTERNET
AB The challenge of COVID-19 has become more prevalent across the world. It is highly demanding an intelligent strategy to outline the precaution measures until the clinical trials find a successful vaccine. With technological advancement, Wireless Multimedia Sensor Networks (WMSNs) has extended its significant role in the development of remote medical point-of-care (RM-PoC). WMSN is generally located on a communication device to sense the vital signaling information that may periodically be transmitted to remote intelligent pouch This modern remote system finds a suitable professional system to inspect the environment condition remotely in order to facilitate the intelligent process. In the past, the RM-PoC has gained more attention for the exploitation of real-time monitoring, treatment follow-up, and action report generation. Even though it has additional advantages in comparison with conventional systems, issues such as security and privacy are seriously considered to protect the modern system information over insecure public networks. Therefore, this study presents a novel Single User Sign-In (SUSI) Mechanism that makes certain of privacy preservation to ensure better protection of multimedia data. It can be achieved over the negotiation of a shared session-key to perform encryption or decryption of sensitive data during the authentication phase. To comply with key agreement properties such as appropriate mutual authentication and secure session key-agreement, a proposed system design is incorporated into the chaotic-map. The above assumption claims that it can not only achieve better security efficiencies but also can moderate the computation, communication, and storage cost of some intelligent systems as compared to elliptic-curve cryptography or RSA. Importantly, in order to offer untraceability and user anonymity, the RM-PoC acquires dynamic identities from proposed SUSI. Moreover, the security efficiencies of proposed SUSI are demonstrated using informal and formal analysis of the real-or-random (RoR) model. Lastly, a simulation study using NS3 is extensively conducted to analyze the communication metrics such as transmission delay, throughput rate, and packet delivery ratio that demonstrates the significance of the proposed SUSI scheme.
C1 [Deebak, B. D.] Vellore Inst Technol, Sch Comp Sci & Engn, Vellore 632014, Tamil Nadu, India.
   [Al-Turjman, Fadi] Near East Univ, Res Ctr Al & IoT, Mersin 10, Nicosia, Turkey.
   [Nayyar, Anand] Duy Tan Univ, Grad Sch, Da Nang 550000, Vietnam.
   [Nayyar, Anand] Duy Tan Univ, Fac Informat Technol, Da Nang 550000, Vietnam.
RP Deebak, BD (corresponding author), Vellore Inst Technol, Sch Comp Sci & Engn, Vellore 632014, Tamil Nadu, India.
EM deebakbd@gmail.com
RI Al-Turjman, Fadi/L-2998-2019; Nayyar, Anand/F-3732-2015; Bakkiam David,
   Deebak/B-2795-2014
OI Al-Turjman, Fadi/0000-0001-5418-873X; Nayyar, Anand/0000-0002-9821-6146;
   Bakkiam David, Deebak/0000-0002-4008-6350
CR Al-Turjman F, 2017, IEEE ACCESS, V5, P24617, DOI 10.1109/ACCESS.2017.2766090
   Amin R, 2017, WIRELESS PERS COMMUN, V96, P4629, DOI 10.1007/s11277-017-4408-8
   Awasthi AK, 2011, COMPUT ELECTR ENG, V37, P869, DOI 10.1016/j.compeleceng.2011.09.015
   Chandrakar P, 2019, INT J AMBIENT COMPUT, V10, P96, DOI 10.4018/IJACI.2019010106
   Chaudhary RRK, 2020, J COMPUT THEOR NANOS, V17, P246
   Chen TH, 2010, ETRI J, V32, P704, DOI 10.4218/etrij.10.1510.0134
   Das AK, 2013, J MED SYST, V37, DOI 10.1007/s10916-013-9969-9
   David DB, 2015, WIRELESS PERS COMMUN, V85, P241, DOI 10.1007/s11277-015-2736-0
   Deebak BD, 2019, IEEE ACCESS, V7, P135632, DOI 10.1109/ACCESS.2019.2941575
   Deebak BD, 2015, WIRELESS PERS COMMUN, V81, P77, DOI 10.1007/s11277-014-2118-z
   Deebak BD, 2016, MULTIMED TOOLS APPL, V75, P5795, DOI 10.1007/s11042-015-2542-4
   Deebak BD, 2017, MULTIMED TOOLS APPL, V76
   Dharminder D, 2019, IEEE ACCESS, P1
   Farash MS, 2016, AD HOC NETW, V36, P152, DOI 10.1016/j.adhoc.2015.05.014
   Franks J, 1999, HTTP AUTHENTICATION, P78
   Gope P, 2019, IEEE T IND INFORM, V15, P4957, DOI 10.1109/TII.2019.2895030
   Gunasinghe H, 2018, IEEE T INF FOREN SEC, V13, P1042, DOI 10.1109/TIFS.2017.2777787
   Hu PF, 2017, IEEE INTERNET THINGS, V4, P1143, DOI 10.1109/JIOT.2017.2659783
   Huang XY, 2011, IEEE T PARALL DISTR, V22, P1390, DOI 10.1109/TPDS.2010.206
   ICS, 2011, 3504050 ICS, P1
   Jiang Q, 2016, J SUPERCOMPUT, V72, P3826, DOI 10.1007/s11227-015-1610-x
   Kumari A, 2019, J DISCRET MATH SCI C, V22, P521, DOI 10.1080/09720529.2019.1637155
   LAMPORT L, 1981, COMMUN ACM, V24, P770, DOI 10.1145/358790.358797
   Li CT, 2018, COMPUT METH PROG BIO, V157, P191, DOI 10.1016/j.cmpb.2018.02.002
   Li JP, 2020, IEEE INTERNET THINGS, V7, P7334, DOI 10.1109/JIOT.2020.2984618
   Li X, 2020, IEEE SYST J, V14, P39, DOI 10.1109/JSYST.2019.2899580
   Li X, 2016, SECUR COMMUN NETW, V9, P2643, DOI 10.1002/sec.1214
   Liu H, 2019, IEEE INTERNET THINGS, V6, P1352, DOI 10.1109/JIOT.2018.2843561
   Liu H, 2015, IEEE T PARALL DISTR, V26, P241, DOI 10.1109/TPDS.2014.2308218
   Madhusudhan R, 2020, PEER PEER NETW APPL, V13, P82, DOI 10.1007/s12083-019-0717-x
   Mo JQ, 2020, SECUR COMMUN NETW, V2020, DOI 10.1155/2020/5047379
   Odelu V, 2015, J INF SECUR APPL, V21, P1, DOI 10.1016/j.jisa.2015.01.001
   Oueida S, 2019, MULTIMED TOOLS APPL, V78, P24573, DOI 10.1007/s11042-018-6647-4
   Oueida S, 2018, SENSORS-BASEL, V18, DOI 10.3390/s18124307
   Shen JJ, 2003, COMPUT SECUR, V22, P591, DOI 10.1016/S0167-4048(03)00709-0
   Srinivas J, 2017, J MED SYST, V41, DOI 10.1007/s10916-017-0720-9
   Turkanovic M, 2014, AD HOC NETW, V20, P96, DOI 10.1016/j.adhoc.2014.03.009
   Wang F, 2020, WIREL COMMUN MOB COM, V3805058, P1
   Wang F, 2019, IEEE ACCESS, V7, P101596
   Wang LL, 2014, J APPL MATH, DOI 10.1155/2014/247836
   Wu F, 2013, J MED SYST, V37, DOI 10.1007/s10916-013-9958-z
   Xuan Hung Le, 2011, Journal of Networks, V6, P355, DOI 10.4304/jnw.6.3.355-364
   Yang GM, 2008, J COMPUT SYST SCI, V74, P1160, DOI 10.1016/j.jcss.2008.04.002
   Yu Y, 2017, IEEE T INF FOREN SEC, V12, P767, DOI 10.1109/TIFS.2016.2615853
   Zhang LH, 2008, CHAOS SOLITON FRACT, V37, P669, DOI 10.1016/j.chaos.2006.09.047
   Zhu H, 2015, J INF HIDING MULTIME, V6, P500
NR 46
TC 0
Z9 0
U1 3
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1380-7501
EI 1573-7721
J9 MULTIMED TOOLS APPL
JI Multimed. Tools Appl.
DI 10.1007/s11042-020-10134-x
EA NOV 2020
PG 26
WC Computer Science, Information Systems; Computer Science, Software
   Engineering; Computer Science, Theory & Methods; Engineering, Electrical
   & Electronic
SC Computer Science; Engineering
GA OQ6CA
UT WOS:000588867800002
PM 33204211
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Cavaliere, D
   Parini, D
   Marano, L
   Cipriani, F
   Di Marzo, F
   Macri, A
   D'Ugo, D
   Roviello, F
   Gronchi, A
AF Cavaliere, Davide
   Parini, Dario
   Marano, Luigi
   Cipriani, Federica
   Di Marzo, Francesco
   Macri, Antonio
   D'Ugo, Domenico
   Roviello, Franco
   Gronchi, Alessandro
CA SICO Italian Soc Surgical Oncology
TI Surgical management of oncologic patient during and after the COVID-19
   outbreak: practical recommendations from the Italian society of Surgical
   Oncology
SO UPDATES IN SURGERY
LA English
DT Article; Early Access
DE COVID-19; Cancer; Recommendations; Oncologic surgery
ID N95 RESPIRATORS; PERFORMANCE
AB The recent outbreak of COVID-19 in Italy caused a limitation of the resources of the health system, which necessarily led to their rationalization in the critical phase (phase 1) and a reorganization of the system in the following phase (phase 2). The Italian Society of Oncological Surgery-SICO has drafted these practical recommendations, calibrated on the most recent scientific literature and taking into account current health regulations and common sense. Surgical activity during phase 1 and 2 should follow a dynamic model, considering architectural structures, hospital mission, organizational models. Surgical delay should not affect oncological prognosis. However, COVID-19-positive cancer patients should be postponed until the infection is cured. The patients to consider more carefully before delaying surgery are those who have completed neoadjuvant therapy, patients with high biological aggressiveness tumors or without therapeutic alternatives. The multidisciplinary discussions are fundamental for sharing clinical decisions; videoconference meetings are preferable and use of telemedicine for follow-up is recommended. Especially in phase 1, maximum effort must be made to reduce the spread of the pandemic. Prefer intra-corporeal rather than open anastomosis during laparoscopy and mechanical rather than hand-sewn anastomosis in open surgery. Consider PPE for caregivers during stoma management. Minimal invasive surgery is not discouraged, because there is little evidence for augmented risk. Specific procedures have to be followed and use of energy devices has to be limited. Training programs with COVID-19 + patients are not recommended. All staff in OR should be trained with specific courses on specific PPE use. Differentiate recommendations are presented for every district cancer. Surgical oncology during phase 2 should be guaranteed by individual and distinct protocols and pathways between cancer patients and COVID-19 + patients with resources specifically addressed to the two distinct kind of patients to limit diagnostic/therapeutic interferences or slowdowns. These recommendations are based on currently available evidence about management of oncologic patients during COVID-19 pandemic, were endorsed by the SICO Executive Board, and are considered suitable for nationwide diffusion. They will be subject to updates and revisions in case of new and relevant scientific acquisitions.
C1 [Cavaliere, Davide] Ausl Romagna, Morgagni Pierantoni Hosp, Gen & Oncol Surg, Forli, Italy.
   [Parini, Dario] Santa Maria Misericordia Hosp, Gen Surg Unit, Rovigo, Italy.
   [Marano, Luigi; Roviello, Franco] Univ Siena, Dept Med Surg & Neurosci, Gen Surg & Surg Oncol, I-53100 Siena, Italy.
   [Cipriani, Federica] Osped San Raffaele, Hepatobiliary Surg Div, Via Olgettina 60, Milan, Italy.
   [Di Marzo, Francesco] Osped Valtiberina, UOC Chirurg Gen, Usl Toscana Sud Est, Sansepolcro, Arezzo, Italy.
   [Macri, Antonio] Messina Univ, Med Sch Hosp, Peritoneal Surface Malignancy & Soft Tissue Sarco, Messina, Italy.
   [D'Ugo, Domenico] Fdn Policlin Univ Agostino Gemelli IRCCS, Dipartimento Sci Med & Chirurg, UOC Chirurg Gen, Rome, Italy.
   [Gronchi, Alessandro] Fdn IRCCS Ist Nazl Tumori, Dept Surg, Milan, Italy.
RP Marano, L (corresponding author), Univ Siena, Dept Med Surg & Neurosci, Gen Surg & Surg Oncol, I-53100 Siena, Italy.
EM luigi.marano@unisi.it
RI Parini, Dario/ABC-5476-2020; Marano, Luigi/K-4944-2013
OI Parini, Dario/0000-0002-4683-9691; Marano, Luigi/0000-0002-9777-9588; Di
   Marzo, Francesco/0000-0001-6435-5693; DE LUCA,
   RAFFAELE/0000-0002-9337-0769
FU Universita degli Studi di Siena within the CRUI-CARE Agreement
FX Open access funding provided by Universita degli Studi di Siena within
   the CRUI-CARE Agreement.
CR Chen Y H, 2020, Zhonghua Wei Chang Wai Ke Za Zhi, V23, pI, DOI 10.3760/cma.j.issn.1671-0274.2020.02.001
   Di Marzo F, 2020, BRIT J SURG, V1, P391
   Kamer E, 2020, TURK J COLORECTAL DI, V30, P1, DOI [DOI 10.4274/TJCD.GALENOS.2020.2020-3-7, 10.4274/tjcd.galenos.2020.2020-3-7]
   Lee SA, 2008, ANN OCCUP HYG, V52, P177, DOI 10.1093/annhyg/men005
   Marano L, 2020, EJSO-EUR J SURG ONC, V46, P1184, DOI 10.1016/j.ejso.2020.04.004
   Maringe C, 2020, LANCET ONCOL, V21, P1023, DOI 10.1016/S1470-2045(20)30388-0
   Mazzaferro V, 2020, ANN SURG, V272, pE84, DOI 10.1097/SLA.0000000000004005
   Pang JX, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030623
   Pata F, 2020, COLORECTAL DIS, V22, P985, DOI 10.1111/codi.15279
   Qian YG, 1998, AM IND HYG ASSOC J, V59, P128, DOI 10.1080/15428119891010389
   Restivo A, 2020, EJSO-EUR J SURG ONC, V46, P1186, DOI 10.1016/j.ejso.2020.04.003
   Spinelli A, 2020, BRIT J SURG, V107, P785, DOI 10.1002/bjs.11627
   Spolverato G, 2020, SURGERY, V168, P4, DOI 10.1016/j.surg.2020.04.036
   Torzilli G, 2020, ANN SURG, V272, pE112, DOI 10.1097/SLA.0000000000004081
   Tuech JJ, 2020, J VISC SURG, V157, pS7, DOI 10.1016/j.jviscsurg.2020.03.008
   Zheng MH, MINIMALLY INVASIVE S
NR 16
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 2038-131X
EI 2038-3312
J9 UPDATES SURG
JI Updates Surg.
DI 10.1007/s13304-020-00921-4
EA NOV 2020
PG 9
WC Surgery
SC Surgery
GA OQ5TF
UT WOS:000588844900001
PM 33184782
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Steiner, A
   Znidar, D
   Otvos, SB
   Snead, DR
   Dallinger, D
   Kappe, CO
AF Steiner, Alexander
   Znidar, Desiree
   otvos, Sandor B.
   Snead, David R.
   Dallinger, Doris
   Kappe, C. Oliver
TI A High-Yielding Synthesis of EIDD-2801 from Uridine**
SO EUROPEAN JOURNAL OF ORGANIC CHEMISTRY
LA English
DT Article
DE EIDD&#8208; 2801; COVID&#8208; 19; Continuous flow; Acetonide
   deprotection; Triazolation
AB A simple reordering of the reaction sequence allowed the improved synthesis of EIDD-2801, an antiviral drug with promising activity against the SARS-CoV-2 virus, starting from uridine. Compared to the original route, the yield was enhanced from 17 % to 61 %, and fewer isolation/purification steps were needed. In addition, a continuous flow procedure for the final acetonide deprotection was developed, which proved to be favorable toward selectivity and reproducibility.
C1 [Steiner, Alexander; Znidar, Desiree; otvos, Sandor B.; Dallinger, Doris; Kappe, C. Oliver] Karl Franzens Univ Graz, Inst Chem, NAWI Graz, Heinrichstr 28, A-8010 Graz, Austria.
   [Steiner, Alexander; Znidar, Desiree; otvos, Sandor B.; Dallinger, Doris; Kappe, C. Oliver] Res Ctr Pharmaceut Engn GmbH RCPE, Ctr Continuous Flow Synth & Proc CCFLOW, Inffeldgasse 13, A-8010 Graz, Austria.
   [Snead, David R.] Med All Inst, 737 N 5th St,Box 980100, Richmond, VA 23298 USA.
RP Dallinger, D; Kappe, CO (corresponding author), Karl Franzens Univ Graz, Inst Chem, NAWI Graz, Heinrichstr 28, A-8010 Graz, Austria.; Dallinger, D; Kappe, CO (corresponding author), Res Ctr Pharmaceut Engn GmbH RCPE, Ctr Continuous Flow Synth & Proc CCFLOW, Inffeldgasse 13, A-8010 Graz, Austria.
EM do.dallinger@uni-graz.at; oliver.kappe@uni-graz.at
CR Gobert SRL, 2017, ORG PROCESS RES DEV, V21, P531, DOI 10.1021/acs.oprd.6b00359
   Gopalsamuthiram V, 2020, SYNLETT, DOI 10.1055/a-1275-2848
   Gutmann B., 2015, ANGEW CHEM, V127, P6788, DOI DOI 10.1002/ANGE.201409318
   Gutmann B, 2015, ANGEW CHEM INT EDIT, V54, P6688, DOI 10.1002/anie.201409318
   Miah A, 1997, NUCLEOS NUCLEOT, V16, P53, DOI 10.1080/07328319708002521
   Painter G. R., 2019, Patent No. [WO2019113462A1, 2019113462, WO 2019/113462 A1]
   Plutschack MB, 2017, CHEM REV, V117, P11796, DOI 10.1021/acs.chemrev.7b00183
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Vasudevan N, 2020, CHEM COMMUN, V56, P13363, DOI 10.1039/d0cc05944g
NR 9
TC 0
Z9 0
U1 3
U2 3
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1434-193X
EI 1099-0690
J9 EUR J ORG CHEM
JI Eur. J. Org. Chem.
PD NOV 22
PY 2020
VL 2020
IS 43
BP 6736
EP 6739
DI 10.1002/ejoc.202001340
EA NOV 2020
PG 4
WC Chemistry, Organic
SC Chemistry
GA OU2WD
UT WOS:000588400500001
DA 2021-01-01
ER

PT J
AU Punyaratabandhu, P
   Chirachanakul, P
AF Punyaratabandhu, Preawphan
   Chirachanakul, Pornchai
TI Cutaneous eruption in COVID-19-infected patients in Thailand: An
   observational descriptive study
SO JOURNAL OF DERMATOLOGY
LA English
DT Article; Early Access
DE corona virus; COVID&#8208; 19; cutaneous eruption; drug eruption; skin
   manifestation
AB Coronavirus disease 2019 (COVID-19) emerged in Thailand in January 2020. Thailand was the first to report a confirmed case outside China. Cutaneous eruption in COVID-19 has been reported since the disease became pandemic but limited in tropical countries such as Thailand. The aim of this study was to observe the incidence, characteristics and relation of cutaneous eruption with COVID-19 at Bamrasnaradura Infectious Diseases Institute, a referral center of emerging infectious diseases in Thailand. An observational descriptive study observed the incidence and characteristics of cutaneous eruption in 204 COVID-19-infected patients at Bamrasnaradura Infectious Diseases Institute. We report five patients, who represented six incidences of skin eruption with four characteristics: maculopapular rash (50%), acute generalized exanthematous pustulosis (16.67%), Stevens-Johnson syndrome (16.67%) and urticarial vasculitis (16.67%). Incidences of cutaneous eruption in COVID-19 at Bamrasnaradura Infectious Diseases Institute were low. Most of the incidents were associated with medication used to treat COVID-19 infection, so drug allergy cannot be excluded as a cause of the rashes. Therefore, drug allergy should always be ruled out, and skin manifestation in COVID-19-infected patients should be further observed.
C1 [Punyaratabandhu, Preawphan; Chirachanakul, Pornchai] Minist Publ Hlth, Bamrasnaradura Infect Dis Inst, Dept Dis Control, 38 Soi Tiwanon 14,Tiwanon Rd, Nonthaburi 11000, Thailand.
RP Punyaratabandhu, P (corresponding author), Minist Publ Hlth, Bamrasnaradura Infect Dis Inst, Dept Dis Control, 38 Soi Tiwanon 14,Tiwanon Rd, Nonthaburi 11000, Thailand.
EM preawphan.p@gmail.com
CR Bouaziz JD, 2020, J EUR ACAD DERMATOL, V34, pE451, DOI 10.1111/jdv.16544
   de Perosanz-Lobo D, 2020, J EUR ACAD DERMATOL, V34, pE566, DOI 10.1111/jdv.16713
   Casas CG, 2020, BRIT J DERMATOL, V183, P71, DOI 10.1111/bjd.19163
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Han Y, 2019, J MED VIROL, V2020, P1
   Kolivras Athanassios, 2020, JAAD Case Rep, V6, P489, DOI 10.1016/j.jdcr.2020.04.011
   Manalo IF, 2020, J AM ACAD DERMATOL, V83, pE157, DOI [10.1016/j.jaad.2020.04.018, 10.1016/j.jaad.2020.05.001]
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE212, DOI 10.1111/jdv.16387
   Sidoroff A, 2001, J CUTAN PATHOL, V28, P113, DOI 10.1034/j.1600-0560.2001.028003113.x
   van Damme C, 2020, J EUR ACAD DERMATOL, V34, pE300, DOI 10.1111/jdv.16523
   Zhang Y, 2020, Zhonghua Xue Ye Xue Za Zhi, V41, pE006, DOI [10.3760/cma.j.issn.0253-2727.2020.008, 10.3760/cma.j.issn.0253-2727.2020.0006]
NR 12
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0385-2407
EI 1346-8138
J9 J DERMATOL
JI J. Dermatol.
DI 10.1111/1346-8138.15625
EA NOV 2020
PG 7
WC Dermatology
SC Dermatology
GA OQ0PX
UT WOS:000588495600001
PM 33180327
OA Bronze
DA 2021-01-01
ER

PT J
AU Lu, L
   Liu, XM
   Jin, R
   Guan, RZ
   Lin, RJ
   Qu, ZH
AF Lu, Ling
   Liu, Xiaomei
   Jin, Rong
   Guan, Renzheng
   Lin, Rongjun
   Qu, Zhenghai
TI Potential Roles of the Renin-Angiotensin System in the Pathogenesis and
   Treatment of COVID-19
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID CONVERTING ENZYME 2; INDUCED LUNG INJURY; PULMONARY-HYPERTENSION; ACE2;
   CORONAVIRUS; PROTECTS; RECEPTOR; SARS; POLYMORPHISM; PREVENTION
AB The spread of pathogenic severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) poses a global health emergency. Based on the symptomatic treatment and supporting therapy, prevention of complications is the major treatment option. Therefore, it is necessary to illustrate the potential mechanisms for the pathogenesis of COVID-19. Angiotensin-converting enzyme 2 (ACE2), the major receptor of SARS-CoV-2, is one of the major members of the renin-angiotensin system (RAS). In this review, we aimed to summarize the crucial roles of ACE2 in the pathogenesis of COVID-19, followed by illustrating potential treatment options relating to ACE2 and the RAS.
C1 [Lu, Ling; Liu, Xiaomei; Jin, Rong; Guan, Renzheng; Lin, Rongjun; Qu, Zhenghai] Qingdao Univ, Affiliated Hosp, Dept Pediat, Qingdao 266003, Peoples R China.
RP Qu, ZH (corresponding author), Qingdao Univ, Affiliated Hosp, Dept Pediat, Qingdao 266003, Peoples R China.
EM luling8899@163.com; liuxiaomei1002@163.com; jinrong523@163.com;
   grz0051@126.com; linrongjun0312@126.com; quzhenghai@163.com
CR Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x
   Balakumar P, 2014, CELL SIGNAL, V26, P2147, DOI 10.1016/j.cellsig.2014.06.011
   Bitker L, 2019, CRIT CARE CLIN, V35, P213, DOI 10.1016/j.ccc.2018.11.002
   Blaes N, 2013, EXPERT OPIN THER TAR, V17, P1145, DOI 10.1517/14728222.2013.827664
   Clerkin KJ, 2020, CIRCULATION, V141, P1648, DOI 10.1161/CIRCULATIONAHA.120.046941
   Deng W, 2015, INT J CLIN EXP PATHO, V8, P15670
   Ding YQ, 2003, J PATHOL, V200, P282, DOI 10.1002/path.1440
   Ferreira AJ, 2009, AM J RESP CRIT CARE, V179, P1048, DOI 10.1164/rccm.200811-1678OC
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Hashimoto T, 2012, NATURE, V487, P477, DOI 10.1038/nature11228
   Heurich A, 2014, J VIROL, V88, P1293, DOI 10.1128/JVI.02202-13
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   HUDSON LD, 1995, AM J RESP CRIT CARE, V151, P293, DOI 10.1164/ajrccm.151.2.7842182
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Jerng JS, 2006, CRIT CARE MED, V34, P1001, DOI 10.1097/01.CCM.0000206107.92476.39
   Jia HP, 2016, SHOCK, V46, P239, DOI 10.1097/SHK.0000000000000633
   Kaparianos A, 2011, CURR MED CHEM, V18, P3506, DOI 10.2174/092986711796642562
   Khan A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1823-x
   Klein N, 2013, CRIT CARE MED, V41, pE334, DOI 10.1097/CCM.0b013e31828a6688
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuba K, 2010, PHARMACOL THERAPEUT, V128, P119, DOI 10.1016/j.pharmthera.2010.06.003
   Lei CH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16048-4
   Marshall RP, 2002, AM J RESP CRIT CARE, V166, P646, DOI 10.1164/rccm.2108086
   Meng Y, 2014, AM J RESP CELL MOL, V50, P723, DOI 10.1165/rcmb.2012-0451OC
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Ng DL, 2016, AM J PATHOL, V186, P652, DOI 10.1016/j.ajpath.2015.10.024
   Raiden S, 2002, J PHARMACOL EXP THER, V303, P45, DOI 10.1124/jpet.102.037382
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Rothlin RP, 2020, DRUG DEVELOP RES, V81, P768, DOI 10.1002/ddr.21679
   Schouten LRA, 2016, CRIT CARE MED, V44, P819, DOI 10.1097/CCM.0000000000001388
   Shrikrishna D, 2012, CLIN SCI, V123, P487, DOI 10.1042/CS20120081
   Shulla A, 2011, J VIROL, V85, P873, DOI 10.1128/JVI.02062-10
   Tan WSD, 2018, CURR OPIN PHARMACOL, V40, P9, DOI 10.1016/j.coph.2017.12.002
   Treml B, 2010, CRIT CARE MED, V38, P596, DOI 10.1097/CCM.0b013e3181c03009
   Ware LB, 2006, SEMIN RESP CRIT CARE, V27, P337, DOI 10.1055/s-2006-948288
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu YC, 2020, J CHIN MED ASSOC, V83, P1, DOI DOI 10.1097/JCMA.0000000000000270
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yamazato Y, 2009, HYPERTENSION, V54, P365, DOI 10.1161/HYPERTENSIONAHA.108.125468
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zambelli Vanessa, 2015, Intensive Care Med Exp, V3, P44, DOI 10.1186/s40635-015-0044-3
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhao YL, 2015, BURNS, V41, P1468, DOI 10.1016/j.burns.2015.04.010
   Zhao Y, 2020, AM J RESP CRIT CARE, V202, P756, DOI 10.1164/rccm.202001-0179LE
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 53
TC 0
Z9 0
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD NOV 11
PY 2020
VL 2020
AR 7520746
DI 10.1155/2020/7520746
PG 7
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA PA5AY
UT WOS:000595649600004
PM 33204713
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dabbagh, A
   Rajaei, S
   Ghahremani, M
   Fathi, M
   Massoudi, N
   Tavana, S
   Fani, K
   Nooraee, N
   Alamdari, NM
   Besharat, S
   Abrandabadi, AN
   Pirsalehi, A
   Khatiri, MAK
AF Dabbagh, Ali
   Rajaei, Samira
   Ghahremani, Mehdi
   Fathi, Mohammad
   Massoudi, Nilofar
   Tavana, Sasan
   Fani, Kamal
   Nooraee, Navid
   Alamdari, Nasser Malekpour
   Besharat, Sara
   Abrandabadi, Arash Najafi
   Pirsalehi, Ali
   Khatiri, Mohammad Ali Khabiri
TI The effect of surfactant on clinical outcome of patients with COVID-19
   under mechanical ventilation: A structured summary of a study protocol
   for a randomised controlled trial
SO TRIALS
LA English
DT Article
DE COVID-19; SARS-COV-2; surfactant; ICU; acute respiratory distress
   syndrome; ventilator; mechanical ventilation; mortality; hospital length
   of stay; hospital discharge rate Randomised controlled trial; protocol
AB ObjectivesAssessing the effect of surfactant on clinical outcome in patients with COVID-19 under mechanical ventilationTrial designSingle centre, two arm, parallel group (1:1 allocation ratio), randomised superiority trial with blinded care and outcome assessment.ParticipantsInclusion criteria: Adult COVID-19 patients admitted to the ICU in Modarres hospital, Tehran, Iran (age range of 18 to 99 years) with moderate to severe ARDS (based on definition of P/F ratio) requiring auxiliary respiratory devices (either intubation or face mask).Exclusion criteria:. Existence of a major underlying pulmonary disease in addition to COVID-19. Underlying congenital heart disease. Patients needing extracorporeal membrane oxygenation (ECMO). ARDS primarily due to any other reason rather than COVID-19. The primary source of pulmonary involvement was bacterial pneumonia or any other etiology except for COVID-10 induced lung involvement. Those who refused to continue the study (either the patient or their family). any patient had any sign of healing before entering the study leading to discharge from ICU in less than 12 hoursIntervention and comparatorIn the intervention group, the dose of the drug is a vial containing 4 ml, equivalent to 100 mg, which is prescribed for an adult weighing about 70 kg each time, and if the patient's weight is much lower or higher, it will be adjusted accordingly. Surfactant is prescribed inside the trachea in two doses, starting on the day of intubation with a second dose 6 hours later. The control group will receive the same volume of normal saline, based on weight, administered into the trachea with the same time schedule.Main outcomes30 days mortality; patient mortality during stay in ICU up to 30 days; ICU length of stay up to 30 days; Time under mechanical ventilation up to 30 days.RandomisationAfter the participant enters the study, i.e. after the qualification of the patients in the trial is confirmed and their informed written consent is taken, we will use a simple randomisation method using a table of random numbers. In order to hide the random allocation process, a central randomisation approach will be used and the random sequence will be at the disposal of one of the researchers, excluding the principal investigator.Blinding (masking)Participants, healthcare providers and the principal investigator assessing the outcomes will all be blinded to the group assignment.Numbers to be randomised (sample size)A total of 60 participants will be randomised in a 1:1 allocation ratio (30 patients allocated to the intervention group and 30 patients allocated to the control group).Trial StatusThe protocol is Version 1.0, May 31, 2020. Recruitment began July 30, 2020, and is anticipated to be completed by October 30, 2020.Trial registrationIRCT registration number: IRCT20091201002804N12Registration date: 1st June 2020, 1399/03/12Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Dabbagh, Ali] Shahid Beheshti Univ Med Sci, Sch Med, Cardiac Anesthesiol Dept, Anesthesiol Res Ctr, Tehran, Iran.
   [Rajaei, Samira] Univ Tehran Med Sci, Sch Med, Immunol Dept, Tehran, Iran.
   [Ghahremani, Mehdi; Fathi, Mohammad; Nooraee, Navid; Abrandabadi, Arash Najafi; Khatiri, Mohammad Ali Khabiri] Shahid Beheshti Univ Med Sci, Sch Med, Anesthesiol Dept, Crit Care Med, Tehran, Iran.
   [Massoudi, Nilofar] Shahid Beheshti Univ Med Sci, Sch Med, Anesthesiol Dept, Tehran, Iran.
   [Tavana, Sasan; Pirsalehi, Ali] Shahid Beheshti Univ Med Sci, Sch Med, Internal Med Dept, Tehran, Iran.
   [Fani, Kamal] Shahid Beheshti Univ Med Sci, Sch Med, Anesthesiol Dept, Cardiac Anesthesia, Tehran, Iran.
   [Alamdari, Nasser Malekpour] Shahid Beheshti Univ Med Sci, Sch Med, Dept Surg, Tehran, Iran.
   [Besharat, Sara] Shahid Beheshti Univ Med Sci, Sch Med, Dept Radiol, Tehran, Iran.
RP Dabbagh, A (corresponding author), Shahid Beheshti Univ Med Sci, Sch Med, Cardiac Anesthesiol Dept, Anesthesiol Res Ctr, Tehran, Iran.
EM alidabbagh@yahoo.com
FU Anesthesiology Research Center, SBMU, Tehran, Iran [22959]; Tekzima Drug
   Alborz Company, Tehran, Iran
FX This research project is funded by the Anesthesiology Research Center,
   SBMU, Tehran, Iran with grant number 22959. Besides, support was
   provided solely from institutional and/or departmental sources. The
   funding body only has an "observation role" in the design of the study
   and collection, analysis, and interpretation of data and in writing the
   manuscript.; The surfactant vials would be provided by Tekzima Drug
   Alborz Company, Tehran, Iran which provided the drugs as a support to
   the study. The drug was provided as "Beraksurf" as 100 mg in 4 mL vials.
   Except for the drugs, there is no relationship between the researchers
   and the latter company or any other company.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD NOV 11
PY 2020
VL 21
IS 1
AR 919
DI 10.1186/s13063-020-04815-z
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OX9UM
UT WOS:000593901100001
PM 33176850
OA DOAJ Gold, Green Accepted
DA 2021-01-01
ER

PT J
AU Lins, PRG
   de Albuquerque, CCC
   Assis, CF
   Rodrigues, BCD
   Campos, BPES
   Valle, ED
   Cabrera, CPS
   Gois, JD
   Segura, GC
   Strufaldi, FL
   Mainardes, LC
   Ribeiro, RG
   Cortes, DDVR
   Lutf, LG
   de Oliveira, MFA
   Sales, GTM
   Smolentzov, I
   Reichert, BV
   Andrade, L
   Seabra, VF
   Rodrigues, CE
AF Gessolo Lins, Paulo Ricardo
   de Albuquerque, Claudia Coimbra Cesar
   Assis, Camila Fernandes
   Duarte Rodrigues, Bruna Cristine
   Pinto e Siqueira Campos, Beatriz
   Valle, Eduardo de Oliveira
   Sandoval Cabrera, Carla Paulina
   Gois, Jeison de Oliveira
   Segura, Gabriela Cardoso
   Strufaldi, Fernando Louzada
   Mainardes, Lorena Catelan
   Ribeiro, Rayra Gomes
   Via Reque Cortes, Daniela Del Pilar
   Lutf, Luciana Gil
   Arantes de Oliveira, Marcia Fernanda
   Montezuma Sales, Gabriel Teixeira
   Smolentzov, Igor
   Reichert, Bernardo Vergara
   Andrade, Lucia
   Seabra, Victor Faria
   Rodrigues, Camila Eleuterio
TI Cov-hep study: heparin in standard anticoagulation based on citrate for
   continuous veno-venous hemodialysis in patients with COVID-19: a
   structured summary of a study protocol for a randomized controlled trial
SO TRIALS
LA English
DT Article
DE COVID-19; Randomized controlled trial; protocol; Acute kidney injury;
   continuous dialysis; heparin; citrate; CVVHD; CVVHDF
AB ObjectivesThe primary objective is to test if heparin added to a standard regional anticoagulation protocol based on citrate is able to reduce dialysis circuit losses by clotting without increasing the risk of thrombocytopenia or bleeding, in patients with COVID-19 with acute kidney injury requiring dialysis.Trial designRandomized, parallel-group, open-label trial, with two arms (ratio 1:1) comparing different continuous renal replacement therapy anticoagulation strategies.ParticipantsEligibility conditions:All ICU patients of University of Sao Paulo General Hospital (Hospital das Clinicas), Brazil will be screened for eligibility conditions.Adults (> 18 years old) with confirmed COVID-19 and acute kidney injury requiring dialysis with agreement between ICU and nephrology teams for the introduction of renal continuous replacement therapy in daily ICU rounds. Continuous renal replacement therapy will be prescribed by consulting nephrologists based on standard clinical guidelines, including acute kidney injury with hemodynamic instability plus hyperkalemia, severe acidosis, volume overload, respiratory distress, multiorgan failure or some combination of these factors.Data Collection:Patients demographics and associated clinical data and comorbidities will be recorded at ICU entry. Demographic information will include the patient's age, sex, and admission dates. Clinical data comprise comorbidities, APACHE 2, SAPS 3, need for mechanical ventilation, and use of vasopressor drugs. Physiological data collected by the day of CRRT start will be vital signs, the arterial oxygen tension/fraction of inspired oxygen (PaO2/FiO2) index, and serum creatinine, blood urea nitrogen, bilirubin, hemoglobin, hematocrit, platelets, white blood cell count levels and Peak D-dimer levels.Patients will be analyzed for the first 72h of CRRT, and they will be evaluated regarding clinical variables, filter patency and any adverse events that could be related to the anticoagulation choice, as bleeding (mild or major) or low platelets counts (<100.000 ui/uL) during treatment period. Mild and major bleeding will be defined by hemorrhagic event without clinical impact or hemoglobin (Hb) fall lesser than 1g/dL and hemorrhagic event with clinical impact or Hb fall higher than 1g/dL, respectively.Exclusion criteria:Hypersensitivity to any of the substances going to be used in the study (Citric acid dextrosol 2.2% and unfractionated heparin); Previous diagnosis of coagulopathy or thrombophilia; Contraindication to the use of unfractionated heparin; Risk of citrate poisoning - (Lactate> 30 mg/dL, international normalized ratio > 2.5, Total bilirubin> 15 mg/dL); Pregnancy; Patients unlikely to survive for more than 24 hours.The trial is being undertaken at the University of Sao Paulo General Hospital (Hospital das Clinicas), Brazil.Intervention and comparatorGroup A (control) - Patients on continuous renal replacement therapy (blood flow 150 ml/min, dose of 30 mL/Kg/h) receiving anticoagulation with sodium citrate at 4 mmol/LGroup B (experiment): Patients on continuous hemodialysis (blood flow 150 mL/min, dose of 30 mL/Kg/h) receiving anticoagulation with sodium citrate at 4 mmol/L associated with unfractionated heparin at 10 U/Kg/h.
   Main outcomesThe percentage of clotted dialyzers within 72 hours in each of the studied groups (Primary outcome)Secondary outcomes: Number of dialyzers used in the first 72 hours of dialysis protocol, Mortality in the first 72 h of dialysis protocol, Bleeding events (Major or minor) in the first 72 h of dialysis protocol, Thrombocytopenia (less than 50.000 platelets) proportion in the first 72 h of dialysis protocol, Dialysis efficiency (Urea sieving) - variation in urea sieving between the first, second and third days of dialysis protocol, Continuous renal replacement therapy pressures (Arterial, Venous, dialysate and pre-filter pressure) in the first 72 h of dialysis protocol, in-hospital mortality.RandomizationRedCap -> randomization - 2 blocks randomization by D-dimer level (5000ng/dL cut-off) and catheter site (Right Internal Jugular versus other sites) with 1:1 allocation ratio.Blinding (masking)No blinding - Open label formatNumbers to be randomized (sample size)Total number of patients 90 (45 per group)Trial StatusTrial version 2.0 - ongoing recruitment.First recruitment: June 29, 2020Estimated date for last recruitment: December 31, 2020Trial registrationResponsible Party: University of Sao Paulo General Hospital (Hospital das Clinicas)ClinicalTrials.gov Identifier: NCT04487990, registered July 27, 2020, ReBec www.ensaiosclinicos.gov.br/rg/RBR-45kf9p/Other Study ID Numbers: U1111-1252-0194Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1) In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Gessolo Lins, Paulo Ricardo; de Albuquerque, Claudia Coimbra Cesar; Assis, Camila Fernandes; Duarte Rodrigues, Bruna Cristine; Pinto e Siqueira Campos, Beatriz; Valle, Eduardo de Oliveira; Sandoval Cabrera, Carla Paulina; Gois, Jeison de Oliveira; Segura, Gabriela Cardoso; Strufaldi, Fernando Louzada; Mainardes, Lorena Catelan; Ribeiro, Rayra Gomes; Via Reque Cortes, Daniela Del Pilar; Lutf, Luciana Gil; Arantes de Oliveira, Marcia Fernanda; Montezuma Sales, Gabriel Teixeira; Smolentzov, Igor; Reichert, Bernardo Vergara; Andrade, Lucia; Seabra, Victor Faria; Rodrigues, Camila Eleuterio] Nivers Sao Paulo, Hosp Clin, Sao Paulo, Brazil.
RP Lins, PRG (corresponding author), Nivers Sao Paulo, Hosp Clin, Sao Paulo, Brazil.
EM paulo.lins@hc.fm.usp.br
OI Gessolo Lins, Paulo Ricardo/0000-0003-1806-1285
FU Fundacao Faculdade de Medicina (Clinics Hospital - University of Sao
   Paulo School Medicine Related Award) #HCCOMVIDA
FX This study was funded by Fundacao Faculdade de Medicina (Clinics
   Hospital -University of Sao Paulo School Medicine Related Award)
   #HCCOMVIDA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD NOV 11
PY 2020
VL 21
IS 1
AR 920
DI 10.1186/s13063-020-04814-0
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OX9UM
UT WOS:000593901100002
PM 33176886
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Alazmi, M
   Motwalli, O
AF Alazmi, Meshari
   Motwalli, Olaa
TI Molecular basis for drug repurposing to study the interface of the S
   protein in SARS-CoV-2 and human ACE2 through docking, characterization,
   and molecular dynamics for natural drug candidates
SO JOURNAL OF MOLECULAR MODELING
LA English
DT Article
DE COVID-19; SARS-CoV-2; Molecular dynamics; Andrographolide; S protein;
   human ACE2 complex
ID CORONAVIRUS SPIKE PROTEIN; VITIS-VINIFERA; FORCE-FIELD; RESVERATROL;
   PTEROSTILBENE; PICEATANNOL; ACTIVATION; GROMACS
AB A novel coronavirus (SARS-CoV-2) identified in Wuhan state of China in 2019 is the causative agent of deadly disease COVID-19. It has spread across the globe (more than 210 countries) within a short period. Coronaviruses pose serious health threats to both humans and animals. A recent publication reported an experimental 3D complex structure of the S protein of SARS-CoV-2 showed that the ectodomain of the SARS-CoV-2 S protein binds to the peptidase domain (PD) of human ACE2 with a dissociation constant (Kd) of similar to 15 nM. In this study, we focused on inhibitors for ACE2: S protein complex using virtual screening and inhibition studies through molecular docking for over 200,000 natural compounds. Toxicity analysis was also performed for the best hits, and the final complex structures for four complexes were subjected to 400 ns molecular dynamics simulations for stability testing. We found two natural origin inhibitors for the S protein: human ACE2 complex (Andrographolide and Pterostilbene) which displayed better inhibition potential for ACE2 receptor and its binding with the S protein of SARS-CoV-2. Comparative studies were also performed to test and verify that these two drug candidates are also better than hydroxychloroquine which is known to inhibit this complex. However, we needed better potential drug candidates to overcome the side effects of hydroxychloroquine. Supplementary experimental studies need to be carried forward to corroborate the viability of these two new inhibitors for ACE2: S protein complex so as to curb down COVID-19.
C1 [Alazmi, Meshari] Univ Hail, Coll Comp Sci & Engn, POB 2440, Hail 81411, Saudi Arabia.
   [Motwalli, Olaa] Saudi Elect Univ SEU, Coll Comp & Informat, Madinah 4153853307, Saudi Arabia.
RP Alazmi, M (corresponding author), Univ Hail, Coll Comp Sci & Engn, POB 2440, Hail 81411, Saudi Arabia.
EM ms.alazmi@uoh.edu.sa
CR Acun B, 2018, IBM J RES DEV, V62, DOI [10.1147/jrd.2018.2888986, 10.1147/JRD.2018.2888986]
   Alazmi M, 2019, CURR COMPUT AIDED DR
   Banerjee P, 2018, NUCLEIC ACIDS RES, V46, pW257, DOI 10.1093/nar/gky318
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E
   Bhakkiyalakshmi E, 2016, EUR J PHARMACOL, V777, P9, DOI 10.1016/j.ejphar.2016.02.054
   Bikadi Z, 2009, J CHEMINFORMATICS, V1, DOI 10.1186/1758-2946-1-15
   Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978-1-4939-2269-7_19
   Danish S, SIMPLE CLICK CLICK P
   Dariya B, 2020, CYTOKINE GROWTH F R, V53, P43, DOI 10.1016/j.cytogfr.2020.05.001
   Gulcin I, 2010, INNOV FOOD SCI EMERG, V11, P210, DOI 10.1016/j.ifset.2009.07.002
   Hanwell MD, 2012, J CHEMINFORMATICS, V4, DOI 10.1186/1758-2946-4-17
   Huang J, 2013, J COMPUT CHEM, V34, P2135, DOI 10.1002/jcc.23354
   Huey R, 2007, J COMPUT CHEM, V28, P1145, DOI 10.1002/jcc.20634
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Illingworth CJR, 2008, J PHYS CHEM A, V112, P12157, DOI 10.1021/jp710169m
   Jarcho JA, 2020, NEW ENGL J MED, V382, P2462, DOI 10.1056/NEJMe2012924
   Jeong E, 2013, PHYTOTHER RES, V27, P610, DOI 10.1002/ptr.4770
   Kasiotis KM, 2013, FOOD CHEM TOXICOL, V61, P112, DOI 10.1016/j.fct.2013.03.038
   Khan M, 2019, NUTRIENTS, V11
   Khan OS, 2016, NUTR CANCER, V68, P365, DOI 10.1080/01635581.2016.1152386
   Koskela A, 2014, MOL VIS, V20, P760
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kwon O, 2018, BMB REP, V51, P302, DOI 10.5483/BMBRep.2018.51.6.024
   LANGCAKE P, 1976, PHYSIOL PLANT PATHOL, V9, P77, DOI 10.1016/0048-4059(76)90077-1
   LANGCAKE P, 1979, PHYTOCHEMISTRY, V18, P1025, DOI 10.1016/S0031-9422(00)91470-5
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   Murias M, 2005, BIOCHEM PHARMACOL, V69, P903, DOI 10.1016/j.bcp.2004.12.001
   Paul S, 2009, CANCER PREV RES, V2, P650, DOI 10.1158/1940-6207.CAPR-08-0224
   Pawar AY, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105984
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Piotrowska H, 2012, MUTAT RES-REV MUTAT, V750, P60, DOI 10.1016/j.mrrev.2011.11.001
   Rane J.S., 2020, TARGETING SARS COV 2
   Seyed MA, 2016, J AGR FOOD CHEM, V64, P725, DOI 10.1021/acs.jafc.5b05993
   Shaw DE, 2020, MOL DYNAMICS SIMULAT
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101
   Simmons G, 2013, ANTIVIR RES, V100, P605, DOI 10.1016/j.antiviral.2013.09.028
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Stierand K, 2007, CHEMMEDCHEM, V2, P853, DOI 10.1002/cmdc.200700010
   Stierand K, 2010, ACS MED CHEM LETT, V1, P540, DOI 10.1021/ml100164p
   Tili E, 2010, CARCINOGENESIS, V31, P1561, DOI 10.1093/carcin/bgq143
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Weiskirchen S, 2016, ADV NUTR, V7, P706, DOI 10.3945/an.115.011627
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yiu CY, 2010, MOLECULES, V15, P7115, DOI 10.3390/molecules15107115
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 54
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1610-2940
EI 0948-5023
J9 J MOL MODEL
JI J. Mol. Model.
PD NOV 11
PY 2020
VL 26
IS 12
AR 338
DI 10.1007/s00894-020-04599-8
PG 10
WC Biochemistry & Molecular Biology; Biophysics; Chemistry,
   Multidisciplinary; Computer Science, Interdisciplinary Applications
SC Biochemistry & Molecular Biology; Biophysics; Chemistry; Computer
   Science
GA OX7BB
UT WOS:000593714400001
PM 33175236
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Alexandra, OG
   Julien, R
   Frederic, L
   Alice, H
   Emmanouil, G
   Jean-Benoit, E
   Thierry, K
   Laurence, D
   Maude, C
   Claire-Anne, H
   Marco, R
   Olivier, P
   Stefano, D
   Mauro, O
   Denis, C
   Lise, P
AF Alexandra, Othenin-Girard
   Julien, Regamey
   Frederic, Lamoth
   Alice, Horisberger
   Emmanouil, Glampedakis
   Jean-Benoit, Epiney
   Thierry, Kuntzer
   Laurence, de Leval
   Maude, Carballares
   Claire-Anne, Hurni
   Marco, Rusca
   Olivier, Pantet
   Stefano, Di Bernardo
   Mauro, Oddo
   Denis, Comte
   Lise, Piquilloud
TI Multisystem inflammatory syndrome with refractory cardiogenic shock due
   to acute myocarditis and mononeuritis multiplex after SARS-CoV-2
   infection in an adult
SO SWISS MEDICAL WEEKLY
LA English
DT Article
DE cardiogenic shock; COVID-19; Kawasaki disease; mononeuritis multiplex;
   multisystem inflammatory syndrome; myocarditis; SARS-CoV-2
ID KAWASAKI-DISEASE; DIAGNOSIS
AB A 22-year-old male with a typical history of pauci-symptomatic COVID-19 3 weeks earlier, confirmed by positive serology for SARS-CoV-2 (IgG), was admitted to the intensive care unit because of severe myocarditis with refractory cardiogenic shock that required extracorporeal life support. Due to a clinical presentation suggestive of Kawasaki-like disease with coronary aneurysm and severe systemic inflammation, intravenous immunoglobulins were administered in combination with tocilizumab. The initial clinical course was favourable with these treatments. However, the patient subsequently developed a severe mononeuritis multiplex leading to bilateral foot drop, which required intensive immunosuppressive therapy (corticosteroids, cyclophosphamide and rituximab). The clinical presentation meets the criteria for multisystem inflammatory syndrome associated with SARS-CoV-2, but includes very severe organ damages. Early recognition, a multidisciplinary approach and aggressive therapeutic intervention can lead to a favourable outcome.
C1 [Alexandra, Othenin-Girard; Claire-Anne, Hurni; Marco, Rusca; Olivier, Pantet; Mauro, Oddo; Lise, Piquilloud] Lausanne Univ Hosp, Adult Intens Care Unit, Lausanne, Switzerland.
   [Alexandra, Othenin-Girard] Lausanne Univ Hosp, Anaesthesiol Serv, Lausanne, Switzerland.
   [Julien, Regamey] Lausanne Univ Hosp, Serv Cardiol, Lausanne, Switzerland.
   [Frederic, Lamoth; Emmanouil, Glampedakis] Lausanne Univ Hosp, Infect Dis Serv, Lausanne, Switzerland.
   [Frederic, Lamoth] Lausanne Univ Hosp, Inst Microbiol, Lausanne, Switzerland.
   [Frederic, Lamoth; Thierry, Kuntzer; Laurence, de Leval; Olivier, Pantet; Stefano, Di Bernardo; Mauro, Oddo; Denis, Comte; Lise, Piquilloud] Univ Lausanne, Fac Biol & Med, Lausanne, Switzerland.
   [Alice, Horisberger; Denis, Comte] Lausanne Univ Hosp, Dept Med, Immunol & Allergy Serv, Lausanne, Switzerland.
   [Jean-Benoit, Epiney; Thierry, Kuntzer] Lausanne Univ Hosp, Dept Clin Neurosci, Neurol Serv, Lausanne, Switzerland.
   [Laurence, de Leval] Lausanne Univ Hosp, Dept Lab Med & Pathol, Inst Pathol, Lausanne, Switzerland.
   [Maude, Carballares] Lausanne Univ Hosp, Emergency Med Serv, Lausanne, Switzerland.
   [Stefano, Di Bernardo] Lausanne Univ Hosp, Dept Woman Mother Child, Paediat Cardiol Serv, Lausanne, Switzerland.
RP Lise, P (corresponding author), Lausanne Univ Hosp CHUV, Adult Intens Care Unit, Rue Bugnon 46, CH-1011 Lausanne, Switzerland.
EM lise.piquil-loud@chuv.ch
OI Comte, Denis/0000-0002-6605-1498
CR Collins MP, 2010, J PERIPHER NERV SYST, V15, P176, DOI 10.1111/j.1529-8027.2010.00281.x
   Collins MP, 2000, NEUROLOGY, V55, P636, DOI 10.1212/WNL.55.5.636
   Craver R, 2020, FETAL PEDIATR PATHOL, V39, P263, DOI 10.1080/15513815.2020.1761491
   Gatterre P, 2012, INTENS CARE MED, V38, P872, DOI 10.1007/s00134-012-2473-8
   Gwathmey KG, 2014, LANCET NEUROL, V13, P67, DOI 10.1016/S1474-4422(13)70236-9
   Health Alert Network, 2020, MULT INFL SYNDR CHIL
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Licciardi F, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-1711
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   McCrindle BW, 2017, CIRCULATION, V135, pE927, DOI 10.1161/CIR.0000000000000484
   Menikou S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01156
   Shaigany S, 2020, LANCET, V396, pE8, DOI 10.1016/S0140-6736(20)31526-9
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Watson C, 1996, CLIN EXP IMMUNOL, V105, P112, DOI 10.1046/j.1365-2249.1996.d01-717.x
   Yokouchi Y, 2013, HISTOPATHOLOGY, V62, P387, DOI 10.1111/his.12007
NR 17
TC 0
Z9 0
U1 0
U2 0
PU E M H SWISS MEDICAL PUBLISHERS LTD
PI MUTTENZ
PA FARNSBURGERSTR 8, CH-4132 MUTTENZ, SWITZERLAND
SN 1424-7860
EI 1424-3997
J9 SWISS MED WKLY
JI Swiss Med. Wkly.
PD NOV 11
PY 2020
VL 150
AR w20387
DI 10.4414/smw.2020.20387
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA OW1YG
UT WOS:000592690700001
PM 33181855
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gurzu, S
   Satala, CB
   Melit, LE
   Streinu-Cercel, A
   Otelea, D
   Capalna, B
   Puiac, CI
   Szederjesi, J
   Jung, I
AF Gurzu, Simona
   Satala, Catalin Bogdan
   Melit, Lorena Elena
   Streinu-Cercel, Adrian
   Otelea, Dan
   Capalna, Brandusa
   Puiac, Claudiu Ioan
   Szederjesi, Janos
   Jung, Ioan
TI COVID-19 Like Findings in a Fatal Case of Idiopathic Desquamative
   Interstitial Pneumonia Associated With IgA Glomerulonephritis in a
   13-Month-Old Child
SO FRONTIERS IN PEDIATRICS
LA English
DT Article
DE infant; interstitial pneumonia; autopsy; SARS; COVID; glomerulopathy;
   IgA; Berger
ID DISEASE
AB In the COVID-19 era, patients with severe acute respiratory syndrome (SARS) are suspected to be associated with SARS-CoV-2 infection. The aim of this paper is to present a case with COVID-like pneumonia, with fatal evolution. The clinical aspects were correlated with the autopsy findings and discussed on the background of the most recent data from the medical literature. A 13-month-old girl was admitted to the emergency room with acute severe shortness of breath and pulmonary bilateral ground-glass opacities and an almost complete opacified left lung. The patient suddenly deteriorated, and death was confirmed 3 h after admission. At autopsy, severe desquamative interstitial pneumonia was diagnosed and was associated with an unusual IgA glomerulonephritis. No SARS-CoV-2 infection was detected in the lung parenchyma by RT- PCR. This is a very unusual case of rapid deterioration of an infant with idiopathic desquamative interstitial pneumonia (IDP) and multiorgan involvement. Based on immunohistochemical stains, we hypothesize that, in IDP, the hyaline membranes arise from necrotizing desquamated pneumocytes. In the COVID-19 era, such cases are extremely difficult to diagnose; they can mimic SARS-CoV-2-induced lung injuries. This pattern of hyaline membrane formation might explain the poor response to oxygen therapy. The present case highlights the importance of autopsy in such challenging cases.
C1 [Gurzu, Simona; Satala, Catalin Bogdan; Jung, Ioan] George Emil Palade Univ Med Pharm Sci & Technol, Dept Pathol, Targu Mures, Romania.
   [Gurzu, Simona; Satala, Catalin Bogdan] Clin Cty Emergency Hosp, Dept Pathol, Targu Mures, Romania.
   [Gurzu, Simona] Univ Med Pharm Sci & Technol, Dept Microscopy, Res Ctr, Targu Mures, Romania.
   [Melit, Lorena Elena; Capalna, Brandusa] Clin Cty Emergency Hosp, Dept Pediat, Targu Mures, Romania.
   [Melit, Lorena Elena] George Emil Palade Univ Med Pharm Sci & Technol, Dept Pediat, Targu Mures, Romania.
   [Streinu-Cercel, Adrian; Otelea, Dan] Natl Inst Infect Dis Matei Bals, Bucharest, Romania.
   [Puiac, Claudiu Ioan; Szederjesi, Janos] George Emil Palade Univ Med Pharm Sci & Technol, Dept Intens Care, Targu Mures, Romania.
RP Gurzu, S (corresponding author), George Emil Palade Univ Med Pharm Sci & Technol, Dept Pathol, Targu Mures, Romania.; Gurzu, S (corresponding author), Clin Cty Emergency Hosp, Dept Pathol, Targu Mures, Romania.; Gurzu, S (corresponding author), Univ Med Pharm Sci & Technol, Dept Microscopy, Res Ctr, Targu Mures, Romania.
EM simonagurzu@yahoo.com
CR Aguiar D, 2020, INT J LEGAL MED, V134, P1271, DOI 10.1007/s00414-020-02318-9
   Balasubramanian S, 2020, INDIAN PEDIATR, V57, P435, DOI 10.1007/s13312-020-1819-5
   Bressieux-Degueldre Sabrina, 2014, BMC Res Notes, V7, P383, DOI 10.1186/1756-0500-7-383
   Brodin P, 2020, ACTA PAEDIATR, V109, P1082, DOI 10.1111/apa.15271
   Cai JH, 2020, CLIN INFECT DIS, V71, P1547, DOI 10.1093/cid/ciaa198
   Clement A, 2010, ORPHANET J RARE DIS, V5, DOI 10.1186/1750-1172-5-22
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Gurzu S, 2011, KOREAN J PATHOL, V45, P139, DOI 10.4132/KoreanJPathol.2011.45.2.139
   Hellemons ME, 2020, EUR RESPIR REV, V29, DOI 10.1183/16000617.0181-2019
   Henry BM, 2020, CLIN CHEM LAB MED, V58, P1135, DOI 10.1515/cclm-2020-0272
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1088, DOI 10.1111/apa.15270
   Nickbakhsh S, 2019, P NATL ACAD SCI USA, V116, P27142, DOI 10.1073/pnas.1911083116
   Ramcharan T, 2020, PEDIATR CARDIOL, V41, P1391, DOI 10.1007/s00246-020-02391-2
   Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]
   Royal College of Paediatrics and Child Health, RCPCH GUID PAED MULT
   SHETH KJ, 1992, CHILD NEPHROL UROL, V12, P43
   Simon AK, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.3085
   Vece TJ, 2010, PEDIAT ALLER IMM PUL, V23, P33, DOI 10.1089/ped.2010.0008
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
NR 20
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-2360
J9 FRONT PEDIATR
JI Front. Pediatr.
PD NOV 11
PY 2020
VL 8
AR 586666
DI 10.3389/fped.2020.586666
PG 8
WC Pediatrics
SC Pediatrics
GA OV0GN
UT WOS:000591899700001
PM 33262964
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Uniyal, A
   Mahapatra, MK
   Tiwari, V
   Sandhir, R
   Kumar, R
AF Uniyal, Ankit
   Mahapatra, Manoj Kumar
   Tiwari, Vinod
   Sandhir, Rajat
   Kumar, Rajnish
TI Targeting SARS-CoV-2 main protease: structure based virtual screening,
   in silico ADMET studies and molecular dynamics simulation for
   identification of potential inhibitors
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Virtual screening; hit identification; SARS-COV-2; main protease; in
   silico ADME; molecular dynamics; anti-viral
ID DOCKING; DISCOVERY; GLIDE
AB COVID-19 pandemic has created a healthcare crisis across the world and has put human life under life-threatening circumstances. The recent discovery of the crystallized structure of the main protease (M-pro) from SARS-CoV-2 has provided an opportunity for utilizing computational tools as an effective method for drug discovery. Targeting viral replication has remained an effective strategy for drug development. M-pro of SARS-COV-2 is the key protein in viral replication as it is involved in the processing of polyproteins to various structural and nonstructural proteins. Thus, M-pro represents a key target for the inhibition of viral replication specifically for SARS-CoV-2. We have used a virtual screening strategy by targeting M-pro against a library of commercially available compounds to identify potential inhibitors. After initial identification of hits by molecular docking-based virtual screening further MM/GBSA, predictive ADME analysis, and molecular dynamics simulation were performed. The virtual screening resulted in the identification of twenty-five top scoring structurally diverse hits that have free energy of binding (Delta G) values in the range of -26-06 (for compound AO-854/10413043) to -59.81 Kcal/mol (for compound 329/06315047). Moreover, the top-scoring hits have favorable AMDE properties as calculated using in silico algorithms. Additionally, the molecular dynamics simulation revealed the stable nature of protein-ligand interaction and provided information about the amino acid residues involved in binding. Overall, this study led to the identification of potential SARS-CoV-2 M-pro hit compounds with favorable pharmacokinetic properties. We believe that the outcome of this study can help to develop novel M-pro inhibitors to tackle this pandemic.
   Communicated by Ramaswamy H. Sarma
C1 [Uniyal, Ankit; Tiwari, Vinod; Kumar, Rajnish] Indian Inst Technol BHU, Dept Pharmaceut Engn & Technol, Varanasi 221005, Uttar Pradesh, India.
   [Mahapatra, Manoj Kumar] Kanak Manjari Inst Pharmaceut Sci, Rourkela, India.
   [Sandhir, Rajat] Panjab Univ, Dept Biochem, Chandigarh, India.
RP Kumar, R (corresponding author), Indian Inst Technol BHU, Dept Pharmaceut Engn & Technol, Varanasi 221005, Uttar Pradesh, India.
EM rajnish.phe@iitbhu.ac.in
RI Kumar, Rajnish/C-9316-2015
OI Kumar, Rajnish/0000-0002-7021-6996
FU Indian Institute of Technology (BHU)
FX Indian Institute of Technology (BHU)10.13039/501100002742The work is
   supported by seed grant from Indian Institute of Technology (BHU)
   awarded to RK.
CR Adeshina YO, 2020, P NATL ACAD SCI USA, V117, P18477, DOI 10.1073/pnas.2000585117
   Alavijeh MS, 2004, IDRUGS, V7, P755
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Bowers K., 2006, P 2006 ACM IEEE C SU, P43, DOI [DOI 10.1109/SC.2006.54, 10.1109/SC.2006.54]
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Dill KA, 1997, J BIOL CHEM, V272, P701, DOI 10.1074/jbc.272.2.701
   Du X, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020144
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Goyal B, 2020, ACS COMB SCI, V22, P297, DOI 10.1021/acscombsci.0c00058
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Jacobson MP, 2002, J MOL BIOL, V320, P597, DOI 10.1016/S0022-2836(02)00470-9
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001
   Kim Y, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005531
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Lyne PD, 2006, J MED CHEM, V49, P4805, DOI 10.1021/jm060522a
   Lyu J, 2019, NATURE, V566, P224, DOI 10.1038/s41586-019-0917-9
   Main protease structure and XChem fragment screen, 2020, MAIN PROTEASE STRUCT
   MARTYNA GJ, 1994, J CHEM PHYS, V101, P4177, DOI 10.1063/1.467468
   Ren ZL, 2013, PROTEIN CELL, V4, P248, DOI 10.1007/s13238-013-2841-3
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Schrodinger Release 2020-3, 2020, SCHROD REL 2020 3
   Schrodinger Release 2020-3, 2020, SCHRO REL 2020 3
   Ullrich S, 2020, BIOORG MED CHEM LETT, V30, DOI 10.1016/j.bmcl.2020.127377
   Weekly epidemiological update, 2020, WEEKLY EPIDEMIOLOGIC
   Yadav A, 2016, J BIOMOL STRUCT DYN, V34, P993, DOI 10.1080/07391102.2015.1064830
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 30
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1848636
EA NOV 2020
PG 17
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OU4FA
UT WOS:000591484000001
PM 33226303
OA Bronze
DA 2021-01-01
ER

PT J
AU Koblischke, M
   Traugott, MT
   Medits, I
   Spitzer, FS
   Zoufaly, A
   Weseslindtner, L
   Simonitsch, C
   Seitz, T
   Hoepler, W
   Puchhammer-Stockl, E
   Aberle, SW
   Fodinger, M
   Bergthaler, A
   Kundi, M
   Heinz, FX
   Stiasny, K
   Aberle, JH
AF Koblischke, Maximilian
   Traugott, Marianna T.
   Medits, Iris
   Spitzer, Felicia S.
   Zoufaly, Alexander
   Weseslindtner, Lukas
   Simonitsch, Cara
   Seitz, Tamara
   Hoepler, Wolfgang
   Puchhammer-Stoeckl, Elisabeth
   Aberle, Stephan W.
   Foedinger, Manuela
   Bergthaler, Andreas
   Kundi, Michael
   Heinz, Franz X.
   Stiasny, Karin
   Aberle, Judith H.
TI Dynamics of CD4 T Cell and Antibody Responses in COVID-19 Patients With
   Different Disease Severity
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE SARS-CoV-2; COVID-19 patients; adaptive immunity; SARS-CoV-2-specific
   antibodies; SARS-CoV-2-specific T cells
ID PATHOGENESIS; INFECTION
AB Disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ranges from mild illness to severe respiratory disease and death. In this study, we determined the kinetics of viral loads, antibody responses (IgM, IgG, neutralization) and SARS-CoV-2-specific CD4 T cells by quantifying these parameters in 435 serial respiratory and blood samples collected from a cohort of 29 COVID-19 patients with either moderate or severe disease during the whole period of hospitalization or until death. Remarkably, there was no significant difference in the kinetics and plateau levels of neutralizing antibodies among the groups with different disease severity. In contrast, the dynamics of specific CD4 T cell responses differed considerably, but all patients with moderate or severe disease developed robust SARS-CoV-2-specific responses. Of note, none of the patients had detectable cross-reactive CD4 T cells in the first week after symptom onset, which have been described in 20-50% of unexposed individuals. Our data thus provide novel insights into the kinetics of antibody and CD4 T cell responses as well as viral loads that are key to understanding the role of adaptive immunity in combating the virus during acute infection and provide leads for the timing of immune therapies for COVID-19.
C1 [Koblischke, Maximilian; Medits, Iris; Spitzer, Felicia S.; Weseslindtner, Lukas; Simonitsch, Cara; Puchhammer-Stoeckl, Elisabeth; Aberle, Stephan W.; Heinz, Franz X.; Stiasny, Karin; Aberle, Judith H.] Med Univ Vienna, Ctr Virol, Vienna, Austria.
   [Traugott, Marianna T.; Zoufaly, Alexander; Seitz, Tamara; Hoepler, Wolfgang] Vienna Healthcare Grp, Clin Favoriten, Dept Med 4, Vienna, Austria.
   [Foedinger, Manuela] Vienna Healthcare Grp, Clin Favoriten, Inst Lab Diagnost, Vienna, Austria.
   [Foedinger, Manuela] Sigmund Freud Private Univ, Med Fac, Vienna, Austria.
   [Bergthaler, Andreas] Austrian Acad Sci, Res Ctr Mol Med, Vienna, Austria.
   [Kundi, Michael] Med Univ Vienna, Ctr Publ Hlth, Vienna, Austria.
RP Stiasny, K; Aberle, JH (corresponding author), Med Univ Vienna, Ctr Virol, Vienna, Austria.
EM karin.stiasny@meduniwien.ac.at; judith.aberle@meduniwien.ac.at
RI Bergthaler, Andreas/ABG-5047-2020
OI Bergthaler, Andreas/0000-0003-0597-1976; Weseslindtner,
   Lukas/0000-0001-8950-937X; Hoepler, Wolfgang/0000-0003-2653-3844
FU Medical-Scientific fund of the Mayor of the federal capital Vienna
   [Covid003]
FX This work was supported by the Medical-Scientific fund of the Mayor of
   the federal capital Vienna [grant Covid003].
CR Abraham J, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0365-7
   Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309
   Bar-On YM, 2020, ELIFE, V9, DOI 10.7554/eLife.57309
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Ciceri F, 2020, CLIN IMMUNOL, V217, DOI 10.1016/j.clim.2020.108509
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Crotty S, 2019, IMMUNITY, V50, P1132, DOI 10.1016/j.immuni.2019.04.011
   Deng W, 2020, SCIENCE, V369, P818, DOI 10.1126/science.abc5343
   Ding YQ, 2004, J PATHOL, V203, P622, DOI 10.1002/path.1560
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   John ALS, 2020, J IMMUNOL, V205, P555, DOI 10.4049/jimmunol.2000526
   Koblischke M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01196
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Perera Ranawaka Apm, 2020, Euro Surveill, V25, DOI 10.2807/1560-7917.ES.2020.25.16.2000421
   Premkumar L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc8413
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520
   Schwaiger J, 2014, J VIROL, V88, P7828, DOI 10.1128/JVI.00196-14
   Sette A, 2020, NAT REV IMMUNOL, V20, P457, DOI 10.1038/s41577-020-0389-z
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang PF, 2020, EMERG MICROBES INFEC, V9, P2091, DOI 10.1080/22221751.2020.1823890
   Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071
   Wilkinson TM, 2012, NAT MED, V18, P274, DOI 10.1038/nm.2612
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Zhao JC, 2016, IMMUNITY, V44, P1379, DOI 10.1016/j.immuni.2016.05.006
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 36
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD NOV 11
PY 2020
VL 7
AR 592629
DI 10.3389/fmed.2020.592629
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA OV3FC
UT WOS:000592099300001
PM 33262993
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cimolai, N
AF Cimolai, Nevio
TI Complicating Infections Associated with Common Endemic Human Respiratory
   Coronaviruses
SO HEALTH SECURITY
LA English
DT Article; Early Access
DE COVID-19; Coronavirus; SARS; Epidemiology; Infectious diseases;
   Pneumonia
ID CELL TRANSPLANT RECIPIENTS; ACUTE OTITIS-MEDIA; HOSPITALIZED CHILDREN;
   TRACT INFECTIONS; VIRAL-INFECTIONS; CLINICAL CHARACTERISTICS;
   INTENSIVE-CARE; YOUNG-CHILDREN; SEROEPIDEMIOLOGIC SURVEY; SEASONAL
   CORONAVIRUSES
AB Coronaviruses OC43, 229E, NL63, and HKU1 are endemic human respiratory coronaviruses that typically cause mild to moderate upper respiratory infections, similar to the common cold. They also may cause simple and complicated lower respiratory infections, otitis media, asthma exacerbations, gastroenteritis, and a few systemic complications. These viruses are usually seasonal (with winter dominance) and affect nearly all age groups. The seasonal and annual variation in virus prevalence has implications for understanding the concept of acquired immunity and its persistence or diminution. Coronaviruses generally have outbreak potential in susceptible populations of any age, particularly in patients with comorbidities, who tend to have increased clinical disease. These 4 coronaviruses are often found in the context of what appears to be coinfection with other pathogens, but especially other viruses. If coronaviruses are not specifically tested for, the sole detection of a viral copathogen would suggest the pathogen is the causative agent, when a coronavirus may be culpable, or both. The detection of these viruses in circumstances where respiratory viruses are generally sought in clinical samples is, therefore, justified. These pathogens can be chronically shed from the respiratory tract, which is more likely to occur among immunocompromised and complicated patients. These viruses share the potential for genetic drift. The genome is among the largest of RNA viruses, and the capability of these viruses to further change is likely underestimated. Given the potential disease among humans, it is justified to search for effective antiviral chemotherapy for these viruses and to consider uses in niche situations should effective therapy be defined. Whereas SARS-CoV-2 may follow the epidemiological pattern of SARS-CoV and extinguish slowly over time, there is yet concern that SARS-CoV-2 may establish itself as an endemic human respiratory coronavirus similar to OC43, 2299E, NL63, and HKU1. Until sufficient data are acquired to better understand the potential of SARS-CoV-2, continued work on antiviral therapy and vaccination is imperative.
C1 [Cimolai, Nevio] Univ British Columbia, Fac Med, Dept Pathol & Lab Med, Vancouver, BC, Canada.
   [Cimolai, Nevio] Childrens & Womens Hlth Ctr British Columbia, Pathol & Lab Med, Vancouver, BC, Canada.
RP Cimolai, N (corresponding author), Univ British Columbia, Fac Med, Dept Pathol & Lab Med, Vancouver, BC, Canada.
EM ncimolai@mail.ubc.ca
CR Amer HM, 2016, J MED VIROL, V88, P1086, DOI 10.1002/jmv.24435
   Anastasiou OE, 2020, J MED VIROL, DOI 10.1002/jmv.26477
   Anthony SJ, 2017, VIRUS EVOL, V3, DOI 10.1093/ve/vex012
   Arden KE, 2005, J MED VIROL, V75, P455, DOI 10.1002/jmv.20288
   AROLA M, 1990, PEDIATRICS, V86, P848
   Atmar RL, 1998, ARCH INTERN MED, V158, P2453, DOI 10.1001/archinte.158.22.2453
   Aygun D, 2020, TURK PEDIATR ARSIVI, V55, P166, DOI 10.14744/TurkPediatriArs.2020.39114
   Bastien N, 2005, J CLIN MICROBIOL, V43, P4567, DOI 10.1128/JCM.43.9.4567-4573.2005
   Bastien N, 2005, J INFECT DIS, V191, P503, DOI 10.1086/426869
   Berce V, 2015, WIEN KLIN WOCHENSCHR, V127, pS255, DOI 10.1007/s00508-015-0843-2
   Berkley JA, 2010, JAMA-J AM MED ASSOC, V303, P2051, DOI 10.1001/jama.2010.675
   Beury D, 2020, J CLIN VIROL, V122, DOI 10.1016/j.jcv.2019.104206
   BIANCHI F, 2020, J ASTHMA 0502, DOI DOI 10.1080/02772903.2020.1761981
   Bouvier M, 2018, INFLUENZA OTHER RESP, V12, P299, DOI 10.1111/irv.12538
   Bridevaux PO, 2014, THORAX, V69, P32, DOI 10.1136/thoraxjnl-2013-203581
   Brini I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188325
   BUCKNALL RA, 1972, P SOC EXP BIOL MED, V139, P722
   Bulut Y, 2007, EUR J PEDIATR, V166, P223, DOI 10.1007/s00431-006-0233-x
   Byington CL, 2015, CLIN INFECT DIS, V61, P1217, DOI 10.1093/cid/civ486
   Cabeca TK, 2013, INFLUENZA OTHER RESP, V7, P1040, DOI 10.1111/irv.12101
   Cabeca TK, 2013, BRAZ J MICROBIOL, V44, P335, DOI 10.1590/S1517-83822013000100049
   CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019
   Calvo C, 2020, PEDIATR INFECT DIS J, V39, P653, DOI 10.1097/INF.0000000000002760
   Castillo EM, 2020, J AM COLL EMERG PHYS, V1, P592
   Cebey-Lopez M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136526
   Chang TY, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000021520
   Cheng ZKJ, 2020, INFECTION, V48, P155, DOI 10.1007/s15010-020-01401-y
   Choi EH, 2006, CLIN INFECT DIS, V43, P585, DOI 10.1086/506350
   Chonmaitree T, 2008, CLIN INFECT DIS, V46, P815, DOI 10.1086/528685
   Chung JY, 2007, J MED VIROL, V79, P1238, DOI 10.1002/jmv.20926
   Cimolai N, 2020, J MED VIROL, V92, P1834, DOI 10.1002/jmv.26066
   Corman VM, 2018, ADV VIRUS RES, V100, P163, DOI 10.1016/bs.aivir.2018.01.001
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Cummings Derek A T, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa900
   Davis BM, 2018, INFLUENZA OTHER RESP, V12, P582, DOI 10.1111/irv.12563
   De Rochars VMB, 2017, AM J TROP MED HYG, V96, P144, DOI [10.4269/ajtmh.16-0685, 10.4269/ajtmh.16-0585]
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Dijkman R, 2012, J CLIN VIROL, V53, P135, DOI 10.1016/j.jcv.2011.11.011
   Dominguez SR, 2009, J MED VIROL, V81, P1597, DOI 10.1002/jmv.21541
   Ebihara T, 2005, J MED VIROL, V75, P463, DOI 10.1002/jmv.20289
   El-Sahly HM, 2000, CLIN INFECT DIS, V31, P96, DOI 10.1086/313937
   EMANUELS A, 2020, INFLUENZA OTHER 0622, DOI DOI 10.111/irv.12775
   Esper F, 2006, EMERG INFECT DIS, V12, P775, DOI 10.3201/eid1205.051316
   Esper F, 2005, J INFECT DIS, V191, P492, DOI 10.1086/428138
   Esposito S, 2006, J MED VIROL, V78, P1609, DOI 10.1002/jmv.20745
   Fairchok MP, 2010, J CLIN VIROL, V49, P16, DOI 10.1016/j.jcv.2010.06.013
   FALSEY AR, 1995, J AM GERIATR SOC, V43, P30, DOI 10.1111/j.1532-5415.1995.tb06238.x
   Falsey AR, 2002, J INFECT DIS, V185, P1338, DOI 10.1086/339881
   Falsey AR, 1997, J AM GERIATR SOC, V45, P706, DOI 10.1111/j.1532-5415.1997.tb01474.x
   Fisher BT, 2018, J PEDIAT INF DIS SOC, V7, P275, DOI 10.1093/jpids/pix051
   Folz RJ, 1999, CHEST, V115, P901, DOI 10.1378/chest.115.3.901
   Freymuth F, 1999, J CLIN VIROL, V13, P131, DOI 10.1016/S1386-6532(99)00030-X
   Gagneur A, 2002, J HOSP INFECT, V51, P59, DOI 10.1053/jhin.2002.1179
   Galanti Marta, 2020, J Infect Dis, DOI 10.1093/infdis/jiaa392
   Gerna G, 2006, J MED VIROL, V78, P938, DOI 10.1002/jmv.20645
   Gerna G, 2007, J CLIN VIROL, V38, P244, DOI 10.1016/j.jcv.2006.12.008
   Gilca Rodica, 2020, J Infect Dis, DOI 10.1093/infdis/jiaa477
   GIUDICELLI J, 1995, ARCH PEDIATRIE, V2, P185, DOI 10.1016/0929-693X(95)90150-2
   da Veiga ABG, 2020, J MED VIROL, DOI 10.1002/jmv.26362
   Gorse GJ, 2009, J INFECT DIS, V199, P847, DOI 10.1086/597122
   Hakki M, 2015, J CLIN VIROL, V68, P1, DOI 10.1016/j.jcv.2015.04.012
   Han TH, 2007, J CLIN VIROL, V38, P27, DOI 10.1016/j.jcv.2006.10.009
   Hand J, 2018, EMERG INFECT DIS, V24, P1964, DOI 10.3201/eid2410.180862
   Heimdal I, 2019, J INFECT DIS, V219, P1198, DOI 10.1093/infdis/jiy646
   Heugel J, 2007, PEDIATR INFECT DIS J, V26, P753, DOI 10.1097/INF.0b013e318054e31b
   Hu Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100781
   Huang SH, 2017, J MICROBIOL IMMUNOL, V50, P763, DOI 10.1016/j.jmii.2015.10.008
   Ieven M, 2018, CLIN MICROBIOL INFEC, V24, P1158, DOI 10.1016/j.cmi.2018.02.004
   ISAACS D, 1983, ARCH DIS CHILD, V58, P500, DOI 10.1136/adc.58.7.500
   Jean A, 2013, PEDIATR INFECT DIS J, V32, P325, DOI 10.1097/INF.0b013e3182812787
   Jevsnik M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155555
   Jevsnik M, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-365
   JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225
   Johnstone J, 2008, CHEST, V134, P1141, DOI 10.1378/chest.08-0888
   Kaiser L, 2005, PEDIATR INFECT DIS J, V24, P1015, DOI 10.1097/01.inf.0000183773.80217.12
   Kakuya Fujio, 2020, Jpn J Infect Dis, V73, P377, DOI 10.7883/yoken.JJID.2020.181
   Kamau E, 2019, MICROBIOL RESOUR ANN, V8, DOI 10.1128/MRA.00730-19
   Kanwar A, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx052
   Kapikian AZ., 1974, DEV BIOL STAND, V28, P42
   Kapur N, 2014, ARCH DIS CHILD, V99, P749, DOI 10.1136/archdischild-2013-305147
   KAYE HS, 1971, AM J EPIDEMIOL, V94, P43, DOI 10.1093/oxfordjournals.aje.a121293
   KAYE HS, 1975, AM J EPIDEMIOL, V101, P238, DOI 10.1093/oxfordjournals.aje.a112091
   Kenmoe S, 2016, INFLUENZA OTHER RESP, V10, P386, DOI 10.1111/irv.12391
   Kherad O, 2010, CHEST, V138, P896, DOI 10.1378/chest.09-2225
   Killerby ME, 2018, J CLIN VIROL, V101, P52, DOI 10.1016/j.jcv.2018.01.019
   Kim JM, 2020, J MICROBIOL BIOTECHN, V30, P1495, DOI 10.4014/jmb.2004.04052
   Kim KY, 2017, YONSEI MED J, V58, P174, DOI 10.3349/ymj.2017.58.1.174
   Kim Y-J, 2019, INFECT DIS LOND, V51, P522
   Kin N, 2015, VIRUSES-BASEL, V7, P2358, DOI 10.3390/v7052358
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Kiyuka PK, 2018, J INFECT DIS, V217, P1728, DOI 10.1093/infdis/jiy098
   Ko FWS, 2007, CHEST, V132, P900, DOI 10.1378/chest.07-0530
   Korner RW, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12080880
   Koker SA, 2019, J PEDIAT HEMATOL ONC, V41, pE242, DOI 10.1097/MPH.0000000000001418
   Komabayashi K, 2020, JPN J INFECT DIS, DOI [10.78883/yoken.JJID.2020.525, DOI 10.78883/YOKEN.JJID.2020.525]
   Komabayashi K, 2020, J MED VIROL, DOI 10.1002/jmv.26361
   Kozak R, 2020, J CLIN VIROL, V126, DOI 10.1016/j.jcv.2020.104338
   Kristoffersen AW, 2011, PEDIATR INFECT DIS J, V30, P279, DOI 10.1097/INF.0b013e3181fcb159
   Krvavac Armin, 2020, Mo Med, V117, P346
   Kumar D, 2005, AM J TRANSPLANT, V5, P2031, DOI 10.1111/j.1600-6143.2005.00971.x
   Kuypers J, 2007, PEDIATRICS, V119, pE70, DOI 10.1542/peds.2006-1406
   Kwak HJ, 2016, TOHOKU J EXP MED, V240, P131, DOI 10.1620/tjem.240.131
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Lau SKP, 2006, J CLIN MICROBIOL, V44, P2063, DOI 10.1128/JCM.02614-05
   Lee J, 2014, PEDIATR INFECT DIS J, V33, P814, DOI 10.1097/INF.0000000000000292
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Leung TF, 2009, J CLIN MICROBIOL, V47, P3486, DOI 10.1128/JCM.00832-09
   Li XC, 2018, J MED VIROL, V90, P828, DOI 10.1002/jmv.25040
   Li YT, 2019, J MED VIROL, V91, P1633, DOI 10.1002/jmv.25502
   Li Y, 2020, J INFECT DIS, V222, P1090, DOI 10.1093/infdis/jiaa436
   Li ZJ, 2019, ELIFE, V8, DOI 10.7554/eLife.51230
   Lina B, 1996, J CLIN MICROBIOL, V34, P3007, DOI 10.1128/JCM.34.12.3007-3011.1996
   Liu LL, 2016, VIROL SIN, V31, P94, DOI 10.1007/s12250-015-3687-z
   Pinana JL, 2018, BIOL BLOOD MARROW TR, V24, P563, DOI 10.1016/j.bbmt.2017.11.001
   Magnusson J, 2018, TRANSPLANT DIRECT, V4, DOI 10.1097/TXD.0000000000000808
   Martin ET, 2013, J INFECT DIS, V207, P982, DOI 10.1093/infdis/jis934
   Masse S, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12060630
   Matoba Y, 2018, JPN J INFECT DIS, V71, P167, DOI [10.7883/yoken.JJID.2017.263, 10.7883/yoken.jjid.2017.263]
   MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7
   MCINTOSH K, 1974, J INFECT DIS, V130, P502, DOI 10.1093/infdis/130.5.502
   Milano F, 2010, BLOOD, V115, P2088, DOI 10.1182/blood-2009-09-244152
   MONTO AS, 1974, J INFECT DIS, V129, P271, DOI 10.1093/infdis/129.3.271
   Morfopoulou S, 2016, NEW ENGL J MED, V375, P497, DOI 10.1056/NEJMc1509458
   MURRAY RS, 1992, VIROLOGY, V188, P274, DOI 10.1016/0042-6822(92)90757-G
   MURRAY RS, 1992, ANN NEUROL, V31, P525, DOI 10.1002/ana.410310511
   Naskalska A, 2019, J VIROL, V93, DOI 10.1128/JVI.00355-19
   NICHOLSON KG, 1990, EPIDEMIOL INFECT, V105, P609, DOI 10.1017/S0950268800048251
   Nickbakhsh S, 2020, J INFECT DIS, V222, P17, DOI 10.1093/infdis/jiaa185
   Nilsson A, 2020, INFECT DIS-NOR, V52, P419, DOI 10.1080/23744235.2020.1729403
   Ogimi C, 2019, J PEDIAT INF DIS SOC, V8, P21, DOI 10.1093/jpids/pix093
   Ogimi C, 2017, J INFECT DIS, V216, P203, DOI 10.1093/infdis/jix264
   Ogimi C, 2017, CLIN INFECT DIS, V64, P1532, DOI 10.1093/cid/cix160
   Oosterhof L, 2010, BONE MARROW TRANSPL, V45, P1115, DOI 10.1038/bmt.2009.292
   Patrick David M, 2006, Can J Infect Dis Med Microbiol, V17, P330
   Pene F, 2003, CLIN INFECT DIS, V37, P929, DOI 10.1086/377612
   Perlman S, 1998, ADV EXP MED BIOL, V440, P503
   Pinana Jose Luis, 2020, J Infect Dis, DOI 10.1093/infdis/jiaa553
   Pitkaranta A, 1998, J PEDIATR-US, V133, P390, DOI 10.1016/S0022-3476(98)70276-8
   Pitkaranta A, 1998, PEDIATRICS, V102, P291, DOI 10.1542/peds.102.2.291
   Po-Ca, 2020, ACTA VIROL, V64, P261, DOI 10.4149/av_2020_214
   Prill MM, 2012, PEDIATR INFECT DIS J, V31, P235, DOI 10.1097/INF.0b013e31823e07fe
   Rabenau HF, 2005, MED MICROBIOL IMMUN, V194, P1, DOI 10.1007/s00430-004-0219-0
   Rachow T, 2020, TRANSPL INFECT DIS, DOI 10.1111/tid.13415
   Reckziegel M, 2020, EUR J CLIN MICROBIOL, V39, P1581, DOI 10.1007/s10096-020-03878-9
   Reina J, 2014, REV CLIN ESP, V214, P499, DOI [10.1016/j.rce.2014.05.020, 10.1016/j.rceng.2014.05.003]
   RISKI H, 1980, J MED VIROL, V6, P259, DOI 10.1002/jmv.1890060309
   Schuster JE, 2020, PEDIATR TRANSPLANT, V24, DOI 10.1111/petr.13732
   Simon A, 2007, J PEDIAT HEMATOL ONC, V29, P432, DOI 10.1097/MPH.0b013e31806451c1
   Sippy R, 2020, PEDIATR INFECT DIS J, V39, pE291, DOI 10.1097/INF.0000000000002840
   SIZUN J, 1994, ARCH PEDIATRIE, V1, P477
   Skowronski Danuta M, 2020, Clin Infect Dis, V71, P2285, DOI 10.1093/cid/ciaa626
   Sloots TP, 2006, J CLIN VIROL, V35, P99, DOI 10.1016/j.jcv.2005.09.008
   Smuts H, 2008, INFLUENZA OTHER RESP, V2, P135, DOI 10.1111/j.1750-2659.2008.00049.x
   Smuts H, 2008, J MED VIROL, V80, P906, DOI 10.1002/jmv.21135
   Sonawane AA, 2019, INDIAN J PEDIATR, V86, P433, DOI 10.1007/s12098-018-2840-8
   Soudani N, 2019, J MED VIROL, V91, P1191, DOI 10.1002/jmv.25432
   STEWART JN, 1992, VIROLOGY, V191, P502, DOI 10.1016/0042-6822(92)90220-J
   Subramoney Kathleen, 2018, Health Sci Rep, V1, pe59, DOI 10.1002/hsr2.59
   Sung JY, 2010, PEDIATR INFECT DIS J, V29, P822, DOI [10.1097/INF.0b013e3181de9c2e, 10.1097/INF.0b013e3181e7c18d]
   Szczawinska-Poplonyk A, 2013, INFLUENZA OTHER RESP, V7, P634, DOI 10.1111/irv.12059
   Talbot HK, 2009, PEDIATR INFECT DIS J, V28, P682, DOI 10.1097/INF.0b013e31819d0d27
   Talbot HKB, 2009, J MED VIROL, V81, P853, DOI 10.1002/jmv.21443
   Theamboonlers A, 2007, INTERVIROLOGY, V50, P71, DOI 10.1159/000097392
   Toh TH, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz074
   Tortorici MA, 2019, NAT STRUCT MOL BIOL, V26, P481, DOI 10.1038/s41594-019-0233-y
   Trombetta H, 2016, PATHOG GLOB HEALTH, V110, P113, DOI 10.1080/20477724.2016.1181294
   Tsou P, 2020, ARCH PEDIATRIE, V27, P39, DOI 10.1016/j.arcped.2019.11.006
   Uddin SML, 2018, CLIN INFECT DIS, V67, P1507, DOI 10.1093/cid/ciy317
   UKKONEN P, 1984, J MED VIROL, V13, P131, DOI 10.1002/jmv.1890130204
   Vabret A, 2003, CLIN INFECT DIS, V36, P985, DOI 10.1086/374222
   Vabret A, 2006, CLIN INFECT DIS, V42, P634, DOI 10.1086/500136
   Vabret A, 2005, EMERG INFECT DIS, V11, P1225, DOI 10.3201/eid1108.050110
   Vabret A, 2008, J PAEDIATR CHILD H, V44, P176, DOI 10.1111/j.1440-1754.2007.01246.x
   van der Hoek L, 2005, PLOS MED, V2, P764, DOI 10.1371/journal.pmed.0020240
   van Elden LJR, 2004, J INFECT DIS, V189, P652, DOI 10.1086/381207
   van Rijn AL, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223952
   Vandroux D, 2018, MED MALADIES INFECT, V48, P141, DOI 10.1016/j.medmal.2018.01.001
   Varghese L, 2018, J PEDIAT INF DIS SOC, V7, P151, DOI 10.1093/jpids/pix027
   Vijgen L, 2005, VIROLOGY, V337, P85, DOI 10.1016/j.virol.2005.04.010
   Walsh EE, 2013, J INFECT DIS, V208, P1634, DOI 10.1093/infdis/jit393
   Walsh EE, 1999, AM J RESP CRIT CARE, V160, P791, DOI 10.1164/ajrccm.160.3.9901004
   Wang YQ, 2020, EMERG MICROBES INFEC, V9, P246, DOI 10.1080/22221751.2020.1717999
   Wansaula Z, 2016, INFLUENZA OTHER RESP, V10, P161, DOI 10.1111/irv.12360
   WENZEL RP, 1974, AM REV RESPIR DIS, V109, P621
   WISELKA MJ, 1993, EPIDEMIOL INFECT, V111, P337, DOI 10.1017/S0950268800057046
   Woo P C Y, 2009, Hong Kong Med J, V15 Suppl 9, P46
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Wu PS, 2008, EUR J PEDIATR, V167, P75, DOI 10.1007/s00431-007-0429-8
   Xin C, 2012, INDIAN PEDIATR, V49, P825, DOI 10.1007/s13312-012-0194-1
   Yeh EA, 2004, PEDIATRICS, V113, pE73, DOI 10.1542/peds.113.1.e73
   Zeng ZQ, 2018, EUR J CLIN MICROBIOL, V37, P363, DOI 10.1007/s10096-017-3144-z
NR 192
TC 0
Z9 0
U1 1
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2326-5094
EI 2326-5108
J9 HEALTH SECUR
JI Health Secur.
DI 10.1089/hs.2020.0067
EA NOV 2020
PG 14
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OT7UF
UT WOS:000591046300001
PM 33186086
OA Bronze
DA 2021-01-01
ER

PT J
AU DeKosky, ST
   Kochanek, PM
   Valadka, AB
   Clark, RSB
   Chou, SHY
   Au, AK
   Horvat, C
   Jha, RM
   Mannix, R
   Wisniewski, SR
   Wintermark, M
   Rowell, SE
   Welch, RD
   Lewis, L
   House, S
   Tanzi, RE
   Smith, DR
   Vittor, AY
   Denslow, ND
   Davis, MD
   Glushakova, OY
   Hayes, RL
AF DeKosky, Steven T.
   Kochanek, Patrick M.
   Valadka, Alex B.
   Clark, Robert S. B.
   Chou, Sherry H. -Y.
   Au, Alicia K.
   Horvat, Christopher
   Jha, Ruchira M.
   Mannix, Rebekah
   Wisniewski, Stephen R.
   Wintermark, Max
   Rowell, Susan E.
   Welch, Robert D.
   Lewis, Lawrence
   House, Stacey
   Tanzi, Rudolph E.
   Smith, Darci R.
   Vittor, Amy Y.
   Denslow, Nancy D.
   Davis, Michael D.
   Glushakova, Olena Y.
   Hayes, Ronald L.
TI Blood Biomarkers for Detection of Brain Injury in COVID-19 Patients
SO JOURNAL OF NEUROTRAUMA
LA English
DT Article; Early Access
DE blood biomarkers; CNS injury; COVID-19; GFAP; SARS-CoV-2; UCH-L1
ID FIBRILLARY ACIDIC PROTEIN; NEURON-SPECIFIC ENOLASE; C-TERMINAL
   HYDROLASE-L1; ACUTE ISCHEMIC-STROKE; TARGETED TEMPERATURE MANAGEMENT;
   HOSPITAL CARDIAC-ARREST; CEREBROSPINAL-FLUID; INTRACEREBRAL HEMORRHAGE;
   PROGNOSTIC VALUE; SERUM-LEVELS
AB The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus attacks multiple organs of coronavirus disease 2019 (COVID-19) patients, including the brain. There are worldwide descriptions of neurological deficits in COVID-19 patients. Central nervous system (CNS) symptoms can be present early in the course of the disease. As many as 55% of hospitalized COVID-19 patients have been reported to have neurological disturbances three months after infection by SARS-CoV-2. The mutability of the SARS-COV-2 virus and its potential to directly affect the CNS highlight the urgency of developing technology to diagnose, manage, and treat brain injury in COVID-19 patients. The pathobiology of CNS infection by SARS-CoV-2 and the associated neurological sequelae of this infection remain poorly understood. In this review, we outline the rationale for the use of blood biomarkers (BBs) for diagnosis of brain injury in COVID-19 patients, the research needed to incorporate their use into clinical practice, and the improvements in patient management and outcomes that can result. BBs of brain injury could potentially provide tools for detection of brain injury in COVID-19 patients. Elevations of BBs have been reported in cerebrospinal fluid (CSF) and blood of COVID-19 patients. BB proteins have been analyzed in CSF to detect CNS involvement in patients with infectious diseases, including human immunodeficiency virus and tuberculous meningitis. BBs are approved by the U.S. Food and Drug Administration for diagnosis of mild versus moderate traumatic brain injury and have identified brain injury after stroke, cardiac arrest, hypoxia, and epilepsy. BBs, integrated with other diagnostic tools, could enhance understanding of viral mechanisms of brain injury, predict severity of neurological deficits, guide triage of patients and assignment to appropriate medical pathways, and assess efficacy of therapeutic interventions in COVID-19 patients.
C1 [DeKosky, Steven T.] Univ Florida, Coll Med, McKnight Brain Inst, Gainesville, FL USA.
   [Kochanek, Patrick M.] Univ Pittsburgh, Dept Anesthesiol Pediat Bioengn & Clin & Translat, Dept Crit Care Med, Safar Ctr Resuscitat Res,Sch Med,UPMC Childrens H, Pittsburgh, PA USA.
   [Valadka, Alex B.] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA.
   [Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA.
   [Chou, Sherry H. -Y.] Univ Pittsburgh, Dept Crit Care Med Neurol & Neurosurg, Pittsburgh, PA USA.
   [Au, Alicia K.] Univ Pittsburgh, UPMC Childrens Hosp Pittsburgh, Pittsburgh, PA USA.
   [Horvat, Christopher] Univ Pittsburgh, UPMC Childrens Hosp Pittsburgh, Div Pediat Crit Care, Dept Crit Care Med,Sch Med, Pittsburgh, PA USA.
   [Jha, Ruchira M.] Univ Pittsburgh, Dept Crit Med, Clin & Translat Sci Inst, Safar Ctr Resuscitat Res, Pittsburgh, PA USA.
   [Jha, Ruchira M.] Univ Pittsburgh, Dept Neurol, Clin & Translat Sci Inst, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA.
   [Jha, Ruchira M.] Univ Pittsburgh, Dept Neurol Surg, Clin & Translat Sci Inst, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA.
   [Mannix, Rebekah] Harvard Med Sch, Boston Childrens Hosp, Div Emergency Med, Dept Pediat & Emergency Med,Dept Med, Boston, MA 02115 USA.
   [Wisniewski, Stephen R.] Univ Pittsburgh, Pittsburgh, PA USA.
   [Wintermark, Max] Stanford Univ, Dept Neuroradiol, Stanford, CA 94305 USA.
   [Rowell, Susan E.] Duke Univ, Sch Med, Durham, NC USA.
   [Welch, Robert D.] Wayne State Univ, Sch Med, Dept Emergency Med, Detroit Receiving Hosp,Univ Hlth Ctr, Detroit, MI USA.
   [Lewis, Lawrence] Washington Univ, Dept Emergency Med, St Louis, MO 63110 USA.
   [House, Stacey] Washington Univ, Sch Med, Dept Emergency Med, St Louis, MO USA.
   [Tanzi, Rudolph E.] Harvard Med Sch, Massachusetts Gen Hosp, Genet & Aging Res Unit,Dept Neurol Res,Dept Neuro, McCance Ctr Brain Hlth,Mass Gen Inst Neurodegener, Charlestown, MA USA.
   [Smith, Darci R.] US Navy, Immunodiagnost Dept, Med Res Ctr, Biol Def Res Directorate, Ft Detrick, MD USA.
   [Vittor, Amy Y.] Univ Florida, Emerging Pathogens Inst, Div Infect Dis & Global Med, Gainesville, FL USA.
   [Denslow, Nancy D.] Univ Florida, Dept Physiol Sci, Ctr Environm & Human Toxicol, Gainesville, FL 32610 USA.
   [Denslow, Nancy D.] Univ Florida, Dept Biochem & Mol Biol, Ctr Environm & Human Toxicol, Gainesville, FL 32610 USA.
   [Davis, Michael D.] Indiana Univ, Riley Hosp Children, Dept Pediat, Wells Ctr Pediat Res Pulmonol Allergy & Sleep Med, Indianapolis, IN 46204 USA.
   [Glushakova, Olena Y.] Univ Virginia, Canc Ctr, Charlottesville, VA 22908 USA.
   [Hayes, Ronald L.] Banyan Biomarkers Inc, 13400 Progress Blvd, Alachua, FL 32615 USA.
RP Hayes, RL (corresponding author), Banyan Biomarkers Inc, 13400 Progress Blvd, Alachua, FL 32615 USA.
EM rhayes@banyanbio.com
FU National Institutes of Health (NIH)/National Heart, Lung, and Blood
   Institute (NHLBI)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [P01 HL128192]; Indiana Clinical and
   Translational Sciences Institute; Lilly Endowment; Riley Children's
   Foundation; Eunice Kennedy Shriver National Institute of Child Health
   and Human Development (NICHD)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [1K23HD099331-01A1]; NIH/National Institute of Neurological Disorders
   and Stroke (NINDS)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Neurological Disorders & Stroke (NINDS) [K23101036]; Chuck Noll
   Foundation; Dean's Faculty Award
FX Michael D. Davis is funded by the National Institutes of Health
   (NIH)/National Heart, Lung, and Blood Institute (NHLBI; P01 HL128192),
   the Indiana Clinical and Translational Sciences Institute, the Lilly
   Endowment, and the Riley Children's Foundation. Christopher M. Horvat is
   funded by the Eunice Kennedy Shriver National Institute of Child Health
   and Human Development (NICHD; 1K23HD099331-01A1). Ruchira M. Jha
   receives grant funding from the NIH/National Institute of Neurological
   Disorders and Stroke (NINDS; K23101036), Chuck Noll Foundation, and
   Dean's Faculty Award.
CR Abdel-Mannan O, 2020, JAMA NEUROL, V77, P1440, DOI 10.1001/jamaneurol.2020.2687
   Abdi Siamak, 2020, J Neurol Sci, V416, P117001, DOI 10.1016/j.jns.2020.117001
   Abdulle S, 2007, J NEUROL, V254, P1026, DOI 10.1007/s00415-006-0481-8
   Abiodun OA, 2020, SAUDI J BIOL SCI, V27, P905, DOI 10.1016/j.sjbs.2020.01.026
   Abo-Elwafa H.A., 2019, NEUROSCI MED, V10, P1
   Aboughdir M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050527
   Afshar H, 2020, MULT SCLER RELAT DIS, V43, DOI 10.1016/j.msard.2020.102216
   Al Saiegh F, 2020, J NEUROL NEUROSUR PS, V91, P846, DOI 10.1136/jnnp-2020-323522
   Al-olama M, 2020, ACTA NEUROCHIR, V162, P1495, DOI 10.1007/s00701-020-04402-w
   Alatas OD, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002007
   Alcamo AM, 2020, PEDIATR CRIT CARE ME, V21, P804, DOI 10.1097/PCC.0000000000002355
   Almqvist J, 2020, ANN CLIN TRANSL NEUR, V7, P2057, DOI 10.1002/acn3.51166
   Ameres M, 2020, J NEUROL, V267, P3476, DOI 10.1007/s00415-020-10050-y
   Anderson AM, 2018, J NEUROVIROL, V24, P695, DOI 10.1007/s13365-018-0664-y
   Anderson TN, 2020, J TRAUMA ACUTE CARE, V89, P80, DOI 10.1097/TA.0000000000002706
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Armah HB, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-147
   Asken BM, 2020, J NEUROTRAUM, V37, P1537, DOI 10.1089/neu.2019.6831
   Au AK, 2018, NEUROCRIT CARE, V28, P26, DOI 10.1007/s12028-017-0414-7
   Avula A, 2020, BRAIN BEHAV IMMUN, V87, P115, DOI 10.1016/j.bbi.2020.04.077
   Bai L., 2018, NEUROTRAUMA, P189
   Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Bailey DM, 2011, EXP PHYSIOL, V96, P1196, DOI 10.1113/expphysiol.2011.060178
   Balloy Gaelle, 2020, Clin Neurophysiol, V131, P2059, DOI 10.1016/j.clinph.2020.05.005
   Barnkob MB, 2020, BLOOD ADV, V4, P4990, DOI 10.1182/bloodadvances.2020002657
   Barrios-Lopez JM, 2020, NEUROLOGIA, V35, P295, DOI 10.1016/j.nrl.2020.05.002
   Bastard P., 2020, SCIENCE, V370, peabd4585
   Baz-Martinez M, 2016, SCI REP-UK, V6, DOI 10.1038/srep37007
   Bazarian JJ, 2018, LANCET NEUROL, V17, P782, DOI 10.1016/S1474-4422(18)30231-X
   Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087
   Bembea MM, 2015, CRIT CARE MED, V43, P2202, DOI 10.1097/CCM.0000000000001145
   Bembea MM, 2011, PEDIATR CRIT CARE ME, V12, P572, DOI 10.1097/PCC.0b013e3181fe3ec7
   Benameur K, 2020, EMERG INFECT DIS, V26, P2016, DOI 10.3201/eid2609.202122
   Bernard-Valnet R, 2020, EUR J NEUROL, V27, pE43, DOI 10.1111/ene.14298
   Bharosay A, 2012, INDIAN J CLIN BIOCHE, V27, P186, DOI 10.1007/s12291-011-0172-9
   Bi XJ, 2020, PLATELETS, V31, P674, DOI 10.1080/09537104.2020.1760230
   Bianchetti A, 2020, J NUTR HEALTH AGING, V24, P560, DOI 10.1007/s12603-020-1389-1
   Bielewicz J, 2011, J MOL NEUROSCI, V43, P241, DOI 10.1007/s12031-010-9403-4
   Blennow K, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.84
   Bodro M, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000821
   Bogoslovsky T, 2017, J NEUROTRAUM, V34, P66, DOI 10.1089/neu.2015.4333
   Bohmwald K, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00386
   Boscolo-Rizzo P, 2020, JAMA OTOLARYNGOL, V146, P729, DOI 10.1001/jamaoto.2020.1379
   Bouvier D, 2012, CLIN CHEM, V58, P1116, DOI 10.1373/clinchem.2011.180828
   Bradshaw MJ, 2016, NEUROTHERAPEUTICS, V13, P493, DOI 10.1007/s13311-016-0433-7
   Brann DH, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc5801
   Ferreira MLB, 2020, LANCET NEUROL, V19, P826, DOI 10.1016/S1474-4422(20)30232-5
   Bruggemann R, 2020, THROMB RES, V191, P153, DOI 10.1016/j.thromres.2020.04.046
   Butowt R, 2020, ACS CHEM NEUROSCI, V11, P1200, DOI 10.1021/acschemneuro.0c00172
   Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961
   Callaway CW, 2015, CIRCULATION, V132, pS465, DOI 10.1161/CIR.0000000000000262
   Can S, 2015, PAK J MED SCI, V31, P1110, DOI 10.12669/pjms.315.7702
   Carfi A, 2020, JAMA-J AM MED ASSOC, V324, P603, DOI 10.1001/jama.2020.12603
   Cariddi LP, 2020, J NEUROL, V267, P3157, DOI 10.1007/s00415-020-10001-7
   Carpenter AM, 2016, NAT REV NEUROL, V12, DOI 10.1038/nrneurol.2015.226
   Carrabba G, 2020, LANCET, V395, pE76, DOI 10.1016/S0140-6736(20)30927-2
   Carroll E, 2020, NEUROCRIT CARE, DOI 10.1007/s12028-020-00993-5
   Chachkhiani D, 2020, CLIN NEUROL NEUROSUR, V197, DOI 10.1016/j.clineuro.2020.106173
   Chen Hui, 2019, J Neuroradiol, DOI 10.1016/j.neurad.2019.07.002
   Chen MF, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01948-2020
   Chen W, 2020, SEIZURE-EUR J EPILEP, V81, P198, DOI 10.1016/j.seizure.2020.08.022
   Ciancanelli MJ, 2015, SCIENCE, V348, P448, DOI 10.1126/science.aaa1578
   Co COC, 2020, J CLIN NEUROSCI, V77, P234, DOI 10.1016/j.jocn.2020.05.006
   Colizzi Marco, 2020, Brain Behav Immun Health, V5, P100073, DOI 10.1016/j.bbih.2020.100073
   Lima CFC, 2020, ARQ NEURO-PSIQUIAT, V78, P454, DOI [10.1590/0004-282x20200057, 10.1590/0004-282X20200057]
   Covino M, 2020, GERIATR GERONTOL INT, V20, P704, DOI 10.1111/ggi.13960
   Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127
   Dadas A, 2018, NEUROPSYCH DIS TREAT, V14, P2989, DOI 10.2147/NDT.S125620
   Datta D, 2020, CLIN INFECT DIS, V70, P1161, DOI 10.1093/cid/ciz325
   de Oliveira FAA, 2020, NEUROL SCI, V41, P3021, DOI 10.1007/s10072-020-04694-x
   De Stefano Pia, 2020, Clin Neurophysiol Pract, V5, P125, DOI 10.1016/j.cnp.2020.05.004
   Deliwala S, 2020, CUREUS, V12, DOI 10.7759/cureus.8121
   Demirci Otluoglu G., 2020, BRIT J NEUROSURG, DOI [10.1016/j.ijid.2020.10.044, DOI 10.1016/J.IJID.2020.10.044]
   Desforges M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010014
   Di Micco P, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051371
   Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040
   Dittrich S, 2015, AM J TROP MED HYG, V93, P232, DOI 10.4269/ajtmh.15-0119
   Dixon L, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000789
   Dogan L, 2020, BRAIN BEHAV IMMUN, V87, P155, DOI 10.1016/j.bbi.2020.05.022
   Dogra S, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.104984
   Douglas-Escobar MV, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00273
   Duong LS, 2020, BRAIN BEHAV IMMUN, V87, P33, DOI 10.1016/j.bbi.2020.04.024
   Dvorak F, 2009, CEREBROVASC DIS, V27, P37, DOI 10.1159/000172632
   Ebner F, 2020, RESUSCITATION, V154, P61, DOI 10.1016/j.resuscitation.2020.05.016
   Efe IE, 2020, WORLD NEUROSURG, V140, P46, DOI 10.1016/j.wneu.2020.05.194
   Ehrenreich H, 2011, MOL MED, V17, P1306, DOI 10.2119/molmed.2011.00259
   Elcioglu HK, 2016, MOL CELL BIOCHEM, V420, P21, DOI 10.1007/s11010-016-2762-6
   Ellinghaus D, 2020, NEW ENGL J MED, V383, P1522, DOI 10.1056/NEJMoa2020283
   Ellul MA, 2020, LANCET NEUROL, V19, P767, DOI 10.1016/S1474-4422(20)30221-0
   Elting JW, 2000, J NEUROL SCI, V181, P104, DOI 10.1016/S0022-510X(00)00442-1
   Escalard S, 2020, STROKE, V51, P2540, DOI 10.1161/STROKEAHA.120.030574
   Espinosa PS, 2020, CUREUS, V12, DOI 10.7759/cureus.7930
   Farhadian S, 2020, BMC NEUROL, V20, DOI 10.1186/s12883-020-01812-2
   Fasano A, 2020, NEUROL SCI, V41, P1651, DOI 10.1007/s10072-020-04460-z
   Ferguson I, 2011, ANN EMERG MED, V58, pS213, DOI 10.1016/j.annemergmed.2011.06.133
   Ferini-Strambi L, 2020, J NEUROL, DOI 10.1007/s00415-020-10070-8
   Filatov A, 2020, CUREUS, V12, DOI 10.7759/cureus.7352
   Fink EL, 2016, RESUSCITATION, V101, P65, DOI 10.1016/j.resuscitation.2016.01.024
   Fink EL, 2014, CRIT CARE MED, V42, P664, DOI 10.1097/01.ccm.0000435668.53188.80
   Fitzgerald S, 2020, NEUROLOGY TODAY
   Fletcher-Sandersjoo A, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00512
   Foerch C, 2006, J NEUROL NEUROSUR PS, V77, P181, DOI 10.1136/jnnp.2005.074823
   Foerch C, 2012, CLIN CHEM, V58, P237, DOI 10.1373/clinchem.2011.172676
   Fotuhi M, 2020, J ALZHEIMERS DIS, V76, P3, DOI 10.3233/JAD-200581
   Franceschi AM, 2020, AM J NEURORADIOL, V41, P1173, DOI 10.3174/ajnr.A6595
   Frankel M, 2019, J NEUROTRAUM, V36, P2863, DOI 10.1089/neu.2018.5809
   Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244
   Frontera Jennifer A, 2020, Neurology, DOI 10.1212/WNL.0000000000010979
   Garaci F, 2020, J NEUROL SCI, V414, DOI 10.1016/j.jns.2020.116871
   Garcia-Montojo M, 2018, CRIT REV MICROBIOL, V44, P715, DOI 10.1080/1040841X.2018.1501345
   Geocadin RG, 2019, CIRCULATION, V140, pE517, DOI 10.1161/CIR.0000000000000702
   Ghani MU, 2020, J NEUROVIROL, V26, P602, DOI 10.1007/s13365-020-00869-6
   Gill CM, 2019, SEMIN NEUROL, V39, P419, DOI 10.1055/s-0039-1687839
   Gisslen M, 2016, EBIOMEDICINE, V7, P287, DOI 10.1016/j.ebiom.2016.04.021
   Gisslen M, 2016, EBIOMEDICINE, V3, P135, DOI 10.1016/j.ebiom.2015.11.036
   Glushakova O.Y., 2018, HDB NEUROEMERGENCY C, P139, DOI DOI 10.1016/B978-0-12-804064-5.00008-4
   Glushakova Olena Y, 2017, Brain Circ, V3, P87, DOI 10.4103/bc.bc_27_16
   Glushakova Olena Y, 2016, Brain Circ, V2, P28, DOI 10.4103/2394-8108.178546
   Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080
   Glushakova OY, 2012, TOXICOL SCI, V130, P158, DOI 10.1093/toxsci/kfs224
   Goldberg MF, 2020, AM J NEURORADIOL, V41, P1170, DOI 10.3174/ajnr.A6588
   Gonzalez-Garcia S, 2012, CLIN BIOCHEM, V45, P1302, DOI 10.1016/j.clinbiochem.2012.07.094
   Gonzalez-Pinto T, 2020, EUR J NEUROL, V27, pE35, DOI 10.1111/ene.14286
   Griffin DO, 2020, BRIT J HAEMATOL, V190, pE11, DOI 10.1111/bjh.16792
   Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48
   Guha D, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1617-y
   Guha D, 2019, AIDS, V33, P615, DOI 10.1097/QAD.0000000000002121
   Gulko E, 2020, AM J NEURORADIOL, V41, pE65, DOI 10.3174/ajnr.A6657
   Guo LH, 2013, ALZ DIS ASSOC DIS, V27, P337, DOI 10.1097/WAD.0b013e31827b60d2
   Gupta A, 2020, NAT MED, V26, P1017, DOI 10.1038/s41591-020-0968-3
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hascup ER, 2020, GEROSCIENCE, V42, P1083, DOI 10.1007/s11357-020-00207-y
   Hayashida H, 2010, NEUROCRIT CARE, V12, P252, DOI 10.1007/s12028-009-9318-5
   HEITHOFF B, 2020, GLIA 0921, DOI DOI 10.1101/2020.03.16.993691
   Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597
   Heman-Ackah SM, 2020, NEUROSURGERY, V87, pE147, DOI 10.1093/neuros/nyaa198
   Hemasian H, 2020, REV NEUROL-FRANCE, V176, P521, DOI 10.1016/j.neurol.2020.04.013
   Hepburn M, 2020, NEUROCRIT CARE, DOI 10.1007/s12028-020-01006-1
   Hermansson L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226276
   Hernandez-Fernandez Francisco, 2020, Brain, V143, P3089, DOI 10.1093/brain/awaa239
   Hoiland RL, 2020, BLOOD ADV, V4, P4981, DOI 10.1182/bloodadvances.2020002623
   Hu HT, 2012, CLIN BIOCHEM, V45, P1320, DOI 10.1016/j.clinbiochem.2012.06.003
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang XJ, 2015, J NEUROTRAUM, V32, P1179, DOI 10.1089/neu.2015.3873
   Huang YH, 2020, BRAIN BEHAV IMMUN, V87, P149, DOI 10.1016/j.bbi.2020.05.012
   Iliff JJ, 2013, STROKE, V44, pS93, DOI 10.1161/STROKEAHA.112.678698
   Iwasaki Akiko, 2021, Lancet Infect Dis, V21, P3, DOI 10.1016/S1473-3099(20)30783-0
   Jain V, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-83
   Jasti M, 2020, J NEUROL, DOI 10.1007/s00415-020-09950-w
   Jauch EC, 2006, STROKE, V37, P2508, DOI 10.1161/01.STR.0000242290.01174.9e
   JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1
   Jha RM, 2019, J NEUROTRAUM, V36, P1804, DOI 10.1089/neu.2018.6124
   Jha RM, 2018, J NEUROL NEUROSUR PS, V89, P1152, DOI 10.1136/jnnp-2017-317741
   John S, 2020, AJNR Am J Neuroradiol, V41, P2263, DOI 10.3174/ajnr.A6799
   Kamil K, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00087
   Kanberg N, 2020, NEUROLOGY, V95, pE1754, DOI 10.1212/WNL.0000000000010111
   Kandemirli SG, 2020, RADIOLOGY, V297, pE232, DOI 10.1148/radiol.2020201697
   Kaneko T, 2009, RESUSCITATION, V80, P790, DOI 10.1016/j.resuscitation.2009.04.003
   Karadas O, 2020, NEUROL SCI, V41, P1991, DOI 10.1007/s10072-020-04547-7
   Karimi N., 2020, IRAN RED CRESCENT ME, V3
   Khan N, 2002, J IMMUNOL, V169, P1984, DOI 10.4049/jimmunol.169.4.1984
   Kim BJ, 2014, J STROKE CEREBROVASC, V23, P2437, DOI 10.1016/j.jstrokecerebrovasdis.2014.05.020
   Kinney Jefferson W, 2018, Alzheimers Dement (N Y), V4, P575, DOI 10.1016/j.trci.2018.06.014
   Kishfy L, 2020, J NEUROL SCI, V414, DOI 10.1016/j.jns.2020.116943
   Klok FA, 2020, THROMB RES, V191, P148, DOI 10.1016/j.thromres.2020.04.041
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Kochanek PM, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00640
   Kochanek PM, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00040
   Koh SXT, 2014, SPORTS MED, V44, P369, DOI 10.1007/s40279-013-0119-9
   Koralnik IJ, 2020, ANN NEUROL, V88, P1, DOI 10.1002/ana.25807
   Korber B, 2020, BIORXIV
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296
   Kox M, 2020, JAMA-J AM MED ASSOC, V324, P1565, DOI 10.1001/jama.2020.17052
   Koyama A, 2012, ARCH NEUROL-CHICAGO, V69, P824, DOI 10.1001/archneurol.2011.1841
   Kremer S, 2020, RADIOLOGY, V297, pE242, DOI [10.1148/radiol.2020202222, 10.1148/radiol.202020222]
   Kumar H, 2015, J NEUROSCI RURAL PRA, V6, P326, DOI 10.4103/0976-3147.158751
   Larsson IM, 2014, RESUSCITATION, V85, P1654, DOI 10.1016/j.resuscitation.2014.09.007
   Li JW, 2020, THROMB RES, V193, P22, DOI 10.1016/j.thromres.2020.05.050
   Li W, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac8201
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Li YN, 2020, STROKE VASC NEUROL, V5, P279, DOI 10.1136/svn-2020-000431
   Lindblad C, 2020, J NEUROTRAUM, V37, P1381, DOI 10.1089/neu.2019.6741
   Liotta EM, 2020, ANN CLIN TRANSL NEUR, V7, P2221, DOI 10.1002/acn3.51210
   Llombart V, 2016, J NEUROCHEM, V136, P416, DOI 10.1111/jnc.13419
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Long S.W., 2020, 20202009202220199125
   Lu KL, 2015, J NEUROL SCI, V359, P202, DOI 10.1016/j.jns.2015.10.034
   Lu L, 2020, EPILEPSIA, V61, pE49, DOI 10.1111/epi.16524
   Lu Yiping, 2020, EClinicalMedicine, V25, P100484, DOI 10.1016/j.eclinm.2020.100484
   Ludlow M, 2016, ACTA NEUROPATHOL, V131, P159, DOI 10.1007/s00401-015-1511-3
   Luger S, 2017, CLIN CHEM, V63, P377, DOI 10.1373/clinchem.2016.263335
   Lukiw WJ, 2020, CELL MOL NEUROBIOL, DOI 10.1007/s10571-020-00947-7
   Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024
   Mahammedi A, 2020, RADIOLOGY, V297, pE270, DOI 10.1148/radiol.2020201933
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805
   Mattsson N, 2019, JAMA NEUROL, V76, P791, DOI 10.1001/jamaneurol.2019.0765
   Mattsson N, 2017, ANN NEUROL, V82, P665, DOI 10.1002/ana.25067
   Mazza MG, 2020, BRAIN BEHAV IMMUN, V89, P594, DOI 10.1016/j.bbi.2020.07.037
   McAbee GN, 2020, PEDIATR NEUROL, V109, P94, DOI 10.1016/j.pediatrneurol.2020.04.013
   McFadyen CA, 2019, J NEUROTRAUM, P1, DOI 10.1089/neu.2018.6052
   McKibbin W, 2020, 622020 CAMA
   McMahon PJ, 2015, J NEUROTRAUM, V32, P527, DOI 10.1089/neu.2014.3635
   Medana IM, 2005, T ROY SOC TROP MED H, V99, P610, DOI 10.1016/j.trstmh.2004.11.017
   Medana IM, 2007, J NEUROL SCI, V258, P93, DOI 10.1016/j.jns.2007.03.005
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Meier TB, 2020, ANN NEUROL, V87, P907, DOI 10.1002/ana.25725
   Merkler A.E., 2020, 2020051820105494 MED
   Misra S, 2017, PROTEOM CLIN APPL, V11, DOI 10.1002/prca.201700007
   Mofid B, 2016, INT IMMUNOPHARMACOL, V32, P103, DOI 10.1016/j.intimp.2016.01.015
   Moir RD, 2018, ALZHEIMERS DEMENT, V14, P1602, DOI 10.1016/j.jalz.2018.06.3040
   Mokhtari M, 2018, J CLIN PHARMACOL, V58, P42, DOI 10.1002/jcph.980
   Molad J, 2019, J ALZHEIMERS DIS, V70, P889, DOI 10.3233/JAD-190339
   Mondello S, 2018, J NEUROTRAUM, DOI 10.1089/neu.2017.5182
   Mondello S, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-85
   Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092
   Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286
   Montalvan V, 2020, CLIN NEUROL NEUROSUR, V194, DOI 10.1016/j.clineuro.2020.105921
   Montaner J, 2012, J PROTEOMICS, V75, P4758, DOI 10.1016/j.jprot.2012.01.033
   Morassi M, 2020, J NEUROL, V267, P2185, DOI 10.1007/s00415-020-09885-2
   Moreau A, 2020, J NEUROL, DOI 10.1007/s00415-020-10164-3
   Moriguchi T, 2020, INT J INFECT DIS, V94, P55, DOI 10.1016/j.ijid.2020.03.062
   Mortberg E, 2011, ACTA ANAESTH SCAND, V55, P1132, DOI 10.1111/j.1399-6576.2011.02505.x
   Moseby-Knappe M, 2019, JAMA NEUROL, V76, P64, DOI 10.1001/jamaneurol.2018.3223
   Muhammad S, 2020, BRAIN BEHAV IMMUN, V87, P150, DOI 10.1016/j.bbi.2020.05.015
   Munz M, 2020, J NEUROL, V267, P2196, DOI 10.1007/s00415-020-09934-w
   Novi G, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000797
   Oeckl P, 2019, J ALZHEIMERS DIS, V67, P481, DOI 10.3233/JAD-180325
   Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883
   Olivecrona Z, 2015, BRAIN INJURY, V29, P446, DOI 10.3109/02699052.2014.989403
   Oliveira MF, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006112
   Onteddu Sanjeeva Reddy, 2020, Brain Behav Immun Health, V8, P100131, DOI 10.1016/j.bbih.2020.100131
   Overhage JM, 2012, J AM MED INFORM ASSN, V19, P54, DOI 10.1136/amiajnl-2011-000376
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Pandey A, 2014, NEUROCHEM RES, V39, P1426, DOI 10.1007/s11064-014-1328-9
   Paniz-Mondolfi A, 2020, J MED VIROL, V92, P699, DOI 10.1002/jmv.25915
   Papa L, 2017, J NEUROTRAUM, V34, P2187, DOI 10.1089/neu.2017.5030
   Parker AM, 2015, CRIT CARE MED, V43, P1121, DOI 10.1097/CCM.0000000000000882
   Parsons T, 2020, J NEUROL, V267, P2799, DOI 10.1007/s00415-020-09951-9
   Patanavanich R, 2020, NICOTINE TOB RES, V22, P1653, DOI 10.1093/ntr/ntaa082
   Paterson Ross W, 2020, Brain, V143, P3104, DOI 10.1093/brain/awaa240
   Pendlebury ST, 2020, STROKE, V51, P751, DOI 10.1161/STROKEAHA.119.026927
   Pilotto A, 2020, ANN NEUROL, V88, P423, DOI 10.1002/ana.25783
   Pinto AA, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000813
   Plog BA, 2018, ANNU REV PATHOL-MECH, V13, P379, DOI 10.1146/annurev-pathol-051217-111018
   Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015
   Politi LS, 2020, JAMA NEUROL, V77, P1028, DOI 10.1001/jamaneurol.2020.2125
   Posti JP, 2016, NEUROSURGERY, V79, P456, DOI 10.1227/NEU.0000000000001226
   Poyiadji N, 2020, RADIOLOGY, V296, pE119, DOI 10.1148/radiol.2020201187
   Preische O, 2019, NAT MED, V25, P277, DOI 10.1038/s41591-018-0304-3
   Purrucker JC, 2014, EUR NEUROL, V72, P278, DOI 10.1159/000363569
   Radmanesh A, 2020, AM J NEURORADIOL, V41, P1179, DOI 10.3174/ajnr.A6610
   Radmanesh A, 2020, RADIOLOGY, V297, pE223, DOI 10.1148/radiol.2020202040
   Ragin AB, 2015, ANN CLIN TRANSL NEUR, V2, P12, DOI 10.1002/acn3.136
   Ramani A, 2020, EMBO J, V39, DOI 10.15252/embj.2020106230
   Randall J, 2013, RESUSCITATION, V84, P351, DOI 10.1016/j.resuscitation.2012.07.027
   Reichard RR, 2020, ACTA NEUROPATHOL, V140, P1, DOI 10.1007/s00401-020-02166-2
   Ren CH, 2016, SCI REP-UK, V6, DOI 10.1038/srep24588
   Rhind SG, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-5
   Robinson Christopher P, 2020, Crit Care Explor, V2, pe0107, DOI 10.1097/CCE.0000000000000107
   Roh HT, 2017, J SPORT HEALTH SCI, V6, P225, DOI 10.1016/j.jshs.2016.06.005
   Rohlwink UK, 2017, CLIN INFECT DIS, V65, P1298, DOI 10.1093/cid/cix540
   Rohlwink UK, 2014, CLIN CHEM, V60, P823, DOI 10.1373/clinchem.2013.212472
   Romero-Sanchez CM, 2020, NEUROLOGY, V95, pE1060, DOI 10.1212/WNL.0000000000009937
   Rubenstein R, 2017, JAMA NEUROL, V74, P1063, DOI 10.1001/jamaneurol.2017.0655
   Sanchez-Aguilar M, 2013, J NEUROSURG, V118, P669, DOI 10.3171/2012.12.JNS121084
   Sasannejad C, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2626-z
   Schrage B, 2019, RESUSCITATION, V136, P14, DOI 10.1016/j.resuscitation.2019.01.011
   Senel M, 2020, EUR J NEUROL, V27, P2378, DOI 10.1111/ene.14473
   Shahrokhi N, 2016, ARCH TRAUMA RES, V5, DOI 10.5812/atr.37005
   Sharifi-Razavi A, 2020, NEW MICROB NEW INFEC, V35, DOI 10.1016/j.nmni.2020.100669
   Sharifian-Dorche M, 2020, J NEUROL SCI, V417, DOI 10.1016/j.jns.2020.117085
   Shelton J.F., 2020, 20202009200420188318
   Sierra-Hidalgo F, 2020, J NEUROL, V267, P3441, DOI 10.1007/s00415-020-09967-1
   Singh HV, 2013, CLIN CHIM ACTA, V419, P136, DOI 10.1016/j.cca.2013.02.014
   Sironi M, 2017, J INFECT DIS, V215, P1430, DOI 10.1093/infdis/jix166
   Sohal S, 2020, IDCases, V20, DOI 10.1016/j.idcr.2020.e00782
   Solomon IH, 2020, NEW ENGL J MED, V383, P989, DOI 10.1056/NEJMc2019373
   Somani S, 2020, ANN CLIN TRANSL NEUR, V7, P1240, DOI 10.1002/acn3.51071
   Stammet P, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1729-7
   Stammet P, 2015, J AM COLL CARDIOL, V65, P2104, DOI 10.1016/j.jacc.2015.03.538
   Stanca DM, 2015, J CELL MOL MED, V19, P2253, DOI 10.1111/jcmm.12614
   Stang PE, 2010, ANN INTERN MED, V153, P600, DOI 10.7326/0003-4819-153-9-201011020-00010
   Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165
   Stoyanov GS, 2020, CUREUS, V12, DOI 10.7759/cureus.8070
   Sudre C.H., 2020, 20202006201220129056
   Sun HL, 2020, P NATL ACAD SCI USA, V117, P17204, DOI 10.1073/pnas.1921186117
   Tahar R, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1378-3
   Takala RSK, 2016, WORLD NEUROSURG, V87, P8, DOI 10.1016/j.wneu.2015.10.066
   Tasker RC, 2016, JAMA-J AM MED ASSOC, V315, P749, DOI 10.1001/jama.2016.0701
   Tenforde MW, 2020, MMWR-MORBID MORTAL W, V69, P993, DOI [10.15585/mmwr.mm6930e1, 10.15585/mmwr.mm6930e1externalicon]
   Thomas W, 2020, THROMB RES, V191, P76, DOI 10.1016/j.thromres.2020.04.028
   Tillett Richard L, 2021, Lancet Infect Dis, V21, P52, DOI 10.1016/S1473-3099(20)30764-7
   Tobin MJ, 2020, AM J RESP CRIT CARE, V202, P356, DOI 10.1164/rccm.202006-2157CP
   Troyer EA, 2020, BRAIN BEHAV IMMUN, V87, P34, DOI 10.1016/j.bbi.2020.04.027
   Tsai ST, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00498
   Turbin RE, 2020, ORBIT-ABINGDON, V39, P305, DOI 10.1080/01676830.2020.1768560
   Turtle L, 2020, J MED VIROL, V92, P705, DOI 10.1002/jmv.25828
   U.S. Food and Drug Administration, 2020, EV AUT CLASS 3 DES B
   U.S . Food and Drug Administration Center for Drug Evaluation and Research, 2018, BIOM LETT SUPP
   Unden J, 2009, J NEUROL, V256, P72, DOI 10.1007/s00415-009-0054-8
   Valiuddin Hisham, 2020, Brain Behav Immun Health, V5, P100091, DOI 10.1016/j.bbih.2020.100091
   Varatharaj A, 2020, LANCET PSYCHIAT, V7, P875, DOI 10.1016/S2215-0366(20)30287-X
   Villaverde Chandler, 2020, J Pediatric Infect Dis Soc, V9, P580, DOI 10.1093/jpids/piz082
   Virhammar J, 2020, NEUROLOGY, V95, P445, DOI 10.1212/WNL.0000000000010250
   von Weyhern CH, 2020, LANCET, V395, pE109, DOI 10.1016/S0140-6736(20)31282-4
   Vu D, 2020, EMERG RADIOL, V27, P229, DOI 10.1007/s10140-020-01775-4
   Wahlstrom MR, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-98
   Wan XY, 2020, J NEUROSURG, V133, P496, DOI 10.3171/2019.4.JNS183472
   Wang AR, 2020, J NEUROINTERV SURG, V12, P648, DOI [10.1136/neurintsurg-2020-016220, 10.1136/neurintsurg-2019-015702]
   Wang KK, 2018, EXPERT REV MOL DIAGN, V18, P165, DOI 10.1080/14737159.2018.1428089
   Wee N K, 2020, AJNR Am J Neuroradiol, V41, pE76, DOI 10.3174/ajnr.A6672
   Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149
   Whittaker A, 2020, ACTA NEUROL SCAND, V142, P14, DOI 10.1111/ane.13266
   Wiberg S, 2017, RESUSCITATION, V121, P49, DOI 10.1016/j.resuscitation.2017.10.006
   Wintermark M, 2018, J NEUROTRAUM, V35, P2665, DOI 10.1089/neu.2017.5311
   Wong PF, 2020, CLIN MED, V20, P293, DOI 10.7861/clinmed.2020-0182
   Wright DK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51267-w
   Wu YS, 2020, BRAIN BEHAV IMMUN, V87, P18, DOI 10.1016/j.bbi.2020.03.031
   Wunderlich MT, 2006, CLIN NEUROL NEUROSUR, V108, P558, DOI 10.1016/j.clineuro.2005.12.006
   Wunderlich MT, 2004, J NEUROL SCI, V227, P49, DOI 10.1016/j.jns.2004.08.005
   Xiong LJ, 2015, NEUROL SCI, V36, P2081, DOI 10.1007/s10072-015-2317-8
   Xiong WX, 2020, NEUROLOGY, V95, pE1479, DOI 10.1212/WNL.0000000000010034
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yaeger KA, 2020, AM J NEURORADIOL, V41, P1357, DOI 10.3174/ajnr.A6652
   Yamazaki Y, 2019, NAT REV NEUROL, V15, P501, DOI 10.1038/s41582-019-0228-7
   Yao YM, 2020, J INTENSIVE CARE, V8, DOI 10.1186/s40560-020-00466-z
   Ye MX, 2020, BRAIN BEHAV IMMUN, V88, P945, DOI 10.1016/j.bbi.2020.04.017
   Yeager A, 2020, SCI MAGAZINE
   Zachariadis A, 2020, J NEUROL, V267, P3459, DOI 10.1007/s00415-020-09997-9
   Zaheer S, 2013, ANN INDIAN ACAD NEUR, V16, P504, DOI 10.4103/0972-2327.120442
   Zanin L, 2020, ACTA NEUROCHIR, V162, P1491, DOI 10.1007/s00701-020-04374-x
   Zayet S, 2020, EMERG INFECT DIS, V26, P2258, DOI 10.3201/eid2609.201791
   Zhang BZ, 2020, CELL RES, V30, P928, DOI 10.1038/s41422-020-0390-x
   Zhang CX, 2016, EUR REV MED PHARMACO, V20, P1474
   Zhang LT, 2020, J THROMB HAEMOST, V18, P1324, DOI 10.1111/jth.14859
   Zhang Q, 2020, SCIENCE, V370, P422, DOI 10.1126/science.abd4570
   Zhang YP, 2015, INT J MED SCI, V12, P576, DOI 10.7150/ijms.12111
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhao K., 2020, 20202003201620035105
   Zhou LY, 2020, TRAVEL MED INFECT DI, V36, DOI 10.1016/j.tmaid.2020.101642
   Zoghi Anahita, 2020, Mult Scler Relat Disord, V44, P102324, DOI 10.1016/j.msard.2020.102324
   Zubair AS, 2020, JAMA NEUROL, V77, P1018, DOI 10.1001/jamaneurol.2020.2065
   Zulfiqar AA, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2010472
NR 346
TC 0
Z9 0
U1 6
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
EI 1557-9042
J9 J NEUROTRAUM
JI J. Neurotrauma
DI 10.1089/neu.2020.7332
EA NOV 2020
PG 43
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA OT5OR
UT WOS:000590896000001
PM 33115334
OA Other Gold
DA 2021-01-01
ER

PT J
AU Mizrahi, L
   Shekhidem, HA
   Stern, S
AF Mizrahi, Liron
   Shekhidem, Huda Adwan
   Stern, Shani
TI Age separation dramatically reduces COVID-19 mortality rate in a
   computational model of a large population
SO OPEN BIOLOGY
LA English
DT Article
DE COVID-19; corona virus; network; Erds-Renyi model; computational model;
   age separation
ID INCUBATION PERIOD; SOCIAL NETWORK; TRANSMISSION; WUHAN
AB COVID-19 pandemic has caused a global lockdown in many countries throughout the world. Faced with a new reality, and until a vaccine or efficient treatment is found, humanity must figure out ways to keep the economy going, on one hand, while keeping the population safe, on the other hand, especially those that are susceptible to this virus. Here, we use a Watts-Strogatz network simulation, with parameters that were drawn from what is already known about the virus, to explore five different scenarios of partial lockdown release in two geographical locations with different age distributions. We find that separating age groups by reducing interactions between them protects the general population and reduces mortality rates. Furthermore, the addition of new connections within the same age group to compensate for the lost connections outside the age group still has a strong beneficial influence and reduces the total death toll by about 62%. While complete isolation from society may be the most protective scenario for the elderly population, it would have an emotional and possibly cognitive impact that might outweigh its benefit. Therefore, we propose creating age-related social recommendations or even restrictions, thereby allowing social connections while still offering strong protection for the older population.
C1 [Mizrahi, Liron; Shekhidem, Huda Adwan; Stern, Shani] Univ Haifa, Fac Nat Sci, Sagol Dept Neurobiol, IL-3498838 Haifa, Israel.
RP Stern, S (corresponding author), Univ Haifa, Fac Nat Sci, Sagol Dept Neurobiol, IL-3498838 Haifa, Israel.
EM sstern@univ.haifa.ac.il
OI Stern, Shani/0000-0002-2644-7068
FU Zuckerman STEM Leadership Program
FX This material is based upon work supported by the Zuckerman STEM
   Leadership Program.
CR Armitage R, 2020, LANCET PUBLIC HEALTH, V5, pE256, DOI 10.1016/S2468-2667(20)30061-X
   Backer JA, 2020, EUROSURVEILLANCE, V25, P10, DOI 10.2807/1560-7917.ES.2020.25.5.2000062
   Berg-Weger M, 2020, J NUTR HEALTH AGING, V24, P456, DOI 10.1007/s12603-020-1366-8
   Brooks J, 2020, J MATERN-FETAL NEO M, DOI [10.1080/14767058.2020.1827384, 10.1111/jocn.15274]
   Cacciapaglia G, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72611-5
   Cascella M, 2020, FEATURES EVALUATION
   CIA, 2018, WORLD FACTB IT
   Crooks VC, 2008, AM J PUBLIC HEALTH, V98, P1221, DOI 10.2105/AJPH.2007.115923
   Dong Y, PEDIATRICS, V145
   Erdos Paul, 1959, PUBL MATH-DEBRECEN, Vvi, P290, DOI DOI 10.1109/ICSMC.2006.384625
   Fu LW, 2020, J INFECTION, V80, P656, DOI 10.1016/j.jinf.2020.03.041
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Holtzman RE, 2004, J GERONTOL B-PSYCHOL, V59, pP278, DOI 10.1093/geronb/59.6.P278
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang L, 2020, J INFECTION, V80, pE1, DOI 10.1016/j.jinf.2020.03.006
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Lechien JR, 2020, EUR ARCH OTO-RHINO-L, V277, P2251, DOI 10.1007/s00405-020-05965-1
   Li P, 2020, INT J INFECT DIS, V96, P452, DOI 10.1016/j.ijid.2020.03.027
   Morley JE, 2020, J NUTR HEALTH AGING, V24, P364, DOI 10.1007/s12603-020-1349-9
   Qiu HY, 2020, LANCET INFECT DIS, V20, P689, DOI 10.1016/S1473-3099(20)30198-5
   Rajgor DD, 2020, LANCET INFECT DIS, V20, P776, DOI 10.1016/S1473-3099(20)30244-9
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Statistica, 2020, 2020 COR COVID 19 DE
   Lima CKT, 2020, PSYCHIAT RES, V287, DOI 10.1016/j.psychres.2020.112915
   Tolksdorf K, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.11.2000258
   Torales J, 2020, INT J SOC PSYCHIATR, V66, P317, DOI 10.1177/0020764020915212
   Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918
   Weiss P, 2020, LANCET, V395, P1014, DOI 10.1016/S0140-6736(20)30633-4
   WHO, 2020, REP WHO CHIN JOINT M
   WISE J, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M2294
   Woodward A, 2020, HERES LATEST RES ASY
   World Economic Forum, 2020, 2020 THIS IS MUCH CO
NR 34
TC 0
Z9 0
U1 1
U2 1
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
EI 2046-2441
J9 OPEN BIOL
JI Open Biol
PD NOV 11
PY 2020
VL 10
IS 11
AR 200213
DI 10.1098/rsob.200213
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA OT3PE
UT WOS:000590761700001
PM 33171068
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Anjum, FR
   Anam, S
   Abbas, G
   Mahmood, MS
   Rahman, SU
   Goraya, MU
   Abdullah, RM
   Luqman, M
   Ali, A
   Akram, MK
   Chaudhry, TH
AF Anjum, Faisal Rasheed
   Anam, Sidra
   Abbas, Ghazanfar
   Mahmood, Muhammad Shahid
   Rahman, Sajjad Ur
   Goraya, Mohsan Ullah
   Abdullah, Rana Muhammad
   Luqman, Muhammad
   Ali, Ashiq
   Akram, Muhammad Kamran
   Chaudhry, Tamoor Hamid
TI Type I IFNs: A Blessing in Disguise or Partner in Crime in MERS-CoV-,
   SARS-CoV-, and SARS-CoV-2-Induced Pathology and Potential Use of Type I
   IFNs in Synergism with IFN-gamma as a Novel Antiviral Approach Against
   COVID-19
SO VIRAL IMMUNOLOGY
LA English
DT Article; Early Access
DE COVID-19; type I IFNs; IFN-&#947; antiviral therapy; immunopathogenic
ID ACUTE RESPIRATORY SYNDROME; INNATE LYMPHOID-CELLS; ADAPTIVE
   IMMUNE-RESPONSES; MOUSE HEPATITIS-VIRUS; DOUBLE-STRANDED-RNA; SYNDROME
   CORONAVIRUS; INTERFERON-BETA; ALPHA-INTERFERONS; RATIONAL DESIGN;
   REPLICATION
AB Since the end of 2019, the emergence of novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has accelerated the research on host immune responses toward the coronaviruses. When there is no approved drug or vaccine to use against these culprits, host immunity is the major strategy to fight such infections. Type I interferons are an integral part of the host innate immune system and define one of the first lines of innate immune defense against viral infections. The in vitro antiviral role of type I IFNs against Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV (severe acute respiratory syndrome coronavirus) is well established. Moreover, the involvement of type I IFNs in disease pathology has also been reported. In this study, we have reviewed the protective and the immunopathogenic role of type I IFNs in the pathogenesis of MERS-CoV, SARS-CoV, and SARS-CoV-2. This review will also enlighten the potential implications of type I IFNs for the treatment of COVID-19 when used in combination with IFN-gamma.
C1 [Anjum, Faisal Rasheed; Anam, Sidra; Mahmood, Muhammad Shahid; Rahman, Sajjad Ur; Goraya, Mohsan Ullah; Abdullah, Rana Muhammad; Luqman, Muhammad] Univ Agr Faisalabad, Inst Microbiol, Faisalabad, Pakistan.
   [Abbas, Ghazanfar] Univ Melbourne, Melbourne Vet Sch, Werribee, Vic, Australia.
   [Ali, Ashiq] Univ Agr Faisalabad, Fac Vet Sci, Dept Pathol, Faisalabad, Pakistan.
   [Akram, Muhammad Kamran] Univ Queensland, Queensland Alliance Agr & Food Innovat, Brisbane, Qld, Australia.
   [Chaudhry, Tamoor Hamid] Govt Coll Univ, Dept Microbiol, Faisalabad, Pakistan.
RP Anjum, FR; Mahmood, MS (corresponding author), Univ Agr Faisalabad, Inst Microbiol, Fac Vet Sci, Faisalabad 38000, Pakistan.
EM drfaissaltarar@gmail.com; shahiduaf@gmail.com
OI Kamran, Muhammad/0000-0002-0909-8476
FU Higher Education Commission, PakistanHigher Education Commission of
   Pakistan
FX The author thanks the Higher Education Commission, Pakistan.
CR Al-Tawfiq JA, 2014, INT J INFECT DIS, V20, P42, DOI 10.1016/j.ijid.2013.12.003
   Arabi YM, 2017, AM J RESP CRIT CARE, V195
   Asper M, 2004, J VIROL, V78, P3162, DOI 10.1128/JVI.78.6.3162-3169.2004
   Bal SM, 2016, NAT IMMUNOL, V17, P636, DOI 10.1038/ni.3444
   Califano D, 2018, MUCOSAL IMMUNOL, V11, P209, DOI 10.1038/mi.2017.41
   Cameron MJ, 2007, J VIROL, V81, P8692, DOI 10.1128/JVI.00527-07
   Cervantes-Barragan L, 2007, BLOOD, V109, P1131, DOI 10.1182/blood-2006-05-023770
   Chan JFW, 2013, J INFECTION, V67, P606, DOI 10.1016/j.jinf.2013.09.029
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045
   Channappanavar R, 2019, J CLIN INVEST, V129, P3625, DOI 10.1172/JCI126363
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Chen F, 2004, J CLIN VIROL, V31, P69, DOI 10.1016/j.jcv.2004.03.003
   Chon TW, 2010, J INTERF CYTOK RES, V30, P477, DOI 10.1089/jir.2009.0089
   Cinatl J, 2003, LANCET, V362, P293, DOI 10.1016/S0140-6736(03)13973-6
   CZARNIECKI CW, 1984, J VIROL, V49, P490, DOI 10.1128/JVI.49.2.490-496.1984
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Duerr CU, 2016, NAT IMMUNOL, V17, P65, DOI 10.1038/ni.3308
   Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362
   Faure E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088716
   FLEISCHMANN WR, 1982, CANCER RES, V42, P869
   Frieman M, 2007, J VIROL, V81, P9812, DOI 10.1128/JVI.01012-07
   Frieman MB, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000849
   Fuchizaki U, 2003, J MED VIROL, V69, P188, DOI 10.1002/jmv.10286
   Garcia MA, 2006, MICROBIOL MOL BIOL R, V70, P1032, DOI 10.1128/MMBR.00027-06
   Gazon H, 2018, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02686
   GOMI K, 1986, J PHARMACOBIO-DYNAM, V9, P871
   Gosert R, 2002, J VIROL, V76, P3697, DOI 10.1128/JVI.76.8.3697-3708.2002
   Goyal A, 2016, CLIN DRUG INVEST, V36, P637, DOI 10.1007/s40261-016-0409-8
   Haagmans BL, 2004, NAT MED, V10, P290, DOI 10.1038/nm1001
   Han MY, 2017, AM J RESP CELL MOL, V56, P242, DOI 10.1165/rcmb.2016-0056OC
   Hart BJ, 2014, J GEN VIROL, V95, P571, DOI 10.1099/vir.0.061911-0
   Hensley LE, 2004, EMERG INFECT DIS, V10, P317, DOI 10.3201/eid1002.030482
   Hertzog PJ, 2003, TRENDS IMMUNOL, V24, P534, DOI 10.1016/j.it.2003.08.006
   Hiscott J, 2007, J BIOL CHEM, V282, P15325, DOI 10.1074/jbc.R700002200
   Hogan RJ, 2004, J VIROL, V78, P11416, DOI 10.1128/JVI.78.20.11416-11421.2004
   Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581
   Kim ES, 2016, J KOREAN MED SCI, V31, P1717, DOI 10.3346/jkms.2016.31.11.1717
   Kopecky-Bromberg SA, 2007, J VIROL, V81, P548, DOI 10.1128/JVI.01782-06
   Kurche JS, 2012, J IMMUNOL, V188, P585, DOI 10.4049/jimmunol.1102550
   Larkin J, 2003, J INTERF CYTOK RES, V23, P247, DOI 10.1089/107999003321829962
   Le Bon A, 2002, CURR OPIN IMMUNOL, V14, P432, DOI 10.1016/S0952-7915(02)00354-0
   Lee AJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02061
   Lee S, 2010, INTERVIROLOGY, V53, P146, DOI 10.1159/000274975
   Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909
   LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x
   LEWIS JA, 1989, J VIROL, V63, P4569, DOI 10.1128/JVI.63.11.4569-4578.1989
   Li SF, 2018, CELL PHYSIOL BIOCHEM, V51, P2377, DOI 10.1159/000495897
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Lokugamage KG, 2020, SARS COV 2 SENSITIVE
   Loutfy MR, 2003, JAMA-J AM MED ASSOC, V290, P3222, DOI 10.1001/jama.290.24.3222
   Mahlakoiv T, 2012, J GEN VIROL, V93, P2601, DOI 10.1099/vir.0.046284-0
   Mantlo E, 2020, ANTIVIR RES, V179, DOI 10.1016/j.antiviral.2020.104811
   MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N
   Mizukoshi E, 1999, J INTERF CYTOK RES, V19, P1019, DOI 10.1089/107999099313235
   Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1038/ni.2131, 10.1031/ni.2131]
   Montoya M, 2002, BLOOD, V99, P3263, DOI 10.1182/blood.V99.9.3263
   Mordstein M, 2010, J VIROL, V84, P5670, DOI 10.1128/JVI.00272-10
   Morgenstern B, 2005, BIOCHEM BIOPH RES CO, V326, P905, DOI 10.1016/j.bbrc.2004.11.128
   Moro K, 2016, NAT IMMUNOL, V17, P76, DOI 10.1038/ni.3309
   Nelemans T, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100961
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Pereda R, 2020, THERAPEUTIC EFFECTIV
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Pestka S, 2004, IMMUNOL REV, V202, P8, DOI 10.1111/j.0105-2896.2004.00204.x
   Petrera E, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-45
   Pfeffer LM, 1998, CANCER RES, V58, P2489
   Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604
   Reghunathan R, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-2
   Rempel JD, 2004, VIROLOGY, V318, P381, DOI 10.1016/j.virol.2003.09.023
   Sainz B, 2004, VIROLOGY, V329, P11, DOI 10.1016/j.virol.2004.08.011
   Sainz B, 2002, J VIROL, V76, P11541, DOI 10.1128/JVI.76.22.11541-11550.2002
   Sainz B, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-14
   Scagnolari C, 2004, ANTIVIR THER, V9, P1003
   Scagnolari C, 2007, INTERVIROLOGY, V50, P156, DOI 10.1159/000098242
   SCHWARZ LA, 1984, J BIOL RESP MODIF, V3, P608
   Sekellick MJ, 1998, J INTERF CYTOK RES, V18, P407, DOI 10.1089/jir.1998.18.407
   Sheahan T, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000240
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   SIM IS, 1987, ANTIVIR RES, V8, P209, DOI 10.1016/0166-3542(87)90075-1
   Simmons DP, 2012, J IMMUNOL, V188, P3116, DOI 10.4049/jimmunol.1101313
   Snijder EJ, 2006, J VIROL, V80, P5927, DOI 10.1128/JVI.02501-05
   Spiegel M, 2004, J CLIN VIROL, V30, P211, DOI 10.1016/j.jcv.2003.11.013
   Stark GR, 2012, IMMUNITY, V36, P503, DOI 10.1016/j.immuni.2012.03.013
   Stier MT, 2017, J IMMUNOL, V199, P510, DOI 10.4049/jimmunol.1601984
   Stifter SA, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005378
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Stroher U, 2004, J INFECT DIS, V189, P1164, DOI 10.1086/382597
   Sugawara R, 2016, J EXP MED, V213, P555, DOI 10.1084/jem.20141388
   Tan ELC, 2004, EMERG INFECT DIS, V10, P581, DOI 10.3201/eid1004.030458
   Thiel V, 2008, CYTOKINE GROWTH F R, V19, P121, DOI 10.1016/j.cytogfr.2008.01.001
   Todt D, 2016, ANTIMICROB AGENTS CH, V60, P2132, DOI 10.1128/AAC.02427-15
   Totura AL, 2015, MBIO, V6, DOI 10.1128/mBio.00638-15
   Uematsu S, 2007, J BIOL CHEM, V282, P15319, DOI 10.1074/jbc.R700009200
   Versteeg GA, 2007, VIROLOGY, V361, P18, DOI 10.1016/j.virol.2007.01.020
   Wathelet MG, 2007, J VIROL, V81, P11620, DOI 10.1128/JVI.00702-07
   Weber F, 2006, J VIROL, V80, P5059, DOI 10.1128/JVI.80.10.5059-5064.2006
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yoneyama M, 2007, J BIOL CHEM, V282, P15315, DOI 10.1074/jbc.R700007200
   Yu SY, 2005, WORLD J GASTROENTERO, V11, P5037, DOI 10.3748/wjg.v11.i32.5037
   Zaiss DM, 2006, SCIENCE, V314, P1746, DOI 10.1126/science.1133715
   Zheng BJ, 2004, J INTERF CYTOK RES, V24, P388, DOI 10.1089/1079990041535610
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou HX, 2007, J VIROL, V81, P568, DOI 10.1128/JVI.01512-06
   Zhou Q, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01061
   Zust R, 2007, PLOS PATHOG, V3, P1062, DOI 10.1371/journal.ppat.0030109
NR 111
TC 0
Z9 0
U1 2
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0882-8245
EI 1557-8976
J9 VIRAL IMMUNOL
JI Viral Immunol.
DI 10.1089/vim.2020.0085
EA NOV 2020
PG 9
WC Immunology; Virology
SC Immunology; Virology
GA OT5UP
UT WOS:000590911400001
PM 33181057
OA Bronze
DA 2021-01-01
ER

PT J
AU Khan, S
   Fakhar, Z
   Hussain, A
   Ahmad, A
   Jairajpuri, DS
   Alajmi, MF
   Hassan, MI
AF Khan, Shama
   Fakhar, Zeynab
   Hussain, Afzal
   Ahmad, Aijaz
   Jairajpuri, Deeba Shamim
   Alajmi, Mohamed F.
   Hassan, Md. Imtaiyaz
TI Structure-based identification of potential SARS-CoV-2 main protease
   inhibitors
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID19; SARS-CoV-2; Main protease inhibitor; Pharmacophore modeling;
   Molecular docking; ADMET; Molecular dynamics simulations
ID MOLECULAR-DYNAMICS; CORONAVIRUSES; PERCEPTION; THERAPY; DOCKING; GLIDE;
   MODEL
AB To address coronavirus disease (COVID-19), currently, no effective drug or vaccine is available. In this regard, molecular modeling approaches are highly useful to discover potential inhibitors of the main protease (M-pro) enzyme of SARS-CoV-2. Since, the M-pro enzyme plays key roles in mediating viral replication and transcription; therefore, it is considered as an attractive drug target to control SARS-CoV-2 infection. By using structure-based drug design, pharmacophore modeling, and virtual high throughput drug screening combined with docking and all-atom molecular dynamics simulation approach, we have identified five potential inhibitors of SARS-CoV-2 M-pro. MD simulation studies revealed that compound 54035018 binds to the M-pro with high affinity (Delta G (bind) -37.40 kcal/mol), and the complex is more stable in comparison with other protein-ligand complexes. We have identified promising leads to fight COVID-19 infection as these compounds fulfill all drug-likeness properties. However, experimental and clinical validations are required for COVID-19 therapy.
   Communicated by Ramaswamy H. Sarma
C1 [Khan, Shama; Ahmad, Aijaz] Univ Witwatersrand, Sch Pathol, Dept Clin Microbiol & Infect Dis, Johannesburg, South Africa.
   [Fakhar, Zeynab] Univ Witwatersrand, Sch Chem, Mol Sci Inst, Johannesburg, South Africa.
   [Hussain, Afzal; Alajmi, Mohamed F.] King Saud Univ, Coll Pharm, Dept Pharmacognosy, Riyadh, Saudi Arabia.
   [Ahmad, Aijaz] Charlotte Maxeke Johannesburg Acad Hosp, Infect Control, Natl Hlth Lab Serv, Johannesburg, South Africa.
   [Jairajpuri, Deeba Shamim] Arabian Gulf Univ, Coll Med & Med Sci, Dept Med Biochem, Manama, Bahrain.
   [Hassan, Md. Imtaiyaz] Jamia Millia Islamia, Ctr Interdisciplinary Res Basic Sci, New Delhi 110025, India.
RP Hassan, MI (corresponding author), Jamia Millia Islamia, Ctr Interdisciplinary Res Basic Sci, New Delhi 110025, India.
EM mihassan@jmi.ac.in
RI Hassan, Imtaiyaz/G-7072-2017
OI Hassan, Imtaiyaz/0000-0002-3663-4940
FU King Saud University, Riyadh, Kingdom of Saudi ArabiaKing Saud
   University [RSP-2020-122]; University of the Witwatersrand URC
   postdoctoral fellowship
FX SK and ZF would like to acknowledge the CHPC server based in Cape Town,
   South Africa, and SK would also like to thank the University of the
   Witwatersrand URC postdoctoral fellowship for conducting this research.
   MFA and AH acknowledge the generous support from Research Supporting
   Project (No. RSP-2020-122) by King Saud University, Riyadh, Kingdom of
   Saudi Arabia.
CR Ahmed FS, 2020, VIRUSES, V12, pE254, DOI DOI https://doi.org/10.3390/v12030254
   Ahn DG, 2020, J MICROBIOL BIOTECHN, V30, P313, DOI 10.4014/jmb.2003.03011
   Amir M, 2020, J BIOMOL STRUCT DYN, V38, P1514, DOI 10.1080/07391102.2019.1610500
   [Anonymous], 2020, SCHROD REL 2020 1 PR
   [Anonymous], 2020, SCHROD REL 2020 1
   Arnittali Maria, 2019, Procedia Computer Science, V156, P69, DOI 10.1016/j.procs.2019.08.181
   ASRANI P, 2020, EXPERT REV RESP 1002, DOI DOI https://doi.org/10.1080/17476348.2021.1823833
   ASRANI P, 2020, MOL CELL BIOCHE 1016, DOI DOI https://doi.org/10.1007/s11010-020-03935-z
   Asrani P, 2020, OMICS, V24, P634, DOI 10.1089/omi.2020.0131
   Beg A, 2019, J BIOMOL STRUCT DYN, V37, P2179, DOI 10.1080/07391102.2018.1479310
   Case D., 2018, AMBER 2018
   Chang L, 2020, TRANSFUS MED REV, V34, P75, DOI 10.1016/j.tmrv.2020.02.003
   Chen H, 2019, LANGMUIR, V35, P2443, DOI 10.1021/acs.langmuir.8b03440
   Dahiya R, 2019, RSC ADV, V9, P23302, DOI 10.1039/c9ra02864a
   Dixon SL, 2006, J COMPUT AID MOL DES, V20, P647, DOI 10.1007/s10822-006-9087-6
   Fakhar Z, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1801510
   Fakhar Z, 2017, MOL BIOSYST, V13, P1223, DOI 10.1039/c7mb00110j
   Fatima U, 2020, J INTERF CYTOK RES, V40, P469, DOI 10.1089/jir.2020.0105
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Gulzar M, 2019, J BIOMOL STRUCT DYN, V37, P4327, DOI 10.1080/07391102.2018.1546621
   Gupta P., 2019, SCI REP, V9, P1
   Gupta P, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2094635
   Gupta P, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109245
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864
   Harrach MF, 2014, J CHEM PHYS, V140, DOI 10.1063/1.4872239
   Harvey MJ, 2009, J CHEM THEORY COMPUT, V5, P2371, DOI 10.1021/ct900275y
   Hornak V, 2006, PROTEINS, V65, P712, DOI 10.1002/prot.21123
   Janert P. K., 2009, GNUPLOT ACTION UNDER
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   Karplus M, 2002, NAT STRUCT BIOL, V9, P646, DOI 10.1038/nsb0902-646
   Khan S, 2019, CELL BIOCHEM BIOPHYS, V77, P203, DOI 10.1007/s12013-019-00882-5
   Khan S, 2018, FUTURE MED CHEM, V10, P1003, DOI 10.4155/fmc-2017-0275
   Kim S, 2016, NUCLEIC ACIDS RES, V44, pD1202, DOI 10.1093/nar/gkv951
   Kumari P, 2020, CLIN CHIM ACTA, V510, P488, DOI [10.1016/j.cca.2020.08.013, 10.1016/j.caa.2020.08.013]
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Langer T, 2010, MOL INFORM, V29, P470, DOI 10.1002/minf.201000022
   Lee TS, 2018, J CHEM INF MODEL, V58, P2043, DOI 10.1021/acs.jcim.8b00462
   Li HO, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00483-20
   Lin YQ, 2017, J CHEM PHYS, V146, DOI 10.1063/1.4978807
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Loving K, 2009, J COMPUT AID MOL DES, V23, P541, DOI 10.1007/s10822-009-9268-1
   Martinez L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119264
   MCCAMMON JA, 1977, NATURE, V267, P585, DOI 10.1038/267585a0
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   Mohammad T, 2020, VIRUS RES, V288, DOI 10.1016/j.virusres.2020.198102
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Naqvi AA, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165878
   Onufriev AV, 2019, ANNU REV BIOPHYS, V48, P275, DOI 10.1146/annurev-biophys-052118-115325
   Pang JX, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030623
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5
   Salam NK, 2009, J CHEM INF MODEL, V49, P2356, DOI 10.1021/ci900212v
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Shamsi Anas, 2020, Biosci Rep, V40, DOI 10.1042/BSR20201256
   Shanmugaraj B, 2020, ASIAN PAC J ALLERGY, V38, P10, DOI 10.12932/AP-200220-0773
   Skjaerven L, 2011, FUTURE MED CHEM, V3, P2079, DOI [10.4155/FMC.11.159, 10.4155/fmc.11.159]
   Tang T, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104792
   TON AT, 2020, MOL INFORM 0323, DOI DOI https://doi.org/10.1002/minf.202000028
   Wang EC, 2019, CHEM REV, V119, P9478, DOI 10.1021/acs.chemrev.9b00055
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   WANG JM, 2001, ABSTR PAP AM CHEM 1, V222
   Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 71
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1848634
EA NOV 2020
PG 14
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OS7WK
UT WOS:000590369400001
PM 33210561
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Di Domenico, SL
   Coen, D
   Bergamaschi, M
   Albertini, V
   Ghezzi, L
   Cazzaniga, MM
   Tombini, V
   Colombo, R
   Capsoni, N
   Coen, T
   Cazzola, KB
   Di Fiore, M
   Angaroni, L
   Strozzi, MA
AF Di Domenico, Sandro Luigi
   Coen, Daniele
   Bergamaschi, Marta
   Albertini, Valentina
   Ghezzi, Leonardo
   Cazzaniga, Michela Maria
   Tombini, Valeria
   Colombo, Riccardo
   Capsoni, Nicolo
   Coen, Tommaso
   Cazzola, Katia Barbara
   Di Fiore, Marina
   Angaroni, Laura
   Strozzi, Marco Alberto
TI Clinical characteristics and respiratory support of 310 COVID-19
   patients, diagnosed at the emergency room: a single-center retrospective
   study
SO INTERNAL AND EMERGENCY MEDICINE
LA English
DT Article; Early Access
DE SARS-CoV-2 infection; COVID-19; CPAP (continuous positive airway
   pressure); NIV (non-invasive ventilation); Epidemiology
ID NONINVASIVE VENTILATION
AB An ongoing outbreak of pneumonia associated with severe acute respiratory coronavirus 2 (SARS-CoV-2) occurred at the end of February 2020 in Lombardy, Italy. We analyzed data from a retrospective, single-center case series of 310 consecutive patients, with confirmed SARS-CoV-2 infection, admitted to the emergency room. We aimed to describe the clinical course, treatment and outcome of a cohort of patients with COVID-19 pneumonia, with special attention to oxygen delivery and ventilator support. Throughout the study period, 310 consecutive patients, with confirmed SARS-CoV-2 infection, attended the Emergency Room (ER), of these, 34 were discharged home directly from the ER. Of the remaining 276 patients, the overall mortality was 30.4%: 7 patients died in the ER and 77 during hospitalization. With respect to oxygen delivery: 22 patients did not need any oxygen support (8.0%), 151 patients were treated with oxygen only (54.7%), and 49 (17.8%) were intubated. 90 patients (32.6%) were treated with CPAP (Continuous Positive Airway Pressure) or NIV (Non Invasive Ventilation); in this group, 27 patients had a Do Not Intubate (DNI) order and were treated with CPAP/NIV as an upper threshold therapy, showing high mortality rate (88.9%). Among the 63 patients treated with CPAP/NIV without DNI, NIV failure occurred in 36 patients (57.1%), with mortality rate of 47.2%. Twenty-seven (27) patients were treated with CPAP/NIV without needing mechanical ventilation and 26 were discharged alive (96.3%). The study documents the poor prognosis of patients with severe respiratory failure, although a considerable minority of patients treated with CPAP/NIV had a positive outcome.
C1 [Di Domenico, Sandro Luigi; Coen, Daniele; Ghezzi, Leonardo; Cazzaniga, Michela Maria; Tombini, Valeria; Colombo, Riccardo; Cazzola, Katia Barbara; Di Fiore, Marina; Angaroni, Laura; Strozzi, Marco Alberto] ASST Grande Osped Metropolitano Niguarda, Dept Emergency Med, Piazza Osped Maggiore 3, I-20162 Milan, Italy.
   [Bergamaschi, Marta; Albertini, Valentina; Capsoni, Nicolo] Univ Milano Bicocca, Piazza Ateneo Nuovo 1, I-20126 Milan, Italy.
   [Coen, Tommaso] Brown Univ, Dept Econ, Providence, RI 02912 USA.
RP Di Domenico, SL (corresponding author), ASST Grande Osped Metropolitano Niguarda, Dept Emergency Med, Piazza Osped Maggiore 3, I-20162 Milan, Italy.
EM didomenico.sandro@gmail.com
OI Di Domenico, Sandro Luigi/0000-0002-4460-2244
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Bellani G, 2017, AM J RESP CRIT CARE, V195, P67, DOI 10.1164/rccm.201606-1306OC
   Buonsenso D, 2020, LANCET RESP MED, V8, pE27, DOI 10.1016/S2213-2600(20)30120-X
   Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014
   Fang YC, 2020, RADIOLOGY, V296, pE115, DOI 10.1148/radiol.2020200432
   Gao C, 2020, EUR HEART J, V41, P2058, DOI 10.1093/eurheartj/ehaa433
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gnavi Roberto, 2020, Clin Infect Dis, V71, P2291, DOI 10.1093/cid/ciaa634
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   He HY, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2575-6
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Italian Institute for International Political Studies, COVID 19 ITALYS CASE
   Marini JJ, 2020, JAMA-J AM MED ASSOC, V323, P2329, DOI 10.1001/jama.2020.6825
   Masclans JR, 2013, CLIN MICROBIOL INFEC, V19, P249, DOI 10.1111/j.1469-0691.2012.03797.x
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Namendys-Silva SA, 2020, LANCET RESP MED, V8, pE18, DOI 10.1016/S2213-2600(20)30110-7
   Peng QY, 2020, INTENS CARE MED, V46, P849, DOI 10.1007/s00134-020-05996-6
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Shah SK, 2020, INT J RHEUM DIS, V23, P613, DOI 10.1111/1756-185X.13842
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wang Y., 2020, EARLY LOW DOSE SHORT, DOI [10.1101/2020.03.06.20032342., DOI 10.1101/2020.03.06.20032342, 10.1101/2020.03.06. 20032342.]
   WHO, 2020, CLIN MAN SERV ACT RE
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zha L, 2020, MED J AUSTRALIA, V212, P416, DOI 10.5694/mja2.50577
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 30
TC 0
Z9 0
U1 3
U2 3
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1828-0447
EI 1970-9366
J9 INTERN EMERG MED
JI Intern. Emerg. Med.
DI 10.1007/s11739-020-02548-0
EA NOV 2020
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA OQ1XB
UT WOS:000588582800001
PM 33175297
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Mandala, VS
   McKay, MJ
   Shcherbakov, AA
   Dregni, AJ
   Kolocouris, A
   Hong, M
AF Mandala, Venkata S.
   McKay, Matthew J.
   Shcherbakov, Alexander A.
   Dregni, Aurelio J.
   Kolocouris, Antonios
   Hong, Mei
TI Structure and drug binding of the SARS-CoV-2 envelope protein
   transmembrane domain in lipid bilayers
SO NATURE STRUCTURAL & MOLECULAR BIOLOGY
LA English
DT Article
ID CORONAVIRUS E-PROTEIN; RESPIRATORY SYNDROME CORONAVIRUS; CORRELATION
   SPECTROSCOPY; AMANTADINE BINDING; ION CHANNELS; STATE; MODEL; PORE;
   POLARIZATION; ASSIGNMENT
AB An essential protein of the SARS-CoV-2 virus, the envelope protein E, forms a homopentameric cation channel that is important for virus pathogenicity. Here we report a 2.1-angstrom structure and the drug-binding site of E's transmembrane domain (ETM), determined using solid-state NMR spectroscopy. In lipid bilayers that mimic the endoplasmic reticulum-Golgi intermediate compartment (ERGIC) membrane, ETM forms a five-helix bundle surrounding a narrow pore. The protein deviates from the ideal alpha-helical geometry due to three phenylalanine residues, which stack within each helix and between helices. Together with valine and leucine interdigitation, these cause a dehydrated pore compared with the viroporins of influenza viruses and HIV. Hexamethylene amiloride binds the polar amino-terminal lumen, whereas acidic pH affects the carboxy-terminal conformation. Thus, the N- and C-terminal halves of this bipartite channel may interact with other viral and host proteins semi-independently. The structure sets the stage for designing E inhibitors as antiviral drugs.
   A solid-state NMR structure of the transmembrane domain from SARS-CoV-2 envelope protein in the phospholipid environment reveals determinants of cation selectivity, a dehydrated pore and an N-terminal drug-binding site.
C1 [Mandala, Venkata S.; McKay, Matthew J.; Shcherbakov, Alexander A.; Dregni, Aurelio J.; Hong, Mei] MIT, Dept Chem, Cambridge, MA 02139 USA.
   [Kolocouris, Antonios] Natl & Kapodistrian Univ Athens, Dept Pharmaceut Chem, Athens, Greece.
RP Hong, M (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.
EM meihong@mit.edu
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [GM088204]; MIT School
   of Science Sloan Fund; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [P41 GM111135, P41
   GM132079]
FX This research is funded by National Institutes of Health grant GM088204
   to M.H and the MIT School of Science Sloan Fund to V.S.M. and A.A.S. The
   experiments made use of NMR spectrometers at the MIT/Harvard Center for
   Magnetic Resonance, supported by NIH grant P41 GM132079. Structure
   calculation made use of NMRbox, supported by NIH grant P41 GM111135.
CR Abramson A, 2019, SCIENCE, V363, P611, DOI 10.1126/science.aau2277
   Arbely E, 2004, J MOL BIOL, V341, P769, DOI 10.1016/j.jmb.2004.06.044
   Baldus M, 1998, MOL PHYS, V95, P1197, DOI 10.1080/002689798166215
   Cady SD, 2007, J AM CHEM SOC, V129, P5719, DOI 10.1021/ja070305e
   Cady SD, 2010, NATURE, V463, P689, DOI 10.1038/nature08722
   Chipot C, 2018, CHEM REV, V118, P3559, DOI 10.1021/acs.chemrev.7b00570
   Choma C, 2000, NAT STRUCT BIOL, V7, P161
   DeDiego ML, 2007, J VIROL, V81, P1701, DOI 10.1128/JVI.01467-06
   Dickson VK, 2014, NATURE, V516, P213, DOI 10.1038/nature13913
   Doherty T, 2009, J MAGN RESON, V196, P39, DOI 10.1016/j.jmr.2008.10.001
   Dregni AJ, 2020, BIOCHEMISTRY-US, V59, P2237, DOI 10.1021/acs.biochem.0c00342
   Dregni AJ, 2019, P NATL ACAD SCI USA, V116, P16357, DOI 10.1073/pnas.1906839116
   Duart G, 2020, OPEN BIOL, V10, DOI 10.1098/rsob.200209
   GULLION T, 1989, J MAGN RESON, V81, P196, DOI 10.1016/0022-2364(89)90280-1
   Helmus JJ, 2013, J BIOMOL NMR, V55, P355, DOI 10.1007/s10858-013-9718-x
   Hong M, 1998, J AM CHEM SOC, V120, P7113, DOI 10.1021/ja980775w
   Hong M, 2012, PROTEIN SCI, V21, P1620, DOI 10.1002/pro.2158
   Hou GJ, 2013, J MAGN RESON, V232, P18, DOI 10.1016/j.jmr.2013.04.009
   Hou XW, 2012, SCIENCE, V338, P1308, DOI 10.1126/science.1228757
   Lange A, 2002, J AM CHEM SOC, V124, P9704, DOI 10.1021/ja026691b
   Lee C, 2017, NATURE, V547, P472, DOI 10.1038/nature23269
   Lee W, 2015, BIOINFORMATICS, V31, P1325, DOI 10.1093/bioinformatics/btu830
   Lehninger A. L., 1993, PRINCIPLES BIOCH
   Lesage A, 2006, J AM CHEM SOC, V128, P8246, DOI 10.1021/ja060866q
   Li Y, 2014, J BIOL CHEM, V289, P12535, DOI 10.1074/jbc.M114.560094
   Lu JX, 2010, PROTEIN SCI, V19, P1877, DOI 10.1002/pro.474
   Maciejewski MW, 2017, BIOPHYS J, V112, P1529, DOI 10.1016/j.bpj.2017.03.011
   Mandala VS, 2020, NAT STRUCT MOL BIOL, V27, P160, DOI 10.1038/s41594-019-0371-2
   Nieto-Torres JL, 2015, VIROLOGY, V485, P330, DOI 10.1016/j.virol.2015.08.010
   Nieto-Torres JL, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004077
   Nieto-Torres JL, 2011, VIROLOGY, V415, P69, DOI 10.1016/j.virol.2011.03.029
   Park SH, 2003, J MOL BIOL, V333, P409, DOI 10.1016/j.jmb.2003.08.048
   Parthasarathy K, 2008, BIOPHYS J, V95, pL39, DOI 10.1529/biophysj.108.133041
   Parthasarathy K, 2012, PROTEIN EXPRES PURIF, V85, P133, DOI 10.1016/j.pep.2012.07.005
   Pervushin K, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000511
   Rienstra CM, 2000, J AM CHEM SOC, V122, P10979, DOI 10.1021/ja001092v
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9
   Shcherbakov AA, 2020, J BIOMOL NMR, V74, P193, DOI 10.1007/s10858-020-00306-0
   Shcherbakov AA, 2018, J BIOMOL NMR, V71, P31, DOI 10.1007/s10858-018-0187-0
   Shen Y, 2013, J BIOMOL NMR, V56, P227, DOI 10.1007/s10858-013-9741-y
   Smart OS, 1996, J MOL GRAPH MODEL, V14, P354, DOI 10.1016/S0263-7855(97)00009-X
   Surya W, 2018, BBA-BIOMEMBRANES, V1860, P1309, DOI 10.1016/j.bbamem.2018.02.017
   Torres J, 2005, BIOPHYS J, V88, P1283, DOI 10.1529/biophysj.104.051730
   Torres J, 2007, PROTEIN SCI, V16, P2065, DOI 10.1110/ps.062730007
   Torres J, 2006, BIOPHYS J, V91, P938, DOI 10.1529/biophysj.105.080119
   Verdia-Baguena C, 2012, VIROLOGY, V432, P485, DOI 10.1016/j.virol.2012.07.005
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   Williams JK, 2014, J MAGN RESON, V247, P118, DOI 10.1016/j.jmr.2014.08.007
   Wilson L, 2004, VIROLOGY, V330, P322, DOI 10.1016/j.virol.2004.09.033
   Wilson L, 2006, VIROLOGY, V353, P294, DOI 10.1016/j.virol.2006.05.028
   Xu CF, 2020, NATURE, V585, P129, DOI 10.1038/s41586-020-2646-5
   Yang TT, 2014, SCIENCE, V346, P355, DOI 10.1126/science.1259723
NR 53
TC 0
Z9 0
U1 7
U2 7
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1545-9993
EI 1545-9985
J9 NAT STRUCT MOL BIOL
JI Nat. Struct. Mol. Biol.
PD DEC
PY 2020
VL 27
IS 12
BP 1202
EP U270
DI 10.1038/s41594-020-00536-8
EA NOV 2020
PG 24
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA PB0QF
UT WOS:000588581800001
PM 33177698
OA Bronze
DA 2021-01-01
ER

PT J
AU Aliabadi, F
   Ajami, M
   Pazoki-Toroudi, H
AF Aliabadi, Fatemeh
   Ajami, Marjan
   Pazoki-Toroudi, Hamidreza
TI Why does COVID-19 pathology have several clinical forms?
SO BIOESSAYS
LA English
DT Article
DE coronaviruses; COVID&#8208; 19; drug discovery; outbreak; pathology;
   prostaglandin E2 (PGE2)
ID NF-KAPPA-B; EP4 PROSTANOID RECEPTORS; PROSTAGLANDIN E-2; INFLAMMATORY
   RESPONSE; RESPIRATORY RESPONSE; MESSENGER-RNA; ACTIVATION; PGE(2);
   EXPRESSION; MICE
AB The outbreak of a new, potentially fatal virus, SARS-COV-2, which started in December 2019 in Wuhan, China, and since developed into a pandemic has stimulated research for an effective treatment and vaccine. For this research to be successful, it is necessary to understand the pathology of the virus. So far, we know that this virus can harm different organs of the body. Although the exact mechanisms are still unknown, this phenomenon may result from the body's secretion of prostaglandin E2 (PGE2), which is involved in several inflammation and immunity pathways. Noticeably, the expression of this molecule can lead to a cytokine storm causing a variety of side effects. In this paper, we discuss those side effects in SARS-COV-2 infection separately to determine whether PGE2 is, indeed, an important causative factor. Lastly, we propose a mechanism by which PGE2 production increases in response to COVID-19 disease and suggest the possible direct relation between PGE2 levels and the severity of this disease. Also see the video abstract here: https://youtu.be/SnPFAcjxxKw.
C1 [Aliabadi, Fatemeh; Pazoki-Toroudi, Hamidreza] Iran Univ Med Sci, Dept Med, Physiol Res Ctr, Tehran, Iran.
   [Ajami, Marjan] Shahid Beheshti Univ Med Sci, Dept Food & Nutr Policy & Planning Res, Natl Nutr & Food Technol Res Inst, Tehran, Iran.
   [Pazoki-Toroudi, Hamidreza] Iran Univ Med Sci, Dept Med, Dept Physiol, Tehran, Iran.
RP Pazoki-Toroudi, H (corresponding author), Iran Univ Med Sci, Dept Med, Physiol Res Ctr, Tehran, Iran.
EM pazokihamidrezatoroudi95@gmail.com
CR Baud D, 2020, JAMA-J AM MED ASSOC, V323, P2198, DOI 10.1001/jama.2020.7233
   Bernard MP, 2008, CURR PHARM DESIGN, V14, P2051, DOI 10.2174/138161208785294654
   Bushinsky DA, 2001, AM J PHYSIOL-RENAL, V281, pF1058, DOI 10.1152/ajprenal.0355.2000
   Cashman JN, 1996, DRUGS, V52, P13, DOI 10.2165/00003495-199600525-00004
   Chaplin DD, 2010, J ALLERGY CLIN IMMUN, V125, pS3, DOI 10.1016/j.jaci.2009.12.980
   Chen IY, 2010, J VIROL, V84, P7703, DOI 10.1128/JVI.02560-09
   Coceani F, 1998, ANN NY ACAD SCI, V856, P76, DOI 10.1111/j.1749-6632.1998.tb08315.x
   COCEANI F, 1986, YALE J BIOL MED, V59, P169
   Dumais N, 1998, J BIOL CHEM, V273, P27306, DOI 10.1074/jbc.273.42.27306
   Eitsuka T, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101605
   Ek M, 2000, J COMP NEUROL, V428, P5, DOI 10.1002/1096-9861(20001204)428:1<5::AID-CNE2>3.0.CO;2-M
   Ek M, 2001, NATURE, V410, P430, DOI 10.1038/35068632
   Elander L, 2007, AM J PHYSIOL-REG I, V292, pR258, DOI 10.1152/ajpregu.00511.2006
   Fabre JE, 2001, J CLIN INVEST, V107, P603, DOI 10.1172/JCI10881
   FARRELL JP, 1987, J IMMUNOL, V138, P902
   Fujino H, 2005, MOL PHARMACOL, V68, P251, DOI 10.1124/mol.105.011833
   Fujino H, 2002, J BIOL CHEM, V277, P2614, DOI 10.1074/jbc.M109440200
   Fujino H, 2003, J BIOL CHEM, V278, P12151, DOI 10.1074/jbc.M212665200
   Gomez I, 2013, PROSTAG LEUKOTR ESS, V89, P55, DOI 10.1016/j.plefa.2013.04.004
   Gouin O, 2017, PROTEIN CELL, V8, P644, DOI 10.1007/s13238-017-0395-5
   Grace M, 2012, THORAX, V67, P891, DOI 10.1136/thoraxjnl-2011-201443
   Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003
   He WJ, 2020, LEUKEMIA, V34, P1637, DOI 10.1038/s41375-020-0836-7
   Henkel J, 2012, LAB INVEST, V92, P1597, DOI 10.1038/labinvest.2012.128
   Hofstetter AO, 2007, P NATL ACAD SCI USA, V104, P9894, DOI 10.1073/pnas.0611468104
   Hong W., 2020, CELEBREX ADJUVANT TH
   Hu XQ, 2016, J LIPID RES, V57, P663, DOI 10.1194/jlr.M066530
   Iyu D, 2011, PROSTAG OTH LIPID M, V94, P9, DOI 10.1016/j.prostaglandins.2010.11.001
   Jang Y, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-1703-1
   Jia ZJ, 2013, AM J PHYSIOL-RENAL, V304, pF214, DOI 10.1152/ajprenal.00588.2011
   Jones Veena G, 2020, Hosp Pediatr, V10, P537, DOI 10.1542/hpeds.2020-0123
   Kalinski P, 2012, J IMMUNOL, V188, P21, DOI 10.4049/jimmunol.1101029
   Kamei D, 2004, J BIOL CHEM, V279, P33684, DOI 10.1074/jbc.M400199200
   KARIM SMM, 1970, BRIT MED J, V3, P198, DOI 10.1136/bmj.3.5716.198
   Kawabata A, 2011, BIOL PHARM BULL, V34, P1170, DOI 10.1248/bpb.34.1170
   KERNACKI KA, 1994, J OCUL PHARMACOL, V10, P281, DOI 10.1089/jop.1994.10.281
   Kochi AN, 2020, J CARDIOVASC ELECTR, V31, P1003, DOI 10.1111/jce.14479
   Kollarik M, 2007, PULM PHARMACOL THER, V20, P402, DOI 10.1016/j.pupt.2006.11.010
   Kopf BS, 2011, PHARMACOL BIOCHEM BE, V99, P437, DOI 10.1016/j.pbb.2011.04.006
   Li P, 2009, NEUROSCIENCE, V164, P948, DOI 10.1016/j.neuroscience.2009.08.044
   Li W, 2017, CELL PHYSIOL BIOCHEM, V43, P1152, DOI 10.1159/000481756
   Li WJ, 2008, NEUROCHEM RES, V33, P490, DOI 10.1007/s11064-007-9462-2
   Li Yuanyuan, 2018, Oncotarget, V9, P26586, DOI 10.18632/oncotarget.25005
   Liao QJ, 2005, ACTA BIOCH BIOPH SIN, V37, P607, DOI 10.1111/j.1745-7270.2005.00082.x
   Liu XH, 2002, J BIOL CHEM, V277, P50081, DOI 10.1074/jbc.M201095200
   Maher SA, 2009, AM J RESP CRIT CARE, V180, P923, DOI 10.1164/rccm.200903-0388OC
   Malin S, 2011, J NEUROSCI, V31, P10516, DOI 10.1523/JNEUROSCI.2992-10.2011
   Moriuchi M, 2001, J VIROL, V75, P192, DOI 10.1128/JVI.75.1.192-198.2001
   Nahama A., 2020, MED DRUG DISCOV, V5
   Nakamura K, 2000, J COMP NEUROL, V421, P543, DOI 10.1002/(SICI)1096-9861(20000612)421:4<543::AID-CNE6>3.0.CO;2-3
   NAKANO J, 1973, EUR J PHARMACOL, V24, P61, DOI 10.1016/0014-2999(73)90114-3
   Nishigaki N, 1996, MOL PHARMACOL, V50, P1031
   Norregaard R, 2015, KIDNEY RES CLIN PRAC, V34, P194, DOI 10.1016/j.krcp.2015.10.004
   ONTA T, 1993, MICROBIOL IMMUNOL, V37, P573, DOI 10.1111/j.1348-0421.1993.tb01679.x
   Ozen G, 2019, INT J OBESITY, V43, P1724, DOI 10.1038/s41366-018-0235-6
   Pace S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03696-8
   Pantos C, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02934-2
   Pflucke D, 2013, J PAIN, V14, P897, DOI 10.1016/j.jpain.2013.02.012
   PHIPPS RP, 1991, IMMUNOL TODAY, V12, P349, DOI 10.1016/0167-5699(91)90064-Z
   Pyeon D, 2000, J VIROL, V74, P5740, DOI 10.1128/JVI.74.12.5740-5745.2000
   RASTOGI N, 1992, FEMS MICROBIOL IMMUN, V89, P273, DOI 10.1016/0378-1097(92)90007-B
   REINER NE, 1984, CELL IMMUNOL, V88, P501, DOI 10.1016/0008-8749(84)90181-3
   Ricciotti E, 2011, ARTERIOSCL THROM VAS, V31, P986, DOI 10.1161/ATVBAHA.110.207449
   Robertson RP, 2017, DIABETES, V66, P1464, DOI 10.2337/dbi17-0017
   Saha J, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117731
   Sander WJ, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00089
   Shim J, 2012, OPHTHALMOLOGY, V119, P2211, DOI 10.1016/j.ophtha.2012.05.038
   Siljehav V, 2014, J APPL PHYSIOL, V117, P1027, DOI 10.1152/japplphysiol.00542.2014
   Siljehav V, 2012, PEDIATR RES, V72, P460, DOI 10.1038/pr.2012.119
   Smeitink J., 2020, HYPOTHESIS MPGES 1 D
   Song Y, 2020, GUT, V69, P1143, DOI 10.1136/gutjnl-2020-320891
   Steer SA, 2003, VIRAL IMMUNOL, V16, P447, DOI 10.1089/088282403771926283
   STEVEN K, 1981, GASTROENTEROLOGY, V80, P1562
   SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463
   SUGIMOTO Y, 1994, NEUROSCIENCE, V62, P919, DOI 10.1016/0306-4522(94)90483-9
   Suzuki J, 2011, INT HEART J, V52, P266, DOI 10.1536/ihj.52.266
   Tai TC, 2000, AM J PHYSIOL-REG I, V278, pR1460
   Talbot S, 2015, NEURON, V87, P341, DOI 10.1016/j.neuron.2015.06.007
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Tang YJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01708
   Thivierge M, 1998, BLOOD, V92, P40, DOI 10.1182/blood.V92.1.40.413k43_40_45
   Trankner D, 2014, P NATL ACAD SCI USA, V111, P11515, DOI 10.1073/pnas.1411032111
   Vieira AS, 2016, LIFE SCI, V166, P8, DOI 10.1016/j.lfs.2016.10.001
   Wang W, 2005, J EXP CLIN CANC RES, V24, P99
   Wang Z, 2011, MOL VIS, V17, P3137
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Wienecke T, 2009, CEPHALALGIA, V29, P509, DOI 10.1111/j.1468-2982.2008.01748.x
   WILEY TL, 1989, INT J GYNECOL OBSTET, V28, P171, DOI 10.1016/0020-7292(89)90478-5
   Wu D, 1998, AM J PHYSIOL-CELL PH, V275, pC661
   Yu ZY, 2018, SAUDI J BIOL SCI, V25, P1468, DOI 10.1016/j.sjbs.2017.05.005
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zmigrodzka M, 2018, J PHYSIOL PHARMACOL, V69, P653, DOI 10.26402/jpp.2018.5.01
NR 93
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0265-9247
EI 1521-1878
J9 BIOESSAYS
JI Bioessays
PD DEC
PY 2020
VL 42
IS 12
AR e2000198
DI 10.1002/bies.202000198
EA NOV 2020
PG 10
WC Biochemistry & Molecular Biology; Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics
GA PA5YK
UT WOS:000588049600001
PM 33174637
OA Bronze
DA 2021-01-01
ER

PT J
AU Shiina, S
   Gani, RA
   Yokosuka, O
   Maruyama, H
   Nagamatsu, H
   Payawal, DA
   Dokmeci, AK
   Lesmana, LA
   Tanwandee, T
   Lau, G
   Sarin, SK
   Omata, M
AF Shiina, Shuichiro
   Gani, Rino A.
   Yokosuka, Osamu
   Maruyama, Hitoshi
   Nagamatsu, Hiroaki
   Payawal, Diana Alcantara
   Dokmeci, A. Kadir
   Lesmana, Laurentius A.
   Tanwandee, Tawesak
   Lau, George
   Sarin, Shiv Kumar
   Omata, Masao
TI APASL practical recommendations for the management of hepatocellular
   carcinoma in the era of COVID-19
SO HEPATOLOGY INTERNATIONAL
LA English
DT Article; Early Access
DE The novel coronavirus; Liver cancer; Asian-Pacific; Chronic liver
   disease; Asymptomatically infected; Hospital preparedness; Surveillance;
   Diagnosis; Facemask; CT screening for COVID-19; Treatment;
   Decision-making; Personal protective equipment; Aerosol generating
   procedure
ID GUIDELINES; PNEUMONIA; WUHAN; CHINA
AB Background COVID-19 has been giving the devastating impact on the current medical care system. There are quite many guidelines on COVID-19, but only a few on the management of hepatocellular carcinoma (HCC) during COVID-19 pandemic. Aims We develop these recommendations to preserve adequate clinical practice for the management of HCC. Methods Experts of HCC in the Asia-Pacific region exchanged opinions via webinar, and these recommendations were formed. Results Close contact should be minimized to reduce possible exposure of both medical staff and patients to the novel coronavirus. To prevent transmission of the virus, meticulous hygiene measures are important. With the decrease in regular medical service, the medical staff may be mobilized to provide COVID-19-related patient care. However, diagnosis and treatment of HCC should not be delayed because of COVID-19 pandemic. The management of HCC should be the same as in non-pandemic circumstances. HCC is highly malignant, thus it is recommended not to delay curative treatment such as surgery and ablation. However, a kind of triage is necessary even among patients with HCC when resources are insufficient for all to be treated. Curative treatments should be periodized and cytoreductive or non-curative treatment such as vascular interventions and systemic therapy may be postponed until it can be performed safely with sufficient resources. For patients with confirmed or suspected to be infected with the novel coronavirus, diagnosis and treatment should be postponed until the virus is eliminated or they are confirmed as not being infected with it. Conclusions These are collection of measures implemented by front-line medical professionals. We would evolve these recommendations over time as more real-world data becomes available.
C1 [Shiina, Shuichiro; Maruyama, Hitoshi; Nagamatsu, Hiroaki] Juntendo Univ, Dept Gastroenterol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.
   [Gani, Rino A.] Univ Indonesia, Cipto Mangunkusumo Hosp, Dept Internal Med, Jakarta, Indonesia.
   [Yokosuka, Osamu] Chiba Univ, Chiba, Japan.
   [Payawal, Diana Alcantara] Cardinal Santos Med Ctr, Dept Hepatol, Manila, Philippines.
   [Dokmeci, A. Kadir] Ankara Univ, Sch Med, Dept Gastroenterol, Ankara, Turkey.
   [Lesmana, Laurentius A.] Univ Indonesia, Digest Dis & GI Oncol Ctr, Jakarta, Indonesia.
   [Tanwandee, Tawesak] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Med, Bangkok, Thailand.
   [Lau, George] Humanity & Hlth Med Grp, Humanity & Hlth Clin Trial Ctr, Hong Kong, Peoples R China.
   [Lau, George] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Liver Dis & Transplant Ctr, Beijing, Peoples R China.
   [Sarin, Shiv Kumar] Inst Liver & Biliary Sci, Dept Hepatol, New Delhi 110070, India.
   [Omata, Masao] Yamanashi Prefectural Cent Hosp, Dept Gastroenterol, Kofu, Yamanashi, Japan.
   [Omata, Masao] Univ Tokyo, Tokyo, Japan.
RP Shiina, S (corresponding author), Juntendo Univ, Dept Gastroenterol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.
EM sshiina@juntendo.ac.jp
OI Dokmeci, Abdulkadir/0000-0003-4463-0031
CR Abramowicz JS, 2020, ULTRASOUND MED BIOL, V46, P1821, DOI 10.1016/j.ultrasmedbio.2020.03.033
   American College of Radiology, 2020, ACR REC US CHEST RAD
   American Institute Of Ultrasound In Medicine, 2020, QUICK GUID COVID 19
   American Society for Radiation Oncology, 2020, COVID 19 REC INF
   American Society of Clinical Oncology, 2020, ASCO COR RES
   [Anonymous], 2020, COVID 19 GUID TRIAG
   [Anonymous], 2020, UPD INT GEN SURG GUI
   Boettler Tobias, 2020, JHEP Rep, V2, P100113, DOI 10.1016/j.jhepr.2020.100113
   Center for Disease Control and Prevention, 2020, PEOPL WHO AR HIGH RI
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   European Respiratory Society, 2020, COVID 19 GUID REC DI
   European Society for Medical Oncology, 2020, ESMO MAN TREATM REC
   European Society of Medical Oncology, 2020, CANC PAT MAN COVID 1
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hirotsu Y, 2020, INFECT CONT HOSP EP, V41, P1105, DOI 10.1017/ice.2020.144
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   International Liver Cancer Association, 2020, MAN HCC COVID 19 ILC
   Izumi N, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.4002
   Ji D, 2020, J HEPATOL, V73, P451, DOI 10.1016/j.jhep.2020.03.044
   Kumar D, 2003, AM J TRANSPLANT, V3, P977, DOI 10.1034/j.1600-6143.2003.00197.x
   Lau G, 2020, HEPATOL INT, V14, P415, DOI 10.1007/s12072-020-10054-w
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Liu HL, 2020, HEPATOL INT, V14, P432, DOI 10.1007/s12072-020-10043-z
   Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
   National Health Service England, 2020, AER GEN PROC
   Omata M, 2017, HEPATOL INT, V11, P317, DOI 10.1007/s12072-017-9799-9
   Saigal S, 2020, HEPATOL INT, V14, P429, DOI 10.1007/s12072-020-10041-1
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   The Royal College of Radiologists, 2020, STAT US CT CHEST SCR
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, CANCER
   World Health Organization, 2020, RAT US PERS PROT EQ
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 37
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1936-0533
EI 1936-0541
J9 HEPATOL INT
JI Hepatol. Int.
DI 10.1007/s12072-020-10103-4
EA NOV 2020
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA OP7DS
UT WOS:000588246000001
PM 33174159
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kumar, P
   Bhardwaj, T
   Kumar, A
   Gehi, BR
   Kapuganti, SK
   Garg, N
   Nath, G
   Giri, R
AF Kumar, Prateek
   Bhardwaj, Taniya
   Kumar, Ankur
   Gehi, Bhuvaneshwari R.
   Kapuganti, Shivani K.
   Garg, Neha
   Nath, Gopal
   Giri, Rajanish
TI Reprofiling of approved drugs against SARS-CoV-2 main protease: an
   in-silico study
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; COVID-19; Nsp5; Mpro; approved drug; protease
ID PHARMACOKINETIC PROPERTIES; MANAGEMENT; OCTREOTIDE; DYNAMICS; BINDING;
   DOCKING; GLIDE
AB Given the COVID-19 pandemic, currently, there are many drugs in clinical trials against this virus. Among the excellent drug targets of SARS-CoV-2 are its proteases (Nsp3 and Nsp5) that plays vital role in polyprotein processing giving rise to functional nonstructural proteins, essential for viral replication and survival. Nsp5 (also known as M-pro) hydrolyzes replicase polyprotein (1ab) at eleven different sites. For targeting M-pro, we have employed drug repurposing approach to identify potential inhibitors of SARS-CoV-2 in a shorter time span. Screening of approved drugs through docking reveals Hyaluronic acid and Acarbose among the top hits which are showing strong interactions with catalytic site residues of M-pro. We have also performed docking of drugs Lopinavir, Ribavirin, and Azithromycin on SARS-CoV-2 M-pro. Further, binding of these compounds (Hyaluronic acid, Acarbose, and Lopinavir) is validated by extensive molecular dynamics simulation of 500 ns where these drugs show stable binding with M-pro. We believe that the high-affinity binding of these compounds will help in designing novel strategies for structure-based drug discovery against SARS-CoV-2.
   Communicated by Ramaswamy H. Sarma
C1 [Kumar, Prateek; Bhardwaj, Taniya; Kumar, Ankur; Gehi, Bhuvaneshwari R.; Kapuganti, Shivani K.; Giri, Rajanish] Indian Inst Technol Mandi, Sch Basic Sci, Mandi 175005, Himachal Prades, India.
   [Garg, Neha] Banaras Hindu Univ, Fac Ayurveda, Inst Med Sci, Dept Med Chem, Varanasi, Uttar Pradesh, India.
   [Nath, Gopal] Banaras Hindu Univ, Inst Med Sci, Fac Med, Dept Microbiol, Varanasi, Uttar Pradesh, India.
RP Giri, R (corresponding author), Indian Inst Technol Mandi, Sch Basic Sci, Mandi 175005, Himachal Prades, India.
EM rajanishgiri@iitmandi.ac.in
RI ; Giri, Rajanish/Q-6530-2018
OI Kumar, Prateek/0000-0001-7392-5045; Bhardwaj,
   Taniya/0000-0002-7226-6348; Garg, Neha/0000-0003-2227-8292; Giri,
   Rajanish/0000-0002-2046-836X
FU Department of Biotechnology, Govt of IndiaDepartment of Biotechnology
   (DBT) India [BT/11/IYBA/2018/06]; Department of Science and
   TechnologyDepartment of Science & Technology (India); MHRD fellowship,
   Govt. of India
FX All the authors would like to thank IIT Mandi for providing HPC
   facilities. RG would like to thank the Department of Biotechnology, Govt
   of India (BT/11/IYBA/2018/06). TB is grateful to the Department of
   Science and Technology for INSPIRE fellowship. PK, SK, AK, and BRG are
   supported by MHRD fellowship, Govt. of India.
CR Aarthy M, 2018, GENE, V658, P159, DOI 10.1016/j.gene.2018.03.026
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   [Anonymous], 2020, COVID19 RING BASED P
   Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468
   BATTERSHILL PE, 1989, DRUGS, V38, P658, DOI 10.2165/00003495-198938050-00002
   BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E
   Breckenridge A, 2019, NAT REV DRUG DISCOV, V18, P1, DOI 10.1038/nrd.2018.92
   Cao B, 2020, NEW ENGL J MED, V382
   Cermelli C, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-141
   Chandwani Ashish, 2008, Ther Clin Risk Manag, V4, P1023
   David CC, 2014, METHODS MOL BIOL, V1084, P193, DOI 10.1007/978-1-62703-658-0_11
   Davidson RN, 2009, T ROY SOC TROP MED H, V103, P653, DOI 10.1016/j.trstmh.2008.09.008
   DiNicolantonio JJ, 2015, OPEN HEART, V2, DOI 10.1136/openhrt-2014-000230
   Ennifar E, 2006, NUCLEIC ACIDS RES, V34, P2328, DOI 10.1093/nar/gkl317
   Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Giri R., 2020, DARKNESS BECOMES RAY, DOI [10.1101/2020.03.13.990598, DOI 10.1101/2020.03.13.990598, https://doi.org/10.1101/2020.03.13.990598]
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Halgren TA, 2009, J CHEM INF MODEL, V49, P377, DOI 10.1021/ci800324m
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Hofland LJ, 1996, BAILLIERE CLIN ENDOC, V10, P163, DOI 10.1016/S0950-351X(96)80362-4
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Khalili JS, 2020, J MED VIROL, V92, P740, DOI 10.1002/jmv.25798
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Krilov Leonard R., 2001, Curr Infect Dis Rep, V3, P242, DOI 10.1007/s11908-001-0026-3
   Kumar A, 2018, ACS OMEGA, V3, P18132, DOI 10.1021/acsomega.8b01002
   Kumar D, 2020, ACS OMEGA, V5, P11217, DOI 10.1021/acsomega.0c01353
   Kumar D, 2020, J BIOMOL STRUCT DYN, V38, P4827, DOI 10.1080/07391102.2019.1689851
   Kumar P, 2020, J BIOMOL STRUCT DYN, V38, P4997, DOI 10.1080/07391102.2019.1696231
   Kumar P, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8030128
   Kumar Y, 2020, J INFECT PUBLIC HEAL, V13, P1210, DOI 10.1016/j.jiph.2020.06.016
   Li J, 2005, J BIOL CHEM, V280, P28766, DOI 10.1074/jbc.M500588200
   Loustaud-Ratti V, 2016, WORLD J HEPATOL, V8, P123, DOI 10.4254/wjh.v8.i2.123
   McKeage K, 2003, DRUGS, V63, P2473, DOI 10.2165/00003495-200363220-00014
   McMullan BJ, 2015, AUST PRESCR, V38, P87, DOI 10.18773/austprescr.2015.030
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   PETERS DH, 1992, DRUGS, V44, P750, DOI 10.2165/00003495-199244050-00007
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Ramirez MS, 2017, MOLECULES, V22, DOI 10.3390/molecules22122267
   Reddy KR, 2009, J HEPATOL, V50, P402, DOI 10.1016/j.jhep.2008.11.006
   Sang P, 2020, RSC ADV, V10, P15775, DOI 10.1039/d0ra01899f
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Shalev-Benami M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01664-4
   Sharma N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1797538
   Sharma N, 2017, INT J BIOL MACROMOL, V104, P1046, DOI 10.1016/j.ijbiomac.2017.06.105
   Shirley M, 2019, DRUGS, V79, P555, DOI 10.1007/s40265-019-01095-z
   Tamma PD, 2012, CLIN MICROBIOL REV, V25, P450, DOI 10.1128/CMR.05041-11
   Victorovich K. V., 2020, TRANSLATION ASS MUTA, DOI [https://doi.org/10.1101/2020.05.05.078238, DOI 10.1101/2020.05.05.078238]
   Widjaja LK, 2014, J BIOMED MATER RES A, V102, P3056, DOI 10.1002/jbm.a.34976
   Wishart D. S., 2018, NUCL ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yadav R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2019.1709546
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 55
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1845976
EA NOV 2020
PG 15
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OQ1CH
UT WOS:000588527900001
PM 33179586
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Sharma, S
   Deep, S
AF Sharma, Shilpa
   Deep, Shashank
TI In-silico drug repurposing for targeting SARS-CoV-2 main protease
   (M-pro)
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; MD simulation; repurposing; EGCG
ID GREEN TEA; EPIGALLOCATECHIN GALLATE; CORONAVIRUS; INFECTION; DISCOVERY;
   COVID-19
AB COVID-19, caused by novel coronavirus or SARS-CoV-2, is a viral disease which has infected millions worldwide. Considering the urgent need of the drug for fighting against this infectious disease, we have performed in-silico drug repurposing followed by molecular dynamics (MD) simulation and MM-GBSA calculation. The main protease (M-pro) is one of the best-characterized drug targets among coronaviruses, therefore, this was screened for already known FDA approved drugs and some natural compounds. Comparison of docking and MD simulation results of complexes of drugs with that of inhibitor N3 (experimentally obtained) suggests EGCG, withaferin, dolutegravir, artesunate as potential inhibitors of the main protease (M-pro). Further, in silico docking and MD simulation suggest that EGCG analogues ZINC21992196 and ZINC 169337541 may act as a better inhibitor.
   Communicated by Ramaswamy H. Sarma
C1 [Sharma, Shilpa; Deep, Shashank] Indian Inst Technol Delhi, Dept Chem, New Delhi 110016, India.
RP Deep, S (corresponding author), Indian Inst Technol Delhi, Dept Chem, New Delhi 110016, India.
EM sdeep@chemistry.iitd.ac.in
FU University Grants Commission (UGC)University Grants Commission, India
FX SS thank University Grants Commission (UGC) for financial support.
CR Abraham M. J., 2015, GROMACS USER MANUAL
   Adem S., 2020, IDENTIFICATION POTEN, V46, P1, DOI [10.20944/preprints202003.0333.v1., 10.20944/preprints202003.0333.v1, DOI 10.20944/PREPRINTS202003.0333.V1]
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   [Anonymous], MARVINSKETCH 17230
   Benelli R, 2002, BIOL CHEM, V383, P101, DOI 10.1515/BC.2002.010
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Cai Z, 2015, CELL BIOCHEM BIOPHYS, V72, P727, DOI 10.1007/s12013-015-0524-9
   Case D., 2018, AMBER 2018
   Efferth T, 2008, CLIN INFECT DIS, V47, P804, DOI 10.1086/591195
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Ho HY, 2009, J AGR FOOD CHEM, V57, P6140, DOI 10.1021/jf901128u
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Keiser M. J., 2007, NAT BIOTECHNOL, V25, P2, DOI DOI https://doi.org/10.1038/nbt1284
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Lisewski AM, 2014, CELL, V158, P916, DOI 10.1016/j.cell.2014.07.011
   Min S, 2010, ANTIMICROB AGENTS CH, V54, P254, DOI 10.1128/AAC.00842-09
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Nance CL, 2009, J ALLERGY CLIN IMMUN, V123, P459, DOI 10.1016/j.jaci.2008.12.024
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Onufriev AV, 2019, ANNU REV BIOPHYS, V48, P275, DOI 10.1146/annurev-biophys-052118-115325
   PETERSEN HG, 1995, J CHEM PHYS, V103, P3668, DOI 10.1063/1.470043
   Principi N, 2020, LANCET INFECT DIS, V20, P1118, DOI 10.1016/S1473-3099(20)30296-6
   Santos MMM, 2007, MINI-REV MED CHEM, V7, P1040, DOI 10.2174/138955707782110105
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Singh AK, 2020, DIABETES METAB SYND, V14, P241, DOI 10.1016/j.dsx.2020.03.011
   Song JM, 2005, ANTIVIR RES, V68, P66, DOI 10.1016/j.antiviral.2005.06.010
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Trag J, 2019, J MOL MODEL, V25, DOI 10.1007/s00894-018-3911-5
   Trott O., 2010, J COMPUTATIONAL CHEM, V31, pP455
   Verma D., 2020, POTENTIAL INHIBITORS, DOI [10.20944/preprints202004.0149.v1, DOI 10.20944/PREPRINTS202004.0149.V1]
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Weber JM, 2003, ANTIVIR RES, V58, P167, DOI 10.1016/S0166-3542(02)00212-7
   Weiser J, 1999, J COMPUT CHEM, V20, P217, DOI 10.1002/(SICI)1096-987X(19990130)20:2<217::AID-JCC4>3.0.CO;2-A
   Wishart D. S., 2006, NUCL ACIDS RES, V34, pD668, DOI DOI https://doi.org/10.1093/nar/gkj067
   Worldometers, CORONAVIRUS
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 42
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1844058
EA NOV 2020
PG 8
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OQ0US
UT WOS:000588508200001
PM 33179568
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Goss, MB
   Munoz, FM
   Ruan, W
   Galvan, NTN
   O'Mahony, CA
   Rana, A
   Cotton, RT
   Moreno, NF
   Heczey, AA
   Leung, DH
   Goss, JA
AF Goss, Matthew B.
   Munoz, Flor M.
   Ruan, Wenly
   Galvan, N. Thao N.
   O'Mahony, Christine A.
   Rana, Abbas
   Cotton, Ronald T.
   Moreno, Nicolas F.
   Heczey, Andras A.
   Leung, Daniel H.
   Goss, John A.
TI Liver transplant in a recently COVID-19 positive child with
   hepatoblastoma
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article; Early Access
DE hepatoblastoma; pediatric liver transplantation; viral infection
AB We describe the successful pediatric liver transplant for unresectable hepatoblastoma in a 4-year-old male with COVID-19 prior to transplant. The first negative NP swab was documented 1 month after initial diagnosis, when SARS-CoV-2 antibodies were also detected. The patient was actively listed for liver transplant after completing four blocks of a SIOPEL-4 based regimen due to his PRETEXT IV disease which remained unresectable. Following three additional negative NP swabs and resolution of symptoms for 4 weeks, he underwent a whole-organ pediatric liver transplant. COVID-19 positivity determined via NP swab SARS-CoV-2 real-time RT-PCR (Hologic Aptima SARS-CoV-2 RT-PCR assay). IgG and IgM total SARS- CoV-2 antibodies detected by Ortho Clinical Diagnostics VITROS (R) Immunodiagnostics Products Anti-SARS-CoV-2 Test. Patient received standard prednisone and tacrolimus-based immunosuppression without induction therapy following transplant. Post-transplant course was remarkable for neutropenia and thrombocytopenia, with discharge home on post-transplant day #11. Surveillance tests have remained negative with persistent SARS-CoV-2 IgG antibodies at 6 weeks after transplant. We describe one of the earliest, if not the first case of liver transplant following recent recovery from COVID-19 in a pediatric patient with a lethal malignant liver tumor. A better understanding of how to balance the risk profile of transplant in the setting of COVID-19 with disease progression if transplant is not performed is needed. We followed existing ASTS guidelines to document clearance of the viral infection and resolution of symptoms before transplant. This case highlights that pediatric liver transplantation can be safely performed upon clearance of COVID-19.
C1 [Goss, Matthew B.; Moreno, Nicolas F.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Houston, TX 77030 USA.
   [Munoz, Flor M.] Baylor Coll Med, Dept Pediat, Div Infect Dis, Houston, TX 77030 USA.
   [Ruan, Wenly; Leung, Daniel H.] Baylor Coll Med, Dept Pediat, Div Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA.
   [Galvan, N. Thao N.; O'Mahony, Christine A.; Rana, Abbas; Cotton, Ronald T.; Goss, John A.] Baylor Coll Med, Dept Surg, Div Abdominal Transplantat, Houston, TX 77030 USA.
   [Heczey, Andras A.] Baylor Coll Med, Dept Pediat, Div Hematol & Oncol, Houston, TX 77030 USA.
RP Goss, MB (corresponding author), Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Houston, TX 77030 USA.
EM matthew.b.goss@uth.tmc.edu
OI Goss, Matthew/0000-0003-4663-0086; Moreno, Nicolas/0000-0001-8661-676X
CR Alberici F, 2020, KIDNEY INT, V97, P1083, DOI 10.1016/j.kint.2020.04.002
   [Anonymous], 2020, ORG RETR TRANSPL COV
   [Anonymous], 2020, CLIN BEST PRACT ADV
   ASTS, 2020, COVID 19 STRIK FORC
   Bhoori S, 2020, LANCET GASTROENTEROL, V5, P532, DOI 10.1016/S2468-1253(20)30116-3
   Doglietto F, 2020, JAMA SURG, V155, P691, DOI 10.1001/jamasurg.2020.2713
   Feng GZ, 2020, CASE STUD THERM ENG, V21, DOI 10.1016/j.csite.2020.100685
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Galvan NTN, AM J TRANSPL
   Huang JF, 2020, AM J TRANSPLANT, V20, P1907, DOI 10.1111/ajt.15909
   Khanna R, 2013, INDIAN J MED RES, V138, P796
   Nahshon C, 2020, WORLD J SURG, V44, P2477, DOI 10.1007/s00268-020-05575-2
   Perilongo G, 2000, Lancet Oncol, V1, P94, DOI 10.1016/S1470-2045(00)00018-8
   Travi G, 2020, AM J TRANSPLANT, V20, P2628, DOI 10.1111/ajt.16069
   Tschopp J, 2020, AM J TRANSPLANT, V20, P2876, DOI 10.1111/ajt.16062
NR 15
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
AR e13880
DI 10.1111/petr.13880
EA NOV 2020
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA OP8IJ
UT WOS:000588333600001
PM 32979013
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Hill, JB
   Garcia, D
   Crowther, M
   Savage, B
   Peress, S
   Chang, K
   Deitelzweig, S
AF Hill, Jason B.
   Garcia, David
   Crowther, Mark
   Savage, Bryan
   Peress, Shira
   Chang, Kevin
   Deitelzweig, Steven
TI Frequency of venous thromboembolism in 6513 patients with COVID-19: a
   retrospective study
SO BLOOD ADVANCES
LA English
DT Article
ID HOSPITALIZED MEDICAL PATIENTS; RISK; THROMBOPROPHYLAXIS
AB Patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appear to be at increased risk for venous thromboembolism (VTE), especially if they become critically ill with COVID-19. Some centers have reported very high rates of thrombosis despite anticoagulant prophylaxis. The electronic health record (EHR) of a New Orleans-based health system was searched for all patients with polymerase chain reaction-confirmed SARS-CoV-2 infection who were either admitted to hospital or treated and discharged from an emergency department between 1 March 2020 and 1 May 2020. From this cohort, patients with confirmed VTE (either during or after their hospital encounter) were identified by administrative query of the EHR.: Between 1 March 2020 and 1 May 2020, 6153 patients with COVID-19 were identified; 2748 of these patients were admitted, while 3405 received care exclusively through the emergency department. In total, 637 patients required mechanical ventilation and 206 required renal replacement therapy. Within the hospitalized cohort, the overall mortality rate was 24.5% and VTE occurred in 86 patients (3.1%). In the 637 patients who required mechanical ventilation at some point during their hospital stay, 45 developed VTE (7.2%). After a median follow-up of 14.6 days, VTE had been diagnosed in 3 of the 2075 admitted who were discharged alive (0.14%). Among 6153 patients with COVID-19 who were hospitalized or treated in emergency departments, we did not find evidence of unusually high VTE risk. Pending further evidence from prospective, controlled trials, our findings support a traditional approach to primary VTE prevention in patients with COVID-19.
C1 [Hill, Jason B.; Deitelzweig, Steven] Ochsner Hlth, Dept Hosp Med, New Orleans, LA 70121 USA.
   [Garcia, David] Univ Washington, Dept Med, Seattle, WA USA.
   [Crowther, Mark] McMaster Univ, Dept Med, Hamilton, ON, Canada.
   [Savage, Bryan; Peress, Shira; Chang, Kevin] Univ Queensland, Sch Med, Brisbane, Qld, Australia.
RP Hill, JB (corresponding author), Ochsner Hlth Syst, OMC NS Hosp Med, CMIO, 100 Med Ctr Dr, Slidell, LA 70460 USA.
EM jahill@ochsner.org
CR Barbar S, 2010, J THROMB HAEMOST, V8, P2450, DOI 10.1111/j.1538-7836.2010.04044.x
   Bilaloglu S, 2020, JAMA-J AM MED ASSOC, V324, P799, DOI 10.1001/jama.2020.13372
   Cattaneo M, 2020, THROMB HAEMOSTASIS, V120, P1230, DOI 10.1055/s-0040-1712097
   Chiasakul T, 2019, THROMB RES, V184, P58, DOI 10.1016/j.thromres.2019.10.027
   Cook DJ, 2010, CRIT CARE MED, V38, pS76, DOI 10.1097/CCM.0b013e3181c9e344
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Kaplan D, 2015, CHEST, V148, P1224, DOI 10.1378/chest.15-0287
   Klok FA, 2020, THROMB RES, V191, P148, DOI 10.1016/j.thromres.2020.04.041
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   Poissy J, 2020, CIRCULATION, V142, P184, DOI 10.1161/CIRCULATIONAHA.120.047430
   Roberts LN, 2020, BLOOD, V136, P1347, DOI 10.1182/blood.2020008086
   Spyropoulos AC, 2011, CHEST, V140, P706, DOI 10.1378/chest.10-1944
NR 13
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 2473-9529
EI 2473-9537
J9 BLOOD ADV
JI Blood Adv.
PD NOV 10
PY 2020
VL 4
IS 21
BP 5373
EP 5377
DI 10.1182/bloodadvances.2020003083
PG 5
WC Hematology
SC Hematology
GA OS7VS
UT WOS:000590367600005
PM 33137202
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Islam, AMMK
   Khan, MAAK
AF Islam, Abul Bashar Mir Md Khademul
   Khan, Md Abdullah-Al-Kamran
TI Lung transcriptome of a COVID-19 patient and systems biology predictions
   suggest impaired surfactant production which may be druggable by
   surfactant therapy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CYTOKINE STORM; PROTEIN-C; SP-B; PULMONARY; HYPOXIA; ACTIVATION; GENE;
   HIF; ENCYCLOPEDIA; PATHOGENESIS
AB An incomplete understanding of the molecular mechanisms behind impairment of lung pathobiology by COVID-19 complicates its clinical management. In this study, we analyzed the gene expression pattern of cells obtained from biopsies of COVID-19-affected patient and compared to the effects observed in typical SARS-CoV-2 and SARS-CoV-infected cell-lines. We then compared gene expression patterns of COVID-19-affected lung tissues and SARS-CoV-2-infected cell-lines and mapped those to known lung-related molecular networks, including hypoxia induced responses, lung development, respiratory processes, cholesterol biosynthesis and surfactant metabolism; all of which are suspected to be downregulated following SARS-CoV-2 infection based on the observed symptomatic impairments. Network analyses suggest that SARS-CoV-2 infection might lead to acute lung injury in COVID-19 by affecting surfactant proteins and their regulators SPD, SPC, and TTF1 through NSP5 and NSP12; thrombosis regulators PLAT, and EGR1 by ORF8 and NSP12; and mitochondrial NDUFA10, NDUFAF5, and SAMM50 through NSP12. Furthermore, hypoxia response through HIF-1 signaling might also be targeted by SARS-CoV-2 proteins. Drug enrichment analysis of dysregulated genes has allowed us to propose novel therapies, including lung surfactants, respiratory stimulants, sargramostim, and oseltamivir. Our study presents a distinct mechanism of probable virus induced lung damage apart from cytokine storm.
C1 [Islam, Abul Bashar Mir Md Khademul] Univ Dhaka, Dept Genet Engn & Biotechnol, Dhaka 1000, Bangladesh.
   [Khan, Md Abdullah-Al-Kamran] BRAC Univ, Dept Math & Nat Sci, Dhaka, Bangladesh.
RP Islam, AMMK (corresponding author), Univ Dhaka, Dept Genet Engn & Biotechnol, Dhaka 1000, Bangladesh.
EM khademul@du.ac.bd
OI Islam, Abul/0000-0002-7274-0855
CR Akman HO, 2001, BLOOD, V98, P3324, DOI 10.1182/blood.V98.12.3324
   ANDERS S, 2010, GENOME BIOL, V11, DOI DOI 10.1186/GB-2010-11-10-R106
   Andrews S., 2010, BABRAHAM BIOINFORMAT
   [Anonymous], 2020, NCBI GENE
   [Anonymous], 2020, WORLDOMETER, P1
   Aquino-Jarquin G, 2019, NANOMED-NANOTECHNOL, V18, P428, DOI 10.1016/j.nano.2019.03.006
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bales MJ, 2004, ANN PHARMACOTHER, V38, P1722, DOI 10.1345/aph.1E039
   Barnes PJ, 2009, ANNU REV PHYSIOL, V71, P451, DOI 10.1146/annurev.physiol.010908.163257
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Bruno MD, 2000, J BIOL CHEM, V275, P1043, DOI 10.1074/jbc.275.2.1043
   Butler D. J., 2020, HOST VIRAL ENV TRANS, DOI [10.1101/2020.04.20.048066, DOI 10.1101/2020.04.20.048066]
   Calabro P, 2012, INTERN EMERG MED, V7, P425, DOI 10.1007/s11739-011-0643-2
   Cascella M, 2020, STATPEARLS
   Cavadas MAS, 2016, SCI REP-UK, V6, DOI 10.1038/srep31355
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Cloonan SM, 2016, J CLIN INVEST, V126, P809, DOI 10.1172/JCI81113
   Czyzewski AM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25009-3
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Faiz A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30602-7
   Fang JH, 2014, FREE RADICAL BIO MED, V68, P80, DOI 10.1016/j.freeradbiomed.2013.11.028
   Fessler MB, 2017, ANN AM THORAC SOC, V14, pS399, DOI 10.1513/AnnalsATS.201702-136AW
   Flicek P, 2008, NUCLEIC ACIDS RES, V36, pD707, DOI 10.1093/nar/gkm988
   Fung SY, 2020, EMERG MICROBES INFEC, V9, P558, DOI 10.1080/22221751.2020.1736644
   Fung TS, 2019, ANNU REV MICROBIOL, V73, P529, DOI 10.1146/annurev-micro-020518-115759
   Galiatsatos P., 2020, WHAT CORONAVIRUS DOE
   Glasser JR, 2012, MICROBES INFECT, V14, P17, DOI 10.1016/j.micinf.2011.08.019
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Gouveia L., EXPLORING EFFECT PDG
   Gu J, 2007, AM J PATHOL, V170, P1136, DOI 10.2353/ajpath.2007.061088
   Han H, 2018, NUCLEIC ACIDS RES, V46, pD380, DOI 10.1093/nar/gkx1013
   Han S, 2015, ANN AM THORAC SOC, V12, P765, DOI 10.1513/AnnalsATS.201411-507FR
   Hansen KD, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq224
   He X., A28 ADV COPD ASTHMA, pA1200
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang HY, 2020, NUCLEIC ACIDS RES, V48, pD148, DOI 10.1093/nar/gkz896
   Huang RL, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00445
   Hubbard TJP, 2007, NUCLEIC ACIDS RES, V35, pD610, DOI 10.1093/nar/gkl996
   Ikegami M, 2006, RESPIROLOGY, V11, pS24, DOI 10.1111/j.1440-1843.2006.00803.x
   Ivan M, 2017, MOL CELL, V66, P772, DOI 10.1016/j.molcel.2017.06.002
   Jassal B, 2020, NUCLEIC ACIDS RES, V48, pD498, DOI 10.1093/nar/gkz1031
   Jiang SB, 2020, EMERG MICROBES INFEC, V9, P275, DOI 10.1080/22221751.2020.1723441
   JOHANSSON J, 1992, FEBS LETT, V301, P165, DOI 10.1016/0014-5793(92)81239-I
   JOHANSSON J, 1988, FEBS LETT, V232, P61, DOI 10.1016/0014-5793(88)80386-7
   Jourquin J, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-S8-S20
   Kaiser L, 2003, ARCH INTERN MED, V163, P1667, DOI 10.1001/archinte.163.14.1667
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kasinski A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093480
   Kauffmann Audrey, 2009, Bioinformatics, V25, P415, DOI 10.1093/bioinformatics/btn647
   Kron M, 2011, J NEUROPHYSIOL, V105, P3067, DOI 10.1152/jn.00822.2010
   Kulkarni HS, 2018, J ALLERGY CLIN IMMUN, V141, P1582, DOI 10.1016/j.jaci.2017.11.046
   Lachmann A, 2010, BIOINFORMATICS, V26, P2438, DOI 10.1093/bioinformatics/btq466
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Lei CQ, 2015, J INNATE IMMUN, V7, P153, DOI 10.1159/000365971
   Li L, 2015, CELL PHYSIOL BIOCHEM, V37, P1113, DOI 10.1159/000430236
   Li L, 2015, CELL REP, V10, P654, DOI 10.1016/j.celrep.2015.01.011
   Li RB, 2018, ELIFE, V7, DOI 10.7554/eLife.36865
   Liao Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt214
   Liao YX, 2019, NUCLEIC ACIDS RES, V47, pW199, DOI 10.1093/nar/gkz401
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Manjarrez-Zavala M. E., 2013, RESP DIS INFECT NEW, DOI [10.5772/54287, DOI 10.5772/54287]
   Manley GCA, 2019, J VIROL, V93, DOI 10.1128/JVI.01659-18
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Martinez Fernando O, 2014, F1000Prime Rep, V6, P13, DOI 10.12703/P6-13
   Matissek SJ, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-00540-x
   Medvedeva YA, 2015, DATABASE-OXFORD, DOI 10.1093/database/bav067
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mo XH, 2018, 2018 IEEE INTERNATIONAL CONFERENCE ON COMPUTER AND COMMUNICATION ENGINEERING TECHNOLOGY (CCET), P80, DOI 10.1109/CCET.2018.8542452
   Mortaz Esmaeil, 2011, Tanaffos, V10, P7
   Mulugeta S, 2006, MICROBES INFECT, V8, P2317, DOI 10.1016/j.micinf.2006.04.009
   Nayak A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00131
   Niedermeyer J, 1993, Z Gesamte Inn Med, V48, P332
   Noutsios GT, 2015, AM J PHYSIOL-LUNG C, V309, pL147, DOI 10.1152/ajplung.00088.2015
   Olajuyin AM, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0147-9
   Ouiddir A, 1999, AM J RESP CELL MOL, V21, P710, DOI 10.1165/ajrcmb.21.6.3751
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Perez-Llamas C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019541
   Pfefferle S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002331
   Pinero J, 2020, NUCLEIC ACIDS RES, V48, pD845, DOI 10.1093/nar/gkz1021
   Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722
   Romero P, 2005, GENOME BIOL, V6
   Rotzinger DC, 2020, THROMB RES, V190, P58, DOI 10.1016/j.thromres.2020.04.011
   Saito A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082460
   Salsman J, 2017, SCI REP-UK, V7, DOI 10.1038/srep45038
   Schafer A, 2017, PATHOGENS, V6, DOI 10.3390/pathogens6010008
   Schaible B, 2010, RESP PHYSIOL NEUROBI, V174, P235, DOI 10.1016/j.resp.2010.08.006
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shimoda LA, 2011, AM J RESP CRIT CARE, V183, P152, DOI 10.1164/rccm.201009-1393PP
   Silveyra P, 2013, GENE, V531, P126, DOI 10.1016/j.gene.2012.09.111
   Sisson TH, 2007, CURR DRUG TARGETS, V8, P1016, DOI 10.2174/138945007781662319
   Skokic F, 2010, PEDIATR INFECT DIS J, V29, P387, DOI [10.1097/INF.0b013e3181cf2eaa, 10.1097/INF.0b013e3181ce8e81]
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23
   Sorensen GL, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00018
   Sperandio S, 2009, MOL CARCINOGEN, V48, P38, DOI 10.1002/mc.20454
   Srinivasan S, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040360
   Sulemane S, 2020, EUR HEART J-CARD IMG, V21, P1054, DOI 10.1093/ehjci/jeaa115
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Tazawa R, 2019, NEW ENGL J MED, V381, P923, DOI 10.1056/NEJMoa1816216
   To KKW, 2005, J BIOL CHEM, V280, P38102, DOI 10.1074/jbc.M504342200
   Tong Z, 2019, NUCLEIC ACIDS RES, V47, pD253, DOI 10.1093/nar/gky1023
   Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120
   Veldhuizen EJA, 2000, BBA-BIOMEMBRANES, V1467, P255, DOI 10.1016/S0005-2736(00)00256-X
   Walther FJ, 2019, EXPERT REV RESP MED, V13, P499, DOI 10.1080/17476348.2019.1589372
   Wishart DS, 2006, NUCLEIC ACIDS RES, V34, pD668, DOI 10.1093/nar/gkj067
   Wright JR, 2005, NAT REV IMMUNOL, V5, P58, DOI 10.1038/nri1528
   Xiong Y, 2020, EMERG MICROBES INFEC, V9, P761, DOI 10.1080/22221751.2020.1747363
   Yamano G, 2001, FEBS LETT, V508, P221, DOI 10.1016/S0014-5793(01)03056-3
   Yan SF, 1999, ARTERIOSCL THROM VAS, V19, P2029, DOI 10.1161/01.ATV.19.9.2029
   Yang MC, 2006, BIOCHEM BIOPH RES CO, V344, P484, DOI 10.1016/j.bbrc.2006.03.158
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Yoshikawa T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008729
   Zhang JZ, 1999, AM J KIDNEY DIS, V34, P189, DOI 10.1016/S0272-6386(99)70131-9
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou Y, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007096
   Zhu J, 2012, CHEST, V142, P347, DOI 10.1378/chest.11-1581
NR 119
TC 0
Z9 0
U1 3
U2 3
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 10
PY 2020
VL 10
IS 1
AR 19395
DI 10.1038/s41598-020-76404-8
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OZ8DJ
UT WOS:000595149800006
PM 33173052
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Peters, MH
   Bastidas, O
   Kokron, DS
   Henze, CE
AF Peters, Michael H.
   Bastidas, Oscar
   Kokron, Daniel S.
   Henze, Christopher E.
TI Static all-atom energetic mappings of the SARS-Cov-2 spike protein and
   dynamic stability analysis of "Up" versus "Down" protomer states
SO PLOS ONE
LA English
DT Article
AB The SARS-CoV-2 virion responsible for the current world-wide pandemic COVID-19 has a characteristic Spike protein (S) on its surface that embellishes both a prefusion state and fusion state. The prefusion Spike protein (S) is a large trimeric protein where each protomer may be in a so-called Up state or Down state, depending on the configuration of its receptor binding domain (RBD) within its distal, prefusion S1 domain. The Up state is believed to allow binding of the virion to ACE-2 receptors on human epithelial cells, whereas the Down state is believed to be relatively inactive or reduced in its binding behavior. We have performed detailed all-atom, dominant energy landscape mappings for noncovalent interactions (charge, partial charge, and van der Waals) of the SARS-CoV-2 Spike protein in its static prefusion state based on two recent and independent experimental structure publications. We included both interchain interactions and intrachain (domain) interactions in our mappings in order to determine any telling differences (different so-called "glue" points) between residues in the Up and Down state protomers. The S2 proximal, fusion domain demonstrated no appreciable energetic differences between Up and Down protomers, including interchain as well as each protomer's intrachain, S1-S2 interactions. However, the S1 domain interactions across neighboring protomers, which include the RBD-NTD cross chain interactions, showed significant energetic differences between Up-Down and Down-Down neighboring protomers. This included, for example, a key RBD residue ARG357 in the Up-Down interaction and a three residue sequence ALA520-PRO521-ALA522, associated with a turn structure in the RBD of the Up state protomer, acting as a stabilizing interaction with the NTD of its neighbor protomer. Additionally, our intra chain dominant energy mappings within each protomer, identified a significant "glue" point or possible "latch" for the Down state protomer between the S1 subdomain, SD1, and the RBD domain of the same protomer that was completely missing in the Up state protomer analysis. Ironically, this dominant energetic interaction in the Down state protomer involved the backbone atoms of the same three residue sequence ALA520-PRO521-ALA522 of the RBD with the amino acid R-group of GLN564 in the SD1 domain. Thus, this same three residue sequence acts as a stabilizer of the RBD in the Up conformation through its interactions with its neighboring NTD chain and a kind of latch in the Down state conformation through its interactions with its own SD1 domain. The dominant interaction energy residues identified here are also conserved across reported variations of SARS-CoV-2, as well as the closely related virions SARS-Cov and the bat corona virus RatG13. We conducted preliminary molecular dynamics simulations across 0.1 mu seconds to see if this latch provided structural stability and indeed found that a single point mutation (Q564G) resulted in the latch releasing transforming the protomer from the Down to the Up state conformation. Full trimeric Spike protein studies of the same mutation across all protomers, however, did not exhibit latch release demonstrating the critical importance of interchain interactions across the S1 domain, including RBD-NTD neighboring chain interactions. Therapies aimed at disrupting these noncovalent interactions could be a viable route for the physico-chemical mitigation of this deadly virion.
C1 [Peters, Michael H.] Virginia Commonwealth Univ, Dept Chem & Life Sci Engn, Richmond, VA 23284 USA.
   [Bastidas, Oscar] Univ Minnesota, Coll Biol Sci, Minneapolis, MN USA.
   [Kokron, Daniel S.; Henze, Christopher E.] NASA, Ames Res Ctr, Moffett Field, CA 94035 USA.
RP Peters, MH (corresponding author), Virginia Commonwealth Univ, Dept Chem & Life Sci Engn, Richmond, VA 23284 USA.
EM mpeters@vcu.edu
FU V.C.U. Office of Vice President for Research; National Institutes of
   Health Institutional Research and Academic Career Development
   AwardUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [K12GM119955]; COVID-19 HPC Consortium
FX M.H.P was partly supported by the V.C.U. Office of Vice President for
   Research. O.B. was supported by the National Institutes of Health
   Institutional Research and Academic Career Development Award
   K12GM119955. M.H.P and O. B. would like to acknowledge the support
   provided via the COVID-19 HPC Consortium
   (https://covid19-hpc-consortium.org/), which is a unique private-public
   effort to bring together government, industry, and academic leaders who
   are volunteering free compute time and resources, in support of COVID-19
   research.
CR Bastidas OH, 2016, SCI REP-UK, V6, DOI 10.1038/srep36499
   Cai YF, 2020, SCIENCE, V369, P1586, DOI 10.1126/science.abd4251
   Henderson R, 2020, NAT STRUCT MOL BIOL, V27, P925, DOI 10.1038/s41594-020-0479-4
   Jo S, 2008, J COMPUT CHEM, V29, P1859, DOI 10.1002/jcc.20945
   Krall A, 2014, PROTEINS, V82, P2253, DOI 10.1002/prot.24592
   Li T, 2020, BIORXIV, DOI [10.1101/2020.03.16.994152, DOI 10.1101/2020.03.16.994152]
   McCallum M, 2020, NAT STRUCT MOL BIOL, DOI 10.1038/s41594-020-0483-8
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Shaw DE, 2020, MOL DYNAMICS SIMULAT
   Walls AC, 2020, STRUCTURE FUNCTION A, DOI [10.1101/2020.02.19.956581, DOI 10.1101/2020.02.19.956581]
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
NR 13
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 10
PY 2020
VL 15
IS 11
AR e0241168
DI 10.1371/journal.pone.0241168
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OV7KH
UT WOS:000592383400012
PM 33170884
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Albariqi, AH
   Chang, RYK
   Tai, WT
   Ke, WR
   Chow, MYT
   Tang, PT
   Kwok, PCL
   Chan, HK
AF Albariqi, Ahmed H.
   Chang, Rachel Yoon Kyung
   Tai, Waiting
   Ke, Wei-Ren
   Chow, Michael Y. T.
   Tang, Patricia
   Kwok, Philip Chi Lip
   Chan, Hak-Kim
TI Inhalable Hydroxychloroquine Powders for Potential Treatment of COVID-19
SO JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY
LA English
DT Article; Early Access
DE COVID-19; dry powder aerosol; HCQ; inhalable hydroxychloroquine; jet
   mill; relative humidity
ID CHLOROQUINE; PHARMACOKINETICS
AB Background: Hydroxychloroquine (HCQ) is one of the repurposed drugs proposed for the treatment of coronavirus disease 2019 (COVID-19). However, all the published clinical trials involve oral administration of the drug, although the disease is primarily a respiratory one. Direct inhaled delivery could reduce the side effects associated with oral use and ensure a high concentration of the drug in the lungs. In this study, inhalable HCQ powders were prepared and characterized for potential COVID-19 therapy.
   Methods: Hydroxychloroquine sulfate (HCQ-sul) was jet milled (JM) followed by conditioning by storage at different relative humidities (43%, 53%, 58%, and 75% RHs) for 7 days. The solid-state properties, including particle morphology and size distribution, crystallinity, and vapor moisture profiles of HCQ-sul samples, were characterized by scanning electron microscopy, laser diffraction, X-ray powder diffraction, differential scanning calorimetry, thermogravimetric analysis, and dynamic water vapor sorption. The aerosol performance of the HCQ-sul powders was assessed using a medium-high resistance Osmohaler coupling to a next-generation impactor (NGI) at a flow rate of 60 L/min.
   Results: The jet-milled powder showed a volume median diameter of 1.7 mu m (span 1.5) and retained the same crystalline form as the raw HCQ-sul. A small amount of amorphous materials was present in the jet-milled HCQ-sul, which was convertible to the stable, crystalline state after conditioning at 53%, 58%, and 75% RH. The recovered fine particle fraction (FPF)(recovered) and the emitted fine particle fraction (FPFemitted) of the HCQ-sul sample immediately after jet milling and the samples after conditioning at 43%, 53%, and 58% RH were similar at similar to 43% and 61%, respectively. In contrast, the sample having conditioned at 75%RH showed lower corresponding values at 33% and 26% respectively, due to the formation of solid bridges caused by excessive moisture.
   Conclusion: Inhalable crystalline powders of HCQ-sul were successfully prepared, which can be used for clinical testing as a potential inhaled COVID-19 treatment.
C1 [Albariqi, Ahmed H.; Chang, Rachel Yoon Kyung; Tai, Waiting; Ke, Wei-Ren; Chow, Michael Y. T.; Tang, Patricia; Kwok, Philip Chi Lip; Chan, Hak-Kim] Univ Sydney, Fac Med & Hlth, Sydney Pharm Sch, Adv Drug Delivery Grp, Sydney, NSW 2006, Australia.
   [Albariqi, Ahmed H.] Jazan Univ, Fac Pharm, Dept Pharmaceut, Jazan, Saudi Arabia.
RP Chan, HK (corresponding author), Univ Sydney, Fac Med & Hlth, Sydney Pharm Sch, Adv Drug Delivery Grp, Sydney, NSW 2006, Australia.
EM kim.chan@sydney.edu.au
OI Albariqi, Ahmed H./0000-0002-1937-6775; Ke, Wei-Ren/0000-0002-1303-6497
FU Jazan University (Saudi Arabia)
FX A.H.A. is sponsored by Jazan University (Saudi Arabia). The authors are
   indebted to Dr. Igor Gonda for his generous help in reviewing the
   article and providing valuable comments. The authors also thank the
   Australian Centre for Microscopy and Microanalysis, The University of
   Sydney, for the scientific and technical assistance. H.-K.C. is grateful
   to Mr. Richard Stenlake for his financial support as a donation to the
   University of Sydney.
CR Biot C, 2006, J MED CHEM, V49, P2845, DOI 10.1021/jm0601856
   Borghardt JM, 2018, CAN RESPIR J, V2018, DOI 10.1155/2018/2732017
   British Pharmacopia, 2020, APP 12 C CONS FORM P
   Butterfield JM, 2013, ANTIMICROB AGENTS CH, V57, P864, DOI [10.1128/AAC.00539-13, 10.1128/AAC.02000-12]
   Chowdhury MDS, 2020, ACAD EMERG MED, V27, P493, DOI 10.1111/acem.14005
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   D'Acquarica I, 2020, DRUG DISCOV TODAY, V25, P1121, DOI 10.1016/j.drudis.2020.04.021
   Fassihi SC, 2020, BRIT J PHARMACOL, V10, P1111
   Moraes ANF, 2020, J THERM ANAL CALORIM, V140, P2283, DOI 10.1007/s10973-019-08953-8
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gbinigie Kome, 2020, BJGP Open, V4, DOI 10.3399/bjgpopen20X101069
   Geller David E, 2005, Respir Care, V50, P1313
   Huang YX, 2020, AGING-US, V12, P11224, DOI 10.18632/aging.103370
   Johns Hopkins University, 2020, COVID 19 MAP JOHNS H
   Kavanagh O, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.110110
   Klimke A, 2020, MED HYPOTHESES, V142, DOI 10.1016/j.mehy.2020.109783
   Lau M, 2017, DRUG DEV IND PHARM, V43, P1229, DOI 10.1080/03639045.2017.1313858
   Laube BL, 2013, MIDDLETONS ALLERGY P, P1066
   Lima TA, 2018, J CHEM PHYS, V148, DOI 10.1063/1.5030083
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Maisonnasse P, 2020, NATURE, V585, P584, DOI 10.1038/s41586-020-2558-4
   Marmor MF, 2016, OPHTHALMOLOGY, V123, P1386, DOI 10.1016/j.ophtha.2016.01.058
   MCCHESNEY EW, 1967, TOXICOL APPL PHARM, V10, P501, DOI 10.1016/0041-008X(67)90089-0
   Mitchell JP, 2020, J AEROSOL MED PULM D, V33, P235, DOI 10.1089/jamp.2020.1622
   National Institutes of Health (US), 2020, COR DIS 2019 COVID 1
   Royal Society of Chemistry, 2001, CHEMSP SYNTH PAG HYD
   Ruiz-Irastorza G, 2010, ANN RHEUM DIS, V69, P20, DOI 10.1136/ard.2008.101766
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Sheokand S, 2014, J PHARM SCI-US, V103, P3364, DOI 10.1002/jps.24160
   Srinivasa Amar, 2017, J Rheumatol, V44, P398, DOI 10.3899/jrheum.161063
   TETT SE, 1988, BRIT J CLIN PHARMACO, V26, P303, DOI 10.1111/j.1365-2125.1988.tb05281.x
   Tomas Norling MB, 2016, PHASE 1 STUDY INVEST
   U.S. Food and Drug Administration, 2020, COVID 19 UPD FDA BRO
   US Food & Drug Administration, 2020, FDA CAUT US HYDR CHL
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang LS, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105948
   World Health Organization, 2020, NAM COR DIS COVID 19
   Xiaodong Li GY, 2018, China patent, Patent No. [CN108727263A, 108727263]
   Xu RL, 2003, POWDER TECHNOL, V132, P145, DOI 10.1016/S0032-5910(03)00048-2
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 41
TC 0
Z9 0
U1 1
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1941-2711
EI 1941-2703
J9 J AEROSOL MED PULM D
JI J. Aerosol Med. Pulm. Drug Deliv.
DI 10.1089/jamp.2020.1648
EA NOV 2020
PG 12
WC Respiratory System
SC Respiratory System
GA OV3AV
UT WOS:000592088200001
PM 33179983
OA Bronze
DA 2021-01-01
ER

PT J
AU Wu, M
   Chen, YB
   Xia, H
   Wang, CL
   Tan, CY
   Cai, XH
   Liu, YF
   Ji, FH
   Xiong, P
   Liu, R
   Guan, YL
   Duan, YQ
   Kuang, D
   Xu, SP
   Cai, HH
   Xia, Q
   Yang, DH
   Wang, MW
   Chiu, IM
   Cheng, C
   Ahern, PP
   Liu, L
   Wang, GP
   Surana, NK
   Xia, T
   Kasper, DL
AF Wu, Meng
   Chen, Yaobing
   Xia, Han
   Wang, Changli
   Tan, Chin Yee
   Cai, Xunhui
   Liu, Yufeng
   Ji, Fenghu
   Xiong, Peng
   Liu, Ran
   Guan, Yuanlin
   Duan, Yaqi
   Kuang, Dong
   Xu, Sanpeng
   Cai, Hanghang
   Xia, Qin
   Yang, Dehua
   Wang, Ming-Wei
   Chiu, Isaac M.
   Cheng, Chao
   Ahern, Philip P.
   Liu, Liang
   Wang, Guoping
   Surana, Neeraj K.
   Xia, Tian
   Kasper, Dennis L.
TI Transcriptional and proteomic insights into the host response in fatal
   COVID-19 cases
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE COVID-19; SARS-CoV-2; neutrophil; fibrosis; NETosis
ID NEUTROPHIL EXTRACELLULAR TRAPS; READ ALIGNMENT; LUNG
AB Coronavirus disease 2019 (COVID-19), the global pandemic caused by SARS-CoV-2, has resulted thus far in greater than 933,000 deaths worldwide; yet disease pathogenesis remains unclear. Clinical and immunological features of patients with COVID-19 have highlighted a potential role for changes in immune activity in regulating disease severity. However, little is known about the responses in human lung tissue, the primary site of infection. Here we show that pathways related to neutrophil activation and pulmonary fibrosis are among the major up-regulated transcriptional signatures in lung tissue obtained from patients who died of COVID-19 in Wuhan, China. Strikingly, the viral burden was low in all samples, which suggests that the patient deaths may be related to the host response rather than an active fulminant infection. Examination of the colonic transcriptome of these patients suggested that SARS-CoV-2 impacted host responses even at a site with no obvious pathogenesis. Further proteomics analysis validated our transcriptome findings and identified several key proteins, such as the SARS-CoV-2 entry-associated protease cathepsins B and L and the inflammatory response modulator S100A8/A9, that are highly expressed in fatal cases, revealing potential drug targets for COVID-19.
C1 [Chen, Yaobing; Duan, Yaqi; Kuang, Dong; Xu, Sanpeng; Wang, Guoping; Xia, Tian] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Inst Pathol, Wuhan 430074, Peoples R China.
   [Xia, Han; Guan, Yuanlin] Hugobiotech Co Ltd, Dept Res & Dev, Beijing 100000, Peoples R China.
   [Xia, Han] Xi An Jiao Tong Univ, Fac Elect & Informat Engn, Sch Automat Sci & Engn, Xian 710049, Peoples R China.
   [Wang, Changli; Duan, Yaqi; Wang, Guoping] Huazhong Univ Sci & Technol, Sch Basic Med, Tongji Med Coll, Dept Pathol, Wuhan 430074, Peoples R China.
   [Tan, Chin Yee; Surana, Neeraj K.] Duke Univ, Dept Pediat, Sch Med, Durham, NC 27710 USA.
   [Cai, Xunhui; Liu, Yufeng; Ji, Fenghu; Xiong, Peng; Surana, Neeraj K.] Duke Univ, Dept Mol Genet & Microbiol, Sch Med, Durham, NC 27710 USA.
   [Liu, Yufeng; Ji, Fenghu; Xiong, Peng; Xia, Tian] Huazhong Univ Sci & Technol, Inst Artificial Intelligence, Wuhan 430074, Peoples R China.
   [Xia, Qin] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pathol, Wuhan 430030, Peoples R China.
   [Yang, Dehua; Wang, Ming-Wei] Chinese Acad Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, Shanghai 201203, Peoples R China.
   [Cheng, Chao] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
   [Ahern, Philip P.] Cleveland Clin, Dept Cardiovasc & Metab Sci, Lerner Res Inst, Cleveland, OH 44195 USA.
   [Liu, Liang] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Forens Med, Wuhan 430030, Peoples R China.
   [Surana, Neeraj K.] Duke Univ, Dept Immunol, Sch Med, Durham, NC 27710 USA.
   [Kasper, Dennis L.] Harvard Med Sch, Blavatnik Inst, Dept Immunol, Boston, MA 02115 USA.
RP Wang, GP; Xia, T (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Inst Pathol, Wuhan 430074, Peoples R China.; Wang, GP (corresponding author), Huazhong Univ Sci & Technol, Sch Basic Med, Tongji Med Coll, Dept Pathol, Wuhan 430074, Peoples R China.; Surana, NK (corresponding author), Duke Univ, Dept Pediat, Sch Med, Durham, NC 27710 USA.; Surana, NK (corresponding author), Duke Univ, Dept Mol Genet & Microbiol, Sch Med, Durham, NC 27710 USA.; Xia, T (corresponding author), Huazhong Univ Sci & Technol, Inst Artificial Intelligence, Wuhan 430074, Peoples R China.; Liu, L (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Forens Med, Wuhan 430030, Peoples R China.; Surana, NK (corresponding author), Duke Univ, Dept Immunol, Sch Med, Durham, NC 27710 USA.; Kasper, DL (corresponding author), Harvard Med Sch, Blavatnik Inst, Dept Immunol, Boston, MA 02115 USA.
EM liuliang@mail.tjmu.du.cn; wanggp@hust.edu.cn; neil.surana@duke.edu;
   tianxia@hust.edu.cn; dennis_kasper@hms.harvard.edu
OI Shah, Pallav/0000-0002-9052-4638; Tan, Chin Yee/0000-0003-1104-6082
FU Clinical Foundation of Tongji Hospital [XXGZBDYJ010]; Ministry of
   Science and Technology of P. R. China Plan [2020YFC0844700]; National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [61571202]; NIH/National Institute of Allergy and
   Infectious DiseasesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01AI148273]; National
   University of Singapore Development Grant
FX We thank all the healthcare workers who fight SARS-COV-2 on the front
   line. We thank the Ting laboratory for sharing their data in National
   Center for Biotechnology Information and David Ting for discussion. We
   also thank Zhenni Liu and Xinqiao Zhang for their technical assistance
   in RNA-Seq library preparation. This work was supported by Clinical
   Foundation of Tongji Hospital (Grant XXGZBDYJ010) and Ministry of
   Science and Technology of P. R. China Plan (Grant 2020YFC0844700). T.X.
   is supported by the National Natural Science Foundation of China
   (61571202). M.W. and D.L.K. are supported by NIH/National Institute of
   Allergy and Infectious Diseases R01AI148273. C.Y.T. is supported by a
   National University of Singapore Development Grant. N.K.S. receives
   support as a Translating Duke Health Scholar and a Whitehead Scholar.
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Amarnani Abhimanyu, 2019, J Proteomics Bioinform, V12, P104, DOI 10.35248/0974-276X.12.19.503
   Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Baral P, 2018, NAT MED, V24, P417, DOI 10.1038/nm.4501
   Beigel J. H., 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2007764.0028-4793, DOI 10.1056/NEJMOA2007764.0028-4793]
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Branchfield K, 2016, SCIENCE, V351, P707, DOI 10.1126/science.aad7969
   Butler D. J., 2020, BIORXIV
   Carbon S, 2009, BIOINFORMATICS, V25, P288, DOI 10.1093/bioinformatics/btn615
   Caudrillier A, 2012, J CLIN INVEST, V122, P2661, DOI 10.1172/JCI61303
   Chen LT, 2020, CELL MOL IMMUNOL, V17, P992, DOI 10.1038/s41423-020-0492-x
   Coveney AP, 2015, SCI REP-UK, V5, DOI 10.1038/srep13694
   DeLuca DS, 2012, BIOINFORMATICS, V28, P1530, DOI 10.1093/bioinformatics/bts196
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Ellinghaus D, 2020, NEW ENGL J MED, V383, P1522, DOI 10.1056/NEJMoa2020283
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Fox SE, 2020, LANCET RESP MED, V8, P681, DOI 10.1016/S2213-2600(20)30243-5
   Fuchs TA, 2010, P NATL ACAD SCI USA, V107, P15880, DOI 10.1073/pnas.1005743107
   Furlow B, 2020, LANCET RHEUMATOL, V2, pE592, DOI 10.1016/S2665-9913(20)30313-1
   Gardinassi LG, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2222-5
   Gollomp K, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.99445
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huh JR, 2020, NAT REV IMMUNOL, V20, P217, DOI 10.1038/s41577-019-0247-z
   Jari Oksanen FGB, 2019, VEGAN COMMUNITY ECOL
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Mao R, 2020, LANCET GASTROENTEROL, V5, P426, DOI 10.1016/S2468-1253(20)30076-5
   Marini JJ, 2020, JAMA-J AM MED ASSOC, V323, P2329, DOI 10.1001/jama.2020.6825
   Movassagh H, 2018, AM J RESP CELL MOL, V58, P21, DOI 10.1165/rcmb.2017-0171TR
   Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105
   Pirofski LA, 2020, MBIO, V11, DOI 10.1128/mBio.01175-20
   Polak SB, 2020, MODERN PATHOL, V33, P2128, DOI 10.1038/s41379-020-0603-3
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Riva L, 2020, NATURE, V586, P113, DOI 10.1038/s41586-020-2577-1
   Rosas I., 2020, TOCILIZUMAB HOSP PAT
   Saintigny P, 2012, MOL CANCER THER, V11, P2021, DOI 10.1158/1535-7163.MCT-12-0030
   Schulte-Schrepping J, 2020, CELL, V182, P1419, DOI 10.1016/j.cell.2020.08.001
   Silvin A, 2020, CELL, V182, P1401, DOI 10.1016/j.cell.2020.08.002
   Sui PF, 2018, SCIENCE, V360, P1086, DOI 10.1126/science.aan8546
   Sun J, 2020, CELL, V182, P734, DOI 10.1016/j.cell.2020.06.010
   Thille AW, 2013, LANCET RESP MED, V1, P395, DOI 10.1016/S2213-2600(13)70053-5
   Wang SW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01298
   Wei J., 2020, BIORXIV
   Wilk AJ, 2020, NAT MED, V26, P1070, DOI 10.1038/s41591-020-0944-y
   Wisniewski JR, 2013, PROTEOM CLIN APPL, V7, P225, DOI 10.1002/prca.201200046
   Wohlfahrt JG, 2004, J IMMUNOL, V172, P843, DOI 10.4049/jimmunol.172.2.843
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu JC, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01445-6
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zuo Y, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138999
NR 55
TC 2
Z9 2
U1 3
U2 3
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 10
PY 2020
VL 117
IS 45
BP 28336
EP 28343
DI 10.1073/pnas.2018030117
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OT3JC
UT WOS:000590745300016
PM 33082228
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Gao, K
   Song, YP
   Song, AN
AF Gao, Kai
   Song, Yan-Ping
   Song, Anna
TI Exploring active ingredients and function mechanisms of Ephedra-bitter
   almond for prevention and treatment of Corona virus disease 2019
   (COVID-19) based on network pharmacology
SO BIODATA MINING
LA English
DT Article
DE COVID-19; Ephedra-bitter almond; Molecular docking simulation;
   Traditional Chinese medicine; Molecular mechanisms of pharmacological
   action
ID NF-KAPPA-B; DRUG DISCOVERY; INFLAMMATORY RESPONSES; SYSTEMS
   PHARMACOLOGY; LUTEOLIN; REPLICATION; INHIBITION; CYTOSCAPE; INFECTION;
   AMYGDALIN
AB Background COVID-19 has caused a global pandemic, and there is no wonder drug for epidemic control at present. However, many clinical practices have shown that traditional Chinese medicine has played an important role in treating the outbreak. Among them, ephedra-bitter almond is a common couplet medicine in anti-COVID-19 prescriptions. This study aims to conduct an exploration of key components and mechanisms of ephedra-bitter almond anti-COVID-19 based on network pharmacology. Material and methods We collected and screened potential active components of ephedra-bitter almond based on the TCMSP Database, and we predicted targets of the components. Meanwhile, we collected relevant targets of COVID-19 through the GeneCards and CTD databases. Then, the potential targets of ephedra-bitter almond against COVID-19 were screened out. The key components, targets, biological processes, and pathways of ephedra-bitter almond anti-COVID-19 were predicted by constructing the relationship network of herb-component-target (H-C-T), protein-protein interaction (PPI), and functional enrichment. Finally, the key components and targets were docked by AutoDock Vina to explore their binding mode. Results Ephedra-bitter almond played an overall regulatory role in anti-COVID-19 via the patterns of multi-component-target-pathway. In addition, some key components of ephedra-bitter almond, such as beta-sitosterol, estrone, and stigmasterol, had high binding activity to 3CL and ACE2 by molecular docking simulation, which provided new molecular structures for new drug development of COVID-19. Conclusion Ephedra-bitter almonds were used to prevent and treat COVID-19 through directly inhibiting the virus, regulating immune responses, and promoting body repair. However, this work is a prospective study based on data mining, and the findings need to be interpreted with caution.
C1 [Gao, Kai] Shaanxi Univ Chinese Med, Pharm Coll, Xianyang, Shaanxi, Peoples R China.
   [Song, Yan-Ping] Shaanxi Acad Tradit Chinese Med, Xian, Shaanxi, Peoples R China.
   [Song, Anna] Michigan State Univ, E Lansing, MI 48824 USA.
RP Song, YP (corresponding author), Shaanxi Acad Tradit Chinese Med, Xian, Shaanxi, Peoples R China.
EM sypdd2003@163.com
CR Ahn DG, 2020, J MICROBIOL BIOTECHN, V30, P313, DOI 10.4014/jmb.2003.03011
   Alam MA, 2015, RECENT PAT ANTI-CANC, V10, P87
   Assenov Y, 2008, BIOINFORMATICS, V24, P282, DOI 10.1093/bioinformatics/btm554
   Batlle D, 2020, CLIN SCI, V134, P543, DOI 10.1042/CS20200163
   Berger SI, 2009, BIOINFORMATICS, V25, P2466, DOI 10.1093/bioinformatics/btp465
   Bohmwald K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00452
   Cao WJ, 2020, PSYCHIAT RES, V287, DOI 10.1016/j.psychres.2020.112934
   Casas AI, 2019, P NATL ACAD SCI USA, V116, P7129, DOI 10.1073/pnas.1820799116
   Chen J, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110281
   Cheng FX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09186-x
   Cheng FX, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05116-5
   Cheng YQ, 2020, SHANGHAI J TRADIT CH, V54, P32
   Chiow KH, 2016, ASIAN PAC J TROP MED, V9, P1, DOI 10.1016/j.apjtm.2015.12.002
   Fan WC, 2016, VIRUS RES, V220, P112, DOI 10.1016/j.virusres.2016.04.021
   Fishilevich S, 2016, DATABASE-OXFORD, DOI 10.1093/database/baw030
   Gysi DM, 2020, ARXIV200407229V1
   Hao DC, 2014, DRUG DEVELOP RES, V75, P299, DOI 10.1002/ddr.21214
   Hopkins AL, 2007, NAT BIOTECHNOL, V25, P1110, DOI 10.1038/nbt1007-1110
   Hu BL, 2015, AUTOPHAGY, V11, P503, DOI 10.1080/15548627.2015.1017184
   Huang C, 2014, BRIEF BIOINFORM, V15, P710, DOI 10.1093/bib/bbt035
   Huang YJ, 2020, ATMOS RES, V240, DOI 10.1016/j.atmosres.2020.104939
   Ibragic S, 2015, BOSNIAN J BASIC MED, V15, P21, DOI 10.17305/bjbms.2015.539
   Kalliolias GD, 2016, NAT REV RHEUMATOL, V12, P49, DOI 10.1038/nrrheum.2015.169
   Kudchodkar SB, 2009, REV MED VIROL, V19, P359, DOI 10.1002/rmv.630
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lee WY, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9080362
   Li QX, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8081250
   Li SR, 2020, EUR J CLIN MICROBIOL, V39, P1021, DOI 10.1007/s10096-020-03883-y
   Ling XY, 2020, J CHINESE MED MAT, P1766
   Liu H, 2013, J ETHNOPHARMACOL, V146, P773, DOI 10.1016/j.jep.2013.02.004
   LIU J, 2016, EVID-BASED COMPL ALT, V2016
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu YZ, 2020, EUR J MED CHEM, V206, DOI 10.1016/j.ejmech.2020.112711
   Luo TT, 2020, CHIN J INTEGR MED, V26, P72, DOI 10.1007/s11655-019-3064-0
   Maarouf M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051379
   Mizutani T, 2004, VIROLOGY, V327, P169, DOI 10.1016/j.virol.2004.07.005
   Mizutani T, 2006, BIOCHEM BIOPH RES CO, V347, P261, DOI 10.1016/j.bbrc.2006.06.086
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Park CM, 2011, EUR J PHARMACOL, V660, P454, DOI 10.1016/j.ejphar.2011.04.007
   Peng MH, 2017, ANTIVIR RES, V143, P176, DOI 10.1016/j.antiviral.2017.03.026
   Ren JL, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104743
   Ricciotti E, 2011, ARTERIOSCL THROM VAS, V31, P986, DOI 10.1161/ATVBAHA.110.207449
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758-2946-6-13
   Rumzhum NN, 2016, CLIN EXP ALLERGY, V46, P397, DOI 10.1111/cea.12697
   Ryzhakov G, 2011, J IMMUNOL, V187, P5357, DOI 10.4049/jimmunol.1100917
   Seeliger D, 2010, J COMPUT AID MOL DES, V24, P417, DOI 10.1007/s10822-010-9352-6
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shi JM, 2019, CANCER MED-US, V8, P3004, DOI 10.1002/cam4.2197
   Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Tian S, 2015, ADV DRUG DELIVER REV, V86, P2, DOI 10.1016/j.addr.2015.01.009
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Unterholzner L, 2019, IMMUNOLOGY, V156, P217, DOI 10.1111/imm.13030
   Wan SX, 2020, J MED VIROL, V92, P797, DOI 10.1002/jmv.25783
   Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090
   Wang YX, 2020, EUR REV MED PHARMACO, V24, P3360, DOI 10.26355/eurrev_202003_20704
   Wei WY, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00961
   Wu WJ, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8010006
   Xie YB, 2019, MOL MED REP, V19, P783, DOI 10.3892/mmr.2018.9713
   Xin SY, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110500
   Xu X, 2012, INT J MOL SCI, V13, P6964, DOI 10.3390/ijms13066964
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yan HY, 2019, J NAT MED-TOKYO, V73, P487, DOI 10.1007/s11418-019-01287-7
   Yang RC, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104820
   Yang XY, 2018, MOL MED REP, V17, P2501, DOI 10.3892/mmr.2017.8188
   Yang Y, 2020, INT J BIOL SCI, V16, P1708, DOI 10.7150/ijbs.45538
   Yao CG, 2018, VIROL J, V15, DOI 10.1186/s12985-018-1023-6
   Yu H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037608
   Zhang A, 2017, INFLAMMATION, V40, P745, DOI 10.1007/s10753-017-0518-4
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang RZ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00123
   Zhang YL, 2020, TRADIT MED RES, V5, P201, DOI 10.12032/TMR20200507178
   Zhao JY, 2020, CHINESE MED J-PEKING, V133, P1347, DOI 10.1097/CM9.0000000000000866
   Zheng CL, 2015, SCI REP-UK, V5, DOI 10.1038/srep11970
   Zheng YJ, 2013, CELL MOL IMMUNOL, V10, P330, DOI 10.1038/cmi.2013.3
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 76
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1756-0381
J9 BIODATA MIN
JI BioData Min.
PD NOV 10
PY 2020
VL 13
IS 1
AR 19
DI 10.1186/s13040-020-00229-4
PG 20
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA OV8NZ
UT WOS:000592460700001
PM 33292385
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tanga, V
   Leroy, S
   Fayada, J
   Hamila, M
   Allegra, M
   Messaoudi, Z
   Bonnetaud, C
   Lespinet, V
   Bordone, O
   Washetine, K
   Griffonnet, J
   Maniel, C
   Philibert, L
   Selva, E
   Benzaquen, J
   Ilie, M
   Long, EL
   Lassalle, S
   Lanteri, E
   Marquette, CH
   Hofman, V
   Hofman, P
AF Tanga, Virginie
   Leroy, Sylvie
   Fayada, Julien
   Hamila, Marame
   Allegra, Maryline
   Messaoudi, Zeineb
   Bonnetaud, Christelle
   Lespinet, Virgine
   Bordone, Olivier
   Washetine, Kevin
   Griffonnet, Jennifer
   Maniel, Charlotte
   Philibert, Lorene
   Selva, Eric
   Benzaquen, Jonathan
   Ilie, Marius
   Long, Elodie
   Lassalle, Sandra
   Lanteri, Elisabeth
   Marquette, Charles-Hugo
   Hofman, Veronique
   Hofman, Paul
TI Establishment of a Collection of Blood-Derived Products from COVID-19
   Patients for Translational Research: Experience of the LPCE Biobank
   (Nice, France)
SO BIOPRESERVATION AND BIOBANKING
LA English
DT Article
DE COVID-19; SARS-CoV-2; blood; biobank; research
ID BIOSPECIMENS
AB In only a few months after its inception, the COVID-19 pandemic lead to the death of hundreds of thousands of patients and to the infection of millions of people on most continents, mostly in the United States and in Europe. During this crisis, it was demonstrated that a better understanding of the pathogenicity, virulence, and contagiousness of SARS-CoV-2, all of which were initially underestimated, was urgently needed. The development of diagnostic tests to identify SARS-CoV-2 or to detect anti-SARS-CoV2 antibodies in blood, of vaccines, and of preventive and curative treatments has been relying on intense activity of scientists in academia and industry. It is noteworthy that these scientists depend on the use of high-quality biological samples taken from positive COVID-19 patients in a manner that preserves their integrity. Given this unique and emergent situation, it was necessary to urgently establish biological collections clinically annotated for immediate development of clinical and translational research projects focusing on COVID-19 biological aspects. It is in this very specific context that biobanks must rapidly adapt their infrastructure and/or operational capacity to fulfill new critical needs. We report the establishment of a biobank dedicated to the collection of blood-derived products (plasma, serum, and leukocytes) from COVID-19 patients hospitalized in the Nice Pasteur Hospital (Nice, France).
C1 [Tanga, Virginie; Fayada, Julien; Hamila, Marame; Allegra, Maryline; Messaoudi, Zeineb; Bonnetaud, Christelle; Lespinet, Virgine; Bordone, Olivier; Washetine, Kevin; Selva, Eric; Ilie, Marius; Long, Elodie; Lassalle, Sandra; Lanteri, Elisabeth; Hofman, Veronique; Hofman, Paul] Univ Cote Azur, Nice Hosp Univ, Lab Clin & Expt Pathol LPCE, Biobank BB 0033 00025,FHU OncoAge, Nice, France.
   [Tanga, Virginie; Ilie, Marius; Long, Elodie; Lassalle, Sandra; Lanteri, Elisabeth; Marquette, Charles-Hugo; Hofman, Veronique; Hofman, Paul] Univ Cote Azur, FHU OncoAge, Ctr Antoine Lacassagne, IRCAN,CNRS,INSERM, Nice, France.
   [Leroy, Sylvie; Griffonnet, Jennifer; Maniel, Charlotte; Philibert, Lorene; Benzaquen, Jonathan; Marquette, Charles-Hugo] Univ Cote Azur, Nice Hosp Univ, FHU OncoAge, Dept Pneumol, Nice, France.
RP Hofman, P (corresponding author), Univ Cote Azur, Pasteur Hosp, Lab Clin & Expt Pathol, 30 Ave Voie Romaine, F-06000 Nice, France.
EM hofman.p@chu-nice.fr
CR American Association of Blood Banks, 2020, UPD IMP 2019 NOV COR
   [Anonymous], 2020, NAT MED, DOI 10.1038/s41591-020-0852-1
   [Anonymous], 2020, NF S96 900 BIOL RES
   Banerjee A, 2020, EMERG INFECT DIS, V26, P2054, DOI 10.3201/eid2609.201495
   Berkley S, 2020, SCIENCE, V367, P1407, DOI 10.1126/science.abb8654
   Bohlken J, 2020, PSYCHIAT PRAX, V47, P190, DOI 10.1055/a-1159-5551
   Callaway Ewen, 2020, Nature, DOI 10.1038/d41586-020-01247-2
   CDC, 2020, INT LAB BIOS GUID HA
   Chang L, 2020, TRANSFUS MED REV, V34, P75, DOI 10.1016/j.tmrv.2020.02.003
   Chen WL, 2020, EMERG MICROBES INFEC, V9, P469, DOI 10.1080/22221751.2020.1732837
   Chen XH, 2020, CLIN INFECT DIS, V71, P1937, DOI 10.1093/cid/ciaa449
   Clement B, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3010444
   CNBC, 2020, ROCH CEO CALLS SOM C
   Cooreman A, 2017, POINT VIEW TRACEABIL
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Covid 19 Host Genetics Initiative, 2020, EUR J HUM GENET, V28, P715, DOI 10.1038/s41431-020-0636-6
   COVIDSurg Collaborative, 2020, BRIT J SURG, V107, P1097, DOI 10.1002/bjs.11646
   Doucet M, 2017, BIOPRESERV BIOBANK, V15, P270, DOI 10.1089/bio.2016.0053
   Ellervik C, 2015, CLIN CHEM, V61, P914, DOI 10.1373/clinchem.2014.228783
   FDA, 2020, FDA GUID COND CLIN T
   Frater JL, 2020, INT J LAB HEMATOL, V42, P11, DOI 10.1111/ijlh.13229
   French LS, 2020, FRONT CELL NEUROSCI, V14, DOI 10.3389/fncel.2020.00183
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Pollitt KJG, 2020, HUM GENOMICS, V14, DOI 10.1186/s40246-020-00267-3
   Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923
   Hofman P, 2020, TRANSL LUNG CANCER R, V9, P1543, DOI 10.21037/tlcr-20-594
   Hofman P, 2020, NAT MED, V26, P809, DOI 10.1038/s41591-020-0890-8
   Hofman P, 2014, VIRCHOWS ARCH, V464, P3, DOI 10.1007/s00428-013-1524-z
   Huang Y, 2020, GEN ANXIETY DISORDER, DOI [10.1101/2020.02.19.20025395., DOI 10.1101/2020.02.19.20025395, 10.1101/2020.02.19.20025395.20025395]
   IMF International Monetary Fund, 2020, FISC MON
   IMI Innovative Medicine Initiative, 2020, IMI2 CALL 21 DEV THE
   Kaiser J., 2020, SCIENCE, DOI [10.1126/science.abb9192, DOI 10.1126/SCIENCE.ABB9192]
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Kowalik MM, 2020, CARDIOL J, V27, P99, DOI 10.5603/CJ.a2020.0065
   Lakdawala SS, 2020, SCIENCE, V368, P942, DOI 10.1126/science.abc6141
   Lehmann S, 2012, BIOPRESERV BIOBANK, V10, P366, DOI 10.1089/bio.2012.0012
   Lin C-Y, 2020, SOCIAL HLTH BEHAV, V3, P1, DOI [10.4103/SHB.SHB_11_20, DOI 10.4103/SHB.SHB_11_20]
   Lippi G, 2020, CLIN CHEM LAB MED, V58, P1070, DOI 10.1515/cclm-2020-0285
   Loeffelholz MJ, 2020, EMERG MICROBES INFEC, V9, P747, DOI 10.1080/22221751.2020.1745095
   Million M, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101738
   Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4
   Redelmeier DA, 2020, LANCET PUBLIC HEALTH, V5, pE306, DOI 10.1016/S2468-2667(20)30096-7
   Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520
   Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282
   Simeon-Dubach D, 2020, BIOPRESERV BIOBANK, V18, P144, DOI 10.1089/bio.2019.0095
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   UCSF, 2020, COVID 19 BIOSP GUID
   Vaught J, 2020, BIOPRESERV BIOBANK, V18, P153, DOI 10.1089/bio.2020.29069.jjv
   Vaught J, 2019, BIOPRESERV BIOBANK, V17, P1, DOI 10.1089/bio.2019.29048.jjv
   Venter M, 2020, J CLIN PATHOL, V73, P370, DOI 10.1136/jclinpath-2020-206685
   Verbeek JH, 2020, COCHRANE DB SYST REV, V4, P1
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Washetine K, 2018, CANCERS, V10, DOI 10.3390/cancers10070220
   WHO, 2020, LAB BIOS GUID RAL CO
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Xiao L, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050491
   Yang Y, 2020, J ALLERGY CLIN IMMUN, V146, P119, DOI 10.1016/j.jaci.2020.04.027
NR 57
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1947-5535
EI 1947-5543
J9 BIOPRESERV BIOBANK
JI Biopreserv. Biobank.
PD DEC 1
PY 2020
VL 18
IS 6
BP 517
EP 524
DI 10.1089/bio.2020.0055
EA NOV 2020
PG 8
WC Cell Biology; Chemistry, Applied; Medical Laboratory Technology
SC Cell Biology; Chemistry; Medical Laboratory Technology
GA PF0CN
UT WOS:000590820000001
PM 33175565
OA Bronze
DA 2021-01-01
ER

PT J
AU Wu, CM
   Hou, DN
   Du, CL
   Cai, YP
   Zheng, JH
   Xu, J
   Chen, XY
   Chen, CC
   Hu, XL
   Zhang, YY
   Song, J
   Wang, L
   Chao, YC
   Feng, Y
   Xiong, WN
   Chen, DC
   Zhong, M
   Hu, J
   Jiang, JJ
   Bai, CX
   Zhou, X
   Xu, JF
   Song, YL
   Gong, FY
AF Wu, Chaomin
   Hou, Dongni
   Du, Chunling
   Cai, Yanping
   Zheng, Junhua
   Xu, Jie
   Chen, Xiaoyan
   Chen, Cuicui
   Hu, Xianglin
   Zhang, Yuye
   Song, Juan
   Wang, Lu
   Chao, Yen-cheng
   Feng, Yun
   Xiong, Weining
   Chen, Dechang
   Zhong, Ming
   Hu, Jie
   Jiang, Jinjun
   Bai, Chunxue
   Zhou, Xin
   Xu, Jinfu
   Song, Yuanlin
   Gong, Fengyun
TI Corticosteroid therapy for coronavirus disease 2019-related acute
   respiratory distress syndrome: a cohort study with propensity score
   analysis
SO CRITICAL CARE
LA English
DT Article
DE Corticosteroids; Coronavirus disease 2019; Severe acute respiratory
   syndrome coronavirus 2; Mortality; Propensity score; Methylprednisolone
ID CRITICALLY-ILL PATIENTS; ARDS; BIAS
AB Background The impact of corticosteroid therapy on outcomes of patients with coronavirus disease 2019 (COVID-19) is highly controversial. We aimed to compare the risk of death between COVID-19-related ARDS patients with corticosteroid treatment and those without. Methods In this single-center retrospective observational study, patients with ARDS caused by COVID-19 between January 20, 2020, and February 24, 2020, were enrolled. The primary outcome was 60-day in-hospital death. The exposure was prescribed systemic corticosteroids or not. Time-dependent Cox regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for 60-day in-hospital mortality. Results A total of 382 patients [60.7 +/- 14.1 years old (mean +/- SD), 61.3% males] were analyzed. The median of sequential organ failure assessment (SOFA) score was 2.0 (IQR 2.0-3.0). Of these cases, 94 (24.6%) patients had invasive mechanical ventilation. The number of patients received systemic corticosteroids was 226 (59.2%), and 156 (40.8%) received standard treatment. The maximum dose of corticosteroids was 80.0 (IQR 40.0-80.0) mg equivalent methylprednisolone per day, and duration of corticosteroid treatment was 7.0 (4.0-12.0) days in total. In Cox regression analysis using corticosteroid treatment as a time-varying variable, corticosteroid treatment was associated with a significant reduction in risk of in-hospital death within 60 days after adjusting for age, sex, SOFA score at hospital admission, propensity score of corticosteroid treatment, comorbidities, antiviral treatment, and respiratory supports (HR 0.42; 95% CI 0.21, 0.85; p = 0.0160). Corticosteroids were not associated with delayed viral RNA clearance in our cohort. Conclusion In this clinical practice setting, low-dose corticosteroid treatment was associated with reduced risk of in-hospital death within 60 days in COVID-19 patients who developed ARDS.
C1 [Wu, Chaomin; Du, Chunling; Song, Yuanlin] Fudan Univ, Zhongshan Hosp, QingPu Branch, Dept Pulm & Crit Care Med, Shanghai, Peoples R China.
   [Wu, Chaomin; Hou, Dongni; Chen, Xiaoyan; Chen, Cuicui; Hu, Xianglin; Zhang, Yuye; Song, Juan; Wang, Lu; Chao, Yen-cheng; Hu, Jie; Jiang, Jinjun; Bai, Chunxue; Song, Yuanlin] Fudan Univ, Zhongshan Hosp, Dept Pulm & Crit Care Med, Shanghai, Peoples R China.
   [Cai, Yanping; Gong, Fengyun] Wuhan Jin Yin Tan Hosp, Infect Div, Wuhan, Peoples R China.
   [Zheng, Junhua] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Urol, Shanghai, Peoples R China.
   [Xu, Jie] Fengxian Guhua Hosp, Dept Infect Dis, Shanghai, Peoples R China.
   [Feng, Yun] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Sch Med, Dept Gastroenterol, Shanghai, Peoples R China.
   [Xiong, Weining] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Resp & Crit Care Med, Shanghai, Peoples R China.
   [Chen, Dechang] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Crit Care Med, Shanghai, Peoples R China.
   [Zhong, Ming] Fudan Univ, Zhongshan Hosp, Dept Crit Care Med, Shanghai, Peoples R China.
   [Zhou, Xin] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1, Dept Pulm Med, Shanghai, Peoples R China.
   [Xu, Jinfu] Shanghai Pulm Hosp, Dept Resp & Crit Care Med, Shanghai, Peoples R China.
   [Song, Yuanlin] Shanghai Resp Res Inst, Shanghai, Peoples R China.
   [Song, Yuanlin] Fudan Univ, Natl Clin Res Ctr Aging & Med, Huashan Hosp, Shanghai, Peoples R China.
   [Song, Yuanlin] Fudan Univ, Jinshan Hosp, Shanghai, Peoples R China.
RP Song, YL (corresponding author), Fudan Univ, Zhongshan Hosp, QingPu Branch, Dept Pulm & Crit Care Med, Shanghai, Peoples R China.; Gong, FY (corresponding author), Wuhan Jin Yin Tan Hosp, Infect Div, Wuhan, Peoples R China.
EM ylsong70@163.com; gfy.yuyingzi@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [82041003, 81630001, 81770075, 81800008];
   Science and Technology Commission of Shanghai MunicipalityScience &
   Technology Commission of Shanghai Municipality (STCSM) [20411950402,
   20XD1401200]; Shanghai Municipal Key Clinical Specialty
   [shslczdzk02201]; Shanghai Key Discipline of Medicine [ZK2019B06];
   Shanghai Sailing Program [18YF1404300]; Academic Leader of Shanghai
   Qingpu District Healthcare Commission [WD2019-36]; Sub-specialist
   Project of Qingpu Branch of Zhongshan Hospital, Fudan University [YZK
   2019-04]; Construction of GCP Platform for Pulmonary Tuberculosis Drugs
   [2020ZX09201001]
FX This study was supported by The National Natural Science Foundation of
   China (82041003, 81630001, 81770075, 81800008), Science and Technology
   Commission of Shanghai Municipality (20411950402, 20XD1401200), Shanghai
   Municipal Key Clinical Specialty (shslczdzk02201), Shanghai Key
   Discipline of Medicine (ZK2019B06), Shanghai Sailing Program
   (18YF1404300), Academic Leader of Shanghai Qingpu District Healthcare
   Commission (WD2019-36), and Sub-specialist Project of Qingpu Branch of
   Zhongshan Hospital, Fudan University (YZK 2019-04), Construction of GCP
   Platform for Pulmonary Tuberculosis Drugs (2020ZX09201001).
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Austin PC, 2006, J EVAL CLIN PRACT, V12, P601, DOI 10.1111/j.1365-2753.2005.00624.x
   Bosco JLF, 2010, J CLIN EPIDEMIOL, V63, P64, DOI 10.1016/j.jclinepi.2009.03.001
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan MHM, 2006, PATHOLOGY, V38, P229, DOI 10.1080/00313020600696231
   Chen RC, 2006, CHEST, V129, P1441, DOI 10.1378/chest.129.6.1441
   Guan WJ, 2019, NEW ENGL J MED, V2020, P181
   Gum PA, 2001, JAMA-J AM MED ASSOC, V286, P1187, DOI 10.1001/jama.286.10.1187
   Hashimoto S, 2017, J INTENSIVE CARE, V5, DOI 10.1186/s40560-017-0222-3
   Horby P, 2020, NEW ENGL J MED, DOI [10.3390/ijerph17186845, DOI 10.3390/IJERPH17186845]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jeronimo Christiane Maria Prado, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1177
   Joffe MM, 1999, AM J EPIDEMIOL, V150, P327
   Lee DTS, 2004, CLIN INFECT DIS, V39, P1247, DOI 10.1086/424016
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Lee N, 2009, J INFECT DIS, V200, P492, DOI 10.1086/600383
   Meduri GU, 2007, CHEST, V131, P954, DOI 10.1378/chest.06-2100
   Meduri GU, 2016, INTENS CARE MED, V42, P829, DOI 10.1007/s00134-015-4095-4
   Meduri GU, 2009, CHEST, V136, P1631, DOI 10.1378/chest.08-2408
   Pastores SM, 2018, INTENS CARE MED, V44, P474, DOI 10.1007/s00134-017-4951-5
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rice TW, 2007, CHEST, V132, P410, DOI 10.1378/chest.07-0617
   Ruan SY, 2014, CRIT CARE, V18, DOI 10.1186/cc13819
   Russell CD, 2020, LANCET, VS0140-6736, P30317
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023
   Tomazini BM, 2020, JAMA-J AM MED ASSOC, V324, P1307, DOI 10.1001/jama.2020.17021
   Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, CLIN MAN SEV AC RESP
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xiao AT, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104346
   Xiao Jian-zhong, 2004, Zhonghua Nei Ke Za Zhi, V43, P179
   Yang JW, 2020, CLIN MICROBIOL INFEC, V26, P1171, DOI 10.1016/j.cmi.2020.06.020
NR 35
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1364-8535
EI 1466-609X
J9 CRIT CARE
JI Crit. Care
PD NOV 10
PY 2020
VL 24
IS 1
AR 643
DI 10.1186/s13054-020-03340-4
PG 10
WC Critical Care Medicine
SC General & Internal Medicine
GA OR3UU
UT WOS:000589399700001
PM 33172477
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU De Vita, S
   Chini, MG
   Lauro, G
   Bifulco, G
AF De Vita, Simona
   Chini, Maria Giovanna
   Lauro, Gianluigi
   Bifulco, Giuseppe
TI Accelerating the repurposing of FDA-approved drugs against coronavirus
   disease-19 (COVID-19)
SO RSC ADVANCES
LA English
DT Article
ID CURRENT ANTIVIRAL DRUGS; BIOLOGICAL-MATERIALS; BINDING-SITES;
   LOMITAPIDE; HEPATITIS; DYNAMICS; OUTBREAK; WUHAN
AB The recent release of the main protein structures belonging to SARS CoV-2, responsible for the coronavirus disease-19 (COVID-19), strongly pushed for identifying valuable drug treatments. With this aim, we show a repurposing study on FDA-approved drugs applying a new computational protocol and introducing a novel parameter called IVSratio. Starting with a virtual screening against three SARS CoV-2 targets (main protease, papain-like protease, spike protein), the top-ranked molecules were reassessed combining the Inverse Virtual Screening novel approach and MM-GBSA calculations. Applying this protocol, a list of drugs was identified against the three investigated targets. Also, the top-ranked selected compounds on each target (rutin vs. main protease, velpatasvir vs. papain-like protease, lomitapide vs. spike protein) were further tested with molecular dynamics simulations to confirm the promising binding modes, obtaining encouraging results such as high stability of the complex during the simulation and a good protein-ligand interaction network involving some important residues of each target. Moreover, the recent outcomes highlighting the inhibitory activity of quercetin, a natural compound strictly related to rutin, on the SARS-CoV-2 main protease, strengthened the applicability of the proposed workflow.
C1 [De Vita, Simona; Lauro, Gianluigi; Bifulco, Giuseppe] Univ Salerno, Dept Pharm, Via Giovanni Paolo II 132, I-84084 Fisciano, Italy.
   [Chini, Maria Giovanna] Univ Molise, Dept Biosci & Terr, I-86090 Pesche, IS, Italy.
RP Lauro, G; Bifulco, G (corresponding author), Univ Salerno, Dept Pharm, Via Giovanni Paolo II 132, I-84084 Fisciano, Italy.
EM glauro@unisa.it; bifulco@unisa.it
FU AIRCAssociazione Italiana per la Ricerca sul Cancro (AIRC) [IG 2018-ID,
   21397, MFAG 2017-ID, 20160]
FX The research leading to these results has received funding from AIRC
   under IG 2018-ID. 21397 project - P.I. Bifulco Giuseppe and MFAG
   2017-ID. 20160 project - P.I. Lauro Gianluigi.
CR Abd El-Mordy FM, 2020, RSC ADV, V10, P32148, DOI 10.1039/d0ra05679k
   Abian O, 2020, INT J BIOL MACROMOL, V164, P1693, DOI 10.1016/j.ijbiomac.2020.07.235
   Al-Zahrani AA, 2020, NAT PROD COMMUN, V15, DOI 10.1177/1934578X20953951
   Alexpandi R, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01796
   [Anonymous], 2020, SCHROD REL 2020 1 SI
   [Anonymous], 2020, SCHROD REL 2020 1 LI
   [Anonymous], 2016, SCHROD REL 2020 1 PR
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Buonaguro FM, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02333-9
   Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD464, DOI 10.1093/nar/gky1004
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chaudhuri R, 2011, J MOL BIOL, V414, P272, DOI 10.1016/j.jmb.2011.09.030
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   De Vita S, 2019, J CHEM INF MODEL, V59, P4678, DOI 10.1021/acs.jcim.9b00428
   Elmi A., 2020, CHEMRXIV, DOI [10.26434/chemrxiv.12325844.v1, DOI 10.26434/CHEMRXIV.12325844.V1]
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Ferraz WR, 2020, FUTURE MED CHEM, V12, P1815, DOI 10.4155/fmc-2020-0165
   Gentile D, 2020, MAR DRUGS, V18, DOI 10.3390/md18040225
   Ghosh AK, 2020, CHEMMEDCHEM, V15, P907, DOI 10.1002/cmdc.202000223
   Greig SL, 2016, DRUGS, V76, P1567, DOI 10.1007/s40265-016-0648-2
   Hagar M., 2020, INT J MOL SCI, P21
   Halgren TA, 2009, J CHEM INF MODEL, V49, P377, DOI 10.1021/ci800324m
   Halgren T, 2007, CHEM BIOL DRUG DES, V69, P146, DOI 10.1111/j.1747-0285.2007.00483.x
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Huynh T., 2020, CHEMRXIV, DOI [10.26434/chemrxiv.12281078.v1, DOI 10.26434/CHEMRXIV.12281078.V1]
   Ibrahim IM, 2020, J INFECTION, V80, P554, DOI 10.1016/j.jinf.2020.02.026
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Ju J., 2020, BIORXIV, DOI [10.1101/2020.01.30.927574, DOI 10.1101/2020.01.30.927574, 10.1101/2020.01.30.927574.]
   Kairys V, 2019, EXPERT OPIN DRUG DIS, V14, P755, DOI 10.1080/17460441.2019.1623202
   Kim J, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02430-9
   Kumar N, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.2020.1792990, 10.1080/03601234.2020.1808416]
   Kumar N, 2020, J PROTEOME RES, V19, P4678, DOI 10.1021/acs.jproteome.0c00367
   Kumar N, 2020, J CHEM INF MODEL, V60, P421, DOI 10.1021/acs.jcim.9b01051
   Kumar N, 2019, ACS OMEGA, V4, P21370, DOI 10.1021/acsomega.9b03035
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lauro G, 2012, BIOORGAN MED CHEM, V20, P3596, DOI 10.1016/j.bmc.2012.03.072
   Lauro G, 2011, J NAT PROD, V74, P1401, DOI 10.1021/np100935s
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu X, 2017, AM J CARDIOVASC DRUG, V17, P299, DOI 10.1007/s40256-017-0214-7
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mevada V., 2020, CHEMRXIV, DOI [10.26434/chemrxiv.12115251.v2, DOI 10.26434/CHEMRXIV.12115251.V2]
   Neef D, 2016, EXPERT REV CLIN PHAR, V9, P655, DOI 10.1586/17512433.2016.1162095
   Ngo Son Tung, 2020, J Chem Inf Model, DOI 10.1021/acs.jcim.0c00491
   Novakova L, 2018, J PHARMACEUT BIOMED, V147, P378, DOI 10.1016/j.jpba.2017.07.003
   Novakova L, 2018, J PHARMACEUT BIOMED, V147, P400, DOI 10.1016/j.jpba.2017.06.071
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Oldfield V, 2009, DRUGS, V69, P609, DOI 10.2165/00003495-200969050-00007
   Olubiyi OO, 2020, MOLECULES, V25, DOI 10.3390/molecules25143193
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Rehman M. T., 2020, CHEMRXIV, DOI [10.26434/chemrxiv.12362333.v2, DOI 10.26434/CHEMRXIV.12362333.V2]
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Sang P, 2020, RSC ADV, V10, P15775, DOI 10.1039/d0ra01899f
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Shahinshavali S, 2020, TETRAHEDRON LETT, V61, DOI 10.1016/j.tetlet.2020.152336
   Siebenmorgen T, 2020, WIRES COMPUT MOL SCI, V10, DOI 10.1002/wcms.1448
   Sood D, 2019, ACS OMEGA, V4, P16233, DOI 10.1021/acsomega.9b02578
   Taguchi YH, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238907
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yadav M, 2020, EUR J PHARM SCI, V155, DOI 10.1016/j.ejps.2020.105522
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 64
TC 0
Z9 0
U1 1
U2 1
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046-2069
J9 RSC ADV
JI RSC Adv.
PD NOV 10
PY 2020
VL 10
IS 67
BP 40867
EP 40875
DI 10.1039/d0ra09010g
PG 9
WC Chemistry, Multidisciplinary
SC Chemistry
GA OQ7RL
UT WOS:000588975500024
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Yessayan, LT
   Heung, M
   Girard, FA
   Shaikhouni, S
   Szamosfalvi, B
AF Yessayan, Lenar T.
   Heung, Michael
   Girard, Francine A.
   Shaikhouni, Salma
   Szamosfalvi, Balazs
TI Deployment of a New CRRT/PIRRT Device during the COVID-19 Pandemic
   Emergency: Organizational Challenges and Implementation Results
SO BLOOD PURIFICATION
LA English
DT Article; Early Access
DE Virtual continuous renal replacement treatment training; Renal
   replacement therapy; Coronavirus disease 2019; Coronavirus pandemic;
   SAMI
ID INTERMITTENT RENAL REPLACEMENT; LOW-EFFICIENCY DIALYSIS; ACUTE KIDNEY
   INJURY; THERAPY; ANTICOAGULATION; HEMODIALYSIS; EFFICACY; SAFETY
AB Introduction: The coronavirus disease 2019 (COVID-19) pandemic led to increased demand nationwide for dialysis equipment, including supplies and machines. To meet the demand in our institution, our surge plan included rapid mobilization of a novel continuous renal replacement treatment (CRRT) machine named SAMI. The SAMI is a push-pull filtration enhanced dialysis machine that can conjugate extremely high single-pass solute removal efficiency with very precise fluid balance control. Material and Methods: Machine assembly was conducted on-site by local biomedical engineers with remote assistance by the vendor. One 3-h virtual training session of 3 dialysis nurses was conducted before SAMI deployment. The SAMI was deployed in prolonged intermittent replacement therapy (PIRRT) mode to maximize patients covered per machine per day. Live on-demand vendor support was provided to troubleshoot any issues for the first few cases. After 4 weeks of the SAMI implementation, data on treatments with the SAMI were collected, and a questionnaire was provided to the nurse trainees to assess device usability. Results: On-site installation of the SAMI was accomplished with remote assistance. Delivery of remote training was successfully achieved. 23 PIRRT treatments were conducted in 10 patients. 7/10 of patients had CO-VID-19. The median PIRRT dose was 50 mL/kg/h (IQR [interquartile range] 44 - 62 mL/kg/h), and duration of the treatment was 8 h (IQR 6.3 - 8 h). Solute control was adequate. The user response was favorable to the set of usability questions involving user interface, on-screen instructions, machine setup, troubleshooting, and the ease of moving the machine. Conclusion: Assembly of the SAMI and training of nurses remotely are possible when access to vendor employees is restricted during states of emergency. The successful deployment of the SAMI in our institution during the pandemic with only 3-h virtual training supports that operating the SAMI is simple and safe.
C1 [Yessayan, Lenar T.; Heung, Michael; Girard, Francine A.; Shaikhouni, Salma; Szamosfalvi, Balazs] Univ Michigan, Dept Med, Div Nephrol, Ann Arbor, MI 48109 USA.
RP Yessayan, LT (corresponding author), Univ Michigan, Div Nephrol, 3914 Taubman Ctr,1500 E M, Ann Arbor, MI 48109 USA.
EM lenar@umich.edu
CR Abelson R, 2020, THE NEW YORK TIMES
   Berbece AN, 2006, KIDNEY INT, V70, P963, DOI 10.1038/sj.ki.5001700
   Buckberry C, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229233
   Clark JA, 2008, CLIN J AM SOC NEPHRO, V3, P736, DOI 10.2215/CJN.03460807
   Edrees F, 2016, ADV CHRONIC KIDNEY D, V23, P195, DOI 10.1053/j.ackd.2016.03.003
   Fiaccadori E, 2013, CLIN J AM SOC NEPHRO, V8, P1670, DOI 10.2215/CJN.00510113
   Gashti CN, 2008, AM J KIDNEY DIS, V51, P804, DOI 10.1053/j.ajkd.2008.01.012
   Goldfarb DS, 2020, CLIN J AM SOC NEPHRO, V15, P880, DOI 10.2215/CJN.05180420
   Heung M, 2017, CRIT CARE CLIN, V33, P365, DOI 10.1016/j.ccc.2016.12.003
   Kitchlu A, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882-015-0123-4
   Kumar VA, 2000, AM J KIDNEY DIS, V36, P294, DOI 10.1053/ajkd.2000.8973
   Lee K, 2012, ASAIO J, V58, P232, DOI 10.1097/MAT.0b013e318248d8d7
   Marshall MR, 2011, NEPHROL DIAL TRANSPL, V26, P2169, DOI 10.1093/ndt/gfq694
   Marshall MR, 2004, NEPHROL DIAL TRANSPL, V19, P877, DOI 10.1093/ndt/gfg625
   Morti SM, 1998, ASAIO J, V44, P319, DOI 10.1097/00002480-199807000-00016
   Pistolesi V, 2019, ANTIMICROB AGENTS CH, V63, DOI 10.1128/AAC.00583-19
   Schwenger V, 2012, CRIT CARE, V16, DOI 10.1186/cc11445
   Szamosfalvi B, 2020, NAT REV NEPHROL, V16, P560, DOI 10.1038/s41581-020-0326-1
   Szamosfalvi B, 2012, BLOOD PURIFICAT, V34, P80, DOI 10.1159/000341644
   Teo BW, 2007, NEPHROL DIAL TRANSPL, V22, P2304, DOI 10.1093/ndt/gfm190
NR 20
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0253-5068
EI 1421-9735
J9 BLOOD PURIFICAT
JI Blood Purif.
DI 10.1159/000511726
EA NOV 2020
PG 9
WC Hematology; Urology & Nephrology
SC Hematology; Urology & Nephrology
GA OQ4MG
UT WOS:000588759000001
PM 33171460
DA 2021-01-01
ER

PT J
AU Coll, E
   Fernandez-Ruiz, M
   Sanchez-Alvarez, JE
   Martinez-Fernandez, JR
   Crespo, M
   Gayoso, J
   Bada-Bosch, T
   Oppenheimer, F
   Moreso, F
   Lopez-Oliva, MO
   Melilli, E
   Rodriguez-Ferrero, ML
   Bravo, C
   Burgos, E
   Facundo, C
   Lorenzo, I
   Yanez, I
   Galeano, C
   Roca, A
   Cabello, M
   Gomez-Bueno, M
   Garcia-Cosio, MD
   Graus, J
   Llado, L
   de Pablo, A
   Loinaz, C
   Aguado, B
   Hernandez, D
   Dominguez-Gil, B
AF Coll, Elisabeth
   Fernandez-Ruiz, Mario
   Sanchez-Alvarez, J. Emilio
   Martinez-Fernandez, Jose R.
   Crespo, Marta
   Gayoso, Jorge
   Bada-Bosch, Teresa
   Oppenheimer, Federico
   Moreso, Francesc
   Lopez-Oliva, Maria O.
   Melilli, Edoardo
   Rodriguez-Ferrero, Marisa L.
   Bravo, Carlos
   Burgos, Elena
   Facundo, Carme
   Lorenzo, Inmaculada
   Yanez, Inigo
   Galeano, Cristina
   Roca, Ana
   Cabello, Mercedes
   Gomez-Bueno, Manuel
   Garcia-Cosio, Ma Dolores
   Graus, Javier
   Llado, Laura
   de Pablo, Alicia
   Loinaz, Carmelo
   Aguado, Beatriz
   Hernandez, Domingo
   Dominguez-Gil, Beatriz
CA Spanish Grp Study Covid-19 Transpl
TI COVID-19 in transplant recipients: The Spanish experience
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article; Early Access
DE clinical research; practice; infectious disease; infection and
   infectious agents &#8208; viral; antibiotic; antiviral; clinical
   decision&#8208; making; complication; infectious
ID CLINICAL IMPACT; INFECTION
AB We report the nationwide experience with solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients diagnosed with coronavirus disease 2019 (COVID-19) in Spain until 13 July 2020. We compiled information for 778 (423 kidney, 113 HSCT, 110 liver, 69 heart, 54 lung, 8 pancreas, 1 multivisceral) recipients. Median age at diagnosis was 61 years (interquartile range [IQR]: 52-70), and 66% were male. The incidence of COVID-19 in SOT recipients was two-fold higher compared to the Spanish general population. The median interval from transplantation was 59 months (IQR: 18-131). Infection was hospital-acquired in 13% of cases. No donor-derived COVID-19 was suspected. Most patients (89%) were admitted to the hospital. Therapies included hydroxychloroquine (84%), azithromycin (53%), protease inhibitors (37%), and interferon-beta (5%), whereas immunomodulation was based on corticosteroids (41%) and tocilizumab (21%). Adjustment of immunosuppression was performed in 85% of patients. At the time of analysis, complete follow-up was available from 652 patients. Acute respiratory distress syndrome occurred in 35% of patients. Ultimately, 174 (27%) patients died. In univariate analysis, risk factors for death were lung transplantation (odds ratio [OR]: 2.5; 95% CI: 1.4-4.6), age >60 years (OR: 3.7; 95% CI: 2.5-5.5), and hospital-acquired COVID-19 (OR: 3.0; 95% CI: 1.9-4.9).
C1 [Coll, Elisabeth; Martinez-Fernandez, Jose R.; Gayoso, Jorge; Dominguez-Gil, Beatriz] Spanish Natl Transplant Org, Org Nacl Trasplantes, Madrid, Spain.
   [Fernandez-Ruiz, Mario] Hosp Univ 12 Octubre, Grp Study Infect Transplantat & Immunocompromised, Spanish Soc Infect Dis & Clin Microbiol SEIMC, Unit Infect Dis,Inst Invest Sanitaria,imas12, Madrid, Spain.
   [Fernandez-Ruiz, Mario] Spanish Soc Infect Dis & Clin Microbiol SEIMC, Grp Study Infect Transplantat & Immunocompromi, Madrid, Spain.
   [Sanchez-Alvarez, J. Emilio] Hosp Univ Cabuenes, Dept Nephrol, Gijon, Spain.
   [Sanchez-Alvarez, J. Emilio] Spanish Soc Nephrol SEN, Gijon, Spain.
   [Crespo, Marta] Hosp del Mar, Dept Nephrol, Barcelona, Spain.
   [Crespo, Marta] Spanish Soc Nephrol SEN, Transplant Working Grp, Barcelona, Spain.
   [Crespo, Marta] REDinREN RD16 0009 0013, Barcelona, Spain.
   [Bada-Bosch, Teresa] Hosp Univ 12 Octubre, Dept Nephrol, Madrid, Spain.
   [Oppenheimer, Federico] Hosp Clin Barcelona, Dept Nephrol, Barcelona, Spain.
   [Moreso, Francesc] Hosp Univ Vall dHebron, Dept Nephrol, Kidney Transplant Unit, Barcelona, Spain.
   [Lopez-Oliva, Maria O.] Hosp Univ La Paz, Dept Nephrol, Madrid, Spain.
   [Melilli, Edoardo] Hosp Univ Bellvitge, Dept Nephrol, Kidney Transplant Unit, Barcelona, Spain.
   [Rodriguez-Ferrero, Marisa L.] Hosp Gen Univ Gregorio Maranon, Dept Nephrol, Madrid, Spain.
   [Bravo, Carlos] Hosp Univ Vall dHebron, Lung Transplant Unit, Dept Pulmonol, Barcelona, Spain.
   [Burgos, Elena] Hosp Badalona Germans Trias & Pujol, Dept Nephrol, Badalona, Spain.
   [Facundo, Carme] Fdn Puigvert, Kidney Transplant Unit, Barcelona, Spain.
   [Lorenzo, Inmaculada] Complejo Hosp Univ Albacete, Dept Nephrol, Albacete, Spain.
   [Yanez, Inigo] Hosp Univ Cruces, Dept Nephrol, Baracaldo, Spain.
   [Galeano, Cristina] Hosp Univ Ramon y Cajal, Kidney Transplant Unit, Madrid, Spain.
   [Roca, Ana] Complejo Hosp Univ Toledo, Dept Nephrol, Toledo, Spain.
   [Cabello, Mercedes] Hosp Reg Univ Malaga, Dept Nephrol, Malaga, Spain.
   [Gomez-Bueno, Manuel] Hosp Univ Puerta Hierro, Dept Cardiol, Madrid, Spain.
   [Garcia-Cosio, Ma Dolores] Hosp Univ 12 Octubre, Inst Invest Sanitaria, Hosp 12 Octubre, Cardiol Serv,imas12, Madrid, Spain.
   [Garcia-Cosio, Ma Dolores] Ctr Invest Biomed Red Cardiovasc CIBERCV, Madrid, Spain.
   [Graus, Javier] Hosp Univ Ramon y Cajal, Dept Gastroenterol, Madrid, Spain.
   [Llado, Laura] Hosp Univ Bellvitge, Liver Transplant Unit, Barcelona, Spain.
   [de Pablo, Alicia] Hosp Univ 12 Octubre, Dept Pneumol, Lung Transplant Unit, Madrid, Spain.
   [Loinaz, Carmelo] Hosp Univ 12 Octubre, Dept Gen Surg Digest Tract & Abdominal Organ Tran, Transplant Unit, Madrid, Spain.
   [Aguado, Beatriz] Hosp Univ La Princesa, Transplant Unit, Dept Hematol, Madrid, Spain.
   [Hernandez, Domingo] Hosp Reg Univ, Dept Nephrol, Malaga, Spain.
   [Hernandez, Domingo] Inst Invest Biomed Malaga IBIMA, Malaga, Spain.
   [Hernandez, Domingo] Spanish Soc Transplantat SET, Malaga, Spain.
RP Dominguez-Gil, B (corresponding author), Spanish Natl Transplant Org, Org Nacl Trasplantes, Madrid, Spain.
EM bdominguez@sanidad.gob.es
OI Moreso, Francesc/0000-0002-7267-3963; Fernandez-Ruiz,
   Mario/0000-0002-0315-8001
FU Spanish Ministry of Science and Innovation, Instituto de Salud Carlos
   IIIInstituto de Salud Carlos IIISpanish Government [CP 18/00073]
FX The Spanish group for the Study of COVID-19 in transplant recipients is
   a joint effort of the Spanish Organizacion Nacional de Trasplantes and
   the Spanish Society of Nephrology, that promoted the national collection
   of data on transplant recipients with COVID19. The authors thank
   professionals from all Spanish centers for the provision of data to both
   registries. This study received no funding. Many kidney transplant
   nephrologists are endorsed by the Kidney Research Net, REDinREN
   (RD16/0009). M.F.R. holds a research contract "Miguel Servet" (CP
   18/00073) from the Spanish Ministry of Science and Innovation, Instituto
   de Salud Carlos III.
CR Aigner C, 2020, J HEART LUNG TRANSPL, V39, P610, DOI 10.1016/j.healun.2020.04.004
   Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   Alberici F, 2020, KIDNEY INT REP, V5, P580, DOI 10.1016/j.ekir.2020.04.001
   AlGhamdi M, 2015, AM J TRANSPLANT, V15, P1101, DOI 10.1111/ajt.13085
   Banerjee D, 2020, KIDNEY INT, V97, P1076, DOI 10.1016/j.kint.2020.03.018
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bhoori S, 2020, LANCET GASTROENTEROL, V5, P532, DOI 10.1016/S2468-1253(20)30116-3
   Billah M, 2020, TRANSPL INT, V33, P1140, DOI 10.1111/tri.13635
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014
   Colmenero Jordi, 2021, J Hepatol, V74, P148, DOI 10.1016/j.jhep.2020.07.040
   Cravedi P, 2020, AM J TRANSPLANT, V20, P3140, DOI 10.1111/ajt.16185
   Dominguez-Gil B, 2020, AM J TRANSPLANT, V20, P2593, DOI 10.1111/ajt.15983
   Sanchez-Alvarez JE, 2020, NEFROLOGIA, V40, P272, DOI 10.1016/j.nefro.2020.04.002
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Fontana F, 2020, AM J TRANSPLANT, V20, P1902, DOI 10.1111/ajt.15935
   Garbino J, 2006, CLIN INFECT DIS, V43, P1009, DOI 10.1086/507898
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hammami MB, 2020, AM J TRANSPLANT, V20, P2254, DOI 10.1111/ajt.15985
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ison MG, 2009, AM J TRANSPLANT, V9, P1929, DOI 10.1111/j.1600-6143.2009.02700.x
   Kates OS, 2020, AM J TRANSPLANT, V20, P1885, DOI 10.1111/ajt.15944
   Kim Y, 2020, AM J TRANSPLANT, V20, P2269, DOI 10.1111/ajt.15947
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Kumar D, 2003, AM J TRANSPLANT, V3, P977, DOI 10.1034/j.1600-6143.2003.00197.x
   Liang WH, 2020, JAMA INTERN MED, V180, P1081, DOI 10.1001/jamainternmed.2020.2033
   Lopez V, 2020, NEFROLOGIA, V40, P265, DOI 10.1016/j.nefro.2020.03.002
   Meziyerh S, 2020, AM J TRANSPLANT, V20, P1896, DOI 10.1111/ajt.15943
   Michaels MG, 2020, AM J TRANSPLANT, V20, P1768, DOI 10.1111/ajt.15832
   Mitja Oriol, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1009
   Nair V, 2020, AM J TRANSPLANT, V20, P1819, DOI 10.1111/ajt.15967
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Ritschl PV, 2020, AM J TRANSPLANT, V20, P1826, DOI 10.1111/ajt.15933
   Romanelli A, 2020, AM J TRANSPLANT, V20, P1947, DOI 10.1111/ajt.15905
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Skipper CP, 2020, ANN INTERN MED, V173, P623, DOI 10.7326/M20-4207
   Veronese N, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00170
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu L, 2020, EUR UROL, V77, P748, DOI 10.1016/j.eururo.2020.03.039
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 47
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
DI 10.1111/ajt.16369
EA NOV 2020
PG 13
WC Surgery; Transplantation
SC Surgery; Transplantation
GA OP0NI
UT WOS:000587772200001
PM 33098200
OA Bronze
DA 2021-01-01
ER

PT J
AU Sharma, P
   Reddy, PK
   Kumar, B
AF Sharma, Priyanka
   Reddy, Prasanna Kumar
   Kumar, Bhuvnesh
TI Trace Element Zinc, a Nature's Gift to Fight Unprecedented Global
   Pandemic COVID-19
SO BIOLOGICAL TRACE ELEMENT RESEARCH
LA English
DT Article; Early Access
DE COVID-19; Host defense; SARS; Trace elements; Zinc
ID ACUTE RESPIRATORY SYNDROME; ANGIOTENSIN-CONVERTING ENZYME; SYNDROME
   CORONAVIRUS; CYSTEINE RESIDUES; OXIDATIVE STRESS; HUMAN HEALTH;
   DEFICIENCY; IRON; AGE; SUPPLEMENTATION
AB With the advent of twenty-first century, we are in cruel grip of a pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the associated illness being called as COVID-19. Since its outbreak in December 2019 in Wuhan, China, there are no medicines to cure the disease till date. Based on their experience, scientists say that developing a coronavirus vaccine could take at least a year. There are many steps in place before the vaccine comes for the distribution like its safety and cost-effectiveness, especially for the developing countries. In this scenario, the only way to prevent the disease is by following certain safety guidelines and to boost up the body's immune system. Zinc, a crucial trace element involved in several biological and metabolic processes, has been found to play a pivotal role in promoting and appropriately regulating the host defense mechanisms against viral infections. Zinc is naturally present in some foods, fortified in others and also available as dietary supplement. The current RDA (Recommended Daily Allowance) of zinc is 12 and 10 mg for males and females respectively. Zinc is the second most common trace mineral after iron in the cell. It is present in all organs and tissues in the body as it forms catalytic component of all 6 classes of enzymes encompassing almost 2000 enzymes in the body. Zinc is biologically essential for cellular processes, including growth and development, as well as DNA synthesis and RNA transcription. Zinc deficiency results in a number of metabolic changes besides a compromised immune system. In this review, the role of zinc in regulating the host defense and viral replication is being discussed with the main focus on COVID-19.
C1 [Sharma, Priyanka; Reddy, Prasanna Kumar; Kumar, Bhuvnesh] Def Inst Physiol & Allied Sci, Lucknow Rd, Delhi 110054, India.
RP Sharma, P (corresponding author), Def Inst Physiol & Allied Sci, Lucknow Rd, Delhi 110054, India.
EM ps24july@gmail.com
CR Andreini C, 2012, J INORG BIOCHEM, V111, P150, DOI 10.1016/j.jinorgbio.2011.11.020
   Barretto N, 2005, J VIROL, V79, P15189, DOI 10.1128/JVI.79.24.15189-15198.2005
   BUNNING P, 1985, J INORG BIOCHEM, V24, P183, DOI 10.1016/0162-0134(85)85002-9
   Cunningham-Rundles S, 2005, J ALLERGY CLIN IMMUN, V115, P1119, DOI 10.1016/j.jaci.2005.04.036
   DiSilvestro RA, 2000, J NUTR, V130, p1509S, DOI 10.1093/jn/130.5.1509S
   Ekmekci OB, 2003, BIOL TRACE ELEM RES, V95, P203, DOI 10.1385/BTER:95:3:203
   Filippini T, 2018, J TRACE ELEM MED BIO, V50, P508, DOI 10.1016/j.jtemb.2018.03.001
   Freedman JC, 2012, CELL PHYSL SOURCE BO
   Garnier-Crussard A, 2020, J AM GERIATR SOC, V68, P939, DOI 10.1111/jgs.16407
   Goldberg SB, 2012, J THORAC ONCOL, V7, P1602, DOI 10.1097/JTO.0b013e318262de4a
   Goldsmith CS, 2004, EMERG INFECT DIS, V10, P320, DOI 10.3201/eid1002.030913
   Gosert R, 2002, J VIROL, V76, P3697, DOI 10.1128/JVI.76.8.3697-3708.2002
   Haase H, 2008, EXP GERONTOL, V43, P394, DOI 10.1016/j.exger.2007.12.002
   Haase Hajo, 2009, Immun Ageing, V6, P9, DOI 10.1186/1742-4933-6-9
   Hara T, 2017, J PHYSIOL SCI, V67, P283, DOI 10.1007/s12576-017-0521-4
   Heurich A, 2014, J VIROL, V88, P1293, DOI 10.1128/JVI.02202-13
   Himoto T, 2018, NUTRIENTS, V10, DOI 10.3390/nu10010088
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hojyo S, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/6762343
   Hui DS, 2014, CURR OPIN PULM MED, V20, P233, DOI 10.1097/MCP.0000000000000046
   JACKSON MA, 1989, APPL ENVIRON MICROB, V55, P649, DOI 10.1128/AEM.55.3.649-655.1989
   Kambe T, 2014, CELL MOL LIFE SCI, V71, P3281, DOI 10.1007/s00018-014-1617-0
   Kazi TG, 2008, BIOL TRACE ELEM RES, V122, P1, DOI 10.1007/s12011-007-8062-y
   King JC, 2000, J NUTR, V130, p1360S, DOI 10.1093/jn/130.5.1360S
   Krenn BM, 2009, J VIROL, V83, P58, DOI 10.1128/JVI.01543-08
   Kuba K, 2006, CURR OPIN PHARMACOL, V6, P271, DOI 10.1016/j.coph.2006.03.001
   Kumar Amit, 2020, Med Hypotheses, V144, P109848, DOI 10.1016/j.mehy.2020.109848
   Kumssa DB, 2015, SCI REP-UK, V5, DOI 10.1038/srep10974
   Lambert SA, 2018, CELL, V172, P650, DOI 10.1016/j.cell.2018.01.029
   Li M, 2013, J BIOL CHEM, V288, P35769, DOI 10.1074/jbc.M113.511212
   Lin MH, 2018, ANTIVIR RES, V150, P155, DOI 10.1016/j.antiviral.2017.12.015
   Lind SE, 2009, TRANSL RES, V154, P153, DOI 10.1016/j.trsl.2009.06.002
   Lopez LA, 2008, J VIROL, V82, P3000, DOI 10.1128/JVI.01914-07
   Ma YY, 2015, P NATL ACAD SCI USA, V112, P9436, DOI 10.1073/pnas.1508686112
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   Nielsen FH, 2012, ADV NUTR, V3, P783, DOI 10.3945/an.112.002881
   Olechnowicz J, 2018, J PHYSIOL SCI, V68, P19, DOI 10.1007/s12576-017-0571-7
   Overbeck S, 2008, ARCH IMMUNOL THER EX, V56, P15, DOI 10.1007/s00005-008-0003-8
   Prasad AS, 2013, ADV NUTR, V4, P176, DOI 10.3945/an.112.003210
   Prasad AS, 2009, CURR OPIN CLIN NUTR, V12, P646, DOI 10.1097/MCO.0b013e3283312956
   PRASAD AS, 1961, AM J MED, V31, P532, DOI 10.1016/0002-9343(61)90137-1
   Prentice E, 2004, J BIOL CHEM, V279, P10136, DOI 10.1074/jbc.M306124200
   Read SA, 2019, ADV NUTR, V10, P696, DOI 10.1093/advances/nmz013
   Rossi GP, 2020, ELIFE, V9, DOI 10.7554/eLife.57278
   Sandstead HH, 2010, AM J PUBLIC HEALTH, V100, P970, DOI 10.2105/AJPH.2009.187773
   Scozzafava A, 2002, CURR MED CHEM, V9, P1167, DOI 10.2174/0929867023370077
   Shankar AH, 1998, AM J CLIN NUTR, V68, p447S, DOI 10.1093/ajcn/68.2.447S
   Sharma L, 2020, J PEERSCI, V2, pe1000016, DOI 10.5281/zenodo.3774086
   Shulzhenko N, 2011, NAT MED, V17, P1585, DOI 10.1038/nm.2505
   Siva S, 2017, INFLAMM BOWEL DIS, V23, P152, DOI 10.1097/MIB.0000000000000989
   Skalny AV, 2020, INT J MOL MED, V46, P17, DOI 10.3892/ijmm.2020.4575
   Spyroulias GA, 2004, CURR TOP MED CHEM, V4, P403, DOI 10.2174/1568026043451294
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   TEVELTHUIS AJW, 2010, PLOS PATHOG, V0006
   To PK, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082991
   Vasto S, 2006, BIOGERONTOLOGY, V7, P315, DOI 10.1007/s10522-006-9046-6
   Webb P, 2007, NUTR REV, V65, P233, DOI 10.1111/j.1753-4887.2007.tb00300.x
   Wessells KR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050568
   Wong CP, 2013, J NUTR BIOCHEM, V24, P353, DOI 10.1016/j.jnutbio.2012.07.005
   Xue J., 2014, GLOB HEART, V9, pe317, DOI DOI 10.1371/journal.pone.0109180
   Yu HJ, 2009, BIOCHEM J, V417, P133, DOI 10.1042/BJ20081421
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Ziebuhr J, 2005, CURR TOP MICROBIOL, V287, P57, DOI 10.1007/3-540-26765-4_3
NR 66
TC 0
Z9 0
U1 4
U2 4
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0163-4984
EI 1559-0720
J9 BIOL TRACE ELEM RES
JI Biol. Trace Elem. Res.
DI 10.1007/s12011-020-02462-8
EA NOV 2020
PG 9
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA OP6XQ
UT WOS:000588229400002
PM 33170448
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Wu, XD
   Li, YY
   Zhang, M
   Li, MM
   Zhang, R
   Lu, X
   Gao, W
   Li, Q
   Xia, Y
   Pan, PH
   Li, Q
AF Wu, Xiaodong
   Li, Yuanyuan
   Zhang, Ming
   Li, Miaomiao
   Zhang, Rong
   Lu, Xin
   Gao, Wei
   Li, Qin
   Xia, Yang
   Pan, Pinhua
   Li, Qiang
TI Etiology of Severe Community-Acquired Pneumonia in Adults Based on
   Metagenomic Next-Generation Sequencing: A Prospective Multicenter Study
SO INFECTIOUS DISEASES AND THERAPY
LA English
DT Article
DE Etiology; Metagenomic next-generation sequencing; Severe
   community-acquired pneumonia
ID BRONCHOALVEOLAR LAVAGE; RESPIRATORY PATHOGENS; DIAGNOSIS; PSITTACOSIS;
   OUTBREAK
AB Background Metagenomic next-generation sequencing (mNGS) of bronchoalveolar lavage fluid (BALF) has the potential to improve the pathogen identification in severe community-acquired pneumonia (SCAP). Methods In this 1.5-year, multicenter, prospective study, we investigated the usefulness of mNGS of BALF for identifying pathogens of SCAP in hospitalized adults, comparing it with other laboratory methods. Results Of 329 SCAP adults, a microbial etiology was established in 304 cases (92.4%). The overall microbial yield was 90.3% for mNGS versus 39.5% for other methods (P < 0.05). The most frequently detected pathogens in immunocompetent patients were Streptococcus pneumoniae (14.8%), rhinovirus (9.8%), Haemophilus influenzae (9.1%), Staphylococcus aureus (8.7%), and Chlamydia psittaci (8.0%), while in immunocompromised patients they were Pneumocystis jirovecii (44.6%), Klebsiella pneumoniae (18.5%), Streptococcus pneumoniae (15.4%), Haemophilus influenzae (13.8%), and Pseudomonas aeruginosa (13.8%). Notably, novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified from two patients solely by mNGS in January 2020; uncommon pathogens including Orientia tsutsugamushi and Nocardia otitidiscaviarum were identified from one patient, respectively. Furthermore, mixed infections were detected in 56.8% of the patients. Conclusions A high microbial detection rate was achieved in SCAP adults using mNGS testing of BALF. The most frequently detected pathogens of SCAP differed between immunocompetent and immunocompromised patients. mNGS testing may be an powerful tool for early identification of potential pathogens for SCAP to initiate a precise antimicrobial therapy.
C1 [Wu, Xiaodong; Li, Qin] Tongji Univ, Shanghai East Hosp, Dept Resp & Crit Care Med, Shanghai, Peoples R China.
   [Li, Yuanyuan; Pan, Pinhua] Cent South Univ, Xiangya Hosp, Dept Resp & Crit Care Med, Dept Resp Med,Natl Key Clin Specialty, Changsha, Peoples R China.
   [Zhang, Ming] Soochow Univ, Affiliated Hosp 3, Dept Resp & Crit Care Med, Changzhou, Jiangsu, Peoples R China.
   [Li, Miaomiao] Zhejiang Univ, Sch Med, Affiliated Hosp 4, Dept Resp & Crit Care Med, Hangzhou, Peoples R China.
   [Zhang, Rong] Second Mil Med Univ, Changhai Hosp, Dept Resp & Crit Care Med, Shanghai, Peoples R China.
   [Lu, Xin] Nanjing Med Univ, Affiliated Jiangning Hosp, Dept Resp & Crit Care Med, Nanjing, Peoples R China.
   [Gao, Wei] Jinan Univ, Shenzhen Peoples Hosp, Clin Med Coll 2, Dept Resp & Crit Care Med, Shenzhen, Peoples R China.
   [Li, Qin; Xia, Yang] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Resp & Crit Care Med, Hangzhou, Peoples R China.
RP Pan, PH (corresponding author), Cent South Univ, Xiangya Hosp, Dept Resp & Crit Care Med, Dept Resp Med,Natl Key Clin Specialty, Changsha, Peoples R China.; Xia, Y (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Resp & Crit Care Med, Hangzhou, Peoples R China.
EM yxia@zju.edu.cn; pinhuapan668@hotmail.com; liqressh@hotmail.com
FU Top-level Clinical Discipline Project of Shanghai Pudong [PWYgy2018-06];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81700006]; National Key R&D Program of China
   [2018YFC1311900]
FX This work was supported by the Top-level Clinical Discipline Project of
   Shanghai Pudong (grant no. PWYgy2018-06), the National Natural Science
   Foundation of China (grant no. 81700006), and the National Key R&D
   Program of China (2018YFC1311900). The Rapid Service Fee is funded by
   the authors.
CR Ai JW, 2020, EMERG MICROBES INFEC, V9, P597, DOI 10.1080/22221751.2020.1738905
   Baudel JL, 2014, ANN INTENSIVE CARE, V4, DOI 10.1186/s13613-014-0035-7
   Blauwkamp TA, 2019, NAT MICROBIOL, V4, P663, DOI 10.1038/s41564-018-0349-6
   Chen LJ, 2020, EMERG MICROBES INFEC, V9, P313, DOI 10.1080/22221751.2020.1725399
   Chiu CY, 2017, EMERG INFECT DIS, V23, P1694, DOI 10.3201/eid2310.161986
   Cilloniz C, 2019, EXPERT REV ANTI-INFE, V17, P787, DOI 10.1080/14787210.2019.1671823
   Di Pasquale MF, 2019, CLIN INFECT DIS, V68, P1482, DOI 10.1093/cid/ciy723
   Dickson RP, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004923
   Dubourg G, 2015, J CLIN MICROBIOL, V53, P994, DOI 10.1128/JCM.02918-14
   Dumke R, 2015, EMERG INFECT DIS, V21, P426, DOI 10.3201/eid2103.140927
   Fischer N, 2014, EMERG INFECT DIS, V20, P1072, DOI 10.3201/eid2006.131526
   Gadsby NJ, 2016, CLIN INFECT DIS, V62, P817, DOI 10.1093/cid/civ1214
   Grumaz S, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0326-8
   Guan HZ, 2016, J NEUROVIROL, V22, P240, DOI 10.1007/s13365-015-0390-7
   Hogerwerf L, 2017, EPIDEMIOL INFECT, V145, P3096, DOI [10.1017/s0950268817002060, 10.1017/S0950268817002060]
   Hohenadel IA, 2001, THORAX, V56, P115, DOI 10.1136/thorax.56.2.115
   Huang ZD, 2019, J INFECTION, V78, P158, DOI 10.1016/j.jinf.2018.10.002
   Jain S, 2015, NEW ENGL J MED, V373, P415, DOI 10.1056/NEJMoa1500245
   Lal Gupta C, 2020, ENVIRON INT, V138, P105667
   Langelier C, 2018, P NATL ACAD SCI USA, V115, pE12353, DOI 10.1073/pnas.1809700115
   Langelier C, 2018, AM J RESP CRIT CARE, V197, P524, DOI 10.1164/rccm.201706-1097LE
   Maartens G, 2020, CLIN INFECT DIS, V70, P1147, DOI 10.1093/cid/ciz332
   Magazine R, 2013, SAHEL MED J, V16, P102
   Marrie TJ, 2003, EUR RESPIR J, V21, P779, DOI 10.1183/09031936.03.00095403
   Metlay JP, 2019, AM J RESP CRIT CARE, V200, pE45, DOI 10.1164/rccm.201908-1581ST
   Miao Q, 2018, CLIN INFECT DIS, V67, pS231, DOI 10.1093/cid/ciy693
   Musher DM, 2013, J INFECTION, V67, P11, DOI 10.1016/j.jinf.2013.03.003
   Pan TT, 2019, J INFECTION, V79, P73, DOI 10.1016/j.jinf.2018.11.005
   Shaw KA, 2019, EMERG INFECT DIS, V25, P2143, DOI [10.3201/eid2512.190703, 10.3201/eid2511.190703]
   Simner PJ, 2018, CLIN INFECT DIS, V66, P778, DOI 10.1093/cid/cix881
   Sundell N, 2019, J CLIN MICROBIOL, V57, DOI 10.1128/JCM.00716-18
   Torres A, 2019, INTENS CARE MED, V45, P159, DOI 10.1007/s00134-019-05519-y
   Tsai CM, 2017, PEDIATR NEONATOL, V58, P430, DOI 10.1016/j.pedneo.2016.09.004
   Wilson MR, 2019, NEW ENGL J MED, V380, P2327, DOI 10.1056/NEJMoa1803396
   Xie Y, 2019, J INFECTION, V78, P164, DOI 10.1016/j.jinf.2018.09.004
   Zhang Y, 2019, J INFECTION, V78, P166, DOI 10.1016/j.jinf.2018.08.013
   Zinn MK, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8091379
NR 37
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 2193-8229
EI 2193-6382
J9 INFECT DIS THER
JI Infect. Dis. Ther.
PD DEC
PY 2020
VL 9
IS 4
BP 1003
EP 1015
DI 10.1007/s40121-020-00353-y
EA NOV 2020
PG 13
WC Infectious Diseases
SC Infectious Diseases
GA OU0TA
UT WOS:000588223600002
PM 33170499
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kumar, J
   Qureshi, R
   Sagurthi, SR
   Qureshi, IA
AF Kumar, Janish
   Qureshi, Rahila
   Sagurthi, Someswar R.
   Qureshi, Insaf Ahmed
TI Designing of Nucleocapsid Protein Based Novel Multi-epitope Vaccine
   Against SARS-COV-2 Using Immunoinformatics Approach
SO INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS
LA English
DT Article; Early Access
DE SARS-CoV-2; Nucleocapsid protein; Multi-epitope vaccine;
   Immunoinformatics approach; TLR3 receptor; Molecular dynamics simulation
ID CORONAVIRUS; EXPRESSION; CANDIDATE; TARGETS
AB The COVID-19 disease is caused by SARS-CoV-2 and spreading rapidly worldwide with extremely high infection rate. Since effective and specific vaccine is not available to combat the deadly COVID-19, the objective of our study was to design a multi-epitope vaccine using immunoinformatics approach with translational implications. Nucleocapsid (N) protein of SARS-CoV-2 is stable, conserved and highly immunogenic along with being less prone to mutations during infection, which makes it a suitable candidate for designing vaccine. In our study, B- and T-cells epitopes were identified from N protein and screened based on crucial parameters to design the multi-epitope vaccine construct. Additionally, human beta-defensin-2 was incorporated into the vaccine construct as an adjuvant along with suitable linkers followed by its further evaluation based on crucial parameters including allergenicity, antigenicity, stability etc. Combined major histocompatibility complexes (MHC-I and MHC-II) binding epitopes presented broader population coverage of the vaccine throughout the world. The three-dimensional structure of vaccine candidate implied strong interaction with toll-like receptor 3 (TLR3) using molecular docking. The vaccine-TLR3 complex was observed to be highly stable during simulation and electrostatic free energy was foremost contributor for stabilization of the structure. Subsequently, in silico cloning of vaccine candidate was carried out to generate the construct into pET-28a(+) expression vector succeeded by its virtual confirmation. Altogether, our results advocate that the designed vaccine candidate could be an effective and promising weapon to fight with COVID-19 infection worldwide.
C1 [Kumar, Janish; Qureshi, Insaf Ahmed] Univ Hyderabad, Sch Life Sci, Dept Biotechnol & Bioinformat, Prof CR Rao Rd, Hyderabad 500046, India.
   [Qureshi, Rahila; Sagurthi, Someswar R.] Osmania Univ, Dept Genet, Hyderabad 500007, India.
RP Qureshi, IA (corresponding author), Univ Hyderabad, Sch Life Sci, Dept Biotechnol & Bioinformat, Prof CR Rao Rd, Hyderabad 500046, India.
EM insaf@uohyd.ac.in
OI Qureshi, Insaf Ahmed/0000-0001-7720-7067
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Ahlen G, 2020, J VIROL, V94, DOI 10.1128/JVI.01279-20.
   Ahmad B, 2019, MICROB PATHOGENESIS, V132, P243, DOI 10.1016/j.micpath.2019.05.010
   Ahmad S, 2020, EUR J PHARM SCI, V151, DOI 10.1016/j.ejps.2020.105387
   Astuti I, 2020, DIABETES METAB SYND, V14, P407, DOI 10.1016/j.dsx.2020.04.020
   Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z
   Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6
   Chen XY, 2013, ADV DRUG DELIVER REV, V65, P1357, DOI 10.1016/j.addr.2012.09.039
   Cong YY, 2020, J VIROL, V94, DOI 10.1128/JVI.01925-19
   Duits LA, 2002, IMMUNOLOGY, V106, P517, DOI 10.1046/j.1365-2567.2002.01430.x
   Dutta NK, 2020, J VIROL, V94, DOI 10.1128/JVI.00647-20
   Dutta NK, 2008, IMMUNOL LETT, V118, P65, DOI 10.1016/j.imlet.2008.03.003
   Edgar A, 2018, BRIT J CANCER, V119, P9
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Gao WT, 2003, LANCET, V362, P1895, DOI 10.1016/S0140-6736(03)14962-8
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Hyun-Jung Lee Chloe, 2020, F1000Res, V9, P145, DOI 10.12688/f1000research.22507.1
   Jyotisha, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1844060
   Kalita P, 2020, MICROB PATHOGENESIS, V145, DOI 10.1016/j.micpath.2020.104236
   Kang SS, 2020, ACTA PHARMACOL SIN B, V10, P1228, DOI 10.1016/j.apsb.2020.04.009
   Kar PP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02213
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Leung DTM, 2004, J INFECT DIS, V190, P379, DOI 10.1086/422040
   Makrides SC, 1996, MICROBIOL REV, V60, P512, DOI 10.1128/MMBR.60.3.512-538.1996
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   Mu JF, 2020, SCI CHINA LIFE SCI, DOI 10.1007/s11427-020-1692-1
   Mukherjee S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020290
   PELLEQUER JL, 1991, METHOD ENZYMOL, V203, P176
   Perrie Y, 2008, INT J PHARMACEUT, V364, P272, DOI 10.1016/j.ijpharm.2008.04.036
   Petersen B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015079
   Ruan YJ, 2003, LANCET, V361, P1779, DOI 10.1016/S0140-6736(03)13414-9
   Phan T, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104211
   Van Regenmortal Marc H. V., 1996, Methods (Orlando), V9, P465, DOI 10.1006/meth.1996.0054
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 36
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1573-3149
EI 1573-3904
J9 INT J PEPT RES THER
JI Int. J. Pept. Res. Ther.
DI 10.1007/s10989-020-10140-5
EA NOV 2020
PG 16
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA OP7KW
UT WOS:000588265700001
PM 33192207
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Rahman, MS
   Islam, MR
   Ul Alam, ASMR
   Islam, I
   Hoque, MN
   Akter, S
   Rahaman, MM
   Sultana, M
   Hossain, MA
AF Rahman, M. Shaminur
   Islam, M. Rafiul
   Ul Alam, A. S. M. Rubayet
   Islam, Israt
   Hoque, M. Nazmul
   Akter, Salma
   Rahaman, Md. Mizanur
   Sultana, Munawar
   Hossain, M. Anwar
TI Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein and its
   consequences
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE CDC; COVID&#8208; 19; deletions; mutations; N protein; primer;
   SARS&#8208; CoV&#8208; 2; stability
ID WEB SERVER; FOLDX
AB The emerged novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created a global health crisis that warrants an accurate and detailed characterization of the rapidly evolving viral genome for understanding its epidemiology, pathogenesis, and containment. Here, we explored 61,485 sequences of the nucleocapsid (N) protein, a potent diagnostic and prophylactic target, for identifying the mutations to review their roles in real-time polymerase chain reaction based diagnosis and observe consequent impacts. Compared to the Wuhan reference strain, a total of 1034 unique nucleotide mutations were identified in the mutant strains (49.15%, n = 30,221) globally. Of these mutations, 367 occupy primer binding sites including the 3 '-end mismatch to the primer-pair of 11 well-characterized primer sets. Noteworthily, CDC (USA) recommended the N2 primer set contained a lower mismatch than the other primer sets. Moreover, 684 amino acid (aa) substitutions were located across 317 (75.66% of total aa) unique positions including 82, 21, and 83 of those in the RNA binding N-terminal domain (NTD), SR-rich region, and C-terminal dimerization domain, respectively. Moreover, 11 in-frame deletions, mostly (n = 10) within the highly flexible linker region, were revealed, and the rest was within the NTD region. Furthermore, we predicted the possible consequence of high-frequency mutations (>= 20) and deletions on the tertiary structure of the N protein. Remarkably, we observed that a high frequency (67.94% of mutated sequences) co-occuring mutations (R203K and G204R) destabilized and decreased overall structural flexibility. The N protein of SARS-CoV-2 comprises an average of 1.2 mutations per strain compared to 4.4 and 0.4 in Middle East respiratory syndrome-related coronavirus and SARS-CoV, respectively. Despite being proposed as the alternative target to spike protein for vaccine and therapeutics, the ongoing evolution of the N protein may challenge these endeavors, thus needing further immunoinformatics analyses. Therefore, continuous monitoring is required for tracing the ongoing evolution of the SARS-CoV-2 N protein in prophylactic and diagnostic interventions.
C1 [Rahman, M. Shaminur; Islam, M. Rafiul; Islam, Israt; Hoque, M. Nazmul; Akter, Salma; Rahaman, Md. Mizanur; Sultana, Munawar; Hossain, M. Anwar] Univ Dhaka, Dept Microbiol, Dhaka 1000, Bangladesh.
   [Ul Alam, A. S. M. Rubayet] Jashore Univ Sci & Technol, Dept Microbiol, Jashore, Bangladesh.
   [Hoque, M. Nazmul] Bangabandhu Sheikh Mujibur Rahman Agr Univ, Dept Gynecol Obstet & Reprod Hlth, Gazipur, Bangladesh.
   [Akter, Salma] Jahangirnagar Univ, Dept Microbiol, Dhaka, Bangladesh.
   [Hossain, M. Anwar] Jashore Univ Sci & Technol, Jashore, Bangladesh.
RP Hossain, MA (corresponding author), Univ Dhaka, Dept Microbiol, Dhaka 1000, Bangladesh.; Hossain, MA (corresponding author), Jashore Univ Sci & Technol, Jashore, Bangladesh.
EM hossaina@du.ac.bd
OI Alam, A. S. M. Rubayet Ul/0000-0001-9295-9865; Islam,
   Rafiul/0000-0002-0061-3910; Rahman, Md. Shaminur/0000-0002-3039-9337
CR Alam ARU, 2020, VIRULENCE
   Banerjee R, 2020, BIORXIV, DOI [10.1101/2020.08.18.255570, DOI 10.1101/2020.08.18.255570]
   Buss O, 2018, COMPUT STRUCT BIOTEC, V16, P25, DOI 10.1016/j.csbj.2018.01.002
   Cascarina SM, 2020, FASEB J, V34, P9832, DOI 10.1096/fj.202001351
   Delano WL, 2002, PYMOL MOL GRAPHICS S
   Delgado J, 2019, BIOINFORMATICS, V35, P4168, DOI 10.1093/bioinformatics/btz184
   Dutta NK, 2020, J VIROL, V94, DOI 10.1128/JVI.00647-20
   ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543
   Garcia-Boronat M, 2008, NUCLEIC ACIDS RES, V36, pW35, DOI 10.1093/nar/gkn211
   Goethe M, 2015, J CHEM THEORY COMPUT, V11, P351, DOI 10.1021/ct500696p
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Gussow AB, 2020, P NATL ACAD SCI USA, V117, P15193, DOI 10.1073/pnas.2008176117
   Hoque MNA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49468-4
   Hoque M Nazmul, 2020, Genomics, V112, P5188, DOI 10.1016/j.ygeno.2020.09.039
   Hoque MN, 2020, PEERJ, V8, DOI 10.7717/peerj.9689
   Hurst KR, 2009, J VIROL, V83, P7221, DOI 10.1128/JVI.00440-09
   Islam MR, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70812-6
   Islam MR, 2020, TRANSBOUND EMERG DIS, DOI 10.1111/tbed.13687
   Jia Y., 2020, BIORXIV, DOI [10.1101/2020.04.09.034942, DOI 10.1101/2020.04.09.034942]
   KABAT EA, 1977, J BIOL CHEM, V252, P6609
   Kamau E, 2017, J CLIN VIROL, V88, P21, DOI 10.1016/j.jcv.2016.12.011
   Kang SS, 2020, ACTA PHARMACOL SIN B, V10, P1228, DOI 10.1016/j.apsb.2020.04.009
   Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053
   Koyama T, 2020, B WORLD HEALTH ORGAN, V98, P495, DOI 10.2471/BLT.20.253591
   Kumar T.A., 2013, WIDE SPECTRUM, V1, P15, DOI DOI 10.5281/ZENODO.50733
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Liang YW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01022
   Lin Z, 2020, NUCLEOCAPSID PROTEIN, DOI [10.2139/ssrn.3561932, DOI 10.2139/SSRN.3561932]
   Liu WY, 2020, NEW ENGL J MED, V382, P1370, DOI 10.1056/NEJMc2003717
   Mercatelli D, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01800
   Mo Pingzheng, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa270
   Nalla AK, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00557-20
   Nature News Feature, 2020, NATURE NEWS FEA 0809
   Ozono S, 2020, BIORXIV, DOI [10.1101/2020.06.15.151779, DOI 10.1101/2020.06.15.151779]
   Pachetti M, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02344-6
   Park M, 2020, EXP MOL MED, V52, P963, DOI 10.1038/s12276-020-0452-7
   RAHMAN MS, 2020, TRANSBOUND EMER 1006
   Rainer TH, 2004, ANN INTERN MED, V140, P614, DOI 10.7326/0003-4819-140-8-200404200-00008
   Rana DRSJB, 2020, MOL CELL PROBE, V53, DOI 10.1016/j.mcp.2020.101599
   Rodrigues CHM, 2018, NUCLEIC ACIDS RES, V46, pW350, DOI 10.1093/nar/gky300
   Schymkowitz J, 2005, NUCLEIC ACIDS RES, V33, pW382, DOI 10.1093/nar/gki387
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Studer RA, 2014, P NATL ACAD SCI USA, V111, P2223, DOI 10.1073/pnas.1310811111
   Surjit M, 2010, MOLECULAR BIOLOGY OF THE SARS-CORONAVIRUS, P129, DOI 10.1007/978-3-642-03683-5_9
   Toyoshima Y, 2020, J HUM GENET, V65, P1075, DOI 10.1038/s10038-020-0808-9
   Phan T, 2020, INFECT GENET EVOL, V81, DOI 10.1016/j.meegid.2020.104260
   Udugama B, 2020, ACS NANO, V14, P3822, DOI 10.1021/acsnano.0c02624
   van Gunsteren WF, 1996, BIOMOLECULAR SIMULAT, P86
   Wang Q, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-99
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Ye QZ, 2020, PROTEIN SCI, V29, P1890, DOI 10.1002/pro.3909
   Zeng WH, 2020, BIOCHEM BIOPH RES CO, V527, P618, DOI 10.1016/j.bbrc.2020.04.136
   Zhang Z, 2016, SCI REP-UK, V6, DOI 10.1038/srep25049
   Zhao ZM, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-21
   Zhou Z-J, 2020, BIORXIV, DOI [10.1101/2020.06.04.135293, DOI 10.1101/2020.06.04.135293]
   Zinzula L, 2020, RCSB PROTEIN DATA BA, V1
NR 58
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26626
EA NOV 2020
PG 19
WC Virology
SC Virology
GA OO9XM
UT WOS:000587729300001
PM 33095454
OA Bronze
DA 2021-01-01
ER

PT J
AU Rammo, R
   Gostkowski, M
   Rasmussen, PA
   Nagel, S
   Machado, A
AF Rammo, Richard
   Gostkowski, Michal
   Rasmussen, Peter A.
   Nagel, Sean
   Machado, Andre
TI The Need for Digital Health Solutions in Deep Brain Stimulation for
   Parkinson's Disease in the Time of COVID-19 and Beyond
SO NEUROMODULATION
LA English
DT Article; Early Access
DE COVID&#8208; 19; deep brain stimulation; digital health; distance
   health; Parkinson&apos; s disease; telehealth
ID TELEMEDICINE; RELIABILITY; PATIENT; VISITS; CARE
AB Objectives Deep brain stimulation (DBS) is a well-established therapy for the management of patients with advanced Parkinson's disease and other movement disorders. Patients implanted with DBS require life-long management of the medical device as well as medications. Patients are often challenged to frequently visit the specialized DBS centers and such challenges are aggravated depending on geography, socioeconomic factors, and support systems. We discuss the need for digital health solutions to overcome these barriers to better and safely take care of patients, especially in the current COVID-19 pandemic.
   Materials and Methods A review of the literature was conducted for technology and logistics necessary in forming a digital health program.
   Results Digital health encounters can take place in both a synchronous and asynchronous manner. Factors involving patients include cognitive capacity, physical safety, physical capacity, connectivity, and technological security. Physician factors include examining the patient, system diagnostics, and adjusting stimulation or medications. Technology is focused on bridging the gap between patient and physician through integrating the DBS lead, implantable pulse generator (IPG), programmer, novel devices/applications to grade motor function, and teleconference modalities.
   Conclusions For patients with Parkinson's disease, digital health has the potential to drastically change the landscape after DBS surgery. Furthermore, technology is fundamental in connectivity, diagnostic evaluation, and security in order to create stable and useful patient-focused care.
C1 [Rammo, Richard; Gostkowski, Michal; Nagel, Sean; Machado, Andre] Cleveland Clin Fdn, Neurol Inst, Dept Neurosurg, Ctr Neurol Restorat, 9500 Euclid Ave, Cleveland, OH 44195 USA.
   [Rasmussen, Peter A.] Cleveland Clin Fdn, Neurol Inst, Dept Neurosurg, Cerebrovasc Ctr, 9500 Euclid Ave, Cleveland, OH 44195 USA.
RP Rammo, R (corresponding author), Cleveland Clin Fdn, Ctr Neurol Restorat, S-30,9500 Euclid Ave, Cleveland, OH 44195 USA.
EM rammor@ccf.org
CR Abdolahi A, 2013, PARKINSONISM RELAT D, V19, P218, DOI 10.1016/j.parkreldis.2012.10.008
   Achey M, 2014, MOVEMENT DISORD, V29, P871, DOI 10.1002/mds.25903
   Beck CA, 2017, NEUROLOGY, V89, P1152, DOI 10.1212/WNL.0000000000004357
   Clayton PD, 1997, ACAD MED, V72, P522, DOI 10.1097/00001888-199706000-00019
   Dorsey ER, 2015, J PARKINSON DIS, V5, P505, DOI 10.3233/JPD-150549
   Elson MJ, 2018, TELEMED E-HEALTH, V24, P722, DOI 10.1089/tmj.2017.0210
   Fleming John E, 2020, Front Neurosci, V14, P639, DOI 10.3389/fnins.2020.00639
   Goetz CG, 2004, MOVEMENT DISORD, V19, P1453, DOI 10.1002/mds.20220
   Hassan A, 2018, TELEMED E-HEALTH, V24, P979, DOI 10.1089/tmj.2017.0295
   HUBBLE JP, 1993, MOVEMENT DISORD, V8, P380, DOI 10.1002/mds.870080326
   Ishihara LS, 2007, J NEUROL NEUROSUR PS, V78, P1304, DOI 10.1136/jnnp.2006.100107
   Mahar JH, 2018, CLEV CLIN J MED, V85, P938, DOI 10.3949/ccjm.85a.17062
   Maldonado-Naranjo A, 2019, PARKINSONS DIS-US, V2019, DOI 10.1155/2019/6850478
   Mammen JR, 2018, TELEMED E-HEALTH, V24, P255, DOI 10.1089/tmj.2017.0119
   Ozinga SJ, 2017, NEUROREHABILITATION, V41, P211, DOI 10.3233/NRE-171473
   Ozinga SJ, 2015, MOVEMENT DISORD, V30, P1214, DOI 10.1002/mds.26214
   Pagano G, 2016, NEUROLOGY, V86, P1400, DOI 10.1212/WNL.0000000000002461
   Rovini E, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00555
   Schneider R, 2016, J AM GERIATR SOC, V64, P218, DOI 10.1111/jgs.13909
   Slager HK, 2019, OTOL NEUROTOL, V40, pE260, DOI 10.1097/MAO.0000000000002119
   Spear KL, 2019, J PARKINSON DIS, V9, P401, DOI 10.3233/JPD-181557
   Swann NC, 2018, J NEUROSURG, V128, P605, DOI 10.3171/2016.11.JNS161162
   Telkes I, 2020, FRONT HUM NEUROSCI, V14, DOI 10.3389/fnhum.2020.00145
   Trister AD, 2016, NPJ PARKINSONS DIS, V2, DOI 10.1038/npjparkd.2016.6
   Venkataraman Vinayak, 2014, Neurol Clin Pract, V4, P146
   Zhang CC, 2018, STEREOT FUNCT NEUROS, V96, P272, DOI 10.1159/000491603
NR 26
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1094-7159
EI 1525-1403
J9 NEUROMODULATION
JI Neuromodulation
DI 10.1111/ner.13307
EA NOV 2020
PG 6
WC Medicine, Research & Experimental; Clinical Neurology
SC Research & Experimental Medicine; Neurosciences & Neurology
GA OP3GF
UT WOS:000587969900001
PM 33174292
OA Bronze
DA 2021-01-01
ER

PT J
AU Klein, SJ
   Bellmann, R
   Dejaco, H
   Eschertzhuber, S
   Fries, D
   Furtwangler, W
   Gasteiger, L
   Hasibeder, W
   Helbok, R
   Hochhold, C
   Hofer, S
   Kirchmair, L
   Krismer, C
   Ladner, E
   Lehner, GF
   Mathis, S
   Mayr, A
   Mittermayr, M
   Peer, A
   Hernandez, CP
   Reitter, B
   Strohle, M
   Swoboda, M
   Thome, C
   Joannidis, M
AF Klein, Sebastian J.
   Bellmann, Romuald
   Dejaco, Hannes
   Eschertzhuber, Stephan
   Fries, Dietmar
   Furtwaengler, Wilhelm
   Gasteiger, Lukas
   Hasibeder, Walter
   Helbok, Raimund
   Hochhold, Christoph
   Hofer, Stefanie
   Kirchmair, Lukas
   Krismer, Christoph
   Ladner, Eugen
   Lehner, Georg F.
   Mathis, Simon
   Mayr, Andreas
   Mittermayr, Markus
   Peer, Andreas
   Preuss Hernandez, Christian
   Reitter, Bruno
   Stroehle, Mathias
   Swoboda, Michael
   Thome, Claudius
   Joannidis, Michael
TI Structured ICU resource management in a pandemic is associated with
   favorable outcome in critically ill COVID-19 patients
SO WIENER KLINISCHE WOCHENSCHRIFT
LA English
DT Article
DE SARS-CoV8209; 2; Comorbidity; Invasive mechanical ventilation;
   Extracorporeal membrane oxygenation; Acute kidney injury
AB Introduction On February 25, 2020, the first 2 patients were tested positive for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in Tyrol, Austria. Rapid measures were taken to ensure adequate intensive care unit (ICU) preparedness for a surge of critically ill coronavirus disease-2019 (COVID-19) patients. Methods This cohort study included all COVID-19 patients admitted to an ICU with confirmed or strongly suspected COVID-19 in the State of Tyrol, Austria. Patients were recorded in the Tyrolean COVID-19 intensive care registry. Date of final follow-up was July 17, 2020. Results A total of 106 critically ill patients with COVID-19 were admitted to 1 of 13 ICUs in Tyrol from March 9 to July 17, 2020. Median age was 64 years (interquartile range, IQR 54-74 years) and the majority of patients were male (76 patients, 71.7%). Median simplified acute physiology score III (SAPS III) was 56 points (IQR 49-64 points). The median duration from appearance of first symptoms to ICU admission was 8 days (IQR 5-11 days). Invasive mechanical ventilation was required in 72 patients (67.9%) and 6 patients (5.6%) required extracorporeal membrane oxygenation treatment. Renal replacement therapy was necessary in 21 patients (19.8%). Median ICU length of stay (LOS) was 18 days (IQR 5-31 days), median hospital LOS was 27 days (IQR 13-49 days). The ICU mortality was 21.7% (23 patients), hospital mortality was 22.6%. There was no significant difference in ICU mortality in patients receiving invasive mechanical ventilation and in those not receiving it (18.1% vs. 29.4%, px202f;= 0.284). As of July 17th, 2020, two patients are still hospitalized, one in an ICU, one on a general ward. Conclusion Critically ill COVID-19 patients in Tyrol showed high severity of disease often requiring complex treatment with increased lengths of ICU and hospital stay. Nevertheless, the mortality was found to be remarkably low, which may be attributed to our adaptive surge response providing sufficient ICU resources.
C1 [Klein, Sebastian J.; Bellmann, Romuald; Lehner, Georg F.; Peer, Andreas; Swoboda, Michael; Joannidis, Michael] Med Univ Innsbruck, Div Intens Care & Emergency Med, Dept Internal Med, Anichstr 35, A-6020 Innsbruck, Austria.
   [Klein, Sebastian J.] Univ Innsbruck, Doctoral Coll Med Law & Healthcare, Fac Law, Innsbruck, Austria.
   [Dejaco, Hannes; Gasteiger, Lukas; Mathis, Simon; Mittermayr, Markus] Med Univ Innsbruck, Dept Anesthesia & Crit Care Med, Innsbruck, Austria.
   [Eschertzhuber, Stephan] Hosp Hall, Dept Anesthesia & Intens Care Med, Hall In Tirol, Austria.
   [Fries, Dietmar; Hochhold, Christoph; Stroehle, Mathias] Med Univ Innsbruck, Dept Gen & Surg Intens Care Med, Innsbruck, Austria.
   [Furtwaengler, Wilhelm] Hosp Kufstein, Dept Anesthesia & Intens Care Med, Kufstein, Austria.
   [Hasibeder, Walter] Hosp St Vinzenz Zams, Dept Anesthesiol & Crit Care Med, Zams, Austria.
   [Helbok, Raimund] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria.
   [Hofer, Stefanie] Hosp Hall, Dept Internal Med, Hall In Tirol, Austria.
   [Kirchmair, Lukas] Hosp Schwaz, Dept Anesthesia & Crit Care Med, Schwaz, Austria.
   [Krismer, Christoph] Hosp St Vinzenz Zams, Dept Internal Med, Zams, Austria.
   [Ladner, Eugen] Hosp Reutte, Dept Anesthesia & Intens Care Med, Reutte, Austria.
   [Mayr, Andreas] Hosp Lienz, Dept Anesthesia & Intens Care Med, Lienz, Austria.
   [Preuss Hernandez, Christian; Thome, Claudius] Med Univ Innsbruck, Dept Neurosurg, Innsbruck, Austria.
   [Reitter, Bruno] Hosp St Johann In Tyrol, Dept Anesthesia & Intens Care Med, St Johann In Tyrol, Austria.
RP Joannidis, M (corresponding author), Med Univ Innsbruck, Div Intens Care & Emergency Med, Dept Internal Med, Anichstr 35, A-6020 Innsbruck, Austria.
EM michael.joannidis@i-med.ac.at
FU University of Innsbruck; Medical University of Innsbruck
FX Open access funding provided by University of Innsbruck and Medical
   University of Innsbruck.
CR [Anonymous], 2018, DOCUMENTATION LKF HO
   Apicella M, 2020, LANCET DIABETES ENDO, V8, P782, DOI 10.1016/S2213-8587(20)30238-2
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Auld SC, 2020, CRIT CARE MED, V48, pE799, DOI 10.1097/CCM.0000000000004457
   Aziz S, 2020, INTENS CARE MED, V46, P1303, DOI 10.1007/s00134-020-06092-5
   Azoulay E, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03021-2
   Barron E, 2020, LANCET DIABETES ENDO, V8, P813, DOI 10.1016/S2213-8587(20)30272-2
   Bartlett RH, 2020, ASAIO J, V66, P472, DOI 10.1097/MAT.0000000000001173
   Bellelli G, 2020, INTENS CARE MED, V46, P1634, DOI 10.1007/s00134-020-06087-2
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Bulletin Italian Ministry of Health, 2020, B ITALIAN MINISTRY H
   Cariou B, 2020, DIABETOLOGIA, V63, P1500, DOI 10.1007/s00125-020-05180-x
   Davies A, 2009, JAMA-J AM MED ASSOC, V302, P1888, DOI 10.1001/jama.2009.1535
   Dreher M, 2020, DTSCH ARZTEBL INT, V117, P271, DOI 10.3238/arztebl.2020.0271
   Gabarre P, 2020, INTENS CARE MED, V46, P1339, DOI 10.1007/s00134-020-06153-9
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Joannidis M, 2020, INTENS CARE MED, V46, P654, DOI 10.1007/s00134-019-05869-7
   Karagiannidis C, 2020, LANCET RESP MED, V8, P853, DOI 10.1016/S2213-2600(20)30316-7
   Klein SJ, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03139-3
   Myers LC, 2020, JAMA-J AM MED ASSOC, V323, P2195, DOI 10.1001/jama.2020.7202
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Vergano M, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02891-w
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wiedemann D, 2020, WIEN KLIN WOCHENSCHR, V132, P671, DOI 10.1007/s00508-020-01708-8
   Yang XH, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03065-4
NR 27
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0043-5325
EI 1613-7671
J9 WIEN KLIN WOCHENSCHR
JI Wien. Klin. Wochen.
PD NOV
PY 2020
VL 132
IS 21-22
SI SI
BP 653
EP 663
DI 10.1007/s00508-020-01764-0
EA NOV 2020
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA PD0SK
UT WOS:000588250400001
PM 33170333
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Marak, BN
   Dowarah, J
   Khiangte, L
   Singh, VP
AF Marak, Brilliant N.
   Dowarah, Jayanta
   Khiangte, Laldingluaia
   Singh, Ved Prakash
TI Step toward repurposing drug discovery for COVID-19 therapeutics through
   in silico approach
SO DRUG DEVELOPMENT RESEARCH
LA English
DT Article; Early Access
DE anti&#8208; inflammatory; antiparasitic; COVID; docking; drug;
   SARS&#8208; CoV&#8208; 2
ID AMPHOTERICIN-B; CORONAVIRUS; TRANSCRIPTION
AB The outbreak of SARS-CoV-2 has become a threat to global health and has led to a global economic crisis. Although the researchers worldwide are putting tremendous effort toward gaining more insights into this zoonotic virus and developing vaccines and therapeutic drugs, no vaccine or drug is yet available to combat COVID-19 effectively. Drug discovery is often a laborious, time-consuming, and expensive task. In this time of crisis, employing computational methods could provide a feasible alternative approach that can potentially be used for drug discovery. Therefore, a library of several antiparasitic and anti-inflammatory drugs was virtually screened against SARS-CoV-2 proteases to identify potential inhibitors. The identified inhibitory drugs were further analyzed to confirm their activities against SARS-CoV-2. Our results could prove to be helpful in repurposing the drug discovery approach, which could substantially reduce the expenses, time, and resources required.
C1 [Marak, Brilliant N.; Dowarah, Jayanta; Khiangte, Laldingluaia; Singh, Ved Prakash] Mizoram Univ, Sch Phys Sci, Dept Chem, Aizawl 796004, Mizoram, India.
RP Singh, VP (corresponding author), Mizoram Univ, Sch Phys Sci, Dept Chem, Aizawl 796004, Mizoram, India.
EM vpsingh@mzu.edu.in
FU Department of Biotechnology, Ministry of Science and Technology
   [BT/PR16249/NER/95/105/2015]
FX Department of Biotechnology, Ministry of Science and Technology,
   Grant/Award Number: BT/PR16249/NER/95/105/2015
CR Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Cascella M, 2020, STATPEARLS
   Chen C, 2020, Zhonghua Shao Shang Za Zhi, V36, P471, DOI 10.3760/cma.j.cn501120-20200224-00088
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   de Haan CAM, 2005, ADV VIRUS RES, V64, P165, DOI 10.1016/S0065-3527(05)64006-7
   de Wilde AH, 2018, CURR TOP MICROBIOL, V419, P1, DOI 10.1007/82_2017_25
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227
   Ghosh AK, 2020, CHEMMEDCHEM, V15, P907, DOI 10.1002/cmdc.202000223
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hussain S, 2005, J VIROL, V79, P5288, DOI 10.1128/JVI.79.9.5288-5295.2005
   International Centre for Diarrhoeal Disease Research Bangladesh, 2020, EFF SAF IV DOX COMB
   Kim H, 2004, J MICROBIOL BIOTECHN, V14, P121
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Konopka K, 1999, ANTIVIR RES, V42, P197, DOI 10.1016/S0166-3542(99)00028-5
   Liu Qian, 2020, J FORENSIC MED, V36, P19, DOI DOI 10.12116/J.ISSN.1004-5619.2020.01.00
   Liu Y, 2020, 2019 NOVEL CORONAVIR, DOI [10.12074/202002.00018, DOI 10.12074/202002.00018]
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   Mortola E, 2004, FEBS LETT, V576, P174, DOI 10.1016/j.febslet.2004.09.009
   Mukherjee S, 2016, CURR DRUG METAB, V17, P937, DOI 10.2174/1389200217666161004143152
   Neuman BW, 2011, J STRUCT BIOL, V174, P11, DOI 10.1016/j.jsb.2010.11.021
   Nieto-Torres JL, 2011, VIROLOGY, V415, P69, DOI 10.1016/j.virol.2011.03.029
   Perrier A, 2019, J BIOL CHEM, V294, P14406, DOI 10.1074/jbc.RA119.008964
   Phadke M, 2020, DRUG DEVELOP RES, V81, P541, DOI 10.1002/ddr.21666
   Principi N, 2020, LANCET INFECT DIS, V20, P1118, DOI 10.1016/S1473-3099(20)30296-6
   Rajter JC, 2020, ICON IVERMECTIN COVI, DOI [10.1101/2020.06.06.20124461, DOI 10.1101/2020.06.06.20124461]
   Sawicki SG, 2005, CURR TOP MICROBIOL, V287, P31, DOI 10.1007/3-540-26765-4_2
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Shiota H., 1976, PARASITES FUNGI VIRU, P339, DOI [10.1007/978-1-4684-3129-2_49, DOI 10.1007/978-1-4684-3129-2_49]
   Singh AK, 2020, DIABETES METAB SYND, V14, P241, DOI 10.1016/j.dsx.2020.03.011
   Siu YL, 2008, J VIROL, V82, P11318, DOI 10.1128/JVI.01052-08
   Song HC, 2004, J VIROL, V78, P10328, DOI 10.1128/JVI.78.19.10328-10335.2004
   Song Z, 2019, VIRUSES, V11, P1
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Varghese F. S., 2019, ACCESS MICROBIOLOGY, V1, P41, DOI [10.1099/acmi.imav2019.po0027, DOI 10.1099/ACMI.IMAV2019.P00027]
   Walker J, 2004, J PARASITOL, V90, P1155, DOI 10.1645/GE-3347
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wang C, 2016, ONCOTARGET, V8, P12686, DOI DOI 10.18632/ONCOTARGET.8475
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   WHO, 2020, US NONST ANT DRUGS N
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yu F, 2020, MICROBES INFECT, V22, P74, DOI 10.1016/j.micinf.2020.01.003
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 46
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0272-4391
EI 1098-2299
J9 DRUG DEVELOP RES
JI Drug Dev. Res.
DI 10.1002/ddr.21757
EA NOV 2020
PG 19
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OP0UQ
UT WOS:000587794900001
PM 33170521
OA Bronze
DA 2021-01-01
ER

PT J
AU Lammi, C
   Arnoldi, A
AF Lammi, Carmen
   Arnoldi, Anna
TI Food-derived antioxidants and COVID-19
SO JOURNAL OF FOOD BIOCHEMISTRY
LA English
DT Article; Early Access
DE COVID&#8208; 19; food antioxidants; metal&#8208; cheating agents;
   SARS&#8208; CoV&#8208; 2
ID IRON-ABSORPTION; ANTIVIRAL ACTIVITY; SOY PROTEIN; VITAMIN-C;
   SUPPLEMENTATION; INHIBITION; ACTIVATION; PREVENTION; CHELATION;
   QUERCETIN
AB SARS-CoV-2 (previously 2019-nCoV), the pathogenic agent of COVID-19 disease, started to expand from Wuhan, China, on December 2019 and in 2 months, it spread worldwide giving origin to a pandemic. COVID-19 has a stronger transmission capacity by inhalation of infectious aerosols and after an incubation time of 3-14 days, it may be responsible for diseases ranging from the asymptomatic to fatal consequences. COVID-19 has emerged as a multifaceted, multisystem, multi-organ disorder, which produces its pathogenic effects through a quite ubiquitous target at the level of multiple organs and in which oxidative stress and inflammatory process play relevant roles. Thus, besides the development of a pharmacological therapy, in the field of alternative and coadjutant therapeutic, the use of dietary supplements or nutraceuticals for the prevention or treatment of SARS-CoV-2 infection may be a useful strategy. Herein, we specifically comment on some literature evidences, which link the food-derived antioxidants and metal-chelating agents with treatment and prevention of oxidative stress and inflammation that play a key role in the progression of COVID-19.
   Practical applications Oxidative stress and inflammation are key factors increasing COVID-19 severity especially in the presence of chronic diseases associated with the antioxidant system fragility. These evidences support the recommendation of antioxidants supplementation as useful strategies against COVID-19. In light with these observations, herein, a comment which describes the major antioxidants and metal-chelating agents from food sources that might be useful for the treatment and prevention of oxidative stress and inflammation during COVID-19.
C1 [Lammi, Carmen; Arnoldi, Anna] Univ Milan, Dept Pharmaceut Sci, Via Mangiagalli 25, I-20133 Milan, Italy.
RP Lammi, C (corresponding author), Univ Milan, Dept Pharmaceut Sci, Via Mangiagalli 25, I-20133 Milan, Italy.
EM carmen.lammi@unimi.it
OI Lammi, Carmen/0000-0002-7428-4486
CR Amengual J, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102388
   [Anonymous], 2020, LANCET INFECT DIS, V20, P261, DOI 10.1016/S1473-3099(20)30072-4
   Bachmetov L, 2012, J VIRAL HEPATITIS, V19, pE81, DOI 10.1111/j.1365-2893.2011.01507.x
   Backer J.A., 2020, EUROSURVEILLANCE, V25, P20, DOI DOI 10.2807/1560-7917.ES.2020.25.5.2000062
   Bedoya LM, 2016, AIDS, V30, P2767, DOI 10.1097/QAD.0000000000001283
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bernabe-Pineda M, 2004, SPECTROCHIM ACTA A, V60, P1105, DOI 10.1016/S1386-1425(03)00344-5
   Caccialanza R, 2020, NUTRITION, V74, DOI 10.1016/j.nut.2020.110835
   Carrasco-Castilla J, 2012, FOOD CHEM, V135, P1789, DOI 10.1016/j.foodchem.2012.06.016
   Cavezzi A, 2020, CLINICS PRACT, V10, P24, DOI 10.4081/cp.2020.1271
   Chen L, 2020, NUTRIENTS, V12, DOI 10.3390/nu12041193
   Chen Y, 2013, J BIOL CHEM, V288, P19450, DOI 10.1074/jbc.M113.467670
   de Oliveira CF, 2015, J FOOD SCI TECH MYS, V52, P2668, DOI 10.1007/s13197-014-1317-7
   Fan DS, 2011, FITOTERAPIA, V82, P805, DOI 10.1016/j.fitote.2011.04.007
   Farombi EO, 2005, CLIN EXP PHARMACOL P, V32, P667, DOI 10.1111/j.0305-1870.2005.04248.x
   Foong LC, 2015, J AGR FOOD CHEM, V63, P9029, DOI 10.1021/acs.jafc.5b03420
   Grant WB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12061620
   Guzik TJ, 2020, CARDIOVASC RES, V116, P1666, DOI 10.1093/cvr/cvaa106
   Hemila H, 2017, NUTRIENTS, V9, DOI 10.3390/nu9040339
   HUANG CG, 1991, ACTA PHARMACOL SIN, V12, P526
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huijskens MJAJ, 2014, J LEUKOCYTE BIOL, V96, P1165, DOI 10.1189/jlb.1TA0214-121RR
   HUNT C, 1994, INT J VITAM NUTR RES, V64, P212
   HURRELL RF, 1992, AM J CLIN NUTR, V56, P573
   Iddir M, 2020, NUTRIENTS, V12, DOI 10.3390/nu12061562
   Infusino F, 2020, NUTRIENTS, V12, DOI 10.3390/nu12061718
   Jiao Y, 2006, FREE RADICAL BIO MED, V40, P1152, DOI 10.1016/j.freeradbiomed.2005.11.003
   Jiao Y, 2009, BLOOD, V113, P462, DOI 10.1182/blood-2008-05-155952
   Johari J, 2012, INT J MOL SCI, V13, P16785, DOI 10.3390/ijms131216785
   Kibangou IB, 2005, PEDIATR RES, V58, P731, DOI 10.1203/01.PDR.0000180555.27710.46
   Krinsky Norman I., 2005, Molecular Aspects of Medicine, V26, P459
   Lammi C, 2020, NUTRIENTS, V12, DOI 10.3390/nu12061723
   Lammi C, 2019, J FUNCT FOODS, V55, P135, DOI 10.1016/j.jff.2019.02.016
   Li Y, 2016, INFLAMMATION IMMUNIT, V8, P167, DOI DOI 10.3390/NU8030167
   Liu ZH, 2015, INT J CLIN EXP PATHO, V8, P3441
   Martineau AR, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.i6583
   Melikian G, 2001, NUTRITION, V17, P567, DOI 10.1016/S0899-9007(01)00567-6
   Mendonca P, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9080659
   Naithani R, 2008, MINI-REV MED CHEM, V8, P1106, DOI 10.2174/138955708785909943
   Quiles JL, 2020, ENVIRON RES, V191, DOI 10.1016/j.envres.2020.110053
   Reddy MB, 1996, AM J CLIN NUTR, V63, P203
   Solnier J, 2020, PHYTOCHEM REV, DOI 10.1007/s11101-020-09720-6
   Song PP, 2020, CLIN CHIM ACTA, V509, P280, DOI 10.1016/j.cca.2020.06.017
   Soy M, 2020, CLIN RHEUMATOL, V39, P2085, DOI 10.1007/s10067-020-05190-5
   Traber MG, 2011, FREE RADICAL BIO MED, V51, P1000, DOI 10.1016/j.freeradbiomed.2011.05.017
   Udenigwe CC, 2012, J FOOD SCI, V77, pR11, DOI 10.1111/j.1750-3841.2011.02455.x
   Utomo R. Y., 2020, REVEALING POTENCY CI, DOI [10.20944/preprints202003.0214.v1, DOI 10.20944/PREPRINTS202003.0214.V1, 10.20944/preprints202003.0214.v1.]
   Visioli F, 1998, BIOCHEM BIOPH RES CO, V247, P60, DOI 10.1006/bbrc.1998.8735
   Walston J, 2006, AM J EPIDEMIOL, V163, P18, DOI 10.1093/aje/kwj007
   Walters ME, 2018, FOODS, V7, DOI 10.3390/foods7100172
   Wu D, 2020, INT J INFECT DIS, V94, P44, DOI 10.1016/j.ijid.2020.03.004
   Xu D, 2019, MOLECULES, V24, DOI 10.3390/molecules24061123
   Yamada K, 2009, ANTIVIR RES, V83, P35, DOI 10.1016/j.antiviral.2009.03.002
   Zhong Q, 2016, CZECH J FOOD SCI, V34, P325, DOI 10.17221/425/2015-CJFS
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 55
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-8884
EI 1745-4514
J9 J FOOD BIOCHEM
JI J. Food Biochem.
AR e13557
DI 10.1111/jfbc.13557
EA NOV 2020
PG 6
WC Biochemistry & Molecular Biology; Food Science & Technology
SC Biochemistry & Molecular Biology; Food Science & Technology
GA OP2FE
UT WOS:000587893700001
PM 33171544
DA 2021-01-01
ER

PT J
AU Araimo, F
   Imperiale, C
   Tordiglione, P
   Ceccarelli, G
   Borrazzo, C
   Alessandri, F
   Santinelli, L
   Innocenti, GP
   Pinacchio, C
   Mauro, V
   Recchia, GE
   Zancla, S
   Calo, A
   Poscia, R
   Ruberto, F
   d'Ettorre, G
   Bilotta, F
   Mastroianni, C
   Pugliese, F
AF Araimo, Fabio
   Imperiale, Carmela
   Tordiglione, Paolo
   Ceccarelli, Giancarlo
   Borrazzo, Cristian
   Alessandri, Francesco
   Santinelli, Letizia
   Innocenti, Giuseppe Pietro
   Pinacchio, Claudia
   Mauro, Vera
   Recchia, Gregorio Egidio
   Zancla, Serena
   Calo, Andrea
   Poscia, Roberto
   Ruberto, Franco
   d'Ettorre, Gabriella
   Bilotta, Federico
   Mastroianni, Claudio
   Pugliese, Francesco
TI Ozone as adjuvant support in the treatment of COVID-19: A preliminary
   report of probiozovid trial
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE autohemotherapy; ozone; respiratory insufficiency
ID PROBIOTICS; THERAPY; COULD
AB The evaluation of new therapeutic resources against coronavirus disease 2019 (COVID-19) represents a priority in clinical research considering the minimal options currently available. To evaluate the adjuvant use of systemic oxygen-ozone administration in the early control of disease progression in patients with COVID-19 pneumonia. PROBIOZOVID is an ongoing, interventional, randomized, prospective, and double-arm trial enrolling patient with COVID-19 pneumonia. From a total of 85 patients screened, 28 were recruited. Patients were randomly divided into ozone-autohemotherapy group (14) and control group (14). The procedure consisted in a daily double-treatment with systemic Oxygen-ozone administration for 7 days. All patients were treated with ad interim best available therapy. The primary outcome was delta in the number of patients requiring orotracheal-intubation despite treatment. Secondary outcome was the difference of mortality between the two groups. Moreover, hematological parameters were compared before and after treatment. No differences in the characteristics between groups were observed at baseline. As a preliminary report we have observed that one patient for each group needed intubation and was transferred to ITU. No deaths were observed at 7-14 days of follow up. Thirty-day mortality was 8.3% for ozone group and 10% for controls. Ozone therapy did not significantly influence inflammation markers, hematology profile, and lymphocyte subpopulations of patients treated. Ozone therapy had an impact on the need for the ventilatory support, although did not reach statistical significance. Finally, no adverse events related to the use of ozone-autohemotherapy were reported. Preliminary results, although not showing statistically significant benefits of ozone on COVID-19, did not report any toxicity.
C1 [Araimo, Fabio; Imperiale, Carmela; Tordiglione, Paolo; Alessandri, Francesco; Zancla, Serena; Calo, Andrea; Ruberto, Franco; Bilotta, Federico; Pugliese, Francesco] Sapienza Univ Rome, Dept Anesthesia & Intens Care Med, Viale Policlin 155, I-00161 Rome, Italy.
   [Ceccarelli, Giancarlo; Poscia, Roberto; Mastroianni, Claudio; Pugliese, Francesco] Azienda Univ Osped Policlin Umberto I, Dept Anesthesia & Intens Care Med, Rome, Italy.
   [Ceccarelli, Giancarlo; Borrazzo, Cristian; Santinelli, Letizia; Innocenti, Giuseppe Pietro; Pinacchio, Claudia; Mauro, Vera; Recchia, Gregorio Egidio; d'Ettorre, Gabriella; Mastroianni, Claudio] Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Rome, Italy.
RP Calo, A (corresponding author), Sapienza Univ Rome, Dept Anesthesia & Intens Care Med, Viale Policlin 155, I-00161 Rome, Italy.
EM andrea.calo@uniroma1.it
CR Akour A, 2020, LETT APPL MICROBIOL, V71, P229, DOI 10.1111/lam.13334
   Alessandri F, 2020, J NEUROANESTHESIOL C, V7, P54
   BOCCI V, 1994, J INT MED RES, V22, P131, DOI 10.1177/030006059402200301
   Catanzaro M, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0191-1
   Ceccarelli Giancarlo, 2020, J Travel Med, DOI 10.1093/jtm/taaa171
   Ceccarelli G, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03226-5
   Ceccarelli G, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106029
   Ceccarelli G, 2020, LANCET GASTROENTEROL, V5, P721, DOI 10.1016/S2468-1253(20)30196-5
   Chistolini A, 2020, BRIT J HAEMATOL, V190, pE214, DOI 10.1111/bjh.17003
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   d'Ettorre Gabriele, 2020, Early Hum Dev, P105156, DOI 10.1016/j.earlhumdev.2020.105156
   d'Ettorre G, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000021803
   d'Ettorre G, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00389
   Dhar D, 2020, VIRUS RES, V285, DOI 10.1016/j.virusres.2020.198018
   Fernandez-Cuadros ME, 2020, CLIN MED, V2, P1, DOI [10.1007/s42399-020-00374-1, DOI 10.1007/S42399-020-00374-1]
   Franzini M, 2020, INT IMMUNOPHARMACOL, V88, DOI 10.1016/j.intimp.2020.106879
   Gasbarrini G, 2020, EUR REV MED PHARMACO, V24, P5189, DOI 10.26355/eurrev_202005_21218
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Gu Silan, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa709
   Hernandez A, 2020, REV ESP ANEST REANIM, V67, P245, DOI 10.1016/j.redar.2020.03.004
   Hernandez A, 2020, AM J CASE REP, V21, DOI 10.12659/AJCR.925849
   Iddir M, 2020, NUTRIENTS, V12, DOI 10.3390/nu12061562
   Infusino F, 2020, NUTRIENTS, V12, DOI 10.3390/nu12061718
   Italian Society of Anaesthesiology Analgesia Resuscitation and Intensive Care (SIAARTI), CAR PATHW PAT COVID
   Kalantar-Zadeh K, 2020, ACS NANO, V14, P5179, DOI 10.1021/acsnano.0c03402
   Kwenandar F, 2020, IJC HEART VASC, V29, DOI 10.1016/j.ijcha.2020.100557
   Lai JS, 2003, QUAL LIFE RES, V12, P485, DOI 10.1023/A:1025014509626
   Mak JWY, 2020, LANCET GASTROENTEROL, V5, P644, DOI 10.1016/S2468-1253(20)30122-9
   Martinez-Sanchez G, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9050389
   Oliva A, 2020, INFECTION, DOI 10.1007/s15010-020-01483-8
   Promoter of the study: NUOVA F.I.O. (Italian Oxygen-Ozone Federation), 2020, J Biol Regul Homeost Agents, V34, P757, DOI 10.23812/20-250-E-56
   Ricevuti G, 2020, OZONE THERAPY, V5, DOI [DOI 10.4081/ozone.2020.9014, 10.4081/ozone.2020.9014]
   SIMIT, 2020, SEZ REG LOMB VAD CUR
   Valdenassi L, 2020, EUR REV MED PHARMACO, V24, P4059, DOI 10.26355/eurrev_202004_20976
   Vannucci Jacopo, 2020, J Glob Antimicrob Resist, V23, P67, DOI 10.1016/j.jgar.2020.07.030
   Violi F, 2020, REDOX BIOL, V36, DOI 10.1016/j.redox.2020.101655
   Violi F, 2020, CIRC RES, V127, P400, DOI 10.1161/CIRCRESAHA.120.317173
   Violi F, 2020, ANTIOXID REDOX SIGN, DOI 10.1089/ars.2020.8142
   Zheng ZS, 2020, J MED VIROL, V92, P2348, DOI 10.1002/jmv.26040
   Zuo T, 2020, GASTROENTEROLOGY, V159, P944, DOI 10.1053/j.gastro.2020.05.048
NR 40
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26636
EA NOV 2020
PG 11
WC Virology
SC Virology
GA OP0AB
UT WOS:000587736400001
PM 33111980
OA Bronze
DA 2021-01-01
ER

PT J
AU Marchini, S
   Zaurino, E
   Bouziotis, J
   Brondino, N
   Delvenne, V
   Delhaye, M
AF Marchini, Simone
   Zaurino, Elena
   Bouziotis, Jason
   Brondino, Natascia
   Delvenne, Veronique
   Delhaye, Marie
TI Study of resilience and loneliness in youth (18-25 years old) during the
   COVID-19 pandemic lockdown measures
SO JOURNAL OF COMMUNITY PSYCHOLOGY
LA English
DT Article; Early Access
DE COVID&#8208; 19 pandemic; emerging adulthood; loneliness; mental health;
   PTSD; resilience; youth
ID SCALE; VALIDITY; ADULTS
AB This study evaluated the risks and protective factors in mental health in 825 emerging adults aged from 18 to 25 years old in Belgium and in Italy. Resilience, loneliness and social, and family context were explored to determine their specific role in coping with the emotional distress that spread worldwide during the coronavirus disease 2019 (COVID-19) pandemic. We conducted an online survey on the secured platform Research Electronic Data Capture (c). Data were collected between April 7th and May 4th, 2020. The primary outcomes were the resilience scale for adults (RSA) and the University of California Los Angeles Loneliness Scale. The secondary outcomes included mental health status in terms of professional help seeking, use of psychotropic drugs, admission to a psychiatric department before and during lockdown measures. Responders were divided into three groups following the mental healthcare needs (MHCN) before and after the lockdown measures. The group who experienced an increase in MHCN represented almost 5% of the assessed youth. Statistically significant differences were found in means of RSA total score and RSA perception of self. This study enlightens the possibly traumatic impact of the COVID-19 pandemic on at-risk youth's mental health. Early detection and intervention should be structured in large-scale disasters.
C1 [Marchini, Simone] Erasme Univ Hosp, Dept Child & Adolescent Psychiat, Route Lennik 808, B-1070 Brussels, Belgium.
   [Marchini, Simone; Delvenne, Veronique] Queen Fabiola Childrens Univ Hosp, Dept Child & Adolescent Psychiat, Brussels, Belgium.
   [Marchini, Simone; Bouziotis, Jason; Delvenne, Veronique; Delhaye, Marie] Univ Libre Bruxelles ULB, Fac Med, Brussels, Belgium.
   [Zaurino, Elena] Katholieke Univ Leuven KUL, Dept Econ, Leuven, Belgium.
   [Bouziotis, Jason] Erasme Univ Hosp, Dept Biomed Res, Brussels, Belgium.
   [Brondino, Natascia] Univ Pavia, Dept Brain & Behav Sci, Pavia, Italy.
RP Marchini, S (corresponding author), Erasme Univ Hosp, Dept Child & Adolescent Psychiat, Route Lennik 808, B-1070 Brussels, Belgium.
EM simone.marchini@ulb.be
OI Brondino, Natascia/0000-0002-3128-1592; , Simone/0000-0002-0432-5705;
   Bouziotis, Jason/0000-0001-6656-451X
FU King Baudouin Foundation
FX King Baudouin Foundation
CR Alonso J, 2004, ACTA PSYCHIAT SCAND, V420, P21, DOI DOI 10.1111/J.1600-0047.2004.00327.X]
   Baskin TW, 2010, COUNS PSYCHOL, V38, P626, DOI 10.1177/0011000009358459
   BAUMEISTER RF, 1995, PSYCHOL BULL, V117, P497, DOI 10.1037/0033-2909.117.3.497
   Boffo M, 2012, TPM-TEST PSYCHOM MET, V19, P345, DOI 10.4473/TPM19.4.7
   Bonfiglio NS, 2016, PSYCHOL ADDICT BEHAV, V30, P509, DOI 10.1037/adb0000176
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Cacioppo S, 2015, PERSPECT PSYCHOL SCI, V10, P238, DOI 10.1177/1745691615570616
   Cleland J, 2020, MED EDUC, V54, P589, DOI 10.1111/medu.14170
   Colombo S., 2020, DESING EMERGENCY
   Crowe A, 2016, MENT HLTH PREV, V4, P63, DOI DOI 10.1016/J.MHP.2015.12.001
   Friborg O, 2006, PERS INDIV DIFFER, V40, P873, DOI 10.1016/j.paid.2005.08.015
   Friborg O, 2005, INT J METH PSYCH RES, V14, P29, DOI 10.1002/mpr.15
   Friborg O, 2003, INT J METH PSYCH RES, V12, P65, DOI 10.1002/mpr.143
   Galea S, 2020, JAMA INTERN MED, V180, P817, DOI 10.1001/jamainternmed.2020.1562
   Grace G. R., 1993, REV CAN SCI COMPORT, V25, P12, DOI 10.12691/ajap-2-4-3
   Hjemdal O, 2001, J NORW PSYCHOL ASSOC, V38, P310
   Hjemdal O, 2011, INT J TEST, V11, P53, DOI 10.1080/15305058.2010.508570
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Kessler RC, 2007, CURR OPIN PSYCHIATR, V20, P359, DOI 10.1097/YCO.0b013e32816ebc8c
   Labana R. V., 2020, PUBLIC MENTAL HLTH C, DOI [10.20944/preprints202005.0050.v1, DOI 10.20944/PREPRINTS202005.0050.V1]
   Lengnick-Hall CA, 2005, J MANAGE, V31, P738, DOI 10.1177/0149206305279367
   Loades ME, 2020, J AM ACAD CHILD PSY, V59, P1218, DOI 10.1016/j.jaac.2020.05.009
   Mengin A, 2020, ENCEPHALE, V46, pS43, DOI 10.1016/j.encep.2020.04.007
   Neria Y, 2008, PSYCHOL MED, V38, P467, DOI 10.1017/S0033291707001353
   Pancani L., 2020, PSYARXIV, DOI [10.31234/osf.io/uacfj, DOI 10.31234/OSF.IO/UACFJ]
   Poletti B, 2020, COUNS PSYCHOL Q, DOI 10.1080/09515070.2020.1769557
   Ramos E., 2011, PROCESSUS DAUTONOMIS
   Reich J. W., 2010, HDB ADULT RESILIENCE
   Rossi R, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00790
   Russell DW, 1996, J PERS ASSESS, V66, P20, DOI 10.1207/s15327752jpa6601_2
   Salmoiraghi A, 2015, J PSYCHIATR PRACT, V21, P389, DOI 10.1097/PRA.0000000000000103
   Sciensano, 2020, ENQ SANT COVID 19 BE
   Stevens A, 1999, AM J PSYCHIAT, V156, P783
   Yap MBH, 2011, PSYCHIAT RES, V188, P123, DOI 10.1016/j.psychres.2011.01.014
   Zhou SJ, 2020, EUR CHILD ADOLES PSY, V29, P749, DOI 10.1007/s00787-020-01541-4
NR 35
TC 0
Z9 0
U1 13
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0090-4392
EI 1520-6629
J9 J COMMUNITY PSYCHOL
JI J. Community Psychol.
DI 10.1002/jcop.22473
EA NOV 2020
PG 13
WC Public, Environmental & Occupational Health; Psychology,
   Multidisciplinary; Social Work
SC Public, Environmental & Occupational Health; Psychology; Social Work
GA OO9OP
UT WOS:000587703400001
PM 33169377
OA Bronze
DA 2021-01-01
ER

PT J
AU Garcia, LY
   Cerda, AA
AF Garcia, Leidy Y.
   Cerda, Arcadio A.
TI Acceptance of a COVID-19 vaccine: A multifactorial consideration
SO VACCINE
LA English
DT Letter
C1 [Garcia, Leidy Y.; Cerda, Arcadio A.] Univ Talca, Fac Econ & Business, 1 Poniente 1141, Talca, Chile.
RP Garcia, LY (corresponding author), Univ Talca, Fac Econ & Business, 1 Poniente 1141, Talca, Chile.
EM lgarcia@utalca.cl; acerda@utalca.cl
OI Garcia, Leidy/0000-0002-7487-5999; Cerda, Arcadio/0000-0002-3791-854X
CR Feleszko Wojciech, 2020, PIOTR CZARNECKI ADAM, DOI [10.2139/ssrn.3631972, DOI 10.2139/SSRN.3631972]
   Garcia LY, 2020, VACCINE, V38, P5424, DOI 10.1016/j.vaccine.2020.06.068
   Harrison EA, 2020, EUR J EPIDEMIOL, V35, P325, DOI 10.1007/s10654-020-00634-3
   Paakkari L, 2020, LANCET PUBLIC HEALTH, V5, pE249, DOI 10.1016/S2468-2667(20)30086-4
   Schaffer DeRoo S, 2020, JAMA-J AM MED ASSOC, V323, P2458, DOI 10.1001/jama.2020.8711
NR 5
TC 0
Z9 0
U1 9
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD NOV 10
PY 2020
VL 38
IS 48
BP 7587
EP 7587
DI 10.1016/j.vaccine.2020.10.026
PG 1
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OH5OQ
UT WOS:000582634800005
PM 33121656
OA Green Published
DA 2021-01-01
ER

PT J
AU Coudeville, L
   Gomez, GB
   Jollivet, O
   Harris, RC
   Thommes, E
   Druelles, S
   Chit, A
   Chaves, SS
   Mahe, C
AF Coudeville, L.
   Gomez, G. B.
   Jollivet, O.
   Harris, R. C.
   Thommes, E.
   Druelles, S.
   Chit, A.
   Chaves, S. S.
   Mahe, C.
TI Exploring uncertainty and risk in the accelerated response to a COVID-19
   vaccine: Perspective from the pharmaceutical industry
SO VACCINE
LA English
DT Article
ID IMMUNE-RESPONSE
C1 [Coudeville, L.; Gomez, G. B.; Jollivet, O.; Druelles, S.; Chaves, S. S.; Mahe, C.] Sanofi Pasteur, Vaccine Epidemiol & Modeling, 14 Espace Henry Vallee, F-69007 Lyon, France.
   [Gomez, G. B.] London Sch Hyg & Trop Med, Dept Global Hlth & Dev, London, England.
   [Harris, R. C.; Chit, A.] Sanofi Pasteur, Vaccine Epidemiol & Modeling, 38 Beach Rd, Singapore 189767, Singapore.
   [Harris, R. C.] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.
   [Thommes, E.] Sanofi Pasteur, Vaccine Epidemiol & Modeling, Discovery Dr, Swiftwater, PA 18370 USA.
   [Thommes, E.] Univ Guelph, Dept Math & Stat, Guelph, ON, Canada.
   [Chit, A.] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada.
RP Coudeville, L; Chaves, SS (corresponding author), Sanofi Pasteur, Vaccine Epidemiol & Modeling, 14 Espace Henry Vallee, F-69007 Lyon, France.
EM Laurent.Coudeville@sanofi.com; Sandra.Chaves@sanofi.com
FU Sanofi Pasteur, France
FX This work was funded by Sanofi Pasteur, France.
CR ANDERSON RM, 1985, NATURE, V318, P323, DOI 10.1038/318323a0
   [Anonymous], 2020, REUTERS
   [Anonymous], 2017, INTEGRATING CLIN RES
   [Anonymous], 2020, NIH LAUNCH PUBL PRIV
   Banaji M., 2020, WIRE, V33, P34
   Buss L. F, 2020, COVID 19 HERD IMMUNI, DOI [DOI 10.1101/2020.09.16.20194787, 10.1101/2020.09.16.20194787]
   CALLOW KA, 1985, J HYG-CAMBRIDGE, V95, P173, DOI 10.1017/S0022172400062410
   CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019
   Edwards KM, 2020, ANNU REV VIROL, DOI [10.1146/annurev-virology-013120-013123., DOI 10.1146/ANNUREV-VIR0L0GY-013120-013123]
   Fontanet A, 2020, NAT REV IMMUNOL, V20, P583, DOI 10.1038/s41577-020-00451-5
   Imperial College London, PERC TOT POP INF
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Korber B, 2020, SPIKE MUTATION PIPEL, V12, P122, DOI [10.1101/2020.04.29.069054, DOI 10.1101/2020.04.29.069054]
   Liu W, 2006, J INFECT DIS, V193, P792, DOI 10.1086/500469
   Liu WJ, 2017, ANTIVIR RES, V137, P82, DOI 10.1016/j.antiviral.2016.11.006
   Lowe D., SCI TRANSLATIONAL ME
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Monto AS, 2020, J INFECT DIS, V222, P9, DOI 10.1093/infdis/jiaa161
   Murray CJ, 2020, MEDRXIV, DOI [10.1101/2020.04.21.20074732, DOI 10.1101/2020.04.21.20074732]
   Neville S., 2020, FINANCIAL TIMES
   Stringhini S, 2020, REPEATED SEROPREVALE, DOI [10.1101/2020.05.02.20088898, DOI 10.1101/2020.05.02.20088898]
   US CDC, MATH MOD FOR TOT DEA
   Wolf J, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0204-7
   World Health Organization, SOL CLIN TRIAL COVID
   World Health Organization, 2005, WHO GLOB INFL PREP P
NR 25
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD NOV 10
PY 2020
VL 38
IS 48
BP 7588
EP 7595
DI 10.1016/j.vaccine.2020.10.034
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OH5OQ
UT WOS:000582634800006
PM 33097312
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Safavi, A
   Kefayat, A
   Mahdevar, E
   Abiri, A
   Ghahremani, F
AF Safavi, Ashkan
   Kefayat, Amirhosein
   Mahdevar, Elham
   Abiri, Ardavan
   Ghahremani, Fatemeh
TI Exploring the out of sight antigens of SARS-CoV-2 to design a candidate
   multi-epitope vaccine by utilizing immunoinformatics approaches
SO VACCINE
LA English
DT Article
DE SARS-CoV-2; Immunoinformatics; Vaccine; COVID-19; In silico
ID ASSEMBLING PROTEIN NANOPARTICLES; SPIKE PROTEIN; DNA VACCINE; PREDICTION
   TOOLS; ACCURATE DOCKING; PEPTIDE VACCINE; CELL EPITOPES; CODON USAGE;
   WEB SERVER; CORONAVIRUS
AB SARS-CoV-2 causes a severe respiratory disease called COVID-19. Currently, global health is facing its devastating outbreak. However, there is no vaccine available against this virus up to now. In this study, a novel multi-epitope vaccine against SARS-CoV-2 was designed to provoke both innate and adaptive immune responses. The immunodominant regions of six non-structural proteins (nsp7, nsp8, nsp9, nsp10, nsp12 and nsp14) of SARS-CoV-2 were selected by multiple immunoinformatic tools to provoke T cell immune response. Also, immunodominant fragment of the functional region of SARS-CoV-2 spike (400-510 residues) protein was selected for inducing neutralizing antibodies production. The selected regions' sequences were connected to each other by furin-sensitive linker (RVRR). Moreover, the functional region of beta-defensin as a well-known agonist for the TLR-4/MD complex was added at the N-terminus of the vaccine using (EAAAK)3 linker. Also, a CD4 + T-helper epitope, PADRE, was used at the C-terminal of the vaccine by GPGPG and A(EAAAK)2A linkers to form the final vaccine construct. The physicochemical properties, allergenicity, antigenicity, functionality and population coverage of the final vaccine construct were analyzed. The final vaccine construct was an immunogenic, non-allergen and unfunctional protein which contained multiple CD8 + and CD4 + overlapping epitopes, IFN-gamma inducing epitopes, linear and conformational B cell epitopes. It could form stable and significant interactions with TLR-4/MD according to molecular docking and dynamics simulations. Global population coverage of the vaccine for HLA-I and II were estimated 96.2% and 97.1%, respectively. At last, the final vaccine construct was reverse translated to design the DNA vaccine. Although the designed vaccine exhibited high efficacy in silico, further experimental validation is necessary. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Safavi, Ashkan] Islamic Azad Univ, Dept Biol, Sci & Res Branch, Tehran, Iran.
   [Kefayat, Amirhosein] Isfahan Univ Med Sci, Canc Prevent Res Ctr, Dept Oncol, Esfahan, Iran.
   [Mahdevar, Elham] Sci & Arts Univ, Fac Sci & Engn, Dept Biol, Yazd, Iran.
   [Abiri, Ardavan] Kerman Univ Med Sci, Fac Pharm, Dept Med Chem, Kerman, Iran.
   [Ghahremani, Fatemeh] Arak Univ Med Sci, Arak Sch Paramed, Dept Med Phys & Radiotherapy, Arak, Iran.
RP Ghahremani, F (corresponding author), Arak Univ Med Sci, Arak Sch Paramed, Dept Med Phys & Radiotherapy, Arak, Iran.
EM F.ghahremani@arakmu.ac.ir
RI Abiri, Ardavan/J-9062-2019
OI Abiri, Ardavan/0000-0003-3021-6147; Safavi, Ashkan/0000-0001-7307-0147
FU Arak University of Medical Sciences [3626]
FX This research was supported by Arak University of Medical Sciences
   (grant number: 3626).
CR Abdelmageed MI, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2683286
   Peele KA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1770127
   Adhikari UK, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/6718083
   Ahmadi K, 2019, MOL IMMUNOL, V114, P88, DOI 10.1016/j.molimm.2019.05.016
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Beebe M, 2008, HUM VACCINES, V4, P210, DOI 10.4161/hv.4.3.5291
   Berry JD, 2010, NEUTRALIZING EPITOPE
   Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736
   Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310
   Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771
   Brandau DT, 2003, J PHARM SCI-US, V92, P218, DOI 10.1002/jps.10296
   Briesemeister S, 2009, J PROTEOME RES, V8, P5363, DOI 10.1021/pr900665y
   Cai CZ, 2003, NUCLEIC ACIDS RES, V31, P3692, DOI 10.1093/nar/gkg600
   Campbell K.M., 2020, PREDICTION SARS COV
   Castiglione F, 2012, COMPUT MATH METHOD M, DOI 10.1155/2012/842329
   Chakraborty I, 2014, ACS APPL MATER INTER, V6, P16472, DOI 10.1021/am5044592
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Comeau SR, 2004, NUCLEIC ACIDS RES, V32, pW96, DOI 10.1093/nar/gkh354
   Cornejo-Granados F, 2019, GENOMICS, V111, P1514, DOI 10.1016/j.ygeno.2018.10.007
   Dey AK, 2014, EXPERT REV VACCINES, V13, P671, DOI 10.1586/14760584.2014.907528
   Dhanda SK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01369
   Doytchinova I. A, 2008, OPEN VACCINE J, V1, P4, DOI DOI 10.2174/1875035400801010022
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Faezi S, 2016, INT J MOL CELL MED, V5, P37
   Fang LC, 2019, POULTRY SCI, V98, P1121, DOI 10.3382/ps/pey475
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Fleri W, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00278
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Gangaev A., 2020, PROFOUND CD8 T CELL
   Garbuglia AR, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00188
   Gfeller D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01716
   Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376
   Guex N, 2009, ELECTROPHORESIS, V30, pS162, DOI 10.1002/elps.200900140
   Gupta J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142548
   Hagemeijer MC, 2010, J VIROL, V84, P2134, DOI 10.1128/JVI.01716-09
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Hattotuwagama CK, 2004, J MOL GRAPH MODEL, V22, P195, DOI 10.1016/S1093-3263(03)00160-8
   Huang J.-D., 2020, MAPPING IMMUNODOMINA
   Ikram A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34254-5
   Jensen KK, 2018, IMMUNOLOGY, V154, P394, DOI 10.1111/imm.12889
   Johansson MU, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-173
   Johnson CR, 2007, J GEN VIROL, V88, P1184, DOI 10.1099/vir.0.82587-0
   Joshi A, 2020, INFORM MED UNLOCKED, V19
   Ka T, 2020, INT J BIOL MACROMOL, V164, P871
   Kaba SA, 2018, VACCINE, V36, P906, DOI 10.1016/j.vaccine.2017.12.001
   Kallberg M, 2012, NAT PROTOC, V7, P1511, DOI 10.1038/nprot.2012.085
   Kazi A, 2018, PATHOG GLOB HEALTH, V112, P123, DOI 10.1080/20477724.2018.1446773
   Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053
   Khailany RA, 2020, GENE REP, V19, DOI 10.1016/j.genrep.2020.100682
   Khalili S, 2015, J THEOR BIOL, V379, P66, DOI 10.1016/j.jtbi.2015.04.026
   Kozakov D, 2006, PROTEINS, V65, P392, DOI 10.1002/prot.21117
   Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169
   Kozakov D, 2013, PROTEINS, V81, P2159, DOI 10.1002/prot.24403
   Kringelum JV, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002829
   Kumar S.J., 2020, DRUG VACCINE DESIGN
   Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424
   Li HL, 2009, J IMMUNOL, V182, P6369, DOI 10.4049/jimmunol.0804287
   Lo YS, 2010, NUCLEIC ACIDS RES, V38, pW516, DOI 10.1093/nar/gkq464
   Luo D, 2006, INFECT IMMUN, V74, P2734, DOI 10.1128/IAI.74.5.2734-2741.2006
   Magnan CN, 2010, BIOINFORMATICS, V26, P2936, DOI 10.1093/bioinformatics/btq551
   Majid M, 2019, SCI REP, V9, P1
   Maurer-Stroh S, 2019, BIOINFORMATICS, V35, P3020, DOI 10.1093/bioinformatics/btz029
   Nabel GJ, 2013, NEW ENGL J MED, V368, P551, DOI 10.1056/NEJMra1204186
   Nezafat N, 2014, J THEOR BIOL, V349, P121, DOI 10.1016/j.jtbi.2014.01.018
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Nielsen M, 2005, IMMUNOGENETICS, V57, P33, DOI 10.1007/s00251-005-0781-7
   Nielsen M, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-238
   Nielsen M, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-296
   Oany AR, 2014, DRUG DES DEV THER, V8, P1139, DOI [10.2147/DDDT.567861, 10.2147/DDDT.S67861]
   Ortega JT, 2020, EXCLI J, V19, P410, DOI 10.17179/excli2020-1167
   Pandey RK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19456-1
   Paul Sinu, 2016, Curr Protoc Immunol, V114, DOI 10.1002/cpim.12
   Pierleoni A, 2006, BIOINFORMATICS, V22, pE408, DOI 10.1093/bioinformatics/btl222
   PJAib Klasse, 2014, ADV BIOL
   Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514
   Pourshojaei Y., 2019, SCI REP, V9, P1
   Prasad S, 2011, APPL ENVIRON MICROB, V77, P4603, DOI 10.1128/AEM.05259-11
   Pritam M, 2020, INT J BIOL MACROMOL, V158, P159, DOI 10.1016/j.ijbiomac.2020.04.191
   Puigbo P, 2007, NUCLEIC ACIDS RES, V35, pW126, DOI 10.1093/nar/gkm219
   Radivojac P, 2010, PROTEINS, V78, P365, DOI 10.1002/prot.22555
   Raman S, 2009, PROTEINS, V77, P89, DOI 10.1002/prot.22540
   Rapin N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009862
   Rawi R, 2018, BIOINFORMATICS, V34, P1092, DOI 10.1093/bioinformatics/btx662
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5
   Safavi A, 2020, HUM VACC IMMUNOTHER, DOI 10.1080/21645515.2020.1763693
   Safavi A, 2019, INT J PEPT RES THER, V25, P1343, DOI 10.1007/s10989-018-9780-z
   Safavi A, 2019, INT IMMUNOPHARMACOL, V74, DOI 10.1016/j.intimp.2019.105719
   Saha S, 2004, INT C ART IMM SYST
   Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078
   Salehi-Sangani G, 2019, IRAN J BASIC MED SCI, V22, P1493, DOI 10.22038/IJBMS.2019.14051
   Sankar S, 2017, BIOINFORMATION, V13, P231, DOI 10.6026/97320630013231
   Sarkar B, 2020, IMMUNOBIOLOGY, V225, DOI 10.1016/j.imbio.2020.151955
   Schrodinger LJV, 2010, PYMOL MOL GRAPHICS S, V1
   Seder RA, 2000, NATURE, V406, P793, DOI 10.1038/35021239
   Sexton NR, 2016, J VIROL, V90, P7415, DOI 10.1128/JVI.00080-16
   Shi JD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144475
   Shin HS, 2019, CLIN INFECT DIS, V68, P984, DOI 10.1093/cid/ciy595
   Singh G, 2020, COMPUT BIOL CHEM, V86, DOI 10.1016/j.compbiolchem.2020.107259
   Singh G, 2019, MICROB PATHOGENESIS, V136, DOI 10.1016/j.micpath.2019.103704
   Singh SP, 2015, J TROP MED-US, V2015, DOI 10.1155/2015/709216
   Singh SP, 2016, HUM IMMUNOL, V77, P295, DOI 10.1016/j.humimm.2015.11.012
   Song YF, 2013, STRUCTURE, V21, P1735, DOI 10.1016/j.str.2013.08.005
   Soria-Guerra RE, 2015, J BIOMED INFORM, V53, P405, DOI 10.1016/j.jbi.2014.11.003
   Stavnezer J, 2014, J IMMUNOL, V193, P5370, DOI 10.4049/jimmunol.1401849
   Steentoft C, 2013, EMBO J, V32, P1478, DOI 10.1038/emboj.2013.79
   Stranzl T, 2010, IMMUNOGENETICS, V62, P357, DOI 10.1007/s00251-010-0441-4
   Sunita, 2020, HUM VACC IMMUNOTHER, V16, P723, DOI 10.1080/21645515.2019.1670035
   Tang XC, 2009, BMC EVOL BIOL, V9, DOI 10.1186/1471-2148-9-52
   Tornavaca O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025746
   Ul Qamar MT, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2116-8
   Vazquez E, 2011, MICROB CELL FACT, V10, DOI 10.1186/1475-2859-10-60
   Vita R, 2010, NUCLEIC ACIDS RES, V38, pD854, DOI 10.1093/nar/gkp1004
   Wahome N, 2012, CHEM BIOL DRUG DES, V80, P349, DOI 10.1111/j.1747-0285.2012.01423.x
   Watanabe Y, 2019, BBA-GEN SUBJECTS, V1863, P1480, DOI 10.1016/j.bbagen.2019.05.012
   Wilkins MR, 1999, METH MOL B, V112, P531
   Wolfert MA, 2013, NAT CHEM BIOL, V9, P776, DOI [10.1038/NCHEMBIO.1403, 10.1038/nchembio.1403]
   Xie J, 2013, PLOS ONE, V8
   Yamada C, 2006, J BIOL CHEM, V281, P21771, DOI 10.1074/jbc.M513041200
   Zhang DM, 2020, J MASS SPECTROM, DOI 10.1002/jms.4626
   Zobayer N, 2019, BIOINFORMATION, V15, P530, DOI 10.6026/97320630015530
NR 123
TC 0
Z9 0
U1 18
U2 18
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD NOV 10
PY 2020
VL 38
IS 48
BP 7612
EP 7628
DI 10.1016/j.vaccine.2020.10.016
PG 17
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OH5OQ
UT WOS:000582634800009
PM 33082015
OA Green Published
DA 2021-01-01
ER

PT J
AU Vergkizi, S
   Nikolakakis, I
AF Vergkizi, Souzan
   Nikolakakis, Ioannis
TI Bacillus Calmette-Guerin (BCG) vaccine generates immunoregulatory cells
   in the cervical lymph nodes in guinea pigs injected intra dermally
SO VACCINE
LA English
DT Article
DE BCG vaccine; M. leprae; Proliferation; Guinea pigs; T cells;
   Macrophages; Covid-19
ID SUPPRESSOR-CELLS; MYCOBACTERIAL GRANULOMAS; ALVEOLAR MACROPHAGES;
   MEDIATED REGULATION; LANGERHANS CELLS; IMMUNE-RESPONSE; ANTIGEN;
   LYMPHOCYTES; POPULATIONS; INHIBITION
AB This work demonstrates the presence of immune regulatory cells in the cervical lymph nodes draining Bacillus Calmette-Guerin (BCG) vaccinated site on the dorsum of the ear in guinea pigs. It is shown that whole cervical lymph node cells did not proliferate in vitro in the presence of soluble mycobacterial antigens (PPD or leprosin) despite being responsive to whole mycobacteria. Besides, T cells from these lymph nodes separated as a non-adherent fraction on a nylon wool column, proliferated to PPD in the presence of autologous antigen presenting cells. Interestingly, addition of as low as 20% nylon wool adherent cells to these, sharply decreased the proliferation by 83%. Looking into what cells in the adherent fraction suppressed the proliferation, it was found that neither the T cell nor the macrophage enriched cell fractions of this population individually showed suppressive effect, indicating that their co-presence was necessary for the suppression. Since BCG induced granulomas resolve much faster than granulomas induced by other mycobacteria such as Mycobacterium leprae the present experimental findings add to the existing evidence that intradermal BCG vaccination influences subsequent immune responses in the host and may further stress upon its beneficial role seen in Covid-19 patients. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Vergkizi, Souzan] Aristotle Univ Thessaloniki, Fac Hlth Sci, Sch Med, Dept Microbiol, Thessaloniki 54124, Greece.
   [Nikolakakis, Ioannis] Aristotle Univ Thessaloniki, Fac Hlth Sci, Sch Pharm, Dept Pharmaceut Technol, Thessaloniki 54124, Greece.
RP Vergkizi, S (corresponding author), Aristotle Univ Thessaloniki, Fac Hlth Sci, Sch Med, Dept Microbiol, Thessaloniki 54124, Greece.
EM sverg@auth.gr; yannikos@pharm.auth.gr
OI NIKOLAKAKIS, IOANNIS/0000-0003-1690-1885
FU British Leprosy Relief Association (LEPRA)
FX Part of this article is from the PhD Thesis of Dr S. Vergkizi conducted
   at the Royal College of Surgeons of the University of London. The work
   was funded by the British Leprosy Relief Association (LEPRA) and is
   dedicated to late Prof John L. Turk and late Dr Jill Curtis, stalwarts
   in mycobacterial research of that time.
CR Angelidou A, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00332
   Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010
   BAKER D, 1988, INT ARCH ALLER A IMM, V86, P350, DOI 10.1159/000234596
   Baker D, 2018, BRAIN, V141, P2834, DOI 10.1093/brain/awy239
   BECKER MJ, 1981, CLIN EXP IMMUNOL, V45, P439
   Berg MK, 2020, MANDATED BACILLUS CA
   Boer MC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00217
   Boer MC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094192
   BULLOCK WE, 1982, CLIN EXP IMMUNOL, V49, P105
   BULLOCK WE, 1978, J IMMUNOL, V120, P1709
   Covian C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00970
   Covian C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02806
   Dhochak N, 2020, PATHOPHYSIOLOGY COVI, P1
   El-Gendy AO, 2020, VACCINE, V38, P5564, DOI 10.1016/j.vaccine.2020.06.083
   ELLNER JJ, 1978, J IMMUNOL, V121, P2573
   GOODWIN JS, 1980, CLIN IMMUNOL IMMUNOP, V15, P106, DOI 10.1016/0090-1229(80)90024-0
   GREY HM, 1985, IMMUNOL TODAY, V6, P101, DOI 10.1016/0167-5699(85)90025-8
   GUPTA S, 1985, CELL IMMUNOL, V91, P425, DOI 10.1016/0008-8749(85)90240-0
   Hegarty PK, 2020, 2020 BCGVCOVID 19 20
   Hiruma K, 2012, J NANOTECHNOL, V2012, DOI 10.1155/2012/169284
   HOLT PG, 1979, IMMUNOLOGY, V37, P429
   JAMES SP, 1982, J IMMUNOL, V128, P1149
   Jiang H, 2004, J CLIN INVEST, V114, P1198, DOI 10.1172/JCI200423411
   Kar UK, 2020, NAT IMMUNOL, V21, P115, DOI 10.1038/s41590-019-0583-y
   KATZ SI, 1974, NATURE, V251, P550, DOI 10.1038/251550a0
   Klinger D, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030378
   Kono H, 2008, NAT REV IMMUNOL, V8, P279, DOI 10.1038/nri2215
   Ley K, 2017, ARTERIOSCL THROM VAS, V37, P764, DOI 10.1161/ATVBAHA.117.308611
   Liang LC, 2005, DNA CELL BIOL, V24, P485, DOI 10.1089/dna.2005.24.485
   LITVIN DA, 1984, METHOD ENZYMOL, V108, P298
   MATHEW RC, 1983, J PATHOL, V141, P435, DOI 10.1002/path.1711410402
   Merle CSC, 2010, EXPERT REV VACCINES, V9, P209, DOI 10.1586/ERV.09.161
   Miller A, 2020, CORRELATION UNIVERSA, DOI 10.1101/2020.03.24.20042937
   Moorlag Simone J C F M, 2020, Cell Rep Med, V1, P100073, DOI 10.1016/j.xcrm.2020.100073
   MORIKAWA Y, 1990, CELL IMMUNOL, V131, P338, DOI 10.1016/0008-8749(90)90259-T
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   MURRAY HW, 1986, INFECT IMMUN, V54, P487, DOI 10.1128/IAI.54.2.487-493.1986
   NARAYANAN RB, 1982, J PATHOL, V138, P219, DOI 10.1002/path.1711380304
   NARAYANAN RB, 1981, J PATHOL, V134, P253, DOI 10.1002/path.1711340402
   NATH I, 1984, CLIN EXP IMMUNOL, V58, P522
   OHKAWA S, 1987, CLIN EXP IMMUNOL, V67, P43
   PTAK W, 1975, J IMMUNOL, V115, P1346
   ROSENTHA.AS, 1973, J EXP MED, V138, P1194, DOI 10.1084/jem.138.5.1194
   Sabat R, 2010, CYTOKINE GROWTH F R, V21, P315, DOI 10.1016/j.cytogfr.2010.11.001
   Shevach EM, 2011, J IMMUNOL, V186, P3805, DOI 10.4049/jimmunol.1100364
   Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0
   SY MS, 1977, J IMMUNOL, V119, P240
   TURCOTTE R, 1987, IMMUNOLOGY, V62, P439
   TURCOTTE R, 1981, INFECT IMMUN, V34, P315, DOI 10.1128/IAI.34.2.315-322.1981
   TURCOTTE R, 1982, INFECT IMMUN, V36, P263, DOI 10.1128/IAI.36.1.263-270.1982
   TURK JL, 1982, IMMUNOBIOLOGY, V161, P274, DOI 10.1016/S0171-2985(82)80083-1
   TWOMEY JJ, 1975, J CLIN INVEST, V56, P467, DOI 10.1172/JCI108113
   VERGHESE S, 1988, INT ARCH ALLER A IMM, V87, P392, DOI 10.1159/000234708
   Vincendeau P, 2006, AN ACAD BRAS CIENC, V78, P645, DOI 10.1590/S0001-37652006000400004
   WALKER C, 1983, J IMMUNOL, V130, P1770
   Wang H, 2020, CELL, V182, P713, DOI 10.1016/j.cell.2020.06.008
   WEINBERG DS, 1981, J IMMUNOL, V126, P794
   Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015
   Zhai X., 2020, BIORXIV PREPRINT, DOI [10.1101/2020.05.08.084061, DOI 10.1101/2020.05.08.084061]
NR 59
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD NOV 10
PY 2020
VL 38
IS 48
BP 7629
EP 7637
DI 10.1016/j.vaccine.2020.10.009
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OH5OQ
UT WOS:000582634800010
PM 33071000
OA Green Published
DA 2021-01-01
ER

PT J
AU Goldman, RD
   Yan, TD
   Seiler, M
   Cotanda, CP
   Brown, JC
   Klein, EJ
   Hoeffe, J
   Gelernter, R
   Hall, JE
   Davis, AL
   Griffiths, MA
   Mater, A
   Manzano, S
   Gualco, G
   Shimizu, N
   Hurt, TL
   Ahmed, S
   Hansen, M
   Sheridan, D
   Ali, S
   Thompson, GC
   Gaucher, N
   Staubli, G
AF Goldman, Ran D.
   Yan, Tyler D.
   Seiler, Michelle
   Cotanda, Cristina Parra
   Brown, Julie C.
   Klein, Eileen J.
   Hoeffe, Julia
   Gelernter, Renana
   Hall, Jeanine E.
   Davis, Adrienne L.
   Griffiths, Mark A.
   Mater, Ahmed
   Manzano, Sergio
   Gualco, Gianluca
   Shimizu, Naoki
   Hurt, Thomas L.
   Ahmed, Sara
   Hansen, Matt
   Sheridan, David
   Ali, Samina
   Thompson, Graham C.
   Gaucher, Nathalie
   Staubli, Georg
CA Int COVID-19 Parental Attitude Stu
TI Caregiver willingness to vaccinate their children against COVID-19:
   Cross sectional survey
SO VACCINE
LA English
DT Article
DE COVID-19; Coronavirus; Vaccination; Pandemic; Child; Emergency
   Department
ID PARENTS; HESITANCY
AB Background: More than 100 COVID-19 vaccine candidates are in development since the SARS-CoV-2 genetic sequence was published in January 2020. The uptake of a COVID-19 vaccine among children will be instrumental in limiting the spread of the disease as herd immunity may require vaccine coverage of up to 80% of the population. Prior history of pandemic vaccine coverage was as low as 40% among children in the United States during the 2009 H1N1 influenza pandemic.
   Purpose: To investigate predictors associated with global caregivers' intent to vaccinate their children against COVID-19, when the vaccine becomes available.
   Method: An international cross sectional survey of 1541 caregivers arriving with their children to 16 pediatric Emergency Departments (ED) across six countries from March 26 to May 31, 2020.
   Results: 65% (n = 1005) of caregivers reported that they intend to vaccinate their child against COVID-19, once a vaccine is available. A univariate and subsequent multivariate analysis found that increased intended uptake was associated with children that were older, children with no chronic illness, when fathers completed the survey, children up-to-date on their vaccination schedule, recent history of vaccination against influenza, and caregivers concerned their child had COVID-19 at the time of survey completion in the ED. The most common reason reported by caregivers intending to vaccinate was to protect their child (62%), and the most common reason reported by caregivers refusing vaccination was the vaccine's novelty (52%).
   Conclusions: The majority of caregivers intend to vaccinate their children against COVID-19, though uptake will likely be associated with specific factors such as child and caregiver demographics and vaccination history. Public health strategies need to address barriers to uptake by providing evidence about an upcoming COVID-19 vaccine's safety and efficacy, highlighting the risks and consequences of infection in children, and educating caregivers on the role of vaccination. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Goldman, Ran D.; Yan, Tyler D.] Univ British Columbia, Pediat Res Emergency Therapeut PRETx Program, Dept Pediat, Div Emergency Med, Vancouver, BC, Canada.
   [Goldman, Ran D.; Yan, Tyler D.] BC Childrens Hosp, Res Inst, Vancouver, BC, Canada.
   [Seiler, Michelle; Staubli, Georg] Univ Childrens Hosp Zurich, Emergency Dept, Zurich, Switzerland.
   [Cotanda, Cristina Parra] Hosp St Joan Deu Barcelona, Pediat Emergency Dept, Barcelona, Spain.
   [Brown, Julie C.; Klein, Eileen J.] Seattle Childrens Hosp, Seattle, WA USA.
   [Brown, Julie C.; Klein, Eileen J.] Univ Washington, Sch Med, Seattle, WA USA.
   [Hoeffe, Julia] Univ Hosp Bern, Pediat Emergency Med, Inselspital, Bern, Switzerland.
   [Gelernter, Renana] Tel Aviv Univ, Assaf Harofeh Med Ctr, Pediat Emergency Med Unit, Tel Aviv, Israel.
   [Gelernter, Renana] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
   [Hall, Jeanine E.] Childrens Hosp Los Angeles, USC Keck Sch Med, Div Emergency & Transport Med, Los Angeles, CA 90027 USA.
   [Davis, Adrienne L.] Hosp Sick Children, Pediat Emergency Med, Toronto, ON, Canada.
   [Davis, Adrienne L.] Univ Toronto, Toronto, ON, Canada.
   [Griffiths, Mark A.] Emory Sch Med, Div Pediat Emergency Med, Childrens Healthcare Atlanta, Atlanta, GA USA.
   [Mater, Ahmed] Jim Pattison Childrens Hosp, Pediat Emergency Med, Saskatoon, SK, Canada.
   [Mater, Ahmed] Univ Saskatchewan, Saskatoon, SK, Canada.
   [Manzano, Sergio] Univ Geneva, Geneva Univ Hosp, Geneva Childrens Hosp, Dept Pediat Emergency Med, Geneva, Switzerland.
   [Manzano, Sergio] Univ Geneva, Fac Med, Geneva, Switzerland.
   [Gualco, Gianluca] Pediat Inst Italian Part Switzerland, Pediat Emergency Dept, Ticino, Switzerland.
   [Shimizu, Naoki] St Marianna Univ, Dept Pediat, Sch Med, Kawasaki, Kanagawa, Japan.
   [Hurt, Thomas L.; Ahmed, Sara] Mary Bridge Childrens Hosp, Dept Emergency Med, Tacoma, WA USA.
   [Hansen, Matt; Sheridan, David] Oregon Hlth & Sci Univ, Doernbecher Childrens Hosp, Emergency Med, Portland, OR 97201 USA.
   [Ali, Samina] Univ Alberta, Fac Med & Dent, Women & Childrens Hlth Res Inst, Dept Pediat, Edmonton, AB, Canada.
   [Thompson, Graham C.] Alberta Childrens Prov Gen Hosp, Pediat & Emergency Med, Calgary, AB, Canada.
   [Thompson, Graham C.] Univ Calgary, Calgary, AB, Canada.
   [Gaucher, Nathalie] Univ Montreal, Pediat Emergency Med CHU St Justine, Montreal, PQ, Canada.
RP Goldman, RD (corresponding author), Univ British Columbia, Dept Pediat, BC Childrens Hosp, Res Inst, 4480 Oak St, Vancouver, BC, Canada.
EM rgoldman@cw.bc.ca
RI Yan, Tyler/AAK-9489-2020; Manzano, Sergio/ABG-6281-2020
OI Manzano, Sergio/0000-0001-9603-5520; Yan, Tyler/0000-0002-1898-7136
CR Akis S, 2011, EUR J PEDIATR, V170, P1165, DOI 10.1007/s00431-011-1425-6
   Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107
   Brussoni M, 2011, J DEV BEHAV PEDIATR, V32, P491, DOI 10.1097/DBP.0b013e31821bd1f5
   Centers for Disease Control and Prevention, 2011, FIN EST 2009 10 SEAS
   Cheung EW, 2020, JAMA-J AM MED ASSOC, V324, P294, DOI 10.1001/jama.2020.10374
   Cohen E, 2020, CNN
   Determann D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102505
   Dube E, 2014, VACCINE, V32, P6649, DOI 10.1016/j.vaccine.2014.09.039
   Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657
   Faasse K, 2020, PUBLIC PERCEPTIONS C
   Fadda M, 2020, INT J PUBLIC HEALTH, V65, P711, DOI 10.1007/s00038-020-01404-4
   Grant VJ, 2003, CAN MED ASSOC J, V168, P39
   Jung M, 2013, VACCINE, V31, P4860, DOI 10.1016/j.vaccine.2013.07.068
   Kennedy AM, 2005, PUBLIC HEALTH REP, V120, P252, DOI 10.1177/003335490512000306
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Lau JTF, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4164
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   MAHASE E, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M1679
   Murphy Vallieres Bentall, 2020, PSYARXIV
   Nicholson A, 2019, EXPL LESS LEARN CENT
   Padhi BK, 2020, DETERMINANTS COVID 1
   Rubin GJ, 2011, VACCINE, V29, P2421, DOI 10.1016/j.vaccine.2011.01.035
   Salmon DA, 2005, ARCH PEDIAT ADOL MED, V159, P470, DOI 10.1001/archpedi.159.5.470
   Schaffer DeRoo S, 2020, JAMA-J AM MED ASSOC, V323, P2458, DOI 10.1001/jama.2020.8711
   Schwarzinger M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010199
   Setbon M, 2010, EUR J PUBLIC HEALTH, V20, P490, DOI 10.1093/eurpub/ckq054
   Shim E, 2012, J R SOC INTERFACE, V9, P2234, DOI 10.1098/rsif.2012.0115
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Thunstrom L, 2020, SSRN ELECT J
   Torun SD, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-596
   Ward J, 2020, SOCARXIV
   Wenger OK, 2011, PEDIATRICS, V128, P79, DOI 10.1542/peds.2009-2599
NR 32
TC 0
Z9 0
U1 15
U2 15
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD NOV 10
PY 2020
VL 38
IS 48
BP 7668
EP 7673
DI 10.1016/j.vaccine.2020.09.084
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OH5OQ
UT WOS:000582634800015
PM 33071002
OA Green Published
DA 2021-01-01
ER

PT J
AU Mahmood, A
   Eqan, M
   Pervez, S
   Alghamdi, HA
   Tabinda, AB
   Yasar, A
   Brindhadevi, K
   Pugazhendhi, A
AF Mahmood, Adeel
   Eqan, Maryam
   Pervez, Saher
   Alghamdi, Huda Ahmed
   Tabinda, Amtul Bari
   Yasar, Abdullah
   Brindhadevi, Kathirvel
   Pugazhendhi, Arivalagan
TI COVID-19 and frequent use of hand sanitizers; human health and
   environmental hazards by exposure pathways
SO SCIENCE OF THE TOTAL ENVIRONMENT
LA English
DT Article
DE Hand sanitizers; COVID-19: Human health hazards: Environmental impact of
   hand rubs
ID ALCOHOL-INTOXICATION; INGESTION; SKIN; ABSORPTION
AB Till date no medication or vaccine is available to cope with the COVID-19 infection and infection rate is increasing drastically across the globe. Only preventive measures and healthy life style with efficient immune system have been suggested by WHO to fight and stay safe from COVID-19. WHO recommended alcohol based hand sanitizers for frequent hand hygiene, which are mainly made up from ethanol, isopropyl alcohols, hydrogen peroxides in different combinations. These preparations may become toxic to human health and environment when misused. These chemicals have known toxic and hazardous impact on environment when released by evaporation. In early live months of 2020, American Association of Poison Control Center reported 9504 alcoholic hand sanitize r exposure cases in children under the age of 12 years and recognized that even a small amount of alcohol can cause alcohol poisoning in children that is responsible for confusion, vomiting and drowsiness, and in severe cases, respiratory arrest and death. Furthermore, frequent usage of said hand sanitizers has reported increased chance of antimicrobial resistance and chance of other viral diseases. Current review is designed with main objective to highlight the toxic and serious health risks to human health and environment by frequent using hand hygiene products with alcohols based formulations. (C) 2020 Published by Elsevier B.V.
C1 [Mahmood, Adeel; Eqan, Maryam; Pervez, Saher] GC Women Univ Sialkot, Dept Environm Sci, Sialkot, Pakistan.
   [Tabinda, Amtul Bari; Yasar, Abdullah] Govt Coll Univ, Sustainable Dev Study Ctr, Lahore, Pakistan.
   [Brindhadevi, Kathirvel; Pugazhendhi, Arivalagan] Ton Duc Thang Univ, Fac Environm & Labour Safety, Innovat Green Prod Synth & Renewable Environm Dev, Ho Chi Minh City, Vietnam.
   [Alghamdi, Huda Ahmed] King Khalid Univ, Coll Sci, Dept Biol, Abha, Saudi Arabia.
RP Pugazhendhi, A (corresponding author), Ton Duc Thang Univ, Fac Environm & Labour Safety, Innovat Green Prod Synth & Renewable Environm Dev, Ho Chi Minh City, Vietnam.
EM arivalagan.pugazhendhi@tdtu.edu.vn
OI yasir, abdullah/0000-0002-3634-8864; Pugazhendhi,
   Arivalagan/0000-0002-9529-3306
FU Deanship of Scientific Research at King Khalid University
   [R.G.P-2/49/40]
FX Authors extend their appreciation to the Deanship of Scientific Research
   at King Khalid University for funding this work through research groups
   program under Grant No. R.G.P-2/49/40.
CR ADELSON L, 1962, AM J CLIN PATHOL, V38, P144
   American Association of Poison Control Centers (AAPCC), 2020, HAND SAN
   Archer JRH, 2007, BRIT MED J, V335, P1154, DOI 10.1136/bmj.39274.583472.AE
   ASHKAR FS, 1971, SOUTHERN MED J, V64, P1409, DOI 10.1097/00007611-197111000-00028
   ATSDR, 2002, HYDROGEN PEROXIDE
   ATSDR, 2014, HYDROGEN PEROXIDE
   BABEC, 2001, MAT SAF DAT SHEET IS
   Barrett MJ, 2015, MED J AUSTRALIA, V203, P43, DOI 10.5694/mja14.01493
   Blaney DD, 2011, AM J INFECT CONTROL, V39, P296, DOI 10.1016/j.ajic.2010.10.010
   Bolton PR, 2018, QUANTUM BEAM SCI, V2, DOI 10.3390/qubs2040025
   Bouthoorn SH, 2011, CLIN PEDIATR, V50, P244, DOI 10.1177/0009922810388509
   Ellis-Caleo T., 2017, P UCLA HEALTHC, P21
   Emadi A, 2007, NEW ENGL J MED, V356, P530, DOI 10.1056/NEJMc063237
   Food and drug administration (FDA), 2003, OR HLTH CAR DRUG PRO
   Fuller HC, 1926, J LAB CLIN MED, V12, P326
   Gerchow J., 2005, ALKOHOL STRASSENVERK, P532
   GIMENEZ E R, 1968, Clinical Toxicology, V1, P39
   Gormley NJ, 2012, CRIT CARE MED, V40, P290, DOI 10.1097/CCM.0b013e31822f09c0
   Gosselin RE, 1984, CLIN TOXICOLOGY COMM
   HARPIN V, 1982, ARCH DIS CHILD, V57, P477, DOI 10.1136/adc.57.6.477
   Hayat Aliya, 2016, International Journal of Biology and Biotechnology, V13, P427
   Henry MC, 1996, J TOXICOL-CLIN TOXIC, V34, P323, DOI 10.3109/15563659609013797
   HERA, 2005, HYDROGEN PEROXIDE
   HSDB, 2012, NAT LIB MED TOXNET I
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jones AW, 1997, J ANAL TOXICOL, V21, P587, DOI 10.1093/jat/21.7.587
   Kirschner MH, 2009, LANGENBECK ARCH SURG, V394, P151, DOI 10.1007/s00423-007-0237-7
   Kramer A, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-117
   Kratzel A, 2020, EMERG INFECT DIS, V26, P1592, DOI 10.3201/eid2607.200915
   Lachenmeier DW, 2008, J OCCUP MED TOXICOL, V3, DOI 10.1186/1745-6673-3-26
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Langer S, 2004, EUR J MED RES, V9, P449
   Leeper SC, 2000, VET HUM TOXICOL, V42, P15
   Mancini AJ, 2004, PEDIATRICS, V113, P1114
   MassDEP, 2011, LARG VOL ETH SPILLS
   Matteucci M.J., 2011, POISONING DRUG OVERD
   MCBAY AJ, 1973, CLIN CHEM, V19, P361
   MCFADDEN SW, 1969, PEDIATRICS, V43, P622
   Moon JM, 2006, J EMERG MED, V30, P403, DOI 10.1016/j.jemermed.2005.05.036
   Morgan W., 2020, PHYSORG         0417
   MOSS MH, 1970, PEDIATRICS, V46, P445
   NEIWPCC-New England Interstate Water Pollution Control Commission/NESCAUM-Northeast States for Coordinated Air Use Management, 2001, HLTH ENV EC IMP ADD
   New Jersey Department of Health (NJH), 2016, HAZ SUBST FACT SHEET
   NIGGEMEYER H, 1964, Munch Med Wochenschr, V106, P1631
   Pendlington RU, 2001, FOOD CHEM TOXICOL, V39, P169, DOI 10.1016/S0278-6915(00)00120-4
   Pidot SJ, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aar6115
   Public Health England, 2015, METH TOX OV
   Salomone A, 2018, J ANAL TOXICOL, V42, P157, DOI 10.1093/jat/bkx094
   Sanap M, 2003, Crit Care Resusc, V5, P106
   Santos C, 2017, MMWR-MORBID MORTAL W, V66, P23, DOI 10.15585/mmwr.mm6608a5
   Slaughter RJ, 2014, CLIN TOXICOL, V52, P470, DOI 10.3109/15563650.2014.914527
   STALJAWAD, 1983, ARCH DIS CHILD, V58, P395, DOI 10.1136/adc.58.5.395
   Stremski E, 2000, PEDIATR EMERG CARE, V16, P238, DOI 10.1097/00006565-200008000-00005
   Sung J, 2018, CUREUS, V10, DOI 10.7759/cureus.2136
   Suthivarakom G., 2020, NY TIMES
   Tachikawa T., 2020, KYODO NEWS      0225
   Trummel J, 1996, ANN EMERG MED, V27, P368, DOI 10.1016/S0196-0644(96)70274-3
   *USEPA, 2011, ECOTOX DAT
   Vermeulen R, 1966, Pa Med, V69, P53
   Vogel L, 2011, CAN MED ASSOC J, V183, pE799, DOI 10.1503/cmaj.109-3922
   Vonghia L, 2008, EUR J INTERN MED, V19, P561, DOI 10.1016/j.ejim.2007.06.033
   Watt Barbara E, 2004, Toxicol Rev, V23, P51, DOI 10.2165/00139709-200423010-00006
   Wilson M E, 2015, Indian J Nephrol, V25, P57, DOI 10.4103/0971-4065.135351
   WISE JR, 1969, NEW ENGL J MED, V280, P840
   World Health Organization, 2020, WHO GUID HAND HYG HL
   Zaman F, 2002, AM J KIDNEY DIS, V40, DOI 10.1053/ajkd.2002.34938
NR 66
TC 8
Z9 8
U1 39
U2 39
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0048-9697
EI 1879-1026
J9 SCI TOTAL ENVIRON
JI Sci. Total Environ.
PD NOV 10
PY 2020
VL 742
AR 140561
DI 10.1016/j.scitotenv.2020.140561
PG 7
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA NO3WJ
UT WOS:000569416200001
PM 32623176
OA Green Published
DA 2021-01-01
ER

PT J
AU Wang, YX
   Ru, YH
   Zhuo, GW
   Sheng, MZ
   Wang, SQ
   Ma, JR
   Zhou, CY
   Sun, XH
   Zeng, YQ
   Zhang, Y
   Li, H
   Lu, ZG
   Wu, DP
   Wu, MH
AF Wang, Yuxuan
   Ru, Yuhua
   Zhuo, Guowei
   Sheng, Maozheng
   Wang, Shuangqiu
   Ma, Jiarui
   Zhou, Chongyi
   Sun, Xiaohe
   Zeng, Yanqi
   Zhang, Ya
   Li, Hui
   Lu, Zhigang
   Wu, Depei
   Wu, Minghua
TI Investigation of the Potential Mechanism Governing the Effect of the
   Shen Zhu San on COVID-19 by Network Pharmacology
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID CHINESE HERBAL MEDICINE; ACUTE RESPIRATORY SYNDROME; TRADITIONAL
   CHINESE; SIGNALING PATHWAYS; CYTOKINE RESPONSES; HUMAN MACROPHAGES;
   ASIASARI-RADIX; GENE ONTOLOGY; SARS; EXPRESSION
AB Background. Since December 2019, coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 infection has emerged in Wuhan and rapidly spread throughout China and even to other countries. Combined therapy with modern medicine and traditional Chinese medicine has been proposed, in which Shen Zhu San (SZS) was regarded as one of the basic prescriptions. Methods. Network pharmacological approaches along with candidate compound screening, target prediction, target tissue location, protein-protein interaction network, gene ontology (GO), KEGG enrichment analyses, and gene microarray analyses were applied. Results. A total of 627 targets of the 116 active ingredients of SZS were identified. Targets in immune cells and tissues were much more abundant than those in other tissues. A total of 597 targets were enriched in the GO biological cellular process, while 153 signaling pathways were enriched according to the KEGG analysis. A total of 450 SARS-related targets were integrated and intersected with the targets of SZS to identify 40 common targets that were significantly enriched in five immune function aspects of the immune system process during GO analysis. Several inflammation-related pathways were found to be significantly enriched throughout the study. Conclusions. The therapeutic mechanisms of the effects of SZS on COVID-19 potentially involve four effects: suppressing cytokine storms, protecting the pulmonary alveolar-capillary barrier, regulating the immune response, and mediating cell death and survival.
C1 [Wang, Yuxuan; Li, Hui; Wu, Minghua] Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Affiliated Hosp, Dept Neurol, Nanjing 210029, Jiangsu, Peoples R China.
   [Wang, Yuxuan; Lu, Zhigang] Nanjing Univ Chinese Med, Key Lab Acupuncture & Med Res, Minist Educ, Nanjing 210046, Peoples R China.
   [Wang, Yuxuan] Nanjing Univ Chinese Med, State Key Lab Cultivat Base TCM Qual & Efficacy, Nanjing 210046, Jiangsu, Peoples R China.
   [Ru, Yuhua; Wu, Depei] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Suzhou 215006, Jiangsu, Peoples R China.
   [Zhuo, Guowei; Zeng, Yanqi; Zhang, Ya] Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Affiliated Hosp, Clin Med Sch 1, Nanjing 210046, Jiangsu, Peoples R China.
   [Sheng, Maozheng; Ma, Jiarui] Nanjing Univ Chinese Med, Sch Med & Holist Integrat Med, Prov Key Lab Drug Target & Drug Degenerat, Nanjing 210046, Jiangsu, Peoples R China.
   [Wang, Shuangqiu; Zhou, Chongyi; Sun, Xiaohe] Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Affiliated Hosp, Dept Respirat, Nanjing 210029, Jiangsu, Peoples R China.
RP Wu, MH (corresponding author), Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Affiliated Hosp, Dept Neurol, Nanjing 210029, Jiangsu, Peoples R China.; Lu, ZG (corresponding author), Nanjing Univ Chinese Med, Key Lab Acupuncture & Med Res, Minist Educ, Nanjing 210046, Peoples R China.; Wu, DP (corresponding author), Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Suzhou 215006, Jiangsu, Peoples R China.
EM 039014221@njucm.edu.cn; ruyuhua@yeah.net; 384647448@qq.com;
   mzsheng84@gmail.com; wwsq0824@163.com; ma9912@foxmail.com;
   zhou1997@vip.qq.com; qxsxsxh@126.com; zengyanqi1996@163.com;
   706455327@qq.com; mlihui79@gmail.com; amen0614@126.com;
   drwudepei@163.com; mhuawu@163.com
OI Zhou, Guowei/0000-0001-8907-9453
FU Evidence-Based Capacity Building Project [2019XZZX-NB007]; Jiangsu
   Province Administration Project [2017ZX09304021]; Jiangsu Medical
   Outstanding Talents Project [JCRCA2016002]; Jiangsu Provincial Key
   Medical Center [YXZXA2016002]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81673412]
FX The authors gratefully appreciate all the people fighting with the
   COVID-19 epidemics in the world. This research was funded by grants from
   the Evidence-Based Capacity Building Project (2019XZZX-NB007), Jiangsu
   Province Administration Project (2017ZX09304021), Jiangsu Medical
   Outstanding Talents Project (JCRCA2016002), and Jiangsu Provincial Key
   Medical Center (YXZXA2016002) to W. D. P. and the National Natural
   Science Foundation of China (81673412) to L.Z.G.
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Aisa Y, 2020, MED CHEM RES, V29, P793, DOI 10.1007/s00044-020-02524-5
   Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI 10.1093/nar/gkh131
   Arbour N, 2002, J EXP MED, V195, P801, DOI 10.1084/jem.20011481
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Azietaku JT, 2017, J ETHNOPHARMACOL, V202, P241, DOI 10.1016/j.jep.2017.03.022
   Bai XP, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/2432416
   Bassetti M, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13209
   Granado-Serrano AB, 2012, NUTR CANCER, V64, P588, DOI 10.1080/01635581.2012.661513
   Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101
   Chan J. F. W., 2020, FAMILIAL CLUSTER PNE
   Chan MCW, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-135
   Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z
   Chen CL, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/985176
   Chen LD, 2018, J ETHNOPHARMACOL, V219, P359, DOI 10.1016/j.jep.2017.12.011
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Z, 2004, PHYTOTHER RES, V18, P592, DOI 10.1002/ptr.1485
   Chen ZJ, 2018, FOOD CHEM TOXICOL, V119, P309, DOI 10.1016/j.fct.2018.02.050
   Cheng Y, 2016, MOL MED REP, V14, P3704, DOI 10.3892/mmr.2016.5713
   Chinese Pharmacopoeia Commission, 2020, PHARM PEOPL REP CHIN, V1, P40
   Cinatl J, 2003, LANCET, V361, P2045, DOI 10.1016/S0140-6736(03)13615-X
   Clark D Russell J. E. M., 2020, CLIN EVIDENCE DOES N
   Ctortecka C, 2018, MOL CELL PROTEOMICS, V17, P2434, DOI 10.1074/mcp.RA118.000713
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Di Lorenzo A, 2009, P NATL ACAD SCI USA, V106, P14552, DOI 10.1073/pnas.0904073106
   Dong PZ, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/2760918
   Eng YS, 2019, MOLECULES, V24, DOI 10.3390/molecules24193505
   Fang YC, 2020, RADIOLOGY, V295, P208, DOI [10.1148/radiol.2020200280, 10.1148/2020200280]
   Fernandez ML, 2005, CARDIOVASC DRUG REV, V23, P57
   Gao L, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18325-7
   Gao L, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004389
   Gao L, 2016, SCI REP-UK, V6, DOI 10.1038/srep24944
   Global Biodefense, 2020, WHO NAM DIS CAUS NEW
   Gong JY, 2013, BIOINFORMATICS, V29, P1827, DOI 10.1093/bioinformatics/btt270
   Gorbalenya A. E., 2020, SEVERE ACUTE RESP SY
   Gralinski LE, 2013, MBIO, V4, DOI 10.1128/mBio.00271-13
   Guo W, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01185
   Hegde VL, 2013, J BIOL CHEM, V288, P36810, DOI 10.1074/jbc.M113.503037
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang YX, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.105046
   Isbrucker RA, 2006, REGUL TOXICOL PHARM, V46, P167, DOI 10.1016/j.yrtph.2006.06.002
   Jihong B., 2013, EFFECTS QUERCETIN SE, P18
   Kalil AC, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2539-x
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kim HK, 2007, BIOGERONTOLOGY, V8, P399, DOI 10.1007/s10522-007-9083-9
   Lan WJ, 2006, BIOMED ENVIRON SCI, V19, P249
   Lerner TN, 2016, CELL, V164, P1136, DOI 10.1016/j.cell.2016.02.027
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Leung PC, 2007, AM J CHINESE MED, V35, P575, DOI 10.1142/S0192415X07005077
   Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B
   Li LC, 2016, MOL MED REP, V13, P536, DOI 10.3892/mmr.2015.4546
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li T, 2013, ANTIVIR RES, V97, P1, DOI 10.1016/j.antiviral.2012.10.006
   Lin L, 2020, Zhonghua Yi Xue Za Zhi, V100, pE001, DOI 10.3760/cma.j.issn.0376-2491.2020.0001
   Liu B, 2020, BIOMED PHARMACOTHER, V123, DOI 10.1016/j.biopha.2019.109664
   Liu JJ, 2005, CELL MOL IMMUNOL, V2, P455
   Liu JP, 2004, J ALTERN COMPLEM MED, V10, P1041, DOI 10.1089/acm.2004.10.1041
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luo Y, 2019, AM J CHINESE MED, V47, P1223, DOI 10.1142/S0192415X19500629
   Mason RJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00607-2020
   Matthay MA, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0069-0
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   McKimm-Breschkin JL, 2018, ANTIVIR RES, V149, P118, DOI 10.1016/j.antiviral.2017.11.013
   Mizutani T, 2007, ANN NY ACAD SCI, V1102, P86, DOI 10.1196/annals.1408.006
   Mizutani T, 2005, BBA-MOL BASIS DIS, V1741, P4, DOI 10.1016/j.bbadis.2005.04.004
   Mizutani T, 2004, FEBS LETT, V577, P187, DOI 10.1016/j.febslet.2004.10.005
   Mlecnik B, 2019, BIOINFORMATICS, V35, P3864, DOI 10.1093/bioinformatics/btz163
   Mlecnik B, 2018, J PROTEOMICS, V171, P2, DOI 10.1016/j.jprot.2017.03.016
   Na-Bangchang K, 2017, J EVID BASED COMPLEM, V2017, P16, DOI DOI 10.1155/2017/5929234
   Olave NC, 2010, J CELL BIOCHEM, V111, P720, DOI 10.1002/jcb.22760
   Osterlund P, 2010, J VIROL, V84, P1414, DOI 10.1128/JVI.01619-09
   Otasek D, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1758-4
   Park WY, 2001, AM J RESP CRIT CARE, V164, P1896, DOI 10.1164/ajrccm.164.10.2104013
   Peng H., 1996, ZHONGYI FANGJI DACID, V7, P1091
   Peng H., 2014, P INT C MAT ENV ENG
   Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892
   Puente-Marin S, 2018, GENES-BASEL, V9, DOI 10.3390/genes9040202
   Ramalingam M, 2015, TROP J PHARM RES, V14, P545, DOI 10.4314/tjpr.v14i3.26
   Ramesh T, 2009, DRUG CHEM TOXICOL, V32, P243, DOI 10.1080/01480540902873837
   Ren X, 2020, J ETHNOPHARMACOL, V258, DOI 10.1016/j.jep.2020.112932
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Rojas JM, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/6104054
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758-2946-6-13
   Song L, 2019, MOL MED REP, V20, P4654, DOI 10.3892/mmr.2019.10698
   Song P, 2020, J TRADIT CHIN MED, V40, P497, DOI 10.19852/j.cnki.jtcm.2020.03.019
   Song ZY, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/5194016
   Sun J, 2016, SCI REP-UK, V6, DOI 10.1038/srep34328
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Tanaka T, 2016, IMMUNOTHERAPY-UK, V8, P959, DOI 10.2217/imt-2016-0020
   The State Council Information Office, 2020, SCIO BRIEF JOINT RES
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Tsai MH, 2016, J INVEST DERMATOL, V136, P1398, DOI 10.1016/j.jid.2015.11.034
   Tse GMK, 2004, J CLIN PATHOL, V57, P260, DOI 10.1136/jcp.2003.013276
   Varshney B, 2011, BIOCHEMISTRY-US, V50, P5419, DOI 10.1021/bi200303r
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang FS, 2020, LANCET, V395, P391, DOI 10.1016/S0140-6736(20)30300-7
   Wang HH, 2020, EUR J CLIN MICROBIOL, V39, P1629, DOI 10.1007/s10096-020-03899-4
   Wang LQ, 2015, ACTA PHARM SIN B, V5, P310, DOI [10.1016//j.apsb.2015.05.005, 10.1016/j.apsb.2015.05.005]
   Wang PQ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01288
   Wang XM, 2020, POTENTIAL ANAL, DOI 10.1007/s11118-019-09821-8
   Wang YX, 2020, EUR REV MED PHARMACO, V24, P3360, DOI 10.26355/eurrev_202003_20704
   Wang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep28089
   [王玉光 Wang Yuguang], 2020, [中医杂志, Journal of Traditional Chinese Medicine], V61, P281
   World Health Organisation, 2020, WHO DIR GEN STAT IHR
   Wu CL, 2016, NUCLEIC ACIDS RES, V44, pD313, DOI 10.1093/nar/gkv1104
   Wu Y, 2019, NUCLEIC ACIDS RES, V47, pD1110, DOI 10.1093/nar/gky1021
   [吴媛媛 WU Yuan-yuan], 2009, [时珍国医国药, Lishizhen Medicine and Materia Medica Research], V20, P625
   Xie GG, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/3951783
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang B., 2020, RES SQUARE, V1
   Yang Y, 2020, INT J BIOL SCI, V16, P1708, DOI 10.7150/ijbs.45538
   Yi D., 2008, NUTRIENTS, V6
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Yu MX, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/5801591
   Zhang MM, 2004, WORLD J GASTROENTERO, V10, P3500
   Zhang XW, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50064-9
   [郑文科 Zheng Wenke], 2020, [中医杂志, Journal of Traditional Chinese Medicine], V61, P277
   Zhong LDLD, 2020, AM J CHINESE MED, V48, P1051, DOI 10.1142/S0192415X20500512
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 120
TC 0
Z9 0
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD NOV 9
PY 2020
VL 2020
AR 8468303
DI 10.1155/2020/8468303
PG 23
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA PA4WF
UT WOS:000595637300001
PM 33224256
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Min, J
   Kim, HW
   Koo, HK
   Ko, Y
   Oh, JY
   Kim, J
   Yang, J
   Kwon, Y
   Park, YJ
   Kang, JY
   Lee, SS
   Park, JS
   Kim, JS
AF Min, Jinsoo
   Kim, Hyung Woo
   Koo, Hyeon-Kyoung
   Ko, Yousang
   Oh, Jee Youn
   Kim, Jaetae
   Yang, Jiyeon
   Kwon, Yunhyung
   Park, Young-Joon
   Kang, Ji Young
   Lee, Sung-Soon
   Park, Jae Seuk
   Kim, Ju Sang
TI National PPM Tuberculosis Control Project in Korea: the Korean PPM
   Monitoring Database between July 2019 and June 2020
SO JOURNAL OF KOREAN MEDICAL SCIENCE
LA English
DT Article
DE SARS Virus; Coronavirus; Treatment Outcome; Public-private Sector
   Partnerships; Quality Indicators
ID COVID-19
AB Background: The coronavirus disease 2019 (COVID-19) pandemic caused disruptions to healthcare systems and endangered the control and prevention of tuberculosis (TB). We investigated the nationwide effects of COVID-19 on the national Public-Private Mix (PPM) TB control project in Korea, using monitoring indicators from the Korean PPM monitoring database.
   Methods: The Korean PPM monitoring database includes data from patients registered at PPM hospitals throughout the country. Data of six monitoring indicators for active TB cases updated between July 2019 and June 2020 were collected. The data of each cohort throughout the country and in Daegu-Gyeongbuk, Seoul Metropolitan Area, and Jeonnam-Jeonbuk were collated to provide nationwide data. The data were compared using the chi(2) test for trend to evaluate quarterly trends of each monitoring indicator at the national level and in the prespecified regions.
   Results: Test coverages of sputum smear (P = 0.622) and culture (P = 0.815), drug susceptibility test (P = 0.750), and adherence rate to initial standard treatment (P = 0.901) at the national level were not significantly different during the study period. The rate of loss to follow-up among TB cases at the national level was not significantly different (P = 0.088); however, the treatment success rate among the smear-positive drug-susceptible pulmonary TB cohort at the national level significantly decreased, from 90.6% to 84.1% (P < 0.001). Treatment success rate in the Seoul metropolitan area also significantly decreased during the study period, from 89.4% to 84.5% (P = 0.006).
   Conclusion: Our study showed that initial TB management during the COVID-19 pandemic was properly administered under the PPM project in Korea. However, our study cannot confirm or conclude a decreased treatment success rate after the COVID-19 pandemic due to limited data.
C1 [Min, Jinsoo] Catholic Univ Korea, Daejeon St Marys Hosp, Div Pulm & Crit Care Med, Dept Internal Med,Coll Med, Seoul, South Korea.
   [Kim, Hyung Woo; Kim, Ju Sang] Catholic Univ Korea, Incheon St Marys Hosp, Div Pulm & Crit Care Med, Dept Internal Med,Coll Med, Seoul, South Korea.
   [Koo, Hyeon-Kyoung; Lee, Sung-Soon] Inje Univ, Ilsan Paik Hosp, Div Pulm & Crit Care Med, Dept Internal Med,Coll Med, Goyang, South Korea.
   [Ko, Yousang] Hallym Univ, Kangdong Sacred Heart Hosp, Div Pulm Allergy & Crit Care Med, Dept Internal Med,Coll Med, Seoul, South Korea.
   [Oh, Jee Youn] Korea Univ, Guro Hosp, Div Pulm Allergy & Crit Care Med, Dept Internal Med,Coll Med, Seoul, South Korea.
   [Kim, Jaetae; Yang, Jiyeon; Kwon, Yunhyung] Korea Dis Control & Prevent Agcy, Bur Infect Dis Policy, Div TB Prevent & Control, Osong, South Korea.
   [Park, Young-Joon] Korea Dis Control & Prevent Agcy, Epidemiol Investigat Anal, Publ Hlth Emergency Preparedness, Cheongju, South Korea.
   [Kang, Ji Young] Catholic Univ Korea, Seoul St Marys Hosp, Div Pulm & Crit Care Med, Dept Internal Med,Coll Med, Seoul, South Korea.
   [Park, Jae Seuk] Dankook Univ, Div Pulm Med, Dept Internal Med, Coll Med, Cheonan, South Korea.
RP Kim, JS (corresponding author), Catholic Univ Korea, Incheon St Marys Hosp, Div Pulm & Crit Care Med, Dept Internal Med,Coll Med, 56 Dongsu Ro, Incheon 21431, South Korea.
EM kimjusang@catholic.ac.kr
RI ; Min, Jinsoo/D-5181-2018
OI Koo, Hyeon-Kyoung/0000-0002-1200-9892; Kang, Ji
   Young/0000-0003-4942-013X; Min, Jinsoo/0000-0001-6091-518X; Ko,
   Yousang/0000-0002-1703-6590
FU National Health Promotion Fund - Ministry of Health and Welfare,
   Republic of Korea
FX The national Public-Private Mix (PPM) tuberculosis (TB) control project
   is supported by the National Health Promotion Fund, funded by the
   Ministry of Health and Welfare, Republic of Korea in 2020.
CR Alene KA, 2020, TROP MED INFECT DIS, V5, DOI 10.3390/tropicalmed5030123
   Chudasama YV, 2020, DIABETES METAB SYND, V14, P965, DOI 10.1016/j.dsx.2020.06.042
   Desta KT, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7574-7
   Kang Hae-Young, 2016, Osong Public Health Res Perspect, V7, P320, DOI 10.1016/j.phrp.2016.08.002
   Kim M, 2020, PUBLIC HLTH WKLY REP, V13, P2032
   Korea Centers for Disease Control & Prevention, 2020, KOR GUID TUB, P2020
   Korea Centers for Disease Control & Prevention, 2020, ANN REP NOT TUB KOR
   Kwak N, 2020, EMERG INFECT DIS, V26, P2506, DOI [10.3201/eid2610.20-2782, 10.3201/eid2610.202782]
   Magassouba AS, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09230-2
   McQuaid CF, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01718-2020
   Min J, 2020, TUBERC RESPIR DIS, V83, P218, DOI 10.4046/trd.2020.0016
   Oh J, 2020, HEALTH SYST REFORM, V6, DOI 10.1080/23288604.2020.1753464
   Parpia AS, 2016, EMERG INFECT DIS, V22, P433, DOI 10.3201/eid2203.150977
   Visca D, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01998-2020
   World Health Organization, 2013, DEF REP FRAM TUB 201
   World Health Organization, COVID 19 CONS TUB TB
   World Health Organization, 2020, COR DIS 2019 COVID 1
NR 17
TC 0
Z9 0
U1 0
U2 0
PU KOREAN ACAD MEDICAL SCIENCES
PI SEOUL
PA 302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA
SN 1011-8934
EI 1598-6357
J9 J KOREAN MED SCI
JI J. Korean Med. Sci.
PD NOV 9
PY 2020
VL 35
IS 43
AR e388
DI 10.3346/jkms.2020.35.e388
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA OY0PN
UT WOS:000593956300006
PM 33169559
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sang, L
   Chen, SB
   Zheng, X
   Guan, WJ
   Zhang, ZH
   Liang, WH
   Zhong, M
   Jiang, L
   Pan, C
   Zhang, W
   Xia, J
   Chen, NS
   Wu, WJ
   Wu, HK
   Xu, YH
   Liu, XS
   Liu, XQ
   He, JX
   Li, SY
   Zhang, DY
   Zhong, NS
   Li, YM
AF Sang, Ling
   Chen, Sibei
   Zheng, Xia
   Guan, Weijie
   Zhang, Zhihui
   Liang, Wenhua
   Zhong, Ming
   Jiang, Li
   Pan, Chun
   Zhang, Wei
   Xia, Jiaan
   Chen, Nanshan
   Wu, Wenjuan
   Wu, Hongkai
   Xu, Yonghao
   Liu, Xuesong
   Liu, Xiaoqing
   He, Jianxing
   Li, Shiyue
   Zhang, Dingyu
   Zhong, Nanshan
   Li, Yimin
TI The incidence, risk factors and prognosis of acute kidney injury in
   severe and critically ill patients with COVID-19 in mainland China: a
   retrospective study
SO BMC PULMONARY MEDICINE
LA English
DT Article
DE Coronavirus disease 2019; Acute respiratory distres; Syndrome; Acute
   kidney injury; Intensive care unit; Mechanical ventilation
ID AKI; HYPOXIA; EPIDEMIOLOGY; VENTILATION; FAILURE; SEPSIS
AB Background The clinical correlates, prognosis and determinants of acute kidney injury (AKI) in patients with coronavirus disease 2019 (Covid-19) remain largely unclear. Methods We retrospectively reviewed medical records of all adult patients with laboratory-confirmed Covid-19 who were admitted to the intensive care unit (ICU) between January 23rd 2020 and April 6th 2020 at Wuhan JinYinTan Hospital and The First Affiliated Hospital of Guangzhou Medical University. Results Among 210 patients, 131 were males (62.4%). The median Age was 64 years (IQR: 56-71). Of 92 (43.8%) patients who developed AKI during hospitalization, 13 (14.1%), 15 (16.3%) and 64 (69.6%) were classified as being at stage 1, 2 and 3, respectively. 54 patients (58.7%) received continuous renal replacement therapy. Age, sepsis, nephrotoxic drug, invasive mechanical ventilation and elevated baseline serum creatinine levels were associated with the occurrence of AKI. Renal recovery during hospitalization was identified among 16 patients with AKI (17.4%), who had a significantly shorter time from admission to AKI diagnosis, lower incidence of right heart failure and higher ratio of partial pressure of oxygen to the fraction of inspired oxygen. Of 210 patients, 93 deceased within 28 days of ICU admission. AKI stage 3, critical disease, greater Age and the lowest ratio of partial pressure of oxygen to the fraction of inspired oxygen being < 150 mmHg were independently associated with death. Conclusions Among patients with Covid-19, the incidence of AKI was high. Our findings of the risk factors of the development of AKI and factors associated with renal function recovery may inform clinical management of patients with critical illness of Covid-19.
C1 [Sang, Ling; Chen, Sibei; Guan, Weijie; Zhang, Zhihui; Xu, Yonghao; Liu, Xuesong; Liu, Xiaoqing; Li, Shiyue; Zhong, Nanshan; Li, Yimin] Guangzhou Med Univ, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis, Dept Pulm & Crit Care Med,Affiliated Hosp 1, Guangzhou, Peoples R China.
   [Zheng, Xia] Zhejiang Univ, Dept Crit Care Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China.
   [Liang, Wenhua; He, Jianxing] Guangzhou Med Univ, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis, Dept Thorax Surg,Affiliated Hosp 1, Guangzhou, Peoples R China.
   [Zhong, Ming] Fudan Univ, Dept Crit Care Med, Zhongshan Hosp, Shanghai, Peoples R China.
   [Jiang, Li] Capital Med Univ, Xuanwu Hosp, Dept Crit Care Med, Beijing, Peoples R China.
   [Pan, Chun] Southeast Univ, Zhongda Hosp, Dept Crit Care Med, Nanjing, Peoples R China.
   [Zhang, Wei] 900th Hosp Joint Serv Corps Chinese PLA, Emergency Dept, Fuzhou, Peoples R China.
   [Xia, Jiaan] Wuhan Jinyintan Hosp, Dept TB, Wuhan, Peoples R China.
   [Chen, Nanshan] Wuhan Jinyintan Hosp, Dept Resp & Crit Care Med, Wuhan, Peoples R China.
   [Wu, Wenjuan] Wuhan Jinyintan Hosp, Dept Crit Care Med, Wuhan, Peoples R China.
   [Wu, Hongkai] Guangzhou Med Univ, Affiliated Hosp 1, Natl Clin Res Ctr Resp Dis, State Key Lab Resp Dis, Guangzhou, Peoples R China.
   [Zhang, Dingyu] Wuhan Jinyintan Hosp, Res Ctr Translat Med, Wuhan, Peoples R China.
   [Zhang, Dingyu] Chinese Acad Sci, Wuhan Inst Virol, Joint Lab Infect Dis & Hlth, Wuhan, Peoples R China.
   [Zhang, Dingyu] Chinese Acad Sci, Wuhan Jinyintan Hosp, Wuhan, Peoples R China.
RP Li, YM (corresponding author), Guangzhou Med Univ, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis, Dept Pulm & Crit Care Med,Affiliated Hosp 1, Guangzhou, Peoples R China.
EM dryiminli@vip.163.com
FU National Science and Technology Major Project [2017ZX10204401003001];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [82070084]; Special Project of Guangdong
   Science and Technology Department [2020B111105001]; Science and
   Technology Program of Guangzhou, China [202008040003]; Ministry of
   science and technology [2020YFC0841300, 2020YFC0845100]; Natural Science
   Foundation of Guangdong Province, ChinaNational Natural Science
   Foundation of Guangdong Province [2020A1515011459]
FX The study was funded by National Science and Technology Major Project
   (No.2017ZX10204401003001), National Natural Science Foundation of China
   (No. 82070084), the Special Project of Guangdong Science and Technology
   Department (No. 2020B111105001), the Science and Technology Program of
   Guangzhou, China (No. 202008040003), the Major special projects of the
   Ministry of science and technology (No. 2020YFC0845100), the Major
   special projects of the Ministry of science and technology (No.
   2020YFC0841300) and Natural Science Foundation of Guangdong Province,
   China (No.2020A1515011459). The funding body had no role in the study
   design, the collection, analysis or interpretation of the data.
CR [Anonymous], COR DIS COVID 19 SIT
   Chawla LS, 2017, NAT REV NEPHROL, V13, P241, DOI 10.1038/nrneph.2017.2
   Chen KP, 2016, CLIN J AM SOC NEPHRO, V11, P602, DOI 10.2215/CJN.08080715
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Dessap AM, 2016, INTENS CARE MED, V42, P862, DOI 10.1007/s00134-015-4141-2
   Fu QW, 2016, CLIN MED RES, V14, P15, DOI 10.3121/cmr.2015.1282
   Fuhrman DY, 2018, ANN INTENSIVE CARE, V8, DOI 10.1186/s13613-018-0373-y
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Haase VH, 2013, J AM SOC NEPHROL, V24, P537, DOI 10.1681/ASN.2012080855
   Hoste E, 2015, INTENS CARE MED, V41, P1411, DOI 10.1007/s00134-015-3934-7
   Komaru Yohei, 2020, Shock, V54, P280, DOI 10.1097/SHK.0000000000001511
   Lombardi R, 2017, SHOCK, V48, P411, DOI 10.1097/SHK.0000000000000871
   Nin N, 2011, INTENS CARE MED, V37, P768, DOI 10.1007/s00134-011-2167-7
   Palevsky PM, 2013, AM J KIDNEY DIS, V61, P649, DOI 10.1053/j.ajkd.2013.02.349
   Palmieri T, 2010, BURNS, V36, P205, DOI 10.1016/j.burns.2009.08.012
   Panitchote A, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1439-2
   Panitchote A, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0552-5
   Parolari A, 2012, ANN THORAC SURG, V93, P584, DOI 10.1016/j.athoracsur.2011.09.073
   Paudel MS, 2012, RENAL FAILURE, V34, P1217, DOI 10.3109/0886022X.2012.723515
   Ranieri VM, 2000, JAMA-J AM MED ASSOC, V284, P43, DOI 10.1001/jama.284.1.43
   Samanta A, 2018, SAUDI J KIDNEY DIS T, V29, P879, DOI 10.4103/1319-2442.239653
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Susantitaphong P, 2013, CLIN J AM SOC NEPHRO, V8, P1482, DOI 10.2215/CJN.00710113
   Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327
   van den Akker JPC, 2013, CRIT CARE, V17, DOI 10.1186/cc12743
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Xu X, 2015, CLIN J AM SOC NEPHRO, V10, P1510, DOI 10.2215/CJN.02140215
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zarbock A, 2014, CURR OPIN CRIT CARE, V20, P588, DOI 10.1097/MCC.0000000000000153
NR 31
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2466
J9 BMC PULM MED
JI BMC Pulm. Med.
PD NOV 9
PY 2020
VL 20
IS 1
AR 290
DI 10.1186/s12890-020-01305-5
PG 10
WC Respiratory System
SC Respiratory System
GA OV2SP
UT WOS:000592066800001
PM 33167955
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Noor, S
   Guo, Y
   Shah, SHH
   Fournier-Viger, P
   Nawaz, MS
AF Noor, Saleha
   Guo, Yi
   Shah, Syed Hamad Hassan
   Fournier-Viger, Philippe
   Nawaz, M. Saqib
TI Analysis of public reactions to the novel Coronavirus (COVID-19)
   outbreak on Twitter
SO KYBERNETES
LA English
DT Article; Early Access
DE Clusters; VOSviewer; COVID-19; Sequential pattern mining; Tweets
ID SOCIAL MEDIA
AB Purpose
   The novel Coronavirus (COVID-19) pandemic, which started in late December 2019, has spread to more than 200 countries. As no vaccine is yet available for this pandemic, government and health agencies are taking draconian steps to contain it. This pandemic is also trending on social media, particularly on Twitter. The purpose of this study is to explore and analyze the general public reactions to the COVID-19 outbreak on Twitter.
   Design/methodology/approach
   This study conducts a thematic analysis of COVID-19 tweets through VOSviewer to examine people's reactions related to the COVID-19 outbreak in the world. Moreover, sequential pattern mining (SPM) techniques are used to find frequent words/patterns and their relationship in tweets.
   Findings
   Seven clusters (themes) were found through VOSviewer: Cluster 1 (green): public sentiments about COVID-19 in the USA. Cluster 2 (red): public sentiments about COVID-19 in Italy and Iran and a vaccine, Cluster 3 (purple): public sentiments about doomsday and science credibility. Cluster 4 (blue): public sentiments about COVID-19 in India. Cluster 5 (yellow): public sentiments about COVID-19's emergence. Cluster 6 (light blue): public sentiments about COVID-19 in the Philippines. Cluster 7 (orange): Public sentiments about COVID-19 US Intelligence Report. The most frequent words/patterns discovered with SPM were "COVID-19," "Coronavirus," "Chinese virus" and the most frequent and high confidence sequential rules were related to "Coronavirus, testing, lockdown, China and Wuhan."
   Research limitations/implications
   The methodology can be used to analyze the opinions/thoughts of the general public on Twitter and to categorize them accordingly. Moreover, the categories (generated by VOSviewer) can be correlated with the results obtained with pattern mining techniques.
   Social implications
   This study has a significant socio-economic impact as Twitter offers content posting and sharing to billions of users worldwide.
   Originality/value
   According to the authors' best knowledge, this may be the first study to carry out a thematic analysis of COVID-19 tweets at a glance and mining the tweets with SPM to investigate how people reacted to the COVID-19 outbreak on Twitter.
C1 [Noor, Saleha; Guo, Yi] East China Univ Sci & Technol, Sch Informat Sci & Engn, Shanghai, Peoples R China.
   [Shah, Syed Hamad Hassan] Donghua Univ, Glorious Sun Sch Business & Management, Shanghai, Peoples R China.
   [Fournier-Viger, Philippe; Nawaz, M. Saqib] Harbin Inst Technol Shenzhen, Sch Humanities & Social Sci, Shenzhen, Peoples R China.
RP Guo, Y (corresponding author), East China Univ Sci & Technol, Sch Informat Sci & Engn, Shanghai, Peoples R China.
EM salehanoorse@gmail.com; guoyi@ecust.edu.cn; hamad74shah@gmail.com;
   philfv8@yahoo.com; msaqibnawaz@hit.edu.cn
CR Agrawal R., 1994, P 20 INT C VER LARG, V1215, P487, DOI DOI 10.1109/69.250074
   Al-Barakati A, 2018, INT J SEMANT WEB INF, V14, P184, DOI 10.4018/IJSWIS.2018070109
   Aladwani AM, 2015, INT J INFORM MANAGE, V35, P15, DOI 10.1016/j.ijinfomgt.2014.09.003
   Apostolopoulos ID, 2020, PHYS ENG SCI MED, V43, P635, DOI 10.1007/s13246-020-00865-4
   Barstugan M., 2020, ABS200309424 CORR
   Bragazzi NL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185263
   Breland JY, 2017, AM J PUBLIC HEALTH, V107, P1890, DOI 10.2105/AJPH.2017.304098
   Butt C, 2020, APPL INTELL, DOI 10.1007/s10489-020-01714-3
   Chan MPS, 2018, SOC SCI MED, V212, P50, DOI 10.1016/j.socscimed.2018.07.007
   Dabbagh Mohammad, 2020, Blockchain and Applications. International Congress. Advances in Intelligent Systems and Computing (1010), P27, DOI 10.1007/978-3-030-23813-1_4
   Fournier-Viger Philippe, 2014, Advances in Knowledge Discovery and Data Mining. 18th Pacific-Asia Conference (PAKDD 2014). Proceedings: LNCS 8443, P40, DOI 10.1007/978-3-319-06608-0_4
   Fournier-Viger Philippe, 2013, Advanced Data Mining and Applications. 9th International Conference, ADMA 2013. Proceedings: LNCS 8346, P109, DOI 10.1007/978-3-642-53914-5_10
   Fournier-Viger P., 2017, DATA SCI PATTERN REC, V1, P54
   Fournier-Viger P., 2019, HIGH UTILITY PATTERN, V51, DOI [10.1007/978-3-030-04921-8_1, DOI 10.1007/978-3-030-04921-8]
   Fournier-Viger P, 2016, LECT NOTES ARTIF INT, V9853, P36, DOI 10.1007/978-3-319-46131-1_8
   Fournier-Viger P, 2014, LECT NOTES COMPUT SC, V8819, P108, DOI 10.1007/978-3-319-12571-8_10
   Fu KW, 2016, AM J INFECT CONTROL, V44, P1700, DOI 10.1016/j.ajic.2016.04.253
   Fung ICH, 2016, AM J INFECT CONTROL, V44, P1660, DOI 10.1016/j.ajic.2016.05.011
   Henning K.J., 2004, MMWR MORBIDITY MORTA, V53
   Khan AS, 2010, AM J PUBLIC HEALTH, V100, P1237, DOI 10.2105/AJPH.2009.180489
   Kim EHJ, 2016, J INF SCI, V42, P763, DOI 10.1177/0165551515608733
   Kraemer MUG, 2018, EPJ DATA SCI, V7, DOI 10.1140/epjds/s13688-018-0144-x
   Kumar A, 2018, KYBERNETES, V47, P1053, DOI 10.1108/K-06-2017-0210
   Lehnert JD, 2017, J PUBLIC HEALTH MAN, V23, P608, DOI 10.1097/PHH.0000000000000537
   Li KH, 2020, INVEST RADIOL, V55, P327, DOI 10.1097/RLI.0000000000000672
   Mishra Prerna, 2016, 2016 International Conference on Information Technology (InCITe): Next-Generation IT Summit on the Theme "Internet of Things: Connect Your Worlds", P148, DOI 10.1109/INCITE.2016.7857607
   Mohamadou Y, 2020, APPL INTELL, V50, P3913, DOI 10.1007/s10489-020-01770-9
   Nawaz MS, 2017, J MED IMAG HEALTH IN, V7, P1365, DOI 10.1166/jmihi.2017.2148
   Noor Saleha, 2020, Knowledge Science, Engineering and Management. 13th International Conference, KSEM 2020. Proceedings. Lecture Notes in Artificial Intelligence. Subseries of Lecture Notes in Computer Science (LNAI 12274), P341, DOI 10.1007/978-3-030-55130-8_30
   Noor S., 2020, INT J KNOWLEDGE MANA, V16, P33, DOI [10.4018/IJKM.2020070103, DOI 10.4018/IJKM.2020070103]
   Noor S, 2020, INT J SEMANT WEB INF, V16, P88, DOI 10.4018/IJSWIS.2020070106
   Odlum M, 2015, AM J INFECT CONTROL, V43, P563, DOI 10.1016/j.ajic.2015.02.023
   Organization W.H., 2020, WHO B
   Ozturk T, 2020, COMPUT BIOL MED, V121, DOI 10.1016/j.compbiomed.2020.103792
   Shah S. H. H., 2020, INT J INFORM MANAGE, V31, P79, DOI 10.6186/IJIMS.202003
   Shah SHH, 2020, KYBERNETES, V49, P1020, DOI 10.1108/K-12-2018-0696
   Shahzad B, 2017, INF DISCOV DELIV, V45, P130, DOI 10.1108/IDD-03-2017-0023
   Shi Feng, 2020, IEEE Rev Biomed Eng, VPP, DOI 10.1109/RBME.2020.2987975
   Signorini A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019467
   Sinha A.K., 2018, SENTIMENT ANAL TWITT, P170, DOI [10.4018/978-1-5225-3787-8.ch011, DOI 10.4018/978-1-5225-3787-8.CH011]
   Sinnenberg L, 2017, AM J PUBLIC HEALTH, V107, pE1, DOI 10.2105/AJPH.2016.303512
   Ueda M, 2017, SOC SCI MED, V189, P158, DOI 10.1016/j.socscimed.2017.06.032
   Van Eck N.J., 2018, VOSVIEWER MANUAL, DOI [DOI 10.3402/JAC.V8.30072, 10.3402/jac.v8.30072]
   van Eck NJ, 2009, J AM SOC INF SCI TEC, V60, P1635, DOI 10.1002/asi.21075
   Vosner HB, 2017, KYBERNETES, V46, P750, DOI 10.1108/K-10-2016-0292
   Waltman L, 2010, J INFORMETR, V4, P629, DOI 10.1016/j.joi.2010.07.002
   Wang YM, 2015, KNOWL-BASED SYST, V88, P12, DOI 10.1016/j.knosys.2015.08.013
   Wang ZJ, 2019, LECT NOTES ARTIF INT, V11888, P658, DOI 10.1007/978-3-030-35231-8_48
   Wood MJ, 2018, CYBERPSYCH BEH SOC N, V21, P485, DOI 10.1089/cyber.2017.0669
   Yoon Y.S., 2018, 9 INT C INF COMM TEC, DOI [10.1109/ICTC.2018.8539363, DOI 10.1109/ICTC.2018.8539363]
   Zarrad A., 2014, P 2014 IEEE ACM 7 IN, DOI [10.1109/UCC.2014.107, DOI 10.1109/UCC.2014.107]
   Zupic I, 2015, ORGAN RES METHODS, V18, P429, DOI 10.1177/1094428114562629
NR 52
TC 0
Z9 0
U1 3
U2 3
PU EMERALD GROUP PUBLISHING LTD
PI BINGLEY
PA HOWARD HOUSE, WAGON LANE, BINGLEY BD16 1WA, W YORKSHIRE, ENGLAND
SN 0368-492X
EI 1758-7883
J9 KYBERNETES
JI Kybernetes
DI 10.1108/K-05-2020-0258
EA NOV 2020
PG 21
WC Computer Science, Cybernetics
SC Computer Science
GA OV2ZT
UT WOS:000592085400001
DA 2021-01-01
ER

PT J
AU Munoz-Alcaraz, MN
   Perula-de-Torres, LA
   Serrano-Merino, J
   Jimenez-Vilchez, AJ
   Olmo-Carmona, MV
   Munoz-Garcia, MT
   Bartolome-Moreno, C
   Olivan-Blazquez, B
   Magallon-Botaya, R
AF Nieves Munoz-Alcaraz, Maria
   Angel Perula-de-Torres, Luis
   Serrano-Merino, Jesus
   Jose Jimenez-Vilchez, Antonio
   Victoria Olmo-Carmona, Maria
   Teresa Munoz-Garcia, Maria
   Bartolome-Moreno, Cruz
   Olivan-Blazquez, Barbara
   Magallon-Botaya, Rosa
TI Efficacy and efficiency of a new therapeutic approach based on
   activity-oriented proprioceptive antiedema therapy (TAPA) for edema
   reduction and improved occupational performance in the rehabilitation of
   breast cancer-related arm lymphedema in women: a controlled, randomized
   clinical trial
SO BMC CANCER
LA English
DT Article
DE Occupational therapy (OT); Breast cancer (BC) - lymphedema (L);
   Activity-oriented proprioceptive antiedema therapy (TAPA in Spanish);
   Health-related quality of life (HRQOL); Complex decongestive therapy
   (CDT)
ID SURGERY
AB BackgroundBreast cancer (BC) is a major public health issue. More than one out of five women treated for breast cancer will develop lymphedema in an upper extremity. Current evidence advocates transdisciplinary oncological rehabilitation. Therefore, research in this area is necessary since limited consensus having been reached with regard to the basic essential components of this rehabilitation.Consensus has, however, been reached on the use of decongestive lymphedema therapy (DLT), but due to a lack of tests, the necessary dosages are unknown and its level is moderately strong.This study attempts to verify both the efficacy of activity-oriented proprioceptive antiedema therapy (TAPA), as compared to conventional treatments such as DLT or Complex Physical Therapy (CPT), as well as its efficiency in terms of cost-effectiveness, for patients affected by breast cancer-related arm lymphedema.MethodsControlled, randomized clinical trial with dual stratification, two parallel arms, longitudinal and single blind. 64 women with breast cancer-related arm lymphedema will take part in the study. The experimental group intervention will be the same for stage I and II, and will consist of neuro-dynamic exercises oriented to the activity, proprioceptive neuromuscular facilitation activities and proprioceptive anti-edema bandaging. The control group intervention, depending on the stage, will consist of preventive measures, skin care and exercise-prescribed training in the lymphedema workshop as well as compression garments (Stage I) or conservative Complex Decongestive Therapy treatment (skin care, multi-layer bandaging, manual lymphatic drainage and massage therapy) (Stage II).ResultsSociodemographic and clinical variables will be collected for the measurement of edema volume and ADL performance. Statistical analysis will be performed on intent to treat.DiscussionIt has been recommended that patient training be added to DLT, as well as a re-designing of patient lifestyles and the promotion of health-related aspects. In addition, clinical trials should be undertaken to assess neural mobilization techniques and proprioceptive neuromuscular facilitation should be included in the therapy. Cohesive bandaging will also be performed as an early form of pressotherapy. The proposed study combines all of these aspects in order to increased comfort and promote the participation of individuals with lymphedema in everyday situations.LimitationsThe authors have proposed the assessment of the experimental treatment for stages I and II. One possible limitation is the lack of awareness of whether or not this treatment would be effective for other stages as well as the concern for proper hand cleansing during use of bandages, given the current COVID-19 pandemic situation.Trial registrationThis trial was registered in ClinicalTrials.gov (NCT03762044). Date of registration: 23 November 2018. Prospectively Registered.
C1 [Nieves Munoz-Alcaraz, Maria; Angel Perula-de-Torres, Luis; Serrano-Merino, Jesus] Andalusia Hlth Serv, Cordoba & Guadalquivir Hlth Dist, Cordoba, Spain.
   [Nieves Munoz-Alcaraz, Maria; Angel Perula-de-Torres, Luis; Serrano-Merino, Jesus] Univ Cordoba, Andalusia Hlth Serv, Maimonides Inst Res Cordoba IMIBIC, Cordoba, Spain.
   [Jose Jimenez-Vilchez, Antonio] Valle Pedroches Hosp, Pozoblanco, Spain.
   [Victoria Olmo-Carmona, Maria; Teresa Munoz-Garcia, Maria] Reina Sofia Hosp, Cordoba, Spain.
   [Bartolome-Moreno, Cruz; Olivan-Blazquez, Barbara; Magallon-Botaya, Rosa] Inst Hlth Res Aragon IIS Aragon, Zaragoza, Spain.
   [Bartolome-Moreno, Cruz] Aragones Heath Serv, Zaragoza, Spain.
   [Olivan-Blazquez, Barbara; Magallon-Botaya, Rosa] Univ Zaragoza, Zaragoza, Spain.
RP Olivan-Blazquez, B (corresponding author), Inst Hlth Res Aragon IIS Aragon, Zaragoza, Spain.; Olivan-Blazquez, B (corresponding author), Univ Zaragoza, Zaragoza, Spain.
EM bolivan@unizar.es
OI Olivan Blazquez, Barbara/0000-0001-6565-9699
FU Primary Health Care Research Group of Aragon - Government of Aragon
   (Spain) [GAIAP-B21-17R]; Feder Funds "Another way to make Europe";
   Professional College of Occupational Therapists of Extremadura (Spain)
FX This project has been granted by Professional College of Occupational
   Therapists of Extremadura (Spain). This project has been also awarded a
   financial contribution by the Primary Health Care Research Group of
   Aragon (GAIAP-B21-17R group), recognized and funded by the Government of
   Aragon (Spain) and by Feder Funds "Another way to make Europe". The
   funding source has no direct roles in the design of this protocol, data
   collection, analysis and interpretation of the data.
CR Alba Conejo E, 2011, JUNTA ANDALUCIA
   Alonso alvarez B, 2016, ADAPTACION TRANSCULT
   [Anonymous], 2013, LYMPHOLOGY, V46, P1
   Arias-Cuadrado A, 2010, REHAB, V44, P29, DOI DOI 10.1016/J.RH.2010.06.007
   Asociacion Espanola Contra el Cancer (Spanish Association Againts Cancer), TOD QUE NEC SAB
   Baxter MF, 2017, AM J OCCUP THER, V71, DOI [10.5014/ajot.2017.713001, 10.5014/ajot.2011.713001]
   Beaton DE, 2005, J BONE JOINT SURG AM, V87A, P1038, DOI 10.2106/JBJS.D.02060
   Boudier-Reveret M, 2017, MUSCULOSKEL SCI PRAC, V31, P45, DOI 10.1016/j.msksp.2017.07.004
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Cameselle Teijeiro JF, 2000, ATEN PRIM, V26, P419
   Cuello Villaverde E, 2003, REHABILITACION, V37, P22, DOI [10.1016/S0048-7120(03)73329-5, DOI 10.1016/S0048-7120(03)73329-5]
   Diaz ID, 2017, J CHIROPR MED, V16, P31, DOI 10.1016/j.jcm.2016.09.001
   de Miguel Benadiba C, 2016, REV SENOL PATOL MAMA, V29, P157, DOI [10.1016/j.senol.2016.06.003, DOI 10.1016/J.SEN0L.2016.06.003]
   Esteban-Vico Juan Ramón, 2016, Cir. plást. iberolatinoam., V42, P347
   Forner Cordero I, 2003, REHABILITACION, V37, P141, DOI [10.1016/S0048-7120(03)73357-X, DOI 10.1016/S0048-7120(03)73357-X]
   Franks PJ, 2013, INT WOUND J, V10, P203, DOI 10.1111/j.1742-481X.2012.00958.x
   Gonzalez Viejo MA, 2001, REHABILITACION, V35, P68, DOI [10.1016/S0048-7120(01)73143-X, DOI 10.1016/S0048-7120(01)73143-X]
   Ha KJ, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00959
   Ha KJ, 2014, MED SCI SPORT EXER, V46, P368, DOI 10.1249/01.mss.0000494278.59620.af
   Herdman M, 2001, Aten Primaria, V28, P425
   Hwang WT, 2015, J PHYS THER SCI, V27, P3341, DOI 10.1589/jpts.27.3341
   Jeffs Eunice, 2018, JBI Database System Rev Implement Rep, V16, P453, DOI 10.11124/JBISRIR-2016-003185
   Johnson KC, 2014, LYMPHAT RES BIOL, V12, P216, DOI 10.1089/lrb.2014.0019
   Karki A, 2005, J REHABIL MED, V37, P180, DOI 10.1080/16501970410024181
   Kisely S, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004408.pub2
   Kizil R, 2018, LYMPHAT RES BIOL, V16, P263, DOI 10.1089/lrb.2017.0018
   Lasinski BB, 2012, PM&R, V4, P580, DOI 10.1016/j.pmrj.2012.05.003
   Loh SY, 2015, BREAST CANCER-TARGET, V7, DOI 10.2147/BCTT.S47012
   Longhurst E, 2018, SUPPORT CARE CANCER, V26, P2625, DOI 10.1007/s00520-018-4093-5
   Martin ML, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-94
   Lpez-Martn M, 2010, REHABILITACION S1, V44, P49, DOI [10.1016/j.rh.2010.06.005, DOI 10.1016/J.RH.2010.06.005]
   Luctkar-Flude M, 2018, CURR ONCOL, V25, P196, DOI 10.3747/co.25.3826
   Maria Eugenia Bravo M, 2015, REV MED CLIN CONDES, V24, P578, DOI [10.1016/S0716-8640(13)70198-6, DOI 10.1016/S0716-8640(13)70198-6]
   Martin ML, 2011, REHABILITACION, V45, P127, DOI DOI 10.1016/J.RH.2011.03.008
   Martinez Jaimez P, 2017, ADAPTACION ESPANOLA
   Moffatt CJ, 2012, BRIT J DERMATOL, V166, P624, DOI 10.1111/j.1365-2133.2011.10731.x
   Morgan P, 2006, BEST PRACTICE MANAGE
   Navarro-Brazalez B, 2014, FISIOTERAPIA, V36, P49
   Puigdellivol Serafi C, 2017, GUIA ORIENTACION DIA
   Roman Lizano CR., 2018, DISENO PROGRAMA LINF
   Romero Culleres G, 2004, REHABILITACION MADR, V38, P72, DOI 10.1016/S0048-7120(04)73431-3
   Servicio Andaluz de Salud, 2003, REH FIS AT PRIM GUIA
   Servicio de Medicina Fisica y Rehabilitacion, 2008, MEDICINA B AIRES, P72
   Silver Julie K, 2011, Am J Phys Med Rehabil, V90, pS5, DOI 10.1097/PHM.0b013e31820be4ae
   Smoot B, 2014, J HAND THER, V27, P4, DOI 10.1016/j.jht.2013.08.021
   Stout NL, 2016, ARCH PHYS MED REHAB, V97, P2006, DOI 10.1016/j.apmr.2016.05.002
   Tambour M, 2018, BRIT J CANCER, V119, P1215, DOI 10.1038/s41416-018-0306-4
   Hervas MT, 2006, MED CLIN-BARCELONA, V127, P441, DOI 10.1157/13093053
   Zarate V, 2010, REV MED CHILE, V138, P93, DOI 10.4067/S0034-98872010001000007
NR 49
TC 0
Z9 0
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD NOV 9
PY 2020
VL 20
IS 1
AR 1074
DI 10.1186/s12885-020-07558-x
PG 11
WC Oncology
SC Oncology
GA OT2TL
UT WOS:000590704100006
PM 33167921
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Self, WH
   Semler, MW
   Leither, LM
   Casey, JD
   Angus, DC
   Brower, RG
   Chang, SY
   Collins, SP
   Eppensteiner, JC
   Filbin, MR
   Files, DC
   Gibbs, KW
   Ginde, AA
   Gong, MN
   Harrell, FE
   Hayden, DL
   Hough, CL
   Johnson, NJ
   Khan, A
   Lindsell, CJ
   Matthay, MA
   Moss, M
   Park, PK
   Rice, TW
   Robinson, BRH
   Schoenfeld, DA
   Shapiro, NI
   Steingrub, JS
   Ulysse, CA
   Weissman, A
   Yealy, DM
   Thompson, BT
   Brown, SM
AF Self, Wesley H.
   Semler, Matthew W.
   Leither, Lindsay M.
   Casey, Jonathan D.
   Angus, Derek C.
   Brower, Roy G.
   Chang, Steven Y.
   Collins, Sean P.
   Eppensteiner, John C.
   Filbin, Michael R.
   Files, D. Clark
   Gibbs, Kevin W.
   Ginde, Adit A.
   Gong, Michelle N.
   Harrell, Frank E.
   Hayden, Douglas L.
   Hough, Catherine L.
   Johnson, Nicholas J.
   Khan, Akram
   Lindsell, Christopher J.
   Matthay, Michael A.
   Moss, Marc
   Park, Pauline K.
   Rice, Todd W.
   Robinson, Bryce R. H.
   Schoenfeld, David A.
   Shapiro, Nathan, I
   Steingrub, Jay S.
   Ulysse, Christine A.
   Weissman, Alexandra
   Yealy, Donald M.
   Thompson, B. Taylor
   Brown, Samuel M.
CA Natl Heart Lung Blood Inst PETAL C
TI Effect of Hydroxychloroquine on Clinical Status at 14 Days in
   Hospitalized Patients With COVID-19 A Randomized Clinical Trial
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID CHLOROQUINE
AB Importance Data on the efficacy of hydroxychloroquine for the treatment of coronavirus disease 2019 (COVID-19) are needed. Objective To determine whether hydroxychloroquine is an efficacious treatment for adults hospitalized with COVID-19. Design, Setting, and Participants This was a multicenter, blinded, placebo-controlled randomized trial conducted at 34 hospitals in the US. Adults hospitalized with respiratory symptoms from severe acute respiratory syndrome coronavirus 2 infection were enrolled between April 2 and June 19, 2020, with the last outcome assessment on July 17, 2020. The planned sample size was 510 patients, with interim analyses planned after every 102 patients were enrolled. The trial was stopped at the fourth interim analysis for futility with a sample size of 479 patients. Interventions Patients were randomly assigned to hydroxychloroquine (400 mg twice daily for 2 doses, then 200 mg twice daily for 8 doses) (n = 242) or placebo (n = 237). Main Outcomes and Measures The primary outcome was clinical status 14 days after randomization as assessed with a 7-category ordinal scale ranging from 1 (death) to 7 (discharged from the hospital and able to perform normal activities). The primary outcome was analyzed with a multivariable proportional odds model, with an adjusted odds ratio (aOR) greater than 1.0 indicating more favorable outcomes with hydroxychloroquine than placebo. The trial included 12 secondary outcomes, including 28-day mortality. Results Among 479 patients who were randomized (median age, 57 years; 44.3% female; 37.2% Hispanic/Latinx; 23.4% Black; 20.1% in the intensive care unit; 46.8% receiving supplemental oxygen without positive pressure; 11.5% receiving noninvasive ventilation or nasal high-flow oxygen; and 6.7% receiving invasive mechanical ventilation or extracorporeal membrane oxygenation), 433 (90.4%) completed the primary outcome assessment at 14 days and the remainder had clinical status imputed. The median duration of symptoms prior to randomization was 5 days (interquartile range [IQR], 3 to 7 days). Clinical status on the ordinal outcome scale at 14 days did not significantly differ between the hydroxychloroquine and placebo groups (median [IQR] score, 6 [4-7] vs 6 [4-7]; aOR, 1.02 [95% CI, 0.73 to 1.42]). None of the 12 secondary outcomes were significantly different between groups. At 28 days after randomization, 25 of 241 patients (10.4%) in the hydroxychloroquine group and 25 of 236 (10.6%) in the placebo group had died (absolute difference, -0.2% [95% CI, -5.7% to 5.3%]; aOR, 1.07 [95% CI, 0.54 to 2.09]). Conclusions and Relevance Among adults hospitalized with respiratory illness from COVID-19, treatment with hydroxychloroquine, compared with placebo, did not significantly improve clinical status at day 14. These findings do not support the use of hydroxychloroquine for treatment of COVID-19 among hospitalized adults.
C1 [Self, Wesley H.; Collins, Sean P.] Vanderbilt Univ, Med Ctr, Dept Emergency Med, 1313 21st Ave S,Oxford House 312, Nashville, TN 37232 USA.
   [Semler, Matthew W.; Casey, Jonathan D.; Rice, Todd W.] Vanderbilt Univ, Med Ctr, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA.
   [Leither, Lindsay M.; Brown, Samuel M.] Intermt Med Ctr, Div Pulm & Crit Care Med, Murray, KY USA.
   [Leither, Lindsay M.; Brown, Samuel M.] Univ Utah, Salt Lake City, UT USA.
   [Angus, Derek C.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA.
   [Brower, Roy G.] Johns Hopkins Univ, Sch Med, Dept Med, Pulm & Crit Care Med, Baltimore, MD 21205 USA.
   [Chang, Steven Y.] Univ Calif Los Angeles, David Geffen Sch Med, Ronald Reagan UCLA Med Ctr, Div Pulm & Crit Care Med,Dept Med, Los Angeles, CA 90095 USA.
   [Eppensteiner, John C.] Duke Univ, Dept Surg, Durham, NC USA.
   [Filbin, Michael R.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
   [Files, D. Clark; Gibbs, Kevin W.] Wake Forest Sch Med, Dept Med, Sect Pulm Crit Care Allergy & Immunol Dis, Winston Salem, NC 27101 USA.
   [Ginde, Adit A.] Univ Colorado, Dept Emergency Med, Sch Med, Aurora, CO USA.
   [Gong, Michelle N.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Div Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
   [Harrell, Frank E.; Lindsell, Christopher J.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA.
   [Hayden, Douglas L.; Schoenfeld, David A.; Ulysse, Christine A.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
   [Hough, Catherine L.; Khan, Akram] Oregon Hlth & Sci Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Portland, OR 97201 USA.
   [Johnson, Nicholas J.] Univ Washington, Dept Emergency Med, Seattle, WA 98195 USA.
   [Johnson, Nicholas J.] Univ Washington, Div Pulm Crit Care & Sleep Med, Seattle, WA 98195 USA.
   [Matthay, Michael A.] Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA.
   [Matthay, Michael A.] Univ Calif San Francisco, Cardiovasc Res Inst, Dept Anesthesia, San Francisco, CA USA.
   [Moss, Marc] Univ Colorado, Sch Med, Div Pulm Sci & Crit Care Med, Aurora, CO USA.
   [Park, Pauline K.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA.
   [Robinson, Bryce R. H.] Univ Washington, Dept Surg, Seattle, WA 98195 USA.
   [Shapiro, Nathan, I] Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA.
   [Shapiro, Nathan, I] Harvard Med Sch, Boston, MA 02115 USA.
   [Steingrub, Jay S.] Univ Massachusetts, Med Sch Baystate, Dept Med, Springfield, MA USA.
   [Weissman, Alexandra; Yealy, Donald M.] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA USA.
   [Thompson, B. Taylor] Massachusetts Gen Hosp, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02114 USA.
RP Self, WH (corresponding author), Vanderbilt Univ, Med Ctr, Dept Emergency Med, 1313 21st Ave S,Oxford House 312, Nashville, TN 37232 USA.
EM wesley.self@vumc.org
RI Leither, Lindsay/ABG-4892-2020
OI , Neil/0000-0002-0922-8824
FU NHLBIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [3U01HL123009-06S1, U01HL123009, U01HL122998,
   U01HL123018, U01HL123023, U01HL123008, U01HL123031, U01HL123004,
   U01HL123027, U01HL123010, U01HL123033, U01HL122989, U01HL123022,
   U01HL123020]; NCATSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [5UL1TR002243]; Harvard
   Catalyst/Harvard Clinical and Translational Science Center (NCATS, NIH)
   [UL1TR001102, UL1TR002541-01]
FX This study was supported by grants from the NHLBI (3U01HL123009-06S1,
   U01HL123009, U01HL122998, U01HL123018, U01HL123023, U01HL123008,
   U01HL123031, U01HL123004, U01HL123027, U01HL123010, U01HL123033,
   U01HL122989, U01HL123022, and U01HL123020). The REDCap data tools used
   for this study were supported by a grant from NCATS (5UL1TR002243). The
   work at Massachusetts General Hospital was supported in part by the
   Harvard Catalyst/Harvard Clinical and Translational Science Center
   (NCATS, NIH awards UL1TR001102 and UL1TR002541-01). Sandoz, a Novartis
   division, supplied the hydroxychloroquine and placebo used in this
   trial.
CR [Anonymous], 2019, COR DIS 2019 COVID 1
   Azoulay E, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03194-w
   Beigel JH, 2020, NEW ENGL J MED, V383, P994, DOI 10.1056/NEJMc2022236
   Bhimraj Adarsh, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa478
   Casey JD, 2020, ANN AM THORAC SOC, V17, P1144, DOI 10.1513/AnnalsATS.202005-478SD
   Cavalcanti AB, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2019014, DOI 10.1056/NEJM0A2019014]
   Derwand R, 2020, MED HYPOTHESES, V142, DOI 10.1016/j.mehy.2020.109815
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   Food and Drug Administration (FDA), LETT REV EUA CHLOR P
   Food and Drug Administration (FDA), REQ EM US AUTH US CH
   Food and Drug Administration (FDA), FACT SHEET HEALTHC P
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x
   Hoffmann M, 2020, NATURE, V585, P588, DOI 10.1038/s41586-020-2575-3
   Horby P, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2022926, DOI 10.1056/NEJM0A2022926]
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Maisonnasse P, 2020, NATURE, V585, P584, DOI 10.1038/s41586-020-2558-4
   Massachusetts General Hospital, MASS GEN HOSP COVID
   Medicines and Healthcare Products Regulatory Agency, MHRA SUSP RECR COVID
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   RECOVERY Investigators, 2020, NO CLIN BEN US HYDR
   Roden DM, 2020, CIRCULATION, V141, pE906, DOI 10.1161/CIRCULATIONAHA.120.047521
   Rubin EJ, 2020, NEW ENGL J MED, V382, P2461, DOI 10.1056/NEJMe2015903
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349
   Vanderbilt University Medical Center, CLIN REC TREATM COVI
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang R, 2007, NEW ENGL J MED, V357, P2189, DOI 10.1056/NEJMsr077003
   WILLIAMS A, 1990, HEALTH POLICY, V16, P199
   World Health Organization, WHO COR DIS COVID 19
   World Health Organization, WHO R D BLUEPR NOV C
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yehya N, 2019, AM J RESP CRIT CARE, V200, P828, DOI 10.1164/rccm.201810-2050CP
   Zhao M, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105982
NR 36
TC 1
Z9 1
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD DEC 1
PY 2020
VL 324
IS 21
BP 2165
EP 2176
DI 10.1001/jama.2020.22240
EA NOV 2020
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA PA4NB
UT WOS:000592279600002
PM 33165621
OA Bronze
DA 2021-01-01
ER

PT J
AU Fadaka, AO
   Aruleba, RT
   Sibuyi, NRS
   Klein, A
   Madiehe, AM
   Meyer, M
AF Fadaka, Adewale Oluwaseun
   Aruleba, Raphael Taiwo
   Sibuyi, Nicole Remaliah Samantha
   Klein, Ashwil
   Madiehe, Abram Madimabe
   Meyer, Mervin
TI Inhibitory potential of repurposed drugs against the SARS-CoV-2 main
   protease: a computational-aided approach
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Protease inhibitor; SARS-CoV-2; COVID-19; lamivudine; lopinavir;
   docking; Mpro
ID MOLECULAR DOCKING; PRADIMICIN-A; ACCURATE PREDICTION;
   LOPINAVIR/RITONAVIR; TRANSMISSION; DYNAMICS; SARS
AB The exponential increase in cases and mortality of coronavirus disease (COVID-19) has called for a need to develop drugs to treat this infection. Using in silico and molecular docking approaches, this study investigated the inhibitory effects of Pradimicin A, Lamivudine, Plerixafor and Lopinavir against SARS-CoV-2 M-pro. ADME/Tox of the ligands, pharmacophore hypothesis of the co-crystalized ligand and the receptor, and docking studies were carried out on different modules of Schrodinger (2019-4) Maestro v12.2. Among the ligands subjected to ADME/Tox by QikProp, Lamivudine demonstrated drug-like physico-chemical properties. A total of five pharmacophore binding sites (A3, A4, R9, R10, and R11) were predicted from the co-crystalized ligand and the binding cavity of the SARS-CoV-2 M-pro. The docking result showed that Lopinavir and Lamivudine bind with a higher affinity and lower free energy than the standard ligand having a glide score of -9.2 kcal/mol and -5.3 kcal/mol, respectively. Plerixafor and Pradimicin A have a glide score of -3.7 kcal/mol and -2.4 kcal/mol, respectively, which is lower than the co-crystallized ligand with a glide score of -5.3 kcal/mol. Molecular dynamics confirmed that the ligands maintained their interaction with the protein with lower RMSD fluctuations over the trajectory period of 100 nsecs and that GLU166 residue is pivotal for binding. On the whole, present study specifies the repurposing aptitude of these molecules as inhibitors of SARS-CoV-2 M-pro with higher binding scores and forms energetically stable complexes with M-pro.
   Communicated by Ramaswamy H. Sarma
C1 [Fadaka, Adewale Oluwaseun; Sibuyi, Nicole Remaliah Samantha; Madiehe, Abram Madimabe; Meyer, Mervin] Univ Western Cape, Dept Biotechnol, Dept Sci & Innovat, Fac Nat Sci,Mintek Nanotechnol Innovat Ctr, Bellville, South Africa.
   [Aruleba, Raphael Taiwo] Univ Cape Town, Dept Mol & Cell Biol, Cape Town, South Africa.
   [Klein, Ashwil] Univ Western Cape, Dept Biotechnol, Fac Nat Sci, Bellville, South Africa.
   [Madiehe, Abram Madimabe] Univ Western Cape, Dept Biotechnol, Nanobiotechnol Res Grp, Fac Nat Sci, Bellville, South Africa.
RP Fadaka, AO; Madiehe, AM; Meyer, M (corresponding author), Univ Western Cape, Dept Biotechnol, Dept Sci & Innovat, Fac Nat Sci,Mintek Nanotechnol Innovat Ctr, Bellville, South Africa.; Aruleba, RT (corresponding author), Univ Cape Town, Dept Mol & Cell Biol, Cape Town, South Africa.; Madiehe, AM (corresponding author), Univ Western Cape, Dept Biotechnol, Nanobiotechnol Res Grp, Fac Nat Sci, Bellville, South Africa.
EM afadaka@uwc.ac.za; arlrap@muct.ac.za; amadiehe@uwc.ac.za;
   memeyer@uwc.ac.za
RI ; ADEWALE, FADAKA/O-8760-2017
OI MADIEHE, ABRAM/0000-0002-3935-467X; Meyer, Mervin/0000-0002-8296-4860;
   ADEWALE, FADAKA/0000-0002-3952-2098
CR Abdullahi M, 2017, BIOTECHNOL LETT, V39, P1843, DOI 10.1007/s10529-017-2432-0
   Al-Shabib NA, 2018, J MOL LIQ, V269, P511, DOI 10.1016/j.molliq.2018.07.122
   AlAjmi MF, 2018, INT J BIOL MACROMOL, V116, P173, DOI 10.1016/j.ijbiomac.2018.05.023
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   [Anonymous], 2018, SCHROD REL 2018 1 MA
   Aruleba R. T., 2018, IDENTIFICATION STRUC
   Aruleba RT, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020386
   Balzarini J, 2007, J VIROL, V81, P362, DOI 10.1128/JVI.01404-06
   Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Fadaka AO, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194899
   Fadaka AO, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1819880
   Fadaka AO, 2020, CANCERS, V12, DOI 10.3390/cancers12030662
   Fadaka AO, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205190
   Greenwood JR, 2010, J COMPUT AID MOL DES, V24, P591, DOI 10.1007/s10822-010-9349-1
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   HOOVER WG, 1985, PHYS REV A, V31, P1695, DOI 10.1103/PhysRevA.31.1695
   Huang N, 2006, PHYS CHEM CHEM PHYS, V8, P5166, DOI 10.1039/b608269f
   Huynh J, 2012, J VIROL, V86, P12816, DOI 10.1128/JVI.00906-12
   Jani KS, 2012, BIOINFORM BIOL INSIG, V6, P23, DOI 10.4137/BBI.S8971
   Jarvis B, 1999, DRUGS, V58, P101, DOI 10.2165/00003495-199958010-00015
   Jin M, 2011, P NATL ACAD SCI USA, V108, P5819, DOI 10.1073/pnas.1017033108
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   Keating GM, 2011, DRUGS, V71, P1623, DOI 10.2165/11206040-000000000-00000
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI [10.20944/preprints202003.0226.v1, DOI 10.20944/PREPRINTS202003.0226.V1, 10.20944/preprints202003.0226.v1.]
   KIM S, 2016, NUCL ACIDS RES, V44, DOI DOI https://doi.org/10.1093/nar/gkv951
   Kumar V, 2020, SAR QSAR ENVIRON RES, V31, P511, DOI 10.1080/1062936X.2020.1776388
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Ligprep M., 2011, QIKPROP
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Lyne PD, 2006, J MED CHEM, V49, P4805, DOI 10.1021/jm060522a
   Mandlik Vineetha, 2016, F1000Res, V5, P1610
   Mehra M, 2020, LANCET
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Negi B, 2014, CHEMMEDCHEM, V9, P2439, DOI 10.1002/cmdc.201402240
   Ojo OA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1819425
   Omar S., 2020, SILICO IDENTIFICATIO
   Priya AS, 2018, J MOL STRUCT, V1160, P1, DOI 10.1016/j.molstruc.2018.01.054
   Release S., 2017, 2 LIGPREP SCHRODINGE
   Repasky Matthew P, 2007, Curr Protoc Bioinformatics, VChapter 8, DOI 10.1002/0471250953.bi0812s18
   Salam NK, 2009, J CHEM INF MODEL, V49, P2356, DOI 10.1021/ci900212v
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   TANABETOCHIKURA A, 1990, VIROLOGY, V176, P467, DOI 10.1016/0042-6822(90)90016-K
   van der Meer FJUM, 2007, J ANTIMICROB CHEMOTH, V60, P741, DOI 10.1093/jac/dkm301
   Veeramachaneni GK, 2015, DRUG DES DEV THER, V9, P4397, DOI 10.2147/DDDT.S84052
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Ye XT, 2020, EUR REV MED PHARMACO, V24, P3390, DOI 10.26355/eurrev_202003_20706
   Ye ZW, 2020, INT J BIOL SCI, V16, P1686, DOI 10.7150/ijbs.45472
   Yu ZY, 2006, J COMPUT CHEM, V27, P72, DOI 10.1002/jcc.20307
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhong NS, 2004, PHILOS T R SOC B, V359, P1115, DOI 10.1098/rstb.2004.1491
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
NR 60
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1847197
EA NOV 2020
PG 12
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OS0JL
UT WOS:000589850100001
PM 33200673
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Basak, P
   Sachdeva, N
   Dayal, D
AF Basak, Preetam
   Sachdeva, Naresh
   Dayal, Devi
TI Can BCG vaccine protect against COVID-19 via trained immunity and
   tolerogenesis?
SO BIOESSAYS
LA English
DT Article; Early Access
DE BCG; COVID&#8208; 19; epigenetic reprogramming; innate immune cells;
   regulatory T cells; SARS&#8208; CoV&#8208; 2; trained immunity
ID BACILLUS-CALMETTE-GUERIN; HUMAN DENDRITIC CELLS; REGULATORY T-CELLS;
   MYCOBACTERIUM-BOVIS; TUBERCULOSIS; INFECTION; CYTOKINE; INDUCTION;
   INTERPLAY; LEPROSY
AB As the number of infections and mortalities from the SARS-CoV-2 pandemic continues to rise, the development of an effective therapy against COVID-19 becomes ever more urgent. A few reports showing a positive correlation between BCG vaccination and reduced COVID-19 mortality have ushered in some hope. BCG has been suggested to confer a broad level of nonspecific protection against several pathogens, mainly via eliciting "trained immunity" in innate immune cells. Secondly, BCG has also been proven to provide benefits in autoimmune diseases by inducing tolerogenicity. Being an acute inflammatory disease, COVID-19 requires a therapy that induces early priming of anti-viral immune responses and regulates aberrant hyperactivity of innate-immune cells. Here, we hypothesize that BCG can offer reliable spatiotemporal protection from COVID-19 by triggering trained immunity and tolerogenesis, through multiple cellular pathways. We propose further research on BCG-mediated immunoprotection, especially in vulnerable individuals, as a strategy to halt the progress of the SARS-CoV-2 pandemic. Also see the video abstract here https://youtu.be/P2D2RXfq6Vg.
C1 [Basak, Preetam; Sachdeva, Naresh] Post Grad Inst Med Educ & Res, Dept Endocrinol, Chandigarh, India.
   [Dayal, Devi] Post Grad Inst Med Educ & Res, Dept Pediat, Chandigarh, India.
RP Sachdeva, N (corresponding author), Post Grad Inst Med Educ & Res, Dept Endocrinol, Chandigarh, India.; Dayal, D (corresponding author), Post Grad Inst Med Educ & Res, Dept Pediat, Chandigarh, India.
EM naresh_pgi@hotmail.com; drdevidayal@gmail.com
OI Sachdeva, Naresh/0000-0001-6289-4749
CR Aaby P, 2014, NAT IMMUNOL, V15, P895, DOI 10.1038/ni.2961
   Agarwal A., 2020, CONVALESCENT PLASMA, DOI [10.1101/2020.09.03.20187252, DOI 10.1101/2020.09.03.20187252]
   Akkoc T, 2010, PEDIAT ALLERG IMM-UK, V21, P1059, DOI 10.1111/j.1399-3038.2010.01051.x
   Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010
   Arts RJW, 2016, CELL REP, V17, P2562, DOI 10.1016/j.celrep.2016.11.011
   Berg M. K., 2020, MANDATED BACILLUS CA, DOI [10.1101/2020.04.05.20054163, DOI 10.1101/2020.04.05.20054163]
   BISTONI F, 1986, INFECT IMMUN, V51, P668, DOI 10.1128/IAI.51.2.668-674.1986
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Boer MC, 2015, CLIN VACCINE IMMUNOL, V22, P778, DOI 10.1128/CVI.00162-15
   Boer MC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094192
   Boer MC, 2013, EUR J IMMUNOL, V43, P1925, DOI 10.1002/eji.201243286
   Calmette A., 1922, INFECT BACILLAIRE TU
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen TT, 2016, J INFECT DIS, V214, P300, DOI 10.1093/infdis/jiw141
   Chen X, 2007, J IMMUNOL, V179, P154, DOI 10.4049/jimmunol.179.1.154
   Chen X, 2013, J IMMUNOL, V190, P1076, DOI 10.4049/jimmunol.1202659
   Cirovic B, 2020, CELL HOST MICROBE, V28, P322, DOI 10.1016/j.chom.2020.05.014
   Covian C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00970
   Covian C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02806
   Dayal D, 2020, CONNECTING BCG VACCI, DOI [10.1101/2020.04.07.20053272., DOI 10.1101/2020.04.07.20053272, 10.1101/2020.04.07.20053272]
   De Rosa V, 2015, NAT IMMUNOL, V16, P1174, DOI 10.1038/ni.3269
   Escobar LE, 2020, P NATL ACAD SCI USA, V117, P17720, DOI 10.1073/pnas.2008410117
   Etchegaray JP, 2016, MOL CELL, V62, P695, DOI 10.1016/j.molcel.2016.05.029
   Faustman D. L., 2018, VALUE BCG TNF AUTOIM
   Gervassi A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107816
   Gharbharan A, 2020, CONVALESCENT PLASMA, DOI [10.1101/2020.07.01.20139857, DOI 10.1101/2020.07.01.20139857, 10.1101/2020.07.01.20139857.]
   Glisic S, 2020, J PROTEOME RES, V19, P4649, DOI 10.1021/acs.jproteome.0c00410
   Hadjadj J., 2020, IMPAIRED TYPE 1 INTE, DOI [10.1101/2020.04.19.20068015, DOI 10.1101/2020.04.19.20068015]
   Hanekom WA, 2005, ANN NY ACAD SCI, V1062, P69, DOI 10.1196/annals.1358.010
   Hegarty PK, 2020, EUR UROL ONCOL, V3, P259, DOI 10.1016/j.euo.2020.04.001
   Heldwein KA, 2003, J LEUKOCYTE BIOL, V74, P277, DOI 10.1189/jlb.0103026
   Holla S, 2016, SCI REP-UK, V6, DOI 10.1038/srep24193
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Joyner Michael J, 2020, medRxiv, DOI 10.1101/2020.08.12.20169359
   Kativhu CL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162148
   Kaufmann E, 2018, CELL, V172, P176, DOI 10.1016/j.cell.2017.12.031
   Kowalewicz-Kulbat M, 2017, EXPERT REV VACCINES, V16, P699, DOI 10.1080/14760584.2017.1333906
   Kuhtreiber WM, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0062-8
   Lagranderie M, 2014, EXPERT REV CLIN IMMU, V10, P741, DOI 10.1586/1744666X.2014.909286
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Lingeswaran M, 2020, INDIAN J CLIN BIOCHE, V35, P260, DOI 10.1007/s12291-020-00897-3
   MACKANESS GB, 1964, J EXP MED, V120, P105, DOI 10.1084/jem.120.1.105
   Mangalmurti N, 2020, IMMUNITY, V53, P19, DOI 10.1016/j.immuni.2020.06.017
   Martino A, 2004, J LEUKOCYTE BIOL, V76, P827, DOI 10.1189/jlb.0703313
   Martino A, 2010, J IMMUNOL, V184, P2038, DOI 10.4049/jimmunol.0903348
   Mason RJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00607-2020
   Mathew D, 2020, SCIENCE, V369, P1209, DOI 10.1126/science.abc8511
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Miller A, 2020, CORRELATION UNIVERSA, DOI [DOI 10.1101/2020.03.24.20042937, 10.1101/2020.03.24.20042937]
   Moliva Juan I, 2017, Front Immunol, V8, P407, DOI 10.3389/fimmu.2017.00407
   Mukherjee S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180143
   Munoz-Fontela C, 2020, NATURE, V586, P509, DOI 10.1038/s41586-020-2787-6
   Murray RA, 2006, J IMMUNOL, V177, P5647, DOI 10.4049/jimmunol.177.8.5647
   Nemes E, 2018, NEW ENGL J MED, V379, P138, DOI [10.1056/NEJMoa1714021, 10.1056/nejmoa1714021]
   Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6
   Netea MG, 2014, SEMIN IMMUNOL, V26, P512, DOI 10.1016/j.smim.2014.09.006
   Netea MG, 2011, CELL HOST MICROBE, V9, P355, DOI 10.1016/j.chom.2011.04.006
   Nguipdop-Djomo P, 2016, LANCET INFECT DIS, V16, P219, DOI 10.1016/S1473-3099(15)00400-4
   Nigou J, 2001, J IMMUNOL, V166, P7477, DOI 10.4049/jimmunol.166.12.7477
   O'Brien TR, 2020, CLIN INFECT DIS, V71, P1410, DOI 10.1093/cid/ciaa453
   O'Neill LAJ, 2016, NAT REV IMMUNOL, V16, P553, DOI 10.1038/nri.2016.70
   OREGE PA, 1993, INT J LEPROSY, V61, P542
   Parameswaran N., 2020, PDF TRIAL CTRI
   Park A, 2020, CELL HOST MICROBE, V27, P870, DOI 10.1016/j.chom.2020.05.008
   Pearce EJ, 2018, NAT REV IMMUNOL, V18, P81, DOI 10.1038/nri.2017.139
   Pierce CA, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abd5487
   Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604
   PONNIGHAUS JM, 1992, LANCET, V339, P636, DOI 10.1016/0140-6736(92)90794-4
   Portaels F, 2002, CLIN DIAGN LAB IMMUN, V9, P1389, DOI 10.1128/CDLI.9.6.1389-1391.2002
   Procaccini C, 2016, IMMUNITY, V44, P406, DOI 10.1016/j.immuni.2016.01.028
   Pullinger EJ, 1936, J HYG-CAMBRIDGE, V36, P456, DOI 10.1017/S0022172400043783
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Quintin J, 2012, CELL HOST MICROBE, V12, P223, DOI 10.1016/j.chom.2012.06.006
   RATZAN KR, 1972, INFECT IMMUN, V5, P499, DOI 10.1128/IAI.5.4.499-504.1972
   Ristori G, 2018, CURR OPIN IMMUNOL, V55, P89, DOI 10.1016/j.coi.2018.09.016
   Salem A, 2013, PEDIATR DERMATOL, V30, P60, DOI 10.1111/j.1525-1470.2012.01848.x
   Schoggins JW, 2011, NATURE, V472, P481, DOI 10.1038/nature09907
   Sebina I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051381
   Sendide K, 2005, J IMMUNOL, V174, P4210, DOI 10.4049/jimmunol.174.7.4210
   Setia MS, 2006, LANCET INFECT DIS, V6, P162, DOI 10.1016/S1473-3099(06)70412-1
   Shaffer Leah, 2020, Nat Med, DOI 10.1038/d41591-020-00019-9
   Sharma A, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2720-9
   Sheridan C, 2020, NAT BIOTECHNOL, V38, P655, DOI 10.1038/d41587-020-00011-1
   Shrock Ellen, 2020, Science, V370, DOI 10.1126/science.abd4250
   Silva CL, 1999, IMMUNOLOGY, V97, P573
   Sinha A., INDIAN J BIOCH BIOPH, V44, P279
   Sinha S., 2020, PDF TRIAL CTRI
   Soares AP, 2008, J IMMUNOL, V180, P3569, DOI 10.4049/jimmunol.180.5.3569
   Soares AP, 2013, J INFECT DIS, V207, P1084, DOI 10.1093/infdis/jis941
   Sorup S, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofv204
   Sorup S, 2014, JAMA-J AM MED ASSOC, V311, P826, DOI 10.1001/jama.2014.470
   Sorup S, 2011, INT J EPIDEMIOL, V40, P955, DOI 10.1093/ije/dyr063
   Stensballe LG, 2005, VACCINE, V23, P1251, DOI 10.1016/j.vaccine.2004.09.006
   Tan L, 2020, SIGNAL TRANSDUCTION, V5, P1, DOI [10.1038/s41392-019-0089-y, DOI 10.1038/S41392-019-0089-Y]
   Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006
   Tsuji S, 2000, INFECT IMMUN, V68, P6883, DOI 10.1128/IAI.68.12.6883-6890.2000
   U.S. National Library of Medicine, RED HLTH CAR WORK AB
   U.S. National Library of Medicine, BCG VACC PROT HEALTH
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   Vekemans J, 2001, EUR J IMMUNOL, V31, P1531, DOI 10.1002/1521-4141(200105)31:5<1531::AID-IMMU1531>3.0.CO;2-1
   Walk J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08659-3
   Wardhana, 2011, Acta Med Indones, V43, P185
   Weir RE, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-9
   Wong CC, 2017, ONCOGENE, V36, P3359, DOI 10.1038/onc.2016.485
   Ye LL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00583
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Zhang XS, 2013, MICROBIOL-SGM, V159, P366, DOI 10.1099/mic.0.058198-0
   Zhao QW, 2020, INT J INFECT DIS, V96, P131, DOI 10.1016/j.ijid.2020.04.086
   Zheng HY, 2020, CELL MOL IMMUNOL, V17, P541, DOI 10.1038/s41423-020-0401-3
   Zhou Z, 2020, CELL HOST MICROBE, V27, P883, DOI 10.1016/j.chom.2020.04.017
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   1969, LANCET, V1, P111, DOI DOI 10.1016/S0140-6736(69)91133-7
NR 112
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0265-9247
EI 1521-1878
J9 BIOESSAYS
JI Bioessays
AR e2000200
DI 10.1002/bies.202000200
EA NOV 2020
PG 14
WC Biochemistry & Molecular Biology; Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics
GA OO9CQ
UT WOS:000587671400001
PM 33169410
OA Bronze
DA 2021-01-01
ER

PT J
AU Nunez-Gil, IJ
   Fernandez-Perez, C
   Estrada, V
   Becerra-Munoz, VM
   El-Battrawy, I
   Uribarri, A
   Fernandez-Rozas, I
   Feltes, G
   Viana-Llamas, MC
   Trabattoni, D
   Lopez-Pais, J
   Pepe, M
   Romero, R
   Castro-Mejia, AF
   Cerrato, E
   Astrua, TC
   D'Ascenzo, F
   Fabregat-Andres, O
   Moreu, J
   Guerra, F
   Signes-Costa, J
   Marin, F
   Buosenso, D
   Bardaji, A
   Raposeiras-Roubin, S
   Elola, J
   Molino, A
   Gomez-Doblas, JJ
   Abumayyaleh, M
   Aparisi, A
   Molina, M
   Guerri, A
   Arroyo-Espliguero, R
   Assanelli, E
   Mapelli, M
   Garcia-Acuna, JM
   Brindicci, G
   Manzone, E
   Ortega-Armas, ME
   Bianco, M
   Trung, CP
   Nunez, MJ
   Castellanos-Lluch, C
   Garcia-Vazquez, E
   Cabello-Clotet, N
   Jamhour-Chelh, K
   Tellez, MJ
   Fernandez-Ortiz, A
   Macaya, C
AF Nunez-Gil, Ivan J.
   Fernandez-Perez, Cristina
   Estrada, Vicente
   Becerra-Munoz, Victor M.
   El-Battrawy, Ibrahim
   Uribarri, Aitor
   Fernandez-Rozas, Inmaculada
   Feltes, Gisela
   Viana-Llamas, Maria C.
   Trabattoni, Daniela
   Lopez-Pais, Javier
   Pepe, Martino
   Romero, Rodolfo
   Castro-Mejia, Alex F.
   Cerrato, Enrico
   Astrua, Thamar Capel
   D'Ascenzo, Fabrizio
   Fabregat-Andres, Oscar
   Moreu, Jose
   Guerra, Federico
   Signes-Costa, Jaime
   Marin, Francisco
   Buosenso, Danilo
   Bardaji, Alfredo
   Raposeiras-Roubin, Sergio
   Elola, Javier
   Molino, Angel
   Gomez-Doblas, Juan J.
   Abumayyaleh, Mohammad
   Aparisi, Alvaro
   Molina, Maria
   Guerri, Asuncion
   Arroyo-Espliguero, Ramon
   Assanelli, Emilio
   Mapelli, Massimo
   Garcia-Acuna, Jose M.
   Brindicci, Gaetano
   Manzone, Edoardo
   Ortega-Armas, Maria E.
   Bianco, Matteo
   Trung, Chinh Pham
   Nunez, Maria Jose
   Castellanos-Lluch, Carmen
   Garcia-Vazquez, Elisa
   Cabello-Clotet, Noemi
   Jamhour-Chelh, Karim
   Tellez, Maria J.
   Fernandez-Ortiz, Antonio
   Macaya, Carlos
CA HOPE COVID-19 Investigators
TI Mortality risk assessment in Spain and Italy, insights of the HOPE
   COVID-19 registry
SO INTERNAL AND EMERGENCY MEDICINE
LA English
DT Article; Early Access
DE COVID-19; Mortality; Score; Registry; Prognosis
AB Recently the coronavirus disease (COVID-19) outbreak has been declared a pandemic. Despite its aggressive extension and significant morbidity and mortality, risk factors are poorly characterized outside China. We designed a registry, HOPE COVID-19 (NCT04334291), assessing data of 1021 patients discharged (dead or alive) after COVID-19, from 23 hospitals in 4 countries, between 8 February and 1 April. The primary end-point was all-cause mortality aiming to produce a mortality risk score calculator. The median age was 68 years (IQR 52-79), and 59.5% were male. Most frequent comorbidities were hypertension (46.8%) and dyslipidemia (35.8%). A relevant heart or lung disease were depicted in 20%. And renal, neurological, or oncological disease, respectively, were detected in nearly 10%. Most common symptoms were fever, cough, and dyspnea at admission. 311 patients died and 710 were discharged alive. In the death-multivariate analysis, raised as most relevant: age, hypertension, obesity, renal insufficiency, any immunosuppressive disease, 02 saturation < 92% and an elevated C reactive protein (AUC = 0.87; Hosmer-Lemeshow test, p > 0.999; bootstrap-optimist: 0.0018). We provide a simple clinical score to estimate probability of death, dividing patients in four grades (I-IV) of increasing probability. Hydroxychloroquine (79.2%) and antivirals (67.6%) were the specific drugs most commonly used. After a propensity score adjustment, the results suggested a slight improvement in mortality rates (adjusted-ORhydroxychloroquine 0.88; 95% CI 0.81-0.91, p = 0.005; adjusted-ORantiviral 0.94; 95% CI 0.87-1.01; p = 0.115). COVID-19 produces important mortality, mostly in patients with comorbidities with respiratory symptoms. Hydroxychloroquine could be associated with survival benefit, but this data need to be confirmed with further trials. Trial Registration: NCT04334291/EUPAS34399.
C1 [Nunez-Gil, Ivan J.; Estrada, Vicente; Molino, Angel; Nunez, Maria Jose; Cabello-Clotet, Noemi; Tellez, Maria J.; Fernandez-Ortiz, Antonio; Macaya, Carlos] Univ Complutense Madrid, Hosp Clin San Carlos, Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, Prof Martin Lagos St, Madrid 28040, Spain.
   [Becerra-Munoz, Victor M.; Gomez-Doblas, Juan J.] Univ Malaga UMA, Ctr Invest Biomed Red Enfermedades Cardiovasc CIB, Unidad Gest Clin Area Corazon, Inst Invest Biomed Malaga IBIMA,Hosp Univ Virgen, Malaga, Spain.
   [El-Battrawy, Ibrahim; Abumayyaleh, Mohammad] Univ Mannheim, Mannheim, Germany.
   [Uribarri, Aitor; Aparisi, Alvaro] Hosp Clin Univ Valladolid, Valladolid, Spain.
   [Fernandez-Rozas, Inmaculada; Molina, Maria] Hosp Severo Ochoa, Leganes, Spain.
   [Feltes, Gisela; Guerri, Asuncion] Hosp Nuestra Senora Amer, Madrid, Spain.
   [Viana-Llamas, Maria C.; Arroyo-Espliguero, Ramon] Hosp Univ Guadalajara, Guadalajara, Spain.
   [Trabattoni, Daniela; Assanelli, Emilio; Mapelli, Massimo] IRCCS, Ctr Cardiol Monzino, Milan, Italy.
   [Fernandez-Perez, Cristina; Lopez-Pais, Javier; Garcia-Acuna, Jose M.] Complejo Hosp Univ Santiago de Compostela, Santiago De Compostela, Spain.
   [Pepe, Martino; Brindicci, Gaetano] Azienda Osped Univ Consorziale Policlin Bari, Bari, Italy.
   [Romero, Rodolfo; Manzone, Edoardo] Hosp Univ Getafe, Madrid, Spain.
   [Castro-Mejia, Alex F.; Ortega-Armas, Maria E.] Hosp Gen Norte Guayaquil IESS Los Ceibos, Guayaquil, Ecuador.
   [Cerrato, Enrico; Bianco, Matteo] San Luigi Gonzaga Univ Hosp, Div Cardiol, Turin, Italy.
   [Astrua, Thamar Capel; Trung, Chinh Pham] Hosp Virgen del Mar, Madrid, Spain.
   [D'Ascenzo, Fabrizio] San Giovanni Battista, Turin, Italy.
   [Fabregat-Andres, Oscar] Hosp IMED, Valencia, Spain.
   [Moreu, Jose] Complejo Hosp Toledo, Toledo, Spain.
   [Guerra, Federico] Osped Riuniti Umberto I Lancisi Salesi, Cardiol & Arrhythmol Clin, Ancona, Italy.
   [Signes-Costa, Jaime; Castellanos-Lluch, Carmen; HOPE COVID-19 Investigators] Univ Valencia, Hosp Clin Univ, Incl, Valencia, Spain.
   [Marin, Francisco; Garcia-Vazquez, Elisa] Hosp Clin Univ Virgen de la Arreixaca, Murcia, Spain.
   [Buosenso, Danilo] Fdn Policlin Univ A Gemelli IRCCS, Dept Woman & Child Hlth & Publ Hlth, Rome, Italy.
   [Bardaji, Alfredo] Univ Hosp Joan XXIII, Tarragona, Spain.
   [Raposeiras-Roubin, Sergio; Jamhour-Chelh, Karim] Univ Hosp Alvaro Cunqueiro, Vigo, Spain.
   [Fernandez-Perez, Cristina; Elola, Javier] Fdn Inst Mejora Asistencia Sanitaria IMAS, Madrid, Spain.
   [Mapelli, Massimo] Univ Milan, Cardiovasc Sect, Dept Clin Sci & Community Hlth, Milan, Italy.
   [Marin, Francisco; Garcia-Vazquez, Elisa] Univ Murcia, IMIB Arreixaca, Murcia, Spain.
   [Cerrato, Enrico] Rivoli Infermi Hosp, Turin, Italy.
RP Nunez-Gil, IJ (corresponding author), Univ Complutense Madrid, Hosp Clin San Carlos, Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, Prof Martin Lagos St, Madrid 28040, Spain.
EM ibnsky@yahoo.es
RI Mapelli, Massimo/AAB-6433-2020; Uribarri, Aitor/G-2393-2017; Assanelli,
   Emilio/ABH-4902-2020
OI Mapelli, Massimo/0000-0001-9985-7407; Uribarri,
   Aitor/0000-0002-6911-7480; Castro-Mejia., Alex
   Fernando/0000-0003-4208-1681
FU FUNDACION INTERHOSPITALARIA PARA LA INVESTIGACION CARDIOVASCULAR, FIC.
   Madrid, Spain
FX Non-conditioned grant (FUNDACION INTERHOSPITALARIA PARA LA INVESTIGACION
   CARDIOVASCULAR, FIC. Madrid, Spain). This nonprofit institution had no
   role in the study design; in the collection, analysis, interpretation of
   data; in the writing of the report; nor in the decision to submit the
   paper for publication.
CR Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Centers for Disease Control and Prevention (CDC), PEOPL HIGH RISK FLU
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Collins GS, 2015, CIRCULATION, V131, P211, DOI 10.1161/CIRCULATIONAHA.114.014508
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Di Cesare M, 2016, LANCET, V387, P1377, DOI 10.1016/S0140-6736(16)30054-X
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Emami A, 2020, ARCH ACAD EMERG MED, V8
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lee SJ, 2011, NAT REV NEPHROL, V7, P718, DOI 10.1038/nrneph.2011.150
   Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9
   Louie JK, 2009, JAMA-J AM MED ASSOC, V302, P1896, DOI 10.1001/jama.2009.1583
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Nie W, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-61
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Oudit GY, 2009, EUR J CLIN INVEST, V39, P618, DOI 10.1111/j.1365-2362.2009.02153.x
   Ritchie AI, 2020, LANCET, V395, P1111, DOI 10.1016/S0140-6736(20)30691-7
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Smits SL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000756
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang TB, 2020, LANCET, V395, pE52, DOI 10.1016/S0140-6736(20)30558-4
   World Health Organization, 2019, WHO STAT REG CLUST P
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Yao XH, 2020, ZHONGHUA BING LI XUE, V49, P411, DOI [DOI 10.3760/CMA.J.CN112151-20200312-00193, 10.3760/cma.j.cn112151-20200312-00193]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 27
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1828-0447
EI 1970-9366
J9 INTERN EMERG MED
JI Intern. Emerg. Med.
DI 10.1007/s11739-020-02543-5
EA NOV 2020
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA OP3PF
UT WOS:000587993300001
PM 33165755
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ezzikouri, S
   Nourlil, J
   Tsukiyama-Kohara, K
   Kohara, M
   El Ossmani, H
   Windisch, MP
   Benjelloun, S
AF Ezzikouri, Sayeh
   Nourlil, Jalal
   Tsukiyama-Kohara, Kyoko
   Kohara, Michinori
   El Ossmani, Hicham
   Windisch, Marc P.
   Benjelloun, Soumaya
TI Nanobodies: an unexplored opportunity to combat COVID-19
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Camelid; heavy-chain antibody; SARS-CoV-2; therapeutic; diagnostic
AB Coronavirus disease 2019 (COVID-19) is a highly contagious disease caused by severe acute respiratory coronavirus 2 (SARS-CoV-2). This virus is capable of human-to-human transmission, and is spreading rapidly round the globe, with markedly high fatality rates. Unfortunately, there are neither vaccines nor specific therapies available to combat it, and the developments of such approaches depend on pursuing multiple avenues in biomedical science. Accordingly, in this paper we highlight one such avenue-nanobodies-for potential utility in therapeutic and diagnostic interventions to combat COVID-19.
   Communicated by Ramaswamy H. Sarma
C1 [Ezzikouri, Sayeh; Benjelloun, Soumaya] Inst Pasteur Maroc, Viral Hepatitis Lab, Virol Unit, Casablanca 20360, Morocco.
   [Nourlil, Jalal] Inst Pasteur Maroc, Med Virol & Lab BSL3, Casablanca, Morocco.
   [Tsukiyama-Kohara, Kyoko] Kagoshima Univ, Transboundary Anim Dis Ctr, Joint Fac Vet Med, Kagoshima, Japan.
   [Kohara, Michinori] Tokyo Metropolitan Inst Med Sci, Dept Microbiol & Cell Biol, Tokyo, Japan.
   [El Ossmani, Hicham] Inst Criminalist Gendarmerie Royale, Rabat, Morocco.
   [Windisch, Marc P.] Inst Pasteur Korea, Discovery Biol Dept, Appl Mol Virol Lab, Gyeonggi Do, South Korea.
RP Ezzikouri, S (corresponding author), Inst Pasteur Maroc, Viral Hepatitis Lab, Virol Unit, Casablanca 20360, Morocco.
EM sayeh.ezzikouri@pasteur.ma
OI Benjelloun, Soumaya/0000-0001-5573-8684
CR De Vlieger D, 2018, ANTIBODIES, V8, DOI 10.3390/antib8010001
   Detalle L, 2016, ANTIMICROB AGENTS CH, V60, P6, DOI 10.1128/AAC.01802-15
   Dorner T, 2017, ANN RHEUM DIS, V76, P575, DOI 10.1136/annrheumdis-2017-eular.3746
   Ezzikouri S, 2020, HUM VACC IMMUNOTHER, DOI 10.1080/21645515.2020.1787068
   HANKE L, 2020, NAT COMMUN, V11, DOI DOI https://doi.org/10.1038/s41467-020-18174-5
   Huang C., 2020, LANCET, V15, P395
   Huo JD, 2020, NAT STRUCT MOL BIOL, V27, P846, DOI 10.1038/s41594-020-0469-6
   Ibanez LI, 2011, J INFECT DIS, V203, P1063, DOI 10.1093/infdis/jiq168
   Jailkhani N, 2019, P NATL ACAD SCI USA, V116, P14181, DOI 10.1073/pnas.1817442116
   Jovcevska I, 2020, BIODRUGS, V34, P11, DOI 10.1007/s40259-019-00392-z
   Kupferschmidt K, 2020, SCIENCE, V367, P1412, DOI 10.1126/science.367.6485.1412
   Mitch L., 2018, SCIENCE
   Raj VS, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aas9667
   Respaud R, 2015, EXPERT OPIN DRUG DEL, V12, P1027, DOI 10.1517/17425247.2015.999039
   Rissiek B, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00344
   Sanaei M, 2020, IMMUNOL INVEST, V49, P875, DOI 10.1080/08820139.2019.1688828
   Sheridan C, 2020, NAT BIOTECHNOL, V38, P515, DOI 10.1038/d41587-020-00010-2
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   World Health Organization, COR DIS COVID 19 WEE
   Wrapp D, 2020, CELL, V181, P1436, DOI 10.1016/j.cell.2020.05.047
   Zhao GY, 2018, J VIROL, V92, DOI 10.1128/JVI.00837-18
   Zhao R, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa523, DOI 10.1093/CID/CIAA523]
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 23
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1845801
EA NOV 2020
PG 3
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OP5WV
UT WOS:000588157700001
PM 33172342
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Sari, C
   Simsek, EC
   Ozdogan, O
AF Sari, Cenk
   Simsek, Ersin Cagri
   Ozdogan, Oner
TI The outcomes of the postulated interaction between SARS-CoV-2 and the
   renin-angiotensin system on the clinician's attitudes toward
   hypertension treatment
SO JOURNAL OF HUMAN HYPERTENSION
LA English
DT Article; Early Access
ID CONVERTING ENZYME-2; RECEPTOR
AB Concern has arisen about the role played in coronavirus disease 2019 (COVID-19) infection by angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs). This study was designed to assess the practice behaviors of physicians toward hypertension treatment with ACE-i or ARBs during the COVID-19 pandemic. A self-administered survey questionnaire consisting of 26 questions about current hypertension treatment with ACE-i/ ARBs was applied to cardiologists, internists, and family physicians in central and western Turkey, between 01 and 19 May 2020. A total of 460 physicians were approached, and 220 (47.8%) participated in the study. Of the total respondents, 78.7% reported that they had not changed their antihypertensive medication prescribing pattern, 8.6% of clinicians had changed ACE-i/ ARBs medicine of patients during the COVID-19 pandemic and 12.7% of them were undecided. The median (+/- interquartile range) score indicating general reliance level of physicians in ACE-i/ARBs therapy was 8 +/- 4 (range, 1-10). In multiple comparison analyses, the general reliance level in ACE-i/ARBs, reliance level when starting a new ACEi/ARBs and changing behavior in heart failure patients were significantly different with regard to the specialties (p:0.02, p:0.009, p:0.005 respectively). Although most of the physicians found the publications about ACE-i/ ARBs during the COVID-19 pandemic untrustworthy, there were variable levels of knowledge and reliance among different physicians and specialty groups. In general, the ACE-i/ ARBs prescribing habits were not affected by safety concerns during the COVID-19 pandemic in Turkey.
C1 [Sari, Cenk; Ozdogan, Oner] Univ Hlth Sci Turkey, Tepecik Educ & Res Hosp, Dept Cardiol, Izmir, Turkey.
   [Simsek, Ersin Cagri] Balikesir State Hosp, Dept Cardiol, Balikesir, Turkey.
RP Sari, C (corresponding author), Univ Hlth Sci Turkey, Tepecik Educ & Res Hosp, Dept Cardiol, Izmir, Turkey.
EM drcenksari@gmail.com
OI sari, Cenk/0000-0003-1115-493X
CR Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Bozkurt B, 2020, J CARD FAIL, V26, P370, DOI 10.1016/j.cardfail.2020.04.013
   Doumas M, 2020, J HUM HYPERTENS, V34, P764, DOI 10.1038/s41371-020-0380-y
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Fernandez-Ruiz I, 2020, NAT REV CARDIOL, V17, P383, DOI 10.1038/s41569-020-0401-0
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Gabrial S, 2020, NEW ENGL J MED, V383, P397, DOI 10.1056/NEJMc2005396
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Gu HJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep19840
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang ML, 2010, CLIN EXP PHARMACOL P, V37, pe1, DOI 10.1111/j.1440-1681.2009.05302.x
   Huang SJ, 2020, HYPERTENS RES, V43, P824, DOI 10.1038/s41440-020-0485-2
   Ishiyama Y, 2004, HYPERTENSION, V43, P970, DOI 10.1161/01.HYP.0000124667.34652.1a
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li XC, 2017, PHARMACOL RES, V125, P21, DOI 10.1016/j.phrs.2017.06.005
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Nadar SK, 2020, J HUM HYPERTENS, V34, P415, DOI 10.1038/s41371-020-0356-y
   Ocaranza MP, 2006, HYPERTENSION, V48, P572, DOI 10.1161/01.HYP.0000237862.94083.45
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Sodhi CP, 2018, AM J PHYSIOL-LUNG C, V314, pL17, DOI 10.1152/ajplung.00498.2016
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zou Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4594
NR 26
TC 0
Z9 0
U1 2
U2 2
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-9240
EI 1476-5527
J9 J HUM HYPERTENS
JI J. Hum. Hypertens.
DI 10.1038/s41371-020-00436-w
EA NOV 2020
PG 9
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA OP3JX
UT WOS:000587979500002
PM 33168943
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU English, W
   Bedwani, NH
   Smith, C
   Doganay, E
   Marsden, M
   Muse, S
   Mak, WK
   Chana, M
   Eves, J
   Shatkar, V
AF English, W.
   Habib Bedwani, N.
   Smith, C.
   Doganay, E.
   Marsden, M.
   Muse, S.
   Mak, W. K.
   Chana, M.
   Eves, J.
   Shatkar, V.
TI Suspected appendicitis and COVID-19, a change in investigation and
   management-a multicentre cohort study
SO LANGENBECKS ARCHIVES OF SURGERY
LA English
DT Article; Early Access
DE COVID-19; Appendicitis; Laparoscopy; RIF pain
ID UNCOMPLICATED ACUTE APPENDICITIS; RANDOMIZED CLINICAL-TRIAL;
   ANTIBIOTIC-THERAPY; APPENDECTOMY
AB Purpose The COVID-19 pandemic has reformed global healthcare delivery. On 25 March 2020, Intercollegiate guidelines were published in the UK to promote safe surgical provision during the COVID-19 outbreak advocating non-operative management or avoidance of laparoscopy when surgery is essential. The effects of this on the investigation and management of appendicitis remain unknown. Methods We performed a multicentre, prospective, observational study from the start of the new guidelines to the 6th of May 2020. We included all patients referred to surgical teams with suspected appendicitis. A recent historical cohort was identified for comparison. The primary outcome was the impact of the COVID-19 pandemic on the use of non-operative management in appendicitis. Secondary outcomes included imaging, negative appendicectomy rate (NAR), length of stay (LOS) and 30-day complications. Results A total of 63/164 (38%) patients compared to 79/191 (41%) were diagnosed with appendicitis before and after the guidelines were introduced (p = 0.589). CT scanning increased (71/164 vs 105/191; p = 0.033) while ultrasound scanning decreased (71/164 vs 62/191; p = 0.037). Appendicitis was more likely to be managed non-operatively (11/63 vs 51/79; p < 0.001) and, of those managed surgically, with an open approach (3/52 vs 26/28 p < 0.001). The NAR also reduced (5/52 vs 0/28; p = 0.157). LOS was shorter in non-operatively managed patients (1 day vs 3 days; p < 0.001) without a difference in complications (10/51 vs 4/28; p = 0.760). Conclusion Introduction of the guidelines was associated with changes in practice. Despite these changes, short-term complications did not increase and LOS decreased. Questions remain on the longer-term complication rates in non-operatively managed patients.
C1 [English, W.; Habib Bedwani, N.; Smith, C.; Shatkar, V.] BHR NHS Trust, Queens Hosp, Dept Gen Surg, London, England.
   [English, W.] QMUL, Blizard Inst, Natl Bowel Res Ctr, London, England.
   [Doganay, E.; Marsden, M.] Barts Hlth NHS Trust, Royal London Hosp, Dept Gen Surg, London, England.
   [Muse, S.; Mak, W. K.; Chana, M.] Royal Devon & Exeter Hosp NHS Fdn Trust, Dept Gen Surg, Exeter, Devon, England.
   [Eves, J.] Imperial Coll Healthcare NHS Trust, St Marys Hosp, Dept Gen Surg, London, England.
RP English, W (corresponding author), BHR NHS Trust, Queens Hosp, Dept Gen Surg, London, England.; English, W (corresponding author), QMUL, Blizard Inst, Natl Bowel Res Ctr, London, England.
EM Billy.english100@gmail.com
OI Smith, Christopher/0000-0003-2795-0922
CR ADDISS DG, 1990, AM J EPIDEMIOL, V132, P910, DOI 10.1093/oxfordjournals.aje.a115734
   Al-gaithy ZK, 2012, WORLD J EMERG SURG, V7, DOI 10.1186/1749-7922-7-32
   Alnaser MKH, 2018, INT J SURG OPEN, V10, P1, DOI 10.1016/j.ijso.2017.11.007
   [Anonymous], COR COVID 19 UK
   Collard M, 2020, J VISC SURG, V157, pS33, DOI 10.1016/j.jviscsurg.2020.04.014
   COVIDsurg Collaborative, 2020, LANCET, V396, P27, DOI 10.1016/S0140-6736(20)31182-X
   Di Saverio S, 2020, WORLD J EMERG SURG, V15, DOI 10.1186/s13017-020-00306-3
   Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae
   English W, 2020, BRIT J SURG, V107, pE337, DOI 10.1002/bjs.11787
   Garcia S, 2020, J AM COLL CARDIOL, V75, P2871, DOI 10.1016/j.jacc.2020.04.011
   Haijanen J, 2018, BMC SURG, V18, DOI 10.1186/s12893-018-0451-y
   Jaschinski T, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001546.pub4
   Lahaye MJ, 2015, EUR RADIOL, V25, P1464, DOI 10.1007/s00330-014-3531-0
   Lee M, 2014, ANN ROY COLL SURG, V96, P517, DOI 10.1308/003588414X13946184903801
   Lei Shaoqing, 2020, EClinicalMedicine, V21, P100331, DOI 10.1016/j.eclinm.2020.100331
   Mowbray NG, 2020, BRIT J SURG, V107, P1406, DOI 10.1002/bjs.11679
   Myles PS, 2020, LANCET, V396, P2, DOI 10.1016/S0140-6736(20)31256-3
   Nepogodiev D, 2020, BRIT J SURG, V107, P1440, DOI 10.1002/bjs.11746
   Nepogodiev D, 2020, BRIT J SURG, V107, P73, DOI 10.1002/bjs.11440
   Park HC, 2017, BRIT J SURG, V104, P1785, DOI 10.1002/bjs.10660
   Podda M, 2019, ANN SURG, V270, P1028, DOI 10.1097/SLA.0000000000003225
   Rogers William, 2015, Evid Based Med, V20, P3, DOI 10.1136/ebmed-2014-110075
   Royal College of Surgeons, ROYAL COLL SURG ENGL
   Sallinen V, 2016, BRIT J SURG, V103, P656, DOI 10.1002/bjs.10147
   Salminen P, 2018, JAMA-J AM MED ASSOC, V320, P1259, DOI 10.1001/jama.2018.13201
   Siegler JE, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.104953
   Sippola S, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-023623
   Soreide K, 2020, BRIT J SURG, V107, P1250, DOI 10.1002/bjs.11670
   Stewart B, 2014, BRIT J SURG, V101, pE9, DOI 10.1002/bjs.9329
   Torales J, 2020, INT J SOC PSYCHIATR, V66, P317, DOI 10.1177/0020764020915212
   Yang ZY, 2019, BMC SURG, V19, DOI 10.1186/s12893-019-0578-5
   Zheng MH, 2020, ANN SURG, V272, pE5, DOI 10.1097/SLA.0000000000003924
NR 32
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1435-2443
EI 1435-2451
J9 LANGENBECK ARCH SURG
JI Langenbecks Arch. Surg.
DI 10.1007/s00423-020-02023-6
EA NOV 2020
PG 9
WC Surgery
SC Surgery
GA OP2YG
UT WOS:000587949200001
PM 33169297
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Huppe, D
   Niederau, C
   Serfert, Y
   Hartmann, H
   Wedemeyer, H
AF Hueppe, Dietrich
   Niederau, Claus
   Serfert, Yvonne
   Hartmann, Heinz
   Wedemeyer, Heiner
CA DHC-R
TI Problems in treating patients with chronic HCV infection due to the
   COVID-19 pandemic and during the lockdown phase in Germany
SO ZEITSCHRIFT FUR GASTROENTEROLOGIE
LA German
DT Article; Early Access
DE German Hepatitis C Registry; COVID-19 pandemic; hepatitis C virus
   infection; lockdown; patient care
AB Zusammenfassung
   Einleitung Die COVID-19-Pandemie und die damit verbundenen Lockdown-Verordnungen stellen das Gesundheitswesen und die Patientenversorgung vor Herausforderungen. Um den Einfluss der COVID-19-Pandemie und der mit ihr verbundenen Einschrankungen auf die Versorgung von Patienten mit chronischer Hepatitis C zu erfassen, haben wir unter den am Deutschen Hepatitis C-Register (DHC-R) mitwirkenden Zentren eine Umfrage durchgefuhrt.
   Methodik Alle 320 fur die Dokumentation im DHC-R freigeschalteten Zentren wurden zu einer internetbasierten Umfrage eingeladen. Davon hatten 74 Zentren im Verlauf der letzten 12 Monate mindestens 5 neue Patienten dokumentiert und zumindest die Screeningvisite abgeschlossen.
   Ergebnisse 64 Zentren haben an der Befragung teilgenommen. Aufgrund des Lockdowns zwischen Marz und Mai 2020 hatten 11% der Zentren ihre Lebersprechstunde vorubergehend eingestellt, 58% teilweise eingeschrankt und 32% unverandert fortgesetzt. Mehr als die Halfte der Terminabsagen ging von den Patienten aus. 52% der Zentren haben neue oder zusatzliche Telefonsprechstunden und 17% neue Videosprechstunden eingerichtet. Zwischen Marz und Mai 2020 wurden deutlich weniger neue Patienten antiviral behandelt als im gleichen Zeitraum 2019. Ab Juli 2020 kehrten alle Zentren zum ublichen Sprechstundenangebot zuruck. Fast 80% der befragten Zentren gaben keine wesentliche Einschrankung der Patientenversorgung an. Immerhin stellten aber 22% der Zentren fest, dass eine Leberdekompensation erst spater erkannt, und 9,4% gaben an, dass ein hepatozellulares Karzinom verzogert diagnostiziert wurde. Ausreichend Schutzausrustung war bei 56% der Zentren vorhanden. Mit den behordlichen Informationen waren 63% der Zentren zufrieden.
   Zusammenfassung Diagnostik, Therapie und uberwachung von chronischen Lebererkrankungen waren durch die COVID-19-Pandemie beeintrachtigt. Nach Einschatzung der Mehrheit der Zentren kam es jedoch mittel- und langfristig zu keiner Unterversorgung. Sorge bereitete hingegen, dass gerade die akut lebensbedrohlichen Komplikationen wie die Leberdekompensation in erheblichem Ma ss verspatet erkannt wurden.
   Abstract
   Background Healthcare services were faced with unprecedented challenges due to the COVID-19 pandemic and its associated lockdown regulations. In order to analyse the influence of the pandemic on the healthcare of patients with chronic hepatitis C in Germany, we carried out a structured questionnaire among all centres participating in the German Hepatitis C-Registry (DHC-R).
   Methods 320 centres of the DHC-R were invited to participate in an online survey. Of these, 74 centres had included >= 5 patients in the last 12 months.
   Findings A fully answered questionnaire was sent back by 64 centres. Due to the lockdown regulations, 11% of the centres had stopped their regular consultation between March and May 2020; 58% had reduced the consultations and 32% did not change the consultations. More than 50% of the appointment cancellations were done by the patients. 52% of the centres offered a new or additional telephone consultation and 17% offered a new video consultation. Between March and May 2020, the number of patients newly treated with antivirals was markedly lower when compared with the same period in 2019. All centres had returned to their usual consultation procedures in July 2020. Almost 80% indicated that there were no significant limitations in patient's healthcare. However, 22% of the centres stated that liver decompensation was diagnosed late and 9.4% stated that diagnosis of hepatocellular carcinoma was delayed. An adequate amount of personal protective equipment (including disinfectants) was available in 56% of the centres. Official information by public healthcare authorities was considered sufficient by 63% of the centres.
   Summary Diagnosis, therapy and monitoring of patients with chronic hepatitis C were impaired during the COVID-19 pandemic. Nevertheless, the majority of the centres did not see healthcare problems for these patients in the medium and long term. However, the fact that the diagnosis of liver decompensations with potential lethal consequences was delayed in a considerable number of patients causes major concern.
C1 [Hueppe, Dietrich] Gastroenterol Gemeinschaftspraxis Herne, Herne, Germany.
   [Niederau, Claus] Postfach 10 12 03, D-46012 Oberhausen, Germany.
   [Serfert, Yvonne; Hartmann, Heinz; Wedemeyer, Heiner] Leberstiftungs GmbH Deutschland, Carl Neuberg Str 1, D-30625 Hannover, Germany.
   [Wedemeyer, Heiner] Hannover Med Sch, Klin Gastroenterol Hepatol & Endokrinol, Hannover, Germany.
RP Wedemeyer, H (corresponding author), Leberstiftungs GmbH Deutschland, Carl Neuberg Str 1, D-30625 Hannover, Germany.
EM claus.niederau@yahoo.de; info@leberstiftungs-gmbh.de
CR Bohmer MM, 2020, LANCET INFECT DIS, V20, P920, DOI 10.1016/S1473-3099(20)30314-5
   Bujard M, ELTERN WAHREND CORON
   Hagen B., FRUHERKENNUNGSKOLOSK
   Kuhlen R, 2020, DTSCH ARZTEBLATT, V27-28, P488
   Lescure FX, 2020, LANCET INFECT DIS, V20, P697, DOI 10.1016/S1473-3099(20)30200-0
   Mangiapane S, VERANDERUNG VERTRAGS
   Ricciardiello Luigi, 2020, Clin Gastroenterol Hepatol, DOI 10.1016/j.cgh.2020.09.008
   RKI, 2020, EPIDEMIOLOGISCHES B, V2, P26, DOI 10.25646/6206.2
   Schmidt C, 2020, Z GASTROENTEROL, V58, P1
   World Health Organization, WHO COR DIS COVID 19
NR 10
TC 0
Z9 0
U1 0
U2 0
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0044-2771
EI 1439-7803
J9 Z GASTROENTEROL
JI Z. Gastroent.
DI 10.1055/a-1291-8518
EA NOV 2020
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA OO9DG
UT WOS:000587673100001
PM 33167051
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Verma, J
   Mishra, AS
AF Verma, Jaya
   Mishra, Amar Shankar
TI COVID-19 infection: Disease detection and mobile technology
SO PEERJ
LA English
DT Article
DE COVID-19; SARS-CoV-2; Pandemic; Epidemiology; Mobile technology
ID CHLOROQUINE
AB Background: A pneumonia outbreak of unknown etiology took place in Wuhan, Hubei province, China and spread quickly worldwide in December 2019. Chinese Center for Disease Control and Prevention identified a novel beta-coronavirus called 2019-nCoV, now officially known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) that is responsible for the pandemic. The coronavirus COVID-19 affected 215 countries and territories around the world and more than 99 hundred thousand people at present (Nature Nanatechnology, 2020). At present, there are no specific vaccines or treatments available for COVID-19. However, there are many ongoing clinical trials evaluating potential treatments. At this time the experts recommend precautions such as social distancing, hand washing, and wearing face masks to reduce disease transmission. This review article aims to improve the readers' awareness towards the important role of mobile technology for SARS-CoV-2.
   Methodology: To achieve this objective, we performed a COVID-19 literature review from various sources that include data from the published articles as well as World Health Organization reports on coronavirus disease and how mobile technology is useful to fight against this disease.
   Results: Mobile technology can be helpful in mapping disease spread and provides an easy way to provide awareness that promotes safety and adoption of necessary precautions to mitigate and stop community transmission.
   Conclusion: The spread rate of COVID-19 is very high and until now no vaccines are available to control this disease. To this end we should leverage other avenues such as digital technologies to protect ourselves from this disease. Mobile technology such as smartphones are playing an important role in this pandemic, by launching apps to track coronavirus infected people. These apps are very easy to use and provide self-isolation guidelines as well as other safety tips.
C1 [Verma, Jaya] Amity Univ, Noida, Uttar Pradesh, India.
   [Mishra, Amar Shankar] CIPL, Delhi, India.
RP Verma, J (corresponding author), Amity Univ, Noida, Uttar Pradesh, India.
EM jayaverma745@gmail.com
CR [Anonymous], 2020, NATURE, V580, P563, DOI 10.1038/d41586-020-01264-1
   [Anonymous], 2020, NAT NANOTECHNOL, V15, P239, DOI 10.1038/s41565-020-0680-y
   APK Center, 2020, HOM QUAR
   Business Today, 2020, BUSINESS TODAY
   Busvine D, 2020, REUTERS
   Butcher M., 2020, TECHCRUNCH
   Chaturvedi A., 2020, GEOSPATIAL WORLD
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Cookson C, 2020, FINANCIAL TIMES
   COVID Watch, 2020, COV WATCH PUBL HLTH
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Eddy N., 2020, TECHNOLOGY CAN HELP
   *EUR CDCP, 2020, ANT CONS DAT ESAC NE
   Gould M., 2020, TECHNOLOGY NHS
   Grout D, 2020, SECURITY PRIVACY IMP
   Guermazi B., 2020, LEVERAGING DIGITAL T
   Hausfeld, 2020, COVID 19 CONT TRAC A
   Huckman RS, 2018, HARVARD BUSINESS REV
   Joshi D., 2020, WIRE
   Jun C, 2020, CELL DEATH DIS, V11, P1, DOI 10.1038/s41419-019-2182-0.
   Koh D., 2020, MOBILE HLTH NEWS
   Ma J, 2006, JI BING JIAN CE, V21, P1
   Mallapaty Smriti, 2020, Nature, DOI 10.1038/d41586-020-01095-0
   Maxmen A, 2020, NATURE, DOI [10.1038/d41586-020-01163-5, DOI 10.1038/D41586-020-01163-55]
   McKendry RA, 2020, NATURE, V580, P29, DOI 10.1038/d41586-020-00908-6
   Meo SA, 2020, EUR REV MED PHARMACO, V24, P4539, DOI 10.26355/eurrev_202004_21038
   Morley J, 2020, NATURE, V582, P29, DOI 10.1038/d41586-020-01578-0
   Novianty D., 2020, MELIHAT CARA KERJA A
   Pulla Priyanka, 2020, Nature, DOI 10.1038/d41586-020-01619-8
   Rocher L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10933-3
   Saleh M, 2020, CIRC-ARRHYTHMIA ELEC, V13, DOI 10.1161/CIRCEP.120.008662
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Stoye E., 2020, NATURE BRIEFING
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Ting DSW, 2020, NAT MED, DOI 10.1038/s41591-020-0824-5
   UCLG, 2020, LIV LEARN EXP IMM OU
   UNESCO, 2020, FIGHT COVID 19 DIG I
   United Nations, 2020, DIG TECHN CRIT FAC C
   Villa A, 2020, ORAL DIS, V5, P1
   Wakefield J., 2020, BBC
   Wang NS, 2013, CELL RES, V23, P986, DOI 10.1038/cr.2013.92
   Wikimedia Commons Contributors, 2020, 3D MED AN COR STRUCT
   Winer S., 2020, HLTH MINISTRY LAUNCH
   World Health Organization, 2020, PRIOR DIS RES DEV EM
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xiao Y, 2020, 10 TECHNOLOGY TRENDS
   Yang CH, 2009, B WORLD HEALTH ORGAN, V87, P619, DOI 10.2471/BLT.08.060905
   Zargar A., 2020, PRIVACY SECURITY CON
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
NR 50
TC 0
Z9 0
U1 0
U2 0
PU PEERJ INC
PI LONDON
PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167-8359
J9 PEERJ
JI PeerJ
PD NOV 9
PY 2020
VL 8
AR e10345
DI 10.7717/peerj.10345
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OO7ZB
UT WOS:000587593100009
PM 33240654
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Katayama, H
AF Katayama, Hiroshi
TI Can immunological manipulation defeat SARS-CoV-2? Why G-CSF induced
   neutrophil expansion is worth a clinical trial G-CSF treatment against
   COVID-19
SO BIOESSAYS
LA English
DT Article; Early Access
DE COVID&#8208; 19; G&#8208; CSF; natural Th17 cells; neutrophils;
   tissue&#8208; resident memory T cells
ID T-CELLS; VIRUS-INFECTION; CUTTING EDGE; HOST-DEFENSE; TH17 CELLS;
   INTERLEUKIN-17; EXPRESSION; CHEMOKINE; FEATURES; IMMUNITY
AB Immunity against SARS-CoV-2 that is acquired by convalescent COVID-19 patients is examined in reference to (A) the Th17 cell generation system in psoriatic epidermis and (B) a recently discovered phenomenon in which Th17 cells are converted into tissue-resident memory T (T-RM) cells with Th1 phenotype. Neutrophils that are attracted to the site of infection secrete IL-17A, which stimulates lung epithelial cells to express CCL20. Natural Th17 (nTh17) cells are recruited to the infection site by CCL20 and expand in the presence of IL-23. These nTh17 cells are converted to T-RM cells upon encounter with SARS-CoV-2 and continue to exist as ex-Th17 cells, which exert Th1-like immunity during a memory response. G-CSF can induce nTh17 cell accumulation at the infection site because it promotes neutrophil egress from the bone marrow. Hence, G-CSF may be effective against COVID-19. Administration of G-CSF to patients infected with SARS-CoV-2 is worth a clinical trial.
C1 [Katayama, Hiroshi] Katayama Dermatol Clin, Maebashi, Gunma, Japan.
RP Katayama, H (corresponding author), Omote Cho 1-25-12, Maebashi, Gumma 3710024, Japan.
EM ochibataki@bi.wakwak.com
OI Katayama, Hiroshi/0000-0001-7254-4726
CR Andersohn F, 2007, ANN INTERN MED, V146, P657, DOI 10.7326/0003-4819-146-9-200705010-00009
   Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663
   Bending D, 2009, J CLIN INVEST, V119, P565, DOI 10.1172/JCI37865
   Bettelli E, 2008, NATURE, V453, P1051, DOI 10.1038/nature07036
   Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385
   Elkon KB, 2018, ARTHRITIS RHEUMATOL, V70, P805, DOI 10.1002/art.40452
   Gaffen SL, 2014, NAT REV IMMUNOL, V14, P585, DOI 10.1038/nri3707
   Geerdink RJ, 2015, J ALLERGY CLIN IMMUN, V136, P838, DOI 10.1016/j.jaci.2015.06.034
   Happel KI, 2003, J IMMUNOL, V170, P4432, DOI 10.4049/jimmunol.170.9.4432
   Hastie AT, 1996, CYTOKINE, V8, P730, DOI 10.1006/cyto.1996.0097
   Hernandez-Santos N, 2018, CELL HOST MICROBE, V23, P511, DOI 10.1016/j.chom.2018.02.011
   Hiroki CH, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03108
   Hirota K, 2011, NAT IMMUNOL, V12, P255, DOI 10.1038/ni.1993
   Iijima N, 2014, SCIENCE, V346, P93, DOI 10.1126/science.1257530
   Ishikawa H, 2016, VIROLOGY, V499, P23, DOI 10.1016/j.virol.2016.08.025
   Iwanaga N, 2019, IMMUNOLOGY, V156, P3, DOI 10.1111/imm.13006
   Katayama H, 2020, BRAIN BEHAV, V10, DOI 10.1002/brb3.1504
   Katayama H, 2018, EXP DERMATOL, V27, P1084, DOI 10.1111/exd.13746
   Kumar BV, 2017, CELL REP, V20, P2921, DOI 10.1016/j.celrep.2017.08.078
   Kumar P, 2013, CURR OPIN IMMUNOL, V25, P373, DOI 10.1016/j.coi.2013.03.011
   Lee YK, 2009, IMMUNITY, V30, P92, DOI 10.1016/j.immuni.2008.11.005
   Levy R, 2016, P NATL ACAD SCI USA, V113, pE8277, DOI 10.1073/pnas.1618300114
   LI YL, 2018, CONTROL ENG SER BIRK, P1, DOI DOI 10.1007/978-3-319-64246-8_1
   Martin-Orozco N, 2009, EUR J IMMUNOL, V39, P216, DOI 10.1002/eji.200838475
   Matsuzaki G, 2018, MICROBIOL IMMUNOL, V62, P1, DOI 10.1111/1348-0421.12560
   Naumenko V, 2018, CELL TISSUE RES, V371, P505, DOI 10.1007/s00441-017-2763-0
   O'Rielly Darren D, 2019, J Rheumatol Suppl, V95, P46, DOI 10.3899/jrheum.190119
   Okada S, 2015, SCIENCE, V349, P606, DOI 10.1126/science.aaa4282
   Opasawatchai A, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03007
   Oshima Y, 2019, CYTOKINE, V119, P47, DOI 10.1016/j.cyto.2019.02.013
   Rajput C, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121882
   Rivadeneyra L, 2018, J MOL CELL CARDIOL, V125, P149, DOI 10.1016/j.yjmcc.2018.08.029
   Saitoh T, 2012, CELL HOST MICROBE, V12, P109, DOI 10.1016/j.chom.2012.05.015
   Schwarzenberger P, 1998, J IMMUNOL, V161, P6383
   Tate MD, 2009, J IMMUNOL, V183, P7441, DOI 10.4049/jimmunol.0902497
   Taylor PR, 2014, NAT IMMUNOL, V15, P143, DOI 10.1038/ni.2797
   Teijaro JR, 2011, J IMMUNOL, V187, P5510, DOI 10.4049/jimmunol.1102243
   Thierry AR, 2020, CLIN SCI, V134, P1295, DOI 10.1042/CS20200531
   Vesely MCA, 2019, CELL, V178, P1176, DOI 10.1016/j.cell.2019.07.032
   Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519
   Ye P, 2001, AM J RESP CELL MOL, V25, P335, DOI 10.1165/ajrcmb.25.3.4424
   Zuo Y, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138999
NR 42
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0265-9247
EI 1521-1878
J9 BIOESSAYS
JI Bioessays
AR e2000232
DI 10.1002/bies.202000232
EA NOV 2020
PG 5
WC Biochemistry & Molecular Biology; Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics
GA OO5OT
UT WOS:000587428300001
PM 33166093
OA Other Gold
DA 2021-01-01
ER

PT J
AU Garavaglia, C
   Sancino, A
   Trivellato, B
AF Garavaglia, Christian
   Sancino, Alessandro
   Trivellato, Benedetta
TI Italian mayors and the management of COVID-19: adaptive leadership for
   organizing local governance
SO EURASIAN GEOGRAPHY AND ECONOMICS
LA English
DT Article; Early Access
DE Urban governance; public leadership; emergency management; disaster
   response; collaborative governance
ID DIRECTLY ELECTED MAYORS; PUBLIC VALUE; FRAMEWORK; SERVICES
AB Drawing on a survey of 25 mayors of municipalities belonging to the Metropolitan City of Milan, Italy this paper presents an investigation into the main problems they faced during Phase 1 (lockdown) and Phase 2 (post-lockdown, pre-vaccine); the leadership actions they implemented in Phases 1 and 2; and the leadership actions they would prioritize in case of a new emergency. The results contribute to the building of knowledge on local governance and leadership models - specifically regarding conditions of emergency. Four key issues emerged: (i) the importance of adaptive leadership and of anticipatory governance frameworks aimed at providing direction in situations of emergency (e.g. what to do in case of scarce mask availability and/or of local coronavirus disease 2019 [COVID-19] hotspots); (ii) the importance of promoting institutional spaces for cooperation and collaboration with citizens in their role as volunteers and of other organizational stakeholders willing to contribute to public value co-creation; (iii) the role of technology as an enabler and medium for sharing information and crowdsourcing resources; and (iv) the importance of safe and trusted platforms for knowledge sharing among the mayors and with the relevant organizational stakeholders.
C1 [Garavaglia, Christian] Univ Milano Bicocca, Dept Econ Management & Stat, Piazza Ateneo Nuovo 1,Bldg U7,2 Floor, I-20126 Milan, Italy.
   [Garavaglia, Christian] Bocconi Univ, ICRIOS, Milan, Italy.
   [Garavaglia, Christian] Katholieke Univ Leuven, LICOS, Leuven, Belgium.
   [Sancino, Alessandro] Univ Milano Bicocca, Dept Business & Law, Milan, Italy.
   [Sancino, Alessandro] Open Univ, Dept Publ Leadership & Social Enterprise, Milton Keynes, Bucks, England.
   [Trivellato, Benedetta] Univ Milano Bicocca, Dept Sociol & Social Res, Milan, Italy.
RP Garavaglia, C (corresponding author), Univ Milano Bicocca, Dept Econ Management & Stat, Piazza Ateneo Nuovo 1,Bldg U7,2 Floor, I-20126 Milan, Italy.
EM christian.garavaglia@unimib.it
OI Sancino, Alessandro/0000-0002-1892-9622; Trivellato,
   Benedetta/0000-0002-5125-257X
CR Ansell C., 2012, INNOVATION J, V17, P1
   Ansell C, 2020, PUBLIC ADMIN, V98, P261, DOI 10.1111/padm.12636
   Aslund A, 2020, EURASIAN GEOGR ECON, V61, P532, DOI 10.1080/15387216.2020.1778499
   Avellaneda CN, 2009, J PUBL ADM RES THEOR, V19, P285, DOI 10.1093/jopart/mun001
   Back H, 2006, EUROPEAN MAYOR, P1, DOI 10.1007/978-3-531-90005-6
   Baldini G, 2002, J MOD ITAL STUD, V7, P364, DOI 10.1080/1354571021000026616
   Beal V, 2014, INT J URBAN REGIONAL, V38, P302, DOI 10.1111/1468-2427.12018
   Beer A, 2019, REG STUD, V53, P171, DOI 10.1080/00343404.2018.1447662
   Berg R., 2005, TRANSFORMING POLITIC
   Bolden R, 2020, INT J PUBLIC ADMIN, V43, P26, DOI 10.1080/01900692.2019.1604748
   Borraz O, 2004, INT J URBAN REGIONAL, V28, P107, DOI 10.1111/j.0309-1317.2004.00505.x
   Bryson J, 2017, PUBLIC MANAG REV, V19, P640, DOI 10.1080/14719037.2016.1192164
   Budd L, 2016, REG STUD REG SCI, V3, P129, DOI 10.1080/21681376.2015.1125306
   Clarke V, 2013, PSYCHOLOGIST, V26, P120
   Copus C, 2004, LOCAL GOV STUD, V30, P576, DOI 10.1080/0300393042000318003
   Cristofoli D, 2020, J MANAG GOV, DOI 10.1007/s10997-020-09505-1
   Crosby BC, 2018, PUBLIC MANAG REV, V20, P1265, DOI 10.1080/14719037.2017.1348731
   Ebrahim A.H., 2020, AM J EC, V10, DOI [10.5923/j.economics.20201005.04, DOI 10.5923/J.ECONOMICS.20201005.04]
   Gissendanner S, 2004, URBAN AFF REV, V40, P44, DOI 10.1177/1078087404267188
   Grint Keith., 2005, LEADERSHIP LIMITS PO
   Hambleton R, 2015, LEADING THE INCLUSIVE CITY: PLACE-BASED INNOVATION FOR A BOUNDED PLANET, P1
   Hartley J, 2018, INT J PUBLIV LEADERS, V14, P202, DOI 10.1108/IJPL-09-2018-0048
   Heifetz R.A., 2009, PRACTICE ADAPTIVE LE
   Heinelt H, 2018, GOV PUBLIC MANAG, P1, DOI 10.1007/978-3-319-67410-0
   Huxham C, 2000, ACAD MANAGE J, V43, P1159, DOI 10.2307/1556343
   Istat-ISS, 2020, IMP EP COV 19 MORT T
   Jayne M, 2012, SOC CULT GEOGR, V13, P29, DOI 10.1080/14649365.2011.635800
   Karsten N, 2017, LEADERSHIP-LONDON, V13, P154, DOI 10.1177/1742715016651711
   Kouril P, 2020, EURASIAN GEOGR ECON, V61, P587, DOI 10.1080/15387216.2020.1783338
   Lever W. F., 2001, SPACE POLITY, V5, P113, DOI [10.1080/13562570120104436, DOI 10.1080/13562570120104436]
   Macpherson R., 2020, LEADING CRISIS USING
   Magnier A, 2006, EUROPEAN MAYOR, P201, DOI 10.1007/978-3-531-90005-6_9
   McNeill D, 2001, T I BRIT GEOGR, V26, P340, DOI 10.1111/1475-5661.00026
   Mulgan G., 2020, NOT WASTE CRISIS
   Nabatchi T, 2017, PUBLIC ADMIN REV, V77, P766, DOI 10.1111/puar.12765
   Ospina SM, 2017, PUBLIC ADMIN REV, V77, P275, DOI 10.1111/puar.12706
   Pagani M., 2020, VOLUNTARY SECTOR REV, DOI [10.1332/204080520X15902277850841, DOI 10.1332/204080520X15902277850841]
   REN XF, 2020, EURASIAN GEOGR 0510, DOI DOI 10.1080/ 15387216.2020.1762103
   Ren XF, 2020, EURASIAN GEOGR ECON, V61, P423, DOI 10.1080/15387216.2020.1762103
   Sancino A., 2018, ROUTLEDGE HDB INT LO, DOI 10.4324/9781315306278-6
   Sancino A., 2020, IL SOLE 24 ORE
   Sancino A, 2020, PUBLIC MONEY MANAGE, DOI 10.1080/09540962.2020.1815380
   Sancino A, 2016, PUBLIC MONEY MANAGE, V36, P153, DOI 10.1080/09540962.2016.1118945
   Skelcher C, 2013, UNDERSTAND GOVERN
   Sonn JW, 2020, EURASIAN GEOGR ECON, V61, P482, DOI 10.1080/15387216.2020.1768423
   Sorensen E, 2019, PUBLIC MANAG REV, V21, P1443, DOI 10.1080/14719037.2018.1559342
   Tonurist P., 2018, OECD SCI TECHNOLOGY, DOI [10.1787/sti_in_outlook-2018-16-en, DOI 10.1787/STI_IN_OUTLOOK-2018-16-EN]
   Torfing J, 2020, POLICY SOC, V39, P592, DOI 10.1080/14494035.2020.1794749
   Torfing J, 2019, INT J PUBLIV LEADERS, V15, P58, DOI 10.1108/IJPL-12-2018-0059
   Trivellato B, 2019, PUBLIC ADMIN, V97, P311, DOI 10.1111/padm.12559
   Trovati G., 2020, IL SOLE 24 ORE
   Vangen S, 2015, PUBLIC MANAG REV, V17, P1237, DOI 10.1080/14719037.2014.903658
   Wallis J, 2009, INT J PUBLIC ADMIN, V32, P250, DOI 10.1080/01900690902732608
   White L, 2016, LEADERSHIP QUART, V27, P280, DOI 10.1016/j.leaqua.2016.01.004
NR 54
TC 0
Z9 0
U1 6
U2 6
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1538-7216
EI 1938-2863
J9 EURASIAN GEOGR ECON
JI Eurasian Geogr. Econ.
DI 10.1080/15387216.2020.1845222
EA NOV 2020
PG 17
WC Area Studies; Geography
SC Area Studies; Geography
GA OO7CM
UT WOS:000587533600001
OA Bronze
DA 2021-01-01
ER

PT J
AU Akan, S
   Ediz, C
   Kizilkan, YE
   Alcin, A
   Tavukcu, HH
   Yilmaz, O
AF Akan, Serkan
   Ediz, Caner
   Kizilkan, Yunus Emre
   Alcin, Adem
   Tavukcu, Hasan Huseyin
   Yilmaz, Omer
TI COVID-19 infection threat in patients with high-risk non-muscle invasive
   bladder cancer receiving intravesical BCG therapy
SO INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
LA English
DT Article; Early Access
AB Aim We evaluated the COVID-19 infection threat in patients receiving intravesical BCG therapy which has immunotherapeutic effects and is of vital importance in most of the individuals with high-risk non-muscle-invasive bladder cancer (NMIBC) and investigated the need for postponement of this therapy.
   Methods A total of 71 patients, who were diagnosed with high-risk NMIBC and on intravesical BCG treatment regularly (induction or maintenance), were enrolled in the study. The patients were classified into two groups depending on whether they were diagnosed with COVID-19 during the pandemic period or not.
   Results Of 71 patients, 26 underwent a COVID-19 polymerase chain reaction test with clinical suspicion during the pandemic period. Of these 26 patients, 4 were diagnosed with COVID-19. Age of the patients, working status (working/retired), compliance with containment measures against the pandemic, number of BCG courses, adverse effects after BCG therapy and systemic immune-inflammation index, which is an inflammation-related parameter, were not different between groups (P > .05). Neutrophil/lymphocyte ratio was significantly higher in the COVID-19 positive group (P < .05). COVID-19 positivity was higher in age groups 50-64 (6.6%) and 65-80 (5.8%) years than that in similar age groups of the normal population.
   Conclusion Every effort should be made to administer intravesical BCG treatment in high-risk NMIBC patients even during the pandemic period. However, increased risk of COVID-19 transmission should be kept in mind and protective measures against COVID-19 for healthcare providers and patients before the procedure should be taken optimally. The procedure should be postponed in patients with lymphopenia in recent complete blood count.
C1 [Akan, Serkan; Ediz, Caner; Kizilkan, Yunus Emre; Alcin, Adem; Tavukcu, Hasan Huseyin; Yilmaz, Omer] Univ Hlth Sci, Sultan Abdulhamid Han Training & Res Hosp, Dept Urol, Istanbul, Turkey.
RP Akan, S (corresponding author), Sultan Abdulhamid Han Training & Res Hosp, Dept Urol, Istanbul, Turkey.
EM drserkanakan@hotmail.com
RI Ediz, Caner/H-9473-2018; YILMAZ, Omer/P-6396-2017
OI Ediz, Caner/0000-0001-9717-1209; YILMAZ, Omer/0000-0002-4433-9431;
   KIZILKAN, Yunus Emre/0000-0001-7915-5731
CR [Anonymous], 2020, COVID 19 PAND UR GUI
   [Anonymous], 2020, COVID 19 RES
   Babjuk M, 2019, EUR UROL, V76, P639, DOI 10.1016/j.eururo.2019.08.016
   Bouffet E, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28327
   Crispen PL, 2020, CANCER IMMUNOL IMMUN, V69, P3, DOI 10.1007/s00262-019-02443-4
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Desouky E, 2020, WORLD J UROL, DOI 10.1007/s00345-020-03251-7
   Donin NM, 2017, J UROLOGY, V197, P14, DOI 10.1016/j.juro.2016.02.3005
   Elmamoun MH, 2014, BJU INT, V113, pE34, DOI 10.1111/bju.12340
   Hegarty PK, 2020, PREPRINT
   Kaufmann SHE, 2020, IMMUNE BOOST CORONA
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Luo Y, 2013, CANC TREATMENT CONVE, P319, DOI [10.5772/55283, DOI 10.5772/55283]
   Mahase E, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1252
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Miller A, 2020, CORRELATION UNIVERSA, DOI [DOI 10.1101/2020.03.24.20042937, 10.1101/2020.03.24.20042937]
   Oddens JR, 2004, EUR UROL, V46, P336, DOI 10.1016/j.eururo.2004.05.003
   Ribal MJ, 2020, EUR UROL, V78, P21, DOI 10.1016/j.eururo.2020.04.056
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   South AM, 2020, AM J PHYSIOL-HEART C, V318, pH1084, DOI 10.1152/ajpheart.00217.2020
   Tastan C, 2020, TURK J BIOL, V44, P192, DOI 10.3906/biy-2004-113
   Teoh JYC, 2020, WORLD J UROL, DOI 10.1007/s00345-020-03218-8
   Zlotta AR, 1997, CLIN EXP IMMUNOL, V109, P157, DOI 10.1046/j.1365-2249.1997.4141313.x
NR 23
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1368-5031
EI 1742-1241
J9 INT J CLIN PRACT
JI Int. J. Clin. Pract.
AR e13752
DI 10.1111/ijcp.13752
EA NOV 2020
PG 5
WC Medicine, General & Internal; Pharmacology & Pharmacy
SC General & Internal Medicine; Pharmacology & Pharmacy
GA OO5QQ
UT WOS:000587433200001
PM 33064918
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ediz, C
   Tavukcu, HH
   Akan, S
   Kizilkan, YE
   Alcin, A
   Oz, K
   Yilmaz, O
AF Ediz, Caner
   Tavukcu, Hasan Huseyin
   Akan, Serkan
   Kizilkan, Yunus Emre
   Alcin, Adem
   Oz, Kerem
   Yilmaz, Omer
TI Is there any association of COVID-19 with testicular pain and
   epididymo-orchitis?
SO INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
LA English
DT Article; Early Access
ID RECOMMENDATIONS; MANAGEMENT; DIAGNOSIS; EPIDEMIOLOGY; THERAPY; CANCERS;
   DAMAGE
AB Aims This study aims to analyse the novel Coronavirus disease- (COVID-19) related testicular pain in hospitalised patients because of COVID-19 and to review as an aetiological factor for epididymitis, orchitis or both.
   Methods A total of 91 patients were included in the study. A questionnaire was formed for the questioning of testicular pain or epididymo-orchitis in patients with COVID-19. Demographics and past medical history was also recorded. Patients' neutrophil and lymphocyte counts, neutrophil-lymphocyte ratios (NLR), C-reactive protein (CRP) levels and D-dimer values were recorded. Patients with COVID-19 were divided into two groups according to absence or presence of testicular pain or epididymo-orchitis as group 1 and group 2. All results were compared for both groups.
   Results The median age of patients was similar in both groups. Testicular pain was occurred in 10.98% of the patients. Clinical presentation of epididymo-orchitis was diagnosed in only one patient. No statistically significant difference was reported in terms of patients' age, levels of CRP and D-Dimer or NLR and results of questionnaire form queries between the two groups (P > .05).
   Conclusion Testicular pain was observed more frequently in hospitalised COVID-19 cases. While no inflammation marker which is related to predict of testicular pain or epididymo-orchitis was found in patients with COVID-19.
C1 [Ediz, Caner; Tavukcu, Hasan Huseyin; Akan, Serkan; Kizilkan, Yunus Emre; Alcin, Adem; Oz, Kerem; Yilmaz, Omer] Sultan Abdulhamid Han Educ & Res Hosp, Dept Urol, TR-34668 Istanbul, Turkey.
RP Ediz, C (corresponding author), Sultan Abdulhamid Han Educ & Res Hosp, Dept Urol, TR-34668 Istanbul, Turkey.
EM drcanerediz@gmail.com
RI Ediz, Caner/H-9473-2018
OI Ediz, Caner/0000-0001-9717-1209
CR Assi T, 2020, FUTURE ONCOL, V16, P1455, DOI 10.2217/fon-2020-0361
   Aversa A, 2020, MINERVA ENDOCRINOL, V45, P77, DOI 10.23736/S0391-1977.20.03207-1
   Azmat CE, 2020, ORCHITIS
   Bhowmick NA, 2020, ENDOCR-RELAT CANCER, V27, pR281, DOI 10.1530/ERC-20-0165
   Borchert A, 2020, UROLOGY, V141, P7, DOI 10.1016/j.urology.2020.04.059
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Corona G, 2020, J ENDOCRINOL INVEST, V43, P1153, DOI 10.1007/s40618-020-01290-w
   de la Pena E, 2020, ARCH ESP UROL, V73, P374
   De Paoli P, 2005, FEMS MICROBIOL REV, V29, P897, DOI 10.1016/j.femsre.2005.01.005
   Fan C, 2020, ACE2 EXPRESSION KIDN, DOI [10.1101/2020.02.12.20022418, DOI 10.1101/2020.02.12.20022418]
   Gagliardi L, 2020, PEDIATR INFECT DIS J, V39, pE200, DOI 10.1097/INF.0000000000002769
   Rivas JG, 2020, ARCH ESP UROL, V73, P367
   Heldwein FL, 2020, EUR UROL FOCUS, V6, P1070, DOI 10.1016/j.euf.2020.05.020
   Illiano E, 2020, ANDROLOGIA, V52, DOI 10.1111/and.13654
   Kanda T, 2014, INT J UROL, V21, P426, DOI 10.1111/iju.12305
   Kim J, 2020, AM J EMERG MED, V38, DOI 10.1016/j.ajem.2020.03.052
   Kurscheidt FA, 2019, NAT REV UROL, V16, P211, DOI 10.1038/s41585-019-0149-7
   Liu JM, 2017, CAN J INFECT DIS MED, V2017, DOI 10.1155/2017/1506857
   Ludwig M, 2008, ANDROLOGIA, V40, P76, DOI 10.1111/j.1439-0272.2007.00823.x
   Ma WQ, 2016, CELL, V167, P1511, DOI 10.1016/j.cell.2016.11.016
   Mejean A, 2020, PROG UROL, V30, P221, DOI 10.1016/j.purol.2020.03.009
   Mohammadi S, 2020, J THROMB THROMBOLYS, V50, P604, DOI 10.1007/s11239-020-02177-6
   Nowroozi A, 2020, UROL J, V17, P326, DOI 10.22037/uj.v0i0.6065
   Ronco C, 2020, LANCET RESP MED, V8, P738, DOI 10.1016/S2213-2600(20)30229-0
   Sigalos JT, 2017, TRANSL ANDROL UROL, V6, pS37, DOI 10.21037/tau.2017.05.23
   South AM, 2020, AM J PHYSIOL-HEART C, V318, pH1084, DOI 10.1152/ajpheart.00217.2020
   Sun J, 2020, EMERG MICROBES INFEC, V9, P991, DOI 10.1080/22221751.2020.1760144
   Teoh JYC, 2020, WORLD J UROL, DOI 10.1007/s00345-020-03218-8
   Vishvkarma R, 2020, ANDROLOGIA, V52, DOI 10.1111/and.13712
   Wallis CJD, 2020, EUR UROL, V78, P29, DOI 10.1016/j.eururo.2020.04.063
   Wang T, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051574
   Zaorsky NG, 2020, ADV RADIAT ONCOL, V5, P659, DOI 10.1016/j.adro.2020.03.010
   Zhang YH, 2020, BIOMED PHARMACOTHER, V127, DOI 10.1016/j.biopha.2020.110195
NR 33
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1368-5031
EI 1742-1241
J9 INT J CLIN PRACT
JI Int. J. Clin. Pract.
AR e13753
DI 10.1111/ijcp.13753
EA NOV 2020
PG 5
WC Medicine, General & Internal; Pharmacology & Pharmacy
SC General & Internal Medicine; Pharmacology & Pharmacy
GA OO5SD
UT WOS:000587437100001
PM 33063899
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Nelson, EUE
   Dumbili, EW
   Odeigah, OW
AF Nelson, Ediomo-Ubong Ekpo
   Dumbili, Emeka W.
   Odeigah, Ogochukwu Winifred
TI Drug use treatment during COVID-19 pandemic: community-based services in
   Nigeria
SO JOURNAL OF SUBSTANCE USE
LA English
DT Article; Early Access
DE COVID-19; drug use; drug treatment; Nigeria; pandemic
ID SUBSTANCE USE DISORDERS
AB Introduction
   This study examined the utilization of community-based treatment services by people who use drugs (PWUD) in Nigeria during the lockdown following the COVID-19 outbreak.
   Methods
   Data were collected from six drop-in centers (DICs) for PWUD operated by NGOs in four geo-political regions in Nigeria, using a short questionnaire administered to the project managers by e-mail. It sought information on service utilization, sex distribution of service users, types of drugs used, types of services provided, and modes of service delivery for the period of October 2019 to May 2020. Data were analyzed using descriptive statistical techniques.
   Results
   Service utilization declined from 375 users in October 2019 to 198 in April, before reaching 321 in May. Female users were more affected by the disruption than men. Cannabis was the drug most commonly used by service users. There were significant gaps in service provision, including limited face-to-face counseling and discontinuation of other services.
   Conclusion
   The lockdown limited the range and quality of services provided, and constrained uptake by PWUD. Addressing gender-related barriers, improving funding, and adopting risk reduction measures are recommended for improving service delivery and uptake.
C1 [Nelson, Ediomo-Ubong Ekpo] Ctr Res & Informat Subst Abuse, Uyo, Nigeria.
   [Nelson, Ediomo-Ubong Ekpo] Int Blue Cross, Benin, Nigeria.
   [Dumbili, Emeka W.] Inst Therapy & Hlth Res, Kiel, Germany.
   [Dumbili, Emeka W.] Nnamdi Azikiwe Univ, Dept Sociol & Anthropol, Awka, Nigeria.
   [Odeigah, Ogochukwu Winifred] Univ Ibadan, Dept Psychol, Ibadan, Nigeria.
   [Odeigah, Ogochukwu Winifred] Chrisland Univ, Coll Arts Management & Social Sci, Dept Psychol, Abeokuta, Nigeria.
RP Nelson, EUE (corresponding author), Ctr Res & Informat Subst Abuse, Uyo, Nigeria.
EM degreatnelson@yahoo.com
RI Dumbili, Emeka/H-3348-2019
OI Dumbili, Emeka/0000-0002-3563-1617; Odeigah, Ogochukwu
   Winifred/0000-0002-3897-9635
CR Abiola T, 2015, J SUBST ABUSE TREAT, V58, P72, DOI [10.1016/j.jsat2015.06.012, 10.1016/j.jsat.2015.06.012]
   Addiction Policy Forum, 2020, COVID 19 PAND IMP PA
   Arya S, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102086
   Atilola O, 2016, GLOB MENT HEALTH, V3, DOI 10.1017/gmh.2016.25
   Bickel WK, 2014, ANNU REV CLIN PSYCHO, V10, P641, DOI 10.1146/annurev-clinpsy-032813-153724
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Dumbili EW, 2020, J DRUG ISSUES, V50, P286, DOI 10.1177/0022042620912805
   Ebigbo PO, 2012, J CONTEMP PSYCHOTHER, V42, P257, DOI 10.1007/s10879-012-9213-9
   European Monitoring Centre for Drugs and Drug Addiction, 2020, IMP COVID 19 DRUG SE
   European Monitoring Centre for Drugs and Drug Addiction, 2020, EMCDDA UPD IMPL COVI
   Ezenwa M., 2020, B NARCOTICS, VLXII, P27, DOI [10.17863/CAM.50293, DOI 10.17863/CAM.50293]
   Ganesh A, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102120
   Governors Board Medical Council of India, 2020, TEL PRACT GUID EN RE
   Gureje O, 2007, DRUG ALCOHOL DEPEN, V91, P1, DOI 10.1016/j.drugalcdep.2007.04.010
   Hale T, 2020, OXFORD COVID 19 GOVT
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   LAMBO TA, 1960, BRIT MED J, V2, P1696, DOI 10.1136/bmj.2.5214.1696
   Li Q, 2020, N ENGL J MED, V382
   Marsden J, 2020, ADDICTION, V115, P1007, DOI 10.1111/add.15080
   Mehanovic E, 2020, DRUG ALCOHOL DEPEN, V206, DOI 10.1016/j.drugalcdep.2019.04.028
   Nelson EUE, 2019, J PSYCHOACTIVE DRUGS, V51, P383, DOI 10.1080/02791072.2019.1605103
   Nigeria Centre for Disease Control, 2020, 100 DAYS NIG COVID 1
   Nigeria Centre for Disease Control, 2020, 1 CAS COR DIS CONF N
   Obot I. S., 2004, INT J DRUG POLICY, V15, P17, DOI DOI 10.1016/S0955-3959(03)00110-5
   Office of the Secretary to the Government of the Federation, 2020, FURTH MEAS TAK FED G
   Office of the Secretary to the Government of the Federation, 2020, IMPL GUID CONT COVID
   Ong SWX, 2020, JAMA-J AM MED ASSOC, V323, P1610, DOI 10.1001/jama.2020.3227
   Onifade PO, 2011, SUBST ABUSE TREAT PR, V6, DOI 10.1186/1747-597X-6-25
   Palmer F, 2012, PRIM CARE RESP J, V21, P377, DOI 10.4104/pcrj.2012.00069
   Scally G, 2020, BMJ, V369, pm1932, DOI 10.1136/bmj.m193232414712
   Sordo L, 2017, BMJ, V357, pj1550
   State House, 2020, COMMUNICATION
   Substance Abuse and Mental Health Services Administration, 2020, COVID 19 OP TREATM P
   United Nations Office On Drugs And Crime, 2018, DRUG US NIG
   Vimalananda VG, 2015, J TELEMED TELECARE, V21, P323, DOI 10.1177/1357633X15582108
   Whitfield Mark, 2020, Int J Drug Policy, V83, P102851, DOI 10.1016/j.drugpo.2020.102851
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2020, STAT M INT HLTH INT
   World Health Organization, 2020, 157 WHO
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhu N, 2020, NEW ENGL J MED, V382, P8, DOI DOI https://doi.org/10.1056/NEJMoa2001017
NR 42
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1465-9891
EI 1475-9942
J9 J SUBST USE
JI J. Subst. Use
DI 10.1080/14659891.2020.1838640
EA NOV 2020
PG 6
WC Substance Abuse
SC Substance Abuse
GA OO7NH
UT WOS:000587561700001
OA Bronze
DA 2021-01-01
ER

PT J
AU Li, SY
   Zhang, SH
   Wu, RF
   Su, YW
AF Li, Siying
   Zhang, Suhan
   Wu, Ruifang
   Su, Yuwen
TI COVID-19 and psoriasis: Recommendation for patients on regular
   infliximab therapy
SO DERMATOLOGIC THERAPY
LA English
DT Article; Early Access
DE infliximab; psoriasis; telemedicine
AB During COVID-19 outbreak hospitals were congested and infliximab was interrupted. Thus, we performed this observational study to understand the consequent burden of complications in these special cluster of psoriatic patients. We followed up 56 psoriatic patients who were receiving Infliximab treatment by telephone. The majority of patients had lesions exacerbation, accompanied by anxiety emotion. It is suggested that reserving common drugs for psoriasis at home is necessary. Besides, telemedicine should be advocated as a main medical visit mode during the outbreak of COVID-19.
C1 [Li, Siying; Zhang, Suhan; Wu, Ruifang; Su, Yuwen] Cent South Univ, Xiangya Hosp 2, Hunan Key Lab Med Epigen, Dept Dermatol, Changsha, Hunan, Peoples R China.
RP Su, YW (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Dermatol, 139 Renmin Middle Rd, Changsha 410011, Hunan, Peoples R China.
EM suyuwen1963@csu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81573051, 81872534]
FX National Natural Science Foundation of China, Grant/Award Numbers:
   81573051, 81872534
CR Bragazzi NL, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13508
   Cinelli E, 2020, SUPPORT CARE CANCER, V28, P3991, DOI 10.1007/s00520-020-05563-1
   Cristaudo A, 2020, CONTACT DERMATITIS, V83, P536, DOI 10.1111/cod.13683
   Damiani G, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13475
   Elmas OF, 2020, DERMATOL THER, DOI 10.1111/dth.13858
   Gironi LC, 2020, J DERMATOL TREAT, DOI 10.1080/09546634.2020.1789044
   Jakhar D, 2020, CLIN EXP DERMATOL, V45, P739, DOI 10.1111/ced.14227
   Pacifico A, 2020, BRIT J DERMATOL, V183, P375, DOI 10.1111/bjd.19145
   Rendon A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061475
NR 9
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
AR e14472
DI 10.1111/dth.14472
EA NOV 2020
PG 3
WC Dermatology
SC Dermatology
GA OO9HG
UT WOS:000587683700001
PM 33124705
OA Bronze
DA 2021-01-01
ER

PT J
AU Armesto, S
   Vela, CG
   Sanchez, J
   Illaro, A
   Mayorga, J
   Sundh, ALE
   Fernandez, CN
   Palmou, N
   Gomez-Fernandez, C
   Lopez, MGA
   Gonzalez-Gay, MA
AF Armesto, Susana
   Gonzalez Vela, Carmen
   Sanchez, Julia
   Illaro, Aitziber
   Mayorga, Jesus
   Lopez Sundh, Ana E.
   Naharro Fernandez, Cristina
   Palmou, Natalia
   Gomez-Fernandez, Cristina
   Gonzalez Lopez, Marcos A.
   Gonzalez-Gay, Miguel A.
TI Treating multidrug-resistant psoriasis with brodalumab, apremilast,
   methotrexate and prednisone combination therapy in the COVID-19 pandemic
SO DERMATOLOGIC THERAPY
LA English
DT Letter; Early Access
C1 [Armesto, Susana; Lopez Sundh, Ana E.; Naharro Fernandez, Cristina; Gomez-Fernandez, Cristina; Gonzalez Lopez, Marcos A.] Hosp Univ Marques Valdecilla, Dept Dermatol, Santander, Spain.
   [Gonzalez Vela, Carmen] Hosp Univ Marques Valdecilla, Dept Pathol, Santander, Spain.
   [Sanchez, Julia; Illaro, Aitziber; Mayorga, Jesus] Hosp Univ Marques Valdecilla, Dept Pharm, Santander, Spain.
   [Palmou, Natalia; Gonzalez-Gay, Miguel A.] Hosp Univ Marques Valdecilla, Dept Rheumatol, Santander, Spain.
RP Armesto, S (corresponding author), Hosp Univ Marques Valdecilla, Ave Valdecilla S-N, Santander, Spain.
EM susana.armesto@scsalud.es
RI Armesto, Susana/P-5544-2019
OI Armesto, Susana/0000-0002-8081-0606; Palmou Fontana,
   Natalia/0000-0002-8609-0283; Lopez-Sundh, Ana
   Elisabet/0000-0002-2660-2347
CR AbuHilal M, 2016, J CUTAN MED SURG, V20, P313, DOI 10.1177/1203475416631328
   Amerio P, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13434
   Melis D, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13722
   Mrowietz U, 2014, J EUR ACAD DERMATOL, V28, P438, DOI 10.1111/jdv.12118
   Parisi R, 2013, J INVEST DERMATOL, V133, P377, DOI 10.1038/jid.2012.339
   Price KN, 2020, J AM ACAD DERMATOL, V82, pE173, DOI 10.1016/j.jaad.2020.03.046
   Queiro Silva R, 2020, DERMATOL THER, pe13961
   Sacchelli L, 2019, CLIN EXP DERMATOL, V44, pE243, DOI 10.1111/ced.14000
   Snehalatha K, 2018, INT J BASIC CLIN PHA, V7, P1450, DOI [10.18203/2319-2003.ijbcp20183013, DOI 10.18203/2319-2003.IJBCP20183013]
NR 9
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
AR e14464
DI 10.1111/dth.14464
EA NOV 2020
PG 3
WC Dermatology
SC Dermatology
GA OO3WX
UT WOS:000587314200001
PM 33112014
OA Bronze
DA 2021-01-01
ER

PT J
AU Ranza, E
   Mammi, P
   Rampello, A
   Annamaria, S
   Brianti, R
AF Ranza, E.
   Mammi, P.
   Rampello, A.
   Annamaria, S.
   Brianti, R.
TI Botulinum toxin therapy during the COVID-19 outbreak: Experience of an
   Italian multidisciplinary team
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Letter; Early Access
DE botulinum toxin therapy; COVID-19; neurorehabilitation; physiatry
C1 [Ranza, E.; Mammi, P.; Rampello, A.; Annamaria, S.; Brianti, R.] Univ Hosp Parma, Geriatr & Rehabil Dept, Rehabil Med Unit, Parma, Italy.
RP Ranza, E (corresponding author), Azienda Osped Univ Parma, UO Med Riabilitat, Via Gramsci 14, I-43100 Parma, Italy.
EM eranza@ao.pr.it
CR Baricich A, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00719
   Leocani L, 2020, EUR J NEUROL, V27, pE50, DOI 10.1111/ene.14320
NR 2
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-5101
EI 1468-1331
J9 EUR J NEUROL
JI Eur. J. Neurol.
DI 10.1111/ene.14569
EA NOV 2020
PG 1
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA OO1KF
UT WOS:000587144800001
PM 33012098
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Dhama, K
   Patel, SK
   Natesan, S
   Vora, KS
   Yatoo, MI
   Tiwari, R
   Saxena, SK
   Singh, KP
   Singh, R
   Malik, YS
AF Dhama, Kuldeep
   Patel, Shailesh Kumar
   Natesan, Senthilkumar
   Vora, Kranti Suresh
   Yatoo, Mohd Iqbal
   Tiwari, Ruchi
   Saxena, Shailendra K.
   Singh, Karam Pal
   Singh, Rajendra
   Malik, Yashpal Singh
TI COVID-19 in the elderly people and advances in vaccination approaches
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article; Early Access
DE SARS-CoV-2; covid-19; elderly people; vaccine
AB The rapid worldwide spread of the COVID-19 pandemic, caused by the newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in tens of millions of infections and over one million deaths. SARS-CoV-2 infection affects all age groups; however, those over 60 years old are affected more severely. Moreover, pre-existing co-morbidities result in higher COVID-19-associated mortality in the geriatric population. This article highlights the associated risk factors of SARS-CoV-2 infection in older people and progress in developing COVID-19 vaccines, especially for efficient vaccination of the older population. There is also a summary of immunomodulatory and immunotherapeutic approaches to ameliorate the outcome of COVID-19 in older individuals.
C1 [Dhama, Kuldeep; Patel, Shailesh Kumar; Singh, Karam Pal; Singh, Rajendra] ICAR Indian Vet Res Inst, Div Pathol, Bareilly 243122, Uttar Pradesh, India.
   [Natesan, Senthilkumar; Vora, Kranti Suresh] Indian Inst Publ Hlth Gandhinagar, Dept Infect Dis, Ganghinagar, Gujarat, India.
   [Vora, Kranti Suresh] Univ Canberra, Hlth Res Inst, Canberra, ACT, Australia.
   [Yatoo, Mohd Iqbal] Sher E Kashmir Univ Agr Sci & Technol Kashmir, Fac Vet Sci & Anim Husb, Div Vet Clin Complex, Srinagar, Jammu & Kashmir, India.
   [Tiwari, Ruchi] Uttar Pradesh Pandit Deen Dayal Upadhyaya Pashu C, Dept Vet Microbiol & Immunol, Coll Vet Sci, Mathura, India.
   [Saxena, Shailendra K.] King Georges Med Univ KGMU, Fac Med, Ctr Adv Res CFAR, Lucknow, Uttar Pradesh, India.
   [Malik, Yashpal Singh] ICAR Indian Vet Res Inst, Div Biol Standardizat, Bareilly 243122, Uttar Pradesh, India.
RP Dhama, K (corresponding author), ICAR Indian Vet Res Inst, Div Pathol, Bareilly 243122, Uttar Pradesh, India.; Malik, YS (corresponding author), ICAR Indian Vet Res Inst, Div Biol Standardizat, Bareilly 243122, Uttar Pradesh, India.
EM kdhama@rediffmail.com; malikyps@gmail.com
RI ; Dhama, Kuldeep/B-7852-2015
OI Yatoo, Dr. Mohd. Iqbal/0000-0002-4501-7354; Saxena, Shailendra
   K/0000-0003-2856-4185; Tiwari, Dr Ruchi/0000-0001-6897-3472; Dhama,
   Kuldeep/0000-0001-7469-4752; Singh, Rajendra/0000-0002-8586-3221
CR Alijotas-Reig J, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102569
   Angelopoulou A, 2020, ENVIRON RES, V188, DOI 10.1016/j.envres.2020.109858
   [Anonymous], 2020, PREVENTING MANAGING
   Asakura H, 2020, J THROMB HAEMOST, V18, P1521, DOI 10.1111/jth.14858
   Bachanova V, 2020, BIOL BLOOD MARROW TR, V26, P1239, DOI 10.1016/j.bbmt.2020.04.008
   Becker RC, 2020, J THROMB THROMBOLYS, V50, P54, DOI 10.1007/s11239-020-02134-3
   Belen-Apak FB, 2020, J THROMB THROMBOLYS, V50, P278, DOI 10.1007/s11239-020-02129-0
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Bonanad Clara, 2020, Rev Esp Cardiol (Engl Ed), V73, P569, DOI 10.1016/j.rec.2020.05.001
   Brasiel PGD, 2020, CLIN NUTR ESPEN, V38, P65, DOI 10.1016/j.clnesp.2020.06.003
   Burrage DR, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01844
   Calina D, 2020, INT J MOL MED, V46, P3, DOI 10.3892/ijmm.2020.4596
   Chen L, 2020, NUTRIENTS, V12, DOI 10.3390/nu12041193
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Clay CC, 2014, IMMUN AGEING, V11, DOI 10.1186/1742-4933-11-4
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Dent E, 2019, LANCET, V394, P1376, DOI 10.1016/S0140-6736(19)31785-4
   Dhama K, 2020, CLIN MICROBIOL REV, V33, DOI 10.1128/CMR.00028-20
   Dhama K, 2020, TRAVEL MED INFECT DI, V37, DOI 10.1016/j.tmaid.2020.101755
   Dhochak N, 2020, INDIAN J PEDIATR, V87, P537, DOI 10.1007/s12098-020-03322-y
   Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC
   Frater JL, 2020, INT J LAB HEMATOL, V42, P11, DOI 10.1111/ijlh.13229
   Galanakis CM, 2020, FOODS, V9, DOI 10.3390/foods9040523
   Gates B., 2020, WHAT YOU NEED KNOW C
   Giesecke J, 2020, LANCET, V395, pE98, DOI 10.1016/S0140-6736(20)31035-7
   Golonka RM, 2020, PHYSIOL GENOMICS, V52, P217, DOI 10.1152/physiolgenomics.00033.2020
   Gupta A, 2020, HUM VACC IMMUNOTHER, DOI 10.1080/21645515.2020.1808410
   Heaton PM, 2020, NEW ENGL J MED, V383, P1986, DOI 10.1056/NEJMe2025111
   Hippensteel JA, 2020, AM J PHYSIOL-LUNG C, V319, pL211, DOI 10.1152/ajplung.00199.2020
   Infusino F, 2020, NUTRIENTS, V12, DOI 10.3390/nu12061718
   Iqbal Yatoo Mohd, 2020, Hum Vaccin Immunother, P1, DOI 10.1080/21645515.2020.1788310
   Isaia G, 2020, AM J GERIAT PSYCHIAT, V28, P790, DOI [10.1016/j.jagp.2020.04.018, 10.1016/j.archger.2004.04.022]
   Jahan I, 2020, TURK J BIOL, V44, P228, DOI 10.3906/biy-2005-114
   Jahanshahlu L, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110337
   Jayawardena R, 2020, DIABETES METAB SYND, V14, P367, DOI 10.1016/j.dsx.2020.04.015
   Johnson and Johnson, 2020, DEV VACC ID THER COV
   Khoury M, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00858-2020
   Koff WC, 2020, NEW ENGL J MED, V383, P804, DOI 10.1056/NEJMp2006761
   Koirala A, 2020, PAEDIATR RESPIR REV, V35, P43, DOI 10.1016/j.prrv.2020.06.010
   Kumar GV, 2020, NEW MICROB NEW INFEC, V35, DOI 10.1016/j.nmni.2020.100682
   Lax SF, 2020, ANN INTERN MED, V173, P350, DOI 10.7326/M20-2566
   Lillicrap D, 2020, J THROMB HAEMOST, V18, P786, DOI 10.1111/jth.14781
   Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005
   Mardani R, 2020, ARCH ACAD EMERG MED, V8
   Market M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01512
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Morais AHA, 2020, NUTRIENTS, V12, DOI 10.3390/nu12061737
   NJH, 2020, CLIN TRIALS MON ANT
   Oh SJ, 2019, IMMUNE NETW, V19, DOI 10.4110/in.2019.19.e37
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Paczek L, 2009, AGING CLIN EXP RES, V21, P9
   Panyod Suraphan, 2020, J Tradit Complement Med, V10, P420, DOI 10.1016/j.jtcme.2020.05.004
   Patel SK, 2020, J INFECT DEV COUNTR, V14, P450, DOI 10.3855/jidc.12744
   Pawelec G, 2020, IMMUN AGEING, V17, DOI 10.1186/s12979-020-00180-2
   Poulas K, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01373
   Rahmati M., 2020, EURASIAN J MED ONCOL, V4, DOI [10.14744/ejmo.2020.72142., DOI 10.14744/EJMO.2020.72142, 10.14744/ejmo.2020.72142]
   Ramos-Suzarte M., 2020, USE HUMANIZED ANTICD, DOI [10.1101/2020.07.24.20153833, DOI 10.1101/2020.07.24.20153833]
   Rapkiewicz Amy V, 2020, EClinicalMedicine, V24, P100434, DOI 10.1016/j.eclinm.2020.100434
   Rastogi Sanjeev, 2020, J Ayurveda Integr Med, DOI 10.1016/j.jaim.2020.04.002
   Rios P., 2020, GUIDELINES PREVENTIN, DOI [10.1101/2020.03.19.20039180, DOI 10.1101/2020.03.19.20039180]
   Saavedra D., 2020, IMMUNITY AGEING, DOI [10.21203/rs.3.rs-32335/v1, DOI 10.21203/RS.3.RS-32335/V1]
   Selvi V, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2606058
   Shanmugaraj B, 2020, ASIAN PAC J ALLERGY, V38, P10, DOI 10.12932/AP-200220-0773
   Sharun K, 2020, EXPERT OPIN BIOL TH, V20, P1033, DOI 10.1080/14712598.2020.1796963
   Shirato K, 2018, VIROLOGY, V517, P9, DOI 10.1016/j.virol.2017.11.012
   Skloot GS, 2017, CLIN GERIATR MED, V33, P447, DOI 10.1016/j.cger.2017.06.001
   Sputnik V., 2020, 1 REGISTERED VACCINE
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   TOI, COR VACC COV RUSS VA
   Tse LV, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00658
   Vellingiri B, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138277
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang L, 2020, J INFECTION, V80, P639, DOI 10.1016/j.jinf.2020.03.019
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu YX, 2020, CURR RES TRANSL MED, V68, P111, DOI 10.1016/j.retram.2020.06.003
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang Y., 2020, EPIDEMIOLOGICAL CLIN, DOI [10.1101/2020.02.10.20021675, DOI 10.1101/2020.02.10.20021675]
NR 82
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
DI 10.1080/21645515.2020.1842683
EA NOV 2020
PG 6
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA PB4BS
UT WOS:000596268800001
PM 33270497
OA Bronze
DA 2021-01-01
ER

PT J
AU Chauhan, A
   Agarwal, A
   Jaiswal, N
   Singh, M
AF Chauhan, Anil
   Agarwal, Amit
   Jaiswal, Nishant
   Singh, Meenu
TI ChAdOx1 nCoV-19 vaccine for SARS-CoV-2
SO LANCET
LA English
DT Letter
C1 [Chauhan, Anil; Agarwal, Amit; Jaiswal, Nishant] Postgrad Inst Med Educ & Res, Dept Telemed, Chandigarh 160012, India.
   [Singh, Meenu] Postgrad Inst Med Educ & Res, ICMR Ctr Adv Res Evidence Based Child Hlth, Dept Pediat, Chandigarh 160012, India.
RP Singh, M (corresponding author), Postgrad Inst Med Educ & Res, ICMR Ctr Adv Res Evidence Based Child Hlth, Dept Pediat, Chandigarh 160012, India.
EM meenusingh4@gmail.com
OI Agarwal, Amit/0000-0001-7136-8206
CR Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   McNeil MM, 2018, J ALLERGY CLIN IMMUN, V141, P463, DOI 10.1016/j.jaci.2017.12.971
   Tomblyn Marcie R, 2007, Hematology Am Soc Hematol Educ Program, P489
NR 3
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD NOV 7
PY 2020
VL 396
IS 10261
BP 1485
EP 1486
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA OO7II
UT WOS:000587548800028
PM 33160563
OA Bronze
DA 2021-01-01
ER

PT J
AU Lodge, A
AF Lodge, Archie
TI ChAdOx1 nCoV-19 vaccine for SARS-CoV-2
SO LANCET
LA English
DT Letter
C1 [Lodge, Archie] Univ Oxford, John Radcliffe Hosp, Div Med Sci, Oxford OX3 9DU, England.
RP Lodge, A (corresponding author), Univ Oxford, John Radcliffe Hosp, Div Med Sci, Oxford OX3 9DU, England.
EM archie.lodge@worc.ox.ac.uk
CR Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
NR 1
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD NOV 7
PY 2020
VL 396
IS 10261
BP 1486
EP 1486
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA OO7II
UT WOS:000587548800029
PM 33160564
OA Bronze
DA 2021-01-01
ER

PT J
AU Voysey, M
   Pollard, AJ
AF Voysey, Merryn
   Pollard, Andrew J.
TI ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 reply
SO LANCET
LA English
DT Letter
C1 [Pollard, Andrew J.] Univ Oxford, Oxford Vaccine Grp, Dept Paediat, Oxford OX3 7LE, England.
   Oxford Biomed Res Ctr, Natl Inst Hlth Res, Oxford, England.
RP Pollard, AJ (corresponding author), Univ Oxford, Oxford Vaccine Grp, Dept Paediat, Oxford OX3 7LE, England.
EM andrew.pollard@paediatrics.ox.ac.uk
CR Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
NR 1
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD NOV 7
PY 2020
VL 396
IS 10261
BP 1486
EP 1487
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA OO7II
UT WOS:000587548800030
PM 33160565
OA Bronze
DA 2021-01-01
ER

PT J
AU Lee, N
   Ison, M
   Dunning, J
AF Lee, Nelson
   Ison, Michael
   Dunning, Jake
TI Early triple antiviral therapy for COVID-19
SO LANCET
LA English
DT Letter
C1 [Lee, Nelson] Univ Alberta, Dept Med, Edmonton, AB T6G 2G3, Canada.
   [Ison, Michael] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Ison, Michael] Northwestern Univ, Comprehens Transplant Ctr, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Dunning, Jake] Imperial Coll London, Natl Heart & Lung Inst, London, England.
RP Lee, N (corresponding author), Univ Alberta, Dept Med, Edmonton, AB T6G 2G3, Canada.
EM laishunn@ualberta.ca
CR Arabi YM, 2020, CLIN INFECT DIS, V70, P1837, DOI 10.1093/cid/ciz544
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Kain T, 2020, EMERG INFECT DIS, V26, P1102, DOI 10.3201/eid2606.200037
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 6
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD NOV 7
PY 2020
VL 396
IS 10261
BP 1487
EP 1488
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA OO7II
UT WOS:000587548800031
PM 33160566
OA Bronze
DA 2021-01-01
ER

PT J
AU Hung, IFN
   Yuen, KY
AF Hung, Ivan Fan-Ngai
   Yuen, Kwok-Yung
TI Early triple antiviral therapy for COVID-19 Reply
SO LANCET
LA English
DT Letter
ID LOPINAVIR/RITONAVIR
C1 [Hung, Ivan Fan-Ngai] Univ Hong Kong, Dept Med, Queen Mary Hosp, Hong Kong, Peoples R China.
   [Yuen, Kwok-Yung] Univ Hong Kong, State Key Lab Emerging Infect Dis, Carol Yu Ctr Infect, Hong Kong, Peoples R China.
RP Yuen, KY (corresponding author), Univ Hong Kong, State Key Lab Emerging Infect Dis, Carol Yu Ctr Infect, Hong Kong, Peoples R China.
EM kyyuen@hku.hk
CR Cao B, 2020, NEW ENGL J MED, V382
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Yuan SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12060628
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD NOV 7
PY 2020
VL 396
IS 10261
BP 1488
EP 1488
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA OO7II
UT WOS:000587548800032
PM 33160568
OA Bronze
DA 2021-01-01
ER

PT J
AU Han, E
   Tan, MMJ
   Turk, E
   Sridhar, D
   Leung, GM
   Shibuya, K
   Asgari, N
   Oh, J
   Garcia-Basteiro, AL
   Hanefeld, J
   Cook, AR
   Hsu, L
   Teo, YY
   Heymann, D
   Clark, H
   McKee, M
   Legido-Quigley, H
AF Han, Emeline
   Tan, Melisa Mei Jin
   Turk, Eva
   Sridhar, Devi
   Leung, Gabriel M.
   Shibuya, Kenji
   Asgari, Nima
   Oh, Juhwan
   Garcia-Basteiro, Alberto L.
   Hanefeld, Johanna
   Cook, Alex R.
   Hsu, Li Yang
   Teo, Yik Ying
   Heymann, David
   Clark, Helen
   McKee, Martin
   Legido-Quigley, Helena
TI Lessons learnt from easing COVID-19 restrictions: an analysis of
   countries and regions in Asia Pacific and Europe
SO LANCET
LA English
DT Article
AB The COVID-19 pandemic is an unprecedented global crisis. Many countries have implemented restrictions on population movement to slow the spread of severe acute respiratory syndrome coronavirus 2 and prevent health systems from becoming overwhelmed; some have instituted full or partial lockdowns. However, lockdowns and other extreme restrictions cannot be sustained for the long term in the hope that there will be an effective vaccine or treatment for COVID-19. Governments worldwide now face the common challenge of easing lockdowns and restrictions while balancing various health, social, and economic concerns. To facilitate cross-country learning, this Health Policy paper uses an adapted framework to examine the approaches taken by nine high-income countries and regions that have started to ease COVID-19 restrictions: five in the Asia Pacific region (ie, Hong Kong [Special Administrative Region], Japan, New Zealand, Singapore, and South Korea) and four in Europe (ie, Germany, Norway, Spain, and the UK). This comparative analysis presents important lessons to be learnt from the experiences of these countries and regions. Although the future of the virus is unknown at present, countries should continue to share their experiences, shield populations who are at risk, and suppress transmission to save lives.
C1 [Han, Emeline; Tan, Melisa Mei Jin; Cook, Alex R.; Hsu, Li Yang; Teo, Yik Ying; Legido-Quigley, Helena] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117549, Singapore.
   [Turk, Eva] Univ South East Norway, Dept Nursing & Hlth Sci, Drammen, Norway.
   [Turk, Eva] Univ Maribor, Med Fac, Maribor, Slovenia.
   [Sridhar, Devi] Univ Edinburgh, Coll Med & Vet Med, Edinburgh, Midlothian, Scotland.
   [Leung, Gabriel M.] Univ Hong Kong, LKS Fac Med, Hong Kong, Peoples R China.
   [Shibuya, Kenji] Kings Coll London, Inst Populat Hlth, London, England.
   [Asgari, Nima] WHO Reg Off South East Asia, Asia Pacific Observ Hlth Syst & Policies, New Delhi, India.
   [Oh, Juhwan] Seoul Natl Univ, Coll Med, Seoul, South Korea.
   [Garcia-Basteiro, Alberto L.] Univ Barcelona, Hosp Clin, ISGlobal, Barcelona, Spain.
   [Garcia-Basteiro, Alberto L.] Ctr Invest Saude Manhica, Maputo, Mozambique.
   [Hanefeld, Johanna; Legido-Quigley, Helena] London Sch Hyg & Trop Med, Dept Global Hlth & Dev, London, England.
   [Heymann, David] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.
   [McKee, Martin] London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, London, England.
   [Hanefeld, Johanna] Robert Koch Inst, Ctr Int Hlth Protect, Berlin, Germany.
   [Clark, Helen] Helen Clark Fdn, Auckland, New Zealand.
RP Legido-Quigley, H (corresponding author), Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117549, Singapore.
EM ephhlq@nus.edu.sg
OI Han, Emeline/0000-0002-4955-7112
FU Singapore Ministry of Health's National Medical Research Council under
   the Centre Grant Programme-Singapore Population Health Improvement
   CentreMinistry of Health-SingaporeNational Medical Research Council,
   Singapore [NMRC/CG/C026/2017_NUHS]
FX This Health Policy was supported by the Singapore Ministry of Health's
   National Medical Research Council under the Centre Grant
   Programme-Singapore Population Health Improvement Centre
   (NMRC/CG/C026/2017_NUHS). The funder had no role in the study design,
   data analysis, interpretation, preparation, or writing of the
   manuscript.
CR [Anonymous], 2020, GUARDIAN
   [Anonymous], 2020, OUR WORLD DATA CORON
   Big Data Institute University of Oxford, 2020, DIG CONT TRAC CAN SL
   Block P, 2020, NAT HUM BEHAV, V4, P588, DOI 10.1038/s41562-020-0898-6
   Carreno B, 2020, SPAIN FIGHT POVERTY
   Cave D, 2020, NY TIMES
   Cheng VCC, 2020, INFECT CONT HOSP EP, V41, P493, DOI [10.1017/ice.2020.58, 10.1017/ice.2020.282]
   Choi S, 2020, CLIN EXP EMERG MED, V7, P73, DOI 10.15441/ceem.20.032
   Cook AR, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-017355
   Coscieme L, 2020, WOMEN POWER FEMALE L, DOI [10.1101/2020.07.13.20152397, DOI 10.1101/2020.07.13.20152397]
   COVID-19 National Emergency Response Center Epidemiology & Case Management Team Korea Centers for Disease Control & Prevention, 2020, Osong Public Health Res Perspect, V11, P60, DOI 10.24171/j.phrp.2020.11.1.09
   Davis N, 2020, GUARDIAN
   Dickens BL, 2020, LANCET, V395, P1541, DOI 10.1016/S0140-6736(20)31016-3
   Eddy Melissa, 2020, NY TIMES
   Elgin C, 2020, COVID 19 EC STIMULUS
   Folkehelseinstituttet, 2020, UN TEST STOR GRUPP F
   Georgieva K, 2020, TELEGRAPH
   Government of Japan, 2020, BAS POL NOV COR DIS
   Government of Singapore, 2020, TACKL TRANSM MIGR WO
   Government of Singapore, 2020, RED NEW REUS MASK
   GREENHALGH T, 2020, BMJ-BRIT MED J, V370, DOI DOI 10.1136/BMJ.M3026
   Haddon C, 2020, GOVT HANDLING DOMINI
   Hille Kathrin, 2020, FINANCIAL TIMES
   Htun HL, 2020, CLIN INFECT DIS, V71, P1947, DOI 10.1093/cid/ciaa468
   Information Services Department the Government of Hong Kong Special Administrative Region, 2020, SOM ANT MEAS EAS
   Korea Centers for Disease Control and Prevention, 2020, UPD COVID 19 KOR 29
   Leung G., 2020, NY TIMES
   Linde P., 2020, PAIS
   Lovelace B Jr, 2020, WHO COUNTRIES RUSH L
   Mayorga L, 2020, DETECTION ISOLATION, DOI [10.1101/2020.04.23.20077255, DOI 10.1101/2020.04.23.20077255]
   Minder R, 2020, NY TIMES
   Ministerio de Sanidad, 2020, PLAN TRANS HAC NUEV
   Ministry of Health and Welfare (South Korea), 2020, COVID 19 RESP KOR GO
   Ministry of Health Singapore, 2020, END CIRC BREAK PHAS
   Ministry of Health Singapore, 2020, 15 SEPT 2020 DAIL RE
   Mitze T, 2020, 13319 IZA DP IZA I L
   Neville S., 2020, FINANCIAL TIMES
   New Zealand Government, 2020, COVID 19 AL SYST UN
   Norwegian Institute of Public Health, 2020, INF CONTR ADV TRAV E
   Organisation for Economic Co-operation and Development, 2020, CONT HLTH SYST RESP
   Park J, 2020, REUTERS
   Peckham R, 2020, LANCET, V395, P850, DOI 10.1016/S0140-6736(20)30468-2
   Phua J, 2020, CRIT CARE MED, V48, P654, DOI 10.1097/CCM.0000000000004222
   Public Health England, 2020, DISP RISK OUTC COVID
   Rawaf S, 2020, E MEDITERR HEALTH J, V26, P499, DOI 10.26719/emhj.20.028
   Roberts M, 2020, BBC NEWS
   Sabbagh D., 2020, GUARDIAN
   The World Bank, 2020, COVID 19 PLUNG GLOB
   UK Government, 2020, FAC COV WEAR ON EX M
   UK Government, COR COVID 19 M OTH S
   UK Government, 2020, OUR PLAN REB UK GOV
   UNICEF, 2020, DONT LET CHILDR BE H
   Vigsnaes M., 2020, NYE TESTKRITERIER SL
   World Health Organization, 2020, WHO COR DIS COVID 19
   Zastrow Mark, 2020, Nature, DOI 10.1038/d41586-020-00740-y
NR 55
TC 5
Z9 5
U1 4
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD NOV 7
PY 2020
VL 396
IS 10261
BP 1525
EP 1534
DI 10.1016/S0140-6736(20)32007-9
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA OO7II
UT WOS:000587548800041
PM 32979936
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kubatova, N
   Qureshi, NS
   Altincekic, N
   Abele, R
   Bains, JK
   Ceylan, B
   Ferner, J
   Fuks, C
   Hargittay, B
   Hutchison, MT
   de Jesus, V
   Kutz, F
   Martin, MAW
   Meiser, N
   Linhard, V
   Pyper, DJ
   Trucks, S
   Furtig, B
   Hengesbach, M
   Lohr, F
   Richter, C
   Saxena, K
   Schlundt, A
   Schwalbe, H
   Sreeramulu, S
   Wacker, A
   Weigand, JE
   Wirmer-Bartoschek, J
   Wohnert, J
AF Kubatova, N.
   Qureshi, N. S.
   Altincekic, N.
   Abele, R.
   Bains, J. K.
   Ceylan, B.
   Ferner, J.
   Fuks, C.
   Hargittay, B.
   Hutchison, M. T.
   de Jesus, V.
   Kutz, F.
   Wirtz Martin, M. A.
   Meiser, N.
   Linhard, V.
   Pyper, D. J.
   Trucks, S.
   Furtig, B.
   Hengesbach, M.
   Lohr, F.
   Richter, C.
   Saxena, K.
   Schlundt, A.
   Schwalbe, H.
   Sreeramulu, S.
   Wacker, A.
   Weigand, J. E.
   Wirmer-Bartoschek, J.
   Woehnert, J.
TI H-1, C-13, and N-15 backbone chemical shift assignments of coronavirus-2
   non-structural protein Nsp10
SO BIOMOLECULAR NMR ASSIGNMENTS
LA English
DT Article; Early Access
DE SARS-CoV-2; Non-structural protein; Solution NMR-spectroscopy;
   Covid19-NMR
ID NMR RELAXATION; VIRUS; EXORIBONUCLEASE; REPLICATION; EXCISION
AB The international Covid19-NMR consortium aims at the comprehensive spectroscopic characterization of SARS-CoV-2 RNA elements and proteins and will provide NMR chemical shift assignments of the molecular components of this virus. The SARS-CoV-2 genome encodes approximately 30 different proteins. Four of these proteins are involved in forming the viral envelope or in the packaging of the RNA genome and are therefore called structural proteins. The other proteins fulfill a variety of functions during the viral life cycle and comprise the so-called non-structural proteins (nsps). Here, we report the near-complete NMR resonance assignment for the backbone chemical shifts of the non-structural protein 10 (nsp10). Nsp10 is part of the viral replication-transcription complex (RTC). It aids in synthesizing and modifying the genomic and subgenomic RNAs. Via its interaction with nsp14, it ensures transcriptional fidelity of the RNA-dependent RNA polymerase, and through its stimulation of the methyltransferase activity of nsp16, it aids in synthesizing the RNA cap structures which protect the viral RNAs from being recognized by the innate immune system. Both of these functions can be potentially targeted by drugs. Our data will aid in performing additional NMR-based characterizations, and provide a basis for the identification of possible small molecule ligands interfering with nsp10 exerting its essential role in viral replication.
C1 [Kubatova, N.; Qureshi, N. S.; Altincekic, N.; Bains, J. K.; Ceylan, B.; Ferner, J.; Fuks, C.; Hargittay, B.; Hutchison, M. T.; de Jesus, V.; Kutz, F.; Wirtz Martin, M. A.; Meiser, N.; Linhard, V.; Pyper, D. J.; Trucks, S.; Furtig, B.; Hengesbach, M.; Richter, C.; Saxena, K.; Schwalbe, H.; Sreeramulu, S.; Wacker, A.; Wirmer-Bartoschek, J.] Goethe Univ Frankfurt, Inst Organ Chem & Chem Biol, Max von Laue Str 7, D-60438 Frankfurt, Germany.
   [Abele, R.] Goethe Univ Frankfurt, Inst Biochem, Bioctr, Max von Laue Str 7, D-60438 Frankfurt, Germany.
   [Schlundt, A.; Woehnert, J.] Goethe Univ Frankfurt, Inst Mol Biosci, Max von Laue Str 7, D-60438 Frankfurt, Germany.
   [Lohr, F.] Goethe Univ Frankfurt, Ctr Biomol Magnet Resonance BMRZ, Inst Biophys Chem, Max von Laue Str 7, D-60438 Frankfurt, Germany.
   [Weigand, J. E.] Tech Univ Darmstadt, Dept Biol, Schnittspahnstr 10, D-64287 Darmstadt, Germany.
RP Hengesbach, M; Schwalbe, H (corresponding author), Goethe Univ Frankfurt, Inst Organ Chem & Chem Biol, Max von Laue Str 7, D-60438 Frankfurt, Germany.
EM hengesbach@nmr.uni-frankfurt.de; schwalbe@nmr.uni-frankfurt.de
OI Altincekic, Nadide/0000-0001-6370-3414; Weigand,
   Julia/0000-0003-4247-1348; Qureshi, Nusrat/0000-0002-5753-5984
FU Projekt DEAL
FX Open Access funding enabled and organized by Projekt DEAL.
CR Aouadi W, 2017, J VIROL, V91, DOI 10.1128/JVI.02217-16
   Baxter NJ, 1997, J BIOMOL NMR, V9, P359, DOI 10.1023/A:1018334207887
   Bouvet M, 2014, J BIOL CHEM, V289, P25783, DOI 10.1074/jbc.M114.577353
   Bouvet M, 2012, P NATL ACAD SCI USA, V109, P9372, DOI 10.1073/pnas.1201130109
   Bouvet M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000863
   Brockway SM, 2004, J VIROL, V78, P11551, DOI 10.1128/JVI.78.21.11551-11562.2004
   Chen Y, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002294
   Daffis S, 2010, NATURE, V468, P452, DOI 10.1038/nature09489
   de la Torre JG, 2000, J MAGN RESON, V147, P138, DOI 10.1006/jmre.2000.2170
   Decroly E, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002059
   Farjon J, 2009, J AM CHEM SOC, V131, P8571, DOI 10.1021/ja901633y
   Ferron F, 2018, P NATL ACAD SCI USA, V115, pE162, DOI 10.1073/pnas.1718806115
   Joseph JS, 2006, J VIROL, V80, P7894, DOI 10.1128/JVI.00467-06
   Kornhaber GJ, 2006, J BIOMOL NMR, V34, P259, DOI 10.1007/s10858-006-0027-5
   Krafcikova P, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17495-9
   Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161
   LAI MMC, 1990, ANNU REV MICROBIOL, V44, P303, DOI 10.1146/annurev.mi.44.100190.001511
   Lee D, 2006, J MAGN RESON, V178, P72, DOI 10.1016/j.jmr.2005.08.014
   Lee W, 2015, BIOINFORMATICS, V31, P1325, DOI 10.1093/bioinformatics/btu830
   Ma YY, 2015, P NATL ACAD SCI USA, V112, P9436, DOI 10.1073/pnas.1508686112
   Matthes N, 2006, FEBS LETT, V580, P4143, DOI 10.1016/j.febslet.2006.06.061
   Minskaia E, 2006, P NATL ACAD SCI USA, V103, P5108, DOI 10.1073/pnas.0508200103
   Rennella E, 2013, CHEMPHYSCHEM, V14, P3059, DOI 10.1002/cphc.201300339
   Shen Y, 2013, J BIOMOL NMR, V56, P227, DOI 10.1007/s10858-013-9741-y
   Snijder EJ, 2016, ADV VIRUS RES, V96, P59, DOI 10.1016/bs.aivir.2016.08.008
   Solyom Z, 2013, J BIOMOL NMR, V55, P311, DOI 10.1007/s10858-013-9715-0
   Su D, 2006, J VIROL, V80, P7902, DOI 10.1128/JVI.00483-06
   Viswanathan T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17496-8
   Wang Y, 2015, J VIROL, V89, P8416, DOI 10.1128/JVI.00948-15
   Wishart DS, 2011, PROG NUCL MAG RES SP, V58, P62, DOI 10.1016/j.pnmrs.2010.07.004
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zust R, 2011, NAT IMMUNOL, V12, P137, DOI 10.1038/ni.1979
NR 32
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1874-2718
EI 1874-270X
J9 BIOMOL NMR ASSIGN
JI Biomol. NMR Assign.
DI 10.1007/s12104-020-09984-1
EA NOV 2020
PG 7
WC Biophysics; Spectroscopy
SC Biophysics; Spectroscopy
GA OO3CO
UT WOS:000587260500001
PM 33159807
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Desai, D
   Shende, P
AF Desai, Drashti
   Shende, Pravin
TI Nanoconjugates-Based Stem Cell Therapy for the Management of COVID-19
SO STEM CELL REVIEWS AND REPORTS
LA English
DT Article; Early Access
DE Corona virus; Lung injury; Regeneration; Inflammation; Pre-clinical
   trials
ID NANOPARTICLES; CORONAVIRUS; DELIVERY; CANCER; DOTS
AB A potential ability of stem cells (SCs) is to regenerate and repair tissues in the human body by providing great prospects for therapeutic applications in the field of medicine. Currently, SC therapy is used in various conditions like diabetes, neurodegenerative disorders, etc. but faces some limitations like patient biocompatibility and chances of cross-infection. SCs are further modulated with nanoconjugates to overcome such challenges and will offer an advantage in the treatment of COVID-19. This pandemic requires design and development of proper treatment to save the life of human beings. Advancements in SC-based nanoconjugated therapy will open new avenues and create a significant impact in the development of futuristic nanomedicine. It may also emerge as a potential therapy for the management of infection in patients suffering from SARS-CoV-2 and related diseases such as pneumonia and virus-induced lung injuries.
C1 [Desai, Drashti; Shende, Pravin] SVKMS NMIMS, Shobhaben Pratapbhai Patel Sch Pharm & Technol Ma, Mumbai, India.
RP Shende, P (corresponding author), SVKMS NMIMS, Shobhaben Pratapbhai Patel Sch Pharm & Technol Ma, Mumbai, India.
EM shendepravin94@gmail.com
OI Shende, Pravin/0000-0001-8144-7645; Desai, Drashti/0000-0002-1525-114X
CR Abbad S, 2015, J BIOMED NANOTECHNOL, V11, P486, DOI 10.1166/jbn.2015.1924
   Abbasi E, 2014, NANOSCALE RES LETT, V9, DOI 10.1186/1556-276X-9-247
   Acharya R, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.110084
   Al-Anazi K., 2015, PROGR STEM CELL TRAN
   Alatyyat SM, 2020, TISSUE CELL, V65, DOI 10.1016/j.tice.2020.101351
   Auffinger B, 2013, ONCOTARGET, V4, P378, DOI 10.18632/oncotarget.937
   Bao L, 2020, BIORXIV
   Bennet D., 2014, APPL NANOTECHNOLOGY, P257, DOI DOI 10.5772/58422
   Biehl JK, 2009, J CARDIOVASC NURS, V24, P98, DOI 10.1097/JCN.0b013e318197a6a5
   Bolhassani A, 2014, HUM VACC IMMUNOTHER, V10, P321, DOI 10.4161/hv.26796
   Boopathi S, 2019, J BIOMOL STRUCT DYN, V2020, P1
   Canham MA, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02532-4
   Chen J., 2020, ENGINEERING
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Choumerianou DM, 2008, TISSUE ENG PART B-RE, V14, P53, DOI 10.1089/teb.2007.0216
   Chow L, 2020, STEM CELL TRANSL MED, V9, P235, DOI 10.1002/sctm.19-0092
   Chrzanowski W, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00554
   Cotter EJ, 2012, STEM CELLS CANC STEM, V8, P79, DOI [10.1007/978-94-007-4798-2_8, DOI 10.1007/978-94-007-4798-2_8]
   Darabi R, 2020, J CELL BIOCHEM, V121, P4696, DOI 10.1002/jcb.29816
   Dayem AA, 2018, NANOMATERIALS-BASEL, V8, DOI 10.3390/nano8100761
   Deng X., 2019, J VIROLOGY, V93
   Desai D., 2020, J PHARM INNOV, P1
   Dinh PUC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14344-7
   Du J, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01699-3
   Fathi-Achachelouei M, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00113
   Food and Drug Administration, 2019, APPR CELL GEN THER P
   Golchin A, 2020, STEM CELL REV REP, V16, P427, DOI 10.1007/s12015-020-09973-w
   Gulla SK, 2018, ACS OMEGA, V3, P8663, DOI 10.1021/acsomega.8b01051
   Gunasekaran Thirumurugan, 2014, Asian Pacific Journal of Tropical Biomedicine, V4, pS1, DOI 10.12980/APJTB.4.2014C980
   Gurunathan S, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10091645
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Jahanshahlu L, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110337
   Johnson V, 2017, SCI REP, V7, P1, DOI DOI 10.1038/s41598-016-0028-x
   Johnston RL, 2012, FRONT NANOSCI, V3, P1, DOI 10.1016/B978-0-08-096357-0.00006-6
   Khatri M, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0774-8
   Khoury M, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00858-2020
   Khurana V., 2017, EMERGING NANOTECHNOL, P85
   Krasnodembskaya A, 2010, STEM CELLS, V28, P2229, DOI 10.1002/stem.544
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Li SH, 2016, COLLOID SURFACE B, V145, P251, DOI 10.1016/j.colsurfb.2016.05.007
   Li W., 2020, STEM CELLS INT
   Li YZ, 2020, PEDIATR PULM, V55, pE1, DOI 10.1002/ppul.24734
   Loy H, 2019, J INFECT DIS, V219, P186, DOI 10.1093/infdis/jiy478
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lukomska B, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/9628536
   Mahajan A., 2020, BIOMEDICAL J
   Majolo F., 2020, STEM CELL REV REP, P1
   Malcherek G, 2014, LEUKEMIA, V28, P2388, DOI 10.1038/leu.2014.273
   Mandpe P, 2020, STEM CELL REV REP, V16, P103, DOI 10.1007/s12015-019-09933-z
   Matea CT, 2017, INT J NANOMED, V12, P5421, DOI 10.2147/IJN.S138624
   Miller LA, 2017, ILAR J, V58, P269, DOI 10.1093/ilar/ilx030
   Namba F, 2019, PEDIATR INT, V61, P945, DOI 10.1111/ped.14001
   Nie W., 2020, ANGEW CHEM, V132, P2034, DOI DOI 10.1002/ANGE.201912524
   Plusa Tadeusz, 2020, Pol Merkur Lekarski, V48, P199
   Puri A., 2009, CRITICAL REV THERAPE, V26
   Qin H, 2020, PROTEIN CELL, V11, P707, DOI 10.1007/s13238-020-00738-2
   Ramasamy M, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/1851242
   Hajiagha SHR, 2020, SOFT COMPUT, DOI 10.1007/s00500-020-05204-z
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Shah TG, 2019, CLIN TRANSL MED, V8, DOI 10.1186/s40169-019-0242-9
   Shende P., 2020, INT J POLYM MATER PO, P1
   Shende P., 2019, NANOSPONGES SYNTHESI, P173
   Shende P, 2019, STEM CELL REV REP, V15, P637, DOI 10.1007/s12015-019-09903-5
   Shende P, 2017, BIOMED PHARMACOTHER, V91, P693, DOI 10.1016/j.biopha.2017.04.126
   Shende P, 2017, MAT SCI ENG C-MATER, V76, P959, DOI 10.1016/j.msec.2017.03.184
   Shende PK, 2018, CRIT REV THER DRUG, V35, P469, DOI 10.1615/CritRevTherDrugCarrierSyst.2018020229
   Shetty AK, 2020, AGING DIS, V11, P462, DOI 10.14336/AD.2020.0301
   Sutton MT, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5303048
   Tan ELC, 2004, EMERG INFECT DIS, V10, P581, DOI 10.3201/eid1004.030458
   Thanunchai M, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/860950
   Tran TTD, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11070325
   Van Linthout S, 2011, EUR HEART J, V32, P2168, DOI 10.1093/eurheartj/ehq467
   Vissers C, 2019, ADV DRUG DELIVER REV, V148, P239, DOI 10.1016/j.addr.2019.02.007
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang Z, 2009, NANOSCALE RES LETT, V4, P593, DOI 10.1007/s11671-009-9292-z
   WHO, COVID 19 WEEKL EP UP
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu XF, 2018, CELL, V172, P423, DOI 10.1016/j.cell.2017.11.018
   Yaqoob AA, 2020, FRONT CHEM, V8, DOI 10.3389/fchem.2020.00341
   Yoshitani J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68184-y
   Zakrzewski W, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1165-5
   Zhao RCH, 2020, STEM CELLS DEV, V29, P679, DOI 10.1089/scd.2020.0071
   Zhou X, 2018, RSC ADV, V8, P17656, DOI 10.1039/c8ra02424c
NR 83
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2629-3269
EI 2629-3277
J9 STEM CELL REV REP
JI Stem Cell Rev. Rep.
DI 10.1007/s12015-020-10079-6
EA NOV 2020
PG 10
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
SC Cell Biology; Research & Experimental Medicine
GA OO3MG
UT WOS:000587286000002
PM 33161559
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Saez-Gimenez, B
   Berastegui, C
   Barrecheguren, M
   Revilla-Lopez, E
   Los Arcos, I
   Alonso, R
   Aguilar, M
   Mora, VM
   Otero, I
   Reig, JP
   Quezada, CA
   Perez, V
   Valle, M
   Laporta, R
   Deu, M
   Sacanell, J
   Bravo, C
   Gavalda, J
   Lopez-Meseguer, M
   Monforte, V
AF Saez-Gimenez, Berta
   Berastegui, Cristina
   Barrecheguren, Miriam
   Revilla-Lopez, Eva
   Los Arcos, Ibai
   Alonso, Rodrigo
   Aguilar, Myriam
   Mora, Victor M.
   Otero, Isabel
   Reig, Juan P.
   Quezada, Carlos A.
   Perez, Virginia
   Valle, Manuel
   Laporta, Rosalia
   Deu, Maria
   Sacanell, Judith
   Bravo, Carles
   Gavalda, Joan
   Lopez-Meseguer, Manuel
   Monforte, Victor
TI COVID-19 in lung transplant recipients: A multicenter study
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article; Early Access
DE clinical research; practice; critical care; intensive care management;
   drug toxicity; infection and infectious agents &#8208; viral; infectious
   disease; lung disease; infectious; lung transplantation; pulmonology
AB This study describes the clinical presentation, treatment, and outcomes of SARS-CoV-2 infection in lung transplant recipients (LTRs). This is a multicenter, retrospective study of all adult LTRs with confirmed SARS-CoV-2 infection from March 4 until April 28, 2020 in six Spanish reference hospitals for lung transplantation. Clinical and radiological data, treatment characteristics, and outcomes were reviewed. Forty-four cases were identified in that period. The median time from transplantation was 4.2 (interquartile range: 1.11-7.3) years. Chest radiography showed acute parenchymal abnormalities in 32 (73%) cases. Hydroxychloroquine was prescribed in 41 (93%), lopinavir/ritonavir (LPV/r) in 14 (32%), and tocilizumab in 19 (43%) patients. There was a strong interaction between tacrolimus and LPV/r in all cases. Thirty-seven (84%) patients required some degree of respiratory support and/or oxygen therapy, and 13 (30%) were admitted to intermediate or intensive critical care units. Seventeen (39%) patients had died and 20 (45%) had been discharged at the time of the last follow-up. Deceased patients had a worse respiratory status and chest X-ray on admission and presented with higher D-dimer, interleukin-6, and lactate dehydrogenase levels. In this multicenter LTR cohort, SARS-CoV-2 presented with high mortality. Additionally, the severity of disease on presentation predicted subsequent mortality.
C1 [Saez-Gimenez, Berta; Berastegui, Cristina; Barrecheguren, Miriam; Revilla-Lopez, Eva; Bravo, Carles; Lopez-Meseguer, Manuel; Monforte, Victor] Hosp Valle De Hebron, Lung Transplant Unit, Dept Resp Med, Barcelona, Spain.
   [Los Arcos, Ibai; Gavalda, Joan] Hosp Valle De Hebron, Dept Infect Dis, Barcelona, Spain.
   [Alonso, Rodrigo; Quezada, Carlos A.; Perez, Virginia] Hosp 12 Octubre, Lung Transplant Unit, Dept Resp Med, Madrid, Spain.
   [Aguilar, Myriam; Valle, Manuel; Laporta, Rosalia] Hosp Puerta de Hierro, Lung Transplant Unit, Majadahonda, Spain.
   [Mora, Victor M.] Hosp Marques de Valdecilla, Lung Transplant Unit, Dept Resp Med, Santander, Spain.
   [Otero, Isabel] Hosp A Coruna, Dept Resp Med, La Coruna, Spain.
   [Reig, Juan P.] Hosp La Fe, Lung Transplant Unit, Dept Resp Med, Valencia, Spain.
   [Deu, Maria] Hosp Valle De Hebron, Dept Thorac Surg, Barcelona, Spain.
   [Sacanell, Judith] Hosp Valle De Hebron, Dept Intens Care Med, Barcelona, Spain.
RP Lopez-Meseguer, M (corresponding author), Hosp Valle De Hebron, Lung Transplant Unit, Dept Resp Med, Barcelona, Spain.
EM manuelop@vhebron.net
RI Monforte, Victor/D-8733-2018; Lopez Meseguer, Manuel/D-6177-2018;
   Los-Arcos, Ibai/P-2997-2015
OI Monforte, Victor/0000-0002-2918-7679; Lopez Meseguer,
   Manuel/0000-0003-2650-9238; Mora Cuesta, Victor
   Manuel/0000-0002-8161-0462; Revilla Lopez, Eva/0000-0002-7751-4291;
   Los-Arcos, Ibai/0000-0001-8835-2702
CR Agencia Espanola de Medicamentos y Productos Sanitarios, TRAT DISP PAR MAN IN
   Aigner C, 2020, J HEART LUNG TRANSPL
   Aslam S, 2020, J HEART LUNG TRANSPL, V39, P408, DOI 10.1016/j.healun.2020.03.007
   Centro de Coordinacion de Alertas y Emergencias, ACT 147 ENF COR COVI
   Cheng SY, 2020, ANN INTERN MED, V173, P638, DOI 10.7326/M20-2927
   Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Fishman JA, 2014, CLIN MICROBIOL INFEC, V20, P4, DOI 10.1111/1469-0691.12593
   Gandolfini I, 2020, AM J TRANSPLANT, V20, P1941, DOI 10.1111/ajt.15891
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang JF, 2020, AM J TRANSPLANT, V20, P1907, DOI 10.1111/ajt.15909
   Ison MG, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00042-19
   Li F, 2020, J HEART LUNG TRANSPL, V39, P496, DOI 10.1016/j.healun.2020.03.006
   Mazo C, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.01512-2018
   Peghin M, 2017, AM J TRANSPLANT, V17, P1304, DOI 10.1111/ajt.14042
   Peghin M, 2019, CLIN INFECT DIS, V69, P1192, DOI 10.1093/cid/ciy1047
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Verleden GM, 2020, AM J TRANSPLANT, V20, P3234, DOI 10.1111/ajt.16212
   Wang DZ, 2020, INT J MULTIMED DATA, V11, P1, DOI 10.4018/IJMDEM.2020040101
   World Health Organization, 112 WHO
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zhang H, 2020, EUR UROL
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu L, 2020, AM J TRANSPLANT, V20, P1859, DOI 10.1111/ajt.15869
NR 27
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
DI 10.1111/ajt.16364
EA NOV 2020
PG 9
WC Surgery; Transplantation
SC Surgery; Transplantation
GA ON6WY
UT WOS:000586839700001
PM 33089648
OA Bronze
DA 2021-01-01
ER

PT J
AU Rivera-Caravaca, JM
   Nunez-Gil, IJ
   Vivas, D
   Viana-Llamas, MC
   Uribarri, A
   Becerra-Munoz, VM
   Trabattoni, D
   Rozas, IF
   Feltes, G
   Lopez-Pais, J
   El-Battrawy, I
   Macaya, C
   Fernandez-Ortiz, A
   Estrada, V
   Marin, F
AF Rivera-Caravaca, Jose Miguel
   Nunez-Gil, Ivan J.
   Vivas, David
   Viana-Llamas, Maria C.
   Uribarri, Aitor
   Becerra-Munoz, Victor Manuel
   Trabattoni, Daniela
   Fernandez Rozas, Inmaculada
   Feltes, Gisela
   Lopez-Pais, Javier
   El-Battrawy, Ibrahim
   Macaya, Carlos
   Fernandez-Ortiz, Antonio
   Estrada, Vicente
   Marin, Francisco
CA HOPE COVID-19 Investigators
TI Clinical profile and prognosis in patients on oral anticoagulation
   before admission for COVID-19
SO EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
DE anticoagulant; atrial fibrillation; Coronavirus disease 2019;
   SARS&#8208; CoV&#8208; 2; thrombosis; venous thromboembolism
AB Background The coronavirus disease 2019 (COVID-19) shows high morbidity and mortality, particularly in patients with concomitant cardiovascular diseases. Some of these patients are under oral anticoagulation (OAC) at admission, but to date, there are no data on the clinical profile, prognosis and risk factors of such patients during hospitalization for COVID-19.
   Design Subanalysis of the international 'real-world' HOPE COVID-19 registry. All patients with prior OAC at hospital admission for COVID-19 were suitable for the study. All-cause mortality was the primary endpoint.
   Results From 1002 patients included, 110 (60.9% male, median age of 81.5 [IQR 75-87] years, median Short-Form Charlson Comorbidity Index [CCI] of 1 [IQR 1-3]) were on OAC at admission, mainly for atrial fibrillation and venous thromboembolism. After propensity score matching, 67.9% of these patients died during hospitalization, which translated into a significantly higher mortality risk compared to patients without prior OAC (HR 1.53, 95% CI 1.08-2.16). After multivariate Cox regression analysis, respiratory insufficiency during hospitalization (HR 6.02, 95% CI 2.18-16.62), systemic inflammatory response syndrome (SIRS) during hospitalization (HR 2.29, 95% CI 1.34-3.91) and the Short-Form CCI (HR 1.24, 95% CI 1.03-1.49) were the main risk factors for mortality in patients on prior OAC.
   Conclusions Compared to patients without prior OAC, COVID-19 patients on OAC therapy at hospital admission showed lower survival and higher mortality risk. In these patients on OAC therapy, the prevalence of several comorbidities is high. Respiratory insufficiency and SIRS during hospitalization, as well as higher comorbidity, pointed out those anticoagulated patients with increased mortality risk.
C1 [Rivera-Caravaca, Jose Miguel; Marin, Francisco] Univ Murcia, Hosp Clin Univ Virgen Arrixaca, Inst Murciano Invest Biosanitaria IMIB Arrixaca, CIBERCV,Dept Cardiol, Murcia, Spain.
   [Nunez-Gil, Ivan J.; Vivas, David; Macaya, Carlos; Fernandez-Ortiz, Antonio; Estrada, Vicente] Univ Complutense Madrid, Inst Invest Sanitaria, Hosp Clin San Carlos IdISSC, Madrid, Spain.
   [Viana-Llamas, Maria C.] Hosp Univ Guadalajara, Dept Cardiol, Guadalajara, Spain.
   [Uribarri, Aitor] Hosp Clin Univ Valladolid, Valladolid, Spain.
   [Becerra-Munoz, Victor Manuel] Univ Malaga UMA, Ctr Invest Biomed Red Enfermedades Cardiovasc CIB, Inst Invest Biomed Malaga IBIMA, Hosp Univ Virgen Victoria,Unidad Gest Clin Area C, Malaga, Spain.
   [Trabattoni, Daniela] IRCCS, Ctr Cardiol Monzino, Milan, Italy.
   [Fernandez Rozas, Inmaculada] Hosp Severo Ochoa, Leganes, Spain.
   [Feltes, Gisela] Hosp Nuestra Senora Amer, Madrid, Spain.
   [Lopez-Pais, Javier] Complejo Hosp Univ Santiago De Compostela, Santiago De Compostela, Spain.
   [El-Battrawy, Ibrahim] Univ Mannheim, Mannheim, Germany.
RP Marin, F (corresponding author), Univ Murcia, Dept Cardiol, Hosp Clin Univ Virgen Arrixaca, Ctra Madrid Cartagena S-N, El Palmar 30120, Murcia, Spain.
EM fcomarino@hotmail.com
RI Rivera-Caravaca, Jose Miguel/O-5611-2016; Uribarri, Aitor/G-2393-2017
OI Rivera-Caravaca, Jose Miguel/0000-0003-0492-6241; Uribarri,
   Aitor/0000-0002-6911-7480
FU Fundacion Interhospitalaria para la investigacion Cardiovascular, FIC.
   Madrid, Spain
FX This study was supported by the nonconditioned grant (Fundacion
   Interhospitalaria para la investigacion Cardiovascular, FIC. Madrid,
   Spain). This nonprofit institution had no role in the study design; in
   the collection, analysis and interpretation of data; in the writing of
   the report; nor in the decision to submit the paper for publication.
CR [Anonymous], 2020, INT COVID19 CLIN EVA
   Austin PC, 2011, PHARM STAT, V10, P150, DOI 10.1002/pst.433
   Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697
   Bangalore S, 2020, NEW ENGL J MED, V382, P2478, DOI 10.1056/NEJMc2009020
   BERKMAN LF, 1992, ANN INTERN MED, V117, P1003, DOI 10.7326/0003-4819-117-12-1003
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Carbone F, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13311
   Carsana L, 2020, LANCET INFECT DIS, V20, P1135, DOI 10.1016/S1473-3099(20)30434-5
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Clerkin KJ, 2020, CIRCULATION, V141, P1648, DOI 10.1161/CIRCULATIONAHA.120.046941
   Connors JM, 2020, J THROMB HAEMOST, V18, P1559, DOI 10.1111/jth.14849
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Del Sole F, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13378
   Dolhnikoff M, 2020, J THROMB HAEMOST, V18, P1517, DOI 10.1111/jth.14844
   European Society of Cardiology, ESC GUIDANCE DIAGNOS
   Fan BE, 2020, AM J HEMATOL, V95, pE131, DOI 10.1002/ajh.25774
   Figliozzi S, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13362
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kornej J, 2020, CIRC RES, V127, P4, DOI 10.1161/CIRCRESAHA.120.316340
   Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9
   Lip GYH, 2017, THROMB HAEMOSTASIS, V117, P1230, DOI 10.1160/TH16-11-0876
   Lippi G, 2020, THROMB HAEMOSTASIS, V120, P876, DOI 10.1055/s-0040-1709650
   Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005
   Liverpool Drug Interaction Group, DETAILED RECOMMENDAT
   Malaty M, 2020, EUR J CLIN INVEST, DOI 10.1111/eci.13428
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Moores LK, 2020, CHEST, V158, P1143, DOI 10.1016/j.chest.2020.05.559
   Mueck W, 2013, BRIT J CLIN PHARMACO, V76, P455, DOI 10.1111/bcp.12075
   Nopp S, 2020, RES PRACT THROMB HAE, V4, P1178, DOI 10.1002/rth2.12439
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Ranucci M, 2020, J THROMB HAEMOST, V18, P1747, DOI 10.1111/jth.14854
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   Testa S, 2020, J THROMB HAEMOST, V18, P1320, DOI 10.1111/jth.14871
   Testa S, 2020, INTERN EMERG MED, V15, P751, DOI 10.1007/s11739-020-02331-1
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Thachil J, 2020, J THROMB HAEMOST, V18, P1020, DOI 10.1111/jth.14821
   Violi F, 2020, THROMB HAEMOSTASIS, V120, P949, DOI 10.1055/s-0040-1710317
   Vivas D, 2020, REV ESP CARDIOL, V73, P749, DOI 10.1016/j.recesp.2020.04.006
   Wang L, 2020, J INFECTION, V80, P639, DOI 10.1016/j.jinf.2020.03.019
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   World Health Organization, 2020, WHO ANNOUNCES COVID
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 47
TC 1
Z9 1
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2972
EI 1365-2362
J9 EUR J CLIN INVEST
JI Eur. J. Clin. Invest.
PD JAN
PY 2021
VL 51
IS 1
AR e13436
DI 10.1111/eci.13436
EA NOV 2020
PG 11
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA PH0JP
UT WOS:000586990900001
PM 33080051
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Qu, J
   Li, GH
   Wang, JJ
   He, GF
   Huang, JJ
   Chen, Y
   Qu, Q
   Chen, XY
   Lu, Q
AF Qu, Jian
   Li, Guo-Hua
   Wang, Jiao-Jiao
   He, Ge-Fei
   Huang, Juan-Juan
   Chen, Ying
   Qu, Qiang
   Chen, Xiang-Yu
   Lu, Qiong
TI Comparative effectiveness of Lopinavir/Ritonavir-based regimens in
   COVID-19
SO CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
LA English
DT Article; Early Access
DE Arbidol; COVID&#8208; 19; interferon; Lopinavir; Ritonavir; Novaferon;
   SARS&#8208; CoV&#8208; 2
ID SARS
AB The coronavirus disease 2019 (COVID-19) is an epidemic disease caused by the Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) and spreading throughout the world rapidly. Here we evaluated the efficacy of the Lopinavir/Ritonavir (LPV/r) and its combination with other drugs in the treatment of COVID-19. We included 170 confirmed COVID-19 patients who had been cured and discharged. Their antiviral therapies were LPV/r alone or combinations with interferon (IFN), Novaferon and Arbidol. We evaluated the medication efficacy by comparing the time of the negative nucleic acid conversion and the length of hospitalization mainly. The LPV/r + Novaferon [6.00 (4.00-8.00) and 7.50 (5.00-10.00) days] had shorter time of the negative nucleic acid conversion (P = .0036) and shorter time of hospitalization (P < .001) compared with LPV/r alone [9.00 (5.00-12.00) and 12.00 (11.00-15.00) days] and LPV/r + IFN [9.00 (7.25-11.00) and 12.00 (10.00-13.50) days]. On the contrary, LPV/r + IFN [9.00 (7.25-11.00) and 12.00 (10.00-13.50) days] had shorter time of the negative nucleic acid conversion (P = .031) and shorter time of hospitalization (P < .001) compared with LPV/r + IFN +Novaferon [10.00 (8.00-11.25) and 13.50 (11.50-17.00) days] and LPV/r + IFN +Arbidol [14.00 (9.75-19.00) and 19.50 (13.25-24.00) days]. In conclusion, the combination of LPV/r and Novaferon may have better efficacy against COVID-19. However, adding IFN based on LPV/r + Novaferon or adding Arbidol based on LPV/r + IFN may not improve the efficacy.
C1 [Qu, Jian; Li, Guo-Hua; Wang, Jiao-Jiao; Lu, Qiong] Cent South Univ, Xiangya Hosp 2, Dept Pharm, 139 Middle Renmin Rd, Changsha 410011, Hunan, Peoples R China.
   [Qu, Jian; Li, Guo-Hua; Wang, Jiao-Jiao; Lu, Qiong] Cent South Univ, Inst Clin Pharm, Changsha, Peoples R China.
   [He, Ge-Fei; Huang, Juan-Juan] First Hosp Changsha, Changsha, Peoples R China.
   [Chen, Ying] Wuhan Univ, Renmin Hosp, Dept Pharm, Wuhan, Peoples R China.
   [Qu, Qiang] Cent South Univ, Xiangya Hosp, Dept Pharm, Changsha, Peoples R China.
   [Chen, Xiang-Yu] Cent South Univ, Xiangya Hosp 2, Dept Radiol, 139 Middle Renmin Rd, Changsha 410011, Hunan, Peoples R China.
RP Lu, Q (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Pharm, 139 Middle Renmin Rd, Changsha 410011, Hunan, Peoples R China.; Chen, XY (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Radiol, 139 Middle Renmin Rd, Changsha 410011, Hunan, Peoples R China.
EM chenxiangyu@csu.edu.cn; christy_luq@csu.edu.cn
FU Novel coronavirus pneumonia major project of Hunan [2020SK3014]
FX Novel coronavirus pneumonia major project of Hunan, Grant/Award Number:
   2020SK3014
CR [Anonymous], 2020, INFECT DIS INFORM, V33
   Chan KW, 2019, AM J CHINESE MED, V2020, P1
   Chen J., 2020, CHINESE J INFECT DIS, V38, pE008, DOI [10.3760/cma.j.cn311365-20200210-00050, DOI 10.3760/CMA.J.CN311365-20200210-00050]
   Cheng CY, 2020, J MICROBIOL IMMUNOL, V53, P488, DOI 10.1016/j.jmii.2020.03.032
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Deng L, 2020, J INFECTION, V81, P1
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Du B, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P173, DOI 10.3760/cma.j.issn.1001-0939.2020.03.005
   Jing HL, 2013, CLIN NUCL MED, V38, P664, DOI 10.1097/RLU.0b013e3182996293
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li M, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-8
   Luo YP, 2015, CLIN NUCL MED, V40, P501, DOI 10.1097/RLU.0000000000000655
   NHC, DIAGN TREATM PROT SE
   Panoutsopoulos Alexios A, 2020, Genes Dis, V7, P528, DOI 10.1016/j.gendis.2020.06.007
   Panoutsopoulos Alexios A, 2020, SN Compr Clin Med, P1, DOI 10.1007/s42399-020-00360-7
   Prokunina-Olsson L, 2020, J EXP MED, V217, DOI 10.1084/jem.20200653
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Scavone C, 2020, BRIT J PHARMACOL, V177, P4813, DOI 10.1111/bph.15072
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Su B, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01472
   Vankadari N, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105998
   Wang X, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0169-8
   Wen CY, 2020, ZHONGHUA NEI KE ZA Z, V59, pE012
   WHO, 2020, 118 WHO
   Xu Kaijin, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P147, DOI 10.3785/j.issn.1008-9292.2020.02.02
   Ye XT, 2020, EUR REV MED PHARMACO, V24, P3390, DOI 10.26355/eurrev_202003_20706
   Yuan J, 2020, INFLAMM RES, V69, P599, DOI 10.1007/s00011-020-01342-0
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zheng F, 2020, MEDRXIV, DOI [10.1101/2020.04.24.20077735, DOI 10.1101/2020.04.24.20077735]
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 30
TC 0
Z9 0
U1 5
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0305-1870
EI 1440-1681
J9 CLIN EXP PHARMACOL P
JI Clin. Exp. Pharmacol. Physiol.
DI 10.1111/1440-1681.13425
EA NOV 2020
PG 8
WC Pharmacology & Pharmacy; Physiology
SC Pharmacology & Pharmacy; Physiology
GA ON5BI
UT WOS:000586715900001
PM 33090501
OA Bronze
DA 2021-01-01
ER

PT J
AU Zhang, YM
   Wang, L
   Liu, XZ
   Zhang, H
AF Zhang, Yue-Miao
   Wang, Lin
   Liu, Xing-Zi
   Zhang, Hong
TI The COVID-19 Pandemic from a Human Genetic Perspective
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE SARS-CoV-2; a human genetic perspective; transmission; pathogenesis;
   susceptibility; severity; drug prioritization
AB The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has impacted a large portion of the world population. From a virus genetic perspective, a recent study described what genomic data revealed about the origin and emergence of SARS-CoV-2, proposing stronger action against illegal wildlife trade. In the current "big data" era, an increasing number of large-scale, multidimensional omics data sets were publicly available. Herein, we review how human genetics tells us about the transmission, pathogenesis, susceptibility, severity, and drug prioritization of COVID-19. We further drafted a genetic roadmap of COVID-19, which was also expected to be applicable to other viruses with known receptors. Our review provides insights into the way of understanding a pandemic from a human genetic perspective.
C1 [Zhang, Yue-Miao; Liu, Xing-Zi; Zhang, Hong] Peking Univ First Hosp, Dept Med, Renal Div, Beijing 100871, Peoples R China.
   [Zhang, Yue-Miao; Liu, Xing-Zi; Zhang, Hong] Peking Univ, Inst Nephrol, Beijing 100871, Peoples R China.
   [Zhang, Yue-Miao; Liu, Xing-Zi; Zhang, Hong] Chinese Acad Med Sci, Res Units Diag & Treatment Immune Mediated Kidney, Beijing 100871, Peoples R China.
   [Wang, Lin] Peking Univ, Dept Microbiol & Infect Dis Ctr, Sch Basic Med Sci, Hlth Sci Ctr, Beijing 100871, Peoples R China.
RP Zhang, H (corresponding author), Peking Univ First Hosp, Dept Med, Renal Div, Beijing 100871, Peoples R China.; Zhang, H (corresponding author), Peking Univ, Inst Nephrol, Beijing 100871, Peoples R China.; Zhang, H (corresponding author), Chinese Acad Med Sci, Res Units Diag & Treatment Immune Mediated Kidney, Beijing 100871, Peoples R China.
EM hongzh@bjmu.edu.cn
OI zhang, yuemiao/0000-0001-9863-4738
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81800636]
FX This study was supported by the National Natural Science Foundation of
   China (81800636).
CR Bilinska K, 2020, ACS CHEM NEUROSCI, V11, P1555, DOI 10.1021/acschemneuro.0c00210
   Braun F, 2020, LANCET, V396, P597, DOI 10.1016/S0140-6736(20)31759-1
   Buniello A, 2019, NUCLEIC ACIDS RES, V47, pD1005, DOI 10.1093/nar/gky1120
   Cao YN, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0147-1
   Chen M., 2020, EUR RESPIR J, V8
   Covid 19 Host Genetics Initiative, 2020, EUR J HUM GENET, V28, P715, DOI 10.1038/s41431-020-0636-6
   Diao B, 2020, HUMAN KIDNEY IS TARG, DOI [10.1101/2020.03.04.20031120, DOI 10.1101/2020.03.04.20031120]
   Ellul MA, 2020, LANCET NEUROL, V19, P767, DOI 10.1016/S1474-4422(20)30221-0
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Gralinski LE, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005504
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hemani G, 2018, ELIFE, V7, DOI 10.7554/eLife.34408
   Hoehl S, 2020, NEW ENGL J MED, V382, P1278, DOI 10.1056/NEJMc2001899
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu ZL, 2020, SCI CHINA LIFE SCI, V63, P706, DOI 10.1007/s11427-020-1661-4
   Jin X, 2020, GUT, V69, P1002, DOI 10.1136/gutjnl-2020-320926
   Lamers MM, 2020, SCIENCE, V369, P50, DOI 10.1126/science.abc1669
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Morbini P., 2020, JAMA OTOLARYNGOL HEA, V146, P972
   Murphy TL, 2013, NAT REV IMMUNOL, V13, P499, DOI 10.1038/nri3470
   Puntmann Valentina O, 2020, JAMA Cardiol, V5, P1265, DOI 10.1001/jamacardio.2020.3557
   Richardson TG, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13921-9
   Selby NM, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1963
   Solomon IH, 2020, NEW ENGL J MED, V383, P989, DOI 10.1056/NEJMc2019373
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   Sungnak W., 2020, ARXIV200306122
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Weng L, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2004794
   Wu YJ, 2020, LANCET GASTROENTEROL, V5, P434, DOI 10.1016/S2468-1253(20)30083-2
   Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
   Zhang BZ, 2020, CELL RES, V30, P928, DOI 10.1038/s41422-020-0390-x
   Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035
   Zhang YM, 2020, CLIN J AM SOC NEPHRO, V15, P1044, DOI 10.2215/CJN.04370420
   Zheng J., 2020, MULTIOMICS STUDY REV, DOI [10.1101/2020.05.07.20093286, DOI 10.1101/2020.05.07.20093286]
   Zheng J, 2020, NAT GENET, V52, P1122, DOI 10.1038/s41588-020-0682-6
   Zheng SF, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1443
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou W, 2018, NAT GENET, V50, P1335, DOI 10.1038/s41588-018-0184-y
   Zhou ZL, 2020, GASTROENTEROLOGY, V158, P2294, DOI 10.1053/j.gastro.2020.03.020
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
NR 44
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD NOV 6
PY 2020
VL 19
IS 11
BP 4374
EP 4379
DI 10.1021/acs.jproteome.0c00671
PG 6
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA OS1RZ
UT WOS:000589944200014
PM 33084340
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Stamatakis, G
   Samiotaki, M
   Mpakali, A
   Panayotou, G
   Stratikos, E
AF Stamatakis, George
   Samiotaki, Martina
   Mpakali, Anastasia
   Panayotou, George
   Stratikos, Efstratios
TI Generation of SARS-CoV-2 S1 Spike Glycoprotein Putative Antigenic
   Epitopes in Vitro by Intracellular Aminopeptidases
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE enzyme; antigen; peptide; immune system; aminopeptidase; epitope;
   SARS-CoV-2; COVID-19; HLA; LC-MS/MS
AB Presentation of antigenic peptides by MHCl is central to cellular immune responses against viral pathogens. While adaptive immune responses versus SARS-CoV-2 can be of critical importance to both recovery and vaccine efficacy, how protein antigens from this pathogen are processed to generate antigenic peptides is largely unknown. Here, we analyzed the proteolytic processing of overlapping precursor peptides spanning the entire sequence of the S1 spike glycoprotein of SARS-CoV-2, by three key enzymes that generate antigenic peptides, aminopeptidases ERAP1, ERAP2, and IRAP. All enzymes generated shorter peptides with sequences suitable for binding onto HLA alleles, but with distinct specificity fingerprints. ERAP1 was the most efficient in generating peptides 8-11 residues long, the optimal length for HLA binding, while IRAP was the least efficient. The combination of ERAP1 with ERAP2 greatly limited the variability of peptide sequences produced. Less than 7% of computationally predicted epitopes were found to be produced experimentally, suggesting that aminopeptidase processing may constitute a significant filter to epitope presentation. These experimentally generated putative epitopes could be prioritized for SARS-CoV-2 immunogenicity studies and vaccine design. We furthermore propose that this in vitro trimming approach could constitute a general filtering method to enhance the prediction robustness for viral antigenic epitopes.
C1 [Stamatakis, George; Samiotaki, Martina; Panayotou, George] BiomedicalSci Res Ctr Alexander Fleming, Vari 16672, Attica, Greece.
   [Mpakali, Anastasia; Stratikos, Efstratios] Natl Ctr Sci Res Demokritos, Aghia Paraskevi 15310, Attica, Greece.
RP Stratikos, E (corresponding author), Natl Ctr Sci Res Demokritos, Aghia Paraskevi 15310, Attica, Greece.
EM stratos@rrp.demokritos.gr
RI ; Stratikos, Efstratios/N-2969-2014
OI Reis, AlessanRSS/0000-0001-8486-7469; Mpakali,
   Anastasia/0000-0003-0869-9680; Stratikos, Efstratios/0000-0002-3566-2309
FU NCSR Demokritos; "InfrafrontierGR/Phenotypos" - Operational Programme
   "Competitiveness, Entrepreneurship and Innovation" (NSRF 2014-2020) [MIS
   5002135]; "The Greek Research Infrastructure for Personalised Medicine
   (pMED-GR)" - Operational Programme "Competitiveness, Entrepreneurship
   and Innovation" (NSRF 2014-2020) [MIS 5002802]; EU (ERDF)European Union
   (EU)
FX This research was supported by NCSR Demokritos and by
   "InfrafrontierGR/Phenotypos" (MIS 5002135) and by "The Greek Research
   Infrastructure for Personalised Medicine (pMED-GR)" (MIS 5002802), both
   funded by the Operational Programme "Competitiveness, Entrepreneurship
   and Innovation" (NSRF 2014-2020) and cofinanced by Greece and the EU
   (ERDF).
CR Chang SC, 2005, P NATL ACAD SCI USA, V102, P17107, DOI 10.1073/pnas.0500721102
   Chen HN, 2016, SCI REP-UK, V6, DOI 10.1038/srep28902
   Evnouchidou I, 2014, J IMMUNOL, V193, P901, DOI 10.4049/jimmunol.1302855
   Evnouchidou I, 2011, J IMMUNOL, V186, P1909, DOI 10.4049/jimmunol.1003337
   Georgiadou D, 2010, J IMMUNOL, V185, P1584, DOI 10.4049/jimmunol.0902502
   Giastas P, 2019, P NATL ACAD SCI USA, V116, P26709, DOI 10.1073/pnas.1912070116
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Hammer GE, 2007, IMMUNITY, V26, P397, DOI 10.1016/j.immuni.2007.04.003
   Hearn A, 2009, J IMMUNOL, V183, P5526, DOI 10.4049/jimmunol.0803663
   Hulsen T, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-488
   Infantes S, 2010, J IMMUNOL, V184, P3351, DOI 10.4049/jimmunol.0901560
   John ALS, 2020, J IMMUNOL, V205, P555, DOI 10.4049/jimmunol.2000526
   Komov L, 2018, PROTEOMICS, V18, DOI 10.1002/pmic.201700248
   Kuiper JJW, 2014, HUM MOL GENET, V23, P6081, DOI 10.1093/hmg/ddu307
   Leslie M, 2020, SCIENCE, V368, P809, DOI 10.1126/science.368.6493.809
   Li KY, 2020, SCAND J IMMUNOL, V92, DOI 10.1111/sji.12895
   de Castro JAL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02463
   Lorente E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079596
   Manners C, 2020, CUREUS, V12, DOI 10.7759/cureus.8399
   Mavridis G, 2020, J BIOL CHEM, V295, P7193, DOI 10.1074/jbc.RA120.012976
   Mpakali A, 2015, J BIOL CHEM, V290, P26021, DOI 10.1074/jbc.M115.685909
   Mpakali A, 2015, J IMMUNOL, V195, P2842, DOI 10.4049/jimmunol.1501103
   Mukherjee S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020290
   Nguyen A, 2020, J VIROL, V94, DOI 10.1128/JVI.00510-20
   Peeples L, 2020, P NATL ACAD SCI USA, V117, P8218, DOI 10.1073/pnas.2005456117
   Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106
   Reynisson B, 2020, NUCLEIC ACIDS RES, V48, pW449, DOI 10.1093/nar/gkaa379
   Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739
   Sarkizova S, 2020, NAT BIOTECHNOL, V38, P199, DOI 10.1038/s41587-019-0322-9
   Saveanu L, 2005, NAT IMMUNOL, V6, P689, DOI 10.1038/ni1208
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Song PP, 2020, CLIN CHIM ACTA, V509, P280, DOI 10.1016/j.cca.2020.06.017
   Stamogiannos A, 2017, BIOCHEMISTRY-US, V56, P1546, DOI 10.1021/acs.biochem.6b01170
   Stratikos E, 2013, MOL IMMUNOL, V55, P212, DOI 10.1016/j.molimm.2013.03.002
   Thomas C, 2019, CURR OPIN IMMUNOL, V58, P9, DOI 10.1016/j.coi.2019.01.001
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Vita R, 2010, NUCLEIC ACIDS RES, V38, pD854, DOI 10.1093/nar/gkp1004
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang W, 2020, HLA, V96, P194, DOI 10.1111/tan.13941
   Weimershaus M, 2013, CURR OPIN IMMUNOL, V25, P90, DOI 10.1016/j.coi.2012.10.001
   Wilk AJ, 2020, NAT MED, V26, P1070, DOI 10.1038/s41591-020-0944-y
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zervoudi E, 2011, BIOCHEM J, V435, P411, DOI 10.1042/BJ20102049
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 45
TC 0
Z9 0
U1 1
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD NOV 6
PY 2020
VL 19
IS 11
BP 4398
EP 4406
DI 10.1021/acs.jproteome.0c00457
PG 9
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA OS1RZ
UT WOS:000589944200018
PM 32931291
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Goh, GKM
   Dunker, AK
   Foster, JA
   Uversky, VN
AF Goh, Gerard Kian-Meng
   Dunker, A. Keith
   Foster, James A.
   Uversky, Vladimir N.
TI Shell Disorder Analysis Suggests That Pangolins Offered a Window for a
   Silent Spread of an Attenuated SARS-CoV-2 Precursor among Humans
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE pangolin; intrinsic; disorder; protein; nucleocapsid; virulence; shell;
   COVID; coronavirus; vaccine; immune; antibody; shell; nucleoprotein;
   matrix; attenuate
AB A model to predict the relative levels of respiratory and fecal-oral transmission potentials of coronaviruses (CoVs) by measuring the percentage of protein intrinsic disorder (PID) of the M (Membrane) and N (Nucleoprotein) proteins in their outer and inner shells, respectively, was built before the MERS-CoV outbreak. With Mpw = 8.6% and N-PID = 50.2%, the 2003 SARS-CoV falls into group B, which consists of CoVs with intermediate levels of both fecal-oral and respiratory transmission potentials. Further validation of the model came with MERS-CoV (M-PID = 9%, N-PID = 44 %) and SARS-CoV-2 PID = 5.5%, N-PID = 48%) falling into the groups C and B, respectively. Group C contains CoVs with higher fecal-oral but lower respiratory transmission potentials. Unlike SARS-CoV, SARS-CoV-2 with Mini) = 5.5% has one of the hardest outer shells among CoVs. Because the hard shell is able to resist the antimicrobial enzymes in body fluids, the infected person is able to shed large quantities of viral particles via saliva and mucus, which could account for the higher contagiousness of SARS-COV-2. Further searches have found that high rigidity of the outer shell is characteristic for the CoVs of burrowing animals, such as rabbits (M-PID = 5. 6 %) and pangolins (M-PID = 5-6%), which are in contact with the buried feces. A closer inspection of pangolin-CoVs from 2017 to 2019 reveals that pangolins provided a unique window of opportunity for the entry of an attenuated SARS-CoV-2 precursor into the human population in 2017 or earlier, with the subsequent slow and silent spread as a mild cold that followed by its mutations into the current more virulent form. Evidence of this lies in both the genetic proximity of the pangolin-CoVs to SARS-CoV-2 (similar to 90%) and differences in N disorder. A 2017 pangolin-CoV strain shows evidence of higher levels of attenuation and higher fecal-oral transmission associated with lower human infectivity via having lower N-PID (44.8%). Our shell disorder model predicts this to be a SARS-CoV-2 vaccine strain, as lower inner shell disorder is associated with the lesser virulence in a variety of viruses.
C1 [Dunker, A. Keith] Indiana Univ Sch Med, Ctr Computat Biol & Bioinformat, Indianapolis, IN 46202 USA.
   [Foster, James A.] Univ Idaho, Dept Biol Sci, Moscow, ID 83844 USA.
   [Foster, James A.] Univ Idaho, Inst Bioinformat & Evolutionary Studies, Moscow, ID 83844 USA.
   [Uversky, Vladimir N.] Univ S Florida, Morsani Coll Med, USF Hlth Byrd Alzheimers Res Inst, Dept Mol Med, Tampa, FL 33620 USA.
   [Uversky, Vladimir N.] Russian Acad Sci, Lab New Methods Biol, Inst Biol Instrumentat, Fed Res Ctr,Pushchino Sci Ctr Biol Res, Moscow 119991, Russia.
   [Goh, Gerard Kian-Meng] Gohs BioComp, Singapore 548957, Singapore.
RP Goh, GKM (corresponding author), Gohs BioComp, Singapore 548957, Singapore.
EM gohsbiocomputing@yahoo.com
OI Goh, Gerard Kian-Meng/0000-0003-3635-0806
CR Acheson N. H., 2007, FUNDAMENTALS MOL VIR, P1
   Anand P, 2020, ELIFE, V9, DOI 10.7554/eLife.58603
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Cheng YG, 2007, BIOCHEMISTRY-US, V46, P13468, DOI 10.1021/bi7012273
   Cole AM, 1999, INFECT IMMUN, V67, P3267, DOI 10.1128/IAI.67.7.3267-3275.1999
   Fan HH, 2020, CHINESE MED J-PEKING, V133, P1051, DOI [10.1097/CM9.0000000000000797, 10.1080/15384047.2020.1792218]
   Ferguson NM, 2014, LANCET INFECT DIS, V14, P93, DOI 10.1016/S1473-3099(13)70691-1
   Garner E., 1999, GENOME INFORM WORKSH, V10, P41, DOI DOI 10.11234/GI1990.10.41
   Goh G., 2020, NOVEL STRATEGY
   Goh G. K., 2017, VIRAL SHAPESHIFTERS, V1st, P1
   Goh GKM, 2020, MICROB PATHOGENESIS, V144, DOI 10.1016/j.micpath.2020.104177
   Goh GKM, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10020331
   Goh GKM, 2020, MICROB PATHOGENESIS, V141, DOI 10.1016/j.micpath.2020.103976
   Goh GKM, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110710
   Goh GKM, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9050178
   Goh GKM, 2016, MOL BIOSYST, V12, P1881, DOI 10.1039/c6mb00228e
   Goh GKM, 2012, J PATHOG, V2012, DOI 10.1155/2012/738590
   Goh GKM, 2015, MOL BIOSYST, V11, P2337, DOI 10.1039/c5mb00240k
   Goh GKM, 2015, MOL BIOSYST, V11, P2312, DOI 10.1039/c5mb00277j
   Goh Gerard Kian-Meng, 2013, PLoS Curr, V5, DOI 10.1371/currents.outbreaks.22254b58675cdebc256dbe3c5aa6498b
   Goh GKM, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-126
   Goh GKM, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-69
   Goh GKM, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-S2-S4
   Habchi J, 2012, MOL BIOSYST, V8, P69, DOI 10.1039/c1mb05204g
   Hanley Kathryn A, 2011, Evolution (N Y), V4, P635
   Ji W, 2020, J MED VIROL, V92, P433, DOI 10.1002/jmv.25682
   Li X., 1999, GENOME INFORM SER WO, V10, P30
   Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI [10.1016/j.jaci.2020.04.006, 10.1002/jmv.25731]
   Lin CM, 2015, J VIROL, V89, P3332, DOI 10.1128/JVI.03196-14
   Liu P, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008421
   Lu S., 2020, SARS COV 2 NUCLEOCAP, DOI [10.1101/2020.07.30.228023., DOI 10.1101/2020.07.30.228023]
   Macossay-Castillo M, 2019, J MOL BIOL, V431, P1650, DOI 10.1016/j.jmb.2019.03.008
   Malamud D, 2011, Adv Dent Res, V23, P34, DOI 10.1177/0022034511399282
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   Mousavizadeh Leila, 2020, J Microbiol Immunol Infect, DOI 10.1016/j.jmii.2020.03.022
   Oldfield CJ, 2005, BIOCHEMISTRY-US, V44, P12454, DOI 10.1021/bi050736e
   R Core Team, 2019, R FDN STAT COMP
   Richer RA, 1997, AFR J ECOL, V35, P361, DOI 10.1111/j.1365-2028.1997.101-89101.x
   Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2
   Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.0.CO;2-7
   Watanabe S, 2006, J VIROL, V80, P3743, DOI 10.1128/JVI.80.8.3743-3751.2006
   WHO, NOV CONN 2019 NCOV
   WHO, MIDDLE E RESP SYNDRO
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110
   Xue B, 2010, PROTEIN PEPTIDE LETT, V17, P932, DOI 10.2174/092986610791498984
   Zhang CX, 2020, J PROTEOME RES, V19, P1351, DOI 10.1021/acs.jproteome.0c00129
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 51
TC 1
Z9 1
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD NOV 6
PY 2020
VL 19
IS 11
BP 4543
EP 4552
DI 10.1021/acs.jproteome.0c00460
PG 10
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA OS1RZ
UT WOS:000589944200029
PM 32790362
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Nadeau, R
   Fard, SS
   Scheer, A
   Hashimoto-Roth, E
   Nygard, D
   Abramchuk, I
   Chung, YE
   Bennett, SAL
   Lavallee-Adam, M
AF Nadeau, Rachel
   Fard, Soroush Shahryari
   Scheer, Amit
   Hashimoto-Roth, Emily
   Nygard, Dallas
   Abramchuk, Iryna
   Chung, Yun-En
   Bennett, Steffany A. L.
   Lavallee-Adam, Mathieu
TI Computational Identification of Human Biological Processes and Protein
   Sequence Motifs Putatively Targeted by SARS-CoV-2 Proteins Using
   Protein-Protein Interaction Networks
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE COVID-19; SARS-CoV-2; protein-protein interaction network; motif
   discovery; gene ontology; enrichment analysis; clustering; statistics;
   graph theory
AB While the COVID-19 pandemic is causing important loss of life, knowledge of the effects of the causative SARS-CoV-2 virus on human cells is currently limited. Investigating protein-protein interactions (PPIs) between viral and host proteins can provide a better understanding of the mechanisms exploited by the virus and enable the identification of potential drug targets. We therefore performed an in-depth computational analysis of the interactome of SARS-CoV-2 and human proteins in infected HEK 293 cells published by Gordon et al. (Nature 2020, 583, 459-468) to reveal processes that are potentially affected by the virus and putative protein binding sites. Specifically, we performed a set of network-based functional and sequence motif enrichment analyses on SARS-CoV-2-interacting human proteins and on PPI networks generated by supplementing viral-host PPIs with known interactions. Using a novel implementation of our GoNet algorithm, we identified 329 Gene Ontology terms for which the SARS-CoV-2-interacting human proteins are significantly clustered in PPI networks. Furthermore, we present a novel protein sequence motif discovery approach, LESMoN-Pro, that identified 9 amino acid motifs for which the associated proteins are clustered in PPI networks. Together, these results provide insights into the processes and sequence motifs that are putatively implicated in SARS-CoV-2 infection and could lead to potential therapeutic targets.
C1 [Nadeau, Rachel; Fard, Soroush Shahryari; Scheer, Amit; Hashimoto-Roth, Emily; Nygard, Dallas; Abramchuk, Iryna; Chung, Yun-En; Lavallee-Adam, Mathieu] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada.
   [Nadeau, Rachel; Fard, Soroush Shahryari; Scheer, Amit; Hashimoto-Roth, Emily; Nygard, Dallas; Abramchuk, Iryna; Chung, Yun-En] Univ Ottawa, Ottawa Inst Syst Biol, Ottawa, ON K1H 8M5, Canada.
   [Nadeau, Rachel; Fard, Soroush Shahryari; Scheer, Amit; Hashimoto-Roth, Emily; Nygard, Dallas; Abramchuk, Iryna; Chung, Yun-En] Univ Ottawa, Fac Med, Ottawa, ON K1H 8M5, Canada.
   [Bennett, Steffany A. L.] Univ Ottawa, Dept Biochem Microbiol & Immunol, Immunol uOttawa Brain & Mind Res Inst, Ottawa, ON K1H 8M5, Canada.
   [Bennett, Steffany A. L.] Univ Ottawa, Ottawa Inst Syst Biol, uOttawa Brain & Mind Res Inst, Ottawa, ON K1H 8M5, Canada.
   [Bennett, Steffany A. L.] Univ Ottawa, Ctr Catalysis & Res Innovat, Dept Chem & Biomol Sci, Ottawa, ON K1H 8M5, Canada.
RP Lavallee-Adam, M (corresponding author), Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada.
EM mathieu.lavallee@uottawa.ca
OI Lavallee-Adam, Mathieu/0000-0003-2124-3872
FU Natural Sciences and Engineering Research Council (NSERC) of
   CanadaNatural Sciences and Engineering Research Council of Canada; NSERC
   Canada Graduate ScholarshipNatural Sciences and Engineering Research
   Council of Canada; Ontario Graduate ScholarshipOntario Graduate
   Scholarship; Canadian Institutes of Health Research Canada Graduate
   ScholarshipCanadian Institutes of Health Research (CIHR); NSERC CREATE
   in Metabolomics Advanced Training and International Exchange (MATRIX)
   Program; NSERC Undergraduate Student Research AwardNatural Sciences and
   Engineering Research Council of Canada; Compute Ontario; Compute Canada
FX The authors acknowledge funding from the following sources: Natural
   Sciences and Engineering Research Council (NSERC) of Canada Discovery
   grants to M.L.A. R.N. held a NSERC Canada Graduate Scholarship and an
   Ontario Graduate Scholarship. S.S.F. held a Canadian Institutes of
   Health Research Canada Graduate Scholarship. E.H.R. and D.N. were funded
   by a stipend from the NSERC CREATE in Metabolomics Advanced Training and
   International Exchange (MATRIX) Program. A.S., I.A., and Y.-E.C. held a
   NSERC Undergraduate Student Research Award. This research was enabled in
   part by support provided by Compute Ontario (https://computeontario.ca/)
   and Compute Canada (www.computecanada.ca) with Resource Allocation to
   M.L.A.
CR Adedeji AO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036521
   Ahmadpour D, 2020, IRAN J KIDNEY DIS, V14, P167
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   [Anonymous], 2003, SUMM PROB SARS CAS O
   [Anonymous], 2019, WHO MERS GLOB SUMM A
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2
   Bailey TL, 2009, NUCLEIC ACIDS RES, V37, pW202, DOI 10.1093/nar/gkp335
   Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049
   Bauer S, 2008, BIOINFORMATICS, V24, P1650, DOI 10.1093/bioinformatics/btn250
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bojkova D, 2020, NATURE, V583, P469, DOI 10.1038/s41586-020-2332-7
   Breitkreutz A, 2010, SCIENCE, V328, P1043, DOI 10.1126/science.1176495
   Brocker C, 2012, P NATL ACAD SCI USA, V109, P1991, DOI 10.1073/pnas.1117797109
   Cagliani R, 2020, INFECT GENET EVOL, V83, DOI 10.1016/j.meegid.2020.104353
   Choi H, 2011, NAT METHODS, V8, P70, DOI 10.1038/NMETH.1541
   Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1
   Croft D, 2011, NUCLEIC ACIDS RES, V39, pD691, DOI 10.1093/nar/gkq1018
   El-Gebali S, 2019, NUCLEIC ACIDS RES, V47, pD427, DOI 10.1093/nar/gky995
   Enright AJ, 2002, NUCLEIC ACIDS RES, V30, P1575, DOI 10.1093/nar/30.7.1575
   Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4
   Gavin AC, 2006, NATURE, V440, P631, DOI 10.1038/nature04532
   Go C. D., 2019, PROXIMITY BIOTINYLAT, DOI [10.1101/796391, DOI 10.1101/796391]
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu F, 2015, J BIOL CHEM, V290, P26373, DOI 10.1074/jbc.M115.657940
   Keum YS, 2012, BIOCHEM PHARMACOL, V84, P1351, DOI 10.1016/j.bcp.2012.08.012
   King AD, 2004, BIOINFORMATICS, V20, P3013, DOI 10.1093/bioinformatics/bth351
   Kuznetsova I, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2671-2
   Lavallee-Adam M, 2017, NUCLEIC ACIDS RES, V45, P10415, DOI 10.1093/nar/gkx751
   Lavallee-Adam M, 2013, J PROTEOME RES, V12, P272, DOI 10.1021/pr300778b
   Lavallee-Adam M, 2011, J PROTEOME RES, V10, P886, DOI 10.1021/pr100795z
   Lavallee-Adam M, 2010, J COMPUT BIOL, V17, P443, DOI 10.1089/cmb.2009.0165
   Li ST, 2011, IMMUNITY, V35, P426, DOI 10.1016/j.immuni.2011.06.014
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10
   Mirza MU, 2020, J PHARM ANAL, V10, P320, DOI 10.1016/j.jpha.2020.04.008
   Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29
   Puthenveedu MA, 2006, NAT CELL BIOL, V8, P238, DOI 10.1038/ncb1366
   Romano M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051267
   Salgado-Benvindo C, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00900-20
   Sen TZ, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-355
   Shu T, 2020, VIROL SIN, V35, P321, DOI 10.1007/s12250-020-00242-1
   Shulla A, 2011, J VIROL, V85, P873, DOI 10.1128/JVI.02062-10
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042
   Subissi L, 2014, ANTIVIR RES, V101, P122, DOI 10.1016/j.antiviral.2013.11.006
   Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Tang T, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104792
   Wagih O, 2017, BIOINFORMATICS, V33, P3645, DOI 10.1093/bioinformatics/btx469
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   Yu MS, 2012, BIOORG MED CHEM LETT, V22, P4049, DOI 10.1016/j.bmcl.2012.04.081
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 57
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD NOV 6
PY 2020
VL 19
IS 11
BP 4553
EP 4566
DI 10.1021/acs.jproteome.0c00422
PG 14
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA OS1RZ
UT WOS:000589944200030
PM 33103435
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Barros, RO
   Junior, FLCC
   Pereira, WS
   Oliveira, NMN
   Ramos, RM
AF Barros, Romulo O.
   Junior, Fabio L. C. C.
   Pereira, Wildrimak S.
   Oliveira, Neiva M. N.
   Ramos, Ricardo M.
TI Interaction of Drug Candidates with Various SARS-CoV-2 Receptors: An in
   Silico Study to Combat COVID-19
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE SARS-CoV-2; COVID-19; docking
AB The world is currently facing the COVID-19 pandemic caused by the SARS-CoV-2 virus. The pandemic is causing the death of people around the world, and public and social health measures to slow or prevent the spread of COVID-19 are being implemented with the involvement of all members of society. Research institutions are accelerating the discovery of vaccines and therapies for COVID-19. In this work, molecular docking was used to study (in silico) the interaction of 24 ligands, divided into four groups, with four SARS-CoV-2 receptors, Nsp9 replicase, main protease (Mpro), NSP15 endoribonuclease, and spike protein (Sprotein) interacting with human ACE2. The results showed that the antimalarial drug Metaquine and anti-HIV antiretroviral Saquinavir interacted with all the studied receptors, indicating that they are potential candidates for multitarget drugs for COVID-19.
C1 [Barros, Romulo O.; Junior, Fabio L. C. C.; Pereira, Wildrimak S.; Oliveira, Neiva M. N.; Ramos, Ricardo M.] Fed Inst Piaui, Dept Informat Environm Hlth & Food Prod, Res Lab Informat Syst, LaPeSI IFPI, BR-64019368 Teresina, Piaui, Brazil.
RP Ramos, RM (corresponding author), Fed Inst Piaui, Dept Informat Environm Hlth & Food Prod, Res Lab Informat Syst, LaPeSI IFPI, BR-64019368 Teresina, Piaui, Brazil.
EM ricardo@ifpi.edu.br
RI Ramos, Ricardo/Q-2133-2017
OI Ramos, Ricardo/0000-0003-2016-3344
FU Federal Institute of Piaui
FX We thank the professors of the Graduate Program in Chemistry (PPGQ),
   especially Prof. Dr. Antonio Luiz Martins Maia Filho, Prof. Dr.
   Francielle Alline Martins, and Prof. Dr. Valdileia Teixeira Uchoa from
   the State University of Piaui. Prof. Dr. Francisco das Chagas Alves Lima
   and Prof. Dr. Rosemarie Brandim Marques, from the State University of
   Piaui. To the professors of the Department of Information, Environment,
   Health and Food Production (DIASPA), especially Prof. Dr. Bruna de
   Freitas Iwata and Prof. Dr. Rosana Martins Carneiro, from the Federal
   Institute of Piaui. We thank the Federal Institute of Piaui for
   financial support.
CR Balleza-Tapia H, 2020, MOL NEUROBIOL, V57, P1170, DOI 10.1007/s12035-019-01779-3
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Burgess SJ, 2010, J MED CHEM, V53, P6477, DOI 10.1021/jm1006484
   Chavez Summer, 2020, Am J Emerg Med, DOI 10.1016/j.ajem.2020.03.036
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen YT, 2019, ECOTOX ENVIRON SAFE, V167, P435, DOI 10.1016/j.ecoenv.2018.10.062
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Dascombe MJ, 2005, J MED CHEM, V48, P5423, DOI 10.1021/jm0408013
   Desai M, 2015, LANCET, V386, P2507, DOI 10.1016/S0140-6736(15)00310-4
   Ezawa T, 2018, AAPS PHARMSCITECH, V19, P923, DOI 10.1208/s12249-017-0908-9
   Ferreira JV, 2020, J CHROMATOGR B, V1137, DOI 10.1016/j.jchromb.2019.121939
   Fielding AJ, 2017, CHEM-EUR J, V23, P6811, DOI 10.1002/chem.201605099
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Hashizume Katsumi, 2020, J Biosci Bioeng, V129, P322, DOI 10.1016/j.jbiosc.2019.09.021
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jayaswal A, 2019, ARCH VIROL, V164, P949, DOI 10.1007/s00705-019-04153-9
   Jiang F, 2020, J GEN INTERN MED, V35, P1545, DOI 10.1007/s11606-020-05762-w
   Kang ST, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105950
   Kawamura K, 2018, INT J ANTIMICROB AG, V51, P918, DOI 10.1016/j.ijantimicag.2018.02.009
   Khadim S., 2020, PH DEV DIFFERENTIAL, DOI [10.26434/chemrxiv.12009018.v1, DOI 10.26434/CHEMRXIV.12009018.V1]
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Liu F, 2020, INT J INFECT DIS, V95, P183, DOI 10.1016/j.ijid.2020.03.013
   Liu Y., 2020, PREPRINTS, DOI [10.20944/preprints202003.0413.v1, DOI 10.20944/PREPRINTS202003.0413.V1]
   Manayi A, 2018, CURR MED CHEM, V25, P4918, DOI 10.2174/0929867324666170523120656
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Narnoliya LK, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-016-3437-0
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Rosenberger DC, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-019-02200-2
   Sahraei Z, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105945
   Sekhar T., 2020, PREPRINTS, DOI [10.20944/ preprints202002.0418.v2, DOI 10.20944/PREPRINTS202002.0418.V2, 10.20944/preprints202002.0418.v2]
   Shabani-Nooshabadi M, 2017, J IRAN CHEM SOC, V14, P955, DOI 10.1007/s13738-016-1045-1
   Shariati S, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108776
   Singh AK, 2020, DIABETES METAB SYND, V14, P241, DOI 10.1016/j.dsx.2020.03.011
   Smith M., 2020, REPURPOSING THERAPEU, DOI 10.26434/chemrxiv.11871402.v3
   Carvalho GFS, 2020, J ETHNOPHARMACOL, V247, DOI 10.1016/j.jep.2019.112259
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Walmsley SL, 2013, NEW ENGL J MED, V369, P1807, DOI 10.1056/NEJMoa1215541
   Wang H., 2018, J OVARIAN RES, V11, P11
   Wang LS, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105948
   Wang Y, 2019, INT J BIOL MACROMOL, V134, P43, DOI 10.1016/j.ijbiomac.2019.05.039
   Weng D, 2019, BIOMED PHARMACOTHER, V110, P440, DOI 10.1016/j.biopha.2018.11.090
   World Health Organization, 176 WHO
   Xing J, 2019, INT IMMUNOPHARMACOL, V66, P146, DOI 10.1016/j.intimp.2018.11.016
   Xu X., 2020, SCI CHINA LIFE SCI, V63, P457, DOI [DOI 10.1007/s11427-020-1637-5, 10.1007/s11427-020-1637-5]
   Xu Z., 2020, NELFINAVIR WAS PREDI, DOI [10.1101/2020.01.27.921627, DOI 10.1101/2020.01.27.921627]
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Zeng SN, 2019, INT J ANTIMICROB AG, V53, P362, DOI 10.1016/j.ijantimicag.2018.12.009
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang HL, 2020, ANN INTERN MED, V172, P629, DOI 10.7326/M20-0533
   Zhao Yanan, 2015, J Trauma Acute Care Surg, V79, pS121, DOI 10.1097/TA.0000000000000737
   Zhao YX, 2020, SCI CHINA CHEM, DOI 10.1007/s11426-020-9864-7
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 54
TC 1
Z9 1
U1 1
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD NOV 6
PY 2020
VL 19
IS 11
BP 4567
EP 4575
DI 10.1021/acs.jproteome.0c00327
PG 9
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA OS1RZ
UT WOS:000589944200031
PM 32786890
OA Green Published
DA 2021-01-01
ER

PT J
AU Di Paola, L
   Hadi-Alijanvand, H
   Song, XY
   Hu, G
   Giuliani, A
AF Di Paola, Luisa
   Hadi-Alijanvand, Hamid
   Song, Xingyu
   Hu, Guang
   Giuliani, Alessandro
TI The Discovery of a Putative Allosteric Site in the SARS-CoV-2 Spike
   Protein Using an Integrated Structural/Dynamic Approach
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE COVID-19; spike protein; ACE2 binding; protein contact networks;
   allosteric drugs; binding patch softness; elastic networks modeling;
   drug discovery
AB SARS-CoV-2 has caused the largest pandemic of the twenty-first century (COVID-19), threatening the life and economy of all countries in the world. The identification of novel therapies and vaccines that can mitigate or control this global health threat is among the most important challenges facing biomedical sciences. To construct a long-term strategy to fight both SARS-CoV-2 and other possible future threats from coronaviruses, it is critical to understand the molecular mechanisms underlying the virus action. The viral entry and associated infectivity stems from the formation of the SARS-CoV-2 spike protein complex with angiotensin-converting enzyme 2 (ACE2). The detection of putative allosteric sites on the viral spike protein molecule can be used to elucidate the molecular pathways that can be targeted with allosteric drugs to weaken the spike-ACE2 interaction and, thus, reduce viral infectivity. In this study, we present the results of the application of different computational methods aimed at detecting allosteric sites on the SARS-CoV-2 spike protein. The adopted tools consisted of the protein contact networks (PCNs), SEPAS (Affinity by Flexibility), and perturbation response scanning (PRS) based on elastic network modes. All of these methods were applied to the ACE2 complex with both the SARS-CoV2 and SARS-CoV spike proteins. All of the adopted analyses converged toward a specific region (allosteric modulation region [AMR]), present in both complexes and predicted to act as an allosteric site modulating the binding of the spike protein with ACE2. Preliminary results on hepcidin (a molecule with strong structural and sequence with AMR) indicated an inhibitory effect on the binding affinity of the spike protein toward the ACE2 protein.
C1 [Hadi-Alijanvand, Hamid] Inst Adv Studies Basic Sci IASBS, Dept Biol Sci, Zanjan 4513766731, Iran.
   [Song, Xingyu; Hu, Guang] Soochow Univ, Sch Biol & Basic Med Sci, Dept Bioinformat, Ctr Syst Biol, Suzhou 215123, Peoples R China.
   [Giuliani, Alessandro] Ist Super Sanita, Environm & Hlth Dept, I-00161 Rome, Italy.
   [Di Paola, Luisa] Univ Campus Biomed Roma, Dept Engn, Unit Chem Phys Fundamentals Chem Engn, I-00128 Rome, Italy.
RP Hu, G (corresponding author), Soochow Univ, Sch Biol & Basic Med Sci, Dept Bioinformat, Ctr Syst Biol, Suzhou 215123, Peoples R China.; Di Paola, L (corresponding author), Univ Campus Biomed Roma, Dept Engn, Unit Chem Phys Fundamentals Chem Engn, I-00128 Rome, Italy.
EM l.dipaola@unicampus.it; huguang@suda.edu.cn
OI Di Paola, Luisa/0000-0001-5329-8689
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31872723]; Priority Academic Program
   Development (PAPD) of Jiangsu Higher Education Institutions
FX The authors thank the encouraging support and the fruitful discussion
   from Prof. C. Serangeli. The project was supported by National Natural
   Science Foundation of China (31872723) and the Priority Academic Program
   Development (PAPD) of Jiangsu Higher Education Institutions.
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Amamuddy OS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030847
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Atilgan AR, 2001, BIOPHYS J, V80, P505, DOI 10.1016/S0006-3495(01)76033-X
   Atilgan C, 2010, BIOPHYS J, V99, P933, DOI 10.1016/j.bpj.2010.05.020
   Bakan A, 2011, BIOINFORMATICS, V27, P1575, DOI 10.1093/bioinformatics/btr168
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Benvenuto D, 2020, J MED VIROL, V92, P455, DOI 10.1002/jmv.25688
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cimini S, 2016, PLANT MOL BIOL, V92, P401, DOI 10.1007/s11103-016-0515-2
   Csermely P, 2013, CURR TOP MED CHEM, V13, P2, DOI 10.2174/1568026611313010002
   De Ruvo M, 2012, BIOPHYS CHEM, V165, P21, DOI 10.1016/j.bpc.2012.03.001
   Di Paola L, 2015, FRONT BIOENG BIOTECH, V3, DOI 10.3389/fbioe.2015.00170
   Di Paola L, 2016, CURR PROTEIN PEPT SC, V17, P30, DOI 10.2174/1389203716666150923104054
   Di Paola L, 2015, CURR OPIN STRUC BIOL, V31, P43, DOI 10.1016/j.sbi.2015.03.001
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Ehsani S., 2020, DISTANT SEQUENCE SIM
   Giuliani A, 2002, CHEM REV, V102, P1471, DOI 10.1021/cr0101499
   Giuliani A, 2009, CURR PROTEOMICS, V6, P235, DOI 10.2174/157016409789973743
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Gu J, 2007, AM J PATHOL, V170, P1136, DOI 10.2353/ajpath.2007.061088
   Gur M, 2013, J CHEM PHYS, V139, DOI 10.1063/1.4816375
   Hadi-Alijanvand H, 2020, J PROTEOME RES, V19, P409, DOI 10.1021/acs.jproteome.9b00594
   Hadi-Alijanvand H, 2020, J BIOMOL STRUCT DYN, V38, P3587, DOI 10.1080/07391102.2019.1662328
   He YX, 2004, BIOCHEM BIOPH RES CO, V324, P773, DOI 10.1016/j.bbrc.2004.09.106
   Higueruelo AP, 2013, CURR OPIN PHARMACOL, V13, P791, DOI 10.1016/j.coph.2013.05.009
   Jiang S, 2012, EMERGING MICROBES IN, V1, P1
   Kirchdoerfer R. N, 2018, CELL, V176, P1864
   Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu ZX, 2020, J MED VIROL, V92, P595, DOI 10.1002/jmv.25726
   Mandell A. J., 1998, BIOPOLYMERS, P1, DOI [10.1002/(sici)1097-0282(199808)46:23.3.co;2-d, DOI 10.1002/(SICI)1097-0282(199808)46:23.3.CO;2-D]
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Minicozzi V, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1719202
   Mustafa S., 2019, ADV BIOINF, V2019, P1
   Nussinov R, 2012, CURR PHARM DESIGN, V18, P1311
   Peracchi A, 2011, BBA-PROTEINS PROTEOM, V1814, P922, DOI 10.1016/j.bbapap.2010.10.008
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Platania CBM, 2015, FRONT PHARMACOL, V6, DOI [10.3389/tphar.7015.00248, 10.3389/fphar.2015.00248]
   Romanov B. K., 2020, SAFE RISK PHARMACOTH, V8, P3, DOI [DOI 10.30895/2312-7821-2020-8-1-3-8, 10.30895/2312-7821-2020-8-1-3-8]
   Savojardo C, 2017, BIOINFORMATICS, V33, P1656, DOI 10.1093/bioinformatics/btx044
   Schymkowitz J, 2005, NUCLEIC ACIDS RES, V33, pW382, DOI 10.1093/nar/gki387
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Tasdighian S, 2014, J CHEM INF MODEL, V54, P159, DOI 10.1021/ci400218v
   Vishveshwara S., 2002, J THEOR COMPUT CHEM, V1, P187, DOI DOI 10.1142/S0219633602000117
   Wagner JR, 2016, CHEM REV, V116, P6370, DOI 10.1021/acs.chemrev.5b00631
   Wang QH, 2016, ANTIVIR RES, V133, P165, DOI 10.1016/j.antiviral.2016.07.015
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wrighting DM, 2006, BLOOD, V108, P3204, DOI 10.1182/blood-2006-06-027631
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang L., 2015, NORMAL MODE ANAL, P41
   Yuan Y, 2017, NAT COMMUN, V8, P1
   Zhang Y, 2005, COMPUT BIOL CHEM, V29, P254, DOI 10.1016/j.compbiolchem.2005.04.008
   Zhou YS, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010060
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 57
TC 5
Z9 5
U1 2
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD NOV 6
PY 2020
VL 19
IS 11
BP 4576
EP 4586
DI 10.1021/acs.jproteome.0c00273
PG 11
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA OS1RZ
UT WOS:000589944200032
PM 32551648
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Verkhivker, GM
AF Verkhivker, Gennady M.
TI Molecular Simulations and Network Modeling Reveal an Allosteric
   Signaling in the SARS-CoV-2 Spike Proteins
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE SARS-CoV-2 spike proteins; prefusion trimer; biophysical modeling;
   network analysis; allosteric signaling; regulatory hotspots; dynamic
   switching; allosteric drug discovery
AB The development of computational strategies for the quantitative characterization of the functional mechanisms of SARS-CoV-2 spike proteins is of paramount importance in efforts to accelerate the discovery of novel therapeutic agents and vaccines combating the COVID-19 pandemic. Structural and biophysical studies have recently characterized the conformational landscapes of the SARS-CoV-2 spike glycoproteins in the prefusion form, revealing a spectrum of stable and more dynamic states. By employing molecular simulations and network modeling approaches, this study systematically examined functional dynamics and identified the regulatory centers of allosteric interactions for distinct functional states of the wild-type and mutant variants of the SARS-CoV-2 prefusion spike trimer. This study presents evidence that the SARS-CoV-2 spike protein can function as an allosteric regulatory engine that fluctuates between dynamically distinct functional states. Perturbation-based modeling of the interaction networks revealed a key role of the cross-talk between the effector hotspots in the receptor binding domain and the fusion peptide proximal region of the SARS-CoV-2 spike protein. The results have shown that the allosteric hotspots of the interaction networks in the SARS-CoV-2 spike protein can control the dynamic switching between functional conformational states that are associated with virus entry to the host receptor. This study offers a useful and novel perspective on the underlying mechanisms of the SARS-CoV-2 spike protein through the lens of allosteric signaling as a regulatory apparatus of virus transmission that could open up opportunities for targeted allosteric drug discovery against SARS-CoV-2 proteins and contribute to the rapid response to the current and potential future pandemic scenarios.
C1 [Verkhivker, Gennady M.] Chapman Univ, Keck Ctr Sci & Engn, Grad Program Computat & Data Sci, Schmid Coll Sci & Technol, Orange, CA 92866 USA.
   [Verkhivker, Gennady M.] Chapman Univ, Dept Biomed & Pharmaceut Sci, Sch Pharm, Irvine, CA 92618 USA.
RP Verkhivker, GM (corresponding author), Chapman Univ, Keck Ctr Sci & Engn, Grad Program Computat & Data Sci, Schmid Coll Sci & Technol, Orange, CA 92866 USA.; Verkhivker, GM (corresponding author), Chapman Univ, Dept Biomed & Pharmaceut Sci, Sch Pharm, Irvine, CA 92618 USA.
EM verkhivk@chapman.edu
RI Verkhivker, Gennady/V-9404-2018
OI Verkhivker, Gennady/0000-0002-4507-4471
FU Chapman University; Kay Family Foundation [A20-0032]
FX This work was partly supported by institutional funding from Chapman
   University. The author acknowledges support by the Kay Family Foundation
   Grant A20-0032.
CR Abdizadeh H, 2016, PHYS CHEM CHEM PHYS, V18, P7916, DOI 10.1039/c5cp05107j
   Amaro RE, 2012, METHODS MOL BIOL, V819, P575, DOI 10.1007/978-1-61779-465-0_34
   Armijos-Jaramillo V, 2020, EVOL APPL, V13, P2168, DOI 10.1111/eva.12980
   Ashkenazy H, 2016, NUCLEIC ACIDS RES, V44, pW344, DOI 10.1093/nar/gkw408
   Ashkenazy H, 2010, NUCLEIC ACIDS RES, V38, pW529, DOI 10.1093/nar/gkq399
   Astl L, 2020, J CHEM INF MODEL, V60, P1614, DOI 10.1021/acs.jcim.9b01045
   Astl L, 2019, J CHEM THEORY COMPUT, V15, P3362, DOI 10.1021/acs.jctc.9b00119
   Astuti I, 2020, DIABETES METAB SYND, V14, P407, DOI 10.1016/j.dsx.2020.04.020
   Atilgan C, 2010, BIOPHYS J, V99, P933, DOI 10.1016/j.bpj.2010.05.020
   Atilgan C, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000544
   Bahar I, 2010, ANNU REV BIOPHYS, V39, P23, DOI 10.1146/annurev.biophys.093008.131258
   Ben Chorin A, 2020, PROTEIN SCI, V29, P258, DOI 10.1002/pro.3779
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bhattacharya D, 2016, NUCLEIC ACIDS RES, V44, pW406, DOI 10.1093/nar/gkw336
   Brielle ES, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050497
   Brinda KV, 2005, BIOPHYS J, V89, P4159, DOI 10.1529/biophysj.105.064485
   Brown DK, 2017, BIOINFORMATICS, V33, P2768, DOI 10.1093/bioinformatics/btx349
   Cai YF, 2020, SCIENCE, V369, P1586, DOI 10.1126/science.abd4251
   Casalino Lorenzo, 2020, bioRxiv, DOI 10.1101/2020.06.11.146522
   Chakraborti S, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-73
   Ciemny MP, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030606
   Czemeres J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0190267
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   del Sol A, 2009, STRUCTURE, V17, P1042, DOI 10.1016/j.str.2009.06.008
   Di Paola L, 2020, J PROTEOME RES, V19, P4576, DOI 10.1021/acs.jproteome.0c00273
   Dokholyan NV, 2016, CHEM REV, V116, P6463, DOI 10.1021/acs.chemrev.5b00544
   Dutta A, 2015, STRUCTURE, V23, P1692, DOI 10.1016/j.str.2015.07.002
   El-Gebali S, 2019, NUCLEIC ACIDS RES, V47, pD427, DOI 10.1093/nar/gky995
   Eyal E, 2015, BIOINFORMATICS, V31, P1487, DOI 10.1093/bioinformatics/btu847
   Fan XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17371-6
   Fernandez-Fuentes N, 2006, NUCLEIC ACIDS RES, V34, pW173, DOI 10.1093/nar/gkl113
   Finn RD, 2014, NUCLEIC ACIDS RES, V42, pD364, DOI 10.1093/nar/gkt1210
   Fiser A, 2003, BIOINFORMATICS, V19, P2500, DOI 10.1093/bioinformatics/btg362
   FLOYD RW, 1962, COMMUN ACM, V5, P345, DOI 10.1145/367766.368168
   General IJ, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003624
   Girvan M, 2002, P NATL ACAD SCI USA, V99, P7821, DOI 10.1073/pnas.122653799
   Glaser F, 2005, PROTEINS, V58, P610, DOI 10.1002/prot.20305
   Goldenberg O, 2009, NUCLEIC ACIDS RES, V37, pD323, DOI 10.1093/nar/gkn822
   Grant OC, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71748-7
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Hagberg A.A., 2008, 7 PYTH SCI C SCIPY20, P11, DOI DOI 10.1016/J.JELECTROCARD.2010.09.003
   Harbison A, 2020, GLYCOBIOLOGY, V30, P420, DOI 10.1093/glycob/cwz101
   He YX, 2005, J IMMUNOL, V174, P4908, DOI 10.4049/jimmunol.174.8.4908
   Henderson R, 2020, NAT STRUCT MOL BIOL, V27, P925, DOI 10.1038/s41594-020-0479-4
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hsieh CL, 2020, SCIENCE, V369, P1501, DOI 10.1126/science.abd0826
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang CD, 2017, ANNU REV BIOPHYS, V46, P317, DOI 10.1146/annurev-biophys-070816-033701
   Jaimes JA, 2020, J MOL BIOL, V432, P3309, DOI 10.1016/j.jmb.2020.04.009
   Jalalypour F, 2020, J CHEM THEORY COMPUT, V16, P3825, DOI 10.1021/acs.jctc.9b01222
   Jiang YJ, 2017, J MOL BIOL, V429, P2667, DOI 10.1016/j.jmb.2017.07.007
   Jo S, 2016, GLYCOBIOLOGY, V26, P19, DOI 10.1093/glycob/cwv083
   Kalathiya U, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051473
   Kalinka Alex T, 2011, Bioinformatics, V27, P2011, DOI 10.1093/bioinformatics/btr311
   Karami Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32079-w
   Kmiecik S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113496
   Kmiecik S, 2016, CHEM REV, V116, P7898, DOI 10.1021/acs.chemrev.6b00163
   Kolinski A, 2004, ACTA BIOCHIM POL, V51, P349
   Kovacs IA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012528
   Kurcinski M, 2019, BIOINFORMATICS, V35, P694, DOI 10.1093/bioinformatics/bty685
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li HC, 2017, NUCLEIC ACIDS RES, V45, pW374, DOI 10.1093/nar/gkx385
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lombardi LE, 2016, BIOINFORMATICS, V32, P1235, DOI 10.1093/bioinformatics/btv740
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Madu IG, 2009, J VIROL, V83, P7411, DOI 10.1128/JVI.00079-09
   McCallum M, 2020, NAT STRUCT MOL BIOL, DOI 10.1038/s41594-020-0483-8
   Mistry J, 2013, NUCLEIC ACIDS RES, V41, DOI [10.1093/nar/gkt263, 10.1093/nar/gkt1223]
   Newman MEJ, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.036104
   Penkler D, 2017, J CHEM INF MODEL, V57, P1359, DOI 10.1021/acs.jcim.6b00775
   Penkler DL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-35835-0
   Penlder DL, 2018, J CHEM INF MODEL, V58, P383, DOI 10.1021/acs.jcim.7b00630
   Ponzoni L, 2018, P NATL ACAD SCI USA, V115, P4164, DOI 10.1073/pnas.1715896115
   Popovych N, 2006, NAT STRUCT MOL BIOL, V13, P831, DOI 10.1038/nsmb1132
   Rose PW, 2017, NUCLEIC ACIDS RES, V45, pD271, DOI 10.1093/nar/gkw1000
   Rotkiewicz P, 2008, J COMPUT CHEM, V29, P1460, DOI 10.1002/jcc.20906
   Rozewicki J, 2019, NUCLEIC ACIDS RES, V47, pW5, DOI 10.1093/nar/gkz342
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Sethi A, 2009, P NATL ACAD SCI USA, V106, P6620, DOI 10.1073/pnas.0810961106
   Shah M., 2020, RES SQ, DOI [10.21203/rs.3.rs-16932/v1., DOI 10.21203/RS.3.RS-16932/V1]
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Spinello A, 2020, J PHYS CHEM LETT, V11, P4785, DOI 10.1021/acs.jpclett.0c01148
   Stetz Gabrielle, 2020, J Chem Theory Comput, V16, P4706, DOI 10.1021/acs.jctc.0c00280
   Stetz G, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25329-4
   Stetz G, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005299
   Stetz G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143752
   Suzek BE, 2007, BIOINFORMATICS, V23, P1282, DOI 10.1093/bioinformatics/btm098
   Suzek BE, 2015, BIOINFORMATICS, V31, P926, DOI 10.1093/bioinformatics/btu739
   Szalay-Beko M, 2012, BIOINFORMATICS, V28, P2202, DOI 10.1093/bioinformatics/bts352
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Tsai CJ, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003394
   Tzeng SR, 2009, NATURE, V462, P368, DOI 10.1038/nature08560
   Vijayabaskar MS, 2010, BIOPHYS J, V99, P3704, DOI 10.1016/j.bpj.2010.08.079
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wang YJ, 2020, P NATL ACAD SCI USA, V117, P13967, DOI 10.1073/pnas.2008209117
   Watanabe Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16567-0
   Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983
   Wodak SJ, 2019, STRUCTURE, V27, P566, DOI 10.1016/j.str.2019.01.003
   Woo H, 2020, J PHYS CHEM B, V124, P7128, DOI 10.1021/acs.jpcb.0c04553
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Xiong XL, 2020, NAT STRUCT MOL BIOL, DOI 10.1038/s41594-020-0478-5
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang LW, 2006, NUCLEIC ACIDS RES, V34, pW24, DOI 10.1093/nar/gkl084
   Yang TJ, 2020, P NATL ACAD SCI USA, V117, P1438, DOI 10.1073/pnas.1908898117
   Yi Y, 2020, INT J BIOL SCI, V16, P1753, DOI 10.7150/ijbs.45134
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 117
TC 1
Z9 1
U1 1
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD NOV 6
PY 2020
VL 19
IS 11
BP 4587
EP 4608
DI 10.1021/acs.jproteome.0c00654
PG 22
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA OS1RZ
UT WOS:000589944200033
PM 33006900
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zeng, XX
   Song, X
   Ma, TF
   Pan, XQ
   Zhou, YD
   Hou, Y
   Zhang, Z
   Li, KL
   Karypis, G
   Cheng, FX
AF Zeng, Xiangxiang
   Song, Xiang
   Ma, Tengfei
   Pan, Xiaoqin
   Zhou, Yadi
   Hou, Yuan
   Zhang, Zheng
   Li, Kenli
   Karypis, George
   Cheng, Feixiong
TI Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep
   Learning
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE COVID-19; deep learning; drug repurposing; knowledge graph;
   representation learning; SARS-CoV-2
AB There have been more than 2.2 million confirmed cases and over 120 000 deaths from the human coronavirus disease 2019 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), in the United States alone. However, there is currently a lack of proven effective medications against COVID-19. Drug repurposing offers a promising route for the development of prevention and treatment strategies for COVID-19. This study reports an integrative, network-based deep-learning methodology to identify repurposable drugs for COVID-19 (termed CoV-KGE). Specifically, we built a comprehensive knowledge graph that includes 15 million edges across 39 types of relationships connecting drugs, diseases, proteins/genes, pathways, and expression from a large scientific corpus of 24 million PubMed publications. Using Amazon's AWS computing resources and a network-based, deep-learning framework, we identified 41 repurposable drugs (including dexamethasone, indomethacin, niclosamide, and toremifene) whose therapeutic associations with COVID-19 were validated by transcriptomic and proteomics data in SARS-CoV-2-infected human cells and data from ongoing clinical trials. Whereas this study by no means recommends specific drugs, it demonstrates a powerful deep-learning methodology to prioritize existing drugs for further investigation, which holds the potential to accelerate therapeutic development for COVID-19.
C1 [Zeng, Xiangxiang; Ma, Tengfei; Pan, Xiaoqin; Li, Kenli] Hunan Univ, Sch Comp Sci & Engn, Changsha 410012, Peoples R China.
   [Song, Xiang; Zhang, Zheng] AWS Shanghai Lab, Shanghai 200335, Peoples R China.
   [Zhou, Yadi; Hou, Yuan; Cheng, Feixiong] Cleveland Clin, Lerner Res Inst, Genom Med Inst, Cleveland, OH 44106 USA.
   [Zhang, Zheng] New York Univ Shanghai, Shanghai 200122, Peoples R China.
   [Karypis, George] AWS AI, East Palo Alto, CA 94303 USA.
   [Karypis, George] Univ Minnesota, Dept Comp Sci & Engn, Minneapolis, MN 55455 USA.
   [Cheng, Feixiong] Case Western Reserve Univ, Cleveland Clin, Dept Mol Med, Lerner Coll Med, Cleveland, OH 44195 USA.
   [Cheng, Feixiong] Case Western Reserve Univ, Case Comprehens Canc Ctr, Sch Med, Cleveland, OH 44106 USA.
RP Cheng, FX (corresponding author), Cleveland Clin, Lerner Res Inst, Genom Med Inst, Cleveland, OH 44106 USA.; Karypis, G (corresponding author), AWS AI, East Palo Alto, CA 94303 USA.; Karypis, G (corresponding author), Univ Minnesota, Dept Comp Sci & Engn, Minneapolis, MN 55455 USA.; Cheng, FX (corresponding author), Case Western Reserve Univ, Cleveland Clin, Dept Mol Med, Lerner Coll Med, Cleveland, OH 44195 USA.; Cheng, FX (corresponding author), Case Western Reserve Univ, Case Comprehens Canc Ctr, Sch Med, Cleveland, OH 44106 USA.
EM karypis@umn.edu; chengf@ccf.org
OI Cheng, Feixiong/0000-0002-1736-2847
CR Amici C, 2006, ANTIVIR THER, V11, P1021
   Avorn J, 2015, NEW ENGL J MED, V372, P1877, DOI 10.1056/NEJMp1500848
   Boga JA, 2012, REV MED VIROL, V22, P323, DOI 10.1002/rmv.1714
   Bojkova D, 2020, NATURE, V583, P469, DOI 10.1038/s41586-020-2332-7
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Castillo R. R., 2020, MELATONIN RES, V3, P297, DOI [10.32794/mr11250063., DOI 10.32794/MR11250063]
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Cheng FX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10744-6
   Cheng FX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09186-x
   Cheng FX, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05116-5
   Cheng FX, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1005074
   Chorin E, 2020, QT INTERVAL PATIENTS, V2020, DOI [10.1101/2020.04.02.20047050, DOI 10.1101/2020.04.02.20047050]
   Cong Y., 2018, PLOS ONE, V13
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Gassen NC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13659-4
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Johansen LM, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005471
   Josset L, 2013, MBIO, V4, DOI 10.1128/mBio.00165-13
   Kim YI, 2020, CELL HOST MICROBE, V27, P704, DOI 10.1016/j.chom.2020.03.023
   KIVINEN S, 1990, J STEROID BIOCHEM, V36, P217, DOI 10.1016/0022-4731(90)90008-G
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Lasso G, 2019, CELL, V178, P1526, DOI 10.1016/j.cell.2019.08.005
   Li H, 2020, LEUKEMIA, V34, P1503, DOI 10.1038/s41375-020-0848-3
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Percha B, 2018, BIOINFORMATICS, V34, P2614, DOI 10.1093/bioinformatics/bty114
   Powers D. M. W., 2011, J MACH LEARN TECHNOL, V2, P37, DOI DOI 10.9735/2229-3981
   Rajeshkumar N. V., 2020, BIORXIV, DOI [10.1101/2020.03.31.018556., DOI 10.1101/2020.03.31.018556, 10.1101/2020.03.31.018556]
   Ramamoorthy S, 2016, RHEUM DIS CLIN N AM, V42, P15, DOI 10.1016/j.rdc.2015.08.002
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Reghunathan R, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-2
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Sirota M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001318
   Stokes JM, 2020, CELL, V180, P688, DOI 10.1016/j.cell.2020.01.021
   Sun Z., 2019, ARXIV190210197CS
   Thompson IM, 2013, J CLIN ONCOL, V31, P515, DOI 10.1200/JCO.2012.46.6151
   VALAVAARA R, 1988, EUR J CANCER CLIN ON, V24, P785, DOI 10.1016/0277-5379(88)90316-1
   van der Maaten L, 2008, J MACH LEARN RES, V9, P2579
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang M., 2019, ARXIV190901315CS
   Wang XL, 2020, CELL MOL IMMUNOL, DOI 10.1038/s41423-020-0424-9
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Xu T., 2020, BIORXIV, DOI DOI 10.1101/2020.04.01.017624
   Yuan SF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08015-x
   Zeng XX, 2020, CHEM SCI, V11, P1775, DOI 10.1039/c9sc04336e
   Zeng XX, 2019, BIOINFORMATICS, V35, P5191, DOI 10.1093/bioinformatics/btz418
   Zhao YG, 2016, NATURE, V535, P169, DOI 10.1038/nature18615
   Zheng SJ, 2020, NAT MACH INTELL, V2, P134, DOI 10.1038/s42256-020-0152-y
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 53
TC 2
Z9 2
U1 3
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD NOV 6
PY 2020
VL 19
IS 11
BP 4624
EP 4636
DI 10.1021/acs.jproteome.0c00316
PG 13
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA OS1RZ
UT WOS:000589944200035
PM 32654489
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Maffucci, I
   Contini, A
AF Maffucci, Irene
   Contini, Alessandro
TI In Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike
   Proteins
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE SARS-CoV-2; COVID-19; virtual screening; main proteinase; 3CLpro; spike
   protein; molecular dynamics; MM-GBSA; drug repurposing
ID RECEPTOR-BINDING DOMAIN; SARS CORONAVIRUS; LIGAND DOCKING; OPEN-LABEL;
   INHIBITORS; GENERATION; PARAMETERS; PREDICTION; RIBAVIRIN; ENERGIES
AB The pandemic caused by SARS-CoV-2 is currently representing a major health and economic threat to humanity. So far, no specific treatment to this viral infection has been developed and the emergency still requires an efficient intervention. In this work, we used virtual screening to facilitate drug repurposing against SARS-CoV-2, targeting viral main proteinase and spike protein with 3000 existing drugs. We used a protocol based on a docking step followed by a short molecular dynamic simulation and rescoring by the Nwat-MMGBSA approach. Our results provide suggestions for prioritizing in vitro and/or in vivo tests of already available compounds.
C1 [Maffucci, Irene] Univ Technol Compiegne, CNRS, Enzyme & Cell Engn, UPJV, F-60203 Compiegne, France.
   [Contini, Alessandro] Univ Milan, Dipartimento Sci Farmaceut, Sez Chim Gen & Organ A Marchesini, I-20133 Milan 21, Italy.
RP Maffucci, I (corresponding author), Univ Technol Compiegne, CNRS, Enzyme & Cell Engn, UPJV, F-60203 Compiegne, France.; Contini, A (corresponding author), Univ Milan, Dipartimento Sci Farmaceut, Sez Chim Gen & Organ A Marchesini, I-20133 Milan 21, Italy.
EM irene.maffucci@utc.fr; alessandro.contini@unimi.it
RI ; Contini, Alessandro/F-5064-2012
OI MAFFUCCI, IRENE/0000-0002-4524-1137; Contini,
   Alessandro/0000-0002-4394-8956
CR Abobaker A., 2020, EUR J CLIN PHARMACOL, P1
   Amaro RE, 2018, BIOPHYS J, V114, P2271, DOI 10.1016/j.bpj.2018.02.038
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Anandakrishnan R, 2012, NUCLEIC ACIDS RES, V40, pW537, DOI 10.1093/nar/gks375
   [Anonymous], 2019, 20190102 CHEM COMP G
   BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Cai WT, 2015, ANTIVIR RES, V118, P82, DOI 10.1016/j.antiviral.2015.03.008
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Case D., 2018, AMBER 2018
   Cavasotto CN, 2007, CURR TOP MED CHEM, V7, P1006, DOI 10.2174/156802607780906753
   CHANG RS, 1991, P SOC EXP BIOL MED, V197, P59
   Chen J, 2020, RANDOM MATRICES-THEO, V9, DOI 10.1142/S2010326320500094
   Chen Q, 2012, ACTA PHARMACOL SIN, V33, P1332, DOI 10.1038/aps.2012.79
   Chen YK, 2020, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.03079
   Choudhary S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01664
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Clark DE, 2008, EXPERT OPIN DRUG DIS, V3, P841, DOI 10.1517/17460441.3.8.841
   CLUMECK N, 1985, SURV IMMUNOL RES, V4, P58
   Contini A., 2020, VIRTUAL SCREENING FD, DOI [10.26434/Chemrxiv.11847381.V1., DOI 10.26434/CHEMRXIV.11847381.V1, 10.26434/chemrxiv.11847381.v1]
   Coughlin M, 2007, VIROLOGY, V361, P93, DOI 10.1016/j.virol.2006.09.029
   Douglas GC, 2004, ENDOCRINOLOGY, V145, P4703, DOI 10.1210/en.2004-0443
   Du LY, 2014, J VIROL, V88, P7045, DOI 10.1128/JVI.00433-14
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   JANIN J, 1990, J BIOL CHEM, V265, P16027
   Jayakumar T., 2013, EVID-BASED COMPL ALT, V2013, DOI DOI 10.1155/2013/846740
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Katie Heiser, 2020, PREPRINT, DOI [10.1101/ 2020.04.21.054387., DOI 10.1101/2020.04.21.054387]
   Kim S. Y., 2020, 041459 BIORXIV
   Korb O, 2010, CHEMMEDCHEM, V5, P1001, DOI 10.1002/cmdc.201000090
   Korb O, 2009, J CHEM INF MODEL, V49, P84, DOI 10.1021/ci800298z
   Laha S., 2020, INFECT GENET EVOL, V85, P85
   Lamiable A, 2016, NUCLEIC ACIDS RES, V44, pW449, DOI 10.1093/nar/gkw329
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lawitz E, 2015, LANCET, V385, P1075, DOI 10.1016/S0140-6736(14)61795-5
   Lei CH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16048-4
   Li Y, 2015, CELL RES, V25, P1237, DOI 10.1038/cr.2015.113
   Liu L, 2020, BIORXIV, V05
   Maffucci I, 2018, FRONT CHEM, V6, DOI 10.3389/fchem.2018.00043
   Maffucci I, 2016, J CHEM INF MODEL, V56, P1692, DOI 10.1021/acs.jcim.6b00196
   Maffucci I, 2013, J CHEM THEORY COMPUT, V9, P2706, DOI 10.1021/ct400045d
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   MASCARTLEMONE F, 1983, LANCET, V2, P735
   Massova I, 2000, PERSPECT DRUG DISCOV, V18, P113, DOI 10.1023/A:1008763014207
   Mycroft-West Su D., 2020, 2019 CORONAVIRUS SAR
   Nguyen H, 2013, J CHEM THEORY COMPUT, V9, P2020, DOI 10.1021/ct3010485
   NGUYEN TD, 1987, ANN INST PASTEUR VIR, V138, P331, DOI 10.1016/S0769-2617(87)80019-9
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Patick AK, 1998, CLIN MICROBIOL REV, V11, P614, DOI 10.1128/CMR.11.4.614
   Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5
   Sajib A., 2020, PREPRINT, DOI [10.20944/Preprints202004.0369.V1., DOI 10.20944/PREPRINTS202004.0369.V1]
   Schrodinger L., 2015, PYMOL MOL GRAPHICS S
   Senathilake K. S., 2020, PREPRINTS, DOI [10.20944/preprints202003.0042.v2, DOI 10.20944/PREPRINTS202003.0042.V2, 10.20944/ Preprints202003.0042.V2]
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Spinello A., 2020, IS RIGIDITY SARS COV, DOI [10.26434/chemrxiv.12091260.v3., DOI 10.26434/CHEMRXIV.12091260.V3]
   Turlington M, 2013, BIOORG MED CHEM LETT, V23, P6172, DOI 10.1016/j.bmcl.2013.08.112
   Vasanthakumar N, 2020, MED HYPOTHESES, V142, DOI 10.1016/j.mehy.2020.109809
   Vishal M., 2020, DRUG REPURPOSING APP, DOI [10.26434/Chem- rxiv.12115251.V1, DOI 10.26434/CHEM-RXIV.12115251.V1]
   Waheed Yasir, 2015, World J Virol, V4, P33, DOI 10.5501/wjv.v4.i1.33
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang M., 2020, RES SQUARE, DOI [10.21203/RS.3.RS-19872/V1, DOI 10.21203/RS.3.RS-19872/V1]
   Waters L, 2007, EXPERT OPIN INV DRUG, V16, P899, DOI 10.1517/13543784.16.6.899
   Wei-Ya C, 2020, EUR J PHARM SCI, V147
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xia S, 2014, VIRUS RES, V194, P200, DOI 10.1016/j.virusres.2014.10.007
   Xu LH, 2010, ACS MED CHEM LETT, V1, P209, DOI 10.1021/ml1000257
   Yang YS, 2020, MITOCHONDRIAL DNA B, V5, P1949, DOI 10.1080/23802359.2020.1756949
   Zhang CX, 2020, J PROTEOME RES, V19, P1351, DOI 10.1021/acs.jproteome.0c00129
   Zhang G., 2020, 999318 BIORXIV
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zignego A. L., 2018, ACTA BIOMEDICA, V1885, P321
NR 78
TC 1
Z9 1
U1 1
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD NOV 6
PY 2020
VL 19
IS 11
BP 4637
EP 4648
DI 10.1021/acs.jproteome.0c00383
PG 12
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA OS1RZ
UT WOS:000589944200036
PM 32893632
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Glisic, S
   Perovic, VR
   Sencanski, M
   Paessler, S
   Veljkovic, V
AF Glisic, Sanja
   Perovic, Vladimir R.
   Sencanski, Milan
   Paessler, Slobodan
   Veljkovic, Veljko
TI Biological Rationale for the Repurposing of BCG Vaccine against
   SARS-CoV-2
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE SARS-CoV-2; COVID-19; BCG; vaccine; clinical study
AB The Bacillus Calmette-Guerin vaccine is still widely used in the developing world. The vaccination prevents infant death not only from tuberculosis but also from unrelated infectious agents, especially respiratory tract infections and neonatal sepsis. It is proposed that these off-target protective effects of the BCG vaccine are mediated by the general long-term boosting of innate immune mechanisms, also termed "trained innate immunity". Recent studies indicate that both COVID-19 incidence and total deaths are strongly associated with the presence or absence of national mandatory BCG vaccination programs and encourage the initiation of several clinical studies with the expectation that revaccination with BCG could reduce the incidence and severity of COVID-19. Here, presented results from the bioinformatics analysis of the Mycobacterium bovis (strain BCG/Pasteur 1173P2) proteome suggests four immunodominant antigens that could induce an immune response against SARS-CoV-2.
C1 [Glisic, Sanja; Perovic, Vladimir R.; Sencanski, Milan] Univ Belgrade, Inst Nucl Sci Vinca, Natl Inst Republ Serbia, Lab Bioinformat & Computat Chem, Serbia 11001, Serbia.
   [Paessler, Slobodan] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.
   [Paessler, Slobodan] Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA.
   [Veljkovic, Veljko] Biomed Protect, Galveston, TX 77550 USA.
RP Glisic, S (corresponding author), Univ Belgrade, Inst Nucl Sci Vinca, Natl Inst Republ Serbia, Lab Bioinformat & Computat Chem, Serbia 11001, Serbia.
EM sanja@vinca.rs
OI Sencanski, Milan/0000-0002-7296-3223; Glisic, Sanja/0000-0001-5691-1055
FU Ministry of Education, Science and Technological Development of the
   Republic of Serbia
FX This work was supported by the Ministry of Education, Science and
   Technological Development of the Republic of Serbia.
CR Escobar LE, 2020, P NATL ACAD SCI USA, V117, P17720, DOI 10.1073/pnas.2008410117
   Higgins JPT, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5170
   Koma T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20185-8
   Miller A, 2020, CORRELATION UNIVERSA, DOI [DOI 10.1101/2020.03.24.20042937, 10.1101/2020.03.24.20042937]
   O'Neill LAJ, 2020, NAT REV IMMUNOL, V20, P335, DOI 10.1038/s41577-020-0337-y
   Rao V, 2003, SCAND J IMMUNOL, V58, P449, DOI 10.1046/j.1365-3083.2003.01321.x
   van Meijgaarden KE, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004671
   Veljkovic N, 2003, J PEPT RES, V62, P158, DOI 10.1034/j.1399-3011.2003.00081.x
   VELJKOVIC V, 1987, CANCER BIOCHEM BIOPH, V9, P139
   VELJKOVIC V, 1985, IEEE T BIO-MED ENG, V32, P337, DOI 10.1109/TBME.1985.325549
   VELJKOVIC V, 1973, PHYS LETT A, VA 45, P41, DOI 10.1016/0375-9601(73)90497-0
   VELJKOVIC V, 1972, PHYS REV LETT, V29, P105, DOI 10.1103/PhysRevLett.29.105
   Veljkovic Veljko, 2020, F1000Res, V9, P52, DOI 10.12688/f1000research.22149.1
NR 13
TC 1
Z9 1
U1 2
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD NOV 6
PY 2020
VL 19
IS 11
BP 4649
EP 4654
DI 10.1021/acs.jproteome.0c00410
PG 6
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA OS1RZ
UT WOS:000589944200037
PM 32794723
DA 2021-01-01
ER

PT J
AU Martin, WR
   Cheng, FX
AF Martin, William R.
   Cheng, Feixiong
TI Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the
   Spike Glycoprotein and NSP14 of SARS-CoV-2
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE COVID-19; drug repurposing; SARS-CoV-2; methyltransferase nonstructural
   protein 14 (NSP14); molecular docking; spike glycoprotein; toremifene
AB The global pandemic of Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to the death of more than 675,000 worldwide and over 150,000 in the United States alone. However, there are currently no approved effective pharmacotherapies for COVID-19. Here, we combine homology modeling, molecular docking, molecular dynamics simulation, and binding affinity calculations to determine potential targets for toremifene, a selective estrogen receptor modulator which we have previously identified as a SARS-CoV-2 inhibitor. Our results indicate the possibility of inhibition of the spike glycoprotein by toremifene, responsible for aiding in fusion of the viral membrane with the cell membrane, via a perturbation to the fusion core. An interaction between the dimethylamine end of toremifene and residues Q954 and N955 in heptad repeat 1 (HR1) perturbs the structure, causing a shift from what is normally a long, helical region to short helices connected by unstructured regions. Additionally, we found a strong interaction between toremifene and the methyltransferase nonstructural protein (NSP) 14, which could be inhibitory to viral replication via its active site. These results suggest potential structural mechanisms for toremifene by blocking the spike protein and NSP14 of SARS-CoV-2, offering a drug candidate for COVID-19.
C1 [Martin, William R.; Cheng, Feixiong] Cleveland Clin, Lerner Res Inst, Genom Med Inst, Cleveland, OH 44195 USA.
   [Cheng, Feixiong] Case Western Reserve Univ, Dept Mol Med, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44195 USA.
   [Cheng, Feixiong] Case Western Reserve Univ, Case Comprehens Canc Ctr, Sch Med, Cleveland, OH 44106 USA.
RP Cheng, FX (corresponding author), Case Western Reserve Univ, Dept Mol Med, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44195 USA.; Cheng, FX (corresponding author), Case Western Reserve Univ, Case Comprehens Canc Ctr, Sch Med, Cleveland, OH 44106 USA.
EM chengf@ccf.org
OI Cheng, Feixiong/0000-0002-1736-2847; Martin, William/0000-0003-0616-0462
FU National Heart, Lung, and Blood Institute of the National Institutes of
   Health (NIH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [R00 HL138272]; National Institute of AgingUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG066707,
   3R01AG066707-01S1]; VeloSano Pilot Program (Cleveland Clinic Taussig
   Cancer Institute)
FX This work was supported by the National Heart, Lung, and Blood Institute
   of the National Institutes of Health (NIH) under Award Number R00
   HL138272 and the National Institute of Aging under Award Number
   R01AG066707 and 3R01AG066707-01S1 to F.C. This work was supported, in
   part, by the VeloSano Pilot Program (Cleveland Clinic Taussig Cancer
   Institute).
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Almeida MS, 2007, J VIROL, V81, P3151, DOI 10.1128/JVI.01939-06
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Arya R, 2020, POTENTIAL INHIBITORS, DOI [10.26434/chemrxiv.11860011.v2, DOI 10.26434/CHEMRXIV.11860011.V2, 10.26434/chemrxiv.11860011.v2.]
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Best RB, 2012, J CHEM THEORY COMPUT, V8, P3257, DOI 10.1021/ct300400x
   Braga C, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2013227
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Cheng FX, 2016, TRENDS MOL MED, V22, P919, DOI 10.1016/j.molmed.2016.09.006
   Cheng FX, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1005074
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Webb Benjamin, 2016, Curr Protoc Protein Sci, V86, DOI [10.1002/0471140864.ps0209s50, 10.1002/0471250953.bi0506s15, 10.1002/cpbi.3, 10.1002/cpps.20]
   Fan HL, 2017, SCI REP-UK, V7, DOI 10.1038/srep41226
   Fujimura T, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1871-z
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Gershanovich M, 1997, BREAST CANCER RES TR, V45, P251, DOI 10.1023/A:1005891506092
   Grosdidier A, 2011, NUCLEIC ACIDS RES, V39, pW270, DOI 10.1093/nar/gkr366
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Irwin JJ, 2012, J CHEM INF MODEL, V52, P1757, DOI 10.1021/ci3001277
   Jeon S, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00819-20
   Jia ZH, 2019, NUCLEIC ACIDS RES, V47, P6538, DOI 10.1093/nar/gkz409
   Jo S, 2008, J COMPUT CHEM, V29, P1859, DOI 10.1002/jcc.20945
   Johansen LM, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005471
   Kim D, 2020, CELL, V181, P914, DOI 10.1016/j.cell.2020.04.011
   Kim S, 2017, J COMPUT CHEM, V38, P1879, DOI 10.1002/jcc.24829
   Kim Y, 2020, PROTEIN SCI, V29, P1596, DOI 10.1002/pro.3873
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Lai AL, 2017, J MOL BIOL, V429, P3875, DOI 10.1016/j.jmb.2017.10.017
   Lee J, 2016, J CHEM THEORY COMPUT, V12, P405, DOI 10.1021/acs.jctc.5b00935
   Ma YY, 2015, P NATL ACAD SCI USA, V112, P9436, DOI 10.1073/pnas.1508686112
   Mustonen MVJ, 2014, WORLD J CLIN ONCOL, V5, P393, DOI 10.5306/wjco.v5.i3.393
   Parks JM, 2020, NEW ENGL J MED, V382, P2261, DOI 10.1056/NEJMcibr2007042
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Si L., 2020, HUMAN ORGANS CHIPS T, P1, DOI [10.1101/2020.04.13.039917, DOI 10.1101/2020.04.13.039917, 10.1101/ 2020.04.13.039917.]
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Vanommeslaeghe K, 2010, J COMPUT CHEM, V31, P671, DOI 10.1002/jcc.21367
   VERLET L, 1967, PHYS REV, V159, P98, DOI 10.1103/PhysRev.159.98
   Volzke H, 2007, J CLIN ENDOCR METAB, V92, P4039, DOI 10.1210/jc.2007-0816
   Wallner B, 2005, PROTEIN SCI, V14, P1315, DOI 10.1110/ps.041253405
   WIEBE VJ, 1990, CANCER CHEMOTH PHARM, V25, P247, DOI 10.1007/BF00684880
   Wiseman LR, 1997, DRUGS, V54, P141, DOI 10.2165/00003495-199754010-00014
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xu XL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006217
   Zhao YG, 2016, NATURE, V535, P169, DOI 10.1038/nature18615
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 50
TC 1
Z9 1
U1 2
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD NOV 6
PY 2020
VL 19
IS 11
BP 4670
EP 4677
DI 10.1021/acs.jproteome.0c00397
PG 8
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA OS1RZ
UT WOS:000589944200039
PM 32907334
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Kumar, N
   Sood, D
   van der Spek, PJ
   Sharma, HS
   Chandra, R
AF Kumar, Neeraj
   Sood, Damini
   van der Spek, Peter J.
   Sharma, Hari S.
   Chandra, Ramesh
TI Molecular Binding Mechanism and Pharmacology Comparative Analysis of
   Noscapine for Repurposing against SARS-CoV-2 Protease
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE SARS-CoV-2; drug repurposing; COVID-19; molecular dynamics simulation
   molecular docking
AB Originating in the city of Wuhan in China in December 2019, COVID-19 has emerged now as a global health emergency with a high number of deaths worldwide. COVID-19 is caused by a novel coronavirus, referred to as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulting in pandemic conditions around the globe. We are in the battleground to fight against the virus by rapidly developing therapeutic strategies in tackling SARS-CoV-2 and saving human lives from COVID-19. Scientists are evaluating several known drugs either for the pathogen or the host; however, many of them are reported to be associated with side effects. In the present study, we report the molecular binding mechanisms of the natural alkaloid, noscapine, for repurposing against the main protease of SARS-CoV-2, a key enzyme involved in its reproduction. We performed the molecular dynamics (MD) simulation in an explicit solvent to investigate the molecular mechanisms of noscapine for stable binding and conformational changes to the main protease (Mpro) of SARS-CoV-2. The drug repurposing study revealed the high potential of noscapine and proximal binding to the Mpro enzyme in a comparative binding pattern analyzed with chloroquine, ribavirin, and favipiravir. Noscapine binds dosely to binding pocket-3 of the Mpro enzyme and depicted stable binding with RMSD 0.1-1.9 angstrom and RMSF profile peak conformational fluctuations at 202-306 residues, and a Rg score ranging from 21.9 to 22.4 angstrom. The MM/PB (GB) SA calculation landscape revealed the most significant contribution in terms of binding energy with Delta PB -19.08 and Delta GB -27.17 kcal/mol. The electrostatic energy distribution in MM energy was obtained to be -71.16 kcal/mol and depicted high free energy decomposition (electrostatic energy) at 155-306 residues (binding pocket-3) of Mpro by a MM force field. Moreover, the dynamical residue cross-correlation map also stated that the high pairwise correlation occurred at binding residues 200-306 of the Mpro enzyme (binding pocket-3) with noscapine. Principal component analysis depicted the enhanced movement of protein atoms with a high number of static hydrogen bonds. The obtained binding results of noscapine were also well correlated with the pharmacokinetic parameters of antiviral drugs.
C1 [Kumar, Neeraj; Sood, Damini; Chandra, Ramesh] Univ Delhi, Dept Chem, Drug Discovery & Dev Lab, Delhi 110007, India.
   [van der Spek, Peter J.; Sharma, Hari S.] Univ Med Ctr, Dept Pathol, Div Clin Bioinformat, Erasmus MC, NL-3015 GD Rotterdam, Netherlands.
   [van der Spek, Peter J.; Sharma, Hari S.] Erasmus Ctr Data Anal ECDA, Rotterdam, Netherlands.
RP Chandra, R (corresponding author), Univ Delhi, Dept Chem, Drug Discovery & Dev Lab, Delhi 110007, India.
EM acbrdu@hotmail.com
OI kumar, neeraj/0000-0002-9348-458X
FU CSIRCouncil of Scientific & Industrial Research (CSIR) - India;
   DST-Purse; DST-SERBDepartment of Science & Technology (India)Science
   Engineering Research Board (SERB), India; UGCUniversity Grants
   Commission, India
FX R.C. is grateful to CSIR, DST-Purse, and DST-SERB for providing
   financial assistance. N.K. particularly thanks CSIR for Research
   Associate fellowship and University of Delhi for Guest Assistant
   Professor Opportunity to conduct research smoothly. D.S. thanks UGC for
   the SRF fellowship.
CR Acuff C., 2011, United States Patent Application, Patent No. [20110274651-A1, 20110274651]
   [Anonymous], CORONAVIRUS DIS COVI
   Borysiewicz L, 2009, CLIN MED, V9, P572, DOI 10.7861/clinmedicine.9-6-572
   Chaudhary M, 2020, J BIOMOL STRUCT DYN, V38, P1335, DOI 10.1080/07391102.2019.1604266
   Chaudhary M, 2020, J BIOMOL STRUCT DYN, V38, P200, DOI 10.1080/07391102.2019.1578264
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   Graham BS, 2013, IMMUNOL REV, V255, P230, DOI 10.1111/imr.12098
   Grant BJ, 2006, BIOINFORMATICS, V22, P2695, DOI 10.1093/bioinformatics/btl461
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Ke Y, 2000, CANCER IMMUNOL IMMUN, V49, P217, DOI 10.1007/s002620000109
   Kim DE, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110696
   Kumar D, 2019, CHEMISTRYSELECT, V4, P4892, DOI 10.1002/slct.201803360
   Kumar N, 2020, J CHEM INF MODEL, V60, P421, DOI 10.1021/acs.jcim.9b01051
   Kumar N, 2018, ARTIF CELL NANOMED B, V46, P1288, DOI 10.1080/21691401.2017.1369423
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Landen JW, 2004, CLIN CANCER RES, V10, P5187, DOI 10.1158/1078-0432.CCR-04-0360
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Laskowski RA, 2018, PROTEIN SCI, V27, P129, DOI 10.1002/pro.3289
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Lin Liang-Tzung, 2014, J Tradit Complement Med, V4, P24, DOI 10.4103/2225-4110.124335
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Macindoe G, 2010, NUCLEIC ACIDS RES, V38, pW445, DOI 10.1093/nar/gkq311
   Martin KW, 2003, ANTIVIR THER, V8, P77
   McGibbon RT, 2015, BIOPHYS J, V109, P1528, DOI 10.1016/j.bpj.2015.08.015
   MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407
   Navas-Martin S, 2003, VIRAL IMMUNOL, V16, P461, DOI 10.1089/088282403771926292
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Rida PCG, 2015, MED RES REV, V35, P1072, DOI 10.1002/med.21357
   Singh A, 2018, CURR TOP MED CHEM, V18, P2056, DOI 10.2174/1568026619666181129125524
   Singh AK, 2020, DIABETES METAB SYND, V14, P241, DOI 10.1016/j.dsx.2020.03.011
   Singh P, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02795
   Singh VK, 2016, FRONT BIOENG BIOTECH, V4, DOI 10.3389/fbioe.2016.00069
   Sood D, 2019, ACS OMEGA, V4, P16233, DOI 10.1021/acsomega.9b02578
   Sood D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35384-6
   Sood Damini, 2018, Genomics & Informatics, V16, P44, DOI 10.5808/GI.2018.16.3.44
   VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V
   Wong SSY, 2008, J ANTIMICROB CHEMOTH, V62, P437, DOI 10.1093/jac/dkn243
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Yang Jing-Fang, 2020, Brief Bioinform, V21, P2206, DOI 10.1093/bib/bbz141
NR 41
TC 3
Z9 3
U1 4
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD NOV 6
PY 2020
VL 19
IS 11
BP 4678
EP 4689
DI 10.1021/acs.jproteome.0c00367
PG 12
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA OS1RZ
UT WOS:000589944200040
PM 32786685
DA 2021-01-01
ER

PT J
AU Chien, MC
   Anderson, TK
   Jockusch, S
   Tao, CJ
   Li, XX
   Kumar, S
   Russo, JJ
   Kirchdoerfer, RN
   Ju, JY
AF Chien, Minchen
   Anderson, Thomas K.
   Jockusch, Steffen
   Tao, Chuanjuan
   Li, Xiaoxu
   Kumar, Shiv
   Russo, James J.
   Kirchdoerfer, Robert N.
   Ju, Jingyue
TI Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug
   Target for COVID-19
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE COVID-19; SARS-CoV-2; RNA-dependent RNA polymerase; nucleotide analogues
AB SARS-CoV-2 is responsible for the current COVID-19 pandemic. On the basis of our analysis of hepatitis C virus and coronavirus replication, and the molecular structures and activities of viral inhibitors, we previously demonstrated that three nucleotide analogues (the triphosphates of Sofosbuvir, Alovudine, and AZT) inhibit the SARS-CoV RNA-dependent RNA polymer-ase (RdRp). We also demonstrated that a library of additional nucleotide analogues terminate RNA synthesis catalyzed by the SARS-CoV-2 RdRp, a well-established drug target for COVID-19. Here, we used polymerase extension experiments to demonstrate that the active triphosphate form of Sofosbuvir (an FDA-approved hepatitis C drug) is incorporated by SARS-CoV-2 RdRp and blocks further incorporation. Using the molecular insight gained from the previous studies, we selected the active triphosphate forms of six other antiviral agents, Alovudine, Tenofovir alafenamide, AZT, Abacavir, Lamivudine, and Emtricitabine, for evaluation as inhibitors of the SARS-CoV-2 RdRp and demonstrated the ability of these viral polymerase inhibitors to be incorporated by SARS-CoV-2 RdRp, where they terminate further polymerase extension with varying efficiency. These results provide a molecular basis for inhibition of the SARS-CoV-2 RdRp by these nucleotide analogues. If sufficient efficacy of some of these FDA-approved drugs in inhibiting viral replication in cell culture is established, they may be explored as potential COVID-19 therapeutics.
C1 [Chien, Minchen; Tao, Chuanjuan; Li, Xiaoxu; Kumar, Shiv; Russo, James J.; Ju, Jingyue] Columbia Univ, Ctr Genome Technol & Biomol Engn, New York, NY 10027 USA.
   [Chien, Minchen; Tao, Chuanjuan; Li, Xiaoxu; Kumar, Shiv; Russo, James J.] Columbia Univ, Dept Chem Engn, New York, NY 10027 USA.
   [Anderson, Thomas K.; Kirchdoerfer, Robert N.] Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.
   [Anderson, Thomas K.; Kirchdoerfer, Robert N.] Univ Wisconsin, Inst Mol Virol, Madison, WI 53706 USA.
   [Jockusch, Steffen] Columbia Univ, Ctr Genome Technol & Biomol Engn & Chem, New York, NY 10027 USA.
   [Ju, Jingyue] Columbia Univ, Dept Pharmacol, New York, NY 10027 USA.
RP Ju, JY (corresponding author), Columbia Univ, Ctr Genome Technol & Biomol Engn, New York, NY 10027 USA.; Ju, JY (corresponding author), Columbia Univ, Dept Pharmacol, New York, NY 10027 USA.
EM dj222@columbia.edu
OI Jockusch, Steffen/0000-0002-4592-5280
FU Columbia University; Jack Ma Foundation; National Institute of Allergy
   and Infectious DiseaseUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [AI123498]; Fast Grants
FX This research is supported by Columbia University, a grant from the Jack
   Ma Foundation, a generous gift from the Columbia Engineering Member of
   the Board of Visitors Dr. Bing Zhao, and Fast Grants to J.J. and a
   National Institute of Allergy and Infectious Disease grant AI123498 to
   R.N.K.
CR Alanazi AS, 2019, ACS MED CHEM LETT, V10, P2, DOI 10.1021/acsmedchemlett.8b00586
   Birkus G, 2016, ANTIMICROB AGENTS CH, V60, P316, DOI 10.1128/AAC.01834-15
   Buonaguro L, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02355-3
   Chien M., 2020, NUCLEOTIDE ANALOGUES, DOI [10.1101/ 2020/03/18.997585, DOI 10.1101/2020/03/18.997585]
   De Clercq E, 2016, BIOCHEM PHARMACOL, V119, P1, DOI 10.1016/j.bcp.2016.04.015
   De Clercq E, 2016, CLIN MICROBIOL REV, V29, P695, DOI 10.1128/CMR.00102-15
   del Amo J, 2020, ANN INTERN MED, V173, P536, DOI 10.7326/M20-3689
   Dustin LB, 2016, CLIN MICROBIOL INFEC, V22, P826, DOI 10.1016/j.cmi.2016.08.025
   Eastman RT, 2020, ACS CENTRAL SCI, V6, P672, DOI 10.1021/acscentsci.0c00489
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Eltahla AA, 2015, VIRUSES-BASEL, V7, P5206, DOI 10.3390/v7102868
   Faletto MB, 1997, ANTIMICROB AGENTS CH, V41, P1099, DOI 10.1128/AAC.41.5.1099
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Hung M, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0706-x
   Jockusch S, 2020, ANTIVIR RES, V180, DOI 10.1016/j.antiviral.2020.104857
   Ju J., 2020, NUCLEOTIDE ANALOGUES, DOI [10.1101/2020.03.12.989186, DOI 10.1101/2020.03.12.989186]
   Ju J., 2020, BIORXIV, DOI [10.1101/2020.01.30.927574, DOI 10.1101/2020.01.30.927574, 10.1101/2020.01.30.927574.]
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Lim SG, 2006, ARCH INTERN MED, V166, P49, DOI 10.1001/archinte.166.1.49
   Lou L, 2013, J CLIN TRANSL HEPATO, V1, P33, DOI 10.14218/JCTH.2013.004XX
   Lu G., 2020, DEV SIMPLE VITRO ASS, DOI [10.1101/2020.07.16.205799, DOI 10.1101/2020.07.16.205799]
   Margot N, 2018, J CLIN VIROL, V103, P37, DOI 10.1016/j.jcv.2018.03.012
   MCKENNA CE, 1989, ACS SYM SER, V401, P1
   Mesci P, 2020, BIORXIV, DOI [10.1101/2020.05.30.125856, DOI 10.1101/2020.05.30.125856]
   Oberg B, 2006, ANTIVIR RES, V71, P90, DOI 10.1016/j.antiviral.2006.05.012
   Quercia R, 2018, JAIDS-J ACQ IMM DEF, V78, P125, DOI 10.1097/QAI.0000000000001660
   Ray AS, 2002, J BIOL CHEM, V277, P40479, DOI 10.1074/jbc.M205303200
   Sacramento C. Q., 2020, BIORXIV, DOI [10.1101/2020.06.15.153411, DOI 10.1101/2020.06.15.153411]
   Sayad B, 2020, ARCH MED RES, V51, P577, DOI 10.1016/j.arcmed.2020.04.018
   Selisko B, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020059
   Smith EC, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003565
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   te Velthuis AJW, 2014, CELL MOL LIFE SCI, V71, P4403, DOI 10.1007/s00018-014-1695-z
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 36
TC 3
Z9 3
U1 6
U2 6
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD NOV 6
PY 2020
VL 19
IS 11
BP 4690
EP 4697
DI 10.1021/acs.jproteome.0c00392
PG 8
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA OS1RZ
UT WOS:000589944200041
PM 32692185
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Zhao, Z
   Bourne, PE
AF Zhao, Zheng
   Bourne, Philip E.
TI Structural Insights into the Binding Modes of Viral RNA-Dependent RNA
   Polymerases Using a Function-Site Interaction Fingerprint Method for RNA
   Virus Drug Discovery
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE RNA virus; SARS-CoV-2; COVID-19; RNA-dependent RNA polymerase (RDRP);
   structural RDRP data set; protein-ligand interaction fingerprint;
   structure-based drug design; function-site interaction fingerprint; drug
   repurposing; drug virtual screening
ID FACTOR XA INHIBITOR; VENOUS THROMBOEMBOLISM; PROTEIN; FRAGMENT;
   CORONAVIRUS; PERFORMANCE; PREVENTION; DOCKING; HIP
AB The coronavirus disease of 2019 (COVID-19) pandemic speaks to the need for drugs that not only are effective but also remain effective given the mutation rate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To this end, we describe structural binding-site insights for facilitating COVID-19 drug design when targeting RNA-dependent RNA polymerase (RDRP), a common conserved component of RNA viruses. We combined an RDRP structure data set, including 384 RDRP PDB structures and all corresponding RDRP-ligand interaction fingerprints, thereby revealing the structural characteristics of the active sites for application to RDRP-targeted drug discovery. Specifically, we revealed the intrinsic ligand-binding modes and associated RDRP structural characteristics. Four types of binding modes with corresponding binding pockets were determined, suggesting two major subpockets available for drug discovery. We screened a drug data set of 7894 compounds against these binding pockets and presented the top-10 small molecules as a starting point in further exploring the prevention of virus replication. In summary, the binding characteristics determined here help rationalize RDRP-targeted drug discovery and provide insights into the specific binding mechanisms important for containing the SARS-CoV-2 virus.
C1 [Zhao, Zheng; Bourne, Philip E.] Univ Virginia, Sch Data Sci, Charlottesville, VA 22904 USA.
   [Zhao, Zheng; Bourne, Philip E.] Univ Virginia, Dept Biomed Engn, Charlottesville, VA 22904 USA.
RP Bourne, PE (corresponding author), Univ Virginia, Sch Data Sci, Charlottesville, VA 22904 USA.; Bourne, PE (corresponding author), Univ Virginia, Dept Biomed Engn, Charlottesville, VA 22904 USA.
RI zhao, zheng/S-7147-2016
OI zhao, zheng/0000-0003-1453-3230
FU University of Virginia
FX We thank Dr. Lei Xie (CUNY) and Dr. Cameron Mura (UVA) for helpful
   discussions. This work was partly supported by the University of
   Virginia (PEB).
CR Agnelli G, 2007, J THROMB HAEMOST, V5, P746, DOI 10.1111/j.1538-7836.2007.02436.x
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   [Anonymous], 2014, MARVIN 6 2 0
   [Anonymous], 2014, JCHEM 6 2 0
   Anwar A, 2020, ACS CHEM NEUROSCI, V11, P2378, DOI 10.1021/acschemneuro.9b00613
   Barnes GD, 2020, J THROMB THROMBOLYS, V50, P72, DOI 10.1007/s11239-020-02138-z
   Baud D, 2017, LANCET, V390, P2099, DOI [10.1016/S0140-6736(17)31450-2, 10.1016/s0140-6736(17)31450-2]
   Beigel J. H., 2020, N ENGL J MED
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Chafekar A, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020093
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Da Silva F, 2018, CHEMMEDCHEM, V13, P507, DOI 10.1002/cmdc.201700505
   Deng Z, 2004, J MED CHEM, V47, P337, DOI 10.1021/jm030331x
   Eriksson BI, 2007, J THROMB HAEMOST, V5, P1660, DOI 10.1111/j.1538-7836.2007.02644.x
   Forster P, 2020, P NATL ACAD SCI USA, V117, P9241, DOI 10.1073/pnas.2004999117
   Hu Y, 2009, CHEMMEDCHEM, V4, P540, DOI 10.1002/cmdc.200800408
   Jain AN, 2007, J COMPUT AID MOL DES, V21, P281, DOI 10.1007/s10822-007-9114-2
   Jain AN, 1996, J COMPUT AID MOL DES, V10, P427, DOI 10.1007/BF00124474
   Jain AN, 2003, J MED CHEM, V46, P499, DOI 10.1021/jm020406h
   Kellenberger E, 2006, J CHEM INF MODEL, V46, P717, DOI 10.1021/ci050372x
   KOONIN EV, 1991, J GEN VIROL, V72, P2197, DOI 10.1099/0022-1317-72-9-2197
   Li C, 2015, ELIFE, V4, DOI 10.7554/eLife.06587
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Maggiora G, 2014, J MED CHEM, V57, P3186, DOI 10.1021/jm401411z
   Marcou G, 2007, J CHEM INF MODEL, V47, P195, DOI 10.1021/ci600342e
   Maynard A, 2014, J MED CHEM, V57, P1902, DOI 10.1021/jm400317w
   Noble CG, 2016, J BIOL CHEM, V291, P8541, DOI 10.1074/jbc.M115.710731
   Oki Y, 2017, HAEMATOLOGICA, V102, P1923, DOI 10.3324/haematol.2017.172882
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Plotch SJ, 1999, J VIROL, V73, P140, DOI 10.1128/JVI.73.1.140-151.1999
   R Core Team, 2016, R LANG ENV STAT COMP
   Radifar M, 2013, BIOINFORMATION, V9, P325, DOI 10.6026/97320630009325
   Ritchie DW, 2016, BIOINFORMATICS, V32, P2650, DOI 10.1093/bioinformatics/btw300
   Ritchie DW, 2012, BIOINFORMATICS, V28, P3274, DOI 10.1093/bioinformatics/bts618
   Rogers D, 2010, J CHEM INF MODEL, V50, P742, DOI 10.1021/ci100050t
   Shu B, 2017, RNA BIOL, V14, P1314, DOI 10.1080/15476286.2017.1300221
   Sigrist CJA, 2013, NUCLEIC ACIDS RES, V41, pE344, DOI 10.1093/nar/gks1067
   Subissi L, 2018, J INFECT DIS, V218, pS287, DOI 10.1093/infdis/jiy280
   Tan CS, 2015, LANCET ONCOL, V16, pE447, DOI 10.1016/S1470-2045(15)00246-6
   Tsang K, 2003, RESPIROLOGY, V8, pS25, DOI 10.1046/j.1440-1843.2003.00525.x
   Venkataraman S, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020076
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958
   Wobser M, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0719-4
   Wu JQ, 2015, INT J MOL SCI, V16, P12943, DOI 10.3390/ijms160612943
   Xie L, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-S4-S9
   Xie L, 2008, P NATL ACAD SCI USA, V105, P5441, DOI 10.1073/pnas.0704422105
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Zhang Y, 2005, NUCLEIC ACIDS RES, V33, P2302, DOI 10.1093/nar/gki524
   Zhao Z, 2020, J CHEM THEORY COMPUT, V16, P3152, DOI 10.1021/acs.jctc.9b01134
   Zhao Z, 2019, J CHEM INF MODEL, V59, P453, DOI 10.1021/acs.jcim.8b00458
   Zhao Z, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179936
   Zhao Z, 2016, J MED CHEM, V59, P4326, DOI 10.1021/acs.jmedchem.5b02041
   Zhao Z, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-0941-9
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 55
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD NOV 6
PY 2020
VL 19
IS 11
BP 4698
EP 4705
DI 10.1021/acs.jproteome.0c00623
PG 8
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA OS1RZ
UT WOS:000589944200042
PM 32946692
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Achutha, AS
   Pushpa, VL
   Suchitra, S
AF Achutha, A. S.
   Pushpa, V. L.
   Suchitra, Surendran
TI Theoretical Insights into the Anti-SARS-CoV-2 Activity of Chloroquine
   and Its Analogs and In Silico Screening of Main Protease Inhibitors
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE SARS-CoV-2; COVID-19; 3CL(Pro); chloroquine; hydroxychloroquine;
   molecular docking; regression; antiviral screening molecular dynamics
AB Corona virus disease (COVID-19) is a dangerous disease rapidly spreading all over the world today. Currently there are no treatment options for it. Drug repurposing studies explored the potency of antimalarial drugs, chloroquine and hydroxychloroquine, against SARS-CoV-2 virus. These drugs can inhibit the viral protease, called chymotrypsin-like cysteine protease, also known as Main protease (3CL(Pro)); hence, we studied the binding efficiencies of 4-aminoquinoline and 8-aminoquinoline analogs of chloroquine. Six compounds furnished better binding energies than chloroquine and hydroxychloroquine. The interactions with the active site residues especially with Cys145 and His41, which are involved in catalytic diad for proteolysis, make these compounds potent main protease inhibitors. A regression model correlating binding energy and the molecular descriptors for chloroquine analogs was generated with R-2 = 0.9039 and Q(2) = 0.8848. This model was used to screen new analogs of primaquine and molecules from the Asinex compound library. The docking and regression analysis showed these analogs to be more potent inhibitors of 3CLP(Pro) than hydroxychloroquine and primaquine. The molecular dynamic simulations of the hits were carried out to determine the binding stabilities. Finally, we propose four compounds that show drug likeness toward SARS-CoV-2 that can be further validated through in vitro and in vivo studies.
C1 [Achutha, A. S.; Pushpa, V. L.; Suchitra, Surendran] Sree Narayana Coll, PG & Res Dept Chem, Kollam 691001, Kerala, India.
RP Pushpa, VL (corresponding author), Sree Narayana Coll, PG & Res Dept Chem, Kollam 691001, Kerala, India.
EM drvlpushpa2017@gmail.com
FU Kerala State Council for Science, Technology and Environment (KSCSTE)
   [414/2020/KSCSTE]
FX The authors gratefully acknowledge generous funding from Kerala State
   Council for Science, Technology and Environment (KSCSTE) for the Junior
   Research Fellowship (No. 414/2020/KSCSTE).
CR Abdulfatai U, 2016, COGENT CHEM, V2, DOI 10.1080/23312009.2016.1166538
   Aguiar ACC, 2018, INT J PARASITOL-DRUG, V8, P459, DOI 10.1016/j.ijpddr.2018.10.002
   Al-Bari MAA, 2015, J ANTIMICROB CHEMOTH, V70, P1608, DOI 10.1093/jac/dkv018
   [Anonymous], 2019, SWISSPDB VIEW
   [Anonymous], 2018, AVOGADRO OPEN SOURCE
   [Anonymous], 2019, COR DIS COVID 19 WEE
   Astuti I, 2020, DIABETES METAB SYND, V14, P407, DOI 10.1016/j.dsx.2020.04.020
   Babu S, 2019, MOL DIVERS, V23, P845, DOI 10.1007/s11030-018-09913-4
   Baird JK, 2004, CLIN INFECT DIS, V39, P1336, DOI 10.1086/424663
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Borgio JF, 2020, ARCH MED SCI, V16, P508, DOI 10.5114/aoms.2020.94567
   Brandl M, 2001, J MOL BIOL, V307, P357, DOI 10.1006/jmbi.2000.4473
   Chang L, 2020, TRANSFUS MED REV, V34, P75, DOI 10.1016/j.tmrv.2020.02.003
   Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285
   Chinnasamy S, 2020, J BIOMOL STRUCT DYN, V38, P4325, DOI 10.1080/07391102.2019.1674695
   Chtita S, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e01304
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Edache E. I., 2015, J COMPUT METHODS MOL, V5, P135
   Elsasser B., 2020, ACS CATAL, V7, P486
   Forbes CR, 2017, J AM CHEM SOC, V139, P1842, DOI 10.1021/jacs.6b08415
   Gramatica P, 2014, J COMPUT CHEM, V35, P1036, DOI 10.1002/jcc.23576
   Gramatica P, 2013, J COMPUT CHEM, V34, P2121, DOI 10.1002/jcc.23361
   Graves PM, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008152.pub5
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Hall L.H., 1991, REV COMPUTATIONAL CH, VII, P367, DOI DOI 10.1002/9780470125793.CH
   Hanwell MD, 2012, J CHEMINFORMATICS, V4, DOI 10.1186/1758-2946-4-17
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Idicula-Thomas S, 2005, PROTEIN SCI, V14, P582, DOI 10.1110/ps.041009005
   Jain M, 2004, J MED CHEM, V47, P285, DOI 10.1021/jm0304562
   Jain M, 2004, BIOORGAN MED CHEM, V12, P1003, DOI 10.1016/j.bmc.2003.12.029
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jo S, 2008, J COMPUT CHEM, V29, P1859, DOI 10.1002/jcc.20945
   Kim S, 2017, J COMPUT CHEM, V38, P1879, DOI 10.1002/jcc.24829
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lythgoe MP, 2020, TRENDS PHARMACOL SCI, V41, P363, DOI 10.1016/j.tips.2020.03.006
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Morrison R. T., 2011, ORGANIC CHEM, P765
   Panda S, 2012, BIOINFORMATION, V8, P891, DOI 10.6026/97320630008891
   Parhizgar AR, 2017, IRAN J MED SCI, V42, P115
   Pastick KA, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa130
   Phillips JC, 2020, J CHEM PHYS, V153, DOI 10.1063/5.0014475
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Priya R, 2015, PHARMACOGN MAG, V11, pS414, DOI 10.4103/0973-1296.168947
   PubChem, 2020, PUBCHEM DAT
   PUKRITTAYAKAMEE S, 1994, J INFECT DIS, V169, P932, DOI 10.1093/infdis/169.4.932
   Radwan A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234215
   Rastija V., 2018, COMB CHEM HIGH THROU, V21, P1
   Rolain JM, 2007, INT J ANTIMICROB AG, V30, P297, DOI 10.1016/j.ijantimicag.2007.05.015
   Roy K, 1999, INDIAN J CHEM B, V38, P942
   Sarithamol S., 2018, INT J CURR PHARM RES, V10, P43
   Sarithamol S, 2020, CHEM BIOL DRUG DES, V95, P503, DOI 10.1111/cbdd.13667
   Singh AK, 2020, DIABETES METAB SYND, V14, P241, DOI 10.1016/j.dsx.2020.03.011
   Sivaprakasam P, 2009, J CHEM INF MODEL, V49, P1787, DOI 10.1021/ci9000663
   Syahri J, 2017, ASIAN PAC J TROP BIO, V7, P675, DOI 10.1016/j.apjtb.2017.07.004
   Udugama B, 2020, ACS NANO, V14, P3822, DOI 10.1021/acsnano.0c02624
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Wang HL, 2008, CELL RES, V18, P290, DOI 10.1038/cr.2008.15
   Wang LS, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105948
   Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004
   Yap CW, 2011, J COMPUT CHEM, V32, P1466, DOI 10.1002/jcc.21707
   Yin YM, 2015, MOL INFORM, V34, P679, DOI 10.1002/minf.201400119
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
NR 64
TC 2
Z9 2
U1 3
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD NOV 6
PY 2020
VL 19
IS 11
BP 4706
EP 4717
DI 10.1021/acs.jproteome.0c00683
PG 12
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA OS1RZ
UT WOS:000589944200043
PM 32960061
OA Green Published
DA 2021-01-01
ER

PT J
AU Okajima, M
   Takahashi, Y
   Kaji, T
   Ogawa, N
   Mouri, H
AF Okajima, Masaki
   Takahashi, Yoshinori
   Kaji, Takaaki
   Ogawa, Naohiko
   Mouri, Hideyuki
TI Nafamostat mesylate-induced hyperkalemia in critically ill patients with
   COVID-19: Four case reports
SO WORLD JOURNAL OF CLINICAL CASES
LA English
DT Article
DE COVID-19; Nafamostat; Hyperkalemia; Disseminated intravascular
   coagulation; Respiratory insufficiency; Case report
AB BACKGROUND
   Nafamostat mesylate (NM) may prove to be one of the key drugs effective against coronavirus disease 2019 (COVID-19) because of its anti-viral properties and the potential to manage coagulopathy. However, NM tends to increase serum potassium levels.
   CASE SUMMARY
   We observed hyperkalemia immediately after NM administration (200 mg/d) in four consecutive patients who were admitted to the Kanazawa University Hospital with severe COVID-19 pneumonia. Urinary potassium excretion decreased after NM administration in three patients who underwent urinalysis.
   CONCLUSION
   NM is likely to produce hyperkalemia in patients with COVID-19. Therefore, it is necessary to monitor serum potassium values closely after NM initiation in COVID-19 patients who need respiratory support.
C1 [Okajima, Masaki; Mouri, Hideyuki] Kanazawa Univ Hosp, Intens Care Unit, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan.
   [Takahashi, Yoshinori] Kanazawa Univ Hosp, Dept Rheumatol, Kanazawa, Ishikawa 9208641, Japan.
   [Kaji, Takaaki] Kanazawa Univ Hosp, Dept Nephrol, Kanazawa, Ishikawa 9208641, Japan.
   [Ogawa, Naohiko] Kanazawa Univ Hosp, Dept Resp Med, Kanazawa, Ishikawa 9208641, Japan.
RP Okajima, M (corresponding author), Kanazawa Univ Hosp, Intens Care Unit, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan.
EM mmokaji@gmail.com
CR Asakura H, 2020, J THROMB HAEMOST, V18, P1521, DOI 10.1111/jth.14858
   Muto S, 1995, GEN PHARMACOL, V26, P1627, DOI 10.1016/0306-3623(95)00072-0
   Nishimura H, 2015, TOHOKU J EXP MED, V237, P45, DOI 10.1620/tjem.237.45
   Nomoto H, 2020, AM J INFECT CONTROL, V48, P969, DOI 10.1016/j.ajic.2020.05.034
   Yamamoto M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12060629
   Zhang LT, 2020, J THROMB HAEMOST, V18, P1324, DOI 10.1111/jth.14859
NR 6
TC 0
Z9 0
U1 1
U2 1
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 2307-8960
J9 WORLD J CLIN CASES
JI World J. Clin. Cases
PD NOV 6
PY 2020
VL 8
IS 21
BP 5320
EP 5325
DI 10.12998/wjcc.v8.i21.5320
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA PA5RI
UT WOS:000595692200022
PM 33269265
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Toelzer, C
   Gupta, K
   Yadav, SKN
   Borucu, U
   Davidson, AD
   Williamson, MK
   Shoemark, DK
   Garzoni, F
   Staufer, O
   Milligan, R
   Capin, J
   Mulholland, AJ
   Spatz, J
   Fitzgerald, D
   Berger, I
   Schaffitzel, C
AF Toelzer, Christine
   Gupta, Kapil
   Yadav, Sathish K. N.
   Borucu, Ufuk
   Davidson, Andrew D.
   Williamson, Maia Kavanagh
   Shoemark, Deborah K.
   Garzoni, Frederic
   Staufer, Oskar
   Milligan, Rachel
   Capin, Julien
   Mulholland, Adrian J.
   Spatz, Joachim
   Fitzgerald, Daniel
   Berger, Imre
   Schaffitzel, Christiane
TI Free fatty acid binding pocket in the locked structure of SARS-CoV-2
   spike protein
SO SCIENCE
LA English
DT Article
ID CRYO-EM STRUCTURE; CORONAVIRUS; RHINOVIRUS; VALIDATION; EXPRESSION;
   INFECTION
AB Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), represents a global crisis. Key to SARS-CoV-2 therapeutic development is unraveling the mechanisms that drive high infectivity, broad tissue tropism, and severe pathology. Our 2.85-angstrom cryo-electron microscopy structure of SARS-CoV-2 spike (S) glycoprotein reveals that the receptor binding domains tightly bind the essential free fatty acid linoleic acid (LA) in three composite binding pockets. A similar pocket also appears to be present in the highly pathogenic severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). LA binding stabilizes a locked S conformation, resulting in reduced angiotensin-converting enzyme 2 (ACE2) interaction in vitro. In human cells, LA supplementation synergizes with the COVID-19 drug remdesivir, suppressing SARS-CoV-2 replication. Our structure directly links LA and S, setting the stage for intervention strategies that target LA binding by SARS-CoV-2.
C1 [Toelzer, Christine; Gupta, Kapil; Yadav, Sathish K. N.; Borucu, Ufuk; Shoemark, Deborah K.; Capin, Julien; Berger, Imre; Schaffitzel, Christiane] Univ Bristol, Sch Biochem, 1 Tankards Close, Bristol BS8, Avon, England.
   [Toelzer, Christine; Gupta, Kapil; Yadav, Sathish K. N.; Borucu, Ufuk; Shoemark, Deborah K.; Capin, Julien; Berger, Imre; Schaffitzel, Christiane] Bristol Synthet Biol Ctr BrisSynBio, 24 Tyndall Ave, Bristol BS8, Avon, England.
   [Davidson, Andrew D.; Williamson, Maia Kavanagh; Milligan, Rachel] Univ Bristol, Sch Cellular & Mol Med, Bristol BS8, Avon, England.
   [Garzoni, Frederic] Imophoron Ltd, St Philips Cent, Albert Rd, Bristol BS2 0XJ, Avon, England.
   [Staufer, Oskar; Spatz, Joachim] Max Planck Inst Med Res, Dept Cellular Biophys, Jahnstr 29, D-69120 Heidelberg, Germany.
   [Staufer, Oskar; Spatz, Joachim] Heidelberg Univ, Inst Phys Chem, Dept Biophys Chem, Neuenheimer Feld 253, D-69120 Heidelberg, Germany.
   [Staufer, Oskar; Spatz, Joachim] Max Planck Sch Matter Life, Jahnstr 29, D-69120 Heidelberg, Germany.
   [Staufer, Oskar; Spatz, Joachim; Berger, Imre] Max Planck Bristol Ctr Minimal Biol, Cantocks Close, Bristol BS8, Avon, England.
   [Mulholland, Adrian J.; Berger, Imre] Univ Bristol, Sch Chem, Cantocks Close, Bristol BS8, Avon, England.
   [Fitzgerald, Daniel] Geneva Biotech Sarl, Ave Roseraie 64, CH-1205 Geneva, Switzerland.
RP Berger, I; Schaffitzel, C (corresponding author), Univ Bristol, Sch Biochem, 1 Tankards Close, Bristol BS8, Avon, England.; Berger, I; Schaffitzel, C (corresponding author), Bristol Synthet Biol Ctr BrisSynBio, 24 Tyndall Ave, Bristol BS8, Avon, England.; Berger, I (corresponding author), Max Planck Bristol Ctr Minimal Biol, Cantocks Close, Bristol BS8, Avon, England.; Berger, I (corresponding author), Univ Bristol, Sch Chem, Cantocks Close, Bristol BS8, Avon, England.
EM imre.berger@bristol.ac.uk; cb14941@bristol.ac.uk
RI Gupta, Kapil/ABH-4503-2020; Spatz, Joachim P/A-1107-2017
OI Gupta, Kapil/0000-0002-2115-3503; Spatz, Joachim P/0000-0003-3419-9807;
   Reis, AlessanRSS/0000-0001-8486-7469; Borucu, Ufuk/0000-0001-6746-5409;
   Staufer, Oskar/0000-0002-8015-3132; Toelzer,
   Christine/0000-0001-9984-5940; /0000-0002-1240-8463; garzoni,
   Frederic/0000-0001-9668-9348
FU Elizabeth Blackwell Institute for Health Research; EPSRCEngineering &
   Physical Sciences Research Council (EPSRC) [EP/R511663/1, EP/M022609/1];
   University of Bristol; BrisSynBio, a BBSRC/EPSRC Research Centre for
   synthetic biology at the University of Bristol [BB/L01386X/1];
   BBSRCBiotechnology and Biological Sciences Research Council (BBSRC)
   [BB/P000940/1, BB/R000484/1]; Oracle Higher Education and Research
   program; EPSRCEngineering & Physical Sciences Research Council (EPSRC);
   Wellcome TrustWellcome Trust [202904/Z/16/Z, 206181/Z/17/Z,
   210701/Z/18/Z, 106115/Z/14/Z]; University of Bristol's Alumni and
   Friends; Elisabeth Muerer Foundation; Max Planck School Matter to
   LifeMax Planck Society; Heidelberg Biosciences International Graduate
   School; U.S. Food and Drug Administration [HHSF223201510104C]; UK
   Research and Innovation/Medical Research Council (MRC) [MR/V027506/1];
   MRCMedical Research Council UK (MRC) [MR/V027506/1, MR/R020566/1];
   British Society for Antimicrobial Chemotherapy [BSAC-COVID-30]; EPSRC
   Future Vaccine Manufacturing and Research HubEngineering & Physical
   Sciences Research Council (EPSRC) [EP/R013764/1]
FX This research received support from the Elizabeth Blackwell Institute
   for Health Research and the EPSRC Impact Acceleration Account
   EP/R511663/1, University of Bristol; from BrisSynBio, a BBSRC/EPSRC
   Research Centre for synthetic biology at the University of Bristol
   (BB/L01386X/1 to I.B., A.J.M., and D.K.S.); and from the BBSRC
   (BB/P000940/1 to C.S. and I.B.). This work received generous support
   from the Oracle Higher Education and Research program to enable cryo-EM
   data processing using Oracle's high-performance public cloud
   infrastructure (https://cloud.oracle.com/en_US/cloudinfrastructure) and
   from the EPSRC through a COVID-19 project award via HECBioSim to access
   ARCHER (to A.J.M.). We acknowledge support and assistance by the Wolfson
   Bioimaging Facility and the GW4 Facility for High-Resolution Electron
   CryoMicroscopy funded by the Wellcome Trust (202904/Z/16/Z and
   206181/Z/17/Z) and BBSRC (BB/R000484/1). We would like to acknowledge
   support of the University of Bristol's Alumni and Friends, who funded
   the ImageXpress Pico Imaging System. O.S. acknowledges support from the
   Elisabeth Muerer Foundation, the Max Planck School Matter to Life, and
   the Heidelberg Biosciences International Graduate School. A.D.D. is
   supported by the U.S. Food and Drug Administration (HHSF223201510104C)
   and the UK Research and Innovation/Medical Research Council (MRC)
   (MR/V027506/1). M.K.W. is supported by MRC grants MR/R020566/1 and
   MR/V027506/1 (awarded to A.D.D). A.J.M. is supported the British Society
   for Antimicrobial Chemotherapy (BSAC-COVID-30) and the EPSRC
   (EP/M022609/1, CCP-BioSim). I.B. acknowledges support from the EPSRC
   Future Vaccine Manufacturing and Research Hub (EP/R013764/1). C.S. and
   I.B. are Investigators of the Wellcome Trust (210701/Z/18/Z and
   106115/Z/14/Z).
CR Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   BADGER J, 1988, P NATL ACAD SCI USA, V85, P3304, DOI 10.1073/pnas.85.10.3304
   Barad BA, 2015, NAT METHODS, V12, P943, DOI [10.1038/nmeth.3541, 10.1038/NMETH.3541]
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E
   Berger I, 2004, NAT BIOTECHNOL, V22, P1583, DOI 10.1038/nbt1036
   Cai YF, 2020, SCIENCE, V369, P1586, DOI 10.1126/science.abd4251
   Casanova V, 2018, FUTURE VIROL, V13, P505, DOI 10.2217/fvl-2018-0016
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Daly JL, 2020, SCIENCE, V370, P861, DOI 10.1126/science.abd3072
   Davidson AD, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00763-0
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Fairhead Michael, 2015, Methods Mol Biol, V1266, P171, DOI 10.1007/978-1-4939-2272-7_12
   Sousa da Silva Alan W, 2012, BMC Res Notes, V5, P367, DOI [10.1186/1756-0500-5-185, 10.1186/1756-0500-5-367]
   Fitzgerald DJ, 2006, NAT METHODS, V3, P1021, DOI 10.1038/nmeth983
   GLATZ JFC, 1983, J BIOCHEM BIOPH METH, V8, P57, DOI 10.1016/0165-022X(83)90021-0
   Goddard TD, 2007, J STRUCT BIOL, V157, P281, DOI 10.1016/j.jsb.2006.06.010
   Goodwin CM, 2015, TRENDS MICROBIOL, V23, P789, DOI 10.1016/j.tim.2015.08.007
   Gullett JM, 2019, J BIOL CHEM, V294, P16416, DOI 10.1074/jbc.RA119.010659
   Hauff S, 2009, J AGR FOOD CHEM, V57, P3423, DOI 10.1021/jf803665u
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Kimura I, 2020, PHYSIOL REV, V100, P171, DOI 10.1152/physrev.00041.2018
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li ZJ, 2019, ELIFE, V8, DOI 10.7554/eLife.51230
   Liebschner D, 2019, ACTA CRYSTALLOGR D, V75, P861, DOI 10.1107/S2059798319011471
   Lindorff-Larsen K, 2010, PROTEINS, V78, P1950, DOI 10.1002/prot.22711
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Moriarty NW, 2009, ACTA CRYSTALLOGR D, V65, P1074, DOI 10.1107/S0907444909029436
   OLIVEIRA MA, 1993, STRUCTURE, V1, P51, DOI 10.1016/0969-2126(93)90008-5
   Ou XY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15216
   Puelles VG, 2020, NEW ENGL J MED, V383, P590, DOI [10.1056/NEJMc2011400, 10.1056/NEJMc2013400]
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Rohou A, 2015, J STRUCT BIOL, V192, P216, DOI 10.1016/j.jsb.2015.08.008
   Scheres SHW, 2012, J STRUCT BIOL, V180, P519, DOI 10.1016/j.jsb.2012.09.006
   Schoggins JW, 2013, CELL HOST MICROBE, V14, P379, DOI 10.1016/j.chom.2013.09.010
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shen B, 2020, CELL, V182, P59, DOI 10.1016/j.cell.2020.05.032
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Terwilliger TC, 2018, ACTA CRYSTALLOGR D, V74, P545, DOI 10.1107/S2059798318004655
   To KKW, 2017, J FORMOS MED ASSOC, V116, P496, DOI 10.1016/j.jfma.2017.04.009
   Tortorici MA, 2019, NAT STRUCT MOL BIOL, V26, P481, DOI 10.1038/s41594-019-0233-y
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   VORK MM, 1990, MOL CELL BIOCHEM, V98, P111, DOI 10.1007/BF00231374
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2016, NAT STRUCT MOL BIOL, V23, P899, DOI 10.1038/nsmb.3293
   Wang J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60242-9
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang Qian, 2017, Biochem Biophys Rep, V10, P318, DOI 10.1016/j.bbrep.2017.05.001
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wrobel AG, 2020, NAT STRUCT MOL BIOL, V27, P763, DOI 10.1038/s41594-020-0468-7
   Yan BP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010073
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zaman MM, 2010, AM J PHYSIOL-LUNG C, V299, pL599, DOI 10.1152/ajplung.00346.2009
   Zheng SQ, 2017, NAT METHODS, V14, P331, DOI 10.1038/nmeth.4193
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 62
TC 5
Z9 5
U1 2
U2 2
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD NOV 6
PY 2020
VL 370
IS 6517
SI SI
BP 725
EP +
DI 10.1126/science.abd3255
PG 38
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ON7IB
UT WOS:000586868600047
PM 32958580
OA Other Gold
DA 2021-01-01
ER

PT J
AU Cardoso, NP
   Mansilla, FC
   Benedetti, E
   Turco, CS
   Barone, LJ
   Iserte, JA
   Soria, I
   Baumeister, E
   Capozzo, AV
AF Cardoso, Nancy Patricia
   Mansilla, Florencia Celeste
   Benedetti, Estefania
   Turco, Cecilia Soledad
   Barone, Lucas Jose
   Iserte, Javier Alonso
   Soria, Ivana
   Baumeister, Elsa
   Capozzo, Alejandra Victoria
TI Bovine Interferon Lambda Is a Potent Antiviral Against SARS-CoV-2
   Infection in vitro
SO FRONTIERS IN VETERINARY SCIENCE
LA English
DT Article
DE COVID-19; bovine IFN-&#955; antivirals; respiratory viruses;
   biotherapeutic agent
ID RESPIRATORY SYNDROME; STIMULATED GENES; III INTERFERONS; ALPHA;
   INTERLEUKIN-6; RIBAVIRIN; SEVERITY; RATIO
AB Interferon lambda (IFN-lambda) is an antiviral naturally produced in response to viral infections, with activity on cells of epithelial origin and located in the mucosal surfaces. This localized activity results in reduced toxicity compared to type I IFNs, whose receptors are ubiquitously expressed. IFN-lambda has been effective in the therapy of respiratory viral infections, playing a crucial role in potentiating adaptive immune responses that initiate at mucosal surfaces. Human IFN-lambda has polymorphisms that may cause differences in the interaction with the specific receptor in the human population. Interestingly, bovine IFN-lambda 3 has an in silico-predicted higher affinity for the human receptor than its human counterparts, with high identity with different human IFN-lambda variants, making it a suitable antiviral therapeutic candidate for human health. Here, we demonstrate that a recombinant bovine IFN-lambda (rbIFN-lambda) produced in HEK-293 cells is effective in preventing SARS-CoV-2 infection of VERO cells, with an inhibitory concentration 50% (IC50) between 30 and 50 times lower than that of human type I IFN tested here (alpha 2b and beta 1a). We also demonstrated the absence of toxicity of rbIFN-lambda in human PBMCs and the lack of proinflammatory activity on these cells. Altogether, our results show that rbIFN-lambda is as an effective antiviral potentially suitable for COVID-19 therapy. Among other potential applications, rbIFN-lambda could be useful to preclude virus dispersion to the lungs and/or to reduce transmission from infected people. Moreover, and due to the non-specific activity of this IFN, it can be potentially effective against other respiratory viruses that may be circulating together with SARS-CoV-2.
C1 [Cardoso, Nancy Patricia; Mansilla, Florencia Celeste; Turco, Cecilia Soledad; Barone, Lucas Jose; Soria, Ivana; Capozzo, Alejandra Victoria] Inst Nacl Tecnol Agr INTA, Consejo Nacl Invest Cient & Tecn CONICET, Inst Virol & Innovac Tecnol IVIT, Hurlingham, Argentina.
   [Benedetti, Estefania; Baumeister, Elsa] INEI ANLIS Dr Carlos G Malbran, Inst Nacl Enfermedades Infecciosas, Serv Virosis Resp, Buenos Aires, DF, Argentina.
   [Iserte, Javier Alonso] Fdn Inst Leloir, Struct Bioinformat Grp, Buenos Aires, DF, Argentina.
RP Capozzo, AV (corresponding author), Inst Nacl Tecnol Agr INTA, Consejo Nacl Invest Cient & Tecn CONICET, Inst Virol & Innovac Tecnol IVIT, Hurlingham, Argentina.
EM capozzo.alejandra@inta.gob.ar
FU Subvencion COVID Federal [IF-2020-37418385-APN-SSFCTEI MCT]; INEI ANLIS
FX This study was supported by Subvencion COVID Federal
   IF-2020-37418385-APN-SSFCTEI MCT awarded to AC; by the services provided
   by AC group through STAN-CONICET; and by INEI ANLIS Dr. Carlos G.
   Malbran through the work carried out by the working group led by EBa.
CR Ahidjo BA, 2020, ACS INFECT DIS, V6, P1624, DOI 10.1021/acsinfecdis.0c00236
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
   Malacari DA, 2018, FRONT VET SCI, V5, DOI 10.3389/fvets.2018.00075
   Ansari M. A., 2020, GENE LOCUS CONTROLS, DOI [10.1101/2020.04.26.20080408, DOI 10.1101/2020.04.26.20080408]
   Bamford CGG, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007307
   Bekisz J, 2004, GROWTH FACTORS, V22, P243, DOI 10.1080/08977190400000833
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Chu H, 2020, CLIN INFECT DIS, V71, P1400, DOI 10.1093/cid/ciaa410
   Chung JH, 2020, CYTOKINE, V125, DOI 10.1016/j.cyto.2019.154833
   Crotta S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003773
   Dellgren C, 2009, GENES IMMUN, V10, P125, DOI 10.1038/gene.2008.87
   DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259
   Quintana ME, 2018, J VIROL METHODS, V260, P75, DOI 10.1016/j.jviromet.2018.07.010
   Felgenhauer U, 2020, J BIOL CHEM, V295, P13958, DOI 10.1074/jbc.AC120.013788
   Fray MD, 2001, J IMMUNOL METHODS, V249, P235, DOI 10.1016/S0022-1759(00)00359-8
   Galani IE, 2015, ADV EXP MED BIOL, V850, P1, DOI 10.1007/978-3-319-15774-0_1
   Gao LL, 2010, VACCINE, V28, P4445, DOI 10.1016/j.vaccine.2010.03.062
   Gibbert K, 2013, BRIT J PHARMACOL, V168, P1048, DOI 10.1111/bph.12010
   Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jordan WJ, 2007, GENES IMMUN, V8, P13, DOI 10.1038/sj.gene.6364348
   Kim UJ, 2016, ANTIVIR THER, V21, P455, DOI 10.3851/IMP3002
   Kotenko SV, 2017, J BIOL CHEM, V292, P7295, DOI 10.1074/jbc.R117.777102
   Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875
   Laskowski RA, 1997, TRENDS BIOCHEM SCI, V22, P488, DOI 10.1016/S0968-0004(97)01140-7
   Lazear HM, 2019, IMMUNITY, V50, P907, DOI 10.1016/j.immuni.2019.03.025
   Lazear HM, 2015, IMMUNITY, V43, P15, DOI 10.1016/j.immuni.2015.07.001
   Lokugamage KG, 2020, J VIROL, V94, DOI 10.1128/JVI.01410-20
   Loutfy MR, 2003, JAMA-J AM MED ASSOC, V290, P3222, DOI 10.1001/jama.290.24.3222
   Manry J, 2011, J EXP MED, V208, P2747, DOI 10.1084/jem.20111680
   Mantlo E, 2020, ANTIVIR RES, V179, DOI 10.1016/j.antiviral.2020.104811
   Mendoza JL, 2017, IMMUNITY, V46, P379, DOI 10.1016/j.immuni.2017.02.017
   Munoz-Ruiz A, 2019, J NANOMATER, V2019, DOI 10.1155/2019/2875375
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Perez-Martin E, 2012, J VIROL, V86, P4477, DOI 10.1128/JVI.06683-11
   Prokunina-Olsson L, 2020, J EXP MED, V217, DOI 10.1084/jem.20200653
   Rahmani H, 2020, INT IMMUNOPHARMACOL, V88, DOI 10.1016/j.intimp.2020.106903
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Santer DM, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008515
   Schneider WM, 2014, ANNU REV IMMUNOL, V32, P513, DOI 10.1146/annurev-immunol-032713-120231
   Schoggins JW, 2011, CURR OPIN VIROL, V1, P519, DOI 10.1016/j.coviro.2011.10.008
   Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873
   Taniguchi T, 1999, CRIT CARE MED, V27, P1262, DOI 10.1097/00003246-199907000-00005
   Taniguchi T, 1999, AM J EMERG MED, V17, P548, DOI 10.1016/S0735-6757(99)90194-8
   Wang N, 2020, CELL HOST MICROBE, V28, P455, DOI 10.1016/j.chom.2020.07.005
   Yu DB, 2016, DRUG DES DEV THER, V10, DOI 10.2147/DDDT.S91455
   Zhou JH, 2018, CELL PHYSIOL BIOCHEM, V51, P173, DOI 10.1159/000495172
NR 47
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2297-1769
J9 FRONT VET SCI
JI Front. Vet. Sci.
PD NOV 6
PY 2020
VL 7
AR 603622
DI 10.3389/fvets.2020.603622
PG 11
WC Veterinary Sciences
SC Veterinary Sciences
GA OT9YS
UT WOS:000591194700001
PM 33240967
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Matschinske, J
   Salgado-Albarran, M
   Sadegh, S
   Bongiovanni, D
   Baumbach, J
   Blumenthal, DB
AF Matschinske, Julian
   Salgado-Albarran, Marisol
   Sadegh, Sepideh
   Bongiovanni, Dario
   Baumbach, Jan
   Blumenthal, David B.
TI Individuating Possibly Repurposable Drugs and Drug Targets for COVID-19
   Treatment through Hypothesis-Driven Systems Medicine Using CoVex
SO ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
LA English
DT Article
DE systems medicine; network-based drug repurposing; SARS-CoV-2
ID DATABASE
AB Coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, has developed into a pandemic causing major disruptions and hundreds of thousands of deaths in wide parts of the world. As of July 3, 2020, neither vaccines nor approved drugs for effective treatment are available. In this article, we showcase how to individuate drug targets and potentially repurposable drugs in silico using CoVex a recently presented systems medicine platform for COVID-19 drug repurposing. Starting from initial hypotheses, CoVex leverages network algorithms to individuate host proteins involved in COVID-19 disease mechanisms, as well as existing drugs targeting these potential drug targets. Our analysis reveals GLA, PLAT, and GGCX as potential drug targets, and urokinase, argatroban, dabigatran etexilate, betrixaban, ximelagatran and anisindione as potentially repurposable drugs.
C1 [Matschinske, Julian; Salgado-Albarran, Marisol; Sadegh, Sepideh; Baumbach, Jan; Blumenthal, David B.] Tech Univ Munich, Chair Expt Bioinformat, D-85354 Freising Weihenstephan, Germany.
   [Salgado-Albarran, Marisol] Univ Autonoma Metropolitana Cuajimalpa, Nat Sci Dept, Mexico City, DF, Mexico.
   [Bongiovanni, Dario] Tech Univ Munich, Univ Hosp Rechts Isar, Sch Med, Dept Internal Med 1, Munich, Germany.
   [Bongiovanni, Dario] German Ctr Cardiovasc Res DZHK, Munich Heart Alliance, Partner Site, Munich, Germany.
   [Bongiovanni, Dario] Humanitas Univ, Dept Cardiovasc Med, Humanitas Clin & Res Ctr, IRCCS, Milan, Italy.
RP Baumbach, J; Blumenthal, DB (corresponding author), Tech Univ Munich, Chair Expt Bioinformat, D-85354 Freising Weihenstephan, Germany.
EM jan.baumbach@wzw.tum.de; david.blumenthal@wzw.tum.de
FU H2020 grant REPO-TRIAL [777111]; CONACYTConsejo Nacional de Ciencia y
   Tecnologia (CONACyT) [CVU659273, 312021]; German Academic Exchange
   Service, DAADDeutscher Akademischer Austausch Dienst (DAAD) [91693321];
   H2020 grant FeatureCloud [826078]; BMBF grant Sys_CAREFederal Ministry
   of Education & Research (BMBF) [5103388]; German Center for
   Cardiovascular Research, DZHK [81X3600606]
FX J.B. and S.S. are grateful for financial support from H2020 grant
   REPO-TRIAL (no. 777111). M.S.-A. is a doctoral student from "Programa de
   Maestria y Doctorado en Ciencias Bioquimicas, UNAM'' and is grateful for
   a PhD fellowship funding from CONACYT (CVU659273 and 312021) and the
   German Academic Exchange Service, DAAD (ref. 91693321). J.B. and J.M.
   acknowledge financial support from H2020 grant FeatureCloud (no. 826078)
   and BMBF grant Sys_CARE (no. 5103388). D.B.B. gratefully acknowledges
   financial support from the German Center for Cardiovascular Research,
   DZHK (no. 81X3600606).
CR Alcaraz Nicolas, 2016, F1000Res, V5, P1531, DOI 10.12688/f1000research.9054.1
   Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI 10.1093/nar/gkh131
   Armstrong JF, 2020, NUCLEIC ACIDS RES, V48, pD1006, DOI 10.1093/nar/gkz951
   Atallah B, 2020, EUR HEART J-CARD PHA, V6, P260, DOI 10.1093/ehjcvp/pvaa036
   Barbarino JM, 2018, WIRES SYST BIOL MED, V10, DOI 10.1002/wsbm.1417
   Baumbach J., 2018, SYSTEMS MED, V1, P1, DOI [10.1089/sysm.2017.28999.jba, DOI 10.1089/SYSM.2017.28999.JBA]
   Budnik I, 2018, TRENDS IMMUNOL, V39, P610, DOI 10.1016/j.it.2018.04.010
   Casas AI, 2019, P NATL ACAD SCI USA, V116, P7129, DOI 10.1073/pnas.1820799116
   Germain DP, 2010, ORPHANET J RARE DIS, V5, DOI 10.1186/1750-1172-5-30
   Gilson MK, 2016, NUCLEIC ACIDS RES, V44, pD1045, DOI 10.1093/nar/gkv1072
   GLA gene, GLA GEN
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Guney E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10331
   GYONGYI Z, 2004, P 30 INT C VER LARG, V30, P2004
   Gysi DM, 2020, NETWORK MED FRAMEWOR
   Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2
   Kacprowski T, 2013, BIOINFORMATICS, V29, P1471, DOI 10.1093/bioinformatics/btt164
   Karen Julie K, 2005, Dermatol Online J, V11, P8
   Kotlyar M, 2019, NUCLEIC ACIDS RES, V47, pD581, DOI 10.1093/nar/gky1037
   Mendez D, 2019, NUCLEIC ACIDS RES, V47, pD930, DOI 10.1093/nar/gky1075
   Oudkerk M, 2020, RADIOLOGY, V297, pE216, DOI 10.1148/radiol.2020201629
   Palta S, 2014, INDIAN J ANAESTH, V58, P515, DOI 10.4103/0019-5049.144643
   Presnell SR, 2002, THROMB HAEMOSTASIS, V87, P937
   Raudvere U, 2019, NUCLEIC ACIDS RES, V47, pW191, DOI 10.1093/nar/gkz369
   Sadegh S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17189-2
   Senanayake S. L., 2020, FUTURE DRUG DISCOVER, V2, pFDD40, DOI [10.4155/fdd-2020-0010, DOI 10.4155/FDD-2020-0010]
   Ursu O, 2019, NUCLEIC ACIDS RES, V47, pD963, DOI 10.1093/nar/gky963
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Wang YX, 2020, NUCLEIC ACIDS RES, V48, pD1031, DOI 10.1093/nar/gkz981
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang YH, 2020, BIOMED PHARMACOTHER, V127, DOI 10.1016/j.biopha.2020.110195
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 34
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-658X
EI 1557-8127
J9 ASSAY DRUG DEV TECHN
JI ASSAY DRUG DEV. TECHNOL.
PD DEC 1
PY 2020
VL 18
IS 8
BP 348
EP 355
DI 10.1089/adt.2020.1010
EA NOV 2020
PG 8
WC Biochemical Research Methods; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA OZ5FU
UT WOS:000590861100001
PM 33164550
OA Bronze
DA 2021-01-01
ER

PT J
AU Hong, WX
   Chen, Y
   You, K
   Tan, SL
   Wu, FM
   Tao, JW
   Chen, XD
   Zhang, JY
   Xiong, Y
   Yuan, F
   Yang, Z
   Chen, TT
   Chen, XW
   Peng, P
   Tai, Q
   Wang, J
   Zhang, FC
   Li, YX
AF Hong, Wenxin
   Chen, Yan
   You, Kai
   Tan, Shenglin
   Wu, Feima
   Tao, Jiawang
   Chen, Xudan
   Zhang, Jiaye
   Xiong, Yue
   Yuan, Fang
   Yang, Zhen
   Chen, Tingting
   Chen, Xinwen
   Peng, Ping
   Tai, Qiang
   Wang, Jian
   Zhang, Fuchun
   Li, Yin-Xiong
TI Celebrex Adjuvant Therapy on Coronavirus Disease 2019: An Experimental
   Study
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE COVID-19; COX-2; prostaglandins; PGE(2); celebrex
ID SARS; CYCLOOXYGENASE-2; PROSTAGLANDINS; EXPRESSION; PROTEIN
AB Background: The pandemic of coronavirus disease 2019 (COVID-19) resulted in grave morbidity and mortality worldwide. There is currently no effective drug to cure COVID-19. Based on analyses of available data, we deduced that excessive prostaglandin E-2 (PGE(2)) produced by cyclooxygenase-2 was a key pathological event of COVID-19.
   Methods: A prospective clinical study was conducted in one hospital for COVID-19 treatment with Celebrex to suppress the excessive PGE(2) production. A total of 44 COVID-19 cases were enrolled, 37 cases in the experimental group received Celebrex as adjuvant (full dose: 0.2 g, bid; half dose: 0.2 g, qd) for 7-14 days, and the dosage and duration was adjusted for individuals, while seven cases in the control group received the standard therapy. The clinical outcomes were evaluated by measuring the urine PGE(2) levels, lab tests, CT scans, vital signs, and other clinical data. The urine PGE(2) levels were measured by mass spectrometry. The study was registered and can be accessed at .
   Results: The concentrations of PGE(2) in urine samples of COVID-19 patients were significantly higher than those of PGE(2) in urine samples of healthy individuals (mean value: 170 ng/ml vs 18.8 ng/ml, p < 0.01) and positively correlated with the progression of COVID-19. Among those 37 experimental cases, there were 10 cases with age over 60 years (27%, 10/37) and 13 cases (35%, 13/37) with preexisting conditions including cancer, atherosclerosis, and diabetes. Twenty-five cases had full dose, 11 cases with half dose of Celebrex, and one case with ibuprofen. The remission rates in midterm were 100%, 82%, and 57% of the full dose, half dose, and control group, respectively, and the discharged rate was 100% at the endpoint with Celebrex treatment. Celebrex significantly reduced the PGE(2) levels and promoted recovery of ordinary and severe COVID-19. Furthermore, more complications, severity, and death rate were widely observed and reported in the COVID-19 group of elders and with comorbidities; however, this phenomenon did not appear in this particular Celebrex adjunctive treatment study.
   Conclusion: This clinical study indicates that Celebrex adjuvant treatment promotes the recovery of all types of COVID-19 and further reduces the mortality rate of elderly and those with comorbidities.
C1 [Chen, Yan; You, Kai; Tan, Shenglin; Tao, Jiawang; Zhang, Jiaye; Xiong, Yue; Yuan, Fang; Yang, Zhen; Chen, Tingting; Chen, Xinwen; Li, Yin-Xiong] Chinese Acad Sci, Inst Publ Hlth, Guangzhou Inst Biomed & Hlth, Guangzhou, Peoples R China.
   [Hong, Wenxin; Chen, Xudan; Peng, Ping; Wang, Jian; Zhang, Fuchun] Eighth Peoples Hosp Guangzhou, Guangzhou, Peoples R China.
   [Chen, Yan; You, Kai; Zhang, Jiaye; Li, Yin-Xiong] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Guangdong Prov Key Lab Biocomp, Guangzhou, Peoples R China.
   [Tan, Shenglin; Tao, Jiawang; Xiong, Yue; Yuan, Fang; Yang, Zhen; Li, Yin-Xiong] Univ Chinese Acad Sci, Beijing, Peoples R China.
   [Wu, Feima] Guangzhou Med Univ, Guangzhou Inst Cardiovasc Dis, Guangdong Key Lab Vasc Dis, State Key Lab Resp Dis,Affiliated Hosp 2, Guangzhou, Peoples R China.
   [Chen, Xinwen; Li, Yin-Xiong] Guangzhou Regenerat Med & Hlth Guangdong Lab, Guangzhou, Peoples R China.
   [Tai, Qiang] Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Peoples R China.
RP Li, YX (corresponding author), Chinese Acad Sci, Inst Publ Hlth, Guangzhou Inst Biomed & Hlth, Guangzhou, Peoples R China.; Wang, J; Zhang, FC (corresponding author), Eighth Peoples Hosp Guangzhou, Guangzhou, Peoples R China.; Li, YX (corresponding author), Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Guangdong Prov Key Lab Biocomp, Guangzhou, Peoples R China.; Li, YX (corresponding author), Univ Chinese Acad Sci, Beijing, Peoples R China.; Li, YX (corresponding author), Guangzhou Regenerat Med & Hlth Guangdong Lab, Guangzhou, Peoples R China.
EM li_yinxiong@gibh.ac.cn; gz8hwj@126.com; gz8hzfc@126.com
FU Emergency and Special Research Project for Prevention and Control of
   COVID-19 from Guangdong Province [2020B111117001]; National Key Research
   and Development Program of China [2020YFC0842400]; Guangzhou
   Regenerative Medicine and Health Guangdong Laboratory [2020GZR110106005,
   2018GZR110105011]; National Major Scientific and Technological Special
   Project [2018ZX10102-001]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [31871379];
   Science and Technology Project of Guangdong Province [2018A050506070];
   Guangzhou Science and Technology Project [201704020212]; Chinese
   Postdoctoral Science FoundationChina Postdoctoral Science Foundation
   [2019M663142, 2019M652848]
FX This study was supported by the Emergency and Special Research Project
   for Prevention and Control of COVID-19 fromGuangdong Province
   (2020B111117001), the National Key Research and Development Program of
   China (2020YFC0842400), Guangzhou Regenerative Medicine and Health
   Guangdong Laboratory (2020GZR110106005, 2018GZR110105011), National
   Major Scientific and Technological Special Project (2018ZX10102-001),
   National Natural Science Foundation of China (31871379), Science and
   Technology Project of Guangdong Province (2018A050506070), Guangzhou
   Science and Technology Project (201704020212), Chinese Postdoctoral
   Science Foundation (2019M663142, 2019M652848).
CR Amici C, 2006, ANTIVIR THER, V11, P1021
   Cao H, 2008, ANAL BIOCHEM, V372, P41, DOI 10.1016/j.ab.2007.08.041
   Ding YQ, 2003, J PATHOL, V200, P282, DOI 10.1002/path.1440
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   HAMBERG M, 1971, J BIOL CHEM, V246, P6713
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hong W., CELEBREX ADJUVANT TH, DOI [10.1101/2020.05.05.20077610, DOI 10.1101/2020.05.05.20077610]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Liu M, 2007, FASEB J, V21, P1586, DOI 10.1096/fj.06-6589com
   Morimoto K, 2014, J IMMUNOL, V192, P1130, DOI 10.4049/jimmunol.1300290
   Ng DL, 2016, AM J PATHOL, V186, P652, DOI 10.1016/j.ajpath.2015.10.024
   Niwa H, 2009, CLIN IMMUNOL, V132, P184, DOI 10.1016/j.clim.2009.04.012
   Park GY, 2006, AM J PHYSIOL-LUNG C, V290, pL797, DOI 10.1152/ajplung.00513.2005
   Raaben M, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-55
   Rumzhum NN, 2016, CLIN EXP ALLERGY, V46, P397, DOI 10.1111/cea.12697
   Safholm J, 2013, BRIT J PHARMACOL, V168, P794, DOI 10.1111/j.1476-5381.2012.02189.x
   Tomera K., 2020, HOSPITALIZED COVID 1, DOI [10.2139/ssrn.3646583, DOI 10.2139/SSRN.3646583]
   Yan XH, 2006, INT J BIOCHEM CELL B, V38, P1417, DOI 10.1016/j.biocel.2006.02.003
   ZAMORA CA, 1993, J APPL PHYSIOL, V74, P224
   Zheng BJ, 2008, P NATL ACAD SCI USA, V105, P8091, DOI 10.1073/pnas.0711942105
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   刘茜, 2020, [法医学杂志, Journal of Forensic Medicine], V36, P21
NR 22
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 6
PY 2020
VL 11
AR 561674
DI 10.3389/fphar.2020.561674
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OT0MD
UT WOS:000590547800001
PM 33312125
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Briguglio, M
   Porta, M
   Zuffada, F
   Bona, AR
   Crespi, T
   Pino, F
   Perazzo, P
   Mazzocchi, M
   Giorgino, R
   De Angelis, G
   Ielasi, A
   De Blasio, G
   Turiel, M
AF Briguglio, Matteo
   Porta, Mauro
   Zuffada, Francesca
   Bona, Alberto R.
   Crespi, Tiziano
   Pino, Fabio
   Perazzo, Paolo
   Mazzocchi, Marco
   Giorgino, Riccardo
   De Angelis, Giuseppe
   Ielasi, Alfonso
   De Blasio, Giuseppe
   Turiel, Maurizio
TI SARS-CoV-2 Aiming for the Heart: A Multicenter Italian Perspective About
   Cardiovascular Issues in COVID-19
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Article
DE cardiovascular system; coronavirus; SARS-CoV-2; COVID-19; infections;
   virulence; host-pathogen interactions; quality of health care
ID ACUTE RESPIRATORY SYNDROME; DISEASE 2019 COVID-19; DENDRITIC CELLS;
   PLAQUE RUPTURE; INFECTION; ACE2; INFLAMMATION; PATHOGENESIS;
   COAGULATION; TISSUE
AB The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the high fatality rate of coronavirus disease 2019 (COVID-19) have been putting a strain on the world since December 2019. Infected individuals exhibit unpredictable symptoms that tend to worsen if age is advanced, a state of malnutrition persists, or if cardiovascular comorbidities are present. Once transmitted, the virus affects the lungs and in predisposed individuals can elicit a sequela of fatal cardiovascular consequences. We aim to present the pathophysiology of COVID-19, emphasizing the major cellular and clinical manifestations from a cardiological perspective. As a roaming viral particle or more likely via the Trojan horse route, SARS-CoV-2 can access different parts of the body. Cardiovascular features of COVID-19 can count myocardial injuries, vasculitis-like syndromes, and atherothrombotic manifestations. Deviations in the normal electrocardiogram pattern could hide pericardial effusion or cardiac inflammation, and dispersed microthrombi can cause ischemic damages, stroke, or even medullary reflex dysfunctions. Tailored treatment for reduced ejection fraction, arrhythmias, coronary syndromes, macrothrombosis and microthrombosis, and autonomic dysfunctions is mandatory. Confidently, evidence-based therapies for this multifaceted nevertheless purely cardiological COVID-19 will emerge after the global assessment of different approaches.
C1 [Briguglio, Matteo] IRCCS Orthoped Inst Galeazzi, Sci Direct, Milan, Italy.
   [Porta, Mauro] IRCCS Orthoped Inst Galeazzi, Neurol Unit, Milan, Italy.
   [Zuffada, Francesca] ICCS Ist Clin Citta Studi, Cardiol Unit, Milan, Italy.
   [Bona, Alberto R.] ICCS Ist Clin Citta Studi, Neurosurg Unit, Milan, Italy.
   [Crespi, Tiziano; Pino, Fabio; Perazzo, Paolo; Mazzocchi, Marco] IRCCS Orthoped Inst Galeazzi, Intens Care Unit, Milan, Italy.
   [Giorgino, Riccardo] Univ Milan, Residency Program Orthoped & Traumatol, Milan, Italy.
   [De Angelis, Giuseppe] ASST Rhodense, Cardiol Unit, Rho, Italy.
   [Ielasi, Alfonso] Ist Clin St Ambrogio, Cardiol Unit, Milan, Italy.
   [De Blasio, Giuseppe; Turiel, Maurizio] IRCCS Orthoped Inst Galeazzi, Cardiol Unit, Milan, Italy.
RP Briguglio, M (corresponding author), IRCCS Orthoped Inst Galeazzi, Sci Direct, Milan, Italy.
EM matteo.briguglio@grupposandonato.it
RI Briguglio, Matteo/J-4957-2018
OI Briguglio, Matteo/0000-0003-0801-2359
CR Abe H, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10859-w
   Abe H, 2017, J ATHEROSCLER THROMB, V24, P884, DOI 10.5551/jat.RV17009
   Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Anand A, 2014, INT J CARDIOL, V174, P574, DOI 10.1016/j.ijcard.2014.04.131
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Arroyo LH, 1999, CARDIOVASC RES, V41, P369, DOI 10.1016/S0008-6363(98)00308-3
   Bangalore S, 2020, NEW ENGL J MED, V382, P2478, DOI 10.1056/NEJMc2009020
   Basu-Ray I., 2020, CARDIAC MANIFESTATIO
   Benghanem S, 2020, CRIT CARE, V24, DOI 10.1186/s13054-019-2718-9
   Bhaskar S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01648
   Bonow RO, 2020, JAMA-J AM MED ASSOC, V324, P1131, DOI 10.1001/jama.2020.15088
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Briguglio M, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.565052
   Briguglio M, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00671
   Briguglio M, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00146
   Briguglio M, 2020, NUTRIENTS, V12, DOI 10.3390/nu12020386
   Briguglio M, 2019, NUTR CLIN METAB, V33, P190, DOI 10.1016/j.nupar.2019.04.002
   Burki NK, 2010, CHEST, V138, P1196, DOI 10.1378/chest.10-0534
   Campbell LA, 2015, ARCH MED RES, V46, P339, DOI 10.1016/j.arcmed.2015.05.006
   Carter P, 2020, EUR HEART J, V41, P2516, DOI 10.1093/eurheartj/ehaa342
   Chand K, 2020, ARAB J CHEM, V13, P8248, DOI [10.1142/S0192415X20500378, 10.1016/j.arabjc.2020.01.009]
   Chang JC, 2019, THROMB J, V17, DOI 10.1186/s12959-019-0198-4
   Chang L, 2020, TRANSFUS MED REV, V34, P75, DOI 10.1016/j.tmrv.2020.02.003
   Chen KQ, 2016, INT IMMUNOPHARMACOL, V34, P1, DOI 10.1016/j.intimp.2016.02.007
   Chen PCH, 2004, J PATHOL, V203, P729, DOI 10.1002/path.1575
   Cheng XS, 1999, CARDIOVASC RES, V42, P651, DOI 10.1016/S0008-6363(98)00317-4
   Chong PY, 2004, ARCH PATHOL LAB MED, V128, P195
   Chu H, 2020, CLIN INFECT DIS, V71, P1400, DOI 10.1093/cid/ciaa410
   CHUNG MK, 1990, CIRC RES, V67, P753, DOI 10.1161/01.RES.67.3.753
   Cicco S, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/7527953
   Clerkin KJ, 2020, CIRCULATION, V141, P1648, DOI 10.1161/CIRCULATIONAHA.120.046941
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Corrales-Medina VF, 2015, JAMA-J AM MED ASSOC, V313, P264, DOI 10.1001/jama.2014.18229
   Cutsforth-Gregory JK, 2017, NEUROLOGY, V88, P1187, DOI 10.1212/WNL.0000000000003751
   Danzi GB, 2020, EUR HEART J, V41, P1858, DOI 10.1093/eurheartj/ehaa254
   Datta PK, 2020, THERANOSTICS, V10, P7448, DOI 10.7150/thno.48076
   de Abajo FJ, 2020, LANCET, V395, P1705, DOI 10.1016/S0140-6736(20)31030-8
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Eriksson U, 2003, NAT MED, V9, P1484, DOI 10.1038/nm960
   Escher R, 2020, THROMB RES, V190, P62, DOI 10.1016/j.thromres.2020.04.014
   Ferrari F, 2020, ARQ BRAS CARDIOL, V114, P823, DOI 10.36660/abc.20200215
   FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560
   Fried JA, 2020, CIRCULATION, V141, P1930, DOI 10.1161/CIRCULATIONAHA.120.047164
   Goldstein DS, 2020, CLIN AUTON RES, V30, P299, DOI 10.1007/s10286-020-00714-0
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Granot T, 2017, IMMUNITY, V46, P504, DOI 10.1016/j.immuni.2017.02.019
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Harapan H, 2020, J INFECT PUBLIC HEAL, V13, P667, DOI 10.1016/j.jiph.2020.03.019
   Hasan W, 2013, ORGANOGENESIS, V9, P176, DOI 10.4161/org.24892
   Hendren NS, 2020, CIRCULATION, V141, P1903, DOI 10.1161/CIRCULATIONAHA.120.047349
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu Hongde, 2020, Eur Heart J, DOI 10.1093/eurheartj/ehaa190
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui H, 2020, CLIN RADIOGRAPHIC FE, DOI [10.1101/2020.02.24.20027052, DOI 10.1101/2020.02.24.20027052]
   Inciardi RM, 2020, JAMA CARDIOL, V5, P819, DOI 10.1001/jamacardio.2020.1096
   Jones Veena G, 2020, Hosp Pediatr, V10, P537, DOI 10.1542/hpeds.2020-0123
   Kabbani N, 2020, MOL PHARMACOL, V97, P351, DOI 10.1124/molpharm.120.000014
   Kalil AC, 2020, JAMA-J AM MED ASSOC, V323, P1897, DOI 10.1001/jama.2020.4742
   Kougias P, 2010, MED SCI MONITOR, V16, pRA1
   Lakkireddy DR, 2020, HEART RHYTHM, V17, pE233, DOI 10.1016/j.hrthm.2020.03.028
   Larsen CP, 2020, KIDNEY INT REP, V5, P935, DOI 10.1016/j.ekir.2020.04.002
   Leppkes M, 2020, EBIOMEDICINE, V58, DOI 10.1016/j.ebiom.2020.102925
   Leung JM, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00688-2020
   Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9
   Li G, 2013, LUNG, V191, P327, DOI 10.1007/s00408-013-9470-8
   Li H, 2020, LANCET, V395, P1517, DOI 10.1016/S0140-6736(20)30920-X
   Li K, 2016, J INFECT DIS, V213, P712, DOI 10.1093/infdis/jiv499
   Lillicrap D, 2020, J THROMB HAEMOST, V18, P786, DOI 10.1111/jth.14781
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Lindner D, 2014, BASIC RES CARDIOL, V109, DOI 10.1007/s00395-014-0428-7
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Logmin K, 2020, J NEUROL, V267, P2490, DOI 10.1007/s00415-020-09904-2
   Ludewig P, 2016, BBA-MOL BASIS DIS, V1862, P352, DOI 10.1016/j.bbadis.2015.11.003
   Madjid M, 2007, TEX HEART I J, V34, P11
   Manganelli F, 2020, NEUROL SCI, V41, P1663, DOI 10.1007/s10072-020-04487-2
   Mason RJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00607-2020
   Matsushita K, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051407
   Mazeraud A, 2016, CLIN CHEST MED, V37, P333, DOI 10.1016/j.ccm.2016.01.013
   Mazzotta F, 2020, EUR J PEDIAT DERMATO, V30, P75, DOI DOI 10.26326/2281-9649.30.2.2103
   MCKAY DG, 1967, ARCH INTERN MED, V120, P129, DOI 10.1001/archinte.120.2.129
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Meyer P, 2020, EUR HEART J, V41, P1860, DOI 10.1093/eurheartj/ehaa306
   Miller AJ, 2019, CLIN AUTON RES, V29, P231, DOI 10.1007/s10286-018-0572-5
   Mirza M., 2020, NEUROANATOMY AREA PO
   Moccia F, 2020, GEROSCIENCE, V42, P1021, DOI 10.1007/s11357-020-00198-w
   Mukhopadhyay S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01348
   Mycroft-West C., 2020, BIORXIV, P1, DOI [10.1101/2020.02.29.971093, DOI 10.1101/2020.02.29.971093]
   Netland J, 2008, J VIROL, V82, P7264, DOI 10.1128/JVI.00737-08
   Nguyen JL, 2016, JAMA CARDIOL, V1, P274, DOI 10.1001/jamacardio.2016.0433
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Oudit GY, 2009, EUR J CLIN INVEST, V39, P618, DOI 10.1111/j.1365-2362.2009.02153.x
   Pagliaro P, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00335
   Papa A, 2020, PAIN THER, V9, P805, DOI 10.1007/s40122-020-00174-4
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Park Matthew D, 2020, Nat Rev Immunol, V20, P351, DOI 10.1038/s41577-020-0317-2
   Perazzo P, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.566770
   Peteranderl C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00313
   Pilling Darrell, 2012, Methods Mol Biol, V904, P191, DOI 10.1007/978-1-61779-943-3_16
   Pilling D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007475
   Pober JS, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016345
   Ramanathan K, 2020, LANCET RESP MED, V8, P518, DOI 10.1016/S2213-2600(20)30121-1
   Remy KE, 2020, LANCET RESP MED, V8, P946, DOI 10.1016/S2213-2600(20)30217-4
   Ribas VR, 2020, HEMATOL TRANSF CELL, V42, P206, DOI 10.1016/j.htct.2020.06.004
   Rokni M, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2107
   Ronco C, 2020, LANCET RESP MED, V8, P738, DOI 10.1016/S2213-2600(20)30229-0
   SANTAMBROGIO G, 1982, PHYSIOL REV, V62, P531
   Sardu C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051417
   Sattar N, 2020, CIRCULATION, V142, P4, DOI 10.1161/CIRCULATIONAHA.120.047659
   Schelegle ES, 2003, ANAT REC PART A, V270A, P11, DOI 10.1002/ar.a.10004
   Schoenhagen P, 2002, CIRCULATION, V106, P760, DOI 10.1161/01.CIR.0000025708.36290.05
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Shibata S, 2020, HYPERTENS RES, V43, P1028, DOI 10.1038/s41440-020-0515-0
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Spyropoulos AC, 2020, LANCET, V395, pE75, DOI 10.1016/S0140-6736(20)30926-0
   Stefanini GG, 2020, CIRCULATION, V141, P2113, DOI 10.1161/CIRCULATIONAHA.120.047525
   Strutz F, 2006, J AM SOC NEPHROL, V17, P2992, DOI 10.1681/ASN.2006050420
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   Sun T, 2020, EUR J NEUROL, V27, pE52, DOI 10.1111/ene.14227
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Tassorelli C, 2020, EUR J NEUROL, V27, pE41, DOI 10.1111/ene.14275
   Tavazzi G, 2020, EUR J HEART FAIL, V22, P911, DOI 10.1002/ejhf.1828
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Thachil J, 2020, J THROMB HAEMOST, V18, P1020, DOI 10.1111/jth.14821
   Timmers HJLM, 2003, J PHYSIOL-LONDON, V553, P3, DOI 10.1113/jphysiol.2003.052415
   Tobin MJ, 2020, AM J RESP CRIT CARE, V202, P356, DOI 10.1164/rccm.202006-2157CP
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Van der Borght K, 2018, CELL IMMUNOL, V330, P105, DOI 10.1016/j.cellimm.2018.03.011
   van Gestel Arnoldus J R, 2010, J Thorac Dis, V2, P215, DOI 10.3978/j.issn.2072-1439.2010.02.04.5
   van Gorp ECM, 1999, J INFECT DIS, V180, P176, DOI 10.1086/314829
   van Nieuwenhoven FA, 2013, VASC PHARMACOL, V58, P182, DOI 10.1016/j.vph.2012.07.003
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Wang J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02063
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wang XL, 2016, NPJ AGING MECH DIS, V2, DOI 10.1038/npjamd.2016.24
   Wenzhong L, 2019, PREPRINT, DOI [10.26434/chemrxiv.11938173.v9, DOI 10.26434/CHEMRXIV.11938173.V9]
   Wu CI, 2020, HEART RHYTHM, V17, P1456, DOI 10.1016/j.hrthm.2020.03.024
   Wu L, 2020, BIOCHEM PHARMACOL, V178, DOI 10.1016/j.bcp.2020.114114
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xia HJ, 2008, J NEUROCHEM, V107, P1482, DOI 10.1111/j.1471-4159.2008.05723.x
   Xiong TY, 2020, EUR HEART J, V41, P1798, DOI 10.1093/eurheartj/ehaa231
   Xu J, 2020, J DENT RES, V99, P989, DOI 10.1177/0022034520918518
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang WJ, 2020, EUR RADIOL, V30, P4874, DOI 10.1007/s00330-020-06827-4
   Yang Y, 2016, CELL MOL IMMUNOL, V13, P432, DOI 10.1038/cmi.2016.1
   Yao BC, 2019, J INT MED RES, V47, P1429, DOI 10.1177/0300060519826820
   Yogasundaram H, 2014, CAN J CARDIOL, V30, P1706, DOI 10.1016/j.cjca.2014.08.016
   YOKOYAMA T, 1993, J CLIN INVEST, V92, P2303, DOI 10.1172/JCI116834
   Yufu K, 2006, DIABETES RES CLIN PR, V72, P12, DOI 10.1016/j.diabres.2005.08.011
   Zeng JH, 2020, INFECTION, V48, P773, DOI 10.1007/s15010-020-01424-5
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zisman LS, 2003, CIRCULATION, V108, P1707, DOI 10.1161/01.CIR.0000094734.67990.99
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 155
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PD NOV 6
PY 2020
VL 11
AR 571367
DI 10.3389/fphys.2020.571367
PG 11
WC Physiology
SC Physiology
GA OS9ZP
UT WOS:000590515000001
PM 33240098
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Navarro, C
   Yanez, AM
   Garcia, A
   Segui, A
   Gazquez, F
   Marino, JA
   Ibarra, O
   Serrano-Ripoll, MJ
   Gomez-Juanes, R
   Bennasar-Veny, M
   Salva, J
   Olivan, B
   Roca, M
   Gili, M
   Garcia-Toro, M
AF Navarro, Capilla
   Yanez, Aina M.
   Garcia, Aurora
   Segui, Andrea
   Gazquez, Francisco
   Marino, Jose Antonio
   Ibarra, Olga
   Serrano-Ripoll, Maria J.
   Gomez-Juanes, Rocio
   Bennasar-Veny, Miquel
   Salva, Joan
   Olivan, Barbara
   Roca, Miquel
   Gili, Margalida
   Garcia-Toro, Mauro
TI Effectiveness of a healthy lifestyle promotion program as adjunctive
   teletherapy for treatment-resistant major depression during COVID 19
   pandemic A randomized clinical trial protocol
SO MEDICINE
LA English
DT Article
DE COVID-19; mindfulness-based cognitive therapy; multicomponent lifestyle
   program; treatment-resistant depression
ID INSOMNIA SEVERITY INDEX; QUALITY-OF-LIFE; PSYCHOMETRIC PROPERTIES;
   MEDITERRANEAN DIET; SPANISH VERSION; THERAPY; MINDFULNESS; EFFICACY;
   EUROQOL; DISEASE
AB Introduction: Treatment-resistant depression (TRD) has a high prevalence and can be exacerbated by poor physical health and economic hardships, which have become common stressors during the current COVID-19 pandemic. The therapeutic approaches used to treat these patients are not always available, may be not be accepted by some patients, and often require face-to-face interactions. Objective: The main aim of this study will be to evaluate the effectiveness of an Internet-based adjuvant lifestyle-based intervention for patients with TRD. Methods: This will be a parallel, randomized, and controlled clinical trial. A total of 180 patients with TRD will be randomly allocated (1:1:1) to 1 of 3 groups: treatment prescribed by the mental health team and written suggestions for lifestyle changes (placebo control group); treatment prescribed by the mental health team, written suggestions for lifestyle changes, and an 8-week mindfulness-based cognitive therapy program (active control group); or treatment prescribed by the mental health team, written suggestions for lifestyle changes, and an 8-week lifestyle change promotion program (intervention group). We will perform this study during the COVID-19 pandemic, and will administer interventions by teletherapy, and contact participants by telephone calls, text messages, and/or teleconferences. We will collect patient data using questionnaires administered at baseline, immediately after the intervention, and after 6 and 12 months. The primary outcome will be score on the Beck Depression Inventory-II. The secondary outcomes will be score on the Clinical Global Impressions Scale (used to quantify and track patient progress and treatment response over time) and health-related quality of life measured using the European Quality of Life-5 Dimensions Questionnaire. Discussion: Patients with TRD are especially vulnerable when face-to-face psychotherapy is unavailable. The main strength of the proposed study is the novelty of the intervention to be used as an adjuvant therapy. Our results may provide guidance for treatment of patients with TRD in future situations that require lockdown measures.
C1 [Navarro, Capilla; Garcia, Aurora; Segui, Andrea; Gazquez, Francisco; Marino, Jose Antonio; Ibarra, Olga; Gomez-Juanes, Rocio; Salva, Joan; Roca, Miquel; Gili, Margalida; Garcia-Toro, Mauro] Univ Balearic Isl, Res Inst Hlth Sci, IUNICS, IDISBA, Palma De Mallorca, Spain.
   [Yanez, Aina M.; Bennasar-Veny, Miquel] Univ Balearic Isl, Dept Nursing & Physiotherapy, Palma De Mallorca, Spain.
   [Yanez, Aina M.; Bennasar-Veny, Miquel] Univ Balearic Isl, Res Grp Global Hlth & Human Dev, Palma De Mallorca, Spain.
   [Serrano-Ripoll, Maria J.] Univ Balearic Isl, Balearic Islands Hlth Serv, Primary Care Res Unit Majorca, Palma De Mallorca, Spain.
   [Serrano-Ripoll, Maria J.] Univ Balearic Isl, Dept Psychol, Palma De Mallorca, Spain.
   [Olivan, Barbara] Univ Zaragoza, Dept Psychol & Sociol, Zaragoza, Spain.
   [Olivan, Barbara] Prevent Act & Hlth Promot Network, REDIAPP G06 170, Zaragoza, Spain.
RP Yanez, AM (corresponding author), Univ Balearic Isl, Res Grp Global Hlth & Human Dev, Palma De Mallorca, Spain.
EM aina.yanez@uib.es
RI Bennasar-Veny, Miquel/C-5881-2008; Serrano-Ripoll, Maria J./R-8722-2017
OI Bennasar-Veny, Miquel/0000-0003-1668-2141; Yanez, Aina
   M/0000-0001-8527-3937; Serrano-Ripoll, Maria J./0000-0002-1869-1132;
   Olivan Blazquez, Barbara/0000-0001-6565-9699
FU Spanish Ministry of Science, Innovation and Universities
   [RTI2018-093590-B-I00]
FX This work was supported by the Spanish Ministry of Science, Innovation
   and Universities grant number RTI2018-093590-B-I00, following a rigorous
   peer-reviewed funding process. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Andersson G, 2019, CAN J PSYCHIAT, V64, P465, DOI 10.1177/0706743719839381
   Andrews G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013196
   Badia X, 1999, MED CLIN-BARCELONA, V112, P79
   Baer RA, 2006, ASSESSMENT, V13, P27, DOI 10.1177/1073191105283504
   Barcelo-Soler A, 2019, ACTAS ESP PSIQUIATRI, V47, P236
   Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4
   Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13
   Bond FW, 2011, BEHAV THER, V42, P676, DOI 10.1016/j.beth.2011.03.007
   Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6
   Busner Joan, 2007, Psychiatry (Edgmont), V4, P28
   Button KS, 2015, PSYCHOL MED, V45, P3269, DOI 10.1017/S0033291715001270
   Castro A, 2020, J AFFECT DISORDERS, V260, P514, DOI 10.1016/j.jad.2019.09.023
   Castro A, 2018, COGN BEHAV THERAPY, V47, P246, DOI 10.1080/16506073.2017.1366546
   Cebolla A, 2012, EUR J PSYCHIAT, V26, P118, DOI 10.4321/S0213-61632012000200005
   Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583
   Cladder-Micus MB, 2018, DEPRESS ANXIETY, V35, P914, DOI 10.1002/da.22788
   Cook JE, 2002, CYBERPSYCHOL BEHAV, V5, P95, DOI 10.1089/109493102753770480
   Daly EJ, 2018, JAMA PSYCHIAT, V75, P139, DOI 10.1001/jamapsychiatry.2017.3739
   de la Revilla-Ahumada L, 1991, MED FAM, V8, P688
   Eisendrath SJ, 2016, PSYCHOTHER PSYCHOSOM, V85, P99, DOI 10.1159/000442260
   Fam Pract Manag WHO, 2010, INT CLASS DIS ICD 10
   Fernandez-Mendoza J, 2012, SLEEP MED, V13, P207, DOI 10.1016/j.sleep.2011.06.019
   Ferrando L, 2000, MINIINTERNATIONAL NE
   Ferrari AJ, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001547
   Garcia-Campayo J, 2014, HEALTH QUAL LIFE OUT, V12, DOI 10.1186/1477-7525-12-4
   Garcia-Toro M, 2016, ACTAS ESP PSIQUIATRI, V44, P46
   Garcia-Toro M, 2012, J AFFECT DISORDERS, V140, P200, DOI 10.1016/j.jad.2012.03.031
   Garcia-Toro M, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-404
   Golden RN, 2005, AM J PSYCHIAT, V162, P656, DOI 10.1176/appi.ajp.162.4.656
   Gomez-Juanes R, 2017, PSIQUIATR BIOL, V24, P97, DOI [10.1016/j.psiq.2017.10.004, DOI 10.1016/J.PSIQ.2017.10.004]
   Goracci A, 2016, J AFFECT DISORDERS, V196, P20, DOI 10.1016/j.jad.2016.02.034
   Gordon BR, 2018, JAMA PSYCHIAT, V75, P566, DOI 10.1001/jamapsychiatry.2018.0572
   Guy W., 1976, ECDEU ASSESSMENT MAN
   Hidaka BH, 2012, J AFFECT DISORDERS, V140, P205, DOI 10.1016/j.jad.2011.12.036
   Johnston KM, 2019, J AFFECT DISORDERS, V242, P195, DOI 10.1016/j.jad.2018.06.045
   Josephine K, 2017, J AFFECT DISORDERS, V223, P28, DOI 10.1016/j.jad.2017.07.021
   Katon WJ, 2003, BIOL PSYCHIAT, V54, P216, DOI 10.1016/S0006-3223(03)00273-7
   Kim Y, 2013, PUBLIC HEALTH NUTR, V16, P440, DOI 10.1017/S1368980012002996
   Kladnitski N, 2020, INTERNET INTERV, V20, DOI 10.1016/j.invent.2020.100310
   Kupfer David J, 2016, Focus (Am Psychiatr Publ), V14, P266, DOI 10.1176/appi.focus.140208
   Kurtze N, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-63
   Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9
   Lopresti AL, 2013, J AFFECT DISORDERS, V148, P12, DOI 10.1016/j.jad.2013.01.014
   MARTINEZGONZALE.MA, 2010, INT J EPIDEMIOL, V41, P377, DOI DOI 10.1093/ije/dyq250
   McIntyre RS, 2014, J AFFECT DISORDERS, V156, P1, DOI 10.1016/j.jad.2013.10.043
   Meerlo P, 2015, CURR TOP BEHAV NEURO, V25, P459, DOI 10.1007/7854_2015_367
   Neff KD, 2003, SELF IDENTITY, V2, P223, DOI 10.1080/15298860390209035
   Olivan-Blazquez B, 2018, BMC PSYCHIATRY, V18, P1
   Roca M, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0900-z
   Roman-Vinas B, 2010, EUR J SPORT SCI, V10, P297, DOI 10.1080/17461390903426667
   Ruiz FJ, 2013, PSICOTHEMA, V25, P123, DOI 10.7334/psicothema2011.239
   Sagner M, 2014, INT J CLIN PRACT, V68, P1289, DOI 10.1111/ijcp.12509
   Sanchez-Villegas A, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-208
   Sanchez-Villegas A, 2011, NUTR NEUROSCI, V14, P195, DOI 10.1179/1476830511Y.0000000011
   Sanz J., 2005, CLIN SALUD, V16, P121
   Sarris J, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-107
   Schroder H, 2011, J NUTR, V141, P1140, DOI 10.3945/jn.110.135566
   Seoane B, 2009, REV MED CHILE, V137, P1163, DOI [10.4067/S0034-98872009000900004, /S0034-98872009000900004]
   Ripoll MJS, 2015, J AFFECT DISORDERS, V183, P221, DOI 10.1016/j.jad.2015.04.059
   SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B
   Toobert DJ, 2007, INT J BEHAV NUTR PHY, V4, DOI 10.1186/1479-5868-4-1
   Walsh R, 2011, AM PSYCHOL, V66, P579, DOI 10.1037/a0021769
   Walters SJ, 2005, QUAL LIFE RES, V14, P1523, DOI 10.1007/s11136-004-7713-0
   WILLIAMS A, 1990, HEALTH POLICY, V16, P199
NR 64
TC 0
Z9 0
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD NOV 6
PY 2020
VL 99
IS 45
DI 10.1097/MD.0000000000022958
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA OP6AW
UT WOS:000588168200031
PM 33157937
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Frecer, V
   Miertus, S
AF Frecer, Vladimir
   Miertus, Stanislav
TI Antiviral agents against COVID-19: structure-based design of specific
   peptidomimetic inhibitors of SARS-CoV-2 main protease
SO RSC ADVANCES
LA English
DT Article
ID DENSITY FUNCTIONALS; DRUG SOLUBILITY; 3C PROTEASE; AB-INITIO; BASIS-SET;
   CORONAVIRUS; PREDICTION; SUBSTRATE; SOLVATION; MECHANICS
AB Despite the intense development of vaccines and antiviral therapeutics, no specific treatment of coronavirus disease 2019 (COVID-19), caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently available. Recently, X-ray crystallographic structures of a validated pharmacological target of SARS-CoV-2, the main protease (M-pro also called 3CL(pro)) in complex with peptide-like irreversible inhibitors have been published. We have carried out computer-aided structure-based design and optimization of peptidomimetic irreversible alpha-ketoamide M-pro inhibitors and their analogues using MM, MD and QM/MM methodology, with the goal to propose lead compounds with improved binding affinity to SARS-CoV-2 M-pro, enhanced specificity for pathogenic coronaviruses, decreased peptidic character, and favourable drug-like properties. The best inhibitor candidates designed in this work show largely improved interaction energies towards the M-pro and enhanced specificity due to 6 additional hydrogen bonds to the active site residues. The presented results on new SARS-CoV-2 M-pro inhibitors are expected to stimulate further research towards the development of specific anti-COVID-19 drugs.
C1 [Frecer, Vladimir] Comenius Univ, Fac Pharm, Dept Phys Chem Drugs, SK-83232 Bratislava, Slovakia.
   [Frecer, Vladimir; Miertus, Stanislav] Int Ctr Appl Res & Sustainable Technol ICARST, SK-84104 Bratislava, Slovakia.
   [Miertus, Stanislav] Univ Ss Cyril & Methodius, Fac Nat Sci, Dept Biotechnol, SK-91701 Trnava, Slovakia.
RP Frecer, V (corresponding author), Comenius Univ, Fac Pharm, Dept Phys Chem Drugs, SK-83232 Bratislava, Slovakia.; Frecer, V (corresponding author), Int Ctr Appl Res & Sustainable Technol ICARST, SK-84104 Bratislava, Slovakia.
EM frecer@fpharm.uniba.sk
FU Slovak Research and Development AgencySlovak Research and Development
   Agency [APVV-17-0239, PP-COVID-20-0010]; Granting Agency of Slovak
   Ministry of Education; Slovak Academy of Sciences [VEGA 1/0228/17]
FX Partial financial support by the Slovak Research and Development Agency
   grant APVV-17-0239 and PP-COVID-20-0010 as well as Granting Agency of
   Slovak Ministry of Education and Slovak Academy of Sciences grant VEGA
   1/0228/17 is gratefully acknowledged. This work was supported by
   services, staff expertise and high-performance computing facilities
   CLARA@UNIBA.SK of the Centre for Information Technology of Comenius
   University in Bratislava.
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   [Anonymous], 2020, DESM MOL DYN SYST VE
   [Anonymous], 2020, SMALL MOL DISC SUIT
   Barnard DL, 2006, CURR PHARM DESIGN, V12, P1379, DOI 10.2174/138161206776361129
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bochevarov AD, 2013, INT J QUANTUM CHEM, V113, P2110, DOI 10.1002/qua.24481
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chuck CP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013197
   Darvas Ferenc, 2002, Current Topics in Medicinal Chemistry, V2, P1287, DOI 10.2174/1568026023392841
   Dragovich PS, 1999, J MED CHEM, V42, P1213, DOI 10.1021/jm9805384
   Dragovich PS, 1999, BIOORGAN MED CHEM, V7, P589, DOI 10.1016/S0968-0896(99)00005-X
   Duffy E. M., 2000, OCTANOL WATER, V12, P2878, DOI 10.10.1021/ja993663t
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Egli M, 2007, ACCOUNTS CHEM RES, V40, P197, DOI 10.1021/ar068174u
   Frecer V, 2008, J MOL GRAPH MODEL, V27, P376, DOI 10.1016/j.jmgm.2008.06.006
   Frecer V, 2011, J COMPUT AID MOL DES, V25, P31, DOI 10.1007/s10822-010-9399-4
   Frecer V, 2010, J COMPUT AID MOL DES, V24, P195, DOI 10.1007/s10822-010-9326-8
   Frecer V, 2009, EUR J MED CHEM, V44, P3009, DOI 10.1016/j.ejmech.2008.12.028
   Ghosh AK, 2005, J MED CHEM, V48, P6767, DOI 10.1021/JM050548m
   Ghosh AK, 2007, BIOORG MED CHEM LETT, V17, P5876, DOI 10.1016/j.bmcl.2007.08.031
   Ghosh AK, 2020, CHEMMEDCHEM, V15, P907, DOI 10.1002/cmdc.202000223
   Goetz DH, 2007, BIOCHEMISTRY-US, V46, P8744, DOI 10.1021/bi0621415
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jorgensen WL, 2000, BIOORG MED CHEM LETT, V10, P1155, DOI 10.1016/S0960-894X(00)00172-4
   Jorgensen WL, 2002, ADV DRUG DELIVER REV, V54, P355, DOI 10.1016/S0169-409X(02)00008-X
   Kaminski GA, 2001, J PHYS CHEM B, V105, P6474, DOI 10.1021/jp003919d
   Kolossvary I, 1996, J AM CHEM SOC, V118, P5011, DOI 10.1021/ja952478m
   KRISHNAN R, 1980, J CHEM PHYS, V72, P650, DOI 10.1063/1.438955
   Lin D., ALPHA KETOAMIDES BRO
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Marten B, 1996, J PHYS CHEM-US, V100, P11775, DOI 10.1021/jp953087x
   MARTYNA GJ, 1992, J CHEM PHYS, V97, P2635, DOI 10.1063/1.463940
   MARTYNA GJ, 1994, J CHEM PHYS, V101, P4177, DOI 10.1063/1.467468
   MULLIKEN RS, 1955, J CHEM PHYS, V23, P1833, DOI 10.1063/1.1740588
   Murphy RB, 2000, J COMPUT CHEM, V21, P1442, DOI 10.1002/1096-987X(200012)21:16<1442::AID-JCC3>3.0.CO;2-O
   Philipp DM, 1999, J COMPUT CHEM, V20, P1468, DOI 10.1002/(SICI)1096-987X(19991115)20:14<1468::AID-JCC2>3.0.CO;2-0
   Pillaiyar T, 2015, MED CHEM, V47, pe181, DOI [10.4172/2161-0444.1000287, DOI 10.4172/2161-0444.1000287]
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Regnier T, 2009, BIOORG MED CHEM LETT, V19, P2722, DOI 10.1016/j.bmcl.2009.03.118
   Rocha-Pereira J, 2014, ANTIMICROB AGENTS CH, V58, P4675, DOI 10.1128/AAC.02546-13
   Rut W., 2020, BIORXIV, DOI [10.1101/2020.03.07.981928, DOI 10.1101/2020.03.07.981928]
   SAPSE AM, 1992, INT J PEPT PROT RES, V39, P18
   Scavone C, 2020, BRIT J PHARMACOL, V177, P4813, DOI 10.1111/bph.15072
   Shelley JC, 2007, J COMPUT AID MOL DES, V21, P681, DOI 10.1007/s10822-007-9133-z
   STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038
   Tan JZ, 2013, J VIROL, V87, P4339, DOI 10.1128/JVI.01123-12
   Wiberg KB, 2004, J COMPUT CHEM, V25, P1342, DOI 10.1002/jcc.20058
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Yang S, 2006, J MED CHEM, V49, P4971, DOI 10.1021/jm0603926
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang LL, 2020, J MED CHEM, V63, P4562, DOI 10.1021/acs.jmedchem.9b01828
   Zhao Y, 2008, THEOR CHEM ACC, V120, P215, DOI 10.1007/s00214-007-0310-x
   Zhao Y, 2008, ACCOUNTS CHEM RES, V41, P157, DOI 10.1021/ar700111a
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 58
TC 0
Z9 0
U1 1
U2 1
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046-2069
J9 RSC ADV
JI RSC Adv.
PD NOV 6
PY 2020
VL 10
IS 66
BP 40244
EP 40263
DI 10.1039/d0ra08304f
PG 20
WC Chemistry, Multidisciplinary
SC Chemistry
GA OP2PK
UT WOS:000587926200030
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Balaramnavar, VM
   Ahmad, K
   Saeed, M
   Ahmad, I
   Kamal, M
   Jawed, T
AF Balaramnavar, Vishal M.
   Ahmad, Khurshid
   Saeed, Mohd
   Ahmad, Irfan
   Kamal, Mehnaz
   Jawed, Talaha
TI Pharmacophore-based approaches in the rational repurposing technique for
   FDA approved drugs targeting SARS-CoV-2 M-pro
SO RSC ADVANCES
LA English
DT Article
ID ANTIVIRAL ACTIVITY; IDENTIFICATION; FLUVASTATIN; ADIPOGENESIS;
   DYSLIPIDEMIA; GENERATION; INHIBITORS; DATABASE; CHARMM
AB Novel coronavirus (CoV) is the primary etiological virus responsible for the pandemic that started in Wuhan in 2019-2020. This viral disease is extremely prevalent and has spread around the world. Preventive steps are restricted social contact and isolation of the sick individual to avoid person-to-person transmission. There is currently no cure available for the disease and the search for novel medications or successful therapeutics is intensive, time-consuming, and laborious. An effective approach in managing this pandemic is to develop therapeutically active drugs by repurposing or repositioning existing drugs or active molecules. In this work, we developed a feature-based pharmacophore model using reported compounds that inhibit SARS-CoV-2. This model was validated and used to screen the library of 565 FDA-approved drugs against the viral main protease (M-pro), resulting in 66 drugs interacting with M-pro with higher binding scores in docking experiments than drugs previously reported for the target diseases. The study identified drugs from many important classes, viz. D-2 receptor antagonist, HMG-CoA inhibitors, HIV reverse transcriptase and protease inhibitors, anticancer agents and folate inhibitors, which can potentially interact with and inhibit the SARS-CoV-2 M-pro. This validated approach may help in finding the urgently needed drugs for the SARS-CoV-2 pandemic with infinitesimal chances of failure.
C1 [Balaramnavar, Vishal M.] Global Inst Pharmaceut Educ & Res, Dept Med & Pharmaceut Chem, Jaspur Rd, Kashipur 244713, India.
   [Ahmad, Khurshid] Yeungnam Univ, Dept Med Biotechnol, Gyongsan 38541, South Korea.
   [Saeed, Mohd] Univ Hail, Dept Biol, Coll Sci, Hail, Saudi Arabia.
   [Ahmad, Irfan] King Khalid Univ, Coll Appl Med Sci, Dept Clin Lab Sci, Abha, Saudi Arabia.
   [Ahmad, Irfan] King Khalid Univ, Res Ctr Adv Mat Sci, Abha, Saudi Arabia.
   [Kamal, Mehnaz] Prince Sattam Bin Abdulaziz Univ, Coll Pharm, Dept Pharmaceut Chem, POB 173, Al Kharj 11942, Saudi Arabia.
   [Jawed, Talaha] Al Imam Mohammad Ibn Saud Islamic Univ IMSIU, Coll Med, Dept Pharmacol, Riyadh 13317, Saudi Arabia.
RP Balaramnavar, VM (corresponding author), Global Inst Pharmaceut Educ & Res, Dept Med & Pharmaceut Chem, Jaspur Rd, Kashipur 244713, India.
EM v.balaramnavar@gmail.com
RI Kamal, Mehnaz/AAE-7681-2019; Ahmad, Irfan/AAU-4179-2020
OI Kamal, Mehnaz/0000-0002-3585-0828; Ahmad, Irfan/0000-0002-9500-4623;
   Saeed, Mohd/0000-0003-3443-386X
FU King Khalid University under the Research Center for Advanced Materials
   Science at King Khalid University, Saudi Arabia [RCAMS/KKU/001/20]
FX The authors would like to acknowledge the support of the King Khalid
   University through a grant RCAMS/KKU/001/20 under the Research Center
   for Advanced Materials Science at King Khalid University, Saudi Arabia.
   The authors are also like to acknowledge BIOVIA for granting us
   SARS-CoV-2 Discovery Studio Academic Research License Suite for the
   project work.
CR Agrawal AS, 2015, J VIROL, V89, P3659, DOI 10.1128/JVI.03427-14
   Ahmad K, 2019, MOLECULES, V24, DOI 10.3390/molecules24091827
   Ahmad K, 2014, CNS NEUROL DISORD-DR, V13, P1346, DOI 10.2174/1871527313666141023120843
   Altay O, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101303
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Bader T, 2013, J VIRAL HEPATITIS, V20, P622, DOI 10.1111/jvh.12085
   Bader T, 2008, AM J GASTROENTEROL, V103, P1383, DOI 10.1111/j.1572-0241.2008.01876.x
   Balaramnavar VM, 2014, EUR J MED CHEM, V87, P578, DOI 10.1016/j.ejmech.2014.09.097
   Balaramnavar VM, 2012, J MED CHEM, V55, P8248, DOI 10.1021/jm300985d
   Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287
   BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211
   Das P, 2013, ACS MED CHEM LETT, V4, P517, DOI 10.1021/ml300464h
   De Clercq E, 2016, CLIN MICROBIOL REV, V29, P695, DOI 10.1128/CMR.00102-15
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Gehlhaar D. K., 1998, Evolutionary Programming VII. 7th International Conference, EP98. Proceedings, P449
   Gupta A, 2017, METABOLISM, V73, P109, DOI 10.1016/j.metabol.2017.05.005
   Gurung AB, 2020, LIFE SCI, V255, DOI 10.1016/j.lfs.2020.117831
   Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Luo Y, 2010, BIOORGAN MED CHEM, V18, P5048, DOI 10.1016/j.bmc.2010.05.076
   Mekheimer RA, 2020, RSC ADV, V10, P19867, DOI 10.1039/d0ra02786c
   MILNE GWA, 1994, J CHEM INF COMP SCI, V34, P1219, DOI 10.1021/ci00021a032
   Monforte AM, 2008, BIOORGAN MED CHEM, V16, P7429, DOI 10.1016/j.bmc.2008.06.012
   Panda PK, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb8097
   PENDRAK I, 1994, J ORG CHEM, V59, P2623, DOI 10.1021/jo00088a057
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Rajan S, 2018, METABOLISM, V85, P1, DOI 10.1016/j.metabol.2018.03.001
   Sabbu S, 2018, EUR J MED CHEM, V143, P780, DOI 10.1016/j.ejmech.2017.11.041
   Sayed AM, 2020, RSC ADV, V10, P19790, DOI 10.1039/d0ra04199h
   Shen L, 2019, J VIROL, V93, DOI 10.1128/JVI.00023-19
   Sheridan DA, 2014, LIVER INT, V34, P737, DOI 10.1111/liv.12316
   Sprague PW, 1995, PERSPECT DRUG DISCOV, V3, P1, DOI 10.1007/BF02174464
   Srivastava S, 2013, LIPIDS, V48, P1017, DOI 10.1007/s11745-013-3824-0
   St John SE, 2015, BIOORGAN MED CHEM, V23, P6036, DOI 10.1016/j.bmc.2015.06.039
   Thomsen R, 2006, J MED CHEM, V49, P3315, DOI 10.1021/jm051197e
   Huynh T, 2020, J PHYS CHEM LETT, V11, P4413, DOI 10.1021/acs.jpclett.0c00994
   Tonelli M, 2010, BIOORGAN MED CHEM, V18, P2937, DOI 10.1016/j.bmc.2010.02.037
   Tonelli M, 2008, CHEM BIODIVERS, V5, P2386, DOI 10.1002/cbdv.200890203
   Varshney S, 2014, J LIPID RES, V55, P1019, DOI 10.1194/jlr.M039925
   World Health Organization, 2020, WEEKL OP UPD COVID 1
   Zhao Z, 2003, J MED MICROBIOL, V52, P715, DOI 10.1099/jmm.0.05320-0
   Zou RM, 1996, J MED CHEM, V39, P3477, DOI 10.1021/jm960157v
NR 44
TC 1
Z9 1
U1 0
U2 0
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046-2069
J9 RSC ADV
JI RSC Adv.
PD NOV 6
PY 2020
VL 10
IS 66
BP 40264
EP 40275
DI 10.1039/d0ra06038k
PG 12
WC Chemistry, Multidisciplinary
SC Chemistry
GA OP2PK
UT WOS:000587926200031
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Ngo, ST
   Nguyen, HM
   Huong, LT
   Quan, PM
   Truong, VK
   Tung, NT
   Vu, V
AF Son Tung Ngo
   Hung Minh Nguyen
   Thuy Huong, Le Thi
   Pham Minh Quan
   Vi Khanh Truong
   Nguyen Thanh Tung
   Vu, Van V.
TI Assessing potential inhibitors of SARS-CoV-2 main protease from
   available drugs using free energy perturbation simulations
SO RSC ADVANCES
LA English
DT Article
AB The main protease (Mpro) of the novel coronavirus SARS-CoV-2, which has caused the COVID-19 pandemic, is responsible for the maturation of its key proteins. Thus, inhibiting SARS-CoV-2 Mpro could prevent SARS-CoV-2 from multiplying. Because new inhibitors require thorough validation, repurposing current drugs could help reduce the validation process. Many recent studies used molecular docking to screen large databases for potential inhibitors of SARS-CoV-2 Mpro. However, molecular docking does not consider molecular dynamics and thus can be prone to error. In this work, we developed a protocol using free energy perturbation (FEP) to assess the potential inhibitors of SARS-CoV-2 Mpro. First, we validated both molecular docking and FEP on a set of 11 inhibitors of SARS-CoV-2 Mpro with experimentally determined inhibitory data. The experimentally deduced binding free energy exhibits significantly stronger correlation with that predicted by FEP (R = 0.94 +/- 0.04) than with that predicted by molecular docking (R = 0.82 +/- 0.08). This result clearly shows that FEP is the most accurate method available to predict the binding affinity of SARS-CoV-2 Mpro + ligand complexes. We subsequently used FEP to validate the top 33 compounds screened with molecular docking from the ZINC15 database. Thirteen of these compounds were predicted to bind strongly to SARS-CoV-2 Mpro, most of which are currently used as drugs for various diseases in humans. Notably, delamanid, an anti-tuberculosis drug, was predicted to inhibit SARS-CoV-2 Mpro in the nanomolar range. Because both COVID-19 and tuberculosis are lung diseases, delamanid has higher probability to be suitable for treating COVID-19 than other predicted compounds. Analysis of the complexes of SARS-CoV-2 Mpro and the top inhibitors revealed the key residues involved in the binding, including the catalytic dyad His14 and Cys145, which is consistent with the structural studies reported recently.
C1 [Son Tung Ngo] Ton Duc Thang Univ, Lab Theoret & Computat Biophys, Ho Chi Minh City 700000, Vietnam.
   [Son Tung Ngo] Ton Duc Thang Univ, Fac Appl Sci, Ho Chi Minh City 700000, Vietnam.
   [Hung Minh Nguyen] Duy Tan Univ, Inst Res & Dev, Ctr Mol Biol, Da Nang 550000, Vietnam.
   [Hung Minh Nguyen] Duy Tan Univ, Fac Pharm, Da Nang 550000, Vietnam.
   [Thuy Huong, Le Thi; Pham Minh Quan] Vietnam Acad Sci & Technol, Inst Nat Prod Chem, Hanoi 100000, Vietnam.
   [Thuy Huong, Le Thi; Pham Minh Quan] Grad Univ Sci & Technol, Vietnam Acad Sci & Technol, Hanoi 100000, Vietnam.
   [Vi Khanh Truong] RMIT Univ, Sch Sci, GPO Box 2476, Melbourne, Vic 3001, Australia.
   [Nguyen Thanh Tung] Vietnam Acad Sci & Technol, Inst Mat Sci, Hanoi 100000, Vietnam.
   [Vu, Van V.] Nguyen Tat Thanh Univ, NTT Hitech Inst, Ho Chi Minh City 700000, Vietnam.
RP Ngo, ST (corresponding author), Ton Duc Thang Univ, Lab Theoret & Computat Biophys, Ho Chi Minh City 700000, Vietnam.; Ngo, ST (corresponding author), Ton Duc Thang Univ, Fac Appl Sci, Ho Chi Minh City 700000, Vietnam.; Vu, V (corresponding author), Nguyen Tat Thanh Univ, NTT Hitech Inst, Ho Chi Minh City 700000, Vietnam.
EM ngosontung@tdtu.edu.vn; vanvu@ntt.edu.vn
RI Ngo, Son Tung/F-8964-2013; Vu, Van/B-2098-2010; Truong, Vi
   Khanh/M-1054-2018
OI Ngo, Son Tung/0000-0003-1034-1768; Vu, Van/0000-0003-0009-6703; Truong,
   Vi Khanh/0000-0002-6016-6438
FU Vietnam National Foundation for Science & Technology Development
   (NAFOSTED)National Foundation for Science & Technology Development
   (NAFOSTED) [104.99-2019.57]
FX This work was supported by Vietnam National Foundation for Science &
   Technology Development (NAFOSTED) grant #104.99-2019.57.
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Alexpandi R, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01796
   Aliev AE, 2014, PROTEINS, V82, P195, DOI 10.1002/prot.24350
   Azim Kazi Faizul, 2020, Inform Med Unlocked, V20, P100367, DOI 10.1016/j.imu.2020.100367
   Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398
   BENNETT CH, 1976, J COMPUT PHYS, V22, P245, DOI 10.1016/0021-9991(76)90078-4
   BEVERIDGE DL, 1989, ANNU REV BIOPHYS BIO, V18, P431, DOI 10.1146/annurev.bb.18.060189.002243
   Case D., 2018, AMBER 18, V18
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Fauquet CM, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-64
   Ferraz WR, 2020, FUTURE MED CHEM, V12, P1815, DOI 10.4155/fmc-2020-0165
   Sousa da Silva Alan W, 2012, BMC Res Notes, V5, P367, DOI [10.1186/1756-0500-5-185, 10.1186/1756-0500-5-367]
   Jin ZM, 2020, NAT STRUCT MOL BIOL, V27, P529, DOI 10.1038/s41594-020-0440-6
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kim S, 2016, NUCLEIC ACIDS RES, V44, pD1202, DOI 10.1093/nar/gkv951
   Marinho EM, 2020, MICROB PATHOGENESIS, V148, DOI 10.1016/j.micpath.2020.104365
   Ngo Son Tung, 2020, J Chem Inf Model, DOI 10.1021/acs.jcim.0c00491
   Ngo ST, 2020, J COMPUT CHEM, V41, P611, DOI 10.1002/jcc.26130
   Nguyen NT, 2020, J CHEM INF MODEL, V60, P204, DOI 10.1021/acs.jcim.9b00778
   Nukoolkarn V, 2008, J THEOR BIOL, V254, P861, DOI 10.1016/j.jtbi.2008.07.030
   Olubiyi OO, 2020, MOLECULES, V25, DOI 10.3390/molecules25143193
   Pham MQ, 2020, RSC ADV, V10, P31991, DOI 10.1039/d0ra06212j
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Schrodinger LLC, 2010, PYMOL MOL GRAPH SYST
   Seow J., 2020, MEDRXIV, DOI [10.1101/2020.07.09.20148429, DOI 10.1101/2020.07.09.20148429]
   Shahinshavali S, 2020, TETRAHEDRON LETT, V61, DOI 10.1016/j.tetlet.2020.152336
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Ytreberg FM, 2009, J CHEM PHYS, V130, DOI 10.1063/1.3119261
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhavoronkov A., 2020, CHEMRXIV, DOI [10.26434/chemrxiv.12301457.v1, DOI 10.26434/CHEMRXIV.12301457.V1]
   ZWANZIG RW, 1954, J CHEM PHYS, V22, P1420, DOI 10.1063/1.1740409
NR 34
TC 0
Z9 0
U1 0
U2 0
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046-2069
J9 RSC ADV
JI RSC Adv.
PD NOV 6
PY 2020
VL 10
IS 66
BP 40284
EP 40290
DI 10.1039/d0ra07352k
PG 7
WC Chemistry, Multidisciplinary
SC Chemistry
GA OP2PK
UT WOS:000587926200033
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Jyotisha
   Singh, S
   Qureshi, IA
AF Jyotisha
   Singh, Samayaditya
   Qureshi, Insaf Ahmed
TI Multi-epitope vaccine against SARS-CoV-2 applying immunoinformatics and
   molecular dynamics simulation approaches
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; receptor-binding domain; immunoinformatic approach;
   multi-epitope vaccine; molecular dynamics simulation
ID SPIKE PROTEIN; CORONAVIRUS
AB COVID-19, caused by SARS-CoV-2, is severe respiratory illnesses leading to millions of deaths worldwide in very short span. The high case fatality rate and the lack of medical counter measures emphasize for an urgent quest to develop safe and effective vaccine. Receptor-binding domain (RBD) of spike protein of SARS-CoV-2 binds to the ACE2 receptor on human host cell for the viral attachment and entry, hence considered as a key target to develop vaccines, antibodies and therapeutics. In this study, immunoinformatics approach was employed to design a novel multi-epitope vaccine using RBD of SARS-CoV-2 spike protein. The potential B- and T-cell epitopes were selected from RBD sequence using various bioinformatics tools to design the vaccine construct. The in silico designed multi-epitope vaccine encompasses 146 amino acids with an adjuvant (human beta-defensin-2), which was further computationally evaluated for several parameters including antigenicity, allergenicity and stability. Subsequently, three-dimensional structure of vaccine construct was modelled and then docked with various toll-like receptors. Molecular dynamics (MD) study of docked TLR3-vaccine complex delineated it to be highly stable during simulation time and the stabilization of interaction was majorly contributed by electrostatic energy. The docked complex also showed low deformation and increased rigidity in motion of residues during dynamics. Furthermore, in silico cloning of the multi-epitope vaccine was carried out to generate the plasmid construct for expression in a bacterial system. Altogether, our study suggests that the designed vaccine candidate containing RBD region could provide the specific humoral and cell-mediated immune responses against SARS-CoV-2.
   Communicated by Ramaswamy H. Sarma
C1 [Jyotisha; Singh, Samayaditya; Qureshi, Insaf Ahmed] Univ Hyderabad, Sch Life Sci, Dept Biotechnol & Bioinformat, Hyderabad 500046, Telangana, India.
RP Qureshi, IA (corresponding author), Univ Hyderabad, Sch Life Sci, Dept Biotechnol & Bioinformat, Hyderabad 500046, Telangana, India.
EM insaf@uohyd.ac.in
RI Qureshi, Insaf Ahmed/W-1957-2019
OI Qureshi, Insaf Ahmed/0000-0001-7720-7067
FU Indian Council of Medical Research (ICMR), Government of IndiaIndian
   Council of Medical Research (ICMR)
FX The authors acknowledge Indian Council of Medical Research (ICMR),
   Government of India for financial assistance, and Centre for Modelling
   Simulation & Design (CMSD), University of Hyderabad, Hyderabad for
   computational resources for MD simulation studies. The authors are
   thankful to Dr. N.P. Prabhu for his suggestions during revision of the
   manuscript.
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Peele KA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1770127
   Ahmad B, 2019, MICROB PATHOGENESIS, V132, P243, DOI 10.1016/j.micpath.2019.05.010
   Ahmad S, 2020, EUR J PHARM SCI, V151, DOI 10.1016/j.ejps.2020.105387
   Best R. B., 2012, J CHEM THEORY COMPUT, V8, P3257, DOI DOI https://doi.org/10.1021/ct300400x
   Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z
   Chen WH, 2020, HUM VACC IMMUNOTHER, V16, P1239, DOI 10.1080/21645515.2020.1740560
   Chen XY, 2013, ADV DRUG DELIVER REV, V65, P1357, DOI 10.1016/j.addr.2012.09.039
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760
   Kalita P, 2020, MICROB PATHOGENESIS, V145, DOI 10.1016/j.micpath.2020.104236
   Kar PP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02213
   Kar T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67749-1
   Kim J, 2018, VIROL J, V15, DOI 10.1186/s12985-018-1035-2
   Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lester SN, 2014, J MOL BIOL, V426, P1246, DOI 10.1016/j.jmb.2013.11.024
   Li X, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02911-9
   Liu SW, 2004, LANCET, V363, P938, DOI 10.1016/S0140-6736(04)15788-7
   Lopez-Blanco J.R., 2014, NUCL ACIDS RES, V42, pW271, DOI DOI https://doi.org/10.1093/nar/gku339
   Makrides SC, 1996, MICROBIOL REV, V60, P512, DOI 10.1128/MMBR.60.3.512-538.1996
   McLoughlin RM, 2008, J IMMUNOL, V181, P1323, DOI 10.4049/jimmunol.181.2.1323
   Perrie Y, 2008, INT J PHARMACEUT, V364, P272, DOI 10.1016/j.ijpharm.2008.04.036
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Rehman HM, 2020, BIOLOGY-BASEL, V9, DOI 10.3390/biology9090296
   ROSE GD, 1985, ADV PROTEIN CHEM, V37, P1, DOI 10.1016/S0065-3233(08)60063-7
   Sabetian S, 2019, J BIOMOL STRUCT DYN, V37, P2546, DOI 10.1080/07391102.2018.1491890
   Samadi A, 2020, J MACROMOL SCI B, V59, P376, DOI [10.1080/00222348.2020.1730573, 10.1080/07391102.2020.1792347]
   Solanki V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41496-4
   ul Qamar MT, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020288
   Tina KG, 2007, NUCL ACIDS RES, V35, pW473, DOI DOI https://doi.org/10.1093/nar/gkm423
   Phan T, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104211
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Zheng W, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134835
   Zhou YS, 2018, EXPERT REV VACCINES, V17, P677, DOI 10.1080/14760584.2018.1506702
   Zhu N, 2020, NEW ENGL J MED, V382, P8, DOI DOI https://doi.org/10.1056/NEJMoa2001017
   Zhu XJ, 2013, J THORAC DIS, V5, pS142, DOI 10.3978/j.issn.2072-1439.2013.06.06
NR 41
TC 1
Z9 1
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1844060
EA NOV 2020
PG 17
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OO7FW
UT WOS:000587542400001
PM 33164664
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Candon, S
   Guerrot, D
   Drouot, L
   Lemoine, M
   Lebourg, L
   Hanoy, M
   Boyer, O
   Bertrand, D
AF Candon, Sophie
   Guerrot, Dominique
   Drouot, Laurent
   Lemoine, Mathilde
   Lebourg, Ludivine
   Hanoy, Melanie
   Boyer, Olivier
   Bertrand, Dominique
TI T cell and antibody responses to SARS-CoV-2: Experience from a French
   transplantation and hemodialysis center during the COVID-19 pandemic
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article; Early Access
DE immunobiology; infection and infectious agents &#8208; viral; kidney
   transplantation; nephrology; monitoring; immune; translational research;
   science
AB Immunosuppressed organ-transplanted patients are considered at risk for severe forms of COVID-19. Moreover, exaggerated innate and adaptive immune responses might be involved in severe progression of the disease. However, no data on the immune response to SARS-CoV-2 in transplanted patients are currently available. Here, we report the first assessment of antibody and T cell responses to SARS-CoV-2 in 11 kidney-transplanted patients recovered from RT-PCR-confirmed (n = 5) or initially suspected (n = 6) COVID-19. After reduction of immunosuppressive therapy, RT-PCR-confirmed COVID-19 transplant patients were able to mount vigorous antiviral T cell and antibody responses, as efficiently as two nontherapeutically immunosuppressed COVID-19 patients on hemodialysis. By contrast, six RT-PCR-negative patients displayed no antibody response. Among them, three showed very low numbers of SARS-CoV-2-reactive T cells, whereas no T cell response was detected in the other three, potentially ruling out COVID-19 diagnosis. Low levels of T cell reactivity to SARS-CoV-2 were also detected in seronegative healthy controls without known exposure to the virus. These results suggest that during COVID-19, monitoring both T cell and serological immunity might be helpful for the differential diagnosis of COVID-19 but are also needed to evaluate a potential role of antiviral T cells in the development of severe forms of the disease.
C1 [Candon, Sophie; Boyer, Olivier] Rouen Univ Hosp, Dept Immunol & Biotherapies, Rouen, France.
   [Candon, Sophie; Drouot, Laurent; Boyer, Olivier] Univ Rouen Normandy, INSERM U1234, Rouen, France.
   [Guerrot, Dominique; Lemoine, Mathilde; Lebourg, Ludivine; Hanoy, Melanie; Bertrand, Dominique] Rouen Univ Hosp, Dept Nephrol Transplantat & Hemodialysis, Rouen, France.
RP Candon, S (corresponding author), Rouen Univ Hosp, Dept Immunol & Biotherapies, Rouen, France.; Candon, S (corresponding author), Univ Rouen Normandy, INSERM U1234, Rouen, France.
EM sophie.candon@inserm.fr
RI Boyer, Olivier/N-6552-2013
OI Boyer, Olivier/0000-0002-7591-307X
CR Arnaout R, 2020, BIORXIV
   Banerjee D, 2020, KIDNEY INT, V97, P1076, DOI 10.1016/j.kint.2020.03.018
   Benotmane I, 2020, AM J TRANSPLANT, V20, P3162, DOI 10.1111/ajt.16251
   Bererhi L, 2012, TRANSPL INT, V25, P545, DOI 10.1111/j.1432-2277.2012.01451.x
   Braun J., 2020, PRESENCE SARS COV 2
   Coates PT, 2020, KIDNEY INT, V97, P1074, DOI 10.1016/j.kint.2020.04.001
   Freeman AJ, 2004, J INFECT DIS, V190, P1093, DOI 10.1086/422605
   Gallais F, 2020, INTRAFAMILIAL EXPOSU
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Huang AT, 2020, SYSTEMATIC REV ANTIB
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ibarrondo FJ, 2020, NEW ENGL J MED, V383
   Kroemer M, 2020, J INFECT
   Le Bert N, 2020, NATURE, DOI 10.1038/s41586-020-2550-z
   Liu WJ, 2017, ANTIVIR RES, V137, P82, DOI 10.1016/j.antiviral.2016.11.006
   Lucia M, 2014, CLIN INFECT DIS, V59, P1537, DOI 10.1093/cid/ciu589
   Mateus J, 2020, SCIENCE
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Sekine T, 2020, CELL
   Seow J., 2020, LONGITUDINAL EVALUAT
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071
   Young BE, 2020, JAMA
NR 25
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
DI 10.1111/ajt.16348
EA NOV 2020
PG 10
WC Surgery; Transplantation
SC Surgery; Transplantation
GA OM3AP
UT WOS:000585898300001
PM 33047493
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ibrahim, TM
   Ismail, MI
   Bauer, MR
   Bekhit, AA
   Boeckler, FM
AF Ibrahim, Tamer M.
   Ismail, Muhammad I.
   Bauer, Matthias R.
   Bekhit, Adnan A.
   Boeckler, Frank M.
TI Supporting SARS-CoV-2 Papain-Like Protease Drug Discovery: In silico
   Methods and Benchmarking
SO FRONTIERS IN CHEMISTRY
LA English
DT Article
DE COVID-19; docking; VS; benchmarking; DEKOIS 2; 0; PLpro
ID RESPIRATORY-SYNDROME-CORONAVIRUS; SCORING FUNCTIONS; DOCKING;
   RECOGNITION; INHIBITORS; UBIQUITIN; OPTIMIZATION; PNEUMONIA; QUALITY;
   MERS
AB The coronavirus disease 19 (COVID-19) is a rapidly growing pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Its papain-like protease (SARS-CoV-2 PLpro) is a crucial target to halt virus replication. SARS-CoV PLpro and SARS-CoV-2 PLpro share an 82.9% sequence identity and a 100% sequence identity for the binding site reported to accommodate small molecules in SARS-CoV. The flexible key binding site residues Tyr269 and Gln270 for small-molecule recognition in SARS-CoV PLpro exist also in SARS-CoV-2 PLpro. This inspired us to use the reported small-molecule binders to SARS-CoV PLpro to generate a high-quality DEKOIS 2.0 benchmark set. Accordingly, we used them in a cross-benchmarking study against SARS-CoV-2 PLpro. As there is no SARS-CoV-2 PLpro structure complexed with a small-molecule ligand publicly available at the time of manuscript submission, we built a homology model based on the ligand-bound SARS-CoV structure for benchmarking and docking purposes. Three publicly available docking tools FRED, AutoDock Vina, and PLANTS were benchmarked. All showed better-than-random performances, with FRED performing best against the built model. Detailed performance analysis via pROC-Chemotype plots showed a strong enrichment of the most potent bioactives in the early docking ranks. Cross-benchmarking against the X-ray structure complexed with a peptide-like inhibitor confirmed that FRED is the best-performing tool. Furthermore, we performed cross-benchmarking against the newly introduced X-ray structure complexed with a small-molecule ligand. Interestingly, its benchmarking profile and chemotype enrichment were comparable to the built model. Accordingly, we used FRED in a prospective virtual screen of the DrugBank(1) database. In conclusion, this study provides an example of how to harness a custom-made DEKOIS 2.0 benchmark set as an approach to enhance the virtual screening success rate against a vital target of the rapidly emerging pandemic.
C1 [Ibrahim, Tamer M.] Kafrelsheikh Univ, Fac Pharm, Dept Pharmaceut Chem, Kafrelsheikh, Egypt.
   [Ismail, Muhammad I.] British Univ Egypt, Fac Pharm, Dept Pharmaceut Chem, Cairo, Egypt.
   [Bauer, Matthias R.] AstraZeneca, R&D, Struct Biophys & Fragment Based Lead Generat, Discovery Sci, Cambridge, England.
   [Bauer, Matthias R.; Boeckler, Frank M.] Eberhard Karls Univ Tubingen, Dept Pharm, Tubingen, Germany.
   [Bekhit, Adnan A.] Alexandria Univ, Fac Pharm, Dept Pharmaceut Chem, Alexandria, Egypt.
   [Bekhit, Adnan A.] Univ Bahrain, Coll Hlth & Sport Sci, Allied Hlth Dept, Pharm Program, Zallaq, Bahrain.
RP Ibrahim, TM (corresponding author), Kafrelsheikh Univ, Fac Pharm, Dept Pharmaceut Chem, Kafrelsheikh, Egypt.
EM tamer_mohamad@pharm.kfs.edu.eg
OI Ismail, Muhammad/0000-0003-2562-4357
CR [Anonymous], 2018, MOL OPERATING ENV
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Baez-Santos YM, 2014, J MED CHEM, V57, P2393, DOI 10.1021/jm401712t
   Barretto N, 2005, J VIROL, V79, P15189, DOI 10.1128/JVI.79.24.15189-15198.2005
   Bauer MR, 2013, J CHEM INF MODEL, V53, P1447, DOI [10.1021/ci400115bl, 10.1021/ci400115b]
   Bekes M, 2016, MOL CELL, V62, P572, DOI 10.1016/j.molcel.2016.04.016
   Bekhit AA, 2019, EUR J MED CHEM, V163, P353, DOI 10.1016/j.ejmech.2018.11.067
   Benkert P, 2011, BIOINFORMATICS, V27, P343, DOI 10.1093/bioinformatics/btq662
   Berthold M. R., 2007, KNIME KONSTANZ INFOR, DOI [10.1007/978-3-540-78246-9_38, DOI 10.1007/978-3-540-78246-9_38]
   Boeckler Frank M, 2014, J Cheminform, V6, pO24
   BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201
   Chou CY, 2014, ACTA CRYSTALLOGR D, V70, P572, DOI 10.1107/S1399004713031040
   Clark RD, 2008, J COMPUT AID MOL DES, V22, P141, DOI 10.1007/s10822-008-9181-z
   Clemente V, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103492
   COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916
   Daczkowski CM, 2017, J MOL BIOL, V429, P1661, DOI 10.1016/j.jmb.2017.04.011
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Freitas BT, 2020, ACS INFECT DIS, V6, P2099, DOI 10.1021/acsinfecdis.0c00168
   Ghosh AK, 2010, J MED CHEM, V53, P4968, DOI 10.1021/jm1004489
   Ghosh AK, 2009, J MED CHEM, V52, P5228, DOI 10.1021/jm900611t
   Hsih WH, 2020, J MICROBIOL IMMUNOL, V53, P459, DOI 10.1016/j.jmii.2020.03.008
   Ibrahim TM, 2015, J CHEM INF MODEL, V55, P2297, DOI 10.1021/acs.jcim.5b00475
   Ibrahim TM, 2015, J CHEMINFORMATICS, V7, DOI 10.1186/s13321-015-0074-6
   Ibrahim TM, 2014, J CHEMINFORM S1, V6, P19, DOI [DOI 10.1186/1758-2946-6-S1-P19, 10.1186/1758-2946-6-S1-P19]
   Korb O, 2009, J CHEM INF MODEL, V49, P84, DOI 10.1021/ci800298z
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Lee H, 2015, ACS CHEM BIOL, V10, P1456, DOI 10.1021/cb500917m
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Li XG, 2020, J MED VIROL, V92, P501, DOI 10.1002/jmv.25701
   Lin MH, 2018, ANTIVIR RES, V150, P155, DOI 10.1016/j.antiviral.2017.12.015
   Liu TQ, 2007, NUCLEIC ACIDS RES, V35, pD198, DOI 10.1093/nar/gkl999
   McGann M, 2012, J COMPUT AID MOL DES, V26, P897, DOI 10.1007/s10822-012-9584-8
   McGann M, 2011, J CHEM INF MODEL, V51, P578, DOI 10.1021/ci100436p
   Mielech AM, 2015, J VIROL, V89, P4907, DOI 10.1128/JVI.00338-15
   Mysinger MM, 2012, J MED CHEM, V55, P6582, DOI 10.1021/jm300687e
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Pontius J, 1996, J MOL BIOL, V264, P121, DOI 10.1006/jmbi.1996.0628
   Qian X, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00650-1
   Rabaan Ali A, 2020, Infez Med, V28, P174
   Rabi FA, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030231
   Ratia K, 2006, P NATL ACAD SCI USA, V103, P5717, DOI 10.1073/pnas.0510851103
   Ratia K, 2008, P NATL ACAD SCI USA, V105, P16119, DOI 10.1073/pnas.0805240105
   Ratia K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004113
   Robert X, 2014, NUCLEIC ACIDS RES, V42, pW320, DOI 10.1093/nar/gku316
   Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57
   Santiago DN, 2012, J CHEM INF MODEL, V52, P2192, DOI 10.1021/ci300073m
   SAVES, 2020, STRUCT AN VER SERV W
   Schapira M, 2003, J MED CHEM, V46, P3045, DOI 10.1021/jm0300173
   Schneider G, 2010, NAT REV DRUG DISCOV, V9, P273, DOI 10.1038/nrd3139
   Scior T, 2012, J CHEM INF MODEL, V52, P867, DOI 10.1021/ci200528d
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Tilocca B, 2020, MICROBES INFECT, V22, P188, DOI 10.1016/j.micinf.2020.04.002
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Vogel SM, 2011, J CHEM INF MODEL, V51, P2650, DOI 10.1021/ci2001549
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Wei BQQ, 2002, J MOL BIOL, V322, P339, DOI 10.1016/S0022-2836(02)00777-5
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Yang D, 2015, VIRUS RES, V206, P120, DOI 10.1016/j.virusres.2015.02.025
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 61
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-2646
J9 FRONT CHEM
JI Front. Chem.
PD NOV 5
PY 2020
VL 8
AR 592289
DI 10.3389/fchem.2020.592289
PG 17
WC Chemistry, Multidisciplinary
SC Chemistry
GA OU5VW
UT WOS:000591597400001
PM 33251185
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Richardson, LJ
   Belanger, JJ
AF Richardson, Lindsy J.
   Belanger, Jocelyn J.
TI COVID-19 Knowledge Test: An Assessment Tool for Health Educators During
   the COVID-19 Pandemic
SO FRONTIERS IN PUBLIC HEALTH
LA English
DT Article
DE COVID-19; knowledge; health education; test; scale development; Rasch
   analysis
AB Background: As of August 11, 2020, Coronavirus disease 2019 (COVID-19) has infected 19,936,210 persons and led to 732,499 deaths worldwide. The impact has been immense, and with no vaccine currently available, the best way to protect our communities is health education. We developed a brief COVID-19 knowledge test for health educators that can be used to assess deficits in clients' understanding of the disease.
   Methods: COVID-19 Knowledge Test items were developed by the research team and administered to participants. An alternate-choice item format was selected for the knowledge test, and data analysis was based on an American sample of 273 respondents. A detailed analysis of the data was conducted with classical test theory and Rasch analysis.
   Findings: The final instrument was found to be a unidimensional measure of COVID-19 knowledge. Results provided evidence for absolute model fit and model fit for individual items. All items included on the scale were monotonically increasing and split-half reliability was considered acceptable. Total test information revealed that the test is suitable for individuals with low to average knowledge of COVID-19.
   Interpretation: Rasch analysis provides support for the COVID-19 Knowledge Test to be used as an assessment tool for health educators. The final version of the test consists of 34 high-quality test items that can be administered in <10 min. Normative data and suggested cutoff scores are also provided.
C1 [Richardson, Lindsy J.] Walden Univ, Coll Social & Behav Sci, Minneapolis, MN 55401 USA.
   [Belanger, Jocelyn J.] New York Univ, Dept Psychol, Abu Dhabi, U Arab Emirates.
RP Richardson, LJ (corresponding author), Walden Univ, Coll Social & Behav Sci, Minneapolis, MN 55401 USA.
EM lindsyrichardson@gmail.com
OI Belanger, Jocelyn/0000-0003-3881-0335
CR [Anonymous], 2020, J CHANGE MANAGEMENT
   BICHI AA, 2018, INT J EVALUATION RES, V7, P142
   Blais M, 2018, SPECTRA INDICES PSYC
   BOCK RD, 1981, PSYCHOMETRIKA, V46, P443, DOI 10.1007/BF02293801
   Boone WJ, 2016, CBE-LIFE SCI EDUC, V15, DOI 10.1187/cbe.16-04-0148
   Burmester MA, 1966, SCI ED, V50, P467, DOI [10.1002/sce.3730500512, DOI 10.1002/SCE.3730500512]
   Chalmers RP, 2012, J STAT SOFTW, V48, P1
   Downing S. M, 1992, ED MEASUREMENT ISSUE, V11, P27, DOI [10.1111/j.1745-3992.1992.tb00248.x, DOI 10.1111/J.1745-3992.1992.TB00248.X]
   EBEL RL, 1982, J EDUC MEAS, V19, P267, DOI 10.1111/j.1745-3984.1982.tb00133.x
   Ebel RL, 1981, ANN M NAT COUNC MEAS
   Finch WH, 2015, LATENT VARIABLE MODE, DOI [10.4324/9781315869797, DOI 10.4324/9781315869797]
   Frankel TC, 2020, WASHINGTON POST
   Garrett L, 2020, LANCET, V395, P942, DOI 10.1016/S0140-6736(20)30600-0
   HATTIE J, 1985, APPL PSYCH MEAS, V9, P139, DOI 10.1177/014662168500900204
   Hoehl S, 2020, NEW ENGL J MED, V382, P1278, DOI 10.1056/NEJMc2001899
   Kalichman SC, 2000, AM J PREV MED, V18, P325, DOI 10.1016/S0749-3797(00)00121-5
   Lamprianou I, 2019, APPL RASCH MODEL SOC, DOI [10.4324/9781315146850, DOI 10.4324/9781315146850]
   Lee BY, 2020, FORBES
   Levy Benjamin, 2017, Infect Dis Model, V2, P323, DOI 10.1016/j.idm.2017.06.004
   Li WG, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-3312
   Ruch GM, 1925, J EDUC PSYCHOL, V16, P89, DOI 10.1037/h0072894
   Taber KS, 2018, RES SCI EDUC, V48, P1273, DOI 10.1007/s11165-016-9602-2
   Van den Broucke S, 2020, HEALTH PROMOT INT, V35, P181, DOI 10.1093/heapro/daaa042
   Williams BJ, 1957, 14TH YB NATIONAL COU, P63
   Wolf MS, 2020, ANN INTERN MED, V173, P100, DOI 10.7326/M20-1239
   World Health Organization W., 2020, 204 WHO
NR 26
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-2565
J9 FRONT PUBLIC HEALTH
JI Front. Public Health
PD NOV 5
PY 2020
VL 8
AR 580204
DI 10.3389/fpubh.2020.580204
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OU5TC
UT WOS:000591590200001
PM 33251174
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Whaley, CM
   Pera, MF
   Cantor, J
   Chang, J
   Velasco, J
   Hagg, HK
   Sood, N
   Bravata, DM
AF Whaley, Christopher M.
   Pera, Megan F.
   Cantor, Jonathan
   Chang, Jennie
   Velasco, Julia
   Hagg, Heather K.
   Sood, Neeraj
   Bravata, Dena M.
TI Changes in Health Services Use Among Commercially Insured US Populations
   During the COVID-19 Pandemic
SO JAMA NETWORK OPEN
LA English
DT Article
AB IMPORTANCE The coronavirus disease 2019 (COVID-19) pandemic has placed unprecedented strain on patients and health care professionals and institutions, but the association of the pandemic with use of preventive, elective, and nonelective care, as well as potential disparities in use of health care, remain unknown.
   OBJECTIVE To examine changes in health care use during the first 2 months of the COVID-19 pandemic in March and April of 2020 relative to March and April of 2019 and 2018, and to examine whether changes in use differ by patient's zip code-level race/ethnicity or income.
   DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study analyzed health insurance claims for patients from all 50 US states who receive health insurance through their employers. Changes in use of preventive services, nonelective care, elective procedures, prescription drugs, in-person office visits, and telemedicine visits were examined during the first 2 months of the COVID-19 pandemic in 2020 relative to existing trends in 2019 and 2018. Disparities in the association of the pandemic with health care use based on patient's zip code-level race and income were also examined. RESULTS Data from 5.6, 6.4, and 6.8 million US individuals with employer-sponsored insurance in 2018, 2019, and 2020, respectively, were analyzed. Patient demographics were similar in all 3 years (mean [SD] age, 34.3 [18.6] years in 2018, 34.3 [18.5] years in 2019, and 34.5 [18.5] years in 2020); 50.0% women in 2018, 49.5% women in 2019, and 49.5% women in 2020). In March and April 2020, regression-adjusted use rate per 10 000 persons changed by -28.2 (95% CI, -30.5 to -25.9) and -64.5 (95% CI, -66.8 to -62.2) for colonoscopies; -149.1 (95% CI, -162.0 to -16.2) and -342.1 (95% CI, -355.0 to -329.2) for mammograms; -60.0 (95% CI, -63.3 to -54.7) and -118.1 (95% CI, -112.4 to -113.9) for hemoglobin A1c tests; -300.5 (95% CI, -346.5 to -254.5) and -369.0 (95% CI, -414.7 to -323.4) for child vaccines; -4.6 (95% CI, -5.3 to -3.9) and -10.9 (95% CI, -11.6 to -10.2) for musculoskeletal surgery; -1.1 (95% CI, -1.4 to -0.7) and -3.4 (95% CI, -3.8 to -3.0) for cataract surgery; -13.4 (95% CI, -14.6 to -12.2) and -31.4 (95% CI, -32.6 to -30.2) formagnetic resonance imaging; and - 581.1 (95% CI, -612.9 to -549.3) and -1465 (95% CI, -1496 to -1433) for in-person office visits. Use of telemedicine services increased by 227.9 (95% CI, 221.7 to 234.1) per 10 000 persons and 641.6 (95% CI, 635.5 to 647.8) per 10 000 persons. Patients living in zip codes with lower-income or majority racial/ethnic minority populations experienced smaller reductions in in-person visits (similar to 80% racial/ethnic minority zip code: 200.0 per 10 000 [95% CI, 128.9-270.1]; 79%-21% racial/ethnic minority zip code: 54.2 per 10 000 [95% CI, 33.6-74.9]) but also had lower rates of adoption of telemedicine (similar to 80% racial/ethnic minority zip code: -71.6 per 10 000 [95% CI, -87.6 to -55.5]; 79%-21% racial/ethnic minority zip code: -15.1 per 10 000 [95% CI, -19.8 to -10.4]).
   CONCLUSIONS AND RELEVANCE In this cross-sectional study of a large US population with employer-sponsored insurance, the first 2 months of the COVID-19 pandemic were associated with dramatic reductions in the use of preventive and elective care. Use of telemedicine increased rapidly but not enough to account for reductions in in-person primary care visits. Race and income disparities at the zip code level exist in use of telemedicine.
C1 [Whaley, Christopher M.; Cantor, Jonathan] RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA.
   [Pera, Megan F.; Chang, Jennie; Velasco, Julia; Hagg, Heather K.; Bravata, Dena M.] Castlight Hlth, San Francisco, CA USA.
   [Sood, Neeraj] Univ Southern Calif, Sol Price Sch Publ Policy, Los Angeles, CA 90007 USA.
   [Sood, Neeraj] Univ Southern Calif, Schaeffer Ctr, Los Angeles, CA 90007 USA.
   [Sood, Neeraj] NBER, Cambridge, MA 02138 USA.
   [Bravata, Dena M.] Ctr Primary Care & Outcomes Res, Stanford, CA USA.
RP Whaley, CM (corresponding author), RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA.
EM cwhaley@rand.org
FU National Institutes on AgingUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Aging (NIA) [1K01AG061274]; National Cancer InstituteUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [NCI R21 CA219229]
FX Support was provided by the National Institutes on Aging (1K01AG061274,
   Dr Whaley) and the National Cancer Institute (NCI R21 CA219229, Dr
   Whaley).
CR Adams-Prassl A., 2020, IMPACT CORONAVIRUS L
   Alexander D, 2020, DO STAY AT HOME ORDE
   Barnett M, 2020, COVID 19 UPCOMING FI, DOI [DOI 10.1056/CAT.20.0153, 10.1056/CAT.20.0153]
   Baum A, 2020, JAMA-J AM MED ASSOC, V324, P96, DOI 10.1001/jama.2020.9972
   Bibbins-Domingo K, 2020, ANN INTERN MED, V173, P233, DOI 10.7326/M20-2247
   Brindle ME, 2020, ANN SURG, V272, pE1, DOI 10.1097/SLA.0000000000003923
   Carlos RC, 2020, J AM COLL RADIOL, V17, P927, DOI 10.1016/j.jacr.2020.05.032
   Centers for Medicare & Medicaid Services, 2020, COVID 19 EM DECL BLA
   Chatterji P, 2020, EFFECTS COVID 19 PAN, DOI [10.3386/w27173, DOI 10.3386/W27173]
   Courtemanche C, 2020, HEALTH AFFAIR, V39, P1237, DOI 10.1377/hlthaff.2020.00608
   Coven J, 2020, DISPARITIES MOBILITY
   Glied S, 2020, JAMA-J AM MED ASSOC, V323, P2001, DOI 10.1001/jama.2020.6644
   Gupta S, 2020, TRACKING PUBLIC PRIV
   Hartnett KP, 2020, MMWR-MORBID MORTAL W, V69, P699, DOI 10.15585/mmwr.mm6923e1
   Hileman G, 2016, ACCURACY CLAIMS BASE
   IBM Watson Health, 2018, MED EP GROUP APPL ME
   Khatana SAM, 2020, J GEN INTERN MED, V35, P2431, DOI 10.1007/s11606-020-05916-w
   Kim EJ, 2020, J GEN INTERN MED, V35, P2441, DOI 10.1007/s11606-020-05881-4
   Kliff S, 2020, NY TIMES
   Kronick R., 2020, HLTH AFFAIRS BLOG, DOI DOI 10.1377/HBLOG20200518.567886/FULL/
   Lau J, 2020, HEALTH AFFAIR, V39, P1437, DOI 10.1377/hlthaff.2020.00903
   Mehrotra A., 2020, IMPACT COVID 19 PAND
   Montenovo L, 2020, DETERMINANTS DISPARI
   Nouri S, 2020, NEJM CATALYST INNOVA, DOI 10.1056/CAT.20.0123
   Office for Civil Rights, 2020, NOT ENF DISCR TEL
   Peterson C, 2019, SAGE OPEN MED, V7, DOI 10.1177/2050312119840200
   Rittenmeyer R, 2020, COVID 19 OPERATIONAL
   Rogers H, 2020, ESTIMATING IMPACT CO
   Rubin R, 2020, JAMA-J AM MED ASSOC, V324, P321, DOI 10.1001/jama.2020.11254
   Rudin RS, 2020, HLTH AFFAIRS BLOG
   Sasson C, 2012, NEW ENGL J MED, V367, P1607, DOI 10.1056/NEJMoa1110700
   Sen S, 2020, JAMA-J AM MED ASSOC, V323, P2522, DOI 10.1001/jama.2020.9176
   Shachar C, 2020, JAMA-J AM MED ASSOC, V323, P2375, DOI 10.1001/jama.2020.7943
   Song Gao, 2020, SIGSPATIAL Special, V12, P16, DOI 10.1145/3404820.3404824
   Uscher-Pines L, 2020, JAMA-J AM MED ASSOC, V324, P39, DOI 10.1001/jama.2020.3940
   White House, 2020, PROCL DECL NAT EM NO
NR 36
TC 1
Z9 1
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2574-3805
J9 JAMA NETW OPEN
JI JAMA Netw. Open
PD NOV 5
PY 2020
VL 3
IS 11
DI 10.1001/jamanetworkopen.2020.24984
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA OU0NX
UT WOS:000591234400008
PM 33151319
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Branch, AD
AF Branch, Andrea D.
TI How to Survive COVID-19 Even If the Vaccine Fails
SO HEPATOLOGY COMMUNICATIONS
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; CORONAVIRUS INFECTION; CELL RESPONSES;
   ANTIBODY; BIOLOGY
AB Coronavirus disease 2019 (COVID-19) has created an emergency of epic proportions. While a vaccine may be forthcoming, this is not guaranteed, as discussed herein. The potential problems and ominous signs include (1) lung injury that developed in animals given an experimental vaccine for the severe acute respiratory syndrome coronavirus (SARS-CoV)-1; (2) a perversion of adaptive immune responses called antibody-dependent enhancement of infection that occurs in SARS-CoV-1 and that may occur in people vaccinated for COVID-19; (3) the frequent and recurrent infections that are caused by respiratory coronaviruses; and (4) the appearance of mutations in SARS-CoV-2 proteins, which raise the specter of vaccine escape mutants. Because success is uncertain, alternatives to vaccines need to be vigorously pursued during this critical moment in the pandemic. Alternatives include (1) engineered monoclonal antibodies that do not cause antibody-dependent enhancement; (2) cocktails of antiviral drugs and inhibitors of the cellular proteins required for SARS-CoV-2 replication; (3) interferons; and (4) anticoagulants, antioxidants, and immune modulators. To organize and coordinate the systematic investigation of existing therapies and new therapies (as they emerge), a Covid-19 clinical trials network is needed to provide (1) robust funding (on a par with vaccine funding) and administration; (2) an adaptive trial design committee to prioritize interventions and review results in real time; (3) a computer interface to facilitate patient enrollment, make data available to investigators, and present findings; (4) a practice guidelines study group; and (5) a mobile corps of COVID-19 experts available for rapid deployment, to assist local health care providers and enroll patients in trials as outbreaks occur. To combat the COVID-19 pandemic and future mass contagions, the network would be a cornerstone of a comprehensive infectious diseases research program.
C1 [Branch, Andrea D.] Icahn Sch Med Mt Sinai, Dept Med, Div Liver Dis, New York, NY 10029 USA.
RP Branch, AD (corresponding author), Icahn Sch Med Mt Sinai, Dept Med, Div Liver Dis, New York, NY 10029 USA.
EM andrea.branch@mssm.edu
FU Prevent Cancer Foundation; National Institution of Occupational Safety
   and Health [01148]
FX Supported by the Prevent Cancer Foundation and the National Institution
   of Occupational Safety and Health (Grant/Award No. 01148).
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bibbins-Domingo K, 2016, JAMA-J AM MED ASSOC, V315, P2564, DOI 10.1001/jama.2016.5989
   Boni MF, 2020, NAT MICROBIOL, V5, P1408, DOI 10.1038/s41564-020-0771-4
   Boyle A, 2020, GEEKWIRE
   Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9
   CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019
   Chau TN, 2004, HEPATOLOGY, V39, P302, DOI 10.1002/hep.20111
   Cyranoski D, 2020, NATURE, V581, P22, DOI 10.1038/d41586-020-01315-7
   Da BL, 2020, HEPATOLOGY, V72, P1102, DOI 10.1002/hep.31307
   Galanti Marta, 2020, J Infect Dis, DOI 10.1093/infdis/jiaa392
   Gharbharan A, 2020, CONVALESCENT PLASMA, DOI [10.1101/2020.07.01.20139857, DOI 10.1101/2020.07.01.20139857, 10.1101/2020.07.01.20139857.]
   Hadjadj J., 2020, IMPAIRED TYPE 1 INTE, DOI [10.1101/2020.04.19.20068015, DOI 10.1101/2020.04.19.20068015]
   Head MG, 2020, LANCET GLOB HEALTH, DOI [10.2139/ssrn.3552831, DOI 10.2139/SSRN.3552831]
   Hindson J, 2020, NAT REV GASTRO HEPAT, V17, P259, DOI 10.1038/s41575-020-0295-7
   Horby P, 2020, EFFECT DEXAMETHASONE, DOI [10.1101/2020.06.22.20137273, DOI 10.1101/2020.06.22.20137273]
   Hui KPY, 2020, LANCET RESP MED, V8, P687, DOI 10.1016/S2213-2600(20)30193-4
   Huisman W, 2009, VACCINE, V27, P505, DOI 10.1016/j.vaccine.2008.10.087
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Iwasaki A, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0321-6
   Ji D, 2020, J HEPATOL, V73, P451, DOI 10.1016/j.jhep.2020.03.044
   Knipe DM, 2013, FIELDS VIROLOGY, P825
   Korber B, 2020, SPIKE MUTATION PIPEL, V12, P122, DOI [10.1101/2020.04.29.069054, DOI 10.1101/2020.04.29.069054]
   Lamers MM, 2020, SCIENCE, V369, P50, DOI 10.1126/science.abc1669
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P1, DOI DOI 10.1001/jama.2020.10044
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Loutfy MR, 2003, JAMA-J AM MED ASSOC, V290, P3222, DOI 10.1001/jama.290.24.3222
   Mahlakoiv T, 2012, J GEN VIROL, V93, P2601, DOI 10.1099/vir.0.046284-0
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Mordstein M, 2010, J VIROL, V84, P5670, DOI 10.1128/JVI.00272-10
   Perlman S, 2016, INT J INFECT DIS, V47, P23, DOI 10.1016/j.ijid.2016.04.008
   Puelles VG, 2020, NEW ENGL J MED, V383, P590, DOI [10.1056/NEJMc2011400, 10.1056/NEJMc2013400]
   RIVERA GK, 1993, NEW ENGL J MED, V329, P1289, DOI 10.1056/NEJM199310283291801
   Saab S, 2018, HEPATOLOGY, V67, P2449, DOI 10.1002/hep.29685
   SCHMIDT OW, 1986, AM J EPIDEMIOL, V123, P862, DOI 10.1093/oxfordjournals.aje.a114315
   Tang F, 2011, J IMMUNOL, V186, P7264, DOI 10.4049/jimmunol.0903490
   VENNEMA H, 1990, J VIROL, V64, P1407, DOI 10.1128/JVI.64.3.1407-1409.1990
   Wander P, 2020, AM J GASTROENTEROL, V115, P941, DOI 10.14309/ajg.0000000000000660
   Wang QD, 2016, ACS INFECT DIS, V2, P361, DOI 10.1021/acsinfecdis.6b00006
   Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]
   Yang LT, 2006, CLIN IMMUNOL, V120, P171, DOI 10.1016/j.clim.2006.05.002
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou Q, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01061
NR 47
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 2471-254X
J9 HEPATOL COMMUN
JI Hepatol. Commun.
PD DEC
PY 2020
VL 4
IS 12
BP 1864
EP 1879
DI 10.1002/hep4.1588
EA NOV 2020
PG 16
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA OZ6QK
UT WOS:000590804800001
PM 33305156
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Al-Shamsi, HO
   Coomes, EA
   Aldhaheri, K
   Alrawi, S
AF Al-Shamsi, Humaid O.
   Coomes, Eric A.
   Aldhaheri, Khuloud
   Alrawi, Sadir
TI Serial Screening for COVID-19 in Asymptomatic Patients Receiving
   Anticancer Therapy in the United Arab Emirates
SO JAMA ONCOLOGY
LA English
DT Letter; Early Access
AB This cohort study examines the implementation of a microbiologic screening pilot program in Al Zahra Hospital in the United Arab Emirates for identifying presymptomatic COVID-19 in patients with cancer.
C1 [Al-Shamsi, Humaid O.] Burjeel Oncol Burjeel Med City, 28th St,POB 9054, Abu Dhabi, U Arab Emirates.
   [Al-Shamsi, Humaid O.] Univ Sharjah, Dept Med, Sharjah, U Arab Emirates.
   [Al-Shamsi, Humaid O.] Emirates Oncol Soc, Dubai, U Arab Emirates.
   [Coomes, Eric A.] Univ Toronto, Dept Med, Div Infect Dis, Toronto, ON, Canada.
   [Aldhaheri, Khuloud] Univ Toronto, Dept Med, Toronto, ON, Canada.
   [Alrawi, Sadir] Alzahra Hosp Dubai, Med Oncol Dept, Dubai, U Arab Emirates.
RP Al-Shamsi, HO (corresponding author), Burjeel Oncol Burjeel Med City, 28th St,POB 9054, Abu Dhabi, U Arab Emirates.
EM humaid.al-shamsi@medportal.ca
OI Al-Shamsi, Humaid O./0000-0003-3819-0500
FU Roche Pharmaceuticals Middle East Free Zone Company, Dubai, United Arab
   Emirates
FX Roche Pharmaceuticals Middle East Free Zone Company, Dubai, United Arab
   Emirates.
CR Al-Muharraqi MA, 2020, BRIT J ORAL MAX SURG, V58, P503, DOI 10.1016/j.bjoms.2020.04.014
   Al-Shamsi HO, 2020, JAMA ONCOL, V6, P1627, DOI 10.1001/jamaoncol.2020.2548
   Al-Shamsi HO, 2020, ONCOLOGIST, V25, pE936, DOI 10.1634/theoncologist.2020-0213
   Arons MM, 2020, NEW ENGL J MED, V382, P2081, DOI 10.1056/NEJMoa2008457
   Treibel TA, 2020, LANCET, V395, P1608, DOI 10.1016/S0140-6736(20)31100-4
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 6
TC 0
Z9 0
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2374-2437
EI 2374-2445
J9 JAMA ONCOL
JI JAMA Oncol.
DI 10.1001/jamaoncol.2020.5745
EA NOV 2020
PG 2
WC Oncology
SC Oncology
GA OT4BG
UT WOS:000590793200006
PM 33151260
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lee, CH
   Pinho, MP
   Buckley, PR
   Woodhouse, IB
   Ogg, G
   Simmons, A
   Napolitani, G
   Koohy, H
AF Lee, Chloe H.
   Pinho, Mariana Pereira
   Buckley, Paul R.
   Woodhouse, Isaac B.
   Ogg, Graham
   Simmons, Alison
   Napolitani, Giorgio
   Koohy, Hashem
TI Potential CD8+T Cell Cross-Reactivity Against SARS-CoV-2 Conferred by
   Other Coronavirus Strains
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE cross-reactivity; antigen presentation; predict immunogenicity;
   epitopes; CD8+T cell recognition; COVID-19; SARS-CoV-2
ID EPITOPES
AB While individuals infected with coronavirus disease 2019 (COVID-19) manifested a broad range in susceptibility and severity to the disease, the pre-existing immune memory to related pathogens cross-reactive against SARS-CoV-2 can influence the disease outcome in COVID-19. Here, we investigated the potential extent of T cell cross-reactivity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that can be conferred by other coronaviruses and influenza virus, and generated an in silico map of public and private CD8+ T cell epitopes between coronaviruses. We observed 794 predicted SARS-CoV-2 epitopes of which 52% were private and 48% were public. Ninety-nine percent of the public epitopes were shared with SARS-CoV and 5.4% were shared with either one of four common coronaviruses, 229E, HKU1, NL63, and OC43. Moreover, to assess the potential risk of self-reactivity and/or diminished T cell response for peptides identical or highly similar to the host, we identified predicted epitopes with high sequence similarity with human proteome. Lastly, we compared predicted epitopes from coronaviruses with epitopes from influenza virus deposited in IEDB, and found only a small number of peptides with limited potential for cross-reactivity between the two virus families. We believe our comprehensive in silico profile of private and public epitopes across coronaviruses would facilitate design of vaccines, and provide insights into the presence of pre-existing coronavirus-specific memory CD8+ T cells that may influence immune responses against SARS-CoV-2.
C1 [Lee, Chloe H.; Pinho, Mariana Pereira; Buckley, Paul R.; Woodhouse, Isaac B.; Ogg, Graham; Simmons, Alison; Napolitani, Giorgio; Koohy, Hashem] Univ Oxford, Weatherall Inst Mol Med WIMM, MRC Human Immunol Unit, Med Res Council MRC,John Radcliffe Hosp, Oxford, England.
   [Lee, Chloe H.; Pinho, Mariana Pereira; Buckley, Paul R.; Woodhouse, Isaac B.; Ogg, Graham; Napolitani, Giorgio; Koohy, Hashem] Univ Oxford, Radcliffe Dept Med, Oxford, England.
   [Lee, Chloe H.; Buckley, Paul R.; Woodhouse, Isaac B.; Koohy, Hashem] Univ Oxford, MRC Weatherall Inst Mol Med, MRC WIMM Ctr Computat Biol, John Radcliffe Hosp, Oxford, England.
   [Simmons, Alison] John Radcliffe Hosp, Translat Gastroenterol Unit, Oxford, England.
   [Ogg, Graham; Simmons, Alison] NIHR Oxford Biomed Res Ctr, Oxford, England.
RP Koohy, H (corresponding author), Univ Oxford, Weatherall Inst Mol Med WIMM, MRC Human Immunol Unit, Med Res Council MRC,John Radcliffe Hosp, Oxford, England.; Koohy, H (corresponding author), Univ Oxford, Radcliffe Dept Med, Oxford, England.; Koohy, H (corresponding author), Univ Oxford, MRC Weatherall Inst Mol Med, MRC WIMM Ctr Computat Biol, John Radcliffe Hosp, Oxford, England.
EM hashem.koohy@rdm.ox.ac.uk
OI Woodhouse, Isaac/0000-0002-8221-7697
FU Medical Research CouncilMedical Research Council UK (MRC); Wellcome
   Investigator Award [219523/Z/19/Z]; UK Medical Research CouncilMedical
   Research Council UK (MRC); Bristol-Myers SquibbBristol-Myers Squibb;
   UCBUCB Pharma SA; department of Health and Social Care as part of the UK
   Vaccine Network [16/107/01]; Oxford NIHR Biomedical Research
   CentreNational Institute for Health Research (NIHR); MRC Human
   Immunology Unit core funding; UK National Institute of Health Research
   (NIHR)National Institute for Health Research (NIHR)
FX This work has been supported by Medical Research Council. HK and GN are
   funded by MRC Human Immunology Unit core funding. CL is funded by UK
   National Institute of Health Research (NIHR). AS is funded by a Wellcome
   Investigator Award (219523/Z/19/Z), the UK Medical Research Council,
   NIHR, awards from Bristol-Myers Squibb and UCB. MP and GN are funded by
   the department of Health and Social Care (project number:16/107/01) as
   part of the UK Vaccine Network. AS and GO are NIHR Senior Investigators
   and acknowledge support from the Oxford NIHR Biomedical Research Centre.
   The views expressed are those of the author(s) and not necessarily those
   of the NHS, the NIHR, or the Department of Health, UK. This manuscript
   has been released as a pre-print at bioRxiv (34).
CR [Anonymous], 2020, COMM HUM COR
   [Anonymous], SCIENCEDAILY
   Auladell M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01400
   Bojkova D, 2020, NATURE, V583, P469, DOI 10.1038/s41586-020-2332-7
   Caramelo F, 2020, ESTIMATION RISK FACT, V19, DOI [10.1101/2020.02.24.20027268, DOI 10.1101/2020.02.24.20027268]
   Cheng M, 2005, BIOCHEM BIOPH RES CO, V338, P1654, DOI 10.1016/j.bbrc.2005.10.088
   Dijkstra Johannes M, 2020, F1000Res, V9, P285, DOI 10.12688/f1000research.23458.1
   Dowd JB, 2020, P NATL ACAD SCI USA, V117, P9696, DOI 10.1073/pnas.2004911117
   Eisenstein M, 2019, NATURE, V573, pS50, DOI 10.1038/d41586-019-02751-w
   Epstein SL, 2010, EXPERT REV VACCINES, V9, P1325, DOI [10.1586/erv.10.123, 10.1586/ERV.10.123]
   Frank SA, 2002, IMMUNOLOGICAL VARIAB
   Frankild S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001831
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Hassan C, 2015, J BIOL CHEM, V290, P2593, DOI 10.1074/jbc.M114.607028
   Hyun-Jung Lee Chloe, 2020, F1000Res, V9, P145, DOI 10.12688/f1000research.22507.1
   Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893
   Khan Saahir, 2020, bioRxiv, DOI 10.1101/2020.03.24.006544
   Koutsakos M, 2019, NAT IMMUNOL, V20, P613, DOI 10.1038/s41590-019-0320-6
   Lee CH, 2020, C D8 T CELL CROSSREA, DOI [10.1101/2020.05.20.107292., DOI 10.1101/2020.05.20.107292, 10.1101/2020.05.20.107292]
   Lim Yvonne Xinyi, 2016, Diseases, V4, DOI 10.3390/diseases4030026
   Maiers M, 2007, HUM IMMUNOL, V68, P779, DOI 10.1016/j.humimm.2007.04.005
   Nelde A, 2021, NAT IMMUNOL, V22, DOI 10.1038/s41590-020-00808-x
   Nguyen A, 2020, J VIROL, V94, DOI 10.1128/JVI.00510-20
   Nickbakhsh S, 2020, J INFECT DIS, V222, P17, DOI 10.1093/infdis/jiaa185
   Ogishi M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00827
   Peters B, 2020, ANNU REV IMMUNOL, V38, P123, DOI 10.1146/annurev-immunol-082119-124838
   Petrova G, 2012, CRIT REV IMMUNOL, V32, P349
   Rist MJ, 2013, J IMMUNOL, V191, P561, DOI 10.4049/jimmunol.1300292
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Trolle T, 2016, J IMMUNOL, V196, P1480, DOI 10.4049/jimmunol.1501721
   Tsao YP, 2006, BIOCHEM BIOPH RES CO, V344, P63, DOI 10.1016/j.bbrc.2006.03.152
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Zhou MH, 2006, J IMMUNOL, V177, P2138, DOI 10.4049/jimmunol.177.4.2138
NR 34
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD NOV 5
PY 2020
VL 11
AR 579480
DI 10.3389/fimmu.2020.579480
PG 10
WC Immunology
SC Immunology
GA OS6EV
UT WOS:000590255600001
PM 33250893
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cohen, IV
   Makunts, T
   Moumedjian, T
   Issa, MA
   Abagyan, R
AF Cohen, Isaac V.
   Makunts, Tigran
   Moumedjian, Talar
   Issa, Masara A.
   Abagyan, Ruben
TI Cardiac adverse events associated with chloroquine and
   hydroxychloroquine exposure in 20 years of drug safety surveillance
   reports
SO SCIENTIFIC REPORTS
LA English
DT Article
ID INTERLEUKIN-6
AB Chloroquine (CQ) and hydroxychloroquine (HCQ) are on the World Health Organization's List of Essential Medications for treating non-resistant malaria, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). In addition, both drugs are currently used off-label in hospitals worldwide and in numerous clinical trials for the treatment of SARS-CoV-2 infection. However, CQ and HCQ use has been associated with cardiac side effects, which is of concern due to the higher risk of COVID-19 complications in patients with heart related disorders, and increased mortality associated with COVID-19 cardiac complications. In this study we analyzed over thirteen million adverse event reports form the United States Food and Drug Administration Adverse Event Reporting System to confirm and quantify the association of cardiac side effects of CQ and HCQ. Additionally, we identified several confounding factors, including male sex, NSAID coadministration, advanced age, and prior diagnoses contributing to drug related cardiotoxicity. These findings may help guide therapeutic decision making and ethical trial design for COVID-19 treatment.
C1 [Cohen, Isaac V.] Univ Calif San Francisco, Clin Pharmacol & Therapeut CPT Postdoctoral Train, San Francisco, CA 94143 USA.
   [Makunts, Tigran; Moumedjian, Talar; Issa, Masara A.; Abagyan, Ruben] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA.
   [Makunts, Tigran] US FDA, Oak Ridge Inst Sci & Educ ORISE, Clin Pharmacol & Machine Learning Fellowship, Ctr Drug Evaluat & Res, Silver Spring, MD USA.
RP Abagyan, R (corresponding author), Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA.
EM rabagyan@health.ucsd.edu
OI Makunts, Tigran/0000-0001-5536-1266
CR Al-Bari MAA, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.293
   [Anonymous], 2006, PLAQUENIL
   [Anonymous], 2013, ARALEN
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Barnes BJ, 2020, J EXP MED, V217, DOI 10.1084/jem.20200652
   Basu-Ray I., 2020, STATPEARLS
   Chatre C, 2018, DRUG SAFETY, V41, P919, DOI 10.1007/s40264-018-0689-4
   Chorin E, 2020, QT INTERVAL PATIENTS, V2020, DOI [10.1101/2020.04.02.20047050, DOI 10.1101/2020.04.02.20047050]
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Craigle V., 2007, J MED LIBR ASSOC, V95, P224
   Crowson CS, 2013, AM HEART J, V166, P622, DOI 10.1016/j.ahj.2013.07.010
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Division N, 2020, HHS ACCEPTS DONATION
   Fanelli A, 2017, THER ADV DRUG SAF, V8, P173, DOI 10.1177/2042098617690485
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Inciardi RM, 2020, JAMA CARDIOL, V5, P819, DOI 10.1001/jamacardio.2020.1096
   Irabien-Ortiz Angela, 2020, Rev Esp Cardiol (Engl Ed), V73, P503, DOI 10.1016/j.rec.2020.04.005
   Ittaman SV, 2014, CLIN MED RES, V12, P147, DOI 10.3121/cmr.2013.1197
   Knight JS, 2013, CURR OPIN RHEUMATOL, V25, P597, DOI 10.1097/BOR.0b013e328363eba3
   Long B, 2020, AM J EMERG MED, V38, P1504, DOI 10.1016/j.ajem.2020.04.048
   Makunts T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53622-3
   Makunts T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39335-7
   Makunts T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195521
   R Core Team, 2020, R LANG ENV STAT COMP
   Ripley BJM, 2005, ANN RHEUM DIS, V64, P849, DOI 10.1136/ard.2004.022681
   Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701
   Sarayani Amir, 2021, Res Social Adm Pharm, V17, P483, DOI 10.1016/j.sapharm.2020.04.016
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Simsek Yavuz S, 2020, TURK J MED SCI, V50, P611, DOI 10.3906/sag-2004-145
   Symonds MRE, 2011, BEHAV ECOL SOCIOBIOL, V65, P13, DOI 10.1007/s00265-010-1037-6
   Szumilas M, 2010, J CAN ACAD CHILD ADO, V19, P227
   Tackey E, 2004, LUPUS, V13, P339, DOI 10.1191/0961203304lu1023oa
   Tan WY, 2020, INT J CARDIOL, V309, P70, DOI 10.1016/j.ijcard.2020.03.063
   Varga Z, 2017, CUREUS, V9, DOI 10.7759/cureus.1144
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zeng JH, 2020, INFECTION, V48, P773, DOI 10.1007/s15010-020-01424-5
   Zhai P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105955
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
NR 42
TC 0
Z9 0
U1 1
U2 1
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 5
PY 2020
VL 10
IS 1
AR 19199
DI 10.1038/s41598-020-76258-0
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OO9AZ
UT WOS:000587667000056
PM 33154498
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Vai, B
   Cazzetta, S
   Ghiglino, D
   Parenti, L
   Saibene, G
   Toti, M
   Verga, C
   Wykowska, A
   Benedetti, F
AF Vai, Benedetta
   Cazzetta, Silvia
   Ghiglino, Davide
   Parenti, Lorenzo
   Saibene, Giacomo
   Toti, Michelle
   Verga, Chiara
   Wykowska, Agnieszka
   Benedetti, Francesco
TI Risk Perception and Media in Shaping Protective Behaviors: Insights From
   the Early Phase of COVID-19 Italian Outbreak
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Article
DE COVID-19; risk perception; media; social media; containment measures;
   protective behaviors; vaccine; efficacy
ID METAANALYSIS; COMMUNICATION; MOTIVATION
AB In the absence of target treatments or vaccination, the SARS-CoV-2 pandemic can be impeded by effectively implementing containment measures and behaviors. This relies on individuals' adoption of protective behaviors, their perceived risk, and the use and trust of information sources. During a health emergency, receiving timely and accurate information enables individuals to take appropriate actions to protect themselves, shaping their risk perception. Italy was the first western country plagued by COVID-19 and one of the most affected in the early phase. During this period, we surveyed 2,223 Italians before the national lockdown. A quarter of the sample perceived COVID-19 less threatening than flu and would not vaccinate, if a vaccine was available. Besides, most people perceived containment measures, based on social distancing or wearing masks, not useful. This perceived utility was related to COVID-19 threat perception and efficacy beliefs. All these measures were associated with the use of media and their truthfulness: participants declared to mainly use the Internet, while health organizations' websites were the most trusted. Although social networks were frequently used, they were rated lower for trustfulness. Our data differ from those obtained in other community samples, suggesting the relevance to explore changes across different countries and during the different phases of the pandemic. Understanding these phenomena, and how people access the media, may contribute to improve the efficacy of containment measures, tailoring specific policies and health communications.
C1 [Vai, Benedetta; Cazzetta, Silvia; Benedetti, Francesco] IRCCS San Raffaele Sci Inst, Div Neurosci, Psychiat & Clin Psychobiol, Milan, Italy.
   [Vai, Benedetta; Benedetti, Francesco] Univ Vita Salute San Raffaele, Milan, Italy.
   [Vai, Benedetta] Fdn Ctr San Raffaele, Milan, Italy.
   [Ghiglino, Davide; Parenti, Lorenzo; Wykowska, Agnieszka] Ist Italiano Tecnol, Genoa, Italy.
   [Saibene, Giacomo] Quaestio Capital Sgr Spa, Milan, Italy.
   [Toti, Michelle; Verga, Chiara] Sapienza Univ Rome, Dept Psychol, Rome, Italy.
RP Vai, B (corresponding author), IRCCS San Raffaele Sci Inst, Div Neurosci, Psychiat & Clin Psychobiol, Milan, Italy.; Vai, B (corresponding author), Univ Vita Salute San Raffaele, Milan, Italy.; Vai, B (corresponding author), Fdn Ctr San Raffaele, Milan, Italy.
EM Vai.benedetta@hsr.it
FU European Research Council, under the European Union's Horizon 2020
   research and innovation program, G.A. [ERC-2016-StG-715058]
FX DG's contract at IIT and 50% of the contract of AW were supported by the
   European Research Council, under the European Union's Horizon 2020
   research and innovation program, G.A. number ERC-2016-StG-715058.
   However, this publication is not related to the topic of the
   ERC-2016-StG-715058 grant, and the work related to this publication was
   performed outside of working hours.
CR Betsch C, 2020, NAT HUM BEHAV, DOI 10.1038/s41562-020-0866-1
   Brewer NT, 2007, HEALTH PSYCHOL, V26, P136, DOI 10.1037/0278-6133.26.2.136
   Brug J, 2009, INT J BEHAV MED, V16, P3, DOI 10.1007/s12529-008-9000-x
   COLEMAN CL, 1993, COMMUN RES, V20, P611, DOI 10.1177/009365093020004006
   de Bruin WB, 2020, AM J PREV MED, V59, P157, DOI 10.1016/j.amepre.2020.05.001
   de Zwart O, 2009, INT J BEHAV MED, V16, P30, DOI 10.1007/s12529-008-9008-2
   Dolinski D, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051464
   Dryhurst S, 2020, J RISK RES, V23, P994, DOI 10.1080/13669877.2020.1758193
   Dudo AD, 2007, SCI COMMUN, V28, P429, DOI 10.1177/1075547007302211
   Floyd DL, 2000, J APPL SOC PSYCHOL, V30, P407, DOI 10.1111/j.1559-1816.2000.tb02323.x
   Huynh TLD, 2020, DATA BRIEF, V30, DOI 10.1016/j.dib.2020.105530
   Kim Y, 2018, CENT EUR J PUBL HEAL, V26, P54, DOI 10.21101/cejph.a4920
   Kwok KO, 2020, EMERG INFECT DIS, V26, P1575, DOI 10.3201/eid2607.200500
   LANGER EJ, 1975, J PERS SOC PSYCHOL, V32, P311, DOI 10.1037/0022-3514.32.2.311
   Lin CA, 2013, COMMUN RES REP, V30, P127, DOI 10.1080/08824096.2012.762907
   Maekelae MJ, 2020, ROY SOC OPEN SCI, V7, DOI 10.1098/rsos.200644
   Neuwirth K, 2000, RISK ANAL, V20, P721, DOI 10.1111/0272-4332.205065
   Renner B, 2012, VACCINE, V30, P7019, DOI 10.1016/j.vaccine.2012.09.064
   Reynolds B, 2005, J HEALTH COMMUN, V10, P43, DOI 10.1080/10810730590904571
   Rogers R. W., 1983, SOCIAL PSYCHOPHYSIOL, P153, DOI DOI 10.1093/DEAFED/ENT031
   Sheeran P, 2014, PSYCHOL BULL, V140, P511, DOI 10.1037/a0033065
   Huynh TLD, 2020, SAFETY SCI, V130, DOI 10.1016/j.ssci.2020.104872
   Huynh TLD, 2020, ECON BULL, V40, P758
   Van Bavel JJ, 2020, NAT HUM BEHAV, V4, P460, DOI 10.1038/s41562-020-0884-z
   Walter D, 2012, EUROSURVEILLANCE, V17, P9
   WHO, 2020, COR DIS COVID 19 TEC
   Witte K, 2000, HEALTH EDUC BEHAV, V27, P591, DOI 10.1177/109019810002700506
   World Health Organization (WHO), 2017, COMM RISK PUBL HLTH
NR 28
TC 0
Z9 0
U1 10
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD NOV 5
PY 2020
VL 11
AR 563426
DI 10.3389/fpsyg.2020.563426
PG 8
WC Psychology, Multidisciplinary
SC Psychology
GA OS9CB
UT WOS:000590453500001
PM 33250809
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Murugan, NA
   Kumar, S
   Jeyakanthan, J
   Srivastava, V
AF Murugan, Natarajan Arul
   Kumar, Sanjiv
   Jeyakanthan, Jeyaraman
   Srivastava, Vaibhav
TI Searching for target-specific and multi-targeting organics for Covid-19
   in the Drugbank database with a double scoring approach
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MM-PBSA; DOCKING; ACCURACY; OPTIMIZATION; PERFORMANCE; DESIGN; SINGLE;
   DRUGS
AB The current outbreak of Covid-19 infection due to SARS-CoV-2, a virus from the coronavirus family, has become a major threat to human healthcare. The virus has already infected more than 44 M people and the number of deaths reported has reached more than 1.1 M which may be attributed to lack of medicine. The traditional drug discovery approach involves many years of rigorous research and development and demands for a huge investment which cannot be adopted for the ongoing pandemic infection. Rather we need a swift and cost-effective approach to inhibit and control the viral infection. With the help of computational screening approaches and by choosing appropriate chemical space, it is possible to identify lead drug-like compounds for Covid-19. In this study, we have used the Drugbank database to screen compounds against the most important viral targets namely 3C-like protease (3CLpro), papain-like protease (PLpro), RNA-dependent RNA polymerase (RdRp) and the spike (S) protein. These targets play a major role in the replication/transcription and host cell recognition, therefore, are vital for the viral reproduction and spread of infection. As the structure based computational screening approaches are more reliable, we used the crystal structures for 3C-like main protease and spike protein. For the remaining targets, we used the structures based on homology modeling. Further, we employed two scoring methods based on binding free energies implemented in AutoDock Vina and molecular mechanics-generalized Born surface area approach. Based on these results, we propose drug cocktails active against the three viral targets namely 3CLpro, PLpro and RdRp. Interestingly, one of the identified compounds in this study i.e. Baloxavir marboxil has been under clinical trial for the treatment of Covid-19 infection. In addition, we have identified a few compounds such as Phthalocyanine, Tadalafil, Lonafarnib, Nilotinib, Dihydroergotamine, R-428 which can bind to all three targets simultaneously and can serve as multi-targeting drugs. Our study also included calculation of binding energies for various compounds currently under drug trials. Among these compounds, it is found that Remdesivir binds to targets, 3CLpro and RdRp with high binding affinity. Moreover, Baricitinib and Umifenovir were found to have superior target-specific binding while Darunavir is found to be a potential multi-targeting drug. As far as we know this is the first study where the compounds from the Drugbank database are screened against four vital targets of SARS-CoV-2 and illustrates that the computational screening using a double scoring approach can yield potential drug-like compounds against Covid-19 infection.
C1 [Murugan, Natarajan Arul] KTH Royal Inst Technol, Sch Chem Biotechnol & Hlth, Dept Theoret Chem & Biol, S-10691 Stockholm, Sweden.
   [Kumar, Sanjiv; Srivastava, Vaibhav] KTH Royal Inst Technol, Div Glycosci, Dept Chem, Sch Chem Biotechnol & Hlth, Stockholm, Sweden.
   [Jeyakanthan, Jeyaraman] Alagappa Univ, Dept Bioinformat, Karaikkudi, Tamil Nadu, India.
RP Murugan, NA (corresponding author), KTH Royal Inst Technol, Sch Chem Biotechnol & Hlth, Dept Theoret Chem & Biol, S-10691 Stockholm, Sweden.; Srivastava, V (corresponding author), KTH Royal Inst Technol, Div Glycosci, Dept Chem, Sch Chem Biotechnol & Hlth, Stockholm, Sweden.
EM murugan@kth.se; vasri@kth.se
RI Kumar, Sanjiv/H-3756-2011
OI Kumar, Sanjiv/0000-0003-3514-8999
FU Kungliga Tekniska Hogskolan
FX Open Access funding provided by Kungliga Tekniska Hogskolan.
CR Berman H, 2007, NUCLEIC ACIDS RES, V35, pD301, DOI 10.1093/nar/gkl971
   Bhardwaj VK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1766572
   Blum LC, 2009, J AM CHEM SOC, V131, P8732, DOI 10.1021/ja902302h
   Bogner P, 2006, NATURE, V442, P981, DOI 10.1038/442981a
   Brooijmans N, 2003, ANNU REV BIOPH BIOM, V32, P335, DOI 10.1146/annurev.biophys.32.110601.142532
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Case D., 2016, AMBER 16
   Chandel V., 2020, SILICO IDENTIFICATIO, DOI [10.20944/preprints202003.0349.v1, DOI 10.20944/PREPRINTS202003.0349.V1]
   Clark DE, 2000, DRUG DISCOV TODAY, V5, P49, DOI 10.1016/S1359-6446(99)01451-8
   Contini A., 2020, VIRTUAL SCREENING FD, DOI [10.26434/Chemrxiv.11847381.V1., DOI 10.26434/CHEMRXIV.11847381.V1, 10.26434/chemrxiv.11847381.v1]
   Csermely P, 2005, TRENDS PHARMACOL SCI, V26, P178, DOI 10.1016/j.tips.2005.02.007
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Entzeroth M., 2009, CURR PROTOC PHARM, V44, P9
   Ertl P, 2009, J CHEMINFORMATICS, V1, DOI 10.1186/1758-2946-1-8
   Ettayapuram Ramaprasad A. S., 2020, STRUCTURE BASED VIRT, DOI [10.26434/chemrxiv.12143394.v1, DOI 10.26434/CHEMRXIV.12143394.V1]
   Federhen S, 2012, NUCLEIC ACIDS RES, V40, pD136, DOI 10.1093/nar/gkr1178
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Frisch M. J., 2013, GAUSSIAN 09 REVISION
   Furuta Y, 2013, ANTIVIR RES, V100, P446, DOI 10.1016/j.antiviral.2013.09.015
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gentile D, 2020, MAR DRUGS, V18, DOI 10.3390/md18040225
   Goldhill DH, 2018, P NATL ACAD SCI USA, V115, P11613, DOI 10.1073/pnas.1811345115
   Hajduk PJ, 2007, NAT REV DRUG DISCOV, V6, P211, DOI 10.1038/nrd2220
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Hebner CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039163
   Helmy YA, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041225
   Hou TJ, 2011, J COMPUT CHEM, V32, P866, DOI 10.1002/jcc.21666
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kayitare E, 2009, INT J PHARMACEUT, V370, P41, DOI 10.1016/j.ijpharm.2008.11.005
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI [10.20944/preprints202003.0226.v1, DOI 10.20944/PREPRINTS202003.0226.V1, 10.20944/preprints202003.0226.v1.]
   Lee MR, 2007, J CHEM THEORY COMPUT, V3, P1106, DOI 10.1021/ct6003406
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Liu ZC, 2013, DRUG DISCOV TODAY, V18, P110, DOI 10.1016/j.drudis.2012.08.005
   Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h
   Moulder SL, 2004, CLIN CANCER RES, V10, P7127, DOI 10.1158/1078-0432.CCR-04-0901
   Mullard A, 2020, LANCET, V395, P1245, DOI 10.1016/S0140-6736(20)30894-1
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Murugan NA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1777901
   O'Donnell J, 2019, ANTIMICROB AGENTS CH, V63, DOI 10.1128/AAC.01808-18
   Panda PK, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb8097
   Puhl AC, 2019, DRUG DISCOV TODAY, V24, P1139, DOI 10.1016/j.drudis.2019.03.013
   Rastelli G, 2010, J COMPUT CHEM, V31, P797, DOI 10.1002/jcc.21372
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Rome BN, 2020, NEW ENGL J MED, V382, P2282, DOI 10.1056/NEJMp2009457
   Sadee W, 2011, INT J PHARMACEUT, V415, P2, DOI 10.1016/j.ijpharm.2011.04.048
   Schneider G, 2005, NAT REV DRUG DISCOV, V4, P649, DOI 10.1038/nrd1799
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Sgobba M, 2012, EUR J MED CHEM, V58, P431, DOI 10.1016/j.ejmech.2012.10.024
   Shoichet BK, 2002, CURR OPIN CHEM BIOL, V6, P439, DOI 10.1016/S1367-5931(02)00339-3
   Skorenski M, 2013, CURR PHARM DESIGN, V19, P1126
   Sun HY, 2014, PHYS CHEM CHEM PHYS, V16, P22035, DOI 10.1039/c4cp03179b
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Phan T, 2020, INFECT GENET EVOL, V81, DOI 10.1016/j.meegid.2020.104260
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Welscher YMT, 2008, J BIOL CHEM, V283, P6393, DOI 10.1074/jbc.M707821200
   Wensing Annemarie M, 2019, Top Antivir Med, V27, P111
   Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu J, 2020, NEUROCOMPUTING, V395, P78, DOI [10.1080/17435390.2020.1831639, 10.1016/j.neucom.2020.02.017]
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yoshimura K, 1999, P NATL ACAD SCI USA, V96, P8675, DOI 10.1073/pnas.96.15.8675
   Zhang WL, 2017, J CHEM INF MODEL, V57, P403, DOI 10.1021/acs.jcim.6b00491
   Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035
NR 72
TC 0
Z9 0
U1 2
U2 2
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 5
PY 2020
VL 10
IS 1
AR 19125
DI 10.1038/s41598-020-75762-7
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OO9AR
UT WOS:000587666100021
PM 33154404
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tsai, A
   Diawara, O
   Nahass, RG
   Brunetti, L
AF Tsai, Andrew
   Diawara, Oumou
   Nahass, Ronald G.
   Brunetti, Luigi
TI Impact of tocilizumab administration on mortality in severe COVID-19
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CYTOKINE STORM
AB The novel coronavirus disease 2019 (COVID-19) worldwide pandemic has placed a significant burden on hospitals and healthcare providers. The immune response to this disease is thought to lead to an aberrant inflammatory response or cytokine storm, which contributes to the severity of illness. There is an urgent need to confirm whether the use of tocilizumab provides a benefit in individuals with COVID-19. A single-center propensity-score matched cohort study, including all consecutive COVID-19 patients, admitted to the medical center who were either discharged from the medical center or expired between March 1, 2020, and May 5, 2020, was performed. Patients were stratified according to the receipt of tocilizumab for cytokine storm and matched to controls using propensity scores. The primary outcome was in-hospital mortality. A total of 274 patients meeting inclusion and exclusion criteria were identified and 132 patients were included in the matched dataset (tocilizumab = 66; no tocilizumab = 66). Approximately 73% of the patients were male. Hypertension (55%), diabetes mellitus (31%), and chronic pulmonary disease (15%) were the most common comorbidities present. There were 18 deaths (27.3%) in the tocilizumab group and 18 deaths (27.3%) in the no tocilizumab group (odds ratio, 1.0; 95% confidence interval, 0.465 - 2.151; p = 1.00). Advanced age, history of myocardial infarction, dementia, chronic pulmonary disease, heart failure, and malignancy were significantly more common in patients who died. The current analysis does not support the use of tocilizumab for the management of cytokine storm in patients with COVID-19. Use of this therapeutic agent should be limited to the context of a clinical trial until more evidence is available.
C1 [Tsai, Andrew; Diawara, Oumou; Nahass, Ronald G.; Brunetti, Luigi] Robert Wood Johnson Univ Hosp Somerset, 110 Rehill Ave, Somerville, NJ 08876 USA.
   [Nahass, Ronald G.] IDCare, 105 Raider Blvd, Hillsborough, NJ 08844 USA.
   [Brunetti, Luigi] Rutgers State Univ, Ernest Mario Sch Pharm, 160 Frelinghuysen Rd, Piscataway, NJ 08854 USA.
   [Brunetti, Luigi] Ctr Excellence Pharmaceut Translat Res & Educ, 160 Frelinghuysen Rd, Piscataway, NJ 08854 USA.
RP Brunetti, L (corresponding author), Robert Wood Johnson Univ Hosp Somerset, 110 Rehill Ave, Somerville, NJ 08876 USA.; Brunetti, L (corresponding author), Rutgers State Univ, Ernest Mario Sch Pharm, 160 Frelinghuysen Rd, Piscataway, NJ 08854 USA.; Brunetti, L (corresponding author), Ctr Excellence Pharmaceut Translat Res & Educ, 160 Frelinghuysen Rd, Piscataway, NJ 08854 USA.
EM brunetti@pharmacy.rutgers.edu
CR Bastida C, 2018, BRIT J CLIN PHARMACO, V84, P716, DOI 10.1111/bcp.13500
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Coomes E.A., 2020, INTERLEUKIN6 COVID 1
   Gritti GRF, 2020, USE SILTUXIMAB PATIE
   Guan WJ, 2020, EUR RESP J
   Herold T, 2020, J ALLERGY CLIN IMMUN, V146, P128, DOI 10.1016/j.jaci.2020.05.008
   Kernan KF, 2017, INT IMMUNOL, V29, P401, DOI 10.1093/intimm/dxx031
   Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Murthy H, 2019, IMMUNOTARGETS THER, V8, P43, DOI 10.2147/ITT.S202015
   National Institutes of Health, CORONAVIRUS DIS 2019
   Nikolich-Zugich J, 2020, GEROSCIENCE, V42, P1013, DOI 10.1007/s11357-020-00193-1
   Parodi E, 2020, ROCHE RHEUMATOID ART
   Perrone F., 2020, TOCILIZUMAB PATIENTS, V6, P1
   Richardson S., 2020, JAMA
   Roumier M., 2020, INTERLEUKIN6 BLOCKAD
   Ruan Q, 2020, INTENSIVE CARE MED
   Rubin E.J., 2020, N ENGL J MED
   Schmitz N, 2005, J VIROL, V79, P6441, DOI 10.1128/JVI.79.10.6441-6448.2005
   Tate MD, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-57
   von Elm E, 2007, BMJ-BRIT MED J, V335, P806
   Xu X., 2020, P NATL ACAD SCI US
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Yi Y, 2020, INT J BIOL SCI, V16, P1753, DOI 10.7150/ijbs.45134
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 26
TC 0
Z9 0
U1 1
U2 1
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 5
PY 2020
VL 10
IS 1
AR 19131
DI 10.1038/s41598-020-76187-y
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OO9AR
UT WOS:000587666100027
PM 33154452
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Deshpande, RR
   Tiwari, AP
   Nyayanit, N
   Modak, M
AF Deshpande, Rujuta R.
   Tiwari, Arpita Pandey
   Nyayanit, Narendra
   Modak, Manisha
TI In silico molecular docking analysis for repurposing therapeutics
   against multiple proteins from SARS-CoV-2
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Molecular docking; Drug repurposing; SARS-CoV-2; COVID 19
ID CORONAVIRUS; ERIODICTYOL; ANTIOXIDANT; SPIKE
AB SARS-CoV-2 has devastated the world with its rapid spread and fatality. The researchers across the globe are struggling hard to search a drug to treat this infection. Understanding the time constraint, the best approach is to study clinically approved drugs for control of this deadly pandemic of COVID 19. The repurposing of such drugs can be supported with the study of molecular interactions to enhance the possibility of application. The present work is a molecular docking study of proteins responsible for viral propagation namely 3Clpro, Nsp10/16, Spike protein, SARS protein receptor binding domain, Nsp 9 viral single strand binding protein and viral helicase. The protein through virus enters the host cell-human angiotensin-converting enzyme 2 (ACE2) receptor, is also used as a target for molecular docking. The docking was done with most discussed drugs for SARS-CoV-2 like Ritonavir, Lopinavir, Remdesivir, Chlomquine, Hydroxychlomquine (HCQ), routine antiviral drugs like Oseltamivir and Ribavirin. In addition, small molecules with anti-inflammatory actions like Mycophenolic acid (MPA), Pemirolast, Isoniazid and Eriodictyol were also tested. The generated data confirms the potential of Ritonavir, Lopinavir and Remdesivir as a therapeutic candidate against SARS-CoV-2. It is observed that Eriodictyol binds to almost all selected target proteins with good binding energy, suggesting its importance in treatment of COVID 19. Molecular interactions of Ritonavir, Lopinavir and Remdesivir against SARS-CoV-2 proteins enhanced their potential as a candidate drug for treatment of COVID-19. Eriodictyol had emerged as a new repurposing drug that can be used in COVID-19.
C1 [Deshpande, Rujuta R.] Modern Coll, Dept Zool, PGRC, Pune, Maharashtra, India.
   [Tiwari, Arpita Pandey] DY Patil Educ Soc Inst Deemed Be Univ, Ctr Interdisciplinary Res, Dept Stem Cell & Regenerat Med, Kolhapur, Maharashtra, India.
   [Nyayanit, Narendra; Modak, Manisha] Sir Parashurambhau Coll, Dept Zool, Pune, Maharashtra, India.
RP Tiwari, AP (corresponding author), DY Patil Educ Soc Inst Deemed Be Univ, Ctr Interdisciplinary Res, Dept Stem Cell & Regenerat Med, Kolhapur, Maharashtra, India.; Modak, M (corresponding author), Sir Parashurambhau Coll, Dept Zool, Pune, Maharashtra, India.
EM rujuta.rd@gmail.com; arpitaptiwari@gmail.com; nyayanitnv@yahoo.com;
   manisha_ms@yahoo.com
CR Al-Bari MAA, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.293
   Anand A, 2019, GREEN ENERGY TECHNOL, P293, DOI 10.1007/978-981-13-6887-5_14
   Ashok A, 2020, METAL OXIDES, P247, DOI 10.1016/B978-0-12-813357-6.00012-7
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bown D., 1995, ENCY HERBS THEIR USE
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chauhan N., 2020, OSSIBLE DRUG CANDIDA, DOI [10.26434/chemrxiv.11985231.v1., DOI 10.26434/CHEMRXIV.11985231.V1.]
   Cheng F., 2016, TRENDS MOL MED, DOI [10.1016/j.molmed.2016.09.006., DOI 10.1016/J.MOLMED.2016.09.006.]
   Cheng F., 2019, SILICO ONCOLOGY DRUG
   Cheng FX, 2017, BRIEF BIOINFORM, V18, P682, DOI 10.1093/bib/bbw051
   Decroly E, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002059
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Habtemariam S, 2010, PLANTA MED, V76, P589, DOI 10.1055/s-0029-1240604
   Han D.P., 2006, VIROLOGY, DOI [10.1016/j.virol.2006.01.029, DOI 10.1016/J.VIROL.2006.01.029.]
   Hull MW, 2011, ANN MED, V43, P375, DOI 10.3109/07853890.2011.572905
   Jang KJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61432-1
   Jiang SJ, 2020, PHYS STATUS SOLIDI-R, V14, DOI 10.1002/pssr.202000321
   KEMP JP, 1992, ANN ALLERGY, V68, P488
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI [10.20944/preprints202003.0226.v1, DOI 10.20944/PREPRINTS202003.0226.V1, 10.20944/preprints202003.0226.v1.]
   Kim Y., 2020, CRYSTAL STRUCTURE AD, DOI [10.2210/pdb6VXS/pdb., DOI 10.2210/PDB6VXS/PDB.]
   Lai CC, 2020, J MICROBIOL IMMUNOL, V53, P404, DOI 10.1016/j.jmii.2020.02.012
   Lee JK, 2011, ARCH PHARM RES, V34, P671, DOI 10.1007/s12272-011-0418-3
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li W., 2003, LETT NAT, V426
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Minasov G., 2020, 1 95 ANGSTROM RESOLU, DOI [10.2210/pdb6w75/pdb, DOI 10.2210/PDB6W75/PDB.]
   Rossato MF, 2011, BIOCHEM PHARMACOL, V81, P544, DOI 10.1016/j.bcp.2010.11.004
   Salata C, 2017, EXPERT REV ANTI-INFE, V15, P483, DOI 10.1080/14787210.2017.1305888
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Smith M., 2020, REPURPOSING THERAPEU, DOI 10.26434/chemrxiv.11871402.v3
   Tan K., 2020, CRYSTAL STRUCTURE NS, DOI [10.2210/pdb6W4B/pdb., DOI 10.2210/PDB6W4B/PDB.]
   Tian W, 2018, NUCLEIC ACIDS RES, V46, pW363, DOI 10.1093/nar/gky473
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Velthuis AJWT, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001176
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang Y, 2015, J VIROL, V89, P8416, DOI 10.1128/JVI.00948-15
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xu Z, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109926
   XUE J, 2014, PLOS ONE, V9, P1, DOI DOI 10.1371/JOURNAL.PONE.0109180.
   Yan R.H., 2020, ACE2 B0AT1 COMPLEX, DOI [10.2210/pdb6M18/pdb, DOI 10.2210/PDB6M18/PDB.]
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang WY, 2012, J AGR FOOD CHEM, V60, P7652, DOI 10.1021/jf300601z
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhu GF, 2015, EXP THER MED, V10, P2259, DOI 10.3892/etm.2015.2827
NR 48
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD NOV 5
PY 2020
VL 886
AR 173430
DI 10.1016/j.ejphar.2020.173430
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OE6JJ
UT WOS:000580634600010
PM 32758569
OA Green Published
DA 2021-01-01
ER

PT J
AU Khan, S
   Tombuloglu, H
   Hassanein, SE
   Rehman, S
   Bozkurt, A
   Cevik, E
   Abdel-Ghany, S
   Nabi, G
   Ali, A
   Sabit, H
AF Khan, Suliman
   Tombuloglu, Huseyin
   Hassanein, Sameh E.
   Rehman, Suriya
   Bozkurt, Ayhan
   Cevik, Emre
   Abdel-Ghany, Shaimaa
   Nabi, Ghulam
   Ali, Ashaq
   Sabit, Hussein
TI Coronavirus diseases 2019: Current biological situation and potential
   therapeutic perspective
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE COVID-19; Coronavirus; SARS-CoV-2; Treatment; Pathogenicity; Mortality
ID ELECTROCHEMICAL IMMUNOSENSOR; OUTBREAK; COVID-19
AB Coronavirus Disease 2019 (COVID-19) caused by a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) was first reported in Wuhan, China at the end of December 2019. SARS-CoV-2 is a highly pathogenic zoonotic virus and closely related to the Severe Acute Respiratory Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The COVID-19 was declared as a global pandemic due to its high infectiousness, and worldwide morbidities and mortalities. The Chinese scientists at the start of the outbreak reported genome sequences, which made the characterization of glycoproteins and other structural proteins possible. Moreover, researchers across the world have widely focused on understanding basic biology, developing vaccines, and therapeutic drugs against the COVID-19. However, until now, no promising treatment options, as well as vaccines, are available. In this review, we have described SARS-CoV-2's genome, transmission, and pathogenicity. We also discussed novel potential therapeutic agents that can help to treat the COVID-19 patients.
C1 [Khan, Suliman] Zhengzhou Univ, Dept Cerebrovasc Dis, Affiliated Hosp 2, Zhengzhou, Peoples R China.
   [Tombuloglu, Huseyin; Cevik, Emre; Sabit, Hussein] Imam Abdulrahman Bin Faisal Univ, Inst Res & Med Consultat IRMC, Dept Genet, POB 1982, Dammam 31441, Saudi Arabia.
   [Hassanein, Sameh E.] Misr Univ Sci & Technol, Coll Biotechnol, Agr Genet Engn Res Inst AGERI, Bioinformat Dept,Bioinformat & Funct Genom Dept, POB 77, Giza, Egypt.
   [Rehman, Suriya] Imam Abdulrahman Bin Faisal Univ, Inst Res & Med Consultat IRMC, Dept Epidem Dis Res, Dammam 31441, Saudi Arabia.
   [Bozkurt, Ayhan] Imam Abdulrahman Bin Faisal Univ, Inst Med Res & Consultat, Dept Phys, POB 1982, Dammam 31441, Saudi Arabia.
   [Abdel-Ghany, Shaimaa] Misr Univ Sci & Technol, Coll Biotechnol, Dept Environm Biotechnol, POB 77, Giza, Egypt.
   [Nabi, Ghulam] Hebei Normal Univ, Coll Life Sci, Key Lab Anim Physiol Biochem & Mol Biol Hebei Pro, Shijiazhuang 050024, Hebei, Peoples R China.
   [Ali, Ashaq] Chinese Acad Sci, Wuhan Inst Virol, Xiao Hong Shan 44, Wuhan, Peoples R China.
   [Ali, Ashaq] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
RP Sabit, H (corresponding author), Imam Abdulrahman Bin Faisal Univ, Inst Res & Med Consultat IRMC, Dept Genet, POB 1982, Dammam 31441, Saudi Arabia.
EM hhsabit@iau.edu.sa
RI ; Hassanein, Sameh/B-7223-2015
OI Khan, Suliman/0000-0003-4954-0748; Hassanein, Sameh/0000-0001-8997-719X
FU Second Affiliated Hospital of Zhengzhou University; Chinese Postdoctoral
   Science FoundationChina Postdoctoral Science Foundation [2020M672291]
FX The authors acknowledge the postdoctoral research grant from the Second
   Affiliated Hospital of Zhengzhou University and postdoctoral research
   grant from the Chinese Postdoctoral Science Foundation (Grant Number:
   2020M672291) for SK.
CR Allocati N., BATMAN DIS TRANSMISS
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Bloomgarden ZT, 2020, J DIABETES, V12, P347, DOI 10.1111/1753-0407.13027
   Brielle E.S., 2020, BIORXIV, DOI [10.1101/03.10.986398, DOI 10.1101/03.10.986398]
   Cardenas-Conejo Y, 2020, J MED VIROL, V92, P688, DOI 10.1002/jmv.25758
   Chan J.F., INTERSPECIES TRANSMI
   Chand K, 2020, ARAB J CHEM, V13, P8248, DOI [10.1142/S0192415X20500378, 10.1016/j.arabjc.2020.01.009]
   Chen C, 2020, Zhonghua Xin Xue Guan Bing Za Zhi, V48, P567, DOI 10.3760/cma.j.cn112148-20200225-00123
   Chen L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE005, DOI [10.3760/cma.j.issn.1001-0939.2020.03.013, 10.3760/cma.j.issn.1001-0939.2020.0005]
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Cui J, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-304
   Di Pierro F, 2020, MINERVA GASTROENTERO, V66, P172, DOI 10.23736/S1121-421X.20.02697-5
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   FRISKHOLMBERG M, 1983, BRIT J CLIN PHARMACO, V15, P502, DOI 10.1111/j.1365-2125.1983.tb01540.x
   Gorbalenya A.E., 2020, BIORXIV, DOI [10.1101/02.07'037862, DOI 10.1101/02.07'037862]
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Han JH, 2016, SENSOR ACTUAT B-CHEM, V228, P36, DOI 10.1016/j.snb.2015.07.068
   Han YL, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01900
   Huang HY, 2015, BIOSENS BIOELECTRON, V68, P442, DOI 10.1016/j.bios.2015.01.039
   Ibrahim Hiba Siddig, 2020, Methods Mol Biol, V2131, P39, DOI 10.1007/978-1-0716-0389-5_4
   Khan S, 2020, SAUDI PHARM J, V28, P1004, DOI 10.1016/j.jsps.2020.06.022
   Khan S, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00310
   Khan S, 2020, J CLIN MICROBIOL, V58, DOI [10.1128/JCM.01297-20, 10.1128/JCM.00187-20]
   Kim D., 2020, BIORXIV, DOI [10.1101/03.12.988865, DOI 10.1101/03.12.988865]
   Layqah LA, 2019, MICROCHIM ACTA, V186, DOI 10.1007/s00604-019-3345-5
   Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9
   Li H, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE002, DOI 10.3760/cma.j.issn.1001-0939.2020.0002
   Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757
   Li XC, 2017, PHARMACOL RES, V125, P21, DOI 10.1016/j.phrs.2017.06.005
   Li Y X, 2020, Zhonghua Nei Ke Za Zhi, V59, pE003, DOI 3760.10/cma.j.cn112138-20200221-00114
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lin JJ, 2019, P NATL ACAD SCI USA, V116, P19009, DOI 10.1073/pnas.1907626116
   Liu F., 2020, HIGHLY ACE2 EXPRESSI, DOI [10.1101/02.28.20029181, DOI 10.1101/02.28.20029181]
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lucia C., 2020, BIORXIV
   Lv L., 2020, BIORXIV
   Matsuyama S., 2020, BIORXIV, DOI [10.1101/03.11.987016, DOI 10.1101/03.11.987016]
   Meng L, 2020, J DENT RES, V99, P481, DOI 10.1177/0022034520914246
   Patel A, 2020, MMWR-MORBID MORTAL W, V69, P140, DOI 10.15585/mmwr.mm6905e1
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Shi Y., 2020, IMMUNOPATHOLOGICAL C, DOI [10.1101/03.12.20034736, DOI 10.1101/03.12.20034736]
   Shuvra MA, 2019, 2019 IEEE 16TH INTERNATIONAL CONFERENCE ON SMART CITIES: IMPROVING QUALITY OF LIFE USING ICT, IOT AND AI (IEEE HONET-ICT 2019), P100
   Singh R, 2017, SCI REP-UK, V7, DOI 10.1038/srep42771
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   Sun M L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P219, DOI [10.3760/cma.j.issn.1001-0939.2020.0014, 10.3760/cma.j.issn.1001-0939.2020.03.016]
   Wang M., 2020, NANOPORE TARGET SEQU
   World Health Organization, 2020, LAB TEST 2019 NOV CO
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xia Y, 2020, LANCET ONCOL, V21, pE180, DOI 10.1016/S1470-2045(20)30150-9
   Xu B, 2020, LANCET INFECT DIS, V20, P534, DOI 10.1016/S1473-3099(20)30119-5
   Xu Y, 2019, ZHONGGUO FEI AI ZA Z, V2020, P23
   Yang L., 2020, ZHONGHUA ZHONG LIU Z, V42, pE006
   Yang W., 2020, RAPID DETECTION SARS, DOI [10.1101/03.02.20030130, DOI 10.1101/03.02.20030130]
   Zaman W, 2020, PHYTOTHER RES, V34, P2783, DOI 10.1002/ptr.6787
   Zhang B, 2020, IMMUNE PHENOTYPING B, V7, P157, DOI [10.1101/2020.03.12.20035048, DOI 10.1101/2020.03.12.20035048]
   Zhang Jin-Jin, 2020, ALLERGY
   Zhang L., 2020, GENOMIC VARIATIONS S
   Zhao J., 2020, RELATIONSHIP ABO BLO, DOI [10.1101/03.11.20031096, DOI 10.1101/03.11.20031096]
   Zhou L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P167, DOI 10.3760/cma.j.issn.1001-0939.2020.03.003
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhuang QY, 2020, TRANSBOUND EMERG DIS, V67, P1981, DOI 10.1111/tbed.13541
NR 63
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD NOV 5
PY 2020
VL 886
AR 173447
DI 10.1016/j.ejphar.2020.173447
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OE6JJ
UT WOS:000580634600014
PM 32763302
OA Green Published
DA 2021-01-01
ER

PT J
AU Lopachev, AV
   Kazanskaya, RB
   Khutorova, AV
   Fedorova, TN
AF Lopachev, Alexander, V
   Kazanskaya, Rogneda B.
   Khutorova, Anastasiya, V
   Fedorova, Tatiana N.
TI An overview of the pathogenic mechanisms involved in severe cases of
   COVID-19 infection, and the proposal of salicyl-carnosine as a potential
   drug for its treatment
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE COVID-19; Salicyl-carnosine; Inflammation; Oxidative stress; Thrombosis;
   Aspirin
ID OXIDATIVE STRESS; NITRIC-OXIDE; ASPIRIN
AB Multiple organ failure in COVID-19 patients is a serious problem which can result in a fatal outcome. Damage to organs and tissues, including general lung dysfunction, develops as a consequence of ischemia, which, in turn, is caused by thrombosis in small blood vessels and hypoxia, leading to oxidative stress and inflammation. Currently, research is underway to screen existing drugs for antioxidant, antiplatelet and anti-inflammatory properties. Having studied the available publications concerning the mechanisms of damage to tissues and organs of patients with COVID-19, as well as the available treatment strategies, we propose to investigate salicyl-carnosine as a potential drug for treating COVID-19 patients. In a recent study, we described the drug's synthesis procedure, and showed that salicyl-carnosine possesses antioxidant, anti-inflammatory, and antiplatelet effects. Therefore, it can simultaneously act on the three pathogenetic factors involved in tissue and organ damage in COVID-19. Thus, we propose to consider salicyl-carnosine as a potential drug for the treatment of patients with severe cases of COVID-19 infection.
C1 [Lopachev, Alexander, V; Fedorova, Tatiana N.] Res Ctr Neurol, Volokolamskoye Shosse 80, Moscow 125367, Russia.
   [Kazanskaya, Rogneda B.] St Petersburg State Univ, Biol Dept, Univ Skaya Emb 7-9, St Petersburg 199034, Russia.
   [Khutorova, Anastasiya, V] Lomonosov Moscow State Univ, Biol Dept, Leninskiye Gory 1, Moscow 119991, Russia.
RP Lopachev, AV (corresponding author), Res Ctr Neurol, Volokolamskoye Shosse 80, Moscow 125367, Russia.
EM lopachev@neurology.ru
CR Adam F, 2016, BLOOD, V127, P908, DOI 10.1182/blood-2014-05-578781
   Berezhnoy DS, 2019, AMINO ACIDS, V51, P139, DOI 10.1007/s00726-018-2667-7
   Boldyrev AA, 2013, PHYSIOL REV, V93, P1803, DOI 10.1152/physrev.00039.2012
   Buinitskaya Y.G., 2020, HIGHLIGHTS COVID 19
   Carr AC, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02851-4
   Cattaneo M, 2020, THROMB HAEMOSTASIS, V120, P1230, DOI 10.1055/s-0040-1712097
   Cavezzi A, 2020, CLINICS PRACT, V10, P24, DOI 10.4081/cp.2020.1271
   Colafrancesco S, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102573
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Delgado-Roche L, 2020, ARCH MED RES, V51, P384, DOI 10.1016/j.arcmed.2020.04.019
   Dinis-Oliveira RJ, 2007, FREE RADICAL BIO MED, V42, P1017, DOI 10.1016/j.freeradbiomed.2006.12.031
   Duprez DA, 2004, J HYPERTENS, V22, P1085, DOI 10.1097/00004872-200406000-00005
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Fiolaki A, 2017, J NEUROL SCI, V376, P112, DOI 10.1016/j.jns.2017.03.010
   Forstermann U, 2010, PFLUG ARCH EUR J PHY, V459, P923, DOI 10.1007/s00424-010-0808-2
   Gavillet M, 2020, ULTRASOUND OBST GYN, V55, P843, DOI 10.1002/uog.22063
   Geier MR, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109760
   Konig MF, 2020, J CLIN INVEST, V130, P3345, DOI 10.1172/JCI139642
   Kouhpayeh S., 2020, MOL STORY COVID 19 N, DOI [10.20944/preprints202003.0346.v1, DOI 10.20944/PREPRINTS202003.0346.V1]
   Kulikova OI, 2020, DARU, V28, P119, DOI 10.1007/s40199-019-00323-x
   Kwiatkowski S., 2020, ULTRASOUND OBST GYN, DOI [10.1002/uog.22063, DOI 10.1002/UOG.22063]
   Li SR, 2020, EUR J CLIN MICROBIOL, V39, P1021, DOI 10.1007/s10096-020-03883-y
   Lippi G, 2020, HEMATOL TRANSF CELL, V42, P116, DOI 10.1016/j.htct.2020.03.001
   Liu w., 2020, COVID 19 ATTACKS 1 B, pv7, DOI [10.26434/chemrxiv.11938173, DOI 10.26434/CHEMRXIV.11938173]
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   MASTROIANNI F, 2020, INTENS CARE MED, DOI DOI 10.1007/S00134-020-06059-6
   Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222
   McKee DL, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104859
   Mittal M, 2014, ANTIOXID REDOX SIGN, V20, P1126, DOI 10.1089/ars.2012.5149
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   NEEDS CJ, 1985, CLIN PHARMACOKINET, V10, P164, DOI 10.2165/00003088-198510020-00004
   Okabe S, 2005, BIOL PHARM BULL, V28, P1321, DOI 10.1248/bpb.28.1321
   Otani H, 2009, ANTIOXID REDOX SIGN, V11, P1913, DOI [10.1089/ars.2009.2453, 10.1089/ARS.2009.2453]
   Prokopieva VD, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2939087
   Sahni S, 2018, NITRIC OXIDE-BIOL CH, V76, P37, DOI 10.1016/j.niox.2018.03.003
   Sinha Neeraj, 2020, Postgrad Med J, V96, P550, DOI 10.1136/postgradmedj-2020-137785
   Sinha P, 2020, LANCET RESP MED, V8, P247, DOI 10.1016/S2213-2600(19)30369-8
   Soliz J, 2020, RESP PHYSIOL NEUROBI, V279, DOI 10.1016/j.resp.2020.103476
   South AM, 2020, NAT REV NEPHROL, V16, P305, DOI 10.1038/s41581-020-0279-4
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   van Hecke O., 2020, CTR EVIDENCE BASED M
   VANGIJN J, 1993, STROKE, V24, P476, DOI 10.1161/01.STR.24.3.476
   Venereau E, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00422
   Verdecchia P, 2020, EUR J INTERN MED, V76, P14, DOI 10.1016/j.ejim.2020.04.037
   Violi F, 2020, THROMB HAEMOSTASIS, V120, P949, DOI 10.1055/s-0040-1710317
   Wang JZ, 2020, INT J CARDIOL, V312, P137, DOI 10.1016/j.ijcard.2020.04.009
   WOLOS A, 1975, INT J BIOCHEM, V6, P723, DOI 10.1016/0020-711X(75)90123-8
   Xia Xiao, 2015, 2015 Asia-Pacific Microwave Conference (APMC). Proceedings, DOI 10.1109/APMC.2015.7413085
   Xu PY, 2020, ANN HEMATOL, V99, P1205, DOI 10.1007/s00277-020-04019-0
   Xu T, 2015, J GEN VIROL, V96, P2939, DOI 10.1099/jgv.0.000238
   Yang D, 2007, EXP EYE RES, V85, P462, DOI 10.1016/j.exer.2007.06.013
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Zaim S, 2020, CURR PROB CARDIOLOGY, V45, DOI 10.1016/j.cpcardiol.2020.100618
NR 53
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD NOV 5
PY 2020
VL 886
AR 173457
DI 10.1016/j.ejphar.2020.173457
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OE6JJ
UT WOS:000580634600020
PM 32750366
OA Green Published
DA 2021-01-01
ER

PT J
AU Monpara, JD
   Sodha, SJ
   Gupta, PK
AF Monpara, Jasmin D.
   Sodha, Srushti J.
   Gupta, Pardeep K.
TI COVID-19 associated complications and potential therapeutic targets
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE COVID-19; SARS-Cov-2; Pathophysiology; Pharmacotherapy; Clinical trials
ID ENTRY; SARS-COV-2; MANAGEMENT; SEPSIS; SARS
AB The global pandemic COVID-19, caused by novel coronavirus SARS-CoV-2, has emerged as severe public health issue crippling world health care systems. Substantial knowledge has been generated about the pathophysiology of the disease and possible treatment modalities in a relatively short span of time. As of August 19, 2020, there is no approved drug for the treatment of COVID-19. More than 600 clinical trials for potential therapeutics are underway and the results are expected soon. Based on early experience, different treatment such as anti-viral drugs (remdesivir, favipiravir, lopinavir/ritonavir), corticostemids (methylprednisolone, dexamethasone) or convalescent plasma therapy are recommended in addition to supportive care and symptomatic therapy. There are several treatments currently being investigated to address the pathological conditions associated with COVID-19. This review provides currently available information and insight into pathophysiology of the disease, potential targets, and relevant clinical trials for COVID-19.
C1 [Monpara, Jasmin D.; Sodha, Srushti J.; Gupta, Pardeep K.] Univ Sci, 600 South 43rd St, Philadelphia, PA 19104 USA.
RP Monpara, JD (corresponding author), Univ Sci, Philadelphia Coll Pharm, Dept Pharmaceut Sci, 600 South 43rd St, Philadelphia, PA 19104 USA.
EM jmonpara@usciences.edu
OI Reis, AlessanRSS/0000-0001-8486-7469
CR Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x
   Anjaneyulu M, 2004, CLIN EXP PHARMACOL P, V31, P244, DOI 10.1111/j.1440-1681.2004.03982.x
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Armstrong SM, 2013, ANTIVIR RES, V99, P113, DOI 10.1016/j.antiviral.2013.05.003
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Barrett CD, 2020, J THROMB HAEMOST, V18, P2060, DOI 10.1111/jth.14860
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bittmann S., 2020, J REGEN BIOL MED, V2, P1, DOI [10.37191/Mapsci-2582-385X-2(2)-022, DOI 10.37191/MAPSCI-2582-385X-2(2)-022]
   Blaising J, 2013, ANTIVIR RES, V100, P215, DOI 10.1016/j.antiviral.2013.08.008
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Cao YC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101647
   Cascella M, 2020, STATPEARLS
   Casey K, 2020, AM J EMERG MED, V38, DOI 10.1016/j.ajem.2020.04.011
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Chen C, 2020, FAVIPIRAVIR VERSUS A
   Chen R., 2020, OUTCOMES HYPERBARIC
   Cheng H, 2020, J MED VIROL, V92, P726, DOI [10.1002/jmv.25785, 10.2112/JCR-SI112-001.1]
   Connors JM, 2020, J THROMB HAEMOST, V18, P1559, DOI 10.1111/jth.14849
   Couzin-Frankel J, 2020, SCIENCE, V368, P455, DOI 10.1126/science.368.6490.455
   D'Ardes D, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21083003
   Danilczyk U, 2006, CIRC RES, V98, P463, DOI 10.1161/01.RES.0000205761.22353.5f
   Dinsmore WW, 2008, BJU INT, V102, P933, DOI 10.1111/j.1464-410X.2008.07764.x
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Du YX, 2020, CLIN PHARMACOL THER, V108, P242, DOI 10.1002/cpt.1844
   Ebadi M, 2020, EUR J CLIN NUTR, V74, P856, DOI 10.1038/s41430-020-0661-0
   Erickson T B, 2020, Toxicol Commun, V4, P40, DOI 10.1080/24734306.2020.1757967
   Erol A., 2020, ORTHOMOLECULAR MED N
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009
   Giannis D, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104362
   Grant M.C., 2020, PLOS ONE, V15, DOI [10.1371/journal.pone.0231765., DOI 10.1371/JOURNAL.PONE.0231765]
   Grant WB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040988
   Guo JY, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016219
   Gupta D, 2020, BRAZ J INFECT DIS, V24, P369, DOI 10.1016/j.bjid.2020.06.002
   Hamdi H., 2020, HUMAN COVID 19 TANGO, DOI [10.20944/preprints202004.0160.v2., DOI 10.20944/PREPRINTS202004.0160.V2]
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00754-20
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Ignarro LJ, 2020, BRIT J PHARMACOL, V177, P3848, DOI 10.1111/bph.15085
   Jordan RE, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1198
   Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2
   Juurlink DN, 2020, CAN MED ASSOC J, V192, pE450, DOI 10.1503/cmaj.200528
   Kalil AC, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2539-x
   Krotz F, 2004, ARTERIOSCL THROM VAS, V24, P1988, DOI 10.1161/01.ATV.0000145574.90840.7d
   LABUDZYNSKYI D, 2016, DIABETES, V37, P22
   Lang Min, 2020, Lancet Infect Dis, V20, P1365, DOI 10.1016/S1473-3099(20)30367-4
   Lenzer J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1335
   Li H, 2020, LANCET, V395, P1517, DOI 10.1016/S0140-6736(20)30920-X
   Li TH, 2020, EMERG MICROBES INFEC, V9, P687, DOI 10.1080/22221751.2020.1741327
   Lillicrap D, 2020, J THROMB HAEMOST, V18, P786, DOI 10.1111/jth.14781
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005
   Liu PP, 2020, CIRCULATION, V142, P68, DOI 10.1161/CIRCULATIONAHA.120.047549
   Liu Y., 2020, INT J LIGHTWEIGHT MA, V3, P20, DOI DOI 10.1016/J
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344
   Luks Andrew M, 2020, Ann Am Thorac Soc, DOI 10.1513/AnnalsATS.202004-327FR
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   MAHASE E, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M2378
   Mahevas M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1844
   MARTINEAU AR, 2017, BMJ-BRIT MED J, V356, DOI DOI 10.1136/BMJ.I6583
   McCartney D M, 2020, Ir Med J, V113, P58
   McGonagle D, 2020, LANCET RHEUMATOL, V2, pE437, DOI 10.1016/S2665-9913(20)30121-1
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Mehta N, 2020, AM J EMERG MED, V38, P1488, DOI [10.1016/j.ajem.2020.03.011, 10.1016/j.ajem.2020.04.035]
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   Monpara J, 2019, DRUG DELIV TRANSL RE, V9, P106, DOI 10.1007/s13346-018-0571-z
   Moore N, 2020, DRUG SAFETY, V43, P393, DOI 10.1007/s40264-020-00933-4
   National Institute of Health, 2020, COR DIS 2019 COVID 1
   Oldfield V, 2006, DRUGS, V66, P1275, DOI 10.2165/00003495-200666090-00012
   Oudkerk M, 2020, RADIOLOGY, V297, pE216, DOI 10.1148/radiol.2020201629
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Paliani U, 2020, EUR J INTERN MED, V78, P1, DOI 10.1016/j.ejim.2020.06.002
   Park Sungha, 2020, Clin Hypertens, V26, P11, DOI 10.1186/s40885-020-00144-0
   Petrosillo N, 2020, CLIN MICROBIOL INFEC, V26, P729, DOI 10.1016/j.cmi.2020.03.026
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Remy KE, 2020, LANCET RESP MED, V8, P946, DOI 10.1016/S2213-2600(20)30217-4
   Scheim D., 2020, IVERMECTIN COVID 19
   Schmith VD, 2020, CLIN PHARMACOL THER, V108, P762, DOI 10.1002/cpt.1889
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Singh J, 2012, J NANOBIOTECHNOL, V10, DOI 10.1186/1477-3155-10-7
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   South AM, 2020, NAT REV NEPHROL, V16, P305, DOI 10.1038/s41581-020-0279-4
   Spearow J.L., 2020, REV IMPROVING THERAP, DOI [10.31219/osf.io/y7wc2, DOI 10.31219/OSF.IO/Y7WC2]
   Sriram K, 2020, BRIT J PHARMACOL, V177, P4825, DOI 10.1111/bph.15082
   Takashita Emi, 2020, Cold Spring Harb Perspect Med, DOI 10.1101/cshperspect.a038687
   Tan WY, 2020, INT J CARDIOL, V309, P70, DOI 10.1016/j.ijcard.2020.03.063
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   TOLOUIAN R, 2020, J RENAL INJ PREV, V9, pe19, DOI DOI 10.34172/JRIP.2020.19
   Valencia DN, 2020, CUREUS, V12, DOI 10.7759/cureus.7386
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Venkatasubbaiah Meda, 2020, Curr Med Res Pract, V10, P100, DOI 10.1016/j.cmrp.2020.05.013
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Vogelstein J. T., 2020, ALPHA 1 ADRENERGIC R
   Wang HL, 2008, CELL RES, V18, P290, DOI 10.1038/cr.2008.15
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wang Y, 2020, SCI CHINA MATH, DOI 10.1007/s11425-019-1667-5
   WHO, 2020, WHO DISC HYDR LOP RI
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   World Health Organization, 2020, WEEKL EP UPD 1
   Xie J, 2020, MAYO CLIN PROC, V95, P1138, DOI 10.1016/j.mayocp.2020.04.006
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yang ND, 2020, INT J BIOL SCI, V16, P1724, DOI 10.7150/ijbs.45498
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Zaim S, 2020, CURR PROB CARDIOLOGY, V45, DOI 10.1016/j.cpcardiol.2020.100618
   Zanoni I, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01661
   Zeitouni Nathalie E, 2016, Mol Cell Pediatr, V3, P14, DOI 10.1186/s40348-016-0041-y
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu Y., 2020, EFFICACY SAFETY REMD
   Zhu Z, 2020, J INFECTION, V81, pE21, DOI 10.1016/j.jinf.2020.03.060
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
NR 121
TC 0
Z9 0
U1 7
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD NOV 5
PY 2020
VL 886
AR 173548
DI 10.1016/j.ejphar.2020.173548
PG 16
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OE6JJ
UT WOS:000580634600036
PM 32926918
OA Green Published
DA 2021-01-01
ER

PT J
AU Paniri, A
   Hosseini, MM
   Rasoulinejad, A
   Akhavan-Niaki, H
AF Paniri, Alireza
   Hosseini, Mohammad Mahdi
   Rasoulinejad, Ahmad
   Akhavan-Niaki, Haleh
TI Molecular effects and retinopathy induced by hydroxychloroquine during
   SARS-CoV-2 therapy: Role of CYP450 isoforms and epigenetic modulations
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Hydroxychloroquine; SARS-CoV-2; Cytochrome P450 (CYP); Pharmacogenetics;
   Epigenetics; Retinopathy
ID RETINAL-PIGMENT EPITHELIUM; POLYPEPTIDE 1A2 OATP1A2;
   RHEUMATOID-ARTHRITIS; ANTIMALARIAL-DRUGS; CHLOROQUINE; EXPRESSION;
   METABOLISM; PHARMACOKINETICS; AUTOPHAGY; CYP2D6
AB Antimalaria drugs such as chloroquine (CQ) and hydroxychloroquine (HCQ) have been administered to several inflammatory diseases including rheumatoid arthritis and systemic lupus erythematosus, and infectious diseases such as acquired immune deficiency syndrome and influenza. Recently, several patients infected with novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were given HCQ, and showed a discrepant response. HCQ inhibits SARS-CoV-2 cell entry, and inflammatory cascade by interfering with lysosomal and endosomal activities, and autophagy, impeding virus-membrane fusion, and inhibiting cytokine production resulted from inflammatory pathways activation. Despite ongoing administration of HCQ in a wide spectrum of disorders, there are some reports about several side effects, especially retinopathy in some patients treated with HCQ. Cytochrome P450 (CYP450) and its isoforms are the main metabolizers of HCQ and CQ. Pharmacokinetic properties of CYP enzymes are influenced by CYP polymorphism, non-coding RNAs, and epigenetic mechanisms such as DNA methylation, and histone acetylation. Accumulating evidence about side effects of HCQ in some patients raise the possibility that different response of patients to HCQ might be due to difference in their genome. Therefore, CYP450 genotyping especially for CYP2D6 might be helpful to refine HCQ dosage. Also, regular control of retina should be considered for patients under HCQ treatment. The major focus of the present review is to discuss about the pharmacokinetic and pharmacodynamic properties of CQ and HCQ that may be influenced by epigenetic mechanisms, and consequently cause several side effects especially retinopathy during SARS-CoV-2 therapy.
C1 [Paniri, Alireza; Hosseini, Mohammad Mahdi] Babol Univ Med Sci, Student Res Comm, Babol, Iran.
   [Paniri, Alireza; Akhavan-Niaki, Haleh] Babol Univ Med Sci, Fac Med, Genet Dept, Babol, Iran.
   [Rasoulinejad, Ahmad] Babol Univ Med Sci, Rouhani Hosp, Dept Ophthalmol, Babol, Iran.
   [Akhavan-Niaki, Haleh] Pasteur Inst Iran, Zoonoses Res Ctr, Amol, Iran.
RP Akhavan-Niaki, H (corresponding author), Babol Univ Med Sci, Fac Med, Genet Dept, Babol, Iran.; Rasoulinejad, A (corresponding author), Babol Univ Med Sci, Rouhani Hosp, Dept Ophthalmol, Babol, Iran.
EM rasolisa2@gmail.com; halehakhavan@yahoo.com
CR Ali SS, 2018, RHEUMATOLOGY ADV S1, V2, prky033, DOI [10.1093/rap/rky033.014., DOI 10.1093/RAP/RKY033.014, 10.1093/rap/rky033.014]
   An J., 2016, ARTHRITIS RHEUM S10, V68
   An J, 2018, ARTHRITIS RHEUMATOL, V70, P1807, DOI 10.1002/art.40559
   An J, 2015, J IMMUNOL, V194, P4089, DOI 10.4049/jimmunol.1402793
   [Anonymous], 2020, NEWSWEEK
   AUGUSTIJNS P, 1992, EUR J CLIN PHARMACOL, V42, P429
   Bannwarth B, 1996, CLIN PHARMACOKINET, V30, P194, DOI 10.2165/00003088-199630030-00002
   Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x
   BOK D, 1993, J CELL SCI, P189
   Browning D.J., 2014, HYDROXYCHLOROQUINE C, P65
   Chan T, 2015, BRIT J PHARMACOL, V172, P2343, DOI 10.1111/bph.13060
   Chen H, 2009, INVEST OPHTH VIS SCI, V50, P1895, DOI 10.1167/iovs.08-2850
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Chen X, 2020, CHINA PERSPECT-SER, P1
   Chiang G, 1996, CLIN THER, V18, P1080, DOI 10.1016/S0149-2918(96)80063-4
   Collins KP, 2018, J PHARMACOL EXP THER, V365, P447, DOI 10.1124/jpet.117.245639
   Cook KL, 2014, CLIN CANCER RES, V20, P3222, DOI 10.1158/1078-0432.CCR-13-3227
   Cutler D J, 1988, Agents Actions Suppl, V24, P142
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   Dannenberg LO, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-181
   Ding HJ, 2016, RHEUMATOLOGY, V55, P957, DOI 10.1093/rheumatology/kev357
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   FINBLOOM DS, 1985, J RHEUMATOL, V12, P692
   Fox R, 1996, LUPUS, V5, pS4, DOI 10.1177/096120339600500103
   Furst DE, 1996, LUPUS, V5, pS11, DOI 10.1177/096120339600500104
   Gao Y, 2020, J MED VIROL, V92, P791, DOI 10.1002/jmv.25770
   Garway-Heath DF, 2000, OPHTHALMOLOGY, V107, P1809, DOI 10.1016/S0161-6420(00)00284-0
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Herold T, 2020, LEVEL IL 6 PREDICTS
   Ireland JM, 2011, J EXP MED, V208, P2625, DOI 10.1084/jem.20110640
   Jilek JL, 2017, DRUG METAB DISPOS, V45, P512, DOI 10.1124/dmd.116.074344
   Jin YQ, 2016, BIOCHEM PHARMACOL, V113, P88, DOI 10.1016/j.bcp.2016.06.007
   Joyce E, 2013, EUR HEART J-ACUTE CA, V2, P77, DOI 10.1177/2048872612471215
   Kalliokoski A, 2009, BRIT J PHARMACOL, V158, P693, DOI 10.1111/j.1476-5381.2009.00430.x
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Kobak S, 2010, INT J RHEUM DIS, V13, pe11, DOI 10.1111/j.1756-185X.2010.01478.x
   Kyburz D, 2006, NAT CLIN PRACT RHEUM, V2, P458, DOI 10.1038/ncprheum0292
   Ladda MA, 2016, ADV CHRONIC KIDNEY D, V23, P67, DOI 10.1053/j.ackd.2015.10.002
   Lan X, 2016, HEPATOLOGY, V64, P58, DOI 10.1002/hep.28391
   Law I, 2008, BRIT J CLIN PHARMACO, V65, P674, DOI 10.1111/j.1365-2125.2008.03111.x
   Lee DH, 2015, OPHTHALMOLOGY, V122, P1252, DOI 10.1016/j.ophtha.2015.01.014
   Lee JY, 2016, ARTHRITIS RHEUMATOL, V68, P184, DOI 10.1002/art.39402
   Lee W, 2005, J BIOL CHEM, V280, P9610, DOI 10.1074/jbc.M411092200
   Li DY, 2019, J ENVIRON SCI HEAL C, V37, P180, DOI 10.1080/10590501.2019.1639481
   Li J, 2015, BRIT J PHARMACOL, V172, P4639, DOI 10.1111/bph.13206
   Li XQ, 2003, EUR J CLIN PHARMACOL, V59, P429, DOI 10.1007/s00228-003-0636-9
   Li YH, 2018, IEEE ACM DIS SIM, P1
   Li YH, 2019, ACTA PHARM SIN B, V9, P1113, DOI 10.1016/j.apsb.2019.10.001
   Liu BW, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102452
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1166
   Mahon GJ, 2004, CURR EYE RES, V28, P277, DOI 10.1076/ceyr.28.4.277.27835
   MCCHESNEY EW, 1983, AM J MED, V75, P11, DOI 10.1016/0002-9343(83)91265-2
   MCCHESNEY EW, 1967, BIOCHEM PHARMACOL, V16, P2444, DOI 10.1016/0006-2952(67)90233-X
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   Mingo RM, 2015, J VIROL, V89, P2931, DOI 10.1128/JVI.03398-14
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Motta Mario, 2005, J Perinatol, V25, P86, DOI 10.1038/sj.jp.7211208
   Namazi M., 2009, POTENTIAL NEGATIVE I
   Ooi EE, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-39
   Pan X, 2017, DRUG METAB DISPOS, V45, P346, DOI 10.1124/dmd.116.074013
   Pandya HK, 2015, INDIAN J OPHTHALMOL, V63, P570, DOI 10.4103/0301-4738.167120
   Papermaster D.S., 1982, CELL BIOL EYE, P475
   Patel SAA, 2014, BRIT J CANCER, V111, P2287, DOI 10.1038/bjc.2014.540
   Pelle MT, 2002, ARCH DERMATOL, V138, P1231, DOI 10.1001/archderm.138.9.1231
   Pereira BB, 2020, J TOXICOL ENV HEAL B, V23, P177, DOI 10.1080/10937404.2020.1752340
   Projean D, 2003, DRUG METAB DISPOS, V31, P748, DOI 10.1124/dmd.31.6.748
   Rainsford KD, 2015, INFLAMMOPHARMACOLOGY, V23, P231, DOI 10.1007/s10787-015-0239-y
   Razin A, 2005, PROG MOLEC, V38, P151
   Rebecca VW, 2019, CANCER DISCOV, V9, P220, DOI 10.1158/2159-8290.CD-18-0706
   Rebecca VW, 2017, CANCER DISCOV, V7, P1266, DOI 10.1158/2159-8290.CD-17-0741
   Ritter E, 2008, PHOTOCHEM PHOTOBIOL, V84, P911, DOI 10.1111/j.1751-1097.2008.00324.x
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Somer M, 2000, BRIT J CLIN PHARMACO, V49, P549, DOI 10.1046/j.1365-2125.2000.00197.x
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Srivatsan Padmanabhan M., 2020, POTENTIAL DUAL THERA, DOI [10.13140/RG.2.2.28124.74882, DOI 10.13140/RG.2.2.28124.74882]
   STEINBERG RH, 1980, J COMP NEUROL, V190, P501, DOI 10.1002/cne.901900307
   Stokkermans TJ, 2020, CHLOROQUINE HYDROXYC
   Strick DJ, 2009, INVEST OPHTH VIS SCI, V50, P2427, DOI 10.1167/iovs.08-3058
   Sundelin SP, 2002, APMIS, V110, P481, DOI 10.1034/j.1600-0463.2002.100606.x
   Tang XJ, 2015, CURR DRUG METAB, V16, P86, DOI 10.2174/138920021602150713114159
   Terman A, 2004, INT J BIOCHEM CELL B, V36, P1400, DOI 10.1016/j.biocel.2003.08.009
   TETT S, 1990, BAILLIERE CLIN RHEUM, V4, P467, DOI 10.1016/S0950-3579(05)80004-4
   Thompson DA, 2003, PROG RETIN EYE RES, V22, P683, DOI 10.1016/S1350-9462(03)00051-X
   Thwaites R, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00001
   Tiwari A, 2018, CURR CANCER DRUG TAR, V18, P266, DOI 10.2174/1568009617666170630142725
   TOIMELA T, 1995, OPHTHALMIC RES, V27, P150, DOI 10.1159/000267861
   Tracy CL, 2013, JCR-J CLIN RHEUMATOL, V19, P292, DOI 10.1097/RHU.0b013e31829d547b
   Tsuchiya Y, 2006, CANCER RES, V66, P9090, DOI 10.1158/0008-5472.CAN-06-1403
   van den Borne BEEM, 1998, J RHEUMATOL, V25, P1493
   Verdone Loredana, 2006, Briefings in Functional Genomics & Proteomics, V5, P209, DOI 10.1093/bfgp/ell028
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Vishnoi A, 2017, METHODS MOL BIOL, V1509, P1, DOI 10.1007/978-1-4939-6524-3_1
   Wang YT, 2019, J PHARMACOL EXP THER, V368, P353, DOI 10.1124/jpet.118.252940
   Warhurst DC, 2003, J ANTIMICROB CHEMOTH, V52, P188, DOI 10.1093/jac/dkg319
   Wolf G, 2003, NUTR REV, V61, P342, DOI 10.1301/nr.2003.oct.342-346
   Xu CH, 2016, J PHARM SCI-US, V105, P884, DOI 10.1002/jps.24663
   Yang H, 2010, EXP BIOL MED, V235, P32, DOI 10.1258/ebm.2009.009252
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yoon CH, 2013, INVEST OPHTH VIS SCI, V54
   Yusuf IH, 2017, EYE, V31, P828, DOI 10.1038/eye.2016.298
   Zair ZM, 2008, PHARMACOGENOMICS, V9, P597, DOI 10.2217/14622416.9.5.597
   Zeng LJ, 2017, BIOCHEM PHARMACOL, V140, P139, DOI 10.1016/j.bcp.2017.05.018
   Zhang X, 2014, CELL REP, V6, P421, DOI 10.1016/j.celrep.2014.01.003
NR 104
TC 1
Z9 1
U1 4
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD NOV 5
PY 2020
VL 886
AR 173454
DI 10.1016/j.ejphar.2020.173454
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OE6JJ
UT WOS:000580634600019
PM 32763298
OA Green Published
DA 2021-01-01
ER

PT J
AU Soni, VK
   Mehta, A
   Ratre, YK
   Tiwari, AK
   Amit, A
   Singh, RP
   Sonkar, SC
   Chaturvedi, N
   Shukla, D
   Vishvakarma, NK
AF Soni, Vivek Kumar
   Mehta, Arundhati
   Ratre, Yashwant Kumar
   Tiwari, Atul Kumar
   Amit, Ajay
   Singh, Rajat Pratap
   Sonkar, Subash Chandra
   Chaturvedi, Navaneet
   Shukla, Dhananjay
   Vishvakarma, Naveen Kumar
TI Curcumin, a traditional spice component, can hold the promise against
   COVID-19?
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE COVID-19; Curcumin; Cytokine storm; Inflammation; Molecular targets
ID LUNG INFLAMMATION; CYTOKINE RELEASE; VIRUS-INFECTION; INHIBITION;
   EXPRESSION; RECEPTOR; CELLS; MAPK; SIDE; AXIS
AB The severity of the recent pandemic and the absence of any specific medication impelled the identification of existing drugs with potential in the treatment of Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Curcumin, known for its pharmacological abilities especially as an anti-inflammatory agent, can be hypothesized as a potential candidate in the therapeutic regimen. COVID-19 has an assorted range of pathophysiological consequences, including pulmonary damage, elevated inflammatory response, coagulopathy, and multi-organ damage. This review summarizes the several evidences for the pharmacological benefits of curcumin in COVID-19-associated clinical manifestations. Curcumin can be appraised to hinder cellular entry, replication of SARS-CoV-2, and to prevent and repair COVID-19-associated damage of pneumocytes, renal cells, cardiomyocytes, hematopoietic stem cells, etc. The modulation and protective effect of curcumin on cytokine storm-related disorders are also discussed. Collectively, this review provides grounds for its clinical evaluation in the therapeutic management of SARS-CoV-2 infection.
C1 [Soni, Vivek Kumar; Mehta, Arundhati; Ratre, Yashwant Kumar; Singh, Rajat Pratap; Shukla, Dhananjay; Vishvakarma, Naveen Kumar] Guru Ghasidas Vishwavidyalaya, Dept Biotechnol, Bilaspur 495009, Chhattisgarh, India.
   [Tiwari, Atul Kumar] Bhanwar Singh Porte Govt Sci Coll, Dept Zool, Pendra, Chhattisgarh, India.
   [Amit, Ajay] Guru Ghasidas Vishwavidyalaya, Dept Forens Sci, Bilaspur 495009, Chhattisgarh, India.
   [Sonkar, Subash Chandra] Univ Delhi, Maulana Azad Med Coll, Multidisciplinary Res Unit, New Delhi, India.
   [Chaturvedi, Navaneet] Univ Leicester, Dept Mol & Cell Biol, Henry Welcome Bldg, Leicester LE2 6AW, Leics, England.
   [Chaturvedi, Navaneet] Banaras Hindu Univ, Sch Biochem Engn, Indian Inst Technol, IIT BHU, Varanasi 221005, Uttar Pradesh, India.
RP Shukla, D; Vishvakarma, NK (corresponding author), Guru Ghasidas Vishwavidyalaya, Dept Biotechnol, Bilaspur 495009, Chhattisgarh, India.
EM sdhannu@gmail.com; naveenvishva@gmail.com
OI Mehta, Arundhati/0000-0003-2242-0033
FU UGC-SRFUniversity Grants Commission, India; VRETFellowship-GGV
FX Financial supports to VKS [UGC-SRF] and AM & YKR [VRETFellowship-GGV] as
   fellowships are acknowledged. The authors also acknowledge the
   Departments of Biotechnology and Forensic Science [Guru Ghasidas
   Vishwavidyalaya] for necessary facilities in preparation of the
   manuscript.
CR Agrati C, 2020, CELL DEATH DIFFER, V27, P3196, DOI 10.1038/s41418-020-0572-6
   Ahlame S., 2019, SCI REP, V9, P491, DOI [10.1038/s41598-018-36858-3., DOI 10.1038/S41598-018-36858-3]
   Akinyemi AJ, 2015, J FUNCT FOODS, V17, P792, DOI 10.1016/j.jff.2015.06.011
   Almatroodi SA, 2020, MOLECULES, V25, DOI 10.3390/molecules25030724
   [Anonymous], 2020, WHO SIT REP
   Avasarala S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057285
   Barnard DL, 2011, FUTURE VIROL, V6, P615, DOI 10.2217/fvl.11.33
   Bergenfelz C, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00109
   Bosch-Barrera J, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061770
   Buhrmann C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072393
   Burgos-Moron E, 2010, INT J CANCER, V126, P1771, DOI 10.1002/ijc.24967
   Cao JT, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0266-2
   Chen HT, 2018, J CELL PHYSIOL, V233, P8588, DOI 10.1002/jcp.26536
   Chen L, 2020, NUTRIENTS, V12, DOI 10.3390/nu12041193
   D'Ardes D, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21083003
   Dai JP, 2018, INT IMMUNOPHARMACOL, V54, P177, DOI 10.1016/j.intimp.2017.11.009
   Dou YN, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-017-1047-7
   Enmozhi SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760136
   George PM, 2020, LANCET RESP MED, V8, P807, DOI 10.1016/S2213-2600(20)30225-3
   Hasanzadeh S, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.104921
   Henry BM, 2020, AM J EMERG MED, V38, P1722, DOI 10.1016/j.ajem.2020.05.073
   Hirano T, 2020, IMMUNITY, V52, P731, DOI 10.1016/j.immuni.2020.04.003
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hooper P.L., 2020, CELL STRESS CHAPERON, P1, DOI [10.1007/s12192-020-01126-9, DOI 10.1007/S12192-020-01126-9.]
   Horowitz RI, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.109851
   Huang PK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52088-7
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   Katta S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194891
   Ke SW, 2020, J INT MED RES, V48, DOI 10.1177/0300060520910665
   Keihanian F, 2018, J CELL PHYSIOL, V233, P4497, DOI 10.1002/jcp.26249
   Kotha RR, 2019, MOLECULES, V24, DOI 10.3390/molecules24162930
   Kunnumakkara AB, 2019, EXPERT OPIN DRUG MET, V15, P705, DOI 10.1080/17425255.2019.1650914
   Kunnumakkara AB, 2017, BRIT J PHARMACOL, V174, P1325, DOI 10.1111/bph.13621
   Kurien BT, 2011, INT J CANCER, V128, P242, DOI 10.1002/ijc.25290
   Lee JY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023756
   Lelli D, 2017, PHARMACOL RES, V115, P133, DOI 10.1016/j.phrs.2016.11.017
   Lin Liang-Tzung, 2014, J Tradit Complement Med, V4, P24, DOI 10.4103/2225-4110.124335
   Liu ZT, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00479
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mani JS, 2020, VIRUS RES, V284, DOI 10.1016/j.virusres.2020.197989
   Mason RJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00607-2020
   Mattson MP, 2009, CELL METAB, V9, P403, DOI 10.1016/j.cmet.2009.04.002
   Maurya Vimal K., 2020, VirusDisease, V31, DOI 10.1007/s13337-020-00598-8
   McKee DL, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104859
   Moulin S, 2020, THER ADV CHRONIC DIS, V11, DOI 10.1177/2040622320922104
   Pang XF, 2015, DRUG DES DEV THER, V9, P6043, DOI 10.2147/DDDT.S95333
   Praditya D, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00912
   Ravish I, 2014, MED CHEM RES, V23, P2847, DOI 10.1007/s00044-013-0872-1
   Prestes TRR, 2017, CURR DRUG TARGETS, V18, P1301, DOI 10.2174/1389450117666160727142401
   Ronco C, 2020, LANCET RESP MED, V8, P738, DOI 10.1016/S2213-2600(20)30229-0
   Salminen A, 2018, INT IMMUNOPHARMACOL, V61, P231, DOI 10.1016/j.intimp.2018.06.005
   Scavone C, 2020, BRIT J PHARMACOL, V177, P4813, DOI 10.1111/bph.15072
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Sheller JR, 2009, EXP LUNG RES, V35, P883, DOI 10.3109/01902140903019710
   Shim JS, 2003, CHEM BIOL, V10, P695, DOI 10.1016/S1074-5521(03)00169-8
   Soni VK, 2020, INT J BIOCHEM CELL B, V123, DOI 10.1016/j.biocel.2020.105752
   Sordillo PP, 2015, IN VIVO, V29, P1
   Sun Q, 2020, GEOTECH SP, P1
   Sun SC, 2017, NAT REV IMMUNOL, V17, P545, DOI 10.1038/nri.2017.52
   Tabeshpour J, 2018, J CELL BIOCHEM, V119, P8713, DOI 10.1002/jcb.27192
   Huynh T, 2020, J PHYS CHEM LETT, V11, P4413, DOI 10.1021/acs.jpclett.0c00994
   Ting D, 2018, ACS APPL NANO MATER, V1, P5451, DOI 10.1021/acsanm.8b00779
   Titto M, 2020, RESP PHYSIOL NEUROBI, V274, DOI 10.1016/j.resp.2019.103336
   Ulrich H, 2020, STEM CELL REV REP, V16, P434, DOI 10.1007/s12015-020-09976-7
   Vardhana SA, 2020, J EXP MED, V217, DOI 10.1084/jem.20200678
   Vishvakarma NK, 2014, PHYTOCHEM REV, V13, P717, DOI 10.1007/s11101-014-9364-2
   Vishvakarma NK, 2012, TOXICOL APPL PHARM, V263, P111, DOI 10.1016/j.taap.2012.06.004
   Vishvakarma NK, 2011, TOXICOL APPL PHARM, V252, P298, DOI 10.1016/j.taap.2011.03.002
   Wen CC, 2007, J MED CHEM, V50, P4087, DOI 10.1021/jm070295s
   Wu Renyi, 2020, Curr Pharmacol Rep, P1, DOI 10.1007/s40495-020-00216-7
   Xu YM, 2017, INFLUENZA OTHER RESP, V11, P457, DOI 10.1111/irv.12459
   Yamamoto K, 2006, HYPERTENSION, V47, P718, DOI 10.1161/01.HYP.0000205833.89478.5b
   Yao YG, 2016, SCI REP-UK, V6, DOI 10.1038/srep25579
   Yu CC, 2013, CANCER RES, V73, P3425, DOI 10.1158/0008-5472.CAN-12-3840
   Zahedipour F, 2020, PHYTOTHER RES, V34, P2911, DOI 10.1002/ptr.6738
   Zhai P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105955
   Zhang BY, 2019, FASEB J, V33, P13294, DOI 10.1096/fj.201901047RR
   Zhu JJ, 2013, BBA-MOL CELL RES, V1833, P1924, DOI 10.1016/j.bbamcr.2013.04.002
NR 78
TC 1
Z9 1
U1 5
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD NOV 5
PY 2020
VL 886
AR 173551
DI 10.1016/j.ejphar.2020.173551
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OE6JJ
UT WOS:000580634600038
PM 32931783
DA 2021-01-01
ER

PT J
AU Tang, CF
   Ding, H
   Jiao, RQ
   Wu, XX
   Kong, LD
AF Tang, Chuan-Feng
   Ding, Hong
   Jiao, Rui-Qing
   Wu, Xing-Xin
   Kong, Ling-Dong
TI Possibility of magnesium supplementation for supportive treatment in
   patients with COVID-19
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Magnesium supplementation; COVID-19; Supportive treatment
ID VASCULAR SMOOTH-MUSCLE; INTRAVENOUS MAGNESIUM; ACUTE ASTHMA;
   CARDIAC-SURGERY; CATHARTIC INGESTION; SULFATE PROPHYLAXIS;
   DIABETES-MELLITUS; NMDA RECEPTORS; WOMEN; HYDROXYCHLOROQUINE
AB Magnesium as an enzymatic activator is essential for various physiological functions such as cell cycle, metabolic regulation, muscle contraction, and vasomotor tone. A growing body of evidence supports that magnesium supplementation (mainly magnesium sulfate and magnesium oxide) prevents or treats various types of disorders or diseases related to respiratory system, reproductive system, nervous system, digestive system, and cardiovascular system as well as kidney injury, diabetes and cancer. The ongoing pandemic coronavirus disease 19 (COVID-19) characterized by respiratory tract symptoms with different degrees of important organ and tissue damages has attracted global attention. Particularly, effective drugs are still lacking in the COVID-19 therapy. In this review, we find and summarize the effectiveness of magnesium supplementation on the disorders or diseases, and provide a reference to the possibility of magnesium supplementation for supportive treatment in patients with COVID-19.
C1 [Tang, Chuan-Feng; Ding, Hong; Jiao, Rui-Qing; Wu, Xing-Xin; Kong, Ling-Dong] Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing 210023, Peoples R China.
RP Kong, LD (corresponding author), Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing 210023, Peoples R China.
EM kongld@nju.edu.cn
FU National Key R&D Program of China [2019YFC1711000]; Special Funding for
   Emergency Research on COVID-19 in Nanjing University [020814380135]
FX This paper was supported by grants from the Grants from National Key R&D
   Program of China (2019YFC1711000) and Special Funding for Emergency
   Research on COVID-19 in Nanjing University (No. 020814380135).
CR Abiri B, 2020, TRIALS, V21, DOI 10.1186/s13063-020-4122-9
   Adrogue HJ, 2007, NEW ENGL J MED, V356, P1966, DOI 10.1056/NEJMra064486
   Ajib F.A., 2020, STATPEARLS
   Akbar AN, 2020, SCIENCE, V369, P256, DOI 10.1126/science.abb0762
   Alanazi KH, 2020, EMERG INFECT DIS, V26, P166, DOI 10.3201/eid2601.190952
   Alexander JM, 2006, OBSTET GYNECOL, V108, P826, DOI 10.1097/01.AOG.0000235721.88349.80
   Alfaraj SH, 2019, J MICROBIOL IMMUNOL, V52, P501, DOI 10.1016/j.jmii.2018.04.005
   ALTURA BM, 1987, CAN J PHYSIOL PHARM, V65, P729, DOI 10.1139/y87-120
   Applegate WB, 2020, J AM GERIATR SOC, V68, P681, DOI 10.1111/jgs.16426
   Arnaud MJ, 2008, BRIT J NUTR, V99, pS24, DOI 10.1017/S000711450800682X
   Aslam MN, 2020, CANCER PREV RES, V13, P101, DOI 10.1158/1940-6207.CAPR-19-0325
   Ayuk J, 2014, AM J KIDNEY DIS, V63, P691, DOI 10.1053/j.ajkd.2013.07.025
   Baccioglu A, 2016, J ASTHMA, V53, P525, DOI 10.3109/02770903.2015.1095928
   Bachnas Muhammad Adrianes, 2019, J Matern Fetal Neonatal Med, P1, DOI 10.1080/14767058.2019.1619688
   Bani Younes M.D.N., 2020, EAS J ANESTHESIOL CR, V2, P97, DOI [10.36349/easjacc.2020.v02i03.17., DOI 10.36349/EASJACC.2020.V02I03.17]
   Banjanin N, 2018, NUTRIENTS, V10, DOI 10.3390/nu10050581
   Barbosa EB, 2016, INTENS CARE MED, V42, P1084, DOI 10.1007/s00134-016-4276-9
   Benson CA, 2002, J INFECT DIS, V185, P599, DOI 10.1086/339014
   Blauch LR, 2020, PROC IEEE MICR ELECT, P140, DOI 10.1109/MEMS46641.2020.9056311
   Blitz M, 2005, CHEST, V128, P337, DOI 10.1378/chest.128.1.337
   BROWN O, 2020, AM J PERINAT, DOI DOI 10.1055/S-0040-1709993
   Calder PC, 2020, NUTRIENTS, V12, DOI 10.3390/nu12041181
   Chatre C, 2018, DRUG SAFETY, V41, P919, DOI 10.1007/s40264-018-0689-4
   Chen D, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.11122
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Cunha AR, 2017, J HYPERTENS, V35, P89, DOI 10.1097/HJH.0000000000001129
   Damron DP, 2007, OBSTET GYNECOL, V109, P201, DOI 10.1097/01.AOG.0000252280.06718.d6
   Dashraath P, 2020, AM J OBSTET GYNECOL, V222, P521, DOI 10.1016/j.ajog.2020.03.021
   Decollogne S, 1997, PHARMACOL BIOCHEM BE, V58, P261, DOI 10.1016/S0091-3057(96)00555-2
   Du YX, 2020, CLIN PHARMACOL THER, V108, P242, DOI 10.1002/cpt.1844
   ELDerawi WA, 2019, NUTRIENTS, V11, DOI 10.3390/nu11010044
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Escalera-Antezana JP, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101653
   Eshraghi T, 2015, MAGNESIUM RES, V28, P32, DOI 10.1684/mrh.2015.0380
   Fantini J, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105960
   Fenning SJ, 2018, BMJ SUPPORT PALLIAT, V8, P191, DOI 10.1136/bmjspcare-2017-001360
   FLATMAN PW, 1984, J MEMBRANE BIOL, V80, P1, DOI 10.1007/BF01868686
   Gallant KMH, 2017, CURR OSTEOPOROS REP, V15, P214, DOI 10.1007/s11914-017-0368-x
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gomes DR, 2020, J VET PHARMACOL THER, V43, P355, DOI 10.1111/jvp.12851
   Gonzalez JA, 2006, ARCH BRONCONEUMOL, V42, P384, DOI 10.1016/S1579-2129(06)60551-X
   Gourgoulianis KI, 2001, J AEROSOL MED, V14, P301, DOI 10.1089/089426801316970259
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Green R.H., 2016, CLIN EVID
   Grober U, 2015, NUTRIENTS, V7, P8199, DOI 10.3390/nu7095388
   Gu WJ, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-41
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Gupta R, 2020, DIABETES METAB SYND, V14, P211, DOI 10.1016/j.dsx.2020.03.002
   Guzel A, 2019, J INVEST SURG, V32, P331, DOI 10.1080/08941939.2017.1422575
   Hamad A, 2019, INT J NEPHROL, V2019, DOI 10.1155/2019/1875358
   Hamroun A, 2019, DRUGS, V79, P1567, DOI 10.1007/s40265-019-01182-1
   Han F, 2018, ARCH GYNECOL OBSTET, V298, P631, DOI 10.1007/s00404-018-4850-1
   Hansen BA, 2018, J INTENSIVE CARE, V6, DOI 10.1186/s40560-018-0291-y
   Hellgren M, 2006, BIOPHYS CHEM, V120, P1, DOI 10.1016/j.bpc.2005.10.002
   Hirota K, 1999, CRIT CARE MED, V27, P1159, DOI 10.1097/00003246-199906000-00042
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hou HL, 2020, MOL NEUROBIOL, V57, P2539, DOI 10.1007/s12035-020-01871-z
   Hu TY, 2020, NAT NANOTECHNOL, V15, P247, DOI 10.1038/s41565-020-0674-9
   Iotti S, 2020, MAGNESIUM RES, V33, P21, DOI 10.1684/mrh.2020.0465
   Irazuzta JE, 2017, J PEDIAT-BRAZIL, V93, P19, DOI 10.1016/j.jped.2017.06.002
   JAIN A C, 1985, Journal of Neurology, V232, P161
   Jameson RA, 2019, CLIN PERINATOL, V46, P187, DOI 10.1016/j.clp.2019.02.008
   Johnson MD, 2020, J PEDIATR-US, V220, P165, DOI 10.1016/j.jpeds.2020.01.062
   Kachhawa K, 2019, SAUDI J KIDNEY DIS T, V30, P1032, DOI 10.4103/1319-2442.270257
   Kao MC, 2011, J SURG RES, V171, pE97, DOI 10.1016/j.jss.2011.03.028
   Karimi-Zarchi M, 2020, FETAL PEDIATR PATHOL, V39, P246, DOI 10.1080/15513815.2020.1747120
   Kazaks AG, 2010, J ASTHMA, V47, P83, DOI 10.3109/02770900903331127
   Kew KM, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010909.pub2
   Kim JE, 2015, SURG ENDOSC, V29, P3795, DOI 10.1007/s00464-015-4514-1
   Knightly R, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003898.pub6
   Ko Eun A., 2008, Journal of Smooth Muscle Research, V44, P65, DOI 10.1540/jsmr.44.65
   Komiya Y, 2015, INT J DEV BIOL, V59, P281, DOI 10.1387/ijdb.150196lr
   Kontani M, 2005, INTERNAL MED, V44, P448, DOI 10.2169/internalmedicine.44.448
   Kramer B K, 2000, Ther Umsch, V57, P398, DOI 10.1024/0040-5930.57.6.398
   Kreepala C, 2018, NEPHRON, V138, P35, DOI 10.1159/000481463
   Kumar Pratyush, 2019, J Family Med Prim Care, V8, P1671, DOI 10.4103/jfmpc.jfmpc_83_19
   Kutsal E, 2007, PEDIATR EMERG CARE, V23, P570, DOI 10.1097/PEC.0b013e31812eef1c
   Yen LM, 2019, LANCET, V393, P1657, DOI 10.1016/S0140-6736(18)33131-3
   LANDON RA, 1993, J AM DIET ASSOC, V93, P674, DOI 10.1016/0002-8223(93)91675-G
   Lee MH, 2020, HEPATOLOGY, V71, P917, DOI 10.1002/hep.30861
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li W, 2019, CHINESE J PHYSIOL, V62, P203, DOI 10.4103/CJP.CJP_48_19
   Liu H, 2020, J REPROD IMMUNOL, V139, DOI 10.1016/j.jri.2020.103122
   Liu XX, 2016, PEDIATR PULM, V51, P1414, DOI 10.1002/ppul.23482
   Magee LA, 2018, MAYO CLIN PROC, V93, P1664, DOI 10.1016/j.mayocp.2018.04.033
   MATHER HM, 1979, LANCET, V1, P924
   Matsuda Y, 2000, EUR J OBSTET GYN R B, V91, P159, DOI 10.1016/S0301-2115(99)00256-0
   Mauskop A, 2012, J NEURAL TRANSM, V119, P575, DOI 10.1007/s00702-012-0790-2
   MCCUBBIN JH, 1981, LANCET, V1, P1058
   McGuire JK, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.2.e18
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mendonca FT, 2020, EUR J ANAESTH, V37, P224, DOI 10.1097/EJA.0000000000001153
   Meraviglia P, 2004, HIV MED, V5, P334, DOI 10.1111/j.1468-1293.2004.00232.x
   Meyerowitz EA, 2020, FASEB J, V34, P6027, DOI 10.1096/fj.202000919
   Miyashita T, 2012, NEURON, V74, P887, DOI 10.1016/j.neuron.2012.03.039
   Mohd Noh AS, 2020, MALAYS J MED SCI, V27, P6, DOI 10.21315/mjms2020.27.1.2
   Moradian ST, 2017, MAGNESIUM RES, V30, P28, DOI 10.1684/mrh.2017.0420
   Muniyappa R, 2020, AM J PHYSIOL-ENDOC M, V318, pE736, DOI 10.1152/ajpendo.00124.2020
   Na H., 2011, MAGNESIUM CENTRAL NE, P157
   NADLER JL, 1995, ENDOCRIN METAB CLIN, V24, P623, DOI 10.1016/S0889-8529(18)30035-5
   Nasser R, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3627-2
   Nechifor M, 2011, MAGNESIUM RES, V24, P215, DOI 10.1684/mrh.2011.0296
   Nechifor M, 2009, MAGNESIUM RES, V22, p163S
   Oh TK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39106-4
   Ohyama T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174232
   Osawa E, 2018, CRIT CARE RESUSC, V20, P209
   Ozen M, 2020, PEDIATR RES, V87, P463, DOI 10.1038/s41390-019-0557-7
   Palmer BF, 2016, ADV PHYSIOL EDUC, V40, P480, DOI 10.1152/advan.00121.2016
   Palmer SC, 2011, JAMA-J AM MED ASSOC, V305, P1119, DOI 10.1001/jama.2011.308
   Patel K, 2018, AIDS, V32, P2327, DOI [10.1097/QAD.0000000000001980, 10.1097/qad.0000000000001980]
   Pickering G, 2011, MAGNESIUM RES, V24, P28, DOI 10.1684/mrh.2011.0282
   Powell C V E, 2013, Health Technol Assess, V17, pv, DOI 10.3310/hta17450
   Powell C, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003898.pub5
   PRITCHARD JA, 1955, SURG GYNECOL OBSTET, V100, P131
   RAMADAN NM, 1989, HEADACHE, V29, P590, DOI 10.1111/j.1526-4610.1989.hed2909590.x
   Rochelson B, 2007, J REPROD IMMUNOL, V73, P101, DOI 10.1016/j.jri.2006.06.004
   ROMANI A, 1990, NATURE, V346, P841, DOI 10.1038/346841a0
   Ross AC, 2011, Dietary Reference Intakes for Calcium and Vitamin D, P1
   Rouse DJ, 2008, NEW ENGL J MED, V359, P895, DOI 10.1056/NEJMoa0801187
   Rowe B.H., 2000, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001490., DOI 10.1002/14651858.CD001490]
   Saris NEL, 2000, CLIN CHIM ACTA, V294, P1, DOI 10.1016/S0009-8981(99)00258-2
   Saver J.L., 2011, MAGNESIUM CENTRAL NE, P205
   Saver JL, 2015, NEW ENGL J MED, V372, P528, DOI 10.1056/NEJMoa1408827
   Saver JL, 2010, PHARMACOTHERAPY, V30, p62S, DOI 10.1592/phco.30.pt2.62S
   Schwartz David A, 2020, Arch Pathol Lab Med, DOI 10.5858/arpa.2020-0901-SA
   SEELIG MS, 1994, J AM COLL NUTR, V13, P429
   Serefko A, 2013, PHARMACOL REP, V65, P547, DOI 10.1016/S1734-1140(13)71032-6
   Shan ZL, 2013, RESP MED, V107, P321, DOI 10.1016/j.rmed.2012.12.001
   Shepherd J, 2008, HEALTH TECHNOL ASSES, V12, pXI
   Shimosawa T, 2004, HYPERTENSION, V44, P897, DOI 10.1161/01.HYP.0000146536.68208.84
   SIBAI BM, 1990, AM J OBSTET GYNECOL, V162, P1141, DOI 10.1016/0002-9378(90)90002-O
   Singewald N, 2004, NEUROPHARMACOLOGY, V47, P1189, DOI 10.1016/j.neuropharm.2004.08.010
   Sissi C, 2009, NUCLEIC ACIDS RES, V37, P702, DOI 10.1093/nar/gkp024
   Sohn HM, 2017, EUR J ANAESTH, V34, P508, DOI 10.1097/EJA.0000000000000641
   Solanki MH, 2014, AM J PHYSIOL-RENAL, V307, pF369, DOI 10.1152/ajprenal.00127.2014
   Soliman R, 2019, ANN CARD ANAESTH, V22, P151, DOI 10.4103/aca.ACA_32_18
   Stein M, 2000, J RHEUMATOL, V27, P2927
   Tan CW, 2020, COHORT STUDY EVALUAT, DOI [10.1101/2020.06.01.20112334, DOI 10.1101/2020.06.01.20112334]
   Tashiro M, 2005, BIOPHYS J, V89, P3235, DOI 10.1529/biophysj.105.068890
   Teragawa H, 2002, MAGNESIUM RES, V15, P241
   Torres S, 2012, ARCH ARGENT PEDIATR, V110, P291, DOI [10.5546/aap.2012.291, 10.1590/S0325-00752012000400004, 10.5546/aap.2012.eng.291]
   Turner DL, 2017, EUR J PHARMACOL, V801, P79, DOI 10.1016/j.ejphar.2017.03.004
   Uyeki TM, 2016, NEW ENGL J MED, V374, P636, DOI 10.1056/NEJMoa1504874
   Villeneuve EJ, 2006, ANN PHARMACOTHER, V40, P1118, DOI 10.1345/aph.1G496
   Vujovic KS, 2019, PHARMACOL REP, V71, P1014, DOI 10.1016/j.pharep.2019.05.020
   Wallace TC, 2020, J AM COLL NUTR, V39, P685, DOI 10.1080/07315724.2020.1785971
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang YH, 2019, SAUDI J BIOL SCI, V26, P2043, DOI 10.1016/j.sjbs.2019.08.012
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Wark PA, 2012, AM J CLIN NUTR, V96, P622, DOI 10.3945/ajcn.111.030924
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Watt AJ, 2004, NAT NEUROSCI, V7, P518, DOI 10.1038/nn1220
   Wesselink E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10040398
   WHANG R, 1992, ARCH INTERN MED, V152, P40, DOI 10.1001/archinte.152.1.40
   William C.S.J., 2018, MED DEFINITION MAGNE
   Winkler AW, 1942, J CLIN INVEST, V21, P207, DOI 10.1172/JCI101292
   Wong SF, 2004, AM J OBSTET GYNECOL, V191, P292, DOI 10.1016/j.ajog.2003.11.019
   Wongwaree Siriporn, 2019, Asian Pac J Allergy Immunol, DOI 10.12932/AP-190717-0118
   World Health Organization, 2020, COR DIS COVID 2019 S
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu CL, 2007, NAT NEUROSCI, V10, P1578, DOI 10.1038/nn2005
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu Z, 2020, AM J MED QUAL, DOI 10.1177/1062860620956623
   Xu F, 2019, CLIN NEUROL NEUROSUR, V178, P31, DOI 10.1016/j.clineuro.2019.01.007
   Yamamoto T, 2016, J NEUROSURG, V124, P18, DOI 10.3171/2015.1.JNS142757
   Yang JK, 2006, DIABETIC MED, V23, P623, DOI 10.1111/j.1464-5491.2006.01861.x
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Ye QS, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04380-5
   Yogasundaram H, 2014, CAN J CARDIOL, V30, P1706, DOI 10.1016/j.cjca.2014.08.016
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zaigham M, 2020, ACTA OBSTET GYN SCAN, V99, P823, DOI 10.1111/aogs.13867
   ZHANG AM, 1993, BRIT J PHARMACOL, V109, P291, DOI 10.1111/j.1476-5381.1993.tb13568.x
   Zhang Q, 2018, MAGNESIUM RES, V31, P117, DOI 10.1684/mrh.2019.0445
   Zhong GC, 2020, INT J CANCER, V147, P1577, DOI 10.1002/ijc.32939
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 180
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD NOV 5
PY 2020
VL 886
AR 173546
DI 10.1016/j.ejphar.2020.173546
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OE6JJ
UT WOS:000580634600035
PM 32931782
OA Green Published
DA 2021-01-01
ER

PT J
AU MacDonald, NE
   Comeau, J
   Dube, E
   Bucci, L
   Graham, JE
AF MacDonald, Noni E.
   Comeau, Jeannette
   Dube, Eve
   Bucci, Lucie
   Graham, Janice E.
TI A public health timeline to prepare for COVID-19 vaccines in Canada
SO CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE
LA English
DT Article; Early Access
DE COVID-19 vaccines; COVID-19 immunization; Public health; Pandemic
   control; Communication
AB For control of COVID-19, community immunity is required, necessitating widespread immunization. COVID-19 vaccines are coming to Canada, with the government announcing in August 2020 agreements with four different companies for their COVID-19 vaccine if their trials are successful. Never before has public health had to rapidly develop a vaccine introduction program for multiple new but differing vaccines with the added pressure that the program is needed across all ages and in all Canadian communities and there is high probability of not enough vaccine to go around at the start. Traditional public health vaccine introduction planning will need to be both accelerated and more comprehensive to ensure optimal uptake across the country. This overview highlights a number of points for consideration by public health in their planning for COVID-19 vaccines before these COVID-19 vaccines are available, once they are available, once supplies are plentiful, and throughout the vaccine program. Targeted and tailored communications are key elements needed to reach and positively influence diverse communities, regions, ages, languages, education levels and lived experiences.
C1 [MacDonald, Noni E.; Comeau, Jeannette; Graham, Janice E.] Dalhousie Univ, IWK Hlth Ctr, Dept Pediat, Halifax, NS, Canada.
   [Dube, Eve] Inst Natl Sante Publ Quebec, Quebec City, PQ, Canada.
   [Dube, Eve] Univ Laval, Quebec City, PQ, Canada.
   [Bucci, Lucie] Canadian Publ Hlth Assoc, Immunize Canada, Ottawa, ON, Canada.
RP MacDonald, NE (corresponding author), Dalhousie Univ, IWK Hlth Ctr, Dept Pediat, Halifax, NS, Canada.
EM noni.macdonald@dal.ca
CR Bahri P, 2018, BRIT J CLIN PHARMACO, V84, P1696, DOI 10.1111/bcp.13587
   Bettinger J A, 2014, Can Commun Dis Rep, V40, P41
   Celliers Marlie, 2020, Responsible Design, Implementation and Use of Information and Communication Technology. 19th IFIP WG 6.11 Conference on e-Business, e-Services, and e-Society, I3E 2020. Proceedings. Lecture Notes in Computer Science (LNCS 12067), P223, DOI 10.1007/978-3-030-45002-1_19
   Cornwall W, 2020, SCIENCE, V369, P14, DOI 10.1126/science.369.6499.14
   Dawson R, 2018, VACCINE, V36, P1361, DOI 10.1016/j.vaccine.2018.02.007
   Dempsey AF, 2018, JAMA PEDIATR, V172, DOI 10.1001/jamapediatrics.2018.0016
   Dube Eve, 2020, Can Commun Dis Rep, V46, P48, DOI 10.14745/ccdr.v46i23a05
   Gagneur A, 2018, VACCINE, V36, P6553, DOI 10.1016/j.vaccine.2017.10.049
   Gold MS, 2020, VACCINE, V38, P3025, DOI 10.1016/j.vaccine.2020.02.046
   Graven M, 2013, INT J MED INFORM, V82, P954, DOI 10.1016/j.ijmedinf.2013.06.003
   Hampton LM, 2020, VACCINE, V38, P4933, DOI 10.1016/j.vaccine.2020.05.092
   Hibbs BF, 2015, VACCINE, V33, P3171, DOI 10.1016/j.vaccine.2015.05.006
   Hosangadi D, 2020, VACCINE, V38, P4167, DOI 10.1016/j.vaccine.2020.04.037
   Lane S, 2018, VACCINE, V36, P3861, DOI 10.1016/j.vaccine.2018.03.063
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   MacDonald NE, 2020, CAN J PUBLIC HEALTH, V111, P469, DOI 10.17269/s41997-020-00385-4
   MacDonald Noni E, 2020, Can Commun Dis Rep, V46, P20, DOI 10.14745/ccdr.v46i01a04
   MacDonald NE, 2020, VACCINE, V38, P4924, DOI 10.1016/j.vaccine.2019.09.109
   MacDonald NE, 2017, PAED CHILD HEALT-CAN, V22, pE13, DOI 10.1093/pch/pxx073
   Mostafapour M, 2019, VACCINE, V37, P6750, DOI 10.1016/j.vaccine.2019.08.083
   Nichols MK, 2018, VACCINE, V36, P2166, DOI 10.1016/j.vaccine.2018.02.093
   Plotkin SA, 2015, NEW ENGL J MED, V373, P297, DOI 10.1056/NEJMp1506820
   Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012
   Ryan MJ, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2018-001272
   Sadique MZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054149
   Schmid P, 2019, NAT HUM BEHAV, V3, P931, DOI 10.1038/s41562-019-0632-4
   Shelby A, 2013, HUM VACC IMMUNOTHER, V9, P1795, DOI 10.4161/hv.24828
   Steenbeek A, 2012, PUBLIC HEALTH NURS, V29, P71, DOI 10.1111/j.1525-1446.2011.00974.x
   Top KA, 2016, PEDIATR INFECT DIS J, V35, pE384, DOI 10.1097/INF.0000000000001323
   Usher AD, 2020, LANCET, V395, P1822, DOI 10.1016/S0140-6736(20)31354-4
   van der Linden S, 2017, SCIENCE, V358, P1141, DOI 10.1126/science.aar4533
   World Health Organization, 2020, WHO SAGE VAL FRAM AL
NR 32
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 0008-4263
EI 1920-7476
J9 CAN J PUBLIC HEALTH
JI Can. J. Public Health-Rev. Can. Sante Publ.
DI 10.17269/s41997-020-00423-1
EA NOV 2020
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OO1DH
UT WOS:000587126800001
PM 33151510
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Lin, KJ
   Schneeweiss, S
   Tesfaye, H
   D'Andrea, E
   Liu, J
   Lii, J
   Murphy, SN
   Gagne, JJ
AF Lin, Kueiyu Joshua
   Schneeweiss, Sebastian
   Tesfaye, Helen
   D'Andrea, Elvira
   Liu, Jun
   Lii, Joyce
   Murphy, Shawn N.
   Gagne, Joshua J.
TI Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment
   Patterns by Disease Severity
SO DRUGS
LA English
DT Article
AB Background Treatment decisions for Coronavirus Disease 2019 (COVID-19) depend on disease severity, but the prescribing pattern by severity and drivers of therapeutic choices remain unclear.
   Objectives The objectives of the study were to evaluate pharmacological treatment patterns by COVID-19 severity and identify the determinants of prescribing for COVID-19.
   Methods Using electronic health record data from a large Massachusetts-based healthcare system, we identified all patients aged >= 18 years hospitalized with laboratory-confirmed COVID-19 from 1 March to 24 May, 2020. We defined five levels of COVID-19 severity at hospital admission: (1) hospitalized but not requiring supplemental oxygen; (2-4) hospitalized and requiring oxygen <= 2, 3-4, and >= 5 L per minute, respectively; and (5) intubated or admitted to an intensive care unit. We assessed the medications used to treat COVID-19 or as supportive care during hospitalization.
   Results Among 2821 patients hospitalized for COVID-19, we found inpatient mortality increased by severity from 5% for level 1 to 23% for level 5. As compared to patients with severity level 1, those with severity level 5 were 3.53 times (95% confidence interval 2.73-4.57) more likely to receive a medication used to treat COVID-19. Other predictors of treatment were fever, low oxygen saturation, presence of co-morbidities, and elevated inflammatory biomarkers. The use of most COVID-19 relevant medications has dropped substantially while the use of remdesivir and therapeutic anticoagulants has increased over the study period.
   Conclusions Careful consideration of disease severity and other determinants of COVID-19 drug use is necessary for appropriate conduct and interpretation of non-randomized studies evaluating outcomes of COVID-19 treatments.
C1 [Lin, Kueiyu Joshua; Schneeweiss, Sebastian; Tesfaye, Helen; D'Andrea, Elvira; Liu, Jun; Lii, Joyce; Gagne, Joshua J.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA.
   [Lin, Kueiyu Joshua] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
   [Lin, Kueiyu Joshua; Murphy, Shawn N.] Harvard Med Sch, Boston, MA 02115 USA.
   [Murphy, Shawn N.] Mass Gen Brigham Res Informat Sci & Comp, Boston, MA USA.
   [Murphy, Shawn N.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
RP Lin, KJ (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA.; Lin, KJ (corresponding author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.; Lin, KJ (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.
EM jklin@bwh.harvard.edu
CR Adams ML, 2020, EMERG INFECT DIS, V26, P1831, DOI 10.3201/eid2608.200679
   Alattar R, 2020, J MED VIROL, V92, P2042, DOI 10.1002/jmv.25964
   Alzghari SK, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104380
   Andreani J, 2020, MICROB PATHOGENESIS, V145, DOI 10.1016/j.micpath.2020.104228
   Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   Ari A, 2020, RESP MED, V167, DOI 10.1016/j.rmed.2020.105987
   Bajwah S, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00815-2020
   Ballantyne A, 2020, J MED ETHICS, V46, P641, DOI 10.1136/medethics-2020-106460
   Barnes GD, 2020, J THROMB THROMBOLYS, V50, P72, DOI 10.1007/s11239-020-02138-z
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   Beigel JH, 2020, NEW ENGL J MED, V383, P994, DOI 10.1056/NEJMc2022236
   Borrell B, 2020, SCI MAG
   Brojakowska A, 2020, J AM COLL CARDIOL, V75, P3085, DOI 10.1016/j.jacc.2020.04.028
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   FDA, 2020, COR COVID 19 UPD FDA
   Fiolet T, 2020, CLIN MICROBIOL INFEC
   Franzetti M, 2020, INT J INFECT DIS, V97, P215, DOI 10.1016/j.ijid.2020.05.050
   Freedberg DE, 2020, GASTROENTEROLOGY, V159, P1129, DOI 10.1053/j.gastro.2020.05.053
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Gritti G, 2020, USE SILTUXIMAB PATIE, V04, P1912, DOI [10. 1101/2020.04.01.20048561., DOI 10.1101/2020.04.01.20048561, 10.1101/2020.04.01.20048561]
   Hendaus MA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1772110
   Horby P, 2020, N ENGL J MED
   Hyzy R, 2020, HEATED HUMIDIFIED HI
   Ignarro LJ, 2020, BRIT J PHARMACOL, V177, P3848, DOI 10.1111/bph.15085
   Javanmard Shaghayegh Haghjooy, 2020, Infect Control Hosp Epidemiol, P1, DOI 10.1017/ice.2020.195
   Kai H, 2020, HYPERTENS RES, V43, P648, DOI 10.1038/s41440-020-0455-8
   Kollias A, 2020, BRIT J HAEMATOL, V189, P846, DOI 10.1111/bjh.16727
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   Lowe D, 2020, SCI TRANSL MED
   Lu CC, 2020, J CHIN MED ASSOC, V83, P534, DOI 10.1097/JCMA.0000000000000318
   Mantlo E, 2020, ANTIVIR RES, V179, DOI 10.1016/j.antiviral.2020.104811
   Mass General Brigham (MGB), HOSP AFF
   Moghadas SM, 2020, P NATL ACAD SCI USA, V117, P9122, DOI 10.1073/pnas.2004064117
   Moitra VK, 2016, CRIT CARE MED, V44, P655, DOI 10.1097/CCM.0000000000001480
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Monteagudo Luke Adam, 2020, ACR Open Rheumatol, V2, P276, DOI 10.1002/acr2.11135
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Nalichowski Ruth, 2006, AMIA Annu Symp Proc, P1044
   Panigada M, 2020, J THROMB HAEMOST, V18, P1738, DOI 10.1111/jth.14850
   Papazian L, 2020, INTENS CARE MED, V46, P888, DOI 10.1007/s00134-020-05980-0
   Pilkington V, 2020, J VIRUS ERAD, V6, P45
   Reiner Z, 2020, ARCH MED SCI, V16, P490, DOI 10.5114/aoms.2020.94655
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Roser M., 2020, CORONAVIRUS PANDEMIC
   Roth GA, 2018, JAMA CARDIOL, V3, P375, DOI 10.1001/jamacardio.2018.0385
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Treon SP, 2020, BLOOD, V135, P1912, DOI 10.1182/blood.2020006288
   Vaduganathan M, 2020, JAMA-J AM MED ASSOC, V323, P2524, DOI 10.1001/jama.2020.9184
   Vankadari N, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105998
   Vasilevskis EE, 2010, CHEST, V138, P1224, DOI 10.1378/chest.10-0466
   Vitacca M, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00632-2020
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang X., 2020, MATH PROBL ENG, V2020, P1, DOI DOI 10.1136/gutjnl-2019-319766
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zamanian RT, 2020, AM J RESP CRIT CARE, V202, P130, DOI 10.1164/rccm.202004-0937LE
   Zhang SY, 2020, CLIN DRUG INVEST, V40, P511, DOI 10.1007/s40261-020-00917-3
   Zhou ZY, 2017, ANN HUM GENET, V81, P184, DOI 10.1111/ahg.12202
NR 61
TC 0
Z9 0
U1 1
U2 1
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0012-6667
EI 1179-1950
J9 DRUGS
JI Drugs
PD DEC
PY 2020
VL 80
IS 18
BP 1961
EP 1972
DI 10.1007/s40265-020-01424-7
EA NOV 2020
PG 12
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA PA2OX
UT WOS:000587131600001
PM 33151482
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Billon-Denis, E
   Tournier, JN
AF Billon-Denis, Emmanuelle
   Tournier, Jean-Nicolas
TI COVID-19 and vaccination: a global disruption
SO M S-MEDECINE SCIENCES
LA French
DT Article
AB Coronavirus disease (COVID)-19 is an emerging pandemic infection whose significant ability to spread in a naive population is well established. The first response of states to the COVID-19 outbreak was to impose lock-down and social barrier measures, such as wearing a surgical mask or social distancing. One of the consequences of this pandemic in terms of public health was the suspension or slowdown of infant vaccination campaigns, in almost all countries. The indirect effects of COVID-19 may therefore weigh on mortality from measles and polio in developing countries. In this pandemic chaos, the only hope lies in the rapid development of an effective vaccine against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). However, acceptance of this vaccine has not yet been won, as beyond the many unknowns that will inevitably weigh around such rapid development, skepticism among vaccine hesitants is growing.
C1 [Billon-Denis, Emmanuelle; Tournier, Jean-Nicolas] Inst Rech Biomed Armees IRBA, Unite Biotherapies Antiinfect & Immunite, 1 Pl Gen Valerie Andre, F-91220 Bretigny Sur Orge, France.
   [Billon-Denis, Emmanuelle; Tournier, Jean-Nicolas] Inst Pasteur, Innovat Vaccine Lab, F-75015 Paris, France.
   [Tournier, Jean-Nicolas] Ecole Val de Grace, 1 Pl Alphonse Laveran, F-75005 Paris, France.
RP Tournier, JN (corresponding author), Inst Rech Biomed Armees IRBA, Unite Biotherapies Antiinfect & Immunite, 1 Pl Gen Valerie Andre, F-91220 Bretigny Sur Orge, France.; Tournier, JN (corresponding author), Inst Pasteur, Innovat Vaccine Lab, F-75015 Paris, France.
EM jean-nicolas.tournier@intradef.gouv.fr
RI Tournier, Jean-Nicolas/A-7332-2011
OI Tournier, Jean-Nicolas/0000-0002-4542-2421
CR Abbott A, 2020, NATURE, V585, P493, DOI 10.1038/d41586-020-02619-4
   [Anonymous], 2020, CAL VACC NOUR COVID
   [Anonymous], 2020, GUID PRINC IMM ACT D
   [Anonymous], 2020, STRAT VACC CONTR COV
   [Anonymous], 2020, EXP COVID 19 VACC
   Bar-Zeev N, 2020, LANCET, V396, P448, DOI 10.1016/S0140-6736(20)31611-1
   Barre-Sinoussi F, 2020, VACCINS SARS COV 2 9
   Caplan AL, 2020, SCIENCE, V369, P1035, DOI 10.1126/science.abe4440
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Guha-Sapir D, 2020, SCIENCE, V369, P261, DOI 10.1126/science.abc8637
   Hayden EC, 2014, NATURE, V514, P15, DOI 10.1038/514015a
   Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483
   Keech Cheryl, 2020, N Engl J Med, V383, P2320, DOI 10.1056/NEJMoa2026920
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P667, DOI 10.1038/d41573-020-00151-8
   Logunov DY, 2020, LANCET, DOI [10.1016/S0140-6736(20)31866-3-, DOI 10.1016/S0140-6736(20)31866-3-]
   Macklin GR, 2020, SCIENCE, V368, P401, DOI 10.1126/science.aba1238
   Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4
   Nelson R, 2020, LANCET INFECT DIS, V20, P546, DOI 10.1016/S1473-3099(20)30304-2
   Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6
   Pitard B, 2019, M S-MED SCI, V35, P749, DOI 10.1051/medsci/2019143
   Roberton T, 2020, LANCET GLOB HEALTH, V8, pE901, DOI 10.1016/S2214-109X(20)30229-1
   Roberts L, 2020, SCIENCE, V369, P360, DOI 10.1126/science.369.6502.360
   Sahin U, 2020, NATURE
   Vaidyanathan G, 2020, NATURE, V585, P167, DOI 10.1038/d41586-020-02507-x
   Weill A, 2020, 2 EPIPHARE ANSM
   Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6
NR 26
TC 0
Z9 0
U1 5
U2 5
PU EDP SCIENCES S A
PI LES ULIS CEDEX A
PA 17, AVE DU HOGGAR, PA COURTABOEUF, BP 112, F-91944 LES ULIS CEDEX A,
   FRANCE
SN 0767-0974
EI 1958-5381
J9 M S-MED SCI
JI M S-Med. Sci.
PD NOV 5
PY 2020
VL 36
IS 11
BP 1034
EP 1037
DI 10.1051/medsci/2020203
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OO2MG
UT WOS:000587217700015
PM 33151866
OA Bronze
DA 2021-01-01
ER

PT J
AU Nishtala, PS
   Gill, S
   Chyou, TY
AF Nishtala, Prasad S.
   Gill, Sakirat
   Chyou, Te-yuan
TI Analysis of the US FDA adverse event reporting system to identify
   adverse cardiac events associated with hydroxychloroquine in older
   adults
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Article
DE adverse event; data signal; elderly; hydroxychloroquine;
   pharmacoepidemiology; reporting odds ratio
ID INDUCED CARDIOMYOPATHY; COVID-19; RISK
AB Purpose The purpose of this study is to analyze the US FDA Adverse Event Reporting System (FAERS) to identify adverse cardiac events of hydroxychloroquine in older adults.
   Method A case/non-case method was used to determine adverse events associated with hydroxychloroquine as the primary suspect drug between January 1, 2004, and December 31, 2019, for older adults (>= 65 years). Adverse events are preferred terms (PTs) defined in MedDRA. We used frequentist approaches, including the reporting odds ratio (ROR) and the proportional reporting ratio (PRR) to measure disproportionality. We used Bayesian approaches to derive information component (IC) value and Empirical Bayesian Geometric Mean (EBGM) score. Signals were defined as the number of reports > 3 and the lower limit of 95% confidence intervals (CI) of ROR >= 2, PRR >= 2, IC > 0, EBGM > 1.
   Results We identified 334 adverse cardiac events comprising 71 different MedDRA PTs from 2004 to 2019 for hydroxychloroquine in older adults. Strong disproportionality signals were noted for "Restrictive cardiomyopathy" (ROR = 272.43 (138.09-537.47); EBGM = 149.78 (77.34-264.67), "Right ventricular hypertrophy" (219.49 (85.32-564.70); 102.74 (39.67-222.81), "Cardiac septal hypertrophy" (226.77 (78.65-653.80); 93.82 (32.19-219.81), "Myocardial fibrosis" (57.29 (21.06-155.85); 42.99 (14.74-100.75), and "Cardiotoxicity" (43.90 (26.66-72.27); 40.28 (24.02-63.72).
   Conclusions The risk of cardiomyopathy and myocardial disorders is high following exposure to hydroxychloroquine in older adults. Due to the current lack of safety data from randomized controlled trials as well as large observational studies to confirm the risk of adverse cardiac events associated with hydroxychloroquine, findings from analyses of post-marketing data may serve as interim guidance.
C1 [Nishtala, Prasad S.; Gill, Sakirat] Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England.
   [Chyou, Te-yuan] Univ Otago, Dept Biochem, Dunedin, New Zealand.
RP Nishtala, PS (corresponding author), Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England.
EM p.nishtala@bath.ac.uk
OI Nishtala, Prasad/0000-0002-4155-8540
CR Abd-Elsalam S, 2020, AM J TROP MED HYG, V103, P1635, DOI 10.4269/ajtmh.20-0873
   Abella BS, 2020, JAMA INTERN MED, DOI 10.1001/jamainternmed.2020.6319
   Bate A, 2009, PHARMACOEPIDEM DR S, V18, P427, DOI 10.1002/pds.1742
   Bessiere F, 2020, JAMA CARDIOL, V5, P1067, DOI 10.1001/jamacardio.2020.1787
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Centre for Disease Control and Prevention, RISK SEV ILLN INCR A
   Chatre C, 2018, DRUG SAFETY, V41, P919, DOI 10.1007/s40264-018-0689-4
   Chen CY, 2006, CLIN TOXICOL, V44, P173, DOI 10.1080/15563650500514558
   Clark M, 2018, REGUL TOXICOL PHARM, V96, P94, DOI 10.1016/j.yrtph.2018.04.018
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Dal-Re R, 2020, BASIC CLIN PHARMACOL, V127, P445, DOI 10.1111/bcpt.13489
   Elsevier, 2019, PHARMAPENDIUM FACT S
   Jin YF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040372
   Juurlink DN, 2020, CAN MED ASSOC J, V192, pE450, DOI 10.1503/cmaj.200528
   Katayama M, 2018, J ULTRAS MED, V37, P217, DOI 10.1002/jum.14320
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   O'Laughlin JP, 2016, CASE REP CARDIOL, V2016, DOI 10.1155/2016/4626279
   Park KM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156410
   R Core Team, 2019, R LANG ENV STAT COMP
   Rahman MM, 2017, CLIN DRUG INVEST, V37, P1143, DOI 10.1007/s40261-017-0574-4
   Rees KE, 2020, DRUG SAFETY, V43, P607, DOI 10.1007/s40264-020-00928-1
   Sapp JL, 2020, CAN J CARDIOL, V36, P948, DOI 10.1016/j.cjca.2020.04.003
   Soong TR, 2007, HUM PATHOL, V38, P1858, DOI 10.1016/j.humpath.2007.06.013
   Sturrock BRH, 2020, CLIN MED, V20, P278, DOI 10.7861/clinmed.2020-0129
   Sumpter MD, 2012, LUPUS, V21, P1594, DOI 10.1177/0961203312462757
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   Varnava AM, 2000, HEART, V84, P476, DOI 10.1136/heart.84.5.476
   Yogasundaram H, 2014, CAN J CARDIOL, V30, P1706, DOI 10.1016/j.cjca.2014.08.016
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 29
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-8569
EI 1099-1557
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD DEC
PY 2020
VL 29
IS 12
BP 1689
EP 1695
DI 10.1002/pds.5155
EA NOV 2020
PG 7
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA PC0UZ
UT WOS:000585814700001
PM 33078448
DA 2021-01-01
ER

PT J
AU Cattaneo, D
   Pasina, L
   Maggioni, AP
   Giacomelli, A
   Oreni, L
   Covizzi, A
   Bradanini, L
   Schiuma, M
   Antinori, S
   Ridolfo, A
   Gervasoni, C
AF Cattaneo, Dario
   Pasina, Luca
   Maggioni, Aldo Pietro
   Giacomelli, Andrea
   Oreni, Letizia
   Covizzi, Alice
   Bradanini, Lucia
   Schiuma, Marco
   Antinori, Spinello
   Ridolfo, Annalisa
   Gervasoni, Cristina
TI Drug-Drug Interactions and Prescription Appropriateness in Patients with
   COVID-19: A Retrospective Analysis from a Reference Hospital in Northern
   Italy
SO DRUGS & AGING
LA English
DT Article
AB Background Patients hospitalised with severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2; coronavirus 2019 disease (COVID-19)] infection are frequently older with co-morbidities and receiving polypharmacy, all of which are known risk factors for drug-drug interactions (DDIs). The pharmacological burden may be further aggravated by the addition of treatments for COVID-19. Objective The aim of this study was to assess the risk of potential DDIs upon admission and during hospitalisation in patients with COVID-19 treated at our hospital. Methods We retrospectively analysed 502 patients with COVID-19 (mean age 61 +/- 16 years, range 15-99) treated at our hospital with a proven diagnosis of SARS-CoV-2 infection hospitalised between 21 February and 30 April 2020 and treated with at least two drugs. Results Overall, 68% of our patients with COVID-19 were exposed to at least one potential DDI, and 55% were exposed to at least one potentially severe DDI. The proportion of patients experiencing potentially severe DDIs increased from 22% upon admission to 80% during hospitalisation. Furosemide, amiodarone and quetiapine were the main drivers of potentially severe DDIs upon admission, and hydroxychloroquine and particularly lopinavir/ritonavir were the main drivers during hospitalisation. The majority of potentially severe DDIs carried an increased risk of cardiotoxicity. No potentially severe DDIs were identified in relation to tocilizumab and remdesivir. Conclusions Among hospitalised patients with COVID-19, concomitant treatment with lopinavir/ritonavir and hydroxychloroquine led to a dramatic increase in the number of potentially severe DDIs. Given the high risk of cardiotoxicity and the scant and conflicting data concerning their efficacy in treating SARS-CoV-2 infection, the use of lopinavir/ritonavir and hydroxychloroquine in patients with COVID-19 with polypharmacy needs to be carefully considered.
C1 [Cattaneo, Dario; Gervasoni, Cristina] ASST Fatebenefratelli Sacco Univ Hosp, Gest Ambulatoriale Politerapie GAP Outpatient Cli, Milan, Italy.
   [Cattaneo, Dario] ASST Fatebenefratelli Sacco Univ Hosp, Unit Clin Pharmacol, Milan, Italy.
   [Pasina, Luca] Ist Ric Farmacol Mario Negri IRCCS, Dept Neurosci, Milan, Italy.
   [Maggioni, Aldo Pietro] ANMCO Res Ctr, Florence, Italy.
   [Maggioni, Aldo Pietro] Maria Cecilia Hosp, GVM Care & Res, Cotignola, Italy.
   [Giacomelli, Andrea; Oreni, Letizia; Covizzi, Alice; Bradanini, Lucia; Schiuma, Marco; Antinori, Spinello; Ridolfo, Annalisa; Gervasoni, Cristina] ASST Fatebenefratelli Sacco Univ Hosp, Dept Infect Dis, Via GB Grassi 74, I-20157 Milan, Italy.
RP Gervasoni, C (corresponding author), ASST Fatebenefratelli Sacco Univ Hosp, Gest Ambulatoriale Politerapie GAP Outpatient Cli, Milan, Italy.; Gervasoni, C (corresponding author), ASST Fatebenefratelli Sacco Univ Hosp, Dept Infect Dis, Via GB Grassi 74, I-20157 Milan, Italy.
EM cristina.gervasoni@unimi.it
RI Giacomelli, Andrea/AAA-4642-2019; Maggioni, Aldo Pietro/AAL-5334-2020;
   Pasina, Luca/AAB-1877-2020
OI Giacomelli, Andrea/0000-0003-3685-4289; Maggioni, Aldo
   Pietro/0000-0003-2764-6779; Pasina, Luca/0000-0002-4777-1350
CR Abolbashari Mehran, 2017, Cardiovascular & Hematological Agents in Medicinal Chemistry, V15, P31, DOI 10.2174/1871525715666170529093442
   Aggarwal G, 2020, AM J CARDIOL, V128, P147, DOI 10.1016/j.amjcard.2020.04.054
   Aggarwal G, 2020, CURR PROB CARDIOLOGY, V45, DOI 10.1016/j.cpcardiol.2020.100617
   Antoniazzi S, 2015, EUR J INTERN MED, V26, pE52, DOI 10.1016/j.ejim.2015.07.004
   Back D, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25449
   Baumgartner AD, 2020, J CLIN PHARM THER, V45, P453, DOI 10.1111/jcpt.13103
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cattaneo D, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104898
   Cattaneo D, 2019, EXPERT OPIN DRUG MET, V15, P927, DOI 10.1080/17425255.2019.1685495
   Chary A, 2017, EXPERT REV CLIN PHAR, V10, P1329, DOI 10.1080/17512433.2017.1377610
   Chiarelli MT, 2020, EUR J INTERN MED, P30294
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Cooper JA, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009235
   Ferrau F, 2020, J ENDOCRINOL INVEST, DOI 10.1007/s40618-020-01384-5
   Gandhi Zainab, 2020, SN Compr Clin Med, P1, DOI 10.1007/s42399-020-00462-2
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gerard A, 2020, THERAPIE, V75, P371, DOI 10.1016/j.therap.2020.05.002
   Ghasemiyeh P, 2020, THER CLIN RISK MANAG, V16, P595, DOI 10.2147/TCRM.S259152
   Ghibelli S, 2013, DRUG AGING, V30, P821, DOI 10.1007/s40266-013-0109-5
   Jankelson L, 2020, HEART RHYTHM, V17, P1472, DOI 10.1016/j.hrthm.2020.05.008
   Javelot H, 2020, BRIT J CLIN PHARMACO, V86, P1176, DOI 10.1111/bcp.14335
   Kanno Takeshi, 2019, Curr Gastroenterol Rep, V21, P65, DOI 10.1007/s11894-019-0732-3
   Leegwater E, 2020, CLIN INFECT DIS
   Liu XF, 2020, J INFECTION, V81, pE95, DOI 10.1016/j.jinf.2020.04.008
   Mannucci PM, 2018, INTERN EMERG MED, V13, P1191, DOI 10.1007/s11739-018-1941-8
   Martocchia Antonio, 2020, Drugs Real World Outcomes, V7, P243, DOI 10.1007/s40801-020-00193-9
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   Monteiro L, 2019, J MED INTERNET RES, V21, DOI 10.2196/15385
   Pasina L, 2020, EUR J CLIN PHARMACOL, V76, P1011, DOI 10.1007/s00228-020-02871-7
   Pasina L, 2016, DRUG AGING, V33, P143, DOI 10.1007/s40266-015-0336-z
   Pasqualetti G, 2015, CLIN INTERV AGING, V10, P1457, DOI 10.2147/CIA.S87466
   Petrini E, 2020, IRISH J MED SCI, V189, P953, DOI 10.1007/s11845-019-02148-8
   Salahudeen MS, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0029-9
   Saleh M, 2020, CIRC-ARRHYTHMIA ELEC, V13, DOI 10.1161/CIRCEP.120.008662
   Schnoll-Sussman Felice, 2020, Gastrointest Endosc Clin N Am, V30, P239, DOI 10.1016/j.giec.2019.12.005
   Schoergenhofer C, 2020, ANN INTERN MED, V173, P670, DOI 10.7326/M20-1550
   Smith PF, 2020, BRIT J CLIN PHARMACO, DOI 10.1111/bcp.14314
   Thurmann PA, 2020, CURR OPIN ANESTHESIO, V33, P109, DOI 10.1097/ACO.0000000000000814
   Vrdoljak Davorka, 2015, Acta Med Acad, V44, P159, DOI 10.5644/ama2006-124.142
   Wang X, 2020, INT J CLIN PHARM-NET, V42, P23, DOI 10.1007/s11096-019-00958-5
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yang K, 2020, CTS-CLIN TRANSL SCI, V13, P842, DOI 10.1111/cts.12815
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 44
TC 0
Z9 0
U1 1
U2 1
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170-229X
EI 1179-1969
J9 DRUG AGING
JI Drugs Aging
PD DEC
PY 2020
VL 37
IS 12
BP 925
EP 933
DI 10.1007/s40266-020-00812-8
EA NOV 2020
PG 9
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA OZ2RS
UT WOS:000585773200001
PM 33150470
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Barage, S
   Karthic, A
   Bavi, R
   Desai, N
   Kumar, R
   Kumar, V
   Lee, KW
AF Barage, Sagar
   Karthic, A.
   Bavi, Rohit
   Desai, Neetin
   Kumar, Raj
   Kumar, Vikas
   Lee, Keun Woo
TI Identification and characterization of novel RdRp and Nsp15 inhibitors
   for SARS-COV2 using computational approach
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE RdRp; Nsp15; homology modeling; drug repurposing; virtual screening
ID DEPENDENT RNA-POLYMERASE; CRYSTAL-STRUCTURE; SARS-CORONAVIRUS; PROTEIN;
   ENDORIBONUCLEASE; GENERATION; DISCOVERY; DOCKING; TOOL
AB The World Health Organization has declared COVID-19 as a global health emergency. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and highlights an urgent need for therapeutics. Here, we have employed a series of computer-aided drug repurposing campaign to discover inhibitors of RNA dependent RNA polymerase (RdRp) and Nsp15/EndoU. Subsequently, MD simulation has been performed to observe dynamic behavior of identified leads at the active site of RdRp and Nsp15. We successfully identified novel lead molecule such as Alectinib for RdRp while Naldemedine and Ergotamine for NSP15. These lead molecules were accommodated in the active site of the enzyme and stabilized by the networks of the hydrogen bond, pi type and hydrophobic interaction with key residues of either target. Interestingly, identified compounds show molecular mimicry in terms of molecular interactions with key residues of RdRp and Nsp15 essential for catalysis and substrate interaction. Previously, Alectinib, Naldemedine and Ergotamine were used as drug in different diseases might be repurposed against selected protein targets of COVID19. Finally, we propose that the identified inhibitors represent a novel lead molecule to design a more effective inhibitor to stop the progress of pathogen.
   Communicated by Ramaswamy H. Sarma
C1 [Barage, Sagar; Karthic, A.] Amity Univ, Amity Inst Biotechnol, Mumbai 410206, Maharashtra, India.
   [Bavi, Rohit] China Pharmaceut Univ, Sch Engn, Dept Biomed Engn, State Key Lab Nat Med, Nanjing, Peoples R China.
   [Bavi, Rohit] Punyashlok Ahilyadevi Holkar Solapur Univ, Sch Chem Sci, Solapur, Maharashtra, India.
   [Desai, Neetin] NMIMS Univ, SDSOS, Mumbai, Maharashtra, India.
   [Kumar, Raj] Jaypee Univ Informat Technol, Dept Biotechnol & Bioinformat, Solan, Himachal Prades, India.
   [Kumar, Vikas; Lee, Keun Woo] Gyeongsang Natl Univ GNU, Res Inst Nat Sci RINS, Plant Mol Biol & Biotechnol Res Ctr PMBBRC, Div Life Sci,Div Appl Life Sci BK21 Plus, Jinju, South Korea.
RP Barage, S (corresponding author), Amity Univ, Amity Inst Biotechnol, Mumbai 410206, Maharashtra, India.
EM sagarbarage@gmail.com
OI KUMAR, VIKAS/0000-0003-4468-3459; Mogilevskaya, Sofia
   G/0000-0003-3452-7284
CR Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Appleby TC, 2015, SCIENCE, V347, P771, DOI 10.1126/science.1259210
   Barage S, 2017, J MOL GRAPH MODEL, V75, P322, DOI 10.1016/j.jmgm.2017.06.009
   Barage SH, 2018, AMINO ACIDS, V50, P593, DOI 10.1007/s00726-018-2543-5
   Bavi R, 2019, BIOCHEM BIOPH RES CO, V509, P937, DOI 10.1016/j.bbrc.2019.01.028
   Bavi R, 2017, J RECEPT SIG TRANSD, V37, P224, DOI 10.1080/10799893.2016.1212376
   Bavi R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147190
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Bhardwaj K, 2004, J VIROL, V78, P12218, DOI 10.1128/JVI.78.22.12218-12224.2004
   Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034
   Bruenn JA, 2003, NUCLEIC ACIDS RES, V31, P1821, DOI 10.1093/nar/gkg277
   Chan-Yeung M., 2003, RESPIROLOGY S, V8, pS9
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978-1-4939-2269-7_19
   Deng XF, 2019, J VIROL, V93, DOI [10.1128/JVI.02000-18, 10.1128/jvi.02000-18]
   Deng XF, 2018, VIROLOGY, V517, P157, DOI 10.1016/j.virol.2017.12.024
   Deng XF, 2017, P NATL ACAD SCI USA, V114, pE4251, DOI 10.1073/pnas.1618310114
   Dhama K, 2020, CLIN MICROBIOL REV, V33, DOI 10.1128/CMR.00028-20
   ELFIKY AA, 2020, J BIOMOL STRUCT 0424, DOI DOI https://doi.org/10.1080/07391102.2020.1758789
   ELFIKY AA, 2020, J BIOMOL STRUCT 0505, DOI DOI https://doi.org/10.1080/07391102.2020.1761882
   Elfiky AA, 2017, J MED VIROL, V89, P1040, DOI 10.1002/jmv.24736
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Fiser A, 2010, METHODS MOL BIOL, V673, P73, DOI 10.1007/978-1-60761-842-3_6
   Fung TS, 2019, ANNU REV MICROBIOL, V73, P529, DOI 10.1146/annurev-micro-020518-115759
   Gorbalenya AE, 2004, J VIROL, V78, P7863, DOI 10.1128/JVI.78.15.7863-7866.2004
   Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Hou TJ, 2011, J CHEM INF MODEL, V51, P69, DOI 10.1021/ci100275a
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Ibrahim IM, 2019, LIFE SCI, V226, P156, DOI 10.1016/j.lfs.2019.04.022
   Ivanov KA, 2004, P NATL ACAD SCI USA, V101, P12694, DOI 10.1073/pnas.0403127101
   Jia HX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01945
   Joseph JS, 2007, J VIROL, V81, P6700, DOI 10.1128/JVI.02817-06
   Kang H, 2007, J VIROL, V81, P13587, DOI 10.1128/JVI.00547-07
   Kindler E, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006195
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460
   Kumar R, 2019, J MOL GRAPH MODEL, V88, P92, DOI 10.1016/j.jmgm.2018.12.006
   Kumar R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00186-9
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li J, 2016, BRIEF BIOINFORM, V17, P2, DOI 10.1093/bib/bbv020
   MACHITANI M, 2020, CANCER SCI 0912, DOI DOI https://doi.org/10.1111/cas.14618
   Meshram RJ, 2020, J BIOMOL STRUCT DYN, V38, P1168, DOI 10.1080/07391102.2019.1597770
   Miteva MA, 2010, NUCLEIC ACIDS RES, V38, pW622, DOI 10.1093/nar/gkq325
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Ricagno S, 2006, P NATL ACAD SCI USA, V103, P11892, DOI 10.1073/pnas.0601708103
   Richman D.D., 2016, CLIN VIROLOGY
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626
   Sharma A, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106054
   Shen MY, 2006, PROTEIN SCI, V15, P2507, DOI 10.1110/ps.062416606
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Steindl T, 2004, J CHEM INF COMP SCI, V44, P1849, DOI 10.1021/ci049844i
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Stromgaard K., 2016, TXB DRUG DESIGN DISC
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Vorontsov II, 2011, J COMPUT CHEM, V32, P1043, DOI 10.1002/jcc.21683
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu Y, 2010, PROTEIN CELL, V1, P491, DOI 10.1007/s13238-010-0061-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zoete V, 2011, J COMPUT CHEM, V32, P2359, DOI 10.1002/jcc.21816
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 67
TC 1
Z9 1
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1841026
EA NOV 2020
PG 18
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OM5PY
UT WOS:000586077700001
PM 33155531
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ali, KK
   Osman, MS
   Baskonus, HM
   Elazabb, NS
   Ilhan, E
AF Ali, Khalid K.
   Osman, Mohamed S.
   Baskonus, Haci Mehmet
   Elazabb, Nasser S.
   Ilhan, Esin
TI Analytical and numerical study of the HIV-1 infection of CD4(+) T-cells
   conformable fractional mathematical model that causes acquired
   immunodeficiency syndrome with the effect of antiviral drug therapy
SO MATHEMATICAL METHODS IN THE APPLIED SCIENCES
LA English
DT Article; Early Access
DE finite difference method; HIV&#8208; 1 infection of CD4(+) T&#8208;
   cells conformable fractional mathematical model; Kudryashov method;
   modified Kudryashov method
ID FOKAS-LENELLS EQUATION; COMPLEX WAVE SOLUTIONS; SOLITON-SOLUTIONS;
   2019-NCOV; DNA; EW
AB In this paper, we introduce a numerical and analytical study of the HIV-1 infection of CD4(+) T-cells conformable fractional mathematical model. This model is studied analytically by Kudryashov and modified Kudryashov methods and numerically by finite difference method. A comparison between the results of the analytical and numerical methods is investigated. We also give some figures that show how accurate the solutions will be obtained from analytical and numerical methods.
C1 [Ali, Khalid K.] Al Azhar Univ, Fac Sci, Dept Math, Cairo, Egypt.
   [Osman, Mohamed S.; Elazabb, Nasser S.] Cairo Univ, Fac Sci, Dept Math, Giza, Egypt.
   [Osman, Mohamed S.] Umm Al Qura Univ, Fac Appl Sci, Dept Math, Mecca 21955, Saudi Arabia.
   [Baskonus, Haci Mehmet] Harran Univ, Fac Educ, Dept Math & Sci Educ, Sanliurfa, Turkey.
   [Ilhan, Esin] Ahi Evran Univ, Fac Engn & Architecture, TR-40500 Kirsehir, Turkey.
RP Baskonus, HM (corresponding author), Harran Univ, Fac Educ, Dept Math & Sci Educ, Sanliurfa, Turkey.
EM hmbaskonus@gmail.com
RI Baskonus, Haci Mehmet/H-4335-2019; Osman, M. S./E-3084-2013; BASKONUS,
   HACI MEHMET/ABF-9434-2020
OI Baskonus, Haci Mehmet/0000-0003-4085-3625; Osman, M.
   S./0000-0002-5783-0940; BASKONUS, HACI MEHMET/0000-0003-4085-3625
CR Abdel-Gawad HI, 2020, CHINESE J PHYS, V67, P147, DOI 10.1016/j.cjph.2020.05.027
   Abdel-Gawad HI, 2014, INDIAN J PURE AP MAT, V45, P1, DOI 10.1007/s13226-014-0047-x
   Abdel-Gawad HI, 2013, KYUNGPOOK MATH J, V53, P661, DOI 10.5666/KMJ.2013.53.4.680
   Abdel-Gawad HI, 2013, J PHYS SOC JPN, V82, DOI 10.7566/JPSJ.82.044004
   Agosto LM, 2018, CELL REP, V24, P2088, DOI 10.1016/j.celrep.2018.07.079
   Ak T, 2020, J APPL ANAL COMPUT, V10, P2145, DOI 10.11948/20190341
   ALGHAFRI KS, 2019, APPL MATH NONLINEAR, V4, P289, DOI DOI 10.2478/AMNS.2019.2.00026
   Ali KK, 2020, OPTIK, V208, DOI 10.1016/j.ijleo.2019.164132
   Ali KK, 2020, ADV DIFFER EQU-NY, V2020, DOI 10.1186/s13662-020-02951-z
   Ali KK, 2018, OPT QUANT ELECTRON, V50, DOI 10.1007/s11082-018-1330-6
   Ali KK, 2018, CHAOS SOLITON FRACT, V106, P304, DOI 10.1016/j.chaos.2017.11.038
   Ali KK, 2020, CHAOS SOLITON FRACT, V139, P110089
   Ameen I, 2020, CHAOS SOLITON FRACT, V137, DOI 10.1016/j.chaos.2020.109892
   Asla KA, 2020, INT J ELECTROCHEM SC, V15, P3891, DOI 10.20964/2020.05.29
   Atangana A, 2020, CHAOS SOLITON FRACT, V136, DOI 10.1016/j.chaos.2020.109860
   Atangana A, 2020, CHAOS SOLITON FRACT, V130, DOI 10.1016/j.chaos.2019.109399
   Atangana A, 2018, CHAOS SOLITON FRACT, V114, P347, DOI 10.1016/j.chaos.2018.07.022
   Atangana A, 2017, CHAOS SOLITON FRACT, V102, P396, DOI 10.1016/j.chaos.2017.04.027
   Atangana A, 2015, FRACTIONAL DYNAMICS, P174
   Baleanu D, 2020, ADV DIFF EQ, V2020, P1, DOI DOI 10.1186/S13662-020-02684-Z
   Baleanu D, 2020, APPL MATH INFORM SCI, V14, P1
   Brzezinsk Dariusz W., 2018, APPL MATH NONLINEAR, V3, P487, DOI [10.2478/AMNS.2018.2.00038, DOI 10.2478/AMNS.2018.2.00038]
   Cao Y, 2019, CHAOS, V29, DOI 10.1063/1.5085397
   Cattani C., 2018, J ADV ENG COMPUT, V2, P224, DOI [10.25073/jaec.201824.225, DOI 10.25073/jaec.201824.225]
   Cattani C, 2015, FRACTIONAL DYNAMICS, P1
   Cattani C, 2013, B MATH BIOL, V75, P1544, DOI 10.1007/s11538-013-9859-9
   Cetinkaya A, 2013, MATH COMPUT MODEL, V57, P2349, DOI 10.1016/j.mcm.2011.12.015
   Chen LP, 2020, FRONT INFORM TECH EL, V21, P866, DOI 10.1631/FITEE.1900709
   Chen T, 2020, MATH MODEL SIMULATIN, V9, P1, DOI DOI 10.1186/s40249-019-0617-6
   Culshaw RV, 2003, J MATH BIOL, V46, P425, DOI 10.1007/s00285-002-0191-5
   Danane J, 2020, CHAOS SOLITON FRACT, V136, DOI 10.1016/j.chaos.2020.109787
   Ding Y, 2019, OPTIK, V181, P503, DOI 10.1016/j.ijleo.2018.12.064
   El-Sherif AA, 2013, J SOLUTION CHEM, V42, P412, DOI 10.1007/s10953-013-9966-0
   Gao W, 2020, ADV DIFFER EQU-NY, V2020, DOI 10.1186/s13662-020-02831-6
   Gao W, 2020, CHAOS SOLITON FRACT, V138, DOI 10.1016/j.chaos.2020.109929
   Gao W, 2020, BIOLOGY-BASEL, V9, DOI 10.3390/biology9050107
   Goufo EFD, 2020, CHAOS SOLITON FRACT, V139, DOI 10.1016/j.chaos.2020.110030
   Inan B, 2020, MATH METHOD APPL SCI, V43, P2588, DOI 10.1002/mma.6067
   Kayum MA, 2020, EUR PHYS J PLUS, V135, DOI 10.1140/epjp/s13360-020-00573-8
   Khan MA, 2020, ALEX ENG J, V59, P2379, DOI 10.1016/j.aej.2020.02.033
   Kiymaz O, 2013, J NONLINEAR SCI APPL, V9, P3611
   Kumar S., 2020, CHAOS SOLITON FRACT, V141, P110321
   Kumar V. S., 2019, INT J APPL COMPUT MA, V5, P127
   lhan E., 2020, APPL MATH NONLINEAR, V5, P171, DOI [10.2478/amns.2020.1.00016, DOI 10.2478/AMNS.2020.1.00016]
   Liu JG, 2019, OPTIK, V180, P917, DOI 10.1016/j.ijleo.2018.12.002
   Lu D, 2020, PHYSICA A, V537, DOI 10.1016/j.physa.2019.122634
   Lu D, 2019, RESULTS PHYS, V14, DOI 10.1016/j.rinp.2019.102491
   Nuruddeen RI, 2018, COMMUN THEOR PHYS, V70, P405, DOI 10.1088/0253-6102/70/4/405
   ONUR K, 2010, INT J CONT MATH SCI, V5, P1819
   Osman MS, 2018, U POLITEH BUCH SER A, V80, P267
   OSMAN MS, 2019, NONLINEAR ENG, V8, P559, DOI DOI 10.1515/nleng-2018-0163
   Owolabi KM, 2019, CHAOS SOLITON FRACT, V126, P41, DOI 10.1016/j.chaos.2019.06.001
   Owolabi KM, 2019, PHYSICA A, V523, P1072, DOI 10.1016/j.physa.2019.04.017
   Rao JG, 2019, PHYS LETT A, V383, P1138, DOI 10.1016/j.physleta.2018.12.045
   Raslan KR, 2017, EUR PHYS J PLUS, V132, DOI 10.1140/epjp/i2017-11590-9
   Raslan KR, 2017, CHAOS SOLITON FRACT, V103, P404, DOI 10.1016/j.chaos.2017.06.029
   Raslan K. R., 2017, NEW TRENDS MATH SCI, V5, P114
   Raza N, 2020, ADV DIFFER EQU-NY, V2020, DOI 10.1186/s13662-020-02973-7
   Ruelas DS, 2013, CELL, V155, P519, DOI 10.1016/j.cell.2013.09.044
   Singh J, 2018, APPL MATH COMPUT, V316, P504, DOI 10.1016/j.amc.2017.08.048
   Sun Y, 1999, J EXP MED, V189, P1391, DOI 10.1084/jem.189.9.1391
   Xiao-Jun XJ, 2016, THERM SCI, V20, P753, DOI DOI 10.2298/TSCI151224222Y
   Xu SL, 2020, APPL MATH LETT, V106, DOI 10.1016/j.aml.2020.106230
   Yang AM, 2016, THERM SCI, V20, pS717, DOI 10.2298/TSCI16S3717Y
   Yang AM, 2014, ABSTR APPL ANAL, DOI 10.1155/2014/372741
   Yang X. J., 2019, GEN FRACTIONAL DERIV
   Yang XJ, 2019, THERM SCI, V23, P3711, DOI 10.2298/TSCI180825254Y
   Yang XJ, 2019, THERM SCI, V23, P4117, DOI 10.2298/TSCI191028427Y
   Yang XJ, 2019, THERM SCI, V23, P3751, DOI 10.2298/TSCI180921260Y
   Yang XJ, 2019, THERM SCI, V23, P1555, DOI 10.2298/TSCI190220277Y
   Yang XJ, 2018, P ROMANIAN ACAD A, V19, P45
   Yang XJ, 2002, GEN FRACTIONAL DERIV
   YOKUS A, 2019, APPL MATH NONLINEAR, V4, P35, DOI DOI 10.2478/AMNS.2019.1.00004
   Yu WT, 2020, NONLINEAR DYNAM, V100, P1611, DOI 10.1007/s11071-020-05598-3
   Zhang Y, 2015, ENTROPY-SWITZ, V17, P6753, DOI 10.3390/e17106753
NR 75
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0170-4214
EI 1099-1476
J9 MATH METHOD APPL SCI
JI Math. Meth. Appl. Sci.
DI 10.1002/mma.7022
EA NOV 2020
PG 17
WC Mathematics, Applied
SC Mathematics
GA OM2IF
UT WOS:000585850200001
DA 2021-01-01
ER

PT J
AU Baildya, N
   Ghosh, NN
   Chattopadhyay, AP
AF Baildya, Nabajyoti
   Ghosh, Narendra Nath
   Chattopadhyay, Asoke P.
TI Inhibitory activity of hydroxychloroquine on COVID-19 main protease: An
   insight from MD-simulation studies
SO JOURNAL OF MOLECULAR STRUCTURE
LA English
DT Article
DE Hydroxychloroquine; COVID-19 main chain protease; Molecular docking;
   MD-Simulation
ID CORONAVIRUS; OPTIMIZATION; CHLOROQUINE; GROMACS; MODEL
AB The present work is an investigation to test hydroxychloroquine as an inhibitor for the COVID-19 main protease. Molecular docking studies revealed a high docking score and interaction energies and decent level of docking within the cavity in protease moiety. Molecular dynamics simulations also lead to the evaluation of conformational energies, average H-bonding distance, RMSD plots etc. Large RMSD fluctuations for the first 2 ns seem to provide the conformational and rotational changes associated with the drug molecule when it comes into the vicinity on the protease matrix. Snapshots of structural changes with respect to time vividly indicates that drug molecule has a profound impact on the binding sites as well as overall geometry of the protease moiety. On the whole, hydroxyxhloroquine confers good inhibitory response to COVID-19 main protease. We hope the present study should help workers in the field to develop potential vaccines and therapeutics against the novel coronavirus. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Baildya, Nabajyoti; Chattopadhyay, Asoke P.] Univ Kalyani, Dept Chem, Kalyani 741235, W Bengal, India.
   [Ghosh, Narendra Nath] Univ Gour Banga, Dept Chem, Mokdumpur 732103, Malda, India.
RP Chattopadhyay, AP (corresponding author), Univ Kalyani, Dept Chem, Kalyani 741235, W Bengal, India.
EM nabajyotibaildya@gmail.com; ghosh.naren13@gmail.com; asoke@klyuniv.ac.in
OI BAILDYA, NABAJYOTI/0000-0002-6672-9844
CR Abraham MJ, 2011, J COMPUT CHEM, V32, P2031, DOI 10.1002/jcc.21773
   BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E
   Biot C, 2006, J MED CHEM, V49, P2845, DOI 10.1021/jm0601856
   Boonstra S, 2016, J PHYS CHEM B, V120, P3692, DOI 10.1021/acs.jpcb.6b01316
   Bosseboeuf E., 2018, J ANTIVIR ANTIRETROV, V10, P6, DOI [10.4172/1948-5964.1000173, DOI 10.4172/1948-5964.1000173]
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Kahn Jeffrey S, 2005, Pediatr Infect Dis J, V24, pS223, DOI 10.1097/01.inf.0000188166.17324.60
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lee S, 2014, J PHYS CHEM B, V118, P547, DOI 10.1021/jp410344g
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Marmor MF, 2016, OPHTHALMOLOGY, V123, P1386, DOI 10.1016/j.ophtha.2016.01.058
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Philippe C., 2020, INT J ANTIMICROB AG, DOI [10.1016/j.ijantimicag.2020.105923., DOI 10.1016/J.IJANTIMICAG.2020.105923]
   Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   TYRRELL DA, 1966, LANCET, V1, P76
   Wang LS, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105948
NR 22
TC 2
Z9 2
U1 17
U2 17
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-2860
EI 1872-8014
J9 J MOL STRUCT
JI J. Mol. Struct.
PD NOV 5
PY 2020
VL 1219
AR 128595
DI 10.1016/j.molstruc.2020.128595
PG 6
WC Chemistry, Physical
SC Chemistry
GA NO3JO
UT WOS:000569381800007
PM 32834108
OA Green Published
DA 2021-01-01
ER

PT J
AU Hou, FS
   Bi, FY
   Jiao, R
   Luo, D
   Song, KX
AF Hou, Fengsu
   Bi, Fengying
   Jiao, Rong
   Luo, Dan
   Song, Kangxing
TI Gender differences of depression and anxiety among social media users
   during the COVID-19 outbreak in China:a cross-sectional study
SO BMC PUBLIC HEALTH
LA English
DT Article
DE COVID-19; Depression; Anxiety; Gender differences; Social media use
ID INTIMATE PARTNER VIOLENCE; MENTAL-HEALTH; FAMILY-THERAPY; INTERNET USE;
   PREVALENCE; DISORDERS; WECHAT; FACE
AB BackgroundStudies have shown that the outbreak of infectious diseases would result in mental health problems. Females are in greater risk for psychological problems than males. The present study investigated gender differences of depression and anxiety and explored associated factors during the COVID-19 epidemic among Chinese social media users.MethodsWe recruited 3088 participants through social media cross China. Participants completed sociodemographic and the COVID-19 epidemic related questions, the 2-item Patient Health Questionnaire (PHQ-2), and the 2-item Generalized Anxiety Disorder Scale (GAD-2), the Chinese version of the 10-item Connor-Davidson Resilience Scale. We applied Chi-square test and ANOVA for data description and linear regression analysis for exploring factors associated with depression and anxiety.ResultsOf 3063 participants eligible for analysis, the total prevalence of depression and anxiety was 14.14 and 13.25%. Females were experiencing more severe stress and anxiety symptoms, while males showed better resilience to stress. The severity of depression symptoms would decrease with the increase of age resilience, and it would increase if being unemployed, feeling less adapted, being more stressed. The severity of anxiety symptoms would decrease with higher education and better resilience, and it would increase if being female, spending over 60min on COVID-19 related information, less adapted, and being more stressed.ConclusionThe findings show the increased prevalence of depression and anxiety in Chinese population during the COVID-19 epidemic, and females are experiencing more severe anxiety symptoms than males. As social media is the current main resource of information related to COVID-19, interventions should be implemented to help users to limit the time they spend on social media and to get key information related to the epidemic from authoritative and authentic resource to avoid infodemic and prevent mental health problems.
C1 [Hou, Fengsu] Shenzhen Kangning Hosp, Dept Publ Hlth, 1080 Cuizhu Rd, Shenzhen 518020, Guangdong, Peoples R China.
   [Bi, Fengying; Luo, Dan] Cent South Univ, Xiangya Sch Publ Hlth, Dept Social Med, 110 Xiangya Rd, Changsha 410078, Hunan, Peoples R China.
   [Jiao, Rong] Hainan Med Univ, Clin Coll 1, 3 Xueyuan Rd, Haikou 570100, Hainan, Peoples R China.
   [Song, Kangxing] Chinese Peoples Liberat Army Gen Hosp, Dept Cardiol, Med Ctr 1, 51 Fucheng Rd, Beijing 100853, Peoples R China.
RP Song, KX (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Dept Cardiol, Med Ctr 1, 51 Fucheng Rd, Beijing 100853, Peoples R China.
EM skx301@126.com
FU Military Logistics Research Major Project [ALB18J002, BHJ15J003]
FX This study is funded by Military Logistics Research Major Project
   (ALB18J002) and Key Project (BHJ15J003), Kangxing Song is the PI of both
   projects. The funder had no role in study design, data collection, data
   analysis, data interpretation, or writing the manuscript.
CR Afifi M., 2007, SMJ Singapore Medical Journal, V48, P385
   [Anonymous], 2013, R LANGUAGE ENV STAT
   Chan KL, 2012, J INTERPERS VIOLENCE, V27, P793, DOI 10.1177/0886260511423242
   China Internet Network Information Center, 2019, 44 CHIN SAT REP INT
   Dhir A, 2018, INT J INFORM MANAGE, V40, P141, DOI 10.1016/j.ijinfomgt.2018.01.012
   Ellsberg M, 2008, LANCET, V371, P1165, DOI 10.1016/S0140-6736(08)60522-X
   Fox J, 2012, PACKAGE CAR PROGRAM
   Gao G, 1998, INT J INTERCULT REL, V22, P467, DOI 10.1016/S0147-1767(98)00019-4
   Halbreich U, 2007, J AFFECT DISORDERS, V102, P245, DOI 10.1016/j.jad.2006.09.023
   Harwit E, 2017, CHIN J COMMUN, V10, P312, DOI 10.1080/17544750.2016.1213757
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang CJ, 2017, CYBERPSYCH BEH SOC N, V20, P346, DOI 10.1089/cyber.2016.0758
   [黄悦勤 huang Yueqin], 2003, [中国心理卫生杂志, Chinese Mental Health Journal], V17, P521
   Huang YQ, 2019, LANCET PSYCHIAT, V6, P211, DOI 10.1016/S2215-0366(18)30511-X
   James SL, 2018, LANCET, V392, P1789, DOI 10.1016/s0140-6736(18)32279-7
   Kim KS, 2014, J ACAD LIBR, V40, P171, DOI 10.1016/j.acalib.2014.03.001
   Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C
   Kroenke K, 2007, ANN INTERN MED, V146, P317, DOI 10.7326/0003-4819-146-5-200703060-00004
   Kun P, 2009, PUBLIC HEALTH, V123, P703, DOI 10.1016/j.puhe.2009.09.017
   Lee EHM, 2016, PSYCHIAT SERV, V67, P766, DOI 10.1176/appi.ps.201500156
   Li N, 2007, COMPUT EDUC, V48, P301, DOI 10.1016/j.compedu.2005.01.007
   Lin LY, 2016, DEPRESS ANXIETY, V33, P323, DOI 10.1002/da.22466
   Liu L, 2014, J FAM THER, V36, P65, DOI 10.1111/j.1467-6427.2012.00582.x
   Liu ZW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151042
   Luk-Fong PYY, 2006, INT J ADV COUNS, V28, P331, DOI 10.1007/s10447-006-9023-4
   Primack BA, 2017, COMPUT HUM BEHAV, V69, P1, DOI 10.1016/j.chb.2016.11.013
   Qu ZY, 2012, J AFFECT DISORDERS, V136, P117, DOI 10.1016/j.jad.2011.08.021
   QuestMobile, 2020, 2020 CHIN MOB INT WA
   Revelle W., 2017, PSYCH PROCEDURES PER
   Riecher-Rossler A, 2010, EUR PSYCHIAT, V25, P189, DOI 10.1016/j.eurpsy.2009.03.002
   Riecher-Rossler A, 2017, LANCET PSYCHIAT, V4, P8, DOI 10.1016/S2215-0366(16)30348-0
   Shaw LH, 2002, CYBERPSYCHOL BEHAV, V5, P517, DOI 10.1089/109493102321018150
   Simonds VA, 2003, J AFFECT DISORDERS, V77, P197, DOI 10.1016/S0165-0327(02)00113-1
   Sze YT, 2011, AM J FAM THER, V39, P299, DOI 10.1080/01926187.2010.542073
   Tang CSK, 2008, AGGRESS VIOLENT BEH, V13, P10, DOI 10.1016/j.avb.2007.06.001
   Tencent News, 2020, TENCENT NEWS
   Tu S, 2018, BIOCHEM MOL BIOL EDU, V46, P555, DOI 10.1002/bmb.21170
   Vannucci A, 2017, J AFFECT DISORDERS, V207, P163, DOI 10.1016/j.jad.2016.08.040
   Wang L, 2014, SICHUAN MENTAL HLTH, V27, P198, DOI DOI 10.3969/J..1007-3256.2014.03.002
   Weiser EB, 2000, CYBERPSYCHOL BEHAV, V3, P167, DOI 10.1089/109493100316012
   Wu J, 2012, J BUSINESS CASE STUD, V8, P95
   Xiang Y T, 2014, East Asian Arch Psychiatry, V24, P37
   Xie ZT, 2017, J MENT HEALTH, V26, P43, DOI 10.1080/09638237.2016.1276525
   Ye ZJ, 2017, EUR J ONCOL NURS, V27, P36, DOI 10.1016/j.ejon.2017.01.004
   You ZQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130538
   Zarocostas J, 2020, LANCET, V395, P676, DOI 10.1016/S0140-6736(20)30461-X
   Zhang XY, 2019, PUBLIC HEALTH NUTR, V22, P2553, DOI 10.1017/S1368980019001009
   Zhang YL, 2013, ASIA-PAC PSYCHIAT, V5, P268, DOI 10.1111/appy.12103
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zhu X, 2008, SOC BEHAV PERSONAL, V36, P447, DOI 10.2224/sbp.2008.36.4.447
NR 50
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD NOV 4
PY 2020
VL 20
IS 1
AR 1648
DI 10.1186/s12889-020-09738-7
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OU0PP
UT WOS:000591238800001
PM 33148202
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Liu, M
   Zhang, HZ
   Huang, H
AF Liu, Miao
   Zhang, Hongzhong
   Huang, Hui
TI Media exposure to COVID-19 information, risk perception, social and
   geographical proximity, and self-rated anxiety in China
SO BMC PUBLIC HEALTH
LA English
DT Article
DE Self-rated anxiety; Media exposure; Social proximity; Geographical
   proximity; Risk perception
ID KNOWLEDGE
AB BackgroundThe coronavirus disease 2019 (COVID-19) is an emerging infectious disease that spreads around the world. The lack of effective antiviral drugs and vaccines, along with the relatively high mortality rate and high contagiousness, has raised strong public concerns over COVID-19, especially for people living in the most severely affected areas. This study aimed to clarify the influencing factors for the anxiety level among the Chinese people during the COVID-19 pandemic, with a particular focus on the media exposure to different COVID-19 information.MethodsA total of 4991 respondents were randomly recruited from a national online panel from February 12th, 2020 to February 14th, 2020, a period when the number of COVID-19 cases surpassed 10,000 in a single day, with the total cases in China reaching up to 90,000. The relationships between media exposure of COVID-19 information, social and geographical proximity to COVID-19, risk perceptions were assessed using hierarchical ordinary least squares regression analysis.ResultsThe media exposure to COVID-19 information was differently associated with anxiety. Meanwhile, the anxiety level was found to be high in respondents who personally knew someone infected with COVID-19 or those who living in an area with reported cases. Respondents who perceived more risks also reported a higher level of anxiety.ConclusionsThis study highlights the role of media exposure in affecting individuals' anxiety level during the COVID-19 pandemic. Besides, it is recommended that government and health professionals are recommended to adopt effective risk communication strategies to protect citizens' mental health during the pandemic.
C1 [Liu, Miao; Zhang, Hongzhong; Huang, Hui] Beijing Normal Univ, Coll Journalism & Commun, Xinwai Dajie 5 Hao, Beijing, Peoples R China.
RP Zhang, HZ (corresponding author), Beijing Normal Univ, Coll Journalism & Commun, Xinwai Dajie 5 Hao, Beijing, Peoples R China.
EM Hongzhongzhang123@gmail.com
CR Anderson A, 2019, CRIT EDUC, V10
   [Anonymous], 2020, MENTAL HLTH COVID 19
   [Anonymous], 2019, 44 CHINA STAT REPORT
   [Anonymous], 2019, 45 CHINA STAT REPORT
   [Anonymous], 2020, NAMING CORONAVIRUS D
   [Anonymous], 2020, NOTIFICATION VIRAL P
   Bergeron SL, 2005, EMERG INFECT DIS, V11, P732, DOI 10.3201/eid1105.040512
   Blakey SM, 2015, COGNITIVE THER RES, V39, P816, DOI 10.1007/s10608-015-9701-9
   Brug J, 2004, EMERG INFECT DIS, V10, P1486, DOI 10.3201/eid1008.040283
   Goodwin R, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-8
   Kim JH, 2011, EMERG INFECT DIS, V17, P2319, DOI 10.3201/eid1712.110321
   Lufkin B, 2020, CORONAVIRUS PSYCHOL
   Mahoney CT, 2015, INT J AGING HUM DEV, V81, P217, DOI 10.1177/0091415015621309
   Arias JP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186455
   Tavoli A, 2007, BMC GASTROENTEROL, V7, DOI 10.1186/1471-230X-7-28
   Van den Bulck J, 2009, EUR J PUBLIC HEALTH, V19, P370, DOI 10.1093/eurpub/ckp061
   Wheaton MG, 2012, COGNITIVE THER RES, V36, P210, DOI 10.1007/s10608-011-9353-3
   Zhang Q, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-92
   Zou L, 2020, N ENGL J MED
   ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008
NR 20
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD NOV 4
PY 2020
VL 20
IS 1
AR 1649
DI 10.1186/s12889-020-09761-8
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OU0PP
UT WOS:000591238800002
PM 33148201
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Simpson, JK
   Innes, S
AF Simpson, J. Keith
   Innes, Stanley
TI Informed consent, duty of disclosure and chiropractic: where are we?
SO CHIROPRACTIC & MANUAL THERAPIES
LA English
DT Article
DE Chiropractic; Informed consent; Duty of disclosure; Negligence
ID CARE
AB Background The COVID-19 pandemic has seen the emergence of unsubstantiated claims by vertebral subluxation-based chiropractors that spinal manipulative therapy has a role to play in prevention by enhancing the body's immune function. We contend that these claims are unprofessional and demonstrate a disturbing lack of insight into the doctrine of informed consent. As such it is timely to review how informed consent has evolved and continues to do so and also to discuss the attendant implications for contemporary health practitioner practice. We review the origins of informed consent and trace the duty of disclosure and materiality through landmark medical consent cases in four common law (case law) jurisdictions. The duty of disclosure has evolved from a patriarchal exercise to one in which patient autonomy in clinical decision making is paramount. Passing time has seen the duty of disclosure evolve to include non-medical aspects that may influence the delivery of care. We argue that a patient cannot provide valid informed consent for the removal of vertebral subluxation. Further, vertebral subluxation care cannot meet code of conduct standards because it lacks an evidence base and is practitioner-centered. The uptake of the expanded duty of disclosure has been slow and incomplete by practitioners and regulators. The expanded duty of disclosure has implications, both educative and punitive for regulators, chiropractic educators and professional associations. We discuss how practitioners and regulators can be informed by other sources such as consumer law. For regulators, reviewing and updating informed consent requirements is required. For practitioners it may necessitate disclosure of health status, conflict of interest when recommending "inhouse" products, recency of training after attending continuing professional development, practice patterns, personal interests and disciplinary findings. Conclusion Ultimately such matters are informed by the deliberations of the courts. It is our opinion that the duty of a mature profession to critically self-evaluate and respond in the best interests of the patient before these matters arrive in court.
C1 [Simpson, J. Keith; Innes, Stanley] Murdoch Univ, Discipline Psychol Exercise Sci Counselling & Chi, Coll Sci Hlth Engn & Educ SHEE, Murdoch, WA, Australia.
RP Simpson, JK (corresponding author), Murdoch Univ, Discipline Psychol Exercise Sci Counselling & Chi, Coll Sci Hlth Engn & Educ SHEE, Murdoch, WA, Australia.
EM k.simpson@murdoch.edu.au
CR AALG Accreditation Liason Group, 2016, COMP INT ACCR SYST R
   Bal BS, 2012, CLIN ORTHOP RELAT R, V470, P1346, DOI 10.1007/s11999-011-2232-0
   Beauchamp TL, 2011, CAMB Q HEALTHC ETHIC, V20, P515, DOI 10.1017/S0963180111000259
   Bellamy J, 2020, CHIROPRACTORS FALSEL
   Boards A.N, 2020, FALSE MISLEADING ADV
   Brazier M, 2016, MED PATIENTS LAW
   BRODY H, 1989, HASTINGS CENT REP, V19, P5, DOI 10.2307/3562634
   Cave E, 2017, COMMON LAW WORLD REV, V46, P140, DOI DOI 10.1177/1473779517709452
   Constand MK, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-271
   Cote P, 2020, CHIROPR MAN THER, V28, DOI 10.1186/s12998-020-00312-x
   Cruess RL, 2008, PERSPECT BIOL MED, V51, P579, DOI 10.1353/pbm.0.0045
   Daar Judith F, 1995, Whittier Law Rev, V16, P187
   DiGioia A, 2010, J NURS ADMIN, V40, P540, DOI 10.1097/NNA.0b013e3181fc1
   EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221
   Ernst E, 2008, J PAIN SYMPTOM MANAG, V35, P544, DOI 10.1016/j.jpainsymman.2007.07.004
   Faden RR, 1986, HIST THEORY INFORM C
   Garner MJ, 2007, J MANIP PHYSIOL THER, V30, P165, DOI 10.1016/j.jmpt.2007.01.009
   Ginsberg L, 2019, POE STUD, V52, P50
   Ginsberg Marc D., 2010, MICH ST U J MED L, V15, P17
   Glucina TT, 2020, COMPLEMENT THER CLIN, V39, DOI 10.1016/j.ctcp.2020.101105
   Goncalves G, 2018, CHIROPR MAN THER, V26, DOI 10.1186/s12998-018-0179-x
   Hall A, 2014, HASTINGS CENT REP, V44, P41, DOI 10.1002/hast.312
   Henderson CNR, 2012, J ELECTROMYOGR KINES, V22, P632, DOI 10.1016/j.jelekin.2012.03.008
   Hickson GB, 2007, ACAD MED, V82, P1040, DOI 10.1097/ACM.0b013e31815761ee
   ICA. International Chiropractors Association, 2020, IMM FUNCT CHIR WHAT
   ICEC, 2017, CLIN PROF CHIR ED PO
   Innes SI, 2016, CHIROPR MAN THER, V24, DOI 10.1186/s12998-016-0127-6
   Innes SI, 2016, CHIROPR MAN THER, V24, DOI 10.1186/s12998-016-0084-0
   Kawchuk G, 2020, CHIROPR MAN THER, V28, DOI 10.1186/s12998-020-00319-4
   Kawchuk G, 2020, CHIROPR MAN THER, V28, DOI 10.1186/s12998-020-00314-9
   Keating J, 1997, EARLY YEARS CHIROPRA
   Keating Joseph C Jr, 2005, Chiropr Osteopat, V13, P17, DOI 10.1186/1746-1340-13-17
   Kent C, 2018, J PHILOS PRINC PRACT, V2018, P1
   KLERMAN GL, 1990, AM J PSYCHIAT, V147, P409
   KUTCHINS H, 1991, SOC WORK, V36, P106
   LeBlang T R, 1995, Med Law, V14, P429
   Lemmens T, 2014, ROUTLEDGE HDB MED LA, DOI 10.4324/9780203796184.ch3
   Matthew DB, 2011, BUFFALO LAW REV, V59, P715
   McIlwaith J, 2014, HLTH CARE LAW
   Mirtz Timothy A, 2009, Chiropr Osteopat, V17, P13, DOI 10.1186/1746-1340-17-13
   Recher BC, 1976, DRAKE LAW REV, V3, P696
   Ritzer G, 1972, MAN HIS WORK CONFLIC
   Robertson GB, 2017, LEGAL LIABILITY DOCT
   Rodwint A., 1995, AM J LAW MED, VXXI, P241
   Russell D, 2019, J CONT CHIROPR, V2, P4
   Ryan R, 2005, Q REV TORT L, V1, P20
   Sawicki NN, 2016, U ILLINOIS LAW REV, P821
   Sawicki NN, 2016, AM J LAW MED, V42, P85, DOI 10.1177/0098858816644717
   Simpson JK, 2019, CHIROPR MAN THER, V27, DOI 10.1186/s12998-019-0247-x
   Simpson JK, 2017, CHIROPR MAN THER, V25, DOI 10.1186/s12998-017-0157-8
   Slovenko R, 1994, Med Law, V13, P467
   Vernon H, 2009, J MANIP PHYSIOL THER, V32, P344, DOI 10.1016/j.jmpt.2009.04.004
   WALTZ JR, 1969, NORTHWEST U LAW REV, V64, P628
   Wear S, 1998, INFORMED CONSENT PAT
   WFC. World Federation of Chiropractic, 2020, ADV CHIR
NR 55
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2045-709X
J9 CHIROPR MAN THER
JI Chiropr. Man. Ther.
PD NOV 4
PY 2020
VL 28
IS 1
AR 60
DI 10.1186/s12998-020-00342-5
PG 12
WC Rehabilitation
SC Rehabilitation
GA OT0GN
UT WOS:000590533200002
PM 33148281
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wijesundara, DK
   Avumegah, MS
   Lackenby, J
   Modhiran, N
   Isaacs, A
   Young, PR
   Watterson, D
   Chappell, KJ
AF Wijesundara, Danushka K.
   Avumegah, Michael S.
   Lackenby, Julia
   Modhiran, Naphak
   Isaacs, Ariel
   Young, Paul R.
   Watterson, Daniel
   Chappell, Keith J.
TI Rapid Response Subunit Vaccine Design in the Absence of Structural
   Information
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE Disease X; subunit vaccine; molecular clamp; pre-fusion conformation;
   membrane fusion protein; Paramyxoviridae; Arenaviridae; Coalition for
   Epidemic Preparedness Innovations
ID VIRUS; SPIKE
AB Prior to 2020, the threat of a novel viral pandemic was omnipresent but largely ignored. Just 12 months prior to the Coronavirus disease 2019 (COVID-19) pandemic our team received funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to establish and validate a rapid response pipeline for subunit vaccine development based on our proprietary Molecular Clamp platform. Throughout the course of 2019 we conducted two mock tests of our system for rapid antigen production against two potential, emerging viral pathogens, Achimota paramyxovirus and Wenzhou mammarenavirus. For each virus we expressed a small panel of recombinant variants of the membrane fusion protein and screened for expression level, product homogeneity, and the presence of the expected trimeric pre-fusion conformation. Lessons learned from this exercise paved the way for our response to COVID-19, for which our candidate antigen is currently in phase I clinical trial.
C1 [Wijesundara, Danushka K.; Avumegah, Michael S.; Lackenby, Julia; Modhiran, Naphak; Isaacs, Ariel; Young, Paul R.; Watterson, Daniel; Chappell, Keith J.] Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld, Australia.
   [Wijesundara, Danushka K.; Avumegah, Michael S.; Lackenby, Julia; Young, Paul R.; Watterson, Daniel; Chappell, Keith J.] Univ Queensland, Australian Inst Biotechnol & Nanotechnol, St Lucia, Qld, Australia.
   [Modhiran, Naphak; Young, Paul R.; Watterson, Daniel; Chappell, Keith J.] Univ Queensland, Australian Infect Dis Res Ctr, St Lucia, Qld, Australia.
RP Watterson, D; Chappell, KJ (corresponding author), Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld, Australia.; Watterson, D; Chappell, KJ (corresponding author), Univ Queensland, Australian Inst Biotechnol & Nanotechnol, St Lucia, Qld, Australia.; Watterson, D; Chappell, KJ (corresponding author), Univ Queensland, Australian Infect Dis Res Ctr, St Lucia, Qld, Australia.
EM d.watterson@uq.edu.au; k.chappell@uq.edu.au
FU Coalition for Epidemic Preparedness Innovations (CEPI)
FX The work was carried out with a project grant (CFP2) from the Coalition
   for Epidemic Preparedness Innovations (CEPI).
CR Baker KS, 2013, J VIROL, V87, P1348, DOI 10.1128/JVI.01202-12
   Blasdell KR, 2016, ELIFE, V5, DOI 10.7554/eLife.13135
   BRIGANTI G, 1979, INT J RADIAT ONCOL, V5, P1095, DOI 10.1016/0360-3016(79)90625-4
   Cai YF, 2020, SCIENCE, V369, P1586, DOI 10.1126/science.abd4251
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671
   Corti D, 2011, SCIENCE, V333, P850, DOI 10.1126/science.1205669
   Harrison SC, 2015, VIROLOGY, V479, P498, DOI 10.1016/j.virol.2015.03.043
   Hsieh CL, 2020, SCIENCE, V369, P1501, DOI 10.1126/science.abd0826
   Koellhoffer JF, 2014, J MOL BIOL, V426, P1452, DOI 10.1016/j.jmb.2013.12.009
   Loomis RJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00842
   Magro M, 2012, P NATL ACAD SCI USA, V109, P3089, DOI 10.1073/pnas.1115941109
   Mas V, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005859
   McLellan JS, 2013, SCIENCE, V342, P592, DOI 10.1126/science.1243283
   Mercado NB, 2020, NATURE, DOI 10.1038/s41586-020-2607-z
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Pancera M, 2014, NATURE, V514, P455, DOI 10.1038/nature13808
   Rohou A, 2015, J STRUCT BIOL, V192, P216, DOI 10.1016/j.jsb.2015.08.008
   Schlie K, 2010, J VIROL, V84, P983, DOI 10.1128/JVI.02039-09
   Sharker Shazid Md, 2020, Curr Drug Discov Technol, DOI 10.2174/1570163817666200312102137
   van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y
   Wang JX, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007049
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Zivanov J, 2018, ELIFE, V7, DOI 10.7554/eLife.42166
NR 24
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD NOV 4
PY 2020
VL 11
AR 592370
DI 10.3389/fimmu.2020.592370
PG 8
WC Immunology
SC Immunology
GA OS1XR
UT WOS:000589959300001
PM 33250897
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Manansala, M
   Ascoli, C
   Alburquerque, AG
   Perkins, D
   Mirsaedi, M
   Finn, P
   Sweiss, NJ
AF Manansala, Michael
   Ascoli, Christian
   Alburquerque, Ana Goico
   Perkins, David
   Mirsaedi, Mehdi
   Finn, Patricia
   Sweiss, Nadera J.
TI Case Series: COVID-19 in African American Patients With Sarcoidosis
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE sarcoidosis; COVID; 19; immunosuppression; DMARDs; African American
   (AA); SAR-CoV-2
AB Data on the clinical presentation and outcomes of sarcoidosis patients with coronavirus disease 19 (COVID-19) are scarce. In this case series, we identified 5 out of 238 sarcoidosis patients who are enrolled in an ongoing longitudinal observational study who developed COVID-19 during the study period and follow their clinical course. Four patients recovered completely, whereas one patient expired during hospital admission. Our preliminary experience suggests that African American patients with chronic sarcoidosis treated with disease-modifying anti-rheumatic drugs (DMARDs) or anti-tumor necrosis factor (TNF) therapy do not seem to be at increased risk of respiratory or life-threatening complications from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compared with the general population, although at the present time, we advocate for maintaining a high level of vigilance and strict follow-up in this patient population.
C1 [Manansala, Michael; Ascoli, Christian; Alburquerque, Ana Goico; Perkins, David; Finn, Patricia; Sweiss, Nadera J.] Univ Illinois, Dept Internal Med, Chicago, IL 60607 USA.
   [Mirsaedi, Mehdi] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
RP Manansala, M (corresponding author), Univ Illinois, Dept Internal Med, Chicago, IL 60607 USA.
EM mmanan3@uic.edu
FU Bernie Mac Foundation STAR Clinic
FX Funding for publication of this article was provided by the Bernie Mac
   Foundation STAR Clinic.
CR CDC, 2020, PEOPL WHO AR HIGH RI
   Chowkwanyun M, 2020, NEW ENGL J MED, V383, P201, DOI 10.1056/NEJMp2012910
   Haberman R, 2020, NEW ENGL J MED, V383, P85, DOI 10.1056/NEJMc2009567
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Mirsaeidi M, 2015, CHEST, V147, P438, DOI 10.1378/chest.14-1120
   Monti S, 2020, ANN RHEUM DIS, V79, P667, DOI 10.1136/annrheumdis-2020-217424
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Sun PF, 2020, J MED VIROL, V92, P548, DOI 10.1002/jmv.25722
   Sweiss NJ, 2020, CHEST, V158, P892, DOI 10.1016/j.chest.2020.04.033
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
NR 10
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD NOV 4
PY 2020
VL 7
AR 588527
DI 10.3389/fmed.2020.588527
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA OS1XD
UT WOS:000589957800001
PM 33251236
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Widyarman, AS
   Bachtiar, EW
   Theodorea, CF
   Rizal, MI
   Roeslan, MO
   Djamil, MS
   Santosa, DN
   Bachtiar, BM
AF Widyarman, Armelia Sari
   Bachtiar, Endang W.
   Theodorea, Citra Fragrantia
   Rizal, M. Ihsan
   Roeslan, M. Orliando
   Djamil, Melanie S.
   Santosa, Didi N.
   Bachtiar, Boy M.
TI COVID-19 Awareness Among Dental Professionals in Indonesia
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE SARS-COV-2; knowledge; dentist; COVID-19; awareness
AB Background: The COVID-19 pandemic caused by SARS-CoV-2 has claimed thousands of lives worldwide. To enhance knowledge and awareness of COVID-19, considerable online resources have been made available, including aspects related to the dental profession. The study aim was to examine the knowledge, perception, and attitude of dental professionals in Indonesia toward COVID-19. We conducted a survey via a questionnaire created using Google docs and distributed to 632 members of the Indonesian Dental Association in the context of a webinar hosted by the Indonesian Oral Biology Association on first June, 2020.
   Materials and Methods: The questionnaire consisted of 17 items pertaining to demographic data, knowledge and virus identification, awareness regarding drugs commonly used in dentistry during pandemic and research opportunities. Participants were asked to complete the questionnaire after the webinar by choosing one answer to each question. For the analysis, participants were divided into three groups according to their professional background i.e., employment at national hospital, private hospital, or academic faculty. Data were analyzed using descriptive statistics and expressed as frequencies and percentages. The chi-square test was used to investigate the association between professional activity and the level of knowledge, perceptions, and attitudes about COVID-19.
   Results: Sixty percent of the participants correctly identified the pathogenesis of the disease. This knowledge was not associated with their professional affiliation (p = 0.95). Sixty-seven percentage had comprehensive knowledge about virus detection methods. This knowledge was not associated with their affiliation either (p = 0.54). Questions regarding drugs of choice, prevention, and the spread of COVID-19 were correctly answered by 89, 96, and 82% of the participants, respectively. Knowledge of these aspects were significantly associated with the professional affiliation (p < 0.05). All respondents were optimistic regarding research opportunities (p < 0.01). Respondents from academics were more interested in joining COVID-19-related research projects with governmental institutions (p < 0.01).
   Conclusion: Knowledge and awareness of COVID-19 among Indonesian dentists are reasonably good. However, further improvement would be beneficial to manage patients during this pandemic. As the number of COVID-19 cases continue to rise in Indonesia, it is important that dentists keep abreast of the updated knowledge on this moving field. Dentist knowledge on infection control should be strengthened through continuous educational programs.
C1 [Widyarman, Armelia Sari] Trisakti Univ, Dept Microbiol, Fac Dent, Jakarta, Indonesia.
   [Bachtiar, Endang W.; Theodorea, Citra Fragrantia; Bachtiar, Boy M.] Univ Indonesia, Dept Oral Biol, Fac Dent, Depok, Indonesia.
   [Rizal, M. Ihsan; Roeslan, M. Orliando; Djamil, Melanie S.; Santosa, Didi N.] Trisakti Univ, Dept Oral Biol, Fac Dent, Jakarta, Indonesia.
RP Widyarman, AS (corresponding author), Trisakti Univ, Dept Microbiol, Fac Dent, Jakarta, Indonesia.
EM armeliasari@trisakti.ac.id
CR Bhagavathula Akshaya Srikanth, 2020, JMIR Public Health Surveill, V6, pe19160, DOI 10.2196/19160
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   COVID-19 GTPP, GUG TUG PERC PEN COV
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Giovanetti M, 2020, J MED VIROL, V92, P518, DOI 10.1002/jmv.25699
   Guven Y, 2017, J ISTANB UNIV FAC DE, V51, P64, DOI 10.17096/jiufd.04646
   Hp+ P, 2018, EXP MARK IMPR HLTH I
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Khader Y, 2020, JMIR PUBLIC HLTH SUR, V6, P185, DOI 10.2196/18798
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Mosadeghrad AM, 2014, INT J HEALTH POLICY, V3, P77, DOI 10.15171/ijhpm.2014.65
   Quadri MFA, 2020, J INFECT PUBLIC HEAL, V13, P856, DOI 10.1016/j.jiph.2020.05.010
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Rosales-Mendoza S, 2020, TRENDS BIOTECHNOL, V38, P823, DOI 10.1016/j.tibtech.2020.04.016
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
NR 16
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD NOV 4
PY 2020
VL 7
AR 589759
DI 10.3389/fmed.2020.589759
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA OS1YG
UT WOS:000589960800001
PM 33251237
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kasting, ML
   Head, KJ
   Hartsock, JA
   Sturm, L
   Zimet, GD
AF Kasting, Monica L.
   Head, Katharine J.
   Hartsock, Jane A.
   Sturm, Lynne
   Zimet, Gregory D.
TI Public perceptions of the effectiveness of recommended
   non-pharmaceutical intervention behaviors to mitigate the spread of
   SARS-CoV-2
SO PLOS ONE
LA English
DT Article
ID HEALTH BELIEFS; TRUST
AB Background
   The COVID-19 pandemic is an unprecedented public health threat, both in scope and response. With no vaccine available, the public is advised to practice non-pharmaceutical interventions (NPI) including social distancing, mask-wearing, and washing hands. However, little is known about public perceptions of the effectiveness of these measures, and high perceived effectiveness is likely to be critical in order to achieve widespread adoption of NPI.
   Methods
   In May 2020, we conducted a cross-sectional survey among U.S. adults (N = 3,474). The primary outcome was a six-item measure assessing perceived effectiveness of recommended behaviors to prevent SARS-CoV-2 infection from 1 (not at all effective) to 5 (extremely effective). The sample was divided into "higher" and "lower" perceived effectiveness groups. Covariates included demographics, healthcare characteristics, and health beliefs. Variables that were significant at p<0.01 in bivariate analyses were entered into a multivariable logistic regression and a best-fit model was created using a cutoff of p<0.01 to stay in the model.
   Results
   Mean age was 45.5 years and most participants were non-Hispanic White (63%) and female (52.4%). The high perceived effectiveness group was slightly larger than the low perceived effectiveness group (52.7% vs. 47.3%). Almost all health belief variables were significant in the best-fit regression model. COVID-19-related worry (aOR = 1.82; 95% CI = 1.64-2.02), and perceived threat to physical health (aOR = 1.32; 95% CI = 1.20-1.45) were positively associated with perceived effectiveness while perceived severity of COVID-19 (0.84; 95% CI = 0.73-0.96) and perceived likelihood of infection (0.85; 95% CI = 0.77-0.94) switched directions in the adjusted model and were negatively associated with perceived effectiveness.
   Conclusions
   This research indicates people generally believe NPI are effective, but there was variability based on health beliefs and there are mixed rates of engagement in these behaviors. Public health efforts should focus on increasing perceived severity and threat of SARS-CoV-2-related disease, while promoting NPI as effective in reducing threat.
C1 [Kasting, Monica L.] Purdue Univ, Dept Publ Hlth, W Lafayette, IN 47907 USA.
   [Kasting, Monica L.] Indiana Univ, Canc Prevent & Control Program, Simon Comprehens Canc Ctr, Indianapolis, IN 47405 USA.
   [Head, Katharine J.] Indiana Univ Purdue Univ, Dept Commun Studies, Indianapolis, IN USA.
   [Hartsock, Jane A.] Indiana Univ Hlth, Dept Clin & Org Eth, Indianapolis, IN USA.
   [Hartsock, Jane A.] Indiana Univ, Ctr Bioeth, Indianapolis, IN USA.
   [Hartsock, Jane A.] Indiana Univ Purdue Univ, Med Humanities & Hlth Studies Program, Indianapolis, IN USA.
   [Sturm, Lynne; Zimet, Gregory D.] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN USA.
RP Kasting, ML (corresponding author), Purdue Univ, Dept Publ Hlth, W Lafayette, IN 47907 USA.; Kasting, ML (corresponding author), Indiana Univ, Canc Prevent & Control Program, Simon Comprehens Canc Ctr, Indianapolis, IN 47405 USA.
EM mlkastin@purdue.edu
OI Kasting, Monica/0000-0002-9879-7235
FU Purdue University; Indiana University-Purdue University Indianapolis;
   Indiana University Health; Indiana University School of Medicine
FX This study was funded by internal grants at Purdue University (MLK),
   Indiana University-Purdue University Indianapolis (KJH), Indiana
   University Health (JAH), and the Indiana University School of Medicine
   (GDZ). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Andrew S., 2020, CNN
   Bayer R, 2007, EMBO REP, V8, P1099, DOI 10.1038/sj.embor.7401134
   Beeken RJ, 2011, CANCER EPIDEM BIOMAR, V20, P2127, DOI 10.1158/1055-9965.EPI-11-0437
   Bosman J., 2020, NY TIMES
   Cahyanto I, 2016, TOUR MANAG PERSPECT, V20, P195, DOI 10.1016/j.tmp.2016.09.004
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Centers for Disease Control and Prevention, 2020, COR COVID 19
   Costa Robert, 2020, WASHINGTON POST
   Czeisler ME, 2020, MMWR-MORBID MORTAL W, V69, P751, DOI 10.15585/mmwr.mm6924e1
   Elving R, 2020, WHAT IT MEANS TRUMP
   Fan H, 2018, AIDS CARE, V30, P1062, DOI 10.1080/09540121.2018.1442555
   Freimuth VS, 2014, J HEALTH COMMUN, V19, P321, DOI 10.1080/10810730.2013.811323
   Goodnough Abby, 2020, NY TIMES
   Grabb E, 1999, CAN J SOCIOL, V24, P511, DOI 10.2307/3341789
   Hauck G., 2020, US TODAY
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Igielnik R, 2020, MOST AM SAY THEY REG
   Kai D, 2020, UNIVERSAL MASKING IS
   Lake PW, 2020, SUPPORTIVE CARE CANC
   Lardieri A., 2020, US NEWS WORLD REPORT
   Liau A, 1998, SEX TRANSM DIS, V25, P76, DOI 10.1097/00007435-199802000-00004
   Lyu W, 2020, HEALTH AFFAIR, V39, P1419, DOI 10.1377/hlthaff.2020.00818
   Padilla M, 2020, NY TIMES
   RUSHTON JP, 1981, PERS INDIV DIFFER, V2, P293
   Saqr M, 2020, INT J HEALTH SCI-IJH, V14, P4
   Skinner CS, 2015, HLTH BEHAV THEORY RE
   SteelFisher GK, 2012, LANCET INFECT DIS, V12, P845, DOI 10.1016/S1473-3099(12)70206-2
   Teasdale E, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-589
   Thrush G, 2020, NY TIMES
   Walters J, 2020, GUARDIAN
   Weissert W, 2020, ASS PRESS
   Williams L, 2015, PSYCHOL HEALTH MED, V20, P832, DOI 10.1080/13548506.2015.1028946
   WITTE K, 1992, COMMUN MONOGR, V59, P329, DOI 10.1080/03637759209376276
   Wong T, 2020, BBC NEWS, V12, P2020
   World Health Organization, 2020, WHO TIM COVID 19
   World Health Organization, 2020, ADV US MASKS CONT CO
   Wynne B, 2006, COMMUNITY GENET, V9, P211, DOI 10.1159/000092659
NR 37
TC 0
Z9 0
U1 3
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 4
PY 2020
VL 15
IS 11
AR e0241662
DI 10.1371/journal.pone.0241662
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OR6WM
UT WOS:000589609300054
PM 33147261
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gleicher, N
AF Gleicher, Norbert
TI The COVID-19 pandemic through eyes of a NYC fertility center: a unique
   learning experience with often unexpected results
SO REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY
LA English
DT Article
DE COVID-19 and infertility; Herd immunity; COVID virus strains;
   Infectivity; Innate immunity
ID HERD-IMMUNITY; INFECTION; SARS-COV-2; PREGNANCY; REVEALS
AB Affecting basic tenets of human existence such as health, economic as well as personal security and, of course, reproduction, the COVID-19 pandemic transcended medical specialties and professional disciplines. Yet, six months into the pandemic, there still exists no consensus on how to combat the virus in absence of a vaccine. Facing unprecedented circumstances, and in absence of real evidence on how to proceed, our organization early in the pandemic decided to act independently from often seemingly irrational guidance and, instead, to carefully follow a quickly evolving COVID-19 literature. Here described is the, likely, unique journey of a fertility center that maintained services during peaks of COVID-19 and political unrest that followed. Closely following publicly available data, we recognized relatively early that New York City and other East Coast regions, which during the initial COVID-19 wave between March and May represented the hardest-hit areas in the country, during the second wave, beginning in June and still in progress, remained almost completely unaffected. In contrast, south western regions, almost completely unaffected by the initial wave, were severely affected in the second wave. These two distinctively different infectious phenotypes suggested two likely explanations: The country was witnessing infections with two different SARS-CoV-2 viruses and NYC (along with the East Coast) acquired during the first wave much better immunity to the virus than south western regions. Both hypotheses since have been confirmed: East and West Coasts, indeed, were initially infected by two distinctively different lineages of the virus, with the East Coast lineage being 10-times more infectious. In addition, immunologists discovered an up to this point unknown long-term anti-viral innate (cellular) immune response which offers additional and much broader anti-viral immunity than the classical adaptive immunity via immobilizing antibodies that has been known for decades. Consequently, we predict that in the U.S., even in absence of an available vaccine, COVID-19, by September-October, will be at similarly low levels as are currently seen in NYC and other East Coast regions (generally < 1% test-positivity). We, furthermore, predict that, if current mitigation measures are maintained and no newly aggressive mutation of the virus enters the country, a significant fall-wave of COVID-19, in combination with the usual fall wave of influenza, appears unlikely. To continue serving patients uninterrupted throughout the pandemic, turned for all of our center's staff into a highly rewarding experience, garnered respect and appreciation from patients, and turned into an absolutely unique learning experience.
C1 [Gleicher, Norbert] Ctr Human Reprod, 21 East 69th St, New York, NY 10021 USA.
   [Gleicher, Norbert] Fdn Reprod Med, New York, NY 10021 USA.
   [Gleicher, Norbert] Rockefeller Univ, Stem Cell Biol & Mol Embryol Lab, 1230 York Ave, New York, NY 10021 USA.
   [Gleicher, Norbert] Med Univ Vienna, Dept Obstet & Gynecol, Vienna, Austria.
RP Gleicher, N (corresponding author), Ctr Human Reprod, 21 East 69th St, New York, NY 10021 USA.; Gleicher, N (corresponding author), Fdn Reprod Med, New York, NY 10021 USA.
EM ngleicher@thechr.com
CR Ahlander J, SWEDISH ANTIBODY STU
   Alviggi C, 2020, REPROD BIOL ENDOCRIN, V18, DOI 10.1186/s12958-020-00605-z
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   [Anonymous], REUTERS
   [Anonymous], 2020, BLOOMBERG LAW N 0522
   ASRM ESHRE and IFFS, COVID 19 HUM REPR JO
   Baghramian M, 2020, TRUST EXPERTS WHY WH
   Berman R., 2020, ATLANTIC
   Bowen A, CHICAGO TRIBUNE
   Bredderman W, 2020, DAILY BEAST, P12
   Britton T, 2020, SCIENCE, V369, P846, DOI 10.1126/science.abc6810
   Alzamora MC, 2020, AM J PERINAT, V37, P861, DOI 10.1055/s-0040-1710050
   Collins RD, 2020, NAT REV IMMUNOL, V12, P1
   Crudele J., 2016, NEW YORK POST
   Cuomo AM, HLTH ADVISORY SEXUAL
   Deng XD, 2020, SCIENCE, V369, P582, DOI 10.1126/science.abb9263
   Egloff C, 2020, J CLIN VIROL, V128
   Ellington S, 2020, MMMWR, V69
   Fauser BCJM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211150
   Finley A, 2020, WALL STREET J
   Finley A., 2020, WALL STREET J
   Fox J., NEW YORK CITY GOT CO
   Galang RR, 2020, OBSTET GYNECOL, V136, P262, DOI 10.1097/AOG.0000000000004011
   Gallo R, 2020, NY TIMES
   Goldfarb IT, 2020, OBSTET GYNECOL, V136, P300, DOI 10.1097/AOG.0000000000004005
   Goldstein J., 2020, NY TIMES
   Gonzalez-Reiche AS, 2020, SCIENCE, V369, P297, DOI 10.1126/science.abc1917
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Grubaugh ND, 2020, CELL, V182, P794, DOI 10.1016/j.cell.2020.06.040
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huntley BJF, 2020, OBSTET GYNECOL, V136, P303, DOI 10.1097/AOG.0000000000004010
   Insogna Iris G, 2018, AMA J Ethics, V20, pE1152, DOI 10.1001/amajethics.2018.1152
   Jung F, 2020, CLIN HEMORHEOL MICRO, V75, P13, DOI 10.3233/CH-209006
   Khoury R, 2020, OBSTET GYNECOL, V136, P273, DOI 10.1097/AOG.0000000000004025
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Kowitt B, 2020, FORBES
   Landler M, NY TIMES
   Lindberg LD, 2020, EARLY IMPACTS COVID
   Madan M, 2020, PUBLIC HEALTH, V185, P91, DOI 10.1016/j.puhe.2020.05.042
   Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871
   Matheson NJ, 2020, SCIENCE, V369, P510, DOI 10.1126/science.abc6156
   Mertz D, 2017, VACCINE, V35, P521, DOI 10.1016/j.vaccine.2016.12.012
   Sekine T, 2020, ROBUST T CELL IMMUNI, DOI [10.1101/2020.06.29.174888, DOI 10.1101/2020.06.29.174888]
   Terry M, 2020, MUTATED COVID 19 VIR
   The Editorial Board, 2020, WALL STREET J
   The New York Times Coronavirus Map, NY TIMES
   Wilson N, 2020, EMERG INFECT DIS, V26, P1339, DOI 10.3201/eid2606.200320
   World Health Organization, 2018, ZIKA VIRUS      0820
   Zhang L, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-03026-3
NR 49
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477-7827
J9 REPROD BIOL ENDOCRIN
JI Reprod. Biol. Endocrinol.
PD NOV 4
PY 2020
VL 18
IS 1
AR 105
DI 10.1186/s12958-020-00663-3
PG 16
WC Endocrinology & Metabolism; Reproductive Biology
SC Endocrinology & Metabolism; Reproductive Biology
GA OS3LI
UT WOS:000590066400002
PM 33148264
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhang, Q
   Chen, CZ
   Swaroop, M
   Xu, M
   Wang, LH
   Lee, J
   Wang, AQ
   Pradhan, M
   Hagen, N
   Chen, L
   Shen, M
   Luo, ZJ
   Xu, X
   Xu, Y
   Huang, WW
   Zheng, W
   Ye, YH
AF Zhang, Qi
   Chen, Catherine Zhengzheng
   Swaroop, Manju
   Xu, Miao
   Wang, Lihui
   Lee, Juhyung
   Wang, Amy Qiu
   Pradhan, Manisha
   Hagen, Natalie
   Chen, Lu
   Shen, Min
   Luo, Zhiji
   Xu, Xin
   Xu, Yue
   Huang, Wenwei
   Zheng, Wei
   Ye, Yihong
TI Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by
   approved drugs in vitro
SO CELL DISCOVERY
LA English
DT Article
ID VIRUS ENTRY; CORONAVIRUS; SPIKE; MECHANISMS; CLEAVAGE; BINDING; ACE2
AB The cell entry of SARS-CoV-2 has emerged as an attractive drug repurposing target for COVID-19. Here we combine genetics and chemical perturbation to demonstrate that ACE2-mediated entry of SARS-Cov and CoV-2 requires the cell surface heparan sulfate (HS) as an assisting cofactor: ablation of genes involved in HS biosynthesis or incubating cells with a HS mimetic both inhibit Spike-mediated viral entry. We show that heparin/HS binds to Spike directly, and facilitates the attachment of Spike-bearing viral particles to the cell surface to promote viral entry. We screened approved drugs and identified two classes of inhibitors that act via distinct mechanisms to target this entry pathway. Among the drugs characterized, Mitoxantrone is a potent HS inhibitor, while Sunitinib and BNTX disrupt the actin network to indirectly abrogate HS-assisted viral entry. We further show that drugs of the two classes can be combined to generate a synergized activity against SARS-CoV-2-induced cytopathic effect. Altogether, our study establishes HS as an attachment factor that assists SARS coronavirus cell entry and reveals drugs capable of targeting this important step in the viral life cycle.
C1 [Zhang, Qi; Wang, Lihui; Lee, Juhyung; Xu, Yue; Ye, Yihong] NIDDK, Lab Mol Biol, NIH, Bethesda, MD 20892 USA.
   [Chen, Catherine Zhengzheng; Swaroop, Manju; Xu, Miao; Wang, Amy Qiu; Pradhan, Manisha; Hagen, Natalie; Chen, Lu; Shen, Min; Luo, Zhiji; Xu, Xin; Huang, Wenwei; Zheng, Wei] NIH, Natl Ctr Adv Translat Sci, Rockville, MD 20850 USA.
RP Ye, YH (corresponding author), NIDDK, Lab Mol Biol, NIH, Bethesda, MD 20892 USA.
EM yihongy@mail.nih.gov
FU Intramural Research Program of the National Institute of Diabetes,
   Digestive & Kidney Diseases; National Center for Advancing Translational
   Sciences in the National Institutes of Health
FX We thank Susan Buchanan, Martin Gellert (NIDDK), and Liqiang Chen
   (University of Minnesota) for critical reading of the manuscript. The
   plasmids and protocols for PP generation were kind gifts from Dr. Gary
   Whittaker at Cornell University. The work was supported by the
   Intramural Research Program of the National Institute of Diabetes,
   Digestive & Kidney Diseases and of the National Center for Advancing
   Translational Sciences in the National Institutes of Health.
CR Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Burkard C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004502
   Cagno V, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11070596
   Cai YF, 2020, SCIENCE, V369, P1586, DOI 10.1126/science.abd4251
   Christianson HC, 2014, MATRIX BIOL, V35, P51, DOI 10.1016/j.matbio.2013.10.004
   Clausen Thomas Mandel, 2020, bioRxiv, DOI 10.1101/2020.07.14.201616
   CRESPI MD, 1986, BIOCHEM BIOPH RES CO, V136, P521, DOI 10.1016/0006-291X(86)90471-7
   de Haan CAM, 2008, J VIROL, V82, P6078, DOI 10.1128/JVI.00074-08
   Ekins S, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00440-20
   Glebov OO, 2020, FEBS J, V287, P3664, DOI 10.1111/febs.15369
   Henderson R, 2020, NAT STRUCT MOL BIOL, V27, P925, DOI 10.1038/s41594-020-0479-4
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Holmes KV, 2003, NEW ENGL J MED, V348, P1948, DOI 10.1056/NEJMp030078
   Inoue Y, 2007, J VIROL, V81, P8722, DOI 10.1128/JVI.00253-07
   Jeon S, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00819-20
   Kang Yuan-Lin, 2020, bioRxiv, DOI 10.1101/2020.04.21.053058
   KAPUSCINSKI J, 1985, BIOCHEM PHARMACOL, V34, P4203, DOI 10.1016/0006-2952(85)90275-8
   Karpowicz RJ, 2019, LAB INVEST, V99, P971, DOI 10.1038/s41374-019-0195-z
   Kim SY, 2020, ANTIVIR RES, V181, DOI 10.1016/j.antiviral.2020.104873
   Kouznetsova J, 2014, EMERG MICROBES INFEC, V3, DOI 10.1038/emi.2014.88
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lang JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023710
   Le Tourneau Christophe, 2007, Ther Clin Risk Manag, V3, P341, DOI 10.2147/tcrm.2007.3.2.341
   Liu C, 2015, J VIROL, V89, P6121, DOI 10.1128/JVI.00430-15
   Liu Lin, 2020, bioRxiv, DOI 10.1101/2020.05.10.087288
   Marsh M, 2006, CELL, V124, P729, DOI 10.1016/j.cell.2006.02.007
   MAYER GD, 1970, SCIENCE, V169, P1214, DOI 10.1126/science.169.3951.1214
   Melak M, 2017, J CELL SCI, V130, P525, DOI 10.1242/jcs.189068
   Meneghetti MCZ, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2015.0589
   Milewska A, 2018, J VIROL, V92, DOI 10.1128/JVI.01933-17
   Milewska A, 2014, J VIROL, V88, P13221, DOI 10.1128/JVI.02078-14
   Millet JK, 2019, JOVE-J VIS EXP, DOI 10.3791/59010
   Millet JK, 2018, VIROLOGY, V517, P3, DOI 10.1016/j.virol.2017.12.015
   Millet Jean Kaoru, 2016, Bio Protoc, V6, DOI 10.21769/BioProtoc.2035
   Mycroft-West C., 2020, BIORXIV, P1, DOI [10.1101/2020.02.29.971093, DOI 10.1101/2020.02.29.971093]
   Naskalska A, 2019, J VIROL, V93, DOI 10.1128/JVI.00355-19
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Park RJ, 2017, NAT GENET, V49, P193, DOI 10.1038/ng.3741
   Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219
   Sarrazin S, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004952
   Schwegmann-Wessels C, 2003, J VIROL, V77, P11846, DOI 10.1128/JVI.77.21.11846-11848.2003
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Song YL, 2003, J GEN PHYSIOL, V122, P511, DOI 10.1085/jgp.200308866
   Tandon Ritesh, 2020, bioRxiv, DOI 10.1101/2020.06.08.140236
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang HL, 2008, CELL RES, V18, P290, DOI 10.1038/cr.2008.15
   Wernick NLB, 2010, TOXINS, V2, P310, DOI 10.3390/toxins2030310
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yamauchi Y, 2013, J CELL SCI, V126, P1289, DOI 10.1242/jcs.119685
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zang RC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc3582
   Zhang Q, 2020, P NATL ACAD SCI USA, V117, P10865, DOI 10.1073/pnas.1918617117
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 56
TC 0
Z9 0
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
EI 2056-5968
J9 CELL DISCOV
JI Cell Discov.
PD NOV 4
PY 2020
VL 6
IS 1
AR 80
DI 10.1038/s41421-020-00222-5
PG 14
WC Cell Biology
SC Cell Biology
GA ON9RR
UT WOS:000587028800001
PM 33298900
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jereczek-Fossa, BA
   Pepa, M
   Marvaso, G
   Isaksson, JL
   Soatti, CP
   Cazzaniga, LF
   Ivaldi, GB
   Amadori, M
   Antognoni, P
   Arcangeli, S
   Buffoli, A
   Beltramo, G
   Bignardi, M
   Bracelli, S
   Bruschieri, L
   Castiglioni, S
   Catalano, G
   Di Muzio, N
   Fallai, C
   Fariselli, L
   Filippi, AR
   Gramaglia, A
   Italia, C
   Lombardi, F
   Magrini, SM
   Nava, S
   Orlandi, E
   Pasinetti, N
   Sbicego, EL
   Scandolaro, L
   Scorsetti, M
   Stiglich, F
   Tortini, R
   Valdagni, R
   Vavassori, V
   Tonoli, S
   Palazzi, MF
AF Jereczek-Fossa, Barbara Alicja
   Pepa, Matteo
   Marvaso, Giulia
   Isaksson, Johannes Lars
   Soatti, Carlo Pietro
   Cazzaniga, Luigi Franco
   Ivaldi, Giovanni Battista
   Amadori, Marcello
   Antognoni, Paolo
   Arcangeli, Stefano
   Buffoli, Alberto
   Beltramo, Giancarlo
   Bignardi, Mario
   Bracelli, Stefano
   Bruschieri, Lorenza
   Castiglioni, Simona
   Catalano, Gianpiero
   Di Muzio, Nadia
   Fallai, Carlo
   Fariselli, Laura
   Filippi, Andrea Riccardo
   Gramaglia, Alberto
   Italia, Corrado
   Lombardi, Fabrizio
   Magrini, Stefano Maria
   Nava, Simonetta
   Orlandi, Ester
   Pasinetti, Nadia
   Sbicego, Elena Lara
   Scandolaro, Luciano
   Scorsetti, Marta
   Stiglich, Francesco
   Tortini, Roberto
   Valdagni, Riccardo
   Vavassori, Vittorio
   Tonoli, Sandro
   Palazzi, Mauro Filippo
CA CODRAL Board Directors Radiation O
   AIRO-L Italian Assoc Radiotherapy
TI Back to (new) normality-A CODRAL/AIRO-L survey on cancer radiotherapy in
   Lombardy during Italian COVID-19 phase 2
SO MEDICAL ONCOLOGY
LA English
DT Article
DE COVID-19; Survey; Cancer radiotherapy; Lombardy; Northern Italy
ID RADIATION-THERAPY; OUTBREAK; RECOMMENDATIONS; ASSOCIATION; GUIDELINES;
   DISRUPTION; CONSENSUS
AB Background Italy experienced one of the world's severest COVID-19 outbreak, with Lombardy being the most afflicted region. However, the imposed safety measures allowed to flatten the epidemic curve and hence to ease the restrictions and inaugurate, on the 4th of May 2020, the Italian phase (P) 2 of the pandemic. The present survey study, endorsed by CODRAL and AIRO-L, aimed to assess how radiotherapy (RT) departments in Lombardy have dealt with the recovery. Materials and methods A questionnaire dealing with the management of pandemic was developed online and sent to all CODRAL Directors on the 10th of June 2020. Answers were collected in full anonymity one week after. Results All the 33 contacted RT facilities (100%) responded to the survey. Despite the scale of the pandemic, during P1 14 (42.4%) centres managed to safely continue the activity (<= 10% reduction). During P2, 10 (30.3%) centres fully recovered and 14 (42.4%) reported an increase. Nonetheless, 6 (18.2%) declared no changes and, interestingly, 3 (9.1%) reduced activities. Overall, 21 centres (63.6%) reported suspected or positive cases within healthcare workforce since the beginning of the pandemic. Staff units were quarantined in 19 (57.6%) and 6 (18.2%) centres throughout P1 and P2, respectively. In the two phases, about two thirds centres registered positive or suspected cases amongst patients. Conclusion The study revealed a particular attention to anti-contagion measures and a return to normal or even higher clinical workload in most RT centres in Lombardy, necessary to carry out current and previously deferred treatments.
C1 [Jereczek-Fossa, Barbara Alicja; Pepa, Matteo; Marvaso, Giulia; Isaksson, Johannes Lars] European Inst Oncol, Div Radiat Oncol, IRCCS, IEO, Via Ripamonti, I-43520141 Milan, Italy.
   [Jereczek-Fossa, Barbara Alicja; Marvaso, Giulia; Valdagni, Riccardo] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy.
   [Soatti, Carlo Pietro] Osped Manzoni, Radiat Oncol Ctr, Lecce, Italy.
   [Cazzaniga, Luigi Franco] Osped Papa Giovanni XXIII, Radiat Oncol Ctr, Bergamo, Italy.
   [Ivaldi, Giovanni Battista] IRCCS, Radiat Oncol Ctr, Ist Clin Sci Maugeri, Pavia, Italy.
   [Amadori, Marcello] Osped C Poma, Radiat Oncol Ctr, Mantua, Italy.
   [Antognoni, Paolo] Osped Circolo & Fdn Macchi, Radiat Oncol Ctr, ASST Sette Laghi, Varese, Italy.
   [Arcangeli, Stefano] Policlin S Gerardo, Dept Radiat Oncol, Milan, Italy.
   [Arcangeli, Stefano] Univ Milano Bicocca, Milan, Italy.
   [Buffoli, Alberto] Ist Clin S Anna, Radiat Oncol Ctr, Brescia, Italy.
   [Beltramo, Giancarlo] Ctr Diagnost Italiano CDI, Radiat Oncol Ctr, Milan, Italy.
   [Bignardi, Mario] Fdn Poliambulanza, Radiat Oncol Ctr, Brescia, Italy.
   [Bracelli, Stefano] Radiat Oncol Ctr, Busto Arsizio, Italy.
   [Bruschieri, Lorenza] Osped Treviglio, Div Radiat Oncol, Caravaggio Di Treviglio, Treviglio, Italy.
   [Castiglioni, Simona] S Pio X Humanitas, Radiat Oncol Ctr, Milan, Italy.
   [Catalano, Gianpiero] IRCCS Osped Multimed, Radiat Oncol Ctr, Sesto San Giovanni Caste, Italy.
   [Di Muzio, Nadia] IRCCS Osped S Raffaele, Radiat Oncol Ctr, Milan, Italy.
   [Di Muzio, Nadia] Univ Vita Salute, Milan, Italy.
   [Fallai, Carlo; Valdagni, Riccardo] Fdn IRCCS Ist Nazl Tumori, Div Radiotherapy, Milan, Italy.
   [Fariselli, Laura] Fdn IRCCS Ist Neurol Carlo Besta, Radiotherapy Unit, Milan, Italy.
   [Filippi, Andrea Riccardo] Fdn IRCCS Policlin San Matteo, Div Radiotherapy, Pavia, Italy.
   [Filippi, Andrea Riccardo] Univ Pavia, Pavia, Italy.
   [Gramaglia, Alberto] Radiat Oncol Ctr, Policlin, Monza, Italy.
   [Italia, Corrado] Ist Osped Bergamaschi, Radiat Oncol Ctr, Ponte S Pietro Zingonia, Italy.
   [Lombardi, Fabrizio] IRCCS Policlin San Donato, Radiotherapy Unit, San Donato Milanese, Italy.
   [Magrini, Stefano Maria] Brescia Univ, Spedali Civili Hosp, Radiat Oncol Ctr, O Alberti Radium Inst,Radiat Oncol Dept, Brescia, Italy.
   [Nava, Simonetta] Ist Clin Pavia E Vigevano, Radiat Oncol Ctr, Vigevano, Italy.
   [Orlandi, Ester] CNAO, Natl Ctr Oncol Hadrontherapy, Radiat Oncol Ctr, Pavia, Italy.
   [Pasinetti, Nadia] Esine & Univ Brescia, Radiat Oncol Dept, Esine, Italy.
   [Sbicego, Elena Lara] Ist Clin St Ambrogio, Radiat Oncol Ctr, Milan, Italy.
   [Scandolaro, Luciano] ASST Lariana, Osped St Anna, Radiat Oncol Ctr, Como, Italy.
   [Scorsetti, Marta] Humanitas Clin & Res Ctr IRCCS, Radiotherapy & Radiosurg Dept, Milan, Italy.
   [Scorsetti, Marta] Humanitas Univ, Dept Biomed Sci, Milan, Italy.
   [Stiglich, Francesco] Osped Sondrio, Radiat Oncol Ctr, Sondrio, Italy.
   [Tortini, Roberto] Osped Casalpusterlengo, Azienda Osped Prov Lodi, Casalpusterlengo, Italy.
   [Vavassori, Vittorio] Unit Radiotherapy, Clin Gavezzeni SPA, Bergamo, Italy.
   [Tonoli, Sandro] ASST Cremona, Div Radiat Oncol & Nucl Med, Cremona, Italy.
   [Palazzi, Mauro Filippo] ASST Osped Niguarda, Radiotherapy Unit, Milan, Italy.
RP Pepa, M (corresponding author), European Inst Oncol, Div Radiat Oncol, IRCCS, IEO, Via Ripamonti, I-43520141 Milan, Italy.
EM matteo.pepa@ieo.it
RI Magrini, Stefano Maria/ABE-8820-2020; ivaldi, giovanni/AAB-7547-2019
OI Magrini, Stefano Maria/0000-0002-4126-733X; ivaldi,
   giovanni/0000-0002-7280-5698; Pepa, Matteo/0000-0003-1338-9556
FU Italian Ministry of HealthMinistry of Health, Italy; Ricerca
   CorrenteMinistry of Health, ItalyMinistry of Health Italy - Ricerca
   Corrente (MOH-RC); 5 x 1000 funds
FX JLI is a Ph.D. student within the European School of Molecular Medicine
   (SEMM), Milan, Italy. The authors wish to thank Mattia Zaffaroni MSc for
   his contribute to this work. IEO, the Institution of Authors BAJF, MP,
   GM and JLI, was also partially supported by the Italian Ministry of
   Health with Ricerca Corrente and 5 x 1000 funds.
CR Alterio D, 2020, HEAD NECK-J SCI SPEC, V42, P1482, DOI 10.1002/hed.26319
   Barra S, 2020, RADIOL MED, DOI 10.1007/s11547-020-01216-9
   Barton MB, 2014, RADIOTHER ONCOL, V112, P140, DOI 10.1016/j.radonc.2014.03.024
   Catanese S, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000804
   Coles CE, 2020, CLIN ONCOL-UK, V32, P279, DOI 10.1016/j.clon.2020.03.006
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   de Azambuja E, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000793
   De Felice F, 2020, RADIOTHER ONCOL, V147, P84, DOI 10.1016/j.radonc.2020.03.020
   Faivre-Finn C, 2020, CLIN ONCOL-UK, V32, P481, DOI 10.1016/j.clon.2020.05.001
   Guckenberger M, 2020, INT J RADIAT ONCOL, V107, P631, DOI 10.1016/j.ijrobp.2020.05.012
   Guckenberger M, 2020, RADIOTHER ONCOL, V146, P223, DOI 10.1016/j.radonc.2020.04.001
   Han K, 2020, RADIOTHER ONCOL, V151, P15, DOI 10.1016/j.radonc.2020.07.021
   Jereczek-Fossa BA, 2020, CLIN ONCOL-UK, V32, pE160, DOI 10.1016/j.clon.2020.04.007
   Jereczek-Fossa BA, 2020, RADIOTHER ONCOL, V149, P89, DOI 10.1016/j.radonc.2020.04.061
   Jones CM, 2020, BRIT J CANCER, V123, P709, DOI 10.1038/s41416-020-0980-x
   Kumar D, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.010367
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Liao ZX, 2020, LUNG CANCER, V146, P230, DOI 10.1016/j.lungcan.2020.05.029
   Magrini SM, 2020, RADIOTHER ONCOL, V147, P229, DOI 10.1016/j.radonc.2020.04.034
   Mohindra P, 2020, J APPL CLIN MED PHYS, V21, P6, DOI 10.1002/acm2.12898
   Nagar H, 2020, NAT REV CLIN ONCOL, DOI 10.1038/s41571-020-0375-1
   Obek C, 2020, PROSTATE CANCER P D, V23, P398, DOI 10.1038/s41391-020-0258-7
   Passaro A, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000820
   Portaluri M, 2020, Radiother Oncol, V150, P191, DOI 10.1016/j.radonc.2020.06.036
   Siavashpour Z, 2020, J GASTROINTEST CANC, V51, P800, DOI 10.1007/s12029-020-00454-4
   Slotman Berend J, 2020, Radiother Oncol, V150, P40, DOI 10.1016/j.radonc.2020.06.007
   Tchelebi LT, 2020, RADIOTHER ONCOL, V148, P194, DOI 10.1016/j.radonc.2020.04.010
   Thomson DJ, 2020, INT J RADIAT ONCOL, V107, P618, DOI 10.1016/j.ijrobp.2020.04.016
   Vavassori A, 2020, RADIOTHER ONCOL, V149, P73, DOI 10.1016/j.radonc.2020.04.040
   Wang WP, 2020, RADIAT ONCOL, V15, DOI 10.1186/s13014-020-01612-5
   Zhang DK, 2020, CLIN TRANSL RAD ONCO, V24, P88, DOI 10.1016/j.ctro.2020.06.010
NR 31
TC 0
Z9 0
U1 0
U2 0
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357-0560
EI 1559-131X
J9 MED ONCOL
JI Med. Oncol.
PD NOV 4
PY 2020
VL 37
IS 11
AR 108
DI 10.1007/s12032-020-01434-1
PG 9
WC Oncology
SC Oncology
GA OM3SG
UT WOS:000585945800001
PM 33150476
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Jackman, JA
   Yoon, BK
   Ouyang, L
   Wang, N
   Ferhan, AR
   Kim, J
   Majima, T
   Cho, NJ
AF Jackman, Joshua A.
   Yoon, Bo Kyeong
   Ouyang, Lei
   Wang, Nan
   Ferhan, Abdul Rahim
   Kim, Jaeyun
   Majima, Tetsuro
   Cho, Nam-Joon
TI Biomimetic Nanomaterial Strategies for Virus Targeting: Antiviral
   Therapies and Vaccines
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article; Early Access
DE antiviral; biomimetic; COVID&#8208; 19; nanomaterials; therapy; vaccine;
   virus
ID LECTIN AFFINITY PLASMAPHERESIS; MESSENGER-RNA VACCINE;
   ANTIBODY-RESPONSES; ENVELOPED VIRUSES; PEPTIDE NANOCOMPLEXES;
   NANOPARTICLE VACCINE; ACCURATE DESIGN; PORE FORMATION; DISEASE X;
   INFLUENZA
AB The ongoing coronavirus disease 2019 (COVID-19) pandemic highlights the importance of developing effective virus targeting strategies to treat and prevent viral infections. Since virus particles are nanoscale entities, nanomaterial design strategies are ideally suited to create advanced materials that can interact with and mimic virus particles. In this progress report, the latest advances in biomimetic nanomaterials are critically discussed for combating viral infections, including in the areas of nanomaterial-enhanced viral replication inhibitors, biomimetic virus particle capture schemes, and nanoparticle vaccines. Particular focus is placed on nanomaterial design concepts and material innovations that can be readily developed to thwart future viral threats. Pertinent nanomaterial examples from the COVID-19 situation are also covered along with discussion of human clinical trial efforts underway that might lead to next-generation antiviral therapies and vaccines.
C1 [Jackman, Joshua A.; Yoon, Bo Kyeong; Kim, Jaeyun] Sungkyunkwan Univ, Sch Chem Engn, Suwon 16419, South Korea.
   [Jackman, Joshua A.; Yoon, Bo Kyeong; Kim, Jaeyun] Sungkyunkwan Univ, Biomed Inst Convergence, SKKU BICS, Suwon 16419, South Korea.
   [Ouyang, Lei; Wang, Nan; Majima, Tetsuro] Huazhong Univ Sci & Technol, Sch Chem & Chem Engn, Wuhan 430074, Peoples R China.
   [Ferhan, Abdul Rahim; Cho, Nam-Joon] Nanyang Technol Univ, Sch Mat Sci & Engn, Singapore 639798, Singapore.
RP Jackman, JA; Kim, J (corresponding author), Sungkyunkwan Univ, Sch Chem Engn, Suwon 16419, South Korea.; Jackman, JA; Kim, J (corresponding author), Sungkyunkwan Univ, Biomed Inst Convergence, SKKU BICS, Suwon 16419, South Korea.; Majima, T (corresponding author), Huazhong Univ Sci & Technol, Sch Chem & Chem Engn, Wuhan 430074, Peoples R China.; Cho, NJ (corresponding author), Nanyang Technol Univ, Sch Mat Sci & Engn, Singapore 639798, Singapore.
EM jjackman@skku.edu; kimjaeyun@skku.edu; t.majima@hust.edu.cn;
   njcho@ntu.edu.sg
OI Jackman, Joshua/0000-0002-1800-8102
FU National Research Foundation of Korea (NRF) - Korean government (MSIT)
   [2020R1C1C1004385, 2019R1A2C2004765]; "1000 Foreign Experts Program"
   from the National Natural Science Foundation, ChinaNational Natural
   Science Foundation of China (NSFC) [WQ2017420438]; Korea Research
   Fellowship Program through the National Research Foundation of Korea
   (NRF) - Ministry of Science and ICT [2019H1D3A1A01070318]
FX J.A.J. and B.K.Y. contributed equally to this work. This work was
   supported by National Research Foundation of Korea (NRF) grants funded
   by the Korean government (MSIT) (Nos. 2020R1C1C1004385 and
   2019R1A2C2004765) and the "1000 Foreign Experts Program" (No.
   WQ2017420438) from the National Natural Science Foundation, China. In
   addition, this work was supported by the Korea Research Fellowship
   Program through the National Research Foundation of Korea (NRF) funded
   by the Ministry of Science and ICT (2019H1D3A1A01070318). The Table of
   Contents and Scheme 1 graphics were created with BioRender.com under an
   academic lab subscription.
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Ahmed A, 2015, VIRUSES-BASEL, V7, P6716, DOI 10.3390/v7122968
   Alenquer M, 2015, VIRUSES-BASEL, V7, P5066, DOI 10.3390/v7092862
   Andersen AHF, 2018, ACS MACRO LETT, V7, P587, DOI 10.1021/acsmacrolett.8b00179
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Antanasijevic A, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008665
   Aono M, 2016, ADV MATER, V28, P989, DOI 10.1002/adma.201502868
   Arvin AM, 2020, NATURE, DOI 10.1038/s41586-020-2538-8
   Bachmann MF, 1997, ANNU REV IMMUNOL, V15, P235, DOI 10.1146/annurev.immunol.15.1.235
   Badani H, 2014, BBA-BIOMEMBRANES, V1838, P2180, DOI 10.1016/j.bbamem.2014.04.015
   Bale JB, 2016, SCIENCE, V353, P389, DOI 10.1126/science.aaf8818
   BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0
   Bandlow V, 2017, J AM CHEM SOC, V139, P16389, DOI 10.1021/jacs.7b09967
   Baram-Pinto D, 2010, SMALL, V6, P1044, DOI 10.1002/smll.200902384
   Bazzill JD, 2018, NANO LETT, V18, P7832, DOI 10.1021/acs.nanolett.8b03601
   Beltran-Silva S. L., 2016, REV MED HOSP GEN MEX, DOI [10.1016/j.hgmx.2016.09.011, DOI 10.1016/J.HGMX.2016.09.011]
   BENNETT N, 2014, HARVARD BUS REV, V92, P27
   Bergstrom Donald E, 2002, Antivir Chem Chemother, V13, P185
   Berselli GB, 2020, CHEM COMMUN, V56, P11251, DOI 10.1039/d0cc04276e
   Bhatia S, 2020, ANGEW CHEM INT EDIT, V59, P12417, DOI 10.1002/anie.202006145
   Bhatia S, 2017, BIOMATERIALS, V138, P22, DOI 10.1016/j.biomaterials.2017.05.028
   Bobardt MD, 2008, P NATL ACAD SCI USA, V105, P5525, DOI 10.1073/pnas.0801388105
   Brouwer PJM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12080-1
   Bu W, 2019, IMMUNITY, V50, P1305, DOI 10.1016/j.immuni.2019.03.010
   Buttner S, 2014, BLOOD PURIFICAT, V38, P286, DOI 10.1159/000375229
   Burton DR, 2015, NAT IMMUNOL, V16, P571, DOI 10.1038/ni.3158
   Cagno V, 2018, NAT MATER, V17, P195, DOI [10.1038/NMAT5053, 10.1038/nmat5053]
   Camargos VN, 2019, EBIOMEDICINE, V44, P516, DOI 10.1016/j.ebiom.2019.05.014
   Chan KK, 2020, SCIENCE, V369, P1261, DOI 10.1126/science.abc0870
   Chandrasekaran A, 2008, NAT BIOTECHNOL, V26, P107, DOI 10.1038/nbt1375
   Chen HW, 2017, ACS APPL MATER INTER, V9, P39953, DOI 10.1021/acsami.7b09931
   Cheng G, 2008, P NATL ACAD SCI USA, V105, P3088, DOI 10.1073/pnas.0712380105
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Cho NJ, 2020, NAT MATER, V19, P813, DOI 10.1038/s41563-020-0698-4
   Cho NJ, 2009, ACS CHEM BIOL, V4, P1061, DOI 10.1021/cb900149b
   Corbett Kizzmekia S, 2020, Nature, V586, P567, DOI 10.1038/s41586-020-2622-0
   Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671
   Corti D, 2013, ANNU REV IMMUNOL, V31, P705, DOI 10.1146/annurev-immunol-032712-095916
   Cuellar-Camacho JL, 2020, J AM CHEM SOC, V142, P12181, DOI 10.1021/jacs.0c02852
   D'Souza MP, 2020, VACCINE, V38, P187, DOI 10.1016/j.vaccine.2019.10.036
   De Clercq E, 2006, BRIT J PHARMACOL, V147, P1, DOI 10.1038/sj.bjp.0706446
   De Clercq E, 2007, NAT REV DRUG DISCOV, V6, P1001, DOI 10.1038/nrd2424
   Deng L, 2018, ACS INFECT DIS, V4, P1656, DOI 10.1021/acsinfecdis.8b00206
   Dey P, 2018, ACS NANO, V12, P6429, DOI 10.1021/acsnano.8b01616
   Di Iorio D, 2019, ACS NANO, V13, P3413, DOI 10.1021/acsnano.8b09410
   Dimitrov DS, 2004, NAT REV MICROBIOL, V2, P109, DOI 10.1038/nrmicro817
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Egger D, 2002, J VIROL, V76, P5974, DOI 10.1128/JVI.76.12.5974-5984.2002
   Fan YC, 2019, ACS NANO, V13, P11087, DOI 10.1021/acsnano.9b03660
   Fineberg HV, 2014, NEW ENGL J MED, V370, P1335, DOI 10.1056/NEJMra1208802
   Fosgerau K, 2015, DRUG DISCOV TODAY, V20, P122, DOI 10.1016/j.drudis.2014.10.003
   Frich CK, 2019, J CONTROL RELEASE, V294, P298, DOI 10.1016/j.jconrel.2018.12.016
   Fries CN, 2020, NAT NANOTECHNOL, DOI 10.1038/s41565-020-0739-9
   Gates B, 2020, NEW ENGL J MED, V382, P1677, DOI 10.1056/NEJMp2003762
   Gates B, 2018, NEW ENGL J MED, V378, P2057, DOI 10.1056/NEJMp1806283
   Gelman MA, 2011, TRENDS MOL MED, V17, P34, DOI 10.1016/j.molmed.2010.10.005
   Georgiev IS, 2018, ACS INFECT DIS, V4, P788, DOI 10.1021/acsinfecdis.7b00192
   GOLLINS SW, 1986, NATURE, V321, P244, DOI 10.1038/321244a0
   Han QF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10899-2
   Han YX, 2020, ACS NANO, V14, P5143, DOI 10.1021/acsnano.0c02857
   Havenar-Daughton C, 2019, CELL REP, V29, P1756, DOI 10.1016/j.celrep.2019.10.008
   He Linling, 2020, bioRxiv, DOI 10.1101/2020.09.14.296715
   He LL, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz6225
   He LL, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aau6769
   He LL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12041
   HOFFMANN JN, 1995, KIDNEY INT, V48, P1563, DOI 10.1038/ki.1995.448
   Honigsbaum M, 2019, LANCET, V393, P1496, DOI 10.1016/S0140-6736(19)30803-7
   Hu CMJ, 2015, NATURE, V526, P118, DOI 10.1038/nature15373
   Hu CMJ, 2011, P NATL ACAD SCI USA, V108, P10980, DOI 10.1073/pnas.1106634108
   Huang SM, 2019, J COLLOID INTERF SCI, V542, P198, DOI 10.1016/j.jcis.2019.02.010
   Huang YJS, 2014, VIRUSES-BASEL, V6, P4703, DOI 10.3390/v6114703
   Innocenzi P, 2020, CHEM SCI, V11, P6606, DOI 10.1039/d0sc02658a
   Irvine Darrell J, 2020, Curr Opin Immunol, V65, P1, DOI 10.1016/j.coi.2020.01.007
   ITO M, 1987, ANTIVIR RES, V7, P361, DOI 10.1016/0166-3542(87)90018-0
   Iwasaki A, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0321-6
   Jackman JA, 2018, ADV THER-GERMANY, V1, DOI 10.1002/adtp.201800045
   Jackman JA, 2019, ACS INFECT DIS, V5, P4, DOI 10.1021/acsinfecdis.8b00286
   Jackman JA, 2018, NAT MATER, V17, P971, DOI 10.1038/s41563-018-0194-2
   Jackman JA, 2016, SMALL, V12, P1133, DOI 10.1002/smll.201500854
   Jackman JA, 2016, J AM CHEM SOC, V138, P1406, DOI 10.1021/jacs.5b12491
   Jackman JA, 2016, SMALL, V12, P1159, DOI 10.1002/smll.201501914
   Jackman JA, 2015, SMALL, V11, P2372, DOI 10.1002/smll.201403638
   Jackman JA, 2013, J PHYS CHEM B, V117, P16117, DOI 10.1021/jp409716p
   Jackman JA, 2012, BIOINTERPHASES, V7, DOI 10.1007/s13758-011-0018-2
   Jackson NAC, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0159-8
   Jardine J, 2013, SCIENCE, V340, P711, DOI 10.1126/science.1234150
   Jardine JG, 2015, SCIENCE, V349, P156, DOI 10.1126/science.aac5894
   Jiang SB, 2020, VIROL SIN, V35, P263, DOI 10.1007/s12250-020-00206-5
   Jones ST, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax9318
   Kanekiyo M, 2019, NAT IMMUNOL, V20, P362, DOI 10.1038/s41590-018-0305-x
   Kanekiyo M, 2015, CELL, V162, P1090, DOI 10.1016/j.cell.2015.07.043
   Kanekiyo M, 2013, NATURE, V499, P102, DOI 10.1038/nature12202
   Kang JH, 2014, NAT MED, V20, P1211, DOI 10.1038/nm.3640
   Kelly HG, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.136653
   Kim J, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951-020-00611-8
   Kim SO, 2017, ANAL CHEM, V89, P9742, DOI 10.1021/acs.analchem.7b01568
   King NP, 2014, NATURE, V510, P103, DOI 10.1038/nature13404
   Kiran P, 2018, CHEM-EUR J, V24, P19373, DOI 10.1002/chem.201804826
   Kirtane AR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02294-6
   Klasse PJ, 1998, ADV DRUG DELIVER REV, V34, P65, DOI 10.1016/S0169-409X(98)00002-7
   Koch B, 2018, BLOOD PURIFICAT, V46, P126, DOI 10.1159/000487224
   Kong B, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08138-1
   Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3
   Krebs SJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113463
   Kremer S, 2020, RADIOLOGY, V297, pE242, DOI [10.1148/radiol.2020202222, 10.1148/radiol.202020222]
   Kruger F, 2019, ADV SCI, V6, DOI 10.1002/advs.201802095
   Kulkarni R., 2020, DYNAMICS IMMUNE ACTI
   Kwon PS, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-00192-8
   Kwon PS, 2020, NAT CHEM, V12, P26, DOI 10.1038/s41557-019-0369-8
   Kwon SJ, 2017, NAT NANOTECHNOL, V12, P48, DOI [10.1038/nnano.2016.181, 10.1038/NNANO.2016.181]
   Lauster D, 2020, NAT NANOTECHNOL, V15, P373, DOI 10.1038/s41565-020-0660-2
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P667, DOI 10.1038/d41573-020-00151-8
   Li C. Q., 2006, IND BIOTECHNOL, V2, P143, DOI DOI 10.1089/IND.2006.2.143
   Liu X., 2018, ANGEW CHEM, V130
   Maiti Biplab K, 2020, ACS Pharmacol Transl Sci, V3, P783, DOI 10.1021/acsptsci.0c00081
   Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755
   Marano G, 2016, BLOOD TRANSFUS-ITALY, V14, P152, DOI 10.2450/2015.0131-15
   Marcandalli J, 2019, CELL, V176, P1420, DOI 10.1016/j.cell.2019.01.046
   Martin J., 2020, BIORXIV
   Mascola JR, 2020, NAT REV IMMUNOL, V20, P87, DOI 10.1038/s41577-019-0243-3
   McGuire AT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10618
   Medhi R, 2020, ACS APPL NANO MATER, V3, P8557, DOI 10.1021/acsanm.0c01978
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Melo M, 2019, MOL THER, V27, P2080, DOI 10.1016/j.ymthe.2019.08.007
   Menon J. G., 2006, FRONT BIOMED DEVICES, V47632, P31
   Michelow IC, 2011, J INFECT DIS, V203, P175, DOI 10.1093/infdis/jiq025
   Moon JJ, 2011, NAT MATER, V10, P243, DOI 10.1038/NMAT2960
   Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4
   Nagao M, 2019, BIOCONJUGATE CHEM, V30, P1192, DOI 10.1021/acs.bioconjchem.9b00134
   Nie CX, 2020, NANO LETT, V20, P5367, DOI 10.1021/acs.nanolett.0c01723
   Nie CX, 2020, ANGEW CHEM INT EDIT, V59, P15532, DOI 10.1002/anie.202004832
   Park S, 2019, ACS APPL MATER INTER, V11, P13984, DOI 10.1021/acsami.9b01724
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Rao L., P NATL ACAD SCI USA, DOI [10.1073/pnas.2014352117202014352, DOI 10.1073/PNAS.2014352117202014352]
   Rao L, 2020, ACS NANO, V14, P2569, DOI 10.1021/acsnano.0c01665
   Rao L, 2019, NANO LETT, V19, P2215, DOI 10.1021/acs.nanolett.8b03913
   Rappuoli R, 2019, CELL, V176, P1245, DOI 10.1016/j.cell.2019.02.008
   Reichmuth AM, 2016, THER DELIV, V7, P319, DOI 10.4155/tde-2016-0006
   Reina G, 2020, ACS NANO, V14, P9364, DOI 10.1021/acsnano.0c04117
   Reiter-Scherer V, 2019, BIOPHYS J, V116, P1037, DOI 10.1016/j.bpj.2019.01.041
   Richards SJ, 2020, BIOMACROMOLECULES, V21, P1604, DOI 10.1021/acs.biomac.0c00179
   Ringe R. P., 2020, J VIROL, V2020, P94
   Ronco C, 2020, BLOOD PURIFICAT, V49, P255, DOI [10.1159/000507039, 10.1159/000508125]
   Rossman JS, 2011, VIROLOGY, V411, P229, DOI 10.1016/j.virol.2010.12.003
   Rusnati M, 2009, PHARMACOL THERAPEUT, V123, P310, DOI 10.1016/j.pharmthera.2009.05.001
   Scordi-Bello IA, 2005, ANTIMICROB AGENTS CH, V49, P3607, DOI 10.1128/AAC.49.9.3607-3615.2005
   Seiler Benjamin T, 2019, F1000Res, V8, P108, DOI 10.12688/f1000research.17447.1
   Simpson S, 2020, LANCET INFECT DIS, V20, pE108, DOI 10.1016/S1473-3099(20)30123-7
   Sliepen K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10262-5
   Sliepen K, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0210-4
   Smith JD, 2015, CURR OPIN BIOTECH, V34, P217, DOI 10.1016/j.copbio.2015.03.014
   Sok D, 2016, SCIENCE, V353, P1557, DOI 10.1126/science.aah3945
   Song E., 2020, BIORXIV, DOI [10.1101/2020.06.25.1699462020.06.25.169946, DOI 10.1101/2020.06.25.1699462020.06.25.169946]
   Song S, 2020, FOOD FUNCT, V11, P7415, DOI 10.1039/d0fo02017f
   St Vincent MR, 2010, P NATL ACAD SCI USA, V107, P17339, DOI 10.1073/pnas.1010026107
   Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998
   Swanson KA, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aba6466
   Szebeni J, 2018, NAT NANOTECHNOL, V13, P1100, DOI 10.1038/s41565-018-0273-1
   Tabaei SR, 2012, NANO LETT, V12, P5719, DOI 10.1021/nl3029637
   Tang ZM, 2020, NAT REV MATER, V5, P847, DOI 10.1038/s41578-020-00247-y
   Tenzer S, 2013, NAT NANOTECHNOL, V8, P772, DOI 10.1038/nnano.2013.181
   Thalhauser S, 2020, J PHARM SCI-US, V109, P911, DOI 10.1016/j.xphs.2019.10.059
   Tokatlian T, 2019, SCIENCE, V363, P649, DOI 10.1126/science.aat9120
   Tong T, 2020, SMALL, V16, DOI 10.1002/smll.201906206
   Tullis R. H., 2002, J THEOR MED, V4, P157
   Tullis RH, 2004, BLOOD PURIFICAT, V22, P84, DOI 10.1159/000074928
   Tullis RH, 2003, BLOOD PURIFICAT, V21, P58, DOI 10.1159/000067865
   Tullis RH, 2010, BLOOD PURIFICAT, V29, P210, DOI 10.1159/000245649
   Tullis RH, 2009, BLOOD PURIFICAT, V27, P64, DOI 10.1159/000167011
   van Riel D, 2020, NAT MATER, V19, P810, DOI 10.1038/s41563-020-0746-0
   Vigant F, 2015, NAT REV MICROBIOL, V13, P426, DOI 10.1038/nrmicro3475
   Walls Alexandra C, 2020, bioRxiv, DOI 10.1101/2020.08.11.247395
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang WJ, 2020, NAT NANOTECHNOL, V15, P406, DOI 10.1038/s41565-020-0648-y
   Wei XL, 2018, ADV MATER, V30, DOI 10.1002/adma.201802233
   Welsch S, 2007, FEBS LETT, V581, P2089, DOI 10.1016/j.febslet.2007.03.060
   Wilen CB, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006866
   Wolf MC, 2010, P NATL ACAD SCI USA, V107, P3157, DOI 10.1073/pnas.0909587107
   Wu CX, 2020, ACS NANO, V14, P1390, DOI 10.1021/acsnano.9b07165
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Xu ZY, 2020, ADV SCI, V7, DOI 10.1002/advs.201902802
   Yamabe M, 2018, BIOCONJUGATE CHEM, V29, P1490, DOI 10.1021/acs.bioconjchem.8b00045
   Yassine HM, 2015, NAT MED, V21, P1065, DOI 10.1038/nm.3927
   Zacheo A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65892-3
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
   Zhang G, 2020, MBIO, V11, DOI 10.1128/mBio.00903-20
   Zhang JJ, 2015, BIOMATERIALS, V70, P37, DOI 10.1016/j.biomaterials.2015.08.014
   Zhang JJ, 2013, BIOMATERIALS, V34, P3846, DOI 10.1016/j.biomaterials.2013.01.026
   Zhang NN, 2020, CELL, V182, P1271, DOI 10.1016/j.cell.2020.07.024
   Zhang QZ, 2020, NANO LETT, V20, P5570, DOI 10.1021/acs.nanolett.0c02278
   Zhang YN, 2019, NANO LETT, V19, P7226, DOI 10.1021/acs.nanolett.9b02834
   Zhao L, 2014, VACCINE, V32, P327, DOI 10.1016/j.vaccine.2013.11.069
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 196
TC 0
Z9 0
U1 7
U2 7
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616-301X
EI 1616-3028
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
AR 2008352
DI 10.1002/adfm.202008352
EA NOV 2020
PG 25
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA OK6RE
UT WOS:000584774400001
OA Bronze
DA 2021-01-01
ER

PT J
AU Bagate, F
   Tuffet, S
   Masi, P
   Perier, F
   Razazi, K
   de Prost, N
   Carteaux, G
   Payen, D
   Dessap, AM
AF Bagate, Francois
   Tuffet, Samuel
   Masi, Paul
   Perier, Francois
   Razazi, Keyvan
   de Prost, Nicolas
   Carteaux, Guillaume
   Payen, Didier
   Dessap, Armand Mekontso
TI Rescue therapy with inhaled nitric oxide and almitrine in COVID-19
   patients with severe acute respiratory distress syndrome
SO ANNALS OF INTENSIVE CARE
LA English
DT Article
DE iNO; Almitrine; COVID-19; ARDS
ID GAS-EXCHANGE; BISMESYLATE; PREVALENCE; PROGNOSIS; SCORE
AB Background In COVID-19 patients with severe acute respiratory distress syndrome (ARDS), the relatively preserved respiratory system compliance despite severe hypoxemia, with specific pulmonary vascular dysfunction, suggests a possible hemodynamic mechanism for VA/Q mismatch, as hypoxic vasoconstriction alteration. This study aimed to evaluate the capacity of inhaled nitric oxide (iNO)-almitrine combination to restore oxygenation in severe COVID-19 ARDS (C-ARDS) patients. Methods We conducted a monocentric preliminary pilot study in intubated patients with severe C-ARDS. Respiratory mechanics was assessed after a prone session. Then, patients received iNO (10 ppm) alone and in association with almitrine (10 mu g/kg/min) during 30 min in each step. Echocardiographic and blood gases measurements were performed at baseline, during iNO alone, and iNO-almitrine combination. The primary endpoint was the variation of oxygenation (PaO2/FiO(2) ratio). Results Ten severe C-ARDS patients were assessed (7 males and 3 females), with a median age of 60 [52-72] years. Combination of iNO and almitrine outperformed iNO alone for oxygenation improvement. The median of PaO2/FiO(2) ratio varied from 102 [89-134] mmHg at baseline, to 124 [108-146] mmHg after iNO (p = 0.13) and 180 [132-206] mmHg after iNO and almitrine (p < 0.01). We found no correlation between the increase in oxygenation caused by iNO-almitrine combination and that caused by proning. Conclusion In this pilot study of severe C-ARDS patients, iNO-almitrine combination was associated with rapid and significant improvement of oxygenation. These findings highlight the role of pulmonary vascular function in COVID-19 pathophysiology.
C1 [Bagate, Francois; Tuffet, Samuel; Masi, Paul; Perier, Francois; Razazi, Keyvan; de Prost, Nicolas; Carteaux, Guillaume; Dessap, Armand Mekontso] Hop Univ Henri Mondor, AP HP, Serv Med Intens Reanimat, 51 Ave Marechal Lattre de Tassigny, F-94010 Creteil, France.
   [Bagate, Francois; Tuffet, Samuel; Masi, Paul; Perier, Francois; Razazi, Keyvan; de Prost, Nicolas; Carteaux, Guillaume; Dessap, Armand Mekontso] Univ Paris Est Creteil, CARMAS, F-94010 Creteil, France.
   [Payen, Didier] Univ Paris 7 Paris Cite Sorbonne, UFR Med Villemin, Paris, France.
   [Dessap, Armand Mekontso] Univ Paris Est Creteil, IMRB, INSERM, F-94010 Creteil, France.
RP Dessap, AM (corresponding author), Hop Univ Henri Mondor, AP HP, Serv Med Intens Reanimat, 51 Ave Marechal Lattre de Tassigny, F-94010 Creteil, France.; Dessap, AM (corresponding author), Univ Paris Est Creteil, CARMAS, F-94010 Creteil, France.; Dessap, AM (corresponding author), Univ Paris Est Creteil, IMRB, INSERM, F-94010 Creteil, France.
EM armand.dessap@aphp.fr
OI Bagate, Francois/0000-0002-3391-0807
CR Ackermann M, 2020, N ENGL J MED
   Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Akerstrom S, 2005, J VIROL, V79, P1966, DOI 10.1128/JVI.79.3.1966-1969.2005
   B'chir A, 1998, ANESTHESIOLOGY, V89, P823, DOI 10.1097/00000542-199810000-00005
   Boissier F, 2013, INTENS CARE MED, V39, P1725, DOI 10.1007/s00134-013-2941-9
   Cardinale M, 2020, ANAESTH CRIT CARE PA
   Chen LN, 2004, CLIN INFECT DIS, V39, P1531, DOI 10.1086/425357
   Chen L, 2020, AM J RESP CRIT CARE, V201, P178, DOI 10.1164/rccm.201902-0334OC
   Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2
   DellaVolpe J, 2020, CRIT CARE MED, V48, P838, DOI 10.1097/CCM.0000000000004330
   Dessap AM, 2010, CRIT CARE MED, V38, P1786, DOI 10.1097/CCM.0b013e3181eaa9c8
   Esnault P, 2019, ANESTH ANALG, V129, pE48, DOI 10.1213/ANE.0000000000002786
   Gallart L, 1998, AM J RESP CRIT CARE, V158, P1770, DOI 10.1164/ajrccm.158.6.9804066
   Gattinoni L, 2020, AM J RESP CRIT CARE
   Gattinoni L, 2020, INTENSIVE CARE MED
   Helms J, 2020, INTENSIVE CARE MED, DOI 10.1007/s00134-020-06062-x
   Horie K, 2020, ACTA NEUROPATHOL COM, V8, DOI 10.1186/s40478-020-01019-z
   Keyaerts E, 2004, INT J INFECT DIS, V8, P223, DOI 10.1016/j.ijid.2004.04.012
   Kobayashi J, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00681-9
   Koulouras Vasilios, 2016, World J Crit Care Med, V5, P121, DOI 10.5492/wjccm.v5.i2.121
   Lang M, 2020, LANCET INFECT DIS
   LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957
   Lei Chong, 2020, medRxiv, DOI 10.1101/2020.03.09.20033530
   Losser M-R, 2020, ANAESTH CRIT CARE PA
   MacLaren G, 2020, JAMA-J AM MED ASSOC, V323, P1245, DOI 10.1001/jama.2020.2342
   Martel J, 2020, MICROBES INFECT
   Menter T, 2020, HISTOPATHOLOGY, V77, P198, DOI 10.1111/his.14134
   Papazian L, 1999, AM J RESP CRIT CARE, V160, P473, DOI 10.1164/ajrccm.160.2.9809110
   Papazian L, 1999, EUR RESPIR J, V14, P1283, DOI 10.1183/09031936.99.14612839
   Papazian L, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0540-9
   Payen D M, 1999, Curr Opin Anaesthesiol, V12, P37, DOI 10.1097/00001503-199902000-00007
   PAYEN DM, 1987, J APPL PHYSIOL, V62, P61
   Poissy J, 2020, CIRCULATION
   Ramanathan K, 2020, LANCET RESP MED
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Ranucci M, 2020, J THROMB HAEMOST, V18, P1747, DOI 10.1111/jth.14854
   Varga Z, 2020, LANCET
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   WYSOCKI M, 1994, INTENS CARE MED, V20, P254, DOI 10.1007/BF01708960
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 40
TC 0
Z9 0
U1 4
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2110-5820
J9 ANN INTENSIVE CARE
JI Ann. Intensive Care
PD NOV 4
PY 2020
VL 10
IS 1
AR 151
DI 10.1186/s13613-020-00769-2
PG 7
WC Critical Care Medicine
SC General & Internal Medicine
GA OM2MX
UT WOS:000585862400001
PM 33150525
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Navarro-Millan, I
   Sattui, SE
   Lakhanpal, A
   Zisa, D
   Siegel, CH
   Crow, MK
AF Navarro-Millan, Iris
   Sattui, Sebastian E.
   Lakhanpal, Amit
   Zisa, Diane
   Siegel, Caroline H.
   Crow, Mary K.
TI Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A
   Case Series
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
AB Objective To report the clinical experience with anakinra in preventing mechanical ventilation in patients with coronavirus disease 2019 (COVID-19), symptoms of cytokine storm syndrome, and acute hypoxemic respiratory failure.
   Methods To be included in this retrospective case series, patients must have had severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), fever, ferritin levels >1,000 ng/ml with 1 additional laboratory marker of hyperinflammation, and acute hypoxemic respiratory failure. Acute hypoxemic respiratory failure was defined as requiring 15 liters of supplemental oxygen via a nonrebreather mask combined with 6-liter nasal cannula or use of >= 95% oxygen by high-flow nasal cannula. We excluded patients in whom there was suspicion of bacterial infection or who were receiving immunosuppressants. Subcutaneous anakinra was initiated at 100 mg every 6 hours and gradually tapered off completely. The primary outcome was the prevention of mechanical ventilation.
   Results Of the 14 patients who met the criteria, 11 patients received anakinra for a maximum of 19 days. Seven of the patients who started anakinra treatment <= 36 hours after onset of acute hypoxemic respiratory failure did not require mechanical ventilation, and all were discharged home. Four patients who started anakinra >= 4 days after onset of acute hypoxemic respiratory failure required mechanical ventilation. Of those, 3 patients were extubated (2 discharged home and 1 remained hospitalized), and 1 died. All 3 patients who met the criteria but did not receive anakinra required mechanical ventilation. Two patients were extubated (1 discharged home and 1 remained hospitalized), and 1 remained on mechanical ventilation.
   Conclusion Our data suggest that anakinra could be beneficial in treating COVID-19 patients with evidence of cytokine storm syndrome when initiated early after onset of acute hypoxemic respiratory failure. Our patient selection and treatment approach should be considered for investigation in a clinical trial to determine the safety and efficacy of anakinra in treating patients with COVID-19 and symptoms of cytokine storm syndrome.
C1 [Navarro-Millan, Iris] Weill Cornell Med, New York, NY 10021 USA.
   [Navarro-Millan, Iris; Sattui, Sebastian E.; Lakhanpal, Amit; Zisa, Diane; Siegel, Caroline H.; Crow, Mary K.] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA.
RP Navarro-Millan, I (corresponding author), Weill Cornell Med, Div Gen Internal Med, 420 East 70th St, New York, NY 10021 USA.
EM yin9003@med.cornell.edu
OI Sattui, Sebastian E./0000-0002-3945-6828; Navarro-Millan,
   Iris/0000-0002-9540-6614
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases,
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Arthritis &
   Musculoskeletal & Skin Diseases (NIAMS) [K23AR-068449]; Vasculitis
   Clinical Research Consortium-Vasculitis Foundation Fellowship
   [U54-AR057319]
FX Dr. Navarro-Millan's work was supported by the National Institute of
   Arthritis and Musculoskeletal and Skin Diseases, NIH (grant
   K23AR-068449). Dr. Sattui's work was supported by the Vasculitis
   Clinical Research Consortium-Vasculitis Foundation Fellowship (grant
   U54-AR057319).
CR [Anonymous], 2020, WHO R D BLUEPRINT NO
   Aouba A, 2020, ANN RHEUM DIS, DOI 10.1136/
   Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2
   Cavalli G, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01157
   Dinarello Charles A, 2015, Temperature (Austin), V2, P8, DOI 10.1080/23328940.2015.1017086
   Eloseily EM, 2020, ARTHRITIS RHEUMATOL, V72, P326, DOI 10.1002/art.41103
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Monteagudo Luke Adam, 2020, ACR Open Rheumatol, V2, P276, DOI 10.1002/acr2.11135
   NYC Health, 2020, AG ADJ RAT LAB CONF
   Ong EZY, 2020, CELL HOST MICROBE, V27, P879, DOI 10.1016/j.chom.2020.03.021
   Pontali E, 2020, J ALLERGY CLIN IMMUN, V146, P213, DOI 10.1016/j.jaci.2020.05.002
   Quartier P, 2011, ANN RHEUM DIS, V70, P747, DOI 10.1136/ard.2010.134254
   Schulert GS, 2016, J INFECT DIS, V213, P1180, DOI 10.1093/infdis/jiv550
NR 15
TC 6
Z9 7
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2326-5191
EI 2326-5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD DEC
PY 2020
VL 72
IS 12
BP 1990
EP 1997
DI 10.1002/art.41422
EA NOV 2020
PG 8
WC Rheumatology
SC Rheumatology
GA OW7OV
UT WOS:000584909700001
PM 32602262
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Lv, JW
   Su, YY
   Song, LQ
   Gong, X
   Peng, YJ
AF Lv, Jianwei
   Su, Yeyang
   Song, Lingqiao
   Gong, Xia
   Peng, Yaojin
TI Stem cell 'therapy' advertisements in China: Infodemic, regulations and
   recommendations
SO CELL PROLIFERATION
LA English
DT Article
DE stem cell; advertisement; infodemic; regulation; China
AB During the COVID-19 pandemic, in addition to the pandemic itself, a phenomenon called an 'infodemic'-defined by the World Health Organization as the spread of misleading information on the pandemic-has also gained attention. In the field of stem cell research, researchers and regulators have been fighting against false and misleading information, particularly advertisements for unproven and unauthorized stem cell-based interventions for decades. However, how existing legal and regulatory measures, which vary by country, can be employed to combat such false information is unclear. In this article, we examine the situation in China, where the spread of unauthorized stem cell 'therapies' has drawn patients from not only within China but also from abroad. First, we assess how and to what extent online advertisements promote unproven and unauthorized stem cell-based interventions directly to patients and prospective health consumers in China. Next, we survey the landscape for existing regulatory and administrative measures that may be used to combat false and misleading advertisements in this area. Finally, based on our analysis, we provide three main recommendations that may improve the effectiveness and efficiency of the regulatory measures in curtailing illegitimate advertising of unproven and unauthorized stem cell-based interventions in China. In conclusion, we also call for international collaboration among researchers and regulators in studying and strengthening regulations in this critical area that has so far been neglected in scholarly and policy discussions.
C1 [Lv, Jianwei; Su, Yeyang; Song, Lingqiao; Gong, Xia; Peng, Yaojin] Chinese Acad Sci, Inst Zool, State Key Lab Stem Cell & Reprod Biol, Beijing 100101, Peoples R China.
   [Lv, Jianwei; Su, Yeyang; Gong, Xia; Peng, Yaojin] Chinese Acad Sci, Inst Stem Cell & Regenerat, Beijing, Peoples R China.
   [Song, Lingqiao] McGill Univ, Ctr Genom & Policy, Montreal, PQ, Canada.
   [Peng, Yaojin] Univ Chinese Acad Sci, Beijing, Peoples R China.
RP Peng, YJ (corresponding author), Chinese Acad Sci, Inst Zool, State Key Lab Stem Cell & Reprod Biol, Beijing 100101, Peoples R China.
EM yaojin.peng@ioz.ac.cn
OI Peng, Yaojin/0000-0002-3909-6041
FU Ministry of Science and Technology (National Key Research and
   Development Program of China) [2018YFE0204403]; Strategic Priority
   Research Program of the Chinese Academy of SciencesChinese Academy of
   Sciences [XDA16040503]; Program of Academic Divisions of the Chinese
   Academy of Sciences [XBKJLL2019001]; Chinese National Funding of Social
   Sciences [19ZDA109]
FX This work was supported by the Ministry of Science and Technology
   (National Key Research and Development Program of China,
   2018YFE0204403), the Strategic Priority Research Program of the Chinese
   Academy of Sciences (XDA16040503), Program of Academic Divisions of the
   Chinese Academy of Sciences (XBKJLL2019001) and Chinese National Funding
   of Social Sciences (19ZDA109).
CR Alicia Ault, 2019, MEDESCAPE       0906
   Australia Therapeutic Goods Administration, 2019, ADV GUID BUS INV STE
   Caulfield T, 2020, NATURE
   Caulfield T, 2019, BMC MED ETHICS, V20, DOI 10.1186/s12910-019-0388-4
   Caulfield T, 2016, SCIENCE, V352, P776, DOI 10.1126/science.aaf4620
   Lau D, 2008, CELL STEM CELL, V3, P591, DOI 10.1016/j.stem.2008.11.001
   Lysaght T, 2017, J MED ETHICS, V43, P744, DOI 10.1136/medethics-2016-104046
   National Health and Family Planning Commission China Food and Drug Administrations National, 2015, GUID QUAL CONTR PREC
   National Health and Family Planning Commission China Food and Drug Administrations National, 2015, ADM MEAS STEM CELL C
   Rosemann A, 2016, REGEN MED, V11, P5, DOI 10.2217/rme.15.80
   Sipp D, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag0426
   Standing Committee of the National People's Congress, 2018, ADV LAW PEOPL REP CH
   Standing Committee of the National People's Congress, 2013, PROT CONS RIGHTS INT
   Standing Committee of the National People's Congress, 2019, ANT COMP LAW PEOPL R
   Standing Committee of the National People's Congress, 2017, CRIM LAW PEOPL REP C
   State Administration for Industry and Commerce, 2016, INT MEAS ADM INT ADV
   State Administration for Industry and Commerce Ministry of Health, 2006, MEAS ADM MED ADV
   State Drug Administration, 1999, CLASS MAN PRESCR DRU
   Turner L, 2020, CELL STEM CELL, V26, P806, DOI 10.1016/j.stem.2020.05.003
   United States District Court for the Central District of California, 2013, COMPL PERM INJ CIV P
   World. 2020-World Health Organization, 2020, 13 WHO
   World Health Organization, 13 WHO
   Xinhua, 2016, XINHUA
   Xinhua News Agency, 2018, XINHUA
NR 24
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0960-7722
EI 1365-2184
J9 CELL PROLIFERAT
JI Cell Prolif.
PD DEC
PY 2020
VL 53
IS 12
SI SI
AR e12937
DI 10.1111/cpr.12937
EA NOV 2020
PG 7
WC Cell Biology
SC Cell Biology
GA PB0MV
UT WOS:000585637300001
PM 33146925
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Picchio, CA
   Valencia, J
   Doran, J
   Swan, T
   Pastor, M
   Martro, E
   Colom, J
   Lazarus, JV
AF Picchio, Camila A.
   Valencia, Jorge
   Doran, Jason
   Swan, Tracy
   Pastor, Marta
   Martro, Elisa
   Colom, Joan
   Lazarus, Jeffrey, V
TI The impact of the COVID-19 pandemic on harm reduction services in Spain
SO HARM REDUCTION JOURNAL
LA English
DT Article
DE COVID-19; Harm reduction; Healthcare utilisation; Health systems; Spain
ID INJECT DRUGS; PEOPLE; HIV; HCV
AB Background Containment policies and other restrictions introduced by the Spanish government in response to the COVID-19 pandemic present challenges for marginalised populations, such as people who use drugs. Harm reduction centres are often linked to social services, mental health services, and infectious disease testing, in addition to tools and services that help to reduce the harms associated with injecting drugs. This study aimed to explore the impact of the pandemic on these services in four autonomous communities in Spain. Methods This is a cross-sectional study that employed a seven-section structured survey administered electronically to 20 centres in July 2020. Data from the most heavily affected months (March-June) in 2020 were compared to data from the same period in 2019. Averages were calculated with their ranges, rates, and absolute numbers. Results All 11 responding centres reported having had to adapt or modify their services during the Spanish state of alarm (14 March-21 June 2020). One centre reported complete closure for 2 months and four reported increases in their operating hours. The average number of service users across all centres decreased by 22% in comparison to the same period in the previous year and the average needle distribution decreased by 40% in comparison to 2019. Most centres reported a decrease in infectious disease testing rates (hepatitis B and C viruses, human immunodeficiency virus, and tuberculosis) for March, April, and May in 2020 compared to the previous year. Reported deaths as a result of overdose did not increase during the state of alarm, but 2/11 (18%) centres reported an increase in overdose deaths immediately after finalisation of the state of alarm. Conclusion Overall, Spanish harm reduction centres were able to continue operating and offering services by adjusting operating hours. The number of overall service users and needles distributed fell during the Spanish state of alarm lockdown period, suggesting that fewer clients accessed harm reduction services during this time, putting them at greater risk of reusing or sharing injecting equipment, overdosing, acquiring infectious diseases with decreased access to testing or discontinuing ongoing treatment such as methadone maintenance therapy, hepatitis C treatment, or antiretroviral therapy.
C1 [Picchio, Camila A.; Lazarus, Jeffrey, V] Univ Barcelona, Hosp Clin, Barcelona Inst Global Hlth ISGlobal, Barcelona, Spain.
   [Valencia, Jorge] Unidad Movil Reducc Dano SMASD, Madrid, Spain.
   [Doran, Jason] London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, London, England.
   [Pastor, Marta] Comis Ciudadana Antisida Bizkaia, Bilbao, Spain.
   [Martro, Elisa] Hosp Badalona Germans Trias & Pujol, Inst Invest Ciencies Salut Germans Trias & Pujol, Lab Clin Metropolitana Nord, Microbiol Dept, Badalona, Spain.
   [Martro, Elisa] Inst Salud Carlos III, Ctr Invest Biomed Red Epidemiol & Salud Publ CIBE, Madrid, Spain.
   [Colom, Joan] Agcy Publ Hlth Catalonia, Programme Subst Abuse & Prevent Control & Treatme, Barcelona, Spain.
RP Lazarus, JV (corresponding author), Univ Barcelona, Hosp Clin, Barcelona Inst Global Hlth ISGlobal, Barcelona, Spain.
EM Jeffrey.Lazarus@isglobal.org
RI ; Lazarus, Jeffrey/R-6248-2018
OI Doran, Jason/0000-0002-5501-9433; Lazarus, Jeffrey/0000-0001-9618-2299
FU Spanish Ministry of Science, Innovation and Universities through the
   "Centro de Excelencia Severo Ochoa 2019-2023" Programme
   [CEX2018-000806-S]; Government of Catalonia through the CERCA Programme
FX CAP and JVL acknowledge support to ISGlobal from the Spanish Ministry of
   Science, Innovation and Universities through the "Centro de Excelencia
   Severo Ochoa 2019-2023" Programme (CEX2018-000806-S), and support from
   the Government of Catalonia through the CERCA Programme. EM also
   acknowledges support from the Government of Catalonia through the CERCA
   Programme to the Germans Trias i Pujol Research Institute (IGTP). The
   authors would like to thank the focal person from each of the eleven
   centres who took the time to complete and return the survey. From the
   Basque Country: Blanca Bastida, Maria Cristina Marbella Merino, Marta
   Fernandez de Aguirre, and Leticia Ituno. From Catalonia: Alicia Molina,
   Antoni Llort, Cristina Guijarro and Daniel Rodriguez, Lara Grau Lopez,
   Noemi Gonzalez, and Claudio Castillo. From Madrid: Jorge Valencia and
   Jorge alvarez Rodriguez. From Valencia: Alba Moreno. The authors would
   like to thank Adam Palayew (University of Washington, Department of
   Biostatistics and Epidemiology) for his contribution to creating the
   time trend figures.
CR Abdul-Quader AS, 2013, AIDS BEHAV, V17, P2878, DOI 10.1007/s10461-013-0593-y
   [Anonymous], 2017, DELEGACION GOBIERNO
   Borobia AM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061733
   Bowden-Jones O, 2019, ACMD ADVISORY COUNCI
   Centers for Disease Control and Prevention, WHAT KNOW LIV DIS CO
   Chang Judy, 2020, Int J Drug Policy, V83, P102832, DOI 10.1016/j.drugpo.2020.102832
   Comunidad de Madrid, 2020, ENC IMP COVID 19 PAU
   Csete J, 2016, LANCET, V387, P1427, DOI 10.1016/S0140-6736(16)00619-X
   Dastmalchi LN, ABC NEWS
   Day E, 2019, LIVER INT, V39, P20, DOI 10.1111/liv.13949
   Degenhardt L, 2019, LANCET, V394, P1560, DOI 10.1016/S0140-6736(19)32229-9
   Degenhardt L, 2017, LANCET GLOB HEALTH, V5, pE1192, DOI 10.1016/S2214-109X(17)30375-3
   Delegacion del Gobierno para el Plan Nacional sobre drogas, 2017, MEMORIA
   Doran J, 2020, DRUG ALCOHOL DEPEN, V213, DOI 10.1016/j.drugalcdep.2020.108080
   Dunlop A, 2020, HARM REDUCT J, V17, DOI 10.1186/s12954-020-00370-7
   European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2019, SPAIN COUNTR DRUG RE
   European Monitoring Centre for Drugs and Drug Addiction ( EMCDDA), 2020, EMCDDA TRENDSP BRIEF
   European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2020, EMCDDA UPD IMPL COVI
   Huang YF, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001625
   International Network of People who Use Drugs (INPUD), INPUD ONL SURV UNPUB
   Lazarus JV, 2019, J INTERN MED, V286, P503, DOI 10.1111/joim.12972
   Lazarus JV, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240011
   Lazarus JV, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-035621
   Leung JM, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00688-2020
   Ministerio de Sanidad C y BS de E, 2019, INFORME 2019 ALC TAB
   Peter Sarosi, 2020, HARM REDUCTION RESPO
   Phillips KT, 2017, J ADDICT MED, V11, P461, DOI 10.1097/ADM.0000000000000346
   Platt L, 2018, ADDICTION, V113, P545, DOI 10.1111/add.14012
   Soriano JB, 2018, MED CLIN-BARCELONA, V151, P171, DOI 10.1016/j.medcli.2018.05.011
   Sutherland R, 2016, DRUG ALCOHOL DEPEN, V159, P35, DOI 10.1016/j.drugalcdep.2015.10.035
   UNAIDS, WORLDW MOR HALF NEW
   UNAIDS, 2020, GLOB AIDS REP SEIZ M
   United Nations Development Programme (UNDP), 2020, COVID 19 NEW UNDP DA
   United Nations Office on Drugs and Crime IN of P who UDUNP on HUNDPUNPFWHOUSA for ID, 2017, IMPL COMPR HIV HCV P
   WHO, 2019, GLOB HLTH SECT STRAT
   World Drug Report, 2019, WORLD DRUG REP, VE.19.XI.8
   World Health Organization, 2020, RAP COMM ROL GENEXPE
   Worldometer, 2020, COR CAS, DOI [10.1101/2020.01.23.20018549V2, DOI 10.1101/2020.01.23.20018549V2]
NR 38
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477-7517
J9 HARM REDUCT J
JI Harm Reduct. J.
PD NOV 4
PY 2020
VL 17
IS 1
AR 87
DI 10.1186/s12954-020-00432-w
PG 11
WC Substance Abuse
SC Substance Abuse
GA OL1KZ
UT WOS:000585101900001
PM 33143699
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mondal, P
   Natesh, J
   Salam, AAA
   Thiyagarajan, S
   Meeran, SM
AF Mondal, Priya
   Natesh, Jagadish
   Abdul Salam, Abdul Ajees
   Thiyagarajan, Saravanamuthu
   Meeran, Syed Musthapa
TI Traditional medicinal plants against replication, maturation and
   transmission targets of SARS-CoV-2: computational investigation
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; molecular docking; molecular dynamics; medicinal
   plants
ID ANTIVIRAL ACTIVITY; ANTICANCER; PREDICTION; SOFTWARE; BINDING
AB COVID-19 is an infectious pandemic caused by the SARS-CoV-2 virus. The critical components of SARS-CoV-2 are the spike protein (S-protein) and the main protease (M-pro). M-pro is required for the maturation of the various polyproteins involved in replication and transcription. S-protein helps the SARS-CoV-2 to enter the host cells through the angiotensin-converting enzyme 2 (ACE2). Since ACE2 is required for the binding of SARS-CoV-2 on the host cells, ACE2 inhibitors and blockers have got wider attention, in addition to S-protein and M-pro modulators as potential therapeutics for COVID-19. So far, no specific drugs have shown promising therapeutic potential against COVID-19. The current study was undertaken to evaluate the therapeutic potential of traditional medicinal plants against COVID-19. The bioactives from the medicinal plants, along with standard drugs, were screened for their binding against S-protein, M-pro and ACE2 targets using molecular docking followed by molecular dynamics. Based on the higher binding affinity compared with standard drugs, bioactives were selected and further analyzed for their pharmacological properties such as drug-likeness, ADME/T-test, biological activities using in silico tools. The binding energies of several bioactives analyzed with target proteins were relatively comparable and even better than the standard drugs. Based on Lipinski factors and lower binding energies, seven bioactives were further analyzed for their pharmacological and biological characteristics. The selected bioactives were found to have lower toxicity with a higher GI absorption rate and potent anti-inflammatory and anti-viral activities against targets of COVID-19. Therefore, the bioactives from these medicinal plants can be further developed as phytopharmaceuticals for the effective treatment of COVID-19.
C1 [Mondal, Priya; Natesh, Jagadish; Meeran, Syed Musthapa] CSIR Cent Food Technol Res Inst, Dept Biochem, Mysore, Karnataka, India.
   [Mondal, Priya; Natesh, Jagadish; Meeran, Syed Musthapa] Acad Sci & Innovat Res AcSIR, Ghaziabad, Uttar Pradesh, India.
   [Abdul Salam, Abdul Ajees] Manipal Acad Higher Educ, Ctr Appl Nanosci, Dept Atom & Mol Phys, Manipal 576104, Karnataka, India.
   [Thiyagarajan, Saravanamuthu] Inst Bioinformat & Appl Biotechnol IBAB, Biotech Pk,Elect City Phase 1, Bangalore, Karnataka, India.
RP Salam, AAA (corresponding author), Manipal Acad Higher Educ, Ctr Appl Nanosci, Dept Atom & Mol Phys, Manipal 576104, Karnataka, India.; Meeran, SM (corresponding author), CSIR Cent Food Technol Res Inst CSIR CFTRI, Dept Biochem, Lab Canc Epigenet, Mysore 570020, Karnataka, India.
EM abdul.ajees@manipal.edu; s.musthapa@cftri.res.in
RI Abdul Salam, Abdul Ajees/O-6679-2016
OI Abdul Salam, Abdul Ajees/0000-0002-3377-3048
FU UGC, Government of IndiaUniversity Grants Commission, India; DBT,
   Government of IndiaDepartment of Biotechnology (DBT) India; MAHE
   intramural grant [MAHE/DREG/PhD/IMF/2019]; Department of IT, BT, Science
   and Technology, the Government of Karnataka; DST-FISTDepartment of
   Science & Technology (India) [SR/FST/LSI-536/2012]
FX PM acknowledges senior research fellowships from UGC, Government of
   India, and JN from DBT, Government of India. AAAS acknowledges the
   research grant provided by a MAHE intramural grant [grant no.
   MAHE/DREG/PhD/IMF/2019]. ST acknowledges the institutional grant to IBAB
   from the Department of IT, BT, Science and Technology, the Government of
   Karnataka. IBAB is also supported by DST-FIST vide sanction no
   SR/FST/LSI-536/2012.
CR Alam M. Shahidul, 2000, Fitoterapia, V71, P574, DOI 10.1016/S0367-326X(00)00197-0
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   BHARDWAJ VK, 2020, J BIOMOL STRUCT 0520, DOI DOI https://doi.org/10.1080/07391102.2020.1766572
   Bonow RO, 2020, JAMA CARDIOL, V5, P751, DOI 10.1001/jamacardio.2020.1105
   Cai Z, 2015, CELL BIOCHEM BIOPHYS, V72, P727, DOI 10.1007/s12013-015-0524-9
   Case D., 2020, AMBER 2020
   Chen JL, 1998, J NAT PROD, V61, P1295, DOI 10.1021/np980086y
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   DONG J, 2018, J CHEMINFORMATICS, V10, DOI DOI https://doi.org/10.1186/s13321-018-0283-x
   Drwal MN, 2014, NUCLEIC ACIDS RES, V42, pW53, DOI 10.1093/nar/gku401
   Ertl P, 2009, J CHEMINFORMATICS, V1, DOI 10.1186/1758-2946-1-8
   Estari M., 2012, Biology and Medicine, V4, P178
   Favarin DC, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/576479
   Filimonov DA, 2014, CHEM HETEROCYCL COM+, V50, P444, DOI 10.1007/s10593-014-1496-1
   Fiore C, 2008, PHYTOTHER RES, V22, P141, DOI 10.1002/ptr.2295
   Ganjhu Rajesh Kumar, 2015, VirusDisease, V26, P225, DOI 10.1007/s13337-015-0276-6
   Glue P, 1999, CELL MOL NEUROBIOL, V19, P309, DOI 10.1023/A:1006993631057
   Goyal B, 2020, ACS COMB SCI, V22, P297, DOI 10.1021/acscombsci.0c00058
   Hong JF, 2016, MOL MED REP, V13, P4541, DOI 10.3892/mmr.2016.5105
   Huo JD, 2020, CELL HOST MICROBE, V28, P445, DOI 10.1016/j.chom.2020.06.010
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kalarani DH, 2012, INT J DRUG DEV RES, V4, P298
   Kamath PR, 2016, RES CHEM INTERMEDIAT, V42, P5899, DOI 10.1007/s11164-015-2412-8
   Kamath PR, 2015, BIOORG CHEM, V63, P101, DOI 10.1016/j.bioorg.2015.10.001
   Kesharwani A, 2017, BMC COMPLEM ALTERN M, V17, P1, DOI 10.1186/s12906-017-1620-8
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Limban C, 2018, TOXICOL REP, V5, P943, DOI 10.1016/j.toxrep.2018.08.017
   Liperoti R, 2017, J AM COLL CARDIOL, V69, P1188, DOI 10.1016/j.jacc.2016.11.078
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   MarvinSketch, MARVINSKETCH WAS US
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Mishra A, 2018, ANN PHYTOMEDICINE, V7, P78, DOI 10.21276/ap.2018.7.1.9
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Mukhtar M, 2008, VIRUS RES, V131, P111, DOI 10.1016/j.virusres.2007.09.008
   Nagarkar B., 2013, INT J PHARM PHARM SC, V5, P239
   NAIDOO D, 2020, J BIOMOL STRUCT 0718, DOI DOI https://doi.org/10.1080/07391102.2020.1794972
   OBOYLE NM, 2011, J CHEMINFORMATICS, V3, DOI DOI https://doi.org/10.1186/1758-2946-3-33
   Onawole AT, 2018, COMPUT BIOL CHEM, V72, P170, DOI 10.1016/j.compbiolchem.2017.11.006
   Pruthvish R., 2018, INT J CURRENT MICROB, V7, DOI [https://doi.org/10.20546/ijcmas.2018.701.425, DOI 10.20546/IJCMAS.2018.701.425]
   Radchenko EV, 2016, RUSS CHEM B+, V65, P576, DOI 10.1007/s11172-016-1340-0
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V33, DOI 10.1016/j.tmaid.2020.101578
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Roy S, 2016, PHARMACOGN RES, V8, P265, DOI 10.4103/0974-8490.188874
   Salam AAA, 2018, CURR TOP MED CHEM, V18, P2633, DOI 10.2174/1568026619666190119144819
   Seve Pascal, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P73, DOI 10.2174/1568011053352604
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   SHARMA K, 2015, J CLIN DIAGN RES, V9, DOI DOI https://doi.org/10.4103/0973-7847.156317
   Towler P, 2004, J BIOL CHEM, V279, P17996, DOI 10.1074/jbc.M311191200
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   VEERAMACHANENI GK, 2020, J BIOMOL STRUCT 0603, DOI DOI https://doi.org/10.1080/07391102.2020.1773318
   Vellingiri B, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138277
   VERMA HN, 1984, Z PFLANZENK PFLANZEN, V91, P34
   VERMA HN, 1983, P INDIAN AS-PLANT SC, V92, P461
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yao XY, 2013, INT IMMUNOPHARMACOL, V15, P316, DOI 10.1016/j.intimp.2012.12.032
   Yi CY, 2020, CELL MOL IMMUNOL, V17, P621, DOI 10.1038/s41423-020-0458-z
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
NR 60
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1842246
EA NOV 2020
PG 18
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OL7UA
UT WOS:000585538700001
PM 33150860
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Srivastava, S
   Verma, S
   Kamthania, M
   Agarwal, D
   Saxena, AK
   Kolbe, M
   Singh, S
   Kotnis, A
   Rathi, B
   Nayar, SA
   Shin, HJ
   Vashisht, K
   Pandey, KC
AF Srivastava, Sukrit
   Verma, Sonia
   Kamthania, Mohit
   Agarwal, Deepa
   Saxena, Ajay Kumar
   Kolbe, Michael
   Singh, Sarman
   Kotnis, Ashwin
   Rathi, Brijesh
   Nayar, Seema A.
   Shin, Ho-Joon
   Vashisht, Kapil
   Pandey, Kailash C.
TI Computationally validated SARS-CoV-2 CTL and HTL Multi-Patch vaccines,
   designed by reverse epitomics approach, show potential to cover large
   ethnically distributed human population worldwide
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2);
   Coronavirus; epitope; Ag-Patch (antigenic patch); reverse epitomics;
   overlapping-epitope-clusters-to-patches; Multi-Patch Vaccine;
   Multi-Epitope Vaccine; Toll-Like Receptor (TLR)
ID MHC CLASS-I; IMMUNE-RESPONSES; PEPTIDE VACCINE; INNATE IMMUNITY; TAP
   TRANSPORT; EPITOPE; EXPRESSION; DEFENSINS; ACCURACY; COVID-19
AB The SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) is responsible for the COVID-19 outbreak. The highly contagious COVID-19 disease has spread to 216 countries in less than six months. Though several vaccine candidates are being claimed, an effective vaccine is yet to come. A novel reverse epitomics approach, 'overlapping-epitope-clusters-to-patches' method is utilized to identify the antigenic regions from the SARS-CoV-2 proteome. These antigenic regions are named as 'Ag-Patch or Ag-Patches', for Antigenic Patch or Patches. The identification of Ag-Patches is based on the clusters of overlapping epitopes rising from SARS-CoV-2 proteins. Further, we have utilized the identified Ag-Patches to design Multi-Patch Vaccines (MPVs), proposing a novel method for the vaccine design. The designed MPVs were analyzed for immunologically crucial parameters, physiochemical properties and cDNA constructs. We identified 73 CTL (Cytotoxic T-Lymphocyte) and 49 HTL (Helper T-Lymphocyte) novel Ag-Patches from the proteome of SARS-CoV-2. The identified Ag-Patches utilized to design MPVs cover 768 overlapping epitopes targeting 55 different HLA alleles leading to 99.98% of world human population coverage. The MPVs and Toll-Like Receptor ectodomain complex shows stable complex formation tendency. Further, the cDNA analysis favors high expression of the MPVs constructs in a human cell line. We identified highly immunogenic novel Ag-Patches from the entire proteome of SARS CoV-2 by a novel reverse epitomics approach and utilized them to design MPVs. We conclude that the novel MPVs could be a highly potential novel approach to combat SARS-CoV-2, with greater effectiveness, high specificity and large human population coverage worldwide.
C1 [Srivastava, Sukrit; Saxena, Ajay Kumar] Jawaharlal Nehru Univ, Sch Life Sci, Mol Med Lab, New Delhi 110067, India.
   [Srivastava, Sukrit; Kamthania, Mohit; Agarwal, Deepa] Indian Fdn Fundamental Res, Infect Biol Grp, Raebareli, India.
   [Verma, Sonia; Vashisht, Kapil; Pandey, Kailash C.] ICMR Natl Inst Malaria Res, Parasite Host Biol Grp, Prot Biochem & Engn Lab, New Delhi, India.
   [Kolbe, Michael] Ctr Struct Syst Biol CSSB, Dept Struct Infect Biol, Hamburg, Germany.
   [Kolbe, Michael] Helmholtz Ctr Infect Res, Hamburg, Germany.
   [Kolbe, Michael] Univ Hamburg, Fac Math Informat & Nat Sci, Hamburg, Germany.
   [Singh, Sarman] All India Inst Med Sci AIIMS, Dept Microbiol, Bhopal, India.
   [Kotnis, Ashwin] All India Inst Med Sci AIIMS, Dept Biochem, Bhopal, India.
   [Rathi, Brijesh] Univ Delhi, Lab Translat Chem & Drug Discovery, Hansraj Coll, New Delhi, India.
   [Nayar, Seema A.] Govt Med Coll, Dept Microbiol, Trivandrum, Kerala, India.
   [Nayar, Seema A.] Sree Gokulam Med Coll, Dept Microbiol, Trivandrum, Kerala, India.
   [Shin, Ho-Joon] Ajou Univ, Sch Med, Dept Microbiol, Suwon, South Korea.
RP Srivastava, S (corresponding author), Jawaharlal Nehru Univ, Sch Life Sci, Mol Med Lab, New Delhi 110067, India.; Srivastava, S (corresponding author), Indian Fdn Fundamental Res, Det Biol Grp, Raebareli 229316, India.
EM srivastav.sukrit@gmail.com
OI Srivastava, Sukrit/0000-0003-0295-0272; Singh, Prof.
   Sarman/0000-0002-0749-9647
FU IFFR (Indian Foundation For Fundamental Research)
FX IFFR (Indian Foundation For Fundamental Research)
CR Abdelmageed MI, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2683286
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Akhand M. R. N., 2020, GENOME BASED EVOLUTI, DOI [10.1101/2020.04.15.036285, DOI 10.1101/2020.04.15.036285]
   An LL, 2000, VACCINE, V18, P2132, DOI 10.1016/S0264-410X(99)00546-0
   [Anonymous], 2020, WHO WEEKLY EPIDEMIOL
   [Anonymous], 2020, WHO CORONAVIRUS DIS
   Antoniou AN, 2003, CURR OPIN IMMUNOL, V15, P75, DOI 10.1016/S0952-7915(02)00010-9
   Banerjee A., 2020, ENERGETICS BASED EPI, DOI [10.1101/2020.04.02.021725, DOI 10.1101/2020.04.02.021725, 10.1101/2020.04.02.021725.]
   Baruah V, 2020, J MED VIROL, V92, P495, DOI 10.1002/jmv.25698
   Bell JK, 2005, P NATL ACAD SCI USA, V102, P10976, DOI 10.1073/pnas.0505077102
   Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736
   Biragyn A, 2001, J IMMUNOL, V167, P6644, DOI 10.4049/jimmunol.167.11.6644
   Bui HH, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-361
   Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153
   Calis J., 2013, PLOS COMPUT BIOL, V8, P361
   Case D, 2014, AMBER, V14, P29
   Chen XY, 2013, ADV DRUG DELIVER REV, V65, P1357, DOI 10.1016/j.addr.2012.09.039
   Delneste Y, 2007, M S-MED SCI, V23, P67, DOI 10.1051/medsci/200723167
   Dhanda SK, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-30
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Duhovny D, 2002, LECT NOTES COMPUT SC, V2452, P185
   Duits LA, 2003, FEMS IMMUNOL MED MIC, V38, P59, DOI 10.1016/S0928-8244(03)00106-8
   Farina C, 2005, J NEUROIMMUNOL, V159, P12, DOI 10.1016/j.jneuroim.2004.09.009
   Fast E, 2020, POTENTIAL T CELL B C, DOI [10.1101/2020.02.19.955484, DOI 10.1101/2020.02.19.955484]
   Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI DOI 10.1385/1-59259-890-0:571
   Gragert L, 2013, HUM IMMUNOL, V74, P1313, DOI 10.1016/j.humimm.2013.06.025
   Grifoni A., 2020, CELLHOSTMICROBED2000
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Gupta E., 2020, IDENTIFICATION POTEN, DOI [10.1101/2020.04.13.039198, DOI 10.1101/2020.04.13.039198]
   Hajighahramani N, 2017, INFECT GENET EVOL, V48, P83, DOI 10.1016/j.meegid.2016.12.010
   Herst CV, 2020, VACCINE, V38, P4464, DOI 10.1016/j.vaccine.2020.04.034
   Hoof I, 2009, IMMUNOGENETICS, V61, P1, DOI 10.1007/s00251-008-0341-z
   Hoover DM, 2000, J BIOL CHEM, V275, P32911, DOI 10.1074/jbc.M006098200
   Hu WG, 2004, J BIOTECHNOL, V107, P83, DOI 10.1016/j.jbiotec.2003.09.009
   Hyun-Jung Lee Chloe, 2020, F1000Res, V9, P145, DOI 10.12688/f1000research.22507.1
   Ismail S., 2020, IMMUNO INFORM CHARAC, DOI [10.1101/2020.04.05.026005, DOI 10.1101/2020.04.05.026005]
   Kahan BD, 2003, NAT REV IMMUNOL, V3, P831, DOI 10.1038/nri1204
   Khan A., 2020, DESIGN EPITOPE BASED, DOI [10.1101/2020.05.03.074930, DOI 10.1101/2020.05.03.074930]
   Ko J., 2012, NUCL ACIDS RES, V40, pW294, DOI DOI https://doi.org/10.1093/nar/gks493
   Kohlgraf KG, 2010, FUTURE MICROBIOL, V5, P99, DOI 10.2217/FMB.09.104
   Krieger E, 2015, J COMPUT CHEM, V36, P996, DOI 10.1002/jcc.23899
   Kringelum JV, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002829
   Liu G, 2020, CELL SYST, V11, P131, DOI 10.1016/j.cels.2020.06.009
   Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286
   Lu YC, 2014, CLIN CANCER RES, V20, P3401, DOI 10.1158/1078-0432.CCR-14-0433
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Melief CJM, 2005, NAT IMMUNOL, V6, P543, DOI 10.1038/ni0605-543
   Mitra D., 2020, MULTIEPITOPE BASED P, DOI [10.1101/2020.04.23.055467, DOI 10.1101/2020.04.23.055467]
   Morla S, 2016, GENE, V584, P1, DOI 10.1016/j.gene.2016.02.047
   Nagpal G, 2015, SCI REP-UK, V5, DOI 10.1038/srep12478
   Nerli Santrupti, 2020, bioRxiv, DOI 10.1101/2020.03.23.004176
   Nielsen M, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-238
   Peters B, 2003, J IMMUNOL, V171, P1741, DOI 10.4049/jimmunol.171.4.1741
   Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514
   Poran A., 2020, BIORXIV, DOI [10.1101/2020.04.06.027805, DOI 10.1101/2020.04.06.027805]
   Ramaiah A., 2020, INSIGHTS CROSS SPECI, DOI [10.1101/2020.01.29.925867, DOI 10.1101/2020.01.29.925867]
   RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5
   Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5
   Saha R., 2020, SILICO APPROACH DESI, DOI [10.1101/2020.03.31.017459, DOI 10.1101/2020.03.31.017459]
   Saha S, 2006, NUCL ACIDS RES, V34, pW202, DOI DOI https://doi.org/10.1093/nar/gkl343
   Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481
   Sheikhshahrokh A, 2020, IRAN J PUBLIC HEALTH, V49, P18
   Sidney J, 2008, IMMUNOME RES, V4, P1
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Singh A., 2020, DESIGNING MULTIEPITE, DOI [10.1101/2020.04.15.040618, DOI 10.1101/2020.04.15.040618]
   Srivastava S., 2020, STRUCTURAL BASIS DES, DOI [10.1101/2020.04.01.019299, DOI 10.1101/2020.04.01.019299]
   Srivastava S., 2020, Patent, Patent No. 202011037939
   Srivastava S., 2020, Patent, Patent No. 202011037585
   Srivastava Sukrit, 2020, JMIR Bioinform Biotech, V1, pe19371, DOI 10.2196/19371
   Srivastava S, 2019, J BIOMOL STRUCT DYN, V37, P4345, DOI 10.1080/07391102.2018.1548977
   Srivastava S, 2018, INFECT DRUG RESIST, V11, P2377, DOI 10.2147/IDR.S175114
   Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555
   Tenzer S, 2005, CELL MOL LIFE SCI, V62, P1025, DOI 10.1007/s00018-005-4528-2
   Totura AL, 2015, MBIO, V6, DOI 10.1128/mBio.00638-15
   Toukmaji A, 2000, J CHEM PHYS, V113, P10913, DOI 10.1063/1.1324708
   ul Qamar M.T., 2020, DESIGNING NEXT GENER, DOI [10.1101/2020.02.28.970343, DOI 10.1101/2020.02.28.970343]
   Vashi Y., 2020, UNDERSTANDING B T CE, DOI [10.1101/2020.04.08.013516., DOI 10.1101/2020.04.08.013516, 10.1101/2020.04.08.013516]
   Wang P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-568
   Wang Z., 2013, BIOINFORMATICS, V29, pi266
   Wilson SS, 2013, J MOL BIOL, V425, P4965, DOI 10.1016/j.jmb.2013.09.038
   Wu XL, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-469
   Xu D, 2011, BIOPHYS J, V101, P2525, DOI 10.1016/j.bpj.2011.10.024
   Yadav R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060785
   Yang D, 2002, TRENDS IMMUNOL, V23, P291, DOI 10.1016/S1471-4906(02)02246-9
   Yarmarkovich Mark, 2020, Cell Rep Med, V1, P100036, DOI 10.1016/j.xcrm.2020.100036
   Yarmarkovich M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00069
   Yazdani Z., 2020, DESIGN EFFICIENT MUL, DOI [10.1101/2020.04.20.051557., DOI 10.1101/2020.04.20.051557, 10.1101/2020.04.20.051557]
NR 87
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1838329
EA NOV 2020
PG 20
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OM5OE
UT WOS:000586073100001
PM 33155524
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Beksac, MS
   Donmez, HG
AF Beksac, Mehmet Sinan
   Donmez, Hanife Guler
TI Impact of hydroxychloroquine on the gestational outcomes of pregnant
   women with immune system problems that necessitate the use of the drug
SO JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
LA English
DT Article; Early Access
DE hydroxychloroquine; immune system disorders; rheumatoid arthritis;
   Sjogren syndrome; systemic lupus erythematosis
ID DISEASE 2019 COVID-19; ANTIRHEUMATIC DRUGS; CHLOROQUINE; LUPUS;
   PHARMACOKINETICS
AB Aim To evaluate the impact of hydroxychloroquine (HCQ) on the perinatal outcomes of pregnancies with immune system disorders that necessitate the use of the drug.
   Methods This cohort consisted of 202 pregnancies with poor obstetric history and immune system problems. Patients enrolled in special antenatal care program were administered low-dose low-molecular-weight heparin, low-dose salicylic acid and low-dose corticosteroid (prophylaxis protocol) as soon as their pregnancies were confirmed. Pregnancies with systemic lupus erythematosis, Sjogren syndrome and rheumatoid arthritis were additionally administered HCQ 200 mg daily as a part of their routine treatment. Pregnancies using HCQ were included in the study group (n = 39) while the remainders were included in control group (n = 163). We compared the groups in terms of the presence of miscarriage, fetal growth restriction (FGR), preeclampsia and preterm birth, as well as gestational week at birth, birthweight and "APGAR score of <7" at 10th minute.
   Results Miscarriage rates were 28.2% and 28.2% while preterm birth rates were 16.6% and 28.2% in the control and study groups, respectively (P = 0.215). Preeclampsia and HCQ-related side effects were not detected in the groups. There were also no significant differences between the groups in terms of FGR, gestational day at birth, birthweight and the presence of "APGAR score <7" at 10th minute (P = 0.462, P = 0.064, P = 0.273 and P = 0.627, respectively).
   Conclusion Low-dose low-molecular-weight heparin, low-dose salicylic acid and low-dose corticosteroid prophylaxis together with HCQ seem to be promising in pregnancies with immune system disorders. HCQ seems to be a safe and effective drug in low dosages.
C1 [Beksac, Mehmet Sinan] Hacettepe Univ, Dept Gynecol & Obstet, Div Perinatol, Ankara, Turkey.
   [Donmez, Hanife Guler] Hacettepe Univ, Fac Sci, Dept Biol, TR-06800 Ankara, Turkey.
RP Donmez, HG (corresponding author), Hacettepe Univ, Fac Sci, Dept Biol, TR-06800 Ankara, Turkey.
EM hnftnr@gmail.com
OI Beksac, M.Sinan/0000-0001-6362-787X; DONMEZ, HANIFE
   GULER/0000-0002-7413-4939
CR Baer AN, 2011, OBSTET GYNECOL SURV, V66, P639, DOI 10.1097/OGX.0b013e318239e1ee
   Balevic SJ, 2019, J RHEUMATOL, V46, P57, DOI 10.3899/jrheum.180158
   Balevic SJ, 2019, CLIN PHARMACOKINET, V58, P525, DOI 10.1007/s40262-018-0712-z
   Beksac K, 2017, J CLIN DIAGNOSTIC RE, V11, P10
   Beksac K, 2017, J TURK-GER GYNECOL A, V18, P56, DOI 10.4274/jtgga.2016.0198
   Beksac MS, 2020, J MATERN-FETAL NEO M, DOI 10.1080/14767058.2020.1760834
   Beksac MS, 2015, GYNECOL OBSTET REPRO, V21, P10
   Biot C, 2006, J MED CHEM, V49, P2845, DOI 10.1021/jm0601856
   Costedoat-Chalumcau N, 2002, ARTHRITIS RHEUM, V46, P1123, DOI 10.1002/art.10150
   Costedoat-Chalumeau N, 2003, ARTHRITIS RHEUM, V48, P3207, DOI 10.1002/art.11304
   de Moreuil C, 2020, BRIT J CLIN PHARMACO, V86, P39, DOI 10.1111/bcp.14131
   Diav-Citrin O, 2013, REPROD TOXICOL, V39, P58, DOI 10.1016/j.reprotox.2013.04.005
   Fadiloglu Erdem, 2020, Human Antibodies, V28, P179, DOI 10.3233/HAB-200401
   Flint J, 2016, RHEUMATOLOGY, V55, P1693, DOI 10.1093/rheumatology/kev404
   Furst DE, 1996, LUPUS, V5, pS11, DOI 10.1177/096120339600500104
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gottenberg JE, 2014, JAMA-J AM MED ASSOC, V312, P249, DOI 10.1001/jama.2014.7682
   Hernandez AV, 2020, ANN INTERN MED, V173, P287, DOI 10.7326/M20-2496
   Izmirly PM, 2012, CIRCULATION, V126, P76, DOI 10.1161/CIRCULATIONAHA.111.089268
   Jallouli M, 2015, ARTHRITIS RHEUMATOL, V67, P2176, DOI 10.1002/art.39194
   KRUIZE AA, 1993, ANN RHEUM DIS, V52, P360, DOI 10.1136/ard.52.5.360
   Levy RA, 2001, LUPUS, V10, P401, DOI 10.1191/096120301678646137
   Li X, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2721-8
   Lim HS, 2009, ANTIMICROB AGENTS CH, V53, P1468, DOI 10.1128/AAC.00339-08
   Mumusoglu S, 2016, J MATERN-FETAL NEO M, V29, P2352, DOI 10.3109/14767058.2015.1085964
   Orgul G, 2018, J OBSTET GYNAECOL, V38, P185, DOI 10.1080/01443615.2017.1336614
   Ozyuncu O, 2018, SAJOG-S AFR J OBSTET, V24, P28
   Pereira BB, 2020, J TOXICOL ENV HEAL B, V23, P177, DOI 10.1080/10937404.2020.1752340
   Plantone D, 2018, CLIN DRUG INVEST, V38, P653, DOI 10.1007/s40261-018-0656-y
   Poon LC, 2020, ULTRASOUND OBST GYN, V55, P848, DOI 10.1002/uog.22061
   Rempenault C, 2020, ARTHRIT CARE RES, V72, P36, DOI 10.1002/acr.23826
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Skorpen CG, 2016, ANN RHEUM DIS, V75, P795, DOI 10.1136/annrheumdis-2015-208840
   Talabi MB, 2020, CURR OPIN RHEUMATOL, V32, P238, DOI 10.1097/BOR.0000000000000710
   Tanacan A, 2019, J BRAS REPROD ASSIST, V23, P361, DOI 10.5935/1518-0557.20190034
   Tanacan A, 2019, IRISH J MED SCI, V188, P1261, DOI 10.1007/s11845-019-02029-0
   Tanacan Atakan, 2019, Human Antibodies, V27, P135, DOI 10.3233/HAB-180359
   Tanacan A, 2019, ARCH GYNECOL OBSTET, V299, P79, DOI 10.1007/s00404-018-4927-x
   Temprano KK, 2005, SEMIN ARTHRITIS RHEU, V35, P112, DOI 10.1016/j.semarthrit.2005.05.002
   Torigoe M, 2018, CLIN IMMUNOL, V195, P1, DOI 10.1016/j.clim.2018.07.003
   Unal C, 2020, INT J RHEUM DIS, V23, P101, DOI 10.1111/1756-185X.13746
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
NR 43
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1341-8076
EI 1447-0756
J9 J OBSTET GYNAECOL RE
JI J. Obstet. Gynaecol. Res.
DI 10.1111/jog.14561
EA NOV 2020
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA OK3CV
UT WOS:000584531400001
PM 33146470
OA Bronze
DA 2021-01-01
ER

PT J
AU Wang, DX
   Baudys, J
   Bundy, JL
   Solano, M
   Keppel, T
   Barr, JR
AF Wang, Dongxia
   Baudys, Jakub
   Bundy, Jonathan L.
   Solano, Maria
   Keppel, Theodore
   Barr, John R.
TI Comprehensive Analysis of the Glycan Complement of SARS-CoV-2 Spike
   Proteins Using Signature Ions-Triggered Electron-Transfer/Higher-Energy
   Collisional Dissociation (EThcD) Mass Spectrometry
SO ANALYTICAL CHEMISTRY
LA English
DT Article
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a global pandemic of coronavirus disease 2019 (COVID-19). The spike protein expressed on the surface of this virus is highly glycosylated and plays an essential role during the process of infection. We conducted a comprehensive mass spectrometric analysis of the N-glycosylation profiles of the SARS-CoV-2 spike proteins using signature ions-triggered electron-transfer/higher-energy collision dissociation (EThcD) mass spectrometry. The patterns of N-glycosylation within the recombinant ectodomain and S1 subunit of the SARS-CoV-2 spike protein were characterized using this approach. Significant variations were observed in the distribution of glycan types as well as the specific individual glycans on the modification sites of the ectodomain and subunit proteins. The relative abundance of sialylated glycans in the S1 subunit compared to the fulllength protein could indicate differences in the global structure and function of these two species. In addition, we compared N-glycan profiles of the recombinant spike proteins produced from different expression systems, including human embryonic kidney (HEK 293) cells and Spodoptera frugiperda (SF9) insect cells. These results provide useful information for the study of the interactions of SARS-CoV-2 viral proteins and for the development of effective vaccines and therapeutics.
C1 [Wang, Dongxia; Baudys, Jakub; Bundy, Jonathan L.; Solano, Maria; Keppel, Theodore; Barr, John R.] Ctr Dis Control & Prevent, Div Lab Sci, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA.
RP Wang, DX; Barr, JR (corresponding author), Ctr Dis Control & Prevent, Div Lab Sci, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA.
EM dov2@cdc.gov; jbarr@cdc.gov
OI Bundy, Jonathan/0000-0003-3987-471X
CR [Anonymous], 2020, COVID 19 WEEKL EP UP, P2020
   Bassetti M, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13209
   Behrens AJ, 2017, J VIROL, V91, DOI 10.1128/JVI.01894-16
   Bern M, 2007, ANAL CHEM, V79, P1393, DOI 10.1021/ac0617013
   Bezstarosti K, 2020, BIORXIV, P1
   Bhide GP, 2017, HISTOCHEM CELL BIOL, V147, P149, DOI 10.1007/s00418-016-1520-x
   Blake TA, 2009, ANAL CHEM, V81, P3109, DOI 10.1021/ac900095h
   Caval T, 2019, ANAL CHEM, V91, P10401, DOI 10.1021/acs.analchem.9b02125
   Chalk R., 2020, BIORXIV, P1
   Chang D, 2019, MOL CELL PROTEOMICS, V18, P2348, DOI 10.1074/mcp.R119.001491
   Cipollo JF, 2020, MASS SPECTROM REV, V39, P371, DOI 10.1002/mas.21629
   Coon JJ, 2005, P NATL ACAD SCI USA, V102, P9463, DOI 10.1073/pnas.0503189102
   da Costa VG, 2020, ARCH VIROL, V165, P1517, DOI 10.1007/s00705-020-04628-0
   Davis AK, 2020, BATHROOM BATTLEGROUNDS: HOW PUBLIC RESTROOMS SHAPE THE GENDER ORDER, P1
   Frese CK, 2013, J PROTEOME RES, V12, P1520, DOI 10.1021/pr301130k
   Frese CK, 2012, ANAL CHEM, V84, P9668, DOI 10.1021/ac3025366
   Garcia BA, 2005, METHODS, V35, P256, DOI 10.1016/j.ymeth.2004.08.017
   Hargett AA, 2019, CURR OPIN VIROL, V36, P56, DOI 10.1016/j.coviro.2019.05.003
   Hever Helga, 2019, Methods Mol Biol, V1934, P93, DOI 10.1007/978-1-4939-9055-9_8
   Hoffmann M, 2016, MOL CELL PROTEOMICS, V15, P624, DOI 10.1074/mcp.M115.053546
   Hu H, 2016, GLYCOCONJUGATE J, V33, P285, DOI 10.1007/s10719-015-9633-3
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Johnson A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128982
   Kaul Dinesh, 2020, Curr Med Res Pract, V10, P54, DOI 10.1016/j.cmrp.2020.04.001
   Klein J. A., 2020, BIORXIV, P1
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lermyte F, 2018, MASS SPECTROM REV, V37, P750, DOI 10.1002/mas.21560
   Leung KK, 2020, P NATL ACAD SCI USA, V117, P7764, DOI 10.1073/pnas.1917947117
   Lin BR, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9041022
   Mikesh LM, 2006, BBA-PROTEINS PROTEOM, V1764, P1811, DOI 10.1016/j.bbapap.2006.10.003
   Mishra V, 2020, PROTEIN PEPTIDE LETT, V27, P529, DOI 10.2174/0929866526666191112152646
   Morgenstern K, 2018, VACCINE, V36, P6144, DOI 10.1016/j.vaccine.2018.08.065
   Neubert P, 2016, MOL CELL PROTEOMICS, V15, P1323, DOI 10.1074/mcp.M115.057505
   Nilsson J, 2016, GLYCOCONJUGATE J, V33, P261, DOI 10.1007/s10719-016-9649-3
   Pierce CL, 2017, VACCINE, V35, P5011, DOI 10.1016/j.vaccine.2017.07.049
   Pierce CL, 2011, ANAL CHEM, V83, P4729, DOI 10.1021/ac2006526
   Ridenour C, 2015, INFLUENZA OTHER RESP, V9, P263, DOI 10.1111/irv.12322
   Riley NM, 2020, J PROTEOME RES, V19, P3286, DOI 10.1021/acs.jproteome.0c00218
   Saba J., 2012, INT J PROTEOMICS, V2012
   Sanda M., 2020, BIORXIV, P1
   Santana WI, 2014, ANAL CHEM, V86, P4088, DOI 10.1021/ac4040778
   Shajahan Asif, 2020, Glycobiology, V30, P981, DOI 10.1093/glycob/cwaa042
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shi XZ, 2007, CURR DRUG TARGETS, V8, P1116, DOI 10.2174/138945007782151360
   Syka JEP, 2004, P NATL ACAD SCI USA, V101, P9528, DOI 10.1073/pnas.0402700101
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2016, NAT STRUCT MOL BIOL, V23, P899, DOI 10.1038/nsmb.3293
   Walls AC, 2016, NATURE, V531, P114, DOI 10.1038/nature16988
   Watanabe Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16567-0
   Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983
   Watanabe Y, 2019, BBA-GEN SUBJECTS, V1863, P1480, DOI 10.1016/j.bbagen.2019.05.012
   Williams TL, 2008, VACCINE, V26, P2510, DOI 10.1016/j.vaccine.2008.03.014
   Williams TL, 2012, VACCINE, V30, P2475, DOI 10.1016/j.vaccine.2011.12.056
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yang LJ, 2019, CHEM SCI, V10, P9302, DOI 10.1039/c9sc02491c
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yu Q, 2017, J AM SOC MASS SPECTR, V28, P1751, DOI 10.1007/s13361-017-1701-4
   Zhang YL, 2020, BIOSCI BIOTECH BIOCH, V84, P943, DOI 10.1080/09168451.2019.1703639
   Zhao P, 2020, CELL HOST MICROBE, V28, P586, DOI 10.1016/j.chom.2020.08.004
NR 59
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
EI 1520-6882
J9 ANAL CHEM
JI Anal. Chem.
PD NOV 3
PY 2020
VL 92
IS 21
BP 14730
EP 14739
DI 10.1021/acs.analchem.0c03301
PG 10
WC Chemistry, Analytical
SC Chemistry
GA OR1OS
UT WOS:000589246100057
PM 33064451
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hamilton, P
   Hanumapura, P
   Castelino, L
   Henney, R
   Parker, K
   Kumar, M
   Murphy, M
   Al-Sayed, T
   Pinnington, S
   Felton, T
   Challiner, R
   Ebah, L
AF Hamilton, Patrick
   Hanumapura, Prasanna
   Castelino, Laveena
   Henney, Robert
   Parker, Kathrine
   Kumar, Mukesh
   Murphy, Michelle
   Al-Sayed, Tamer
   Pinnington, Sarah
   Felton, Tim
   Challiner, Rachael
   Ebah, Leonard
TI Characteristics and outcomes of hospitalised patients with acute kidney
   injury and COVID-19
SO PLOS ONE
LA English
DT Article
ID INFECTION
AB Introduction
   COVID-19 has spread globally to now be considered a pandemic by the World Health Organisation. Initially patients appeared to have a respiratory limited disease but there are now increasing reports of multiple organ involvement including renal disease in association with COVID-19. We studied the development and outcomes of acute kidney injury (AKI) in patients with COVID-19, in a large multicultural city hospital trust in the UK, to better understand the role renal disease has in the disease process.
   Methods
   This was a retrospective review using electronic records and laboratory data of adult patients admitted to the four Manchester University Foundation Trust Hospitals between March 10 and April 30 2020 with a diagnosis of COVID-19. Records were reviewed for baseline characteristics, medications, comorbidities, social deprivation index, observations, biochemistry and outcomes including mortality, admission to critical care, mechanical ventilation and the need for renal replacement therapy.
   Results
   There were 1032 patients included in the study of whom 210 (20.3%) had AKI in association with the diagnosis of COVID-19. The overall mortality with AKI was considerably higher at 52.4% compared to 26.3% without AKI (p-value <0.001). More patients with AKI required escalation to critical care (34.8% vs 11.2%, p-value <0.001). Following admission to critical care those with AKI were more likely to die (54.8% vs 25.0%, p-value <0.001) and more likely to require mechanical ventilation (86.3% vs 66.3%, p-value 0.006).
   Discussion
   We have shown that the development of AKI is associated with dramatically worse outcomes for patients, in both mortality and the requirement for critical care. Patients with COVID-19 presenting with, or at risk of AKI should be closely monitored and appropriately managed to prevent any decline in renal function, given the significant risk of deterioration and death.
C1 [Hamilton, Patrick; Hanumapura, Prasanna; Castelino, Laveena; Henney, Robert; Parker, Kathrine; Kumar, Mukesh; Murphy, Michelle; Al-Sayed, Tamer; Pinnington, Sarah; Challiner, Rachael; Ebah, Leonard] Manchester Univ NHS Fdn Trust, Manchester Inst Nephrol & Transplantat, Manchester, Lancs, England.
   [Hamilton, Patrick; Hanumapura, Prasanna; Henney, Robert; Parker, Kathrine; Challiner, Rachael; Ebah, Leonard] Manchester Acad Hlth Sci Ctr MAHSC, Manchester, Lancs, England.
   [Hamilton, Patrick] Univ Manchester, Div Cell Matrix Biol & Regenerat Med, Wellcome Ctr Cell Matrix Res, Sch Biol Sci,Fac Biol Med & Hlth, Manchester, Lancs, England.
   [Felton, Tim] Univ Manchester, Fac Biol Med & Hlth, Div Infect Immun & Resp Med, Manchester, Lancs, England.
   [Felton, Tim] Manchester Univ NHS Fdn Trust, Wythenshawe Hosp, Intens Care Unit, Manchester, Lancs, England.
   [Felton, Tim] NIHR Manchester Biomed Res Ctr, Manchester, Lancs, England.
RP Hamilton, P (corresponding author), Manchester Univ NHS Fdn Trust, Manchester Inst Nephrol & Transplantat, Manchester, Lancs, England.; Hamilton, P (corresponding author), Manchester Acad Hlth Sci Ctr MAHSC, Manchester, Lancs, England.; Hamilton, P (corresponding author), Univ Manchester, Div Cell Matrix Biol & Regenerat Med, Wellcome Ctr Cell Matrix Res, Sch Biol Sci,Fac Biol Med & Hlth, Manchester, Lancs, England.
EM patrick.hamilton@mft.nhs.uk
RI ; Hamilton, Patrick/H-1474-2015
OI Parker, Kathrine/0000-0001-9908-5160; Hamilton,
   Patrick/0000-0001-6703-3745
CR [Anonymous], 2019, R LANG ENV STAT COMP
   [Anonymous], 2017, ONCOGENESIS, V6, pe345
   [Anonymous], 2020, BMJ-BRIT MED J, V369, pm2170, DOI 10.1136/bmj.m2170
   Batlle D, 2020, J AM SOC NEPHROL, V31, P1380, DOI 10.1681/ASN.2020040419
   Care D of H and S England PH, COR CAS UK DAIL UPD
   Challiner R, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-84
   Chan Lili, 2020, medRxiv, DOI 10.1101/2020.05.04.20090944
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC
   Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8
   Fominskiy Evgeny V, 2020, Blood Purif, P1, DOI 10.1159/000508657
   Forni LG, 2017, INTENS CARE MED, V43, P855, DOI 10.1007/s00134-017-4809-x
   Gasparini A., 2018, J OPEN SOURCE SOFTW, V3, P648
   Government M of HC& L, 2019, ENGL IND DEPR 2019
   Hirsch JS, 2020, KIDNEY INT, V98, P209, DOI 10.1016/j.kint.2020.05.006
   Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2
   Kolhe NV, 2016, INT J CLIN PRACT, V70, P330, DOI 10.1111/ijcp.12774
   Larsen CP, 2020, KIDNEY INT REP, V5, P935, DOI 10.1016/j.ekir.2020.04.002
   Li KH, 2020, INVEST RADIOL, V55, P327, DOI 10.1097/RLI.0000000000000672
   M RJM, 1997, CLIN INTENSIVE CARE, V8, P100, DOI [10.3109/tcic.8.2.93.110, DOI 10.3109/TCIC.8.2.93.110]
   Pei GC, 2020, J AM SOC NEPHROL, V31, P1157, DOI 10.1681/ASN.2020030276
   Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Ronco C, 2020, LANCET RESP MED, V8, P738, DOI 10.1016/S2213-2600(20)30229-0
   Ronco C, 2020, NAT REV NEPHROL, V16, P308, DOI 10.1038/s41581-020-0284-7
   Rubin S, 2020, CLIN KIDNEY J, V13, P354, DOI 10.1093/ckj/sfaa099
   Sharma P, 2020, J AM SOC NEPHROL, V31, P1948, DOI 10.1681/ASN.2020050699
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   Varatharaj A, 2020, LANCET PSYCHIAT, V7, P875, DOI 10.1016/S2215-0366(20)30287-X
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Wan SX, 2020, J MED VIROL, V92, P797, DOI 10.1002/jmv.25783
   Wang LW, 2020, AM J NEPHROL, V51, P343, DOI 10.1159/000507471
   WHO, 2020, PNEUM UNKN CAUS CHIN
   WHO Timeline - COVID-19, WHO TIM COVID 19
   Wilbers Thom J, 2020, J Crit Care, V60, P103, DOI 10.1016/j.jcrc.2020.07.025
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhao W, 2020, AM J ROENTGENOL, V214, P1072, DOI 10.2214/AJR.20.22976
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 41
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 3
PY 2020
VL 15
IS 11
AR e0241544
DI 10.1371/journal.pone.0241544
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OP8YL
UT WOS:000588376700031
PM 33141867
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Chen, C
   Wang, F
   Chen, P
   Jiang, JG
   Cui, GL
   Zhou, N
   Moroni, F
   Moslehi, JJ
   Ammirati, E
   Wang, DW
AF Chen, Chen
   Wang, Feng
   Chen, Peng
   Jiang, Jiangang
   Cui, Guanglin
   Zhou, Ning
   Moroni, Francesco
   Moslehi, Javid J.
   Ammirati, Enrico
   Wang, Dao Wen
TI Mortality and Pre-Hospitalization use of Renin-Angiotensin System
   Inhibitors in Hypertensive COVID-19 Patients
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE COVID&#8208; 19; angiotensin converting enzyme&#8208; 2; angiotensin
   converting enzyme inhibitors; angiotensin receptor blockers; severe
   acute respiratory syndrome coronavirus&#8208; 2
AB Background
   There has been significant controversy regarding the effects of pre-hospitalization use of renin-angiotensin system (RAS) inhibitors on the prognosis of hypertensive COVID-19 patients.
   Methods and Results
   We retrospectively assessed 2,297 hospitalized COVID-19 patients at Tongji Hospital in Wuhan, China, from January 10(th) to March 30(th), 2020; and identified 1,182 patients with known hypertension on pre-hospitalization therapy. We compared the baseline characteristics and in-hospital mortality between hypertensive patients taking RAS inhibitors (N=355) versus non-RAS inhibitors (N=827). Of the 1,182 hypertensive patients (median age 68 years, 49.1% male), 12/355 (3.4%) patients died in the RAS inhibitors group vs. 95/827 (11.5%) patients in the non-RAS inhibitors group (p<0.0001). Adjusted hazard ratio for mortality was 0.28 (95% CI 0.15-0.52, p<0.0001) at 45 days in the RAS inhibitors group compared with non-RAS inhibitors group. Similar findings were observed when patients taking angiotensin receptor blockers (N=289) or angiotensin converting enzyme inhibitors (N=66) were separately compared with non-RAS inhibitors group. The RAS inhibitors group compared with non-RAS inhibitors group had lower levels of C-reactive protein (median 13.5 vs. 24.4 pg/mL; p=0.007) and interleukin-6 (median 6.0 vs. 8.5 pg/mL; p=0.026) on admission. The protective effect of RAS inhibitors on mortality was confirmed in a meta-analysis of published data when our data were added to previous studies (odd ratio 0.44, 95% CI 0.29-0.65, p<0.0001).
   Conclusions
   In a large single center retrospective analysis we observed a protective effect of pre-hospitalization use of RAS inhibitors on mortality in hypertensive COVID-19 patients; which might be associated with reduced inflammatory response.
C1 [Chen, Chen; Wang, Feng; Chen, Peng; Jiang, Jiangang; Cui, Guanglin; Zhou, Ning; Wang, Dao Wen] Huazhong Univ Sci & Technol, Div Cardiol, Dept Internal Med, Wuhan, Peoples R China.
   [Chen, Chen; Wang, Feng; Chen, Peng; Jiang, Jiangang; Cui, Guanglin; Zhou, Ning; Wang, Dao Wen] Huazhong Univ Sci & Technol, Hubei Key Lab Genet & Mol Mech Cardiol Disorders, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China.
   [Moroni, Francesco] Vita Saluta San Raffaele Univ, Milan, Italy.
   [Moslehi, Javid J.] Vanderbilt Univ, Med Ctr, Dept Med, Cardiooncol Program, Nashville, TN USA.
   [Ammirati, Enrico] ASST Grande Osped Metropolitano Niguarda, De Gasperis Cardio Ctr, Piazza Osped Maggiore 3, I-20162 Milan, Italy.
   [Ammirati, Enrico] ASST Grande Osped Metropolitano Niguarda, Transplant Ctr, Piazza Osped Maggiore 3, I-20162 Milan, Italy.
RP Ammirati, E (corresponding author), ASST Grande Osped Metropolitano Niguarda, De Gasperis Cardio Ctr, Piazza Osped Maggiore 3, I-20162 Milan, Italy.; Ammirati, E (corresponding author), ASST Grande Osped Metropolitano Niguarda, Transplant Ctr, Piazza Osped Maggiore 3, I-20162 Milan, Italy.; Wang, DW (corresponding author), Huazhong Univ Sci & Technol, Div Cardiol, Dept Internal Med, Tongji Hosp,Tongji Med Coll, 1095 Jiefang Ave, Wuhan 430030, Peoples R China.
EM enrico.ammirati@ospedaleniguarda.it; dwwang@tjh.tjmu.edu.cn
OI Wang, Dao Wen/0000-0002-9774-3980; Moroni,
   Francesco/0000-0002-6101-1403; Ammirati, Enrico/0000-0002-1676-5257
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01HL141466]
FX JM has served on advisory boards for Pfizer, Novartis, Bristol Myers
   Squibb, Takeda, GSK and AstraZeneca and is supported by the National
   Institutes of Health (R01HL141466). The remaining authors have no
   disclosures to report.
CR [Anonymous], 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.017736
NR 1
TC 2
Z9 2
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD NOV 3
PY 2020
VL 9
IS 21
AR e017736
DI 10.1161/JAHA.120.017736
PG 40
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OP8XG
UT WOS:000588373500006
PM 32807002
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU McNamara, RP
   Caro-Vegas, C
   Landis, JT
   Moorad, R
   Pluta, LJ
   Eason, AB
   Thompson, C
   Bailey, A
   Villamor, FCS
   Lange, PT
   Wong, JP
   Seltzer, T
   Seltzer, J
   Zhou, YJ
   Vahrson, W
   Juarez, A
   Meyo, JO
   Calabre, T
   Broussard, G
   Rivera-Soto, R
   Chappell, DL
   Baric, RS
   Damania, B
   Miller, MB
   Dittmer, DP
AF McNamara, Ryan P.
   Caro-Vegas, Carolina
   Landis, Justin T.
   Moorad, Razia
   Pluta, Linda J.
   Eason, Anthony B.
   Thompson, Cecilia
   Bailey, Aubrey
   Villamor, Femi Cleola S.
   Lange, Philip T.
   Wong, Jason P.
   Seltzer, Tischan
   Seltzer, Jedediah
   Zhou, Yijun
   Vahrson, Wolfgang
   Juarez, Angelica
   Meyo, James O.
   Calabre, Tiphaine
   Broussard, Grant
   Rivera-Soto, Ricardo
   Chappell, Danielle L.
   Baric, Ralph S.
   Damania, Blossom
   Miller, Melissa B.
   Dittmer, Dirk P.
TI High-Density Amplicon Sequencing Identifies Community Spread and Ongoing
   Evolution of SARS-CoV-2 in the Southern United States
SO CELL REPORTS
LA English
DT Article
ID PHYLOGENETIC ANALYSIS; CORONAVIRUS; SPIKE; EPIDEMIC; REGION;
   TRANSMISSION; PSEUDOKNOT; PNEUMONIA; OUTBREAK; PROTEIN
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is constantly evolving. Prior studies focused on high-case-density locations, such as the northern and western metropolitan areas of the United States. This study demonstrates continued SARS-CoV-2 evolution in a suburban southern region of the United States by high-density amplicon sequencing of symptomatic cases. 57% of strains carry the spike D614G variant, which is associated with higher genome copy numbers, and its prevalence expands with time. Four strains carry a deletion in a predicted stem loop of the 30 UTR. The data are consistent with community spread within local populations and the larger continental United States. The data instill confidence in current testing sensitivity and validate "testing by sequencing'' as an option to uncover cases, particularly nonstandard coronavirus disease 2019 (COVID-19) clinical presentations. This study contributes to the understanding of COVID-19 through an extensive set of genomes from a non-urban setting and informs vaccine design by defining D614G as a dominant and emergent SARS-CoV-2 isolate in the United States.
C1 [McNamara, Ryan P.; Caro-Vegas, Carolina; Landis, Justin T.; Moorad, Razia; Pluta, Linda J.; Eason, Anthony B.; Villamor, Femi Cleola S.; Lange, Philip T.; Wong, Jason P.; Seltzer, Tischan; Seltzer, Jedediah; Zhou, Yijun; Juarez, Angelica; Meyo, James O.; Broussard, Grant; Rivera-Soto, Ricardo; Chappell, Danielle L.; Damania, Blossom; Dittmer, Dirk P.] Univ North Carolina Chapel Hill, Dept Microbiol & Immunol, Sch Med, Chapel Hill, NC 27599 USA.
   [McNamara, Ryan P.; Caro-Vegas, Carolina; Landis, Justin T.; Moorad, Razia; Pluta, Linda J.; Eason, Anthony B.; Villamor, Femi Cleola S.; Lange, Philip T.; Wong, Jason P.; Seltzer, Tischan; Seltzer, Jedediah; Zhou, Yijun; Juarez, Angelica; Baric, Ralph S.; Damania, Blossom; Dittmer, Dirk P.] Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Thompson, Cecilia; Miller, Melissa B.] Univ North Carolina Chapel Hill, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.
   [Thompson, Cecilia; Miller, Melissa B.] UNC Med Ctr, Clin Microbiol Lab, Chapel Hill, NC 27599 USA.
   [Bailey, Aubrey] Kuopio Ctr Gene & Cell Therapy, Kuopio, Finland.
   [Meyo, James O.; Broussard, Grant; Rivera-Soto, Ricardo] Genet Curriculum, Chapel Hill, NC 27599 USA.
   [Calabre, Tiphaine] Ecole Super Chim Phys Elect CPE, Lyon, France.
   [Chappell, Danielle L.] Dept Pharmacol, Univ North Carolina Chapel Hill, Chapel Hill, NC 27599 USA.
   [Baric, Ralph S.] Univ North Carolina Chapel Hill, Dept Epidemiol, Chapel Hill, NC 27599 USA.
RP Dittmer, DP (corresponding author), Univ North Carolina Chapel Hill, Dept Microbiol & Immunol, Sch Med, Chapel Hill, NC 27599 USA.; Dittmer, DP (corresponding author), Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.; Miller, MB (corresponding author), Univ North Carolina Chapel Hill, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.; Miller, MB (corresponding author), UNC Med Ctr, Clin Microbiol Lab, Chapel Hill, NC 27599 USA.
EM melissa.miller@unchealth.unc.edu; dirkdittmer@me.com
OI McNamara, Ryan/0000-0002-8866-3532; Eason, Anthony/0000-0002-6723-7999;
   Thompson, Cecilia/0000-0002-1013-7313; Landis,
   Justin/0000-0001-5501-4934
FU NIH public health service grants [CA016086, CA019014, CA239583];
   University Cancer Research Fund; UNC School of Medicine; North Carolina
   Policy Collaboratory at UNC; North Carolina Coronavirus Relief Fund
FX This work was funded by NIH public health service grants CA016086,
   CA019014, and CA239583 to D.P.D. Funding was also provided by the
   University Cancer Research Fund and the UNC School of Medicine. This
   project was supported by the North Carolina Policy Collaboratory at UNC
   with funding from the North Carolina Coronavirus Relief Fund established
   and appropriated by the North Carolina General Assembly. The authors
   would like to thank all the members of the Damania and Dittmer labs,
   Corbin Jones, and Nicole Fischer for critical reading, comments, and
   suggestions. We also thank the participants and the nurses and
   physicians at the UNC Pulmonary Intensive Care Unit and Department of
   Infectious Diseases who, in addition to their heroic patient care,
   ensure that de-identified excess samples are available for discovery
   research and rapidly validating novel diagnostic approaches.
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Arons MM, 2020, NEW ENGL J MED, V382, P2081, DOI 10.1056/NEJMoa2008457
   Bartolini B, 2020, EMERG INFECT DIS, V26, P1842, DOI 10.3201/eid2608.201525
   Becerra-Flores M, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13525
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P422, DOI 10.15585/mmwr.mm6914e4
   Canhui Cao, 2020, Genes Dis, V7, P567, DOI 10.1016/j.gendis.2020.05.006
   Ceraolo C, 2020, J MED VIROL, V92, P522, DOI 10.1002/jmv.25700
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Corman V. M., 2020, EURO SURVEILL, V25
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Eaaswarkhanth M, 2020, INT J INFECT DIS, V96, P459, DOI 10.1016/j.ijid.2020.05.071
   Fauver JR, 2020, CELL, V181, P990, DOI 10.1016/j.cell.2020.04.021
   Forster P, 2020, P NATL ACAD SCI USA, V117, P9241, DOI 10.1073/pnas.2004999117
   GISAID, 2020, GEN EP HCOV 19
   Goebel SJ, 2004, J VIROL, V78, P669, DOI 10.1128/JVI.78.2.669-682.2004
   Graham RL, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0175-7
   Graham RL, 2012, NAT MED, V18, P1820, DOI 10.1038/nm.2972
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407
   He JF, 2004, SCIENCE, V303, P1666, DOI 10.1126/science.1092002
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Hijnen D, 2020, EMERG INFECT DIS, V26, P1935, DOI 10.3201/eid2608.201235
   Hilscher C, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni181
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Isabel Sandra, 2020, Sci Rep, V10, P14031, DOI 10.1038/s41598-020-70827-z
   Jabara CB, 2011, P NATL ACAD SCI USA, V108, P20166, DOI 10.1073/pnas.1110064108
   Jaimes JA, 2020, J MOL BIOL, V432, P3309, DOI 10.1016/j.jmb.2020.04.009
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Kim YI, 2020, CELL HOST MICROBE, V27, P704, DOI 10.1016/j.chom.2020.03.023
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Kozlovskaya L, 2020, INT J INFECT DIS, V99, P40, DOI 10.1016/j.ijid.2020.07.024
   Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li QQ, 2020, CELL, V182, P1284, DOI 10.1016/j.cell.2020.07.012
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lock EF, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-386
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Lu J, 2020, CELL, V181, P997, DOI 10.1016/j.cell.2020.04.023
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Petrackova A, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00851
   SABUZI F, 2020, EUROSURVEILLANCE, V25, DOI DOI 10.3390/MOLECULES25010133
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454
   Sellers SA, 2020, INFLUENZA OTHER RESP, V14, P465, DOI 10.1111/irv.12734
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494
   Tamura K, 2004, P NATL ACAD SCI USA, V101, P11030, DOI 10.1073/pnas.0404206101
   Thao TTN, 2020, NATURE, V582, P561, DOI 10.1038/s41586-020-2294-9
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   van Dorp L, 2020, INFECT GENET EVOL, V83, DOI 10.1016/j.meegid.2020.104351
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   WANG W, 2020, EMERG INFECT DIS, V20, DOI DOI 10.1186/S12879-019-4746-0
   Williams GD, 1999, J VIROL, V73, P8349, DOI 10.1128/JVI.73.10.8349-8355.1999
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu KJ, 2020, CLIN INFECT DIS, V71, P799, DOI 10.1093/cid/ciaa351
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
   Yang XM, 2020, EMERG MICROBES INFEC, V9, P1287, DOI 10.1080/22221751.2020.1773745
   Yu FT, 2020, CLIN INFECT DIS, V71, P793, DOI 10.1093/cid/ciaa345
   Zehender G, 2020, J MED VIROL, V92, P1637, DOI 10.1002/jmv.25794
   Zhang XN, 2020, NATURE, V583, P437, DOI 10.1038/s41586-020-2355-0
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
   Zust R, 2008, J VIROL, V82, P1214, DOI 10.1128/JVI.01690-07
NR 70
TC 0
Z9 0
U1 0
U2 0
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD NOV 3
PY 2020
VL 33
IS 5
AR 108352
DI 10.1016/j.celrep.2020.108352
PG 15
WC Cell Biology
SC Cell Biology
GA OO6CK
UT WOS:000587464900024
PM 33113345
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Liu, C
   Mendonca, L
   Yang, Y
   Gao, YZ
   Shen, CG
   Liu, JW
   Ni, T
   Ju, B
   Liu, CC
   Tang, X
   Wei, JL
   Ma, XM
   Zhu, YN
   Liu, WL
   Xu, SM
   Liu, YX
   Yuan, J
   Wu, J
   Liu, Z
   Zhang, Z
   Liu, L
   Wang, PY
   Zhang, PJ
AF Liu, Chuang
   Mendonca, Luiza
   Yang, Yang
   Gao, Yuanzhu
   Shen, Chenguang
   Liu, Jiwei
   Ni, Tao
   Ju, Bin
   Liu, Congcong
   Tang, Xian
   Wei, Jinli
   Ma, Xiaomin
   Zhu, Yanan
   Liu, Weilong
   Xu, Shuman
   Liu, Yingxia
   Yuan, Jing
   Wu, Jing
   Liu, Zheng
   Zhang, Zheng
   Liu, Lei
   Wang, Peiyi
   Zhang, Peijun
TI The Architecture of Inactivated SARS-CoV-2 with Postfusion Spikes
   Revealed by Cryo-EM and Cryo-ET
SO STRUCTURE
LA English
DT Article
ID VISUALIZATION
AB The ongoing global pandemic of coronavirus disease 2019 (COVID-19) resulted from the outbreak of SARS-CoV-2 in December 2019. Currently, multiple efforts are being made to rapidly develop vaccines and treatments to fight COVID-19. Current vaccine candidates use inactivated SARS-CoV-2 viruses; therefore, it is important to understand the architecture of inactivated SARS-CoV-2. We have genetically and structurally characterized ii-propiolactone-inactivated viruses from a propagated and purified clinical strain of SARS-CoV-2. We observed that the virus particles are roughly spherical or moderately pleiomorphic. Although a small fraction of prefusion spikes are found, most spikes appear nail shaped, thus resembling a postfusion state, where the S1 protein of the spike has disassociated from S2. Cryoelectron tomography and subtomogram averaging of these spikes yielded a density map that closely matches the overall structure of the SARS-CoV postfusion spike and its corresponding glycosylation site. Our findings have major implications for SARS-CoV-2 vaccine design, especially those using inactivated viruses.
C1 [Liu, Chuang; Gao, Yuanzhu; Ma, Xiaomin; Wang, Peiyi] Southern Univ Sci & Technol, Dept Biol, Shenzhen 518055, Guangdong, Peoples R China.
   [Mendonca, Luiza; Liu, Jiwei; Ni, Tao; Zhu, Yanan; Zhang, Peijun] Univ Oxford, Div Struct Biol, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   [Yang, Yang; Shen, Chenguang; Ju, Bin; Tang, Xian; Wei, Jinli; Liu, Weilong; Liu, Yingxia; Zhang, Zheng; Liu, Lei] Shenzhen Third Peoples Hosp, Natl Clin Res Ctr Infect Dis, Inst Hepatol, Shenzhen 518112, Guangdong, Peoples R China.
   [Liu, Chuang; Gao, Yuanzhu; Liu, Congcong; Ma, Xiaomin; Xu, Shuman; Wu, Jing; Liu, Zheng; Wang, Peiyi] Southern Univ Sci & Technol, Cryo EM Ctr, Shenzhen 518055, Guangdong, Peoples R China.
   [Liu, Yingxia; Yuan, Jing] Shenzhen Third Peoples Hosp, Dept Infect Dis, Shenzhen 518112, Guangdong, Peoples R China.
   [Liu, Congcong; Zhang, Zheng; Liu, Lei] Southern Univ Sci & Technol, Sch Med, Affiliated Hosp 2, Shenzhen 518055, Guangdong, Peoples R China.
   [Zhang, Peijun] Harwell Sci & Innovat Campus, Diamond Light Source, Electron Bioimaging Ctr, Didcot OX11 0DE, Oxon, England.
RP Wang, PY (corresponding author), Southern Univ Sci & Technol, Dept Biol, Shenzhen 518055, Guangdong, Peoples R China.; Zhang, PJ (corresponding author), Univ Oxford, Div Struct Biol, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.; Zhang, Z; Liu, L (corresponding author), Shenzhen Third Peoples Hosp, Natl Clin Res Ctr Infect Dis, Inst Hepatol, Shenzhen 518112, Guangdong, Peoples R China.; Wang, PY (corresponding author), Southern Univ Sci & Technol, Cryo EM Ctr, Shenzhen 518055, Guangdong, Peoples R China.; Zhang, Z; Liu, L (corresponding author), Southern Univ Sci & Technol, Sch Med, Affiliated Hosp 2, Shenzhen 518055, Guangdong, Peoples R China.; Zhang, PJ (corresponding author), Harwell Sci & Innovat Campus, Diamond Light Source, Electron Bioimaging Ctr, Didcot OX11 0DE, Oxon, England.
EM zhangzheng1975@aliyun.com; liulei3322@aliyun.com; wangpy@sustech.edu.cn;
   peijun@strubi.ox.ac.uk
OI Liu, Congcong/0000-0002-8675-9100
FU Science and Technology Innovation Committee of Shenzhen Municipality
   [202002073000002, JSGG 20200207155251653]; National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [P50A1150481]; UK Wellcome Trust
   Investigator Award [206422/Z/17/Z]; UK Biotechnology and Biological
   Sciences Research CouncilBiotechnology and Biological Sciences Research
   Council (BBSRC) [BB/S003339/1]
FX We acknowledge the work and contribution of all the health providers
   from the Third People's Hospital of Shenzhen. We sincerely thank both
   the cryo-EM center and the BSL-3 laboratory of the Second Affiliated
   Hospital, School of Medicine, in South University of Science and
   Technology for providing the facilities and technical support. We thank
   J. Dong, C. Freeman, and R. Esnouf for computer system support. We also
   thank Professors Dongfeng Gu and Mingzhao Xing and Ms. Anna Rackley for
   their valuable advice and reading of the manuscript. This research was
   supported by the Science and Technology Innovation Committee of Shenzhen
   Municipality (202002073000002 and JSGG 20200207155251653) and National
   Institutes of Health grant P50A1150481 (P.Z.), UK Wellcome Trust
   Investigator Award 206422/Z/17/Z (P.Z.), and UK Biotechnology and
   Biological Sciences Research Council grant BB/S003339/1 (P.Z.).
CR Castano-Diez D, 2012, J STRUCT BIOL, V178, P139, DOI 10.1016/j.jsb.2011.12.017
   Chen H., 2020, BIORXIV
   Fan XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17371-6
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Hagen WJH, 2017, J STRUCT BIOL, V197, P191, DOI 10.1016/j.jsb.2016.06.007
   Himes BA, 2018, NAT METHODS, V15, P955, DOI 10.1038/s41592-018-0167-z
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Killikelly AM, 2016, SCI REP-UK, V6, DOI 10.1038/srep34108
   Kremer JR, 1996, J STRUCT BIOL, V116, P71, DOI 10.1006/jsbi.1996.0013
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Mastronarde DN, 2005, J STRUCT BIOL, V152, P36, DOI 10.1016/j.jsb.2005.07.007
   McLellan JS, 2013, SCIENCE, V340, P1113, DOI 10.1126/science.1234914
   Ni T, 2020, NAT STRUCT MOL BIOL, V27, P855, DOI 10.1038/s41594-020-0467-8
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Sutton G, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18243-9
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   World Health Organization, 2020, WHO COR DIS COVID 19
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Wrapp D., 2020, CRYO EM STRUCTURE 20
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang Y, 2019, J INFECTION, V79, P391, DOI 10.1016/j.jinf.2019.07.010
   Yang Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep17554
   Yang YA, 2013, PROTEIN CELL, V4, P331, DOI 10.1007/s13238-013-2093-2
   Zhang PJ, 2019, CURR OPIN STRUC BIOL, V58, P249, DOI 10.1016/j.sbi.2019.05.021
   Zheng SQ, 2017, NAT METHODS, V14, P331, DOI 10.1038/nmeth.4193
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 34
TC 0
Z9 0
U1 2
U2 2
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0969-2126
EI 1878-4186
J9 STRUCTURE
JI Structure
PD NOV 3
PY 2020
VL 28
IS 11
BP 1218
EP +
DI 10.1016/j.str.2020.10.001
PG 11
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA OO4BY
UT WOS:000587327300006
PM 33058760
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Rao, L
   Xia, S
   Xu, W
   Tian, R
   Yu, GC
   Gu, CJ
   Pan, P
   Meng, QF
   Cai, X
   Qu, D
   Lu, L
   Xie, YH
   Jiang, SB
   Chen, XY
AF Rao, Lang
   Xia, Shuai
   Xu, Wei
   Tian, Rui
   Yu, Guocan
   Gu, Chenjian
   Pan, Pan
   Meng, Qian-Fang
   Cai, Xia
   Qu, Di
   Lu, Lu
   Xie, Youhua
   Jiang, Shibo
   Chen, Xiaoyuan
TI Decoy nanoparticles protect against COVID-19 by concurrently adsorbing
   viruses and inflammatory cytokines
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE COVID-19; SARS-CoV-2; cytokine storm; nanodecoy; cell membrane vesicle
ID ZIKA VIRUS; DELIVERY; CORONAVIRUS; OUTBREAK
AB The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has highlighted the urgent need to rapidly develop therapeutic strategies for such emerging viruses without effective vaccines or drugs. Here, we report a decoy nanoparticle against COVID-19 through a powerful two-step neutralization approach: virus neutralization in the first step followed by cytokine neutralization in the second step. The nanodecoy, made by fusing cellular membrane nanovesicles derived from human monocytes and genetically engineered cells stably expressing angiotensin converting enzyme II (ACE2) receptors, possesses an antigenic exterior the same as source cells. By competing with host cells for virus binding, these nanodecoys effectively protect host cells from the infection of pseudoviruses and authentic SARS-CoV-2. Moreover, relying on abundant cytokine receptors on the surface, the nanodecoys efficiently bind and neutralize inflammatory cytokines including interleukin 6 (IL-6) and granulocyte-macrophage colony-stimulating factor (GM-CSF), and significantly suppress immune disorder and lung injury in an acute pneumonia mouse model. Our work presents a simple, safe, and robust antiviral nanotechnology for ongoing COVID-19 and future potential epidemics.
C1 [Rao, Lang; Tian, Rui; Yu, Guocan; Chen, Xiaoyuan] NIBIB, Lab Mol Imaging & Nanomed, NIH, Bethesda, MD 20892 USA.
   [Xia, Shuai; Xu, Wei; Gu, Chenjian; Cai, Xia; Qu, Di; Lu, Lu; Xie, Youhua; Jiang, Shibo] Fudan Univ, Key Lab Med Mol Virol, Sch Basic Med Sci,Chinese Acad Med Sci, Biosafety Level Lab 3,Minist Educ,Natl Hlth Commi, Shanghai 200032, Peoples R China.
   [Pan, Pan] Jinan Univ, Inst Med Microbiol, Guangzhou 510632, Peoples R China.
   [Pan, Pan] Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Peoples R China.
   [Meng, Qian-Fang] Wuhan Univ, Sch Phys & Technol, Wuhan 430072, Peoples R China.
RP Chen, XY (corresponding author), NIBIB, Lab Mol Imaging & Nanomed, NIH, Bethesda, MD 20892 USA.; Lu, L; Xie, YH; Jiang, SB (corresponding author), Fudan Univ, Key Lab Med Mol Virol, Sch Basic Med Sci,Chinese Acad Med Sci, Biosafety Level Lab 3,Minist Educ,Natl Hlth Commi, Shanghai 200032, Peoples R China.
EM lul@fudan.edu.cn; yhxie@fudan.edu.cn; shibojiang@fudan.edu.cn;
   chen9647@gmail.com
RI Rao, Lang/H-4666-2017
OI Rao, Lang/0000-0001-5010-0729
FU Intramural Research Program of the National Institute of Biomedical
   Imaging and Bioengineering, NIH; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [82041025,
   81822045]; Development Programs for COVID-19 of Shanghai Science and
   Technology Commission [20431900401]; China Postdoctoral Science
   FoundationChina Postdoctoral Science Foundation [2018M640341,
   2019T120302]
FX We thank Dr. Zhi-Jun Sun at School and Hospital of Stomatology, Wuhan
   University, for his kind help in animal experiments, and the members of
   Core Facility of Microbiology and Parasitology of Fudan University,
   especially Dr. Qian Wang, and the members of Biosafety Level 3
   Laboratory in Shanghai Medical College of Fudan University for their
   continuous support. This work was supported by the Intramural Research
   Program of the National Institute of Biomedical Imaging and
   Bioengineering, NIH, the National Natural Science Foundation of China
   (Nos. Grants 82041025 and 81822045), the Development Programs for
   COVID-19 of Shanghai Science and Technology Commission (Grant
   20431900401), and the China Postdoctoral Science Foundation (Grants
   2018M640341 and 2019T120302).
CR Banerjee A, 2020, EMERG INFECT DIS, V26, P2054, DOI 10.3201/eid2609.201495
   Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Cagno V, 2018, NAT MATER, V17, P195, DOI [10.1038/NMAT5053, 10.1038/nmat5053]
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Choy EH, 2020, NAT REV RHEUMATOL, V16, P335, DOI 10.1038/s41584-020-0419-z
   Chu DF, 2015, ACS NANO, V9, P11800, DOI 10.1021/acsnano.5b05583
   He YX, 2006, VACCINE, V24, P5498, DOI 10.1016/j.vaccine.2006.04.054
   Henry BD, 2015, NAT BIOTECHNOL, V33, P81, DOI 10.1038/nbt.3037
   Hirotani T, 2005, J IMMUNOL, V174, P3650, DOI 10.4049/jimmunol.174.6.3650
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu CMJ, 2013, NAT NANOTECHNOL, V8, P336, DOI [10.1038/NNANO.2013.54, 10.1038/nnano.2013.54]
   Hu CMJ, 2011, P NATL ACAD SCI USA, V108, P10980, DOI 10.1073/pnas.1106634108
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jackman JA, 2018, NAT MATER, V17, P971, DOI 10.1038/s41563-018-0194-2
   Jiang SB, 2020, LANCET, V395, P949, DOI 10.1016/S0140-6736(20)30419-0
   Keller MD, 2020, NATURE, V579, P260, DOI 10.1038/s41586-020-2066-6
   Lang FM, 2020, NAT REV IMMUNOL, V20, P507, DOI 10.1038/s41577-020-0357-7
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397
   Rao L, 2020, ACS NANO, V14, P2569, DOI 10.1021/acsnano.0c01665
   Rao L, 2019, NANO LETT, V19, P2215, DOI 10.1021/acs.nanolett.8b03913
   Rao L, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201803531
   Richner JM, 2017, CELL, V168, P1114, DOI 10.1016/j.cell.2017.02.017
   Sanders J.M., 2019, JAMA-J AM MED ASSOC, V323, P1824, DOI DOI 10.1001/jama.2020.6019
   Thamphiwatana S, 2017, P NATL ACAD SCI USA, V114, P11488, DOI 10.1073/pnas.1714267114
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang JH, 2020, J COMPUT NONLIN DYN, V15, DOI 10.1115/1.4047337
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Williamson BN, 2020, NATURE, DOI 10.1038/s41586-020-2423-5
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xia S, 2020, CELL MOL IMMUNOL, V17, P765, DOI 10.1038/s41423-020-0374-2
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Zhang PF, 2018, ADV MATER, V30, DOI 10.1002/adma.201705350
   Zhang PF, 2015, P NATL ACAD SCI USA, V112, pE6129, DOI 10.1073/pnas.1505799112
   Zhang QZ, 2020, NANO LETT, V20, P5570, DOI 10.1021/acs.nanolett.0c02278
   Zhang QZ, 2018, NAT NANOTECHNOL, V13, P1182, DOI 10.1038/s41565-018-0254-4
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 40
TC 0
Z9 0
U1 5
U2 5
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 3
PY 2020
VL 117
IS 44
BP 27141
EP 27147
DI 10.1073/pnas.2014352117
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OO6QW
UT WOS:000587503000018
PM 33024017
OA Other Gold
DA 2021-01-01
ER

PT J
AU Li, Z
   Li, X
   Huang, YY
   Wu, YX
   Liu, RD
   Zhou, LL
   Lin, YX
   Wu, DY
   Zhang, L
   Liu, H
   Xu, XM
   Yu, KQ
   Zhang, YX
   Cui, J
   Zhan, CG
   Wang, X
   Luo, HB
AF Li, Zhe
   Li, Xin
   Huang, Yi-You
   Wu, Yaoxing
   Liu, Runduo
   Zhou, Lingli
   Lin, Yuxi
   Wu, Deyan
   Zhang, Lei
   Liu, Hao
   Xu, Ximing
   Yu, Kunqian
   Zhang, Yuxia
   Cui, Jun
   Zhan, Chang-Guo
   Wang, Xin
   Luo, Hai-Bin
TI Identify potent SARS-CoV-2 main protease inhibitors via accelerated free
   energy perturbation-based virtual screening of existing drugs
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE virtual screening; SARS-CoV-2; drug repurposing; free energy
   perturbation; main protease
ID MOLECULAR-DYNAMICS; DISCOVERY; CORONAVIRUSES; PREDICTIONS; CHLOROQUINE;
   ACCURATE
AB The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global crisis. There is no therapeutic treatment specific for COVID-19. It is highly desirable to identify potential antiviral agents against SARS-CoV-2 from existing drugs available for other diseases and thus repurpose them for treatment of COVID-19. In general, a drug repurposing effort for treatment of a new disease, such as COVID-19, usually starts from a virtual screening of existing drugs, followed by experimental validation, but the actual hit rate is generally rather low with traditional computational methods. Here we report a virtual screening approach with accelerated free energy perturbation-based absolute binding free energy (FEP-ABFE) predictions and its use in identifying drugs targeting SARS-CoV-2 main protease (M-pro). The accurate FEP-ABFE predictions were based on the use of a restraint energy distribution (RED) function, making the practical FEP-ABFE-based virtual screening of the existing drug library possible. As a result, out of 25 drugs predicted, 15 were confirmed as potent inhibitors of SARS-CoV-2 M-pro. The most potent one is dipyridamole (inhibitory constant K-i = 0.04 mu M) which has shown promising therapeutic effects in subsequently conducted clinical studies for treatment of patients with COVID-19. Additionally, hydroxychloroquine (K-i = 0.36 mu M) and chloroquine (K-i = 0.56 mu M) were also found to potently inhibit SARS-CoV-2 M-pro. We anticipate that the FEP-ABFE prediction-based virtual screening approach will be useful in many other drug repurposing or discovery efforts.
C1 [Li, Zhe; Huang, Yi-You; Liu, Runduo; Wu, Deyan; Luo, Hai-Bin] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Design & Evaluat, Guangzhou 510006, Peoples R China.
   [Li, Xin; Lin, Yuxi; Xu, Ximing; Wang, Xin] Ocean Univ China, Ctr Innovat Marine Drug Screening & Evaluat, Sch Med & Pharm, Qingdao 266100, Peoples R China.
   [Li, Xin; Lin, Yuxi] Lanzhou Univ, Sch Life Sci, Lanzhou 734000, Peoples R China.
   [Wu, Yaoxing; Zhou, Lingli; Zhang, Lei; Cui, Jun] Sun Yat Sen Univ, Sch Life Sci, Key Lab Gene Funct & Regulat, State Key Lab Biocontrol,Minist Educ MOE, Guangzhou 510006, Peoples R China.
   [Liu, Hao] High Performance Comp Ctr, Pilot Natl Lab Marine Sci & Technol, Qingdao 266237, Peoples R China.
   [Xu, Ximing; Wang, Xin] Marine Biomed Res Inst Qingdao, Qingdao 266100, Peoples R China.
   [Yu, Kunqian] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China.
   [Yu, Kunqian] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Zhang, Yuxia] Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Guangzhou Inst Pediat, State Key Lab Resp Dis, Guangzhou 510623, Peoples R China.
   [Zhan, Chang-Guo] Univ Kentucky, Coll Pharm, Mol Modeling & Biopharmaceut Ctr, Lexington, KY 40536 USA.
   [Zhan, Chang-Guo] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Luo, Hai-Bin] Hainan Univ, Sch Life & Pharmaceut Sci, Minist Educ, Key Lab Trop Biol Resources, Haikou 570228, Hainan, Peoples R China.
RP Luo, HB (corresponding author), Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Design & Evaluat, Guangzhou 510006, Peoples R China.; Wang, X (corresponding author), Ocean Univ China, Ctr Innovat Marine Drug Screening & Evaluat, Sch Med & Pharm, Qingdao 266100, Peoples R China.; Cui, J (corresponding author), Sun Yat Sen Univ, Sch Life Sci, Key Lab Gene Funct & Regulat, State Key Lab Biocontrol,Minist Educ MOE, Guangzhou 510006, Peoples R China.; Wang, X (corresponding author), Marine Biomed Res Inst Qingdao, Qingdao 266100, Peoples R China.; Zhan, CG (corresponding author), Univ Kentucky, Coll Pharm, Mol Modeling & Biopharmaceut Ctr, Lexington, KY 40536 USA.; Zhan, CG (corresponding author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.; Luo, HB (corresponding author), Hainan Univ, Sch Life & Pharmaceut Sci, Minist Educ, Key Lab Trop Biol Resources, Haikou 570228, Hainan, Peoples R China.
EM cuij5@mail.sysu.edu.cn; zhan@uky.edu; wx8399@ouc.edu.cn;
   luohb77@mail.sysu.edu.cn
FU National Key R&D Program of China [2017YFB0202600]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [81903542, 81522041, 21877134]; Science Foundation of Guangdong
   ProvinceNational Natural Science Foundation of Guangdong Province
   [2020A111128007, 2018A030313215, 201904020023]; Guangdong Provincial Key
   Laboratory of Construction Foundation [2017B030314030]; Fundamental
   Research Funds for the Central Universities (Sun Yat-Sen University)
   [18ykpy23]; Local Innovative and Research Teams Project of Guangdong
   Pearl River Talents Program [2017BT01Y093]; National Science and
   Technology Major Projects for "Major New Drugs Innovation and
   Development" [2018ZX09711003-003-005]; Strategic Priority Research
   Program of the Chinese Academy of SciencesChinese Academy of Sciences
   [XDC01040100]; NSFNational Science Foundation (NSF) [CHE-1111761];
   Taishan Scholars Program [tsqn201909170]; Innovative Leader of Qingdao
   Program [19-3-2-26-zhc]; Pilot National Laboratory for Marine Science
   and Technology [QNLM202001]; Zhejiang University; Sun Yat-Sen University
FX We cordially acknowledge Tencent Cloud, National Supercomputing centers
   in Shenzhen, Tianjing, and Guangzhou, and Beijing Super Cloud Computing
   Center for providing high performance computing resources for virtual
   screening and FEP calculations. We cordially acknowledge National Key
   R&D Program of China (Grant 2017YFB0202600), National Natural Science
   Foundation of China (Grants 81903542, 81522041, and 21877134), Science
   Foundation of Guangdong Province (Grants 2020A111128007, 2018A030313215,
   and 201904020023), Guangdong Provincial Key Laboratory of Construction
   Foundation (Grant 2017B030314030), Fundamental Research Funds for the
   Central Universities (Sun Yat-Sen University, Grant 18ykpy23), Local
   Innovative and Research Teams Project of Guangdong Pearl River Talents
   Program (Grant 2017BT01Y093), the National Science and Technology Major
   Projects for "Major New Drugs Innovation and Development" (Grant
   2018ZX09711003-003-005), the Strategic Priority Research Program of the
   Chinese Academy of Sciences (Grant XDC01040100), the NSF (Grant
   CHE-1111761), the Taishan Scholars Program (Grant tsqn201909170), the
   Innovative Leader of Qingdao Program (Grant 19-3-2-26-zhc), the special
   scientific research fund for COVID-19 from the Pilot National Laboratory
   for Marine Science and Technology (Grant QNLM202001), Sun Yat-Sen
   University and Zhejiang University special scientific research fund for
   COVID-19 prevention and control, and philanthropy donation from
   individuals. The funders had no roles in the design and execution of the
   study.
CR Abel R, 2017, ACCOUNTS CHEM RES, V50, P1625, DOI 10.1021/acs.accounts.7b00083
   Adedeji AO, 2014, CURR OPIN VIROL, V8, P45, DOI 10.1016/j.coviro.2014.06.002
   Al-Bari MAA, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.293
   Aldeghi M, 2017, J AM CHEM SOC, V139, P946, DOI 10.1021/jacs.6b11467
   Aldeghi M, 2016, CHEM SCI, V7, P207, DOI 10.1039/c5sc02678d
   Briggs JM, 1996, TRENDS CARDIOVAS MED, V6, P198, DOI 10.1016/S1050-1738(96)00068-0
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chodera JD, 2011, CURR OPIN STRUC BIOL, V21, P150, DOI 10.1016/j.sbi.2011.01.011
   Chorin E, 2020, HEART RHYTHM, V17, P1425, DOI 10.1016/j.hrthm.2020.05.014
   Cournia Z, 2020, J CHEM INF MODEL, V60, P4153, DOI 10.1021/acs.jcim.0c00116
   Cournia Z, 2017, J CHEM INF MODEL, V57, P2911, DOI 10.1021/acs.jcim.7b00564
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Farag A., 2020, IDENTIFICATION FDA A, DOI [10.26434/ chemrxiv.12003930.v1, DOI 10.26434/CHEMRXIV.12003930.V1]
   Fintelman-Rodrigues N., 2020, BIORXIV, DOI [10.1101/2020.04.04.020925, DOI 10.1101/2020.04.04.020925]
   Garcia-Cremades M, 2020, CLIN PHARMACOL THER, V108, P253, DOI 10.1002/cpt.1856
   Gilson MK, 1997, BIOPHYS J, V72, P1047, DOI 10.1016/S0006-3495(97)78756-3
   Gorgulla C, 2020, NATURE, V580, P663, DOI 10.1038/s41586-020-2117-z
   Heinzelmann G., 2020, AUTOMATED DOCKING RE, DOI DOI 10.1101/2020.04.15.043240
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jorgensen WL, 2016, BIOORGAN MED CHEM, V24, P4768, DOI 10.1016/j.bmc.2016.07.039
   Jorgensen WL, 2009, ACCOUNTS CHEM RES, V42, P724, DOI 10.1021/ar800236t
   JORGENSEN WL, 1985, J CHEM PHYS, V83, P3050, DOI 10.1063/1.449208
   Kim JT, 2006, J AM CHEM SOC, V128, P15372, DOI 10.1021/ja066472g
   Li Z, 2019, J MED CHEM, V62, P2099, DOI 10.1021/acs.jmedchem.8b01763
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Liu XY, 2020, ACTA PHARMACOL SIN B, V10, P1205, DOI 10.1016/j.apsb.2020.04.008
   MCCAMMON JA, 1987, SCIENCE, V238, P486, DOI 10.1126/science.3310236
   Peach ML, 2009, J CHEMINFORMATICS, V1, DOI 10.1186/1758-2946-1-6
   Radmer RJ, 1997, J COMPUT CHEM, V18, P902, DOI 10.1002/(SICI)1096-987X(199705)18:7<902::AID-JCC4>3.0.CO;2-V
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Shivanna V, 2014, VIROLOGY, V464, P287, DOI 10.1016/j.virol.2014.07.025
   Steinbrecher TB, 2015, J CHEM INF MODEL, V55, P2411, DOI 10.1021/acs.jcim.5b00538
   SUN YX, 1992, J CHEM PHYS, V97, P5108, DOI 10.1063/1.463832
   Traebert M, 2004, EUR J PHARMACOL, V484, P41, DOI 10.1016/j.ejphar.2003.11.003
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang G., 2020, MECHANISTIC INSIGHTS, DOI [10.1101/2020.05.21.108605, DOI 10.1101/2020.05.21.108605]
   Wang L, 2015, J AM CHEM SOC, V137, P2695, DOI 10.1021/ja512751q
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren GL, 2006, J MED CHEM, V49, P5912, DOI 10.1021/jm050362n
   Wereszczynski J, 2012, Q REV BIOPHYS, V45, P1, DOI 10.1017/S0033583511000096
   WONG CF, 1986, J AM CHEM SOC, V108, P3830, DOI 10.1021/ja00273a048
   Xiong R, 2020, PROTEIN CELL, V11, P723, DOI 10.1007/s13238-020-00768-w
   Xu Z, 2020, NELFINAVIR IS ACTIVE, DOI [10.26434/chemrxiv.12039888.v1, DOI 10.26434/CHEMRXIV.12039888.V1]
   Zhou S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67283-0
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 47
TC 0
Z9 0
U1 6
U2 6
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 3
PY 2020
VL 117
IS 44
BP 27381
EP 27387
DI 10.1073/pnas.2010470117
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OO6QW
UT WOS:000587503000048
PM 33051297
OA Other Gold
DA 2021-01-01
ER

PT J
AU Merow, C
   Urban, MC
AF Merow, Cory
   Urban, Mark C.
TI Seasonality and uncertainty in global COVID-19 growth rates
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE SARS-CoV-2; climate; pandemic; UV light; humidity
ID ABSOLUTE-HUMIDITY; TRANSMISSION; INACTIVATION; TEMPERATURE; CORONAVIRUS;
   OUTBREAK
AB The virus causing COVID-19 has spread rapidly worldwide and threatens millions of lives. It remains unknown, as of April 2020, whether summer weather will reduce its spread, thereby alleviating strains on hospitals and providing time for vaccine development. Early insights from laboratory studies and research on related viruses predicted that COVID-19 would decline with higher temperatures, humidity, and ultraviolet (UV) light. Using current, fine-scaled weather data and global reports of infections, we develop a model that explains 36% of the variation in maximum COVID-19 growth rates based on weather and demography (17%) and country-specific effects (19%). UV light is most strongly associated with lower COVID-19 growth. Projections suggest that, without intervention, COVID-19 will decrease temporarily during summer, rebound by autumn, and peak next winter. Validation based on data from May and June 2020 confirms the generality of the climate signal detected. However, uncertainty remains high, and the probability of weekly doubling rates remains >20% throughout summer in the absence of social interventions. Consequently, aggressive interventions will likely be needed despite seasonal trends.
C1 [Merow, Cory] Univ Connecticut, Eversource Energy Ctr, Storrs, CT 06268 USA.
   [Merow, Cory; Urban, Mark C.] Univ Connecticut, Ctr Biol Risk, Storrs, CT 06268 USA.
   [Merow, Cory; Urban, Mark C.] Univ Connecticut, Dept Ecol & Evolutionary Biol, Storrs, CT 06268 USA.
RP Merow, C (corresponding author), Univ Connecticut, Eversource Energy Ctr, Storrs, CT 06268 USA.; Merow, C (corresponding author), Univ Connecticut, Ctr Biol Risk, Storrs, CT 06268 USA.; Merow, C (corresponding author), Univ Connecticut, Dept Ecol & Evolutionary Biol, Storrs, CT 06268 USA.
EM cory.merow@gmail.com
FU NSFNational Science Foundation (NSF) [HDR-1394790, DEB-1555876]; Center
   of Biological Risk; University of Connecticut
FX NSF Award HDR-1394790 supported C.M., and NSF Award DEB-1555876 and the
   Center of Biological Risk supported M.C.U. The University of
   Connecticut's Vice Provost of Research supported both C.M. and M.C.U. We
   thank the Center for Systems Science and Engineering at Johns Hopkins
   University for providing publicly available COVID-19 data.
CR Araujo M. B., 2020, SPREAD SARS COV 2 CO, V03, DOI [10.1101/2020.03.12.20034728, DOI 10.1101/2020.03.12.20034728]
   Baker R. E., 2020, SUSCEPTIBLE SUPPLY L, DOI [DOI 10.1101/2020.04.03.20052787, 10.1101/2020.04.03.20052787]
   Baker RE, 2020, SCIENCE, V369, P315, DOI 10.1126/science.abc2535
   Barreca AI, 2012, AM J EPIDEMIOL, V176, pS114, DOI 10.1093/aje/kws259
   Chan K, 2011, ADV OPTOELECTRON, V2011, DOI [10.1155/2011/734690, 10.1155/2011/196707]
   Chen B., 2020, ROLES METEOROLOGICAL, DOI [10.1101/2020.03.16.20037168, DOI 10.1101/2020.03.16.20037168]
   Chin AWH, 2020, LANCET MICROBE, V1, pe10, DOI [DOI 10.1101/2020.03.15.20036673, heresAdoi. moll 0.10161 S2666-5247(20130003-3, 10.1016/S2666-5247(20)130003-3]
   Chipperfield J. D., 2020, INADEQUACY SPECIES D, DOI [10.32942/osf.io/mr6pn, DOI 10.32942/OSF.IO/MR6PN]
   Copernicus Climate Change Service, 2018, COPERNICUS CLIMATE C
   Darnell MER, 2004, J VIROL METHODS, V121, P85, DOI 10.1016/j.jviromet.2004.06.006
   Dietze MC, 2018, P NATL ACAD SCI USA, V115, P1424, DOI 10.1073/pnas.1710231115
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Ferguson N.M., 2020, 9 IMP COLL LOND
   Fick SE, 2017, INT J CLIMATOL, V37, P4302, DOI 10.1002/joc.5086
   Goodrich B., RSTANARM BAYESIAN AP
   Grant WB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040988
   Ianevski A, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030207
   Ilie PC, 2020, AGING CLIN EXP RES, V32, P1195, DOI 10.1007/s40520-020-01570-8
   Kudo E, 2019, P NATL ACAD SCI USA, V116, P10905, DOI 10.1073/pnas.1902840116
   Lau FH, 2020, VITAMIN D INSUFFICIE, DOI [10.1101/2020.04.24.20075838, DOI 10.1101/2020.04.24.20075838]
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu PL, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0896-0
   Lytle CD, 2005, J VIROL, V79, P14244, DOI 10.1128/JVI.79.22.14244-14252.2005
   Martinez ME, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007327
   Martinez-Alvarez M, 2020, LANCET GLOB HEALTH, V8, pE631, DOI 10.1016/S2214-109X(20)30123-6
   National Academies of Sciences, 2020, MED RAP EXP CONS SAR
   Pacheco M. T., 2020, EXPONENTIAL PHASE CO, DOI [10.1101/2020.04.02.20050773, DOI 10.1101/2020.04.02.20050773]
   Petchey OL, 2015, ECOL LETT, V18, P597, DOI 10.1111/ele.12443
   Price RHM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37481-y
   Raftery A. E., 1995, PRACTICAL MARKOV CHA, V7, P763
   Roussel M, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3114-x
   Sajadi MM, 2020, TEMPERATURE LATITUDE
   Shaman J, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000316
   Shaman J, 2009, P NATL ACAD SCI USA, V106, P3243, DOI 10.1073/pnas.0806852106
   Tamerius JD, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003194
   Tan JG, 2005, J EPIDEMIOL COMMUN H, V59, P186, DOI 10.1136/jech.2004.020180
   te Beest DE, 2013, AM J EPIDEMIOL, V178, P1469, DOI 10.1093/aje/kwt132
   U.S. National Academy of Sciences, 1975, UND CLIM CHANG PROGR
   Urban MC, 2016, SCIENCE, V353, P1113, DOI 10.1126/science.aad8466
   Vehtari A, 2017, STAT COMPUT, V27, P1413, DOI 10.1007/s11222-016-9696-4
   Wang Y, 2020, MATER HIGH TEMP, V37, P155, DOI 10.1080/09603409.2020.1731257
   Yuan JS, 2006, AM J INFECT CONTROL, V34, P234, DOI 10.1016/j.ajic.2005.12.006
   Zurell D, 2016, GLOBAL CHANGE BIOL, V22, P2651, DOI 10.1111/gcb.13251
NR 43
TC 4
Z9 4
U1 9
U2 9
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 3
PY 2020
VL 117
IS 44
BP 27456
EP 27464
DI 10.1073/pnas.2008590117
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OO6QW
UT WOS:000587503000055
PM 33051302
OA Other Gold
DA 2021-01-01
ER

PT J
AU Chen, WH
   Tao, XR
   Agrawal, AS
   Algaissi, A
   Peng, BH
   Pollet, J
   Strych, U
   Bottazzi, ME
   Hotez, PJ
   Lustigman, S
   Du, LY
   Jiang, SB
   Tseng, CT
AF Chen, Wen-Hsiang
   Tao, Xinrong
   Agrawal, Anurodh Shankar
   Algaissi, Abdullah
   Peng, Bi-Hung
   Pollet, Jeroen
   Strych, Ulrich
   Bottazzi, Maria Elena
   Hotez, Peter J.
   Lustigman, Sara
   Du, Lanying
   Jiang, Shibo
   Tseng, Chien-Te K.
TI Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1)
   formulated with aluminum hydroxide induces protective immunity and
   reduces immune enhancement
SO VACCINE
LA English
DT Article
DE Coronavirus; Vaccine; Eosinophil infiltration; Severe acute respiratory
   syndrome; Recombinant protein
ID ACUTE RESPIRATORY SYNDROME; SPIKE PROTEIN; CORONAVIRUS; VACCINE;
   IMMUNIZATION; MICE; PNEUMONIA; INFECTION; EPITOPES
AB We developed a severe acute respiratory syndrome (SARS) subunit recombinant protein vaccine candidate based on a high-yielding, yeast-engineered, receptor-binding domain (RBD219-N1) of the SARS beta-coronavirus (SARS-CoV) spike (S) protein. When formulated with Alhydrogel (R), RBD219-N1 induced high levels of neutralizing antibodies against both pseudotyped virus and a clinical (mouse-adapted) isolate of SARS-CoV. Here, we report that mice immunized with RBD219-N1/Alhydroger were fully protected from lethal SARS-CoV challenge (0% mortality), compared to similar to 30% mortality in mice immunized with the SARS S protein formulated with Alhydrogel (R), and 100% mortality in negative controls. An RBD219-N1 formulation with Alhydrogel (R) was also superior to the S protein, unadjuvanted RBD, and AddaVax (MF59-like adjuvant)-formulated RBD in inducing specific antibodies and preventing cellular infiltrates in the lungs upon SARS-CoV challenge. Specifically, a formulation with a 1:25 ratio of RBD219-N1 to Alhydrogel (R) provided high neutralizing antibody titers, 100% protection with nondetectable viral loads with minimal or no eosinophilic pulmonary infiltrates. As a result, this vaccine formulation is under consideration for further development against SARS-CoV and potentially other emerging and re-emerging beta-CoVs such as SARS-CoV-2. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Chen, Wen-Hsiang; Pollet, Jeroen; Strych, Ulrich; Bottazzi, Maria Elena; Hotez, Peter J.] Texas Childrens Hosp, Ctr Vaccine Dev, Houston, TX 77030 USA.
   [Chen, Wen-Hsiang; Pollet, Jeroen; Strych, Ulrich; Bottazzi, Maria Elena; Hotez, Peter J.] Baylor Coll Med, Natl Sch Trop Med, Dept Pediat, Houston, TX 77030 USA.
   [Chen, Wen-Hsiang; Pollet, Jeroen; Strych, Ulrich; Bottazzi, Maria Elena; Hotez, Peter J.] Baylor Coll Med, Natl Sch Trop Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.
   [Tao, Xinrong; Agrawal, Anurodh Shankar; Algaissi, Abdullah; Tseng, Chien-Te K.] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA.
   [Peng, Bi-Hung] Univ Texas Med Branch, Dept Neurosci Cell Biol & Anat, Galveston, TX 77555 USA.
   [Bottazzi, Maria Elena; Hotez, Peter J.] Baylor Univ, Dept Biol, Waco, TX 76798 USA.
   [Bottazzi, Maria Elena; Hotez, Peter J.] Rice Univ, James A Baker III Inst Publ Policy, Houston, TX USA.
   [Lustigman, Sara; Du, Lanying; Jiang, Shibo] New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA.
   [Tao, Xinrong] Anhui Univ Sci & Technol, Sch Med, Huainan, Anhui, Peoples R China.
   [Algaissi, Abdullah] Jazan Univ, Coll Appl Med Sci, Dept Med Labs Technol, Jazan, Saudi Arabia.
RP Tseng, CT (corresponding author), Univ Texas Med Branch, 301 Univ Blvd, Galveston, TX 77555 USA.; Bottazzi, ME (corresponding author), 1 Baylor Plaza, Houston, TX 77030 USA.
EM bottazzi@bcm.edu; sktseng@utmb.edu
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01AI098775]
FX This study was supported by a grant from the National Institutes of
   Health (R01AI098775).
CR Agrawal AS, 2016, HUM VACC IMMUNOTHER, V12, P2351, DOI 10.1080/21645515.2016.1177688
   [Anonymous], 2020, MICROBES INFECT
   Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11
   Center_ for_Disease_Control_and_Prevention, ADM VACC
   Chen WH, 2017, J PHARM SCI-US, V106, P1961, DOI 10.1016/j.xphs.2017.04.037
   Chen WH, 2014, HUM VACC IMMUNOTHER, V10, P648, DOI 10.4161/hv.27464
   Clinicaltrials.gov, 2000, TOC COVID 19 PNEUM T
   Czub M, 2005, VACCINE, V23, P2273, DOI 10.1016/j.vaccine.2005.01.033
   Dias PM, 2013, J AUTOIMMUN, V40, P9, DOI 10.1016/j.jaut.2012.07.004
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Du L, 2007, VACCINE, V25
   Du LY, 2007, VACCINE, V25, P2832, DOI 10.1016/j.vaccine.2006.10.031
   Du LY, 2010, VIRAL IMMUNOL, V23, P211, DOI 10.1089/vim.2009.0090
   Du LY, 2009, VIROLOGY, V393, P144, DOI 10.1016/j.virol.2009.07.018
   Du LY, 2009, BIOCHEM BIOPH RES CO, V384, P486, DOI 10.1016/j.bbrc.2009.05.003
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Garcon N, 2018, PLOTKINS VACCINES
   He YX, 2006, J IMMUNOL, V176, P6085, DOI 10.4049/jimmunol.176.10.6085
   He YX, 2005, J IMMUNOL, V174, P4908, DOI 10.4049/jimmunol.174.8.4908
   Honda-Okubo Y, 2015, J VIROL, V89, P2995, DOI 10.1128/JVI.02980-14
   Jaume M, 2012, Hong Kong Med J, V18 Suppl 2, P31
   Jiang SB, 2005, EMERG INFECT DIS, V11, P1016, DOI 10.3201/1107.050219
   Jiang SB, 2012, EXPERT REV VACCINES, V11, P1405, DOI [10.1586/erv.12.126, 10.1586/ERV.12.126]
   Keely S, 2015, IMMUNITY, V43, P7, DOI 10.1016/j.immuni.2015.07.010
   Kommareddy S, 2017, IMMUNOPOTENTIATORS IN MODERN VACCINES, 2ND EDITION, P249, DOI 10.1016/B978-0-12-804019-5.00013-X
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Perlman S, 2005, NAT REV IMMUNOL, V5, P917, DOI 10.1038/nri1732
   Roberts A, 2007, PLOS PATHOG, V3, P23, DOI 10.1371/journal.ppat.0030005
   Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421
   Tseng CTK, 2007, J VIROL, V81, P1162, DOI 10.1128/JVI.01702-06
   Wang QD, 2016, ACS INFECT DIS, V2, P361, DOI 10.1021/acsinfecdis.6b00006
   Weingartl H, 2004, J VIROL, V78, P12672, DOI 10.1128/JVI.78.22.12672-12676.2004
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Yasui F, 2008, J IMMUNOL, V181, P6337, DOI 10.4049/jimmunol.181.9.6337
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang YC, 2004, INFECT IMMUN, V72, P4410, DOI 10.1128/IAI.72.8.4410-4415.2004
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zuckerman JN, 2000, BRIT MED J, V321, P1237, DOI 10.1136/bmj.321.7271.1237
NR 39
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD NOV 3
PY 2020
VL 38
IS 47
BP 7533
EP 7541
DI 10.1016/j.vaccine.2020.09.061
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OH5OL
UT WOS:000582634300019
PM 33039209
OA Green Published
DA 2021-01-01
ER

PT J
AU Xia, QD
   Xun, Y
   Lu, JL
   Lu, YC
   Yang, YY
   Zhou, P
   Hu, J
   Li, C
   Wang, SG
AF Xia, Qi-Dong
   Xun, Yang
   Lu, Jun-Lin
   Lu, Yu-Chao
   Yang, Yuan-Yuan
   Zhou, Peng
   Hu, Jia
   Li, Cong
   Wang, Shao-Gang
TI Network pharmacology and molecular docking analyses on Lianhua Qingwen
   capsule indicate Akt1 is a potential target to treat and prevent
   COVID-19
SO CELL PROLIFERATION
LA English
DT Article
DE Akt1; Chinese patent medicine; COVID&#8208; 19; Lianhua Qingwen capsule;
   molecular docking; network pharmacology
ID INTEGRATING INFORMATION; PI3K/AKT/MTOR PATHWAY; CELL-DEVELOPMENT; LUNG
   INJURY; GENES; KINASE; CYTOSCAPE
AB Objectives Coronavirus disease 2019 (COVID-19) is rapidly spreading worldwide. Lianhua Qingwen capsule (LQC) has shown therapeutic effects in patients with COVID-19. This study is aimed to discover its molecular mechanism and provide potential drug targets.
   Materials and Methods An LQC target and COVID-19-related gene set was established using the Traditional Chinese Medicine Systems Pharmacology database and seven disease-gene databases. Gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis and protein-protein interaction (PPI) network were performed to discover the potential mechanism. Molecular docking was performed to visualize the patterns of interactions between the effective molecule and targeted protein.
   Results A gene set of 65 genes was generated. We then constructed a compound-target network that contained 234 nodes of active compounds and 916 edges of compound-target pairs. The GO and KEGG indicated that LQC can act by regulating immune response, apoptosis and virus infection. PPI network and subnetworks identified nine hub genes. The molecular docking was conducted on the most significant gene Akt1, which is involved in lung injury, lung fibrogenesis and virus infection. Six active compounds of LQC can enter the active pocket of Akt1, namely beta-carotene, kaempferol, luteolin, naringenin, quercetin and wogonin, thereby exerting potential therapeutic effects in COVID-19.
   Conclusions The network pharmacological strategy integrates molecular docking to unravel the molecular mechanism of LQC. Akt1 is a promising drug target to reduce tissue damage and help eliminate virus infection.
C1 [Xia, Qi-Dong; Xun, Yang; Lu, Jun-Lin; Lu, Yu-Chao; Yang, Yuan-Yuan; Zhou, Peng; Hu, Jia; Li, Cong; Wang, Shao-Gang] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Urol, Tongji Med Coll, Wuhan, Peoples R China.
RP Hu, J; Li, C; Wang, SG (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Dept Urol, Tongji Med Coll, Wuhan, Peoples R China.
EM jiahutjm@163.com; licongtjm@163.com; sgwangtjm@163.com
OI Lu, Junlin/0000-0002-3438-0297; Wang, Shaogang/0000-0002-3206-1495
CR Amberger JS, 2015, NUCLEIC ACIDS RES, V43, pD789, DOI 10.1093/nar/gku1205
   Appelberg S, 2020, EMERG MICROBES INFEC, V9, P1748, DOI 10.1080/22221751.2020.1799723
   Barbarino JM, 2018, WIRES SYST BIOL MED, V10, DOI 10.1002/wsbm.1417
   Bateman A, 2015, NUCLEIC ACIDS RES, V43, pD204, DOI 10.1093/nar/gku989
   Beijing News Network World Health Organization (WHO), 2020, DECL NOV COR EP GLOB
   Boezio B, 2017, MOL INFORM, V36, DOI 10.1002/minf.201700048
   Bouadma L, 2020, J CLIN IMMUNOL, V40, P1082, DOI 10.1007/s10875-020-00839-x
   Chen HQ, 2020, TOXICOL LETT, V334, P4, DOI 10.1016/j.toxlet.2020.09.008
   Chen K, 2011, CHIN J EXP TRADIT ME, V18, P275
   Chen X, 2002, NUCLEIC ACIDS RES, V30, P412, DOI 10.1093/nar/30.1.412
   Chiarini M, 2020, J NEUROIMMUNOL, V345, DOI 10.1016/j.jneuroim.2020.577282
   Cohen MM, 2013, AM J MED GENET A, V161, P2931, DOI 10.1002/ajmg.a.36101
   Biancatelli RMLC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01451
   Cong LH, 2020, J CELL MOL MED, V24, P8532, DOI 10.1111/jcmm.15475
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Esfandiarei M, 2004, J VIROL, V78, P4289, DOI 10.1128/JVI.78.8.4289-4298.2004
   Gao D, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00746
   He JJ, 2020, ACTA BIOCH BIOPH SIN, V52, P810, DOI 10.1093/abbs/gmaa067
   Huang CY, 2020, NUTRIENTS, V12, DOI 10.3390/nu12061742
   Jones N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10023-4
   Kindrachuk J, 2015, ANTIMICROB AGENTS CH, V59, P1088, DOI 10.1128/AAC.03659-14
   Kiyohara H, 2012, J NAT MED-TOKYO, V66, P55, DOI 10.1007/s11418-011-0550-x
   Lee CH, 2004, J IMMUNOL, V172, P7841
   Li M, 2019, CELL MOL IMMUNOL, V16, P757, DOI 10.1038/s41423-018-0185-x
   Li Xin, 2020, Pharmacol Res, V160, P105036, DOI 10.1016/j.phrs.2020.105036
   Liang XL, 2020, J PHARM ANAL, V10, P130, DOI 10.1016/j.jpha.2019.09.005
   Liu M, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104896
   Lucas CL, 2014, NAT IMMUNOL, V15, P88, DOI 10.1038/ni.2771
   Mironova GD, 2020, EUR REV MED PHARMACO, V24, P8585, DOI 10.26355/eurrev_202008_22658
   Mizutani T, 2007, ANN NY ACAD SCI, V1102, P86, DOI 10.1196/annals.1408.006
   National Health Commission of the People's Republic of China, GUID DIAGN TREATM CO
   Nile SH, 2020, FOOD CHEM TOXICOL, V135, DOI 10.1016/j.fct.2019.110985
   O'Leary EM, 2020, AM J RESP CELL MOL B
   Pan A, 2017, ACTA CRYSTALLOGR D, V73, P402, DOI 10.1107/S2059798317003849
   Pinero J, 2017, NUCLEIC ACIDS RES, V45, pD833, DOI 10.1093/nar/gkw943
   Ping YU, 2020, CHIN J PHARM, P1
   Rebhan M, 1997, TRENDS GENET, V13, P163, DOI 10.1016/S0168-9525(97)01103-7
   Rogel A, 2017, P NATL ACAD SCI USA, V114, pE1178, DOI 10.1073/pnas.1611299114
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758-2946-6-13
   Saikia S, 2019, CURR DRUG TARGETS, V20, P501, DOI 10.2174/1389450119666181022153016
   Schoenrich Gunther, 2020, Advances in Biological Regulation, V77, P100741, DOI 10.1016/j.jbior.2020.100741
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Suh J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51889-0
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Tang Y, 2015, BIOSYSTEMS, V127, P67, DOI 10.1016/j.biosystems.2014.11.005
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Vergadi E, 2017, J IMMUNOL, V198, P1006, DOI 10.4049/jimmunol.1601515
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang XQ, 2014, ARCH VIROL, V159, P2091, DOI 10.1007/s00705-014-2016-4
   Wang YL, 2017, NUCLEIC ACIDS RES, V45, pD955, DOI 10.1093/nar/gkw1118
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   World Health Organization (WHO), WHO DIR GEN OP REM M
   Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807
   Xiao Z, 2020, PHARMACOL RES, V153, DOI 10.1016/j.phrs.2020.104637
   Yang CG, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/3196375
   Yu JZ, 2019, BIOMEDECINE PHARMACO, V118
   Yuan HD, 2017, MOLECULES, V22, DOI 10.3390/molecules22071135
   Zeng ZL, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03255-0
   Zhang RH, 2017, BIOMED PHARMACOTHER, V89, P660, DOI 10.1016/j.biopha.2017.02.081
   Zhang S, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00954-7
   Zhang Y, 2013, IMMUNOLOGY, V140, P143, DOI 10.1111/imm.12123
   Zhao Z, 2020, PHYTOMEDICINE, P153308, DOI 10.1016/j.phymed.2020.153308
   Zhou W, 2013, AM J CHINESE MED, V41, P743, DOI 10.1142/S0192415X1350050X
   Zhu Z, 2019, LIFE SCI ALLIANCE, V2
NR 64
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0960-7722
EI 1365-2184
J9 CELL PROLIFERAT
JI Cell Prolif.
PD DEC
PY 2020
VL 53
IS 12
SI SI
AR e12949
DI 10.1111/cpr.12949
EA NOV 2020
PG 13
WC Cell Biology
SC Cell Biology
GA PB0MV
UT WOS:000583848400001
PM 33140889
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bharadwaj, S
   Azhar, EI
   Kamal, MA
   Bajrai, LH
   Dubey, A
   Jha, K
   Yadava, U
   Kang, SG
   Dwivedi, VD
AF Bharadwaj, Shiv
   Azhar, Esam Ibraheem
   Kamal, Mohammad Amjad
   Bajrai, Leena Hussein
   Dubey, Amit
   Jha, Kanupriya
   Yadava, Umesh
   Kang, Sang Gu
   Dwivedi, Vivek Dhar
TI SARS-CoV-2 M-pro inhibitors: identification of anti-SARS-CoV-2 M-pro
   compounds from FDA approved drugs
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; drug repurposing; structure-based virtual screening; molecular
   docking; molecular dynamics simulation
ID HUMAN CORONAVIRUS; MAIN PROTEASE; VIRUS
AB Recent outbreak of COVID-19 pandemic caused by severe acute respiratory syndrome-Coronavirus-2 (SARS-CoV-2) has raised serious global concern for public health. The viral main 3-chymotrypsin-like cysteine protease (M-pro), known to control coronavirus replication and essential for viral life cycle, has been established as an essential drug discovery target for SARS-CoV-2. Herein, we employed computationally screening of Druglib database containing FDA approved drugs against active pocket of SARS-CoV-2 M(pro )using MTiopen screen web server, yields a total of 1051 FDA approved drugs with docking energy >-7 kcal/mol. The top 10 screened potential compounds against SARS-CoV-2 M-pro were then studied by re-docking, binding affinity, intermolecular interaction, and complex stability via 100 ns all atoms molecular dynamics (MD) simulation followed by post-simulation analysis, including end point binding free energy, essential dynamics, and residual correlation analysis against native crystal structure ligand N3 inhibitor. Based on comparative molecular simulation and interaction profiling of the screened drugs with SARS-CoV-2 M(pro )revealed R428 (-10.5 kcal/mol), Teniposide (-9.8 kcal/mol), VS-5584 (-9.4 kcal/mol), and Setileuton (-8.5 kcal/mol) with stronger stability and affinity than other drugs and N3 inhibitor; and hence, these drugs are advocated for further validation using in vitro enzyme inhibition and in vivo studies against SARS-CoV-2 infection.
   Communicated by Ramaswamy H. Sarma
C1 [Bharadwaj, Shiv; Kang, Sang Gu] Yeungnam Univ, Coll Life & Appl Sci, Inst Biotechnol, Dept Biotechnol, Gyongsan, South Korea.
   [Azhar, Esam Ibraheem] King Abdulaziz Univ, Fac Appl Med Sci, Med Lab Sci Dept, Jeddah, Saudi Arabia.
   [Azhar, Esam Ibraheem; Bajrai, Leena Hussein] King Abdulaziz Univ, King Fahd Med Res Ctr, Special Infect Agents Unit, Jeddah, Saudi Arabia.
   [Kamal, Mohammad Amjad] King Abdulaziz Univ, King Fahd Med Res Ctr, Jeddah, Saudi Arabia.
   [Kamal, Mohammad Amjad] Novel Global Community Educ Fdn, Enzymo, Hebersham, Australia.
   [Bajrai, Leena Hussein] King Abdulaziz Univ, Fac Sci, Biochem Dept, Jeddah, Saudi Arabia.
   [Dubey, Amit] Univ Allahabad, Dept Biochem, Prayagraj, India.
   [Jha, Kanupriya; Dwivedi, Vivek Dhar] Pathfinder Res & Training Fdn, Ctr Bioinformat Computat & Syst Biol, Greater Noida, India.
   [Yadava, Umesh] Deen Dayal Upadhyaya Gorakhpur Univ, Dept Phys, Gorakhpur, Uttar Pradesh, India.
RP Kang, SG (corresponding author), Yeungnam Univ, Coll Life & Appl Sci, Inst Biotechnol, Dept Biotechnol, Gyongsan, South Korea.; Azhar, EI (corresponding author), King Abdulaziz Univ, Fac Appl Med Sci, Med Lab Sci Dept, Jeddah, Saudi Arabia.; Azhar, EI (corresponding author), King Abdulaziz Univ, King Fahd Med Res Ctr, Special Infect Agents Unit, Jeddah, Saudi Arabia.; Dwivedi, VD (corresponding author), Pathfinder Res & Training Fdn, Ctr Bioinformat Computat & Syst Biol, Greater Noida, India.
EM eazhar@kau.edu.sa; kangsg@ynu.ac.kr; vivek_bioinformatics@yahoo.com
RI Azhar, Esam/ABI-1044-2020
OI Dwivedi, Vivek/0000-0003-0767-1328; Yadava, Umesh/0000-0002-9127-532X
FU Deanship of Scientific Research (DSR) at King Abdulaziz University,
   Jeddah, Saudi Arabia [FP-3-42]
FX This study was supported by The Deanship of Scientific Research (DSR) at
   King Abdulaziz University, Jeddah, Saudi Arabia, under grant no.
   FP-3-42.
CR BHARADWAJ S, 2019, SCI REP UK, V9, DOI DOI https://doi.org/10.1038/s41598-019-55723-5
   BHARADWAJ S, 2020, J BIOMOL STRUCT 0403, DOI DOI https://doi.org/10.1080/07391102.2020.1747545
   Bharadwaj S, 2020, J MOL LIQ, V311, DOI 10.1016/j.molliq.2020.113322
   Bharadwaj S, 2020, LIFE SCI, V257, DOI 10.1016/j.lfs.2020.118080
   Bowers K. J., 2006, SC 06 P 2006 ACM IEE
   Canducci F, 2008, J MED VIROL, V80, P716, DOI 10.1002/jmv.21108
   Chang CK, 2016, DRUG DISCOV TODAY, V21, P562, DOI 10.1016/j.drudis.2015.11.015
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Du Toit A, 2020, NAT REV MICROBIOL, V18, P123, DOI 10.1038/s41579-020-0332-0
   DWIVEDI VD, 2020, J BIOMOL STRUCT 0306, DOI DOI https://doi.org/10.1080/07391102.2020.1734485
   Dwivedi Vivek Dhar, 2016, VirusDisease, V27, P220, DOI 10.1007/s13337-016-0328-6
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Giwa Al, 2020, Emerg Med Pract, V22, P1
   Grant BJ, 2006, BIOINFORMATICS, V22, P2695, DOI 10.1093/bioinformatics/btl461
   Hing Esther, 2006, Adv Data, P1
   Jevsnik M, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-365
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kim Jeong-Min, 2020, Osong Public Health Res Perspect, V11, P3, DOI 10.24171/j.phrp.2020.11.1.02
   Kirtipal N, 2020, INFECT GENET EVOL, V85, DOI 10.1016/j.meegid.2020.104502
   Kupferschmidt K, 2020, SCIENCE, V367, P1412, DOI 10.1126/science.367.6485.1412
   Labbe CM, 2015, NUCLEIC ACIDS RES, V43, pW448, DOI 10.1093/nar/gkv306
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Mena-Ulecia K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142774
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Team R. C, 2013, R LANG ENV STAT COMP
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Vabret A, 2006, CLIN INFECT DIS, V42, P634, DOI 10.1086/500136
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhao Q, 2008, J VIROL, V82, P8647, DOI 10.1128/JVI.00298-08
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 38
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1842807
EA NOV 2020
PG 16
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OL6VA
UT WOS:000585473700001
PM 33150855
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Hua, TF
   Li, M
   Li, XY
AF Hua, Tianfeng
   Li, Ming
   Li, Xiuyong
TI Therapeutic plasma exchange therapy support for critical COVID-19: A
   case report
SO THERAPEUTIC APHERESIS AND DIALYSIS
LA English
DT Letter; Early Access
C1 [Hua, Tianfeng] Anhui Med Univ, Hosp Affiliated 2, Dept Intens Care Unit 2, Hefei, Peoples R China.
   [Li, Ming] 2 Peoples Hosp Fuyang City, Dept Hepatol, Fuyang, Anhui, Peoples R China.
   [Li, Xiuyong] 2 Peoples Hosp Fuyang City, Dept Nephrol, Fuyang, Anhui, Peoples R China.
RP Hua, TF (corresponding author), Anhui Med Univ, Hosp Affiliated 2, Dept Intens Care Unit 2, Hefei, Peoples R China.
EM covidbp@163.com
CR Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Daoud AM, 2020, THER APHER DIAL, DOI 10.1111/1744-9987.13568
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jia X, 2020, CLIN SIGNIFICANCE IG, DOI [10.1101/2020.02.28.20029025, DOI 10.1101/2020.02.28.20029025]
   Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9
NR 5
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1744-9979
EI 1744-9987
J9 THER APHER DIAL
JI Ther. Apher. Dial.
DI 10.1111/1744-9987.13586
EA NOV 2020
PG 2
WC Hematology; Urology & Nephrology
SC Hematology; Urology & Nephrology
GA OK2MW
UT WOS:000584485800001
PM 32940386
OA Bronze
DA 2021-01-01
ER

PT J
AU Sharma, P
   Joshi, T
   Mathpal, S
   Joshi, T
   Pundir, H
   Chandra, S
   Tamta, S
AF Sharma, Priyanka
   Joshi, Tushar
   Mathpal, Shalini
   Joshi, Tanuja
   Pundir, Hemlata
   Chandra, Subhash
   Tamta, Sushma
TI Identification of natural inhibitors against Mpro of SARS-CoV-2 by
   molecular docking, molecular dynamics simulation, and MM/PBSA methods
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Coronavirus; Mpro; COVID-19; molecular docking; molecular dynamic
   simulation
AB The recent outbreak of SARS-CoV-2 disease, also known as COVID-19, has emerged as a pandemic. The unavailability of specific therapeutic drugs and vaccines urgently demands sincere efforts for drug discovery against COVID-19. The main protease (Mpro) of SARS-CoV-2 is a critical drug target as it plays an essential role in virus replication. Therefore for the identification of potential inhibitors of SARS-CoV-2 Mpro, we applied a structure-based virtual screening approach followed by molecular dynamics (MD) study. A library of 686 phytochemicals was subjected to virtual screening which resulted in 28 phytochemicals based on binding energy. These phytochemicals were further subjected to drug-likeness and toxicity analysis, which resulted in seven drug-like hits. Out of seven, five phytochemicals viz., Mpro-Dehydrtectol (-10.3 kcal/mol), Epsilon-viniferin (-8.6 kcal/mol), Peimisine (-8.6 kcal/mol), Gmelanone (-8.4 kcal/mol), and Isocolumbin (-8.4 kcal/mol) were non-toxic. Consequently, these phytochemicals are subjected to MD, post MD analysis, and MM/PBSA calculations. The results of 100 ns MD simulation, RMSF, SASA, Rg, and MM/PBSA show that Epsilon-viniferin (-29.240 kJ/mol), Mpro-Peimisine (-43.031 kJ/mol) and Gmelanone (-13.093 kJ/mol) form a stable complex with Mpro and could be used as potential inhibitors of SARS-CoV-2 Mpro. However, further investigation of these inhibitors against Mpro receptor of COVID-19 is needed to validate their candidacy for clinical trials.
   Communicated by Ramaswamy H. Sarma
C1 [Sharma, Priyanka; Tamta, Sushma] Kumaun Univ, Dept Bot, DSB Campus, Naini Tal, Uttarakhand, India.
   [Joshi, Tushar; Mathpal, Shalini; Pundir, Hemlata] Kumaun Univ Uttarakhand, Dept Biotechnol, Bhimtal Campus, Bhimtal, Uttarakhand, India.
   [Joshi, Tanuja; Chandra, Subhash] Kumaun Univ, Dept Bot, SSJ Campus, Almora, Uttarakhand, India.
RP Tamta, S (corresponding author), Kumaun Univ, Dept Bot, DSB Campus, Naini Tal, Uttarakhand, India.; Chandra, S (corresponding author), Kumaun Univ, Dept Bot, SSJ Campus, Almora, Uttarakhand, India.
EM scjnu@yahoo.co.in; sushmatamta@gmail.com
RI Joshi, Tushar/AAJ-9626-2020
OI Chandra, Subhash/0000-0002-8978-5427
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Benvenuto D, 2020, J MED VIROL, V92, P455, DOI 10.1002/jmv.25688
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Ceraolo C, 2020, J MED VIROL, V92, P522, DOI 10.1002/jmv.25700
   Cheng J., 2020, EXPLORING ACTIVE COM
   Chopra S, 2019, J GLOB ONCOL, V5, P1, DOI 10.1200/JGO.18.00250
   De Clercq E, 2002, NAT REV DRUG DISCOV, V1, P13, DOI 10.1038/nrd703
   Habbu PV, 2009, INDIAN J EXP BIOL, V47, P121
   Hirono S., 2002, JAPANESE J CLIN PATH, V50
   Huang C, 2019, LANCET, V2020, P395
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Jee B, 2018, J BIOMOL STRUCT DYN, V36, P3434, DOI 10.1080/07391102.2017.1389305
   Joseph J, 2017, BIOINFORMATION, V13, P116, DOI 10.6026/97320630013116
   Kumar A, 2018, DATA, V3, DOI 10.3390/data3010007
   Lipinski CA, 2000, J PHARMACOL TOX MET, V44, P235, DOI 10.1016/S1056-8719(00)00107-6
   Mabkhot YN, 2016, MOLECULES, V21, DOI 10.3390/molecules21020222
   Milind Parle, 2006, Indian Journal of Traditional Knowledge, V5, P484
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Panchal S, 2016, AIP ADV, V6, DOI 10.1063/1.4944517
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722
   Singh J, 2003, PHOTO-EXCITED PROCESSES, DIAGNOSTICS AND APPLICATIONS: FUNDAMENTALS AND ADVANCED TOPICS, P25
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Van Norman Gail A, 2016, JACC Basic Transl Sci, V1, P170, DOI 10.1016/j.jacbts.2016.03.002
   Vanommeslaeghe K, 2010, J COMPUT CHEM, V31, P671, DOI 10.1002/jcc.21367
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   WHO, 2020, COR DIS COVID 19 PAN
NR 27
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1842806
EA NOV 2020
PG 12
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OK5XI
UT WOS:000584722800001
PM 33143552
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Madariaga, MLL
   Guthmiller, JJ
   Schrantz, S
   Jansen, MO
   Christensen, C
   Kumar, M
   Prochaska, M
   Wool, G
   Durkin-Celauro, A
   Oh, WH
   Trockman, L
   Vigneswaran, J
   Keskey, R
   Shaw, DG
   Dugan, H
   Zheng, NY
   Cobb, M
   Utset, H
   Wang, J
   Stovicek, O
   Bethel, C
   Matushek, S
   Giurcanu, M
   Beavis, KG
   di Sabato, D
   Meltzer, D
   Ferguson, MK
   Kress, JP
   Shanmugarajah, K
   Matthews, JB
   Fung, JF
   Wilson, PC
   Alverdy, JC
   Donington, JS
AF Madariaga, M. L. L.
   Guthmiller, J. J.
   Schrantz, S.
   Jansen, M. O.
   Christensen, C.
   Kumar, M.
   Prochaska, M.
   Wool, G.
   Durkin-Celauro, A.
   Oh, W. H.
   Trockman, L.
   Vigneswaran, J.
   Keskey, R.
   Shaw, D. G.
   Dugan, H.
   Zheng, N-y
   Cobb, M.
   Utset, H.
   Wang, J.
   Stovicek, O.
   Bethel, C.
   Matushek, S.
   Giurcanu, M.
   Beavis, K. G.
   di Sabato, D.
   Meltzer, D.
   Ferguson, M. K.
   Kress, J. P.
   Shanmugarajah, K.
   Matthews, J. B.
   Fung, J. F.
   Wilson, P. C.
   Alverdy, J. C.
   Donington, J. S.
TI Clinical predictors of donor antibody titre and correlation with
   recipient antibody response in a COVID-19 convalescent plasma clinical
   trial
SO JOURNAL OF INTERNAL MEDICINE
LA English
DT Article; Early Access
DE convalescent plasma; COVID&#8208; 19; antibody titre
ID BLOOD-GROUP; THERAPY
AB Background Convalescent plasma therapy for COVID-19 relies on transfer of anti-viral antibody from donors to recipients via plasma transfusion. The relationship between clinical characteristics and antibody response to COVID-19 is not well defined. We investigated predictors of convalescent antibody production and quantified recipient antibody response in a convalescent plasma therapy clinical trial.
   Methods Multivariable analysis of clinical and serological parameters in 103 confirmed COVID-19 convalescent plasma donors 28 days or more following symptom resolution was performed. Mixed-effects regression models with piecewise linear trends were used to characterize serial antibody responses in 10 convalescent plasma recipients with severe COVID-19.
   Results Donor antibody titres ranged from 0 to 1 : 3892 (anti-receptor binding domain (RBD)) and 0 to 1 : 3289 (anti-spike). Higher anti-RBD and anti-spike titres were associated with increased age, hospitalization for COVID-19, fever and absence of myalgia (all P < 0.05). Fatigue was significantly associated with anti-RBD (P = 0.03). In pairwise comparison amongst ABO blood types, AB donors had higher anti-RBD and anti-spike than O donors (P < 0.05). No toxicity was associated with plasma transfusion. Non-ECMO recipient anti-RBD antibody titre increased on average 31% per day during the first three days post-transfusion (P = 0.01) and anti-spike antibody titre by 40.3% (P = 0.02).
   Conclusion Advanced age, fever, absence of myalgia, fatigue, blood type and hospitalization were associated with higher convalescent antibody titre to COVID-19. Despite variability in donor titre, 80% of convalescent plasma recipients showed significant increase in antibody levels post-transfusion. A more complete understanding of the dose-response effect of plasma transfusion amongst COVID-19-infected patients is needed.
C1 [Madariaga, M. L. L.; Durkin-Celauro, A.; Oh, W. H.; Trockman, L.; Vigneswaran, J.; Keskey, R.; di Sabato, D.; Ferguson, M. K.; Shanmugarajah, K.; Matthews, J. B.; Fung, J. F.; Alverdy, J. C.; Donington, J. S.] Univ Chicago, Dept Surg, Chicago, IL 60637 USA.
   [Guthmiller, J. J.; Schrantz, S.; Jansen, M. O.; Kumar, M.; Prochaska, M.; Zheng, N-y; Cobb, M.; Utset, H.; Wang, J.; Stovicek, O.; Meltzer, D.; Kress, J. P.; Wilson, P. C.] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
   [Christensen, C.; Wool, G.] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA.
   [Shaw, D. G.; Dugan, H.] Univ Chicago, Comm Immunol, Chicago, IL 60637 USA.
   [Bethel, C.; Matushek, S.] Univ Chicago, Clin Microbiol & Immunol Lab, Chicago, IL 60637 USA.
   [Giurcanu, M.] Univ Chicago, Dept Publ Hlth Sci, Chicago, IL 60637 USA.
   [Beavis, K. G.] Univ Chicago, Dept Pathol, Biol Sci Div, Chicago, IL 60637 USA.
RP Madariaga, MLL (corresponding author), Univ Chicago, Dept Surg, Chicago, IL 60637 USA.; Madariaga, MLL (corresponding author), Univ Chicago, Med & Biol Sci, 5841 S Maryland Ave,MC5047, Chicago, IL 60637 USA.
EM mlmadariaga@uchiago.edu
FU Department of Surgery University of Chicago; National Institute of
   Allergy and Infectious Diseases (NIAID) Collaborative Influenza Vaccine
   Innovation Centers (CIVIC) [75N93019C00051]
FX Department of Surgery University of Chicago, National Institute of
   Allergy and Infectious Diseases (NIAID) Collaborative Influenza Vaccine
   Innovation Centers (CIVIC) contract 75N93019C00051.
CR Ahn JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e149
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Cheng YF, 2005, JAMA-J AM MED ASSOC, V293, P1450, DOI 10.1001/jama.293.12.1450-c
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Ellingson KD, 2017, TRANSFUSION, V57, P1588, DOI 10.1111/trf.14165
   Fleming AB, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104388
   Guillon P, 2008, GLYCOBIOLOGY, V18, P1085, DOI 10.1093/glycob/cwn093
   Halstead SB, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.AID-0022-2014
   Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Joyner M, 2020, EARLY SAFETY INDICAT
   Lazzerini M, 2020, LANCET CHILD ADOLESC, V4, pE10, DOI 10.1016/S2352-4642(20)30108-5
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Liu STH, 2020, NAT MED, V26, P1708, DOI 10.1038/s41591-020-1088-9
   McGuire LW, 1918, J AMER MED ASSOC, V71, P1311, DOI 10.1001/jama.1918.26020420013013e
   Rojas M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102554
   Salazar E, 2020, TREATMENT COVID 19 P
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Stadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Wajnberg A, 2020, HUMORAL IMMUNE RESPO
   Wu F, 2020, NEUTRALIZING ANTIBOD
   Zhang B, 2020, CHEST, V158, pE9, DOI 10.1016/j.chest.2020.03.039
   Zhao J, 2020, RELATIONSHIP ABO BLO
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zhou BP, 2007, NEW ENGL J MED, V357, P1450, DOI 10.1056/NEJMc070359
NR 30
TC 1
Z9 1
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0954-6820
EI 1365-2796
J9 J INTERN MED
JI J. Intern. Med.
DI 10.1111/joim.13185
EA NOV 2020
PG 15
WC Medicine, General & Internal
SC General & Internal Medicine
GA OK1HY
UT WOS:000584403600001
PM 33034095
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Cheruiyot, I
   Sehmi, P
   Ominde, B
   Bundi, P
   Mislani, M
   Ngure, B
   Olabu, B
   Ogeng'o, JA
AF Cheruiyot, Isaac
   Sehmi, Prabjot
   Ominde, Beryl
   Bundi, Paul
   Mislani, Musa
   Ngure, Brian
   Olabu, Beda
   Ogeng'o, Julius A.
TI Intracranial hemorrhage in coronavirus disease 2019 (COVID-19) patients
SO NEUROLOGICAL SCIENCES
LA English
DT Article; Early Access
DE COVID-19; Intracranial hemorrhage; Hemorrhagic stroke
ID THROMBOTIC COMPLICATIONS
AB Background Emerging evidence suggests that a subset of coronavirus disease 2019 (COVID-19) patients may present with or develop cerebrovascular disease during the course of hospitalization. Whereas ischemic stroke in COVID-19 patients has been well described, data on intracranial hemorrhage (ICH) in these patients is still limited. We, therefore, conducted a rapid systematic review of current scientific literature to identify and consolidate evidence of ICH in COVID-19 patients. Methods A systematic search of literature was conducted between November 1, 2019, and August 14, 2020, on PubMed and China National Knowledge Infrastructure (CNKI) to identify eligible studies. Results A total of 23 studies describing ICH in 148 COVID-19 patients were included. The pooled incidence of ICH in COVID-19 patients was 0.7% (95% CI 0.5-0.9), with low levels of inter-study heterogeneity observed (I-2 = 33.6%, Cochran's Q = 12.05, p = 0.149). Most of the patients were elderly male patients (65.8%) with comorbidities, the most common being systemic hypertension (54%). Hemorrhage involving multiple cranial compartments was reported in 9.5% of cases. Single compartments were involved in the rest, with intraparenchymal hemorrhage (IPH) being the most common variety (62.6%) and intraventricular hemorrhage (IVH) the least common (1.4%). Half of these patients were on some form of anticoagulation. Overall, the mortality rate in the COVID-19 patients with ICH was about 48.6%. Conclusion Although relatively uncommon among COVID-19 patients, ICH is associated with a high mortality rate. Early identification of patients at risk of developing ICH, particularly with comorbid conditions and on anticoagulant therapy, may be important to improve outcomes.
C1 [Cheruiyot, Isaac; Sehmi, Prabjot; Mislani, Musa; Ngure, Brian; Olabu, Beda; Ogeng'o, Julius A.] Univ Nairobi, Dept Human Anat, Nairobi, Kenya.
   [Cheruiyot, Isaac] Univ Nairobi, Sch Med, Nairobi, Kenya.
   [Ominde, Beryl] Kenya Methodist Univ, Dept Human Anat, Meru, Kenya.
   [Bundi, Paul] Kenya Methodist Univ, Dept Internal Med, Meru, Kenya.
RP Cheruiyot, I (corresponding author), Univ Nairobi, Dept Human Anat, Nairobi, Kenya.; Cheruiyot, I (corresponding author), Univ Nairobi, Sch Med, Nairobi, Kenya.
EM isaacbmn@outlook.com
CR Aggarwal G, 2020, INT J STROKE, V15, P385, DOI 10.1177/1747493020921664
   Al Saiegh F, 2020, J NEUROL NEUROSUR PS, V91, P1
   Al-Mufti F, 2018, INTERV NEUROL, V7, P118, DOI 10.1159/000484571
   Al-olama M, 2020, ACTA NEUROCHIR, V162, P1495, DOI 10.1007/s00701-020-04402-w
   Alenina N, 2019, NEUROCHEM RES, V44, P1323, DOI 10.1007/s11064-018-2679-4
   Altschul DJ, 2020, CLIN NEUROL NEUROSUR, V198, DOI 10.1016/j.clineuro.2020.106112
   An SJ, 2017, J STROKE, V19, P3, DOI 10.5853/jos.2016.00864
   Bermejo-Martin JF, 2020, CARDIOVASC RES, V116, pE132, DOI 10.1093/cvr/cvaa140
   Boehme AK, 2017, CIRC RES, V120, P472, DOI 10.1161/CIRCRESAHA.116.308398
   Ciulla MM, 2020, HYPERTENS RES, V43, P985, DOI 10.1038/s41440-020-0488-z
   Dogra S, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.104984
   Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020
   Haddadi K, 2020, CUREUS, V12, DOI 10.7759/cureus.7869
   Heman-Ackah SM, 2020, NEUROSURGERY, V87, pE147, DOI 10.1093/neuros/nyaa198
   Hernandez-Fernandez Francisco, 2020, Brain, V143, P3089, DOI 10.1093/brain/awaa239
   Karadas O, 2020, NEUROL SCI, V41, P1991, DOI 10.1007/s10072-020-04547-7
   Katz JM, 2020, STROKE, V51, pE227, DOI 10.1161/STROKEAHA.120.031265
   Kempuraj D, 2020, NEUROSCIENTIST, DOI 10.1177/1073858420941476
   Klok FA, 2020, THROMB RES, V191, P148, DOI 10.1016/j.thromres.2020.04.041
   Li Y, 2020, STROKE VASC NEUROL, V5, P1
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   MARTIN JF, 1991, EUR J CLIN INVEST, V21, P355, DOI 10.1111/j.1365-2362.1991.tb01382.x
   Mehrpour M, 2020, INT J STROKE, DOI 10.1177/1747493020937397
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Melmed KR, 2020, J THROMB THROMBOLYS, DOI 10.1007/s11239-020-02288-0
   Morassi M, 2020, J NEUROL, V267, P2185, DOI 10.1007/s00415-020-09885-2
   Moriguchi T, 2020, INT J INFECT DIS, V94, P55, DOI 10.1016/j.ijid.2020.03.062
   Muhammad S, 2020, BRAIN BEHAV IMMUN, V87, P150, DOI 10.1016/j.bbi.2020.05.015
   Nawabi J, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082543
   Ntaios G, 2020, STROKE, V51, pE254, DOI 10.1161/STROKEAHA.120.031208
   Panigada M, 2020, J THROMB HAEMOST, V18, P1738, DOI 10.1111/jth.14850
   Pinna P, 2020, J NEUROL SCI, V415, DOI 10.1016/j.jns.2020.116969
   Pons-Escoda A, 2020, AM J NEURORADIOL, V41, P1365, DOI 10.3174/ajnr.A6627
   Pranata R, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.104949
   Reddy ST, 2020, CASE REP NEUROL, V12, P199, DOI 10.1159/000508958
   Romero-Sanchez CM, 2020, NEUROLOGY, V95, pE1060, DOI 10.1212/WNL.0000000000009937
   Rothstein A, 2020, STROKE, V51, pE219, DOI 10.1161/STROKEAHA.120.030995
   Sardu C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051417
   Scullen T, 2020, WORLD NEUROSURG, V141, pE437, DOI 10.1016/j.wneu.2020.05.192
   Sharifi-Razavi A, 2020, NEW MICROB NEW INFEC, V35, DOI 10.1016/j.nmni.2020.100669
   Silhol F, 2020, HYPERTENS RES, V43, P854, DOI 10.1038/s41440-020-0476-3
   Sprague AH, 2009, BIOCHEM PHARMACOL, V78, P539, DOI 10.1016/j.bcp.2009.04.029
   Sweid A, 2020, INT J STROKE, V0, P1
   Tan YK, 2020, J THROMB THROMBOLYS, V50, P587, DOI 10.1007/s11239-020-02228-y
   Thomas W, 2020, THROMB RES, V191, P76, DOI 10.1016/j.thromres.2020.04.028
   Thompson RW, 1996, ANN NY ACAD SCI, V800, P157, DOI 10.1111/j.1749-6632.1996.tb33307.x
   Varatharaj A, 2020, LANCET PSYCHIAT, V7, P875, DOI 10.1016/S2215-0366(20)30287-X
   Verdecchia P, 2020, EUR J INTERN MED, V76, P14, DOI 10.1016/j.ejim.2020.04.037
   Vicenzi M, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01157-2020
   Viguier A, 2020, J NEURORADIOLOGY, V47, P395, DOI 10.1016/j.neurad.2020.04.003
   Yachou Y, 2020, NEUROL SCI, V41, P2657, DOI 10.1007/s10072-020-04575-3
   Zhou LY, 2020, TRAVEL MED INFECT DI, V36, DOI 10.1016/j.tmaid.2020.101642
   Zhou ZQ, 2020, J NEUROL, V267, P2179, DOI 10.1007/s00415-020-09929-7
NR 55
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1590-1874
EI 1590-3478
J9 NEUROL SCI
JI Neurol. Sci.
DI 10.1007/s10072-020-04870-z
EA NOV 2020
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA OK0WN
UT WOS:000584373500001
PM 33140308
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Alanazi, SA
   Kamruzzaman, MM
   Alruwaili, M
   Alshammari, N
   Alqahtani, SA
   Karime, A
AF Alanazi, Saad Awadh
   Kamruzzaman, M. M.
   Alruwaili, Madallah
   Alshammari, Nasser
   Alqahtani, Salman Ali
   Karime, Ali
TI Measuring and Preventing COVID-19 Using the SIR Model and Machine
   Learning in Smart Health Care
SO JOURNAL OF HEALTHCARE ENGINEERING
LA English
DT Article
ID AI; BLOCKCHAIN; FRAMEWORK; IOT
AB COVID-19 presents an urgent global challenge because of its contagious nature, frequently changing characteristics, and the lack of a vaccine or effective medicines. A model for measuring and preventing the continued spread of COVID-19 is urgently required to provide smart health care services. This requires using advanced intelligent computing such as artificial intelligence, machine learning, deep learning, cognitive computing, cloud computing, fog computing, and edge computing. This paper proposes a model for predicting COVID-19 using the SIR and machine learning for smart health care and the well-being of the citizens of KSA. Knowing the number of susceptible, infected, and recovered cases each day is critical for mathematical modeling to be able to identify the behavioral effects of the pandemic. It forecasts the situation for the upcoming 700 days. The proposed system predicts whether COVID-19 will spread in the population or die out in the long run. Mathematical analysis and simulation results are presented here as a means to forecast the progress of the outbreak and its possible end for three types of scenarios: "no actions," "lockdown," and "new medicines." The effect of interventions like lockdown and new medicines is compared with the "no actions" scenario. The lockdown case delays the peak point by decreasing the infection and affects the area equality rule of the infected curves. On the other side, new medicines have a significant impact on infected curve by decreasing the number of infected people about time. Available forecast data on COVID-19 using simulations predict that the highest level of cases might occur between 15 and 30 November 2020. Simulation data suggest that the virus might be fully under control only after June 2021. The reproductive rate shows that measures such as government lockdowns and isolation of individuals are not enough to stop the pandemic. This study recommends that authorities should, as soon as possible, apply a strict long-term containment strategy to reduce the epidemic size successfully.
C1 [Alanazi, Saad Awadh; Kamruzzaman, M. M.; Alshammari, Nasser] Jouf Univ, Coll Comp & Informat Sci, Dept Comp Sci, Sakakah, Saudi Arabia.
   [Alruwaili, Madallah] Jouf Univ, Coll Comp & Informat Sci, Dept Comp Engn & Networks, Sakakah, Saudi Arabia.
   [Alqahtani, Salman Ali] King Saud Univ, Coll Comp & Informat Sci, Dept Comp Engn, POB 51178, Riyadh 11543, Saudi Arabia.
   [Karime, Ali] Royal Mil Coll Canada, Dept Elect & Comp Engn, Kingston, ON, Canada.
RP Kamruzzaman, MM (corresponding author), Jouf Univ, Coll Comp & Informat Sci, Dept Comp Sci, Sakakah, Saudi Arabia.
EM sanazi@ju.edu.sa; mmkamruzzaman@ju.edu.sa; madallah@ju.edu.sa;
   nashamri@ju.edu.sa; salmanq@ksu.edu.sa; ali.karime@rmc-cmr.ca
OI Kamruzzaman, M.M./0000-0001-8464-1523
FU Deanship of Scientific Research at Jouf University [CV-14-41]
FX The authors extend their appreciation to the Deanship of Scientific
   Research at Jouf University for funding this work through research grant
   no. CV-14-41.
CR Abd EL-Latif AA, 2020, OPT LASER TECHNOL, V124, DOI 10.1016/j.optlastec.2019.105942
   Abd El-Latif AA, 2018, IEEE ACCESS, V6, P10332, DOI 10.1109/ACCESS.2018.2799879
   Abdulsalam Y., 2020, IEEE T NETW SCI ENG, DOI [10.1109/TNSE.2020.3026637, DOI 10.1109/TNSE.2020.3026637]
   Abou-Nassar EM, 2020, IEEE ACCESS, V8, P111223, DOI 10.1109/ACCESS.2020.2999468
   Alhussein M, 2018, MOBILE NETW APPL, V23, P1624, DOI 10.1007/s11036-018-1113-0
   [Anonymous], 2020, POPULATION PYRAMIDS
   [Anonymous], 2020, 40JHU CSSE COVID 19
   Balkew T. M., 2010, THESIS
   Chamola V, 2020, IEEE ACCESS, V8, P90225, DOI 10.1109/ACCESS.2020.2992341
   Chen M, 2020, INFORM FUSION, V64, P252, DOI 10.1016/j.inffus.2020.08.002
   Chen M, 2018, IEEE COMMUN MAG, V56, P14, DOI 10.1109/MCOM.2018.1700571
   Chen NC, 2017, IEEE INT CONGR BIG, P1, DOI 10.1109/BigDataCongress.2017.10
   Chen Y, 2020, MECH TIME-DEPEND MAT, DOI 10.1007/s11043-020-09460-2
   CovsirPhy, 2020, COVSIRPHY
   Durbin R P, 1975, Am J Physiol, V229, P1726
   Fang Q, 2015, IEEE T MULTIMEDIA, V17, P1031, DOI 10.1109/TMM.2015.2430819
   He S, 2020, MATH BIOSCI ENG, V17, P2792, DOI 10.3934/mbe.2020153
   Hethcote HW, 2000, SIAM REV, V42, P599, DOI 10.1137/S0036144500371907
   Hossain MS, 2020, IEEE NETWORK, V34, P126, DOI 10.1109/MNET.011.2000458
   Hossain MS, 2019, ACM T MULTIM COMPUT, V15, DOI 10.1145/3241056
   Hossain MS, 2019, INFORM FUSION, V49, P69, DOI 10.1016/j.inffus.2018.09.008
   Hossain MS, 2018, IEEE INTERNET THINGS, V5, P2399, DOI 10.1109/JIOT.2017.2772959
   Hossain MS, 2019, MULTIMEDIA SYST, V25, P565, DOI 10.1007/s00530-017-0561-x
   Hossain MS, 2017, IEEE SYST J, V11, P118, DOI 10.1109/JSYST.2015.2470644
   Hossain MS, 2014, INT J DISTRIB SENS N, DOI 10.1155/2014/858712
   Hu L, 2015, IEEE WIREL COMMUN, V22, P67, DOI 10.1109/MWC.2015.7368826
   Jia WP, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00169
   Jo H., 2020, ANAL COVID 19 SPREAD, DOI [10.1101/2020.04.13.20063412, DOI 10.1101/2020.04.13.20063412]
   Kamruzzaman MM, 2020, WIREL COMMUN MOB COM, V2020, DOI 10.1155/2020/3685614
   Kamruzzaman M. M., 2020, P IEEE INT C MULT EX, P1, DOI [10.1109/ICMEW46912.2020.9106026, DOI 10.1109/ICMEW46912.2020.9106026]
   Laamarti F, 2020, IEEE ACCESS, V8, P105950, DOI 10.1109/ACCESS.2020.2999871
   Liang R., 2019, ACTA MICROSCOPICA, V28
   Miao Y, 2019, ACM T MULTIM COMPUT, V15, DOI 10.1145/3311747
   Muhammad G, 2011, BIOMED ENG ONLINE, V10, DOI 10.1186/1475-925X-10-41
   Ndiaye B., 2020, COMP PREDICTION CONF
   Rahman MA, 2020, IEEE NETWORK, V34, P98, DOI 10.1109/MNET.011.2000353
   Sedik A, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12070769
   Tsafack N, 2020, IEEE ACCESS, V8, P137731, DOI 10.1109/ACCESS.2020.3010794
   Yang ZF, 2020, J THORAC DIS, V12, P165, DOI 10.21037/jtd.2020.02.64
   Yin Pei, 2019, Revista Cientifica, Facultad de Ciencias Veterinarias, Universidad del Zulia, V29, P188
   Zhang Y, 2018, J NETW COMPUT APPL, V117, P10, DOI 10.1016/j.jnca.2018.05.007
NR 41
TC 0
Z9 0
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2040-2295
EI 2040-2309
J9 J HEALTHC ENG
JI J. Healthc. Eng.
PD NOV 2
PY 2020
VL 2020
AR 8857346
DI 10.1155/2020/8857346
PG 12
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA OY6BZ
UT WOS:000594331300001
PM 33204404
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wang, SB
   Li, WY
   Hui, H
   Tiwari, SK
   Zhang, Q
   Croker, B
   Rawlings, S
   Smith, D
   Carlin, AF
   Rana, TM
AF Wang, Shaobo
   Li, Wanyu
   Hui, Hui
   Tiwari, Shashi Kant
   Zhang, Qiong
   Croker, Ben A.
   Rawlings, Stephen
   Smith, Davey
   Carlin, Aaron F.
   Rana, Tariq M.
TI Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses
   by depleting membrane cholesterol
SO EMBO JOURNAL
LA English
DT Article
DE cholesterol 25&#8208; hydroxylase; COVID&#8208; 19 treatment; innate
   immunity; restriction factor of coronaviruses; viral fusion
ID INTERFERONS; PROTEIN; ENTRY
AB Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2 and has spread across the globe. SARS-CoV-2 is a highly infectious virus with no vaccine or antiviral therapy available to control the pandemic; therefore, it is crucial to understand the mechanisms of viral pathogenesis and the host immune responses to SARS-CoV-2. SARS-CoV-2 is a new member of the betacoronavirus genus like other closely related viruses including SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV). Both SARS-CoV and MERS-CoV have caused serious outbreaks and epidemics in the past eighteen years. Here, we report that one of the interferon-stimulated genes (ISGs), cholesterol 25-hydroxylase (CH25H), is induced by SARS-CoV-2 infection in vitro and in COVID-19-infected patients. CH25H converts cholesterol to 25-hydrocholesterol (25HC) and 25HC shows broad anti-coronavirus activity by blocking membrane fusion. Furthermore, 25HC inhibits USA-WA1/2020 SARS-CoV-2 infection in lung epithelial cells and viral entry in human lung organoids. Mechanistically, 25HC inhibits viral membrane fusion by activating the ER-localized acyl-CoA:cholesterol acyltransferase (ACAT) which leads to the depletion of accessible cholesterol from the plasma membrane. Altogether, our results shed light on a potentially broad antiviral mechanism by 25HC through depleting accessible cholesterol on the plasma membrane to suppress virus-cell fusion. Since 25HC is a natural product with no known toxicity at effective concentrations, it provides a potential therapeutic candidate for COVID-19 and emerging viral diseases in the future.
C1 [Wang, Shaobo; Li, Wanyu; Hui, Hui; Tiwari, Shashi Kant; Zhang, Qiong; Rana, Tariq M.] Univ Calif San Diego, Program Immunol, Inst Genom Med, Div Genet,Dept Pediat, La Jolla, CA 92093 USA.
   [Li, Wanyu; Hui, Hui] Univ Calif San Diego, Dept Biol, La Jolla, CA USA.
   [Hui, Hui] Univ Calif San Diego, Bioinformat Program, La Jolla, CA 92093 USA.
   [Croker, Ben A.] Univ Calif San Diego, Dept Pediat, Div Allergy Immunol & Rheumatol, La Jolla, CA 92093 USA.
   [Rawlings, Stephen; Smith, Davey; Carlin, Aaron F.] Univ Calif San Diego, Dept Med, Div Infect Dis & Global Publ Hlth, La Jolla, CA USA.
RP Rana, TM (corresponding author), Univ Calif San Diego, Program Immunol, Inst Genom Med, Div Genet,Dept Pediat, La Jolla, CA 92093 USA.
EM trana@ucsd.edu
FU Centers for Disease Control and Prevention and obtained through BEI
   Resources, NIAID, NIH [USAWA1/2020, NR-52281]; Career Award for Medical
   Scientists from the Burroughs Wellcome FundBurroughs Wellcome Fund; John
   and Mary Tu Foundation; National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [CA177322, DA039562, DA049524, AI125103]
FX We thank Arun Radhakrishnan and Kristen Johnson from UT Southwestern
   Medical Center for their advice on ALOD4 purification. We thank members
   of the Rana laboratory for helpful discussions and advice. The following
   reagent was deposited by the Centers for Disease Control and Prevention
   and obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus
   2, Isolate USAWA1/2020, NR-52281. This work was supported by a Career
   Award for Medical Scientists from the Burroughs Wellcome Fund to AFC,
   John and Mary Tu Foundation, and in part by grants from the National
   Institutes of Health (CA177322, DA039562, DA049524, and AI125103).
CR Abrams ME, 2020, NAT MICROBIOL, V5, P929, DOI 10.1038/s41564-020-0701-5
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Castiglione V, 2020, EUR HEART J-CARD PHA, V6, P258, DOI 10.1093/ehjcvp/pvaa042
   Chazal N, 2003, MICROBIOL MOL BIOL R, V67, P226, DOI 10.1128/MMBR.67.2.226-237.2003
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Daamen AR, 2020, PREPRINT, DOI [10.1101/2020.05.28.121889, DOI 10.1101/2020.05.28.121889]
   Das A, 2014, INTERACT J MED RES, V3, P65, DOI 10.2196/ijmr.2847
   Dashti-Khavidaki S, 2020, PHARMACOTHERAPY, V40, P484, DOI 10.1002/phar.2397
   de Weerd NA, 2012, IMMUNOL CELL BIOL, V90, P483, DOI 10.1038/icb.2012.9
   Dong DS, 2020, LIGHT-SCI APPL, V9, DOI 10.1038/s41377-020-0249-4
   Du XM, 2004, J BIOL CHEM, V279, P47010, DOI 10.1074/jbc.M408690200
   Endapally Shreya, 2019, Methods Mol Biol, V1949, P153, DOI 10.1007/978-1-4939-9136-5_12
   Osuna-Ramos JF, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00388
   Fukushi S, 2005, J GEN VIROL, V86, P2269, DOI 10.1099/vir.0.80955-0
   Gay A, 2015, BIOPHYS J, V108, P1459, DOI 10.1016/j.bpj.2015.02.008
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann MS, 2020, LEARN INDIVID DIFFER, V78, DOI 10.1016/j.lindif.2019.101817
   Leibel SL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49696-8
   Li CF, 2017, IMMUNITY, V46, P446, DOI 10.1016/j.immuni.2017.02.012
   Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9
   Liu SY, 2013, IMMUNITY, V38, P92, DOI 10.1016/j.immuni.2012.11.005
   Lund EG, 1998, J BIOL CHEM, V273, P34316, DOI 10.1074/jbc.273.51.34316
   Mantlo E, 2020, ANTIVIR RES, V179, DOI 10.1016/j.antiviral.2020.104811
   Meng Z., 2020, EXPT TRIAL RECOMBINA, DOI [10.1101/2020.04.11.20061473., DOI 10.1101/2020.04.11.20061473, 10.1101/2020.04.11.20061473]
   Miller AJ, 2019, NAT PROTOC, V14, P518, DOI 10.1038/s41596-018-0104-8
   Park A, 2020, CELL HOST MICROBE, V27, P870, DOI 10.1016/j.chom.2020.05.008
   Schneider WM, 2014, ANNU REV IMMUNOL, V32, P513, DOI 10.1146/annurev-immunol-032713-120231
   Shin YH, 2017, HEART VESSELS, V32, P618, DOI 10.1007/s00380-016-0936-5
   Spann NJ, 2013, NAT IMMUNOL, V14, P893, DOI 10.1038/ni.2681
   Sun JM, 2020, TRENDS MOL MED, V26, P483, DOI 10.1016/j.molmed.2020.02.008
   Tikoo K, 2015, BIOCHEM PHARMACOL, V93, P343, DOI 10.1016/j.bcp.2014.11.013
   Whitt MA, 2010, J VIROL METHODS, V169, P365, DOI 10.1016/j.jviromet.2010.08.006
   Yang ST, 2016, CHEM PHYS LIPIDS, V199, P136, DOI 10.1016/j.chemphyslip.2016.05.003
   Yang ST, 2015, NAT CHEM BIOL, V11, P424, DOI [10.1038/NCHEMBIO.1800, 10.1038/nchembio.1800]
   Zang RC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc3582
   Zhang XJ, 2020, CELL METAB, V32, P176, DOI 10.1016/j.cmet.2020.06.015
   Zhou Q, 2020, INTERFERON A2B TREAT, DOI [10.1101/2020.04.06.20042580, DOI 10.1101/2020.04.06.20042580]
NR 38
TC 1
Z9 1
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
PD NOV 2
PY 2020
VL 39
IS 21
AR e106057
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA OP5OX
UT WOS:000588137100014
PM 32944968
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Lee, PY
   Day-Lewis, M
   Henderson, LA
   Friedman, KG
   Lo, J
   Roberts, JE
   Lo, MS
   Platt, CD
   Chou, J
   Hoyt, KJ
   Baker, AL
   Banzon, TM
   Chang, MH
   Cohen, E
   de Ferranti, SD
   Dionne, A
   Habiballah, S
   Halyabar, O
   Hausmann, JS
   Hazen, MM
   Janssen, E
   Meidan, E
   Nelson, RW
   Nguyen, AA
   Sundel, RP
   Dedeoglu, F
   Nigrovic, PA
   Newburger, JW
   Son, MBF
AF Lee, Pui Y.
   Day-Lewis, Megan
   Henderson, Lauren A.
   Friedman, Kevin G.
   Lo, Jeffrey
   Roberts, Jordan E.
   Lo, Mindy S.
   Platt, Craig D.
   Chou, Janet
   Hoyt, Kacie J.
   Baker, Annette L.
   Banzon, Tina M.
   Chang, Margaret H.
   Cohen, Ezra
   de Ferranti, Sarah D.
   Dionne, Audrey
   Habiballah, Saddiq
   Halyabar, Olha
   Hausmann, Jonathan S.
   Hazen, Melissa M.
   Janssen, Erin
   Meidan, Esra
   Nelson, Ryan W.
   Nguyen, Alan A.
   Sundel, Robert P.
   Dedeoglu, Fatma
   Nigrovic, Peter A.
   Newburger, Jane W.
   Son, Mary Beth F.
TI Distinct clinical and immunological features of SARS-CoV-2-induced
   multisystem inflammatory syndrome in children
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID JUVENILE IDIOPATHIC ARTHRITIS; KAWASAKI-DISEASE; COVID-19; MYOCARDITIS;
   BLOCKADE; ANAKINRA
AB BACKGROUND. Pediatric SARS-CoV-2 infection can be complicated by a dangerous hyperinflammatory condition termed multisystem inflammatory syndrome in children (MIS-C). The clinical and immunologic spectrum of MIS-C and its relationship to other inflammatory conditions of childhood have not been studied in detail.
   METHODS. We retrospectively studied confirmed cases of MIS-C at our institution from March to June 2020. The clinical characteristics, laboratory studies, and treatment response were collected. Data were compared with historic cohorts of Kawasaki disease (KO) and macrophage activation syndrome (MAS).
   RESULTS. Twenty-eight patients fulfilled the case definition of MIS-C. Median age at presentation was 9 years (range: 1 month to 17 years); 50% of patients had preexisting conditions. All patients had laboratory confirmation of SARS-CoV-2 infection. Seventeen patients (61%) required intensive care, including 7 patients (25%) who required inotrope support. Seven patients (25%) met criteria for complete or incomplete KO, and coronary abnormalities were found in 6 cases. Lymphopenia, thrombocytopenia, and elevation in inflammatory markers, D-dimer, B-type natriuretic peptide, IL-6, and IL-10 levels were common but not ubiquitous. Cytopenias distinguished MIS-C from KO and the degree of hyperferritinemia and pattern of cytokine production differed between MIS-C and MAS. Immunomodulatory therapy given to patients with MIS-C included intravenous immune globulin (IVIG) (71%), corticosteroids (61%), and anakinra (18%). Clinical and laboratory improvement were observed in all cases, including 6 cases that did not require immunomodulatory therapy. No mortality was recorded in this cohort.
   CONCLUSION. MIS-C encompasses a broad phenotypic spectrum with clinical and laboratory features distinct from KO and MAS.
C1 [Lee, Pui Y.; Day-Lewis, Megan; Henderson, Lauren A.; Lo, Jeffrey; Roberts, Jordan E.; Lo, Mindy S.; Platt, Craig D.; Chou, Janet; Hoyt, Kacie J.; Banzon, Tina M.; Chang, Margaret H.; Cohen, Ezra; Habiballah, Saddiq; Halyabar, Olha; Hausmann, Jonathan S.; Hazen, Melissa M.; Janssen, Erin; Meidan, Esra; Nelson, Ryan W.; Nguyen, Alan A.; Sundel, Robert P.; Dedeoglu, Fatma; Nigrovic, Peter A.; Son, Mary Beth F.] Harvard Med Sch, Div Immunol, Boston, MA USA.
   [Friedman, Kevin G.; Baker, Annette L.; de Ferranti, Sarah D.; Dionne, Audrey; Newburger, Jane W.] Boston Childrens Hosp, Harvard Med Sch, Dept Cardiol, Boston, MA USA.
   [Cohen, Ezra] Boston Med Ctr, Div Pediat Rheumatol, Dept Pediat, Boston, MA USA.
   [Hausmann, Jonathan S.] Beth Israel Deaconess Med Ctr, Div Rheumatol & Clin Immunol, Boston, MA USA.
   [Nigrovic, Peter A.] Brigham & Womens Hosp, Div Rheumatol Inflammat & Immun, Boston, MA USA.
RP Lee, PY; Son, MBF (corresponding author), Boston Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.
EM pui.lee@childrens.harvard.edu; marybeth.son@childrens.harvard.edu
OI Nguyen, Alan/0000-0003-3560-3605; Habiballah,
   Saddiq/0000-0003-3796-9328; Roberts, Jordan/0000-0002-0976-5697
FU National Institutes of Health, National Institute of Arthritis and
   Musculoskeletal and Skin DiseasesUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)
   [K08-AR074562, K08-AR073339, R01-AR065538, R01-AR073201, P30-AR070253];
   National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [5T32AI007512-34]; Rheumatology Research Foundation; Boston Childrens
   Hospital Faculty Career Development Awards; McCance Family Foundation;
   Samara Jan Turkel Center
FX We thank the frontline staff at Boston Childrens Hospital for their
   dedication and excellent patient care. We thank the MAS Collaborative
   for helpful discussions. This work was supported by the National
   Institutes of Health, National Institute of Arthritis and
   Musculoskeletal and Skin Diseases K08-AR074562 (to PYL), K08-AR073339
   (to LAH), R01-AR065538, R01-AR073201, and P30-AR070253 (to PAN); the
   National Institute of Allergy and Infectious Diseases 5T32AI007512-34
   (to JL, JR, TB, AAN, and RWN); Rheumatology Research Foundation
   Investigator Awards (to PYL and LAH), and Medical Education Award (to
   JSH); Boston Childrens Hospital Faculty Career Development Awards (to
   PYL and LAH); the McCance Family Foundation (to JWN); and the Samara Jan
   Turkel Center (to JC, RPS, MBFS).
CR Aouba A, 2020, ANN RHEUM DIS, V79, P1381, DOI 10.1136/annrheumdis-2020-217706
   Belhadjer Z, 2020, CIRCULATION, V142, P429, DOI 10.1161/CIRCULATIONAHA.120.048360
   Blondiaux E, 2020, RADIOLOGY, V297, pE283, DOI 10.1148/radiol.2020202288
   Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2
   Cavalli G, 2016, CRIT CARE MED, V44, pE751, DOI 10.1097/CCM.0000000000001654
   CDC, MULT INFL SYNDR DISC
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen ZG, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.141514
   Cheung EW, 2020, JAMA-J AM MED ASSOC, V324, P294, DOI 10.1001/jama.2020.10374
   Chiotos K, 2020, J PEDIAT INF DIS SOC, V9, P393, DOI 10.1093/jpids/piaa069
   Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2
   Cohen S, 2012, ANN RHEUM DIS, V71, P2059, DOI 10.1136/annrheumdis-2012-201658
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   DRUCKER NA, 1994, CIRCULATION, V89, P252, DOI 10.1161/01.CIR.89.1.252
   Dufort EM, 2020, NEW ENGL J MED, V383, P347, DOI 10.1056/NEJMoa2021756
   Feldstein LR, 2020, NEW ENGL J MED, V383, P334, DOI 10.1056/NEJMoa2021680
   Grimaud M, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00690-8
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Henderson LA, 2020, ARTHRITIS RHEUMATOL, V72, P1059, DOI 10.1002/art.41285
   Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039
   Herold T, 2020, J ALLERGY CLIN IMMUN, V146, P128, DOI 10.1016/j.jaci.2020.05.008
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lee PY, 2020, ANN RHEUM DIS, V79, P225, DOI 10.1136/annrheumdis-2019-216030
   Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   McCrindle BW, 2017, CIRCULATION, V135, pE927, DOI 10.1161/CIR.0000000000000484
   Petty RE, 2004, J RHEUMATOL, V31, P390
   Pontali E, 2020, J ALLERGY CLIN IMMUN, V146, P213, DOI 10.1016/j.jaci.2020.05.002
   Put K, 2015, RHEUMATOLOGY, V54, P1507, DOI 10.1093/rheumatology/keu524
   Ravelli A, 2016, ARTHRITIS RHEUMATOL, V68, P566, DOI 10.1002/art.39332
   Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]
   Royal College of Paediatrics and Child Health, GUID PAED MULT INFL
   Shekerdemian LS, 2020, JAMA PEDIATR, V174, P868, DOI 10.1001/jamapediatrics.2020.1948
   Strouse JJ, 2008, PEDIATR BLOOD CANCER, V50, P1006, DOI 10.1002/pbc.21336
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Toubiana J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2094
   United States Census Bureau, QUICKFACTS BOST MASS
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Wadhera RK, 2020, JAMA-J AM MED ASSOC, V323, P2192, DOI 10.1001/jama.2020.7197
   Webb Hooper M, 2020, JAMA-J AM MED ASSOC, V323, P2466, DOI 10.1001/jama.2020.8598
   Whittaker E, 2020, JAMA-J AM MED ASSOC, V324, P259, DOI 10.1001/jama.2020.10369
   World Health Organization, MULT INFL SYNDR CHIL
   Ye Q, 2015, ARTHRITIS RHEUMATOL, V67, P1943, DOI 10.1002/art.39112
NR 43
TC 10
Z9 10
U1 2
U2 2
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD NOV 2
PY 2020
VL 130
IS 11
BP 5942
EP 5950
DI 10.1172/JCI141113
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OO5JD
UT WOS:000587413700031
PM 32701511
OA Bronze
DA 2021-01-01
ER

PT J
AU Ali, S
   Luxmi, S
   Anjum, F
   Muhaymin, SM
   Uddin, SM
   Ali, A
   Ali, MR
   Tauheed, S
   Khan, M
   Bajwa, M
   Baig, SU
   Shalim, E
   Ahmed, I
   Khan, AS
   Quraishy, S
AF Ali, Shaukat
   Luxmi, Shobha
   Anjum, Fatima
   Muhaymin, Sheikh Muhammad
   Uddin, Syed Muneeb
   Ali, Ayesha
   Ali, Mir Rashid
   Tauheed, Sohaib
   Khan, Mujtaba
   Bajwa, Mohsin
   Baig, Saif Ullah
   Shalim, Elisha
   Ahmed, Iqra
   Khan, Abdul Samad
   Quraishy, Saeed
TI Hyperimmune anti-COVID-19 IVIG (C-IVIG) Therapy for Passive Immunization
   of Severe and Critically Ill COVID-19 Patients: A structured summary of
   a study protocol for a randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; passive immunization;
   anti-COVID19 IVIG; single dose; C-IVIG; convalescent plasma
AB Objectives: The aim of this trial is to investigate the safety and clinical efficacy of passive immunization therapy through Hyperimmune anti-COVID-19 Intravenous Immunoglobulin (C-IVIG: 5% liquid formulation), on severe and critically ill patients with COVID-19.
   Trial design: This is a phase I/II single centre, randomised controlled, single-blinded, superiority trial, through parallel-group design with sequential assignment. Participants will be randomised either to receive both C-IVIG and standard care or only standard care (4:1).
   Participants: The study is mono-centric with the participants including COVID19 infected individuals (positive SARS-CoV-2 PCR on nasopharyngeal and/or oropharyngeal swabs) admitted in institute affiliated with Dow University Hospital, Dow University of Health Sciences, Karachi, Pakistan. Consenting patients above 18 years that are classified by the treating physician as severely ill i.e. showing symptoms of COVID-19 pneumonia; dyspnea, respiratory rate >= 30/min, blood oxygen saturation <= 93%, PaO2/FiO(2) <300, and lung infiltrates >50% on CXR; or critically ill i.e. respiratory failure, septic shock, and multiple organ dysfunction or failure. Patients with reported IgA deficiency, autoimmune disorder, thromboembolic disorder, and allergic reaction to immunoglobulin treatment were excluded from study. Similarly, pregnant females, patients requiring two or more inotropic agents to maintain blood pressure and patients with acute or chronic kidney injury/failure, were also excluded from the study.
   Intervention and comparator: The study consists of four interventions and one comparator arm. All participants receive standard hospital care which includes airway support, anti-viral medication, antibiotics, fluid resuscitation, hemodynamic support, steroids, painkillers, and anti-pyretics. Randomised test patients will receive single dose of C-IVIG in following four dosage groups:
   Group 1: 0.15g/Kg with standard hospital care Group 2: 0.2g/Kg with standard hospital care Group 3: 0.25g/Kg with standard hospital care Group 4: 0.3g/Kg with standard hospital care Group 5 (comparator) will receive standard hospital care only
   Main outcomes: The primary outcomes are assessment and follow-up of participants to observe 28-day mortality and,
   center dot the level and duration of assisted ventilation during hospital stay,
   center dot number of days to step down (shifting from ICU to isolation ward),
   center dot number of days to hospital discharge,
   center dot adverse events (Kidney failure, hypersensitivity with cutaneous or hemodynamic manifestations, aseptic meningitis, hemolytic anemia, leuko-neutropenia, transfusion related acute lung injury (TRALI)) during hospital stay,
   center dot change in C-Reactive Protein (CRP) levels,
   center dot change in neutrophil lymphocyte ratio to monitor inflammation.
   Randomisation: Consenting participants who fulfill the criteria are allocated to either intervention or comparator arm with a ratio of 4:1, using sequentially numbered opaque sealed envelope simple randomization method. The participant allocated for intervention will be sequentially assigned dosage group 1-4 in ascending order. Participants will not be recruited in the next dosage group before a set number of participants in one group (10) are achieved.
   Blinding (masking): Single blinded study, with participants blinded to allocation.
   Numbers to be randomised (sample size): Total 50 patients are randomised. The intervention arms consist of 40 participants divided in four groups of 10 participants while the comparator group consists of 10 patients.
   Trial Status: Current version of the protocol is "Version 2" dated 29(th) September, 2020. Participants are being recruited. Recruitment started on June, 2020 and is estimated to primarily end on January, 2021.
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1).
C1 [Ali, Shaukat; Muhaymin, Sheikh Muhammad; Uddin, Syed Muneeb; Ali, Ayesha; Ali, Mir Rashid; Khan, Mujtaba; Shalim, Elisha; Ahmed, Iqra] Dow Univ Hlth Sci, Dow Coll Biotechnol, Karachi, Pakistan.
   [Luxmi, Shobha; Bajwa, Mohsin; Baig, Saif Ullah] Dow Univ Hlth Sci, Dow Univ Hosp, Karachi, Pakistan.
   [Anjum, Fatima] Dow Univ Hlth Sci, Dow Res Inst Biotechnol & Biomed Sci, Karachi, Pakistan.
   [Tauheed, Sohaib] Dow Univ Hlth Sci, Dow Int Med Coll, Karachi, Pakistan.
   [Khan, Abdul Samad] Natl Control Lab Biol, Islamabad, Pakistan.
   [Quraishy, Saeed] Dow Univ Hlth Sci, Karachi, Pakistan.
RP Ali, S (corresponding author), Dow Univ Hlth Sci, Dow Coll Biotechnol, Karachi, Pakistan.
EM ali.shaukat@duhs.edu.pk
FU Higher Education Commission (HEC), PakistanHigher Education Commission
   of Pakistan
FX Higher Education Commission (HEC), Pakistan, will be funding the study.
   HEC has no role in the design of the study and collection, analysis, and
   interpretation of data and in writing the manuscript.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD NOV 2
PY 2020
VL 21
IS 1
AR 905
DI 10.1186/s13063-020-04839-5
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OP7SL
UT WOS:000588286800001
PM 33138867
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Carrouel, F
   Viennot, S
   Valette, M
   Cohen, JM
   Dussart, C
   Bourgeois, D
AF Carrouel, Florence
   Viennot, Stephane
   Valette, Martine
   Cohen, Jean-Marie
   Dussart, Claude
   Bourgeois, Denis
TI Salivary and Nasal Detection of the SARS-CoV-2 Virus After Antiviral
   Mouthrinses (BBCovid): A structured summary of a study protocol for a
   randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; mouthwash;
   beta-cyclodextrin; citrox (R); salivary and real-time PCR
AB Objectives: - To describe the evolution of the SARS-CoV-2 salivary viral load of patients infected with Covid-19, performing 7 days of tri-daily mouthwashes with and without antivirals.
   - To compare the evolution of the SARS-CoV-2 nasal and salivary viral load according to the presence or absence of antivirals in the mouthwash.
   Trial design: This is a multi-center, randomised controlled trial (RCT) with two parallel arms (1:1 ratio).
   Participants: Inclusion criteria - Age: 18-85 years old
   - Clinical diagnosis of Covid-19 infection
   - Clinical signs have been present for less than 8 days
   - Virological confirmation
   - Understanding and acceptance of the trial
   - Written agreement to participate in the trial
   Exclusion criteria
   - Pregnancy, breastfeeding, inability to comply with protocol, lack of written agreement - Patients using mouthwash on a regular basis (more than once a week)
   - Patient at risk of infectious endocarditis
   - Patients unable to answer questions
   - Uncooperative patient
   The clinical trial is being conducted with the collaboration of three French hospital centers: Hospital Center Emile Roux (Le Puy en Velay, France), Clinic of the Protestant Infirmary (Lyon, France) and Intercommunal Hospital Center (Mont de Marsan, France).
   Intervention and comparator: Eligible participants will be allocated to one of the two study groups. Intervention group: patients perform a tri-daily mouthwash with mouthwash containing antivirals (beta-cyclodextrin and Citrox (R)) for a period of 7 days. Control group: patients perform a tri-daily mouthwash with a placebo mouthwash for a period of 7 days.
   Main outcomes: Primary Outcome Measures: Change from Baseline amount of SARS-CoV-2 in salivary samples at 4 and 9 hours, 1, 2, 3, 4, 5 and 6 days. Real-time PCR assays are performed to assess salivary SARS-CoV 2 viral load.
   Secondary Outcome Measures: Change from Baseline amount of SARS-CoV-2 virus in nasal samples at 6 days. Real-time PCR assays are performed to assess nasal SARS-CoV-2 viral load.
   Randomisation: Participants meeting all eligibility requirements are allocated to one of the two study arms (mouthwash with beta-cyclodextrin and Citrox (R) or mouthwash without beta-cyclodextrin and Citrox (R)) in a 1:1 ratio using simple randomisation with computer generated random numbers.
   Blinding (masking): Participants, doctors and nurses caring for participants, laboratory technicians and investigators assessing the outcomes will be blinded to group assignment.
   Numbers to be randomised (sample size): Both the intervention and control groups will be composed of 103 participants, so the study will include a total of 206 participants.
   Trial Status: The current protocol version is 6, August 4(th), 2020. Recruitment began on April 6, 2020 and is anticipated to be complete by April 5, 2021.
   As of October 2, 2020, forty-two participants have been included.
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol." The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2)."
C1 [Carrouel, Florence; Viennot, Stephane; Dussart, Claude; Bourgeois, Denis] Univ Claude Bernard Lyon 1, Univ Lyon, Lab Syst Hlth Care, EA4129, Lyon, France.
   [Valette, Martine] North Hosp Network, Infect Agents Inst, Dept Virol, Natl Reference Ctr Resp Viruses, Lyon, France.
   [Cohen, Jean-Marie] Open Rome Organize & Promote Epidemiol Network, Paris, France.
RP Carrouel, F (corresponding author), Univ Claude Bernard Lyon 1, Univ Lyon, Lab Syst Hlth Care, EA4129, Lyon, France.
EM florence.carrouel@univ-lyon1.fr
RI Carrouel, F/X-4952-2019; Bourgeois, Denis/ABI-3060-2020
OI Carrouel, F/0000-0002-6823-1636; Bourgeois, Denis/0000-0003-4754-2512
FU Laboratory "Systemic Health Care", University of Lyon, France
FX The funds for the study were provided by the Laboratory "Systemic Health
   Care", EA4129, University of Lyon, France.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD NOV 2
PY 2020
VL 21
IS 1
AR 906
DI 10.1186/s13063-020-04846-6
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OP7SL
UT WOS:000588286800002
PM 33138848
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bosnjak, B
   Stein, SC
   Willenzon, S
   Cordes, AK
   Puppe, W
   Bernhardt, G
   Ravens, I
   Ritter, C
   Schultze-Florey, CR
   Godecke, N
   Martens, J
   Kleine-Weber, H
   Hoffmann, M
   Cossmann, A
   Yilmaz, M
   Pink, I
   Hoeper, MM
   Behrens, GMN
   Pohlmann, S
   Blasczyk, R
   Schulz, TF
   Forster, R
AF Bosnjak, Berislav
   Stein, Saskia Catherina
   Willenzon, Stefanie
   Cordes, Anne Katrin
   Puppe, Wolfram
   Bernhardt, Guenter
   Ravens, Inga
   Ritter, Christiane
   Schultze-Florey, Christian R.
   Goedecke, Nina
   Martens, Joerg
   Kleine-Weber, Hannah
   Hoffmann, Markus
   Cossmann, Anne
   Yilmaz, Mustafa
   Pink, Isabelle
   Hoeper, Marius M.
   Behrens, Georg M. N.
   Poehlmann, Stefan
   Blasczyk, Rainer
   Schulz, Thomas F.
   Foerster, Reinhold
TI Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly
   affected COVID-19 convalescent patients revealed by two different
   detection methods
SO CELLULAR & MOLECULAR IMMUNOLOGY
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; Neutralizing antibody; Serum; ELISA
ID SARS-COV-2; RESPONSES
AB Neutralizing antibodies targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry into cells via surface-expressed angiotensin-converting enzyme 2 (ACE2). We used a surrogate virus neutralization test (sVNT) and SARS-CoV-2 S protein-pseudotyped vesicular stomatitis virus (VSV) vector-based neutralization assay (pVNT) to assess the degree to which serum antibodies from coronavirus disease 2019 (COVID-19) convalescent patients interfere with the binding of SARS-CoV-2 S to ACE2. Both tests revealed neutralizing anti-SARS-CoV-2 S antibodies in the sera of similar to 90% of mildly and 100% of severely affected COVID-19 convalescent patients. Importantly, sVNT and pVNT results correlated strongly with each other and to the levels of anti-SARS-CoV-2 S1 IgG and IgA antibodies. Moreover, levels of neutralizing antibodies correlated with the duration and severity of clinical symptoms but not with patient age. Compared to pVNT, sVNT is less sophisticated and does not require any biosafety labs. Since this assay is also much faster and cheaper, sVNT will not only be important for evaluating the prevalence of neutralizing antibodies in a population but also for identifying promising plasma donors for successful passive antibody therapy.
C1 [Bosnjak, Berislav; Willenzon, Stefanie; Bernhardt, Guenter; Ravens, Inga; Ritter, Christiane; Schultze-Florey, Christian R.; Foerster, Reinhold] Hannover Med Sch, Inst Immunol, Hannover, Germany.
   [Stein, Saskia Catherina; Cordes, Anne Katrin; Puppe, Wolfram; Schulz, Thomas F.] Hannover Med Sch, Inst Virol, Hannover, Germany.
   [Schultze-Florey, Christian R.] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany.
   [Goedecke, Nina; Martens, Joerg; Blasczyk, Rainer] Hannover Med Sch, Inst Transfus Med & Transplant Engn, Hannover, Germany.
   [Kleine-Weber, Hannah; Hoffmann, Markus; Poehlmann, Stefan] Leibniz Inst Primate Res, German Primate Ctr, Gottingen, Germany.
   [Kleine-Weber, Hannah; Hoffmann, Markus; Poehlmann, Stefan] Univ Gottingen, Fac Biol & Psychol, Gottingen, Germany.
   [Cossmann, Anne; Behrens, Georg M. N.] Hannover Med Sch, Dept Rheumatol & Immunol, Hannover, Germany.
   [Yilmaz, Mustafa] Dept Publ Hlth, Hannover, Germany.
   [Pink, Isabelle; Hoeper, Marius M.] Hannover Med Sch, Dept Pneumol, Hannover, Germany.
   [Pink, Isabelle; Hoeper, Marius M.] Hannover Med Sch, German Ctr Lung Res DZL, Hannover, Germany.
   [Schulz, Thomas F.] German Ctr Infect Res DZIF, Partner Site Hannover Braunschweig, Hannover, Germany.
   [Foerster, Reinhold] Hannover Med Sch, Cluster Excellence RESIST EXC 2155, Hannover, Germany.
RP Bosnjak, B; Forster, R (corresponding author), Hannover Med Sch, Inst Immunol, Hannover, Germany.; Forster, R (corresponding author), Hannover Med Sch, Cluster Excellence RESIST EXC 2155, Hannover, Germany.
EM bosnjak.berislav@mh-hannover.de; foerster.reinhold@mh-hannover.de
RI Bosnjak, Berislav/H-7370-2019; Bernhardt, Gunter/F-6946-2012
OI Bosnjak, Berislav/0000-0003-3374-7488; Bernhardt,
   Gunter/0000-0002-0510-2853
FU Deutsche Forschungsgemeinschaft, DFG Excellence StrategyGerman Research
   Foundation (DFG) [EXC 2155"RESIST", ID39087428]; state of Lower Saxony
   [14-76103-184 CORONA-11/20, 1476103-184 CORONA-12/20]; BMBFFederal
   Ministry of Education & Research (BMBF) [01K11723D]
FX We thank all study participants for providing us with the samples. This
   work was supported by Deutsche Forschungsgemeinschaft, DFG Excellence
   Strategy EXC 2155"RESIST" (Project ID39087428) and by funds of the state
   of Lower Saxony (14-76103-184 CORONA-11/20) to RF and (1476103-184
   CORONA-12/20) to TFS and by funds of BMBF (RAPID consortium, 01K11723D).
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Alshukairi AN, 2016, EMERG INFECT DIS, V22, P1113, DOI 10.3201/eid2206.160010
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9
   Brinkmann C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189073
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Hanika A, 2005, J GEN VIROL, V86, P1455, DOI 10.1099/vir.0.80788-0
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Hou YXJ, 2020, CELL, V182, P429, DOI 10.1016/j.cell.2020.05.042
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Lassauniere R, 2020, EVALUATION 9 COMMERC, DOI DOI 10.1101/2020.04.09.20056325V1
   Liu PP, 2020, CIRCULATION, V142, P68, DOI 10.1161/CIRCULATIONAHA.120.047549
   Liu W, 2006, J INFECT DIS, V193, P792, DOI 10.1086/500469
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Lou B, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.00763-2020
   Menter T, 2020, HISTOPATHOLOGY, V77, P198, DOI 10.1111/his.14134
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Odak I, 2020, EBIOMEDICINE, V57, DOI 10.1016/j.ebiom.2020.102885
   Ozcurumez MK, 2020, J ALLERGY CLIN IMMUN, V146, P35, DOI 10.1016/j.jaci.2020.05.020
   Oran DP, 2020, ANN INTERN MED, V173, P362, DOI 10.7326/M20-3012
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Petherick A, 2020, LANCET, V395, P1101, DOI 10.1016/S0140-6736(20)30788-1
   Premkumar L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc8413
   Procko E, 2020, PREPR SERV BIOL, V2, P21
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Spertini V, 2011, GMS HYG INFECT CONTR, V6
   Tan CW, 2020, NAT BIOTECHNOL, V38, P1073, DOI 10.1038/s41587-020-0631-z
   Tang F, 2011, J IMMUNOL, V186, P7264, DOI 10.4049/jimmunol.0903490
   TANNE JH, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1256
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wooding DJ, 2020, CLIN MICROBIOL INFEC, V26, P1436, DOI 10.1016/j.cmi.2020.08.005
   Wu F., 2020, NEUTRALIZING ANTIBOD, DOI [10.2139/ssrn.3566211, DOI 10.2139/SSRN.3566211]
   Wu LP, 2007, EMERG INFECT DIS, V13, P1562, DOI 10.3201/eid1310.070576
   Yi CY, 2020, CELL MOL IMMUNOL, V17, P621, DOI 10.1038/s41423-020-0458-z
   Zhang GX, 2020, J INFECT DIS, V222, P183, DOI 10.1093/infdis/jiaa229
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
   Zhu JY, 2020, J MED VIROL, V92, P1902, DOI 10.1002/jmv.25884
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 43
TC 0
Z9 0
U1 2
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1672-7681
EI 2042-0226
J9 CELL MOL IMMUNOL
JI Cell. Mol. Immunol.
DI 10.1038/s41423-020-00573-9
EA NOV 2020
PG 9
WC Immunology
SC Immunology
GA OM4ET
UT WOS:000585979900005
PM 33139905
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Gollapalli, P
   Sharath, BS
   Rimac, H
   Patil, P
   Nalilu, SK
   Kandagalla, S
   Shetty, P
AF Gollapalli, Pavan
   Sharath, B. S.
   Rimac, Hrvoje
   Patil, Prakash
   Nalilu, Suchetha Kumari
   Kandagalla, Shivanandha
   Shetty, Praveenkumar
TI Pathway enrichment analysis of virus-host interactome and prioritization
   of novel compounds targeting the spike glycoprotein receptor binding
   domain-human angiotensin-converting enzyme 2 interface to combat
   SARS-CoV-2
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; protein&#8211; protein interactions (PPIs); spike
   glycoprotein; virtual screening; molecular docking; molecular dynamics
ID MOLECULAR-DYNAMICS; PROTEIN; VISUALIZATION; CORONAVIRUS; PREDICTIONS;
   INHIBITOR; MECHANICS; DISCOVERY; BIOLOGY; SYSTEM
AB SARS-CoV-2 has become a pandemic causing a serious global health concern. The absence of effective drugs for treatment of the disease has caused its rapid spread on a global scale. Similarly to the SARS-CoV, the SARS-CoV-2 is also involved in a complex interplay with the host cells. This infection is characterized by a diffused alveolar damage consistent with the Acute Respiratory Disease Syndrome (ARDS). To explore the complex mechanisms of the disease at the system level, we used a network medicine tools approach. The protein-protein interactions (PPIs) between the SARS-CoV and the associated human cell proteins are crucial for the viral pathogenesis. Since the cellular entry of SARS-CoV-2 is accomplished by binding of the spike glycoprotein binding domain (RBD) to the human angiotensin-converting enzyme 2 (hACE2), a molecule that can bind to the spike RDB-hACE2 interface could block the virus entry. Here, we performed a virtual screening of 55 compounds to identify potential molecules that can bind to the spike glycoprotein and spike-ACE2 complex interface. It was found that the compound ethyl 1-{3-[(2,4-dichlorobenzyl) carbamoyl]-1-ethyl-6-fluoro-4-oxo-1,4-dihydro-7-quinolinyl}-4-piperidine carboxylate (the S54 ligand) and ethyl 1-{3-[(2,4-dichlorobenzyl) carbamoyl]-1-ethyl-6-fluoro-4-oxo-1,4-dihydro-7-quinolinyl}-4 piperazine carboxylate (the S55 ligand) forms hydrophobic interactions with Tyr41A, Tyr505B and Tyr553B, Leu29A, Phe495B, respectively of the spike glycoprotein, the hotspot residues in the spike glycoprotein RBD-hACE2 binding interface. Furthermore, molecular dynamics simulations and free energy calculations using the MM-GBSA method showed that the S54 ligand is a stronger binder than a known SARS-CoV spike inhibitor SSAA09E3 (N-(9,10-dioxo-9, 10-dihydroanthracen-2-yl) benzamide).
   Communicated by Ramaswamy H. Sarma
C1 [Gollapalli, Pavan; Patil, Prakash; Nalilu, Suchetha Kumari; Shetty, Praveenkumar] Nitte Deemed Univ, KS Hegde Med Acad, Cent Res Lab, Mangalore, India.
   [Sharath, B. S.] Kuvempu Univ, Dept Biotechnol & Bioinformat, Shankaraghatta, Shivamogga, India.
   [Rimac, Hrvoje] Univ Zagreb, Fac Pharm & Biochem, Dept Med Chem, Zagreb, Croatia.
   [Rimac, Hrvoje; Kandagalla, Shivanandha] South Ural State Univ, Higher Med & Biol Sch, Lab Computat Modelling Drugs, Chelyabinsk, Russia.
RP Shetty, P (corresponding author), Nitte Deemed Univ, KS Hegde Med Acad, Cent Res Lab, Mangalore, India.
EM praveenkumarshetty@nitte.edu.in
RI Rimac, Hrvoje/E-8383-2016
OI Rimac, Hrvoje/0000-0001-7232-6489; Patil, Prakash/0000-0002-1263-8517
CR ABDELLI I, 2020, J BIOMOL STRUCT 0513, DOI DOI HTTPS://DOI.ORG/10.1080/07391102.2020.1763199
   Adedeji AO, 2013, J VIROL, V87, P8017, DOI 10.1128/JVI.00998-13
   Albert R, 2002, REV MOD PHYS, V74, P47, DOI 10.1103/RevModPhys.74.47
   Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272
   BASIT A, 2020, J BIOMOL STRUCT 0519, DOI DOI https://doi.org/10.1080/07391102.2020.1768150
   Berman H. M., 2000, NUCL ACIDS RES, V28, pD235, DOI DOI HTTPS://DOI.ORG/10.1093/NAR/28.1.235
   Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101
   Case D. A., 2016, AMBER 2016 REFERENCE
   Cereto-Massague A, 2015, METHODS, V71, P58, DOI 10.1016/j.ymeth.2014.08.005
   COOK HV, 2018, VIRUSES BASEL, V10, DOI DOI https://doi.org/10.3390/v10100519
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Ferenczy G. G., 2015, THERMODYNAMICS KINET, P37
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Goddard TD, 2018, PROTEIN SCI, V27, P14, DOI 10.1002/pro.3235
   Gohlke H, 2003, J MOL BIOL, V330, P891, DOI 10.1016/S0022-2836(03)00610-7
   Hashem HMA, 2018, FUTURE MED CHEM, V10, P201, DOI 10.4155/fmc-2017-0126
   Homeyer N, 2012, MOL INFORM, V31, P114, DOI 10.1002/minf.201100135
   Hou TJ, 2011, J CHEM INF MODEL, V51, P69, DOI 10.1021/ci100275a
   JEANQUARTIER F, 2015, BMC BIOINFORMATICS, V16, DOI DOI https://doi.org/10.1186/s12859-015-0615-z
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Kortemme T., 2004, SCI STKE, P12, DOI DOI 10.1126/STKE.2192004PL2
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Laskowski RA, 2018, PROTEIN SCI, V27, P129, DOI 10.1002/pro.3289
   Liu C, 2020, PHYS REP, V846, P1, DOI 10.1016/j.physrep.2019.12.004
   Lupala C. S., 2020, COMPUTATIONAL ANAL A, DOI [10.1101/2020.05.03.075473, DOI 10.1101/2020.05.03.075473]
   Machado MR, 2020, J CHEM THEORY COMPUT, V16, P1367, DOI 10.1021/acs.jctc.9b00953
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Marzi A, 2004, J VIROL, V78, P12090, DOI 10.1128/JVI.78.21.12090-12095.2004
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Matsuyama Y, 2018, LECT NOTES COMPUT SC, V10955, P279, DOI 10.1007/978-3-319-95933-7_35
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Niedermeier S, 2009, J MED CHEM, V52, P4257, DOI 10.1021/jm900411s
   OBOYLE NM, 2011, J CHEMINFORMATICS, V3, DOI DOI https://doi.org/10.1186/1758-2946-3-33
   Pawson T, 2007, ONCOGENE, V26, P1268, DOI 10.1038/sj.onc.1210255
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Rastelli G, 2010, J COMPUT CHEM, V31, P797, DOI 10.1002/jcc.21372
   Riniker S, 2013, J CHEMINFORMATICS, V5, P26, DOI DOI https://doi.org/10.1186/1758-2946-5-26
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5
   Rydberg P, 2010, ACS MED CHEM LETT, V1, P96, DOI 10.1021/ml100016x
   Schrodinger Release 2020-1: Maestro, 2020, SCHROD REL 2020 1 MA
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Su Gang, 2014, Curr Protoc Bioinformatics, V47, DOI 10.1002/0471250953.bi0813s47
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Trott O., 2009, J COMPUT CHEM, V31, pNA461
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang SP, 2019, MSYSTEMS, V4, DOI 10.1128/mSystems.00303-18
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 53
TC 1
Z9 1
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1841681
EA NOV 2020
PG 14
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OL5UO
UT WOS:000585404900001
PM 33146070
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Song, KH
   Gong, HY
   Xu, B
   Dong, XR
   Li, LJ
   Hu, WD
   Wang, Q
   Xie, ZB
   Rao, ZG
   Luo, ZG
   Chu, Q
   Li, F
   Wang, J
AF Song, Kehan
   Gong, Hongyun
   Xu, Bin
   Dong, Xiaorong
   Li, Linjun
   Hu, Weidong
   Wang, Qun
   Xie, Zhibin
   Rao, Zhiguo
   Luo, Zhiguo
   Chu, Qian
   Li, Feng
   Wang, Jie
TI Association between recent oncologic treatment and mortality among
   patients with carcinoma who are hospitalized with COVID-19: A
   multicenter study
SO CANCER
LA English
DT Article; Early Access
DE cancer; coronavirus disease 2019 (COVID-19); mortality; oncologic
   treatment; outcome
ID CHINA
AB Background To the authors' knowledge, little is known regarding the association between recent oncologic treatment and mortality in patients with cancer who are infected with coronavirus disease 2019 (COVID-19). The objective of the current study was to determine whether recent oncologic treatment is associated with a higher risk of death among patients with carcinoma who are hospitalized with COVID-19.
   Methods Data regarding 248 consecutive patients with carcinoma who were hospitalized with COVID-19 were collected retrospectively from 33 hospitals in Hubei Province, China, from January 1, 2020, to March 25, 2020. The follow-up cutoff date was July 22, 2020. Univariable and multivariable logistic regression analyses were performed to identify variables associated with a higher risk of death.
   Results Of the 248 patients enrolled, the median age was 63 years and 128 patients (52%) were male. On admission, 147 patients (59%) did not undergo recent oncologic treatment, whereas 32 patients (13%), 25 patients (10%), 12 patients (5%), and 10 patients (4%), respectively, underwent chemotherapy, surgery, targeted therapy, and radiotherapy. At the time of last follow-up, 51 patients (21%) were critically ill during hospitalization, 40 of whom had died. Compared with patients without receipt of recent oncologic treatment, the mortality rate of patients who recently received oncologic treatment was significantly higher (24.8% vs 10.2%; hazard ratio, 2.010 [95% CI, 1.079-3.747; P = .027]). After controlling for confounders, recent receipt of chemotherapy (odds ratio [OR], 7.495; 95% CI, 1.398-34.187 [P = .015]), surgery (OR, 8.239; 95% CI, 1.637-41.955 [P = .012]), and radiotherapy (OR, 15.213; 95% CI, 2.091-110.691 [P = .007]) were identified as independently associated with a higher risk of death.
   Conclusions The results of the current study demonstrated a possible association between recent receipt of oncologic treatment and a higher risk of death among patients with carcinoma who are hospitalized with COVID-19.
C1 [Song, Kehan; Li, Feng] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, State Key Lab Mol Oncol, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, 17 Pan Jia Yuan South Lane, Beijing 100021, Peoples R China.
   [Gong, Hongyun; Xu, Bin] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Orthopaed Surg, Tongji Med Coll, 1095 Jiefang Ave, Wuhan 430030, Peoples R China.
   [Dong, Xiaorong] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Tongji Med Coll, 1095 Jiefang Ave, Wuhan 430030, Peoples R China.
   [Li, Linjun] Wuhan Univ, Renmin Hosp, Canc Ctr, Wuhan, Peoples R China.
   [Hu, Weidong] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Peoples R China.
   [Wang, Qun] Hubei Prov Hosp Integrated Chinese & Western Med, Dept Oncol, Wuhan, Peoples R China.
   [Xie, Zhibin] Fifth Hosp Wuhan, Dept Oncol, Wuhan, Peoples R China.
   [Rao, Zhiguo] Wuhan Univ Sci & Technol, Xiaogan Hosp, Dept Resp & Crit Care Med, Xiaogan, Peoples R China.
   [Luo, Zhiguo] Gen Hosp Cent Theater Command, Peoples Liberat Army, Dept Oncol, Wuhan, Peoples R China.
   [Chu, Qian] Hubei Univ Med, Taihe Hosp, Dept Oncol, Shiyan, Peoples R China.
RP Wang, J (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, State Key Lab Mol Oncol, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, 17 Pan Jia Yuan South Lane, Beijing 100021, Peoples R China.; Li, F (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Dept Orthopaed Surg, Tongji Med Coll, 1095 Jiefang Ave, Wuhan 430030, Peoples R China.; Chu, Q (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Tongji Med Coll, 1095 Jiefang Ave, Wuhan 430030, Peoples R China.
EM qianchu@tjh.tjmu.edu.cn; lifengmd@hust.edu.cn; zlhuxi@163.com
OI Hu, Weidong/0000-0003-3646-8572
CR Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kamboj M, 2009, LANCET ONCOL, V10, P589, DOI 10.1016/S1470-2045(09)70069-5
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Longbottom ER, 2016, ANN SURG, V264, P370, DOI 10.1097/SLA.0000000000001484
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Wynants L, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1328
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 15
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
DI 10.1002/cncr.33240
EA NOV 2020
PG 12
WC Oncology
SC Oncology
GA OI6JL
UT WOS:000583382300001
PM 33136293
OA Bronze
DA 2021-01-01
ER

PT J
AU Rothe, K
   Feihl, S
   Schneider, J
   Wallnofer, F
   Wurst, M
   Lukas, M
   Treiber, M
   Lahmer, T
   Heim, M
   Dommasch, M
   Waschulzik, B
   Zink, A
   Querbach, C
   Busch, DH
   Schmid, RM
   Schneider, G
   Spinner, CD
AF Rothe, Kathrin
   Feihl, Susanne
   Schneider, Jochen
   Wallnoefer, Fabian
   Wurst, Milena
   Lukas, Marina
   Treiber, Matthias
   Lahmer, Tobias
   Heim, Markus
   Dommasch, Michael
   Waschulzik, Birgit
   Zink, Alexander
   Querbach, Christiane
   Busch, Dirk H.
   Schmid, Roland M.
   Schneider, Gerhard
   Spinner, Christoph D.
TI Rates of bacterial co-infections and antimicrobial use in COVID-19
   patients: a retrospective cohort study in light of antibiotic
   stewardship
SO EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
LA English
DT Article; Early Access
DE COVID-19; Antibiotic stewardship; Bacterial co-infections; Diagnostic
   stewardship
ID CARE; SOCIETY
AB The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. Bacterial co-infections are associated with unfavourable outcomes in respiratory viral infections; however, microbiological and antibiotic data related to COVID-19 are sparse. Adequate use of antibiotics in line with antibiotic stewardship (ABS) principles is warranted during the pandemic. We performed a retrospective study of clinical and microbiological characteristics of 140 COVID-19 patients admitted between February and April 2020 to a German University hospital, with a focus on bacterial co-infections and antimicrobial therapy. The final date of follow-up was 6 May 2020. Clinical data of 140 COVID-19 patients were recorded: The median age was 63.5 (range 17-99) years; 64% were males. According to the implemented local ABS guidelines, the most commonly used antibiotic regimen was ampicillin/sulbactam (41.5%) with a median duration of 6 (range 1-13) days. Urinary antigen tests for Legionella pneumophila and Streptococcus peumoniae were negative in all cases. In critically ill patients admitted to intensive care units (n = 50), co-infections with Enterobacterales (34.0%) and Aspergillus fumigatus (18.0%) were detected. Blood cultures collected at admission showed a diagnostic yield of 4.2%. Bacterial and fungal co-infections are rare in COVID-19 patients and are mainly prevalent in critically ill patients. Further studies are needed to assess the impact of antimicrobial therapy on therapeutic outcome in COVID-19 patients to prevent antimicrobial overuse. ABS guidelines could help in optimising the management of COVID-19. Investigation of microbial patterns of infectious complications in critically ill COVID-19 patients is also required.
C1 [Rothe, Kathrin; Feihl, Susanne; Busch, Dirk H.] Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, Sch Med, Trogerstr 30, D-81675 Munich, Germany.
   [Schneider, Jochen; Wallnoefer, Fabian; Wurst, Milena; Lukas, Marina; Treiber, Matthias; Lahmer, Tobias; Schmid, Roland M.; Spinner, Christoph D.] Tech Univ Munich, Sch Med, Dept Internal Med 2, Munich, Germany.
   [Heim, Markus; Schneider, Gerhard] Tech Univ Munich, Sch Med, Dept Anaesthesiol & Intens Care Med, Munich, Germany.
   [Dommasch, Michael] Tech Univ Munich, Sch Med, Dept Internal Med 1, Munich, Germany.
   [Waschulzik, Birgit] Tech Univ Munich, Inst Med Informat Stat & Epidemiol, Sch Med, Munich, Germany.
   [Zink, Alexander] Tech Univ Munich, Sch Med, Dept Dermatol & Allergol, Munich, Germany.
   [Querbach, Christiane] Tech Univ Munich, Sch Med, Hosp Pharm, Munich, Germany.
   [Busch, Dirk H.; Spinner, Christoph D.] German Ctr Infect Res DZIF, Partner Site Munich, Munich, Germany.
RP Rothe, K (corresponding author), Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, Sch Med, Trogerstr 30, D-81675 Munich, Germany.
EM kathrin.rothe@tum.de
OI Spinner, Christoph/0000-0002-3875-5367
FU Projekt DEAL
FX Open Access funding enabled and organized by Projekt DEAL.
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Cao JL, 2020, CLIN INFECT DIS, V71, P748, DOI 10.1093/cid/ciaa243
   Cevik M, 2020, CLIN MICROBIOL INFEC, V26, P842, DOI 10.1016/j.cmi.2020.04.023
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Cox Michael J, 2020, Lancet Microbe, V1, pe11, DOI 10.1016/S2666-5247(20)30009-4
   de With K, 2016, INFECTION, V44, P395, DOI 10.1007/s15010-016-0885-z
   Dellit TH, 2007, CLIN INFECT DIS, V44, P159, DOI 10.1086/510393
   Du Y, 2020, AM J RESP CRIT CARE, DOI [10.1164/rccm.202003-0543OC, DOI 10.1164/RCCM.202003-05430C]
   Dubourg G, 2019, EXPERT REV MOL DIAGN, V19, P161, DOI 10.1080/14737159.2019.1568241
   Ewig SGH, 2016, MANAGEMENT ADULT COM
   Ferrer R, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2091-0
   Gilbert EH, 1996, ANN EMERG MED, V27, P305, DOI 10.1016/S0196-0644(96)70264-0
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huttner BD, 2020, CLIN MICROBIOL INFEC, V26, P808, DOI 10.1016/j.cmi.2020.04.024
   Kelly AM, 1998, J ACCID EMERG MED, V15, P254
   Kim D, 2020, JAMA-J AM MED ASSOC, V323, P2085, DOI 10.1001/jama.2020.6266
   Kock R, 2018, MICROORGANISMS, V6, DOI 10.3390/microorganisms6010011
   Koehler P, 2020, MYCOSES, V63, P528, DOI 10.1111/myc.13096
   Lamy B, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00697
   Lansbury L, 2020, J INFECTION, V81, P266, DOI 10.1016/j.jinf.2020.05.046
   Lescure FX, 2020, LANCET INFECT DIS, V20, P697, DOI 10.1016/S1473-3099(20)30200-0
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mason JW, 2017, J ANTIMICROB CHEMOTH, V72, P1272, DOI 10.1093/jac/dkw591
   Mathieu C, 2019, EXPERT REV ANTI-INFE, V17, P79, DOI 10.1080/14787210.2019.1561275
   Mazdeyasna H, 2020, CURR INFECT DIS REP, V22, DOI 10.1007/s11908-020-00734-x
   Nicastri E, 2020, INFECT DIS REP, V12, P3, DOI 10.4081/idr.2020.8543
   Patel R, 2018, CLIN INFECT DIS, V67, P799, DOI 10.1093/cid/ciy077
   Rawson Timothy M, 2020, Clin Infect Dis, V71, P2459, DOI 10.1093/cid/ciaa530
   Schuetz P, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007498.pub3
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Stevens MP, 2020, INFECT CONT HOSP EP, V41, P744, DOI 10.1017/ice.2020.69
   Sticchi C, 2018, J HOSP INFECT, V99, P8, DOI 10.1016/j.jhin.2017.12.008
   Vaughn Valerie M, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1239
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Whippy A, 2011, JT COMM J QUAL PATIE, V37, P483, DOI 10.1016/S1553-7250(11)37061-4
   WHO, 2016, DIAGN STEW GUID IMPL
   WHO, 2020, CLIN MAN SEV AC RESP
   Worster A, 2005, ANN EMERG MED, V45, P448, DOI 10.1016/j.annemergmed.2004.11.021
   Yap FHY, 2004, CLIN INFECT DIS, V39, P511, DOI 10.1086/422641
   Youngs J, 2020, J INFECTION, V81, pE55, DOI 10.1016/j.jinf.2020.06.056
   Zhang J, 2020, CLIN MICROBIOL INFEC, V26, P767, DOI 10.1016/j.cmi.2020.04.012
   Zhang JN, 2020, LANCET RESP MED, V8, pE11, DOI 10.1016/S2213-2600(20)30071-0
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou PC, 2020, INFECT CONT HOSP EP, V41, P1124, DOI 10.1017/ice.2020.156
NR 46
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0934-9723
EI 1435-4373
J9 EUR J CLIN MICROBIOL
JI Eur. J. Clin. Microbiol. Infect. Dis.
DI 10.1007/s10096-020-04063-8
EA NOV 2020
PG 11
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA OK0MS
UT WOS:000584347500001
PM 33140176
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Gungor, ES
   Yalcin, M
   Tuzer, MY
   Keles, DB
   Bas, TO
   Ergelen, M
   Bulbul, A
   Kirsavoglu, B
   Gunes, M
AF Sonmez Gungor, Ekin
   Yalcin, Murat
   Yerebakan Tuzer, Melike
   Besikci Keles, Didem
   Ocek Bas, Tuba
   Ergelen, Mine
   Bulbul, Alper
   Kirsavoglu, Betul
   Gunes, Mustafa
TI Adverse drug reactions associated with concurrent acute psychiatric
   treatment and Covid-19 drug therapy
SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
LA English
DT Article; Early Access
DE COVID-19; adverse drug reactions; acute psychiatry; psychopharmacology;
   drug side effects
ID ELECTROCONVULSIVE-THERAPY; GENDER
AB Objective
   Psychiatric patients are at increased risk of contamination, morbidity, and mortality associated with COVID-19, together with potentially more pronounced adverse effects. We present and discuss the adverse effects observed in an acute psychiatric clinic that has admitted COVID-19 patients during the first three months of the pandemic in Turkey.
   Methods
   The COVID-19 treatment schemes were formed in accordance with the national and regional guidelines at the time of admittance, which were mainly based on the use of hydroxychloroquine and other drugs. The sample consisted exclusively of inpatients, and all patients were enrolled in the study regardless of their specific diagnosis or treatment schemes.
   Results
   4 out of 23 patients (17.4%) had experienced adverse effects, two of which had mild hepatic enzyme elevation and one had mild sinus bradycardia. Of note is that we haven't encountered any serious complications or life-threatening events during inpatient treatment. The most emphasised adverse effect in the literature, namely QTc prolongation and ECG changes, were not observed in our sample. The adverse effects were not found to be significantly associated with patient-related factors nor dose of antipsychotic medication.
   Conclusions
   From our point of view, non-cardiac adverse effects should not be overlooked while treating comorbid psychiatric and COVID-19 patients.
C1 [Sonmez Gungor, Ekin; Yalcin, Murat; Yerebakan Tuzer, Melike; Besikci Keles, Didem; Ocek Bas, Tuba; Ergelen, Mine; Bulbul, Alper; Kirsavoglu, Betul; Gunes, Mustafa] Univ Hlth Sci, Erenkoy Mental Hlth & Neurol Disorders Training &, Istanbul, Turkey.
RP Gungor, ES (corresponding author), Univ Hlth Sci, Erenkoy Mental Hlth & Neurol Disorders Training &, Istanbul, Turkey.
EM ekinsonmez88@gmail.com
RI Yalcin, Murat/ABI-3328-2020
CR AFP, 2020, COR PAND STILL ACC W, P24
   Bilbul M, 2020, PSYCHOSOMATICS, V61, P411, DOI 10.1016/j.psym.2020.05.006
   Bishara D, 2020, THER ADV PSYCHOPHARM, V10, DOI 10.1177/2045125320935306
   Boland X, 2020, J ECT, V36, P223, DOI 10.1097/YCT.0000000000000708
   Boland X, 2020, INT J PSYCHIAT CLIN, DOI 10.1080/13651501.2020.1801755
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Campion J, 2020, LANCET PSYCHIAT, V7, P657, DOI 10.1016/S2215-0366(20)30240-6
   Chatterjee SS, 2020, ASIAN J PSYCHIATR, V52, DOI 10.1016/j.ajp.2020.102173
   Dudley K, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007778.pub2
   Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024
   Ilie PC, 2020, AGING CLIN EXP RES, V32, P1195, DOI 10.1007/s40520-020-01570-8
   Iversen TSJ, 2018, PROG NEURO-PSYCHOPH, V82, P263, DOI 10.1016/j.pnpbp.2017.11.004
   Javelot H, 2020, ENCEPHALE, V46
   Kumar Amit, 2020, Med Hypotheses, V144, P109848, DOI 10.1016/j.mehy.2020.109848
   Li LM, 2020, PSYCHIAT SERV, V71, P624, DOI 10.1176/appi.ps.202000166
   Li X, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2721-8
   Monzani A, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13258
   Naksuk N, 2020, EUR HEART J-ACUTE CA, V9, P215, DOI 10.1177/2048872620922784
   NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154
   Niddkd NIODADAKD., 2012, LIVERTOX CLIN RES IN
   Nielsen J, 2012, SCHIZOPHRENIA BULL, V38, P592, DOI 10.1093/schbul/sbq137
   Roden DM, 2020, J AM COLL CARDIOL, V75, P2623, DOI 10.1016/j.jacc.2020.04.016
   Sienaert P, 2020, AM J GERIAT PSYCHIAT, V28, P772, DOI 10.1016/j.jagp.2020.04.013
   Siskind D, 2020, J PSYCHIATR NEUROSCI, V45
   Smith S, 2010, INT REV PSYCHIATR, V22, P472, DOI 10.3109/09540261.2010.515965
   Wang T, 2020, THELANCET, V395, P10228
   Wu Renyi, 2020, Curr Pharmacol Rep, P1, DOI 10.1007/s40495-020-00216-7
   Yao H, 2020, LANCET PSYCHIAT, V7, pE21, DOI 10.1016/S2215-0366(20)30090-0
NR 28
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1365-1501
EI 1471-1788
J9 INT J PSYCHIAT CLIN
JI Int. J. Psychiat. Clin.
DI 10.1080/13651501.2020.1843182
EA NOV 2020
PG 5
WC Psychiatry
SC Psychiatry
GA OK5RT
UT WOS:000584708200001
PM 33143519
OA Bronze
DA 2021-01-01
ER

PT J
AU Ahamad, S
   Gupta, D
   Kumar, V
AF Ahamad, Shahzaib
   Gupta, Dinesh
   Kumar, Vijay
TI Targeting SARS-CoV-2 nucleocapsid oligomerization: Insights from
   molecular docking and molecular dynamics simulations
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; nucleocapsid; C-terminal domain; anti-N drugs; molecular
   docking; molecular dynamics simulation
ID SARS CORONAVIRUS; CRYSTAL-STRUCTURE; SELF-ASSOCIATION; TERMINAL DOMAIN;
   PROTEIN; NUCLEOPROTEIN; BINDING; REPLICATION; DISCOVERY; MEMBRANE
AB The outbreak of COVID-19 caused by SARS-CoV-2 virus continually led to infect a large population worldwide. Currently, there is no specific viral protein-targeted therapeutics. The Nucleocapsid (N) protein of the SARS-CoV-2 virus is necessary for viral RNA replication and transcription. The C-terminal domain of N protein (CTD) involves in the self-assembly of N protein into a filament that is packaged into new virions. In this study, the CTD (PDB ID: 6WJI) was targeted for the identification of possible inhibitors of oligomerization of N protein. Herein, multiple computational approaches were employed to explore the potential mechanisms of binding and inhibitor activity of five antiviral drugs toward CTD. The five anti-N drugs studied in this work are 4E1RCat, Silmitasertib, TMCB, Sapanisertib, and Rapamycin. Among the five drugs, 4E1RCat displayed highest binding affinity (-10.95 kcal/mol), followed by rapamycin (-8.91 kcal/mol), silmitasertib (-7.89 kcal/mol), TMCB (-7.05 kcal/mol), and sapanisertib (-6.14 kcal/mol). Subsequently, stability and dynamics of the protein-drug complex were examined with molecular dynamics (MD) simulations. Overall, drug binding increases the stability of the complex with maximum stability observed in the case of 4E1RCat. The CTD-drug complex systems behave differently in terms of the free energy landscape and showed differences in population distribution. Overall, the MD simulation parameters like RMSD, RMSF, Rg, hydrogen bonds analysis, PCA, FEL, and DCCM analysis indicated that 4E1RCat and TMCB complexes were more stable as compared to silmitasertib and sapanisertib and thus could act as effective drug compounds against CTD.
   Communicated by Ramaswamy H. Sarma
C1 [Ahamad, Shahzaib; Gupta, Dinesh] Int Ctr Genet Engn & Biotechnol ICGEB, Translat Bioinformat Grp, New Delhi, India.
   [Kumar, Vijay] Amity Univ, Amity Inst Neuropsychol & Neurosci AINN, Noida 201313, UP, India.
RP Kumar, V (corresponding author), Amity Univ, Amity Inst Neuropsychol & Neurosci AINN, Noida 201313, UP, India.; Gupta, D (corresponding author), Int Ctr Genet Engn & Biotechnol, Translat Bioinformat Grp, Aruna Asaf Ali Marg, New Delhi, India.
EM dinesh@icgeb.res.in; vkumar33@amity.edu
FU Indian Council of Medical Research, IndiaIndian Council of Medical
   Research (ICMR) [ISRM/11(83)/2019]; Department of Biotechnology,
   Government of IndiaDepartment of Biotechnology (DBT) India
   [BT/BI/04/001/2018]
FX S.A is thankful for Research Associate, supported by the Indian Council
   of Medical Research, India, for financial assistance (2019-6039 File No.
   ISRM/11(83)/2019). D.G is endowed with funding by the Department of
   Biotechnology, Government of India (Grant No. BT/BI/04/001/2018).
CR BARIC RS, 1988, J VIROL, V62, P4280, DOI 10.1128/JVI.62.11.4280-4287.1988
   BERENDSEN HJC, 1987, J PHYS CHEM-US, V91, P6269, DOI 10.1021/j100308a038
   Chen HL, 2005, PROTEINS, V61, P21, DOI 10.1002/prot.20514
   Chenavas S, 2013, FUTURE MICROBIOL, V8, P1537, DOI 10.2217/fmb.13.128
   Cong YY, 2020, J VIROL, V94, DOI 10.1128/JVI.01925-19
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Delano WL, 2002, PYMOL MOL GRAPHICS S
   Gerritz SW, 2011, P NATL ACAD SCI USA, V108, P15366, DOI 10.1073/pnas.1107906108
   Gil C, 2020, J MED CHEM, V63, P12359, DOI 10.1021/acs.jmedchem.0c00606
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Gupta R, 2020, J BIOL CHEM, V295, P11742, DOI 10.1074/jbc.RA120.014873
   He RT, 2004, VIRUS RES, V105, P121, DOI 10.1016/j.virusres.2004.05.002
   He RT, 2004, BIOCHEM BIOPH RES CO, V316, P476, DOI 10.1016/j.bbrc.2004.02.074
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Holmes KV, 2003, SCIENCE, V300, P1377, DOI 10.1126/science.1086418
   Hung HC, 2012, ANAL CHEM, V84, P6391, DOI 10.1021/ac2022426
   Ivanov P, 2019, CSH PERSPECT BIOL, V11, DOI 10.1101/cshperspect.a032813
   Jendele L, 2019, NUCLEIC ACIDS RES, V47, pW345, DOI 10.1093/nar/gkz424
   Kindrachuk J, 2015, ANTIMICROB AGENTS CH, V59, P1088, DOI 10.1128/AAC.03659-14
   Kumar V, 2018, BIOCHEM J, V475, P1701, DOI 10.1042/BCJ20180085
   Kuo L, 2002, J VIROL, V76, P4987, DOI 10.1128/JVI.76.10.4987-4999.2002
   Lejal N, 2013, ANTIMICROB AGENTS CH, V57, P2231, DOI 10.1128/AAC.02335-12
   Lin SY, 2014, J MED CHEM, V57, P2247, DOI 10.1021/jm500089r
   Lo YS, 2013, FEBS LETT, V587, P120, DOI 10.1016/j.febslet.2012.11.016
   Lu XL, 2011, VIRUS GENES, V42, P37, DOI 10.1007/s11262-010-0544-x
   Luo HB, 2006, BIOCHEMISTRY-US, V45, P11827, DOI 10.1021/bi0609319
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   Monod A, 2015, EXPERT OPIN DRUG DIS, V10, P345, DOI 10.1517/17460441.2015.1019859
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Nakagawa K, 2018, J VIROL, V92, DOI 10.1128/JVI.00902-18
   Narayanan K, 2003, VIRUS RES, V98, P131, DOI 10.1016/j.virusres.2003.08.021
   Negi SS, 2007, BIOINFORMATICS, V23, P3397, DOI 10.1093/bioinformatics/btm474
   Nelson GW, 2000, J GEN VIROL, V81, P181, DOI 10.1099/0022-1317-81-1-181
   PARRINELLO M, 1980, PHYS REV LETT, V45, P1196, DOI 10.1103/PhysRevLett.45.1196
   Prakash A, 2019, J BIOMOL STRUCT DYN, V37, P2219, DOI 10.1080/07391102.2018.1486228
   Prasad K, 2020, INT J BIOL MACROMOL, V163, P1, DOI 10.1016/j.ijbiomac.2020.06.228
   Raaben M, 2007, CELL MICROBIOL, V9, P2218, DOI 10.1111/j.1462-5822.2007.00951.x
   Reineke LC, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00596-16
   Robert X, 2014, NUCLEIC ACIDS RES, V42, pW320, DOI 10.1093/nar/gku316
   SARMA P, 2020, J BIOMOL STRUCT 0516, DOI DOI https://doi.org/10.1080/07391102.2020.1753580
   Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Surjit M, 2005, J VIROL, V79, P11476, DOI 10.1128/JVI.79.17.11476-11486.2005
   Tarus B, 2015, J BIOMOL STRUCT DYN, V33, P1899, DOI 10.1080/07391102.2014.979230
   Tian W, 2018, NUCLEIC ACIDS RES, V46, pW363, DOI 10.1093/nar/gky473
   Troyer L, 2020, AM J EMERG MED, V38, P1494, DOI 10.1016/j.ajem.2020.04.036
   TSENG YT, 2014, J BIOMED SCI, V21, DOI DOI https://doi.org/10.1186/1423-0127-21-34
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Wada M, 2018, P NATL ACAD SCI USA, V115, pE10157, DOI 10.1073/pnas.1811675115
   Yang J, 2013, CHIN J ENDOCRINOL ME, V29, p5b
   Ye QZ, 2020, PROTEIN SCI, V29, P1890, DOI 10.1002/pro.3909
   Yu IM, 2006, J BIOL CHEM, V281, P17134, DOI 10.1074/jbc.M602107200
   Zhou B, 2008, J VIROL, V82, P6962, DOI 10.1128/JVI.00133-08
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 56
TC 0
Z9 0
U1 6
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1839563
EA NOV 2020
PG 14
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OJ6JL
UT WOS:000584065000001
PM 33140703
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Erukainure, OL
   Atolani, O
   Muhammad, A
   Katsayal, SB
   Ebhuoma, OO
   Ibeji, CU
   Mesaik, MA
AF Erukainure, Ochuko L.
   Atolani, Olubunmi
   Muhammad, Aliyu
   Katsayal, Sanusi B.
   Ebhuoma, Osadolor O.
   Ibeji, Collins U.
   Mesaik, M. Ahmed
TI Targeting the initiation and termination codons of SARS-CoV-2 spike
   protein as possible therapy against COVID-19: the role of novel
   harpagide 5-O-beta-D-glucopyranoside from Clerodendrum volubile P Beauv.
   (Labiatae)
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Clerodendrum volubile; COVID-19; harpagide 5-O-&#946;
   -D-glucopyranoside; SARS-COV-2; and spike protein
ID PHAGOCYTIC OXIDATIVE BURST; ENZYMES; DRUGS; ABSORPTION; PREDICTION;
   GLYCOSIDES; FRACTION; INHIBIT; BINDING; LEAVES
AB The global spread of the coronavirus infections disease - 2019 (COVID-19) and the search for new drugs from natural products particularly from plants are receiving much attention recently. In this study, the therapeutic potential of a new iridoid glycoside isolated from the leaves of Clerodendrum volubile against COVID-19 was investigated. Harpagide 5-O-beta-D-glucopyranoside (HG) was isolated, characterised and investigated for its druglikeness, optimized geometry, and pharmacokinetics properties. Its immunomodulatory was determined by chemiluminescence assay using polymorphonuclear neutrophils (PMNs) in addition to T-cell proliferation assay. In silico analysis was used in determining its molecular interaction with severe acute respiratory syndrome coronavirus-2 (SARS-COV-2). HG displayed potent druglikeness properties, with no inhibitory effect on cytochrome P-450 (1A2, 2C19, 2C9, 2D6 and 3A4) and a predicted LD50 of 2000 mg/kg. Its H-1-NMR chemical shifts showed a little deviation of 0.01 and 0.11 ppm for H-4 and H-9, respectively. HG significantly suppressed oxidative bursts in PMNs, while concomitantly inhibiting T-cell proliferation. It also displayed a very strong binding affinity with the translation initiation and termination sequence sites of spike (S) protein mRNA of SARS-COV-2, its gene product, and host ACE2 receptor. These results suggest the immunomodulatory properties and anti-SARS-COV-2 potentials of HG which can be explored in the treatment and management of COVID-19.
   Communicated by Ramaswamy H. Sarma
C1 [Erukainure, Ochuko L.] Univ Free State, Dept Pharmacol, ZA-9300 Bloemfontein, South Africa.
   [Atolani, Olubunmi] Univ Ilorin, Dept Chem, Ilorin, Nigeria.
   [Muhammad, Aliyu; Katsayal, Sanusi B.] Ahmadu Bello Univ, Dept Biochem, Zaria, Nigeria.
   [Ebhuoma, Osadolor O.] Univ KwaZulu Natal, Sch Agr Earth & Environm Sci, Durban, South Africa.
   [Ibeji, Collins U.] Univ Nigeria, Dept Pure & Ind Chem, Nsukka, Nigeria.
   [Mesaik, M. Ahmed] Univ Karachi, Int Ctr Chem & Biol Sci, Dr Panjwani Ctr Mol Med & Drug Res, Karachi, Pakistan.
   [Mesaik, M. Ahmed] Univ Tabuk, Fac Med, Tabuk, Saudi Arabia.
RP Erukainure, OL (corresponding author), Univ Free State, Dept Pharmacol, ZA-9300 Bloemfontein, South Africa.
EM loreks@yahoo.co.uk
FU World Academy of Sciences
FX This work was supported by The World Academy of Sciences.
CR ALLEN RC, 1994, ENVIRON HEALTH PERSP, V102, P201, DOI 10.2307/3432239
   Alyiu M., 2014, NUTR THER METAB, V32, DOI [10.5301/NTM.2014.12285, http://dx.doi.org/10.5301/]
   Banerjee P, 2018, NUCLEIC ACIDS RES, V46, pW257, DOI 10.1093/nar/gky318
   Burkill HM, 1985, USEFUL PLANTS W TROP
   Cances E, 1997, J CHEM PHYS, V107, P3032, DOI 10.1063/1.474659
   Chao PDL, 2006, ACS SYM SER, V925, P212
   Cheng AC, 2007, NAT BIOTECHNOL, V25, P71, DOI 10.1038/nbt1273
   Ciz M, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/181295
   Constantinides PP, 2007, J PHARM SCI-US, V96, P235, DOI 10.1002/jps.20780
   da Silva RG, 2020, CHAOS SOLITON FRACT, V139, DOI 10.1016/j.chaos.2020.110027
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   De Souza LA, 2017, CHEM PHYS LETT, V676, P46, DOI 10.1016/j.cplett.2017.03.038
   Truong DH, 2019, J FOOD QUALITY, DOI 10.1155/2019/8178294
   Doak BC, 2014, CHEM BIOL, V21, P1115, DOI 10.1016/j.chembiol.2014.08.013
   Dong J, 2018, J CHEMINFORMATICS, V10, DOI 10.1186/s13321-018-0283-x
   Erukainure O. L., 2017, Comparative Clinical Pathology, V26, P663, DOI 10.1007/s00580-017-2438-y
   Erukainure O.L., 2011, INT FOOD RES J, V4, P1393
   Erukainure O. L., 2018, POLYPHENOLS MECH ACT
   Erukainure OL, 2020, J ETHNOPHARMACOL, V255, DOI 10.1016/j.jep.2020.112744
   Erukainure OL, 2018, BIOMED PHARMACOTHER, V106, P1144, DOI 10.1016/j.biopha.2018.07.013
   Erukainure OL, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00251
   Erukainure OL, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00008
   Erukainure OL, 2017, BIOMED PHARMACOTHER, V93, P529, DOI 10.1016/j.biopha.2017.06.060
   Erukainure OL, 2017, BIOMED PHARMACOTHER, V86, P307, DOI 10.1016/j.biopha.2016.12.035
   Erukainure OL, 2016, BIOMED PHARMACOTHER, V83, P1478, DOI 10.1016/j.biopha.2016.09.002
   European Centre for Disease Prevention and Control (ECDC), 2020, COVID 19 DAT
   Frisch M. J., 2013, GAUSSIAN 09 REVISION
   Gan H., 2020, CHINESE J EPIDEMIOLO, V41, DOI [10.3760/cma.j.cn112338-20200301-00223, DOI 10.3760/CMA.J.CN112338-20200301-00223]
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Harun Nurul Hikmah, 2015, Asian Pacific Journal of Tropical Biomedicine, V5, P48, DOI 10.1016/S2221-1691(15)30170-2
   He F, 2020, J MED VIROL, V92, P719, DOI [10.1002/jmv.25766, 10.3171/2020.3.JNS193202]
   HELFAND SL, 1982, J EXP MED, V156, P492, DOI 10.1084/jem.156.2.492
   Holman N, 2020, LANCET DIABETES ENDO, V8, P823, DOI 10.1016/S2213-8587(20)30271-0
   Jayaram B, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S17-S7
   JENSEN SR, 1989, PHYTOCHEMISTRY, V28, P97, DOI 10.1016/0031-9422(89)85017-4
   Jiang SB, 2012, EMERG MICROBES INFEC, V1, DOI 10.1038/emi.2012.1
   Johnson III R. D., 1999, 101 NIST
   Kim RB, 2002, DRUG METAB REV, V34, P47, DOI 10.1081/DMR-120001389
   Kraemer MUG, 2020, SCIENCE, V368, P493, DOI 10.1126/science.abb4218
   Kumar BRP, 2010, MED CHEM RES, V19, P1000, DOI 10.1007/s00044-009-9246-0
   Kuster GM, 2020, EUR HEART J, V41, P1801, DOI 10.1093/eurheartj/ehaa235
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Manguro LOA, 2011, REC NAT PROD, V5, P147
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mitja O, 2020, LANCET GLOB HEALTH, V8, pE639, DOI 10.1016/S2214-109X(20)30114-5
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Nielsen M, 2003, PROTEIN SCI, V12, P1007, DOI 10.1110/ps.0239403
   Obach RS, 2006, J PHARMACOL EXP THER, V316, P336, DOI 10.1124/jpet.105.093229
   Oboh Ganiyu, 2017, Journal of Dietary Supplements, V14, P358, DOI 10.1080/19390211.2016.1237401
   Olanrewaju AA, 2020, J MOL STRUCT, V1211, DOI 10.1016/j.molstruc.2020.128057
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Pang KS, 2003, DRUG METAB DISPOS, V31, P1507, DOI 10.1124/dmd.31.12.1507
   Pascarella G, 2020, J INTERN MED, V288, P192, DOI 10.1111/joim.13091
   Roser M., 2020, CORONAVIRUS PANDEMIC
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Tang DL, 2020, AUTOPHAGY, V16, P2273, DOI 10.1080/15548627.2020.1796014
   Thamkaew G, 2020, CRIT REV FOOD SCI, DOI 10.1080/10408398.2020.1765309
   Tian X., 2020, ELECTRONICS, V9, P1, DOI DOI 10.1080/22221751.2020.1729069
   Venditti A, 2017, J INTERCULT ETHNOPHA, V6, P144, DOI 10.5455/jice.20170327073801
   Vijayan P, 2004, INDIAN J MED RES, V120, P24
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   WHO, 2020, 67 WHO
   WOLINSKI K, 1990, J AM CHEM SOC, V112, P8251, DOI 10.1021/ja00179a005
   World Health Organisation, 2018, MORT BURD DIS
   Yang BJ, 2013, J PHOTOCH PHOTOBIO B, V128, P35, DOI 10.1016/j.jphotobiol.2013.08.006
   Yusof I, 2014, DRUG DISCOV TODAY, V19, P680, DOI 10.1016/j.drudis.2014.01.005
   Yusof I, 2013, DRUG DISCOV TODAY, V18, P659, DOI 10.1016/j.drudis.2013.02.008
   Zhang Y, 2020, ZHONGHUA XUE YE XUE, V41, pE006
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhu Z., 2020, ZHONGHUA YU FANG YI, V54, pE022, DOI https://doi.org/10.3760/cma.j.cn112150-20200222-00163
NR 79
TC 0
Z9 0
U1 5
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1840439
EA NOV 2020
PG 14
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OJ6HW
UT WOS:000584060900001
PM 33140706
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ghosh, R
   Chakraborty, A
   Biswas, A
   Chowdhuri, S
AF Ghosh, Rajesh
   Chakraborty, Ayon
   Biswas, Ashis
   Chowdhuri, Snehasis
TI Computer aided identification of potential SARS CoV-2 main protease
   inhibitors from diterpenoids and biflavonoids of Torreya nucifera leaves
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; SARS CoV-2 main protease; docking; molecular dynamics
   simulation; Torreya nucifera diterpenoids and biflavonoids
ID MOLECULAR-DYNAMICS; ANTIVIRAL ACTIVITIES; MUTATIONS V32I; HIV-1
   PROTEASE; CORONAVIRUS; RESISTANCE; PNEUMONIA; MECHANISM; BINDING; DESIGN
AB SARS CoV-2 is the causative agent of the pandemic disease COVID-19. There is an urgent need for effective drugs or vaccines which can effectively combat this outbreak. The main protease (Mpro), a key component for the SARS CoV-2 replication, is considered to be one of the important drug targets for developing anti-COVID-19 drugs. This SARS CoV-2 Mpro/cysteine protease has high sequence similarity with the same protease from SARS CoV-1. Previously, it has been shown experimentally that eight diterpenoids and four biflavonoids derived from the leaf of Torreya nucifera show inhibitory effect on the cleavage/catalytic activity of the SARS CoV-1 Mpro. But whether these phytochemicals exhibit any inhibitory effect on SARS CoV-2 Mpro is unclear. To understand this fact, here, we have adopted various in-silico approaches. Diterpenoids and biflavonoids those qualified pharmacological test (hinokiol, amentoflavone, bilobetin and ginkgetin) and two well-known Mpro inhibitors (N3 and lopinavir) were subjected for molecular docking studies. Only three biflavonoids (amentoflavone, bilobetin and ginkgetin) were selected by comparing their binding affinities with N3 and lopinavir. They interacted with two most important catalytic residues of Mpro (His41 and Cys145). Molecular dynamics studies further revealed that these three Mpro-biflavonoid complexes are highly stable and share a similar degree of compactness. Besides, these complexes experience less conformational fluctuations and more expansion than Mpro-N3 and/or Mpro-lopinavir complex. MM-GBSA and H-bond analysis further corroborated these findings. Altogether, our study suggested that these three biflavonoids could possibly inhibit the proteolytic/catalytic activity of SARS CoV-2 Mpro and might be useful for COVID-19 treatment.
   Communicated by Ramaswamy H. Sarma
C1 [Ghosh, Rajesh; Chakraborty, Ayon; Biswas, Ashis; Chowdhuri, Snehasis] Indian Inst Technol Bhubaneswar, Sch Basic Sci, Bhubaneswar 752050, Odisha, India.
RP Biswas, A; Chowdhuri, S (corresponding author), Indian Inst Technol Bhubaneswar, Sch Basic Sci, Bhubaneswar 752050, Odisha, India.
EM abiswas@iitbbs.ac.in; snehasis@iitbbs.ac.in
OI Chakraborty, Ayon/0000-0002-1155-7862
FU IIT Bhubaneswar
FX RG acknowledges IIT Bhubaneswar for providing fellowship. The authors
   thank IIT Delhi HPC facility for computational resources.
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Adnan Muhammad, 2020, Food Chem Toxicol, V145, P111642, DOI 10.1016/j.fct.2020.111642
   Agudelo-Gomez L. S., 2012, PHARMACOLOGYONLINE, V1
   ALAMRI MA, 2020, J BIOMOL STRUCT 0623, DOI DOI https://doi.org/10.1080/07391102.2020.1782768
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Baby Krishnaprasad, 2020, Arch Med Res, DOI 10.1016/j.arcmed.2020.09.013
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Bharadwaj S, 2020, LIFE SCI, V257, DOI 10.1016/j.lfs.2020.118080
   BHARDWAJ VK, 2020, J BIOMOL STRUCT 0520, DOI DOI https://doi.org/10.1080/07391102.2020.1766572
   Bhargava S, 2019, NAT PROD RES, V33, P851, DOI 10.1080/14786419.2017.1413574
   Biovia D. S., 2017, DISCOVERY STUDIO MOD
   Chakraborty A, 2018, INT J BIOL MACROMOL, V119, P604, DOI 10.1016/j.ijbiomac.2018.07.151
   Chen JZ, 2016, RSC ADV, V6, P58573, DOI 10.1039/c6ra09201b
   Chen JZ, 2015, J CHEM INF MODEL, V55, P1903, DOI 10.1021/acs.jcim.5b00173
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chou KC, 2003, BIOCHEM BIOPH RES CO, V308, P148, DOI 10.1016/S0006-291X(03)01342-1
   CHOUDHURY C, 2020, J BIOMOL STRUCT 0527, DOI DOI https://doi.org/10.1080/07391102.2020.1771424
   Coulerie P, 2013, PLANTA MED, V79, P1313, DOI 10.1055/s-0033-1350672
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Das BK, 2019, COMPUT BIOL CHEM, V78, P37, DOI 10.1016/j.compbiolchem.2018.11.005
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Fan KQ, 2004, J BIOL CHEM, V279, P1637, DOI 10.1074/jbc.M310875200
   Frisch M.J., 2016, GAUSSIAN16 REVISION
   Fritz D, 2007, J ETHNOPHARMACOL, V113, P517, DOI 10.1016/j.jep.2007.07.013
   GHOSH R, 2020, J BIOMOL STRUCT 0620, DOI DOI https://doi.org/10.1080/07391102.2020.1779818
   GHOSH R, 2020, J BIOMOL STRUCT 0806, DOI DOI https://doi.org/10.1080/07391102.2020.1802347
   Gorla Uma Sankar, 2020, Comb Chem High Throughput Screen, DOI 10.2174/1386207323999200818162706
   Gurung AB, 2020, LIFE SCI, V255, DOI 10.1016/j.lfs.2020.117831
   Hage-Melim LID, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.117963
   Hakmi M, 2020, BIOINFORMATION, V16, P301, DOI 10.6026/97320630016301
   HAYASHI K, 1992, ANTIMICROB AGENTS CH, V36, P1890, DOI 10.1128/AAC.36.9.1890
   Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Hou TJ, 2011, J CHEM INF MODEL, V51, P69, DOI 10.1021/ci100275a
   Hsu MF, 2005, J BIOL CHEM, V280, P31257, DOI 10.1074/jbc.M502577200
   Islam MT, 2020, PHYTOTHER RES, V34, P674, DOI 10.1002/ptr.6562
   Jimenez-Alberto A, 2020, COMPUT BIOL CHEM, V88, DOI 10.1016/j.compbiolchem.2020.107325
   Jin ZM, 2020, NAT STRUCT MOL BIOL, V27, P529, DOI 10.1038/s41594-020-0440-6
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Joshi T, 2020, EUR REV MED PHARMACO, V24, P4529, DOI 10.26355/eurrev_202004_21036
   JOSHI T, 2020, MOL DIVERS 0629, DOI DOI https://doi.org/10.1007/s11030-020-10118-x
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   Kim Y, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005531
   KUMAR V, 2020, J BIOMOL STRUCT 0530, DOI DOI https://doi.org/10.1080/07391102.2020.1772108
   Lee WP, 2018, AM J CHINESE MED, V46, P835, DOI [10.1142/s0192415x18500441, 10.1142/S0192415X18500441]
   Lin YM, 1999, PLANTA MED, V65, P120, DOI 10.1055/s-1999-13971
   Lin YM, 1997, J NAT PROD, V60, P884, DOI 10.1021/np9700275
   Ma SC, 2001, BIOL PHARM BULL, V24, P311, DOI 10.1248/bpb.24.311
   Macchiagodena M, 2020, CHEM PHYS LETT, V750, DOI 10.1016/j.cplett.2020.137489
   MAZZINI S, 2020, MOLECULES, V25, DOI DOI https://doi.org/10.3390/molecules25163745
   Miki K, 2007, BIOORG MED CHEM LETT, V17, P772, DOI 10.1016/j.bmcl.2006.10.075
   Mirza MU, 2020, J PHARM ANAL, V10, P320, DOI 10.1016/j.jpha.2020.04.008
   MITTAL L, 2020, J BIOMOL STRUCT 0519, DOI DOI https://doi.org/10.1080/07391102.2020.1768151
   MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805
   Morris Garrett M, 2008, Curr Protoc Bioinformatics, VChapter 8, DOI 10.1002/0471250953.bi0814s24
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Muramatsu T, 2016, P NATL ACAD SCI USA, V113, P12997, DOI 10.1073/pnas.1601327113
   Nandi SK, 2016, RSC ADV, V6, P62146, DOI 10.1039/c6ra00167j
   Odhar HA, 2020, BIOINFORMATION, V16, P236, DOI 10.6026/97320630016236
   Oostenbrink C, 2004, J COMPUT CHEM, V25, P1656, DOI 10.1002/jcc.20090
   Orhan IE, 2020, NAT PRODUCT BIOPROSP, V10, P171, DOI 10.1007/s13659-020-00250-4
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Pathak RK, 2014, BIOINFORMATION, V10, P428, DOI 10.6026/97320630010428
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Ramaiah R, 2013, INT J PHARM SCI RES, V4, P475, DOI 10.13040/IJPSR.0975-8232.4(1).475-82
   Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722
   Roa-Linares VC, 2016, EUR J MED CHEM, V108, P79, DOI 10.1016/j.ejmech.2015.11.009
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Ryu YB, 2010, BIOORGAN MED CHEM, V18, P7940, DOI 10.1016/j.bmc.2010.09.035
   Sayed AM, 2020, RSC ADV, V10, P19790, DOI 10.1039/d0ra04199h
   Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   TRIPATHI MK, 2020, J BIOMOL STRUCT 0706, DOI DOI https://doi.org/10.1080/07391102.2020.1790425
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wen CC, 2007, J MED CHEM, V50, P4087, DOI 10.1021/jm070295s
   Wilsky S, 2012, ARCH VIROL, V157, P259, DOI 10.1007/s00705-011-1164-z
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   ZHANG JR, 2020, NAT PROD RES 0819, DOI DOI https://doi.org/10.1080/14786419.2020.1808636
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhao W, 2020, AM J ROENTGENOL, V214, P1072, DOI 10.2214/AJR.20.22976
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 88
TC 0
Z9 0
U1 6
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1841680
EA NOV 2020
PG 16
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OJ6LF
UT WOS:000584069600001
PM 33140695
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kumar, A
   Kumar, D
   Kumar, R
   Singh, P
   Chandra, R
   Kumari, K
AF Kumar, Ajay
   Kumar, Durgesh
   Kumar, Ravinder
   Singh, Prashant
   Chandra, Ramesh
   Kumari, Kamlesh
TI DFT and docking studies of designed conjugates of noscapines &
   repurposing drugs: promising inhibitors of main protease of SARS-CoV-2
   and falcipan-2
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Noscapine; repurposing drugs; hybrids; docking; DFT
ID COVID-19
AB First case of the present epidemic, coronavirus disease (COVID-19) is reported in the Wuhan, a city of the China and all the countries throughout the world are being affected. COVID-19 is named by World Health Organization and it stands for coronavirus disease-19. As on 27(th) October, 2020, 73,776,588 people around the world are infected. It is also known as SARS-CoV-2 infection. Till date, there is no promising drug or vaccine available in market to cure from this lethal infection. As the literature reported that noscapine a promising candidate to cure from malaria as well reported to be cough suppressant and anti-cancerous. In our previous work, a derivative of noscapine has shown potential behavior against the main protease of novel coronavirus or SARS-CoV-2. Based on the previous study, hybrid molecules based on noscapine and repurposing (antiviral) drugs were designed to target the main protease of novel coronavirus and falcipan-2 using molecular docking. It is proposed that the designed hydrids or conjugates may have promising antiviral property i.e. against the main protease of novel coronavirus and falcipan-2. The designed molecules were thoroughly studied by DFT and different thermodynamic parameters were determined. Further, infrared and Raman spectra of the designed hybrid molecules were determined and studied.
   Communicated by Ramaswamy H. Sarma
C1 [Kumar, Ajay] Indian Inst Technol, Dept Chem, Delhi, India.
   [Kumar, Ajay] Babasaheb Bhimrao Ambedkar Univ, Dept Appl Chem, Lucknow, Uttar Pradesh, India.
   [Kumar, Durgesh; Singh, Prashant] Univ Delhi, Atma Ram Sanatan Dharma Coll, Dept Chem, Delhi, India.
   [Kumar, Ravinder] Gurukula Kangri Vishwavidyalaya, Dept Chem, Haridwar, India.
   [Chandra, Ramesh] Univ Delhi, Dept Chem, Drug Discovery & Dev Lab, Delhi, India.
   [Kumari, Kamlesh] Univ Delhi, Deen Dayal Upadhyaya Coll, Dept Zool, Delhi, India.
RP Singh, P (corresponding author), Univ Delhi, Atma Ram Sanatan Dharma Coll, Dept Chem, Delhi, India.; Chandra, R (corresponding author), Univ Delhi, Dept Chem, Drug Discovery & Dev Lab, Delhi, India.; Kumari, K (corresponding author), Univ Delhi, Deen Dayal Upadhyaya Coll, Dept Zool, Delhi, India.
EM psingh@arsd.du.ac.in; acbrdu@hotmail.com; biotechnano@gmail.com
OI Kumar, Ajay/0000-0001-6219-9842
CR Abraham CS, 2019, SPECTROCHIM ACTA A, V222, DOI 10.1016/j.saa.2019.117188
   Afifi TH, 2019, MED CHEM RES, V28, P1471, DOI 10.1007/s00044-019-02387-5
   AHMED K, 2020, BRIT J SURG 1013, DOI DOI https://doi.org/10.1002/bjs.12046
   Ajayi TJ, 2019, J MOL STRUCT, V1197, P308, DOI 10.1016/j.molstruc.2019.07.060
   Al-Mandhari A, 2020, E MEDITERR HEALTH J, V26, P992, DOI 10.26719/2020.26.9.992
   Al-Tawfiq J. A., 2020, TRAVEL MED INFECT DI, V38
   ATAL S, 2020, BIODRUGS 1013, DOI DOI https://doi.org/10.1007/s40259-020-00448-5
   Bakouny Z, 2020, CANCER CELL, V38, P629, DOI 10.1016/j.ccell.2020.09.018
   Berekaa Mahmoud M, 2021, Front Biosci (Elite Ed), V13, P117
   Celik S, 2020, J BIOMOL STRUCT DYN, V38, P1354, DOI 10.1080/07391102.2019.1604263
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Di L, 2005, CURR OPIN DRUG DISC, V8, P495
   Dublin Sascha, 2020, medRxiv, DOI 10.1101/2020.07.06.20120386
   Durgesh K., 2020, HELIYON, V6
   El Bakri Y, 2020, J MOL STRUCT, V1202, DOI 10.1016/j.molstruc.2019.127317
   Dehaghi Behzad Fouladi, 2020, Invest. educ. enferm, V38, pe13, DOI 10.17533/udea.iee.v38n2e13
   Frisch M.J., 2016, GAUSSIAN 16 REV B 01
   Froberg A, 2020, J AM COLL HEALTH, DOI 10.1080/07448481.2020.1817037
   Gupta A, 2007, PROTEIN PEPTIDE LETT, V14, P632
   GUPTA L, 2020, RHEUMATOL INT 1013, DOI DOI https://doi.org/10.1007/s00296-020-04718-x
   Heo J, 2020, J MED INTERNET RES, V22, DOI 10.2196/22131
   HOOSHMAND SA, 2020, MOL DIVERS 0930, DOI DOI https://doi.org/10.1007/s11030-020-10144-9
   Hsieh KL, 2020, J MOTOR BEHAV, DOI 10.1080/00222895.2020.1814195
   Hsu KC, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-S1-S33
   Ino Hiroyasu, 2021, Camb Q Healthc Ethics, V30, P51, DOI 10.1017/S0963180120000481
   Kaddouri Y, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e03185
   Koren G, 2020, INT J MED EDUC, V11, P155, DOI 10.5116/ijme.5f09.79e2
   Kumar D, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1779131
   Kumar D, 2020, CHEMISTRYSELECT, V5, P4210, DOI 10.1002/slct.202000768
   Kumar D, 2020, J BIOMOL STRUCT DYN, V38, P3018, DOI 10.1080/07391102.2019.1650830
   Kumar D, 2019, CHEMISTRYSELECT, V4, P4892, DOI 10.1002/slct.201803360
   Kumar N., 2020, J PROTEOME RES, DOI [10.1021/acs.jproteome.0c00367, DOI 10.1021/ACS.JPR0TE0ME.0C00367]
   Kumar N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1808072
   Larki M, 2020, E MEDITERR HEALTH J, V26, P994, DOI 10.26719/emhj.20.097
   Liu CH, 2020, J AM COLL HEALTH, DOI 10.1080/07448481.2020.1803882
   Mahdian S, 2020, J DIABETES METAB DIS, DOI 10.1007/s40200-020-00546-9
   Mary YS, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02175
   Masoudi-Sobhanzadeh Y, 2020, BIOIMPACTS, V10, P205, DOI 10.34172/bi.2020.25
   Maurya N, 2019, ACS OMEGA, V4, P15829, DOI 10.1021/acsomega.9b01543
   Maurya N, 2019, MOL PHARMACEUT, V16, P952, DOI 10.1021/acs.molpharmaceut.8b00864
   Meyer-Almes FJ, 2020, COMPUT BIOL CHEM, V88, DOI 10.1016/j.compbiolchem.2020.107351
   Mucke HAM, 2020, ASSAY DRUG DEV TECHN, V18, P211, DOI 10.1089/adt.2020.996
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Rebeiro PF, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25627
   Sacco G, 2020, GERIATR PSYCHOL NEUR, V18, P135, DOI 10.1684/pnv.2020.0863
   Singh P., 2013, J ADV BIOL, V2
   Singh P., 2017, AM J PHARM PHARMACOT, V4, P9
   Singh P, 2016, INT J DRUG DEV RES, V8, P49
   Singh P, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02795
   Singhal S, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02596
   Vishvakarma V. K., 2017, BIOCHEM PHARMACOL, V6, P1
   Vishvakarma V. K., 2017, INFOR SCI LETT, V3, P1
   Vishvakarma VK, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02124
   Vishyakarma VK, 2019, CHEMISTRYSELECT, V4, P9410, DOI 10.1002/slct.201901119
NR 54
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1841030
EA NOV 2020
PG 21
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OJ6KY
UT WOS:000584068900001
PM 33140690
OA Bronze
DA 2021-01-01
ER

PT J
AU Kulkarni, S
AF Kulkarni, Spoorthy
TI Hypertension management in 2030: a kaleidoscopic view
SO JOURNAL OF HUMAN HYPERTENSION
LA English
DT Article; Early Access
ID BLOOD-PRESSURE CONTROL; METAANALYSIS; REGIMENS; THERAPY; WEIGHT; DIET;
   RISK
AB The last decade has witnessed the healthcare system going paperless with increased use of electronic healthcare records. Artificial intelligence tools including smartphones and smart watches have changed the landscape of day-to-day lives. Digitisation, decentralisation of healthcare and empowerment of allied healthcare providers and patients themselves have made shared clinical decision-making a reality. The year 2020 quickly turned into an unprecedented time in our lives with the entry of COVID-19. Amidst a pandemic, healthcare systems rapidly adapted and transformed, and changes that otherwise would have taken a decade, took a mere few weeks (Webster, Lancet 395:1180-1, 2020). This essay reviews evidence of transformation in the realm of hypertension management, namely diagnosis, lifestyle changes, therapeutics and prevention of hypertension at both individual and population levels, and presents an extrapolation of how this transformation might shape the next decade.
C1 [Kulkarni, Spoorthy] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England.
RP Kulkarni, S (corresponding author), Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England.
EM Spoorthyburli@gmail.com
CR Alexander S, 2017, J GERIATR CARDIOL, V14, P327, DOI 10.11909/j.issn.1671-5411.2017.05.014
   [Anonymous], 2020, CHANGE4LIFE
   BEANEY T, 2018, EUR HEART J, V2019, P2006, DOI DOI 10.1093/eurheartj/ehz300
   Bengtsson U, 2016, J CLIN HYPERTENS, V18, P101, DOI 10.1111/jch.12682
   Burnier M, 2019, CIRC RES, V124, P1124, DOI 10.1161/CIRCRESAHA.118.313220
   Cramer H, 2018, DTSCH ARZTEBL INT, V115, P833, DOI 10.3238/arztebl.2018.0833
   Dzau VJ, 2019, HYPERTENSION, V74, P450, DOI 10.1161/HYPERTENSIONAHA.119.13437
   Elmer PJ, 2006, ANN INTERN MED, V144, P485, DOI 10.7326/0003-4819-144-7-200604040-00007
   Heidenreich PA, 2011, CIRCULATION, V123, P933, DOI 10.1161/CIR.0b013e31820a55f5
   Hermida Ramon C, 2019, Eur Heart J, DOI 10.1093/eurheartj/ehz754
   Hoy SM, 2018, DRUGS, V78, P1625, DOI 10.1007/s40265-018-0983-6
   Kai H, 2020, HYPERTENS RES, V43, P648, DOI 10.1038/s41440-020-0455-8
   Kent L, 2013, NUTR METAB, V10, DOI 10.1186/1743-7075-10-58
   Leshem A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01341
   Mukhtar O, 2018, AM HEART J, V204, P102, DOI 10.1016/j.ahj.2018.05.006
   Neter JE, 2003, HYPERTENSION, V42, P878, DOI 10.1161/01.HYP.0000094221.86888.AE
   Nolan RP, 2018, CIRC-CARDIOVASC QUAL, V11, DOI 10.1161/CIRCOUTCOMES.117.004420
   Ogink PAM, 2019, J MED INTERNET RES, V21, DOI 10.2196/11164
   Omboni S, 2018, OPEN HEART, V5, DOI 10.1136/openhrt-2017-000687
   Pachori AS, 2001, HYPERTENSION, V37, P357, DOI 10.1161/01.HYP.37.2.357
   Marquez PHP, 2019, J HUM HYPERTENS, V33, P237, DOI 10.1038/s41371-018-0130-6
   Portune KJ, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201600252
   Ray KK, 2017, NEW ENGL J MED, V376, P1430, DOI 10.1056/NEJMoa1615758
   Rorie DA, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2318-4
   Souto EB, 2019, PHARM DEV TECHNOL, V24, P1044, DOI 10.1080/10837450.2019.1630426
   Storch U, 2012, J BIOL CHEM, V287, P3530, DOI 10.1074/jbc.M111.283218
   Thompson D, 2017, JMIR MHEALTH UHEALTH, V5, P13, DOI 10.2196/mhealth.6998
   Tompson A, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-027986
   Turnbull F, 2008, BMJ-BRIT MED J, V336, P1121, DOI 10.1136/bmj.39548.738368.BE
   Uijl E, 2019, HYPERTENSION, V73, P1249, DOI 10.1161/HYPERTENSIONAHA.119.12703
   Vazquez J, 2005, HYPERTENSION, V45, P115, DOI 10.1161/01.HYP.0000150161.78556.c6
   Webster P, 2020, LANCET, V395, P1180, DOI 10.1016/S0140-6736(20)30818-7
   Wolley MJ, 2017, J ENDOCR SOC, V1, P149, DOI 10.1210/js.2016-1107
   Zhou B, 2017, LANCET, V389, P37, DOI 10.1016/S0140-6736(16)31919-5
NR 34
TC 0
Z9 0
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-9240
EI 1476-5527
J9 J HUM HYPERTENS
JI J. Hum. Hypertens.
DI 10.1038/s41371-020-00438-8
EA NOV 2020
PG 6
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA OK1DZ
UT WOS:000584393200001
PM 33139827
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Abu Esba, LC
   Alqahtani, RA
   Thomas, A
   Shamas, N
   Alswaidan, L
   Mardawi, G
AF Abu Esba, Laila Carolina
   Alqahtani, Rahaf Ali
   Thomas, Abin
   Shamas, Nour
   Alswaidan, Lolowa
   Mardawi, Gahdah
TI Ibuprofen and NSAID Use in COVID-19 Infected Patients Is Not Associated
   with Worse Outcomes: A Prospective Cohort Study
SO INFECTIOUS DISEASES AND THERAPY
LA English
DT Article; Early Access
DE COVID-19; COVID-19 outcomes; Ibuprofen; NSAIDs
ID NUCLEOPROTEIN; NAPROXEN
AB Introduction Ibuprofen disappeared from the pharmacy shelves during the 2019 coronavirus (COVID-19) pandemic. However, a while later, information circulated that ibuprofen should be avoided as it could worsen COVID-19 symptoms. The aim of our study was to assess the association of acute and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) with worse COVID-19 outcomes. Methods We did a prospective cohort study between April 12 and June 1, 2020. Adults consecutively diagnosed with COVID-19 were included. Information on NSAID use was collected through a telephone questionnaire, and patients were followed up for COVID-19 infection outcomes, including death, admission, severity, time to clinical improvement, oxygen requirement and length of stay. Results Acute use of ibuprofen was not associated with a greater risk of mortality relative to non-use (adjusted hazard ratio [HR] 0.632 [95% CI 0.073-5.441; P = 0.6758]). Chronic NSAID use was also not associated with a greater risk of mortality (adjusted HR 0.492 [95% CI 0.178-1.362; P = 0.1721]). Acute ibuprofen use was not associated with a higher risk of admission compared to non-NSAID users (adjusted odds ratio OR 1.271; 95% CI 0.548-2.953). NSAID users did not have a significantly longer time to clinical improvement or length of stay. Conclusion Acute or chronic use of ibuprofen and other NSAIDs was not associated with worse COVID-19 disease outcomes.
C1 [Abu Esba, Laila Carolina; Alqahtani, Rahaf Ali; Alswaidan, Lolowa; Mardawi, Gahdah] Minist Natl Guard, Hlth Affairs, Pharmaceut Care Dept, Riyadh, Saudi Arabia.
   [Abu Esba, Laila Carolina; Alqahtani, Rahaf Ali; Shamas, Nour; Alswaidan, Lolowa; Mardawi, Gahdah] King Abdullah Int Med Res Ctr, Riyadh, Saudi Arabia.
   [Abu Esba, Laila Carolina; Alqahtani, Rahaf Ali; Shamas, Nour; Alswaidan, Lolowa; Mardawi, Gahdah] King Saud Bin Abdulaziz Univ Hlth Sci, Coll Pharm, Riyadh, Saudi Arabia.
   [Thomas, Abin] Cardiff Univ, Coll Biomed & Life Sci, Cardiff, Wales.
   [Shamas, Nour] Minist Natl Guard, Hlth Affairs, Infect Prevent & Control Dept, Riyadh, Saudi Arabia.
RP Abu Esba, LC (corresponding author), Minist Natl Guard, Hlth Affairs, Pharmaceut Care Dept, Riyadh, Saudi Arabia.
EM abuesbala@ngha.med.sa
OI Abu Esba, Laila Carolina/0000-0003-2459-1485; Thomas,
   Abin/0000-0002-8283-6762
FU King Abdullah International Medical Research Center (KAIMRC)
FX No funding was provided for the research or writing of this manuscript.
   The Rapid Service Fees were funded by King Abdullah International
   Medical Research Center (KAIMRC).
CR Agency EM, 2020, EMA GIV ADV US NONST
   Amici C, 2006, ANTIVIR THER, V11, P1021
   [Anonymous], 2020, NEWS B
   [Anonymous], 2018, TIMES P
   [Anonymous], 2020, TODAY U
   [Anonymous], 2020, NEWS N
   Castro VM, 2020, IDENTIFYING COMMON P, DOI [10.1101/2020.04.11.20061994, DOI 10.1101/2020.04.11.20061994]
   Chandler M, 2019, GLOBAL IBUPROFEN SHO
   Curhan GC, 2002, PHARMACOEPIDEM DR S, V11, P687, DOI 10.1002/pds.732
   DRUG USF, 2020, FDA ADV PAT US NONST
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   GOV.UK, 2020, COMM HUM MED ADV IB
   Khan A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1823-x
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lejal N, 2013, ANTIMICROB AGENTS CH, V57, P2231, DOI 10.1128/AAC.02335-12
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Micallef J, 2020, THERAPIE, V75, P355, DOI 10.1016/j.therap.2020.05.003
   Paulose-Ram R, 2005, PHARMACOEPIDEM DR S, V14, P257, DOI 10.1002/pds.983
   Qiao WL, 2015, CARDIOLOGY, V131, P97, DOI 10.1159/000375362
   SafiDahaj F, 2020, RE RESPONSE EMERGING
   Smart L, 2020, INFLAMMOPHARMACOLOGY, V28, P1141, DOI 10.1007/s10787-020-00745-z
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   WHO, 2020, R D BLUEPR COVID 19
   Willsher K, 2020, ANTIINFLAMMATORIES M
   Yang PH, 2014, SCI REP-UK, V4, DOI 10.1038/srep07027
   Zheng WN, 2019, CELL REP, V27, P1875, DOI 10.1016/j.celrep.2019.04.053
NR 26
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 2193-8229
EI 2193-6382
J9 INFECT DIS THER
JI Infect. Dis. Ther.
DI 10.1007/s40121-020-00363-w
EA NOV 2020
PG 16
WC Infectious Diseases
SC Infectious Diseases
GA OJ0CG
UT WOS:000583635100001
PM 33135113
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Brown, RE
   Tahseen, D
AF Brown, Robert E.
   Tahseen, Danyal
TI Pharmacologic Correlates that Address the Clinicopathobiology of
   COVID-19
SO ANNALS OF CLINICAL AND LABORATORY SCIENCE
LA English
DT Article
DE pharmacology; clinicopathobiology; COVID-19
ID TO-THE-EDITOR; MORPHOPROTEOMICS
AB COVID-19 could remain a pandemic until we get a SARS-CoV-2 vaccine to immunize the world population. In the interim, we have the opportunity to consider its clinicopathobiology in the context of the pharmacologic correlates available from the existing medical literature to prevent the COVID-19 infected patient from progressing into a fatal stage. This commentary serves as a forum for that end and suggests relatively non-toxic therapies that could be applied in a combinatorial fashion for consideration by the physicians and their patients with COVID-19 infection.
C1 [Brown, Robert E.] UTHlth McGovern Med Sch Houston, Dept Pathol & Lab Med, Houston, TX USA.
   [Tahseen, Danyal] UTHlth McGovern Med Sch Houston, Houston, TX USA.
RP Brown, RE (corresponding author), Assoc Clin Scientists, 6432 Fannin St, Houston, TX 77030 USA.; Brown, RE (corresponding author), UTHlth McGovern Med Sch, 6432 Fannin St, Houston, TX 77030 USA.
EM robert.brown@uth.tmc.edu
CR Ahidjo BA, 2020, ACS INFECT DIS, V6, P1624, DOI 10.1021/acsinfecdis.0c00236
   Ahmed F, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8040374
   Amici C, 2006, ANTIVIR THER, V11, P1021
   Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   Encinar JA, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050525
   Bassendine MF, 2020, J DIABETES, V12, P649, DOI 10.1111/1753-0407.13052
   Brown RE, 2020, ANN CLIN LAB SCI, V50, P699
   Brown RE, 2020, ANN CLIN LAB SCI, V50, P308
   Brown RE, 2020, ANN CLIN LAB SCI, V50, P287
   Chan JFW, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00310-20
   Chang B, 2004, MICROB PATHOGENESIS, V37, P295, DOI 10.1016/j.micpath.2004.10.002
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Drucker DJ, 2020, ENDOCR REV, V41, P457, DOI 10.1210/endrev/bnaa011
   Ghosh S, 2020, EXCLI J, V19, P528, DOI 10.17179/excli2020-1328
   Gomeni R, 2020, J PHARMACOKINET PHAR, V47, P189, DOI 10.1007/s10928-020-09690-4
   Grandi G, 2020, EXPERT REV CLIN PHAR, DOI [10.1080/17512433.2020.1750365, 10.1080/13625187.2020.1766017]
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Hoxha M, 2020, EUR J CLIN PHARMACOL, V76, P1501, DOI 10.1007/s00228-020-02941-w
   Huang W, 2020, CYTOM PART A, V97, P772, DOI 10.1002/cyto.a.24172
   Jiang YJ, 2020, CLIN IMMUNOL, V218, DOI 10.1016/j.clim.2020.108516
   Khan M, 2010, J MED VIROL, V82, P817, DOI 10.1002/jmv.21663
   Kwiek JJ, 2004, BIOCHEMISTRY-US, V43, P4538, DOI 10.1021/bi035923w
   Miroliaee AE, 2018, J CRIT CARE, V44, P300, DOI 10.1016/j.jcrc.2017.08.040
   Russell B, ECANCERMEDICALSCIENC
   Scavone C, 2020, BRIT J PHARMACOL, V177, P4813, DOI 10.1111/bph.15072
   Schonrich G, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00207
   Sharma S, 2020, DIABETES RES CLIN PR, V164, DOI 10.1016/j.diabres.2020.108183
   Solerte SB, 2020, ACTA DIABETOL, V57, P779, DOI 10.1007/s00592-020-01539-z
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Yamamoto N, 2004, BIOCHEM BIOPH RES CO, V318, P719, DOI 10.1016/j.bbrc.2004.04.083
   Yaqinuddin A, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109777
   Yoshimoto FK, 2020, PROTEIN J, V39, P198, DOI 10.1007/s10930-020-09901-4
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhao M, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105982
   Zheng Y, 2020, J MED VIROL, DOI 10.1002/jmv.26218
NR 36
TC 0
Z9 0
U1 0
U2 0
PU ASSOC CLINICAL SCIENTISTS
PI MIDDLEBURY
PA PO BOX 1287, MIDDLEBURY, VT 05753 USA
SN 0091-7370
EI 1550-8080
J9 ANN CLIN LAB SCI
JI Ann. Clin. Lab. Sci.
PD NOV-DEC
PY 2020
VL 50
IS 6
BP 837
EP 841
PG 5
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA PG7XW
UT WOS:000599944900019
PM 33334802
DA 2021-01-01
ER

PT J
AU Lempel, M
   Lempel, A
   Bielory, L
AF Lempel, Matthew
   Lempel, Allen
   Bielory, Leonard
TI Correlation of Point of Care SARS-CoV-2 Serological Assay with
   Quantitative ELISA
SO ANNALS OF CLINICAL AND LABORATORY SCIENCE
LA English
DT Article
AB Due to the COVID-19 pandemic, the Food and Drug Administration issued an Emergency Use Authorization to permit developers of certain serological tests to market their product prior to a comprehensive review. Nonetheless, the reliability of these assays is of great importance in order to be useful as a tool in estimating the relative proportions of different populations that have been exposed to SARS-CoV-2. We provide a sampling of 145 individuals from an ambulatory setting simultaneously tested with a qualitative point of care rapid finger prick Lateral Wave (R) IgM and IgG assay and a sample for the Mayo Clinic enzyme linked immunosorbent assay (ELISA) IgM/IgG antibody assay. Significant discrepancies did exist between the purported antibody responses as demonstrated by each assay.
C1 [Lempel, Matthew] Yale Sch Med, Yale New Haven Hosp, Waterbury Program, Dept Med, Waterbury, CT USA.
   [Lempel, Allen] Ocean Cty Internal Med Associates, Lakewood, NJ USA.
   [Bielory, Leonard] Seton Hall Univ, Hackensack Meridian Sch Med, Dept Med Allergy Immunol & Ophthalmol, Hackensack, NJ USA.
RP Lempel, M (corresponding author), Yale New Haven Med Ctr, Waterbury Program, Dept Internal Med, 64 Robbins St, Waterbury, CT 06708 USA.
EM Matthew.Lempel@yale.edu
CR [Anonymous], 2020, COVID 19 SEROLOGY SU
   [Anonymous], 2020, SYMPT COR
   Commissioner Office of the, 2020, COR COVID 19 UPD SER
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Menni C, 2020, NAT MED, V26, P1037, DOI 10.1038/s41591-020-0916-2
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ASSOC CLINICAL SCIENTISTS
PI MIDDLEBURY
PA PO BOX 1287, MIDDLEBURY, VT 05753 USA
SN 0091-7370
EI 1550-8080
J9 ANN CLIN LAB SCI
JI Ann. Clin. Lab. Sci.
PD NOV-DEC
PY 2020
VL 50
IS 6
BP 852
EP 854
PG 3
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA PG7XW
UT WOS:000599944900022
PM 33334805
DA 2021-01-01
ER

PT J
AU Grosshennig, A
   Koch, A
AF Grosshennig, Anika
   Koch, Armin
TI COVID-19 hits a trial: Arguments against hastily deviating from the plan
SO CONTEMPORARY CLINICAL TRIALS
LA English
DT Article
DE Clinical trial; COVID-19; Consistency; Trial adaptation; Impact of the
   pandemic on trial conduct
AB The COVID-19 pandemic has substantially impacted the conduct of clinical trials. While initially preparing for a period of time, where it would likely be impossible to supervise trials in the usual way and precautionary measures had to be implemented to care for medication supply and general safety of study participants it is now important to consider, how the impact of the pandemic on trial outcome can be assessed, which measures are needed to decide, how to proceed with the trial and what is needed to compensate to irregularity introduced by the pandemic situation. Obviously not all trials will suffer to the same degree: some trials may be close to finalizing recruitment, others may not yet have started. Similarly not all clinical trials investigate vulnerable patient populations, but some will and may in addition have recruited to an extent that beneficial effects achieved in the initial phase of the trial may be outweighed by an increase e.g. in mortality that impacts both treatment groups. The situation is further complicated by the fact that the pandemic reached different countries in the world and even cities in one country at different points in time with different severity. Our example is a randomized and double-blind clinical trial comparing digitoxin and placebo in patients with advanced chronic heart failure. This trial has recruited roughly 1/3 of the overall 2200 patients when the disease outbreak reached Germany. We discuss how simulations and theoretical considerations can be used to address questions about the need to increase the overall sample-size to be recruited to compensate for a potential shrinkage of the treatment effect caused by the COVID-19 pandemic and what role the degree of consistency could play when comparing pre-, duringand postCOVID-19 periods of trial conduct regarding the question, whether the treatment effect can be considered consistent and with this generalizable. This is dependent on the size of the treatment effect and the impact of the pandemic. We argue, that in case of doubt, it may be wise to proceed with the original study plan.
C1 [Grosshennig, Anika; Koch, Armin] Hannover Med Sch, Inst Biometrie, Carl Neuberg Str 1, D-30625 Hannover, Germany.
RP Grosshennig, A; Koch, A (corresponding author), Hannover Med Sch, Inst Biometrie, Carl Neuberg Str 1, D-30625 Hannover, Germany.
EM grosshennig.anika@mh-hannover.de; koch.armin@mh-hannover.de
FU Federal Ministry of Education and Research (BMBF)Federal Ministry of
   Education & Research (BMBF) [01KG1303]
FX This work has been funded by the Federal Ministry of Education and
   Research (BMBF; 01KG1303).
CR [Anonymous], 2020, GUIDANCE MANAGEMENT
   [Anonymous], 2020, FDA GUIDANCE CONDUCT
   Bavendiek U, 2019, EUR J HEART FAIL, V21, P676, DOI 10.1002/ejhf.1452
   Castagno D, 2012, EUR HEART J, V33, P1137, DOI 10.1093/eurheartj/ehs004
   Deutsches Arzteblatt, 2020, COVID 19 FOLG WEN HE
   Statistisches Bundesamt Bundesamt, 2020, STERB APR 2020 8 DUR
NR 6
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1551-7144
EI 1559-2030
J9 CONTEMP CLIN TRIALS
JI Contemp. Clin. Trials
PD NOV
PY 2020
VL 98
AR 106155
DI 10.1016/j.cct.2020.106155
PG 4
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA OY1BN
UT WOS:000593988500022
PM 32961360
OA Other Gold
DA 2021-01-01
ER

PT J
AU Sun, YH
   Li, H
   Luo, GF
   Meng, XJ
   Guo, W
   Fitzpatrick, T
   Ao, YL
   Feng, AP
   Liang, BW
   Zhan, YW
   Sande, A
   Xie, F
   Wang, Y
   Qian, HZ
   Cai, Y
   Zou, HC
AF Sun, Yinghui
   Li, Hui
   Luo, Ganfeng
   Meng, Xiaojun
   Guo, Wei
   Fitzpatrick, Thomas
   Ao, Yunlong
   Feng, Anping
   Liang, Bowen
   Zhan, Yuewei
   Sande, Amakobe
   Xie, Feng
   Wang, Ying
   Qian, Han-Zhu
   Cai, Yong
   Zou, Huachun
TI Antiretroviral treatment interruption among people living with HIV
   during COVID-19 outbreak in China: a nationwide cross-sectional study
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Article
DE antiretroviral therapy interruption; antiretroviral therapy; HIV;
   lockdown; COVID&#8208; 19; China
AB Introduction Social disruption associated with coronavirus disease 2019 (COVID-19) threatens to impede access to regular healthcare, including for people living with HIV (PLHIV), potentially resulting in antiretroviral therapy (ART) interruption (ATI). We aimed to explore the characteristics and factors associated with ATI during the COVID-19 outbreak in China.
   Methods We conducted an online survey among PLHIV by convenience sampling through social media between 5 and 17 February 2020. Respondents were asked to report whether they were at risk of ATI (i.e. experienced ATI, risk of imminent ATI, threatened but resolved risk of ATI [obtaining ART prior to interruption]) or were not at risk of ATI associated with the COVID-19 outbreak. PLHIV were also asked to report perceived risk factors for ATI and sources of additional ART. The factors associated with the risk of ATI were assessed using logistic regression. We also evaluated the factors associated with experienced ATI.
   Results A total of 5084 PLHIV from 31 provinces, autonomous regions and municipalities in mainland China completed the survey, with valid response rate of 99.4%. The median age was 31 years (IQR 27 to 37), 96.5% of participants were men, and 71.3% were men who had sex with men. Over one-third (35.1%, 1782/5084) reported any risk of ATI during the COVID-19 outbreak, including 2.7% (135/5084) who experienced ATI, 18.0% (917/5084) at risk of imminent ATI and 14.4% (730/5084) at threatened but resolved risk. PLHIV with ATI were more likely to have previous interruptions in ART (aOR 8.3, 95% CI 5.6 to 12.3), travelled away from where they typically receive HIV care (aOR 3.0, 95% CI 2.1 to 4.5), stayed in an area that implemented citywide lockdowns or travel restrictions to control COVID-19 (aOR 2.5, 95% CI 1.4 to 4.6), and be in permanent residence in a rural area (aOR 3.7, 95% CI 2.3 to 5.8).
   Conclusions A significant proportion of PLHIV in China are at risk of ATI during the COVID-19 outbreak and some have already experienced ATI. Correlates of ATI and self-reported barriers to ART suggest that social disruptions from COVID-19 have contributed to ATI. Our findings demonstrate an urgent need for policies and interventions to maintain access to HIV care during public health emergencies.
C1 [Sun, Yinghui; Luo, Ganfeng; Feng, Anping; Liang, Bowen; Zhan, Yuewei; Zou, Huachun] Sun Yat Sen Univ, Sch Publ Hlth Shenzhen, Shenzhen, Peoples R China.
   [Li, Hui] Shizhong Dist Ctr Dis Control & Prevent, Jinan, Peoples R China.
   [Meng, Xiaojun] Wuxi Municipal Ctr Dis Control & Prevent, Wuxi, Jiangsu, Peoples R China.
   [Guo, Wei; Sande, Amakobe] UNAIDS China Off, Beijing, Peoples R China.
   [Fitzpatrick, Thomas] Univ Washington, Dept Internal Med, Seattle, WA 98195 USA.
   [Ao, Yunlong] Guangzhou Med Sch, Dept Infect Dis, Guangzhou Peoples Hosp 8, Guangzhou, Peoples R China.
   [Xie, Feng] Chongqing Blue Sky Nongovt Org, Chongqing, Peoples R China.
   [Wang, Ying; Cai, Yong; Zou, Huachun] Shanghai Jiao Tong Univ, Sch Publ Hlth, Sch Med, Shanghai, Peoples R China.
   [Qian, Han-Zhu] Shanghai Jiao Tong Univ SJTU, SJTU Yale Joint Ctr Biostat & Data Sci, Sch Life Sci & Biotechnol, Dept Bioinformat & Biostat, Shanghai, Peoples R China.
   [Qian, Han-Zhu] Yale Sch Publ Hlth, New Haven, CT USA.
   [Zou, Huachun] Shenzhen Ctr Dis Control & Prevent, Shenzhen, Peoples R China.
   [Zou, Huachun] Univ New South Wales, Kirby Inst, Sydney, NSW, Australia.
RP Cai, Y (corresponding author), 227 South Chongqing Rd, Shanghai 200025, Peoples R China.; Zou, HC (corresponding author), 74 Zhongshan 2nd Rd, Guangzhou 510085, Guangdong, Peoples R China.
EM caiyong202028@hotmail.com; zouhuachun@mail.sysu.edu.cn
OI Meng, Xiaojun/0000-0001-5201-0452; Sun, Yinghui/0000-0001-9946-9877
FU Natural Science Foundation of China Excellent Young Scientists Fund
   [82022064]; Natural Science Foundation of China International/Regional
   Research Collaboration Project [72061137001]; Natural Science Foundation
   of China Young Scientist Fund [81703278]; Australian National Health and
   Medical Research Commission (NHMRC) Early Career FellowshipNational
   Health and Medical Research Council of Australia [APP1092621]; National
   Science and Technology Major Project of China [2018ZX10721102]; Sanming
   Project of Medicine in Shenzhen [SZSM201811071]; High Level Project of
   Medicine in Longhua, Shenzhen [HLPM201907020105]; National Key Research
   and Development Program of China [2020YFC0840900]
FX This study was supported by the Natural Science Foundation of China
   Excellent Young Scientists Fund [82022064], the Natural Science
   Foundation of China International/Regional Research Collaboration
   Project [72061137001], Natural Science Foundation of China Young
   Scientist Fund [81703278], the Australian National Health and Medical
   Research Commission (NHMRC) Early Career Fellowship (grant number
   APP1092621), the National Science and Technology Major Project of China
   [2018ZX10721102], the Sanming Project of Medicine in Shenzhen
   [SZSM201811071], the High Level Project of Medicine in Longhua, Shenzhen
   [HLPM201907020105], and the National Key Research and Development
   Program of China [2020YFC0840900]. All funding parties did not have any
   role in the design of the study or in the explanation of the data.
CR Ahonkhai AA, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1137-z
   [Anonymous], 2020, WE MUST ENS HIV TREA
   [Anonymous], 2020, VOL DRIV WUH
   [Anonymous], 2020, COMM NETW EXT ARMS C
   Boyer S, 2011, SOC SCI MED, V72, P1383, DOI 10.1016/j.socscimed.2011.02.030
   Chen W, 2020, Zhonghua Yu Fang Yi Xue Za Zhi, V54, P239, DOI 10.3760/cma.j.issn.0253-9624.2020.03.003
   China News, 2019, CHINA NEWS
   Govindasamy D, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.19032
   Grosso A, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25042
   Guo W, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P662, DOI 10.3760/cma.j.cn112338-20200314-00345
   Hao Y, 2014, CHIN J DIS CONTROL P, V18, P369
   Hu XH, 2020, ZHONGHUA WEI CHANG W, V23, pE002
   Jiang HB, 2020, LANCET HIV, V7, pE308, DOI 10.1016/S2352-3018(20)30105-3
   Leal L, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030442
   Liao YH, 2020, J CLIN CARDIOL, V36, P1
   Ma Y, 2018, CLIN INFECT DIS, V66, P833, DOI 10.1093/cid/cix911
   Montag C, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.02247
   National Health Commission of the People's Republic of China, 2020, UPD COVID 19 OUTBR 2
   Petersen E, 2020, INT J INFECT DIS, V96, P233, DOI 10.1016/j.ijid.2020.04.035
   Shiau S, 2020, AIDS BEHAV, V24, P2244, DOI 10.1007/s10461-020-02871-9
   Tan Wei, 2016, China Tropical Medicine, V16, P782
   UNAIDS, 2020, ENS PEOPL LIV HIV PH
   UNAIDS, 2019, PEOPL LIV HIV REC AR
   UNAIDS, 2020, UNAIDS CHIN WORK TOG
   Wang J, 2018, CAPITAL J PUBLIC HEA, V12, P282
   Wu ZY, 2019, CURR HIV-AIDS REP, V16, P458, DOI 10.1007/s11904-019-00471-4
   Xu Yan, 2020, Zhongguo Fei Ai Za Zhi, V23, P136, DOI 10.3779/j.issn.1009-3419.2020.03.02
   Zhang FJ, 2005, CELL RES, V15, P877, DOI 10.1038/sj.cr.7290362
   Zhang FJ, 2007, AIDS, V21, pS143, DOI 10.1097/01.aids.0000304710.10036.2b
NR 29
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD NOV
PY 2020
VL 23
IS 11
AR e25637
DI 10.1002/jia2.25637
PG 12
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA PB3FQ
UT WOS:000596211100007
PM 33247541
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tamagusko, T
   Ferreira, A
AF Tamagusko, Tiago
   Ferreira, Adelino
TI Data-Driven Approach to Understand the Mobility Patterns of the
   Portuguese Population during the COVID-19 Pandemic
SO SUSTAINABILITY
LA English
DT Article
DE COVID-19; mobility patterns; Rt; changepoint; modeling; Portugal
AB SARS-CoV-2 emerged in late 2019. Since then, it has spread to several countries, becoming classified as a pandemic. So far, there is no definitive treatment or vaccine, so the best solution is to prevent transmission between individuals through social distancing. However, it is not easy to measure the effectiveness of these distance measures. Therefore, this study uses data from Google COVID-19 Community Mobility Reports to understand the Portuguese population's mobility patterns during the COVID-19 pandemic. In this study, the Rt value was modeled for Portugal. In addition, the changepoint was calculated for the population mobility patterns. Thus, the mobility pattern change was used to understand the impact of social distance measures on the dissemination of COVID-19. As a result, it can be stated that the initial Rt value in Portugal was very close to 3, falling to values close to 1 after 25 days. Social isolation measures were adopted quickly. Furthermore, it was observed that public transport was avoided during the pandemic. Finally, until the emergence of a vaccine or an effective treatment, this is the new normal, and it must be understood that new patterns of mobility, social interaction, and hygiene must be adapted to this reality.
C1 [Tamagusko, Tiago; Ferreira, Adelino] Univ Coimbra, Dept Civil Engn, Res Ctr Terr Transports & Environm, P-3030788 Coimbra, Portugal.
RP Ferreira, A (corresponding author), Univ Coimbra, Dept Civil Engn, Res Ctr Terr Transports & Environm, P-3030788 Coimbra, Portugal.
EM tamagusko@gmail.com; adelino@dec.uc.pt
FU Research Center for Territory, Transports and Environment (CITTA); ACIV
FX This research was funded by the Research Center for Territory,
   Transports and Environment (CITTA), and also by ACIV.
CR Aktay A., 2020, ARXIV200404145
   [Anonymous], 2020, WHO NOV COR CHIN 11
   Carteni A, 2020, SCI TOTAL ENVIRON, V741, DOI 10.1016/j.scitotenv.2020.140489
   Chinazzi M, 2020, SCIENCE, V368, P395, DOI 10.1126/science.aba9757
   Flaxman S, 2020, NATURE, V584, P257, DOI 10.1038/s41586-020-2405-7
   Gondauri D, 2020, ELECTRON J GEN MED, V17, DOI 10.29333/ejgm/8212
   Gopalan A, 2020, J INDIAN I SCI, V100, P863, DOI 10.1007/s41745-020-00210-4
   Haydon DT, 2003, P ROY SOC B-BIOL SCI, V270, P121, DOI 10.1098/rspb.2002.2191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jenelius E., 2020, TRANSP RES INTERDISC, V8, P100242, DOI 10.1016/j.trip.2020.100242
   Killick R, 2012, J AM STAT ASSOC, V107, P1590, DOI 10.1080/01621459.2012.737745
   Killick R, 2014, J STAT SOFTW, V58, P1
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Loewenthal G, 2020, EMBO MOL MED, DOI 10.15252/emmm.202013171
   Nishiura H, 2020, INT J INFECT DIS, V93, P284, DOI 10.1016/j.ijid.2020.02.060
   R Core Team, 2017, R LANG ENV STAT COMP
   Rodriguez-Barranco Miguel, 2021, Environ Res, V192, P110223, DOI 10.1016/j.envres.2020.110223
   Roser M., CORONAVIRUS PANDEMIC
   RStudio Team, 2020, RSTUDIO INT DEV R
   SCOTT AJ, 1974, BIOMETRICS, V30, P507, DOI 10.2307/2529204
   Silva C, 2019, TRANSP RES PROC, V41, P637, DOI 10.1016/j.trpro.2019.09.113
   Slater SJ, 2020, PREV CHRONIC DIS, V17, DOI 10.5888/pcd17.200204
   Spiteri G, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.9.2000178
   Venter ZS, 2020, ENVIRON RES LETT, V15, DOI 10.1088/1748-9326/abb396
   Wallinga J, 2007, P ROY SOC B-BIOL SCI, V274, P599, DOI 10.1098/rspb.2006.3754
   Wallinga J, 2004, AM J EPIDEMIOL, V160, P509, DOI 10.1093/aje/kwh255
   WHO, 2020, CONS QUAR IND CONT C, P3
   WISE J, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M2294
NR 28
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2071-1050
J9 SUSTAINABILITY-BASEL
JI Sustainability
PD NOV
PY 2020
VL 12
IS 22
AR 9775
DI 10.3390/su12229775
PG 12
WC Green & Sustainable Science & Technology; Environmental Sciences;
   Environmental Studies
SC Science & Technology - Other Topics; Environmental Sciences & Ecology
GA OY9JU
UT WOS:000594555800001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Baroutjian, A
   Sanchez, C
   Boneva, D
   McKenney, M
   Elkbuli, A
AF Baroutjian, Amanda
   Sanchez, Carol
   Boneva, Dessy
   McKenney, Mark
   Elkbuli, Adel
TI SARS-CoV-2 pharmacologic therapies and their safety/effectiveness
   according to level of evidence
SO AMERICAN JOURNAL OF EMERGENCY MEDICINE
LA English
DT Article
DE SARS-CoV-2; COVID-19 pharmacologic treatments; Drug effectiveness; Drug
   safety; COVID-19 clinical outcomes
ID COVID-19
AB Introduction: There is a pressing need for COVID-19 transmission control and effective treatments. We aim to evaluate the safety and effectiveness of SARS-CoV-2 pharmacologic therapies as of August 2, 2020 according to study level of evidence.
   Methods: PubMed, ScienceDirect, Cochrane Library, JAMA Network and PNAS were searched. The following keywords were used: ((COVID-19) OR (SARS-CoV-2)) AND ((((((therapeutics) OR (treatment)) OR (vaccine)) OR (hydroxychloroquine)) OR (antiviral)) OR (prognosis)). Results included peer-reviewed studies published in English.
   Results: 15 peer-reviewed articles met study inclusion criteria, of which 14 were RCTs and one was a systematic review with meta-analysis. The following pharmacologic therapies were evaluated: chloroquine (CQ), hydroxychloroquine (HCQ), antivirals therapies, plasma therapy, anti-inflammatories, and a vaccine.
   Conclusion: According to level 1 evidence reviewed here, the most effective SARS-Co-V-2 pharmacologic treatments include remdesivir for mild to severe disease, and a triple regimen therapy consisting of lopinavirritonavir, ribavirin and interferon beta-1b for mild to moderate disease. Also, dexamethasone significantly reduced mortality in those requiring respiratory support. However, there is still a great need for detailed level 1 evidence on pharmacologic therapies. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Baroutjian, Amanda; Sanchez, Carol; Boneva, Dessy; McKenney, Mark; Elkbuli, Adel] Kendall Reg Med Ctr, Dept Surg, Div Trauma & Acute Care Surg, Miami, FL USA.
   [Boneva, Dessy] Univ S Florida, Dept Surg, Tampa, FL USA.
RP Elkbuli, A (corresponding author), 11750 Bird Rd, Miami, FL 33175 USA.
EM Adel.Elkbuli@hcahealthcare.com
CR Ahn DG, 2020, J MICROBIOL BIOTECHN, V30, P313, DOI 10.4014/jmb.2003.03011
   Al-Quteimat OM, 2020, AM J CLIN ONCOL-CANC, V43, P452, DOI 10.1097/COC.0000000000000712
   Alanagreh L, 2020, INT J RISK SAF MED, V31, P111, DOI 10.3233/JRS-200024
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bessiere F, 2020, JAMA CARDIOL, V5, P1067, DOI 10.1001/jamacardio.2020.1787
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Burns PB, 2011, PLAST RECONSTR SURG, V128, P305, DOI 10.1097/PRS.0b013e318219c171
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cao Y, 2020, J ALLERGY CLIN IMMUN, V146, P137, DOI 10.1016/j.jaci.2020.05.019
   Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014
   Chatre C, 2018, DRUG SAFETY, V41, P919, DOI 10.1007/s40264-018-0689-4
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   de Abajo FJ, 2020, LANCET, V395, P1705, DOI 10.1016/S0140-6736(20)31030-8
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Gevers S, 2020, CLIN MICROBIOL INFEC, V26, P1276, DOI 10.1016/j.cmi.2020.05.006
   Goldman Jason D, 2020, N Engl J Med, V383, P1827, DOI 10.1056/NEJMoa2015301
   Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Jin YF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040372
   Kaafarani HMA, 2020, ANN SURG, V272, pE61, DOI 10.1097/SLA.0000000000004004
   Kowalik MM, 2020, CARDIOL J, V27, P99, DOI 10.5603/CJ.a2020.0065
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Li Yueping, 2020, Med (N Y), V1, P105, DOI 10.1016/j.medj.2020.04.001
   Pan XW, 2020, INTENS CARE MED, V46, P1114, DOI 10.1007/s00134-020-06026-1
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Reihani H, 2020, AM J EMERG MED, DOI [10.1016/j.ajem.2020.05.001, DOI 10.1016/J.AJEM.2020.05.001S0735-6757(20)30317-X]
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Sarma P, 2020, J MED VIROL, V92, P776, DOI 10.1002/jmv.25898
   Shah K, 2020, AM J EMERG MED, V38, DOI 10.1016/j.ajem.2020.04.075
   Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849
   Thomas SHL, 2016, BRIT J CLIN PHARMACO, V81, P420, DOI 10.1111/bcp.12726
   US Food and Drug Administration, 2020, EM US AUTH
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   World Health Organization, 2020, ADV US POINT IMM TES
   Ye ZW, 2020, INT J BIOL SCI, V16, P1686, DOI 10.7150/ijbs.45472
   Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6
NR 40
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0735-6757
EI 1532-8171
J9 AM J EMERG MED
JI Am. J. Emerg. Med.
PD NOV
PY 2020
VL 38
IS 11
BP 2405
EP 2415
DI 10.1016/j.ajem.2020.08.091
PG 11
WC Emergency Medicine
SC Emergency Medicine
GA PG1ON
UT WOS:000599512200030
PM 33041111
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Stafford, EG
   Riviere, JE
   Xu, X
   Kawakami, J
   Wyckoff, GJ
   Jaberi-Douraki, M
AF Stafford, Emma G.
   Riviere, Jim E.
   Xu, Xuan
   Kawakami, Jessica
   Wyckoff, Gerald J.
   Jaberi-Douraki, Majid
TI Pharmacovigilance in patients with diabetes: A data-driven analysis
   identifying specific RAS antagonists with adverse pulmonary safety
   profiles that have implications for COVID-19 morbidity and mortality
SO JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION
LA English
DT Article
AB Objectives: The current demographic information from China reports that 10%-19% of patients hospitalized with coronavirus disease (COVID-19) were diabetic. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are considered first-line agents in patients with diabetes because of their nephroprotective effects, but administration of these drugs leads to upregulation of angiotensin-converting enzyme 2 (ACE2), which is responsible for the viral entry of severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2). Data are lacking to determine what pulmonary effects ACEIs or ARBs may have in patients with diabetes, which could be relevant in the management of patients infected with SARS-CoV-2. This study aims to assess the prevalence of pulmonary adverse drug effects (ADEs) in patients with diabetes who were taking ACEI or ARBs to provide guidance as to how these medications could affect outcomes in acute respiratory illnesses such as SARS-CoV-2 infection.
   Methods: 1DATA, a unique data platform resulting from collaboration across veterinary and human health care, used an intelligent medicine recommender system (1DrugAssist) developed using several national and international databases to evaluate all ADEs reported to the Food and Drug Administration for patients with diabetes taking ACEIs or ARBs.
   Results: Mining of this data elucidated the proportion of a cluster of pulmonary ADEs associated with specific medications in these classes, which may aid health care professionals in understanding how these medications could worsen or predispose patients with diabetes to infections affecting the respiratory system, specifically COVID-19. Based on this data mining process, captopril was found to have a statistically significantly higher incidence of pulmonary ADEs compared with other ACEIs (P = 0.005) as well as ARBs (P = 0.012), though other specific drugs also had important pulmonary ADEs associated with their use.
   Conclusion: These analyses suggest that pharmacists and clinicians will need to consider the specific medication's adverse event profile, particularly captopril, on how it may affect infections and other acute disease states that alter pulmonary function, such as COVID-19. (C) 2020 American Pharmacists Association (R). Published by Elsevier Inc.
C1 [Stafford, Emma G.] Univ Missouri, Div Pharmacol & Pharmaceut Sci, Consortium 1DATA, Sch Pharm, Kansas City, MO 64110 USA.
   [Riviere, Jim E.] Kansas State Univ, Consortium 1DATA, Manhattan, KS 66506 USA.
   [Xu, Xuan; Jaberi-Douraki, Majid] Kansas State Univ, Dept Math, Inst Computat Comparat Med, Consortium 1DATA, 1800 Denison St,P-200 Mosier Hall, Manhattan, KS 66506 USA.
   [Kawakami, Jessica] Univ Missouri, Sch Biol & Chem Sci, Consortium 1DATA, Kansas City, MO 64110 USA.
   [Wyckoff, Gerald J.] Univ Missouri, Sch Pharm, Consortium 1DATA, Mol Biol & Biochem,Sch Biol & Chem Sci,Div Pharma, Kansas City, MO 64110 USA.
RP Jaberi-Douraki, M (corresponding author), Kansas State Univ, Dept Math, Inst Computat Comparat Med, Consortium 1DATA, 1800 Denison St,P-200 Mosier Hall, Manhattan, KS 66506 USA.
EM jaberi@k-state.edu
OI Kawakami, Jessica/0000-0002-7141-5698
FU BioNexus KC
FX Gerald J. Wyckoff and Majid Jaberi-Douraki accepted funding from
   BioNexus KC for this project.
CR American Diabetes Association, 2020, Clin Diabetes, V38, P10, DOI 10.2337/cd20-as01
   B_ohm R, PRIMER DISPROPORTION
   Brett AS, NEJM J WATCH
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Furberg CD, 2001, J AM COLL CARDIOL, V37, P1456, DOI 10.1016/S0735-1097(01)01161-5
   Hilal-Danden R., 2020, GOODMAN GILMANS PHAR, pHilal
   James PA, 2014, JAMA-J AM MED ASSOC, V311, P1809, DOI 10.1001/jama.2013.284427
   Patel AB, 2020, JAMA-J AM MED ASSOC, V323, P1769, DOI 10.1001/jama.2020.4812
   Staley J, 2019, TOP COMPANION ANIM M, V37, DOI 10.1016/j.tcam.2019.100367
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   U.S. Food and Drug Administration, TISS GUID
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wishart DS, 2006, NUCLEIC ACIDS RES, V34, pD668, DOI 10.1093/nar/gkj067
   Xu X, 2019, TOP COMPANION ANIM M, V37, DOI 10.1016/j.tcam.2019.100366
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1544-3191
EI 1544-3450
J9 J AM PHARM ASSOC
JI J. Am. Pharm. Assoc.
PD NOV-DEC
PY 2020
VL 60
IS 6
BP E145
EP E152
DI 10.1016/j.japh.2020.05.018
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OM1AL
UT WOS:000585761700030
PM 32561317
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bollag, WB
   Gonzales, JN
AF Bollag, Wendy B.
   Gonzales, Joyce N.
TI Phosphatidylglycerol and surfactant: A potential treatment for COVID-19?
SO MEDICAL HYPOTHESES
LA English
DT Article
DE COVID-19; Innate immunity; Phosphatidylglycerol; SARS-CoV-2; Surfactant
ID RESPIRATORY-DISTRESS-SYNDROME; BOVINE NATURAL SURFACTANT; PULMONARY
   SURFACTANT; LUNG SURFACTANT; SEPTIC SHOCK; TOLL; ARDS; INFLAMMATION;
   PROTEINS; TENSION
AB A hypothesis concerning the potential utility of surfactant supplementation for the treatment of critically ill patients with COVID-19 is proposed, along with a brief summary of the data in the literature supporting this idea. It is thought that surfactant, which is already approved by the Food and Drug Administration for intratracheal administration to treat neonatal respiratory distress syndrome in pre-term infants, could benefit COVID-19-infected individuals by: (1) restoring surfactant damaged by lung infection and/or decreased due to the virus-induced death of the type II pneumocytes that produce it and (2) reducing surface tension to decrease the work of breathing and limit pulmonary edema. In addition, a constituent of surfactant, phosphatidylglycerol, could mitigate COVID-19-induced lung pathology by: (3) decreasing excessive innate immune system stimulation via its inhibition of toll-like receptor-2 and -4 activation by microbial components and cellular proteins released by damaged cells, thereby limiting inflammation and the resultant pulmonary edema, and (4) possibly blocking spread of the viral infection to non-infected cells in the lung. Therefore, it is suggested that surfactant preparations containing phosphatidylglycerol be tested for their ability to improve lung function in critically ill patients with COVID-19.
C1 [Bollag, Wendy B.] Charlie Norwood VA Med Ctr, Augusta, GA 30904 USA.
   [Bollag, Wendy B.] Augusta Univ, Med Coll Georgia, Dept Physiol, Augusta, GA 30912 USA.
   [Bollag, Wendy B.] Augusta Univ, Med Coll Georgia, Dept Dermatol, Augusta, GA 30912 USA.
   [Bollag, Wendy B.; Gonzales, Joyce N.] Augusta Univ, Med Coll Georgia, Dept Med, Augusta, GA 30912 USA.
RP Bollag, WB (corresponding author), Augusta Univ, Med Coll Georgia, Dept Physiol, Augusta, GA 30912 USA.
EM wbollag@augusta.edu
FU Veterans Affairs Merit AwardUS Department of Veterans Affairs
   [CX001357]; National Institutes of Health/National Eye Institute award
   [R01EY030576]
FX The authors would like to acknowledge and thank Dr. William Davis
   (Augusta University) for helpful feedback on this work. This work
   received no specific funding. WBB was supported in part by Veterans
   Affairs Merit Award #CX001357 and in part by National Institutes of
   Health/National Eye Institute award #R01EY030576. These sponsors had no
   role in the research, the writing of the manuscript or the decision to
   publish. The contents of this article do not represent the official
   views of the Department of Veterans Affairs or the United States
   Government.
CR Albert RK, 2012, AM J RESP CRIT CARE, V185, P702, DOI 10.1164/rccm.201109-1667PP
   ALBERT RK, 1979, J CLIN INVEST, V63, P1015, DOI 10.1172/JCI109369
   [Anonymous], 2005, Paediatr Child Health, V10, P109
   Anzueto A, 2002, EUR RESPIR J, V19, P787, DOI 10.1183/09031936.02.00284902
   Autilio C, 2019, ARCH DIS CHILD-FETAL, V104, pF443, DOI 10.1136/archdischild-2018-315413
   Cao W, 2020, CELL RES, V30, P367, DOI 10.1038/s41422-020-0327-4
   Casals C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01998
   Ceribelli A, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102442
   Chiba H, 2006, RESPIROLOGY, V11, pS2, DOI 10.1111/j.1440-1843.2006.00797.x
   Choudhary V, 2020, MOL PHARMACOL, V97, P324, DOI 10.1124/mol.119.118166
   Choudhary V, 2019, J INVEST DERMATOL, V139, P868, DOI 10.1016/j.jid.2018.10.021
   Christmann U, 2009, J VET INTERN MED, V23, P612, DOI 10.1111/j.1939-1676.2009.0298.x
   Christmann U, 2009, J VET INTERN MED, V23, P227, DOI 10.1111/j.1939-1676.2008.0269.x
   Contentti EC, 2020, MULT SCLER RELAT DIS, V41, DOI 10.1016/j.msard.2020.102097
   De Luca D, 2013, CRIT CARE, V17, DOI 10.1186/cc12842
   Erridge C, 2010, J LEUKOCYTE BIOL, V87, P989, DOI 10.1189/jlb.1209775
   Fox SE, 2020, LANCET RESP MED
   Funk CJ, 2012, J GEN VIROL, V93, P494, DOI 10.1099/vir.0.038414-0
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Glasser JR, 2012, MICROBES INFECT, V14, P17, DOI 10.1016/j.micinf.2011.08.019
   Gregor MF, 2011, ANNU REV IMMUNOL, V29, P415, DOI 10.1146/annurev-immunol-031210-101322
   Gunther A, 2002, EUR RESPIR J, V19, P797, DOI 10.1183/09031936.02.00243302
   Han SW, 2020, CANCER MED-US, V9, P6667, DOI 10.1002/cam4.3289
   Henderson LA, 2020, ARTHRITIS RHEUMATOL, V72, P1059, DOI 10.1002/art.41285
   Ikegami M, 2009, AM J RESP CELL MOL, V41, P433, DOI 10.1165/rcmb.2008-0359OC
   Jeon Ga Won, 2019, Korean J Pediatr, V62, P155, DOI 10.3345/kjp.2018.07185
   Ji YY, 2009, CELL PHYSIOL BIOCHEM, V23, P265, DOI 10.1159/000218173
   Kandasamy P, 2016, J LIPID RES, V57, P993, DOI 10.1194/jlr.M065201
   Kandasamy P, 2011, J BIOL CHEM, V286, P7841, DOI 10.1074/jbc.M110.170241
   Kitsiouli E, 2009, BBA-MOL BASIS DIS, V1792, P941, DOI 10.1016/j.bbadis.2009.06.007
   Kuronuma K, 2009, J BIOL CHEM, V284, P25488, DOI 10.1074/jbc.M109.040832
   Lester SN, 2014, J MOL BIOL, V426, P1246, DOI 10.1016/j.jmb.2013.11.024
   Lewis JF, 2003, CRIT CARE MED, V31, pS324, DOI 10.1097/01.CCM.0000057911.19145.9F
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Martin TR, 2020, EBIOMEDICINE, V57, DOI 10.1016/j.ebiom.2020.102836
   Mason RJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00607-2020
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   McCarthy CG, 2016, FASEB J, V30, P34, DOI 10.1096/fj.15-279588
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mohlenkamp S, 2020, HERZ, V45, P329, DOI 10.1007/s00059-020-04923-1
   More JM, 2010, BMC PULM MED, V10, DOI 10.1186/1471-2466-10-53
   Mossel EC, 2008, VIROLOGY, V372, P127, DOI 10.1016/j.virol.2007.09.045
   Nugent K, 2019, J THORAC DIS, V11, P4031, DOI 10.21037/jtd.2019.09.02
   Numata M, 2020, J BIOL CHEM, V295, P1704, DOI 10.1074/jbc.RA119.012053
   Numata M, 2013, J LIPID RES, V54, P2133, DOI 10.1194/jlr.M037077
   Numata M, 2012, AM J RESP CELL MOL, V46, P479, DOI 10.1165/rcmb.2011-0194OC
   Numata M, 2010, P NATL ACAD SCI USA, V107, P320, DOI 10.1073/pnas.0909361107
   Phua J, 2020, LANCET RESP MED, V8, P506, DOI 10.1016/S2213-2600(20)30161-2
   Preuss S, 2014, PULM PHARMACOL THER, V28, P25, DOI 10.1016/j.pupt.2013.10.002
   Qian ZH, 2013, AM J RESP CELL MOL, V48, P742, DOI 10.1165/rcmb.2012-0339OC
   ROONEY SA, 1984, ENVIRON HEALTH PERSP, V55, P205
   Sanders JM, 2020, JAMA
   Schenck DM, 2016, ACS APPL MATER INTER, V8, P5917, DOI 10.1021/acsami.6b00294
   Schenck EJ, 2018, CRIT CARE MED, V46, P791, DOI 10.1097/CCM.0000000000003007
   Schwartzstein RM, 2006, RESP PHYSL CLIN APPR
   Seeds MC, 2012, AM J MED SCI, V343, P446, DOI 10.1097/MAJ.0b013e318239c96c
   SEEGER W, 1993, EUR RESPIR J, V6, P971
   Spragg RG, 2011, AM J RESP CRIT CARE, V183, P1055, DOI 10.1164/rccm.201009-1424OC
   Taut FJH, 2008, CHEST, V134, P724, DOI 10.1378/chest.08-0362
   TIERNEY DF, 1965, J APPL PHYSIOL, V20, P1253
   Voelker DR, 2019, J BIOL CHEM, V294, P4282, DOI 10.1074/jbc.AW118.003229
   Walmrath D, 2002, EUR RESPIR J, V19, P805, DOI 10.1183/09031936.02.00243402
   Walmrath D, 1996, AM J RESP CRIT CARE, V154, P57, DOI 10.1164/ajrccm.154.1.8680699
   WARBURTON D, 1983, J CLIN INVEST, V72, P433, DOI 10.1172/JCI110991
   Wu YZ, 2003, AM J RESP CRIT CARE, V168, P692, DOI 10.1164/rccm.200304-467OC
   Xie D, 2018, J PHARMACOL EXP THER, V366, P1, DOI 10.1124/jpet.117.244756
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhang LN, 2013, EXP THER MED, V5, P237, DOI 10.3892/etm.2012.746
   Zhang XN, 2016, J DIABETES RES, V2016, DOI [10.1155/2016/5639129, 10.1155/2016/2543268, 10.1155/2016/2319741]
NR 70
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD NOV
PY 2020
VL 144
AR 110277
DI 10.1016/j.mehy.2020.110277
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OY1AM
UT WOS:000593985800036
PM 33254581
OA Green Published
DA 2021-01-01
ER

PT J
AU Kumar, A
   Sharma, K
   Dixit, AR
AF Kumar, Amit
   Sharma, Kamal
   Dixit, Amit Rai
TI Role of graphene in biosensor and protective textile against viruses
SO MEDICAL HYPOTHESES
LA English
DT Article
DE COVID-19; Graphene; Sensors; Textile
ID OXIDE; PERFORMANCE; INFLUENZA; BLOCKING; SENSOR; DOTS
AB Coronavirus disease (COVID-19) is a recently discovered infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Graphene is an emerging material due to its extraordinary performance in the field of electronics and antimicrobial textiles. Special attention devoted to graphene oxide-based materials due to its surface to volume ratio is very high which make it easy to attach biomolecules by simple adsorption or by crosslinking between reactive groups and the graphene surface. In response to the COVID-19 pandemic, we have summarized the recent developments of graphene and its derivatives with possible virus detection and textile applications. Moreover, graphene strain sensors can be executed on high-performance textiles and high-throughput drug efficacy screening.
C1 [Kumar, Amit; Dixit, Amit Rai] Indian Sch Mines, Indian Inst Technol, Dept Mech Engn, Dhanbad 826004, Bihar, India.
   [Kumar, Amit; Sharma, Kamal] GLA Univ, Inst Engn & Technol, Dept Mech Engn, Mathura 281406, India.
RP Kumar, A (corresponding author), Indian Sch Mines, Indian Inst Technol, Dept Mech Engn, Dhanbad 826004, Bihar, India.
EM amit9532@gmail.com
RI Kumar, Amit/N-8778-2017
OI Kumar, Amit/0000-0001-8995-5150
CR Abd Muain MF, 2018, BIOELECTROCHEMISTRY, V122, P199, DOI 10.1016/j.bioelechem.2018.04.004
   Afroj S, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202000293
   Afsahi S, 2018, BIOSENS BIOELECTRON, V100, P85, DOI 10.1016/j.bios.2017.08.051
   Bhattacharjee S, 2019, ADV MATER INTERFACES, V6, DOI 10.1002/admi.201900622
   Bugli F, 2018, INTERFACE FOCUS, V8, DOI 10.1098/rsfs.2017.0059
   Cesewski E, 2020, BIOSENS BIOELECTRON, V159, DOI 10.1016/j.bios.2020.112214
   Eninger RM, 2008, ANN OCCUP HYG, V52, P385, DOI 10.1093/annhyg/men019
   Heerema SJ, 2016, NAT NANOTECHNOL, V11, P127, DOI [10.1038/nnano.2015.307, 10.1038/NNANO.2015.307]
   Hidayah N, 2017, AIP C P
   Hu JH, 2019, ACS SUSTAIN CHEM ENG, V7, P7686, DOI 10.1021/acssuschemeng.8b06361
   Huang JL, 2016, ANAL CHIM ACTA, V913, P121, DOI 10.1016/j.aca.2016.01.050
   Innocenzi P, 2020, CHEM SCI, V11, P6606, DOI 10.1039/d0sc02658a
   Joshi SR, 2020, MAT SCI ENG C-MATER, V108, DOI 10.1016/j.msec.2019.110465
   Kinnamon DS, 2018, J ELECTROCHEM SOC, V165, pB3084, DOI 10.1149/2.0131808jes
   Kowalczyk D, 2017, CELLULOSE, V24, P4057, DOI 10.1007/s10570-017-1389-4
   Kumar A, 2020, J MATER SCI, V55, P2682, DOI 10.1007/s10853-019-04196-y
   Kumar A, 2020, CARBON LETT, DOI 10.1007/s42823-020-00161-x
   Kumar A, 2019, J MATER SCI, V54, P5992, DOI 10.1007/s10853-018-03244-3
   Kumar Raghav Pawan, 2020, Med Hypotheses, V144, P110031, DOI 10.1016/j.mehy.2020.110031
   Li DP, 2016, NANOSCALE, V8, P19491, DOI 10.1039/c6nr07249f
   Li JW, 2020, ELECTROCHEM COMMUN, V110, DOI 10.1016/j.elecom.2019.106601
   Li S, 2020, CURR OPIN BIOMED ENG, V13, P32, DOI [10.1016/j.cobme.2019.08.016, DOI 10.1016/J.COBME.2019.08.016]
   Luo SY, 2015, NANOSCALE RES LETT, V10, P1, DOI 10.1186/s11671-015-0866-7
   Meng L, 2020, J DENT RES, V99, P481, DOI 10.1177/0022034520914246
   Molina J, 2016, RSC ADV, V6, P68261, DOI 10.1039/c6ra12365a
   Mousavizadeh Leila, 2020, J Microbiol Immunol Infect, DOI 10.1016/j.jmii.2020.03.022
   Nag A, 2018, SENSOR ACTUAT A-PHYS, V270, P177, DOI 10.1016/j.sna.2017.12.028
   Navakul K, 2017, NANOMED-NANOTECHNOL, V13, P549, DOI 10.1016/j.nano.2016.08.009
   Noor N, 2019, POLYMERS-BASEL, V11, DOI 10.3390/polym11122000
   Omar NAS, 2019, OPT LASER TECHNOL, V114, P204, DOI 10.1016/j.optlastec.2019.01.038
   Palmieri V, 2020, NANO TODAY, V33, DOI 10.1016/j.nantod.2020.100883
   Pan NY, 2018, COLLOID SURFACE A, V555, P765, DOI 10.1016/j.colsurfa.2018.07.056
   Pena-Bahamonde J, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951-018-0400-z
   Seah I, 2020, EYE, V34, P1155, DOI 10.1038/s41433-020-0790-7
   Seo G, 2020, ACS NANO, V14, P5135, DOI 10.1021/acsnano.0c02823
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Tang XN, 2015, SYNTHETIC MET, V202, P82, DOI 10.1016/j.synthmet.2015.01.017
   Wasfi A, 2018, BIOSENS BIOELECTRON, V119, P191, DOI 10.1016/j.bios.2018.07.072
   Xu GY, 2017, DYES PIGMENTS, V141, P470, DOI 10.1016/j.dyepig.2017.02.046
   Yang XX, 2017, NANOSCALE, V9, P16086, DOI 10.1039/c7nr06520e
   Ye SY, 2015, ACS APPL MATER INTER, V7, P21571, DOI 10.1021/acsami.5b06876
   Zhao JM, 2013, ADV HEALTHC MATER, V2, P1259, DOI 10.1002/adhm.201200437
NR 42
TC 0
Z9 0
U1 1
U2 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD NOV
PY 2020
VL 144
AR 110253
DI 10.1016/j.mehy.2020.110253
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OY1AM
UT WOS:000593985800009
PM 33254558
OA Green Published
DA 2021-01-01
ER

PT J
AU Rossi, M
   Piagnerelli, M
   Van Meerhaeghe, A
   Boudjeltia, KZ
AF Rossi, Maxime
   Piagnerelli, Michael
   Van Meerhaeghe, Alain
   Boudjeltia, Karim Zouaoui
TI Heme oxygenase-1 (HO-1) cytoprotective pathway: A potential treatment
   strategy against coronavirus disease 2019 (COVID-19)-induced cytokine
   storm syndrome
SO MEDICAL HYPOTHESES
LA English
DT Article
DE COVID-19; SARS-CoV-2; heme oxygenase-1 (HO-1); Hemin; Cytokine storm;
   Acute respiratory distress syndrome (ARDS)
ID ACUTE KIDNEY INJURY; VIRUS-REPLICATION; INTERLEUKIN-10; INDUCTION
AB The outbreak of coronavirus disease 2019 (COVID-19) requires urgent need for effective treatment. Severe COVID-19 is characterized by a cytokine storm syndrome with subsequent multiple organ failure (MOF) and acute respiratory distress syndrome (ARDS), which may lead to intensive care unit and increased risk of death.
   While awaiting a vaccine, targeting COVID-19-induced cytokine storm syndrome appears currently as the efficient strategy to reduce the mortality of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
   The stress-responsive enzyme, heme oxygenase-1 (HO-1) is largely known to protect against inflammatory response in animal models. HO-1 is induced by hemin, a well-tolerated molecule, used for decades in the treatment of acute intermittent porphyria. Experimental studies showed that hemin-induced HO-1 mitigates cytokine storm and lung injury in mouse models of sepsis and renal ischemia-reperfusion injury. Furthermore, HO-1 may also control numerous viral infections by inhibiting virus replication.
   In this context, we suggest the hypothesis that HO-1 cytoprotective pathway might be a promising target to control SARS-CoV-2 infection and mitigate COVID-19-induced cytokine storm and subsequent ARDS.
C1 [Rossi, Maxime] Univ Libre Bruxelles, Inst Med Immunol IMI, Gosselies, Belgium.
   [Rossi, Maxime] Univ Libre Bruxelles, CHU Charleroi, Dept Urol, Charleroi, Belgium.
   [Piagnerelli, Michael] Univ Libre Bruxelles, CHU Charleroi, Dept Intens Care, Charleroi, Belgium.
   [Piagnerelli, Michael; Van Meerhaeghe, Alain; Boudjeltia, Karim Zouaoui] Univ Libre Bruxelles, CHU Charleroi, A Vesale Hosp, Lab Expt Med,ULB Unit 222, Montignies le Tilleul, Belgium.
RP Rossi, M (corresponding author), Univ Libre Bruxelles ULB, Inst Med Immunol IMI, Sch Med, 8 Rue Adrienne Bolland, B-6041 Gosselies, Belgium.
EM Maxime.Rossi@ulb.be
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Anderson KE, 2005, ANN INTERN MED, V142, P439, DOI 10.7326/0003-4819-142-6-200503150-00010
   Andres-Hernando A, 2011, AM J PHYSIOL-RENAL, V301, pF907, DOI 10.1152/ajprenal.00107.2011
   Bharucha AE, 2010, CLIN PHARMACOL THER, V87, P187, DOI 10.1038/clpt.2009.221
   Chen HL, 2012, INFLAMMATION, V35, P1087, DOI 10.1007/s10753-011-9415-4
   Chen SF, 2005, P NATL ACAD SCI USA, V102, P7251, DOI 10.1073/pnas.0502407102
   Chok Mohammed Koussai, 2009, Inflammation & Allergy Drug Targets, V8, P252
   Espinoza JA, 2017, J IMMUNOL, V199, P212, DOI 10.4049/jimmunol.1601414
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Han SW, 2020, CANCER MED-US, V9, P6667, DOI 10.1002/cam4.3289
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240
   Li H, 2020, LANCET ENGLAND LONDO
   Liu BW, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102452
   Ma LL, 2019, VIROLOGY, V528, P80, DOI 10.1016/j.virol.2018.11.016
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mumby S, 2004, CRIT CARE MED, V32, P1130, DOI 10.1097/01.CCM.0000124869.86399.F2
   Naito Y, 2014, ARCH BIOCHEM BIOPHYS, V564, P83, DOI 10.1016/j.abb.2014.09.005
   Rossi M, 2019, FREE RADICAL RES, V53, P1035, DOI 10.1080/10715762.2019.1668936
   Rossi M, 2018, BIOCHEM BIOPH RES CO, V503, P2820, DOI 10.1016/j.bbrc.2018.08.046
   Rossi M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00220-w
   Ruan Q, 2020, INTENSIVE CARE MED
   Ryter SW, 2016, TRANSL RES, V167, P7, DOI 10.1016/j.trsl.2015.06.011
   Shen YX, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.02.47
   Sheu CC, 2009, INTENS CARE MED, V35, P1343, DOI 10.1007/s00134-009-1504-6
   Thomas RAB, 2016, TRANSPLANTATION, V100, P176, DOI 10.1097/TP.0000000000000770
   Tsoyi K, 2009, MOL PHARMACOL, V76, P173, DOI 10.1124/mol.109.055137
   Tzima S, 2009, J EXP MED, V206, P1167, DOI 10.1084/jem.20081582
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhang M, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120596
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 31
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD NOV
PY 2020
VL 144
AR 110242
DI 10.1016/j.mehy.2020.110242
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OY1AM
UT WOS:000593985800007
PM 33254548
OA Green Published
DA 2021-01-01
ER

PT J
AU Sarohan, AR
AF Sarohan, Aziz Rodan
TI COVID-19: Endogenous Retinoic Acid Theory and Retinoic Acid Depletion
   Syndrome
SO MEDICAL HYPOTHESES
LA English
DT Article
DE Retinol; Retinoid; Carotenoid; Retinoic acid; RIG-I; IFN; Zinc; COVID-19
ID VITAMIN-A; RIG-I; CUTTING EDGE; RECEPTORS; VIRUS; RECOGNITION;
   INHIBITION; CHEMISTRY; INFECTION; CELL
AB This study presents two new concepts and definitions to the medical literature. One of those is "endogenous retinoic acid theory" and the other "retinoic acid depletion syndrome". A new classification will be provided for the immune system: "retinoic acid-dependent component" and "retinoic acid non-dependent component". If this theory is verified, all the diseases where the retinoic acid metabolism is defective and retinoic acid levels are low will be identified and new approaches will be developed fortreating such diseases. When the need for retinoic acids increases, such as acute infection, high fever, severe catabolic process, or chronic antigenic stimulation, cytochrome oxidase enzymes are inhibited by drugs or internal mechanisms. Metabolism and excretion of retinoic acids stored in the liver are prevented. In this way, retinoic acid levels in the blood are raised to therapeutic levels. This is called "Endogenous Retinoic Acid Theory". Retinoic acids also manage their metabolism through feedback mechanisms. Despite compensatory mechanisms, causes such as high fever, serious catabolic process and excessively large viral genome (SARS-CoV-2), excessive use of RIG-I and Type I interferon synthesis pathway using retinoic acid causes emptying of retinoic acid stores. As a result, the RIG-I pathway becomes ineffective, Type I IFN synthesis stops, and the congenital immune system collapses. Then the immune mechanism passes to TLR3, TLR7, TLR8, TLR9, MDA5 and UPS pathways in the monocyte, macrophage, neutrophil and dendritic cells of the adaptive immune defense system that do not require retinoic acid. This leads to excessive TNF alpha and cytokine discharge from the pathway. With the depletion of retinoic acid stores as a result of this overuse, the immune defense mechanism switches from the congenital immune system to the adaptive immune system, where retinoic acids cannot be used. As a result of this depletion of retinoic acids, the shift of the immune system to the NF kappa B arm, which causes excessive cytokine release, is called "retinoic acid depletion syndrome". COVID-19 and previously defined sepsis, SIRS and ARDS are each retinoic acid depletion syndrome. We claim that retinoic acid metabolism is defective in most inflammatory diseases, particularly COVID-19 (cytokine storm) sepsis, SIRS and ARDS. Finding a solution to this mechanism will bring a new perspective and treatment approach to such diseases.
C1 [Sarohan, Aziz Rodan] Ozel Baglar Hastanesi, Obstetr & Gynocol, Diyarbakir, Turkey.
RP Sarohan, AR (corresponding author), Ozel Baglar Hastanesi, Obstetr & Gynocol, Diyarbakir, Turkey.
EM azizrodan@gmail.com
CR Al Tanoury Z, 2013, J LIPID RES, V54, P1761, DOI 10.1194/jlr.R030833
   ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30
   [Anonymous], 2020, GIL ANN RES PHAS 3 T
   Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Blomhoff R, 2006, J NEUROBIOL, V66, P606, DOI 10.1002/neu.20242
   Cassani B, 2012, MOL ASPECTS MED, V33, P63, DOI 10.1016/j.mam.2011.11.001
   Chang H, 2014, EXP THER MED, V7, P1703, DOI 10.3892/etm.2014.1638
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chiu YH, 2009, CELL, V138, P576, DOI 10.1016/j.cell.2009.06.015
   Choe J, 2005, SCIENCE, V309, P581, DOI 10.1126/science.1115253
   Colavita Francesca, 2020, ANN INTERNAL MED
   Danielson PB, 2002, CURRENT DRUG METABOL, V3
   Dowell SF, 1996, PEDIATR INFECT DIS J, V15, P782, DOI 10.1097/00006454-199609000-00009
   Doyle SL, 2006, BIOCHEM PHARMACOL, V72, P1102, DOI 10.1016/j.bcp.2006.07.010
   Fang YF, 2011, MOL CARCINOGEN, V50, P24, DOI 10.1002/mc.20687
   FAO WHO, 2004, VIT MIN REQ HUM NUTR
   Gebhardt A, 2017, J INTERF CYTOK RES, V37, P184, DOI 10.1089/jir.2016.0092
   Goubau D, 2014, NATURE, V514, P372, DOI 10.1038/nature13590
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gudas LJ, 2012, BBA-MOL CELL BIOL L, V1821, P213, DOI 10.1016/j.bbalip.2011.08.002
   Hochheiser K, 2016, J IMMUNOL, V196, P2439, DOI 10.4049/jimmunol.1501958
   Huiming Y, 2005, COCHRANE DB SYST REV, V2005, DOI DOI 10.1002/14651858.CD001479.PUB2
   Irwin JJ, 2012, J CHEM INF MODEL, V52, P1757, DOI 10.1021/ci3001277
   Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581
   Karroum NB, 2019, J MED CHEM, V62, P7015, DOI 10.1021/acs.jmedchem.9b00411
   Kell AM, 2015, VIROLOGY, V479, P110, DOI 10.1016/j.virol.2015.02.017
   Kiser PD, 2014, CHEM REV, V114, P194, DOI 10.1021/cr400107q
   Kong L, 2009, CELL HOST MICROBE, V6, P150, DOI 10.1016/j.chom.2009.06.008
   Lai CC, 2020, INT J ANTIMICROB AGE, V19
   Lane MA, 2005, PROG NEUROBIOL, V75, P275, DOI 10.1016/j.pneurobio.2005.03.002
   Liu Yiliu Olagnier, 2017, FRONT IMMUNOL VIROL, V03, P110
   Mao L, 2020, JAMA NEUROL, P10
   Mehta S, 2007, VITAM HORM, V75, P355, DOI 10.1016/s0083-6729(06)75013-0
   Melchjorsen J, 2010, J VIROL, V84, P11350, DOI 10.1128/JVI.01106-10
   Mora JR, 2009, SEMIN IMMUNOL, V21, P28, DOI 10.1016/j.smim.2008.08.002
   Morris Deborah R, 2013, J NUTRBIOCHEM, V24, DOI 10.1016.
   Navigatore-Fonzo LS, 2013, J NUTR BIOCHEM, V24, P859, DOI 10.1016/j.jnutbio.2012.05.006
   Nelson CH, 2013, CURR TOP MED CHEM, V13, P1402
   Nevzat Yuksel, 2001, J CLIN PSY, V4, P5
   Pantazi E, 2015, J IMMUNOL, V195, P1368, DOI 10.4049/jimmunol.1500989
   Park Su Eun, 2020, Clin Exp Pediatr, V63, P119, DOI 10.3345/cep.2020.00493
   Pelkonen O, 2000, TOXICOLOGY, V144, P139, DOI 10.1016/S0300-483X(99)00200-0
   Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604
   Poyiadji N, 2020, RADIOLOGY, V31
   Raverdeau M, 2014, J IMMUNOL, V192, P2953, DOI 10.4049/jimmunol.1303245
   Ross AC, 2011, ANNU REV NUTR, V31, P65, DOI 10.1146/annurev-nutr-072610-145127
   Solis M, 2011, J VIROL, V85, P1224, DOI 10.1128/JVI.01635-10
   Soye KJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022323
   Stipanuk Martha, 2012, VITAMIN A BIOCH PHYS, P968
   Usmani Khawja A, 2004, CURR PROTOC TOXICOL
   Vahlquist A, 2014, BRIT J DERMATOL, V170, P173, DOI 10.1111/bjd.12626
   Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359
   Weber M, 2013, CELL HOST MICROBE, V13, P336, DOI 10.1016/j.chom.2013.01.012
   Wirbelauer J, 2009, J PERINATOL, V29, pS18, DOI 10.1038/jp.2009.30
   World Health Organization, 2020, NOV COR SIT REP 2
   Wu Canrong, 2020, ACTA PHARM SIN B
   Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhao H, 2020, LANCET NEUROL, V19, P383, DOI 10.1016/S1474-4422(20)30109-5
   Zhiyi H., 2018, J CLIN MED, V7, P258
NR 60
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD NOV
PY 2020
VL 144
AR 110250
DI 10.1016/j.mehy.2020.110250
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OY1AM
UT WOS:000593985800030
PM 33254555
OA Green Published
DA 2021-01-01
ER

PT J
AU Vavougios, GD
AF Vavougios, George D.
TI Host - virus - drug interactions as determinants of COVID-19's
   phenotypes: A data-driven hypothesis
SO MEDICAL HYPOTHESES
LA English
DT Article
ID SELENIUM; EXPRESSION; IMPACT
AB There is a growing body of evidence on the significance of interactions between comorbidities, their treatments and COVID-19 clinical phenotypes. The hypothesis explored herein is that pharmaceutical compounds currently in use are affecting COVID-19 susceptibility and phenotypes by overlapping transcriptional networks.
   Using two distinct SARS-CoV-2 - host interactomes, gene set enrichment analysis is used to discover compounds and assorted gene signatures derived from SARS-CoV-2 interactomes. Micronutrients, antiplatelets, ACE2 inhibitors, NSAIDs, corticosteroids and tyrosine kinase inhibitors are among the compounds discovered. Considering the implication of their associated comorbidities such as diabetes and cardiovascular disease that are associated with severe COVID-19, this study outlines the need to consider specific compounds as modulators of the observed COVID-19 spectrum. Furthermore, given that micronutrient trafficking may be targeted by viral processes, and display synergism with other enriched compounds, such as statins, studies assessing their levels prior and during infection are more than warranted.
C1 [Vavougios, George D.] Athens Naval Hosp, Dept Neurol, Athens 11521, Greece.
   [Vavougios, George D.] Univ Thessaly, Fac Med, Dept Resp Med, Larisa 41500, Greece.
   [Vavougios, George D.] Univ Thessaly, Dept Comp Sci & Telecommun, Papasiopoulou 2-4, Galaneika 35131, Lamia, Greece.
RP Vavougios, GD (corresponding author), 70 Deinokratous St, Athens 11125, Greece.
EM gvavougyios@uth.gr
CR Beck MA, 1997, BIOMED ENVIRON SCI, V10, P307
   Beck MA, 1997, J NUTR, V127, pS966, DOI 10.1093/jn/127.5.966S
   Beck MA, 2007, J NUTR, V137, P1338
   Bojkova D, 2020, NATURE, V583, P469, DOI 10.1038/s41586-020-2332-7
   Briguglio M, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00146
   Chen YC, 2020, DIABETES CARE, V43, P1399, DOI 10.2337/dc20-0660
   Chen ZR, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00950
   Clough E, 2016, METHODS MOL BIOL, V1418, P93, DOI 10.1007/978-1-4939-3578-9_5
   Dhingra S, 2006, CHEM-BIOL INTERACT, V161, P49, DOI 10.1016/j.cbi.2006.02.008
   Elmadfa I, 2019, ENDOCR METAB IMMUNE, V19, P1100, DOI 10.2174/1871530319666190529101816
   Fang LQ, 2015, VIRUSES-BASEL, V7, P333, DOI 10.3390/v7010333
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Guzzi PH, 2020, J CLIN MED, V9, DOI 10.3390/jcm9040982
   Horby P, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2021436, 10. 1056/NEJMoa2021436., DOI 10.1056/NEJMOA2021436.]
   Kollias A, 2020, BRIT J HAEMATOL, V189, P846, DOI 10.1111/bjh.16727
   Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377
   LI C, 2019, ANTIOXIDANTS BASEL, V8
   Parihar SP, 2019, NAT REV IMMUNOL, V19, P104, DOI 10.1038/s41577-018-0094-3
   Ricetti MM, 1999, INT J CLIN LAB RES, V29, P80, DOI 10.1007/s005990050068
   Rupp JC, 2017, VIROL J, V14, DOI 10.1186/s12985-016-0671-7
   Sivaloganathan H, 2020, BRIT J HAEMATOL, V190, pE192, DOI 10.1111/bjh.16968
   Song Y, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106080
   Taylor EW, 2016, CURR TOP MED CHEM, V16, P1530, DOI 10.2174/1568026615666150915121633
   Vargas-Vargas M, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.72
   Vavougios GD, 2020, FREE RADIC BIOL MED, DOI [10.1016/j.freeradbiomed.2020., DOI 10.1016/J.FREERADBIOMED.2020]
   Vavougios GD, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109759
   Vitoux D, 1996, ANN BIOL CLIN-PARIS, V54, P181
   Wang J, 2020, J LEUKOCYTE BIOL, V108, P17, DOI 10.1002/JLB.3COVR0520-272R
   Yamamoto M, 2017, J GEN VIROL, V98, P275, DOI 10.1099/jgv.0.000701
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang G, 2020, HYPERTENSION, V76, P51, DOI 10.1161/HYPERTENSIONAHA.120.15143
   Yoo M, 2015, BIOINFORMATICS, V31, P3069, DOI 10.1093/bioinformatics/btv313
   Zhang JS, 2020, AM J CLIN NUTR, V111, P1297, DOI 10.1093/ajcn/nqaa095
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
NR 34
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD NOV
PY 2020
VL 144
AR 110275
DI 10.1016/j.mehy.2020.110275
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OY1AM
UT WOS:000593985800010
PM 33254579
OA Green Published
DA 2021-01-01
ER

PT J
AU Canoglu, K
   Saylan, B
AF Canoglu, Kadir
   Saylan, Bengu
TI Therapeutic dosing of low-molecular-weight heparin may decrease
   mortality in patients with severe COVID-19 infection
SO ANNALS OF SAUDI MEDICINE
LA English
DT Article
AB BACKGROUND: Venous thromboembolism or extensive thrombosis is relatively common in patients with severe COVID-19 infection and has been associated with increased mortality. During the current COVID-19 pandemic, several prophylactic doses and types of low-molecular-weight heparin (LMWH) are being used worldwide; however, there are no high-quality studies or recommendations for an optimal prophylactic LMWH dose.
   OBJECTIVES: Investigate the relationship between coagulation parameters and the LMWH dose, and mortality and ICU admission in hospitalized patients with severe COVID-19 pneumonia.
   DESIGN: Retrospective.
   SETTING: Tertiary care hospital.
   PATIENTS AND METHODS: Data on clinical features, coagulation parameters and anticoagulant medications of inpatients with severe COVID-19 were collected for the period between 11 March 2020 and 31 April 2020.
   MAIN OUTCOME MEASURES: Mortality and ICU admission for prophylactic dose LMWH (0.5 mg/kg twice daily) and therapeutic dose LMWH (1 mg/kg twice daily).
   SAMPLE SIZE: 154 cases.
   RESULTS: Ninety-eight (63.6%) patients were treated with the LMWH prophylactic dose and 56 (36.4%) patients were treated with the therapeutic dose. Forty-four (44.9%) of 98 patients using the prophylactic dose LMWH died, while 10 (17.9%) of 56 patients using the therapeutic dose LMWH died (P=.001). Mortality was 6.4-fold higher in the prophylactic dose LMWH users than in the therapeutic dose LMWH users (OR=6.5, 95% CI: 2.4-17.6, P<.001).
   CONCLUSIONS: Therapeutic dosing of LMWH may decrease mortality in patients with severe COVID-19 infected pneumonia. More aggressive thromboprophylaxis regimens using higher doses of heparin should be evaluated in prospective studies.
   LIMITATIONS: Lack of information about bleeding complications. LMWH was not compared with other anticoagulant therapies. There was no comparison between our two groups on the APACHE score. Used different doses of LMWH in different clinics in our hospital. Single-center, retrospective study.
C1 [Canoglu, Kadir; Saylan, Bengu] Sultan Abdulhamid Han Training & Res Hosp, Dept Pulmonol, Istanbul, Turkey.
RP Canoglu, K (corresponding author), Sultan Abdulhamid Han Training & Res Hosp, Dept Pulmonol, Istanbul, Turkey.
EM kadircano@gmail.com
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x
   [Anonymous], 2020, WHO DIR GEN OP REM M
   [Anonymous], 2020, COR DIS COVID 19 DAS
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Artifoni M, 2020, J THROMB THROMBOLYS, V50, P211, DOI 10.1007/s11239-020-02146-z
   Atallah B, 2020, EUR HEART J-CARD PHA, V6, P260, DOI 10.1093/ehjcvp/pvaa036
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Conti CB, 2020, EUR J INTERN MED, V77, P147, DOI 10.1016/j.ejim.2020.05.002
   Dadashzadeh N, 2020, IMMUNOPATHOL PERSA, V6, DOI 10.34172/ipp.2020.16
   Eck RJ, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122039
   Giannis D, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104362
   Khan IH, 2020, J VASC SURG
   Kreuziger LB, 2020, COVID 19 VTE ANT FRE
   Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9
   Lippi G, 2020, THROMB HAEMOSTASIS, V120, P876, DOI 10.1055/s-0040-1709650
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Marietta M, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04475-z
   McGonagle D, 2020, LANCET RHEUMATOL, V2, pE437, DOI 10.1016/S2665-9913(20)30121-1
   Petrosillo N, 2020, CLIN MICROBIOL INFEC, V26, P729, DOI 10.1016/j.cmi.2020.03.026
   Republic of Turkey Ministry of Health, 2020, GUID COVID 19 SARS C
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Song JC, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00247-7
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Thachil J, 2020, J THROMB HAEMOST, V18, P1020, DOI 10.1111/jth.14821
   West Suffolk NHS Foundation Trust, 2020, CLIN GUID CG13093 1
   World Health Organization, 2020, CLIN MAN COVID 19 IN
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 28
TC 0
Z9 0
U1 0
U2 0
PU K FAISAL SPEC HOSP RES CENTRE
PI RIYADH
PA PUBLICATIONS OFFICE PO BOX 3354, RIYADH 11211, SAUDI ARABIA
SN 0256-4947
EI 1319-9226
J9 ANN SAUDI MED
JI Ann. Saudi Med.
PD NOV-DEC
PY 2020
VL 40
IS 6
BP 462
EP 468
DI 10.5144/0256-4947.2020.462
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA PE4PN
UT WOS:000598347200003
PM 33307734
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Hemmati, S
   Behzadipour, Y
   Haddad, M
AF Hemmati, Shiva
   Behzadipour, Yasaman
   Haddad, Mahdi
TI Decoding the proteome of severe acute respiratory syndrome coronavirus 2
   (SARS-CoV-2) for cell-penetrating peptides involved in pathogenesis or
   applicable as drug delivery vectors
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Coronavirus; SARS-CoV-2; COVID-19; Cell-penetrating peptide; Drug
   delivery; Bioactive peptide
ID ARGININE-RICH PEPTIDES; WEB SERVER; FUNCTIONAL ANALYSES;
   CRYSTAL-STRUCTURE; RNA-POLYMERASE; UNIQUE DOMAIN; MEMBRANE; PROTEINS;
   TRANSLOCATION; PROTEASE
AB Synthetic or natural derived cell-penetrating peptides (CPPs) are vastly investigated as tools for the intracellular delivery of membrane-impermeable molecules. As viruses are intracellular obligate parasites, viral originated CPPs have been considered as suitable intracellular shuttling vectors for cargo transportation. A total of CPPs were identified in the proteome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Screening the proteome of the cause of COVID-19 reveals that SARS-CoV-2 CPPs (SCV2-CPPs) span the regions involved in replication, protein-nucleotide and protein-protein interaction, protein-metal ion interaction, stabilization of homo/hetero-oligomers. However, to find the most appropriate peptides as drug delivery vectors, one might face several hurdles. Computational analyses showed that 94.3% of the identified SCV2-CPPs are toxins, and 38% are neither antigenic nor allergenic. Interestingly, 36.70% of SCV2-CPPs were resistant to four groups of protease families. Nearly 1/3 of SCV2-CPPs had sufficient inherent or induced helix and sheet conformation leading to increased uptake efficiency. Heliquest lipid-binding discrimination factor revealed 44.30% of the helical SCV2-CPPs are lipid-binding helices. Although Cys-rich derived CPPs of helicase (NSP13) can potentially fold into a cyclic conformation in endosomes with a higher rate of endosomal release, the most optimal SCV2-CPP candidates as vectors for drug delivery were SCV2-CPP118, SCV2-CPP119, SCV2-CPP122, and SCV2-CPP129 of NSP12 (RdRp). Ten experimentally validated viral-derived CPPs were also used as positive control to check the scalability and reliability of our protocol in SCV2-CPP retrieval. Some peptides with a cell-penetration ability known as bioactive peptides are adopted as biotherapeutics themselves. Therefore, 59.60%, 29.63%, and 32.32% of SCV2-CPPs were identified as potential antibacterial, antiviral, and antifungals, respectively. While 63.64% of SCV2-CPPs had immuno-modulatory properties, 21.89% were recognized as anti cancers. Conclusively, the workflow of this study provides a platform for profound screening of viral proteomes as a rich source of biotherapeutics or drug delivery carriers.
C1 [Hemmati, Shiva; Behzadipour, Yasaman; Haddad, Mahdi] Shiraz Univ Med Sci, Sch Pharm, Dept Pharmaceut Biotechnol, POB 71345-1583, Shiraz, Iran.
   [Hemmati, Shiva] Shiraz Univ Med Sci, Biotechnol Res Ctr, Shiraz, Iran.
   [Hemmati, Shiva] Shiraz Univ Med Sci, Pharmaceut Sci Res Ctr, Shiraz, Iran.
RP Hemmati, S (corresponding author), Shiraz Univ Med Sci, Sch Pharm, Dept Pharmaceut Biotechnol, POB 71345-1583, Shiraz, Iran.
EM hemmatish@sums.ac.ir
RI Hemmati, Shiva/K-1624-2013
OI Hemmati, Shiva/0000-0001-9071-9569
FU Shiraz University of Medical Sciences, Shiraz, Iran [99-01-106-22161]
FX This work was supported by Shiraz University of Medical Sciences,
   Shiraz, Iran; project number 99-01-106-22161.
CR Ahn DG, 2011, ANTIVIR RES, V91, P1, DOI 10.1016/j.antiviral.2011.04.009
   Akahoshi A, 2016, SCI TECHNOL ADV MAT, V17, P245, DOI 10.1080/14686996.2016.1178056
   Arndt AL, 2010, J VIROL, V84, P11418, DOI 10.1128/JVI.01131-10
   Athmer J, 2017, MBIO, V8, DOI 10.1128/mBio.02320-16
   Behzadipour Y, 2019, MOLECULES, V24, DOI 10.3390/molecules24234318
   Bhardwaj K, 2008, J BIOL CHEM, V283, P3655, DOI 10.1074/jbc.M708375200
   Bottger R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178943
   Boman HG, 2000, IMMUNOL REV, V173, P5, DOI 10.1034/j.1600-065X.2000.917301.x
   Bouvet M, 2014, J BIOL CHEM, V289, P25783, DOI 10.1074/jbc.M114.577353
   Braun E, 2019, CLIN TRANSL IMMUNOL, V8, DOI 10.1002/cti2.1073
   Carnevale KJF, 2018, BIOCONJUGATE CHEM, V29, P3273, DOI 10.1021/acs.bioconjchem.8b00429
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chang CK, 2016, DRUG DISCOV TODAY, V21, P562, DOI 10.1016/j.drudis.2015.11.015
   Chang CK, 2014, ANTIVIR RES, V103, P39, DOI 10.1016/j.antiviral.2013.12.009
   Chaudhary K, 2016, SCI REP-UK, V6, DOI 10.1038/srep22843
   Chen W, 2016, ONCOTARGET, V7, P16895, DOI 10.18632/oncotarget.7815
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cieslik M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137193
   Cornillez-Ty CT, 2009, J VIROL, V83, P10314, DOI 10.1128/JVI.00842-09
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Dadar M, 2019, INFLAMM RES, V68, P125, DOI 10.1007/s00011-018-1208-x
   Decroly E, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002059
   Derakhshankhah H, 2018, BIOMED PHARMACOTHER, V108, P1090, DOI 10.1016/j.biopha.2018.09.097
   Di Pisa M, 2015, BIOCHEMISTRY-US, V54, P194, DOI 10.1021/bi501392n
   Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5
   Drin G, 2010, FEBS LETT, V584, P1840, DOI 10.1016/j.febslet.2009.10.022
   Duong HHP, 2013, INT J PHARMACEUT, V454, P486, DOI 10.1016/j.ijpharm.2013.06.017
   Egloff MP, 2004, P NATL ACAD SCI USA, V101, P3792, DOI 10.1073/pnas.0307877101
   Eiriksdottir E, 2010, BBA-BIOMEMBRANES, V1798, P1119, DOI 10.1016/j.bbamem.2010.03.005
   EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7
   Ferre F, 2005, NUCLEIC ACIDS RES, V33, pW230, DOI 10.1093/nar/gki412
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Freire JM, 2014, FEBS J, V281, P191, DOI 10.1111/febs.12587
   Frieman M, 2007, J VIROL, V81, P9812, DOI 10.1128/JVI.01012-07
   Fu TK, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10010101
   Fu XZ, 2019, IEEE ACCESS, V7, P163547, DOI 10.1109/ACCESS.2019.2952738
   Futaki S, 2007, BIOCHEM SOC T, V35, P784, DOI 10.1042/BST0350784
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200
   Gaspar D, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00294
   Gautam A, 2015, METHODS MOL BIOL, V1324, P59, DOI 10.1007/978-1-4939-2806-4_4
   Gautier R, 2008, BIOINFORMATICS, V24, P2101, DOI 10.1093/bioinformatics/btn392
   Gupta S, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-016-1103-6
   Gupta S, 2015, METHODS MOL BIOL, V1268, P143, DOI 10.1007/978-1-4939-2285-7_7
   Hakkarainen T, 2005, J GENE MED, V7, P898, DOI 10.1002/jgm.737
   Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434
   Heard KR, 2013, J MED CHEM, V56, P8339, DOI 10.1021/jm400423p
   Issa E., 2020, SARS COV 2 ORF3A NON, DOI DOI 10.1101/2020.03.27.012013
   Jha D, 2011, BIOCONJUGATE CHEM, V22, P319, DOI 10.1021/bc100045s
   Jia ZH, 2019, NUCLEIC ACIDS RES, V47, P6538, DOI 10.1093/nar/gkz409
   JOHAR H, 2020, CELL, V18
   Johnson MA, 2010, J MOL BIOL, V400, P724, DOI 10.1016/j.jmb.2010.05.027
   Joseph JS, 2007, J VIROL, V81, P6700, DOI 10.1128/JVI.02817-06
   Kalafatovic D, 2017, MOLECULES, V22, DOI 10.3390/molecules22111929
   Keane SC, 2013, J VIROL, V87, P3502, DOI 10.1128/JVI.03112-12
   Keller AA, 2013, PHARMACEUTICALS, V6, P184, DOI 10.3390/ph6020184
   Keller RCA, 2011, INT J MOL SCI, V12, P5577, DOI 10.3390/ijms12095577
   Kim HY, 2015, SCI REP-UK, V5, DOI 10.1038/srep11719
   Kim Y, 2020, PROTEIN SCI, V29, P1596, DOI 10.1002/pro.3873
   Kobayashi S, 2009, BIOCONJUGATE CHEM, V20, P953, DOI 10.1021/bc800530v
   Kramer RM, 2012, BIOPHYS J, V102, P1907, DOI 10.1016/j.bpj.2012.01.060
   Kruger DM, 2018, RNA, V24, P1457, DOI 10.1261/rna.066464.118
   Kuriakose A, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/1298473
   Kusov Y, 2015, VIROLOGY, V484, P313, DOI 10.1016/j.virol.2015.06.016
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   Langedijk JPM, 2002, J BIOL CHEM, V277, P5308, DOI 10.1074/jbc.M104147200
   Langel U., 2019, CPP CELL PENETRATING, DOI 10.1007/978-981-13-8747-0.
   Lee CC, 2010, BIOPHYS J, V98, P2236, DOI 10.1016/j.bpj.2010.02.001
   Lehmann KC, 2015, VIRUS RES, V202, P12, DOI 10.1016/j.virusres.2014.12.001
   Lei J, 2018, ANTIVIR RES, V149, P58, DOI 10.1016/j.antiviral.2017.11.001
   Li K, 2013, SCI REP-UK, V3, DOI 10.1038/srep01150
   Li WJ, 2004, ADV DRUG DELIVER REV, V56, P967, DOI 10.1016/j.addr.2003.10.041
   Lin L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061166
   Lomize AL, 2017, NUCLEIC ACIDS RES, V45, pD250, DOI 10.1093/nar/gkw712
   Lonn P, 2016, SCI REP-UK, V6, DOI 10.1038/srep32301
   Ma YY, 2015, P NATL ACAD SCI USA, V112, P9436, DOI 10.1073/pnas.1508686112
   Manavalan B, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00276
   Manayalan B, 2018, J PROTEOME RES, V17, P2715, DOI 10.1021/acs.jproteome.8b00148
   Mathur D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196829
   Mathur D, 2016, SCI REP-UK, V6, DOI 10.1038/srep27413
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   McBride R, 2012, VIRUSES-BASEL, V4, P2902, DOI 10.3390/v4112902
   Menachery VD, 2014, VIRUS RES, V194, P191, DOI 10.1016/j.virusres.2014.09.009
   Montrose K, 2014, BIOCHEM BIOPH RES CO, V453, P64, DOI 10.1016/j.bbrc.2014.09.057
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   Muth D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33487-8
   Nakase I, 2009, MOL THER, V17, P1868, DOI 10.1038/mt.2009.192
   Narayanan K, 2015, VIRUS RES, V202, P89, DOI 10.1016/j.virusres.2014.11.019
   Neuman BW, 2016, ANTIVIR RES, V135, P97, DOI 10.1016/j.antiviral.2016.10.005
   Owji H, 2018, 3 BIOTECH, V8, DOI 10.1007/s13205-018-1517-3
   Parenteau J, 2005, FEBS LETT, V579, P4873, DOI 10.1016/j.febslet.2005.07.064
   Ratia K, 2006, P NATL ACAD SCI USA, V103, P5717, DOI 10.1073/pnas.0510851103
   Reissmann S, 2014, J PEPT SCI, V20, P760, DOI 10.1002/psc.2672
   Ricagno S, 2006, P NATL ACAD SCI USA, V103, P11892, DOI 10.1073/pnas.0601708103
   Sadeghian I, 2018, TOXICOL APPL PHARM, V346, P9, DOI 10.1016/j.taap.2018.03.023
   Sakai Y, 2017, VIROLOGY, V510, P165, DOI 10.1016/j.virol.2017.07.019
   Schaduangrat N, 2019, MOLECULES, V24, DOI 10.3390/molecules24101973
   Schweizer F, 2009, EUR J PHARMACOL, V625, P190, DOI 10.1016/j.ejphar.2009.08.043
   Seelig J, 2004, BBA-BIOMEMBRANES, V1666, P40, DOI 10.1016/j.bbamem.2004.08.004
   Shankar G, 2014, AAPS J, V16, P658, DOI 10.1208/s12248-014-9599-2
   Shannon A, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104793
   Shin MC, 2014, J CONTROL RELEASE, V194, P197, DOI 10.1016/j.jconrel.2014.08.030
   Siu KL, 2019, FASEB J, V33, P8865, DOI 10.1096/fj.201802418R
   Snijder EJ, 2016, ADV VIRUS RES, V96, P59, DOI 10.1016/bs.aivir.2016.08.008
   Song JN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050300
   Spinello A., 2020, IS RIGIDITY SARS COV, DOI [10.26434/chemrxiv.12091260.v3., DOI 10.26434/CHEMRXIV.12091260.V3]
   Splith K, 2011, EUR BIOPHYS J BIOPHY, V40, P387, DOI 10.1007/s00249-011-0682-7
   Steel R, 2012, ACS MED CHEM LETT, V3, P407, DOI 10.1021/ml300041g
   Su D, 2006, J VIROL, V80, P7902, DOI 10.1128/JVI.00483-06
   Su R, 2020, BRIEF BIOINFORM, V21, P408, DOI 10.1093/bib/bby124
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Tan JZ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000428
   Tanaka T, 2012, J VIROL, V86, P11128, DOI 10.1128/JVI.01700-12
   Tiwari PM, 2014, BIOMATERIALS, V35, P9484, DOI 10.1016/j.biomaterials.2014.07.032
   Tseng YT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064013
   Ujike M, 2015, VIRUSES-BASEL, V7, P1700, DOI 10.3390/v7041700
   Varkhede N, 2020, J PHARM SCI-US, V109, P191, DOI 10.1016/j.xphs.2019.08.005
   Venkataraman S, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020076
   Wang B, 2017, FOOD CHEM, V218, P1, DOI 10.1016/j.foodchem.2016.08.106
   Wang YF, 2011, MOL THER, V19, P1849, DOI 10.1038/mt.2011.82
   White JM, 2016, TRAFFIC, V17, P593, DOI 10.1111/tra.12389
   Win TS, 2017, FUTURE MED CHEM, V9, P275, DOI 10.4155/fmc-2016-0188
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Xiao YB, 2012, J VIROL, V86, P4444, DOI 10.1128/JVI.06635-11
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Yu WT, 2018, J BIOL CHEM, V293, P15221, DOI 10.1074/jbc.RA118.004823
   Zaharieva N, 2017, J PROTEOM BIOINFORM, V10, P298, DOI [DOI 10.4172/JPB.1000454, 10.4172/jpb.1000454]
   Zhai YJ, 2005, NAT STRUCT MOL BIOL, V12, P980, DOI 10.1038/nsmb999
   Zhang L., 2020, BINDING MECH REMDESI, DOI [10. 20944/preprints202003.0267.v1., DOI 10.20944/PREPRINTS202003.0267.V1]
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang PW, 2018, CELL, V174, P1465, DOI 10.1016/j.cell.2018.07.031
   Zhang R, 2015, J VIROL, V89, P3598, DOI 10.1128/JVI.03535-14
   Zhukovsky MA, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00291
NR 135
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD NOV
PY 2020
VL 85
AR 104474
DI 10.1016/j.meegid.2020.104474
PG 27
WC Infectious Diseases
SC Infectious Diseases
GA OX9YZ
UT WOS:000593913000004
PM 32712315
OA Green Published
DA 2021-01-01
ER

PT J
AU Nambou, K
   Anakpa, M
AF Nambou, Komi
   Anakpa, Manawa
TI Deciphering the co-adaptation of codon usage between respiratory
   coronaviruses and their human host uncovers candidate therapeutics for
   COVID-19
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Coronavirus; COVID-19; Codon usage; Transcriptome; Virus-host
   co-adaptation; Treatment drugs
ID DINUCLEOTIDE FREQUENCY; GLUTAMATE PRODUCTION; ADAPTATION INDEX; VIRUSES;
   SARS; BIAS; VACCINES; PATTERN; GENOME
AB Coronavirus disease 2019 (COVID-19) has caused thousands of deaths worldwide and has become an urgent public health concern. The extraordinary interhuman transmission of this disease has urged scientists to examine the various facets of its pathogenic agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Herein, based on publicly available genomic data, we analyzed the codon usage co-adaptation profiles of SARSCoV-2 and other respiratory coronaviruses (CoVs) with their human host, identified CoV-responsive human genes and their functional roles on the basis of both the relative synonymous codon usage (RSCU)-based correlation of viral genes with human genes and differential gene expression analysis, and predicted potential drugs for COVID-19 treatment based on these genes. The relatively high codon adaptation index (CAI) values (> 0.70) signposted the gene expressivity efficiency of CoVs in human. The ENc-GC3 plot indicated that SARS-CoV-2 genome was under strict selection pressure while SARS-CoV and MERS-CoV were under selection and mutational pressures. The RSCU-based correlation analysis indicated that the viral genomes shared similar codons with a panoply of human genes. The merging of RSCU-based correlation data and SARS-CoV-2-responsive differentially expressed genes allowed the identification of human genes potentially affected by SARS-CoV-2 infection. Functional enrichment analysis indicated that these genes were enriched in biological processes and pathways related to host response to viral infection and immune response. Using the drug-gene interaction database, we screened a list of drugs that could target these genes as potential COVID-19 therapeutics. Our findings not only will contribute in vaccine development but also provide a useful set of drugs that could guide practitioners in strategical monitoring of COVID-19. We recommend practitioners to scrupulously screen this list of predicted drugs in order to authenticate those qualified for treating COVID-19 symptoms.
C1 [Nambou, Komi] Shenzhen Nambou1 Biotech, 506,Block B,5010 Baoan Ave, Shenzhen, Peoples R China.
   [Anakpa, Manawa] Beijing Univ Posts & Telecommun, Minist Educ, Sch Sofware, Key Lab Trustworthy Distributed Comp & Serv, 10 Xitucheng Rd, Beijing 100876, Peoples R China.
RP Nambou, K (corresponding author), Shenzhen Nambou1 Biotech, 506,Block B,5010 Baoan Ave, Shenzhen, Peoples R China.
EM noelnambou@yahoo.fr
CR Agrawal P, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01117
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Ahn DG, 2020, J MICROBIOL BIOTECHN, V30, P313, DOI 10.4014/jmb.2003.03011
   Antoniak S, 2014, BLOOD, V123, P2605, DOI 10.1182/blood-2013-09-526277
   Anwar Ali Mostafa, 2019, F1000Res, V8, P2137, DOI 10.12688/f1000research.21763.1
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Butt AM, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.106
   Carbone A, 2003, BIOINFORMATICS, V19, P2005, DOI 10.1093/bioinformatics/btg272
   Casey K, 2020, AM J EMERG MED, V38, DOI 10.1016/j.ajem.2020.04.011
   Castells M, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0780-y
   Cava C, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040404
   Chen Y, 2017, ONCOTARGET, V8, P110337, DOI 10.18632/oncotarget.22738
   Cotto Kelsy C, 2018, Nucleic Acids Res, V46, pD1068, DOI 10.1093/nar/gkx1143
   Darzentas N, 2010, BIOINFORMATICS, V26, P2620, DOI 10.1093/bioinformatics/btq484
   Deb B, 2020, ARCH VIROL, V165, P557, DOI 10.1007/s00705-020-04533-6
   Dickherber ML, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1265-y
   Dilucca M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050498
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   ELLIS J, 1993, GENE, V126, P163, DOI 10.1016/0378-1119(93)90363-8
   Erdmann N, 2007, J NEUROCHEM, V102, P539, DOI 10.1111/j.1471-4159.2007.04594.x
   Friedman HM, 2006, J CLIN VIROL, V35, P103, DOI 10.1016/j.jcv.2005.03.008
   Gu WJ, 2004, VIRUS RES, V101, P155, DOI 10.1016/j.virusres.2004.01.006
   Guo FC, 2019, J INFECTION, V79, P181, DOI 10.1016/j.jinf.2019.04.013
   Jenkins GM, 2003, VIRUS RES, V92, P1, DOI 10.1016/S0168-1702(02)00309-X
   JOHNSON AM, 1990, J MOL EVOL, V30, P383, DOI 10.1007/BF02101892
   Kandeel M, 2017, BIOL PHARM BULL, V40, P1086, DOI 10.1248/bpb.b17-00168
   Kitano H, 2002, SCIENCE, V295, P1662, DOI 10.1126/science.1069492
   Kumar N, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10110604
   Kunec D, 2016, CELL REP, V14, P55, DOI 10.1016/j.celrep.2015.12.011
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lee S, 2010, EVOL BIOINFORM, V6, P47
   Li E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a019133
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Liang Y, 2014, VIRUS RES, V192, P46, DOI 10.1016/j.virusres.2014.08.013
   Licastro D, 2020, J VIROL, V94, DOI 10.1128/JVI.00543-20
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Lu H, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/3018357
   Mesquita I, 2016, CELL MOL LIFE SCI, V73, P1225, DOI 10.1007/s00018-015-2119-4
   Miller J.B., 2017, BIOMED GENET GENOMIC, V2, P1
   Morgunov AS, 2014, NAT STRUCT MOL BIOL, V21, P1023, DOI 10.1038/nsmb.2926
   Mueller S, 2006, J VIROL, V80, P9687, DOI 10.1128/JVI.00738-06
   Murray MF, 2003, CLIN INFECT DIS, V36, P453, DOI 10.1086/367544
   Oldfield CJ, 2020, CELL MOL LIFE SCI, V77, P149, DOI 10.1007/s00018-019-03166-6
   Ou JJ, 2020, J INFECTION, V80, P677, DOI 10.1016/j.jinf.2020.01.004
   Pang MY, 2011, BMC IMMUNOL, V12, DOI 10.1186/1471-2172-12-55
   Paraskevis D, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104212
   Ren JL, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104743
   Robson B, 2020, COMPUT BIOL MED, V119, DOI 10.1016/j.compbiomed.2020.103670
   ROTHBERG PG, 1981, NUCLEIC ACIDS RES, V9, P6221, DOI 10.1093/nar/9.23.6221
   Sah R, 2020, MICROBIOL RESOUR ANN, V9, DOI 10.1128/MRA.00169-20
   Seronello S, 2010, J BIOL CHEM, V285, P845, DOI 10.1074/jbc.M109.045740
   Sexton NR, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11070643
   SHARP PM, 1986, J MOL EVOL, V24, P28, DOI 10.1007/BF02099948
   Sheikh A, 2020, J VIROL METHODS, V277, DOI 10.1016/j.jviromet.2019.113806
   Singh AK, 2020, DIABETES METAB SYND, V14, P241, DOI 10.1016/j.dsx.2020.03.011
   Singhal A, 2019, INT IMMUNOL, V31, P59, DOI 10.1093/intimm/dxy068
   Smutzer Gregory, 1994, Molecular Marine Biology and Biotechnology, V3, P112
   Stano M, 2016, DATABASE-OXFORD, DOI 10.1093/database/baw162
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Stefanelli P., 2020, EURO SURVEILL, V25
   Stoermer KA, 2011, VIROLOGY, V411, P362, DOI 10.1016/j.virol.2010.12.045
   Sutton TC, 2015, VIROLOGY, V479, P247, DOI 10.1016/j.virol.2015.02.030
   Takata MA, 2017, NATURE, V550, P124, DOI 10.1038/nature24039
   Tort FL, 2020, VIRUS RES, V283, DOI 10.1016/j.virusres.2020.197976
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Vetsigian K, 2009, P NATL ACAD SCI USA, V106, P215, DOI 10.1073/pnas.0810122106
   Vicario S, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-226
   Victor MP, 2019, GENOMICS, V111, P1292, DOI 10.1016/j.ygeno.2018.08.009
   Wada Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035069
   WOLD S, 1987, CHEMOMETR INTELL LAB, V2, P37, DOI 10.1016/0169-7439(87)80084-9
   Woo PCY, 2007, VIROLOGY, V369, P431, DOI 10.1016/j.virol.2007.08.010
   Wright Christopher, 2020, Evid Based Dent, V21, P64, DOI 10.1038/s41432-020-0098-2
   WRIGHT F, 1990, GENE, V87, P23, DOI 10.1016/0378-1119(90)90491-9
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Yadav Pragya D, 2020, Indian J Med Res, V151, P200, DOI 10.4103/ijmr.IJMR_663_20
   Yamagishi K, 2002, DNA RES, V9, P19, DOI 10.1093/dnares/9.1.19
   Yan ZQ, 2019, VIRULENCE, V10, P1, DOI 10.1080/21505594.2018.1551708
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yew TD, 2004, VIRUS GENES, V28, P41, DOI 10.1023/B:VIRU.0000012262.89898.c7
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Yu SW, 2020, ANN PALLIAT MED, V9, P437, DOI 10.21037/apm.2020.03.27
   Zalucki YM, 2009, TRENDS MICROBIOL, V17, P146, DOI 10.1016/j.tim.2009.01.005
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang YM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110442
   Zhao JX, 2004, J NEUROCHEM, V88, P169, DOI 10.1046/j.1471-4159.2003.02146.x
   Zheng J, 2020, INT J BIOL SCI, V16, P1678, DOI 10.7150/ijbs.45053
   Zhong J, 2007, VIRUS GENES, V35, P767, DOI 10.1007/s11262-007-0159-z
   Zhou JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077239
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 90
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD NOV
PY 2020
VL 85
AR 104471
DI 10.1016/j.meegid.2020.104471
PG 15
WC Infectious Diseases
SC Infectious Diseases
GA OX9YZ
UT WOS:000593913000005
PM 32707288
OA Green Published
DA 2021-01-01
ER

PT J
AU Parashar, NC
   Poddar, J
   Chakrabarti, S
   Parashar, G
AF Parashar, Nidarshana Chaturvedi
   Poddar, Jit
   Chakrabarti, Sasanka
   Parashar, Gaurav
TI Repurposing of SARS-CoV nucleocapsid protein specific nuclease resistant
   RNA aptamer for therapeutics against SARS-CoV-2
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE SARS-CoV-2; RNA aptamer; Repurposing; Therapeutics; Nucleocapsid
   protein; Spike protein
AB COVID-19 pandemic is rapidly advancing among human population. Development of new interventions including therapeutics and vaccines against SARS-CoV-2 will require time and validation before it could be made available for public use. Keeping in view of the emergent and evolving situation the motive is to repurpose and test the immediate efficacy of available drugs and therapeutics against COVID-19. Through this article we propose and discuss the possibility of repurposing the available nuclease resistant RNA aptamer against the nucleocapsid protein of SARS-CoV as a potential therapeutic agent for COVID-19.
C1 [Parashar, Nidarshana Chaturvedi; Parashar, Gaurav] Maharishi Markandeshwar Univ, Dept Biotechnol, Mullana, Haryana, India.
   [Poddar, Jit; Chakrabarti, Sasanka] Maharishi Markandeshwar Univ, MM Inst Med Sci & Res, Dept Biochem & Cent Res Cell, Mullana, Haryana, India.
RP Parashar, G (corresponding author), Maharishi Markandeshwar, Dept Biotechnol, Ambala 133207, Haryana, India.
EM parashar_panchal@yahoo.co.in
OI CHAKRABARTI, SASANKA/0000-0002-9429-4892
FU Maharishi Markandeshwar (deemed to be) University, Mullana; Department
   of Health Research (DHR), Ministry of Health and Family Welfare, India
   [R.12014/10/2018-HR]
FX Authors duly acknowledge the research support provided by Maharishi
   Markandeshwar (deemed to be) University, Mullana. Dr. Gaurav Parashar is
   supported by Department of Health Research (DHR), Ministry of Health and
   Family Welfare, India under DHR-YSS scheme (File No.
   R.12014/10/2018-HR).
CR Ahn DG, 2009, ANALYST, V134, P1896, DOI 10.1039/b906788d
   [Anonymous], 2020, COVID 19 CORONAVIRUS
   Chakrabarti SS, 2020, AGING DIS, V11, P480, DOI 10.14336/AD.2020.0402
   Cho SJ, 2011, J BIOSCI BIOENG, V112, P535, DOI 10.1016/j.jbiosc.2011.08.014
   Cui L, 2015, J VIROL, V89, P9029, DOI 10.1128/JVI.01331-15
   Magalhaes MLB, 2012, MOL THER, V20, P616, DOI 10.1038/mt.2011.277
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   Song YL, 2020, ANAL CHEM, V92, P9895, DOI 10.1021/acs.analchem.0c01394
   Zhou JH, 2013, MOL THER, V21, P192, DOI 10.1038/mt.2012.226
   Zou XR, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01462
   Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595
NR 11
TC 1
Z9 1
U1 7
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD NOV
PY 2020
VL 85
AR 104497
DI 10.1016/j.meegid.2020.104497
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA OX9YZ
UT WOS:000593913000008
PM 32791240
OA Green Published
DA 2021-01-01
ER

PT J
AU Porto, PS
   Anjos, D
   Dabilla, N
   da Fonseca, SG
   Souza, M
AF Porto, Pedro Soares
   Anjos, Deborah
   Dabilla, Nathania
   da Fonseca, Simone Goncalves
   Souza, Menira
TI Immunoinformatic construction of an adenovirus-based modular vaccine
   platform and its application in the design of a SARS-CoV-2 vaccine
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Immunoinformatics; SARS-CoV-2 vaccine; Epitope display; HAdV vectors;
   Immunomodulatory prediction; Vaccine strategy
ID NEUTRALIZING ANTIBODIES; IMMUNE-RESPONSES; CELL EPITOPES; PENTON BASE;
   SEROTYPE 5; VECTORS; IDENTIFICATION; PROTEINS; SPIKE
AB The current SARS-CoV-2 pandemic has imposed new challenges and demands for health systems, especially in the development of new vaccine strategies. Vaccines for many pathogens were developed based on the display of foreign epitopes in the variable regions of the human adenovirus (HAdV) major capsid proteins (hexon, penton and fiber). The humoral immune response against the HAdV major capsid proteins was demonstrated to play a role in the development of an immune response against the epitopes in display. Through the immunoinformatic profiling of the major capsid proteins of HAdVs from different species, we developed a modular concept that can be used in the development of vaccines based on HAdV vectors. Our data suggests that different immunomodulatory potentials can be observed in the conserved regions, present in the hexon and penton proteins, from different species. Using this modular approach, we developed a HAdV-5 based vaccine strategy for SARSCoV-2, constructed through the display of SARS-CoV-2 epitopes indicated by our prediction analysis as immunologically relevant. The sequences of the HAdV vector major capsid proteins were also edited to enhance the IFN-gamma induction and antigen presenting cells activation. This is the first study proposing a modular HAdV platform developed to aid the design of new vaccines by inducing an immune response more suited for the epitopes in display.
C1 [Porto, Pedro Soares; Anjos, Deborah; Dabilla, Nathania; Souza, Menira] Univ Fed Goias, Inst Patol Trop & Saude Publ, Lab Virol & Cell Culture, Goiania, Go, Brazil.
   [da Fonseca, Simone Goncalves] Univ Fed Goias, Inst Patol Trop & Saude Publ, Immunoregulat Lab, Goiania, Go, Brazil.
RP Souza, M (corresponding author), Univ Fed Goias, Inst Patol Trop & Saude Publ, Lab Virol & Cell Culture, Setor Univ, Rua 235 S-N,Sala 420, BR-74605050 Goiania, Go, Brazil.
EM menirasouza@gmail.com
OI Carvalho dos Anjos, Deborah Carolina/0000-0002-5258-5587
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -Brasil
   (Capes)CAPES
FX This study was financed in part by the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior -Brasil (Capes).
CR Ahi YS, 2011, CURR GENE THER, V11, P307
   Anchim A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00124
   Backert L, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0245-0
   Bahrami AA, 2019, INT REV IMMUNOL, V38, P307, DOI 10.1080/08830185.2019.1657426
   Baruah V, 2020, J MED VIROL, V92, P495, DOI 10.1002/jmv.25698
   Bazmara S, 2019, MED HYPOTHESES, V130, DOI 10.1016/j.mehy.2019.109267
   BAZZAZ BSF, 2020, INT J PEPT RES THER, DOI DOI 10.1007/S10989-019-10003-8
   Bui HH, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-361
   Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6
   Crystal RG, 2014, HUM GENE THER, V25, P3, DOI 10.1089/hum.2013.2527
   Curiel D.T., 2016, ADENOVIRAL VECTORS G, DOI DOI 10.1016/C2013-0-15164-1
   CUZANGE A, 1994, GENE, V146, P257, DOI 10.1016/0378-1119(94)90302-6
   Dhanda SK, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/263952
   Dhanda SK, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-30
   Ebner K, 2006, J VIROL, V80, P2586, DOI 10.1128/JVI.80.5.2586.2006
   Emmer KL, 2020, MUCOSAL VACCINES: INNOVATION FOR PREVENTING INFECTIOUS DISEASES, 2ND EDITION, P419, DOI 10.1016/B978-0-12-811924-2.00024-9
   Farrow AL, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003089
   Garcia-Boronat M, 2008, NUCLEIC ACIDS RES, V36, pW35, DOI 10.1093/nar/gkn211
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Gupta S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01430
   Gupta S, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0928-3
   Hiwarkar P, 2018, REV MED VIROL, V28, DOI 10.1002/rmv.1980
   Hoelscher MA, 2006, LANCET, V367, P475, DOI 10.1016/S0140-6736(06)68076-8
   Hong SS, 2003, J VIROL, V77, P10366, DOI 10.1128/JVI.77.19.10366-10375.2003
   Hossain R, 2018, J IMMUNOL METHODS, V455, P55, DOI 10.1016/j.jim.2018.01.005
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hutnick NA, 2010, VACCINE, V28, P1932, DOI 10.1016/j.vaccine.2009.10.091
   Jensen KK, 2018, IMMUNOLOGY, V154, P394, DOI 10.1111/imm.12889
   Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893
   Krause A, 2006, J VIROL, V80, P5523, DOI 10.1128/JVI.02667-05
   Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022
   Lanzi A, 2011, VACCINE, V29, P1463, DOI 10.1016/j.vaccine.2010.12.025
   Layne SP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb1469
   Leen AM, 2005, BRIT J HAEMATOL, V128, P135, DOI 10.1111/j.1365-2141.2004.05218.x
   Leen AM, 2004, BLOOD, V104, P2432, DOI 10.1182/blood-2004-02-0646
   Leen AM, 2008, J VIROL, V82, P546, DOI 10.1128/JVI.01689-07
   Liu WJ, 2017, ANTIVIR RES, V137, P82, DOI 10.1016/j.antiviral.2016.11.006
   Lopez-Gordo E, 2014, HUM GENE THER, V25, P285, DOI 10.1089/hum.2013.228
   Madeira F, 2019, NUCLEIC ACIDS RES, V47, pW636, DOI 10.1093/nar/gkz268
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Nagpal G, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1560-1
   Nagpal G, 2017, SCI REP-UK, V7, DOI 10.1038/srep42851
   Neukirch L, 2020, EXPERT REV VACCINES, V19, P25, DOI 10.1080/14760584.2020.1711054
   Nezafat N, 2014, J THEOR BIOL, V349, P121, DOI 10.1016/j.jtbi.2014.01.018
   Onion D, 2007, J GEN VIROL, V88, P2417, DOI 10.1099/vir.0.82867-0
   Palma C, 2011, VACCINE, V29, P1683, DOI 10.1016/j.vaccine.2010.12.040
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Poh WP, 2009, J MED VIROL, V81, P1131, DOI 10.1002/jmv.21571
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Ralph R, 2020, J INFECT DEV COUNTR, V14, P3, DOI 10.3855/jidc.12425
   Robinson CM, 2013, SCI REP-UK, V3, DOI 10.1038/srep01812
   Rux JJ, 2003, J VIROL, V77, P9553, DOI 10.1128/JVI.77.17.9553-9566.2003
   Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078
   Saini HS, 2016, 2016 3RD INTERNATIONAL CONFERENCE ON SIGNAL PROCESSING AND INTEGRATED NETWORKS (SPIN), P577
   Shayakhmetov DM, 2005, J VIROL, V79, P1053, DOI 10.1128/JVI.79.2.1053-1061.2005
   Shiratsuchi T, 2010, J CLIN INVEST, V120, P3688, DOI 10.1172/JCI39812
   Sumida SM, 2005, J IMMUNOL, V174, P7179, DOI 10.4049/jimmunol.174.11.7179
   Sumida SM, 2004, J VIROL, V78, P2666, DOI 10.1128/JVI.78.6.2666-2673.2004
   Tang XY, 2017, J VIROL, V91, DOI 10.1128/JVI.02462-16
   Teigler JE, 2014, CLIN VACCINE IMMUNOL, V21, P1137, DOI 10.1128/CVI.00207-14
   Tischer S, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1042-2
   van Winkel CAJ, 2018, MOL PHARMACEUT, V15, P5446, DOI 10.1021/acs.molpharmaceut.8b00591
   Vigne E, 1999, J VIROL, V73, P5156, DOI 10.1128/JVI.73.6.5156-5161.1999
   Vujadinovic M, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6030081
   WHO W.H. organization, 2020, COR DIS PAND
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu D, 2020, INT J INFECT DIS, V94, P44, DOI 10.1016/j.ijid.2020.03.004
   Wu WH, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0364-7
   Yang YS, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102487
   Zhang YM, 2005, J VIROL, V79, P12125, DOI 10.1128/JVI.79.19.12125-12131.2005
   Zhou DM, 2013, MOL THER, V21, P696, DOI 10.1038/mt.2012.248
   Zubieta C, 2005, MOL CELL, V17, P121, DOI 10.1016/j.molcel.2004.11.041
NR 72
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD NOV
PY 2020
VL 85
AR 104489
DI 10.1016/j.meegid.2020.104489
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA OX9YZ
UT WOS:000593913000002
PM 32758675
DA 2021-01-01
ER

PT J
AU Saha, I
   Ghosh, N
   Maity, D
   Sharma, N
   Sarkar, JP
   Mitra, K
AF Saha, Indrajit
   Ghosh, Nimisha
   Maity, Debasree
   Sharma, Nikhil
   Sarkar, Jnanendra Prasad
   Mitra, Kaushik
TI Genome-wide analysis of Indian SARS-CoV-2 genomes for the identification
   of genetic mutation and SNP
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Multiple sequence alignment; Point mutation; SNPs; SARS-CoV-2
ID CORONAVIRUS; PNEUMONIA; VACCINE
AB The wave of COVID-19 is a big threat to the human population. Presently, the world is going through different phases of lock down in order to stop this wave of pandemic; India being no exception. We have also started the lock down on 23rd March 2020. In this current situation, apart from social distancing only a vaccine can be the proper solution to serve the population of human being. Thus it is important for all the nations to perform the genome-wide analysis in order to identify the genetic variation in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) so that proper vaccine can be designed. This fast motivated us to analyze publicly available 566 Indian complete or near complete SARS-CoV-2 genomes to find the mutation points as substitution, deletion and insertion. In this regard, we have performed the multiple sequence alignment in presence of reference sequence from NCBI. After the alignment, a consensus sequence is built to analyze each genome in order to identify the mutation points. As a consequence, we have found 933 substitutions, 2449 deletions and 2 insertions, in total 3384 unique mutation points, in 566 genomes across 29.9 K bp. Further, it has been classified into three groups as 100 clusters of mutations (mostly deletions), 1609 point mutations as substitution, deletion and insertion and 64 SNPs. These outcomes are visualized using BioCircos and bar plots as well as plotting entropy value of each genomic location. Moreover, phylogenetic analysis has also been performed to see the evolution of SARS-CoV-2 virus in India. It also shows the wide variation in tree which indeed vivid in genomic analysis. Finally, these SNPs can be the useful target for virus classification, designing and defining the effective dose of vaccine for the heterogeneous population.
C1 [Saha, Indrajit] Natl Inst Tech Teachers Training & Res, Dept Comp Sci & Engn, Kolkata, W Bengal, India.
   [Ghosh, Nimisha] Siksha O Anusandhan Deemed Be Univ, Inst Tech Educ & Res, Dept Comp Sci & Informat Technol, Bhubaneswar, Orissa, India.
   [Maity, Debasree] MCKV Inst Engn, Dept Elect & Commun Engn, Howrah, W Bengal, India.
   [Sharma, Nikhil] Jaypee Inst Informat Technol, Dept Elect & Commun Engn, Noida, Uttar Pradesh, India.
   [Sarkar, Jnanendra Prasad] Larsen & Toubro Infotech, Pune, Maharashtra, India.
   [Sarkar, Jnanendra Prasad] Jadavpur Univ, Dept Comp Sci & Engn, Kolkata, W Bengal, India.
   [Mitra, Kaushik] Burdwan Med Coll, Dept Community Med, Barddhaman, W Bengal, India.
RP Saha, I (corresponding author), Natl Inst Tech Teachers Training & Res, Dept Comp Sci & Engn, Kolkata, W Bengal, India.
EM indrajit@nitttrkol.ac.in
OI MITRA, KAUSHIK/0000-0002-8865-373X
FU CRG short term research grant on COVID-19 from Science and Engineering
   Research Board (SERB), Department of Science and Technology, Govt. of
   India [CVD/2020/000991]
FX This work has been partially supported by CRG short term research grant
   on COVID-19 (CVD/2020/000991) from Science and Engineering Research
   Board (SERB), Department of Science and Technology, Govt. of India.
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chothe SK, 2018, VIROLOGY, V522, P27, DOI 10.1016/j.virol.2018.06.015
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Fleischmann W.R.J., 1996, VIRAL GENETICS
   Jenkins GM, 2002, J MOL EVOL, V54, P156, DOI 10.1007/s00239-001-0064-3
   Jeon JS, 2016, VIROLOGY, V496, P277, DOI 10.1016/j.virol.2016.06.017
   Lu IN, 2020, VIRUS RES, V283, DOI 10.1016/j.virusres.2020.197963
   Paital B, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138914
   Pavlovic-Lazetic GM, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-65
   Stuessy T.F., 2009, PLANT TAXONOMY SYSTE
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Wallace A, 2005, J JUDIC ADM, V15
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   Woo PCY, 2009, EXP BIOL MED, V234, P1117, DOI 10.3181/0903-MR-94
   Worldometer, 2020, COR DIS 2019 COVID 1
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 18
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD NOV
PY 2020
VL 85
AR 104457
DI 10.1016/j.meegid.2020.104457
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA OX9ZU
UT WOS:000593915100014
PM 32659347
OA Green Published
DA 2021-01-01
ER

PT J
AU Marchetti, A
   Bhutani, T
   Lockshin, B
   Siegel, DM
   Behringer, F
AF Marchetti, Albert
   Bhutani, Tina
   Lockshin, Benjamin
   Siegel, Daniel M.
   Behringer, Frederick
TI Therapies for Psoriasis: Clinical and Economic Comparisons
SO JOURNAL OF DRUGS IN DERMATOLOGY
LA English
DT Article
ID SEVERE PLAQUE PSORIASIS; UNITED-STATES; HEALTH-CARE; ARTHRITIS;
   MODERATE; PREVALENCE; SAFETY; BURDEN
AB Background: Clinical and economic comparisons of therapies for plaque psoriasis are regularly updated following each new development in the field. With the recent availability of a novel accessory (Multi Micro Dose (TM) [MMD (R)] tip) for the 308nm excimer laser (XTRAC (R), Strata Skin Sciences, Horsham, PA), which can determine and deliver an optimal therapeutic dose (OTD (TM) of ultraviolet-B light in an improved protocol, the need for comparative health-economic assessment recurs. To this end, a comprehensive evaluation of treatment-related costs was undertaken from the payer perspective. Results show that outcomes are influenced by many factors; most importantly, the severity and extent of disease, treatment selection, and patient preference, as well as compliance, adherence, and persistence with care. Among study comparators, the 308nm excimer laser - XTRAC - with its latest MMD enhancement, is safe and delivers incremental clinical benefits with the potential for significant cost savings. These benefits are particularly relevant today in the context of SARS-CoV-2 virus and the COVid-19 pandemic.
C1 [Marchetti, Albert] MED ERA Inc, New York, NY 10305 USA.
   [Marchetti, Albert] Rutgers New Jersey Med Sch, Newark, NJ 07103 USA.
   [Bhutani, Tina] Univ Calif San Francisco, Psoriasis & Skin Treatment Ctr, San Francisco, CA 94143 USA.
   [Bhutani, Tina] Univ Calif San Francisco, Dermatol Clin Res Unit, San Francisco, CA 94143 USA.
   [Lockshin, Benjamin] Clin Trials Ctr, Silver Spring, MD USA.
   [Lockshin, Benjamin] Derm Associates, Silver Spring, MD USA.
   [Siegel, Daniel M.] SUNY Downstate & Brooklyn Vet Adm, New York, NY USA.
   [Behringer, Frederick] Suncoast Skin Solut, Ocala, FL USA.
RP Marchetti, A (corresponding author), MED ERA Inc, New York, NY 10305 USA.; Marchetti, A (corresponding author), Rutgers New Jersey Med Sch, Newark, NJ 07103 USA.
EM albertmarchetti@yahoo.com
CR American Academy of Dermatology, GUID US MED COVID 19
   [Anonymous], 2015, PHYS DESK REFERENCE
   [Anonymous], DRUG SAF COMM DRUG L
   Armstrong AW, 2018, BMC DERMATOL, V18, DOI 10.1186/s12895-018-0072-2
   Armstrong AW, 2017, DERMATOLOGY THER, V7, P97, DOI 10.1007/s13555-016-0153-2
   Armstrong AW, 2013, JAMA DERMATOL, V149, P1180, DOI 10.1001/jamadermatol.2013.5264
   Augustin M, 2009, J DTSCH DERMATOL GES, V7, P329, DOI 10.1111/j.1610-0387.2008.06919.x
   Baliwag J, 2015, CYTOKINE, V73, P342, DOI 10.1016/j.cyto.2014.12.014
   Bhutani T, 2013, JAMA DERMATOL, V149, P717, DOI 10.1001/jamadermatol.2013.133
   Brezinski EA, 2015, JAMA DERMATOL, V151, P651, DOI 10.1001/jamadermatol.2014.3593
   British Association of Dermatologists, 2020, DERM ADV REG MED ACT
   Campanati A, 2016, CURR DRUG SAF, V11, P4, DOI 10.2174/1574886310666151014115532
   Centers for Disease Control, PEOPL WHO AR HIGH RI
   Duffin KC, 2014, BRIT J DERMATOL, V170, P672, DOI 10.1111/bjd.12745
   Feldman S., TREATMENT PSORIASIS
   Fraser I, 2008, HEALTH SERV RES, V43, P1781, DOI 10.1111/j.1475-6773.2008.00904.x
   Gelfand JM, 2005, J AM ACAD DERMATOL, V52, P23, DOI 10.1016/j.jaad.2004.07.045
   Gilbertson EO, 1998, J AM ACAD DERMATOL, V38, P318, DOI 10.1016/S0190-9622(98)70573-0
   GOMEZ EC, 1976, ARCH DERMATOL, V112, P1559, DOI 10.1001/archderm.112.11.1559
   Gottlieb AB, 2005, NAT REV DRUG DISCOV, V4, P19, DOI 10.1038/nrd1607
   Hanley T, 2016, PSORIASIS-TARGETS TH, V6, P41, DOI 10.2147/PTT.S68869
   Helmick CG, 2014, AM J PREV MED, V47, P37, DOI 10.1016/j.amepre.2014.02.012
   Hengge UR, 2006, J AM ACAD DERMATOL, V54, P1, DOI 10.1016/j.jaad.2005.01.010
   Hong CH, 2017, J EUR ACAD DERMATOL, V31, P1876, DOI 10.1111/jdv.14515
   Javitz HS, 2002, J AM ACAD DERMATOL, V46, P850, DOI 10.1067/mjd.2002.119669
   Jennum P, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010662
   Kalb RE, 2015, JAMA DERMATOL, V151, P961, DOI 10.1001/jamadermatol.2015.0718
   Kamata M, 2018, J DERMATOL, V45, P279, DOI 10.1111/1346-8138.14096
   Kimball AB, 2015, AM J PHARM BENEFIST, V7, pE44
   Korman NJ, 2016, DERMATOL ONLINE J, V22
   Krueger JG, 2005, ANN RHEUM DIS, V64, P30, DOI 10.1136/ard.2004.031120
   Krueger JG, 1994, J AM ACAD DERMATOL 2, V11, P937, DOI [10.1016/s0190-9622(84)80018-3, DOI 10.1016/S0190-9622(84)80018-3]
   Larsen MH, 2019, AM J CLIN DERMATOL, V20, P13, DOI 10.1007/s40257-018-0390-5
   Lebwohl M, 2018, ANN INTERN MED, V168, pITC49, DOI 10.7326/AITC201804030
   Mansouri Yasaman, 2015, J Clin Aesthet Dermatol, V8, P30
   Menter A, 2008, J AM ACAD DERMATOL, V58, P826, DOI 10.1016/j.jaad.2008.02.039
   Menter A, 2019, J AM ACAD DERMATOL, V80, P1029, DOI 10.1016/j.jaad.2018.11.057
   Menter A, 2010, J AM ACAD DERMATOL, V62, P114, DOI 10.1016/j.jaad.2009.08.026
   Menter A, 2009, J AM ACAD DERMATOL, V61, P451, DOI 10.1016/j.jaad.2009.03.027
   Menter A, 2009, J AM ACAD DERMATOL, V60, P643, DOI 10.1016/j.jaad.2008.12.032
   Morris S., 2012, EMERG INFECT DIS, DOI DOI 10.3201/EID0702.010227
   Murage MJ, 2018, J MED ECON, V21, P745, DOI 10.1080/13696998.2018.1472097
   Papp Kim A, 2007, Ther Clin Risk Manag, V3, P245, DOI 10.2147/tcrm.2007.3.2.245
   Schaefer CP, 2015, J AM ACAD DERMATOL, V73, P585, DOI 10.1016/j.jaad.2015.06.049
   Scott RD, 2001, EMERG INFECT DIS, V7, P282, DOI 10.3201/eid0702.010227
   Stern RS, 2004, J INVEST DERM SYMP P, V9, P136, DOI 10.1046/j.1087-0024.2003.09102.x
   Stern RS, 1996, J AM ACAD DERMATOL, V35, P543, DOI 10.1016/S0190-9622(96)90676-3
   Takeshita J, 2017, J AM ACAD DERMATOL, V76, P377, DOI 10.1016/j.jaad.2016.07.064
   Thakkar S, 2015, NATL J LNTEGR RES ME, V6, P15
   Thibodeaux Q, 2020, J DRUGS DERMATOL, V19, P349, DOI 10.36849/JDD.2020.4891
   West JD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148657
NR 51
TC 0
Z9 0
U1 3
U2 3
PU JOURNAL OF DRUGS IN DERMATOLOGY
PI NEW YORK
PA 377 PARK AVE SOUTH, 6TH FLOOR, NEW YORK, NY 10016 USA
SN 1545-9616
J9 J DRUGS DERMATOL
JI J. Drugs Dermatol.
PD NOV
PY 2020
VL 19
IS 11
BP 1101
EP 1108
DI 10.36849/JDD.2020.5510
PG 8
WC Dermatology
SC Dermatology
GA OY1EQ
UT WOS:000593996600014
PM 33196750
DA 2021-01-01
ER

PT J
AU Litchman, GL
   Marson, JW
   Bhatia, N
   Berman, B
AF Litchman, Graham L.
   Marson, Justin W.
   Bhatia, Neal
   Berman, Brian
TI Revisiting Handwashing - As It Is Absolutely Essential
SO JOURNAL OF DRUGS IN DERMATOLOGY
LA English
DT Article
AB As the coronavirus pandemic continues into the second half of 2020, states across the US remain steadfast in their search to determine the safest methods of returning to normalcy. Without a readily available, effective COVID-19 vaccine, and as the numbers of infected individuals continues to climb, the best practices to ensure public safety are rooted in good personal hygiene and prevention of transmission of the novel coronavirus SARS-CoV-2. To that end, in addition to properly wearing adequate facial covering, individuals should properly wash their hands to prevent direct auto-inoculation.
C1 [Litchman, Graham L.] St Johns Episcopal Hosp, Dept Dermatol, New York, NY USA.
   [Marson, Justin W.] Natl Soc Cutaneous Med, New York, NY USA.
   [Bhatia, Neal] Therapeut Clin Res, San Diego, CA USA.
   [Berman, Brian] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
   [Berman, Brian] Ctr Cosmet & Clin Res, Aventura, FL 33180 USA.
RP Berman, B (corresponding author), Univ Miami, Miller Sch Med, Miami, FL 33136 USA.; Berman, B (corresponding author), Ctr Cosmet & Clin Res, Aventura, FL 33180 USA.
EM bbmdphd@gmail.com
CR [Anonymous], 2020, WASH YOUR HANDS
   [Anonymous], 2010, BIOSCIENCES LAB FINA
   [Anonymous], DRY SKIN RELIEF COVI
   Aronson JK, 2016, MEYLERS SIDE EFFECTS, P418
   FAIR G. M., 1948, Journal of the American Water Works Association, V40, P1051
   FAIR G. M., 1947, Journal of the New England Water Works Association, V61, P285
   Gebel J, 2013, GMS HYG INFECT CONTR, V8, DOI 10.3205/dgkh000210
   Hon KL, 2016, J DERMATOL TREAT, V27, P156, DOI 10.3109/09546634.2015.1067669
   Ma QX, 2020, J MED VIROL, V92, P1567, DOI 10.1002/jmv.25805
   Majewski S, 2019, PEDIATR DERMATOL, V36, P442, DOI 10.1111/pde.13842
   Najnin N, 2019, AM J TROP MED HYG, V100, P742, DOI 10.4269/ajtmh.18-0644
   Pradhan D, 2020, ARCH MED RES, V51, P363, DOI 10.1016/j.arcmed.2020.04.020
   Prater KJ, 2016, AM J INFECT CONTROL, V44, P66, DOI 10.1016/j.ajic.2015.08.012
   Thibodeau R., 2020, STATPEARLS
NR 14
TC 0
Z9 0
U1 0
U2 0
PU JOURNAL OF DRUGS IN DERMATOLOGY
PI NEW YORK
PA 377 PARK AVE SOUTH, 6TH FLOOR, NEW YORK, NY 10016 USA
SN 1545-9616
J9 J DRUGS DERMATOL
JI J. Drugs Dermatol.
PD NOV
PY 2020
VL 19
IS 11
BP 1127
EP 1129
DI 10.36849/JDD.2020.5557
PG 3
WC Dermatology
SC Dermatology
GA OY1EQ
UT WOS:000593996600022
PM 33196736
DA 2021-01-01
ER

PT J
AU Hasford, J
AF Hasford, Joerg
TI Large Simple Double-Blind Randomized Trials for the Rapid Assessment of
   the Effectiveness of COVID-19 Vaccines
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Letter
C1 [Hasford, Joerg] Univ Munich, Inst Med Informat Proc Biometry & Epidemiol, Marchioninistr 15, D-81377 Munich, Germany.
   [Hasford, Joerg] Assoc Med Eth Comm Germany, Berlin, Germany.
RP Hasford, J (corresponding author), Univ Munich, Inst Med Informat Proc Biometry & Epidemiol, Marchioninistr 15, D-81377 Munich, Germany.
EM has@ibe.med.uni-muenchen.de
OI Hasford, Joerg/0000-0002-9685-4769
CR Centers for Disease Control and Prevention, VACC SAF DAT
   Eyal N, 2020, J INFECT DIS, V221, P1752, DOI 10.1093/infdis/jiaa152
   HUNT D, 1992, LANCET, V339, P753
   Lambert SM, 2000, ARCH PEDIAT ADOL MED, V154, P512, DOI 10.1001/archpedi.154.5.512
   Medikura, PAT SAF DIG
   Metzger WG, 2019, TROP MED INT HEALTH, DOI 10.1111/tmi.13320
   Wagner A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00717
   YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421
NR 8
TC 1
Z9 1
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2020
VL 222
IS 9
BP 1571
EP 1572
DI 10.1093/infdis/jiaa456
PG 2
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA OW9PE
UT WOS:000593209200022
PM 32845317
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Rabelo-da-Ponte, FD
   Silvello, D
   Scherer, JN
   Ayala, AR
   Klamt, F
AF Rabelo-da-Ponte, Francisco Diego
   Silvello, Daiane
   Scherer, Juliana Nichterwitz
   Ayala, Alejandro Raul
   Klamt, Fabio
TI Convalescent Plasma Therapy in Patients With Severe or Life-Threatening
   COVID-19: A Metadata Analysis
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Letter
C1 [Rabelo-da-Ponte, Francisco Diego] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Lab Mol Psychiat, Porto Alegre, RS, Brazil.
   [Rabelo-da-Ponte, Francisco Diego; Silvello, Daiane; Scherer, Juliana Nichterwitz] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Ctr Drug & Alcohol Res, Porto Alegre, RS, Brazil.
   [Rabelo-da-Ponte, Francisco Diego] Univ Fed Rio Grande do Sul, Grad Program Psychiat & Behav Sci, Porto Alegre, RS, Brazil.
   [Silvello, Daiane] Univ Fed Rio Grande do Sul, Grad Program Pulm Sci, Porto Alegre, RS, Brazil.
   [Scherer, Juliana Nichterwitz] Univ Vale Rio dos Sinos, Sao Leopoldo, Brazil.
   [Ayala, Alejandro Raul] Univ Miami, Dept Internal Med, Miami, FL USA.
   [Klamt, Fabio] Univ Fed Rio Grande do Sul, Inst Basic Hlth Sci, Dept Biochem, Lab Cellular Biochem, Porto Alegre, RS, Brazil.
   [Klamt, Fabio] Natl Inst Sci & Technol Translat Med, Porto Alegre, RS, Brazil.
RP Klamt, F (corresponding author), Univ Fed Rio Grande do Sul, ICBS, Dept Biochem, Lab Cellular Biochem, 2600 Ramiro Barcelos St, BR-90035003 Porto Alegre, RS, Brazil.
EM fabio.Klamt@ufrgs.br
RI Scherer, Juliana/M-6344-2016
OI Scherer, Juliana/0000-0002-9235-0416
FU Brazilian Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [465458/2014-9]; Programa de Apoio aos Nucleos de
   Excelencia/Fundacao de Amparo a Pesquisa do estado do Rio Grande do Sul
   [16/2551-00004994]; Ministerio de Ciencia e Tecnologia/CNPq
   [306439/2014-0]
FX This work was supported by the Brazilian Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq) (grant number Instituto
   Nacional de Ciencia & Tecnologia -Translacional em
   Medicina/CNPq/Fundacao de Amparo a Pesquisa do estado de Sao
   Paulo-465458/2014-9); and Programa de Apoio aos Nucleos de
   Excelencia/Fundacao de Amparo a Pesquisa do estado do Rio Grande do Sul
   (grant number 16/2551-00004994). F. K. received a fellowship from
   Ministerio de Ciencia e Tecnologia/CNPq (grant number 306439/2014-0).
CR Ahn JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e149
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Joyner MJ, 2020, J CLIN INVEST, V130, P4791, DOI 10.1172/JCI140200
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Liu STH, 2020, CONVALESCENT PLASMA, DOI [10.1101/2020.05.20.20102236, DOI 10.1101/2020.05.20.20102236]
   Salazar E, 2020, AM J PATHOL, V190, P1680, DOI 10.1016/j.ajpath.2020.05.014
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Ye MX, 2020, J MED VIROL, V92, P1890, DOI 10.1002/jmv.25882
   Zeng QL, 2020, J INFECT DIS, V222, P38, DOI 10.1093/infdis/jiaa228
   Zhang B, 2020, CHEST, V158, pE9, DOI 10.1016/j.chest.2020.03.039
NR 10
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2020
VL 222
IS 9
BP 1575
EP 1578
DI 10.1093/infdis/jiaa509
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA OW9PE
UT WOS:000593209200025
PM 32777038
OA Green Accepted, Bronze
DA 2021-01-01
ER

PT J
AU Zeng, QL
   Yu, ZJ
   Ji, FP
AF Zeng, Qing-Lei
   Yu, Zu-Jiang
   Ji, Fanpu
TI Convalescent Plasma Therapy in Patients With Severe or Life-Threatening
   COVID-19: A Metadata Analysis Reply
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Letter
C1 [Zeng, Qing-Lei; Yu, Zu-Jiang] Zhengzhou Univ, Affiliated Hosp 1, Dept Infect Dis, 1 Eastern Jianshe Rd, Zhengzhou, Henan, Peoples R China.
   [Ji, Fanpu] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Infect Dis, Xian, Shaanxi, Peoples R China.
RP Zeng, QL (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Infect Dis, 1 Eastern Jianshe Rd, Zhengzhou, Henan, Peoples R China.
EM zengqinglei2009@163.com
OI Zeng, Qing-Lei/0000-0002-2094-4784
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81970517]; Zhongyuan (Henan) Thousand
   Outstanding Talents Plan [ZYQR201912179]; Foundation for Distinguished
   Young Talents of Zhengzhou University Medical School [2020ZQLMS]; Key
   Scientific Research Project of Henan Higher Education Institutions of
   China [20B320028]
FX This work was supported by the National Natural Science Foundation of
   China (grant number 81970517); Zhongyuan (Henan) Thousand Outstanding
   Talents Plan (grant number ZYQR201912179); Foundation for Distinguished
   Young Talents of Zhengzhou University Medical School (grant number
   2020ZQLMS); and the Key Scientific Research Project of Henan Higher
   Education Institutions of China (grant number 20B320028).
CR Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Zeng QL, 2020, J INFECT DIS, V222, P510, DOI 10.1093/infdis/jiaa313
   Zeng QL, 2020, J INFECT DIS, V222, P38, DOI 10.1093/infdis/jiaa228
NR 3
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2020
VL 222
IS 9
BP 1578
EP 1578
DI 10.1093/infdis/jiaa510
PG 1
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA OW9PE
UT WOS:000593209200026
PM 32777045
OA Green Accepted
DA 2021-01-01
ER

PT J
AU Abouelkhair, MA
AF Abouelkhair, Mohamed A.
TI Targeting adenosinergic pathway and adenosine A(2A) receptor signaling
   for the treatment of COVID-19: A hypothesis
SO MEDICAL HYPOTHESES
LA English
DT Article
DE COVID-19; Immunotherapy; CD73; Adenosine; CD39
ID SARS-COV; SURFACE; CANCER
AB The most serious health issue today is the rapid outbreak of Coronavirus Disease 2019 (COVID-19). More than 6,973,427 confirmed cases were diagnosed in nearly 213 countries and territories around the world and two international conveyances, causing globally over 400,000 deaths. Epidemiology, risk factors, and clinical characteristics of COVID-19 patients have been identified, but the factors influencing the immune system against COVID-19 have not been well established. Upon infection or cell damage, high amounts of adenosine triphosphate (ATP) are released from damaged cells, which serve as mediators of inflammation through purinergic cell surface receptor signaling. As a protective mechanism to prevent excessive damage to host tissue, adenosine counteracts ATP's effects by adenosine receptor stimulation to suppress the pro-inflammatory response. Adenosine is seen as a major obstacle to the efficacy of immune therapies, and the adenosinergic axis components are critical therapeutic targets for cancer and microbial infections. Pharmacologic inhibitors or antibodies specific to adenosinergic pathway components or adenosine receptors in microbial and tumor therapy have shown efficacy in pre-clinical studies and are entering the clinical arena. In this review, we provide a novel hypothesis explaining the potential for improving the efficiency of innate and adaptive immune systems by targeting adenosinergic pathway components and adenosine A(2A) receptor signaling for the treatment of COVID-19.
C1 [Abouelkhair, Mohamed A.] Univ Tennessee, Dept Biomed & Diagnost Sci, Coll Vet Med, 2407 River Dr, Knoxville, TN 37996 USA.
RP Abouelkhair, MA (corresponding author), Univ Tennessee, Dept Biomed & Diagnost Sci, Coll Vet Med, 2407 River Dr, Knoxville, TN 37996 USA.
EM mabouelk@vols.utk.edu
CR Abdel-Magid Ahmed F, 2017, ACS Med Chem Lett, V8, P781, DOI 10.1021/acsmedchemlett.7b00255
   Abouelkhair MA, 2020, VET MICROBIOL, V246, DOI 10.1016/j.vetmic.2020.108720
   Allard D, 2019, IMMUNOL LETT, V205, P31, DOI 10.1016/j.imlet.2018.05.001
   Antonioli L, 2008, PHARMACOL THERAPEUT, V120, P233, DOI 10.1016/j.pharmthera.2008.08.010
   Azambuja JH, 2020, MOL NEUROBIOL, V57, P635, DOI 10.1007/s12035-019-01730-6
   Bastid J, 2015, CANCER IMMUNOL RES, V3, P254, DOI 10.1158/2326-6066.CIR-14-0018
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Gong YP, 2018, EXPERT OPIN THER PAT, V28, P167, DOI 10.1080/13543776.2018.1407756
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Harvey JB, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00508
   Johnson TA, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00098
   Kindler E, 2016, CELL HOST MICROBE, V19, P139, DOI 10.1016/j.chom.2016.01.012
   Lawson KV, 2018, DISCOVERY CHARACTERI
   Leone RD, 2015, COMPUT STRUCT BIOTEC, V13, P265, DOI 10.1016/j.csbj.2015.03.008
   Lokugamage KG, 2020, BIORXIV
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a
   Parkin J, 2001, LANCET, V357, P1777, DOI 10.1016/S0140-6736(00)04904-7
   POWDERLY JD, 2019, J CLIN ONCOL S, V37
   Renauld JC, 2003, NAT REV IMMUNOL, V3, P667, DOI 10.1038/nri1153
   Seif F, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0177-y
   Siu LL, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-CT180
   Taghizadeh-Hesary F, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109762
   Terp MG, 2013, J IMMUNOL, V191, P4165, DOI 10.4049/jimmunol.1301274
   Vigano S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00925
   Willingham SB, A2AR ANTAGONISM CPI
   Wolk KE, 2008, AM J RESP CRIT CARE, V178, P969, DOI 10.1164/rccm.200803-455OC
   Worldometer, 2020, COVID 19 COR PAND
   Zhang CF, 2017, J IMMUNOL, V199, P1372, DOI 10.4049/jimmunol.1700187
NR 30
TC 2
Z9 2
U1 1
U2 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD NOV
PY 2020
VL 144
AR 110012
DI 10.1016/j.mehy.2020.110012
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OY1AK
UT WOS:000593985600005
PM 32590324
OA Green Published
DA 2021-01-01
ER

PT J
AU Kjellberg, A
   De Maio, A
   Lindholm, P
AF Kjellberg, Anders
   De Maio, Antonio
   Lindholm, Peter
TI Can hyperbaric oxygen safely serve as an anti-inflammatory treatment for
   COVID-19?
SO MEDICAL HYPOTHESES
LA English
DT Article
ID REPERFUSION INJURY; THERAPY; MECHANISMS; PROTECTS; MORTALITY;
   DECOMPRESSION; INFECTIONS; NEUTROPHIL; TOXICITY; ISCHEMIA
AB Introduction: SARS-CoV-2 affects part of the innate immune response and activates an inflammatory cascade stimulating the release of cytokines and chemokines, particularly within the lung. Indeed, the inflammatory response during COVID19 is likely the cause for the development of acute respiratory distress syndrome (ARDS). Patients with mild symptoms also show significant changes on pulmonary CT-scan suggestive of severe inflammatory involvement.
   Hypothesis: The overall hypothesis is that HBO2 is safe and reduces the inflammatory response in COVID-19 pneumonitis by attenuation of the innate immune system, increase hypoxia tolerance and thereby prevent organ failure and reduce mortality.
   Evaluation of the hypothesis: HBO2 is used in clinical practice to treat inflammatory conditions but has not been scientifically evaluated for COVID-19. Experimental and empirical data suggests that HBO2 may reduce inflammatory response in COVID-19. However, there are concerns regarding pulmonary safety in patients with pre-existing viral pneumonitis.
   Empirical data: Anecdotes from "compassionate use" and two published case reports show promising results. Consequences of the hypothesis and discussion: Small prospective clinical trials are on the way and we are conducting a randomized clinical trial.
C1 [Kjellberg, Anders; Lindholm, Peter] Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden.
   [Kjellberg, Anders] Karolinska Univ Hosp, Perioperat Med & Intens Care Med, Stockholm, Sweden.
   [De Maio, Antonio] Univ Calif San Diego, Dept Surg, Div Trauma Crit Care Burns & Acute Care Surg, La Jolla, CA 92093 USA.
   [De Maio, Antonio] Univ Calif San Diego, Dept Neurosci, Sch Med, La Jolla, CA 92093 USA.
   [Lindholm, Peter] Univ Calif San Diego, Dept Emergency Med, La Jolla, CA 92093 USA.
RP Kjellberg, A (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden.
EM anders.kjellberg@ki.se
FU Swedish Research CouncilSwedish Research Council; Kenny
   RodriguezWallberg at the department of Pathology-Oncology, Karolinska
   Institutet
FX This article has no funding. The randomized controlled trial has been
   planned and initiated with funding from the Swedish Research Council,
   made available by redirecting funds from Kenny RodriguezWallberg at the
   department of Pathology-Oncology, Karolinska Institutet.
CR Arabi YM, 2020, INTENSIVE CARE MED
   Bennett MH, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005005.pub4
   Benson RM, 2003, CLIN EXP IMMUNOL, V134, P57, DOI 10.1046/j.1365-2249.2003.02248.x
   Bessereau J, 2017, INT MARIT HEALTH, V68, P46, DOI 10.5603/IMH.2017.0008
   Buras JA, 2007, NEUROL RES, V29, P127, DOI 10.1179/016164107X174147
   Buras JA, 2006, CRIT CARE MED, V34, P2624, DOI 10.1097/01.CCM.0000239438.22758.E0
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chavko M, 2008, EUR J APPL PHYSIOL, V102, P525, DOI 10.1007/s00421-007-0611-8
   De Maio A, 2020, CELL STRESS CHAPERON, V25, P717, DOI 10.1007/s12192-020-01121-0
   Dong HY, 2013, BMC IMMUNOL, V14, DOI 10.1186/1471-2172-14-25
   Drescher B, 2013, VIRUS RES, V171, P1, DOI 10.1016/j.virusres.2012.11.002
   Dulai PS, 2018, AM J GASTROENTEROL
   Edremitlioglu M, 2005, SURG TODAY, V35, P653, DOI 10.1007/s00595-004-3000-5
   Fuller AM, 2013, CELL STRESS CHAPERON, V18, P97, DOI 10.1007/s12192-012-0362-2
   Geng M, 2015, INT J CLIN EXP PATHO, V8, P1797
   Gill AL, 2004, QJM-INT J MED, V97, P385, DOI 10.1093/qjmed/hch074
   Godman CA, 2010, CELL STRESS CHAPERON, V15, P431, DOI 10.1007/s12192-009-0159-0
   Guerard S, 2016, AM J PATHOL
   Guo DZ, 2020, UNDERSEA HYPERBAR M, V47, P181
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Halbach JL, 2019, AM J PHYSIOL-REG I, V317, pR160, DOI 10.1152/ajpregu.00083.2019
   Han CH, 2017, MED GAS RES, V7, P236, DOI 10.4103/2045-9912.215749
   Harrison LE, 2018, CELL STRESS CHAPERON, V23, P1143, DOI 10.1007/s12192-018-0944-8
   Heyboer M, 2017, ADV WOUND CARE, V6, P210, DOI 10.1089/wound.2016.0718
   Kallet RH, 2016, RESP CARE, V61, P801, DOI 10.4187/respcare.04933
   Kirby John P, 2019, Mo Med, V116, P198
   Kirby John P, 2019, Mo Med, V116, P188
   Ledford H., 2020, NATURE
   Lin HC, 2005, EUR J PHARMACOL, V508, P249, DOI 10.1016/j.ejphar.2004.12.021
   Lisagors I. L., 2008, Anesteziologiya i Reanimatologiya, P34
   Anguiano-Hernandez YM, 2019, UNDERSEA HYPERBAR M, V46, P35
   Moon RE, 2020, UNDERSEA HYPERBAR M, V47, P177
   Novak S, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/7141430
   Oscarsson N, 2019, LANCET ONCOL
   Oyaizu T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19670-x
   Pan F, 2019, RADIOLOGY, V2020
   Pedoto A, 2003, CLIN EXP PHARMACOL P, V30, P482, DOI 10.1046/j.1440-1681.2003.03865.x
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Salhanick SD, 2006, ACAD EMERG MED, V13, P707, DOI 10.1197/j.aem.2006.01.029
   Tezgin D, 2020, CELL STRESS CHAPERON, V25, P667, DOI 10.1007/s12192-020-01100-5
   Thibodeaux K, 2020, J WOUND CARE, V29, pS4, DOI 10.12968/jowc.2020.29.Sup5a.S4
   THOM SR, 1986, J INFECT DIS, V154, P504, DOI 10.1093/infdis/154.3.504
   Thom SR, 2011, PLAST RECONSTR SURG, V127, p131S, DOI 10.1097/PRS.0b013e3181fbe2bf
   Thom SR, 2009, J APPL PHYSIOL, V106, P988, DOI 10.1152/japplphysiol.91004.2008
   WEISLOW OS, 1974, INFECT IMMUN, V10, P546, DOI 10.1128/IAI.10.3.546-552.1974
   Wilson JG, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2778-x
   Wingelaar TT, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.01263
   Yu SY, 2005, J SURG RES, V128, P28, DOI 10.1016/j.jss.2005.04.025
   Zhang H, 2020, ANN INTERN MED
   Zhang LC, 2019, J PHYSIOL SCI, V69, P779, DOI 10.1007/s12576-019-00694-5
NR 50
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD NOV
PY 2020
VL 144
AR 110224
DI 10.1016/j.mehy.2020.110224
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OY1AJ
UT WOS:000593985500007
PM 33254531
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lovetrue, B
AF Lovetrue (Zhipan Ren), Bragi
TI The AI-discovered aetiology of COVID-19 and rationale of the irinotecan
   plus etoposide combination therapy for critically ill COVID-19 patients
SO MEDICAL HYPOTHESES
LA English
DT Article
DE Aetiology; Treatment; Cytokine storm; ICU; COVID-19; ACE2; Irinotecan;
   Etoposide; SARS-CoV-2
ID HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; ACTIVATION; ACE2
AB We present the AI-discovered aetiology of COVID-19, based on a precise disease model of COVID-19 built under five weeks that best matches the epidemiological characteristics, transmission dynamics, clinical features, and biological properties of COVID-19 and consistently explains the rapidly expanding COVID-19 literature. We present that SARS-CoV-2 implements a unique unbiased survival strategy of balancing viral replication with viral spread by increasing its dependence on (i) ACE2-expressing cells for viral entry and spread, (ii) PI3K signaling in ACE2-expressing cells for viral replication and egress, and (iii) viral non-structural-and-accessory-protein-dependent immunomodulation to balance viral spread and viral replication. We further propose the combination of irinotecan (an in-market topoisomerase I inhibitor) and etoposide (an in-market topoisomerase II inhibitor) could potentially be an exceptionally effective treatment to protect critically ill patients from death caused by COVID-19-specific cytokine storms triggered by sepsis, ARDS, and other fatal comorbidities.
C1 [Lovetrue (Zhipan Ren), Bragi] Demiurge Technol AG, Baarerstr 14, CH-6300 Zug, Switzerland.
RP Lovetrue, B (corresponding author), Demiurge Technol AG, Baarerstr 14, CH-6300 Zug, Switzerland.
EM bragi@demiurge.ch
CR Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   He HL, 2015, CELL TRANSPLANT, V24, P1699, DOI 10.3727/096368914X685087
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Jarajapu YPR, 2013, DIABETES, V62, P1258, DOI 10.2337/db12-0808
   Kumar P, 2012, FASEB J, V26
   Lehmberg K, 2015, HAEMATOLOGICA, V100, P997, DOI 10.3324/haematol.2015.123562
   Liu DX, 2014, ANTIVIR RES, V109, P97, DOI 10.1016/j.antiviral.2014.06.013
   Mao L., 2020, NEUROLOGICAL MANIFES, DOI [10.1101/2020.02.22.20026500., 10.1101/2020.02.22.20026500, DOI 10.1101/2020.02.22.20026500]
   Otrock ZK, 2015, AM J HEMATOL, V90, P220, DOI 10.1002/ajh.23911
   Pedersen KB, 2013, BBA-GENE REGUL MECH, V1829, P1225, DOI 10.1016/j.bbagrm.2013.09.007
   Pena-Silva RA, 2012, STROKE, V43, P3358, DOI 10.1161/STROKEAHA.112.667063
   Rialdi A, 2016, SCIENCE, V352, DOI 10.1126/science.aad7993
   Sanada F, 2018, FRONT CARDIOVASC MED, V5, DOI 10.3389/fcvm.2018.00012
   Tukiainen T, 2017, NATURE, V550, P244, DOI 10.1038/nature24265
   van Montfort T, 2019, EBIOMEDICINE, V42, P97, DOI 10.1016/j.ebiom.2019.02.014
   Vick EJ, 2017, BLOOD ADV, V1, P779, DOI 10.1182/bloodadvances.2017005561
   Wang L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130660
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou Y., PERSPECTIVE PATHOGEN
   Zhu Y., 2020, SINGLE CELL ANAL ACE, DOI [10.20944/PREPRINTS202002.0221.V1., DOI 10.20944/PREPRINTS202002.0221.V1, 10.20944/preprints202002.0221.v1]
NR 22
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD NOV
PY 2020
VL 144
AR 110180
DI 10.1016/j.mehy.2020.110180
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OY1AJ
UT WOS:000593985500001
PM 33254502
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Sen, A
AF Sen, Amarnath
TI Repurposing prolactin as a promising immunomodulator for the treatment
   of COVID-19: Are common Antiemetics the wonder drug to fight
   coronavirus?
SO MEDICAL HYPOTHESES
LA English
DT Article
DE COVID-19; Coronavirus; SARS-CoV-2; COVID; Prolactin; Immunotherapy;
   Dopamine; Immune modulation; Antiemetics; Domperidone; Metoclopramide
ID ALLERGIC INFLAMMATORY RESPONSE; NEUROENDOCRINE HORMONES; SERUM
   PROLACTIN; GROWTH-HORMONE; IMMUNE; HYPERPROLACTINEMIA; EXPRESSION;
   SURVIVAL; DISEASE
AB Prolactin (PRL), the well-known lactogenic hormone, plays a crucial role in immune function given the fact that long term hypoprolactinemia (serum prolactin level below normal) can even lead to death from opportunistic infection. High blood PRL level is known to provide an immunological advantage in many pathological conditions (with some exceptions like autoimmune diseases) and women, because of their higher blood PRL level, get an advantage in this regard. It has been reported that by controlled enhancement of blood PRL level (within the physiological limit and in some cases a little elevated above the normal to induce mild hyperprolactinemia) using dopamine antagonists such immune-stimulatory advantage can led to survival of the patients in many critical conditions. Here it is hypothesized that through controlled augmentation of blood PRL level using dopamine antagonists like domperidone/metoclopramide, which are commonly used drugs for the treatment of nausea and vomiting, both innate and adaptive immunity can be boosted to evade or tone down COVID-19. The hypothesis is strengthened from the fact that at least seven little-understood salient observations in coronavirus patients can apparently be explained by considering the role of enhanced PRL in line with the proposed hypothesis and hence, clinical trials (both therapeutic and prophylactic) on the role of enhanced PRL on the course and outcome of coronavirus patients should be conducted accordingly.
C1 [Sen, Amarnath] 40 Jadunath Sarbovouma Lane, Kolkata 700035, India.
RP Sen, A (corresponding author), 40 Jadunath Sarbovouma Lane, Kolkata 700035, India.
EM amarns2@yahoo.co.in
CR Adan N, 2013, J CLIN INVEST, V123, P3902, DOI 10.1172/JCI69485
   AminJafari A, 2020, INT IMMUNOPHARMACOL, V83, DOI 10.1016/j.intimp.2020.106455
   Angka L, 2020, J CLIN INVEST, V130, P3954, DOI 10.1172/JCI140530
   Blanco-Favela F, 2012, B MED HOSP INFANT M, V69, P329
   Borba VV, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00073
   Cejkova P, 2012, PHYSIOL RES, V61, P481, DOI 10.33549/physiolres.932262
   Chuang Ellie, 2007, Acta Biomed, V78 Suppl 1, P255
   Cristiani L, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00749-2020
   De Bellis Annamaria, 2005, Pituitary, V8, P25
   Diamanti AP, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093330
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Felmet KA, 2005, J IMMUNOL, V174, P3765, DOI 10.4049/jimmunol.174.6.3765
   Felsenstein S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108448
   Freedberg DE, 2020, GASTROENTEROLOGY, DOI [10.1101/2020.05.01.20086694, DOI 10.1101/2020.05.01.20086694]
   Fuhrman BP, 2011, PAEDIAT CRITICAL CAR, P1303
   Gonzalez-Rubio J, 2020, WHAT IS HAPPENING SM, DOI [10.20944/preprints202004, DOI 10.20944/PREPRINTS202004]
   GUYDA HJ, 1973, PEDIATR RES, V7, P534, DOI 10.1203/00006450-197305000-00007
   Imrich Richard, 2002, Endocr Regul, V36, P95
   Jin J-M, 2020, FRONT PUBLIC HEALTH, V29, P1
   Kopelman PG, 2000, INT J OBESITY, V24, pS104, DOI 10.1038/sj.ijo.0801291
   Liu DH, 2020, AM J ROENTGENOL, V215, P127, DOI [10.2214/AJR.20.23072, 10.1080/13813455.2020.1799018]
   Lopez-Meza JE, 2010, OPEN NEUROENDOCRINOL, V3, P175
   LUCAS A, 1990, ARCH DIS CHILD, V65, P977, DOI 10.1136/adc.65.9.977
   Magro Giuseppe, 2020, Cytokine X, V2, P100029, DOI 10.1016/j.cytox.2020.100029
   Maier CL, 2020, LANCET, V395, P1758, DOI 10.1016/S0140-6736(20)31209-5
   Majumdar Abha, 2013, J Hum Reprod Sci, V6, P168, DOI 10.4103/0974-1208.121400
   Matalka KZ, 2003, CYTOKINE, V21, P187, DOI 10.1016/S1043-4666(02)00496-9
   McCreary EK, 2020, OPEN FORUM INFECT DI, V7, P1, DOI [10.1093/ofid/ofaa105, DOI 10.1093/0FID/0FAA105]
   Molitch ME, 2005, MAYO CLIN PROC, V80, P1050, DOI 10.4065/80.8.1050
   MURPHY WJ, 1992, J IMMUNOL, V148, P3799
   Ochoa-Amaya JE, 2016, LIFE SCI, V151, P281, DOI 10.1016/j.lfs.2016.03.027
   Ochoa-Amaya JE, 2015, LIFE SCI, V142, P66, DOI 10.1016/j.lfs.2015.10.016
   Orlander H, 2009, W INDIAN MED J, V58, P207
   Parra A, 2013, ADV NEUROIMMUNE BIOL, V4, P1, DOI 10.3233/NIB-130050
   Parra A, 2012, HEMATOLOGY, V17, P85, DOI 10.1179/102453312X13221316477930
   Pena B, 2016, FISH PHYSIOL BIOCHEM, V42, P509, DOI 10.1007/s10695-015-0155-5
   Suarez ALP, 2015, ADV EXP MED BIOL, V846, P243, DOI 10.1007/978-3-319-12114-7_11
   Plaze M, 2020, ENCEPHALE, V46, P169, DOI 10.1016/j.encep.2020.05.006
   Redelman D, 2008, CELL IMMUNOL, V252, P111, DOI 10.1016/j.cellimm.2007.12.003
   Remy KE, 2020, LANCET RESP MED, DOI [10.1016/S2213-2600(20)30217-4, DOI 10.1016/S2213-2600(20)30217-4.]
   Ryan PM, 2020, OBESITY, V28, P1191, DOI 10.1002/oby.22843
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   SAWIN CT, 1989, J GERONTOL, V44, pM131
   Schijns V, 2020, EUR J IMMUNOL, V50, P932, DOI 10.1002/eji.202048693
   Shelly S, 2012, AUTOIMMUN REV, V11, pA465, DOI 10.1016/j.autrev.2011.11.009
   Sykes Lynne, 2012, Mediators Inflamm, V2012, P416739, DOI 10.1155/2012/416739
   Torre Daria La, 2007, Ther Clin Risk Manag, V3, P929
   WILKINS JN, 1982, PSYCHOPHARMACOLOGY, V78, P305, DOI 10.1007/BF00433730
   Wu XX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0151-z
   Yao ZX, 2020, AGING-US, V12, P7639, DOI 10.18632/aging.103101
   Yu-Lee LY, 2002, RECENT PROG HORM RES, V57, P435, DOI 10.1210/rp.57.1.435
   YuLee LY, 1997, P SOC EXP BIOL MED, V215, P35, DOI 10.3181/00379727-215-44111
   Zellweger R, 1998, J TRAUMA, V44, P70, DOI 10.1097/00005373-199801000-00006
   Zhong JX, 2020, LANCET RHEUMATOL, V2, pE428, DOI 10.1016/S2665-9913(20)30120-X
   Zhou M, 2020, FRONT MED-PRC, V14, P126, DOI 10.1007/s11684-020-0767-8
   Zhu Z, 2020, INT J INFECT DIS, V95, P332, DOI 10.1016/j.ijid.2020.04.041
NR 56
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD NOV
PY 2020
VL 144
AR 110208
DI 10.1016/j.mehy.2020.110208
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OY1AJ
UT WOS:000593985500004
PM 33254515
OA Green Published
DA 2021-01-01
ER

PT J
AU Takahashi, H
AF Takahashi, Harutaka
TI Role of latent tuberculosis infections in reduced COVID-19 mortality:
   Evidence from an instrumental variable method analysis
SO MEDICAL HYPOTHESES
LA English
DT Article
DE COVID-19; BCG; Trained immunity; Innate immunity; Latent tuberculosis
   infection; Instrumental variable method
AB Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, there has been significant interest in the potential protective effect of the Bacillus Calmette-Guerin (BCG) vaccine against COVID-19 mortality. This effect has been attributed to innate immune responses induced by BCG vaccination. However, these studies ignore an important fact: according to World Health Organization estimates, about a quarter of the world's population may have latent tuberculosis infection (LTBI), a condition in which there is no evidence of clinically active tuberculosis but persistent immune responses are stimulated by Mycobacterium tuberculosis antigens. Thus, both LTBI and BCG induce lifelong immunity and may provide immunological protection against COVID19. In this study, the relationship between LTBI and reduced COVID-19 mortality was analyzed using the instrumental variable method. The results showed with robust statistical support that LTBI was also associated with reduced COVID-19 mortality.
C1 [Takahashi, Harutaka] Kobe Univ, Grad Sch Econ, Rokko Dai 2-1, Kobe, Hyogo 6578501, Japan.
   [Takahashi, Harutaka] Kobe Univ, Meiji Gakuin Univ, Grad Sch Econ, Rokko Dai 2-1, Kobe, Hyogo 6578501, Japan.
RP Takahashi, H (corresponding author), 5-12-7 Setagaya Ku, Tokyo 1500081, Japan.
EM haru@eco.meijigakuin.ac.jp
CR Behr M, 2019, BMJ-BRIT MED J, V2019, DOI [10.1136/bmj.15770., DOI 10.1136/BMJ.15770]
   Horton KC, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002119
   Miller A, 2020, CORRELATION UNIVERSA, DOI [10.1101/2020.03.24.2004293, DOI 10.1101/2020.03.24.2004293]
   Raham T., 2020, TB PREVALENCE CORREL, DOI [10.1101/2020.05.05.20092395, DOI 10.1101/2020.05.05.20092395[PREPRINT]]
   Shivendu S, 2020, IS THERE EVIDENCE BC
   Singh S., 2020, TRAINED IMMUNITY MYC, DOI [10.1101/2020.07.11.20151308., DOI 10.1101/2020.07.11.20151308]
   Soliman R, 2020, DOES BCG VACCINATION
   Yamamoto N, 2020, MED HYPOTHESES, DOI [10.1016/j.mehy.2010.110160., DOI 10.1016/J.MEHY.2010.110160]
NR 8
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD NOV
PY 2020
VL 144
AR 110214
DI 10.1016/j.mehy.2020.110214
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OY1AJ
UT WOS:000593985500003
PM 33254521
OA Green Published
DA 2021-01-01
ER

PT J
AU Angelino, AF
   Lyketsos, CG
   Ahmed, MS
   Potash, JB
   Cullen, BA
AF Angelino, Andrew F.
   Lyketsos, Constantine G.
   Ahmed, M. Shafeeq
   Potash, James B.
   Cullen, Bernadette A.
TI Design and Implementation of a Regional Inpatient Psychiatry Unit for
   Patients who are Positive for Asymptomatic SARS-CoV-2
SO PSYCHOSOMATICS
LA English
DT Article
DE infectious disease; respiratory disorder; mental health;
   consultation-liaison psychiatry; infection control
AB Background: Patients with psychiatric illnesses are particularly vulnerable to highly contagious, droplet-spread organisms such as SARS-CoV-2. Patients with mental illnesses may not be able to consistently follow up behavioral prescriptions to avoid contagion, and they are frequently found in settings with close contact and inadequate infection control, such as group homes, homeless shelters, residential rehabilitation centers, and correctional facilities. Furthermore, inpatient psychiatry settings are generally designed as communal spaces, with heavy emphasis on group and milieu therapies. As such, inpatient psychiatry services are vulnerable to rampant spread of contagion. Objective: With this in mind, the authors outline the decision process and ultimate design and implementation of a regional inpatient psychiatry unit for patients infected with asymptomatic SARS-CoV-2 and share key points for consideration in implementing future units elsewhere. Conclusion: A major takeaway point of the analysis is the particular expertise of trained experts in psychosomatic medicine for treating patients infected with SARS-CoV-2.
C1 [Angelino, Andrew F.; Potash, James B.; Cullen, Bernadette A.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA.
   [Lyketsos, Constantine G.] Johns Hopkins Bayview Med Ctr, Dept Psychiat, Baltimore, MD 21224 USA.
   [Ahmed, M. Shafeeq] Howard Cty Gen Hosp, VP Med Affairs, Columbia, MD USA.
RP Angelino, AF (corresponding author), Johns Hopkins Howard Cty Gen Hosp, Dept Psychiat, 10710 Charter Dr,Suite G050, Columbia, MD 21044 USA.
EM aangelino@jhmi.edu
CR [Anonymous], 2020, MEDSCAPE
   Benson NM, 2020, LANCET PSYCHIAT, DOI [10.1016/52215-0366(20)30198-X, DOI 10.1016/52215-0366(20)30198-X]
   Centers for Disease Control and Prevention, 2020, DECIS MEMO
   Fagiolini A, 2020, J CLIN PSYCHIAT, V81
   Kim MJ, 2020, INDEPENDENT
   Li LM, 2020, PSYCHIAT SERV, V71, P624, DOI 10.1176/appi.ps.202000166
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
NR 7
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0033-3182
EI 1545-7206
J9 PSYCHOSOMATICS
JI Psychosomatics
PD NOV-DEC
PY 2020
VL 61
IS 6
BP 662
EP 671
PG 10
WC Psychiatry; Psychology
SC Psychiatry; Psychology
GA OT5PF
UT WOS:000590897400010
PM 32800571
OA Green Published
DA 2021-01-01
ER

PT J
AU Ahn, JY
   An, S
   Sohn, Y
   Cho, Y
   Hyun, JH
   Baek, YJ
   Kim, MH
   Jeong, SJ
   Kim, JH
   Ku, NS
   Yeom, JS
   Smith, DM
   Lee, H
   Yong, D
   Lee, YJ
   Kim, JW
   Kim, HR
   Hwang, J
   Choi, JY
AF Ahn, J. Y.
   An, S.
   Sohn, Y.
   Cho, Y.
   Hyun, J. H.
   Baek, Y. J.
   Kim, M. H.
   Jeong, S. J.
   Kim, J. H.
   Ku, N. S.
   Yeom, J-S
   Smith, D. M.
   Lee, H.
   Yong, D.
   Lee, Y-J
   Kim, J. W.
   Kim, H. R.
   Hwang, J.
   Choi, J. Y.
TI Environmental contamination in the isolation rooms of COVID-19 patients
   with severe pneumonia requiring mechanical ventilation or high-flow
   oxygen therapy
SO JOURNAL OF HOSPITAL INFECTION
LA English
DT Article
DE COVID-19; SARS-CoV-2; Environmental contamination; Severe pneumonia
ID CARE; SARS-COV-2
AB Background: Identifying the extent of environmental contamination of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is essential for infection control and prevention. The extent of environmental contamination has not been fully investigated in the context of severe coronavirus disease (COVID-19) patients.
   Aim: To investigate environmental SARS-CoV-2 contamination in the isolation rooms of severe COVID-19 patients requiring mechanical ventilation or high-flow oxygen therapy.
   Methods: Environmental swab samples and air samples were collected from the isolation rooms of three COVID-19 patients with severe pneumonia. Patients 1 and 2 received mechanical ventilation with a closed suction system, while patient 3 received high-flow oxygen therapy and non-invasive ventilation. Real-time reverse transcription-polymerase chain reaction (rRT-PCR) was used to detect SARS-CoV-2; viral cultures were performed for samples not negative on rRT-PCR.
   Findings: Of the 48 swab samples collected in the rooms of patients 1 and 2, only samples from the outside surfaces of the endotracheal tubes tested positive for SARS-CoV-2 by rRT-PCR. However, in patient 3's room, 13 of the 28 environmental samples (fomites, fixed structures, and ventilation exit on the ceiling) showed positive results. Air samples were negative for SARS-CoV-2. Viable viruses were identified on the surface of the endotracheal tube of patient 1 and seven sites in patient 3's room.
   Conclusion: Environmental contamination of SARS-CoV-2 may be a route of viral transmission. However, it might be minimized when patients receive mechanical ventilation with a closed suction system. These findings can provide evidence for guidelines for the safe use of personal protective equipment. (C) 2020 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.
C1 [Ahn, J. Y.; Sohn, Y.; Cho, Y.; Hyun, J. H.; Baek, Y. J.; Kim, M. H.; Jeong, S. J.; Kim, J. H.; Ku, N. S.; Yeom, J-S; Lee, Y-J; Kim, J. W.; Choi, J. Y.] Yonsei Univ, Severance Hosp, Dept Internal Med, Coll Med, Seoul, South Korea.
   [An, S.; Kim, H. R.; Hwang, J.] Yonsei Univ, Sch Mech Engn, Seoul, South Korea.
   [Smith, D. M.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
   [Lee, H.; Yong, D.] Yonsei Univ, Severance Hosp, Dept Lab Med, Coll Med, Seoul, South Korea.
RP Choi, JY (corresponding author), Yonsei Univ, Coll Med, Dept Internal Med, 50 Yonsei Ro, Seoul 120752, South Korea.; Choi, JY (corresponding author), Yonsei Univ, Coll Med, AIDS Res Inst, 50 Yonsei Ro, Seoul 120752, South Korea.
EM seran@yuhs.ac
OI Lee, Hyukmin/0000-0002-8523-4126; Jeong, Su Jin/0000-0003-4025-4542;
   Kim, Jung Ho/0000-0002-5033-3482; Ku, Nam Su/0000-0002-9717-4327; Choi,
   Jun Yong/0000-0002-2775-3315; dongeun, yong/0000-0002-1225-8477; Ahn,
   Jin Young/0000-0002-3740-2826; Yeom, Joon Sup/0000-0001-8940-7170
FU Korea Centers for Disease Control and Prevention [2019-ER5408-00,
   2019-ER5101-00]; Ministry of Health & Welfare, Republic of KoreaMinistry
   of Health & Welfare, Republic of Korea [HI14C1324]; John and Mary Tu
   Foundation
FX This work was supported by the Research Program funded by the Korea
   Centers for Disease Control and Prevention (2019-ER5408-00), research
   grants for deriving the major clinical and epidemiological indicators of
   people with HIV (Korea HIV/AIDS Cohort Study, 2019-ER5101-00), and a
   grant from the Ministry of Health & Welfare, Republic of Korea (grant
   number: HI14C1324). D.S. was supported by the John and Mary Tu
   Foundation.
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Brown J, 2020, ANAESTHESIA, V75, P1116, DOI 10.1111/anae.15097
   Chia PY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16670-2
   Colaneri M, 2020, CLIN MICROBIOL INFEC, V26, DOI 10.1016/j.cmi.2020.05.009
   Cook TM, 2020, ANAESTHESIA, V75, P785, DOI 10.1111/anae.15054
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Guo ZD, 2020, EMERG INFECT DIS, V26, P1586, DOI 10.3201/eid2607.200885
   Tran K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035797
   Kim HR, 2019, J HAZARD MATER, V369, P684, DOI 10.1016/j.jhazmat.2019.02.088
   Kim SH, 2016, CLIN INFECT DIS, V63, P363, DOI 10.1093/cid/ciw239
   Li JY, 2018, J AEROSOL SCI, V115, P133, DOI 10.1016/j.jaerosci.2017.08.007
   Lyons C, 2020, ANAESTHESIA, V75, P843, DOI 10.1111/anae.15073
   Nguyen TT, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofw259
   O'Neil CA, 2017, CLIN INFECT DIS, V65, P1342, DOI 10.1093/cid/cix535
   Ong SWX, 2020, JAMA-J AM MED ASSOC, V323, P1610, DOI 10.1001/jama.2020.3227
   Otter JA, 2016, J HOSP INFECT, V92, P235, DOI 10.1016/j.jhin.2015.08.027
   Pan MH, 2017, MSPHERE, V2, DOI 10.1128/mSphere.00251-17
   Ricard JD, 2011, AM J INFECT CONTROL, V39, P605, DOI 10.1016/j.ajic.2010.10.031
   Santarpia JL, 2020, TRANSMISSION POTENTI
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Wang J, 2020, INT J INFECT DIS, V94, P103, DOI 10.1016/j.ijid.2020.04.024
   WHO, 2020, MOD TRANSM VIR CAUS
   Wilson NM, 2020, ANAESTHESIA, V75, P1086, DOI 10.1111/anae.15093
   World Health Organization, 2020, RAT US PERS PROT EQ
   Wu SJ, 2020, AM J INFECT CONTROL, V48, P910, DOI 10.1016/j.ajic.2020.05.003
   Ye GM, 2020, J INFECTION, V81, pE1, DOI 10.1016/j.jinf.2020.04.034
NR 26
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0195-6701
EI 1532-2939
J9 J HOSP INFECT
JI J. Hosp. Infect.
PD NOV
PY 2020
VL 106
IS 3
BP 570
EP 576
DI 10.1016/j.jhin.2020.08.014
PG 7
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA OM3FE
UT WOS:000585910300019
PM 32828864
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ludwig-Begall, LF
   Wielick, C
   Dams, L
   Nauwynck, H
   Demeuldre, PF
   Napp, A
   Laperre, J
   Haubruge, E
   Thiry, E
AF Ludwig-Begall, L. F.
   Wielick, C.
   Dams, L.
   Nauwynck, H.
   Demeuldre, P-F
   Napp, A.
   Laperre, J.
   Haubruge, E.
   Thiry, E.
TI The use of germicidal ultraviolet light, vaporized hydrogen peroxide and
   dry heat to decontaminate face masks and filtering respirators
   contaminated with a SARS-CoV-2 surrogate virus
SO JOURNAL OF HOSPITAL INFECTION
LA English
DT Article
DE SARS-CoV-2; PRCV; Decontamination (UV, H2O2, dry heat); Respirator;
   Surgical mask
ID CORONAVIRUS; INACTIVATION
AB Background: In the context of the ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, the supply of personal protective equipment remains under severe strain. To address this issue, re-use of surgical face masks and filtering facepiece respirators has been recommended; prior decontamination is paramount to their re-use.
   Aim: We aim to provide information on the effects of three decontamination procedures on porcine respiratory coronavirus (PRCV)-contaminated masks and respirators, presenting a stable model for infectious coronavirus decontamination of these typically single-use-only products.
   Methods: Surgical masks and filtering facepiece respirator coupons and straps were inoculated with infectious PRCV and submitted to three decontamination treatments, ultraviolet (UV) irradiation, vaporized H2O2, and dry heat treatment. Viruses were recovered from sample materials and viral titres were measured in swine testicle cells.
   Findings: UV irradiation, vaporized H2O2 and dry heat reduced infectious PRCV by more than three orders of magnitude on mask and respirator coupons and rendered it undetectable in all decontamination assays.
   Conclusion: This is the first description of stable disinfection of face masks and filtering facepiece respirators contaminated with an infectious SARS-CoV-2 surrogate using UV irradiation, vaporized H2O2 and dry heat treatment. The three methods permit demonstration of a loss of infectivity by more than three orders of magnitude of an infectious coronavirus in line with the United States Food and Drug Administration policy regarding face masks and respirators. It presents advantages of uncomplicated manipulation and utilization in a BSL2 facility, therefore being easily adaptable to other respirator and mask types. (C) 2020 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.
C1 [Ludwig-Begall, L. F.; Wielick, C.; Dams, L.; Thiry, E.] Univ Liege, Fac Vet Med, FARAH Res Ctr, Dept Infect & Parasit Dis,Vet Virol & Anim Viral, Liege, Belgium.
   [Nauwynck, H.] Univ Ghent, Fac Vet Med, Lab Virol, Merelbeke, Belgium.
   [Demeuldre, P-F; Napp, A.] Univ Liege, Univ Hosp Ctr, Dept Hosp Pharm, Liege, Belgium.
   [Laperre, J.] Centexbel Text Res Ctr, Grace Hollogne, Belgium.
   [Haubruge, E.] Univ Liege, TERRA Res Ctr, Gembloux Agrobio Tech, Gembloux, Belgium.
RP Thiry, E (corresponding author), Univ Liege, Fac Vet Med, FARAH Res Ctr, Dept Infect & Parasit Dis,Vet Virol & Anim Viral, Liege, Belgium.
EM etienne.thiry@uliege.be
FU Walloon Region, Belgium [2010053-2020 - MASK]
FX This work was supported by a grant from the Walloon Region, Belgium
   (Project 2010053-2020 - MASK - Decontamination and reuse of surgical
   masks and filtering facepiece respirators).
CR Casanova LM, 2010, APPL ENVIRON MICROB, V76, P2712, DOI 10.1128/AEM.02291-09
   Center for Devices and Radiological Health, 2020, ENF POL FAC MASKS RE
   Chin AWH, 2020, LANCET MICROBE, V1, pe10, DOI [DOI 10.1101/2020.03.15.20036673, heresAdoi. moll 0.10161 S2666-5247(20130003-3, 10.1016/S2666-5247(20)130003-3]
   COX E, 1990, RES VET SCI, V48, P165, DOI 10.1016/S0034-5288(18)30984-6
   Darnell MER, 2004, J VIROL METHODS, V121, P85, DOI 10.1016/j.jviromet.2004.06.006
   Dutch National Institute for Public Health and the Environment (RIVM), 2020, REUSE FFP2 MASKSV, P1
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Kumar A, 2020, N95 MASK DECONTAMINA, P1
   LAUDE H, 1993, VET RES, V24, P125
   Lee J, 2020, FAST EASY DISINFECTI, P1
   LELIE PN, 1987, J MED VIROL, V23, P297, DOI 10.1002/jmv.1890230313
   Leung NHL, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0843-2
   Liao L, 2020, CAN N95 RESPIRATORS, DOI [10.1101/2020.04.01.20050443, DOI 10.1101/2020.04.01.20050443]
   Lindsley WG, 2015, J OCCUP ENVIRON HYG, V12, P509, DOI 10.1080/15459624.2015.1018518
   Lore MB, 2012, ANN OCCUP HYG, V56, P92, DOI 10.1093/annhyg/mer054
   Martin S, 2013, WOODH PUBL SER BIOM, V52, P253, DOI 10.1533/9780857096289.2.253
   PENSAERT M, 1986, VET QUART, V8, P257, DOI 10.1080/01652176.1986.9694050
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Saif LJ, 2019, DIS SWINE, P488, DOI DOI 10.1002/9781119350927.CH31
   Schwartz A, 2020, APPL BIOSAF, DOI 10.1177/1535676020919932
   Viscusi DJ, 2011, J OCCUP ENVIRON HYG, V8, P426, DOI 10.1080/15459624.2011.585927
   WHO, 2020, STRENGTH HLTH SYST R, V8
   Wigginton KR, 2020, VALIDATION N95 FILTE, DOI [10.1101/2020.04.28.20084038., DOI 10.1101/2020.04.28.20084038, 10.1101/2020.04.28.20084038]
   World Health Organization (WHO), 2019, RISK RED COGN DECL D, P1
   Zonta W, 2016, FOOD ENVIRON VIROL, V8, P275, DOI 10.1007/s12560-016-9253-5
NR 25
TC 2
Z9 2
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0195-6701
EI 1532-2939
J9 J HOSP INFECT
JI J. Hosp. Infect.
PD NOV
PY 2020
VL 106
IS 3
BP 577
EP 584
DI 10.1016/j.jhin.2020.08.025
PG 8
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA OM3FE
UT WOS:000585910300020
PM 32889029
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Kornbluth, A
   Kissous-Hunt, M
   George, J
   Legnani, P
AF Kornbluth, Asher
   Kissous-Hunt, Michele
   George, James
   Legnani, Peter
TI Management of Inflammatory Bowel Disease and COVID-19 in New York City
   2020: The Epicenter of IBD in the First Epicenter of the Global Pandemic
SO INFLAMMATORY BOWEL DISEASES
LA English
DT Article
DE COVID-19; New York City; biologic drugs; clinical outcomes; practice
   management
C1 [Kornbluth, Asher; Kissous-Hunt, Michele; George, James; Legnani, Peter] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
RP Kornbluth, A (corresponding author), 1150 Fifth Ave,Suite 1B, New York, NY 10128 USA.
EM asher.kornbluth@gmail.com
CR [Anonymous], ADV MAN INFL BOW DIS
   Brenner EJ, SECURE IBD DATABASE
   Brenner EJ, 2020, GASTROENTEROLOGY, V159, P481, DOI 10.1053/j.gastro.2020.05.032
   COVID ECCO Task Force, 2 INT, DOI [10.1093/ecco-jcc/jjaa160/5877458, DOI 10.1093/ECCO-JCC/JJAA160/5877458]
   Crohn's and Colitis Foundation, COVID 19 COR WHAT IB
   Hanzel J, 2020, CLIN GASTRO HEPATOL
   Kirkcaldy RD, 2020, JAMA-J AM MED ASSOC, V323, P2245, DOI 10.1001/jama.2020.7869
   Krammer F, 2020, SCIENCE, V368, P1060, DOI 10.1126/science.abc1227
   Rubin DT, 2020, GASTROENTEROLOGY, V159, P350, DOI 10.1053/j.gastro.2020.04.012
   Siegel CA, 2020, J CROHNS COLITIS
   Ungaro RC, 2020, CLIN GASTROENTEROL H, V18, P1152, DOI 10.1016/j.cgh.2019.08.012
NR 11
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1078-0998
EI 1536-4844
J9 INFLAMM BOWEL DIS
JI Inflamm. Bowel Dis.
PD NOV
PY 2020
VL 26
IS 11
BP 1779
EP 1785
DI 10.1093/ibd/izaa212
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA OW7BB
UT WOS:000593036300030
PM 32879978
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Horrigan, JM
   Siegel, CA
   Tadros, M
AF Horrigan, Jamie M.
   Siegel, Corey A.
   Tadros, Micheal
TI Management of IBD Patients Who Are Unwilling or Unable to Receive
   Infusion Therapy During the COVID-19 Pandemic
SO INFLAMMATORY BOWEL DISEASES
LA English
DT Letter
DE inflammatory bowel disease; COVID-19
C1 [Horrigan, Jamie M.] Dartmouth Hitchcock Med Ctr, Dept Med, One Med Ctr Dr, Lebanon, NH 03766 USA.
   [Siegel, Corey A.] Dartmouth Hitchcock Med Ctr, Div Gastroenterol & Hepatol, Dept Med, Lebanon, NH 03766 USA.
   [Tadros, Micheal] Albany Med Coll, Dept Med, Div Gastroenterol & Hepatol, Albany, NY 12208 USA.
RP Horrigan, JM (corresponding author), Dartmouth Hitchcock Med Ctr, Dept Med, One Med Ctr Dr, Lebanon, NH 03766 USA.
EM Jamie.m.horrigan@hitchcock.org
CR Dotan I, IOIBD RECOMMENDATION
   Occhipinti V, 2020, INFLAMM BOWEL DIS, V26, P793, DOI 10.1093/ibd/izaa084
   Rubin DT, 2020, GASTROENTEROLOGY
   Sandborn WJ, 2020, GASTROENTEROLOGY, V158, P562, DOI 10.1053/j.gastro.2019.08.027
   Van Assche G, 2012, GUT, V61, P229, DOI 10.1136/gutjnl-2011-300755
NR 5
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1078-0998
EI 1536-4844
J9 INFLAMM BOWEL DIS
JI Inflamm. Bowel Dis.
PD NOV
PY 2020
VL 26
IS 11
BP E137
EP E137
DI 10.1093/ibd/izaa207
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA OW7BB
UT WOS:000593036300002
PM 32737970
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Hilbrands, LB
   Duivenvoorden, R
   Vart, P
   Franssen, CFM
   Hemmelder, MH
   Jager, KJ
   Kieneker, LM
   Noordzij, M
   Pena, MJ
   de Vries, H
   Arroyo, D
   Covic, A
   Crespo, M
   Goffin, E
   Islam, M
   Massy, ZA
   Montero, N
   Oliveira, JP
   Munoz, AR
   Sanchez, JE
   Sridharan, S
   Winzeler, R
   Gansevoort, RT
AF Hilbrands, Luuk B.
   Duivenvoorden, Raphael
   Vart, Priya
   Franssen, Casper F. M.
   Hemmelder, Marc H.
   Jager, Kitty J.
   Kieneker, Lyanne M.
   Noordzij, Marlies
   Pena, Michelle J.
   de Vries, Hanne
   Arroyo, David
   Covic, Adrian
   Crespo, Marta
   Goffin, Eric
   Islam, Mahmud
   Massy, Ziad A.
   Montero, Nuria
   Oliveira, Joao P.
   Roca Munoz, Ana
   Sanchez, J. Emilio
   Sridharan, Sivakumar
   Winzeler, Rebecca
   Gansevoort, Ron T.
CA ERACODA Collaborators
TI COVID-19-related mortality in kidney transplant and dialysis patients:
   results of the ERACODA collaboration
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Article
DE COVID-19; dialysis; kidney; mortality; transplantation
AB Background. Patients on kidney replacement therapy comprise a vulnerable population and may be at increased risk of death from coronavirus disease 2019 (COVID-19). Currently, only limited data are available on outcomes in this patient population.
   Methods. We set up the ERACODA (European Renal Association COVID-19 Database) database, which is specifically designed to prospectively collect detailed data on kidney transplant and dialysis patients with COVID-19. For this analysis, patients were included who presented between 1 February and 1 May 2020 and had complete information available on the primary outcome parameter, 28-day mortality.
   Results. Of the 1073 patients enrolled, 305 (28%) were kidney transplant and 768 (72%) dialysis patients with a mean age of 60 +/- 13 and 67 +/- 14 years, respectively. The 28-day probability of death was 21.3% [95% confidence interval (95% CI) 14.3-30.2%] in kidney transplant and 25.0% (95% CI 20.2-30.0%) in dialysis patients. Mortality was primarily associated with advanced age in kidney transplant patients, and with age and frailty in dialysis patients. After adjusting for sex, age and frailty, in-hospital mortality did not significantly differ between transplant and dialysis patients [hazard ratio (HR) 0.81, 95% CI 0.59-1.10, P 0.18]. In the subset of dialysis patients who were a candidate for transplantation (n = 148), 8 patients died within 28 days, as compared with 7 deaths in 23 patients who underwent a kidney transplantation <1 year before presentation (HR adjusted for sex, age and frailty 0.20, 95% CI 0.07-0.56, P < 0.01).
   Conclusions. The 28-day case-fatality rate is high in patients on kidney replacement therapy with COVID-19 and is primarily driven by the risk factors age and frailty. Furthermore, in the first year after kidney transplantation, patients may be at increased risk of COVID-19-related mortality as compared with dialysis patients on the waiting list for transplantation. This information is important in guiding clinical decision-making, and for informing the public and healthcare authorities on the COVID-19-related mortality risk in kidney transplant and dialysis patients.
C1 [Hilbrands, Luuk B.; Duivenvoorden, Raphael] Radboud Univ Nijmegen, Med Ctr, Dept Nephrol, Nijmegen, Netherlands.
   [Vart, Priya] Radboud Univ Nijmegen, Med Ctr, Dept Hlth Evidence, Nijmegen, Netherlands.
   [Vart, Priya] Radboud Univ Nijmegen, Med Ctr, Dept Cardiol, Nijmegen, Netherlands.
   [Vart, Priya; Franssen, Casper F. M.; Kieneker, Lyanne M.; Noordzij, Marlies; de Vries, Hanne; Gansevoort, Ron T.] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Groningen, Netherlands.
   [Hemmelder, Marc H.] Nefrovisie Fdn, Dutch Renal Registry, Utrecht, Netherlands.
   [Jager, Kitty J.] Univ Amsterdam, Amsterdam Publ Hlth Res Inst, Dept Med Informat, ERA EDTA Registry,Med Ctr, Amsterdam, Netherlands.
   [Pena, Michelle J.] Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands.
   [Arroyo, David] Hosp Gen Univ Gregorio Maranon, Dept Nephrol, Madrid, Spain.
   [Covic, Adrian] Grigore T Popa Univ Med & Pharm, Dr Ci Parhon Hosp, Iasi, Romania.
   [Crespo, Marta] Hosp del Mar, Dept Nephrol, Barcelona, Spain.
   [Goffin, Eric] Catholic Univ Louvain, Clin Univ St Luc, Brussels, Belgium.
   [Islam, Mahmud] Zonguldak Ataturk State Hosp, Dept Nephrol, Zonguldak, Turkey.
   [Massy, Ziad A.] UVSQ Univ Versailles St Quentin En Yvelines Paris, Div Nephrol, Ambroise Pare Univ Hosp, AP HP Assistance Publ Hopitaux Paris, Boulogne Billancourt Par, France.
   [Massy, Ziad A.] Inst Natl Sante & Rech Med INSERM, Villejuif, France.
   [Montero, Nuria] Bellvitge Univ Hosp, Dept Nephrol, Barcelona, Spain.
   [Oliveira, Joao P.] Centrodial, Sao Joao Da Madeira, Portugal.
   [Roca Munoz, Ana] Toledo Univ Hosp, Renal Transplant Unit, Toledo, Spain.
   [Sanchez, J. Emilio] Hosp Univ Cabuenes, Dept Nephrol, Asturias, Spain.
   [Sridharan, Sivakumar] Lister Hosp, Dept Renal Unit, Stevenage, Herts, England.
   [Winzeler, Rebecca] City Hosp Waid & Triemli, Inst Nephrol, Zurich, Switzerland.
RP Gansevoort, RT (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Groningen, Netherlands.
EM r.t.gansevoort@umcg.nl
RI ; Hilbrands, Luuk/B-4921-2011
OI Pena, Michelle/0000-0003-3340-2893; Franssen,
   Casper/0000-0003-1004-9994; Sabiu, Gianmarco/0000-0002-9514-1652;
   Rahimzadeh, Hormat/0000-0003-0801-0978; Hilbrands,
   Luuk/0000-0002-4935-9765
FU ERA-EDTA; Dutch Kidney Foundation; Baxter; SandozNovartis
FX The ERACODA Consortium is financially supported by unrestricted grants
   from the ERA-EDTA, the Dutch Kidney Foundation, Baxter and Sandoz. None
   of these organizations had any role in the design or execution of the
   study, nor in writing of the manuscript.
CR Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   Alberici F, 2020, KIDNEY INT, V97, P1083, DOI 10.1016/j.kint.2020.04.002
   Bikbov B, 2020, LANCET, V395, P709, DOI 10.1016/S0140-6736(20)30045-3
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Crespo M, 2020, AM J TRANSPLANT, V20, P2883, DOI 10.1111/ajt.16096
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Sanchez-Alvarez JE, 2020, NEFROLOGIA, V40, P272, DOI 10.1016/j.nefro.2020.04.002
   Gansevoort RT, 2020, NAT REV NEPHROL, V16, P705, DOI 10.1038/s41581-020-00349-4
   Goicoechea M, 2020, KIDNEY INT, V98, P27, DOI 10.1016/j.kint.2020.04.031
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lighter J, 2020, CLIN INFECT DIS, V71, P896, DOI 10.1093/cid/ciaa415
   Maggiore U, 2020, NEPHROL DIAL TRANSPL, V35, P899, DOI 10.1093/ndt/gfaa130
   Myers LC, 2020, JAMA-J AM MED ASSOC, V323, P2195, DOI 10.1001/jama.2020.7202
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Rockwood K, 2005, CAN MED ASSOC J, V173, P489, DOI 10.1503/cmaj.050051
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Wallis SJ, 2015, QJM-INT J MED, V108, P943, DOI 10.1093/qjmed/hcv066
   Williamson EJ, 2020, NATURE, DOI 10.1038/s41586-020-2521-4
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 22
TC 1
Z9 1
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931-0509
EI 1460-2385
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD NOV
PY 2020
VL 35
IS 11
BP 1973
EP 1983
DI 10.1093/ndt/gfaa261
PG 11
WC Transplantation; Urology & Nephrology
SC Transplantation; Urology & Nephrology
GA OW8GJ
UT WOS:000593117700020
PM 33151337
OA Green Published
DA 2021-01-01
ER

PT J
AU Saleh, M
   Gabriels, J
   Chang, D
   Fishbein, J
   Qiu, M
   Mountantonakis, SE
   Epstein, LM
AF Saleh, Moussa
   Gabriels, James
   Chang, David
   Fishbein, Joanna
   Qiu, Michael
   Mountantonakis, Stavros E.
   Epstein, Laurence M.
CA Northwell COVID-19 Res Consortium
TI Safely Administering Potential QTc Prolonging Therapy Across a Large
   Health Care System in the COVID-19 Era
SO CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY
LA English
DT Article
DE azithromycin; COVID-19; hydroxychloroquine; pandemic; torsade de pointes
AB Background:
   The severe acute respiratory syndrome coronavirus 2 (SARs-CoV-2) has resulted in a global pandemic. Hydroxychloroquine +/- azithromycin have been widely used to treat coronavirus disease 2019 (COVID-19) despite a paucity of evidence regarding efficacy. The incidence of torsade de pointes remains unknown. Widespread use of these medications forced overwhelmed health care systems to search for ways to effectively monitor these patients while simultaneously trying to minimize health care provider exposure and use of personal protective equipment.
   Methods:
   Patients with COVID-19 positive who received hydroxychloroquine +/- azithromycin across 13 hospitals between March 1 and April 15 were included in this study. A comprehensive search of the electronic medical records was performed using a proprietary python script to identify any mention of QT prolongation, ventricular tachy-arrhythmias and cardiac arrest.
   Results:
   The primary outcome of torsade de pointes was observed in 1 (0.015%) out of 6476 hospitalized patients with COVID-19 receiving hydroxychloroquine +/- azithromycin. Sixty-seven (1.03%) had hydroxychloroquine +/- azithromycin held or discontinued due to an average QT prolongation of 60.5 +/- 40.5 ms from a baseline QTc of 473.7 +/- 35.9 ms to a peak QTc of 532.6 +/- 31.6 ms. Of these patients, hydroxychloroquine +/- azithromycin were discontinued in 58 patients (86.6%), while one or more doses of therapy were held in the remaining nine (13.4%). A simplified approach to monitoring for QT prolongation and arrythmia was implemented on April 5. There were no deaths related to the medications with the simplified monitoring approach and health care provider exposure was reduced.
   Conclusions:
   The risk of torsade de pointes is low in hospitalized patients with COVID-19 receiving hydroxychloroquine +/- azithromycin therapy.
C1 [Saleh, Moussa; Gabriels, James; Chang, David; Mountantonakis, Stavros E.; Epstein, Laurence M.] Northwell Hlth, Dept Cardiol, Feinstein Inst Med Res, Inst Hlth Innovat & Outcomes Res, Manhasset, NY USA.
   [Qiu, Michael] Northwell Hlth, Ctr Res Informat & Innovat, Feinstein Inst Med Res, Manhasset, NY USA.
   [Fishbein, Joanna] Northwell Hlth, Biostat Unit, Feinstein Inst Med Res, Manhasset, NY USA.
RP Saleh, M (corresponding author), Dept Cardiol, 300 Community Dr, Manhasset, NY 11030 USA.
EM moussa.a.saleh@gmail.com
OI Saleh, Moussa/0000-0001-7647-397X; Fishbein, Joanna/0000-0002-4524-1639;
   Epstein, Laurence/0000-0001-5410-0291
CR Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Chang D, 2020, J AM COLL CARDIOL, V75, P2992, DOI 10.1016/j.jacc.2020.04.032
   Chorin E, 2020, HEART RHYTHM, V17, P1425, DOI 10.1016/j.hrthm.2020.05.014
   Deisseroth CA, 2019, GENET MED, V21, P1585, DOI 10.1038/s41436-018-0381-1
   Kuhn JH, 2004, CELL MOL LIFE SCI, V61, P2738, DOI 10.1007/s00018-004-4242-5
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   Roden DM, 2016, J PHYSIOL-LONDON, V594, P2459, DOI 10.1113/JP270526
   Saleh M, 2020, CIRC-ARRHYTHMIA ELEC, V13, DOI 10.1161/CIRCEP.120.008662
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   World Health Organization, 2020, CORONAVIRUS DIS 2019
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 14
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-3149
EI 1941-3084
J9 CIRC-ARRHYTHMIA ELEC
JI Circ.-Arrhythmia Electrophysiol.
PD NOV
PY 2020
VL 13
IS 11
DI 10.1161/CIRCEP.120.008937
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OZ3VS
UT WOS:000594858600019
PM 33003964
DA 2021-01-01
ER

PT J
AU Chen, WX
AF Chen, Wangxue
TI Promise and challenges in the development of COVID-19 vaccines
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article
DE COVID-19; SARS-COV-2; vaccine; protective immunity; safety; animal model
AB The pandemic outbreak of COVID-19, caused by coronavirus SARS-CoV-2, created an unprecedented challenge to global public health system and biomedical community. Vaccination is an effective way to prevent viral infection, stop its transmission, and develop herd immunity. Rapid progress and advances have been made to date in the development of COVID-19 vaccines. Currently, more than 115 vaccine candidates have been developed from different technology platforms with several of them in clinical trials. Most of those vaccine candidates are developed based on the experience with other coronaviruses with an aim to induce neutralizing antibodies against the viral spike protein or its different receptor binding domains. Here, we discuss the promise, potential scientific challenges, and future directions for the development of a safe and effective COVID-19 vaccine. We also emphasize the importance of a better understanding of the infection pathogenesis and host defense mechanisms against SARS-CoV-2 infection.
C1 [Chen, Wangxue] Natl Res Council Canada, Human Hlth Therapeut Res Ctr HHT, Ottawa, ON K1A 0R6, Canada.
   [Chen, Wangxue] Brock Univ, Dept Biol, St Catharines, ON, Canada.
RP Chen, WX (corresponding author), Natl Res Council Canada, Human Hlth Therapeut Res Ctr HHT, Ottawa, ON K1A 0R6, Canada.
EM Wangxue.Chen@nrc-cnrc.gc.ca
RI Guo, Shicheng/A-1204-2016
OI Guo, Shicheng/0000-0002-7047-9972
CR Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6
   Cohen J, 2020, SCIENCE, V368, P14, DOI 10.1126/science.368.6486.14
   Deng SQ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020575
   Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227
   Dong C., 2020, CHARACTERIZATION ANT, DOI [10.1101/2020.03.17.20036640, DOI 10.1101/2020.03.17.20036640]
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Eyal N, 2020, J INFECT DIS, V221, P1752, DOI 10.1093/infdis/jiaa152
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jiang SB, 2020, NATURE, V579, P321, DOI 10.1038/d41586-020-00751-9
   Johns Hopkins University, COVID 19 DASH CTR SY
   Kim YI, 2020, CELL HOST MICROBE, V27, P704, DOI 10.1016/j.chom.2020.03.023
   Kumar Swatantra, 2020, VirusDisease, V31, DOI 10.1007/s13337-020-00571-5
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Liu YX, 2020, NATL SCI REV, V7, P1003, DOI 10.1093/nsr/nwaa037
   Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098
   Ong Edison, 2020, bioRxiv, DOI 10.1101/2020.03.20.000141
   Sala G, 2020, ASS BCG VACCINATION, DOI [10.1101/2020.03.30.20048165, DOI 10.1101/2020.03.30.20048165]
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shet A., 2020, DIFFERENTIAL COVID 1, DOI [10.1101/2020.04.01.20049478, DOI 10.1101/2020.04.01.20049478]
   Szigeti R., 2020, BCG PROTECTS COVID 1, DOI [10.1101/2020.04.09.20056903, DOI 10.1101/2020.04.09.20056903]
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Tortorici MA, 2019, NAT STRUCT MOL BIOL, V26, P481, DOI 10.1038/s41594-019-0233-y
   Vankadari N, 2020, EMERG MICROBES INFEC, V9, P601, DOI 10.1080/22221751.2020.1739565
   World Health Organization, 2020, COVID 19 PUBL HLTH E
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhang JY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020153
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zhao JC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000636
   Zheng HY, 2020, CELL MOL IMMUNOL, V17, P541, DOI 10.1038/s41423-020-0401-3
NR 37
TC 3
Z9 3
U1 4
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
PD NOV 1
PY 2020
VL 16
IS 11
BP 2604
EP 2608
DI 10.1080/21645515.2020.1787067
PG 5
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA PC2WP
UT WOS:000596867600007
PM 32703069
OA Bronze
DA 2021-01-01
ER

PT J
AU Dastan, F
   Saffaei, A
   Haseli, S
   Marjani, M
   Moniri, A
   Abtahian, Z
   Abedini, A
   Kiani, A
   Seifi, S
   Jammati, H
   Hashemian, SMR
   Toutkaboni, MP
   Eslaminejad, A
   Heshmatnia, J
   Sadeghi, M
   Nadji, SA
   Dastan, A
   Baghaei, P
   Varahram, M
   Yousefian, S
   Salamzadeh, J
   Tabarsi, P
AF Dastan, Farzaneh
   Saffaei, Ali
   Haseli, Sara
   Marjani, Majid
   Moniri, Afshin
   Abtahian, Zahra
   Abedini, Atefeh
   Kiani, Arda
   Seifi, Sharareh
   Jammati, Hamidreza
   Hashemian, Seyed Mohammad Reza
   Toutkaboni, Mihan Pourabdollah
   Eslaminejad, Alireza
   Heshmatnia, Jalal
   Sadeghi, Mohsen
   Nadji, Seyed Alireza
   Dastan, Alireza
   Baghaei, Parvaneh
   Varahram, Mohammad
   Yousefian, Sahar
   Salamzadeh, Jamshid
   Tabarsi, Payam
TI Promising effects of tocilizumab in COVID-19: A non-controlled,
   prospective clinical trial
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Coronavirus; COVID-19; Interleukin 6; SARS-CoV-2; Tocilizumab
ID CYTOKINE STORM; SAFETY; EFFICACY; THERAPY
AB Background: The clinical presentation of SARS-CoV-2 infection ranges from mild symptoms to severe complications, including acute respiratory distress syndrome. In this syndrome, inflammatory cytokines are released after activation of the inflammatory cascade, with the predominant role of interleukin (IL)-6. The aim of this study was to evaluate the effects of tocilizumab, as an IL-6 antagonist, in patients with severe or critical SARS-CoV-2 infection.
   Methods: In this prospective clinical trial, 76 patients with severe or critical SARS-CoV-2 infection were evaluated for eligibility, and ultimately, 42 patients were included. Tocilizumab was administered at a dose of 400 mg as a single dose via intravenous infusion. Primary outcomes included changes in oxygenation support, need for invasive mechanical ventilation, and death. Secondary outcomes included radiological changes in the lungs, IL-6 plasma levels, C-reactive protein levels, and adverse drug reactions. The data were analyzed using SPSS software.
   Results: Of the 42 included patients, 20 (48%) patients presented the severe infection stage and 22 (52%) were in the critical stage. The median age of patients was 56 years, and the median IL-6 level was 28.55 pg/mL. After tocilizumab administration, only 6 patients (14%) required invasive ventilation. Additionally, 35 patients (83.33%) showed clinical improvement. By day 28, a total of 7 patients died (6 patients in the critical stage and 1 patient in the severe stage). Neurological adverse effects were observed in 3 patients.
   Conclusions: Based on the current results, tocilizumab may be a promising agent for patients with severe or critical SARS-CoV-2 infection, if promptly initiated during the severe stage.
C1 [Dastan, Farzaneh; Yousefian, Sahar; Salamzadeh, Jamshid] Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Clin Pharm, Tehran, Iran.
   [Dastan, Farzaneh; Haseli, Sara; Abedini, Atefeh; Seifi, Sharareh; Jammati, Hamidreza; Hashemian, Seyed Mohammad Reza; Eslaminejad, Alireza; Heshmatnia, Jalal; Sadeghi, Mohsen; Varahram, Mohammad; Yousefian, Sahar] Shahid Beheshti Univ Med Sci, Chron Resp Dis Res Ctr CRDRC, Natl Res Inst TB & Lung Dis NRITLD, Tehran, Iran.
   [Saffaei, Ali] Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Clin Pharm, Student Res Comm, Tehran, Iran.
   [Marjani, Majid; Abtahian, Zahra; Baghaei, Parvaneh; Tabarsi, Payam] Shahid Beheshti Univ Med Sci, Masih Daneshvari Hosp, Clin TB & Epidemiol Res Ctr, Natl Res Inst TB & Lung Dis NRITLD, Tehran, Iran.
   [Moniri, Afshin; Nadji, Seyed Alireza] Shahid Beheshti Univ Med Sci, Masih Daneshvari Hosp, Virol Res Ctr, Natl Res Inst TB & Lung Dis NRITLD, Tehran, Iran.
   [Kiani, Arda] Shahid Beheshti Univ Med Sci, Tracheal Dis Res Ctr, Natl Res Inst TB & Lung Dis NRITLD, Tehran, Iran.
   [Toutkaboni, Mihan Pourabdollah] Shahid Beheshti Univ Med Sci, Lung Transplant Res Ctr, Natl Res Inst TB & Lung Dis NRITLD, Tehran, Iran.
   [Dastan, Alireza] Univ Calif Merced, Sch Engn, Ernest & Julio Gallo Management Program, Merced, CA USA.
RP Tabarsi, P (corresponding author), Shahid Beheshti Univ Med Sci, Clin TB & Epidemiol Res Ctr, Natl Res Inst TB & Lung Dis NRITLD, Daarabad St,Niyavaran St, Tehran 1956944413, Iran.
EM tabarsi@nritld.ac.ir
FU Red Crescent Organization of Republic of China
FX We are thankful to the Red Crescent Organization of Republic of China
   for their support. Also we are thankful to the Nursing Staff and
   Pharmaceutical Care Department of Masih Daneshvari Hospital for their
   support.
CR Alattar R, 2020, J MED VIROL, V92, P2042, DOI 10.1002/jmv.25964
   Asadi-Pooya AA, 2020, J NEUROL SCI, V413, DOI 10.1016/j.jns.2020.116832
   Baig AM, 2020, CNS NEUROSCI THER, V26, P499, DOI 10.1111/cns.13372
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Campochiaro C, 2020, EUR J INTERN MED, V76, P43, DOI 10.1016/j.ejim.2020.05.021
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Dastan F, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106043
   Dastan F, 2020, J GLOB ANTIMICROB RE, V21, P340, DOI 10.1016/j.jgar.2020.04.024
   Fitzgerald JC, 2017, CRIT CARE MED, V45, pE124, DOI 10.1097/CCM.0000000000002053
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Jamaati H, 2020, IRAN J PHARM RES, V19, P31, DOI 10.22037/ijpr.2020.113337.14239
   Jones G, 2018, THER ADV MUSCULOSKEL, V10, P195, DOI 10.1177/1759720X18798462
   Jones G, 2010, CLIN MED INSIGHTS-AR, V3, P81, DOI 10.4137/CMAMD.S4864
   Khafaie Morteza Abdullatif, 2020, Osong Public Health Res Perspect, V11, P74, DOI 10.24171/j.phrp.2020.11.2.03
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Meng LZ, 2020, ANESTHESIOLOGY, V132, P1317, DOI 10.1097/ALN.0000000000003296
   Shabani M, 2020, J MED VIROL, DOI 10.1002/jmv.26124
   Sheppard M, 2017, HUM VACC IMMUNOTHER, V13, P1972, DOI 10.1080/21645515.2017.1316909
   Spychalski P, 2020, LANCET INFECT DIS, V20, P774, DOI [10.1016/S1473-3099(20)30246-2, 10.1016/S1473-3099(20)30245-0]
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
NR 29
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD NOV
PY 2020
VL 88
AR 106869
DI 10.1016/j.intimp.2020.106869
PG 7
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA OP6AD
UT WOS:000588166300087
PM 32889241
OA Green Published
DA 2021-01-01
ER

PT J
AU Franzini, M
   Valdenassi, L
   Ricevuti, G
   Chirumbolo, S
   Depfenhart, M
   Bertossi, D
   Tirelli, U
AF Franzini, Marianno
   Valdenassi, Luigi
   Ricevuti, Giovanni
   Chirumbolo, Salvatore
   Depfenhart, Markus
   Bertossi, Dario
   Tirelli, Umberto
TI Oxygen-ozone (O-2-O-3) immunoceutical therapy for patients with
   COVID-19. Preliminary evidence reported
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Ozone therapy; Immunoceutical; Oxygen; COVID-19; Pneumonia; D-dimer;
   IL-6
ID SARS-COV-2 OUTBREAK; NITRIC-OXIDE; MANAGEMENT
AB Objective: This study evaluated the potential efficacy of a novel approach to treat COVID-19 patients, using an oxygen-ozone (O-2-O-3) mixture, via a process called Oxygen-Ozone- Immunoceutical Therapy. The methodology ma the criteria of a novel, promising approach to treat successfully elderly COVID-19 patients, particularly when hospitalized in intensive care units (ICUs) Experimental design: We investigated the therapeutic effect of 4 cycles of O-2-O-3 in 50 hospitalized COVID-19 subjects suffering from acute respiratory disease syndrome (ARDS), aged more than 60 years, all males and undergoing non invasive mechanical ventilation in ICUs.
   Results: Following O-2-O-3 treatment a significant improvement in inflammation and oxygenation indexes occurred rapidly and within the first 9 days after the treatment, despite the expected 14-20 days. A significant reduction of inflammatory and thromboembolic markers (CRP, IL-6, D-dimer) was observed. Furthermore, amelioration in the major respiratory indexes, such as respiratory and gas exchange markers (SatO(2)%, PaO2/FiO(2) ratio), was reported.
   Conclusion: Our results show that O-2-O-3 treatment would be a promising therapy for COVID-19 patients. It leads patients to a fast recovery from ARDS via the improvement of major respiratory indexes and blood gas parameters, following a relatively short time of dispensed forced ventilation (about one to two weeks). This study may encourage the scientific community to further investigate and evaluate the proposed method for the treatment of COVID-19 patients.
C1 [Franzini, Marianno; Valdenassi, Luigi] Univ Pavia, High Sch Oxygen Ozone Therapy, SIOOT, Pavia, Italy.
   [Franzini, Marianno; Valdenassi, Luigi; Tirelli, Umberto] SIOOT INT, Communian Clin, Gorle Bergamo, Italy.
   [Ricevuti, Giovanni; Tirelli, Umberto] Univ Pavia, Dept Drug Sci, Pavia, Italy.
   [Chirumbolo, Salvatore] Univ Verona, Dept Neurosci Biomed & Movement Sci, Str Le Grazie 9, I-37134 Verona, Italy.
   [Depfenhart, Markus] Venlo Univ BV, Venlo, Netherlands.
   [Bertossi, Dario] Univ Verona, Unit Maxillofacial Surg, Dept Surg Dent Paediat & Gynaecol, Verona, Italy.
RP Chirumbolo, S (corresponding author), Univ Verona, Dept Neurosci Biomed & Movement Sci, Str Le Grazie 9, I-37134 Verona, Italy.
EM salvatore.chirumbolo@univr.it
CR Ahn DG, 2020, J MICROBIOL BIOTECHN, V30, P313, DOI 10.4014/jmb.2003.03011
   Akerstrom S, 2009, VIROLOGY, V395, P1, DOI 10.1016/j.virol.2009.09.007
   Chirumbolo S, 2020, J ALLERGY CLIN IMMUN, V146, P331, DOI 10.1016/j.jaci.2020.05.011
   Deng L, 2018, AM J TRANSL RES, V10, P1829
   Elvis A M, 2011, J Nat Sci Biol Med, V2, P66, DOI 10.4103/0976-9668.82319
   Han H, 2020, CLIN CHEM LAB MED, V58, P1116, DOI 10.1515/cclm-2020-0188
   Hernandez A, 2020, REV ESP ANEST REANIM, V67, P245, DOI 10.1016/j.redar.2020.03.004
   Hernandez V., 2020, OZONE THERAPY PATIEN, DOI [10.1101/2020.06.03.20117994, DOI 10.1101/2020.06.03.20117994]
   Holmlund S, 2020, SEX REPROD HEALTHC, V24, DOI 10.1016/j.srhc.2020.100508
   Hotchkiss RS, 2020, NEW ENGL J MED, V382, P1270, DOI 10.1056/NEJMcibr1917242
   Kahle JJ, 2015, ENVIRON HEALTH PERSP, V123, P310, DOI 10.1289/ehp.1307986
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Li TH, 2020, EMERG MICROBES INFEC, V9, P687, DOI 10.1080/22221751.2020.1741327
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   Marfella R, 2020, DIABETES METAB, V46, P403, DOI 10.1016/j.diabet.2020.05.005
   Pourhoseingholi Mohamad Amin, 2013, Gastroenterol Hepatol Bed Bench, V6, P14
   PUNJABI CJ, 1994, AM J RESP CELL MOL, V11, P165, DOI 10.1165/ajrcmb.11.2.7519435
   Robba C, 2020, RESP PHYSIOL NEUROBI, V279, DOI 10.1016/j.resp.2020.103455
   Rowen RJ, 2019, MED GAS RES, V9, P232, DOI 10.4103/2045-9912.273962
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   SAFARI S, 2020, ARCH ACAD EMERG MED, V8
   Sagai M, 2011, MED GAS RES, V1, DOI 10.1186/2045-9912-1-29
   Simonetti V, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/2169103
   Sorbello M, 2020, ANAESTHESIA, V75, P724, DOI 10.1111/anae.15049
   Valdenassi L, 2020, EUR REV MED PHARMACO, V24, P4059, DOI 10.26355/eurrev_202004_20976
   Wu D, 2020, INT J INFECT DIS, V94, P44, DOI 10.1016/j.ijid.2020.03.004
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
NR 27
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD NOV
PY 2020
VL 88
AR 106879
DI 10.1016/j.intimp.2020.106879
PG 5
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA OP6AD
UT WOS:000588166300058
PM 32795898
OA Green Published
DA 2021-01-01
ER

PT J
AU Goodarzi, P
   Mahdavi, F
   Mirzaei, R
   Hasanvand, H
   Sholeh, M
   Zamani, F
   Sohrabi, M
   Tabibzadeh, A
   Jeda, AS
   Niya, MHK
   Keyvani, H
   Karampoor, S
AF Goodarzi, Pedram
   Mahdavi, Farzad
   Mirzaei, Rasoul
   Hasanvand, Hamze
   Sholeh, Mohammad
   Zamani, Farhad
   Sohrabi, Masodreza
   Tabibzadeh, Alireza
   Jeda, Ali Salimi
   Niya, Mohammad Hadi Karbalaie
   Keyvani, Hossein
   Karampoor, Sajad
TI Coronavirus disease 2019 (COVID-19): Immunological approaches and
   emerging pharmacologic treatments
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE SARS-CoV-2; COVID-19; Drug targets; Antiviral strategies; Immunological
   approaches
ID HUMAN MONOCLONAL-ANTIBODIES; CONVALESCENT PLASMA; STRUCTURAL BASIS;
   EBOLA-VIRUS; SARS CORONAVIRUS; NUCLEAR IMPORT; INHIBITOR; PROTEIN;
   IVERMECTIN; PROTECTION
AB The SARS-CoV-2 virus is an etiological agent of pandemic COVID-19, which spreads rapidly worldwide. No proven effective therapies currently exist for this virus, and efforts to develop antiviral strategies for the treatment of COVID-19 are underway. The rapidly increasing understanding of SARS-CoV-2 virology provides a notable number of possible immunological procedures and drug targets. However, gaps remain in our understanding of the pathogenesis of COVID-19. In this review, we describe the latest information in the context of immunological approaches and emerging current antiviral strategies for COVID-19 treatment.
C1 [Goodarzi, Pedram] Iran Univ Med Sci, Fac Pharm, Tehran, Iran.
   [Mahdavi, Farzad] Guilan Univ Med Sci, Sch Med, Dept Med Parasitol & Mycol, Rasht, Iran.
   [Mirzaei, Rasoul] Hamadan Univ Med Sci, Sch Med, Dept Microbiol, Hamadan, Hamadan, Iran.
   [Hasanvand, Hamze] Iran Univ Med Sci, Sch Med, Tehran, Iran.
   [Sholeh, Mohammad] Iran Univ Med Sci, Sch Med, Dept Microbiol, Tehran, Iran.
   [Zamani, Farhad; Sohrabi, Masodreza; Niya, Mohammad Hadi Karbalaie; Keyvani, Hossein] Iran Univ Med Sci, Gastrointestinal & Liver Dis Res Ctr, Tehran, Iran.
   [Tabibzadeh, Alireza; Jeda, Ali Salimi; Keyvani, Hossein; Karampoor, Sajad] Iran Univ Med Sci, Sch Med, Dept Virol, Tehran, Iran.
RP Keyvani, H (corresponding author), Iran Univ Med Sci, Gastrointestinal & Liver Dis Res Ctr, Tehran, Iran.; Karampoor, S (corresponding author), Iran Univ Med Sci, Sch Med, Dept Virol, Tehran, Iran.
EM H.keyvani@iums.ac.ir; Sajadkarampour1987@gmail.com
OI tabibzadeh, alireza/0000-0003-0070-2208
FU Iran University of Medical Sciences
FX This work was supported by the Iran University of Medical Sciences.
CR Agostini M.L., 2019, J VIROL, V93
   Alberici F., 2020, KIDNEY INT
   Amici C, 2006, ANTIVIR THER, V11, P1021
   Ankrum J., 2020, SCI TRANSL MED, V12
   [Anonymous], 2020, GS5734T GS
   Arabi YM, 2020, CLIN INFECT DIS, V70, P1837, DOI 10.1093/cid/ciz544
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Arshad S., 2020, INT J INFECT DIS
   Barrett CD, 2020, J THROMB HAEMOST, V18, P2060, DOI 10.1111/jth.14860
   Batlle D, 2020, CLIN SCI, V134, P543, DOI 10.1042/CS20200163
   Beigel J.H., 2020, NEW ENGL J MED
   Beigel J.H., 2019, ADV RESP VIRUS THERA
   Belhadi D., 2020, ANTIVIRAL DRUGS EVAL
   Bikdeli B., 2020, J AM COLL CARDIOL
   Brandon V.J.H.D., 2020, COAGULOPATHY COVID 1
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Canga AG, 2008, AAPS J, V10, P42, DOI 10.1208/s12248-007-9000-9
   Cantini F, 2020, J INFECT, VS0163-4453, P30228
   Cao B, 2020, NEW ENGL J MED, V382
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Cavalli G., 2020, LANCET RHEUMATOL
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Chen C, 2020, FAVIPIRAVIR VERSUS A
   Chen J., 2020, ENGINEERING
   Chen N., 2020, SSRN ELECT J, V395, P10223, DOI [10.2139/ssrn.3523861, DOI 10.2139/SSRN.3523861]
   Chen X., 2020, CELL MOL IMMUNOL, P1
   Chen ZW, 2020, EFFICACY HYDROXYCHLO
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Cortegiani A., 2020, J CRITICAL CARE
   Davidson L., 2020, HYDROXYCHLOROQUINE S
   Delang L, 2018, ANTIVIR RES, V153, P85, DOI 10.1016/j.antiviral.2018.03.003
   Deng L., 2020, J INFECT
   Deng Y., 2020, CHINESE MED J
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Ehrlich P., 1908, NOBEL LECT, V11
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Fang L., 2020, LANCET RESP MED
   Fintelman-Rodrigues N, 2020, BIORXIV
   Gao GS, 2020, INFECTION, DOI 10.1007/s15010-020-01485-6
   Gao J., 2020, BIOSCIENCE TRENDS
   Gasmi A, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108409
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J., 2020, NEW ENGL J MED
   Glenn Justin D, 2014, World J Stem Cells, V6, P526, DOI 10.4252/wjsc.v6.i5.526
   Gotz V, 2016, SCI REP-UK, V6, DOI 10.1038/srep23138
   Golchin A, 2019, STEM CELL REV REP, V15, P166, DOI 10.1007/s12015-018-9866-1
   Golchin A, 2019, CURR STEM CELL RES T, V14, P22, DOI 10.2174/1574888X13666180913123424
   Gong J., 2020, CORRELATION ANALYSIS
   Grein J, 2020, NEW ENGL J MED, V382
   Gritti G., 2020, US SILT PAT COVID 19
   Gunn BM, 2018, CELL HOST MICROBE, V24, P221, DOI 10.1016/j.chom.2018.07.009
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui D., 2020, INT J INFECT DIS, V91, P4
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Hwang WC, 2006, J BIOL CHEM, V281, P34610, DOI 10.1074/jbc.M603275200
   Iwabuchi K., 2020, J INFECT CHEMOTHER
   Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836
   Khalili J.S., 2020, J MED VIROL
   Khatri M, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0774-8
   Kim Jeong-Min, 2020, Osong Public Health Res Perspect, V11, P3, DOI 10.24171/j.phrp.2020.11.1.02
   Ko JH, 2018, ANTIVIR THER, V23, P617, DOI 10.3851/IMP3243
   KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0
   Lan X., 2020, LOPINAVIR RITONAVIR
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Lee P.-I., 2020, J MICROBIOL IMMUNOL
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Li B., 2020, IMMUNOGLOBULIN G M C
   Li TH, 2020, EMERG MICROBES INFEC, V9, P687, DOI 10.1080/22221751.2020.1741327
   Liang B, 2020, CLIN REMISSION CRITI, V2, pv1
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   Liu S, 2020, ROUTLEDGE FOCUS, P19
   Lo MK, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau9242
   Lo MK, 2017, SCI REP-UK, V7, DOI 10.1038/srep43395
   Lother S.A., 2020, POST EXPOSURE PROPHY
   Lowe DA, 2020, JAMA INTERN MED, DOI 10.1001/jamainternmed.2020.4153
   Lu H., 2020, J MED VIROL
   Lu R., 2020, CDC WEEKLY, V2, P1
   Lundberg L, 2013, ANTIVIR RES, V100, P662, DOI 10.1016/j.antiviral.2013.10.004
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Marston HD, 2018, NEW ENGL J MED, V378, P1469, DOI 10.1056/NEJMp1802256
   Mastrangelo E, 2012, J ANTIMICROB CHEMOTH, V67, P1884, DOI 10.1093/jac/dks147
   Matsuyama S., 2020, INHALED CORTICOSTERO, DOI [10.1101/2020.03.11.987016, DOI 10.1101/2020.03.11.987016]
   McCreary E.K., 2020, CORONAVIRUS DIS 2019
   Mehta P, 2020, LANCET, V6736, P19
   Mitja O., 2020, CLIN INFECT DIS
   Monteil V, 2020, CELL
   Morra ME, 2018, REV MED VIROL, V28, DOI 10.1002/rmv.1977
   Ni YN, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2395-8
   Nishiura H, 2020, EXTENT TRANSMISSION
   Prabakaran P, 2006, J BIOL CHEM, V281, P15829, DOI 10.1074/jbc.M600697200
   Prabakaran P, 2009, EXPERT OPIN BIOL TH, V9, P355, DOI 10.1517/14712590902763755 
   Ranucci M, 2020, J THROMB HAEMOST, V18, P1747, DOI 10.1111/jth.14854
   Reguera J, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002859
   Reynard O, 2015, VIRUSES-BASEL, V7, P6233, DOI 10.3390/v7122934
   Rockx B, 2008, J VIROL, V82, P3220, DOI 10.1128/JVI.02377-07
   Rosenberg ES, 2020, JAMA
   Salazar G, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0019-3
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Sanders JM, 2020, JAMA
   Saphire EO, 2018, NAT IMMUNOL, V19, P1169, DOI 10.1038/s41590-018-0233-9
   Shamshirian A., 2020, HYDROXYCHLOROQUINE V
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Skipper C.P., 2020, ANN INTERNAL MED
   Smith T., 2020, COVID 19 DRUG THERAP
   Stangel M, 2006, J NEUROL, V253, P18, DOI 10.1007/s00415-006-5003-1
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Sun L, 2011, AM J PHYSIOL-LUNG C, V300, pL341, DOI 10.1152/ajplung.00122.2010
   Tahvildari A., 2020, CLIN FEATURES DIAGNO
   Tan ELC, 2004, EMERG INFECT DIS, V10, P581, DOI 10.3201/eid1004.030458
   Tang N., 2020, J THROMB HAEMOST
   Tay MYF, 2013, ANTIVIR RES, V99, P301, DOI 10.1016/j.antiviral.2013.06.002
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Toots M, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax5866
   Urakova N, 2018, J VIROL, V92, DOI 10.1128/JVI.01965-17
   van Erp EA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00548
   van Griensven J, 2016, NEW ENGL J MED, V374, P33, DOI 10.1056/NEJMoa1511812
   Vijayanand P, 2004, CLIN MED, V4, P152, DOI 10.7861/clinmedicine.4-2-152
   W.H. Organization, 2020, NOVEL CORONAVIRUS 20, V3, P2020
   Wagstaff KM, 2012, BIOCHEM J, V443, P851, DOI 10.1042/BJ20120150
   Wagstaff KM, 2011, J BIOMOL SCREEN, V16, P192, DOI 10.1177/1087057110390360
   Wan S., 2020, CHARACTERISTICS LYMP
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang Y., 2020, LOW DOS SHORT TERM A
   Wang Y., 2020, LANCET
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Watanabe K, 2020, SOC SCI COMPUT REV, DOI 10.1177/0894439320907027
   Weiss ARR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01191
   Widjaja I, 2019, EMERG MICROBES INFEC, V8, P516, DOI 10.1080/22221751.2019.1597644
   Williamson B.N., 2020, BIORXIV
   Winau F, 2004, MICROBES INFECT, V6, P786, DOI 10.1016/j.micinf.2004.04.003
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xu TL, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006934
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yamamoto N., 2020, BIORXIV
   Yamasmith E., 2018, INTERNAL MED ONE HLT
   Yang SNY, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104760
   Yang Y., 2020, EXUBERANT ELEVATION
   Yao T.T., 2020, J MED VIROL
   Yao X, 2020, CLIN INFECT DIS
   Ye MX, 2020, J MED VIROL, V92, P1890, DOI 10.1002/jmv.25882
   Yu XJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep13133
   Zeng Q.-L., 2020, J INFECT DIS
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zheng H, 2020, CURR EYE RES, V45, P1043, DOI [10.1080/02713683.2020.1716986, 10.1080/10408398.2020.1740645]
   Zhou BP, 2007, NEW ENGL J MED, V357, P1450, DOI 10.1056/NEJMc070359
NR 156
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD NOV
PY 2020
VL 88
AR 106885
DI 10.1016/j.intimp.2020.106885
PG 13
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA OP6AD
UT WOS:000588166300125
PM 32795893
OA Green Published
DA 2021-01-01
ER

PT J
AU Kumar, V
AF Kumar, V
TI Understanding the complexities of SARS-CoV2 infection and its
   immunology: A road to immune-based therapeutics
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE SARS-CoV2; COVID-19; Immune response; Immunomodulation; Cytokines
ID RESPIRATORY SYNDROME CORONAVIRUS; NF-KAPPA-B; CONVERTING ENZYME TYPE-2;
   IFN-GAMMA-PRODUCTION; DENDRITIC CELLS; INFLAMMATORY RESPONSES;
   ENDOPLASMIC-RETICULUM; STRUCTURAL BASIS; BAT CORONAVIRUS; CLEAVAGE SITE
AB Emerging infectious diseases always pose a threat to humans along with plant and animal life. SARS-CoV2 is the recently emerged viral infection that originated from Wuhan city of the Republic of China in December 2019. Now, it has become a pandemic. Currently, SARS-CoV2 has infected more than 27.74 million people worldwide, and taken 901,928 human lives. It was named first 'WH 1 Human CoV' and later changed to 2019 novel CoV (2019-nCoV). Scientists have established it as a zoonotic viral disease emerged from Chinese horseshoe bats, which do not develop a severe infection. For example, Rhinolophus Chinese horseshoe bats harboring severe acute respiratory syndrome-related coronavirus (SARSr-CoV) or SARSr-Rh-BatCoV appear healthy and clear the virus within 2-4 months period. The article introduces first the concept of EIDs and some past EIDs, which have affected human life. Next section discusses mysteries regarding SARS-CoV2 origin, its evolution, and human transfer. Third section describes COVID-19 clinical symptoms and factors affecting susceptibility or resistance. The fourth section introduces the SARS-CoV2 entry in the host cell, its replication, and the establishment of productive infection. Section five describes the host's immune response associated with asymptomatic, symptomatic, mild to moderate, and severe COVID-19. The subsequent seventh and eighth sections mention the immune status in COVID-19 convalescent patients and re-emergence of COVID-19 in them. Thereafter, the eighth section describes viral strategies to hijack the host antiviral immune response and generate the "cytokine storm". The ninth section describes about transgenic humane ACE2 (hACE2) receptor expressing mice to study immunity, drugs, and vaccines. The article ends with the development of different immunomodulatory and immunotherapeutics strategies, including vaccines waiting for their approval in humans as prophylaxis or treatment measures.
C1 [Kumar, V] Univ Queensland, Fac Med, Sch Clin Med, Childrens Hlth Queensland Clin Unit,Mater Res, Brisbane, Qld 4078, Australia.
   [Kumar, V] Univ Queensland, Fac Med, Sch Biomed Sci, Brisbane, Qld 4078, Australia.
RP Kumar, V (corresponding author), Univ Queensland, Fac Med, Childrens Hlth Clin Unit, Mater Res, Brisbane, Qld 4078, Australia.
EM vij_tox@yahoo.com
CR Ahn J, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0333-0
   Akhtar H., 2020, GYNECOL OBSTET INVES
   Al-Omari A, 2019, DIAGN MICR INFEC DIS, V93, P265, DOI 10.1016/j.diagmicrobio.2018.10.011
   Allen IC, 2011, IMMUNITY, V34, P854, DOI 10.1016/j.immuni.2011.03.026
   Allocati N, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.48
   [Anonymous], 2020, BIORXIV
   Arunachalam P.S., 2020, SCIENCE
   Atyeo C., IMMUNITY
   BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97
   Bais C, 1998, NATURE, V391, P86
   Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Bao Y, 2014, CELL RES, V24, P161, DOI 10.1038/cr.2013.155
   Barnes C.O., 2020, CELL
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   Barron E., 2020, LANCET DIABETES ENDO
   Baseler L, 2017, ANNU REV PATHOL-MECH, V12, P387, DOI 10.1146/annurev-pathol-052016-100506
   Baud D, 2020, JAMA-J AM MED ASSOC, V323, P2198, DOI 10.1001/jama.2020.7233
   Behr FM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00400
   Beigel J. H., 2020, N ENGL J MED
   Bevan MJ, 2004, NAT REV IMMUNOL, V4, P595, DOI 10.1038/nri1413
   Bian H., 2020, 20040691 MEDRXIV
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Boada-Romero E, 2020, NAT REV MOL CELL BIO, DOI 10.1038/s41580-020-0232-1
   Boni MF, 2020, NAT MICROBIOL, V5, P1408, DOI 10.1038/s41564-020-0771-4
   Bosch BJ, 2008, J VIROL, V82, P8887, DOI 10.1128/JVI.00415-08
   Bosque A, 2005, EUR J IMMUNOL, V35, P1812, DOI 10.1002/eji.200526046
   Bost P, 2020, CELL, V181, P1475, DOI 10.1016/j.cell.2020.05.006
   Boulware D.R., 2020, N ENGL J MED
   Braga FAV, 2015, EUR J IMMUNOL, V45, P2945, DOI 10.1002/eji.201545650
   Branch DR, 2015, TRANSFUSION, V55, pS74, DOI 10.1111/trf.13087
   Brann D, 2020, NONNEURAL EXPRESSION, DOI [10.1101/2020.03.25.009084, DOI 10.1101/2020.03.25.009084, 10.1101/2020.03.25.009084.]
   Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9
   Bronte V, 2020, J CLIN INVEST
   Brook CE, 2015, TRENDS MICROBIOL, V23, P172, DOI 10.1016/j.tim.2014.12.004
   Brumeanu T.D., 2020, BIORXIV
   Byun HJ, 2007, CELL BIOL INT, V31, P257, DOI 10.1016/j.cellbi.2006.11.002
   Cagliani R, 2020, J VIROL, V94, DOI 10.1128/JVI.00411-20
   Cao WCC, 2007, NEW ENGL J MED, V357, P1162, DOI 10.1056/NEJMc070348
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Case J.B., 2020, CELL HOST MICROBE
   Cavalcanti A.B., 2020, NEW ENGLAND J MED
   Centers for Disease Control (CDC), 1981, MMWR Morb Mortal Wkly Rep, V30, P305
   Chai X, 2020, BIORXIV
   Chang SC, 2005, CLIN DIAGN LAB IMMUN, V12, P1455, DOI 10.1128/CDLI.12.12.1455-1457.2005
   Chen C., 2020, CLIN TRANSL MED
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Chen IY, 2015, TRENDS MICROBIOL, V23, P55, DOI 10.1016/j.tim.2014.09.007
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Cheng YF, 2005, JAMA-J AM MED ASSOC, V293, P1450, DOI 10.1001/jama.293.12.1450-c
   Cho E, 2012, ELECTROCHEM COMMUN, V22, P1, DOI 10.1016/j.elecom.2012.05.018
   Cordova ZM, 2016, ONCOTARGET, V7, P54392, DOI 10.18632/oncotarget.11106
   Cottam EM, 2011, AUTOPHAGY, V7, P1335, DOI 10.4161/auto.7.11.16642
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Cugno M., J ALLERGY CLIN IMMUN
   Cush SS, 2007, J IMMUNOL, V179, P141, DOI 10.4049/jimmunol.179.1.141
   da Silva HB, 2020, IMMUNITY, V53, P158, DOI 10.1016/j.immuni.2020.06.010
   da Silva IP, 2014, CANCER IMMUNOL RES, V2, P410, DOI 10.1158/2326-6066.CIR-13-0171
   Davis SM, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1326-y
   de Lartigue J, 2009, TRAFFIC, V10, P883, DOI 10.1111/j.1600-0854.2009.00915.x
   De Luca G., LANCET RHEUMATOLOGY
   Di Mascio Daniele, 2020, Am J Obstet Gynecol MFM, V2, P100107, DOI 10.1016/j.ajogmf.2020.100107
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Dimopoulos G., 2020, CELL HOST MICROBE
   Dinnon KH, 2020, NATURE, DOI 10.1038/s41586-020-2708-8
   Dolin R., 2020, NEW ENGLAND J MED
   Dong C, 2008, NAT REV IMMUNOL, V8, P337, DOI 10.1038/nri2295
   Dong R, 2020, GENES-BASEL, V11, DOI 10.3390/genes11060637
   Eaglesham James B, 2020, Curr Opin Immunol, V66, P27, DOI 10.1016/j.coi.2020.04.002
   Eastman RT, 2020, ACS CENTRAL SCI, V6, P672, DOI 10.1021/acscentsci.0c00489
   Ellinghaus D, 2020, N ENGL J MED
   Escher R, 2020, THROMB RES, V190, P62, DOI 10.1016/j.thromres.2020.04.014
   Fan C., 2020, 20022418 MEDRXIV
   Fauver J.R., 2020, CELL
   Feeley EM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002337
   Ferguson CJ, 2009, HUM MOL GENET, V18, P4868, DOI 10.1093/hmg/ddp460
   Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Forsman A, 2008, J VIROL, V82, P12069, DOI 10.1128/JVI.01379-08
   Fransen F, 2015, IMMUNITY, V43, P527, DOI 10.1016/j.immuni.2015.08.011
   Franzetti M., 2020, INT J INFECT DIS
   Frucht DM, 2001, TRENDS IMMUNOL, V22, P556, DOI 10.1016/S1471-4906(01)02005-1
   Frumento G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00468
   Fung TS, 2019, ANNU REV MICROBIOL, V73, P529, DOI 10.1146/annurev-micro-020518-115759
   GALILI U, 1988, INFECT IMMUN, V56, P1730, DOI 10.1128/IAI.56.7.1730-1737.1988
   Gao DX, 2013, SCIENCE, V341, P903, DOI 10.1126/science.1240933
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Gao T, 2020, 20041962 MEDRXIV
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Giamarellos-Bourboulis E.J., 2020, J CLIN INVEST, V27
   Girbl T, 2018, IMMUNITY, V49, P1062, DOI 10.1016/j.immuni.2018.09.018
   Giudice V, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00857
   Glezen WP, 1996, EPIDEMIOL REV, V18, P64, DOI 10.1093/oxfordjournals.epirev.a017917
   Goel S, 2015, NAT MED, V21, P314, DOI 10.1038/nm.3812
   Goldstein T, 2018, NAT MICROBIOL, V3, P1084, DOI 10.1038/s41564-018-0227-2
   Gong F., 2020, J CLIN INVEST
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Goubau D, 2013, IMMUNITY, V38, P855, DOI 10.1016/j.immuni.2013.05.007
   Gralinski LE, 2018, MBIO, V9, DOI 10.1128/mBio.01753-18
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Gruber C, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0335-0
   Gu J., 2020, GASTROENTEROLOGY
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guaraldi G., LANCET RHEUMATOLOGY
   Gudbjartsson DF, 2020, N ENGL J MED
   Guo JY, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016219
   Hachim MY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01372
   Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027
   Hamilton JA, 2008, NAT REV IMMUNOL, V8, P533, DOI 10.1038/nri2356
   Harjunpaa H, 2020, CLIN EXP IMMUNOL, V200, P108, DOI 10.1111/cei.13407
   Hartmann G, 2017, ADV IMMUNOL, V133, P121, DOI 10.1016/bs.ai.2016.11.001
   Hassan AO, 2020, CELL, V182, P744, DOI 10.1016/j.cell.2020.06.011
   Hegerova L, 2020, BLOOD, V136, P759, DOI 10.1182/blood.2020006964
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Hosier H, 2020, J CLIN INVEST, V130, P4947, DOI 10.1172/JCI139569
   Hou YXJ, 2020, CELL, V182, P429, DOI 10.1016/j.cell.2020.05.042
   Hu D, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0155-5
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang FH, 2019, MATER CHEM FRONT, V3, P10, DOI 10.1039/c8qm90057d
   Huang IC, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001258
   Huet T, 2020, LANCET RHEUMATOL, V2, pE393, DOI 10.1016/S2665-9913(20)30164-8
   Hung I.F.-N., 2020, LANCET INFECT DIS
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Hung SC, 2018, MICROBES INFECT, V20, P615, DOI 10.1016/j.micinf.2017.09.014
   Huo J., 2020, NAT STRUCT MOL BIOL
   Huo J., 2020, CELL HOST MICROBE
   Ibarrondo FJ, 2020, NEW ENGL J MED, V383
   Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317
   Ishikawa H, 2009, NATURE, V461, P788, DOI 10.1038/nature08476
   Iwanaga N., 2020, BIORXIV
   Jackson L.A., 2020, N ENGL J MED
   Jaigirdar SA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01627
   Janssen EM, 2005, NATURE, V434, P88, DOI 10.1038/nature03337
   Janssens K, 2014, J NEUROIMMUNOL, V275, P155, DOI 10.1016/j.jneuroim.2014.08.414
   Ji HL, 2020, PHYSIOL REV, V100, P1065, DOI 10.1152/physrev.00013.2020
   Ji W, 2020, J MED VIROL, V92, P433, DOI 10.1002/jmv.25682
   Jiang RD, 2020, CELL, V182, P50, DOI 10.1016/j.cell.2020.05.027
   Jin JM, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00152
   Jin Z, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00263
   Jones KE, 2008, NATURE, V451, P990, DOI 10.1038/nature06536
   Joyce M.G., 2020, BIORXIV
   Joyner MJ, 2020, J CLIN INVEST, V130, P4791, DOI 10.1172/JCI140200
   Juan J., 2020, ULTRASOUND OBSTET GY
   Junttila IS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00888
   Kaech SM, 2001, NAT IMMUNOL, V2, P415
   Kajani R., 2020, BRAIN BEHAV IMMUN
   Kamitaki N, 2020, NATURE, V582, P577, DOI 10.1038/s41586-020-2277-x
   Kasper LH, 2014, ANN CLIN TRANSL NEUR, V1, P622, DOI 10.1002/acn3.84
   Kelvin A.A., 2020, LANCET INFECT DIS
   Khan A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1823-x
   Khan M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00167
   Kilbourne ED, 2006, EMERG INFECT DIS, V12, P9, DOI 10.3201/eid1201.051254
   Kindhauser MK, 2016, B WORLD HEALTH ORGAN, V94, P675, DOI 10.2471/BLT.16.171082
   Klann K., MOL CELL
   Klein S.L., 2020, J CLIN INVEST
   Komatsu T, 1998, CYTOKINE GROWTH F R, V9, P277, DOI 10.1016/S1359-6101(98)00017-3
   Kondo T, 2012, BIOCHEM BIOPH RES CO, V422, P501, DOI 10.1016/j.bbrc.2012.05.028
   Kopp E, 1999, GENE DEV, V13, P2059, DOI 10.1101/gad.13.16.2059
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Kragten NAM, 2018, EUR J IMMUNOL, V48, P1644, DOI 10.1002/eji.201847771
   Kulkarni R, 2020, INFECTION, DOI 10.1007/s15010-020-01493-6
   Kumagai Y, 2011, IMMUNITY, V35, P320, DOI 10.1016/j.immuni.2011.09.003
   Kumar V, 2010, INT IMMUNOPHARMACOL, V10, P1325, DOI 10.1016/j.intimp.2010.08.012
   Kumar V, 2009, J CHEMOTHERAPY, V21, P159, DOI 10.1179/joc.2009.21.2.159
   Kumar V., 2020, INT REV IMMUNOL
   Kumar V, 2008, EUR J PHARMACOL, V592, P146, DOI 10.1016/j.ejphar.2008.07.019
   Kumar V, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01722
   Kumar V, 2020, INT REV IMMUNOL, V39, P118, DOI [10.1080/08830185.2020.1732958, 10.1080/08830185.2020.1800688]
   Kumar V, 2019, J LEUKOCYTE BIOL, V106, P171, DOI 10.1002/JLB.4MIR1018-397RR
   Kumar V, 2010, INT IMMUNOPHARMACOL, V10, P777, DOI 10.1016/j.intimp.2010.04.008
   Kuri-Cervantes L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd7114
   Laing A.G., 2020, NAT MED
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   Lamers MM, 2020, SCIENCE, V369, P50, DOI 10.1126/science.abc1669
   Lane BR, 2002, J VIROL, V76, P11570, DOI 10.1128/JVI.76.22.11570-11583.2002
   Lane BR, 2001, J VIROL, V75, P5812, DOI 10.1128/JVI.75.13.5812-5822.2001
   LANGMUIR AD, 1961, AM REV RESPIR DIS, V83, P2
   Lau SKP, 2010, J VIROL, V84, P2808, DOI 10.1128/JVI.02219-09
   Lee PY, 2013, J LEUKOCYTE BIOL, V94, P585, DOI 10.1189/jlb.0113014
   Lee WB, 2019, BMB REP, V52, P133, DOI 10.5483/BMBRep.2019.52.2.129
   Lei CQ, 2015, J INNATE IMMUN, V7, P153, DOI 10.1159/000365971
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Leverkus M, 2000, BLOOD, V96, P2628
   Li X., 2020, J MED VIROL
   Li XD, 2013, SCIENCE, V341, P1390, DOI 10.1126/science.1244040
   Li Y, 2013, MICROBES INFECT, V15, P88, DOI 10.1016/j.micinf.2012.10.008
   Li YZ, 2016, P NATL ACAD SCI USA, V113, P2241, DOI 10.1073/pnas.1519657113
   Lian SJ, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004328
   Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9
   Ligthart S, 2014, ARTERIOSCL THROM VAS, V34, P2695, DOI 10.1161/ATVBAHA.114.304306
   Lim Yvonne Xinyi, 2016, Diseases, V4, DOI 10.3390/diseases4030026
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu JY, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02374-0
   Liu L, 2020, MICROBES INFECT, V22, P206, DOI 10.1016/j.micinf.2020.05.008
   Liu P, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008421
   Lo MK, 2017, SCI REP-UK, V7, DOI 10.1038/srep43395
   Long Q.-X., 2020, NAT MED
   LoPresti M., 2020, ROLE HOST GENETIC FA
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luo HB, 2006, INT J BIOCHEM CELL B, V38, P589, DOI 10.1016/j.biocel.2005.10.022
   Ma Y, 2020, MICROBES INFECT, V22, P212, DOI 10.1016/j.micinf.2020.04.011
   MacLean O.A., 2020, BIORXIV
   Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   Maier HJ, 2012, VIRUSES-BASEL, V4, P3440, DOI 10.3390/v4123440
   Mangalmurti N, 2020, IMMUNITY, V53, P19, DOI 10.1016/j.immuni.2020.06.017
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Martinelli I, 2020, THROMB RES, V191, P36, DOI 10.1016/j.thromres.2020.04.022
   Mastellos DC, 2019, NAT REV DRUG DISCOV, V18, P707, DOI 10.1038/s41573-019-0031-6
   MAURER FD, 1962, J AM VET MED ASSOC, V141, P699
   Mazzoni A, 2020, J CLIN INVEST, V130, P4694, DOI [10.1172/JCI138554, 10.1172/JCI138554.]
   McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06
   Meckiff B.J., 2020, BIORXIV
   Menachery VD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131451
   Metcalfe SM, 2011, GENES IMMUN, V12, P157, DOI 10.1038/gene.2011.9
   MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0
   Mizumoto K, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.10.2000180
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Monteiro JM, 1998, J VIROL, V72, P4825, DOI 10.1128/JVI.72.6.4825-4831.1998
   Moreno-Eutimio MA, 2020, MICROBES INFECT, V22, P226, DOI 10.1016/j.micinf.2020.04.009
   Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012
   Morokata T, 1999, IMMUNOLOGY, V98, P345, DOI 10.1046/j.1365-2567.1999.00890.x
   MORRIS SC, 1994, J IMMUNOL, V152, P1047
   Nagai-Singer MA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02419
   Ndow G., 2019, SOCIOCULTURAL DIMENS, P31
   Neuman BW, 2014, TRENDS MICROBIOL, V22, P642, DOI 10.1016/j.tim.2014.06.003
   Neuman BW, 2011, J STRUCT BIOL, V174, P11, DOI 10.1016/j.jsb.2010.11.021
   Ni GX, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007148
   Ni L., 2020, IMMUNITY, V52
   Nie Q, 2020, VIRUS RES, V287, DOI 10.1016/j.virusres.2020.198098
   Nielsen S.C.A., 2020, RES SQ
   O'Connor BP, 2003, IMMUNOL REV, V194, P61, DOI 10.1034/j.1600-065X.2003.00055.x
   ORANGE JS, 1994, J IMMUNOL, V152, P1253
   Ostrowski LE, 2003, MOL THER, V8, P637, DOI 10.1016/S1525-0016(03)00221-1
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Oxenius A, 1999, J IMMUNOL, V162, P965
   Pallanti S, 2020, COMPR PSYCHIAT, V100, DOI 10.1016/j.comppsych.2020.152184
   Panigada M, 2020, J THROMB HAEMOST, V18, P1738, DOI 10.1111/jth.14850
   Papillion A, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw7636
   Peckham H.a.d.G., 2020, LANCET INFECT DIS
   Pedersen S.F., 2020, J CLIN INVEST
   Pelonero AL, 1998, PSYCHIATR SERV, V49, P1163, DOI 10.1176/ps.49.9.1163
   Pesu M, 2006, BLOOD, V108, P983, DOI 10.1182/blood-2005-09-3824
   Pique-Regi R, 2020, ELIFE, V9, DOI 10.7554/eLife.58716
   Pizzorno A., 2020, CELL REP MED, V1
   Pontelli M.C., 2020, BIORXIV
   Post M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00535
   Prentice E, 2004, J VIROL, V78, P9977, DOI 10.1128/JVI.78.18.9977-9986.2004
   Prentice E, 2004, J BIOL CHEM, V279, P10136, DOI 10.1074/jbc.M306124200
   Preston JA, 2004, EUR RESPIR J, V23, P224, DOI 10.1183/09031936.03.00081403
   PUDDINGTON L, 1994, IMMUNITY, V1, P733, DOI 10.1016/S1074-7613(94)80015-4
   Rabb H, 2020, J CLIN INVEST, V130, P2749, DOI 10.1172/JCI138871
   Radzikowska U, 2020, ALLERGY, V75, P2829, DOI 10.1111/all.14429
   Ramasamy S, 2016, P NATL ACAD SCI USA, V113, P1871, DOI 10.1073/pnas.1511380113
   Ramlall V, 2020, NAT MED, V26, P1609, DOI 10.1038/s41591-020-1021-2
   Ratajczak MZ, 2020, STEM CELL REV REP, V16, P1, DOI 10.1007/s12015-019-09951-x
   Rehwinkel J, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0288-3
   Reis FM, 2011, FERTIL STERIL, V95, P176, DOI 10.1016/j.fertnstert.2010.06.060
   Renshaw SA, 2003, J IMMUNOL, V170, P1027, DOI 10.4049/jimmunol.170.2.1027
   RICHMOND A, 1986, J CELL PHYSIOL, V129, P375, DOI 10.1002/jcp.1041290316
   Risitano AM, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0320-7
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Rodrigues-Diez R.R., 2020, BRIT J PHARMACOL
   Rodriguez L., 2020, CELL REPORTS MED, V1
   Roschewski M, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd0110
   Rowe JA, 2007, P NATL ACAD SCI USA, V104, P17471, DOI 10.1073/pnas.0705390104
   Rutherford AC, 2006, J CELL SCI, V119, P3944, DOI 10.1242/jcs.03153
   Sage PT, 2016, NAT IMMUNOL, V17, P1436, DOI 10.1038/ni.3578
   Sage PT, 2014, J CLIN INVEST, V124, P5191, DOI 10.1172/JCI76861
   Sanchez-Cerrillo I., 2020, J CLIN INVEST
   Sattler A., 2020, J CLIN INVEST, P40965
   Schafer S, 2017, NATURE, V552, P110, DOI 10.1038/nature24676
   Schijns VECJ, 1998, J IMMUNOL, V160, P3958
   Schlottau K., LANCET MICROBE
   Schmidt F, 2020, J EXP MED, V217, DOI 10.1084/jem.20201181
   Schoch-Spana M, 2001, PUBLIC HEALTH REP, V116, P32, DOI 10.1016/S0033-3549(04)50137-1
   Schultheiss C, 2020, IMMUNITY, V53, P442, DOI 10.1016/j.immuni.2020.06.024
   Schutyser E, 2005, J LEUKOCYTE BIOL, V78, P14, DOI 10.1189/jlb.1204712
   Schwartz DA, 2017, ARCH PATHOL LAB MED, V141, P18, DOI [10.5858/arpa.2016-0429-ED, 10.5858/arpa.2016-04]
   Scully EP, 2020, NAT REV IMMUNOL, V20, P442, DOI 10.1038/s41577-020-0348-8
   Sehra S.T., 2020, CLIN INFECT DIS
   Sekine T, 2020, CELL
   Sevajol M, 2014, VIRUS RES, V194, P90, DOI 10.1016/j.virusres.2014.10.008
   Seydoux E., ANAL SARS COV 2 INFE
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Sharma A., 2020, CELL REP MED, V1
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shen C, 2020, JAMA
   Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y
   Shisheva A, 2008, CELL BIOL INT, V32, P591, DOI 10.1016/j.cellbi.2008.01.006
   Shubin NJ, 2013, CRIT CARE, V17, DOI 10.1186/cc13131
   Shubin NJ, 2012, J LEUKOCYTE BIOL, V92, P593, DOI 10.1189/jlb.1211641
   Silvin A., CELL
   Singh K., 2020, NETWORK ANAL TRANSCR
   Sisman J., PEDIAT INFECT DIS J
   Siu YL, 2008, J VIROL, V82, P11318, DOI 10.1128/JVI.01052-08
   Skendros P., 2020, J CLIN INVEST
   Smith NL, 2011, CIRCULATION, V123, P1864, DOI 10.1161/CIRCULATIONAHA.110.009480
   Song J.W., 2020, CELL METAB
   Spence JS, 2019, NAT CHEM BIOL, V15, P259, DOI 10.1038/s41589-018-0213-2
   Starr T.N., 2020, CELL
   Sun J, 2020, CELL, V182, P734, DOI 10.1016/j.cell.2020.06.010
   Sun SH, 2020, CELL HOST MICROBE, V28, P124, DOI 10.1016/j.chom.2020.05.020
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Suthar M.S., 2020, CELL REP MED, V1
   Tabata S., 2020, LANCET INFECT DIS
   Takahashi T, 2020, NATURE
   Tan CW, 2020, NAT BIOTECHNOL, V38, P1073, DOI 10.1038/s41587-020-0631-z
   Tang FSM, 2016, RESPIROLOGY, V21, P172, DOI 10.1111/resp.12657
   Tang W, 2020, HYDROXYCHLOROQUINE P, DOI [10.1101/2020.04.10.20060558, DOI 10.1101/2020.04.10.20060558]
   Tang W., 2020, HYDROXYCHLOROQUINE P
   Tchesnokov E.P., 2019, VIRUSES, V4, P11
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Tilocca B, 2020, MICROBES INFECT, V22, P182, DOI 10.1016/j.micinf.2020.05.013
   Timoteo RP, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/7151285
   Tong L, 2020, ADV THEOR SIMUL, V3, DOI 10.1002/adts.202000024
   Torabi A, 2020, ACS CHEM NEUROSCI, V11, P1909, DOI 10.1021/acschemneuro.0c00249
   Totura AL, 2015, MBIO, V6, DOI 10.1128/mBio.00638-15
   Ulrich H, 2020, STEM CELL REV REP, V16, P434, DOI 10.1007/s12015-020-09976-7
   Unger JP, 2020, INT J HEALTH SERV, DOI 10.1177/0020731420946590
   Upadhyay G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00819
   Ursini-Siegel J, 2002, J IMMUNOL, V169, P5505, DOI 10.4049/jimmunol.169.10.5505
   V'kovski P, 2015, VIRUS RES, V202, P33, DOI 10.1016/j.virusres.2014.12.021
   Vaira L.A., 2020, INT FORUM ALLERGY RH
   van Gisbergen KPJM, 2005, FEBS LETT, V579, P6159, DOI 10.1016/j.febslet.2005.09.089
   van Gisbergen KPJM, 2005, J EXP MED, V201, P1281, DOI 10.1084/jem.20041276
   Vaz-Silva J, 2009, REPROD SCI, V16, P247, DOI 10.1177/1933719108327593
   Viboud C, 2016, J INFECT DIS, V213, P738, DOI 10.1093/infdis/jiv534
   Vijay K, 2018, INT IMMUNOPHARMACOL, V59, P391, DOI 10.1016/j.intimp.2018.03.002
   Vivanti AJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17436-6
   Wakeham J, 2000, INFECT IMMUN, V68, P6946, DOI 10.1128/IAI.68.12.6946-6953.2000
   Walls A.C., CELL
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang C, 2009, NAT IMMUNOL, V10, P744, DOI 10.1038/ni.1742
   Wang K, 2020, SARS COV 2 INVADES H, V3, P14, DOI DOI 10.1101/2020.03.14.988345
   Wang N., CELL HOST MICROBE
   Wang Q, 2020, CELL, V182, P417, DOI 10.1016/j.cell.2020.05.034
   Wang R., 2020, BIOINFORMATIC ANAL R
   Wang Y., 2020, J CLIN INVEST, V130
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Wauters E., 2020, BIORXIV
   Wee YS, 2012, INNATE IMMUN-LONDON, V18, P834, DOI 10.1177/1753425912443392
   Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071
   West NR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01093
   Wi SM, 2014, J BIOL CHEM, V289, P35205, DOI 10.1074/jbc.M114.597187
   Wilk AJ, 2020, NAT MED, V26, P1070, DOI 10.1038/s41591-020-0944-y
   Williamson B.N., 2020, BIORXIV
   Winkler E.S., 2020, NAT IMMUNOL
   Wolf Y, 2020, NAT REV IMMUNOL, V20, P173, DOI 10.1038/s41577-019-0224-6
   Woolhouse M, 2007, CRIT REV MICROBIOL, V33, P231, DOI 10.1080/10408410701647560
   Wrapp D, 2020, CELL, V181, P1004, DOI 10.1016/j.cell.2020.04.031
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu J, 2020, BMJ OPEN DIAB RES CA, V8, P1, DOI [10.1136/bmjdrc-2020-0014767298690, DOI 10.1136/BMJDRC-2020-0014767298690]
   Wu JJ, 2020, IMMUNITY, V53, P115, DOI 10.1016/j.immuni.2020.06.009
   Wu JJ, 2019, J EXP MED, V216, P867, DOI 10.1084/jem.20182192
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xia XJ, 2011, IMMUNITY, V34, P843, DOI 10.1016/j.immuni.2011.02.022
   Xia XY, 2020, BLOOD, V136, P755, DOI 10.1182/blood.2020007079
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Ye S, 2012, J BIOL CHEM, V287, P26740, DOI 10.1074/jbc.M112.383265
   Yoshimoto FK, 2020, PROTEIN J, V39, P198, DOI 10.1007/s10930-020-09901-4
   Young BE, 2020, LANCET, V396, P603, DOI 10.1016/S0140-6736(20)31757-8
   Yuan M, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101273
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Yuen KS, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00404-4
   Zang RC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc3582
   Zhang BC, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00157
   Zhang H., 2020, MATH PROBL ENG, V2020, P1, DOI DOI 10.1101/2020.01.30.927806
   Zhang Lizhou, 2020, bioRxiv, DOI 10.1101/2020.06.12.148726
   ZHANG Q, 2019, FRONT ENDOCRINOL, V11, P525, DOI DOI 10.1080/17565529.2018.1442808
   Zhang T., 2020, CURR BIOL
   Zhang T, 2020, J MATER CIVIL ENG, V32, DOI 10.1061/(ASCE)MT.1943-5533.0003063
   Zhang Y., 2020, MATTER, V2, P1
   Zhang ZN, 2020, MOL IMMUNOL, V122, P38, DOI 10.1016/j.molimm.2020.03.022
   Zhao B, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202002019
   Zhao CY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00211
   Zhao X., 2020, BIORXIV
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
   Zhou DRN, 2020, NAT STRUCT MOL BIOL, V27, P950, DOI 10.1038/s41594-020-0480-y
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou H, 2020, CURR BIOL, V30, P2196, DOI 10.1016/j.cub.2020.05.023
   Zhou J, 2020, NAT MED, V26, P1077, DOI 10.1038/s41591-020-0912-6
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou R., 2020, IMMUNITY
   Zhou Y., 2020, BIORXIV
   Zhou Z, 2020, CELL HOST MICROBE, V27, P883, DOI 10.1016/j.chom.2020.04.017
   Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6
   Zhu LH, 2020, CELL METAB, V31, P1068, DOI 10.1016/j.cmet.2020.04.021
   Zhu LX, 2020, MOL IMMUNOL, V122, P124, DOI 10.1016/j.molimm.2020.04.006
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
   Zlotnik A, 2012, IMMUNITY, V36, P705, DOI 10.1016/j.immuni.2012.05.008
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 404
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD NOV
PY 2020
VL 88
AR 106980
DI 10.1016/j.intimp.2020.106980
PG 37
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA OP6AD
UT WOS:000588166300130
PM 33182073
DA 2021-01-01
ER

PT J
AU Mirzaei, R
   Mohammadzadeh, R
   Mahdavi, F
   Badrzadeh, F
   Kazemi, S
   Ebrahimi, M
   Soltani, F
   Kazemi, S
   Jeda, AS
   Darvishmotevalli, M
   Yousefimashouf, R
   Keyvani, H
   Karampoor, S
AF Mirzaei, Rasoul
   Mohammadzadeh, Rokhsareh
   Mahdavi, Farzad
   Badrzadeh, Fariba
   Kazemi, Sheida
   Ebrahimi, Mehdi
   Soltani, Fatemeh
   Kazemi, Sima
   Jeda, Ali Salimi
   Darvishmotevalli, Mohammad
   Yousefimashouf, Rasoul
   Keyvani, Hossein
   Karampoor, Sajad
TI Overview of the current promising approaches for the development of an
   effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
   vaccine
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2; Immunopathogenesis; Vaccines
ID ANTIBODY-DEPENDENT ENHANCEMENT; RECEPTOR-BINDING DOMAIN; INFECTIOUS
   PERITONITIS VIRUS; ELICITS HIGH TITERS; B-CELL RESPONSES;
   SARS-CORONAVIRUS; IMMUNE-RESPONSES; NEUTRALIZING ANTIBODIES; SPIKE
   PROTEIN; MERS-COV
AB Coronavirus disease 2019 (COVID-19) is a pandemic infectious disease caused by the novel coronavirus called SARS-CoV-2. There is a gap in our understanding regarding the immunopathogenesis of COVID-19. However, many clinical trials are underway across the world for screening effective drugs against COVID-19. Nevertheless, currently, no proven effective therapies for this virus exists. The vaccines are deemed as a significant part of disease prevention for emerging viral diseases, since, in several cases, other therapeutic choices are limited or non-existent, or that diseases result in such an accelerated clinical worsening that the efficacy of treatments is restricted. Therefore, effective vaccines against COVID-19 are urgently required to overcome the tremendous burden of mortality and morbidity correlated with SARS-CoV-2. In this review, we will describe the latest evidence regarding outstanding vaccine approaches and the challenges for vaccine production.
C1 [Mirzaei, Rasoul; Kazemi, Sima; Yousefimashouf, Rasoul] Hamadan Univ Med Sci, Sch Med, Dept Microbiol, Hamadan, Iran.
   [Mirzaei, Rasoul] Hamadan Univ Med Sci, Student Res Comm, Hamadan, Iran.
   [Mohammadzadeh, Rokhsareh] Iran Univ Med Sci, Sch Med, Dept Microbiol, Tehran, Iran.
   [Mahdavi, Farzad] Guilan Univ Med Sci, Sch Med, Dept Med Parasitol & Mycol, Rasht, Iran.
   [Badrzadeh, Fariba] Golestan Univ Med Sci, Fac Med, Gorgan, Golestan, Iran.
   [Kazemi, Sheida] Univ Tehran Med Sci, Students Seientif Res Ctr, Tehran, Iran.
   [Ebrahimi, Mehdi] Guilan Univ Med Sci, Sch Hlth, Dept Environm Hlth, Rasht, Iran.
   [Soltani, Fatemeh] Azad Univ, Hlth Safety & Environm Management Dept, Ahvaz Branch, Ahvaz, Iran.
   [Jeda, Ali Salimi; Keyvani, Hossein; Karampoor, Sajad] Iran Univ Med Sci, Sch Med, Dept Virol, Tehran, Iran.
   [Darvishmotevalli, Mohammad] Alborz Univ Med Sci, Res Ctr Hlth Safety & Environm RCHSE, Karaj, Iran.
RP Mirzaei, R (corresponding author), Hamadan Univ Med Sci, Sch Med, Dept Microbiol, Hamadan, Iran.; Mirzaei, R (corresponding author), Hamadan Univ Med Sci, Student Res Comm, Hamadan, Iran.; Keyvani, H; Karampoor, S (corresponding author), Iran Univ Med Sci, Sch Med, Dept Virol, Tehran, Iran.
EM rasoul.micro92@gmail.com; keyvani.h@iums.ac.ir;
   sajadkarampoor1987@gmail.com
FU Hamadan University of Medical Sciences, Hamadan, Iran
FX This work was supported by the Hamadan University of Medical Sciences,
   Hamadan, Iran.
CR Abdulamir AS, 2020, ELECTRON J GEN MED, V17, DOI 10.29333/ejgm/7850
   Aguilar JC, 2007, VACCINE, V25, P3752, DOI 10.1016/j.vaccine.2007.01.111
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Alharbi NK, 2017, VACCINE, V35, P3780, DOI 10.1016/j.vaccine.2017.05.032
   Almazan F, 2013, MBIO, V4, DOI 10.1128/mBio.00650-13
   Amanat F., 2020, SARS COV 2 VACCINES
   [Anonymous], 2020, IVI INOVIO KNIH PART
   [Anonymous], 2020, FULL TITLE MULTI SIT
   [Anonymous], 2020, IMMUNITY SAFETY COVI
   Anton IM, 1996, VIRUS RES, V46, P111, DOI 10.1016/S0168-1702(96)01390-1
   Astuti I, 2020, DIABETES METAB SYND, V14, P407, DOI 10.1016/j.dsx.2020.04.020
   Bao L., 2020, PATHOGENICITY 2019 N, DOI [10.1101/2020.02. 07.939389., DOI 10.1101/2020.02.07.939389, 10.1101/2020.02.07.939389.]
   BioSpace, 2020, HOPES CHALLENGES COV
   Bodewes R, 2010, J VIROL, V84, P7943, DOI 10.1128/JVI.00549-10
   Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11
   Bonam SR, 2017, TRENDS PHARMACOL SCI, V38, P771, DOI 10.1016/j.tips.2017.06.002
   Bowick Gavin C, 2011, Bioeng Bugs, V2, P129, DOI 10.4161/bbug.2.3.15367
   C.C.T.R. (ChiCTR), 2020, RANDOMIZED DOUBLE BL
   Cai SZ, 2020, MOD RHEUMATOL, DOI 10.1080/14397595.2020.1823145
   Cascella M., 2020, FEATURES EVA LUATION
   Cavanagh D, 2003, AVIAN PATHOL, V32, P567, DOI 10.1080/03079450310001621198
   Chan CYY, 2019, MSPHERE, V4, DOI 10.1128/mSphere.00528-19
   Chan KR, 2014, P NATL ACAD SCI USA, V111, P2722, DOI 10.1073/pnas.1317454111
   Channappanavar R, 2014, J VIROL, V88, P11034, DOI 10.1128/JVI.01505-14
   Chen L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE005, DOI [10.3760/cma.j.issn.1001-0939.2020.03.013, 10.3760/cma.j.issn.1001-0939.2020.0005]
   Cho H, 2018, HUM VACC IMMUNOTHER, V14, P304, DOI 10.1080/21645515.2017.1389362
   clinicaltrials, 2020, PHASE II CLIN TRIAL
   clinicaltrials.gov, 2020, SAFETY IMMUNITY COVI
   clinicaltrials.gov, 2020, EVALUATION SAFETY IM
   clinicaltrials.gov, 2020, PHASE IB II TRIAL DE
   clinicaltrials.gov, 2020, STUDY CANDIDATE COVI
   clinicaltrials.gov, 2020, EVALUATING SAFETY TO
   clinicaltrials.gov, 2020, SAFETY TOLERABILITY
   clinicaltrials.gov, 2020, TABLETED COVID 19 TH
   clinicaltrials.gov, 2020, REDUCING HLTH CARE W
   clinicaltrials.gov, 2020, SAFETY IMMUNOGENICIT
   clinicaltrials.gov, 2020, MEASLES VACCINE HCW
   clinicaltrials.gov, 2020, PHASE I CLIN TRIAL C
   Coleman CM, 2017, VACCINE, V35, P1586, DOI 10.1016/j.vaccine.2017.02.012
   Coleman CM, 2014, VACCINE, V32, P3169, DOI 10.1016/j.vaccine.2014.04.016
   Coler RN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016333
   Cong YY, 2020, J VIROL, V94, DOI 10.1128/JVI.01925-19
   covid-vaccine-tracker, 2020, COVID VACCINE TRACKE
   de Alwis R, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102768
   de Haan CAM, 1998, J VIROL, V72, P6838, DOI 10.1128/JVI.72.8.6838-6850.1998
   Deming D, 2006, PLOS MED, V3, P2359, DOI 10.1371/journal.pmed.0030525
   Draper SJ, 2010, NAT REV MICROBIOL, V8, P62, DOI 10.1038/nrmicro2240
   Du L., 2013, PLOS ONE, V8
   Du LY, 2016, EXPERT REV VACCINES, V15, P1123, DOI 10.1586/14760584.2016.1167603
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Enjuanes L., 1995, DEV PROTECTION CORON, P197
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Gillim-Ross L, 2006, CLIN MICROBIOL REV, V19, P614, DOI 10.1128/CMR.00005-06
   GOULD EA, 1989, J GEN VIROL, V70, P1605, DOI 10.1099/0022-1317-70-6-1605
   Graham BS, 2013, IMMUNOL REV, V255, P230, DOI 10.1111/imr.12098
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gupta T, 2020, INT IMMUNOPHARMACOL, V86, DOI 10.1016/j.intimp.2020.106717
   He YX, 2004, BIOCHEM BIOPH RES CO, V325, P445, DOI 10.1016/j.bbrc.2004.10.052
   Hoffmann M, 2020, CELL
   Holmes KV, 2003, J CLIN INVEST, V111, P1605, DOI [10.1172/JCI18819, 10.1172/JCI200318819]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   IMLER JL, 1995, VACCINE, V13, P1143, DOI 10.1016/0264-410X(95)00032-V
   Iwasaki A, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0321-6
   Jiang S., 2020, NEUTRALIZING ANTIBOD
   Jiang SB, 2005, EMERG INFECT DIS, V11, P1016, DOI 10.3201/1107.050219
   Khandia R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00597
   Kim E, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102743
   Kim TW, 2004, J VIROL, V78, P4638, DOI 10.1128/JVI.78.9.4638-4645.2004
   Kobinger GP, 2007, VACCINE, V25, P5220, DOI 10.1016/j.vaccine.2007.04.065
   Koch T., 2020, LANCET INFECT DIS
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lakhan N, 2016, J IMMUNOL METHODS, V439, P37, DOI 10.1016/j.jim.2016.09.008
   Lamirande EW, 2008, J VIROL, V82, P7721, DOI 10.1128/JVI.00304-08
   Lan JM, 2015, EBIOMEDICINE, V2, P1438, DOI 10.1016/j.ebiom.2015.08.031
   Lan JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112602
   Leung DTM, 2004, J INFECT DIS, V190, P379, DOI 10.1086/422040
   Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490
   Li H, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105951
   Li TS, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000024
   Li TS, 2004, J INFECT DIS, V189, P648, DOI 10.1086/381535
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lin JT, 2007, ANTIVIR THER, V12, P1107
   Lin Y, 2003, CELL RES, V13, P141, DOI 10.1038/sj.cr.7290158
   Liu WJ, 2017, ANTIVIR RES, V137, P82, DOI 10.1016/j.antiviral.2016.11.006
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Ma CL, 2006, CELL MOL IMMUNOL, V3, P459
   Ma CQ, 2014, VACCINE, V32, P6170, DOI 10.1016/j.vaccine.2014.08.086
   Martin-Acebes MA, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00044
   Mo HY, 2005, CHINESE MED J-PEKING, V118, P446
   Mousavizadeh L., 2020, J MICROBIOL IMMUNOL
   Muthumani K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac7462
   Navas-Martin S, 2004, J NEUROVIROL, V10, P75, DOI 10.1080/13550280490280292
   Navas-Martin S, 2003, VIRAL IMMUNOL, V16, P461, DOI 10.1089/088282403771926292
   Ng OW, 2016, VACCINE, V34, P2008, DOI 10.1016/j.vaccine.2016.02.063
   Nimmerjahn F, 2014, P NATL ACAD SCI USA, V111, P2404, DOI 10.1073/pnas.1324286111
   OLSEN CW, 1993, VET MICROBIOL, V36, P1, DOI 10.1016/0378-1135(93)90126-R
   Ong EZ, 2017, SCI REP-UK, V7, DOI 10.1038/srep40923
   Ozma M.A., 2020, INF MED, V28
   P. Vaccinations, 2020, AD5 NCOV COVID 19 VA
   Parvin F., 2020, EUROP J PHYSIOTHERAP
   Pawelec G, 2020, IMMUN AGEING, V17, DOI 10.1186/s12979-020-00180-2
   Pourjafar M, 2019, IMMUNOTHERAPY-UK, V11, P795, DOI 10.2217/imt-2018-0213
   Qin C, 2020, CLIN INFECT DIS
   Qu D, 2005, VACCINE, V23, P924, DOI 10.1016/j.vaccine.2004.07.031
   Rajgor DD, 2020, LANCET INFECT DIS
   Ren W., 2020, BIORXIV
   Roberts A, 2008, VIRUS RES, V133, P20, DOI 10.1016/j.virusres.2007.03.025
   Rocha CD, 2004, INT MICROBIOL, V7, P83
   Rolph MS, 1997, CURR OPIN IMMUNOL, V9, P517, DOI 10.1016/S0952-7915(97)80104-5
   Roper RL, 2009, EXPERT REV VACCINES, V8, P887, DOI 10.1586/ERV.09.43
   Sanofi, 2020, SANOFI JOINS FORCES
   See RH, 2006, J GEN VIROL, V87, P641, DOI 10.1099/vir.0.81579-0
   See RH, 2005, CURR IMMUNOL REV, V1, P185, DOI [10.2174/1573395054065106, DOI 10.2174/1573395054065106]
   Stadler K, 2005, EMERG INFECT DIS, V11, P1312, DOI 10.3201/eid1108.041003
   T.W.H. Organization, 2020, CORONAVIRUS DIS COVI
   Tai WB, 2016, VIROLOGY, V499, P375, DOI 10.1016/j.virol.2016.10.005
   Takasuka N, 2004, INT IMMUNOL, V16, P1423, DOI 10.1093/intimm/dxh143
   Tang F, 2011, J IMMUNOL, V186, P7264, DOI 10.4049/jimmunol.0903490
   Tang J, 2015, HUM VACC IMMUNOTHER, V11, P1244, DOI 10.1080/21645515.2015.1021527
   Tang X, 2020, NATL SCI REV
   Tekes G, 2016, ADV VIRUS RES, V96, P193, DOI 10.1016/bs.aivir.2016.08.002
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Tirado SMC, 2003, VIRAL IMMUNOL, V16, P69, DOI 10.1089/088282403763635465
   Tufan A, 2020, TURK J MED SCI, V50, P620, DOI 10.3906/sag-2004-168
   U.S. Pharmacist, 2020, THREE STRATEGIES EME
   van Doremalen N., 2020, BIORXIV
   VENNEMA H, 1990, J VIROL, V64, P1407, DOI 10.1128/JVI.64.3.1407-1409.1990
   Volz A, 2015, J VIROL, V89, P8651, DOI 10.1128/JVI.00614-15
   Wan S., 2020, CHARACTERISTICS LYMP
   Wan Y., 2020, J VIROL, V94
   Wang C, 2017, ONCOTARGET, V8, P12686, DOI 10.18632/oncotarget.8475
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang JQ, 2003, CLIN CHEM, V49, P1989, DOI 10.1373/clinchem.2003.023184
   Wang L., 2015, TRANSBOUND EMERG DIS, V6, P1, DOI DOI 10.1038/NC0MMS8712
   Wang XH, 2008, IMMUNOL LETT, V119, P71, DOI 10.1016/j.imlet.2008.04.005
   Warimwe GM, 2016, SCI REP-UK, V6, DOI 10.1038/srep20617
   Wilder-Smith A, 2019, LANCET, V393, P350, DOI 10.1016/S0140-6736(18)32560-1
   Xiong S, 2004, IMMUNOL LETT, V95, P139, DOI 10.1016/j.imlet.2004.06.014
   Xu XJ, 2004, CELL MOL IMMUNOL, V1, P119
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
   Yang ZY, 2005, P NATL ACAD SCI USA, V102, P797, DOI 10.1073/pnas.0409065102
   Yip M S, 2016, Hong Kong Med J, V22, P25
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zakhartchouk AN, 2005, VACCINE, V23, P4385, DOI 10.1016/j.vaccine.2005.04.011
   Zhang NR, 2016, CELL MOL IMMUNOL, V13, P180, DOI 10.1038/cmi.2015.03
   Zhong XF, 2005, J VIROL, V79, P3401, DOI 10.1128/JVI.79.6.3401-3408.2005
   Zhou ZM, 2006, VACCINE, V24, P3624, DOI 10.1016/j.vaccine.2006.01.059
   Zhu F.-C., LANCET
   Zhu F.-C., 2020, LANCET
   Zhu MS, 2004, IMMUNOL LETT, V92, P237, DOI 10.1016/j.imlet.2004.01.001
   Zust R, 2007, PLOS PATHOG, V3, P1062, DOI 10.1371/journal.ppat.0030109
NR 151
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD NOV
PY 2020
VL 88
AR 106928
DI 10.1016/j.intimp.2020.106928
PG 14
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA OP6AD
UT WOS:000588166300103
PM 32862110
OA Green Published
DA 2021-01-01
ER

PT J
AU Owji, H
   Negahdaripour, M
   Hajighahramani, N
AF Owji, Hajar
   Negahdaripour, Manica
   Hajighahramani, Nasim
TI Immunotherapeutic approaches to curtail COVID-19
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE COVID-19; Pandemic; Severe acute respiratory syndrome coronavirus 2;
   Antibodies; Plasma therapy; Immunotherapy
ID ACUTE RESPIRATORY SYNDROME; HUMAN MONOCLONAL-ANTIBODIES; SYNDROME SARS
   CORONAVIRUS; PAPAIN-LIKE PROTEASE; NEUTRALIZING ANTIBODIES; POTENT
   NEUTRALIZATION; CONVALESCENT PLASMA; KINASE INHIBITORS; CELL ENTRY;
   BINDING
AB COVID-19, the disease induced by the recently emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has imposed an unpredictable burden on the world. Drug repurposing has been employed to rapidly find a cure; but despite great efforts, no drug or vaccine is presently available for treating or prevention of COVID-19. Apart from antivirals, immunotherapeutic strategies are suggested considering the role of the immune response as the host defense against the virus, and the fact that SARS-CoV-2 suppresses interferon induction as an immune evasion strategy. Active immunization through vaccines, interferon administration, passive immunotherapy by convalescent plasma or synthesized monoclonal and polyclonal antibodies, as well as immunomodulatory drugs, are different immunotherapeutic approaches that will be mentioned in this review. The focus would be on passive immunotherapeutic interventions.
   Interferons might be helpful in some stages. Vaccine development has been followed with unprecedented speed. Some of these vaccines have been advanced to human clinical trials. Convalescent plasma therapy is already practiced in many countries to help save the lives of severely ill patients. Different antibodies that target various steps of SARS-CoV-2 pathogenesis or the associated immune responses are also proposed.
   For treating the cytokine storm induced at a late stage of the disease in some patients, immune modulation through JAK inhibitors, corticosteroids, and some other cognate classes are evaluated.
   Given the changing pattern of cytokine induction and immune responses throughout the COVID-19 disease course, different adapted approaches are needed to help patients. Gaining more knowledge about the detailed pathogenesis of SARS-CoV-2, its interplay with the immune system, and viral-mediated responses are crucial to identify efficient preventive and therapeutic approaches. A systemic approach seems essential in this regard.
C1 [Owji, Hajar; Negahdaripour, Manica] Shiraz Univ Med Sci, Pharmaceut Sci Res Ctr, Shiraz, Iran.
   [Negahdaripour, Manica] Shiraz Univ Med Sci, Sch Pharm, Dept Pharmaceut Biotechnol, POB 71345-1583, Shiraz, Iran.
   [Hajighahramani, Nasim] Ardabil Univ Med Sci, Sch Pharm, Dept Pharmaceut Biotechnol, Ardebil, Iran.
RP Negahdaripour, M (corresponding author), Shiraz Univ Med Sci, Sch Pharm, Dept Pharmaceut Biotechnol, POB 71345-1583, Shiraz, Iran.
EM negahdaripour@sums.ac.ir
FU Research Council of Shiraz University of Medical Sciences, Shiraz, Iran
   [99-01-36-23491]
FX This study was supported by Grant No. 99-01-36-23491 from the Research
   Council of Shiraz University of Medical Sciences, Shiraz, Iran.
CR Acharya D, 2020, NAT REV IMMUNOL, V20, P397, DOI 10.1038/s41577-020-0346-x
   Ahn JY, 2020, J KOREAN MED SCI, V35
   AlGhamdi M, 2015, AM J TRANSPLANT, V15, P1101, DOI 10.1111/ajt.13085
   Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   [Anonymous], 2020, DISTRIBUTED BIOOPTIM
   [Anonymous], 2020, IMMUNOPRECISE PROVID
   [Anonymous], 2020, ABCELLERA LILLY CODE
   [Anonymous], 2020, MOUNT SINAI HARBOUR
   [Anonymous], 2020, VIR BIOTECHNOLOGY PR
   [Anonymous], 2020, INFLARX DOSES 1 PATI
   [Anonymous], 2020, NASCENT BIOTECH INVE
   [Anonymous], 2020, 3 ADDITIONAL PATIENT
   [Anonymous], 2020, IDENTIFICATION CHARA
   [Anonymous], 2020, AQUALUNG THERAPEUTIC
   [Anonymous], 2020, EMERGENT BIOSOLUTION
   [Anonymous], 2020, GIGAGEN INITIATES DE
   [Anonymous], 2020, TIZIANA LIFE SCI PLC
   Arabi Y, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1490-9
   Barretto N, 2005, J VIROL, V79, P15189, DOI 10.1128/JVI.79.24.15189-15198.2005
   Belete Tafere Mulaw, 2020, Vacunas, V21, P121, DOI 10.1016/j.vacun.2020.05.002
   Bermejo-Martin JF, 2020, J INFECTION, V80, pE23, DOI 10.1016/j.jinf.2020.02.029
   Berry JD, 2004, J VIROL METHODS, V120, P87, DOI 10.1016/j.jviromet.2004.04.009
   Bersanelli M, 2020, BIOMED REP, V12, P59, DOI 10.3892/br.2019.1265
   Brennan VM, 2003, CLIN EXP IMMUNOL, V133, P247, DOI 10.1046/j.1365-2249.2003.02199.x
   Brown BL, 2020, TRANSFUS APHER SCI, V59, DOI 10.1016/j.transci.2020.102790
   Camp SM, 2015, SCI REP-UK, V5, DOI 10.1038/srep13135
   Carbajo-Lozoya J, 2012, VIRUS RES, V165, P112, DOI 10.1016/j.virusres.2012.02.002
   Chan KH, 2013, J INFECTION, V67, P130, DOI 10.1016/j.jinf.2013.03.015
   Chen GY, 2009, SCIENCE, V323, P1722, DOI 10.1126/science.1168988
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Chen RC, 2006, CHEST, V129, P1441, DOI 10.1378/chest.129.6.1441
   Chen Xin, 2009, Antivir Chem Chemother, V19, P151
   Cho A, 2016, CURR OPIN VIROL, V17, P110, DOI 10.1016/j.coviro.2016.03.002
   Cinar O.E., 2020, TRANSFUS APHERES SCI
   Clark E, 2020, BRIT J HAEMATOL, V190, pE154, DOI 10.1111/bjh.16981
   Coughlin M, 2007, VIROLOGY, V361, P93, DOI 10.1016/j.virol.2006.09.029
   Coughlin MM, 2012, REV MED VIROL, V22, P2, DOI 10.1002/rmv.706
   Cruz-Topete D, 2015, NEUROIMMUNOMODULAT, V22, P20, DOI 10.1159/000362724
   DAnnessa I., 2020, BIORXIV, DOI [10.1101/2020.03.13.990267., DOI 10.1101/2020.03.13.990267]
   Dastan F, 2020, INT IMMUNOPHARMACOL, V85, DOI 10.1016/j.intimp.2020.106688
   Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227
   Duan JZ, 2005, BIOCHEM BIOPH RES CO, V333, P186, DOI 10.1016/j.bbrc.2005.05.089
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Elshabrawy HA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050366
   Fang XW, 2020, J INFECTION, V81, P147, DOI 10.1016/j.jinf.2020.03.039
   Favalli EG, 2020, LANCET INFECT DIS, V20, P1012, DOI 10.1016/S1473-3099(20)30262-0
   Greenough TC, 2005, J INFECT DIS, V191, P507, DOI 10.1086/427242
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Hammarstrom L, 2020, J ALLERGY CLIN IMMUN, V146, P58, DOI 10.1016/j.jaci.2020.04.043
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Homeyer N, 2016, J CHEM INF MODEL, V56, P110, DOI 10.1021/acs.jcim.5b00467
   Horby P., 2020, EFFECT DEXAMETHASONE, DOI [10.1101/2020.06.22., DOI 10.1101/2020.06.22]
   Horiuchi T, 2016, INFLAMM REGEN, V36, DOI 10.1186/s41232-016-0013-6
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Humanigen Partners With CTI A Leading Contract Research Organization, 2020, HUMANIGEN PARTNERS C
   Jalkanen J, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03048-5
   Ju B, 2020, POTENT HUMAN NEUTRAL, DOI [10.1101/2020.03.21.990770, DOI 10.1101/2020.03.21.990770, 10.1101/2020.03.21.990770.]
   Keam S, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2123
   Khan S.U., 2020, DECIPHERING BINDING, DOI [10.26434/chemrxiv.12517535.v1., DOI 10.26434/CHEMRXIV.12517535.V1]
   Kim J, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02430-9
   Kim NH, 2007, IMMUNOLOGY, V122, P607, DOI 10.1111/j.1365-2567.2007.02679.x
   Koirala A, 2020, PAEDIATR RESPIR REV, V35, P43, DOI 10.1016/j.prrv.2020.06.010
   Kong R., 2020, ARXIV200300163
   Konno Y., 2020, BIORXIV
   Kumar GV, 2020, NEW MICROB NEW INFEC, V35, DOI 10.1016/j.nmni.2020.100682
   Kumar S., 2020, PREPRINTS, DOI [10.20944/preprints202003., DOI 10.20944/PREPRINTS202003]
   Langhi DM, 2020, HEMATOL TRANSF CELL, V42, P113, DOI 10.1016/j.htct.2020.04.003
   Ledford H, 2020, NATURE, V582, P469, DOI 10.1038/d41586-020-01824-5
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Li Yu-ming, 2004, Zhonghua Yi Xue Za Zhi, V84, P1348
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Lonberg N, 2005, NAT BIOTECHNOL, V23, P1117, DOI 10.1038/nbt1135
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Magar R., 2020, ARXIV200308447
   Marando M., 2020, SWISS MED WKLY, V150
   Marzo T, 2020, ACS MED CHEM LETT, V11, P1067, DOI 10.1021/acsmedchemlett.0c00190
   Mehta N, 2020, AM J EMERG MED, V38, P1488, DOI [10.1016/j.ajem.2020.03.011, 10.1016/j.ajem.2020.04.035]
   Mira E, 2020, J ALLER CL IMM-PRACT, V8, P2793, DOI 10.1016/j.jaip.2020.06.046
   Muus C., 2020, BIORXIV, DOI [10.1101/2020.04.19., DOI 10.1101/2020.04.19]
   Negahdaripour M, 2020, IRAN J MED SCI, V45, P231, DOI 10.30476/ijms.2020.46689
   Negahdaripour M, 2020, IRAN J MED SCI, V45, P155, DOI 10.30476/ijms.2020.46530
   Negahdaripour M, 2020, IRAN J MED SCI, V45, P81, DOI 10.30476/ijms.2020.46357
   NuGenerex, 2020, II KEY NCOV PEPT VAC
   Oita RC, 2018, AM J RESP CELL MOL, V59, P36, DOI 10.1165/rcmb.2017-0155OC
   Owen C, 2019, CURR ONCOL, V26, pE233, DOI 10.3747/co.26.4345
   Paces J, 2020, PHYSIOL RES, V69, P379, DOI 10.33549/physiolres.934492
   Pak JE, 2009, J MOL BIOL, V388, P815, DOI 10.1016/j.jmb.2009.03.042
   Park T., 2020, BIORXIV, DOI [10.1101/2020.02.22.951178, DOI 10.1101/2020.02.22.951178]
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998
   Praveen D, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105967
   Pu SY, 2018, ANTIVIR RES, V155, P67, DOI 10.1016/j.antiviral.2018.05.001
   Qin YY, 2020, CHINESE MED J-PEKING, V133, P1080, DOI 10.1097/CM9.0000000000000791
   Rajendran K., 2020, J MED VIROL, V2020, P1
   Rao SK, 2004, J BIOL CHEM, V279, P20471, DOI 10.1074/jbc.M400798200
   Ritchie AI, 2020, LANCET, V395, P1111, DOI 10.1016/S0140-6736(20)30691-7
   Rojas M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102554
   Rothan HA, 2020, VIROLOGY, V547, P7, DOI 10.1016/j.virol.2020.05.002
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, P1, DOI 10.3332/ecancer.2020.1022
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Sallard E, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104791
   Savarino A, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0178-0
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Seesuay W, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0031-3
   Shahabinezhad F., 2020, THERAPEUTIC APPROACH, DOI [10.20944/preprints202003.0206.v2, DOI 10.20944/PREPRINTS202003.0206.V2]
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Shanmugaraj B, 2020, ASIAN PAC J ALLERGY, V38, P10, DOI 10.12932/AP-200220-0773
   Shen C., 2020, JAMA-J AM MED ASSOC, V323, P582
   Sorrell FJ, 2016, STRUCTURE, V24, P401, DOI 10.1016/j.str.2015.12.015
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Stech M, 2015, ANTIBODIES, V4, P12, DOI 10.3390/antib4010012
   Strollo R, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3330
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   Sui JH, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000197
   Sun C, 2020, BIORXIV PREPRINT, DOI [10.1101/2020.02.16.951723., DOI 10.1101/2020.02.16.951723, 10.1101/2020.02.16.951723]
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tian RR, 2018, ANTIVIR RES, V157, P9, DOI 10.1016/j.antiviral.2018.07.004
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Tiberghien P, 2020, VOX SANG, V115, P488, DOI 10.1111/vox.12926
   Tobinick E, 2004, CURR MED RES OPIN, V20, P39, DOI 10.1185/030079903125002757
   Tozzi A., 2020, PREPRINT, DOI [10.13140/RG.2.2.19452. 69767., DOI 10.13140/RG.2.2.19452.69767]
   Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080
   van den Brink EN, 2005, J VIROL, V79, P1635, DOI 10.1128/JVI.79.3.1635-1644.2005
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang CH, 2014, CRIT CARE MED, V42, P313, DOI 10.1097/CCM.0b013e3182a2727d
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wei J, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0790-y
   Woo PCY, 2004, CLIN DIAGN LAB IMMUN, V11, P665, DOI 10.1128/CDLI.11.4.665-668.2004
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Xiao Jian-zhong, 2004, Zhonghua Nei Ke Za Zhi, V43, P179
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang ZW, 2020, J INFECTION, V81, pE13, DOI 10.1016/j.jinf.2020.03.062
   Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Yin S, 2019, J NAT GAS SCI ENG, V72, DOI 10.1016/j.jngse.2019.103032
   Yu CJ, 2020, INT IMMUNOPHARMACOL, V86, DOI 10.1016/j.intimp.2020.106740
   Yu YTC, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929-016-0234-7
   Yuen CK, 2020, EMERG MICROBES INFEC, V9, P1418, DOI 10.1080/22221751.2020.1780953
   Zeng LP, 2017, SCI CHINA LIFE SCI, V60, P1399, DOI 10.1007/s11427-017-9189-3
   Zeng QL, 2020, J INFECT DIS, V222, P38, DOI 10.1093/infdis/jiaa228
   Zhang B, 2020, CHEST, V158, pE9, DOI 10.1016/j.chest.2020.03.039
   Zhang Q, 2020, J MED VIROL, V92, P540, DOI [10.1002/jmv.25733, 10.1080/07391102.2020.1771421]
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhao Q, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104358
   Zheng M., 2020, CELL MOL IMMUNOL, P1
   Zheng Y.F., 2020, PREPRINTS, DOI [10.20944/preprints202004.0060.v1., DOI 10.20944/PREPRINTS202004.0060.V1]
   Zheng ZQ, 2020, EUROSURVEILLANCE, V25, P19, DOI 10.2807/1560-7917.ES.2020.25.28.2000291
   Zhou GY, 2020, INT J BIOL SCI, V16, P1718, DOI 10.7150/ijbs.45123
   Zhou Y., 2020, BIORXIV, DOI [10.1101/2020.02.12.945576., DOI 10.1101/2020.02.12.945576.]
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhu HY, 2014, INFLAMMATION, V37, P2091, DOI 10.1007/s10753-014-9943-9
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zhu ZY, 2007, P NATL ACAD SCI USA, V104, P12123, DOI 10.1073/pnas.0701000104
   Ziegler C., 2020, CELL, V5
NR 165
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD NOV
PY 2020
VL 88
AR 106924
DI 10.1016/j.intimp.2020.106924
PG 18
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA OP6AD
UT WOS:000588166300137
PM 32877828
OA Green Published
DA 2021-01-01
ER

PT J
AU Rahmani, H
   Davoudi-Monfared, E
   Nourian, A
   Khalili, H
   Hajizadeh, N
   Jalalabadi, NZ
   Fazeli, MR
   Ghazaeian, M
   Yekaninejad, MS
AF Rahmani, Hamid
   Davoudi-Monfared, Effat
   Nourian, Anahid
   Khalili, Hossein
   Hajizadeh, Nooshin
   Jalalabadi, Narjes Zarei
   Fazeli, Mohammad Reza
   Ghazaeian, Monireh
   Yekaninejad, Mir Saeed
TI Interferon beta-1b in treatment of severe COVID-19: A randomized
   clinical trial
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Interferon beta; COVID-19; SARS-COV-2; Iran
ID EAST RESPIRATORY SYNDROME; LOPINAVIR-RITONAVIR; SARS-CORONAVIRUS;
   COMBINATION
AB In this study, efficacy and safety of interferon (IFN) beta-1b in the treatment of patients with severe COVID-19 were evaluated.
   Among an open-label, randomized clinical trial, adult patients (>= 18 years old) with severe COVID-19 were randomly assigned (1:1) to the IFN group or the control group. Patients in the IFN group received IFN beta-1 b (250 mcg subcutaneously every other day for two consecutive weeks) along with the national protocol medications while in the control group, patients received only the national protocol medications (lopinavir/ritonavir or atazanavir/ritonavir plus hydroxychloroquine for 7-10 days). The primary outcome of the study was time to clinical improvement. Secondary outcomes were in-hospital complications and 28-daymortality.
   Between April 20 and May 20, 2020, 80 patients were enrolled and finally 33 patients in each group completed the study. Time to clinical improvment in the IFN group was significantly shorter than the control group ([9(6-10) vs. 11(9-15) days respectively, p = 0.002, HR = 2.30; 95% CI: 1.33-3.39]). At day 14, the percentage of discharged patients was 78.79% and 54.55% in the IFN and control groups respectively (OR = 3.09; 95% CI: 1.05-9.11, p = 0.03). ICU admission rate in the control group was significantly higher than the IFN group (66.66% vs. 42.42%, p = 0.04). The duration of hospitalization and ICU stay were not significantly different between the groups All-cause 28-day mortality was 6.06% and 18.18% in the IFN and control groups respectively (p = 0.12).
   IFN beta-1b was effective in shortening the time to clinical improvement without serious adverse events in patients with severe COVID-19. Furthermore, admission in ICU and need for invasive mechanical ventilation decreased following administration of IFN beta-1b. Although 28-day mortality was lower in the IFN group, further randomized clinical trials with large sample size are needed for exact estimation of survival benefit of IFN beta-1b.
C1 [Rahmani, Hamid; Davoudi-Monfared, Effat; Nourian, Anahid; Khalili, Hossein] Univ Tehran Med Sci, Dept Pharmacotherapy, Imam Khomeini Hosp Complex, Tehran, Iran.
   [Hajizadeh, Nooshin] Shahid Beheshti Univ Med Sci, Shohadaye Gomnam Hosp, Dept Infect Dis, Tehran, Iran.
   [Jalalabadi, Narjes Zarei] Univ Tehran Med Sci, Dept Internal Med, Imam Khomeini Hosp Complex, Tehran, Iran.
   [Fazeli, Mohammad Reza] Univ Tehran Med Sci, Fac Pharm, Dept Food & Drug Control, Tehran, Iran.
   [Ghazaeian, Monireh] Mazandaran Univ Med Sci, Fac Pharm, Dept Clin Pharm, Sari, Iran.
   [Yekaninejad, Mir Saeed] Univ Tehran Med Sci, Sch Publ Hlth, Dept Epidemiol & Biostat, Tehran, Iran.
RP Khalili, H (corresponding author), Univ Tehran Med Sci, Dept Pharmacotherapy, Tehran, Iran.
EM khalilih@tums.ac.ir
CR Al Ghamdi M, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1492-4
   [Anonymous], 2020, HOM PAG
   Arabi YM, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2427-0
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Cao B, 2020, NEW ENGL J MED, V382
   Cao W, 2020, CELL RES, V30, P367, DOI 10.1038/s41422-020-0327-4
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Dastan F, 2020, INT IMMUNOPHARMACOL, V85, DOI 10.1016/j.intimp.2020.106688
   Davoudi-Monfared Effat, 2020, Antimicrob Agents Chemother, V64, DOI 10.1128/AAC.01061-20
   Estebanez M., 2020, CLIN EVALUATION IFN, DOI [10.1101/2020.05.15.20084293, DOI 10.1101/2020.05.15.20084293]
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Hart BJ, 2014, J GEN VIROL, V95, P571, DOI 10.1099/vir.0.061911-0
   Hensley LE, 2004, EMERG INFECT DIS, V10, P317, DOI 10.3201/eid1002.030482
   Hong SI, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106052
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Lu S., EFFECTIVENESS SAFETY, DOI [10.1101/2020.04.17.20064469, DOI 10.1101/2020.04.17.20064469]
   Payandemehr P, 2020, ADV J EMERG MED, V4, DOI 10.22114/ajem.v4i2s.454
   Peng FJ, 2020, CAN J CARDIOL, V36, P915, DOI 10.1016/j.cjca.2020.04.010
   Peterson RL, 2017, CLIN TRIALS, V14, P264, DOI 10.1177/1740774517697919
   Sainz B, 2004, VIROLOGY, V329, P11, DOI 10.1016/j.virol.2004.08.011
   Sallard E, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104791
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Shalhoub S, 2015, J ANTIMICROB CHEMOTH, V70, P2129, DOI 10.1093/jac/dkv085
   Shao Z., CLIN EFFICACY INTRAV, DOI [10.1101/2020.04.11.20061739, DOI 10.1101/2020.04.11.20061739]
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Spiegel M, 2004, J CLIN VIROL, V30, P211, DOI 10.1016/j.jcv.2003.11.013
   Wang LS, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105948
   Yuan SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12060628
   Zhou Z, 2020, CELL HOST MICROBE, V27, P883, DOI 10.1016/j.chom.2020.04.017
NR 30
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD NOV
PY 2020
VL 88
AR 106903
DI 10.1016/j.intimp.2020.106903
PG 8
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA OP6AD
UT WOS:000588166300127
PM 32862111
OA Green Published
DA 2021-01-01
ER

PT J
AU Wu, M
   Ji, JJ
   Zhong, L
   Shao, ZY
   Xie, QF
   Liu, ZY
   Wang, CL
   Su, L
   Feng, YW
   Liu, ZF
   Yao, YM
AF Wu, Ming
   Ji, Jing-jing
   Zhong, Li
   Shao, Zi-yun
   Xie, Qi-feng
   Liu, Zhe-ying
   Wang, Cong-lin
   Su, Lei
   Feng, Yong-wen
   Liu, Zhi-feng
   Yao, Yong-ming
TI Thymosin alpha 1 therapy in critically ill patients with COVID-19: A
   multicenter retrospective cohort study
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE SARS-COV-2; COVID-19; Thymosin alpha 1; Immunomodulation; Mortality
ID MATURATION; CELLS; INFLAMMATION
AB Background: COVID-19 characterized by refractory hypoxemia increases patient mortality because of immunosuppression effects. This study aimed to evaluate the efficacy of immunomodulatory with thymosin alpha 1 for critical COVID-19 patients.
   Methods: This multicenter retrospective cohort study was performed in 8 government-designated treatment centers for COVID-19 patients in China from Dec. 2019 to Mar. 2020. Thymosin alpha 1 was administrated with 1.6 mg qd or q12 h for > 5 days. The primary outcomes were the 28-day and 60-day mortality, the secondary outcomes were hospital length of stay and the total duration of the disease. Subgroup analysis was carried out according to clinical classification.
   Results: Of the 334 enrolled COVID-19 patients, 42 (12.6%) died within 28 days, and 55 (16.5%) died within 60 days of hospitalization. There was a significant difference in the 28-day mortality between the thymosin alpha 1 and non-thymosin alpha 1-treated groups in adjusted model (P = 0.016), without obvious differences in the 60-day mortality and survival time in the overall cohort (P > 0.05). In the subgroup analysis, it was found that thymosin alpha 1 therapy significantly reduced 28-day mortality (Hazards Ratios HR, 0.11, 95% confidence interval CI 0.02-0.63, P = 0.013) via improvement of PaO2/FiO(2) (P = 0.036) and prolonged the hospital length of stay (P = 0.024) as well as the total duration of the disease (P = 0.001) in the critical type patients, especially those aged over 64 years, with white blood cell > 6.8 x 10(9)/L, neutrophil > 5.3 x 10(9)/L, lymphocyte < 0.73 x 10(9)/L, PaO2/FiO(2) < 196, SOFA > 3, and acute physiology and chronic health evaluation (APACHE) II > 7.
   Conclusion: These results suggest that treatment with thymosin alpha 1 can markedly decrease 28-day mortality and attenuate acute lung injury in critical type COVID-19 patients.
C1 [Wu, Ming; Feng, Yong-wen] Shenzhen Univ, Dept Crit Care Med & Hosp Infect Prevent & Contro, Hlth Sci Ctr, Peoples Hosp Shenzhen 2, Shenzhen 518035, Peoples R China.
   [Wu, Ming; Feng, Yong-wen] Shenzhen Univ, Affiliated Hosp 1, Hlth Sci Ctr, Shenzhen 518035, Peoples R China.
   [Ji, Jing-jing; Xie, Qi-feng; Liu, Zhe-ying; Wang, Cong-lin; Su, Lei; Liu, Zhi-feng] Gen Hosp Southern Theater Command PLA, Dept Crit Care Med, Guangzhou 510010, Peoples R China.
   [Zhong, Li] Guizhou Univ Chinese Med, Affiliated Hosp 1, Dept Crit Care Med, Guiyang 550001, Peoples R China.
   [Shao, Zi-yun] Gen Hosp Cent Theater Command PLA, Dept Nephrol, Wuhan 430070, Peoples R China.
   [Liu, Zhi-feng] Gen Hosp Southern Theater Command PLA, Key Lab Hot Zone Trauma Care & Tissue Repair PLA, Guangzhou 510010, Peoples R China.
   [Yao, Yong-ming] Chinese Peoples Liberat Army Gen Hosp, Trauma Res Ctr, Med Ctr 4, Beijing 100048, Peoples R China.
   [Yao, Yong-ming] Chinese Peoples Liberat Army Gen Hosp, Med Innovat Res Dept, Beijing 100048, Peoples R China.
RP Liu, ZF (corresponding author), Gen Hosp Southern Theater Command PLA, Dept Crit Care Med, Guangzhou 510010, Peoples R China.; Yao, YM (corresponding author), Chinese Peoples Liberat Army PLA Gen Hosp, Trauma Res Ctr, Med Ctr 4, 51 Fucheng Rd, Beijing 100048, Peoples R China.; Yao, YM (corresponding author), Chinese Peoples Liberat Army PLA Gen Hosp, Med Innovat Res Dept, 51 Fucheng Rd, Beijing 100048, Peoples R China.; Feng, YW (corresponding author), Second Peoples Hosp Shenzhen, Dept Crit Care Med, 3002 Sungang West Rd, Shenzhen 518035, Peoples R China.
EM fengyongwen2008@126.com; Zhifengliu7797@163.com; c_ff@sina.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81730057]; People's Liberation Army (PLA)
   Logistics Research Project of China [18CXZ030, CWH17L020, 17CXZ008,
   18CXZ026]; Sanming Project of Medicine in Shenzhen [SZSM20162011];
   Shenzhen Science and Technology Innovation Commission
   [JCYJ20160425103130218, JCYJ20170306091335008]; Clinical Research
   Project of Shenzhen Municipal Health Commission [SZLY2017007]
FX This work was supported by grants from the National Natural Science
   Foundation of China (81730057), the People's Liberation Army (PLA)
   Logistics Research Project of China (18CXZ030, CWH17L020, 17CXZ008,
   18CXZ026), Sanming Project of Medicine in Shenzhen (SZSM20162011),
   Shenzhen Science and Technology Innovation Commission (No.
   JCYJ20160425103130218, JCYJ20170306091335008), and Clinical Research
   Project of Shenzhen Municipal Health Commission (SZLY2017007).
CR Annane D, 2017, INTENS CARE MED, V43, P1751, DOI 10.1007/s00134-017-4919-5
   Arrighi JF, 2001, J IMMUNOL, V166, P3837, DOI 10.4049/jimmunol.166.6.3837
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Camerini R, 2015, EXPERT OPIN BIOL TH, V15, pS117, DOI 10.1517/14712598.2015.1033393
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Gabriella D, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106519
   Gao Zhan-cheng, 2003, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V15, P332
   Giacomini E, 2015, EXPERT OPIN BIOL TH, V15, pS59, DOI 10.1517/14712598.2015.1019460
   Giuliani C, 2000, EUR J IMMUNOL, V30, P778, DOI 10.1002/1521-4141(200003)30:3<778::AID-IMMU778>3.0.CO;2-I
   Guell E, 2019, J CLIN MED, V8, DOI 10.3390/jcm8050754
   Hohlstein P, 2019, J CLIN MED, V8, DOI 10.3390/jcm8030353
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   King R, 2016, VITAM HORM, V102, P151, DOI 10.1016/bs.vh.2016.04.003
   Knutsen AP, 1999, INT J IMMUNOPHARMACO, V21, P15, DOI 10.1016/S0192-0561(98)00060-5
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Liu Q, 2020, Fa Yi Xue Za Zhi, V36, P21, DOI 10.12116/j.issn.1004-5619.2020.01.005
   Liu Y, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa630, 10.1093/cid/ciaa630., DOI 10.1093/CID/CIAA630]
   Loggi E, 2008, J VIRAL HEPATITIS, V15, P442, DOI 10.1111/j.1365-2893.2007.00960.x
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Ouyang Yabo, 2020, Clin Infect Dis, V71, P2052, DOI 10.1093/cid/ciaa462
   Pei F, 2018, EXPERT OPIN BIOL TH, V18, P71, DOI 10.1080/14712598.2018.1484104
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Romani L, 2007, ANN NY ACAD SCI, V1112, P326, DOI 10.1196/annals.1415.002
   Romani L, 2006, BLOOD, V108, P2265, DOI 10.1182/blood-2006-02-004762
   Romani L, 2017, NAT MED, V23, P590, DOI 10.1038/nm.4305
   Yao Q, 2007, IMMUNOL LETT, V110, P110, DOI 10.1016/j.imlet.2007.04.007
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD NOV
PY 2020
VL 88
AR 106873
DI 10.1016/j.intimp.2020.106873
PG 7
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA OP6AD
UT WOS:000588166300093
PM 32795897
OA Green Published
DA 2021-01-01
ER

PT J
AU Potere, N
   Di Nisio, M
   Rizzo, G
   La Vella, M
   Polilli, E
   Agostinone, A
   Spacone, A
   Di Carlo, S
   Costantini, A
   Abbate, A
   Porreca, E
   Parruti, G
AF Potere, Nicola
   Di Nisio, Marcello
   Rizzo, Giulia
   La Vella, Matteo
   Polilli, Ennio
   Agostinone, Adriana
   Spacone, Antonella
   Di Carlo, Silvio
   Costantini, Alberto
   Abbate, Antonio
   Porreca, Ettore
   Parruti, Giustino
TI Low-dose subcutaneous tocilizumab to prevent disease progression in
   patients with moderate COVID-19 pneumonia and hyperin fl ammation
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE COVID-19; SARS-CoV-2; Inflammation; Cytokine release syndrome; IL-6;
   Tocilizumab
AB Aim: This study aimed to evaluate the safety and efficacy profile of low-dose tocilizumab (TCZ), to prevent disease progression, subcutaneously administered to patients with moderate COVID-19 pneumonia and hyperinflammation.
   Methods: Clinical characteristics and outcomes were retrospectively analysed of patients - with laboratoryconfirmed bilateral COVID-19 pneumonia, hyperinflammation (C-reactive protein (CRP) >= 20 mg/dL), no hypoxaemia (oxygen saturation >90%), and no contraindications toTCZ- who were treated with subcutaneous TCZ (324 mg) administered within 48 h from hospitalization on top of standard of care (SOC). They were compared with matched controls treated with SOC only before TCZ was available at the institution. Clinical data were available for all patients until death or until day 35 for those discharged from hospital.
   Findings: Ten consecutive patients (six males, median age 55 years) treated with TCZ on top of SOC, and ten patients (six males, median age 56 years) treated with SOC only were included. TCZ was well-tolerated with no clinically relevant adverse events. TCZwas associated with a reduction in CRP at day 1 (-50%, IQR -28 to -80) and day3 (-89%, IQR -79 to -96; p = 0.005 forwithin-group), whereas therewas no significant change in CRPvalues in the SOC group (p < 0.001 for between-group comparisons at both time points). TCZresulted in a parallel improvement in oxygenation, as assessed by the ratio ofpartial pressure of oxygen to fraction of inspired oxygen (P/F) ratio, which increased at day 1 (+11%, IQR +6 to +16; p = 0.005 for within-group and p = 0.006 for between-group comparisons), and day 3 (+23%, IQR +16 to +34; p = 0.005 for within-group and p = 0.003 for between-group comparisons). None of the TCZ-treated patients had disease progression, defined as requirement of oxygen therapy or mechanical ventilation, whereas progression occurred in five (50%) patients among the SOC group.
   Conclusions: Low-dose subcutaneous TCZ may be a safe and promising therapeutic option administered on top of SOC to prevent disease progression in hospitalised patients with moderate COVID-19 and hyperinflammation. (c) 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Potere, Nicola; Rizzo, Giulia; La Vella, Matteo; Porreca, Ettore] Univ G dAnnunzio, Dept Med Oral & Biotechnol Sci, Chieti, Italy.
   [Potere, Nicola; Abbate, Antonio] Virginia Commonwealth Univ, VCU Pauley Heart Ctr, Richmond, VA USA.
   [Di Nisio, Marcello] Univ G dAnnunzio, Dept Med & Ageing Sci, Chieti, Italy.
   [Di Nisio, Marcello] Acad Med Ctr, Dept Vasc Med, Amsterdam, Netherlands.
   [Polilli, Ennio] Pescara Gen Hosp, Unit Clin Pathol, Pescara, Italy.
   [Agostinone, Adriana; Parruti, Giustino] Pescara Gen Hosp, Infect Dis Unit, Via Fonte Romana 8, I-65124 Pescara, Italy.
   [Spacone, Antonella; Di Carlo, Silvio] Pescara Gen Hosp, Resp Med Unit, Pescara, Italy.
   [Costantini, Alberto] Pescara Gen Hosp, Hosp Pharm, Pescara, Italy.
RP Parruti, G (corresponding author), Pescara Gen Hosp, Infect Dis Unit, Via Fonte Romana 8, I-65124 Pescara, Italy.
EM parrutig@gmail.com
CR Campochiaro C, 2020, EUR J INTERN MED, V76, P43, DOI 10.1016/j.ejim.2020.05.021
   Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Potere N, 2020, ANN RHEUM DIS
   Potere N, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03022-1
   Sciascia S, 2020, CLIN EXP RHEUMATOL, V38
   Siu KL, 2019, FASEB J, V33, P8865, DOI 10.1096/fj.201802418R
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Ucciferri C, 2020, LANCET RHEUMATOL, V2, pE457, DOI 10.1016/S2665-9913(20)30167-3
   World Health Organization, 2020, WHO WELC PREL RES DE
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu X, 2020, P NATL ACAD SCI USA, V117
NR 12
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD NOV
PY 2020
VL 100
BP 421
EP 424
DI 10.1016/j.ijid.2020.07.078
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA OT0QQ
UT WOS:000590560000013
PM 32768701
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wen, JQ
   Cheng, YF
   Ling, RS
   Dai, YR
   Huang, BX
   Huang, WJ
   Zhang, SY
   Jiang, YZ
AF Wen, Jieqi
   Cheng, Yifan
   Ling, Rongsong
   Dai, Yarong
   Huang, Boxuan
   Huang, Wenjie
   Zhang, Siyan
   Jiang, Yizhou
TI Antibody-dependent enhancement of coronavirus
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Antibody-dependent enhancement (ADE); Coronavirus disease 2019
   (COVID-19); Severe acute respiratory syndrome coronavirus 2
   (SARS-CoV-2); Severe acute respiratory syndrome coronavirus (SARS-CoV);
   Middle East respiratory syndrome coronavirus (MERS-CoV)
ID SARS CORONAVIRUS; MEDIATED ENHANCEMENT; INFECTION; RECEPTOR; SPIKE;
   PROTEIN; COV
AB Antibody-dependent enhancement (ADE) exists in several kinds of virus. It has a negative influence on antibody therapy for viral infection. This effect was first identified in dengue virus and has since also been described for coronavirus. To date, the rapid spread of the newly emerged coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing coronavirus disease 2019 (COVID-19), has affected over 3.8 million people across the globe. The novel coronavirus poses a great challenge and has caused a wave of panic. In this review, antibody-dependent enhancements in dengue virus and two kinds of coronavirus are summarized. Possible solutions for the effects are reported. We also speculate that ADE may exist in SARS-CoV-2. (c) 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-ncnd/4.0/).
C1 [Wen, Jieqi; Cheng, Yifan; Ling, Rongsong; Dai, Yarong; Huang, Boxuan; Huang, Wenjie; Zhang, Siyan; Jiang, Yizhou] Shenzhen Univ, Inst Adv Study, Shenzhen 518067, Peoples R China.
RP Jiang, YZ (corresponding author), Shenzhen Univ, Inst Adv Study, Shenzhen 518067, Peoples R China.
EM 1900391007@email.szu.edu.cn; chengdiefan2017@email.szu.edu.cn;
   2017182010@email.szu.edu.cn; daiyarong2019@email.szu.edu.cn;
   huangboxuan2017@email.szu.edu.cn; 2017222014@email.szu.edu.cn;
   zhangsiyan2016@email.szu.edu.cn; jiangyz@szu.edu.cn
FU Shenzhen Peacock Plan Technological Innovation
   [QJSCX2010170728150303243]; Shenzhen Branch Committee on Technology and
   Innovation [JCYJ2018030512481244444]
FX This work was supported by Shenzhen Peacock Plan Technological
   Innovation (QJSCX2010170728150303243) and by the Shenzhen Branch
   Committee on Technology and Innovation (JCYJ2018030512481244444).
CR Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Chan KR, 2011, P NATL ACAD SCI USA, V108, P12479, DOI 10.1073/pnas.1106568108
   de Alwis R, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102768
   Du LY, 2014, J VIROL, V88, P7045, DOI 10.1128/JVI.00433-14
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Dustin ML, 2016, MICROBIOL SPECTR, V4, P2016
   Fleming AB, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104388
   Fung TS, 2019, ANNU REV MICROBIOL, V73, P529, DOI 10.1146/annurev-micro-020518-115759
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Guillon C, 2002, J VIROL, V76, P2827, DOI 10.1128/JVI.76.6.2827-2834.2002
   Hotez PJ, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0323-4
   Jiang SB, 2020, NATURE, V579, P321, DOI 10.1038/d41586-020-00751-9
   Kam YW, 2007, VACCINE, V25, P729, DOI 10.1016/j.vaccine.2006.08.011
   Li Z, 2020, SO WEEKLY
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Luo F, 2018, VIROL SIN, V33, P201, DOI 10.1007/s12250-018-0009-2
   Mahalingam S, 2002, P NATL ACAD SCI USA, V99, P13819, DOI 10.1073/pnas.202415999
   Morrone SR, 2019, CURR OPIN VIROL, V36, P1, DOI 10.1016/j.coviro.2019.02.002
   Prescott J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00205
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   Takano T, 2019, J VET MED SCI, V81, P911, DOI 10.1292/jvms.18-0702
   Taylor A, 2015, IMMUNOL REV, V268, P340, DOI 10.1111/imr.12367
   Tilocca B, 2020, MICROBES INFECT, V22, P182, DOI 10.1016/j.micinf.2020.05.013
   Tilocca B, 2020, MICROBES INFECT, V22, P218, DOI 10.1016/j.micinf.2020.03.002
   von Kietzell K, 2014, J VIROL, V88, P8102, DOI 10.1128/JVI.00649-14
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang QD, 2016, ACS INFECT DIS, V2, P361, DOI 10.1021/acsinfecdis.6b00006
   Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090
   Wilder-Smith A, 2019, LANCET, V393, P350, DOI 10.1016/S0140-6736(18)32560-1
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yip M S, 2016, Hong Kong Med J, V22, P25
   Yip MS, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-82
   Yong CY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01781
NR 33
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD NOV
PY 2020
VL 100
BP 483
EP 489
DI 10.1016/j.ijid.2020.09.015
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA OT0QQ
UT WOS:000590560000024
PM 32920233
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cohen, G
   Russo, MJ
   Campos, JA
   Allegri, RF
AF Cohen, Gabriela
   Russo, Maria Julieta
   Campos, Jorge A.
   Allegri, Ricardo F.
TI Living with dementia: increased level of caregiver stress in times of
   COVID-19
SO INTERNATIONAL PSYCHOGERIATRICS
LA English
DT Article
DE Alzheimer&#8217; s disease (AD); dementia; outpatient
AB COVID-19 pandemic in Argentina has affected the care of older adults with dementia deeply. Our objective was to study how the obligatory social isolation affected stress caregiver and burden of care of family members of subjects living with dementia in the community after the initial 4 weeks of quarantine in our setting. We did a questionnaire survey among 80 family caregivers of persons with Alzheimer's disease (AD) or related dementia collected on April 2020. We designed a visual analog scale to test the level of the burden of care. Characteristics of people with dementia and their caregivers were analyzed with descriptive (mean, standard deviation, frequency and percent) and inferential statistics (chi-square test). The sample included older adults (mean age: 80.51 +/- 7.65) with different stages of dementia. Family was the primary provider of care in 65%. Overall, COVID-19 confinement increased stress caregiver independently of the dementia stage, but those caring for severe cases had more stress compared to milder forms of the disease. Other findings were that half of the subjects with dementia experienced increased anxiety and that most family members discontinued all sort of cognitive and physical therapies. Family members' main concerns were for severe dementia cases, fear of absence of the paid caregiver during the epidemic, and for mild cases fear of spreading the disease while assisting patients with instrumental activities. A partnership between departments of public health, care workers and families must be planned to guarantee continuity of care during these unique COVID-19 times.
C1 [Cohen, Gabriela; Russo, Maria Julieta; Campos, Jorge A.; Allegri, Ricardo F.] Memory & Ageing Ctr, Fdn Lucha Enfermedades Neurol Infancia, Dept Cognit Neurol Neuropsychol & Neuropsychiat F, Buenos Aires, DF, Argentina.
RP Cohen, G (corresponding author), Cognit Dept, Montaneses 2325,8th Floor, RA-1428 Buenos Aires, DF, Argentina.
EM gcohen@fleni.org.ar
CR Austrom MG, 2018, GERONTOLOGIST, V58, pS48, DOI 10.1093/geront/gnx147
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Emami A, 2020, ARCH ACAD EMERG MED, V8
   HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566
   Hughes TB, 2014, INT PSYCHOGERIATR, V26, P1875, DOI 10.1017/S1041610214001240
   Hwang TJ, 2020, INT PSYCHOGERIATR, V32, P1217, DOI 10.1017/S1041610220000988
   Nimon K, 2014, INT J RES METHOD EDU, V37, P256, DOI 10.1080/1743727X.2013.820644
   Savva GM, 2009, BRIT J PSYCHIAT, V194, P212, DOI 10.1192/bjp.bp.108.049619
   2016, CIRE ANTILLES GUYANE, V1, P1
NR 9
TC 2
Z9 2
U1 1
U2 1
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1041-6102
EI 1741-203X
J9 INT PSYCHOGERIATR
JI Int. Psychogeriatr.
PD NOV
PY 2020
VL 32
IS 11
SI SI
BP 1377
EP 1381
AR PII S1041610220001593
DI 10.1017/S1041610220001593
PG 5
WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry;
   Psychology
SC Psychology; Geriatrics & Gerontology; Psychiatry
GA PB7ZN
UT WOS:000596534900019
PM 32729446
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Guedes, F
   Boleo-Tome, JP
   Rodrigues, LV
   Bastos, HN
   Campainha, S
   de Santis, M
   Mota, L
   Bugalho, A
AF Guedes, F.
   Boleo-Tome, J. P.
   Rodrigues, L., V
   Bastos, H. N.
   Campainha, S.
   de Santis, M.
   Mota, L.
   Bugalho, A.
TI Recommendations for interventional pulmonology during COVID-19 outbreak:
   a consensus statement from the Portuguese Pulmonology Society
SO PULMONOLOGY
LA English
DT Article
DE Interventional pulmonology; Bronchoscopy; Thoracocentesis; COVID-19;
   Consensus statement
AB Coronavirus disease 2019 (COVID-19) is an emerging infectious disease caused by a novel SARS-CoV-2 pathogen. Its capacity for human-to-human transmission through respiratory droplets, coupled with a high-level of population mobility, has resulted in a rapid dissemination worldwide. Healthcare workers have been particularly exposed to the risk of infection and represent a significant proportion of COVID-19 cases in the worst affected regions of Europe.
   Like other open airway procedures or aerosol-generating procedures, bronchoscopy poses a significant risk of spreading contaminated droplets, and medical workers must adapt the procedures to ensure safety of both patients and staff. Several recommendation documents were published at the beginning of the pandemic, but as the situation evolves, our thoughts should not only focus on the present, but should also reflect on how we are going to deal with the presence of the virus in the community until there is a vaccine or specific treatment available. It is in this sense that this document aims to guide interventional pulmonology throughout this period, providing a set of recommendations on how to perform bronchoscopy or pleural procedures safely and efficiently. (C) 2020 Sociedade Portuguesa de Pneunnologia. Published by Elsevier Espana, S.L.U.
C1 [Guedes, F.] Ctr Hosp Porto CHP, Hosp Geral Santo Antonio HGSA, Unidade Broncol, Serv Pneumol, Porto, Portugal.
   [Guedes, F.] Univ Porto, Inst Ciencias Biomed Abel Salazar ICBAS, Dept Clin Vet, Porto, Portugal.
   [Guedes, F.] Univ Porto, Inst Ciencias Tecnol & Agroambiente ICETA, Ctr Estudos Ciencia Anim CECA, Praca Gomes Teixeira,Apartado 55142, P-4051401 Porto, Portugal.
   [Boleo-Tome, J. P.] Hosp Prof Doutor Fernando Fonseca, Pulmonol Dept, Amadora, Portugal.
   [Rodrigues, L., V] Hosp Sousa Martins, Pulmonol Dept, Unidade Local Saud Guarda, Guarda, Portugal.
   [Rodrigues, L., V] Univ Beira Interior, Fac Hlth Sci, Covilha, Portugal.
   [Bastos, H. N.] Ctr Hosp Sao Joao, Dept Pneumol, Porto, Portugal.
   [Bastos, H. N.] Univ Porto, Fac Med, Porto, Portugal.
   [Bastos, H. N.] Univ Porto, Inst Invest & Inovacao Saude, IBMC i3S Inst Biol Mol & Celular, Porto, Portugal.
   [Campainha, S.] Vila Nova de Gaia Espinho Hosp Ctr, Pulmonol Dept, Vila Nova De Gaia, Portugal.
   [de Santis, M.] Inst Portugues Oncol IPO, Pulmonol Dept, Coimbra, Portugal.
   [Mota, L.] Ctr Hosp Lisboa Norte, Hosp Pulido Valente, Pulmonol Dept, Lisbon, Portugal.
   [Bugalho, A.] CUF Infante Santo Hosp, Pulmonol Dept, Lisbon, Portugal.
   [Bugalho, A.] CUF Descobertas Hosp, Lisbon, Portugal.
   [Bugalho, A.] NOVA Med Sch, Chron Dis Res Ctr CEDOC, Comprehens Hlth Res Ctr, Lisbon, Portugal.
RP Guedes, F (corresponding author), Ctr Hosp Porto CHP, Hosp Geral Santo Antonio HGSA, Unidade Broncol, Serv Pneumol, Porto, Portugal.; Guedes, F (corresponding author), Univ Porto, Inst Ciencias Biomed Abel Salazar ICBAS, Dept Clin Vet, Porto, Portugal.; Guedes, F (corresponding author), Univ Porto, Inst Ciencias Tecnol & Agroambiente ICETA, Ctr Estudos Ciencia Anim CECA, Praca Gomes Teixeira,Apartado 55142, P-4051401 Porto, Portugal.
EM fernando.t.guedes@gmail.com
OI Rodrigues, Luis/0000-0001-5929-6078
CR Adhikari U, 2019, RISK ANAL, V39, P2608, DOI 10.1111/risa.13389
   Ahmed OG, 2018, INT J PEDIATR OTORHI, V109, P133, DOI 10.1016/j.ijporl.2018.03.016
   Aiolfi A, 2020, ANN THORAC SURG
   American Institute of Architects, 2001, GUID DES CONSTR HOSP
   Baldwin D.R., 2020, RECOMMENDATIONS DAY
   Batra H, 2018, EXPERT REV RESP MED, V12, P509, DOI 10.1080/17476348.2018.1473037
   Bisetli P, 2018, EUR RESPIR J, V51
   Centers for Disease Control and Prevention, 2020, INT INF PREV CONTR R
   Centers for Disease Control and Prevention, HEALTHC INF PREV CON
   Centers for Disease Control and Prevention, 2019, GUIDELINE DISINFECTI
   Chen CC, 2020, CANCER CYTOPATHOL, V128, P309, DOI 10.1002/cncy.22280
   Ding Q, 2020, J MED VIROL, V92, P1549, DOI 10.1002/jmv.25781
   European Centre for Disease Prevention and Control, 2020, COR DIS 2019 COVID 1
   Hallifax R., PLEURAL SERVICES COV
   Healthcare Infection Control Practices Advisory Committee, 2016, ESS EL REPR PROGR FL
   Hetlyer TP, 2020, LANCET RESP MED, V8, P182
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Inui S, 2020, RADIOL CARDIOTHORAC, V2, DOI [10.1148/ryct.2020200110, DOI 10.1148/RYCT.2020200110]
   Tran K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035797
   Lin C, 2020, CLIN IMAG, V63, P7, DOI 10.1016/j.clinimag.2020.02.008
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mazzone PJ, 2020, CHEST, V158, P406, DOI 10.1016/j.chest.2020.04.020
   Mizumoto K, 2020, EURO SURVEILL
   Nishiura H, 2020, INT J INFECT DIS
   Pathak Vikas, 2014, Ann Am Thorac Soc, V11, P628, DOI 10.1513/AnnalsATS.201309-302FR
   Peng QY, 2020, INTENS CARE MED, V46, P849, DOI 10.1007/s00134-020-05996-6
   Pitiot V, 2017, INT J PEDIATR OTORHI, V102, P169, DOI 10.1016/j.ijporl.2017.08.036
   Pritchett MA, 2020, J THORAC DIS, V12, P1781, DOI 10.21037/jtd.2020.04.32
   Rutala WA, 1999, INFECT CONT HOSP EP, V20, P69, DOI 10.1086/501544
   Salehi S, 2020, AM J ROENTGENOL, V215, P87, DOI [10.2214/AJR.20.23034, 10.2214/AJR.20.23034S.]
   Seijo LM, 2001, NEW ENGL J MED, V344, P740, DOI 10.1056/NEJM200103083441007
   Society of Interventional Radiology, AER GEN PROC PERF IN
   Sun RH, 2020, KOREAN J RADIOL, V21, P541, DOI 10.3348/kjr.2020.0180
   Tellier R, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3707-y
   Thompson KA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056278
   Wahidi M.M., 2020, UPDATE AM ASS BRONCH
   Wahidi MM, 2020, J BRONCHOL INTERN PU, V27, pE52, DOI 10.1097/LBR.0000000000000681
   Wilson NM, 2020, ANAESTHESIA, V75, P1086, DOI 10.1111/anae.15093
   World Health Organization, 2020, 99 WHO
   World Health Organization, 2020, LAB TEST COR DIS 201
   World Health Organization, 2020, HLTH SYST RESP COVID
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yarmus L, 2010, LUNG BIOL HEALTH DIS, V230, P1
   Zhu JY, 2020, J MED VIROL, V92, P891, DOI 10.1002/jmv.25910
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou L, 2020, N ENGL J MED
NR 47
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2531-0437
J9 PULMONOLOGY
JI Pulmonology
PD NOV-DEC
PY 2020
VL 26
IS 6
BP 386
EP 397
DI 10.1016/j.pulmoe.2020.07.007
PG 12
WC Respiratory System
SC Respiratory System
GA OK0WI
UT WOS:000584373000010
PM 32868252
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhao, XL
   Zhang, T
   Li, B
   Yu, XX
   Ma, ZY
   Cao, LH
   Gu, QJ
   Dong, C
   Jin, YH
   Fan, JG
   He, G
AF Zhao, Xiaolong
   Zhang, Tong
   Li, Bin
   Yu, Xiaoxu
   Ma, Zhiyue
   Cao, Luhong
   Gu, Qingjia
   Dong, Chuan
   Jin, Yunhua
   Fan, Jiangang
   He, Gang
TI Job-related factors associated with changes in sleep quality among
   healthcare workers screening for 2019 novel coronavirus infection: a
   longitudinal study
SO SLEEP MEDICINE
LA English
DT Article
DE 2019 novel coronavirus (2019-nCoV); Sleep disorder; Work schedule;
   Online cognitive behavioral therapy (CBT); Healthcare workers
AB Background: Sleep disorders may exacerbate many physical and mental health conditions, causing dif-ficulty function in a healthcare setting. Workers screening for the 2019 novel coronavirus (2019-nCoV) infection have a high risk of not only occupational exposure to the virus but also sleep disorders. However, the job-related factors associated with reduced sleep quality remain unclear.
   Methods: All healthcare workers temporarily scheduled to screen the 2019-nCoV patients were asked to complete a self-administered questionnaire that included questions on demographics, job-related factors, and sleep quality as assessed using the Pittsburgh Sleep Quality Index (PSQI). Sleep quality was assessed over a one-month follow-up period.
   Results: A total of 116 doctors and 99 nurses were recruited for this study. The total scheduled work time was 14.78 +/- 6.69 days during follow-up. Some job-related factors, such as number of work days, years of work experience, and subjective psychological stress, were associated with changes in the PSQI score. During the study, some workers tried out cognitive behavioral therapy (CBT) for sleep disorders using methods that were available online and easily accessible. Adopting online CBT was shown to be associated with scores of components of sleep quality, sleep latency, and sleep disturbance (beta =-0.152, P = 0.01; beta =-0.175, P = 0.008; and beta =-0.158, P = 0.011, respectively).
   Conclusions: Healthcare workers involved in screening for 2019-nCoV experienced reduced sleep quality, and a reasonable work schedule may help with maintaining sleep quality. In addition, interventions for healthcare workers should target self-help sleep assistance. (c) 2020 Elsevier B.V. All rights reserved.
C1 [Zhao, Xiaolong; Li, Bin; Yu, Xiaoxu; Ma, Zhiyue; Cao, Luhong; Gu, Qingjia; Dong, Chuan; Jin, Yunhua; Fan, Jiangang] Sichuan Prov Peoples Hosp, Sichuan Acad Med Sci, Dept Otolaryngol Head & Neck Surg, Chengdu, Peoples R China.
   [Zhang, Tong] Tongji Univ, Yangpu Hosp, Sch Med, Dept Clin Lab, Shanghai, Peoples R China.
   [He, Gang] Chengdu Tian Fu New Dist Peoples Hosp, Chengdu, Peoples R China.
RP Zhao, XL; Jin, YH; Fan, JG (corresponding author), Sichuan Prov Peoples Hosp, Sichuan Acad Med Sci, Dept Otolaryngol Head & Neck Surg, Chengdu, Peoples R China.
EM sczhaoxiaolong@163.com; 438154439@qq.com; entscfjg@163.com
OI Zhao, Xiao long/0000-0003-2356-272X
CR Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Deng X, 2020, MEDICINE, V99
   Dickson GT, 2019, SLEEP MED, V63, P142, DOI 10.1016/j.sleep.2019.05.016
   Epstein M, 2019, J CLIN NURS, DOI 10.1111/jocn.15076
   Gu B, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015836
   Harrison EM, 2019, J EMERGENCY MED, V10, P7
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jaradat R, 2020, SLEEP MED, V66, P201, DOI 10.1016/j.sleep.2019.11.1258
   Kalmbach DA, 2020, SLEEP MED, V1, P4
   Mokarami H, 2020, WORK, V65, P137, DOI 10.3233/WOR-193066
   Ogawa R, 2018, BMC MED EDUC, V18, DOI 10.1186/s12909-018-1171-9
   Peter L, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16173081
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   REID KJ, 2018, SLEEP, V41, P1, DOI DOI 10.1093/SLEEP/ZSY131
   Ropponen A, 2018, INT J ENV RES PUB HE, V15, P7
   Song KW, 2019, INT DENT J, V69, P436, DOI 10.1111/idj.12513
   Vanderlinden J, 2020, INT J BEHAV NUTR PHY, V17, DOI 10.1186/s12966-020-0913-3
   Wang MM, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-023157
   WHO, 2020, CLIN MAN SEV AC RESP
NR 19
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1389-9457
EI 1878-5506
J9 SLEEP MED
JI Sleep Med.
PD NOV
PY 2020
VL 75
BP 21
EP 26
DI 10.1016/j.sleep.2020.07.027
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA OT3QB
UT WOS:000590764000005
PM 32853914
OA Green Published
DA 2021-01-01
ER

PT J
AU Cabona, C
   Deleo, F
   Marinelli, L
   Audenino, D
   Arnaldi, D
   Rossi, F
   Di Giacomo, R
   Buffoni, C
   Rosa, GJ
   Didato, G
   Arboscello, E
   de Curtis, M
   Villani, F
AF Cabona, Corrado
   Deleo, Francesco
   Marinelli, Lucio
   Audenino, Daniela
   Arnaldi, Dario
   Rossi, Francesca
   Di Giacomo, Roberta
   Buffoni, Claudia
   Rosa, Giuseppa Jolanda
   Didato, Giuseppe
   Arboscello, Eleonora
   de Curtis, Marco
   Villani, Flavio
TI Epilepsy course during COVID-19 pandemic in three Italian epilepsy
   centers
SO EPILEPSY & BEHAVIOR
LA English
DT Article
DE Epilepsy; COVID-19; First seizure; Status epilepticus; Telemedicine
ID SEIZURES
AB During epidemic outbreaks, epilepsy course can be modified by different physical and psychological stressors and, most importantly, by irregular therapy intake.
   The effect of COVID-19 and quarantine isolation on the course of epilepsy and on incidence of new-onset seizures is still unclear.
   With the aim of managing epilepsy in quarantined patients, three Italian Epilepsy Centers set up telephone consultations using a semistructured interview, allowing a prospective collection of data on seizure course and other seizure-related problems during pandemic. The collected data on seizure course were compared with the analogous period of 2019.
   The level of patients' concern relating to the COVID-19 pandemic was also assessed using a numeric rating scale. To address the effect of COVID-19 pandemic on seizure incidence, data collection included the number of consultations for first seizures, relapse seizures, and status epilepticus (SE) in the emergency department of one of the participating centers.
   Clinical telephone interviews suggest the absence of quarantine effect on epilepsy course in our cohort. No differences in incidence of emergency consultations for seizures over a two-month period were also observed compared with a control period.
   As demonstrated in other infective outbreaks, good antiepileptic drug (AED) supplying, precise information, and reassurance are the most important factors in chronic conditions to minimize psychological and physical stress, and to avoid unplanned treatment interruptions. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Cabona, Corrado; Marinelli, Lucio; Villani, Flavio] IRCCS Osped Policlin San Martino, Div Clin Neurophysiol, Largo Rosanna Benzi 10, Genoa, Italy.
   [Cabona, Corrado; Marinelli, Lucio; Villani, Flavio] IRCCS Osped Policlin San Martino, Epilepsy Ctr, Largo Rosanna Benzi 10, Genoa, Italy.
   [Deleo, Francesco; Di Giacomo, Roberta; Rosa, Giuseppa Jolanda; Didato, Giuseppe; de Curtis, Marco] Fdn IRCCS Ist Neurol C Besta, Epilepsy Unit, Via Celoria, Milan, Italy.
   [Audenino, Daniela] EO Osped Galliera, Neurol Unit, Via Mura delle Cappuccine 14, Genoa, Italy.
   [Arnaldi, Dario] IRCCS Osped Policlin San Martino, Neurol Clin, Largo Rosanna Benzi 10, Genoa, Italy.
   [Marinelli, Lucio; Arnaldi, Dario] Univ Genoa, Dept Neurosci DINOGMI, Via Balbi 5, Genoa, Italy.
   [Rossi, Francesca; Arboscello, Eleonora] IRCCS Osped Policlin San Martino, Emergency Dept, Largo Rosanna Benzi 10, Genoa, Italy.
   [Buffoni, Claudia] IRCCS Osped Policlin San Martino, Anesthesia & Intens Care, Largo Rosanna Benzi 10, Genoa, Italy.
   [Rosa, Giuseppa Jolanda] Azienda Osped Univ St Anna di Cona, Epilepsy Ctr, Via Aldo Moro 8, I-44124 Ferrara, Italy.
RP Cabona, C (corresponding author), IRCCS Osped Policlin San Martino, Div Clin Neurophysiol, Largo Rosanna Benzi 10, Genoa, Italy.; Cabona, C (corresponding author), IRCCS Osped Policlin San Martino, Epilepsy Ctr, Largo Rosanna Benzi 10, Genoa, Italy.
EM corrado.cabona@gmail.com
RI Marinelli, Lucio/K-3141-2012
OI Marinelli, Lucio/0000-0003-0620-7654; Villani,
   Flavio/0000-0002-2762-4599
CR Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Colaneri M, 2020, EUROSURVEILLANCE, V25, P8, DOI 10.2807/1560-7917.ES.2020.25.16.2000460
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Inui A, 1998, ARCH INTERN MED, V158, P274, DOI 10.1001/archinte.158.3.274
   Kobayashi S, 2016, BRAIN DEV-JPN, V38, P623, DOI 10.1016/j.braindev.2016.01.005
   Kuroda N, 2020, EPILEPSY BEHAV, V108, DOI 10.1016/j.yebeh.2020.107122
   Lai SL, 2005, SEIZURE-EUR J EPILEP, V14, P557, DOI 10.1016/j.seizure.2005.08.010
   Leor J, 1996, NEW ENGL J MED, V334, P413, DOI 10.1056/NEJM199602153340701
   Lu L, 2020, EPILEPSIA, V61, pE49, DOI 10.1111/epi.16524
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Misra UK, 2009, SEIZURE-EUR J EPILEP, V18, P583, DOI 10.1016/j.seizure.2009.06.003
   Moriguchi T, 2020, INT J INFECT DIS, V94, P55, DOI 10.1016/j.ijid.2020.03.062
   Omboni S, 2020, TELEMED E-HEALTH, V26, P973, DOI 10.1089/tmj.2020.0106
   Shibahara I, 2013, EPILEPSIA, V54, pe49, DOI 10.1111/epi.12070
   Smith Phil, 2016, Pract Neurol, V16, P475, DOI 10.1136/practneurol-2016-001504
   Sohal S, 2020, IDCases, V20, DOI 10.1016/j.idcr.2020.e00782
   Zhao H, 2020, LANCET NEUROL, V19, P383, DOI 10.1016/S1474-4422(20)30109-5
NR 18
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1525-5050
EI 1525-5069
J9 EPILEPSY BEHAV
JI Epilepsy Behav.
PD NOV
PY 2020
VL 112
AR 107375
DI 10.1016/j.yebeh.2020.107375
PG 4
WC Behavioral Sciences; Clinical Neurology; Psychiatry
SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry
GA OP3TK
UT WOS:000588004200045
PM 32858368
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ferraris, C
   Pasca, L
   Guglielmetti, M
   Marazzi, C
   Trentani, C
   Varesio, C
   Tagliabue, A
   De Giorgis, V
AF Ferraris, Cinzia
   Pasca, Ludovica
   Guglielmetti, Monica
   Marazzi, Claudia
   Trentani, Claudia
   Varesio, Costanza
   Tagliabue, Anna
   De Giorgis, Valentina
TI Comment on: Ketogenic diet therapy provision in the COVID-19 pandemic:
   Dual-center experience and recommendations
SO EPILEPSY & BEHAVIOR
LA English
DT Letter
C1 [Ferraris, Cinzia; Guglielmetti, Monica; Marazzi, Claudia; Trentani, Claudia; Tagliabue, Anna] Univ Pavia, Dept Publ Hlth Expt & Forens Med, Human Nutr & Eating Disorder Res Ctr, Via Agostino Bassi 21, I-27100 Pavia, Italy.
   [Pasca, Ludovica; Varesio, Costanza; De Giorgis, Valentina] IRCCS Mondino Fdn, Dept Child Neurol & Psychiat, Via Mondino 2, I-27100 Pavia, Italy.
RP Ferraris, C (corresponding author), Univ Pavia, Dept Publ Hlth Expt & Forens Med, Human Nutr & Eating Disorder Res Ctr, Via Agostino Bassi 21, I-27100 Pavia, Italy.
EM cinzia.ferraris@unipv.it; ludovica.pasca01@universitadipavia.it;
   monica.guglielmetti@unipv.it; claudiamarazzi@libero.it;
   claudia.trentani@unipv.it; costanza.varesio@gmail.com;
   anna.tagliabue@unipv.it; valentina.degiorgis@mondino.it
RI Varesio, Costanza/AAB-8688-2019; Ferraris, Cinzia/AAB-2563-2019
OI Varesio, Costanza/0000-0001-5645-021X; Ferraris,
   Cinzia/0000-0002-4148-2136
CR Ferraris C, 2020, NUTRIENTS, V12, DOI 10.3390/nu12061833
   French JA, 2020, NEUROLOGY, V94, P1032, DOI 10.1212/WNL.0000000000009632
   Kossoff EH, 2020, EPILEPSY BEHAV, V111, DOI 10.1016/j.yebeh.2020.107181
   Kossoff Eric H, 2018, Epilepsia Open, V3, P175, DOI 10.1002/epi4.12225
   Zini EM, 2018, STUD HEALTH TECHNOL, V247, P481, DOI 10.3233/978-1-61499-852-5-481
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1525-5050
EI 1525-5069
J9 EPILEPSY BEHAV
JI Epilepsy Behav.
PD NOV
PY 2020
VL 112
AR 107399
DI 10.1016/j.yebeh.2020.107399
PG 2
WC Behavioral Sciences; Clinical Neurology; Psychiatry
SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry
GA OP3TK
UT WOS:000588004200067
PM 32861023
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Saleem, T
   Sheikh, N
   Abbasi, MH
   Javed, I
   Khawar, MB
AF Saleem, Tayyaba
   Sheikh, Nadeem
   Abbasi, Muddasir Hassan
   Javed, Iram
   Khawar, Muhammad Babar
TI COVID-19 containment and its unrestrained impact on epilepsy management
   in resource-limited areas of Pakistan
SO EPILEPSY & BEHAVIOR
LA English
DT Article
DE COVID-19; Epilepsy; Outcomes; Lockdown; Pandemic; Telemedicine
ID CHALLENGES
AB The current pandemic of coronavirus disease 2019 (COVID-19) that led to an unprecedented crisis with significant health, social, and economic repercussions presented more serious concerns for those living with some chronic conditions such as epilepsy. This study was aimed to find out impact of the COVID-19 pandemic on management of epilepsy. A cross-sectional study was conducted through telephone interviews, targeting 213 caregivers of pediatric patients with epilepsy, belonging to underserved areas of Faisalabad, Punjab, Pakistan. A simple questionnaire was designed to record the responses of participants relevant to the direct and indirect effects of COVID-19 pandemic and their knowledge about possible ways that can be accessed for the management of epilepsy during an ongoing pandemic. The current study, which holds 77% of the respondents from rural areas and 23% from urban settings, showed that partial measures of lockdown taken to stop or slow the spread of COVID-19 resulted in adverse economic and health outcomes in the said population including cancelation of follow-up visits, worsening of seizures, job loss, burden of antiepileptic drugs (AEDs) costs, and discontinuation of medicines. Furthermore, knowledge about alternative ways to access health facilities was found very poor among caregivers. Income sources of poor people disrupted by lockdown can lead to unintentional nonadherence to medication, which is a clear picture of inequitable distribution of resources. This study highlights the major issues faced by the caregivers during this ongoing pandemic of COVID-19. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Saleem, Tayyaba; Sheikh, Nadeem; Khawar, Muhammad Babar] Univ Punjab, Dept Zool, Cell & Mol Biol Lab, Lahore 54590, Pakistan.
   [Abbasi, Muddasir Hassan] Univ Okara, Dept Zool, Renala Khurd 56300, Pakistan.
   [Javed, Iram] Children Hosp & Inst Child Hlth Faisalabad, Dept Pediat Neurol, Faisalabad 38000, Pakistan.
   [Khawar, Muhammad Babar] Chinese Acad Sci, Inst Zool, State Key Lab Stem Cell & Reprod Biol, Beijing, Peoples R China.
   [Khawar, Muhammad Babar] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
RP Sheikh, N (corresponding author), Univ Punjab, Dept Zool, Cell & Mol Biol Lab, Lahore 54590, Pakistan.
EM nadeem.zool@pu.edu.pk
OI saleem, tayyaba/0000-0003-4920-1463
FU Higher Education Commission, Govt. of PakistanHigher Education
   Commission of Pakistan [8369/PUNJAB/NRPU/RD/HEC/2017]
FX The authors highly acknowledge the role of Higher Education Commission,
   Govt. of Pakistan for Providing funds under grant No.
   8369/PUNJAB/NRPU/R&D/HEC/2017.
CR Adan GH, 2020, CLIN MED, V20, pE104, DOI 10.7861/clinmed.2020-0207
   Ahmed A, 2018, J PAK MED ASSOC, V68, P1820
   Aledo-Serrano A, 2020, EPILEPSIA, V61, P1312, DOI 10.1111/epi.16537
   Basu Saurav, 2020, Indian J Med Ethics, VV, P103, DOI 10.20529/IJME.2020.041
   Beghi E, 2013, EPILEPSIA, V54, P2, DOI 10.1111/epi.12305
   Brigo F, 2020, EPILEPSY BEHAV, V110, DOI 10.1016/j.yebeh.2020.107164
   Chalkidou K, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3651
   Chen D, 2020, ACTA EPILEPTOL, V2, P1, DOI [10.1186/s42494-020-00015-z, DOI 10.1186/S42494-020-00015-Z]
   Crepin S, 2009, CLIN NUTR, V28, P219, DOI 10.1016/j.clnu.2009.03.010
   Finance Mo, 2018, PAK EC SURV 2017 18
   French JA, 2020, NEUROLOGY, V94, P1032, DOI 10.1212/WNL.0000000000009632
   Gayatri NA, 2006, DEV MED CHILD NEUROL, V48, P394, DOI 10.1017/S0012162206000843
   Grossman SN, 2020, NEUROLOGY, V94, P1077, DOI 10.1212/WNL.0000000000009677
   Hamed SA, 2014, EPILEPSY BEHAV, V41, P290, DOI 10.1016/j.yebeh.2014.07.003
   Hamza M, 2020, BRIT J SURG, V107, pE193, DOI 10.1002/bjs.11661
   Keezer MR, 2016, LANCET NEUROL, V15, P106, DOI 10.1016/S1474-4422(15)00225-2
   Khan F, 2017, J REHABIL MED, V49, P10, DOI 10.2340/16501977-2149
   Khatri I A, 2003, J Pak Med Assoc, V53, P594
   Kissani N, 2020, EPILEPSY BEHAV, V103, DOI 10.1016/j.yebeh.2019.106854
   Krijgh EJC, 2018, NEUROPEDIATRICS, V49, P279, DOI 10.1055/s-0038-1654708
   Manji H, 2020, J NEUROL NEUROSUR PS, V91, P568, DOI 10.1136/jnnp-2020-323414
   Mogal Z, 2020, EPILEPSY BEHAV, V102, DOI 10.1016/j.yebeh.2019.106637
   Musselwhite K, 2007, INT J NURS STUD, V44, P1064, DOI 10.1016/j.ijnurstu.2006.05.014
   Newton CR, 2012, LANCET, V380, P1193, DOI 10.1016/S0140-6736(12)61381-6
   Ngugi AK, 2010, EPILEPSIA, V51, P883, DOI 10.1111/j.1528-1167.2009.02481.x
   Radhakrishnan K, 2009, NAT REV NEUROL, V5, P323, DOI 10.1038/nrneurol.2009.53
   Sinha A, 2014, NEUROL RES INT, V2014, DOI 10.1155/2014/869572
   Sveinsson O, 2020, NEUROLOGY, V94, pE419, DOI 10.1212/WNL.0000000000008741
   Tatum WO, 2020, JAMA NEUROL, V77, P593, DOI 10.1001/jamaneurol.2019.4785
   Vancini RL, 2020, EPILEPSY BEHAV, V110, DOI 10.1016/j.yebeh.2020.107154
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 31
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1525-5050
EI 1525-5069
J9 EPILEPSY BEHAV
JI Epilepsy Behav.
PD NOV
PY 2020
VL 112
AR 107476
DI 10.1016/j.yebeh.2020.107476
PG 5
WC Behavioral Sciences; Clinical Neurology; Psychiatry
SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry
GA OP3TK
UT WOS:000588004200117
PM 33181895
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Sanchez-Larsen, A
   Gonzalez-Villar, E
   Diaz-Maroto, I
   Layos-Romero, A
   Martinez-Martin, A
   Alcahut-Rodriguez, C
   Grande-Martin, A
   Sopelana-Garay, D
AF Sanchez-Larsen, Alvaro
   Gonzalez-Villar, Esther
   Diaz-Maroto, Inmaculada
   Layos-Romero, Almudena
   Martinez-Martin, Alvaro
   Alcahut-Rodriguez, Cristian
   Grande-Martin, Alberto
   Sopelana-Garay, David
TI Influence of the COVID-19 outbreak in people with epilepsy: Analysis of
   a Spanish population (EPICOVID registry)
SO EPILEPSY & BEHAVIOR
LA English
DT Article
DE COVID-19; SARS-CoV-2; Coronavirus; Epilepsy; Seizure; Neurology
ID ANTIEPILEPTIC DRUGS; TELEMEDICINE
AB Background: The aim of this study was to have a better understanding of the influence of the coronavirus disease 2019 (COVID-19) pandemic in people with epilepsy (PWE) and to assess whether there have been changes in seizure control during the current COVID-19 outbreak, exploring the possible causes thereof.
   Methods: This is an observational, retrospective study based on prospective data collection of 100 successive patients who attended an epilepsy outpatient clinic either face-to-face or telephonically during the months of the COVID-19 outbreak and national state of emergency.
   Results: One hundred patients were included, 52% women, mean age 42.4 years. During the COVID-19 period, 27% of the patients presented an increase of >50% of seizure frequency. An increase of stress/anxiety (odds ratios (OR): 5.78; p - 0.008) and a prior higher seizure frequency (OR: 12.4; p = 0.001) were associated with worsening of seizures. Other risk factors were exacerbation of depression, sleep deprivation, less physical activity, and history of epilepsy surgery. Three patients had status epilepticus (SE) and one a duster of seizures. Likewise, 9% of patients improved their seizure control. Reduction in stress/anxiety (OR: 0.05; p = 0.03) and recent adjustment of antiepileptics (OR: 0.07; p = 0.01) acted as protecting factors.
   Conclusions: A high proportion of PWE suffered a significant worsening of their seizure control during the months of the COVID-19 pandemic. Emotional distress due to home confinement was the main factor for the change in seizure control. Promoting physical activity and adequate sleep may minimize the potential impact of the pandemic in PWE. Ensuring correct follow-up can prevent decompensation in those PWE at high risk. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Sanchez-Larsen, Alvaro; Gonzalez-Villar, Esther; Diaz-Maroto, Inmaculada; Layos-Romero, Almudena; Martinez-Martin, Alvaro; Alcahut-Rodriguez, Cristian; Sopelana-Garay, David] Complejo Hosp Univ Albacete, Dept Neurol, Calle Hermanos Falco 37, E-02006 Albacete, Castilla La Man, Spain.
   [Grande-Martin, Alberto] Complejo Hosp Univ Albacete, Dept Clin Neurophysiol, Albacete, Castilla La Man, Spain.
RP Sanchez-Larsen, A (corresponding author), Complejo Hosp Univ Albacete, Dept Neurol, Calle Hermanos Falco 37, E-02006 Albacete, Castilla La Man, Spain.
EM aasanchez@sescam.jccm.es
RI Sanchez Larsen, Alvaro/Y-8910-2018
OI Sanchez Larsen, Alvaro/0000-0003-2134-4980; Layos-Romero,
   Almudena/0000-0002-6828-7808
CR Aledo-Serrano A, 2020, EPILEPSIA, V61, P1312, DOI 10.1111/epi.16537
   Arida RM, 2008, SPORTS MED, V38, P607, DOI 10.2165/00007256-200838070-00006
   Arida RM, 2013, EPILEPSY BEHAV, V26, P273, DOI 10.1016/j.yebeh.2012.07.025
   Balloy G, 2020, CLIN NEUROPHYSIOL
   Beghi E, 2011, EPILEPSIA, V52, P40, DOI 10.1111/j.1528-1167.2011.03035.x
   Bohmwald K, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00386
   Centro Nacional de Epidemiologia, SIT EV PAND COVID 19
   de Sanidad de Espana Ministerio, PLAN TRANS HAC NUEV
   Elger CE, 2017, SEIZURE-EUR J EPILEP, V44, P184, DOI 10.1016/j.seizure.2016.10.018
   Epilepsy Foundation, COVID 19 EP MAN EP C
   Fisher RS, 2014, EPILEPSIA, V55, P475, DOI 10.1111/epi.12550
   Forsgren L, 2005, EUR J NEUROL, V12, P245, DOI 10.1111/j.1468-1331.2004.00992.x
   French JA, 2020, NEUROLOGY, V94
   Hao X, EPILEPSIA
   Hatcher-Martin JM, 2020, NEUROLOGY, V94, P30, DOI 10.1212/WNL.0000000000008708
   Lai SL, 2005, SEIZURE-EUR J EPILEP, V14, P557, DOI 10.1016/j.seizure.2005.08.010
   Li YC, 2020, J MED VIROL, V92, P707, DOI 10.1002/jmv.25824
   Lu L, 2020, EPILEPSIA, V61, pE49, DOI 10.1111/epi.16524
   Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159
   Mao L, 2020, JAMA NEUROL
   Moriguchi T., 2020, INT J INFECT DIS
   NAKKEN KO, 1990, EPILEPSIA, V31, P88, DOI 10.1111/j.1528-1157.1990.tb05365.x
   Paniz-Mondolfi AE, 2020, J MED VIROL, V92, P2903, DOI 10.1002/jmv.26381
   Patterson V, 2005, EPILEPSIA, V46, P614, DOI 10.1111/j.1528-1167.2005.05605.x
   Pollan M., 2020, LANCET
   Punia V, 2020, TELEMED E-HEALTH, V26, P1301, DOI 10.1089/tmj.2020.0150
   Romero-Sanchez CM, 2020, NEUROLOGY
   Somani S, 2020, ANN CLIN TRANSL NEUR, V7, P1240, DOI 10.1002/acn3.51071
   Swinkels WAM, 1998, EPILEPSIA, V39, P1203, DOI 10.1111/j.1528-1157.1998.tb01312.x
   Vancini RL, 2020, EPILEPSY BEHAV
   Vollono C, 2020, SEIZURE-EUR J EPILEP, V78, P109, DOI 10.1016/j.seizure.2020.04.009
NR 31
TC 0
Z9 0
U1 1
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1525-5050
EI 1525-5069
J9 EPILEPSY BEHAV
JI Epilepsy Behav.
PD NOV
PY 2020
VL 112
AR 107396
DI 10.1016/j.yebeh.2020.107396
PG 6
WC Behavioral Sciences; Clinical Neurology; Psychiatry
SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry
GA OP3TK
UT WOS:000588004200064
PM 32911299
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Semprino, M
   Fasulo, L
   Fortini, S
   Molina, CIM
   Gonzalez, L
   Ramos, PA
   Martinez, C
   Caraballo, R
AF Semprino, Marcos
   Fasulo, Lorena
   Fortini, Sebastian
   Martorell Molina, Catalina Isabel
   Gonzalez, Lara
   Alejandra Ramos, Paola
   Martinez, Carolina
   Caraballo, Roberto
TI Telemedicine, drug-resistant epilepsy, and ketogenic dietary therapies:
   A patient survey of a pediatric remote-care program during the COVID-19
   pandemic
SO EPILEPSY & BEHAVIOR
LA English
DT Article
DE Drug-resistant epilepsy; Ketogenic diet; Telemedicine; Teleneurology;
   WhatsApp
ID MODIFIED ATKINS DIET; WHATSAPP
AB Objective: The purpose of this study was to assess parent satisfaction with the management of ketogenic diet therapies (KDTs) through telemedicine using WhatsApp as the main tool.
   Methods: Parent satisfaction was longitudinally evaluated through questionnaires. The survey was developed with Google Questionnaire forms and sent via WhatsApp. The questionnaire consisted of 13 items concerning the management of KDTs using telemedicine in the context of the coronavirus disease 2019 (COVID-19) pandemic.
   Our population of patients has limited financial resources and low levels of education. Given that many families did not have either computers or WIFI, or any other access to information or communication technology, WhatsApp was chosen as a tool as it was available on the cell phones of all families and the professionals.
   Results: Our survey showed that 96.3% of the parents were satisfied with the management of KDTs through telemedicine. The main benefits observed were the possibility of continuing treatment during the COVID-19 pandemic and the ease of accessing the professional team from the comfort of their home. Overall. 72.2% of the families would recommend using telemedicine for KDTs in any situation regardless of the pandemic. None of the families reported that they would recommend against treatment by telemedicine. The availability of a social support network (parents WhatsApp group) coordinated by professionals from the KDT team was considered to be useful by most respondents (90%).
   Conclusions: Our study suggests that management of children with DRE on KDTs through telemedicine is feasible, well accepted by the families, and probably as safe as conventional medicine. WhatsApp may be an interesting telemedicine tool to start and maintain KDTs. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Semprino, Marcos; Fasulo, Lorena] Clin San Lucas, Dept Neurol, Neuquen, Argentina.
   [Fortini, Sebastian; Gonzalez, Lara] Hosp Pediat Nino Jesus, Dept Neurol, San Miguel De Tucuman, Argentina.
   [Martorell Molina, Catalina Isabel] Hosp Pediat Nino Jesus, Dept Pediat, San Miguel De Tucuman, Argentina.
   [Semprino, Marcos; Fasulo, Lorena] Clin San Lucas, Dept Nutr, Neuquen, Argentina.
   [Alejandra Ramos, Paola; Martinez, Carolina] Hosp Pediat Nino Jesus, Dept Nutr, San Miguel De Tucuman, Argentina.
   [Caraballo, Roberto] Hosp Pediat Prof Dr Juan P Garrahan, Dept Neurol, Buenos Aires, DF, Argentina.
RP Caraballo, R (corresponding author), Combate los Pozos 1881, RA-1245 Buenos Aires, DF, Argentina.
EM rhcaraballo@arnet.com.ar
CR [Anonymous], 1879, LANCET, V114, P819, DOI DOI 10.1016/S0140-6736(02)47536-8
   Armeno M, 2020, EPILEPSY RES, V163, DOI 10.1016/j.eplepsyres.2020.106340
   Bahrani K, 2017, SEIZURE-EUR J EPILEP, V53, P55, DOI 10.1016/j.seizure.2017.11.003
   Blackford R, 2020, EPILEPSY RES, V162, DOI 10.1016/j.eplepsyres.2020.106307
   Brigo F, 2020, EPILEPSY BEHAV, V110, DOI 10.1016/j.yebeh.2020.107164
   Caraballo R., 2017, DIETA CETOGENICA TRA
   Cervenka MC, 2012, EPILEPSIA, V53, P728, DOI 10.1111/j.1528-1167.2012.03406.x
   Fasulo L, 2019, MEDICINA-BUENOS AIRE, V79, P225
   Ferraris C, 2020, NUTRIENTS, V12, DOI 10.3390/nu12061833
   Fortini S, 2020, EPILEPSY RES, V165, DOI 10.1016/j.eplepsyres.2020.106370
   French JA, 2020, NEUROLOGY, V94, P1032, DOI 10.1212/WNL.0000000000009632
   Ganasegeran K, 2017, INT J MED INFORM, V97, P145, DOI 10.1016/j.ijmedinf.2016.10.013
   Giordano V, 2017, INTERACT J MED RES, V6, DOI 10.2196/ijmr.6214
   Greenhalgh T, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m998
   Hatcher-Martin JM, 2020, NEUROLOGY, V94, P30, DOI 10.1212/WNL.0000000000008708
   Kalilani L, 2018, EPILEPSIA, V59, P2179, DOI 10.1111/epi.14596
   Keesara S, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2005835
   Kissani N, 2020, EPILEPSY BEHAV, V103, DOI 10.1016/j.yebeh.2019.106854
   Kossoff EH, 2008, EPILEPSIA, V49, P1646, DOI 10.1111/j.1528-1167.2008.01580_6.x
   Kossoff EH, 2020, EPILEPSY BEHAV, V111, DOI 10.1016/j.yebeh.2020.107181
   Litewka Sergio, 2005, Acta bioeth., V11, P127, DOI 10.4067/S1726-569X2005000200003
   Lo MD, 2019, J CHILD NEUROL, V34, P22, DOI 10.1177/0883073818807516
   Mars M, 2019, J TELEMED TELECARE, V25, P524, DOI 10.1177/1357633X19873233
   Mars M, 2016, STUD HEALTH TECHNOL, V231, P82, DOI 10.3233/978-1-61499-712-2-82
   Pasca L, 2016, EUR J PEDIATR, V175, P1267, DOI 10.1007/s00431-016-2765-z
   Patel UK, 2019, CUREUS, V11, DOI 10.7759/cureus.4410
   Flumignan CDQ, 2019, SAO PAULO MED J, V137, P184, DOI 10.1590/1516-3180.0177240419
   Rasmusson KA, 2005, EPILEPSIA, V46, P767, DOI 10.1111/j.1528-1167.2005.44804.x
   Santos-Peyret A, 2020, REV NEUROLOGIA, V70, P323, DOI 10.33588/rn.7009.2020173
   Smith AC, 2020, J TELEMED TELECARE, V26, P309, DOI 10.1177/1357633X20916567
   Weissenstein A, 2011, ITAL J PEDIATR, V37, DOI 10.1186/1824-7288-37-31
   Zini EM, 2018, STUD HEALTH TECHNOL, V247, P481, DOI 10.3233/978-1-61499-852-5-481
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1525-5050
EI 1525-5069
J9 EPILEPSY BEHAV
JI Epilepsy Behav.
PD NOV
PY 2020
VL 112
AR 107493
DI 10.1016/j.yebeh.2020.107493
PG 6
WC Behavioral Sciences; Clinical Neurology; Psychiatry
SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry
GA OP3TK
UT WOS:000588004200126
PM 33181913
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Willems, LM
   Balcik, Y
   Noda, AH
   Siebenbrodt, K
   Leimeister, S
   McCoy, J
   Kienitz, R
   Kiyose, M
   Reinecke, R
   Schafer, JH
   Zollner, JP
   Bauer, S
   Rosenow, F
   Strzelczyk, A
AF Willems, Laurent M.
   Balcik, Yunus
   Noda, Anna H.
   Siebenbrodt, Kai
   Leimeister, Sina
   McCoy, Jeannie
   Kienitz, Ricardo
   Kiyose, Makoto
   Reinecke, Raphael
   Schaefer, Jan-Hendrik
   Zoellner, Johann Philipp
   Bauer, Sebastian
   Rosenow, Felix
   Strzelczyk, Adam
TI SARS-CoV-2-related rapid reorganization of an epilepsy outpatient clinic
   from personal appointments to telemedicine services: A German
   single-center experience
SO EPILEPSY & BEHAVIOR
LA English
DT Article
DE COVID; Corona; Pandemic; Seizure; Anticonvulsant
ID ILAE COMMISSION; OPERATIONAL CLASSIFICATION; POSITION PAPER; COVID-19;
   GUIDELINES; COSTS
AB Introduction: When the SARS-CoV-2 pandemic reached Europe in 2020, a German governmental order forced clinics to immediately suspend elective care, causing a problem for patients with chronic illnesses such as epilepsy. Here, we report the experience of one clinic that converted its outpatient care from personal appointments to telemedicine services.
   Methods: Documentations of telephone contacts and telemedicine consultations at the Epilepsy Center Frankfurt Rhine-Main were recorded in detail between March and May 2020 and analyzed for acceptance, feasibility, and satisfaction of the conversion from personal to telemedicine appointments from both patients' and medical professionals' perspectives.
   Results: Telephone contacts for 272 patients (mean age: 38.7 years, range: 17-79 years, 55.5% female) were analyzed. Patient-rated medical needs were either very urgent (6.6%, n = 18), urgent (23.5%, n = 64), less urgent (29.8%, n 81), or nonurgent (39.3%, n = 107). Outpatient service cancelations resulted in a lack of understanding (9.6%, n = 26) or anger and aggression (2.9%, n = 8) in a minority of patients, while 88.6% (n = 241) reacted with understanding, or relief (33%, n= 9). Telemedicine consultations rather than a postponed face-to-face visit were requested by 109 patients (40.1%), and these requests were significantly associated with subjective threat by SARS-CoV-2 (p = 0.004), urgent or very urgent medical needs (p = 0.004), and female gender (p = 0.024). Telemedicine satisfaction by patients and physidans was high. Overall, 9.2% (n = 10) of patients reported general supply problems due to SARS-CoV-2, and 28.4% (n = 31) reported epilepsy-specific problems, most frequently related to prescriptions, or supply problems for antiseizure drugs (ASDs; 22.9%, n 25).
   Conclusion: Understanding and acceptance of elective ambulatory visit cancelations and the conversion to telemedicine consultations was high during the coronavirus disease 2019 (COVID-19) lockdown. Patients who engaged in telemedicine consultations were highly satisfied, supporting the feasibility and potential of telemedicine during the COVID-19 pandemic and beyond. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Willems, Laurent M.; Balcik, Yunus; Noda, Anna H.; Siebenbrodt, Kai; Leimeister, Sina; McCoy, Jeannie; Kienitz, Ricardo; Kiyose, Makoto; Reinecke, Raphael; Schaefer, Jan-Hendrik; Zoellner, Johann Philipp; Bauer, Sebastian; Rosenow, Felix; Strzelczyk, Adam] Univ Hosp, Epilepsy Ctr Frankfurt Rhine Main, Frankfurt, Germany.
   [Willems, Laurent M.; Balcik, Yunus; Noda, Anna H.; Siebenbrodt, Kai; Leimeister, Sina; McCoy, Jeannie; Kienitz, Ricardo; Kiyose, Makoto; Reinecke, Raphael; Schaefer, Jan-Hendrik; Zoellner, Johann Philipp; Bauer, Sebastian; Rosenow, Felix; Strzelczyk, Adam] Univ Hosp, Dept Neurol, Frankfurt, Germany.
   [Willems, Laurent M.; Balcik, Yunus; Noda, Anna H.; Siebenbrodt, Kai; Leimeister, Sina; McCoy, Jeannie; Kienitz, Ricardo; Kiyose, Makoto; Reinecke, Raphael; Schaefer, Jan-Hendrik; Zoellner, Johann Philipp; Bauer, Sebastian; Rosenow, Felix; Strzelczyk, Adam] Goethe Univ Frankfurt, Frankfurt, Germany.
   [Willems, Laurent M.; Balcik, Yunus; Noda, Anna H.; Siebenbrodt, Kai; Leimeister, Sina; McCoy, Jeannie; Kienitz, Ricardo; Kiyose, Makoto; Zoellner, Johann Philipp; Bauer, Sebastian; Rosenow, Felix; Strzelczyk, Adam] Goethe Univ Frankfurt, LOEWE Ctr Personalized Translat Epilepsy Res CePT, Frankfurt, Germany.
RP Strzelczyk, A (corresponding author), Goethe Univ Frankfurt, Epilepsy Ctr Frankfurt Rhine Main, Ctr Neurol & Neurosurg, Schleusenweg 2-16, D-60528 Frankfurt, Germany.
EM strzelczyk@med.uni-frankfurt.de
FU State of Hessen
FX This study analysis was supported by the State of Hessen with a
   LOEWE-Grant to the CePTER Consortium
   (https://www.uni-frankfurt.de/67689811).
CR [Anonymous], 2008, BMJ-BRIT MED J, V336, P35
   Asadi-Pooya AA, 2020, J NEUROL SCI, V413, DOI 10.1016/j.jns.2020.116832
   Benchimol EI, 2015, PLOS MED, V12, DOI [10.1371/journal.pmed.1001885, 10.1016/j.zefq.2016.07.010]
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bouffier V, 2020, 5 VERORDNUNG BEKAMPF
   Brigo F, 2020, EPILEPSY BEHAV, V110, DOI 10.1016/j.yebeh.2020.107164
   Cabezudo-Garcia P, 2020, NEUROLOGY, V95, pE1417, DOI 10.1212/WNL.0000000000010033
   DeStatis, 2020, NUMB DAIL REC COR CO
   DeStatis, 2020, STAT JB 2019
   Ertl J, 2016, SEIZURE-EUR J EPILEP, V41, P9, DOI 10.1016/j.seizure.2016.07.001
   Escoffery C, 2018, TELEMED E-HEALTH, V24, P335, DOI 10.1089/tmj.2017.0136
   Fisher RS, 2017, EPILEPSIA, V58, P531, DOI 10.1111/epi.13671
   Fisher RS, 2017, EPILEPSIA, V58, P522, DOI 10.1111/epi.13670
   French JA, 2020, NEUROLOGY, V94, P1032, DOI 10.1212/WNL.0000000000009632
   Hamer HM, 2012, J NEUROL, V259, P2376, DOI 10.1007/s00415-012-6509-3
   Hanson RE, 2019, MOV DISORD CLIN PRAC, V6, P65, DOI 10.1002/mdc3.12703
   Hollander JE, 2020, NEW ENGL J MED, V382, P1679, DOI 10.1056/NEJMp2003539
   Hua JL, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072309
   Hurst L, 2019, J MED INTERNET RES, V21, DOI 10.2196/13117
   Jimmy Beena, 2011, Oman Med J, V26, P155, DOI 10.5001/omj.2011.38
   Kamal SA, 2020, TECHNOL SOC, V60, DOI 10.1016/j.techsoc.2019.101212
   Khairat S, 2019, JMIR MHEALTH UHEALTH, V7, DOI 10.2196/13772
   Kuroda N, 2020, EPILEPSY BEHAV, V108, DOI 10.1016/j.yebeh.2020.107122
   Kwan P, 2010, EPILEPSIA, V51, P1069, DOI 10.1111/j.1528-1167.2009.02397.x
   Kwan P, 2010, LANCET NEUROL, V9, P27, DOI 10.1016/S1474-4422(09)70304-7
   Lai SL, 2005, SEIZURE-EUR J EPILEP, V14, P557, DOI 10.1016/j.seizure.2005.08.010
   Lowerison MW, 2019, JAMA NEUROL, V76, P1352, DOI 10.1001/jamaneurol.2019.2268
   Lu L, 2020, EPILEPSIA, V61, pE49, DOI 10.1111/epi.16524
   McCall T, 2020, JMIR MENT HEALTH, V7, DOI 10.2196/15801
   Ohannessian R, 2020, JMIR PUBLIC HLTH SUR, V6, P121, DOI 10.2196/18810
   Papa SM, 2020, MOVEMENT DISORD, V35, P711, DOI 10.1002/mds.28067
   Porcheddu R, 2020, J INFECT DEV COUNTR, V14, P125, DOI 10.3855/jidc.12600
   Rho MJ, 2014, CLUST COMPUT, V18
   Rosenow F, 2020, SEIZURE-EUR J EPILEP, V78, P31, DOI 10.1016/j.seizure.2020.02.018
   Rosenow F, 2018, KLIN NEUROPHYSIOL, V49, P208, DOI 10.1055/a-0627-8047
   Rosenow F, 2016, EPILEPSIA, V57, P1215, DOI 10.1111/epi.13449
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Scheffer IE, 2017, EPILEPSIA, V58, P512, DOI 10.1111/epi.13709
   Strzelczyk A, 2016, EPILEPSY BEHAV, V64, P75, DOI 10.1016/j.yebeh.2016.07.037
   Tsai J, 2020, LANCET PUBLIC HEALTH, V5, pE186, DOI 10.1016/S2468-2667(20)30053-0
   Vollono C, 2020, SEIZURE-EUR J EPILEP, V78, P109, DOI 10.1016/j.seizure.2020.04.009
   Waller M, 2018, CURR ALLERGY ASTHM R, V18, DOI 10.1007/s11882-018-0808-4
   Weiner BJ, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0635-3
   Willems LM, 2019, EPILEPSY BEHAV, V91, P86, DOI 10.1016/j.yebeh.2018.04.008
NR 44
TC 1
Z9 1
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1525-5050
EI 1525-5069
J9 EPILEPSY BEHAV
JI Epilepsy Behav.
PD NOV
PY 2020
VL 112
AR 107483
DI 10.1016/j.yebeh.2020.107483
PG 8
WC Behavioral Sciences; Clinical Neurology; Psychiatry
SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry
GA OP3TK
UT WOS:000588004200122
PM 33181898
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Kneller, DW
   Phillips, G
   O'Neill, HM
   Tan, KM
   Joachimiak, A
   Coates, L
   Kovalevsky, A
AF Kneller, Daniel W.
   Phillips, Gwyndalyn
   O'Neill, Hugh M.
   Tan, Kemin
   Joachimiak, Andrzej
   Coates, Leighton
   Kovalevsky, Andrey
TI Room-temperature X-ray crystallography reveals the oxidation and
   reactivity of cysteine residues in SARS-CoV-2 3CL M-pro: insights into
   enzyme mechanism and drug design
SO IUCRJ
LA English
DT Article
DE room-temperature X-ray crystallography; SARS-CoV-2; 3CL main protease;
   3CL M-pro; cysteine oxidation; protonation state; enzyme mechanism; drug
   design
ID MAIN PROTEASE; SARS; INHIBITORS; PROTEINASE; INTERMEDIATE; DIMER; PH
AB The emergence of the novel coronavirus SARS-CoV-2 has resulted in a worldwide pandemic not seen in generations. Creating treatments and vaccines to battle COVID-19, the disease caused by the virus, is of paramount importance in order to stop its spread and save lives. The viral main protease, 3CL M-pro, is indispensable for the replication of SARS-CoV-2 and is therefore an important target for the design of specific protease inhibitors. Detailed knowledge of the structure and function of 3CL M-pro is crucial to guide structure-aided and computational drug-design efforts. Here, the oxidation and reactivity of the cysteine residues of the protease are reported using room-temperature X-ray crystallography, revealing that the catalytic Cys145 can be trapped in the peroxysulfenic acid oxidation state at physiological pH, while the other surface cysteines remain reduced. Only Cys145 and Cys156 react with the alkylating agent N-ethylmaleimide. It is suggested that the zwitterionic Cys145-His45 catalytic dyad is the reactive species that initiates catalysis, rather than Cys145-to-His41 proton transfer via the general acid-base mechanism upon substrate binding. The structures also provide insight into the design of improved 3CL M-pro inhibitors.
C1 [Kneller, Daniel W.; Phillips, Gwyndalyn; O'Neill, Hugh M.; Coates, Leighton; Kovalevsky, Andrey] Oak Ridge Natl Lab, Neutron Scattering Div, 1 Bethel Valley Rd, Oak Ridge, TN 37831 USA.
   [Tan, Kemin; Joachimiak, Andrzej] Univ Chicago, Ctr Struct Genom Infect Dis, Consortium Adv Sci & Engn, Chicago, IL 60667 USA.
   [Tan, Kemin; Joachimiak, Andrzej] Argonne Natl Lab, Xray Sci Div, Struct Biol Ctr, Argonne, IL 60439 USA.
   [Joachimiak, Andrzej] Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60367 USA.
RP Coates, L; Kovalevsky, A (corresponding author), Oak Ridge Natl Lab, Neutron Scattering Div, 1 Bethel Valley Rd, Oak Ridge, TN 37831 USA.
EM coatesl@ornl.gov; kovalevskyay@ornl.gov
OI Joachimiak, Andrzej/0000-0003-2535-6209; Kovalevsky,
   Andrey/0000-0003-4459-9142; Kneller, Daniel/0000-0002-5416-5789;
   Phillips, Gwyndalyn/0000-0001-5858-3825
FU DOE Office of Science through the National Virtual Biotechnology
   Laboratory (NVBL), a consortium of DOE national laboratories focused on
   response to COVID-19United States Department of Energy (DOE);
   Coronavirus CARES Act; National Institute of Allergy and Infectious
   Diseases, National Institutes of Health, Department of Health and Human
   ServicesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [HHSN272201700060C]; DOE Office of Science
   by Argonne National LaboratoryUnited States Department of Energy (DOE)
   [DE-AC02-06CH11357]
FX This research was supported by the DOE Office of Science through the
   National Virtual Biotechnology Laboratory (NVBL), a consortium of DOE
   national laboratories focused on response to COVID-19, with funding
   provided by the Coronavirus CARES Act. Funding for this project was
   provided in part by federal funds from the National Institute of Allergy
   and Infectious Diseases, National Institutes of Health, Department of
   Health and Human Services under Contract No. HHSN272201700060C and by
   the US Department of Energy (DOE) Office of Science, operated for the
   DOE Office of Science by Argonne National Laboratory under Contract No.
   DE-AC02-06CH11357.
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Driggers CM, 2013, J MOL BIOL, V425, P3121, DOI 10.1016/j.jmb.2013.05.028
   Dussault PH, 1999, BIOORG MED CHEM LETT, V9, P3255, DOI 10.1016/S0960-894X(99)00563-6
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Evans PR, 2013, ACTA CRYSTALLOGR D, V69, P1204, DOI 10.1107/S0907444913000061
   Gorbalenya AE, 1996, PERSPECT DRUG DISCOV, V6, P64, DOI 10.1007/BF02174046
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Helmy YA, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041225
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Hill BG, 2009, FREE RADICAL BIO MED, V47, P675, DOI 10.1016/j.freeradbiomed.2009.06.012
   Huang CK, 2004, BIOCHEMISTRY-US, V43, P4568, DOI 10.1021/bi036022q
   Jin ZM, 2020, NAT STRUCT MOL BIOL, V27, P529, DOI 10.1038/s41594-020-0440-6
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   Kneller DW, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16954-7
   Kuo CJ, 2004, BIOCHEM BIOPH RES CO, V318, P862, DOI 10.1016/j.bbrc.2004.04.098
   Liebschner D, 2019, ACTA CRYSTALLOGR D, V75, P861, DOI 10.1107/S2059798319011471
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Ma CL, 2020, CELL RES, V30, P678, DOI 10.1038/s41422-020-0356-z
   MENARD R, 1992, BIOL CHEM H-S, V373, P393, DOI 10.1515/bchm3.1992.373.2.393
   Muramatsu T, 2016, P NATL ACAD SCI USA, V113, P12997, DOI 10.1073/pnas.1601327113
   Paasche A, 2014, BIOCHEMISTRY-US, V53, P5930, DOI 10.1021/bi400604t
   Paasche A, 2013, J CHEM THEORY COMPUT, V9, P1765, DOI 10.1021/ct301082y
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Poole LB, 2020, ESSAYS BIOCHEM, V64, P1, DOI 10.1042/EBC20190050
   Rauwerdink A, 2015, ACS CATAL, V5, P6153, DOI 10.1021/acscatal.5b01539
   Riva L, 2020, NATURE, V586, P113, DOI 10.1038/s41586-020-2577-1
   Rudyk O, 2014, REDOX BIOL, V2, P803, DOI 10.1016/j.redox.2014.06.005
   Simmons CR, 2008, BIOCHEMISTRY-US, V47, P11390, DOI 10.1021/bi801546n
   Solowiej J, 2008, BIOCHEMISTRY-US, V47, P2617, DOI 10.1021/bi702107v
   Tan JZ, 2005, J MOL BIOL, V354, P25, DOI 10.1016/j.jmb.2005.09.012
   Taranto AG, 2008, J MOL GRAPH MODEL, V27, P275, DOI 10.1016/j.jmgm.2008.05.002
   Tong L, 2002, CHEM REV, V102, P4609, DOI 10.1021/cr010184f
   Vagin A, 2010, ACTA CRYSTALLOGR D, V66, P22, DOI 10.1107/S0907444909042589
   Wang L, 2017, EUR J MED CHEM, V137, P450, DOI 10.1016/j.ejmech.2017.05.045
   Wang YP, 2019, ANTIMICROB AGENTS CH, V63, DOI 10.1128/AAC.01735-18
   Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749
   Wu CG, 2013, ACTA CRYSTALLOGR D, V69, P747, DOI 10.1107/S0907444913001315
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu JB, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020244
   Xue XY, 2007, J MOL BIOL, V366, P965, DOI 10.1016/j.jmb.2006.11.073
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhu LL, 2011, ANTIVIR RES, V92, P204, DOI 10.1016/j.antiviral.2011.08.001
NR 47
TC 0
Z9 0
U1 3
U2 3
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
SN 2052-2525
J9 IUCRJ
JI IUCrJ
PD NOV
PY 2020
VL 7
BP 1028
EP 1035
DI 10.1107/S2052252520012634
PN 6
PG 8
WC Chemistry, Multidisciplinary; Crystallography; Materials Science,
   Multidisciplinary
SC Chemistry; Crystallography; Materials Science
GA OQ4MS
UT WOS:000588760200011
PM 33063790
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Shabalin, IG
   Czub, MP
   Majorek, KA
   Brzezinski, D
   Grabowski, M
   Cooper, DR
   Panasiuk, M
   Chruszcz, M
   Minor, W
AF Shabalin, Ivan G.
   Czub, Mateusz P.
   Majorek, Karolina A.
   Brzezinski, Dariusz
   Grabowski, Marek
   Cooper, David R.
   Panasiuk, Mateusz
   Chruszcz, Maksymilian
   Minor, Wladek
TI Molecular determinants of vascular transport of dexamethasone in
   COVID-19 therapy
SO IUCRJ
LA English
DT Article
DE COVID-19; dexamethasone; SARS-CoV-2; coronavirus; drug transport;
   albumin
ID HUMAN-SERUM-ALBUMIN; PLASMA-PROTEIN BINDING; STRUCTURAL BASIS; DRUG;
   VALIDATION; MODEL; HYPOALBUMINEMIA; DICLOFENAC; GLYCATION; REVEALS
AB Dexamethasone, a widely used corticosteroid, has recently been reported as the first drug to increase the survival chances of patients with severe COVID-19. Therapeutic agents, including dexamethasone, are mostly transported through the body by binding to serum albumin. Here, the first structure of serum albumin in complex with dexamethasone is reported. Dexamethasone binds to drug site 7, which is also the binding site for commonly used nonsteroidal anti-inflammatory drugs and testosterone, suggesting potentially problematic binding competition. This study bridges structural findings with an analysis of publicly available clinical data from Wuhan and suggests that an adjustment of the dexamethasone regimen should be further investigated as a strategy for patients affected by two major COVID-19 risk factors: low albumin levels and diabetes.
C1 [Shabalin, Ivan G.; Czub, Mateusz P.; Majorek, Karolina A.; Brzezinski, Dariusz; Grabowski, Marek; Cooper, David R.; Minor, Wladek] Univ Virginia, Dept Mol Physiol & Biol Phys, 1340 Jefferson Pk Ave, Charlottesville, VA 22908 USA.
   [Brzezinski, Dariusz] Polish Acad Sci, Ctr Biocrystallog Res, Inst Bioorgan Chem, PL-61704 Poznan, Poland.
   [Brzezinski, Dariusz] Poznan Univ Tech, Inst Comp Sci, PL-60965 Poznan, Poland.
   [Panasiuk, Mateusz] Med Univ Bialystok, Dept Clin Med, PL-15089 Bialystok, Poland.
   [Chruszcz, Maksymilian] Univ South Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA.
   [Majorek, Karolina A.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland.
RP Minor, W (corresponding author), Univ Virginia, Dept Mol Physiol & Biol Phys, 1340 Jefferson Pk Ave, Charlottesville, VA 22908 USA.
EM wladek@iwonka.med.virginia.edu
RI Czub, Mateusz/Q-1346-2016; Brzezinski, Dariusz/F-7789-2014; Cooper,
   David/R-6071-2016
OI Czub, Mateusz/0000-0001-8973-4569; Minor, Wladek/0000-0001-7075-7090;
   Brzezinski, Dariusz/0000-0001-9723-525X; Cooper,
   David/0000-0001-5240-9789
FU National Institute of General Medical SciencesUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [R01-GM132595,
   U54-GM094662]; Polish National Agency for Academic Exchange
   [PPN/BEK/2018/1/00058/U/00001]; Polish National Science Center
   [2020/01/0/NZ1/00134]; Robert R. Wagner Fellowship at the University of
   Virginia; COVID-19 Research Initiative grant from the Office of the Vice
   President for Research at the University of South Carolina
FX This work was supported by the National Institute of General Medical
   Sciences grants R01-GM132595 and U54-GM094662. DB acknowledges the
   support of the Polish National Agency for Academic Exchange (grant No.
   PPN/BEK/2018/1/00058/U/00001) and Polish National Science Center (grant
   No. 2020/01/0/NZ1/00134). MPC acknowledges the support of the Robert R.
   Wagner Fellowship at the University of Virginia. MC was partially
   supported by a COVID-19 Research Initiative grant from the Office of the
   Vice President for Research at the University of South Carolina.
CR Alangari AA, 2014, ANN THORAC MED, V9, P187, DOI 10.4103/1817-1737.140120
   Anguizola J, 2013, CLIN CHIM ACTA, V425, P64, DOI 10.1016/j.cca.2013.07.013
   Aziz M, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02995-3
   Bagley SC, 2001, J CLIN EPIDEMIOL, V54, P979, DOI 10.1016/S0895-4356(01)00372-9
   Bhattacharya AA, 2000, J BIOL CHEM, V275, P38731, DOI 10.1074/jbc.M005460200
   Bohnert T, 2013, J PHARM SCI-US, V102, P2953, DOI 10.1002/jps.23614
   Borek D, 2010, ACTA CRYSTALLOGR D, V66, P426, DOI 10.1107/S0907444909040177
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen R, 2012, CELL, V148, P1293, DOI 10.1016/j.cell.2012.02.009
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   CUMMINGS DM, 1990, DICP ANN PHARMAC, V24, P229, DOI 10.1177/106002809002400301
   Czub MP, 2020, J MED CHEM, V63, P6847, DOI 10.1021/acs.jmedchem.0c00225
   Czub MP, 2019, CHEM SCI, V10, P1607, DOI 10.1039/c8sc04397c
   de la Rica R, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8081106
   Eakins James, 2009, J Diabetes Sci Technol, V3, P1373
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Garcia-Martinez R, 2013, HEPATOLOGY, V58, P1836, DOI 10.1002/hep.26338
   Gatta A, 2012, INTERN EMERG MED, V7, pS193, DOI 10.1007/s11739-012-0802-0
   Ghuman J, 2005, J MOL BIOL, V353, P38, DOI 10.1016/j.jmb.2005.07.075
   GIAGULLI VA, 2020, ANDROLOGY US 0628, DOI DOI 10.1111/ANDR.12836
   Gore S, 2017, STRUCTURE, V25, P1916, DOI 10.1016/j.str.2017.10.009
   Grabowski M, 2019, STRUCT DYN-US, V6, DOI 10.1063/1.5128672
   Grabowski M, 2016, ACTA CRYSTALLOGR D, V72, P1181, DOI 10.1107/S2059798316014716
   Halpin DMG, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01009-2020
   Halpin DMG, 2020, LANCET RESP MED, V8, P436, DOI 10.1016/S2213-2600(20)30167-3
   Handing KB, 2016, CHEM SCI, V7, P6635, DOI 10.1039/c6sc02267g
   Handing KB, 2016, MOL IMMUNOL, V71, P143, DOI 10.1016/j.molimm.2016.02.003
   Holm L, 2019, BIOINFORMATICS, V35, P5326, DOI 10.1093/bioinformatics/btz536
   Huang JF, 2020, J MED VIROL, V92, P2152, DOI 10.1002/jmv.26003
   Huang W, 2020, SCI CHINA LIFE SCI, V63, P1678, DOI 10.1007/s11427-020-1733-4
   Jellinge ME, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105983
   Kathirvel S, 2020, MICROB PATHOGENESIS, V140, DOI 10.1016/j.micpath.2019.103944
   Kostaras X, 2014, CURR ONCOL, V21, pE493, DOI 10.3747/co.21.1769
   Kowiel M, 2014, ACTA CRYSTALLOGR D, V70, P3290, DOI 10.1107/S1399004714024572
   Lane H Clifford, 2020, N Engl J Med, DOI 10.1056/NEJMe2024638
   Ledford H, 2020, NATURE, V582, P469, DOI 10.1038/d41586-020-01824-5
   Lee P, 2015, CURR PHARM DESIGN, V21, P1862, DOI 10.2174/1381612821666150302115025
   Majorek K. A., 2020, STRUCTURAL BIOL DRUG, P253
   Majorek KA, 2012, MOL IMMUNOL, V52, P174, DOI 10.1016/j.molimm.2012.05.011
   MCELNAY JC, 1983, DRUGS, V25, P495, DOI 10.2165/00003495-198325050-00003
   Merritt EA, 2012, ACTA CRYSTALLOGR D, V68, P468, DOI 10.1107/S0907444911028320
   Minor W, 2006, ACTA CRYSTALLOGR D, V62, P859, DOI 10.1107/S0907444906019949
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Naik PN, 2010, J PHOTOCH PHOTOBIO B, V100, P147, DOI 10.1016/j.jphotobiol.2010.05.014
   Nakajou K, 2003, BBA-GEN SUBJECTS, V1623, P88, DOI 10.1016/j.bbagen.2003.08.001
   Nazha B, 2015, WORLD J GASTRO SURG, V7, P370, DOI 10.4240/wjgs.v7.i12.370
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Painter J, 2006, ACTA CRYSTALLOGR D, V62, P439, DOI 10.1107/S0907444906005270
   Pan SD, 2016, PATIENT PREFER ADHER, V10, P549, DOI 10.2147/PPA.S103156
   Peters Jr T, 1995, ALL ALBUMIN BIOCH GE
   Porebski PJ, 2020, PROTEIN SCI, V29, P120, DOI 10.1002/pro.3747
   Porebski PJ, 2018, PROTEIN SCI, V27, P86, DOI 10.1002/pro.3272
   Pozzilli P, 2020, METABOLISM, V108, DOI 10.1016/j.metabol.2020.154252
   Ramadori G., 2020, HEPATOMA RES, V6, P28, DOI [10.20517/2394-5079.2020.43, DOI 10.20517/2394-5079.2020.43]
   Ray DW, 1999, MOL ENDOCRINOL, V13, P1855, DOI 10.1210/me.13.11.1855
   Raynor JW, 2007, ACTA CRYSTALLOGR E, V63, pO2791, DOI 10.1107/S1600536807020806
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   RECOVERY/University of Oxford, 2020, RECOVERY DEX METH ST
   Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541
   Rifai N., 2018, TIETZ TXB CLIN CHEM
   Roberts JA, 2013, CLIN PHARMACOKINET, V52, P1, DOI 10.1007/s40262-012-0018-5
   Roohk H Vernon, 2008, J Diabetes Sci Technol, V2, P1114
   Sekula B, 2016, J MED CHEM, V59, P82, DOI 10.1021/acs.jmedchem.5b00909
   Shabalin IG, 2018, CRYSTALLOGR REV, V24, P236, DOI 10.1080/0889311X.2018.1521805
   SHAKLAI N, 1984, J BIOL CHEM, V259, P3812
   Soeters PB, 2019, JPEN-PARENTER ENTER, V43, P181, DOI 10.1002/jpen.1451
   Spoorenberg SMC, 2014, BRIT J CLIN PHARMACO, V78, P78, DOI 10.1111/bcp.12295
   Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023
   Sulkowska A, 2004, BIOPOLYMERS, V74, P256, DOI 10.1002/bip.20031
   Trainor GL, 2007, EXPERT OPIN DRUG DIS, V2, P51, DOI 10.1517/17460441.2.1.51
   Ulldemolins M, 2011, CLIN PHARMACOKINET, V50, P99, DOI 10.2165/11539220-000000000-00000
   US Food and Drug Administration, 2012, COLCH PAT INF LEAFL
   Vagin A, 2010, ACTA CRYSTALLOGR D, V66, P22, DOI 10.1107/S0907444909042589
   Weaving G, 2016, ANN CLIN BIOCHEM, V53, P106, DOI 10.1177/0004563215593561
   WEISSMAN DE, 1987, J NEURO-ONCOL, V5, P125, DOI 10.1007/BF02571300
   Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749
   Wlodawer A, 2020, FEBS J, V287, P3703, DOI 10.1111/febs.15366
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yan L, 2020, NAT MACH INTELL, V2, P283, DOI 10.1038/s42256-020-0180-7
   YUANJING C, 2009, COCHRANE DB SYST REV
   Zhang Y, 2015, CHEM BIOL DRUG DES, V86, P1178, DOI 10.1111/cbdd.12583
   Zhao P, 2009, ANAL BIOANAL CHEM, V393, P257, DOI 10.1007/s00216-008-2373-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zimmerman MD, 2014, METHODS MOL BIOL, V1140, P1, DOI 10.1007/978-1-4939-0354-2_1
   Zsila F, 2013, MOL PHARMACEUT, V10, P1668, DOI 10.1021/mp400027q
NR 87
TC 1
Z9 1
U1 0
U2 0
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
SN 2052-2525
J9 IUCRJ
JI IUCrJ
PD NOV
PY 2020
VL 7
BP 1048
EP 1058
DI 10.1107/S2052252520012944
PN 6
PG 11
WC Chemistry, Multidisciplinary; Crystallography; Materials Science,
   Multidisciplinary
SC Chemistry; Crystallography; Materials Science
GA OQ4MS
UT WOS:000588760200013
PM 33063792
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bajiya, VP
   Bugalia, S
   Tripathi, JP
AF Bajiya, Vijay Pal
   Bugalia, Sarita
   Tripathi, Jai Prakash
TI Mathematical modeling of COVID-19: Impact of non-pharmaceutical
   interventions in India
SO CHAOS
LA English
DT Article
ID CORONAVIRUS; WUHAN; TRANSMISSION; 2019-NCOV
AB In the absence of effective vaccine/antiviral strategies for reducing the burden of the coronavirus disease 2019 (COVID-19) pandemic in India, the main focus has been on basic non-pharmaceutical interventions (NPIs), such as nationwide lockdown (travel restrictions and the closure of schools, shopping malls, and worshipping and other gathering places), quarantining of exposed individuals, and isolation of infected individuals. In the present study, we propose a compartmental epidemic model incorporating quarantine and isolation compartments to (i) describe the current transmission patterns of COVID-19 in India, (ii) assess the impact of currently implemented NPIs, and (iii) predict the future course of the pandemic with various scenarios of NPIs in India. For
   R 0 < 1, the system has a globally asymptotically stable disease free equilibrium, while for
   R 0 > 1, the system has one unstable disease free equilibrium and a unique locally stable endemic equilibrium. By using the method of least squares and the best fit curve, we estimate the model parameters to calibrate the model with daily new confirmed cases and cumulative confirmed cases in India for the period from May 1, 2020 to June 25, 2020. Our result shows that the implementation of an almost perfect isolation in India and 33.33% increment in contact-tracing on June 26, 2020 may reduce the number of cumulative confirmed cases of COVID-19 in India by around 53.8% at the end of July 2020. Nationwide lockdown with high efficiency can diminish COVID-19 cases drastically, but combined NPIs may accomplish the strongest and most rapid impact on the spreading of COVID-19 in India.
C1 [Bajiya, Vijay Pal; Bugalia, Sarita; Tripathi, Jai Prakash] Cent Univ Rajasthan, Dept Math, Ajmer 305817, Rajasthan, India.
RP Tripathi, JP (corresponding author), Cent Univ Rajasthan, Dept Math, Ajmer 305817, Rajasthan, India.
EM jtripathi85@curaj.ac.in
FU Council of Scientific AMP; Industrial Research (CSIR), India
   [09/1131(0006)/2017-EMR-I]; CSIR, IndiaCouncil of Scientific &
   Industrial Research (CSIR) - India [09/1131(0025)/2018-EMR-I]; Science
   and Engineering Research Board (SERB), IndiaDepartment of Science &
   Technology (India)Science Engineering Research Board (SERB), India
   [ECR/2017/002786]; UGC-BSR Research Start-Up-Grant, India
   [F.30-356/2017(BSR)]
FX Vijay Pal Bajiya receives funding as senior research fellowship from the
   Council of Scientific & Industrial Research (CSIR), India (File No.
   09/1131(0006)/2017-EMR-I). The research work of Sarita Bugalia is
   supported by the CSIR, India (File No. 09/1131(0025)/2018-EMR-I). The
   research work of Jai Prakash Tripathi is supported by the Science and
   Engineering Research Board (SERB), India (File No. ECR/2017/002786) and
   the UGC-BSR Research Start-Up-Grant, India (No. F.30-356/2017(BSR)). We
   are highly thankful to Dr. Anuj Mubayi (Arizona State University) whose
   constant guidance and support improved the quality of the manuscript.
CR Anastassopoulou C, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230405
   [Anonymous], 2020, SITUATION REPORT 73
   [Anonymous], 2019, LIFE EXPECTANCY OF C
   [Anonymous], 2020, CORONAVIRUS DISEASE
   [Anonymous], 2020, CORONAVIRUS COVID 19
   Bi Q., 2020, MEDRXIV
   Burki TK, 2020, LANCET RESP MED, V8, P238, DOI 10.1016/S2213-2600(20)30056-4
   Castillo-Chavez C, 2004, MATH BIOSCI ENG, V1, P361, DOI 10.3934/mbe.2004.1.361
   Chakraborty T, 2020, CHAOS SOLITON FRACT, V135, DOI 10.1016/j.chaos.2020.109850
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Ribeiro MHD, 2020, CHAOS SOLITON FRACT, V135, DOI 10.1016/j.chaos.2020.109853
   Davies N. G., 2020, MEDRXIV
   Duan B, 2019, Z ANGEW MATH PHYS, V70, DOI 10.1007/s00033-019-1093-3
   Eikenberry SE, 2020, INFECT DIS MODEL, V5, P293, DOI 10.1016/j.idm.2020.04.001
   Fanelli D, 2020, CHAOS SOLITON FRACT, V134, DOI 10.1016/j.chaos.2020.109761
   Ferguson N., 2020, REPORT 9 IMPACT OF N
   Flaxman S, 2020, NATURE, V584, P257, DOI 10.1038/s41586-020-2405-7
   Gorbalenya A. E., 2020, BIORXIV
   Guckenheimer J., 1983, NONLINEAR OSCILATION
   Haushofer J, 2020, SCIENCE, V368, P1063, DOI 10.1126/science.abb6144
   Hellewell J, 2020, LANCET GLOB HEALTH, V8, pE488, DOI 10.1016/S2214-109X(20)30074-7
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Jakhar M., 2020, MEDRXIV
   KALBFLEISCH JD, 1989, TRANSFUSION, V29, P672, DOI 10.1046/j.1537-2995.1989.29890020437.x
   Khajanchi S., 2020, ARXIV 2005 06286
   Khajanchi S, 2020, CHAOS, V30, DOI 10.1063/5.0016240
   Khoshnaw SHA, 2020, MATH MODEL NAT PHENO, V15, DOI 10.1051/mmnp/2020020
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, P553, DOI 10.1016/S1473-3099(20)30144-4
   Lai SJ, 2020, NATURE, V585, P410, DOI 10.1038/s41586-020-2293-x
   LAWLESS JF, 1994, CAN J STAT, V22, P15, DOI 10.2307/3315820
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu Z, 2020, INFECT DIS MODEL, V5, P323, DOI 10.1016/j.idm.2020.03.003
   Michaud J., IS CONTACT TRACING G
   Nadim Sk Shahid, 2020, Chaos Solitons Fractals, V140, P110163, DOI 10.1016/j.chaos.2020.110163
   Ngonghala CN, 2020, MATH BIOSCI, V325, DOI 10.1016/j.mbs.2020.108364
   Pai C, 2020, CHAOS SOLITON FRACT, V138, DOI 10.1016/j.chaos.2020.109988
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Rawson T., 2020, MEDRXIV
   Raza M, 2020, INDIAN J SURG, DOI 10.1007/s12262-020-02501-7
   Riou J, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.4.2000058
   Sardar T, 2020, CHAOS SOLITON FRACT, V139, DOI 10.1016/j.chaos.2020.110078
   Sarkar K, 2020, CHAOS SOLITON FRACT, V139, DOI 10.1016/j.chaos.2020.110049
   Senapati A., 2020, ARXIV 2004 04950
   Sun GQ, 2020, NONLINEAR DYNAM, V101, P1981, DOI 10.1007/s11071-020-05770-9
   Tariq A, 2019, EPIDEMICS-NETH, V26, P128, DOI 10.1016/j.epidem.2019.01.003
   Wilder B., 2020, SSRN 3564800
   World Health Organization, SITUATION REPORT 72
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Yan P., 2004, ESTIMATION INFECT CU, P1
   Yang XJ, 2002, APPL MATH LETT, V15, P615, DOI 10.1016/S0893-9659(02)80014-3
NR 50
TC 0
Z9 0
U1 0
U2 0
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 1054-1500
EI 1089-7682
J9 CHAOS
JI Chaos
PD NOV
PY 2020
VL 30
IS 11
AR 113143
DI 10.1063/5.0021353
PG 19
WC Mathematics, Applied; Physics, Mathematical
SC Mathematics; Physics
GA PA6YS
UT WOS:000595779000002
PM 33261327
OA Bronze
DA 2021-01-01
ER

PT J
AU Ooi, MWX
   Rajai, A
   Patel, R
   Gerova, N
   Godhamgaonkar, V
   Liong, SY
AF Ooi, M. W. X.
   Rajai, A.
   Patel, R.
   Gerova, N.
   Godhamgaonkar, V
   Liong, S. Y.
TI Pulmonary thromboembolic disease in COVID-19 patients on CT pulmonary
   angiography - Prevalence, pattern of disease and relationship to D-dimer
SO EUROPEAN JOURNAL OF RADIOLOGY
LA English
DT Article
DE Coronavirus; COVID-19; Thromboembolism; Pulmonary embolism
ID COMPLICATIONS; COAGULATION
AB Objectives: To define the prevalence of pulmonary thromboembolic (PTE) disease diagnosed on CT pulmonary angiography (CTPA) in COVID-19 patients. To assess distribution of PTE and to evaluate for association between severity of COVID-19 disease, D-dimer values and incidence of PTE.
   Methods: Patients with diagnosis of COVID-19 presenting to 5 different hospitals across Greater Manchester between 1st March 2020 and 30th April 2020 who had CTPA were included. CTPA images were evaluated for presence of PTE, distribution of PTE (in small and/or large vessels) and distribution of PTE within lungs with or without COVID-19 CT changes. Severity of COVID lung changes were graded. D-dimer values within 72 h of CTPA were obtained. Statistical analyses were performed to evaluate for any significant association between variables. p values of <= 0.05 were regarded as statistically significant.
   Results: A total of 974 patients presented across five hospital sites with COVID-19 infection. Eighty-four (n = 84) COVID-19 patients underwent CTPA. Of these, 38 % (32/84) had PTE. PTE was seen in small vessels in 75 % (24/32) and in lungs demonstrating COVID-19 changes in 72 % (23/32). 84 % (27/32) of PTE positive patients had disease severity of moderate or higher score (p = 0.005). D-dimer values were significantly higher (p <= 0.001) in PTE patients, median value in PTE group was 6441mcg/L (range 219-90925). A D-dimer cut off value of 2247mcg/L provides sensitivity of 0.72 and specificity of 0.74.
   Conclusion: There is increased prevalence of PTE in patients with moderate to severe COVID-19 disease. D-dimer values may have potential in guiding anticoagulation therapy and prognostication.
C1 [Ooi, M. W. X.; Patel, R.; Gerova, N.; Godhamgaonkar, V; Liong, S. Y.] Manchester Univ NHS Fdn Trust, Wythenshawe Hosp, Dept Radiol, Southmoor Rd, Manchester M23 9LT, Lancs, England.
   [Rajai, A.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Ctr Biostat, Div Populat Hlth, Manchester, Lancs, England.
   [Rajai, A.] Manchester Univ NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Res & Innovat, Nowgen Bldg,Grafton St, Manchester M13 9WU, Lancs, England.
RP Ooi, MWX (corresponding author), Wythenshawe Hosp, Dept Radiol, Southmoor Rd,Roundthorn Ind Estate, Manchester M23 9LT, Lancs, England.
EM ooi.michelle@gmail.com
OI Rajai, Azita/0000-0002-0376-9945; Patel, Rakeeb/0000-0002-7334-0538
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   [Anonymous], COR COVID 19 UK
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Cattaneo M, 2020, THROMB HAEMOSTASIS, V120, P1230, DOI 10.1055/s-0040-1712097
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Fauvel C, 2020, EUR HEART J, V41, P3058, DOI 10.1093/eurheartj/ehaa500
   Garcia-Olive I, 2020, RESP MED, V169, DOI 10.1016/j.rmed.2020.106023
   Grillet F, 2020, RADIOLOGY, V296, pE186, DOI 10.1148/radiol.2020201544
   Gupta N, 2019, THROMB RES, V181, P77, DOI 10.1016/j.thromres.2019.07.013
   Hess R, 2017, THROMB HAEMOSTASIS, V117, P1896, DOI 10.1160/TH16-12-0904
   Jin JM, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00152
   Kirby T, 2020, LANCET RESP MED, V8, P547, DOI 10.1016/S2213-2600(20)30228-9
   Klok FA, 2020, THROMB RES, V191, P148, DOI 10.1016/j.thromres.2020.04.041
   Leonard-Lorant I, 2020, RADIOLOGY, V296, pE189, DOI 10.1148/radiol.2020201561
   Levi M, 2017, THROMB RES, V149, P38, DOI 10.1016/j.thromres.2016.11.007
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Malato A, 2015, BLOOD TRANSFUS-ITALY, V13, P559, DOI 10.2450/2015.0277-14
   Mestre-Gomez B, 2020, J THROMB THROMBOLYS, DOI 10.1007/s11239-020-02190-9
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   Oudkerk M, 2020, RADIOLOGY, V297, pE216, DOI 10.1148/radiol.2020201629
   Poyiadji N, 2020, RADIOLOGY, V297, pE335, DOI 10.1148/radiol.2020201955
   Pulivarthi S, 2014, N AM J MED SCI, V6, P491, DOI 10.4103/1947-2714.143278
   R Core Team, 2020, R LANG ENV STAT COMP
   White D, 2020, J THROMB THROMBOLYS, V50, P287, DOI 10.1007/s11239-020-02145-0
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0720-048X
EI 1872-7727
J9 EUR J RADIOL
JI Eur. J. Radiol.
PD NOV
PY 2020
VL 132
AR 109336
DI 10.1016/j.ejrad.2020.109336
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA OM2CC
UT WOS:000585834300062
PM 33069986
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Pamplona, MD
   Ysunza, PA
AF del Carmen Pamplona, Maria
   Ysunza, Pablo Antonio
TI Speech pathology telepractice for children with cleft palate in the
   times of COVID-19 pandemic
SO INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY
LA English
DT Article
DE Speech disorders; Articulation; Cleft palate; Telepractice
ID COMPENSATORY ARTICULATION; LANGUAGE; INTERVENTION; THERAPY; DISORDERS;
   SKILLS; LIP
AB Objective: To study whether providing Speech and Language Pathology (SLP) interventions by telepractice (TP) could effectively improve speech performance in children with cleft palate (CCP).
   Methods: Forty-three CCP were treated with TP intervention in 45 min sessions, 2 times per week for a period of one month. Children ages ranged 4-12 years (X = 7.04; SD = 2.59). All children presented with velopharyngeal insufficiency (VPI) and compensatory articulation (CA) after palatal repair. TP was provided in small groups (5-6 children) following the principles of the Whole Language Model (WLM). Severity of CA was evaluated by a standardized scale at the onset and at the end of the TP period.
   Results: At the onset of the TP intervention period, 84% of the patients demonstrated severe CA. At the end of the TP period there was a significant improvement in severity of CA (p < 0.001).
   Conclusion: The results of this study suggests that TP can be a safe and reliable tool for improving CA. Considering that the COVID-19 pandemic will radically modify the delivery of Health Care services in the long term, alternate modes of service delivery should be studied and implemented.
C1 [del Carmen Pamplona, Maria] Hosp Gea Gonzalez, Cleft Palate Clin, Mexico City, DF, Mexico.
   [del Carmen Pamplona, Maria] Hablarte & Integrarte AC, Mexico City, DF, Mexico.
   [del Carmen Pamplona, Maria] Univ San Sebastian, Culiacan, Sinaloa, Mexico.
   [Ysunza, Pablo Antonio] Beaumont Hlth, Neurosci Program, Ian Jackson Craniofacial & Cleft Palate Clin, Royal Oak, MI USA.
RP Pamplona, MD (corresponding author), Mexico City Univ San Sebastian, Hablarte & Integrarte AC, Cleft PalateClin, Hosp Gea Gonzalez, Culiacan, Sinaloa, Mexico.
EM macamenpamplona@hotmail.com; antonio.ysunza@beaumont.edu
OI Pamplona, Maria del Carmen/0000-0002-5798-8238
CR Bloom L, 1978, LANGUAGE DEV LANGUAG
   Broen PA, 1998, J SPEECH LANG HEAR R, V41, P676, DOI 10.1044/jslhr.4103.676
   Pamplona MC, 2012, J MAXILLOFAC ORAL SU, V11, P144, DOI 10.1007/s12663-011-0314-x
   Collett BR, 2010, CLEFT PALATE-CRAN J, V47, P284, DOI 10.1597/08-172.1
   De Araujo M., 2020, FUNDAMENTALS TELEMED, P185
   Pamplona MD, 2017, INT J PEDIATR OTORHI, V93, P17, DOI 10.1016/j.ijporl.2016.12.011
   Pamplona MD, 2009, GAC MED MEX, V145, P475
   Gogia S., 2020, FUNDAMENTALS TELEMED, P11
   Golding-Kushner K., 2001, THERAPY TECHNIQUES C
   Grogan-Johnson S, 2010, J TELEMED TELECARE, V16, P134, DOI 10.1258/jtt.2009.090608
   Hardin-Jones M, 2008, LANG SPEECH HEAR SER, V39, P89, DOI 10.1044/0161-1461(2008/009)
   Hardin-Jones Mary, 2011, Seminars in Speech and Language, V32, P127, DOI 10.1055/s-0031-1277715
   Henningsson G, 2008, CLEFT PALATE-CRAN J, V45, P1, DOI 10.1597/06-086.1
   Hoff E, 2003, CHILD DEV, V74, P1368, DOI 10.1111/1467-8624.00612
   Hoffman P.R., 1992, LANG SPEECH HEAR SER, V23, P254
   Hopper RA, 2014, PLAST RECONSTR SURG, V133, p852E, DOI 10.1097/PRS.0000000000000184
   KERNAHAN D A, 1958, Plast Reconstr Surg Transplant Bull, V22, P435, DOI 10.1097/00006534-195811000-00001
   Mashima Pauline A, 2008, Telemed J E Health, V14, P1101, DOI 10.1089/tmj.2008.0080
   Norris J, 1990, LANG SPEECH HEAR SER, V21, P212
   Norris J., 1995, STORYBOOK CTR THEMES
   Norris J., 1990, LANG SPEECH HEAR SER, V21, P72, DOI [DOI 10.1044/0161-1461.2102.72, 10.1044/0161-1461.2102.72]
   Pamplona C, 2005, INT J PEDIATR OTORHI, V69, P351, DOI 10.1016/j.ijporl.2004.10.012
   Pamplona M.C., 2017, J CLEFT LIP PALATE C, V4, P132, DOI DOI 10.4103/JCLPCA.JCLPCA_53_17
   Pamplona MC, 1999, INT J PEDIATR OTORHI, V49, P21, DOI 10.1016/S0165-5876(99)00040-3
   Pamplona MC, 2000, INT J PEDIATR OTORHI, V54, P81, DOI 10.1016/S0165-5876(00)00332-3
   PAMPLONA MC, 2018, INT ARCH COMMUN DISO, V1, P1
   Peterson-Falzone S., 2006, CLIN GUIDE TREATING
   Richman L., 2008, COMPREHENSIVE CLEFT
   SCHERER NJ, 1995, CLEFT PALATE-CRAN J, V32, P7, DOI 10.1597/1545-1569(1995)032<0007:PQFSEL>2.3.CO;2
   Towey MP, 2012, INT J TELEREHABILITA, V4, P73, DOI [10.5195/IJT.2012.6112, 10.5195/ijt.2012.6112]
   Wales D, 2017, INT J TELEREHABILITA, V9, P55, DOI 10.5195/ijt.2017.6219
   Young SE, 2010, INT J PEDIATR OTORHI, V74, P456, DOI 10.1016/j.ijporl.2010.01.014
   Ysunza A, 1998, PLAST RECONSTR SURG, V102, P675, DOI 10.1097/00006534-199809030-00009
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0165-5876
EI 1872-8464
J9 INT J PEDIATR OTORHI
JI Int. J. Pediatr. Otorhinolaryngol.
PD NOV
PY 2020
VL 138
AR 110318
DI 10.1016/j.ijporl.2020.110318
PG 5
WC Otorhinolaryngology; Pediatrics
SC Otorhinolaryngology; Pediatrics
GA OF4ID
UT WOS:000581172700074
PM 32871515
OA Green Published
DA 2021-01-01
ER

PT J
AU Gelardi, M
   Giancaspro, R
   Fiore, V
   Fortunato, F
   Cassano, M
AF Gelardi, M.
   Giancaspro, R.
   Fiore, V
   Fortunato, F.
   Cassano, M.
TI COVID-19: Effects of lockdown on adenotonsillar hypertrophy and related
   diseases in children
SO INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY
LA English
DT Article
DE COVID-19; Lockdown; OSAS; URTIs; Adenotonsillar hypertrophy; Therapy
ID OBSTRUCTIVE SLEEP-APNEA; CARE
AB Background: In response to the coronavirus pandemic 2019 (COVID-19), Italy established the national school closings from March 5, 2020. It has been shown that during school closures, there are significant decreases in the diagnoses of the respiratory infections. This has brought as well to a reduction in all those symptoms related to adenotonsillar hypertrophy.
   Methods: The study included 162 children, aged between 3 and 13 years, waiting for adenoidectomy and/or tonsillectomy, eventually combined with tympanocentesis or tube insertion. Parents have been called to answer a telephone interview aimed at detecting how the symptoms related to adenotonsillar hypertrophy were changing during lockdown.
   Results: There was an improvement in the overall symptomatology of children during the lockdown period. The value attributed by parents to the children's general assessment during the lockdown period decreased significatively during the quarantine (p = 0,0000).
   Conclusions: The present study demonstrates that lockdown can have a positive impact on those specific diseases derived from precocious socialization and that it results to be particularly effective for the most vulnerable children. Indeed, lockdown has resulted to be so efficient that it has caused a modification in a medical and surgical therapeutic indication.
C1 [Gelardi, M.; Giancaspro, R.; Fiore, V; Cassano, M.] Univ Foggia, Unit Otolaryngol, Via Luigi Pinto 1, I-71122 Foggia, Italy.
   [Fortunato, F.] Univ Foggia, Dept Med & Surg Sci, Sect Hyg, Foggia, Italy.
RP Fiore, V (corresponding author), Univ Foggia, Unit Otolaryngol, Via Luigi Pinto 1, I-71122 Foggia, Italy.
EM matteo.gelardi@unifg.it; rogiancaa@live.it; valeriafiore91@gmail.com;
   francesca.fortunato@unifg.it; michele.cassano@unifg.it
OI gelardi, matteo/0000-0003-4406-0008; Cassano,
   Michele/0000-0002-2293-2832; Giancaspro, Rossana/0000-0002-5082-7271
CR Ari O, 2019, INT J PEDIATR OTORHI, V126, DOI 10.1016/j.ijporl.2019.109624
   Bradley RH, 2003, ARCH PEDIAT ADOL MED, V157, P196
   Cassano P, 2003, INT J PEDIATR OTORHI, V67, P1303, DOI 10.1016/j.ijporl.2003.07.018
   de Andrade-Balieiro FB, 2013, CODAS, V25, P229
   de Martino M, 2007, PEDIAT ALLERG IMM-UK, V18, P13, DOI 10.1111/j.1399-3038.2007.00625.x
   Frimer Z, 2016, SLEEP BREATH, V20, P1313, DOI 10.1007/s11325-016-1361-9
   Hens N, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-187
   Heymann A, 2004, PEDIATR INFECT DIS J, V23, P675, DOI 10.1097/01.inf.0000128778.54105.06
   Izu SC, 2010, BRAZ J OTORHINOLAR, V76, P552, DOI 10.1590/S1808-86942010000500003
   Kheirandish-Gozal L, 2013, EXPERT OPIN INV DRUG, V22, P71, DOI 10.1517/13543784.2013.735230
   Knopke S, 2015, EUR ARCH OTO-RHINO-L, V272, P3651, DOI 10.1007/s00405-014-3421-8
   Lewnard JA, 2020, LANCET INFECT DIS, V20, P631, DOI 10.1016/S1473-3099(20)30190-0
   Mbam TT, 2014, INDIAN J OTOLARYNGOL, V66, P173, DOI 10.1007/s12070-014-0701-y
   Mora R, 2009, J VOICE, V23, P614, DOI 10.1016/j.jvoice.2008.01.008
   Paradise JL, 1997, PEDIATRICS, V99, P318, DOI 10.1542/peds.99.3.318
   Skoloudik L, 2018, EUR ANN OTORHINOLARY, V135, P399, DOI 10.1016/j.anorl.2017.11.011
   Zhou M, 2020, FRONT MED-PRC, V14, P126, DOI 10.1007/s11684-020-0767-8
   Zojaji Ramin, 2014, Iran J Otorhinolaryngol, V26, P199
NR 18
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0165-5876
EI 1872-8464
J9 INT J PEDIATR OTORHI
JI Int. J. Pediatr. Otorhinolaryngol.
PD NOV
PY 2020
VL 138
AR 110284
DI 10.1016/j.ijporl.2020.110284
PG 5
WC Otorhinolaryngology; Pediatrics
SC Otorhinolaryngology; Pediatrics
GA OF4ID
UT WOS:000581172700048
PM 32861977
OA Green Published
DA 2021-01-01
ER

PT J
AU Sahakijpijarn, S
   Moon, C
   Koleng, JJ
   Christensen, DJ
   Williams, RO
AF Sahakijpijarn, Sawittree
   Moon, Chaeho
   Koleng, John J.
   Christensen, Dale J.
   Williams, Robert O., III
TI Development of Remdesivir as a Dry Powder for Inhalation by Thin Film
   Freezing
SO PHARMACEUTICS
LA English
DT Article
DE remdesivir; SARS-CoV-2; COVID-19; dry powder for inhalation; thin film
   freezing; brittle matrix powder
ID AERODYNAMIC PROPERTIES; DRUG-DELIVERY; IN-VITRO; WATER; CRYSTALLINE;
   PARTICLES; PERFORMANCE; SOLUBILITY; VISCOSITY; MIXTURES
AB Remdesivir exhibits in vitro activity against SARS-CoV-2 and was granted approval for emergency use. To maximize delivery to the lungs, we formulated remdesivir as a dry powder for inhalation using thin film freezing (TFF). TFF produces brittle matrix nanostructured aggregates that are sheared into respirable low-density microparticles upon aerosolization from a passive dry powder inhaler. In vitro aerodynamic testing demonstrated that drug loading and excipient type affected the aerosol performance of remdesivir. Remdesivir combined with optimal excipients exhibited desirable aerosol performance (up to 93.0% FPF< 5 mu m; 0.82 mu m mass median aerodynamic diameter). Remdesivir was amorphous after the TFF process, which benefitted drug dissolution in simulated lung fluid. TFF remdesivir formulations are stable after one month of storage at 25 degrees C/60% relative humidity. An in vivo pharmacokinetic evaluation showed that TFF remdesivir-leucine was poorly absorbed into systemic circulation while TFF remdesivir-Captisol(R) demonstrated increased systemic uptake compared to leucine. Remdesivir was hydrolyzed to the nucleoside analog GS-441524 in the lung, and levels of GS-441524 were greater in the lung with leucine formulation compared to Captisol(R). In conclusion, TFF technology produces high-potency remdesivir dry powder formulations for inhalation that are suitable to treat patients with COVID-19 on an outpatient basis and earlier in the disease course where effective antiviral therapy can reduce related morbidity and mortality.
C1 [Sahakijpijarn, Sawittree; Moon, Chaeho; Williams, Robert O., III] Univ Texas Austin, Coll Pharm, Div Mol Pharmaceut & Drug Delivery, Austin, TX 78712 USA.
   [Koleng, John J.; Christensen, Dale J.] TFF Pharmaceut Inc, Austin, TX 78746 USA.
RP Williams, RO (corresponding author), Univ Texas Austin, Coll Pharm, Div Mol Pharmaceut & Drug Delivery, Austin, TX 78712 USA.
EM sawittree.willy@utexas.edu; chaehomoon@utexas.edu;
   jkoleng@alphavektor.com; dchristensen@tffpharma.com;
   bill.williams@austin.utexas.edu
OI Sahakijpijarn, Sawittree/0000-0002-5828-1250; Moon,
   Chaeho/0000-0001-6986-5158; Williams III, Robert/0000-0003-4993-6427
FU TFF Pharmaceuticals, Inc.
FX This research was funded by TFF Pharmaceuticals, Inc. through a
   sponsored research agreement at The University of Texas at Austin.
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Amirian ES, 2020, ONE HEALTH-AMSTERDAM, V9, DOI 10.1016/j.onehlt.2020.100128
   Arora D, 2010, PHARM RES-DORDR, V27, P786, DOI 10.1007/s11095-010-0070-5
   Beig A, 2015, EUR J PHARM SCI, V77, P73, DOI 10.1016/j.ejps.2015.05.024
   Beinborn NA, 2012, EUR J PHARM BIOPHARM, V81, P600, DOI 10.1016/j.ejpb.2012.04.019
   Beinborn NA, 2012, INT J PHARMACEUT, V429, P46, DOI 10.1016/j.ijpharm.2012.03.010
   Besbes R, 2009, J MOL LIQ, V145, P1, DOI 10.1016/j.molliq.2008.09.009
   Blaabjerg LI, 2019, J PHARM SCI-US, V108, P2561, DOI 10.1016/j.xphs.2019.02.028
   Brunaugh A.D., 2020, BROAD SPECTRUM PATIE, DOI [10.1101/2020.09.24.310490, DOI 10.1101/2020.09.24.310490]
   Cares-Pacheco MG, 2014, INT J PHARMACEUT, V475, P69, DOI 10.1016/j.ijpharm.2014.08.029
   Dong E., 2020, COVID 19 DASHBOARD C
   Eriksson J, 2019, MOL PHARMACEUT, V16, P3053, DOI 10.1021/acs.molpharmaceut.9b00289
   European Medicines Agency, 2020, SUMM COMP US REMD GI
   Ferner RE, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1610
   Gardenhire D.S., 2017, GUIDE AEROSOL DELIVE
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Hassoun M, 2018, J DRUG DELIV SCI TEC, V47, P485, DOI 10.1016/j.jddst.2018.08.006
   Hibbert F., 1990, ADV PHYS ORG CHEM, V26, P255, DOI DOI 10.1016/S0065-3160(08)60047-7
   Jiang NYH, 2020, DRY TECHNOL, V38, P889, DOI 10.1080/07373937.2019.1596948
   Jones RM, 2012, XENOBIOTICA, V42, P86, DOI 10.3109/00498254.2011.632827
   Ko WC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105933
   Konrat R, 1999, MONATSH CHEM, V130, P961
   Labiris NR, 2003, BRIT J CLIN PHARMACO, V56, P588, DOI 10.1046/j.1365-2125.2003.01892.x
   Lo MK, 2017, SCI REP-UK, V7, DOI 10.1038/srep43395
   Lobmann K, 2013, EUR J PHARM BIOPHARM, V85, P873, DOI 10.1016/j.ejpb.2013.03.014
   Lockwood SF, 2003, J PHARM SCI, V92, P922, DOI 10.1002/jps.10359
   Longest PW, 2017, PHARM RES-DORDR, V34, P2049, DOI 10.1007/s11095-017-2210-7
   Maity S, 2019, NAT PROD COMMUN, V14, DOI 10.1177/1934578X19849296
   Mangal S, 2019, INT J PHARMACEUT, V568, DOI 10.1016/j.ijpharm.2019.118504
   Mangal S, 2018, PHARM RES-DORDR, V35, DOI 10.1007/s11095-017-2334-9
   Molina C, 2018, DRUG DELIV TRANSL RE, V8, P1769, DOI 10.1007/s13346-017-0462-8
   Moon C, 2019, J DRUG DELIV SCI TEC, V54, DOI 10.1016/j.jddst.2019.101295
   National Library of Medicine (US), 2017, STUD AEROVANC TREATM
   National Library of Medicine (US), 2020, TRIAL REMD AD SEV CO
   National Library of Medicine (US), 2020, TRIAL REMD AD MILD M
   Overhoff KA, 2009, J DRUG DELIV SCI TEC, V19, P89, DOI 10.1016/S1773-2247(09)50016-0
   Overhoff KA, 2007, EUR J PHARM BIOPHARM, V65, P57, DOI 10.1016/j.ejpb.2006.07.012
   Paajanen M, 2009, POWDER TECHNOL, V192, P6, DOI 10.1016/j.powtec.2008.11.005
   Pal A, 2020, ACS OMEGA, V5, P19968, DOI 10.1021/acsomega.0c01228
   Panini P, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11100529
   Pilcer G, 2010, INT J PHARMACEUT, V392, P1, DOI 10.1016/j.ijpharm.2010.03.017
   Pruijssers AJ, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107940
   Rasmussen HB, 2020, AAPS J, V22, DOI 10.1208/s12248-020-00506-4
   Rohrschneider M, 2015, MOL PHARMACEUT, V12, P2618, DOI 10.1021/acs.molpharmaceut.5b00221
   Sahakijpijarn S, 2020, INT J PHARMACEUT, V586, DOI 10.1016/j.ijpharm.2020.119490
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   Sinswat P, 2008, EUR J PHARM BIOPHARM, V69, P1057, DOI 10.1016/j.ejpb.2008.01.037
   Stella VJ, 2020, INT J PHARMACEUT, V583, DOI 10.1016/j.ijpharm.2020.119396
   Sun DX, 2020, AAPS J, V22, DOI 10.1208/s12248-020-00459-8
   The United States Food and Drug Administration, 2020, IN INGR SEARCH APPR
   Thompson JW, 2006, J CHROMATOGR A, V1134, P201, DOI 10.1016/j.chroma.2006.09.006
   Tolman JA, 2009, INT J PHARMACEUT, V379, P25, DOI 10.1016/j.ijpharm.2009.06.003
   Tolman JA, 2009, EUR J PHARM BIOPHARM, V72, P199, DOI 10.1016/j.ejpb.2008.12.014
   United States Securities and Exchange Commission, 2020, US SEC EXCH COMM ANN
   van der Merwe J, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12050393
   Wang YB, 2014, J DRUG DELIV SCI TEC, V24, P390, DOI 10.1016/S1773-2247(14)50079-2
   Wang YB, 2014, AAPS PHARMSCITECH, V15, P981, DOI 10.1208/s12249-014-0126-7
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Watts AB, 2013, PHARM RES-DORDR, V30, P813, DOI 10.1007/s11095-012-0922-2
   WILLIAMSON BN, 2020, NATURE 0609, DOI DOI 10.1038/S41586-020-2423-5
   Wyttenbach N, 2017, EUR J PHARM BIOPHARM, V112, P204, DOI 10.1016/j.ejpb.2016.11.031
   Yan VC, 2020, ACS MED CHEM LETT, V11, P1361, DOI 10.1021/acsmedchemlett.0c00316
   Yang K, 2020, CTS-CLIN TRANSL SCI, V13, P842, DOI 10.1111/cts.12815
NR 64
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD NOV
PY 2020
VL 12
IS 11
AR 1002
DI 10.3390/pharmaceutics12111002
PG 28
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OZ5IN
UT WOS:000594959500001
PM 33105618
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bojarska, J
   Remko, M
   Breza, M
   Madura, I
   Fruzniski, A
   Wolf, WM
AF Bojarska, Joanna
   Remko, Milan
   Breza, Martin
   Madura, Izabela
   Fruzniski, Andrzej
   Wolf, Wojciech M.
TI A Proline-Based Tectons and Supramolecular Synthons for Drug Design 2.0:
   A Case Study of ACEI
SO PHARMACEUTICALS
LA English
DT Article
DE proline; supramolecular synthon engineering; noncovalent interactions;
   drug design and discovery; ACEI; medicinal applications; coronavirus
   (COVID-19)
ID ANGIOTENSIN-CONVERTING ENZYME; CIS-TRANS ISOMERIZATION; X-RAY-STRUCTURE;
   SOLID-STATE CHARACTERIZATION; PERINDOPRIL TERT-BUTYLAMINE;
   MOLECULAR-STRUCTURE; CRYSTAL-STRUCTURES; PEPTIDE-BONDS; AMINO-ACIDS;
   CAPTOPRIL DISULFIDE
AB Proline is a unique, endogenous amino acid, prevalent in proteins and essential for living organisms. It is appreciated as a tecton for the rational design of new bio-active substances. Herein, we present a short overview of the subject. We analyzed 2366 proline-derived structures deposited in the Cambridge Structure Database, with emphasis on the angiotensin-converting enzyme inhibitors. The latter are the first-line antihypertensive and cardiological drugs. Their side effects prompt a search for improved pharmaceuticals. Characterization of tectons (molecular building blocks) and the resulting supramolecular synthons (patterns of intermolecular interactions) involving proline derivatives, as presented in this study, may be useful for in silico molecular docking and macromolecular modeling studies. The DFT, Hirshfeld surface and energy framework methods gave considerable insight into the nature of close inter-contacts and supramolecular topology. Substituents of proline entity are important for the formation and cooperation of synthons. Tectonic subunits contain proline moieties characterized by diverse ionization states: -N and -COOH(-COO-), -N+ and -COOH(-COO-), -NH and -COOH(-COO-), -NH+ and -COOH(-COO-), and -NH2+ and -COOH(-COO-). Furthermore, pharmacological profiles of ACE inhibitors and their impurities were determined via an in silico approach. The above data were used to develop comprehensive classification, which may be useful in further drug design studies.
C1 [Bojarska, Joanna; Fruzniski, Andrzej; Wolf, Wojciech M.] Lodz Univ Technol, Fac Chem, Inst Gen & Ecol Chem, Zeromskiego 116, PL-90924 Lodz, Poland.
   [Remko, Milan] Remedika, Luzna 9, Bratislava 85104, Slovakia.
   [Breza, Martin] Slovak Tech Univ, Dept Phys Chem, Radlinskeho 9, SK-81237 Bratislava, Slovakia.
   [Madura, Izabela] Warsaw Univ Technol, Fac Chem, Noakowskiego 3, PL-00664 Warsaw, Poland.
RP Bojarska, J (corresponding author), Lodz Univ Technol, Fac Chem, Inst Gen & Ecol Chem, Zeromskiego 116, PL-90924 Lodz, Poland.
EM joanna.bojarska@p.lodz.pl; milan.remko@gmail.com; martin.breza@stuba.sk;
   izabela@ch.pw.edu.pl; andrzej.fruzifiski@p.lodz.pl;
   wojciech.wolf@p.lodz.pl
OI Breza, Martin/0000-0001-5995-0279; Madura, Izabela
   D./0000-0001-5009-2554; Bojarska, Joanna/0000-0001-9190-6913; Wolf,
   Wojciech/0000-0002-9162-9933
FU Technical Univeristy of Lodz, Poland
FX Funding by Technical Univeristy of Lodz, Poland.
CR AAKEROY CB, 1995, ACTA CHEM SCAND, V49, P762, DOI 10.3891/acta.chem.scand.49-0762
   Abassi Z, 2009, BIOCHEM PHARMACOL, V78, P933, DOI 10.1016/j.bcp.2009.05.018
   Akif M, 2010, J MOL BIOL, V400, P502, DOI 10.1016/j.jmb.2010.05.024
   ALTONA C, 1972, J AM CHEM SOC, V94, P8205, DOI 10.1021/ja00778a043
   Ancion A, 2019, CARDIOL THER, V8, P179, DOI 10.1007/s40119-019-00150-w
   Anderson NG, 1996, J ORG CHEM, V61, P7955, DOI 10.1021/jo9609539
   ANDERSON PJ, 1995, BRIT J CLIN PHARMACO, V39, P361
   [Anonymous], 2020, EUROPEAN PHARMACOPOE
   ASHIDA T, 1974, B CHEM SOC JPN, V47, P1129, DOI 10.1246/bcsj.47.1129
   Awatef O., 2019, ADV TISSUE ENG REGEN, V5, P85
   BABUL J, 1978, J MOL BIOL, V126, P117, DOI 10.1016/0022-2836(78)90284-X
   BALASUBRAMANIAN R, 1971, INT J PROT RES, V3, P25
   Baldwin RL, 2008, ANNU REV BIOPHYS, V37, P1, DOI 10.1146/annurev.biophys.37.032807.125948
   Barone V, 1998, J PHYS CHEM A, V102, P1995, DOI 10.1021/jp9716997
   Bartlett GJ, 2016, PROTEIN SCI, V25, P887, DOI 10.1002/pro.2896
   Berkholz DS, 2012, P NATL ACAD SCI USA, V109, P449, DOI 10.1073/pnas.1107115108
   Bhattacharya A, 2012, J PHARMACEUT BIOMED, V70, P280, DOI 10.1016/j.jpba.2012.07.011
   Bhuyan BJ, 2011, ORG BIOMOL CHEM, V9, P5185, DOI 10.1039/c1ob05148b
   Bojarska J., 2019, BIOMATERIALS, V129, P1
   Bojarska J., 2020, Z KRISTALLOGR S, V40
   Bojarska J., 2019, INT J NUTR SCI, V4, P1035
   BOJARSKA J, 2018, ADV ORG CHEM, V11, P43
   Bojarska J, 2019, ACTA CRYSTALLOGR A, V75, DOI 10.1107/S205327331908968X
   Bojarska J, 2020, ACTA CRYSTALLOGR C, V76, P328, DOI 10.1107/S2053229620003009
   Bojarska J, 2020, MOLECULES, V25, DOI 10.3390/molecules25051135
   Bojarska J, 2019, J MOL STRUCT, V1190, P11, DOI 10.1016/j.molstruc.2019.04.045
   Bojarska J, 2015, ACTA CRYSTALLOGR C, V71, P199, DOI 10.1107/S2053229615002582
   Bojarska J, 2013, J CHIL CHEM SOC, V58, P1530, DOI 10.4067/S0717-97072013000100006
   Bojarska J, 2013, ACTA CRYSTALLOGR C, V69, P630, DOI 10.1107/S0108270113011025
   Bojarska J, 2012, ACTA CRYSTALLOGR C, V68, pO443, DOI 10.1107/S0108270112041583
   Bojarska J, 2012, ACTA CRYSTALLOGR C, V68, pO341, DOI 10.1107/S0108270112032349
   Borgia A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9861
   Borthwick AD, 2012, CHEM REV, V112, P3641, DOI 10.1021/cr200398y
   Bouabdallah S, 2012, CHROMATOGRAPHIA, V75, P1247, DOI 10.1007/s10337-012-2311-8
   Bouabdallah S, 2014, INT J ANAL CHEM, V2014, DOI 10.1155/2014/494719
   BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026
   Brazin KN, 2002, P NATL ACAD SCI USA, V99, P1899, DOI 10.1073/pnas.042529199
   Buda V, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010164
   Bultet LA, 2016, NUCLEIC ACIDS RES, V44, pD27, DOI 10.1093/nar/gkv1310
   Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD464, DOI 10.1093/nar/gky1004
   Bursell E., 1981, P135
   Cao WB, 2018, CANCER MED-US, V7, P2530, DOI 10.1002/cam4.1478
   Cashman JS, 2019, BIOCHEM J, V476, P3505, DOI 10.1042/BCJ20190635
   Chakrabarti P, 1998, PROTEIN ENG, V11, P631, DOI 10.1093/protein/11.8.631
   Chavan K., 2020, P INT C DRUG DISC IC
   Chen Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0844-y
   Chow L, 2009, MOL CELL ENDOCRINOL, V302, P219, DOI 10.1016/j.mce.2008.08.032
   Christgen SL, 2019, ANTIOXID REDOX SIGN, V30, P683, DOI 10.1089/ars.2017.7335
   Cockcroft JR, 2007, AM J CARDIOVASC DRUG, V7, P303, DOI 10.2165/00129784-200707050-00001
   Cole JC, 2017, ACTA CRYSTALLOGR D, V73, P234, DOI 10.1107/S2059798316014352
   Comes S, 2013, STEM CELL REP, V1, P307, DOI 10.1016/j.stemcr.2013.09.001
   Cornacchia C, 2012, MINI-REV MED CHEM, V12, P2, DOI 10.2174/138955712798868959
   Corpinot MK, 2019, CRYST GROWTH DES, V19, P1426, DOI 10.1021/acs.cgd.8b00972
   Cossi M, 2003, J COMPUT CHEM, V24, P669, DOI 10.1002/jcc.10189
   Craveur P, 2013, AMINO ACIDS, V45, P279, DOI 10.1007/s00726-013-1511-3
   CREMER D, 1975, J AM CHEM SOC, V97, P1354, DOI 10.1021/ja00839a011
   CUSHMAN DW, 1973, EXPERIENTIA, V29, P1032, DOI 10.1007/BF01930447
   Daina A, 2017, J CHEM EDUC, V94, P335, DOI 10.1021/acs.jchemed.6b00596
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   De Groot-Besseling RRJ, 2004, INT J CANCER, V112, P329, DOI 10.1002/ijc.20400
   De Luca L, 2017, CHEM-EUR J, V23, P3474, DOI 10.1002/chem.201605878
   Deshayes F, 2005, TRENDS ENDOCRIN MET, V16, P293, DOI 10.1016/j.tem.2005.07.009
   DESIRAJU GR, 1995, ANGEW CHEM INT EDIT, V34, P2311, DOI 10.1002/anie.199523111
   DETAR DF, 1977, J AM CHEM SOC, V99, P1232, DOI 10.1021/ja00446a040
   DiNicolantonio JJ, 2013, POSTGRAD MED, V125, P154, DOI 10.3810/pgm.2013.07.2687
   Dugave C, 2003, CHEM REV, V103, P2475, DOI 10.1021/cr0104375
   Englander SW, 2014, P NATL ACAD SCI USA, V111, P15873, DOI 10.1073/pnas.1411798111
   Exarchos Konstantinos P., 2009, Genomics Proteomics & Bioinformatics, V7, P138, DOI 10.1016/S1672-0229(08)60042-X
   Fan HB, 2019, J FOOD BIOCHEM, V43, DOI 10.1111/jfbc.12572
   Fani N, 2015, J BIOMOL STRUCT DYN, V33, P2285, DOI 10.1080/07391102.2014.1000377
   Ferrari R, 2005, EXPERT REV CARDIOVAS, V3, P15, DOI 10.1586/14779072.3.1.15
   Ferreira SH, 2000, SEMIN PERINATOL, V24, P7, DOI 10.1016/S0146-0005(00)80046-4
   Fischer G, 2004, REV PHYSIOL BIOCH P, V148, P105, DOI 10.1007/s10254-003-0011-3
   Fischer G, 2000, CHEM SOC REV, V29, P119, DOI 10.1039/a803742f
   FISCHER S, 1994, J AM CHEM SOC, V116, P11931, DOI 10.1021/ja00105a036
   Flaig R, 2002, J AM CHEM SOC, V124, P3407, DOI 10.1021/ja011492y
   Fonteh P, 2015, BIOMETALS, V28, P653, DOI 10.1007/s10534-015-9851-y
   FOSTER JP, 1980, J AM CHEM SOC, V102, P7211, DOI 10.1021/ja00544a007
   Fox K, 2007, EUR HEART J SUPPL, V9, pE10, DOI 10.1093/eurheartj/sum038
   Frisch M. J., 2009, GAUSSIAN 09 REVISION
   FROMMEL C, 1990, FEBS LETT, V277, P159, DOI 10.1016/0014-5793(90)80833-5
   Fujii K, 2012, CRYST GROWTH DES, V12, P6165, DOI 10.1021/cg3013377
   GALARDY RE, 1982, BIOCHEMISTRY-US, V21, P5777, DOI 10.1021/bi00266a008
   Ganguly Himal Kanti, 2020, Biophys Rev, V12, P25, DOI 10.1007/s12551-020-00621-8
   Ganguly P, 2010, CRYSTENGCOMM, V12, P817, DOI 10.1039/b910915c
   GAYATHRI E, 2018, BIOMED PHARMACOL J, V11, P1351, DOI DOI 10.13005/bpj/1498
   Ge M, 2009, EXTREMOPHILES, V13, P481, DOI 10.1007/s00792-009-0233-7
   Glowka ML, 2005, ACTA CRYSTALLOGR D, V61, P433, DOI 10.1107/S0907444905000399
   Gomez-Ruiz JA, 2004, J AGR FOOD CHEM, V52, P6315, DOI 10.1021/jf049532f
   Gonzalez BD, 2012, PSYCHO-ONCOLOGY, V21, P239, DOI 10.1002/pon.1882
   Gorbitz CH, 2015, CRYSTALLOGR REV, V21, P160, DOI 10.1080/0889311X.2014.964229
   Gowka M., 2004, ACTA CRYSTALLOGR A, V60, P165
   Gowka M., 2007, WIADOMOCI CHEM, V61, P161
   Graf M, 2017, NAT PROD REP, V34, P702, DOI 10.1039/c7np00020k
   Grant N, 2001, ACTA CRYSTALLOGR E, V57, pO697, DOI 10.1107/S1600536801010947
   GROCHULSKI P, 1994, PROTEIN SCI, V3, P82
   Groom CR, 2017, ACTA CRYSTALLOGR D, V73, P240, DOI 10.1107/S2059798317000675
   Groom CR, 2016, ACTA CRYSTALLOGR B, V72, P171, DOI 10.1107/S2052520616003954
   Guan LF, 2019, MEDCHEMCOMM, V10, P148, DOI 10.1039/c8md00472b
   Gunther WC, 2017, REGUL TOXICOL PHARM, V91, P68, DOI 10.1016/j.yrtph.2017.10.011
   Harn Z., 2010, U.S. Patent, Patent No. 20100016614
   Harrison C, 2014, J CELL COMMUN SIGNAL, V8, P195, DOI 10.1007/s12079-014-0236-8
   He HY, 2016, CRYST GROWTH DES, V16, P2348, DOI 10.1021/acs.cgd.6b00142
   Hehre W. J., 1986, AB INITIO MOL ORBITA
   Huang RM, 2014, MAR DRUGS, V12, P6213, DOI 10.3390/md12126213
   Hussain Z, 2020, BIOORG MED CHEM LETT, V30, DOI 10.1016/j.bmcl.2020.127072
   Huynh TYL, 2020, MOL CELL BIOCHEM, V466, P35, DOI 10.1007/s11010-020-03685-y
   Ianzer D, 2007, J PHARMACOL EXP THER, V322, P795, DOI 10.1124/jpet.107.120873
   Iwaniak A, 2014, COMPR REV FOOD SCI F, V13, P114, DOI 10.1111/1541-4337.12051
   Janczak J, 1997, ACTA CRYSTALLOGR C, V53, P1954, DOI 10.1107/S0108270197011487
   Jelsch C, 2014, IUCRJ, V1, P119, DOI 10.1107/S2052252514003327
   Joosten RP, 2009, J APPL CRYSTALLOGR, V42, P376, DOI 10.1107/S0021889809008784
   Kim J, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02430-9
   KLAMT A, 1993, J CHEM SOC PERK T 2, P799, DOI 10.1039/p29930000799
   Klussmann M, 2006, ANGEW CHEM INT EDIT, V45, P7985, DOI 10.1002/anie.200602520
   KOETZLE TF, 1973, ACTA CRYSTALLOGR B, VB 29, P231, DOI 10.1107/S0567740873002256
   Lapanja NK, 2017, ACTA CHIM SLOV, V64, P1, DOI 10.17344/acsi.2016.2840
   Lenci E, 2019, SYMMETRY-BASEL, V11, DOI 10.3390/sym11040558
   LEVITT M, 1981, J MOL BIOL, V145, P251, DOI 10.1016/0022-2836(81)90342-9
   Liu K.T., 2019, QUALITY MANAGEMENT Q
   Liu MY, 2016, EUR J PHARM BIOPHARM, V107, P151, DOI 10.1016/j.ejpb.2016.07.008
   Liu YC, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02948-2
   LOSCALZO J, 1973, ARCH BIOCHEM BIOPHYS, V157, P426, DOI 10.1016/0003-9861(73)90658-9
   LOUIS WJ, 1992, CLIN EXP PHARMACOL P, P55, DOI 10.1111/j.1440-1681.1992.tb02811.x
   Lovell SC, 2000, PROTEINS, V40, P389, DOI 10.1002/1097-0134(20000815)40:3<389::AID-PROT50>3.3.CO;2-U
   Lu KP, 2007, NAT CHEM BIOL, V3, P619, DOI 10.1038/nchembio.2007.35
   Lummis SCR, 2005, NATURE, V438, P248, DOI 10.1038/nature04130
   MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H
   Mackenzie CF, 2017, IUCRJ, V4, P575, DOI 10.1107/S205225251700848X
   Malik MS, 2019, J SAUDI CHEM SOC, V23, P503, DOI 10.1016/j.jscs.2019.01.003
   Manoharan Sivananthan, 2017, Afr J Tradit Complement Altern Med, V14, P383, DOI 10.21010/ajtcam.v14i2.39
   Martins MB, 2007, TETRAHEDRON, V63, P9923, DOI 10.1016/j.tet.2007.04.105
   Masuyer G, 2012, SCI REP-UK, V2, DOI 10.1038/srep00717
   Medenica M, 2007, J PHARMACEUT BIOMED, V44, P1087, DOI 10.1016/j.jpba.2007.05.008
   Millies B, 2019, J MED CHEM, V62, P11359, DOI 10.1021/acs.jmedchem.9b01697
   MILNERWHITE EJ, 1992, J MOL BIOL, V228, P725, DOI 10.1016/0022-2836(92)90859-I
   Morgan AA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053785
   Moses S, 2012, J BACTERIOL, V194, P745, DOI 10.1128/JB.06380-11
   Nagel N, 2001, ACTA CRYSTALLOGR E, V57, pO463, DOI 10.1107/S1600536801006948
   Nelson CJ, 2006, CELL, V126, P905, DOI 10.1016/j.cell.2006.07.026
   NEMETHY G, 1992, J PHYS CHEM-US, V96, P6472, DOI 10.1021/j100194a068
   Newberry R.W., 2016, TOP HETEROCYCL CHEM, P1, DOI DOI 10.1007/7081_2015_196
   Nguyen Lien Ai, 2006, Int J Biomed Sci, V2, P85
   Nollet L.M., 2012, HDB ANAL ACTIVE COMP
   Nuchprapha A, 2020, RSC ADV, V10, P12711, DOI 10.1039/d0ra00093k
   Olczak A, 2007, ACTA CRYSTALLOGR D, V63, P319, DOI 10.1107/S0907444906053649
   Olczak A, 2010, ACTA CRYSTALLOGR D, V66, P874, DOI 10.1107/S0907444910019876
   OPIE LH, 1995, CARDIOVASC RES, V30, P18, DOI 10.1016/0008-6363(95)00006-2
   Pahlke D, 2005, BIOINFORMATICS, V21, P685, DOI 10.1093/bioinformatics/bti089
   Pal D, 1999, J MOL BIOL, V294, P271, DOI 10.1006/jmbi.1999.3217
   Pandey AK, 2013, J AM CHEM SOC, V135, P4333, DOI 10.1021/ja3109664
   Pandey J, 2016, RSC ADV, V6, P74135, DOI 10.1039/c6ra13035f
   Pastorino L, 2006, NATURE, V440, P528, DOI 10.1038/nature04543
   Patel SS, 2017, ANTI-CANCER AGENT ME, V17, P955, DOI 10.2174/1871520616666160817143141
   PAULUS EF, 1987, ACTA CRYSTALLOGR C, V43, P938, DOI 10.1107/S0108270187093508
   Phang JM, 2019, ANTIOXID REDOX SIGN, V30, P635, DOI 10.1089/ars.2017.7350
   Pikul P, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00117
   Pink SMM, 2005, ACTA CRYSTALLOGR C, V61, pO506, DOI 10.1107/S0108270105021001
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Pizova H, 2017, MOLECULES, V22, DOI 10.3390/molecules22111969
   PRAKASH KG, 2019, BIOMED PHARMACOL J, V12, P1715, DOI DOI 10.13005/bpj/1800
   PRECIGOUX G, 1986, ACTA CRYSTALLOGR C, V42, P1022, DOI 10.1107/S0108270186093630
   Qidwai Tabish, 2017, In Silico Pharmacology, V5, P6, DOI 10.1007/s40203-017-0026-0
   Rajalakshmi P, 2013, ACTA CRYSTALLOGR C, V69, P1390, DOI 10.1107/S010827011302581X
   RAMACHAN.GN, 1970, BIOCHIM BIOPHYS ACTA, V221, P165, DOI 10.1016/0005-2795(70)90257-6
   Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7
   RAMACHANDRAN GN, 1976, J MOL BIOL, V107, P85, DOI 10.1016/S0022-2836(76)80019-8
   Rayavarapu S, 2015, TOXICOL SCI, V146, P2, DOI 10.1093/toxsci/kfv074
   REED AE, 1983, J CHEM PHYS, V78, P4066, DOI 10.1063/1.445134
   REED AE, 1985, J CHEM PHYS, V83, P735, DOI 10.1063/1.449486
   REED AE, 1985, J CHEM PHYS, V83, P1736, DOI 10.1063/1.449360
   Reid JW, 2016, POWDER DIFFR, V31, P205, DOI 10.1017/S0885715616000294
   Remko M, 2007, CHEM PAP, V61, P133, DOI 10.2478/s11696-007-0010-y
   Remko M, 2013, J MOL STRUCT, V1036, P292, DOI 10.1016/j.molstruc.2012.11.070
   Remko M, 2011, J MOL STRUCT, V997, P103, DOI 10.1016/j.molstruc.2011.05.005
   Remko M, 2015, COMPUT THEOR CHEM, V1062, P50, DOI 10.1016/j.comptc.2015.03.025
   Remko M, 2009, EUR J MED CHEM, V44, P101, DOI 10.1016/j.ejmech.2008.03.012
   Resnati G., 2004, ENCY SUPRAMOLECULAR, V1, P628
   Ressurreicao ASM, 2011, EUR J ORG CHEM, V2011, P217, DOI 10.1002/ejoc.201001330
   Roth GA, 2017, J AM COLL CARDIOL, V70, P1, DOI 10.1016/j.jacc.2017.04.052
   Salaman P., 2011, Patent, Patent No. [EP 2325172, 2325172, EP2325172A1]
   Salunkhe MN, 2017, J LIQ CHROMATOGR R T, V40, P813, DOI 10.1080/10826076.2017.1373670
   Sanchez-Navarro M, 2017, ACCOUNTS CHEM RES, V50, P1847, DOI 10.1021/acs.accounts.7b00204
   Santiveri CM, 2004, J BIOL CHEM, V279, P34963, DOI 10.1074/jbc.M405016200
   Sarkar P, 2007, MOL CELL, V25, P413, DOI 10.1016/j.molcel.2007.01.004
   SCHMID FX, 1993, ADV PROTEIN CHEM, V44, P25, DOI 10.1016/S0065-3233(08)60563-X
   SCHMID FX, 1986, P NATL ACAD SCI USA, V83, P872, DOI 10.1073/pnas.83.4.872
   Schmidt M, 2013, J CHEM PHYS, V138, DOI 10.1063/1.4807586
   Schollmeyer D., 2016, COMMUNICATION
   Schulz G.E., 1979, PRINCIPLES PROTEIN S, P17
   Shebl RI, 2019, IRAN J PHARM RES, V18, P1967, DOI 10.22037/ijpr.2019.1100800
   Shinoda K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16766-8
   Siltari A, 2014, BIOL-TARGETS THER, V8, P59, DOI 10.2147/BTT.S54056
   Singh K, 2014, INT J PHARM SCI RES, V5, P4644, DOI 10.13040/IJPSR.0975-8232.5(11).4644-59
   Sorrenti M, 2013, J PHARM SCI-US, V102, P3596, DOI 10.1002/jps.23660
   Spackman MA, 2002, CRYSTENGCOMM, V4, P378, DOI 10.1039/b203191b
   Spackman MA, 2008, CRYSTENGCOMM, V10, P377, DOI 10.1039/b715227b
   Spackman MA, 2009, CRYSTENGCOMM, V11, P19, DOI 10.1039/b818330a
   Spackman PR, 2019, ANGEW CHEM INT EDIT, V58, P16780, DOI 10.1002/anie.201906602
   SRINIVAS V, 1995, LANGMUIR, V11, P2830, DOI 10.1021/la00007a077
   STEWART DE, 1990, J MOL BIOL, V214, P253, DOI 10.1016/0022-2836(90)90159-J
   Stoll R., 1966, J CHEM EDUC, V43, pA608
   Su D, 1995, SUPRAMOL CHEM, V6, P171, DOI 10.1080/10610279508032533
   Sun H, 2014, INT J FOOD PROP, V17, P386, DOI 10.1080/10942912.2011.642048
   Surov AO, 2018, CRYSTENGCOMM, V20, P6970, DOI 10.1039/c8ce01458b
   Sweetman S. C., 2011, MARTINDALE COMPLETE
   Szabo ZI, 2015, J CHROMATOGR SCI, V53, P424, DOI 10.1093/chromsci/bmu223
   Telejko E, 2007, CURR MED RES OPIN, V23, P953, DOI 10.1185/030079907X182158
   Tilborg A, 2014, EUR J MED CHEM, V74, P411, DOI 10.1016/j.ejmech.2013.11.045
   Torbeev VY, 2013, P NATL ACAD SCI USA, V110, P20051, DOI 10.1073/pnas.1310414110
   Touw WG, 2015, NUCLEIC ACIDS RES, V43, pD364, DOI 10.1093/nar/gku1028
   Trapero A, 2012, J MED CHEM, V55, P10345, DOI 10.1021/jm301682r
   Tumanova N, 2018, CRYST GROWTH DES, V18, P954, DOI 10.1021/acs.cgd.7b01436
   Turkez H, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10050737
   Turner M. J., 2017, CRYSTALEXPLORER17
   Ugliengo P., 2006, MOLDRAW PROGRAM DISP
   Velazquez H., 2014, THESIS
   Vitagliano L, 2001, PROTEIN SCI, V10, P2627, DOI 10.1110/ps.ps.26601a
   Vitali A, 2015, CURR PROTEIN PEPT SC, V16, P147, DOI 10.2174/1389203716666150102110817
   Wang LY, 2020, NEW J CHEM, V44, P3930, DOI 10.1039/c9nj06180k
   Wedemeyer WJ, 2002, BIOCHEMISTRY-US, V41, P14637, DOI 10.1021/bi020574b
   Weiss MS, 1998, NAT STRUCT BIOL, V5, P676, DOI 10.1038/1368
   Whelton PK, 2018, HYPERTENSION, V71, pE13, DOI 10.1161/HYP.0000000000000065
   Williams C.J., 2018, 324517 BIORXIV
   Wuest JD, 2005, CHEM COMMUN, P5830, DOI 10.1039/b512641j
   Wulf G, 2005, NAT CELL BIOL, V7, P435, DOI 10.1038/ncb0505-435
   WYVRATT MJ, 1984, J ORG CHEM, V49, P2816, DOI 10.1021/jo00189a036
   Xu W, 1997, ACTA CRYSTALLOGR C, V53, P1917, DOI 10.1107/S0108270197008287
   Yadav B, 2018, CRYST GROWTH DES, V18, P1047, DOI 10.1021/acs.cgd.7b01514
   Yasumatsu R, 2004, J CANCER RES CLIN, V130, P567, DOI 10.1007/s00432-004-0582-7
   Zhan YA, 2015, ARCH BIOCHEM BIOPHYS, V575, P22, DOI 10.1016/j.abb.2015.03.021
   Zhang L, 2015, J BACTERIOL, V197, P431, DOI 10.1128/JB.02282-14
   Zhang P, 2020, J FUNCT FOODS, V65, DOI 10.1016/j.jff.2019.103751
   Zhao Y, 2008, THEOR CHEM ACC, V120, P215, DOI 10.1007/s00214-007-0310-x
   Zhou B, 2017, LANCET, V389, P37, DOI 10.1016/S0140-6736(16)31919-5
   Zhu ZY, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00094
   Zisman LS, 2005, EUR HEART J, V26, P322, DOI 10.1093/eurheartj/ehi043
NR 237
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1424-8247
J9 PHARMACEUTICALS-BASE
JI Pharmaceuticals
PD NOV
PY 2020
VL 13
IS 11
AR 338
DI 10.3390/ph13110338
PG 42
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OZ4WV
UT WOS:000594929100001
PM 33114370
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Blok, AJ
   Gurnani, P
   Xenopoulos, A
   Burroughs, L
   Duncan, J
   Urbanowicz, RA
   Tsoleridis, T
   Muller-Krauter, H
   Strecker, T
   Ball, JK
   Alexander, C
   Alexander, MR
AF Blok, Andrew J.
   Gurnani, Pratik
   Xenopoulos, Alex
   Burroughs, Laurence
   Duncan, Joshua
   Urbanowicz, Richard A.
   Tsoleridis, Theocharis
   Mueller-Kraeuter, Helena
   Strecker, Thomas
   Ball, Jonathan K.
   Alexander, Cameron
   Alexander, Morgan R.
TI Polymer microarrays rapidly identify competitive adsorbents of
   virus-like particles
SO BIOINTERPHASES
LA English
DT Article
ID DISCOVERY
AB The emergence of SARS-CoV-2 highlights the global need for platform technologies to enable the rapid development of diagnostics, vaccines, treatments, and personal protective equipment (PPE). However, many current technologies require the detailed mechanistic knowledge of specific material-virion interactions before they can be employed, for example, to aid in the purification of vaccine components or in the design of a more effective PPE. Here, we show that an adaption of a polymer microarray method for screening bacterial-surface interactions allows for the screening of polymers for desirable material-virion interactions. Nonpathogenic virus-like particles including fluorophores are exposed to the arrays in an aqueous buffer as a simple model of virions carried to the surface in saliva/sputum. Competitive binding of Lassa and Rubella virus-like particles is measured to probe the relative binding properties of a selection of copolymers. This provides the first step in the development of a method for the discovery of novel materials with promise for viral binding, with the next being development of this method to assess absolute viral adsorption and assessment of the attenuation of the activity of live virus, which we propose would be part of a material scale up step carried out in high containment facilities, alongside the use of more complex media to represent biological fluids.
C1 [Blok, Andrew J.; Gurnani, Pratik; Alexander, Cameron] Univ Nottingham, Sch Pharm, Div Mol Therapeut & Formulat, Nottingham NG7 2RD, England.
   [Xenopoulos, Alex] EMD Millipore, 80 Ashby Rd, Bedford, MA 01730 USA.
   [Burroughs, Laurence; Alexander, Morgan R.] Univ Nottingham, Sch Pharm, Div Adv Mat & Healthcare Technol, Nottingham NG7 2RD, England.
   [Duncan, Joshua; Urbanowicz, Richard A.; Tsoleridis, Theocharis; Ball, Jonathan K.] Univ Nottingham, Fac Med & Hlth Sci, Wolfson Ctr Global Virus Res, Nottingham NG7 2RD, England.
   [Duncan, Joshua; Urbanowicz, Richard A.; Tsoleridis, Theocharis; Ball, Jonathan K.] Queens Med Ctr, Nottingham Biomed Res Ctr, C Floor,South Block, Nottingham NG7 2UH, England.
   [Mueller-Kraeuter, Helena; Strecker, Thomas] Philipps Univ Marburg, Inst Virol, D-35043 Marburg, Germany.
RP Blok, AJ (corresponding author), Univ Nottingham, Sch Pharm, Div Mol Therapeut & Formulat, Nottingham NG7 2RD, England.
RI ; Blok, Andrew/P-8399-2016
OI Urbanowicz, Richard/0000-0002-2461-4993; Strecker,
   Thomas/0000-0002-7857-937X; Blok, Andrew/0000-0002-1686-2989; Burroughs,
   Laurence/0000-0003-0389-5148
FU EMD Millipore Corporation, the life sciences division of Merck KGaA
   Darmstadt, Germany; Department of Health and Social Care; Engineering
   and Physical Sciences Research Council (EPSRC)Engineering & Physical
   Sciences Research Council (EPSRC) [EP/R013764/1]; Royal Society through
   a Wolfson Research Merit Award [WM150086]; Engineering and Physical
   Sciences Research CouncilEngineering & Physical Sciences Research
   Council (EPSRC) [EP/N006615/1]; Deutsche Forschungsgemeinschaft (DFG,
   German Research Foundation)-ProjectGerman Research Foundation (DFG)
   [197785619/SFB1021]; NIHR Nottingham Biomedical Research Centre
FX This research was funded by the EMD Millipore Corporation, the life
   sciences division of Merck KGaA Darmstadt, Germany. This research was
   also funded by the Department of Health and Social Care using UK Aid
   funding and is managed by the Engineering and Physical Sciences Research
   Council (EPSRC, Grant No. EP/R013764/1). This research was also funded
   through the Royal Society through a Wolfson Research Merit Award (No.
   WM150086) to C.A. and supported by the Engineering and Physical Sciences
   Research Council (Grant No. EP/N006615/1]. T.S. received funding from
   the Deutsche Forschungsgemeinschaft (DFG, German Research
   Foundation)-Project No. 197785619/SFB1021. J.D. received funding from
   the NIHR Nottingham Biomedical Research Centre. The views expressed are
   those of the authors and not necessarily those of the NHS, the NIHR, or
   the Department of Health and Social Care.
CR Anderson DG, 2004, NAT BIOTECHNOL, V22, P863, DOI 10.1038/nbt981
   [Anonymous], 2019, PEDIAT PHYS THER, V31, pe31, DOI [10.1097/PEP.0000000000000581, DOI 10.1002/adma.201902023]
   Aydin S, 2015, PEPTIDES, V72, P4, DOI 10.1016/j.peptides.2015.04.012
   Brittain WJ, 2019, ACS APPL MATER INTER, V11, P39397, DOI 10.1021/acsami.9b06838
   Celiz AD, 2014, BIOMATER SCI-UK, V2, P1604, DOI 10.1039/c4bm00054d
   Chiodi E, 2020, ANAL BIOANAL CHEM, V412, P3477, DOI 10.1007/s00216-019-02276-1
   Conde-Gonzalez A, 2020, MAT SCI ENG C-MATER, V108, DOI 10.1016/j.msec.2019.110489
   Duffy CRE, 2014, BIOMATER SCI-UK, V2, P1683, DOI 10.1039/c4bm00112e
   Eickelmann S, 2019, ADV MATER TECHNOL-US, V4, DOI 10.1002/admt.201900503
   Gong JJ, 2019, ACS COMB SCI, V21, P417, DOI 10.1021/acscombsci.9b00031
   Hook AL, 2013, ADV MATER, V25, P2542, DOI 10.1002/adma.201204936
   Hook AL, 2012, NAT BIOTECHNOL, V30, P868, DOI 10.1038/nbt.2316
   Hook AL, 2012, JOVE-J VIS EXP, DOI 10.3791/3636
   Hook AL, 2010, BIOMATERIALS, V31, P187, DOI 10.1016/j.biomaterials.2009.09.037
   Przybycien TM, 2004, CURR OPIN BIOTECH, V15, P469, DOI 10.1016/j.copbio.2004.08.008
   Rosilo H, 2014, NANOSCALE, V6, P11871, DOI 10.1039/c4nr03584d
   Schlie K, 2010, J VIROL, V84, P3178, DOI 10.1128/JVI.02240-09
   Verma Sitansu Kumar, 2015, Adv Biomed Res, V4, P201, DOI 10.4103/2277-9175.166137
   WAXHAM MN, 1985, REV INFECT DIS, V7, pS133
   Zeng XQ, 2012, ANAL BIOANAL CHEM, V402, P3027, DOI 10.1007/s00216-011-5569-z
NR 20
TC 1
Z9 1
U1 0
U2 0
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 1934-8630
EI 1559-4106
J9 BIOINTERPHASES
JI Biointerphases
PD NOV
PY 2020
VL 15
IS 6
AR 061005
DI 10.1116/6.0000586
PG 5
WC Biophysics; Materials Science, Biomaterials
SC Biophysics; Materials Science
GA OZ5YK
UT WOS:000595001100002
PM 33203214
OA Other Gold
DA 2021-01-01
ER

PT J
AU Zou, TJ
   Yin, WH
   Kang, Y
AF Zou, Tongjuan
   Yin, Wanhong
   Kang, Yan
TI Application of Critical Care Ultrasound in Patients With COVID-19: Our
   Experience and Perspective
SO IEEE TRANSACTIONS ON ULTRASONICS FERROELECTRICS AND FREQUENCY CONTROL
LA English
DT Article
DE Lung; Ultrasonic imaging; Acoustics; Frequency control; Probes; Kidney;
   Coronavirus disease-2019 (COVID-19); critical care ultrasound (CCUS);
   experience; lung ultrasound (LUS)
ID LUNG ULTRASOUND; WUHAN; TRANSMISSION; PNEUMONIA; CHINA
AB Up to April 4, 2020, the novel coronavirus disease-2019 COVID-19 has affected more than 1 099000 patients and has become a major global health concern. World Health Organization (WHO) has defined COVID-19 as a global pandemic. Critical care ultrasound (CCUS) can rapidly acquire the image of lung and other organs and demonstrate the pathophysiological changes to guide precise therapy in COVID-19 pneumonia without radiation or interfering with personal protective equipment. In addition, the application of CCUS can cover the whole courses from the fever clinic to the intensive care unit to improve the treatment. We would like to present the CCUS features about COVID-19 pneumonia and share the application experience of CCUS in Wuhan, China, and hope it works for physicians worldwide to solve the problem and improve the outcome.
C1 [Zou, Tongjuan; Yin, Wanhong; Kang, Yan] Sichuan Univ, West China Hosp, West China Sch Med, Chengdu 610041, Peoples R China.
RP Yin, WH (corresponding author), Sichuan Univ, West China Hosp, West China Sch Med, Chengdu 610041, Peoples R China.
EM zoutongjuan@wchscu.cn; yinwanhong@wchscu.cn; kangyan@scu.edu.cn
FU Scientific and Technological Project of New Coronavirus Pneumonia in
   West China Hospital of Sichuan University [HX-2019-nCoV-045]; Key
   project of Sichuan Science and Technology Department [2019YFS0449]
FX This work was supported in part by the Scientific and Technological
   Project of New Coronavirus Pneumonia in West China Hospital of Sichuan
   University under Grant HX-2019-nCoV-045 and in part by the Key project
   of Sichuan Science and Technology Department under Grant 2019YFS0449.
CR [Anonymous], 2020, COVID 19 PNEUM DIAGN
   Beloncle F, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0525-8
   Blaser AR, 2014, ACTA ANAESTH SCAND, V58, P914, DOI 10.1111/aas.12302
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chung MS, 2020, EUR RADIOL, V30, P2182, DOI [10.1148/radiol.2020200230, 10.1007/s00330-019-06574-1]
   Copetti R, 2008, CARDIOVASC ULTRASOUN, V6, DOI 10.1186/1476-7120-6-16
   Corradi F, 2014, CURR OPIN CRIT CARE, V20, P98, DOI 10.1097/MCC.0000000000000042
   Gargani L, 2011, CARDIOVASC ULTRASOUN, V9, DOI 10.1186/1476-7120-9-6
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   He Y, 2020, INFECT CONT HOSP EP, V41, P982, DOI 10.1017/ice.2020.126
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang Y, 2020, PRELIMINARY STUDY UL, DOI [10.2139/ssrn.3544750, DOI 10.2139/SSRN.3544750]
   Kanne JP, 2020, RADIOLOGY, V295, P16, DOI 10.1148/radiol.2020200241
   Koster G, 2017, CURR OPIN CRIT CARE, V23, P326, DOI 10.1097/MCC.0000000000000428
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lerolle N, 2006, INTENS CARE MED, V32, P1553, DOI 10.1007/s00134-006-0360-x
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lichtenstein D, 2014, CURR OPIN CRIT CARE, V20, P315, DOI 10.1097/MCC.0000000000000096
   MacLaren R, 2007, PHARMACOTHERAPY, V27, P860, DOI 10.1592/phco.27.6.860
   McClave SA, 2016, JPEN-PARENTER ENTER, V40, P159, DOI 10.1177/0148607115621863
   Mojoli F, 2019, AM J RESP CRIT CARE, V199, P701, DOI 10.1164/rccm.201802-0236CI
   Moshavegh R, 2019, IEEE T ULTRASON FERR, V66, P309, DOI 10.1109/TUFFC.2018.2885955
   Peng QY, 2020, INTENS CARE MED, V46, P849, DOI 10.1007/s00134-020-05996-6
   Pugin J, 1999, CRIT CARE MED, V27, P304, DOI 10.1097/00003246-199902000-00036
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Riou J, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.4.2000058
   Soummer A, 2012, CRIT CARE MED, V40, P2064, DOI 10.1097/CCM.0b013e31824e68ae
   Vincent JL, 2011, CRIT CARE, V15, DOI 10.1186/cc10291
   Volpicelli G, 2012, INTENS CARE MED, V38, P577, DOI 10.1007/s00134-012-2513-4
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang XT, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1558-0
   Wang XT, 2015, ULTRASOUND MED BIOL, V41, P401, DOI 10.1016/j.ultrasmedbio.2014.09.010
   World Health Organization, 2020, COR VIR DIS COVID 20
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yin M G, 2018, Zhonghua Nei Ke Za Zhi, V57, P397, DOI 10.3760/cma.j.issn.0578-1426.2018.06.004
   Yin WH, 2019, BMC PULM MED, V19, DOI 10.1186/s12890-018-0755-9
   Yin WH, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4687346
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zieleskiewicz L, 2020, ANAESTH CRIT CARE PA, V39, P391, DOI 10.1016/j.accpm.2020.04.015
NR 40
TC 0
Z9 0
U1 1
U2 1
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0885-3010
EI 1525-8955
J9 IEEE T ULTRASON FERR
JI IEEE Trans. Ultrason. Ferroelectr. Freq. Control
PD NOV
PY 2020
VL 67
IS 11
BP 2197
EP 2206
DI 10.1109/TUFFC.2020.3020628
PG 10
WC Acoustics; Engineering, Electrical & Electronic
SC Acoustics; Engineering
GA OJ9LF
UT WOS:000584275100002
PM 32870787
OA Bronze
DA 2021-01-01
ER

PT J
AU Dasari, CM
   Bhukya, R
AF Dasari, Chandra Mohan
   Bhukya, Raju
TI Comparative analysis of protein synthesis rate in COVID-19 with other
   human coronaviruses
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Coronavirus; 2019-nCoV; RSCU; COVID-19; Codon bias; Slow codons; Amino
   acid; ENC
ID CODON ADAPTATION INDEX; MAJOR DETERMINANT; EFFECTIVE NUMBER;
   GENE-EXPRESSION; MESSENGER-RNAS; USAGE BIAS; TRANSLATION; EVOLUTION;
   OPTIMALITY; VIRUSES
AB The genetic code contains information that impacts the efficiency and rate of translation. Translation elongation plays a crucial role in determining the composition of the proteome, errors within a protein contributes towards disease processes. It is important to analyze the novel coronavirus (2019-nCoV) at the codon level to find similarities and variations in hosts to compare with other human coronavirus (CoVs). This requires a comparative and comprehensive study of various human and zoonotic nature CoVs relating to codon usage bias, relative synonymous codon usage (RSCU), proportions of slow codons, and slow di-codons, the effective number of codons (ENC), mutation bias, codon adaptation index (CAI), and codon frequencies. In this work, seven different CoVs were analyzed to determine the protein synthesis rate and the adaptation of these viruses to the host cell. The result reveals that the proportions of slow codons and slow di-codons in human host of 2019-nCoV and SARS-CoV found to be similar and very less compared to the other five coronavirus types, which suggest that the 2019-nCoV and SARS-CoV have faster protein synthesis rate. Zoonotic CoVs have high RSCU and codon adaptation index than human CoVs which implies the high translation rate in zoonotic viruses. All CoVs have more AT% than GC% in genetic codon compositions. The average ENC values of seven CoVs ranged between 38.36 and 49.55, which implies the CoVs are highly conserved and are easily adapted to host cells. The mutation rate of 2019-nCoV is comparatively less than MERS-CoV and NL63 that shows an evidence for genetic diversity. Host-specific codon composition analysis portrays the relation between viral host sequences and the capability of novel virus replication in host cells. Moreover, the analysis provides useful measures for evaluating a virus-host adaptation, transmission potential of novel viruses, and thus contributes to the strategies of anti-viral drug design.
C1 [Dasari, Chandra Mohan; Bhukya, Raju] Natl Inst Technol, Dept Comp Sci & Engn, Warangal 506004, Telangana, India.
RP Dasari, CM (corresponding author), Natl Inst Technol, Dept Comp Sci & Engn, Warangal 506004, Telangana, India.
EM chandu.dasari@student.nitw.ac.in; raju@nitw.ac.in
CR Abdul-Rasool Sahar, 2010, Open Virol J, V4, P76, DOI 10.2174/1874357901004010076
   Brule CE, 2017, TRENDS GENET, V33, P283, DOI 10.1016/j.tig.2017.02.001
   Chan PP, 2009, NUCLEIC ACIDS RES, V37, pD93, DOI 10.1093/nar/gkn787
   Chekulaeva M, 2016, MOL CELL, V63, P918, DOI 10.1016/j.molcel.2016.08.031
   Chevance FFV, 2017, P NATL ACAD SCI USA, V114, P4745, DOI 10.1073/pnas.1614896114
   Chevance FFV, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004392
   Chu D, 2011, NUCLEIC ACIDS RES, V39, P6705, DOI 10.1093/nar/gkr300
   Dana A, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002755
   Gonzalez DL, 2019, INTERFACE FOCUS, V9, DOI 10.1098/rsfs.2019.0038
   Hanson G, 2018, NAT REV MOL CELL BIO, V19, P20, DOI 10.1038/nrm.2017.91
   Harigaya Y, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3237-6
   Health U.D. Services H., 2013, ASS SCH BAS PHYS ACT
   Hoffmann M, 2020, BIORXIV
   Hussmann JA, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005732
   Iwasaki S, 2016, SCIENCE, V352, P1391, DOI 10.1126/science.aag1039
   Jansen R, 2003, NUCLEIC ACIDS RES, V31, P2242, DOI 10.1093/nar/gkg306
   Jenkins GM, 2003, VIRUS RES, V92, P1, DOI 10.1016/S0168-1702(02)00309-X
   Kahn Jeffrey S, 2005, Pediatr Infect Dis J, V24, pS223, DOI 10.1097/01.inf.0000188166.17324.60
   Kandeel M, 2020, J MED VIROL, V92, P660, DOI 10.1002/jmv.25754
   Keller I, 2007, PLOS GENET, V3, P185, DOI 10.1371/journal.pgen.0030022
   Koutmou KS, 2015, TRENDS BIOCHEM SCI, V40, P717, DOI 10.1016/j.tibs.2015.10.005
   Krempl C, 1995, Adv Exp Med Biol, V380, P371
   Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li F, 2015, J VIROL, V89, P1954, DOI 10.1128/JVI.02615-14
   Novoa EM, 2012, TRENDS GENET, V28, P574, DOI 10.1016/j.tig.2012.07.006
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   Neuman BW, 2011, J STRUCT BIOL, V174, P11, DOI 10.1016/j.jsb.2010.11.021
   Pagan I, 2012, J VIROL, V86, P5253, DOI 10.1128/JVI.06050-11
   Pickett BE, 2012, NUCLEIC ACIDS RES, V40, pD593, DOI 10.1093/nar/gkr859
   Plotkin JB, 2011, NAT REV GENET, V12, P32, DOI 10.1038/nrg2899
   Presnyak V, 2015, CELL, V160, P1111, DOI 10.1016/j.cell.2015.02.029
   Radhakrishnan A, 2016, CELL, V167, P122, DOI 10.1016/j.cell.2016.08.053
   Ruch TR, 2012, VIRUSES-BASEL, V4, P363, DOI 10.3390/v4030363
   Sharp PM, 2010, PHILOS T R SOC B, V365, P1203, DOI 10.1098/rstb.2009.0305
   SHARP PM, 1986, NUCLEIC ACIDS RES, V14, P5125, DOI 10.1093/nar/14.13.5125
   SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281
   Sheikh A, 2020, J VIROL METHODS, V277, DOI 10.1016/j.jviromet.2019.113806
   Siddell S.G., 2010, CORONAVIRUSES TOROVI
   SORENSEN MA, 1991, J MOL BIOL, V222, P265, DOI 10.1016/0022-2836(91)90211-N
   Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P139, DOI 10.3760/cma.j.issn.0254-6450.2020.02.002
   Stadler M, 2011, RNA, V17, P2063, DOI 10.1261/rna.02890211
   Stein DA, 2001, ANTISENSE NUCLEIC A, V11, P317, DOI 10.1089/108729001753231696
   Stothard P, 2000, BIOTECHNIQUES, V28, P1102, DOI 10.2144/00286ir01
   Sui JH, 2014, J VIROL, V88, P13769, DOI 10.1128/JVI.02232-14
   Sun XY, 2013, MOL BIOL EVOL, V30, P191, DOI 10.1093/molbev/mss201
   TYRRELL DA, 1966, LANCET, V1, P76
   Wong EHM, 2010, BMC EVOL BIOL, V10, DOI 10.1186/1471-2148-10-253
   WRIGHT F, 1990, GENE, V87, P23, DOI 10.1016/0378-1119(90)90491-9
   Yampolsky L.Y., 2001, MUTATIONAL BIASES
   Yang C.-W., 2020, J MICROBIOLOGY IMMUN
   Zedalis J., 2018, BIOL AP R COURSES
NR 52
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD NOV
PY 2020
VL 85
AR 104432
DI 10.1016/j.meegid.2020.104432
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA OY0BE
UT WOS:000593918700003
PM 32592845
OA Green Published
DA 2021-01-01
ER

PT J
AU Chutiphimon, H
   Thipsunate, A
   Cherdchim, A
   Boonyaphak, B
   Vithayasirikul, P
   Choothong, P
   Vichathai, S
   Ngamchaliew, P
   Vichitkunakorn, P
AF Chutiphimon, Hattaya
   Thipsunate, Apinya
   Cherdchim, Atigun
   Boonyaphak, Bootsarakam
   Vithayasirikul, Panat
   Choothong, Patiphan
   Vichathai, Swit
   Ngamchaliew, Pitchayanont
   Vichitkunakorn, Polathep
TI Effectiveness of Innovation Media for Improving Physical Distancing
   Compliance during the COVID-19 Pandemic: A Quasi-Experiment in Thailand
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE COVID-19; physical distancing; innovation media
ID TRANSMISSION; INTERVENTIONS
AB To flatten the curve of COVID-19 infections, with no effective pharmacological interventions or vaccine available in the imminent future, public health responses must continue to rely on non-pharmacological interventions. We developed three innovation media to promote physical distancing compliance (i.e., a fearful picture, a red one-way arrow sign, and a norm-speech sticker). This study aimed to compare physical distancing compliance between our interventions and conventional interventions. Our study was a quasi-experiment, and we observed a representative sample of university canteen customers via closed-circuit television (CCTV). Each intervention was monitored over non-prime-time hours, per day, on 6-9 August 2020. Among the 400 participants (100 participants in each group), their age group, gender, and physical distancing practices were observed in a university canteen. The number of failures of physical distancing ranged between 93.8% and 17.6%, and on average between 84.2% and 34.2%, dependent on the intervention and the marking point. There were no statistically significant differences in promoting physical distancing compliance between our interventions compared with conventional interventions. However, the participants tended to practice physical distancing at the back of the queue more than at the front, regardless of the interventions.
C1 [Chutiphimon, Hattaya; Thipsunate, Apinya; Cherdchim, Atigun; Boonyaphak, Bootsarakam; Vithayasirikul, Panat; Choothong, Patiphan; Vichathai, Swit] Prince Songkla Univ, Fac Med, Hat Yai 90110, Thailand.
   [Ngamchaliew, Pitchayanont; Vichitkunakorn, Polathep] Prince Songkla Univ, Dept Family & Prevent Med, Fac Med, Hat Yai 90110, Thailand.
RP Vichitkunakorn, P (corresponding author), Prince Songkla Univ, Dept Family & Prevent Med, Fac Med, Hat Yai 90110, Thailand.
EM 5910310167@psu.ac.th; 5910310172@psu.ac.th; 5910310168@psu.ac.th;
   5910310095@psu.ac.th; 5910310104@psu.ac.th; 5910310090@psu.ac.th;
   5910310154@psu.ac.th; pitchayanont@hotmail.com; polathep.v@psu.ac.th
OI Vichitkunakorn, Polathep/0000-0003-2309-5308
FU Institute of Research and Development for Health of Southern Thailand
   (RDH) [MED-PSU-005]
FX This research was funded by of the Institute of Research and Development
   for Health of Southern Thailand (RDH), grant number MED-PSU-005.
CR Arno A, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3272-x
   Bolton KJ, 2012, B WORLD HEALTH ORGAN, V90, P264, DOI 10.2471/BLT.11.093419
   Chu DK, 2020, LANCET, V395, P1973, DOI 10.1016/S0140-6736(20)31142-9
   Dreibelbis R, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13010129
   Geller V., 1976, SCI DIRECT, V12, P1, DOI [10.1016/0022-1031(76)90089-5, DOI 10.1016/0022-1031(76)90089-5]
   Glanz K., 2008, HLTH BEHAV HLTH ED T
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Judah G, 2009, AM J PUBLIC HEALTH, V99, pS405, DOI 10.2105/AJPH.2009.164160
   Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018
   Prem K, 2020, LANCET PUBLIC HEALTH, V5, pE261, DOI 10.1016/S2468-2667(20)30073-6
   Raihan N., 2020, STAGES CHANGE THEORY
   Sutton S., 2001, INT ENCY SOCIAL BEHA
   Tuite AR, 2020, CAN MED ASSOC J, V192, pE1276, DOI 10.1503/cmaj.200476-f
   Tull MT, 2020, PSYCHIAT RES, V289, DOI 10.1016/j.psychres.2020.113098
   WICKLUND RA, 1979, AM SCI, V67, P187
   World Health Organization, UPD WHO REC INT TRAF
   World Health Organization, WHO COR DIS COVID 19
NR 17
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD NOV
PY 2020
VL 17
IS 22
AR 8535
DI 10.3390/ijerph17228535
PG 10
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA OY3LJ
UT WOS:000594150900001
PM 33213080
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lee, SG
   Park, GU
   Moon, YR
   Sung, K
AF Lee, Seung-Geun
   Park, Geun U.
   Moon, Yeo Rae
   Sung, Kihoon
TI Clinical Characteristics and Risk Factors for Fatality and Severity in
   Patients with Coronavirus Disease in Korea: A Nationwide
   Population-Based Retrospective Study Using the Korean Health Insurance
   Review and Assessment Service (HIRA) Database
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE coronavirus; pandemic; comorbidity; death; prognosis
ID COVID-19
AB Background: We aimed to investigate the clinical characteristics and risk factors for fatality and severity in these patients. Methods: In this nationwide population-based retrospective study, we investigated the data of 7339 laboratory-confirmed COVID-19 patients, aged >= 18 years, using the Korean Health Insurance Review and Assessment Service (HIRA) database. Comorbidities and medications used were identified using HIRA codes, and severe COVID-19 was defined as that requiring oxygen therapy, mechanical ventilator, cardiopulmonary resuscitation, or extracorporeal membrane oxygenation. The outcomes were death due to COVID-19 and COVID-19 severity. Results: Mean patient age was 47.1 years; 2970 (40.1%) patients were male. Lopinavir/ritonavir, hydroxychloroquine, antibiotics, ribavirin, oseltamivir, and interferon were administered to 35.8%, 28.4%, 38.1%, 0.1%, 0.3%, and 0.9% of patients, respectively. After adjusting for confounding factors, diabetes mellitus, chronic kidney disease, previous history of pneumonia, aging, and male were significantly associated with increased risk of death and severe disease. No medication was associated with a reduced risk of fatality and disease severity. Conclusions: We found several risk factors for fatality and severity in COVID-19 patients. As the drugs currently used for COVID-19 treatment have not shown significant efficacy, all efforts should be made to develop effective therapeutic modalities for COVID-19.
C1 [Lee, Seung-Geun] Pusan Natl Univ, Pusan Natl Univ Hosp, Sch Med, Div Rheumatol,Dept Internal Med, Busan 49241, South Korea.
   [Lee, Seung-Geun] Pusan Natl Univ Hosp, Biomed Res Inst, Busan 49241, South Korea.
   [Park, Geun U.; Moon, Yeo Rae; Sung, Kihoon] LINEWALKS Inc, Seoul 06235, South Korea.
RP Lee, SG (corresponding author), Pusan Natl Univ, Pusan Natl Univ Hosp, Sch Med, Div Rheumatol,Dept Internal Med, Busan 49241, South Korea.; Lee, SG (corresponding author), Pusan Natl Univ Hosp, Biomed Res Inst, Busan 49241, South Korea.
EM sglee@pusan.ac.kr; geunu@linewalks.com; yeorae@linewalks.com;
   khsung@linewalks.com
OI Park, Geun U/0000-0002-8594-4611; Lee, Seung-Geun/0000-0002-5205-3978;
   Moon, Yeo Rae/0000-0003-2662-5570
CR [Anonymous], COR DIS COVID 19 SIT
   Apicella M, 2020, LANCET DIABETES ENDO, V8, P782, DOI 10.1016/S2213-8587(20)30238-2
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Bulut C, 2020, TURK J MED SCI, V50, P563, DOI 10.3906/sag-2004-172
   Chen RC, 2020, CHEST, V158, P97, DOI 10.1016/j.chest.2020.04.010
   D'Marco L, 2020, CLIN KIDNEY J, V13, P297, DOI 10.1093/ckj/sfaa104
   Drozdzal Sylwester, 2020, Drug Resist Updat, V53, P100719, DOI 10.1016/j.drup.2020.100719
   Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020
   Emami A, 2020, ARCH ACAD EMERG MED, V8
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gudbjartsson DF, 2020, NEW ENGL J MED, V383, P1724, DOI 10.1056/NEJMoa2026116
   Ji W, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e237
   Kario K, 2020, J CLIN HYPERTENS, V22, P1109, DOI 10.1111/jch.13917
   Kim DW, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e243
   Kim DH, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e137
   Koliaki C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072288
   Korean Soc Infect Dis, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e112
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Mills KT, 2020, NAT REV NEPHROL, V16, P223, DOI 10.1038/s41581-019-0244-2
   Nikpouraghdam M, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104378
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Parohan M, 2020, AGING MALE, DOI 10.1080/13685538.2020.1774748
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Zaki N, 2020, DIABETES METAB SYND, V14, P1133, DOI 10.1016/j.dsx.2020.07.005
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 28
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD NOV
PY 2020
VL 17
IS 22
AR 8559
DI 10.3390/ijerph17228559
PG 13
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA OY4TQ
UT WOS:000594241700001
PM 33218161
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Makowska, M
   Boguszewski, R
   Nowakowski, M
   Podkowinska, M
AF Makowska, Marta
   Boguszewski, Rafal
   Nowakowski, Michal
   Podkowinska, Monika
TI Self-Medication-Related Behaviors and Poland's COVID-19 Lockdown
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE self-medication; lockdown; COVID-19; Poland
ID HEALTH; ANTIBIOTICS; MISUSE; RISKS
AB (1) Background: The SARS-CoV-2 pandemic has changed the functioning of Polish health systems. Telemedicine has been developed and access to prescription drugs (Rx) has been facilitated. This study examined whether these changes and the imposition of a three-month lockdown caused Polish people to engage in more self-medication-related behaviors. (2) Method: After the fourth (final) stage of defrosting the Polish economy, an online survey of a quota sample of 1013 Polish respondents was conducted. (3) Results: Almost half of the respondents (45.6%) indicated that they had engaged in at least one behavior associated with inappropriate self-medication during the lockdown (e.g., 16.6% took medication as a precaution, and 16.8% took an Rx formulation without consultation). Some of these people had never engaged in such behaviors prior to the lockdown. Linear regression showed that higher values of a composite ("lockdown") index of self-medication-related behaviors occurring during lockdown were predicted by greater religiosity and the presence of children in a household. Also, independent samples t-tests showed that people who were afraid for their financial future and people who feared for their health obtained higher lockdown index scores than people not having such worries. (4) Conclusions: Self-medication-related behaviors were more common among Poles before lockdown than during the lockdown (which is unsurprising given that the lengths of the periods compared were hugely different), worryingly, many people exhibited such behaviors for the first time during the lockdown.
C1 [Makowska, Marta; Boguszewski, Rafal; Podkowinska, Monika] Warsaw Univ Life Sci, Inst Sociol Sci & Pedag, Nowoursynownska 166 St, PL-02787 Warsaw, Poland.
   [Nowakowski, Michal] Maria Curie Sklodowska Univ Lublin, Dept Social Hlth Problems, Plac Marii Curie Sklodowskiej 5, PL-20031 Lublin, Poland.
RP Boguszewski, R (corresponding author), Warsaw Univ Life Sci, Inst Sociol Sci & Pedag, Nowoursynownska 166 St, PL-02787 Warsaw, Poland.
EM marta_makowska@sggw.edu.pl; rafal_boguszewski@sggw.edu.pl;
   m.nowakowski@poczta.umcs.lublin.pl; monika_podkowinska@sggw.edu.pl
RI Makowska, Marta/S-2762-2018; Podkowinska, Monika/S-1576-2018
OI Makowska, Marta/0000-0002-0785-6237; Boguszewski,
   Rafal/0000-0002-1831-4265; Nowakowski, Michal/0000-0003-2539-6294;
   Podkowinska, Monika/0000-0002-8592-8953
FU Rector of Warsaw University of Life Sciences [504-02-900200-S00127-99]
FX This work was supported by the Rector of Warsaw University of Life
   Sciences under Grant 504-02-900200-S00127-99 made to Monika Podkowinska.
CR Balbuena FR, 2009, DRUG AGING, V26, P51, DOI 10.2165/0002512-200926010-00004
   Benotsch EG, 2014, J COMMUN HEALTH, V39, P688, DOI 10.1007/s10900-013-9811-9
   Bilal M, 2016, J CLIN DIAGN RES, V10, pOC8, DOI 10.7860/JCDR/2016/18294.7730
   Cole A, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5238
   Cooper RJ, 2013, J SUBST USE, V18, P82, DOI 10.3109/14659891.2011.615002
   Czech M., 2020, OCHRONA ZDROWIA PAND
   Du Y, 2009, BRIT J CLIN PHARMACO, V68, P599, DOI 10.1111/j.1365-2125.2009.03477.x
   Ruiz ME, 2010, CURR DRUG SAF, V5, P315, DOI 10.2174/157488610792245966
   Eurostat, 2014, MED USE STAT
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Figueiras A, 2000, EUR J EPIDEMIOL, V16, P19, DOI 10.1023/A:1007608702063
   Fox NJ, 2008, SOCIOL HEALTH ILL, V30, P856, DOI 10.1111/j.1467-9566.2008.01114.x
   Frei MY, 2010, MED J AUSTRALIA, V193, P294, DOI 10.5694/j.1326-5377.2010.tb03911.x
   Gonzales R, 2003, JAMA-J AM MED ASSOC, V289, P2701, DOI 10.1001/jama.289.20.2701
   Graham N. A., 2006, J ADDICT DIS, V25, P61, DOI [10.1300/J069v25S01_06, DOI 10.1300/J069V25S01_06]
   Grigoryan L, 2006, EMERG INFECT DIS, V12, P452, DOI 10.3201/eid1203.050992
   Hoyte CO, 2013, J COMMUN HEALTH, V38, P575, DOI 10.1007/s10900-013-9653-5
   Hughes CM, 2001, DRUG SAFETY, V24, P1027, DOI 10.2165/00002018-200124140-00002
   Ilieva IP, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00198
   Jerez-Roig J, 2014, DRUG AGING, V31, P883, DOI 10.1007/s40266-014-0217-x
   John Hopkins University, 2020, COVID 19
   Koenig Harold G, 2012, ISRN Psychiatry, V2012, P278730, DOI 10.5402/2012/278730
   Krajewski-Siuda K., 2012, SELF MEDICATION, P31
   Kretchy I.A., 2020, RES SOCIAL ADM PHARM
   Kwiatkowska J., 2020, PRZEZ WIRUSA PACJENC
   Lipiec A., 2020, OPERACJA CZASIE EPID
   Makowska M., 2018, PRZEGLD SOCJOL, V67, P97
   Malhotra N.K., 1999, MARKETING RES APPL O
   Mallhi Tauqeer Hussain, 2020, Postgrad Med J, DOI 10.1136/postgradmedj-2020-138447
   MARTINSON OB, 1985, SOC INDIC RES, V16, P301, DOI 10.1007/BF00415128
   Montastruc JL, 1997, THERAPIE, V52, P105
   Moskal W., 2020, CZY POWODU PANDEMII
   Nichols T. R., 2015, WOMEN GENDER FAMILIE, V3, P165, DOI DOI 10.5406/womgenfamcol.3.2.0165
   OLAGOKE A, 2020, J RELIG HEALTH 1030, DOI DOI 10.21203/rs.3.rs-31214/v1
   Paliska E., 2020, PACJENCI ODWOUJ WIZY
   Papakosta M, 2014, RURAL REMOTE HEALTH, V14
   Rather IA, 2017, SAUDI J BIOL SCI, V24, P808, DOI 10.1016/j.sjbs.2017.01.004
   Rogers Lee C, 2020, J Am Podiatr Med Assoc, DOI 10.7547/20-051
   SEGALL A, 1990, MED CARE, V28, P301, DOI 10.1097/00005650-199004000-00002
   Serwis Rzeczpospolitej Polskiej [Website of the Republic of Poland], 2020, NOWE ZASADY ZASANIAN
   Shehnaz SI, 2014, J ADOLESCENT HEALTH, V55, P467, DOI 10.1016/j.jadohealth.2014.07.001
   Sowik P., 2020, NIEETYCZNY BIZNES KO
   Vaandnen MH, 2006, HEALTH POLICY, V77, P166, DOI 10.1016/j.healthpol.2005.07.001
   Wazaify M, 2005, FAM PRACT, V22, P170, DOI 10.1093/fampra/cmh723
   Wdowiak L., 2012, SELF HEALING PUBLIC, P13
   WHO, 2000, GUID REG ASS MED PRO
   Williams SJ, 2008, SOCIOL HEALTH ILL, V30, P813, DOI 10.1111/j.1467-9566.2008.01123.x
   Worldometers, 2020, POLAND
NR 48
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD NOV
PY 2020
VL 17
IS 22
AR 8344
DI 10.3390/ijerph17228344
PG 19
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA OY5NI
UT WOS:000594292900001
PM 33187315
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sanchez-Montanes, M
   Rodriguez-Belenguer, P
   Serrano-Lopez, AJ
   Soria-Olivas, E
   Alakhdar-Mohmara, Y
AF Sanchez-Montanes, Manuel
   Rodriguez-Belenguer, Pablo
   Serrano-Lopez, Antonio J.
   Soria-Olivas, Emilio
   Alakhdar-Mohmara, Yasser
TI Machine Learning for Mortality Analysis in Patients with COVID-19
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE COVID-19; survival analysis; machine learning; feature importance;
   graphical models
ID MODEL
AB This paper analyzes a sample of patients hospitalized with COVID-19 in the region of Madrid (Spain). Survival analysis, logistic regression, and machine learning techniques (both supervised and unsupervised) are applied to carry out the analysis where the endpoint variable is the reason for hospital discharge (home or deceased). The different methods applied show the importance of variables such as age, O-2 saturation at Emergency Rooms (ER), and whether the patient comes from a nursing home. In addition, biclustering is used to globally analyze the patient-drug dataset, extracting segments of patients. We highlight the validity of the classifiers developed to predict the mortality, reaching an appreciable accuracy. Finally, interpretable decision rules for estimating the risk of mortality of patients can be obtained from the decision tree, which can be crucial in the prioritization of medical care and resources.
C1 [Sanchez-Montanes, Manuel] Univ Autonoma Madrid, Escuela Politecn Super, Madrid 28049, Spain.
   [Rodriguez-Belenguer, Pablo; Serrano-Lopez, Antonio J.; Soria-Olivas, Emilio] Univ Valencia, Intelligent Data Anal Lab, ETSE, IDAL, Burjassot 46100, Spain.
   [Alakhdar-Mohmara, Yasser] Univ Valencia, Dept Physiotherapy, Valencia 46010, Spain.
RP Serrano-Lopez, AJ (corresponding author), Univ Valencia, Intelligent Data Anal Lab, ETSE, IDAL, Burjassot 46100, Spain.
EM manuel.smontanes@uam.es; parodbe@gmail.com; antonio.j.serrano@uv.es;
   emilio.soria@uv.es; yasser.alakhdar@uv.es
FU Agencia Estatal de Investigacion AEI/FEDER Spain [PGC2018095895-B-I00];
   Comunidad Autonoma de Madrid, SpainComunidad de Madrid [S2017/BMD-3688]
FX This research was funded by Agencia Estatal de Investigacion AEI/FEDER
   Spain, Project PGC2018095895-B-I00, and Comunidad Autonoma de Madrid,
   Spain, Project S2017/BMD-3688.
CR Al-Rakhami MS, 2020, IEEE ACCESS, V8, P155961, DOI 10.1109/ACCESS.2020.3019600
   Albahri AS, 2020, J MED SYST, V44, DOI 10.1007/s10916-020-01582-x
   Alpaydin E., 2017, INTRO MACHINE LEARNI
   [Anonymous], 2020, FDA CAUTIONS USE HYD
   [Anonymous], 2020, MATPLOTLIB VISUALIZA
   [Anonymous], 2020, CORONAVIRUS DIS COVI
   [Anonymous], 2020, DISC HYDR LOP RIT TR
   [Anonymous], 2020, SCIKIT LEARN MACHINE
   Barabas J, 2020, 2020 43RD INTERNATIONAL CONFERENCE ON TELECOMMUNICATIONS AND SIGNAL PROCESSING (TSP), P645, DOI 10.1109/TSP49548.2020.9163461
   Berenguer J, 2020, CLIN MICROBIOL INFEC, V26, P1525, DOI 10.1016/j.cmi.2020.07.024
   Bernaola N., 2020, OBSERVATIONAL STUDY, DOI [10.1101/2020.07.17.20155960, DOI 10.1101/2020.07.17.20155960]
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Brunese L, 2020, COMPUT METH PROG BIO, V196, DOI 10.1016/j.cmpb.2020.105608
   Burian E, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051514
   Cecilia Jose M., 2020, IET Smart Cities, V2, P58, DOI 10.1049/iet-smc.2020.0037
   Chang A.C., 2020, INTELLIGENCE BASED M
   Cheng FY, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061668
   Condes Emilia, 2020, Enferm Infecc Microbiol Clin, DOI 10.1016/j.eimc.2020.06.005
   Escobedo AA, 2020, TRAVEL MED INFECT DI, V37, DOI 10.1016/j.tmaid.2020.101854
   Fernandez-Delgado M, 2014, J MACH LEARN RES, V15, P3133
   Fields BKK, 2020, CLIN IMAG, V67, P219, DOI 10.1016/j.clinimag.2020.08.014
   Fiolet Thibault, 2020, Clin Microbiol Infect, DOI 10.1016/j.cmi.2020.10.031
   Friedman J, 2001, ELEMENTS STAT LEARNI
   Garcia A., 2020, BMJ-BRIT MED J, V369, P1
   Guirao A, 2020, INFECT DIS MODEL, V5, P652, DOI 10.1016/j.idm.2020.08.010
   HARTIGAN JA, 1972, J AM STAT ASSOC, V67, P123, DOI 10.2307/2284710
   Horry MJ, 2020, IEEE ACCESS, V8, P149808, DOI 10.1109/ACCESS.2020.3016780
   Islam MN, 2020, IEEE ACCESS, V8, P145601, DOI 10.1109/ACCESS.2020.3015102
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Kleinbaum DG, 2012, STAT BIOL HEALTH, P1, DOI 10.1007/978-1-4419-6646-9
   Koller D, 2009, PROBABILISTIC GRAPHI
   Kursa MB, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i11
   Lalmuanawma S, 2020, CHAOS SOLITON FRACT, V139, DOI 10.1016/j.chaos.2020.110059
   Lima MA, 2020, J NEUROL SCI, V418, DOI 10.1016/j.jns.2020.117107
   Izquierdo JL, 2020, J MED INTERNET RES, V22, DOI 10.2196/21801
   Mbunge Elliot, 2020, Diabetes Metab Syndr, V14, P1631, DOI 10.1016/j.dsx.2020.08.029
   Mertz L, 2020, IEEE PULSE, V11, P2, DOI 10.1109/MPULS.2020.3008354
   Naseem M, 2020, J PRIM CARE COMMUNIT, V11, DOI 10.1177/2150132720963634
   Randhawa GS, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232391
   Rodriguez-Bano Jesus, 2020, Clin Microbiol Infect, DOI 10.1016/j.cmi.2020.08.010
   Russell S. J., 2003, PRENTICE HALL SERIES
   Shen B, 2020, CELL, V182, P59, DOI 10.1016/j.cell.2020.05.032
   Shrivastava G, 2020, IEEE TRANS COMPUT SO, V7, P1159, DOI 10.1109/TCSS.2020.3014135
   Tiwari N, 2020, SAUDI PHARM J, V28, P1243, DOI 10.1016/j.jsps.2020.08.015
   Topol E., 2019, DEEP MED ARTIFICIAL
   Wang NW, 2020, IEEE INT CONF ELECTR, P281
   Weisberg S., 2005, APPL LINEAR REGRESSI
   Wendel Garcia Pedro David, 2020, EClinicalMedicine, V25, P100449, DOI 10.1016/j.eclinm.2020.100449
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1
   Yang C., 2019, DATA DRIVEN APPROACH
   YeSIlkanat Cafer Mert, 2020, Chaos Solitons Fractals, V140, P110210, DOI 10.1016/j.chaos.2020.110210
NR 51
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD NOV
PY 2020
VL 17
IS 22
AR 8386
DI 10.3390/ijerph17228386
PG 20
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA OZ4RU
UT WOS:000594916000001
PM 33198392
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Schumann, S
   Kaiser, A
   Nicoletti, F
   Mangano, K
   Fagone, P
   van Wijk, E
   Yan, Y
   Schulz, P
   Ludescher, B
   Niedermaier, M
   von Wegerer, J
   Rauch, P
   Setz, C
   Schubert, U
   Brysch, W
AF Schumann, Sara
   Kaiser, Astrid
   Nicoletti, Ferdinando
   Mangano, Katia
   Fagone, Paolo
   van Wijk, Eduard
   Yan, Yu
   Schulz, Petra
   Ludescher, Beate
   Niedermaier, Michael
   von Wegerer, Joerg
   Rauch, Pia
   Setz, Christian
   Schubert, Ulrich
   Brysch, Wolfgang
TI Immune-Modulating Drug MP1032 with SARS-CoV-2 Antiviral Activity In
   Vitro: A potential Multi-Target Approach for Prevention and Early
   Intervention Treatment of COVID-19
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE COVID-19; SARS-CoV-2; oxidative stress; inflammation; cytokine storm;
   drug development; COVID-19 drugs
ID POLY(ADP-RIBOSE) POLYMERASES; DIFFERENTIATION
AB At least since March 2020, the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic and the multi-organ coronavirus disease 2019 (COVID-19) are keeping a firm grip on the world. Although most cases are mild, older patients and those with co-morbidities are at increased risk of developing a cytokine storm, characterized by a systemic inflammatory response leading to acute respiratory distress syndrome and organ failure. The present paper focuses on the small molecule MP1032, describes its mode of action, and gives rationale why it is a promising option for the prevention/treatment of the SARS-CoV-2-induced cytokine storm. MP1032 is a phase-pure anhydrous polymorph of 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt that exhibits good stability and bioavailability. The physiological action of MP1032 is based on a multi-target mechanism including localized, self-limiting reactive oxygen species (ROS) scavenging activities that were demonstrated in a model of lipopolysaccharide (LPS)-induced joint inflammation. Furthermore, its immune-regulatory and PARP-1-modulating properties, coupled with antiviral effects against SARS-CoV-2, have been demonstrated in various cell models. Preclinical efficacy was elucidated in LPS-induced endotoxemia, a model with heightened innate immune responses that shares many similarities to COVID-19. So far, during oral clinical development with three-month daily administrations, no serious adverse drug reactions occurred, highlighting the outstanding safety profile of MP1032.
C1 [Schumann, Sara; Kaiser, Astrid; Schulz, Petra; Ludescher, Beate; Niedermaier, Michael; von Wegerer, Joerg] MetrioPharm Deutschland GmbH, Borsigturm 100, D-13507 Berlin, Germany.
   [Nicoletti, Ferdinando; Mangano, Katia; Fagone, Paolo] Univ Catania, Dept Biomed & Biotechnol Sci, I-95123 Catania, Italy.
   [van Wijk, Eduard; Yan, Yu] Meluna Res, Dept Biophoton, Koppelsedijk 1A, NL-4191 LC Geldermalsen, Netherlands.
   [Rauch, Pia; Setz, Christian; Schubert, Ulrich] Friedrich Alexander Univ Erlangen Nurnberg FAU, Inst Virol, D-91054 Erlangen, Germany.
   [Brysch, Wolfgang] MetrioPharm AG, Bleicherweg 10, CH-8002 Zurich, Switzerland.
RP Schumann, S (corresponding author), MetrioPharm Deutschland GmbH, Borsigturm 100, D-13507 Berlin, Germany.
EM s.schumann@metriopharm.com; a.kaiser@metriopharm.com; ferdinic@unict.it;
   kmangano@unict.it; paolofagone@yahoo.it; evanwijk@melunaresearch.nl;
   yan@melunaresearch.nl; p.schulz@metriopharm.com;
   b.ludescher@metriopharm.com; m.niedermaier@metriopharm.com;
   j.vonwegerer@metriopharm.com; pia.rauch@uk-erlangen.de;
   christian.setz@uk-erlangen.de; ulrich.schubert@fau.de;
   w.brysch@metriopharm.com
RI NICOLETTI, Ferdinando/M-4428-2016; Mangano, Katia/Q-1156-2016; Fagone,
   Paolo/Q-4455-2016
OI NICOLETTI, Ferdinando/0000-0002-4570-8462; Mangano,
   Katia/0000-0001-5920-4620; Fagone, Paolo/0000-0002-6694-1992; Schumann,
   Sara/0000-0002-6902-142X
FU German Research CouncilGerman Research Foundation (DFG) [GRK 2504]
FX This work was supported by graduate program GRK 2504 from the German
   Research Council a to U.S.
CR Bai P, 2015, MOL CELL, V58, P947, DOI 10.1016/j.molcel.2015.01.034
   Bai P, 2012, FEBS LETT, V586, P3771, DOI 10.1016/j.febslet.2012.09.026
   Begemann H., 1972, ATLAS CLIN HAEMATOLO, P9
   BHATIA M, 1995, BIOCHEM J, V308, P131, DOI 10.1042/bj3080131
   Cain DW, 2020, NAT REV IMMUNOL, V20, P587, DOI 10.1038/s41577-020-00421-x
   Cheng Richard Z, 2020, Med Drug Discov, V5, P100028, DOI 10.1016/j.medidd.2020.100028
   Cifra M, 2014, J PHOTOCH PHOTOBIO B, V139, P2, DOI 10.1016/j.jphotobiol.2014.02.009
   Costela-Ruiz VJ, 2020, CYTOKINE GROWTH F R, V54, P62, DOI 10.1016/j.cytogfr.2020.06.001
   Curtin N, 2020, BRIT J PHARMACOL, V177, P3635, DOI 10.1111/bph.15137
   De Flora S, 2020, FASEB J, V34, P13185, DOI 10.1096/fj.202001807
   Delgado-Roche L, 2020, ARCH MED RES, V51, P384, DOI 10.1016/j.arcmed.2020.04.019
   Fajgenbaum DC, 2020, INFECT DIS THER, V9, P435, DOI 10.1007/s40121-020-00303-8
   Fu JH, 2020, THROMB RES, V192, P3, DOI 10.1016/j.thromres.2020.05.006
   Gjyshi O, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004460
   Gro<ss>e M., 2020, 2020070102 PREPR
   Grunewald ME, 2018, VIROLOGY, V517, P62, DOI 10.1016/j.virol.2017.11.020
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   IKEBUCHI Y, 1991, J BIOL CHEM, V266, P13233
   Jeon S, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00819-20
   Khomich OA, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10080392
   Laforge M, 2020, NAT REV IMMUNOL, V20, P515, DOI 10.1038/s41577-020-0407-1
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Lowery EM, 2013, CLIN INTERV AGING, V8, P1489, DOI 10.2147/CIA.S51152
   Martin T, 2015, Z ANORG ALLG CHEM, V641, P332, DOI 10.1002/zaac.201400604
   Nasi Aikaterini, 2020, Toxicol Rep, V7, P768, DOI 10.1016/j.toxrep.2020.06.003
   Nicoletti F, 1997, EUR J IMMUNOL, V27, P1580, DOI 10.1002/eji.1830270639
   Nunn AVW, 2020, IMMUN AGEING, V17, DOI 10.1186/s12979-020-00204-x
   Pazzaglia S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010041
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Schett G, 2020, NAT REV RHEUMATOL, V16, P465, DOI 10.1038/s41584-020-0451-z
   Schoenrich Gunther, 2020, Advances in Biological Regulation, V77, P100741, DOI 10.1016/j.jbior.2020.100741
   Shi CS, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0181-7
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Tan Y, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/2405291
   Williamson EJ, 2020, NATURE, DOI 10.1038/s41586-020-2521-4
   Xu YZ, 2010, MOL BIOL CELL, V21, P811, DOI 10.1091/mbc.E09-06-0534
   Zhang X, 2008, PROC CVPR IEEE, P117
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 40
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2020
VL 21
IS 22
AR 8803
DI 10.3390/ijms21228803
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA OZ4KC
UT WOS:000594896000001
PM 33233817
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Genet, B
   Vidal, JS
   Cohen, A
   Boully, C
   Beunardeau, M
   Harle, LM
   Goncalves, A
   Boudali, Y
   Hernandorena, I
   Bailly, H
   Lenoir, H
   Piccoli, M
   Chahwakilian, A
   Kermanach, L
   de Jong, L
   Duron, E
   Girerd, X
   Hanon, O
AF Genet, Bastien
   Vidal, Jean-Sebastien
   Cohen, Adrien
   Boully, Clemence
   Beunardeau, Maelle
   Harle, Louise Marine
   Goncalves, Anna
   Boudali, Yasmina
   Hernandorena, Intza
   Bailly, Henri
   Lenoir, Hermine
   Piccoli, Matthieu
   Chahwakilian, Anne
   Kermanach, Lena
   de Jong, Laura
   Duron, Emmanuelle
   Girerd, Xavier
   Hanon, Olivier
TI COVID-19 In-Hospital Mortality and Use of Renin-Angiotensin System
   Blockers in Geriatrics Patients
SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
LA English
DT Article
DE COVID-19; in-hospital mortality; geriatrics;
   renin-angiotensin-aldosterone system blockers; angiotensin receptor
   blockers; angiotensin-converting enzyme inhibitor
ID INFECTION
AB Objective: The role of treatment with renin-angiotensin-aldosterone system blockers at the onset of COVID-19 infection is not known in the geriatric population. The aim of this study was to assess the relationship between angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitor (ACEI) use and in-hospital mortality in geriatric patients hospitalized for COVID-19.
   Design: This observational retrospective study was conducted in a French geriatric department. Patients were included between March 17 and April 18, 2020.
   Setting and Participants: All consecutive 201 patients hospitalized for COVID-19 (confirmed by reverse-transcriptase polymerase chain reaction methods) were included. All nondeceased patients had 30 days of follow-up and no patient was lost to follow-up.
   Methods: Demographic, clinical, and biological data and medications were collected. In-hospital mortality of patients treated or not by ACEI/ARB was analyzed using multivariate Cox models.
   Results: Mean age of the population was 86.3 (8.0) years, 62.7% of patients were institutionalized, 88.6% had dementia, and 53.5% had severe disability (activities of daily living [ADL] score <2). Sixty-three patients were treated with ACEI/ARB and 138 were not. Mean follow-up was 23.4 (10.0) days, 66 (33.8%) patients died after an average of 10.0 days (6.0). Lower mortality rate was observed in patients treated with ACEI/ARB compared with patients not treated with ARB or ACEI (22.2% [14] vs 37.7% [52], hazard ratio [HR] 0.54; 95% confidence interval 0.30-0.97; P =.03). In a multivariate Cox regression model including age, sex, ADL score, Charlson index, renal function, dyspnea, C-reactive protein, and white blood cell count, use of ACEI/ARB was significantly associated with lower in-hospital mortality (HR 0.52 (0.27-0.99), P = .048).
   Conclusion and Implications: In very old subjects hospitalized in geriatric settings for COVID-19, mortality was significantly lower in subjects treated with ARB or ACEI before the onset of infection. The continuation of ACEI/ARB therapy should be encouraged during periods of coronavirus outbreak in older subjects. (C) 2020 AMDA - The Society for Post-Acute and Long-Term Care Medicine.
C1 [Genet, Bastien; Vidal, Jean-Sebastien; Cohen, Adrien; Boully, Clemence; Beunardeau, Maelle; Harle, Louise Marine; Goncalves, Anna; Boudali, Yasmina; Hernandorena, Intza; Bailly, Henri; Lenoir, Hermine; Piccoli, Matthieu; Chahwakilian, Anne; Kermanach, Lena; Hanon, Olivier] Hop Univ Paris Ctr, Hop Broca, AP HP, Serv Geriatrie, F-75013 Paris, France.
   [Vidal, Jean-Sebastien; Cohen, Adrien; Boully, Clemence; Beunardeau, Maelle; Harle, Louise Marine; Goncalves, Anna; Boudali, Yasmina; Hernandorena, Intza; Bailly, Henri; Lenoir, Hermine; Piccoli, Matthieu; Chahwakilian, Anne; Kermanach, Lena; Hanon, Olivier] Univ Paris, EA 4468, F-75013 Paris, France.
   [de Jong, Laura] GHU Paris Psychiat & Neurosci, Ctr Hosp St Anne, F-75014 Paris, France.
   [Duron, Emmanuelle] Hop Paul Brousse, AP HP, Serv Geriatrie, F-94804 Villejuif, France.
   [Duron, Emmanuelle] Univ Paris Sud XI, F-94270 Le Kremlin Bicetre, France.
   [Girerd, Xavier] Fdn Rech Hypertens Arterielle FRHTA, F-75013 Paris, France.
   [Girerd, Xavier] Sorbonne Univ, Hop Pitie Salpetriere, AP HP, F-75013 Paris, France.
RP Hanon, O (corresponding author), Hop Broca, 54-56 Rue Pascal, F-75013 Paris, France.
EM olivier.hanon@brc.aphp.fr
OI Vidal, Jean-Sebastien/0000-0001-6770-0720
CR American Psychiatric Association, 2013, DSM 5 DIAGN STAT MAN
   [Anonymous], 2007, STRAT PRIS CHARG CAS
   Buscemi S, 2020, OBESITY, V28, P1371, DOI 10.1002/oby.22883
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen J, 2020, J INFECTION, V80, pE1, DOI 10.1016/j.jinf.2020.03.004
   Code de la Sante Publique, 2016, CODE SANTE PUBLIQUE
   Conde-Sala JL, 2020, ARCH GERONTOL GERIAT, V89, DOI 10.1016/j.archger.2020.104035
   Courtright KR, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.0038
   de Abajo FJ, 2020, LANCET, V395, P1705, DOI 10.1016/S0140-6736(20)31030-8
   De Spiegeleer A, 2020, J AM MED DIR ASSOC, V21, P909, DOI 10.1016/j.jamda.2020.06.018
   Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951
   Ferrari R, 2020, EUR HEART J, V41, P2050, DOI 10.1093/eurheartj/ehaa326
   Fosbol EL, 2020, JAMA-J AM MED ASSOC, V324, P168, DOI 10.1001/jama.2020.11301
   Gao C, 2020, EUR HEART J, V41, P2058, DOI 10.1093/eurheartj/ehaa433
   Guidet B, 2017, JAMA-J AM MED ASSOC, V318, P1450, DOI 10.1001/jama.2017.13889
   Inciardi RM, 2020, EUR HEART J, V41, P1821, DOI 10.1093/eurheartj/ehaa388
   Instituto Superiore di Sanita, 2020, EPIDEMIA COVID 19 AG
   Jung S, 2020, CLIN INFECT DIS
   KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016
   Kreutz R, 2020, CARDIOVASC RES, V116, P1688, DOI 10.1093/cvr/cvaa097
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006
   Li JY, 2020, JAMA CARDIOL, V5, P825, DOI 10.1001/jamacardio.2020.1624
   Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Marrie TJ, 2000, CLIN INFECT DIS, V31, P1066, DOI 10.1086/318124
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Saavedra JM, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104832
   von Elm E, 2007, PLOS MED, V4, P1623, DOI 10.1371/journal.pmed.0040296
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang G, 2020, HYPERTENSION, V76, P51, DOI 10.1161/HYPERTENSIONAHA.120.15143
   Zhang GQ, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104364
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhang XJ, 2020, CELL METAB, V32, P176, DOI 10.1016/j.cmet.2020.06.015
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 37
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1525-8610
EI 1538-9375
J9 J AM MED DIR ASSOC
JI J. Am. Med. Dir. Assoc.
PD NOV
PY 2020
VL 21
IS 11
BP 1539
EP 1545
DI 10.1016/j.jamda.2020.09.004
PG 7
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA OL4LP
UT WOS:000585314000005
PM 33138935
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ferrari, F
   Visconti, F
   De Amici, M
   Guglielmi, A
   Colombo, CN
   Belliato, M
   Ronco, C
AF Ferrari, Fiorenza
   Visconti, Federico
   De Amici, Mara
   Guglielmi, Angelo
   Colombo, Costanza N.
   Belliato, Mirko
   Ronco, Claudio
TI Coronavirus disease 2019 in critically ill patients: can we re-program
   the immune system? A primer for Intensivists
SO MINERVA ANESTESIOLOGICA
LA English
DT Article
DE COVID-19; Severe acute respiratory syndrome; Cytokines; Immune system
   phenomena
ID REGULATORY T-CELLS; RENAL REPLACEMENT THERAPY; OFF-LABEL USE; SEVERE
   COVID-19; TOCILIZUMAB; SEPSIS; CYTOKINE; ANAKINRA; HEMOFILTRATION;
   PNEUMONIA
AB In December 2019, Coronavirus disease 2019 (COVID-19) emerged in Wuhan and rapidly spread around the word. The immune response is essential to control and eliminate CoV infections, however, multiorgan damage might be due to direct SARS-CoV2 action against the infected organ cells, as well as an imbalanced host immune response. In effect, a "cytokines storm" and an impaired innate immunity were found in the COVID-19 critically ill patients. In this review, we summarized the virus immune response steps, underlying the relevance of introducing the measurement of plasma cytokine levels and of circulating lymphocyte subsets in clinical practice for the follow-up of critically ill COVID-19 patients and support new therapy.
C1 [Ferrari, Fiorenza; Visconti, Federico; Guglielmi, Angelo; Colombo, Costanza N.; Belliato, Mirko] Univ Pavia, IRCCS San Matteo Hosp, Dept Anesthesia & Intens Care Unit, Viale Golgi 19, I-27100 Pavia, Italy.
   [Ferrari, Fiorenza; Ronco, Claudio] Int Renal Res Inst Vicenza IRRIC, Dept Nephrol Dialysis & Transplantat, Vicenza, Italy.
   [De Amici, Mara] IRCCS Polyclin San Matteo Fdn, Immunoallergol Lab Clin Chem Unit, Pavia, Italy.
   [Ronco, Claudio] Univ Padua, Unit Nephrol, Padua, Italy.
   [Ronco, Claudio] San Bortolo Hosp, Dept Nephrol Dialysis & Transplant, AUSSL 8 Reg Veneto, Vicenza, Italy.
RP Ferrari, F (corresponding author), Univ Pavia, IRCCS San Matteo Hosp, Dept Anesthesia & Intens Care Unit, Viale Golgi 19, I-27100 Pavia, Italy.
EM fioreferrari28@gmail.com
CR Alattar R, 2020, J MED VIROL, V92, P2042, DOI 10.1002/jmv.25964
   [Anonymous], 2020, EXPERT CONSENSUS COM
   Aouba A, 2020, ANN RHEUM DIS, V79, P1381, DOI 10.1136/annrheumdis-2020-217706
   Artenstein AW, 2013, CRIT CARE MED, V41, P2770, DOI 10.1097/CCM.0b013e31829eb98f
   Balasubramanian S, 2020, INDIAN PEDIATR, V57, P681
   Benucci M, 2020, J MED VIROL, V92, P2368, DOI 10.1002/jmv.26062
   Bonilla FA, 2010, J ALLERGY CLIN IMMUN, V125, pS33, DOI 10.1016/j.jaci.2009.09.017
   Borku Uysal B, 2020, J MED VIROL
   Campins L, 2020, CLIN EXP RHEUMATOL, V38, P578
   Campochiaro C, 2020, EUR J INTERN MED, V76, P43, DOI 10.1016/j.ejim.2020.05.021
   Capra R, 2020, EUR J INTERN MED, V76, P31, DOI 10.1016/j.ejim.2020.05.009
   Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2
   Cellina M, 2020, DIAGN INTERV IMAG, V101, P323, DOI 10.1016/j.diii.2020.03.010
   Chaidos A, 2020, BRIT J HAEMATOL, V190, pE9, DOI 10.1111/bjh.16787
   Chen L, 2020, ZHONGHUA JIE HE HE H
   Chi Y, 2020, J INFECT DIS, V222, P746, DOI 10.1093/infdis/jiaa363
   Colaneri M, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8050695
   Coyle Justin, 2020, JACC Case Rep, V2, P1331, DOI 10.1016/j.jaccas.2020.04.025
   Dastan F, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106043
   Dastan F, 2020, J GLOB ANTIMICROB RE, V21, P340, DOI 10.1016/j.jgar.2020.04.024
   Day JW, 2020, BRIT J HAEMATOL, V190, pE80, DOI 10.1111/bjh.16873
   De Luna G, 2020, AM J HEMATOL, V95, P876, DOI 10.1002/ajh.25833
   Di Carlo JV, 2005, INT J ARTIF ORGANS, V28, P777
   Di Giambenedetto S, 2020, J MED VIROL, V92, P1787, DOI 10.1002/jmv.25897
   Dimopoulos G, 2020, CELL HOST MICROBE, V28, P117, DOI 10.1016/j.chom.2020.05.007
   Emmi G, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102575
   Faguer S, 2020, ANN INTERN MED, V173, P501, DOI 10.7326/L20-0419
   Ferrey AJ, 2020, AM J NEPHROL, V51, P337, DOI 10.1159/000507417
   Filice G., 2006, INFEZIONI MALATTIE V
   Filocamo G, 2020, INT J INFECT DIS, V96, P607, DOI 10.1016/j.ijid.2020.05.026
   Fontana F, 2020, AM J TRANSPLANT, V20, P1902, DOI 10.1111/ajt.15935
   Franzetti M, 2020, INT J INFECT DIS, V97, P215, DOI 10.1016/j.ijid.2020.05.050
   Gautier-Vargas G, 2020, KIDNEY INT, V98, P508, DOI 10.1016/j.kint.2020.05.022
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009
   Gonzilvez Guardiola P, 2020, CIR ESP
   Hammami MB, 2020, AM J TRANSPLANT, V20, P2254, DOI 10.1111/ajt.15985
   Hassoun A, 2020, J CLIN VIROL, V128, DOI 10.1016/j.jcv.2020.104443
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Holzhauser L, 2020, AM J TRANSPLANT, V20, P2916, DOI 10.1111/ajt.15982
   Honore PM, 2004, CRIT CARE MED, V32, P896, DOI 10.1097/01.CCM.0000115262.31804.46
   Honore PM, 2004, INT J ARTIF ORGANS, V27, P1077
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huet O, 2014, CLIN SCI, V126, P31, DOI 10.1042/CS20120668
   Issa N, 2020, J MED VIROL, DOI 10.1002/jmv.26110
   Jamilloux Y, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102567
   Ke CJ, 2020, CLIN BIOCHEM, V81, P9, DOI 10.1016/j.clinbiochem.2020.04.008
   Khan M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00167
   Klopfenstein T, 2020, MED MALADIES INFECT, V50, P397, DOI 10.1016/j.medmal.2020.05.001
   La Rosee P, 2019, BLOOD, V133, P2465, DOI 10.1182/blood.2018894618
   Lauterio A, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13334
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Li XC, 2010, NAT REV NEPHROL, V6, P577, DOI 10.1038/nrneph.2010.101
   Liu Y, 2020, 2019 NOVEL CORONAVIR
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Luo Song, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P227, DOI 10.3785/j.issn.1008-9292.2020.03.06
   Ma J, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108408
   Marfella R, 2020, DIABETES METAB, V46, P403, DOI 10.1016/j.diabet.2020.05.005
   Mazzitelli M, 2020, J MED VIROL, DOI 10.1002/jmv.26016
   Mazzoni A, 2020, J CLIN INVEST, V130, P4694, DOI [10.1172/JCI138554, 10.1172/JCI138554.]
   Mella A, 2020, TRANSPL INFECT DIS, DOI 10.1111/tid.13348
   Michot JM, 2020, ANN ONCOL, V31, P961, DOI 10.1016/j.annonc.2020.03.300
   Morena V, 2020, EUR J INTERN MED, V76, P36, DOI 10.1016/j.ejim.2020.05.011
   Morillas JA, 2020, AM J TRANSPLANT, V20, P3191, DOI 10.1111/ajt.16080
   Morrison AR, 2020, J MED VIROL, V92, P1791, DOI 10.1002/jmv.25907
   Muhovic D, 2020, LIVER INT, V40, P1901, DOI 10.1111/liv.14516
   Murphy KM, 2007, JANEWAYS IMMUNOBIOLO
   Odievre MH, 2020, AM J HEMATOL, V95, pE192, DOI 10.1002/ajh.25855
   Peng ZY, 2010, CONTRIB NEPHROL, V165, P322, DOI 10.1159/000313773
   Perlman S, 2005, NAT REV IMMUNOL, V5, P917, DOI 10.1038/nri1732
   Pontali E, 2020, J ALLERGY CLIN IMMUN, V146, P213, DOI 10.1016/j.jaci.2020.05.002
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Quartuccio L, 2020, J CLIN VIROL, V129, DOI 10.1016/j.jcv.2020.104444
   Quartuccio L, 2020, J MED VIROL, V92, P2852, DOI 10.1002/jmv.26149
   Radbel J, 2020, CHEST, V158, pE15, DOI 10.1016/j.chest.2020.04.024
   Ronco C, 2003, ARTIF ORGANS, V27, P792, DOI 10.1046/j.1525-1594.2003.07289.x
   Ronco C, 2020, BLOOD PURIFICAT, V49, P255, DOI [10.1159/000507039, 10.1159/000508125]
   Sakaguchi S, 2006, IMMUNOL REV, V212, P8, DOI 10.1111/j.0105-2896.2006.00427.x
   Sakaguchi S, 2010, NAT REV IMMUNOL, V10, P490, DOI 10.1038/nri2785
   Sciascia S, 2020, CLIN EXP RHEUMATOL, V38, P529
   SOBHANI S, 2020, TRANSPL INFECT DIS, V22
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Turvey SE, 2010, J ALLERGY CLIN IMMUN, V125, pS24, DOI 10.1016/j.jaci.2009.07.016
   Ugazio AG, 2017, IMMUNOLOGIA ALLERGOL
   UpToDate Sarilumab, 2020, DRUG INF
   UpToDate Tocilizumab, 2020, DRUG INF
   Valencia-Sanchez C, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102182
   van der Meer JWM, 2015, MOL IMMUNOL, V68, P40, DOI 10.1016/j.molimm.2015.06.019
   van der Ven AJAM, 2015, FRONT MED-LAUSANNE, V2, DOI 10.3389/fmed.2015.00004
   van Kraaij Tom DA, 2020, Eur J Case Rep Intern Med, V7, P001675, DOI 10.12890/2020_001675
   Wada Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035069
   Wang L, 2020, EUR REV MED PHARMACO, V24, P5783, DOI 10.26355/eurrev_202005_21372
   Wang Q, 2020, INT J INFECT DIS, V96, P618, DOI 10.1016/j.ijid.2020.05.065
   Wang W, 2020, DIS CHARACTERISTICS
   Wood KJ, 2003, NAT REV IMMUNOL, V3, P199, DOI 10.1038/nri1027
   Xu CY, 2020, QJM-INT J MED, V113, P569, DOI 10.1093/qjmed/hcaa153
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang Y., 2020, EXUBERANT ELEVATION
   Zhang XH, 2020, BLOOD ADV, V4, P1307, DOI 10.1182/bloodadvances.2020001907
NR 99
TC 0
Z9 0
U1 0
U2 0
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY
SN 0375-9393
EI 1827-1596
J9 MINERVA ANESTESIOL
JI Minerva Anestesiol.
PD NOV
PY 2020
VL 86
IS 11
BP 1214
EP 1233
DI 10.23736/S0375-9393.20.14663-7
PG 20
WC Anesthesiology; Critical Care Medicine
SC Anesthesiology; General & Internal Medicine
GA OW8BV
UT WOS:000593105900014
PM 32755094
DA 2021-01-01
ER

PT J
AU Foti, G
   Giannini, A
   Bottino, N
   Castelli, GP
   Cecconi, M
   Grasselli, G
   Guatteri, L
   Latronico, N
   Langer, T
   Monti, G
   Muttini, S
   Pesenti, A
   Radrizzani, D
   Ranucci, M
   Russotto, V
   Fumagalli, R
AF Foti, Giuseppe
   Giannini, Alberto
   Bottino, Nicola
   Castelli, Gian Paolo
   Cecconi, Maurizio
   Grasselli, Giacomo
   Guatteri, Luca
   Latronico, Nicola
   Langer, Thomas
   Monti, Giacomo
   Muttini, Stefano
   Pesenti, Antonio
   Radrizzani, Danilo
   Ranucci, Marco
   Russotto, Vincenzo
   Fumagalli, Roberto
CA COVID-19 Lombardy ICU Network
TI Management of critically ill patients with COVID-19: suggestions and
   instructions from the coordination of intensive care units of Lombardy
SO MINERVA ANESTESIOLOGICA
LA English
DT Article
DE COVID-19; Respiratory distress syndrome; adult; Pandemics
ID RESPIRATORY SUPPORT; PRESSURE TARGET
AB With 63,098 confirmed cases on 17 April 2020 and 11,384 deaths, Lombardy has been the most affected region in Italy by coronavirus disease 2019 (COVID-19). To cope with this emergency, the COVID-19 Lombardy intensive care units (ICU) network was created. The network identified the need of defining a list of clinical recommendations to standardize treatment of patients with COVID-19 admitted to Intensive Care Unit (ICU). Three core topics were identified: 1) rational use of intensive care resources; 2) ventilation strategies; 3) non-ventilatory interventions. Identification of patients who may benefit from ICU treatment is challenging. Clinicians should consider baseline performance and frailty status and they should adopt disease-specific staging tools. Continuous positive airway pressure, mainly delivered through a helmet as elective method, should be considered as initial treatment for all patients with respiratory failure associated with COVID-19. In case of persisting dyspnea and/or desaturation despite 4-6 hours of noninvasive ventilation, endotracheal intubation and invasive mechanical ventilation should be considered. In the early phase, muscle relaxant use and volume-controlled ventilation is recommended. Prone position should be performed in patients with PaO2/FiO(2)<= 100 mmHg. For patients admitted to ICU with COVID-19 interstitial pneumonia, we do not recommend empiric antibiotic therapy for community-acquired pneumonia. Consultation of an infectious disease specialist is suggested before start of any antiviral therapy. In conclusion, the COVID-19 Lombardy ICU Network identified a list of best practice statements supported by the available evidence and clinical experience or identified as panel members expert opinions for the management of critically ill patients with COVID-19.
C1 [Foti, Giuseppe; Russotto, Vincenzo] San Gerardo Univ Hosp, Dept Emergency & Intens Care, Via Pergolesi 33, I-20900 Monza, Italy.
   [Foti, Giuseppe; Langer, Thomas; Russotto, Vincenzo; Fumagalli, Roberto] Univ Milano Bicocca, Sch Med & Surg, Milan, Italy.
   [Giannini, Alberto; Latronico, Nicola] ASST Spedali Civili Hosp, Childrens Hosp, Unit Pediat Anesthesiol & Intens Care, Brescia, Italy.
   [Bottino, Nicola; Grasselli, Giacomo; Pesenti, Antonio] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Anesthesiol Reanimat & Emergency, Milan, Italy.
   [Castelli, Gian Paolo] ASST Mantua, Carlo Poma Hosp, Dept Anesthesiol & Intens Care, Mantua, Italy.
   [Cecconi, Maurizio] IRCCS Humanitas Clin, Dept Anesthesiol & Intens Care Med, Milan, Italy.
   [Cecconi, Maurizio] Humanitas Univ, Milan, Italy.
   [Grasselli, Giacomo; Pesenti, Antonio] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy.
   [Guatteri, Luca] Sacra Famiglia Fatebenefratelli Hosp, Dept Anesthesiol & Intens Care, Erba, Como, Italy.
   [Latronico, Nicola] Univ Brescia, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Brescia, Italy.
   [Latronico, Nicola] ASST Spedali Civili, Dept Anesthesiol Crit Care & Emergency, Brescia, Italy.
   [Langer, Thomas; Fumagalli, Roberto] ASST Grande Osped Metropolitano Niguarda, Dept Anesthesiol & Intens Care, Milan, Italy.
   [Monti, Giacomo] IRCCS San Raffaele Hosp, Dept Anesthesiol & Intens Care, Milan, Italy.
   [Muttini, Stefano] ASST Santi Paolo & Carlo, San Carlo Hosp, Dept Anesthesiol & Intens Care, Milan, Italy.
   [Radrizzani, Danilo] ASST Ovest Milanese, Hosp Legnano, Dept Anesthesiol & Intens Care, Milan, Italy.
   [Ranucci, Marco] IRCCS San Donato Hosp, Dept Anesthesiol & Intens Care, Milan, Italy.
RP Russotto, V (corresponding author), San Gerardo Univ Hosp, Dept Emergency & Intens Care, Via Pergolesi 33, I-20900 Monza, Italy.
EM vincenzo.russotto@unimib.it
OI ZANGRILLO, Alberto/0000-0002-7687-7648; LANDONI,
   Giovanni/0000-0002-8594-5980
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Anderson F, 1996, J PALLIAT CARE, V12, P5, DOI 10.1177/082585979601200102
   [Anonymous], 2020, RACC ET CLIN FAMM TR
   Asfar P, 2014, NEW ENGL J MED, V370, P1583, DOI 10.1056/NEJMoa1312173
   Beloncle F, 2016, MINERVA ANESTESIOL, V82, P777
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Citerio G, 2020, INTENS CARE MED, V46, P1521, DOI 10.1007/s00134-020-06155-7
   Cortegiani A, 2018, SUPPORT CARE CANCER, V26, P1773, DOI 10.1007/s00520-017-4014-z
   Fan E, 2020, LANCET RESP MED, V8, P816, DOI 10.1016/S2213-2600(20)30304-0
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Gori T, 2020, BASIC RES CARDIOL, V115, DOI 10.1007/s00395-020-0792-4
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103
   Ho Francis, 2008, BMC Palliat Care, V7, P10, DOI 10.1186/1472-684X-7-10
   Huang DT, 2018, NEW ENGL J MED, V379, P236, DOI [10.1056/NEJMoa1802670, 10.1056/nejmoa1802670]
   Istituto Superiore di Sanita, 2020, EP COVID 19
   Kacmarek RM, 2019, RESP CARE, V64, P658, DOI 10.4187/respcare.06671
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Lobo SM, 2017, CHEST, V152, P321, DOI 10.1016/j.chest.2017.04.176
   Lucchini A, 2020, INTENS CRIT CARE NUR, V58, DOI 10.1016/j.iccn.2020.102859
   Mahase E, 2020, BMJ-BRIT MED J, V369, DOI [10.1136/bmj.m2378, 10.1136/bmj.m3378]
   Mehta S, 2012, JAMA-J AM MED ASSOC, V308, P1985, DOI 10.1001/jama.2012.13872
   Mondello Epifanio, 2002, J Clin Monit Comput, V17, P271, DOI 10.1023/A:1021250320103
   Moran I, 2006, INTENS CARE MED, V32, P524, DOI 10.1007/s00134-006-0073-1
   Moss M, 2019, NEW ENGL J MED, V380, P1997, DOI 10.1056/NEJMoa1901686
   Muessig JM, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-018-0847-7
   Panigada M, 2020, J THROMB HAEMOST, V18, P1738, DOI 10.1111/jth.14850
   Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372
   Patel BK, 2016, JAMA-J AM MED ASSOC, V315, P2435, DOI 10.1001/jama.2016.6338
   Pedersen Carsten M, 2009, Intensive Crit Care Nurs, V25, P21, DOI 10.1016/j.iccn.2008.05.004
   Pironi L, 2018, CLIN NUTR, V37, P1798, DOI 10.1016/j.clnu.2018.07.036
   Ranucci M, 2020, J THROMB HAEMOST, V18, P1747, DOI 10.1111/jth.14854
   Reichart D, 2018, EUR J CARDIO-THORAC, V54, P1102, DOI 10.1093/ejcts/ezy222
   Ritchie AI, 2020, LANCET, V395, P1111, DOI 10.1016/S0140-6736(20)30691-7
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Russotto V, 2019, INTENS CARE MED, V45, P1615, DOI 10.1007/s00134-019-05757-0
   Russotto V, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.08.32
   Russotto V, 2017, J CRIT CARE, V41, P98, DOI 10.1016/j.jcrc.2017.05.003
   Schuetz P, 2018, JAMA-J AM MED ASSOC, V319, P925, DOI 10.1001/jama.2018.0852
   Sever Mehmet Sukru, 2018, Am J Disaster Med, V13, P253, DOI 10.5055/ajdm.2018.0305
   Shetty RM, 2018, COCHRANE DB SYST REV, V2
   Taccone FS, 2020, LANCET RESP MED, V8, P539, DOI 10.1016/S2213-2600(20)30172-7
   Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564
NR 44
TC 1
Z9 1
U1 0
U2 0
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY
SN 0375-9393
EI 1827-1596
J9 MINERVA ANESTESIOL
JI Minerva Anestesiol.
PD NOV
PY 2020
VL 86
IS 11
BP 1234
EP 1245
DI 10.23736/S0375-9393.20.14762-X
PG 12
WC Anesthesiology; Critical Care Medicine
SC Anesthesiology; General & Internal Medicine
GA OW8BV
UT WOS:000593105900015
PM 33228329
DA 2021-01-01
ER

PT J
AU Xi, CR
   Di Fazio, A
   Nadvi, NA
   Patel, K
   Xiang, MSW
   Zhang, HE
   Deshpande, C
   Low, JKK
   Wang, XNT
   Chen, YQ
   McMillan, CLD
   Isaacs, A
   Osborne, B
   de Ribeiro, AJV
   McCaughan, GW
   Mackay, JP
   Church, WB
   Gorrell, MD
AF Xi, Cecy R.
   Di Fazio, Arianna
   Nadvi, Naveed Ahmed
   Patel, Karishma
   Xiang, Michelle Sui Wen
   Zhang, Hui Emma
   Deshpande, Chandrika
   Low, Jason K. K.
   Wang, Xiaonan Trixie
   Chen, Yiqian
   McMillan, Christopher L. D.
   Isaacs, Ariel
   Osborne, Brenna
   de Ribeiro, Ana Julia Vieira
   McCaughan, Geoffrey W.
   Mackay, Joel P.
   Church, W. Bret
   Gorrell, Mark D.
TI A Novel Purification Procedure for Active Recombinant Human DPP4 and the
   Inability of DPP4 to Bind SARS-CoV-2
SO MOLECULES
LA English
DT Article
DE recombinant protein; protease; DPP4; Covid-19
ID DIPEPTIDYL PEPTIDASE-IV; ADENOSINE-DEAMINASE; MERS-COV;
   CRYSTAL-STRUCTURE; ENZYME-ACTIVITY; CORONAVIRUS; EXPRESSION; ACTIVATION;
   COMPLEX; PROTEIN
AB Proteases catalyse irreversible posttranslational modifications that often alter a biological function of the substrate. The protease dipeptidyl peptidase 4 (DPP4) is a pharmacological target in type 2 diabetes therapy primarily because it inactivates glucagon-like protein-1. DPP4 also has roles in steatosis, insulin resistance, cancers and inflammatory and fibrotic diseases. In addition, DPP4 binds to the spike protein of the MERS virus, causing it to be the human cell surface receptor for that virus. DPP4 has been identified as a potential binding target of SARS-CoV-2 spike protein, so this question requires experimental investigation. Understanding protein structure and function requires reliable protocols for production and purification. We developed such strategies for baculovirus generated soluble recombinant human DPP4 (residues 29-766) produced in insect cells. Purification used differential ammonium sulphate precipitation, hydrophobic interaction chromatography, dye affinity chromatography in series with immobilised metal affinity chromatography, and ion-exchange chromatography. The binding affinities of DPP4 to the SARS-CoV-2 full-length spike protein and its receptor-binding domain (RBD) were measured using surface plasmon resonance and ELISA. This optimised DPP4 purification procedure yielded 1 to 1.8 mg of pure fully active soluble DPP4 protein per litre of insect cell culture with specific activity >30 U/mg, indicative of high purity. No specific binding between DPP4 and CoV-2 spike protein was detected by surface plasmon resonance or ELISA. In summary, a procedure for high purity high yield soluble human DPP4 was achieved and used to show that, unlike MERS, SARS-CoV-2 does not bind human DPP4.
C1 [Xi, Cecy R.; Di Fazio, Arianna; Nadvi, Naveed Ahmed; Xiang, Michelle Sui Wen; Zhang, Hui Emma; Wang, Xiaonan Trixie; Chen, Yiqian; Osborne, Brenna; de Ribeiro, Ana Julia Vieira; McCaughan, Geoffrey W.; Gorrell, Mark D.] Univ Sydney, Fac Med & Hlth, Centenary Inst, Sydney, NSW 2006, Australia.
   [Nadvi, Naveed Ahmed] Univ Sydney, Res Portfolio Core Res Facil, Sydney, NSW 2006, Australia.
   [Patel, Karishma; Deshpande, Chandrika; Low, Jason K. K.] Univ Sydney, Fac Sci, Sch Life & Environm Sci, Sydney, NSW 2006, Australia.
   [Deshpande, Chandrika; Mackay, Joel P.] Univ Sydney, Core Res Facil, Sydney Analyt, Drug Discovery, Sydney, NSW 2006, Australia.
   [McMillan, Christopher L. D.; Isaacs, Ariel] Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld 4072, Australia.
   [McCaughan, Geoffrey W.] Royal Prince Alfred Hosp, AW Morrow GE & Liver Ctr, Camperdown, NSW 2050, Australia.
   [Church, W. Bret] Univ Sydney, Fac Med & Hlth, Sch Pharm, Sydney, NSW 2006, Australia.
RP Gorrell, MD (corresponding author), Univ Sydney, Fac Med & Hlth, Centenary Inst, Sydney, NSW 2006, Australia.
EM c.xi@centenary.org.au; arianna.difazio@path.ox.ac.uk;
   naveed.nadvi@sydney.edu.au; kpat7951@uni.sydney.edu.au;
   m.xiang@centenary.org.au; e.zhang@centenary.org.au;
   chandrika.deshpande@sydney.edu.au; jason.low@sydney.edu.au;
   twang@centenary.org.au; yiqian.chen@hudson.org.au;
   c.mcmillan1@uq.edu.au; ariel.isaacs@uq.net.au; brenna@sund.ku.dk;
   anajulia.vribeiro@gmail.com; g.mccaughan@centenary.org.au;
   joel.mackay@sydney.edu.au; bret.church@sydney.edu.au;
   m.gorrell@centenary.org.au
RI ; Church, William/H-6040-2013; Mackay, Joel/D-6834-2011
OI Zhang, Hui Emma/0000-0002-4699-4237; Low, Jason/0000-0003-0862-0012;
   Patel, Karishma/0000-0003-3034-3840; Church,
   William/0000-0002-8033-5518; McMillan, Christopher/0000-0002-5316-0986;
   Mackay, Joel/0000-0001-7508-8033; Deshpande,
   Chandrika/0000-0002-5557-519X; Gorrell, Mark/0000-0002-0528-2604
FU Australian National Health and Medical Research CouncilNational Health
   and Medical Research Council of Australia [1105238, 571408]; Rebecca L.
   Cooper Medical Research Foundation
FX This research was funded by project grant 1105238 to M.D.G. and G.W.M.
   and Program Grant 571408 to G.W.M. from the Australian National Health
   and Medical Research Council and grants to M.D.G. and W.B.C. from the
   Rebecca L. Cooper Medical Research Foundation.
CR Abbott C.A., 2020, CHEM-EUR J, V267, P6140, DOI [10.1046/j.1432-1327.2000.01617.x, DOI 10.1046/J.1432-1327.2000.01617.X]
   Abbott CA, 1999, EUR J BIOCHEM, V266, P798, DOI 10.1046/j.1432-1327.1999.00902.x
   Aertgeerts K, 2004, PROTEIN SCI, V13, P412, DOI 10.1110/ps.03460604
   Aertgeerts K, 2004, PROTEIN SCI, V13, P145, DOI 10.1110/ps.03352504
   Ajami K, 2003, BIOCHEMISTRY-US, V42, P694, DOI 10.1021/bi026846s
   Ajami K, 2008, FEBS LETT, V582, P819, DOI 10.1016/j.febslet.2008.02.005
   Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Bassendine MF, 2020, J DIABETES, V12, P649, DOI 10.1111/1753-0407.13052
   Bishnoi R, 2019, CANCER MED-US, V8, P3918, DOI 10.1002/cam4.2278
   Buckley SJ, 2004, INT J BIOCHEM CELL B, V36, P1281, DOI 10.1016/j.biocel.2003.02.001
   DADDONA PE, 1978, J BIOL CHEM, V253, P4617
   Deacon CF, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00080
   DEMEESTER I, 1994, EUR J IMMUNOL, V24, P566, DOI 10.1002/eji.1830240311
   DeMeester I, 1996, J IMMUNOL METHODS, V189, P99, DOI 10.1016/0022-1759(95)00239-1
   Dobers J, 2002, PROTEIN EXPRES PURIF, V25, P527, DOI 10.1016/S1046-5928(02)00043-8
   Du HZ, 2020, J CELL MOL MED, V24, P10274, DOI 10.1111/jcmm.15674
   Dunaevsky YE, 2020, BBA-GEN SUBJECTS, V1864, DOI 10.1016/j.bbagen.2020.129636
   Enz N, 2019, PHARMACOL THERAPEUT, V198, P135, DOI 10.1016/j.pharmthera.2019.02.015
   Frey G, 2010, NAT STRUCT MOL BIOL, V17, P1486, DOI 10.1038/nsmb.1950
   Ghorpade DS, 2018, NATURE, V555, P673, DOI 10.1038/nature26138
   Gorrell MD, 2005, CLIN SCI, V108, P277, DOI 10.1042/CS20040302
   Grehan K, 2015, METHODSX, V2, P379, DOI 10.1016/j.mex.2015.09.003
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jarvis DL, 2009, METHOD ENZYMOL, V463, P191, DOI 10.1016/S0076-6879(09)63014-7
   Keane FM, 2014, FEBS OPEN BIO, V4, P43, DOI 10.1016/j.fob.2013.12.001
   Kirby M, 2010, CLIN SCI, V118, P31, DOI 10.1042/CS20090047
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   LEATHERBARROW RJ, 1980, BIOCHEM J, V189, P27, DOI 10.1042/bj1890027
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Lu GW, 2013, NATURE, V500, P227, DOI 10.1038/nature12328
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mannix C., 2020, CELL ENG, DOI [10.1007/978-94-011-4315-8_3, DOI 10.1007/978-94-011-4315-8_3]
   MENTLEIN R, 1993, REGUL PEPTIDES, V49, P133, DOI 10.1016/0167-0115(93)90435-B
   Moffitt LR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218110
   Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865
   Osborne B, 2014, BBA-PROTEINS PROTEOM, V1844, P1248, DOI 10.1016/j.bbapap.2014.03.015
   Park J., 2008, OPEN ENZ INHIB J, V1, P52, DOI DOI 10.2174/1874940200801010052
   Rasmussen HB, 2003, NAT STRUCT BIOL, V10, P19, DOI 10.1038/nsb882
   Rosenstock J, 2019, JAMA-J AM MED ASSOC, V321, P69, DOI 10.1001/jama.2018.18269
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Sinnathurai P, 2018, INT J RHEUM DIS, V21, P1915, DOI 10.1111/1756-185X.13031
   Song WF, 2014, VIROLOGY, V471, P49, DOI 10.1016/j.virol.2014.10.006
   Stadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100
   Summers M.D., 1978, TEXAS AGR EXPT STATI
   TANAKA T, 1994, P NATL ACAD SCI USA, V91, P3082, DOI 10.1073/pnas.91.8.3082
   Teo ASM, 2006, BIOTECHNOL APPL BIOC, V45, P13, DOI 10.1042/BA20050239
   Thoma R, 2003, STRUCTURE, V11, P947, DOI 10.1016/S0969-2126(03)00160-6
   Vankadari N, 2020, EMERG MICROBES INFEC, V9, P601, DOI 10.1080/22221751.2020.1739565
   Varin EM, 2019, CELL METAB, V29, P320, DOI 10.1016/j.cmet.2018.10.001
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Wang NS, 2013, CELL RES, V23, P986, DOI 10.1038/cr.2013.92
   Wang XM, 2017, IMMUNOL CELL BIOL, V95, P443, DOI 10.1038/icb.2016.116
   Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983
   Weihofen WA, 2005, J BIOL CHEM, V280, P14911, DOI 10.1074/jbc.M413400200
   Weihofen WA, 2004, J BIOL CHEM, V279, P43330, DOI 10.1074/jbc.M405001200
   Ying TL, 2014, J VIROL, V88, P7796, DOI 10.1128/JVI.00912-14
   Yu DMT, 2011, SCAND J IMMUNOL, V73, P102, DOI 10.1111/j.1365-3083.2010.02488.x
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 59
TC 0
Z9 0
U1 3
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD NOV
PY 2020
VL 25
IS 22
AR 5392
DI 10.3390/molecules25225392
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA OZ4UQ
UT WOS:000594923400001
PM 33218025
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mullbacher, A
   Pardo, J
   Furuya, Y
AF Mullbacher, Arno
   Pardo, Julian
   Furuya, Yoichi
TI SARS-CoV-2 Vaccines: Inactivation by Gamma Irradiation for T and B Cell
   Immunity
SO PATHOGENS
LA English
DT Article
DE SARS-CoV-2; COVID-19; Gamma-ray irradiated vaccine
ID DNA VACCINE; VIRUS; SAFETY
AB Despite accumulating preclinical data demonstrating a crucial role of cytotoxic T cell immunity during viral infections, ongoing efforts on developing COVID-19 vaccines are mostly focused on antibodies. In this commentary article, we discuss potential benefits of cytotoxic T cells in providing long-term protection against COVID-19. Further, we propose that gamma-ray irradiation, which is a previously tested inactivation method, may be utilized to prepare an experimental COVID-19 vaccine that can provide balanced immunity involving both B and T cells.
C1 [Mullbacher, Arno] Australian Natl Univ, John Curtin Sch Med Res, Dept Immunol & Infect Dis, Canberra, ACT 0200, Australia.
   [Pardo, Julian] Univ Zaragoza, Aragon Hlth Res Inst IIS Aragon, Biomed Res Ctr Aragon, Immunotherapy Inflammat & Canc,ARAID, Zaragoza 50009, Spain.
   [Furuya, Yoichi] Albany Med Coll, Dept Immunol & Microbial Dis, Albany, NY 12208 USA.
RP Furuya, Y (corresponding author), Albany Med Coll, Dept Immunol & Microbial Dis, Albany, NY 12208 USA.
EM arno.mullbacher@anu.edu.au; pardojim@unizar.es; furuyay@amc.edu
FU American Heart Association Scientist Development GrantAmerican Heart
   Association [17SDG33630188]; NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA
   [1R56AI146434-01]; Health Institute Carlos III (Fondo-COVID19); Ministry
   of Science, Innovation, and Universities [SAF2017-83120-C2-1-R]; Aragon
   Government (Group) [B29_17R]
FX Y.F. is supported by American Heart Association Scientist Development
   Grant (17SDG33630188) and NIH (1R56AI146434-01). J.P. is supported by
   Health Institute Carlos III (Fondo-COVID19); Ministry of Science,
   Innovation, and Universities (SAF2017-83120-C2-1-R); and by Aragon
   Government (Group B29_17R).
CR Alsharifi M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005336
   Aquino-Jarquin G, 2019, NANOMED-NANOTECHNOL, V18, P428, DOI 10.1016/j.nano.2019.03.006
   BACHMANN MF, 1993, J VIROL, V67, P3917, DOI 10.1128/JVI.67.7.3917-3922.1993
   BLANDEN RV, 1974, TRANSPLANT REV, V19, P56
   BRACIALE TJ, 1978, J EXP MED, V147, P1236, DOI 10.1084/jem.147.4.1236
   Cao WCC, 2007, NEW ENGL J MED, V357, P1162, DOI 10.1056/NEJMc070348
   Deng W, 2020, SCIENCE, V369, P818, DOI 10.1126/science.abc5343
   EDRIDGE A, 2020, NAT MED 0914, DOI DOI 10.1101/2020.05.11.20086439
   Furuya Y, 2012, IMMUNOL CELL BIOL, V90, P571, DOI 10.1038/icb.2011.70
   Furuya Y, 2010, J GEN VIROL, V91, P1450, DOI 10.1099/vir.0.018168-0
   Furuya Y, 2010, J VIROL, V84, P4212, DOI 10.1128/JVI.02508-09
   Gorse GJ, 2020, J MED VIROL, V92, P512, DOI 10.1002/jmv.25715
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   He RY, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104361
   Kiyuka PK, 2018, J INFECT DIS, V217, P1728, DOI 10.1093/infdis/jiy098
   Le Bert N, 2020, NATURE, DOI 10.1038/s41586-020-2550-z
   Le TP, 2000, VACCINE, V18, P1893, DOI 10.1016/S0264-410X(99)00407-7
   Liu W, 2006, J INFECT DIS, V193, P792, DOI 10.1086/500469
   Liu ZM, 2020, J INFECTION, V81, P331, DOI 10.1016/j.jinf.2020.03.054
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Lowy RJ, 2001, ANTIVIR RES, V52, P261, DOI 10.1016/S0166-3542(01)00169-3
   MacGregor RR, 1998, J INFECT DIS, V178, P92, DOI 10.1086/515613
   MULLBACHER A, 1994, J EXP MED, V179, P317, DOI 10.1084/jem.179.1.317
   MULLBACHER A, 1988, IMMUNOL CELL BIOL, V66, P153, DOI 10.1038/icb.1988.19
   MULLBACHER A, 1986, J GEN VIROL, V67, P295, DOI 10.1099/0022-1317-67-2-295
   MULLBACHER A, 1979, SCAND J IMMUNOL, V10, P291, DOI 10.1111/j.1365-3083.1979.tb01353.x
   Tacket CO, 1999, VACCINE, V17, P2826, DOI 10.1016/S0264-410X(99)00094-8
   Tillett Richard L, 2021, Lancet Infect Dis, V21, P52, DOI 10.1016/S1473-3099(20)30764-7
   World Health Organization, 2020, DRAFT LANDSC COVID 1
NR 29
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-0817
J9 PATHOGENS
JI Pathogens
PD NOV
PY 2020
VL 9
IS 11
AR 928
DI 10.3390/pathogens9110928
PG 5
WC Microbiology
SC Microbiology
GA OY7GO
UT WOS:000594411900001
PM 33182546
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Shao, D
   Lee, IJ
AF Shao, Dan
   Lee, I-Jui
TI Acceptance and Influencing Factors of Social Virtual Reality in the
   Urban Elderly
SO SUSTAINABILITY
LA English
DT Article
DE social VR; healthy aging; urban elderly; UTAUT model
ID OLDER-ADULTS; PERCEIVED USEFULNESS; USER ACCEPTANCE; LONELINESS;
   TECHNOLOGY; HEALTH; NETWORK; DEPRESSION; ADOPTION; PEOPLE
AB In the stage of aging society and population aging, the social needs of the elderly are widely discussed by researchers. Especially driven by the demand of tele-medical treatment and tele-rehabilitation therapy, it is vital for the elderly to integrate into virtual communities by combining social virtual reality (VR) with different medical services and entertainment needs. In addition, affected by the COVID-19 epidemic, it is more difficult for people to have face-to-face contacts. With more remote consultation, entertainment and virtual social connectivity, the application of social VR is more urgent and valuable. However, there is little discussion on the acceptability and influencing factors of social VR among the elderly at present. Therefore, in order to get further data, we used (1) early stage semi-structured interviews and then (2) Unified Theory of Acceptance and Use of Technology (UTAUT) questionnaires for investigation. One hundred fourteen elderly people aged 60-89 living in the metropolitan area of Taipei were taken as the subjects. To help them understand the situation and state of using social VR, these elderly people were asked to use a head-mounted display (HMD) to experience social VR games. The preliminary results showed that the elderly had obvious preference for entertainment (32.4%) and medical treatment (31.3%). The interview showed that this was related to the physiological condition or medical needs of the age range. In order to further understand how social VR would affect the social life of the elderly, we proposed the further demand structure of UTAUT Model based on the interview of both experts and the elderly. The model structures include (1) Performance Expectancy, (2) Perceived Enjoyment, (3) Social Influence, (4) User Attitude, (5) Behavioral Intention, and so on. These structures were applied to conduct interviews and questionnaires to find out the influence extent and relevance of the elderly on different structural needs, and suggestions were given accordingly. The results of the above interviews showed that (1) the elderly thought that the functions of entertaining and interacting of social VR could increase their social opportunities, and also meet medical needs (teleconference, cognitive decline, etc.), (2) the closeness of social relations (between family members, friends, doctors, and places), and also affect the relevance of Perceived Enjoyment (beta = 0.77, p = 0.000 < 0.05). The results of these phenomena and interviews showed the interplay between the demand structures and their special relevance. They also indicated that as to social VR technologies, various demands and functional issues of the elderly need to be considered, and these demands would appear in the subtle usage, and different social VR interfaces and functions would emerge based on their special living ways and physical and psychological demands.
C1 [Shao, Dan] Natl Taipei Univ Technol, Coll Design, Doctoral Program Design, Taipei 10608, Taiwan.
   [Shao, Dan] Fujian Agr & Forestry Univ, Dept Literature & Art, Jinshan Coll, Fuzhou 350002, Peoples R China.
   [Lee, I-Jui] Natl Taipei Univ Technol, Dept Ind Design, Taipei 10608, Taiwan.
RP Shao, D (corresponding author), Natl Taipei Univ Technol, Coll Design, Doctoral Program Design, Taipei 10608, Taiwan.; Shao, D (corresponding author), Fujian Agr & Forestry Univ, Dept Literature & Art, Jinshan Coll, Fuzhou 350002, Peoples R China.; Lee, IJ (corresponding author), Natl Taipei Univ Technol, Dept Ind Design, Taipei 10608, Taiwan.
EM shaoyaodanqing@gmail.com; ericlee@ntut.edu.tw
FU Fujian Social Science Planning Project [FJ2018C083]
FX This research was funded by Fujian Social Science Planning Project,
   grant number FJ2018C083.
CR Alawadhi S., 2008, P 41 HAW INT C SYST, P219, DOI DOI 10.1109/HICSS.2008.452
   Ali T, 2018, J EPIDEMIOL COMMUN H, V72, P990, DOI 10.1136/jech-2017-210236
   Baecker Ronald M., 2012, Interactions, V19, P32, DOI 10.1145/2168931.2168940
   Bahramnezhad Fatemeh, 2017, Electron Physician, V9, P4306, DOI 10.19082/4306
   Baker Steven, 2019, Proceedings of the ACM on Human-Computer Interaction, V3, DOI 10.1145/3359251
   Baker S., 2019, P 2019 DES INT SYST, P303, DOI [10.1145/3322276.3322361, DOI 10.1145/3322276.3322361]
   Bekhet AK, 2012, ARCH PSYCHIAT NURS, V26, P214, DOI 10.1016/j.apnu.2011.09.007
   Bianchetti L, 2017, AGING CLIN EXP RES, V29, P1173, DOI 10.1007/s40520-017-0726-7
   Briz-Ponce L, 2017, COMPUT HUM BEHAV, V72, P612, DOI 10.1016/j.chb.2016.05.027
   Carver LF, 2018, GERIATRICS-BASEL, V3, DOI 10.3390/geriatrics3040075
   Courtin E, 2017, HEALTH SOC CARE COMM, V25, P799, DOI 10.1111/hsc.12311
   DAVIS FD, 1989, MIS QUART, V13, P319, DOI 10.2307/249008
   Dogruel L, 2015, BEHAV INFORM TECHNOL, V34, P1052, DOI 10.1080/0144929X.2015.1077890
   Domenech-Abella J, 2019, J AFFECT DISORDERS, V246, P82, DOI 10.1016/j.jad.2018.12.043
   Domenech-Abella J, 2017, SOC PSYCH PSYCH EPID, V52, P381, DOI 10.1007/s00127-017-1339-3
   El Shamy N., 2017, P 50 INT C SYST SCI, DOI [10.24251/HICSS.2017.501, DOI 10.24251/HICSS.2017.501]
   Gray A, 2018, AGEING SOC, V38, P615, DOI 10.1017/S0144686X16001239
   Guner H, 2020, UNIVERSAL ACCESS INF, V19, P311, DOI 10.1007/s10209-018-0642-4
   Gunkel S.N.B., 2017, ADJ PUBL 2017 ACM IN, P83, DOI [10.1145/3084289.3089914, DOI 10.1145/3084289.3089914]
   Gunkel S, 2018, TVX 2018: PROCEEDINGS OF THE 2018 ACM INTERNATIONAL CONFERENCE ON INTERACTIVE EXPERIENCES FOR TV AND ONLINE VIDEO, P233, DOI 10.1145/3210825.3213566
   Ha T.V., 2017, P 2017 23 AS PAC C C, P1, DOI [10.23919/APCC.2017.8304017, DOI 10.23919/APCC.2017.8304017]
   Hagan R, 2014, AGING MENT HEALTH, V18, P683, DOI 10.1080/13607863.2013.875122
   Heidicker P, 2017, IEEE SYMP 3D USER, P233, DOI 10.1109/3DUI.2017.7893357
   Herzog AR, 2002, CLIN GERIATR MED, V18, P593, DOI 10.1016/S0749-0690(02)00025-3
   Holmen K, 2002, ARCH GERONTOL GERIAT, V35, P261, DOI 10.1016/S0167-4943(02)00049-3
   Hoque R, 2017, INT J MED INFORM, V101, P75, DOI 10.1016/j.ijmedinf.2017.02.002
   Huang TY, 2020, UNIVERSAL ACCESS INF, V19, P935, DOI 10.1007/s10209-019-00692-9
   Hudson Janella, 2020, J Gerontol B Psychol Sci Soc Sci, V75, P2018, DOI 10.1093/geronb/gbaa119
   Im I, 2011, INFORM MANAGE-AMSTER, V48, P1, DOI 10.1016/j.im.2010.09.001
   Jeng MY, 2017, APPL RES QUAL LIFE, V12, P49, DOI 10.1007/s11482-016-9452-0
   Johnson CS, 2017, J FRALITY AGING, V6, P33, DOI 10.14283/jfa.2016.115
   Khosravi P, 2016, COMPUT HUM BEHAV, V63, P594, DOI 10.1016/j.chb.2016.05.092
   King WR, 2006, INFORM MANAGE-AMSTER, V43, P740, DOI 10.1016/j.im.2006.05.003
   Klimova Blanka, 2019, Applied Physics, System Science and Computers III. 3rd International Conference on Applied Physics, System Science and Computers (APSAC2018). Proceedings: Lecture Notes in Electrical Engineering (LNEE 574), P99, DOI 10.1007/978-3-030-21507-1_15
   Korsgaard D, 2019, PROCEEDINGS OF THE 31ST EUROPEAN CONFERENCE ON COGNITIVE ERGONOMICS: DESIGN FOR COGNITION (ECCE 2019), P168, DOI 10.1145/3335082.3335093
   Lee C, 2015, J PROD INNOVAT MANAG, V32, P747, DOI 10.1111/jpim.12176
   Li J, 2019, CHI 2019: PROCEEDINGS OF THE 2019 CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS, DOI 10.1145/3290605.3300897
   Li R, 2017, J RETAIL CONSUM SERV, V34, P19, DOI 10.1016/j.jretconser.2016.09.003
   Lin CX, 2018, LECT NOTES COMPUT SC, V10927, P89, DOI 10.1007/978-3-319-92037-5_8
   Lin CS, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15040663
   Miori V, 2017, 2017 GLOBAL INTERNET OF THINGS SUMMIT (GIOTS 2017), P31
   Pal D, 2018, IEEE ACCESS, V6, P10483, DOI 10.1109/ACCESS.2018.2808472
   Pedro A, 2016, J PROF ISS ENG ED PR, V142, DOI 10.1061/(ASCE)EI.1943-5541.0000261
   Petersen Fazlyn, 2020, Responsible Design, Implementation and Use of Information and Communication Technology. 19th IFIP WG 6.11 Conference on e-Business, e-Services, and e-Society, I3E 2020. Proceedings. Lecture Notes in Computer Science (LNCS 12067), P61, DOI 10.1007/978-3-030-45002-1_6
   Quinn D, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.5377
   Reed DJ, 2008, LECT NOTES COMPUT SC, V5294, P158, DOI 10.1007/978-3-540-88322-7_16
   Roberts AR, 2019, CLIN GERONTOLOGIST, V42, P27, DOI 10.1080/07317115.2018.1442380
   Ruangkana V., 2019, P 2019 INT C ENG SCI, P1, DOI [10.1109/ICESI.2019.8862993, DOI 10.1109/ICESI.2019.8862993]
   Segel-Karpas D, 2018, AGING MENT HEALTH, V22, P135, DOI 10.1080/13607863.2016.1226770
   Sijia Li, 2020, Journal of Physics: Conference Series, V1631, DOI 10.1088/1742-6596/1631/1/012024
   Syed-Abdul S, 2019, BMC GERIATR, V19, DOI 10.1186/s12877-019-1218-8
   tom Dieck M.C., 2019, AUGMENTED REALITY VI, P89, DOI [10.1007/978-3-030-06246-0_7, DOI 10.1007/978-3-030-06246-0_7]
   van Ingen E, 2017, COMPUT HUM BEHAV, V70, P168, DOI 10.1016/j.chb.2016.12.058
   Venkatesh V, 2003, MIS QUART, V27, P425
   White J, 2000, EDUC GERONTOL, V26, P371, DOI 10.1080/036012700407857
   Yang KM, 2011, AGEING SOC, V31, P1368, DOI 10.1017/S0144686X1000139X
   Yu R, 2015, JMIR RES PROTOC, V4, DOI 10.2196/resprot.4189
   Zamanifard S, 2019, CONFERENCE COMPANION PUBLICATION OF THE 2019 COMPUTER SUPPORTED COOPERATIVE WORK AND SOCIAL COMPUTING (CSCW'19 COMPANION), P438, DOI 10.1145/3311957.3359453
   Zhang LS, 2018, IEEE NETWORK, V32, P160, DOI 10.1109/MNET.2017.1700014
   Zhou GY, 2018, CURR PSYCHOL, V37, P295, DOI 10.1007/s12144-016-9512-5
NR 60
TC 0
Z9 0
U1 4
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2071-1050
J9 SUSTAINABILITY-BASEL
JI Sustainability
PD NOV
PY 2020
VL 12
IS 22
AR 9345
DI 10.3390/su12229345
PG 19
WC Green & Sustainable Science & Technology; Environmental Sciences;
   Environmental Studies
SC Science & Technology - Other Topics; Environmental Sciences & Ecology
GA OZ6TD
UT WOS:000595055100001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Alves, M
   Froes, F
   Caldeira, D
AF Alves, Mariana
   Froes, Filipe
   Caldeira, Daniel
TI Reminder: Cardiovascular Patients Also Benefit from Influenza Vaccine
SO ACTA MEDICA PORTUGUESA
LA English
DT Letter
DE Cardiovascular Diseases; Common Cold; COVID-19; Influenza Vaccines;
   Influenza, Human
C1 [Alves, Mariana] Ctr Hosp Univ Lisboa Norte, Hosp Pulido Valente, Serv Med 3, Lisbon, Portugal.
   [Alves, Mariana; Caldeira, Daniel] Univ Lisbon, Fac Med, Lab Clin Pharmacol & Therapeut, Lisbon, Portugal.
   [Alves, Mariana; Caldeira, Daniel] Univ Lisbon, Fac Med, Inst Med Mol, Lisbon, Portugal.
   [Froes, Filipe] Ctr Hosp Univ Lisboa Norte, Hosp Pulido Valente, Chest Dept, Intens Care Unit, Lisbon, Portugal.
   [Caldeira, Daniel] Ctr Hosp Univ Lisboa Norte, Hosp Univ Santa Maria, Serv Cardiol, Lisbon, Portugal.
   [Caldeira, Daniel] Univ Lisboa Lisboa, Fac Med, CCUL, Lisbon, Portugal.
RP Caldeira, D (corresponding author), Univ Lisbon, Fac Med, Lab Clin Pharmacol & Therapeut, Lisbon, Portugal.; Caldeira, D (corresponding author), Univ Lisbon, Fac Med, Inst Med Mol, Lisbon, Portugal.; Caldeira, D (corresponding author), Ctr Hosp Univ Lisboa Norte, Hosp Univ Santa Maria, Serv Cardiol, Lisbon, Portugal.; Caldeira, D (corresponding author), Univ Lisboa Lisboa, Fac Med, CCUL, Lisbon, Portugal.
EM dgcaldeira@hotmail.com
RI Alves, Mariana/O-3034-2016
OI Alves, Mariana/0000-0002-1369-8423; Caldeira, Daniel/0000-0002-2520-5673
CR Bekkat-Berkani R, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-017-0420-8
   Caldeira D, 2019, EXPERT REV VACCINES, DOI 10.1080/14760584.2019.1690459
   Instituto Nacional de Saude Dr. Ricardo Jorge Observatorio Nacional de Saude (ONSA), 2012, VAC ANT POP PORT 201
   Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483
   Organisation for Economic Co-operation and Development, INFL VACC RAT IND
   Rodrigues BS, 2020, HEART, V106, P350, DOI 10.1136/heartjnl-2019-315193
   Rodrigues BS, TRENDS CARDIOVASC ME
   Soo RJ, 2020, EMERG INFECT DIS J, V26
   Warren-Gash C, 2012, J INFECT DIS, V206, P1652, DOI 10.1093/infdis/jis597
NR 9
TC 0
Z9 0
U1 0
U2 0
PU ORDEM MEDICOS
PI LISBON
PA AV ALMIRANTE GAGO COUTINHO, 151, LISBON, 1749-084, PORTUGAL
SN 1646-0758
J9 ACTA MEDICA PORT
JI Acta Medica Port.
PD NOV
PY 2020
VL 33
IS 11
BP 782
EP 782
DI 10.20344/amp.14606
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA ON2UB
UT WOS:000586561600016
PM 33160429
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Akhand, MRN
   Azim, KF
   Hoque, SF
   Moli, MA
   Joy, BD
   Akter, H
   Afif, IK
   Ahmed, N
   Hasan, M
AF Akhand, Mst Rubaiat Nazneen
   Azim, Kazi Faizul
   Hoque, Syeda Farjana
   Moli, Mahmuda Akther
   Joy, Bijit Das
   Akter, Hafsa
   Afif, Ibrahim Khalil
   Ahmed, Nadim
   Hasan, Mahmudul
TI Genome based evolutionary lineage of SARS-CoV-2 towards the development
   of novel chimeric vaccine
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE SARS-CoV-2; COVID-19; Chimeric vaccine; Evolutionary relationship;
   Normal mode analysis; Molecular docking; Restriction cloning
ID HUMAN CORONAVIRUS; PEPTIDE VACCINE; FUNCTIONAL RECEPTOR; GLOBAL HEALTH;
   SPIKE PROTEIN; ALIGNMENT; DESIGN; PREDICTION; OUTBREAK; TARGET
AB The present study aimed to predict a novel chimeric vaccine by simultaneously targeting four major structural proteins via the establishment of ancestral relationship among different strains of coronaviruses. Conserved regions from the homologous protein sets of spike glycoprotein, membrane protein, envelope protein and nucleocapsid protein were identified through multiple sequence alignment. The phylogeny analyses of whole genome stated that four proteins reflected the close ancestral relation of SARS-CoV-2 to SARS-COV-1 and bat coronavirus. Numerous immunogenic epitopes (both T cell and B cell) were generated from the common fragments which were further ranked on the basis of antigenicity, transmembrane topology, conservancy level, toxicity and allergenicity pattern and population coverage analysis. Top putative epitopes were combined with appropriate adjuvants and linkers to construct a novel multiepitope subunit vaccine against COVID-19. The designed constructs were characterized based on physicochemical properties, allergenicity, antigenicity and solubility which revealed the superiority of construct V3 in terms safety and efficacy. Essential molecular dynamics and normal mode analysis confirmed minimal deformability of the refined model at molecular level. In addition, disulfide engineering was investigated to accelerate the stability of the protein. Molecular docking study ensured high binding affinity between construct V3 and HLA cells, as well as with different host receptors. Microbial expression and translational efficacy of the constructs were checked using pET28a (+) vector of E. coli strain K12. However, the in vivo and in vitro validation of suggested vaccine molecule might be ensured with wet lab trials using model animals for the implementation of the presented data.
C1 [Akhand, Mst Rubaiat Nazneen; Azim, Kazi Faizul; Hoque, Syeda Farjana; Moli, Mahmuda Akther; Joy, Bijit Das; Akter, Hafsa; Ahmed, Nadim; Hasan, Mahmudul] Sylhet Agr Univ, Fac Biotechnol & Genet Engn, Sylhet 3100, Bangladesh.
   [Akhand, Mst Rubaiat Nazneen; Joy, Bijit Das] Sylhet Agr Univ, Dept Biochem & Chem, Sylhet 3100, Bangladesh.
   [Azim, Kazi Faizul] Sylhet Agr Univ, Dept Microbial Biotechnol, Sylhet 3100, Bangladesh.
   [Hoque, Syeda Farjana; Moli, Mahmuda Akther; Hasan, Mahmudul] Sylhet Agr Univ, Dept Pharmaceut & Ind Biotechnol, Sylhet 3100, Bangladesh.
   [Afif, Ibrahim Khalil] Noakhali Sci & Technol Univ, Dept Biotechnol & Genet Engn, Noakhali, Bangladesh.
RP Hasan, M (corresponding author), Sylhet Agr Univ, Fac Biotechnol & Genet Engn, Dept Pharmaceut & Ind Biotechnol, Sylhet 3100, Bangladesh.
EM mhasan.pib@sau.ac.bd
OI Afif, Ibrahim Khalil/0000-0002-7111-6313
CR Abdelmageed MI, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2683286
   [Anonymous], 2020, NIH CLIN TRIAL INV V, P2020
   Awan FM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010139
   Azim K.F., 2019, BIORXIV, DOI [10.1101/2019.12.29.885731, DOI 10.1101/2019.12.29.885731]
   Azim Kazi Faizul, 2020, Inform Med Unlocked, V20, P100367, DOI 10.1016/j.imu.2020.100367
   Azim KF, 2019, INFECT GENET EVOL, V74, DOI 10.1016/j.meegid.2019.103936
   Behbahani M., 2020, BIORXIV, DOI [10.1101/2020.03.10. 985499., DOI 10.1101/2020.03.10.985499]
   Ceraolo C, 2020, J MED VIROL, V92, P522, DOI 10.1002/jmv.25700
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   COOPER NR, 1984, J INVEST DERMATOL, V83, pS121, DOI 10.1111/1523-1747.ep12281847
   Craig DB, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-346
   Cui Q., 2007, BRIEF BIOINFORM, V8, P378, DOI DOI 10.1093/BIB/BBM010
   Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5
   Dimitrov I, 2014, BIOINFORMATICS, V30, P846, DOI 10.1093/bioinformatics/btt619
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Doytchinova IA, 2007, VACCINE, V25, P856, DOI 10.1016/j.vaccine.2006.09.032
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Dudek NL, 2010, CURR PHARM DESIGN, V16, P3149
   EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985
   Fernando A., 2013, MBIO, V4
   Forni D, 2017, TRENDS MICROBIOL, V25, P35, DOI 10.1016/j.tim.2016.09.001
   Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369
   Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI DOI 10.1385/1-59259-890-0:571
   Ghaffari-Nazari H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142563
   Glansbeek HL, 2002, J GEN VIROL, V83, P1, DOI 10.1099/0022-1317-83-1-1
   Gorbalenya A.E., 2017, REFERENCE MODULE BIO
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gupta S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073957
   Hai P, 2004, J GEN VIROL, V85, P3109, DOI 10.1099/vir.0.80111-0
   Hasan M, 2020, J BIOMOL STRUCT DYN, V38, P2898, DOI 10.1080/07391102.2019.1647286
   Hasan M, 2019, INFECT GENET EVOL, V70, P140, DOI 10.1016/j.meegid.2019.03.003
   Hasan M, 2019, MICROB PATHOGENESIS, V130, P19, DOI 10.1016/j.micpath.2019.02.023
   Hu D, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0155-5
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Jaimes Javier A, 2020, bioRxiv, DOI 10.1101/2020.02.10.942185
   Jeong-ho Lee, 2020, CHINESE SCI RACE DEV
   Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346
   Jia W, 1997, GENE, V189, P189, DOI 10.1016/S0378-1119(96)00847-5
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Khan MA, 2015, SCAND J IMMUNOL, V82, P25, DOI 10.1111/sji.12302
   KOLASKAR AS, 1990, FEBS LETT, V276, P172, DOI 10.1016/0014-5793(90)80535-Q
   Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315
   Lanfear R, 2017, MOL BIOL EVOL, V34, P772, DOI 10.1093/molbev/msw260
   Li F, 2015, J VIROL, V89, P1954, DOI 10.1128/JVI.02615-14
   Li WD, 2014, VACCINES-BASEL, V2, P515, DOI 10.3390/vaccines2030515
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu J, 2010, J INFECT DIS, V202, P1171, DOI 10.1086/656315
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Moxon R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02776
   Neuman BW, 2011, J STRUCT BIOL, V174, P11, DOI 10.1016/j.jsb.2010.11.021
   Nieto-Torres JL, 2011, VIROLOGY, V415, P69, DOI 10.1016/j.virol.2011.03.029
   Oany AR, 2014, DRUG DES DEV THER, V8, P1139, DOI [10.2147/DDDT.567861, 10.2147/DDDT.S67861]
   Pandey RK, 2018, VACCINE, V36, P2262, DOI 10.1016/j.vaccine.2018.03.042
   Pang JX, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030623
   Peng J, 2011, PROTEINS, V79, P161, DOI 10.1002/prot.23175
   Petrovsky N, 2004, IMMUNOL CELL BIOL, V82, P488, DOI 10.1111/j.0818-9641.2004.01272.x
   Prabhakar PK, 2016, J BIOMOL STRUCT DYN, V34, P778, DOI 10.1080/07391102.2015.1054430
   Purcell AW, 2007, NAT REV DRUG DISCOV, V6, P404, DOI 10.1038/nrd2224
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Lopez-Blanco JR, 2014, NUCLEIC ACIDS RES, V42, pW271, DOI 10.1093/nar/gku339
   Rappuoli R, 2000, CURR OPIN MICROBIOL, V3, P445, DOI 10.1016/S1369-5274(00)00119-3
   Rasheed M.A., 2020, SILICO IDENTIFICATIO, DOI DOI 10.20944/PREPRINTS202002.0359.V1
   Robert X, 2014, NUCLEIC ACIDS RES, V42, pW320, DOI 10.1093/nar/gku316
   Roland K, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20235
   Ronquist F, 2012, SYST BIOL, V61, P539, DOI 10.1093/sysbio/sys029
   Saha CK, 2017, ASIAN PAC J TROP MED, V10, P601, DOI 10.1016/j.apjtm.2017.06.016
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Sharmin R, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-161
   Shrestha B, 2004, J VIROL, V78, P8312, DOI [10.1128/JVI.78.15.8312-8321.2004, 10.1128/jvi.78.15.8312-8321.2004]
   Sievers F, 2014, METHODS MOL BIOL, V1079, P105, DOI 10.1007/978-1-62703-646-7_6
   Smialowski P, 2007, BIOINFORMATICS, V23, P2536, DOI 10.1093/bioinformatics/btl623
   Smith SA, 2008, BIOINFORMATICS, V24, P715, DOI 10.1093/bioinformatics/btm619
   Solanki V, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26689-7
   Spinney L., 2020, GUARDIAN
   Stamatakis A, 2014, BIOINFORMATICS, V30, P1312, DOI 10.1093/bioinformatics/btu033
   Stratton K., 2003, IMMUNIZATION SAFETY
   Sudhakar A., 2013, J INFECT DIS, V209, P995, DOI DOI 10.1093/INFDIS/JIT609
   Sun JM, 2020, TRENDS MOL MED, V26, P483, DOI 10.1016/j.molmed.2020.02.008
   Sun Z, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051633
   Surya W, 2015, VIRUS RES, V201, P61, DOI 10.1016/j.virusres.2015.02.023
   Tama F, 2006, ANNU REV BIOPH BIOM, V35, P115, DOI 10.1146/annurev.biophys.35.040405.102010
   Tesh RB, 2002, EMERG INFECT DIS, V8, P1392, DOI 10.3201/eid0812.020229
   Thompson AL, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/289597
   VanAalten DMF, 1997, J COMPUT CHEM, V18, P169
   Vita R, 2015, NUCLEIC ACIDS RES, V43, pD405, DOI 10.1093/nar/gku938
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wasmoen T L, 1995, Adv Exp Med Biol, V380, P221
   Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033
   WESSELING JG, 1993, J GEN VIROL, V74, P2061, DOI 10.1099/0022-1317-74-10-2061
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
   World Health Organization (WHO), 2020, INF PREV CONTR HLTH, P2020
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu Y., 2020, BIORXIV, DOI [10.1101/2020.03.04.975995, DOI 10.1101/2020.03.04.975995]
   WUTHRICH K, 1980, BIOPHYS J, V32, P549
   Yang Y, 2015, HUM VACC IMMUNOTHER, V11, P795, DOI 10.1080/21645515.2015.1012017
   Yin C., 2020, 200310965 ARXIV
   Zhao P, 2005, VIROLOGY, V331, P128, DOI 10.1016/j.virol.2004.10.016
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhou YS, 2018, EXPERT REV VACCINES, V17, P677, DOI 10.1080/14760584.2018.1506702
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Ziady Hanna, 2020, BIOT CO MOD SAYS ITS
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 107
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD NOV
PY 2020
VL 85
AR 104517
DI 10.1016/j.meegid.2020.104517
PG 19
WC Infectious Diseases
SC Infectious Diseases
GA OY0AK
UT WOS:000593916700002
PM 32882432
OA Green Published
DA 2021-01-01
ER

PT J
AU Bhattacharya, M
   Sharma, AR
   Mallick, B
   Sharma, G
   Lee, SS
   Chakraborty, C
AF Bhattacharya, Manojit
   Sharma, Ashish Ranjan
   Mallick, Bidyut
   Sharma, Garima
   Lee, Sang-Soo
   Chakraborty, Chiranjib
TI Immunoinformatics approach to understand molecular interaction between
   multi-epitopic regions of SARS-CoV-2 spike-protein with TLR4/MD-2
   complex
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Spike protein; SARS-CoV-2; Antigenicity; Epitopes; TLR4; MD-2 complex
ID PREDICTION; RECOGNITION; RECEPTORS; ADJUVANTS; VACCINES; TLR4
AB Background: The coronavirus (CoV) spike (S) protein is critical for receptor binding, membrane fusion and in-ternalization of the virus into the human cells. We have tried to search the epitopic component of the S-protein that might be served as crucial targets for the vaccine development and also tried to understand the molecular mechanism of epitopes and TLR4/MD-2 complex for adaptive immunity.
   Material and methods: Here we identified the antigenicity and the epitopic divergence of S-protein via immunoinformatics approach. The study was performed to identify the epitopes, composition of amino acids and its distribution in epitopic regions, composition of amino acid between the identified epitopes, secondary structure architecture of epitopes, physicochemical and biochemical parameters and molecular interaction between the identified epitope and TLR4/MD-2 complex. The SARS-CoV-2 can be possibly recognised by TLR4 of host immune cells that are responsible for the adaptive immune response.
   Results: We identified four SARS-CoV-2 S-protein 9mer antigenic epitopes and observed that they bind with the TLR4/MD-2 complex by varied stable molecular bonding interactions. Molecular interaction between these characterized epitopes with TLR4/MD-2 complex might be indicated the binding affinity and downstream signalling of adaptive immune response. Different physicochemical and biochemical parameters such as O-glycosylation and N-glycosylation, Hydrophobicity, GRAVY were identified within epitopic regions of S-protein. These parameters help to understand the protein-protein interaction between epitopes and TLR4/MD-2 complex. The study also revealed different epitopic binding pockets of TLR4/MD-2 complex.
   Conclusions: The identified epitopes impart suitable prospects for the development of novel peptide-based epitopic vaccine for the control of COVID-19 infection.
C1 [Bhattacharya, Manojit; Sharma, Ashish Ranjan; Lee, Sang-Soo; Chakraborty, Chiranjib] Hallym Univ, Chuncheon Sacred Heart Hosp, Inst Skeletal Aging & Orthoped Surg, Chuncheon Si 24252, Gangwon Do, South Korea.
   [Mallick, Bidyut] Galgotias Coll Engn & Technol I, Dept Appl Sci, Knowledge Pk 2, Greater Noida 201306, Uttar Pradesh, India.
   [Sharma, Garima] Kangwon Natl Univ, Coll Pharm, Neuropsychopharmacol & Toxicol Program, Chunchon, South Korea.
   [Chakraborty, Chiranjib] Adamas Univ, Sch Life Sci & Biotechnol, Dept Biotechnol, Barasat Barrackpore Rd, Kolkata 700126, W Bengal, India.
RP Lee, SS (corresponding author), Hallym Univ, Chuncheon Sacred Heart Hosp, Inst Skeletal Aging & Orthoped Surg, Chuncheon Si 24252, Gangwon Do, South Korea.; Chakraborty, C (corresponding author), Adamas Univ, Sch Life Sci & Biotechnol, Dept Biotechnol, Barasat Barrackpore Rd, Kolkata 700126, W Bengal, India.
EM totalhip@hallym.ac.kr; drchiranjib@yahoo.com
OI Bhattacharya, Manojit/0000-0001-9669-1835
FU Hallym University Research Fund; Basic Science Research Program through
   the National Research Foundation of Korea (NRF) - Ministry of Education
   [NRF-2017R1A2B4012944, NRF-2020R1C1C1008694]
FX This research was supported by Hallym University Research Fund and by
   Basic Science Research Program through the National Research Foundation
   of Korea (NRF) funded by the Ministry of Education (NRF-2017R1A2B4012944
   & NRF-2020R1C1C1008694).
CR Agarwala R, 2016, NUCLEIC ACIDS RES, V44, pD7, DOI [10.1093/nar/gkv1290, 10.1093/nar/gkx1095, 10.1093/nar/gks1189]
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Bau D, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-402
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Berry J.D., 2010, NEUTRALIZING EPITOPE, P53
   Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736
   Burzyn D, 2004, J VIROL, V78, P576, DOI 10.1128/JVI.78.2.576-584.2004
   Chakraborty C, 2020, EUR REV MED PHARMACO, V24, P4016, DOI 10.26355/eurrev_202004_20871
   Chakraborty C, 2020, ASIAN PAC J TROP MED, V13, P242, DOI 10.4103/1995-7645.281613
   Chakraborty C, 2020, J MED VIROL, V92, P2314, DOI 10.1002/jmv.25997
   Choudhury A, 2020, J MED VIROL, V92, P2105, DOI 10.1002/jmv.25987
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Duthie MS, 2011, IMMUNOL REV, V239, P178, DOI 10.1111/j.1600-065X.2010.00978.x
   Fransen F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015692
   Georgel P, 2007, VIROLOGY, V362, P304, DOI 10.1016/j.virol.2006.12.032
   Hamby SE, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-500
   Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112
   Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346
   Jimenez-Guardeno JM, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004320
   Julenius K, 2005, GLYCOBIOLOGY, V15, P153, DOI 10.1093/glycob/cwh151
   Kringelum JV, 2013, MOL IMMUNOL, V53, P24, DOI 10.1016/j.molimm.2012.06.001
   Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   Laskowski R.A., 2011, LIGPLOT MULTIPLE LIG
   Laskowski RA, 1997, TRENDS BIOCHEM SCI, V22, P488, DOI 10.1016/S0968-0004(97)01140-7
   Lester SN, 2014, J MOL BIOL, V426, P1246, DOI 10.1016/j.jmb.2013.11.024
   Modhiran N, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3863
   Olejnik J, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007390
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Portal E.B.R., 2011, PROTPARAM TOOL
   Reed SG, 2016, CURR OPIN IMMUNOL, V41, P85, DOI 10.1016/j.coi.2016.06.007
   Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5
   Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Singh H, 2003, BIOINFORMATICS, V19, P1009, DOI 10.1093/bioinformatics/btg108
   Singh H, 2001, BIOINFORMATICS, V17, P1236, DOI 10.1093/bioinformatics/17.12.1236
   Srivastava S, 2019, J BIOMOL STRUCT DYN, V37, P4345, DOI 10.1080/07391102.2018.1548977
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Vita R, 2015, NUCLEIC ACIDS RES, V43, pD405, DOI 10.1093/nar/gku938
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Xi ET, 2017, P NATL ACAD SCI USA, V114, P13345, DOI 10.1073/pnas.1700092114
   Yang YD, 2011, BIOINFORMATICS, V27, P2076, DOI 10.1093/bioinformatics/btr350
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
   Zheng M, 2020, CELL MOL IMMUNOL, V17, P536, DOI 10.1038/s41423-020-0385-z
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 46
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD NOV
PY 2020
VL 85
AR 104587
DI 10.1016/j.meegid.2020.104587
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA OY0BV
UT WOS:000593920400004
PM 33039603
OA Green Published
DA 2021-01-01
ER

PT J
AU Franco-Munoz, C
   Alvarez-Diaz, DA
   Laiton-Donato, K
   Wiesner, M
   Escandon, P
   Usme-Ciro, JA
   Franco-Sierra, ND
   Florez-Sanchez, AC
   Gomez-Rangel, S
   Rodriguez-Calderon, LD
   Barbosa-Ramirez, J
   Ospitia-Baez, E
   Walteros, DM
   Ospina-Martinez, ML
   Mercado-Reyes, M
AF Franco-Munoz, Carlos
   Alvarez-Diaz, Diego A.
   Laiton-Donato, Katherine
   Wiesner, Magdalena
   Escandon, Patricia
   Usme-Ciro, Jose A.
   Franco-Sierra, Nicolas D.
   Florez-Sanchez, Astrid C.
   Gomez-Rangel, Sergio
   Rodriguez-Calderon, Luz D.
   Barbosa-Ramirez, Juliana
   Ospitia-Baez, Erika
   Walteros, Diana M.
   Ospina-Martinez, Martha L.
   Mercado-Reyes, Marcela
TI Substitutions in Spike and Nucleocapsid proteins of SARS-CoV-2
   circulating in South America
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE SARS-CoV-2; Spike; Nucleocapsid; South America; Non-synonymous
   substitutions
AB SARS-CoV-2 is a new member of the genus Betacoronavirus, responsible for the COVID-19 pandemic. The virus crossed the species barrier and established in the human population taking advantage of the spike protein high affinity for the ACE receptor to infect the lower respiratory tract. The Nucleocapsid (N) and Spike (S) are highly immunogenic structural proteins and most commercial COVID-19 diagnostic assays target these proteins. In an unpredictable epidemic, it is essential to know about their genetic variability. The objective of this study was to describe the substitution frequency of the S and N proteins of SARS-CoV-2 in South America. A total of 504 amino acid and nucleotide sequences of the S and N proteins of SARS-CoV-2 from seven South American countries (Argentina, Brazil, Chile, Ecuador, Peru, Uruguay, and Colombia), reported as of June 3, and corresponding to samples collected between March and April 2020, were compared through substitution matrices using the Muscle algorithm. Forty-three sequences from 13 Colombian departments were obtained in this study using the Oxford Nanopore and Illumina MiSeq technologies, following the amplicon-based ARTIC network protocol. The substitutions D614G in S and R203K/G204R in N were the most frequent in South America, observed in 83% and 34% of the sequences respectively. Strikingly, genomes with the conserved position D614 were almost completely replaced by genomes with the G614 substitution between March to April 2020. A similar replacement pattern was observed with R203K/G204R although more marked in Chile, Argentina and Brazil, suggesting similar introduction history and/or control strategies of SARS-CoV-2 in these countries.
   It is necessary to continue with the genomic surveillance of S and N proteins during the SARS-CoV-2 pandemic as this information can be useful for developing vaccines, therapeutics and diagnostic tests.
C1 [Franco-Munoz, Carlos; Alvarez-Diaz, Diego A.; Laiton-Donato, Katherine; Usme-Ciro, Jose A.; Mercado-Reyes, Marcela] Inst Nacl Salud, Direcc Invest Salud Publ, Grp Invest Basica & Aplicada Enfermedades Emergen, Unidad Secuenciac & Genom, Bogota 111321, Colombia.
   [Franco-Munoz, Carlos] Inst Nacl Salud, Direcc Invest Salud Publ, Grp Parasitol, Bogota 111321, Colombia.
   [Wiesner, Magdalena; Escandon, Patricia] Inst Nacl Salud, Direcc Invest Salud Publ, Grp Microbiol, Bogota, Colombia.
   [Usme-Ciro, Jose A.] Univ Cooperat Colombia, Ctr Invest Salud Trop CIST, Santa Marta 470003, Colombia.
   [Franco-Sierra, Nicolas D.] Inst Invest Recursos Biol Alexander von Humboldt, Programa Ciencias Biodiversidad, Bogota 111311, Colombia.
   [Florez-Sanchez, Astrid C.] Inst Nacl Salud, Direcc Redes Salud Publ, Bogota 111321, Colombia.
   [Walteros, Diana M.] Inst Nacl Salud, Direcc Vigilancia Salud Publ, Bogota 111321, Colombia.
   [Gomez-Rangel, Sergio; Rodriguez-Calderon, Luz D.; Barbosa-Ramirez, Juliana; Ospitia-Baez, Erika] Inst Nacl Salud, Direcc Redes Salud Publ, Grp Virol, Bogota 111321, Colombia.
   [Ospina-Martinez, Martha L.] Inst Nacl Salud, Direcc Gen, Bogota 111321, Colombia.
   [Mercado-Reyes, Marcela] Inst Nacl Salud, Direcc Invest Salud Publ, Bogota 111321, Colombia.
RP Franco-Munoz, C (corresponding author), Inst Nacl Salud, Direcc Invest Salud Publ, Grp Invest Basica & Aplicada Enfermedades Emergen, Unidad Secuenciac & Genom, Bogota 111321, Colombia.
EM cefrancom@unal.edu.co
OI Alvarez-Diaz, Diego Alejandro/0000-0002-6534-0079
FU National Institute of Health, Bogota, Colombia
FX This study was funded by the National Institute of Health, Bogota,
   Colombia.
CR Alvarez-Diaz DA, 2020, INFECT GENET EVOL, V84, DOI 10.1016/j.meegid.2020.104390
   [Anonymous], 2020, WHO DIR GEN OP REM M
   [Anonymous], 2020, CORONAVIRUS COVID 19
   Bartolini B, 2020, EMERG INFECT DIS, V26, P1842, DOI 10.3201/eid2608.201525
   Becerra-Flores M, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13525
   Bhattacharyya C., 2020, BIORXIV
   brian-jgi, 2020, BBMAP SHORT READ ALI
   Brufsky A, 2020, J MED VIROL, V92, P1386, DOI 10.1002/jmv.25902
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Gupta A.M., 2020, LOSS EPITOPES SARS C
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   INS, 2020, COR COVID 2019 COL
   Jacofsky D, 2020, J ARTHROPLASTY, V35, pS74, DOI 10.1016/j.arth.2020.04.055
   Kim SJ, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020220
   Korber B, 2020, BIORXIV
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   Lee CYP, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00879
   Li JG, 2020, J INFECTION, V81, P322, DOI 10.1016/j.jinf.2020.04.016
   Nakashima A., 2020, GLOBAL EMERGENCES MU
   Quick J, 2020, NCOV 2019 SEQUENCING
   Rambaut A., 2020, HCOV 2019 LINEAGES
   Romano M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051267
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   SIB, 2020, BET
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   Villabona-Arenas CJ, 2020, NAT MICROBIOL, V5, P876, DOI 10.1038/s41564-020-0738-5
   WHO, 2020, NOV COR 2019 NCOV TE
   Yan Y, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2106
   Yount B, 2005, J VIROL, V79, P14909, DOI 10.1128/JVI.79.23.14909-14922.2005
NR 32
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD NOV
PY 2020
VL 85
AR 104557
DI 10.1016/j.meegid.2020.104557
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA OX9YR
UT WOS:000593912100006
PM 32950697
OA Green Published
DA 2021-01-01
ER

PT J
AU Saha, I
   Ghosh, N
   Maity, D
   Sharma, N
   Mitra, K
AF Saha, Indrajit
   Ghosh, Nimisha
   Maity, Debasree
   Sharma, Nikhil
   Mitra, Kaushik
TI Inferring the genetic variability in Indian SARS-CoV-2 genomes using
   consensus of multiple sequence alignment techniques
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Multiple sequence alignment; Point mutation; SNP; SARS-CoV-2
AB Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is a threat to the human population and has created a worldwide pandemic. Daily thousands of people are getting affected by the SARS-CoV-2 virus; India being no exception. In this situation, there is no doubt that vaccine is the primary prevention strategy to contain the wave of COVID-19 pandemic. In this regard, genome-wide analysis of SARS-CoV-2 is important to understand its genetic variability. This has motivated us to analyse 566 Indian SARS-CoV-2 sequences using multiple sequence alignment techniques viz. ClustalW, MUSCLE, ClustalO and MAFFT to align and subsequently identify the lists of mutations as substitution, deletion, insertion and SNP. Thereafter, a consensus of these results, called as Consensus Multiple Sequence Alignment (CMSA), is prepared to have the final list of mutations so that the advantages of all four alignment techniques can be preserved. The analysis shows 767, 2025 and 54 unique substitutions, deletions and SNPs in Indian SARS-CoV-2 genomes. More precisely, out of 54 SNPs, 4 SNPs are present close to the 60% of the virus population. The results of this experiment can be useful for virus classification, designing and defining the dose of vaccine for the Indian population.
C1 [Saha, Indrajit] Natl Inst Tech Teachers Training & Res, Dept Comp Sci & Engn, Kolkata, W Bengal, India.
   [Ghosh, Nimisha] Siksha O Anusandhan Deemed Univ, Inst Tech Educ & Res, Dept Comp Sci & Informat Technol, Bhubaneswar, Odisha, India.
   [Maity, Debasree] MCKV Inst Engn, Dept Elect & Commun Engn, Howrah, Odisha, India.
   [Sharma, Nikhil] Jaypee Inst Informat Technol, Dept Elect & Commun Engn, Noida, Uttar Pradesh, India.
   [Mitra, Kaushik] Burdwan Med Coll, Dept Community Med, Burdwan, W Bengal, India.
RP Saha, I (corresponding author), Natl Inst Tech Teachers Training & Res, Dept Comp Sci & Engn, Kolkata, W Bengal, India.
EM indrajit@nitttrkol.ac.in
OI MITRA, KAUSHIK/0000-0002-8865-373X
FU Science and Engineering Research Board (SERB), Department of Science and
   Technology, Govt. of India [CVD/2020/000991]
FX This work has been partially supported by CRG short term research grant
   on COVID-19 (CVD/2020/000991) from Science and Engineering Research
   Board (SERB), Department of Science and Technology, Govt.
CR Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Jeon JS, 2016, VIROLOGY, V496, P277, DOI 10.1016/j.virol.2016.06.017
   Katoh K, 2019, BRIEF BIOINFORM, V20, P1160, DOI 10.1093/bib/bbx108
   Lu IN, 2020, VIRUS RES, V283, DOI 10.1016/j.virusres.2020.197963
   Poland GA, 2020, VACCINE, V38, P4219, DOI 10.1016/j.vaccine.2020.04.073
   Saha P, 2020, INFECT GENET EVOL, V81, DOI 10.1016/j.meegid.2020.104270
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Phan T, 2020, INFECT GENET EVOL, V81, DOI 10.1016/j.meegid.2020.104260
   Vellingiri B, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138277
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 12
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD NOV
PY 2020
VL 85
AR 104522
DI 10.1016/j.meegid.2020.104522
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA OY0AK
UT WOS:000593916700012
PM 32889094
OA Green Published
DA 2021-01-01
ER

PT J
AU Cunarro-Lopez, Y
   Cano-Valderrama, O
   Pintado-Recarte, P
   Cueto-Hernandez, I
   Gonzalez-Garzon, B
   Garcia-Tizon, S
   Bujan, J
   Asunsolo, A
   Ortega, MA
   De Leon-Luis, JA
AF Cunarro-Lopez, Yolanda
   Cano-Valderrama, Oscar
   Pintado-Recarte, Pilar
   Cueto-Hernandez, Ignacio
   Gonzalez-Garzon, Blanca
   Garcia-Tizon, Santiago
   Bujan, Julia
   Asunsolo, Angel
   Ortega, Miguel A.
   De Leon-Luis, Juan Antonio
TI Maternal and Perinatal Outcomes in Patients with Suspected COVID-19 and
   Their Relationship with a Negative RT-PCR Result
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE SARS-CoV-2; COVID-19; pregnancy; maternal-perinatal outcomes; RT-PCR
   negative result
ID PREGNANT PATIENTS; SARS-COV-2
AB This study was designed to examine maternal-perinatal outcomes in pregnant women with suspected coronavirus disease 2019 (COVID-19) according to the result of a real-time reverse transcription polymerase chain reaction (RT-PCR) test and to investigate possible variables that could be useful for predicting a negative RT-PCR result. Participants of this retrospective cohort study were obstetrics patients with suspected COVID-19 who underwent an RT-PCR test in a tertiary hospital in Madrid, Spain. Maternal-perinatal features were analysed according to the results of this test. Clinical, radiological and analytical characteristics that could be associated with a negative result were also explored. In a final subgroup analysis, patients were included if they had pneumonia and a negative test result for the virus. Out of the 111 obstetric patients with suspected COVID-19 that were enrolled, 38.7% returned a negative result. In this RT-PCR-negative group, we recorded lower rates of pneumonia (21.4% vs. 45.6%, p = 0.009), severe or critical clinical features (4.7% vs. 11.8% and 0.0% vs. 5.9%, p = 0.02, respectively), lower lactate dehydrogenase (LDH) levels (168 UI/L vs. 224.5 UI/L, p = 0.003), a greater need for maternal treatment (60.3% vs 24.4%, p < 0.001), a reduced need for oxygen therapy (2.4% vs 28.8%, p < 0.001) and a lower rate of intensive care unit admission (0.0% vs. 3.7%, p = 0.046) than the RT-PCR-positive group. While no differences were found in other variables, the monocyte count was higher (946.2/mu L vs. 518.8/mu L, p = 0.022) in this group. The predictive model for a negative test result included the monocyte count, LDH level and no need for oxygen therapy. This model was able to identify 73.5% of patients with a negative RT-PCR result. Only 11% of the patients with pneumonia testing negative for the virus had IgG antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The proportion of pregnant women with suspected COVID-19 and a negative RT-PCR result was nearly 39%. In these patients, the symptoms were mild and the systemic severity of the disease was lower. The monocyte count, LDH level and no need for oxygen therapy were the factors that were more related to a negative test result in this group. These variables could be used to guide the management of patients with suspected COVID-19, mainly while waiting for RT-PCR results or in settings where this test is not available.
C1 [Cunarro-Lopez, Yolanda; Pintado-Recarte, Pilar; Cueto-Hernandez, Ignacio; Gonzalez-Garzon, Blanca; Garcia-Tizon, Santiago; De Leon-Luis, Juan Antonio] Univ Complutense Madrid, Sch Med, Dept Publ & Maternal & Child Hlth, Madrid 28040, Spain.
   [Cunarro-Lopez, Yolanda; Pintado-Recarte, Pilar; Cueto-Hernandez, Ignacio; Gonzalez-Garzon, Blanca; De Leon-Luis, Juan Antonio] Univ Hosp Gregorio Maranon, Dept Obstet & Gynecol, Madrid 28009, Spain.
   [Cunarro-Lopez, Yolanda; Pintado-Recarte, Pilar; Cueto-Hernandez, Ignacio; Gonzalez-Garzon, Blanca; Garcia-Tizon, Santiago; De Leon-Luis, Juan Antonio] Hlth Res Inst Gregorio Maranon, Madrid 28009, Spain.
   [Cano-Valderrama, Oscar] Univ Complutense Madrid, Dept Surg, Madrid 28009, Spain.
   [Bujan, Julia; Ortega, Miguel A.] Univ Alcala De Henares, Dept Med & Med Specialties, Fac Med & Hlth Sci, Madrid 28801, Spain.
   [Bujan, Julia; Asunsolo, Angel; Ortega, Miguel A.] Ramon y Cajal Inst Healthcare Res IRYCIS, Madrid 28034, Spain.
   [Bujan, Julia; Asunsolo, Angel; Ortega, Miguel A.] Univ Ctr Def Madrid CUD ACD, Madrid 28047, Spain.
   [Asunsolo, Angel] Univ Alcala De Henares, Dept Surg Med & Social Sci, Fac Med & Hlth Sci, Madrid 28801, Spain.
   [Asunsolo, Angel] NYU, Grad Sch Publ Hlth & Hlth Policy, Dept Epidemiol & Biostat, New York, NY 10027 USA.
RP Ortega, MA (corresponding author), Univ Alcala De Henares, Dept Med & Med Specialties, Fac Med & Hlth Sci, Madrid 28801, Spain.; Ortega, MA (corresponding author), Ramon y Cajal Inst Healthcare Res IRYCIS, Madrid 28034, Spain.; Ortega, MA (corresponding author), Univ Ctr Def Madrid CUD ACD, Madrid 28047, Spain.
EM yolanda.cunarro@gmail.com; oscarcanovalderrama@hotmail.com;
   ppintadorec@yahoo.es; ignaciocuetohernandez@gmail.com;
   b.glez-garzon@hotmail.com; gineteca@gmail.com; mjulia.bujan@uah.es;
   angel.asunsolo@uah.es; miguel.angel.ortega92@gmail.com; jaleon@ucm.es
RI De LeAn-Luis, Juan/ABI-5828-2020; Cunarro Lopez, Yolanda/H-7860-2017
OI Ortega, Miguel A/0000-0003-2588-1708; bujan, Julia/0000-0003-2419-2476;
   Cano-Valderrama, Oscar/0000-0003-0775-6217; Cunarro Lopez,
   Yolanda/0000-0002-8190-8680
FU University of Alcala [UAH 2019/00003/016/001/023]; Instituto de Salud
   Carlos III (Plan Estatal de I + D+I 2013-2016) [FIS-PI18/00912];
   European Development Regional Fund "A way to achieve Europe"
   (ERDF)European Union (EU) [B2017/BMD-3804 MITIC-CM]
FX The research was funded by the University of Alcala (COVID-19 UAH
   2019/00003/016/001/023) and by (FIS-PI18/00912) the Instituto de Salud
   Carlos III (Plan Estatal de I + D+I 2013-2016) and cofinanced by the
   European Development Regional Fund "A way to achieve Europe" (ERDF) and
   B2017/BMD-3804 MITIC-CM.
CR Atanasova VB, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6091-4
   Carosso A, 2020, EUR J OBSTET GYN R B, V249, P98, DOI 10.1016/j.ejogrb.2020.04.023
   Carosso AR, 2020, AM J OBSTET GYNECOL, V223, P612, DOI 10.1016/j.ajog.2020.06.012
   Centro de coordinacion de Alertas y, 2020, ACT N ENF COR COVID
   Chung MS, 2020, EUR RADIOL, V30, P2182, DOI [10.1148/radiol.2020200230, 10.1007/s00330-019-06574-1]
   Comunidad de Madrid, 2020, REOG AT OBST GIN NEO
   Di Mascio Daniele, 2020, Ultrasound Obstet Gynecol, DOI 10.1002/uog.23107
   Finer N, 2020, CLIN OBES, V10, DOI 10.1111/cob.12365
   Larroca SGT, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-02901-3
   Hantoushzadeh S, 2020, AM J OBSTET GYNECOL, V223, DOI 10.1016/j.ajog.2020.04.030
   Larroca SGT, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1515-1
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Li Y Y, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P427, DOI 10.3760/cma.j.cn112147-20200214-00095
   Li ZT, 2020, J MED VIROL, V92, P1518, DOI 10.1002/jmv.25727
   Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Ng SC, 2020, LANCET GASTROENTEROL, V5, P642, DOI 10.1016/S2468-1253(20)30124-2
   Pacheco LD, 2020, OBSTET GYNECOL, V136, P42, DOI [10.1097/A0G0000000000003929, 10.1097/AOG.0000000000003929]
   Peng FJ, 2020, CAN J CARDIOL, V36, P915, DOI 10.1016/j.cjca.2020.04.010
   RICKHAM PP, 1964, BRIT MED J, V2, P173
   Santos Victor S, 2020, J Pediatr Gastroenterol Nutr, V71, P150, DOI 10.1097/MPG.0000000000002798
   Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831
   Sun SY, 2020, CLIN CHIM ACTA, V507, P174, DOI 10.1016/j.cca.2020.04.024
   Sutton D, 2020, NEW ENGL J MED, V382, P2163, DOI 10.1056/NEJMc2009316
   von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013
   World Health Organization, WEEKLY EPIDEMIOLOGIC
   World Health Organization, 2020, DIAGN TEST SARS COV
   Yang ZY, 2020, J MATERN-FETAL NEO M, DOI 10.1080/14767058.2020.1759541
   Yu X, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02893-8
   Zhao JF, 2019, ELECTRON J DIFFER EQ
   Zheng SF, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1443
NR 31
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD NOV
PY 2020
VL 9
IS 11
AR 3552
DI 10.3390/jcm9113552
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA OX8EW
UT WOS:000593792200001
PM 33158175
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU de Dios, E
   Rios-Navarro, C
   Perez-Sole, N
   Gavara, J
   Marcos-Garces, V
   Rodriguez, E
   Carratala, A
   Forner, MJ
   Navarro, J
   Blasco, ML
   Bondia, E
   Signes-Costa, J
   Vila, JM
   Forteza, MJ
   Chorro, FJ
   Bodi, V
AF de Dios, Elena
   Rios-Navarro, Cesar
   Perez-Sole, Nerea
   Gavara, Jose
   Marcos-Garces, Victor
   Rodriguez, Enrique
   Carratala, Arturo
   Forner, Maria J.
   Navarro, Jorge
   Blasco, Maria L.
   Bondia, Elvira
   Signes-Costa, Jaime
   Vila, Jose M.
   Forteza, Maria J.
   Chorro, Francisco J.
   Bodi, Vicente
TI Similar Clinical Course and Significance of Circulating Innate and
   Adaptive Immune Cell Counts in STEMI and COVID-19
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE COVID-19; myocardial infarction; neutrophils; lymphocyte; prognosis;
   severity
ID ELEVATION MYOCARDIAL-INFARCTION; MICROVASCULAR OBSTRUCTION; PROGNOSTIC
   VALUE; PREDICTION; INJURY; SOON; LYMPHOPENIA; LYMPHOCYTES; HEART
AB This study aimed to assess the time course of circulating neutrophil and lymphocyte counts and their ratio (NLR) in ST-segment elevation myocardial infarction (STEMI) and coronavirus disease (COVID)-19 and explore their associations with clinical events and structural damage. Circulating neutrophil, lymphocyte and NLR were sequentially measured in 659 patients admitted for STEMI and in 103 COVID-19 patients. The dynamics detected in STEMI (within a few hours) were replicated in COVID-19 (within a few days). In both entities patients with events and with severe structural damage displayed higher neutrophil and lower lymphocyte counts. In both scenarios, higher maximum neutrophil and lower minimum lymphocyte counts were associated with more events and more severe organ damage. NLR was higher in STEMI and COVID-19 patients with the worst clinical and structural outcomes. A canonical deregulation of the immune response occurs in STEMI and COVID-19 patients. Boosted circulating innate (neutrophilia) and depressed circulating adaptive immunity (lymphopenia) is associated with more events and severe organ damage. A greater understanding of these critical illnesses is pivotal to explore novel alternative therapies.
C1 [de Dios, Elena; Chorro, Francisco J.; Bodi, Vicente] Ctr Invest Biomed Red Cardiovasc CIBER CV, Madrid 28029, Spain.
   [de Dios, Elena; Forner, Maria J.; Chorro, Francisco J.; Bodi, Vicente] Univ Valencia, Dept Med, Fac Med, Valencia 46010, Spain.
   [Rios-Navarro, Cesar; Perez-Sole, Nerea; Gavara, Jose; Rodriguez, Enrique; Carratala, Arturo; Forner, Maria J.; Navarro, Jorge; Blasco, Maria L.; Signes-Costa, Jaime; Vila, Jose M.; Chorro, Francisco J.; Bodi, Vicente] Inst Hlth Res INCLIVA, Valencia 46010, Spain.
   [Marcos-Garces, Victor; Chorro, Francisco J.; Bodi, Vicente] Hosp Clin Univ, Dept Cardiol, Valencia 46010, Spain.
   [Rodriguez, Enrique; Carratala, Arturo] Hosp Clin Univ, Dept Biochem, Valencia 46010, Spain.
   [Forner, Maria J.] Hosp Clin Univ, Dept Internal Med, Valencia 46010, Spain.
   [Navarro, Jorge] Hosp Clin Univ, Med Directory, Valencia 46010, Spain.
   [Blasco, Maria L.] Hosp Clin Univ, Med Intens Care Unit, Valencia 46010, Spain.
   [Bondia, Elvira; Signes-Costa, Jaime] Hosp Clin Univ, Serv Pneumol, Valencia 46010, Spain.
   [Vila, Jose M.] Univ Valencia, Dept Physiol, Fac Med, Valencia 46010, Spain.
   [Forteza, Maria J.] Karolinska Univ Hosp, Karolinska Inst, Cardiovasc Med Unit, Ctr Mol Med,Dept Med, S-17177 Stockholm, Sweden.
RP Bodi, V (corresponding author), Ctr Invest Biomed Red Cardiovasc CIBER CV, Madrid 28029, Spain.; Bodi, V (corresponding author), Univ Valencia, Dept Med, Fac Med, Valencia 46010, Spain.; Bodi, V (corresponding author), Inst Hlth Res INCLIVA, Valencia 46010, Spain.; Bodi, V (corresponding author), Hosp Clin Univ, Dept Cardiol, Valencia 46010, Spain.
EM elenaddll@gmail.com; cesar_rios1@hotmail.com; neere_8@hotmail.com;
   jose_4_6_90@hotmail.com; vic_mg_cs@hotmail.com; rodriguez_enr@gva.es;
   carratala_art@gva.es; Maria.Jose.Forner@uv.es; jorgenavper@gmail.com;
   blasco_luicor@gva.es; elvirabonre@gmail.com; jaimesignescosta@gmail.com;
   jose.m.salinas@uv.es; maria.forteza.de.los.reyes@ki.se;
   francisco.j.chorro@uv.es; vicente.bodi@uv.es
RI ; Rodriguez Borja, Enrique/D-8035-2018
OI Marcos-Garces, Victor/0000-0001-5565-5547; Blasco/0000-0002-9141-3198;
   Carratala Calvo, Arturo/0000-0003-4513-7214; Bondia,
   Elvira/0000-0001-6638-5466; Rios-Navarro, Cesar/0000-0002-6405-6279;
   Rodriguez Borja, Enrique/0000-0002-0339-6704; Gavara Donate,
   Jose/0000-0002-3483-7066
FU Instituto de Salud Carlos IIIInstituto de Salud Carlos III [PI17/01836,
   PI20/00637, CIBERCV16/11/00486, FI18/00320]; Fondos Europeos de
   Desarrollo Regional FEDEREuropean Union (EU) [PI17/01836, PI20/00637,
   CIBERCV16/11/00486, FI18/00320]
FX This study was funded by "Instituto de Salud Carlos III" and "Fondos
   Europeos de Desarrollo Regional FEDER" (research grants PI17/01836,
   PI20/00637, CIBERCV16/11/00486 and a postgraduate contract FI18/00320 to
   C. R.-N.).
CR [Anonymous], 2020, CHINESE MED J-PEKING, V133, P1087, DOI 10.1097/CM9.0000000000000819
   Boag SE, 2015, J CLIN INVEST, V125, P3063, DOI 10.1172/JCI80055
   Bodi V, 2005, J AM COLL CARDIOL, V46, P1747, DOI 10.1016/j.jacc.2005.07.039
   Bodi V, 2016, RADIOLOGY, V278, P54, DOI 10.1148/radiol.2015142674
   Bodi V, 2009, JACC-CARDIOVASC IMAG, V2, P835, DOI 10.1016/j.jcmg.2009.03.011
   Bodi V, 2009, REV ESP CARDIOL, V62, P1109, DOI 10.1016/S0300-8932(09)72379-6
   Bodi V, 2008, AM HEART J, V156, P1065, DOI 10.1016/j.ahj.2008.07.008
   Bonanad C, 2016, EUR J RADIOL, V85, P585, DOI 10.1016/j.ejrad.2015.12.012
   Carbone F, 2013, THROMB HAEMOSTASIS, V110, P501, DOI 10.1160/TH13-03-0211
   Carsana L, 2020, LANCET INFECT DIS, V20, P1135, DOI 10.1016/S1473-3099(20)30434-5
   Cozzi D, 2020, RADIOL MED, V125, P730, DOI 10.1007/s11547-020-01232-9
   Cui M, 2013, CARDIOLOGY, V124, P76, DOI 10.1159/000345855
   Davoine F, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00570
   de Waha S, 2017, EUR HEART J, V38, P3502, DOI 10.1093/eurheartj/ehx414
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Dyck L, 2017, EUR J IMMUNOL, V47, P765, DOI 10.1002/eji.201646875
   El Homsi Maria, 2020, Eur J Radiol Open, V7, P100239, DOI 10.1016/j.ejro.2020.100239
   Epelman S, 2012, J CARDIOVASC TRANSL, V5, P827, DOI 10.1007/s12265-012-9410-7
   Filippi MD, 2019, BLOOD, V133, P2149, DOI 10.1182/blood-2018-12-844605
   Forteza MJ, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/1975167
   Forteza MJ, 2014, INT J CARDIOL, V177, P8, DOI 10.1016/j.ijcard.2014.09.114
   Fu FF, 2020, EUR RADIOL, V30, P5489, DOI 10.1007/s00330-020-06920-8
   Ge L, 2015, AM J PHYSIOL-HEART C, V308, pH500, DOI 10.1152/ajpheart.00381.2014
   Girardot T, 2017, APOPTOSIS, V22, P295, DOI 10.1007/s10495-016-1325-3
   Hansell DM, 2008, RADIOLOGY, V246, P697, DOI 10.1148/radiol.2462070712
   Hennessy T, 2019, AM HEART J, V215, P62, DOI 10.1016/j.ahj.2019.06.003
   Hofmann U, 2015, CIRC RES, V116, P354, DOI 10.1161/CIRCRESAHA.116.304072
   Husser O, 2011, INFLAMMATION, V34, P73, DOI 10.1007/s10753-010-9209-0
   Lansbury L, 2020, J INFECTION, V81, P266, DOI 10.1016/j.jinf.2020.05.046
   Menees DS, 2013, NEW ENGL J MED, V369, P901, DOI 10.1056/NEJMoa1208200
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Monmeneu JV, 2009, REV ESP CARDIOL, V62, P858, DOI 10.1016/S0300-8932(09)72068-8
   Nunez J, 2006, CURR MED CHEM, V13, P2113, DOI 10.2174/092986706777935221
   Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128
   Prabhu SD, 2016, CIRC RES, V119, P91, DOI 10.1161/CIRCRESAHA.116.303577
   Puhl SL, 2019, FRONT CARDIOVASC MED, V6, DOI 10.3389/fcvm.2019.00025
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Rios-Navarro C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206344
   Taghiloo S, 2020, J MED VIROL, DOI 10.1002/jmv.26505
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Tardif JC, 2019, NEW ENGL J MED, V381, P2497, DOI 10.1056/NEJMoa1912388
   Thygesen K, 2019, EUR HEART J, V40, P237, DOI [10.1093/eurheartj/ehy462, 10.1016/j.jacc.2018.08.1038]
   Zhang SM, 2015, ATHEROSCLEROSIS, V241, P723, DOI 10.1016/j.atherosclerosis.2015.06.035
   ZUO Y, 2020, J THROMB THROMB 1105, DOI DOI 10.1101/2020.04.30.20086736
NR 45
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD NOV
PY 2020
VL 9
IS 11
AR 3484
DI 10.3390/jcm9113484
PG 18
WC Medicine, General & Internal
SC General & Internal Medicine
GA OX9VO
UT WOS:000593903900001
PM 33126723
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Chidambaram, SK
   Ali, D
   Alarifi, S
   Radhakrishnan, S
   Akbar, I
AF Chidambaram, Sathish Kumar
   Ali, Daoud
   Alarifi, Saud
   Radhakrishnan, Surendrakumar
   Akbar, Idhayadhulla
TI In silico molecular docking: Evaluation of coumarin based derivatives
   against SARS-CoV-2
SO JOURNAL OF INFECTION AND PUBLIC HEALTH
LA English
DT Article
DE Coumarin; COVID-19; Molecular docking; Virtual ADME; 5N5O protein
ID DRUG DISCOVERY; INHIBITION; PREDICTION; PERMEABILITY; CONSTITUENTS;
   SOLUBILITY; SARS
AB Background: The unique anthropological coronavirus which has been titled as SARS-CoV-2 was originally arisen in late 2019 in Wuhan, China affecting respiratory infection named as COVID-19. Coronavirus is disturbing human life in an exceptional method and has converted a public health global crisis. Natural products are ahead consideration due to the huge beneficial window and effective antiinflammatory, immunomodulatory, antioxidant and antiviral possessions. Consequently, the present study was intended to display inhibition ability of natural products coumarins and their analogues against SARS coronavirus.
   Methods: The present study, aims to forecast theoretical assembly for the protease of COVID-19 and to discover advance whether this protein may assist as a target for protease inhibitors such as psoralen, bergapten, imperatorin, heraclenin, heraclenol, saxalin, oxepeucedanin, angelicin, toddacoumaquinone, and aesculetin. The docking score of these natural coumarin analogues compared with standard Hydroxychloroquine. Whereas the 3D assembly of main protease of SARS coronavirus was forecast with SWISS MODEL web server, and molecular interaction studies amongst target protein and ligands were done with AutoDock Vina software.
   Results: The study more exposed that all the inhibitors acquired with negative dock energy against the target protein. Molecular docking investigation displayed that natural coumarin analogue toddacoumaquinone displayed a remarkable inhibition ability with the binding energy of -7.8 kcal/mol than other compounds against main protease of SARS coronavirus in intricate with alpha-ketoamide (PDB ID: 5N5O). The synthetic coumarin analogue (1 m) also displayed the comparable inhibition ability with a binding energy of -7.1 kcal/mol against main protease of SARS coronavirus in intricate with alpha-ketoamide. Keeping the overhead results of ADME and toxicity, all tested compounds were recognized as drug-like nature, passing Lipinski's "Rule of 5" with 0 violation except alpha-ketoamide passes Lipinski's "Rule of 5" with 1 violation MW > 500. The projected constraints are within the assortment of recognized values.
   Conclusions: Based upon the results of the manifold sequence alliance, natural and synthetic coumarin binding sites were preserved. The present in silico examination thus, delivers structural awareness about the protease of COVID-19 and molecular relations with some of the recognised protease inhibitors. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.
C1 [Chidambaram, Sathish Kumar; Radhakrishnan, Surendrakumar; Akbar, Idhayadhulla] Bharathidasan Univ, Res Dept Chem, Nehru Mem Coll, Puthanampatti 621007, Tamil Nadu, India.
   [Ali, Daoud; Alarifi, Saud] King Saud Univ KSU, Coll Sci, Dept Zool, POB 2455, Riyadh 11451, Saudi Arabia.
RP Akbar, I (corresponding author), Bharathidasan Univ, Res Dept Chem, Nehru Mem Coll, Puthanampatti 621007, Tamil Nadu, India.
EM idhayadhulla@nmc.ac.in
RI Idhayadhulla, A./V-5016-2019
OI Idhayadhulla, A./0000-0003-0309-6274
FU King Saud University, Riyadh, Saudi ArabiaKing Saud University
   [RSP-2020/27]
FX This work was funded by Researchers Supporting Project number
   (RSP-2020/27), King Saud University, Riyadh, Saudi Arabia.
CR Abdel-Fattah Mostafa A, 2019, RSC ADV, V9, P25533, DOI 10.1039/c9ra04496e
   Azam F, 2012, J YOUNG PHARM, V4, P184, DOI 10.4103/0975-1483.100027
   Daina A, 2016, CHEMMEDCHEM, V11, P1117, DOI 10.1002/cmdc.201600182
   Ertl P, 2000, J MED CHEM, V43, P3714, DOI 10.1021/jm000942e
   Fromm MF, 2000, INT J CLIN PHARM TH, V38, P69
   Guerriero G, 2018, GENES-BASEL, V9, DOI 10.3390/genes9060309
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Hofmann H, 2004, TRENDS MICROBIOL, V12, P466, DOI 10.1016/j.tim.2004.08.008
   ISHIKAWA T, 1995, CHEM PHARM BULL, V43, P1039
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P1045, DOI 10.1080/14756366.2020.1754813
   Lee PY, 2020, J ALLERGY CLIN IMMUN, V146, P1194, DOI 10.1016/j.jaci.2020.07.033
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Malik W, 2020, VET Q, V40, P1, DOI DOI 10.1080/01652176.2020.1727993
   Newby D, 2015, EUR J MED CHEM, V90, P751, DOI 10.1016/j.ejmech.2014.12.006
   Nonoyama T, 2008, J TOXICOL PATHOL, V21, P9, DOI 10.1293/tox.21.9
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V33, DOI 10.1016/j.tmaid.2020.101578
   Shikishima Y, 2001, CHEM PHARM BULL, V49, P877, DOI 10.1248/cpb.49.877
   Taha M, 2015, BIOORG MED CHEM LETT, V25, P3285, DOI 10.1016/j.bmcl.2015.05.069
   Thayil S. M., 2016, INT J PHARMACOGN, V8, P1020
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   World Health Organization, 2020, WAT SAN HYG WAST MAN, P1, DOI DOI 10.1056/NEJMOA2001191.7
   Wu TS, 2001, BIOORGAN MED CHEM, V9, P77, DOI 10.1016/S0968-0896(00)00225-X
   Yang L, 2018, MOLECULES, V23, DOI 10.3390/molecules23040762
   Yeh JY, 2010, J MED CHEM, V53, P1519, DOI 10.1021/jm901570x
   Zakaryan H, 2017, ARCH VIROL, V162, P2539, DOI 10.1007/s00705-017-3417-y
   Zhou P, 2000, PHYTOCHEMISTRY, V53, P689, DOI 10.1016/S0031-9422(99)00554-3
NR 26
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 1876-0341
EI 1876-035X
J9 J INFECT PUBLIC HEAL
JI J. Infect. Public Health
PD NOV
PY 2020
VL 13
IS 11
BP 1671
EP 1677
DI 10.1016/j.jiph.2020.09.002
PG 7
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA ON2KR
UT WOS:000586537200009
PM 33008777
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Desai, A
   Santonocito, OG
   Caltagirone, G
   Kogan, M
   Ghetti, F
   Donadoni, I
   Porro, F
   Savevski, V
   Poretti, D
   Ciccarelli, M
   Boneschi, FM
   Voza, A
AF Desai, Antonio
   Santonocito, Orazio Giuseppe
   Caltagirone, Giuseppe
   Kogan, Maria
   Ghetti, Federica
   Donadoni, Ilaria
   Porro, Francesca
   Savevski, Victor
   Poretti, Dario
   Ciccarelli, Michele
   Martinelli Boneschi, Filippo
   Voza, Antonio
TI Effectiveness of Streptococcus Pneumoniae Urinary Antigen Testing in
   Decreasing Mortality of COVID-19 Co-Infected Patients: A Clinical
   Investigation
SO MEDICINA-LITHUANIA
LA English
DT Article
DE antibodies; bacterial infection 2; COVID-19; SARS-CoV-2; Streptococcus
   pneumoniae
ID COMMUNITY-ACQUIRED PNEUMONIA; RESPIRATORY PATHOGENS; BACTERIAL
   COINFECTION; INFLUENZA; DIAGNOSIS; COMPLICATION; EPIDEMIOLOGY; ADULTS;
   ASSAY; BINAX
AB Background and objectives: Streptococcus pneumoniae urinary antigen (u-Ag) testing has recently gained attention in the early diagnosis of severe and critical acute respiratory syndrome coronavirus-2/pneumococcal co-infection. The aim of this study is to assess the effectiveness of Streptococcus pneumoniae u-Ag testing in coronavirus disease 2019 (COVID-19) patients, in order to assess whether pneumococcal co-infection is associated with different mortality rate and hospital stay in these patients. Materials and Methods: Charts, protocols, mortality, and hospitalization data of a consecutive series of COVID-19 patients admitted to a tertiary hospital in northern Italy during COVID-19 outbreak were retrospectively reviewed. All patients underwent Streptococcus pneumoniae u-Ag testing to detect an underlying pneumococcal co-infection. Covid19+/u-Ag+ and Covid19+/u-Ag- patients were compared in terms of overall survival and length of hospital stay using chi-square test and survival analysis. Results: Out of 575 patients with documented pneumonia, 13% screened positive for the u-Ag test. All u-Ag+ patients underwent treatment with Ceftriaxone and Azithromycin or Levofloxacin. Lopinavir/Ritonavir or Darunavir/Cobicistat were added in 44 patients, and hydroxychloroquine and low-molecular-weight heparin (LMWH) in 47 and 33 patients, respectively. All u-Ag+ patients were hospitalized. Mortality was 15.4% and 25.9% in u-Ag+ and u-Ag- patients, respectively (p = 0.09). Survival analysis showed a better prognosis, albeit not significant, in u-Ag+ patients. Median hospital stay did not differ among groups (10 vs. 9 days, p = 0.71). Conclusions: The routine use of Streptococcus pneumoniae u-Ag testing helped to better target antibiotic therapy with a final trend of reduction in mortality of u-Ag+ COVID-19 patients having a concomitant pneumococcal infection. Randomized trials on larger cohorts are necessary in order to draw definitive conclusion.
C1 [Desai, Antonio; Caltagirone, Giuseppe; Kogan, Maria; Ghetti, Federica; Donadoni, Ilaria; Porro, Francesca; Voza, Antonio] IRCCS, Humanitas Clin & Res Ctr, Emergency Dept, I-20089 Milan, Italy.
   [Desai, Antonio; Caltagirone, Giuseppe] Humanitas Univ, Dept Biomed Sci, I-20090 Pieve Emanuele, Italy.
   [Santonocito, Orazio Giuseppe; Poretti, Dario] IRCCS, Humanitas Clin & Res Ctr, Dept Diagnost & Intervent Radiol, I-20089 Milan, Italy.
   [Savevski, Victor] IRCCS, Humanitas Clin & Res Ctr, Artificial Intelligence Ctr, I-20089 Milan, Italy.
   [Ciccarelli, Michele] IRCCS, Humanitas Clin & Res Ctr, Pneumol Dept, I-20089 Milan, Italy.
   [Martinelli Boneschi, Filippo] Univ Milan, Dept Pathophysiol & Transplantat DEPT, Neurosci Sect, Dino Ferrari Ctr, I-20122 Milan, Italy.
   [Martinelli Boneschi, Filippo] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Neurol Unit, I-20122 Milan, Italy.
   [Martinelli Boneschi, Filippo] Fdn IRCCS Ca Granda Osped Maggiore Policlin, MS Ctr, I-20122 Milan, Italy.
RP Desai, A (corresponding author), IRCCS, Humanitas Clin & Res Ctr, Emergency Dept, I-20089 Milan, Italy.; Desai, A (corresponding author), Humanitas Univ, Dept Biomed Sci, I-20090 Pieve Emanuele, Italy.
EM desaiantonio@gmail.com; giuseppe.santonocito@humanitas.it;
   giuseppe.caltagirone@humanitas.it; maria.kogan@humanitas.it;
   federica.ghetti@humanitas.it; ilaria.donadoni@humanitas.it;
   francesca.porro@humanitas.it; victor.savevski@humanitas.it;
   dario.poretti@humanitas.it; michele.ciccarelli@humanitas.it;
   filippo.martinelli71@gmail.com; antonio.voza@humanitas.it
RI Desai, Antonio/ABH-8942-2020; Desai, Antonio/ABB-4966-2020
OI Desai, Antonio/0000-0003-4674-4905; , Victor/0000-0002-3376-8740
CR (ANSM) Agence nationale de securite du medicament et des produits de sante, ANT VOIE GEN INF RES
   AUSTRIAN R, 1964, ANN INTERN MED, V60, P759, DOI 10.7326/0003-4819-60-5-759
   Beadling C, 2004, CURR OPIN INFECT DIS, V17, P185, DOI 10.1097/00001432-200406000-00003
   Bellantoni G, 2019, eNeurologicalSci, V14, P31, DOI 10.1016/j.ensci.2018.11.021
   Bosch AATM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003057
   Brundage JF, 2006, LANCET INFECT DIS, V6, P303, DOI 10.1016/S1473-3099(06)70466-2
   Burrell A, 2018, NEW ENGL J MED, V378, P2138, DOI 10.1056/NEJMc1717178
   Charton F, 2020, MED MALADIES INFECT, V50, P57, DOI 10.1016/j.medmal.2019.06.009
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chertow DS, 2013, JAMA-J AM MED ASSOC, V309, P275, DOI 10.1001/jama.2012.194139
   Cocco A, 2020, J NEUROL, DOI 10.1007/s00415-020-10135-8
   Contou D, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00736-x
   Dion C.F., 2020, STATPEARLS
   Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402
   Garcia-Vidal Carolina, 2021, Clin Microbiol Infect, V27, P83, DOI 10.1016/j.cmi.2020.07.041
   Garcia-Vidal C, 2011, CLIN INFECT DIS, V53, pE16, DOI 10.1093/cid/cir485
   Giotta Lucifero Alice, 2020, Acta Biomed, V91, P32, DOI 10.23750/abm.v91i7-S.9953
   Giotta Lucifero Alice, 2020, Acta Biomed, V91, P5, DOI 10.23750/abm.v91i7-S.9951
   Giotta Lucifero Alice, 2020, Acta Biomed, V91, P61, DOI 10.23750/abm.v91i7-S.9956
   Guo LX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02752
   Gutierrez F, 2003, CLIN INFECT DIS, V36, P286, DOI 10.1086/345852
   Honore A, 2004, PATHOL BIOL, V52, P429, DOI 10.1016/j.patbio.2004.07.026
   Kim D, 2020, JAMA-J AM MED ASSOC, V323, P2085, DOI 10.1001/jama.2020.6266
   Klein EY, 2016, INFLUENZA OTHER RESP, V10, P394, DOI 10.1111/irv.12398
   Lai CC, 2020, J MICROBIOL IMMUNOL, V53, P505, DOI 10.1016/j.jmii.2020.05.013
   Lansbury L, 2020, J INFECTION, V81, P266, DOI 10.1016/j.jinf.2020.05.046
   Li XX, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-79
   Lim WS, 2003, THORAX, V58, P377, DOI 10.1136/thorax.58.5.377
   Lin DC, 2020, SCI CHINA LIFE SCI, V63, P606, DOI 10.1007/s11427-020-1668-5
   Luzzi S, 2020, ANN ITAL CHIR, V91, P298
   Luzzi Sabino, 2020, Acta Biomed, V91, P18, DOI 10.23750/abm.v91i7-S.9952
   Luzzi Sabino, 2020, Acta Biomed, V91, P79, DOI 10.23750/abm.v91i7-S.9958
   Luzzi Sabino, 2020, Acta Biomed, V91, P51, DOI 10.23750/abm.v91i7-S.9955
   Luzzi S, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02818
   Luzzi S, 2019, WORLD NEUROSURG, V127, P255, DOI 10.1016/j.wneu.2019.04.056
   MacIntyre CR, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3548-0
   Martin-Loeches I, 2017, INTENS CARE MED, V43, P48, DOI 10.1007/s00134-016-4578-y
   Mendelson M, 2020, INT J INFECT DIS, V94, P32, DOI 10.1016/j.ijid.2020.03.030
   Metlay JP, 2019, AM J RESP CRIT CARE, V200, pE45, DOI 10.1164/rccm.201908-1581ST
   MOINE P, 1994, CHEST, V105, P1487, DOI 10.1378/chest.105.5.1487
   Molinos L, 2015, ANN AM THORAC SOC, V12, P1482, DOI 10.1513/AnnalsATS.201505-304OC
   Pasman Lesley, 2012, Yale Journal of Biology and Medicine, V85, P127
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Roson B, 2004, CLIN INFECT DIS, V38, P222, DOI 10.1086/380639
   SAVIOLI G, 2020, MEDICINA-LITHUANIA, V56, DOI DOI 10.3390/medicina56040205
   Schauwvlieghe AFAD, 2018, LANCET RESP MED, V6, P782, DOI 10.1016/S2213-2600(18)30274-1
   Thindwa D, 2020, VACCINE, V38, P5398, DOI 10.1016/j.vaccine.2020.06.047
   von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X
   Weiser JN, 2018, NAT REV MICROBIOL, V16, P354, DOI 10.1038/s41579-018-0001-8
   West Devin M, 2016, ERJ Open Res, V2, DOI 10.1183/23120541.00011-2016
   World Health Organization, 2020, CLIN MAN SEV AC RESP, P21
   Zahariadis George, 2006, Can Respir J, V13, P17
   Zhu XJ, 2020, VIRUS RES, V285, DOI 10.1016/j.virusres.2020.198005
NR 53
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1010-660X
EI 1648-9144
J9 MEDICINA-LITHUANIA
JI Med. Lith.
PD NOV
PY 2020
VL 56
IS 11
AR 572
DI 10.3390/medicina56110572
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA OY0IQ
UT WOS:000593938300001
PM 33138045
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Molinaro, R
   Pasto, A
   Taraballi, F
   Giordano, F
   Azzi, JA
   Tasciotti, E
   Corbo, C
AF Molinaro, Roberto
   Pasto, Anna
   Taraballi, Francesca
   Giordano, Federica
   Azzi, Jamil A.
   Tasciotti, Ennio
   Corbo, Claudia
TI Biomimetic Nanoparticles Potentiate the Anti-Inflammatory Properties of
   Dexamethasone and Reduce the Cytokine Storm Syndrome: An Additional
   Weapon against COVID-19?
SO NANOMATERIALS
LA English
DT Article
DE COVID-19; inflammation; leukocyte-like carriers; cytokine storm;
   biomimetic nanovesicles
ID DELIVERY; SEPSIS
AB Recent studies on coronavirus infectious disease 2019 (COVID-19) pathophysiology indicated the cytokine release syndrome induced by the virus as the main cause of mortality. Patients with severe COVID-19 infection present a systemic hyper inflammation that can lead to lung and multi-organ injuries. Among the most recent treatments, corticosteroids have been identified to be effective in mitigating these catastrophic effects. Our group has recently developed leukocyte-derived nanovesicles, termed leukosomes, able to target in vivo the inflamed vasculature associated with pathological conditions including cancer, cardiovascular diseases, and sepsis. Herein, to gain insights on the anti-inflammatory properties of leukosomes, we investigated their ability to reduce uncontrolled inflammation in a lethal model of lipopolysaccharide (LPS)-induced endotoxemia, recapitulating the cytokine storm syndrome observed in COVID-19 infection after encapsulating dexamethasone. Treated animals showed a significant survival advantage and an improved immune response resolution, as demonstrated by a cytokine array analysis of pro- and anti-inflammatory cytokines, chemokines, and other immune-relevant markers. Our results showed that leukosomes enhance the therapeutic activity of dexamethasone and better control the inflammatory response compared to the free drug. Such an approach could be useful for the development of personalized therapies in the treatment of hyperinflammation related to infectious diseases, including the ones caused by COVID-19.
C1 [Molinaro, Roberto; Pasto, Anna; Tasciotti, Ennio; Corbo, Claudia] Houston Methodist Res Inst, Ctr Biomimet Med, Houston, TX 77030 USA.
   [Molinaro, Roberto] IRCCS San Raffaele Hosp, I-20132 Milan, Italy.
   [Taraballi, Francesca; Giordano, Federica] Houston Methodist Acad Inst, Ctr Musculoskeletal Regenerat, Houston, TX 77030 USA.
   [Taraballi, Francesca; Giordano, Federica; Tasciotti, Ennio] Houston Methodist Hosp, Orthoped & Sport Med, Houston, TX 77030 USA.
   [Azzi, Jamil A.] Harvard Med Sch, Brigham & Womens Hosp, Renal Div, Boston, MA 02115 USA.
   [Tasciotti, Ennio] San Raffaele Univ, Biotechnol Program, I-00166 Rome, RM, Italy.
   [Tasciotti, Ennio] IRCCS San Raffaele Pisana, I-00166 Rome, RM, Italy.
   [Corbo, Claudia] Univ Milano Bicocca, Ctr Nanomed Nanomib, Dept Med & Surg, I-20854 Vedano Al Lambro, MB, Italy.
RP Corbo, C (corresponding author), Houston Methodist Res Inst, Ctr Biomimet Med, Houston, TX 77030 USA.; Corbo, C (corresponding author), Univ Milano Bicocca, Ctr Nanomed Nanomib, Dept Med & Surg, I-20854 Vedano Al Lambro, MB, Italy.
EM molinaro.roberto@hsr.it; anna.pasto@humanitasresearch.it;
   ftaraballi2@houstonmethodist.org; fgiordano@houstonmethodist.org;
   jazzi@bwh.harvard.edu; tasciottiennio@gmail.com; claudia.corbo@unimib.it
RI ; Corbo, Claudia/N-3774-2016; Molinaro, Roberto/O-3085-2016
OI Taraballi, Francesca/0000-0002-4959-1169; Corbo,
   Claudia/0000-0001-6468-2571; Molinaro, Roberto/0000-0002-8030-0892
FU Regenerative Medicine Program Cullen Trust for Health Care [18130014];
   Brown Foundation [18130011]; Hearst Foundation [18130017]; Cancer
   Prevention & Research Institute of Texas [RP170466]
FX This work was supported by The Regenerative Medicine Program Cullen
   Trust for Health Care (Project ID, 18130014), Brown Foundation (Project
   ID, 18130011), the Hearst Foundation (Project ID, 18130017), and Cancer
   Prevention & Research Institute of Texas (Project ID: RP170466) to E.T.
CR Arrighetti N, 2019, CURR MED CHEM, V26, P6132, DOI 10.2174/0929867325666180831150259
   Bellamri N, 2020, J IMMUNOL, V204, P2492, DOI 10.4049/jimmunol.1900790
   Boada C, 2020, CIRC RES, V126, P25, DOI 10.1161/CIRCRESAHA.119.315185
   Cain DW, 2020, NAT REV IMMUNOL, V20, P587, DOI 10.1038/s41577-020-00421-x
   Carvelli J, 2020, NATURE, V588, P146, DOI 10.1038/s41586-020-2600-6
   Coperchini F, 2020, CYTOKINE GROWTH F R, V53, P25, DOI 10.1016/j.cytogfr.2020.05.003
   Corbo C, 2017, NANOSCALE, V9, P14581, DOI 10.1039/c7nr04734g
   Corbo C, 2017, ACS NANO, V11, P3262, DOI 10.1021/acsnano.7b00376
   Corbo C, 2015, CURR DRUG TARGETS, V16, P1540, DOI 10.2174/1389450115666141109211413
   Hu CMJ, 2013, NAT NANOTECHNOL, V8, P336, DOI [10.1038/NNANO.2013.54, 10.1038/nnano.2013.54]
   Lee WL, 2010, NEW ENGL J MED, V363, P689, DOI 10.1056/NEJMcibr1007320
   Martinez JO, 2018, THERANOSTICS, V8, P1131, DOI 10.7150/thno.22078
   Mohammadi MR, 2019, SMALL, V15, DOI 10.1002/smll.201902333
   Molinaro R, 2016, NAT MATER, V15, P1037, DOI 10.1038/NMAT4644
   Molinaro R, 2020, BIOMATER SCI-UK, V8, P333, DOI 10.1039/c9bm01766f
   Molinaro R, 2019, NANOSCALE, V11, P13576, DOI 10.1039/c9nr04253a
   Molinaro R, 2018, ADV MATER, V30, DOI 10.1002/adma.201702749
   Molinaro R, 2018, CURR MED CHEM, V25, P4208, DOI 10.2174/0929867324666170920160030
   Palomba R, 2016, SCI REP-UK, V6, DOI 10.1038/srep34422
   Parodi A, 2017, BIOMATERIALS, V147, P155, DOI 10.1016/j.biomaterials.2017.09.020
   Parodi A, 2015, NANOMEDICINE-UK, V10, P1923, DOI [10.2217/NNM.15.39, 10.2217/nnm.15.39]
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Shen S, 2019, BIOMATERIALS, V189, P60, DOI 10.1016/j.biomaterials.2018.10.029
   Thamphiwatana S, 2017, P NATL ACAD SCI USA, V114, P11488, DOI 10.1073/pnas.1714267114
   Wang TT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03915-4
   Wilson JG, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.140289
   Zhang Y, 2018, NANO LETT, V18, P1908, DOI 10.1021/acs.nanolett.7b05263
NR 27
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2079-4991
J9 NANOMATERIALS-BASEL
JI Nanomaterials
PD NOV
PY 2020
VL 10
IS 11
AR 2301
DI 10.3390/nano10112301
PG 11
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA OX8CS
UT WOS:000593786600001
PM 33233748
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zheng, HW
   Li, H
   Guo, L
   Liang, Y
   Li, J
   Wang, X
   Hu, YG
   Wang, LC
   Liao, Y
   Yang, FM
   Li, YY
   Fan, ST
   Li, DD
   Cui, PF
   Wang, QL
   Shi, HJ
   Chen, YL
   Yang, ZI
   Yang, JL
   Shen, D
   Cun, W
   Zhou, XF
   Dong, XQ
   Wang, YN
   Chen, Y
   Dai, Q
   Jin, WH
   He, ZL
   Li, QH
   Liu, LD
AF Zheng, Huiwen
   Li, Heng
   Guo, Lei
   Liang, Yan
   Li, Jing
   Wang, Xi
   Hu, Yunguang
   Wang, Lichun
   Liao, Yun
   Yang, Fengmei
   Li, Yanyan
   Fan, Shengtao
   Li, Dandan
   Cui, Pingfang
   Wang, Qingling
   Shi, Haijing
   Chen, Yanli
   Yang, Zening
   Yang, Jinling
   Shen, Dong
   Cun, Wei
   Zhou, Xiaofang
   Dong, Xingqi
   Wang, Yunchuan
   Chen, Yong
   Dai, Qing
   Jin, Weihua
   He, Zhanlong
   Li, Qihan
   Liu, Longding
TI Virulence and pathogenesis of SARS-CoV-2 infection in rhesus macaques: A
   nonhuman primate model of COVID-19 progression
SO PLOS PATHOGENS
LA English
DT Article
ID CORONAVIRUS OUTBREAK; SARS
AB Author summary
   Understanding of the pathologic process caused by SARS-CoV-2 is critical for promoting vaccine evaluations and medical treatment. Prior to the development of this model, several animal models of SARS-CoV-2 infection focused on revealing the virus shedding period, the development of interstitial pneumonia, and virus dissemination in respiratory tract. However, data describing the kinetics of the T cell response and local immune response during SARS-CoV-2 infection are lacking. Here, in our rhesus macaque model, in addition to focusing on virus shedding and interstitial pneumonia similar with human cases, we observed the response of T cell subsets and local cytokine/chemokine changes in respiratory tract regarded as the important evaluation parameters for a successful animal model of COVID-19.
   The COVID-19 has emerged as an epidemic, causing severe pneumonia with a high infection rate globally. To better understand the pathogenesis caused by SARS-CoV-2, we developed a rhesus macaque model to mimic natural infection via the nasal route, resulting in the SARS-CoV-2 virus shedding in the nose and stool up to 27 days. Importantly, we observed the pathological progression of marked interstitial pneumonia in the infected animals on 5-7 dpi, with virus dissemination widely occurring in the lower respiratory tract and lymph nodes, and viral RNA was consistently detected from 5 to 21 dpi. During the infection period, the kinetics response of T cells was revealed to contribute to COVID-19 progression. Our findings implied that the antiviral response of T cells was suppressed after 3 days post infection, which might be related to increases in the Treg cell population in PBMCs. Moreover, two waves of the enhanced production of cytokines (TGF-alpha, IL-4, IL-6, GM-CSF, IL-10, IL-15, IL-1 beta), chemokines (MCP-1/CCL2, IL-8/CXCL8, and MIP-1 beta/CCL4) were detected in lung tissue. Our data collected from this model suggested that T cell response and cytokine/chemokine changes in lung should be considered as evaluation parameters for COVID-19 treatment and vaccine development, besides of observation of virus shedding and pathological analysis.
C1 [Zheng, Huiwen; Li, Heng; Guo, Lei; Liang, Yan; Li, Jing; Wang, Xi; Hu, Yunguang; Wang, Lichun; Liao, Yun; Yang, Fengmei; Li, Yanyan; Fan, Shengtao; Li, Dandan; Cui, Pingfang; Wang, Qingling; Shi, Haijing; Chen, Yanli; Yang, Zening; Yang, Jinling; Shen, Dong; Cun, Wei; Wang, Yunchuan; Chen, Yong; Dai, Qing; Jin, Weihua; He, Zhanlong; Li, Qihan; Liu, Longding] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Kunming, Yunnan, Peoples R China.
   [Zhou, Xiaofang] Yunnan Prov Ctr Dis Control & Prevent, Kunming, Yunnan, Peoples R China.
   [Dong, Xingqi] Yunnan Prov Infect Dis Hosp, Kunming, Yunnan, Peoples R China.
RP He, ZL; Li, QH; Liu, LD (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Kunming, Yunnan, Peoples R China.
EM hzl@imbcams.com.cn; liqihan@imbcams.com.cn; longdingl@gmail.com
FU Kunming National High-level Biosafety Primate Research Center
FX We thank the Kunming National High-level Biosafety Primate Research
   Center for its support.
CR Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chang D, 2020, AM J RESP CRIT CARE, V201, P1150, DOI 10.1164/rccm.202003-0524LE
   Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z
   Chen J, 2010, J VIROL, V84, P1289, DOI 10.1128/JVI.01281-09
   Coperchini F, 2020, CYTOKINE GROWTH F R, V53, P25, DOI 10.1016/j.cytogfr.2020.05.003
   Falzarano D, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004250
   Ferretti L, 2020, SCIENCE, V368, P619, DOI 10.1126/science.abb6936
   Gastanaduy PA, 2013, MMWR-MORBID MORTAL W, V62, P480
   Ghinai I, 2020, LANCET, V395, P1137, DOI 10.1016/S0140-6736(20)30607-3
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jiang RD, 2020, CELL, V182, P50, DOI 10.1016/j.cell.2020.05.027
   Liao Y, 2020, J MED VIROL, V92, P2830, DOI 10.1002/jmv.26200
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Lu SY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00269-6
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Munster VJ, 2020, NATURE, DOI 10.1038/s41586-020-2324-7
   Muyayalo KP, 2020, AM J REPROD IMMUNOL, V84, DOI 10.1111/aji.13304
   Patel A, 2020, AM J TRANSPLANT, V20, P889, DOI 10.1111/ajt.15805
   Peng Yanchun, 2020, bioRxiv, DOI 10.1101/2020.06.05.134551
   Qin C, 2005, J PATHOL, V206, P251, DOI 10.1002/path.1769
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Salje H, 2020, SCIENCE, V369, P208, DOI 10.1126/science.abc3517
   Shan C, 2020, CELL RES, V30, P670, DOI 10.1038/s41422-020-0364-z
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang F, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.137799
   Wang WJ, 2020, CELL MOL IMMUNOL, V17, P650, DOI 10.1038/s41423-020-0447-2
   Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071
   WHO, 2020, COR DIS COVID 19 PAN
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Yu Pin, 2020, Animal Model Exp Med, V3, P93, DOI 10.1002/ame2.12108
   Zheng SF, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1443
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 38
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD NOV
PY 2020
VL 16
IS 11
AR e1008949
DI 10.1371/journal.ppat.1008949
PG 23
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA OX9TO
UT WOS:000593898700001
PM 33180882
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Udrea, AM
   Mernea, M
   Buiu, C
   Avram, S
AF Udrea, Ana-Maria
   Mernea, Maria
   Buiu, Catalin
   Avram, Speranta
TI Scutellaria baicalensis Flavones as Potent Drugs against Acute
   Respiratory Injury during SARS-CoV-2 Infection: Structural Biology
   Approaches
SO PROCESSES
LA English
DT Article
DE infections; antiviral; flavonoids; pharmacokinetics; pharmacodynamic;
   SARS-CoV-2; Scutellaria baicalensis; bioinformatics
ID LUNG-CANCER CELLS; SMALL-MOLECULE; MEDICINAL CHEMISTRY; INHIBITION;
   WOGONIN; CYCLOOXYGENASE-2; BAICALIN; DOCKING; PREDICTION; DISCOVERY
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can result in severe damage to the respiratory system. With no specific treatment to date, it is crucial to identify potent inhibitors of SARS-CoV-2 Chymotrypsin-like protease (3CLpro) that could also modulate the enzymes involved in the respiratory damage that accompanies SARS-CoV-2 infection. Here, flavones isolated from Scutellaria baicalensis (baicalein, baicalin, wogonin, norwogonin, and oroxylin A) were studied as possible compounds in the treatment of SARS-CoV-2 and SARS-CoV-2-induced acute lung injuries. We used structural bioinformatics and cheminformatics to (i) identify the critical molecular features of flavones for their binding activity at human and SARS-CoV-2 enzymes; (ii) predict their drug-likeness and lead-likeness features; (iii) calculate their pharmacokinetic profile, with an emphasis on toxicology; (iv) predict their pharmacodynamic profiles, with the identification of their human body targets involved in the respiratory system injuries; and (v) dock the ligands to SARS-CoV-2 3CLpro. All flavones presented appropriate drug-like and kinetics features, except for baicalin. Flavones could bind to SARS-CoV-2 3CLpro at a similar site, but interact slightly differently with the protease. Flavones' pharmacodynamic profiles predict that (i) wogonin strongly binds at the cyclooxygenase2 and nitric oxide synthase; (ii) baicalein and norwogonin could modulate lysine-specific demethylase 4D-like and arachidonate 15-lipoxygenase; and (iii) baicalein, wogonin, norwogonin, and oroxylin A bind to SARS-CoV-2 3CLpro. Our results propose these flavones as possible potent drugs against respiratory damage that occurs during SARS-CoV-2 infections, with a strong recommendation for baicalein.
C1 [Udrea, Ana-Maria; Mernea, Maria; Avram, Speranta] Univ Bucharest, Fac Biol, Dept Anat Anim Physiol & Biophys, 91-95 Splaiul Independentei, Bucharest 050095, Romania.
   [Udrea, Ana-Maria] Natl Inst Laser Plasma & Radiat Phys, Laser Dept, Atomistilor St 409,POB MG-36, RO-077125 Magurele City, Romania.
   [Buiu, Catalin] Univ Politehn Bucuresti, Dept Automat Control & Syst Engn, 313 Splaiul Independentei, Bucharest 060042, Romania.
RP Mernea, M (corresponding author), Univ Bucharest, Fac Biol, Dept Anat Anim Physiol & Biophys, 91-95 Splaiul Independentei, Bucharest 050095, Romania.; Buiu, C (corresponding author), Univ Politehn Bucuresti, Dept Automat Control & Syst Engn, 313 Splaiul Independentei, Bucharest 060042, Romania.
EM m.a.u.anamaria@gmail.com; maria.mernea@bio.unibuc.ro;
   catalin.buiu@upb.ro; speranta.avram@gmail.com
OI Udrea, Ana-Maria/0000-0002-7659-7435
FU Romanian National Authority for Scientific Research and Innovation,
   CNCS/CCCDI-UEFISCDI [PN-III-P1-1.1-PCCDI-2017-0728]
FX This work was funded by the Romanian National Authority for Scientific
   Research and Innovation, CNCS/CCCDI-UEFISCDI [grant no
   PN-III-P1-1.1-PCCDI-2017-0728].
CR Abrial C, 2015, BRIT J PHARMACOL, V172, P4319, DOI 10.1111/bph.13210
   Avram Sorin, 2020, Nucleic Acids Res, DOI 10.1093/nar/gkaa997
   Avram S, 2020, CURR MED CHEM, V27, P78, DOI 10.2174/0929867325666181031123127
   Avram S, 2018, CURR PROTEOMICS, V15, P258, DOI 10.2174/1570164615666180409151111
   Babu BR, 1998, CURR OPIN CHEM BIOL, V2, P491, DOI 10.1016/S1367-5931(98)80125-7
   Bank R.P.D., RCSB PDB 6M2N SARS C
   Betakova T, 2017, CURR PHARM DESIGN, V23, P2616, DOI 10.2174/1381612823666170316123736
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen HS, 2018, TRANSL STROKE RES, V9, P515, DOI 10.1007/s12975-017-0598-3
   Chen YC, 2001, BIOCHEM PHARMACOL, V61, P1417, DOI 10.1016/S0006-2952(01)00594-9
   Choi HJ, 2016, BIOMOL THER, V24, P552, DOI 10.4062/biomolther.2015.200
   Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Danilov AV, 2016, MOL CANCER THER, V15, P2758, DOI 10.1158/1535-7163.MCT-16-0127
   Dinda B, 2017, EUR J MED CHEM, V131, P68, DOI 10.1016/j.ejmech.2017.03.004
   Drwal MN, 2014, NUCLEIC ACIDS RES, V42, pW53, DOI 10.1093/nar/gku401
   Egan WJ, 2000, J MED CHEM, V43, P3867, DOI 10.1021/jm000292e
   Fang Yuan, 2020, Acta Pharm Sin B, DOI 10.1016/j.apsb.2020.06.007
   Ghose AK, 1999, J COMB CHEM, V1, P55, DOI 10.1021/cc9800071
   Grosdidier A, 2011, NUCLEIC ACIDS RES, V39, pW270, DOI 10.1093/nar/gkr366
   Grosdidier A, 2011, J COMPUT CHEM, V32, P2149, DOI 10.1002/jcc.21797
   Han ZQ, 2017, ONCOL LETT, V14, P5959, DOI 10.3892/ol.2017.6940
   Hastings J, 2016, NUCLEIC ACIDS RES, V44, pD1214, DOI 10.1093/nar/gkv1031
   Hsu SL, 2001, EUR J PHARMACOL, V425, P165, DOI 10.1016/S0014-2999(01)01144-X
   Huang Y, 2020, BIODATA MIN, V13, DOI 10.1186/s13040-020-00225-8
   Huang YJ, 2020, ATMOS RES, V240, DOI 10.1016/j.atmosres.2020.104939
   Kayyali US, 2001, J BIOL CHEM, V276, P14359, DOI 10.1074/jbc.M010100200
   Khan NM, 2017, FREE RADICAL BIO MED, V106, P288, DOI 10.1016/j.freeradbiomed.2017.02.041
   Kim HP, 2004, J PHARMACOL SCI, V96, P229, DOI 10.1254/jphs.CRJ04003X
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Labbe RM, 2014, AM J TRANSL RES, V6, P1
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Li TT, 2011, EUR J DRUG METAB PH, V36, P249, DOI 10.1007/s13318-011-0050-0
   Liao Y, 2020, J ETHNOPHARMACOL, V258, DOI 10.1016/j.jep.2020.112917
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Liu H, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101681
   Lovering F, 2009, J MED CHEM, V52, P6752, DOI 10.1021/jm901241e
   Manjili RH, 2020, J IMMUNOL, V205, P12, DOI 10.4049/jimmunol.2000413
   Marini JJ, 2020, JAMA-J AM MED ASSOC, V323, P2329, DOI 10.1001/jama.2020.6825
   McGonagle D, 2020, LANCET RHEUMATOL, V2, pE437, DOI 10.1016/S2665-9913(20)30121-1
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Ni T, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.261
   Ortega JT, 2020, EXCLI J, V19, P400, DOI 10.17179/excli2020-1189
   Pan XH, 2020, PHARMACOL RES, V152, DOI 10.1016/j.phrs.2019.104592
   Park GY, 2006, AM J PHYSIOL-LUNG C, V290, pL797, DOI 10.1152/ajplung.00513.2005
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Pons S, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03062-7
   Racz A, 2018, J CHEMINFORMATICS, V10, DOI 10.1186/s13321-018-0302-y
   Rossaint J, 2012, CRIT CARE, V16, DOI 10.1186/cc11518
   Russo M, 2020, CHEM-BIOL INTERACT, V328, DOI 10.1016/j.cbi.2020.109211
   Saul D, 2019, NUTR METAB, V16, DOI 10.1186/s12986-018-0327-2
   Selvaraj G, 2018, J BIOMED INFORM, V86, P120, DOI 10.1016/j.jbi.2018.09.004
   Shimizu T, 2018, J NAT MED-TOKYO, V72, P181, DOI 10.1007/s11418-017-1129-y
   Shin JW, 2012, AM J CHINESE MED, V40, P85, DOI 10.1142/S0192415X12500073
   Song JW, 2020, CHIN MED-UK, V15, DOI 10.1186/s13020-020-00384-0
   Song Junke, 2021, Biochem Pharmacol, V183, P114302, DOI 10.1016/j.bcp.2020.114302
   Su HX, 2020, ACTA PHARMACOL SIN, V41, P1167, DOI 10.1038/s41401-020-0483-6
   Sun HL, 2016, ENVIRON TOXICOL, V31, P1700, DOI 10.1002/tox.22172
   Tavassoly I, 2019, MOL ONCOL, V13, P1725, DOI 10.1002/1878-0261.12521
   Udrea AM, 2020, J PHOTOCH PHOTOBIO B, V211, DOI 10.1016/j.jphotobiol.2020.111997
   Udrea AM, 2018, FARMACIA, V66, P680, DOI 10.31925/farmacia.2018.4.18
   Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Vilar S, 2008, CURR TOP MED CHEM, V8, P1555, DOI 10.2174/156802608786786624
   Wang X, 2018, CELL DEATH DISCOV, V4, DOI 10.1038/s41420-018-0046-5
   Wood DJ, 2012, J CHEM INF MODEL, V52, P2031, DOI 10.1021/ci3000776
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhao Q, 2016, SCI BULL, V61, P1391, DOI 10.1007/s11434-016-1136-5
   Zhao TT, 2019, J PHARM PHARMACOL, V71, P1353, DOI 10.1111/jphp.13129
   Zheng YC, 2016, BIOORG CHEM, V69, P129, DOI 10.1016/j.bioorg.2016.10.004
   Zhi HJ, 2019, PHYTOMEDICINE, V57, P105, DOI 10.1016/j.phymed.2018.12.009
   Zhu JY, 2020, J MED VIROL, V92, P1902, DOI 10.1002/jmv.25884
NR 75
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2227-9717
J9 PROCESSES
JI Processes
PD NOV
PY 2020
VL 8
IS 11
AR 1468
DI 10.3390/pr8111468
PG 19
WC Engineering, Chemical
SC Engineering
GA OX8IY
UT WOS:000593802800001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Lopes, B
   Bortolon, C
   Jaspal, R
AF Lopes, B.
   Bortolon, C.
   Jaspal, R.
TI Paranoia, hallucinations and compulsive buying during the early phase of
   the COVID-19 outbreak in the United Kingdom: A preliminary experimental
   study
SO PSYCHIATRY RESEARCH
LA English
DT Article
DE Paranoia; Hallucinations; Compulsive buying; Fear of COVID-19; COVID-19
ID SOCIAL ANXIETY; PREDISPOSITION; POPULATION; STRESS; HEALTH; IMPACT
AB This study examines the impact of COVID-19 (in the early phase of the outbreak) on symptoms of psychosis, namely paranoia and hallucinations. Three hundred and sixty-one people in the United Kingdom participated in a 2 (self-isolation vs. no self-isolation) x 2 (perceived COVID-19 symptomatology vs. no perceived COVID-19 symptomatology) x 2 (exposure to COVID-19 news vs. control) experiment online. Participants completed measures of political trust, social network, fear of COVID-19, current paranoid thoughts, hallucinatory experi-ences and compulsive buying. Kruskal-Wallis results showed that employed people and students are more prone to paranoia and hallucinatory experiences in response to COVID-19 news. A multigroup model showed a moderation effect of the news conditions in the COVID-19 news condition, fear of COVID-19 and political trust significantly predict the variance of paranoia, hallucinatory experiences and compulsive buying and these co vary with each other but not in the control condition. In line with cognitive and social theories of paranoia, results suggest that negative affect and low political trust are linked to the presence of paranoid thoughts and hallucinatory experiences and compulsive buying amid COVID-19. Digitized and Tailored Cognitive and Behavioral Therapy are proposed to address the psychiatric impact of COVID-19.
C1 [Lopes, B.] Univ Coimbra, Ctr Res Neuropsychol & Cognit Behav Intervent CIN, Fac Psicol & Ciencias Educ, Rua Colegio Novo, P-3001802 Coimbra, Portugal.
   [Bortolon, C.] Univ Grenoble Alpes UFR SHS, Lab Interuniv Psychol Personnalite Cognit & Chang, 1251 Ave Cent,CS 40700, F-38058 Grenoble 9, France.
   [Jaspal, R.] Nottingham Trent Univ, Sch Social Sci, 50 Shakespeare St, Nottingham NG1 4FQ, England.
RP Lopes, B (corresponding author), Univ Coimbra, Ctr Res Neuropsychol & Cognit Behav Intervent CIN, Fac Psicol & Ciencias Educ, Rua Colegio Novo, P-3001802 Coimbra, Portugal.
EM barbaracslopes@gmail.com; catherine.bortolon@univ-grenoble-alpes.fr;
   rusi.jaspal@ntu.ac.uk
OI Lopes, Barbara/0000-0002-1400-020X
FU Nottingham Trent University in the UK
FX This research was funded by Nottingham Trent University in the UK.
CR Ahorsu DK, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00270-8
   Aupers S, 2012, EUR J COMMUN, V27, P22, DOI 10.1177/0267323111433566
   Benrimoh D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212379
   Berg AO, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-77
   Bortolon C., 2020, PERSECUTORY IDEATION
   Butter S, 2017, PSYCHOSIS, V9, P291, DOI 10.1080/17522439.2017.1349829
   Chalmers RP, 2012, J STAT SOFTW, V48, P1
   Cheung K.C., 2008, SOC WORK PUBLIC HLTH, V5, P41, DOI [10.1080/19371910802053224, DOI 10.1080/19371910802053224]
   Corcoran Cheryl, 2002, CNS Spectr, V7, P33
   da Rocha BM, 2018, SCHIZOPHRENIA BULL, V44, P114, DOI 10.1093/schbul/sbx036
   Lopes BCD, 2020, PSYCHOL TRAUMA-US, V12, P465, DOI 10.1037/tra0000632
   Edwards E. A., 1993, FINANCIAL COUNSELING, V4, P67
   Ellett L, 2003, J NERV MENT DIS, V191, P425, DOI 10.1097/01.NMD.0000081646.33030.EF
   FENIGSTEIN A, 1992, J PERS SOC PSYCHOL, V62, P129, DOI 10.1037/0022-3514.62.1.129
   Freeman D, 2008, PSYCHOL MED, V38, P1121, DOI 10.1017/S0033291708003589
   Freeman D, 2011, PSYCHOL MED, V41, P923, DOI 10.1017/S0033291710001546
   Freeman D, 2005, BRIT J PSYCHIAT, V186, P427, DOI 10.1192/bjp.186.5.427
   Freeman D, 2014, SOC PSYCH PSYCH EPID, V49, P1045, DOI 10.1007/s00127-013-0803-y
   Gallagher CE, 2017, PERS INDIV DIFFER, V104, P37, DOI 10.1016/j.paid.2016.07.023
   Gilbert P, 2001, PSYCHIAT CLIN N AM, V24, P723, DOI 10.1016/S0193-953X(05)70260-4
   Hall E, 2020, J HIGH ENERGY PHYS, DOI 10.1007/JHEP04(2020)042
   Harper D, 2008, SURVEILL SOC, V5, P1
   Harper K, 2019, FOOD VALUES IN EUROPE, P1
   Harrop C, 2001, CLIN PSYCHOL REV, V21, P241, DOI 10.1016/S0272-7358(99)00047-1
   Hier SP, 2003, BRIT J SOCIOL, V54, P3, DOI 10.1080/0007131032000045879
   Jaspal R, 2020, MENT HEALTH RELIG CU, V23, P427, DOI 10.1080/13674676.2020.1784119
   Jaspal R, 2020, COGENT PSYCHOL, V7, DOI 10.1080/23311908.2020.1800924
   Jaspal R, 2020, PSYCHOL TRAUMA-US, V12, pS249, DOI 10.1037/tra0000773
   Jolley D., 2020, CONVERSATION
   Kanter J., 2020, CONVERSATION
   Kline R. B., 2005, PRINCIPLES PRACTICES
   Kramer RM, 2002, HARVARD BUS REV, V80, P62
   Lamster F, 2017, J BEHAV THER EXP PSY, V54, P51, DOI 10.1016/j.jbtep.2016.06.005
   LAUNAY G, 1981, PERS INDIV DIFFER, V2, P221, DOI 10.1016/0191-8869(81)90027-1
   Lincoln TM, 2009, PSYCHOL MED, V39, P1129, DOI 10.1017/S0033291708004613
   Lopes B, 2019, COMMUNITY MENT HLT J, V55, P336, DOI 10.1007/s10597-018-0259-3
   Lopes B., 2020, IMPACT COVID 19 NEWS
   Lopes B, 2015, MENT HEALTH RELIG CU, V18, P380, DOI 10.1080/13674676.2015.1065475
   Lopes B, 2013, BEHAV COGN PSYCHOTH, V41, P221, DOI 10.1017/S1352465812000483
   Lopes BC, 2019, J LEADERSH ORG STUD, V26, P237, DOI 10.1177/1548051818795821
   Lubben J, 2006, GERONTOLOGIST, V46, P503, DOI 10.1093/geront/46.4.503
   Macaskill A, 2013, BRIT J GUID COUNS, V41, P426, DOI 10.1080/03069885.2012.743110
   Morrison AP, 2000, BRIT J CLIN PSYCHOL, V39, P67, DOI 10.1348/014466500163112
   Muller A, 2015, AM J ADDICTION, V24, P132, DOI 10.1111/ajad.12111
   Mutz DC, 2005, AM POLIT SCI REV, V99, P1, DOI 10.1017/S0003055405051452
   OLIVER D, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1153
   Pew Research Center, 2020, NEARL 3 IN 10 AM BEL
   Qiu JY, 2020, GEN PSYCHIAT, V33, DOI 10.1136/gpsych-2020-100213
   Raihani NJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04805-3
   Rothstein Mark A, 2007, Am J Public Health, V97 Suppl 1, pS49, DOI 10.2105/AJPH.2006.097303
   Satorra A, 2000, ADV ST THEO, V36, P233
   Schermelleh-Engel K., 2003, METHODS PSYCHOL RES, V8, P23, DOI DOI 10.1002/0470010940
   Shevlin M., 2020, ANXIETY DEPRESSION T, DOI [10.31234/ osf.io/hb6nq, DOI 10.31234/OSF.IO/HB6NQ, 10.31234/osf.io/hb6nq]
   Stansfeld S., 2016, DIGITAL
   Statista, 2020, UN RAT FOR UK 1 Q 20
   Terry DJ, 2003, AUST PSYCHOL, V38, P92, DOI 10.1080/00050060310001707097
   Thompson RR, 2017, CLIN PSYCHOL SCI, V5, P513, DOI 10.1177/2167702617692030
   Torales J, 2020, INT J SOC PSYCHIATR, V66, P317, DOI 10.1177/0020764020915212
   Towers S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129179
   van Os J, 2009, PSYCHOL MED, V39, P179, DOI 10.1017/S0033291708003814
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Waters F, 2017, SCHIZOPHRENIA BULL, V43, P32, DOI 10.1093/schbul/sbw132
   World Health Organization (WHO), 1993, ICD 10 CLASS MENT BE
   Zhou XY, 2020, TELEMED E-HEALTH, V26, P377, DOI 10.1089/tmj.2020.0068
NR 64
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0165-1781
J9 PSYCHIAT RES
JI Psychiatry Res.
PD NOV
PY 2020
VL 293
AR 113455
DI 10.1016/j.psychres.2020.113455
PG 10
WC Psychiatry
SC Psychiatry
GA OU5SO
UT WOS:000591588800002
PM 32980714
OA Green Published
DA 2021-01-01
ER

PT J
AU Choi, Y
   Shin, B
   Kang, K
   Park, S
   Beck, BR
AF Choi, Yoonjung
   Shin, Bonggun
   Kang, Keunsoo
   Park, Sungsoo
   Beck, Bo Ram
TI Target-Centered Drug Repurposing Predictions of Human
   Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Protease Serine
   Subtype 2 (TMPRSS2) Interacting Approved Drugs for Coronavirus Disease
   2019 (COVID-19) Treatment through a Drug-Target Interaction Deep
   Learning Model
SO VIRUSES-BASEL
LA English
DT Article
DE COVID-19; SARS-CoV-2; coronavirus; deep learning; drug repurposing;
   ACE2; TMPRSS2
ID DISCOVERY; POLYPHARMACOLOGY; PHARMACOLOGY; RECEPTOR; GENE
AB Previously, our group predicted commercially available Food and Drug Administration (FDA) approved drugs that can inhibit each step of the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using a deep learning-based drug-target interaction model called Molecule Transformer-Drug Target Interaction (MT-DTI). Unfortunately, additional clinically significant treatment options since the approval of remdesivir are scarce. To overcome the current coronavirus disease 2019 (COVID-19) more efficiently, a treatment strategy that controls not only SARS-CoV-2 replication but also the host entry step should be considered. In this study, we used MT-DTI to predict FDA approved drugs that may have strong affinities for the angiotensin-converting enzyme 2 (ACE2) receptor and the transmembrane protease serine 2 (TMPRSS2) which are essential for viral entry to the host cell. Of the 460 drugs with K-d of less than 100 nM for the ACE2 receptor, 17 drugs overlapped with drugs that inhibit the interaction of ACE2 and SARS-CoV-2 spike reported in the NCATS OpenData portal. Among them, enalaprilat, an ACE inhibitor, showed a K-d value of 1.5 nM against the ACE2. Furthermore, three of the top 30 drugs with strong affinity prediction for the TMPRSS2 are anti-hepatitis C virus (HCV) drugs, including ombitasvir, daclatasvir, and paritaprevir. Notably, of the top 30 drugs, AT1R blocker eprosartan and neuropsychiatric drug lisuride showed similar gene expression profiles to potential TMPRSS2 inhibitors. Collectively, we suggest that drugs predicted to have strong inhibitory potencies to ACE2 and TMPRSS2 through the DTI model should be considered as potential drug repurposing candidates for COVID-19.
C1 [Choi, Yoonjung; Shin, Bonggun; Park, Sungsoo; Beck, Bo Ram] Deargen Inc, Daejeon 34051, South Korea.
   [Kang, Keunsoo] Dankook Univ, Dept Microbiol, Coll Nat Sci, Cheonan 31116, South Korea.
RP Beck, BR (corresponding author), Deargen Inc, Daejeon 34051, South Korea.
EM yoonjungc@deargen.me; bonggun.shin@deargen.me; kangk1204@dankook.ac.kr;
   sspark@deargen.me; brbr777@deargen.me
OI Beck, Bo Ram/0000-0002-1575-3019
FU National Research Foundation of Korea (NRF) - Ministry of Science and
   ICT (MIST) [NRF-2020M3A9I2081698]
FX The present study was supported by the National Research Foundation of
   Korea (NRF, grant number NRF-2020M3A9I2081698) funded by the Ministry of
   Science and ICT (MIST).
CR Anighoro A, 2014, J MED CHEM, V57, P7874, DOI 10.1021/jm5006463
   Balmeh Negar, 2020, Inform Med Unlocked, V20, P100407, DOI 10.1016/j.imu.2020.100407
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   Brimacombe Kyle R, 2020, bioRxiv, DOI 10.1101/2020.06.04.135046
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Du FH, 2020, J THROMB THROMBOLYS, DOI 10.1007/s11239-020-02224-2
   Duan QN, 2014, NUCLEIC ACIDS RES, V42, pW449, DOI 10.1093/nar/gku476
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Fintelman-Rodrigues Natalia, 2020, Antimicrob Agents Chemother, V64, DOI 10.1128/AAC.00825-20
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hosseini FS, 2020, LIFE SCI, V258, DOI 10.1016/j.lfs.2020.118205
   Jia ZL, 2020, PATHOG DIS, V78, DOI 10.1093/femspd/ftaa036
   Kang K, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12070776
   Keidar S, 2007, CARDIOVASC RES, V73, P463, DOI 10.1016/j.cardiores.2006.09.006
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Lambert DW, 2008, FEBS LETT, V582, P385, DOI 10.1016/j.febslet.2007.11.085
   Lambert DW, 2005, J BIOL CHEM, V280, P30113, DOI 10.1074/jbc.M505111200
   Ledford H, 2020, NATURE, V582, P469, DOI 10.1038/d41586-020-01824-5
   Liu TQ, 2007, NUCLEIC ACIDS RES, V35, pD198, DOI 10.1093/nar/gkl999
   Maggio R, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104837
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   PaoloniGiacobino A, 1997, GENOMICS, V44, P309, DOI 10.1006/geno.1997.4845
   Qu XYA, 2012, DRUG DISCOV TODAY, V17, P1289, DOI 10.1016/j.drudis.2012.07.017
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Shin B., 2019, ARXIV190806760
   Siegel D, 2017, J MED CHEM, V60, P1648, DOI 10.1021/acs.jmedchem.6b01594
   Singh AK, 2020, DIABETES METAB SYND, V14, P641, DOI 10.1016/j.dsx.2020.05.018
   Sonawane K., 2020, HOMOLOGY MODELING DO, DOI [10.26434/chemrxiv.12162360, DOI 10.26434/CHEMRXIV.12162360]
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Sun M L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P219, DOI [10.3760/cma.j.issn.1001-0939.2020.0014, 10.3760/cma.j.issn.1001-0939.2020.03.016]
   Tanoli Z, 2018, DATABASE-OXFORD, DOI 10.1093/database/bay083
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Turner AJ, 2002, CAN J PHYSIOL PHARM, V80, P346, DOI 10.1139/Y02-021
   Uno Y, 2020, INTERN EMERG MED, V15, P1577, DOI 10.1007/s11739-020-02345-9
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Xiao L, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050491
   Zhang WJ, 2016, CURR PHARM DESIGN, V22, P3171, DOI 10.2174/1381612822666160224142812
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 44
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD NOV
PY 2020
VL 12
IS 11
AR 1325
DI 10.3390/v12111325
PG 11
WC Virology
SC Virology
GA OX8BO
UT WOS:000593783600001
PM 33218024
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ansari, MA
   Jamal, QMS
   Rehman, S
   Almatroudi, A
   Alzohairy, MA
   Alomary, MN
   Tripathi, T
   Alharbi, AH
   Adil, SF
   Khan, M
   Malik, MS
AF Ansari, Mohammad Azam
   Jamal, Qazi Mohammad Sajid
   Rehman, Suriya
   Almatroudi, Ahmad
   Alzohairy, Mohammad A.
   Alomary, Mohammad N.
   Tripathi, Takshashila
   Alharbi, Ali H.
   Adil, Syed Farooq
   Khan, Mujeeb
   Malik, M. Shaheer
TI TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease
   (3CLpro): Potential therapeutic intervention to combat COVID-19
SO ARABIAN JOURNAL OF CHEMISTRY
LA English
DT Article
DE SARS-CoV-2; TAT-peptide; 3CL(pro) main protease; COVID-19; In silico;
   Molecular docking; Repurposing drug
ID PNEUMONIA; SARS; DELIVERY; MERS
AB The Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that originated in Chinese city of Wuhan has caused around 906,092 deaths and 28,040,853 confirmed cases worldwide (https://covid19.who.int/, 11 September 2020). In a life-threatening situation, where there is no specific and licensed anti-COVID-19 vaccine or medicine available; the repurposed drug might act as a silver bullet. Currently, more than 211 vaccines, 80 antibodies, 31 antiviral drugs, 35 cell-based, 6 RNA-based and 131 other drugs are in clinical trials. It is therefore utter need of the hour to develop an effective drug that can be used for the treatment of COVID-19 before a vaccine can be developed. One of the best-characterized and attractive drug targets among coronaviruses is the main protease (3CL(pro)). Therefore, the current study focuses on the molecular docking analysis of TAT-peptide(47) (57 )(GRKKRRQRRRP)-conjugated repurposed drugs (i.e., lopinavir, ritonavir, favipiravir, and hydroxychloroquine) with SARS-CoV-2 main protease (3CL(pro)) to discover potential efficacy of TAT-peptide (TP) - conjugated repurposing drugs against SARS-CoV-2. The molecular docking results validated that TP-conjugated ritonavir, lopinavir, favipiravir, and hydroxychloroquine have superior and significantly enhanced interactions with the target SARS-CoV-2 main protease. In-silico approach employed in this study suggests that the combination of the drug with TP is an excelling alternative to develop a novel drug for the treatment of SARS-CoV-2 infected patients. The development of TP based delivery of repurposing drugs might be an excellent approach to enhance the efficacy of the existing drugs for the treatment of COVID-19. The predictions from the results obtained provide invaluable information that can be utilized for the choice of candidate drugs for in vitro, in vivo and clinical trials. The outcome from this work prove crucial for exploring and developing novel cost-effective and biocompatible TP conjugated anti-SARS-CoV-2 therapeutic agents in immediate future. (C) 2020 Published by Elsevier B.V. on behalf of King Saud University.
C1 [Ansari, Mohammad Azam; Rehman, Suriya] Imam Abdulrahman Bin Faisal Univ, Inst Res & Med Consultat IRMC, Dept Epidem Dis Res, POB 1982, Dammam 31441, Saudi Arabia.
   [Jamal, Qazi Mohammad Sajid; Alharbi, Ali H.] Qassim Univ, Coll Publ Hlth & Hlth Informat, Dept Hlth Informat, Al Bukayriyah, Saudi Arabia.
   [Almatroudi, Ahmad; Alzohairy, Mohammad A.] Qassim Univ, Coll Appl Med Sci, Dept Med Labs, Qasim 51431, Saudi Arabia.
   [Alomary, Mohammad N.] King Abdulaziz City Sci & Technol, Life Sci & Environm Res Inst, Natl Ctr Biotechnol, POB 6086, Riyadh, Saudi Arabia.
   [Tripathi, Takshashila] UCL, Dept Neurosci Physiol & Pharmacol, London, England.
   [Adil, Syed Farooq; Khan, Mujeeb] King Saud Univ, Coll Sci, Dept Chem, Riyadh 11451, Saudi Arabia.
   [Malik, M. Shaheer] Umm Al Qura Univ, Fac Appl Sci, Dept Chem, Mecca 21955, Saudi Arabia.
RP Ansari, MA (corresponding author), Imam Abdulrahman Bin Faisal Univ, Inst Res & Med Consultat IRMC, Dept Epidem Dis Res, POB 1982, Dammam 31441, Saudi Arabia.; Almatroudi, A (corresponding author), Qassim Univ, Coll Appl Med Sci, Dept Med Labs, Qasim 51431, Saudi Arabia.; Alomary, MN (corresponding author), King Abdulaziz City Sci & Technol, Life Sci & Environm Res Inst, Natl Ctr Biotechnol, POB 6086, Riyadh, Saudi Arabia.
EM maansari@iau.edu.sa; aamtrody@qu.edu.sa; malomary@kacst.edu.sa
OI Almatroudi, Ahmad/0000-0002-1491-6402; Alharbi, Ali/0000-0003-1815-7287
FU Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
   [Covid19-2020-002-IRMC]
FX Deanship of Scientific Research, Imam Abdulrahman Bin Faisal University,
   Dammam, Saudi Arabia, Grant number Covid19-2020-002-IRMC.
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Ansari M.A., 2020, EXPERT OPIN DRUG DEL, V31, P1
   Bechara C, 2013, FEBS LETT, V587, P1693, DOI 10.1016/j.febslet.2013.04.031
   Benkert P, 2011, BIOINFORMATICS, V27, P343, DOI 10.1093/bioinformatics/btq662
   Bhattacharya Manojit, 2020, Inform Med Unlocked, V20, P100394, DOI 10.1016/j.imu.2020.100394
   Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736
   Chakraborty C, 2020, EUR REV MED PHARMACO, V24, P4016, DOI 10.26355/eurrev_202004_20871
   Chakraborty Chiranjib, 2020, Arch Med Res, V51, P728, DOI 10.1016/j.arcmed.2020.05.021
   Chakraborty C, 2020, ASIAN PAC J TROP MED, V13, P242, DOI 10.4103/1995-7645.281613
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Ciobanasu C, 2010, BIOPHYS J, V99, P153, DOI 10.1016/j.bpj.2010.03.065
   Fang SL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057318
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gaurav C., 2020, ACS NANO, DOI [10.1021/acsnano.0c04006, DOI 10.1021/ACSNANO.0C04006.]
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lamiable A, 2016, NUCLEIC ACIDS RES, V44, pW449, DOI 10.1093/nar/gkw329
   Lembo D, 2018, EXPERT OPIN DRUG DEL, V15, P93, DOI 10.1080/17425247.2017.1360863
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Liu X, 2020, J GENET GENOMICS, V47, P119, DOI 10.1016/j.jgg.2020.02.001
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Nguyen Duc Duy, 2020, bioRxiv, DOI 10.1101/2020.02.05.936013
   Nori A, 2003, BIOCONJUGATE CHEM, V14, P44, DOI 10.1021/bc0255900
   Parn K, 2015, METHODS MOL BIOL, V1324, P223, DOI 10.1007/978-1-4939-2806-4_15
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Quan XB, 2019, PHYS CHEM CHEM PHYS, V21, P10300, DOI 10.1039/c9cp01543d
   Rehman S., 2020, SAUDI J BIOL SCI, DOI [10.1016/2Fj.sjbs.2020.05.024, DOI 10.1016/2FJ.SJBS.2020.05.024.]
   Saha A, 2020, ARCH MED RES, V51, P595, DOI 10.1016/j.arcmed.2020.05.009
   Saha A, 2020, ARCH MED RES, V51, P585, DOI 10.1016/j.arcmed.2020.05.001
   Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481
   Sekhar T., 2020, VIRTUAL SCREENING BA, DOI 10.20944/preprints202002.0418.v2
   Skwarczynski M, 2019, THER DELIV, V10, P465, DOI 10.4155/tde-2019-0042
   Tripathi Prem Prakash, 2018, Oncotarget, V9, P37252, DOI 10.18632/oncotarget.26442
   Vanommeslaeghe K, 2010, J COMPUT CHEM, V31, P671, DOI 10.1002/jcc.21367
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Weiss C, 2020, ACS NANO, V14, P6383, DOI 10.1021/acsnano.0c03697
   Xu Z., 2020, BIORXIV, DOI [10.1101/2020.01.27.921627, DOI 10.1101/2020.01.27.921627.]
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 47
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1878-5352
EI 1878-5379
J9 ARAB J CHEM
JI Arab. J. Chem.
PD NOV
PY 2020
VL 13
IS 11
BP 8069
EP 8079
DI 10.1016/j.arabjc.2020.09.037
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA OJ3FZ
UT WOS:000583851900037
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kumar, D
   Chauhan, G
   Kalra, S
   Kumar, B
   Gill, MS
AF Kumar, Devendra
   Chauhan, Gaurav
   Kalra, Sourav
   Kumar, Bhupinder
   Gill, Manjinder Singh
TI A perspective on potential target proteins of COVID-19: Comparison with
   SARS-CoV for designing new small molecules
SO BIOORGANIC CHEMISTRY
LA English
DT Article
DE SARS-CoV-2; COVID-19; SARS-CoV-2 spike (S) protein; RNA dependent RNA
   polymerase; 3CL or Mpro Protease; Clinical trials
ID RESPIRATORY SYNDROME CORONAVIRUS; RNA-POLYMERASE; BAT CORONAVIRUSES;
   SPIKE PROTEIN; INHIBITORS; SARS-COV-2; DIVERSITY; PNEUMONIA; OUTBREAK;
   BINDING
AB SARS-CoV-2 (COVID-19) epidemic has created an unprecedented medical and economic crisis all over the world. SARS-CoV-2 is found to have more contagious character as compared to MERS-CoV and is spreading in a very fast manner all around the globe. It has affected over 31 million people all over the world till date. This virus shares around 80% of genome similarity with SARS-CoV. In this perspective, we have explored three major targets namely; SARS-CoV-2 spike (S) protein, RNA dependent RNA polymerase, and 3CL or Mpro Protease for the in-hibition of SARS-CoV-2. These targets have attracted attention of the medicinal chemists working on computer aided drug design in developing new small molecules that might inhibit these targets for combating COVID-19 disease. Moreover, we have compared the similarity of these target proteins with earlier reported coronavirus (SARS-CoV). We have observed that both the coronaviruses share around 80% similarity in their amino acid sequence. The key amino acid interactions which can play a crucial role in designing new small molecule in-hibitors against COVID-19 have been reported in this perspective. Authors believe that this study will help the medicinal chemists to understand the key amino acids essential for interactions at the active site of target proteins in SARS-CoV-2, based on their similarity with earlier reported viruses. In this review, we have also described the lead molecules under various clinical trials for their efficacy against COVID-19.
C1 [Kumar, Devendra; Kumar, Bhupinder] ISF Coll Pharm, Dept Pharmaceut Chem, GT Rd, Moga 142001, Punjab, India.
   [Chauhan, Gaurav] Tecnol Monterrey, Sch Engn & Sci, Av Eugenio Garza Sada 2501 Sur, Monterrey 64849, Nuevo Leon, Mexico.
   [Kalra, Sourav; Gill, Manjinder Singh] Natl Inst Pharmaceut Educ & Res, Dept Pharmaceut Technol Proc Chem, SAS Nagar,Sect 67, Mohali 160062, Punjab, India.
RP Kumar, B (corresponding author), ISF Coll Pharm, Dept Pharmaceut Chem, GT Rd, Moga 142001, Punjab, India.; Gill, MS (corresponding author), Natl Inst Pharmaceut Educ & Res, Dept Pharmaceut Technol Proc Chem, SAS Nagar,Sect 67, Mohali 160062, Punjab, India.
EM bhupinderkumar@isfcp.org; msingh@niper.ac.in
OI Kalra, Sourav/0000-0002-0651-4825
FU ICMRIndian Council of Medical Research (ICMR)
FX The authors are thankful to Chairman and Director of ISF College of
   Pharmacy, Moga, Punjab for supporting this work. Sourav is thankful to
   ICMR for RA fellowship. Author's are also thankful to Dr. Vinod Kumar,
   Associate Professor, Central University of Punjab for his valuable
   inputs and guidance and Ms. Karamjeet Kaur, Assistant Professor, ISF
   College of Pharmacy for help in the manuscript.
CR Adedeji AO, 2013, J VIROL, V87, P8017, DOI 10.1128/JVI.00998-13
   Ahn DG, 2012, ARCH VIROL, V157, P2095, DOI 10.1007/s00705-012-1404-x
   Al-Osail AM, 2017, MULTIDISCIP RESP MED, V12, DOI 10.1186/s40248-017-0101-8
   Al-Tawfiq JA, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101615
   Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327
   Anthony SJ, 2017, MBIO, V8, DOI [10.1128/mBio.00373-17, 10.1128/mbio.00373-17]
   Anthony SJ, 2017, VIRUS EVOL, V3, DOI 10.1093/ve/vex012
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Bassetti M, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13209
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Cai GJ, 2020, STEEL RES INT, DOI 10.1002/srin.202000269
   Cai Q., 2020, ENG ACCEPTED, DOI [10.1016/j.52296, DOI 10.1016/J.52296]
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cascella M, 2020, FEATURES EVALUATION
   Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P241
   Chan JFW, 2015, CLIN MICROBIOL REV, V28, P465, DOI 10.1128/CMR.00102-14
   Chauhan G, 2020, ACS NANO, V14, P7760, DOI 10.1021/acsnano.0c04006
   Chen H., 2007, J VIROL, V81, P4012
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng R.Z., 2020, BIOORG CHEM, V5, P100028
   Corman VM, 2016, P NATL ACAD SCI USA, V113, P9864, DOI 10.1073/pnas.1604472113
   Corman VM, 2015, J VIROL, V89, P11858, DOI 10.1128/JVI.01755-15
   Corman VM, 2013, J GEN VIROL, V94, P1984, DOI 10.1099/vir.0.054841-0
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Cui J, 2007, EMERG INFECT DIS, V13, P1526, DOI 10.3201/eid1310.070448
   de Lartigue J, 2009, TRAFFIC, V10, P883, DOI 10.1111/j.1600-0854.2009.00915.x
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Drexler JF, 2014, ANTIVIR RES, V101, P45, DOI 10.1016/j.antiviral.2013.10.013
   Du Toit A, 2020, NAT REV MICROBIOL, V18, P123, DOI 10.1038/s41579-020-0332-0
   Eysenbach Gunther, 2006, AMIA Annu Symp Proc, P244
   Fu XL, 2018, INFECT GENET EVOL, V62, P179, DOI 10.1016/j.meegid.2018.04.031
   Furuta Y, 2013, ANTIVIR RES, V100, P446, DOI 10.1016/j.antiviral.2013.09.015
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Grant WB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040988
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo YR, 2019, MILITARY MED RES, V7, P1
   He JH, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040428
   He KM, 2017, NATURE, V552, P410, DOI 10.1038/nature25146
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hu B, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0422-1
   Hui DSC, 2019, INFECT DIS CLIN N AM, V33, P869, DOI 10.1016/j.idc.2019.07.001
   Ikonomov OC, 2009, BIOCHEM BIOPH RES CO, V382, P566, DOI 10.1016/j.bbrc.2009.03.063
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Johnson MA, 2010, J MOL BIOL, V402, P619, DOI 10.1016/j.jmb.2010.07.043
   Kalra S, 2017, EUR J MED CHEM, V142, P424, DOI 10.1016/j.ejmech.2017.08.071
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lee PI, 2020, J MICROBIOL IMMUNOL, V53, P365, DOI 10.1016/j.jmii.2020.02.001
   Lehmann KC, 2015, NUCLEIC ACIDS RES, V43, P8416, DOI 10.1093/nar/gkv838
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li GL, 2019, ADV EXP MED BIOL, V1101, P149, DOI 10.1007/978-981-13-2050-7_6
   Li H, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105951
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Lin XD, 2017, VIROLOGY, V507, P1, DOI 10.1016/j.virol.2017.03.019
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Loeffelholz MJ, 2020, EMERG MICROBES INFEC, V9, P747, DOI 10.1080/22221751.2020.1745095
   Lukassen S, 2020, EMBO J, DOI 10.15252/embj.20105114
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Lythgoe MP, 2020, J ONCOL PHARM PRACT, DOI 10.1177/1078155220953879
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   McDonald SM, 2013, WIRES RNA, V4, P351, DOI 10.1002/wrna.1164
   Menachery VD, 2016, P NATL ACAD SCI USA, V113, P3048, DOI 10.1073/pnas.1517719113
   Mesa RA, 2012, NAT REV DRUG DISCOV, V11, P103, DOI 10.1038/nrd3652
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   Mishra S.S., 2020, J BIOMOL STRUCT DYN, V2019, P1
   Mokhtari RB, 2017, ONCOTARGET, V8, P38022, DOI 10.18632/oncotarget.16723
   Oldfield V, 2009, DRUGS, V69, P609, DOI 10.2165/00003495-200969050-00007
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peti W, 2005, J VIROL, V79, P12905, DOI 10.1128/JVI.79.20.12905-12913.2005
   Plosker GL, 2012, DRUGS, V72, P2289, DOI 10.2165/11209910-000000000-00000
   Prabakaran P, 2006, J BIOL CHEM, V281, P15829, DOI 10.1074/jbc.M600697200
   Praveen D, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105967
   Qiu R., 2020, OUTCOME REPORTING PR, DOI [10.1101/2020.1103.1104.20031401., DOI 10.1101/2020.1103.1104.20031401.]
   Rabby MII, 2020, J PHARM PHARM SCI, V23, P58, DOI 10.18433/jpps31002
   Rahman N, 2020, MOLECULES, V25, DOI 10.3390/molecules25102271
   Reusken CBEM, 2016, CURR OPIN VIROL, V16, P55, DOI 10.1016/j.coviro.2016.01.004
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Sabir JSM, 2016, SCIENCE, V351, P81, DOI 10.1126/science.aac8608
   Sehgal SN, 2003, TRANSPLANT P, V35, p7S, DOI 10.1016/S0041-1345(03)00211-2
   Sheahan T, 2008, J VIROL, V82, P2274, DOI 10.1128/JVI.02041-07
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Sica DA, 2005, CLIN PHARMACOKINET, V44, P797, DOI 10.2165/00003088-200544080-00003
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101
   Simmons G, 2013, ANTIVIR RES, V100, P605, DOI 10.1016/j.antiviral.2013.09.028
   Smith CS, 2016, ECOHEALTH, V13, P72, DOI 10.1007/s10393-016-1116-x
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Tang XC, 2006, J VIROL, V80, P7481, DOI 10.1128/JVI.00697-06
   Tao Y, 2017, J VIROL, V91, DOI 10.1128/JVI.01953-16
   Thompson R, 2020, LANCET INFECT DIS, V20, P280, DOI 10.1016/S1473-3099(20)30068-2
   Update W., 2003, 31 CORONAVIRUS NEVER, V16
   Velthuis AJWT, 2010, NUCLEIC ACIDS RES, V38, P203, DOI 10.1093/nar/gkp904
   W.H. Organization, 2003, SUMM PROB SARS CAS
   W.H. Organization, 2014, DIS OUTBREAK NE 0208, V14
   Wada Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035069
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang C, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010045
   Wang FH, 2016, SCI REP-UK, V6, DOI 10.1038/srep22677
   Wang X., 2020, TMPRSS2 Transcriptional Inhibition as a Therapeutic Strategy for COVID-19, DOI 10.20944/PREPRINTS202003.0360.V2
   Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Xi J., 2020, VIRUS STRAIN MILD CO, DOI [10.1101/2020.03.10.20033944, DOI 10.1101/2020.03.10.20033944]
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Yang XL, 2016, J VIROL, V90, P3253, DOI 10.1128/JVI.02582-15
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Yuan L, 2020, BIOORG CHEM, V94, DOI 10.1016/j.bioorg.2019.103417
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zeng LP, 2016, J VIROL, V90, P6573, DOI 10.1128/JVI.03079-15
   Zhai YJ, 2005, NAT STRUCT MOL BIOL, V12, P980, DOI 10.1038/nsmb999
   Zhang XH, 2020, BLOOD ADV, V4, P1307, DOI 10.1182/bloodadvances.2020001907
   Zhao Z, 2003, J MED MICROBIOL, V52, P715, DOI 10.1099/jmm.0.05320-0
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zhu R.-f., 2020, SYSTEMATIC REV REGIS, DOI [10.1101/2020.1103.1101.20029611, DOI 10.1101/2020.1103.1101.20029611]
   Ziebuhr J, 2005, CURR TOP MICROBIOL, V287, P57, DOI 10.1007/3-540-26765-4_3
NR 131
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0045-2068
EI 1090-2120
J9 BIOORG CHEM
JI Bioorganic Chem.
PD NOV
PY 2020
VL 104
AR 104326
DI 10.1016/j.bioorg.2020.104326
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA OV9NY
UT WOS:000592528600008
PM 33142431
OA Green Published
DA 2021-01-01
ER

PT J
AU Allocca, M
   Chaparro, M
   Gonzalez, HA
   Bosca-Watts, MM
   Palmela, C
   D'Amico, F
   Zacharopoulou, E
   Kopylov, U
   Ellul, P
   Bamias, G
   Ntelis, V
   Lahat, A
   Mantzaris, GJ
   Papaconstantinou, I
   Katsanos, K
   Uspenskaya, Y
   Christodoulou, D
   Ben Horin, S
   Peyrin-Biroulet, L
   Torres, J
   Sebastian, S
   Gisbert, JP
   Danese, S
   Fiorino, G
AF Allocca, Mariangela
   Chaparro, Maria
   Gonzalez, Haidee Aleman
   Bosca-Watts, Marta Maia
   Palmela, Carolina
   D'Amico, Ferdinando
   Zacharopoulou, Eirini
   Kopylov, Uri
   Ellul, Pierre
   Bamias, Giorgos
   Ntelis, Vassilios
   Lahat, Adi
   Mantzaris, Gerassimos J.
   Papaconstantinou, Ioannis
   Katsanos, Konstantinos
   Uspenskaya, Yulia
   Christodoulou, Dimitrios
   Ben Horin, Shomron
   Peyrin-Biroulet, Laurent
   Torres, Joanna
   Sebastian, Shaji
   Gisbert, Javier P.
   Danese, Silvio
   Fiorino, Gionata
TI Patients with Inflammatory Bowel Disease Are Not at Increased Risk of
   COVID-19: A Large Multinational Cohort Study
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE inflammatory bowel disease; immunosuppression; COVID-19; drugs
AB The impact of COVID-19 on inflammatory bowel disease (IBD) patients under pharmacological immunosuppression is still not clearly understood. We investigated the incidence of COVID-19 and the impact of immunosuppression and containment measures on the risk of SARS-CoV-2 infection in a large IBD cohort, from a multicenter cohort from 21st of February to 30th of June, 2020. Ninety-seven patients with IBD (43 UC, 53 CD, one unclassified IBD) and concomitant COVID-19 over a total of 23,879 patients with IBD were enrolled in the study. The cumulative incidence of SARS-CoV-2 infection in patients with IBD vs. the general population was 0.406% and 0.402% cases, respectively. Twenty-three patients (24%) were hospitalized, 21 (22%) had pneumonia, four (4%) were admitted to the Intensive Care Unit, and one patient died. Lethality in our cohort was 1% compared to 9% in the general population. At multivariable analysis, age > 65 years was associated with increased risk of pneumonia and hospitalization (OR 11.6, 95% CI 2.18-62.60; OR 5.1, 95% CI 1.10-23.86, respectively), treatment with corticosteroids increased the risk of hospitalization (OR 7.6, 95% CI 1.48-40.05), whereas monoclonal antibodies were associated with reduced risk of pneumonia and hospitalization (OR 0.1, 95% CI 0.04-0.52; OR 0.3, 95% CI 0.10-0.90, respectively). The risk of COVID-19 in patients with IBD is similar to the general population. National lockdown was effective in preventing infection in our cohort. Advanced age and treatment with corticosteroids impacted negatively on the outcome of COVID-19, whereas monoclonal antibodies did not seem to have a detrimental effect.
C1 [Allocca, Mariangela; Zacharopoulou, Eirini; Danese, Silvio] IRCCS, Humanitas Clin & Res Ctr, Via Manzoni 56, I-20089 Milan, Italy.
   [Allocca, Mariangela; D'Amico, Ferdinando; Danese, Silvio; Fiorino, Gionata] Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini 4, I-20090 Milan, Italy.
   [Chaparro, Maria; Gisbert, Javier P.] Univ Autonoma Madrid, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Hosp Univ La Princesa, Gastroenterol Unit,Inst Invest Sanitaria Princesa, Madrid 28001, Spain.
   [Gonzalez, Haidee Aleman; Sebastian, Shaji] Hull Univ Hosp NHS Trust, IBD Unit, Kingston Upon Hull HU1, N Humberside, England.
   [Bosca-Watts, Marta Maia] Univ Valencia, Univ Clin Hosp Valencia, Digest Dis Dept, IBD Unit, Valencia 46010, Spain.
   [Palmela, Carolina; Torres, Joanna] Hosp Beatriz Angelo, Div Gastroenterol, P-2620 Loures, Portugal.
   [D'Amico, Ferdinando; Peyrin-Biroulet, Laurent] Nancy Univ Hosp, Lorraine Univ, INSERM, Dept Gastroenterol,NGERE,U1256, F-54500 Vandoeuvre Les Nancy, France.
   [Kopylov, Uri; Lahat, Adi; Ben Horin, Shomron] Tel Aviv Univ, Ramat Gan & Sackler Sch Med, Sheba Med Ctr, Dept Gastroenterol, IL-59623 Jaffa, Israel.
   [Ellul, Pierre] Mater Dei Hosp, Div Gastroenterol, MT-34 Msida, Malta.
   [Bamias, Giorgos] Natl & Kapodistrian Univ Athens, Sotiria Hosp, Med Sch, GI Unit,Acad Dept Internal Med 3, Athens 210, Greece.
   [Ntelis, Vassilios] G Gennimatas Gen Hosp, Athens 210, Greece.
   [Mantzaris, Gerassimos J.] GHA Evaggelismos Ophthalmiatre Athinon Polyklin, Dept Gastroenterol, Athens 210, Greece.
   [Papaconstantinou, Ioannis] Natl & Kapodistrian Univ Athens, Med Sch, Aretaie Hosp, Acad Dept Surg 2, Athens 210, Greece.
   [Katsanos, Konstantinos; Christodoulou, Dimitrios] Univ Hosp, Div Gastroenterol, Ioannina 440, Greece.
   [Katsanos, Konstantinos; Christodoulou, Dimitrios] Univ Ioannina, Ioannina 440, Greece.
   [Uspenskaya, Yulia] Med Ctr Ne Bolit LTT, Leninsky Prospect 66, Moscow, Russia.
RP Allocca, M (corresponding author), IRCCS, Humanitas Clin & Res Ctr, Via Manzoni 56, I-20089 Milan, Italy.; Allocca, M (corresponding author), Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini 4, I-20090 Milan, Italy.
EM mariangela.allocca@humanitas.it; mariachs2005@gmail.com;
   haidee.gonzalez@hey.nhs.uk; maiabosca@yahoo.es;
   palmela.carolina@gmail.com; ferdinando.damico@humanitas.it;
   eirinizachar@gmail.com; ukopylov@gmail.com; ellul.pierre@gmail.com;
   gbamias@gmail.com; basildelis@yahoo.gr; zokadi@gmail.com;
   gjmantzaris@gmail.com; johnpapacon@hotmail.com; khkostas@hotmail.com;
   jusp@mail.ru; dchristodoulou@gmail.com; shomron.benhorin@gmail.com;
   peyrinbiroulet@gmail.com; joanatorres00@gmail.com;
   shaji.sebastian@hey.nhs.uk; javier.p.gisbert@gmail.com;
   sdanese@hotmail.com; gionataf@gmail.com
RI Danese, Silvio/ABH-9571-2020; Fiorino, Gionata/G-3124-2013
OI Danese, Silvio/0000-0001-7341-1351; Papaconstantinou,
   Ioannis/0000-0002-4614-9041; Gisbert, Javier Perez/0000-0003-2090-3445;
   Torres, Joana/0000-0003-2895-5821; Zacharopoulou,
   Eirini/0000-0001-8154-0444; Christodoulou,
   Dimitrios/0000-0001-9694-1160; Fiorino, Gionata/0000-0001-5623-2968
CR Allocca Mariangela, 2020, Pharmacol Res, V160, P105061, DOI 10.1016/j.phrs.2020.105061
   Allocca M, 2020, CLIN GASTROENTEROL H, V18, P2134, DOI 10.1016/j.cgh.2020.04.071
   Aziz M, 2020, INFLAMM BOWEL DIS, V26, pE132, DOI 10.1093/ibd/izaa170
   Aziz M, 2020, J MED VIROL, V92, P2283, DOI 10.1002/jmv.25948
   Bezzio Cristina, 2020, Gut, DOI 10.1136/gutjnl-2020-321760
   Bezzio C, 2020, GUT, V69, P1213, DOI 10.1136/gutjnl-2020-321411
   Brenner EJ, 2020, GASTROENTEROLOGY, V159, P481, DOI 10.1053/j.gastro.2020.05.032
   Carbonnel F, 1996, DIGEST DIS SCI, V41, P2471, DOI 10.1007/BF02100145
   Caruso D, 2020, RADIOLOGY, V296, pE79, DOI 10.1148/radiol.2020201237
   John Hopkins University Coronavirus Resource Center, COR RES CTR COR COV
   Kirchgesner J, 2018, GASTROENTEROLOGY, V155, P337, DOI 10.1053/j.gastro.2018.04.012
   Ma C, 2019, ALIMENT PHARM THER, V50, P5, DOI 10.1111/apt.15297
   Mazza S, 2020, GUT, V69, P1148, DOI 10.1136/gutjnl-2020-321183
   Ng SC, 2017, LANCET, V390, P2769, DOI 10.1016/S0140-6736(17)32448-0
   Panaccione R, 2019, J CROHNS COLITIS, V13, P725, DOI 10.1093/ecco-jcc/jjy223
   Rubin DT, 2020, GASTROENTEROLOGY, V159, P350, DOI 10.1053/j.gastro.2020.04.012
NR 16
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD NOV
PY 2020
VL 9
IS 11
AR 3533
DI 10.3390/jcm9113533
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA OX1KW
UT WOS:000593333600001
PM 33142843
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Belaroussi, Y
   Roblot, P
   Peiffer-Smadja, N
   Delaye, T
   Mathoulin-Pelissier, S
   Lemeux, J
   Le Moal, G
   Caumes, E
   Roblot, F
   Bleibtreu, A
AF Belaroussi, Yaniss
   Roblot, Paul
   Peiffer-Smadja, Nathan
   Delaye, Thomas
   Mathoulin-Pelissier, Simone
   Lemeux, Joffrey
   Le Moal, Gwenael
   Caumes, Eric
   Roblot, France
   Bleibtreu, Alexandre
TI Why Methodology Is Important: Coffee as a Candidate Treatment for
   COVID-19?
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE coronavirus disease 2019 (COVID-19); current therapies; symptomatic
   treatment; trimethylxanthine; methodology
ID CONTROLLED-TRIALS; PREVENTION
AB Background: During this pandemic situation, some studies have led to hasty conclusions about Corona Virus Disease-19 (COVID-19) treatment, due to a lack of methodology. This pedagogic study aimed to highlight potential biases in research on COVID-19 treatment. Methods: We evaluate the effect of coffee's active part, 1,3,7-trimethylxanthine (TMX) on patients with COVID-19. A cohort of 93 patients, with a diagnosis of COVID-19 is analyzed. Results: TMX group and control group included, respectively, 26 and 67 patients. In the TMX group, patients had a median length of stay in hospital of 5.5 days shorter than in the control group (9.5 vs. 15 days, p < 0.05). Patients in the control group were more severe than patients in the TMX group with a significantly higher National Early Warning Score 2 (NEWS-2 score) (8 vs. 6, p = 0.002). Conclusions: Multiple biases prevents us from concluding to an effect of coffee on COVID-19. Despite an important social pressure during this crisis, methodology and conscientiousness are the best way to avoid hasty conclusions that can be deleterious for patients. Identifier: NCT04395742.
C1 [Belaroussi, Yaniss; Roblot, Paul; Mathoulin-Pelissier, Simone; Lemeux, Joffrey] Univ Bordeaux, ISPED, Bordeaux Populat Hlth Res Ctr, INSERM, F-33000 Bordeaux, France.
   [Belaroussi, Yaniss; Roblot, Paul; Lemeux, Joffrey] Ctr Hosp Univ Bordeaux, Dept Neurosurg, F-33000 Bordeaux, France.
   [Peiffer-Smadja, Nathan] Univ Paris, INSERM, IAME, F-75006 Paris, France.
   [Peiffer-Smadja, Nathan] Hop Bichat Claude Bernard, AP HP, Serv Malad Infect & Trop, F-75018 Paris, France.
   [Peiffer-Smadja, Nathan] Imperial Coll London, Natl Inst Hlth Res, Hlth Protect Res Unit Healthcare Associated Infec, London SW7 2AZ, England.
   [Delaye, Thomas; Le Moal, Gwenael; Roblot, France] CHU Poitiers, Serv Malad Infect & Trop, F-86000 Poitiers, France.
   [Mathoulin-Pelissier, Simone] Inst Bergonie, Clin & Epidemiol Res Unit, INSERM CIC1401, F-33000 Bordeaux, France.
   [Le Moal, Gwenael; Roblot, France] Univ Poitiers, INSERM U1070, F-86000 Poitiers, France.
   [Caumes, Eric; Bleibtreu, Alexandre] Hop La Pitie Salpetriere, Hop Univ Pitie Salpetriere Charles Foix, AP HP, Dept Infect Dis, 47-83 Blvd Hop, F-75013 Paris, France.
   [Caumes, Eric; Bleibtreu, Alexandre] Sorbonne Univ, Inst Pierre Louis Epidemiol & Sante Publ, INSERM, F-75013 Paris, France.
   [Caumes, Eric; Bleibtreu, Alexandre] Hop La Pitie Salpetriere, Dept Infect Dis, COVID SMIT PSL STUDY GRP, 47-83 Blvd Hop, F-75013 Paris, France.
RP Bleibtreu, A (corresponding author), Hop La Pitie Salpetriere, Hop Univ Pitie Salpetriere Charles Foix, AP HP, Dept Infect Dis, 47-83 Blvd Hop, F-75013 Paris, France.; Bleibtreu, A (corresponding author), Sorbonne Univ, Inst Pierre Louis Epidemiol & Sante Publ, INSERM, F-75013 Paris, France.; Bleibtreu, A (corresponding author), Hop La Pitie Salpetriere, Dept Infect Dis, COVID SMIT PSL STUDY GRP, 47-83 Blvd Hop, F-75013 Paris, France.
EM yaniss.belaroussi@chu-bordeaux.fr; paul.roblot@chu-bordeaux.fr;
   n.peiffer-smadja@imperial.ac.uk; thomas.delaye@chu-poitiers.fr;
   simone.pelissier@u-bordeaux.fr; joffrey.lemeux@hotmail.com;
   gwenael.le-moal@chu-poitiers.fr; eric.caumes@aphp.fr;
   france.cazenave-roblot@chu-poitiers.fr; alexandre.bleibtreu@aphp.fr
RI Zixuan, Huang/ABI-3557-2020
OI Bleibtreu, Alexandre/0000-0001-5145-4174
CR Barde F, 2020, REV MED INTERNE, V41, P330, DOI 10.1016/j.revmed.2020.02.004
   Booth CM, 2014, BRIT J CANCER, V110, P551, DOI 10.1038/bjc.2013.725
   Chiu K, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2002173
   Collins R, 2020, NEW ENGL J MED, V382, P674, DOI 10.1056/NEJMsb1901642
   Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507
   Cornelis MC, 2018, J INTERN MED, V283, P544, DOI 10.1111/joim.12737
   Fiolet Thibault, 2021, Clin Microbiol Infect, V27, P19, DOI 10.1016/j.cmi.2020.08.022
   Fragkou PC, 2020, CLIN MICROBIOL INFEC, V26, P988, DOI 10.1016/j.cmi.2020.05.019
   Furukawa K, 2020, ENDOCR J, V67, P585, DOI 10.1507/endocrj.EJ19-0370
   Glasziou PP, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1847
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hammond David, 2018, CMAJ Open, V6, pE19, DOI 10.9778/cmajo.20160154
   Harper S, 2019, AM J EPIDEMIOL, V188, P840, DOI 10.1093/aje/kwy280
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Iles Irina Alexandra, 2017, Health Mark Q, V34, P187, DOI 10.1080/07359683.2017.1346432
   Jm V., LACK EFFICACY HYDROX
   Khan MS, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.2622
   Kuss O, 2016, DTSCH ARZTEBL INT, V113, P597, DOI 10.3238/arztebl.2016.0597
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Martin JH, 2020, MED J AUSTRALIA, V212, P450, DOI 10.5694/mja2.50603
   Nunan D, 2018, BMJ EVID-BASED MED, V23, P21, DOI 10.1136/ebmed-2017-110883
   Peiffer-Smadja N, 2020, J ANTIMICROB CHEMOTH, V75, P2708, DOI 10.1093/jac/dkaa223
   Peiffer-Smadja N, 2020, AM J EPIDEMIOL, V189, P1443, DOI 10.1093/aje/kwaa151
   Pizzey FK, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00050
   Salehi S, 2020, AM J ROENTGENOL, V215, P87, DOI [10.2214/AJR.20.23034, 10.2214/AJR.20.23034S.]
   Salje H, 2020, SCIENCE, V369, P208, DOI 10.1126/science.abc3517
   Schunemann H, 2011, J EPIDEMIOL COMMUN H, V65, P392, DOI 10.1136/jech.2010.119933
   Shrier I, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-70
   Stephens RG, 2019, J EXP PSYCHOL LEARN, V45, P320, DOI 10.1037/xlm0000587
   Stovitz Steven D, 2019, BMJ Evid Based Med, V24, P109, DOI 10.1136/bmjebm-2018-111069
   von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013
   Westreich D, 2013, AM J EPIDEMIOL, V177, P292, DOI 10.1093/aje/kws412
   WILLIAMSON E, 2020, NATURE 0708, DOI DOI 10.1101/2020.05.06.20092999
   Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zores F, 2020, FRONT CARDIOVASC MED, V7, DOI 10.3389/fcvm.2020.00071
NR 36
TC 0
Z9 0
U1 3
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD NOV
PY 2020
VL 9
IS 11
AR 3691
DI 10.3390/jcm9113691
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA OX1CZ
UT WOS:000593313100001
PM 33213035
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cordeanu, EM
   Jambert, L
   Severac, F
   Lambach, H
   Tousch, J
   Heitz, M
   Mirea, C
   Hamade, A
   Younes, W
   Frantz, AS
   Merdji, H
   Schini-Kerth, V
   Bilbault, P
   Meziani, F
   Ohlmann, P
   Andres, E
   Stephan, D
AF Cordeanu, Elena-Mihaela
   Jambert, Lucas
   Severac, Francois
   Lambach, Helene
   Tousch, Jonathan
   Heitz, Marie
   Mirea, Corina
   Hamade, Amer
   Younes, Wael
   Frantz, Anne-Sophie
   Merdji, Hamid
   Schini-Kerth, Valerie
   Bilbault, Pascal
   Meziani, Ferhat
   Ohlmann, Patrick
   Andres, Emmanuel
   Stephan, Dominique
TI Outcomes of COVID-19 Hospitalized Patients Previously Treated with
   Renin-Angiotensin System Inhibitors
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE COVID-19; SARS-CoV-2; renin&#8211; angiotensin system inhibitor;
   angiotensin-converting enzyme; angiotensin II receptor blocker;
   propensity score
ID CONVERTING ENZYME 2; ACE2; CORONAVIRUS; ASSOCIATION; SEVERITY
AB (1) Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) penetrates respiratory epithelium through angiotensin-converting enzyme-2 binding, raising concerns about the potentially harmful effects of renin-angiotensin system inhibitors (RASi) on Human Coronavirus Disease 2019 (COVID-19) evolution. This study aimed to provide insight into the impact of RASi on SARS-CoV-2 outcomes in patients hospitalized for COVID-19. (2) Methods: This was a retrospective analysis of hospitalized adult patients with SARS-CoV-2 infection admitted to a university hospital in France. The observation period ended at hospital discharge. (3) Results: During the study period, 943 COVID-19 patients were admitted to our institution, of whom 772 were included in this analysis. Among them, 431 (55.8%) had previously known hypertension. The median age was 68 (56-79) years. Overall, 220 (28.5%) patients were placed under mechanical ventilation and 173 (22.4%) died. According to previous exposure to RASi, we defined two groups, namely, "RASi" (n = 282) and "RASi-free" (n = 490). Severe pneumonia (defined as leading to death and/or requiring intubation, high-flow nasal oxygen, noninvasive ventilation, and/or oxygen flow at a rate of >= 5 L/min) and death occurred more frequently in RASi-treated patients (64% versus 53% and 29% versus 19%, respectively). However, in a propensity score-matched cohort derived from the overall population, neither death (hazard ratio (HR) 0.93 (95% confidence interval (CI) 0.57-1.50), p = 0.76) nor severe pneumonia (HR 1.03 (95%CI 0.73-1.44), p = 0.85) were associated with RASi therapy. (4) Conclusion: Our study showed no correlation between previous RASi treatment and death or severe COVID-19 pneumonia after adjustment for confounders.
C1 [Cordeanu, Elena-Mihaela; Lambach, Helene; Tousch, Jonathan; Heitz, Marie; Mirea, Corina; Frantz, Anne-Sophie; Stephan, Dominique] Strasbourg Reg Univ Hosp, Dept Hypertens Vasc Dis & Clin Pharmacol, F-67091 Strasbourg, France.
   [Jambert, Lucas; Hamade, Amer] Mulhouse Reg Hosp, Dept Vasc Med, F-68100 Mulhouse, France.
   [Severac, Francois] Univ Hosp Strasbourg, Div Publ Hlth Methodol & Biostat, F-67091 Strasbourg, France.
   [Younes, Wael] Colmar Reg Hosp, Dept Vasc Med, F-68000 Colmar, France.
   [Merdji, Hamid; Meziani, Ferhat] Strasbourg Reg Univ Hosp, Intens Care & Reanimat Dept, F-67091 Strasbourg, France.
   [Schini-Kerth, Valerie] Strasbourg Univ, Fac Pharm, INSERM, UMR Regenerat Nanomed 1260, F-67400 Illkirch Graffenstaden, France.
   [Bilbault, Pascal] Strasbourg Reg Univ Hosp, Emergency Dept, F-67091 Strasbourg, France.
   [Ohlmann, Patrick] Strasbourg Reg Univ Hosp, Cardiol Dept, F-67091 Strasbourg, France.
   [Andres, Emmanuel] Strasbourg Reg Univ Hosp, Internal Med Dept, F-67091 Strasbourg, France.
RP Cordeanu, EM (corresponding author), Strasbourg Reg Univ Hosp, Dept Hypertens Vasc Dis & Clin Pharmacol, F-67091 Strasbourg, France.
EM elena-mihaela.cordeanu@chru-strasbourg.fr; jambertlucas@gmail.com;
   francois.severac@chru-strasbourg.fr; helene.lambach@chru-strasbourg.fr;
   jonathan.tousch@chru-strasbourg.fr; marie.heitz2@chru-strasbourg.fr;
   corina.mirea@chru-strasbourg.fr; hamadea@ghrmsa.fr;
   wael.younes@ch-colmar.fr; anne-sophie.frantz@chru-strasbourg.fr;
   hamid.merdji@chru-strasbourg.fr; valerie.schini-kerth@unistra.fr;
   pascal.bilbault@chru-strasbourg.fr; ferhat.meziani@chru-strasbourg.fr;
   patrick.ohlmann@chru-strasbourg.fr; emmanuel.andres@chru-strasbourg.fr;
   Dominique.stephan@chru-strasbourg.fr
OI Andres, Emmanuel/0000-0002-7914-7616; Schini-kerth,
   valerie/0000-0001-9997-9287; Severac, Francois/0000-0002-6611-1921
CR AlGhatrif M, 2020, JAMA CARDIOL, V5, P747, DOI 10.1001/jamacardio.2020.1329
   Cai G., 2020, BULK SINGLE CELL TRA, DOI [10.1101/2020.02.05.20020107, DOI 10.1101/2020.02.05.20020107]
   Cao YN, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0147-1
   Chen L, 2020, CARDIOVASC RES, V116, P1097, DOI 10.1093/cvr/cvaa078
   Cheung KS, 2020, CAN MED ASSOC J, V192, pE635, DOI 10.1503/cmaj.75865
   Christiansen CF, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.017297
   European Centre for Disease Prevention and Control, 2020, EP COVID 19 2020
   Gormez S, 2020, J HUM HYPERTENS, DOI 10.1038/s41371-020-00405-3
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo JY, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016219
   Guo XM, 2020, HYPERTENSION, V76, pE13, DOI 10.1161/HYPERTENSIONAHA.120.15572
   Johnson K., 2020, SSRN ELECT J, DOI [10.2139/ssrn.3631248, DOI 10.2139/SSRN.3631248]
   Kim IC, 2020, KOREAN CIRC J, V50, P543, DOI 10.4070/kcj.2020.0205
   Kreutz R, 2020, CARDIOVASC RES, V116, P1688, DOI 10.1093/cvr/cvaa097
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuba K, 2010, PHARMACOL THERAPEUT, V128, P119, DOI 10.1016/j.pharmthera.2010.06.003
   Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9
   Li MY, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00662-x
   Lippi G, 2020, PROG CARDIOVASC DIS, V63, P390, DOI 10.1016/j.pcad.2020.03.001
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Mackey K, 2020, ANN INTERN MED, V173, P195, DOI 10.7326/M20-1515
   Majdic G, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00327
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Mehta N, 2020, JAMA CARDIOL, V5, P1020, DOI 10.1001/jamacardio.2020.1855
   Morales Daniel R, 2020, medRxiv, DOI 10.1101/2020.06.11.20125849
   Paul M, 2006, PHYSIOL REV, V86, P747, DOI 10.1152/physrev.00036.2005
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Rossi GP, 2020, ELIFE, V9, DOI 10.7554/eLife.57278
   Samavati L, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00317
   Trifiro G, 2020, DRUG SAFETY, V43, P1297, DOI 10.1007/s40264-020-00994-5
   Velavan TP, 2020, INT J INFECT DIS, V95, P304, DOI 10.1016/j.ijid.2020.04.061
   Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wu CQ, 2020, HYPERTENSION, V76, pE29, DOI 10.1161/HYPERTENSIONAHA.120.15782
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang G, 2020, HYPERTENSION, V76, P51, DOI 10.1161/HYPERTENSIONAHA.120.15143
   Zeng FR, 2020, INT J INFECT DIS, V96, P467, DOI 10.1016/j.ijid.2020.05.055
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhang X, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104927
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 43
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD NOV
PY 2020
VL 9
IS 11
AR 3472
DI 10.3390/jcm9113472
PG 16
WC Medicine, General & Internal
SC General & Internal Medicine
GA OX1BM
UT WOS:000593309200001
PM 33126565
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Corvol, H
   de Miranda, S
   Lemonnier, L
   Kemgang, A
   Gaubert, MR
   Chiron, R
   Dalphin, ML
   Durieu, I
   Dubus, JC
   Houdouin, V
   Prevotat, A
   Ramel, S
   Revillion, M
   Weiss, L
   Guillot, L
   Boelle, PY
   Burgel, PR
AF Corvol, Harriet
   de Miranda, Sandra
   Lemonnier, Lydie
   Kemgang, Astrid
   Reynaud Gaubert, Martine
   Chiron, Raphael
   Dalphin, Marie-Laure
   Durieu, Isabelle
   Dubus, Jean-Christophe
   Houdouin, Veronique
   Prevotat, Anne
   Ramel, Sophie
   Revillion, Marine
   Weiss, Laurence
   Guillot, Loic
   Boelle, Pierre-Yves
   Burgel, Pierre-Regis
CA French Cystic Fibrosis Referen
TI First Wave of COVID-19 in French Patients with Cystic Fibrosis
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE COVID-19; SARS-CoV-2; Cystic Fibrosis; acute respiratory distress
   syndrome; lung transplant
ID PULMONARY EXACERBATIONS; SARS-COV-2 INFECTION; CHILDREN; PEOPLE; IMPACT;
   VIRUS
AB Viral infections are known to lead to serious respiratory complications in cystic fibrosis (CF) patients. Hypothesizing that CF patients were a population at high risk for severe respiratory complications from SARS-CoV-2 infection, we conducted a national study to describe the clinical expression of COVID-19 in French CF patients. This prospective observational study involves all 47 French CF centers caring for approximately 7500 CF patients. Between 1 March and 30 June 2020, 31 patients were diagnosed with COVID-19: 19 had positive SARS-CoV-2 RT-PCR in nasopharyngeal swabs; 1 had negative RT-PCR but typical COVID-19 signs on a CT scan; and 11 had positive SARS-CoV-2 serology. Fifteen were males, median (range) age was 31 (9-60) years, and 12 patients were living with a lung transplant. The majority of the patients had CF-related diabetes (n = 19, 61.3%), and a mild lung disease (n = 19, 65%, with percent-predicted forced expiratory volume in 1 s (ppFEV(1)) > 70). Three (10%) patients remained asymptomatic. For the 28 (90%) patients who displayed symptoms, most common symptoms at admission were fever (n = 22, 78.6%), fatigue (n = 14, 50%), and increased cough (n = 14, 50%). Nineteen were hospitalized (including 11 out of the 12 post-lung transplant patients), seven required oxygen therapy, and four (3 post-lung transplant patients) were admitted to an Intensive Care Unit (ICU). Ten developed complications (including acute respiratory distress syndrome in two post-lung transplant patients), but all recovered and were discharged home without noticeable short-term sequelae. Overall, French CF patients were rarely diagnosed with COVID-19. Further research should establish whether they were not infected or remained asymptomatic upon infection. In diagnosed cases, the short-term evolution was favorable with rare acute respiratory distress syndrome and no death. Post-lung transplant patients had more severe outcomes and should be monitored more closely.
C1 [Corvol, Harriet] Hop Trousseau, AP HP, Pediat Pulmonol Dept, F-75012 Paris, France.
   [Corvol, Harriet] Hop Trousseau, AP HP, Pediat CF Ctr, F-75012 Paris, France.
   [Corvol, Harriet; Kemgang, Astrid; Guillot, Loic] Sorbonne Univ, INSERM, UMR S938, Ctr Rech St Antoine CRSA, F-75012 Paris, France.
   [de Miranda, Sandra] Hop Foch, Pulmonol Dept, F-92151 Suresnes, France.
   [de Miranda, Sandra] Hop Foch, CF Ctr, F-92151 Suresnes, France.
   [Lemonnier, Lydie] Assoc Vaincre Mucoviscidose, F-75013 Paris, France.
   [Reynaud Gaubert, Martine] Hop Nord Marseille, AP HP, Pulmonol Dept, F-13915 Marseille, France.
   [Reynaud Gaubert, Martine] Hop Nord Marseille, AP HP, CF Adult Ctr, F-13915 Marseille, France.
   [Reynaud Gaubert, Martine] Aix Marseille Univ, IHU Mediterranee Infect, MEPHI, Inst Rech Dev IRD, F-13005 Marseille, France.
   [Chiron, Raphael] CHU Montpellier, Hop Arnaud Villeneuve, CF Ctr, F-34295 Montpellier, France.
   [Dalphin, Marie-Laure] CHU Besancon, Hop Jean Minjoz, Pediat CF Ctr, F-25030 Besancon, France.
   [Durieu, Isabelle] Univ Lyon, Hosp Civils Lyon, Internal Med Dept, F-69495 Lyon, France.
   [Durieu, Isabelle] Univ Lyon, Hosp Civils Lyon, Adult CF Ctr, EA 7425 HESPER, F-69495 Lyon, France.
   [Dubus, Jean-Christophe] AP HM, Pediat Pulmonol Dept, F-13385 Marseille, France.
   [Dubus, Jean-Christophe] AP HM, Pediat CF Ctr, F-13385 Marseille, France.
   [Houdouin, Veronique] Hop Robert Debre, AP HP, Pediat CF Ctr, F-75019 Paris, France.
   [Prevotat, Anne] Hop Calmette, Adult CF Ctr, F-59037 Lille, France.
   [Prevotat, Anne] Univ Lille, F-59037 Lille, France.
   [Ramel, Sophie] Pediat & Adult CF Ctr, F-29680 Roscoff, France.
   [Revillion, Marine] CHU Lille, Hop Jeanne Flandres, Pediat CF Ctr, F-59037 Lille, France.
   [Weiss, Laurence] Hop Univ Strasbourg, Pediat CF Ctr, F-67098 Strasbourg, France.
   [Boelle, Pierre-Yves] Sorbonne Univ, AP HP, INSERM, Inst Pierre Louis Epidemiol & Sante Publ, F-75012 Paris, France.
   [Burgel, Pierre-Regis] Hop Cochin, AP HP, Resp Med & Natl Reference CF Ctr, F-75014 Paris, France.
   [Burgel, Pierre-Regis] Univ Paris, Inst Cochin, INSERM, U 1016, F-75014 Paris, France.
RP Corvol, H (corresponding author), Hop Trousseau, AP HP, Pediat Pulmonol Dept, F-75012 Paris, France.; Corvol, H (corresponding author), Hop Trousseau, AP HP, Pediat CF Ctr, F-75012 Paris, France.; Corvol, H (corresponding author), Sorbonne Univ, INSERM, UMR S938, Ctr Rech St Antoine CRSA, F-75012 Paris, France.
EM harriet.corvol@aphp.fr; s.demiranda@hopital-foch.com;
   llemonnier@vaincrelamuco.org; astrid-donald.kemgang-fankem@inserm.fr;
   MartineLouise.REYNAUD@ap-hm.fr; r-chiron@chu-montpellier.fr;
   mldalphin@chu-besancon.fr; isabelle.durieu@chu-lyon.fr;
   JeanChristophe.DUBUS@ap-hm.fr; veronique.houdouin@aphp.fr;
   anne.prevotat@chru-lille.fr; sophie.ramel@ildys.org;
   mrevillion@ch-lens.fr; Laurence.WEISS@chru-strasbourg.fr;
   loic.guillot@inserm.fr; pierre-yves.boelle@upmc.fr;
   pierre-regis.burgel@aphp.fr
RI Guillot, Loic/D-8893-2011; Corvol, Harriet/N-5922-2018
OI Guillot, Loic/0000-0001-6853-7945; Corvol, Harriet/0000-0002-7026-7523
FU Association Vaincre La Mucoviscidose and Filiere de Sante Maladies rares
   Muco-CFTR
FX This research is funded by Association Vaincre La Mucoviscidose and
   Filiere de Sante Maladies rares Muco-CFTR.
CR Albani F, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092800
   Bell SC, 2020, LANCET RESP MED, V8, P65, DOI 10.1016/S2213-2600(19)30337-6
   Bellis A, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9092134
   Benn CS, 2013, TRENDS IMMUNOL, V34, P431, DOI 10.1016/j.it.2013.04.004
   Bucher J, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1352-2
   Caro-Dominguez P, 2020, PEDIATR RADIOL, V50, P1354, DOI 10.1007/s00247-020-04747-5
   Caruso D, 2020, RADIOLOGY, V296, pE79, DOI 10.1148/radiol.2020201237
   Colombo C, 2020, LANCET RESP MED, V8, pE35, DOI 10.1016/S2213-2600(20)30177-6
   Corvol H, 2016, TRANSL RES, V168, P40, DOI 10.1016/j.trsl.2015.04.008
   Cosgriff R, 2020, J CYST FIBROS, V19, P355, DOI 10.1016/j.jcf.2020.04.012
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Dasenbrook Elliot, 2020, Cleve Clin J Med, DOI 10.3949/ccjm.87a.ccc005
   Elborn JS, 2016, LANCET, V388, P2519, DOI 10.1016/S0140-6736(16)00576-6
   Gao Zhiru, 2020, J Microbiol Immunol Infect, DOI 10.1016/j.jmii.2020.05.001
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Hendricks MR, 2016, J VIROL, V90, P4258, DOI 10.1128/JVI.01864-15
   Kiedrowski MR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03067
   Kieninger E, 2013, CHEST, V143, P782, DOI 10.1378/chest.12-0954
   Kim YJ, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e204
   Launay O, 2014, VACCINE, V32, P4515, DOI 10.1016/j.vaccine.2014.06.010
   Le Vu S., 2020, PREVALENCE SARS COV, DOI [10.1101/2020.10.20.20213116, DOI 10.1101/2020.10.20.20213116]
   Liu R, 2020, CLIN CHIM ACTA, V505, P172, DOI 10.1016/j.cca.2020.03.009
   Liu Xinjin, 2020, Emerg Microbes Infect, V9, P1175, DOI 10.1080/22221751.2020.1772679
   Martin C, 2016, J CYST FIBROS, V15, P204, DOI 10.1016/j.jcf.2015.09.002
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Mirjalili M, 2020, THER CLIN RISK MANAG, V16, P617, DOI 10.2147/TCRM.S256246
   Mitri C, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01096
   Mitroulis I, 2018, CELL, V172, P147, DOI 10.1016/j.cell.2017.11.034
   Mondejar-Lopez P, 2020, RESP MED, V170, DOI 10.1016/j.rmed.2020.106062
   Nathan N, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092950
   Nathan N, 2020, LANCET, V395, P1481, DOI 10.1016/S0140-6736(20)30980-6
   Netea MG, 2011, CELL HOST MICROBE, V9, P355, DOI 10.1016/j.chom.2011.04.006
   Peckham D, 2020, GENES IMMUN, V21, P260, DOI 10.1038/s41435-020-0103-y
   Ricco M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051515
   RIORDAN JR, 1989, SCIENCE, V245, P1066
   Salje H, 2020, SCIENCE, V369, P208, DOI 10.1126/science.abc3517
   Schogler A, 2015, EUR RESPIR J, V45, P428, DOI 10.1183/09031936.00102014
   Somayaji R, 2017, CLIN INFECT DIS, V64, P1760, DOI 10.1093/cid/cix203
   van Ewijk Bart E, 2005, J Cyst Fibros, V4 Suppl 2, P31, DOI 10.1016/j.jcf.2005.05.011
   van Ewijk BE, 2006, THORAX, V61, P641, DOI 10.1136/thx.2006.062372
   Viviani L, 2011, J CYST FIBROS, V10, P370, DOI 10.1016/j.jcf.2011.06.004
   Waters V, 2015, ANN AM THORAC SOC, V12, pS200, DOI 10.1513/AnnalsATS.201502-098AW
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zimmermann P, 2020, PEDIATR INFECT DIS J, V39, P355, DOI 10.1097/INF.0000000000002660
NR 44
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD NOV
PY 2020
VL 9
IS 11
AR 3624
DI 10.3390/jcm9113624
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA OX0CU
UT WOS:000593245000001
PM 33182847
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gonzalez-Bernal, JJ
   Santamaria-Pelaez, M
   Gonzalez-Santos, J
   Rodriguez-Fernandez, P
   del Barco, BL
   Soto-Camara, R
AF Gonzalez-Bernal, Jeronimo J.
   Santamaria-Pelaez, Mirian
   Gonzalez-Santos, Josefa
   Rodriguez-Fernandez, Paula
   Leon del Barco, Benito
   Soto-Camara, Raul
TI Relationship of Forced Social Distancing and Home Confinement Derived
   from the COVID-19 Pandemic with the Occupational Balance of the Spanish
   Population
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE occupational balance; pandemic; COVID-19; social distancing; home
   confinement
ID LIFE BALANCE; TIME-USE; PEOPLE; THERAPY; ADULTS
AB Abrupt interruption in the performance of everyday occupations as a consequence of forced social distancing and home confinement, coupled with a lack of regulatory capacities and skills, can trigger harmful effects on people's health and well-being. This study aimed to determine the factors related to the occupational balance in the Spanish population during home confinement as a consequence of the coronavirus disease 19 (COVID-19) pandemic. A total of 3261 subjects completed an online survey, which was disseminated through the mainstream social media platforms in Spain and included the Occupational Balance Questionnaire (OBQ), sociodemographic variables, and factors related to COVID-19 infection. The mean age of the participants (81.69% women) was 40.53 years (SD +/- 14.05). Sociodemographic variables were related to a greater occupational balance, and the multivariate analysis showed that age (beta = 0.071; p = 0.001), the perception of having received enough information (beta = 0.071; p <= 0.001), not telecommuting (beta = -0.047; p = 0.022), and not being infected by COVID-19 (beta = 0.055; p = 0.007) contributed to a better occupational balance. There were profiles of people less likely to suffer disturbances in occupational balance during home confinement, but more studies are needed to help understand and analyze the effects of the COVID-19 pandemic on people's occupational and mental health.
C1 [Gonzalez-Bernal, Jeronimo J.; Santamaria-Pelaez, Mirian; Gonzalez-Santos, Josefa; Rodriguez-Fernandez, Paula; Soto-Camara, Raul] Univ Burgos, Dept Hlth Sci, Burgos 09001, Spain.
   [Leon del Barco, Benito] Univ Extremadura, Fac Teacher Training Coll, Dept Psychol, Caceres 10071, Spain.
RP Santamaria-Pelaez, M; Gonzalez-Santos, J (corresponding author), Univ Burgos, Dept Hlth Sci, Burgos 09001, Spain.
EM jejavier@ubu.es; mspelaez@ubu.es; mjgonzalez@ubu.es; prf0011@alu.ubu.es;
   bleon@unex.es; rscamara@ubu.es
RI del Barco, Benito Leon/AAA-4729-2019; Santamaria-Pelaez,
   Mirian/ABI-5794-2020
OI Santamaria-Pelaez, Mirian/0000-0002-4255-7355; Leon del Barco,
   Benito/0000-0003-0061-9498; Rodriguez, Paula/0000-0003-0925-6187
CR Ammar A., 2020, BIOL SPORT, V38, P9, DOI [10.5114/biolsport.2020.96857, DOI 10.5114/BIOLSPORT.2020.96857]
   Ashworth NL, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004017.pub2
   Bejerholm U, 2010, OCCUP THER MENT HEAL, V26, P1, DOI 10.1080/01642120802642197
   Blanca MJ, 2017, PSICOTHEMA, V29, P552, DOI 10.7334/psicothema2016.383
   Clark SC, 2001, J VOCAT BEHAV, V58, P348, DOI 10.1006/jvbe.2000.1759
   Diez Garcia C., 2014, TOG, V11, P12
   Edgelow M, 2011, AM J OCCUP THER, V65, P267, DOI 10.5014/ajot.2011.001313
   Eklund M, 2017, SCAND J OCCUP THER, V24, P41, DOI 10.1080/11038128.2016.1224271
   Eklund M, 2009, PSYCHIATR REHABIL J, V32, P177, DOI 10.2975/32.3.2009.177.191
   Fleming KM, 2020, COMPLEMENT THER MED, V49, DOI 10.1016/j.ctim.2020.102313
   Forhan M, 2010, OTJR-OCCUP PART HEAL, V30, P133, DOI 10.3928/15394492-20090625-01
   Guest DE, 2002, SOC SCI INFORM, V41, P255, DOI 10.1177/0539018402041002005
   Hossain MM, 2020, EPIDEMIOL HEALTH, V42, DOI 10.4178/epih.e2020038
   Hultqvist Jenny, 2019, BMC Psychol, V7, P83, DOI 10.1186/s40359-019-0359-z
   Jiao WY, 2020, J PEDIATR-US, V221, P264, DOI 10.1016/j.jpeds.2020.03.013
   Kamalakannan Sureshkumar, 2020, Wellcome Open Res, V5, P153, DOI 10.12688/wellcomeopenres.16089.1
   Lin CY, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15112499
   Lopez-Bueno R, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.01426
   Matthews T, 2019, PSYCHOL MED, V49, P268, DOI 10.1017/S0033291718000788
   Matuska K, 2013, OTJR-OCCUP PART HEAL, V33, P146, DOI 10.3928/15394492-20130614-03
   MEYER A, 1977, AM J OCCUP THER, V31, P639
   Jurado MDM, 2020, ATEN PRIM, V52, P515, DOI 10.1016/j.aprim.2020.05.001
   Nollet M, 2020, INTERFACE FOCUS, V10, DOI 10.1098/rsfs.2019.0092
   Peral Gomez P., 2017, THESIS
   Power E, 2020, IRISH J PSYCHOL MED, V37, P301, DOI 10.1017/ipm.2020.84
   Rubin GJ, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m313
   Sandin B, 2020, J PSYCHOPATHOLOGY CL, V25, P1, DOI [10.5944/rppc.27569, DOI 10.5944/RPPC.27569]
   Shuja KH, 2020, PSYCHIAT DANUB, V32, P32, DOI 10.24869/psyd.2020.32
   Usher K, 2020, INT J MENT HEALTH NU, V29, P315, DOI 10.1111/inm.12726
   Wada M, 2015, COMMIMITY WORK FAM, V18, P117, DOI 10.1080/13668803.2014.965662
   Wada M, 2014, J OCCUP SCI, V21, P259, DOI 10.1080/14427591.2014.913331
   Wagman P, 2019, J OCCUP SCI, V26, P537, DOI 10.1080/14427591.2018.1512007
   Wagman P, 2014, SCAND J OCCUP THER, V21, P415, DOI 10.3109/11038128.2014.934917
   Wagman P, 2014, SCAND J OCCUP THER, V21, P227, DOI 10.3109/11038128.2014.900571
   Wagman P, 2012, J OCCUP SCI, V19, P106, DOI 10.1080/14427591.2011.575760
   Wagman P, 2012, SCAND J OCCUP THER, V19, P322, DOI 10.3109/11038128.2011.596219
   Wagman P, 2012, SCAND J OCCUP THER, V19, P377, DOI 10.3109/11038128.2011.645552
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Wilcock A, 1997, OCCUP THER INT, V4, P17, DOI DOI 10.1002/OTI.45
NR 39
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD NOV
PY 2020
VL 9
IS 11
AR 3606
DI 10.3390/jcm9113606
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA OX2ZI
UT WOS:000593438800001
PM 33182379
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Krug, S
   Garbe, J
   Konig, S
   Ungewiss, H
   Michl, P
   Rinke, A
   Schrader, J
AF Krug, Sebastian
   Garbe, Jakob
   Koenig, Senta
   Ungewiss, Hanna
   Michl, Patrick
   Rinke, Anja
   Schrader, Joerg
TI Professional Assessment of the Impact of COVID-19 on Handling NET
   Patients
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE NET; neuroendocrine; COVID-19; SARS-COV-2; survey; treatment
ID MANAGEMENT
AB The treatment and monitoring of patients with neuroendocrine tumors (NET) has been a major challenge during the COVID-19 pandemic. In a survey, we investigated the influence of COVID-19 on the care of NET patients in the German speaking countries Germany, Austria and Switzerland. The multidisciplinarity of all treating physicians in the outpatient and inpatient sector was reflected in our survey. Furthermore, we were able to present findings pertaining to the university and non-university medical care. Overall, only a minority of appointments were cancelled, mostly as a result of medical prioritization and less for fear of infection by patients. In the university sector, longer delays for diagnostic measures were observed in comparison to non-university care. During the COVID-19 crisis, NET patients rarely changed their current therapy, but the pandemic impacted the assessment of the different treatment modalities at risk of developing severe COVID-19 disease. This survey provides the first real-world data on the treatment of NET patients from the physicians' perspective during the COVID-19 crisis. Despite delays in diagnostic procedures and outpatient appointments, only a minority of physicians foresee a major impact of COVID-19 on NET patient care.
C1 [Krug, Sebastian; Garbe, Jakob; Koenig, Senta; Michl, Patrick] Martin Luther Univ Halle Wittenberg, Dept Internal Med, Ernst Grube Str 40, D-06120 Halle, Germany.
   [Ungewiss, Hanna] IPSEN Pharma GmbH, Einsteinstr 174, D-81677 Munich, Germany.
   [Rinke, Anja] Univ Hosp Marburg, Dept Gastroenterol & Endocrinol, Baldinger Str, D-35043 Marburg, Germany.
   [Schrader, Joerg] Univ Med Ctr Hamburg Eppendorf, Med Dept Gastroenterol & Hepatol, Martinistr 52, D-20246 Hamburg, Germany.
RP Krug, S (corresponding author), Martin Luther Univ Halle Wittenberg, Dept Internal Med, Ernst Grube Str 40, D-06120 Halle, Germany.
EM sebastian.krug@uk-halle.de; jakob.garbe@uk-halle.de;
   senta.koenig@gmail.com; hanna.ungewiss@ipsen.com;
   patrick.michl@uk-halle.de; sprengea@uni-marburg.de; jschrader@uke.de
RI Krug, Sebastian/ABE-2890-2020
OI Krug, Sebastian/0000-0003-1672-7995; Garbe, Jakob/0000-0001-8043-763X;
   Michl, Patrick/0000-0002-0401-5600
CR Aeppli S, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000852
   Bergsland EK, 2020, PANCREAS, V49, P723, DOI 10.1097/MPA.0000000000001561
   Bodei L, 2020, J NUCL MED, V61, P1094, DOI 10.2967/jnumed.120.249136
   Casey RT, 2020, EUR J ENDOCRINOL, V183, pG79, DOI 10.1530/EJE-20-0424
   Dasari A, 2017, JAMA ONCOL, V3, P1335, DOI 10.1001/jamaoncol.2017.0589
   de Azambuja E, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000793
   Jee J, 2020, J CLIN ONCOL, V38, P3538, DOI 10.1200/JCO.20.01307
   Langley JM, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-219
   Lee LYW, 2020, LANCET ONCOL, V21, P1309, DOI 10.1016/S1470-2045(20)30442-3
   Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018
   Panzuto F, 2020, J ENDOCRINOL INVEST, DOI 10.1007/s40618-020-01393-4
   Pavel M, 2016, NEUROENDOCRINOLOGY, V103, P172, DOI 10.1159/000443167
   Pinato DJ, 2020, CANCER DISCOV, V10, P1465, DOI 10.1158/2159-8290.CD-20-0773
   Ramirez RA, 2020, ONCOLOGIST, V25, P548, DOI 10.1634/theoncologist.2020-0279
   Riechelmann R, 2020, ECANCERMEDICALSCIENC, V14, DOI 10.3332/ecancer.2020.1048
   Rinke A, 2018, Z GASTROENTEROL, V56, P583, DOI 10.1055/a-0604-2924
   Spada F, 2020, ENDOCRINE, V70, P6, DOI 10.1007/s12020-020-02419-w
   Tartarone A, 2020, MED ONCOL, V37, DOI 10.1007/s12032-020-01406-5
   Terrazzano G, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00856
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 20
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD NOV
PY 2020
VL 9
IS 11
AR 3633
DI 10.3390/jcm9113633
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA OX2CJ
UT WOS:000593379100001
PM 33187393
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lasbleiz, A
   Cariou, B
   Darmon, P
   Soghomonian, A
   Ancel, P
   Boullu, S
   Houssays, M
   Romain, F
   Lagier, JC
   Boucekine, M
   Resseguier, N
   Gourdy, P
   Pichelin, M
   Wargny, M
   Dutour, A
   Gaborit, B
AF Lasbleiz, Adele
   Cariou, Bertrand
   Darmon, Patrice
   Soghomonian, Astrid
   Ancel, Patricia
   Boullu, Sandrine
   Houssays, Marie
   Romain, Fanny
   Lagier, Jean Christophe
   Boucekine, Mohamed
   Resseguier, Noemie
   Gourdy, Pierre
   Pichelin, Matthieu
   Wargny, Matthieu
   Dutour, Anne
   Gaborit, Benedicte
TI Phenotypic Characteristics and Development of a Hospitalization
   Prediction Risk Score for Outpatients with Diabetes and COVID-19: The
   DIABCOVID Study
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE COVID-19; diabetes; outpatients; hospitalization risk score; DIABSCORE
ID ASSOCIATION; MORTALITY
AB Diabetes mellitus (DM) has been identified as a risk factor for severe COVID-19. DM is highly prevalent in the general population. Defining strategies to reduce the health care system burden and the late arrival of some patients thus seems crucial. The study aim was to compare phenotypic characteristics between in and outpatients with diabetes and infected by COVID-19, and to build an easy-to-use hospitalization prediction risk score. This was a retrospective observational study. Patients with DM and laboratory- or CT-confirmed COVID-19, who did (n = 185) and did not (n = 159) require hospitalization between 10 March and 10 April 2020, were compared. Data on diabetes duration, treatments, glycemic control, complications, anthropometrics and peripheral oxygen saturation (SpO(2)) were collected from medical records. Stepwise multivariate logistic regressions and ROC analyses were performed to build the DIAB score, a score using no more than five easy-to-collect clinical parameters predicting the risk of hospitalization. The DIAB score was then validated in two external cohorts (n = 132 and n = 2036). Hospitalized patients were older (68.0 +/- 12.6 vs. 55.2 +/- 12.6 years, p < 0.001), with more class III obesity (BMI >= 40 kg/m(2), 9.7 vs. 3.5%, p = 0.03), hypertension (81.6 vs. 44.3%, p < 0.0001), insulin therapy (37% vs. 23.7%, p = 0.009), and lower SpO(2) (91.6 vs. 97.3%, p < 0.0001) than outpatients. Type 2 DM (T2D) was found in 94% of all patients, with 10 times more type 1 DM in the outpatient group (11.3 vs. 1.1%, p < 0.0001). A DIAB score > 27 points predicted hospitalization (sensitivity 77.7%, specificity 89.2%, AUC = 0.895), and death within 28 days. Its performance was validated in the two external cohorts. Outpatients with diabetes were found to be younger, with fewer diabetic complications and less severe obesity than inpatients. DIAB score is an easy-to-use score integrating five variables to help clinicians better manage patients with DM and avert the saturation of emergency care units.
C1 [Lasbleiz, Adele; Darmon, Patrice; Soghomonian, Astrid; Boullu, Sandrine; Dutour, Anne; Gaborit, Benedicte] AP HM, Pole ENDO, Dept Endocrinol Metab Dis & Nutr, F-13005 Marseille, France.
   [Lasbleiz, Adele; Darmon, Patrice; Ancel, Patricia; Boullu, Sandrine; Dutour, Anne; Gaborit, Benedicte] Aix Marseille Univ, INSERM, INRAE, C2VN, F-13005 Marseille, France.
   [Cariou, Bertrand; Pichelin, Matthieu] Univ Nantes, Dept Endocrinol Diabetol & Nutr, Hop Guillaume & Rene Laennec, Inst Thorax,Inserm,CNRS,CHU Nantes, F-44093 Nantes, France.
   [Houssays, Marie] Med Evaluat Dept, AP HM, CIC, CPCET, F-13005 Marseille, France.
   [Romain, Fanny] AP HM, Publ Hlth & Med Informat Dept, F-13005 Marseille, France.
   [Lagier, Jean Christophe] Aix Marseille Univ, AP HM, IHU Mediterranee Infect, IRD,MEPHI, F-13005 Marseille, France.
   [Boucekine, Mohamed; Resseguier, Noemie] Aix Marseille Univ, CEReSS Hlth Serv Res & Qual Life Ctr, EA 3279, F-13005 Marseille, France.
   [Resseguier, Noemie] AP HM, Support Unit Clin Res & Econ Evaluat, F-13005 Marseille, France.
   [Gourdy, Pierre] Univ Toulouse, Dept Endocrinol Diabetol & Nutr, Inst Malad Metabol & Cardiovasc, CHU Toulouse,Inserm,UPS,UMR1048, F-31432 Toulouse, France.
   [Wargny, Matthieu] CHU Nantes, Clin Donnees, CIC EC 1413, F-44000 Nantes, France.
RP Gaborit, B (corresponding author), AP HM, Pole ENDO, Dept Endocrinol Metab Dis & Nutr, F-13005 Marseille, France.; Gaborit, B (corresponding author), Aix Marseille Univ, INSERM, INRAE, C2VN, F-13005 Marseille, France.
EM adele.lasbleiz@ap-hm.fr; bertrand.cariou@univ-nantes.fr;
   patrice.darmon@ap-hm.fr; astrid.soghomonian@ap-hm.fr;
   patricia.ancel@univ-amu.fr; sandrine.boullu@ap-hm.fr;
   marie.houssays@ap-hm.fr; fanny.romain@ap-hm.fr;
   jean-christophe.lagier@ap-hm.fr; mohamed.boucekine@univ-amu.fr;
   noemie.resseguier@univ-amu.fr; pierre.gourdy@inserm.fr;
   matthieu.pichelin@chu-nantes.fr; matthieu.wargny@chu-nantes.fr;
   anne.dutour@ap-hm.fr; benedicte.gaborit@ap-hm.fr
RI Wargny, Matthieu/Y-1071-2018; GABORIT, Benedicte/AAK-3842-2020;
   PICHELIN, Matthieu/D-3562-2015; Resseguier, Noemie/E-8427-2017
OI Wargny, Matthieu/0000-0001-6027-9486; GABORIT,
   Benedicte/0000-0002-4180-158X; PICHELIN, Matthieu/0000-0002-6822-6132;
   Resseguier, Noemie/0000-0003-0816-4053; Cariou,
   Bertrand/0000-0002-1580-8040; Gourdy, Pierre/0000-0002-5362-3813
FU Fondation francophone de recherche sur le diabete (FFRD) - Novo Nordisk;
   M.S.D.; AbbottAbbott Laboratories; AllerganAllergan;
   AstraZenecaAstraZeneca; Elivie; Fortil; Lifescan; LillyEli Lilly; Nantes
   MetropoleRegion Pays de la Loire; N.H.C.; Sanofi; FFD (Federation
   francaise des diabetiques)-CORONADO initiative emergency grant; Societe
   francophone du diabete (SFD)-CORONADO initiative emergency grant; Air
   Liquide Health Care international
FX This study received the following funding: the Fondation francophone de
   recherche sur le diabete (FFRD), supported by Novo Nordisk, M.S.D.,
   Abbott, Allergan, AstraZeneca, Elivie, Fortil, Lifescan, Lilly, Nantes
   Metropole, N.H.C., Sanofi and FFD (Federation francaise des
   diabetiques)-CORONADO initiative emergency grant, Societe francophone du
   diabete (SFD)-CORONADO initiative emergency grant and Air Liquide Health
   Care international. All research facilities are thanked for providing
   research associates and research technicians for clinical investigations
   pro bono. The funders of the study had no role in study design, data
   collection, data analysis, data interpretation, or drafting.
CR [Anonymous], 2016, SYNTH EP
   Cariou B, 2020, DIABETOLOGIA, V63, P1500, DOI 10.1007/s00125-020-05180-x
   Davies MJ, 2018, DIABETES CARE, V41, P2669, DOI 10.2337/dci18-0033
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Huang I, 2020, DIABETES METAB SYND, V14, P395, DOI 10.1016/j.dsx.2020.04.018
   Knight SR, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3339
   Ko Jean Y, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1419
   Maddaloni Ernesto, 2020, Diabetes Res Clin Pract, V169, P108454, DOI 10.1016/j.diabres.2020.108454
   Maddaloni E, 2020, CARDIOVASC DIABETOL, V19, DOI 10.1186/s12933-020-01140-2
   Muniyappa R, 2020, AM J PHYSIOL-ENDOC M, V318, pE736, DOI 10.1152/ajpendo.00124.2020
   Nguyen DT, 2018, J INFECTION, V77, P283, DOI 10.1016/j.jinf.2018.02.009
   Perlini S, 2020, INTERN EMERG MED, V15, P825, DOI 10.1007/s11739-020-02390-4
   Popkin BM, 2020, OBES REV, V21, DOI 10.1111/obr.13128
   Rello J, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01028-2020
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rubino F, 2020, NEW ENGL J MED, V383, P789, DOI [10.1056/NEJMc2018688, 10.1056/NEJMc2021832]
   Shabto JM, 2020, DIABETES RES CLIN PR, V164, DOI 10.1016/j.diabres.2020.108229
   Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831
   Wargny M, 2020, DIABETES CARE, V43, pE174, DOI 10.2337/dc20-1217
   Wilkerson R Gentry, 2020, Am J Emerg Med, V38, DOI 10.1016/j.ajem.2020.05.044
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Wynants L, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1328
   Xie J, 2020, MAYO CLIN PROC, V95, P1138, DOI 10.1016/j.mayocp.2020.04.006
   Xu ZH, 2020, J DIABETES, V12, P909, DOI 10.1111/1753-0407.13084
   Yan YL, 2020, BMJ OPEN DIAB RES CA, V8, DOI 10.1136/bmjdrc-2020-001343
   Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou Y, 2020, DIABETES-METAB RES, DOI 10.1002/dmrr.3377
   Zhu LH, 2020, CELL METAB, V31, P1068, DOI 10.1016/j.cmet.2020.04.021
NR 31
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD NOV
PY 2020
VL 9
IS 11
AR 3726
DI 10.3390/jcm9113726
PG 16
WC Medicine, General & Internal
SC General & Internal Medicine
GA OX0DD
UT WOS:000593245900001
PM 33233575
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Makatsariya, A
   Slukhanchuk, E
   Bitsadze, V
   Khizroeva, J
   Tretyakova, M
   Tsibizova, V
   Dobryakov, A
   Elalamy, I
   Gris, JC
AF Makatsariya, Alexander
   Slukhanchuk, Ekaterina
   Bitsadze, Viktoriya
   Khizroeva, Jamilya
   Tretyakova, Maria
   Tsibizova, Valentina
   Dobryakov, Andrey
   Elalamy, Ismail
   Gris, Jean C.
TI COVID-19, neutrophil extracellular traps and vascular complications in
   obstetric practice
SO JOURNAL OF PERINATAL MEDICINE
LA English
DT Article
DE COVID-19; extracellular neutrophil traps; neutrophil extracellular traps
   (NETs); thrombophilia; vascular complications
ID MOLECULAR-WEIGHT HEPARIN; DISEASE 2019 COVID-19; CORONAVIRUS;
   INFECTIONS; ACTIVATION; THROMBOSIS
AB An issue of the novel coronavirus infection spreading is currently in the first place among others in the list of the international medical community. Due to lack of information, conflicting research findings, multicomponent effect of the virus on the body host, as well as various consequences that the virus triggers in the body, now every medical specialty does study the viral attack pathogenesis. Recent months showed that vascular complications are the most severe in the Coronavirus Disease 2019 (COVID-19) and are the main cause of death in the patients. The mechanisms of vascular complications are complex and affect both the hemostatic system and immune responses, "inflammatory storm", disorders of the reninangiotensin-aldosterone system, endotheliopathy, etc.
   Due to the leading role of vascular complications in the viral infection pathogenesis, several groups of patients are at extra risk, including pregnant women, patients with a burdened obstetric history, with hereditary thrombophilia and antiphospholipid syndrome, and patients after in vitro fertilization (IVF). In this category of pregnant women, use of low-molecular-weight heparins (LMWH) is particularly important for both prevention of vascular and obstetric complications, and for pathogenetic therapy of COVID-19.
C1 [Makatsariya, Alexander; Bitsadze, Viktoriya; Khizroeva, Jamilya; Elalamy, Ismail; Gris, Jean C.] First IM Sechenov Moscow State Med Univ Sechenov, Dept Obstet & Gynecol, Trubetskaya St 8-2, Moscow 119991, Russia.
   [Slukhanchuk, Ekaterina] Petrovsky Natl Res Ctr Surg, Gynecol Unit, Moscow, Russia.
   [Tretyakova, Maria] Med Ctr LLC, Dept Gynecol, Moscow, Russia.
   [Tsibizova, Valentina] Almazov Natl Med Res Ctr, Dept Funct & Ultrasound Diagnost, St Petersburg, Russia.
   [Dobryakov, Andrey] Bakhrushin Bros Hosp, Pathologo Anat Dept City Clin Hosp, Moscow, Russia.
   [Elalamy, Ismail] Med Sorbonne Univ, Tenon Univ Hosp, Hematol Dept Thrombosis Ctr, Paris, France.
   [Gris, Jean C.] Montpellier Univ, Hematol Dept, Montpellier, France.
RP Khizroeva, J (corresponding author), First IM Sechenov Moscow State Med Univ Sechenov, Dept Obstet & Gynecol, Trubetskaya St 8-2, Moscow 119991, Russia.
EM jamatotu@gmail.com
RI Khizroeva, Jamilya/F-8384-2017
OI Khizroeva, Jamilya/0000-0002-0725-9686
CR Adrover JM, 2020, NAT IMMUNOL, V21, P135, DOI 10.1038/s41590-019-0571-2
   Amirkhosravi A, 2008, BLOOD, V112, P2857
   [Anonymous], 2020, COVID 19 TREATM GUID
   [Anonymous], 2020, COR COVID 19 INF PRE
   Antonioli L, 2020, CELL MOL IMMUNOL, V17, P672, DOI 10.1038/s41423-020-0450-7
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Armstrong SM, 2013, VIRULENCE, V4, P537, DOI 10.4161/viru.25779
   Azhar EI, 2019, INFECT DIS CLIN N AM, V33, P891, DOI 10.1016/j.idc.2019.08.001
   Barnes BJ, 2020, J EXP MED, V217, DOI 10.1084/jem.20200652
   Bauer ME, 2020, ANESTH ANALG, V131, P7, DOI 10.1213/ANE.0000000000004856
   Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385
   Burwen DR, 2017, THROMB RES, V150, P78, DOI 10.1016/j.thromres.2016.11.015
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Casu B, 2007, PATHOPHYSIOL HAEMO T, V36, P195, DOI 10.1159/000175157
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chartier AL, 2019, AM J ROENTGENOL, V213, P1170, DOI 10.2214/AJR.19.21400
   Crisci Carlos D, 2020, Curr Treat Options Allergy, P1, DOI 10.1007/s40521-020-00258-8
   De Clercq E, 2016, CLIN MICROBIOL REV, V29, P695, DOI 10.1128/CMR.00102-15
   Di Mascio D, 2020, AM J OBSTET GYNECOL, V2, P100107, DOI [10.1016/j.ajogmf.2020.100107, DOI 10.1016/J.AJ0GMF.2020.100107]
   Di Renzo GC, 2020, ANN RUSS ACAD MED SC, V75, P83, DOI 10.15690/vramn1324
   Elwood C, 2020, J OBSTET GYNAECOL CA, DOI [10.1016/j.jogc.2020.03.012, DOI 10.1016/J.JOGC.2020.03.012]
   Engelbrecht C, 2020, CURR EYE RES, V45, P1101, DOI 10.1080/02713683.2020.1715445
   Fanelli V, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02872-z
   Fiore MM, 2009, THROMB RES, V124, P149, DOI 10.1016/j.thromres.2008.12.047
   Gavins FNE, 2011, J THROMB HAEMOST, V9, P574, DOI 10.1111/j.1538-7836.2010.04176.x
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gheblawi M, 2020, CIRC RES, V126, P1456, DOI 10.1161/CIRCRESAHA.120.317015
   Giaglis S, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00565
   Giannis D, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104362
   Hanley B, 2020, J CLIN PATHOL, V73, P239, DOI 10.1136/jclinpath-2020-206522
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DSC, 2019, INFECT DIS CLIN N AM, V33, P869, DOI 10.1016/j.idc.2019.07.001
   Juan J, 2020, ULTRASOUND OBST GYN, V56, P15, DOI 10.1002/uog.22088
   Juusela A, 2020, AM J OBSTET GYNECOL, V2
   Kambas K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00385
   Khizroeva JH, 2020, OBSTET GYNECOL REPRO, V14, P132
   Klejna K, 2014, CLIN APPL THROMB-HEM, V20, P433, DOI 10.1177/1076029612463424
   Li G, 2020, NUTR METAB CARDIOVAS, V30, P1057, DOI 10.1016/j.numecd.2020.04.001
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Makatsariya AD, 2020, OBSTET GYNECOL REPRO, V14, P123
   Marder W, 2016, LUPUS SCI MED, V3, DOI 10.1136/lupus-2015-000134
   Mathur S, 2020, CAN ASSOC RADIOL J, V71, P396, DOI 10.1177/0846537120906482
   Mizugishi K, 2017, FASEB J, V31, P5577, DOI 10.1096/fj.201700399RR
   Mummery RS, 2000, J IMMUNOL
   Nakazawa D, 2017, J AM SOC NEPHROL, V28, P1753, DOI 10.1681/ASN.2016080925
   Noubouossie DF, 2017, BLOOD, V129, P1021, DOI 10.1182/blood-2016-06-722298
   Olausson N, 2020, J THROMB HAEMOST, V18, P1965, DOI 10.1111/jth.14840
   Pierce-Williams Rebecca A M, 2020, Am J Obstet Gynecol MFM, V2, P100134, DOI 10.1016/j.ajogmf.2020.100134
   Poon LC, 2020, ULTRASOUND OBST GYN, V55, P700, DOI 10.1002/uog.22013
   Poon LC, 2020, INT J GYNECOL OBSTET, V149, P273, DOI 10.1002/ijgo.13156
   Porto BN, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00311
   Rasmussen SA, 2020, AM J OBSTET GYNECOL, V222, P415, DOI 10.1016/j.ajog.2020.02.017
   Schaller T, 2020, JAMA-J AM MED ASSOC, V323, P2518, DOI 10.1001/jama.2020.8907
   SCHOEN P, 1991, THROMB HAEMOSTASIS, V66, P435
   Schonrich G, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00366
   Schwartz DA, 2020, ARCH PATHOL LAB MED, V144, P799, DOI 10.5858/arpa.2020-0901-SA
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Thachil J, 2020, J THROMB HAEMOST, V18, P1032
   Wan S., 2020, CHARACTERISTICS LYMP, DOI [10.20021832, DOI 10.1101/2020.02.10.20021832, 10.1101/2020.02. 10.20021832, 10.1101/2020.02.10.20021832]
   Wendelboe AM, 2016, CIRC RES, V118, P1340, DOI 10.1161/CIRCRESAHA.115.306841
   Wilson JG, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2778-x
   Xu X, 2020, Zhonghua Bing Li Xue Za Zhi, V49, P576, DOI 10.3760/cma.j.cn112151-20200401-00278
   Yi ES, 2020, LANCET INFECT DIS, V20, P1102, DOI 10.1016/S1473-3099(20)30449-7
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhao XX, 2020, EUR J CLIN MICROBIOL, V39, P1209, DOI 10.1007/s10096-020-03897-6
NR 69
TC 0
Z9 1
U1 0
U2 0
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 0300-5577
EI 1619-3997
J9 J PERINAT MED
JI J. Perinat. Med.
PD NOV
PY 2020
VL 48
IS 9
SI SI
BP 985
EP 994
DI 10.1515/jpm-2020-0280
PG 10
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA OS6EO
UT WOS:000590254900017
PM 32739908
OA Bronze
DA 2021-01-01
ER

PT J
AU Giampreti, A
   Eleftheriou, G
   Gallo, M
   Butera, R
   Contessa, G
   Faraoni, L
   Sangiovanni, A
   Negri, G
   Falchi, G
   Bacis, G
AF Giampreti, Andrea
   Eleftheriou, Georgios
   Gallo, Mariapina
   Butera, Raffaella
   Contessa, Gioia
   Faraoni, Lorella
   Sangiovanni, Anna
   Negri, Giulia
   Falchi, Giovanna
   Bacis, Giuseppe
TI Medications prescriptions in COVID-19 pregnant and lactating women: the
   Bergamo Teratology Information Service experience during COVID-19
   outbreak in Italy
SO JOURNAL OF PERINATAL MEDICINE
LA English
DT Article
DE COVID-19; lactation; pregnancy; Teratology; toxicology
ID EXPOSURE; TOCILIZUMAB; LOPINAVIR/RITONAVIR; ANTIBIOTICS; AMOXICILLIN;
   MEMBRANES; EFFICACY; OUTCOMES; PRETERM; RUPTURE
AB Objectives: The severe acute respiratory syndrome coronavirus 2 (COVID-19) outbreak in Italy, especially in Lombardy and Bergamo city, represented probably nowadays one of the first major clusters of COVID-19 in the world. The aim of this report is to describe the activity of Bergamo Teratology Information Service (TIS) in supporting the public and health-care personnel in case of drug prescriptions in suspected/confirmed COVID-19 pregnant and lactating patients during COVID-19 outbreak in Italy.
   Methods: All Bergamo TIS requests concerning COVID-19 pregnant and lactating women have been retrospectively evaluated from 1 March to 15 April 2020. Type of medications, drug's safety profile and compatibility with pregnancy and lactation are reported.
   Results: Our service received information calls concerning 48 (9 pregnant, 35 lactating) patients. Among pregnant and lactating women, the requests of information were related to 16 and 60 drugs prescriptions respectively. More than half concerned drugs prescriptions during the first and second trimester (13/16) and during the first six months of lactation (37/60). Hydroxychloroquine and azithromycin were the most involved.
   Conclusions: Hydroxychloroquine and azithromycin at dosages used for COVID-19 may be considered compatible and reasonably safe either in pregnancy and lactation. Antivirals may be considered acceptable in pregnancy. During lactation lopinavir and ritonavir probably exhibit some supportive data from literature that darunavir and cobicistat do not. Tocilizumab may be considered for COVID-19 treatment because no increased malformation rate were observed until now. However caution may be advised because human data are limited and the potential risk of embryo-fetal toxicity cannot be excluded.
C1 [Giampreti, Andrea; Eleftheriou, Georgios; Gallo, Mariapina; Butera, Raffaella; Contessa, Gioia; Faraoni, Lorella; Sangiovanni, Anna; Negri, Giulia; Falchi, Giovanna; Bacis, Giuseppe] Papa Giovanni XXIII Hosp, Bergamo Teratol Informat Serv, I-24100 Bergamo, Italy.
RP Giampreti, A (corresponding author), Papa Giovanni XXIII Hosp, Bergamo Teratol Informat Serv, I-24100 Bergamo, Italy.
EM agiampreti@asst-pg23.it
CR Andersen JT, 2013, PLOS ONE, V8
   Bar-Oz B, 2008, EUR J OBSTET GYN R B, V141, P31, DOI 10.1016/j.ejogrb.2008.07.008
   Bennett PN, 1996, DRUGS HUMAN LACTATIO
   Berard A, 2015, PHARMACOEPIDEM DR S, V24, P1241, DOI 10.1002/pds.3900
   Bernucci C, 2020, WORLD NEUROSURG, V137, P465, DOI 10.1016/j.wneu.2020.03.179
   Corbett AH, 2014, ANTIVIR THER, V19, P587, DOI 10.3851/IMP2739
   Damkier P, 2019, AM J OBSTET GYNECOL, V221, DOI 10.1016/j.ajog.2019.06.050
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Ehsanipoor RM, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.12.022
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Hoeltzenbein M, 2016, SEMIN ARTHRITIS RHEU, V46, P238, DOI 10.1016/j.semarthrit.2016.05.004
   Kaneko K, 2016, MOD RHEUMATOL, V26, P672, DOI 10.3109/14397595.2016.1140256
   Kaplan Y, 2020, MOTHERISK INT J, V1, P9
   Kaplan YC, 2016, BRIT J CLIN PHARMACO, V81, P835, DOI 10.1111/bcp.12872
   Kawamura S, 1992, NIPPON KAGAKU RYO S1, V40, P238
   Kenyon SL, 2001, LANCET, V357, P979, DOI 10.1016/S0140-6736(00)04233-1
   Lin KJ, 2012, EPIDEMIOLOGY, V23, P699, DOI 10.1097/EDE.0b013e318258cb05
   Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344
   Molgaard-Nielsen D, 2012, PHARMACOEPIDEM DR S, V21, P246, DOI 10.1002/pds.2179
   Nakajima K, 2016, MOD RHEUMATOL, V26, P667, DOI 10.3109/14397595.2016.1147405
   Oumar AA, 2018, J PHARMACOL EXP THER, V366, P479, DOI 10.1124/jpet.118.249938
   Palombi L, 2012, ANTIVIR THER, V17, P1511, DOI 10.3851/IMP2315
   Papp E, 2015, J INFECT DIS, V211, P10, DOI 10.1093/infdis/jiu393
   PAUFIQUE L, 1969, Bulletin des Societes d'Ophtalmologie de France, V69, P466
   Perin A, 2020, J NEURO-ONCOL, V148, P203, DOI 10.1007/s11060-020-03496-7
   Rao GN, 2000, TOXICOLOGIST, V54, P227
   Roberts SS, 2009, JAIDS-J ACQ IMM DEF, V51, P456, DOI 10.1097/QAI.0b013e3181a2813f
   Sarkar Moumita, 2006, BMC Pregnancy Childbirth, V6, P18, DOI 10.1186/1471-2393-6-18
   Sperber K, 2009, PEDIATR RHEUMATOL, V7, DOI 10.1186/1546-0096-7-9
   The U.S. Food and Drug Administration, INF ACTEMRA TOC
   ULLBERG S, 1970, NATURE, V227, P1257, DOI 10.1038/2271257a0
   Weber-Schoendorfer C, 2016, REPROD TOXICOL, V60, P29, DOI 10.1016/j.reprotox.2016.01.002
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Ye XT, 2020, EUR REV MED PHARMACO, V24, P3390, DOI 10.26355/eurrev_202003_20706
   Zhang SY, 2020, CLIN DRUG INVEST, V40, P511, DOI 10.1007/s40261-020-00917-3
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
NR 36
TC 0
Z9 0
U1 0
U2 0
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 0300-5577
EI 1619-3997
J9 J PERINAT MED
JI J. Perinat. Med.
PD NOV
PY 2020
VL 48
IS 9
SI SI
BP 1001
EP 1007
DI 10.1515/jpm-2020-0339
PG 7
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA OS6EO
UT WOS:000590254900020
PM 33055313
OA Bronze
DA 2021-01-01
ER

PT J
AU Azam, TU
   Shadid, HR
   Blakely, P
   O'Hayer, P
   Berlin, H
   Pan, M
   Zhao, PY
   Zhao, LL
   Pennathur, S
   Pop-Busui, R
   Altintas, I
   Tingleff, J
   Stauning, MA
   Andersen, O
   Adami, ME
   Solomonidi, N
   Tsilika, M
   Tober-Lau, P
   Arnaoutoglou, E
   Keitel, V
   Tacke, F
   Chalkias, A
   Loosen, SH
   Giamarellos-Bourboulis, EJ
   Eugen-Olsen, J
   Reiser, J
   Hayek, SS
AF Azam, Tariq U.
   Shadid, Husam R.
   Blakely, Pennelope
   O'Hayer, Patrick
   Berlin, Hanna
   Pan, Michael
   Zhao, Peiyao
   Zhao, Lili
   Pennathur, Subramaniam
   Pop-Busui, Rodica
   Altintas, Izzet
   Tingleff, Jens
   Stauning, Marius A.
   Andersen, Ove
   Adami, Maria-Evangelia
   Solomonidi, Nicky
   Tsilika, Maria
   Tober-Lau, Pinkus
   Arnaoutoglou, Eleni
   Keitel, Verena
   Tacke, Frank
   Chalkias, Athanasios
   Loosen, Sven H.
   Giamarellos-Bourboulis, Evangelos J.
   Eugen-Olsen, Jesper
   Reiser, Jochen
   Hayek, Salim S.
CA Int Study Inflammation COVID-19
TI Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
DE acute renal failure; AKI; urokinase; SuPAR; SARS-CoV-2; coronavirus;
   dialysis; renal replacement therapy; CRP; COVID-19
ID PLASMINOGEN-ACTIVATOR RECEPTOR; ACUTE KIDNEY INJURY; CIRCULATING SUPAR;
   RENAL-FUNCTION; INFLAMMATION; DISEASE; COMPLEX; ADULTS; BLOOD; ENTRY
AB Background AKI commonly occurs in patients with coronavirus disease 2019 (COVID-19). Its pathogenesis is poorly understood. The urokinase receptor system is a key regulator of the intersection between inflammation, immunity, and coagulation, and soluble urokinase plasminogen activator receptor (suPAR) has been identified as an immunologic risk factor for AKI. Whether suPAR is associated with COVID-19-related AKI is unknown.
   Methods In a multinational observational study of adult patients hospitalized for COVID-19, we measured suPAR levels in plasma samples from 352 adult patients that had been collected within 48 hours of admission. We examined the association between suPAR levels and incident in-hospital AKI.
   Results Of the 352 patients (57.4% were male, 13.9% were black, and mean age was 61 years), 91 (25.9%) developed AKI during their hospitalization, of whom 25 (27.4%) required dialysis. The median suPAR level was 5.61 ng/ml. AKI incidence rose with increasing suPAR tertiles, from a 6.0% incidence in patients with suPAR <4.60 ng/ml (first tertile) to a 45.8% incidence of AKI in patients with suPAR levels >6.86 ng/ml (third tertile). None of the patients with suPAR <4.60 ng/ml required dialysis during their hospitalization. In multivariable analysis, the highest suPAR tertile was associated with a 9.15-fold increase in the odds of AKI (95% confidence interval [95% CI], 3.64 to 22.93) and a 22.86-fold increase in the odds of requiring dialysis (95% CI, 2.77 to 188.75). The association was independent of inflammatory markers and persisted across subgroups.
   Conclusions Admission suPAR levels in patients hospitalized for COVID-19 are predictive of in-hospital AKI and the need for dialysis. SuPAR may be a key component of the pathophysiology of AKI in COVID-19.
C1 [Azam, Tariq U.; Blakely, Pennelope; Hayek, Salim S.] Univ Michigan, Dept Internal Med, Div Cardiol, Ann Arbor, MI 48109 USA.
   [Shadid, Husam R.; O'Hayer, Patrick; Berlin, Hanna; Pan, Michael] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.
   [Zhao, Peiyao; Zhao, Lili] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA.
   [Pennathur, Subramaniam] Univ Michigan, Dept Internal Med, Div Nephrol, Ann Arbor, MI 48109 USA.
   [Pop-Busui, Rodica] Univ Michigan, Dept Internal Med, Div Endocrinol, Ann Arbor, MI 48109 USA.
   [Tingleff, Jens; Andersen, Ove; Eugen-Olsen, Jesper] Copenhagen Univ Hosp Amager & Hvidovre, Dept Clin Res, Hvidovre, Denmark.
   [Altintas, Izzet; Stauning, Marius A.] Copenhagen Univ Hosp Amager & Hvidovre, Emergency Dept, Hvidovre, Denmark.
   [Adami, Maria-Evangelia; Solomonidi, Nicky; Tsilika, Maria; Giamarellos-Bourboulis, Evangelos J.] Natl & Kapodistrian Univ Athens, Dept Internal Med 4, Athens, Greece.
   [Tober-Lau, Pinkus] Charite Univ Med Berlin, Dept Infect Dis & Resp Med, Berlin, Germany.
   [Arnaoutoglou, Eleni; Chalkias, Athanasios] Univ Thessaly, Sch Hlth Sci, Dept Anesthesiol, Fac Med, Thessaly, Greece.
   [Keitel, Verena; Loosen, Sven H.] Univ Hosp Dusseldorf, Med Fac, Clin Gastroenterol Hepatol & Infect Dis, Dusseldorf, Germany.
   [Tacke, Frank] Charite Univ Med Berlin, Dept Hepatol & Gastroenterol, Berlin, Germany.
   [Reiser, Jochen] Rush Univ, Med Ctr, Dept Med, Chicago, IL 60612 USA.
RP Hayek, SS (corresponding author), Univ Michigan, Frankel Cardiovasc Ctr, 1500 East Med Ctr Dr,CVC 2709, Ann Arbor, MI 48109 USA.
EM shayek@med.umich.edu
OI Azam, Tariq/0000-0002-1506-5099; Reis, AlessanRSS/0000-0001-8486-7469;
   Berlin, Hanna/0000-0002-9801-3517; Ahm Stauning,
   Marius/0000-0002-5027-4435
FU National Heart, Lung, and Blood InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [1R01HL153384-01]; Frankel
   Cardiovascular Center COVID-19: Impact Research Ignitor [U-M G024231];
   Hellenic Institute for the Study of Sepsis; Charite Universitaetsmedizin
   Berlin; Berlin Institute of Health
FX S. Hayek is funded by National Heart, Lung, and Blood Institute grant
   1R01HL153384-01 and the Frankel Cardiovascular Center COVID-19: Impact
   Research Ignitor (U-M G024231) award. E.J. Giamarellos-Bourboulis is
   supported by the Hellenic Institute for the Study of Sepsis. F. Tacke is
   supported through intramural funds from Charite Universitaetsmedizin
   Berlin and the Berlin Institute of Health.
CR Abdulkader RCRM, 2010, CLIN J AM SOC NEPHRO, V5, P1916, DOI 10.2215/CJN.00840110
   Andersen O, 2008, J MED VIROL, V80, P209, DOI 10.1002/jmv.21114
   Batlle D, 2020, J AM SOC NEPHROL, V31, P1380, DOI 10.1681/ASN.2020040419
   Chan L, 2020, ACUTE KIDNEY INJURY
   Chew-Harris J, 2019, CLIN BIOCHEM, V69, P36, DOI 10.1016/j.clinbiochem.2019.05.010
   Chua HR, 2020, AM J KIDNEY DIS, V76, P392, DOI 10.1053/j.ajkd.2020.05.008
   Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2
   Dal Monte M, 2019, J CELL MOL MED, V23, P1034, DOI 10.1111/jcmm.14004
   De Witte H, 1998, INT J CANCER, V77, P236, DOI 10.1002/(SICI)1097-0215(19980717)77:2<236::AID-IJC12>3.0.CO;2-9
   Del Rosso M, 2011, CURR PHARM DESIGN, V17, P1924
   DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
   Diederichsen MZ, 2018, ATHEROSCLEROSIS, V271, P245, DOI 10.1016/j.atherosclerosis.2018.01.029
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Eapen DJ, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001118
   Gavrilovskaya IN, 1998, P NATL ACAD SCI USA, V95, P7074, DOI 10.1073/pnas.95.12.7074
   Gussen H, 2019, J INTENSIVE CARE, V7, DOI 10.1186/s40560-019-0381-5
   Gustafsson A, 2011, BIOMARK INSIGHTS, V6, P119, DOI 10.4137/BMI.S8326
   Hagele S, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3583-x
   Hahm E, 2017, NAT MED, V23, P100, DOI 10.1038/nm.4242
   Han RH, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.122912
   Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Hayek SS, 2020, NEW ENGL J MED, V382, P416, DOI 10.1056/NEJMoa1911481
   Hayek SS, 2019, J AM SOC NEPHROL, V30, P1305, DOI 10.1681/ASN.2018121227
   Hayek SS, 2017, NAT MED, V23, P945, DOI 10.1038/nm.4362
   Hayek SS, 2017, KIDNEY INT REP, V2, P425, DOI 10.1016/j.ekir.2017.02.001
   Hayek SS, 2015, NEW ENGL J MED, V373, P1916, DOI 10.1056/NEJMoa1506362
   Hirsch JS, 2020, KIDNEY INT, V98, P209, DOI 10.1016/j.kint.2020.05.006
   Hodges GW, 2015, CAN J CARDIOL, V31, P1293, DOI 10.1016/j.cjca.2015.03.023
   Huai Q, 2006, SCIENCE, V311, P656, DOI 10.1126/science.1121143
   Isselbacher EM, 2005, CIRCULATION, V111, P816, DOI 10.1161/01.CIR.0000154569.08857.7A
   Iversen E, 2020, NEW ENGL J MED, V382, P2166, DOI 10.1056/NEJMc2003613
   Khwaja A, 2012, NEPHRON CLIN PRACT, V120, pC179, DOI 10.1159/000339789
   Kissling S, 2020, KIDNEY INT, V98, P228, DOI 10.1016/j.kint.2020.04.006
   Langkilde A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051698
   Larsen CP, 2020, KIDNEY INT REP, V5, P935, DOI 10.1016/j.ekir.2020.04.002
   Levey AS, 2017, ANN INTERN MED, V167, pITC65, DOI 10.7326/AITC201711070
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006
   Luo SY, 2018, CLIN J AM SOC NEPHRO, V13, P1013, DOI 10.2215/CJN.13631217
   Lyngbaek S, 2013, INT J CARDIOL, V167, P2904, DOI 10.1016/j.ijcard.2012.07.018
   Magoon Sandeep, 2020, Kidney Med, V2, P488, DOI 10.1016/j.xkme.2020.05.004
   Mittler E, 2019, ADV VIRUS RES, V104, P185, DOI 10.1016/bs.aivir.2019.07.002
   Mossanen JC, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081662
   Mustonen J, 2017, INFECT DIS-NOR, V49, P321, DOI 10.1080/23744235.2016.1274421
   NYKJAER A, 1994, J IMMUNOL, V152, P505
   Pei GC, 2020, J AM SOC NEPHROL, V31, P1157, DOI 10.1681/ASN.2020030276
   Pettila V, 2011, INTENS CARE MED, V37, P763, DOI 10.1007/s00134-011-2166-8
   PLESNER T, 1994, AM J CLIN PATHOL, V102, P835, DOI 10.1093/ajcp/102.6.835
   Puelles VG, 2020, NEW ENGL J MED, V383, P590, DOI [10.1056/NEJMc2011400, 10.1056/NEJMc2013400]
   R Core Team, 2014, R LANG ENV STAT COMP
   Rabb H, 2016, J AM SOC NEPHROL, V27, P371, DOI 10.1681/ASN.2015030261
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Ronco C, 2020, LANCET RESP MED, V8, P738, DOI 10.1016/S2213-2600(20)30229-0
   Ronco C, 2019, LANCET, V394, P1949, DOI 10.1016/S0140-6736(19)32563-2
   Rovina N, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02897-4
   Schaefer F, 2017, JAMA PEDIATR, V171, DOI 10.1001/jamapediatrics.2017.2914
   Sier CFM, 1999, LAB INVEST, V79, P717
   Smith HW, 2010, NAT REV MOL CELL BIO, V11, P23, DOI 10.1038/nrm2821
   Solberg H, 2001, J HISTOCHEM CYTOCHEM, V49, P237, DOI 10.1177/002215540104900211
   SOLOMON R, 1994, NEW ENGL J MED, V331, P1416, DOI 10.1056/NEJM199411243312104
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   Thuno M, 2009, DIS MARKERS, V27, P157, DOI [10.1155/2009/504294, 10.3233/DMA-2009-0657]
   Vincenti F, 2020, NEPHROL DIAL TRAN S3, V35, pgfaa140
   Wei C, 2008, NAT MED, V14, P55, DOI 10.1038/nm1696
   Wei CL, 2019, J CLIN INVEST, V129, P1946, DOI 10.1172/JCI124793
   Wei CL, 2012, J AM SOC NEPHROL, V23, P2051, DOI 10.1681/ASN.2012030302
   Wei CL, 2011, NAT MED, V17, P952, DOI 10.1038/nm.2411
   Weisbord SD, 2018, NEW ENGL J MED, V378, P603, DOI 10.1056/NEJMoa1710933
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 69
TC 1
Z9 1
U1 1
U2 1
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
EI 1533-3450
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD NOV
PY 2020
VL 31
IS 11
BP 2725
EP 2735
DI 10.1681/ASN.2020060829
PG 11
WC Urology & Nephrology
SC Urology & Nephrology
GA OP9IK
UT WOS:000588403600021
PM 32963090
OA Bronze
DA 2021-01-01
ER

PT J
AU Park, MH
   Kim, AJ
   Lee, MJ
   Kim, YS
   Kim, JS
AF Park, Mi Hwa
   Kim, Ah Jin
   Lee, Man-Jong
   Kim, Young Sam
   Kim, Jung Soo
TI Case Report of Patients with Acute Respiratory Distress Syndrome Caused
   by COVID-19: Successfully Treated by Venovenous Extracorporeal Membrane
   Oxygenation and an Ultra-Protective Ventilation
SO MEDICINA-LITHUANIA
LA English
DT Article
DE COVID-19; acute respiratory distress syndrome; venovenous extracorporeal
   membrane oxygenation; ultra-protective ventilation
AB Coronavirus disease (COVID-19) started in Wuhan (China) at the end of 2019, and then increased rapidly. In patients with severe acute respiratory distress syndrome (ARDS) caused by COVID-19, venovenous extracorporeal membrane oxygenation (VV-ECMO) is considered a rescue therapy that provides adequate gas exchange. The way in which mechanical ventilation is applied during VV-ECMO is not clear, however it is associated with prognosis. Currently, the mortality rate of COVID-19 patients that receive VV-ECMO stands at approximately 50%. Here, we report three patients that successfully recovered from COVID-19-induced ARDS after VV-ECMO and implementation of an ultra-protective ventilation. This ventilation strategy involved maintaining a peak inspiratory pressure of <= 20 cmH(2)O and a positive end-expiratory pressure (PEEP) of <= 10 cmH(2)O, which are lower values than have been previously reported. Thus, we suggest that this ultra-protective ventilation be considered during VV-ECMO as it minimizes the ventilator-induced lung injury.
C1 [Park, Mi Hwa; Kim, Jung Soo] Inha Univ Hosp, Div Pulmonol, Dept Internal Med, Incheon 22332, South Korea.
   [Kim, Ah Jin; Lee, Man-Jong] Inha Univ Hosp, Dept Internal Med, Div Crit Care Med, Incheon 22332, South Korea.
   [Kim, Young Sam] Inha Univ Hosp, Div Thorac Surg, Incheon 22332, South Korea.
RP Kim, JS (corresponding author), Inha Univ Hosp, Div Pulmonol, Dept Internal Med, Incheon 22332, South Korea.
EM bami.park@gmail.com; emjin23@naver.com; likeavirgin@daum.net;
   kimyoungsam@inha.ac.kr; acecloer31@gmail.com
OI Kim, Jung Soo/0000-0001-6603-6768
FU INHA UNIVERSITY Research Grant
FX This research was supported by INHA UNIVERSITY Research Grant.
CR Cabrera-Benitez NE, 2014, ANESTHESIOLOGY, V121, P189, DOI 10.1097/ALN.0000000000000264
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Curley GF, 2016, CHEST, V150, P1109, DOI 10.1016/j.chest.2016.07.019
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Jacobs JP, 2020, ASAIO J, V66, P722, DOI 10.1097/MAT.0000000000001185
   Kim HS, 2019, ANN THORAC SURG, V108, P176, DOI 10.1016/j.athoracsur.2019.01.055
   Meduri GU, 2007, CHEST, V131, P954, DOI 10.1378/chest.06-2100
   Organization WH, 2020, CLIN MAN COVID 19
   Osho AA, 2020, ANN SURG, V272, pE75, DOI 10.1097/SLA.0000000000004084
   Pham T, 2013, AM J RESP CRIT CARE, V187, P276, DOI 10.1164/rccm.201205-0815OC
   Recovery Collaborative Group, 2020, NEW ENGL J MED, DOI [10.3410/f.738341916.793577274, DOI 10.3410/F.738341916.793577274]
   Rozencwajg S, 2019, CRIT CARE MED, V47, P1505, DOI 10.1097/CCM.0000000000003894
   Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zaim S, 2020, CURR PROB CARDIOLOGY, V45, DOI 10.1016/j.cpcardiol.2020.100618
   Zeng YC, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2840-8
NR 16
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1010-660X
EI 1648-9144
J9 MEDICINA-LITHUANIA
JI Med. Lith.
PD NOV
PY 2020
VL 56
IS 11
AR 570
DI 10.3390/medicina56110570
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA OW9IU
UT WOS:000593192400001
PM 33137936
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Marinho, EM
   Neto, JBD
   Silva, J
   da Silva, CR
   Cavalcanti, BC
   Marinho, ES
   Nobre, HV
AF Marinho, Emanuelle Machado
   de Andrade Neto, Joao Batista
   Silva, Jacilene
   da Silva, Cecilia Rocha
   Cavalcanti, Bruno Coelho
   Marinho, Emmanuel Silva
   Nobre Junior, Helio Vitoriano
TI Virtual screening based on molecular docking of possible inhibitors of
   Covid-19 main protease
SO MICROBIAL PATHOGENESIS
LA English
DT Article
DE Molecular docking; COVID-19; Inhibitors
AB Coronavirus (COVID-19) is an enveloped RNA virus that is diversely found in humans and that has now been declared a global pandemic by the World Health Organization. Thus, there is an urgent need to develop effective therapies and vaccines against this disease. In this context, this study aimed to evaluate in silico the molecular interactions of drugs with therapeutic indications for treatment of COVID-19 (Azithromycin, Baricitinib and Hydroxychloroquine) and drugs with similar structures (Chloroquine, Quinacrine and Ruxolitinib) in docking models from the SARS-CoV-2 main protease (M-pro) protein. The results showed that all inhibitors bound to the same enzyme site, more specifically in domain III of the SARS-CoV-2 main protease. Therefore, this study allows proposing the use of baricitinib and quinacrine, in combination with azithromycin; however, these computer simulations are just an initial step for conceiving new projects for the development of antiviral molecules.
C1 [de Andrade Neto, Joao Batista; da Silva, Cecilia Rocha; Nobre Junior, Helio Vitoriano] Univ Fed Ceara, Sch Pharm, Lab Bioprospect Antimicrobial Mol LABIMAN, Fortaleza, CE, Brazil.
   [Marinho, Emanuelle Machado] Univ Fed Ceara, Grp Theoret Chem GQT, Dept Analyt Chem & Phys Chem, Sci Ctr, BR-60455760 Fortaleza, CE, Brazil.
   [Silva, Jacilene; Marinho, Emmanuel Silva] Univ Estadual Ceara, Grp Theoret Chem & Electrochem GQT, Dept Chem, Limoeiro Do Norte, Ceara, Brazil.
   [de Andrade Neto, Joao Batista] Christus Univ Ctr UNICHRISTUS, Fortaleza, CE, Brazil.
   [de Andrade Neto, Joao Batista; da Silva, Cecilia Rocha; Cavalcanti, Bruno Coelho; Nobre Junior, Helio Vitoriano] Univ Fed Ceara, Drug Res & Dev Ctr, Fortaleza, CE, Brazil.
RP Nobre, HV (corresponding author), Univ Fed Ceara, Sch Pharm, Lab Bioprospect Antimicrobial Mol LABIMAN, Fortaleza, CE, Brazil.
EM label_ufc@yahoo.com.br
RI Marinho, Emmanuel Silva/F-1525-2018
OI Marinho, Emmanuel Silva/0000-0002-4774-8775
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CAPES/BrazilCAPES; FUNCAP/Ceara
FX This research was supported by grants and fellowships from CNPq,
   CAPES/Brazil, and FUNCAP/Ceara. We declare no conflicts of interest
   concerning this article.
CR Akdemir A, 2019, J ENZYM INHIB MED CH, V34, P528, DOI 10.1080/14756366.2018.1564045
   [Anonymous], 2019, DISC STUD VIS VERS 1
   [Anonymous], 2020, SEARCH MED TREAT COV
   Borba MGS, 2020, CHLOROQUINE DIPHOSPH, DOI [10.1101/2020.04.07.20056424, DOI 10.1101/2020.04.07.20056424]
   BRAZIL. Ministry of Health, 2020, 52020DAFSCTIEMS MIN, P1
   Cantini G.D., 2020, J INFECT, VS0163-4453, P30228
   Comer JE, 2019, ANTIMICROB AGENTS CH, V63, P1
   De Freitas T. Cavatao, 2019, EXTRACTS J CHEM, DOI [10.1155/2019/3410953, DOI 10.1155/2019/3410953]
   Gasparian AV, 2010, J VIROL, V84, P9390, DOI 10.1128/JVI.02569-09
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gielen V, 2010, EUR RESPIR J, V36, P646, DOI 10.1183/09031936.00095809
   Guerra T.M., 2019, ESTUDOS DOCKING MOL
   Gurung AB, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15027829
   Halgren T.A., 2000, MERCK MOL FORCE FIEL, V11, P520
   Hanwell MD, 2012, J CHEMINFORMATICS, V4, DOI 10.1186/1758-2946-4-17
   Hassan SA, 2020, CUREUS, V12, DOI 10.7759/cureus.7355
   Jeffrey George A., 1997, INTRO HYDROGEN BONDI, P1997
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kandeel M., 2020, VIRTUAL SCREENING RE
   Klaholz BP, 2002, STRUCTURE, V10, P1197, DOI 10.1016/S0969-2126(02)00828-6
   Kumar BS, 2014, EUR J MED CHEM, V86, P740, DOI 10.1016/j.ejmech.2014.09.033
   Kumar BS, 2014, BIOORGAN MED CHEM, V22, P1342, DOI 10.1016/j.bmc.2013.12.067
   Lane J.C., 2020, SAFETY HYDROXYCHLORO, DOI [10.1101/2020.04.08.20054551, DOI 10.1101/2020.04.08.20054551]
   Lu S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173320
   Lucio F.N.M., 2020, METHYLCYTISINE ALCAL, DOI [10.5281/zenodo.3633270., DOI 10.5281/ZENODO.3633270]
   MacKenzie D, 2020, NEW SCI, V245, P10, DOI 10.1016/S0262-4079(20)30525-X
   Milite C, 2019, J ENZYM INHIB MED CH, V34, P1697, DOI 10.1080/14756366.2019.1666836
   Nicola M., 2020, EVIDENCE BASED MANAG
   Parthasarathi R, 2006, CHALL ADV COMPUT CHE, V3, P1, DOI 10.1007/978-1-4020-4853-1_1
   Pascarella G., 2020, COVID 19 DIAGNOSIS M, P1, DOI [10.1111/joim.13091, DOI 10.1111/JOIM.13091]
   Pettersen E.F., 2004, UCSF CHIMERA VISUALI, DOI [10.1002/jcc.20084, DOI 10.1002/JCC.20084]
   Porter JD, 2016, J ANTIMICROB CHEMOTH, V71, P2767, DOI 10.1093/jac/dkw222
   Prakasham AP, 2012, BIOORGAN MED CHEM, V20, P3049, DOI 10.1016/j.bmc.2012.02.057
   Raevsky O.A., 2000, MOL MODEL PREDICT BI
   Re K.K. Martin, 2009, SCIENCE, V325, P1680
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Sandeep S., 2020, ENERGETICS BASED MOD, DOI [10.26434/chemrxiv.12015792., DOI 10.26434/CHEMRXIV.12015792]
   Scavone C, 2020, BRIT J PHARMACOL, V177, P4813, DOI 10.1111/bph.15072
   Shityakov Sergey, 2014, Adv Appl Bioinform Chem, V7, P23, DOI 10.2147/AABC.S63749
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Steiner T., 2002, ANGEW CHEM INT EDIT, DOI [10.1002/1521-3773(20020104)41:1<48.AID-ANIE48>3.0.CO;2-U., DOI 10.1002/1521-3773(20020104)41:1<48.AID-ANIE48>3.0.CO;2-U.]
   Trott O., 2009, SOFTWARE NEWS UPDATE, DOI [10.1002/jcc, DOI 10.1002/JCC]
   Wade R C, 1989, Prog Clin Biol Res, V289, P433
   Yusuf D., 2008, ALTERNATIVE METHOD E, P1411
NR 45
TC 4
Z9 4
U1 2
U2 2
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0882-4010
J9 MICROB PATHOGENESIS
JI Microb. Pathog.
PD NOV
PY 2020
VL 148
AR 104365
DI 10.1016/j.micpath.2020.104365
PG 6
WC Immunology; Microbiology
SC Immunology; Microbiology
GA OV9FN
UT WOS:000592506700005
PM 32619669
DA 2021-01-01
ER

PT J
AU Tohidinia, M
   Sefid, F
AF Tohidinia, Maryam
   Sefid, Fatemeh
TI Identification B and T-Cell epitopes and functional exposed amino acids
   of S protein as a potential vaccine candidate against
   SARS-CoV-2/COVID-19
SO MICROBIAL PATHOGENESIS
LA English
DT Article
DE SARS-CoV-2/COVID-19; Spike protein; T and B cell epitopes prediction;
   Vaccine design
ID NEUTRALIZING ANTIBODIES; WEB SERVER; PREDICTION; GLYCOPROTEIN;
   RECOGNITION; TOPOLOGY; MODEL; WUHAN
AB Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus that it disease spreads in over the world. Coronaviruses are single-stranded, positive-sense RNA viruses with a genome of approximately 30 KD, the largest genome among RNA viruses. Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness and recover without requiring special treatment. Older people and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease, and cancer are more likely to develop serious illness. At this time, there are no specific vaccines or treatments for COVID-19. So, there is an emergency need for vaccines and antiviral strategies. The spike protein is the major surface protein that it uses to bind to a receptor of another protein that acts as a doorway into a human cell. The putative antigenic epitopes may prove effective as novel vaccines for eradication and combating of COV19 infection. A combination of available bioinformatics tools are used to synthesis of such peptides that are important for the development of a vaccine. In conclusion, amino acids 250-800 were selected as effective B cell epitopes, T cell epitopes, and functional exposed amino acids in order to a recombinant vaccine against coronavirus.
C1 [Tohidinia, Maryam] Yazd Univ, Dept Biol, Fac Sci, Safaeih, Yazd, Iran.
   [Sefid, Fatemeh] Shahid Sadoughi Univ Med Sci, Dept Med Genet, Yazd, Iran.
   [Sefid, Fatemeh] Sci & Art Univ, Dept Biol, Yazd, Iran.
RP Tohidinia, M (corresponding author), Yazd Univ, Dept Biol, Fac Sci, Safaeih, Yazd, Iran.
EM Maryamtohidi90@yahoo.com; sefid.fateme@yahoo.com
CR Alsaadi EAJ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11090825
   Bagos PG, 2004, NUCLEIC ACIDS RES, V32, pW400, DOI 10.1093/nar/gkh417
   Beck M., 2020, 2019 2020 NOVEL CORO, P13
   Bryson-Cahn C., 2020, NOVEL APPROACH NOVEL
   Chen J, 2007, AMINO ACIDS, V33, P423, DOI 10.1007/s00726-006-0485-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen ZW, 2005, J VIROL, V79, P2678, DOI 10.1128/JVI.79.5.2678-2688.2005
   Dimitrov I, 2014, BIOINFORMATICS, V30, P846, DOI 10.1093/bioinformatics/btt619
   Esmaeilkhani H., 2019, IMMUNOGENICITY CORK, V11, P180
   Eyal N., 2020, HUMAN CHALLENGE STUD
   Fattahian Y, 2011, MICROB PATHOGENESIS, V51, P402, DOI 10.1016/j.micpath.2011.09.004
   Gupta S, 2015, METHODS MOL BIOL, V1268, P143, DOI 10.1007/978-1-4939-2285-7_7
   Hajiaghatabar Sangroodi Y, 2015, TURK J MED SCI, V45, P1396, DOI 10.3906/sag-1407-45
   He JH, 2020, CLIN CARDIOL, V43, P789, DOI 10.1002/clc.23381
   He YX, 2006, J VIROL, V80, P5757, DOI 10.1128/JVI.00083-06
   Hoffmann M., 2020, NOVEL CORONAVIRUS 20
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Janeway C. A., 2001, IMMUNOBIOLOGY IMMUNE
   Jrjgasb Bryson, 2007, 2 GLOBAL SHIFT OFFSH, V89, P31
   Kaladhar DJIJoPSR, 2011, SARS GENOME, V7, P137
   Kalita P, 2020, MICROB PATHOGENESIS, V145, DOI 10.1016/j.micpath.2020.104236
   Kaper J.B., 2004, OVERVIEW BIOTECHNOLO, P38
   Kawase M, 2019, J VIROL, V93, DOI 10.1128/JVI.00785-19
   Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053
   Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315
   Letko M, 2020, FUNCTIONAL ASSESSMEN
   Lin Q., 2020, CONCEPTUAL MODEL COR
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Ma X.-L., 2020, MANAGEMENT STRATEGIE, P1
   Mallik K., 2020, USE ISOELECTRIC POIN
   Maranas CDJb, 2020, BIOPHYSICAL CHARACTE
   Oezguen N, 2008, MOL IMMUNOL, V45, P3740, DOI 10.1016/j.molimm.2008.05.026
   Pirovano W, 2008, BIOINFORMATICS, V24, P492, DOI 10.1093/bioinformatics/btm636
   Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514
   Saha S, 2004, LECT NOTES COMPUT SC, V3239, P197
   Saha Sudipto, 2007, V409, P387, DOI 10.1007/978-1-60327-118-9_29
   Salarpour A., 2016, LINEAR B CELL EPITOP
   Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520
   Shang J., 2020, STRUCTURE MOUSE CORO, V16
   Singh H, 2001, BIOINFORMATICS, V17, P1236, DOI 10.1093/bioinformatics/17.12.1236
   Sohrabi C., 2020, WHO DECLARES GLOBAL
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Tan KP, 2013, NUCLEIC ACIDS RES, V41, pW314, DOI 10.1093/nar/gkt503
   Tan Y., 2020, NOVEL IMMUNOGLOBULIN
   Tang B, 2020, INFECT DIS MODEL, V5, P248, DOI 10.1016/j.idm.2020.02.001
   Tohidinia M., 2019, FUNCTIONAL EXPOSED A, P1
   Ul Qamar MT, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2116-8
   Vita R, 2015, NUCLEIC ACIDS RES, V43, pD405, DOI 10.1093/nar/gku938
   Walls A.C., 2019, MICROSC MICROANAL, V25, P1300, DOI DOI 10.1017/S1431927619007232
   Wang N, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00298
   Wang W, 2016, DATA BRIEF, V9, P345, DOI 10.1016/j.dib.2016.05.025
   Wang XY, 2018, CURR BIOINFORM, V13, P149, DOI 10.2174/1574893612666170711154318
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Xia S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4580
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yao B., 2020, SVMTRIP METHOD PREDI, P299
   Zdobnov EM, 2001, BIOINFORMATICS, V17, P847, DOI 10.1093/bioinformatics/17.9.847
   Zhang H.-W., 2020, CORONA VIRUS INT PUB
   Zhou ZM, 2006, VACCINE, V24, P3624, DOI 10.1016/j.vaccine.2006.01.059
NR 59
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0882-4010
J9 MICROB PATHOGENESIS
JI Microb. Pathog.
PD NOV
PY 2020
VL 148
AR 104459
DI 10.1016/j.micpath.2020.104459
PG 14
WC Immunology; Microbiology
SC Immunology; Microbiology
GA OV9FB
UT WOS:000592505500009
PM 32835775
OA Green Published
DA 2021-01-01
ER

PT J
AU Bogossian, EG
   Taccone, FS
   Izzi, A
   Yin, N
   Garufi, A
   Hublet, S
   Njimi, H
   Ego, A
   Gorham, J
   Byl, B
   Brasseur, A
   Hites, M
   Vincent, JL
   Creteur, J
   Grimaldi, D
AF Bogossian, Elisa G.
   Taccone, Fabio S.
   Izzi, Antonio
   Yin, Nicolas
   Garufi, Alessandra
   Hublet, Stephane
   Njimi, Hassane
   Ego, Amedee
   Gorham, Julie
   Byl, Baudouin
   Brasseur, Alexandre
   Hites, Maya
   Vincent, Jean-Louis
   Creteur, Jacques
   Grimaldi, David
TI The Acquisition of Multidrug-Resistant Bacteria in Patients Admitted to
   COVID-19 Intensive Care Units: A Monocentric Retrospective Case Control
   Study
SO MICROORGANISMS
LA English
DT Article
DE antimicrobial resistance; Enterobacteriaceae; subarachnoid hemorrhage;
   critically illness; infection control; viral pandemic; SARS-CoV-2
ID INFECTIONS; STAY
AB Whether the risk of multidrug-resistant bacteria (MDRB) acquisition in the intensive care unit (ICU) is modified by the COVID-19 crisis is unknown. In this single center case control study, we measured the rate of MDRB acquisition in patients admitted in COVID-19 ICU and compared it with patients admitted in the same ICU for subarachnoid hemorrhage (controls) matched 1:1 on length of ICU stay and mechanical ventilation. All patients were systematically and repeatedly screened for MDRB carriage. We compared the rate of MDRB acquisition in COVID-19 patients and in control using a competing risk analysis. Of note, although we tried to match COVID-19 patients with septic shock patients, we were unable due to the longer stay of COVID-19 patients. Among 72 patients admitted to the COVID-19 ICUs, 33% acquired 31 MDRB during ICU stay. The incidence density of MDRB acquisition was 30/1000 patient days. Antimicrobial therapy and exposure time were associated with higher rate of MDRB acquisition. Among the 72 SAH patients, 21% acquired MDRB, with an incidence density was 18/1000 patient days. The septic patients had more comorbidities and a greater number of previous hospitalizations than the COVID-19 patients. The incidence density of MDRB acquisition was 30/1000 patient days. The association between COVID-19 and MDRB acquisition (compared to control) risk did not reach statistical significance in the multivariable competing risk analysis (sHR 1.71 (CI 95% 0.93-3.21)). Thus, we conclude that, despite strong physical isolation, acquisition rate of MDRB in ICU patients was at least similar during the COVID-19 first wave compared to previous period.
C1 [Bogossian, Elisa G.; Taccone, Fabio S.; Izzi, Antonio; Garufi, Alessandra; Njimi, Hassane; Ego, Amedee; Gorham, Julie; Brasseur, Alexandre; Vincent, Jean-Louis; Creteur, Jacques; Grimaldi, David] Univ Libre Bruxelles, CUB Hop Erasme, Dept Intens Care, B-1070 Brussels, Belgium.
   [Yin, Nicolas] Univ Libre Bruxelles, LHUB ULB, Dept Microbiol, B-1070 Brussels, Belgium.
   [Hublet, Stephane] Univ Libre Bruxelles, CUB Hop Erasme, Dept Anesthesiol, B-1070 Brussels, Belgium.
   [Byl, Baudouin] Univ Libre Bruxelles, CUB Hop Erasme, Clin Epidemiol & Hyg Hosp, B-1070 Brussels, Belgium.
   [Hites, Maya] Univ Libre Bruxelles, Dept Infect Dis, CUB Hop Erasme, B-1070 Brussels, Belgium.
RP Grimaldi, D (corresponding author), Univ Libre Bruxelles, CUB Hop Erasme, Dept Intens Care, B-1070 Brussels, Belgium.
EM elisagobog@gmail.com; Fabio.Taccone@erasme.ulb.ac.be;
   antonioizzi1201@gmail.com; nicolas.yin@erasme.ulb.ac.be;
   garufi.ale@gmail.com; stephane.hublet@erasme.ulb.ac.be;
   hnjimi@ulb.ac.be; amedee.ego@erasme.ulb.ac.be;
   Julie.Gorham@erasme.ulb.ac.be; Baudouin.Byl@erasme.ulb.ac.be;
   alexandre.brasseur@erasme.ulb.ac.be; Maya.Hites@erasme.ulb.ac.be;
   jlvincent@intensive.org; jacques.creteur@erasme.ulb.ac.be;
   david.grimaldi@erasme.ulb.ac.be
OI Gouvea Bogossian, Elisa/0000-0002-2062-465X; Yin,
   Nicolas/0000-0003-1706-6869
CR Alaraj A, 2017, J CLIN NEUROSCI, V42, P66, DOI 10.1016/j.jocn.2017.03.049
   Bogossian Elisa G, 2020, World Neurosurg, V144, pe883, DOI 10.1016/j.wneu.2020.09.102
   Boyce JM, 2002, AM J INFECT CONTROL, V30, pS1, DOI 10.1067/mic.2002.130391
   Brusselaers N, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-47
   Burn Edward, 2020, medRxiv, DOI 10.1101/2020.04.22.20074336
   CDC, 2013, ANTIBIOTIC RESISTANC
   Chatzopoulou M, 2020, J HOSP INFECT, V104, P125, DOI 10.1016/j.jhin.2019.09.011
   CHETCHOTISAKD P, 1994, CLIN INFECT DIS, V18, P929, DOI 10.1093/clinids/18.6.929
   Clancy Cornelius J, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa524
   COVID19 APHP Grp, 2020, LANCET, V395, P1760, DOI 10.1016/S0140-6736(20)31210-1
   De Bus L, 2016, INTENS CARE MED, V42, P1029, DOI 10.1007/s00134-016-4301-z
   De Waele JJ, 2020, CURR OPIN ANESTHESIO, V33, P156, DOI 10.1097/ACO.0000000000000830
   Falagas ME, 2014, EMERG INFECT DIS, V20, P1170, DOI 10.3201/eid2007.121004
   Godoy LRG, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-002553
   Grimaldi D, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00751-y
   Grundmann H., 1999, Clinical Microbiology and Infection, V5, P355, DOI 10.1111/j.1469-0691.1999.tb00154.x
   Gutierrez-Gutierrez B, 2019, CLIN MICROBIOL INFEC, V25, P932, DOI 10.1016/j.cmi.2019.03.030
   Huttner A, 2013, ANTIMICROB RESIST IN, V2, DOI 10.1186/2047-2994-2-31
   Kerneis S, 2019, SEMIN RESP CRIT CARE, V40, P558, DOI 10.1055/s-0039-1696980
   Li RR, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8297
   Magiorakos AP, 2012, CLIN MICROBIOL INFEC, V18, P268, DOI 10.1111/j.1469-0691.2011.03570.x
   Morens DM, 2008, J INFECT DIS, V198, P962, DOI 10.1086/591708
   Murray AK, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01020
   Nieuwlaat Robby, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa773
   Osterholm MT, 2005, NEW ENGL J MED, V352, P1839, DOI 10.1056/NEJMp058068
   Ranney ML, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2006141
   Rawson TM, 2020, J ANTIMICROB CHEMOTH, V75, P1681, DOI 10.1093/jac/dkaa194
   Rawson Timothy M, 2020, Clin Infect Dis, V71, P2459, DOI 10.1093/cid/ciaa530
   Sturdy A, 2020, J HOSP INFECT, V105, P593, DOI 10.1016/j.jhin.2020.06.027
   The European Committee on Antimicrobial Susceptibility Testing, 2019, BREAKP TABL INT MICS
   Witiw CD, 2013, NEUROCRIT CARE, V18, P291, DOI 10.1007/s12028-013-9815-4
   World Health Organization, 2020, COR DIS COVID 2019 S
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 33
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-2607
J9 MICROORGANISMS
JI Microorganisms
PD NOV
PY 2020
VL 8
IS 11
AR 1821
DI 10.3390/microorganisms8111821
PG 11
WC Microbiology
SC Microbiology
GA OX0RN
UT WOS:000593283300001
PM 33227956
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Morollon, N
   Belvis, R
   De Dios, A
   Pages, N
   Gonzalez-Oria, C
   Latorre, G
   Santos-Lasaosa, S
AF Morollon, N.
   Belvis, R.
   De Dios, A.
   Pages, N.
   Gonzalez-Oria, C.
   Latorre, G.
   Santos-Lasaosa, S.
TI Standard headache and neuralgia treatments and SARS-CoV-2: opinion of
   the Spanish Society of Neurology's Headache Study Group
SO NEUROLOGIA
LA Spanish
DT Article
DE COVID-19; Lisinopril; Candesartan; Ibuprofen; Corticosteroids; Headache
ID RECEPTOR BLOCKERS; CORONAVIRUS
AB Introduction: In recent months, doubts have arisen among patients, general practitioners, and neurologists as to whether some drugs commonly used in patients with headaches and neuralgia may favour or complicate the disease caused by SARS-CoV-2.
   Material and methods: We collected information on the opinions of scientific societies and medicines agencies (American, European, and Spanish) to clarify doubts regarding the use of drugs such as lisinopril, candesartan, ibuprofen, corticosteroids, carbamazepine, and monoclonal antibodies targeting the calcitonin gene-related peptide in the context of the COVID-19 pandemic.
   Results: We make recommendations about the use of standard headache treatments in the context of the COVID-19 pandemic, based on the current scientific evidence.
   Conclusions: At present, there is no robust scientific argument to formally contraindicate any of the standard treatments employed for headaches and neuralgias. (C) 2020 Sociedad Espanola de Neurologia. Published by Elsevier Espana, S.L.U.
C1 [Morollon, N.; Belvis, R.] Hosp Santa Creu & Sant Pau, Serv Neurol, Unidad Cefaleas & Neuralgias, Barcelona, Spain.
   [De Dios, A.; Pages, N.] Hosp Santa Creu & Sant Pau, Serv Farm Hosp, Barcelona, Spain.
   [Gonzalez-Oria, C.] Hosp Univ Fuenlabrada, Serv Neurol, Unidad Cefaleas, Madrid, Spain.
   [Latorre, G.] Hosp Univ Virgen del Rocio, Serv Neurol, Unidad Cefaleas, Seville, Spain.
   [Santos-Lasaosa, S.] Inst Invest Sanitaria Aragon IIS Aragon, Hosp Clin Univ Lozano Blesa, Serv Neurol, Unidad Cefaleas, Zaragoza, Spain.
RP Morollon, N (corresponding author), Hosp Santa Creu & Sant Pau, Serv Neurol, Unidad Cefaleas & Neuralgias, Barcelona, Spain.
EM noemimorollon@gmail.com
CR Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Belvis R, 2020, HEADACHE, V60, P1422, DOI 10.1111/head.13841
   Bolay H, 2020, HEADACHE, V60, P1415, DOI 10.1111/head.13856
   Carod-Artal FJ, 2020, REV NEUROLOGIA, V70, P311, DOI 10.33588/rn.7009.2020179
   European Medicines Agency, 2020, EMA GIV ADV US NONST
   Ezpeleta D, 2015, GUIDELINES SPANISH S
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Food and Drug Administration, FDA ADV PAT US NONST
   Garcia Azorin D, 2020, MANUAL COVID 19 NEUR, P68
   Kanoh S, 2010, CLIN MICROBIOL REV, V23, P590, DOI 10.1128/CMR.00078-09
   MAASSENVANDENBRINK, 2020, J HEADACHE PAIN, V21, DOI DOI 10.1186/S10194-020-01106-5
   Montagud-Marrahi E, 2020, AM J TRANSPLANT, V20, P2958, DOI 10.1111/ajt.15970
   Qiao WL, 2015, CARDIOLOGY, V131, P97, DOI 10.1159/000375362
   Sciensano Epidemiology of Infectious Disease, 2020, INTERIM CLIN GUIDANC
   Soler MJ, 2009, AM J PHYSIOL-RENAL, V296, pF398, DOI 10.1152/ajprenal.90488.2008
   Sormani MP, 2020, LANCET NEUROL, V19, P481, DOI 10.1016/S1474-4422(20)30147-2
   Tschopp J, 2020, AM J TRANSPLANT, V20, P2876, DOI 10.1111/ajt.16062
   Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5
   Wang XX, 2016, J MOL CELL CARDIOL, V97, P180, DOI 10.1016/j.yjmcc.2016.05.012
   World Health Organization, 2020, COULD IB WORS DIS PE
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER ESPANA SLU
PI BARCELONA
PA AV JOSEP TARRADELLAS, 20-30, 1ERA PLANTA, BARCELONA, CP-08029, SPAIN
SN 0213-4853
EI 1578-1968
J9 NEUROLOGIA
JI Neurologia
PD NOV-DEC
PY 2020
VL 35
IS 9
BP 628
EP 632
DI 10.1016/j.nrl.2020.07.007
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA OU8HB
UT WOS:000591762900002
PM 32896463
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Binda, B
   Picchi, G
   Carucci, AC
   Sinatti, G
   Di Norcia, M
   Grimaldi, A
   Lancione, L
   Natili, A
   Chiappori, D
   Montali, F
   Lupi, D
   Martinez, V
   Panarese, A
   D'anselmi, F
   Pisani, F
AF Binda, Barbara
   Picchi, Giovanna
   Carucci, Anna Cecilia
   Sinatti, Gaia
   Di Norcia, Monica
   Grimaldi, Alessandro
   Lancione, Laura
   Natili, Andrea
   Chiappori, Davide
   Montali, Filippo
   Lupi, Diana
   Martinez, Viviana
   Panarese, Alessandra
   D'anselmi, Fabrizio
   Pisani, Francesco
TI Follow-up and Management of Kidney Transplant Recipients During the
   COVID-19 Lockdown: The Experience of an Italian Transplant Center,
   Including Two Cases of COVID-19 Pneumonia
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID INHIBITORS
AB Background. Coronavirus disease 2019 (COVID-19) is a new infectious disease that emerged in China in late 2019 and is now spreading around the world. Social distancing measures were needed to reduce transmission, and lockdown included restricted access to health care facilities. The impact of COVID-19 on transplant recipients is unknown, but considering their immunosuppression status and associated comorbidities, they should be considered a high-risk population.
   Methods. A kidney transplant center in Central Italy implemented a strategy to maintain follow-up of kidney transplant recipients by phone and e-mail during lockdown. Telephone interviews were used to administer a clinical questionnaire to patients, and e-mail was used to receive the results of diagnostic tests conducted in outpatient settings.
   Results. From March 17 to April 23, 2020, a total of 143 kidney transplant recipients were contacted. Twenty-eight patients needed in-hospital consultation for problems unrelated to COVID-19, 3 of whom needed hospitalization. Eleven patients were managed at home for mild urinary or respiratory diseases, and 1 was referred to the hematologist. We identified 2 suspected cases of COVID-19 infection, and the patients were referred to hospital care. Immunosuppressive therapy was modulated, and intravenous corticosteroids and potentially effective antiviral therapy were administered with a favorable outcome.
   Conclusions. In the context of a lockdown, such as that occurring in response to COVID-19, we suggest implementing remote surveillance programs in kidney transplant recipients with the help of any available technology and offering medical consulting and logistic support as needed.
C1 [Binda, Barbara; Lancione, Laura; Natili, Andrea; Chiappori, Davide; D'anselmi, Fabrizio] San Salvatore Hosp, Gen & Transplant Surg Dept, ASL Abruzzo 1, Laquila, Italy.
   [Picchi, Giovanna; Carucci, Anna Cecilia; Sinatti, Gaia; Di Norcia, Monica; Grimaldi, Alessandro] San Salvatore Hosp, Infect Dis Dept, ASL Abruzzo 1, Laquila, Italy.
   [Lupi, Diana; Martinez, Viviana] San Salvatore Hosp, Reg Transplant Coordinat Ctr Abruzzo Molise, ASL Abruzzo 1, Laquila, Italy.
   [Montali, Filippo; Panarese, Alessandra; Pisani, Francesco] Univ Aquila, Gen & Transplant Surg Dept, DISCAB, Laquila, Italy.
RP Binda, B (corresponding author), San Salvatore Hosp, Via Lorenzo Natali, I-67100 Laquila, Italy.
EM bindabarbara@gmail.com
FU Novartis Farma SpA
FX We thank Joanne Dalton, an independent medical writer, who provided
   English language editing and journal styling prior to submission on
   behalf of Springer Healthcare. This assistance was funded by Novartis
   Farma SpA.
CR Alberici F, 2020, KIDNEY INT REP, V5, P580, DOI 10.1016/j.ekir.2020.04.001
   [Anonymous], 2020, IDROSSICLOROCHINA NE
   Chen S, 2020, AM J TRANSPLANT, V20, P1869, DOI 10.1111/ajt.15903
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Fong MW, 2020, EMERG INFECT DIS, V26, P976, DOI 10.3201/eid2605.190995
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Guillen E, 2020, AM J TRANSPLANT, V20, P1875, DOI 10.1111/ajt.15874
   Kleinsteuber A, 2018, TRANSPL P, V50, P3232, DOI 10.1016/j.transproceed.2018.08.028
   Lopez V, 2020, NEFROLOGIA, V40, P265, DOI 10.1016/j.nefro.2020.03.002
   Michaels MG, 2020, AM J TRANSPLANT, V20, P1768, DOI 10.1111/ajt.15832
   Pan A, 2020, JAMA-J AM MED ASSOC, V323, P1915, DOI 10.1001/jama.2020.6130
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Ventura-Aguiar P, 2016, EXPERT OPIN DRUG SAF, V15, P303, DOI 10.1517/14740338.2016.1132698
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang Y, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0158-2
   World Health Organization, 2020, CLIN MANAGEMENT SEVE
   World Health Organization, 2020, CORONAVIRUS DIS 2019
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhu L, 2020, AM J TRANSPLANT, V20, P1859, DOI 10.1111/ajt.15869
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD NOV
PY 2020
VL 52
IS 9
BP 2614
EP 2619
DI 10.1016/j.transproceed.2020.06.026
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA OL1KN
UT WOS:000585100600008
PM 32709413
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Aziz, H
   Lashkari, N
   Yoon, YC
   Kim, J
   Sher, LS
   Genyk, Y
   Kwon, YK
AF Aziz, Hassan
   Lashkari, Nassim
   Yoon, Young Chul
   Kim, Jim
   Sher, Linda S.
   Genyk, Yuri
   Kwon, Yong K.
TI Effects of Coronavirus Disease 2019 on Solid Organ Transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID COVID-19; INFECTION
AB Background. As the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged as a viral pandemic, data on the clinical characteristics and outcomes of patients with SARS-CoV-2 infection undergoing solid organ transplant are emerging. The objective of this systematic review was to assess currently published literature relating to the management, clinical course, and outcome of SARS-CoV-2 infection in liver, kidney, and heart solid organ transplant recipients.
   Methods. We conducted a systematic review to assess currently published literature relating to the management, clinical course, and outcome of SARS-CoV-2 infection in liver, kidney, and heart solid organ transplant recipients. Articles published through June 2020 were searched in the MEDLINE, Clinical Trials.gov, and PubMed databases. We identified 49 eligible studies comprising a total of 403 solid organ transplant recipients.
   Results. Older age, male sex, and preexisting comorbidities, including hypertension and/ or diabetes, were the most common prevailing characteristics among the solid organ transplant recipients. Clinical presentation ranged from mild to severe disease, including multiorgan failure and death. We found an overall mortality rate of 21%.
   Conclusion. Our analysis suggests no increase in overall mortality or worse outcome in solid organ transplant recipients receiving immunosuppressive therapy compared with mortality in the general surgical population with SARS-CoV-2. Our findings suggest that transplant surgery and its immunosuppressive effects should not be a deterrent to proper surgical care for patients in the SARS-CoV-2 era.
C1 [Aziz, Hassan; Lashkari, Nassim; Kim, Jim; Sher, Linda S.; Genyk, Yuri; Kwon, Yong K.] Univ Southern Calif, Keck Sch Med, Dept Surg, Div Hepatobiliary Pancreas & Abdominal Organ Tran, 1510 San Pablo St,Suite 200, Los Angeles, CA 90033 USA.
   [Yoon, Young Chul] Catholic Univ Korea, Dept Surg, Incheon St Marys Hosp, Seoul, South Korea.
RP Kwon, YK (corresponding author), Univ Southern Calif, Keck Sch Med, Dept Surg, Div Hepatobiliary Pancreas & Abdominal Organ Tran, 1510 San Pablo St,Suite 200, Los Angeles, CA 90033 USA.
EM Yong.Kwon@med.usc.edu
CR Abrishami A, 2020, EUR UROL, V78, P281, DOI 10.1016/j.eururo.2020.04.064
   Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   Alberici F, 2020, KIDNEY INT REP, V5, P580, DOI 10.1016/j.ekir.2020.04.001
   [Anonymous], 2020, WHO DIRECTOR GEN OPE
   Arpali E, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13296
   Aziz Hassan, 2020, J Surg Educ, DOI 10.1016/j.jsurg.2020.07.037
   Aziz H, 2020, AM SURGEON, V86, P341
   Banerjee D, 2020, KIDNEY INT, V97, P1076, DOI 10.1016/j.kint.2020.03.018
   Besnier E, 2020, WORLD J SURG, V44, P1695, DOI 10.1007/s00268-020-05501-6
   Bhoori S, 2020, LANCET GASTROENTEROL, V5, P532, DOI 10.1016/S2468-1253(20)30116-3
   Billah M, 2020, TRANSPL INT, V33, P1140, DOI 10.1111/tri.13635
   Boyarsky BJ, 2020, AM J TRANSPLANT, V20, P1809, DOI 10.1111/ajt.15915
   Bush R, 2020, AM J TRANSPLANT, V20, P2942, DOI 10.1111/ajt.16003
   Chen S, 2020, AM J TRANSPLANT, V20, P1869, DOI 10.1111/ajt.15903
   Cheng DR, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13329
   COVIDsurg Collaborative, 2020, LANCET, V396, P27, DOI 10.1016/S0140-6736(20)31182-X
   Crespo M, 2020, AM J TRANSPLANT, V20, P2883, DOI 10.1111/ajt.16096
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Fishman JA, 2017, AM J TRANSPLANT, V17, P856, DOI 10.1111/ajt.14208
   Fishman JA, 2020, AM J TRANSPLANT, V20, P1765, DOI 10.1111/ajt.15890
   Fontana F, 2020, AM J TRANSPLANT, V20, P1902, DOI 10.1111/ajt.15935
   Fung M, 2020, AM J TRANSPLANT, V20, P3225, DOI 10.1111/ajt.16079
   Gandolfini I, 2020, AM J TRANSPLANT, V20, P1941, DOI 10.1111/ajt.15891
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guillen E, 2020, AM J TRANSPLANT, V20, P1875, DOI 10.1111/ajt.15874
   Hammami MB, 2020, AM J TRANSPLANT, V20, P2254, DOI 10.1111/ajt.15985
   Hoek RAS, 2020, TRANSPL INT, V33, P1099, DOI 10.1111/tri.13662
   Holzhauser L, 2020, AM J TRANSPLANT, V20, P2916, DOI 10.1111/ajt.15982
   Hsu JJ, 2020, AM J TRANSPLANT, V20, P1911, DOI 10.1111/ajt.15936
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang JF, 2020, AM J TRANSPLANT, V20, P1907, DOI 10.1111/ajt.15909
   Huang JF, 2020, AM J TRANSPLANT, V20, P1879, DOI 10.1111/ajt.15896
   Kates OS, 2020, AM J TRANSPLANT, V20, P1885, DOI 10.1111/ajt.15944
   Kim Y, 2020, AM J TRANSPLANT, V20, P2269, DOI 10.1111/ajt.15947
   Kumar RN, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13338
   Lagana SM, 2020, ARCH PATHOL LAB MED, V144, P929, DOI 10.5858/arpa.2020-0186-SA
   Latif F, 2020, JAMA CARDIOL, V5, P1165, DOI 10.1001/jamacardio.2020.2159
   Lee BT, 2020, GASTROENTEROLOGY, V159, P1176, DOI 10.1053/j.gastro.2020.05.050
   Lei S, 2020, ECLINICALMEDICINE, V21, DOI [10.1016/j.eclinm.2020.100331.9., DOI 10.1016/JECLINM.2020.200331]
   Li F, 2020, J HEART LUNG TRANSPL, V39, P496, DOI 10.1016/j.healun.2020.03.006
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Liu B, 2020, AM J TRANSPLANT, V20, P1891, DOI 10.1111/ajt.15901
   Machado DJD, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13306
   Marx D, 2020, AM J TRANSPLANT, V20, P1944, DOI 10.1111/ajt.15919
   Michaels MG, 2020, AM J TRANSPLANT, V20, P1768, DOI 10.1111/ajt.15832
   Modi AR, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13351
   Mohan S, 2020, J AM SOC NEPHROL, V31, P1150, DOI 10.1681/ASN.2020030375
   Morand A, 2020, ARCH PEDIATRIE, V27, P275, DOI 10.1016/j.arcped.2020.05.004
   Moris D, 2020, TRANSPL INT, V33, P826, DOI 10.1111/tri.13614
   Nair V, 2020, AM J TRANSPLANT, V20, P1819, DOI 10.1111/ajt.15967
   Ning L, 2020, AM J TRANSPLANT, V20, P1864, DOI 10.1111/ajt.15897
   Patrono D, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13353
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Qin JJ, 2020, HEPATOLOGY, V72, P1491, DOI 10.1002/hep.31257
   Romanelli A, 2020, J BIOMED RES REV, V3, P32
   Romero FA, 2011, WORLD J HEPATOL, V3, P83, DOI 10.4254/wjh.v3.i4.83
   Russell MR, 2020, J HEART LUNG TRANSPL, V39, P732, DOI 10.1016/j.healun.2020.04.021
   Seminari E, 2020, AM J TRANSPLANT, V20, P1882, DOI 10.1111/ajt.15902
   Travi G, 2020, AM J TRANSPLANT, V20, P2628, DOI 10.1111/ajt.16069
   Tschopp J, 2020, AM J TRANSPLANT, V20, P2876, DOI 10.1111/ajt.16062
   Umberto M, 2020, AM J TRANSPLANT, V20, P1840, DOI 10.1111/ajt.15948
   Wang JP, 2020, EUR UROL, V77, P769, DOI 10.1016/j.eururo.2020.03.036
   Yi SG, 2020, TRANSPLANTATION, V104, P2208, DOI 10.1097/TP.0000000000003339
   Zhang H, 2020, EUR UROL, V77, P742, DOI 10.1016/j.eururo.2020.03.030
   Zhong ZB, 2020, AM J TRANSPLANT, V20, P1916, DOI 10.1111/ajt.15928
   Zhu L, 2020, AM J TRANSPLANT, V20, P1859, DOI 10.1111/ajt.15869
NR 67
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD NOV
PY 2020
VL 52
IS 9
BP 2642
EP 2653
DI 10.1016/j.transproceed.2020.09.006
PG 12
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA OL1KN
UT WOS:000585100600013
PM 33127076
OA Green Published
DA 2021-01-01
ER

PT J
AU Aziz, F
   Mandelbrot, D
   Singh, T
   Parajuli, S
   Garg, N
   Mohamed, M
   Astor, BC
   Djamali, A
AF Aziz, Fahad
   Mandelbrot, Didier
   Singh, Tripti
   Parajuli, Sandesh
   Garg, Neetika
   Mohamed, Maha
   Astor, Brad C.
   Djamali, Arjang
TI Early Report on Published Outcomes in Kidney Transplant Recipients
   Compared to Nontransplant Patients Infected With Coronavirus Disease
   2019
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID WUHAN
AB Background. Kidney transplant recipients (KTR) present unique characteristics, including disease vintage, immunosuppression, and single functioning kidneys. We conducted preliminary analyses to assess the impact of coronavirus disease 2019 (COVID-19) on outcomes in KTR compared to nontransplant patients.
   Methods. We evaluated published information in peer-reviewed journals between January 1, 2020, and April 24, 2020, with available data on acute kidney injury (AKI), renal replacement therapy (RRT), intensive care unit (ICU) stay, and death and compared clinical outcomes in KTR vs nontransplant recipients with COVID-19.
   Results. A total of 19 published articles were identified, including a total of 88 KTR and 5342 nontransplant patients. The sample size varied between 2 and 2634. Mean age was 58.6 years vs 58.9 years in KTR vs nontransplant patients. Patient-level incidence of AKI (27.5% vs 13.3%, P < .001), RRT (15.4% vs 3.3%, P < .001), ICU stay (34.1% vs 15.1%, P < .001), and death (22.7% vs 16.2%, P = .10) was higher in KTR, representing relative risks of 2.06 (1.44, 2.96), 4.72 (2.62, 8.51), 2.25 (1.67, 3.03), and 1.41 (0.95, 2.08), respectively.
   Conclusion. Early results suggest that the KTR are at significantly higher risk of AKI, RRT, and ICU stay from SARS-CoV-19 infection compared to the general population. The risk of death may not be significantly different.
C1 [Aziz, Fahad; Mandelbrot, Didier; Singh, Tripti; Parajuli, Sandesh; Garg, Neetika; Mohamed, Maha; Astor, Brad C.; Djamali, Arjang] Univ Wisconsin, Univ Wisconsin Hosp & Clin, Dept Med, Div Nephrol,Sch Med & Publ Hlth, Madison, WI USA.
   [Astor, Brad C.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA.
   [Djamali, Arjang] Univ Wisconsin, Univ Wisconsin Hosp & Clin, Dept Surg, Div Transplantat,Sch Med & Publ Hlth, Madison, WI USA.
RP Aziz, F (corresponding author), 1685 Highland Ave,Mail Code 2281, Madison, WI 53705 USA.
EM faziz@wisc.edu
RI Aziz, Fahad/B-8351-2017
OI aziz, fahad/0000-0001-8230-3889
CR Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   Alberici F, 2020, KIDNEY INT, V97, P1083, DOI 10.1016/j.kint.2020.04.002
   Banerjee D, 2020, KIDNEY INT, V97, P1076, DOI 10.1016/j.kint.2020.03.018
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Columbia University Kidney Transplant Program, 2020, EARLY DESCRIPTION CO
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Gandolfini I, 2020, AM J TRANSPLANT, V20, P1941, DOI 10.1111/ajt.15891
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5
   Wang LW, 2020, AM J NEPHROL, V51, P343, DOI 10.1159/000507471
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 20
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD NOV
PY 2020
VL 52
IS 9
BP 2659
EP 2662
DI 10.1016/j.transproceed.2020.07.002
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA OL1KN
UT WOS:000585100600015
PM 32753243
OA Green Published
DA 2021-01-01
ER

PT J
AU Mathiasen, VD
   Oversoe, SK
   Ott, P
   Jensen-Fangel, S
   Leth, S
AF Mathiasen, Victor Dahl
   Oversoe, Stine Karlsen
   Ott, Peter
   Jensen-Fangel, Soren
   Leth, Steffen
TI Recovery of Moderate Coronavirus Disease 2019 in a Liver Transplant
   Recipient on Continued Immunosuppression: A Case Report
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID COVID-19
AB The global outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had an enormous impact on the world. Owing to limited data available, it remains unclear to what extent liver transplant recipients should be considered at a higher risk of severe disease.
   We describe a moderate course of coronavirus disease 2019 (COVID-19) in a patient who underwent a liver transplant 2 years earlier because of Budd-Chiari syndrome. The patient presented with malaise, headache, dry cough, and fever for 4 days Immunosuppressive therapy with tacrolimus and mycophenolate mofetil was continued throughout the course of infection. Oxygen therapy was given for a single night, and the patient gradually recovered with supportive care only.
   With this case report, we demonstrate that liver transplantation and immunosuppression is not necessarily associated with severe COVID-19 and emphasize that more information on this matter is urgently required. Withdrawal of immunosuppressive therapy could be associated with higher mortality.
C1 [Mathiasen, Victor Dahl; Jensen-Fangel, Soren; Leth, Steffen] Aarhus Univ Hosp, Dept Infect Dis, Palle Juul Jensens Blvd 99, DK-8200 Aarhus N, Denmark.
   [Oversoe, Stine Karlsen; Ott, Peter] Aarhus Univ Hosp, Dept Hepatol & Gastroenterol, Aarhus, Denmark.
RP Mathiasen, VD (corresponding author), Aarhus Univ Hosp, Dept Infect Dis, Palle Juul Jensens Blvd 99, DK-8200 Aarhus N, Denmark.
EM victordahl@gmail.com
RI Dahl Mathiasen, Victor/X-2810-2019
OI Dahl Mathiasen, Victor/0000-0003-2965-6348; Oversoe, Stine
   Karlsen/0000-0001-9762-1679; Leth, Steffen/0000-0003-3194-9844
CR Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   Belli LS, 2020, LANCET GASTROENTEROL, V5, P724, DOI 10.1016/S2468-1253(20)30183-7
   Bhoori S, 2020, LANCET GASTROENTEROL, V5, P532, DOI 10.1016/S2468-1253(20)30116-3
   Boettler Tobias, 2020, JHEP Rep, V2, P100113, DOI 10.1016/j.jhepr.2020.100113
   Cai QX, 2020, J HEPATOL, V73, P566, DOI 10.1016/j.jhep.2020.04.006
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Dahl Mathiasen V, 2020, BMJ CASE REP, V13
   Di Maira T, 2020, NAT REV GASTRO HEPAT, V17, P526, DOI 10.1038/s41575-020-0347-z
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Gavriilidis Paschalis, 2020, J Clin Med Res, V12, P404, DOI 10.14740/jocmr4223
   Hallas Lund LC, 2020, CHARACTERISTICS PRED
   Jothimani D, 2020, J HEPATOL, V73, P1231, DOI 10.1016/j.jhep.2020.06.006
   Lai Q, 2020, TRANSPL INFECT DIS, DOI 10.1111/tid.13404
   Lau G, 2020, HEPATOL INT, V14, P415, DOI 10.1007/s12072-020-10054-w
   Lee BT, 2020, GASTROENTEROLOGY, V159, P1176, DOI 10.1053/j.gastro.2020.05.050
   Lescure FX, 2020, LANCET INFECT DIS, V20, P697, DOI 10.1016/S1473-3099(20)30200-0
   Liu B, 2020, AM J TRANSPLANT, V20, P1891, DOI 10.1111/ajt.15901
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Parente A, 2020, TRANSPL INFECT DIS, DOI 10.1111/tid.13417
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Polak WG, 2020, TRANSPL INT, V33, P1244, DOI 10.1111/tri.13680
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, P1, DOI 10.3332/ecancer.2020.1022
   Sahin TT, 2020, WORLD J GASTROENTERO, V26, P2987, DOI 10.3748/wjg.v26.i22.2987
   Tovikkai C, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006971
   Webb GJ, 2020, LANCET GASTROENTEROL, V5, P643, DOI 10.1016/S2468-1253(20)30125-4
   World Health Organization, 2020, CLIN MANAGEMENT COVI
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD NOV
PY 2020
VL 52
IS 9
BP 2703
EP 2706
DI 10.1016/j.transproceed.2020.09.007
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA OL1KN
UT WOS:000585100600024
PM 33039144
OA Green Published
DA 2021-01-01
ER

PT J
AU Ding, SL
   Laumaea, A
   Benlarbi, M
   Beaudoin-Bussieres, G
   Gasser, R
   Medjahed, H
   Pancera, M
   Stamatatos, L
   McGuire, AT
   Bazin, R
   Finzi, A
AF Ding, Shilei
   Laumaea, Annemarie
   Benlarbi, Mehdi
   Beaudoin-Bussieres, Guillaume
   Gasser, Romain
   Medjahed, Halima
   Pancera, Marie
   Stamatatos, Leonidas
   McGuire, Andrew T.
   Bazin, Renee
   Finzi, Andres
TI Antibody Binding to SARS-CoV-2 S Glycoprotein Correlates with but Does
   Not Predict Neutralization
SO VIRUSES-BASEL
LA English
DT Article
DE COVID-19; SARS-COV-2; convalescent plasma; ELISA; neutralization; virus
   capture assay
ID GP120 INNER DOMAIN; CONVALESCENT PLASMA; THERAPY
AB Convalescent plasma from SARS-CoV-2 infected individuals and monoclonal antibodies were shown to potently neutralize viral and pseudoviral particles carrying the S glycoprotein. However, a non-negligent proportion of plasma samples from infected individuals, as well as S-specific monoclonal antibodies, were reported to be non-neutralizing despite efficient interaction with the S glycoprotein in different biochemical assays using soluble recombinant forms of S or when expressed at the cell surface. How neutralization relates to the binding of S glycoprotein in the context of viral particles remains to be established. Here, we developed a pseudovirus capture assay (VCA) to measure the capacity of plasma samples or antibodies immobilized on ELISA plates to bind to membrane-bound S glycoproteins from SARS-CoV-2 expressed at the surface of lentiviral particles. By performing VCA, ELISA, and neutralization assays, we observed a strong correlation between these parameters. However, while we found that plasma samples unable to capture viral particles did not neutralize, capture did not guarantee neutralization, indicating that the capacity of antibodies to bind to the S glycoprotein at the surface of pseudoviral particles is required but not sufficient to mediate neutralization. Altogether, our results highlight the importance of better understanding the inactivation of S by plasma and neutralizing antibodies.
C1 [Ding, Shilei; Laumaea, Annemarie; Benlarbi, Mehdi; Beaudoin-Bussieres, Guillaume; Gasser, Romain; Medjahed, Halima; Finzi, Andres] Ctr Rech CHUM, Montreal, PQ H2X 0A9, Canada.
   [Laumaea, Annemarie; Beaudoin-Bussieres, Guillaume; Gasser, Romain; Finzi, Andres] Univ Montreal, Dept Microbiol Infectiol & Immunol, Montreal, PQ H2X 0A9, Canada.
   [Pancera, Marie; Stamatatos, Leonidas; McGuire, Andrew T.] Fred Hutchinson Canc Res Ctr, Vaccines & Infect Dis Div, Seattle, WA 98109 USA.
   [Pancera, Marie] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Stamatatos, Leonidas; McGuire, Andrew T.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
   [Bazin, Renee] Hema Quebec, Affaires Med & Innovat, Quebec City, PQ G1V 5C3, Canada.
   [Finzi, Andres] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada.
RP Finzi, A (corresponding author), Ctr Rech CHUM, Montreal, PQ H2X 0A9, Canada.; Finzi, A (corresponding author), Univ Montreal, Dept Microbiol Infectiol & Immunol, Montreal, PQ H2X 0A9, Canada.; Finzi, A (corresponding author), McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada.
EM ding.shilei@gmail.com; annemarie.laumaea@umontreal.ca;
   mben1068@uottawa.ca; guillaume.beaudoin-bussieres@umontreal.ca;
   romain.gasser@umontreal.ca; halima.medjahed.chum@ssss.gouv.qc.ca;
   mpancera@fredhutch.org; lstamata@fredhutch.org; amcguire@fredhutch.org;
   Renee.Bazin@hema-quebec.qc.ca; andres.finzi@umontreal.ca
RI Gasser, Romain/Q-6083-2018
OI Gasser, Romain/0000-0002-8565-1106; Benlarbi, Mehdi/0000-0001-9966-3784
FU Ministere de l'Economie et de l'Innovation du Quebec, Programme de
   soutien aux organismes de recherche et d'innovation; Fondation du CHUM;
   Canadian Institutes of Health Research, via the Immunity Task
   ForceCanadian Institutes of Health Research (CIHR); Canada Research
   Chair on Retroviral Entry [RCHS0235 950-232424]; MITACS Acceleration
   postdoctoral fellowship; CIHR graduate fellowshipCanadian Institutes of
   Health Research (CIHR)
FX This work was supported by the "Ministere de l'Economie et de
   l'Innovation du Quebec, Programme de soutien aux organismes de recherche
   et d'innovation", by the Fondation du CHUM, and by the Canadian
   Institutes of Health Research, via the Immunity Task Force and a
   foundation grant to A.F. Support for this work was also provided by
   generous donations to Fred Hutch COVID-19 Research Fund. A.F. is the
   recipient of a Canada Research Chair on Retroviral Entry #RCHS0235
   950-232424. R.G. is supported by a MITACS Acceleration postdoctoral
   fellowship. GBB is supported by a CIHR graduate fellowship. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript. The authors declare no
   competing interests.
CR Beaudoin-Bussieres G, 2020, MBIO, V11, DOI 10.1128/mBio.02590-20
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Casadevall A, 2020, JAMA-J AM MED ASSOC, V324, P455, DOI 10.1001/jama.2020.10218
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Desormeaux A, 2013, J VIROL, V87, P2549, DOI 10.1128/JVI.03104-12
   Ding SL, 2019, J VIROL, V93, DOI 10.1128/JVI.01403-19
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Finzi A, 2010, MOL CELL, V37, P656, DOI 10.1016/j.molcel.2010.02.012
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Hurlburt Nicholas K, 2020, bioRxiv, DOI 10.1101/2020.06.12.148692
   Joyner MJ, 2020, J CLIN INVEST, V130, P4791, DOI 10.1172/JCI140200
   Kassa A, 2009, J VIROL, V83, P4476, DOI 10.1128/JVI.02110-08
   Ko JH, 2018, ANTIVIR THER, V23, P617, DOI 10.3851/IMP3243
   Liu LH, 2020, NATURE, DOI 10.1038/s41586-020-2571-7
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Pacheco B, 2017, J VIROL, V91, DOI 10.1128/JVI.02219-16
   Prevost Jeremie, 2020, Cell Rep Med, V1, P100126, DOI 10.1016/j.xcrm.2020.100126
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520
   SEOW J, 2020, NAT MICROBIOL 1026, DOI DOI 10.1101/2020.07.09.20148429%JmedRxiv
   Seydoux Emilie, 2020, bioRxiv, DOI 10.1101/2020.05.12.091298
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 26
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD NOV
PY 2020
VL 12
IS 11
AR 1214
DI 10.3390/v12111214
PG 9
WC Virology
SC Virology
GA OX7GO
UT WOS:000593728700001
PM 33114742
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Antonini, C
   Calandrini, S
   Stracci, F
   Dario, C
   Bianconi, F
AF Antonini, Chiara
   Calandrini, Sara
   Stracci, Fabrizio
   Dario, Claudio
   Bianconi, Fortunato
TI Mathematical Modeling and Robustness Analysis to Unravel COVID-19
   Transmission Dynamics: The Italy Case dagger
SO BIOLOGY-BASEL
LA English
DT Article
DE COVID-19; SARS-CoV-2; SEIR model; Bayesian parameter estimation;
   conditional robustness analysis; Italy
ID EPIDEMIC
AB Simple Summary
   In the absence of vaccines and antiviral therapies against COVID-19, non-pharmaceutical interventions represent the only weapon to fight this new coronavirus. In this context, mathematical models are an important tool for supporting the study of spread and transmission of this disease and to understand how restrictive measures could control the epidemic. In the current study, we adopt a new mathematical model representing the dynamics of COVID-19. We estimate model parameters with a new Bayesian method while using the public Italian data, in order to reproduce the pandemic evolution for Italy and one of its regions, Umbria. Once the model is calibrated, we also apply an algorithm, called Conditional Robustness Analysis. This algorithm allows for us to understand the influence of epidemiological parameters and non-pharmaceutical interventions on the number of hospitalized patients. This pipeline of analysis provides a quantitative explanation of the number of underestimated positive cases during the first wave of the epidemic and of the impact of lock-down measures on the hospitalization capacity. Moreover, the calibrated model is quite accurate for making updated estimations of the epidemic evolution.
   This study started from the request of providing predictions on hospitalization and Intensive Care Unit (ICU) rates that are caused by COVID-19 for the Umbria region in Italy. To this purpose, we propose the application of a computational framework to a SEIR-type (Susceptible, Exposed, Infected, Removed) epidemiological model describing the different stages of COVID-19 infection. The model discriminates between asymptomatic and symptomatic cases and it takes into account possible intervention measures in order to reduce the probability of transmission. As case studies, we analyze not only the epidemic situation in Umbria but also in Italy, in order to capture the evolution of the pandemic at a national level. First of all, we estimate model parameters through a Bayesian calibration method, called Conditional Robust Calibration (CRC), while using the official COVID-19 data of the Italian Civil Protection. Subsequently, Conditional Robustness Analysis (CRA) on the calibrated model is carried out in order to quantify the influence of epidemiological and intervention parameters on the hospitalization rates. The proposed pipeline properly describes the COVID-19 spread during the lock-down phase. It also reveals the underestimation of new positive cases and the need of promptly isolating asymptomatic and presymptomatic cases. The results emphasize the importance of the lock-down timeliness and provide accurate predictions on the current evolution of the pandemic.
C1 [Antonini, Chiara; Calandrini, Sara] ICT4life Srl, Via Mario Donati Guerrieri 16, I-06132 Perugia, Italy.
   [Calandrini, Sara] Univ Perugia, Dept Engn, Via Goffredo Duranti 93, I-06125 Perugia, Italy.
   [Stracci, Fabrizio] Univ Perugia, Dept Expt Med, Piazzale Settimio Gambuli, I-06132 Perugia, Italy.
   [Dario, Claudio] Reg Govt Umbria, Corso Vannucci 96, I-06121 Perugia, Italy.
   [Bianconi, Fortunato] Reg Govt Umbria, COVID 19 Epidemiol Unit, Corso Vannucci 96, I-06121 Perugia, Italy.
RP Antonini, C (corresponding author), ICT4life Srl, Via Mario Donati Guerrieri 16, I-06132 Perugia, Italy.
EM chiara.antonini@i4l.company; sara.calandrini@i4l.company;
   fabrizio.stracci@unipg.it; cdario@regione.umbria.it;
   fortunato.bianconi@gmail.com
RI Bianconi, Fortunato/E-6787-2019
OI Bianconi, Fortunato/0000-0002-3132-0061
FU COVID-19 epidemiological unit, Department of Health, Regional Government
   of Umbria [D.G.R. 206/2020]
FX We thank all the components of the COVID-19 epidemiological unit,
   Department of Health, Regional Government of Umbria (D.G.R. 206/2020,
   25/06/2020). We also thank ICT4Life Srl for free support on mathematical
   modeling and for providing computational resources.
CR Antonini C., P 20 INT C BIOINF BI
   Armocida B, 2020, LANCET PUBLIC HEALTH, V5, pE253, DOI 10.1016/S2468-2667(20)30074-8
   Bianconi F., 2020, FRONT APPL MATH STAT, V6, P25, DOI [10.3389/fams.2020.00025, DOI 10.3389/FAMS.2020.00025]
   Bianconi F, 2020, IET SYST BIOL, V14, P107, DOI 10.1049/iet-syb.2018.5091
   Bianconi F, 2020, IEEE T CONTR SYST T, V28, P196, DOI 10.1109/TCST.2018.2844362
   Bianconi F, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2933-z
   Bianconi F, 2015, BMC SYST BIOL, V9, DOI 10.1186/s12918-015-0216-5
   Calafiore GC, 2020, INT J CONTROL, DOI 10.1080/00207179.2020.1782476
   Casella F, 2021, IEEE CONTR SYST LETT, V5, P1079, DOI 10.1109/LCSYS.2020.3009912
   Della Rossa F., 2020, ARXIV200507594
   Fosu G.O., 2020, OPEN J MATH SCI, V4, P261, DOI [10.30538/oms2020.0117, DOI 10.30538/OMS2020.0117]
   Gatto M, 2020, P NATL ACAD SCI USA, V117, P10484, DOI 10.1073/pnas.2004978117
   Giordano G, 2020, NAT MED, V26, P855, DOI 10.1038/s41591-020-0883-7
   Lopez L, 2020, NAT HUM BEHAV, V4, P746, DOI 10.1038/s41562-020-0908-8
   Nande A., 2020, MEDRXIV, DOI [10.1101/2020.06.04.20121673v1.abstract, DOI 10.1101/2020.06.04.20121673V1.ABSTRACT]
   Nishiura H, 2020, INT J INFECT DIS, V94, P154, DOI 10.1016/j.ijid.2020.03.020
   Scala A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70631-9
   Stella L., 2020, ARXIV200903649
   Tonsing C, 2018, STAT METHODS MED RES, V27, P1979, DOI 10.1177/0962280217746444
   Vollmer M., 2020, REPORT 20 SUB NATL A
   Wang YX, 2020, J MED VIROL, V92, P568, DOI 10.1002/jmv.25748
   World Health Organization, 2020, COR DIS 2019 COVID 1
NR 22
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2079-7737
J9 BIOLOGY-BASEL
JI Biology-Basel
PD NOV
PY 2020
VL 9
IS 11
AR 394
DI 10.3390/biology9110394
PG 18
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA OW2TV
UT WOS:000592746800001
PM 33187109
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Chavez-Hernandez, AL
   Sanchez-Cruz, N
   Medina-Franco, JL
AF Chavez-Hernandez, Ana L.
   Sanchez-Cruz, Norberto
   Medina-Franco, Jose L.
TI Fragment Library of Natural Products and Compound Databases for Drug
   Discovery
SO BIOMOLECULES
LA English
DT Article
DE chemoinformatics; COVID-19; drug discovery; drug design; fingerprint;
   food chemicals; natural products fragments; SARS-CoV-2
ID DARK CHEMICAL MATTER
AB Natural products and semi-synthetic compounds continue to be a significant source of drug candidates for a broad range of diseases, including coronavirus disease 2019 (COVID-19), which is causing the current pandemic. Besides being attractive sources of bioactive compounds for further development or optimization, natural products are excellent substrates of unique substructures for fragment-based drug discovery. To this end, fragment libraries should be incorporated into automated drug design pipelines. However, public fragment libraries based on extensive collections of natural products are still limited. Herein, we report the generation and analysis of a fragment library of natural products derived from a database with more than 400,000 compounds. We also report fragment libraries of a large food chemical database and other compound datasets of interest in drug discovery, including compound libraries relevant for COVID-19 drug discovery. The fragment libraries were characterized in terms of content and diversity.
C1 [Chavez-Hernandez, Ana L.; Sanchez-Cruz, Norberto; Medina-Franco, Jose L.] Univ Nacl Autonoma Mexico, Sch Chem, Dept Pharm, DIFACQUIM Res Grp, Ave Univ 3000, Mexico City 04510, DF, Mexico.
RP Medina-Franco, JL (corresponding author), Univ Nacl Autonoma Mexico, Sch Chem, Dept Pharm, DIFACQUIM Res Grp, Ave Univ 3000, Mexico City 04510, DF, Mexico.
EM anachavez3026@gmail.com; norberto.sc90@gmail.com; medinajl@unam.mx
RI Medina-Franco, Jose/AAJ-1633-2020; Sanchez-Cruz, Norberto/ABF-2765-2020
OI Medina-Franco, Jose/0000-0003-4940-1107; Sanchez-Cruz,
   Norberto/0000-0003-2707-3966
FU Programa de Apoyo a la Investigacion y el Posgrado (PAIP), Facultad de
   Quimica, UNAM [5000-9163]; UNAMUniversidad Nacional Autonoma de Mexico
   [LANCAD-UNAM-DGTIC-335]
FX This research was supported by the Programa de Apoyo a la Investigacion
   y el Posgrado (PAIP) grant 5000-9163, Facultad de Quimica, UNAM. We also
   thank Direccion General de Computo y de Tecnologias de Informacion y
   Comunicacion (DGTIC), UNAM, for the computational resources to use
   Miztli supercomputer and UNAM, project LANCAD-UNAM-DGTIC-335.
CR Agrafiotis DK, 2001, J CHEM INF COMP SCI, V41, P159, DOI 10.1021/ci000091j
   Chavez-Hernandez AL, 2020, MOL INFORM, V39, DOI 10.1002/minf.202000050
   Chen Y, 2020, MOL INFORM, V39, DOI 10.1002/minf.202000171
   Chen Y, 2018, J CHEM INF MODEL, V58, P1518, DOI 10.1021/acs.jcim.8b00302
   Christoforow A, 2019, ANGEW CHEM INT EDIT, V58, P14715, DOI 10.1002/anie.201907853
   Cremosnik GS, 2020, NAT PROD REP, V37, P1497, DOI 10.1039/d0np00015a
   Durant JL, 2002, J CHEM INF COMP SCI, V42, P1273, DOI 10.1021/ci010132r
   Feher M, 2003, J CHEM INF COMP SCI, V43, P218, DOI 10.1021/ci0200467
   Ganesan A, 2004, CURR OPIN BIOTECH, V15, P584, DOI 10.1016/j.copbio.2004.09.002
   Gentile D, 2020, MAR DRUGS, V18, DOI 10.3390/md18040225
   Lewell XQ, 1998, J CHEM INF COMP SCI, V38, P511, DOI 10.1021/ci970429i
   Lopez-Vallejo F, 2012, DRUG DISCOV TODAY, V17, P718, DOI 10.1016/j.drudis.2012.04.001
   Martinez-Mayorga K., 2014, FOODINFORMATICS APPL
   Medina-Franco J.L., 2015, EVIDENCE BASED VALID, P455, DOI DOI 10.1016/B978-0-12-800874-4.00021-0
   Medina-Franco JL, 2020, FUTUR SCI OA, V6, DOI 10.2144/fsoa-2020-0068
   Newman DJ, 2020, J NAT PROD, V83, P770, DOI 10.1021/acs.jnatprod.9b01285
   Prachayasittikul V, 2015, CURR TOP MED CHEM, V15, P1780, DOI 10.2174/1568026615666150506151101
   Prieto-Martinez F.D., 2019, PROGR CHEM ORGANIC N, P1
   Probst D, 2020, J CHEMINFORMATICS, V12, DOI 10.1186/s13321-020-0416-x
   Rogers D, 2010, J CHEM INF MODEL, V50, P742, DOI 10.1021/ci100050t
   Sanchez-Cruz Norberto, 2019, F1000Res, V8, DOI 10.12688/f1000research.21540.2
   Santibanez-Moran MG, 2020, RSC ADV, V10, P25089, DOI 10.1039/d0ra04922k
   Santini A, 2020, FOODS, V9, DOI 10.3390/foods9040482
   Sayed AM, 2020, RSC ADV, V10, P19790, DOI 10.1039/d0ra04199h
   Sorokina M, 2020, J CHEMINFORMATICS, V12, DOI 10.1186/s13321-020-00424-9
   Tang Bowen, 2020, bioRxiv, DOI 10.1101/2020.03.03.972133
   The Metabolomics Innovation Centre, MET INN CTR FOODB VE
   Wassermann AM, 2015, NAT CHEM BIOL, V11, P958, DOI 10.1038/nchembio.1936
   WEININGER D, 1988, J CHEM INF COMP SCI, V28, P31, DOI 10.1021/ci00057a005
NR 29
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2218-273X
J9 BIOMOLECULES
JI Biomolecules
PD NOV
PY 2020
VL 10
IS 11
AR 1518
DI 10.3390/biom10111518
PG 16
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA OW5FA
UT WOS:000592911100001
PM 33172012
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tan, Q
   Duan, LM
   Ma, YL
   Wu, F
   Huang, Q
   Mao, KM
   Xiao, WJ
   Xia, H
   Zhang, SJ
   Zhou, E
   Ma, P
   Song, SW
   Li, YM
   Zhao, ZL
   Sun, Y
   Li, ZY
   Geng, W
   Yin, ZR
   Jin, Y
AF Tan, Qi
   Duan, Limin
   Ma, YanLing
   Wu, Feng
   Huang, Qi
   Mao, Kaimin
   Xiao, Wenjing
   Xia, Hui
   Zhang, Shujing
   Zhou, E.
   Ma, Pei
   Song, Siwei
   Li, YuMei
   Zhao, Zilin
   Sun, Yice
   Li, Zeyu
   Geng, Wei
   Yin, Zengrong
   Jin, Yang
TI Is oseltamivir suitable for fighting against COVID-19: In silico
   assessment, in vitro and retrospective study
SO BIOORGANIC CHEMISTRY
LA English
DT Article
DE SARS-CoV-2; COVID-19; Oseltamivir
ID PROTEIN; NEURAMINIDASE; INFLUENZA; DRUG
AB Background: Oseltamivir is a first-line antiviral drug, especially in primary hospitals. During the ongoing out-break of coronavirus disease 2019 (COVID-19), most patients with COVID-19 who are symptomatic have used oseltamivir. Considering its popular and important role as an antiviral drug, it is necessary to evaluate oseltamivir in the treatment of COVID-19.
   Objective: To evaluate the effect of oseltamivir against COVID-19.
   Methods: Swiss-model was used to construct the structure of the N-terminal RNA-binding domain (NRBD) of the nucleoprotein (NC), papain-like protease (PLpro), and RNA-directed RNA polymerase (RdRp) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). TM-align program was performed to compare the structure of the viral proteins with the structure of the neuraminidase of influenza A. Molecular docking was used to analyze the theoretical possibility of effective binding of oseltamivir with the active centers of the viral proteins. In vitro study was used to evaluate the antiviral efficiency of oseltamivir against SARS-CoV-2. By clinical case analysis, we statistically evaluated whether the history of oseltamivir use influenced the progression of the disease.
   Results: The structures of NRBD, PLpro, and RdRp were built successfully. The results from TM-align suggested that the S protein, NRBD, 3C-like protease (3CLpro), PLPrO, and RdRp were structurally similar to the influenza A neuraminidase, with TM-scores of 0.30077, 0.19254, 0.28766, 0.30666, and 0.34047, respectively. Interestingly, the active center of 3CL pro was found to be similar to the active center from the neuraminidase of influenza A. Through an analysis of molecular docking, we discovered that oseltamivir carboxylic acid was more favorable to bind to the active site of 3CLpro effectively, but its inhibitory effect was not strong compared with the positive group. Finally, we used in vitro study and retrospective case analysis to verify our speculations. We found that oseltamivir is ineffective against SARS-CoV-2 in vitro study and the clinical use of oseltamivir did not improve the patients' symptoms and signs and did not slow the disease progression.
   Conclusions: We consider that oseltamivir isn't suitable for the treatment of COVID-19. During the outbreak of novel coronavirus, when oseltamivir is not effective for the patients after they take it, health workers should be highly vigilant about the possibility of COVID-19.
C1 [Tan, Qi; Duan, Limin; Ma, YanLing; Wu, Feng; Huang, Qi; Mao, Kaimin; Xiao, Wenjing; Xia, Hui; Zhang, Shujing; Zhou, E.; Ma, Pei; Song, Siwei; Li, YuMei; Zhao, Zilin; Sun, Yice; Li, Zeyu; Geng, Wei; Yin, Zengrong; Jin, Yang] Huazhong Univ Sci & Technol, Dept Resp & Crit Care Med, NHC Key Lab Pulm Dis, Union Hosp,Tongji Med Coll, Wuhan 430022, Peoples R China.
RP Jin, Y (corresponding author), Huazhong Univ Sci & Technol, Dept Resp & Crit Care Med, NHC Key Lab Pulm Dis, Union Hosp,Tongji Med Coll, Wuhan 430022, Peoples R China.
EM whuhjy@126.om
FU Novel coronavirus pneumonia emergency project, China [2020YFC084430];
   National Major Science and Technology Projects of China (CN)
   [2019ZX09301001]; Ministry of Science and Technology of the People's
   Republic of China (CN) [2020YFC0844300]; Fundamental Research Funds for
   the Central UniversitiesFundamental Research Funds for the Central
   Universities [HUST: 2020kfyXGYJ011]; State Key Laboratory of Drug
   Research, China [2019ZX09301001]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [82041018,
   81770096, 81700091]
FX We thank Guorong Hu for participating in the design of our paper. She is
   from Department of Respiratory Medicine, Second Hospital of Wuhan. We
   thank Leike Zhang and his colleagues for assistance with the in vitro
   experiments. They are from State Key Laboratory of Virology, Wuhan
   Institute of Virology, Center for Biosafety MegaScience, Chinese Academy
   of Sciences. We show our acknowledgments to the medical workers, people
   's liberation army, community workers, police officers, volunteers on
   the front line. This work was supported by Novel coronavirus pneumonia
   emergency project, China (no. 2020YFC084430), National Major Science and
   Technology Projects of China (CN):2019ZX09301001, Ministry of Science
   and Technology of the People's Republic of China (CN):2020YFC0844300,
   and the Fundamental Research Funds for the Central Universities, HUST:
   2020kfyXGYJ011, State Key Laboratory of Drug Research, China (no.
   2019ZX09301001) and the National Natural Science Foundation of China
   (no. 82041018, no. 81770096 and no. 81700091).
CR Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201
   Cai GJ, 2020, STEEL RES INT, DOI 10.1002/srin.202000269
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Escuret V, 2014, J INFECT DIS, V210, P1260, DOI 10.1093/infdis/jiu244
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Hayden FG, 1999, JAMA-J AM MED ASSOC, V282, P1240, DOI 10.1001/jama.282.13.1240
   Huang QL, 2004, BIOCHEMISTRY-US, V43, P6059, DOI 10.1021/bi036155b
   Jefferson T, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006207.pub4
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kuate S, 2007, VIROLOGY, V362, P26, DOI 10.1016/j.virol.2006.12.011
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0
   Meng B, 2006, MOL BIOTECHNOL, V33, P141, DOI 10.1385/MB:33:2:141
   Offord C., 2020, COMBINING MEDICATION
   Ratia K, 2008, P NATL ACAD SCI USA, V105, P16119, DOI 10.1073/pnas.0805240105
   Rossi S., 2006, AUSTR MED HDB SYDNEY
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Vavricka CJ, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002249
   Wang X, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0169-8
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu C., 2020, FURIN POTENTIAL THER
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu YS, 2006, CURR MED CHEM, V13, P2003, DOI 10.2174/092986706777584988
   Xia S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4580
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhang XW, 2004, J MOL STRUC-THEOCHEM, V681, P137, DOI 10.1016/j.theochem.2004.04.065
   Zhang Y, 2005, NUCLEIC ACIDS RES, V33, P2302, DOI 10.1093/nar/gki524
   Zhu MS, 2004, IMMUNOL LETT, V92, P237, DOI 10.1016/j.imlet.2004.01.001
NR 34
TC 0
Z9 0
U1 3
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0045-2068
EI 1090-2120
J9 BIOORG CHEM
JI Bioorganic Chem.
PD NOV
PY 2020
VL 104
AR 104257
DI 10.1016/j.bioorg.2020.104257
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA OV9NL
UT WOS:000592527300001
PM 32927129
OA Green Published
DA 2021-01-01
ER

PT J
AU Gambichler, T
   Reuther, J
   Scheel, CH
   Susok, L
   Kern, P
   Becker, JC
AF Gambichler, Thilo
   Reuther, Judith
   Scheel, Christina H.
   Susok, Laura
   Kern, Peter
   Becker, Jurgen C.
TI Cancer and Immune Checkpoint Inhibitor Treatment in the Era of
   SARS-CoV-2 Infection
SO CANCERS
LA English
DT Article
DE immune checkpoint inhibitors; programmed cell death protein; cytotoxic T
   lymphocyte antigen-4; COVID-19; coronavirus
ID CORONAVIRUS DISEASE 2019; CLINICAL CHARACTERISTICS; COVID-19; MORTALITY;
   RISK; IMMUNOPATHOLOGY; BLOCKADE; PATIENT
AB Simple Summary
   The introduction of immune checkpoint inhibitors (ICI) in 2011 revolutionized the management of many solid cancers and hematological malignancies. However, there are concerns regarding the use of ICI in the era of COVID-19. We present currently available information on the pros and cons of using ICI in cancer patients with respect to the risk of acquiring an infection by SARS-CoV2 and mortality from COVID-19. By means of the present paper, clinicians and researchers may update their knowledge on a highly topical clinical question-is the use of ICI in cancer patients with SARS-CoV2 infection harmful with respect to COVID-19 outcome?
   Whether cancer patients receiving immune checkpoint inhibitors (ICI) are at an increased risk of severe infection and mortality during the corona pandemic is a hotly debated topic that will continue to evolve. Here, we summarize and discuss current studies regarding COVID-19 and anti-cancer treatment with an emphasis on ICI. Importantly, several lines of evidence suggest that patients currently treated with ICI do not display an increased vulnerability to infection with SARS-CoV-2. Data regarding morbidity and mortality associated with COVID-19 in cancer patients receiving ICI are less clear and often conflicting. Although mostly based on experimental data, it is possible that ICI can promote the exacerbated immune response associated with adverse outcome in COVID-19 patients. On the other hand, mounting evidence suggests that ICI might even be useful in the treatment of viral infections by preventing or ameliorating T cell exhaustion. In this context, the right timing of treatment might be essential. Nevertheless, some cancer patients treated with ICI experience autoimmune-related side effects that require the use of immunosuppressive therapies, which in turn may promote a severe course of infection with SARS-CoV-2. Although there is clear evidence that withholding ICI will have more serious consequences, further studies are urgently needed in to better evaluate the effects of ICI in patients with COVID-19 and the use of ICI during the corona pandemic in general.
C1 [Gambichler, Thilo; Reuther, Judith; Scheel, Christina H.; Susok, Laura] Ruhr Univ Bochum, Skin Canc Ctr, Dept Dermatol, D-44791 Bochum, Germany.
   [Scheel, Christina H.] Helmholtz Ctr Munich, Inst Stem Cell Res, D-85764 Neuherberg, Germany.
   [Kern, Peter] Ruhr Univ Bochum, St Elisabeth Hosp, Dept Gynecol, D-44787 Bochum, Germany.
   [Becker, Jurgen C.] Univ Duisburg Essen, German Canc Consortium DKTK, Dermatol, Translat Skin Canc Res, D-45141 Essen, Germany.
   [Becker, Jurgen C.] German Canc Res Ctr, D-69120 Heidelberg, Germany.
RP Gambichler, T (corresponding author), Ruhr Univ Bochum, Skin Canc Ctr, Dept Dermatol, D-44791 Bochum, Germany.
EM t.gambichler@klinikum-bochum.de; judith.reuther@klinikum-bochum.de;
   christina.scheel@klinikum-bochum.de; laura.susok@klinikum-bochum.de;
   peter.kern@klinikum-bochum.de; j.becker@dkfz-heidelberg.de
OI Gambichler, Thilo/0000-0001-7862-3695
FU DFGGerman Research Foundation (DFG)
FX This research received no external funding, except for the DFG Open
   Access Publication fund mentioned above.
CR Abid MB, 2020, JAMA ONCOL, V6, P1529, DOI 10.1001/jamaoncol.2020.2367
   Agrawal AS, 2016, HUM VACC IMMUNOTHER, V12, P2351, DOI 10.1080/21645515.2016.1177688
   Angus DC, 2020, JAMA-J AM MED ASSOC, V324, P1317, DOI 10.1001/jama.2020.17022
   [Anonymous], SHORT TERM REC CUT M
   [Anonymous], MEL COVID 19 ER
   Ascierto PA, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000878
   Bastard P, 2020, SCIENCE, V370, P423, DOI 10.1126/science.abd4585
   Baumann BC, 2020, CANCER-AM CANCER SOC, V126, P3900, DOI 10.1002/cncr.32969
   Bersanelli M, 2020, IMMUNOTHERAPY-UK, V12, P269, DOI 10.2217/imt-2020-0067
   Bersanelli M, 2019, CRIT REV ONCOL HEMAT, V139, P87, DOI 10.1016/j.critrevonc.2019.05.003
   Bi JP, 2020, J INFECTION, V81, pE22, DOI 10.1016/j.jinf.2020.07.018
   Bonam Srinivasa Reddy, 2020, Cell Rep Med, V1, P100016, DOI 10.1016/j.xcrm.2020.100016
   Bonomi L, 2020, J THORAC ONCOL, V15, pE83, DOI 10.1016/j.jtho.2020.03.021
   Cancio M, 2020, CYTOTHERAPY, V22, P474, DOI 10.1016/j.jcyt.2020.04.100
   Catania C, 2020, TUMORI J, DOI 10.1177/0300891620951863
   Chang HL, 2020, LUNG CANCER, V146, P376, DOI 10.1016/j.lungcan.2020.06.013
   Chiappelli F, 2020, BIOINFORMATION, V16, P219, DOI [10.6026/97320630016222, 10.6026/97320630016219]
   Citarella F, 2020, FUTURE ONCOL, V16, P1475, DOI 10.2217/fon-2020-0340
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Darvin P, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0191-1
   Davis AP, 2020, IMMUNOTHERAPY-UK, V12, P545, DOI 10.2217/imt-2020-0096
   Di Cosimo S, 2020, EUR J CANCER, V135, P62, DOI 10.1016/j.ejca.2020.05.026
   Di Noia V, 2020, LUNG CANCER, V145, P208, DOI 10.1016/j.lungcan.2020.05.006
   Diamanti AP, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093330
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Dimitriou F, 2019, J IMMUNOTHER, V42, P29, DOI 10.1097/CJI.0000000000000236
   Dyck L, 2017, EUR J IMMUNOL, V47, P765, DOI 10.1002/eji.201646875
   El-Khoueiry AB, 2017, LANCET, V389, P2492, DOI 10.1016/S0140-6736(17)31046-2
   Elmas OF, 2020, DERMATOL THER, DOI 10.1111/dth.14101
   Gambichler T, 2019, BRIT J DERMATOL, DOI 10.1111/bjd.18379
   Gambichler T, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001145
   Garassino MC, 2020, LANCET ONCOL, V21, P914, DOI 10.1016/S1470-2045(20)30314-4
   Gonzalez-Cao M., 2020, CANC IMMUNOTHERAPY D, DOI [10.1101/2020.05.19.20106971, DOI 10.1101/2020.05.19.20106971]
   Gozzi E, 2020, THORAC CANCER, V11, P1330, DOI 10.1111/1759-7714.13377
   Granier C, 2017, ESMO OPEN, V2, DOI 10.1136/esmoopen-2017-000213
   Hashimoto M, 2018, ANNU REV MED, V69, P301, DOI 10.1146/annurev-med-012017-043208
   Hoiland RL, 2020, BRIT J HAEMATOL, V190, pE150, DOI 10.1111/bjh.16961
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Johnson DB, 2017, CANCER-AM CANCER SOC, V123, P1904, DOI 10.1002/cncr.30642
   Jordan RE, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1198
   Kattan J, 2020, IMMUNOTHERAPY-UK, V12, P351, DOI 10.2217/imt-2020-0077
   Khoja L, 2017, ANN ONCOL, V28, P2377, DOI 10.1093/annonc/mdx286
   Kox M, 2020, JAMA-J AM MED ASSOC, V324, P1565, DOI 10.1001/jama.2020.17052
   Larkin J, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]
   Lee LYW, 2020, LANCET ONCOL, V21, P1309, DOI 10.1016/S1470-2045(20)30442-3
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Leung CS, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0581-y
   Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI [10.1016/j.jaci.2020.04.006, 10.1002/jmv.25731]
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lovly C.M., 2020, RAPIDLY FATAL PNEUMO, DOI [10.1101/2020.04.29.20085738, DOI 10.1101/2020.04.29.20085738]
   Luo J, 2020, CANCER DISCOV, V10, P1121, DOI 10.1158/2159-8290.CD-20-0596
   Lyons-Weiler James, 2020, J Transl Autoimmun, V3, P100051, DOI 10.1016/j.jtauto.2020.100051
   Maio M, 2020, CLIN CANCER RES, V26, P4201, DOI 10.1158/1078-0432.CCR-20-1657
   Mehta V, 2020, CANCER DISCOV, V10, P935, DOI 10.1158/2159-8290.CD-20-0516
   Menetrier-Caux C, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0549-5
   Mertens J, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa376
   Minotti C, 2020, J INFECTION, V81, pE61, DOI 10.1016/j.jinf.2020.04.026
   Miyashita H, 2020, ANN ONCOL, V31, P1088, DOI 10.1016/j.annonc.2020.04.006
   Moujaess E, 2020, CRIT REV ONCOL HEMAT, V150, DOI 10.1016/j.critrevonc.2020.102972
   Nahm S H, 2021, Clin Oncol (R Coll Radiol), V33, pe54, DOI 10.1016/j.clon.2020.06.017
   National Institute for Health and Care Excellence, COVID 19 RAP GUID DE
   Odabasi Zekaver, 2020, Crit Care Explor, V2, pe0141, DOI 10.1097/CCE.0000000000000141
   Pala L, 2020, CANCER INVEST, DOI 10.1080/07357907.2020.1844893
   Patrinely JR, 2020, MELANOMA MANAG, V7, DOI 10.2217/mmt-2020-0012
   Pickles OJ, 2020, BRIT J CANCER, V123, P691, DOI 10.1038/s41416-020-0930-7
   Qin S, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1091-2
   Qin YY, 2020, CHINESE MED J-PEKING, V133, P1080, DOI 10.1097/CM9.0000000000000791
   Quaglino P, 2020, J EUR ACAD DERMATOL, V34, P1395, DOI 10.1111/jdv.16586
   Rassy E, 2020, FUTURE ONCOL, V16, P1153, DOI 10.2217/fon-2020-0312
   Redelman-Sidi G, 2018, CLIN MICROBIOL INFEC, V24, pS95, DOI 10.1016/j.cmi.2018.01.030
   Robilotti EV, 2020, NAT MED, V26, P1218, DOI 10.1038/s41591-020-0979-0
   Robinson AG, 2020, NAT REV CLIN ONCOL, V17, P386, DOI 10.1038/s41571-020-0394-y
   Rolfo C, 2020, J THORAC ONCOL, V15, P1767, DOI 10.1016/j.jtho.2020.06.019
   Rossi E, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000952
   Rotz SJ, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26642
   Saini KS, 2020, EUR J CANCER, V139, P43, DOI 10.1016/j.ejca.2020.08.011
   Schmidle P, 2020, J EUR ACAD DERMATOL, V34, pE465, DOI 10.1111/jdv.16661
   Schon MP, 2020, J DTSCH DERMATOL GES, DOI 10.1111/ddg.14169
   Shah NJ, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0771-1
   Shiohara Tetsuo, 2010, Allergology International, V59, P333, DOI 10.2332/allergolint.10-RAI-0260
   Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023
   Sullivan RJ, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000933
   Suresh K, 2018, J THORAC ONCOL, V13, P1930, DOI 10.1016/j.jtho.2018.08.2035
   Szabados B, 2020, EUR UROL, V78, P276, DOI 10.1016/j.eururo.2020.05.024
   Tagliamento M, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13315
   Toor SM, 2021, IMMUNOLOGY, V162, P30, DOI 10.1111/imm.13262
   Vaddepally RK, 2020, CANCERS, V12, DOI 10.3390/cancers12030738
   Vardhana SA, 2020, J EXP MED, V217, DOI 10.1084/jem.20200678
   Vici P, 2020, IMMUNOTHERAPY-UK, V12, P675, DOI 10.2217/imt-2020-0142
   Vivarelli S, 2020, CANCERS, V12, DOI 10.3390/cancers12082237
   Wang AQ, 2020, ASIA-PAC J CLIN ONCO, V16, P201, DOI 10.1111/ajco.13332
   Wu QJ, 2020, CANCER COMMUN, V40, P374, DOI 10.1002/cac2.12077
   Wykes MN, 2018, NAT REV IMMUNOL, V18, P91, DOI 10.1038/nri.2017.112
   Yang KY, 2020, LANCET ONCOL, V21, P904, DOI 10.1016/S1470-2045(20)30310-7
   Zappasodi R, 2018, CANCER CELL, V33, P581, DOI 10.1016/j.ccell.2018.03.005
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zhang N, 2019, IMMUNOTHERAPY-UK, V11, P429, DOI 10.2217/imt-2018-0110
   Zhang Q, 2020, SCIENCE, V370, P422, DOI 10.1126/science.abd4570
   Zheng CC, 2020, INT J INFECT DIS, V94, P74, DOI 10.1016/j.ijid.2020.03.047
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhuang JL, 2020, THORAC CANCER, V11, P799, DOI 10.1111/1759-7714.13281
NR 101
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD NOV
PY 2020
VL 12
IS 11
AR 3383
DI 10.3390/cancers12113383
PG 14
WC Oncology
SC Oncology
GA OW5KB
UT WOS:000592924200001
PM 33207589
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bojkova, D
   Bechtel, M
   McLaughlin, KM
   McGreig, JE
   Klann, K
   Bellinghausen, C
   Rohde, G
   Jonigk, D
   Braubach, P
   Ciesek, S
   Munch, C
   Wass, MN
   Martin, M
   Cinatl, J
AF Bojkova, Denisa
   Bechtel, Marco
   McLaughlin, Katie-May
   McGreig, Jake E.
   Klann, Kevin
   Bellinghausen, Carla
   Rohde, Gernot
   Jonigk, Danny
   Braubach, Peter
   Ciesek, Sandra
   Muench, Christian
   Wass, Mark N.
   Michaelis, Martin
   Cinatl, Jindrich
TI Aprotinin Inhibits SARS-CoV-2 Replication
SO CELLS
LA English
DT Article
DE severe acute respiratory syndrome coronavirus; severe acute respiratory
   syndrome coronavirus 2; 2019-nCoV; COVID-19; antiviral; drug discovery;
   aprotinin
ID TRANEXAMIC ACID; IN-VITRO; CORONAVIRUS; VIRUS; TMPRSS2; PNEUMONIA; CELLS
AB Severe acute respiratory syndrome virus 2 (SARS-CoV-2) is the cause of the current coronavirus disease 19 (COVID-19) pandemic. Protease inhibitors are under consideration as virus entry inhibitors that prevent the cleavage of the coronavirus spike (S) protein by cellular proteases. Herein, we showed that the protease inhibitor aprotinin (but not the protease inhibitor SERPINA1/alpha-1 antitrypsin) inhibited SARS-CoV-2 replication in therapeutically achievable concentrations. An analysis of proteomics and translatome data indicated that SARS-CoV-2 replication is associated with a downregulation of host cell protease inhibitors. Hence, aprotinin may compensate for downregulated host cell proteases during later virus replication cycles. Aprotinin displayed anti-SARS-CoV-2 activity in different cell types (Caco2, Calu-3, and primary bronchial epithelial cell air-liquid interface cultures) and against four virus isolates. In conclusion, therapeutic aprotinin concentrations exert anti-SARS-CoV-2 activity. An approved aprotinin aerosol may have potential for the early local control of SARS-CoV-2 replication and the prevention of COVID-19 progression to a severe, systemic disease.
C1 [Bojkova, Denisa; Bechtel, Marco; Ciesek, Sandra; Cinatl, Jindrich] Goethe Univ, Univ Hosp, Inst Med Virol, D-60596 Frankfurt, Germany.
   [McLaughlin, Katie-May; McGreig, Jake E.; Wass, Mark N.; Michaelis, Martin] Univ Kent, Sch Biosci, Canterbury CT2 7NJ, Kent, England.
   [Klann, Kevin; Muench, Christian] Goethe Univ, Inst Biochem 2, Fac Med, D-60590 Frankfurt, Germany.
   [Bellinghausen, Carla; Rohde, Gernot] Goethe Univ, Univ Hosp, Dept Resp Med & Allergol, D-60590 Frankfurt, Germany.
   [Jonigk, Danny; Braubach, Peter] Hannover Med Sch MHH, Inst Pathol, D-30625 Hannover, Germany.
   [Jonigk, Danny; Braubach, Peter] Hannover Med Sch MHH, Biomed Res Endstage & Obstruct Lung Dis Hannover, German Ctr Lung Res, D-30625 Hannover, Germany.
   [Ciesek, Sandra] DZIF, German Ctr Infect Res, External Partner Site, D-60596 Frankfurt, Germany.
   [Ciesek, Sandra] Fraunhofer Inst Mol Biol & Appl Ecol IME, Branch Translat Med & Pharmacol, D-60596 Frankfurt, Germany.
   [Muench, Christian] Goethe Univ, Frankfurt Canc Inst, D-60596 Frankfurt, Germany.
   [Muench, Christian] Goethe Univ, Cardiopulm Inst, D-60590 Frankfurt, Germany.
RP Cinatl, J (corresponding author), Goethe Univ, Univ Hosp, Inst Med Virol, D-60596 Frankfurt, Germany.; Wass, MN; Martin, M (corresponding author), Univ Kent, Sch Biosci, Canterbury CT2 7NJ, Kent, England.
EM Denisa.Bojkova@kgu.de; marco.bechtel@kgu.de; km625@kent.ac.uk;
   jem53@kent.ac.uk; klann@em.uni-frankfurt.de;
   c.bellinghausen@med.uni-frankfurt.de; Gernot.rohde@kgu.de;
   jonigk.danny@mh-hannover.de; Braubach.Peter@mh-hannover.de;
   Sandra.ciesek@kgu.de; ch.muench@em.uni-frankfurt.de;
   M.N.Wass@kent.ac.uk; M.Michaelis@kent.ac.uk; Cinatl@em.uni-frankfurt.de
RI ; Rohde, Gernot/F-3060-2013
OI Ciesek, Sandra/0000-0002-1802-7565; Wass, Mark/0000-0001-5428-6479;
   McGreig, Jake/0000-0002-3068-5624; Munch, Christian/0000-0003-3832-090X;
   Michaelis, Martin/0000-0002-5710-5888; Klann, Kevin/0000-0003-2276-8128;
   Rohde, Gernot/0000-0002-5193-7755
FU Hilfe fur krebskranke Kinder Frankfurt e.V.; Frankfurter Stiftung fur
   krebskranke Kinder; Goethe University
FX This research was funded by the Hilfe fur krebskranke Kinder Frankfurt
   e.V. and the Frankfurter Stiftung fur krebskranke Kinder. The APC was
   funded by Goethe University.
CR Azouz Nurit P, 2020, bioRxiv, DOI 10.1101/2020.05.04.077826
   Bestle D, 2020, LIFE SCI ALLIANCE, V3, DOI 10.26508/lsa.202000786
   Bojkova D, 2020, NATURE, V583, P469, DOI 10.1038/s41586-020-2332-7
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng YW, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108254
   Choudhary S, 2020, VIRUS RES, V289, DOI 10.1016/j.virusres.2020.198146
   CINATL J, 1995, ANTIVIR RES, V27, P405, DOI 10.1016/0166-3542(95)00024-G
   Cinatl J, 2005, INT J MOL MED, V15, P323
   Cinatl J, 2003, LANCET, V361, P2045, DOI 10.1016/S0140-6736(03)13615-X
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Dietrich W, 1996, J CARDIOVASC PHARM, V27, pS50
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Esumi M, 2015, HEPATOLOGY, V61, P437, DOI 10.1002/hep.27426
   Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+
   Hoehl S, 2020, NEW ENGL J MED, V382, P1278, DOI 10.1056/NEJMc2001899
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00754-20
   Klann K, 2020, MOL CELL, V77, P913, DOI 10.1016/j.molcel.2019.11.010
   Kuitunen A, 2005, ACTA ANAESTH SCAND, V49, P1272, DOI 10.1111/j.1399-6576.2005.00809.x
   Lega S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020224
   LEVY JH, 1994, ANESTHESIOLOGY, V80, P1013, DOI 10.1097/00000542-199405000-00010
   Li SF, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00334-0
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Marchandot B, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061651
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Michaelis M, 2007, J ANTIMICROB CHEMOTH, V60, P981, DOI 10.1093/jac/dkm307
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Onafuye H, 2019, BEILSTEIN J NANOTECH, V10, P1707, DOI 10.3762/bjnano.10.166
   Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106
   Polycarpou A, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012642
   Ren YJ, 2020, CELL MOL IMMUNOL, V17, P881, DOI 10.1038/s41423-020-0485-9
   Shen LW, 2017, BIOCHIMIE, V142, P1, DOI 10.1016/j.biochi.2017.07.016
   Solun B, 2020, Med Drug Discov, V7, P100052, DOI 10.1016/j.medidd.2020.100052
   Sperzel M, 2007, J THROMB HAEMOST, V5, P2113, DOI 10.1111/j.1538-7836.2007.02717.x
   Straus MR, 2020, VIROLOGY, V543, P43, DOI 10.1016/j.virol.2020.01.004
   Strnad P, 2020, NEW ENGL J MED, V382, P1443, DOI 10.1056/NEJMra1910234
   Terrell MR, 1996, ANN THORAC SURG, V62, P506, DOI 10.1016/0003-4975(96)00317-7
   Toptan T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124396
   Van Wetering S, 2000, AM J PHYSIOL-LUNG C, V278, pL51
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu M, 2016, NAT MED, V22, P1101, DOI 10.1038/nm.4184
   Yamamoto M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12060629
   Zhirnov OP, 2011, ANTIVIR RES, V92, P27, DOI 10.1016/j.antiviral.2011.07.014
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 46
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD NOV
PY 2020
VL 9
IS 11
AR 2377
DI 10.3390/cells9112377
PG 13
WC Cell Biology
SC Cell Biology
GA OW3LN
UT WOS:000592792800001
PM 33143316
OA DOAJ Gold, Green Published, Green Accepted
DA 2021-01-01
ER

PT J
AU Feng, SQ
   Luan, XD
   Wang, YF
   Wang, H
   Zhang, ZY
   Wang, YY
   Tian, Z
   Liu, MX
   Xiao, Y
   Zhao, Y
   Zhou, RL
   Zhang, SY
AF Feng, Siqin
   Luan, Xiaodong
   Wang, Yifei
   Wang, Hui
   Zhang, Zhiyu
   Wang, Yiyang
   Tian, Zhuang
   Liu, Meixi
   Xiao, Ying
   Zhao, Yong
   Zhou, Ruilin
   Zhang, Shuyang
TI Eltrombopag is a potential target for drug intervention in SARS-CoV-2
   spike protein
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE SARS-CoV-2; Virtual drug design; Homology Modeling; Surface plasmon
   resonance
ID TENOFOVIR ALAFENAMIDE; RECEPTOR ANTAGONIST; INITIAL TREATMENT;
   DOUBLE-BLIND; MECHANISM; INFECTION; SARS; SULFONYLUREAS; EMTRICITABINE;
   DOLUTEGRAVIR
AB The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is a current global threat for which there is an urgent need to search for an effective therapy. The transmembrane spike (S) glycoprotein of SARS-CoV-2 directly binds to the host angiotensin-converting enzyme 2 (ACE2) and mediates viral entrance, which is therefore considered as a promising drug target. Considering that new drug development is a time-consuming process, drug repositioning may facilitate rapid drug discovery dealing with sudden infectious diseases. Here, we compared the differences between the virtual structural proteins of SARS-CoV-2 and SARS-CoV, and selected a pocket mainly localizing in the fusion cores of S2 domain for drug screening. A virtual drug design algorithm screened the Food and Drug Administration-approved drug library of 1234 compounds, and 13 top scored compounds were obtained through manual screening. Through in vitro molecular interaction experiments, eltrombopag was further verified to possess a high binding affinity to S protein plus human ACE2 and could potentially affect the stability of the ACE2-S protein complex. Hence, it is worth further exploring eltrombopag as a potential drug for the treatment of SARS-CoV-2 infection.
C1 [Feng, Siqin; Wang, Hui; Zhang, Zhiyu; Tian, Zhuang; Liu, Meixi; Xiao, Ying; Zhou, Ruilin; Zhang, Shuyang] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Peking Union Med Coll, Dept Cardiol, Beijing, Peoples R China.
   [Luan, Xiaodong; Wang, Yifei; Wang, Yiyang; Zhang, Shuyang] Tsinghua Univ, Sch Med, Beijing, Peoples R China.
   [Luan, Xiaodong; Zhang, Shuyang] Tsinghua Univ, Tsinghua Peking Ctr Life Sci, Beijing, Peoples R China.
   [Zhao, Yong] Beijing Beike Deyuan Biopharm Technol Co Ltd, Beijing, Peoples R China.
RP Zhang, SY (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll Hosp, Peking Union Med Coll, Dept Cardiol, Beijing, Peoples R China.; Zhang, SY (corresponding author), Tsinghua Univ, Sch Med, Beijing, Peoples R China.; Zhang, SY (corresponding author), Tsinghua Univ, Tsinghua Peking Ctr Life Sci, Beijing, Peoples R China.
EM shuyangzhang103@nrdrs.org
OI feng, siqin/0000-0003-0823-2175
FU CAMS Innovation Fund for Medical Sciences (CIFMS) [2016-I2M-3-011,
   2016-I2M-1-002]; CAMS Innovation Fund for Medical Sciences
   [2020-I2M-CoV19-001]; "13th Five-Year" National Science and Technology
   Major Project for New Drugs [2019ZX09734001-002]; Tsinghua
   University-Peking University Center for Life Sciences [045-160321001]
FX This work was supported by CAMS Innovation Fund for Medical Sciences
   (CIFMS) [No. 2016-I2M-3-011, 2016-I2M-1-002]; CAMS Innovation Fund for
   Medical Sciences No. (2020-I2M-CoV19-001); "13th Five-Year" National
   Science and Technology Major Project for New Drugs [No:
   2019ZX09734001-002]; Tsinghua University-Peking University Center for
   Life Sciences [No. 045-160321001).
CR BACHMANN W, 1979, EUR J CLIN INVEST, V9, P411, DOI 10.1111/j.1365-2362.1979.tb00905.x
   Bell AM, 2016, INT J HEPATOL, V2016, DOI 10.1155/2016/3852126
   Bogoch II, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa011
   BONORA E, 1992, J ENDOCRINOL INVEST, V15, P1
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Dina R, 2000, AM J HEALTH-SYST PH, V57, P1231, DOI 10.1093/ajhp/57.13.1231
   Erickson-Miller CL, 2009, STEM CELLS, V27, P424, DOI 10.1634/stemcells.2008-0366
   Gallant J, 2017, LANCET, V390, P2063, DOI [10.1016/S0140-6736(17)32299-7, 10.1016/s0140-6736(17)32299-7]
   Giustina A, 2014, EXPERT OPIN INV DRUG, V23, P1619, DOI 10.1517/13543784.2014.942728
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Hilgenfeld R, 2013, ANTIVIR RES, V100, P286, DOI 10.1016/j.antiviral.2013.08.015
   Hjermitslev M, 2017, BASIC CLIN PHARMACOL, V121, P225, DOI 10.1111/bcpt.12800
   Hoever G, 2005, J MED CHEM, V48, P1256, DOI 10.1021/jm0493008
   Karpinski TM, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10020054
   Kim TO, 2018, BLOOD ADV, V2, P454, DOI 10.1182/bloodadvances.2017010660
   Koba Marcin, 2005, Postepy Hig Med Dosw (Online), V59, P290
   Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303
   Li JY, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/872139
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   LI WD, 2020, J PROTEOME RES, DOI DOI 10.1021/ACS.JPROTEOME.0C00129
   Meng J, 2020, EMERG MICROBES INFEC, V9, P757, DOI 10.1080/22221751.2020.1746200
   Miller MM, 2017, AM J HEALTH-SYST PH, V74, P1045, DOI 10.2146/ajhp60632
   Ming LJ, 2013, NAT PROD COMMUN, V8, P415
   Narayanan S, 2016, HEMATOL ONCOL CLIN N, V30, P163, DOI 10.1016/j.hoc.2015.09.008
   OCANA M, 1993, EUR J PHARMACOL, V239, P253, DOI 10.1016/0014-2999(93)91006-9
   Pastorino Giulia, 2018, Phytother Res, V32, P2323, DOI 10.1002/ptr.6178
   Populo H, 2012, INT J MOL SCI, V13, P1886, DOI 10.3390/ijms13021886
   Ptushkin VV, 2018, TERAPEVT ARKH, V90, P70, DOI 10.26442/terarkh201890770-76
   Sax PE, 2017, LANCET, V390, P2073, DOI [10.1016/s0140-6736(17)32340-1, 10.1016/S0140-6736(17)32340-1]
   Sun ZG, 2019, MINI-REV MED CHEM, V19, P826, DOI 10.2174/1389557519666190119111125
   Targett-Adams P, 2011, J VIROL, V85, P6353, DOI 10.1128/JVI.00215-11
   Uyeki TM, 2020, NEW ENGL J MED, V382
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yang HJ, 2013, NATURE, V497, P217, DOI 10.1038/nature12122
   Yisireyili M, 2018, BRAIN BEHAV IMMUN, V69, P167, DOI 10.1016/j.bbi.2017.11.010
   Yoo JH, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e62
   Zamek-Gliszczynski MJ, 2019, DRUG METAB DISPOS, V47, P890, DOI 10.1124/dmd.119.087635
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
NR 44
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD NOV
PY 2020
VL 85
AR 104419
DI 10.1016/j.meegid.2020.104419
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA OX9ZL
UT WOS:000593914200007
PM 32540428
OA Green Published
DA 2021-01-01
ER

PT J
AU Guterres, A
   Lima, CHD
   Miranda, RL
   Gadelha, MR
AF Guterres, Alexandro
   de Azeredo Lima, Carlos Henrique
   Miranda, Renan Lyra
   Gadelha, Monica Roberto
TI What is the potential function of microRNAs as biomarkers and
   therapeutic targets in COVID-19?
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE SARS-CoV-2; COVID-19; microRNA; biomarkers; therapeutic targets
ID REPLICATION; CANCER
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of COVID-19, a pandemic associated with substantial morbidity and mortality. Despite of this, no vaccine or approved drug is available to eradicate the virus. In this manuscript, we present an alternative study area that may contribute to development of diagnostic biomarkers and therapeutic targets for COVID-19. We analyzed sixty SARS-CoV-2 genomes to identify regions that could work as virus-encoded miRNA seed sponges and potentially bind to human miRNA seed sites and prevent interaction with their native targets thereby relieving native miRNA suppression. MicroRNAs (miRNAs) are evolutionally conserved single-stranded RNAs that regulate gene expression at the posttranscriptional level by disrupting translation. MiRNAs are key players in variety of biological processes that regulate differentiation, development and activation of immune cells in both innate and adaptive immunity. We find 34 miRNAs for positive sense viral RNA and 45 miRNAs for negative-sense that can strongly bind to certain key SARS-CoV-2 genes. The disruption and dysfunction of miRNAs may perturb the immune response and stimulate the release of inflammatory cytokines altering the cellular response to viral infection. Previous studies demonstrate that miRNAs have the potential to be used as diagnostic and therapeutic biomarkers. Therefore, its discovery and validation are essential for improving the diagnosis of infection and clinical monitoring in COVID-19.
C1 [Guterres, Alexandro; de Azeredo Lima, Carlos Henrique; Miranda, Renan Lyra; Gadelha, Monica Roberto] Inst Estadual Cerebro Paulo Niemeyer, Neuropathol & Mol Genet Lab, Rio De Janeiro, RJ, Brazil.
   [Guterres, Alexandro] Fundacao Oswaldo Cruz, Hantaviruses & Rickettsioses Lab, Inst Oswaldo Cruz, Rio De Janeiro, RJ, Brazil.
   [Gadelha, Monica Roberto] Univ Fed Rio de Janeiro, Neuroendocrinol Res Ctr, Div Endocrinol, Sch Med, Rio De Janeiro, Brazil.
   [Gadelha, Monica Roberto] Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Rio De Janeiro, Brazil.
RP Guterres, A (corresponding author), Fiocruz MS, Lab Hantaviroses & Rickettsioses, Inst Oswaldo Cruz, Pavilhao Helio & Peggy Pereira,1 Pav Sala B115, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM guterres@ioc.fiocruz.br
RI ; Guterres, Alexandro/B-4881-2014
OI Miranda, Renan/0000-0002-3305-3913; Guterres,
   Alexandro/0000-0001-8323-1477
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil
   (CAPES)CAPES [001]
FX This study was financed in part by the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior - Brasil (CAPES) - Finance Code 001. National
   Council for Scientific and Technological Development - CNPq.
CR Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bertrams W, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-57108-0
   Boldin MP, 2011, J EXP MED, V208, P1189, DOI 10.1084/jem.20101823
   Ellwanger DC, 2011, BIOINFORMATICS, V27, P1346, DOI 10.1093/bioinformatics/btr149
   Girardit E, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00439
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang SY, 2019, MOL THER-NUCL ACIDS, V17, P10, DOI 10.1016/j.omtn.2019.04.028
   Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329
   Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246
   Saha A, 2016, ANTIVIR RES, V134, P42, DOI 10.1016/j.antiviral.2016.08.019
   Trobaugh DW, 2014, NATURE, V506, P245, DOI 10.1038/nature12869
   WHO, 2020, 61 WHO, DOI [10.1001/jama.2020.2633., DOI 10.1001/JAMA.2020.2633]
   Zheng ZH, 2013, J VIROL, V87, P5645, DOI 10.1128/JVI.02655-12
NR 13
TC 2
Z9 2
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD NOV
PY 2020
VL 85
AR 104417
DI 10.1016/j.meegid.2020.104417
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA OX9ZL
UT WOS:000593914200015
PM 32526370
DA 2021-01-01
ER

PT J
AU Sadeghi, A
   Asgari, AA
   Norouzi, A
   Kheiri, Z
   Anushirvani, A
   Montazeri, M
   Hosamirudsai, H
   Afhami, S
   Akbarpour, E
   Aliannejad, R
   Radmard, AR
   Davarpanah, AH
   Levi, J
   Wentzel, H
   Qavi, A
   Garratt, A
   Simmons, B
   Hill, A
   Merat, S
AF Sadeghi, Anahita
   Asgari, Ali Ali
   Norouzi, Alireza
   Kheiri, Zahedin
   Anushirvani, Amir
   Montazeri, Mahnaz
   Hosamirudsai, Hadiseh
   Afhami, Shirin
   Akbarpour, Elham
   Aliannejad, Rasoul
   Radmard, Amir Reza
   Davarpanah, Amir H.
   Levi, Jacob
   Wentzel, Hannah
   Qavi, Ambar
   Garratt, Anna
   Simmons, Bryony
   Hill, Andrew
   Merat, Shahin
TI Sofosbuvir and daclatasvir compared with standard of care in the
   treatment of patients admitted to hospital with moderate or severe
   coronavirus infection (COVID-19): a randomized controlled trial
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article
ID TREATMENT-NAIVE PATIENTS; PEGINTERFERON ALPHA-2A; DOUBLE-BLIND; GENOTYPE
   1; RIBAVIRIN; INHIBITOR; 2A
AB Background: Currently no effective antiviral therapy has been found to treat COVID-19. The aim of this trial was to assess if the addition of sofosbuvir and daclatasvir improved clinical outcomes in patients with moderate or severe COVID-19.
   Methods: This was an open-Label, multicentre, randomized controlled clinical trial in adults with moderate or severe COVID-19 admitted to four university hospitals in Iran. Patients were randomized into a treatment arm receiving sofosbuvir and daclatasvir plus standard care, or a control arm receiving standard care alone. The primary endpoint was clinical recovery within 14 days of treatment. The study is registered with IRCT.ir under registration number IRCT20200128046294N2.
   Results: Between 26 March and 26 April 2020, 66 patients were recruited and allocated to either the treatment arm (n = 33) or the control arm (n = 33). Clinical recovery within 14 days was achieved by 29/33 (88%) in the treatment arm and 22/33 (67%) in the control arm (P= 0.076). The treatment arm had a significantly shorter median duration of hospitalization [6 days (IQR 4-8)] than the control group [8 days (IQR 5-13)]; P= 0.029. Cumulative incidence of hospital discharge was significantly higher in the treatment arm versus the control (Gray's P= 0.041). Three patients died in the treatment arm and five in the control arm. No serious adverse events were reported.
   Conclusions: The addition of sofosbuvir and daclatasvir to standard care significantly reduced the duration of hospital stay compared with standard care alone. Although fewer deaths were observed in the treatment arm, this was not statistically significant. Conducting Larger scale trials seems prudent.
C1 [Sadeghi, Anahita; Asgari, Ali Ali; Anushirvani, Amir; Akbarpour, Elham; Merat, Shahin] Univ Tehran Med Sci, Liver & Pancreatobiliary Dis Res Ctr, Digest Dis Res Inst, Tehran, Iran.
   [Norouzi, Alireza] Golestan Univ Med Sci, Golestan Res Ctr Gastroenterol & Hepatol, Gorgan, Golestan, Iran.
   [Kheiri, Zahedin] Univ Tehran Med Sci, Baharloo Hosp, Dept Internal Med, Tehran, Iran.
   [Montazeri, Mahnaz] Univ Tehran Med Sci, Sina Hosp, Dept Infect Dis, Tehran, Iran.
   [Hosamirudsai, Hadiseh] Univ Tehran Med Sci, Baharloo Hosp, Dept Infect Dis, Tehran, Iran.
   [Afhami, Shirin] Univ Tehran Med Sci, Shariati Hosp, Dept Infect Dis, Tehran, Iran.
   [Aliannejad, Rasoul] Univ Tehran Med Sci, Shariati Hosp, Thorac Res Ctr, Dept Pulm & Crit Care, Tehran, Iran.
   [Radmard, Amir Reza] Univ Tehran Med Sci, Shariati Hosp, Dept Radiol, Tehran, Iran.
   [Davarpanah, Amir H.] Emory Univ, Sch Med, Dept Radiol & Imaging Sci, Atlanta, GA USA.
   [Levi, Jacob] Homerton Univ Hosp, Dept Emergency Med, London, England.
   [Wentzel, Hannah; Qavi, Ambar] Imperial Coll London, Sch Publ Hlth, London, England.
   [Garratt, Anna] Cardiff & Vale Univ Hlth Board, Cardiff, Wales.
   [Simmons, Bryony] Imperial Coll London, Dept Infect Dis, London, England.
   [Hill, Andrew] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool, Merseyside, England.
RP Merat, S (corresponding author), Univ Tehran Med Sci, Liver & Pancreatobiliary Dis Res Ctr, Digest Dis Res Inst, Tehran, Iran.
EM merat@tums.ac.ir
OI Sadeghi, Anahita/0000-0001-9564-4631; Simmons,
   Bryony/0000-0002-3207-9935; levi, jacob/0000-0003-0206-7121
FU Digestive Disease Research Institute of Tehran University of Medical
   Sciences
FX This study was supported by internal funding of the Digestive Disease
   Research Institute of Tehran University of Medical Sciences.
CR Alabboud M, 2020, DLS, V1, P44
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   Bullard-Feibelman KM, 2017, ANTIVIR RES, V137, P134, DOI 10.1016/j.antiviral.2016.11.023
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chien M, 2020, NUCLEOTIDE ANALOGUES
   de Freitas CS, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007072
   Elfiky AA, 2017, J MED VIROL, V89, P1040, DOI 10.1002/jmv.24736
   FDA, 2015, DAKLINZA DACL TABL O, P1
   FDA, 2015, SCI CONS DEM BIOS RE, P1
   Ferreira AC, 2019, ANTIMICROB AGENTS CH, V63, DOI 10.1128/AAC.01389-18
   Freriksen JJM, 2019, ALIMENT PHARM THER, V50, P738, DOI 10.1111/apt.15476
   Gan CS, 2018, CHEM BIOL DRUG DES, V91, P448, DOI 10.1111/cbdd.13091
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Hezode C, 2015, GUT, V64, P948, DOI 10.1136/gutjnl-2014-307498
   Hill A, 2020, J VIRUS ERAD, V6, P61
   Horby P, 2020, EFFECT DEXAMETHASONE
   Izumi N, 2014, ANTIVIR THER, V19, P501, DOI 10.3851/IMP2731
   Joynt GM, 2020, LANCET INFECT DIS, V20, P635, DOI 10.1016/S1473-3099(20)30237-1
   Kirby BJ, 2015, CLIN PHARMACOKINET, V54, P677, DOI 10.1007/s40262-015-0261-7
   Lawitz E, 2013, LANCET INFECT DIS, V13, P401, DOI 10.1016/S1473-3099(13)70033-1
   Liu S, 2020, EVALUATION 19 ANTIVI
   Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2
   Mahdavi A, 2020, IRAN J RADIOL, V17, DOI 10.5812/iranjradiol.102324
   Merat S, 2015, ARCH IRAN MED, V18, P515, DOI 015188/AIM.009
   Nettles RE, 2011, HEPATOLOGY, V54, P1956, DOI 10.1002/hep.24609
   Pol S, 2012, LANCET INFECT DIS, V12, P671, DOI 10.1016/S1473-3099(12)70138-X
   Poustchi H, 2020, J GASTROEN HEPATOL, V35, P1590, DOI 10.1111/jgh.14994
   Rodriguez-Torres M, 2013, J HEPATOL, V58, P663, DOI 10.1016/j.jhep.2012.11.018
   Sulkowski MS, 2017, HEPATOL INT, V11, P188, DOI 10.1007/s12072-017-9788-z
   Tang W, 2020, HYDROXYCHLOROQUINE P, DOI [10.1101/2020.04.10.20060558, DOI 10.1101/2020.04.10.20060558]
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   World Health Organization (WHO), 116 WHO
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zheng SF, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1443
NR 36
TC 3
Z9 3
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
EI 1460-2091
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD NOV
PY 2020
VL 75
IS 11
BP 3379
EP 3385
DI 10.1093/jac/dkaa334
PG 7
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA OW7MG
UT WOS:000593065400039
PM 32812039
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Beovic, B
   Dousak, M
   Ferreira-Coimbra, J
   Nadrah, K
   Rubulotta, F
   Belliato, M
   Berger-Estilita, J
   Ayoade, F
   Rello, J
   Erdem, H
AF Beovic, Bojana
   Dousak, May
   Ferreira-Coimbra, Joao
   Nadrah, Kristina
   Rubulotta, Francesca
   Belliato, Mirko
   Berger-Estilita, Joana
   Ayoade, Folusakin
   Rello, Jordi
   Erdem, Hakan
TI Antibiotic use in patients with COVID-19: a 'snapshot' Infectious
   Diseases International Research Initiative (ID-IRI) survey
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article
AB Background: Antibiotics may be indicated in patients with COVID-19 due to suspected or confirmed bacterial superinfection.
   Objectives: To investigate antibiotic prescribing practices in patients with COVID-19.
   Methods: We performed an international web-based survey and investigated the pattern of antibiotic use as reported by physicians involved in treatment of COVID-19. SPSS Statistics version 25 was used for data analysis.
   Results: The survey was completed by 166 participants from 23 countries and 82 different hospitals. Local guidelines for antibiotic use in COVID-19 patients were reported by 61.8% (n = 102) of participants and for 82.9% (n = 136) they did not differ from Local community-acquired pneumonia guidelines. Clinical presentation was recognized as the most important reason for the start of antibiotics (mean score 4.07 and SD =1.095 on grading scale from 1 to 5). When antibiotics were started, most respondents rated as the highest the need for coverage of atypical pathogens (mean score = 2.8 and SD = 0.99), followed by Staphylococcus aureus (mean score = 2.67 and SD = 1.05 on bi-modal scale, with values 1 and 2 for disagreement and values 3 and 4 for agreement). In the patients on the ward, 29.1% of respondents chose not to prescribe any antibiotic. Combination of beta-Lactams and macrolides or fluoroquinolones was reported by 52.4% (n = 87) of respondents. In patients in the ICU, piperacillin/tazobactam was the most commonly prescribed antibiotic. The mean reported duration of antibiotic treatment was 7.12 (SD = 2.44) days.
   Conclusions: The study revealed widespread broad-spectrum antibiotic use in patients with COVID-19. Implementation of antimicrobial stewardship principles is warranted to mitigate the negative consequences of antibiotic therapy.
C1 [Beovic, Bojana; Nadrah, Kristina] Univ Med Ctr Ljubljana, Ljubljana, Slovenia.
   [Beovic, Bojana] Univ Ljubljana, Fac Med, Ljubljana, Slovenia.
   [Dousak, May] Univ Ljubljana, Fac Social Sci, Ljubljana, Slovenia.
   [Ferreira-Coimbra, Joao] Ctr Hosp Univ Porto, Dept Internal Med, Porto, Portugal.
   [Rubulotta, Francesca] Imperial Coll NHS Trust, Charing Cross Hosp, Dept Intens Care Med, London, England.
   [Belliato, Mirko] IRCCS Fdn Policlin San Matteo, UOC Anestesia & Rianimazone 1, Pavia, Italy.
   [Berger-Estilita, Joana] Univ Bern, Bern Univ Hosp, Dept Anaesthesiol & Pain Med, Inselspital, Bern, Switzerland.
   [Ayoade, Folusakin] Univ Miami, Dept Med, Div Infect Dis, Miami, FL USA.
   [Rello, Jordi] Montpellier Univ, Univ Hosp Nimes, Dept Anaesthesia Crit Care Emergency & Pain Med, Nimes, France.
   [Rello, Jordi] Vall dHebron Inst Res, CIBERES, Barcelona, Spain.
   [Rello, Jordi] Ctr Biomed Invest Biomed Red Enfermedades Resp CI, Madrid, Spain.
   [Erdem, Hakan] ID IRI, Ankara, Turkey.
RP Beovic, B (corresponding author), Univ Med Ctr Ljubljana, Ljubljana, Slovenia.; Beovic, B (corresponding author), Univ Ljubljana, Fac Med, Ljubljana, Slovenia.
EM bojana.beovic@kclj.si
OI Erdem, Hakan/0000-0002-6265-5227; Rubulotta,
   Francesca/0000-0001-8644-1728
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Franki R, SURVEY HYDROXYCHLORO
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huttner BD, 2020, CLIN MICROBIOL INFEC, V26, P808, DOI 10.1016/j.cmi.2020.04.024
   Kalil AC, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2539-x
   Kim D, 2020, JAMA-J AM MED ASSOC, V323, P2085, DOI 10.1001/jama.2020.6266
   Lippi G, 2020, CLIN CHIM ACTA, V505, P190, DOI 10.1016/j.cca.2020.03.004
   University of Ljubljana Faculty of Social Sciences, 1KA WEB SURV
   Wu JY, 2020, INFECT DIS THER, V9, P17, DOI 10.1007/s40121-020-00286-6
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 10
TC 2
Z9 2
U1 2
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
EI 1460-2091
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD NOV
PY 2020
VL 75
IS 11
BP 3386
EP 3390
DI 10.1093/jac/dkaa326
PG 5
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA OW7MG
UT WOS:000593065400040
PM 32766706
OA Green Published
DA 2021-01-01
ER

PT J
AU Masur, J
   Freeman, CW
   Mohan, S
AF Masur, J.
   Freeman, C. W.
   Mohan, S.
TI A Double-Edged Sword: Neurologic Complications and Mortality in
   Extracorporeal Membrane Oxygenation Therapy for COVID-19-Related Severe
   Acute Respiratory Distress Syndrome at a Tertiary Care Center
SO AMERICAN JOURNAL OF NEURORADIOLOGY
LA English
DT Article
AB In this clinical case series, we report our experience to date with neurologic complications of extracorporeal membrane oxygenation therapy for COVID-19 Acute Respiratory Distress Syndrome. We have found an unexpectedly increased rate of complications as demonstrated by neuroimaging compared with meta-analysis data in extracorporeal membrane oxygenation therapy for all Acute Respiratory Distress Syndrome etiologies over the past few decades and compared with the most recent baseline data describing the incidence of neurologic complication in all patients with COVID-19. For our 12-patient cohort, there was a rate of intracranial hemorrhage of 41.7%. Representative cases and images of devastating intracranial hemorrhage are presented. We hypothesize that the interplay between hematologic changes inherent to extracorporeal membrane oxygenation and inflammatory and coagulopathic changes that have begun to be elucidated as part of the COVID-19 disease process are responsible. Continued analysis of extracorporeal membrane oxygenation therapy in this disease paradigm is warranted.
C1 [Masur, J.; Freeman, C. W.; Mohan, S.] Hosp Univ Penn, Dept Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA.
RP Masur, J (corresponding author), Hosp Univ Penn, Dept Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA.
EM jonmasur@gmail.com
OI Freeman, Colbey/0000-0003-0024-1421; Mohan, Suyash/0000-0002-4025-115X
CR Alshahrani MS, 2018, ANN INTENSIVE CARE, V8, DOI 10.1186/s13613-017-0350-x
   Heman-Ackah SM, 2020, NEUROSURGERY, V87, pE147, DOI 10.1093/neuros/nyaa198
   Henry BM, 2020, J CRIT CARE, V58, P27, DOI 10.1016/j.jcrc.2020.03.011
   Jacobs JP, 2020, ASAIO J, V66, P722, DOI 10.1097/MAT.0000000000001185
   Kowalewski M, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02925-3
   Lorusso R, 2017, CRIT CARE MED, V45, P1389, DOI 10.1097/CCM.0000000000002502
   Peek GJ, 2009, LANCET, V374, P1351, DOI 10.1016/S0140-6736(09)61069-2
   Radmanesh A, 2020, AM J NEURORADIOL, V41, P1179, DOI 10.3174/ajnr.A6610
   Sultan I, 2020, J CARDIAC SURG, V35, P1410, DOI 10.1111/jocs.14583
NR 9
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC NEURORADIOLOGY
PI DENVILLE
PA PO BOX 3000, DENVILLE, NJ 07834-9349 USA
SN 0195-6108
EI 1936-959X
J9 AM J NEURORADIOL
JI Am. J. Neuroradiol.
PD NOV
PY 2020
VL 41
IS 11
BP 2009
EP 2011
DI 10.3174/ajnr.A6728
PG 3
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical
   Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA OV0JH
UT WOS:000591906900016
PM 32855187
OA Other Gold
DA 2021-01-01
ER

PT J
AU Colavita, L
   Ciprandi, G
   Salpietro, A
   Cuppari, C
AF Colavita, Laura
   Ciprandi, Giorgio
   Salpietro, Annamaria
   Cuppari, Caterina
TI HMGB1: A pleiotropic activity
SO PEDIATRIC ALLERGY AND IMMUNOLOGY
LA English
DT Article
DE biomarker; HMGB1; inflammation; target therapy
AB High-mobility group box 1 (HMGB1) is a nuclear protein involved in DNA replication, transcription, recombination, and repair. In the extracellular space, the HMGB1 plays an essential role in the onset and perpetuation of inflammation, belonging to the group of damage-associated molecular pattern (DAMP) molecules, also called alarmins. For this, HMGB1 has been studied in several acute and chronic inflammatory diseases as an early biomarker of inflammation. An increased concentration of HMGB1 has been detected in serum, as the expression of systemic inflammation, and in specific samples (such as stool, synovial fluid, nasal lavage fluid, sputum, and cerebrospinal fluid), as the expression of local production, in several infectious and/or inflammatory diseases. These data are particularly important because they open new futuristic possibilities for target therapies, potentially also for the COVID-19 treatment.
C1 [Colavita, Laura; Cuppari, Caterina] Univ Hosp Messina, Dept Adult & Childhood Human Pathol, Unit Pediat Emergency, Messina, Italy.
   [Ciprandi, Giorgio] Casa Cura Villa Montallegro, Allergy Clin, Genoa, Italy.
   [Salpietro, Annamaria] ASST Spedali Civili Brescia, Pediat Clin, Brescia, Italy.
RP Colavita, L (corresponding author), Univ Messina, Univ Hosp Gaetano Martino, Unit Pediat Emergency, Dept Pediat Sci, Via Consolare Valeria 1, I-98125 Messina, Italy.
EM lauracol85@gmail.com
RI Ciprandi, Giorgio/G-7462-2012
OI Ciprandi, Giorgio/0000-0001-7016-8421; Colavita,
   Laura/0000-0003-0984-2290
CR Andersson U, 2020, MOL MED, V26, DOI 10.1186/s10020-020-00172-4
   Cheng Zhe, 2011, Zhonghua Yi Xue Za Zhi, V91, P2981
   Chirico V, 2015, CLIN MICROBIOL INFEC, V21, DOI 10.1016/j.cmi.2014.11.004
   Chirico V, 2014, EUR J PEDIATR, V173, P1123, DOI 10.1007/s00431-014-2327-1
   Dipasquale V, 2017, INT J MOL CELL MED, V6, P148, DOI 10.22088/acadpub.BUMS.6.3.148
   Mandke P, 2019, DNA REPAIR, V83, DOI 10.1016/j.dnarep.2019.102701
   Pellegrini L, 2019, PHARMACOL THERAPEUT, V196, P160, DOI 10.1016/j.pharmthera.2018.12.005
   Street ME, 2020, HORM RES PAEDIAT, V93, P73, DOI 10.1159/000508291
   Wang HL, 2017, MOL MED REP, V16, P2361, DOI 10.3892/mmr.2017.6892
   Yang H, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00484
NR 10
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0905-6157
EI 1399-3038
J9 PEDIAT ALLERG IMM-UK
JI Pediatr. Allergy Immunol.
PD NOV
PY 2020
VL 31
SU 26
SI SI
BP 63
EP 65
DI 10.1111/pai.13358
PG 3
WC Allergy; Immunology; Pediatrics
SC Allergy; Immunology; Pediatrics
GA OU8QC
UT WOS:000591787400020
PM 33236418
OA Bronze
DA 2021-01-01
ER

PT J
AU La Torre, F
   Leonardi, L
   Giardino, G
   Volpi, S
   Federici, S
   Soresina, A
   Cancrini, C
   Lougaris, V
   Castagnoli, R
   Corrente, S
   Cardinale, F
AF La Torre, Francesco
   Leonardi, Lucia
   Giardino, Giuliana
   Volpi, Stefano
   Federici, Silvia
   Soresina, Annarosa
   Cancrini, Caterina
   Lougaris, Vassilios
   Castagnoli, Riccardo
   Corrente, Stefania
   Cardinale, Fabio
CA Immunology Commission Italian Soc
TI Immunological basis of virus-host interaction in COVID-19
SO PEDIATRIC ALLERGY AND IMMUNOLOGY
LA English
DT Article
DE children; COVID&#8208; 19; cytokine storm; immunopathogenesis; Kawasaki
   disease
AB COVID-19 is a complex new viral disease, in which a strict balance between anti-viral immune response and the ensuing organ inflammation has a critical role in determining the clinical course. In adults, compelling evidence exists indicating that an uncontrolled inflammatory response ("cytokine storm") is pivotal in determining disease progression and mortality. Children may rarely present with severe disease. Modulating factors related to the host's genetic factors, age-related susceptibility, and the capability to mount appropriate immune responses might play a role in control virus load at an early stage and regulating the inflammatory reaction. Elucidating these mechanisms seems crucial in developing target therapies according to patient's age, immunologic status, and disease evolution in COVID-19.
C1 [La Torre, Francesco; Cardinale, Fabio] Giovanni XXIII Pediat Hosp, Dept Pediat, Bari, Italy.
   [Leonardi, Lucia] Univ Roma Tor Vergata, Dept Syst Med, Rome, Italy.
   [Giardino, Giuliana] Univ Naples Federico II, Dept Translat Med Sci, Pediat Sect, Naples, Italy.
   [Volpi, Stefano] Univ Genoa, IRCCS Ist Giannina Gaslini, Ctr Autoinflammatory Dis & Immunodeficiency, Genoa, Italy.
   [Federici, Silvia] Osped Pediat Bambino Gesu, Div Rheumatol, IRCCS, Rome, Italy.
   [Soresina, Annarosa] ASST Spedali Civili Brescia, Pediat Clin, Brescia, Italy.
   [Cancrini, Caterina] IRCCS, Bambino Gesu Childrens Hosp, Res Unit Primary Immunodeficiencies, Acad Dept Pediat,Immune & Infect Dis Div, Rome, Italy.
   [Lougaris, Vassilios] Univ Brescia, Pediat Clin, Dept Clin & Expt Sci, Brescia, Italy.
   [Lougaris, Vassilios] Univ Brescia, Inst Mol Med A Nocivelli, Brescia, Italy.
   [Lougaris, Vassilios] ASST Spedali Civili Brescia, Brescia, Italy.
   [Castagnoli, Riccardo] Univ Pavia, Pediat Clin, Fdn IRCCS Policlin San Matteo, Dept Pediat, Pavia, Italy.
   [Corrente, Stefania] Azienda Osped San Camillo Forlanini, Pediat Dept, Rome, Italy.
RP Cardinale, F (corresponding author), Osped Pediat Giovanni XXIII, Via Amendola 207, I-70100 Bari, Italy.
EM fabiocardinale@libero.it
RI Castagnoli, Riccardo/AAF-8555-2019
OI Castagnoli, Riccardo/0000-0003-0029-9383
CR Carsetti R, 2020, LANCET CHILD ADOLESC, V4, P414, DOI 10.1016/S2352-4642(20)30135-8
   Castagnoli R, 2020, JAMA PEDIATR, V174, P882, DOI 10.1001/jamapediatrics.2020.1467
   Felsenstein S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108448
   Henderson LA, 2020, ARTHRITIS RHEUMATOL, V72, P1059, DOI 10.1002/art.41285
   Lu XX, 2020, PEDIAT ALLERG IMM-UK, V31, P449, DOI 10.1111/pai.13267
   Quinti I, 2020, J ALLERGY CLIN IMMUN, V146, P211, DOI 10.1016/j.jaci.2020.04.013
   Soresina A, 2020, PEDIAT ALLERG IMM-UK, V31, P565, DOI 10.1111/pai.13263
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Zhang HX, 2005, J INFECT DIS, V192, P1355, DOI 10.1086/491479
NR 10
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0905-6157
EI 1399-3038
J9 PEDIAT ALLERG IMM-UK
JI Pediatr. Allergy Immunol.
PD NOV
PY 2020
VL 31
SU 26
SI SI
BP 75
EP 78
DI 10.1111/pai.13363
PG 4
WC Allergy; Immunology; Pediatrics
SC Allergy; Immunology; Pediatrics
GA OU8QC
UT WOS:000591787400024
PM 33236427
OA Bronze
DA 2021-01-01
ER

PT J
AU Cianferoni, A
   Votto, M
AF Cianferoni, Antonella
   Votto, Martina
TI COVID-19 and allergy: How to take care of allergic patients during a
   pandemic?
SO PEDIATRIC ALLERGY AND IMMUNOLOGY
LA English
DT Article
DE asthma; atopic dermatitis; atopy; COVID&#8208; 19; food allergy;
   immunotherapy; SARS&#8208; CoV&#8208; 2
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as COVID-19, is a new strain of coronavirus that has not been previously identified in humans. SARS-CoV-2 is recognized as a highly contagious respiratory virus with severe morbidity and mortality, especially in vulnerable populations. Being a novel disease, everyone is susceptible, there are no vaccine and no treatment. To contain the spread of the disease, health authorities throughout the world have restricted the social interactions of individuals in various degrees. Allergists, like other physicians, are faced with the challenge of providing care for their patients, while protecting themselves and patients from getting infected, with strategies that are in continuous evolution as states work through the different stages of social distance. Allergist provides care for patients with the most common non-communicable disease in the world: asthma, allergic rhinitis, food allergy, venom allergy, drug allergy atopic dermatitis, and urticarial syndromes. Some of these diseases are not only considered risk factors for severe reactions but also have symptoms such as cough and sneezing that are in differential diagnosis with COVID-19. As we move forward, allergy symptoms may prevent patients from working, go to school, or access medical services that increasingly are allowing only asymptomatic individuals. In this review, we will outline how to take care safety of different allergic patients during the pandemic.
C1 [Cianferoni, Antonella] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Cianferoni, Antonella] Childrens Hosp Philadelphia, Allergy & Immunol Div, Philadelphia, PA 19104 USA.
   [Votto, Martina] Univ Pavia, Dept Paediat, Paediat Clin, Fdn IRCSS Policlin San Matteo, Pavia, Italy.
RP Cianferoni, A (corresponding author), Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA.
EM cianferonia@email.chop.edu
OI Votto, martina/0000-0002-4271-8649
CR Brough HA, 2020, PEDIAT ALLERG IMM-UK, V31, P442, DOI 10.1111/pai.13262
   Casale TB, 2020, J ALLER CL IMM-PRACT, V8, P1795, DOI 10.1016/j.jaip.2020.04.022
   del Rio C, 2020, JAMA-J AM MED ASSOC, V323, P1039, DOI 10.1001/jama.2020.1490
   Epstein T, 2020, ADM SUBCUTANEOUS ALL
   Groetch Marion, 2020, Ann Allergy Asthma Immunol, DOI 10.1016/j.anai.2020.05.005
   Haberman R, 2020, NEW ENGL J MED, V383, P85, DOI 10.1056/NEJMc2009567
   Nowak-Wegrzyn A, 2020, ANN ALLERG ASTHMA IM, V125, P14, DOI 10.1016/j.anai.2020.04.032
   Shaker MS, 2020, J ALLER CL IMM-PRACT, V8, P1477, DOI 10.1016/j.jaip.2020.03.012
   Vultaggio A, 2020, ALLERGY, V75, P2764, DOI 10.1111/all.14407
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
NR 10
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0905-6157
EI 1399-3038
J9 PEDIAT ALLERG IMM-UK
JI Pediatr. Allergy Immunol.
PD NOV
PY 2020
VL 31
SU 26
SI SI
BP 96
EP 101
DI 10.1111/pai.13367
PG 6
WC Allergy; Immunology; Pediatrics
SC Allergy; Immunology; Pediatrics
GA OU8QC
UT WOS:000591787400030
PM 33236431
OA Bronze
DA 2021-01-01
ER

PT J
AU Kennedy, DA
   Read, AF
AF Kennedy, David A.
   Read, Andrew F.
TI Monitor for COVID-19 vaccine resistance evolution during clinical trials
SO PLOS BIOLOGY
LA English
DT Article
AB Although less common than the evolution of antimicrobial drug resistance, vaccine resistance can and has evolved. How likely is it that COVID-19 vaccines currently in development will be undermined by viral evolution? We argue that this can be determined by repurposing samples that are already being collected as part of clinical trials. Such information would be useful for prioritizing investment among candidate vaccines and maximizing the potential long-term impact of COVID-19 vaccines.
C1 [Kennedy, David A.; Read, Andrew F.] Penn State Univ, Dept Biol, Ctr Infect Dis Dynam, University Pk, PA 16802 USA.
   [Read, Andrew F.] Penn State Univ, Dept Entomol, University Pk, PA 16802 USA.
RP Kennedy, DA (corresponding author), Penn State Univ, Dept Biol, Ctr Infect Dis Dynam, University Pk, PA 16802 USA.
EM dak30@psu.edu
RI ; Read, Andrew/E-7298-2018
OI Kennedy, David/0000-0003-0820-115X; Read, Andrew/0000-0001-7604-7903
FU Institute of General Medical Sciences, National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS); United Kingdom Biotechnology and Biological
   Sciences Research Council as part of the NSF-NIHUSDA Ecology and
   Evolution of Infectious Diseases program [R01GM105244, R01GM140459]
FX The ideas presented here were developed during work funded by the
   Institute of General Medical Sciences, National Institutes of Health and
   United Kingdom Biotechnology and Biological Sciences Research Council as
   part of the NSF-NIHUSDA Ecology and Evolution of Infectious Diseases
   program (R01GM105244) to AFR and (R01GM140459) to DAK. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831
   Dagan R, 2010, VACCINE, V28, P5513, DOI 10.1016/j.vaccine.2010.06.026
   Genton B, 2002, J INFECT DIS, V185, P820, DOI 10.1086/339342
   Kennedy DA, 2018, P NATL ACAD SCI USA, V115, P12878, DOI 10.1073/pnas.1717159115
   Kennedy DA, 2017, P ROY SOC B-BIOL SCI, V284, DOI 10.1098/rspb.2016.2562
   Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3
   Lehmann PV, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00655
   Lipsitch M, 1997, P NATL ACAD SCI USA, V94, P6571, DOI 10.1073/pnas.94.12.6571
   Medlock J, 2009, SCIENCE, V325, P1705, DOI 10.1126/science.1175570
   Octavia S, 2011, MOL BIOL EVOL, V28, P707, DOI 10.1093/molbev/msq245
   Read AF, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002198
   Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520
   Weinberger DM, 2011, LANCET, V378, P1962, DOI 10.1016/S0140-6736(10)62225-8
   World Health Organization, 2020, DRAFT LANDSC COVID 1
NR 14
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1544-9173
EI 1545-7885
J9 PLOS BIOL
JI PLoS. Biol.
PD NOV
PY 2020
VL 18
IS 11
AR e3001000
DI 10.1371/journal.pbio.3001000
PG 5
WC Biochemistry & Molecular Biology; Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics
GA OU9HH
UT WOS:000591833700002
PM 33166303
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Goyal, A
   Cardozo-Ojeda, EF
   Schiffer, JT
AF Goyal, Ashish
   Cardozo-Ojeda, E. Fabian
   Schiffer, Joshua T.
TI Potency and timing of antiviral therapy as determinants of duration of
   SARS-CoV-2 shedding and intensity of inflammatory response
SO SCIENCE ADVANCES
LA English
DT Article
ID CD4(+) T-CELLS; VIRUS; CLEARANCE; SELINEXOR
AB To affect the COVID-19 pandemic, lifesaving antiviral therapies must be identified. The number of clinical trials that can be performed is limited. We developed mathematical models to project multiple therapeutic approaches. Our models recapitulate off-treatment viral dynamics and predict a three-phase immune response. Simulated treatment with remdesivir, selinexor, neutralizing antibodies, or cellular immunotherapy demonstrates that rapid viral elimination is possible if in vivo potency is sufficiently high. Therapies dosed soon after peak viral load when symptoms develop may decrease shedding duration and immune response intensity but have little effect on viral area under the curve (AUC), which is driven by high early viral loads. Potent therapy dosed before viral peak during presymptomatic infection could lower AUC. Drug resistance may emerge with a moderately potent agent dosed before viral peak. Our results support early treatment for COVID-19 if shedding duration, not AUC, is most predictive of clinical severity.
C1 [Goyal, Ashish; Cardozo-Ojeda, E. Fabian; Schiffer, Joshua T.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.
   [Schiffer, Joshua T.] Fred Hutchinson Canc Res Ctr, Clin Res Div, 1124 Columbia St, Seattle, WA 98104 USA.
   [Schiffer, Joshua T.] Univ Washington, Dept Med, Seattle, WA USA.
RP Schiffer, JT (corresponding author), Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.; Schiffer, JT (corresponding author), Fred Hutchinson Canc Res Ctr, Clin Res Div, 1124 Columbia St, Seattle, WA 98104 USA.
EM jschiffe@fredhutch.org
RI ; Goyal, Ashish/E-9727-2013
OI Cardozo Ojeda, Erwing/0000-0001-8690-9896; Schiffer,
   Joshua/0000-0002-2598-1621; Goyal, Ashish/0000-0003-1582-3379
FU Fred Hutchinson Cancer Research Center faculty discretionary funds;
   National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [5R01AI121129-05]
FX This study was supported by Fred Hutchinson Cancer Research Center
   faculty discretionary funds and by National Institute of Allergy and
   Infectious Diseases (grant 5R01AI121129-05).
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Akaike H., 1998, P 2 INT S INF THEOR, P199, DOI DOI 10.1007/978-1-4612-1694-0_15
   Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9
   Cai GJ, 2020, STEEL RES INT, DOI 10.1002/srin.202000269
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan PLS, 2011, J PHARMACOKINET PHAR, V38, P41, DOI 10.1007/s10928-010-9175-z
   Channappanavar R, 2019, J CLIN INVEST, V129, P3625, DOI 10.1172/JCI126363
   Chemaly RF, 2014, CLIN INFECT DIS, V59, pS344, DOI 10.1093/cid/ciu623
   Chen J, 2010, J VIROL, V84, P1289, DOI 10.1128/JVI.01281-09
   Du ZW, 2020, EMERG INFECT DIS, V26, P1341, DOI 10.3201/eid2606.200357
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Garzon R, 2017, BLOOD, V129, P3165, DOI 10.1182/blood-2016-11-750158
   Goncalves A, 2020, CPT-PHARMACOMET SYST, V9, P509, DOI 10.1002/psp4.12543
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Hayden FG, 2018, NEW ENGL J MED, V379, P913, DOI 10.1056/NEJMoa1716197
   HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0
   Holte SE, 2006, JAIDS-J ACQ IMM DEF, V41, P266, DOI 10.1097/01.qai.0000199233.69457.e4
   Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255
   Kim JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e86
   Kim K. S., 2020, MODELLING SARS COV 2
   Korean Soc Infect Dis, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e132
   Lescure FX, 2020, LANCET INFECT DIS, V20, P697, DOI 10.1016/S1473-3099(20)30200-0
   Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9
   Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2
   Lucas C, 2020, NATURE, DOI 10.1038/s41586-020-2588-y
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Mitja O, 2020, LANCET GLOB HEALTH, V8, pE639, DOI 10.1016/S2214-109X(20)30114-5
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Nakayama R, 2016, ONCOTARGET, V7, P16581, DOI 10.18632/oncotarget.7667
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Park Su Eun, 2020, Clin Exp Pediatr, V63, P119, DOI 10.3345/cep.2020.00493
   Pawelek KA, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002588
   Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582
   Peterson TJ, 2020, ANN PHARMACOTHER, V54, P577, DOI 10.1177/1060028019892643
   Reeves DB, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1007626
   Sanjuan R, 2010, J VIROL, V84, P9733, DOI 10.1128/JVI.00694-10
   Schiffer JT, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad6654
   Schiffer JT, 2013, ANTIMICROB AGENTS CH, V57, P5820, DOI 10.1128/AAC.01114-13
   Smith AP, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01554
   Suthar Mehul S, 2020, Cell Rep Med, V1, P100040, DOI 10.1016/j.xcrm.2020.100040
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Uddin M. H., 2020, DRUG DISCOV TODAY
   Wajnberg A., HUMORAL IMMUNE RESPO
   Walker P., 2020, GLOBAL IMPACT COVID, DOI [DOI 10.25561/77735, 10.25561/77735]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071
   WILLIAMSON BN, 2020, NATURE 0609, DOI DOI 10.1038/S41586-020-2423-5
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Xue KS, 2017, ELIFE, V6, DOI [10.7554/elife.26875, 10.7554/eLife.26875]
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zhao JC, 2016, IMMUNITY, V44, P1379, DOI 10.1016/j.immuni.2016.05.006
   Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10
   Zheng SF, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1443
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 59
TC 0
Z9 0
U1 2
U2 2
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375-2548
J9 SCI ADV
JI Sci. Adv.
PD NOV
PY 2020
VL 6
IS 47
AR eabc7112
DI 10.1126/sciadv.abc7112
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OV4HQ
UT WOS:000592173500026
PM 33097472
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Chaudhary, R
   Kreutz, RP
   Bliden, KP
   Tantry, US
   Gurbel, PA
AF Chaudhary, Rahul
   Kreutz, Rolf P.
   Bliden, Kevin P.
   Tantry, Udaya S.
   Gurbel, Paul A.
TI Personalizing Antithrombotic Therapy in COVID-19: Role of
   Thromboelastography and Thromboelastometry
SO THROMBOSIS AND HAEMOSTASIS
LA English
DT Letter
C1 [Chaudhary, Rahul] Mayo Clin, Div Hosp Internal Med, Rochester, MN USA.
   [Chaudhary, Rahul; Bliden, Kevin P.; Tantry, Udaya S.; Gurbel, Paul A.] Sinai Hosp Baltimore, Sinai Ctr Thrombosis Res, Baltimore, MD USA.
   [Kreutz, Rolf P.] Indiana Univ Sch Med, Dept Internal Med, Krannert Inst ofCardiol, Indianapolis, IN 46202 USA.
RP Chaudhary, R (corresponding author), Mayo Clin, Div Hosp Internal Med, Dept Internal Med, 200 First St SW, Rochester, MN 55905 USA.
EM Chaudhary.rahul@mayo.edu
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Barnes GD, 2020, J THROMB THROMBOLYS, V50, P72, DOI 10.1007/s11239-020-02138-z
   Fox SE, 2020, LANCET RESP MED, V8, P681, DOI 10.1016/S2213-2600(20)30243-5
   Gurbel PA, 2005, J AM COLL CARDIOL, V46, P1820, DOI 10.1016/j.jacc.2005.07.041
   Gurbel PA, 2016, PLATELETS, V27, P642, DOI 10.3109/09537104.2016.1153617
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kabrhel C, 2010, ACAD EMERG MED, V17, P589, DOI 10.1111/j.1553-2712.2010.00765.x
   Kahn SR, 2012, CHEST, V141, pE195S, DOI 10.1378/chest.11-2296
   Lippi G, 2020, THROMB HAEMOSTASIS, V120, P876, DOI 10.1055/s-0040-1709650
   Maatman TK, 2020, CRIT CARE MED, V48, pE783, DOI 10.1097/CCM.0000000000004466
   Mortus JR, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.11192
   Panigada M, 2020, J THROMB HAEMOST, V18, P1738, DOI 10.1111/jth.14850
   Pavoni V, 2020, J THROMB THROMBOLYS, V50, P281, DOI 10.1007/s11239-020-02130-7
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Wright FL, 2020, J AM COLL SURGEONS, V231, P193, DOI 10.1016/j.jamcollsurg.2020.05.007
NR 17
TC 1
Z9 1
U1 0
U2 0
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0340-6245
EI 2567-689X
J9 THROMB HAEMOSTASIS
JI Thromb. Haemost.
PD NOV
PY 2020
VL 120
IS 11
BP 1594
EP 1596
DI 10.1055/s-0040-1714217
PG 3
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA OO4KS
UT WOS:000587350200015
PM 32679595
OA Bronze
DA 2021-01-01
ER

PT J
AU Su, L
   Tu, Y
   Kong, DP
   Chen, DG
   Zhang, CX
   Zhang, WN
   Zhuang, CL
   Wang, ZB
AF Su, Li
   Tu, Ye
   Kong, De-pei
   Chen, Da-gui
   Zhang, Chen-xi
   Zhang, Wan-nian
   Zhuang, Chun-lin
   Wang, Zhi-bin
TI Drug repurposing of anti-infective clinical drugs: Discovery of two
   potential anti-cytokine storm agents
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Cytokine storm; COVID-19; Entecavir; Imipenem; Drug repurposing;
   Anti-inflammation
ID CORONAVIRUS; DISEASE
AB Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2) has been widely spread in the world with a high mortality. Cytokine storm syndrome (CSS) and acute lung injury caused by SARS-CoV-2 infection severely threaten the patients. With the purpose to find effective and low-toxic drugs to mitigate CSS, entecavir and imipenem were identified to reduce TNF-alpha using a LPS-induced macrophage model from the anti-infective drug library. Entecavir and imipenem efficiently suppressed the release of inflammatory cytokines by partly intervention of NF-kappa B activity. The acute lung injury was also alleviated and the survival time was prolonged in mice. In addition, entecavir and imipenem inhibited the release of TNF-alpha and IL-10 in human peripheral blood mononuclear cells (hPBMCs). Collectively, we proposed that entecavir and imipenem might be candidates for the treatment of CSS.
C1 [Su, Li; Kong, De-pei; Chen, Da-gui; Zhang, Chen-xi] Shanghai Univ, Inst Translat Med, Shanghai, Peoples R China.
   [Tu, Ye] Tongji Univ, Shanghai East Hosp, Dept Med, Shanghai 200120, Peoples R China.
   [Zhang, Wan-nian; Zhuang, Chun-lin; Wang, Zhi-bin] Second Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R China.
   [Zhang, Wan-nian; Zhuang, Chun-lin] Ningxia Med Univ, Sch Pharm, Yinchuan 750004, Ningxia, Peoples R China.
RP Zhuang, CL; Wang, ZB (corresponding author), Second Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R China.
EM zclnathan@163.com; methyl@smmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81872880]; Young Elite Scientists
   Sponsorship Program by the China Association for Science and Technology
   [2017QNRC061]
FX We thank Profs Weiheng Xu and Pei Wang from Second Military Medical
   University, Drs Min Liu and Weiyuan Li from Tongren Hospital Affiliated
   to Shanghai Jiaotong University, China for the essential assistances
   with this study. We thank Taozhixing biotechnology (Shanghai, China) for
   providing us with the reagents and consumables urgently needed for the
   experiment. This work was supported in part by grants from the National
   Natural Science Foundation of China (81872880) and the Young Elite
   Scientists Sponsorship Program by the China Association for Science and
   Technology(2017QNRC061).
CR [Anonymous], 2020, NEW CORONAVIRUS PNEU
   [Anonymous], 2020, 193 WHO
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen XY, 2017, J BIOL CHEM, V292, P21291, DOI 10.1074/jbc.M117.805937
   Chousterman BG, 2017, SEMIN IMMUNOPATHOL, V39, P517, DOI 10.1007/s00281-017-0639-8
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Creagh EM, 2006, TRENDS IMMUNOL, V27, P352, DOI 10.1016/j.it.2006.06.003
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DSC, 2019, INFECT DIS CLIN N AM, V33, P869, DOI 10.1016/j.idc.2019.07.001
   Innaimo SF, 1997, ANTIMICROB AGENTS CH, V41, P1444, DOI 10.1128/AAC.41.7.1444
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li Y, 2013, MICROBES INFECT, V15, P88, DOI 10.1016/j.micinf.2012.10.008
   Liao QJ, 2005, ACTA BIOCH BIOPH SIN, V37, P607, DOI 10.1111/j.1745-7270.2005.00082.x
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Luo W., 2020, CLIN PATHOLOGY CRITI
   Malaviya R, 2017, PHARMACOL THERAPEUT, V180, P90, DOI 10.1016/j.pharmthera.2017.06.008
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Monick MM, 2003, J BIOL CHEM, V278, P53035, DOI 10.1074/jbc.M308093200
   Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320
   Okabayashi T, 2006, J MED VIROL, V78, P417, DOI 10.1002/jmv.20556
   Opio CK, 2005, NAT REV DRUG DISCOV, V4, P535, DOI 10.1038/nrd1780
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Qu Q., 2020, HOT SPOTS PREVENTION
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Rockx B, 2009, J VIROL, V83, P7062, DOI 10.1128/JVI.00127-09
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Smits SL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000756
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang WC, 2017, PROCEEDINGS OF THE 2017 ASIAN HARDWARE ORIENTED SECURITY AND TRUST SYMPOSIUM (ASIANHOST), P13, DOI 10.1109/AsianHOST.2017.8353988
   Wei H., 2020, NATL SCI REV, V7, P998
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yao XH, 2020, ZHONGHUA BING LI XUE, V49, P411, DOI [DOI 10.3760/CMA.J.CN112151-20200312-00193, 10.3760/cma.j.cn112151-20200312-00193]
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zhang S, 2018, JCI INSIGHT, V3
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu SM, 2017, GUT, V66, P802, DOI 10.1136/gutjnl-2016-312141
   Zumla A, 2020, LANCET, V395, pE35, DOI 10.1016/S0140-6736(20)30305-6
NR 45
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD NOV
PY 2020
VL 131
AR 110643
DI 10.1016/j.biopha.2020.110643
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA OH6KI
UT WOS:000582699600022
PM 32846329
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Mandal, M
   Jana, S
   Khatua, A
   Kar, TK
AF Mandal, Manotosh
   Jana, Soovoojeet
   Khatua, Anupam
   Kar, T. K.
TI Modeling and control of COVID-19: A short-term forecasting in the
   context of india
SO CHAOS
LA English
DT Article
ID SIR EPIDEMIC MODEL; TUBERCULOSIS; BIFURCATION; COMPUTATION; STABILITY;
   DYNAMICS; DISEASE
AB The coronavirus disease 2019 (COVID-19) outbreak, due to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), originated in Wuhan, China and is now a global pandemic. The unavailability of vaccines, delays in diagnosis of the disease, and lack of proper treatment resources are the leading causes of the rapid spread of COVID-19. The world is now facing a rapid loss of human lives and socioeconomic status. As a mathematical model can provide some real pictures of the disease spread, enabling better prevention measures. In this study, we propose and analyze a mathematical model to describe the COVID-19 pandemic. We have derived the threshold parameter basic reproduction number, and a detailed sensitivity analysis of this most crucial threshold parameter has been performed to determine the most sensitive indices. Finally, the model is applied to describe COVID-19 scenarios in India, the second-largest populated country in the world, and some of its vulnerable states. We also have short-term forecasting of COVID-19, and we have observed that controlling only one model parameter can significantly reduce the disease's vulnerability. Published under license by AIP Publishing.
C1 [Mandal, Manotosh] Tamralipta Mahavidyalaya, Dept Math, Tamluk 721636, W Bengal, India.
   [Jana, Soovoojeet] Ramsaday Coll, Dept Math, Howrah 711401, W Bengal, India.
   [Khatua, Anupam; Kar, T. K.] Indian Inst Engn Sci & Technol, Dept Math, Sibpur 711103, Howrah, India.
RP Jana, S (corresponding author), Ramsaday Coll, Dept Math, Howrah 711401, W Bengal, India.
EM manotosh09@gmail.com; soovoojeet@gmail.com; akhatua06@gmail.com;
   tkar1117@gmail.com
RI Khatua, Anupam/AAC-5464-2019
OI Khatua, Anupam/0000-0001-7349-6084; Jana, Soovoojeet/0000-0002-0123-9940
FU Department of Science and Technology & Biotechnology, Government of West
   Bengal [201 (Sanc.)/ST/P/ST/16G-12/2018]; Department of Science and
   Technology-INSPIRE, Government of India [DST/INSPIRE
   Fellowship/2016/IF160667]
FX The work of S. Jana was partially supported by the Department of Science
   and Technology & Biotechnology, Government of West Bengal [vide Memo No.
   201 (Sanc.)/ST/P/S&T/16G-12/2018 dated 19 February 2019]. The research
   work of A. Khatua was financially supported by the Department of Science
   and Technology-INSPIRE, Government of India (No. DST/INSPIRE
   Fellowship/2016/IF160667, dated: 21 September 2016). Also, the authors
   would like to thank the anonymous reviewers and Professor Juergen
   Kurths, the handling editor of the journal, for their constructive
   comments and useful suggestions, which helped us to improve the quality
   and presentation of the manuscript significantly.
CR Acuna-Zegarra MA, 2020, MATH BIOSCI, V325, DOI 10.1016/j.mbs.2020.108370
   [Anonymous], 2020, OBSTET GYNECOL, V135, pe1, DOI DOI 10.1016/J.CHAOS.2020.109846
   Birkoff G., 1982, ORDINARY DIFFERENTIA
   Buonomo B, 2008, MATH BIOSCI, V216, P9, DOI 10.1016/j.mbs.2008.07.011
   Castillo-Chavez C, 2004, MATH BIOSCI ENG, V1, P361, DOI 10.3934/mbe.2004.1.361
   Castillo-Chavez C, 2002, IMA VOL MATH APPL, V125, P229
   Ribeiro MHD, 2020, CHAOS SOLITON FRACT, V135, DOI 10.1016/j.chaos.2020.109853
   Das DK, 2020, APPL MATH COMPUT, V366, DOI 10.1016/j.amc.2019.124732
   DIEKMANN O, 1990, J MATH BIOL, V28, P365
   Fanelli D, 2020, CHAOS SOLITON FRACT, V134, DOI 10.1016/j.chaos.2020.109761
   Faranda D, 2020, CHAOS, V30, DOI 10.1063/5.0008834
   Fulford GR, 2002, THEOR POPUL BIOL, V61, P15, DOI 10.1006/tpbi.2001.1553
   He SB, 2020, NONLINEAR DYNAM, V101, P1667, DOI 10.1007/s11071-020-05743-y
   Hellewell J, 2020, LANCET GLOB HEALTH, V8, pE488, DOI 10.1016/S2214-109X(20)30074-7
   Hou C, 2020, J MED VIROL, V92, P841, DOI 10.1002/jmv.25827
   Jana S, 2016, ACTA BIOTHEOR, V64, P65, DOI 10.1007/s10441-015-9273-9
   Kar TK, 2019, CHAOS SOLITON FRACT, V120, P188, DOI 10.1016/j.chaos.2019.01.025
   Kermack WO, 1927, P R SOC LOND A-CONTA, V115, P700, DOI 10.1098/rspa.1927.0118
   Khajanchi S, 2020, CHAOS, V30, DOI 10.1063/5.0016240
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, P553, DOI 10.1016/S1473-3099(20)30144-4
   Kwuimy CAK, 2020, NONLINEAR DYNAM, V101, P1545, DOI 10.1007/s11071-020-05815-z
   Li L, 2018, INT J BIOMATH, V11, DOI 10.1142/S1793524518500304
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Manchein C, 2020, CHAOS, V30, DOI 10.1063/5.0009454
   Mandal M, 2020, CHAOS SOLITON FRACT, V136, DOI 10.1016/j.chaos.2020.109889
   Mizumoto K, 2020, INFECT DIS MODEL, V5, P264, DOI 10.1016/j.idm.2020.02.003
   Nadim S. S., 2020, ARXIV200308150
   Ngonghala CN, 2020, MATH BIOSCI, V325, DOI 10.1016/j.mbs.2020.108364
   Paul A., 2020, PREDICTION COVID 19
   Prem K, 2020, LANCET PUBLIC HEALTH, V5, pE261, DOI 10.1016/S2468-2667(20)30073-6
   Ross R, 1916, P R SOC LOND A-CONTA, V92, P204, DOI 10.1098/rspa.1916.0007
   Sardar T, 2020, CHAOS SOLITON FRACT, V139, DOI 10.1016/j.chaos.2020.110078
   van den Driessche P, 2002, MATH BIOSCI, V180, P29, DOI 10.1016/S0025-5564(02)00108-6
   Wang W, 2004, MATH BIOSCI, V190, P97, DOI 10.1016/j.mbs.2004.11.001
   Zegarra MA, 2018, J THEOR BIOL, V457, P19, DOI DOI 10.1016/j.jtbi.2018.08.025
   Zhang X, 2008, J MATH ANAL APPL, V348, P433, DOI 10.1016/j.jmaa.2008.07.042
   Zhou YG, 2014, ACTA BIOTHEOR, V62, P171, DOI 10.1007/s10441-014-9216-x
NR 37
TC 0
Z9 0
U1 0
U2 0
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 1054-1500
EI 1089-7682
J9 CHAOS
JI Chaos
PD NOV
PY 2020
VL 30
IS 11
AR 113119
DI 10.1063/5.0015330
PG 19
WC Mathematics, Applied; Physics, Mathematical
SC Mathematics; Physics
GA OU2FS
UT WOS:000591349700008
PM 33261356
DA 2021-01-01
ER

PT J
AU Tang, Y
   Li, CC
   Chen, YY
   Chen, ZY
   Zhang, PH
   Wang, AS
   Huang, XQ
   Qu, J
   Li, MC
   Ma, SW
   Vasudevan, B
AF Tang, Yuan
   Li, Chunchun
   Chen, Yanyan
   Chen, Zhangyan
   Zhang, Peihua
   Wang, Aisun
   Huang, Xiaoqiong
   Qu, Jia
   Li, Mengchen
   Ma, Siwen
   Vasudevan, Balamurali
TI Effect of Intraocular Pressure on Aerosol Density Generated by
   Noncontact Tonometer Measurement
SO JOURNAL OF GLAUCOMA
LA English
DT Article
DE noncontact tonometer; aerosol; glaucoma; infection; coronavirus
   disease-19
ID VIRUS; TEARS
AB Precis: Aerosols generated by a noncontact tonometer (NCT) were quantified. There was a positive correlation between aerosols and intraocular pressure (IOP), and the concentration of aerosols beside the air jet port was the highest. Purpose: To investigate the effects of IOP on the aerosol density generated during the use of an NCT and provide references and suggestions for daily protection of ophthalmic medical staff during the coronavirus disease-19 (COVID-19) outbreak. Objective and Methods: This cross-sectional clinical trial included 214 eyes of 140 patients from a hospital in Wenzhou city, Zhejiang Province. All subjects' IOPs were measured by an NCT (39 eyes with low IOP, 90 eyes with normal IOP, 37 eyes with moderately high IOP, and 48 eyes with very high IOP) between March 7 and June 17, 2020. The density of particulate matter (PM) 2.5 and PM10 generated during the process of IOP measurement with an NCT was analyzed. IOP values were recorded simultaneously. The aerosols generated during different IOP measurements were plotted in scatter plots. Results: PM2.5 was generated more at the air jet port of the tonometer during the process of IOP measurement (H=2.731, P=0.019). Larger quantities of PM2.5 and PM10 were generated when the IOP was higher, and these differences were statistically significant (PM2.5: H=119.476, PH=160.801, P<0.001). Linear correlation analysis with one variable demonstrated that IOP had significantly positive correlations with PM2.5 (r=0.756, P<0.001) and PM10 (r=0.864, P<0.001). Conclusions: Aerosols can be generated while using an NCT to measure IOP, and aerosols and IOP are positively correlated. Patients with moderately high IOP or very high IOP tend to generate more aerosols during the IOP measurement. The concentration of aerosols beside the air jet port was the highest.
C1 [Tang, Yuan; Chen, Yanyan; Qu, Jia; Ma, Siwen] Wenzhou Med Univ, Natl Clin Res Ctr Ocular Dis, Sch Optometry & Ophthalmol, Wenzhou, Zhejiang, Peoples R China.
   [Li, Chunchun; Chen, Yanyan; Chen, Zhangyan; Zhang, Peihua; Wang, Aisun; Huang, Xiaoqiong; Qu, Jia; Li, Mengchen] Wenzhou Med Univ, Eye Hosp, Natl Clin Res Ctr Ocular Dis, Xueyuan Rd 270, Wenzhou 325027, Zhejiang, Peoples R China.
   [Vasudevan, Balamurali] Midwestern Univ, Coll Optometry, Glendale, AZ USA.
RP Chen, YY (corresponding author), Wenzhou Med Univ, Eye Hosp, Natl Clin Res Ctr Ocular Dis, Xueyuan Rd 270, Wenzhou 325027, Zhejiang, Peoples R China.
EM wzcyymail@163.com
FU National Health and Family Planning Commission - Key Project of Zhejiang
   Province Major Medical and Health Science and Technology Plan
   [WKJ-ZJ-1727]; Wenzhou Municipal City Emergency Research Grant for the
   Prevention of SARS-CoV-2 [ZY 2020001]
FX This study was funded by the scientific research fund of the National
   Health and Family Planning Commission - Key Project of Zhejiang Province
   Major Medical and Health Science and Technology Plan (WKJ-ZJ-1727) and
   Wenzhou Municipal City Emergency Research Grant for the Prevention of
   SARS-CoV-2 (ZY 2020001).
CR Bonn D, 2004, LANCET INFECT DIS, V4, P480, DOI 10.1016/S1473-3099(04)01093-X
   BRITT JM, 1991, ARCH OPHTHALMOL-CHIC, V109, P225, DOI 10.1001/archopht.1991.01080020071046
   Cao C, 2014, ENVIRON SCI TECHNOL, V48, P1499, DOI 10.1021/es4048472
   Han Y, 2011, AIDS, V25, P1925, DOI 10.1097/QAD.0b013e32834b3578
   Komatsu H, 2012, J INFECT DIS, V206, P478, DOI 10.1093/infdis/jis293
   Li C, 2020, CHIN J EXP OPHTHALMO, V38, P212, DOI DOI 10.3760/CMA.J.ISSN.115989-20200226-00112
   Liu Y, 2020, NATURE, V582, P557, DOI 10.1038/s41586-020-2271-3
   Pfaender S, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00504
   Tang S, 2020, ENVIRON INT, V144, DOI 10.1016/j.envint.2020.106039
   The General Office of the National Health And Wellness Commission of the People's Republic of China Office of the National Administration of Traditional Chinese Medicine, 2020, CHINA MED, V15, P801, DOI DOI 10.3760/j.issn.163477.2020.06.001
   Wang BY, 2014, COMP INTRAOCULAR PRE
   [王跃丽 Wang Yueli], 2007, [中国组织工程研究与临床康复, Journal of Clinical Rehabilitative Tissue Engineering Research], V11, P934
   Wilson NM, 2020, ANAESTHESIA, V75, P1086, DOI 10.1111/anae.15093
   Wu QM, 2003, J AGR SCI TECH CHINA, V5, P17
   Zemouri C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178007
   [郑美琴 Zheng Meiqin], 2020, [中华实验眼科杂志, Chinese Journal of Experimental Ophthalmology], V38, P257
   晋秀明, 2020, [中华眼科杂志, Chinese Journal of Ophthalmology], V56, P477
NR 17
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1057-0829
EI 1536-481X
J9 J GLAUCOMA
JI J. Glaucoma
PD NOV
PY 2020
VL 29
IS 11
BP 1001
EP 1005
DI 10.1097/IJG.0000000000001669
PG 5
WC Ophthalmology
SC Ophthalmology
GA OU2YI
UT WOS:000591398800003
PM 32941321
DA 2021-01-01
ER

PT J
AU Preskorn, SH
   Quadri, S
AF Preskorn, Sheldon H.
   Quadri, Syeda
TI Why Are Patients With COVID-19 at Risk for Drug-Drug Interactions?
SO JOURNAL OF PSYCHIATRIC PRACTICE
LA English
DT Article
DE Coronavirus Disease 2019 (COVID-19); drug-drug interactions;
   polypharmacy; multiple medication use; psychiatric medications;
   cytochrome P450 enzymes; University of Liverpool drug interaction
   checker
ID POLYPHARMACY; POPULATION
AB The goal of this column is to provide information to health care professionals about drug-drug interactions (DDIs) and why DDIs are important to consider in those at serious risk of illness with Coronavirus Disease 2019 (COVID-19). Important considerations discussed in this column include the frequency and complexity of multiple medication use, particularly important for the older patient who often has multiple comorbid illnesses. The column covers the following issues: (1) Why patients at high risk for serious illness from COVID-19 are also at high risk for DDIs. (2) Application of results of pharmacoepidemiological studies to the population at risk for serious COVID-19 illness. (3) Mechanisms underlying DDIs, frequency and potential complexity of DDIs, and how DDIs can present clinically. (4) Methods for preventing or mitigating DDIs. (5) An introduction to the University of Liverpool drug interaction checker as a tool to reduce the risk of adverse DDIs while treating patients for COVID-19. Commentary is also provided on issues related to specific psychiatric and nonpsychiatric medications a patientmay be taking. A subsequent column will focus on DDIs between psychiatric medications and emerging COVID-19 treatments, as a detailed discussion of that topic is beyond the scope of this column.
C1 [Preskorn, Sheldon H.; Quadri, Syeda] Kansas Univ, Sch Med Wichita, Wichita, KS USA.
RP Preskorn, SH (corresponding author), Univ Kansas, Med Ctr, 1010 North Kansas, Wichita, KS 67217 USA.
CR [Anonymous], 2020, FACT SHEET HLTH CAR
   Bjerrum L, 1998, EUR J CLIN PHARMACOL, V54, P197, DOI 10.1007/s002280050445
   Bjerrum L, 1997, EUR J CLIN PHARMACOL, V53, P7, DOI 10.1007/s002280050329
   Centers for Disease Control and Prevention, 2020, COR 2019 COVID 19 PE
   Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337
   Pinkowski J, 2020, DRUG DRUG INTERACTIO
   Preskorn S H, 2001, J Psychiatr Pract, V7, P48, DOI 10.1097/00131746-200101000-00006
   Preskorn SH, 2018, DRUG DRUG INTERACTIO
   Preskorn Sheldon H, 2005, J Psychiatr Pract, V11, P5, DOI 10.1097/00131746-200501000-00002
   Rosholm JU, 1998, DAN MED BULL, V45, P210
   Silkey Beryl, 2005, J Psychiatr Pract, V11, P16, DOI 10.1097/00131746-200501000-00003
   U.S. Food and Drug Administration, 2020, COVID 19 UPD FDA BRO
   University of Liverpool, 2020, INT CHECK COVID 19 D
   Valent F, 2019, ANN I SUPER SANITA, V55, P233, DOI 10.4415/ANN_19_03_06
NR 14
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1527-4160
EI 1538-1145
J9 J PSYCHIATR PRACT
JI J. Psychiatr. Pract.
PD NOV
PY 2020
VL 26
IS 6
BP 485
EP 492
DI 10.1097/PRA.0000000000000502
PG 8
WC Psychiatry
SC Psychiatry
GA OU2YH
UT WOS:000591398700006
PM 33275385
DA 2021-01-01
ER

PT J
AU Annie, FH
   Sirbu, C
   Frazier, KR
   Broce, M
   Lucas, BD
AF Annie, Frank H.
   Sirbu, Cristian
   Frazier, Keely R.
   Broce, Mike
   Lucas, B. Daniel, Jr.
TI Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World
   Experience Assessing Mortality
SO PHARMACOTHERAPY
LA English
DT Article
DE Antimalarial; azithromycin; coronavirus; hydroxychloroquine; macrolide;
   severe acute respiratory syndrome coronavirus 2
ID CHLOROQUINE; DESIGN; DRUG
AB Introduction
   Hydroxychloroquine (HCQ) for coronavirus disease 2019 (COVID-19) is presently being used off-label or within a clinical trial.
   Objectives
   We investigated a multinational database of patients with COVID-19 with real-world data containing outcomes and their relationship to HCQ use. The primary outcome was all-cause mortality within 30 days of follow-up.
   Methods
   This was a retrospective cohort study of patients receiving HCQ within 48 hours of hospital admission. Medications, preexisting conditions, clinical measures on admission, and outcomes were recorded.
   Results
   Among patients with a diagnosis of COVID-19 in our propensity-matched cohort, the mean ages +/- SD were 62.3 +/- 15.9 years (53.7% male) and 61.9 +/- 16.0 years (53.0% male) in the HCQ and no-HCQ groups, respectively. There was no difference in overall 30-day mortality between the HCQ and no-HCQ groups (HCQ 13.1%, n=367; no HCQ 13.6%, n=367; odds ratio 0.95, 95% confidence interval 0.62-1.46) after propensity matching. Although statistically insignificant, the HCQ-azithromycin (AZ) group had an overall mortality rate of 14.6% (n=199) compared with propensity-matched no-HCQ-AZ cohort's rate of 12.1% (n=199, OR 1.24, 95% CI 0.70-2.22). Importantly, however, there was no trend in this cohort's overall mortality/arrhythmogenesis outcome (HCQ-AZ 17.1%, no HCQ-no AZ 17.1%; OR 1.0, 95% CI 0.6-1.7).
   Conclusions
   We report from a large retrospective multinational database analysis of COVID-19 outcomes with HCQ and overall mortality in hospitalized patients. There was no statistically significant increase in mortality and mortality-arrhythmia with HCQ or HCQ-AZ.
C1 [Annie, Frank H.; Sirbu, Cristian; Frazier, Keely R.; Broce, Mike; Lucas, B. Daniel, Jr.] Charleston Area Med Ctr Hlth Educ & Res Inst, 3200 MacCorkle Ave, Charleston, WV 25304 USA.
RP Lucas, BD (corresponding author), Charleston Area Med Ctr Hlth Educ & Res Inst, 3200 MacCorkle Ave, Charleston, WV 25304 USA.
EM dan.lucas@camc.org
OI Annie, Frank/0000-0001-8423-4119; Lucas, B. Daniel/0000-0002-0551-3564
FU NIGMS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [2U54GM104942-02] Funding Source: Medline
CR [Anonymous], 2020, INT J ANTIMICROBIAL
   [Anonymous], 2020, SOLIDARITY CLIN TRIA
   Arshad S, 2020, INT J INFECT DIS, V97, P396, DOI 10.1016/j.ijid.2020.06.099
   Bessiere F, 2020, JAMA CARDIOL, V5, P1067, DOI 10.1001/jamacardio.2020.1787
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Catteau L, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106144
   Cavalcanti AB, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2019014, DOI 10.1056/NEJM0A2019014]
   Chugh SS, 2009, CIRCULATION, V119, P663, DOI 10.1161/CIRCULATIONAHA.108.797035
   COVID-19 Treatment Guidelines Panel, 2020, COR DIS 2019 COVID 1
   Feldmann M, 2020, LANCET, V395, P1407, DOI 10.1016/S0140-6736(20)30858-8
   Gao JJ, 2020, BIOSCI TRENDS, V14, P156, DOI 10.5582/bst.2020.03072
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024
   Horby P, 2020, EFFECT HYDROXYCHLORO, DOI [10.1056/NEJMe2025674, DOI 10.1056/NEJME2025674]
   Imbens GW, 2015, CASUAL INFERENCE STA
   Kapoor R, 2020, PHARMACOVIGILANCE ME
   Lane JCE, 2020, LANCET RHEUMATOL, V2, pE698, DOI 10.1016/S2665-9913(20)30276-9
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   Mikami T, 2020, J GEN INTERN MED, DOI 10.1007/s11606-020-05983-z
   Mohamad Alkhouli AN, 2020, MAYO CLIN P, V95, P1613
   Mousa Albeir Y, 2021, J Vasc Surg, V73, P13, DOI 10.1016/j.jvs.2020.04.503
   Normand Sharon-Lise T, 2020, N Engl J Med, DOI 10.1056/NEJMe2025674
   Risch HA, 2020, AM J EPIDEMIOL, V189, P1218, DOI 10.1093/aje/kwaa093
   Roden DM, 2016, J PHYSIOL-LONDON, V594, P2459, DOI 10.1113/JP270526
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Simpson T, 2020, CARDIOL MAG
   Skipper CP, 2020, ANN INTERN MED, V173, P623, DOI 10.7326/M20-4207
   Stapff M., 2017, PHARM IND, V79, P204
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Yoshida K, 2015, NAT REV RHEUMATOL, V11, P437, DOI 10.1038/nrrheum.2015.30
NR 35
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0277-0008
EI 1875-9114
J9 PHARMACOTHERAPY
JI Pharmacotherapy
PD NOV
PY 2020
VL 40
IS 11
BP 1072
EP 1081
DI 10.1002/phar.2467
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OT2ER
UT WOS:000590665600001
PM 33044019
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zhou, YD
   Hou, Y
   Shen, JY
   Mehra, R
   Kallianpur, A
   Culver, DA
   Gack, MU
   Farha, S
   Zein, J
   Comhair, S
   Fiocchi, C
   Stappenbeck, T
   Chan, T
   Eng, C
   Jung, JU
   Jehi, L
   Erzurum, S
   Cheng, FX
AF Zhou, Yadi
   Hou, Yuan
   Shen, Jiayu
   Mehra, Reena
   Kallianpur, Asha
   Culver, Daniel A.
   Gack, Michaela U.
   Farha, Samar
   Zein, Joe
   Comhair, Suzy
   Fiocchi, Claudio
   Stappenbeck, Thaddeus
   Chan, Timothy
   Eng, Charis
   Jung, Jae U.
   Jehi, Lara
   Erzurum, Serpil
   Cheng, Feixiong
TI A network medicine approach to investigation and population-based
   validation of disease manifestations and drug repurposing for COVID-19
SO PLOS BIOLOGY
LA English
DT Article
ID ARACHIDONIC-ACID METABOLISM; PROTEOME-SCALE MAP; GENE-EXPRESSION;
   NITRIC-OXIDE; DATABASE; MUTATIONS; ASTHMA; ASSOCIATION; KINASE; CANCER
AB The global coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to unprecedented social and economic consequences. The risk of morbidity and mortality due to COVID-19 increases dramatically in the presence of coexisting medical conditions, while the underlying mechanisms remain unclear. Furthermore, there are no approved therapies for COVID-19. This study aims to identify SARS-CoV-2 pathogenesis, disease manifestations, and COVID-19 therapies using network medicine methodologies along with clinical and multi-omics observations. We incorporate SARS-CoV-2 virus-host protein-protein interactions, transcriptomics, and proteomics into the human interactome. Network proximity measurement revealed underlying pathogenesis for broad COVID-19-associated disease manifestations. Analyses of single-cell RNA sequencing data show that co-expression of ACE2 and TMPRSS2 is elevated in absorptive enterocytes from the inflamed ileal tissues of Crohn disease patients compared to uninflamed tissues, revealing shared pathobiology between COVID-19 and inflammatory bowel disease. Integrative analyses of metabolomics and transcriptomics (bulk and single-cell) data from asthma patients indicate that COVID-19 shares an intermediate inflammatory molecular profile with asthma (including IRAK3 and ADRB2). To prioritize potential treatments, we combined network-based prediction and a propensity score (PS) matching observational study of 26,779 individuals from a COVID-19 registry. We identified that melatonin usage (odds ratio [OR] = 0.72, 95% CI 0.56-0.91) is significantly associated with a 28% reduced likelihood of a positive laboratory test result for SARS-CoV-2 confirmed by reverse transcription-polymerase chain reaction assay. Using a PS matching user active comparator design, we determined that melatonin usage was associated with a reduced likelihood of SARS-CoV-2 positive test result compared to use of angiotensin II receptor blockers (OR = 0.70, 95% CI 0.54-0.92) or angiotensin-converting enzyme inhibitors (OR = 0.69, 95% CI 0.52-0.90). Importantly, melatonin usage (OR = 0.48, 95% CI 0.31-0.75) is associated with a 52% reduced likelihood of a positive laboratory test result for SARS-CoV-2 in African Americans after adjusting for age, sex, race, smoking history, and various disease comorbidities using PS matching. In summary, this study presents an integrative network medicine platform for predicting disease manifestations associated with COVID-19 and identifying melatonin for potential prevention and treatment of COVID-19.
C1 [Zhou, Yadi; Hou, Yuan; Shen, Jiayu; Kallianpur, Asha; Eng, Charis; Cheng, Feixiong] Cleveland Clin, Lerner Res Inst, Genom Med Inst, Cleveland, OH 44195 USA.
   [Mehra, Reena; Kallianpur, Asha; Zein, Joe; Comhair, Suzy; Fiocchi, Claudio; Stappenbeck, Thaddeus; Chan, Timothy; Eng, Charis; Jung, Jae U.; Jehi, Lara; Erzurum, Serpil; Cheng, Feixiong] Case Western Reserve Univ, Cleveland Clin, Dept Mol Med, Lerner Coll Med, Cleveland, OH 44195 USA.
   [Mehra, Reena; Jehi, Lara] Cleveland Clin, Neurol Inst, Cleveland, OH 44106 USA.
   [Culver, Daniel A.; Farha, Samar; Zein, Joe; Comhair, Suzy; Fiocchi, Claudio; Stappenbeck, Thaddeus; Chan, Timothy; Eng, Charis; Jung, Jae U.; Erzurum, Serpil] Cleveland Clin, Lerner Res Inst, Cleveland, OH 44195 USA.
   [Culver, Daniel A.; Farha, Samar] Cleveland Clin, Dept Pulm Med, Resp Inst, Cleveland, OH 44195 USA.
   [Gack, Michaela U.] Cleveland Clin, Florida Res & Innovat Ctr, Port St Lucie, FL USA.
   [Eng, Charis] Case Western Reserve Univ, Sch Med, Dept Genet & Genome Sci, Cleveland, OH USA.
   [Eng, Charis; Cheng, Feixiong] Case Western Reserve Univ, Sch Med, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.
RP Cheng, FX (corresponding author), Cleveland Clin, Lerner Res Inst, Genom Med Inst, Cleveland, OH 44195 USA.; Cheng, FX (corresponding author), Case Western Reserve Univ, Cleveland Clin, Dept Mol Med, Lerner Coll Med, Cleveland, OH 44195 USA.; Cheng, FX (corresponding author), Case Western Reserve Univ, Sch Med, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.
EM chengf@ccf.org
OI Shen, Jia Yu/0000-0002-2279-3502
FU National Institute of AgingUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Aging (NIA) [R01AG066707, 3R01AG066707-01S1]; National Heart, Lung,
   and Blood InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [R00HL138272]; VeloSano Pilot Program
   (Cleveland Clinic Taussig Cancer Institute)
FX This work was supported by the National Institute of Aging (R01AG066707
   and 3R01AG066707-01S1) and the National Heart, Lung, and Blood Institute
   (R00HL138272) to F.C. This work has been also supported in part by the
   VeloSano Pilot Program (Cleveland Clinic Taussig Cancer Institute) to
   F.C. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Agarwala R, 2016, NUCLEIC ACIDS RES, V44, pD7, DOI [10.1093/nar/gkv1290, 10.1093/nar/gkx1095, 10.1093/nar/gks1189]
   Akaike T, 2000, IMMUNOLOGY, V101, P300, DOI 10.1046/j.1365-2567.2000.00142.x
   Ali S, 2013, J IMMUNOL, V190, P3949, DOI 10.4049/jimmunol.1201015
   [Anonymous], 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/glan290
   [Anonymous], 2013, NUCLEIC ACIDS RES, V41, pD43
   Aw D, 2007, IMMUNOLOGY, V120, P435, DOI 10.1111/j.1365-2567.2007.02555.x
   Balaci L, 2007, AM J HUM GENET, V80, P1103, DOI 10.1086/518259
   Baldi E, 2020, NEW ENGL J MED, V383, P496, DOI 10.1056/NEJMc2010418
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Beers MF, 2017, CELL TISSUE RES, V367, P481, DOI 10.1007/s00441-016-2554-z
   Behzad S, 2020, CLIN IMAG, V66, P35, DOI 10.1016/j.clinimag.2020.05.013
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bello SM, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032839
   Berger A, 1999, BRIT MED J, V319, P90, DOI 10.1136/bmj.319.7202.90
   Bezginov A, 2013, MOL BIOL EVOL, V30, P332, DOI 10.1093/molbev/mss218
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Bojkova D, 2020, NATURE, V583, P469, DOI 10.1038/s41586-020-2332-7
   Breuer K, 2013, NUCLEIC ACIDS RES, V41, pD1228, DOI 10.1093/nar/gks1147
   Brunk E, 2018, NAT BIOTECHNOL, V36, P272, DOI 10.1038/nbt.4072
   Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096
   Calabrese C, 2000, ALLERGY, V55, P27, DOI 10.1034/j.1398-9995.2000.00504.x
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng Feixiong, 2020, Cleve Clin J Med, DOI 10.3949/ccjm.87a.ccc037
   Cheng FX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10744-6
   Cheng FX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09186-x
   Cheng FX, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05116-5
   Cheng FX, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1005074
   Cheng FX, 2014, MOL BIOL EVOL, V31, P2156, DOI 10.1093/molbev/msu167
   Cheng FX, 2014, ONCOTARGET, V5, P3697, DOI 10.18632/oncotarget.1984
   Clerkin KJ, 2020, CIRCULATION, V141, P1648, DOI 10.1161/CIRCULATIONAHA.120.046941
   Comhair SAA, 2015, J IMMUNOL, V195, P643, DOI 10.4049/jimmunol.1500736
   Cong Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194868
   Cowley MJ, 2012, NUCLEIC ACIDS RES, V40, pD862, DOI 10.1093/nar/gkr967
   Csabai Luca, 2018, Methods Mol Biol, V1819, P53, DOI 10.1007/978-1-4939-8618-7_3
   D'Amico F, 2020, CLIN GASTROENTEROL H, V18, P1663, DOI 10.1016/j.cgh.2020.04.001
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dinkel H, 2011, NUCLEIC ACIDS RES, V39, pD261, DOI 10.1093/nar/gkq1104
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Fan E, 2020, LANCET RESP MED, V8, P816, DOI 10.1016/S2213-2600(20)30304-0
   Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929
   Fung TS, 2019, ANNU REV MICROBIOL, V73, P529, DOI 10.1146/annurev-micro-020518-115759
   Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777
   Golbeck J., 2013, ANAL SOCIAL WEB
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gupta A, 2020, NAT MED, V26, P1017, DOI 10.1038/s41591-020-0968-3
   Gysi DM, 2020, ARXIV200407229V2
   Hamosh A, 2005, NUCLEIC ACIDS RES, V33, pD514
   Hirsh AE, 2005, MOL BIOL EVOL, V22, P174, DOI 10.1093/molbev/msh265
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, NATURE, V585, P588, DOI 10.1038/s41586-020-2575-3
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Holguin F, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.131733
   Horby P, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2021436, DOI 10.1056/NEJM0A2021436]
   Hornbeck PV, 2015, NUCLEIC ACIDS RES, V43, pD512, DOI 10.1093/nar/gku1267
   Hou TY, 2015, INT J CLIN EXP MED, V8, P15238
   Hu JF, 2014, BIOINFORMATICS, V30, P141, DOI 10.1093/bioinformatics/btt627
   Huttlin EL, 2015, CELL, V162, P425, DOI 10.1016/j.cell.2015.06.043
   Jarcho JA, 2020, NEW ENGL J MED, V382, P2462, DOI 10.1056/NEJMe2012924
   Jeon S, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00819-20
   Johansen LM, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005471
   Josset L, 2013, MBIO, V4, DOI 10.1128/mBio.00165-13
   Kanehisa M, 2016, NUCLEIC ACIDS RES, V44, pD457, DOI 10.1093/nar/gkv1070
   Kittler R, 2007, NAT CELL BIOL, V9, P1401, DOI 10.1038/ncb1659
   Korelitz BI, 2013, WORLD J GASTROENTERO, V19, P2979, DOI 10.3748/wjg.v19.i20.2979
   Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3
   Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Lamers MM, 2020, SCIENCE, V369, P50, DOI 10.1126/science.abc1669
   Law V, 2014, NUCLEIC ACIDS RES, V42, pD1091, DOI 10.1093/nar/gkt1068
   Li GP, 2020, J AUTOIMMUN, V112, DOI 10.1016/j.jaut.2020.102463
   Licata L, 2012, NUCLEIC ACIDS RES, V40, pD857, DOI 10.1093/nar/gkr930
   Liu C, 2020, PHYS REP, V846, P1, DOI 10.1016/j.physrep.2019.12.004
   Liu C, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1007701
   Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653
   Lukassen S, 2020, EMBO J, DOI 10.15252/embj.20105114
   Maisonnasse P, 2020, NATURE, V585, P584, DOI 10.1038/s41586-020-2558-4
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Martin JC, 2019, CELL, V178, P1493, DOI 10.1016/j.cell.2019.08.008
   MARTIN RR, 2020, ELECTRON J COMB, V27
   Mehta N, 2020, JAMA CARDIOL, V5, P1020, DOI 10.1001/jamacardio.2020.1855
   Menche J, 2015, SCIENCE, V347, DOI 10.1126/science.1257601
   Meyer MJ, 2013, BIOINFORMATICS, V29, P1577, DOI 10.1093/bioinformatics/btt181
   Modena BD, 2014, AM J RESP CRIT CARE, V190, P1363, DOI 10.1164/rccm.201406-1099OC
   Muise AM, 2011, GASTROENTEROLOGY, V141, P633, DOI 10.1053/j.gastro.2011.04.057
   Nakashima K, 2006, J HUM GENET, V51, P284, DOI 10.1007/s10038-005-0358-1
   Natarajan A, 2020, J TRANSL MED, V18
   Nogee LM, 2002, AM J RESP CELL MOL, V26, P641, DOI 10.1165/ajrcmb.26.6.f241
   Orchard S, 2014, NUCLEIC ACIDS RES, V42, pD358, DOI 10.1093/nar/gkt1115
   Oughtred R, 2019, NUCLEIC ACIDS RES, V47, pD529, DOI 10.1093/nar/gky1079
   Pawson AJ, 2014, NUCLEIC ACIDS RES, V42, pD1098, DOI 10.1093/nar/gkt1143
   Perry CM, 2004, DRUGS, V64, P1433, DOI 10.2165/00003495-200464130-00004
   Pfefferle S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002331
   Pichlmair A, 2012, NATURE, V487, P486, DOI 10.1038/nature11289
   Pino-Yanes M, 2012, J ALLERGY CLIN IMMUN, V129, P573, DOI 10.1016/j.jaci.2011.10.001
   Pornputtapong N, 2015, DATABASE-OXFORD, DOI 10.1093/database/bav068
   Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892
   Prescott HC, 2020, JAMA-J AM MED ASSOC, V324, P739, DOI 10.1001/jama.2020.14103
   Puelles VG, 2020, NEW ENGL J MED, V383, P590, DOI [10.1056/NEJMc2011400, 10.1056/NEJMc2013400]
   Reghunathan R, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-2
   REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334, DOI 10.1165/ajrcmb/8.3.334
   Rolland T, 2014, CELL, V159, P1212, DOI 10.1016/j.cell.2014.10.050
   Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209
   Rubino F, 2020, NEW ENGL J MED, V383, P789, DOI [10.1056/NEJMc2018688, 10.1056/NEJMc2021832]
   SAMUELSSON B, 1991, Z RHEUMATOL, V50, P3
   Seinen ML, 2016, THER DRUG MONIT, V38, P621, DOI 10.1097/FTD.0000000000000326
   Shang Y, 2009, CHINESE MED J-PEKING, V122, P1388, DOI 10.3760/cma.j.issn.0366-6999.2009.12.006
   Shen B, 2020, CELL, V182, P59, DOI 10.1016/j.cell.2020.05.032
   Shimokawa H, 2016, CIRC RES, V118, P352, DOI 10.1161/CIRCRESAHA.115.306532
   Smith IN, 2019, AM J HUM GENET, V104, P861, DOI 10.1016/j.ajhg.2019.03.009
   Sondka Z, 2018, NAT REV CANCER, V18, P696, DOI 10.1038/s41568-018-0060-1
   Song J, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4618-7
   Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349
   Stenson PD, 2003, HUM MUTAT, V21, P577, DOI 10.1002/humu.10212
   Stijnen T, 2010, STAT MED, V29, P3046, DOI 10.1002/sim.4040
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Swaroopa D, 2016, INDIAN J CRIT CARE M, V20, P518, DOI 10.4103/0972-5229.190369
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Wan X, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-135
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang QM, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz7086
   Wang XJ, 2015, ANTIVIR RES, V120, P140, DOI 10.1016/j.antiviral.2015.06.007
   Wang XB, 2019, BIOCHEM BIOPH RES CO, V519, P402, DOI 10.1016/j.bbrc.2019.09.005
   Watanabe T, 2014, CELL HOST MICROBE, V16, P795, DOI 10.1016/j.chom.2014.11.002
   Weathington N, 2019, AM J RESP CRIT CARE, V200, P837, DOI 10.1164/rccm.201811-2221OC
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD608, DOI 10.1093/nar/gkx1089
   Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yan L, 2020, NAT MACH INTELL, V2, P283, DOI 10.1038/s42256-020-0180-7
   Yang H, 2016, NUCLEIC ACIDS RES, V44, pD1069, DOI 10.1093/nar/gkv1230
   Yang SP, 2019, MSYSTEMS, V4, DOI 10.1128/mSystems.00303-18
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yang ZH, 2000, TRENDS ECOL EVOL, V15, P496, DOI 10.1016/S0169-5347(00)01994-7
   Yuan SF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08015-x
   Zaouil K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10570-w
   Zhang H, 2020, GUT, V69, P1010, DOI 10.1136/gutjnl-2020-320953
   Zhang JB, 2020, J CELL PHYSIOL, V235, P2847, DOI 10.1002/jcp.29190
   Zhang ML, 2011, AM J HUM GENET, V88, P755, DOI 10.1016/j.ajhg.2011.05.006
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhang W, 2013, GENES IMMUN, V14, P310, DOI 10.1038/gene.2013.19
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
   de Paiva ACZ, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-8
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 151
TC 0
Z9 0
U1 4
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1544-9173
EI 1545-7885
J9 PLOS BIOL
JI PLoS. Biol.
PD NOV
PY 2020
VL 18
IS 11
AR e3000970
DI 10.1371/journal.pbio.3000970
PG 43
WC Biochemistry & Molecular Biology; Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics
GA OU1PQ
UT WOS:000591307300003
PM 33156843
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Pierrakos, C
   Attou, R
   Iesu, E
   Baelongandi, H
   Honore, PM
   Bos, LDJ
   Schultz, MJ
   De Bels, D
AF Pierrakos, Charalampos
   Attou, Rachid
   Iesu, Enrica
   Baelongandi, Hugues
   Honore, Patrick M.
   Bos, Lieuwe D. J.
   Schultz, Marcus J.
   De Bels, David
TI Case Report: Lung Ultrasound for the Guidance of Adjunctive Therapies in
   Two Invasively Ventilated Patients with COVID-19
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID POINT
AB Two patients with respiratory failure due to confirmed COVID-19 were examined using bedside lung ultrasound (LUS) shortly after intubation and start of invasive ventilation. In the first patient, LUS revealed extensive atelectatic areas. A recruitment maneuver was applied, resulting in some reaeration of areas that showed atelectasis, and some improvement in oxygenation was observed. Oxygenation improved further with the use of prone positioning. In the second patient, LUS showed diffuse abnormalities without atelectatic areas, and ventilation proceeded without a recruitment maneuver but with prone positioning. These two cases illustrate how LUS could be useful in identifying different lung morphologies early after the start of invasive ventilation and help decide on adjunctive therapies. This has possible implications for ventilator management in resource-limited settings, with limited availability of chest computed tomography and blood gas analyzers. Tailoring invasive ventilation based on LUS findings early after the start of invasive ventilation is feasible, but this should be further evaluated in future studies.
C1 [Pierrakos, Charalampos; Attou, Rachid; Honore, Patrick M.; De Bels, David] Univ Libre Bruxelles, Brugmann Univ Hosp, Dept Intens Care, Brussels, Belgium.
   [Pierrakos, Charalampos; Bos, Lieuwe D. J.; Schultz, Marcus J.] Univ Amsterdam, Dept Intens Care, Amsterdam UMC, Amsterdam, Netherlands.
   [Iesu, Enrica; Baelongandi, Hugues] Univ Libre Bruxelles, Brugmann Univ Hosp, Dept Anesthesiol, Brussels, Belgium.
   [Bos, Lieuwe D. J.; Schultz, Marcus J.] Univ Amsterdam, Lab Expt Intens Care & Anesthesiol LEICA, Amsterdam UMC, Amsterdam, Netherlands.
   [Bos, Lieuwe D. J.] Univ Amsterdam, Dept Resp Med, Amsterdam UMC, Amsterdam, Netherlands.
   [Schultz, Marcus J.] Mahidol Univ, Mahidol Oxford Trop Med Res Unit MORU, Bangkok, Thailand.
   [Schultz, Marcus J.] Univ Oxford, Nuffield Dept Med, Oxford, England.
RP Pierrakos, C (corresponding author), Brugmann Univ Hosp, Dept Intens Care, A van Gehuchtenpl 4, B-1020 Brussels, Belgium.
EM charalampos.pierrakos@chu-brugmann.de; rachid.attou@chu-brugmann.be;
   enrica.iesu@chu-brugmann.be; hugues.baelongandi@chu-brugmann.be;
   patrick.honore@chu-brugmann.be; lieuwe.bos@gmail.com;
   marcus.j.schultz@gmail.com; david.debels@chu-brugmann.be
CR Bos LDJ, 2020, ANN AM THORAC SOC, V17, P1161, DOI 10.1513/AnnalsATS.202004-376RL
   Bouhemad B, 2011, AM J RESP CRIT CARE, V183, P341, DOI 10.1164/rccm.201003-0369OC
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Cavalcanti AB, 2017, JAMA-J AM MED ASSOC, V318, P1335, DOI 10.1001/jama.2017.14171
   Chiumello D, 2018, CRIT CARE MED, V46, P1761, DOI 10.1097/CCM.0000000000003340
   Constantin JM, 2019, LANCET RESP MED, V7, P870, DOI 10.1016/S2213-2600(19)30138-9
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P130, DOI 10.1164/rccm.201910-2005ED
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   House DR, 2020, INT J EMERG MED, V13, DOI 10.1186/s12245-020-00273-1
   Johns Hopkins University (JHU), 2020, COVID 19 DASHB CTR S
   Lomoro Pascal, 2020, Eur J Radiol Open, V7, P100231, DOI 10.1016/j.ejro.2020.100231
   Peng QY, 2020, INTENS CARE MED, V46, P849, DOI 10.1007/s00134-020-05996-6
   Rode B, 2012, WIEN KLIN WOCHENSCHR, V124, P842, DOI 10.1007/s00508-012-0303-1
   Schultz MJ, 2020, AM J TROP MED HYG, V102, P1162, DOI 10.4269/ajtmh.20-0323
   Sivakorn C, 2020, AM J TROP MED HYG, V102, P940, DOI 10.4269/ajtmh.20-0203
   Umuhire OF, 2019, ULTRASOUND J, V11, DOI 10.1186/s13089-019-0133-8
   Yasukawa K, 2020, AM J TROP MED HYG, V102, P1198, DOI 10.4269/ajtmh.20-0280
NR 18
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2020
VL 103
IS 5
BP 1978
EP 1982
DI 10.4269/ajtmh.20-0538
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA OP9PM
UT WOS:000588422900042
PM 32909535
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Allameh, SF
   Nemati, S
   Ghalehtaki, R
   Mohammadnejad, E
   Aghili, SM
   Khajavirad, N
   Beigmohammadi, MT
   Salehi, M
   Mirfazaelian, H
   Edalatifard, M
   Kazemizadeh, H
   Manshadi, SAD
   Hasannezhad, M
   Amoozadeh, L
   Radnia, M
   Khatami, SR
   Nahvijou, A
   Seyyedsalehi, MS
   Rashidian, L
   Yazdi, NA
   Toosi, MN
   Sadeghniiat-Haghighi, K
   Jafarian, A
   Yunesian, M
   Zendehdel, K
AF Allameh, Seyed Farshad
   Nemati, Saeed
   Ghalehtaki, Reza
   Mohammadnejad, Esmaeil
   Aghili, Seyed Mojtaba
   Khajavirad, Nasim
   Beigmohammadi, Mohammad-Taghi
   Salehi, Mohammadreza
   Mirfazaelian, Hadi
   Edalatifard, Maryam
   Kazemizadeh, Hossein
   Manshadi, Seyed Ali Dehghan
   Hasannezhad, Maliheh
   Amoozadeh, Laya
   Radnia, Masoud
   Khatami, Seyedeh Rana
   Nahvijou, Azin
   Seyyedsalehi, Monireh Sadat
   Rashidian, Laleh
   Yazdi, Niloofar Ayoobi
   Toosi, Mohsen Nasiri
   Sadeghniiat-Haghighi, Khosro
   Jafarian, Ali
   Yunesian, Masud
   Zendehdel, Kazem
TI Clinical Characteristics and Outcomes of 905 COVID-19 Patients Admitted
   to Imam Khomeini Hospital Complex in the Capital City of Tehran, Iran
SO ARCHIVES OF IRANIAN MEDICINE
LA English
DT Article
DE Clinical characteristics; Iran; Mortality; Outcome; SARS-CoV-2
ID RISK-FACTORS
AB Background: We studied the clinical characteristics and outcomes of 905 hospitalized coronavirus disease 2019 (COVID-19) patients admitted to Imam Khomeini Hospital Complex (IKHC), Tehran, Iran.
   Methods: COVID-19 patients were recruited based on clinical symptoms and patterns of computed tomography (CT) imaging between February 20 and March 19. All patients were tested for the presence of COVID-19 RNA. The Poisson regression model estimated the incidence rate ratio (IRR) for different parameters.
   Results: The average age (standard deviation) was 56.9 (+/- 15.7) years and 61.77% were male. The most common symptoms were fever (93.59%), dry cough (79.78%), and dyspnea (75.69%). Only 43.76% of patients were positive for the RT-PCR COVID-19 test. Prevalence of lymphopenia was 42.9% and more than 90% had elevated lactate dehydrogenase (LDH) or C-reactive protein (CRP). About 11% were severe cases, and 13.7% died in the hospital. The median length of stay (LOS) was 3 days. We found higher risks of mortality in patients who were older than 70 years (IRR = 11.77, 95% CI 3.63-38.18), underwent mechanical ventilation (IRR = 7.36, 95% CI 5.06-10.7), were admitted to the intensive care unit (ICU) (IRR = 5.47, 95% CI 4.00-8.38), tested positive on the COVID-19 test (IRR = 2.80, 95% CI 1.64-3.55), and reported a history of comorbidity (IRR = 1.76, 95% CI 1.07-2.89) compared to their corresponding reference groups. Hydroxychloroquine therapy was not associated with mortality in our study.
   Conclusion: Older age, experiencing a severe form of the disease, and having a comorbidity were the most important prognostic factors for COVID-19 infection. Larger studies are needed to perform further subgroup analyses and verify high-risk groups.
C1 [Allameh, Seyed Farshad] Univ Tehran Med Sci, Gastroenterol Ward, Imam Khomeini Hosp Complex IKHC, Tehran, Iran.
   [Nemati, Saeed; Nahvijou, Azin; Seyyedsalehi, Monireh Sadat; Zendehdel, Kazem] Univ Tehran Med Sci, Canc Inst Iran, Canc Res Ctr, Tehran, Iran.
   [Ghalehtaki, Reza] Univ Tehran Med Sci, Inst Canc, Imam Khomeini Hosp Complex IKHC, Dept Radiat Oncol, Tehran, Iran.
   [Ghalehtaki, Reza] Univ Tehran Med Sci, Canc Res Inst, Radiat Oncol Res Ctr, Tehran, Iran.
   [Mohammadnejad, Esmaeil] Univ Tehran Med Sci, Sch Nursing & Midwifery, Dept Med Surg Nursing & Basic Sci, Tehran, Iran.
   [Aghili, Seyed Mojtaba] Univ Tehran Med Sci, Imam Khomeini Hosp Complex IKHC, Dept Emergency Med, Tehran, Iran.
   [Khajavirad, Nasim; Radnia, Masoud] Univ Tehran Med Sci, Imam Khomeini Hosp Complex IKHC, Dept Internal Med, Tehran, Iran.
   [Beigmohammadi, Mohammad-Taghi; Mirfazaelian, Hadi; Amoozadeh, Laya] Univ Tehran Med Sci, Imam Khomeini Hosp Complex IKHC, Dept Anesthesiol & Intens Care, Tehran, Iran.
   [Salehi, Mohammadreza; Manshadi, Seyed Ali Dehghan; Hasannezhad, Maliheh] Univ Tehran Med Sci, Imam Khomeini Hosp Complex IKHC, Dept Infect Dis & Trop Med, Tehran, Iran.
   [Edalatifard, Maryam; Kazemizadeh, Hossein] Univ Tehran Med Sci, Imam Khomeini Hosp Complex IKHC, Dept Pulm, Tehran, Iran.
   [Edalatifard, Maryam; Kazemizadeh, Hossein; Khatami, Seyedeh Rana] Univ Tehran Med Sci, Thorac Res Ctr, Tehran, Iran.
   [Rashidian, Laleh] Univ Tehran Med Sci, Fac Med, Tehran, Iran.
   [Yazdi, Niloofar Ayoobi] Univ Tehran Med Sci, Imam Khomeini Hosp, Dept Radiol, Tehran, Iran.
   [Toosi, Mohsen Nasiri; Jafarian, Ali] Univ Tehran Med Sci, Liver Transplantat Res Ctr, Tehran, Iran.
   [Sadeghniiat-Haghighi, Khosro] Univ Tehran Med Sci, Occupat Sleep Res Ctr, Tehran, Iran.
   [Jafarian, Ali] Univ Tehran Med Sci, Sch Med, Hepatobiliary Surg & Liver Transplantat Div, Dept Gen Surg,Imam Khomeini Hosp Complex, Tehran, Iran.
   [Yunesian, Masud] Univ Tehran Med Sci, Sch Publ Hlth, Dept Environm Hlth Engn, Tehran, Iran.
   [Yunesian, Masud] Univ Tehran Med Sci, Inst Environm Res IER, Ctr Air Pollut Res CAPR, Tehran, Iran.
   [Zendehdel, Kazem] Univ Tehran Med Sci, Canc Inst Iran, Canc Biol Res Ctr, Tehran, Iran.
   [Zendehdel, Kazem] Univ Tehran Med Sci, Canc Inst Iran, Breast Dis Res Ctr, Tehran, Iran.
RP Zendehdel, K (corresponding author), Univ Tehran Med Sci, Canc Inst Iran, Canc Res Ctr, Tehran, Iran.
EM kzendeh@tums.ac.ir
FU Tehran University of Medical Sciences, Tehran, IranTehran University of
   Medical Sciences [991-101-47253]
FX We would like to appreciate all the doctors and nurses who put their
   lives at risk with limited logistics to care for COVID-19 patients in
   these harsh conditions. We would also like to thank Mrs. Mina Khaki and
   Mrs. Vahideh Peyghambari for helping us with data collection during this
   difficult time. This study was granted by Tehran University of Medical
   Sciences, Tehran, Iran (Grant No.: 991-101-47253).
CR Al-Tawfiq JA, 2020, J HOSP INFECT, V105, P154, DOI 10.1016/j.jhin.2020.03.001
   [Anonymous], 2020, WHO DIR GEN OP REM M
   [Anonymous], 2020, COR COVID 19 GLOB CA
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Deputy of Public Relations of Ministry of Health of Islamic Republic of Iran, 2020, DEATH 1 2 PAT NEW CO
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Esteghamati A, 2010, METAB SYNDR RELAT D, V8, P209, DOI 10.1089/met.2009.0064
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Fang YC, 2020, RADIOLOGY, V296, pE115, DOI 10.1148/radiol.2020200432
   Farsalinos K, 2020, SMOKING VAPING HOSP, DOI [10.32388/Z69O8A.13, DOI 10.32388/Z69O8A.13]
   Faust JS, 2020, JAMA INTERN MED, V180, P1045, DOI 10.1001/jamainternmed.2020.2306
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hopman J, 2020, JAMA-J AM MED ASSOC, V323, P1549, DOI 10.1001/jama.2020.4169
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iftimie S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234452
   Jiang F, 2020, J GEN INTERN MED, V35, P1545, DOI 10.1007/s11606-020-05762-w
   Lighter J, 2020, CLIN INFECT DIS, V71, P896, DOI 10.1093/cid/ciaa415
   Lipsitch M, 2020, NEW ENGL J MED, V382, P1194, DOI 10.1056/NEJMp2002125
   Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2
   MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1166
   Meysamie A, 2010, TOB CONTROL, V19, P125, DOI 10.1136/tc.2009.030759
   Ministry of Health and Medical Education of Iran, DAIL SIT REP COR DIS
   Nikpouraghdam M, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104378
   Porcheddu R, 2020, J INFECT DEV COUNTR, V14, P125, DOI 10.3855/jidc.12600
   Rajgor DD, 2020, LANCET INFECT DIS, V20, P776, DOI 10.1016/S1473-3099(20)30244-9
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Takian A, 2020, LANCET, V395, P1035, DOI 10.1016/S0140-6736(20)30668-1
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang YS, 2020, J MED VIROL, V92, P538, DOI 10.1002/jmv.25721
   Weiss P, 2020, LANCET, V395, P1014, DOI 10.1016/S0140-6736(20)30633-4
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhao QW, 2020, J MED VIROL, V92, P1915, DOI 10.1002/jmv.25889
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 42
TC 0
Z9 0
U1 0
U2 0
PU ACAD MEDICAL SCIENCES I R IRAN
PI TEHRAN
PA PO BOX 19395-5655, TEHRAN, 00000, IRAN
SN 1029-2977
EI 1735-3947
J9 ARCH IRAN MED
JI Arch. Iran. Med.
PD NOV
PY 2020
VL 23
IS 11
BP 766
EP 775
DI 10.34172/aim.2020.102
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA OT5HD
UT WOS:000590876100008
PM 33220695
OA Other Gold
DA 2021-01-01
ER

PT J
AU Sahu, JK
   Madaan, P
   Chand, P
   Kumar, A
   Linn, K
   Mynak, ML
   Poudel, P
   Wanigasinghe, J
AF Sahu, Jitendra Kumar
   Madaan, Priyanka
   Chand, Prem
   Kumar, Amit
   Linn, Kyaw
   Mynak, Mimi Lhamu
   Poudel, Prakash
   Wanigasinghe, Jithangi
TI Management of West syndrome during COVID-19 pandemic: A viewpoint from
   South Asian West Syndrome Research Group
SO EPILEPSY RESEARCH
LA English
DT Article
DE Infantile spasms; Epileptic spasms; Infants; COVID-19
ID INFANTILE SPASMS
AB In the wake of the pandemic COVID-19 and nationwide lockdowns gripping many countries globally, the national healthcare systems are either overwhelmed or preparing to combat this pandemic. Despite all the containment measures in place, experts opine that this novel coronavirus is here to stay as a pandemic or an endemic. Hence, it is apt to be prepared for the confrontation and its aftermath. From protecting the vulnerable individuals to providing quality care for all health conditions and maintaining essential drug supplies, it is going to be a grueling voyage. Preparedness to sustain optimal care for each health condition is a must. With a higher risk for severe COVID-19 disease in infants, need of high-dose hormonal therapy with a concern of consequent severe disease, presence of comorbidities, and a need for frequent investigations and follow-up; children with West syndrome constitute a distinctive group with special concerns. In this viewpoint, we discuss the important issues and concerns related to the management of West syndrome during COVID-19 pandemic in the South Asian context and provide potential solutions to these concerns based on the current evidence, adeptness, and consensus. Some plausible solutions include the continuation of containment and mitigation measures for COVID-19, therapeutic decision- making for West syndrome based on risk stratification, and tele-epileptology.
C1 [Sahu, Jitendra Kumar; Madaan, Priyanka] Postgrad Inst Med Educ & Res, Dept Pediat, Pediat Neurol Unit, Chandigarh 160012, India.
   [Chand, Prem] Aga Khan Univ, Karachi, Pakistan.
   [Kumar, Amit] All India Inst Med Sci, Dept Neurol, New Delhi, India.
   [Linn, Kyaw] Yangon Children Hosp, Pediat Neurol Unit, Yangon, Myanmar.
   [Mynak, Mimi Lhamu] Jigme Dorji Wangchuck Natl Referral Hosp, Dept Pediat, Thimphu, Bhutan.
   [Poudel, Prakash] BP Koirala Inst Hlth Sci, Dept Pediat, Dharan, Nepal.
   [Wanigasinghe, Jithangi] Univ Colombo, Dept Paediat, Colombo, Sri Lanka.
RP Sahu, JK (corresponding author), Postgrad Inst Med Educ & Res, Dept Pediat, Pediat Neurol Unit, Chandigarh 160012, India.
EM jsh2003@gmail.com
OI Poudel, Prakash/0000-0002-9375-2847; Sahu, Jitendra/0000-0001-5194-9951
CR Aledo-Serrano A, 2020, EPILEPSIA, V61, P1312, DOI 10.1111/epi.16537
   Chiotos Kathleen, 2020, J Pediatric Infect Dis Soc, DOI 10.1093/jpids/piaa045
   DEALBA GOG, 1984, CLIN ELECTROENCEPHAL, V15, P140, DOI 10.1177/155005948401500304
   Grinspan ZM, 2020, J CHILD NEUROL, V35, P828, DOI 10.1177/0883073820933739
   Harini C, 2020, EPILEPSIA, V61, P702, DOI 10.1111/epi.16468
   Lu L, 2020, EPILEPSIA, V61, pE49, DOI 10.1111/epi.16524
   Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1088, DOI 10.1111/apa.15270
   Madaan Priyanka, 2020, Epilepsia Open, V5, P461, DOI 10.1002/epi4.12419
   Marlais M, 2020, LANCET CHILD ADOLESC, V4, pE17, DOI 10.1016/S2352-4642(20)30145-0
   Minotti C, 2020, J INFECTION, V81, pE61, DOI 10.1016/j.jinf.2020.04.026
   O'Callaghan FJK, 2011, EPILEPSIA, V52, P1359, DOI 10.1111/j.1528-1167.2011.03127.x
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, DOI 10.3332/ecancer.2020.1023
   Sugiura C, 2007, EPILEPSY RES, V77, P102, DOI 10.1016/j.eplepsyres.2007.09.003
   Vaddi VK, 2018, INDIAN J PEDIATR, V85, P836, DOI 10.1007/s12098-018-2630-3
   Wirrell EC, 2020, J CHILD NEUROL, V35, P924, DOI 10.1177/0883073820940189
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0920-1211
EI 1872-6844
J9 EPILEPSY RES
JI Epilepsy Res.
PD NOV
PY 2020
VL 167
AR 106453
DI 10.1016/j.eplepsyres.2020.106453
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA OP1HC
UT WOS:000587830900026
PM 32927329
OA Green Published
DA 2021-01-01
ER

PT J
AU Waghmare, A
   Abidi, MZ
   Boeckh, M
   Chemaly, RF
   Dadwal, S
   El Boghdadly, Z
   Kamboj, M
   Papanicolaou, GA
   Pergam, SA
   Shahid, Z
AF Waghmare, Alpana
   Abidi, Maheen Z.
   Boeckh, Michael
   Chemaly, Roy F.
   Dadwal, Sanjeet
   El Boghdadly, Zeinab
   Kamboj, Mini
   Papanicolaou, Genovefa A.
   Pergam, Steven A.
   Shahid, Zainab
TI Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation
   and Cellular Therapy Recipients
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE COVID-19; SARS-CoV-2; hematopoietic cell transplan; cellular therapy
ID ACUTE RESPIRATORY SYNDROME; ANAKINRA; TOCILIZUMAB; ARTHRITIS; RECEPTOR;
   OUTCOMES; SARS
AB There are currently limited data on the epidemiology, clinical manifestations, and optimal management of Coronavirus Disease 2019 (COVID-19) in hematopoietic cell transplantation and cellular therapy recipients. Given the experience with other respiratory viruses, we anticipate that patients may develop severe clinical disease and thus provide the following general principles for cancer centers across the nation. These guidelines were developed by members of the American Society for Transplantation and Cellular Therapy Infectious Diseases Special Interest Group. Specific practices may vary depending on local epidemiology and testing capacity, and the guidance provided in this document may change as new information becomes available. (C) 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.
C1 [Waghmare, Alpana] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle Childrens Hosp, Seattle, WA 98195 USA.
   [Abidi, Maheen Z.] Univ Colorado, Denver, CO 80202 USA.
   [Boeckh, Michael] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA.
   [Chemaly, Roy F.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [Dadwal, Sanjeet] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA.
   [El Boghdadly, Zeinab] Ohio State Univ, Med Ctr, James Canc Ctr, Columbus, OH 43210 USA.
   [El Boghdadly, Zeinab] Solove Res Inst, Columbus, OH USA.
   [Kamboj, Mini; Papanicolaou, Genovefa A.] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, New York, NY USA.
   [Pergam, Steven A.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA 98195 USA.
   [Shahid, Zainab] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA.
RP Waghmare, A (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave North, Seattle, WA 98109 USA.
EM awaghmar@fredhutch.org
FU Ansun; GileadGilead Sciences; JanssenJohnson & Johnson USAJanssen
   Biotech Inc; National Institute of Allergy and Infectious DiseasesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U01-AI132004]; MerckMerck & Company; AiCuris; Gilead
   SciencesGilead Sciences; AstellasAstellas Pharmaceuticals; Siemens; VB
   Tech; Amazon; Allovir; Global Life Technologies; Karius; Chimerix;
   Viracor; Takeda/Shire
FX A.W. receives research support from Ansun, VB Tech, Amazon and Allovir,
   and is a consultant for Kyorin. M.B. receives research support from
   Gilead, Janssen, Ansun, Vir Bio, VB Tech, and Amazon and is a consultant
   for Kyorin, Gilead, ReViral, Janssen, Ansun, Moderna, Vir Bio, GSK,
   Pulmocide, Pulmotect, Bavarian Nordic, ADMA, and Allovir. S.A.P.
   receives research support from Global Life Technologies and participates
   in research trials with Chimerix and Merck & Co. He also currently
   participates in a clinical trial sponsored by the National Institute of
   Allergy and Infectious Diseases (U01-AI132004); vaccines for this trial
   are provided by Sanofi-Aventis. R.F.C. receives research grants from
   Merck, Karius, Chimerix, Viracor, Takeda/Shire, AiCuris, Janssen, Ansun
   Pharmaceuticals, Oxford Immunotec, and Gilead Sciences. He is a
   consultant for Merck, Ansun, Oxford Immunotec, Shire, Janssen, Partner
   Therapeutics, ADMA Biologics, and Oxford Immunotec. S.D. receives
   research support from Merck, Gilead, Ansun, Shire/Takeda, and Karius and
   serves on advisory boards for Merck and Janssen. He is a consultant and
   part of a speaker's bureau for Merck. G.A.P. has received research
   support from Merck, Shire/Takeda, Chimerix, and Astellas and consulting
   and other fees from Merck, Astellas, Chimerix, Octapharma, Partner
   Therapeutics, ADMA Biologics, Shionogi, Cidara, Ampynx, and Siemens.
CR Alattar R, 2020, J MED VIROL, V92, P2042, DOI 10.1002/jmv.25964
   American Association of Blood Banks, UPD IMP 2019 NOV COR
   American Society of Hematology, COVID 19 COAG FREQ A
   Anurathapan U, 2020, BONE MARROW TRANSPL, V55, P2359, DOI 10.1038/s41409-020-0969-3
   Aouba A, 2020, ANN RHEUM DIS, DOI [10.1136/annr-heumdis-2020-217706, DOI 10.1136/ANNR-HEUMDIS-2020-217706]
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Arons MM, 2020, NEW ENGL J MED, V382, P2081, DOI 10.1056/NEJMoa2008457
   Auyeung TW, 2005, J INFECTION, V51, P98, DOI 10.1016/j.jinf.2004.09.008
   Bachanova V, 2020, BIOL BLOOD MARROW TR, V26, P1239, DOI 10.1016/j.bbmt.2020.04.008
   Barnes GD, 2020, J THROMB THROMBOLYS, V50, P72, DOI 10.1007/s11239-020-02138-z
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Ben-Zvi I, 2017, ARTHRITIS RHEUMATOL, V69, P854, DOI 10.1002/art.39995
   Bevans M, 2017, BIOL BLOOD MARROW TR, V23, P538, DOI 10.1016/j.bbmt.2016.09.011
   Boonyaratanakornkit J, 2020, J INFECT DIS, V221, P379, DOI 10.1093/infdis/jiz470
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Bruck N, 2011, JCR-J CLIN RHEUMATOL, V17, P23, DOI 10.1097/RHU.0b013e318205092d
   Bullard Jared, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa638
   Campbell CM, 2020, CIRCULATION, V141, P1739, DOI 10.1161/CIRCULATIONAHA.120.047419
   Cantini F, 2020, J INFECTION, V81, P318, DOI 10.1016/j.jinf.2020.04.017
   Capra R, 2020, EUR J INTERN MED, V76, P31, DOI 10.1016/j.ejim.2020.05.009
   Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2
   Centers for Disease Control and Prevention, OV TEST SARS COV 2
   Centers for Disease Control and Prevention, DEC REUS FILT FAC RE
   Chang L, 2020, TRANSFUS MED REV, V34, P75, DOI 10.1016/j.tmrv.2020.02.003
   Chen RC, 2006, CHEST, V129, P1441, DOI 10.1378/chest.129.6.1441
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Clerkin KJ, 2020, CIRCULATION, V141, P1648, DOI 10.1161/CIRCULATIONAHA.120.046941
   Colaneri M, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8050695
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Genovese MC, 2016, NEW ENGL J MED, V374, P1243, DOI 10.1056/NEJMoa1507247
   Goldman Jason D, 2020, N Engl J Med, V383, P1827, DOI 10.1056/NEJMoa2015301
   Government of Canada, 2020, INF PREV CONTR COVID
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Ho JC, 2003, AM J RESP CRIT CARE, V168, P1449, DOI 10.1164/rccm.200306-766OC
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huet T, 2020, LANCET RHEUMATOL, V2, pE393, DOI 10.1016/S2665-9913(20)30164-8
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Infectious Diseases Society of America, GUID INF PREV PAT SY
   Infectious Diseases Society of America, IDSA COVID 19 ANT TE
   Jaume M, 2011, J VIROL, V85, P10582, DOI 10.1128/JVI.00671-11
   Joyner Michael, 2020, medRxiv, DOI 10.1101/2020.05.12.20099879
   Koehler P, 2020, MYCOSES, V63, P528, DOI 10.1111/myc.13096
   Korean Centers for Disease Control, FIND INV AN REP CAS
   Leegwater Emiel, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa883
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Lippi G, 2020, THROMB HAEMOSTASIS, V120, P876, DOI 10.1055/s-0040-1709650
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Ljungman P, 2020, BONE MARROW TRANSPL, V55, P2071, DOI 10.1038/s41409-020-0919-0
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Mahmoudjafari Z, 2020, BIOL BLOOD MARROW TR, V26, P1043, DOI 10.1016/j.bbmt.2020.04.005
   Majhail NS, 2013, BIOL BLOOD MARROW TR, V19, P1498, DOI 10.1016/j.bbmt.2013.07.020
   Mehra MR, 2020, NEW ENGL J MED, V382, P2582, DOI 10.1056/NEJMc2021225
   Mermel LA, 2020, INFECT CONT HOSP EP, V41, P1326, DOI 10.1017/ice.2020.286
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   National Institutes of Health, COR DIS 2019 COVID 1
   Negro F, 2020, SWISS MED WEEKLY, V150
   Nishimoto N, 2008, BLOOD, V112, P3959, DOI 10.1182/blood-2008-05-155846
   Pawar A, 2019, ANN RHEUM DIS, V78, P456, DOI 10.1136/annrheumdis-2018-214367
   Price CC, 2020, CHEST, V158, P1397, DOI 10.1016/j.chest.2020.06.006
   Radbel J, 2020, CHEST, V158, pE15, DOI 10.1016/j.chest.2020.04.024
   Rawson Timothy M, 2020, Clin Infect Dis, V71, P2459, DOI 10.1093/cid/ciaa530
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Tang W, 2020, HYDROXYCHLOROQUINE P, DOI [10.1101/2020.04.10.20060558, DOI 10.1101/2020.04.10.20060558]
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   U.S. Food and Drug Administration, REC INV COVID 19 CON
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   US Food and Drug Administration, UPD INF HUM CELL TIS
   US Food and Drug Administration, COR COVID 19 UPD FDA
   US Food and Drug Administration, EM US AUTH PERS PROT
   van Arkel ALE, 2020, AM J RESP CRIT CARE, V202, P132, DOI 10.1164/rccm.202004-1038LE
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   WHO, 2020, TRANSM SARS COV 2 IM
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   World Health Organization, 2020, INF PREV CONTR HLTH
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xiao Ai Tang, 2020, Clin Infect Dis, V71, P2249, DOI 10.1093/cid/ciaa460
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yang JR, 2020, J MED VIROL, V92, P1681, DOI 10.1002/jmv.25940
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yang Yang M, 2020, EVALUATING ACCURACY, DOI [10.1101/2020.02.11.20021493, DOI 10.1101/2020.02.11.20021493]
   Zeng QL, 2020, J INFECT DIS, V222, P38, DOI 10.1093/infdis/jiaa228
   Zhang B, 2020, CHEST, V158, pE9, DOI 10.1016/j.chest.2020.03.039
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 93
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD NOV
PY 2020
VL 26
IS 11
BP 1983
EP 1994
DI 10.1016/j.bbmt.2020.07.027
PG 12
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA OJ3LJ
UT WOS:000583866400009
PM 32736007
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Wang, SR
   Green, HC
   Wilder, ML
   Du, Q
   Kmush, BL
   Collins, MB
   Larsen, DA
   Zeng, T
AF Wang, Shiru
   Green, Hyatt C.
   Wilder, Maxwell L.
   Du, Qian
   Kmush, Brittany L.
   Collins, Mary B.
   Larsen, David A.
   Zeng, Teng
TI High-throughput wastewater analysis for substance use assessment in
   central New York during the COVID-19 pandemic
SO ENVIRONMENTAL SCIENCE-PROCESSES & IMPACTS
LA English
DT Article
ID SOLID-PHASE EXTRACTION; RESOLUTION MASS-SPECTROMETRY; IN-SEWER
   TRANSFORMATION; PERSONAL CARE PRODUCTS; LIQUID-CHROMATOGRAPHY; ILLICIT
   DRUGS; PSYCHOACTIVE SUBSTANCES; TREATMENT PLANTS; COMMUNITY CONSUMPTION;
   ANTIBIOTIC USE
AB Wastewater entering sewer networks represents a unique source of pooled epidemiological information. In this study, we coupled online solid-phase extraction with liquid chromatography-high resolution mass spectrometry to achieve high-throughput analysis of health and lifestyle-related substances in untreated municipal wastewater during the coronavirus disease 2019 (COVID-19) pandemic. Twenty-six substances were identified and quantified in influent samples collected from six wastewater treatment plants during the COVID-19 pandemic in central New York. Over a 12 week sampling period, the mean summed consumption rate of six major substance groups (i.e., antidepressants, antiepileptics, antihistamines, antihypertensives, synthetic opioids, and central nervous system stimulants) correlated with disparities in household income, marital status, and age of the contributing populations as well as the detection frequency of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in wastewater and the COVID-19 test positivity in the studied sewersheds. Nontarget screening revealed the covariation of piperine, a nontarget substance, with SARS-CoV-2 RNA in wastewater collected from one of the sewersheds. Overall, this proof-of-the-concept study demonstrated the utility of high-throughput wastewater analysis for assessing the population-level substance use patterns during a public health crisis such as COVID-19.
C1 [Wang, Shiru; Zeng, Teng] Syracuse Univ, Dept Civil & Environm Engn, Syracuse, NY 13244 USA.
   [Green, Hyatt C.; Wilder, Maxwell L.] SUNY Coll Environm, Dept Environm & Forest Biol, Syracuse, NY 13210 USA.
   [Du, Qian] Quadrant Biosci Inc, Syracuse, NY 13210 USA.
   [Kmush, Brittany L.; Larsen, David A.] Syracuse Univ, Dept Publ Hlth, Syracuse, NY 13244 USA.
   [Collins, Mary B.] SUNY Coll Environm Sci & Forestry, Dept Environm Studies, Syracuse, NY 13210 USA.
RP Zeng, T (corresponding author), Syracuse Univ, Dept Civil & Environm Engn, Syracuse, NY 13244 USA.
EM tezeng@syr.edu
RI ; Zeng, Teng/B-6446-2012
OI Wang, Shiru/0000-0003-2438-2341; Zeng, Teng/0000-0002-0374-9549
FU Collaboration for Unprecedented Success and Excellence (CUSE) Grant
   Program; Faculty Fellows Program from the New York State Department of
   Economic Development [C150183]
FX We gratefully acknowledge wastewater treatment plant operators for their
   assistance in wastewater sampling despite severe logistical constraints
   during the pandemic. We thank Pruthvi Kilaru (Department of Public
   Health, Syracuse University) and Ariana Fenty (Department of
   Environmental and Forest Biology, SUNY-ESF) for coordinating sample
   delivery and processing. We also thank other team members of the SARS2
   Early Warning Wastewater Surveillance Platform (SARS2-EWSP) for their
   support. We further thank the editor and anonymous reviewers for their
   constructive feedback. This work was supported by the Collaboration for
   Unprecedented Success and Excellence (CUSE) Grant Program administered
   by Syracuse University's Office of Research and the Faculty Fellows
   Program administered by the Syracuse Center of Excellence for
   Environmental and Energy Systems (SyracuseCoE) through an award from the
   New York State Department of Economic Development under Award Number
   #C150183.
CR Ahmed W, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138764
   [Anonymous], 2020, NEW YORK STAT STAT C
   [Anonymous], 2019, MULTIWAY COMPONENT M
   [Anonymous], MZCLOUD ADV MASS SPE
   Asghar H, 2014, J INFECT DIS, V210, pS294, DOI 10.1093/infdis/jiu384
   Bade R, 2020, ADDICTION, DOI 10.1111/add.15256
   Baker DR, 2014, SCI TOTAL ENVIRON, V487, P629, DOI 10.1016/j.scitotenv.2013.11.107
   Baz-Lomba JA, 2016, ANAL CHIM ACTA, V914, P81, DOI 10.1016/j.aca.2016.01.056
   BHAT BG, 1986, TOXICOLOGY, V40, P83, DOI 10.1016/0300-483X(86)90048-X
   Bishop N, 2020, SCI TOTAL ENVIRON, V745, DOI 10.1016/j.scitotenv.2020.140697
   Boogaerts T, 2019, TALANTA, V200, P340, DOI 10.1016/j.talanta.2019.03.052
   Burgard DA, 2014, ENVIRON SCI TECHNOL, V48, P1362, DOI 10.1021/es4044648
   Castiglioni S, 2013, ENVIRON SCI TECHNOL, V47, P1452, DOI 10.1021/es302722f
   Causanilles A, 2017, CHEMOSPHERE, V184, P1186, DOI 10.1016/j.chemosphere.2017.06.101
   Chen C, 2014, SCI TOTAL ENVIRON, V487, P621, DOI 10.1016/j.scitotenv.2013.11.075
   Chiaia AC, 2008, ENVIRON SCI TECHNOL, V42, P8841, DOI 10.1021/es802309v
   Choi P. M., 2020, NEW PARADIGM ENV CHE, P99
   Choi PM, 2019, P NATL ACAD SCI USA, V116, P21864, DOI 10.1073/pnas.1910242116
   Choi PM, 2018, TRAC-TREND ANAL CHEM, V105, P453, DOI 10.1016/j.trac.2018.06.004
   Choi PM, 2020, SCI TOTAL ENVIRON, V709, DOI 10.1016/j.scitotenv.2019.136228
   CHOI PM, 2020, ENVIRON SCI TECH LET, V7, P567, DOI DOI 10.1021/ACS.ESTLETT.0C00392
   Dave RA, 2016, BIOPHARM DRUG DISPOS, V37, P287, DOI 10.1002/bdd.2013
   Deitman C., 2020, COMMUNICATION
   Diamanti K, 2019, SCI TOTAL ENVIRON, V685, P1058, DOI 10.1016/j.scitotenv.2019.06.173
   Dong Z, 2013, REGUL TOXICOL PHARM, V65, P60, DOI 10.1016/j.yrtph.2012.07.003
   Fahrenfeld N, 2016, ENVIRON SCI-WAT RES, V2, P788, DOI 10.1039/c6ew00158k
   Fedorova G, 2014, CHEMOSPHERE, V111, P55, DOI 10.1016/j.chemosphere.2014.02.067
   Foladori P, 2020, SCI TOTAL ENVIRON, V743, DOI 10.1016/j.scitotenv.2020.140444
   Gao JF, 2017, SCI TOTAL ENVIRON, V609, P1172, DOI 10.1016/j.scitotenv.2017.07.231
   Gonzalez R, 2020, WATER RES, V186, DOI 10.1016/j.watres.2020.116296
   Gonzalez-Marino I, 2012, ANAL CHEM, V84, P1708, DOI 10.1021/ac202989e
   Gracia-Lor E, 2017, SCI TOTAL ENVIRON, V609, P1582, DOI 10.1016/j.scitotenv.2017.07.258
   Gracia-Lor E, 2017, ENVIRON INT, V99, P131, DOI 10.1016/j.envint.2016.12.016
   Gracia-Lor E, 2016, SCI TOTAL ENVIRON, V573, P1648, DOI 10.1016/j.scitotenv.2016.09.179
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Green H. C., 2020, MEDRXIV, DOI [10.1101/2020.05.21.20109181, DOI 10.1101/2020.05.21.20109181]
   Iahtisham-Ul Haq, 2020, PHYTOTHER RES, DOI 10.1002/ptr.6855
   Hart OE, 2020, SCI TOTAL ENVIRON, V730, DOI 10.1016/j.scitotenv.2020.138875
   Hatcher SM, 2020, MMWR-MORBID MORTAL W, V69, P1166, DOI 10.15585/mmwr.mm6934e1
   Hendriksen RS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08853-3
   Hernandez F, 2011, ANAL CHIM ACTA, V684, P96, DOI 10.1016/j.aca.2010.10.043
   Heuett NV, 2015, SCI TOTAL ENVIRON, V511, P319, DOI 10.1016/j.scitotenv.2014.12.043
   Huntscha S, 2012, J CHROMATOGR A, V1268, P74, DOI 10.1016/j.chroma.2012.10.032
   Jelic A, 2015, WATER RES, V68, P98, DOI 10.1016/j.watres.2014.09.033
   Jemberie WB, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00714
   Andres-Costa MJ, 2017, TRAC-TREND ANAL CHEM, V94, P21, DOI 10.1016/j.trac.2017.06.012
   Kapo KE, 2017, SCI TOTAL ENVIRON, V603, P445, DOI 10.1016/j.scitotenv.2017.06.075
   Kassambara A., 2020, FACTOEXTRA EXTRACT V
   Kim KY, 2020, J HAZARD MATER, V396, DOI 10.1016/j.jhazmat.2020.122622
   Kumar M, 2020, SCI TOTAL ENVIRON, V746, DOI 10.1016/j.scitotenv.2020.141326
   La Rosa G., 2021, SCI TOTAL ENVIRON, V750, P141711
   La Rosa G, 2020, SCI TOTAL ENVIRON, V736, DOI 10.1016/j.scitotenv.2020.139652
   Li JY, 2018, ENVIRON SCI TECHNOL, V52, P1561, DOI 10.1021/acs.est.7b05109
   Lopez-Garcia E, 2018, J CHROMATOGR A, V1576, P80, DOI 10.1016/j.chroma.2018.09.038
   Lorenzo-Seva U., 2006, METHODOLOGY, V2, P57, DOI [10.1027/1614-2241.2.2.57, DOI 10.1027/1614-2241.2.2.57]
   Magnuson BA, 2016, NUTR REV, V74, P670, DOI 10.1093/nutrit/nuw032
   Gutierrez-Villagomez JM, 2020, J PHYS CHEM LETT, V11, P8008, DOI 10.1021/acs.jpclett.0c01685
   Martin J, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12101144
   McCall AK, 2016, WATER RES, V88, P933, DOI 10.1016/j.watres.2015.10.040
   Medema G., 2020, ENVIRON SCI TECH LET, V7, P511, DOI DOI 10.1021/ACS.ESTLETT.0C00357
   Medema Gertjan, 2020, Curr Opin Environ Sci Health, V17, P49, DOI 10.1016/j.coesh.2020.09.006
   Mitchell DC, 2014, FOOD CHEM TOXICOL, V63, P136, DOI 10.1016/j.fct.2013.10.042
   Miyani B., 2020, J ENV ENG, V146, P06020004
   Mourad Ahmad, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1374
   Neault N., 2020, MEDRXIV 2020 2020 09
   Nemudryi Artem, 2020, Cell Rep Med, V1, P100098, DOI 10.1016/j.xcrm.2020.100098
   New York State Water Resources Institute, 2011, SEPTIC SYSTEMS
   Nurenberg G, 2015, J CHROMATOGR A, V1426, P77, DOI 10.1016/j.chroma.2015.11.014
   Ochalek TA, 2020, JAMA-J AM MED ASSOC, V324, P1673, DOI 10.1001/jama.2020.17477
   Pagsuyoin S, 2019, ACS SYM SER, V1319, P167
   Pandopulos AJ, 2020, J CHROMATOGR A, V1612, DOI 10.1016/j.chroma.2019.460623
   Pasin D, 2017, ANAL BIOANAL CHEM, V409, P5821, DOI 10.1007/s00216-017-0441-4
   Peccia J, 2020, NAT BIOTECHNOL, V38, P1164, DOI 10.1038/s41587-020-0684-z
   Pemberton JA, 2020, RAPID COMMUN MASS SP, V34, DOI 10.1002/rcm.8618
   Postigo C, 2008, ANAL CHEM, V80, P3123, DOI 10.1021/ac702060j
   Purschke K, 2020, ANAL CHEM, V92, P12273, DOI 10.1021/acs.analchem.0c01897
   Ramin P, 2016, ENVIRON SCI TECHNOL, V50, P13397, DOI 10.1021/acs.est.6b03049
   Randazzo W, 2020, WATER RES, V181, DOI 10.1016/j.watres.2020.115942
   Rawson Timothy M, 2020, Clin Infect Dis, V71, P2459, DOI 10.1093/cid/ciaa530
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rico M, 2017, J HAZARD MATER, V323, P156, DOI 10.1016/j.jhazmat.2016.05.079
   Salgueiro-Gonzalez N, 2019, SCI TOTAL ENVIRON, V689, P679, DOI 10.1016/j.scitotenv.2019.06.336
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Sherchan SP, 2020, SCI TOTAL ENVIRON, V743, DOI 10.1016/j.scitotenv.2020.140621
   Sims N, 2020, ENVIRON INT, V139, DOI 10.1016/j.envint.2020.105689
   Slavova S, 2020, DRUG ALCOHOL DEPEN, V214, DOI 10.1016/j.drugalcdep.2020.108176
   Subedi B, 2019, ACS SYM SER, V1319, P79
   Subedi B, 2015, SCI TOTAL ENVIRON, V514, P273, DOI 10.1016/j.scitotenv.2015.01.098
   Subedi B, 2014, ENVIRON SCI TECHNOL, V48, P13668, DOI 10.1021/es504769c
   Subedi B, 2014, ENVIRON SCI TECHNOL, V48, P6661, DOI 10.1021/es501709a
   Sylvetsky AC, 2016, PHYSIOL BEHAV, V164, P446, DOI 10.1016/j.physbeh.2016.03.030
   Thai PK, 2019, ENVIRON SCI TECH LET, V6, P265, DOI 10.1021/acs.estlett.8b00673
   Thai PK, 2019, SCI TOTAL ENVIRON, V671, P248, DOI 10.1016/j.scitotenv.2019.03.231
   Thai PK, 2016, ENVIRON INT, V94, P307, DOI 10.1016/j.envint.2016.05.033
   Thai PK, 2014, WATER RES, V48, P538, DOI 10.1016/j.watres.2013.10.019
   Thiebault T, 2017, SCI TOTAL ENVIRON, V596, P246, DOI 10.1016/j.scitotenv.2017.04.130
   Thomaidis NS, 2016, ENVIRON SCI TECHNOL, V50, P10065, DOI 10.1021/acs.est.6b02417
   Trottier J, 2020, ONE HEALTH-AMSTERDAM, V10, DOI 10.1016/j.onehlt.2020.100157
   Tscharke BJ, 2019, ENVIRON SCI TECHNOL, V53, P10303, DOI 10.1021/acs.est.9b03447
   Tscharke BJ, 2016, SCI TOTAL ENVIRON, V565, P384, DOI 10.1016/j.scitotenv.2016.04.183
   van Dorn A, 2020, LANCET, V395, P1243, DOI 10.1016/S0140-6736(20)30893-X
   Volkow ND, 2020, ANN INTERN MED, V173, P61, DOI 10.7326/M20-1212
   Walker K., 2020, TIDYCENSUS LOAD US C
   Walker K., 2020, TIGRIS LOAD CENSUS T
   Wang Monica L, 2020, Transl Behav Med, V10, P516, DOI 10.1093/tbm/ibaa055
   Wang QQ, 2020, MOL PSYCHIATR, DOI 10.1038/s41380-020-00880-7
   Wang Shiru, 2020, Environ Sci Technol, V54, P13759, DOI 10.1021/acs.est.0c04775
   Webb Hooper M, 2020, JAMA-J AM MED ASSOC, V323, P2466, DOI 10.1001/jama.2020.8598
   Wei YF, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13070155
   Westhaus S., 2020, SCI TOTAL ENVIRON, P141750
   Winstock A. R., 2020, GLOBAL DRUG SURVEY S
   Wu FQ, 2020, MSYSTEMS, V5, DOI 10.1128/mSystems.00614-20
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xagoraraki I., 2020, WOMEN WATER QUALITY, P75, DOI DOI 10.1007/978-3-030-17819-2_5
   Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548
   Yao B, 2016, CHEMOSPHERE, V160, P208, DOI 10.1016/j.chemosphere.2016.06.092
   Zhang YZ, 2019, ENVIRON INT, V125, P152, DOI 10.1016/j.envint.2019.01.061
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 118
TC 0
Z9 0
U1 3
U2 3
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050-7887
EI 2050-7895
J9 ENVIRON SCI-PROC IMP
JI Environ. Sci.-Process Impacts
PD NOV 1
PY 2020
VL 22
IS 11
BP 2147
EP 2161
DI 10.1039/d0em00377h
PG 15
WC Chemistry, Analytical; Environmental Sciences
SC Chemistry; Environmental Sciences & Ecology
GA OS8DB
UT WOS:000590386700002
PM 33104143
DA 2021-01-01
ER

PT J
AU Hou, X
   Zhang, XM
   Wu, X
   Lu, MY
   Wang, D
   Xu, M
   Wang, HY
   Liang, T
   Dai, JY
   Duan, H
   Xu, YC
   Yu, XB
   Li, YZ
AF Hou, Xin
   Zhang, Xiaomei
   Wu, Xian
   Lu, Minya
   Wang, Dan
   Xu, Meng
   Wang, Hongye
   Liang, Te
   Dai, Jiayu
   Duan, Hu
   Xu, Yingchun
   Yu, Xiaobo
   Li, Yongzhe
TI Serum Protein Profiling Reveals a Landscape of Inflammation and Immune
   Signaling in Early-stage COVID-19 Infection
SO MOLECULAR & CELLULAR PROTEOMICS
LA English
DT Article
ID MOUSE MODEL; CORONAVIRUS; INHIBITOR; PNEUMONIA; ARTHRITIS; MYOSITIS;
   BINDARIT
AB Coronavirus disease 2019 (COVID-19) is a highly contagious infection and threating the human lives in the world. The elevation of cytokines in blood is crucial to induce cytokine storm and immunosuppression in the transition of severity in COVID-19 patients. However, the comprehensive changes of serum proteins in COVID-19 patients throughout the SARS-CoV-2 infection is unknown. In this work, we developed a high-density antibody microarray and performed an in-depth proteomics analysis of serum samples collected from early COVID-19 (n = 15) and influenza (n = 13) patients. We identified a large set of differentially expressed proteins (n = 132) that participate in a landscape of inflammation and immune signaling related to the SARS-CoV-2 infection. Furthermore, the significant correlations of neutrophil and lymphocyte with the CCL2 and CXCL10 mediated cytokine signaling pathways was identified. These information are valuable for the understanding of COVID-19 pathogenesis, identification of biomarkers and development of the optimal anti-inflammation therapy.
C1 [Hou, Xin; Wu, Xian; Lu, Minya; Xu, Yingchun; Li, Yongzhe] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Clin Lab, Beijing, Peoples R China.
   [Hou, Xin; Wu, Xian; Lu, Minya; Xu, Yingchun; Li, Yongzhe] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Beijing Key Lab Mech Res & Precis Diag Invas Fung, Beijing, Peoples R China.
   [Zhang, Xiaomei; Wang, Dan; Xu, Meng; Wang, Hongye; Liang, Te; Dai, Jiayu; Duan, Hu; Yu, Xiaobo] Beijing Inst Life, Natl Ctr Prot Sci Beijing PHOENIX Ctr, Beijing Proteome Res Ctr, State Key Lab Prote, Beijing, Peoples R China.
RP Xu, YC; Li, YZ (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Clin Lab, Beijing, Peoples R China.; Xu, YC; Li, YZ (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Beijing Key Lab Mech Res & Precis Diag Invas Fung, Beijing, Peoples R China.; Yu, XB (corresponding author), Beijing Inst Life, Natl Ctr Prot Sci Beijing PHOENIX Ctr, Beijing Proteome Res Ctr, State Key Lab Prote, Beijing, Peoples R China.
EM xycpumch@139.com; yuxiaobo@mail.ncpsb.org; yongzhelipumch@126.com
FU National Key R&D Program of China [2020YFE0202200]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [81671618, 81871302, 81673040, 31870823]; CAMS Innovation Fund
   for Medical Sciences (CIFMS) [2017I2M-3-001, 2017-I2M-BR-01]; State Key
   Laboratory of Proteomics [SKLP-C202001, SKLP-O201703, SKLP-K201505];
   Beijing Municipal Education CommissionBeijing Municipal Commission of
   Education; National Program on Key Basic Research ProjectNational Basic
   Research Program of China [2018YFA0507503, 2017YFC0906703,
   2018ZX09733003]
FX This research was supported by grants from the National Key R&D Program
   of China (2020YFE0202200), National Natural Science Foundation of China
   Grants (81671618, 81871302, 81673040, 31870823), CAMS Innovation Fund
   for Medical Sciences (CIFMS) (2017I2M-3-001, 2017-I2M-B&R-01), the State
   Key Laboratory of Proteomics (SKLP-C202001, SKLP-O201703, SKLP-K201505),
   the Beijing Municipal Education Commission and the National Program on
   Key Basic Research Project (2018YFA0507503, 2017YFC0906703,
   2018ZX09733003).
CR Aomatsu T, 2012, INT J MOL MED, V30, P1152, DOI 10.3892/ijmm.2012.1094
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101
   Campbell CM, 2020, CIRCULATION, V141, P1739, DOI 10.1161/CIRCULATIONAHA.120.047419
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Chen IY, 2010, J VIROL, V84, P7703, DOI 10.1128/JVI.02560-09
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chu VT, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-7-r118
   Fan XX, 2019, J INVEST SURG, DOI 10.1080/08941939.2019.1698679
   Franz M, 2016, BIOINFORMATICS, V32, P309, DOI 10.1093/bioinformatics/btv557
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang L, 2020, BLOOD SINGLE CELL IM
   Kindrachuk J, 2015, ANTIMICROB AGENTS CH, V59, P1088, DOI 10.1128/AAC.03659-14
   Liu ML, 2011, CYTOKINE GROWTH F R, V22, P121, DOI 10.1016/j.cytogfr.2011.06.001
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mi HY, 2016, NUCLEIC ACIDS RES, V44, pD336, DOI 10.1093/nar/gkv1194
   Mizutani T, 2005, BBA-MOL BASIS DIS, V1741, P4, DOI 10.1016/j.bbadis.2005.04.004
   Risitano AM, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0366-6
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Rulli NE, 2011, J INFECT DIS, V204, P1026, DOI 10.1093/infdis/jir470
   Rulli NE, 2009, ARTHRITIS RHEUM-US, V60, P2513, DOI 10.1002/art.24682
   Sabbatucci M, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-014-0132-6
   Schett G, 2020, NAT REV IMMUNOL, V20, P271, DOI 10.1038/s41577-020-0312-7
   Scully EP, 2020, NAT REV IMMUNOL, V20, P442, DOI 10.1038/s41577-020-0348-8
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Takahashi Takehiro, 2020, medRxiv, DOI 10.1101/2020.06.06.20123414
   Tanaka T, 2016, IMMUNOTHERAPY-UK, V8, P959, DOI 10.2217/imt-2016-0020
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu M, 2019, THERANOSTICS, V9, P2475, DOI 10.7150/thno.31144
   Yu XB, 2013, BIOTECHNIQUES, V54, P257, DOI 10.2144/000114028
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 35
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 1535-9476
EI 1535-9484
J9 MOL CELL PROTEOMICS
JI Mol. Cell. Proteomics
PD NOV
PY 2020
VL 19
IS 11
BP 1749
EP 1759
DI 10.1074/mcp.RP120.002128
PG 11
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA OP8PL
UT WOS:000588352500002
PM 32788344
DA 2021-01-01
ER

PT J
AU Song, KH
   Choi, S
AF Song, Ki-Han
   Choi, Solsaem
TI A Study on the Behavioral Change of Passengers on Sustainable Air
   Transport after COVID-19
SO SUSTAINABILITY
LA English
DT Article
DE passenger behavior; air transport sustainability; structural equation
   modeling
ID AIRLINE CHOICE; AIRPORT CHOICE; MIXED LOGIT; TRAVELERS; DECISION;
   DRIVERS; SERVICE; LOYALTY; TAIWAN; MODELS
AB From the perspective of the sustainability of aviation demand, we investigated passenger perceptions with regards to whether or not Korean people will resume the use of air transport after COVID-19. Based on five factors-the prevalence of COVID-19, requirements for self-isolation, circumstances at the destination, social atmosphere with regards to overseas travel, and level of preventative measures employed in the aviation service sector-a structured questionnaire was developed using confirmatory factor analysis. Based on these, the main levels of determination per factor were derived and a structured path for the recovery of aviation demand via structural equation analysis between factors was analyzed. The five factors established above were found to have a significant impact on passenger perceptions with regards to the restart of using air transport. It was found that people may consider resuming overseas travel with air transport, prior to the development of a COVID-19 cure or vaccine, corresponding to relaxed requirements for self-isolation if there is a fall in the number of confirmed cases. In addition, it was determined that the unconditional lifting of self-isolation requirements without considerations for the hygienic conditions of the destination has limitations in how much it will lead to the resumption of air travel. We hope that this study will serve as a starting point for other studies monitoring passenger behavior in the future and that it will lead to the development of sustainable strategies for recovering aviation demand.
C1 [Song, Ki-Han; Choi, Solsaem] Korea Transport Inst, Dept Aviat, Sejong Si 30147, South Korea.
RP Choi, S (corresponding author), Korea Transport Inst, Dept Aviat, Sejong Si 30147, South Korea.
EM kihansong@koti.re.kr; thftoa9@koti.re.kr
OI song, ki han/0000-0002-5442-5704
FU Korea Transport Institute [31-20-014]
FX This study was funded by Korea Transport Institute for its task to
   "Research project for enhancement of airport competitiveness and
   regional development in Korea by the year 2020", grant number 31-20-014
   And The APC was funded by Korea Transport Institute.
CR [Anonymous], 2020, SMITHSONIAN MAGAZINE
   Becker's Hospital, 2020, BECKERS HOSP REV
   BENTLER PM, 1980, PSYCHOL BULL, V88, P588, DOI 10.1037/0033-2909.107.2.238
   BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.107.2.238
   Bogicevic V, 2016, J AIR TRANSP MANAG, V57, P122, DOI 10.1016/j.jairtraman.2016.07.019
   Browne MW, 1993, SOCIOL METHOD RES, P136
   Chen HT, 2015, J AIR TRANSP MANAG, V49, P53, DOI 10.1016/j.jairtraman.2015.08.002
   Chiou YC, 2010, J AIR TRANSP MANAG, V16, P226, DOI 10.1016/j.jairtraman.2009.11.005
   Currie GM, 2020, J MED IMAGING RADIAT, V51, P361, DOI 10.1016/j.jmir.2020.06.004
   Dolnicar S, 2011, TOURISM MANAGE, V32, P1020, DOI 10.1016/j.tourman.2010.08.014
   Forgas S, 2012, J AIR TRANSP MANAG, V18, P43, DOI 10.1016/j.jairtraman.2011.08.003
   FORNELL C, 1981, J MARKETING RES, V18, P39, DOI 10.2307/3151312
   Fornell C, 1982, P AM MARK ASS ED C, V2
   Han H, 2013, TOURISM MANAGE, V37, P125, DOI 10.1016/j.tourman.2013.01.008
   Hong S, 2000, KOREAN J CLIN PSYCHO, V19, P161
   INNES JD, 1990, J TRANSP ENG-ASCE, V116, P507, DOI 10.1061/(ASCE)0733-947X(1990)116:4(507)
   International Air Transport Association, 2020, PASS INS TIM PAND
   International Air Transport Association IATA, 2020, IATA EC CHART WEEK W
   International Civil Aviation Organization, 2020, EFF NOV COR COVID 19
   Ishii J, 2009, J URBAN ECON, V65, P216, DOI 10.1016/j.jue.2008.12.001
   Jenatabadi HS, 2014, J AIR TRANSP MANAG, V40, P25, DOI 10.1016/j.jairtraman.2014.05.005
   Kelloway E. K., 1998, USING LISREL STRUCTU
   Kim S.E, 2018, THESIS
   Kline R. B., 1998, PRINCIPLES PRACTICE
   Lai SL, 2005, J AIR TRANSP MANAG, V11, P455, DOI 10.1016/j.jairtraman.2005.06.001
   Lee G, 2009, TOURISM MANAGE, V30, P922, DOI 10.1016/j.tourman.2008.11.013
   Lee H.S, 2008, STRUCTURAL EQUATION
   Lee JK, 2016, J AIR TRANSP MANAG, V56, P131, DOI 10.1016/j.jairtraman.2016.04.020
   Lirn TC, 2009, TRANSPORT RES F-TRAF, V12, P404, DOI 10.1016/j.trf.2009.06.001
   Lucini FR, 2020, J AIR TRANSP MANAG, V83, DOI 10.1016/j.jairtraman.2019.101760
   Martin-Consuegra D, 2007, J AIR TRANSP MANAG, V13, P383, DOI 10.1016/j.jairtraman.2007.08.001
   McFadden D, 2000, J APPL ECONOMET, V15, P447, DOI 10.1002/1099-1255(200009/10)15:5<447::AID-JAE570>3.3.CO;2-T
   McFadden D., 1974, J PUBLIC ECON, V3, P303, DOI [10.1016/0047-2727(74)90003-6, DOI 10.1016/0047-2727(74)90003-6]
   Mikulic J, 2011, J AIR TRANSP MANAG, V17, P237, DOI 10.1016/j.jairtraman.2010.09.005
   NAKO SM, 1992, LOGIST TRANSPORT REV, V28, P395
   Ong WL, 2010, J AIR TRANSP MANAG, V16, P209, DOI 10.1016/j.jairtraman.2009.06.001
   Pels E, 2001, REG STUD, V35, P1, DOI 10.1080/00343400120025637
   Revelt D, 1998, REV ECON STAT, V80, P647, DOI 10.1162/003465398557735
   Satorra A., 1988, AM STAT ASS 1988 P B, P308
   SKINNER RE, 1976, TRANSPORT ENG-J ASCE, V102, P871
   Suzuki Y, 2007, TRANSPORT RES E-LOG, V43, P1, DOI 10.1016/j.tre.2005.05.005
   TUCKER LR, 1973, PSYCHOMETRIKA, V38, P1, DOI 10.1007/bf02291170
   Ullman J.B., 2006, STRUCTURAL EQUATION
   Verikios George, 2020, Socioecon Plann Sci, V71, P100898, DOI 10.1016/j.seps.2020.100898
   Wang HL, 2018, SAFETY SCI, V108, P104, DOI 10.1016/j.ssci.2018.04.022
   WINDLE R, 1995, J TRANSP ENG-ASCE, V121, P332, DOI 10.1061/(ASCE)0733-947X(1995)121:4(332)
   Yang KC, 2012, J AIR TRANSP MANAG, V20, P52, DOI 10.1016/j.jairtraman.2011.12.007
   Yoo K. E., 1996, TRANSPORT RES REC, V1562, P1, DOI DOI 10.1177/0361198196156200101
NR 48
TC 0
Z9 0
U1 9
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2071-1050
J9 SUSTAINABILITY-BASEL
JI Sustainability
PD NOV
PY 2020
VL 12
IS 21
AR 9207
DI 10.3390/su12219207
PG 18
WC Green & Sustainable Science & Technology; Environmental Sciences;
   Environmental Studies
SC Science & Technology - Other Topics; Environmental Sciences & Ecology
GA OR3WJ
UT WOS:000589404400001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Nunez, DDF
   Leon, L
   Mucientes, A
   Rodriguez-Rodriguez, L
   Urgelles, JF
   Garcia, AM
   Colomer, JI
   Jover, JA
   Fernandez-Gutierrez, B
   Abasolo, L
AF Freites Nunez, Dalifer D.
   Leon, Leticia
   Mucientes, Arkaitz
   Rodriguez-Rodriguez, Luis
   Font Urgelles, Judit
   Madrid Garcia, Alfredo
   Colomer, Jose, I
   Jover, Juan A.
   Fernandez-Gutierrez, Benjamin
   Abasolo, Lydia
TI Risk factors for hospital admissions related to COVID-19 in patients
   with autoimmune inflammatory rheumatic diseases
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Article
ID CORONAVIRUS
AB Objectives To describe patients with autoimmune inflammatory rheumatic diseases (AIRD) who had COVID-19 disease; to compare patients who required hospital admission with those who did not and assess risk factors for hospital admission related to COVID-19.
   Methods An observational longitudinal study was conducted during the pandemic peak of severe acute respiratory syndrome coronavirus 2 (1 March 2020 to 24 April). All patients attended at the rheumatology outpatient clinic of a tertiary hospital in Madrid, Spain with a medical diagnosis of AIRD and with symptomatic COVID-19 were included. The main outcome was hospital admission related to COVID-19. The covariates were sociodemographic, clinical and treatments. We ran a multivariable logistic regression model to assess risk factors for the hospital admission.
   Results The study population included 123 patients with AIRD and COVID-19. Of these, 54 patients required hospital admission related to COVID-19. The mean age on admission was 69.7 (15.7) years, and the median time from onset of symptoms to hospital admission was 5 (3-10) days. The median length of stay was 9 (6-14) days. A total of 12 patients died (22%) during admission. Compared with outpatients, the factors independently associated with hospital admission were older age (OR: 1.08; p=0.00) and autoimmune systemic condition (vs chronic inflammatory arthritis) (OR: 3.55; p=0.01). No statistically significant findings for exposure to disease-modifying antirheumatic drugs were found in the final model.
   Conclusion Our results suggest that age and having a systemic autoimmune condition increased the risk of hospital admission, whereas disease-modifying antirheumatic drugs were not associated with hospital admission.
C1 [Freites Nunez, Dalifer D.; Leon, Leticia; Mucientes, Arkaitz; Rodriguez-Rodriguez, Luis; Madrid Garcia, Alfredo; Colomer, Jose, I; Abasolo, Lydia] Fdn Invest Biomed Hosp Clin San Carlos, Rheumatol Dept, Madrid, Spain.
   [Freites Nunez, Dalifer D.; Leon, Leticia; Mucientes, Arkaitz; Rodriguez-Rodriguez, Luis; Madrid Garcia, Alfredo; Colomer, Jose, I; Abasolo, Lydia] Fdn Invest Biomed Hosp Clin San Carlos, IDISSC, Madrid, Spain.
   [Leon, Leticia] Univ Camilo Jose Cela, Dept Hlth & Educ, Madrid, Spain.
   [Font Urgelles, Judit; Jover, Juan A.; Fernandez-Gutierrez, Benjamin] Hosp Clin San Carlos, Rheumatol Dept, Madrid, Spain.
   [Jover, Juan A.] Univ Complutense Madrid, Med Dept, Madrid, Comunidad De Ma, Spain.
RP Leon, L (corresponding author), Fdn Invest Biomed Hosp Clin San Carlos, IDISSC, Madrid, Spain.; Leon, L (corresponding author), Fdn Invest Biomed Hosp Clin San Carlos, Rheumatol, Madrid, Spain.
EM lleon.hcsc@salud.madrid.org
RI ; Rodriguez-Rodriguez, Luis/H-5880-2013
OI Mucientes, Arkaitz/0000-0002-7431-7225; Freites Nunez,
   Dalifer/0000-0002-0966-2778; Leon, Leticia/0000-0001-7142-0545;
   Rodriguez-Rodriguez, Luis/0000-0002-2869-7861
FU Instituto de Salud Carlos III (ISCIII), Ministry of Health, Spain
   [CP16/00916, PI18/01188, RD16/0012/0014]; Fondo Europeo de Desarrollo
   Regional (FEDER)European Union (EU)
FX This work was supported by the Instituto de Salud Carlos III (ISCIII),
   Ministry of Health, Spain (CP16/00916; PI18/01188; and RD16/0012/0014)
   and cofunded by el Fondo Europeo de Desarrollo Regional (FEDER). The
   funders had no role in study design, data collection, analysis,
   manuscript preparation or decision to publish.
CR [Anonymous], COVID 19 SITUACION C
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Corominas H, 2020, EUR J RHEUMATOL, V7, pS107, DOI 10.5152/eurjrheum.2020.20061
   Cron RQ, 2020, J RHEUMATOL, V47, P1723, DOI [10.3899/jrheum.200744, 10.3899/jrheum.200334]
   Favalli EG, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102523
   Fernandez-Gutierrez B, 2020, REUMATOL CLIN, V16, P253, DOI 10.1016/j.reuma.2020.04.001
   Figueroa-Parra G, 2020, ANN RHEUM DIS, V79, P839, DOI 10.1136/annrheumdis-2020-217322
   Gianfrancesco M, 2020, ANN RHEUM DIS, V79, P859, DOI [10.1136/annrheumdis-2020-217871, 10.1136/annrheumdis-2020-218328, 10.1136/annrheumdis-2020-218713]
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Haberman R, 2020, NEW ENGL J MED, V383, P85, DOI 10.1056/NEJMc2009567
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Liu ZM, 2020, J INFECTION, V81, P331, DOI 10.1016/j.jinf.2020.03.054
   Monti S, 2020, ANN RHEUM DIS, V79, P667, DOI 10.1136/annrheumdis-2020-217424
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Yang JK, 2006, DIABETIC MED, V23, P623, DOI 10.1111/j.1464-5491.2006.01861.x
   Yang JK, 2010, ACTA DIABETOL, V47, P193, DOI 10.1007/s00592-009-0109-4
   Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 21
TC 1
Z9 1
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD NOV
PY 2020
VL 79
IS 11
BP 1393
EP 1399
DI 10.1136/annrheumdis-2020-217984
PG 7
WC Rheumatology
SC Rheumatology
GA OE7HU
UT WOS:000580698100016
PM 32769150
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Schultze, A
   Walker, AJ
   MacKenna, B
   Morton, CE
   Bhaskaran, K
   Brown, JP
   Rentsch, CT
   Williamson, E
   Drysdale, H
   Croker, R
   Bacon, S
   Hulme, W
   Bates, C
   Curtis, HJ
   Mehrkar, A
   Evans, D
   Inglesby, P
   Cockburn, J
   McDonald, HI
   Tomlinson, L
   Mathur, R
   Wing, K
   Wong, AYS
   Forbes, H
   Parry, J
   Hester, F
   Harper, S
   Evans, SJW
   Quint, J
   Smeeth, L
   Douglas, IJ
   Goldacre, B
AF Schultze, Anna
   Walker, Alex J.
   MacKenna, Brian
   Morton, Caroline E.
   Bhaskaran, Krishnan
   Brown, Jeremy P.
   Rentsch, Christopher T.
   Williamson, Elizabeth
   Drysdale, Henry
   Croker, Richard
   Bacon, Seb
   Hulme, William
   Bates, Chris
   Curtis, Helen J.
   Mehrkar, Amir
   Evans, David
   Inglesby, Peter
   Cockburn, Jonathan
   McDonald, Helen, I
   Tomlinson, Laurie
   Mathur, Rohini
   Wing, Kevin
   Wong, Angel Y. S.
   Forbes, Harriet
   Parry, John
   Hester, Frank
   Harper, Sam
   Evans, Stephen J. W.
   Quint, Jennifer
   Smeeth, Liam
   Douglas, Ian J.
   Goldacre, Ben
CA OpenSAFELY Collaborative
TI Risk of COVID-19-related death among patients with chronic obstructive
   pulmonary disease or asthma prescribed inhaled corticosteroids: an
   observational cohort study using the OpenSAFELY platform
SO LANCET RESPIRATORY MEDICINE
LA English
DT Article
ID COPD; HOSPITALIZATION; PNEUMONIA; RATES
AB Background Early descriptions of patients admitted to hospital during the COVID-19 pandemic showed a lower prevalence of asthma and chronic obstructive pulmonary disease (COPD) than would be expected for an acute respiratory disease like COVID-19, leading to speculation that inhaled corticosteroids (ICSs) might protect against infection with severe acute respiratory syndrome coronavirus 2 or the development of serious sequelae. We assessed the association between ICS and COVID-19-related death among people with COPD or asthma using linked electronic health records (EHRs) in England, UK.
   Methods In this observational study, we analysed patient-level data for people with COPD or asthma from primary care EHRs linked with death data from the Office of National Statistics using the OpenSAFELY platform. The index date (start of follow-up) for both cohorts was March 1, 2020; follow-up lasted until May 6, 2020. For the COP D cohort, individuals were eligible if they were aged 35 years or older, had COPD, were a current or former smoker, and were prescribed an ICS or long-acting beta agonist plus long-acting muscarinic antagonist (LABA-LAMA) as combination therapy within the 4 months before the index date. For the asthma cohort, individuals were eligible if they were aged 18 years or older, had been diagnosed with asthma within 3 years of the index date, and were prescribed an ICS or short-acting beta agonist (SABA) only within the 4 months before the index date. We compared the outcome of COVID-19-related death between people prescribed an ICS and those prescribed alternative respiratory medications: ICSs versus LABA-LAMA for the COPD cohort, and low-dose or medium-dose and high-dose ICSs versus SABAs only in the asthma cohort. We used Cox regression models to estimate hazard ratios (HRs) and 95% CIs for the association between exposure categories and the outcome in each population, adjusted for age, sex, and all other prespecified covariates. We calculated e-values to quantify the effect of unmeasured confounding on our results.
   Findings We identified 148 557 people with COPD and 818 490 people with asthma who were given relevant respiratory medications in the 4 months before the index date. People with COPD who were prescribed ICSs were at increased risk of COVID-19-related death compared with those prescribed LABA-LAMA combinations (adjusted HR 1.39 [95% CI 1.10-1.761). Compared with those prescribed SABAs only, people with asthma who were prescribed high-dose ICS were at an increased risk of death (1.55 [1.10-2.18]), whereas those given a low or medium dose were not (1.14 [0.85-1.54]). Sensitivity analyses showed that the apparent harmful association we observed could be explained by relatively small health differences between people prescribed ICS and those not prescribed ICS that were not recorded in the database (e value lower 95% CI 1.43).
   Interpretation Our results do not support a major role for regular ICS use in protecting against COVID-19-related death among people with asthma or COPD. Observed increased risks of COVID-19-related death can be plausibly explained by unmeasured confounding due to disease severity. Copyright (C) 2020 The Author(s). Published by Elsevier Ltd.
C1 [Schultze, Anna; Bhaskaran, Krishnan; Brown, Jeremy P.; Rentsch, Christopher T.; Williamson, Elizabeth; McDonald, Helen, I; Tomlinson, Laurie; Mathur, Rohini; Wing, Kevin; Wong, Angel Y. S.; Forbes, Harriet; Evans, Stephen J. W.; Smeeth, Liam; Douglas, Ian J.] London Sch Hyg & Trop Med, London, England.
   [Walker, Alex J.; MacKenna, Brian; Morton, Caroline E.; Drysdale, Henry; Croker, Richard; Bacon, Seb; Hulme, William; Curtis, Helen J.; Mehrkar, Amir; Evans, David; Inglesby, Peter; Goldacre, Ben] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, DataLab, Oxford OX2 6GG, England.
   [Bates, Chris; Cockburn, Jonathan; Parry, John; Hester, Frank; Harper, Sam] Phoenix Partnership TPP, TPP House, Leeds, W Yorkshire, England.
   [McDonald, Helen, I; Smeeth, Liam] NIHR Hlth Protect Res Unit Immunisat, London, England.
   [Quint, Jennifer] Imperial Coll London, Natl Heart & Lung Inst, London, England.
RP Goldacre, B (corresponding author), Univ Oxford, Nuffield Dept Primary Care Hlth Sci, DataLab, Oxford OX2 6GG, England.
EM ben.goldacre@phc.ox.ac.uk
RI ; Smeeth, Liam/X-5862-2018; Wing, Kevin/I-7807-2015
OI Quint, Jennifer/0000-0003-0149-4869; Evans, Stephen/0000-0002-1474-2596;
   Bhaskaran, Krishnan/0000-0001-5364-8757; Smeeth,
   Liam/0000-0002-9168-6022; Wing, Kevin/0000-0003-2335-9641; Rentsch,
   Christopher/0000-0002-1408-7907
FU UK Medical Research CouncilMedical Research Council UK (MRC)
   [MR/V015737/1]
FX We thank the TPP Technical Operations team for all their support
   throughout this work, and for generous assistance from the information
   governance and database teams at NHS England and NHSX. We also thank
   patient representatives from Asthma UK and the British Lung Foundation
   for their valuable comments on an early draft of this Article. This work
   was supported by the UK Medical Research Council (MR/V015737/1). TPP
   provided technical expertise and infrastructure within their data centre
   pro bono in the context of a national emergency. The views expressed are
   those of the authors and not necessarily those of the NIHR, NHS England,
   Public Health England, or the Department of Health and Social Care.
   Additional information on Information Governance and Technical Detail
   for OpenSAFELY is in the appendix (p 44).
CR Austin PC, 2016, CIRCULATION, V133, P601, DOI 10.1161/CIRCULATIONAHA.115.017719
   Bloom CI, 2019, AM J RESP CRIT CARE, V199, P446, DOI 10.1164/rccm.201808-1516OC
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2
   Crim C, 2009, EUR RESPIR J, V34, P641, DOI 10.1183/09031936.00193908
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Ernst P, 2007, AM J RESP CRIT CARE, V176, P162, DOI 10.1164/rccm.200611-1630OC
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hahn B, 2018, RESP MED, V139, P65, DOI 10.1016/j.rmed.2018.04.014
   Halpin DMG, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01009-2020
   Halpin DMG, 2020, LANCET RESP MED, V8, P436, DOI 10.1016/S2213-2600(20)30167-3
   Heffler E, 2020, ALLERGY, DOI 10.1111/all.14532
   Janson C, 2020, ADV THER, V37, P1124, DOI 10.1007/s12325-020-01233-0
   Lipworth BJ, 2020, BMJ
   Lund Jennifer L, 2015, Curr Epidemiol Rep, V2, P221
   MacKenna B., 2020, IMPACT COVID 19 PRES
   Matsuyama S., 2020, INHALED CORTICOSTERO, DOI [10.1101/2020.03.11.987016, DOI 10.1101/2020.03.11.987016]
   Nagar Saurabh, 2018, Manag Care, V27, P40
   National Health Service England, 2020, COR COVID 19 RES PLA
   National Institute for Health and Care Excellence, 2020, CORT INH
   National Institute for Health care and Excellence, 2019, CHRON OBSTR PULM DIS
   Nissen F, 2018, BRIT J GEN PRACT, V68, pE775, DOI 10.3399/bjgp18X699389
   OpenSAFELY Codelists, 2020, HIGH DOS ICS INH
   Quint JK, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005540
   Reilev Mette, 2020, Int J Epidemiol, V49, P1468, DOI 10.1093/ije/dyaa140
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rothnie KJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151357
   Simpson JL, 2016, CHEST, V149, P704, DOI 10.1016/j.chest.2015.12.018
   Singanayagam A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04574-1
   Soriano JB, 2017, LANCET RESP MED, V5, P691, DOI 10.1016/S2213-2600(17)30293-X
   Suissa S, 2013, THORAX, V68, P1029, DOI 10.1136/thoraxjnl-2012-202872
   UK Government, 2019, ENGL IND DEPR 2019 T
   VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16-2607
   WHO, 2020, EM US ICD COD COVID
   Williamson EJ, 2020, NATURE, DOI 10.1038/s41586-020-2521-4
   World Health Organization, 2020, GLOB STRAT DIET PHYS
   Wurst KE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105296
   Yamaya M, 2020, RESPIR INVESTIG, V58, P155, DOI 10.1016/j.resinv.2019.12.005
NR 39
TC 3
Z9 3
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2213-2600
J9 LANCET RESP MED
JI Lancet Resp. Med.
PD NOV
PY 2020
VL 8
IS 11
BP 1106
EP 1120
DI 10.1016/S2213-2600(20)30415-X
PG 15
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA OJ3ZE
UT WOS:000583902900022
PM 32979987
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Balkrishna, A
   Solleti, SK
   Verma, S
   Varshney, A
AF Balkrishna, Acharya
   Solleti, Siva Kumar
   Verma, Sudeep
   Varshney, Anurag
TI Application of Humanized Zebrafish Model in the Suppression of
   SARS-CoV-2 Spike Protein Induced Pathology by Tri-Herbal Medicine
   Coronil via Cytokine Modulation
SO MOLECULES
LA English
DT Article
DE humanized zebrafish; SARS-CoV-2 infection; anti-inflammatory; behavioral
   fever; swim bladder; Coronil; herbal medicine; Ayurveda
ID ACUTE RESPIRATORY SYNDROME; TRANSCRIPTION FACTORS; FUNCTIONAL RECEPTOR;
   EPITHELIAL-CELLS; IMMUNE-RESPONSE; CORONAVIRUS; INNATE; TISSUE; VIRUS;
   REPLICATION
AB Zebrafish has been a reliable model system for studying human viral pathologies. SARS-CoV-2 viral infection has become a global chaos, affecting millions of people. There is an urgent need to contain the pandemic and develop reliable therapies. We report the use of a humanized zebrafish model, xeno-transplanted with human lung epithelial cells, A549, for studying the protective effects of a tri-herbal medicine Coronil. At human relevant doses of 12 and 58 mu g/kg, Coronil inhibited SARS-CoV-2 spike protein, induced humanized zebrafish mortality, and rescued from behavioral fever. Morphological and cellular abnormalities along with granulocyte and macrophage accumulation in the swim bladder were restored to normal. Skin hemorrhage, renal cell degeneration, and necrosis were also significantly attenuated by Coronil treatment. Ultra-high-performance liquid chromatography (UHPLC) analysis identified ursolic acid, betulinic acid, withanone, withaferine A, withanoside IV-V, cordifolioside A, magnoflorine, rosmarinic acid, and palmatine as phyto-metabolites present in Coronil. In A549 cells, Coronil attenuated the IL-1 beta induced IL-6 and TNF-alpha cytokine secretions, and decreased TNF-alpha induced NF-kappa B/AP-1 transcriptional activity. Taken together, we show the disease modifying immunomodulatory properties of Coronil, at human equivalent doses, in rescuing the pathological features induced by the SARS-CoV-2 spike protein, suggesting its potential use in SARS-CoV-2 infectivity.
C1 [Balkrishna, Acharya; Solleti, Siva Kumar; Verma, Sudeep; Varshney, Anurag] Patanjali Res Inst, Drug Discovery & Dev Div, NH-58, Haridwar 249405, Uttarakhand, India.
   [Balkrishna, Acharya; Varshney, Anurag] Univ Patanjali, Dept Allied & Appl Sci, Roorkee Haridwar Rd, Haridwar 249405, Uttarakhand, India.
RP Varshney, A (corresponding author), Patanjali Res Inst, Drug Discovery & Dev Div, NH-58, Haridwar 249405, Uttarakhand, India.; Varshney, A (corresponding author), Univ Patanjali, Dept Allied & Appl Sci, Roorkee Haridwar Rd, Haridwar 249405, Uttarakhand, India.
EM pyp@divyayoga.com; siva.kumar@prft.co.in; sudeepverma@prft.co.in;
   anurag@prft.co.in
RI Varshney, Anurag/Y-6381-2019
OI Varshney, Anurag/0000-0001-8509-0882
FU Patanjali Research Foundation Trust, Hardwar, India
FX This research received no external funding. This presented work was
   conducted using internal research funds from the Patanjali Research
   Foundation Trust, Hardwar, India.
CR Balkrishna A, 2020, RES SQUARE, DOI [10.21203/rs.3.rs-17806/v1, DOI 10.21203/RS.3.RS-17806/V1]
   Balkrishna A, 2020, COMB CHEM HIGH THROU
   Balkrishna A, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10070971
   Barnes PJ, 2006, LAB INVEST, V86, P867, DOI 10.1038/labinvest.3700456
   Batlle D, 2020, J AM SOC NEPHROL, V31, P1380, DOI 10.1681/ASN.2020040419
   Benedetti C, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00423
   BETHEA JR, 1992, J CELL PHYSIOL, V152, P264, DOI 10.1002/jcp.1041520207
   Bhatia M, 2012, AM J RESP CELL MOL, V46, P566, DOI 10.1165/rcmb.2011-0392TR
   Boltana S, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.1381
   Borse S, 2020, RES SQUARE, DOI [10.21203/rs.3.rs-30361/v1, DOI 10.21203/RS.3.RS-30361/V1]
   Brocker Chad, 2010, Human Genomics, V5, P30
   CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666
   Carterson AJ, 2005, INFECT IMMUN, V73, P1129, DOI 10.1128/IAI.73.2.1129-1140.2005
   Chibber P, 2020, EUR J PHARMACOL, V883, DOI 10.1016/j.ejphar.2020.173372
   Chikhale RV, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1778539
   Chowdhury P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1803968
   Cohen Marc Maurice, 2014, J Ayurveda Integr Med, V5, P251, DOI 10.4103/0975-9476.146554
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Coperchini F, 2020, CYTOKINE GROWTH F R, V53, P25, DOI 10.1016/j.cytogfr.2020.05.003
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Ducharme NA, 2015, REPROD TOXICOL, V55, P3, DOI 10.1016/j.reprotox.2014.09.005
   Ernst E, 2010, FOCUS ALTERN COMPLEM, V8, P98
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Galindo-Villegas J, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00680
   Gomes MC, 2020, TRENDS MICROBIOL, V28, P10, DOI 10.1016/j.tim.2019.08.005
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Haga S, 2008, P NATL ACAD SCI USA, V105, P7809, DOI 10.1073/pnas.0711241105
   Haick AK, 2014, J GEN VIROL, V95, P578, DOI 10.1099/vir.0.061986-0
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hernandez-Rodas MC, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201700479
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153
   Illesca P, 2019, BIOMED PHARMACOTHER, V109, P2472, DOI 10.1016/j.biopha.2018.11.120
   Krupanidhi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1787226
   Kuba K, 2006, CURR OPIN PHARMACOL, V6, P271, DOI 10.1016/j.coph.2006.03.001
   Kumar A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1772112
   Kumar V, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.2020.1775704, 10.1080/07391102.2020.1772108]
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lee BH, 2017, J MICROBIOL, V55, P488, DOI 10.1007/s12275-017-7088-x
   Lee IS, 2018, IMMUNOPHARM IMMUNOT, V40, P83, DOI 10.1080/08923973.2017.1414836
   Levraud JP, 2014, TRENDS MICROBIOL, V22, P490, DOI 10.1016/j.tim.2014.04.014
   Li RF, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104761
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu JX, 2017, ANTIVIR RES, V144, P34, DOI 10.1016/j.antiviral.2017.04.010
   Mantovani A, 2011, NAT REV IMMUNOL, V11, P519, DOI 10.1038/nri3024
   Menter T, 2020, HISTOPATHOLOGY, V77, P198, DOI 10.1111/his.14134
   Miller M, 2009, J IMMUNOL, V182, P684, DOI 10.4049/jimmunol.182.1.684
   Moon Chang, 2020, Nat Rev Immunol, V20, P277, DOI 10.1038/s41577-020-0304-7
   Nagata N, 2008, AM J PATHOL, V172, P1625, DOI 10.2353/ajpath.2008.071060
   Panchabhai TS, 2008, PHYTOTHER RES, V22, P425, DOI 10.1002/ptr.2347
   Pattanayak Priyabrata, 2010, Pharmacogn Rev, V4, P95, DOI 10.4103/0973-7847.65323
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Phan VK, 2010, FITOTERAPIA, V81, P485, DOI 10.1016/j.fitote.2010.01.005
   Qamar Uddin, 2012, Journal of Applied Pharmaceutical Science, V2, P170
   Rastogi Sanjeev, 2020, J Ayurveda Integr Med, DOI 10.1016/j.jaim.2020.04.002
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Ren JL, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104743
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sepahi A, 2019, P NATL ACAD SCI USA, V116, P12428, DOI 10.1073/pnas.1900083116
   Sharma P, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/643847
   Sharma U, 2012, J ETHNOPHARMACOL, V141, P918, DOI 10.1016/j.jep.2012.03.027
   Shen WY, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01460-z
   Shin Jang-Woo, 2010, [Journal of Korean Medicine, 대한한의학회지], V31, P1
   Siu KL, 2014, CELL MOL IMMUNOL, V11, P141, DOI 10.1038/cmi.2013.61
   Takayama K, 2020, TRENDS PHARMACOL SCI, V41, P513, DOI 10.1016/j.tips.2020.05.005
   Tao L, METABOLIC CONTROL VI, DOI DOI 10.1101/731208V3.FULL
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Taylor KL, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-11
   Tohme MJ, 2019, INT J ANTIMICROB AG, V54, P601, DOI 10.1016/j.ijantimicag.2019.07.015
   Tripathi MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1790425
   Tsui PT, 2003, EMERG INFECT DIS, V9, P1064
   Varela M, 2017, ANTIVIR RES, V139, P59, DOI 10.1016/j.antiviral.2016.12.013
   Vyas Vivek K., 2011, Journal of Natural Remedies, V11, P1
   Wagner J, 2020, INT J LAB HEMATOL, V42, P761, DOI 10.1111/ijlh.13288
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yang L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00243-2
   Yao DC, 2009, FEBS J, V276, P2599, DOI 10.1111/j.1742-4658.2009.06988.x
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhao QW, 2020, INT J INFECT DIS, V96, P131, DOI 10.1016/j.ijid.2020.04.086
NR 82
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD NOV
PY 2020
VL 25
IS 21
AR 5091
DI 10.3390/molecules25215091
PG 25
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA OR2VI
UT WOS:000589332600001
PM 33147850
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gendrot, M
   Andreani, J
   Jardot, P
   Hutter, S
   Delandre, O
   Boxberger, M
   Mosnier, J
   Le Bideau, M
   Duflot, I
   Fonta, I
   Rolland, C
   Bogreau, H
   La Scola, B
   Pradines, B
AF Gendrot, Mathieu
   Andreani, Julien
   Jardot, Priscilla
   Hutter, Sebastien
   Delandre, Oceane
   Boxberger, Manon
   Mosnier, Joel
   Le Bideau, Marion
   Duflot, Isabelle
   Fonta, Isabelle
   Rolland, Clara
   Bogreau, Herve
   La Scola, Bernard
   Pradines, Bruno
TI In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2
SO MOLECULES
LA English
DT Article
DE COVID-19; SARS-CoV-2; doxycycline; treatment; prophylaxis; antiviral;
   anti-inflammatory
ID HYDROXYCHLOROQUINE; PHARMACOKINETICS; TETRACYCLINES
AB In December 2019, a new severe acute respiratory syndrome coronavirus (SARS-CoV-2), causing coronavirus disease 2019 (COVID-19), emerged in Wuhan, China. Despite containment measures, SARS-CoV-2 spread in Asia, Southern Europe, then in America and currently in Africa. Identifying effective antiviral drugs is urgently needed. An efficient approach to drug discovery is to evaluate whether existing approved drugs can be efficient against SARS-CoV-2. Doxycycline, which is a second-generation tetracycline with broad-spectrum antimicrobial, antimalarial and anti-inflammatory activities, showed in vitro activity on Vero E6 cells infected with a clinically isolated SARS-CoV-2 strain (IHUMI-3) with median effective concentration (EC50) of 4.5 +/- 2.9 mu M, compatible with oral uptake and intravenous administrations. Doxycycline interacted both on SARS-CoV-2 entry and in replication after virus entry. Besides its in vitro antiviral activity against SARS-CoV-2, doxycycline has anti-inflammatory effects by decreasing the expression of various pro-inflammatory cytokines and could prevent co-infections and superinfections due to broad-spectrum antimicrobial activity. Therefore, doxycycline could be a potential partner of COVID-19 therapies. However, these results must be taken with caution regarding the potential use in SARS-CoV-2-infected patients: it is difficult to translate in vitro study results to actual clinical treatment in patients. In vivo evaluation in animal experimental models is required to confirm the antiviral effects of doxycycline on SARS-CoV-2 and more trials of high-risk patients with moderate to severe COVID-19 infections must be initiated.
C1 [Gendrot, Mathieu; Delandre, Oceane; Mosnier, Joel; Fonta, Isabelle; Bogreau, Herve; Pradines, Bruno] Inst Rech Biomed Armees, Dept Microbiol & Malad Infect, Unite Parasitol & Entomol, F-13005 Marseille, France.
   [Gendrot, Mathieu; Hutter, Sebastien; Delandre, Oceane; Mosnier, Joel; Fonta, Isabelle; Bogreau, Herve; Pradines, Bruno] Aix Marseille Univ, AP HM, VITROME, SSA,IRD, F-13005 Marseille, France.
   [Gendrot, Mathieu; Andreani, Julien; Jardot, Priscilla; Hutter, Sebastien; Delandre, Oceane; Boxberger, Manon; Mosnier, Joel; Le Bideau, Marion; Duflot, Isabelle; Fonta, Isabelle; Rolland, Clara; Bogreau, Herve; La Scola, Bernard; Pradines, Bruno] IHU Mediterranee Infect, F-13005 Marseille, France.
   [Andreani, Julien; Jardot, Priscilla; Boxberger, Manon; Le Bideau, Marion; Duflot, Isabelle; Rolland, Clara; La Scola, Bernard] Aix Marseille Univ, AP HM, IRD, MEPHI, F-13005 Marseille, France.
   [Mosnier, Joel; Fonta, Isabelle; Bogreau, Herve; Pradines, Bruno] Ctr Natl Reference Paludisme, F-13005 Marseille, France.
RP Pradines, B (corresponding author), Inst Rech Biomed Armees, Dept Microbiol & Malad Infect, Unite Parasitol & Entomol, F-13005 Marseille, France.; Pradines, B (corresponding author), Aix Marseille Univ, AP HM, VITROME, SSA,IRD, F-13005 Marseille, France.; La Scola, B; Pradines, B (corresponding author), IHU Mediterranee Infect, F-13005 Marseille, France.; La Scola, B (corresponding author), Aix Marseille Univ, AP HM, IRD, MEPHI, F-13005 Marseille, France.; Pradines, B (corresponding author), Ctr Natl Reference Paludisme, F-13005 Marseille, France.
EM ma.gendrot@laposte.net; miaguiabidou@gmail.com;
   Priscilla.JARDOT@univ-amu.fr; sebastien.hutter@univ-amu.fr;
   o.delandre@gmail.com; manon.boxberger@hotmail.fr; joelmosnier@orange.fr;
   Marion.LE-BIDEAU@ap-hm.fr; isabelle.duflot@etu.univ-amu.fr;
   isabelle.fonta.09@gmail.com; rolland.clara@sfr.fr;
   hervebogreau@yahoo.fr; bernard.la-scola@univ-amu.fr;
   bruno.pradines@gmail.com
RI Gendrot, Mathieu/ABI-6205-2020; La Scola, Bernard/P-6477-2016
OI gendrot, mathieu/0000-0002-2322-5427; La Scola,
   Bernard/0000-0001-8006-7704
FU National Research Agency, program "Investissement d'avenir"French
   National Research Agency (ANR) [ANR-10-IAHU-03]; Institut
   Hospitalo-Universiare (IHU) Mediterranee Infection grant [COVID-19];
   L'Occitane Society
FX This research was funded by the National Research Agency, program
   "Investissement d'avenir"grant number ANR-10-IAHU-03" and Institut
   Hospitalo-Universiare (IHU) Mediterranee Infection grant number
   COVID-19. Manon Boxberger received e PhD grant supported by L'Occitane
   Society.
CR Abd-Elsalam S, 2020, AM J TROP MED HYG, V103, P1635, DOI 10.4269/ajtmh.20-0873
   Acharya Y, 2020, THER ADV INFECT DIS, V7, DOI 10.1177/2049936120947517
   Ahmad I, 2020, DOXYCYCLINE HYDROXYC, DOI [10.1101/2020.05.18.20066902, DOI 10.1101/2020.05.18.20066902]
   Alam MM, 2020, CUREUS, V12, DOI 10.7759/cureus.9658
   Amrane S, 2020, TRAVEL MED INFECT DI, V36, DOI 10.1016/j.tmaid.2020.101632
   Andreani J, 2020, MICROB PATHOGENESIS, V145, DOI 10.1016/j.micpath.2020.104228
   Arshad S, 2020, INT J INFECT DIS, V97, P396, DOI 10.1016/j.ijid.2020.06.099
   Beringer PM, 2012, ANTIMICROB AGENTS CH, V56, P70, DOI 10.1128/AAC.05710-11
   Bharadwaj S, 2020, LIFE SCI, V257, DOI 10.1016/j.lfs.2020.118080
   BLANCHARD P, 1975, CHEMOTHERAPY, V21, P8, DOI 10.1159/000221886
   Cairoli E, 2020, MED CLIN-BARCELONA, V155, P134, DOI 10.1016/j.medcli.2020.05.006
   Castro JEZ, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/370872
   Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014
   Cazalis J, 2008, J PERIODONTOL, V79, P1762, DOI [10.1902/jop.2008.080051, 10.1902/jop.2008.080051 ]
   Di Caprio R, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/329418
   Fan HH, 2020, CHINESE MED J-PEKING, V133, P1051, DOI [10.1097/CM9.0000000000000797, 10.1080/15384047.2020.1792218]
   Gaillard T, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0980-0
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Gendrot M, 2020, TRAVEL MED INFECT DI, V37, DOI 10.1016/j.tmaid.2020.101873
   Gengenbacher M, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.02479-19
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Gschwend MH, 2007, ARZNEIMITTEL-FORSCH, V57, P347
   Hong KS, 2020, INFECT CHEMOTHER, V52, P396, DOI 10.3947/ic.2020.52.3.396
   Krakauer T, 2003, ANTIMICROB AGENTS CH, V47, P3630, DOI 10.1128/AAC.47.11.3630-3633.2003
   Lagier JC, 2020, TRAVEL MED INFECT DI, V36, DOI 10.1016/j.tmaid.2020.101791
   Lago K, 2020, AM J TROP MED HYG, V102, P821, DOI 10.4269/ajtmh.19-0648
   Li YM, 2017, FEMS MICROBIOL LETT, V364, DOI 10.1093/femsle/fnx170
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lopez A, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106136
   Maisonnasse P, 2020, NATURE, V585, P584, DOI 10.1038/s41586-020-2558-4
   Malek AE, 2020, IDCases, V21, DOI 10.1016/j.idcr.2020.e00864
   Marra F, 2017, J AM MED DIR ASSOC, V18, DOI 10.1016/j.jamda.2017.09.018
   Mazzini S, 2020, MOLECULES, V25, DOI 10.3390/molecules25163745
   Michalopoulos A, 1973, Curr Med Res Opin, V1, P445, DOI 10.1185/03007997309111706
   Million M, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101738
   Mitja Oriol, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1009
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Paccoud Olivier, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa791
   Patel A, 2020, INFLAMMATION, V43, P1035, DOI 10.1007/s10753-020-01188-y
   Pizzorno A, 2020, ANTIVIR RES, V181, DOI 10.1016/j.antiviral.2020.104878
   Plouffe JF, 2000, CLIN INFECT DIS, V31, pS35, DOI 10.1086/314058
   Rana A, 2020, BRAIN INJURY, V34, P1039, DOI 10.1080/02699052.2020.1772508
   Rempe S., 2007, Endocrine Metabolic & Immune Disorders-Drug Targets, V7, P232, DOI 10.2174/187153007782794344
   Rothan HA, 2013, TROP BIOMED, V30, P681
   Rothan HA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126360
   Rothan HA, 2014, ARCH VIROL, V159, P711, DOI 10.1007/s00705-013-1880-7
   Sachdeva C, 2020, OMICS, V24, P568, DOI 10.1089/omi.2020.0071
   Sencanski M, 2020, MOLECULES, V25, DOI 10.3390/molecules25173830
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Sharifi A, 2017, COMPUT BIOL CHEM, V70, P1, DOI 10.1016/j.compbiolchem.2017.06.003
   Singh B, 2019, PULM PHARMACOL THER, V58, DOI 10.1016/j.pupt.2019.101831
   Touret F, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70143-6
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   WELLING PG, 1977, ANTIMICROB AGENTS CH, V11, P462, DOI 10.1128/AAC.11.3.462
   Weston S, 2020, J VIROL, V94, DOI 10.1128/JVI.01218-20
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu ZC, 2015, FEMS MICROBIOL LETT, V362, DOI 10.1093/femsle/fnv195
   Xue HY, 2020, J MED VIROL, V92, P2523, DOI 10.1002/jmv.26193
   Yang JM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000428
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Ziebuhr J, 2005, CURR TOP MICROBIOL, V287, P57, DOI 10.1007/3-540-26765-4_3
NR 63
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD NOV
PY 2020
VL 25
IS 21
AR 5064
DI 10.3390/molecules25215064
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA OR1IK
UT WOS:000589229700001
PM 33142770
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kishk, SM
   Kishk, RM
   Yassen, ASA
   Nafie, MS
   Nemr, NA
   ElMasry, G
   Al-Rejaie, S
   Simons, C
AF Kishk, Safaa M.
   Kishk, Rania M.
   Yassen, Asmaa S. A.
   Nafie, Mohamed S.
   Nemr, Nader A.
   ElMasry, Gamal
   Al-Rejaie, Salim
   Simons, Claire
TI Molecular Insights into Human Transmembrane Protease Serine-2 (TMPS2)
   Inhibitors against SARS-CoV2: Homology Modelling, Molecular Dynamics,
   and Docking Studies
SO MOLECULES
LA English
DT Article
DE TMPS2; SARS-CoV2; homology model; molecular dynamics
ID ANGIOTENSIN-CONVERTING ENZYME-2; CORONAVIRUS; NAFAMOSTAT;
   IDENTIFICATION; RECEPTOR; SPIKE
AB The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), which caused novel corona virus disease-2019 (COVID-19) pandemic, necessitated a global demand for studies related to genes and enzymes of SARS-CoV2. SARS-CoV2 infection depends on the host cell Angiotensin-Converting Enzyme-2 (ACE2) and Transmembrane Serine Protease-2 (TMPRSS2), where the virus uses ACE2 for entry and TMPRSS2 for S protein priming. The TMPRSS2 gene encodes a Transmembrane Protease Serine-2 protein (TMPS2) that belongs to the serine protease family. There is no crystal structure available for TMPS2, therefore, a homology model was required to establish a putative 3D structure for the enzyme. A homology model was constructed using SWISS-MODEL and evaluations were performed through Ramachandran plots, Verify 3D and Protein Statistical Analysis (ProSA). Molecular dynamics simulations were employed to investigate the stability of the constructed model. Docking of TMPS2 inhibitors, camostat, nafamostat, gabexate, and sivelestat, using Molecular Operating Environment (MOE) software, into the constructed model was performed and the protein-ligand complexes were subjected to MD simulations and computational binding affinity calculations. These in silico studies determined the tertiary structure of TMPS2 amino acid sequence and predicted how ligands bind to the model, which is important for drug development for the prevention and treatment of COVID-19.
C1 [Kishk, Safaa M.] Suez Canal Univ, Fac Pharm, Pharmaceut Med Chem Dept, Ismailia 41522, Egypt.
   [Kishk, Rania M.] Suez Canal Univ, Fac Med, Microbiol & Immunol Dept, Ismailia 41522, Egypt.
   [Yassen, Asmaa S. A.] Suez Canal Univ, Fac Pharm, Pharmaceut Organ Chem Dept, Ismailia 41522, Egypt.
   [Nafie, Mohamed S.] Suez Canal Univ, Fac Sci, Chem Dept, Ismailia 41522, Egypt.
   [Nemr, Nader A.] Suez Canal Univ, Fac Med, Endem & Infect Dis Dept, Ismailia 41522, Egypt.
   [ElMasry, Gamal] Suez Canal Univ, Fac Agr, Ismailia 41522, Egypt.
   [ElMasry, Gamal; Al-Rejaie, Salim] King Saud Univ, Coll Pharm, Dept Pharmacol & Toxicol, Riyadh 11564, Saudi Arabia.
   [Simons, Claire] Cardiff Univ, Sch Pharm & Pharmaceut Sci, King Edward VII Ave, Cardiff CF10 3NB, Wales.
RP Kishk, SM (corresponding author), Suez Canal Univ, Fac Pharm, Pharmaceut Med Chem Dept, Ismailia 41522, Egypt.
EM safaa_keshk@pharm.suez.edu.eg; raniakishk@med.suez.edu.eg;
   asmaa_yaseeen@pharm.suez.edu.eg; Mohamed_nafie@science.suez.edu.eg;
   nadernemr@med.suez.edu.eg; gamal.elmasry@agr.suez.edu.eg;
   rejaie@ksu.edu.sa; simonsc@cardiff.ac.uk
RI ; Simons, Claire/N-5788-2014
OI Nafie, Mohamed S./0000-0003-4454-6390; Kishk, Safaa/0000-0001-5822-0581;
   Simons, Claire/0000-0002-9487-1100; Yassen, Asmaa/0000-0002-7956-9739;
   ElMasry, Gamal/0000-0001-6586-1950; Kishk, Rania/0000-0002-8235-3103
FU King Saud University, Riyadh, Saudi ArabiaKing Saud University
   [RSP-2020/120]
FX The authors extend their appreciation to the Researchers Supporting
   Project Number (RSP-2020/120) King Saud University, Riyadh, Saudi Arabia
   for financial support.
CR [Anonymous], 2019, CHEM COMPUTING
   Barile E, 2020, MOLECULES, V25, DOI 10.3390/molecules25102424
   Binjubair FA, 2020, CHEMMEDCHEM, V15, P1294, DOI 10.1002/cmdc.202000250
   Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421
   Chang JH, 2009, GUT LIVER, V3, P205, DOI 10.5009/gnl.2009.3.3.205
   Di Paola L, 2020, J PROTEOME RES, V19, P4576, DOI 10.1021/acs.jproteome.0c00273
   Dong MZ, 2020, BIOMED PHARMACOTHER, V131, DOI 10.1016/j.biopha.2020.110678
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Eleftheriou P, 2020, MOLECULES, V25, DOI 10.3390/molecules25112529
   EMBL-EBI, SEARCH SEQUENCE ANAL
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Gorbalenya AE, 2006, VIRUS RES, V117, P17, DOI 10.1016/j.virusres.2006.01.017
   Han Sung Joon, 2018, Korean J Thorac Cardiovasc Surg, V51, P114, DOI 10.5090/kjtcs.2018.51.2.114
   Hempel T, 2020, MOL MECH SARS COV 2, DOI [10.1101/2020.07.21.214098, DOI 10.1101/2020.07.21.214098]
   Hofmann H, 2005, P NATL ACAD SCI USA, V102, P7988, DOI 10.1073/pnas.0409465102
   Hou TJ, 2011, J CHEM INF MODEL, V51, P69, DOI 10.1021/ci100275a
   Hu D, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0155-5
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Jang S, 2020, INT J INFECT DIS, V96, P500, DOI 10.1016/j.ijid.2020.05.072
   Kalra RS, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9070546
   Kawase M, 2012, J VIROL, V86, P6537, DOI 10.1128/JVI.00094-12
   Kim HS, 2016, KIDNEY RES CLIN PRAC, V35, P187, DOI 10.1016/j.krcp.2015.10.003
   Lewicki DN, 2002, J BIOL CHEM, V277, P19727, DOI 10.1074/jbc.M201837200
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lin CC, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/879326
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10
   MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407
   SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X
   Shi M, 2016, NATURE, V540, P539, DOI 10.1038/nature20167
   Shirato K., 2020, J VIROL, V517, P9, DOI [10.1016/j.virol.2017.11.012, DOI 10.1016/J.VIROL.2017.11.01229217279]
   Shulla A, 2011, J VIROL, V85, P873, DOI 10.1128/JVI.02062-10
   Strope JD, 2020, J CLIN PHARMACOL, V60, P801, DOI 10.1002/jcph.1641
   Williams CJ, 2018, PROTEIN SCI, V27, P293, DOI 10.1002/pro.3330
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yamamoto M, 2016, ANTIMICROB AGENTS CH, V60, P6532, DOI 10.1128/AAC.01043-16
   Yamaya M, 2015, PULM PHARMACOL THER, V33, P66, DOI 10.1016/j.pupt.2015.07.001
   Yushun W, 2020, STUDIES J VIROL, V94, P1
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
   Zirkel F, 2011, MBIO, V2, DOI 10.1128/mBio.00077-11
NR 42
TC 0
Z9 0
U1 3
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD NOV
PY 2020
VL 25
IS 21
AR 5007
DI 10.3390/molecules25215007
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA OR2QG
UT WOS:000589319000001
PM 33137894
OA DOAJ Gold, Green Published, Green Accepted
DA 2021-01-01
ER

PT J
AU Tejera, E
   Munteanu, CR
   Lopez-Cortes, A
   Cabrera-Andrade, A
   Perez-Castillo, Y
AF Tejera, Eduardo
   Munteanu, Cristian R.
   Lopez-Cortes, Andres
   Cabrera-Andrade, Alejandro
   Perez-Castillo, Yunierkis
TI Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for
   Possible Inhibitors of the SARS-CoV-2 M-pro Protease
SO MOLECULES
LA English
DT Article
DE SARS-CoV-2; COVID-19; QSAR; drugs repurposing; molecular dynamics
ID CORONAVIRUS; SARS; VALIDATION; ALGORITHM; DESIGN; ACE2
AB Wuhan, China was the epicenter of the first zoonotic transmission of the severe acute respiratory syndrome coronavirus clade 2 (SARS-CoV-2) in December 2019 and it is the causative agent of the novel human coronavirus disease 2019 (COVID-19). Almost from the beginning of the COVID-19 outbreak several attempts were made to predict possible drugs capable of inhibiting the virus replication. In the present work a drug repurposing study is performed to identify potential SARS-CoV-2 protease inhibitors. We created a Quantitative Structure-Activity Relationship (QSAR) model based on a machine learning strategy using hundreds of inhibitor molecules of the main protease (M-pro) of the SARS-CoV coronavirus. The QSAR model was used for virtual screening of a large list of drugs from the DrugBank database. The best 20 candidates were then evaluated in-silico against the M-pro of SARS-CoV-2 by using docking and molecular dynamics analyses. Docking was done by using the Gold software, and the free energies of binding were predicted with the MM-PBSA method as implemented in AMBER. Our results indicate that levothyroxine, amobarbital and ABP-700 are the best potential inhibitors of the SARS-CoV-2 virus through their binding to the M-pro enzyme. Five other compounds showed also a negative but small free energy of binding: nikethamide, nifurtimox, rebimastat, apomine and rebastinib.
C1 [Tejera, Eduardo; Cabrera-Andrade, Alejandro; Perez-Castillo, Yunierkis] Univ Amer, Grp Bioquimioinformat, Quito 170513, Ecuador.
   [Tejera, Eduardo] Univ Amer, Fac Ingn & Ciencias Aplicadas, Quito 170513, Ecuador.
   [Munteanu, Cristian R.] Univ A Coruna, Fac Comp Sci, Ctr Informat & Commun Technol Res CITIC, La Coruna 15007, Spain.
   [Munteanu, Cristian R.] Univ Hosp Complex A Coruna CHUAC, Biomed Res Inst A Coruna INIBIC, La Coruna 15006, Spain.
   [Lopez-Cortes, Andres] Univ UTE, Fac Ciencias Salud Eugenio Espejo, Ctr Invest Genet & Genom, Quito 170129, Ecuador.
   [Lopez-Cortes, Andres] Latin Amer Network Implementat & Validat Clin Pha, Madrid 28029, Spain.
   [Cabrera-Andrade, Alejandro] Univ Amer, Fac Ciencias Salud, Carrera Enfermeria, Quito 170513, Ecuador.
   [Perez-Castillo, Yunierkis] Univ Amer, Escuela Ciencias Fis & Matemat, Quito 170513, Ecuador.
RP Tejera, E (corresponding author), Univ Amer, Grp Bioquimioinformat, Quito 170513, Ecuador.; Tejera, E (corresponding author), Univ Amer, Fac Ingn & Ciencias Aplicadas, Quito 170513, Ecuador.; Munteanu, CR (corresponding author), Univ A Coruna, Fac Comp Sci, Ctr Informat & Commun Technol Res CITIC, La Coruna 15007, Spain.; Munteanu, CR (corresponding author), Univ Hosp Complex A Coruna CHUAC, Biomed Res Inst A Coruna INIBIC, La Coruna 15006, Spain.
EM eduardo.tejera@udla.edu.ec; c.munteanu@udc.es; aalc84@gmail.com;
   raul.cabrera@udla.edu.ec; yunierkis.perez@udla.edu.ec
RI Lopez-Cortes, Andres/ABG-3700-2020
OI Lopez-Cortes, Andres/0000-0003-1503-1929
FU Universidad de LasAmericas, Quito, Ecuador [BIO.TPA.20.03];
   Collaborative Project in Genomic Data Integration (CICLOGEN) - Carlos
   III Health Institute from the Spanish National plan for Scientific and
   Technical Research and Innovation 2013-2016 [PI17/01826]; European
   Regional Development Funds (FEDER)-"A way to build Europe"European Union
   (EU); Consolidation and Structuring of Competitive Research
   Units-Competitive Reference Groups - Ministry of Education, University
   and Vocational Training of the Xunta de Galicia [ED431C 2018/49]; EU
   FEDER fundsEuropean Union (EU); Universidad de Las Americas, Quito,
   Ecuador
FX This research was funded by Universidad de LasAmericas, Quito, Ecuador,
   grant number BIO.TPA.20.03, the Collaborative Project in Genomic Data
   Integration (CICLOGEN) PI17/01826 funded by the Carlos III Health
   Institute from the Spanish National plan for Scientific and Technical
   Research and Innovation 2013-2016, the European Regional Development
   Funds (FEDER)-"A way to build Europe", the Consolidation and Structuring
   of Competitive Research Units-Competitive Reference Groups (ED431C
   2018/49), funded by the Ministry of Education, University and Vocational
   Training of the Xunta de Galicia endowed with EU FEDER funds. The APC
   was funded by the Universidad de Las Americas, Quito, Ecuador.
CR Ahmad J, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e04502
   Altay O, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101303
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Bellera CL, 2014, SCI WORLD J, DOI 10.1155/2014/279618
   Cao YN, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0147-1
   Case D.A, 2018, AMBER 2018 REFERENCE
   Cournia Z, 2020, J CHEM INF MODEL, V60, P4153, DOI 10.1021/acs.jcim.0c00116
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Davis J., 2006, P 23 INT C MACH LEAR, V23, P233, DOI DOI 10.1145/1143844.1143874
   Do Av Sa L.G., 2019, FUTURE MICROBIOL, V14, P1477, DOI [10.2217/fmb-2019-0075, DOI 10.2217/FMB-2019-0075]
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Durdagi S., 2020, SCREENING CLIN APPRO, DOI [10.26434/chemrxiv.12032712.v2., DOI 10.26434/CHEMRXIV.12032712.V2]
   Duvenaud C, 2015, NEURAL INFORM PROCES
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Eleftheriou P, 2020, MOLECULES, V25, DOI 10.3390/molecules25112529
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Gurung AB, 2020, LIFE SCI, V255, DOI 10.1016/j.lfs.2020.117831
   Guy RK, 2020, SCIENCE, V368, P829, DOI 10.1126/science.abb9332
   Gysi D.M, ARXIV20040722
   Hastie T., 2009, SPRINGER SERIES STAT
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jin ZM, 2020, NAT STRUCT MOL BIOL, V27, P529, DOI 10.1038/s41594-020-0440-6
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kim M, 2020, RES SQ, DOI [10.21203/RS.3.RS-21849/V1, DOI 10.21203/RS.3.RS-21849/V1]
   Kumar Y, 2020, J INFECT PUBLIC HEAL, V13, P1210, DOI 10.1016/j.jiph.2020.06.016
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Lopes SP, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235916
   Lopez-Cortes A., 2020, SILICO ANAL IMMUNE S, DOI [10.26434/CHEMRXIV.12408074.V1, DOI 10.26434/CHEMRXIV.12408074.V1]
   Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h
   Nukoolkarn V, 2008, J THEOR BIOL, V254, P861, DOI 10.1016/j.jtbi.2008.07.030
   Oberfeld B, 2020, CELL, V181, P954, DOI 10.1016/j.cell.2020.04.013
   Ortiz-Prado E, 2020, DIAGN MICR INFEC DIS, V98, DOI 10.1016/j.diagmicrobio.2020.115094
   Perez-Castillo Y, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/6345429
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pizzorno A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00060
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Sangjae S, 2020, SUPERCOMPUTER AIDED, P2, DOI [10.26434/chemrxiv.12101457.v1, DOI 10.26434/CHEMRXIV.12101457.V1]
   Sugandh K., 2020, IDENTIFICATION DRUGS, DOI [10.26434/chemrxiv.12366938.v1, DOI 10.26434/CHEMRXIV.12366938.V1]
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Tsuji M, 2020, FEBS OPEN BIO, V10, P995, DOI 10.1002/2211-5463.12875
   Turkez H, 2019, MOLECULES, V24, DOI 10.3390/molecules24132411
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhao Qi, 2013, Recent Pat Antiinfect Drug Discov, V8, P150
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
NR 60
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD NOV
PY 2020
VL 25
IS 21
AR 5172
DI 10.3390/molecules25215172
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA OR1MM
UT WOS:000589240300001
PM 33172092
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dionne, A
   Mah, DY
   Son, MBF
   Lee, PY
   Henderson, L
   Baker, AL
   de Ferranti, SD
   Fulton, DR
   Newburger, JW
   Friedman, KG
AF Dionne, Audrey
   Mah, Douglas Y.
   Son, Mary Beth F.
   Lee, Pui Y.
   Henderson, Lauren
   Baker, Annette L.
   de Ferranti, Sarah D.
   Fulton, David R.
   Newburger, Jane W.
   Friedman, Kevin G.
TI Atrioventricular Block in Children With Multisystem Inflammatory
   Syndrome
SO PEDIATRICS
LA English
DT Article
ID KAWASAKI-DISEASE; MANAGEMENT; STATEMENT; DIAGNOSIS; THERAPY; SOCIETY
AB BACKGROUND: Children are at risk for multisystem inflammatory syndrome in children (MIS-C) after infection with severe acute respiratory syndrome coronavirus 2. Cardiovascular complications, including ventricular dysfunction and coronary dilation, are frequent, but there are limited data on arrhythmic complications. METHODS: Retrospective cohort study of children and young adults aged <= 21 years admitted with MIS-C. Demographic characteristics, electrocardiogram (ECG) and echocardiogram findings, and hospital course were described. RESULTS: Among 25 patients admitted with MIS-C (60% male; median age 9.7 [interquartile range 2.7-15.0] years), ECG anomalies were found in 14 (56%). First-degree atrioventricular block (AVB) was seen in 5 (20%) patients a median of 6 (interquartile range 5-8) days after onset of fever and progressed to second- or third-degree AVB in 4 patients. No patient required intervention for AVB. All patients with AVB were admitted to the ICU (before onset of AVB) and had ventricular dysfunction on echocardiograms. All patients with second- or third-degree AVB had elevated brain natriuretic peptide levels, whereas the patient with first-degree AVB had a normal brain natriuretic peptide level. No patient with AVB had an elevated troponin level. QTc prolongation was seen in 7 patients (28%), and nonspecific ST segment changes were seen in 14 patients (56%). Ectopic atrial tachycardia was observed in 1 patient, and none developed ventricular arrhythmias. CONCLUSIONS: Children with MIS-C are at risk for atrioventricular conduction disease, especially those who require ICU admission and have ventricular dysfunction. ECGs should be monitored for evidence of PR prolongation. Continuous telemetry may be required in patients with evidence of first-degree AVB because of risk of progression to high-grade AVB.
   In this study, we describe the incidence of AVB in children with MIS-C.
C1 [Son, Mary Beth F.; Lee, Pui Y.; Henderson, Lauren] Boston Childrens Hosp, Div Immunol, Boston, MA USA.
   [Dionne, Audrey; Mah, Douglas Y.; Baker, Annette L.; de Ferranti, Sarah D.; Fulton, David R.; Newburger, Jane W.; Friedman, Kevin G.] Boston Childrens Hosp, Dept Cardiol, 300 Longwood Ave, Boston, MA 02115 USA.
   [Dionne, Audrey; Mah, Douglas Y.; Son, Mary Beth F.; Lee, Pui Y.; Henderson, Lauren; Baker, Annette L.; de Ferranti, Sarah D.; Fulton, David R.; Newburger, Jane W.; Friedman, Kevin G.] Harvard Univ, Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA.
RP Dionne, A (corresponding author), Boston Childrens Hosp, Dept Cardiol, 300 Longwood Ave, Boston, MA 02115 USA.
EM audrey.dionne@cardio.chboston.org
CR Azarkish M, 2020, EUR HEART J, V41, P2131, DOI 10.1093/eurheartj/ehaa307
   Belhadjer Z, 2020, CIRCULATION, V142, P429, DOI 10.1161/CIRCULATIONAHA.120.048360
   Caforio ALP, 2013, EUR HEART J, V34, P2636, DOI 10.1093/eurheartj/eht210
   Centers for Disease Control and Prevention, 2020, MULT INFL SYNDR CHIL
   CIESIELSKI CA, 1989, REV INFECT DIS, V11, pS1435
   Creel-Bulos C, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2010459
   El-Assaad Iqbal, 2020, JACC Case Rep, V2, P1351, DOI 10.1016/j.jaccas.2020.05.023
   Lakkireddy DR, 2020, CIRCULATION, V141, pE823, DOI 10.1161/CIRCULATIONAHA.120.047063
   Liu WY, 2020, NEW ENGL J MED, V382, P1370, DOI 10.1056/NEJMc2003717
   MCALISTER HF, 1989, ANN INTERN MED, V110, P339, DOI 10.7326/0003-4819-110-5-339
   McCrindle BW, 2007, CIRCULATION, V116, P174, DOI 10.1161/CIRCULATIONAHA.107.690875
   McCrindle BW, 2017, CIRCULATION, V135, pE927, DOI 10.1161/CIR.0000000000000484
   Mehra MR, 2020, NEW ENGL J MED, V382, P2582, DOI 10.1056/NEJMc2021225
   Miyake CY, 2014, AM J CARDIOL, V113, P535, DOI 10.1016/j.amjcard.2013.10.021
   Rijnbeek PR, 2001, EUR HEART J, V22, P702, DOI 10.1053/euhj.2000.2399
   Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   STEERE AC, 1980, ANN INTERN MED, V93, P1, DOI 10.7326/0003-4819-93-1-1
   Tersalvi G, 2020, J CARD FAIL, V26, P470, DOI 10.1016/j.cardfail.2020.04.009
   VANDERLINDE MR, 1991, SCAND J INFECT DIS, P81
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wormser GP, 2006, CLIN INFECT DIS, V43, P1089, DOI 10.1086/508667
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
NR 25
TC 0
Z9 0
U1 0
U2 0
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD NOV
PY 2020
VL 146
IS 5
AR e2020009704
DI 10.1542/peds.2020-009704
PG 7
WC Pediatrics
SC Pediatrics
GA OR7AT
UT WOS:000589620500043
PM 32855347
OA Bronze
DA 2021-01-01
ER

PT J
AU House, SA
   Shubkin, CD
   Lahey, T
   Brosco, JP
   Lantos, J
AF House, Samantha A.
   Shubkin, Catherine D.
   Lahey, Tim
   Brosco, Jeffrey P.
   Lantos, John
TI COVID-19 Trial Enrollment for Those Who Cannot Consent: Ethical
   Challenges Posed by a Pandemic
SO PEDIATRICS
LA English
DT Article
AB In this article, we provide a discussion surrounding the ethical implications of clinical trial enrollment for a child with neurocognitive impairment in state custody.
   The current coronavirus disease 2019 (COVID-19) pandemic has triggered an intense global research effort to inform the life-saving work of frontline clinicians who need reliable information as soon as possible. Yet research done in pressured circumstances can lead to ethical dilemmas, especially for vulnerable research subjects. We present the case of a child with neurocognitive impairment who is diagnosed with COVID-19 infection after presenting with fever and a seizure. The child lives in a group home and is in the custody of the state; her parents lost parental rights many years ago. Some members of the health care team want to enroll her in a randomized clinical trial evaluating an experimental treatment of COVID-19. For minor patients to enroll in this clinical trial, the institutional review board requires assent of patients and consent of guardians. An ethics consult is called to help identify relevant concerns in enrollment. In the accompanying case discussion, we address historical perspectives on research involving people with disabilities; proper management of research participation for people with disabilities including consent by proxy, therapeutic misconception, and other threats to the ethical validity of clinical trials; and the potentially conflicting obligations of researchers and clinicians.
C1 [House, Samantha A.; Shubkin, Catherine D.] Dartmouth Coll, Dept Pediat, Geisel Sch Med Dartmouth, Hanover, NH 03755 USA.
   [House, Samantha A.; Shubkin, Catherine D.] Dartmouth Hitchcock Med Ctr, Dept Pediat, Childrens Hosp, 1 Med Ctr Dr, Lebanon, NH 03756 USA.
   [Lahey, Tim] Univ Vermont, Div Infect Dis, Larner Coll Med, Burlington, VT USA.
   [Lahey, Tim] Univ Vermont, Med Ctr, Burlington, VT USA.
   [Brosco, Jeffrey P.] Univ Miami, Miller Sch Med, Inst Bioeth & Hlth Policy, Miami, FL 33136 USA.
   [Lantos, John] Childrens Mercy Hosp, Bioeth Ctr, Kansas City, MO 64108 USA.
RP House, SA (corresponding author), Dartmouth Hitchcock Med Ctr, Dept Pediat, Childrens Hosp, 1 Med Ctr Dr, Lebanon, NH 03756 USA.
EM samantha.a.house@hitchcock.org
CR Arons MM, 2020, NEW ENGL J MED, V382, P2081, DOI 10.1056/NEJMoa2008457
   Bero L, 2017, JAMA-J AM MED ASSOC, V317, P1723, DOI 10.1001/jama.2017.3854
   Feudtner C, 2011, DEV DISABIL RES REV, V17, P52, DOI 10.1002/ddrr.139
   FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304
   KRUGMAN S, 1958, PEDIATRICS, V22, P1016
   Shekerdemian LS, 2020, JAMA PEDIATR, V174, P868, DOI 10.1001/jamapediatrics.2020.1948
   Wilson MC, 2014, RES DEV DISABIL, V35, P294, DOI 10.1016/j.ridd.2013.11.003
NR 7
TC 0
Z9 0
U1 0
U2 0
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD NOV
PY 2020
VL 146
IS 5
AR e2020010728
DI 10.1542/peds.2020-010728
PG 5
WC Pediatrics
SC Pediatrics
GA OR7AT
UT WOS:000589620500022
PM 33028661
DA 2021-01-01
ER

PT J
AU Gonzalez, R
   Curtis, K
   Bivins, A
   Bibby, K
   Weir, MH
   Yetka, K
   Thompson, H
   Keeling, D
   Mitchell, J
   Gonzalez, D
AF Gonzalez, Raul
   Curtis, Kyle
   Bivins, Aaron
   Bibby, Kyle
   Weir, Mark H.
   Yetka, Kathleen
   Thompson, Hannah
   Keeling, David
   Mitchell, Jamie
   Gonzalez, Dana
TI COVID-19 surveillance in Southeastern Virginia using wastewater-based
   epidemiology
SO WATER RESEARCH
LA English
DT Article
DE Wastewater-based epidemiology; COVID-19; SARS-CoV-2; RT-ddPCR
ID VIRUSES
AB Wastewater-based epidemiology (WBE) has been used to analyze markers in wastewater treatment plant (WWTP) influent to characterize emerging chemicals, drug use patterns, or disease spread within com-munities. This approach can be particularly helpful in understanding outbreaks of disease like the novel Coronavirus disease-19 (COVID-19) when combined with clinical datasets. In this study, three RT-ddPCR assays (N1, N2, N3) were used to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in weekly samples from nine WWTPs in southeastern Virginia. In the first several weeks of sampling, SARS-CoV-2 detections were sporadic. Frequency of detections and overall concentrations of RNA within samples increased from mid March into late July. During the twenty-one week study, SARS-CoV-2 concentrations ranged from 10(1) to 10(4) copies 100 mL(-1) in samples where viral RNA was detected. Fluctuations in population normalized loading rates in several of the WWTP service areas agreed with known outbreaks during the study. Here we propose several ways that data can be presented spatially and temporally to be of greatest use to public health officials. As the COVID-19 pandemic wanes, it is likely that communities will see increased incidence of small, localized outbreaks. In these instances, WBE could be used as a pre-screening tool to better target clinical testing needs in communities with limited resources. (c) 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
C1 [Gonzalez, Raul; Curtis, Kyle; Yetka, Kathleen; Thompson, Hannah; Keeling, David; Mitchell, Jamie; Gonzalez, Dana] Hampton Roads Sanitat Dist, 1434 Air Rail Ave, Virginia Beach, VA 23455 USA.
   [Bivins, Aaron; Bibby, Kyle] Univ Notre Dame, Civil & Environm Engn & Earth Sci, 156 Fitzpatrick Hall, Notre Dame, IN 46556 USA.
   [Weir, Mark H.] Ohio State Univ, Div Environm Hlth Sci, Coll Publ Hlth, 1841 Neil Ave, Columbus, OH 43210 USA.
RP Gonzalez, R (corresponding author), Hampton Roads Sanitat Dist, 1434 Air Rail Ave, Virginia Beach, VA 23455 USA.
EM rgonzalez@hrsd.com
RI Bibby, Kyle/C-6189-2018
OI Bibby, Kyle/0000-0003-3142-6090; Gonzalez, Raul/0000-0002-8115-7709
FU Hampton Roads Sanitation District; National Science FoundationNational
   Science Foundation (NSF) [2027752]
FX This work was supported by Hampton Roads Sanitation District and the
   National Science Foundation award 2027752.
CR Ahmed W, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138764
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Baz-Lomba JA, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3686-5
   Bisseux M, 2018, EUROSURVEILLANCE, V23, P16, DOI 10.2807/1560-7917.ES.2018.23.7.17-00237
   Bivins A., 2020, WASTEWATER BASED EPI
   Brouwer AF, 2018, P NATL ACAD SCI USA, V115, pE10625, DOI 10.1073/pnas.1808798115
   Cai JH, 2020, CLIN INFECT DIS, V71, P1547, DOI 10.1093/cid/ciaa198
   Causanilles A, 2017, SCI TOTAL ENVIRON, V599, P98, DOI 10.1016/j.scitotenv.2017.04.202
   Centers for Disease Control and Prevention, 2020, EV TEST PERS COR DIS
   Choi PM, 2018, TRAC-TREND ANAL CHEM, V105, P453, DOI 10.1016/j.trac.2018.06.004
   Gerrity D., 2020, IMPLICATIONS COVID 1
   Hellmer M, 2014, APPL ENVIRON MICROB, V80, P6771, DOI 10.1128/AEM.01981-14
   Hovi T, 2012, EPIDEMIOL INFECT, V140, P1, DOI 10.1017/S095026881000316X
   Kocamemi B.A., 2020, 1 DATA SET SARS COV
   Kumar M, 2020, SCI TOTAL ENVIRON, V746, DOI 10.1016/j.scitotenv.2020.141326
   La Rosa G., 2020, 1 DETECTION SARS COV
   Medema G., 2020, ENV SCI TECH LETT
   Murakami M., 2020, ENV SCI TECH
   Peccia J., 2020, SARS COV 2 RNA CONCE
   R Core Team, 2020, R LANG ENV STAT COMP
   Randazzo W, 2020, WATER RES, V181, DOI 10.1016/j.watres.2020.115942
   Rose J.B., 2005, REDUCTION PATHOGENS
   Sherchan SP, 2020, SCI TOTAL ENVIRON, V743, DOI 10.1016/j.scitotenv.2020.140621
   Tang A, 2020, EMERG INFECT DIS, V26, P1337, DOI 10.3201/eid2606.200301
   Uyeki TM, 2020, NEW ENGL J MED, V382
   van Nuijs ALN, 2011, SCI TOTAL ENVIRON, V409, P3564, DOI 10.1016/j.scitotenv.2010.05.030
   Vogels C.B., 2020, NATURE MICROBIOLOGY, P1
   WANG W, 2020, EMERG INFECT DIS, V20, DOI DOI 10.1186/S12879-019-4746-0
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Worley-Morse T, 2019, WATER ENVIRON RES, V91, P830, DOI 10.1002/wer.1096
   Wu F., 2020, SARS COV 2 TITERS WA
   Wurtzer S., 2020, EVALUATION LOCKDOWN
   Wurtzer S., 2020, TIME COURSE QUANTITA
   Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055
   Yongchen Zhang, 2020, Emerg Microbes Infect, V9, P833, DOI 10.1080/22221751.2020.1756699
   Zang R., 2020, BIORXIV
   Zhang JC, 2020, J MED VIROL, V92, P680, DOI 10.1002/jmv.25742
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 40
TC 2
Z9 2
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0043-1354
J9 WATER RES
JI Water Res.
PD NOV 1
PY 2020
VL 186
AR 116296
DI 10.1016/j.watres.2020.116296
PG 9
WC Engineering, Environmental; Environmental Sciences; Water Resources
SC Engineering; Environmental Sciences & Ecology; Water Resources
GA OS2BA
UT WOS:000589968700009
PM 32841929
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Catalan-Matamoros, D
   Elias, C
AF Catalan-Matamoros, Daniel
   Elias, Carlos
TI Vaccine Hesitancy in the Age of Coronavirus and Fake News: Analysis of
   Journalistic Sources in the Spanish Quality Press
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE content analysis; media; newspaper; public health; sources; journalism;
   vaccine
ID SCIENCE JOURNALISM; GERMAN PRINT; HEALTH; COVERAGE
AB The study of the quality press and the use of sources is relevant to understand the role of journalists in scientific controversies. The objective was to examine media sourcing patterns, using the case of vaccines as a backdrop. Articles were retrieved from the national quality press in Spain. Content analysis was undertaken on the sources and on other variables such as tone, frames and journalistic genre. The software myNews and NVivo were used for data collection and coding, while SPSS and Excel were used for statistical analysis. Findings indicate that sources related to the government, professional associations and scientific companies are the most frequently used, confirming the central role of government institutions as journalistic sources. These were followed by university scientists, scientific journals and clinicians. On the other hand, NGOs and patients groups were included in fewer than 5% of the articles. More than 30% included none or just one source expressing unbalanced perspectives. Frequent use of certain source types, particularly governmental, may indicate state structures of power. The study provides a better understanding of journalistic routines in the coverage of vaccines, including fresh perspectives in the current COVID-19 pandemic.
C1 [Catalan-Matamoros, Daniel; Elias, Carlos] Univ Carlos III Madrid, Dept Commun Studies, Madrid 28903, Spain.
   [Catalan-Matamoros, Daniel] Univ Almeria, Hlth Res Ctr, Almeria 04120, Spain.
   [Catalan-Matamoros, Daniel] Univ Nebrija, Res Grp Anal & Anticipat Journalism, Madrid 20240, Spain.
RP Catalan-Matamoros, D (corresponding author), Univ Carlos III Madrid, Dept Commun Studies, Madrid 28903, Spain.; Catalan-Matamoros, D (corresponding author), Univ Almeria, Hlth Res Ctr, Almeria 04120, Spain.; Catalan-Matamoros, D (corresponding author), Univ Nebrija, Res Grp Anal & Anticipat Journalism, Madrid 20240, Spain.
EM dacatala@hum.uc3m.es; celias@hum.uc3m.es
OI CATALAN, DANIEL JESUS/0000-0001-7783-4984
FU Ministry of Science, Innovation and Universities of the Government of
   Spain "Rationality and counter-knowledge. Epistemology of the detection
   of false stories informative" [RTI2018-097709-B-I00]; Health Research
   Centre, University of Almeria, Spain
FX Jean Monnet Chair "EU, Disinformation & Fake News" (Erasmus+ Programme
   of the EU) and Ministry of Science, Innovation and Universities of the
   Government of Spain "Rationality and counter-knowledge. Epistemology of
   the detection of false stories informative" (RTI2018-097709-B-I00). This
   research was also supported financially by the Health Research Centre,
   University of Almeria, Spain.
CR AIMC-Asociacion para la investigacion de medios de comunicacion, 2017, EST GEN MED ESP 2017
   Amend E, 2012, SCI COMMUN, V34, P241, DOI 10.1177/1075547011409952
   Nguyen A, 2020, MEDIA COMMUN-LISBON, V8, P323, DOI 10.17645/mac.v8i2.3352
   Barrera Paez L., 2016, REV ESPANOLA COMUNIC, V7, P15, DOI [10.20318/recs.2016.3118, DOI 10.20318/RECS.2016.3118]
   Boumans JW, 2016, EUR J COMMUN, V31, P260, DOI 10.1177/0267323116629879
   Boyce T, 2006, JOURNALISM STUD, V7, P889, DOI DOI 10.1080/14616700600980652
   Cacciatore MA, 2012, NEW MEDIA SOC, V14, P1039, DOI 10.1177/1461444812439061
   CALSAMIGLIA H, 2003, STUD, V5, P147, DOI DOI 10.1177/1461445603005002308
   Carrillo-Santisteve P, 2012, CLIN MICROBIOL INFEC, V18, P50, DOI 10.1111/j.1469-0691.2012.03982.x
   Casciotti DM, 2014, J ADOLESCENCE, V37, P133, DOI 10.1016/j.adolescence.2013.11.004
   Catalan-Matamoros D, 2019, HEALTH COMMUN, V34, P415, DOI 10.1080/10410236.2017.1405485
   Catalan-Matamoros D, 2017, REV ESP COMUN SALUD, V8, P114, DOI 10.20318/recs.2017.3995
   Catalan-Matamoros D, 2019, PERSPECT PUBLIC HEAL, V139, P34, DOI 10.1177/1757913918780142
   Cooke NA, 2017, LIBR QUART, V87, P211, DOI 10.1086/692298
   Cornwall W, 2020, SCIENCE
   Davis A., 2002, PUBLIC RELATIONS DEM
   Davis A., 2003, NEWS PUBLIC RELATION
   Di Salvo P, 2016, JOURNALISM, V17, P805, DOI 10.1177/1464884915595472
   Dimitrova DV, 2012, JOURNALISM, V13, P604, DOI 10.1177/1464884911431546
   Donsbach W., 2004, JOURNALISM, V5, P131, DOI [DOI 10.1177/146488490452002, 10.1177/146488490452002]
   Donsbach W., 2008, INT ENCY COMMUNICATI
   Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657
   Elias C., 2019, SCI ROPES DECLINE SC
   Elias C., 2008, FUNDAMENTOS PERIODIS
   Elias C, 2020, MEDIA COMMUN-LISBON, V8, P462, DOI 10.17645/mac.v8i2.3217
   Ericson R.V., 1989, NEGOTIATING CONTROL
   Field A., 2009, DISCOVERING STAT USI
   Guenther L, 2019, JOURNALISM STUD, V20, P40, DOI 10.1080/1461670X.2017.1353432
   Gupta A, 2010, J COMMUN, V1, P19, DOI DOI 10.1080/0976691X.2010.11884766
   Haas T., 2007, PURSUIT PUBLIC JOURN
   Hansen A, 1994, PUBLIC UNDERST SCI, V3, P111, DOI DOI 10.1088/0963-6625/3/2/001
   HOLTZMAN NA, 2005, PUBLIC HEALTH GENOM, V8, P133, DOI DOI 10.1159/000086756
   Johnston J, 2017, DIGIT JOURNAL, V5, P943, DOI 10.1080/21670811.2017.1355026
   Lewis J, 2003, NAT REV IMMUNOL, V3, P913, DOI 10.1038/nri1228
   LEWIS M, 2017, J STUD, V20, P1, DOI DOI 10.1080/1461670X.2017
   Maat HP, 2013, JOURNALISM, V14, P348, DOI 10.1177/1464884912448914
   McIntosh White J., 2006, THESIS
   Meyer SB, 2016, J HEALTH COMMUN, V21, P1088, DOI 10.1080/10810730.2016.1222038
   Peters MA, 2017, EDUC PHILOS THEORY, V49, P567, DOI 10.1080/00131857.2017.1288782
   Priest S., 2013, B SCI TECHNOL SOC, V33, P138, DOI [10.1177/0270467614529707, DOI 10.1177/0270467614529707]
   Rappuoli R, 2011, NAT REV IMMUNOL, V11, P865, DOI 10.1038/nri3085
   Reich Z., 2009, HAMPTON PRESS COMMUN
   Riobo P., 2016, REV ESP COMUN SAL S1, V7, P133, DOI [10.20318/recs.2016.3132, DOI 10.20318/RECS.2016.3132]
   Salgado S, 2012, JOURNALISM, V13, P144, DOI 10.1177/1464884911427797
   Schneider B, 2012, JOURNALISM, V13, P71, DOI 10.1177/1464884911421573
   Schudson M., 1996, POWER NEWS
   Schudson M., 2012, SOCIOLOGY NEWS
   Secko DM, 2013, JOURNAL PRACT, V7, P62, DOI 10.1080/17512786.2012.691351
   Semetko HA, 2000, J COMMUN, V50, P93, DOI 10.1111/j.1460-2466.2000.tb02843.x
   Sparks Colin, 1987, EUROPEAN J COMMUNICA, V2, P455, DOI DOI 10.1177/0267323137002004005
   Sperbeck J.M., 1997, J APPL COMMUN, V81, DOI [10.4148/1051-0834.1432, DOI 10.4148/1051-0834.1432]
   St John Burton 3rd, 2010, Commun Med, V7, P75
   Stroobant J, 2018, JOURNAL PRACT, V12, P344, DOI 10.1080/17512786.2017.1294027
   Summ A, 2016, PUBLIC UNDERST SCI, V25, P775, DOI 10.1177/0963662515583419
   Tiffen R, 2014, JOURNALISM STUD, V15, P374, DOI 10.1080/1461670X.2013.831239
   Tobitt C., 2020, 2 3S BRITS SAY COVID
   van der Meer TGLA, 2017, JOURNALISM, V18, P1107, DOI 10.1177/1464884916648095
   WHO, IMM PUBL MIS
   World Health Organization, 10 THREATS GLOB HLTH
NR 59
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD NOV
PY 2020
VL 17
IS 21
AR 8136
DI 10.3390/ijerph17218136
PG 15
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA OQ9CU
UT WOS:000589073000001
PM 33158059
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Giesen, N
   Sprute, R
   Ruthrich, M
   Khodamoradi, Y
   Mellinghoff, SC
   Beutel, G
   Lueck, C
   Koldehoff, M
   Hentrich, M
   Sandherr, M
   von Bergwelt-Baildon, M
   Wolf, HH
   Hirsch, HH
   Wormann, B
   Cornely, OA
   Kohler, P
   Schalk, E
   Von Lilienfeld-Toal, M
AF Giesen, Nicola
   Sprute, Rosanne
   Ruthrich, Maria
   Khodamoradi, Yascha
   Mellinghoff, Sibylle C.
   Beutel, Gernot
   Lueck, Catherina
   Koldehoff, Michael
   Hentrich, Marcus
   Sandherr, Michael
   von Bergwelt-Baildon, Michael
   Wolf, Hans-Heinrich
   Hirsch, Hans H.
   Wormann, Bernhard
   Cornely, Oliver A.
   Koehler, Philipp
   Schalk, Enrico
   Von Lilienfeld-Toal, Marie
TI Evidence-based management of COVID-19 in cancer patients: Guideline by
   the Infectious Diseases Working Party (AGIHO) of the German Society for
   Haematology and Medical Oncology (DGHO)
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE COVID-19; SARS-CoV-2; Coronavirus; Cancer; Haematological malignancy;
   Guideline
ID CLINICAL CHARACTERISTICS; RISK-FACTORS; HAND-RUB; SARS-COV-2;
   MALIGNANCIES; MULTICENTER; MORTALITY; IMPACT; VIRUS; MASKS
AB Since its first detection in China in late 2019 the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the associated infectious disease COVID-19 continue to have a major impact on global healthcare and clinical practice. Cancer patients, in particular those with haematological malignancies, seem to be at an increased risk for a severe course of infection. Deliberations to avoid or defer potentially immunosuppressive therapies in these patients need to be balanced against the overarching goal of providing optimal antineoplastic treatment. This poses a unique challenge to treating physicians. This guideline provides evidence-based recommendations regarding prevention, diagnostics and treatment of SARS-CoV-2 infection and COVID-19 as well as strategies towards safe antineoplastic care during the COVID-19 pandemic. It was prepared by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO) by critically reviewing the currently available data on SARS-CoV-2 and COVID-19 in cancer patients applying evidence-based medicine criteria. (C) 2020 The Author(s). Published by Elsevier Ltd.
C1 [Giesen, Nicola] Univ Hosp Heidelberg, Dept Haematol & Oncol, Internal Med 5, Neuenheimer Feld 410, D-69120 Heidelberg, Germany.
   [Sprute, Rosanne; Mellinghoff, Sibylle C.; Cornely, Oliver A.; Koehler, Philipp] Univ Cologne, Fac Med, Cologne, Germany.
   [Sprute, Rosanne; Mellinghoff, Sibylle C.; Cornely, Oliver A.; Koehler, Philipp] Univ Hosp Cologne, German Ctr Infect Res, Partner Site Bonn Cologne,Ctr Integrated Oncol CI, Dept Internal Med 1,Excellence Ctr Med Mycol ECMM, Cologne, Germany.
   [Sprute, Rosanne; Mellinghoff, Sibylle C.; Cornely, Oliver A.; Koehler, Philipp] Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, Cologne, Germany.
   [Ruthrich, Maria; Von Lilienfeld-Toal, Marie] Univ Hosp Jena, Dept Haematol & Med Oncol, Clin Internal Med 2, Jena, Germany.
   [Ruthrich, Maria; Von Lilienfeld-Toal, Marie] Hans Knoell Inst, Leibniz Inst Nat Prod Res & Infect Biol, Jena, Germany.
   [Khodamoradi, Yascha] Goethe Univ Frankfurt, Dept Internal Med, Infect Dis, Frankfurt, Germany.
   [Beutel, Gernot; Lueck, Catherina] Hannover Med Sch, Dept Haematol Haemostasis Oncol & Stem Cell Trans, Hannover, Germany.
   [Beutel, Gernot; Lueck, Catherina; Koldehoff, Michael; von Bergwelt-Baildon, Michael; Schalk, Enrico] German Soc Haematol & Med Oncol DGHO, Working Party Intens Care Haematol & Oncol Patien, Berlin, Germany.
   [Koldehoff, Michael] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Bone Marrow Transplantat, Essen, Germany.
   [Hentrich, Marcus] Red Cross Hosp, Dept Med Haematol Oncol 3, Munich, Germany.
   [Sandherr, Michael] Med Care Ctr Penzberg, Clin Haematol & Oncol, Penzberg, Germany.
   [von Bergwelt-Baildon, Michael] LMU Univ Hosp, Dept Internal Med 3, CCC Munich, DKTK Partner Site Munich,BZKF Partner Site Munich, Munich, Germany.
   [Wolf, Hans-Heinrich] Sudharzklinikum, Dept Haematol Oncol & Haemostaseol, Internal Med 3, Nordhausen, Germany.
   [Hirsch, Hans H.] Univ Basel, Transplantat & Clin Virol, Dept Biomed, Haus Peterspl, Basel, Switzerland.
   [Hirsch, Hans H.] Univ Hosp Basel, Lab Med, Clin Virol, Basel, Switzerland.
   [Hirsch, Hans H.] Univ Hosp Basel, Infect Dis & Hosp Epidemiol, Basel, Switzerland.
   [Wormann, Bernhard] Charite Univ Med Berlin, Dept Med, Div Haematol Oncol & Tumor Immunol, Berlin, Germany.
   [Schalk, Enrico] Otto von Guericke Univ, Med Ctr, Dept Haematol & Oncol, Magdeburg, Germany.
RP Giesen, N (corresponding author), Univ Hosp Heidelberg, Dept Haematol & Oncol, Internal Med 5, Neuenheimer Feld 410, D-69120 Heidelberg, Germany.
EM nicola.giesen@med.uni-heidelberg.de
RI Sprute, Rosanne/AAC-5249-2020; Cornely, Oliver A/J-5095-2013; Schalk,
   Enrico/X-9283-2019; Koehler, Philipp/J-7985-2019
OI Sprute, Rosanne/0000-0003-2457-6437; Cornely, Oliver
   A/0000-0001-9599-3137; Schalk, Enrico/0000-0003-1892-5098; Koehler,
   Philipp/0000-0002-7386-7495; Giesen, Nicola/0000-0002-9615-2564
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Al-Shamsi HO, 2020, JAMA ONCOL, V6, P1627, DOI 10.1001/jamaoncol.2020.2548
   [Anonymous], 2020, WHO R BLUEPRINT NOVE
   Aries JA, 2020, BRIT J HAEMATOL, V190, pE64, DOI 10.1111/bjh.16852
   Arons MM, 2020, NEW ENGL J MED, V382, P2081, DOI 10.1056/NEJMoa2008457
   Assaad S, 2020, EUR J CANCER, V135, P251, DOI 10.1016/j.ejca.2020.05.028
   Bartoszko JJ, 2020, INFLUENZA OTHER RESP, V14, P365, DOI 10.1111/irv.12745
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bekele A, 2018, J INTERN MED, V284, P292, DOI 10.1111/joim.12767
   Benani A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01841
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Brenner EJ, 2020, GASTROENTEROLOGY, V159, P481, DOI 10.1053/j.gastro.2020.05.032
   Cai Q, 2020, ENG BEIJING
   Campochiaro C, 2020, EUR J INTERN MED, V76, P43, DOI 10.1016/j.ejim.2020.05.021
   Cantini F, 2020, J INFECTION, V81, P673, DOI 10.1016/j.jinf.2020.06.052
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cao W, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa102
   Cao Y, 2020, J ALLERGY CLIN IMMUN, V146, P137, DOI 10.1016/j.jaci.2020.05.019
   Chaidos A, 2020, BRIT J HAEMATOL, V190, pE9, DOI 10.1111/bjh.16787
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2139, DOI 10.1093/cid/ciaa644
   Cheng VCC, 2020, J INFECTION, V81, P107, DOI 10.1016/j.jinf.2020.04.024
   Cheuk Sally, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa797
   Cho SY, 2020, BRIT J HAEMATOL, V190, pE33, DOI 10.1111/bjh.16818
   Chu DK, 2020, LANCET, V395, P1973, DOI 10.1016/S0140-6736(20)31142-9
   Cinar P, 2020, J NATL COMPR CANC NE, V18, P504, DOI 10.6004/jnccn.2020.7572
   Cook G, 2020, BRIT J HAEMATOL, V190, pE83, DOI 10.1111/bjh.16874
   COVIDsurg Collaborative, 2020, LANCET, V396, P27, DOI 10.1016/S0140-6736(20)31182-X
   Cowling BJ, 2020, LANCET PUBLIC HEALTH, V5, pE279, DOI 10.1016/S2468-2667(20)30090-6
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   de Abajo FJ, 2020, LANCET, V395, P1705, DOI 10.1016/S0140-6736(20)31030-8
   de Joode K, 2020, EUR J CANCER, V136, P132, DOI 10.1016/j.ejca.2020.06.019
   Dhakal B, 2020, LEUKEMIA
   Dockery DM, 2020, J EMERG MED, V59, P137, DOI 10.1016/j.jemermed.2020.04.060
   Duan K, 2020, FEASIBILITY CONVALES
   Engelhardt M, 2020, HAEMATOLOGICA, V105, P2872, DOI 10.3324/haematol.2020.262758
   Fallet B, 2020, ARTHRITIS RHEUMATOL, V72, P1581, DOI 10.1002/art.41380
   Fang YC, 2020, RADIOLOGY, V296, pE115, DOI 10.1148/radiol.2020200432
   Fattizzo B, 2020, LEUKEMIA, V34, P1957, DOI 10.1038/s41375-020-0877-y
   Felgenhauer U, 2020, J BIOL CHEM, V295, P13958, DOI 10.1074/jbc.AC120.013788
   Feng Y, 2020, J AEROSOL SCI, V147, DOI 10.1016/j.jaerosci.2020.105585
   Ferrara F, 2020, LEUKEMIA, V34, P2254, DOI 10.1038/s41375-020-0925-7
   Foa R, 2020, BRIT J HAEMATOL, V190, pE3, DOI 10.1111/bjh.16758
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Garassino MC, 2020, LANCET ONCOL, V21, P914, DOI 10.1016/S1470-2045(20)30314-4
   Giacomelli A, 2020, CLIN INFECT DIS, V71, P889, DOI 10.1093/cid/ciaa330
   Goldman Jason D, 2020, N Engl J Med, V383, P1827, DOI 10.1056/NEJMoa2015301
   Grayson ML, 2009, CLIN INFECT DIS, V48, P285, DOI 10.1086/595845
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Hao SR, 2020, J INFECT DIS, V222, P367, DOI 10.1093/infdis/jiaa311
   Hastie CE, 2020, DIABETES METAB SYND, V14, P1315, DOI 10.1016/j.dsx.2020.07.021
   He WJ, 2020, LEUKEMIA, V34, P1637, DOI 10.1038/s41375-020-0836-7
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huet T, 2020, LANCET RHEUMATOL, V2
   Joyner M, 2020, EARLY SAFETY INDICAT
   Kahn SR, 2012, CHEST, V141, pE195S, DOI 10.1378/chest.11-2296
   Kalinsky K, 2020, BREAST CANCER RES TR, V182, P239, DOI 10.1007/s10549-020-05667-6
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Key NS, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.01461
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Korth J, 2020, J CLIN VIROL, V128
   Kratzel A, 2020, EMERG INFECT DIS, V26, P1592, DOI 10.3201/eid2607.200915
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Kung CT, 2020, J MICROBIOL IMMUNOL, p[S1684, 30120]
   La Rosee F, 2020, LEUKEMIA, V34, P1805, DOI 10.1038/s41375-020-0891-0
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Leung Nancy H L, 2020, Nat Med, V26, P676, DOI 10.1038/s41591-020-0843-2
   Leuzinger K, 2020, J INFECT DIS, V222, P1270, DOI 10.1093/infdis/jiaa464
   Lewnard JA, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1923
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Li WM, 2020, LEUKEMIA, V34, P1799, DOI 10.1038/s41375-020-0853-6
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Liang YW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01022
   Ljungman P, 2020, BONE MARROW TRANSPL, V55, P2071, DOI 10.1038/s41409-020-0919-0
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Luo J, 2020, ANN ONCOL, V31, P1386, DOI 10.1016/j.annonc.2020.06.007
   Luo J, 2020, CANCER DISCOV, V10, P1121, DOI 10.1158/2159-8290.CD-20-0596
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   MacIntyre CR, 2011, INFLUENZA OTHER RESP, V5, P170, DOI 10.1111/j.1750-2659.2011.00198.x
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Martin-Moro F, 2020, BRIT J HAEMATOL, V190, pE16, DOI 10.1111/bjh.16801
   Matrajt L, 2020, EMERG INFECT DIS, V26, P1740, DOI 10.3201/eid2608.201093
   Mehta V, 2020, CANCER DISCOV, V10, P935, DOI 10.1158/2159-8290.CD-20-0516
   Meng YF, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00907-0
   Nawar T, 2020, AM J HEMATOL, V95, pE210, DOI 10.1002/ajh.25870
   Offeddu V, 2017, CLIN INFECT DIS, V65, P1934, DOI 10.1093/cid/cix681
   Oh WK, 2020, ANN ONCOL, V31, P838, DOI 10.1016/j.annonc.2020.03.297
   Omarini C, 2020, EUR J CANCER, V133, P29, DOI 10.1016/j.ejca.2020.04.034
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Park HC, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000018782
   Prem K, 2020, LANCET PUBLIC HEALTH, V5, pE261, DOI 10.1016/S2468-2667(20)30073-6
   Price CC, 2020, CHEST, VS0012-3692, P31670
   Ramos-Esquivel A, 2018, BREAST CANCER-TOKYO, V25, P479, DOI 10.1007/s12282-018-0848-6
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Rieger CT, 2018, ANN ONCOL, V29, P1354, DOI 10.1093/annonc/mdy117
   Rojas-Marte G, 2020, QJM-INT J MED, V113, P546, DOI 10.1093/qjmed/hcaa206
   Ryu BH, 2020, AM J INFECT CONTROL, V48, P875, DOI 10.1016/j.ajic.2020.05.027
   Salazar E, 2020, AM J PATHOL
   Savolainen-Kopra C, 2012, J MED VIROL, V84, P543, DOI 10.1002/jmv.23222
   Shah V, 2020, BRIT J HAEMATOL, V190, pE279, DOI 10.1111/bjh.16935
   Shander A, 2020, ANESTH ANALG, V131, P74, DOI 10.1213/ANE.0000000000004844
   Shekar K, 2020, ASAIO J
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Shoumariyeh K, 2020, CANCER MED-US, V9, P8412, DOI 10.1002/cam4.3460
   Somers Emily C, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa954
   Spicer J, 2020, NAT REV CLIN ONCOL, DOI 10.1038/s41571-020-0370-6
   Tang LV, 2020, LANCET ONCOL, V21, P862, DOI 10.1016/S1470-2045(20)30311-9
   Tang W, 2020, HYDROXYCHLOROQUINE P, DOI [10.1101/2020.04.10.20060558, DOI 10.1101/2020.04.10.20060558]
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Tepasse PR, 2020, BRIT J HAEMATOL, V190, P185, DOI 10.1111/bjh.16896
   Thibaud S, 2020, BRIT J HAEMATOL, V190, pE73, DOI 10.1111/bjh.16863
   Thornburg A, 2007, CHEST, V131, P1572, DOI 10.1378/chest.06-1734
   Tian JB, 2020, LANCET ONCOL, V21, P893, DOI 10.1016/S1470-2045(20)30309-0
   Tobin MJ, 2020, AM J RESP CRIT CARE, V202, P356, DOI 10.1164/rccm.202006-2157CP
   Treon SP, 2020, BLOOD, V135, P1912, DOI 10.1182/blood.2020006288
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   Ullmann AJ, 2012, CLIN MICROBIOL INFEC, V18, P53, DOI 10.1111/1469-0691.12041
   van de Haar J, 2020, NAT MED, V26, P665, DOI [10.1038/s41591-020-0874-8, 10.1038/s41591-020-0948-7]
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Vehreschild JJ, 2014, ANN ONCOL, V25, P1709, DOI 10.1093/annonc/mdu035
   Venkatesulu BP, 2020, SYSTEMATIC REV META
   von Lilienfeld-Toal M, 2016, EUR J CANCER, V67, P200, DOI 10.1016/j.ejca.2016.08.015
   Vuagnat P, 2020, BREAST CANCER RES, V22, DOI 10.1186/s13058-020-01293-8
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Weinkove R, 2020, MED J AUSTRALIA, V212, P481, DOI 10.5694/mja2.50607
   Weisel KC, 2020, ONCOL RES TREAT, V43, P307, DOI 10.1159/000508272
   Williamson EJ, 2020, NATURE, DOI 10.1038/s41586-020-2521-4
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wu HX, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-018-0677-6
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Wyllie AL, 2020, SALIVA IS MORE SENSI
   Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543
   Xiang F, 2020, CLIN INFECT DIS, V71, P1930, DOI 10.1093/cid/ciaa461
   Xie Y, 2020, J INFECTION, V81, P340, DOI 10.1016/j.jinf.2020.03.044
   Xu KJ, 2020, CLIN INFECT DIS, V71, P799, DOI 10.1093/cid/ciaa351
   Yahalom J, 2020, BLOOD, V135, P1829, DOI 10.1182/blood.2020006028
   Yan YC, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13310
   Yang CG, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00249
   Yang F, 2020, J MED VIROL, V92, P2067, DOI 10.1002/jmv.25972
   Yang KY, 2020, LANCET ONCOL, V21, P904, DOI 10.1016/S1470-2045(20)30310-7
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yarza R, 2020, EUR J CANCER, V135, P242, DOI 10.1016/j.ejca.2020.06.001
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zhao R, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa523, DOI 10.1093/CID/CIAA523]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou Q, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01061
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
   Zhu L, 2020, EUR UROL, V77, P748, DOI 10.1016/j.eururo.2020.03.039
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou You, 2020, J Infect Dis, V222, P1784, DOI 10.1093/infdis/jiaa301
NR 156
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD NOV
PY 2020
VL 140
BP 86
EP 104
DI 10.1016/j.ejca.2020.09.009
PG 19
WC Oncology
SC Oncology
GA OP5UC
UT WOS:000588150600011
PM 33068941
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Caffo, O
   Gasparro, D
   Di Lorenzo, G
   Dalla Volta, A
   Guglielmini, P
   Zucali, P
   Bortolus, R
   Cavo, A
   Ceresoli, G
   Chiari, R
   Fornarini, G
   Fratino, L
   Iaculli, A
   Maruzzo, M
   Masini, C
   Morelli, F
   Mucciarini, C
   Procopio, G
   Sabbatini, R
   Verri, E
   Kinspergher, S
   Maines, F
   Messina, C
   Veccia, A
   Donini, M
AF Caffo, Orazio
   Gasparro, Donatello
   Di Lorenzo, Giuseppe
   Dalla Volta, Alberto
   Guglielmini, Pamela
   Zucali, Paolo
   Bortolus, Roberto
   Cavo, Alessia
   Ceresoli, Giovanni
   Chiari, Rita
   Fornarini, Giuseppe
   Fratino, Lucia
   Iaculli, Alessandro
   Maruzzo, Marco
   Masini, Cristina
   Morelli, Franco
   Mucciarini, Claudia
   Procopio, Giuseppe
   Sabbatini, Roberto
   Verri, Elena
   Kinspergher, Stefania
   Maines, Francesca
   Messina, Carlo
   Veccia, Antonello
   Donini, Maddalena
TI Incidence and outcomes of severe acute respiratory syndrome coronavirus
   2 infection in patients with metastatic castration-resistant prostate
   cancer
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE Androgen deprivation therapy; COVID-19; Metastatic castrationresistant
   prostate cancer; SARS-CoV-2 infection
ID ANDROGEN; EXPRESSION; COVID-19
AB Background: Patients with cancer are at increased risk of complicated severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, but it is still unclear if the risk of mortality is influenced by cancer type or ongoing anti-cancer treatments. An interesting debate concerning the potential relationship between androgen deprivation therapy (ADT) and SARS-CoV-2 infection has recently been opened in the case of prostate cancer (PC), and the aim of this multi-centre cohort study was to investigate the incidence and outcomes of SARS-CoV-2 infection in patients with metastatic castration-resistant prostrate cancer (mCRPC).
   Patients and methods: We retrospectively reviewed the clinical records of patients with mCRPC who developed SARS-CoV-2 infection, and recorded their baseline clinical characteristics, their history of PC and SARS-CoV-2 infection, and their oncological status and treatment at the time of infection. The primary study end point was the death rate and the possible impact of the patients' PC-related history and treatments on mortality.
   Results: Thirty-four of the 1433 patients with mCRPC attending the participating centres (2.3%) developed SARS-CoV-2 infection, 22 (64.7%) of whom were hospitalised. Most of the patients were symptomatic, the most frequent symptoms being fever (70.6%), dyspnoea (61.8%), cough (52.9%) and fatigue (38.2%). After a median follow-up of 21 days (interquartile range: 13-41), 13 patients had died (38.2%), 17 recovered (50.0%) and four (11.7%) were still infected. The number of treatments previously administered for mCRPC had a significant impact on mortality (p = 0.004).
   Conclusions: Our findings contribute additional data to the current debate concerning the postulated protective role of ADT, which seems to be less in patients with metastatic PC. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Caffo, Orazio; Kinspergher, Stefania; Maines, Francesca; Messina, Carlo; Veccia, Antonello] Santa Chiara Hosp, Med Oncol Dept, I-38122 Trento, Italy.
   [Gasparro, Donatello] Univ Hosp Parma, Med Oncol Unit, Viale Gramsci 14, I-43126 Parma, Italy.
   [Di Lorenzo, Giuseppe] Tortora Hosp, Med Oncol Dept, Via Gasperi 59, I-84016 Pagani, Italy.
   [Dalla Volta, Alberto] Univ Brescia, Med Oncol Unit, ASST Spedali Civili, Piazzale Spedali Civili 31, I-25123 Brescia, Italy.
   [Guglielmini, Pamela] SS Antonio & Biagio & Cesare Arrigo Hosp, Med Oncol Unit, Via Venezia 16, I-15121 Alessandria, Italy.
   [Zucali, Paolo] IRCCS, Dept Oncol, Humanitas Clin & Res Ctr, Via Manzoni 56, I-20089 Milan, Italy.
   [Bortolus, Roberto] Ctr Riferimento Oncol Aviano CRO IRCCS, Dept Radiat Oncol, Via Franco Gallini 2, I-33081 Aviano, Italy.
   [Cavo, Alessia] Villa Scassi Hosp, Oncol Unit, Corso Onofrio Scassi 1, I-16149 Genoa, Italy.
   [Ceresoli, Giovanni] Humanitas Gavazzeni, Thorac & Urol Oncol Unit, Via Mauro Gavazzeni 21, I-24125 Bergamo, Italy.
   [Chiari, Rita] Immacolata Concez Hosp, Oncol Unit, Via S Rocco 8, I-35028 Piove Di Sacco, Italy.
   [Fornarini, Giuseppe] IRCCS Azienda Osped Univ San Martino, Med Oncol Dept, IST Ist Nazl Ric Canc, Largo Benzi 10, I-16132 Genoa, Italy.
   [Fratino, Lucia] Ctr Riferimento Oncol Aviano CRO IRCCS, Dept Med Oncol, Via Franco Gallini 2, I-33081 Aviano, Italy.
   [Iaculli, Alessandro] Bolognini Hosp, Med Oncol Unit, Via Paderno 21, I-24068 Seriate, Italy.
   [Maruzzo, Marco] Veneto Inst Oncol IOV IRCCS, Oncol 1, Dept Oncol, Via Gattamelata 64, I-35128 Padua, Italy.
   [Masini, Cristina] IRCCS Reggio Emilia, Azienda USL, Azienda Unita Sanit Locale, Med Oncol Unit, Reggio Emilia, Italy.
   [Morelli, Franco] Casa Sollievo Della Sofferenza Hosp, Med Oncol Dept, IRCCS, Viale Cappuccini 1, I-71013 San Giovanni Rotondo, Italy.
   [Mucciarini, Claudia] Ramazzini Hosp, Med Oncol Dept, Via Guido Molinari 2, I-41012 Carpi, Italy.
   [Procopio, Giuseppe] Fdn IRCCS Ist Nazl Tumori Milan, Genitourinary Oncol Unit, Via Venezian 1, I-20133 Milan, Italy.
   [Sabbatini, Roberto] Univ Hosp Modena, Med Oncol Unit, Largo Pozzo 71, I-41125 Modena, Italy.
   [Verri, Elena] European Inst Oncol IRCCS, Med Oncol Div Urogenital & Head & Neck Tumours, IEO, Via Ripamonti 435, I-20141 Milan, Italy.
   [Donini, Maddalena] ASST Cremona, Med Oncol Dept, Viale Concordia 1, I-26100 Cremona, Italy.
RP Caffo, O (corresponding author), Santa Chiara Hosp, Med Oncol Dept, I-38122 Trento, Italy.
EM orazio.caffo@apss.tn.it
OI caffo, orazio/0000-0001-7968-2531
CR Barlesi F, 2020, P 111 ANN M AM ASS C
   Desai Aakash, 2020, JCO Glob Oncol, V6, P557, DOI 10.1200/GO.20.00097
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Horn L, 2020, J CLIN ONCOL, V38
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Lee LYW, 2020, LANCET ONCOL, V21, P1309, DOI 10.1016/S1470-2045(20)30442-3
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lin BY, 1999, CANCER RES, V59, P4180
   Montopoli M, 2020, ANN ONCOL, V31, P1040, DOI 10.1016/j.annonc.2020.04.479
   Mostaghel EA, 2007, CANCER RES, V67, P5033, DOI 10.1158/0008-5472.CAN-06-3332
   Patel VG, 2020, ANN ONCOL, V31, P1419, DOI 10.1016/j.annonc.2020.06.023
   Sharifi N, 2020, ENDOCR-RELAT CANCER, V27, pE1, DOI 10.1530/ERC-20-0133
   Wambier CG, 2020, DRUG DEVELOP RES, V81, P771, DOI 10.1002/ddr.21688
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 14
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD NOV
PY 2020
VL 140
BP 140
EP 146
DI 10.1016/j.ejca.2020.09.018
PG 7
WC Oncology
SC Oncology
GA OP5UC
UT WOS:000588150600015
PM 33091718
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Pollard, BS
   Blanco, JC
   Pollard, JR
AF Pollard, Bette S.
   Blanco, Jorge C.
   Pollard, John R.
TI Classical Drug Digitoxin Inhibits Influenza Cytokine Storm, With
   Implications for Covid-19 Therapy
SO IN VIVO
LA English
DT Article
DE Virus; influenza; coronavirus; SARS; COVID-19; RNA-virus; cardiac
   glycosides; digitoxin; digoxin; ouabain; oleandrin; inflammation;
   cytokine storm; TNF alpha; GRO/KC; MIP-2; MCP1; IFN gamma
ID NF-KAPPA-B; VIRUS; PHARMACOKINETICS; INFLAMMATION; MICE; CFTR; KC
AB Background/Aim: Influenza viruses, corona viruses and related pneumotropic viruses cause sickness and death partly by inducing cytokine storm, a hyper-proinflammatory host response by immune cells and cytokines in the host airway. Based on our in vivo experience with digitoxin as an inhibitor of TNF alpha-driven NF kappa B signaling for cytokine expression in prostate cancer in rats and in cystic fibrosis in humans, we hypothesize that this drug will also block a virally-activated cytokine storm. Materials Methods: Digitoxin was administered intraperitoneally to cotton rats, followed by intranasal infection with 107TCID50/100 g of cotton rat with influenza strain A/Wuhan/H3N2/359/95. Daily digitoxin treatment continued until harvest on day 4 of the experiment. Results: The cardiac glycoside digitoxin significantly and differentially suppressed levels of the cytokines TNF alpha, GRO/KC, MIP2, MCP1, and IFN gamma, in the cotton rat lung in the presence of influenza virus. Conclusion: Since cytokine storm is a host response, we suggest that digitoxin may have a therapeutic potential not only for influenza and but also for coronavirus infections.
C1 [Pollard, Bette S.] Silver Pharmaceut, 11008 Lamplighter, Rockville, MD 20854 USA.
   [Blanco, Jorge C.] Sigmovir Biosyst, Rockville, MD USA.
   [Pollard, John R.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
   [Pollard, John R.] Christiana Care Epilepsy Ctr, Newark, DE USA.
RP Pollard, BS (corresponding author), Silver Pharmaceut, 11008 Lamplighter, Rockville, MD 20854 USA.
EM BettePollard@SilverPharmaceuticals.com
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   AMARELLE L, 2018, INT J MOL SCI, V19, P43028, DOI DOI 10.3390/IJMS19072154
   Burkard C, 2015, J VIROL, V89, P4434, DOI 10.1128/JVI.03274-14
   Cho J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72879-7
   Dam S, 2016, J VIROL, V90, P7980, DOI 10.1128/JVI.00946-16
   De Filippo K, 2008, J IMMUNOL, V180, P4308, DOI 10.4049/jimmunol.180.6.4308
   DeDiego ML, 2014, J VIROL, V88, P913, DOI 10.1128/JVI.02576-13
   Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027
   Farag A, 2020, IDENTIFICATION ATOVA, DOI [10.26434/chemrxiv.12003930, DOI 10.26434/CHEMRXIV.12003930]
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hoffman BJ, 1990, DIGITALIS ALLIED CAR
   Hol J, 2010, J LEUKOCYTE BIOL, V87, P501, DOI 10.1189/jlb.0809532
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ichinohe T, 2009, J EXP MED, V206, P79, DOI 10.1084/jem.20081667
   Jolly L, 2014, J BIOL CHEM, V289, P35246, DOI 10.1074/jbc.M114.582262
   Kalb DM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215602
   Ko M., 2020, SCREENING FDA APPROV, DOI [10.1101/2020.02.25.965582, DOI 10.1101/2020.02.25.965582]
   Kumar N, 2008, J VIROL, V82, P9880, DOI 10.1128/JVI.00909-08
   Liu Bo, 2019, J Microbiol Immunol Infect, DOI 10.1016/j.jmii.2019.07.009
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Mah AY, 2016, CRIT REV IMMUNOL, V36, P131, DOI 10.1615/CritRevImmunol.2016017387
   Mifsud EJ, 2018, EXPERT OPIN DRUG DIS, V13, P1131, DOI 10.1080/17460441.2018.1540586
   Miller SC, 2010, BIOCHEM PHARMACOL, V79, P1272, DOI 10.1016/j.bcp.2009.12.021
   Mills PR, 1999, AM J RESP CRIT CARE, V160, pS38, DOI 10.1164/ajrccm.160.supplement_1.11
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976-0105.177703
   Nimmerjahn F, 2004, J GEN VIROL, V85, P2347, DOI 10.1099/vir.0.79958-0
   Ottolini MG, 2005, J GEN VIROL, V86, P2823, DOI 10.1099/vir.0.81145-0
   PERRIER D, 1977, CLIN PHARMACOKINET, V2, P292, DOI 10.2165/00003088-197702040-00005
   Pollard BS, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00630
   Prince GA, 2001, J GEN VIROL, V82, P2881, DOI 10.1099/0022-1317-82-12-2881
   Schmolke M, 2009, J IMMUNOL, V183, P5180, DOI 10.4049/jimmunol.0804198
   Senathilake K. S., 2020, PREPRINTS, DOI [10.20944/preprints202003.0042.v2, DOI 10.20944/PREPRINTS202003.0042.V2, 10.20944/ Preprints202003.0042.V2]
   Sica A, 1997, J BIOL CHEM, V272, P30412, DOI 10.1074/jbc.272.48.30412
   Sichelstiel A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098440
   Srivastava M, 2004, P NATL ACAD SCI USA, V101, P7693, DOI 10.1073/pnas.0402030101
   Teijaro JR, 2014, VIROLOGY, V452, P152, DOI 10.1016/j.virol.2014.01.003
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Wang H, 2016, CELL PHYSIOL BIOCHEM, V40, P1063, DOI 10.1159/000453162
   Wei TZ, 2020, CHIN J INTEGR MED, V26, P663, DOI 10.1007/s11655-020-3427-6
   Wurzer WJ, 2004, J BIOL CHEM, V279, P30931, DOI 10.1074/jbc.M403258200
   Yan HY, 2018, VIROL J, V15, DOI 10.1186/s12985-018-0995-6
   Yang MH, 2013, BIOCHEM PHARMACOL, V86, P410, DOI 10.1016/j.bcp.2013.05.013
   Yang Q, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1214-8
   Yang QF, 2005, P NATL ACAD SCI USA, V102, P9631, DOI 10.1073/pnas.0504097102
   Yang Qing Feng, 2013, J Carcinog, V12, P8, DOI 10.4103/1477-3163.112268
   Yang S, 2017, J BIOL CHEM, V292, P3379, DOI 10.1074/jbc.M116.756536
   Zeitlin PL, 2017, ANN AM THORAC SOC, V14, P220, DOI 10.1513/AnnalsATS.201608-649OC
   Zhang Q, 2017, CELL, V168, P37, DOI 10.1016/j.cell.2016.12.012
NR 48
TC 0
Z9 0
U1 0
U2 0
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0258-851X
EI 1791-7549
J9 IN VIVO
JI In Vivo
PD NOV-DEC
PY 2020
VL 34
IS 6
BP 3723
EP 3730
DI 10.21873/invivo.12221
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OP2QN
UT WOS:000587929100081
PM 33144490
OA Bronze
DA 2021-01-01
ER

PT J
AU Zabini, F
   Albanese, L
   Becheri, FR
   Gavazzi, G
   Giganti, F
   Giovanelli, F
   Gronchi, G
   Guazzini, A
   Laurino, M
   Li, Q
   Marzi, T
   Mastorci, F
   Meneguzzo, F
   Righi, S
   Viggiano, MP
AF Zabini, Federica
   Albanese, Lorenzo
   Becheri, Francesco Riccardo
   Gavazzi, Gioele
   Giganti, Fiorenza
   Giovanelli, Fabio
   Gronchi, Giorgio
   Guazzini, Andrea
   Laurino, Marco
   Li, Qing
   Marzi, Tessa
   Mastorci, Francesca
   Meneguzzo, Francesco
   Righi, Stefania
   Viggiano, Maria Pia
TI Comparative Study of the Restorative Effects of Forest and Urban Videos
   during COVID-19 Lockdown: Intrinsic and Benchmark Values
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE anxiety; audio-visual stimulation; COVID-19; environmental enrichment;
   forest environments; forest therapy; lockdown; mental health; stress;
   quarantine
ID SHINRIN-YOKU; NATURAL-ENVIRONMENT; EXPOSURE; ANXIETY; STRESS; HEALTH;
   TREES; PHYTONCIDE; ATMOSPHERE; RECOVERY
AB The prolonged lockdown imposed to contain the COrona VIrus Disease 19 COVID-19 pandemic prevented many people from direct contact with nature and greenspaces, raising alarms for a possible worsening of mental health. This study investigated the effectiveness of a simple and affordable remedy for improving psychological well-being, based on audio-visual stimuli brought by a short computer video showing forest environments, with an urban video as a control. Randomly selected participants were assigned the forest or urban video, to look at and listen to early in the morning, and questionnaires to fill out. In particular, the State-Trait Anxiety Inventory (STAI) Form Y collected in baseline condition and at the end of the study and the Part II of the Sheehan Patient Rated Anxiety Scale (SPRAS) collected every day immediately before and after watching the video. The virtual exposure to forest environments showed effective to reduce perceived anxiety levels in people forced by lockdown in limited spaces and environmental deprivation. Although significant, the effects were observed only in the short term, highlighting the limitation of the virtual experiences. The reported effects might also represent a benchmark to disentangle the determinants of health effects due to real forest experiences, for example, the inhalation of biogenic volatile organic compounds (BVOC).
C1 [Zabini, Federica; Albanese, Lorenzo; Meneguzzo, Francesco] CNR, Inst Bioecon, 10 Via Madonna del Piano, I-50019 Sesto Fiorentino, FI, Italy.
   [Becheri, Francesco Riccardo] Pian Termini Forest Therapy Stn, 2311 Via Pratorsi, I-51028 San Marcello Piteglio, Italy.
   [Gavazzi, Gioele; Giganti, Fiorenza; Giovanelli, Fabio; Gronchi, Giorgio; Marzi, Tessa; Righi, Stefania; Viggiano, Maria Pia] Univ Florence, Sect Psychol, Dept Neurosci, Psychol Drug Res & Childs Hlth NEUROFARBA, 12 Via San Salvi, I-50135 Florence, Italy.
   [Guazzini, Andrea] Univ Florence, Dept Educ Languages Intercultural Studies Literat, 12 Via San Salvi, I-50135 Florence, Italy.
   [Laurino, Marco; Mastorci, Francesca] CNR, Inst Clin Physiol, 1 Via Giuseppe Moruzzi, I-56124 Pisa, Italy.
   [Li, Qing] Nippon Med Sch, Dept Rehabil & Phys Med, Grad Sch Med, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138603, Japan.
   [Meneguzzo, Francesco] Italian Alpine Club, Cent Sci Comm, 19 Via E Petrella, I-20124 Milan, Italy.
RP Zabini, F; Meneguzzo, F (corresponding author), CNR, Inst Bioecon, 10 Via Madonna del Piano, I-50019 Sesto Fiorentino, FI, Italy.; Meneguzzo, F (corresponding author), Italian Alpine Club, Cent Sci Comm, 19 Via E Petrella, I-20124 Milan, Italy.
EM federica.zabini@cnr.it; lorenzo.albanese@cnr.it;
   ricerca@terapiaforestale.it; gioele.gavazzi@unifi.it;
   fiorenza.giganti@unifi.it; fabio.giovannelli@unifi.it;
   giorgio.gronchi@unifi.it; andrea.guazzini@unifi.it; laurino@ifc.cnr.it;
   qing-li@nms.ac.jp; tessa.marzi@unifi.it; mastorcif@ifc.cnr.it;
   francesco.meneguzzo@cnr.it; stefania.righi@unifi.it;
   mariapia.viggiano@unifi.it
RI Meneguzzo, Francesco/R-2969-2018; Gronchi, Giorgio/O-9134-2016;
   Giovannelli, Fabio/K-8978-2016
OI Meneguzzo, Francesco/0000-0002-5952-9166; Gronchi,
   Giorgio/0000-0003-0543-4900; Laurino, Marco/0000-0003-4798-5196; Zabini,
   Federica/0000-0003-1505-0839; Giganti, Fiorenza/0000-0002-9362-5258;
   Giovannelli, Fabio/0000-0003-1059-9945
CR Antonelli M, 2019, INT J BIOMETEOROL, V63, P1117, DOI 10.1007/s00484-019-01717-x
   Bang KS, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15091977
   Bielinis E, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17010118
   Bratman GN, 2012, ANN NY ACAD SCI, V1249, P118, DOI 10.1111/j.1749-6632.2011.06400.x
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Browning MHEM, 2020, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.02667
   Calfapietra C, 2013, ENVIRON POLLUT, V183, P71, DOI 10.1016/j.envpol.2013.03.012
   Chun MH, 2017, INT J NEUROSCI, V127, P199, DOI 10.3109/00207454.2016.1170015
   Corazon SS, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16101711
   de Kort YAW, 2006, J ENVIRON PSYCHOL, V26, P309, DOI 10.1016/j.jenvp.2006.09.001
   Depledge MH, 2011, ENVIRON SCI TECHNOL, V45, P4660, DOI 10.1021/es103907m
   Dodev Y, 2020, FOREST POLICY ECON, V118, DOI 10.1016/j.forpol.2020.102249
   Farrow Marc R, 2019, Glob Adv Health Med, V8, p2164956119848654, DOI 10.1177/2164956119848654
   Frumkin H, 2017, ENVIRON HEALTH PERSP, V125, DOI 10.1289/EHP1663
   Furuyashiki A, 2019, ENVIRON HEALTH PREV, V24, DOI 10.1186/s12199-019-0800-1
   Godinic D, 2020, INT J INNOV EC DEV, V6, P61, DOI [10.18775/ijied.1849-7551-7020.2015.61.2005, DOI 10.18775/IJIED.1849-7551-7020.2015.61.2005]
   Gruber J., 2020, CLIN PSYCHOL SCI CAL, DOI [10.31234/osf.io/desg9, DOI 10.31234/OSF.IO/DESG9]
   Hansen MM, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14080851
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Janeczko E, 2020, FORESTS, V11, DOI 10.3390/f11050591
   Kaplan R., 1989, EXPERIENCE NATURE PS
   Kjellgren A, 2010, J ENVIRON PSYCHOL, V30, P464, DOI 10.1016/j.jenvp.2010.01.011
   Leung K, 2020, LANCET, V395, P1382, DOI 10.1016/S0140-6736(20)30746-7
   Li Q, 2009, INT J IMMUNOPATH PH, V22, P951, DOI 10.1177/039463200902200410
   Li Q, 2006, IMMUNOPHARM IMMUNOT, V28, P319, DOI 10.1080/08923970600809439
   Li Q, 2019, SANTE PUBLIQUE, V31, P135, DOI 10.3917/spub.190.0135
   Litleskare S, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051738
   Mattila O, 2020, COMPUT HUM BEHAV, V107, DOI 10.1016/j.chb.2020.106295
   Meneguzzo F, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16244915
   Ohly H, 2016, J TOXICOL ENV HEAL B, V19, P305, DOI 10.1080/10937404.2016.1196155
   Park Bum Jin, 2010, Environmental Health and Preventive Medicine, V15, P18, DOI 10.1007/s12199-009-0086-9
   Park Bum-Jin, 2007, Journal of Physiological Anthropology, V26, P123, DOI 10.2114/jpa2.26.123
   Pfefferbaum B, 2020, NEW ENGL J MED, V383, P510, DOI 10.1056/NEJMp2008017
   Qiu JY, 2020, GEN PSYCHIAT, V33, DOI 10.1136/gpsych-2020-100213
   Rajkumar RP, 2020, ASIAN J PSYCHIATR, V52, DOI 10.1016/j.ajp.2020.102066
   Saraev V., 2020, SCOPING STUDY VALUIN
   Schebella MF, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17010056
   SHEEHAN DV, 1983, PROG NEURO-PSYCHOPH, V7, P599, DOI 10.1016/0278-5846(83)90031-3
   Silva RA, 2018, ENVIRON SCI TECHNOL, V52, P9545, DOI 10.1021/acs.est.8b01781
   Song CR, 2019, URBAN FOR URBAN GREE, V44, DOI 10.1016/j.ufug.2019.126437
   Song CR, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15020213
   Song CR, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13080781
   Spielberger CD, 1983, MANUAL STATE TRAIT A, P49
   Tang F, 2020, PSYCHOL HEALTH, DOI 10.1080/08870446.2020.1782410
   Tang IC, 2017, LANDSCAPE URBAN PLAN, V162, P137, DOI 10.1016/j.landurbplan.2017.02.007
   Tsunetsugu Yuko, 2007, Journal of Physiological Anthropology, V26, P135, DOI 10.2114/jpa2.26.135
   Tsunetsugu Yuko, 2010, Environmental Health and Preventive Medicine, V15, P27, DOI 10.1007/s12199-009-0091-z
   Tsutsumi M, 2017, JPN J NURS SCI, V14, P3, DOI 10.1111/jjns.12131
   Twohig-Bennett C, 2018, ENVIRON RES, V166, P628, DOI 10.1016/j.envres.2018.06.030
   Ulrich R. S., 1983, HUMAN BEHAV ENV ADV, P85, DOI DOI 10.1007/978-1-4613-3539-9_4
   ULRICH RS, 1991, J ENVIRON PSYCHOL, V11, P201, DOI 10.1016/S0272-4944(05)80184-7
   ULRICH RS, 1984, SCIENCE, V224, P420, DOI 10.1126/science.6143402
   van den Berg AE, 2003, J ENVIRON PSYCHOL, V23, P135, DOI 10.1016/S0272-4944(02)00111-1
   Wang XB, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16183263
   WEINER AA, 1986, ACTA PSYCHIAT SCAND, V73, P559, DOI 10.1111/j.1600-0447.1986.tb02725.x
   Wen Y, 2019, ENVIRON HEALTH PREV, V24, DOI 10.1186/s12199-019-0822-8
   White MP, 2018, NEUROPSYCH DIS TREAT, V14, P3001, DOI 10.2147/NDT.S179038
   Woo J, 2020, EXP NEUROBIOL, V29, P120, DOI 10.5607/en20013
   Xu SQ, 2020, LANCET, V395, P1321, DOI 10.1016/S0140-6736(20)30845-X
   Yao H, 2020, LANCET PSYCHIAT, V7, pE21, DOI 10.1016/S2215-0366(20)30090-0
NR 60
TC 0
Z9 0
U1 3
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD NOV
PY 2020
VL 17
IS 21
AR 8011
DI 10.3390/ijerph17218011
PG 13
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA OQ9BW
UT WOS:000589070600001
PM 33143327
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Verkhivker, G
AF Verkhivker, Gennady
TI Coevolution, Dynamics and Allostery Conspire in Shaping Cooperative
   Binding and Signal Transmission of the SARS-CoV-2 Spike Protein with
   Human Angiotensin-Converting Enzyme 2
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE SARS-CoV spike protein; ACE2; coevolution; molecular dynamics; alanine
   scanning; binding free energy; allosteric interactions; signal
   transmission
ID RECEPTOR-BINDING; WEB SERVER; EVOLUTIONARY CONSERVATION; STATISTICAL
   POTENTIALS; STRUCTURE PREDICTION; MOLECULAR-DYNAMICS; MUTUAL
   INFORMATION; CORONAVIRUS; DOMAIN; STABILITY
AB Binding to the host receptor is a critical initial step for the coronavirus SARS-CoV-2 spike protein to enter into target cells and trigger virus transmission. A detailed dynamic and energetic view of the binding mechanisms underlying virus entry is not fully understood and the consensus around the molecular origins behind binding preferences of SARS-CoV-2 for binding with the angiotensin-converting enzyme 2 (ACE2) host receptor is yet to be established. In this work, we performed a comprehensive computational investigation in which sequence analysis and modeling of coevolutionary networks are combined with atomistic molecular simulations and comparative binding free energy analysis of the SARS-CoV and SARS-CoV-2 spike protein receptor binding domains with the ACE2 host receptor. Different from other computational studies, we systematically examine the molecular and energetic determinants of the binding mechanisms between SARS-CoV-2 and ACE2 proteins through the lens of coevolution, conformational dynamics, and allosteric interactions that conspire to drive binding interactions and signal transmission. Conformational dynamics analysis revealed the important differences in mobility of the binding interfaces for the SARS-CoV-2 spike protein that are not confined to several binding hotspots, but instead are broadly distributed across many interface residues. Through coevolutionary network analysis and dynamics-based alanine scanning, we established linkages between the binding energy hotspots and potential regulators and carriers of signal communication in the virus-host receptor complexes. The results of this study detailed a binding mechanism in which the energetics of the SARS-CoV-2 association with ACE2 may be determined by cumulative changes of a number of residues distributed across the entire binding interface. The central findings of this study are consistent with structural and biochemical data and highlight drug discovery challenges of inhibiting large and adaptive protein-protein interfaces responsible for virus entry and infection transmission.
C1 [Verkhivker, Gennady] Chapman Univ, Schmid Coll Sci & Technol, Grad Program Computat & Data Sci, Orange, CA 92866 USA.
   [Verkhivker, Gennady] Chapman Univ, Dept Biomed & Pharmaceut Sci, Sch Pharm, Irvine, CA 92618 USA.
RP Verkhivker, G (corresponding author), Chapman Univ, Schmid Coll Sci & Technol, Grad Program Computat & Data Sci, Orange, CA 92866 USA.; Verkhivker, G (corresponding author), Chapman Univ, Dept Biomed & Pharmaceut Sci, Sch Pharm, Irvine, CA 92618 USA.
EM verkhivk@chapman.edu
RI Verkhivker, Gennady/V-9404-2018
OI Verkhivker, Gennady/0000-0002-4507-4471
CR Ali Amanat, 2020, Sci Rep, V10, P14214, DOI 10.1038/s41598-020-71188-3
   Anandakrishnan R, 2012, NUCLEIC ACIDS RES, V40, pW537, DOI 10.1093/nar/gks375
   Armijos-Jaramillo V, 2020, EVOL APPL, V13, P2168, DOI 10.1111/eva.12980
   Ashkenazy H, 2016, NUCLEIC ACIDS RES, V44, pW344, DOI 10.1093/nar/gkw408
   Astuti I, 2020, DIABETES METAB SYND, V14, P407, DOI 10.1016/j.dsx.2020.04.020
   Ben Chorin A, 2020, PROTEIN SCI, V29, P258, DOI 10.1002/pro.3779
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bernstein KE, 2013, PHARMACOL REV, V65, P1, DOI 10.1124/pr.112.006809
   Bhattacharya D, 2016, NUCLEIC ACIDS RES, V44, pW406, DOI 10.1093/nar/gkw336
   Brielle ES, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050497
   BUNNING P, 1985, J INORG BIOCHEM, V24, P183, DOI 10.1016/0162-0134(85)85002-9
   Casalino L, 2020, ACS CENTRAL SCI, V6, P1722, DOI 10.1021/acscentsci.0c01056
   Chakrabarti S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008591
   Chakrabarti S, 2009, PROTEINS, V75, P231, DOI 10.1002/prot.22239
   Chakraborti S, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-73
   Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071
   Christensen NJ, 2013, J CHEM THEORY COMPUT, V9, P3210, DOI 10.1021/ct4002152
   Christensen NJ, 2012, J CHEM INF MODEL, V52, P3028, DOI 10.1021/ci300398z
   Ciemny MP, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030606
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Dehouck Y, 2006, BIOPHYS J, V90, P4010, DOI 10.1529/biophysj.105.079434
   Dehouck Y, 2013, NUCLEIC ACIDS RES, V41, pW333, DOI 10.1093/nar/gkt450
   Dehouck Y, 2009, BIOINFORMATICS, V25, P2537, DOI 10.1093/bioinformatics/btp445
   Di Paola L, 2020, J PROTEOME RES, V19, P4576, DOI 10.1021/acs.jproteome.0c00273
   Di Pierro M, 2015, J CHEM THEORY COMPUT, V11, P5624, DOI 10.1021/acs.jctc.5b00648
   Dunn SD, 2008, BIOINFORMATICS, V24, P333, DOI 10.1093/bioinformatics/btm604
   El-Gebali S, 2019, NUCLEIC ACIDS RES, V47, pD427, DOI 10.1093/nar/gky995
   Fernandez-Fuentes N, 2006, NUCLEIC ACIDS RES, V34, pW173, DOI 10.1093/nar/gkl113
   Finn RD, 2014, NUCLEIC ACIDS RES, V42, pD364, DOI 10.1093/nar/gkt1210
   Fiser A, 2003, BIOINFORMATICS, V19, P2500, DOI 10.1093/bioinformatics/btg362
   Guerois R, 2002, J MOL BIOL, V320, P369, DOI 10.1016/S0022-2836(02)00442-4
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   He YX, 2005, J IMMUNOL, V174, P4908, DOI 10.4049/jimmunol.174.8.4908
   Hekkelman ML, 2010, NUCLEIC ACIDS RES, V38, pW719, DOI 10.1093/nar/gkq453
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang CD, 2017, ANNU REV BIOPHYS, V46, P317, DOI 10.1146/annurev-biophys-070816-033701
   Hwang WC, 2006, J BIOL CHEM, V281, P34610, DOI 10.1074/jbc.M603275200
   Jaimes JA, 2020, J MOL BIOL, V432, P3309, DOI 10.1016/j.jmb.2020.04.009
   Jeon J, 2011, MOL BIOL EVOL, V28, P2675, DOI 10.1093/molbev/msr094
   Jiang YJ, 2017, J MOL BIOL, V429, P2667, DOI 10.1016/j.jmb.2017.07.007
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Kalathiya U, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051473
   Kmiecik S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113496
   Kmiecik S, 2016, CHEM REV, V116, P7898, DOI 10.1021/acs.chemrev.6b00163
   Kolinski A, 2004, ACTA BIOCHIM POL, V51, P349
   Kuhn JH, 2004, CELL MOL LIFE SCI, V61, P2738, DOI 10.1007/s00018-004-4242-5
   Kurcinski M, 2019, BIOINFORMATICS, V35, P694, DOI 10.1093/bioinformatics/bty685
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lee BC, 2008, PROTEINS, V72, P863, DOI 10.1002/prot.21972
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lombardi LE, 2016, BIOINFORMATICS, V32, P1235, DOI 10.1093/bioinformatics/btv740
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f
   Macours N, 2004, INT REV CYTOL, V239, P47, DOI 10.1016/S0074-7696(04)39002-9
   Buslje CM, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000978
   Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291
   Martin LC, 2005, BIOINFORMATICS, V21, P4116, DOI 10.1093/bioinformatics/bti671
   MARTYNA GJ, 1992, J CHEM PHYS, V97, P2635, DOI 10.1063/1.463940
   MARTYNA GJ, 1994, J CHEM PHYS, V101, P4177, DOI 10.1063/1.467468
   Mistry J, 2013, NUCLEIC ACIDS RES, V41, DOI [10.1093/nar/gkt263, 10.1093/nar/gkt1223]
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Popovych N, 2006, NAT STRUCT MOL BIOL, V13, P831, DOI 10.1038/nsmb1132
   Procko Erik, 2020, bioRxiv, DOI 10.1101/2020.03.16.994236
   Rose PW, 2017, NUCLEIC ACIDS RES, V45, pD271, DOI 10.1093/nar/gkw1000
   Rotkiewicz P, 2008, J COMPUT CHEM, V29, P1460, DOI 10.1002/jcc.20906
   Rozewicki J, 2019, NUCLEIC ACIDS RES, V47, pW5, DOI 10.1093/nar/gkz342
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Schymkowitz J, 2005, NUCLEIC ACIDS RES, V33, pW382, DOI 10.1093/nar/gki387
   Shah M., 2020, RES SQ, DOI [10.21203/rs.3.rs-16932/v1., DOI 10.21203/RS.3.RS-16932/V1]
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Simonetti FL, 2013, NUCLEIC ACIDS RES, V41, pW8, DOI 10.1093/nar/gkt427
   Spinello A, 2020, J PHYS CHEM LETT, V11, P4785, DOI 10.1021/acs.jpclett.0c01148
   Starr TN, 2020, CELL, V182, P1295, DOI 10.1016/j.cell.2020.08.012
   Stetz G, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25329-4
   Stetz G, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005299
   Suzek BE, 2015, BIOINFORMATICS, V31, P926, DOI 10.1093/bioinformatics/btu739
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Teppa E, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-235
   Tillier ERM, 2003, BIOINFORMATICS, V19, P750, DOI 10.1093/bioinformatics/btg072
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Towler P, 2004, J BIOL CHEM, V279, P17996, DOI 10.1074/jbc.M311191200
   Tse A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130203
   Tzeng SR, 2009, NATURE, V462, P368, DOI 10.1038/nature08560
   Van Durme J, 2011, BIOINFORMATICS, V27, P1711, DOI 10.1093/bioinformatics/btr254
   Vangone A, 2015, ELIFE, V4, DOI 10.7554/eLife.07454
   Veeramachaneni GK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1773318
   Verkhivker GM, 2020, J PROTEOME RES, V19, P4587, DOI 10.1021/acs.jproteome.0c00654
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wang YJ, 2020, P NATL ACAD SCI USA, V117, P13967, DOI 10.1073/pnas.2008209117
   Warner FJ, 2004, CELL MOL LIFE SCI, V61, P2704, DOI 10.1007/s00018-004-4240-7
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu CH, 2006, NUCLEIC ACIDS RES, V34, pD187, DOI 10.1093/nar/gkj161
   Wu KL, 2011, J VIROL, V85, P5331, DOI 10.1128/JVI.02274-10
   Xue LC, 2016, BIOINFORMATICS, V32, P3676, DOI 10.1093/bioinformatics/btw514
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yi Y, 2020, INT J BIOL SCI, V16, P1753, DOI 10.7150/ijbs.45134
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 105
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2020
VL 21
IS 21
AR 8268
DI 10.3390/ijms21218268
PG 31
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA OQ9EO
UT WOS:000589077900001
PM 33158276
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Temesgen, Z
   Assi, M
   Shweta, FNU
   Vergidis, P
   Rizza, SA
   Bauer, PR
   Pickering, BW
   Razonable, RR
   Libertin, CR
   Burger, CD
   Orenstein, R
   Vargas, HE
   Palraj, R
   Dababneh, AS
   Chappell, G
   Chappell, D
   Ahmed, O
   Sakemura, R
   Durrant, C
   Kenderian, SS
   Badley, AD
AF Temesgen, Zelalem
   Assi, Mariam
   Shweta, F. N. U.
   Vergidis, Paschalis
   Rizza, Stacey A.
   Bauer, Philippe R.
   Pickering, Brian W.
   Razonable, Raymund R.
   Libertin, Claudia R.
   Burger, Charles D.
   Orenstein, Robert
   Vargas, Hugo E.
   Palraj, Raj
   Dababneh, Ala S.
   Chappell, Gabrielle
   Chappell, Dale
   Ahmed, Omar
   Sakemura, Reona
   Durrant, Cameron
   Kenderian, Saad S.
   Badley, Andrew D.
TI GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A
   Case-Cohort Study
SO MAYO CLINIC PROCEEDINGS
LA English
DT Article
ID CYTOKINE RELEASE SYNDROME; CLINICAL CHARACTERISTICS; CELLS; WUHAN; CD19
AB Objective: To assess the efficacy and safety of lenzilumab in patients with severe coronavirus disease 2019 (COVID-19) pneumonia.
   Methods: Hospitalized patients with COVID-19 pneumonia and risk factors for poor outcomes were treated with lenzilumab 600 mg intravenously for three doses through an emergency single-use investigational new drug application. Patient characteristics, clinical and laboratory outcomes, and adverse events were recorded. We also identified a cohort of patients matched to the lenzilumab patients for age, sex, and disease severity. Study dates were March 13, 2020, to June 18, 2020. All patients were followed through hospital discharge or death.
   Results: Twelve patients were treated with lenzilumab; 27 patients comprised the matched control cohort (untreated). Clinical improvement, defined as improvement of at least 2 points on the 8-point ordinal clinical endpoints scale, was observed in 11 of 12 (91.7%) patients treated with lenzilumab and 22 of 27 (81.5%) untreated patients. The time to clinical improvement was significantly shorter for the lenzilumab-treated group compared with the untreated cohort with a median of 5 days versus 11 days (P=.006). Similarly, the proportion of patients with acute respiratory distress syndrome (oxygen saturation/fraction of inspired oxygen<315 mm Hg) was significantly reduced over time when treated with lenzilumab compared with untreated (P<.001). Significant improvement in inflammatory markers (C-reactive protein and interleukin 6) and markers of disease severity (absolute lymphocyte count) were observed in patients who received lenzilumab, but not in untreated patients. Cytokine analysis showed a reduction in inflammatory myeloid cells 2 days after lenzilumab treatment. There were no treatment-emergent adverse events attributable to lenzilumab.
   Conclusion: In high-risk COVID-19 patients with severe pneumonia, granulocyte-macrophage colony-stimulating factor neutralization with lenzilumab was safe and associated with faster improvement in clinical outcomes, including oxygenation, and greater reductions in inflammatory markers compared with a matched control cohort of patients hospitalized with severe COVID-19 pneumonia. A randomized, placebo-controlled clinical trial to validate these findings is ongoing (NCT04351152). (C) 2020 Mayo Foundation for Medical Education and Research
C1 [Temesgen, Zelalem; Assi, Mariam; Shweta, F. N. U.; Vergidis, Paschalis; Rizza, Stacey A.; Razonable, Raymund R.; Palraj, Raj; Dababneh, Ala S.; Badley, Andrew D.] Mayo Clin, Div Infect Dis, 200 First St SW, Rochester, MN 55905 USA.
   [Bauer, Philippe R.] Mayo Clin, Div Pulm & Crit Care Med, Rochester, MN 55905 USA.
   [Pickering, Brian W.] Mayo Clin, Dept Anesthesia & Crit Care Med, Rochester, MN 55905 USA.
   [Sakemura, Reona; Kenderian, Saad S.] Mayo Clin, T Cell Engn, Rochester, MN 55905 USA.
   [Sakemura, Reona; Kenderian, Saad S.] Mayo Clin, Div Hematol, Rochester, MN 55905 USA.
   [Kenderian, Saad S.] Mayo Clin, Dept Immunol, Rochester, MN 55905 USA.
   [Kenderian, Saad S.; Badley, Andrew D.] Mayo Clin, Dept Mol Med, Rochester, MN 55905 USA.
   [Libertin, Claudia R.] Mayo Clin, Div Infect Dis, Jacksonville, FL 32224 USA.
   [Burger, Charles D.] Mayo Clin, Div Pulm Med, Jacksonville, FL 32224 USA.
   [Orenstein, Robert] Mayo Clin, Div Infect Dis, Scottsdale, AZ USA.
   [Vargas, Hugo E.] Mayo Clin, Div Gastroenterol & Hepatol, Scottsdale, AZ USA.
   [Chappell, Gabrielle; Chappell, Dale; Ahmed, Omar; Durrant, Cameron] Humanigen Inc, Burlingame, CA USA.
RP Temesgen, Z (corresponding author), Mayo Clin, Div Infect Dis, 200 First St SW, Rochester, MN 55905 USA.
EM Temesgen.zelalem@mayo.edu
OI Vargas, Hugo E./0000-0002-7802-688X; Razonable,
   Raymund/0000-0001-5248-0227; Bauer, Philippe/0000-0001-8429-3581;
   Shweta, FNU/0000-0001-6634-6272
FU Mayo Clinic K2R Career Development Program; NIAIDUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [AI
   110173, AI120698]; Amfar [109593-62-RGRL]; HH Sheikh Khalifa Bin Zayed
   Al-Nahyan named professorship from Mayo Clinic;  [K12CA090628]
FX Lenzilumab was provided by Humanigen, Inc. This work was supported
   through grants from K12CA090628 (S.S.K.), Mayo Clinic K2R Career
   Development Program (S.S.K.), Dr Badley is supported by grant numbers AI
   110173 and AI120698 from NIAID, 109593-62-RGRL from Amfar, and the HH
   Sheikh Khalifa Bin Zayed Al-Nahyan named professorship from Mayo Clinic.
CR Arnaldez FI, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000930
   Ascierto PA, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000878
   Brudno JN, 2016, BLOOD, V127, P3321, DOI 10.1182/blood-2016-04-703751
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cox MJ, 2019, BLOOD S, V2019, P3868
   Emergency Use of an Investigational Drug or Biologic, 1998, GUIDANCE I REV BOARD
   Fitzgerald JC, 2017, CRIT CARE MED, V45, pE124, DOI 10.1097/CCM.0000000000002053
   Gust J, 2017, CANCER DISCOV, V7, P1404, DOI 10.1158/2159-8290.CD-17-0698
   Hay KA, 2017, DRUGS, V77, P237, DOI 10.1007/s40265-017-0690-8
   Henry BM, 2020, CLIN CHEM LAB MED, V58, P1021, DOI 10.1515/cclm-2020-0369
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jordan RE, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1198
   June CH, 2018, NEW ENGL J MED, V379, P64, DOI 10.1056/NEJMra1706169
   Li X, 2020, INT J INFECT DIS, V94, P128, DOI 10.1016/j.ijid.2020.03.053
   Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866
   McGonagle D, 2020, LANCET RHEUMATOL, V2, pE437, DOI 10.1016/S2665-9913(20)30121-1
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Molfino NA, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-007709
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447
   Padron E, 2013, BLOOD, V121, P5068, DOI 10.1182/blood-2012-10-460170
   Patnaik MM, 2020, BLOOD, V136, P909, DOI 10.1182/blood.2019004352
   Schram AM, 2015, BLOOD, V125, P2908, DOI 10.1182/blood-2015-01-551622
   Sterner RM, 2019, BLOOD, V133, P697, DOI 10.1182/blood-2018-10-881722
   Teachey DT, 2016, CANCER DISCOV, V6, P664, DOI 10.1158/2159-8290.CD-16-0040
   Wang F, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.137799
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xiong Y, 2020, EMERG MICROBES INFEC, V9, P761, DOI 10.1080/22221751.2020.1747363
   Zhou Y, 2020, BIORXIV, DOI [10.1101/2020.02.12.945576, DOI 10.1101/2020.02.12.945576]
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0025-6196
EI 1942-5546
J9 MAYO CLIN PROC
JI Mayo Clin. Proc.
PD NOV
PY 2020
VL 95
IS 11
BP 2382
EP 2394
DI 10.1016/j.mayocp.2020.08.038
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA OP5UX
UT WOS:000588152700021
PM 33153629
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Rakib, A
   Sami, SA
   Islam, MA
   Ahmed, S
   Faiz, FB
   Khanam, BH
   Marma, KKS
   Rahman, M
   Uddin, MMN
   Nainu, F
   Bin Emran, T
   Simal-Gandara, J
AF Rakib, Ahmed
   Sami, Saad Ahmed
   Islam, Md Ashiqul
   Ahmed, Shahriar
   Faiz, Farhana Binta
   Khanam, Bibi Humayra
   Marma, Kay Kay Shain
   Rahman, Maksuda
   Uddin, Mir Muhammad Nasir
   Nainu, Firzan
   Bin Emran, Talha
   Simal-Gandara, Jesus
TI Epitope-Based Immunoinformatics Approach on Nucleocapsid Protein of
   Severe Acute Respiratory Syndrome-Coronavirus-2
SO MOLECULES
LA English
DT Article
DE COVID-19; SARS-CoV-2; vaccine; nucleocapsid protein; bioinformatics;
   immunoinformatics; epitope
ID B-CELL EPITOPES; SARS-CORONAVIRUS; IMMUNE-RESPONSES; PEPTIDE VACCINE;
   ANTIGENIC DETERMINANTS; STRUCTURE PREDICTION; VIRUS; IDENTIFICATION;
   DESIGN; WEB
AB With an increasing fatality rate, severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) has emerged as a promising threat to human health worldwide. Recently, the World Health Organization (WHO) has announced the infectious disease caused by SARS-CoV-2, which is known as coronavirus disease-2019 (COVID-2019), as a global pandemic. Additionally, the positive cases are still following an upward trend worldwide and as a corollary, there is a need for a potential vaccine to impede the progression of the disease. Lately, it has been documented that the nucleocapsid (N) protein of SARS-CoV-2 is responsible for viral replication and interferes with host immune responses. We comparatively analyzed the sequences of N protein of SARS-CoV-2 for the identification of core attributes and analyzed the ancestry through phylogenetic analysis. Subsequently, we predicted the most immunogenic epitope for the T-cell and B-cell. Importantly, our investigation mainly focused on major histocompatibility complex (MHC) class I potential peptides and NTASWFTAL interacted with most human leukocyte antigen (HLA) that are encoded by MHC class I molecules. Further, molecular docking analysis unveiled that NTASWFTAL possessed a greater affinity towards HLA and also available in a greater range of the population. Our study provides a consolidated base for vaccine design and we hope that this computational analysis will pave the way for designing novel vaccine candidates.
C1 [Rakib, Ahmed; Sami, Saad Ahmed; Islam, Md Ashiqul; Ahmed, Shahriar; Faiz, Farhana Binta; Khanam, Bibi Humayra; Marma, Kay Kay Shain; Rahman, Maksuda; Uddin, Mir Muhammad Nasir] Univ Chittagong, Fac Biol Sci, Dept Pharm, Chittagong 4331, Bangladesh.
   [Islam, Md Ashiqul] Mawlana Bhashani Sci & Technol Univ, Dept Pharm, Santosh 1902, Tangail, Bangladesh.
   [Nainu, Firzan] Hasanuddin Univ, Fac Pharm, Kota Makassar 90245, Sulawesi Selata, Indonesia.
   [Bin Emran, Talha] BGC Trust Univ Bangladesh, Dept Pharm, Chittagong 4381, Bangladesh.
   [Simal-Gandara, Jesus] Univ Vigo, Dept Analyt & Food Chem, Nutr & Bromatol Grp, Fac Food Sci & Technol, Ourense Campus, E-32004 Orense, Spain.
RP Bin Emran, T (corresponding author), BGC Trust Univ Bangladesh, Dept Pharm, Chittagong 4381, Bangladesh.; Simal-Gandara, J (corresponding author), Univ Vigo, Dept Analyt & Food Chem, Nutr & Bromatol Grp, Fac Food Sci & Technol, Ourense Campus, E-32004 Orense, Spain.
EM rakib.pharmacy.cu@gmail.com; s.a.samil8pharm@gmail.com;
   ashiqulanik@gmail.com; shahriarahmed65@gmail.com;
   farhanafaiz037@gmail.com; humayra.Khanam@cu.ac.bd; kkshainapu@gmail.com;
   maksudarahman777@gmail.com; nasirmir@cu.ac.bd; firzannainu@unhas.ac.id;
   talhabmb@bgctub.ac.bd; jsimal@uvigo.es
RI Bin Emran, Talha/P-9184-2016; Nainu, Firzan/E-2447-2017; Simal-Gandara,
   Jesus/A-9533-2009
OI Bin Emran, Talha/0000-0003-3188-2272; Nainu, Firzan/0000-0003-0989-4023;
   Simal-Gandara, Jesus/0000-0001-9215-9737; Rakib,
   Ahmed/0000-0003-3335-0368
CR Ahmed S, 2019, CLIN PHYTOSCIENCE, V5, P1, DOI [DOI 10.1186/S40816-019-0127-X, 10.1186/s40816-019-0127-x]
   Alberts B, 2002, MOL BIOL CELL
   Amrun SN, 2020, EBIOMEDICINE, V58, DOI 10.1016/j.ebiom.2020.102911
   Arthur LO, 1998, AIDS RES HUM RETROV, V14, pS311
   Briney B, 2016, CELL, V166, P1459, DOI 10.1016/j.cell.2016.08.005
   Bui HH, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-361
   Buus S, 2003, TISSUE ANTIGENS, V62, P378, DOI 10.1034/j.1399-0039.2003.00112.x
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Caubet JC, 2014, IMMUNOL ALLERGY CLIN, V34, P597, DOI 10.1016/j.iac.2014.04.004
   Chakraborty Sajib, 2010, In Silico Biology, V10, P235, DOI 10.3233/ISB-2010-0435
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Channappanavar R, 2014, J VIROL, V88, P11034, DOI 10.1128/JVI.01505-14
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Chhabra HS, 2020, INDIAN J ORTHOP, V54, P411, DOI 10.1007/s43465-020-00135-1
   Chiou SS, 2012, J GEN VIROL, V93, P1185, DOI 10.1099/vir.0.040238-0
   Choi KS, 2005, CLIN DIAGN LAB IMMUN, V12, P114, DOI 10.1128/CDLI.12.1.114-121.2005
   CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343
   Dallakyan S, 2008, SCRIPPS RES I, V2010, DOI [10.1016/j.jcice.2007.01.003, DOI 10.1016/J.JCICE.2007.01.003]
   Dalsass M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00113
   Dermine S, 2004, BBA-REV CANCER, V1704, P11, DOI 10.1016/j.bbcan.2004.03.002
   Dimitrov I, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S6-S4
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Dunbrack RL, 2002, CURR OPIN STRUC BIOL, V12, P431, DOI 10.1016/S0959-440X(02)00344-5
   EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985
   Flower Darren R., 2007, V409, P1, DOI 10.1007/978-1-60327-118-9_1
   Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681
   Giguere S, 2013, J IMMUNOL METHODS, V400, P30, DOI 10.1016/j.jim.2013.10.003
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Gupta S, 2015, METHODS MOL BIOL, V1268, P143, DOI 10.1007/978-1-4939-2285-7_7
   Hasan MA, 2013, BIOINFORM BIOL INSIG, V7, P347, DOI 10.4137/BBI.S13402
   HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang Y, 1997, J VIROL, V71, P4378, DOI 10.1128/JVI.71.6.4378-4384.1997
   Hyun-Jung Lee Chloe, 2020, F1000Res, V9, P145, DOI 10.12688/f1000research.22507.1
   Islam R, 2012, FUTURE VIROL, V7, P1029, DOI 10.2217/FVL.12.95
   Jahan I, 2020, MOLECULES, V25, DOI 10.3390/molecules25153536
   Johnson M, 2008, NUCLEIC ACIDS RES, V36, pW5, DOI 10.1093/nar/gkn201
   Kallinich T, 2007, EUR RESPIR J, V29, P1246, DOI 10.1183/09031936.00094306
   KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768
   Khalili S, 2014, ACTA MICROBIOL IMM H, V61, P285, DOI 10.1556/AMicr.61.2014.3.4
   Khan F, 2018, INT J PEPT RES THER, V24, P323, DOI 10.1007/s10989-017-9617-1
   Khan MK, 2014, MOL IMMUNOL, V61, P16, DOI 10.1016/j.molimm.2014.04.009
   Kharisma VD, 2020, J PURE APPL MICROBIO, V14, P999, DOI 10.22207/JPAM.14.SPL1.38
   Kim DE, 2004, NUCLEIC ACIDS RES, V32, pW526, DOI 10.1093/nar/gkh468
   Kim TW, 2004, J VIROL, V78, P4638, DOI 10.1128/JVI.78.9.4638-4645.2004
   Kiyotani K, 2020, J HUM GENET, V65, P569, DOI 10.1038/s10038-020-0771-5
   Knudsen NPH, 2014, P NATL ACAD SCI USA, V111, P1096, DOI 10.1073/pnas.1314973111
   KOLASKAR AS, 1990, FEBS LETT, V276, P172, DOI 10.1016/0014-5793(90)80535-Q
   Larsen Jens Erik Pontoppidan, 2006, Immunome Res, V2, P2, DOI 10.1186/1745-7580-2-2
   Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Lazoura E, 2006, IMMUNOLOGY, V119, P306, DOI 10.1111/j.1365-2567.2006.02434.x
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li WZ, 2015, NUCLEIC ACIDS RES, V43, pW580, DOI 10.1093/nar/gkv279
   Lin Y, 2003, CELL RES, V13, P141, DOI 10.1038/sj.cr.7290158
   Liniger M, 2008, VACCINE, V26, P2164, DOI 10.1016/j.vaccine.2008.01.057
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Liu ZQ, 2003, IMMUNOBIOLOGY, V208, P423, DOI 10.1078/0171-2985-00286
   Lundegaard C, 2008, NUCLEIC ACIDS RES, V36, pW509, DOI 10.1093/nar/gkn202
   Lundkvist A, 1996, VIROLOGY, V216, P397, DOI 10.1006/viro.1996.0075
   Maupetit J, 2009, NUCLEIC ACIDS RES, V37, pW498, DOI 10.1093/nar/gkp323
   Meloen RH, 2001, BIOLOGICALS, V29, P233, DOI 10.1006/biol.2001.0298
   Mishra S. T, 2020, T CELL EPITOPE BASED, DOI [10.26434/chemrxiv.12029523.v1, DOI 10.26434/CHEMRXIV.12029523.V1]
   Mishra S, 2020, ROY SOC OPEN SCI, V7, DOI 10.1098/rsos.201141
   Moutaftsi M, 2006, NAT BIOTECHNOL, V24, P817, DOI 10.1038/nbt1215
   Narayanan K, 2008, VIRUS RES, V133, P113, DOI 10.1016/j.virusres.2007.10.009
   Nardin EH, 2001, J IMMUNOL, V166, P481, DOI 10.4049/jimmunol.166.1.481
   Noorimotlagh Z, 2020, INT IMMUNOPHARMACOL, V86, DOI 10.1016/j.intimp.2020.106738
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Oany AR, 2014, DRUG DES DEV THER, V8, P1139, DOI [10.2147/DDDT.567861, 10.2147/DDDT.S67861]
   Olsson SE, 2007, VACCINE, V25, P4931, DOI 10.1016/j.vaccine.2007.03.049
   Parashar NC, 2020, INFECT GENET EVOL, V85, DOI 10.1016/j.meegid.2020.104497
   Pedersen SR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145629
   Peng H, 2006, VIROLOGY, V351, P466, DOI 10.1016/j.virol.2006.03.036
   Peters B, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-132
   Peters B, 2003, J IMMUNOL, V171, P1741, DOI 10.4049/jimmunol.171.4.1741
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pietersz GA, 2006, CURR MED CHEM, V13, P1591, DOI 10.2174/092986706777441922
   Rakib A, 2020, MOLECULES, V25, DOI 10.3390/molecules25173936
   Rakib A, 2020, COMPUT BIOL MED, V124, DOI 10.1016/j.compbiomed.2020.103967
   Rappuoli R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw2888
   RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293
   Sabara M, 1995, BIOTECHNOL ADV, V13, P803
   Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078
   Seah JN, 2000, VET MICROBIOL, V75, P11, DOI 10.1016/S0378-1135(00)00202-9
   Shey RA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40833-x
   Suarez DL, 2000, DEV COMP IMMUNOL, V24, P269, DOI 10.1016/S0145-305X(99)00078-6
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI [10.1093/molbev/msr121, 10.1093/molbev/mst197]
   Thomas JA, 2008, VIRUS RES, V134, P39, DOI 10.1016/j.virusres.2007.12.006
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   VAPALAHTI O, 1995, J MED VIROL, V46, P293, DOI 10.1002/jmv.1890460402
   VIHINEN M, 1994, PROTEINS, V19, P141, DOI 10.1002/prot.340190207
   Vivona S, 2008, TRENDS BIOTECHNOL, V26, P190, DOI 10.1016/j.tibtech.2007.12.006
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang TB, 2020, LANCET, V395, pE52, DOI 10.1016/S0140-6736(20)30558-4
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Wu F, 2020, BIORXIV, p20200124919183, DOI [10.1101/2020.01.24.919183, DOI 10.1101/2020.01.24.919183]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yu ZP, 2018, FOOD FUNCT, V9, P364, DOI 10.1039/c7fo01558e
   Zhang XW, 2013, COMPUT BIOL CHEM, V45, P30, DOI 10.1016/j.compbiolchem.2013.03.003
   Zhao P, 2005, VIROLOGY, V331, P128, DOI 10.1016/j.virol.2004.10.016
   Zhou MH, 2006, J IMMUNOL, V177, P2138, DOI 10.4049/jimmunol.177.4.2138
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 107
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD NOV
PY 2020
VL 25
IS 21
AR 5088
DI 10.3390/molecules25215088
PG 25
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA OR1IZ
UT WOS:000589231200001
PM 33147821
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jeans, EB
   Hu, YH
   Stish, BJ
   King, B
   Davis, M
   Harmsen, WS
   Fruth, KM
   Locher, SE
   Deufel, CL
   Evans, JD
   Martenson, JA
   Lester, SC
AF Jeans, Elizabeth B.
   Hu, Yue-Houng
   Stish, Bradley J.
   King, Brian
   Davis, Mark
   Harmsen, William S.
   Fruth, Kristin M.
   Locher, Sarah E.
   Deufel, Christopher L.
   Evans, Jaden D.
   Martenson, James A.
   Lester, Scott C.
TI Low-Dose Hypofractionated Total Skin Electron Beam Therapy for Adult
   Cutaneous T-Cell Lymphoma
SO PRACTICAL RADIATION ONCOLOGY
LA English
DT Article
ID MYCOSIS-FUNGOIDES; RADIATION-THERAPY; SEZARY-SYNDROME
AB Purpose: Historically, the standard of care for total skin electron beam therapy (TSEBT) delivered 30 to 36 Gy over 5 to 10 weeks. Given the high risk of relapse, a majority of patients require additional treatments. Therefore, attempts to use a shortened course of TSEBT have been investigated.
   Methods and Materials: We conducted a single-institution retrospective review to evaluate disease response, control, and toxicity using a low-dose, hypofractionated course of TSEBT (HTSEBT) in patients with mycosis fungoides.
   Results: Forty patients received 57 courses of HTSEBT. Median dose (Gy)/fractionation was 12/3, spanning a median time of 2.4 weeks. Overall response rate of patients assessed (n = 54) was 100%. Thirty-one courses (57.4%) resulted in a complete response and 23 courses (42.6%) resulted in a partial response. Cumulative incidence of progressive skin disease at 3 months was 37.2%, at 6 months, 56.9%, and at 1 year, 81.5%. Of the 40 patients treated with a first course of HTSEBT, 31 received subsequent courses of radiotherapy. Cumulative incidence of subsequent treatment was 28.0% at 3 months, 46.8% at 6 months, and 70.0% at 1 year. Patients who underwent repeat courses of HTSEBT continued to have similar treatment responses to repeat courses without increased toxicities. Toxicities from all courses were acceptable with the exception of 1 patient, who experienced grade 4 skin toxicity (moist desquamation requiring hospitalization).
   Conclusions: Low-dose HTSEBT provides good palliation in patients with cutaneous T-cell lymphoma with a satisfactory response and toxicity profile. HTSEBT allows therapy to be completed in far fewer treatments. Low-dose HTSEBT is an appropriate treatment option for patients unable to come for daily treatment. HTSEBT provides a way to decrease exposure to other patients and staff during public health emergencies such as the coronavirus disease 2019 (COVID-19) pandemic. (C) 2020 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.
C1 [Jeans, Elizabeth B.; Hu, Yue-Houng; Stish, Bradley J.; Locher, Sarah E.; Deufel, Christopher L.; Evans, Jaden D.; Martenson, James A.; Lester, Scott C.] Mayo Clin, Dept Radiat Oncol, Rochester, MN 55902 USA.
   [King, Brian; Davis, Mark] Mayo Clin, Dept Dermatol, Rochester, MN USA.
   [Harmsen, William S.; Fruth, Kristin M.] Mayo Clin, Dept Biomed Stat & Informat, Rochester, MN USA.
   [Evans, Jaden D.] Intermt Healthcare, Dept Radiat Oncol, Ogden, UT USA.
RP Lester, SC (corresponding author), Mayo Clin, Dept Radiat Oncol, Rochester, MN 55902 USA.
EM lester.scott@mayo.edu
CR Achard V, INT J RAD ONCOL BIOL
   de Moraes FY, 2014, REP PRACT ONCOL RADI, V19, P92, DOI 10.1016/j.rpor.2013.08.003
   Deufel CL, 2013, J APPL CLIN MED PHYS, V14, P115, DOI 10.1120/jacmp.v14i5.4309
   Elsayad K, 2015, INT J RADIAT ONCOL, V93, P1077, DOI 10.1016/j.ijrobp.2015.08.041
   Evans Jaden D, 2016, Adv Radiat Oncol, V1, P101, DOI 10.1016/j.adro.2016.03.005
   Filippi AR, INT J RAD ONCOL BIOL
   Georgakopoulos I, 2019, CLIN TRANSL RAD ONCO, V15, P26, DOI 10.1016/j.ctro.2018.12.002
   Harrison C, 2011, INT J RADIAT ONCOL, V81, pE651, DOI 10.1016/j.ijrobp.2011.01.023
   Hoppe RT, 2015, J AM ACAD DERMATOL, V72, P286, DOI 10.1016/j.jaad.2014.10.014
   HOPPE RT, 1990, CURR PROB CANCER, V14, P295
   HOPPE RT, 1991, FRONT RADIAT THER ON, V25, P80
   Kamstrup MR, 2015, INT J RADIAT ONCOL, V92, P138, DOI 10.1016/j.ijrobp.2015.01.047
   King BJ, 2020, J AM ACAD DERMATOL, V82, P634, DOI 10.1016/j.jaad.2019.07.040
   Kroeger K, 2017, STRAHLENTHER ONKOL, V193, P1024, DOI 10.1007/s00066-017-1188-8
   LEBOURGEOIS JP, 1987, INT J RADIAT ONCOL, V13, P189, DOI 10.1016/0360-3016(87)90126-X
   MICAILY B, 1983, INT J RADIAT ONCOL, V9, P475, DOI 10.1016/0360-3016(83)90063-9
   Morris S, 2017, INT J RADIAT ONCOL, V99, P627, DOI 10.1016/j.ijrobp.2017.05.052
   Morris SL, 2013, INT J RADIAT ONCOL, V86, P936, DOI 10.1016/j.ijrobp.2013.04.042
   Navi D, 2011, ARCH DERMATOL, V147, P561, DOI 10.1001/archdermatol.2011.98
   NISCE LZ, 1982, INT J RADIAT ONCOL, V8, P1587, DOI 10.1016/0360-3016(82)90621-6
   Olsen EA, 2011, J CLIN ONCOL, V29, P2598, DOI 10.1200/JCO.2010.32.0630
   Rivers CI, 2019, CL LYMPH MYELOM LEUK, V19, P83, DOI 10.1016/j.clml.2018.11.015
   Specht L, 2015, INT J RADIAT ONCOL, V92, P32, DOI 10.1016/j.ijrobp.2015.01.008
   Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2
   Zaorsky NG, ADV RAD ONCOL
NR 25
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1879-8500
J9 PRACT RADIAT ONCOL
JI Pract. Radiat. Oncol.
PD NOV-DEC
PY 2020
VL 10
IS 6
BP E529
EP E537
DI 10.1016/j.prro.2020.08.001
PG 9
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA OP0LT
UT WOS:000587767900013
PM 32781247
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bouteraa, Y
   Ben Abdallah, I
   Ibrahim, A
   Ahanger, TA
AF Bouteraa, Yassine
   Ben Abdallah, Ismail
   Ibrahim, Atef
   Ahanger, Tariq Ahamed
TI Development of an IoT-Based Solution Incorporating Biofeedback and Fuzzy
   Logic Control for Elbow Rehabilitation
SO APPLIED SCIENCES-BASEL
LA English
DT Article
DE rehabilitation robotics; human&#8211; robot interaction; gesture
   control; Internet of Things
ID WRIST REHABILITATION; ADMITTANCE CONTROL; ROBOT; SYSTEM; RECOGNITION;
   EXOSKELETON; DESIGN
AB The last few years have seen significant advances in neuromotor rehabilitation technologies, such as robotics and virtual reality. Rehabilitation robotics primarily focuses on devices, control strategies, scenarios and protocols aimed at recovering sensory, motor and cognitive impairments often experienced by stroke victims. Remote rehabilitation can be adopted to relieve stress in healthcare facilities by limiting the movement of patients to clinics, mainly in the current COVID-19 pandemic. In this context, we have developed a remote controlled intelligent robot for elbow rehabilitation. The proposed system offers real-time monitoring and ultimately provides an electronic health record (EHR). Rehabilitation is an area of medical practice that treats patients with pain. However, this pain can prevent a person from positively interacting with therapy. To cope with this matter, the proposed solution incorporates a cascading fuzzy decision system to estimate patient pain. Indeed, as a safety measure, when the pain exceeds a certain threshold, the robot must stop the action even if the desired angle has not yet been reached. A fusion of sensors incorporating an electromyography (EMG) signal, feedback from the current sensor and feedback from the position encoder provides the fuzzy controller with the data needed to estimate pain. This measured pain is fed back into the control loop and processed to generate safe robot actions. The main contribution was to integrate vision-based gesture control, a cascade fuzzy logic-based decision system and IoT (Internet of Things) to help therapists remotely take care of patients efficiently and reliably. Tests carried out on three different subjects showed encouraging results.
C1 [Bouteraa, Yassine; Ibrahim, Atef; Ahanger, Tariq Ahamed] Prince Sattam Bin Abdulaziz Univ, Coll Comp Engn & Sci, Al Kharj 16268, Saudi Arabia.
   [Bouteraa, Yassine; Ben Abdallah, Ismail] Univ Sfax, CEM Lab ENIS, Sfax 3038, Tunisia.
   [Bouteraa, Yassine; Ben Abdallah, Ismail] Univ Sfax, Digital Res Ctr Sfax, Sfax 3038, Tunisia.
RP Bouteraa, Y (corresponding author), Prince Sattam Bin Abdulaziz Univ, Coll Comp Engn & Sci, Al Kharj 16268, Saudi Arabia.; Bouteraa, Y (corresponding author), Univ Sfax, CEM Lab ENIS, Sfax 3038, Tunisia.; Bouteraa, Y (corresponding author), Univ Sfax, Digital Res Ctr Sfax, Sfax 3038, Tunisia.
EM yassine.bouteraa@isbs.usf.tn; ismail.benabdallah@enis.tn;
   aa.mohamed@psau.edu.sa; t.ahanger@psau.edu.sa
OI ibrahim, atef/0000-0002-1115-4051
FU Deanship of Scientific Research at Prince Sattam Bin Abdulaziz
   University [2020/01/16466]
FX The authors would like to acknowledge the support of the Deanship of
   Scientific Research at Prince Sattam Bin Abdulaziz University under the
   research project number 2020/01/16466.
CR Abdallah I., 2016, P IEEE 4 INT C CONTR, P1
   Ali A., 2018, 2018 1 INT WORKSH MO, P1, DOI DOI 10.1109/IWMTS.2018.8454697
   Ayas MS, 2017, CONTROL ENG PRACT, V59, P44, DOI 10.1016/j.conengprac.2016.11.015
   Baniasad MA, 2011, STUD HEALTH TECHNOL, V163, P39, DOI 10.3233/978-1-60750-706-2-39
   Ben Aabdallah I, 2016, INT J SMART SENS INT, V9, P1029
   Ben Abdallah I., 2015, P 7 INT C  MOD ID CO
   Ben Abdallah I, 2016, ADV HUM-COMPUT INTER, V2016, DOI 10.1155/2016/7921295
   Bi LZ, 2019, BIOMED SIGNAL PROCES, V51, P113, DOI 10.1016/j.bspc.2019.02.011
   Birouas FI, 2020, SYMMETRY-BASEL, V12, DOI 10.3390/sym12091470
   Birouas FI, 2019, 2019 15TH INTERNATIONAL CONFERENCE ON ENGINEERING OF MODERN ELECTRIC SYSTEMS (EMES), P17, DOI 10.1109/EMES.2019.8795179
   Bouteraa Y, 2020, IND ROBOT, V47, P489, DOI 10.1108/IR-02-2020-0041
   Bouteraa Y, 2019, J INTELL ROBOT SYST, V96, P31, DOI 10.1007/s10846-018-0966-6
   Bouteraa Y, 2018, COMPUT ELECTR ENG, V67, P629, DOI 10.1016/j.compeleceng.2017.02.004
   Bouteraa Y, 2017, IND ROBOT, V44, P575, DOI 10.1108/IR-12-2016-0356
   Chih-Hsiao T., 2015, INT J DISTRIB SENS N, V2015
   Cram J.R., 2010, INTRO SURFACE ELECTR
   Ding IJ, 2015, APPL MATH MODEL, V39, P5769, DOI 10.1016/j.apm.2014.12.054
   Freedman B, 2010, U.S. Patent, Patent No. [2010/0118123, 20100118123, 20100118123 A1]
   Gayda M, 2005, ARCH PHYS MED REHAB, V86, P210, DOI 10.1016/j.apmr.2004.07.351
   Ghassemi M, 2019, IEEE T NEUR SYS REH, V27, P283, DOI 10.1109/TNSRE.2019.2894102
   Harischandra PAD, 2019, INT J INTELL ROBOT, V3, P59, DOI 10.1007/s41315-019-00080-9
   Ibanez R, 2014, ADV ENG SOFTW, V76, P171, DOI 10.1016/j.advengsoft.2014.07.005
   Keemink AQL, 2018, INT J ROBOT RES, V37, P1421, DOI 10.1177/0278364918768950
   Krebs HI, 2007, IEEE T NEUR SYS REH, V15, P327, DOI 10.1109/TNSRE.2007.903899
   Krebs HI, 2003, AUTON ROBOT, V15, P7, DOI 10.1023/A:1024494031121
   Lee HW, 2015, SMART SCI, V3, P117, DOI 10.1080/23080477.2015.11665645
   Li BYL, 2013, IEEE WORK APP COMP, P186, DOI 10.1109/WACV.2013.6475017
   Lin BS, 2018, IEEE ACCESS, V6, P2720, DOI 10.1109/ACCESS.2017.2785122
   Liu J., 2019, IEEE T BIOMED ENG, V99, P272, DOI [10.1109/TBME.2019.293518231425016, DOI 10.1109/TBME.2019.293518231425016]
   Luo J, 2019, APPL SCI-BASEL, V9, DOI 10.3390/app9102099
   Mazzoleni S, 2018, IEEE T NEUR SYS REH, V26, P1889, DOI 10.1109/TNSRE.2018.2864935
   Meng Q, 2019, J MED SYST, V43, DOI 10.1007/s10916-019-1166-z
   Miao YM, 2018, MOBILE NETW APPL, V23, P1645, DOI 10.1007/s11036-018-1110-3
   Moshaii AA, 2019, IND ROBOT, V46, P839, DOI 10.1108/IR-05-2019-0110
   Omarkulov N, 2016, P IEEE RAS-EMBS INT, P962, DOI 10.1109/BIOROB.2016.7523753
   Pan LZ, 2019, FRONT ROBOT AI, V6, DOI 10.3389/frobt.2019.00102
   Perry JC, 2007, IEEE-ASME T MECH, V12, P408, DOI 10.1109/TMECH.2007.901934
   Phinyomark A, 2012, EXPERT SYST APPL, V39, P7420, DOI 10.1016/j.eswa.2012.01.102
   Samaee S, 2020, BIOMED SIGNAL PROCES, V57, DOI 10.1016/j.bspc.2019.101739
   Squeri V, 2014, IEEE T NEUR SYS REH, V22, P312, DOI 10.1109/TNSRE.2013.2250521
   Strbac M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/740469
   Tappeiner L., 2017, P 7 INT WORKSH COMP, P174
   Tkach D, 2010, J NEUROENG REHABIL, V7, DOI 10.1186/1743-0003-7-21
   Tsai TC, 2020, APPL SCI-BASEL, V10, DOI 10.3390/app10010043
   Van Boxtel A, 1998, PSYCHOPHYSIOLOGY, V35, P690, DOI 10.1017/S0048577298970317
   Vogel O, 2011, IEEE IMAGE PROC, P5, DOI 10.1109/ICIP.2011.6116621
   Voon K, 2016, BURNS, V42, P1797, DOI 10.1016/j.burns.2016.06.007
   Xu GZ, 2011, ADV ROBOTICS, V25, P229, DOI 10.1163/016918610X538561
   Xu ZH, 2017, 2017 IEEE INTERNATIONAL CONFERENCE ON ROBOTICS AND BIOMIMETICS (IEEE ROBIO 2017), P1583, DOI 10.1109/ROBIO.2017.8324643
   Yamamoto I, 2018, SENSOR MATER, V30, P1825, DOI 10.18494/SAM.2018.1901
   YBouteraa, 2020, INT J COMPUT COMMUN, V15, DOI 10.15837/ijccc.2020.4.3814
   Zhang LG, 2020, APPL SCI-BASEL, V10, DOI 10.3390/app10196684
NR 52
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3417
J9 APPL SCI-BASEL
JI Appl. Sci.-Basel
PD NOV
PY 2020
VL 10
IS 21
AR 7793
DI 10.3390/app10217793
PG 18
WC Chemistry, Multidisciplinary; Engineering, Multidisciplinary; Materials
   Science, Multidisciplinary; Physics, Applied
SC Chemistry; Engineering; Materials Science; Physics
GA OQ7HF
UT WOS:000588948900001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Alrasheed, H
   Althnian, A
   Kurdi, H
   Al-Mgren, H
   Alharbi, S
AF Alrasheed, Hend
   Althnian, Alhanoof
   Kurdi, Heba
   Al-Mgren, Heila
   Alharbi, Sulaiman
TI COVID-19 Spread in Saudi Arabia: Modeling, Simulation and Analysis
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE COVID-19; simulation model; network-based epidemic model; contact
   network; node susceptibility
ID EPIDEMIC; NETWORKS; DYNAMICS; CHINA; PREDICTION; OUTBREAKS; PATTERNS;
   DISEASES
AB The novel coronavirus Severe Acute Respiratory Syndrome (SARS)-Coronavirus-2 (CoV-2) has resulted in an ongoing pandemic and has affected over 200 countries around the world. Mathematical epidemic models can be used to predict the course of an epidemic and develop methods for controlling it. As social contact is a key factor in disease spreading, modeling epidemics on contact networks has been increasingly used. In this work, we propose a simulation model for the spread of Coronavirus Disease 2019 (COVID-19) in Saudi Arabia using a network-based epidemic model. We generated a contact network that captures realistic social behaviors and dynamics of individuals in Saudi Arabia. The proposed model was used to evaluate the effectiveness of the control measures employed by the Saudi government, to predict the future dynamics of the disease in Saudi Arabia according to different scenarios, and to investigate multiple vaccination strategies. Our results suggest that Saudi Arabia would have faced a nationwide peak of the outbreak on 21 April 2020 with a total of approximately 26 million infections had it not imposed strict control measures. The results also indicate that social distancing plays a crucial role in determining the future local dynamics of the epidemic. Our results also show that the closure of schools and mosques had the maximum impact on delaying the epidemic peak and slowing down the infection rate. If a vaccine does not become available and no social distancing is practiced from 10 June 2020, our predictions suggest that the epidemic will end in Saudi Arabia at the beginning of November with over 13 million infected individuals, and it may take only 15 days to end the epidemic after 70% of the population receive a vaccine.
C1 [Alrasheed, Hend; Althnian, Alhanoof] King Saud Univ, Coll Comp & Informat Sci, Dept Informat Technol, Riyadh 11451, Saudi Arabia.
   [Kurdi, Heba] King Saud Univ, Coll Comp & Informat Sci, Dept Comp Sci, Riyadh 11451, Saudi Arabia.
   [Kurdi, Heba] MIT, Dept Mech Engn, Sch Engn, Cambridge, MA 02142 USA.
   [Al-Mgren, Heila] King Saud Univ, Coll Comp & Informat Sci, Dept Software Engn, Riyadh 11451, Saudi Arabia.
   [Alharbi, Sulaiman] King Saud Univ, Coll Sci, Dept Bot & Microbiol, Riyadh 11451, Saudi Arabia.
RP Alrasheed, H (corresponding author), King Saud Univ, Coll Comp & Informat Sci, Dept Informat Technol, Riyadh 11451, Saudi Arabia.
EM halrasheed@ksu.edu.sa; aalthnian@ksu.edu.sa; hkurdi@ksu.edu.sa;
   heila.almogren@gmail.com; sharbi@ksu.edu.sa
OI Kurdi, Heba/0000-0001-6110-9657; Althnian, Alhanoof/0000-0003-1837-3860
FU General Directorate for Research and Studies, Ministry of Health, Saudi
   Arabia [RSP-2020/204]; King Saud University, Riyadh, Saudi ArabiaKing
   Saud University
FX The authors would like to thank the General Directorate for Research and
   Studies, Ministry of Health, Saudi Arabia and Researchers Supporting
   Unit, Project number (RSP-2020/204), King Saud University, Riyadh, Saudi
   Arabia.
CR ABBEY HELEN, 1952, HUMAN BIOL, V24, P201
   Ahmed QA, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101631
   Ajelli M, 2017, J THEOR BIOL, V419, P1, DOI 10.1016/j.jtbi.2017.01.041
   Al-Khraif R, 2020, SAGE OPEN, V10, DOI 10.1177/2158244020914556
   Alboaneen D, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17124568
   Aletreby W, 2020, SAUDI CRIT CARE J, V4, P79, DOI [10.4103/sccj.sccj_19_ 20, DOI 10.4103/SCCJ.SCCJ_19_20]
   Alharbi Y, 2020, APPL SCI-BASEL, V10, DOI 10.3390/app10175895
   ANDERSON R M, 1991
   Armstrong J.S., 2001, PRINCIPLES FORECASTI
   Ball F, 2019, J MATH BIOL, V78, P1875, DOI 10.1007/s00285-019-01329-4
   Bansal S, 2007, J R SOC INTERFACE, V4, P879, DOI 10.1098/rsif.2007.1100
   Barry M, 2020, J EPIDEMIOL GLOB HEA, V10, P1, DOI 10.2991/jegh.k.200218.003
   Bearman PS, 2004, AM J SOCIOL, V110, P44, DOI 10.1086/386272
   Benvenuto D, 2020, DATA BRIEF, V29, DOI 10.1016/j.dib.2020.105340
   Bian L, 2012, ANN ASSOC AM GEOGR, V102, P1016, DOI 10.1080/00045608.2012.674844
   Chawla NV, 2002, J ARTIF INTELL RES, V16, P321, DOI 10.1613/jair.953
   Chen C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174202
   Danon Leon, 2011, Interdiscip Perspect Infect Dis, V2011, P284909, DOI 10.1155/2011/284909
   Eagle N, 2006, PERS UBIQUIT COMPUT, V10, P255, DOI 10.1007/s00779-005-0046-3
   Ebrahim SH, 2020, LANCET, V395, pE48, DOI 10.1016/S0140-6736(20)30466-9
   Ebrahim SH, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101617
   Ebrahim SH, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa029
   Eubank S, 2004, NATURE, V429, P180, DOI 10.1038/nature02541
   Fanelli D, 2020, CHAOS SOLITON FRACT, V134, DOI 10.1016/j.chaos.2020.109761
   Fang YQ, 2020, J MED VIROL, V92, P645, DOI 10.1002/jmv.25750
   Ferguson N.M., 2020, PREPRINT, P16, DOI [DOI 10.25561/77482, 10.25561/77482]
   Ferguson NM, 2006, NATURE, V442, P448, DOI 10.1038/nature04795
   General Authority for Statistics, POP BAS GEND AG GROU
   General Authority for Statistics, 2010, POP DISTR MAIN ADM R
   Gong K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083489
   Grijalva CG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118457
   Halloran ME, 2008, P NATL ACAD SCI USA, V105, P4639, DOI 10.1073/pnas.0706849105
   Hellewell J, 2020, LANCET GLOB HEALTH, V8, pE488, DOI 10.1016/S2214-109X(20)30074-7
   Hou C, 2020, J MED VIROL, V92, P841, DOI 10.1002/jmv.25827
   Keeling MJ, 2005, J R SOC INTERFACE, V2, P295, DOI 10.1098/rsif.2005.0051
   Kermack WO, 1927, P R SOC LOND A-CONTA, V115, P700, DOI 10.1098/rspa.1927.0118
   Kirkcaldy RD, 2020, JAMA-J AM MED ASSOC, V323, P2245, DOI 10.1001/jama.2020.7869
   Kiss IZ, 2008, J R SOC INTERFACE, V5, P791, DOI 10.1098/rsif.2007.1272
   Komies S., 2020, COVID 19 OUTCOMES SA, DOI [10.1101/2020.04.25.20079640, DOI 10.1101/2020.04.25.20079640]
   Kraemer MUG, 2020, SCIENCE, V368, P493, DOI 10.1126/science.abb4218
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Lin QY, 2020, INT J INFECT DIS, V93, P211, DOI 10.1016/j.ijid.2020.02.058
   Liu F, 2020, SCI BULL, V65, P1297, DOI 10.1016/j.scib.2020.04.043
   Manzo G, 2020, SOCIOLOGY, V14, P31, DOI [10.6092/issn.1971-8853/10839, DOI 10.6092/ISSN.1971-8853/10839]
   Meyers LA, 2005, J THEOR BIOL, V232, P71, DOI 10.1016/j.jtbi.2004.07.026
   Meyers LA, 2007, B AM MATH SOC, V44, P63
   Miller JC, 2014, MATH MODEL NAT PHENO, V9, P4, DOI 10.1051/mmnp/20149202
   Miller JC, 2012, J R SOC INTERFACE, V9, P890, DOI 10.1098/rsif.2011.0403
   Mossong J, 2008, PLOS MED, V5, P381, DOI 10.1371/journal.pmed.0050074
   Newman MEJ, 2004, PHYS REV E, V69, DOI [10.1103/PhysRevE.69.026113, 10.1103/PhysRevE.69.066133]
   Newman MEJ, 2003, SIAM REV, V45, P167, DOI 10.1137/S003614450342480
   Peirlinck M, 2020, BIOMECH MODEL MECHAN, V19, P2179, DOI 10.1007/s10237-020-01332-5
   Prem K, 2020, LANCET PUBLIC HEALTH, V5, pE261, DOI 10.1016/S2468-2667(20)30073-6
   Prem K, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005697
   Read JM, 2003, P ROY SOC B-BIOL SCI, V270, P699, DOI 10.1098/rspb.2002.2305
   Rong XM, 2020, MATH BIOSCI ENG, V17, P2725, DOI 10.3934/mbe.2020149
   Roosa K, 2020, INFECT DIS MODEL, V5, P256, DOI 10.1016/j.idm.2020.02.002
   Salathe M, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000736
   SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047
   Staudt Christian L, 2017, Appl Netw Sci, V2, P36, DOI 10.1007/s41109-017-0054-z
   Stegehuis C, 2016, SCI REP-UK, V6, DOI 10.1038/srep29748
   Tang B, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020462
   Tang J, 2014, DATA CLASSIFICATION, V2014, P37, DOI DOI 10.1201/B17320
   Volz E, 2008, J MATH BIOL, V56, P293, DOI 10.1007/s00285-007-0116-4
   Volz E, 2007, P ROY SOC B-BIOL SCI, V274, P2925, DOI 10.1098/rspb.2007.1159
   Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918
   Weston S, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00203-20
   Yang ZF, 2020, J THORAC DIS, V12, P165, DOI 10.21037/jtd.2020.02.64
   Yen MY, 2020, J MICROBIOL IMMUNOL, V53, P377, DOI 10.1016/j.jmii.2020.03.011
   Yuen KS, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00404-4
   Zhao SL, 2020, QUANT BIOL, V8, P11, DOI 10.1007/s40484-020-0199-0
NR 71
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD NOV
PY 2020
VL 17
IS 21
AR 7744
DI 10.3390/ijerph17217744
PG 24
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA OQ6SU
UT WOS:000588911400001
PM 33113936
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Humer, E
   Stippl, P
   Pieh, C
   Schimbock, W
   Probst, T
AF Humer, Elke
   Stippl, Peter
   Pieh, Christoph
   Schimboeck, Wolfgang
   Probst, Thomas
TI Psychotherapy via the Internet: What Programs Do Psychotherapists Use,
   How Well-Informed Do They Feel, and What Are Their Wishes for Continuous
   Education?
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE psychotherapy; internet; COVID-19; software; information needs
ID HEALTH; IMPACT
AB The outbreak of the COVID-19 pandemic has caused changes in the provision of psychotherapy around the world. The common format of delivering in-person psychotherapy is replaced by psychotherapy via the Internet to a great extent. This study examined how well Austrian psychotherapists feel informed about the use of the Internet in psychotherapy, where additional information needs exist, and which software is used. A link to an online survey was sent to all psychotherapists providing a valid email address in the official list of licensed psychotherapists at the start of the COVID-19 lockdown in Austria. A total of 1547 people took part in the survey. The results show that psychotherapy via the Internet was primarily offered via Skype and Zoom during the COVID-19 pandemic and that the majority of the therapists felt well-informed about psychotherapy via the Internet; however, several therapists stated that they wish to have further information on data protection and security. Overall, the study shows that Austrian psychotherapists coped well with the rapid change from the provision of psychotherapy through personal contact to psychotherapy via the Internet. Security and data protection aspects of therapy via the Internet should be addressed in training and further education of psychotherapists. As this study was conducted online, it might have caused some respondent bias towards a higher participation of psychotherapists with higher preference for new technologies.
C1 [Humer, Elke; Pieh, Christoph; Probst, Thomas] Danube Univ Krems, Dept Psychotherapy & Biopsychosocial Hlth, A-3500 Krems, Austria.
   [Stippl, Peter; Schimboeck, Wolfgang] Austrian Fed Assoc Psychotherapy, A-1030 Vienna, Austria.
   [Schimboeck, Wolfgang] Viktor Frankl Educ Austria ABILE, A-3390 Melk, Austria.
RP Probst, T (corresponding author), Danube Univ Krems, Dept Psychotherapy & Biopsychosocial Hlth, A-3500 Krems, Austria.
EM elke.humer@donau-uni.ac.at; oebvp.stippl@psychotherapie.at;
   christoph.pieh@donau-uni.ac.at; wolfgang.schimboeck@liwest.at;
   thomas.probst@donau-uni.ac.at
RI Probst, Thomas/J-8318-2018
OI Probst, Thomas/0000-0002-6113-2133; Humer, Elke/0000-0001-9776-0353;
   Pieh, Christoph/0000-0003-2708-303X
CR Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Bundesministerium fur Gesundheit und Frauen, 2005, PSYCHOTHER FORUM, V13, pS43
   Carlbring P, 2018, COGN BEHAV THERAPY, V47, P1, DOI 10.1080/16506073.2017.1401115
   Connolly SL, 2020, CLIN PSYCHOL-SCI PR, V27, DOI 10.1111/cpsp.12311
   Fletcher TL, 2018, CURR PSYCHIAT REP, V20, DOI 10.1007/s11920-018-0922-y
   Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208
   Hasson-Ohayon I., 2020, PSYCHOL Q, V1, P9, DOI [10.1080/09515070.2020.1781595, DOI 10.1080/09515070.2020.1781595]
   Hilty DM, 2013, TELEMED E-HEALTH, V19, P444, DOI 10.1089/tmj.2013.0075
   Hubley S, 2016, WORLD J PSYCHIATR, V6, P269, DOI 10.5498/wjp.v6.i2.269
   Humer Elke, 2020, J Med Internet Res, V22, pe20246, DOI 10.2196/20246
   Humer E, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17134811
   Korecka N, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17217756
   Pieh C, 2020, J PSYCHOSOM RES, V136, DOI 10.1016/j.jpsychores.2020.110186
   Probst T, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.559100
   Probst T, 2020, J AFFECT DISORDERS, V277, P962, DOI 10.1016/j.jad.2020.09.047
   Probst T, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17113815
   Qiu JY, 2020, GEN PSYCHIAT, V33, DOI 10.1136/gpsych-2020-100213
   Salari N, 2020, GLOBALIZATION HEALTH, V16, DOI 10.1186/s12992-020-00589-w
   Schlosser A.M, 2019, PSYCHOANALYTIC EXPLO
   Schuster R, 2018, J MED INTERNET RES, V20, DOI 10.2196/11007
   Wind TR, 2020, INTERNET INTERV, V20, DOI 10.1016/j.invent.2020.100317
   Wright JH, 2020, PSYCHOTHER PSYCHOSOM, V89, P130, DOI 10.1159/000507376
   Xiong JQ, 2020, J AFFECT DISORDERS, V277, P55, DOI 10.1016/j.jad.2020.08.001
NR 23
TC 1
Z9 1
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD NOV
PY 2020
VL 17
IS 21
AR 8182
DI 10.3390/ijerph17218182
PG 9
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA OQ6OB
UT WOS:000588899100001
PM 33167478
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Faranda, D
   Alberti, T
AF Faranda, Davide
   Alberti, Tommaso
TI Modeling the second wave of COVID-19 infections in France and Italy via
   a stochastic SEIR model
SO CHAOS
LA English
DT Article
ID EPIDEMIC; DYNAMICS; EVENTS
AB COVID-19 has forced quarantine measures in several countries across the world. These measures have proven to be effective in significantly reducing the prevalence of the virus. To date, no effective treatment or vaccine is available. In the effort of preserving both public health and the economical and social textures, France and Italy governments have partially released lockdown measures. Here, we extrapolate the long-term behavior of the epidemic in both countries using a susceptible-exposed-infected-recovered model, where parameters are stochastically perturbed with a lognormal distribution to handle the uncertainty in the estimates of COVID-19 prevalence and to simulate the presence of super-spreaders. Our results suggest that uncertainties in both parameters and initial conditions rapidly propagate in the model and can result in different outcomes of the epidemic leading or not to a second wave of infections. Furthermore, the presence of super-spreaders adds instability to the dynamics, making the control of the epidemic more difficult. Using actual knowledge, asymptotic estimates of COVID-19 prevalence can fluctuate of the order of
   10 x
   10 6 units in both countries.
C1 [Faranda, Davide] Univ Paris Saclay, CNRS, Lab Sci Climat & Environm, CEA Saclay Orme Merisiers,CEA,UVSQ,UMR 8212, F-91191 Gif Sur Yvette, France.
   [Faranda, Davide] IPSL, F-91191 Gif Sur Yvette, France.
   [Faranda, Davide] London Math Lab, 8 Margravine Gardens, London W6 8RH, England.
   [Faranda, Davide] PSL Res Univ, Ecole Normale Super, LMD, IPSL, F-75005 Paris, France.
   [Alberti, Tommaso] INAF Ist Astrofis & Planetol Spaziali, Via Fosso Cavaliere 100, I-00133 Rome, Italy.
RP Faranda, D (corresponding author), Univ Paris Saclay, CNRS, Lab Sci Climat & Environm, CEA Saclay Orme Merisiers,CEA,UVSQ,UMR 8212, F-91191 Gif Sur Yvette, France.; Faranda, D (corresponding author), IPSL, F-91191 Gif Sur Yvette, France.; Faranda, D (corresponding author), London Math Lab, 8 Margravine Gardens, London W6 8RH, England.; Faranda, D (corresponding author), PSL Res Univ, Ecole Normale Super, LMD, IPSL, F-75005 Paris, France.
EM davide.faranda@lsce.ipsl.fr
RI ; Faranda, Davide/K-5831-2015
OI Alberti, Tommaso/0000-0001-6096-0220; Faranda,
   Davide/0000-0001-5001-5698
CR Al-Tawfiq JA, 2020, J HOSP INFECT, V105, P111, DOI 10.1016/j.jhin.2020.04.002
   Alberti T, 2020, COMMUN NONLINEAR SCI, V90, DOI 10.1016/j.cnsns.2020.105372
   Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   Andersson H., 2012, STOCHASTIC EPIDEMIC, V151
   [Anonymous], 2020, COR MIL 41ENN FEBBR
   [Anonymous], 2020, COM VANN LETT DAT CO
   Arin K., 2020, THE KOREA HERALD
   Brauer F, 2008, LECT NOTES MATH, V1945, P19
   Cascella M, 2020, FEATURES EVALUATION
   Cellini N, 2020, J SLEEP RES, V29, DOI 10.1111/jsr.13074
   Chinazzi M, 2020, SCIENCE, V368, P395, DOI 10.1126/science.aba9757
   Chintalapudi N, 2020, J MICROBIOL IMMUNOL, V53, P396, DOI 10.1016/j.jmii.2020.04.004
   Cohen J, 2020, SCIENCE, V367, P1287, DOI 10.1126/science.367.6484.1287
   Coibion O., 2020, TECHNICAL REPORT
   Consolini Giuseppe, 2020, Chaos Solitons Fractals, V140, P110113, DOI 10.1016/j.chaos.2020.110113
   D'Emilio F., 2020, ABC NEWS
   d'Onofrio A, 2007, THEOR POPUL BIOL, V71, P301, DOI 10.1016/j.tpb.2007.01.001
   Daunizeau J., 2020, MODELLING LOCKDOWN I, DOI [10.1101/2020.06.24.20139444, DOI 10.1101/2020.06.24.20139444]
   De Natale G, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051564
   Desai AN, 2019, HEALTH SECUR, V17, P268, DOI 10.1089/hs.2019.0022
   Deslandes A, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.106006
   DiDomenico L., 2020, EXPECTED IMPACT LOCK, DOI [10.1101/2020.04.13.20063933, DOI 10.1101/2020.04.13.20063933]
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Dureau J, 2013, BIOSTATISTICS, V14, P541, DOI 10.1093/biostatistics/kxs052
   Faranda D, 2017, PHYS REV LETT, V119, DOI 10.1103/PhysRevLett.119.014502
   Faranda D, 2020, CHAOS, V30, DOI 10.1063/5.0008834
   Faranda D, 2014, PHYSICA D, V280, P86, DOI 10.1016/j.physd.2014.04.011
   Fernandes N., 2020, EC EFFECTS CORONAVIR
   Ferrari L., 2020, ARXIV200512170
   Flaxman S., 2020, REPORT 13 ESTIMATING, DOI [10.25561/77731, DOI 10.25561/77731, 10.25561/77731.]
   Gatto M, 2020, P NATL ACAD SCI USA, V117, P10484, DOI 10.1073/pnas.2004978117
   Gaunt ER, 2010, J CLIN MICROBIOL, V48, P2940, DOI 10.1128/JCM.00636-10
   Ghanbari Behzad, 2020, Chaos Solitons Fractals, V140, P110176, DOI 10.1016/j.chaos.2020.110176
   Ghoshal B., 2020, ARXIV200310769
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Hale T., 2020, 31 BLAVATNIK SCH GOV
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kashnitsky I, 2020, WORLD DEV, V136, DOI 10.1016/j.worlddev.2020.105170
   Kellam P, 2020, J GEN VIROL, V101, P791, DOI 10.1099/jgv.0.001439
   Khajanchi S., 2020, ARXIV200506286
   Khajanchi S, 2020, CHAOS, V30, DOI 10.1063/5.0016240
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Lavezzo E, 2020, NATURE, V584, P425, DOI 10.1038/s41586-020-2488-1
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Liu Y, 2020, LANCET, V395, pE47, DOI 10.1016/S0140-6736(20)30462-1
   Lloyd-Smith JO, 2005, NATURE, V438, P355, DOI 10.1038/nature04153
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Maleki M, 2020, TRAVEL MED INFECT DI, V37, DOI 10.1016/j.tmaid.2020.101742
   Mena R. H., 2020, ARXIV200502294
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Nunes-Vaz R., 2020, GLOBAL BIOSECURITY, V1, P1, DOI [10.31646/gbio.61, DOI 10.31646/GBIO.61]
   OLSEN LF, 1990, SCIENCE, V249, P499, DOI 10.1126/science.2382131
   Peng L, 2020, ARXIV200206563
   Polonsky JA, 2019, PHILOS T R SOC B, V374, DOI 10.1098/rstb.2018.0276
   Pullano G, 2020, POPULATION MOBILITY, DOI [10.1101/2020.05.29.20097097, DOI 10.1101/2020.05.29.20097097]
   Renardy M, 2020, J THEOR BIOL, V507, DOI 10.1016/j.jtbi.2020.110461
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Roux J., 2020, COVID 19 ONE MONTH I
   Salje H, 2020, SCIENCE, V369, P208, DOI 10.1126/science.abc3517
   Sarkar K, 2020, CHAOS SOLITON FRACT, V139, DOI 10.1016/j.chaos.2020.110049
   Tanne JH, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1090
   Viceconte G, 2020, INFECT DIS REP, V12, P1, DOI 10.4081/idr.2020.8516
   Wang L, 2014, CHINESE SCI BULL, V59, P3511, DOI 10.1007/s11434-014-0499-8
   WHO, 2020, COR DIS COVID 2019 S, P51
   Wu J, 2020, NY TIMES
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Xiao AT, 2020, J INFECTION, V81, P174, DOI 10.1016/j.jinf.2020.03.012
   Yuan H.-Y., 2020, IMPORTANCE TIMING QU, DOI [10.1101/2020.05.03.20089482, DOI 10.1101/2020.05.03.20089482]
   Zhang JJ, 2020, LANCET INFECT DIS, V20, P793, DOI 10.1016/S1473-3099(20)30230-9
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   2020, MMWR MORBID MORTAL W, V69, P343
NR 72
TC 0
Z9 0
U1 3
U2 3
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 1054-1500
EI 1089-7682
J9 CHAOS
JI Chaos
PD NOV
PY 2020
VL 30
IS 11
AR 111101
DI 10.1063/5.0015943
PG 13
WC Mathematics, Applied; Physics, Mathematical
SC Mathematics; Physics
GA OQ0MW
UT WOS:000588487700001
PM 33261336
DA 2021-01-01
ER

PT J
AU Manalac, J
   Yee, J
   Calayag, K
   Nguyen, L
   Patel, PM
   Zhou, D
   Shi, RZ
AF Manalac, Justin
   Yee, Jennifer
   Calayag, Kyle
   Nguyen, Linda
   Patel, Payal M.
   Zhou, Daniel
   Shi, Run-Zhang
TI Evaluation of Abbott anti-SARS-CoV-2 CMIA IgG and Euroimmun ELISA
   IgG/IgA assays in a clinical lab
SO CLINICA CHIMICA ACTA
LA English
DT Article
DE Specificity; Serology; SARS-CoV-2; Architect; Euroimmun
AB Background: We report our findings of test performance especially specificity of a fully automated Abbott Architect anti-SARS-CoV-2 CMIA IgG and Euroimmun anti-SARS-CoV-2 ELISA IgA/IgG in human plasma.
   Methods: We used positive cohort of 97 samples from Covid-19 patients or healthcare workers, collected at late time points from symptom onsets. We also included another cohort of 215 samples as negative controls, 78 of which had positive serology test results of other infectious diseases or autoimmunity. Assay specificity was assessed by using a total of 847 anonymized samples which were collected before the Covid-19 pandemic from local patient populations seeking clinical care for rheumatoid diseases, thyroid cancer, and therapeutic drug monitoring.
   Results: Abbott IgG, Euroimmun IgG/IgA had high precision, demonstrated by both infra- and inter-day CVs of < 2%. There was no Abbott or Euroimmun IgG assay cross reactivity in the 78 samples with positive serology of non-SARS-CoV-2 infectious diseases and positive autoimmune antibodies. The Abbott IgG has specificity of 99.6%, while Euroimmun IgG and IgA were as high as 91.5% and 71.5%, respectively.
   Conclusions: Our evaluation confirmed high specificity of the Abbott IgG assay, while it was lower for Euroimmun IgG. Euroimmun IgA has suboptimal specificity which may limit its clinical use. Assay sensitivity was high for both Abbott and Euroimmun IgG assays.
C1 [Manalac, Justin; Yee, Jennifer; Nguyen, Linda; Patel, Payal M.; Zhou, Daniel; Shi, Run-Zhang] Stanford Hlth Care, Clin Chem & Immunol Sect, Clin Labs, Palo Alto, CA USA.
   [Calayag, Kyle; Shi, Run-Zhang] Stanford Univ, Sch Med, Dept Pathol, 3375 Hillview Ave, Palo Alto, CA 94304 USA.
RP Shi, RZ (corresponding author), Stanford Univ, Sch Med, Dept Pathol, 3375 Hillview Ave, Palo Alto, CA 94304 USA.
EM rzshi@stanford.edu
CR Bryan A, 2020, POLICY PRACT, P8
   Infectious Disease Society of America, 2020, IDSA COVID 19 ANT PR
   Jaaskelainen AJ, 2020, J CLIN VIROL, V129, DOI 10.1016/j.jcv.2020.104512
   Shunmugavel C.H. Anandakumar, SEROLOGIC CROSS REAC
   Tang M.S., 2020, CLIN CHEM
   World Health Organization, IMM PASSP CONT COVID
NR 6
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0009-8981
EI 1873-3492
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD NOV
PY 2020
VL 510
BP 687
EP 690
DI 10.1016/j.cca.2020.09.002
PG 4
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA OH3XC
UT WOS:000582504300108
PM 32910980
OA Green Published
DA 2021-01-01
ER

PT J
AU Korecka, N
   Rabenstein, R
   Pieh, C
   Stippl, P
   Barke, A
   Doering, B
   Gossmann, K
   Humer, E
   Probst, T
AF Korecka, Nicole
   Rabenstein, Rafael
   Pieh, Christoph
   Stippl, Peter
   Barke, Antonia
   Doering, Bettina
   Gossmann, Katharina
   Humer, Elke
   Probst, Thomas
TI Psychotherapy by Telephone or Internet in Austria and Germany Which CBT
   Psychotherapists Rate It more Comparable to Face-to-Face Psychotherapy
   in Personal Contact and Have more Positive Actual Experiences Compared
   to Previous Expectations?
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE psychotherapists; remote psychotherapy; telephone; internet;
   experiences; expectations; comparability; COVID-19
ID TELEMENTAL HEALTH; MENTAL-HEALTH; ATTITUDES; THERAPY; CARE;
   TELEPSYCHOTHERAPY
AB Objectives: COVID-19 has led to changes in the provision in mental health services. The current study investigated influencing factors on: (i) the comparability of psychotherapy via internet/telephone with psychotherapy in face-to-face contact as well as (ii) the actual experience with psychotherapy via internet/telephone compared to respective prior expectations in CBT therapists. Methods: A quantitative cross-sectional study was conducted in the form of an online survey. The research samples, registered cognitive-behavioral therapy (CBT) psychotherapists in Austria and Germany, were contacted by e-mail. Results: One hundred and ninety CBT therapists were analyzed in this study. The total number of patients treated via telephone/internet is a decisive factor for the subjective evaluation of the comparability of psychotherapy via telephone/internet and psychotherapy in personal contact. This factor also influences the extent (positive/negative) of the assessment of the actual experience with psychotherapy via internet/telephone compared to previous expectations. Neither age nor gender were associated with comparability of psychotherapy via internet/telephone with psychotherapy in face-to-face contact or the actual experience with psychotherapy via internet/telephone compared to respective prior expectations. Conclusions: Implications of the results are that attitudes towards remote psychotherapy might be increased in CBT therapists when they treat more patients remotely and experiences with remote psychotherapies should be included in psychotherapy training.
C1 [Korecka, Nicole; Rabenstein, Rafael; Pieh, Christoph; Humer, Elke; Probst, Thomas] Danube Univ Krems, Dept Psychotherapy & Biopsychosocial Hlth, A-3500 Krems, Austria.
   [Stippl, Peter] Austrian Fed Assoc Psychotherapy, Lowengasse 3, A-1030 Vienna, Austria.
   [Barke, Antonia; Doering, Bettina; Gossmann, Katharina] Catholic Univ Eichstatt Ingolstadt, Clin & Biol Psychol, Ostenstr 26, D-85072 Eichstatt, Germany.
RP Probst, T (corresponding author), Danube Univ Krems, Dept Psychotherapy & Biopsychosocial Hlth, A-3500 Krems, Austria.
EM nicole.korecka@edu.donau-uni.ac.at; rafael.rabenstein@donau-uni.ac.at;
   christoph.pieh@donau-uni.ac.at; oebvp.stippl@psychotherapie.at;
   antonia.barke@ku.de; bettina.doering@ku.de; katharina.gossmann@ku.de;
   elke.humer@donau-uni.ac.at; thomas.probst@donau-uni.ac.at
RI Probst, Thomas/J-8318-2018; Doering, Bettina/AAC-8122-2019; Barke,
   Antonia/D-9286-2011
OI Probst, Thomas/0000-0002-6113-2133; Barke, Antonia/0000-0002-6863-3213
FU University for Continuing Education Krems
FX Open Access Funding by the University for Continuing Education Krems.
CR American Psychiatric Association and American Telemedicine Association, BEST PRACT VID BAS T
   Ayanian J., 2020, COVID 19 JAMA HLTH F, V1, DOI 10.1001/jamahealthforum.2020.0397
   Bekes V, 2020, J PSYCHOTHER INTEGR, V30, P238, DOI 10.1037/int0000214
   Bundesministerium fur Soziales Gesundheit Pflege und Konsumentenschutz (BMSGPK), INT KRIT AUSG PSYCH
   Bundespsychotherapeutenkammer (BPtK), PRAX INF VID
   Carlbring P, 2018, COGN BEHAV THERAPY, V47, P1, DOI 10.1080/16506073.2017.1401115
   Cipolletta S, 2018, PSYCHOTHER RES, V28, P909, DOI 10.1080/10503307.2016.1259533
   Clark DM, 2018, ANNU REV CLIN PSYCHO, V14, P159, DOI [10.1146/annurev-clinpsy-050817084833, 10.1146/annurev-clinpsy-050817-084833]
   Connolly SL, 2020, CLIN PSYCHOL-SCI PR, V27, DOI 10.1111/cpsp.12311
   Eichenberg C., 2016, RESONANZEN, V4, P93
   Eichenberg C, 2013, PSYCHOTHERAPEUT, V58, P485, DOI 10.1007/s00278-011-0833-4
   Faija CL, 2020, BMC PSYCHIATRY, V20, DOI 10.1186/s12888-020-02761-3
   Fisk M., 2014, GLOBAL TELEMEDICINE, V7, P1998
   Galea S, 2020, JAMA INTERN MED, V180, P817, DOI 10.1001/jamainternmed.2020.1562
   Gilmore AK, 2019, J TELEMED TELECARE, V25, P59, DOI 10.1177/1357633X17735559
   Hailey D, 2009, J TELEMED TELECARE, V15, P28, DOI 10.1258/jtt.2008.080609
   Hanson D, 2009, TELEMED J E-HEALTH, V15, P39, DOI 10.1089/tmj.2008.0052
   Hilty DM, 2013, TELEMED E-HEALTH, V19, P444, DOI 10.1089/tmj.2013.0075
   Humer E., 2020, JMIR PREPR, DOI [10.2196/preprints.20246, DOI 10.2196/PREPRINTS.20246]
   Humer E, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17134811
   Jefee-Bahloul H, 2016, TELEMED E-HEALTH, V22, P31, DOI 10.1089/tmj.2015.0021
   Jenkins-Guarnieri MA, 2015, TELEMED E-HEALTH, V21, P652, DOI 10.1089/tmj.2014.0165
   Jones EA, 2013, COGN BEH THER, V6, DOI 10.1017/S1754470X13000226
   Jordan DN, 2020, TELEMED E-HEALTH, DOI 10.1089/tmj.2019.0284
   Kruse CS, 2018, J TELEMED TELECARE, V24, P4, DOI 10.1177/1357633X16674087
   Kruse CS, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016242
   MacMullin K, 2020, J PSYCHOTHER INTEGR, V30, P248, DOI 10.1037/int0000213
   Mendes-Santos C, 2020, JMIR MENT HEALTH, V7, DOI 10.2196/16817
   Mohr DC, 2012, JAMA-J AM MED ASSOC, V307, P2278, DOI 10.1001/jama.2012.5588
   Perle JG, 2013, J CLIN PSYCHOL, V69, P100, DOI 10.1002/jclp.21912
   Polinski JM, 2016, J GEN INTERN MED, V31, P269, DOI 10.1007/s11606-015-3489-x
   Probst T, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.559100
   Probst T, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17113815
   Rushton K, 2020, BMC PSYCHIATRY, V20, DOI 10.1186/s12888-020-02564-6
   Schroder J, 2017, COGNITIVE THER RES, V41, P745, DOI 10.1007/s10608-017-9850-0
   Schuster R, 2020, INTERNET INTERV, V21, DOI 10.1016/j.invent.2020.100326
   Schuster R, 2018, J MED INTERNET RES, V20, DOI 10.2196/11007
   Shigekawa E, 2018, HEALTH AFFAIR, V37, P1975, DOI 10.1377/hlthaff.2018.05132
   Shore JH, 2013, AM J PSYCHIAT, V170, P256, DOI 10.1176/appi.ajp.2012.12081064
   Steinmetz H., 2020, ZPID SCI INF ONLINE, P20, DOI [10.23668/psycharchives.3019, DOI 10.23668/PSYCHARCHIVES.3019]
   Van Daele T, 2020, J PSYCHOTHER INTEGR, V30, P160, DOI 10.1037/int0000218
   Wangberg SC, 2007, CYBERPSYCHOL BEHAV, V10, P418, DOI 10.1089/cpb.2006.9937
   Werner P, 2004, TELEMED J E-HEALTH, V10, P286, DOI 10.1089/tmj.2004.10.286
   Wright JH, 2020, PSYCHOTHER PSYCHOSOM, V89, P130, DOI 10.1159/000507376
   Xiang YT, 2020, LANCET PSYCHIAT, V7, P228, DOI 10.1016/S2215-0366(20)30046-8
NR 45
TC 1
Z9 1
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD NOV
PY 2020
VL 17
IS 21
AR 7756
DI 10.3390/ijerph17217756
PG 11
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA OQ6DS
UT WOS:000588872200001
PM 33114136
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Few, M
AF Few, Martha
TI Epidemics, indigenous communities, and public health in the COVID-19
   era: views from smallpox inoculation campaigns in colonial Guatemala
SO JOURNAL OF GLOBAL HISTORY
LA English
DT Article
DE colonialism; humanitarianism; indigeneity; pandemic; smallpox; vaccine
AB This article explores the tensions between well-intentioned humanitarianism and coercive colonialism during smallpox outbreaks in eighteenth-century Guatemala, when the state extended inoculation programmes to its predominant, culturally diverse Maya communities. Evidence from anti-epidemic campaigns shows public debates broadly comparable to the current COVID-19 crisis: debates about the measurably higher mortality rates for indigenous people and other marginalized groups; debates about the extent of the state's responsibility for the health of its peoples; and debates on whether or not coercion and violence should be used to ensure compliance with quarantines and public health campaigns. While inoculations provided medical assistance and material help to Maya communities, and resulted in demonstrably lower mortality rates from smallpox, at the same time they functioned as avenues for the expansion of colonial power to intervene in the daily lives of people in those communities, characterized by colonial actors as necessary for their own good, and for the broader public good.
C1 [Few, Martha] Penn State Univ, Dept Hist, 108 Weaver Bldg, University Pk, PA 16801 USA.
RP Few, M (corresponding author), Penn State Univ, Dept Hist, 108 Weaver Bldg, University Pk, PA 16801 USA.
EM mzf52@psu.edu
CR Achim Miruna, 2008, LAGARTIJAS MED REMED
   Alchon S., 2003, PEST LAND NEW WORLD
   Alchon Suzanne Austin, 1991, NATIVE SOC DIS COLON, P13
   [Anonymous], 1795, COMMUNICATION   0819
   [Anonymous], 1795, COMMUNICATION   0105
   [Anonymous], 1795, COMMUNICATION   1005
   [Anonymous], 1798, COMMUNICATION   0203
   [Anonymous], 1804, COMMUNICATION   0806
   [Anonymous], 1800, COMMUNICATION   0531
   [Anonymous], 1780, COMMUNICATION   1001
   [Anonymous], 1795, COMMUNICATION   0906
   [Anonymous], 1798, COMMUNICATION   0102
   [Anonymous], 1795, COMMUNICATION   1005
   [Anonymous], 2020, HAIDA GWAII STATE EM
   [Anonymous], 1804, COMMUNICATION   0102
   [Anonymous], 1795, COMMUNICATION   0108
   Barnett M., 2011, EMPIRE HUMANITY HIST
   Crosby Alfred W., 1972, COLUMBIAN EXCHANGE B
   De Vos P, 2004, COLON LAT AM HIST R, V13, P249
   Duran Carlos Martinez, 1964, CIENCIAS MED GUATEMA, P328
   Fenner F., 1988, SMALLPOX ITS ERADICA
   Few M., 2015, ALL HUMANITY MESOAME
   Flores Jose, 1782, ESPECIFICO NUEVAMENT
   Flores Jose, 1796, COMMUNICATION   1119
   Flores Jose, 1794, A1611856786 ARCH GEN
   Furlow Bryan, 2020, PROPUBLICA      0613
   Gomez P. F., 2017, EXPERIENTIAL CARIBBE
   Herrarte Mariano Jose, 1784, RETURN DESCRIBING PL
   Jenner E., 1798, INQUIRY CAUSES EFFEC
   Kelton Paul, 2015, CHEROKEE MED COLONIA
   Koch A, 2019, QUATERNARY SCI REV, V207, P13, DOI 10.1016/j.quascirev.2018.12.004
   Lovell W. George, 1996, GEOGR REV, V6, P400
   LOVELL WG, 1994, LAT AM RES REV, V29, P133
   Morris L, 2020, WASHINGTON POST
   Noble D, 1996, ENVIRONMENT INDUSTRY: THE WASHINGTON MEETING, P33
   Phillips Dom, GUARDIAN
   Ramirez Paul, 2019, ENLIGHTENED IMMUNITY
   United Nations Human Rights Office of the High Commissioner, 2020, DISPR IMP COVID 19 R
   Warren A., 2010, MED POLITICS COLONIA
   Ximenez fray Francisco, 1967, HIST NATURAL REINO G
   y Porras Manuel Avalos, 1769, A12715909 AGCA
NR 41
TC 0
Z9 0
U1 1
U2 1
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 1740-0228
EI 1740-0236
J9 J GLOBAL HIST
JI J. Glob. Hist.
PD NOV
PY 2020
VL 15
IS 3
SI SI
BP 380
EP 393
DI 10.1017/S1740022820000297
PG 14
WC History
SC History
GA ON6KD
UT WOS:000586806400005
OA Bronze
DA 2021-01-01
ER

PT J
AU Cheudjeu, A
AF Cheudjeu, Antony
TI Correlation of D-xylose with severity and morbidity-related factors of
   COVID-19 and possible therapeutic use of D-xylose and antibiotics for
   COVID-19
SO LIFE SCIENCES
LA English
DT Article
DE Xylose; Xylitol, SARS-Cov-2; Inflammatory; Lung; Acute kidney injury;
   Diabetes; Scurvy
ID HEPARAN-SULFATE PROTEOGLYCANS; CELL-ADHESION MOLECULES;
   XYLOSYLTRANSFERASE ACTIVITY; INTESTINAL PERMEABILITY; LUNG INJURY;
   VITAMIN-C; CANCER; GLYCOSAMINOGLYCANS; XYLITOL; INFLAMMATION
AB The SARS-Cov-2 pandemic that currently affects the entire world has been shown to be especially dangerous in the elderly (>= 65 years) and in smokers, with notably strong comorbidity in patients already suffering from chronic diseases, such as Type 2 diabetes, cancers, chronic respiratory diseases, obesity, and hypertension. Inflammation of the lungs is the main factor leading to respiratory distress in patients with chronic respiratory disease and in patients with severe COVID-19. Several studies have shown that inflammation of the lungs in general and Type 2 diabetes are accompanied by the degradation of glycosaminoglycans (GAGs), especially heparan sulfate (HS). Several studies have also shown the importance of countering the degradation of HS in lung infections and Type 2 diabetes. D-xylose, which is the initiating element for different sulfate GAG chains (especially HS), has shown regeneration properties for GAGs. D-xylose and xylitol have demonstrated anti-inflammatory, antiglycemic, antiviral, and antibacterial properties in lung infections, alone or in combination with antibiotics. Considering the existing research on COVID-19 and related to D-xylose/xylitol, this review offers a perspective on why the association between D-xylose and antibiotics may contribute to significantly reducing the duration of treatment of COVID-19 patients and why some anti-inflammatory drugs may increase the severity of COVID-19. A strong correlation with scurvy, based on gender, age, ethnicity, smoking status, and obesity status, is also reviewed. Related to this, the effects of treatment with plants such as Artemisia are also addressed.
C1 [Cheudjeu, Antony] La COLOMBE Hlth Ctr, Fokoue, Cameroon.
RP Cheudjeu, A (corresponding author), 7 Rue Eric Tabarly, F-91300 Massy, France.
EM contact@unaffiliated-researchers.com
CR Abassi Z., 2020, HEPARANASE ADV EXP M, V1221
   Abassi Z, 2017, ONCOTARGET, V8, P34191, DOI 10.18632/oncotarget.16573
   Afratis N, 2012, FEBS J, V279, P1177, DOI 10.1111/j.1742-4658.2012.08529.x
   Ahmad N. E. Q, 2015, J BIOSCI MED, V03, P54
   ALBELDA SM, 1994, FASEB J, V8, P504
   Amo K, 2011, J CLIN BIOCHEM NUTR, V49, P1, DOI 10.3164/jcbn.10-111
   [Anonymous], DOSAGE VITAMINE C SA
   Aquino RS, 2016, FRONT BIOSCI-LANDMRK, V21, P1260, DOI 10.2741/4455
   Bendas Gerd, 2012, Int J Cell Biol, V2012, P676731, DOI 10.1155/2012/676731
   BEVILACQUA MP, 1994, ANNU REV MED, V45, P361, DOI 10.1146/annurev.med.45.1.361
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   BJARNASON I, 1991, GUT, V32, P275, DOI 10.1136/gut.32.3.275
   Bonazzi M, 2011, J CELL BIOL, V195, P348, DOI 10.1083/jcb.201106011
   Boretti A, 2020, PHARMANUTRITION, V12, DOI 10.1016/j.phanu.2020.100190
   Brielle ES, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050497
   Buijsers B., 2020, INCREASED PLASMA HEP, DOI [10.1101/2020.06.12.20129304., DOI 10.1101/2020.06.12.20129304]
   Burton DC, 2010, AM J PUBLIC HEALTH, V100, P1904, DOI 10.2105/AJPH.2009.181313
   Cagno V, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11070596
   CHAN PC, 1958, J BIOL CHEM, V231, P231
   Chang Y, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0264
   Cheong DHJ, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104901
   Colombo R., 2001, SCI VIVANT
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P333, DOI 10.23812/Editorial-Conti-2
   COOK GC, 1975, T ROY SOC TROP MED H, V69, P143, DOI 10.1016/0035-9203(75)90024-3
   Cooke MW, 2004, EMERG MED J, V21, P575, DOI 10.1136/emj.2004.015081
   Coombe D.R., 2020, SULPHATED XYLANS TRE
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   CRAIG RM, 1988, GASTROENTEROLOGY, V95, P223, DOI 10.1016/0016-5085(88)90318-6
   Daus S, 2010, MACROMOL BIOSCI, V10, P211, DOI 10.1002/mabi.200900201
   De Miguel C, 2015, CURR HYPERTENS REP, V17, DOI 10.1007/s11906-014-0507-z
   Ding M, 2020, RESP MED, V167, DOI 10.1016/j.rmed.2020.105981
   Dinh QN, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/406960
   Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020
   Dumas M., 1999, UTILISATIONS XYLOSE
   DYER NH, 1971, ANN RHEUM DIS, V30, P626, DOI 10.1136/ard.30.6.626
   Egeberg M, 2001, BBA-MOL CELL RES, V1541, P135, DOI 10.1016/S0167-4889(01)00132-X
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Fatovich DM, 2003, EMERG MED J, V20, P406, DOI 10.1136/emj.20.5.406
   Feldman SA, 2000, J VIROL, V74, P6442, DOI 10.1128/JVI.74.14.6442-6447.2000
   Garcia-Diaz DF, 2014, J NUTR SCI VITAMINOL, V60, P367, DOI 10.3177/jnsv.60.367
   Ferreira AS, 2011, BRAZ ARCH BIOL TECHN, V54, P1211, DOI 10.1590/S1516-89132011000600017
   Ferrer CM, 2016, J MOL BIOL, V428, P3282, DOI 10.1016/j.jmb.2016.05.028
   Fiehn O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015234
   FISHMAN WH, 1951, J CLIN INVEST, V30, P685, DOI 10.1172/JCI102481
   Foo CH, 2009, VIROLOGY, V385, P368, DOI [10.1016/j.virol.2008.12.019, 10.1016/j.virol.2008.12.029]
   Ganz ML, 2014, DIABETOL METAB SYNDR, V6, DOI 10.1186/1758-5996-6-50
   Gariani Karim, 2010, Rev Med Suisse, V6, P1193
   George PM, 2020, LANCET RESP MED, V8, P807, DOI 10.1016/S2213-2600(20)30225-3
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Gotting C, 2008, DIABETES CARE, V31, P2018, DOI 10.2337/dc08-0909
   Grande-Allen KJ, 2007, CARDIOVASC RES, V76, P19, DOI 10.1016/j.cardiores.2007.05.014
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo J, 2019, INFLAMMATION, V42, P1951, DOI 10.1007/s10753-019-01055-5
   Guo YP, 2015, CHIN MED-UK, V10, DOI 10.1186/s13020-015-0044-y
   Haeger SM, 2016, AM J RESP CELL MOL, V55, P5, DOI 10.1165/rcmb.2016-0043TR
   HALLGREN R, 1989, AM REV RESPIR DIS, V139, P682
   Hao W., 2020, BIORXIV, DOI [10.1101/2020.05.17.100537., DOI 10.1101/2020.05.17.100537]
   Haq FU, 2020, PHYTOTHER RES, V34, P2423, DOI 10.1002/ptr.6733
   Hart GW, 2009, ESSENTIALS GLYCOBIOL
   Herrmann C., 2020, COVID 19 TESTS MIRAC
   Hidalgo AA, 2018, CAN J INFECT DIS MED, V2018, DOI 10.1155/2018/3467219
   Hiebert LM, 2017, CURR PHARM DESIGN, V23, P1500, DOI 10.2174/1381612823666170125154915
   Hiebert LM, 2014, ANTIOXID REDOX SIGN, V21, P1032, DOI 10.1089/ars.2013.5695
   Hollmann S., 2012, NONGLYCOLYTIC PATHWA
   Holst AG, 2010, CIRCULATION, V121, P1896, DOI 10.1161/CIRCULATIONAHA.109.921460
   Hongping Y., 2018, APPL XYLAN ESTERIFIC
   Irwin RE, 2020, GLOBALIZATION HEALTH, V16, DOI 10.1186/s12992-020-00588-x
   Islam MS, 2012, ANN NUTR METAB, V61, P57, DOI 10.1159/000338440
   Jain Archana, 2013, Indian J Endocrinol Metab, V17, pS318, DOI 10.4103/2230-8210.119647
   Jedrychowski W, 1998, PUBLIC HEALTH, V112, P189, DOI 10.1016/S0033-3506(98)00226-1
   JOHNSON SL, 1986, CLIN PHARMACOL THER, V39, P697, DOI 10.1038/clpt.1986.121
   Joladarashi D, 2011, GLYCOBIOLOGY, V21, P960, DOI 10.1093/glycob/cwr029
   Jones A.H., 1999, XYLITOL COMPOSITIONS
   Jun YJ, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1261-0
   KENDALL MJ, 1971, BRIT MED J, V1, P533, DOI 10.1136/bmj.1.5748.533
   KENDALL MJ, 1970, GUT, V11, P1020, DOI 10.1136/gut.11.12.1020
   KENDALL MJ, 1970, GUT, V11, P498, DOI 10.1136/gut.11.6.498
   Kim S.Y., 2020, BIORXIV, DOI [10.1101/2020.04.14.041459, DOI 10.1101/2020.04.14.041459, 10.1101/2020.04.14.041459.]
   Kirkman MS, 2012, DIABETES CARE, V35, P2650, DOI 10.2337/dc12-1801
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Koslowski R, 2001, EUR RESPIR J, V18, P347, DOI 10.1183/09031936.01.00085601
   Lee H, 2011, MOL CELL TOXICOL, V7, P87, DOI 10.1007/s13273-011-0012-2
   Leidig P, 2001, DEUT MED WOCHENSCHR, V126, P1357, DOI 10.1055/s-2001-18650
   Li W, 2015, INT J CLIN EXP MED, V8, P12463
   Li XM, 2018, CLIN CANCER RES, V24, P4798, DOI 10.1158/1078-0432.CCR-17-3284
   Lighter J, 2020, CLIN INFECT DIS, V71, P896, DOI 10.1093/cid/ciaa415
   Lim E, 2015, NUTR RES, V35, P626, DOI 10.1016/j.nutres.2015.05.012
   Little P, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1185
   Liu MH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00947
   Loria CM, 1998, AM J EPIDEMIOL, V147, P587, DOI 10.1093/oxfordjournals.aje.a009491
   Lunds Universitet, 2010, SCIENCEDAILY
   Luo GG, 2015, VIROL SIN, V30, P83, DOI 10.1007/s12250-015-3599-y
   Lykkesfeldt J., SMOKING DEPLETES VIT
   Ma ZY, 2014, J BIOL CHEM, V289, P34457, DOI 10.1074/jbc.R114.577718
   Malagon I, 2005, J THORAC CARDIOV SUR, V130, P265, DOI 10.1016/j.jtcvs.2005.02.047
   Mannucci E, 2020, TRENDS ANAESTH CRIT, V33, P33, DOI 10.1016/j.tacc.2020.05.002
   MARKIEWICZ A, 1975, POL J PHARMACOL PHAR, V27, P265
   Marshall MC, 2005, POSTGRAD MED J, V81, P734, DOI 10.1136/pgmj.2004.028274
   Meyer KC, 2004, AGEING RES REV, V3, P55, DOI 10.1016/j.arr.2003.07.002
   MILLER M. M., 1932, Journal of Biological Chemistry, V98, P133
   Mine S, 2006, ENDOCR J, V53, P761, DOI 10.1507/endocrj.K05-119
   Mitsuhashi M, 1998, RES COMMUN MOL PATH, V99, P225
   Moh MC, 2009, CELL ADHES MIGR, V3, P334, DOI 10.4161/cam.3.4.9246
   Mong M.A., 2020, MARIK ACCELERATED HY, DOI [10.1101/2020.04.19.20071647., DOI 10.1101/2020.04.19.20071647]
   Morla S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081963
   Murashima M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56615-4
   Nagarajan A, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00483
   Nordstrom A, 2016, J CLIN ENDOCR METAB, V101, P3740, DOI 10.1210/jc.2016-1915
   O'Hearn A, 2015, J VIROL, V89, P5441, DOI 10.1128/JVI.03689-14
   Office of the Surgeon General & Office on Smoking and Health, 2004, HLTH CONS SMOK REP S
   Okegawa T, 2004, ACTA BIOCHIM POL, V51, P445
   Organization for economic co-operation and development/European Union, 2018, CYCLE, P94
   Park E, 2015, BIOTECHNOL LETT, V37, P983, DOI 10.1007/s10529-014-1757-1
   Peesa JP, 2016, J ACUTE DIS, V5, P364, DOI 10.1016/j.joad.2016.08.002
   Persson PG, 2000, J INTERN MED, V248, P103, DOI 10.1046/j.1365-2796.2000.00708.x
   Pizarro-Cerda J, 2006, CELL, V124, P715, DOI 10.1016/j.cell.2006.02.012
   Price ZK, 2018, CANCERS, V10, DOI 10.3390/cancers10120482
   Rabb H, 2016, J AM SOC NEPHROL, V27, P371, DOI 10.1681/ASN.2015030261
   Rahman MA, 2014, J FOOD SCI, V79, pH1436, DOI 10.1111/1750-3841.12520
   Raisonnier A., FMPMC PS RESERVES EN
   Rajas O, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2418-5
   Raybaud P.-J., COVID 19 PROPOSITION
   REULER JB, 1985, JAMA-J AM MED ASSOC, V253, P805, DOI 10.1001/jama.253.6.805
   Ronco C, 2020, LANCET RESP MED, V8, P738, DOI 10.1016/S2213-2600(20)30229-0
   Rops ALWMM, 2004, KIDNEY INT, V65, P768, DOI 10.1111/j.1523-1755.2004.00451.x
   Rothuizen L.E., 2020, REV MED SUISSE, V691-2, P852
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, DOI 10.3332/ecancer.2020.1023
   Sarrazin S, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004952
   Sasaki M, 2018, J INFECT DIS, V217, P1740, DOI 10.1093/infdis/jiy081
   Schiller JT, 2014, RECENT RESULTS CANC, V193, P1, DOI 10.1007/978-3-642-38965-8_1
   Schleicher RL, 2009, AM J CLIN NUTR, V90, P1252, DOI 10.3945/ajcn.2008.27016
   Schmidt EP, 2016, AM J RESP CRIT CARE, V194, P439, DOI 10.1164/rccm.201511-2281OC
   Schmidt EP, 2012, NAT MED, V18, P1217, DOI 10.1038/nm.2843
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Sigthorsson G, 1998, GUT, V43, P506, DOI 10.1136/gut.43.4.506
   Singh N, 2019, ANN AFR MED, V18, P121, DOI 10.4103/aam.aam_56_18
   Song JW, 2018, NEPHROL DIAL TRANSPL, V33, P203, DOI 10.1093/ndt/gfx076
   SPITZ IM, 1970, METABOLIS, V19, P24, DOI 10.1016/0026-0495(70)90114-9
   Stern R, 2008, SEMIN CANCER BIOL, V18, P237, DOI 10.1016/j.semcancer.2008.04.001
   Stowell A, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-17
   Trachootham D, 2017, NUTR CANCER, V69, P862, DOI 10.1080/01635581.2017.1339097
   Tsalamandris S, 2019, EUR CARDIOL REV, V14, P50, DOI 10.15420/ecr.2018.33.1
   Van Kerkhove MD, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001053
   Vardavas CI, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/119324
   Villagra NA, 2012, J ANTIMICROB CHEMOTH, V67, P921, DOI 10.1093/jac/dkr573
   Vives R.R., 2011, HEPARANES SULFATE ST
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang Z, 2009, DIABETES, V58, P309, DOI 10.2337/db08-0994
   WEGNER CD, 1992, CHEST, V101, pS34, DOI 10.1378/chest.101.3.34S
   Wells L, 2003, CELL MOL LIFE SCI, V60, P222, DOI 10.1007/s000180300017
   Welsh M.J., 2004, US Patent, Patent No. [6. 716.819: B2, 6716819]
   Winnall W.R., 2020, TOBACCO AUSTR FACTS
   Xie G, 2008, PHYTOCHEMISTRY, V69, P1359, DOI 10.1016/j.phytochem.2008.01.009
   Xu ML, 2016, BIOL PHARM BULL, V39, P540, DOI 10.1248/bpb.b15-00773
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yang Y, 2020, INT J BIOL SCI, V16, P1708, DOI 10.7150/ijbs.45538
   Yin SY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084633
   Yip GW, 2006, MOL CANCER THER, V5, P2139, DOI 10.1158/1535-7163.MCT-06-0082
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhao RR, 2018, CIRCULATION, V137, P2497, DOI 10.1161/CIRCULATIONAHA.117.030353
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 163
TC 0
Z9 0
U1 6
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD NOV 1
PY 2020
VL 260
AR 118335
DI 10.1016/j.lfs.2020.118335
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA OH5FK
UT WOS:000582605800028
PM 32846167
OA Green Published
DA 2021-01-01
ER

PT J
AU Duerr, GD
   Heine, A
   Hamiko, M
   Zimmer, S
   Luetkens, JA
   Nattermann, J
   Rieke, G
   Isaak, A
   Jehle, J
   Held, SAE
   Wasmuth, JC
   Wittmann, M
   Strassburg, CP
   Brossart, P
   Coburn, M
   Treede, H
   Nickenig, G
   Kurts, C
   Velten, M
AF Duerr, G. D.
   Heine, A.
   Hamiko, M.
   Zimmer, S.
   Luetkens, J. A.
   Nattermann, J.
   Rieke, G.
   Isaak, A.
   Jehle, J.
   Held, S. A. E.
   Wasmuth, J. C.
   Wittmann, M.
   Strassburg, C. P.
   Brossart, P.
   Coburn, M.
   Treede, H.
   Nickenig, G.
   Kurts, C.
   Velten, M.
TI Parameters predicting COVID-19-induced myocardial injury and mortality
SO LIFE SCIENCES
LA English
DT Article
DE COVID-19; SARS-CoV-2; Pericardial effusion; CD8; Treg; Monocyte
AB Clinical manifestations of COVID-19 affect many organs, including the heart. Cardiovascular disease is a dominant comorbidity and prognostic factors predicting risk for critical courses are highly needed. Moreover, immunomechanisms underlying COVID-induced myocardial damage are poorly understood.
   Objective: To elucidate prognostic markers to identify patients at risk.
   Results: Only patients with pericardial effusion (PE) developed a severe disease course, and those who died could be identified by a high CD8/Treg/monocyte ratio. Ten out of 19 COVID-19 patients presented with PE, 7 (78%) of these had elevated APACHE-II mortality risk-score, requiring mechanical ventilation. At admission, PE patients showed signs of systemic and cardiac inflammation in NMR and impaired cardiac function as detected by transthoracic echocardiography (TTE), whereas parameters of myocardial injury e.g. high sensitive troponin-t (hs-TnT) were not yet increased. During the course of disease, hs-TnT rose in 8 of the PE-patients above 16 ng/1, 7 had to undergo ventilatory therapy and 4 of them died. FACS at admission showed in PE patients elevated frequencies of CD3(+)CD8(+) T cells among all CD3(+) T-cells, and lower frequencies of Tregs and CD14(+)HLA(-)DR(+)-monocytes. A high CD8/Treg/monocyte ratio predicted a severe disease course in PE patients, and was associated with high serum levels of antiviral cytokines. By contrast, patients without PE and PE patients with a low CD8/Treg/monocyte ratio neither had to be intubated, nor died.
   Conclusions: PE predicts cardiac injury in COVID-19 patients. Therefore, TTE should be performed at admission. Immunological parameters for dysfunctional antiviral immunity, such as the CD8/Treg/monocyte ratio used here, supports risk assessment by predicting poor prognosis.
C1 [Duerr, G. D.; Hamiko, M.; Treede, H.] Univ Bonn, Univ Hosp Bonn, Dept Cardiovasc Surg, Venusberg Campus 1, D-53127 Bonn, Germany.
   [Heine, A.; Held, S. A. E.; Brossart, P.] Univ Bonn, Univ Hosp Bonn, Dept Internal Med Hematol Oncol Rheumatol & Immun, Venusberg Campus 1, D-53127 Bonn, Germany.
   [Zimmer, S.; Jehle, J.] Univ Bonn, Univ Hosp Bonn, Dept Internal Med Cardiol 2, Venusberg Campus 1, D-53127 Bonn, Germany.
   [Luetkens, J. A.; Isaak, A.] Univ Bonn, Univ Hosp Bonn, Dept Radiol, Quantitat Imaging Lab Bonn QILaB, Venusberg Campus 1, D-53127 Bonn, Germany.
   [Nattermann, J.; Rieke, G.; Wasmuth, J. C.; Strassburg, C. P.; Nickenig, G.] Univ Bonn, Univ Hosp Bonn, Dept Internal Med 1, Venusberg Campus 1, D-53127 Bonn, Germany.
   [Kurts, C.] Univ Bonn, Univ Hosp Bonn, Inst Expt Immunol, Venusberg Campus 1, D-53127 Bonn, Germany.
   [Wittmann, M.; Coburn, M.; Velten, M.] Univ Bonn, Univ Hosp Bonn, Dept Anesthesiol & Intens Care Med, Venusberg Campus 1, D-53127 Bonn, Germany.
RP Kurts, C; Velten, M (corresponding author), Univ Bonn, Univ Hosp Bonn, Dept Anesthesiol & Intens Care Med, Venusberg Campus 1, D-53127 Bonn, Germany.
EM ckurts@uni-bonn.de; markus.velten@ukbonn.de
FU German Heart Foundation [F/27/20, F/28/29]; Deutsche
   Forschungsgemeinschaft (DFG)German Research Foundation (DFG) [EXC2151 -
   390873048, CRCTR259]
FX Supported by grants from the German Heart Foundation F/27/20 and F/28/29
   (to Drs. Durr, Heine, Luetkens and Velten), from the Deutsche
   Forschungsgemeinschaft (DFG EXC2151 - 390873048 to Drs. Heine and Kurts,
   DFG CRCTR259 to Drs. Zimmer, Nickenig and Kurts, and a DFG
   Gottfried-Wilhelm Leibniz Price to Dr. Kurts).
CR Babapoor-Farrokhran S, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117723
   Buonsenso D, 2020, LANCET RESP MED, V8, pE27, DOI 10.1016/S2213-2600(20)30120-X
   De Maria A, 2000, HUM IMMUNOL, V61, P74, DOI 10.1016/S0198-8859(99)00169-X
   Doyen D, 2020, LANCET, V395, P1516, DOI 10.1016/S0140-6736(20)30912-0
   Fox SE, 2020, CIRCULATION, V142, P1123, DOI 10.1161/CIRCULATIONAHA.120.049465
   Ganji A, 2020, BLOOD CELL MOL DIS, V83, DOI 10.1016/j.bcmd.2020.102437
   Guzik TJ, 2020, CARDIOVASC RES, V116, P1666, DOI 10.1093/cvr/cvaa106
   Hajivalili M, 2020, LIFE SCI, V257, DOI 10.1016/j.lfs.2020.118058
   Libby Peter, 2020, JACC Basic Transl Sci, V5, P537, DOI 10.1016/j.jacbts.2020.04.001
   Lindner Diana, 2020, JAMA Cardiol, V5, P1281, DOI 10.1001/jamacardio.2020.3551
   Luetkens JA, 2020, CIRC-CARDIOVASC IMAG, V13, DOI 10.1161/CIRCIMAGING.120.010897
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Puelles VG, 2020, NEW ENGL J MED, V383, P590, DOI [10.1056/NEJMc2011400, 10.1056/NEJMc2013400]
   Puntmann Valentina O, 2020, JAMA Cardiol, V5, P1265, DOI 10.1001/jamacardio.2020.3557
   Shi SB, 2020, EUR HEART J, V41, P2070, DOI 10.1093/eurheartj/ehaa408
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
NR 16
TC 1
Z9 1
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD NOV 1
PY 2020
VL 260
AR 118400
DI 10.1016/j.lfs.2020.118400
PG 5
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA OH5FK
UT WOS:000582605800045
PM 32918975
OA Green Published
DA 2021-01-01
ER

PT J
AU Barh, D
   Tiwari, S
   Weener, ME
   Azevedo, V
   Goes-Neto, A
   Gromiha, MM
   Ghosh, P
AF Barh, Debmalya
   Tiwari, Sandeep
   Weener, Marianna E.
   Azevedo, Vasco
   Goes-Neto, Aristoteles
   Gromiha, M. Michael
   Ghosh, Preetam
TI Multi-omits-based identification of SARS-CoV-2 infection biology and
   candidate drugs against COVID-19
SO COMPUTERS IN BIOLOGY AND MEDICINE
LA English
DT Article
DE COVID-19; SARS-CoV-2; Proteome; Transcriptome; Interactome; Infection
   pathways; Candidate drugs; Prophylaxis agents
AB SARS-CoV-2 has ushered a global pandemic with no effective drug being available at present. Although several FDA-approved drugs are currently under clinical trials for drug repositioning, there is an on-going global effort for new drug identification. In this paper, using multi-omits (interactome, proteome, transcriptome, and bibhome) data and subsequent integrated analysis, we present the biological events associated with SARS-CoV-2 infection and identify several candidate drugs against this viral disease. We found that: (i) Interactome-based infection pathways differ from the other three omits-based profiles. (ii) Viral process, mRNA splicing, cytokine and interferon signaling, and ubiquitin mediated proteolysis are important pathways in SARS-CoV-2 infection. (iii) SARS-CoV-2 infection also shares pathways with Influenza A, Epstein-Barr virus, HTLV-I, Measles, and Hepatitis virus. (iv) Further, bacterial, parasitic, and protozoan infection pathways such as Tuberculosis, Malaria, and Leishmaniasis are also shared by this virus. (v) A total of 50 candidate drugs, including the prophylaxis agents and pathway specific inhibitors are identified against COVID-19. (vi) Betamethasone, Estrogen, Simvastatin, Hydrocortisone, Tositumomab, Cyclosporin A etc. are among the important drugs. (vii) Ozone, Nitric oxide, plasma components, and photosensitizer drugs are also identified as possible therapeutic candidates. (viii) Curcumin, Retinoic acids, Vitamin D, Arsenic, Copper, and Zinc may be the candidate prophylaxis agents. Nearly 70% of our identified agents are previously suggested to have anti-COVID-19 effects or under clinical trials. Among our identified drugs, the ones that are not yet tested, need validation with caution while an appropriate drug combination from these candidate drugs along with a SARS-CoV-2 specific antiviral agent is needed for effective COVID-19 management.
C1 [Barh, Debmalya] Inst Integrat Omics & Appl Biotechnol IIOAB, Purba Medinipur, WB, India.
   [Tiwari, Sandeep; Azevedo, Vasco] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Genet Ecol & Evolucao, Lab Genet Celular & Mol, Belo Horizonte, MG, Brazil.
   [Weener, Marianna E.] CRO, Oftalmic, Clin Res Ctr, Bardina Str 22-4, Moscow 119334, Russia.
   [Goes-Neto, Aristoteles] Univ Fed Minas Gerais UFMG, Inst Ciencias Biol, Dept Microbiol, Lab Biol Mol & Computat Fungos, Belo Horizonte, MG, Brazil.
   [Gromiha, M. Michael] Indian Inst Technol Madras IIT M, Bhupat & Jyoti Mehta Sch Biosci, Dept Biotechnol, Chennai 600036, Tamil Nadu, India.
   [Ghosh, Preetam] Virginia Commonwealth Univ, Dept Comp Sci, Richmond, VA 23284 USA.
RP Barh, D (corresponding author), Inst Integrat Omics & Appl Biotechnol IIOAB, Purba Medinipur, WB, India.
EM dr.barh@gmail.com
RI Barh, Debmalya/O-4246-2015; Azevedo, Vasco A/B-1556-2019; Weener,
   Marianna/L-5374-2018
OI Barh, Debmalya/0000-0002-2557-7768; Azevedo, Vasco
   A/0000-0002-4775-2280; Weener, Marianna/0000-0002-1089-4293; Ghosh,
   Preetam/0000-0003-3880-5886
CR A.M.G.o. India, 2020, ADV COR VIR HOM PREV
   Abruzzese E., 2020, MEDITERR J HEMATOL I, V12
   Ahn JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e149
   Al-Motawa M.A., 2020, FRONT PHARM
   Annunziata G, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10090473
   Biesalski H. K., 2020, NFS Journal, V20, P10, DOI 10.1016/j.nfs.2020.06.001
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Bojkova D, 2020, NATURE, V583, P469, DOI 10.1038/s41586-020-2332-7
   Breithaupt-Faloppa AC, 2020, CLINICS, V75, DOI 10.6061/clinics/2020/e1980
   Breuer K, 2013, NUCLEIC ACIDS RES, V41, pD1228, DOI 10.1093/nar/gks1147
   Briedis K., 2020, AM J CARDIOL, V131
   Cava C, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040404
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   chemat S., 2020, SILICO STUDIES ANTIM
   Chen J., NUCL ACIDS RES, V37
   Chen L, 2020, NUTRIENTS, V12, DOI 10.3390/nu12041193
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chowdhury R.G., 2020, SILICO IDENTIFICATIO
   Cour M, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03014-1
   Dittmar M., 2020, BIORXIV
   Enmozhi SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760136
   Favilli A, 2020, J MATERN-FETAL NEO M, DOI 10.1080/14767058.2020.1774875
   Gil C, 2020, J MED CHEM, V63, P12359, DOI 10.1021/acs.jmedchem.0c00606
   Glebov OO, 2020, FEBS J, V287, P3664, DOI 10.1111/febs.15369
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Gu J, 2020, INFECTION, DOI 10.1007/s15010-020-01484-7
   He B., 2020, PREDICTION REPURPOSE
   Horby P, 2020, EFFECT DEXAMETHASONE
   Jena A.B., 2020, RES SQUARE
   Kadioglu O.S., 2020, B WORLD HEALTH ORGAN, DOI DOI 10.2471/BLT.20.255943.
   Kanehisa M., NUCL ACIDS RES, V45
   Ke Y.-Y., 2020, BIOMED J, pS2319
   Kobayashi J, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00681-9
   Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377
   Kumar A., 2020, HYPOTHESES, V144
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Li A.P.M. Fuhai, 2020, REPURPOSING DRUGS CO
   Liao Y, 2019, NUCLEIC ACIDS RES, V47, DOI 10.1093/nar/gkz114
   Lin SC, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2253-8
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lovetrue B., 2020, MED HYPOTHESES, V144
   Marinella MA, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13535
   Martinez-Sanchez G, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9050389
   Mehta DR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031688
   Mi HY, 2019, NUCLEIC ACIDS RES, V47, pD419, DOI 10.1093/nar/gky1038
   Mirabelli C., 2020, BIORXIV
   Mishra A., 2020, RES SQUARE
   Mishra PM, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109790
   Nazarullah A, 2020, AM J CLIN PATHOL, V154, P319, DOI 10.1093/ajcp/aqaa108
   Olisova O.Y., 2020, DERMATOLOGIC THERAPY
   Onstad M, 2020, DRUGS, V80, P1525, DOI 10.1007/s40265-020-01382-0
   Panarese A, 2020, ALIMENT PHARM THER, V51, P993, DOI 10.1111/apt.15752
   Papamichalis P, 2020, INT J INFECT DIS, V97, P90, DOI 10.1016/j.ijid.2020.05.118
   Pinero J, 2020, NUCLEIC ACIDS RES, V48, pD845, DOI 10.1093/nar/gkz1021
   Raha S, 2020, MED HYPOTHESES, V142, DOI 10.1016/j.mehy.2020.109814
   Smeitink J., 2020, HYPOTHESIS MPGES 1 D
   Stelzig KE, 2020, AM J PHYSIOL-LUNG C, V318, pL1280, DOI 10.1152/ajplung.00153.2020
   Sultan I., 2020, RES SQUARE
   Tabatabai A, 2020, A A PRACT, V14, DOI 10.1213/XAA.0000000000001236
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   Ulhaq Z.S., 2020, SSRN ELECT J, DOI [10.2139/ssrn.3606018., DOI 10.2139/SSRN.3606018.]
   Uzun T, 2020, CHIN MED-UK, V15, DOI 10.1186/s13020-020-00336-8
   Veronese N, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00170
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warnes SL, 2015, MBIO, V6, DOI 10.1128/mBio.01697-15
   Wishart DS, 2006, NUCLEIC ACIDS RES, V34, pD668, DOI 10.1093/nar/gkj067
   World Health Organization, 2020, WEEKL EP UPD COR DIS
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xiong Y, 2020, EMERG MICROBES INFEC, V9, P761, DOI 10.1080/22221751.2020.1747363
   Xu T.G., 2020, BIORXIV
   Yiu CY, 2010, MOLECULES, V15, P7115, DOI 10.3390/molecules15107115
   Yoo M, 2015, BIOINFORMATICS, V31, P3069, DOI 10.1093/bioinformatics/btv313
   Zhou GY, 2019, NUCLEIC ACIDS RES, V47, pW234, DOI 10.1093/nar/gkz240
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zimniak M.K., 2020, BIORXIV
NR 76
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0010-4825
EI 1879-0534
J9 COMPUT BIOL MED
JI Comput. Biol. Med.
PD NOV
PY 2020
VL 126
AR 104051
DI 10.1016/j.compbiomed.2020.104051
PG 13
WC Biology; Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Computer Science;
   Engineering; Mathematical & Computational Biology
GA OH6RT
UT WOS:000582723600039
PM 33131530
OA Green Published
DA 2021-01-01
ER

PT J
AU Ibrahim, MAA
   Abdelrahman, AHM
   Hussien, TA
   Badr, EAA
   Mohamed, TA
   El-Seedi, HR
   Pare, PW
   Efferth, T
   Hegazy, MEF
AF Ibrahim, Mahmoud A. A.
   Abdelrahman, Alaa H. M.
   Hussien, Taha A.
   Badr, Esraa A. A.
   Mohamed, Tarik A.
   El-Seedi, Hesham R.
   Pare, Paul W.
   Efferth, Thomas
   Hegazy, Mohamed-Elamir F.
TI In silico drug discovery of major metabolites from spices as SARS-CoV-2
   main protease inhibitors
SO COMPUTERS IN BIOLOGY AND MEDICINE
LA English
DT Article
DE Spices; Secondary metabolites; SARS-CoV-2 main protease; Molecular
   dynamics; Molecular docking
ID LOPINAVIR/RITONAVIR
AB Coronavirus Disease 2019 (COVID-19) is an infectious illness caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), originally identified in Wuhan, China (December 2019) and has since expanded into a pandemic. Here, we investigate metabolites present in several common spices as possible inhibitors of COVID-19. Specifically, 32 compounds isolated from 14 cooking seasonings were examined as inhibitors for SARS-CoV-2 main protease (MPrn), which is required for viral multiplication. Using a drug discovery approach to identify possible antiviral leads, in silico molecular docking studies were performed. Docking calculations revealed a high potency of salvianolic acid A and curcumin as MPr inhibitors with binding energies of 9.7 and 9.2 kcal/mol, respectively. Binding mode analysis demonstrated the ability of salvianolic acid A and curcumin to form nine and six hydrogen bonds, respectively with amino acids proximal to MPr 's active site. Stabilities and binding affinities of the two identified natural spices were calculated over 40 ns molecular dynamics simulations and compared to an antiviral protease inhibitor (lopinavir). Molecular mechanics-generalized Born surface area energy calculations revealed greater salvianolic acid A affinity for the enzyme over curcumin and lopinavir with energies of 44.8, 34.2 and 34.8 kcal/mol, respectively. Using a STRING database, protein-protein interactions were identified for salvianolic acid A included the biochemical signaling genes ACE, MAPK14 and ESR1; and for curcumin, EGFR and TNF. This study establishes salvianolic acid A as an in silico natural product inhibitor against the SARS-CoV-2 main protease and provides a promising inhibitor lead for in vitro enzyme testing.
C1 [Ibrahim, Mahmoud A. A.; Abdelrahman, Alaa H. M.; Badr, Esraa A. A.] Menia Univ, Fac Sci, Chem Dept, Computat Chem Lab, Al Minya 61519, Egypt.
   [Hussien, Taha A.] Deraya Univ, Fac Pharm, Pharmacognosy Dept, Al Minya, Egypt.
   [Mohamed, Tarik A.; Hegazy, Mohamed-Elamir F.] Natl Res Ctr, Chem Med Plants Dept, 33 El Bohouth St, Giza 12622, Egypt.
   [El-Seedi, Hesham R.] Stockholm Univ, Wenner Gren Inst, Dept Mol Biosci, S-10691 Stockholm, Sweden.
   [El-Seedi, Hesham R.] Jiangsu Univ, Int Res Ctr Food Nutr & Safety, Zhenjiang 212013, Jiangsu, Peoples R China.
   [Pare, Paul W.] Texas Tech Univ, Dept Chem & Biochem, Lubbock, TX 79409 USA.
   [Efferth, Thomas; Hegazy, Mohamed-Elamir F.] Johannes Gutenberg Univ Mainz, Inst Pharmaceut & Biomed Sci, Dept Pharmaceut Biol, Staudinger Weg 5, D-55128 Mainz, Germany.
RP Ibrahim, MAA (corresponding author), Menia Univ, Fac Sci, Chem Dept, Computat Chem Lab, Al Minya 61519, Egypt.; Hegazy, MEF (corresponding author), Natl Res Ctr, Chem Med Plants Dept, 33 El Bohouth St, Giza 12622, Egypt.
EM m.ibrahim@compchem.net; me.fathy@nrc.sci.eg
RI Ibrahim, Mahmoud/J-2936-2014; Pare, Paul/E-3055-2013; Hegazy, Mohamed
   Elamir/AAA-3454-2019
OI Ibrahim, Mahmoud/0000-0003-4819-2040; Pare, Paul/0000-0003-1644-723X;
   Hegazy, Mohamed Elamir/0000-0002-0343-4969
FU Science and Technology Development Fund, STDF, EgyptScience and
   Technology Development Fund (STDF) [5480, 7972]
FX The computational work was completed with resources supported by the
   Science and Technology Development Fund, STDF, Egypt, Grants No. 5480 &
   7972 (Granted to Mahmoud Ibrahim).
CR [Anonymous], 2016, SZYBKI OPENEYE SCI S
   [Anonymous], 2013, OMEGA OPENEYE SCI SO
   BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Case D. A, 2016, AMBER
   Chandwani Ashish, 2008, Ther Clin Risk Manag, V4, P1023
   Forli S, 2016, NAT PROTOC, V11, P905, DOI 10.1038/nprot.2016.051
   Frisch M.J, 2009, GAUSSIAN 09 REV B 01
   GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2
   Gbadamosi I. T., 2016, Journal of Applied Biosciences, V98, P9240
   Gbadamosi I.T., 2012, J MED PLANTS, V2, P140
   Gbadamosi I.T., 2019, HIDDEN TREASURES ETH
   Gbadamosi I.T., 2020, AFR J BIOMED RES, V23, P131
   Gordon JC, 2005, NUCLEIC ACIDS RES, V33, pW368, DOI 10.1093/nar/gki464
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   Heberle H, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0611-3
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Ibrahim MAA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1791958
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Lee GA, 2004, AIDS, V18, P641, DOI 10.1097/00002030-200403050-00008
   Li R, 2019, J CELL BIOCHEM, V120, P11265, DOI 10.1002/jcb.28404
   Lin Liang-Tzung, 2014, J Tradit Complement Med, V4, P24, DOI 10.4103/2225-4110.124335
   Liu ZX, 2020, J MED VIROL, V92, P595, DOI 10.1002/jmv.25726
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Massova I, 2000, PERSPECT DRUG DISCOV, V18, P113, DOI 10.1023/A:1008763014207
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Pagadala Nataraj S, 2017, Biophys Rev, V9, P91, DOI 10.1007/s12551-016-0247-1
   Palau V, 2020, NEPHROL DIAL TRANSPL, V35, P1071, DOI 10.1093/ndt/gfaa093
   Pantsar T, 2018, MOLECULES, V23, DOI 10.3390/molecules23081899
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Woo PCY, 2010, VIRUSES-BASEL, V2, P1804, DOI 10.3390/v2081803
   World Health Organization (WHO), 2020, WHO DIRECTOR GENERAL
   Ye XT, 2020, EUR REV MED PHARMACO, V24, P3390, DOI 10.26355/eurrev_202003_20706
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhao YH, 2002, PHARM RES-DORDR, V19, P1446, DOI 10.1023/A:1020444330011
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 38
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0010-4825
EI 1879-0534
J9 COMPUT BIOL MED
JI Comput. Biol. Med.
PD NOV
PY 2020
VL 126
AR 104046
DI 10.1016/j.compbiomed.2020.104046
PG 10
WC Biology; Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Computer Science;
   Engineering; Mathematical & Computational Biology
GA OH6RT
UT WOS:000582723600036
PM 33065388
OA Green Published
DA 2021-01-01
ER

PT J
AU Skariyachan, S
   Gopal, D
   Chakrabarti, S
   Kempanna, P
   Uttarkar, A
   Muddebihalkar, AG
   Niranjan, V
AF Skariyachan, Sinosh
   Gopal, Dharshini
   Chakrabarti, Shweta
   Kempanna, Priya
   Uttarkar, Akshay
   Muddebihalkar, Aditi G.
   Niranjan, Vidya
TI Structural and molecular basis of the interaction mechanism of selected
   drugs towards multiple targets of SARS-CoV-2 by molecular docking and
   dynamic simulation studies- deciphering the scope of repurposed drugs
SO COMPUTERS IN BIOLOGY AND MEDICINE
LA English
DT Article
DE Repurposed drugs; COVID-19; SARS-CoV-2; Potential molecular targets;
   Computational models; Structural and molecular mechanism
ID HIGH-THROUGHPUT
AB The repurposing of FDA approved drugs is presently receiving attention for COVID-19 drug discovery. Previous studies revealed the binding potential of several FDA-approved drugs towards specific targets of SARS-CoV-2; however, limited studies are focused on the structural and molecular basis of interaction of these drugs towards multiple targets of SARS-CoV-2. The present study aimed to predict the binding potential of six FDA drugs towards fifteen protein targets of SARS-CoV-2 and propose the structural and molecular basis of the interaction by molecular docking and dynamic simulation. Based on the literature survey, fifteen potential targets of SARS-CoV-2, and six FDA drugs (Chloroquine, Hydroxychloroquine, Favipiravir, Lopinavir, Remdesivir, and Ritonavir) were selected. The binding potential of individual drug towards the selected targets was predicted by molecular docking in comparison with the binding of the same drugs with their usual targets. The stabilities of the bestdocked conformations were confirmed by molecular dynamic simulation and energy calculations. Among the selected drugs, Ritonavir and Lopinavir showed better binding towards the prioritized targets with minimum binding energy (kcal/mol), cluster-RMS, number of interacting residues, and stabilizing forces when compared with the binding of Chloroquine, Favipiravir, and Hydroxychloroquine, later drugs demonstrated better binding when compared to the binding with their usual targets. Remdesvir showed better binding to the prioritized targets in comparison with the binding of Chloroquine, Favipiravir, and Hydroxychloroquine, but showed lesser binding potential when compared to the interaction between Ritonavir and Lopinavir and the prioritized targets. The structural and molecular basis of interactions suggest that the FDA drugs can be repurposed towards multiple targets of SARS-CoV-2, and the present computational models provide insights on the scope of repurposed drugs against COVID-19.
C1 [Skariyachan, Sinosh] St Pius X Coll Rajapuram, Dept Microbiol, Kasaragod, Kerala, India.
   [Gopal, Dharshini; Chakrabarti, Shweta] Manipal Acad Higher Educ, Dept Bioinformat, Manipal, Karnataka, India.
   [Kempanna, Priya] Dayananda Sagar Coll Engn, Dept Biotechnol, Bangalore, Karnataka, India.
   [Uttarkar, Akshay; Muddebihalkar, Aditi G.; Niranjan, Vidya] RV Coll Engn, Dept Biotechnol, Bengaluru, Karnataka, India.
RP Skariyachan, S (corresponding author), St Pius X Coll Rajapuram, Dept Microbiol, Kasaragod, Kerala, India.
EM sinoshmicro@stpius.ac.in
OI Uttarkar, Akshay/0000-0001-9326-1426
CR Al-Khafaji K, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764392
   Amano M., 2020, SCI REP, V7
   Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   [Anonymous], 2019, MAESTRO DESMOND INTE
   Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398
   Berman H.M., 2020, NUCLEIC ACIDS RES, V28, P235
   Bonanno J.B., 2003, N Y TIMES WEB, pC2
   Buonaguro L, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02355-3
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761882
   Fan HT, 2019, NATURE, V573, P287, DOI 10.1038/s41586-019-1530-7
   Fritz-Wolf K., 2020, PNAS US, V100, P13821
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Glebov OO, 2020, FEBS J, V287, P3664, DOI 10.1111/febs.15369
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Havlichek Jr D, 2020, NEW ENGL J MED, V382, pe68, DOI [10.1056/NEJMc2008043, DOI 10.1056/NEJMC2008043]
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Li XQ, 2020, FASEB J, V34, P6008, DOI 10.1096/fj.202000502
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE019, DOI [10.3760/cma.j.issn.1001-0939.2020.03.009, 10.3760/cma.j.issn.1001-0939.2020.0019]
   Naqvi AA, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165878
   Nutho B, 2020, BIOCHEMISTRY-US, V59, P1769, DOI 10.1021/acs.biochem.0c00160
   Pal M, 2020, CUREUS, V12, DOI 10.7759/cureus.7423
   Pardo Joe, 2020, Drugs Context, V9, DOI 10.7573/dic.2020-4-14
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   Saber-Ayad M, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13050096
   Sevrioukova IF, 2010, P NATL ACAD SCI USA, V107, P18422, DOI 10.1073/pnas.1010693107
   Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652
   Towler P, 2004, J BIOL CHEM, V279, P17996, DOI 10.1074/jbc.M311191200
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   World Health Organization, 2020, WHO COR DIS COVID 19
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Yao TT, 2020, J MED VIROL, V92, P556, DOI 10.1002/jmv.25729
   Yao X., 2020, IN VITRO ANTIVIRAL A, DOI [10.1093/cid/ciaa237, DOI 10.1093/CID/CIAA237]
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 45
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0010-4825
EI 1879-0534
J9 COMPUT BIOL MED
JI Comput. Biol. Med.
PD NOV
PY 2020
VL 126
AR 104054
DI 10.1016/j.compbiomed.2020.104054
PG 24
WC Biology; Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Computer Science;
   Engineering; Mathematical & Computational Biology
GA OH6RT
UT WOS:000582723600040
PM 33074111
OA Green Published
DA 2021-01-01
ER

PT J
AU Albahri, OS
   Al-Obaidi, JR
   Zaidan, AA
   Albahri, AS
   Zaidan, BB
   Salih, MM
   Qays, A
   Dawood, KA
   Mohammed, RT
   Abdulkareem, KH
   Aleesa, AM
   Alamoodi, AH
   Chyad, MA
   Zulkifli, CZ
AF Albahri, O. S.
   Al-Obaidi, Jameel R.
   Zaidan, A. A.
   Albahri, A. S.
   Zaidan, B. B.
   Salih, Mahmood M.
   Qays, Abdulhadi
   Dawood, K. A.
   Mohammed, R. T.
   Abdulkareem, Karrar Hameed
   Aleesa, A. M.
   Alamoodi, A. H.
   Chyad, M. A.
   Zulkifli, Che Zalina
TI Helping doctors hasten COVID-19 treatment: Towards a rescue framework
   for the transfusion of best convalescent plasma to the most critical
   patients based on biological requirements via ml and novel MCDM methods
SO COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
LA English
DT Article
DE COVID-19; Convalescent plasma therapy; Serological; Protein biomarker;
   Machine learning; MCDM; SODOSM
ID DECISION-MAKING; MULTICRITERIA ANALYSIS; TRACKING CHANNELS; COHERENT
   TAXONOMY; SELECTION PROBLEM; OPEN ISSUES; BENCHMARKING; PERFORMANCE;
   PRODUCTS; PRIORITIZATION
AB Context: People who have recently recovered from the threat of deteriorating coronavirus disease-2019 (COVID-19) have antibodies to the coronavirus circulating in their blood. Thus, the transfusion of these antibodies to deteriorating patients could theoretically help boost their immune system. Biologically, two challenges need to be surmounted to allow convalescent plasma (CP) transfusion to rescue the most se vere COVID-19 patients. First, convalescent subjects must meet donor selection plasma criteria and comply with national health requirements and known standard routine procedures. Second, multi-criteria decision-making (MCDM) problems should be considered in the selection of the most suitable CP and the prioritisation of patients with COVID-19.
   Objective: This paper presents a rescue framework for the transfusion of the best CP to the most critical patients with COVID-19 on the basis of biological requirements by using machine learning and novel MCDM methods.
   Method: The proposed framework is illustrated on the basis of two distinct and consecutive phases (i.e. testing and development). In testing, ABO compatibility is assessed after classifying donors into the four blood types, namely, A, B, AB and 0, to indicate the suitability and safety of plasma for administration in order to refine the CP tested list repository. The development phase includes patient and donor sides. In the patient side, prioritisation is performed using a contracted patient decision matrix constructed between 'serological/protein biomarkers and the ratio of the partial pressure of oxygen in arterial blood to fractional inspired oxygen criteria' and 'patient list based on novel MCDM method known as subjective and objective decision by opinion score method'. Then, the patients with the most urgent need are classified into the four blood types and matched with a tested CP list from the test phase in the donor side. Thereafter, the prioritisation of CP tested list is performed using the contracted CP decision matrix.
   Result: An intelligence-integrated concept is proposed to identify the most appropriate CP for corresponding prioritised patients with COVID-19 to help doctors hasten treatments.
   Discussion: The proposed framework implies the benefits of providing effective care and prevention of the extremely rapidly spreading COVID-19 from affecting patients and the medical sector. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Albahri, O. S.; Zaidan, A. A.; Zaidan, B. B.; Qays, Abdulhadi; Alamoodi, A. H.; Chyad, M. A.; Zulkifli, Che Zalina] Univ Pendidikan, Fac Arts Comp & Creat Ind, Dept Comp, Tanjung Malim 35900, Malaysia.
   [Al-Obaidi, Jameel R.] Univ Pendidikan Sultan Idris, Fac Sci & Math, Dept Biol, Tanjong Malim 35900, Perak, Malaysia.
   [Dawood, K. A.; Mohammed, R. T.] Univ Putra Malaysia, Fac Comp Sci & Informat Technol, Seri Kembangan, Malaysia.
   [Abdulkareem, Karrar Hameed] Univ Tun Hussein Onn Malaysia, Fac Comp Sci & Informat Technol, Parit Raja, Malaysia.
   [Aleesa, A. M.] Univ Tun Hussein Onn, Fac Elect & Elect Engn, Batu Pahat 86400, Johor, Malaysia.
   [Salih, Mahmood M.] Tikrit Univ, Comp Sci & Math Coll, Dept Comp Sci, Tikrit 34001, Iraq.
   [Albahri, A. S.] Iraqi Commiss Comp & Informat ICCI, Informat Inst Postgrad Studies IIPS, Baghdad, Iraq.
RP Zaidan, AA (corresponding author), Univ Pendidikan, Fac Arts Comp & Creat Ind, Dept Comp, Tanjung Malim 35900, Malaysia.
EM aws.alaa@gmail.com
RI Abdulkareem, Karrar Hameed/V-1741-2017; zaidan, aws alaa/F-7289-2010;
   Albahri, A.S./E-7428-2018; Abdulkareem, Karrar Hameed/AAD-1500-2020;
   Al-Obaidi, Jameel R./H-4651-2017; Albahri, Osamah Shihab/D-5150-2018
OI Abdulkareem, Karrar Hameed/0000-0001-7302-2049; zaidan, aws
   alaa/0000-0001-6090-0391; Albahri, A.S./0000-0003-3335-457X;
   Abdulkareem, Karrar Hameed/0000-0001-7302-2049; Al-Obaidi, Jameel
   R./0000-0002-5705-0223; Albahri, Osamah Shihab/0000-0002-7844-3990;
   Aleesa, Ahmed/0000-0003-3968-4422; Salih, Mahmood/0000-0002-1245-1904
CR Abdulkareem K.H., 2020, INT J INF TECHNOL DE
   Abdulkareem KH, 2020, NEURAL COMPUT APPL, DOI 10.1007/s00521-020-05020-4
   Abdullateef BN, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-1828-y
   Ahn JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e149
   Alaa M, 2019, IEEE ACCESS, V7, P126201, DOI 10.1109/ACCESS.2019.2936898
   Albahri AS, 2020, J MED SYST, V44, DOI 10.1007/s10916-020-01582-x
   Albahri AS, 2019, IEEE ACCESS, V7, P37269, DOI 10.1109/ACCESS.2019.2898214
   Albahri AS, 2018, J MED SYST, V42, DOI 10.1007/s10916-018-0983-9
   Albahri OS, 2019, IEEE ACCESS, V7, P50052, DOI 10.1109/ACCESS.2019.2910411
   Albahri OS, 2018, J MED SYST, V42, DOI 10.1007/s10916-018-1006-6
   Albahri OS, 2018, J MED SYST, V42, DOI 10.1007/s10916-018-0943-4
   Almahdi EM, 2019, J MED SYST, V43, DOI 10.1007/s10916-019-1339-9
   Almahdi EM, 2019, J MED SYST, V43, DOI 10.1007/s10916-019-1336-z
   Alsalem MA, 2019, J MED SYST, V43, DOI 10.1007/s10916-019-1338-x
   Alsalem MA, 2018, J MED SYST, V42, DOI 10.1007/s10916-018-1064-9
   AlSattar H., 2018, MOGSABAT METAHEURIST, P1
   Aminudin N., 2018, PERFORMANCE, V7, P102
   [Anonymous], 2012, WHOBLOOD DON SEL GUI
   [Anonymous], 2020, COR DIS 2019 COVID 1
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Araujo JDB, 2020, J BRAS PNEUMOL, V46, DOI 10.36416/1806-3756/e20200114
   Benej M, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02438
   Brown JF, 2018, J INFECT DIS, V218, P555, DOI 10.1093/infdis/jiy199
   Brugha C.M., 1998, P 13 INT C MULT CRIT, P229, DOI DOI 10.1007/978-3-642-45772-2_1
   Burnouf T, 2000, BLOOD REV, V14, P94, DOI 10.1054/blre.2000.0129
   Burnouf T, 2014, TRANSFUS APHER SCI, V51, P120, DOI 10.1016/j.transci.2014.10.003
   Cao W., 2020, CLIN FEATURES LAB IN
   Casadevall A, 2020, J CLIN INVEST, V130
   Chen JH, 2004, P NATL ACAD SCI USA, V101, P17039, DOI 10.1073/pnas.0407992101
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Chou SY, 2008, EUR J OPER RES, V189, P132, DOI 10.1016/j.ejor.2007.05.006
   Cunningham AC, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2818-6
   Deng C., 2015, P IEEE INT S MULT VA
   Deng XY, 2019, SOFT COMPUT, V23, P683, DOI 10.1007/s00500-017-2993-9
   Desogus C., 2017, P IEEE INT S BROADB
   Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227
   dos Santos BM, 2019, J CLEAN PROD, V207, P498, DOI 10.1016/j.jclepro.2018.09.235
   Duan K, 2020, P NATL ACAD SCI
   Enaizan O, 2020, HEALTH TECHNOL-GER, V10, P795, DOI 10.1007/s12553-018-0278-7
   Fayiz, 2020, INT J INF TECHNOL DE
   Ferraz A, 2010, PROCEDIA ENGINEER, V5, P496, DOI 10.1016/j.proeng.2010.09.155
   Ferraz A., 2010, AUTOMATIC DETERMINAT
   Ferraz A, 2017, NEURAL COMPUT APPL, V28, P2029, DOI 10.1007/s00521-015-2151-1
   Ferraz A, 2017, MEASUREMENT, V97, P165, DOI 10.1016/j.measurement.2016.11.015
   Ferraz A, 2011, SENSOR ACTUAT A-PHYS, V172, P308, DOI 10.1016/j.sna.2011.02.022
   Garraud O, 2017, TRANSFUS APHER SCI, V56, P31, DOI 10.1016/j.transci.2016.12.014
   Groner A, 2018, TRANSFUSION, V58, P41, DOI 10.1111/trf.14390
   Gupta H, 2017, J CLEAN PROD, V152, P242, DOI 10.1016/j.jclepro.2017.03.125
   Harmening D. M., 2018, MODERN BLOOD BANKING
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Ibrahim N., 2019, MULTICRITERIA EVALUT, V7
   Jens J., 2012, PRODUCTION PLASMA PR, P381
   Jin C, 2020, RES SQUARE, DOI [DOI 10.21203/RS.3.RS-17718/V1, 10.21203/rs.3.rs-17718/v1]
   Jumaah FM, 2018, TELECOMMUN SYST, V68, P425, DOI 10.1007/s11235-017-0401-5
   Jumaah FM, 2018, MEASUREMENT, V118, P83, DOI 10.1016/j.measurement.2018.01.011
   Kalid N, 2018, J MED SYST, V42, DOI 10.1007/s10916-018-0916-7
   Kalid N, 2018, J MED SYST, V42, DOI 10.1007/s10916-017-0883-4
   Keil SD, 2016, TRANSFUSION, V56, P2948, DOI 10.1111/trf.13860
   Keller MA, 2000, CLIN MICROBIOL REV, V13, P602, DOI 10.1128/CMR.13.4.602-614.2000
   Khatari M, 2019, INT J INF TECH DECIS, V18, P1187, DOI 10.1142/S0219622019300039
   Lai KY, 2014, INFECT DIS POVERTY, V3, DOI 10.1186/2049-9957-3-43
   Leung LC, 2000, EUR J OPER RES, V124, P102, DOI 10.1016/S0377-2217(99)00118-6
   Lin ZZ, 2017, IEEE T CIRCUITS-II, V65, P206
   Madic M, 2017, OPT LASER TECHNOL, V89, P214, DOI 10.1016/j.optlastec.2016.10.005
   Marano G, 2016, BLOOD TRANSFUS-ITALY, V14, P152, DOI 10.2450/2015.0131-15
   Mathhew H., 2020, BLOOD PLASMA RECOVER
   Maxmen A., 2020, NATURE
   Miljkovic B, 2017, FILOMAT, V31, P2991, DOI 10.2298/FIL1710991M
   Mohammed KI, 2020, IEEE ACCESS, V8, P91521, DOI 10.1109/ACCESS.2020.2994746
   Mohammed KI, 2020, COMPUT METH PROG BIO, V185, DOI 10.1016/j.cmpb.2019.105151
   Mohammed KI, 2019, J MED SYST, V43, DOI 10.1007/s10916-019-1362-x
   Mohammed R.T., 2020, INT J INF TECHNOL DE
   Napi NM, 2019, HEALTH TECHNOL-GER, V9, P679, DOI 10.1007/s12553-019-00357-w
   Nigim K, 2004, RENEW ENERG, V29, P1775, DOI 10.1016/j.renene.2004.02.012
   Opricovic S, 2007, EUR J OPER RES, V178, P514, DOI 10.1016/j.ejor.2006.01.020
   Orfao A., 2009, APONTAMENTOS ANATOMI, V25, P347
   Organization W.H., 2020, 72 WHO
   Oved K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120012
   Petkovic D, 2017, FACTA UNIV-SER MECH, V15, P97, DOI 10.22190/FUME151120001P
   Polatidis H, 2006, ENERG SOURCE PART B, V1, P181, DOI 10.1080/009083190881607
   PPTA, 2020, NEW COR SARS COV 2 S
   Qader MA, 2017, MEASUREMENT, V111, P38, DOI 10.1016/j.measurement.2017.07.024
   Rahmatullah B., 2017, P 4 INT C CONTR DEC
   Rajam Gowrisankar, 2010, Recent Pat Antiinfect Drug Discov, V5, P157
   Rezaei J, 2015, OMEGA-INT J MANAGE S, V53, P49, DOI 10.1016/j.omega.2014.11.009
   Salih MM, 2019, COMPUT OPER RES, V104, P207, DOI 10.1016/j.cor.2018.12.019
   Salman OH, 2017, INT J INF TECH DECIS, V16, P1211, DOI 10.1142/S0219622017500225
   Talal M, 2019, TELECOMMUN SYST, V72, P285, DOI 10.1007/s11235-019-00575-7
   Vinogradova I, 2018, SYMMETRY-BASEL, V10, DOI 10.3390/sym10060205
   Ward MD, 2019, CLIN PROTEOM, V16, DOI 10.1186/s12014-019-9227-3
   WHO, 1994, WHOTECHNICAL REP SER
   Wu J, 2011, EXPERT SYST APPL, V38, P5162, DOI 10.1016/j.eswa.2010.10.046
   Xiong W, 2012, J MED SYST, V36, P1651, DOI 10.1007/s10916-010-9626-5
   Yas Q.M., 2017, DEV FRAMEWORK EVALUA, V31
   Yas QM, 2018, MEASUREMENT, V114, P243, DOI 10.1016/j.measurement.2017.09.027
   Yasemin S., 2020, BLOOD CURED CORONAVI
   Yuen K.-.S., 2020, SARS COV 2 COVID 19, V10, P1
   Yunoki M, 2004, VOX SANG, V87, P302, DOI 10.1111/j.1423-0410.2004.00577.x
   Zaidan AA, 2020, NEURAL COMPUT APPL, V32, P8315, DOI 10.1007/s00521-019-04325-3
   Zaidan AA, 2020, ARTIF INTELL REV, V53, P141, DOI 10.1007/s10462-018-9648-9
   Zaidan AA, 2018, HEALTH TECHNOL-GER, V8, P223, DOI 10.1007/s12553-018-0223-9
   Zaidan AA, 2015, DECIS SUPPORT SYST, V78, P15, DOI 10.1016/j.dss.2015.07.002
   Zaidan AA, 2015, J CIRCUIT SYST COMP, V24, DOI 10.1142/S0218126615500231
   Zaidan AA, 2014, ENG APPL ARTIF INTEL, V32, P136, DOI 10.1016/j.engappai.2014.03.002
   Zaidan AA, 2014, INT J PATTERN RECOGN, V28, DOI 10.1142/S0218001414590010
   Zaidan AA, 2014, NEUROCOMPUTING, V131, P397, DOI 10.1016/j.neucom.2013.10.003
   Zaidan AA, 2013, INT J PATTERN RECOGN, V27, DOI 10.1142/S0218001413500122
   Zaidan A.A., 2013, ANTIPORNOGRAPHY ALGO
   ZAIDAN AA, 2015, EVALUATION SELECTION, V53, P390, DOI DOI 10.1016/J.JBI.2014.11.012
   Zaidan B., 2017, INT J INF TECH DECIS, P1
   Zaidan BB, 2018, MEASUREMENT, V117, P277, DOI 10.1016/j.measurement.2017.12.019
   Zaidan BB, 2017, SOFTWARE PRACT EXPER, V47, P1365, DOI 10.1002/spe.2465
   Zaidan BB, 2017, J CIRCUIT SYST COMP, V26, DOI 10.1142/S021812661750116X
   Zavadskas EK, 2016, INT J INF TECH DECIS, V15, P267, DOI 10.1142/S0219622016500036
   Zughoul O, 2018, IEEE ACCESS, V6, P73245, DOI 10.1109/ACCESS.2018.2881282
NR 117
TC 1
Z9 1
U1 4
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0169-2607
EI 1872-7565
J9 COMPUT METH PROG BIO
JI Comput. Meth. Programs Biomed.
PD NOV
PY 2020
VL 196
AR 105617
DI 10.1016/j.cmpb.2020.105617
PG 13
WC Computer Science, Interdisciplinary Applications; Computer Science,
   Theory & Methods; Engineering, Biomedical; Medical Informatics
SC Computer Science; Engineering; Medical Informatics
GA OE5ZU
UT WOS:000580609200041
PM 32593060
OA Green Published
DA 2021-01-01
ER

PT J
AU Libotte, GB
   Lobato, FS
   Platt, GM
   Neto, AJS
AF Libotte, Gustavo Barbosa
   Lobato, Fran Sergio
   Platt, Gustavo Mendes
   Silva Neto, Antonio J.
TI Determination of an optimal control strategy for vaccine administration
   in COVID-19 pandemic treatment
SO COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
LA English
DT Article
DE Mathematical modeling of COVID-19; Inverse problem; Optimal control
   problem; Differential evolution algorithm; Multi-objective optimization
ID SEIR MODEL; TRANSMISSION; WUHAN; OPTIMIZATION; ALGORITHM; EVOLUTION;
   CHINA
AB Background and objective: For decades, mathematical models have been used to predict the behavior of physical and biological systems, as well as to define strategies aiming at the minimization of the effects regarding different types of diseases. In the present days, the development of mathematical models to simulate the dynamic behavior of the novel coronavirus disease (COVID-19) is considered an important theme due to the quantity of infected people worldwide. In this work, the objective is to determine an optimal control strategy for vaccine administration in COVID-19 pandemic treatment considering real data from China. Two optimal control problems (mono- and multi-objective) to determine a strategy for vaccine administration in COVID-19 pandemic treatment are proposed. The first consists of minimizing the quantity of infected individuals during the treatment. The second considers minimizing together the quantity of infected individuals and the prescribed vaccine concentration during the treatment.
   Methods: An inverse problem is formulated and solved in order to determine the parameters of the compartmental Susceptible-Infectious-Removed model. The solutions for both optimal control problems proposed are obtained by using Differential Evolution and Multi-objective Optimization Differential Evolution algorithms.
   Results: A comparative analysis on the influence related to the inclusion of a control strategy in the population subject to the epidemic is carried out, in terms of the compartmental model and its control parameters. The results regarding the proposed optimal control problems provide information from which an optimal strategy for vaccine administration can be defined.
   Conclusions: The solution of the optimal control problem can provide information about the effect of vaccination of a population in the face of an epidemic, as well as essential elements for decision making in the economic and governmental spheres. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Libotte, Gustavo Barbosa] Natl Lab Sci Comp LNCC MCTI, Petropolis, RJ, Brazil.
   [Libotte, Gustavo Barbosa; Silva Neto, Antonio J.] Univ Estado Rio De Janeiro, Polytech Inst, Nova Friburgo, Brazil.
   [Lobato, Fran Sergio] Univ Fed Uberlandia, Chem Engn Fac, Uberlandia, MG, Brazil.
   [Platt, Gustavo Mendes] Fed Univ Rio Grande, Sch Chem & Food, Santo Antonio Da Patrulh, Brazil.
RP Libotte, GB (corresponding author), Natl Lab Sci Comp LNCC MCTI, Petropolis, RJ, Brazil.; Libotte, GB (corresponding author), Univ Estado Rio De Janeiro, Polytech Inst, Nova Friburgo, Brazil.
EM glibotte@lncc.br; fslobato@ufu.br; gmplatt@furg.br; ajsneto@iprj.uerj.br
RI Libotte, Gustavo/ABI-1724-2020; Neto, Antonio Jose Silva/W-4333-2019; da
   Silva Neto, Antonio Jose/C-9207-2018
OI Neto, Antonio Jose Silva/0000-0002-9616-6093; da Silva Neto, Antonio
   Jose/0000-0002-9616-6093; Platt, Gustavo/0000-0003-0506-2561
FU Coordenacao de Aperfeicoamente de Pessoal de Nivel Superior Brasil
   (CAPES)CAPES [001]; Fundacao Carlos Chagas Filho de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ); Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)National
   Council for Scientific and Technological Development (CNPq)
FX This study was financed in part by the Coordenacao de Aperfeicoamente de
   Pessoal de Nivel Superior Brasil (CAPES) Finance Code 001, Fundacao
   Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro
   (FAPERJ), and Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq).
CR Al-Sheikh S.A., 2013, GLOBAL J SCI FRONTIE, V12, P56
   [Anonymous], 2013, AUTONOMA BARCELONA 2, V2013, P17
   Azam S, 2020, COMPUT METH PROG BIO, V193, DOI 10.1016/j.cmpb.2020.105429
   Bauch CT, 2009, VACCINE, V27, P4090, DOI 10.1016/j.vaccine.2009.04.079
   Benvenuto D, 2020, DATA BRIEF, V29, DOI 10.1016/j.dib.2020.105340
   Biegler LT, 2002, CHEM ENG SCI, V57, P575, DOI 10.1016/S0009-2509(01)00376-1
   Biswas MHA, 2014, MATH BIOSCI ENG, V11, P761, DOI 10.3934/mbe.2014.11.761
   Blackwood J. C., 2018, LETT BIOMATH, V5, P195, DOI DOI 10.1080/23737867.2018.1509026
   Bowong S, 2010, PHYS LETT A, V374, P4496, DOI 10.1016/j.physleta.2010.09.008
   Bryson A. E., 1975, APPL OPTIMAL CONTROL
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chretien JP, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0094130, 10.1371/currents.outbreaks.3408774290b1a0f2dd7cae877c8b8ff6]
   Cooper Kathryn M, 2016, AMIA Annu Symp Proc, V2016, P431
   Deb K, 2002, IEEE T EVOLUT COMPUT, V6, P182, DOI 10.1109/4235.996017
   Feehery WF, 1996, COMPUT CHEM ENG, V20, pS707, DOI 10.1016/0098-1354(96)00127-5
   Fehlberg E., 1964, PMM-J APPL MATH MEC, V44, DOI [10.1002/zamm.19640441310., DOI 10.1002/ZAMM.19640441310]
   Forgoston E, 2013, B MATH BIOL, V75, P1450, DOI 10.1007/s11538-013-9855-0
   Gorbalenya AE, 2020, SEVERE ACUTE RESP SY, V5, P536, DOI [10.1101/2020.02.07.937862, DOI 10.1101/2020.02.07.937862]
   Hethcote HW, 2000, SIAM REV, V42, P599, DOI 10.1137/S0036144500371907
   Hu XL, 2005, ENG OPTIMIZ, V37, P351, DOI 10.1080/03052150500035658
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Johns Hopkins Resource Center, 2020, MAPP 2019 NCOV
   Keeling M., 2007, MODELING INFECT DIS
   Keeling MJ, 2000, J THEOR BIOL, V203, P51, DOI 10.1006/jtbi.1999.1064
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lin QY, 2020, INT J INFECT DIS, V93, P211, DOI 10.1016/j.ijid.2020.02.058
   Lobato F.S., 2011, J ARTIFICIAL INTELLI, V1, P259
   Lobato F.S., 2004, THESIS
   Lobato FS, 2016, COMPUT METH PROG BIO, V131, P51, DOI 10.1016/j.cmpb.2016.04.004
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Mathews J.H., 1998, NUMERICAL METHODS US, V3
   Mukandavire Z, 2009, NONLINEAR ANAL-THEOR, V71, P1082, DOI 10.1016/j.na.2008.11.026
   Neilan RM, 2010, DIMACS SER DISCRET M, V75, P67
   Neto F.D. Moura, 2013, INTRO INVERSE PROBLE, DOI [10.1007/978- 3-642- 32557-1., DOI 10.1007/978-3-642-32557-1]
   Pesco P, 2014, EPIDEMICS-NETH, V7, P13, DOI 10.1016/j.epidem.2014.04.001
   Price K. V., 2005, NAT COMP SER
   Riou J, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.4.2000058
   Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282
   Sethi SK, 2019, SUPERHYDROPHOBIC POLYMER COATINGS: FUNDAMENTALS, DESIGN, FABRICATION, AND APPLICATIONS, P3, DOI 10.1016/B978-0-12-816671-0.00001-1
   Storn R, 1997, J GLOBAL OPTIM, V11, P341, DOI 10.1023/A:1008202821328
   Trawicki MB, 2017, MATHEMATICS-BASEL, V5, DOI 10.3390/math5010007
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang HW, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0148-0
   Wearing HJ, 2005, PLOS MED, V2, P621, DOI 10.1371/journal.pmed.0020174
   Wei W, 2020, RADIOTHER ONCOL, V148, P203, DOI 10.1016/j.radonc.2020.03.029
   Weiss H., 2013, MAT MATEMATICS, V2013, P17
   Widyaningsih P, 2018, AIP CONF PROC, V2014, DOI 10.1063/1.5054569
   World Health Organization, 2020, NAM COR DIS COVID 19
NR 48
TC 1
Z9 1
U1 10
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0169-2607
EI 1872-7565
J9 COMPUT METH PROG BIO
JI Comput. Meth. Programs Biomed.
PD NOV
PY 2020
VL 196
AR 105664
DI 10.1016/j.cmpb.2020.105664
PG 13
WC Computer Science, Interdisciplinary Applications; Computer Science,
   Theory & Methods; Engineering, Biomedical; Medical Informatics
SC Computer Science; Engineering; Medical Informatics
GA OE5ZU
UT WOS:000580609200062
PM 32736332
OA Green Published
DA 2021-01-01
ER

PT J
AU Verna, EC
   Serper, M
   Chu, J
   Corey, K
   Fix, OK
   Hoyt, K
   Page, KA
   Loomba, R
   Li, M
   Everson, GT
   Fried, MW
   Garcia-Tsao, G
   Terrault, N
   Lok, AS
   Chung, RT
   Reddy, KR
AF Verna, Elizabeth C.
   Serper, Marina
   Chu, Jaime
   Corey, Kathleen
   Fix, Oren K.
   Hoyt, Karen
   Page, Kimberly A.
   Loomba, Rohit
   Li, Ming
   Everson, Gregory T.
   Fried, Michael W.
   Garcia-Tsao, Guadalupe
   Terrault, Norah
   Lok, Anna S.
   Chung, Raymond T.
   Reddy, K. Rajender
TI Clinical Research in Hepatology in the COVID-19 Pandemic and
   Post-Pandemic Era: Challenges and the Need for Innovation
SO HEPATOLOGY
LA English
DT Article
ID HEPATITIS-C; TRIAL; THERAPY; HEALTH; STATES
AB The severe acute respiratory syndrome coronavirus 2 pandemic has drastically altered all facets of clinical care and research. Clinical research in hepatology has had a rich tradition in several domains, including the discovery and therapeutic development for diseases such as hepatitis B and C and studying the natural history of many forms of chronic liver disease. National Institutes of Health, foundation, and industry funding have provided important opportunities to advance the academic careers of young investigators while they strived to make contributions to the field. Instantaneously, however, all nonessential research activities were halted when the pandemic started, forcing those involved in clinical research to rethink their research strategy, including a shift to coronavirus disease 2019 research while endeavoring to maintain their preexisting agenda. Strategies to maintain the integrity of ongoing studies, including patient follow-up, safety assessments, and continuation of investigational products, have included a shift to telemedicine, remote safety laboratory monitoring, and shipping of investigational products to study subjects. As a revamp of research is being planned, unique issues that face the research community include maintenance of infrastructure, funding, completion of studies in the predetermined time frame, and the need to reprogram career path timelines. Real-world databases, biomarker and long-term follow up studies, and research involving special groups (children, the homeless, and other marginalized populations) are likely to face unique challenges. The implementation of telemedicine has been dramatically accelerated and will serve as a backbone for the future of clinical research. As we move forward, innovation in clinical trial design will be essential for conducting optimized clinical research.
C1 [Verna, Elizabeth C.] Columbia Univ, Irving Med Ctr, Ctr Liver Dis & Transplantat, New York, NY USA.
   [Serper, Marina; Reddy, K. Rajender] Univ Penn, Div Gastroenterol & Hepatol, 2 Dulles,3400 Spruce St, Philadelphia, PA 19104 USA.
   [Chu, Jaime] Mt Sinai Sch Med, Div Pediat Hepatol, New York, NY USA.
   [Corey, Kathleen; Chung, Raymond T.] Massachusetts Gen Hosp, Ctr Liver, Boston, MA USA.
   [Fix, Oren K.] Swedish Med Ctr, Organ Transplant & Liver Ctr, Seattle, WA USA.
   [Hoyt, Karen] Southern Nazarene Univ, Bethel, OK USA.
   [Page, Kimberly A.] Univ New Mexico, Sch Med, Dept Internal Med, Div Epidemiol Biostat & Prevent Med, Albuquerque, NM USA.
   [Loomba, Rohit] UC San Diego Sch Med, Div Gastroenterol, San Diego, CA USA.
   [Li, Ming; Terrault, Norah] Keck Sch Med USC, Los Angeles, CA USA.
   [Everson, Gregory T.] Univ Colorado, Denver Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, Aurora, CO USA.
   [Everson, Gregory T.] HepQuant LLC, Greenwood Village, CO USA.
   [Fried, Michael W.] Univ N Carolina, Sch Med, Div Gastroenterol & Hepatol, Chapel Hill, NC 27515 USA.
   [Garcia-Tsao, Guadalupe] Yale Sch Med, Sect Digest Dis, New Haven, CT USA.
   [Lok, Anna S.] Univ Michigan, Sch Med, Div Gastroenterol, Ann Arbor, MI USA.
RP Reddy, KR (corresponding author), Univ Penn, Div Gastroenterol & Hepatol, 2 Dulles,3400 Spruce St, Philadelphia, PA 19104 USA.
EM reddyr@pennmedicine.upenn.edu
RI Garcia-Tsao, Guadalupe/ABF-7374-2020
OI Serper, Marina/0000-0003-4899-2160
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR001442] Funding Source: Medline;
   NIDDK NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [R01 DK106419, R01 DK121378, R01
   DK124318, P30 DK120515] Funding Source: Medline; NIEHS NIH HHSUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Environmental Health
   Sciences (NIEHS) [P42 ES010337] Funding Source: Medline
CR Abrahamson M, 2017, CONT CLIN TRIAL COMM, V7, P158, DOI 10.1016/j.conctc.2017.07.002
   Alessandra M, 2020, PANDEMIC FEMALE ACAD
   Alonso EM, 2017, HEPATOLOGY, V65, P1026, DOI 10.1002/hep.28944
   Amero S, 2020, EXTRAMURAL NEXUS
   Anguera Joaquin A, 2016, BMJ Innov, V2, P14
   Antinori S, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104899
   Atkins D, 2017, ANNU REV PUBL HEALTH, V38, P467, DOI 10.1146/annurev-publhealth-031816-044255
   Azzi L, 2020, J INFECTION, V81, pE45, DOI 10.1016/j.jinf.2020.04.005
   Barrett JR, 2004, ENVIRON HEALTH PERSP, V112, pA51, DOI 10.1289/ehp.112-a51
   Bezerra JA, 2018, HEPATOLOGY, V68, P1163, DOI 10.1002/hep.29905
   Borno HT, 2020, CONTEMP CLIN TRIALS, V92, DOI 10.1016/j.cct.2020.105997
   Borno HT, 2018, ONCOLOGIST, V23, P1242, DOI 10.1634/theoncologist.2017-0628
   Chowkwanyun M, 2020, NEW ENGL J MED, V383, P201, DOI 10.1056/NEJMp2012910
   Di Bisceglie AM, 2008, NEW ENGL J MED, V359, P2429, DOI 10.1056/NEJMoa0707615
   Duley L, 2008, CLIN TRIALS, V5, P40, DOI 10.1177/1740774507087704
   Evon DM, 2019, J HEPATOL, V71, P486, DOI 10.1016/j.jhep.2019.04.016
   Fabio C, 2020, CLIN IMMUNOL, V217, P108509
   Falade-Nwulia O, 2017, ANN INTERN MED, V166, P637, DOI [10.7326/M16-2575, 10.7326/m16-2575]
   Food and Drug Administration, 2020, FDA GUID COND CLIN T
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gaziano JM, 2016, J CLIN EPIDEMIOL, V70, P214, DOI 10.1016/j.jclinepi.2015.09.016
   Gould B, LYFT UBER ADDRESS TR
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Hughes Summer R, 2019, BMC Res Notes, V12, P165, DOI 10.1186/s13104-019-4211-6
   Janssen KJM, 2010, J CLIN EPIDEMIOL, V63, P721, DOI 10.1016/j.jclinepi.2009.12.008
   Kakkar AK, 2018, INDIAN J PHARMACOL, V50, P105, DOI 10.4103/ijp.IJP_391_18
   Kim AHJ, 2020, ANN INTERN MED, V172, P819, DOI 10.7326/M20-1223
   King TE, 2002, NEW ENGL J MED, V346, P1400, DOI 10.1056/NEJM200205023461812
   Lei BUW, 2019, BIOMED MICRODEVICES, V21, DOI 10.1007/s10544-019-0412-y
   Lucy F, 2020, MOVING REMOTE POSTPA
   Marrero JA, 2018, HEPATOLOGY, V68, P723, DOI 10.1002/hep.29913
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Mehta HB, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-039978
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   MENDENHALL CL, 1993, HEPATOLOGY, V17, P564, DOI 10.1002/hep.1840170407
   Mishra P, 2017, GASTROENTEROLOGY, V153, P626, DOI 10.1053/j.gastro.2017.07.025
   Morgan TR, 2005, GASTROENTEROLOGY, V128, P882, DOI 10.1053/j.gastro.2005.01.057
   National Center for Immunization and Respiratory Diseases (NCIRD) Division of Viral Diseases, 2020, INT LAB BIOS GUID HA
   National Institutes of Health, 2020, GUID NIH FUND CLIN T
   National Institutes of Health, 2020, NIH BEG STUD QUANT U
   Nicola D, 2019, TELEMEDICINE FUTURE
   Nouri S, 2020, NEJM CATALYST INNOVA, V1
   Orri M, 2014, CONTEMP CLIN TRIALS, V38, P190, DOI 10.1016/j.cct.2014.04.009
   Padala PR, 2020, J AM GERIATR SOC, V68, pE14, DOI 10.1111/jgs.16500
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   SEEFF LB, 1987, NEW ENGL J MED, V316, P965, DOI 10.1056/NEJM198704163161601
   Seidler Elizabeth M., 2014, CLIN INVESTIGATION, V4, P373
   Sherman RE, 2016, NEW ENGL J MED, V375, P2293, DOI 10.1056/NEJMsb1609216
   Society of Pediatric Liver Transplantation, COVID 19 POSTL TRANS
   Squires JE, 2020, J PEDIATR GASTR NUTR, V70, P79, DOI 10.1097/MPG.0000000000002489
   Thabane L, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-92
   U.S. Department of Health and Human Services Office for Human Research Protections Food and Drug Administration Center for Drug Evaluation and Research, 2016, US EL INF CONS QUEST
   U.S. National Library of Medicine, 2020, TREND CHARTS MAPS
   Uren SC, 2013, J ONCOL PRACT, V9, pE13, DOI 10.1200/JOP.2012.000666
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   World Health Organization, 2011, MHEALTH NEW HORIZONS
   Yin G, 2012, CLIN TRIAL DESIGN BA
   Younossi ZM, 2019, LANCET, V394, P2184, DOI 10.1016/S0140-6736(19)33041-7
   Zoulim F, 2016, CURR OPIN VIROL, V18, P109, DOI 10.1016/j.coviro.2016.06.004
NR 61
TC 1
Z9 1
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD NOV
PY 2020
VL 72
IS 5
BP 1819
EP 1837
DI 10.1002/hep.31491
PG 19
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA ON6SU
UT WOS:000586828900024
PM 32740969
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Li, YM
   Li, H
   Zhu, SS
   Xie, YJ
   Wang, B
   He, L
   Zhang, DQ
   Zhang, YX
   Yuan, HL
   Wu, C
   Sun, W
   Zhang, YT
   Li, M
   Cui, L
   Cai, Y
   Wang, J
   Yang, YL
   Lv, Q
   Zhang, L
   Xie, MX
AF Li, Yuman
   Li, He
   Zhu, Shuangshuang
   Xie, Yuji
   Wang, Bin
   He, Lin
   Zhang, Danqing
   Zhang, Yongxing
   Yuan, Hongliang
   Wu, Chun
   Sun, Wei
   Zhang, Yanting
   Li, Meng
   Cui, Li
   Cai, Yu
   Wang, Jing
   Yang, Yali
   Lv, Qing
   Zhang, Li
   Xie, Mingxing
TI Prognostic Value of Right Ventricular Longitudinal Strain in Patients
   With COVID-19
SO JACC-CARDIOVASCULAR IMAGING
LA English
DT Article
DE COVID-19; right ventricular function; SARS-CoV-2; speckle tracking
   echocardiography; strain
ID SPECKLE-TRACKING ECHOCARDIOGRAPHY; EUROPEAN ASSOCIATION; AMERICAN
   SOCIETY; HEART; TETRALOGY; FALLOT; ADULTS
AB OBJECTIVES The aim of this study was to investigate whether right ventricular longitudinal strain (RVLS) was independently predictive of higher mortality in patients with coronavirus disease-2019 (COVID-19).
   BACKGROUND RVLS obtained from 2-dimensional speckle-tracking echocardiography has been recently demonstrated to be a more accurate and sensitive tool to estimate right ventricular (RV) function. The prognostic value of RVLS in patients with COVID-19 remains unknown.
   METHODS One hundred twenty consecutive patients with COVID-19 who underwent echocardiographic examinations were enrolled in our study. Conventional RV functional parameters, including RV fractional area change, tricuspid annular plane systolic excursion, and tricuspid tissue Doppler annular velocity, were obtained. RVLS was determined using 2-dimensional speckle-tracking echocardiography. RV function was categorized in tertiles of RVLS.
   RESULTS Compared with patients in the highest RVLS tertile, those in the lowest tertile were more likely to have higher heart rate; elevated levels of D-dimer and C-reactive protein; more high-flow oxygen and invasive mechanical ventilation therapy; higher incidence of acute heart injury, acute respiratory distress syndrome, and deep vein thrombosis; and higher mortality. After a median follow-up period of 51 days, 18 patients died. Compared with survivors, nonsurvivors displayed enlarged right heart chambers, diminished RV function, and elevated pulmonary artery systolic pressure. Male sex, acute respiratory distress syndrome, RVLS, RV fractional area change, and tricuspid annular plane systolic excursion were significant univariate predictors of higher risk for mortality (p < 0.05 for all). A Cox model using RVLS (hazard ratio: 1.33; 95% confidence interval [CI]: 1.15 to 1.53; p < 0.001; Akaike information criterion = 129; C-index = 0.89) was found to predict higher mortality more accurately than a model with RV fractional area change (Akaike information criterion = 142, Cindex = 0.84) and tricuspid annular plane systolic excursion (Akaike information criterion = 144, C-index = 0.83). The best cutoff value of RVLS for prediction of outcome was similar to 23% (AUC: 0.87; p < 0.001; sensitivity, 94.4%; specificity, 64.7%).
   CONCLUSIONS RVLS is a powerful predictor of higher mortality in patients with COVID-19. These results support the application of RVLS to identify higher risk patients with COVID-19. (C) 2020 by the American College of Cardiology Foundation.
C1 [Li, Yuman; Li, He; Zhu, Shuangshuang; Xie, Yuji; Wang, Bin; He, Lin; Zhang, Danqing; Zhang, Yongxing; Yuan, Hongliang; Wu, Chun; Sun, Wei; Zhang, Yanting; Li, Meng; Cui, Li; Cai, Yu; Wang, Jing; Yang, Yali; Lv, Qing; Zhang, Li; Xie, Mingxing] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Ultrasound, Wuhan, Peoples R China.
   [Li, Yuman; Li, He; Zhu, Shuangshuang; Xie, Yuji; Wang, Bin; He, Lin; Zhang, Danqing; Zhang, Yongxing; Yuan, Hongliang; Wu, Chun; Sun, Wei; Zhang, Yanting; Li, Meng; Cui, Li; Cai, Yu; Wang, Jing; Yang, Yali; Lv, Qing; Zhang, Li; Xie, Mingxing] Hubei Prov Key Lab Mol Imaging, Wuhan, Peoples R China.
RP Zhang, L (corresponding author), Huazhong Univ Sci & Technol, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China.; Xie, MX (corresponding author), 1277 Jie Fang Ave, Wuhan 430022, Hubei, Peoples R China.
EM zli429@hust.edu.cn; xiemx@hust.edu.cn
RI Zhang, L/A-8465-2019
OI Zhang, L/0000-0003-1620-1512; Xie, Mingxing/0000-0003-4984-1567
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81727805, 81922033, 81401432]
FX This work was supported by the National Natural Science Foundation of
   China (grants 81727805, 81922033, and 81401432). The authors have
   reported that they have no relationships relevant to the contents of
   this paper to disclose.
CR Alashi A, 2018, JACC-CARDIOVASC IMAG, V11, P673, DOI 10.1016/j.jcmg.2017.02.016
   Cameli M, 2012, TRANSPL P, V44, P2013, DOI 10.1016/j.transproceed.2012.06.018
   Carluccio E, 2018, CIRC-CARDIOVASC IMAG, V11, DOI 10.1161/CIRCIMAGING.117.006894
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   D'Ascenzi F, 2019, JACC-CARDIOVASC IMAG, V12, P1755, DOI 10.1016/j.jcmg.2018.09.021
   World Medical Association, 2013, JAMA, V310, P2191, DOI 10.1001/jama.2013.281053
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Houard L, 2019, JACC-CARDIOVASC IMAG, V12, P2373, DOI 10.1016/j.jcmg.2018.11.028
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lang RM, 2015, J AM SOC ECHOCARDIOG, V28, P1, DOI 10.1016/j.echo.2014.10.003
   Lazzeri C, 2016, J CRIT CARE, V33, P132, DOI 10.1016/j.jcrc.2016.01.004
   Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9
   Li SSL, 2003, CIRCULATION, V108, P1798, DOI 10.1161/01.CIR.0000094737.21775.32
   Li YM, 2015, ECHOCARDIOGR-J CARD, V32, P135, DOI 10.1111/echo.12581
   Lin CL, 2004, CHEST, V126, P509, DOI 10.1378/chest.126.2.509
   Longobardo L, 2017, J AM SOC ECHOCARDIOG, V30, P937, DOI 10.1016/j.echo.2017.06.016
   Mast TP, 2019, JACC-CARDIOVASC IMAG, V12, P446, DOI 10.1016/j.jcmg.2018.01.012
   Medvedofsky D, 2020, J AM SOC ECHOCARDIOG, V33, P452, DOI 10.1016/j.echo.2019.11.014
   Mor-Avi V, 2011, EUR J ECHOCARDIOGR, V12, P167, DOI 10.1093/ejechocard/jer021
   Motoki H, 2014, J AM SOC ECHOCARDIOG, V27, P726, DOI 10.1016/j.echo.2014.02.007
   Park SJ, 2015, JACC-CARDIOVASC IMAG, V8, P161, DOI 10.1016/j.jcmg.2014.10.011
   Rudski LG, 2010, J AM SOC ECHOCARDIOG, V23, P685, DOI 10.1016/j.echo.2010.05.010
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Xie MX, 2015, INT J CARDIOL, V178, P300, DOI 10.1016/j.ijcard.2014.10.027
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 26
TC 22
Z9 22
U1 5
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1936-878X
EI 1876-7591
J9 JACC-CARDIOVASC IMAG
JI JACC-Cardiovasc. Imag.
PD NOV
PY 2020
VL 13
IS 11
BP 2287
EP 2299
DI 10.1016/j.jcmg.2020.04.014
PG 13
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
   Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
   Medical Imaging
GA OM3OS
UT WOS:000585936200001
PM 32654963
OA Green Published
DA 2021-01-01
ER

PT J
AU Zhu, YM
   Yu, DW
   Han, Y
   Yan, HX
   Chong, HH
   Ren, LL
   Wang, JW
   Li, TS
   He, YX
AF Zhu, Yuanmei
   Yu, Danwei
   Han, Yang
   Yan, Hongxia
   Chong, Huihui
   Ren, Lili
   Wang, Jianwei
   Li, Taisheng
   He, Yuxian
TI Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from
   recovered SARS patients and immunized animals
SO SCIENCE ADVANCES
LA English
DT Article
ID RECEPTOR-BINDING DOMAIN; CORONAVIRUS SPIKE PROTEIN; IDENTIFICATION;
   VACCINE; COV; EPITOPES; SITES
AB The current coronavirus disease 2019 (COVID-19) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus genetically close to SARS-CoV. To investigate the effects of previous SARS-CoV infection on the ability to recognize and neutralize SARS-CoV-2, we analyzed 20 convalescent serum samples collected from individuals infected with SARS-CoV during the 2003 SARS outbreak. All patient sera reacted strongly with the S1 subunit and receptor binding domain (RBD) of SARS-CoV; cross-reacted with the S ectodomain, S1, RBD, and S2 proteins of SARS-CoV-2; and neutralized both SARS-CoV and SARS-CoV-2 S protein-driven infections. Analysis of antisera from mice and rabbits immunized with a full-length S and RBD immunogens of SARS-CoV verified cross-reactive neutralization against SARS-CoV-2. A SARS-CoV-derived RBD from palm civets elicited more potent cross-neutralizing responses in immunized animals than the RBD from a human SARS-CoV strain, informing strategies for development of universal vaccines against emerging coronaviruses.
C1 [Zhu, Yuanmei; Yu, Danwei; Yan, Hongxia; Chong, Huihui; Ren, Lili; Wang, Jianwei; He, Yuxian] Chinese Acad Med Sci & Peking Union Med Coll, Inst Pathogen Biol, NHC Key Lab Syst Biol Pathogens, Beijing, Peoples R China.
   [Han, Yang; Li, Taisheng] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Infect Dis, Beijing, Peoples R China.
RP Wang, JW; He, YX (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Pathogen Biol, NHC Key Lab Syst Biol Pathogens, Beijing, Peoples R China.; Li, TS (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Infect Dis, Beijing, Peoples R China.
EM wangjw28@163.com; litsh@263.net; yhe@ipb.pumc.edu.cn
OI yu, danwei/0000-0002-2379-2210
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81630061, 82041006]; CAMS Innovation Fund
   for Medical Sciences [2017-I2M-1-014]
FX This work was supported by grants from the National Natural Science
   Foundation of China (81630061 and 82041006) and the CAMS Innovation Fund
   for Medical Sciences (2017-I2M-1-014).
CR Cao ZL, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-299
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   He YX, 2006, VACCINE, V24, P5498, DOI 10.1016/j.vaccine.2006.04.054
   He YX, 2006, J IMMUNOL, V176, P6085, DOI 10.4049/jimmunol.176.10.6085
   He YX, 2006, J VIROL, V80, P5757, DOI 10.1128/JVI.00083-06
   He YX, 2005, VIRAL IMMUNOL, V18, P327, DOI 10.1089/vim.2005.18.327
   He YX, 2005, J CLIN MICROBIOL, V43, P3718, DOI 10.1128/JCM.43.8.3718-3726.2005
   He YX, 2005, J IMMUNOL, V174, P4908, DOI 10.4049/jimmunol.174.8.4908
   He YX, 2005, VIROLOGY, V334, P74, DOI 10.1016/j.virol.2005.01.034
   He YX, 2004, J CLIN MICROBIOL, V42, P5309, DOI 10.1128/JCM.42.11.5309-5314.2004
   He YX, 2004, BIOCHEM BIOPH RES CO, V325, P445, DOI 10.1016/j.bbrc.2004.10.052
   He YX, 2004, BIOCHEM BIOPH RES CO, V324, P773, DOI 10.1016/j.bbrc.2004.09.106
   He YX, 2004, J IMMUNOL, V173, P4050, DOI 10.4049/jimmunol.173.6.4050
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li TS, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000024
   Liu LF, 2011, SCAND J INFECT DIS, V43, P515, DOI 10.3109/00365548.2011.560184
   Lv HB, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107725
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhou GY, 2020, INT J BIOL SCI, V16, P1718, DOI 10.7150/ijbs.45123
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zhu YM, 2020, J VIROL, V94, DOI 10.1128/JVI.01358-19
NR 35
TC 1
Z9 1
U1 9
U2 9
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375-2548
J9 SCI ADV
JI Sci. Adv.
PD NOV
PY 2020
VL 6
IS 45
AR eabc9999
DI 10.1126/sciadv.abc9999
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OO7GP
UT WOS:000587544300033
PM 33036961
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Vultaggio, A
   Agache, I
   Akdis, CA
   Akdis, M
   Bavbek, S
   Bossios, A
   Bousquet, J
   Boyman, O
   Chaker, AM
   Chan, SS
   Chatzipetrou, A
   Feleszko, W
   Firinu, D
   Jutel, M
   Kauppi, P
   Klimek, L
   Kolios, A
   Kothari, A
   Kowalski, ML
   Matucci, A
   Palomares, O
   Pfaar, O
   Rogala, B
   Untersmayr, E
   Eiwegger, T
AF Vultaggio, Alessandra
   Agache, Ioana
   Akdis, Cezmi A.
   Akdis, Mubeccel
   Bavbek, Sevim
   Bossios, Apostolos
   Bousquet, Jean
   Boyman, Onur
   Chaker, Adam M.
   Chan, Susan
   Chatzipetrou, Alexia
   Feleszko, Wojciech
   Firinu, Davide
   Jutel, Marek
   Kauppi, Paula
   Klimek, Ludger
   Kolios, Antonios
   Kothari, Akash
   Kowalski, Marek L.
   Matucci, Andrea
   Palomares, Oscar
   Pfaar, Oliver
   Rogala, Barbara
   Untersmayr, Eva
   Eiwegger, Thomas
TI Considerations on biologicals for patients with allergic disease in
   times of the COVID-19 pandemic: An EAACI statement
SO ALLERGY
LA English
DT Article
ID OMALIZUMAB; GUIDELINES; RESPONSES; ASTHMA; INFECTIONS; IMMUNOLOGY; IGE
AB The outbreak of the SARS-CoV-2-induced coronavirus disease 2019 (COVID-19) pandemic re-shaped doctor-patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex patients with severe allergic disease. A significant number of the patients are on treatment with biologicals, and clinicians face the challenge to provide optimal care during the pandemic. Uncertainty of the potential risks for these patients is related to the fact that the exact sequence of immunological events during SARS-CoV-2 is not known. Severe COVID-19 patients may experience a "cytokine storm" and associated organ damage characterized by an exaggerated release of pro-inflammatory type 1 and type 3 cytokines. These inflammatory responses are potentially counteracted by anti-inflammatory cytokines and type 2 responses. This expert-based EAACI statement aims to provide guidance on the application of biologicals targeting type 2 inflammation in patients with allergic disease. Currently, there is very little evidence for an enhanced risk of patients with allergic diseases to develop severe COVID-19. Studies focusing on severe allergic phenotypes are lacking. At present, noninfected patients on biologicals for the treatment of asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, or chronic spontaneous urticaria should continue their biologicals targeting type 2 inflammation via self-application. In case of an active SARS-CoV-2 infection, biological treatment needs to be stopped until clinical recovery and SARS-CoV-2 negativity is established and treatment with biologicals should be re-initiated. Maintenance of add-on therapy and a constant assessment of disease control, apart from acute management, are demanded.
C1 [Vultaggio, Alessandra; Matucci, Andrea] Careggi Univ Hosp, Immunoallergol Unit, Florence, Italy.
   [Agache, Ioana] Transylvania Univ, Brasov, Romania.
   [Akdis, Cezmi A.; Akdis, Mubeccel] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland.
   [Bavbek, Sevim] Ankara Univ, Sch Med, Div Immunol & Allergy, Dept Chest Dis, Ankara, Turkey.
   [Bossios, Apostolos] Karolinska Univ Hosp, Dept Resp Med & Allergy, Stockholm, Sweden.
   [Bossios, Apostolos] Karolinska Inst, Dept Med, Stockholm, Sweden.
   [Bossios, Apostolos] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden.
   [Bousquet, Jean] Humboldt Univ, Charite Univ Med Berlin, Berlin, Germany.
   [Bousquet, Jean] Berlin Inst Hlth, Comprehens Allergy Ctr, Dept Dermatol & Allergy, Berlin, Germany.
   [Bousquet, Jean; Kolios, Antonios] MACVIA France, Montpellier, France.
   [Bousquet, Jean; Kolios, Antonios] CHU Montpellier, Montpellier, France.
   [Boyman, Onur; Kolios, Antonios] Univ Hosp Zurich, Dept Immunol, Zurich, Switzerland.
   [Boyman, Onur] Univ Zurich, Fac Med, Zurich, Switzerland.
   [Chaker, Adam M.] Tech Univ Munich, Ctr Allergy & Environm, Klinikumrechts Isar, TUM Sch Med,Dept Otolaryngol, Munich, Germany.
   [Chan, Susan] Guys & St Thomas NHS Fdn Trust, United Kingdom Kings Coll London, Sch Life Course Sci, Sch Immunol & Microbial Sci,Kings Hlth Partners, London, England.
   [Chatzipetrou, Alexia] Natl Univ Athens, Univ Gen Hosp ATTIKON, Dept Dermatol & Venereol 2, Allergy Unit,Med Sch, Athens, Greece.
   [Feleszko, Wojciech] Med Univ Warsaw, Dept Pediat Allergy & Pneumol, Warsaw, Poland.
   [Firinu, Davide] Univ Cagliari, Dept Med Sci & Publ Hlth, Monserrato, Italy.
   [Jutel, Marek] Wroclaw Med Univ, Dept Clin Immunol, Wroclaw, Poland.
   [Jutel, Marek] ALL MED Med Res Inst, Wroclaw, Poland.
   [Kauppi, Paula] Helsinki Univ Hosp, Inflammat Ctr, Dept Allergy, Helsinki, Finland.
   [Kauppi, Paula] Univ Helsinki, Helsinki, Finland.
   [Klimek, Ludger] Ctr Rhinol & Allergy, Wiesbaden, Germany.
   [Kolios, Antonios] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA.
   [Kothari, Akash; Eiwegger, Thomas] Hosp Sick Children, Peter Gilgan Ctr Res & Learning, Translat Med Program, Toronto, ON, Canada.
   [Kowalski, Marek L.] Med Univ Lodz, Dept Immunol & Allergy, Lodz, Poland.
   [Palomares, Oscar] Univ Complutense Madrid, Chem Sch, Dept Biochem & Mol Biol, Madrid, Spain.
   [Pfaar, Oliver] Philipps Univ Marburg, Univ Hosp Marburg, Sect Rhinol & Allergy, Dept Otorhinolaryngol Head & Neck Surg, Marburg, Germany.
   [Rogala, Barbara] Univ Silesia, Dept Internal Dis Allergol & Clin Immunol Med, Katowice, Poland.
   [Untersmayr, Eva] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Inst Pathophysiol & Allergy Res, Vienna, Austria.
   [Eiwegger, Thomas] Univ Toronto, Hosp Sick Children, Div Immunol & Allergy, Food Allergy & Anaphylaxis Program,Dept Paediat, Toronto, ON, Canada.
   [Eiwegger, Thomas] Univ Toronto, Hosp Sick Children, Div Immunol & Allergy, Food Allergy & Anaphylaxis Program,Dept Immunol, Toronto, ON, Canada.
   [Eiwegger, Thomas] Univ Toronto, Dept Immunol, Toronto, ON, Canada.
RP Eiwegger, T (corresponding author), Univ Toronto, Hosp Sick Children, Dept Paediat & Immunol,Div Immunol & Allergy, Food Allergy & Anaphylaxis Program,Res Inst, 555 Univ Ave, Toronto, ON, Canada.
EM thomas.eiwegger@sickkids.ca
RI Palomares, Oscar/ABG-5229-2020; Bossios, Apostolos/ABH-8262-2020;
   Feleszko, Wojciech/ABH-2616-2020; Kothari, Akash/ABE-2204-2020
OI Bossios, Apostolos/0000-0002-0494-2690; Feleszko,
   Wojciech/0000-0001-6613-2012; Kothari, Akash/0000-0003-1980-161X;
   Boyman, Onur/0000-0001-8279-5545
CR Agache I, 2020, ALLERGY, V75, P1043, DOI 10.1111/all.14235
   Agache I, 2020, ALLERGY, V75, P1058, DOI 10.1111/all.14268
   Agache I, 2020, ALLERGY, V75, P1023, DOI 10.1111/all.14221
   Agache I, 2019, ALLERGY, V74, P855, DOI 10.1111/all.13749
   Agache I, 2019, J CLIN INVEST, V129, P1493, DOI 10.1172/JCI124611
   Aoshi T, 2011, CURR OPIN VIROL, V1, P226, DOI 10.1016/j.coviro.2011.07.002
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Boyman O, 2015, ALLERGY, V70, P727, DOI 10.1111/all.12616
   Breiteneder H, 2019, ALLERGY, V74, P2293, DOI 10.1111/all.13851
   BUSSE W, 2020, J ALLERGY CLIN IMM S, V145, pAB17
   Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Chen IY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00050
   Dong X, 2020, ALLERGY, V75, P1699, DOI 10.1111/all.14289
   Dreher M, 2020, DTSCH ARZTEBL, V117, P271, DOI DOI 10.3238/arztebl.2020.0271
   Edwards MR, 2017, J ALLERGY CLIN IMMUN, V140, P909, DOI 10.1016/j.jaci.2017.07.025
   Eyerich S, 2020, ALLERGY, V75, P546, DOI 10.1111/all.14027
   Fokkens WJ, 2019, ALLERGY, V74, P2312, DOI 10.1111/all.13875
   Fokkens WJ, 2019, ALLERGY, V74, P1415, DOI 10.1111/all.13797
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   GlaxoSmithKline, 2018, SIRIUS MEA115575 CLI, V35, P552, DOI [10.5114/ada.2017.71273., DOI 10.5114/ADA.2017.71273]
   GlaxoSmithKline, MUSCA MEA 200862 CLI, P663
   GlaxoSmithKline, MENSA MEA115588 CLIN, P643
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310
   Hassani M, 2018, ALLERGY, V73, P1979, DOI 10.1111/all.13451
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jartti T, 2019, ALLERGY, V74, P40, DOI 10.1111/all.13624
   Jonstam K, 2019, ALLERGY, V74, P743, DOI 10.1111/all.13685
   Kowalski ML, ALERGIA ASTMA IMMUNO, V25, P2
   Krohn IK, 2020, ALLERGY, V75, P1155, DOI 10.1111/all.14132
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Mitamura Y, 2018, ALLERGY, V73, P1881, DOI 10.1111/all.13437
   Pajno GB, 2018, ALLERGY, V73, P799, DOI 10.1111/all.13319
   Palomares O, 2020, ALLERGY, V75, P936, DOI 10.1111/all.14024
   Pfaller Birgit, 2020, Allergy, DOI 10.1111/all.14282
   Pineros YSS, 2019, ALLERGY, V74, P1898, DOI 10.1111/all.13802
   Roberts G, 2018, ALLERGY, V73, P765, DOI 10.1111/all.13317
   Rowe RK, 2018, J PEDIAT INF DIS SOC, V7, pS54, DOI 10.1093/jpids/piy110
   Shaker MS, 2020, J ALLER CL IMM-PRACT, V8, P1477, DOI 10.1016/j.jaip.2020.03.012
   Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052
   Sturm GJ, 2018, ALLERGY, V73, P744, DOI 10.1111/all.13262
   Tan HTT, 2019, ALLERGY, V74, P294, DOI 10.1111/all.13619
   Teach SJ, 2015, J ALLERGY CLIN IMMUN, V136, P1476, DOI 10.1016/j.jaci.2015.09.008
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Wollenberg A, 2020, J EUR ACAD DERMATOL
   Wong JJM, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.09.28
   Xu XJ, 2004, CELL MOL IMMUNOL, V1, P119
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zuberbier T, 2018, ALLERGY, V73, P1393, DOI 10.1111/all.13397
NR 52
TC 9
Z9 9
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD NOV
PY 2020
VL 75
IS 11
BP 2764
EP 2774
DI 10.1111/all.14407
PG 11
WC Allergy; Immunology
SC Allergy; Immunology
GA OM6NT
UT WOS:000586139600004
PM 32500526
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Starks, TJ
   Jones, SS
   Sauermilch, D
   Benedict, M
   Adebayo, T
   Cain, D
   Simpson, KN
AF Starks, Tyrel J.
   Jones, S. Scott
   Sauermilch, Daniel
   Benedict, Matthew
   Adebayo, Trinae
   Cain, Demetria
   Simpson, Kit N.
TI Evaluating the impact of COVID-19: A cohort comparison study of drug use
   and risky sexual behavior among sexual minority men in the USA
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE SARS-CoV-2; Marijuana; Sexual risk taking; HIV; Gay and bisexual males
ID MARIJUANA USE; SUBSTANCE USE; HIV RISK; GAY; MSM; PARTNERS
AB Background: Sexual minority men who use drugs have high sexual HIV transmission risk. Sexual interactions may also increase COVID-19 risk.This study compared marijuana use, other illegal drugs use (i.e. cocaine/crack, methamphetamine, MDMA/ecstasy, GHB, and ketamine) and sexual behavior with casual partners among sexual minority cismen active on social networking and dating applications before and during the COVID-19 epidemic.
   Methods: This cohort-control study compared 455 adult respondents (surveyed May 6th to 17th, 2020) and a matched sample selected from 65,707 respondents surveyed pre-COVID. Participants were recruited on social networking and dating applications and completed surveys online.
   Results: The proportion reporting marijuana use declined significantly in the COVID cohort (34.5 % versus 45.7 % pre-COVID,p < .001) as did their illegal drug use (11.0 % versus 22.9 % pre-COVID, p < .001). While the number of casual partners per month was stable, the proportion reporting condomless anal sex with casual partners declined significantly during COVID (26.4 % versus 71.6 % pre-COVID, p < .001). The effect of illegal drug use (excluding marijuana) on number of casual partners per month (aRR = 1.45 pre-COVID versus 2.84, p < .01) and odds of condomless anal sex (aOR = 2.00 pre-COVID versus 5.22, p = .04) were significantly greater in the COVID cohort.
   Conclusions: While the proportion of participants reporting drug use and condomless anal sex with casual partners declined in the COVID cohort, the association between drug use and sexual behavior was magnified. Sexual minority men who use drugs are significantly more likely to engage in sexual behaviors that place them at risk for HIV and COVID-19 transmission.
C1 [Starks, Tyrel J.; Jones, S. Scott; Benedict, Matthew; Adebayo, Trinae; Cain, Demetria] CUNY, Hunter Coll, Dept Psychol, New York, NY 10021 USA.
   [Starks, Tyrel J.] CUNY, Grad Ctr, Hlth Psychol & Clin Sci Program, New York, NY USA.
   [Sauermilch, Daniel] Columbia Univ, Teachers Coll, New York, NY 10027 USA.
   [Simpson, Kit N.] Med Univ South Carolina, Coll Hlth Profess, Charleston, SC 29425 USA.
RP Starks, TJ (corresponding author), CUNY, Hunter Coll, 695 Pk Ave 611 Hunter North, New York, NY 10065 USA.
EM tstarks@hunter.cuny.edu
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA
FX This project was funded by grants from the National Institutes of
   Health. The funder was not directly involved in the design or execution
   of the study.
CR Adler GJ, 2019, CATHOL PRACT N AMER, P1
   Andrade LF, 2013, AM J DRUG ALCOHOL AB, V39, P266, DOI 10.3109/00952990.2013.803112
   [Anonymous], 2018, DIAGN HIV INF US DEP
   Barron-Limon S, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-433
   Card KG, 2017, AIDS EDUC PREV, V29, P154, DOI 10.1521/aeap.2017.29.2.154
   Centers for Disease Control and Prevention, 2019, HIV TRANSM
   Centers for Disease Control and Prevention, 2020, HIV US DEP AR
   Centers for Disease Control and Prevention, 2020, SOC DIST
   Coronavirus Resource Center, 2020, COR COVID 19 GLOB CA
   Coronavirus Resource Center, 2020, NEW CAS COVID 19 US
   Daskalopoulou M, 2014, LANCET HIV, V1, pE22, DOI 10.1016/S2352-3018(14)70001-3
   Eaton LA, 2020, J BEHAV MED, V43, P341, DOI 10.1007/s10865-020-00157-y
   European Monitoring Centre for Drugs and Drug Addiction ( EMCDDA), 2020, EMCDDA TRENDSP BRIEF
   European Monitoring Centre for Drugs and Drug Addiction Europol, 2020, EU DRUG MARK IMP COV
   Everett BG, 2013, ARCH SEX BEHAV, V42, P225, DOI 10.1007/s10508-012-9902-1
   Evers YJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216732
   Gafos M, 2019, AIDS BEHAV, V23, P1708, DOI 10.1007/s10461-018-2300-5
   Haqqi A, 2020, J MED VIROL, DOI 10.1002/jmv.26144
   He L, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3091-z
   Johnson MW, 2017, PSYCHOPHARMACOLOGY, V234, P599, DOI 10.1007/s00213-016-4493-5
   Kahler CW, 2018, J CONSULT CLIN PSYCH, V86, P645, DOI 10.1037/ccp0000322
   Koirala A, 2020, PAEDIATR RESPIR REV, V35, P43, DOI 10.1016/j.prrv.2020.06.010
   Koo JR, 2020, LANCET INFECT DIS, V20, P678, DOI 10.1016/S1473-3099(20)30162-6
   Kurka T, 2015, SEX TRANSM INFECT, V91, pA4, DOI 10.1136/sextrans-2015-052126.10
   Medley G, 2016, NSDUH DATA REV
   Melendez-Torres GJ, 2017, INT J STD AIDS, V28, P250, DOI 10.1177/0956462416642125
   Melendez-Torres GJ, 2016, AIDS BEHAV, V20, P646, DOI 10.1007/s10461-015-1127-6
   Metrik J, 2016, J STUD ALCOHOL DRUGS, V77, P104, DOI 10.15288/jsad.2016.77.104
   Mimiaga MJ, 2018, BMC PUBLIC HEALTH, V18, DOI [10.1186/s12889-018-5815-9, 10.1186/s12889-018-5838-2, 10.1186/s12889-018-5856-0]
   Mitchell JW, 2016, AIDS BEHAV, V20, P2904, DOI 10.1007/s10461-016-1355-4
   Mor Z, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7747-4
   Morgan E, 2016, AIDS BEHAV, V20, P600, DOI 10.1007/s10461-015-1195-7
   Mota P, 2020, PSYCHIAT RES, V290, DOI 10.1016/j.psychres.2020.113142
   Naar S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.14650
   Ottaway Z, 2017, INT J STD AIDS, V28, P91, DOI 10.1177/0956462416666753
   Pakianathan M, 2018, HIV MED, V19, P485, DOI 10.1111/hiv.12629
   Parsons JT, 2017, HEALTH PSYCHOL, V36, P695, DOI 10.1037/hea0000509
   Parsons JT, 2014, J CONSULT CLIN PSYCH, V82, P9, DOI 10.1037/a0035311
   Passaro RC, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4517-y
   Petersson FJM, 2016, SUBST USE MISUSE, V51, P1093, DOI 10.3109/10826084.2016.1160117
   Reback CJ, 2014, ADDICT BEHAV, V39, P1286, DOI 10.1016/j.addbeh.2011.11.029
   Rendina HJ, 2015, DRUG ALCOHOL DEPEN, V154, P199, DOI 10.1016/j.drugalcdep.2015.06.045
   Sanchez TH, 2020, AIDS BEHAV, V24, P2024, DOI 10.1007/s10461-020-02894-2
   Santangelo G, 2020, AGING MENT HEALTH, DOI 10.1080/13607863.2020.1839860
   Schuler MS, 2019, LGBT HEALTH, V6, P68, DOI 10.1089/lgbt.2018.0125
   Semple SJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186814
   Starks TJ, 2019, JMIR RES PROTOC, V8, DOI 10.2196/13015
   Stuart EA, 2010, STAT SCI, V25, P1, DOI 10.1214/09-STS313
   Sullivan PS, 2009, AIDS, V23, P1153, DOI 10.1097/QAD.0b013e32832baa34
   World Health Organization, 2020, 172 WHO
   Zhang XY, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-016-3905-0
NR 51
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0376-8716
EI 1879-0046
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD NOV 1
PY 2020
VL 216
AR 108260
DI 10.1016/j.drugalcdep.2020.108260
PG 7
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA OI3ZW
UT WOS:000583221900031
PM 32890975
OA Green Published
DA 2021-01-01
ER

PT J
AU Wong, CK
   Luk, HKH
   Lai, WH
   Lau, YM
   Zhang, RR
   Wong, ACP
   Lo, GCS
   Chan, KH
   Hung, IFN
   Tse, HF
   Woo, PCY
   Lau, SKP
   Siu, CW
AF Wong, Chun-Ka
   Luk, Hayes Kam-Hei
   Lai, Wing-Hon
   Lau, Yee-Man
   Zhang, Ricky Ruiqi
   Wong, Antonio Cheuk-Pui
   Lo, George Chi-Shing
   Chan, Kwok-Hung
   Hung, Ivan Fan-Ngai
   Tse, Hung-Fat
   Woo, Patrick Chiu-Yat
   Lau, Susanna Kar-Pui
   Siu, Chung-Wah
TI Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Platform to
   Study SARS-CoV-2 Related Myocardial Injury
SO CIRCULATION JOURNAL
LA English
DT Article
DE COVID-19; Myocarditis; SARS-CoV-2; Stem cells
ID ACE2
AB Background: SARS-CoV-2 infection is associated with myocardial injury, but there is a paucity of experimental platforms for the condition.
   Methods and Results: Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) infected by SARS-CoV-2 for 3 days ceased beating and exhibited cytopathogenic changes with reduced viability. Active viral replication was evidenced by an increase in supernatant SARS-CoV-2 and the presence of SARS-CoV-2 nucleocaspid protein within hiPSC-CMs. Expressions of BNP, CXCL1, CXCL2, IL-6, IL-8 and TNF-alpha were upregulated, while ACE2 was downregulated.
   Conclusions: Our hiPSC-CM-based in-vitro SARS-CoV-2 myocarditis model recapitulated the cytopathogenic effects and cytokine/chemokine response. It could be exploited as a drug screening platform.
C1 [Wong, Chun-Ka; Lai, Wing-Hon; Lau, Yee-Man; Tse, Hung-Fat; Siu, Chung-Wah] Univ Hong Kong, Li Ka Shing Fac Med, Dept Med, Div Cardiol, Hong Kong, Peoples R China.
   [Luk, Hayes Kam-Hei; Wong, Antonio Cheuk-Pui; Lo, George Chi-Shing; Woo, Patrick Chiu-Yat; Lau, Susanna Kar-Pui] Univ Hong Kong, Li Ka Shing Fac Med, Dept Microbiol, Hong Kong, Peoples R China.
   [Zhang, Ricky Ruiqi; Chan, Kwok-Hung; Hung, Ivan Fan-Ngai] Univ Hong Kong, Li Ka Shing Fac Med, Dept Med, Div Infect Dis, Hong Kong, Peoples R China.
RP Siu, CW (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Dept Med, Div Cardiol, Hong Kong, Peoples R China.; Lau, SKP (corresponding author), Univ Hong Kong, Dept Microbiol, Hong Kong, Peoples R China.
EM skplau@hku.hk; cwdsiu@hku.hk
OI Luk, Hayes Kam Hei/0000-0002-9831-2912
FU Theme-based Research Scheme, University Grant Committee [T11-707/15-R];
   University Development Fund, The University of Hong Kong, Hong Kong SAR,
   ChinaUniversity of Hong Kong; Collaborative Innovation Center for
   Diagnosis and Treatment of Infectious Diseases, Ministry of Education,
   ChinaMinistry of Education, China
FX This work was partly supported by the Theme-based Research Scheme
   (Project no. T11-707/15-R), University Grant Committee; University
   Development Fund, The University of Hong Kong, Hong Kong SAR, China; and
   the Collaborative Innovation Center for Diagnosis and Treatment of
   Infectious Diseases, Ministry of Education, China.
CR Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lai WH, 2010, CELL REPROGRAM, V12, P641, DOI 10.1089/cell.2010.0051
   Lee YK, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.005677
   Liu HN, 2020, CARDIOVASC RES, V116, P1733, DOI 10.1093/cvr/cvaa191
   Oudit GY, 2009, EUR J CLIN INVEST, V39, P618, DOI 10.1111/j.1365-2362.2009.02153.x
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Trogen B, 2020, PEDIATR INFECT DIS J, V39, pE204, DOI 10.1097/INF.0000000000002788
   Wang L, 2018, EUR HEART J, V39, P1818, DOI 10.1093/eurheartj/ehy085
NR 10
TC 0
Z9 0
U1 1
U2 1
PU JAPANESE CIRCULATION SOC
PI TOYKO
PA 18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO,
   100-0011, JAPAN
SN 1346-9843
EI 1347-4820
J9 CIRC J
JI Circ. J.
PD NOV
PY 2020
VL 84
IS 11
BP 2027
EP 2031
DI 10.1253/circj.CJ-20-0881
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OK2ML
UT WOS:000584484700020
PM 32981925
OA Other Gold
DA 2021-01-01
ER

PT J
AU Yasuda, H
   Tsukune, Y
   Watanabe, N
   Sugimoto, K
   Uchimura, A
   Tateyama, M
   Miyashita, Y
   Ochi, Y
   Komatsu, N
AF Yasuda, Hajime
   Tsukune, Yutaka
   Watanabe, Naoki
   Sugimoto, Kazuya
   Uchimura, Ayana
   Tateyama, Misa
   Miyashita, Yosuke
   Ochi, Yusuke
   Komatsu, Norio
TI Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2
   Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma
SO CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
LA English
DT Article
DE Atypical presentation; CHOP; Coronavirus; Hematological malignancy;
   Obinutuzumab
C1 [Yasuda, Hajime; Tsukune, Yutaka; Watanabe, Naoki; Sugimoto, Kazuya; Uchimura, Ayana; Komatsu, Norio] Juntendo Univ, Sch Med, Dept Hematol, Tokyo, Japan.
   [Tateyama, Misa; Miyashita, Yosuke; Ochi, Yusuke] Juntendo Univ, Sch Med, Dept Resp Med, Tokyo, Japan.
RP Yasuda, H (corresponding author), Juntendo Univ, Sch Med, Dept Hematol, Bunkyo Ku, 2-1-1 Hongou, Tokyo 1138421, Japan.
EM hyasuda@juntendo.ac.jp
CR Eisenberg RA, 2013, J CLIN IMMUNOL, V33, P388, DOI 10.1007/s10875-012-9813-x
   Gea-Banacloche JC, 2010, SEMIN HEMATOL, V47, P187, DOI 10.1053/j.seminhematol.2010.01.002
   Nazi I, 2013, BLOOD, V122, P1946, DOI 10.1182/blood-2013-04-494096
   Salles G, 2011, LANCET, V377, P42, DOI 10.1016/S0140-6736(10)62175-7
   Shah V, 2020, BRIT J HAEMATOL, V190, pE279, DOI 10.1111/bjh.16935
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
NR 6
TC 0
Z9 0
U1 0
U2 0
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 2152-2650
EI 2152-2669
J9 CL LYMPH MYELOM LEUK
JI Clin. Lymphoma Myeloma Leuk.
PD NOV
PY 2020
VL 20
IS 11
BP 774
EP 776
DI 10.1016/j.clml.2020.08.017
PG 3
WC Oncology; Hematology
SC Oncology; Hematology
GA OL1PV
UT WOS:000585114800031
PM 32933879
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Meyer, H
AF Meyer, Harris
TI After A COVID-19 Vaccine: Collaboration Or Competition?
SO HEALTH AFFAIRS
LA English
DT Article
EM harris_meyer@yahoo.com
CR [Anonymous], 2020, DEV LIC VACC PREV CO
   Berkley S., 2020, FORTUNE
   Callaway Ewen, 2020, Nature, V584, P506, DOI 10.1038/d41586-020-02450-x
   Centers for Disease Control and Prevention, COVID 19 HOSP DEATH
   Chua K-P, 2020, HLTH AFFAIRS BLOG, DOI DOI 10.1377/HBLOG20200623.498157/FULL/
   Emanuel EJ, 2020, NY TIMES
   Guarascio F, 2020, US NEWS WORLD REPORT
   Hamburg MA, 2020, WASHINGTON POST
   Hancock J., 2020, KAISER HLTH NEWS
   Hopkins JS, 2020, WALL STREET J
   Johnson C. Y., 2020, WASHINGTON POST
   Mancini DP, 2020, FINACIAL TIMES  0902
   McAdams D, 2020, INCENTIVIZING WEALTH
   OKeefe SM, 2020, GALLUP
   Rauhala Emily, 2020, WASHINGTON POST
   Robbins R, 2020, STAT
   Shah S, 2020, WALL STREET J
   Silverman E., 2020, STAT
   Stacey K., 2020, FINANCIAL TIMES
   Szabo L, 2020, KAISER HLTH NEWS
   Wilner M, 2020, CTR DAILY TIMES
   World Health Organization, 2012, MAIN OP LESS LEARNT
NR 22
TC 0
Z9 0
U1 2
U2 2
PU PROJECT HOPE
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA
SN 0278-2715
J9 HEALTH AFFAIR
JI Health Aff.
PD NOV
PY 2020
VL 39
IS 11
BP 1856
EP 1860
DI 10.1377/hlthaff.2020.01732
PG 5
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA OM9LK
UT WOS:000586336300002
PM 32986500
DA 2021-01-01
ER

PT J
AU Kogut, SJ
AF Kogut, Stephen J.
TI Racial disparities in medication use: imperatives for managed care
   pharmacy
SO JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY
LA English
DT Article
ID ETHNIC DISPARITIES; HEALTH-CARE; BLACK; WHITE; PRESCRIPTION; ADHERENCE;
   MEN; AMERICAN; COVERAGE; OUTCOMES
AB The COVID-19 pandemic and the social unrest pervading U.S. cities in response to the killings of George Floyd and other Black citizens at the hands of police are historically significant. These events exemplify dismaying truths about race and equality in the United States.
   Racial health disparities are an inexcusable lesion on the U.S. health care system. Many health disparities involve medications, including antidepressants, anticoagulants, diabetes medications, drugs for dementia, and statins, to name a few. Managed care pharmacy has a rote in perpetuating racial disparities in medication use. For example, pharmacy benefit designs are increasingly shifting costs of expensive medications to patients, creating affordability crises for lower income workers, who are disproportionally persons of color. In addition, the quest to maximize rebates serves to inflate list prices paid by the uninsured, among which Black and Hispanic people are over-represented. While medication cost is a foremost barrier for many patients, other factors also propagate racial disparities in medication use. Even when cost sharing is minimal or zero, medication adherence rates have been documented to be lower among Blacks as compared with Whites. Deeper understandings are needed about how racial disparities in medication use are influenced by factors such as culture, provider bias, and patient trust in medical advice.
   Managed care pharmacy can address racial disparities in medication use in several ways. First, it should be acknowledged that racial disparities in medication use are pervasive and must be resolved urgently. We must not believe that entrenched health system, societal, and political structures are impermeable to change. Second, the voices of community members and their advocates must be amplified. Coverage policies, program designs, and quality initiatives should be developed in consultation with those directly affected by racial disparities. Third, the industry should commit to dramatically reducing patient cost sharing for essential medication therapies. Federal and state efforts to limit annual out-of-pocket pharmacy spending should be supported, even though increased premiums may be an undesirable (yet more equitable) consequence. Finally, information about race should be incorporated into all internal and external reporting and quality improvement activities.
C1 [Kogut, Stephen J.] Univ Rhode Isl, Dept Pharm Practice, Coll Pharm, Kingston, RI 02881 USA.
RP Kogut, SJ (corresponding author), Univ Rhode Isl, Dept Pharm Practice, Coll Pharm, Kingston, RI 02881 USA.
EM SKogut@URI.edu
FU National Institute of General Medical Sciences of the National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [U54GM115677, P20GM125507]
FX No funding was received for the development of this manuscript. Kogut is
   partially supported by Institutional Development Award Numbers
   U54GM115677 and P20GM125507 from the National Institute of General
   Medical Sciences of the National Institutes of Health, which funds
   Advance Clinical and Translational Research (Advance-CTR), and the RI
   Lifespan Center of Biomedical Research Excellence (COBRE) on Opioids and
   Overdose, respectively. The content is solely the responsibility of the
   author and does not necessarily represent the official views of the
   National Institutes of Health.
CR Admon LK, 2018, OBSTET GYNECOL, V132, P1158, DOI 10.1097/AOG.0000000000002937
   Agency for Healthcare Research and Quality, 2018, 2018 NAT HEALTHC QUA
   AMCP, MAN CAR GLOSS
   [Anonymous], 2019, OUTOFPOCKET COST BUR
   Baumgartner JC, 2020, AFFORDABLE CARE ACT
   Bond MJ, 2016, AM J PUBLIC HEALTH, V106, P1167, DOI 10.2105/AJPH.2016.303251
   Buchmueller TC, 2020, HEALTH AFFAIR, V39, P395, DOI 10.1377/hlthaff.2019.01394
   Chaiyachati KH, 2016, AM J MANAG CARE, V22, pE393
   Clements JM, 2020, DIABETES RES CLIN PR, V159, DOI 10.1016/j.diabres.2019.107984
   Cooper D., 2018, WORKING EC BLOG
   Cruz-Flores S, 2011, STROKE, V42, P2091, DOI 10.1161/STR.0b013e3182213e24
   Doshi JA, 2016, AM J MANAG CARE, V22, P188
   Ejike CO, 2019, AM J RESP CRIT CARE, V200, P423, DOI 10.1164/rccm.201810-1909PP
   Forno E, 2012, AM J RESP CRIT CARE, V185, P1033, DOI 10.1164/rccm.201202-0350ED
   Gleason PP, 2009, J MANAGE CARE PHARM, V15, P648, DOI 10.18553/jmcp.2009.15.8.648
   Goldman DP, 2007, JAMA-J AM MED ASSOC, V298, P61, DOI 10.1001/jama.298.1.61
   Hall-Lipsy EA, 2010, AM J HEALTH-SYST PH, V67, P462, DOI 10.2146/ajhp090161
   HARRIS MI, 1990, DIABETES METAB REV, V6, P71, DOI 10.1002/dmr.5610060202
   Heckler MM, 1985, REPORT SECRETARYS TA
   Herman D, 2015, AM J PUBLIC HEALTH, V105, pE48, DOI 10.2105/AJPH.2015.302712
   HHS Office of the Assistant Secretary for Planning and Evaluation and Office of Minority Health, 2015, HHS ACT PLAN RED RAC
   Himmelstein DU, 2009, AM J MED, V122, P741, DOI 10.1016/j.amjmed.2009.04.012
   Howard G, 2016, STROKE, V47, P1893, DOI 10.1161/STROKEAHA.115.012631
   ICON, 2019, CISC VIS NETW IND GL
   Institute of Medicine, 2003, UNEQUAL TREATMENT CO
   Ji X, 2018, PSYCHIAT SERV, V69, P322, DOI 10.1176/appi.ps.201600469
   Jung K, 2014, PSYCHIAT SERV, V65, P1140, DOI 10.1176/appi.ps.201300182
   Kaiser Family Foundation, 2019, 2019 EMPL HLTH BEN S
   Kaiser Family Foundation, 2001, PRESCRIPTION DRUG TR
   Karpinski SA, 2019, J MANAG CARE SPEC PH, V25, P1358, DOI 10.18553/jmcp.2019.25.12.1358
   Kirby RS, 2017, AM J PUBLIC HEALTH, V107, P644, DOI 10.2105/AJPH.2017.303735
   Kushel MB, 2006, J GEN INTERN MED, V21, P71
   Kyanko KA, 2013, J URBAN HEALTH, V90, P323, DOI 10.1007/s11524-012-9724-4
   Marron MM, 2018, J AM GERIATR SOC, V66, P1980, DOI 10.1111/jgs.15534
   Mckee M, 2012, J PUBLIC HEALTH RES, V1, P236, DOI 10.4081/jphr.2012.e37
   Mehta KM, 2005, NEUROLOGY, V65, P159, DOI 10.1212/01.wnl.0000167545.38161.48
   Millett GA, 2012, LANCET, V380, P341, DOI 10.1016/S0140-6736(12)60899-X
   Mullins CD, 2018, J COMP EFFECT RES, V7, P603, DOI 10.2217/cer-2017-0105
   Nguyen NH, 2020, CLIN GASTROENTEROI H, DOI [10.1016/j,cgh.2020.05.056, DOI 10.1016/JCGH.2020.05.056]
   Pan L., 2009, Morbidity and Mortality Weekly Report, V58, P740
   Pennel CL, 2015, AM J PUBLIC HEALTH, V105, pE103, DOI 10.2105/AJPH.2014.302286
   Pestka DL, 2020, J AM COLL CLIN PHARM, V3, P1038
   Pew Research Center, 2016, VIEWS RAC IN BLACKS
   Philippart M., 2018, FINANCIAL TIMES
   Physicians for a National Health Program, 2020, PHYS NATL HLTH PROGR
   Probst JC, 2020, AM J PUBLIC HEALTH, V110, P1325, DOI 10.2105/AJPH.2020.305703
   Qian F, 2013, CIRC-CARDIOVASC QUAL, V6, P284, DOI 10.1161/CIRCOUTCOMES.113.000211
   Sarnak DO, 2017, PAYING PRESCRIPTION
   Saud N, 2020, CISC VIS NETW IND GL
   Schlaifer M, 2020, AMCP STANDS RACIAL I
   Shenolikar RA, 2006, J NATL MED ASSOC, V98, P1071
   Smith GD, 1998, LANCET, V351, P934, DOI 10.1016/S0140-6736(05)60603-4
   Snell K, 2020, WGBH NEWS       0717
   Stulpin C., 2020, HEALIO INFECT DIS NE
   Surratt HL, 2015, AIDS CARE, V27, P307, DOI 10.1080/09540121.2014.967656
   Tai Don Bambino Geno, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa815
   Tolbert J, 2019, KEY FACTS UN POP
   Trinacty CM, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-24
   U.S Bureau of Labor Statistics, 2019, BLS REPORT
   U.S. Department of Health and Human Services, 2011, HHS ACT PLAN RED RAC
   Warren E, 2020, COMMUNICATION   0805
   Wiltshire JC, 2016, AM J PUBLIC HEALTH, V106, P1086, DOI 10.2105/AJPH.2016.303137
   Youn B, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25382
   Young CL, 2020, THERE ARE CLEAR RACE
NR 64
TC 1
Z9 1
U1 8
U2 8
PU ACAD MANAGED CARE PHARMACY
PI ALEXANDRIA
PA 100 N PITT ST, 400, ALEXANDRIA, VA 22314-3134 USA
SN 2376-0540
EI 2376-1032
J9 J MANAG CARE SPEC PH
JI J. Manag. Care Spec. Pharm.
PD NOV
PY 2020
VL 26
IS 11
BP 1468
EP 1474
DI 10.18553/jmcp.2020.26.11.1468
PG 7
WC Health Care Sciences & Services; Pharmacology & Pharmacy
SC Health Care Sciences & Services; Pharmacology & Pharmacy
GA OJ2KC
UT WOS:000583793900012
PM 33119445
DA 2021-01-01
ER

PT J
AU Long, SW
   Olsen, RJ
   Christensen, PA
   Bernard, DW
   Davis, JJ
   Shukla, M
   Nguyen, M
   Saavedra, MO
   Yerramilli, P
   Pruitt, L
   Subedi, S
   Kuo, HC
   Hendrickson, H
   Eskandari, G
   Nguyen, HAT
   Long, JH
   Kumaraswami, M
   Goike, J
   Boutz, D
   Gollihar, J
   McLellan, JS
   Chou, CW
   Javanmardi, K
   Finkelstein, IJ
   Musser, JM
AF Long, S. Wesley
   Olsen, Randall J.
   Christensen, Paul A.
   Bernard, David W.
   Davis, James J.
   Shukla, Maulik
   Nguyen, Marcus
   Saavedra, Matthew Ojeda
   Yerramilli, Prasanti
   Pruitt, Layne
   Subedi, Sishir
   Kuo, Hung-Che
   Hendrickson, Heather
   Eskandari, Ghazaleh
   Nguyen, Hoang A. T.
   Long, J. Hunter
   Kumaraswami, Muthiah
   Goike, Jule
   Boutz, Daniel
   Gollihar, Jimmy
   McLellan, Jason S.
   Chou, Chia-Wei
   Javanmardi, Kamyab
   Finkelstein, Ilya J.
   Musser, James M.
TI Molecular Architecture of Early Dissemination and Massive Second Wave of
   the SARS-CoV-2 Virus in a Major Metropolitan Area
SO MBIO
LA English
DT Article
DE SARS-CoV-2; COVID-19 disease; genome sequencing; molecular population
   genomics; evolution; COVID-19
ID EBOLA-VIRUS
AB We sequenced the genomes of 5,085 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains causing two coronavirus disease 2019 (COVID-19) disease waves in metropolitan Houston, TX, an ethnically diverse region with 7 million residents. The genomes were from viruses recovered in the earliest recognized phase of the pandemic in Houston and from viruses recovered in an ongoing massive second wave of infections. The virus was originally introduced into Houston many times independently. Virtually all strains in the second wave have a Gly614 amino acid replacement in the spike protein, a polymorphism that has been linked to increased transmission and infectivity. Patients infected with the Gly614 variant strains had significantly higher virus loads in the nasopharynx on initial diagnosis. We found little evidence of a significant relationship between virus genotype and altered virulence, stressing the linkage between disease severity, underlying medical conditions, and host genetics. Some regions of the spike protein-the primary target of global vaccine efforts-are replete with amino acid replacements, perhaps indicating the action of selection. We exploited the genomic data to generate defined single amino acid replacements in the receptor binding domain of spike protein that, importantly, produced decreased recognition by the neutralizing monoclonal antibody CR3022. Our report represents the first analysis of the molecular architecture of SARS-CoV-2 in two infection waves in a major metropolitan region. The findings will help us to understand the origin, composition, and trajectory of future infection waves and the potential effect of the host immune response and therapeutic maneuvers on SARS-CoV-2 evolution.
   IMPORTANCE There is concern about second and subsequent waves of COVID-19 caused by the SARS-CoV-2 coronavirus occurring in communities globally that had an initial disease wave. Metropolitan Houston, TX, with a population of 7 million, is experiencing a massive second disease wave that began in late May 2020. To understand SARS-CoV-2 molecular population genomic architecture and evolution and the relationship between virus genotypes and patient features, we sequenced the genomes of 5,085 SARS-CoV-2 strains from these two waves. Our report provides the first molecular characterization of SARS-CoV-2 strains causing two distinct COVID-19 disease waves.
C1 [Long, S. Wesley; Olsen, Randall J.; Christensen, Paul A.; Bernard, David W.; Saavedra, Matthew Ojeda; Yerramilli, Prasanti; Pruitt, Layne; Subedi, Sishir; Hendrickson, Heather; Eskandari, Ghazaleh; Nguyen, Hoang A. T.; Long, J. Hunter; Kumaraswami, Muthiah; Gollihar, Jimmy; Musser, James M.] Houston Methodist Hosp, Ctr Mol & Translat Human Infect Dis Res, Dept Pathol & Genom Med, Houston Methodist Res Inst, Houston, TX 77030 USA.
   [Long, S. Wesley; Olsen, Randall J.; Bernard, David W.; Musser, James M.] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY 10065 USA.
   [Long, S. Wesley; Olsen, Randall J.; Bernard, David W.; Musser, James M.] Weill Cornell Med Coll, Dept Microbiol & Immunol, New York, NY 10065 USA.
   [Davis, James J.; Shukla, Maulik; Nguyen, Marcus] Univ Chicago, Consortium Adv Sci & Engn, Chicago, IL 60637 USA.
   [Davis, James J.; Shukla, Maulik; Nguyen, Marcus] Argonne Natl Lab, Comp Environm & Life Sci, Lemont, IL USA.
   [Kuo, Hung-Che; Goike, Jule; McLellan, Jason S.; Chou, Chia-Wei; Javanmardi, Kamyab; Finkelstein, Ilya J.] Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA.
   [Kuo, Hung-Che; Goike, Jule; McLellan, Jason S.; Chou, Chia-Wei; Javanmardi, Kamyab; Finkelstein, Ilya J.] Univ Texas Austin, Inst Cell & Mol Biol, Austin, TX 78712 USA.
   [Boutz, Daniel; Gollihar, Jimmy] Univ Texas Austin, CCDC Army Res Lab South, Austin, TX 78712 USA.
   [Finkelstein, Ilya J.] Univ Texas Austin, Ctr Syst & Synthet Biol, Austin, TX 78712 USA.
RP Musser, JM (corresponding author), Houston Methodist Hosp, Ctr Mol & Translat Human Infect Dis Res, Dept Pathol & Genom Med, Houston Methodist Res Inst, Houston, TX 77030 USA.; Musser, JM (corresponding author), Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY 10065 USA.; Musser, JM (corresponding author), Weill Cornell Med Coll, Dept Microbiol & Immunol, New York, NY 10065 USA.
EM jmmusser@houstonmethodist.org
RI Long, S. Wesley/A-9651-2008
OI Long, S. Wesley/0000-0003-3043-5307; Javanmardi,
   Kamyab/0000-0002-6449-6709
FU Fondren Foundation; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [GM120554, GM124141,
   AI127521]; Welch FoundationThe Welch Foundation [F-1808]; National
   Science FoundationNational Science Foundation (NSF) [1453358]; NIAID
   Bacterial and Viral Bioinformatics resource center award
   [75N93019C00076]; Houston Methodist Hospital and Research Institute
FX `This study was supported by the Fondren Foundation, Houston Methodist
   Hospital and Research Institute (to J. M. Musser), NIH grant AI127521
   (to J. S. McLellan), NIH grants GM120554 and GM124141 (to I. J.
   Finkelstein), the Welch Foundation (F-1808 to I. J. Finkelstein), and
   the National Science Foundation (1453358 to I. J. Finkelstein). I. J.
   Finkelstein is a CPRIT Scholar in Cancer Research. J. J. Davis, M.
   Shukla, and M. Nguyen are supported by the NIAID Bacterial and Viral
   Bioinformatics resource center award (contract number 75N93019C00076).
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Allel K, 2020, GLOB PUBLIC HEALTH, V15, P1589, DOI 10.1080/17441692.2020.1814835
   Alsoussi WB, 2020, J IMMUNOL, V205, P915, DOI 10.4049/jimmunol.2000583
   [Anonymous], 2020, WHO COR DIS 2019 COV, VWHO
   Barnes CO, 2020, CELL, V182, P828, DOI 10.1016/j.cell.2020.06.025
   Baum A., 2020, BIORXIV, DOI [10.1101/2020.08.02.233320, DOI 10.1101/2020.08.02.233320]
   Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831
   Bedford Trevor, 2020, medRxiv, DOI 10.1101/2020.04.02.20051417
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902
   Cai YF, 2020, SCIENCE, V369, P1586, DOI 10.1126/science.abd4251
   Candido DS, 2020, SCIENCE, V369, P1255, DOI 10.1126/science.abd2161
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Chen TQ, 2016, KDD'16: PROCEEDINGS OF THE 22ND ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING, P785, DOI 10.1145/2939672.2939785
   Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952
   China National Center for Bioinformation (CNCB), 2019, NOV COR RES 2019NCOV
   Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671
   Covid 19 Host Genetics Initiative, 2020, EUR J HUM GENET, V28, P715, DOI 10.1038/s41431-020-0636-6
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Diehl WE, 2016, CELL, V167, P1088, DOI 10.1016/j.cell.2016.10.014
   Dietzel E, 2017, J VIROL, V91, DOI [10.1128/JVI.01913-16, 10.1128/jvi.01913-16]
   Ellinghaus D, 2020, NEW ENGL J MED, V383, P1522, DOI 10.1056/NEJMoa2020283
   Emerson M, 2012, HOUSTON REGION GROWS
   FERREIRA MJ, 2020, J CLIN INVEST, V2020, DOI DOI 10.1172/JCI141206
   FERREIRA MJ, 2020, AM J PATHOL, V2020, DOI DOI 10.1016/J.AJPATH.2020.08.001
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Goldman Jason D, 2020, N Engl J Med, V383, P1827, DOI 10.1056/NEJMoa2015301
   Gonzalez-Reiche AS, 2020, SCIENCE, V369, P297, DOI 10.1126/science.abc1917
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Greaney Allison J, 2020, bioRxiv, DOI 10.1101/2020.09.10.292078
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Gudbjartsson DF, 2020, NEW ENGL J MED, V382, P2302, DOI 10.1056/NEJMoa2006100
   Hansen J, 2020, SCIENCE, V369, P1010, DOI 10.1126/science.abd0827
   Hassan AO, 2020, CELL, V182, P744, DOI 10.1016/j.cell.2020.06.011
   Hsieh CL, 2020, SCIENCE, V369, P1501, DOI 10.1126/science.abd0826
   Hu J., 2020, BIORXIV, DOI [10.1101/2020.06.20.161323, DOI 10.1101/2020.06.20.161323]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huo JD, 2020, CELL HOST MICROBE, V28, P445, DOI 10.1016/j.chom.2020.06.010
   Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Kachroo P, 2019, NAT GENET, V51, P548, DOI 10.1038/s41588-018-0343-1
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   King County, 2020, DAIL COVID 19 OUTBR
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Lemieux Jacob E, 2020, medRxiv, DOI 10.1101/2020.08.23.20178236
   Li T, 2020, BIORXIV, DOI [10.1101/2020.09.11.292631, DOI 10.1101/2020.09.11.292631]
   Liu LH, 2020, NATURE, DOI 10.1038/s41586-020-2571-7
   Long SW, 2017, MBIO, V8, DOI [10.1128/mbio.00489-17, 10.1128/mBio.00489-17]
   Long SW, 2020, BIORXIV, DOI [10.1101/2020.05.01.072652, DOI 10.1101/2020.05.01.072652]
   Lorenzo-Redondo Ramon, 2020, medRxiv, DOI 10.1101/2020.05.19.20107144
   Luo J, 2020, J MATER CHEM B, V8, P2020, DOI 10.1039/c9tb02756d
   Lv Z, 2020, SCIENCE, V369, P1505, DOI 10.1126/science.abc5881
   Mercado NB, 2020, NATURE, DOI 10.1038/s41586-020-2607-z
   Nguyen M, 2019, J CLIN MICROBIOL, V57, DOI 10.1128/JCM.01260-18
   Nguyen M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18972-w
   NYC Health, 2020, COVID 19 DAT
   Olender Susan A, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1041
   Pedregosa F, 2011, J MACH LEARN RES, V12, P2825
   Perlman S, 2020, NEW ENGL J MED, V382, P760, DOI 10.1056/NEJMe2001126
   Plante Jessica A, 2020, bioRxiv, DOI 10.1101/2020.09.01.278689
   Price MN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009490
   Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520
   Shannon A, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104793
   Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349
   Starr TN, 2020, CELL, V182, P1295, DOI 10.1016/j.cell.2020.08.012
   Steffen TL, 2020, BIORXIV, DOI [10.1101/2020.08.21.261727, DOI 10.1101/2020.08.21.261727]
   Stucker KM, 2015, EUROSURVEILLANCE, V20, P20, DOI 10.2807/1560-7917.ES2015.20.18.21122
   Urbanowicz RA, 2016, CELL, V167, P1079, DOI 10.1016/j.cell.2016.10.013
   Vahidy FS, 2020, JAMA-J AM MED ASSOC, V324, P998, DOI 10.1001/jama.2020.15301
   van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y
   Volz E. M, 2020, EVALUATING EFFECTS S, DOI [10.1101/2020.07.31.20166082, DOI 10.1101/2020.07.31.20166082]
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033
   Wec AZ, 2020, SCIENCE, V369, P731, DOI 10.1126/science.abc7424
   Weisblum Yiska, 2020, bioRxiv, DOI 10.1101/2020.07.21.214759
   WILLIAMSON BN, 2020, NATURE 0609, DOI DOI 10.1038/S41586-020-2423-5
   Woo H, 2020, J PHYS CHEM B, V124, P7128, DOI 10.1021/acs.jpcb.0c04553
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Yurkovetskiy Leonid, 2020, bioRxiv, DOI 10.1101/2020.07.04.187757
   Zhang Lizhou, 2020, bioRxiv, DOI 10.1101/2020.06.12.148726
   Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zost SJ, 2020, NATURE, DOI 10.1038/s41586-020-2548-6
NR 92
TC 1
Z9 1
U1 5
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD NOV-DEC
PY 2020
VL 11
IS 6
AR e02707-20
DI 10.1128/mBio.02707-20
PG 30
WC Microbiology
SC Microbiology
GA OJ3CM
UT WOS:000583842800006
PM 33127862
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Martins, RB
   Castro, IA
   Pontelli, M
   Souza, JP
   Lima, TM
   Melo, SR
   Siqueira, JPZ
   Caetano, MH
   Arruda, E
   de Almeida, MTG
AF Martins, Ronaldo B.
   Castro, Italo A.
   Pontelli, Marjorie
   Souza, Juliano P.
   Lima, Thais M.
   Melo, Stella Rezende
   Zen Siqueira, Joao Paulo
   Caetano, Maicon Henrique
   Arruda, Eurico
   Gottardo de Almeida, Margarete Teresa
TI SARS-CoV-2 Inactivation by Ozonated Water: A Preliminary Alternative for
   Environmental Disinfection
SO OZONE-SCIENCE & ENGINEERING
LA English
DT Article; Early Access
DE Ozone; SARS-CoV-2; COVID-19; ozonated water; disinfection; infection
   control; virus inactivation
ID OZONE
AB The rapid spread of SARS-CoV-2 caused a global pandemic. Due to the lack of treatment and vaccines, safety strategies must be found to stop the virus dissemination. The objective of this study was to evaluate the virucidal activity of ozonated water, a powerful oxidizing agent, against SARS-CoV-2. A special faucet was the source of ozonated water at a low concentration (0.2-0.8 ppm). At this concentration, tests with SARS-Cov-2 in Vero CCL81 lineage showed two log(10) reduction in virus infectivity upon 1 min exposure to ozonated water, in comparison to controls. It shows the potential as an efficient and rapid alternative for controlling viral spread in hospitals and other environments.
C1 [Martins, Ronaldo B.; Castro, Italo A.; Pontelli, Marjorie; Souza, Juliano P.; Lima, Thais M.; Melo, Stella Rezende; Arruda, Eurico] Univ Sao Paulo, Dept Biol Celular, Fac Med Ribeirao Preto, BR-14049900 Ribeirao Preto, Brazil.
   [Zen Siqueira, Joao Paulo; Gottardo de Almeida, Margarete Teresa] Fac Med Sao Jose do Rio Preto FAMERP, Dept Doencas Dermatol Infecciosas & Parasitarias, BR-15090000 Sao Jose Do Rio Preto, Brazil.
   [Caetano, Maicon Henrique] Univ Estadual Paulista UNESP, BR-15054000 Sao Jose Do Rio Preto, Brazil.
RP de Almeida, MTG (corresponding author), Fac Med Sao Jose do Rio Preto, Dept Infect Dis, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil.
EM margarete@famerp.br
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -
   BrazilCAPES [001]; National Council for Scientific and Technological
   Development CNPq BrazilNational Council for Scientific and Technological
   Development (CNPq); National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq) [403201/2020-9]; State
   of Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa
   do Estado de Sao Paulo (FAPESP) [2018/25605-6]
FX MHC would like to thank the Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior - Brazil (CAPES) - Financial Code 001, and MTGA the
   National Council for Scientific and Technological Development CNPq
   Brazil, for the scholarships granted.; EA thanks the National Research
   Council (CNPq) (grant number 403201/2020-9) and the State of Sao Paulo
   Research Foundation (FAPESP) (grant number 2018/25605-6). We are
   grateful to Dr. Edison L. Durigon (Institute of Biomedical Science,
   University of Sao Paulo, Brazil) for sharing the initial SARS CoV-2
   clinical isolate.
CR Chen LJ, 2020, EMERG MICROBES INFEC, V9, P313, DOI 10.1080/22221751.2020.1725399
   Harcourt J, 2020, EMERG INFECT DIS, V26, P1266, DOI 10.3201/eid2606.200516
   Hudson JB, 2009, OZONE-SCI ENG, V31, P216, DOI 10.1080/01919510902747969
   Jiang HJ, 2019, BIOMED ENVIRON SCI, V32, P324, DOI 10.3967/bes2019.044
   Kampf G, 2020, J HOSP INFECT, V105, P587, DOI 10.1016/j.jhin.2020.01.022.
   Komanapalli IR, 1998, APPL MICROBIOL BIOT, V49, P766, DOI 10.1007/s002530051244
   Li CS, 2003, AIHA J, V64, P533, DOI 10.1080/15428110308984851
   Nalla AK, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00557-20
   Rabenau HF, 2005, J HOSP INFECT, V61, P107, DOI 10.1016/j.jhin.2004.12.023
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Tizaoui C, 2020, OZONE-SCI ENG, V42, P378, DOI 10.1080/01919512.2020.1795614
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
NR 12
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0191-9512
EI 1547-6545
J9 OZONE-SCI ENG
JI Ozone-Sci. Eng.
DI 10.1080/01919512.2020.1842998
EA NOV 2020
PG 4
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA OK6HK
UT WOS:000584749000001
OA Bronze
DA 2021-01-01
ER

PT J
AU Weiss, SL
   Peters, MJ
   Agus, MSD
   Alhazzani, W
   Choong, K
   Flori, HR
   Inwald, DP
   Nadel, S
   Nunnally, ME
   Schlapbach, LJ
   Tasker, RC
   Tissieres, P
   Kissoon, N
AF Weiss, Scott L.
   Peters, Mark J.
   Agus, Michael S. D.
   Alhazzani, Waleed
   Choong, Karen
   Flori, Heidi R.
   Inwald, David P.
   Nadel, Simon
   Nunnally, Mark E.
   Schlapbach, Luregn J.
   Tasker, Robert C.
   Tissieres, Pierre
   Kissoon, Niranjan
CA Management Septic Shock Sepsis-Ass
TI Perspective of the Surviving Sepsis Campaign on the Management of
   Pediatric Sepsis in the Era of Coronavirus Disease 2019*
SO PEDIATRIC CRITICAL CARE MEDICINE
LA English
DT Article
DE children; coronavirus disease 2019; sepsis; septic shock; severe acute
   respiratory syndrome coronavirus 2
ID SEPTIC SHOCK; INTERNATIONAL GUIDELINES; ORGAN DYSFUNCTION
AB Severe acute respiratory syndrome coronavirus 2 is a novel cause of organ dysfunction in children, presenting as either coronavirus disease 2019 with sepsis and/or respiratory failure or a hyperinflammatory shock syndrome. Clinicians must now consider these diagnoses when evaluating children for septic shock and sepsis-associated organ dysfunction. The Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-associated Organ Dysfunction in Children provide an appropriate framework for the early recognition and initial resuscitation of children with sepsis or septic shock caused by all pathogens, including severe acute respiratory syndrome coronavirus 2. However, the potential benefits of select adjunctive therapies may differ from non-coronavirus disease 2019 sepsis.
C1 [Weiss, Scott L.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Peters, Mark J.] Great Ormond St Hosp Sick Children, UCL Great Ormond St Inst Child Hlth, London, England.
   [Peters, Mark J.] NIHR Biomed Res Ctr London, London, England.
   [Agus, Michael S. D.; Tasker, Robert C.] Boston Childrens Hosp, Boston, MA USA.
   [Agus, Michael S. D.; Tasker, Robert C.] Harvard Med Sch, Boston, MA 02115 USA.
   [Alhazzani, Waleed; Choong, Karen] McMaster Univ, Hamilton, ON, Canada.
   [Flori, Heidi R.] CS Mott Childrens Hosp, Ann Arbor, MI USA.
   [Inwald, David P.; Nadel, Simon] Addenbrookes Hosp, London, England.
   [Nunnally, Mark E.] NYU, Langone Med Ctr, New York, NY USA.
   [Schlapbach, Luregn J.] Univ Queensland, Brisbane, Qld, Australia.
   [Schlapbach, Luregn J.] Queensland Childrens Hosp, Brisbane, Qld, Australia.
   [Tissieres, Pierre] Paris Saclay Univ Hosp, AP HP, Paris, France.
   [Kissoon, Niranjan] British Columbia Childrens Hosp, Vancouver, BC, Canada.
RP Weiss, SL (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Philadelphia, PA 19104 USA.
EM WeissS@email.chop.edu
FU National Institute of General Medical SciencesUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [K23GM110496];
   National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; Academic Health
   Science Centre Alternative Funding Plan Innovation Fund; McMaster
   University; National Heart, Lung, and Blood InstituteUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI); Eunice Kennedy
   Shriver National Institute of Child Health and Human DevelopmentUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD); Society of Critical Care Medicine
FX Dr. Weiss's institution received funding from National Institute of
   General Medical Sciences K23GM110496. Drs. Agus and Flori received
   support for article research from the National Institutes of Health. Dr.
   Choong's institution received funding from Academic Health Science
   Centre Alternative Funding Plan Innovation Fund; and she received
   funding from McMaster University. Dr. Flori's institution received
   funding from the National Heart, Lung, and Blood Institute and Eunice
   Kennedy Shriver National Institute of Child Health and Human Development
   and she received funding from the Society of Critical Care Medicine. The
   remaining authors have disclosed that they do not have any potential
   conflicts of interest. For information regarding this article, E-mail:
   WeissS@email.chop.edu
CR Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P422, DOI 10.15585/mmwr.mm6914e4
   Ceneviva G, 1998, PEDIATRICS, V102, part. no., DOI 10.1542/peds.102.2.e19
   Centers for Disease Control and Prevention, 2020, INF CONTR GUID HEALT
   Centers for Disease Control and Prevention Health Alert Network, 2020, MULT INFL SYNDR CHIL
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Han H, 2020, J MED VIROL, V92, P819, DOI 10.1002/jmv.25809
   Hartman ME, 2013, PEDIATR CRIT CARE ME, V14, P686, DOI 10.1097/PCC.0b013e3182917fad
   Jouvet P, 2015, PEDIATR CRIT CARE ME, V16, P428, DOI 10.1097/PCC.0000000000000350
   Kesici S, 2020, P NATL ACAD SCI USA, V117, P12526, DOI 10.1073/pnas.2006691117
   Kim D, 2020, JAMA-J AM MED ASSOC, V323, P2085, DOI 10.1001/jama.2020.6266
   Latimer G, 2020, LANCET CHILD ADOLESC, V4, P552, DOI 10.1016/S2352-4642(20)30163-2
   Mamede S, 2014, ACAD MED, V89, P114, DOI 10.1097/ACM.0000000000000077
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Parri N, 2020, NEW ENGL J MED, V383, P187, DOI 10.1056/NEJMc2007617
   Ranjit S, 2014, PEDIATR CRIT CARE ME, V15, pE17, DOI 10.1097/PCC.0b013e3182a5589c
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]
   Roberton T, 2020, LANCET GLOB HEALTH, V8, pE901, DOI 10.1016/S2214-109X(20)30229-1
   Royal College of Paediatrics and Child Health, 2020, GUID PAED MULT INFL
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Saghazadeh A, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106560
   Shekerdemian LS, 2020, JAMA PEDIAT
   Weiss SL, 2020, INTENS CARE MED, V46, P10, DOI 10.1007/s00134-019-05878-6
   Weiss SL, 2020, PEDIATR CRIT CARE ME, V21, pE52, DOI 10.1097/PCC.0000000000002198
   Whittaker E, 2020, JAMA
   World Health Organization, 2020, INF PREV CONTR HLTH
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 27
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1529-7535
EI 1947-3893
J9 PEDIATR CRIT CARE ME
JI Pediatr. Crit. Care Med.
PD NOV
PY 2020
VL 21
IS 11
BP E1031
EP E1037
DI 10.1097/PCC.0000000000002553
PG 7
WC Critical Care Medicine; Pediatrics
SC General & Internal Medicine; Pediatrics
GA OK5BF
UT WOS:000584665000045
PM 32886460
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Adhikari, P
   Ching, WY
AF Adhikari, Puja
   Ching, Wai-Yim
TI Amino acid interacting network in the receptor-binding domain of
   SARS-CoV-2 spike protein
SO RSC ADVANCES
LA English
DT Article
ID ELECTRONIC POPULATION ANALYSIS; COMPUTATIONAL DESIGN; MICROSCOPY
AB The relation between amino acid (AA) sequence and biologically active conformation controls the process of polypeptide chains folding into three-dimensional (3d) protein structures. The recent achievements in the resolution achieved in cryo-electron microscopy coupled with improvements in computational methodologies have accelerated the analysis of structures and properties of proteins. However, the detailed interaction between AAs has not been fully elucidated. Herein, we present a de novo method to evaluate inter-amino acid interactions based on the concept of accurately evaluating the amino acid bond pairs (AABP). The results obtained enabled the identification of complex 3d long-range interconnected AA interacting network in proteins. The method is applied to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. We show that although nearest-neighbor AAs in the primary sequence have large AABP, other nonlocal AAs make substantial contribution to AABP with significant participation of both covalent and hydrogen bonding. Detailed analysis of AABP in RBD reveals the pivotal role they play in sequence conservation with profound implications on residue mutations and for therapeutic drug design. This approach could be easily applied to many other proteins of biomedical interest in life sciences.
C1 [Adhikari, Puja; Ching, Wai-Yim] Univ Missouri, Dept Phys & Astron, Kansas City, MO 64110 USA.
RP Ching, WY (corresponding author), Univ Missouri, Dept Phys & Astron, Kansas City, MO 64110 USA.
EM chingw@umkc.edu
FU DOEUnited States Department of Energy (DOE) [DE-AC03-76SF00098];
   Research Computing Support Services (RCSS) of the University of Missouri
   System; National Science Foundation of USANational Science Foundation
   (NSF) [RAPID DMR/CMMT-2028803]
FX This research used the resources of the National Energy Research
   Scientific Computing Center supported by DOE under Contract No.
   DE-AC03-76SF00098 and the Research Computing Support Services (RCSS) of
   the University of Missouri System. This project is funded by the
   National Science Foundation of USA: RAPID DMR/CMMT-2028803. We would
   like to thank Professor Reidun Twarock for discussion and valuable
   suggestions.
CR Adhikari P, 2020, PHYS CHEM CHEM PHYS, V22, P18272, DOI 10.1039/d0cp03145c
   Adhikari P, 2014, SCI REP-UK, V4, DOI 10.1038/srep05605
   ADRIAN M, 1984, NATURE, V308, P32, DOI 10.1038/308032a0
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223
   Anishchenko I, 2017, P NATL ACAD SCI USA, V114, P9122, DOI 10.1073/pnas.1702664114
   Callaway E, 2020, NATURE, V582, P156, DOI 10.1038/d41586-020-01658-1
   Cheng Y, 2015, CELL, V161, P438, DOI 10.1016/j.cell.2015.03.050
   Ching W.-Y., 2012, ELECT STRUCTURE METH
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Doerr A, 2017, NAT METHODS, V14, P34, DOI 10.1038/nmeth.4115
   DUBOCHET J, 1981, J MICROSC-OXFORD, V124, pRP3
   Eifler J, 2016, INT J QUANTUM CHEM, V116, P681, DOI 10.1002/qua.25089
   Glasgow AA, 2019, SCIENCE, V366, P1024, DOI 10.1126/science.aax8780
   Guy RK, 2020, SCIENCE, V368, P829, DOI 10.1126/science.abb9332
   Han YX, 2020, ACS NANO, V14, P5143, DOI 10.1021/acsnano.0c02857
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Lockless SW, 1999, SCIENCE, V286, P295, DOI 10.1126/science.286.5438.295
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   MULLIKEN RS, 1955, J CHEM PHYS, V23, P1833, DOI 10.1063/1.1740588
   MULLIKEN RS, 1955, J CHEM PHYS, V23, P1841, DOI 10.1063/1.1740589
   Panda PK, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb8097
   Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Poudel L, 2017, J PHYS CHEM B, V121, P6321, DOI 10.1021/acs.jpcb.7b02569
   Poudel L, 2016, PHYS CHEM CHEM PHYS, V18, P21573, DOI 10.1039/c6cp04357g
   Qiao BF, 2020, ACS NANO, V14, P10616, DOI 10.1021/acsnano.0c04798
   Roy S., 2020, BIORXIV, P1, DOI [10.1101/2020.04.20.052290, DOI 10.1101/2020.04.20.052290]
   Sesterhenn F, 2020, SCIENCE, V368, P730, DOI 10.1126/science.aay5051
   Smith M., 2020, REPURPOSING THERAPEU, DOI [10.26434/chemrxiv.11871402.v4, DOI 10.26434/CHEMRXIV.11871402.V4]
   Sruthi CK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198645
   Starr Tyler N, 2020, bioRxiv, DOI 10.1101/2020.06.17.157982
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang JJ, 2020, CURR EYE RES, DOI 10.1080/02713683.2020.1789174
   Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983
   Weigt M, 2009, P NATL ACAD SCI USA, V106, P67, DOI 10.1073/pnas.0805923106
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yip K. M., 2020, BIORXIV, DOI [10.1101/2020.05.21.106740, DOI 10.1101/2020.05.21.106740]
   Zhang LZ, 2020, BRIT J NUTR, V124, P189, DOI 10.1017/S0007114520000999
   Zou J., 2020, CHEMRXIV, P1, DOI [10.26434/chemrxiv.11902623.v2, DOI 10.26434/CHEMRXIV.11902623.V2]
NR 42
TC 0
Z9 0
U1 2
U2 2
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046-2069
J9 RSC ADV
JI RSC Adv.
PD NOV 1
PY 2020
VL 10
IS 65
BP 39831
EP 39841
DI 10.1039/d0ra08222h
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA OK0DX
UT WOS:000584324000050
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Bellanti, JA
AF Bellanti, Joseph A.
TI The role of the allergist/immunologist in the COVID-19 pandemic: A
   Janus-faced presentation
SO ALLERGY AND ASTHMA PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT Eastern Allergy Conference
CY AUG 16-17, 2020
CL Palm Beach, FL
ID ALLERGY
AB Background: Following its initial description in December 2019 in Wuhan, China, coronavirus-2 (COVID-19) has rapidly progressed into a worldwide pandemic, affecting millions of lives. Although every specialty of medicine has been affected, the field of allergy/immunology holds a special place in the battle against this modern-day plague. Because of the specialized training in allergy and clinical immunology, and the familiarity with comorbid contributing conditions, the allergist/immunologist is uniquely poised to play a major role both in the delivery of specialized therapeutic procedures and practices that can improve the health of patients with COVID-19 as well as in the use of forthcoming vaccines for the prevention of its spread.
   Objective: The purpose of this report is to examine the current body of evidence supporting the two phases of infection and inflammation that influence the pathogenesis of COVID-19 and to provide a classification of COVID-19 disease presentations and potential therapeutic targets with which the allergist/immunologist has particular expertise.
   Methods: This article was based on a literature review of articles published in PubMed related to COVID-19 and the immune response, and the author's own research and clinical experiences in the field of immunology.
   Results: Currently, the management of COVID-19 disease is being directed by a preventive strategy based on social distancing, quarantine, and facemasks to reduce the spread of the virus. Numerous clinical trials are being initiated to identify effective treatments for COVID-19 and are directed toward treatment of the two phases of infection and inflammation that influence the pathogenesis of COVID-19. An important resource for the allergist/immunologist is the COVID-19 Treatment Guidelines Panel (COVID-19 TGP), a National Institutes of Health sponsored panel of U.S. physicians, statisticians, and other experts, which has developed a set of continuously updated treatment guidelines intended for clinicians caring for patients during the rapidly evolving COVID-19 pandemic.
   Conclusion: COVID-19 is unique among other infectious diseases because, in many cases, the host immune inflammatory response can cause greater harm to the individual who is infected than the pathogen itself. In this report, the pathogenesis of COVID-19 and the influence it has on COVID-19 presentations is reviewed, together with recommended potential therapeutic targets and treatment recommendations.
C1 [Bellanti, Joseph A.] Georgetown Univ, Med Ctr, Dept Pediat & Microbiol Immunol, Washington, DC 20007 USA.
   [Bellanti, Joseph A.] Georgetown Univ, Med Ctr, Int Ctr Interdisciplinary Studies Immunol, Washington, DC 20007 USA.
RP Bellanti, JA (corresponding author), Georgetown Univ, Med Ctr, 3900 Reservoir Rd NW, Washington, DC 20097 USA.
EM bellantj@georgetown.edu
FU Eastern Allergy Conference
FX Funding provided by the Eastern Allergy Conference
CR [Anonymous], CORONAVIRUS DIS 2019
   Arabi YM, 2020, CLIN INFECT DIS, V70, P1837, DOI 10.1093/cid/ciz544
   Bansal P, 2020, J ALLER CL IMM-PRACT, V8, P1781, DOI 10.1016/j.jaip.2020.04.001
   Beigel J. H., 2020, N ENGL J MED
   Beigel JH, 2018, LANCET INFECT DIS, V18, P410, DOI 10.1016/S1473-3099(18)30002-1
   BELLANTI JA, 1971, LANCET, V2, P526
   Bellanti JA, 2012, IMMUNOLOGY 4 CLINICA, VIV
   Bonini S, 2020, ALLERGY, V75, P2542, DOI 10.1111/all.14409
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Chatham WW, 2020, J RHEUMATOL
   Cornwall W, 2020, SCIENCE, V369, P14, DOI 10.1126/science.369.6499.14
   Cron RQ, 2020, LANCET RHEUMATOL, V2, pE370, DOI 10.1016/S2665-9913(20)30165-X
   Folegatti PM, 2020, LANCET INFECT DIS, V20, P816, DOI 10.1016/S1473-3099(20)30160-2
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Henderson LA, 2020, ARTHRITIS RHEUMATOL, V72, P1059, DOI 10.1002/art.41285
   Hu BY, 2020, J MED VIROL, DOI 10.1002/jmv.26232
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iglesia EGA, 2020, ANN ALLERG ASTHMA IM, V125, P126, DOI 10.1016/j.anai.2020.04.007
   Jackson L.A., 2020, N ENGL J MED
   Jamilloux Y, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102567
   Johnston SL, 2020, ALLERGY, V75, P1543, DOI 10.1111/all.14348
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Malipiero G, 2020, CLIN TRANSL ALLERGY, V10, DOI 10.1186/s13601-020-00333-y
   Mueller AL, 2020, AGING-US, V12, P9959, DOI 10.18632/aging.103344
   Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018
   Nile SH, 2020, CYTOKINE GROWTH F R, V53, P66, DOI 10.1016/j.cytogfr.2020.05.002
   Pfaar O, 2020, ALLERGY
   Price D, 2017, J ASTHMA ALLERGY, V10, P209, DOI 10.2147/JAA.S134300
   Ranieri VM, 2020, JAMA
   Roschewski M, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd0110
   Schulert GS, 2016, J INFECT DIS, V213, P1180, DOI 10.1093/infdis/jiv550
   Shaker MS, 2020, J ALLER CL IMM-PRACT, V8, P1477, DOI 10.1016/j.jaip.2020.03.012
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Soy M, 2020, CLIN RHEUMATOL, V39, P2085, DOI 10.1007/s10067-020-05190-5
   Vardhana SA, 2020, J EXP MED, V217, DOI 10.1084/jem.20200678
   Wang J, 2020, J LEUKOCYTE BIOL, V108, P17, DOI 10.1002/JLB.3COVR0520-272R
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Zhang JS, 2005, J MED VIROL, V77, P147, DOI 10.1002/jmv.20431
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu FC, 2020, LANCET
NR 41
TC 0
Z9 0
U1 1
U2 1
PU OCEAN SIDE PUBLICATIONS INC
PI PROVIDENCE
PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA
SN 1088-5412
EI 1539-6304
J9 ALLERGY ASTHMA PROC
JI Allergy Asthma Proc.
PD NOV 1
PY 2020
VL 41
IS 6
BP 397
EP 412
DI 10.2500/aap.2020.41.200072
PG 16
WC Allergy
SC Allergy
GA OI3IV
UT WOS:000583177600004
PM 32797762
DA 2021-01-01
ER

PT J
AU Hooks, M
   Bart, B
   Vardeny, O
   Westanmo, A
   Adabag, S
AF Hooks, Matthew
   Bart, Bradley
   Vardeny, Orly
   Westanmo, Anders
   Adabag, Selcuk
TI Effects of hydroxychloroquine treatment on QT interval
SO HEART RHYTHM
LA English
DT Article
DE Drug-induced arrhythmia; Drugs; Electrocardiogram; Long QT syndrome;
   Mortality
ID RISK; PROLONGATION; METHADONE
AB BACKGROUND Hydroxychloroquine (HCQ) has been promoted as a potential treatment of coronavirus disease 2019 (COVID-19), but there are safety concerns.
   OBJECTIVE The purpose of this study was to determine the effects of HCQ treatment on QT interval.
   METHODS We retrospectively studied the electrocardiograms of 819 patients treated with HCQ for rheumatologic diseases from 2000 to 2020. The primary outcome was corrected QT (QTc) interval, by Bazett formula, during HCQ therapy.
   RESULTS Mean patient age was 64.0 +/- 10.9 years, and 734 patients (90%) were men. Median dosage of HCQ was 400 mg daily, and median (25th-75th percentile) duration of HCQ therapy was 1006 (471-2075) days. Mean on-treatment QTc was 430.9 +/- 31.8 ms. In total, 55 patients (7%) had QTc 470-500 ms, and 12 (1.5%) had QTc >500 ms. Chronic kidney disease (CKD), history of atrial fibrillation (AF), and heart failure were independent risk factors for prolonged QTc. In a subset of 591 patients who also had a pretreatment electrocardiogram, mean QTc increased from 424.4 +/- 29.7 ms to 432.0 +/- 32.3 ms (P <.0001) during HCQ treatment. Of these patients, 23 (3.9%) had either prolongation of QTc >15% or on-treatment QTc >500 ms. Over median 5.97 (3.33-10.11) years of follow-up, 269 patients (33%) died. QTc >470 ms during HCQ treatment was associated with a greater mortality risk (hazard ratio 1.78; 95% confidence interval 1.16-2.71; P = .008) in univariable but not in multivariable analysis.
   CONCLUSION HCQ is associated with QT prolongation in a significant fraction of patients. The risk of QT prolongation is higher among patients with CKD, AF, and heart failure, who may benefit from greater scrutiny.
C1 [Hooks, Matthew; Bart, Bradley; Vardeny, Orly; Adabag, Selcuk] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA.
   [Bart, Bradley; Adabag, Selcuk] Minneapolis VA Hlth Care Syst, Div Cardiol, Minneapolis, MN USA.
   [Vardeny, Orly] Minneapolis VA Hlth Care Syst, Ctr Care Delivery & Outcomes Res, Minneapolis, MN USA.
   [Westanmo, Anders] Minneapolis VA Hlth Care Syst, Dept Pharm, Minneapolis, MN USA.
RP Adabag, S (corresponding author), Div Cardiol 111C, One Vet Dr, Minneapolis, MN 55417 USA.
EM adaba001@umn.edu
OI Adabag, Selcuk/0000-0003-2154-8596; Hooks, Matthew/0000-0002-0220-8046
CR Al-Khatib SM, 2003, JAMA-J AM MED ASSOC, V289, P2120, DOI 10.1001/jama.289.16.2120
   Anand Vidhu, 2016, JACC Clin Electrophysiol, V2, P777, DOI 10.1016/j.jacep.2016.05.007
   Bart G, 2017, J ADDICT MED, V11, P489, DOI 10.1097/ADM.0000000000000353
   Bogossian H, 2014, HEART RHYTHM, V11, P2273, DOI 10.1016/j.hrthm.2014.08.026
   Chen CY, 2006, CLIN TOXICOL, V44, P173, DOI 10.1080/15563650500514558
   Chorin E, 2020, HEART RHYTHM, V17, P1425, DOI 10.1016/j.hrthm.2020.05.014
   Costedoat-Chalumeau N, 2007, RHEUMATOLOGY, V46, P808, DOI 10.1093/rheumatology/kel402
   Coumbe AG, 2013, HEART, V99, P334, DOI 10.1136/heartjnl-2012-302770
   Fried JA, 2020, CIRCULATION, V141, P1930, DOI 10.1161/CIRCULATIONAHA.120.047164
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024
   GODEAU P, 1981, ANN MED INTERNE, V132, P234
   Hinton D., 2020, RE REQUEST EMERGENCY
   Issa Z, 2018, CLIN ARRHYTHMOLOGY E
   Jain R, 2014, CIRC-CARDIOVASC QUAL, V7, P151, DOI 10.1161/CIRCOUTCOMES.113.000329
   Jain S, 2020, HEART RHYTHM, V17, P1417, DOI 10.1016/j.hrthm.2020.04.047
   Jankelson L, 2020, HEART RHYTHM, V17, P1472, DOI 10.1016/j.hrthm.2020.05.008
   Jordan P, 1999, J TOXICOL-CLIN TOXIC, V37, P861, DOI 10.1081/CLT-100102466
   Ko B, 2012, EUR HEART J, V33, P2065, DOI 10.1093/eurheartj/ehr493
   Lakkireddy DR, 2020, CIRCULATION, V141, pE823, DOI 10.1161/CIRCULATIONAHA.120.047063
   Li Z, 2020, SSRN ELECT J, DOI [10.2139/ssrn.3559601, DOI 10.2139/SSRN.3559601]
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Madjid M, 2020, JAMA CARDIOL, V5, P831, DOI 10.1001/jamacardio.2020.1286
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Mahevas M, 2020, NO EVIDENCE CLIN EFF, P369, DOI [10.1101/2020.04.10.20060699, DOI 10.1101/2020.04.10.20060699]
   Mason JW, 2007, J ELECTROCARDIOL, V40, P228, DOI 10.1016/j.jelectrocard.2006.09.003
   McGhie TK, 2018, CLIN EXP RHEUMATOL, V36, P545
   Mitra Raman L, 2020, HeartRhythm Case Rep, V6, P244, DOI 10.1016/j.hrcr.2020.03.016
   Morgan ND, 2013, JCR-J CLIN RHEUMATOL, V19, P286, DOI 10.1097/RHU.0b013e31829d5e50
   Moulki N, 2018, J INTERV CARD ELECTR, V52, P335, DOI 10.1007/s10840-018-0389-0
   National Institutes of Health, COR DIS 2019 COVID 1
   O'Laughlin JP, 2016, CASE REP CARDIOL, V2016, DOI 10.1155/2016/4626279
   Rector TS, 2016, AM J PSYCHIAT, V173, P896, DOI 10.1176/appi.ajp.2016.15111444
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Szekely Y, 2020, HEART RHYTHM, V17, P1452, DOI 10.1016/j.hrthm.2020.04.046
   Tang W, 2020, HYDROXYCHLOROQUINE P, DOI [10.1101/2020.04.10.20060558, DOI 10.1101/2020.04.10.20060558]
   Torp-Pedersen C, 1999, NEW ENGL J MED, V341, P857, DOI 10.1056/NEJM199909163411201
   U.S. Food and Drug Administration, PLAQUENIL HYDR SULF
   Vardeny O, 2020, CIRCULATION, V141, P1667, DOI 10.1161/CIRCULATIONAHA.120.046837
   Weeke P, 2013, EUROPACE, V15, P1791, DOI 10.1093/europace/eut153
   Westanmo A, 2015, PAIN MED, V16, P1019, DOI 10.1111/pme.12699
   Westermeyer J, 2016, AM J ADDICTION, V25, P499, DOI 10.1111/ajad.12423
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 44
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1547-5271
EI 1556-3871
J9 HEART RHYTHM
JI Heart Rhythm
PD NOV
PY 2020
VL 17
IS 11
BP 1930
EP 1935
DI 10.1016/j.hrthm.2020.06.029
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OI5BM
UT WOS:000583293800014
PM 32610165
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Samuel, S
   Friedman, RA
   Sharma, C
   Ganigara, M
   Mitchell, E
   Schleien, C
   Blaufox, AD
AF Samuel, Sharmeen
   Friedman, Richard A.
   Sharma, Chetan
   Ganigara, Madhusudan
   Mitchell, Elizabeth
   Schleien, Charles
   Blaufox, Andrew D.
TI Incidence of arrhythmias and electrocardiographic abnormalities in
   symptomatic pediatric patients with PCR-positive SARS-CoV-2 infection,
   including drug-induced changes in the corrected QT interval
SO HEART RHYTHM
LA English
DT Article
DE COVID-19; Pediatric; Arrhythmias; Drug-induced prolonged QT;
   Hydroxychloroquine
ID STATEMENT
AB BACKGROUND There is limited data regarding the electrophysiological abnormalities and arrhythmias in children with COVID-19, including those associated with treatment using potentially proarrhythmic hydroxychloroquine (HCQ) and azithromycin (AZN).
   OBJECTIVES To describe the electrophysiologic findings and arrhythmias associated with pediatric COVID-19 and its treatment.
   METHODS A single-center retrospective chart review was undertaken and included all patients with (1) symptoms of COVID-19 and (2) PCR-positive nasopharyngeal swabs for SARS-CoV-2 who were placed on continuous telemetry for the duration of their hospitalization during March through May, 2020.
   RESULTS Thirty-six patients were included in the study. Significant arrhythmias were found in 6 (nonsustained ventricular tachycardia in 5 and sustained atrial tachycardia in 1). All were self-resolving and half prompted prophylactic antiarrhythmic therapy. Patients with significant arrhythmias were likely to have noncardiac comorbidities (4/6), but these were not more common than in patients without arrhythmias (20/30, P = 1). The use of HCQ was associated with statistically significant QTc prolongation (413 +/- 19 ms vs 425 +/- 16 ms, P = .005). QTc was not statistically different in patients with and without arrhythmias (425 +/- 15 ms vs 425 +/- 15 ms, P = 1).
   CONCLUSIONS In pediatric patients with PCR-positive active COVID-19 infection, significant arrhythmias are infrequent, but are more common than expected in a general pediatric population. Comorbidities are not more common in patients with arrhythmias than in patients without arrhythmias. COVID-19 treatment using HCQ is associated with QTc prolongation but was not associated with arrhythmias in pediatric patients.
C1 [Samuel, Sharmeen; Friedman, Richard A.; Sharma, Chetan; Ganigara, Madhusudan; Mitchell, Elizabeth; Blaufox, Andrew D.] Hofstra Univ, Pediat Cardiol Sect, Donald & Barbara Zucker Sch Med, Cohen Childrens Med Ctr,Northwell Hlth Syst, New Hyde Pk, NY USA.
   [Samuel, Sharmeen; Friedman, Richard A.; Sharma, Chetan; Ganigara, Madhusudan; Mitchell, Elizabeth; Schleien, Charles; Blaufox, Andrew D.] Hofstra Univ, Dept Pediat, Donald & Barbara Zucker Sch Med, Cohen Childrens Med Ctr,Northwell Hlth Syst, New Hyde Pk, NY USA.
RP Samuel, S (corresponding author), Cohen Childrens Hosp, Div Pediat Cardiol, 1111 Marcus Ave,4B, New Hyde Pk, NY 11042 USA.
EM ssamuel21@northwell.edu
CR Aghagoli G, 2020, J CARDIAC SURG, V35, P1302, DOI 10.1111/jocs.14538
   Basu-Ray I., 2020, CARDIAC MANIFESTATIO
   Bessiere F, 2020, JAMA CARDIOL, DOI DOI 10.1001/JAMACARDIO.2020.1787
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Chen ZW, 2020, EFFICACY HYDROXYCHLO
   Chorin E, 2020, NAT MED, V26, P808, DOI 10.1038/s41591-020-0888-2
   Crosson JE, 2014, HEART RHYTHM, V11, pE55, DOI 10.1016/j.hrthm.2014.05.010
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   DAVIGNON A, 1980, PEDIATR CARDIOL, V1, P123, DOI 10.1007/BF02083144
   FAUCHIER JP, 1993, ARCH MAL COEUR VAISS, V86, P757
   Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Kochav SM, 2020, CIRC-ARRHYTHMIA ELEC, V13, DOI 10.1161/CIRCEP.120.008719
   Kupferschmidt K, 2020, SCIENCE, V367, P1412, DOI 10.1126/science.367.6485.1412
   Lakkireddy DR, 2020, HEART RHYTHM, V17, pE233, DOI 10.1016/j.hrthm.2020.03.028
   Rautaharju PM, 2009, J AM COLL CARDIOL, V53, P982, DOI 10.1016/j.jacc.2008.12.014
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 20
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1547-5271
EI 1556-3871
J9 HEART RHYTHM
JI Heart Rhythm
PD NOV
PY 2020
VL 17
IS 11
BP 1960
EP 1966
DI 10.1016/j.hrthm.2020.06.033
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OI5BM
UT WOS:000583293800019
PM 32621881
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Lapid, MI
   Seiner, S
   Heintz, H
   Hermida, AP
   Nykamp, L
   Sanghani, SN
   Mueller, M
   Petrides, G
   Forester, BP
AF Lapid, Maria I.
   Seiner, Stephen
   Heintz, Hannah
   Hermida, Adriana P.
   Nykamp, Louis
   Sanghani, Sohag N.
   Mueller, Martina
   Petrides, Georgios
   Forester, Brent P.
TI Electroconvulsive Therapy Practice Changes in Older Individuals Due to
   COVID-19: Expert Consensus Statement
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE ECT; coronavirus; aerosol-generating
AB The ubiquitous coronavirus 2019 (COVID-19) pandemic has required healthcare providers across all disciplines to rapidly adapt to public health guidelines to reduce risk while maintaining quality of care. Electroconvulsive therapy (ECT), which involves an aerosol-generating procedure from manual ventilation with a bag mask valve while under anesthesia, has undergone drastic practice changes in order to minimize disruption of treatment in the midst of COVID-19. In this paper, we provide a consensus statement on the clinical practice changes in ECT specific to older adults based on expert group discussions of ECT practitioners across the country and a systematic review of the literature. There is a universal consensus that ECT is an essential treatment of severe mental illness. In addition, there is a clear consensus on what modifications are imperative to ensure continued delivery of ECT in a manner that is safe for patients and staff, while maintaining the viability of ECT services. Approaches to modifications in ECT to address infection control, altered ECT procedures, and adjusting ECT operations are almost uniform across the globe. With modified ECT procedures, it is possible to continue to meet the needs of older patients while mitigating risk of transmission to this vulnerable population.
C1 [Lapid, Maria I.] Mayo Clin, Dept Psychiat & Psychol, Rochester, MN 55905 USA.
   [Seiner, Stephen] McLean Hosp, Neurotherapeut Program, Boston, MA USA.
   [Seiner, Stephen; Forester, Brent P.] Harvard Med Sch, Boston, MA 02115 USA.
   [Heintz, Hannah; Forester, Brent P.] McLean Hosp, Div Geriatr Psychiat, Boston, MA USA.
   [Hermida, Adriana P.] Emory Univ, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA.
   [Nykamp, Louis] Pine Rest Christian Mental Hlth Ctr, Grand Rapids, MI USA.
   [Sanghani, Sohag N.; Petrides, Georgios] Northwell Hlth Syst, Zucker Hillside Hosp, Glen Oaks, NY USA.
   [Sanghani, Sohag N.; Petrides, Georgios] Hofstra Northwell, Zucker Sch Med, Hempstead, NY USA.
   [Mueller, Martina] Med Univ South Carolina, Coll Nursing, Charleston, SC 29425 USA.
   [Mueller, Martina] Med Univ South Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA.
RP Lapid, MI (corresponding author), Mayo Clin, Dept Psychiat & Psychol, Rochester, MN 55905 USA.
EM Lapid.Maria@mayo.edu
OI Mueller, Martina/0000-0003-2041-5142
FU NIA NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)
   [R01 AG061100] Funding Source: Medline
CR APA, PRACT GUID COVID 19
   Braithwaite R, 2020, J ECT, V36, P222, DOI 10.1097/YCT.0000000000000706
   Bryson EO, 2020, J ECT, V36, P149, DOI 10.1097/YCT.0000000000000702
   Burhan AM, 2020, AM J GERIAT PSYCHIAT, V28, P900, DOI 10.1016/j.jagp.2020.05.007
   CDC, COR DIS 2019 COVID 1
   Colbert SA, 2020, J ECT, V36, P86, DOI 10.1097/YCT.0000000000000688
   Davidson PM, 2020, J CLIN NURS, V29, P2758, DOI 10.1111/jocn.15297
   Espinoza RT, 2020, J ECT, V36, P78, DOI 10.1097/YCT.0000000000000689
   Flexman AM, 2020, J NEUROSURG ANESTH, V32, P202, DOI 10.1097/ANA.0000000000000691
   Hermida AP, 2020, AM J GERIAT PSYCHIAT, V28, P157, DOI 10.1016/j.jagp.2019.09.008
   ISEN, COVID 19 ECT LETT
   Luccarelli J, 2020, PSYCHOTHER PSYCHOSOM, V89, P314, DOI 10.1159/000509113
   Meyer JP, 2018, PSYCHIAT CLIN N AM, V41, P79, DOI 10.1016/j.psc.2017.10.007
   Sienaert P, 2020, AM J GERIAT PSYCHIAT, V28, P772, DOI 10.1016/j.jagp.2020.04.013
   Tenenbeim M, COVID 19 GUIDELINES
   Tor PC, 2020, J ECT, V36, P80, DOI 10.1097/YCT.0000000000000690
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
NR 17
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD NOV
PY 2020
VL 28
IS 11
BP 1133
EP 1145
DI 10.1016/j.jagp.2020.08.001
PG 13
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA OI5JJ
UT WOS:000583314300002
PM 32863137
OA Green Published
DA 2021-01-01
ER

PT J
AU Davis, MW
   McManus, D
   Koff, A
   Jaszczur, GR
   Malinis, M
   Dela Cruz, C
   Britto, CJ
   Price, C
   Azmy, V
   Kaman, K
   Gaston, D
   Early, K
   DeWitt, M
   Song, JS
   Ortiz, C
   Juthani-Mehta, M
   Topal, JE
AF Davis, Matthew W.
   McManus, Dayna
   Koff, Alan
   Jaszczur, Gregory R.
   Malinis, Maricar
   Dela Cruz, Charles
   Britto, Clemente J.
   Price, Christina
   Azmy, Veronica
   Kaman, Kelsey
   Gaston, David
   Early, Kevin
   DeWitt, Michelle
   Song, Ju-Sung
   Ortiz, Claudia
   Juthani-Mehta, Manisha
   Topal, Jeffrey E.
TI Repurposing antimicrobial stewardship tools in the electronic medical
   record for the management of COVID-19 patients
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
AB During the COVID-19 pandemic, the antimicrobial stewardship module in our electronic medical record was reconfigured for the management of COVID-19 patients. This change allowed our subspecialist providers to review charts quickly to optimize potential therapy and management during the patient surge.
C1 [Davis, Matthew W.; McManus, Dayna; Topal, Jeffrey E.] Yale New Haven Med Ctr, Dept Pharm Serv, 20 York St, New Haven, CT 06504 USA.
   [Koff, Alan; Malinis, Maricar; Gaston, David; Juthani-Mehta, Manisha; Topal, Jeffrey E.] Yale Univ, Sch Med, Sect Infect Dis, New Haven, CT USA.
   [Jaszczur, Gregory R.; Early, Kevin; DeWitt, Michelle; Song, Ju-Sung; Ortiz, Claudia] Yale New Haven Hlth Syst, Informat Technol Serv, New Haven, CT USA.
   [Dela Cruz, Charles; Britto, Clemente J.] Yale Univ, Sch Med, Sect Pulm Crit Care & Sleep Med, New Haven, CT USA.
   [Price, Christina; Azmy, Veronica; Kaman, Kelsey] Yale Univ, Sch Med, Sect Rheumatol Allergy & Immunol, New Haven, CT USA.
RP Davis, MW; McManus, D (corresponding author), Yale New Haven Med Ctr, Dept Pharm Serv, 20 York St, New Haven, CT 06504 USA.
EM dayna.mcmanus@ynhh.org; Matthew.Davis2@YNHH.ORG
OI Koff, Alan/0000-0003-1229-7860; Davis, Matthew/0000-0002-6509-0487;
   McManus, Dayna/0000-0002-8153-3284; Malinis, Maricar/0000-0002-5720-9994
CR Centers for Disease Control and Prevention, COR DIS 2019 COVID 1
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kullar R, 2013, CLIN INFECT DIS, V57, P1005, DOI 10.1093/cid/cit318
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   WHO, 2020, PNEUM UNKN CAUS CHIN
NR 8
TC 0
Z9 0
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0899-823X
EI 1559-6834
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD NOV
PY 2020
VL 41
IS 11
BP 1335
EP 1337
AR PII S0899823X20002810
DI 10.1017/ice.2020.281
PG 3
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA OI5PB
UT WOS:000583329100017
PM 32507113
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tascini, C
   Sermann, G
   Pagotto, A
   Sozio, E
   De Carlo, C
   Giacinta, A
   Sbrana, F
   Ripoli, A
   Castaldo, N
   Merelli, M
   Cadeo, B
   Macor, C
   De Monte, A
AF Tascini, Carlo
   Sermann, Giovanni
   Pagotto, Alberto
   Sozio, Emanuela
   De Carlo, Chiara
   Giacinta, Alessandro
   Sbrana, Francesco
   Ripoli, Andrea
   Castaldo, Nadia
   Merelli, Maria
   Cadeo, Barbara
   Macor, Cristiana
   De Monte, Amato
TI Blood ozonization in patients with mild to moderate COVID-19 pneumonia:
   a single centre experience
SO INTERNAL AND EMERGENCY MEDICINE
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; Cytokine release syndrome (CRS); Medical O-3; O-3
   therapy; O-3 gas; Autotransfusion; Oxidative stress; Reactive oxidative
   species; Lipid ozonation products
ID OZONE THERAPY
AB The emerging outbreak of the coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread worldwide. We prescribed some promising medication to our patients with mild to moderate pneumonia due to SARS-CoV-2, however such drugs as chloroquine, hydrossichloroquine, azithromycin, antivirals (lopinavir/ritonavir, darunavir/cobicistat) and immunomodulating agents (steroids, tocilizumab) were not confirmed as effective against SARS-CoV2. We, therefore, started to use auto-hemotherapy treated with an oxygen/ozone (O-2/O-3) gaseous mixture as adjuvant therapy. In Udine University Hospital (Italy) we performed a case-control study involving hospitalized adult patients with confirmed COVID-19 with mild to moderate pneumonia. Clinical presentations are based upon clinical phenotypes identified by the Italian Society of Emergency and Urgency Medicine (SIMEU-Societa Italiana di Medicina di Emergenza-Urgenza) and patients that met criteria of phenotypes 2 to 4 were treated with best available therapy (BAT), with or without O-3-autohemotherapy. 60 patients were enrolled in the study: 30 patients treated with BAT and O-2/O-3 mixture, as adjuvant therapy and 30 controls treated with BAT only. In the group treated with O-3-autohemotherapy plus BAT, patients were younger but with more severe clinical phenotypes. A decrease of SIMEU clinical phenotypes was observed (2.70 +/- 0.67 vs. 2.35 +/- 0.88, p = 0.002) in all patients during hospitalization but this clinical improvement was statistically significant only in O-3-treated patients (2.87 +/- 0.78 vs. 2.27 +/- 0.83, p < 0.001), differently to the control group (2.53 +/- 0.51 vs. 2.43 +/- 0.93, p = 0.522). No adverse events were observed associated with the application of O-2/O-3 gaseous mixture. O-2/O-3 therapy as adjuvant therapy could be useful in mild to moderate pneumonia due to SARS-CoV-2. Randomized prospective study is ongoing [Clinical Trials.gov ID: Z7C2CA5837].
C1 [Tascini, Carlo; Pagotto, Alberto; Sozio, Emanuela; De Carlo, Chiara; Giacinta, Alessandro; Castaldo, Nadia; Merelli, Maria; Cadeo, Barbara] Univ Udine, Dipartimento Med, UO Malattie Infett, Via Pozzuolo 330, I-33100 Udine, Italy.
   [Tascini, Carlo; Pagotto, Alberto; Sozio, Emanuela; De Carlo, Chiara; Giacinta, Alessandro; Castaldo, Nadia; Merelli, Maria; Cadeo, Barbara] Univ Integrata Udine, Via Pozzuolo 330, I-33100 Udine, Italy.
   [Sermann, Giovanni; Macor, Cristiana; De Monte, Amato] Univ Udine, SOC Anestesia Rianimazione Uno, Via Pozzuolo 330, I-33100 Udine, Italy.
   [Sermann, Giovanni; Macor, Cristiana; De Monte, Amato] Azienda Sanitaria Univ Integrata Udine, Via Pozzuolo 330, I-33100 Udine, Italy.
   [Sozio, Emanuela] HDU Livorno, Azienda USL, Pronto Soccorso Med Urgenza, I-33100 Livorno, Italy.
   [Sbrana, Francesco] Fdn Toscana Gabriele Monasterio, UO Lipoapheresis & Ctr Inherited Dyslipidemias, Via Moruzzi 1, I-56124 Pisa, Italy.
   [Ripoli, Andrea] Fdn Toscana Gabriele Monasterio, Deep Hlth Unit, Via Moruzzi 1, I-56124 Pisa, Italy.
RP Tascini, C (corresponding author), Univ Udine, Dipartimento Med, UO Malattie Infett, Via Pozzuolo 330, I-33100 Udine, Italy.; Tascini, C (corresponding author), Univ Integrata Udine, Via Pozzuolo 330, I-33100 Udine, Italy.; Sbrana, F (corresponding author), Fdn Toscana Gabriele Monasterio, UO Lipoapheresis & Ctr Inherited Dyslipidemias, Via Moruzzi 1, I-56124 Pisa, Italy.
EM c.tascini@gmail.com; francesco.sbrana@ftgm.it
RI ; Sozio, Emanuela/B-1450-2017
OI Sbrana, Francesco/0000-0003-4607-0373; Sozio,
   Emanuela/0000-0001-6247-5958
CR Bocci VA, 2006, ARCH MED RES, V37, P425, DOI 10.1016/j.arcmed.2005.08.006
   Bocci VA, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-66
   Caliskan B, 2011, SCAND J CLIN LAB INV, V71, P473, DOI 10.3109/00365513.2011.587022
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Clavo B, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8120588
   Elvis A M, 2011, J Nat Sci Biol Med, V2, P66, DOI 10.4103/0976-9668.82319
   Erika P, 2020, INTERN EMERG MED, V15, P879, DOI 10.1007/s11739-020-02350-y
   Fanin A, 2020, INTERN EMERG MED, V15, P841, DOI 10.1007/s11739-020-02388-y
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Gulmen S, 2013, J SURG RES, V185, P64, DOI 10.1016/j.jss.2013.05.085
   Leon OS, 1998, MEDIAT INFLAMM, V7, P289, DOI 10.1080/09629359890983
   Lu CC, 2020, J CHIN MED ASSOC, V83, P534, DOI 10.1097/JCMA.0000000000000318
   Perlini S, 2020, INTERN EMERG MED, V15, P825, DOI 10.1007/s11739-020-02390-4
   R Core Team, 2013, R LANG ENV STAT COMP
   Ricevuti G, 2020, OZONE THERAPY, V5, DOI [DOI 10.4081/ozone.2020.9014, 10.4081/ozone.2020.9014]
   Rowen R. J., 2016, African Journal of Infectious Diseases, V10, P49, DOI 10.4314/ajid.v10i1.10
   Rowen RJ, 2019, MED GAS RES, V9, P232, DOI 10.4103/2045-9912.273962
   Smith NL, 2017, MED GAS RES, V7, P212, DOI 10.4103/2045-9912.215752
   World Health Organization, SIT UPD JUL 20 2020
   World Health Organization (WHO), 2020, CLIN MAN COVID 19 IN
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
NR 22
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1828-0447
EI 1970-9366
J9 INTERN EMERG MED
JI Intern. Emerg. Med.
DI 10.1007/s11739-020-02542-6
EA NOV 2020
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA OJ0BY
UT WOS:000583634300002
PM 33131033
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Saba, L
   Sverzellati, N
AF Saba, Luca
   Sverzellati, Nicola
TI Is COVID Evolution Due to Occurrence of Pulmonary Vascular Thrombosis?
SO JOURNAL OF THORACIC IMAGING
LA English
DT Letter
DE pulmonary thrombosis; COVID; lung
ID CT; EMBOLISM
AB In this hypothesis paper, we suggest that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may induce intravascular pulmonary thrombosis, which may result in the rapid worsening of clinical conditions and, eventually, exitus. Previously published papers have demonstrated that increased levels of D-dimer at hospital admission correlate with a more severe disease (0.5 mg/L) or occurrence of death (1 mg/L). The potential prothrombotic action of the SARS-CoV-2 is supported by the topographical involvement of the lung regions with a predilection for the lower lobe with peripheral involvement. If this hypothesis is demonstrated, this could suggest the benefit of using antithrombotic/coagulation regimens for SARS-CoV-2 and, at the same time, the urgency to identify drugs that could alter the inflammatory storm, thus protecting the vessel wall.
C1 [Saba, Luca] Azienda Osped Univ AOU, Dept Radiol, Cagliari Polo Monserrato Ss 554, I-09045 Cagliari, Italy.
   [Sverzellati, Nicola] Univ Parma, Div Radiol, Dept Med & Surg, Parma, Italy.
RP Saba, L (corresponding author), Azienda Osped Univ AOU, Dept Radiol, Cagliari Polo Monserrato Ss 554, I-09045 Cagliari, Italy.
EM lucasaba@tiscali.it
CR Gladish GW, 2006, RADIOLOGY, V240, P246, DOI 10.1148/radiol.2401051129
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Jimenez D, 2010, AM J RESP CRIT CARE, V181, P983, DOI 10.1164/rccm.200908-1204OC
   Kubak MP, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.05.55
   Lu T, 2020, J THORAC IMAG, V35, pW90, DOI 10.1097/RTI.0000000000000508
   Marongiu F, 2019, SEMIN THROMB HEMOST, V45, P778, DOI 10.1055/s-0039-1696942
   Ritchie G, 2007, THORAX, V62, P536, DOI 10.1136/thx.2006.062299
   SANTOLICANDRO A, 1995, AM J RESP CRIT CARE, V152, P336, DOI 10.1164/ajrccm.152.1.7599843
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   Winer-Muram HT, 2004, RADIOLOGY, V233, P806, DOI 10.1148/radiol.2333031744
   Yang Y, 2016, CELL MOL IMMUNOL, V13, P432, DOI 10.1038/cmi.2016.1
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu TT, 2020, J THORAC IMAG, V35, pW97, DOI 10.1097/RTI.0000000000000513
NR 14
TC 8
Z9 8
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0883-5993
EI 1536-0237
J9 J THORAC IMAG
JI J. Thorac. Imaging
PD NOV
PY 2020
VL 35
IS 6
BP 344
EP 345
DI 10.1097/RTI.0000000000000530
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA OI6RP
UT WOS:000583403600006
PM 32349055
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Hajdu, SD
   Marto, JP
   Saliou, G
AF Hajdu, Steven D.
   Marto, Joao Pedro
   Saliou, Guillaume
TI Response by Hajdu et al to Letter Regarding Article, "Acute Stroke
   Management During the COVID-19 Pandemic: Does Confinement Impact
   Eligibility for Endovascular Therapy?"
SO STROKE
LA English
DT Letter
C1 [Hajdu, Steven D.; Saliou, Guillaume] Lausanne Univ Hosp, Dept Intervent & Diagnost Radiol, Rue Bugnon 47, CH-1011 Lausanne, Switzerland.
   [Marto, Joao Pedro] Ctr Hosp Lisboa Ocidental, Hosp Egas Moniz, Dept Neurol, Lisbon, Portugal.
RP Hajdu, SD (corresponding author), Lausanne Univ Hosp, Dept Intervent & Diagnost Radiol, Rue Bugnon 47, CH-1011 Lausanne, Switzerland.
EM steven.hajdu@chuv.ch
OI Marto, Joao Pedro/0000-0003-2277-5950
CR Hajdu SD, 2020, STROKE, V51, P2593, DOI 10.1161/STROKEAHA.120.030794
NR 1
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD NOV
PY 2020
VL 51
IS 11
BP E340
EP E341
DI 10.1161/STROKEAHA.120.032096
PG 2
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA OI1PM
UT WOS:000583059500023
PM 33104477
DA 2021-01-01
ER

PT J
AU Kwan, J
   Lobotesis, K
   Banerjee, S
AF Kwan, Joseph
   Lobotesis, Kyriakos
   Banerjee, Soma
TI Letter by Kwan et al Regarding Article, "Acute Stroke Management During
   the COVID-19 Pandemic: Does Confinement Impact Eligibility for
   Endovascular Therapy?"
SO STROKE
LA English
DT Letter
C1 [Kwan, Joseph; Banerjee, Soma] Imperial Coll London NHS Healthcare Trust, Charing Cross Hosp, Dept Stroke Med, London, England.
   [Lobotesis, Kyriakos] Imperial Coll London NHS Healthcare Trust, Charing Cross Hosp, Imaging Dept, London, England.
RP Kwan, J (corresponding author), Imperial Coll London NHS Healthcare Trust, Charing Cross Hosp, Dept Stroke Med, London, England.
OI Kwan, Joseph/0000-0003-4635-3322
CR Hajdu SD, 2020, STROKE, V51, P2593, DOI 10.1161/STROKEAHA.120.030794
NR 1
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD NOV
PY 2020
VL 51
IS 11
BP E338
EP E339
DI 10.1161/STROKEAHA.120.031638
PG 2
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA OI1PM
UT WOS:000583059500022
PM 33104467
DA 2021-01-01
ER

PT J
AU Yessayan, L
   Szamosfalvi, B
   Napolitano, L
   Singer, B
   Kurabayashi, K
   Song, YJ
   Westover, A
   Humes, HD
AF Yessayan, Lenar
   Szamosfalvi, Balazs
   Napolitano, Lena
   Singer, Benjamin
   Kurabayashi, Katsuo
   Song, Yujing
   Westover, Angela
   Humes, H. David
TI Treatment of Cytokine Storm in COVID-19 Patients With Immunomodulatory
   Therapy
SO ASAIO JOURNAL
LA English
DT Article
DE ARDS; COVID-19; COVID treatment; immunomodulation; extracorporeal
   therapy
ID KIDNEY; DEVICE
AB Observational evidence suggests that excessive inflammation with cytokine storm may play a critical role in development of acute respiratory distress syndrome (ARDS) in COVID-19. We report the emergency use of immunomodulatory therapy utilizing an extracorporeal selective cytopheretic device (SCD) in two patients with elevated serum interleukin (IL)-6 levels and refractory COVID-19 ARDS requiring extracorporeal membrane oxygenation (ECMO). The two patients were selected based on clinical criteria and elevated levels of IL-6 (>100 pg/ml) as a biomarker of inflammation. Once identified, emergency/expanded use permission for SCD treatment was obtained and patient consented. Six COVID-19 patients (four on ECMO) with severe ARDS were also screened with IL-6 levels less than 100 pg/ml and were not treated with SCD. The two enrolled patients' PaO2/FiO(2) ratios increased from 55 and 58 to 200 and 192 at 52 and 50 hours, respectively. Inflammatory indices also declined with IL-6 falling from 231 and 598 pg/ml to 3.32 and 116 pg/ml, respectively. IL-6/IL-10 ratios also decreased from 11.8 and 18 to 0.7 and 0.62, respectively. The two patients were successfully weaned off ECMO after 17 and 16 days of SCD therapy, respectively. The results observed with SCD therapy on these two critically ill COVID-19 patients with severe ARDS and elevated IL-6 is encouraging. A multicenter clinical trial is underway with an FDA-approved investigational device exemption to evaluate the potential of SCD therapy to effectively treat COVID-19 intensive care unit patients.
C1 [Yessayan, Lenar; Szamosfalvi, Balazs; Westover, Angela; Humes, H. David] Univ Michigan, Dept Med, Div Nephrol, 3914 Taubman Ctr,1500 E Med Ctr Dr 5364, Ann Arbor, MI 48109 USA.
   [Napolitano, Lena] Univ Michigan, Dept Surg, Div Acute Care Surg, Ann Arbor, MI 48109 USA.
   [Singer, Benjamin] Univ Michigan, Dept Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA.
   [Kurabayashi, Katsuo; Song, Yujing] Univ Michigan, Dept Mech Engn, Ann Arbor, MI 48109 USA.
   [Kurabayashi, Katsuo] Univ Michigan, Dept Elect Engn & Comp Sci, Ann Arbor, MI 48109 USA.
RP Yessayan, L (corresponding author), Univ Michigan, Dept Med, Div Nephrol, 3914 Taubman Ctr,1500 E Med Ctr Dr 5364, Ann Arbor, MI 48109 USA.
EM lenar@med.umich.edu
FU National Science FoundationNational Science Foundation (NSF) [CBET
   1931905]; Cancer Research Institute [AWD012546]; NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [UL1TR002240]
FX Drs Yessayan, Szamosfalvi, Napolitano, Singer, Kurabayashi, and Song
   have nothing to disclose. Drs Humes and Westover have financial
   interests in SeaStar Medical, Inc., which has an exclusive license from
   the University of Michigan to develop the Selective Cytopheretic Device
   technology. Rapid cytokine measurements were funded by the National
   Science Foundation CBET 1931905 and the Cancer Research Institute
   AWD012546. MICHR is funded by NIH UL1TR002240. The content is solely the
   responsibility of the authors and does not represent the official views
   of University of Michigan.
CR de Brito RDCM, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0324-z
   Ding F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018584
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Honore PM, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0530-y
   Lehner GF, 2014, MINERVA ANESTESIOL, V80, P595
   Nishimoto N, 2008, BLOOD, V112, P3959, DOI 10.1182/blood-2008-05-155846
   Pino CJ, 2018, KIDNEY INT REP, V3, P771, DOI 10.1016/j.ekir.2017.12.012
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Szamosfalvi B, 2016, ASAIO J, V62, P623, DOI 10.1097/MAT.0000000000000400
   Szamosfalvi B, 2010, BLOOD PURIFICAT, V29, P204, DOI 10.1159/000245648
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Tumlin JA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132482
   Tumlin JA, 2013, SEMIN DIALYSIS, V26, P616, DOI 10.1111/sdi.12032
NR 13
TC 1
Z9 1
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1058-2916
EI 1538-943X
J9 ASAIO J
JI Asaio J.
PD NOV-DEC
PY 2020
VL 66
IS 10
BP 1079
EP 1083
DI 10.1097/MAT.0000000000001239
PG 5
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA OK6JW
UT WOS:000584755400007
PM 33136592
OA Bronze
DA 2021-01-01
ER

PT J
AU Criscuolo, E
   Diotti, RA
   Strollo, M
   Rolla, S
   Ambrosi, A
   Locatelli, M
   Burioni, R
   Mancini, N
   Clementi, M
   Clementi, N
AF Criscuolo, Elena
   Diotti, Roberta A.
   Strollo, Marta
   Rolla, Serena
   Ambrosi, Alessandro
   Locatelli, Massimo
   Burioni, Roberto
   Mancini, Nicasio
   Clementi, Massimo
   Clementi, Nicola
TI Weak correlation between antibody titers and neutralizing activity in
   sera from SARS-CoV-2 infected subjects
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE COVID&#8208; 19 diagnostic assays; neutralizing activity; SARS&#8208;
   CoV&#8208; 2 serology
ID CURVES
AB Plenty of serologic tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed so far, thus documenting the importance of evaluating the relevant features of the immune response to this viral agent. The performance of these assays is currently under investigation. Amongst them, LIAISON (R) SARS-CoV-2 S1/S2 IgG by DiaSorin and Elecsys Anti-SARS-CoV-2 cobas (R) by Roche are currently used by laboratory medicine hospital departments in Italy and many other countries. In the present study, we firstly compared two serologic tests on serum samples collected at two different time points from 46 laboratory-confirmed coronavirus disease-2019 (COVID-19) subjects. Secondly, 85 negative serum samples collected before the SARS-CoV-2 pandemic were analyzed. Thirdly, possible correlations between antibody levels and the resulting neutralizing activity against a clinical isolate of SARS-CoV-2 were evaluated. Results revealed that both tests are endowed with low sensitivity on the day of hospital admission, which increased to 97.8% and 100% for samples collected after 15 days for DiaSorin and Roche tests, respectively. The specificity evaluated for the two tests ranges from 96.5% to 100%, respectively. Importantly, a poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study. These data further shed light on both potentials and possible limitations related to SARS-CoV-2 serology. In this context, great efforts are still necessary for investigating antibody kinetics to develop novel diagnostic algorithms. Moreover, further investigations on the role of neutralizing antibodies and their correlate of protection will be of paramount importance for the development of effective vaccines.
C1 [Criscuolo, Elena; Diotti, Roberta A.; Burioni, Roberto; Mancini, Nicasio; Clementi, Massimo; Clementi, Nicola] Univ Vita Salute San Raffaele, Lab Med Microbiol & Virol, Via Olgettina 58, I-20132 Milan, Italy.
   [Strollo, Marta; Rolla, Serena; Locatelli, Massimo] IRCCS San Raffaele Hosp, Lab Med Serv, Milan, Italy.
   [Ambrosi, Alessandro] Univ Vita Salute San Raffaele, Fac Med & Surg, Milan, Italy.
   [Mancini, Nicasio; Clementi, Massimo; Clementi, Nicola] IRCCS San Raffaele Hosp, Lab Med Microbiol & Virol, Milan, Italy.
RP Clementi, N (corresponding author), Univ Vita Salute San Raffaele, Lab Med Microbiol & Virol, Via Olgettina 58, I-20132 Milan, Italy.
EM clementi.nicola@hsr.it
RI Clementi, Massimo/F-6646-2013; Ambrosi, Alessandro/H-4424-2011;
   Clementi, Nicola/G-8545-2014
OI Ambrosi, Alessandro/0000-0003-1976-5663; Criscuolo,
   Elena/0000-0003-0185-3147; Clementi, Nicola/0000-0002-1822-9861
CR Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Bonelli F, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.01224-20
   Boukli N, 2020, J CLIN MICROBIOL, P1
   DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
   DiaSorin, LIAISON SARS COV 2 S
   Focosi D, 2020, REV MED VIROL, V7821, P437
   Giurgea LT, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0198-1
   Liu W, 2020, J CLIN MICROBIOL, V58, P514
   Long QX, 2020, ANTIBODY RESPONSES S, DOI [10.1101/2020.03.18.20038018, DOI 10.1101/2020.03.18.20038018]
   Ma H, 2020, SCI CHINA LIFE SCI, DOI 10.1007/s11427-020-1805-0
   Nuccetelli M, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-0275-2
   Roche, EL ANT COV 2 IMM QUA
   Seow G., 2020, LONGITUDINAL EVALUAT, DOI [10.1101/2020.07.09.20148429., 10.1101/2020.07.09.20148429, DOI 10.1101/2020.07.09.20148429]
   Tang MS, 2020, CLIN CHEM, V323, P1582
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   WHO, 2020, IMM PASSP CONT COVID
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]
   Wu J, 2020, SARS COV 2 INFECT IN, DOI [10.1101/2020.07.21.20159178, DOI 10.1101/2020.07.21.20159178]
   Zhang B, 2020, IMMUNE PHENOTYPING B, V7, P157, DOI [10.1101/2020.03.12.20035048, DOI 10.1101/2020.03.12.20035048]
   Zhou X-H, 2014, STAT METHODS DIAGNOS
   Zou KH, 1997, STAT MED, V16, P2143
NR 21
TC 0
Z9 0
U1 6
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26605
EA NOV 2020
PG 8
WC Virology
SC Virology
GA OI3QO
UT WOS:000583197700001
PM 33064340
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Goldenberg, NA
   Sochet, A
   Albisetti, M
   Biss, T
   Bonduel, M
   Jaffray, J
   MacLaren, G
   Monagle, P
   O'Brien, S
   Raffini, L
   Revel-Vilk, S
   Sirachainan, N
   Williams, S
   Zia, A
   Male, C
AF Goldenberg, Neil A.
   Sochet, Anthony
   Albisetti, Manuela
   Biss, Tina
   Bonduel, Mariana
   Jaffray, Julie
   MacLaren, Graeme
   Monagle, Paul
   O'Brien, Sarah
   Raffini, Leslie
   Revel-Vilk, Shoshana
   Sirachainan, Nongnuch
   Williams, Suzan
   Zia, Ayesha
   Male, Christoph
CA Pediat Neonatal Hemostas
TI Consensus-based clinical recommendations and research priorities for
   anticoagulant thromboprophylaxis in children hospitalized for
   COVID-19-related illness
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Article
DE children; COVID&#8208; 19; SARS&#8208; CoV&#8208; 2; thromboprophylaxis;
   venous thromboembolism
ID VENOUS THROMBOEMBOLISM; TRIALS
AB Background Observational studies indicate that children hospitalized with COVID-19-related illness, like adults, are at increased risk for venous thromboembolism (VTE). A multicenter phase 2 clinical trial of anticoagulant thromboprophylaxis in children hospitalized with COVID-19-related illness has recently been initiated in the United States. To date, there remains a paucity of high-quality evidence to inform clinical practice world-wide. Therefore, the objective of this scientific statement is to provide consensus-based recommendations on the use of anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illnesses, and to identify priorities for future research.
   Methods We surveyed 20 pediatric hematologists and pediatric critical care physicians from several continents who were identified by Pediatric/Neonatal Hemostasis and Thrombosis Subcommittee leadership as having experience and expertise in the use of anticoagulant thromboprophylaxis and/or the management of COVID-19-related illness in children. A comprehensive review of the literature on COVID-19 in children was also performed.
   Results Response rate was 90%. Based on consensus of expert opinions, we suggest the administration of low-dose low molecular weight heparin subcutaneously twice-daily as anticoagulant thromboprophylaxis (in the absence of contraindications, and in combination with mechanical thromboprophylaxis with sequential compression devices, where feasible) in children hospitalized for COVID-19-related illness (including the multisystem inflammatory syndrome in children [MIS-C]) who have markedly elevated D-dimer levels or superimposed clinical risk factors for hospitalassociated VTE. For children who are clinically unstable or have severe renal impairment, we suggest the use of unfractionated heparin by continuous intravenous infusion as anticoagulant thromboprophylaxis. In addition, continued efforts to characterize VTE risk and risk factors in children with COVID-19, as well as to evaluate the safety and efficacy of anticoagulant thromboprophylaxis strategies in children hospitalized with COVID-19-related illness (including MIS-C) via cooperative multicenter trials, were identified among several key priorities for future research.
   Conclusion These consensus-based recommendations on the use of anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illnesses and priorities for future research will be updated as high-quality evidence emerges.
C1 [Goldenberg, Neil A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Hematol, Baltimore, MD 21205 USA.
   [Goldenberg, Neil A.] Johns Hopkins Univ, Sch Med, Dept Med, Div Hematol, Baltimore, MD 21205 USA.
   [Goldenberg, Neil A.; Sochet, Anthony] Johns Hopkins All Childrens Hosp, St Petersburg, FL USA.
   [Goldenberg, Neil A.; Sochet, Anthony] Johns Hopkins All Childrens Inst Clin & Translat, St Petersburg, FL USA.
   [Sochet, Anthony] Johns Hopkins Univ, Sch Med, Dept Anesthesia & Crit Care Med, Div Pediat Crit Care Med, Baltimore, MD USA.
   [Albisetti, Manuela] Univ Childrens Hosp Zurich, Div Hematol, Zurich, Switzerland.
   [Biss, Tina] Newcastle Tyne Hosp NHS Fdn Trust, Dept Haematol, Newcastle Upon Tyne, Tyne & Wear, England.
   [Bonduel, Mariana] Hosp Pediat Prof Dr Juan P Garrahan, Serv Hematol Oncol, Buenos Aires, DF, Argentina.
   [Jaffray, Julie] Univ Southern Calif, Dept Pediat, Div Hematol Oncol, Keck Sch Med, Los Angeles, CA 90007 USA.
   [Jaffray, Julie] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA.
   [MacLaren, Graeme] Univ Melbourne, Dept Pediat, Div Crit Care, Melbourne, Vic, Australia.
   [MacLaren, Graeme] Royal Childrens Hosp, Melbourne, Vic, Australia.
   [MacLaren, Graeme] Natl Univ Singapore Hosp, Div Crit Care, Singapore, Singapore.
   [Monagle, Paul] Univ Melbourne, Dept Pediat, Melbourne, Vic, Australia.
   [Monagle, Paul] Royal Childrens Hosp, Dept Haematol, Melbourne, Vic, Australia.
   [Monagle, Paul] Murdoch Childrens Res Inst, Haematol Res, Melbourne, Vic, Australia.
   [O'Brien, Sarah] Ohio State Univ, Dept Pediat, Div Hematol Oncol, Columbus, OH 43210 USA.
   [O'Brien, Sarah] Nationwide Childrens Hosp, Columbus, OH USA.
   [Raffini, Leslie] Univ Penn, Dept Pediat, Div Hematol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Revel-Vilk, Shoshana] Hebrew Univ Jerusalem, Sch Med, Dept Pediat, Pediat Hematol Oncol Unit, Jerusalem, Israel.
   [Revel-Vilk, Shoshana] Shaare Zedek Med Ctr, Jerusalem, Israel.
   [Sirachainan, Nongnuch] Mahidol Univ, Div Hematol Oncol, Dept Pediat, Fac Med,Ramathibodi Hosp, Bangkok, Thailand.
   [Williams, Suzan] Univ Toronto, Dept Pediat, Div Hematol Oncol, Fac Med, Toronto, ON, Canada.
   [Williams, Suzan] Hosp Sick Children, Toronto, ON, Canada.
   [Zia, Ayesha] Univ Texas Southwestern, Sch Med, Dept Pediat, Div Hematol Oncol, Dallas, TX USA.
   [Male, Christoph] Med Univ Vienna, Dept Pediat, Div Cardiol, Vienna, Austria.
RP Goldenberg, NA (corresponding author), 501 6th Ave South,Suite 3200, St Petersburg, FL 33701 USA.
EM neil@jhmi.edu
OI O'Brien, Sarah/0000-0001-8855-9746; MacLaren, Graeme/0000-0002-1307-4274
CR American Society of Hematology, COVID 19 VTE ANT FRE
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Branchford BR, 2017, J THROMB HAEMOST, V15, P2274, DOI 10.1111/jth.13848
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cruz AT, 2020, PEDIATRICS, V145, P6
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Dufort EM, 2020, NEW ENGL J MED, V383, P347, DOI 10.1056/NEJMoa2021756
   Feldstein LR, 2020, NEW ENGL J MED, V383, P334, DOI 10.1056/NEJMoa2021680
   Henderson LA, 2020, ARTHRITIS RHEUMATOL, V72, P1791, DOI 10.1002/art.41454
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Loi M, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28485
   Mahajerin A, 2015, HAEMATOLOGICA, V100, P1045, DOI 10.3324/haematol.2015.123455
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   Mitchell LG, 2011, J THROMB HAEMOST, V9, P1856, DOI 10.1111/j.1538-7836.2011.04433.x
   Moores LK, 2020, CHEST, V158, P1143, DOI 10.1016/j.chest.2020.05.559
   Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]
   She JT, 2020, J MED VIROL, V92, P747, DOI 10.1002/jmv.25807
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Wang Y, 2020, CLIN NEUROPATHOL, V39, P7, DOI 10.5414/NP301203
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
NR 21
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1538-7933
EI 1538-7836
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD NOV
PY 2020
VL 18
IS 11
BP 3099
EP 3105
DI 10.1111/jth.15073
PG 7
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA OH9XG
UT WOS:000582941600034
PM 33174388
OA Bronze
DA 2021-01-01
ER

PT J
AU Chandrasekaran, S
   Diamond-Smith, N
   Srinivasan, K
   Dalvie, S
AF Chandrasekaran, Sruthi
   Diamond-Smith, Nadia
   Srinivasan, Karthik
   Dalvie, Suchitra
TI Preparing for an Increased Need for Abortion Access in India during and
   after COVID-19: Challenges and Strategies
SO STUDIES IN FAMILY PLANNING
LA English
DT Article; Early Access
ID MEDICAL ABORTION; PHYSICIANS
AB Access to safe abortion is a reproductive rights and justice issue, and it is imperative that safe abortion access during and after the COVID-19 pandemic is a reality for all. India imposed a lockdown in March 2020 to contain the spread of the pandemic. Limited mobility, lack of clarity about abortion as an essential service and abortion as a service permitted through telemedicine, shut down of services providing long-acting and permanent methods of contraception, and changes to decision-making about birthing and parenting during a pandemic are factors that may impact the demand for abortion during and after the lockdown. Shortage of raw materials and limited inter- and intra- state transport of drugs may result in breakages in the supply of medication abortion. Given that 73 percent of abortions in India in 2015 occurred outside of health facilities, the pandemic may have several implications on the need for evidence-based information and quality abortion services, as well as if and how medication abortion is accessed in India, and what self-managed abortion looks like in the COVID-19 era. We discuss factors contributing to reduced access to abortion, changes in abortion need, and suggest strategies to respond to an increased demand for abortion in India.
C1 [Chandrasekaran, Sruthi] Ibis Reprod Hlth, Suite 320,2067 Massachusetts Ave, Cambridge, MA 02140 USA.
   [Diamond-Smith, Nadia] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94158 USA.
   [Srinivasan, Karthik] Int Planned Parenthood Federat, London SE1 3UZ, England.
   [Dalvie, Suchitra] Asia Safe Abort Partnership, Mumbai, Maharashtra, India.
RP Chandrasekaran, S (corresponding author), Ibis Reprod Hlth, Suite 320,2067 Massachusetts Ave, Cambridge, MA 02140 USA.
EM schandrasekaran@ibisreproductivehealth.org
FU David and Lucile Packard FoundationThe David & Lucile Packard Foundation
FX We thank the David and Lucile Packard Foundation for their support.
CR Akhter HH, 2001, EXPANDING ACCESS MID
   [Anonymous], 2020, INDIA TODAY
   [Anonymous], 2020, BBC NEWS
   Berer M, 2009, B WORLD HEALTH ORGAN, V87, P58, DOI 10.2471/BLT.07.050138
   Chandna Himani, 2020, LOCKDOWN CONDOM SALE
   Chandra Jagriti, 2020, HINDU
   Duggal R, 2004, REPROD HEALTH MATTER, V12, P122, DOI 10.1016/S0968-8080(04)24009-5
   Endler M, 2019, BJOG-INT J OBSTET GY, V126, P1094, DOI 10.1111/1471-0528.15684
   Ganatra B, 2005, REPROD HEALTH MATTER, V13, P65, DOI 10.1016/S0968-8080(05)26215-8
   Geneva: World Health Organization, 2018, MED MAN AB, DOI [10.1385/BMM:2:3:237, DOI 10.1385/BMM:2:3:237]
   Gerdts C, 2018, BMJ SEX REPROD HEAL, V44, P286, DOI 10.1136/bmjsrh-2018-200102
   Hindustan Times, 2020, HINDUSTAN TIMES
   Indian Medical Council, 2020, TEL PRACT GUID
   International Institute for Population Sciences, 2017, NAT FAM HLTH SURV NF
   International Planned Parenthood Federation, 2020, COVID 19 PAND CUTS A
   Ipas Development Foundation, 2020, COMPR AB ACC DUE COV
   Jejeebhoy SJ, 2012, INT PERSPECT SEX R H, V38, P133, DOI 10.1363/3813312
   Jejeebhoy SJ, 2011, CONTRACEPTION, V84, P615, DOI 10.1016/j.contraception.2011.08.010
   Ministry of Health and Family Welfare, 2020, EN DEL ESS HLTH SERV
   Pandey V, 2020, BBC NEWS
   Santoshini Sarita, 2020, FOREIGN POLICY  0513
   Singh S, 2018, LANCET GLOB HEALTH, V6, pE111, DOI [10.1016/S2214-109X(17)30453-9, 10.1016/s2214-109x(17)30453-9]
   Singh Susheela, 2018, ABORTION UNINTENDED
   Srivastava A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216738
   Srivastava Roli, 2020, REUTERS
   Tamang A, 2018, CONTRACEPTION, V97, P137, DOI 10.1016/j.contraception.2017.09.004
   The World Bank, 2018, RUR POP TOT POP DAT
   Warriner IK, 2011, LANCET, V377, P1155, DOI 10.1016/S0140-6736(10)62229-5
   WORLD HEALTH ORGANIZATION, 2017, HUM RIGHTS HLTH
   Zurbriggen R, 2018, CONTRACEPTION, V97, P108, DOI 10.1016/j.contraception.2017.07.170
NR 30
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0039-3665
EI 1728-4465
J9 STUD FAMILY PLANN
JI Stud. Fam. Plan.
DI 10.1111/sifp.12139
EA NOV 2020
PG 7
WC Demography; Public, Environmental & Occupational Health
SC Demography; Public, Environmental & Occupational Health
GA OI3ZN
UT WOS:000583221000001
PM 33135170
OA Bronze
DA 2021-01-01
ER

PT J
AU Bennani, NN
   Bennani-Baiti, IM
AF Bennani, N. N.
   Bennani-Baiti, I. M.
TI Androgen deprivation therapy may constitute a more effective COVID-19
   prophylactic than therapeutic strategy
SO ANNALS OF ONCOLOGY
LA English
DT Letter
C1 [Bennani, N. N.] Mayo Clin, Dept Med, Div Hematol, Rochester, MN USA.
   [Bennani, N. N.] Mayo Clin, Coll Med, Rochester, MN USA.
   [Bennani-Baiti, I. M.] Canc Epigenet Soc, Vienna, Austria.
RP Bennani-Baiti, IM (corresponding author), Canc Epigenet Soc, Vienna, Austria.
EM ibennani@b2sg.org
CR Baratchian Mehdi, 2020, bioRxiv, DOI 10.1101/2020.04.21.051201
   Furman D, 2014, P NATL ACAD SCI USA, V111, P869, DOI 10.1073/pnas.1321060111
   Goren A, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13365
   Leach DA, 2020, TMPRSS2 REQUIRED SAR, DOI [10.21203/rs.3.rs-34503/v1, DOI 10.21203/RS.3.RS-34503/V1]
   Mikkonen L, 2010, MOL CELL ENDOCRINOL, V317, P14, DOI 10.1016/j.mce.2009.12.022
   Montopoli M, 2020, ANN ONCOL, V31, P1040, DOI 10.1016/j.annonc.2020.04.479
   Polesso F, 2020, J IMMUNOL S1, V204
   The Human Protein Atlas, TMPRSS2 HUM PROT ATL
   The Human Protein Atlas. AR, HUM PROT ATL
NR 9
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD NOV
PY 2020
VL 31
IS 11
BP 1585
EP 1586
DI 10.1016/j.annonc.2020.08.2095
PG 3
WC Oncology
SC Oncology
GA OH5PO
UT WOS:000582637200023
PM 32822832
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zumerle, S
   Montopoli, M
   Rugge, M
   Alimonti, A
AF Zumerle, S.
   Montopoli, M.
   Rugge, M.
   Alimonti, A.
TI Reply to the Letter to the Editor "Androgen deprivation therapy may
   constitute a more effective prophylactic than therapeutic strategy in
   COVID-19 patients" by N. Bennani and I. M. Bennani-Baiti
SO ANNALS OF ONCOLOGY
LA English
DT Letter
C1 [Zumerle, S.; Rugge, M.; Alimonti, A.] Univ Padua, Dept Med, Padua, Italy.
   [Zumerle, S.; Montopoli, M.; Alimonti, A.] Fdn Ric Biomed Avanzata, VIMM Veneto Inst Mol Med, Padua, Italy.
   [Montopoli, M.] Univ Padua, Dept Pharmaceut & Pharmacol Sci, Padua, Italy.
   [Rugge, M.] Veneto Tumour Registry Azienda Zero, Padua, Italy.
   [Alimonti, A.] Univ Svizzera italiana, Oncol Res Inst, Oncol Inst Southern Switzerland, Bellinzona, Switzerland.
   [Alimonti, A.] Swiss Fed Inst Technol, Dept Hlth Sci & Technol, Zurich, Switzerland.
RP Alimonti, A (corresponding author), Univ Padua, Dept Med, Padua, Italy.; Alimonti, A (corresponding author), Fdn Ric Biomed Avanzata, VIMM Veneto Inst Mol Med, Padua, Italy.; Alimonti, A (corresponding author), Univ Svizzera italiana, Oncol Res Inst, Oncol Inst Southern Switzerland, Bellinzona, Switzerland.; Alimonti, A (corresponding author), Swiss Fed Inst Technol, Dept Hlth Sci & Technol, Zurich, Switzerland.
EM andrea.alimonti@ior.iosi.ch
FU European Research CouncilEuropean Research Council (ERC) [683136]; Swiss
   Cancer League [4267]; Swiss National Science Foundation [SNSF]Swiss
   National Science Foundation (SNSF) [176045]; Prostate Cancer Foundation
   [19CHAL08]; Italian Association for Cancer Research Investigator
   GrantAssociazione Italiana per la Ricerca sul Cancro (AIRC) [22030]
FX This work was supported by the following grants to AA: European Research
   Council Consolidator Grant [grant number 683136], Swiss Cancer League
   [grant number 4267], Swiss National Science Foundation [SNSF; grant
   number 176045], Prostate Cancer Foundation [grant number 19CHAL08], and
   Italian Association for Cancer Research Investigator Grant [grant number
   22030].
CR Baratchian Mehdi, 2020, bioRxiv, DOI 10.1101/2020.04.21.051201
   Barnes BJ, 2020, J EXP MED, V217, DOI 10.1084/jem.20200652
   Bennani NN, 2020, ANN ONCOL, V31, P1585, DOI 10.1016/j.annonc.2020.08.2095
   Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90
   Mikkonen L, 2010, MOL CELL ENDOCRINOL, V317, P14, DOI 10.1016/j.mce.2009.12.022
   Patel VG, 2020, ANN ONCOL, V31, P1419, DOI 10.1016/j.annonc.2020.06.023
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
NR 7
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD NOV
PY 2020
VL 31
IS 11
BP 1586
EP 1587
DI 10.1016/j.annonc.2020.07.023
PG 3
WC Oncology
SC Oncology
GA OH5PO
UT WOS:000582637200024
PM 33239192
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Giulia, B
   Patrizia, A
AF Giulia, Bardasi
   Patrizia, Alvisi
TI SARS-CoV-2 infection in severe pediatric Crohn's disease. What about
   anti-tumor necrosis factor a therapy?
SO DIGESTIVE AND LIVER DISEASE
LA English
DT Letter
C1 [Giulia, Bardasi] Univ Bologna, St Orsola Malpighi Hosp, Dept Pediat, Bologna, Italy.
   [Patrizia, Alvisi] Maggiore Hosp, Pediat Gastroenterol Unit, Bologna, Italy.
RP Patrizia, A (corresponding author), Maggiore Hosp, Pediat Gastroenterol Unit, Bologna, Italy.
EM patrizia.alvisi@ausl.bologna.it
CR Brenner EJ, SECURE IBD DATABASE
   Brenner EJ, 2020, GASTROENTEROLOGY
   Dolinger MT, 2020, J PEDIAT GASTROENTER
   Garazzino S, 2020, EURO SURVEILL, V25
   Kennedy NA, 2020, GUT, V69, P984, DOI 10.1136/gutjnl-2020-321244
   Loeffelholz MJ, 2020, EMERG MICROBES INFEC, V9, P747, DOI 10.1080/22221751.2020.1745095
   Norsa L, 2020, GASTROENTEROLOGY
   Turner D, 2020, J PEDIATR GASTR NUTR, V70, P727, DOI 10.1097/MPG.0000000000002729
   Zingone F, 2020, DIG LIVER DIS
NR 9
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1590-8658
EI 1878-3562
J9 DIGEST LIVER DIS
JI Dig. Liver Dis.
PD NOV
PY 2020
VL 52
IS 11
BP 1244
EP 1245
DI 10.1016/j.dld.2020.06.047
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA OH6KB
UT WOS:000582698800010
PM 32703727
OA Bronze
DA 2021-01-01
ER

PT J
AU Festa, S
   Aratari, A
   De Biasio, F
   Fasci-Spurio, F
   Papi, C
AF Festa, Stefano
   Aratari, Annalisa
   De Biasio, Fabiola
   Fasci-Spurio, Federica
   Papi, Claudio
TI Screening for active COVID-19 infection prior to biologic therapy in IBD
   patients: Let's not increase our uncertainty without reducing our
   concerns
SO DIGESTIVE AND LIVER DISEASE
LA English
DT Letter
ID INFLAMMATORY-BOWEL-DISEASE
C1 [Festa, Stefano; Aratari, Annalisa; De Biasio, Fabiola; Papi, Claudio] S Filippo Neri Hosp, IBD Unit, Rome, Italy.
   [Fasci-Spurio, Federica] DellAngelo Hosp, Gastroenterol Unit, Venice, Italy.
RP Festa, S (corresponding author), S Filippo Neri Hosp, IBD Unit, Rome, Italy.
EM festa.stefano@gmail.com
CR [Anonymous], IOIBD UPD COVID19 PA
   Bezzio C, 2020, GUT, V69, P1213, DOI 10.1136/gutjnl-2020-321411
   D'Amico F, 2020, GASTROENTEROLOGY, V159, P14, DOI 10.1053/j.gastro.2020.04.059
   Gutin LS, 2020, DIGEST DIS SCI, V65, P1571, DOI 10.1007/s10620-020-06299-y
   Hanzel J, 2020, CLIN GASTROENTEROL H, V18, P2143, DOI 10.1016/j.cgh.2020.04.033
   Monteleone G, 2020, J CROHNS COLITIS, V14, P1334, DOI 10.1093/ecco-jcc/jjaa061
   Zingone F, 2020, DIGEST LIVER DIS, V52, P604, DOI 10.1016/j.dld.2020.04.004
NR 7
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1590-8658
EI 1878-3562
J9 DIGEST LIVER DIS
JI Dig. Liver Dis.
PD NOV
PY 2020
VL 52
IS 11
BP 1246
EP 1247
DI 10.1016/j.dld.2020.05.037
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA OH6KB
UT WOS:000582698800011
PM 32527654
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Zingone, F
   Buda, A
   Savarino, E
AF Zingone, Fabiana
   Buda, Andrea
   Savarino, Edoardo
TI Reply to comment: Screening for active COVID-19 infection prior to
   biologic therapy in IBD patients: primum non nocere
SO DIGESTIVE AND LIVER DISEASE
LA English
DT Letter
C1 [Zingone, Fabiana; Savarino, Edoardo] Univ Padua, Gastroenterol Unit, Dept Surg Oncol & Gastroenterol Sci, Via Giustiniani 2, I-35128 Padua, Italy.
   [Buda, Andrea] S Maria Prato Hosp, Gastroenterol Unit, Dept Oncol Gastrointestinal Surg, Feltre, Italy.
RP Savarino, E (corresponding author), Univ Padua, Gastroenterol Unit, Dept Surg Oncol & Gastroenterol Sci, Via Giustiniani 2, I-35128 Padua, Italy.
EM edoardo.savarino@unipd.it
RI Zingone, Fabiana/O-5361-2018
OI Zingone, Fabiana/0000-0003-1133-1502; Buda, Andrea/0000-0002-3099-8612
CR Bezzio C, 2020, GUT, V69, P1213, DOI 10.1136/gutjnl-2020-321411
   Festa S, 2020, DIGEST LIVER DIS, V52, P1246, DOI 10.1016/j.dld.2020.05.037
   Kennedy NA, 2020, GUT, V69, P984, DOI 10.1136/gutjnl-2020-321244
   Lamb CA, 2019, GUT, V68, pS1, DOI 10.1136/gutjnl-2019-318484
   Lavezzo E, 2020, NATURE, V584, P425, DOI 10.1038/s41586-020-2488-1
   Lukin DJ, 2020, GASTROENTEROLOGY, V159, P1541, DOI 10.1053/j.gastro.2020.05.066
   Rubin DT, 2020, GASTROENTEROLOGY, V159, P350, DOI 10.1053/j.gastro.2020.04.012
   Zingone F, 2020, DIGEST LIVER DIS, V52, P604, DOI 10.1016/j.dld.2020.04.004
   Zingone Fabiana, 2020, J Crohns Colitis, DOI 10.1093/ecco-jcc/jjaa102
   Zingone F, 2020, LANCET GASTROENTEROL, V5, P525, DOI 10.1016/S2468-1253(20)30085-6
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1590-8658
EI 1878-3562
J9 DIGEST LIVER DIS
JI Dig. Liver Dis.
PD NOV
PY 2020
VL 52
IS 11
BP 1248
EP 1249
DI 10.1016/j.dld.2020.07.021
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA OH6KB
UT WOS:000582698800012
PM 32811778
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Prentice, RE
   Al-Ani, AH
   Bond, K
   Johnson, D
   Christensen, B
AF Prentice, Ralley E.
   Al-Ani, Aysha H.
   Bond, Katherine
   Johnson, Doug
   Christensen, Britt
TI Asymptomatic screening for SARS CoV-2 prior to commencement of biologic
   therapies in patients with inflammatory bowel disease - a potentially
   harmful practice
SO DIGESTIVE AND LIVER DISEASE
LA English
DT Letter
C1 [Prentice, Ralley E.; Al-Ani, Aysha H.; Christensen, Britt] Royal Melbourne Hosp, Dept Gastroenterol, Melbourne, Vic, Australia.
   [Bond, Katherine; Johnson, Doug] Royal Melbourne Hosp, Dept Infect Dis, Melbourne, Vic, Australia.
RP Christensen, B (corresponding author), Royal Melbourne Hosp, Dept Gastroenterol, Melbourne, Vic, Australia.
EM britt.christensen@mh.org.au
CR Allez M, 2020, J CROHNS COLITIS
   Barrameda R, 2020, PUBLIC HEALTH REP, V135, P785, DOI 10.1177/0033354920951140
   Bond K, 2020, J INFECT DIS
   Brenner EJ, 2020, GASTROENTEROLOGY
   Hayee BH, 2020, GUT
   Joint G, 2020, COVID 19 CLIN INSIGH, P15
   National center for immunization and respiratory diseases (NCIRD) dovd, INT GUID COVID 19 AN
   Rubin DT, 2020, GASTROENTEROLOGY, V159, P6, DOI 10.1053/j.gastro.2020.04.002
   Simon D, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17703-6
   Zingone F, 2020, DIGEST LIVER DIS, V52, P604, DOI 10.1016/j.dld.2020.04.004
NR 10
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1590-8658
EI 1878-3562
J9 DIGEST LIVER DIS
JI Dig. Liver Dis.
PD NOV
PY 2020
VL 52
IS 11
BP 1250
EP 1251
DI 10.1016/j.dld.2020.08.035
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA OH6KB
UT WOS:000582698800013
PM 32928674
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Zingone, F
   Buda, A
   Savarino, E
AF Zingone, Fabiana
   Buda, Andrea
   Savarino, Edoardo
TI Reply to comment: Asymptomatic screening for SARS COV-2 prior to
   commencement of biologic therapies in patients with inflammatory bowel
   disease - a potentially harmful practice
SO DIGESTIVE AND LIVER DISEASE
LA English
DT Letter
ID COVID-19; IBD
C1 [Zingone, Fabiana; Savarino, Edoardo] Univ Padua, Gastroenterol Unit, Dept Surg Oncol & Gastroenterol Sci, Padua, Italy.
   [Buda, Andrea] S Maria Prato Hosp, Gastroenterol Unit, Dept Oncol Gastrointestinal Surg, Feltre, Italy.
RP Savarino, E (corresponding author), Univ Padua, Gastroenterol Unit, Dept Surg Oncol & Gastroenterol Sci, Padua, Italy.
EM edoardo.savarino@unipd.it
RI ; Zingone, Fabiana/O-5361-2018
OI Buda, Andrea/0000-0002-3099-8612; Zingone, Fabiana/0000-0003-1133-1502
CR Bezzio C, 2020, GUT, V69, P1213, DOI 10.1136/gutjnl-2020-321411
   Brenner EJ, 2020, GASTROENTEROLOGY, V159, P481, DOI 10.1053/j.gastro.2020.05.032
   Magro F, 2020, J CROHNS COLITIS
   Prentice RE, 2020, DLD
   ZINGONE F, 2020, J CROHNS COLITIS, V19
   Zingone F, 2020, DIGEST LIVER DIS, V52, P604, DOI 10.1016/j.dld.2020.04.004
   Zingone F, 2020, LANCET GASTROENTEROL, V5, P525, DOI 10.1016/S2468-1253(20)30085-6
NR 7
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1590-8658
EI 1878-3562
J9 DIGEST LIVER DIS
JI Dig. Liver Dis.
PD NOV
PY 2020
VL 52
IS 11
BP 1252
EP 1253
DI 10.1016/j.dld.2020.09.020
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA OH6KB
UT WOS:000582698800014
PM 33051162
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Jena, A
   Singh, AK
   Kumar-M, P
   Sharma, V
   Sebastian, S
AF Jena, Anuraag
   Singh, Anupam Kumar
   Kumar-M, Praveen
   Sharma, Vishal
   Sebastian, Shaji
TI Systematic review on failure to adhere to IBD therapies during the
   COVID-19 pandemic: Correct information is crucial
SO DIGESTIVE AND LIVER DISEASE
LA English
DT Letter
C1 [Jena, Anuraag; Singh, Anupam Kumar; Sharma, Vishal] Postgrad Inst Med Educ & Res, Dept Gastroenterol, Chandigarh, India.
   [Kumar-M, Praveen] Postgrad Inst Med Educ & Res, Pharmacol, Chandigarh, India.
   [Sebastian, Shaji] Hull Univ Teaching Hosp NHS Trust, Kingston Upon Hull, N Humberside, England.
RP Sharma, V (corresponding author), Postgrad Inst Med Educ & Res, Dept Gastroenterol, Chandigarh, India.; Sebastian, S (corresponding author), Hull Univ Teaching Hosp NHS Trust, Kingston Upon Hull, N Humberside, England.
EM docvishalsharma@gmail.com; shaji.sebastian@hey.nhs.uk
RI ; Kumar-M, Praveen/V-5511-2019
OI Jena, Anuraag/0000-0001-9074-6698; Kumar-M, Praveen/0000-0002-9318-1167
CR An P, 2020, LANCET GASTROENTEROL, V5, P525, DOI 10.1016/S2468-1253(20)30121-7
   Danese S, 2020, NAT REV GASTRO HEPAT, V17, P253, DOI 10.1038/s41575-020-0294-8
   Marafini I, 2020, DIGEST LIVER DIS, V52, P1234, DOI 10.1016/j.dld.2020.06.007
   Occhipinti V, 2020, INFLAMM BOWEL DIS, V26, P793, DOI 10.1093/ibd/izaa084
   Rubin DT, 2020, GASTROENTEROLOGY, V159, P350, DOI 10.1053/j.gastro.2020.04.012
   Rubin DT, 2020, GASTROENTEROLOGY, V159, P6, DOI 10.1053/j.gastro.2020.04.002
   Tian WN, 2020, INFLAMM BOWEL DIS, V26, pE116, DOI 10.1093/ibd/izaa197
   Zhang YF, 2020, J GASTROEN HEPATOL, DOI 10.1111/jgh.15205
NR 8
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1590-8658
EI 1878-3562
J9 DIGEST LIVER DIS
JI Dig. Liver Dis.
PD NOV
PY 2020
VL 52
IS 11
BP 1254
EP 1256
DI 10.1016/j.dld.2020.09.012
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA OH6KB
UT WOS:000582698800015
PM 33011089
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU He, JL
   Huang, F
   Zhang, JH
   Chen, QW
   Zheng, ZW
   Zhou, Q
   Chen, DL
   Li, J
   Chen, JP
AF He, Jinlei
   Huang, Fan
   Zhang, Jianhui
   Chen, Qiwei
   Zheng, Zhiwan
   Zhou, Qi
   Chen, Dali
   Li, Jiao
   Chen, Jianping
TI Vaccine design based on 16 epitopes of SARS-CoV-2 spike protein
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE epitope; non&#8208; synonymous mutation; SARS&#8208; CoV&#8208; 2; spike
   protein; vaccine
ID SARS-CORONAVIRUS; IMMUNE-RESPONSES; PREDICTION; DIAGNOSTICS; PRINCIPLES;
   RESOURCE; COVERAGE
AB The global outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) urgently requires an effective vaccine for prevention. In this study, 66 epitopes containing pentapeptides of SARS-CoV-2 spike protein in the IEDB database were compared with the amino acid sequence of SARS-CoV-2 spike protein, and 66 potentially immune-related peptides of SARS-CoV-2 spike protein were obtained. Based on the single-nucleotide polymorphisms analysis of spike protein of 1218 SARS-CoV-2 isolates, 52 easily mutated sites were identified and used for vaccine epitope screening. The best vaccine candidate epitopes in the 66 peptides of SARS-CoV-2 spike protein were screened out through mutation and immunoinformatics analysis. The best candidate epitopes were connected by different linkers in silico to obtain vaccine candidate sequences. The results showed that 16 epitopes were relatively conservative, immunological, nontoxic, and nonallergenic, could induce the secretion of cytokines, and were more likely to be exposed on the surface of the spike protein. They were both B- and T-cell epitopes, and could recognize a certain number of HLA molecules and had high coverage rates in different populations. Moreover, epitopes 897-913 were predicted to have possible cross-immunoprotection for SARS-CoV and SARS-CoV-2. The results of vaccine candidate sequences screening suggested that sequences (without linker, with linker GGGSGGG, EAAAK, GPGPG, and KK, respectively) were the best. The proteins translated by these sequences were relatively stable, with a high antigenic index and good biological activity. Our study provided vaccine candidate epitopes and sequences for the research of the SARS-CoV-2 vaccine.
C1 [He, Jinlei; Zhang, Jianhui; Chen, Qiwei; Zheng, Zhiwan; Zhou, Qi; Chen, Dali; Li, Jiao; Chen, Jianping] Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Dept Pathogen Biol, Third Part South Renmin Rd, Chengdu 610041, Peoples R China.
   [Huang, Fan] Chengdu Shuangliu Hosp Tradit Chinese Med, Dept Surg 1, Chengdu, Peoples R China.
   [Chen, Jianping] Anim Dis Prevent & Food Safety Key Lab Sichuan Pr, Chengdu, Peoples R China.
RP Li, J; Chen, JP (corresponding author), Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Dept Pathogen Biol, Third Part South Renmin Rd, Chengdu 610041, Peoples R China.
EM joyleeql2019@163.com; jpchen007@163.com
OI CHEN, JIANPING/0000-0001-7617-2800
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31572240, 31802184, 31872959, 81672048];
   China Scholarship CouncilChina Scholarship Council [201706240018]
FX National Natural Science Foundation of China, Grant/Award Numbers:
   31572240, 31802184, 31872959, 81672048; China Scholarship Council,
   Grant/Award Number: 201706240018
CR Andreatta M, 2016, BIOINFORMATICS, V32, P511, DOI 10.1093/bioinformatics/btv639
   Bartlett BL, 2009, DERMATOL THER, V22, P104, DOI 10.1111/j.1529-8019.2009.01223.x
   Baruah V, 2020, J MED VIROL, V92, P495, DOI 10.1002/jmv.25698
   Buchholz UJ, 2004, P NATL ACAD SCI USA, V101, P9804, DOI 10.1073/pnas.0403492101
   Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153
   Burland T G, 2000, Methods Mol Biol, V132, P71
   Cai YF, 2020, SCIENCE, V369, P1586, DOI 10.1126/science.abd4251
   Chen XY, 2013, ADV DRUG DELIVER REV, V65, P1357, DOI 10.1016/j.addr.2012.09.039
   Choi YJ, 2013, PEERJ, V1, DOI 10.7717/peerj.1
   Deng HX, 2020, VACCINE, V38, P3671, DOI 10.1016/j.vaccine.2020.03.023
   Dhanda SK, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/263952
   Dhanda SK, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-30
   Dimitrov I, 2014, BIOINFORMATICS, V30, P846, DOI 10.1093/bioinformatics/btt619
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Ferretti AP, 2020, COVID 19 PATIENTS FO
   Forster R, 2012, J PHARMACOL TOX MET, V66, P1, DOI 10.1016/j.vascn.2012.04.003
   Francisco RD, 2015, IMMUNOGENETICS, V67, P651, DOI 10.1007/s00251-015-0875-9
   Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI DOI 10.1385/1-59259-890-0:571
   Guo JP, 2004, VIROLOGY, V324, P251, DOI 10.1016/j.virol.2004.04.017
   He JL, 2019, ACTA TROP, V191, P50, DOI 10.1016/j.actatropica.2018.12.035
   He YX, 2004, J IMMUNOL, V173, P4050, DOI 10.4049/jimmunol.173.6.4050
   Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346
   Kardani K, 2016, VACCINE, V34, P413, DOI 10.1016/j.vaccine.2015.11.062
   Karimzadeh H, 2019, GASTROENTEROLOGY, V156, P1820, DOI 10.1053/j.gastro.2019.02.003
   Kobinger GP, 2007, VACCINE, V25, P5220, DOI 10.1016/j.vaccine.2007.04.065
   Konstantinou GN, 2017, METHODS MOL BIOL, V1592, P211, DOI 10.1007/978-1-4939-6925-8_17
   Korber B, 2020, BIORXIV
   Lu S, 2009, CURR OPIN IMMUNOL, V21, P346, DOI 10.1016/j.coi.2009.05.016
   Lucchese G, 2020, CELL MOL IMMUNOL, V17, P539, DOI 10.1038/s41423-020-0377-z
   Magnusson SE, 2018, IMMUNOL RES, V66, P224, DOI 10.1007/s12026-018-8991-x
   Nagpal G, 2017, SCI REP-UK, V7, DOI 10.1038/srep42851
   Oyarzun P, 2016, HUM VACC IMMUNOTHER, V12, P763, DOI 10.1080/21645515.2015.1094595
   Reche PA, 2004, IMMUNOGENETICS, V56, P405, DOI 10.1007/s00251-004-0709-7
   Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078
   Schuler Mathias M., 2007, V409, P75
   Schulze K, 2008, VACCINE, V26, P6678, DOI 10.1016/j.vaccine.2008.09.006
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Vetter V, 2018, ANN MED, V50, P110, DOI 10.1080/07853890.2017.1407035
   Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Xu XJ, 2004, CELL MOL IMMUNOL, V1, P119
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yachdav G, 2014, NUCLEIC ACIDS RES, V42, pW337, DOI 10.1093/nar/gku366
   Yadav R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060785
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zepp F, 2016, METHODS MOL BIOL, V1403, P57, DOI 10.1007/978-1-4939-3387-7_3
   Zhang BZ, 2020, CELL RES, V30, P702, DOI 10.1038/s41422-020-0366-x
   Zheng W, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134835
NR 50
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26596
EA NOV 2020
PG 17
WC Virology
SC Virology
GA OI3RU
UT WOS:000583200900001
PM 33091154
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Yun, HE
   Ryu, BY
   Choe, YJ
AF Yun, Hyo Eun
   Ryu, Bo Young
   Choe, Young June
TI Impact of social distancing on incidence of vaccine-preventable
   diseases, South Korea
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE coronavirus; COVID&#8208; 19; social distancing; vaccine&#8208;
   preventable disease
ID COVID-19
AB While vaccination remains the cornerstone of controlling vaccine-preventive diseases (VPD), little is known about the effect of social distancing on incidence of VPDs. We investigated the impact of social distancing practiced during the coronavirus disease 2019 (COVID-19) pandemic on the incidence of selected VPDs in South Korea. National surveillance data on monthly incidence of hepatitis A, hepatitis B, varicella, mumps, invasive pneumococcal disease (IPD), and pertussis were retrieved and compared the VPD incidences in 2020 to the average of the last 4 years (2015-2019) of the corresponding months. In 2020, there were 44% decline for mumps, 44% decline for varicella, 28% decline for pertussis, 22% decline for IPD, 14% decline in incidence of hepatitis A, and no change for hepatitis B incidences, compared to baseline years (2015-2019). The largest decline of total VPDs was in April (65%) and in May (67%), during the intensified social distancing measures. In the setting of sustained vaccination coverage, social distancing may provide additional public health benefit in controlling the VPDs.
C1 [Yun, Hyo Eun; Choe, Young June] Hallym Univ, Coll Med, Dept Social & Prevent Med, 1 Hallymdaehak Gil, Chuncheon Si 24252, Gangwon Do, South Korea.
   [Ryu, Bo Young] Korea Dis Control & Prevent Agcy, Gyeongnam Reg Ctr Dis Control & Prevent, Div Infect Dis Response, Busan, South Korea.
RP Choe, YJ (corresponding author), Hallym Univ, Coll Med, Dept Social & Prevent Med, 1 Hallymdaehak Gil, Chuncheon Si 24252, Gangwon Do, South Korea.
EM ychoe@hallym.ac.kr
OI Choe, Young June/0000-0003-2733-0715
FU Hallym University Research Fund [HRF-201912-009]
FX Hallym University Research Fund, Grant/Award Number: HRF-201912-009
CR Cho EJ, 2017, CLIN MOL HEPATOL, V23, P205, DOI 10.3350/cmh.2017.0104
   Choe Young June, 2020, Osong Public Health Res Perspect, V11, P91, DOI 10.24171/j.phrp.2020.11.3.07
   Choe YJ, 2020, VACCINE, V38, P712, DOI 10.1016/j.vaccine.2019.11.048
   Choe YJ, 2015, J KOREAN MED SCI, V30, pS115, DOI 10.3346/jkms.2015.30.S2.S115
   Chu DK, 2020, LANCET, V395, P1973, DOI 10.1016/S0140-6736(20)31142-9
   Mutnal MB, 2020, J MED VIROL, V92, P2130, DOI 10.1002/jmv.26010
   Olsen SJ, 2020, MMWR-MORBID MORTAL W, V69, P1305, DOI 10.15585/mmwr.mm6937a6
   Park S, 2014, EPIDEMIOL HEALTH, V36, DOI 10.4178/epih/e2014030
   Wesseh C S, 2017, Public Health Action, V7, pS82, DOI 10.5588/pha.16.0104
NR 9
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26614
EA NOV 2020
PG 3
WC Virology
SC Virology
GA OI3RG
UT WOS:000583199500001
PM 33079384
OA Bronze
DA 2021-01-01
ER

PT J
AU Rolfo, C
   Cardona, AF
   Ruiz-Patino, A
   Ariza, S
   Zatarain-Barron, L
   Pino, LE
   Viola, L
   Russo, A
   Rojas, L
   Ricaurte, L
   Arrieta, O
AF Rolfo, Christian
   Cardona, Andres F.
   Ruiz-Patino, Alejandro
   Ariza, Santiago
   Zatarain-Barron, Lucia
   Pino, Luis E.
   Viola, Lucia
   Russo, Alessandro
   Rojas, Leonardo
   Ricaurte, Luisa
   Arrieta, Oscar
TI Atypical Skin Manifestations During Immune Checkpoint Blockage in
   Coronavirus Disease 2019-Infected Patients With Lung Cancer
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Article
DE Anti-PD-1 therapy; COVID-19; Lung cancer; Erythema multiforme;
   Urticarial; Vasculitis
AB A new coronavirus, named severe acute respiratory syn-drome-coronavirus-2 by the WHO, has rapidly spread around the world since its first reported case in late December of 2019 from Wuhan, the People's Republic of China. As of mid-April 2020, this virus has affected more than 180 countries and territories, infecting more than 1,650,000 individuals and causing over 100,000 deaths. With approximately 20 million new cases globally per year, cancer affects a substantial portion of the population. Individuals affected by cancer are more susceptible to infections owing to coexisting chronic diseases (cardiovascular, pulmonary, and diabetes), overall poor health status, and systemic immunosuppressive states caused by both cancer and the anticancer treatment. As a consequence, patients with malignancies, especially those with lung cancer who develop coronavirus disease 2019, experience more difficult outcomes. A recent multicenter study carried out by the Hubei Anti-Cancer Association has also documented that patients with lung cancer had an increased risk of death, intensive care unit requirement, risk of presenting severe or critical symptoms, and use of invasive mechanical ventilation. Here, we present two representative cases of patients with lung cancer and coronavirus disease 2019 without respiratory compromise and with atypical and severe skin manifestations-findings that could be influenced by the long-term use of anti- programmed cell death protein 1 antibody. (C) 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
C1 [Rolfo, Christian; Russo, Alessandro] Univ Maryland, Marlene & Stewart Comprehens Canc Ctr, Thorac Oncol Unit, Baltimore, MD 21201 USA.
   [Cardona, Andres F.; Ruiz-Patino, Alejandro; Rojas, Leonardo] Fdn Clin & Appl Canc Res FICMAC, Bogota, Colombia.
   [Cardona, Andres F.; Ruiz-Patino, Alejandro; Rojas, Leonardo] Univ Bosque, Mol Oncol & Biol Syst Res Grp FOX G, Bogota, Colombia.
   [Cardona, Andres F.; Rojas, Leonardo] Clin Country, Clin & Traslat Oncol Grp, Bogota, Colombia.
   [Ariza, Santiago] Clin Colsanitas, Dermatol Oncol Dept, Bogota, Colombia.
   [Zatarain-Barron, Lucia; Arrieta, Oscar] Inst Nacl Cancerol INCan, Thorac Oncol Unit, Mexico City, DF, Mexico.
   [Pino, Luis E.] Fdn Santa Fe Bogota, Carlos Ardila Lulle Canc Inst ICAL, Inst Oncol, Oncol Dept, Bogota, Colombia.
   [Viola, Lucia] Fdn Neumol Colombiana FNM, Thorac Oncol Unit, Bogota, Colombia.
   [Russo, Alessandro] AO Papardo, Med Oncol Unit, Messina, Italy.
   [Rojas, Leonardo] Clin Colsanitas, Clin Oncol Dept, Bogota, Colombia.
   [Ricaurte, Luisa] Mayo Clin, Pathol Dept, Rochester, MN USA.
RP Cardona, AF (corresponding author), Fdn Clin & Appl Canc Res FICMAC, Bogota, Colombia.; Cardona, AF (corresponding author), Univ Bosque, Mol Oncol & Biol Syst Res Grp FOX G, Bogota, Colombia.; Cardona, AF (corresponding author), Clin Country, Clin & Traslat Oncol Grp, Bogota, Colombia.
EM christian.rolfo@umm.edu
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Belum VR, 2016, EUR J CANCER, V60, P12, DOI 10.1016/j.ejca.2016.02.010
   Coomes EA, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2141
   Correia O, 2002, J AM ACAD DERMATOL, V47, P58, DOI 10.1067/mjd.2002.120473
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Casas CG, 2020, BRIT J DERMATOL, V183, P71, DOI 10.1111/bjd.19163
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Nunan D, COVID 19 SIGNS SYMPT
   Pierard-Franchimont C, 2011, ONCOL LETT, V2, P769, DOI 10.3892/ol.2011.352
   Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE212, DOI 10.1111/jdv.16387
   Sibaud V, 2016, CURR OPIN ONCOL, V28, P254, DOI 10.1097/CCO.0000000000000290
   Sidaway P, 2020, NAT REV CLIN ONCOL, DOI 10.1038/s41571-020-0366-2
   Stepaniuk P, 2018, ALLERGY ASTHMA CL IM, V14, DOI 10.1186/s13223-018-0310-5
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Weber JS, 2017, J CLIN ONCOL, V35, P785, DOI 10.1200/JCO.2015.66.1389
NR 17
TC 3
Z9 3
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD NOV
PY 2020
VL 15
IS 11
BP 1767
EP 1772
DI 10.1016/j.jtho.2020.06.019
PG 6
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA OH6UG
UT WOS:000582730500016
PM 32653627
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Brocato, RL
   Principe, LM
   Kim, RK
   Zeng, XK
   Williams, JA
   Liu, YN
   Li, R
   Smith, JM
   Golden, JW
   Gangemi, D
   Youssef, S
   Wang, ZD
   Glanville, J
   Hooper, JW
AF Brocato, Rebecca L.
   Principe, Lucia M.
   Kim, Robert K.
   Zeng, Xiankun
   Williams, Janice A.
   Liu, Yanan
   Li, Rong
   Smith, Jeffrey M.
   Golden, Joseph W.
   Gangemi, Dave
   Youssef, Sawsan
   Wang, Zhongde
   Glanville, Jacob
   Hooper, Jay W.
TI Disruption of Adaptive Immunity Enhances Disease in SARS-CoV-2-Infected
   Syrian Hamsters
SO JOURNAL OF VIROLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2; Syrian hamster; animal models; cyclophosphamide;
   disease; monoclonal antibody
AB Animal models recapitulating human COVID-19 disease, especially severe disease, are urgently needed to understand pathogenesis and to evaluate candidate vaccines and therapeutics. Here, we develop novel severe-disease animal models for COVID-19 involving disruption of adaptive immunity in Syrian hamsters. Cyclophosphamide (CyP) immunosuppressed or RAG2 knockout (KO) hamsters were exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the respiratory route. Both the CyP-treated and RAG2 KO hamsters developed clinical signs of disease that were more severe than those in immunocompetent hamsters, notably weight loss, viral loads, and fatality (RAG2 KO only). Disease was prolonged in transiently immunosuppressed hamsters and was uniformly lethal in RAG2 KO hamsters. We evaluated the protective efficacy of a neutralizing monoclonal antibody and found that pretreatment, even in immunosuppressed animals, limited infection. Our results suggest that functional B and/or T cells are not only important for the clearance of SARS-CoV-2 but also play an early role in protection from acute disease.
   IMPORTANCE Syrian hamsters are in use as a model of disease caused by SARS-CoV-2. Pathology is pronounced in the upper and lower respiratory tract, and disease signs and endpoints include weight loss and viral RNA and/or infectious virus in swabs and organs (e.g., lungs). However, a high dose of virus is needed to produce disease, and the disease resolves rapidly. Here, we demonstrate that immunosuppressed hamsters are susceptible to low doses of virus and develop more severe and prolonged disease. We demonstrate the efficacy of a novel neutralizing monoclonal antibody using the cyclophosphamide transient suppression model. Furthermore, we demonstrate that RAG2 knockout hamsters develop severe/fatal disease when exposed to SARS-CoV-2. These immunosuppressed hamster models provide researchers with new tools for evaluating therapies and vaccines and understanding COVID-19 pathogenesis.
C1 [Brocato, Rebecca L.; Principe, Lucia M.; Smith, Jeffrey M.; Golden, Joseph W.; Hooper, Jay W.] US Army Res Inst Infect Dis, Virol Div, Frederick, MD 21702 USA.
   [Kim, Robert K.; Zeng, Xiankun; Williams, Janice A.] US Army Res Inst Infect Dis, Pathol Div, Frederick, MD USA.
   [Liu, Yanan; Li, Rong; Wang, Zhongde] Utah State Univ, Dept Anim Dairy & Vet Sci, Logan, UT 84322 USA.
   [Gangemi, Dave; Youssef, Sawsan; Glanville, Jacob] Distributed Bio Inc, San Francisco, CA USA.
   [Gangemi, Dave; Youssef, Sawsan; Glanville, Jacob] Centivax Inc, San Francisco, CA USA.
RP Hooper, JW (corresponding author), US Army Res Inst Infect Dis, Virol Div, Frederick, MD 21702 USA.
EM jay.w.hooper.civ@mail.mil
OI Zeng, Xiankun (Kevin)/0000-0003-3526-8755; Golden,
   Joseph/0000-0002-9709-313X
FU Defense Health Program
FX We acknowledge the tireless efforts of the Comparative Medicine Division
   Histology Lab and Aerobiological Sciences technicians at USAMRIID. We
   thank Joshua Moore, Jimmy Fiallos, Steven Stephens, Leslie Klosterman,
   Lynda Miller, Jua Liu, April Babka, Neil Davis, and Dave Dyer for
   assistance with veterinary care, histology and molecular assays, and
   hematology. Additionally, we thank Brian Kearney, Kathleen Gibson, and
   the Unified Culture Collection for providing the virus. Funding was
   provided through the Defense Health Program. The opinions,
   interpretations, conclusions, and recommendations contained here are
   those of the authors and are not necessarily endorsed by the U.S.
   Department of Defense.
CR Boudewijns R, 2020, STAT2 SIGNALING DOUB, DOI [DOI 10.1101/2020.04.23.056838, 10.1101/2020.04.23.056838]
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Cohen J, 2020, SCIENCE, V368, P221, DOI 10.1126/science.368.6488.221
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Goldsmith CS, 2004, EMERG INFECT DIS, V10, P320, DOI 10.3201/eid1002.030913
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Hodge LM, 2001, INFECT IMMUN, V69, P2328, DOI 10.1128/IAI.69.4.2328-2338.2001
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Kim ES, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e142
   Kim Jeong-Min, 2020, Osong Public Health Res Perspect, V11, P3, DOI 10.24171/j.phrp.2020.11.1.02
   Liu J, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.139042
   Miao JX, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10050243
   Min CK, 2016, SCI REP-UK, V6, DOI 10.1038/srep25359
   National Research Council, 2011, GUIDE CARE USE LAB A
   Neuman BW, 2006, J VIROL, V80, P7918, DOI 10.1128/JVI.00645-06
   Rogers Thomas F, 2020, bioRxiv, DOI 10.1101/2020.05.11.088674
   Sahin A., 2020, EURASIAN J MED ONCOL, V4, P1, DOI DOI 10.14744/ejmo.2020.12220
   Schaecher SR, 2008, VIROLOGY, V380, P312, DOI 10.1016/j.virol.2008.07.026
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Vardhana SA, 2020, J EXP MED, V217, DOI 10.1084/jem.20200678
   Ward P, 2020, COVID 19 SARS COV 2
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Zhang XN, 2020, NATURE, V583, P437, DOI 10.1038/s41586-020-2355-0
NR 25
TC 0
Z9 0
U1 5
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD NOV
PY 2020
VL 94
IS 22
AR e01683-20
DI 10.1128/JVI.01683-20
PG 13
WC Virology
SC Virology
GA OH6TU
UT WOS:000582729300006
PM 32900822
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Froggatt, HM
   Heaton, BE
   Heaton, NS
AF Froggatt, Heather M.
   Heaton, Brook E.
   Heaton, Nicholas S.
TI Development of a Fluorescence-Based, High-Throughput SARS-CoV-2
   3CL(p)(ro) Reporter Assay
SO JOURNAL OF VIROLOGY
LA English
DT Article
DE antivirals; coronavirus; FlipGFP; protease; screening
ID SUBSTRATE-SPECIFICITY; 3C-LIKE PROTEASES; CORONAVIRUS; TRANSMISSION;
   INHIBITION
AB In late 2019, a human coronavirus, now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged, likely from a zoonotic reservoir. This virus causes COVID-19, has infected millions of people, and has led to hundreds of thousands of deaths across the globe. While the best interventions to control and ultimately stop the pandemic are prophylactic vaccines, antiviral therapeutics are important to limit morbidity and mortality in those already infected. At this time, only one FDA-approved anti-SARS-CoV-2 antiviral drug, remdesivir, is available, and unfortunately, its efficacy appears to be limited. Thus, the identification of new and efficacious antivirals is of the highest importance. In order to facilitate rapid drug discovery, flexible, sensitive, and high-throughput screening methods are required. With respect to drug targets, most attention is focused on either the viral RNA-dependent RNA polymerase or the main viral protease, 3CL(p)(ro). 3CL(p)(ro) is an attractive target for antiviral therapeutics, as it is essential for processing newly translated viral proteins and the viral life cycle cannot be completed without protease activity. In this work, we report a new assay to identify inhibitors of 3CL(p)(ro). Our reporter is based on a green fluorescent protein (GFP)-derived protein that fluoresces only after cleavage by 3CL(p)(ro). This experimentally optimized reporter assay allows for antiviral drug screening in human cell culture at biosafety level 2 (BSL2) with high-throughput compatible protocols. Using this screening approach in combination with existing drug libraries may lead to the rapid identification of novel antivirals to suppress SARS-CoV-2 replication and spread.
   IMPORTANCE The COVID-19 pandemic has already led to more than 700,000 deaths and innumerable changes to daily life worldwide. Along with development of a vaccine, identification of effective antivirals to treat infected patients is of the highest importance. However, rapid drug discovery requires efficient methods to identify novel compounds that can inhibit the virus. In this work, we present a method for identifying inhibitors of the SARS-CoV-2 main protease, 3CL(p)(ro). This reporter-based assay allows for antiviral drug screening in human cell culture at biosafety level 2 (BSL2) with high-throughput compatible sample processing and analysis. This assay may help identify novel antivirals to control the COVID-19 pandemic.
C1 [Froggatt, Heather M.; Heaton, Brook E.; Heaton, Nicholas S.] Duke Univ, Sch Med, Dept Mol Genet & Microbiol, Durham, NC 27708 USA.
RP Heaton, NS (corresponding author), Duke Univ, Sch Med, Dept Mol Genet & Microbiol, Durham, NC 27708 USA.
EM nicholas.heaton@duke.edu
OI Heaton, Nicholas/0000-0002-5307-3428
FU Defense Advanced Research Projects Agency's (DARPA) PReemptive
   Expression of Protective Alleles and Response Elements (PREPARE) program
   [HR00111920008]; National Institutes of Health, National Institute of
   Allergy and Infectious DiseasesUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [UC6-AI058607]
FX N.S.H. is partially funded by the Defense Advanced Research Projects
   Agency's (DARPA) PReemptive Expression of Protective Alleles and
   Response Elements (PREPARE) program (cooperative agreement number
   HR00111920008). The views, opinions, and/or findings expressed are those
   of the authors and should not be interpreted as representing the
   official views or policies of the U.S. government. The following reagent
   was deposited by the Centers for Disease Control and Prevention and
   obtained through BEI Resources, NIAID, NIH: SARS-related coronavirus 2,
   isolate USA-WA1/2020, NR-52281. Biocontainment work was performed in the
   Duke Regional Biocontainment Laboratory, which received partial support
   for construction from the National Institutes of Health, National
   Institute of Allergy and Infectious Diseases (UC6-AI058607). We thank
   Clare Smith for help establishing SARS-CoV-2 infection assays at BSL3
   and Laura Froggatt for designing the FlipGFP diagram. Duke University
   may file for intellectual property protection for the technology
   described in this report.
CR Blanchard JE, 2004, CHEM BIOL, V11, P1445, DOI 10.1016/j.chembiol.2004.08.011
   Brister JR, 2015, NUCLEIC ACIDS RES, V43, pD571, DOI 10.1093/nar/gku1207
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Chu DK, 2020, LANCET, V395, P1973, DOI 10.1016/S0140-6736(20)31142-9
   Chuck CP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027228
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Deng X, 2014, J VIROL, V88, P11886, DOI 10.1128/JVI.01528-14
   Fan KQ, 2005, BIOCHEM BIOPH RES CO, V329, P934, DOI 10.1016/j.bbrc.2005.02.061
   Fan KQ, 2004, J BIOL CHEM, V279, P1637, DOI 10.1074/jbc.M310875200
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   John's Hopkins Coronavirus Resource Center, 2020, COVID 19 MAP
   Kiemer L, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-72
   Kilianski A, 2013, J VIROL, V87, P11955, DOI 10.1128/JVI.02105-13
   Kim Y, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005531
   Kim Y, 2012, J VIROL, V86, P11754, DOI 10.1128/JVI.01348-12
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Ma CL, 2020, CELL RES, V30, P678, DOI 10.1038/s41422-020-0356-z
   Nutho B, 2020, BIOCHEMISTRY-US, V59, P1769, DOI 10.1021/acs.biochem.0c00160
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Stobart CC, 2013, J VIROL, V87, P12611, DOI 10.1128/JVI.02050-13
   Tse LV, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00658
   Vuong W, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18096-2
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang Q, 2019, J AM CHEM SOC, V141, P4526, DOI 10.1021/jacs.8b13042
   Zhou JW, 2019, FASEB J, V33, P14575, DOI 10.1096/fj.201901624RR
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 34
TC 0
Z9 0
U1 6
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD NOV
PY 2020
VL 94
IS 22
AR e01265-20
DI 10.1128/JVI.01265-20
PG 9
WC Virology
SC Virology
GA OH6TU
UT WOS:000582729300009
PM 32843534
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Gentry, CA
   Humphrey, MB
   Thind, SK
   Hendrickson, SC
   Kurdgelashvili, G
   Williams, RJ
AF Gentry, Chris A.
   Humphrey, Mary Beth
   Thind, Sharanjeet K.
   Hendrickson, Sage C.
   Kurdgelashvili, George
   Williams, Riley J., II
TI Long-term hydroxychloroquine use in patients with rheumatic conditions
   and development of SARS-CoV-2 infection: a retrospective cohort study
SO LANCET RHEUMATOLOGY
LA English
DT Article
AB Background Hydroxychloroquine is one of several agents being evaluated in the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We aimed to examine whether patients with rheumatological conditions receiving chronic hydroxychloroquine therapy are at less risk of developing SARS-CoV-2 infection than those not receiving hydroxychloroquine.
   Methods This retrospective cohort study included de-identified information of all veterans in the US Veterans Health Administration clinical administrative database aged 18 years or older with rheumatoid arthritis, systemic lupus erythematosus, or associated rheumatological conditions (based on International Classification of Diseases, 10th edition, diagnostic codes) who were alive on March 1, 2020. A propensity score was calculated for each patient, and each patient who was receiving hydroxychloroquine was matched to two patients who were not receiving hydroxychloroquine (controls). The primary endpoint was the proportion of patients with PCR-confirmed SARS-CoV-2 infection among those receiving chronic hydroxychloroquine versus the propensity-matched patients not receiving chronic hydroxychloroquine between March 1 and June 30, 2020. Secondary outcomes were hospital admission associated with SARS-CoV-2 infection; intensive care requirement associated with SARS-CoV-2 infection; mortality associated with SARS-CoV-2 infection; and overall rates of any hospital admission and mortality (ie, all cause). Multivariate logistic regression analysis was done to determine independent variables for the development of active SARS-CoV-2 infection.
   Findings Between March 1 and June 30, 2020, 10 703 patients receiving hydroxychloroquine and 21 406 patients not receiving hydroxychloroquine were included in the primary analysis. The incidence of active SARS-CoV-2 infections during the study period did not differ between patients receiving hydroxychloroquine and patients not receiving hydroxychloroquine (31 [0.3%] of 10 703 vs 78 [0.4%] of 21 406; odds ratio 0.79, 95% CI 0.52-1.20, p=0.27). There were no significant differences in secondary outcomes between the two groups in patients who developed active SARS-CoV-2 infection. For all patients in the study, overall mortality was lower in the hydroxychloroquine group than in the group of patients who did not receive hydroxychloroquine (odds ratio 0.70, 95% CI 0.55-0.89, p=0.0031). In multivariate logistic regression analysis, receipt of hydroxychloroquine was not associated with the development of active SARS-CoV-2 infection (odds ratio 0.79, 95% CI 0.51-1.42).
   Interpretation Hydroxychloroquine was not associated with a preventive effect against SARS-CoV-2 infection in a large group of patients with rheumatological conditions. Copyright (c) 2020 Elsevier Ltd. All rights reserved.
C1 [Gentry, Chris A.; Hendrickson, Sage C.; Williams, Riley J., II] Oklahoma City Vet Affairs Healthcare Syst, Med Serv, Pharm Serv, Oklahoma City, OK 73104 USA.
   [Humphrey, Mary Beth] Oklahoma City Vet Affairs Healthcare Syst, Sect Rheumatol Immunol, Med Serv, Oklahoma City, OK 73104 USA.
   [Thind, Sharanjeet K.; Kurdgelashvili, George] Oklahoma City Vet Affairs Healthcare Syst, Sect Infect Dis, Med Serv, Oklahoma City, OK 73104 USA.
   [Humphrey, Mary Beth] Univ Oklahoma, Hlth Sci Ctr, Sect Rheumatol Immunol, Dept Med, Oklahoma City, OK USA.
   [Thind, Sharanjeet K.; Kurdgelashvili, George] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Sect Infect Dis, Oklahoma City, OK USA.
RP Gentry, CA (corresponding author), Oklahoma City Vet Affairs Healthcare Syst, Pharm Serv, Oklahoma City, OK 73104 USA.
EM chris.gentry@va.gov
CR Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Chu CM, 2004, CAN MED ASSOC J, V171, P1349, DOI 10.1503/cmaj.1040398
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gendelman O, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102566
   Hernandez AV, 2020, ANN INTERN MED, V173, P287, DOI 10.7326/M20-2496
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Mahevas M, 2020, NO EVIDENCE CLIN EFF, P369, DOI [10.1101/2020.04.10.20060699, DOI 10.1101/2020.04.10.20060699]
   National Center for Veterans Analysis and Statistics, 2016, DEP VET AFF STAT GLA
   Paton NI, 2012, JAMA-J AM MED ASSOC, V308, P353, DOI 10.1001/jama.2012.6936
   Raebel MA, 2013, MED CARE, V51, pS11, DOI 10.1097/MLR.0b013e31829b1d2a
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Singh AK, 2020, DIABETES METAB SYND, V14, P589, DOI 10.1016/j.dsx.2020.05.017
   Singh JA, 2016, ARTHRIT CARE RES, V68, P1, DOI 10.1002/acr.22783
   SPERBER K, 1993, J RHEUMATOL, V20, P803
   US Department of Veterans Affairs, DEP VET AFF COVID 19
   Wang LS, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105948
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yazdany J, 2020, ANN INTERN MED, V172, P754, DOI 10.7326/M20-1334
NR 26
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2665-9913
J9 LANCET RHEUMATOL
JI Lancet Rheumatol.
PD NOV
PY 2020
VL 2
IS 11
BP E689
EP E697
DI 10.1016/S2665-9913(20)30305-2
PG 9
WC Rheumatology
SC Rheumatology
GA OH4EI
UT WOS:000582523300023
PM 32984847
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Lane, JCE
   Weaver, J
   Kostka, K
   Duarte-Salles, T
   Abrahao, MTF
   Alghoul, H
   Alser, O
   Alshammari, TM
   Biedermann, P
   Banda, JM
   Burn, E
   Casajust, P
   Conover, MM
   Culhane, AC
   Davydov, A
   DuVall, SL
   Dymshyts, D
   Fernandez-Bertolin, S
   Fister, K
   Hardin, J
   Hester, L
   Hripcsak, G
   Kaas-Hansen, BS
   Kent, S
   Khosla, S
   Kolovos, S
   Lambert, CG
   van der Lei, J
   Lynch, KE
   Makadia, R
   Margulis, AV
   Matheny, ME
   Mehta, P
   Morales, DR
   Morgan-Stewart, H
   Mosseveld, M
   Newby, D
   Nyberg, F
   Ostropolets, A
   Park, RW
   Prats-Uribe, A
   Rao, GA
   Reich, C
   Reps, J
   Rijnbeek, P
   Sathappan, SMK
   Schuemie, M
   Seager, S
   Sena, AG
   Shoaibi, A
   Spotnitz, M
   Suchard, MA
   Torre, CO
   Vizcaya, D
   Wen, HN
   de Wilde, M
   Xie, JQ
   You, SC
   Zhang, L
   Zhuk, O
   Ryan, P
   Prieto-Alhambra, D
AF Lane, Jennifer C. E.
   Weaver, James
   Kostka, Kristin
   Duarte-Salles, Talita
   Abrahao, Maria Tereza F.
   Alghoul, Heba
   Alser, Osaid
   Alshammari, Thamir M.
   Biedermann, Patricia
   Banda, Juan M.
   Burn, Edward
   Casajust, Paula
   Conover, Mitchell M.
   Culhane, Aedin C.
   Davydov, Alexander
   DuVall, Scott L.
   Dymshyts, Dmitry
   Fernandez-Bertolin, Sergio
   Fister, Kristina
   Hardin, Jill
   Hester, Laura
   Hripcsak, George
   Kaas-Hansen, Benjamin Skov
   Kent, Seamus
   Khosla, Sajan
   Kolovos, Spyros
   Lambert, Christophe G.
   van der Lei, Johan
   Lynch, Kristine E.
   Makadia, Rupa
   Margulis, Andrea, V
   Matheny, Michael E.
   Mehta, Paras
   Morales, Daniel R.
   Morgan-Stewart, Henry
   Mosseveld, Mees
   Newby, Danielle
   Nyberg, Fredrik
   Ostropolets, Anna
   Park, Rae Woong
   Prats-Uribe, Albert
   Rao, Gowtham A.
   Reich, Christian
   Reps, Jenna
   Rijnbeek, Peter
   Sathappan, Selva Muthu Kumaran
   Schuemie, Martijn
   Seager, Sarah
   Sena, Anthony G.
   Shoaibi, Azza
   Spotnitz, Matthew
   Suchard, Marc A.
   Torre, Carmen O.
   Vizcaya, David
   Wen, Haini
   de Wilde, Marcel
   Xie, Junqing
   You, Seng Chan
   Zhang, Lin
   Zhuk, Oleg
   Ryan, Patrick
   Prieto-Alhambra, Daniel
CA OHDSI-COVID-19 Consortium
TI Risk of hydroxychloroquine alone and in combination with azithromycin in
   the treatment of rheumatoid arthritis: a multinational, retrospective
   study
SO LANCET RHEUMATOLOGY
LA English
DT Article
ID CHLOROQUINE; DRUG
AB Background Hydroxychloroquine, a drug commonly used in the treatment of rheumatoid arthritis, has received much negative publicity for adverse events associated with its authorisation for emergency use to treat patients with COVID-19 pneumonia. We studied the safety of hydroxychloroquine, alone and in combination with azithromycin, to determine the risk associated with its use in routine care in patients with rheumatoid arthritis.
   Methods In this multinational, retrospective study, new user cohort studies in patients with rheumatoid arthritis aged 18 years or older and initiating hydroxychloroquine were compared with those initiating sulfasalazine and followed up over 30 days, with 16 severe adverse events studied. Self-controlled case series were done to further establish safety in wider populations, and included all users of hydroxychloroquine regardless of rheumatoid arthritis status or indication. Separately, severe adverse events associated with hydroxychloroquine plus azithromycin (compared with hydroxychloroquine plus amoxicillin) were studied. Data comprised 14 sources of claims data or electronic medical records from Germany, Japan, the Netherlands, Spain, the UK, and the USA. Propensity score stratification and calibration using negative control outcomes were used to address confounding. Cox models were fitted to estimate calibrated hazard ratios (HRs) according to drug use. Estimates were pooled where the I-2 value was less than 0.4.
   Findings The study included 956 374 users of hydroxychloroquine, 310 350 users of sulfasalazine, 323 122 users of hydroxychloroquine plus azithromycin, and 351 956 users of hydroxychloroquine plus amoxicillin. No excess risk of severe adverse events was identified when 30-day hydroxychloroquine and sulfasalazine use were compared. Selfcontrolled case series confirmed these findings. However, long-term use of hydroxychloroquine appeared to be associated with increased cardiovascular mortality (calibrated HR 1.65 [95% CI 1.12-2.44]). Addition of azithromycin appeared to be associated with an increased risk of 30-day cardiovascular mortality (calibrated HR 2.19 [95% CI 1.22-3.95]), chest pain or angina (1.15 [1.05-1.26]), and heart failure (1.22 [1.02-1.45]).
   Interpretation Hydroxychloroquine treatment appears to have no increased risk in the short term among patients with rheumatoid arthritis, but in the long term it appears to be associated with excess cardiovascular mortality. The addition of azithromycin increases the risk of heart failure and cardiovascular mortality even in the short term. We call for careful consideration of the benefit-risk trade-off when counselling those on hydroxychloroquine treatment. Copyright (c) 2020 The Author(s). Published by Elsevier Ltd.
C1 [Lane, Jennifer C. E.; Burn, Edward; Kolovos, Spyros; Prats-Uribe, Albert; Xie, Junqing; Prieto-Alhambra, Daniel] Univ Oxford, Ctr Stat Med, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England.
   [Weaver, James; Conover, Mitchell M.; Hardin, Jill; Hester, Laura; Makadia, Rupa; Rao, Gowtham A.; Reps, Jenna; Schuemie, Martijn; Sena, Anthony G.; Shoaibi, Azza; Ryan, Patrick] Janssen Res & Dev, Titusville, NJ 08560 USA.
   [Kostka, Kristin; Morgan-Stewart, Henry; Reich, Christian; Seager, Sarah; Torre, Carmen O.] IQVIA, Real World Solut, Cambridge, MA USA.
   [Duarte-Salles, Talita; Burn, Edward; Fernandez-Bertolin, Sergio; Prieto-Alhambra, Daniel] Fundacio Inst Univ Recerca Atencio Primaria Salut, Barcelona, Spain.
   [Abrahao, Maria Tereza F.] Univ Sao Paulo, Fac Med, Sao Paulo, SP, Brazil.
   [Alghoul, Heba] Islamic Univ Gaza, Fac Med, Gaza, Palestine.
   [Alser, Osaid] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA.
   [Alshammari, Thamir M.] King Saud Univ, Medicat Safety Res Chair, Riyadh, Saudi Arabia.
   [Biedermann, Patricia] Actelion Pharmaceut, Allschwil, Switzerland.
   [Banda, Juan M.] Georgia State Univ, Dept Comp Sci, Atlanta, GA 30303 USA.
   [Casajust, Paula] Trial Form Support, Real World Evidence, Barcelona, Spain.
   [Culhane, Aedin C.] Harvard TH Chan Sch Publ Hlth, Dana Farber Canc Inst, Dept Data Sci, Dept Biostat, Boston, MA USA.
   [Davydov, Alexander; Dymshyts, Dmitry; Zhuk, Oleg] Odysseus Data Serv, Med Ontol Solut, Cambridge, MA USA.
   [DuVall, Scott L.; Lynch, Kristine E.] Dept Vet Affairs, Western Inst Biomed Res, Salt Lake City, UT USA.
   [DuVall, Scott L.; Lynch, Kristine E.] Univ Utah, Sch Med, Dept Internal Med, Div Epidemiol, Salt Lake City, UT USA.
   [Fister, Kristina] Univ Zagreb, Sch Med, Andrija Stampar Sch Publ Hlth, Zagreb, Croatia.
   [Hripcsak, George; Ostropolets, Anna; Spotnitz, Matthew; Ryan, Patrick] Columbia Univ, Dept Biomed Informat, Irving Med Ctr, New York, NY USA.
   [Hripcsak, George] New York Presbyterian Hosp, New York, NY USA.
   [Kaas-Hansen, Benjamin Skov] Zealand Univ Hosp, Clin Pharmacol Unit, Roskilde, Denmark.
   [Kaas-Hansen, Benjamin Skov] Univ Copenhagen, NNF Ctr Prot Res, Copenhagen, Denmark.
   [Kent, Seamus] Natl Inst Hlth & Care Excellence, London, England.
   [Khosla, Sajan] AstraZeneca, Real World Sci & Digital, Cambridge, England.
   [Lambert, Christophe G.] Ctr Global Hlth, Dept Internal Med, Albuquerque, NM USA.
   [Lambert, Christophe G.] Div Translat Informat, Albuquerque, NM USA.
   [van der Lei, Johan; Mosseveld, Mees; Rijnbeek, Peter; Sena, Anthony G.; de Wilde, Marcel] Erasmus MC, Dept Med Informat, Rotterdam, Netherlands.
   [Margulis, Andrea, V] RTI Hlth Solut, Barcelona, Spain.
   [Matheny, Michael E.] Tennessee Valley Healthcare Syst VA, Geriatr Res Educ & Clin Care Ctr, Nashville, TN USA.
   [Matheny, Michael E.] Vanderbilt Univ, Dept Biomed Informat, Med Ctr, Nashville, TN USA.
   [Mehta, Paras] Univ Arizona, Coll Med, Tucson, AZ USA.
   [Morales, Daniel R.] Univ Dundee, Div Populat Hlth & Genom, Dundee, Scotland.
   [Newby, Danielle] Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford, England.
   [Nyberg, Fredrik] Univ Gothenburg, Sahlgrenska Acad, Sch Publ Hlth & Community Med, Inst Med, Gothenburg, Sweden.
   [Park, Rae Woong; You, Seng Chan] Ajou Univ, Dept Biomed Informat, Sch Med, Suwon, Gyeonggi Do, South Korea.
   [Sathappan, Selva Muthu Kumaran] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore.
   [Suchard, Marc A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, Los Angeles, CA 90095 USA.
   [Vizcaya, David] Bayer Pharmaceut, Barcelona, Spain.
   [Wen, Haini] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pharm, Shanghai, Peoples R China.
   [Zhang, Lin] Peking Union Med Coll Chinese Acad Med Sci, Sch Populat Med & Publ Hlth, Beijing, Peoples R China.
   [Zhang, Lin] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia.
RP Ryan, P (corresponding author), Janssen Res & Dev, Titusville, NJ 08560 USA.
EM ryan@ohdsi.org
RI Alser, Osaid/P-5509-2017; Culhane, Aedin/AAG-8490-2019; Margulis,
   Andrea/G-2833-2013
OI Alser, Osaid/0000-0001-6743-803X; Culhane, Aedin/0000-0002-1395-9734;
   Margulis, Andrea/0000-0001-7388-6082; Banda, Juan/0000-0001-8499-824X;
   Prats Uribe, Albert/0000-0003-1202-9153; Casajust,
   Paula/0000-0003-2733-5436; Matheny, Michael/0000-0003-3217-4147;
   Abrahao, Maria Tereza Fernandes/0000-0003-2701-670X; zhang,
   lin/0000-0002-2064-8440; Kaas-Hansen, Benjamin Skov/0000-0003-1023-0371;
   Burn, Edward/0000-0002-9286-1128
FU UK National Institute for Health Research (NIHR) Oxford Biomedical
   Research CentreNational Institute for Health Research (NIHR); Korea
   Health Industry Development Institute - Korean Ministry of Health and
   Welfare [HI16C0992]; UK Medical Research Council (MRC) Doctoral Training
   Partnership [MR/K501256/1]; MRCMedical Research Council UK (MRC)
   [MR/K501256/1, MR/N013468/1]; Fundacion Alfonso Martin Escudero;
   Innovation Fund Denmark [5153-00002B]; Novo Nordisk FoundationNovo
   Nordisk Foundation [NNF14CC0001]; Singapore Ministry of Health's
   National Medical Research Council Open Fund Large Collaborative Grant
   [NMRC/OFLCG/001/2017]; NIHR Senior Research Fellowship
   [SRF-2018-11-ST2-004]; Innovative Medicines Initiative 2 Joint
   Undertaking [806968]; EUEuropean Union (EU); European Federation of
   Pharmaceutical Industries and Associations; US National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA; Janssen Research and Development;
   IQVIA; Versus ArthritisVersus Arthritis [21605]; VINCI [VA HSR RES
   13-457]; US Department of Veterans AffairsUS Department of Veterans
   Affairs
FX This research received partial support from the UK National Institute
   for Health Research (NIHR) Oxford Biomedical Research Centre, US
   National Institutes of Health, US Department of Veterans Affairs,
   Janssen Research and Development, IQVIA, and by a grant from the Korea
   Health Technology R&D Project through the Korea Health Industry
   Development Institute, funded by the Korean Ministry of Health and
   Welfare (grant number HI16C0992 to SCY). Personal funding was provided
   by Versus Arthritis (21605; to JCEL), UK Medical Research Council (MRC)
   Doctoral Training Partnership (MR/K501256/1; to JCEL); MRC (MR/K501256/1
   and MR/N013468/1; to AP-U) and Fundacion Alfonso Martin Escudero (to
   AP-U); Innovation Fund Denmark (5153-00002B) and the Novo Nordisk
   Foundation (NNF14CC0001; to BSK-H); Singapore Ministry of Health's
   National Medical Research Council Open Fund Large Collaborative Grant
   (NMRC/OFLCG/001/2017; to SMKS); VINCI (VA HSR RES 13-457; to SLD, MEM,
   and KEL); and NIHR Senior Research Fellowship (SRF-2018-11-ST2-004 to
   DP-A). The European Health Data and Evidence Network has received
   funding from the Innovative Medicines Initiative 2 Joint Undertaking
   under grant agreement number 806968. The Innovative Medicines Initiative
   2 Joint Undertaking receives support from the EU's Horizon 2020 research
   and innovation programme and European Federation of Pharmaceutical
   Industries and Associations. The views and opinions expressed are those
   of the authors and do not necessarily reflect those of the NIHR senior
   Research Fellowship programme, NIHR, US Department of Veterans Affairs,
   or the US Government, UK National Health Service, or the UK Department
   of Health. We thank Catherine Hartley and Eli Harriss (Bodleian Health
   Care Libraries, University of Oxford, Oxford, UK), Runsheng Wang
   (Division of Rheumatology, Columbia University Irving Medical Center,
   New York, NY, USA), Joel Swerdel (Janssen Research and Development,
   Titusville, NJ, USA), Zeshan Ghory (IQVIA, Cambridge, MA, USA), Michael
   Kallfelz (Odysseus Data Services, Berlin, Germany), and Nigel Hughes
   (Janssen Research and Development, Beerse, Belgium). Finally, we
   acknowledge the tremendous work and dedication of the 350 participants
   from 30 nations in the March, 2020, Observational Health Data Sciences
   and Informatics COVID-19 Virtual Study-a-thon, without whom this study
   could not have been realised.
CR Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Chatre C, 2018, DRUG SAFETY, V41, P919, DOI 10.1007/s40264-018-0689-4
   Chen YM, 2015, RHEUMATOLOGY, V54, P1244, DOI 10.1093/rheumatology/keu451
   Chorin E, 2020, NAT MED, V26, P808, DOI 10.1038/s41591-020-0888-2
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Costello R, 2019, CLIN THER, V41, P1376, DOI 10.1016/j.clinthera.2019.04.030
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Guo DH, 2010, PHARMAZIE, V65, P631, DOI 10.1691/ph.2010.0644
   HOFSCHNEIDER PH, 1992, RHEUMATOL INT, V12, P175, DOI 10.1007/BF00302149
   Lu ZK, 2015, EXPERT OPIN DRUG SAF, V14, P295, DOI 10.1517/14740338.2015.989210
   Luo M., 2020, HER MED, V39, P505, DOI [10.3870/j.issn.1004-0781.2020.04.014, DOI 10.3870/j.issn.1004-0781.2020.04.014]
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMoa1003833
   RECOVERY, 2020, STAT CHIEF INV RAND
   Roden DM, 2020, CIRCULATION, V141, pE906, DOI 10.1161/CIRCULATIONAHA.120.047521
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Schuemie MJ, 2016, STAT MED, V35, P3883, DOI 10.1002/sim.6977
   Schuemie MJ, 2014, STAT MED, V33, P209, DOI 10.1002/sim.5925
   Sepriano A, 2020, ANN RHEUM DIS, V79, P760, DOI 10.1136/annrheumdis-2019-216653
   Shinjo SK, 2010, ARTHRITIS RHEUM-US, V62, P855, DOI 10.1002/art.27300
   Simpson SE, 2013, BIOMETRICS, V69, P893, DOI 10.1111/biom.12078
   Suchard MA, 2019, LANCET, V394, P1816, DOI 10.1016/S0140-6736(19)32317-7
   Suchard MA, 2013, ACM T MODEL COMPUT S, V23, DOI 10.1145/2414416.2414791
   Tian YX, 2018, INT J EPIDEMIOL, V47, P2005, DOI 10.1093/ije/dyy120
   Tselios K, 2018, LUPUS, V27, P591, DOI 10.1177/0961203317734922
   US Food and Drug Administration, 2020, FDA REV EM US AUTH C
   Vigerust DJ, 2007, TRENDS MICROBIOL, V15, P211, DOI 10.1016/j.tim.2007.03.003
   Voss EA, 2017, J BIOMED INFORM, V66, P72, DOI 10.1016/j.jbi.2016.12.005
   Wallace DJ, 2012, NAT REV RHEUMATOL, V8, P522, DOI 10.1038/nrrheum.2012.106
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wasko MCM, 2007, JAMA-J AM MED ASSOC, V298, P187, DOI 10.1001/jama.298.2.187
   World Health Organization, 2020, SOL CLIN TRIAL COVID
NR 39
TC 7
Z9 7
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2665-9913
J9 LANCET RHEUMATOL
JI Lancet Rheumatol.
PD NOV
PY 2020
VL 2
IS 11
BP E698
EP E711
DI 10.1016/S2665-9913(20)30276-9
PG 14
WC Rheumatology
SC Rheumatology
GA OH4EI
UT WOS:000582523300024
PM 32864627
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Casas-Rojo, JM
   Anton-Santos, JM
   Millan-Nunez-Cortes, J
   Lumbreras-Bermejo, C
   Ramos-Rincon, JM
   Roy-Vallejo, E
   Artero-Mora, A
   Arnalich-Fernandez, F
   Garcia-Brunen, JM
   Vargas-Nunez, JA
   Freire-Castro, S
   Manzano-Espinosa, L
   Perales-Fraile, I
   Crestelo-Vieitez, A
   Puchades-Gimeno, F
   Rodilla-Sala, E
   Solis-Marquinez, MN
   Bonet-Tur, D
   Fidalgo-Moreno, MP
   Fonseca-Aizpuru, EM
   Carrasco-Sanchez, FJ
   Rabadan-Pejenaute, E
   Rubio-Rivas, M
   Torres-Pena, JD
   Gomez-Huelgas, R
AF Casas-Rojo, J. M.
   Anton-Santos, J. M.
   Millan-Nunez-Cortes, J.
   Lumbreras-Bermejo, C.
   Ramos-Rincon, J. M.
   Roy-Vallejo, E.
   Artero-Mora, A.
   Arnalich-Fernandez, F.
   Garcia-Brunen, J. M.
   Vargas-Nunez, J. A.
   Freire-Castro, Sj
   Manzano-Espinosa, L.
   Perales-Fraile, I
   Crestelo-Vieitez, A.
   Puchades-Gimeno, F.
   Rodilla-Sala, E.
   Solis-Marquinez, M. N.
   Bonet-Tur, D.
   Fidalgo-Moreno, M. P.
   Fonseca-Aizpuru, E. M.
   Carrasco-Sanchez, F. J.
   Rabadan-Pejenaute, E.
   Rubio-Rivas, M.
   Torres-Pena, J. D.
   Gomez-Huelgas, R.
CA Grp SEMI-COVID-19 Network
TI Clinical characteristics of patients hospitalized with COVID-19 in
   Spain: Results from the SEMI-COVID-19 Registry
SO REVISTA CLINICA ESPANOLA
LA Spanish
DT Article
DE 2019-nCoV; SARS-CoV-2; Coronavirus; COVID-19; Spain
AB Background: Spain has been one of the countries most affected by the COVID-19 pandemic.
   Objective: To create a registry of patients with COVID-19 hospitalized in Spain, in order to improve our knowledge of the clinical, diagnostic, therapeutic, and prognostic aspects of this disease.
   Methods: A multicentre retrospective cohort study, including consecutive patients hospitalized with confirmed COVID-19 throughout Spain. Epidemiological and clinical data, additional tests at admission and at seven days, treatments administered, and progress at 30 days of hospitalization were collected from electronic medical records.
   Results: Up to June 30th 2020, 15,111 patients from 150 hospitals were included. Their median age was 69.4 years (range: 18-102 years) and 57.2% were male. Prevalences of hypertension, dyslipidemia, and diabetes mellitus were 50.9%, 39.7%, and 19.4%, respectively. The most frequent symptoms were fever (84.2%) and cough (73.5%). High values of ferritin (73.5%), lactate dehydrogenase (73.9%), and D-dimer (63.8%), as welt as lymphopenia (52.8%), were frequent. The most used antiviral drugs were hydroxychloroquine (85.6%) and lopinavir/ritonavir (61.4%); 33.1% developed respiratory distress. Overall mortality rate was 21.0%, with a marked increase with age (50-59 years: 4.7%, 60-69 years: 10.5%, 70-79 years: 26.9%, >= 80 years: 46.0%).
   Conclusions: The SEMI-COVID-19 Network provides data on the clinical characteristics of patients with COVID-19 hospitalized in Spain. Patients with COVID-19 hospitalized in Spain are mostly severe cases, as one in three patients developed respiratory distress and one in five patients died. These findings confirm a close relationship between advanced age and mortality. (C) 2020 The Authors. Published by Elsevier Espana, S.L.U.
C1 [Casas-Rojo, J. M.; Anton-Santos, J. M.] HU Infanta Cristina, Serv Med Interna, Madrid, Spain.
   [Millan-Nunez-Cortes, J.] HU Gregorio Maranon, Serv Med Interna, Madrid, Spain.
   [Lumbreras-Bermejo, C.] HU 12 Octubre, Serv Med Interna, Madrid, Spain.
   [Ramos-Rincon, J. M.] Univ Miguel Hernandez, Dept Med Clin, Alicante, Spain.
   [Roy-Vallejo, E.] HU La Princesa, Serv Med Interna, Madrid, Spain.
   [Artero-Mora, A.] HU Dr Peset, Serv Med Interna, Valencia, Spain.
   [Arnalich-Fernandez, F.] HU La Paz, Serv Med Interna, Madrid, Spain.
   [Garcia-Brunen, J. M.] HU Miguel Servet, Serv Med Interna, Zaragoza, Spain.
   [Vargas-Nunez, J. A.] HU Puerta Hierro, Serv Med Interna, Madrid, Spain.
   [Freire-Castro, Sj] HU A Coruna, Serv Med Interna, La Coruna, Spain.
   [Manzano-Espinosa, L.] HU Ramon y Cajal, Serv Med Interna, Madrid, Spain.
   [Perales-Fraile, I] HU Infanta Sofia, Serv Med Interna, Madrid, Spain.
   [Crestelo-Vieitez, A.] H Royo Villanova, Serv Med Interna, Zaragoza, Spain.
   [Puchades-Gimeno, F.] Univ Catolica Valencia, Fac Med, Valencia, Spain.
   [Rodilla-Sala, E.] H Sagunto, Serv Med Interna, Valencia, Spain.
   [Solis-Marquinez, M. N.] HU San Agustin, Serv Med Interna, Aviles, Asturias, Spain.
   [Bonet-Tur, D.] HU San Juan Alicante, Serv Med Interna, Alicante, Spain.
   [Fidalgo-Moreno, M. P.] HU Henares, Serv Med Interna, Madrid, Spain.
   [Fonseca-Aizpuru, E. M.] HU Cabuenes, Serv Med Interna, Gijon, Asturias, Spain.
   [Carrasco-Sanchez, F. J.] HU Juan Ramon Jimenez, Serv Med Interna, Huelva, Spain.
   [Rabadan-Pejenaute, E.] HU San Pedro, Serv Med Interna, Logrono, La Rioja, Spain.
   [Rubio-Rivas, M.] HU Bellvitge, Serv Med Interna, Hosp Llobregat, Barcelona, Spain.
   [Torres-Pena, J. D.] HU Reina Sofia, Serv Med Interna, Cordoba, Spain.
   [Gomez-Huelgas, R.] H Reg Univ Malaga, Serv Med Interna, Malaga, Spain.
RP Anton-Santos, JM (corresponding author), HU Infanta Cristina, Serv Med Interna, Madrid, Spain.; Gomez-Huelgas, R (corresponding author), H Reg Univ Malaga, Serv Med Interna, Malaga, Spain.
EM jmanton.hugf@salud.madrid.org; rgh@uma.es
RI Pena, Jose D. Torres/ABH-3312-2020; Rodilla, Enrique/L-1284-2014; Ramos,
   Jose M./B-6420-2018; Bernal Lopez, M Rosa/N-3564-2016
OI Pena, Jose D. Torres/0000-0003-1366-5549; Rodilla,
   Enrique/0000-0003-3669-4270; Ramos, Jose M./0000-0002-6501-9867;
   Magallanes Gamboa, Jeffrey Oskar/0000-0001-6889-6876; Bernal Lopez, M
   Rosa/0000-0002-0238-0890; Sanchez-Ortiz, David/0000-0002-3551-6416;
   Lumbreras, Carlos/0000-0003-4748-8288; Gomez Huelgas,
   Ricardo/0000-0002-9909-3555
CR Borobia AM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061733
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Liang WH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00562-2020
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, 2020, 175 WHO
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 11
TC 5
Z9 5
U1 0
U2 0
PU EDICIONES DOYMA S A
PI BARCELONA
PA TRAV DE GRACIA 17-21, 08021 BARCELONA, SPAIN
SN 0014-2565
EI 1578-1860
J9 REV CLIN ESP
JI Rev. Clin. Esp.
PD NOV
PY 2020
VL 220
IS 8
BP 480
EP 494
DI 10.1016/j.rce.2020.07.003
PG 15
WC Medicine, General & Internal
SC General & Internal Medicine
GA OH4FX
UT WOS:000582527400003
PM 32762922
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ma, SY
   Kim, DD
   Cohen, JT
   Neumann, PJ
AF Ma, Siyu
   Kim, David D.
   Cohen, Joshua T.
   Neumann, Peter J.
TI Measuring "Fearonomic Effects" in Valuing Therapies: An Application to
   COVID-19 in China
SO VALUE IN HEALTH
LA English
DT Article
ID PREVENTION
AB Objectives: To develop a checklist that helps quantify the economic impact associated with fear of contagion and to illustrate how one might use the checklist by presenting a case study featuring China during the coronavirus disease 2019 (COVID-19) outbreak.
   Methods: Based on "fearonomic effects," a qualitative framework that conceptualizes the direct and indirect economic effects caused by the fear of contagion, we created a checklist to facilitate empirical estimation. As a case study, we first identified relevant sectors affected by China's lockdown policies implemented just before the Lunar New Year (LNY) week. To quantify the immediate impact, we then estimated the projected spending levels in 2020 in the absence of COVID-19 and compared these projections with actual spending during the LNY week. Data sources used include Chinese and global websites. To characterize uncertainty, we reported upper and lower bound estimates and calculated midpoints for each range.
   Results: The COVID-19 epidemic is estimated to cost China's economy $283 billion ($196-369 billion), that is, U2.0 trillion renminbi (U1.4-U2.6 trillion), during the LNY week. Reduced restaurant and movie theater business ($106 [$103-$109] billion, 37.5% [36.4%-38.5%]) and reduced public transportation utilization ($96 [$13-$179] billion dollars, 33.9% [4.6%-63.3%]) explain most of this loss, followed by travel restrictions and the resulting loss of hotel business and tourism ($80.36 billion, 28.4%).
   Conclusion: Our checklist can help quantify the immediate and near-term impact of COVID-19 on a country's economy. It can also help researchers and policy makers consider the broader economic and social consequences when valuing future vaccines and treatments.
C1 [Ma, Siyu; Kim, David D.; Cohen, Joshua T.] Tufts Med Ctr, Ctr Evaluat Value & Risk Hlth, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA.
   [Kim, David D.; Cohen, Joshua T.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA.
RP Ma, SY (corresponding author), Tufts Med Ctr, CEVR, 800 Washington St, Boston, MA 02111 USA.
EM sma3@tuftsmedicalcenter.org
FU PhRMA Foundation Center of Excellence in Value Assessment Award
FX This work was funded by the PhRMA Foundation Center of Excellence in
   Value Assessment Award to the Center for Enhanced Value Assessment at
   the Center for the Evaluation for Value and Risk in Health at Tufts
   Medical Center.
CR Anderson K., 2020, MORNINGSTARS VIEW IM
   [Anonymous], 2020, IMPACT NEW CORONAVIR
   [Anonymous], 2020, CHINESE TOURISTS IGN
   [Anonymous], 2020, COMMENTARY MILESTONE
   Barnighausen T, 2014, P NATL ACAD SCI USA, V111, P12313, DOI 10.1073/pnas.1400475111
   Bali S, 2016, BMJ GLOB HEALTH, V1, DOI 10.1136/bmjgh-2016-000111
   Cooper C, 2016, BMC MED, V14, DOI 10.1186/s12916-015-0548-4
   Kim DD, 2020, MED DECIS MAKING, V40, P251, DOI 10.1177/0272989X20922987
   International Air Transport Association, 2020, NEW COR PNEUM EP CAU
   Keogh-Brown MR, 2008, HEALTH POLICY, V88, P110, DOI 10.1016/j.healthpol.2008.03.003
   Lakdawalla DN, 2018, VALUE HEALTH, V21, P131, DOI 10.1016/j.jval.2017.12.007
   Mattingly TJ, 2019, PATIENT, V12, P631, DOI 10.1007/s40271-019-00378-7
   Remy V, 2014, VALUE HEALTH, V17, pA450, DOI 10.1016/j.jval.2014.08.1211
   World Health Organization, 2003, UPD 87 WHO CHANG LAS
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xinhua Headlines, 2019, XINHUA HEADLINE 0211
NR 17
TC 1
Z9 1
U1 4
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1098-3015
EI 1524-4733
J9 VALUE HEALTH
JI Value Health
PD NOV
PY 2020
VL 23
IS 11
BP 1405
EP 1408
DI 10.1016/j.jval.2020.06.002
PG 4
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA OH6RL
UT WOS:000582722700002
PM 33127009
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Salazar, E
   Christensen, PA
   Graviss, EA
   Nguyen, DT
   Castillo, B
   Chen, J
   Lopez, BV
   Eagar, TN
   Yi, X
   Zhao, PC
   Rogers, J
   Shehabeldin, A
   Joseph, D
   Leveque, C
   Olsen, RJ
   Bernard, DW
   Gollihar, J
   Musser, JM
AF Salazar, Eric
   Christensen, Paul A.
   Graviss, Edward A.
   Nguyen, Duc T.
   Castillo, Brian
   Chen, Jian
   Lopez, Bevin, V
   Eagar, Todd N.
   Yi, Xin
   Zhao, Picheng
   Rogers, John
   Shehabeldin, Ahmed
   Joseph, David
   Leveque, Christopher
   Olsen, Randall J.
   Bernard, David W.
   Gollihar, Jimmy
   Musser, James M.
TI Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma
   Reveals a Signal of Significantly Decreased Mortality
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID THERAPY
AB Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, has spread globally, and proven treatments are limited. Transfusion of convalescent plasma collected from donors who have recovered from COVID-19 is among many approaches being studied as potentially efficacious therapy. We are conducting a prospective, propensity score-matched study assessing the efficacy of COVID-19 convalescent plasma transfusion versus standard of care as treatment for severe and/or critical COVID-19. We present herein the results of an interim analysis of 316 patients enrolled at Houston Methodist hospitals from March 28 to July 6, 2020. Of the 316 transfused patients, 136 met a 28-day outcome and were matched to 251 non-transfused control COVID-19 patients. Matching criteria included age, sex, body mass index, comorbidities, and baseline ventilation requirement 48 hours from admission, and in a second matching analysis, ventilation status at day 0. Variability in the timing of transfusion relative to admission and titer of antibodies of plasma transfused allowed for analysis in specific matched cohorts. The analysis showed a significant reduction (P = 0.047) in mortality within 28 days, specifically in patients transfused within 72 hours of admission with plasma with an anti-spike protein receptor binding domain titer of >= 1:1350. These data suggest that treatment of COVID-19 with high anti-receptor binding domain IgG titer convalescent plasma is efficacious in early-disease patients.
C1 [Salazar, Eric; Christensen, Paul A.; Graviss, Edward A.; Castillo, Brian; Chen, Jian; Eagar, Todd N.; Yi, Xin; Zhao, Picheng; Rogers, John; Shehabeldin, Ahmed; Joseph, David; Leveque, Christopher; Olsen, Randall J.; Bernard, David W.; Musser, James M.] Houston Methodist Hosp, Dept Pathol & Genom Med, Houston, TX 77030 USA.
   [Salazar, Eric; Eagar, Todd N.; Yi, Xin; Olsen, Randall J.; Bernard, David W.; Musser, James M.] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY USA.
   [Graviss, Edward A.; Nguyen, Duc T.; Olsen, Randall J.; Musser, James M.] Houston Methodist Res Inst, Ctr Mol & Translat Human Infect Dis, Houston, TX USA.
   [Lopez, Bevin, V] Houston Methodist Res Inst, Acad Off Clin Trials, Houston, TX USA.
   [Gollihar, Jimmy] Univ Texas Austin, Combat Capabil Dev Command Army Res Lab South, Austin, TX 78712 USA.
RP Musser, JM (corresponding author), Houston Methodist Hosp, 6565 Fannin St,Ste B490, Houston, TX 77030 USA.
EM jmmusser@houstonmethodist.org
FU Fondren Foundation; Houston Methodist Hospital; Houston Methodist
   Research Institute
FX Supported by the Fondren Foundation (J.M.M.), the Houston Methodist
   Hospital (J.M.M.), and the Houston Methodist Research Institute
   (J.M.M.).
CR Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Arabi YM, 2016, EMERG INFECT DIS, V22, P1554, DOI 10.3201/eid2209.151164
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Casadevall A, 2004, NAT REV MICROBIOL, V2, P695, DOI 10.1038/nrmicro974
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Cecil R L, 1932, Br Med J, V2, P657
   Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Eckhardt CM, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04422-y
   Finland M, 1930, NEW ENGL J MED, V202, P1244, DOI 10.1056/NEJM193006262022605
   Fragkou PC, 2020, CLIN MICROBIOL INFEC, V26, P988, DOI 10.1016/j.cmi.2020.05.019
   Gharbharan A, 2020, CONVALESCENT PLASMA, DOI [10.1101/2020.07.01.20139857, DOI 10.1101/2020.07.01.20139857, 10.1101/2020.07.01.20139857.]
   Hastie T., 2015, STAT LEARNING SPARSI
   Hegerova L, 2020, BLOOD, V136, P759, DOI 10.1182/blood.2020006964
   Hung IFN, 2013, CHEST, V144, P712, DOI 10.1378/chest.13-0571
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   ISRCTN Registry, 2020, ISRCTN REGISTRY VACC, DOI 10.1186/ISRCTN89951424
   Joyner MJ, 2020, MAYO CLIN PROC, V95, P1888, DOI 10.1016/j.mayocp.2020.06.028
   Joyner MJ, 2020, J CLIN INVEST, V130, P4791, DOI 10.1172/JCI140200
   Ko JH, 2018, ANTIVIR THER, V23, P617, DOI 10.3851/IMP3243
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lasso SS, 2020, STATA REFERENCE MANU
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P1, DOI DOI 10.1001/jama.2020.10044
   Liu STH, 2020, NAT MED, V26, P1708, DOI 10.1038/s41591-020-1088-9
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Mehta HB, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-039978
   Nasrallah AA, 2020, J CLIN EPIDEMIOL, V125, P170, DOI 10.1016/j.jclinepi.2020.06.005
   Prevention USCfDCa, 2020, PREV USCFDCA NAT HEA
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Salazar E, 2020, RELATIONSHIP ANTISPI
   Salazar E, 2020, AM J PATHOL, V190, P1680, DOI 10.1016/j.ajpath.2020.05.014
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   van Griensven J, 2016, NEW ENGL J MED, V374, P33, DOI 10.1056/NEJMoa1511812
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Ye MX, 2020, J MED VIROL, V92, P1890, DOI 10.1002/jmv.25882
   Zeng QL, 2020, J INFECT DIS, V222, P38, DOI 10.1093/infdis/jiaa228
   Zhang B, 2020, CHEST, V158, pE9, DOI 10.1016/j.chest.2020.03.039
NR 42
TC 3
Z9 3
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD NOV
PY 2020
VL 190
IS 11
BP 2290
EP 2303
DI 10.1016/j.ajpath.2020.08.001
PG 14
WC Pathology
SC Pathology
GA OF1BX
UT WOS:000580953600010
PM 32795424
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mastellos, DC
   da Silva, BGPP
   Fonseca, BAL
   Fonseca, NP
   Auxiliadora-Martins, M
   Mastaglio, S
   Ruggeri, A
   Sironi, M
   Radermacher, P
   Chrysanthopoulou, A
   Skendros, P
   Ritis, K
   Manfra, I
   Iacobelli, S
   Huber-Lang, M
   Nilsson, B
   Yancopoulou, D
   Connolly, ES
   Garlanda, C
   Ciceri, F
   Risitano, AM
   Calado, RT
   Lambris, JD
AF Mastellos, Dimitrios C.
   Pires da Silva, Bruno G. P.
   Fonseca, Benedito A. L.
   Fonseca, Natasha P.
   Auxiliadora-Martins, Maria
   Mastaglio, Sara
   Ruggeri, Annalisa
   Sironi, Marina
   Radermacher, Peter
   Chrysanthopoulou, Akrivi
   Skendros, Panagiotis
   Ritis, Konstantinos
   Manfra, Ilenia
   Iacobelli, Simona
   Huber-Lang, Markus
   Nilsson, Bo
   Yancopoulou, Despina
   Connolly, E. Sander
   Garlanda, Cecilia
   Ciceri, Fabio
   Risitano, Antonio M.
   Calado, Rodrigo T.
   Lambris, John D.
TI Complement C3 vs C5 inhibition in severe COVID-19: Early clinical
   findings reveal differential biological efficacy
SO CLINICAL IMMUNOLOGY
LA English
DT Article
DE COVID-19; Thromboinflammation; C3 inhibition; C5 blockade; AMY-101;
   Eculizumab; Drug efficacy; Biomarkers
ID ACTIVATION; PLASMA
AB Growing clinical evidence has implicated complement as a pivotal driver of COVID-19 immunopathology. Deregulated complement activation may fuel cytokine-driven hyper-inflammation, thrombotic microangiopathy and NET-driven immunothrombosis, thereby leading to multi-organ failure. Complement therapeutics have gained traction as candidate drugs for countering the detrimental consequences of SARS-CoV-2 infection. Whether blockade of terminal complement effectors (C5, C5a, or C5aR1) may elicit similar outcomes to upstream intervention at the level of C3 remains debated. Here we compare the efficacy of the C5-targeting monoclonal antibody eculizumab with that of the compstatin-based C3-targeted drug candidate AMY-101 in small independent cohorts of severe COVID-19 patients. Our exploratory study indicates that therapeutic complement inhibition abrogates COVID-19 hyper-inflammation. Both C3 and C5 inhibitors elicit a robust anti-inflammatory response, reflected by a steep decline in C-reactive protein and IL-6 levels, marked lung function improvement, and resolution of SARS-CoV-2-associated acute respiratory distress syndrome (ARDS). C3 inhibition afforded broader therapeutic control in COVID-19 patients by attenuating both C3a and sC5b-9 generation and preventing FB consumption. This broader inhibitory profile was associated with a more robust decline of neutrophil counts, attenuated neutrophil extracellular trap (NET) release, faster serum LDH decline, and more prominent lymphocyte recovery. These early clinical results offer important insights into the differential mechanistic basis and underlying biology of C3 and C5 inhibition in COVID-19 and point to a broader pathogenic involvement of C3-mediated pathways in thromboinflammation. They also support the evaluation of these complement-targeting agents as COVID-19 therapeutics in large prospective trials.
C1 [Mastellos, Dimitrios C.] Natl Ctr Sci Res Demokritos, Athens, Greece.
   [Pires da Silva, Bruno G. P.; Fonseca, Natasha P.; Calado, Rodrigo T.] Univ Sao Paulo, Sch Med, Dept Med Imaging Hematol & Clin Oncol, Ribeirao Preto, Brazil.
   [Fonseca, Benedito A. L.] Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Internal Med, Ribeirao Preto, Brazil.
   [Auxiliadora-Martins, Maria] Univ Sao Paulo, Ribeirao Preto Sch Med, Intens Care Unit, Univ Hosp, Ribeirao Preto, Brazil.
   [Mastaglio, Sara; Ruggeri, Annalisa; Ciceri, Fabio] IRCCS San Raffaele Sci Inst, Hematol & Bone Marrow Transplantat Unit, Milan, Italy.
   [Sironi, Marina; Garlanda, Cecilia] IRCCS, Humanitas Clin & Res Ctr, Milan, Italy.
   [Radermacher, Peter] Univ Hosp Ulm, Sekt Anasthesiol Pathophysiol & Verfahrensentwick, Ulm, Germany.
   [Chrysanthopoulou, Akrivi; Skendros, Panagiotis; Ritis, Konstantinos] Democritus Univ Thrace, Univ Hosp Alexandroupolis, Dept Internal Med 1, Alexandroupolis, Greece.
   [Chrysanthopoulou, Akrivi; Skendros, Panagiotis; Ritis, Konstantinos] Democritus Univ Thrace, Univ Hosp Alexandroupolis, Lab Mol Hematol, Alexandroupolis, Greece.
   [Manfra, Ilenia; Risitano, Antonio M.] AORN San Giuseppe Moscati, Hematol & Hematopoiet Stem Cell Transplantat Unit, Avellino, Italy.
   [Iacobelli, Simona] Univ Roma Tor Vergata, Dept Biol, Rome, Italy.
   [Huber-Lang, Markus] Univ Hosp Ulm, Inst Clin & Expt Trauma Immunol, Ulm, Germany.
   [Nilsson, Bo] Uppsala Univ Hosp, Div Clin Immunol, Uppsala, Sweden.
   [Yancopoulou, Despina] Amyndas Pharmaceut, Glifadha, Greece.
   [Connolly, E. Sander] Columbia Univ, Dept Neurol Surg, New York, NY USA.
   [Garlanda, Cecilia] Humanitas Univ, Milan, Italy.
   [Ciceri, Fabio] Univ Vita Salute San Raffaele, Milan, Italy.
   [Risitano, Antonio M.] Federico II Univ Naples, Naples, Italy.
   [Lambris, John D.] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Lambris, JD (corresponding author), Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
EM lambris@pennmedicine.upenn.edu
RI Calado, Rodrigo T/G-2619-2011
OI Calado, Rodrigo T/0000-0002-7966-6029; Skendros,
   Panagiotis/0000-0003-0456-7015
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [13/08135-2]; NIHUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA
   [P01AI068730]; Institutional National 5 x 1000 Grant; Dolce & Gabbana
   Fashion Firm
FX The authors thank Quidel Corporation for the generous gift of its
   proprietary ELISA kits for the measurement of C3a AND sC5b-9 levels in
   all COVID-19 patients. This study was supported in part by the Sao Paulo
   Research Foundation (FAPESP) grant no. 13/08135-2 (to R.T.C.), NIH grant
   P01AI068730 (to J.D.L.) the Institutional National 5 x 1000 Grant (to
   F.C.) and the Dolce & Gabbana Fashion Firm (to C.G.). J.D.L. thanks
   Ralph and Sallie Weaver for the generous endowment of his professorship.
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Bennet W, 1999, DIABETES, V48, P1907, DOI 10.2337/diabetes.48.10.1907
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Campbell CM, 2020, CIRCULATION, V141, P1739, DOI 10.1161/CIRCULATIONAHA.120.047419
   Carvelli J, 2020, NATURE, V588, P146, DOI 10.1038/s41586-020-2600-6
   Chen Z., 2020, NAT REV IMMUNOL, P1
   Ciceri F, 2020, CLIN IMMUNOL, V217, DOI 10.1016/j.clim.2020.108509
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Crockard AD, 1998, INT J CLIN LAB RES, V28, P110, DOI 10.1007/s005990050029
   Cugno M, 2020, J ALLERGY CLIN IMMUN, V146, P215, DOI 10.1016/j.jaci.2020.05.006
   de Bont CM, 2019, CELL MOL IMMUNOL, V16, P19, DOI 10.1038/s41423-018-0024-0
   DELATOUR RP, 2020, HAEMATOLOGICA, DOI DOI 10.3324/HAEMATOL.2020.260117
   Della-Torre E, 2020, CLIN IMMUNOL, V217, DOI 10.1016/j.clim.2020.108490
   Diurno F, 2020, EUR REV MED PHARMACO, V24, P4040, DOI 10.26355/eurrev_202004_20875
   Ekdahl KN, 2007, CLIN VACCINE IMMUNOL, V14, P549, DOI 10.1128/CVI.00486-06
   Facciabene A, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1326442
   Felsenstein S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108448
   Gal Z., 2020, SCI REP, V10, P1
   Gao T, 2020, HIGHLY PATHOGENIC CO, DOI [10.1101/2020.03.29.20041962, DOI 10.1101/2020.03.29.20041962]
   Gavriilaki E, 2020, BRIT J HAEMATOL, V189, pE227, DOI 10.1111/bjh.16783
   Ghebrehiwet B, 2020, J CLIN INVEST, V130, P5674, DOI 10.1172/JCI142780
   Giudice V, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00857
   Gralinski LE, 2018, MBIO, V9, DOI 10.1128/mBio.01753-18
   Gupta A, 2020, NAT MED, V26, P1017, DOI 10.1038/s41591-020-0968-3
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ibrahim H, 2020, CLIN IMMUNOL, V219, DOI 10.1016/j.clim.2020.108544
   Java A, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.140711
   Kessenbrock K, 2009, NAT MED, V15, P623, DOI 10.1038/nm.1959
   Lam Lk Metthew, 2020, medRxiv, DOI 10.1101/2020.05.20.20104398
   Laurence J, 2020, CLIN IMMUNOL, V219, DOI 10.1016/j.clim.2020.108555
   Liao DY, 2020, LANCET HAEMATOL, V7, pE671, DOI 10.1016/S2352-3026(20)30217-9
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   Mastaglio S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108450
   Mastellos DC, 2019, NAT REV DRUG DISCOV, V18, P707, DOI 10.1038/s41573-019-0031-6
   Merrill JT, 2020, NAT REV RHEUMATOL, V16, P581, DOI 10.1038/s41584-020-0474-5
   Morales-Ortega A, 2020, CLIN IMMUNOL, V218, DOI 10.1016/j.clim.2020.108518
   Morigi M, 2011, J IMMUNOL, V187, P172, DOI 10.4049/jimmunol.1100491
   Primikyri A, 2017, J CHROMATOGR B, V1041, P19, DOI 10.1016/j.jchromb.2016.12.004
   Ramlall V, 2020, NAT MED, V26, P1609, DOI 10.1038/s41591-020-1021-2
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Risitano AM, 2020, NAT REV IMMUNOL, V2020, P1
   Risitano AM, 2018, AM J HEMATOL, V93, P564, DOI 10.1002/ajh.25016
   Sauter RJ, 2018, CIRCULATION, V138, P1720, DOI 10.1161/CIRCULATIONAHA.118.034600
   Skendros P, 2020, J CLIN INVEST, V130, P6151, DOI 10.1172/JCI141374
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yan B., 2020, SARS COV2 DRIVES JAK
   Yu K, 2020, CELL RES, V30, P814, DOI 10.1038/s41422-020-0391-9
   Zuo Y, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138999
NR 48
TC 6
Z9 6
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
EI 1521-7035
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD NOV
PY 2020
VL 220
AR 108598
DI 10.1016/j.clim.2020.108598
PG 10
WC Immunology
SC Immunology
GA OH2JS
UT WOS:000582396200015
PM 32961333
OA Green Published
DA 2021-01-01
ER

PT J
AU Kremer, S
   Lersy, F
   de Seze, J
   Ferre, JC
   Maamar, A
   Carsin-Nicol, B
   Collange, O
   Bonneville, F
   Adam, G
   Martin-Blondel, G
   Rafiq, M
   Geeraerts, T
   Delamarre, L
   Grand, S
   Krainik, A
AF Kremer, Stephane
   Lersy, Francois
   de Seze, Jerome
   Ferre, Jean-Christophe
   Maamar, Adel
   Carsin-Nicol, Beatrice
   Collange, Olivier
   Bonneville, Fabrice
   Adam, Gilles
   Martin-Blondel, Guillaume
   Rafiq, Marie
   Geeraerts, Thomas
   Delamarre, Louis
   Grand, Sylvie
   Krainik, Alexandre
CA SFNR-COVID Grp
TI Brain MRI Findings in Severe COVID 19: A Retrospective Observational
   Study
SO RADIOLOGY
LA English
DT Article
ID CENTRAL-NERVOUS-SYSTEM; CORONAVIRUS
AB Background: Brain MRI parenchymal signal abnormalities have been associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
   Purpose: To describe the neuroimaging findings (excluding ischemic infarcts) in patients with severe coronavirus disease 2019 (COVID-19) infection.
   Materials and Methods: This was a retrospective study of patients evaluated from March 23, 2020, to April 27, 2020, at 16 hospitals. Inclusion criteria were (a) positive nasopharyngeal or lower respiratory tract reverse transcriptase polymerase chain reaction assays, (b) severe COVID-19 infection defined as a requirement for hospitalization and oxygen therapy, (c) neurologic manifestations, and (d) abnormal brain MRI findings. Exclusion criteria were patients with missing or noncontributory data regarding brain MRI or brain MRI showing ischemic infarcts, cerebral venous thrombosis, or chronic lesions unrelated to the current event. Categorical data were compared using the Fisher exact test. Quantitative data were compared using the Student t test or Wilcoxon test. P<.05 represented a significant difference.
   Results: Thirty men (81%) and seven women (19%) met the inclusion criteria, with a mean age of 61 years 6 12 (standard deviation) (age range, 8-78 years). The most common neurologic manifestations were alteration of consciousness (27 of 37, 73%), abnormal wakefulness when sedation was stopped (15 of 37, 41%), confusion (12 of 37, 32%), and agitation (seven of 37, 19%). The most frequent MRI findings were signal abnormalities located in the medial temporal lobe in 16 of 37 patients (43%; 95% confidence interval [CI]: 27%, 59%), nonconfluent multifocal white matter hyperintense lesions seen with fluid-attenuated inversion recovery and diffusion-weighted sequences with variable enhancement, with associated hemorrhagic lesions in 11 of 37 patients (30%; 95% CI: 15%, 45%), and extensive and isolated white matter microhemorrhages in nine of 37 patients (24%; 95% CI: 10%, 38%). A majority of patients (20 of 37, 54%) had intracerebral hemorrhagic lesions with a more severe clinical presentation and a higher admission rate in intensive care units (20 of 20 patients [100%] vs 12 of 17 patients without hemorrhage [71%], P =.01) and development of the acute respiratory distress syndrome (20 of 20 patients [100%] vs 11 of 17 patients [65%], P =.005). Only one patient had SARS-CoV-2 RNA in the cerebrospinal fluid.
   Conclusion: Patients with severe coronavirus disease 2019 and without ischemic infarcts had a wide range of neurologic manifestations that were associated with abnormal brain MRI scans. Eight distinctive neuroradiologic patterns were described. (C) RSNA, 2020
C1 [Kremer, Stephane; Lersy, Francois] Hop Univ Strasbourg, Serv Imagerie 2, Hop Hautepierre, Strasbourg, France.
   [Kremer, Stephane] Univ Strasbourg, Integrat Multimodal Imaging Healthcare, Comp Sci & Imaging Lab ICube, Engn Sci,CNRS, Strasbourg, France.
   [de Seze, Jerome] Hop Univ Strasbourg, Serv Neurol, Strasbourg, France.
   [Ferre, Jean-Christophe; Carsin-Nicol, Beatrice] CHU Rennes, Dept Neuroradiol, Rennes, France.
   [Maamar, Adel] CHU Rennes, Serv Malad Infect & Reanimat Med, Rennes, France.
   [Collange, Olivier] Hop Univ Strasbourg, Nouvel Hop Civil, Serv Anesthesie Reanimat, Strasbourg, France.
   [Bonneville, Fabrice; Adam, Gilles] CHU Toulouse, Serv Neuroradiol, Toulouse, France.
   [Martin-Blondel, Guillaume] Toulouse Univ Hosp, Dept Infect & Trop Dis, Toulouse, France.
   [Rafiq, Marie] Toulouse Univ Hosp, Dept Neurol, Toulouse, France.
   [Geeraerts, Thomas; Delamarre, Louis] Univ Toulouse 3 Paul Sabatier, Dept Anesthesia & Crit Care, Toulouse Univ Hosp, Toulouse, France.
   [Grand, Sylvie; Krainik, Alexandre] Ctr Hosp Univ Alpes, Serv Neuroradiol Diagnost & Intervent, Grenoble, France.
RP Kremer, S (corresponding author), Hop Univ Strasbourg, Serv Imagerie 2, Hop Hautepierre, Strasbourg, France.; Kremer, S (corresponding author), Univ Strasbourg, Integrat Multimodal Imaging Healthcare, Comp Sci & Imaging Lab ICube, Engn Sci,CNRS, Strasbourg, France.
EM stephane.kremer@chru-strasbourg.fr
RI ; Martin-Blondel, Guillaume/K-6762-2014
OI Ferre, Jean-Christophe/0000-0003-3911-1800; Maamar,
   Adel/0000-0001-8352-3613; ARDELLIER,
   Francois-Daniel/0000-0003-1380-238X; Bapst, Blanche/0000-0003-4958-7458;
   Martin-Blondel, Guillaume/0000-0002-8363-7028
CR Arabi YM, 2015, INFECTION, V43, P495, DOI 10.1007/s15010-015-0720-y
   Bohmwald K, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00386
   Budhram A, 2019, CAN MED ASSOC J, V191, pE529, DOI 10.1503/cmaj.181548
   Desforges M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010014
   Desforges M, 2014, VIRUS RES, V194, P145, DOI 10.1016/j.virusres.2014.09.011
   Franceschi AM, 2020, AM J NEURORADIOL, V41, P1173, DOI 10.3174/ajnr.A6595
   Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597
   Kandemirli SG, 2020, RADIOLOGY, V297, pE232, DOI 10.1148/radiol.2020201697
   Katyal N, 2018, CUREUS, V10, DOI 10.7759/cureus.2481
   KHAN S, 2016, BMJ CASE REP, V2016, DOI DOI 10.1155/2016/3460416
   Kim JE, 2017, J CLIN NEUROL, V13, P227, DOI 10.3988/jcn.2017.13.3.227
   Kishfy L, 2020, J NEUROL SCI, V414, DOI 10.1016/j.jns.2020.116943
   Li YY, 2016, INTERVIROLOGY, V59, P163, DOI 10.1159/000453066
   Mahammedi A, RADIOLOGY, DOI [10.1148/radiol.2020201933, DOI 10.1148/RADIOL.202020193]
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Moriguchi T, 2020, INT J INFECT DIS, V94, P55, DOI 10.1016/j.ijid.2020.03.062
   Needham EJ, 2020, NEUROCRIT CARE, V32, P667, DOI 10.1007/s12028-020-00978-4
   Parsons T, 2020, J NEUROL, V267, P2799, DOI 10.1007/s00415-020-09951-9
   Pohl D, 2016, NEUROLOGY, V87, pS38, DOI 10.1212/WNL.0000000000002825
   Poyiadji N, 2020, RADIOLOGY, V296, pE119, DOI 10.1148/radiol.2020201187
   Radmanesh A, 2020, RADIOLOGY, V297, pE223, DOI 10.1148/radiol.2020202040
   Radmanesh F, 2020, J CLIN NEUROSCI, V76, P236, DOI 10.1016/j.jocn.2020.04.054
   Reichard RR, 2020, ACTA NEUROPATHOL, V140, P1, DOI 10.1007/s00401-020-02166-2
   Romero-Sanchez CM, 2020, NEUROLOGY, V95, pE1060, DOI 10.1212/WNL.0000000000009937
   Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327
   World Health Organization, PROT REAL TIM RT PCR
   Yeh EA, 2004, PEDIATRICS, V113, pE73, DOI 10.1542/peds.113.1.e73
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 28
TC 37
Z9 37
U1 7
U2 7
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0033-8419
J9 RADIOLOGY
JI Radiology
PD NOV
PY 2020
VL 297
IS 2
BP E242
EP E251
DI 10.1148/radiol.202020222
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA OG4UW
UT WOS:000581882100001
PM 32544034
DA 2021-01-01
ER

PT J
AU Singh, PK
   Pathania, S
   Rawal, RK
AF Singh, P. K.
   Pathania, S.
   Rawal, R. K.
TI Exploring RdRp-remdesivir interactions to screen RdRp inhibitors for the
   management of novel coronavirus 2019-nCoV
SO SAR AND QSAR IN ENVIRONMENTAL RESEARCH
LA English
DT Article
DE Remdesivir&#8211; RdRp complex; molecular docking; scoring refinement;
   molecular dynamics; COVID-19
AB A novel coronavirus recently identified in Wuhan, China (2019-nCoV) has resulted in an increasing number of patients globally, and has become a highly lethal pathogenic member of the coronavirus family affecting humans. 2019-nCoV has established itself as one of the most threatening pandemics that human beings have faced, and therefore analysis and evaluation of all possible responses against infection is required. One such strategy includes utilizing the knowledge gained from the SARS and MERS outbreaks regarding existing antivirals. Indicating a potential for success, one of the drugs, remdesivir, under repurposing studies, has shown positive results in initial clinical studies. Therefore, in the current work, the authors have attempted to utilize the remdesivir-RdRp complex - RdRp (RNA-dependent RNA polymerase) being the putative target for remdesivir - to screen a library of the already reported RdRp inhibitor database. Further clustering on the basis of structural features and scoring refinement was performed to filter out false positive hits. Finally, molecular dynamics simulation was carried out to validate the identification of hits as RdRp inhibitors against novel coronavirus 2019-nCoV. The results yielded two putative hits which can inhibit RdRp with better potency than remdesivir, subject to further biological evaluation.
C1 [Singh, P. K.] Univ Sassari, Dept Chem & Pharm, Sassari, Italy.
   [Pathania, S.] ISF Coll Pharm, Dept Pharmaceut Chem, Moga, India.
   [Rawal, R. K.] North East Inst Sci & Technol, CSIR, Chem Sci & Technol Div CSTD, Jorhat, Assam, India.
RP Singh, PK (corresponding author), Univ Sassari, Dept Chem & Pharm, Sassari, Italy.
EM maan.pankajsingh@gmail.com
RI Singh, Pankaj Kumar/AAG-1935-2019
OI Singh, Pankaj Kumar/0000-0002-4774-6358
CR Amin SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1780946
   Andersen PI, 2020, INT J INFECT DIS, V93, P268, DOI 10.1016/j.ijid.2020.02.018
   Boraei ATA, 2019, EUR J MED CHEM, V182, DOI 10.1016/j.ejmech.2019.111621
   C.C.G. Inc, 2016, MOL OP ENV MOE
   Cao YC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101647
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Costanzo M, 2020, CURR MED CHEM, V27, P4536, DOI 10.2174/0929867327666200416131117
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Dong J, 2018, J CHEMINFORMATICS, V10, DOI 10.1186/s13321-018-0283-x
   ELFIKY AA, 2020, J BIOMOL STRUCT 0505, DOI DOI 10.1080/07391102.2020.176188
   Gao Y., 2020, STRUCTURE RNA DEPEND, DOI [10.1101/2020.03.16.993386, DOI 10.1101/2020.03.16.993386]
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Jin YF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040372
   Kumar V, 2020, SAR QSAR ENVIRON RES, V31, P511, DOI 10.1080/1062936X.2020.1776388
   Lythgoe MP, 2020, TRENDS PHARMACOL SCI, V41, P363, DOI 10.1016/j.tips.2020.03.006
   Pala N, 2020, ACS MED CHEM LETT, V11, P1986, DOI 10.1021/acsmedchemlett.0c00009
   Pala N, 2015, ACS MED CHEM LETT, V6, P866, DOI 10.1021/acsmedchemlett.5b00109
   Schomburg I, 2017, J BIOTECHNOL, V261, P194, DOI 10.1016/j.jbiotec.2017.04.020
   Singh PK, 2017, SAR QSAR ENVIRON RES, V28, P221, DOI 10.1080/1062936X.2017.1300189
   Singh PK, 2019, J BIOMOL STRUCT DYN, V37, P2593, DOI 10.1080/07391102.2018.1491893
   Singh PK, 2019, BIOORG MED CHEM LETT, V29, P1565, DOI 10.1016/j.bmcl.2019.05.004
   Tan L, 2008, J CHEM INF MODEL, V48, P2308, DOI 10.1021/ci800322y
   Vilar S, 2008, CURR TOP MED CHEM, V8, P1555, DOI 10.2174/156802608786786624
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Zhai P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105955
NR 31
TC 0
Z9 0
U1 5
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1062-936X
EI 1029-046X
J9 SAR QSAR ENVIRON RES
JI SAR QSAR Environ. Res.
PD NOV 1
PY 2020
VL 31
IS 11
BP 857
EP 867
DI 10.1080/1062936X.2020.1825014
PG 11
WC Chemistry, Multidisciplinary; Computer Science, Interdisciplinary
   Applications; Environmental Sciences; Mathematical & Computational
   Biology; Toxicology
SC Chemistry; Computer Science; Environmental Sciences & Ecology;
   Mathematical & Computational Biology; Toxicology
GA OH4SL
UT WOS:000582564500004
PM 33100032
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Yayla, BCC
   Ozsurekci, Y
   Aykac, K
   Oygar, PD
   Gurlevik, SL
   Ilbay, S
   Kukul, MG
   Karahan, S
   Cengiz, AB
   Ceyhan, M
AF Yayla, Burcu Ceylan Cura
   Ozsurekci, Yasemin
   Aykac, Kubra
   Oygar, Pembe Derin
   Gurlevik, Sibel Lacinel
   Ilbay, Sare
   Kukul, Musa Gurel
   Karahan, Sevilay
   Cengiz, Ali Bulent
   Ceyhan, Mehmet
TI Characteristics and Management of Children with COVID-19 in Turkey
SO BALKAN MEDICAL JOURNAL
LA English
DT Article
DE COVID-19; children; favipiravir; refugees; Turkey
AB Aims: Limited data about disease management strategies are available for pediatric patients with coronavirus disease-20I9. particularly in Turkey. This study aimed to share the data on patients aged under 18 years in our country to be beneficial for understanding the disease course in children.
   Methods: A retrospective review of the medical records of pediatric patients aged under 18 years who were confirmed as coronavirus disease-2019 between March 11, and June 23, 2020, and were admitted to our hospitals was conducted.
   Results: A total of 220 pediatric patients with coronavirus disease-2019 were evaluated, of which 48.2% were boys. with a median age of 10 years, and 9.5% had underlying diseases. Patients were classified according to severity. with the percentages of asymptomatic, mild, moderate, and criticaksevere cases determined to be 25.5%, 45%, 26.8%, and 2.7%, respectively. Extracorporeal membrane oxygenation was required in two patients (0.9%) and mechanical ventilation in three (1.4%). Targeted therapies were used in six patients (2.7 degrees 0,. with hydroxychloroquine being the most commonly used agent either alone (one patient) or in combination with favipiravir (five patients). Two patients (0.9%) died, and nine (4.1%) were still hospitalized during the study period.
   Conclusion: Although the disease course of coronavirus disease-2019 seems to be mild in children, critical illness is significant, and the treatment strategy primarily should consist of supportive care according to our preliminary observations.
C1 [Yayla, Burcu Ceylan Cura; Aykac, Kubra] Univ Hlth Sci Turkey, Ankara Training & Res Hosp, Dept Pediat Infect Dis, Ankara, Turkey.
   [Ozsurekci, Yasemin; Oygar, Pembe Derin; Gurlevik, Sibel Lacinel; Ilbay, Sare; Kukul, Musa Gurel; Cengiz, Ali Bulent; Ceyhan, Mehmet] Hacettepe Univ, Dept Pediat Infect Dis, Sch Med, Ankara, Turkey.
   [Karahan, Sevilay] Hacettepe Univ, Dept Biostat, Sch Med, Ankara, Turkey.
RP Aykac, K (corresponding author), Univ Hlth Sci Turkey, Ankara Training & Res Hosp, Dept Pediat Infect Dis, Ankara, Turkey.
EM kubraklnc.kk@gmail.com
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P422, DOI 10.15585/mmwr.mm6914e4
   Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen A, 2020, RADIOL CARDIOTHORACI, V2, DOI [10.1148/ryct.2020200117, DOI 10.1148/RYCT.2020200117]
   Chen W, 2020, ANN CLIN MICROB ANTI, V19, DOI 10.1186/s12941-020-00362-2
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Du WJ, 2020, INFECTION, V48, P445, DOI 10.1007/s15010-020-01427-2
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kollias A, 2020, BRIT J HAEMATOL, V189, P846, DOI 10.1111/bjh.16727
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Ma HJ, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01596-9
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Pascutti MF, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00364
   Shekerdemian LS, 2020, JAMA PEDIATR, V174, P868, DOI 10.1001/jamapediatrics.2020.1948
   Shen KL, 2020, WORLD J PEDIATR, V16, P232, DOI 10.1007/s12519-020-00362-4
   Song WL, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104377
   Wang X F, 2020, Zhonghua Er Ke Za Zhi, V58, pE008, DOI 10.3760/cma.j.issn.0578-1310.2020.0008
   Wang YL, 2020, PEDIATR INFECT DIS J, V39, pE91, DOI 10.1097/INF.0000000000002739
   Wei M, 2020, JAMA-J AM MED ASSOC, V323, P1313, DOI 10.1001/jama.2020.2131
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xia W, 2020, PEDIATR PULM, V55, P1169, DOI 10.1002/ppul.24718
   Zhang John J Y, 2020, Clin Infect Dis, V71, P2199, DOI 10.1093/cid/ciaa576
   Zimmermann P, 2020, PEDIATR INFECT DIS J, V39, P355, DOI 10.1097/INF.0000000000002660
NR 26
TC 1
Z9 1
U1 1
U2 1
PU GALENOS YAYINCILIK
PI FINDIKZADE
PA MOLLA GURANI MAHALLESI KACAMAK SOKAK NO 21, FINDIKZADE, ISTANBUL 34093,
   TURKEY
SN 2146-3123
EI 2146-3131
J9 BALK MED J
JI Balk. Med. J.
PD NOV
PY 2020
VL 37
IS 6
BP 341
EP 347
DI 10.4274/balkanmedj.galenos.2020.2020.7.52
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA OG8RI
UT WOS:000582143700007
PM 32865382
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Khoury, M
   Rocco, PRM
   Phinney, DG
   Krampera, M
   Martin, I
   Viswanathan, S
   Nolta, JA
   LeBlanc, K
   Galipeau, J
   Weiss, DJ
AF Khoury, Maroun
   Rocco, Patricia R. M.
   Phinney, Donald G.
   Krampera, Mauro
   Martin, Ivan
   Viswanathan, Sowmya
   Nolta, Jan A.
   LeBlanc, Katarina
   Galipeau, Jacques
   Weiss, Daniel J.
TI Cell-based therapies for coronavirus disease 2019: proper clinical
   investigations are essential
SO CYTOTHERAPY
LA English
DT Article
DE acute respiratory distress syndrome; cell therapy; coronavirus;
   COVID-19; mesenchymal stromal cells; MSCs
ID MESENCHYMAL STROMAL CELLS
AB The serious consequences of the global coronavirus disease 2019 (COVID-19) pandemic have prompted a rapid global response to develop effective therapies that can lessen disease severity in infected patients. Cell-based approaches, primarily using mesenchymal stromal cells (MSCs), have demonstrated a strong safety profile and possible efficacy in patients with acute respiratory distress syndrome (ARDS), but whether these therapies are effective for treating respiratory virus-induced ARDS is unknown. According to the World Health Organization International Clinical Trials Registry Platform and the National Institutes of Health ClinicalTrials.gov databases, 27 clinical investigations of MSC-based cell therapy approaches have begun in China since the onset of the COVID-19 outbreak, with a growing number of academic and industry trials elsewhere as well. Several recent published reports have suggested potential efficacy; however, the available data presented are either anecdotal or from incomplete, poorly controlled investigations. Therefore, although there may be a potential role for MSCs and other cell-based therapies in treatment of COVID-19, these need to be investigated in a rationally designed, controlled approach if safety and efficacy are to be demonstrated accurately. The authors urge that the field proceed by finding a balance between swift experimentation and communication of results and scientifically coherent generation and analysis of clinical data. (C) 2020 Published by Elsevier Inc. on behalf of International Society for Cell & Gene Therapy.
C1 [Khoury, Maroun] Univ Los Andes, Fac Med, Lab Nanoregenerat Med, Santiago, Chile.
   [Khoury, Maroun] Chilean Consortium Regenerat Med, Cells Cells & Consorcio Regenero, Santiago, Chile.
   [Rocco, Patricia R. M.] Univ Fed Rio de Janeiro, Carlos Chagas Filho Inst Biophys, Lab Pulm Invest, Rio De Janeiro, Brazil.
   [Rocco, Patricia R. M.] Natl Inst Sci & Technol Regenerat Med, Rio De Janeiro, Brazil.
   [Phinney, Donald G.] Scripps Res Inst, Dept Mol Med, Jupiter, FL USA.
   [Krampera, Mauro] Univ Verona, Sect Hematol, Dept Med, Verona, Italy.
   [Martin, Ivan] Univ Basel, Univ Basel Hosp, Dept Biomed, Basel, Switzerland.
   [Viswanathan, Sowmya] Univ Hlth Network, Krembil Res Inst, Toronto, ON, Canada.
   [Viswanathan, Sowmya] Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada.
   [Viswanathan, Sowmya] Univ Toronto, Dept Med, Toronto, ON, Canada.
   [Nolta, Jan A.] Univ Calif Davis Hlth, Inst Regenerat Cures, Sacramento, CA USA.
   [LeBlanc, Katarina] Karolinska Inst, Dept Lab Med,Karolinska Univ Hosp, Cell Therapy & Allogene Stem Cell Transplant, Patient Area Cell Therapies & Allogene Stem Cell, Stockholm, Sweden.
   [Galipeau, Jacques] Univ Wisconsin, Dept Med, Carbone Comprehens Canc Ctr, Madison, WI USA.
   [Weiss, Daniel J.] Univ Vermont, Dept Med, Burlington, VT USA.
RP Weiss, DJ (corresponding author), Univ Vermont, Dept Med, Hlth Sci Res Facil 226, Burlington, VT 05405 USA.
EM daniel.weiss@med.uvm.edu
OI Viswanathan, Sowmya/0000-0002-4552-0179
CR Armitage J, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.02369-2017
   Chen J, 2020, ENG BEIJING, DOI [10.1016/j.eng.2020.02.006, DOI 10.1016/J.ENG.2020.02.006.TAGEDEND]
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   FDA, 2020, FDA GUID COND CLIN T
   FDA, 2020, COR TREATM ACC PROGR
   Galipeau J, 2018, CELL STEM CELL, V22, P824, DOI 10.1016/j.stem.2018.05.004
   Keusch GT, 2017, NTEGRATING CLIN RES, DOI 10.17226/24739.
   Khoury M, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00858-2020
   Lalu MM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047559
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Matthay MA, 2019, LANCET RESP MED, V7, P154, DOI 10.1016/S2213-2600(18)30418-1
   Simonson OE, 2015, STEM CELL TRANSL MED, V4, P1199, DOI 10.5966/sctm.2015-0021
   WHO, 2016, GUID MAN ETH ISS INF
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 14
TC 8
Z9 8
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1465-3249
EI 1477-2566
J9 CYTOTHERAPY
JI Cytotherapy
PD NOV
PY 2020
VL 22
IS 11
BP 602
EP 605
DI 10.1016/j.jcyt.2020.04.089
PG 4
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Hematology; Medicine, Research & Experimental
SC Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research
   & Experimental Medicine
GA OG8WX
UT WOS:000582158200002
PM 32933835
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Addetia, A
   Crawford, KHD
   Dingens, A
   Zhu, HY
   Roychoudhury, P
   Huang, ML
   Jerome, KR
   Bloom, JD
   Greninger, AL
AF Addetia, Amin
   Crawford, Katharine H. D.
   Dingens, Adam
   Zhu, Haiying
   Roychoudhury, Pavitra
   Huang, Meei-Li
   Jerome, Keith R.
   Bloom, Jesse D.
   Greninger, Alexander L.
TI Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in
   Humans during a Fishery Vessel Outbreak with a High Attack Rate
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2; attack rate; boat; correlates; fishing;
   neutralizing antibodies; protection; vessel
ID SYNDROME CORONAVIRUS 2; ALIGNMENT
AB The development of vaccines against SARS-CoV-2 would be greatly facilitated by the identification of immunological correlates of protection in humans. However, to date, studies on protective immunity have been performed only in animal models and correlates of protection have not been established in humans. Here, we describe an outbreak of SARS-CoV-2 on a fishing vessel associated with a high attack rate. Predeparture serological and viral reverse transcription-PCR (RT-PCR) testing along with repeat testing after return to shore was available for 120 of the 122 persons on board over a median follow-up of 32.5 days (range, 18.8 to 50.5 days). A total of 104 individuals had an RT-PCR-positive viral test with a cycle threshold (C-T) of <35 or seroconverted during the follow-up period, yielding an attack rate on board of 85.2% (104/122 individuals). Metagenomic sequencing of 39 viral genomes suggested that the outbreak originated largely from a single viral Glade. Only three crew members tested seropositive prior to the boat's departure in initial serological screening and also had neutralizing and spike-reactive antibodies in follow-up assays. None of the crew members with neutralizing antibody titers showed evidence of bona fide viral infection or experienced any symptoms during the viral outbreak. Therefore, the presence of neutralizing antibodies from prior infection was significantly associated with protection against reinfection (Fisher's exact test, P = 0.002).
C1 [Addetia, Amin; Zhu, Haiying; Roychoudhury, Pavitra; Huang, Meei-Li; Jerome, Keith R.; Greninger, Alexander L.] Univ Washington, Sch Med, Dept Lab Med & Pathol, Seattle, WA 98195 USA.
   [Crawford, Katharine H. D.; Dingens, Adam; Bloom, Jesse D.] Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1124 Columbia St, Seattle, WA 98104 USA.
   [Crawford, Katharine H. D.; Dingens, Adam; Bloom, Jesse D.] Fred Hutchinson Canc Res Ctr, Computat Biol Program, 1124 Columbia St, Seattle, WA 98104 USA.
   [Crawford, Katharine H. D.; Bloom, Jesse D.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.
   [Crawford, Katharine H. D.] Univ Washington, Med Scientist Training Program, Seattle, WA 98195 USA.
   [Roychoudhury, Pavitra; Huang, Meei-Li; Jerome, Keith R.; Greninger, Alexander L.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.
   [Bloom, Jesse D.] Howard Hughes Med Inst, Seattle, WA USA.
RP Greninger, AL (corresponding author), Univ Washington, Sch Med, Dept Lab Med & Pathol, Seattle, WA 98195 USA.; Greninger, AL (corresponding author), Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.
EM agrening@uw.edu
RI Bloom, Jesse/C-6837-2013
OI Bloom, Jesse/0000-0003-1267-3408
FU Department of Laboratory Medicine and Pathology; NIAID of the NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R01AI141707, F30AI149928]
FX Work performed in the clinical laboratory was supported by the
   Department of Laboratory Medicine and Pathology. This research was
   supported by the following grants from the NIAID of the NIH: R01AI141707
   (to J.D.B.) and F30AI149928 (to K.H.D.C.). J.D.B. is an Investigator of
   the Howard Hughes Medical Institute.
CR Addetia A, 2020, J CLIN VIROL, V129, DOI 10.1016/j.jcv.2020.104523
   Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Bankevich A, 2012, J COMPUT BIOL, V19, P455, DOI 10.1089/cmb.2012.0021
   Bryan A, 2020, ANTISARS COV 2 IGG A, DOI [10.1101/2020.05.22.20110551, DOI 10.1101/2020.05.22.20110551]
   Bryan A, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00941-20
   Burbelo PD, 2020, J INFECT DIS, V222, P206, DOI 10.1093/infdis/jiaa273
   Byrnes James R, 2020, medRxiv, DOI 10.1101/2020.05.27.20114652
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671
   Crawford KHD, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050513
   Crawford KH, 2020, DYNAMICS NEUTRALIZIN, DOI [10.1101/2020.08.06.20169367, DOI 10.1101/2020.08.06.20169367]
   Dawson L, 2020, J INFECT DIS, V222, P514, DOI 10.1093/infdis/jiaa314
   Deng W, 2020, SCIENCE, V369, P818, DOI 10.1126/science.abc5343
   Dingens AS, 2020, SEROLOGICAL IDENTIFI, DOI [10.1101/2020.05.26.20114124, DOI 10.1101/2020.05.26.20114124]
   Eyal N, 2020, J INFECT DIS, V221, P1752, DOI 10.1093/infdis/jiaa152
   Fang F, 2020, ROUTL STUD SOCIOLING, P8
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Hachim A, 2020, SPIKE IDENTIFICATION, DOI [10.1101/2020.04.30.20085670, DOI 10.1101/2020.04.30.20085670]
   Hassan AO, 2020, CELL, V182, P744, DOI 10.1016/j.cell.2020.06.011
   Iyer Anita S, 2020, medRxiv, DOI 10.1101/2020.07.18.20155374
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Kakimoto K, 2020, MMWR-MORBID MORTAL W, V69, P312, DOI 10.15585/mmwr.mm6911e2
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Lee YL, 2020, J INFECTION, V81, pE55, DOI 10.1016/j.jinf.2020.04.019
   Li N, 2020, J MED VIROL, V92, P2286, DOI 10.1002/jmv.25952
   Lieberman JA, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00821-20
   Liu LH, 2020, NATURE, DOI 10.1038/s41586-020-2571-7
   Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871
   Mercado NB, 2020, NATURE, DOI 10.1038/s41586-020-2607-z
   Moriarty LF, 2020, MMWR-MORBID MORTAL W, V69, P347, DOI 10.15585/mmwr.mm6912e3
   Nalla AK, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00557-20
   Nguyen Linh Chi, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa935
   Payne DC, 2020, MMWR-MORBID MORTAL W, V69, P714, DOI [10.15585/mmwr.mm6923e4, 10.15585/mmwr.mm6923e4externalicon]
   Price MN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009490
   Rambaut Andrew, 2020, Nat Microbiol, V5, P1403, DOI 10.1038/s41564-020-0770-5
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520
   Salazar Eric, 2020, bioRxiv, DOI 10.1101/2020.06.08.138990
   Seow G., 2020, LONGITUDINAL EVALUAT, DOI [10.1101/2020.07.09.20148429., 10.1101/2020.07.09.20148429, DOI 10.1101/2020.07.09.20148429]
   Shah SK, 2020, SCIENCE, V368, P832, DOI 10.1126/science.abc1076
   Stadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100
   Tang MS, 2020, CLIN CHEM, V66, P1107, DOI 10.1093/clinchem/hvaa132
   Tang MS, 2020, CLIN CHEM, V66, P1055, DOI 10.1093/clinchem/hvaa120
   van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y
   Van Elslande J, 2020, CLIN MICROBIOL INFEC, V26, DOI 10.1016/j.cmi.2020.07.038
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Weisblum Yiska, 2020, bioRxiv, DOI 10.1101/2020.07.21.214759
   Yu Guangchuang, 2020, Curr Protoc Bioinformatics, V69, pe96, DOI 10.1002/cpbi.96
   Zhang YC, 2020, EMERG MICROBES INFEC, V9, P833, DOI 10.1080/22221751.2020.1756699
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 51
TC 10
Z9 9
U1 1
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD NOV
PY 2020
VL 58
IS 11
AR e02107-20
DI 10.1128/JCM.02107-20
PG 11
WC Microbiology
SC Microbiology
GA OG9TW
UT WOS:000582218400039
PM 32826322
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Walker, SN
   Chokkalingam, N
   Reuschel, EL
   Purwar, M
   Xu, ZY
   Gary, EN
   Kim, KY
   Helble, M
   Schultheis, K
   Walters, J
   Ramos, S
   Muthumani, K
   Smith, TRF
   Broderick, KE
   Tebas, P
   Patel, A
   Weiner, DB
   Kulp, DW
AF Walker, Susanne N.
   Chokkalingam, Neethu
   Reuschel, Emma L.
   Purwar, Mansi
   Xu, Ziyang
   Gary, Ebony N.
   Kim, Kevin Y.
   Helble, Michaela
   Schultheis, Katherine
   Walters, Jewell
   Ramos, Stephanie
   Muthumani, Kar
   Smith, Trevor R. F.
   Broderick, Kate E.
   Tebas, Pablo
   Patel, Ami
   Weiner, David B.
   Kulp, Daniel W.
TI SARS-CoV-2 Assays To Detect Functional Antibody Responses That Block
   ACE2 Recognition in Vaccinated Animals and Infected Patients
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
DE SARS-CoV-2; COVID-19; ACE2 blocking assay; serological tests; functional
   antibodies; SARS-CoV-2 vaccine; SARS-CoV-2 immunity
ID ANGIOTENSIN-CONVERTING ENZYME-2
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic of COVID-19, resulting in cases of mild to severe respiratory distress and significant mortality. The global outbreak of this novel coronavirus has now infected >20 million people worldwide, with >5 million cases in the United States (11 August 2020). The development of diagnostic and research tools to determine infection and vaccine efficacy is critically needed. We have developed multiple serologic assays using newly designed SARS-CoV-2 reagents for detecting the presence of receptor-binding antibodies in sera. The first assay is surface plasmon resonance (SPR) based and can quantitate both antibody binding to the SARS-CoV-2 spike protein and blocking to the Angiotensin-converting enzyme 2 (ACE2) receptor in a single experiment. The second assay is enzyme-linked immunosorbent assay (ELISA) based and can measure competition and blocking of the ACE2 receptor to the SARS-CoV-2 spike protein with antispike antibodies. The assay is highly versatile, and we demonstrate the broad utility of the assay by measuring antibody functionality of sera from small animals and nonhuman primates immunized with an experimental SARS-CoV-2 vaccine. In addition, we employ the assay to measure receptor blocking of sera from SARS-CoV-2-infected patients. The assay is shown to correlate with pseudovirus neutralization titers. This type of rapid, surrogate neutralization diagnostic can be employed widely to help study SARS-CoV-2 infection and assess the efficacy of vaccines.
C1 [Walker, Susanne N.; Chokkalingam, Neethu; Reuschel, Emma L.; Purwar, Mansi; Xu, Ziyang; Gary, Ebony N.; Kim, Kevin Y.; Helble, Michaela; Muthumani, Kar; Patel, Ami; Weiner, David B.; Kulp, Daniel W.] Wistar Inst Anat & Biol, Vaccine & Immunotherapy Ctr, 3601 Spruce St, Philadelphia, PA 19104 USA.
   [Schultheis, Katherine; Walters, Jewell; Ramos, Stephanie; Smith, Trevor R. F.; Broderick, Kate E.] Inovio Pharmaceut, Plymouth Meeting, PA USA.
   [Tebas, Pablo] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Kulp, Daniel W.] Univ Penn, Dept Microbiol, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Kulp, DW (corresponding author), Wistar Inst Anat & Biol, Vaccine & Immunotherapy Ctr, 3601 Spruce St, Philadelphia, PA 19104 USA.; Kulp, DW (corresponding author), Univ Penn, Dept Microbiol, Perelman Sch Med, Philadelphia, PA 19104 USA.
EM dwkulp@wistar.org
OI Ramos, Stephanie/0000-0002-5326-4937
FU Coalition for Epidemic Preparedness Innovations (CEPI)
FX This work was supported by a grant from the Coalition for Epidemic
   Preparedness Innovations (CEPI).; T.R.F.S. and K.S. are employees of
   Inovio Pharmaceuticals and as such receive salary and benefits,
   including ownership of stock and stock options, from the company. D.B.W.
   has received grant funding, participates in industry collaborations, has
   received speaking honoraria, and has received fees for consulting,
   including serving on scientific review committees and board services.
   Remuneration received by D.B.W. includes direct payments or stock or
   stock options, and in the interest of disclosure, he notes potential
   conflicts associated with this work with Inovio and possibly others. In
   addition, D.B.W. has patent pending and patented DNA vaccine
   technologies owned by Wistar Institute with certain rights licensed to
   Inovio Pharmaceuticals. We declare no other competing interests.
CR Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6
   Chen ZN, 2005, J INFECT DIS, V191, P755, DOI 10.1086/427811
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Harvala H, 2020, CONVALESCENT PLASMA, DOI [10.1101/2020.05.20.20091694, DOI 10.1101/2020.05.20.20091694]
   Huentelman MJ, 2004, HYPERTENSION, V44, P903, DOI 10.1161/01.HYP.0000146120.29648.36
   Krammer F, 2020, SCIENCE, V368, P1060, DOI 10.1126/science.abc1227
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lassauniere R, 2020, EVALUATION 9 COMMERC, DOI [10.1101/2020.04.09.20056325, DOI 10.1101/2020.04.09.20056325]
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Masson JF, 2020, ANALYST, V145, P3776, DOI 10.1039/d0an00316f
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Patel A, 2020, BIORXIV, DOI [10.1101/2020.07.28.225649, DOI 10.1101/2020.07.28.225649]
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shirato Kazuya, 2020, Jpn J Infect Dis, V73, P304, DOI 10.7883/yoken.JJID.2020.061
   Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang K, 2020, SARS COV 2 INVADES H, V3, P14, DOI DOI 10.1101/2020.03.14.988345
   Wec AZ, 2020, SCIENCE, V369, P731, DOI 10.1126/science.abc7424
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Xiao XD, 2003, BIOCHEM BIOPH RES CO, V312, P1159, DOI 10.1016/j.bbrc.2003.11.054
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhang JS, 2005, J MED VIROL, V77, P147, DOI 10.1002/jmv.20431
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zost SJ, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0998-x
   Zost Seth J, 2020, bioRxiv, DOI 10.1101/2020.05.12.091462
NR 33
TC 0
Z9 0
U1 4
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD NOV
PY 2020
VL 58
IS 11
AR e01533-20
DI 10.1128/JCM.01533-20
PG 13
WC Microbiology
SC Microbiology
GA OG9TW
UT WOS:000582218400023
PM 32855181
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Patel, B
   Eskander, MA
   Ruparel, NB
AF Patel, Biraj
   Eskander, Michael A.
   Ruparel, Nikita B.
TI To Drill or Not to Drill: Management of Endodontic Emergencies and In
   -Process Patients during the COVID-19 Pandemic
SO JOURNAL OF ENDODONTICS
LA English
DT Article
DE Aerosol-generating procedure; COVID-19; endodontic emergencies;
   long-term calcium hydroxide; palliative care
ID CALCIUM HYDROXIDE; IRREVERSIBLE PULPITIS; PREOPERATIVE PAIN;
   CONTAMINATION; FORMULATIONS; GUIDELINES; IBUPROFEN; DENTIN
AB Introduction: Dental professionals are at high risk of contracting coronavirus disease 2019 (COVID-19) infection because of their scope of practice with aerosol-generating procedures. Recommendation by the Centers for Disease Control and Prevention to suspend elective dental procedures and avoid aerosol-generating procedures posed significant challenges in the management of patients presenting with endodontic emergencies and uncertainty of outcomes for endodontic procedures initiated, but not completed, before shutdown. The purpose of this study was to evaluate the success of palliative care on endodontic emergencies during the COVID-19 pandemic and to evaluate the stability of teeth with long-term Ca(OH)(2) placement because of delays in treatment completion. Methods: Patients presenting for endodontic emergencies during COVID-19 Shelter-in-Place orders received palliative care, including pharmacologic therapy and/or non aerosol-generating procedural interventions. Part I of the study evaluated the effectiveness of palliative care, and need for aerosol-generating procedures or extractions was quantified. Part II of the study evaluated survivability and rate of adverse events for teeth that received partial or full root canal debridement and placement of calcium hydroxide before shutdown. Results: Part I: Twenty-one patients presented with endodontic emergencies in 25 teeth during statewide shutdown. At a follow-up rate of 96%, 83% of endodontic emergencies required no further treatment or intervention after palliative care. Part II: Thirty-one teeth had received partial or full root canal debridement before statewide shutdown. Mean time to complete treatment was 13 weeks. At a recall rate of 100%, 77% of teeth did not experience any adverse events due to delays in treatment completion. The most common adverse event was a fractured provisional restoration (13%), followed by painful and/or infectious flare-up (6.4%), which were managed appropriately and therefore seemed successful. Only 1 tooth was fractured and nonrestorable (3%), leading to a failed outcome of tooth extraction. The remaining 4 outcome failures (13%) were due to patient unwillingness to undergo school-mandated COVID testing or patient unwillingness to continue treatment because of perceived risk of COVID infection. Conclusions: Palliative care for management of endodontic emergencies is a successful option when aerosol -generating procedures are restricted. This treatment approach may be considered in an effort to reduce risk of transmission of COVID-19 infection during subsequent shutdowns. Prolonged Ca(OH)(2) medicament because of COVID-19 related delays in treatment completion appeared to have minimal effect on survival of teeth.
C1 [Patel, Biraj; Eskander, Michael A.; Ruparel, Nikita B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Endodont, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
RP Ruparel, NB (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Endodont, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM ruparel@uthscsa.edu
CR Andersson L, 2018, PEDIATR DENT, V40, P424, DOI 10.1111/j.1600-9657.2012.01125.x
   Andreasen JO, 2002, DENT TRAUMATOL, V18, P134, DOI 10.1034/j.1600-9657.2002.00097.x
   [Anonymous], 2020, COVID 19
   [Anonymous], CORONAVIRUS HELP DES
   Ather A, 2020, J ENDODONT, V46, P584, DOI 10.1016/j.joen.2020.03.008
   Baumgartner JC, 2003, J ENDODONT, V29, P44, DOI 10.1097/00004770-200301000-00012
   BENTLEY CD, 1994, J AM DENT ASSOC, V125, P579, DOI 10.14219/jada.archive.1994.0093
   CDC, COR 19 DENT SETT
   Coulthard P, 2020, BRIT DENT J, V228, P503, DOI 10.1038/s41415-020-1482-1
   Cvek M, 1978, J Endod, V4, P232, DOI 10.1016/S0099-2399(78)80153-8
   DiAngelis Anthony J, 2016, Pediatr Dent, V38, P358
   Divya R., 2019, DRUG INVENT TODAY, V12, P1845
   Eren B, 2018, INT ENDOD J, V51, pE227, DOI 10.1111/iej.12851
   Estrela Carlos, 2011, Braz. Dent. J., V22, P306, DOI 10.1590/S0103-64402011000400008
   FDA, PPE SHORT
   Gordon Sharon M, 2010, Dent Clin North Am, V54, P611, DOI 10.1016/j.cden.2010.06.002
   HASSELGREN G, 1989, J ENDODONT, V15, P254, DOI 10.1016/S0099-2399(89)80219-5
   Hawkins JJ, 2015, DENT TRAUMATOL, V31, P380, DOI 10.1111/edt.12175
   Hunt K, 2011, J HEALTH SERV RES PO, V16, P108, DOI 10.1258/jhsrp.2010.009131
   Kim MK, 2012, OR SURG OR MED OR PA, V114, P312, DOI 10.1016/j.tripleo.2011.07.043
   Leung Nancy H L, 2020, Nat Med, V26, P676, DOI 10.1038/s41591-020-0843-2
   LIESINGER A, 1993, J ENDODONT, V19, P35, DOI 10.1016/S0099-2399(06)81039-3
   Manarte-Monteiro P, 2013, REV PORT ESTOMATOL M, V54, P2, DOI 10.1016/j.rpemd.2012.10.002
   Nusstein JM, 2003, ORAL SURG ORAL MED O, V96, P207, DOI 10.1016/S1079-2104(02)91732-4
   Owatz CB, 2007, J ENDODONT, V33, P552, DOI 10.1016/j.joen.2007.01.023
   Peng X, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0075-9
   Ranney ML, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2006141
   Rechenberg DK, 2016, BMC ORAL HEALTH, V16, DOI 10.1186/s12903-016-0222-z
   Rosenberg B, 2007, DENT TRAUMATOL, V23, P26, DOI 10.1111/j.1600-9657.2006.00453.x
   Smith EA, 2017, J ENDODONT, V43, P7, DOI 10.1016/j.joen.2016.09.010
   Taggar T, 2017, J ENDODONT, V43, P674, DOI 10.1016/j.joen.2016.12.017
   The New York Times Coronavirus Map, NY TIMES
   Timmerman MF, 2004, J CLIN PERIODONTOL, V31, P458, DOI 10.1111/j.1600-051X.2004.00511.x
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Watts K, 2019, J ENDODONT, V45, P94, DOI 10.1016/j.joen.2018.11.005
   Yu JJ, 2020, J ENDODONT, V46, P730, DOI 10.1016/j.joen.2020.04.001
NR 36
TC 2
Z9 2
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0099-2399
EI 1878-3554
J9 J ENDODONT
JI J. Endod.
PD NOV
PY 2020
VL 46
IS 11
BP 1559
EP 1569
DI 10.1016/j.joen.2020.08.008
PG 11
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA OF4LI
UT WOS:000581181000004
PM 32841654
OA Green Published
DA 2021-01-01
ER

PT J
AU Derespina, KR
   Kaushik, S
   Plichta, A
   Conway, EE
   Bercow, A
   Choi, J
   Eisenberg, R
   Gillen, J
   Sen, AI
   Hennigan, CM
   Zerihun, LM
   Doymaz, S
   Keenaghan, MA
   Jarrin, S
   Oulds, F
   Gupta, M
   Pierre, L
   Grageda, M
   Ushay, HM
   Nadkarni, VM
   Agus, MSD
   Medar, SS
AF Derespina, Kim R.
   Kaushik, Shubhi
   Plichta, Anna
   Conway, Edward E.
   Bercow, Asher
   Choi, Jaeun
   Eisenberg, Ruth
   Gillen, Jennifer
   Sen, Anita, I
   Hennigan, Claire M.
   Zerihun, Lillian M.
   Doymaz, Sule
   Keenaghan, Michael A.
   Jarrin, Stephanie
   Oulds, Franscene
   Gupta, Manoj
   Pierre, Louisdon
   Grageda, Melissa
   Ushay, H. Michael
   Nadkarni, Vinay M.
   Agus, Michael S. D.
   Medar, Shivanand S.
TI Clinical Manifestations and Outcomes of Critically Ill Children and
   Adolescents with Coronavirus Disease 2019 in New York City
SO JOURNAL OF PEDIATRICS
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME
AB Objectives To describe the clinical manifestations and outcomes of critically ill children with coronavirus disease-19 (COVID-19) in New York City.
   Study design Retrospective observational study of children 1 month to 21 years admitted March 14 to May 2, 2020, to 9 New York City pediatric intensive care units (PICUs) with severe acute respiratory syndrome coronavirus 2 infection.
   Results Of 70 children admitted to PICUs, median age was 15 (IQR 9, 19) years; 61.4% male; 38.6% Hispanic; 32.9% black; and 74.3% with comorbidities. Fever (72.9%) and cough (71.4%) were the common presenting symptoms. Twelve patients (17%) met severe sepsis criteria; 14 (20%) required vasopressor support; 21 (30%) developed acute respiratory distress syndrome (ARDS); 9 (12.9%) met acute kidney injury criteria; 1 (1.4%) required renal-replacement therapy, and 2 (2.8%) had cardiac arrest. For treatment, 27 (38.6%) patients received hydroxychloroquine; 13 (18.6%) remdesivir; 23 (32.9%) corticosteroids; 3 (4.3%) tocilizumab; and 1 (1.4%) anakinra; no patient was given immunoglobulin or convalescent plasma. Forty-nine (70%) patients required respiratory support: 14 (20.0%) noninvasive mechanical ventilation, 20 (28.6%) invasive mechanical ventilation (IMV), 7 (10%) prone position, 2 (2.8%) inhaled nitric oxide, and 1 (1.4%) extracorporeal membrane oxygenation. Nine (45%) of the 20 patients requiring IMV were extubated by day 14 with median IMV duration of 218 (IQR 79, 310.4) hours. Presence of ARDS was significantly associated with duration of PICU and hospital stay, and lower probability of PICU and hospital discharge at hospital day 14 (P < .05 for all).
   Conclusions Critically ill children with COVID-19 predominantly are adolescents, have comorbidities, and require some form of respiratory support. The presence of ARDS is significantly associated with prolonged PICU and hospital stay.
C1 [Derespina, Kim R.; Plichta, Anna; Ushay, H. Michael; Medar, Shivanand S.] Childrens Hosp Montefiore, Dept Pediat, Div Crit Care Med, Bronx, NY USA.
   [Kaushik, Shubhi; Gillen, Jennifer] Kravis Childrens Hosp Mt Sinai, Dept Pediat, Div Crit Care Med, New York, NY USA.
   [Conway, Edward E.; Bercow, Asher] Jacobi Med Ctr, Dept Pediat, Div Crit Care Med, Bronx, NY USA.
   [Choi, Jaeun; Eisenberg, Ruth] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
   [Sen, Anita, I] Columbia Univ, Dept Pediat, Div Crit Care Med, Med Ctr, New York, NY USA.
   [Hennigan, Claire M.] New York Presbyterian Morgan Stanley Childrens Ho, Dept Pediat, New York, NY USA.
   [Zerihun, Lillian M.] Columbia Univ, Vagelos Coll Phys & Surg, New York, NY USA.
   [Doymaz, Sule] State Univ New York Downstate Hlth Sci Univ, Dept Pediat, Div Crit Care Med, Brooklyn, NY USA.
   [Keenaghan, Michael A.; Jarrin, Stephanie] Kings Cty Med Ctr, Dept Pediat, Div Crit Care Med, Brooklyn, NY USA.
   [Keenaghan, Michael A.] St Georges Univ, Dept Pediat, Grenada, WI USA.
   [Jarrin, Stephanie] State Univ New York Downstate, Dept Pediat, Brooklyn, NY USA.
   [Oulds, Franscene; Gupta, Manoj] Lincoln Med & Mental Hlth Ctr, Dept Pediat, Div Crit Care Med, Bronx, NY 10451 USA.
   [Gupta, Manoj; Medar, Shivanand S.] Childrens Hosp Montefiore, Dept Pediat, Div Cardiol, Bronx, NY USA.
   [Pierre, Louisdon] Brooklyn Hosp Ctr, Dept Pediat, Div Crit Care Med, Brooklyn, NY USA.
   [Grageda, Melissa] Richmond Univ, Dept Pediat, Div Crit Care Med, Med Ctr, Staten Isl, NY USA.
   [Nadkarni, Vinay M.] Childrens Hosp Philadelphia, Div Crit Care Med, Philadelphia, PA 19104 USA.
   [Agus, Michael S. D.] Boston Childrens Hosp, Div Med Crit Care, Boston, MA USA.
RP Medar, SS (corresponding author), Albert Einstein Coll Med, Div Pediat Crit Care Med & Pediat Cardiol, 3411 Wayne Ave,Suite 808B, Bronx, NY 10467 USA.
EM smedar@montefiore.org
OI Grageda, Melissa/0000-0002-7225-3643; Gupta, Manoj/0000-0002-5511-6348;
   Derespina, Kim/0000-0002-9138-9415
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Andrist E, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2019-0748
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Castagnoli R, 2020, JAMA PEDIATR, V174, P882, DOI 10.1001/jamapediatrics.2020.1467
   Chao JY, 2020, J PEDIATR-US, V223, P14, DOI 10.1016/j.jpeds.2020.05.006
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Gotzinger F, 2020, LANCET CHILD ADOLESC, V4, P653, DOI 10.1016/S2352-4642(20)30177-2
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103
   Jouvet P, 2015, PEDIATR CRIT CARE ME, V16, P428, DOI 10.1097/PCC.0000000000000350
   Kaushik A, 2020, INDIAN J PEDIATR, DOI 10.1007/s12098-020-03374-0
   Kellum JA, 2013, CRIT CARE, V17, DOI 10.1186/cc11454
   Khemani RG, 2019, LANCET RESP MED, V7, P115, DOI 10.1016/S2213-2600(18)30344-8
   Khemani RG, 2018, AM J RESP CRIT CARE, V198, P77, DOI 10.1164/rccm.201707-1404OC
   Koh JWJC, 2017, PEDIATR PULM, V52, P1076, DOI 10.1002/ppul.23702
   New York State Department of Health, HLTH ADV PED MULT IN
   Qiu HY, 2020, LANCET INFECT DIS, V20, P689, DOI 10.1016/S1473-3099(20)30198-5
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Shekerdemian LS, 2020, JAMA PEDIAT
   Slater A, 2003, INTENS CARE MED, V29, P278, DOI 10.1007/s00134-002-1601-2
   Tagarro A, 2020, JAMA PEDIAT
   US Census, QUICKFACTS BRONX COU
   Wadhera RK, 2020, JAMA-J AM MED ASSOC, V323, P2192, DOI 10.1001/jama.2020.7197
   Weiss SL, 2020, PEDIATR CRIT CARE ME, V21, pE52, DOI 10.1097/PCC.0000000000002198
   WHO, 2020, CLIN MAN SEV AC RESP
   Zachariah P, 2020, JAMA PEDIAT
NR 28
TC 4
Z9 4
U1 1
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-3476
EI 1097-6833
J9 J PEDIATR-US
JI J. Pediatr.
PD NOV
PY 2020
VL 226
BP 55
EP +
DI 10.1016/j.jpeds.2020.07.039
PG 11
WC Pediatrics
SC Pediatrics
GA OG9WY
UT WOS:000582226400011
PM 32681989
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Al Hashmi, AM
   Ozdemir, AO
   Shuaib, A
   Al-Jehani, H
   Mansour, OY
   Alhazzani, A
   Aladhem, F
   Farhoudi, M
   John, S
   Saqqur, M
AF Al Hashmi, Amal M.
   Ozdemir, Atilla Ozcan
   Shuaib, Ashfaq
   Al-Jehani, Hosam
   Mansour, Ossama Yassin
   Alhazzani, Adel
   Aladhem, Farid
   Farhoudi, Mehdi
   John, Seby
   Saqqur, Maher
TI Current Recommendations for the Management of Stroke Patients in the
   Middle East in the Era of COVID-19 Pandemic; Statement from the MENA
   SINO
SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
LA English
DT Article
DE COVID-19 Pandemic; World StrokeOrganization (WSO); Acute Stroke; Middle
   East and North Africa Stroke and Interventional Neurotherapies
   Organization (MENA SINO); Stroke Care; Stroke Services; Challenges;
   Recommendations
AB COVID-19 pandemic has led to a change in the way we manage acute medical illnesses. This pandemic had a negative impact on stroke care worldwide. The World Stroke Organization (WSO) has raised concerns due to the lack of available care and compromised acute stroke services globally. The numbers of thrombolysis and thrombectomy therapies are declining. As well as, the rates and door-to treatment times for thrombolysis and thrombectomy therapies are increasing. The stroke units are being reallocated to serve COVID-19 patients, and stroke teams are being redeployed to COVID-19 centers. Covid 19 confirmed cases and deaths are rising day by day. This pandemic clearly threatened and threatening all stroke care achievements regionally. Managing stroke patients during this pandemic is even more challenging at our region. The Middle East and North Africa Stroke and Interventional Neurotherapies Organization (MENA-SINO) is the main stroke organization regionally. MENA-SINO urges the need to developing new strategies and recommendations for stroke care during this pandemic. This will require multiple channels of interventions and create a protective code stroke with fast triaging path. Developing and expanding the tele-stroke programs are urgently required. There is an urgent need for enhancing collaboration and cooperation between stroke expertise regionally and internationally. Integrating such measures will inevitably lead to an improvement and upgrading of the services to a satisfactory level.
C1 [Al Hashmi, Amal M.] Khoula Hosp, Cent Stroke Unit, Head Cent Stroke Unit Oman, Minist Hlth Oman, Muscat, Oman.
   [Ozdemir, Atilla Ozcan] Eskisehir Osmangazi Univ, Div Neurol, Neurocrit Care, Eskisehir, Turkey.
   [Shuaib, Ashfaq; Saqqur, Maher] Univ Alberta, Dept Med, Div Neurol, Edmonton, AB, Canada.
   [Al-Jehani, Hosam] King Fahad Hosp Univ Imam Abdulrahman, Dept Neurosurg Intervent Neuroradiol & Crit Care, Al Khobar, Saudi Arabia.
   [Mansour, Ossama Yassin] Alexandria Fac Med, Dept Neurol, Riyadh, Saudi Arabia.
   [Alhazzani, Adel] King Saud Univ Riyadh, Coll Med, Med Dept, Neurol Unit, Riyadh, Saudi Arabia.
   [Aladhem, Farid] Specialty Hosp, Amman, Jordan.
   [Farhoudi, Mehdi] Tabriz Univ Med Sci, Neurosci Res Ctr, Tabriz, Iran.
   [John, Seby] Cleveland Clin Abu Dhabi, Neurol & Neurointervent Surg, Abu Dhabi, U Arab Emirates.
   [Saqqur, Maher] Univ Toronto Mississauga, Trillium Hosp, Mississauga, ON, Canada.
RP Saqqur, M (corresponding author), Univ Alberta, Med & Neurol, 2E3 WC Mackenzie Hlth Sci Ctr, Edmonton, AB T6G 2R7, Canada.
EM msaqqur@ualberta.ca
CR Aggarwal G, 2020, INT J STROKE, V15, P385, DOI 10.1177/1747493020921664
   Arbour N, 2000, J VIROL, V74, P8913, DOI 10.1128/JVI.74.19.8913-8921.2000
   Bao L, 2020, PATHOGENICITY SARS C
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Kerleroux B, 2020, STROKE, V51, P2012, DOI 10.1161/STROKEAHA.120.030373
   Li Y, 2020, OBSERVATIONAL STUDY, V2020
   Luo X, 2020, INT J MACH LEARN CYB, V11, P197, DOI 10.1007/s13042-019-00967-w
   Mao L, 2020, MEDIA, V2020
   Oxley Thomas J, 2020, FIFI MDNEJ MED
   Protected Code Stroke, 2020, HYP STROK MAN COR DI
   Rudilosso S, 2020, STROKE, V51, P1991, DOI 10.1161/STROKEAHA.120.030329
   Yaghi S, 2020, STROKE, V51, P2002, DOI 10.1161/STROKEAHA.120.030335
NR 12
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1052-3057
EI 1532-8511
J9 J STROKE CEREBROVASC
JI J. Stroke Cerebrovasc. Dis.
PD NOV
PY 2020
VL 29
IS 11
AR 105181
DI 10.1016/j.jstrokecerebrovasdis.2020.105181
PG 5
WC Neurosciences; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA OD0CS
UT WOS:000579523100010
PM 33066945
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Wang, CC
   Chao, JK
   Wang, ML
   Yang, YP
   Chien, CS
   Lai, WY
   Yang, YC
   Chang, YH
   Chou, CL
   Kao, CL
AF Wang, Chien-Chih
   Chao, Jian-Kang
   Wang, Mong-Lien
   Yang, Yi-Ping
   Chien, Chien-Shiu
   Lai, Wei-Yi
   Yang, Yi-Chiang
   Chang, Yu-Hui
   Chou, Chen-Liang
   Kao, Chung-Lan
TI Care for Patients with Stroke During the COVID-19 Pandemic: Physical
   Therapy and Rehabilitation Suggestions for Preventing Secondary Stroke
SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
LA English
DT Article
DE COVID-19; Patients with stroke; Coagulopathy; Physical therapy
   Rehabilitation
ID RENIN-ANGIOTENSIN SYSTEM; RESPIRATORY SYNDROME SARS;
   ELECTRICAL-STIMULATION; CORONAVIRUS; BALANCE
AB Infection with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes the development of the novel 2019 coronavirus disease (COVID-19) and associated clinical symptoms, which typically presents as an upper respiratory syndrome such as pneumonia. Growing evidence indicates an increased prevalence of neurological involvement (e.g., in the form of stroke) during virus infection. COVID-19 has been suggested to be more than a lung infection because it affects the vasculature of the lungs and other organs and increases the risk of thrombosis. Patients with stroke are vulnerable to secondary events as a result not only of their poor vascular condition but also of their lack of access to rehabilitation resources. Herein, we review current knowledge regarding the pathophysiology of COVID-19, its possible association with neurological involvement, and current drug therapies. Suggestions are also offered regarding the potential for current neurorehabilitation therapies to be taught and practiced at home.
C1 [Wang, Chien-Chih] Taipei Vet Gen Hosp, Dept Phys Med & Rehabil, Yuli Branch, Hualien, Taiwan.
   [Wang, Chien-Chih; Wang, Mong-Lien; Yang, Yi-Ping; Chien, Chien-Shiu; Lai, Wei-Yi; Kao, Chung-Lan] Natl Yang Ming Univ, Inst Clin Med, Taipei, Taiwan.
   [Chao, Jian-Kang] Natl Pingtung Univ Sci & Technol, Dept Social Work, Pingtung, Taiwan.
   [Chao, Jian-Kang] Taipei Vet Gen Hosp, Dept Psychiat, Yuli Branch, Hualien, Taiwan.
   [Wang, Mong-Lien; Yang, Yi-Ping; Chien, Chien-Shiu; Lai, Wei-Yi] Taipei Vet Gen Hosp, Dept Med Res, Taipei, Taiwan.
   [Yang, Yi-Chiang; Chou, Chen-Liang; Kao, Chung-Lan] Taipei Vet Gen Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan.
   [Chang, Yu-Hui] Taipei Vet Gen Hosp, Dept Nursing, Taipei, Taiwan.
   [Chou, Chen-Liang; Kao, Chung-Lan] Natl Yang Ming Univ, Sch Med, Dept Phys Med & Rehabil, Taipei, Taiwan.
   [Kao, Chung-Lan] Natl Chiao Tung Univ, Ctr Intelligent Drug Syst & Smart Biodevices IDS2, Hsinchu, Taiwan.
RP Kao, CL (corresponding author), Natl Yang Ming Univ, Inst Clin Med, Taipei, Taiwan.; Kao, CL (corresponding author), Taipei Vet Gen Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan.; Kao, CL (corresponding author), Natl Yang Ming Univ, Sch Med, Dept Phys Med & Rehabil, Taipei, Taiwan.; Kao, CL (corresponding author), Natl Chiao Tung Univ, Ctr Intelligent Drug Syst & Smart Biodevices IDS2, Hsinchu, Taiwan.
EM clkao@vghtpe.gov.tw
FU Taipei Veterans General Hospital, Yuli branch [VHYL-108-01]; Ministry of
   Science and Technology [108-2314-B-010 -042 -MY3]; Taipei Veterans
   General Hospital-National Yang-Ming University Excellent Physician
   Scientists Cultivation Program [108-V-B-008]
FX This work was financially supported by Taipei Veterans General Hospital,
   Yuli branch (VHYL-108-01), Ministry of Science and Technology
   (108-2314-B-010 -042 -MY3) and Taipei Veterans General Hospital-National
   Yang-Ming University Excellent Physician Scientists Cultivation Program
   No. 108-V-B-008.
CR Abiodun OA, 2020, SAUDI J BIOL SCI, V27, P905, DOI 10.1016/j.sjbs.2020.01.026
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Arroja Mariana Moreira Coutinho, 2016, Exp Transl Stroke Med, V8, P8
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Bennion DM, 2015, CURR HYPERTENS REP, V17, DOI 10.1007/s11906-014-0512-2
   Cabello-Verrugio C, 2015, MED RES REV, V35, P437, DOI 10.1002/med.21343
   Callaway E, 2020, NATURE, V579, P482, DOI 10.1038/d41586-020-00758-2
   Cao B, 2020, NEW ENGL J MED, V382
   Carvalho Diana, 2013, Int Arch Med, V6, P41, DOI 10.1186/1755-7682-6-41
   Chatre C, 2018, DRUG SAFETY, V41, P919, DOI 10.1007/s40264-018-0689-4
   Chen C, 2020, FAV VERS ARB DOL COV
   Chen F, 2004, J CLIN VIROL, V31, P69, DOI 10.1016/j.jcv.2004.03.003
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Danzi GB, 2020, EUR HEART J
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Di Gennaro F, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17082690
   Ding YQ, 2004, J PATHOL, V203, P622, DOI 10.1002/path.1560
   Ding YQ, 2003, J PATHOL, V200, P282, DOI 10.1002/path.1440
   Divani AA, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.104941
   Duncan PW, 2011, NEW ENGL J MED, V364, P2026, DOI 10.1056/NEJMoa1010790
   Eliezer M, 2020, JAMA OTOLARYNGOL HEA
   FIEVET P, 1986, J HYPERTENS, V4, pS88
   Gandhi DBC, 2020, THER CLIN RISK MANAG, V16, P75, DOI 10.2147/TCRM.S206883
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gheblawi M, 2020, CIRC RES
   Grein J, 2020, NEW ENGL J MED, V382
   Grillet F, RADIOLOGY
   Han H, 2020, CLIN CHEM LAB MED, V58, P1116, DOI 10.1515/cclm-2020-0188
   Han SW, 2020, CANCER MED-US, V9, P6667, DOI 10.1002/cam4.3289
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   In T, 2016, MED SCI MONITOR, V22, P4046, DOI 10.12659/MSM.898157
   Ishiguro T, 2019, RESPIR MED CASE REP, V28, DOI 10.1016/j.rmcr.2019.100884
   Jung KS, 2017, GAIT POSTURE, V54, P183, DOI 10.1016/j.gaitpost.2017.03.007
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Laver KE, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008349.pub2
   Lentini G, 2020, MOLECULES, V25, DOI 10.3390/molecules25081834
   Liu H, 2017, AM J PHYS MED REHAB, V96, P687, DOI 10.1097/PHM.0000000000000748
   Lowe DA, 2020, JAMA INTERN MED, DOI 10.1001/jamainternmed.2020.4153
   Magro C, 2020, TRANSL RES J LAB CLI
   Mahmood A, 2019, ARCH PHYS MED REHAB, V100, P751, DOI 10.1016/j.apmr.2018.10.016
   Mao L, 2020, JAMA NEUROL
   Mayo NE, 2016, STROKE, V47, P1685, DOI 10.1161/STROKEAHA.116.011309
   Mayo NE, 2013, CLIN REHABIL, V27, P659, DOI 10.1177/0269215513476312
   McGlinchey MP, 2018, SYST REV-LONDON, V7, DOI 10.1186/s13643-018-0870-y
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Mekbib DB, 2020, BRAIN INJURY, V34, P456, DOI 10.1080/02699052.2020.1725126
   Mogi M, 2014, GERIATR GERONTOL INT, V14, P793, DOI 10.1111/ggi.12167
   Oudkerk M, RADIOLOGY
   Oudkerk M, 2020, RADIOLOGY, V297, pE216, DOI 10.1148/radiol.2020201629
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Regenhardt RW, 2014, CLIN SCI, V126, P195, DOI 10.1042/CS20130324
   Rose-John S, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028415
   Rutherford AI, 2018, ANN RHEUM DIS, V77, P905, DOI 10.1136/annrheumdis-2017-212825
   Sharififar S, 2018, ANN PHYS REHABIL MED, V61, P339, DOI 10.1016/j.rehab.2018.06.005
   Tang W., 2020, HYDROXYCHLOROQUINE P
   Thieme H, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008449.pub3
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   Umapathi T, 2004, J NEUROL, V251, P1227, DOI 10.1007/s00415-004-0519-8
   Utkan Karasu A, 2018, J REHABIL MED, V50, P406, DOI 10.2340/16501977-2331
   Vaduganathan M, 2020, NEW ENGL J MED, V382
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang K, 2020, INV HOST CELLS VIA N
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Xie FL, 2019, ARTHRIT CARE RES, V71, P1004, DOI 10.1002/acr.23737
   Yao X, 2020, CLIN INFECT DIS PUBL
   Zhang Q, 2020, J MED VIROL, V92, P713, DOI 10.1002/jmv.25803
NR 69
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1052-3057
EI 1532-8511
J9 J STROKE CEREBROVASC
JI J. Stroke Cerebrovasc. Dis.
PD NOV
PY 2020
VL 29
IS 11
AR 105182
DI 10.1016/j.jstrokecerebrovasdis.2020.105182
PG 6
WC Neurosciences; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA OD0CS
UT WOS:000579523100011
PM 33066878
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Badr, HS
   Du, HR
   Marshall, M
   Dong, ES
   Squire, MM
   Gardner, LM
AF Badr, Hamada S.
   Du, Hongru
   Marshall, Maximilian
   Dong, Ensheng
   Squire, Marietta M.
   Gardner, Lauren M.
TI Association between mobility patterns and COVID-19 transmission in the
   USA: a mathematical modelling study
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
AB Background Within 4 months of COVID-19 first being reported in the USA, it spread to every state and to more than 90% of all counties. During this period, the US COVID-19 response was highly decentralised, with stay-at-home directives issued by state and local officials, subject to varying levels of enforcement. The absence of a centralised policy and timeline combined with the complex dynamics of human mobility and the variable intensity of local outbreaks makes assessing the effect of large-scale social distancing on COVID-19 transmission in the USA a challenge.
   Methods We used daily mobility data derived from aggregated and anonymised cell (mobile) phone data, provided by Teralytics (Zurich, Switzerland) from Jan 1 to April 20, 2020, to capture real-time trends in movement patterns for each US county, and used these data to generate a social distancing metric. We used epidemiological data to compute the COVID-19 growth rate ratio for a given county on a given day. Using these metrics, we evaluated how social distancing, measured by the relative change in mobility, affected the rate of new infections in the 25 counties in the USA with the highest number of confirmed cases on April 16, 2020, by fitting a statistical model for each county.
   Findings Our analysis revealed that mobility patterns are strongly correlated with decreased COVID-19 case growth rates for the most affected counties in the USA, with Pearson correlation coefficients above 0.7 for 20 of the 25 counties evaluated. Additionally, the effect of changes in mobility patterns, which dropped by 35-63% relative to the normal conditions, on COVID-19 transmission are not likely to be perceptible for 9-12 days, and potentially up to 3 weeks, which is consistent with the incubation time of severe acute respiratory syndrome coronavirus 2 plus additional time for reporting. We also show evidence that behavioural changes were already underway in many US counties days to weeks before state-level or local-level stay-at-home policies were implemented, implying that individuals anticipated public health directives where social distancing was adopted, despite a mixed political message.
   Interpretation This study strongly supports a role of social distancing as an effective way to mitigate COVID-19 transmission in the USA. Until a COVID-19 vaccine is widely available, social distancing will remain one of the primary measures to combat disease spread, and these findings should serve to support more timely policy making around social distancing in the USA in the future. Copyright (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Badr, Hamada S.] Johns Hopkins Univ, Dept Earth & Planetary Sci, Baltimore, MD 21218 USA.
   [Du, Hongru; Marshall, Maximilian; Dong, Ensheng; Squire, Marietta M.; Gardner, Lauren M.] Johns Hopkins Univ, Dept Civil & Syst Engn, Baltimore, MD 21218 USA.
RP Gardner, LM (corresponding author), Johns Hopkins Univ, Dept Civil & Syst Engn, Baltimore, MD 21218 USA.
EM l.gardner@jhu.edu
OI Badr, Hamada/0000-0002-9808-2344; Dong, Ensheng/0000-0002-9785-5739
CR Bi QF, 2020, LANCET INFECT DIS, V20, P911, DOI 10.1016/S1473-3099(20)30287-5
   Buckee CO, 2020, SCIENCE, V368, P145, DOI 10.1126/science.abb8021
   Chinazzi M, 2020, SCIENCE, V368, P395, DOI 10.1126/science.aba9757
   COVID Tracking Project, 2020, US COVID 19 TESTING
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Kraemer MUG, 2020, SCIENCE, V368, P493, DOI 10.1126/science.abb4218
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, P553, DOI 10.1016/S1473-3099(20)30144-4
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Sjodin H, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.13.2000280
   Tian HY, 2020, SCIENCE, V368, P638, DOI 10.1126/science.abb6105
   US CDC, 2020, SOC DIST
   WHO, 2020, ADV PUBL
   WHO, 2020, PNEUM UNK CAUS
   World Health Organization, 2020, NOV COR CHIN EM PREP
   World Health Organization, 2020, 106 WHO
   Zhao S, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa022
NR 20
TC 17
Z9 17
U1 7
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD NOV
PY 2020
VL 20
IS 11
BP 1247
EP 1254
DI 10.1016/S1473-3099(20)30553-3
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA OG9HI
UT WOS:000582185500038
PM 32621869
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Buehrle, DJ
   Decker, BK
   Wagener, MM
   Adalja, A
   Singh, N
   McEllistrem, MC
   Nguyen, MH
   Clancy, CJ
AF Buehrle, Deanna J.
   Decker, Brooke K.
   Wagener, Marilyn M.
   Adalja, Amesh
   Singh, Nina
   McEllistrem, Mary C.
   Nguyen, M. Hong
   Clancy, Cornelius J.
TI Antibiotic Consumption and Stewardship at a Hospital outside of an Early
   Coronavirus Disease 2019 Epicenter
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
DE COVID-19; SARS-CoV-2; antibiotics; antimicrobial stewardship
AB There are scant data on the impact of coronavirus disease 2019 (COVID19) on hospital antibiotic consumption, and no data from outside epicenters. At our nonepicenter hospital, antibiotic days of therapy (DOT) and bed days of care (BDOC) were reduced by 151.5/month and 285/month, respectively, for March to June 2020 compared to 2018-2019 (P = 0.001 and P < 0.001). DOT per 1,000 BDOC was increased (8.1/month; P = 0.001). COVID-19 will impact antibiotic consumption, stewardship, and resistance in ways that will likely differ temporally and by region.
C1 [Buehrle, Deanna J.; Decker, Brooke K.; Wagener, Marilyn M.; Adalja, Amesh; Singh, Nina; McEllistrem, Mary C.; Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Infect Dis Sect, Pittsburgh, PA 15240 USA.
   [Decker, Brooke K.; Singh, Nina; Nguyen, M. Hong; Clancy, Cornelius J.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
   [Adalja, Amesh] VA Pittsburgh Healthcare Syst, Crit Care Sect, Pittsburgh, PA USA.
   [Adalja, Amesh] Johns Hopkins Ctr Hlth Secur, Baltimore, MD USA.
RP Buehrle, DJ (corresponding author), VA Pittsburgh Healthcare Syst, Infect Dis Sect, Pittsburgh, PA 15240 USA.
EM deanna.buehrle@va.gov
FU AstellasAstellas Pharmaceuticals; MerckMerck & Company; Melinta;
   Medicines Company; T2Biosystems; Medicines Company, Scynexis; Shionogi
FX There was no funding for the study. C. J. Clancy has been awarded
   investigatorinitiated research grants from Astellas, Merck, Melinta, and
   Cidara for studies unrelated to this project, served on advisory boards
   or consulted for Astellas, Merck, the Medicines Company, Cidara,
   Scynexis, Shionogi, Qpex, and Needham & Company, and spoken at symposia
   sponsored by Merck and T2Biosystems. M. H. Nguyen has been awarded
   investigator-initiated research grants from Astellas, Merck, Melinta,
   and Cidara for projects unrelated to this study and has served on
   advisory boards for Astellas, Merck, the Medicines Company, Scynexis,
   and Shionogi. A. Adalja is on the speakers bureau, serves on the
   advisory board, and is a consultant for Merck; he is also a Merck
   shareholder. The other authors report no conflicts.
CR Abelenda-Alonso G, 2020, INFECT CONT HOSP EP, V41, P1371, DOI 10.1017/ice.2020.381
   Clancy CJ, 2020, JAC ANTIMICROB RESIS, DOI [10.1093/jacamr/dlaa049., DOI 10.1093/JACAMR/DLAA049]
   Clancy Cornelius J, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa524
   Collignon PJ, 2020, JAC ANTIMICROB RESIS, DOI [10.1093/jacamr/dlaa051., DOI 10.1093/JACAMR/DLAA051]
   Langford BJ, 2020, CLIN MICROBIOL INFEC, DOI [10.1016/j.cmi.2020.07 .016., DOI 10.1016/J.CMI.2020.07]
   Nestler Matthew J, 2020, Infect Control Hosp Epidemiol, P1, DOI 10.1017/ice.2020.362
   Vaduganathan M, 2020, JAMA-J AM MED ASSOC, V323, P2524, DOI 10.1001/jama.2020.9184
   Velasco-Arnaiz Eneritz, 2020, Infect Control Hosp Epidemiol, P1, DOI 10.1017/ice.2020.312
NR 8
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD NOV
PY 2020
VL 64
IS 11
AR e01011-20
DI 10.1128/AAC.01011-20
PG 6
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA OE6ML
UT WOS:000580642600006
PM 32816693
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Le, MP
   Le Hingrat, Q
   Jaquet, P
   Wicky, PH
   Bunel, V
   Massias, L
   Visseaux, B
   Messika, J
   Descamps, D
   Mal, H
   Timsit, JF
   Peytavin, G
AF Le, Minh Patrick
   Le Hingrat, Quentin
   Jaquet, Pierre
   Wicky, Paul-Henri
   Bunel, Vincent
   Massias, Laurent
   Visseaux, Benoit
   Messika, Jonathan
   Descamps, Diane
   Mal, Herve
   Timsit, Jean-Francois
   Peytavin, Gilles
TI Removal of Remdesivir's Metabolite GS-441524 by Hemodialysis in a Double
   Lung Transplant Recipient with COVID-19
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
DE hemodialysis; pharmacokinetics; remdesivir
AB Remdesivir has reported efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro and in vivo. Drug-drug interactions limit therapeutic options in transplant patients. Remdesivir and its metabolite GS-441524 are excreted principally in urine. In intensive care unit (ICU) settings, in which multiple-organ dysfunctions can occur rapidly, hemodialysis may be a viable option for maintaining remdesivir treatment, while improving tolerance, by removing both remdesivir's metabolite (GS-441524) and sulfobutylether beta-cyclodextrin sodium (SEBCD). Additional studies may prove informative, particularly in the evaluations of therapeutic options for coronavirus disease 2019 (COVID-19).
C1 [Le, Minh Patrick; Massias, Laurent; Peytavin, Gilles] Bichat Claude Bernard Hosp, AP HP, Pharmacol Toxicol Dept, Paris, France.
   [Le, Minh Patrick] Univ Paris, INSERM, UMRS 1144, Paris, France.
   [Le Hingrat, Quentin; Visseaux, Benoit; Descamps, Diane] Bichat Claude Bernard Hosp, AP HP, Virol Dept, Paris, France.
   [Le Hingrat, Quentin; Massias, Laurent; Visseaux, Benoit; Descamps, Diane; Timsit, Jean-Francois; Peytavin, Gilles] Univ Paris, INSERM, IAME, UMRS 1137, Paris, France.
   [Jaquet, Pierre; Wicky, Paul-Henri; Timsit, Jean-Francois] Bichat Claude Bernard Hosp, AP HP, Med & Infect Dis ICU MI2, Paris, France.
   [Bunel, Vincent; Messika, Jonathan; Mal, Herve] Bichat Claude Bernard Hosp, AP HP, Pneumol B & Lung Transplant Dept, INSERM 1152, Paris, France.
RP Le, MP (corresponding author), Bichat Claude Bernard Hosp, AP HP, Pharmacol Toxicol Dept, Paris, France.; Le, MP (corresponding author), Univ Paris, INSERM, UMRS 1144, Paris, France.
EM minh.le@aphp.fi
OI Visseaux, Benoit/0000-0002-9279-5538; WICKY,
   Paul-Henri/0000-0002-1105-4667
CR Avataneo V, 2020, J ANTIMICROB CHEMOTH, V75, P1772, DOI 10.1093/jac/dkaa152
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cao YC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101647
   European Medicines Agency, 2020, SUMM COMP US
   Hoover RK, 2018, J CLIN PHARMACOL, V58, P814, DOI 10.1002/jcph.1077
   Luke DR, 2012, NEPHROL DIAL TRANSPL, V27, P1207, DOI 10.1093/ndt/gfr472
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Murthy S, 2020, JAMA-J AM MED ASSOC, V323, P1499, DOI 10.1001/jama.2020.3633
   Tempestilli M, 2020, J ANTIMICROB CHEMOTH, V75, P2977, DOI 10.1093/jac/dkaa239
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
NR 10
TC 2
Z9 2
U1 2
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD NOV
PY 2020
VL 64
IS 11
AR e01521-20
DI 10.1128/AAC.01521-20
PG 4
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA OE6ML
UT WOS:000580642600026
PM 32868327
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Li, T
   Lu, L
   Zhang, WS
   Tao, Y
   Wang, LM
   Bao, J
   Liu, B
   Duan, J
AF Li, Tao
   Lu, Lei
   Zhang, Weishuo
   Tao, Yu
   Wang, Liuming
   Bao, Jing
   Liu, Bao
   Duan, Jun
TI Clinical characteristics of 312 hospitalized older patients with
   COVID-19 in Wuhan, China
SO ARCHIVES OF GERONTOLOGY AND GERIATRICS
LA English
DT Article
DE Clinical characteristics; Older patients; COVID-19; Severity; Risk
   factors; Outcomes
ID CORONAVIRUS; ACE2
AB Objectives: Much of the previous research on COVID-19 was based on all population. But substantial numbers of severe episodes occur in older patients. There is a lack of data about COVID-19 in older adults. The aims of this study were to analyze the clinical characteristics of older adult patients with COVID-19.
   Methods: Retrospective study of older patients hospitalized with COVID-19 from February 1 st to March 31 st, 2020 was conducted in the Sino-French New City Branch of Tongjing Hospital in Wuhan, China. According to the degree of severity of COVID-19 during hospitalization, 312 older patients were divided into non-severe and severe cases.
   Results: the mean age of the patients was 69.2 +/- 7.3 years, and 47.4 % of patients had exposure history. 77.2 % of patients had a co-morbidity, with hypertension being the most common (57.1 %), followed by diabetes (38.8 %) and cardiovascular disease (29.8 %). Multivariable regression showed increasing odds of severe COVID-19 associated with age(OR 1.59, 95 %CI 1.13 - 2.08), SOFA score(OR 5.89, 95 %CI 3.48 - 7.96), APACHEII score (OR 3.13, 95 %CI 1.85 - 5.62), platelet count < 125 x 10(9) /L(OR 2.36, 95 %CI 1.03 - 4.14), D-dimer (OR 4.37, 95 %CI 2.58 - 7.16), creatinine > 133 mu mol/L(OR 1.85, 95 %CI 1.12 - 3.04), interleukin-6(OR 4.32, 95 %CI 2.07 - 7.13), and lung consolidation(OR 1.94, 95 %CI 1.45 - 4.27) on admission. The most common complication was acute respiratory distress syndrome (35.6 %), followed by acute cardiac injury (33.0 %) and coagulation disorders (30.8 %). 91.7 % of patients were prescribed antiviral therapy, followed by immune globulin (52.9 %) and systemic glucocorticoids (43.6 %). 21.8 % of patients received invasive ventilation, 1.92 % for extracorporeal membrane oxygenation. The overall mortality was 6.73 %, and mortality of severe patients was 17.1 %, which was higher than non-severe patients (0.962 %).
   Conclusions: Older patients with COVID-19 had much more co-morbidity, complications and mortality. More attention should be paid to older patients with COVID-19.
C1 [Li, Tao; Bao, Jing; Liu, Bao; Duan, Jun] China Japan Friendship Hosp, Surgury Intens Care Unit, 2 YingHua East St, Beijing, Peoples R China.
   [Lu, Lei] Jiaxing Univ, Dept Emergency, Affiliated Hosp 2, Jiaxing, Zhejiang, Peoples R China.
   [Zhang, Weishuo] China Japan Friendship Hosp, Med Affairs Off, 2 YingHua East St, Beijing, Peoples R China.
   [Tao, Yu; Wang, Liuming] Huazhong Univ Sci & Technol, Med Affairs Off, Tongji Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
RP Duan, J (corresponding author), China Japan Friendship Hosp, Surgury Intens Care Unit, 2 YingHua East St, Beijing, Peoples R China.
EM junjununun@163.com
OI LI, TAO/0000-0001-9701-8765
CR Bao CP, 2020, J AM COLL RADIOL, V17, P701, DOI 10.1016/j.jacr.2020.03.006
   Chen LK, 2020, ARCH GERONTOL GERIAT, V89, DOI 10.1016/j.archger.2020.104124
   Duarte R, 2020, ACTA MEDICA PORT, V33, P155, DOI 10.20344/amp.13547
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Feng Y, 2020, AM J RESP CRIT CARE, V201, P1380, DOI 10.1164/rccm.202002-0445OC
   Fu LW, 2020, J INFECTION, V80, P656, DOI 10.1016/j.jinf.2020.03.041
   GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Gupta Vishal, 2017, J Assoc Physicians India, V65, P47
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang XY, 2020, ARCH IRAN MED, V23, P268, DOI 10.34172/aim.2020.09
   Jain S, 2018, TRANSFUS APHER SCI, V57, P705, DOI 10.1016/j.transci.2018.10.009
   Jia HP, 2016, SHOCK, V46, P239, DOI 10.1097/SHK.0000000000000633
   Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group, 2012, KDIGO CLIN PRACTICE
   King H, 2018, LANCET, V391, P1354, DOI 10.1016/S0140-6736(18)30490-2
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Metlay JP, 2019, AM J RESP CRIT CARE, V200, pE45, DOI 10.1164/rccm.201908-1581ST
   Niu SM, 2020, ARCH GERONTOL GERIAT, V89
   Opal SM, 2005, CLIN INFECT DIS, V41, pS504, DOI 10.1086/432007
   Qiao Q, 2012, J INT MED RES, V40, P1114, DOI 10.1177/147323001204000331
   Rabaan Ali A, 2020, Infez Med, V28, P174
   Sanz F, 2011, EUR RESP J S55, V38, P2492
   Servello A, 2020, ARCH GERONTOL GERIAT, V89, DOI 10.1016/j.archger.2020.104111
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Smits SL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000756
   Tartarisco G, 2012, NEUROMUSCULAR DISORD, V22, pS192, DOI 10.1016/j.nmd.2012.10.009
   WHO, 2020, CLIN MAN SEV AC RESP
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 33
TC 4
Z9 4
U1 5
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167-4943
EI 1872-6976
J9 ARCH GERONTOL GERIAT
JI Arch. Gerontol. Geriatr.
PD NOV-DEC
PY 2020
VL 91
AR 104185
DI 10.1016/j.archger.2020.104185
PG 6
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA OC9DZ
UT WOS:000579456600007
PM 32688107
OA Green Published
DA 2021-01-01
ER

PT J
AU Al Kasab, S
   Almallouhi, E
   Alawieh, A
   Levitt, MR
   Jabbour, P
   Sweid, A
   Starke, RM
   Saini, V
   Wolfe, SQ
   Fargen, KM
   Arthur, AS
   Goyal, N
   Pandhi, A
   Fragata, I
   Maier, I
   Matouk, C
   Grossberg, JA
   Howard, BM
   Kan, P
   Hafeez, M
   Schirmer, CM
   Crowley, RW
   Joshi, KC
   Tjoumakaris, SI
   Chowdry, S
   Ares, W
   Ogilvy, C
   Gomez-Paz, S
   Rai, AT
   Mokin, M
   Guerrero, W
   Park, MS
   Mascitelli, JR
   Yoo, A
   Williamson, R
   Grande, AW
   Crosa, RJ
   Webb, S
   Psychogios, MN
   Ducruet, AF
   Holmstedt, CA
   Ringer, AJ
   Spiotta, AM
AF Al Kasab, Sami
   Almallouhi, Eyad
   Alawieh, Ali
   Levitt, Michael R.
   Jabbour, Pascal
   Sweid, Ahmad
   Starke, Robert M.
   Saini, Vasu
   Wolfe, Stacey Q.
   Fargen, Kyle M.
   Arthur, Adam S.
   Goyal, Nitin
   Pandhi, Abhi
   Fragata, Isabel
   Maier, Ilko
   Matouk, Charles
   Grossberg, Jonathan A.
   Howard, Brian M.
   Kan, Peter
   Hafeez, Muhammad
   Schirmer, Clemens M.
   Crowley, R. Webster
   Joshi, Krishna C.
   Tjoumakaris, Stavropoula I.
   Chowdry, Shakeel
   Ares, William
   Ogilvy, Christopher
   Gomez-Paz, Santiago
   Rai, Ansaar T.
   Mokin, Maxim
   Guerrero, Waldo
   Park, Min S.
   Mascitelli, Justin R.
   Yoo, Albert
   Williamson, Richard
   Grande, Andrew Walker
   Crosa, Roberto Javier
   Webb, Sharon
   Psychogios, Marios N.
   Ducruet, Andrew F.
   Holmstedt, Christine A.
   Ringer, Andrew J.
   Spiotta, Alejandro M.
CA STAR Collaborators
TI International experience of mechanical thrombectomy during the COVID-19
   pandemic: insights from STAR and ENRG
SO JOURNAL OF NEUROINTERVENTIONAL SURGERY
LA English
DT Article
ID ACUTE ISCHEMIC-STROKE; GENERAL-ANESTHESIA; ENDOVASCULAR TREATMENT;
   CONSCIOUS SEDATION; THERAPY; ASSOCIATION; MANAGEMENT; SOCIETY; CARE
AB Background In response to the COVID-19 pandemic, many centers altered stroke triage protocols for the protection of their providers. However, the effect of workflow changes on stroke patients receiving mechanical thrombectomy (MT) has not been systematically studied.
   Methods A prospective international study was launched at the initiation of the COVID-19 pandemic. All included centers participated in the Stroke Thrombectomy and Aneurysm Registry (STAR) and Endovascular Neurosurgery Research Group (ENRG). Data was collected during the peak months of the COVID-19 surge at each site. Collected data included patient and disease characteristics. A generalized linear model with logit link function was used to estimate the effect of general anesthesia (GA) on in-hospital mortality and discharge outcome controlling for confounders.
   Results 458 patients and 28 centers were included from North America, South America, and Europe. Five centers were in high-COVID burden counties (HCC) in which 9/104 (8.7%) of patients were positive for COVID-19 compared with 4/354 (1.1%) in low-COVID burden counties (LCC) (P<0.001). 241 patients underwent pre-procedure GA. Compared with patients treated awake, GA patients had longer door to reperfusion time (138 vs 100 min, P=<0.001). On multivariate analysis, GA was associated with higher probability of in-hospital mortality (RR 1.871, P=0.029) and lower probability of functional independence at discharge (RR 0.53, P=0.015).
   Conclusion We observed a low rate of COVID-19 infection among stroke patients undergoing MT in LCC. Overall, more than half of the patients underwent intubation prior to MT, leading to prolonged door to reperfusion time, higher in-hospital mortality, and lower likelihood of functional independence at discharge.
C1 [Al Kasab, Sami; Spiotta, Alejandro M.] Med Univ South Carolina, Neurosurg, Charleston, SC 29425 USA.
   [Al Kasab, Sami; Almallouhi, Eyad; Holmstedt, Christine A.] Med Univ South Carolina, Neurol, Charleston, SC 29425 USA.
   [Alawieh, Ali] Emory Univ, Neurosurg, Atlanta, GA 30322 USA.
   [Alawieh, Ali] Med Univ South Carolina, Microbiol & Immunol, Charleston, SC USA.
   [Levitt, Michael R.] Univ Washington, Sch Med, Neurol Surg, Seattle, WA USA.
   [Jabbour, Pascal; Sweid, Ahmad; Tjoumakaris, Stavropoula I.] Thomas Jefferson Univ Hosp, Neurol Surg, Philadelphia, PA 19107 USA.
   [Starke, Robert M.] Univ Miami, Miller Sch Med, Neurol Surg, Miami Beach, FL USA.
   [Starke, Robert M.; Saini, Vasu] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
   [Wolfe, Stacey Q.; Fargen, Kyle M.] Wake Forest Sch Med, Neurosurg, Winston Salem, NC 27101 USA.
   [Arthur, Adam S.] Semmes Murphey Neurol & Spine Inst, Memphis, TN USA.
   [Arthur, Adam S.] Univ Tennessee, Hlth Sci Ctr, Neurosurg, Memphis, TN USA.
   [Goyal, Nitin; Pandhi, Abhi] Univ Tennessee, Hlth Sci Ctr, Neurol, Memphis, TN USA.
   [Fragata, Isabel] Ctr Hosp Lisboa Cent, Neuroradiol, Lisbon, Portugal.
   [Maier, Ilko] Univ Med Goettingen, Neurol, Gottingen, NS, Germany.
   [Matouk, Charles] Yale Univ, Neurosurg, New Haven, CT USA.
   [Grossberg, Jonathan A.] Emory Univ, Sch Med, Neurosurg & Radiol, Atlanta, GA USA.
   [Howard, Brian M.] Emory Univ, Sch Med, Neurosurg, Atlanta, GA USA.
   [Howard, Brian M.] Emory Univ, Sch Med, Radiol & Imaging Sci, Atlanta, GA USA.
   [Kan, Peter] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
   [Hafeez, Muhammad] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA.
   [Schirmer, Clemens M.] Geisinger Hlth Syst, Neurosurg, Wilkes Barre, PA USA.
   [Crowley, R. Webster] Rush Univ, Chicago, IL 60612 USA.
   [Joshi, Krishna C.] Rush Univ, Med Ctr, Neurol Surg, Chicago, IL 60612 USA.
   [Chowdry, Shakeel] North Shore Univ Hlth Syst, Evanston, IL USA.
   [Ares, William] North Shore Univ Hlth Syst, Neurosurg, Evanston, IL USA.
   [Ogilvy, Christopher; Gomez-Paz, Santiago] BIDMC, Neurosurg, Boston, MA USA.
   [Rai, Ansaar T.] West Virginia Univ, Dept Neurointervent Radiol, Morgantown, WV 26506 USA.
   [Mokin, Maxim; Guerrero, Waldo] Univ S Florida, Neurosurg, Tampa, FL 33620 USA.
   [Park, Min S.] Univ Virginia, Neurosurg, Charlottesville, VA USA.
   [Mascitelli, Justin R.] Univ Texas Hlth Sci Ctr San Antonio, Neurosurg, San Antonio, TX 78229 USA.
   [Yoo, Albert] Texas Stroke Inst, Ft Worth, TX USA.
   [Williamson, Richard] Allegheny Hlth Network, Stroke & Cerebrovasc Ctr, Pittsburgh, PA USA.
   [Grande, Andrew Walker] Univ Minnesota, Neurosurg Radiol & Neurol, Mendota Hts, MN USA.
   [Crosa, Roberto Javier] Medica Uruguaya, Endovasc Neurosurg, Montevideo, Uruguay.
   [Webb, Sharon] Bon Secours St Francis Hosp, Neurosurg, Greenville, SC USA.
   [Psychogios, Marios N.] Univ Hosp Basel, Dept Neuroradiol, Clin Radiol & Nucl Med, Basel, Switzerland.
   [Ducruet, Andrew F.] Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
   [Ringer, Andrew J.] Univ Cincinnati, Mayfield Clin, Neurosurg, Cincinnati, OH USA.
RP Spiotta, AM (corresponding author), Med Univ South Carolina, Neurosurg, Charleston, SC 29425 USA.
EM spiotta@musc.edu
OI Alawieh, Ali/0000-0003-2601-8850; Levitt, Michael/0000-0003-3612-3347;
   Saini, Vasu/0000-0002-6796-5881
CR Aggour M, 2020, J NEUROINTERV SURG, V12, P542, DOI 10.1136/neurintsurg-2020-016137
   Berkhemer OA, 2016, NEUROLOGY, V87, P656, DOI 10.1212/WNL.0000000000002976
   Campbell Doug, 2021, J Neurosurg Anesthesiol, V33, P21, DOI 10.1097/ANA.0000000000000646
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Filatov A, 2020, CUREUS, V12, DOI 10.7759/cureus.7352
   Fiorella D, 2020, J NEUROINTERV SURG, V12, P537, DOI 10.1136/neurintsurg-2020-016117
   Fraser JF, 2020, J NEUROINTERV SURG, V12, P539, DOI 10.1136/neurintsurg-2020-016098
   Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Henden PL, 2017, STROKE, V48, P1601, DOI 10.1161/STROKEAHA.117.016554
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Levi M, 2020, LANCET HAEMATOL
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li YN, 2020, STROKE VASC NEUROL, V5, P279, DOI 10.1136/svn-2020-000431
   Liu W, 2020, CHINESE MED J-PEKING, V133, P1032, DOI 10.1097/CM9.0000000000000775
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Mei H, 2020, Zhonghua Xue Ye Xue Za Zhi, V41, P185, DOI 10.3760/cma.j.issn.0253-2727.2020.0002
   Nguyen TN, 2020, STROKE, V51, P1896, DOI 10.1161/STROKEAHA.120.030100
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Poyiadji N, 2020, RADIOLOGY, V296, pE119, DOI 10.1148/radiol.2020201187
   Schonenberger S, 2019, JAMA-J AM MED ASSOC, V322, P1283, DOI 10.1001/jama.2019.11455
   Sharma D, 2020, J NEUROSURG ANESTH, V32, P193, DOI 10.1097/ANA.0000000000000688
   Simonsen CZ, 2018, JAMA NEUROL, V75, P470, DOI 10.1001/jamaneurol.2017.4474
   Smith MS, 2020, STROKE, V51, P1902, DOI 10.1161/STROKEAHA.120.029863
   Thachil J, 2020, J THROMB HAEMOST, V18, P1020, DOI 10.1111/jth.14821
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Zhang Y, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.118.011754
NR 29
TC 0
Z9 0
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1759-8478
EI 1759-8486
J9 J NEUROINTERV SURG
JI J. NeuroInterventional Surg.
PD NOV
PY 2020
VL 12
IS 11
BP 1039
EP +
DI 10.1136/neurintsurg-2020-016671
PG 7
WC Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA OE3TY
UT WOS:000580458200004
PM 32843359
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU DomBourian, MG
   Annen, K
   Huey, L
   Andersen, G
   Merkel, PA
   Jung, S
   Dominguez, SR
   Knight, V
AF DomBourian, Melkon G.
   Annen, Kyle
   Huey, Leah
   Andersen, Gillian
   Merkel, Patricia A.
   Jung, Sarah
   Dominguez, Samuel R.
   Knight, Vijaya
TI Analysis of COVID-19 convalescent plasma for SARS-CoV-2 IgG using two
   commercial immunoassays
SO JOURNAL OF IMMUNOLOGICAL METHODS
LA English
DT Article
AB Coronavirus Disease 2019 (COVID-19) convalescent plasma (CCP) was approved by the FDA for use in severe cases of COVID-19 under an emergency Investigational New Drug (IND) protocol. Eligibility criteria for CCP donors includes documentation of evidence of COVID-19 either by viral RNA detection at the time of illness or positive SARS-CoV-2 IgG after recovery if diagnostic testing for COVID-19 was not performed at the time of illness. In addition to analysis of CCP, analysis of SARS-CoV-2 IgG provides information for possible past exposure and may support diagnosis when SARS-CoV-2 PCR is negative and clinical suspicion for COVID-19 is high. Furthermore, assays with high sensitivity and specificity for SARS-CoV-2 IgG are critical for understanding community exposure rates to SARS-CoV-2. Currently, there are several assays that test for antibodies to SARS-CoV-2 using a variety of methods, including point-of-care lateral flow-based devices, high throughput immunoassay analyzers, and manual methods such as ELISA. These assays target a number of SARS-CoV-2 antigens, including the nucleocapsid protein (N), full length spike protein (S), S1 subunit, or receptor binding domain (RBD) of the S protein. Given the heterogeneity among methods for, and antigenic targets used in SARS-CoV-2 antibody assays, it is necessary for careful evaluation of these assays prior to implementation for clinical use. We compared two assays that had received the CE mark of regulatory approval and that used either the N antigen or Sl-RBD antigen as the target for analysis of a large set of CCP samples. Our data indicates that sensitivity and specificity vary between these assays and that more than one antigenic target may be required to improve the sensitivity and specificity of IgG detection to SARS-CoV-2.
C1 [DomBourian, Melkon G.; Annen, Kyle] Univ Colorado, Dept Pathol, Sch Med, 12631 East 17th Ave, Aurora, CO 80045 USA.
   [Huey, Leah; Merkel, Patricia A.; Dominguez, Samuel R.; Knight, Vijaya] Univ Colorado, Dept Pediat, Sch Med, 13123 East 16th Ave,Box 065, Aurora, CO 80045 USA.
   [DomBourian, Melkon G.; Annen, Kyle; Huey, Leah; Andersen, Gillian; Merkel, Patricia A.; Jung, Sarah; Dominguez, Samuel R.; Knight, Vijaya] Childrens Hosp Colorado, 13123 East 16th Ave, Aurora, CO 80045 USA.
RP DomBourian, MG (corresponding author), Univ Colorado, Dept Pathol, Sch Med, 12631 East 17th Ave, Aurora, CO 80045 USA.
EM melkon.dombourian@childrenscolorado.org
FU Department of Pediatrics at the University of Colorado School of
   Medicine; Department of Pathology at the University of Colorado School
   of Medicine; Children's Hospital Colorado
FX The Departments of Pediatrics and Pathology at the University of
   Colorado School of Medicine, and Children's Hospital Colorado.
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   [Anonymous], 2020, REC INV COVID 19 CON
   [Anonymous], 2014, INT GUID NAT HLTH AU
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Infectious Diseases Society of America, 2020, IDSA COVID 19 ANT TE
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   New York State Department of Health, 2020, HLTH ADV COVID 19 SE
   WHO, 2020, 134 WHO
   Zhou BP, 2007, NEW ENGL J MED, V357, P1450, DOI 10.1056/NEJMc070359
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 12
TC 2
Z9 2
U1 8
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-1759
EI 1872-7905
J9 J IMMUNOL METHODS
JI J. Immunol. Methods
PD NOV
PY 2020
VL 486
AR 112837
DI 10.1016/j.jim.2020.112837
PG 5
WC Biochemical Research Methods; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA OF3AN
UT WOS:000581085200004
PM 32828791
OA Green Published
DA 2021-01-01
ER

PT J
AU Choudhary, S
   Silakari, O
AF Choudhary, Shalki
   Silakari, Om
TI Scaffold morphing of arbidol (umifenovir) in search of multi-targeting
   therapy halting the interaction of SARS-CoV-2 with ACE2 and other
   proteases involved in COVID-19
SO VIRUS RESEARCH
LA English
DT Article
DE COVID-19; SARS-CoV-2; Scaffold morphing; Molecular docking; ADME;
   Arbidol
ID INHIBITORS; MECHANISM
AB The rapid emergence of novel coronavirus, SARS-comnavims 2 (SARS-CoV-2), originated from Wuhan, China, imposed a global health emergency. Angiotensin-converting enzyme 2 (ACE2) receptor serves as an entry point for this deadly virus while the proteases like furin, transmembrane protease serine 2 (TMPRSS2) and 3 chymotrypsin-like protease (3CLpro) are involved in the further processing and replication of SARS-CoV-2. The interaction of SP with ACE2 and these proteases results in the SARS-CoV-2 invasion and fast epidemic spread. The small molecular inhibitors are reported to limit the interaction of SP with ACE2 and other proteases. Arbidol, a membrane fusion inhibitor approved for influenza virus is currently undergoing clinical trials against COVID-19. In this context, we report some analogues of arbidol designed by scaffold morphing and structure-based designing approaches with a superior therapeutic profile. The representative compounds A_BR4, A_BR9, A_BR18, A_BR22 and A_BR28 restricted the interaction of SARS-CoV-2 SP with ACE2 and host proteases furin and TMPRSS2. For 3CLPro, Compounds A_BR5, A_BR6, A_BR9 and A_BR18 exhibited high binding affinity, docking score and key residue interactions. Overall, A_BR18 and A_BR28 demonstrated multi-targeting potential against all the targets. Among these top-scoring molecules A_BR9, A_BR18, A_BR22 and A_BR28 were predicted to confer favorable ADME properties.
C1 [Choudhary, Shalki; Silakari, Om] Punjabi Univ, Dept Pharmaceut Sci & Drug Res, Mol Modelling Lab MML, Patiala 147002, Punjab, India.
RP Silakari, O (corresponding author), Punjabi Univ, Dept Pharmaceut Sci & Drug Res, Mol Modelling Lab MML, Patiala 147002, Punjab, India.
EM omsilakari@gmail.com
FU Indian Council of Medical Research (ICMR), New DelhiIndian Council of
   Medical Research (ICMR) [ISRM/11(61)/2017]
FX The authors thank Dr. Anshuman Dixit, Institute of Life Sciences (ILS),
   Bhubaneswar, for help and support in molecular docking analysis. S
   Choudhary would like to acknowledge the Indian Council of Medical
   Research (ICMR), New Delhi for providing SRF under sanction no:
   ISRM/11(61)/2017.
CR Abdelli I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763199
   [Anonymous], BIORXIV, DOI [10.1101/2020.04.06.028522, DOI 10.1101/2020.04.06.028522]
   Asadi-Pooya AA, 2020, J NEUROL SCI, V413, DOI 10.1016/j.jns.2020.116832
   Bedford J, 2020, LANCET, V395, P1015, DOI 10.1016/S0140-6736(20)30673-5
   Bestle D., 2020, BIORXIV, DOI [10.1101/2020.04.15.042085, DOI 10.1101/2020.04.15.042085]
   Blaising J, 2014, ANTIVIR RES, V107, P84, DOI 10.1016/j.antiviral.2014.04.006
   Chen C., 2020, FAVIPIRAVIR VERSUS A, DOI [10.1101/2020.03.17.20037432, DOI 10.1101/2020.03.17.20037432]
   Choudhary S, 2019, J MOL GRAPH MODEL, V91, P148, DOI 10.1016/j.jmgm.2019.06.012
   Ciliberto G, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01590-2
   Di Mola A, 2014, BIOORGAN MED CHEM, V22, P6014, DOI 10.1016/j.bmc.2014.09.013
   Dick A, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13030036
   Du J, 2011, J COMPUT CHEM, V32, P2800, DOI 10.1002/jcc.21859
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Haider MK, 2011, J CHEM INF MODEL, V51, P1092, DOI 10.1021/ci100469n
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang JS, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041131
   Kadam RU, 2017, P NATL ACAD SCI USA, V114, P206, DOI 10.1073/pnas.1617020114
   Kelder J, 1999, PHARMACEUT RES, V16, P1514, DOI 10.1023/A:1015040217741
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Langdon SR, 2010, MOL INFORM, V29, P366, DOI 10.1002/minf.201000019
   Leneva IA, 2009, ANTIVIR RES, V81, P132, DOI 10.1016/j.antiviral.2008.10.009
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Lythgoe MP, 2020, TRENDS PHARMACOL SCI, V41, P363, DOI 10.1016/j.tips.2020.03.006
   Manjunatha MR, 2019, ACS MED CHEM LETT, V10, P1480, DOI 10.1021/acsmedchemlett.9b00343
   McKee DL, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104859
   Mevada V., 2020, DRUG REPURPOSING APP, DOI [10.26434/chemrxiv.12115251.v2., DOI 10.26434/CHEMRXIV.12115251.V2]
   Nath V., 2020, J MOL STRUCT, V1224, P129006, DOI [10.1016/j.molstruc.2020.129006, DOI 10.1016/J.MOLSTRUC.2020.129006]
   Pathak D, 2020, MOL DIVERS, DOI 10.1007/s11030-020-10036-y
   Pecheur EI, 2007, BIOCHEMISTRY-US, V46, P6050, DOI 10.1021/bi700181j
   Release S., 2019, 3 MAESTRO
   Schrodinger L., 2013, SCHRODINGER RELEASE
   Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652
   Shan J., 2019, CURR COMPUT AID DRUG, DOI [10.2174/, DOI 10.2174/]
   Singh PK, 2018, BIOORG CHEM, V79, P163, DOI 10.1016/j.bioorg.2018.04.001
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   South AM, 2020, NAT REV NEPHROL, V16, P305, DOI 10.1038/s41581-020-0279-4
   Sun HY, 2014, PHYS CHEM CHEM PHYS, V16, P22035, DOI 10.1039/c4cp03179b
   Vankadari N, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105998
   Rosa SGV, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.40
   Wang LS, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105948
   Wang Q, 2020, VIROL SIN, V35, P337, DOI 10.1007/s12250-020-00212-7
   Wilkinson J., 2020, STAT REV FAVIPIRAVIR, DOI [10.1101/2020.03.17.20037432., DOI 10.1101/2020.03.17.20037432]
   Wright ZVF, 2017, BIOORG MED CHEM LETT, V27, P3744, DOI 10.1016/j.bmcl.2017.06.074
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu YH, 2020, CELL RES, DOI 10.1038/s41422-020-00411-7
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhao M, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105982
   Zhu Z, 2020, J INFECTION, V81, pE21, DOI 10.1016/j.jinf.2020.03.060
NR 49
TC 3
Z9 3
U1 15
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-1702
EI 1872-7492
J9 VIRUS RES
JI Virus Res.
PD NOV
PY 2020
VL 289
AR 198146
DI 10.1016/j.virusres.2020.198146
PG 20
WC Virology
SC Virology
GA OE6FT
UT WOS:000580625200007
PM 32866534
OA Green Published
DA 2021-01-01
ER

PT J
AU Gadotti, AC
   Deus, MD
   Telles, JP
   Wind, R
   Goes, M
   Ossoski, RGC
   de Padua, AM
   de Noronha, L
   Moreno-Amaral, A
   Baena, CP
   Tuon, FF
AF Gadotti, Ana Carolina
   Deus, Marina de Castro
   Telles, Joao Paulo
   Wind, Rafael
   Goes, Marina
   Charello Ossoski, Roberta Garcia
   de Padua, Alessandra Michalski
   de Noronha, Lucia
   Moreno-Amaral, Andrea
   Baena, Cristina Pellegrino
   Tuon, Felipe Francisco
TI IFN-gamma is an independent risk factor associated with mortality in
   patients with moderate and severe COVID-19 infection
SO VIRUS RESEARCH
LA English
DT Article
DE COVID-19; Immune response; Interleukin; Cytokines
ID INHIBITION
AB Background: Innate and adaptive immune responses have been evaluated in infected patients with COVID-19. The severity of the disease has been supposed to be associated with some profile not reported with other bacterial and viral pneumonia. We proposed a study in patients with moderate to severe COVID-19 infection to evaluate the interleukin patterns and its role as prognosis factors.
   Methods: A prospective cohort with moderate and severe cases of COVID-19 infection from June to July 2020. Blood samples from patients were collected regularly to evaluate IFN-gamma, TNIF-alpha, IL-4, IL-6, and IL-10. Clinical, laboratory, radiological data, and outcomes were recorded. The outcome variable was in-hospital death, survival, mechanical ventilation, and admission at the intensive care unit. Data are presented in median and interquartile range [IQR].
   Results: We evaluated the Th1 and Th2 responses according to evolution, distinguishing possible predictive markers. The IFN-gamma median of 323 pg/mL [IQR 166-570] was found in patients who died and 208 pg/mL [IQR 155-392] in the survival group (p = 0.017). IFN-gamma was also higher in the early stages of the disease (394 pg/mL [IQR 229-575] against 162 pg/mL [IQR 117-259], p < 0.001). IL-4 that was increased in late-stage (182 pg/mL [IQR 162-199] against 131 pg/mL [IQR 124-152], p < 0.001) but not associated with mortality. Also, death was also related to male gender (relative risk = 1.5 [95 % confidence interval = 1.1-2.0]).
   Conclusion: Our results suggest that the activation of the host immune response between Th1 or Th2 in COVID-19 infection may be related to the final result between discharge or death. This implies an attempt to control cytokines, such as IFN-gamma, with combined therapies for clinical treatment.
C1 [Gadotti, Ana Carolina; Deus, Marina de Castro; Moreno-Amaral, Andrea] Pontificia Univ Catolica Parana, Lab Anemia & Immunol Res LabAIRe, Curitiba, Parana, Brazil.
   [Telles, Joao Paulo; Wind, Rafael; Goes, Marina] Hosp Univ Evangelico Mackenzie, Curitiba, Parana, Brazil.
   [Telles, Joao Paulo] Pontificia Univ Catolica Parana, Hosp Univ Cajuru, Curitiba, Parana, Brazil.
   [Charello Ossoski, Roberta Garcia; de Padua, Alessandra Michalski; Baena, Cristina Pellegrino] Pontificia Univ Catolica Parana, Sch Med, PUC PR, Curitiba, Parana, Brazil.
   [de Noronha, Lucia] Pontificia Univ Catolica Parana, Expt Pathol Lab, Curitiba, Parana, Brazil.
   [Tuon, Felipe Francisco] Pontificia Univ Catolica Parana, Lab Emerging Infect Dis, Curitiba, Parana, Brazil.
RP Tuon, FF (corresponding author), Pontificia Univ Catolica Parana, Lab Emerging Infect Dis, Curitiba, Parana, Brazil.
EM felipe.tuon@pucpr.br
CR Abate SM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235653
   Arnaldez FI, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000930
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   De Biasi S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17292-4
   Ellinghaus D, 2020, NEW ENGL J MED, V383, P1522, DOI 10.1056/NEJMoa2020283
   FORTI RL, 1985, J CLIN MICROBIOL, V21, P689, DOI 10.1128/JCM.21.5.689-693.1985
   Gimenez E, 2020, J MED VIROL, DOI 10.1002/jmv.26213
   Gong J, 2020, CLIN INFECT DIS, V71, P833, DOI 10.1093/cid/ciaa443
   Han H, 2020, EMERG MICROBES INFEC, V9, P1123, DOI 10.1080/22221751.2020.1770129
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Levy DE, 2001, CYTOKINE GROWTH F R, V12, P143, DOI 10.1016/S1359-6101(00)00027-7
   Liang W, 2020, JAMA INT MED, DOI [10.1001/jamainternmed.2020.2033, DOI 10.1001/]
   Lucas C, 2020, NATURE, DOI 10.1038/s41586-020-2588-y
   Luo Y., 2020, J CLIN IMMUNOL, DOI [10.1007/s10875-020-00821-00827., DOI 10.1007/S10875-020-00821-00827]
   Murphy KM, 2000, ANNU REV IMMUNOL, V18, P451, DOI 10.1146/annurev.immunol.18.1.451
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Robinson CM, 2010, J INNATE IMMUN, V2, P56, DOI 10.1159/000247156
   Stetson DB, 2003, J EXP MED, V198, P1069, DOI 10.1084/jem.20030630
   Vidal SM, 2011, CURR OPIN VIROL, V1, P497, DOI 10.1016/j.coviro.2011.10.017
   WHO, 2020, CLIN MAN SEV AC RESP
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wurtz O, 2004, INT IMMUNOL, V16, P501, DOI 10.1093/intimm/dxh050
   Xiong XL, 2020, DATA BRIEF, V31, DOI 10.1016/j.dib.2020.105953
   XU B, 2020, J INFECTION, V81, pE51, DOI 10.1016/j.jinf.2020.04.012
   Xu Dachun, 2020, medRxiv, DOI 10.1101/2020.04.30.20081257
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yin KS, 2005, SHOCK, V24, P396, DOI 10.1097/01.shk.0000175556.03300.c6
   Zhang Haocheng, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa663
   Zhang XN, 2020, NATURE, V583, P437, DOI 10.1038/s41586-020-2355-0
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-1702
EI 1872-7492
J9 VIRUS RES
JI Virus Res.
PD NOV
PY 2020
VL 289
AR 198171
DI 10.1016/j.virusres.2020.198171
PG 7
WC Virology
SC Virology
GA OE6FT
UT WOS:000580625200019
PM 32979474
OA Green Published
DA 2021-01-01
ER

PT J
AU Rangel, HR
   Ortega, JT
   Maksoud, S
   Pujol, FH
   Serrano, ML
AF Rangel, H. R.
   Ortega, J. T.
   Maksoud, S.
   Pujol, F. H.
   Serrano, M. L.
TI SARS-CoV-2 host tropism: An in silico analysis of the main cellular
   factors
SO VIRUS RESEARCH
LA English
DT Article
DE COVID-19; SARS-CoV-2; Receptor ACE2; TMPRSS2; GRP78
ID SPIKE PROTEIN; SWISS-MODEL; CORONAVIRUS; RECEPTOR; VIRUS; ACE2;
   PATHOGENICITY; RECOGNITION; ENVIRONMENT; VACCINES
AB Recent reports have shown that small and big felines could be infected by SARS-CoV-2, while other animals, like swines and mice, are apparently not susceptible to this infection. These findings raise the question of the role of cell factors associated with early stages of the viral infection in host selectivity. The cellular receptor for SARS-CoV-2 is the Angiotensin Converting Enzyme (ACE2). Transmembrane protease serine 2 (TMPRSS2) has been shown to prime the viral spike for its interaction with its receptor. GRP78 has also been proposed as a possible coreceptor. In this study, we used several bioinformatics approaches to bring clues in the interaction of ACE2, TMPRSS2, and GRP78 with SARS-CoV-2. We selected several mammalian hosts that could play a key role in viral spread by acting as secondary hosts (cats, dogs, pigs, mice, and ferrets) and evaluated their predicted permissiveness by in silico analysis. Results showed that ionic pairs (salt bridges, N-O pair, and long-range interactions) produced between ACE2 and the viral spike has an essential function in the host interaction. On the other hand, TMPRSS2 and GRP78 are proteins with high homology in all the evaluated hosts. Thus, these proteins do not seem to play a role in host selectivity, suggesting that other factors may play a role in the non-permissivity in some of these hosts. These proteins represent however interesting cell targets that could be explored in order to control the virus replication in humans and in the intermediary hosts.
C1 [Rangel, H. R.; Pujol, F. H.] Inst Venezolano Invest Cient, Ctr Microbiol & Biol Celular, Lab Virol Mol, Caracas, Venezuela.
   [Ortega, J. T.] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA.
   [Maksoud, S.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02129 USA.
   [Maksoud, S.] Massachusetts Gen Hosp, Expt Therapeut & Mol Imaging Lab, Boston, MA 02129 USA.
   [Serrano, M. L.] Univ Cent Venezuela, Fac Farm, Unidad Quim Med, Caracas 1041A, Venezuela.
RP Serrano, ML (corresponding author), Univ Cent Venezuela, Fac Farm, Unidad Quim Med, Caracas 1041A, Venezuela.
EM maria.serrano@ucv.ve
RI Rangel, Hector/E-5575-2010
OI Rangel, Hector/0000-0001-5937-9690; Serrano, Maria
   Luisa/0000-0002-2936-5092
CR Ahn DG, 2020, J MICROBIOL BIOTECHN, V30, P313, DOI 10.4014/jmb.2003.03011
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770
   Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Chu H, 2018, J BIOL CHEM, V293, P11709, DOI 10.1074/jbc.RA118.001897
   DeDiego ML, 2008, VIROLOGY, V376, P379, DOI 10.1016/j.virol.2008.03.005
   Demogines A, 2012, J VIROL, V86, P6350, DOI 10.1128/JVI.00311-12
   Elfiky AA, 2020, J MED VIROL, V92, P3759, DOI 10.1002/jmv.25737
   Fagerberg L, 2014, MOL CELL PROTEOMICS, V13, P397, DOI 10.1074/mcp.M113.035600
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Ge RW, 2019, CANCERS, V11, DOI 10.3390/cancers11111787
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hou YX, 2010, ARCH VIROL, V155, P1563, DOI 10.1007/s00705-010-0729-6
   Ibrahim IM, 2020, J INFECTION, V80, P554, DOI 10.1016/j.jinf.2020.02.026
   Jindadamrongwech S, 2004, ARCH VIROL, V149, P915, DOI 10.1007/s00705-003-0263-x
   Kleine-Weber H, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34859-w
   Kumar S, 2002, BIOPHYS J, V83, P1595, DOI 10.1016/S0006-3495(02)73929-5
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li F, 2013, ANTIVIR RES, V100, P246, DOI 10.1016/j.antiviral.2013.08.014
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Luan JW, 2020, BIOCHEM BIOPH RES CO, V526, P165, DOI 10.1016/j.bbrc.2020.03.047
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   Nain M, 2017, J VIROL, V91, DOI [10.1128/JVI.02274-16, 10.1128/jvi.02274-16]
   Ortega JT, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10060954
   Ortega JT, 2013, INTERCIENCIA, V38, P836
   Ortega JT, 2020, EXCLI J, V19, P400, DOI 10.17179/excli2020-1189
   Ortega JT, 2020, EXCLI J, V19, P410, DOI 10.17179/excli2020-1167
   Parvez MK, 2017, INTERVIROLOGY, V60, P1, DOI 10.1159/000478729
   Pedretti A, 2004, J COMPUT AID MOL DES, V18, P167, DOI 10.1023/B:JCAM.0000035186.90683.f2
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Pierce BG, 2014, BIOINFORMATICS, V30, P1771, DOI 10.1093/bioinformatics/btu097
   Ricke D., 2020, MED COUNTERMEASURES, DOI [10.2139/ssrn.3546070, DOI 10.2139/SSRN.3546070]
   Sanchez-Linares I, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S14-S13
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shen M., 2020, SARS COV 2 INFECTION, V2020040116
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Sigrist CJA, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104759
   Tarnow C, 2014, J VIROL, V88, P4744, DOI 10.1128/JVI.03799-13
   Ortega JT, 2019, EXCLI J, V18, P1037, DOI 10.17179/excli2019-1837
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   Vanommeslaeghe K, 2010, J COMPUT CHEM, V31, P671, DOI 10.1002/jcc.21367
   Wang M, 2009, ANTIOXID REDOX SIGN, V11, P2307, DOI [10.1089/ars.2009.2485, 10.1089/ARS.2009.2485]
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Xue LC, 2016, BIOINFORMATICS, V32, P3676, DOI 10.1093/bioinformatics/btw514
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 53
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-1702
EI 1872-7492
J9 VIRUS RES
JI Virus Res.
PD NOV
PY 2020
VL 289
AR 198154
DI 10.1016/j.virusres.2020.198154
PG 10
WC Virology
SC Virology
GA OE6FT
UT WOS:000580625200013
PM 32918944
OA Green Published
DA 2021-01-01
ER

PT J
AU Weber, S
   Ramirez, C
   Doerfler, W
AF Weber, Stefanie
   Ramirez, Christina
   Doerfler, Walter
TI Signal hotspot mutations in SARS-CoV-2 genomes evolve as the virus
   spreads and actively replicates in different parts of the world
SO VIRUS RESEARCH
LA English
DT Article
DE Severe acute respiratory syndrome; Coronavirus-2 (SARS-CoV-2); Sequence
   comparisons between 570 viral genomes to Wuhan isolate; Selection of
   viral hotspot mutations; Impact on replication-relevant viral proteins;
   Consequences for secondary and tertiary structures of viral RNA;
   Questions about immunogenesis and vaccine development
AB Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) was first identified in Wuhan, China late in 2019. Nine months later (Sept. 23, 2020), the virus has infected > 31.6 million people around the world and caused > 971.000 (3.07 %) fatalities in 220 countries and territories. Research on the genetics of the SARS-CoV-2 genome, its mutants and their penetrance can aid future defense strategies. By analyzing sequence data deposited between December 2019 and end of May 2020, we have compared nucleotide sequences of 570 SARS-CoV-2 genomes from China, Europe, the US, and India to the sequence of the Wuhan isolate. During worldwide spreading among human populations, at least 10 distinct hotspot mutations had been selected and found in up to > 80 % of viral genomes. Many of these mutations led to amino acid exchanges in replication-relevant viral proteins. Mutations in the SARS-CoV-2 genome would also impinge upon the secondary structure of the viral RNA molecule and its repertoire of interactions with essential cellular and viral proteins. The increasing frequency of SARS-CoV-2 mutation hotspots might select for dangerous viral pathogens. Alternatively, in a 29.900 nucleotide-genome, there might be a limit to the number of mutable and selectable sites which, when exhausted, could prove disadvantageous to viral survival. The speed, at which novel SARS-CoV-2 mutants are selected and dispersed around the world, could pose problems for the development of vaccines and therapeutics.
C1 [Weber, Stefanie; Doerfler, Walter] Friedrich Alexander Univ FAU Erlangen Nurnberg, Inst Clin & Mol Virol, Schlossgarten 4, D-91054 Erlangen, Germany.
   [Ramirez, Christina] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90095 USA.
   [Doerfler, Walter] Univ Cologne, Inst Genet, D-50674 Cologne, Germany.
RP Doerfler, W (corresponding author), Friedrich Alexander Univ FAU Erlangen Nurnberg, Inst Clin & Mol Virol, Schlossgarten 4, D-91054 Erlangen, Germany.
EM walter.doerfler@t-online.de
FU Dr. Robert Pfleger Stiftung in Bamberg, Germany
FX We are grateful to Esteban Domingo, Universidad Autonoma de Madrid for
   alerting us to the Duarte et al. 1992 study. We thank Barbara Weiser and
   Harold Burger, University of California, Davis School of Medicine for
   critical comments on the manuscript. This research was funded by the Dr.
   Robert Pfleger Stiftung in Bamberg, Germany [5.12.2018]. W.D. is
   indebted to the Institute for Clinical and Molecular Virology of FAU in
   Erlangen, Germany for their continued hospitality extended to the
   Epigenetics Group.
CR Bohmer M., 2020, LANCET INFECT DIS, V2020, DOI [10.1016/S1473-3099(20)30314-30315, DOI 10.1016/S1473-3099(20)30314-30315]
   Cawood R, 2007, CELL CYCLE, V6, P863, DOI 10.4161/cc.6.7.4032
   Di Giorgio S, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb5813
   DUARTE E, 1992, P NATL ACAD SCI USA, V89, P6015, DOI 10.1073/pnas.89.13.6015
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Hartenian E, 2020, J BIOL CHEM, V295, P12910, DOI 10.1074/jbc.REV120.013930
   Helmy YA, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041225
   Isabel S., 2020, EVOLUTIONARY STRUCTU, DOI [10.1101/2020.06.08.140459, DOI 10.1101/2020.06.08.140459]
   Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483
   KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Laamarti M., 2020, BIORXIV, DOI [10.1101/2020.05.03.074567, DOI 10.1101/2020.05.03.074567]
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Pachetti M, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02344-6
   Simmonds P, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00408-20.
   Su Y.C.F., 2020, DISCOVERY GENOMIC CH, DOI [10.1128/mBio.01610-20, DOI 10.1128/MBIO.01610-20]
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Wang Q, 2020, CELL, V182, P417, DOI 10.1016/j.cell.2020.05.034
   WHO, 2020, COR DIS COVID 19 PAN
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 20
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-1702
EI 1872-7492
J9 VIRUS RES
JI Virus Res.
PD NOV
PY 2020
VL 289
AR 198170
DI 10.1016/j.virusres.2020.198170
PG 6
WC Virology
SC Virology
GA OE6FT
UT WOS:000580625200018
PM 32979477
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Sudhakar, D
   Jneid, H
   Lakkis, N
   Kayani, WT
AF Sudhakar, Deepthi
   Jneid, Hani
   Lakkis, Nasser
   Kayani, Waleed T.
TI Primary Percutaneous Coronary Intervention or Fibrinolytic Therapy in
   COVID 19 Patients Presenting With ST-Segment Elevation Myocardial
   Infarction
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Letter
C1 [Sudhakar, Deepthi; Jneid, Hani; Lakkis, Nasser; Kayani, Waleed T.] Baylor Coll Med, Houston, TX 77030 USA.
RP Kayani, WT (corresponding author), Baylor Coll Med, Houston, TX 77030 USA.
CR Bangalore S, 2020, NEW ENGL J MED, V382, P2478, DOI 10.1056/NEJMc2009020
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Hamadeh A, 2020, AM J CARDIOL, V131, P1, DOI 10.1016/j.amjcard.2020.06.063
   Mahmud E, 2020, CATHETER CARDIO INTE, V96, P336, DOI 10.1002/ccd.28946
   Stefanini GG, 2020, CIRCULATION, V141, P2113, DOI 10.1161/CIRCULATIONAHA.120.047525
NR 5
TC 0
Z9 0
U1 0
U2 0
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
EI 1879-1913
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD NOV 1
PY 2020
VL 134
BP 158
EP 158
DI 10.1016/j.amjcard.2020.08.021
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OD3GL
UT WOS:000579739200029
PM 32841613
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Reddy, YNV
   Walensky, RP
   Mendu, ML
   Green, N
   Reddy, KP
AF Reddy, Yuvaram N., V
   Walensky, Rochelle P.
   Mendu, Mallika L.
   Green, Nathaniel
   Reddy, Krishna P.
TI Estimating Shortages in Capacity to Deliver Continuous Kidney
   Replacement Therapy During the COVID-19 Pandemic in the United States
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
ID DIALYSIS; INJURY
AB Rationale & Objective: During the coronavirus disease 2019 (COVID-19) pandemic, New York encountered shortages in continuous kidney replacement therapy (CKRT) capacity for critically ill patients with acute kidney injury stage 3 requiring dialysis. To inform planning for current and future crises, we estimated CKRT demand and capacity during the initial wave of the US COVID-19 pandemic.
   Study Design: We developed mathematical models to project nationwide and statewide CKRT demand and capacity. Data sources included the Institute for Health Metrics and Evaluation model, the Harvard Global Health Institute model, and published literature.
   Setting & Population: US patients hospitalized during the initial wave of the COVID-19 pandemic (February 6, 2020, to August 4, 2020).
   Intervention: CKRT.
   Outcomes: CKRT demand and capacity at peak resource use; number of states projected to encounter CKRT shortages.
   Model, Perspective, & Timeframe: Health sector perspective with a 6-month time horizon.
   Results: Under base-case model assumptions, there was a nationwide CKRT capacity of 7,032 machines, an estimated shortage of 1,088 (95% uncertainty interval, 910-1,568) machines, and shortages in 6 states at peak resource use. In sensitivity analyses, varying assumptions around: (1) the number of pre-COVID-19 surplus CKRT machines available and (2) the incidence of acute kidney injury stage 3 requiring dialysis requiring CKRT among hospitalized patients with COVID-19 resulted in projected shortages in 3 to 8 states (933-1,282 machines) and 4 to 8 states (945-1,723 machines), respectively. In the best- and worst-case scenarios, there were shortages in 3 and 26 states (614 and 4,540 machines).
   Limitations: Parameter estimates are influenced by assumptions made in the absence of published data for CKRT capacity and by the Institute for Health Metrics and Evaluation model's limitations.
   Conclusions: Several US states are projected to encounter CKRT shortages during the COVID-19 pandemic. These findings, although based on limited data for CKRT demand and capacity, suggest there being value during health care crises such as the COVID-19 pandemic in establishing an inpatient kidney replacement therapy national registry and maintaining a national stockpile of CKRT equipment.
C1 [Reddy, Yuvaram N., V; Mendu, Mallika L.] Brigham & Womens Hosp, Renal Div, 75 Francis St, Boston, MA 02115 USA.
   [Reddy, Yuvaram N., V; Walensky, Rochelle P.; Mendu, Mallika L.; Reddy, Krishna P.] Harvard Med Sch, Boston, MA 02115 USA.
   [Reddy, Yuvaram N., V; Walensky, Rochelle P.; Reddy, Krishna P.] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, 100 Cambridge St,Ste 1600, Boston, MA 02114 USA.
   [Reddy, Yuvaram N., V] Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA.
   [Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
   [Green, Nathaniel] Amer Biomed Grp Inc, Oklahoma City, OK USA.
   [Reddy, Krishna P.] Massachusetts Gen Hosp, Div Pulm & Crit Care Med, Boston, MA 02114 USA.
RP Reddy, YNV (corresponding author), Massachusetts Gen Hosp, Med Practice Evaluat Ctr, 100 Cambridge St,Ste 1600, Boston, MA 02114 USA.
EM yreddy@partners.org
OI Reddy, Yuvaram/0000-0003-1974-5216
FU National Institute of Diabetes and Digestive and Kidney Diseases of the
   National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
   [T32DK007527]; Massachusetts General Hospital Executive Committee on
   Research Stephen and Deborah Gorlin Research Scholar Award
FX Research reported in this publication was supported by the National
   Institute of Diabetes and Digestive and Kidney Diseases of the National
   Institutes of Health (NIH) under award number T32DK007527 supporting Dr
   Y. Reddy and the Massachusetts General Hospital Executive Committee on
   Research Stephen and Deborah Gorlin Research Scholar Award supporting Dr
   Walensky. The NIH and Massachusetts General Hospital had no role in the
   study design; collection, analysis, and interpretation of the data;
   writing the report; or the decision to submit the report for
   publication. Mr Green works at American Biomedical Group, Inc, a company
   with diversified product/R&D arms. One aim of this company is to limit
   expenditures on biomedical equipment while providing higher quality
   biomedical support services. Mr Green analyzes capital expenditures for
   biomedical equipment. Within this company, he also works on AllTraq, a
   tracking technology product that locates equipment and personnel in
   GPS-denied environments. His company, American Biomedical Group, Inc,
   had no role in study design; collection, analysis, and interpretation of
   data; writing the report; funding for the study (apart from employment
   of Mr Green); or the decision to submit the report for publication.
   Specifically, the company did not impose any limits on authors' access
   to the study data or the content of the report.
CR American Hospital Association, 2018, AHA HOSP STAT
   American Hospital Directory, HOSP STAT STAT
   [Anonymous], REUTERS
   Argenziano MG, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1996
   Baio G, 2015, STAT METHODS MED RES, V24, P615, DOI 10.1177/0962280211419832
   Burgner A, 2020, CLIN J AM SOC NEPHRO, V15, P720, DOI 10.2215/CJN.03750320
   Center for Systems Science and Engineering, COR COVID 19 GLOB CA
   Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2
   El Shamy O, 2020, J AM SOC NEPHROL, V31, P1680, DOI 10.1681/ASN.2020050599
   El Shamy Osama, 2020, Kidney Med, V2, P377, DOI 10.1016/j.xkme.2020.04.001
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   Melo FDF, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0226325
   Goldfarb DS, 2020, CLIN J AM SOC NEPHRO, V15, P880, DOI 10.2215/CJN.05180420
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Hirsch JS, 2020, KIDNEY INT, V98, P209, DOI 10.1016/j.kint.2020.05.006
   Jewell NP, 2020, JAMA-J AM MED ASSOC, V323, P1893, DOI 10.1001/jama.2020.6585
   Jewell NP, 2020, ANN INTERN MED, V173, P226, DOI 10.7326/M20-1565
   Kliger A, 2020, HOSP CARE TREATMENT
   Mendu ML, 2017, CLIN J AM SOC NEPHRO, V12, P228, DOI 10.2215/CJN.07170716
   Murray CJL, 2020, COVID 19 HLTH SERVIC, DOI DOI 10.1101/2020.03.27.20043752V1
   Naicker S, 2020, KIDNEY INT, V97, P824, DOI 10.1016/j.kint.2020.03.001
   Palevsky PM, 2008, NEW ENGL J MED, V359, P7, DOI 10.1056/NEJMoa0802639
   Propublica, FED HELP NEW YORK DO
   Ranney ML, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2006141
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Sise ME, 2020, NEW ENGL J MED, V382, P2147, DOI 10.1056/NEJMcpc2002418
   Sourial MY, 2020, AM J KIDNEY DIS, V76, P401, DOI 10.1053/j.ajkd.2020.06.001
   The New York Times Coronavirus Map, NY TIMES
   Truog RD, 2020, NEW ENGL J MED, V382, P1973, DOI 10.1056/NEJMp2005689
   Cruz MV, 2020, WORLD J SURG, V44, P2464, DOI 10.1007/s00268-020-05600-4
   Vijayan A, 2020, OVERCOMING CHALLENGE
   Zhang GQ, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104364
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 33
TC 1
Z9 1
U1 2
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
EI 1523-6838
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD NOV
PY 2020
VL 76
IS 5
BP 696
EP +
DI 10.1053/j.ajkd.2020.07.005
PG 15
WC Urology & Nephrology
SC Urology & Nephrology
GA OE6HP
UT WOS:000580630000013
PM 32730812
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Liew, YX
   Lee, WHL
   Tan, LY
   Kwa, ALH
   Thien, SY
   Cherng, BPZ
   Chung, SJ
AF Liew, Yixin
   Lee, Winnie Hui Ling
   Tan, Lunyi
   Kwa, Andrea Lay Hoon
   Thien, Siew Yee
   Cherng, Benjamin Pei Zhi
   Chung, Shimin Jasmine
TI Antimicrobial stewardship programme: a vital resource for hospitals
   during the global outbreak of coronavirus disease 2019 (COVID-19)
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE COVID-19; Antimicrobial stewardship; ASP; ASP interventions
AB Healthcare resources are being diverted for the containment and control of coronavirus disease 2019 (COVID-19). During this outbreak, it is cautioned that antibiotic misuse may be increased, especially for respiratory tract infections. With stewardship interventions, the duration of antibiotic therapy and length of stay of hospitalized patients can be reduced significantly. Antibiotic stewardship programmes should continually engage and educate prescribers to mitigate antibiotic misuse during the COVID-19 pandemic. (C) 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.
C1 [Liew, Yixin; Lee, Winnie Hui Ling; Kwa, Andrea Lay Hoon] Singapore Gen Hosp, Dept Pharm, Singapore, Singapore.
   [Tan, Lunyi] Singapore Gen Hosp, Dept Clin Qual & Performance Management, Singapore, Singapore.
   [Thien, Siew Yee; Cherng, Benjamin Pei Zhi; Chung, Shimin Jasmine] Singapore Gen Hosp, Dept Infect Dis, Level 3 Acad,20 Coll Rd, Singapore 169856, Singapore.
RP Chung, SJ (corresponding author), Singapore Gen Hosp, Dept Infect Dis, Level 3 Acad,20 Coll Rd, Singapore 169856, Singapore.
EM jasmine.chung.s.m@singhealth.com.sg
CR Huttner BD, 2020, CLIN MICROBIOL INFEC, V26, P808, DOI 10.1016/j.cmi.2020.04.024
   Loo LW, 2019, INT J ANTIMICROB AG, V53, P606, DOI 10.1016/j.ijantimicag.2019.01.008
   Ministry of Health Singapore, 2020, SING UPD COVID 19 CO
   Rawson TM, 2020, J ANTIMICROB CHEMOTH, V75, P1681, DOI 10.1093/jac/dkaa194
   World Health Organization, 2020, COR DIS 2019 COVID 1
NR 5
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD NOV
PY 2020
VL 56
IS 5
AR 106145
DI 10.1016/j.ijantimicag.2020.106145
PG 3
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA OD2VU
UT WOS:000579711500002
PM 32860880
OA Green Published
DA 2021-01-01
ER

PT J
AU Rodriguez, Y
   Novelli, L
   Rojas, M
   De Santis, M
   Acosta-Ampudia, Y
   Monsalve, DM
   Ramirez-Santana, C
   Costanzo, A
   Ridgway, WM
   Ansari, AA
   Gershwin, ME
   Selmi, C
   Anaya, JM
AF Rodriguez, Yhojan
   Novelli, Lucia
   Rojas, Manuel
   De Santis, Maria
   Acosta-Ampudia, Yeny
   Monsalve, Diana M.
   Ramirez-Santana, Carolina
   Costanzo, Antonio
   Ridgway, William M.
   Ansari, Aftab A.
   Gershwin, M. Eric
   Selmi, Carlo
   Anaya, Juan-Manuel
TI Autoinflammatory and autoimmune conditions at the crossroad of COVID-19
SO JOURNAL OF AUTOIMMUNITY
LA English
DT Article
DE SARS-CoV-2; COVID-19; Autoimmunity; Antiphospholipid syndrome;
   Cytopenia; Guillain-Barre syndrome; Kawasaki disease; Cytokine storm
   syndrome; Vaccines
ID MACROPHAGE ACTIVATION SYNDROME; HEPATITIS-C VIRUS; MEMORY T-CELLS;
   CYTOKINE STORM; SEX-DIFFERENCES; DISEASE; CORONAVIRUS; INFECTION;
   LYMPHOPENIA; LYMPHOCYTES
AB Coronavirus disease 2019 (COVID-19) has been categorized as evolving in overlapping phases. First, there is a viral phase that may well be asymptomatic or mild in the majority, perhaps 80% of patients. The pathophysiological mechanisms resulting in minimal disease in this initial phase are not well known. In the remaining 20% of cases, the disease may become severe and/or critical. In most patients of this latter group, there is a phase characterized by the hyperresponsiveness of the immune system. A third phase corresponds to a state of hypercoagulability. Finally, in the fourth stage organ injury and failure occur. Appearance of autoinflammatory/autoimmune phenomena in patients with COVID-19 calls attention for the development of new strategies for the management of life-threatening conditions in critically ill patients. Antiphospholipid syndrome, autoimmune cytopenia, Guillain-Barre syndrome and Kawasaki disease have each been reported in patients with COVID-19. Here we present a scoping review of the relevant immunological findings in COVID-19 as well as the current reports about autoinflammatory/autoimmune conditions associated with the disease. These observations have crucial therapeutic implications since immunomodulatory drugs are at present the most likely best candidates for COVID-19 therapy. Clinicians should be aware of these conditions in patients with COVID-19, and these observations should be considered in the current development of vaccines.
C1 [Rodriguez, Yhojan; Rojas, Manuel; Acosta-Ampudia, Yeny; Monsalve, Diana M.; Ramirez-Santana, Carolina; Anaya, Juan-Manuel] Univ Rosario, Ctr Autoimmune Dis Res CREA, Sch Med & Hlth Sci, Carrera 26-63-B-51, Bogota 110010, Colombia.
   [Novelli, Lucia; De Santis, Maria; Selmi, Carlo] Humanitas Clin & Res Ctr IRCCS, Rheumatol & Clin Immunol, Milan, Italy.
   [Costanzo, Antonio] IRCCS, Humanitas Clin & Res Ctr, Dermatol, Milan, Italy.
   [Costanzo, Antonio; Selmi, Carlo] Humanitas Univ, Dept Biomed Sci, Milan, Italy.
   [Ridgway, William M.; Ansari, Aftab A.; Gershwin, M. Eric] Univ Calif Davis, Div Rheumatol Allergy & Clin Immunol, Davis, CA 95616 USA.
RP Anaya, JM (corresponding author), Univ Rosario, Ctr Autoimmune Dis Res CREA, Sch Med & Hlth Sci, Carrera 26-63-B-51, Bogota 110010, Colombia.; Selmi, C (corresponding author), Humanitas Univ, Dept Biomed Sci, Milan, Italy.; Gershwin, ME (corresponding author), Univ Calif Davis, Div Rheumatol Allergy & Clin Immunol, Davis, CA 95616 USA.
EM megershwin@ucdavis.edu; carlo.selmi@hunimed.eu;
   juan.anaya@urosario.edu.co
RI De Santis, Maria/K-2644-2018
OI De Santis, Maria/0000-0002-3196-1336; Rojas, Manuel/0000-0002-8604-4658
FU Universidad del Rosario [ABN-011]
FX This work was supported by Universidad del Rosario (ABN-011).
CR Aguiar CL, 2013, THER ADV MUSCULOSKEL, V5, P305, DOI 10.1177/1759720X13502919
   Ahmed MZ, 2020, BRIT J HAEMATOL, V189, P1057, DOI 10.1111/bjh.16769
   Ahn DG, 2020, J MICROBIOL BIOTECHN, V30, P313, DOI 10.4014/jmb.2003.03011
   Alberti P, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000741
   Anaya J.M, 2013, AUTOIMMUNITY BENCH B
   Antoniou KM, 2013, CASE REP MED, DOI 10.1155/2013/981232
   Arnaud S, 2020, CLIN NEUROPHYSIOL, V131, P1652, DOI 10.1016/j.clinph.2020.05.003
   Atkinson B, 2020, LANCET, V395, P1339, DOI 10.1016/S0140-6736(20)30868-0
   Baggio G, 2017, G ITAL MED LAV ERGON, V39, P196
   Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Bao L., 2020, BIORXIV, DOI [10.1101/2020.03.13, DOI 10.1101/2020.03.13]
   Behrens EM, 2019, CYTOKINE STORM SYNDROME, P197, DOI 10.1007/978-3-030-22094-5_12
   Behrens EM, 2017, ARTHRITIS RHEUMATOL, V69, P1135, DOI 10.1002/art.40071
   Belhadjer Z, 2020, CIRCULATION, DOI [10.1161/CIRCULATIONAHA.120, DOI 10.1161/CIRCULATIONAHA.120, 10.1161/CIRCULATIONAHA.120.]
   Bin Dhuban K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01532
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Bomhof G, 2020, BRIT J HAEMATOL, V190, pE61, DOI 10.1111/bjh.16850
   Bowles L, 2020, NEW ENGL J MED, V383, P288, DOI 10.1056/NEJMc2013656
   Boyman O, 2009, EUR J IMMUNOL, V39, P2088, DOI 10.1002/eji.200939444
   Braciale TJ, 2013, IMMUNOL REV, V255, P5, DOI 10.1111/imr.12109
   Braun J., 2020, PRESENCE SARS COV 2, DOI [10.1101/2020.04.17.20061440, 10.1101/2020.04.17.20061440., DOI 10.1101/2020.04.17.20061440]
   Bullard Jared, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa638
   Cacoub P, 2014, ANN RHEUM DIS, V73, P24, DOI 10.1136/annrheumdis-2013-203883
   Cameron MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045842
   Cantini F, 2020, J INFECTION, V81, P318, DOI 10.1016/j.jinf.2020.04.017
   Caso F, 2018, CLIN RHEUMATOL, V37, P2305, DOI 10.1007/s10067-018-4209-9
   Castiblanco J, 2015, CURR GENOMICS, V16, P47, DOI 10.2174/1389202916666141223220551
   CDC Korea, 2020, FIND INV AN REP CAS
   Ceribelli A, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102442
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen DB, 2020, INT J INFECT DIS, V93, P297, DOI 10.1016/j.ijid.2020.03.003
   Chen DY, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4193
   Chen J, 2015, CLIN RHEUMATOL, V34, P691, DOI 10.1007/s10067-015-2868-3
   Chen WX, 2020, LANCET HAEMATOL, V7, pE624, DOI 10.1016/S2352-3026(20)30175-7
   Chu H, 2016, J INFECT DIS, V213, P904, DOI 10.1093/infdis/jiv380
   Clay C, 2012, J VIROL, V86, P4234, DOI 10.1128/JVI.06791-11
   Coen M, 2020, BRAIN BEHAV IMMUN, V87, P111, DOI 10.1016/j.bbi.2020.04.074
   Costello FE, 2020, NEUROLOGY, V94, P241, DOI 10.1212/WNL.0000000000008913
   Crayne CB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00119
   Croft M, 2009, IMMUNOL REV, V229, P173, DOI 10.1111/j.1600-065X.2009.00766.x
   Crosslin KL, 2011, GENDER MED, V8, P365, DOI 10.1016/j.genm.2011.10.003
   Davis LS, 2011, J INTERF CYTOK RES, V31, P781, DOI 10.1089/jir.2011.0047
   Deane S, 2010, INT ARCH ALLERGY IMM, V153, P109, DOI 10.1159/000312628
   Del Valle Diane Marie, 2020, medRxiv, DOI 10.1101/2020.05.28.20115758
   Devarajan P, 2013, IMMUNOL RES, V57, P12, DOI 10.1007/s12026-013-8448-1
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Dinkin M, 2020, NEUROLOGY, V95, P221, DOI 10.1212/WNL.0000000000009700
   Doria A, 2012, AUTOIMMUN REV, V12, P22, DOI 10.1016/j.autrev.2012.07.018
   Dostal C, 1997, ANN NY ACAD SCI, V815, P334, DOI 10.1111/j.1749-6632.1997.tb52078.x
   Du SQ, 2020, J MED VIROL, V92, P1615, DOI 10.1002/jmv.25866
   Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC
   Duret PM, 2020, ANN RHEUM DIS, V79, P1250, DOI [10.1136/annrheumdis-2020-217362, 10.1080/17843286.2020.1812830]
   Ellinghaus D., 2020, ABO BLOOD GROUP LOCU, DOI [10.1101/2020.05.31.20114991, DOI 10.1101/2020.05.31.20114991]
   Emmi G, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102575
   FafiKremer S., 2020, SEROLOGIC RESPONSES, DOI [10.1101/2020.05.19.20101832, DOI 10.1101/2020.05.19.20101832]
   Fernandez-Cooke E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215665
   Ferro F, 2020, CLIN EXP RHEUMATOL, V38, P373
   Filippi CM, 2008, DIABETES, V57, P2863, DOI 10.2337/db07-1023
   Franco A, 2010, AUTOIMMUNITY, V43, P317, DOI 10.3109/08916930903405891
   Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4
   Casas CG, 2020, BRIT J DERMATOL, V183, P71, DOI 10.1111/bjd.19163
   Generali E, 2018, AUTOIMMUN REV, V17, P935, DOI 10.1016/j.autrev.2018.04.002
   Gerfaud-Valentin M, 2014, AUTOIMMUN REV, V13, P708, DOI 10.1016/j.autrev.2014.01.058
   Geurtsvan Kessel CH, 2020, NEXT PHASE EVALUATIO, DOI [10.1101/2020.04.23.20077156, 10.1101/2020.04 .23.20077156, DOI 10.1101/2020.04.23.20077156]
   Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009
   Gorse GJ, 2020, J MED VIROL, V92, P512, DOI 10.1002/jmv.25715
   Gray JI, 2018, IMMUNOLOGY, V154, P574, DOI 10.1111/imm.12929
   Guilpain Philippe, 2021, Ann Rheum Dis, V80, pe10, DOI 10.1136/annrheumdis-2020-217549
   Gutierrez-Ortiz C, 2020, NEUROLOGY, V95, pE601, DOI 10.1212/WNL.0000000000009619
   Harzallah I, 2020, J THROMB HAEMOST, V18, P2778, DOI 10.1111/jth.14937
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin JM, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00152
   Jones Veena G, 2020, Hosp Pediatr, V10, P537, DOI 10.1542/hpeds.2020-0123
   Joyner MJ, 2020, J CLIN INVEST, V130, P4791, DOI 10.1172/JCI140200
   Caamano DSJ, 2020, J CLIN NEUROSCI, V77, P230, DOI 10.1016/j.jocn.2020.05.016
   Kahlenberg JM, 2011, J IMMUNOL, V187, P6143, DOI 10.4049/jimmunol.1101284
   Kanduc D, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108426
   Khoruts A, 2005, IMMUNOL LETT, V98, P23, DOI 10.1016/j.imlet.2004.10.022
   Knochelmann HM, 2018, CELL MOL IMMUNOL, V15, P458, DOI 10.1038/s41423-018-0004-4
   Lazarian G, 2020, BRIT J HAEMATOL, V190, P29, DOI 10.1111/bjh.16794
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li MY, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00662-x
   Li S, 2020, CLIN REV ALLERG IMMU, V58, P71, DOI 10.1007/s12016-019-08747-8
   Liblau RS, 2002, IMMUNITY, V17, P1, DOI 10.1016/S1074-7613(02)00338-2
   Liu F, 2020, INT J INFECT DIS, V95, P183, DOI 10.1016/j.ijid.2020.03.013
   Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Liu YX, 2020, NATL SCI REV, V7, P1003, DOI 10.1093/nsr/nwaa037
   Lokman SM, 2020, INFECT GENET EVOL, V84, DOI 10.1016/j.meegid.2020.104389
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Lopez C, 2020, BRIT J HAEMATOL, V190, P31, DOI 10.1111/bjh.16786
   Lucchese G, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102556
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Maeda K, 2005, BLOOD, V106, P879, DOI 10.1182/blood-2005-02-0456
   Mathew Divij, 2020, bioRxiv, DOI 10.1101/2020.05.20.106401
   Matsubara T, 2005, CLIN EXP IMMUNOL, V141, P381, DOI 10.1111/j.1365-2249.2005.02821.x
   Mazzoni A, 2020, J CLIN INVEST, V130, P4694, DOI [10.1172/JCI138554, 10.1172/JCI138554.]
   McGonagle D, 2006, PLOS MED, V3, P1242, DOI 10.1371/journal.pmed.0030297
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mihai C, 2020, ANN RHEUM DIS, V79, P668, DOI 10.1136/annrheumdis-2020-217442
   Moutsopoulos HM, 2020, ANN RHEUM DIS, V79, P1253, DOI 10.1136/annrheumdis-2020-217562
   Murt A, 2020, J MED VIROL, DOI 10.1002/jmv.26138
   Nathan N, 2020, LANCET, V395, P1481, DOI 10.1016/S0140-6736(20)30980-6
   Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485
   Novelli L, 2019, LUPUS, V28, P621, DOI 10.1177/0961203319838063
   O'Sullivan BJ, 2006, J IMMUNOL, V176, P7278, DOI 10.4049/jimmunol.176.12.7278
   Ortona E, 2015, ITALIAN J GENDER SPE, V1, P45, DOI DOI 10.1723/2188.23636
   Ottaviani D, 2020, NEUROL SCI, V41, P1351, DOI 10.1007/s10072-020-04449-8
   Pacheco Y, 2019, J AUTOIMMUN, V103, DOI 10.1016/j.jaut.2019.06.012
   Patterson B.K., 2020, DISRUPTION CCL5 RANT, DOI [10.1101/2020.05.02, DOI 10.1101/2020.05.02]
   Perrone F., 2020, PROTOCOL TITLE MULTI, P1
   Pouchot J, 2012, BEST PRACT RES CL RH, V26, P477, DOI 10.1016/j.berh.2012.07.002
   Puelles VG, 2020, NEW ENGL J MED, V383, P590, DOI [10.1056/NEJMc2011400, 10.1056/NEJMc2013400]
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Quintero OL, 2012, J AUTOIMMUN, V38, pJ109, DOI 10.1016/j.jaut.2011.10.003
   Ramos-Casals M, 2005, MEDICINE, V84, P81, DOI 10.1097/01.md.0000157397.30055.c9
   Ramos-Casals M, 2014, LANCET, V383, P1503, DOI 10.1016/S0140-6736(13)61048-X
   Raucci F, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102572
   Rawlings DJ, 2012, NAT REV IMMUNOL, V12, P282, DOI 10.1038/nri3190
   Rigamonti C, 2020, CLIN GASTROENTEROL H, V18, P2369, DOI 10.1016/j.cgh.2020.05.047
   Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]
   Rivera-Figueroa EI, 2020, INDIAN PEDIAT
   Robbiani Davide F, 2020, bioRxiv, DOI 10.1101/2020.05.13.092619
   Rodriguez Y, 2018, CELL MOL IMMUNOL, V15, P547, DOI 10.1038/cmi.2017.142
   Rojas M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102554
   Rojas M, 2018, J AUTOIMMUN, V95, P100, DOI 10.1016/j.jaut.2018.10.012
   Roussou E, 2011, CLIN RHEUMATOL, V30, P121, DOI 10.1007/s10067-010-1581-5
   Rowley AH, 2011, J INFECT DIS, V203, P1021, DOI 10.1093/infdis/jiq136
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Ruggieri M.C.G. Anna, 2020, J GENDER SPECIFIC ME, V6, P49
   Sanderson NSR, 2017, P NATL ACAD SCI USA, V114, P734, DOI 10.1073/pnas.1614472114
   Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
   Sbidian E, 2019, BRIT J DERMATOL, DOI 10.1111/bjd.18203
   Scheidl E, 2020, J PERIPHER NERV SYST, V25, P204, DOI 10.1111/jns.12382
   Schulert GS, 2014, BEST PRACT RES CL RH, V28, P277, DOI 10.1016/j.berh.2014.03.002
   Schulze-Koops H, 2004, ARTHRITIS RES THER, V6, P178, DOI 10.1186/ar1208
   Sethuraman N, 2020, JAMA-J AM MED ASSOC, V323, P2249, DOI 10.1001/jama.2020.8259
   Seydoux E, 2020, IMMUNITY, V53, P98, DOI 10.1016/j.immuni.2020.06.001
   Shamsizadeh A, 2014, JUNDISHAPUR J MICROB, V7, DOI 10.5812/jjm.11014
   Sharmeen S, 2020, SEMIN ARTHRITIS RHEU, V50, P680, DOI 10.1016/j.semarthrit.2020.05.010
   Shi Y, 2020, IMMUNOPATHOLOGICAL C, V160, P261, DOI [10.1101/2020.03.12.20034736, 10.1111/imm.13223, DOI 10.1101/2020.03.12.20034736]
   Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9
   Singh JA, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008331.pub2
   Smatti MK, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11080762
   Son MBF, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2123
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Suthar Mehul S, 2020, Cell Rep Med, V1, P100040, DOI 10.1016/j.xcrm.2020.100040
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Tanaka T, 2016, IMMUNOTHERAPY-UK, V8, P959, DOI 10.2217/imt-2016-0020
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Teuwen LA, 2020, NAT REV IMMUNOL, V20, P389, DOI 10.1038/s41577-020-0343-0
   Theofilopoulos AN, 2001, J CLIN INVEST, V108, P335, DOI 10.1172/JCI200112173
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Tincani L.A. Angela, 2018, J GENDER SPECIFIC ME, V4, pe79, DOI [10.1723/3013, DOI 10.1723/3013]
   Toscano G, 2020, NEW ENGL J MED, V382, P2574, DOI 10.1056/NEJMc2009191
   Toubiana J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2094
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   van de Veerdonk FL, 2020, ELIFE, V9, DOI 10.7554/eLife.57555
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Virani A, 2020, IDCases, V20, DOI 10.1016/j.idcr.2020.e00771
   Vojdani A, 2020, CLIN IMMUNOL, V217, DOI 10.1016/j.clim.2020.108480
   Wang F, 2020, J INFECT DIS, V221, P1762, DOI 10.1093/infdis/jiaa150
   Wang W, 2020, HLA, V96, P194, DOI 10.1111/tan.13941
   Wang XL, 2020, CELL MOL IMMUNOL, V17, P894, DOI 10.1038/s41423-020-0498-4
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   World Health Organisation, 2020, 52 WHO
   WOUTERS JMGW, 1988, ANN RHEUM DIS, V47, P764, DOI 10.1136/ard.47.9.764
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Wu LP, 2007, EMERG INFECT DIS, V13, P1562, DOI 10.3201/eid1310.070576
   Xiang F, 2020, CLIN INFECT DIS, V71, P1930, DOI 10.1093/cid/ciaa461
   Xiong Y, 2020, EMERG MICROBES INFEC, V9, P761, DOI 10.1080/22221751.2020.1747363
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Xu X, 2020, NAT MED, V26, P1193, DOI 10.1038/s41591-020-0949-6
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang Y., 2020, EXUBERANT ELEVATION, DOI [10.1101/2020.03.02.20029975, DOI 10.1101/2020.03.02.20029975]
   Zang RC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc3582
   Zeng Q., 2020, MORTALITY COVID 19 I, DOI [10.1101/2020.03.08.20031229, DOI 10.1101/2020.03.08.20031229]
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhang ZL, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1246-x
   Zhao Y, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.139834
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
   Zheng SG, 2008, J IMMUNOL, V180, P7112, DOI 10.4049/jimmunol.180.11.7112
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041
   Zhou Z, 2020, CELL HOST MICROBE, V27, P883, DOI 10.1016/j.chom.2020.04.017
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zhu YW, 2007, BLOOD, V109, P4882, DOI 10.1182/blood-2006-10-043463
   Zulfiqar AA, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2010472
   Zuo Yu, 2020, medRxiv, DOI 10.1101/2020.04.09.20059626
NR 194
TC 10
Z9 10
U1 10
U2 10
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0896-8411
EI 1095-9157
J9 J AUTOIMMUN
JI J. Autoimmun.
PD NOV
PY 2020
VL 114
AR 102506
DI 10.1016/j.jaut.2020.102506
PG 18
WC Immunology
SC Immunology
GA OD4ZH
UT WOS:000579860500004
PM 32563547
OA Green Published
DA 2021-01-01
ER

PT J
AU Lens, S
   Miquel, M
   Mateos-Munoz, B
   Garcia-Samaniego, J
   Forns, X
AF Lens, Sabela
   Miquel, Mireia
   Mateos-Munoz, Beatriz
   Garcia-Samaniego, Javier
   Forns, Xavier
TI SARS-CoV-2 in patients on antiviral HBV and HCV therapy in Spain
SO JOURNAL OF HEPATOLOGY
LA English
DT Letter
C1 [Lens, Sabela; Forns, Xavier] Univ Barcelona, Hosp Clin, IDIBAPS, Liver Unit, Barcelona, Spain.
   [Lens, Sabela; Miquel, Mireia; Mateos-Munoz, Beatriz; Garcia-Samaniego, Javier; Forns, Xavier] CIBERehd, Barcelona, Spain.
   [Miquel, Mireia] Univ Autonoma Barcelona, Parc Tauli Hosp Univ, I3PT, Hepatol Unit,Digest Dis Dept, Sabadell, Spain.
   [Mateos-Munoz, Beatriz] Hosp Univ Ramon y Cajal, Hepatol Dept, Madrid, Spain.
   [Garcia-Samaniego, Javier] Hosp Univ La Paz, Liver Unit, IdiPAZ, Madrid, Spain.
RP Lens, S (corresponding author), Hosp Clin Barcelona, Liver Unit, Barcelona, Spain.
EM slens@clinc.cat
OI Lens, Sabela/0000-0003-4900-411X; Forns, Xavier/0000-0002-8188-1764
FU Instituto de Salud Carlos III (ISCIII)Instituto de Salud Carlos III
   [PI18/00079]; Plan Estrategico Nacional contra la hepatitis C (Spanish
   Health Ministry); Secretaria d'Universitats i Recerca del Departament
   d'Economia i Coneixement [2017_SGR_1753]; CERCA Programme/Generalitat de
   Catalunya; Asociacion Espanola para el Estudio del Higado (AEEH)
FX XF: Instituto de Salud Carlos III (ISCIII) PI18/00079, Plan Estrategico
   Nacional contra la hepatitis C (Spanish Health Ministry), Secretaria
   d'Universitats i Recerca del Departament d'Economia i Coneixement (grant
   2017_SGR_1753) and CERCA Programme/Generalitat de Catalunya. SL: grant
   from Asociacion Espanola para el Estudio del Higado (AEEH).
CR Anugwom Chimaobi M, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa592
   Chen X, 2020, CLIN CHARACTERISTICS, DOI [10.1101/2020.03.23.20040733., DOI 10.1101/2020.03.23.20040733]
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Chien M, 2020, J PROTEOME RES, DOI [10.1021/acs.jproteome. 0c00392., DOI 10.1021/ACS.JPR0TE0ME.0C00392]
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Jacome R, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66440-9
   Moon AM, 2020, J HEPATOL, V73, P705, DOI 10.1016/j.jhep.2020.05.013
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rodriguez-Tajes S, 2020, J GASTROEN HEPATOL, V35, P1570, DOI 10.1111/jgh.14984
NR 10
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD NOV
PY 2020
VL 73
IS 5
BP 1262
EP 1263
DI 10.1016/j.jhep.2020.07.007
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA OD4GA
UT WOS:000579809700027
PM 32673740
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Weston, S
   Coleman, CM
   Haupt, R
   Logue, J
   Matthews, K
   Li, YZ
   Reyes, HM
   Weiss, SR
   Frieman, MB
AF Weston, Stuart
   Coleman, Christopher M.
   Haupt, Robert
   Logue, James
   Matthews, Krystal
   Li, Yize
   Reyes, Hanako M.
   Weiss, Susan R.
   Frieman, Matthew B.
TI Broad Anti-coronavirus Activity of Food and Drug Administration-Approved
   Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo
SO JOURNAL OF VIROLOGY
LA English
DT Article
DE FDA-approved drugs; SARS-CoV-2; antiviral therapeutics; coronavirus;
   drug repurposing; nCoV-2019; pandemic
ID RESPIRATORY SYNDROME CORONAVIRUS; CHLOROQUINE; INHIBITORS; THERAPY;
   DISEASE; VIRUS
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in China at the end of 2019 and has rapidly caused a pandemic, with over 20 million recorded COVID-19 cases in August 2020 (https://covid19.who.int/). There are no FDA-approved antivirals or vaccines for any coronavirus, including SARS-CoV-2. Current treatments for COVID-19 are limited to supportive therapies and off-label use of FDA-approved drugs. Rapid development and human testing of potential antivirals is urgently needed. Numerous drugs are already approved for human use, and subsequently, there is a good understanding of their safety profiles and potential side effects, making them easier to fast-track to clinical studies in COVID-19 patients. Here, we present data on the antiviral activity of 20 FDA-approved drugs against SARS-CoV-2 that also inhibit SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV). We found that 17 of these inhibit SARS-CoV-2 at non-cytotoxic concentrations. We directly followed up seven of these to demonstrate that all are capable of inhibiting infectious SARS-CoV-2 production. Moreover, we evaluated two of these, chloroquine and chlorpromazine, in vivo using a mouse-adapted SARS-CoV model and found that both drugs protect mice from clinical disease.
   IMPORTANCE There are no FDA-approved antivirals for any coronavirus, including SARS-CoV-2. Numerous drugs are already approved for human use that may have antiviral activity and therefore could potentially be rapidly repurposed as antivirals. Here, we present data assessing the antiviral activity of 20 FDA-approved drugs against SARS-CoV-2 that also inhibit SARS-CoV and MERS-CoV in vitro. We found that 17 of these inhibit SARS-CoV-2, suggesting that they may have pan-anti-coronaviral activity. We directly followed up seven of these and found that they all inhibit infectious-SARS-CoV-2 production. Moreover, we evaluated chloroquine and chlorpromazine in vivo using mouse-adapted SARS-CoV. We found that neither drug inhibited viral replication in the lungs, but both protected against clinical disease.
C1 [Weston, Stuart; Coleman, Christopher M.; Haupt, Robert; Logue, James; Matthews, Krystal; Frieman, Matthew B.] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA.
   [Li, Yize; Reyes, Hanako M.; Weiss, Susan R.] Univ Penn, Dept Microbiol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Coleman, Christopher M.] Univ Nottingham, Queens Med Ctr, Sch Life Sci, Nottingham, England.
RP Frieman, MB (corresponding author), Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA.
EM MFrieman@som.umaryland.edu
OI Logue, James/0000-0002-7410-9741
FU Emergent BioSolutions; BMGF [INV-006099, ASPR-20-01495]; NIAIDUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [75N93019C00051]; DARPAUnited States Department of
   DefenseDefense Advanced Research Projects Agency (DARPA)
   [HR0011-20-2-0040];  [R01-AI-140442]
FX We kindly thank Emergent BioSolutions for financial support to perform
   these experiments. S.W. is supported by R01-AI-140442. M.B.F. is
   supported by BMGF INV-006099, ASPR-20-01495, NIAID contract
   75N93019C00051, and DARPA HR0011-20-2-0040.
CR Al-Bari MAA, 2015, J ANTIMICROB CHEMOTH, V70, P1608, DOI 10.1093/jac/dkv018
   Baird JK, 2005, NEW ENGL J MED, V352, P1565, DOI 10.1056/NEJMra043207
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Brown AJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104541
   Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Coleman Christopher M, 2015, Curr Protoc Microbiol, V37, DOI 10.1002/9780471729259.mc15e02s37
   Coleman CM, 2016, J VIROL, V90, P8924, DOI 10.1128/JVI.01429-16
   Dyall J, 2018, J INFECT DIS, V218, pS592, DOI 10.1093/infdis/jiy345
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Frieman M, 2012, J VIROL, V86, P884, DOI 10.1128/JVI.05957-11
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Madrid PB, 2015, ACS INFECT DIS, V1, P317, DOI 10.1021/acsinfecdis.5b00030
   Madrid PB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060579
   Mercorelli B, 2018, TRENDS MICROBIOL, V26, P865, DOI 10.1016/j.tim.2018.04.004
   Mingo RM, 2015, J VIROL, V89, P2931, DOI 10.1128/JVI.03398-14
   Pastick KA, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa130
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Rainsford KD, 2015, INFLAMMOPHARMACOLOGY, V23, P231, DOI 10.1007/s10787-015-0239-y
   Roberts A, 2007, PLOS PATHOG, V3, P23, DOI 10.1371/journal.ppat.0030005
   Rockx B, 2009, J VIROL, V83, P7062, DOI 10.1128/JVI.00127-09
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Sisk JM, 2018, J GEN VIROL, V99, P619, DOI 10.1099/jgv.0.001047
   Sisk JM, 2015, ACS INFECT DIS, V1, P401, DOI 10.1021/acsinfecdis.5b00089
   Smits SL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000756
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Xu M, 2016, NAT MED, V22, P1101, DOI 10.1038/nm.4184
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   ZIEGLER HK, 1982, P NATL ACAD SCI-BIOL, V79, P175, DOI 10.1073/pnas.79.1.175
NR 34
TC 4
Z9 4
U1 2
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD NOV
PY 2020
VL 94
IS 21
AR e01218-20
DI 10.1128/JVI.01218-20
PG 13
WC Virology
SC Virology
GA OD4PJ
UT WOS:000579834200027
PM 32817221
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kumar, A
   Quraishi, MN
   Segal, JP
   Raine, T
   Brookes, MJ
AF Kumar, Aditi
   Quraishi, Mohammed Nabil
   Segal, Jonathan P.
   Raine, Tim
   Brookes, Matthew J.
TI COVID-19 vaccinations in patients with inflammatory bowel disease
SO LANCET GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Letter
ID STRATEGIES; VACCINE
C1 [Kumar, Aditi; Brookes, Matthew J.] Royal Wolverhampton Trust, New Cross Hosp, Wolverhampton WV10 0QP, England.
   [Kumar, Aditi; Brookes, Matthew J.] Univ Wolverhampton, Fac Sci & Engn, Wolverhampton, England.
   [Quraishi, Mohammed Nabil] Univ Birmingham, Microbiome Treatment Ctr, Birmingham, W Midlands, England.
   [Quraishi, Mohammed Nabil] Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp Birmingham, Dept Gastroenterol, Birmingham, W Midlands, England.
   [Segal, Jonathan P.] St Marys Hosp London, Dept Gastroenterol & Hepatol, London, England.
   [Raine, Tim] Cambridge Univ Hosp, Dept Gastroenterol, Cambridge, England.
RP Kumar, A (corresponding author), Royal Wolverhampton Trust, New Cross Hosp, Wolverhampton WV10 0QP, England.; Kumar, A (corresponding author), Univ Wolverhampton, Fac Sci & Engn, Wolverhampton, England.
EM aditikumar@nhs.net
RI Brookes, Matthew/ABE-6952-2020
OI Raine, Tim/0000-0002-5855-9873; Brookes, Matthew/0000-0002-8782-0292
CR Apte M, 2018, PRACT GASTROENTEROL, V42, P64
   Fiorino G, 2012, INFLAMM BOWEL DIS, V18, P1042, DOI 10.1002/ibd.21800
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Huth K, 2015, INFLAMM BOWEL DIS, V21, P1761, DOI 10.1097/MIB.0000000000000425
   Melmed GY, 2006, AM J GASTROENTEROL, V101, P1834, DOI 10.1111/j.1572-0241.2006.00646.x
   Pan Daniel, 2020, EClinicalMedicine, V23, P100404, DOI 10.1016/j.eclinm.2020.100404
   Rahier JF, 2014, J CROHNS COLITIS, V8, P443, DOI 10.1016/j.crohns.2013.12.013
   Stoffel NU, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01313
   Zhang C, 2016, HUM VACC IMMUNOTHER, V12, P2064, DOI 10.1080/21645515.2016.1165908
NR 9
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
EI 2468-1253
J9 LANCET GASTROENTEROL
JI Lancet Gastroenterol. Hepatol.
PD NOV
PY 2020
VL 5
IS 11
BP 965
EP 966
DI 10.1016/S2468-1253(20)30295-8
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA OE4CD
UT WOS:000580479500007
PM 32971020
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Aktug, ZB
   Demir, NA
AF Aktug, Zait Burak
   Demir, Nazlim Aktug
TI An Exercise Prescription for COVID-19 Pandemic
SO PAKISTAN JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE COVID-19; Exercise prescription; Health
ID MODERATE-INTENSITY EXERCISE; PHYSICAL-ACTIVITY; CARDIORESPIRATORY
   FITNESS; DEPRESSION; METAANALYSIS; IMPACT; HYPERTENSION; PREVENTION;
   ANXIETY
AB COVID-19 is an alarming public health concern worldwide. COVID-19 is highly contagious and has no approved treatment or vaccine yet. Therefore, the best strategy is prevention. Studies have shown that a healthy lifestyle, regular exercise, balanced eating, and quality sleep are the key elements for protection from this disease. We are going through a distressful period as a nation and as the human race in general. We need to manage this period in the best way possible in physiological and psychological terms. Physical activity is one of the major steps in managing this period in a healthy way. Individuals should be provided information about exercise so that they can perform correct physical activities within their means. This article presents an exercise prescription that can be followed in the days of the COVID-19 pandemic.
C1 [Aktug, Zait Burak] Nigde Omer Halisdemir Univ, Sports Sci Fac, Nigde, Turkey.
   [Demir, Nazlim Aktug] Selcuk Univ, Fac Med, Dept Clin Microbiol & Infect Dis, Konya, Turkey.
RP Aktug, ZB (corresponding author), Nigde Omer Halisdemir Univ, Sports Sci Fac, Nigde, Turkey.
EM zaitburak@gmail.com
CR Altena E, 2020, J SLEEP RES, V29, DOI 10.1111/jsr.13052
   Aman F, 2020, PAK J MED SCI, V36, pS121, DOI 10.12669/pjms.36.COVID19-S4.2776
   [Anonymous], 1948, WHO CONSTITUTION
   Berger BG, 1998, PERCEPT MOTOR SKILL, V87, P611, DOI 10.2466/pms.1998.87.2.611
   Blanchard CM, 2001, J SCI MED SPORT, V4, P30, DOI 10.1016/S1440-2440(01)80005-0
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Brunes A, 2015, SOC PSYCH PSYCH EPID, V50, P419, DOI 10.1007/s00127-014-0915-z
   Celebi MM, 2016, TURKIYE KLIN J SPORT, V2, P59
   Centers for Disease Control and Prevention, 2020, INT CLIN GUID MAN PA
   Chalder M, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16100
   Dunn A L, 1991, Exerc Sport Sci Rev, V19, P41
   Fariz B, 2015, TURK J SPORTS MED, V50, P131
   Harber MP, 2017, PROG CARDIOVASC DIS, V60, P11, DOI 10.1016/j.pcad.2017.03.001
   Hashmi AM, 2020, PAK J MED SCI, V36, pS95, DOI 10.12669/pjms.36.COVID19-S4.2792
   Howe TE, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000333.pub2
   Huai PC, 2013, HYPERTENSION, V62, P1021, DOI 10.1161/HYPERTENSIONAHA.113.01965
   Kim SW, 2020, BRAIN BEHAV IMMUN, V87, P4, DOI 10.1016/j.bbi.2020.03.025
   King AC, 1997, JAMA-J AM MED ASSOC, V277, P32, DOI 10.1001/jama.277.1.32
   Lavie CJ, 2019, CIRC RES, V124, P799, DOI 10.1161/CIRCRESAHA.118.312669
   Lee IM, 2003, MED SCI SPORT EXER, V35, P1823, DOI 10.1249/01.MSS.0000093620.27893.23
   Legrand F, 2007, J SPORT EXERCISE PSY, V29, P348, DOI 10.1123/jsep.29.3.348
   Loh Siew Yim, 2015, Glob J Health Sci, V8, P238, DOI 10.5539/gjhs.v8n1p238
   Lok S, 2016, CURRENT APPROACHES P, V8, P354
   Mammen G, 2013, AM J PREV MED, V45, P649, DOI 10.1016/j.amepre.2013.08.001
   Mead GE, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004366.pub3
   Nabkasorn C, 2006, EUR J PUBLIC HEALTH, V16, P179, DOI 10.1093/eurpub/cki159
   Nauman J, 2017, PROG CARDIOVASC DIS, V60, P78, DOI 10.1016/j.pcad.2017.01.009
   NICOLOFF G, 1995, PHYSICIAN SPORTSMED, V23, P44, DOI 10.1080/00913847.1995.11947838
   Ozemek C, 2019, PROG CARDIOVASC DIS, V62, P102, DOI 10.1016/j.pcad.2019.02.004
   Ozemek C, 2018, PROG CARDIOVASC DIS, V61, P484, DOI 10.1016/j.pcad.2018.11.005
   Perlman S, 2020, NEW ENGL J MED, V382, P760, DOI 10.1056/NEJMe2001126
   RANSFORD CP, 1982, MED SCI SPORT EXER, V14, P1, DOI 10.1249/00005768-198201000-00001
   Rethorst CD, 2009, SPORTS MED, V39, P491, DOI 10.2165/00007256-200939060-00004
   SALLIS JF, 1986, PREV MED, V15, P331, DOI 10.1016/0091-7435(86)90001-0
   Sui XM, 2017, PROG CARDIOVASC DIS, V60, P56, DOI 10.1016/j.pcad.2017.02.006
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   Teixeira RB, 2015, DIABETES VASC DIS RE, V12, P445, DOI 10.1177/1479164115602651
   WHO, 2020, NOV COR 2019 NCOV TE
   Wipfli BM, 2008, J SPORT EXERCISE PSY, V30, P392, DOI 10.1123/jsep.30.4.392
   Wu WZ, 2020, J MED VIROL, V92, P1962, DOI 10.1002/jmv.25914
NR 40
TC 0
Z9 0
U1 2
U2 2
PU PROFESSIONAL MEDICAL PUBLICATIONS
PI SADDAR
PA PANORAMA CENTRE, RM 522, 5TH FLOOR, BLDG 2, RAJA GHAZANFAR ALI RD, PO
   BOX 8766, SADDAR, KARACHI 00000, PAKISTAN
SN 1682-024X
J9 PAK J MED SCI
JI Pak. J. Med. Sci.
PD NOV-DEC
PY 2020
VL 36
IS 7
BP 1732
EP 1736
DI 10.12669/pjms.36.7.2929
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA OD7SI
UT WOS:000580048400054
PM 33235606
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tan, GP
   Ho, S
   Fan, BWE
   Chotirmall, SH
   Tan, CH
   Lew, SJW
   Chia, PY
   Young, BE
   Abisheganaden, JA
   Puah, SH
AF Tan, Geak Poh
   Ho, Sharlene
   Fan, Bingwen Eugene
   Chotirmall, Sanjay H.
   Tan, Cher Heng
   Lew, Sennen Jin Wen
   Chia, Po Ying
   Young, Barnaby E.
   Abisheganaden, John Arputhan
   Puah, Ser Hon
TI Reversible platypnea-orthodeoxia in COVID-19 acute respiratory distress
   syndrome survivors
SO RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY
LA English
DT Article
DE Coronavirus; Critical care; Pneumonia; Respiratory physiology;
   Rehabilitation
AB Platypnea-orthodeoxia syndrome (POS) is a rare clinical syndrome characterized by orthostatic oxygen desaturation and positional dyspnea from supine to an upright position. We observed POS in 5 of 20 cases of severe 2019 novel coronavirus (COVID-19) pneumonia, which demonstrated persistently elevated shunt fraction even after liberation from mechanical ventilation. POS was first observed during physiotherapy sessions; median oxygen desaturation was 8 % (range: 8-12 %). Affected individuals were older (median 64 vs 53 years old, p = 0.05) and had lower body mass index (median 24.7 vs 27.6 kg/m(2), p = 0.03) compared to those without POS. While POS caused alarm and reduced tolerance to therapy, this phenomenon resolved over a median of 17 days with improvement of parenchymal disease. The mechanisms of POS are likely due to gravitational redistribution of pulmonary blood flow resulting in increased basal physiological shunting and upper zone dead space ventilation due to the predominantly basal distribution of consolidative change and reported vasculoplegia and microthmmbi in severe COVID-19 disease.
C1 [Tan, Geak Poh; Ho, Sharlene; Lew, Sennen Jin Wen; Abisheganaden, John Arputhan; Puah, Ser Hon] Tan Tock Seng Hosp, Dept Resp & Crit Care Med, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
   [Fan, Bingwen Eugene; Chotirmall, Sanjay H.; Chia, Po Ying; Young, Barnaby E.; Abisheganaden, John Arputhan] Lee Kong Chian Sch Med, Clin Sci Bldg,11 Mandalay Rd, Singapore 308232, Singapore.
   [Fan, Bingwen Eugene; Abisheganaden, John Arputhan] Natl Univ Singapore, Yong Loo Lin Sch Med, 10 Med Dr, Singapore 117597, Singapore.
   [Fan, Bingwen Eugene] Tan Tock Seng Hosp, Dept Haematol, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
   [Fan, Bingwen Eugene] Khoo Teck Puat Hosp, Dept Lab Med, 90 Yishun Cent, Singapore 768828, Singapore.
   [Tan, Cher Heng] Tan Tock Seng Hosp, Dept Diagnost Radiol, 11 Jalan Tan Tock Seng Hosp, Singapore 308433, Singapore.
   [Chia, Po Ying; Young, Barnaby E.] Natl Ctr Infect Dis, 16 Jalan Tan Tock Seng, Singapore 308442, Singapore.
   [Chia, Po Ying; Young, Barnaby E.] Tan Tock Seng Hosp, Dept Infect Dis, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
RP Tan, GP (corresponding author), Tan Tock Seng Hosp, Dept Resp & Crit Care Med, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
EM geak_poh_tan@ttsh.com.sg; sharlene.ho@mohh.com.sg;
   Bingwen_Eugene_FAN@ttsh.com.sg; schotirmall@ntu.edu.sg;
   Cher_Heng_TAN@ttsh.com.sg; Sennen_Jw_LEW@ttsh.com.sg;
   Po_Ying_CHIA@ttsh.com.sg; barnaby_young@ncid.sg;
   John_Abisheganaden@ttsh.com.sg; Ser_Hon_PUAH@ttsh.com.sg
RI Fan, Bingwen Eugene/AAR-3121-2020; Chotirmall, Sanjay Haresh/K-4127-2015
OI Fan, Bingwen Eugene/0000-0003-4367-5182; Chotirmall, Sanjay
   Haresh/0000-0003-0417-7607
FU Singapore National Medical Research Council through the COVID-19
   Research Fund [COVID19RF-001]; Singapore National Medical Research
   Council (NMRC) Research Training Fellowship [NMRC/Fellowship/0056/2018]
FX This work was funded in part by the Singapore National Medical Research
   Council through the COVID-19 Research Fund (Ref: COVID19RF-001). Author
   Dr. Po Ying Chia is supported by the Singapore National Medical Research
   Council (NMRC) Research Training Fellowship (NMRC/Fellowship/0056/2018).
CR Agrawal A, 2017, RESP MED, V129, P31, DOI 10.1016/j.rmed.2017.05.016
   Dessap AM, 2010, CRIT CARE MED, V38, P1786, DOI 10.1097/CCM.0b013e3181eaa9c8
   Fox SE, 2020, LANCET RESP MED, V8, P681, DOI 10.1016/S2213-2600(20)30243-5
   Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450
   HERT R, 1994, THORAX, V49, P8, DOI 10.1136/thx.49.1.8
   Lumb A.B., 2010, NUNNS APPL RESP PHYS
   MCGREGOR M, 1961, CIRC RES, V9, P1089, DOI 10.1161/01.RES.9.5.1089
   Ministry of Health Singapore, 2020, SIT REP 29 MAY 2020
   Radermacher P, 2017, AM J RESP CRIT CARE, V196, P964, DOI 10.1164/rccm.201610-2156SO
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
NR 10
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1569-9048
EI 1878-1519
J9 RESP PHYSIOL NEUROBI
JI Respir. Physiol. Neuro.
PD NOV
PY 2020
VL 282
AR 103515
DI 10.1016/j.resp.2020.103515
PG 5
WC Physiology; Respiratory System
SC Physiology; Respiratory System
GA OC8LS
UT WOS:000579408900004
PM 32777268
OA Green Published
DA 2021-01-01
ER

PT J
AU Vianello, A
   Arcaro, G
   Molena, B
   Turato, C
   Sukthi, A
   Guarnieri, G
   Lugato, F
   Senna, G
   Navalesi, P
AF Vianello, Andrea
   Arcaro, Giovanna
   Molena, Beatrice
   Turato, Cristian
   Sukthi, Andi
   Guarnieri, Gabriella
   Lugato, Francesca
   Senna, Gianenrico
   Navalesi, Paolo
TI High-flow nasal cannula oxygen therapy to treat patients with hypoxemic
   acute respiratory failure consequent to SARS-CoV-2 infection
SO THORAX
LA English
DT Article
DE critical care; viral infection; respiratory infection; non invasive
   ventilation
AB This observational study aims to assess the outcome and safety of O-2-therapy by high-flow nasal cannula (HFNC) in 28 consecutive patients with severe hypoxemic acute respiratory failure (hARF) consequent to SARS-CoV-2 infection, unresponsive to conventional O-2-therapy. Nineteen patients had a positive response. Nine patients required escalation of treatment to non-invasive ventilation (five subsequently intubated). None of the staff had a positive swab testing during the study period and the following 14 days. Severity of hypoxemia and C reactive protein level were correlated with HFNC failure. These data suggest HFNC to be a safe treatment for less severe patients with SARS-CoV-2 hARF and efficacy will need to be assessed as part of a clinical trial.
C1 [Vianello, Andrea] Univ Padua, Dept Cardiac Thorac Vasc Sci & Publ Hlth, Padua, Italy.
   [Arcaro, Giovanna; Molena, Beatrice; Sukthi, Andi; Guarnieri, Gabriella; Lugato, Francesca] Univ City Hosp Padova, Dept Cardiac Thorac & Vasc Sci, Padua, Italy.
   [Turato, Cristian] Univ Pavia, Dept Mol Med, Pavia, Italy.
   [Senna, Gianenrico] Univ Verona, Dept Med, Verona, Italy.
   [Navalesi, Paolo] Univ Padua, Dept Med DIMED, Padua, Italy.
RP Vianello, A (corresponding author), Univ Padua, Dept Cardiac Thorac Vasc Sci & Publ Hlth, Padua, Italy.
EM andrea.vianello@aopd.veneto.it
RI Navalesi, Paolo/I-9584-2019
OI Navalesi, Paolo/0000-0002-3733-3453; Vianello,
   Andrea/0000-0002-8790-6029
CR Alhazzani W, INTENSIVE CARE MED, V28
   Branson RD, 1995, RESP CARE EQUIPMENT, P55
   Cheung JCH, 2020, LANCET RESP MED, V8, pE19, DOI 10.1016/S2213-2600(20)30084-9
   Hui DS, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.02339-2018
   Nishimura M, 2015, J INTENSIVE CARE, V3, DOI 10.1186/s40560-015-0084-5
   Spoletini G, 2015, CHEST, V148, P253, DOI 10.1378/chest.14-2871
   Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016
   World Health Organization, 2020, INT GUID, DOI 10.15585/mmwr.mm6942a5
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 9
TC 1
Z9 1
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0040-6376
EI 1468-3296
J9 THORAX
JI Thorax
PD NOV
PY 2020
VL 75
IS 11
BP 998
EP 1000
DI 10.1136/thoraxjnl-2020-214993
PG 3
WC Respiratory System
SC Respiratory System
GA OE3NG
UT WOS:000580440800011
PM 32703883
OA Bronze
DA 2021-01-01
ER

PT J
AU Baralic, K
   Jorgovanovic, D
   Zivancevic, K
   Miljakovic, EA
   Antonijevic, B
   Djordjevic, AB
   Curcic, M
   Dukic-Cosic, D
AF Baralic, Katarina
   Jorgovanovic, Dragica
   Zivancevic, Katarina
   Miljakovic, Evica Antonijevic
   Antonijevic, Biljana
   Djordjevic, Aleksandra Buha
   Curcic, Marijana
   Dukic-Cosic, Danijela
TI Safety assessment of drug combinations used in COVID-19 treatment: in
   silico toxicogenomic data-mining approach
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE Lopinavir; Ritonavir; Chloroquine; Azithromycin; Anti-COVID-19 Therapy;
   in silico; Approach
ID CHLOROQUINE; EFFICACY
AB Improvement of COVID-19 clinical condition was seen in studies where combination of antiretroviral drugs, lopinavir and ritonavir, as well as immunomodulant antimalaric, chloroquine/hydroxychloroquine together with the macrolide-type antibiotic, azithromycin, was used for patient's treatment. Although these drugs are "old", their pharmacological and toxicological profile in SARS-CoV-2 - infected patients are still unknown. Thus, by using in silico toxicogenomic data-mining approach, we aimed to assess both risks and benefits of the COVID-19 treatment with the most promising candidate drugs combinations: lopinavir/ritonavir and chloroquine/hydroxychloroquine + azithromycin. The Comparative Toxicogenomics Database (CTD; http://CTD.mdibl.org), Cytoscape software (https://cytoscape.org) and ToppGene Suite portal (https://toppgene.cchmc.org) served as a foundation in our research. Our results have demonstrated that lopinavir/ritonavir increased the expression of the genes involved in immune response and lipid metabolism (IL6, ICAM1, CCL2, TNF, APOA1, etc.). Chloroquine/hydroxychloroquine + azithromycin interacted with 6 genes (CCL2, CTSB, CXCL8, IL1B, IL6 and TNF), whereas chloroquine and azithromycin affected two additional genes (BCL2L1 and CYP3A4), which might be a reason behind a greater number of consequential diseases. In contrast to lopinavir/ritonavir, chloroquine/ hydroxychloroquine + azithromycin downregulated the expression of TNF and IL6. As expected, inflammation, cardiotoxicity, and dyslipidaemias were revealed as the main risks of lopinavir/ritonavir treatment, while chloroquine/hydroxychloroquine + azithromycin therapy was additionally linked to gastrointestinal and skin diseases. According to our results, these drug combinations should be administrated with caution to patients suffering from cardiovascular problems, autoimmune diseases, or acquired and hereditary lipid disorders.
C1 [Baralic, Katarina; Jorgovanovic, Dragica; Zivancevic, Katarina; Miljakovic, Evica Antonijevic; Antonijevic, Biljana; Djordjevic, Aleksandra Buha; Curcic, Marijana; Dukic-Cosic, Danijela] Univ Belgrade, Ctr Toxicol Risk Assessment, Dept Toxicol Akad Danilo Soldatovic, Fac Pharm, Belgrade, Serbia.
RP Curcic, M; Dukic-Cosic, D (corresponding author), Univ Belgrade, Fac Pharm, Vojvode Stepe 450, Belgrade 11221, Serbia.
EM katarinab@pharmacy.bg.ac.rs; evica.antonijevic@pharmacy.bg.ac.rs;
   biljana.antonijevic@pharmacy.bg.ac.rs;
   aleksandra.buha@pharmacy.bg.ac.rs; marijana.curcic@pharmacy.bg.ac.rs;
   danijela.djukic.cosic@pharmacy.bg.ac.rs
RI Baralic, Katarina/AAX-8347-2020
OI Baralic, Katarina/0000-0003-3290-2204; Zivancevic,
   Katarina/0000-0002-2369-3060
FU Ministry of Education, Science and Technological Development, Republic
   of Serbia [451-03-68/2020-14/200161]
FX This work is supported by the Ministry of Education, Science and
   Technological Development, Republic of Serbia under the call for
   COVID-19 investigation (No. 451-03-68/2020-14/200161).
CR Abedi F, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104808
   Beigelman A, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-90
   Bellisarii F L, 2001, Ital Heart J, V2, P408
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Boverhof DR, 2006, TOXICOL SCI, V89, P352, DOI 10.1093/toxsci/kfj018
   Casillo GM, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104791
   Chatre C, 2018, DRUG SAFETY, V41, P919, DOI 10.1007/s40264-018-0689-4
   Chen DQ, 2019, CARDIOVASC THER, V2019, DOI 10.1155/2019/8490707
   Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427
   Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-S4-S11
   Cline MS, 2007, NAT PROTOC, V2, P2366, DOI 10.1038/nprot.2007.324
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Davis AP, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-48
   Davis AP, 2019, NUCLEIC ACIDS RES, V47, pD948, DOI 10.1093/nar/gky868
   Davis KM, 2011, J CLIN INVEST, V121, P3666, DOI 10.1172/JCI57761
   Friis-Moller N, 2003, AIDS, V17, P1179, DOI 10.1097/00002030-200305230-00010
   Gaffen SL, 2008, CYTOKINE, V43, P402, DOI 10.1016/j.cyto.2008.07.017
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Hachim MY, 2020, J LEUKOCYTE BIOL, V108, P323, DOI 10.1002/JLB.3MIR0120-625R
   Harris SM, 2020, ENVIRON RES, V184, DOI 10.1016/j.envres.2020.109259
   Kanda T, 2004, JPN HEART J, V45, P183, DOI 10.1536/jhj.45.183
   Khyzha N, 2019, P NATL ACAD SCI USA, V116, P16410, DOI 10.1073/pnas.1904108116
   Kim KA, 2003, ARCH PHARM RES, V26, P631, DOI 10.1007/BF02976712
   Kumar H, 2011, INT REV IMMUNOL, V30, P16, DOI 10.3109/08830185.2010.529976
   Liang JS, 2001, NAT MED, V7, P1327, DOI 10.1038/nm1201-1327
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu YX, 2020, NATL SCI REV, V7, P1003, DOI 10.1093/nsr/nwaa037
   Maggi P, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2626-z
   Meng QY, 2013, ENVIRON HEALTH PERSP, V121, P558, DOI 10.1289/ehp.1205793
   Motawi T, 2012, MED SCI MONITOR, V18, pCR381, DOI 10.12659/MSM.882908
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Nguyen Dung V, 2012, Front Endocrinol (Lausanne), V3, P170, DOI 10.3389/fendo.2012.00170
   Philpott DJ, 2014, NAT REV IMMUNOL, V14, P9, DOI 10.1038/nri3565
   Ren JL, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104743
   Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113
   Saavedra JM, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104832
   Santoro MG, 2003, EMBO J, V22, P2552, DOI 10.1093/emboj/cdg267
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   Tufan A, 2020, TURK J MED SCI, V50, P620, DOI 10.3906/sag-2004-168
   Tung CW, 2020, ARCH TOXICOL, V94, P485, DOI 10.1007/s00204-019-02641-0
   van Breda SGJ, 2015, ARCH TOXICOL, V89, P1959, DOI 10.1007/s00204-014-1351-2
   Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383
   Wang J., 2019, BIOSCI REP, V39
   Wang XM, 2009, PAIN, V142, P275, DOI 10.1016/j.pain.2009.02.001
   Waters MD, 2004, NAT REV GENET, V5, P936, DOI 10.1038/nrg1493
   WHO, 2020, COR DIS 2019, V2019, P2633, DOI 10.1001/jama.2020.2633.
   World Health Organization, 2020, WAT SAN HYG WAST MAN, P1, DOI DOI 10.1056/NEJMOA2001191.7
   Wozniacka A, 2006, LUPUS, V15, P268, DOI 10.1191/0961203306lu2299oa
   Wu YC, 2020, J CHIN MED ASSOC, V83, P217, DOI 10.1097/JCMA.0000000000000270
   Wujtewicz MA, 2020, ANAESTH INTENSIVE TH, V52, P34, DOI 10.5114/ait.2020.93756
   Xie ST, 2010, J IMMUNOL, V184, P2289, DOI 10.4049/jimmunol.0903133
   Xu RX, 2020, 58TH ANNUAL MEETING OF THE ASSOCIATION FOR COMPUTATIONAL LINGUISTICS (ACL 2020): SYSTEM DEMONSTRATIONS, P1
   Yao X., 2020, CLIN INFECT DIS, V83, P217
   Ye XT, 2020, EUR REV MED PHARMACO, V24, P3390, DOI 10.26355/eurrev_202003_20706
NR 59
TC 0
Z9 0
U1 5
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0041-008X
EI 1096-0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD NOV 1
PY 2020
VL 406
AR 115237
DI 10.1016/j.taap.2020.115237
PG 15
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA OE4SM
UT WOS:000580522200013
PM 32920000
OA Green Published
DA 2021-01-01
ER

PT J
AU Kostev, K
   Lauterbach, S
AF Kostev, Karel
   Lauterbach, Silke
TI Panic buying or good adherence? Increased pharmacy purchases of drugs
   from wholesalers in the last week prior to Covid-19 lockdown
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Corona; Covid-19; Lockdown; Sell-in; Panic buying
AB Aims: The aim of this study was to examine the development of drug purchases during the corona crisis.
   Methods: The evaluations in this retrospective cross-sectional study are based on the IMS RPM (R) (Regional Pharmaceutical Market) Weekly database, which shows the weekly purchases of public pharmacies from fully-stocked wholesalers at the time the pharmacy purchase is made in Germany. The outcome of this investigation was the development in psychotropic, neurological, and cardiovascular drug purchases by packing unit between Calendar Weeks 6 and 16.
   Results: In analyses, performed for psychotropic and neurological drugs, compared to Week 11, the largest increases in Week 12 were for anti-Parkinson drugs and tranquilizers (both 24%), followed by antiepileptics (23%). Purchases of antidementive drugs increased by 16% between Week 11 and Week 12. The increase was 43% for vitamin k antagonists, 39% for ACE inhibitors, and 37% for betablockers.
   Conclusion: The results of this retrospective cross-sectional study suggest that the Covid-19 lockdown in Germany was associated with a significant surge in purchasing behavior in pharmacies for different markets including psychotropic, neurological, and cardiovascular drugs. Further studies are needed to investigate the sell-out data and to estimate the differences in panic buying by age and sex.
C1 [Kostev, Karel; Lauterbach, Silke] IQVIA, Epidemiol, Frankfurt, Germany.
   [Kostev, Karel; Lauterbach, Silke] Red Cross Hosp, Pharm, Kassel, Germany.
RP Kostev, K (corresponding author), IQVIA, Unterschweinstiege 2-14, D-60549 Frankfurt, Germany.
EM karel.kostev@iqvia.com
CR Aslani P, 2020, HEALTH EXPECT, V23, P257, DOI 10.1111/hex.13052
   Bacon AM, 2020, BRIT J HEALTH PSYCH, V25, P839, DOI 10.1111/bjhp.12423
   Jacob L, 2017, INT J CLIN PHARM TH, V55, P9, DOI 10.5414/CP202729
   Kjeldsen S, 2014, DRUGS, V74, P2033, DOI 10.1007/s40265-014-0306-5
   Lau H, 2020, J MICROBIOL IMMUNOL, V53, P467, DOI 10.1016/j.jmii.2020.03.026
   Leung C, 2020, MECH AGEING DEV, V188, DOI 10.1016/j.mad.2020.111255
   Liu S, 2020, INT J CLIN PHARM-NET, V42, P299, DOI 10.1007/s11096-020-01017-0
   Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018
   Qiu WQ, 2018, J ENVIRON PUBLIC HEA, V2018, DOI 10.1155/2018/2710185
   Sim K, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.113015
   Wang WE, 2020, J MED VIROL, V92, P441, DOI 10.1002/jmv.25689
   Zhang J, 2020, CLIN MICROBIOL INFEC, V26, P767, DOI 10.1016/j.cmi.2020.04.012
NR 12
TC 0
Z9 0
U1 6
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
EI 1879-1379
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD NOV
PY 2020
VL 130
BP 19
EP 21
DI 10.1016/j.jpsychires.2020.07.005
PG 3
WC Psychiatry
SC Psychiatry
GA OC5DT
UT WOS:000579177600003
PM 32768709
OA Green Published
DA 2021-01-01
ER

PT J
AU Ottaviani, S
   Franc, M
   Ebstein, E
   Demaria, L
   Lheure, C
   Debray, MP
   Khalil, A
   Crestani, B
   Borie, R
   Dieude, P
AF Ottaviani, S.
   Franc, M.
   Ebstein, E.
   Demaria, L.
   Lheure, C.
   Debray, M. P.
   Khalil, A.
   Crestani, B.
   Borie, R.
   Dieude, P.
TI Lung ultrasonography in patients with COVID-19: comparison with CT
SO CLINICAL RADIOLOGY
LA English
DT Article
ID ULTRASOUND
AB AIM: To determine whether findings from lung ultrasound and chest high-resolution computed tomography (HRCT) correlate when evaluating COVID-19 pulmonary involvement.
   MATERIALS AND METHODS: The present prospective single-centre study included consecutive symptomatic patients with reverse transcription polymerase chain reaction (RT-PCR)proven COVID-19 who were not in the intensive care unit. All patients were assessed using HRCT and ultrasound of the lungs by distinct operators blinded to each other's findings. The number of areas (0-12) with B-lines and/or consolidations was evaluated using ultrasound and compared to the percentage and classification (absent or limited, 10%; moderate, 10 25%; extensive, 25-50%; severe, 50-75%; critical, 75%) of lung involvement on chest HRCT.
   RESULTS: Data were analysed for 21 patients with COVID-19 (median [range] age 65 [37 90] years, 76% male) and excellent correlation was found between the ultrasound score for B-lines and the classification (p<0.01) and percentage of lung involvement on chest HRCT (r=0.935, p<0.001). In addition, the ultrasound score correlated positively with supplemental oxygen therapy (r=0.45, p=0.041) and negatively with minimal oxygen saturation at ambient air (r=-0.652, p<0.01).
   CONCLUSION: The present study suggests that among COVID-19 patients, lung ultrasound and HRCT findings agree in quantifying lung involvement and oxygen parameters. In the context of the COVID-19 pandemic, lung ultrasound could be a relevant alternative to chest HRCT. (c) 2020 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
C1 [Ottaviani, S.; Franc, M.; Ebstein, E.; Demaria, L.; Dieude, P.] Univ Paris, Hop Bichat, AP HP, Serv Rhumatol,Unite Covid 19, Paris, France.
   [Lheure, C.] Univ Paris, Hop Bichat, AP HP, Serv Dermatol,Unite Covid 19, Paris, France.
   [Debray, M. P.; Khalil, A.] Univ Paris, Hop Bichat, AP HP, Serv Radiol, Paris, France.
   [Crestani, B.; Borie, R.] Univ Paris, Hop Bichat, AP HP, Serv Pneumol A,Ctr Reference Malad Pulm Rares, Paris, France.
RP Ottaviani, S (corresponding author), Hop Bichat Claude Bernard, AP HP, Serv Rhumatol, 46 Rue Henri Huchard, F-75018 Paris, France.
EM sebastien.ottaviani@aphp.fr
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Alzahrani SA, 2017, CRIT ULTRASOUND J, V9, DOI 10.1186/s13089-017-0059-y
   Bandi V, 2008, CHEST, V133, P881, DOI 10.1378/chest.07-1656
   Bouhemad B, 2011, AM J RESP CRIT CARE, V183, P341, DOI 10.1164/rccm.201003-0369OC
   Buonsenso D, 2020, EUR REV MED PHARMACO, V24, P2776, DOI 10.26355/eurrev_202003_20549
   Chung M, 2020, RADIOLOGY, V295, P202, DOI 10.1148/radiol.2020200230
   Convissar DL, 2020, ANESTH ANALG, V131, P345, DOI 10.1213/ANE.0000000000004929
   Demi L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13078-9
   Demi L, 2014, MULTIDISCIP RESP MED, V9, DOI 10.1186/2049-6958-9-27
   Dietrich CF, 2016, J THORAC DIS, V8, DOI 10.21037/jtd.2016.04.55
   Fiala MJ, 2020, ANN EMERG MED, V75, P784, DOI 10.1016/j.annemergmed.2020.03.033
   Gargani L, 2014, CARDIOVASC ULTRASOUN, V12, DOI 10.1186/1476-7120-12-25
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Koo HJ, 2018, RADIOGRAPHICS, V38, P719, DOI 10.1148/rg.2018170048
   Lomoro Pascal, 2020, Eur J Radiol Open, V7, P100231, DOI 10.1016/j.ejro.2020.100231
   Lu WZ, 2020, ULTRASCHALL MED, V41, P300, DOI 10.1055/a-1154-8795
   Mayo PH, 2019, INTENS CARE MED, V45, P1200, DOI 10.1007/s00134-019-05725-8
   Mojoli F, 2019, AM J RESP CRIT CARE, V199, P701, DOI 10.1164/rccm.201802-0236CI
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Poggiali E, 2020, RADIOLOGY, V295, pE6, DOI 10.1148/radiol.2020200847
   Revel MP, 2020, EUR RADIOL, V30, P4903, DOI 10.1007/s00330-020-06865-y
   Smith MJ, 2020, ANAESTHESIA, V75, P1096, DOI 10.1111/anae.15082
   Sofia S, 2020, J ULTRASOUND, V23, P217, DOI 10.1007/s40477-020-00458-7
   Soldati G, 2020, J ULTRAS MED, V39, P1413, DOI 10.1002/jum.15285
   Thomas A, 2020, CMAJ
   Volpicelli G, 2006, AM J EMERG MED, V24, P689, DOI 10.1016/j.ajem.2006.02.013
   World Health Association, WHO COR DIS DASHB UP
   Xing CY, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02876-9
NR 28
TC 1
Z9 1
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0009-9260
EI 1365-229X
J9 CLIN RADIOL
JI Clin. Radiol.
PD NOV
PY 2020
VL 75
IS 11
DI 10.1016/j.crad.2020.07.024
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA OC1ED
UT WOS:000578904900016
PM 32854921
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Gallagher, S
   Wetherell, MA
AF Gallagher, Stephen
   Wetherell, Mark A.
TI Risk of depression in family caregivers: unintended consequence of
   COVID-19
SO BJPSYCH OPEN
LA English
DT Article
DE Caregivers; COVID-19; depression; isolation; loneliness
ID MENTAL-ILLNESS; VALIDITY; STRESS; LIFE
AB Background
   Coronavirus disease 2019 (COVID-19) is likely to exacerbate the symptoms of poor mental health in family caregivers.
   Aims
   To investigate whether rates of depressive symptomatology increased in caregivers during COVID-19 and whether the unintended consequences of health protective measures, i.e., social isolation, exacerbated this risk. Another aim was to see if caregivers accessed any online/phone psychological support during COVID.
   Method
   Data (1349 caregivers; 6178 non-caregivers) was extracted from Understanding Society, a UK population-level data-set. The General Health Questionnaire cut-off scores identified those who are likely to have depression.
   Results
   After adjustment for confounding caregivers had a higher risk of having depressive symptoms compared with non-caregivers, odds ratio (OR) = 1.22 (95% CI 1.05-1.40, P= 0.008) evidenced by higher levels of depression pre-COVID-19 (16.7% caregiversv.12.1% non-caregivers) and during the COVID-19 pandemic (21.6% caregiversv.17.9% non-caregivers), respectively. Further, higher levels of loneliness increased the risk of depression symptoms almost four-fold in caregivers, OR = 3.85 (95% 95% CI 3.08-4.85, P< 0.001), whereas accessing therapy attenuated the risk of depression (43%). A total of 60% of caregivers with depression symptoms reported not accessing any therapeutic support (for example online or face to face) during the COVID-19 pandemic.
   Conclusions
   COVID-19 has had a negative impact on family caregivers' mental health with loneliness a significant contributor to depressive symptomatology. However, despite these detriments in mental health, the majority of caregivers do not access any online or phone psychiatric support. Finally, psychiatric services and healthcare professionals should aim to focus on reducing feelings of loneliness to support at-risk caregivers.
C1 [Gallagher, Stephen] Univ Limerick, Ctr Social Issues Res, Dept Psychol, Study Anxiety Stress & Hlth Lab, Limerick, Ireland.
   [Gallagher, Stephen] Univ Limerick, Hlth Res Inst, Limerick, Ireland.
   [Wetherell, Mark A.] Northumbria Univ, Dept Psychol, Stress Res Grp, Newcastle, NSW, Australia.
RP Gallagher, S (corresponding author), Univ Limerick, Ctr Social Issues Res, Dept Psychol, Study Anxiety Stress & Hlth Lab, Limerick, Ireland.; Gallagher, S (corresponding author), Univ Limerick, Hlth Res Inst, Limerick, Ireland.
EM stephen.gallagher@ul.ie
OI Wetherell, Mark/0000-0002-1026-2798; , Stephen/0000-0002-5471-7774
CR [Anonymous], 2020, BMJ-BRIT MED J, V369, pm2170, DOI 10.1136/bmj.m2170
   CARERS UK, 2019, POL BRIEF FACTS CAR
   Gallagher S, 2008, BRAIN BEHAV IMMUN, V22, P565, DOI 10.1016/j.bbi.2007.11.007
   Gallagher S, 2010, J PEDIATR PSYCHOL, V35, P728, DOI 10.1093/jpepsy/jsp093
   Goldberg DP, 1997, PSYCHOL MED, V27, P191, DOI 10.1017/S0033291796004242
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Lovell B, 2011, NEUROSCI BIOBEHAV R, V35, P1342, DOI 10.1016/j.neubiorev.2011.02.007
   Lundin A, 2016, PUBLIC HEALTH, V136, P66, DOI 10.1016/j.puhe.2016.03.005
   Luykx JJ, 2020, JAMA PSYCHIAT, V77, P1097, DOI 10.1001/jamapsychiatry.2020.1225
   Mann F, 2017, SOC PSYCH PSYCH EPID, V52, P627, DOI 10.1007/s00127-017-1392-y
   McEwen BS, 1998, ANN NY ACAD SCI, V840, P33, DOI 10.1111/j.1749-6632.1998.tb09546.x
   O'Dwyer ST, 2014, MATURITAS, V77, P375, DOI 10.1016/j.maturitas.2014.01.013
   Pappa S, 2020, BRAIN BEHAV IMMUN, V88, P901, DOI 10.1016/j.bbi.2020.05.026
   Phillips Dominique, 2020, HRB Open Res, V3, P24, DOI 10.12688/hrbopenres.13059.1
   Reinhard SC, 2008, PATIENT SAFETY QUALI
   Smith L, 2014, BRIT J PSYCHIAT, V205, P197, DOI 10.1192/bjp.bp.112.125369
   Stansfeld S, 2014, SOC SCI MED, V120, P190, DOI 10.1016/j.socscimed.2014.09.025
   Szmukler GI, 1996, SOC PSYCH PSYCH EPID, V31, P137, DOI 10.1007/BF00785760
   Trail T, 2020, J MED INTERNET RES, V22, DOI 10.2196/16423
   University of Essex Institute for Social and Economic Research, 2020, UND SOC COVID 19 STU, DOI [10.5255/UKDA-SN-8644-3, DOI 10.5255/UKDA-SN-8644-3]
   University of Essex Institute for Social and Economic Research NatCen Social Research Kantar Public, 2019, UND SOC WAV 1 8 2009, DOI [10.5255/UKDA-SN-6614-13, DOI 10.5255/UKDA-SN-6614-13]
   World Health Organization, 2020, MENT HLHT PSYCH CONS
NR 22
TC 0
Z9 0
U1 6
U2 6
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 2056-4724
J9 BJPSYCH OPEN
JI BJPsych Open
PD NOV
PY 2020
VL 6
IS 6
AR e119
DI 10.1192/bjo.2020.99
PG 5
WC Psychiatry
SC Psychiatry
GA OB4GB
UT WOS:000578428500001
PM 33040759
OA DOAJ Gold, Green Published, Green Accepted
DA 2021-01-01
ER

PT J
AU Xie, YX
   Du, D
   Karki, CB
   Guo, WH
   Lopez-Hernandez, AE
   Sun, SJ
   Juarez, BY
   Li, HT
   Wang, J
   Li, L
AF Xie, Yixin
   Du, Dan
   Karki, Chitra B.
   Guo, Wenhan
   Lopez-Hernandez, Alan E.
   Sun, Shengjie
   Juarez, Brenda Y.
   Li, Haotian
   Wang, Jun
   Li, Lin
TI Revealing the Mechanism of SARS-CoV-2 Spike Protein Binding With ACE2
SO COMPUTING IN SCIENCE & ENGINEERING
LA English
DT Article
AB A large population in the world has been infected by COVID-19. Understanding the mechanisms of Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) is important for the management and treatment of COVID-19. When it comes to the infection process, one of the most important proteins in SARS-CoV-2 is the spike (S) protein, which is able to bind to human Angiotensin-Converting Enzyme 2 (ACE2) and initializes the entry of the host cell. In this study, we implemented multiscale computational approaches to study the electrostatic features of the interfaces of the SARS-CoV-2 S protein receptor binding domain and ACE2. The simulations and analyses were performed on high-performance computing resources in the Texas Advanced Computing Center. Our study identified key residues on SARS-CoV-2, which can be used as targets for future drug design. The results shed light on future drug design and therapeutic targets for COVID-19.
C1 [Xie, Yixin; Du, Dan] Univ Texas El Paso, Computat Sci, El Paso, TX 79968 USA.
   [Karki, Chitra B.; Guo, Wenhan; Lopez-Hernandez, Alan E.; Sun, Shengjie] Univ Texas El Paso, Computat Sci Dept, El Paso, TX 79968 USA.
   [Juarez, Brenda Y.] Univ Texas El Paso, Phys Premed Concentrat, El Paso, TX 79968 USA.
   [Li, Haotian; Wang, Jun] Univ Texas El Paso, El Paso, TX 79968 USA.
   [Li, Lin] Univ Texas El Paso, Phys Dept, El Paso, TX 79968 USA.
RP Xie, YX (corresponding author), Univ Texas El Paso, Computat Sci, El Paso, TX 79968 USA.
EM yxie4@miners.utep.edu; ddu2@miners.utep.edu; cbkarki@miners.utep.edu;
   wguo1@miners.utep.edu; aelopezhern@miners.utep.edu;
   ssun1@miners.utep.edu; byjuarez@miners.utep.edu; 767265653@qq.com;
   junwangwx@gmail.com; lli5@utep.edu
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [SC1GM132043-01];
   National Institutes on Minority Health and Health Disparities, a
   component of the NIH [5U54MD007592]
FX The calculations and analyses were performed at the Texas Advanced
   Computing Center. This work was supported in part by the National
   Institutes of Health under Grant SC1GM132043-01; in part by the National
   Institutes on Minority Health and Health Disparities, a component of the
   NIH under Grant 5U54MD007592.
CR Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   He JH, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040428
   Li C, 2012, J COMPUT CHEM, V33, P1960, DOI 10.1002/jcc.23033
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Li L, 2016, SCI REP-UK, V6, DOI 10.1038/srep31523
   Li L, 2016, SCI REP-UK, V6, DOI 10.1038/srep23249
   Li L, 2015, FRONT MOL BIOSCI, V2, DOI 10.3389/fmolb.2015.00005
   Li L, 2012, BMC BIOPHYS, V5, DOI 10.1186/2046-1682-5-9
   Organization W.H, 2020, COR DIS 2019 COVID 1
   SITKOFF D, 1994, J PHYS CHEM-US, V98, P1978, DOI 10.1021/j100058a043
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xian YJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081876
NR 12
TC 0
Z9 0
U1 15
U2 15
PU IEEE COMPUTER SOC
PI LOS ALAMITOS
PA 10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1314 USA
SN 1521-9615
EI 1558-366X
J9 COMPUT SCI ENG
JI Comput. Sci. Eng.
PD NOV
PY 2020
VL 22
IS 6
BP 21
EP 29
DI 10.1109/MCSE.2020.3015511
PG 9
WC Computer Science, Interdisciplinary Applications
SC Computer Science
GA OA6XN
UT WOS:000577925400004
OA Bronze
DA 2021-01-01
ER

PT J
AU Amara, RE
   Mulholland, AJ
AF Amara, Rommie E.
   Mulholland, Adrian J.
TI Biomolecular Simulations in the Time of COVID-19, and After
SO COMPUTING IN SCIENCE & ENGINEERING
LA English
DT Article
AB COVID-19 has changed life for people worldwide. Despite lockdowns globally, computational research has pressed on, working remotely and collaborating virtually on research questions in COVID-19 and the virus it is caused by, SARS-CoV-2. Molecular simulations can help to characterize the function of viral and host proteins and have the potential to contribute to the search for vaccines and treatments. Changes in the modus operandi of research groups include broader adoption of the use of preprint servers, earlier and more open sharing of methods, models, and data, the use of social media to rapidly disseminate information, online seminars, and cloud-based virtual collaboration. Research funders and computing providers worldwide recognized the need to provide rapid and significant access to computational architectures. In this article, we discuss how the interplay of all of these factors is influencing the impact-both potential and realized-of biomolecular simulations in the fight against SARS-CoV-2.
C1 [Amara, Rommie E.] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.
   [Mulholland, Adrian J.] Univ Bristol, Chem, Bristol, Avon, England.
RP Amara, RE (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.
EM ramaro@ucsd.edu; Adrian.Mulholland@bristol.ac.uk
FU Texas Advanced Computing Center; NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [GM132826]; NSF
   RAPIDNational Science Foundation (NSF) [MCB-2032054]; RCSA Research
   Corp; UC San Diego Moore's Cancer Center; EPSRCEngineering & Physical
   Sciences Research Council (EPSRC) [EP/M022609/1]; British Society for
   Antimicrobial Chemotherapy [BSAC-COVID-30]; Elizabeth Blackwell
   Institute for Health Research, University of Bristol
FX We thank Dr. Lorenzo Casalino (UC San Diego) and Becca Walters
   (University of Bristol) for creating Figure 1 and Figure 2,
   respectively. We also thank our research groups, as well as
   collaborators in the work described. We also thank especially Prof.
   Elisa Fadda (Maynooth University) and her research group, Prof. Michael
   Feig and Dr. Lim Heo (Michigan State University), Prof. SymaKhalid
   (University of Southampton), Prof. Carlos Simmerling and his research
   group (SUNY Stony Brook), Prof. Ben Neuman (Texas A&M University), Prof.
   Greg Voth and Dr. Viviana Monje-Galvan (University of Chicago), Prof.
   Julien Michel (University of Edinburgh) and his research group, Prof.
   Jean-Philip Piquemal (Sorbonne University), Prof. Alessio Lodola
   (University of Parma), Prof. Vicente Moliner and Dr. Katarzyna Swiderek
   (Universitat Jaume I), Prof. Garrett Morris and Prof. Fernanda Duarte
   (Oxford University), Prof. Paolo Carloni (Julich) and Dr. Reda Rawi (NIH
   Vaccine Research Center) for helpful discussions. Rommie E. Amaro thanks
   the Texas Advanced Computing Center for support and assistance with
   using Frontera. Adrian J. Mulholland thanks the Advanced Computing
   Research Centre, University of Bristol, the Isambard GW4 EPSRC Tier 2
   HPC Centre, HECBioSim/EPSRC and Oracle for Research for computer time
   and technical support. The work of Rommie E. Amaro was supported by NIH
   GM132826, NSF RAPID MCB-2032054, an award fromthe RCSA Research Corp,
   and a UC San Diego Moore's Cancer Center 2020 SARS-COV-2 seed Grant. The
   work of Adrian J. Mulholland was supported by EPSRC (CCP-BioSim, Grant
   number EP/M022609/1), the British Society for Antimicrobial Chemotherapy
   (Grant number BSAC-COVID-30) and the Elizabeth Blackwell Institute for
   Health Research, University of Bristol.
CR Amaro RE, 2020, J CHEM INF MODEL, V60, P2653, DOI 10.1021/acs.jcim.0c00319
   Arafet K., MECH INHIBITION SARS, DOI [10.26434/chemrxiv.12941819.v1, DOI 10.26434/CHEMRXIV.12941819.V1]
   Casalino L, 2020, ACS CENTRAL SCI, V6, P1722, DOI 10.1021/acscentsci.0c01056
   Chodera J, 2020, NAT CHEM, V12, P581, DOI 10.1038/s41557-020-0496-2
   Daly J. L., 2020, ARXIV20200605134114
   Deeks H. M., INTERACTIVE MOL DYNA, DOI [10.26434/chemrxiv.12834335.v2, DOI 10.26434/CHEMRXIV.12834335.V2]
   Oliveira A. S. F., 2020, ARXIV20200716206680
   Ramos-Guzman C. A., UNRAVELING SARS COV, DOI [10.26434/chemrxiv.12501734.v2, DOI 10.26434/CHEMRXIV.12501734.V2]
   Smith M., 2020, REPURPOSING THERAPEU, DOI [10.26434/chemrxiv.11871402.v3, DOI 10.26434/CHEMRXIV.11871402.V3]
   Turonova B, 2020, SCIENCE, V370, P203, DOI 10.1126/science.abd5223
   Zhao P, 2020, CELL HOST MICROBE, V28, P586, DOI 10.1016/j.chom.2020.08.004
   Zimmerman M. I., 2020, ARXIV20200627175430
NR 12
TC 1
Z9 1
U1 1
U2 1
PU IEEE COMPUTER SOC
PI LOS ALAMITOS
PA 10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1314 USA
SN 1521-9615
EI 1558-366X
J9 COMPUT SCI ENG
JI Comput. Sci. Eng.
PD NOV
PY 2020
VL 22
IS 6
BP 30
EP 36
DI 10.1109/MCSE.2020.3024155
PG 7
WC Computer Science, Interdisciplinary Applications
SC Computer Science
GA OA6XN
UT WOS:000577925400005
PM 33100917
DA 2021-01-01
ER

PT J
AU Ahammad, I
   Lira, SS
AF Ahammad, Ishtiaque
   Lira, Samia Sultana
TI Designing a novel mRNA vaccine against SARS-CoV-2: An immunoinformatics
   approach
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE SARS-CoV-2; mRNA vaccine; Immunoinformatics
ID EPITOPE PEPTIDE VACCINE; CORONAVIRUS SPIKE PROTEIN; T-CELL
   DIFFERENTIATION; B-CELL; IMMUNE-RESPONSES; SARS CORONAVIRUS; DENDRITIC
   CELLS; CODON USAGE; NUCLEOSIDE MODIFICATIONS; MOLECULAR-BASIS
AB SARS-CoV-2 is the deadly virus behind COVID-19, the disease that went on to ravage the world and caused the biggest pandemic 21st century has witnessed so far. On the face of ongoing death and destruction, the urgent need for the discovery of a vaccine against the virus is paramount. This study resorted to the emerging discipline of immunoinformatics in order to design a multi-epitope mRNA vaccine against the spike glycoprotein of SARS-CoV-2. Various immunoinformatics tools were utilized to predict T and B lymphocyte epitopes. The epitopes were channeled through a filtering pipeline comprised of antigenicity, toxicity, allergenicity, and cytokine inducibility evaluation with the goal of selecting epitopes capable of generating both T and B cell-mediated immune responses. Molecular docking simulation between the epitopes and their corresponding MHC molecules was carried out. 13 epitopes, a highly immunogenic adjuvant, elements for proper sub-cellular trafficking, a secretion booster, and appropriate linkers were combined for constructing the vaccine. The vaccine was found to be antigenic, almost neutral at physiological pH, non-toxic, non-allergenic, capable of generating a robust immune response and had a decent worldwide population coverage. Based on these parameters, this design can be considered a promising choice for a vaccine against SARS-CoV-2. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Ahammad, Ishtiaque] North South Univ, Dept Biochem & Microbiol, Dhaka 1229, Bangladesh.
   [Lira, Samia Sultana] Univ Dhaka, Dept Biochem & Mol Biol, Dhaka 1000, Bangladesh.
RP Ahammad, I (corresponding author), North South Univ, Dept Biochem & Microbiol, Dhaka 1229, Bangladesh.
EM ishtiaque.ahammad@northsouth.edu
RI Ahammad, Ishtiaque/J-9218-2018
OI Ahammad, Ishtiaque/0000-0003-0473-7803; Lira, Samia
   Sultana/0000-0002-2611-4220
CR Abdulla F, 2019, MICROB PATHOGENESIS, V137, DOI 10.1016/j.micpath.2019.103791
   ABSHER M, 1969, NATURE, V223, P715, DOI 10.1038/223715a0
   Ahammad I, 2020, INT J PEPT RES THER, V26, P1923, DOI 10.1007/s10989-019-09992-3
   Ahmad T. A., 2016, TRIALS VACCINOLOGY, V5, P71, DOI DOI 10.1016/J.TRIVAC.2016.04.003
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Alberer M, 2017, LANCET, V390, P1511, DOI 10.1016/S0140-6736(17)31665-3
   Alberts B., 2002, GARLAND SCI
   Ali Sumaia A., 2019, Advances in Bioinformatics, V2019, P1270485, DOI 10.1155/2019/1270485
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Amanna IJ, 2007, NEW ENGL J MED, V357, P1903, DOI 10.1056/NEJMoa066092
   Anderson BR, 2011, NUCLEIC ACIDS RES, V39, P9329, DOI 10.1093/nar/gkr586
   Anderson BR, 2010, NUCLEIC ACIDS RES, V38, P5884, DOI 10.1093/nar/gkq347
   Andries O, 2015, J CONTROL RELEASE, V217, P337, DOI 10.1016/j.jconrel.2015.08.051
   Arai R, 2001, PROTEIN ENG, V14, P529, DOI 10.1093/protein/14.8.529
   Arya S, 2020, MOL THER-NUCL ACIDS, V19, P1098, DOI 10.1016/j.omtn.2019.12.044
   Asquith B, 2007, P NATL ACAD SCI USA, V104, P6365, DOI 10.1073/pnas.0700666104
   Azim KF, 2019, INFECT GENET EVOL, V74, DOI 10.1016/j.meegid.2019.103936
   Bahl K, 2017, MOL THER, V25, P1316, DOI 10.1016/j.ymthe.2017.03.035
   Baruah V, 2020, J MED VIROL, V92, P495, DOI 10.1002/jmv.25698
   Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049
   Batista FD, 2001, NATURE, V411, P489, DOI 10.1038/35078099
   Beniac DR, 2006, NAT STRUCT MOL BIOL, V13, P751, DOI 10.1038/nsmb1123
   Benson DA, 2008, NUCLEIC ACIDS RES, V36, pD25, DOI 10.1093/nar/gkm929
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659
   Bin Sayed S, 2020, INT J PEPT RES THER, V26, P2089, DOI 10.1007/s10989-019-10003-8
   Bounds CE, 2017, HUM VACC IMMUNOTHER, V13, P2824, DOI 10.1080/21645515.2017.1329788
   Buhr F, 2016, MOL CELL, V61, P341, DOI 10.1016/j.molcel.2016.01.008
   Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153
   Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD464, DOI 10.1093/nar/gky1004
   Calis JJA, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003266
   Carralot Jean-Philippe, 2005, Genet Vaccines Ther, V3, P6, DOI 10.1186/1479-0556-3-6
   Castiglione F., 2012, COMPUT MATH METHOD M, V2012, P1, DOI DOI 10.1016/J.2556463
   CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263
   CERINO A, 1991, J IMMUNOL, V147, P2692
   Chen LJ, 2020, EMERG MICROBES INFEC, V9, P313, DOI 10.1080/22221751.2020.1725399
   Chen NH, 2017, IUBMB LIFE, V69, P297, DOI 10.1002/iub.1625
   Chen XY, 2013, ADV DRUG DELIVER REV, V65, P1357, DOI 10.1016/j.addr.2012.09.039
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chesler DA, 2002, CYTOKINE GROWTH F R, V13, P441, DOI 10.1016/S1359-6101(02)00044-8
   Chetverin AB, 2004, FEBS LETT, V567, P35, DOI 10.1016/j.febslet.2004.03.066
   Combadiere B, 2004, J EXP MED, V199, P1585, DOI 10.1084/jem.20032083
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978-1-4939-2269-7_19
   Dassault Systemes BIOVIA, 2015, DISCOVERY STUDIO MOD
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   deHaro C, 1996, FASEB J, V10, P1378
   DELMAS B, 1990, J VIROL, V64, P5367, DOI 10.1128/JVI.64.11.5367-5375.1990
   Dhanda SK, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/263952
   Dhanda SK, 2013, BIOL DIRECT, V8, P1
   Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5
   Dittmer U, 2001, J VIROL, V75, P654, DOI 10.1128/JVI.75.2.654-660.2001
   Do RKG, 2000, J EXP MED, V192, P953, DOI 10.1084/jem.192.7.953
   Dorner T, 2007, IMMUNITY, V27, P384, DOI 10.1016/j.immuni.2007.09.002
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Du LY, 2017, EXPERT OPIN THER TAR, V21, P131, DOI 10.1080/14728222.2017.1271415
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Du L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12326
   Duffy S, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.3000003
   Duret L, 2002, CURR OPIN GENET DEV, V12, P640, DOI 10.1016/S0959-437X(02)00353-2
   Eckerle LD, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000896
   El-Manzalawy Y, 2008, J MOL RECOGNIT, V21, P243, DOI 10.1002/jmr.893
   Elango N, 2005, BIOCHEM BIOPH RES CO, V330, P958, DOI 10.1016/j.bbrc.2005.03.067
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Fang DF, 2018, J EXP MED, V215, P2705, DOI 10.1084/jem.20180927
   Farhadi T, 2015, INT J PEPT RES THER, V21, P325, DOI 10.1007/s10989-015-9461-0
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   FIELD AK, 1967, P NATL ACAD SCI USA, V58, P1004, DOI 10.1073/pnas.58.3.1004
   Forthal DN, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.AID-0019-2014
   Fotin-Mleczek M, 2011, J IMMUNOTHER, V34, P1, DOI 10.1097/CJI.0b013e3181f7dbe8
   Fu Y, 2019, CRIT REV FOOD SCI, V59, P2011, DOI 10.1080/10408398.2018.1436038
   GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108
   Gandhi RT, 2016, JAIDS-J ACQ IMM DEF, V71, P246, DOI 10.1097/QAI.0000000000000852
   Geall AJ, 2012, P NATL ACAD SCI USA, V109, P14604, DOI 10.1073/pnas.1209367109
   Geissler M, 1997, J IMMUNOL, V158, P1231
   George Tijith Kuzhiyil, 2020, Proceedings of the Indian National Science Academy Part B Biological Sciences, V90, P381, DOI 10.1007/s40011-019-01110-z
   Gorbalenya A.E., 2020, NAT MICROBIOL
   Goulder PJR, 2004, NAT REV IMMUNOL, V4, P630, DOI 10.1038/nri1417
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Grudzien E, 2006, J BIOL CHEM, V281, P1857, DOI 10.1074/jbc.M509121200
   Grudzien-Nogalska E, 2007, RNA, V13, P1745, DOI 10.1261/rna.701307
   Gu Y, 2017, PROCEEDINGS OF 2017 INTERNATIONAL CONFERENCE ON PUBLIC ADMINISTRATION (12TH) & INTERNATIONAL SYMPOSIUM ON WEST AFRICAN STUDIES (1ST), VOL II, P80
   Guan W, 2020, CLIN CHARACTERISTICS
   Gustafsson C, 2004, TRENDS BIOTECHNOL, V22, P346, DOI 10.1016/j.tibtech.2004.04.006
   Hajighahramani N, 2017, INFECT GENET EVOL, V48, P83, DOI 10.1016/j.meegid.2016.12.010
   Hamaoka T, 1988, Princess Takamatsu Symp, V19, P265
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hasan M, 2020, J BIOMOL STRUCT DYN, V38, P2898, DOI 10.1080/07391102.2019.1647286
   He YX, 2006, J VIROL, V80, P5757, DOI 10.1128/JVI.00083-06
   Ho BK, 2003, PROTEIN SCI, V12, P2508, DOI 10.1110/ps.03235203
   HODGKIN PD, 1994, EUR J IMMUNOL, V24, P239, DOI 10.1002/eji.1830240138
   Hoffmann M., 2020, NOVEL CORONAVIRUS 20
   Holling TM, 2004, HUM IMMUNOL, V65, P282, DOI 10.1016/j.humimm.2004.01.005
   Hollingsworth JA, 2010, NANOCRYSTAL QUANTUM DOTS, SECOND EDITION, P1, DOI 10.1201/9781420079272-c1
   Holtkamp S, 2006, BLOOD, V108, P4009, DOI 10.1182/blood-2006-04-015024
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huber SR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00171
   ISAACS A, 1963, LANCET, V2, P113
   Iwasaki A, 1997, J IMMUNOL, V158, P4591
   Jaschke A, 2003, CHEM BIOL, V10, P1148, DOI 10.1016/j.chembiol.2003.12.003
   Kaech SM, 2001, NAT IMMUNOL, V2, P415
   Kaech SM, 2007, IMMUNITY, V27, P393, DOI 10.1016/j.immuni.2007.08.007
   Kalia V, 2006, CURR OPIN IMMUNOL, V18, P255, DOI 10.1016/j.coi.2006.03.020
   Kalita P, 2020, MICROB PATHOGENESIS, V145, DOI 10.1016/j.micpath.2020.104236
   Kanaya S, 2001, J MOL EVOL, V53, P290, DOI 10.1007/s002390010219
   Kareko BW, 2020, J INFECT DIS, V221, P2018, DOI 10.1093/infdis/jiz374
   Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008
   Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200
   Kariko K, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr695
   Khalili S, 2014, ACTA MICROBIOL IMM H, V61, P285, DOI 10.1556/AMicr.61.2014.3.4
   Khan MA, 2015, SCAND J IMMUNOL, V82, P25, DOI 10.1111/sji.12302
   Khan M I, 2019, SCI REP, V9, P1, DOI DOI 10.1038/s41598-018-37186-2
   Koehorst JJ, 2018, BIOINFORMATICS, V34, P1401, DOI 10.1093/bioinformatics/btx767
   Koprowski H., 1998, DNA VACCINATION GENE
   Kou YM, 2017, IMMUNOL LETT, V190, P51, DOI 10.1016/j.imlet.2017.07.007
   KOZAK M, 1991, GENE EXPRESSION, V1, P111
   KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134
   KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2
   Krautler NJ, 2017, J EXP MED, V214, P1259, DOI 10.1084/jem.20161533
   Kreiter S, 2008, J IMMUNOL, V180, P309, DOI 10.4049/jimmunol.180.1.309
   KRIEG PA, 1987, METHOD ENZYMOL, V155, P397
   Kudla G, 2006, PLOS BIOL, V4, P933, DOI 10.1371/journal.pbio.0040180
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424
   Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148
   Lata KS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25281-3
   Lechmann M, 1996, HEPATOLOGY, V24, P790
   LEHTINEN M, 1995, BIOCHEM BIOPH RES CO, V209, P541, DOI 10.1006/bbrc.1995.1535
   Leslie AJ, 2004, NAT MED, V10, P282, DOI 10.1038/nm992
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li BL, 2020, COMMUN MATH BIOL NEU, DOI 10.28919/cmbn/4262
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li Q., 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2001316, DOI 10.1056/NEJMOA2001316P]
   Li WD, 2014, VACCINES-BASEL, V2, P515, DOI 10.3390/vaccines2030515
   Liang SL, 2006, IUBMB LIFE, V58, P508, DOI 10.1080/15216540600838232
   Lin L, 2020, GUT, V69, P997, DOI 10.1136/gutjnl-2020-321013
   Liu QP, 2005, BIOSYSTEMS, V81, P281, DOI 10.1016/j.biosystems.2005.05.005
   Liu SW, 2004, LANCET, V363, P938, DOI 10.1016/S0140-6736(04)15788-7
   Livingston B, 2002, J IMMUNOL, V168, P5499, DOI 10.4049/jimmunol.168.11.5499
   Loudon PT, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011021
   Lu GW, 2013, NATURE, V500, P227, DOI 10.1038/nature12328
   Lu L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4067
   Luan JW, 2020, BIOCHEM BIOPH RES CO, V526, P165, DOI 10.1016/j.bbrc.2020.03.047
   Lucchese G, 2020, CELL MOL IMMUNOL, V17, P539, DOI 10.1038/s41423-020-0377-z
   Luckheeram RV, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/925135
   Madeira F, 2019, NUCLEIC ACIDS RES, V47, pW636, DOI 10.1093/nar/gkz268
   Magnan CN, 2010, BIOINFORMATICS, V26, P2936, DOI 10.1093/bioinformatics/btq551
   Maini MK, 2000, J EXP MED, V191, P1269, DOI 10.1084/jem.191.8.1269
   MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077
   Manavalan B., 2018, FRONT IMMUNOL, V9
   Maria Ribas-Aparicio Rosa, 2017, VACCINES
   MARTIN SA, 1975, J BIOL CHEM, V250, P9322
   McKee AS, 2017, CURR OPIN IMMUNOL, V47, P44, DOI 10.1016/j.coi.2017.06.005
   Michel-Todo L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02698
   MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783
   MITCHISON A, 1992, EUR J IMMUNOL, V22, P123, DOI 10.1002/eji.1830220119
   Mobbs JI, 2017, J BIOL CHEM, V292, P17203, DOI 10.1074/jbc.M117.806976
   Mockey M, 2006, BIOCHEM BIOPH RES CO, V340, P1062, DOI 10.1016/j.bbrc.2005.12.105
   Moise L, 2009, VACCINE, V27, P6471, DOI 10.1016/j.vaccine.2009.06.018
   Moutaftsi M, 2006, NAT BIOTECHNOL, V24, P817, DOI 10.1038/nbt1215
   MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441
   Nagpal G, 2017, SCI REP-UK, V7, DOI 10.1038/srep42851
   Nezafat N, 2016, COMPUT BIOL CHEM, V62, P82, DOI 10.1016/j.compbiolchem.2016.04.006
   NOELLE RJ, 1991, FASEB J, V5, P2770
   Nosrati M, 2019, MOL IMMUNOL, V116, P106, DOI 10.1016/j.molimm.2019.09.018
   O'Connor BP, 2002, J EXP MED, V195, P737, DOI 10.1084/jem.20011626
   Oferkin Igor V, 2015, Adv Bioinformatics, V2015, P126858, DOI 10.1155/2015/126858
   Ogando NS, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01813
   Ooi JD, 2017, NATURE, V545, P243, DOI 10.1038/nature22329
   Pandey RK, 2018, J CELL BIOCHEM, V119, P7631, DOI 10.1002/jcb.27110
   Pandey RK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19456-1
   Pardi N, 2017, NATURE, V543, P248, DOI 10.1038/nature21428
   Pardi N, 2015, J CONTROL RELEASE, V217, P345, DOI 10.1016/j.jconrel.2015.08.007
   Pascolo S., DNA VACCINES, P23
   Petsch B, 2012, NAT BIOTECHNOL, V30, P1210, DOI 10.1038/nbt.2436
   Pickett BE, 2012, NUCLEIC ACIDS RES, V40, pD593, DOI 10.1093/nar/gkr859
   Plotkin SA, 2009, CLIN VACCINE IMMUNOL, V16, P1709, DOI 10.1128/CVI.00290-09
   Probst J, 2007, GENE THER, V14, P1175, DOI 10.1038/sj.gt.3302964
   Pulendran B, 2006, CELL, V124, P849, DOI 10.1016/j.cell.2006.02.019
   Rahman A, 2018, 2018 2ND INTERNATIONAL CONFERENCE ON ENERGY CONSERVATION AND EFFICIENCY (ICECE), P6, DOI 10.1109/ECE.2018.8554977
   Rapin N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009862
   Richner JM, 2017, CELL, V168, P1114, DOI 10.1016/j.cell.2017.02.017
   Rigsby RE, 2016, BIOCHEM MOL BIOL EDU, V44, P433, DOI 10.1002/bmb.20966
   Robson B, 2020, COMPUT BIOL MED, V119, DOI 10.1016/j.compbiomed.2020.103670
   Rojas JM, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/6104054
   Routy JP, 2010, CLIN IMMUNOL, V134, P140, DOI 10.1016/j.clim.2009.09.009
   Sabbagh L, 2004, J IMMUNOL, V173, P5425, DOI 10.4049/jimmunol.173.9.5425
   Sanchez-Trincado JL, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/2680160
   Schafer JRA, 1998, VACCINE, V16, P1880, DOI 10.1016/S0264-410X(98)00173-X
   Scheel B, 2005, EUR J IMMUNOL, V35, P1557, DOI 10.1002/eji.200425656
   SCHENBORN ET, 1985, NUCLEIC ACIDS RES, V13, P6223, DOI 10.1093/nar/13.17.6223
   Schlake T, 2012, RNA BIOL, V9, P1319, DOI 10.4161/rna.22269
   Schmidt ST, 2016, PHARMACEUTICS, V8, DOI 10.3390/pharmaceutics8010007
   Schnee M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004746
   Shey RA, 2019, SCI REPORTS, V9, p1~18, DOI [10.1038/s41598-018-37186-2., DOI 10.1038/S41598-018-37186-2]
   Smith EC, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003565
   SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127
   Stepinski J, 2001, RNA, V7, P1486
   Suschak JJ, 2017, HUM VACC IMMUNOTHER, V13, P2837, DOI 10.1080/21645515.2017.1330236
   Tahir RA, 2018, J THEOR BIOL, V459, P162, DOI 10.1016/j.jtbi.2018.10.005
   Tam HH, 2016, P NATL ACAD SCI USA, V113, pE6639, DOI 10.1073/pnas.1606050113
   Tanji H, 2015, NAT STRUCT MOL BIOL, V22, P109, DOI 10.1038/nsmb.2943
   Tcherepanova IY, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-90
   Thess A, 2015, MOL THER, V23, P1456, DOI 10.1038/mt.2015.103
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Travers P., 2009, B CELL ACTIVATION AR
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tsui NBY, 2002, CLIN CHEM, V48, P1647
   Ul Qamar MT, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2116-8
   VENKATESAN S, 1980, J BIOL CHEM, V255, P903
   Vetter V, 2018, ANN MED, V50, P110, DOI 10.1080/07853890.2017.1407035
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-568
   Wang QH, 2016, ANTIVIR RES, V133, P165, DOI 10.1016/j.antiviral.2016.07.015
   Wang WE, 2020, J MED VIROL, V92, P441, DOI 10.1002/jmv.25689
   Wang ZR, 1999, MOL CELL BIOL, V19, P4552
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Wilkie GS, 2003, TRENDS BIOCHEM SCI, V28, P182, DOI 10.1016/S0968-0004(03)00051-3
   Wilkins M.R., 2019, 2 D PROTEOME ANAL PR, P531
   Woelfel R., 2020, CLIN PRESENTATION VI
   WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918
   Wong SH, 2020, J GASTROEN HEPATOL, V35, P744, DOI 10.1111/jgh.15047
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   XIANG ZQ, 1995, IMMUNITY, V2, P129, DOI 10.1016/S1074-7613(95)80001-8
   Yadav R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060785
   Yadav S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176403
   Yang HN, 2020, CLIN CARDIOL, V43, P450, DOI 10.1002/clc.23341
   Yu CH, 2015, MOL CELL, V59, P744, DOI 10.1016/j.molcel.2015.07.018
   Zahroh H, 2016, DRUG TARGET INSIGHT, V10, P19, DOI 10.4137/DTI.S38458
   Zhang ZK, 2016, IMMUNITY, V45, P737, DOI 10.1016/j.immuni.2016.09.011
   Zhao YB, 2010, CANCER RES, V70, P9053, DOI 10.1158/0008-5472.CAN-10-2880
   Zhou J., 2020, SARS COV 2 MAY PERSI
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Ziebuhr J, 2004, CURR OPIN MICROBIOL, V7, P412, DOI 10.1016/j.mib.2004.06.007
   Zohra FT, 2007, BIOCHEM BIOPH RES CO, V358, P373, DOI 10.1016/j.bbrc.2007.04.059
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 240
TC 0
Z9 0
U1 34
U2 34
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141-8130
EI 1879-0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD NOV 1
PY 2020
VL 162
BP 820
EP 837
DI 10.1016/j.ijbiomac.2020.06.213
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA OA7DW
UT WOS:000577941900008
PM 32599237
OA Green Published
DA 2021-01-01
ER

PT J
AU Evangelidis, N
   Tong, A
   Howell, M
   Teixeira-Pinto, A
   Elliott, JH
   Azevedo, LC
   Bersten, A
   Cervantes, L
   Chew, DP
   Crowe, S
   Douglas, IS
   Flemyng, E
   Horby, P
   Lee, J
   Lorca, E
   Lynch, D
   Marshall, JC
   McKenzie, A
   Mehta, S
   Mer, M
   Morris, AC
   Nseir, S
   Povoa, P
   Reid, M
   Sakr, Y
   Shen, N
   Smyth, AR
   Snelling, T
   Strippoli, GFM
   Torres, A
   Turner, T
   Webb, S
   Williamson, PR
   Woc-Colburn, L
   Zhang, JH
   Baumgart, A
   Cabrera, S
   Cho, YJ
   Cooper, T
   Guha, C
   Liu, E
   Gonzalez, AM
   McLeod, C
   Natale, P
   Saglimbene, V
   Viecelli, AK
   Craig, JC
AF Evangelidis, Nicole
   Tong, Allison
   Howell, Martin
   Teixeira-Pinto, Armando
   Elliott, Julian H.
   Azevedo, Luciano Cesar
   Bersten, Andrew
   Cervantes, Lilia
   Chew, Derek P.
   Crowe, Sally
   Douglas, Ivor S.
   Flemyng, Ella
   Horby, Peter
   Lee, Jaehee
   Lorca, Eduardo
   Lynch, Deena
   Marshall, John C.
   McKenzie, Anne
   Mehta, Sangeeta
   Mer, Mervyn
   Morris, Andrew Conway
   Nseir, Saad
   Povoa, Pedro
   Reid, Mark
   Sakr, Yasser
   Shen, Ning
   Smyth, Alan R.
   Snelling, Tom
   Strippoli, Giovanni F. M.
   Torres, Antoni
   Turner, Tari
   Webb, Steve
   Williamson, Paula R.
   Woc-Colburn, Laila
   Zhang, Junhua
   Baumgart, Amanda
   Cabrera, Sebastian
   Cho, Yeoungjee
   Cooper, Tess
   Guha, Chandana
   Liu, Emma
   Gonzalez, Andrea Matus
   McLeod, Charlie
   Natale, Patrizia
   Saglimbene, Valeria
   Viecelli, Andrea K.
   Craig, Jonathan C.
CA COVID-19-Core Outcomes Set Survey
TI International Survey to Establish Prioritized Outcomes for Trials in
   People With Coronavirus Disease 2019
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE clinical trial; coronavirus; critical care; infection; patients; sepsis
AB Objectives: There are over 4,000 trials conducted in people with coronavirus disease 2019. However, the variability of outcomes and the omission of patient-centered outcomes may diminish the impact of these trials on decision-making. The aim of this study was to generate a consensus-based, prioritized list of outcomes for coronavirus disease 2019 trials. Design: In an online survey conducted in English, Chinese, Italian, Portuguese, and Spanish languages, adults with coronavirus disease 2019, their family members, health professionals, and the general public rated the importance of outcomes using a 9-point Likert scale (7-9, critical importance) and completed a Best-Worst Scale to estimate relative importance. Participant comments were analyzed thematically. Setting: International. Subjects: Adults 18 years old and over with confirmed or suspected coronavirus disease 2019, their family members, members of the general public, and health professionals (including clinicians, policy makers, regulators, funders, and researchers). Interventions: None. Measurements: None. Main Results: In total, 9,289 participants from 111 countries (776 people with coronavirus disease 2019 or family members, 4,882 health professionals, and 3,631 members of the public) completed the survey. The four outcomes of highest priority for all three groups were: mortality, respiratory failure, pneumonia, and organ failure. Lung function, lung scarring, sepsis, shortness of breath, and oxygen level in the blood were common to the top 10 outcomes across all three groups (mean > 7.5, median >= 8, and > 70% of respondents rated the outcome as critically important). Patients/family members rated fatigue, anxiety, chest pain, muscle pain, gastrointestinal problems, and cardiovascular disease higher than health professionals. Four themes underpinned prioritization: fear of life-threatening, debilitating, and permanent consequences; addressing knowledge gaps; enabling preparedness and planning; and tolerable or infrequent outcomes. Conclusions: Life-threatening respiratory and other organ outcomes were consistently highly prioritized by all stakeholder groups. Patients/family members gave higher priority to many patient-reported outcomes compared with health professionals.
C1 [Evangelidis, Nicole; Tong, Allison; Howell, Martin; Teixeira-Pinto, Armando; Snelling, Tom; Strippoli, Giovanni F. M.; Baumgart, Amanda; Cabrera, Sebastian; Cooper, Tess; Guha, Chandana; Liu, Emma; Gonzalez, Andrea Matus; Natale, Patrizia; Saglimbene, Valeria] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, Australia.
   [Evangelidis, Nicole; Tong, Allison; Howell, Martin; Teixeira-Pinto, Armando; Baumgart, Amanda; Cabrera, Sebastian; Cooper, Tess; Guha, Chandana; Liu, Emma; Gonzalez, Andrea Matus] Childrens Hosp Westmead, Ctr Kidney Res, Westmead, NSW, Australia.
   [Elliott, Julian H.; Turner, Tari; Webb, Steve] Monash Univ, Cochrane Australia, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia.
   [Azevedo, Luciano Cesar] Hosp Sirio Libanes, Dept Crit Care Med, Sao Paulo, Brazil.
   [Bersten, Andrew; Chew, Derek P.; Craig, Jonathan C.] Flinders Univ S Australia, Coll Med & Publ Hlth, Adelaide, SA, Australia.
   [Cervantes, Lilia; Reid, Mark] Denver Hlth, Dept Med, Denver, CO USA.
   [Crowe, Sally] Crowe Associates Ltd, Thame, Oxon, England.
   [Douglas, Ivor S.] Denver Hlth, Pulm Sci & Crit Care, Dept Med, Denver, CO USA.
   [Douglas, Ivor S.] Univ Colorado Anschutz, Sch Med, Denver, CO USA.
   [Flemyng, Ella] Cochrane, Editorial & Methods Dept, London, England.
   [Horby, Peter] Univ Oxford, Nuffield Dept Med, Oxford, England.
   [Lee, Jaehee] Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea.
   [Lorca, Eduardo] Univ Chile, Dept Internal Med, Fac Med, Santiago, Chile.
   [Lynch, Deena] Jonze Soc, Brisbane, Qld, Australia.
   [Marshall, John C.] Univ Toronto, Dept Surg, Toronto, ON, Canada.
   [McKenzie, Anne] Telethon Kids Inst, Perth, WA, Australia.
   [Mehta, Sangeeta] Univ Toronto, Dept Med, Toronto, ON, Canada.
   [Mehta, Sangeeta] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada.
   [Mer, Mervyn] Univ Witwatersrand, Div Crit Care & Pulmonol, Dept Med, Charlotte Maxeke Johannesburg Acad Hosp, Johannesburg, South Africa.
   [Mer, Mervyn] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa.
   [Morris, Andrew Conway] Univ Cambridge, Dept Med, Cambridge, England.
   [Nseir, Saad] CHU Lille, Crit Care Ctr, F-59000 Lille, France.
   [Nseir, Saad] Lille Univ, F-59000 Lille, France.
   [Povoa, Pedro] Univ Nova Lisboa, Sao Francisco Xavier Hosp, Nova Med Sch, CHRC,Polyvalent Intens Care Unit,CHLO, Lisbon, Portugal.
   [Povoa, Pedro] OUH Odense Univ Hosp, Ctr Clin Epidemiol, Odense, Denmark.
   [Povoa, Pedro] OUH Odense Univ Hosp, Res Unit Clin Epidemiol, Odense, Denmark.
   [Sakr, Yasser] Jena Univ Hosp, Dept Anesthesiol & Intens Care, Jena, Germany.
   [Shen, Ning] Peking Univ Third Hosp, Dept Resp Med, Beijing, Peoples R China.
   [Smyth, Alan R.] Univ Nottingham, Evidence Based Child Hlth Grp, Nottingham, England.
   [Strippoli, Giovanni F. M.; Natale, Patrizia; Saglimbene, Valeria] Univ Bari, Dept Emergency & Organ Transplantat, Bari, Italy.
   [Torres, Antoni] Univ Barcelona, Hosp Clin, Dept Pulmonol, CIBERES,IDIBAPS,ICREA, Barcelona, Spain.
   [Williamson, Paula R.] Univ Liverpool, Dept Biostat, Liverpool, Merseyside, England.
   [Woc-Colburn, Laila] Baylor Coll Med, Dept Med, Natl Sch Trop Med, Sect Infect Dis, Houston, TX 77030 USA.
   [Zhang, Junhua] Tianjin Univ Tradit Chinese Med, Evidence Based Med Ctr, Tianjin, Peoples R China.
   [Cho, Yeoungjee; Viecelli, Andrea K.] Univ Queensland, Fac Med, Brisbane, Qld, Australia.
   [McLeod, Charlie] Perth Childrens Hosp, Dept Infect Dis, Perth, WA, Australia.
RP Tong, A (corresponding author), Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, Australia.; Tong, A (corresponding author), Childrens Hosp Westmead, Ctr Kidney Res, Westmead, NSW, Australia.
EM Allison.tong@sydney.edu.au
OI Snelling, Thomas/0000-0003-4670-0638; Sautenet,
   Benedicte/0000-0001-8430-4543; Flemyng, Ella/0000-0002-9845-9076;
   McLeod, Charlie/0000-0002-3197-7493; Smyth, Alan/0000-0001-5494-5438
FU Flinders University; National Coronavirus Disease 2019 Clinical Evidence
   Taskforce; Australian GovernmentAustralian GovernmentCGIAR; Victorian
   Department of Health and Human Services; Ian Potter Foundation; Walter
   Cottman Endowment Fund; Lord Mayor's Charitable Foundation
FX The project is funded by the Flinders University and the National
   Coronavirus Disease 2019 Clinical Evidence Taskforce, convened by the
   Australian Living Evidence Consortium, hosted by Cochrane Australia,
   School of Public Health and Preventive Medicine, Monash University
   supported by the Australian Government, Victorian Department of Health
   and Human Services, Ian Potter Foundation, Walter Cottman Endowment Fund
   (managed by Equity Trustees), and the Lord Mayor's Charitable
   Foundation).
CR [Anonymous], 2020, LANCET INFECT DIS, V20, P511
   Auld SC, 2020, CRIT CARE MED, V48, pE799, DOI 10.1097/CCM.0000000000004457
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   BRADLEY RA, 1952, BIOMETRIKA, V39, P324, DOI 10.2307/2334029
   Calvert M, 2018, JAMA-J AM MED ASSOC, V319, P483, DOI 10.1001/jama.2017.21903
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   COMET: The COMET Initiative, 2020, COMET COMET INITIATI
   Cortegiani A, 2020, J CRIT CARE, V59, P176, DOI 10.1016/j.jcrc.2020.06.019
   Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020
   Flynn TN, 2007, J HEALTH ECON, V26, P171, DOI 10.1016/j.jhealeco.2006.04.002
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Jin X, 2020, ENGINEERING BEIJING
   Kirkham JJ, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002148
   Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI [10.1016/j.jaci.2020.04.006, 10.1002/jmv.25731]
   Liu Y, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102106
   Qiu RJ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00781
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Sarma P, 2020, J MED VIROL, V92, P776, DOI 10.1002/jmv.25898
   Schunemann H, 2020, GRADE HDB GRADING QU
   Tian SJ, 2020, J INFECTION, V80, P401, DOI 10.1016/j.jinf.2020.02.018
   WHO, 2020, INT CLIN TRIALS REG
   WILLIAMSON PR, 2017, TRIALS S3, V18, DOI DOI 10.1186/S13063-017-1978-4
   World Health Organisation (WHO), 2020, COR DIS COV 19 PAND
   Yang ZW, 2020, J INFECTION, V81, pE13, DOI 10.1016/j.jinf.2020.03.062
   Zhang K, 2020, BRIT J PSYCHIAT, V217, P351, DOI 10.1192/bjp.2020.84
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 28
TC 0
Z9 0
U1 4
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD NOV
PY 2020
VL 48
IS 11
BP 1612
EP 1621
DI 10.1097/CCM.0000000000004584
PG 10
WC Critical Care Medicine
SC General & Internal Medicine
GA NZ2OL
UT WOS:000576935300035
PM 32804789
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Tong, A
   Elliott, JH
   Azevedo, LC
   Baumgart, A
   Bersten, A
   Cervantes, L
   Chew, DP
   Cho, YJ
   Cooper, T
   Crowe, S
   Douglas, IS
   Evangelidis, N
   Flemyng, E
   Hannan, E
   Horby, P
   Howell, M
   Lee, JH
   Liu, E
   Lorca, E
   Lynch, D
   Marshall, JC
   Gonzalez, AM
   McKenzie, A
   Manera, KE
   McLeod, C
   Mehta, S
   Mer, M
   Morris, AC
   Nseir, S
   Povoa, P
   Reid, M
   Sakr, Y
   Shen, N
   Smyth, AR
   Snelling, T
   Strippoli, GFM
   Teixeira-Pinto, A
   Torres, A
   Turner, T
   Viecelli, AK
   Webb, S
   Williamson, PR
   Woc-Colburn, L
   Zhang, JH
   Craig, JC
AF Tong, Allison
   Elliott, Julian H.
   Azevedo, Luciano Cesar
   Baumgart, Amanda
   Bersten, Andrew
   Cervantes, Lilia
   Chew, Derek P.
   Cho, Yeoungjee
   Cooper, Tess
   Crowe, Sally
   Douglas, Ivor S.
   Evangelidis, Nicole
   Flemyng, Ella
   Hannan, Elyssa
   Horby, Peter
   Howell, Martin
   Lee, Jaehee
   Liu, Emma
   Lorca, Eduardo
   Lynch, Deena
   Marshall, John C.
   Gonzalez, Andrea Matus
   McKenzie, Anne
   Manera, Karine E.
   McLeod, Charlie
   Mehta, Sangeeta
   Mer, Mervyn
   Morris, Andrew Conway
   Nseir, Saad
   Povoa, Pedro
   Reid, Mark
   Sakr, Yasser
   Shen, Ning
   Smyth, Alan R.
   Snelling, Tom
   Strippoli, Giovanni F. M.
   Teixeira-Pinto, Armando
   Torres, Antoni
   Turner, Tari
   Viecelli, Andrea K.
   Webb, Steve
   Williamson, Paula R.
   Woc-Colburn, Laila
   Zhang, Junhua
   Craig, Jonathan C.
CA COVID-19-Core Outcomes Set Worksho
TI Core Outcomes Set for Trials in People With Coronavirus Disease 2019
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE clinical trial; coronavirus; critical care; infection; patients; sepsis
ID SOCIETY
AB Objectives: The outcomes reported in trials in coronavirus disease 2019 are extremely heterogeneous and of uncertain patient relevance, limiting their applicability for clinical decision-making. The aim of this workshop was to establish a core outcomes set for trials in people with suspected or confirmed coronavirus disease 2019. Design: Four international online multistakeholder consensus workshops were convened to discuss proposed core outcomes for trials in people with suspected or confirmed coronavirus disease 2019, informed by a survey involving 9,289 respondents from 111 countries. The transcripts were analyzed thematically. The workshop recommendations were used to finalize the core outcomes set. Setting: International. Subjects: Adults 18 years old and over with confirmed or suspected coronavirus disease 2019, their family members, members of the general public and health professionals (including clinicians, policy makers, regulators, funders, researchers). Interventions: None. Measurements: None. Main Results: Six themes were identified. "Responding to the critical and acute health crisis" reflected the immediate focus on saving lives and preventing life-threatening complications that underpinned the high prioritization of mortality, respiratory failure, and multiple organ failure. "Capturing different settings of care" highlighted the need to minimize the burden on hospitals and to acknowledge outcomes in community settings. "Encompassing the full trajectory and severity of disease" was addressing longer term impacts and the full spectrum of illness (e.g. shortness of breath and recovery). "Distinguishing overlap, correlation and collinearity" meant recognizing that symptoms such as shortness of breath had distinct value and minimizing overlap (e.g. lung function and pneumonia were on the continuum toward respiratory failure). "Recognizing adverse events" refers to the potential harms of new and evolving interventions. "Being cognizant of family and psychosocial wellbeing" reflected the pervasive impacts of coronavirus disease 2019. Conclusions: Mortality, respiratory failure, multiple organ failure, shortness of breath, and recovery are critically important outcomes to be consistently reported in coronavirus disease 2019 trials.
C1 [Tong, Allison; Baumgart, Amanda; Cooper, Tess; Evangelidis, Nicole; Hannan, Elyssa; Howell, Martin; Liu, Emma; Gonzalez, Andrea Matus; Manera, Karine E.; Snelling, Tom; Strippoli, Giovanni F. M.; Teixeira-Pinto, Armando] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, Australia.
   [Tong, Allison; Baumgart, Amanda; Cooper, Tess; Evangelidis, Nicole; Hannan, Elyssa; Howell, Martin; Liu, Emma; Gonzalez, Andrea Matus; Manera, Karine E.; Teixeira-Pinto, Armando] Childrens Hosp Westmead, Ctr Kidney Res, Sydney, NSW, Australia.
   [Elliott, Julian H.; Turner, Tari; Webb, Steve] Monash Univ, Cochrane Australia, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia.
   [Azevedo, Luciano Cesar] Hosp Sirio Libanes, Dept Crit Care Med, Sao Paulo, Brazil.
   [Bersten, Andrew; Chew, Derek P.; Craig, Jonathan C.] Flinders Univ S Australia, Coll Med & Publ Hlth, Adelaide, SA, Australia.
   [Cervantes, Lilia; Reid, Mark] Denver Hlth, Dept Med, Denver, CO USA.
   [Cho, Yeoungjee; Viecelli, Andrea K.] Univ Queensland, Princess Alexandra Hosp, Fac Med, Brisbane, Qld, Australia.
   [Crowe, Sally] Crowe Associates Ltd, Thame, Oxon, England.
   [Douglas, Ivor S.] Denver Hlth, Dept Med Pulm Sci & Crit Care, Aurora, CO USA.
   [Douglas, Ivor S.] Univ Colorado Anschutz, Sch Med Denver, Aurora, CO USA.
   [Flemyng, Ella] Cochrane, Dept Editorial & Methods, London, England.
   [Horby, Peter] Univ Oxford, Nuffield Dept Med, Oxford, England.
   [Lee, Jaehee] Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea.
   [Lorca, Eduardo] Univ Chile, Dept Internal Med, Fac Med, Santiago, Chile.
   [Lynch, Deena] Jonze Soc, Brisbane, Qld, Australia.
   [Marshall, John C.] Univ Toronto, Dept Surg, Toronto, ON, Canada.
   [McKenzie, Anne] Telethon Kids Inst, Perth, WA, Australia.
   [McLeod, Charlie] Perth Childrens Hosp, Dept Infect Dis, Perth, WA, Australia.
   [Mehta, Sangeeta] Univ Toronto, Dept Med, Toronto, ON, Canada.
   [Mehta, Sangeeta] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada.
   [Mer, Mervyn] Univ Witwatersrand, Dept Med, Div Crit Care & Pulmonol, Charlotte Maxeke Johannesburg Acad Hosp, Johannesburg, South Africa.
   [Mer, Mervyn] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa.
   [Morris, Andrew Conway] Univ Cambridge, Dept Med, Cambridge, England.
   [Nseir, Saad] CHU Lille, Crit Care Ctr, F-59000 Lille, France.
   [Nseir, Saad] Lille Univ, F-59000 Lille, France.
   [Povoa, Pedro] Univ Nova Lisboa, Nova Med Sch, Sao Francisco Xavier Hosp, CHLO,CHRC,Polyvalent Intens Care Unit, Lisbon, Portugal.
   [Povoa, Pedro] OUH Odense Univ Hosp, Ctr Clin Epidemiol, Odense, Denmark.
   [Povoa, Pedro] OUH Odense Univ Hosp, Res Unit Clin Epidemiol, Odense, Denmark.
   [Sakr, Yasser] Jena Univ Hosp, Dept Anesthesiol & Intens Care, Jena, Germany.
   [Shen, Ning] Peking Univ Third Hosp, Dept Resp Med, Beijing, Peoples R China.
   [Smyth, Alan R.] Univ Nottingham, Evidence Based Child Hlth Grp, Nottingham, England.
   [Strippoli, Giovanni F. M.] Univ Bari, Dept Emergency & Organ Transplantat, Bari, Italy.
   [Torres, Antoni] Univ Barcelona, Hosp Clin, Dept Pulmonol, CIBERES,IDIBAPS, Barcelona, Spain.
   [Williamson, Paula R.] Univ Liverpool, Dept Biostat, Liverpool, Merseyside, England.
   [Woc-Colburn, Laila] Baylor Coll Med, Sect Infect Dis Dept Med, Natl Sch Trop Med, Houston, TX 77030 USA.
   [Zhang, Junhua] Tianjin Univ Tradit Chinese Med, Evidence Based Med Ctr, Tianjin, Peoples R China.
RP Tong, A (corresponding author), Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, Australia.; Tong, A (corresponding author), Childrens Hosp Westmead, Ctr Kidney Res, Sydney, NSW, Australia.
EM Allison.tong@sydney.edu.au
RI Azevedo, Luciano CP/H-2652-2012; Craig, Jonathan/AAR-1768-2020; Manera,
   Karine/ABH-9074-2020; Piva, Simone/E-1902-2014
OI Azevedo, Luciano CP/0000-0001-6759-3910; Craig,
   Jonathan/0000-0002-2548-4035; Manera, Karine/0000-0002-0552-6074;
   McLeod, Charlie/0000-0002-3197-7493; Chew, Derek/0000-0003-3593-296X;
   Smyth, Alan/0000-0001-5494-5438; Bersten, Andrew/0000-0001-9908-394X;
   Piva, Simone/0000-0002-5483-8007; Flemyng, Ella/0000-0002-9845-9076;
   Sautenet, Benedicte/0000-0001-8430-4543
FU Flinders University; National Coronavirus Disease 2019 Clinical Evidence
   Taskforce; Australian GovernmentAustralian GovernmentCGIAR; Victorian
   Department of Health and Human Services; Ian Potter Foundation; Walter
   Cottman Endowment Fund; Lord Mayor's Charitable Foundation
FX Supported, in part, by the Flinders University and the National
   Coronavirus Disease 2019 Clinical Evidence Taskforce, convened by the
   Australian Living Evidence Consortium, hosted by Cochrane Australia,
   School of Public Health and Preventive Medicine, Monash University
   supported by the Australian Government, Victorian Department of Health
   and Human Services, Ian Potter Foundation, Walter Cottman Endowment Fund
   (managed by Equity Trustees), and the Lord Mayor's Charitable
   Foundation.
CR [Anonymous], 2020, LANCET INFECT DIS, V20, P511
   Benameur K, 2020, EMERG INFECT DIS, V26, P2016, DOI 10.3201/eid2609.202122
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Braun V., 2019, HDB RES METHODS HLTH, P833, DOI [DOI 10.1007/978-981-10-5251-4_103, 10.1007/978-981-10-5251-4_103]
   Chalmers I, 2014, LANCET, V383, P156, DOI 10.1016/S0140-6736(13)62229-1
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen RC, 2020, CHEST, V158, P97, DOI 10.1016/j.chest.2020.04.010
   COMET: The COMET Initiative, 2020, COR OUTC SET DEV RES
   COVID-19-COS, 2020, COVID 19 COS COVID 1
   Gandhi GY, 2008, JAMA-J AM MED ASSOC, V299, P2543, DOI 10.1001/jama.299.21.2543
   Garcia-Castrillo L, 2020, EUR J EMERG MED, V27, P174, DOI 10.1097/MEJ.0000000000000701
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Jin X, 2020, ENGINEERING
   Lee CCM, 2020, ANAESTHESIA, V75, P861, DOI 10.1111/anae.15074
   Maves RC, 2020, CHEST, V158, P212, DOI 10.1016/j.chest.2020.03.063
   Parshall MB, 2012, AM J RESP CRIT CARE, V185, P435, DOI 10.1164/rccm.201111-2042ST
   Qiu RJ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00781
   Ramachandran P, 2020, CHEST, VS0012-3692, P31398
   Sanders JM, JAMA, V323, P1824
   Souto-Miranda S, 2019, CLIN REHABIL, V33, P805, DOI 10.1177/0269215518821405
   Tong A, 2020, BMJ OPINION
   Tong A, 2017, NEPHROL DIAL TRANSPL, V32, P1963, DOI 10.1093/ndt/gfx288
   Turnbull AE, 2017, CRIT CARE MED, V45, P1001, DOI 10.1097/CCM.0000000000002435
   WHO, 2020, INT CLIN TRIALS REG
   WILLIAMSON PR, 2017, TRIALS S3, V18, DOI DOI 10.1186/S13063-017-1978-4
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 26
TC 0
Z9 0
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD NOV
PY 2020
VL 48
IS 11
BP 1622
EP 1635
DI 10.1097/CCM.0000000000004585
PG 14
WC Critical Care Medicine
SC General & Internal Medicine
GA NZ2OL
UT WOS:000576935300036
PM 32804792
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Xia, JE
   Zhang, Y
   Ni, L
   Chen, L
   Zhou, CZ
   Gao, C
   Wu, XJ
   Duan, J
   Xie, JG
   Guo, Q
   Zhao, JP
   Hu, Y
   Cheng, ZS
   Zhan, QY
AF Xia, Jingen
   Zhang, Yi
   Ni, Lan
   Chen, Lei
   Zhou, Changzhi
   Gao, Chang
   Wu, Xiaojing
   Duan, Jun
   Xie, Jungang
   Guo, Qiang
   Zhao, Jianping
   Hu, Yi
   Cheng, Zhenshun
   Zhan, Qingyuan
TI High-Flow Nasal Oxygen in Coronavirus Disease 2019 Patients With Acute
   Hypoxemic Respiratory Failure: A Multicenter, Retrospective Cohort
   Study*
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE acute hypoxemic respiratory failure; acute respiratory distress
   syndrome; coronavirus disease 2019; high-flow nasal oxygen
ID CANNULA; THERAPY; INTUBATION; PNEUMONIA; ADULTS
AB Objectives: An ongoing outbreak of coronavirus disease 2019 is spreading globally. Acute hypoxemic respiratory failure is the most common complication of coronavirus disease 2019. However, the clinical effectiveness of early high-flow nasal oxygen treatment in patients with coronavirus disease 2019 with acute hypoxemic respiratory failure has not been explored. This study aimed to analyze the effectiveness of high-flow nasal oxygen treatment and to identify the variables predicting high-flow nasal oxygen treatment failure in coronavirus disease 2019 patients with acute hypoxemic respiratory failure. Design: A multicenter, retrospective cohort study. Setting: Three tertiary hospitals in Wuhan, China. Patients: Forty-three confirmed coronavirus disease 2019 adult patients with acute hypoxemic respiratory failure treated with high-flow nasal oxygen. Interventions: None. Measurements and Main Results: Mean age of the enrolled patients was 63.0 +/- 9.7 years; female patients accounted for 41.9%. High-flow nasal oxygen failure (defined as upgrading respiratory support to positive pressure ventilation or death) was observed in 20 patients (46.5%), of which 13 (30.2%) required endotracheal intubation. Patients with high-flow nasal oxygen success had a higher median oxygen saturation (96.0% vs 93.0%;p< 0.001) at admission than those with high-flow nasal oxygen failure. High-flow nasal oxygen failure was more likely in patients who were older (p= 0.030) and male (p= 0.037), had a significant increase in respiratory rate and a significant decrease in the ratio of oxygen saturation/Fio(2)to respiratory rate index within 3 days of high-flow nasal oxygen treatment. In a multivariate logistic regression analysis model, male and lower oxygen saturation at admission remained independent predictors of high-flow nasal oxygen failure. The hospital mortality rate of the cohort was 32.5%; however, the hospital mortality rate in patients with high-flow nasal oxygen failure was 65%. Conclusions: High-flow nasal oxygen may be effective for treating coronavirus disease 2019 patients with mild to moderate acute hypoxemic respiratory failure. However, high-flow nasal oxygen failure was associated with a poor prognosis. Male and lower oxygenation at admission were the two strong predictors of high-flow nasal oxygen failure.
C1 [Xia, Jingen; Zhang, Yi; Wu, Xiaojing; Zhan, Qingyuan] Chinese Acad Med Sci, Dept Pulm & Crit Care Med, Natl Clin Res Ctr Resp Dis, Inst Resp Med,China Japan Friendship Hosp, Beijing, Peoples R China.
   [Xia, Jingen] Beihang Univ, Sch Biol Sci & Med Engn, Beijing, Peoples R China.
   [Ni, Lan; Cheng, Zhenshun] Wuhan Univ, Zhongnan Hosp, Dept Pulm & Crit Care Med, Wuhan, Hubei, Peoples R China.
   [Chen, Lei; Xie, Jungang; Zhao, Jianping] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Pulm & Crit Care Med, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
   [Zhou, Changzhi; Hu, Yi] Cent Hosp Wuhan, Dept Pulm & Crit Care Med, Wuhan, Hubei, Peoples R China.
   [Gao, Chang; Guo, Qiang] Soochow Univ, Affiliated Hosp 1, Dept Crit Care Med, Suzhou, Jiangsu, Peoples R China.
   [Duan, Jun] China Japan Friendship Hosp, Dept Surg Intens Care Unit, Beijing, Peoples R China.
RP Zhan, QY (corresponding author), Chinese Acad Med Sci, Dept Pulm & Crit Care Med, Natl Clin Res Ctr Resp Dis, Inst Resp Med,China Japan Friendship Hosp, Beijing, Peoples R China.; Cheng, ZS (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Pulm & Crit Care Med, Wuhan, Hubei, Peoples R China.; Zhao, JP (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Dept Pulm & Crit Care Med, Tongji Med Coll, Wuhan, Hubei, Peoples R China.; Guo, Q; Hu, Y (corresponding author), Cent Hosp Wuhan, Dept Pulm & Crit Care Med, Wuhan, Hubei, Peoples R China.; Guo, Q (corresponding author), Soochow Univ, Affiliated Hosp 1, Dept Crit Care Med, Suzhou, Jiangsu, Peoples R China.
EM guojiang@suda.edu.cn; zhaojp88@126.com; huyi@zxhospital.com;
   chzs1990@163.com; drzhanqy@163.com
FU Zhejiang University special scientific research fund for coronavirus
   disease 2019 prevention and control [2020XGZX008]; National Key Research
   and Development Program of China [2016YFC1304300]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [81870072]; Chinese Academy of Medical Sciences (CAMS) Innovation
   Fund for Medical Sciences [2018-I2M-1-003]; Nonprofit Central Research
   Institute Fund of CAMS [2019TX320006]
FX This study was supported by Zhejiang University special scientific
   research fund for coronavirus disease 2019 prevention and control
   (number 2020XGZX008); National Key Research and Development Program of
   China (number 2016YFC1304300); National Natural Science Foundation of
   China (number 81870072); Chinese Academy of Medical Sciences (CAMS)
   Innovation Fund for Medical Sciences (number 2018-I2M-1-003); and
   Nonprofit Central Research Institute Fund of CAMS (number 2019TX320006).
CR [Anonymous], 2020, GLOB HLTH 50 50 MEN
   Cai H, 2020, LANCET RESP MED, V8, pE20, DOI 10.1016/S2213-2600(20)30117-X
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Coudroy R, 2016, ANN INTENSIVE CARE, V6, DOI 10.1186/s13613-016-0151-7
   Frat JP, 2018, CRIT CARE MED, V46, P208, DOI 10.1097/CCM.0000000000002818
   Frat JP, 2016, LANCET RESP MED, V4, P646, DOI 10.1016/S2213-2600(16)30093-5
   Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.02339-2018
   Ischaki E, 2017, EUR RESPIR REV, V26, DOI 10.1183/16000617.0028-2017
   Kang BJ, 2015, INTENS CARE MED, V41, P623, DOI 10.1007/s00134-015-3693-5
   Leung CCH, 2019, J HOSP INFECT, V101, P84, DOI 10.1016/j.jhin.2018.10.007
   Messika J, 2015, RESP CARE, V60, P162, DOI 10.4187/respcare.03423
   Mo Pingzheng, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa270
   Namendys-Silva SA, 2020, LANCET RESP MED, V8, pE18, DOI 10.1016/S2213-2600(20)30110-7
   Ni YN, 2017, CHEST, V151, P764, DOI 10.1016/j.chest.2017.01.004
   Papazian L, 2016, INTENS CARE MED, V42, P1336, DOI 10.1007/s00134-016-4277-8
   Peeri NC, 2020, INT J EPIDEMIOL, V49, P717, DOI 10.1093/ije/dyaa033
   Rello J, 2012, J CRIT CARE, V27, P434, DOI 10.1016/j.jcrc.2012.04.006
   Roca O, 2019, AM J RESP CRIT CARE, V199, P1368, DOI 10.1164/rccm.201803-0589OC
   Roca O, 2016, J CRIT CARE, V35, P200, DOI 10.1016/j.jcrc.2016.05.022
   Rochwerg B, 2019, INTENS CARE MED, V45, P563, DOI 10.1007/s00134-019-05590-5
   Scully EP, 2020, NAT REV IMMUNOL, V20, P442, DOI 10.1038/s41577-020-0348-8
   Spoletini G, 2015, CHEST, V148, P253, DOI 10.1378/chest.14-2871
   Sztrymf B, 2011, INTENS CARE MED, V37, P1780, DOI 10.1007/s00134-011-2354-6
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, CLIN MAN SERV AC RES
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
   Xie JF, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.5619
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zu ZY, 2020, RADIOLOGY, V296, pE15, DOI 10.1148/radiol.2020200490
NR 34
TC 1
Z9 1
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD NOV
PY 2020
VL 48
IS 11
BP E1079
EP E1086
DI 10.1097/CCM.0000000000004558
PG 8
WC Critical Care Medicine
SC General & Internal Medicine
GA NZ2OL
UT WOS:000576935300011
PM 32826432
OA Green Published
DA 2021-01-01
ER

PT J
AU Somadi, G
   Sivan, SK
AF Somadi, Gururaj
   Sivan, Sree Kanth
TI Identification of therapeutic target in S2 domain of SARS nCov-2 Spike
   glycoprotein: Key to design and discover drug candidates for inhibition
   of viral entry into host cell
SO JOURNAL OF THEORETICAL & COMPUTATIONAL CHEMISTRY
LA English
DT Article
DE Severe acute respiratory syndrome novel coronavirus-2; spike
   glycoprotein; S2 domain; heptad repeat 1 region; central helical region;
   Troxerutin and Thymopentin
ID RESPIRATORY-DISTRESS-SYNDROME; MOLECULAR DOCKING; ACCURATE DOCKING;
   CORONAVIRUS; PROTEIN; PHARMACOKINETICS; DACLATASVIR; THYMOPENTIN;
   SARS-COV-2; RITONAVIR
AB Humanity is facing a grieve danger of coronavirus disease-19 caused by severe acute respiratory syndrome novel coronavirus-2 (SARS nCov-2). There is an urgent need of therapeutics that can help in overcoming this global pandemic. Identifying novel therapeutic target and screening already approved drug is a faster approach in this situation. Spike glycoprotein (Sgp) of SARS nCoV-2 is potentials target where in researchers have targeted receptor binding domain (RBD) of S1 domain. The S2 domain of Sgp also plays a pivotal role in viral entry, but the mechanism is less understood. We analyzed the structure of Sgp S2 domain in pre-fusion state and Heptad repeat region in its post-fusion state available from protein data bank. Sgp shows three major regions in S2 domain, the fusion peptide (FP), heptad repeat 1 (HR1) and central helical (CH) region. The HR1 region undergoes structural changes by flipping approximately 180 degrees and coil up to form a rod like structure during fusion process implying its role in viral entry into the host cell. This structural change in S2 domain helices is crucial step, if this process is hindered by targeting the HR1 and CH region then the progression of virus can be stopped. Possible binding cavity was identified near the HR1 and CH region in S2 domain and docking-based virtual screening of FDA approved drugs was performed. Promising candidates like Troxerutin, Thymopentin and Daclatasvir can be used as therapeutics provided an immediate in-vitro and clinical studies are carried out by research groups.
C1 [Somadi, Gururaj; Sivan, Sree Kanth] Osmania Univ, Dept Chem, Nizam Coll, Hyderabad 500001, India.
RP Sivan, SK (corresponding author), Osmania Univ, Dept Chem, Nizam Coll, Hyderabad 500001, India.
EM grsomadi@gmail.com; sivan.sreekanth@gmail.com
FU Department of Chemistry, Nizam College
FX The authors thank the administration of Nizam College, the Osmania
   University and Department of Chemistry, Nizam College for their support.
CR Afhami S, PROSPECTIVE RANDOMIZ
   [Anonymous], 2020, WHO CORONAVIRUS DIS
   Belema M, 2014, J MED CHEM, V57, P5057, DOI 10.1021/jm500335h
   Bussel JB, 2014, BLOOD, V123, P3887, DOI 10.1182/blood-2013-07-514398
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cheng Feixiong, 2019, Methods Mol Biol, V1878, P243, DOI 10.1007/978-1-4939-8868-6_15
   Cheng FX, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05116-5
   Cheng FX, 2016, TRENDS MOL MED, V22, P919, DOI 10.1016/j.molmed.2016.09.006
   Cheng FX, 2017, BRIEF BIOINFORM, V18, P682, DOI 10.1093/bib/bbw051
   Cheng Z, 2016, MOL SYST BIOL, V12, DOI 10.15252/msb.20156423
   CLUMECK N, 1984, INT J CLIN PHARM RES, V4, P459
   DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303
   ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Halgren TA, 2009, J CHEM INF MODEL, V49, P377, DOI 10.1021/ci800324m
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613
   Martinez-Zapata MJ, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003229.pub3
   Ke YY, 2020, BIOMED J, V43, P355, DOI 10.1016/j.bj.2020.05.001
   Kim SH, 2014, HAEMATOLOGICA, V99, P1191, DOI 10.3324/haematol.2013.096776
   Kortuem KM, 2013, BLOOD, V121, P893, DOI 10.1182/blood-2012-10-459883
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Lu J, 2011, BRAIN, V134, P783, DOI 10.1093/brain/awq376
   Lyne PD, 2006, J MED CHEM, V49, P4805, DOI 10.1021/jm060522a
   MASCARTLEMONE F, 1983, LANCET, V2, P735
   Mathias AA, 2010, CLIN PHARMACOL THER, V87, P322, DOI 10.1038/clpt.2009.228
   Munnaluri R, 2015, MED CHEM RES, V24, P829, DOI 10.1007/s00044-014-1185-8
   Peddi SR, 2018, STRUCT CHEM, V29, P1753, DOI 10.1007/s11224-018-1154-9
   Peng Q, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-3218-x
   Peterson LE, SILICO MOL DYNAMICS, DOI [10.13140/RG.2.2.17657.83045, DOI 10.13140/RG.2.2.17657.83045]
   Riccioni C, 2004, Minerva Cardioangiol, V52, P43
   RUBIN BK, 1992, CHEST, V101, P1080, DOI 10.1378/chest.101.4.1080
   Rusnak DW, 2001, MOL CANCER THER, V1, P85
   Santos R, 2017, NAT REV DRUG DISCOV, V16, P19, DOI 10.1038/nrd.2016.230
   Schiller DS, 2007, CLIN THER, V29, P1862, DOI 10.1016/j.clinthera.2007.09.015
   Schrodinger LLC New York, 2010, PROT PREP
   SEHGAL SS, 1994, J NATL MED ASSOC, V86, P46
   Stefanie H, 2015, DIAGNOSTIC AGENTS DR, P527, DOI [10.1016/B978-0-12-408078-2.00021-4, DOI 10.1016/B978-0-12-408078-2.00021-4]
   Sulkowski MS, 2014, NEW ENGL J MED, V370, P211, DOI 10.1056/NEJMoa1306218
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Vangala R, 2020, J COMPUT AID MOL DES, V34, P39, DOI 10.1007/s10822-019-00258-0
   Wald A, 2016, JAMA-J AM MED ASSOC, V315, P185, DOI 10.1001/jama.2015.16994
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   Wang QH, 2014, CELL HOST MICROBE, V16, P328, DOI 10.1016/j.chom.2014.08.009
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xia S, 2020, CELL MOL IMMUNOL, V17, P765, DOI 10.1038/s41423-020-0374-2
   Zeldin RK, 2004, J ANTIMICROB CHEMOTH, V53, P4, DOI 10.1093/jac/dkh029
   Zhang YJ, 2004, ACTA PHARMACOL SIN, V25, P1341
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhu MX, 2015, EXP CELL RES, V331, P387, DOI 10.1016/j.yexcr.2014.12.012
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 55
TC 0
Z9 0
U1 13
U2 13
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0219-6336
EI 1793-6888
J9 J THEOR COMPUT CHEM
JI J. Theor. Comput. Chem.
PD NOV
PY 2020
VL 19
IS 7
AR 2050028
DI 10.1142/S0219633620500285
PG 15
WC Chemistry, Multidisciplinary
SC Chemistry
GA NY8ZW
UT WOS:000576674400008
DA 2021-01-01
ER

PT J
AU Tenforde, AS
   Borgstrom, H
   Polich, G
   Steere, H
   Davis, IS
   Cotton, K
   O'Donnell, M
   Silver, JK
AF Tenforde, Adam S.
   Borgstrom, Haylee
   Polich, Ginger
   Steere, Hannah
   Davis, Irene S.
   Cotton, Kester
   O'Donnell, Mary
   Silver, Julie K.
TI Outpatient Physical, Occupational, and Speech Therapy Synchronous
   Telemedicine A Survey Study of Patient Satisfaction with Virtual Visits
   During the COVID-19 Pandemic
SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION
LA English
DT Article
DE Rehabilitation; Physical Therapy; Occupational Therapy; Speech Therapy;
   Telemedicine; Telehealth; Pandemics
ID TELEHEALTH; LANGUAGE; REHABILITATION; TELEPRACTICE; PERSPECTIVES
AB The COVID-19 pandemic transformed health care delivery, including rapid expansion of telehealth. Telerehabilitation, defined as therapy provided by physical therapy, occupational therapy, and speech and language pathology, was rapidly adopted with goals to provide access to care and limit contagion. The purpose of this brief report was to describe the feasibility of and satisfaction with telerehabilitation. A total of 205 participants completed online surveys after a telerehabilitation visit. Most commonly, participants were women (53.7%), 35-64 yrs old, and completed physical therapy (53.7%) for established visits of 30-44 mins in duration for primary impairments in sports, lower limb injuries, and pediatric neurology. Overall, high ratings ("excellent" or "very good" responses) were observed for all patient-centered outcome metrics (range, 93.7%-99%) and value in future telehealth visit (86.8%) across telerehabilitation visits. Women participated more frequently and provided higher ratings than male participants did. Other benefits included eliminating travel time, incorporating other health care advocates, and convenience delivering care in familiar environment to pediatric patients. Technology and elements of hands-on aspects of care were observed limitations. Recognizing reduced indirect costs of care that telerehabilitation may provide along with high patient satisfaction are reasons policy makers should adopt these services into future health care delivery models.
C1 [Tenforde, Adam S.; Borgstrom, Haylee; Polich, Ginger; Steere, Hannah; Davis, Irene S.; Silver, Julie K.] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA USA.
   [Tenforde, Adam S.; Borgstrom, Haylee; Polich, Ginger; Steere, Hannah; Davis, Irene S.; Silver, Julie K.] Spaulding Rehabil Hosp, Boston, MA USA.
   [Polich, Ginger; Silver, Julie K.] Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Cotton, Kester] Spaulding Outpatient Ctr Wellesley, Wellesley, MA USA.
   [O'Donnell, Mary] Spaulding Outpatient Ctr Children Lexington, Lexington, MA USA.
   [Silver, Julie K.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Silver, JK (corresponding author), 300 1st Ave, Charlestown, MA 02025 USA.
RI Silver, Julie K/AAE-7163-2019
CR [Anonymous], COVID 19 DAIL DASHB
   Azma K, 2018, J TELEMED TELECARE, V24, P560, DOI 10.1177/1357633X17723368
   Bush ML, 2016, OTOL NEUROTOL, V37, P1466, DOI 10.1097/MAO.0000000000001236
   Cason J, 2014, INT J TELEREHABILITA, V6, P29, DOI 10.5195/ijt.2014.6148
   Cason J, 2009, INT J TELEREHABILITA, V1, P29
   Clawson Betsy, 2008, Pediatr Nurs, V34, P213
   Craig L, 2010, J MARRIAGE FAM, V72, P1344, DOI 10.1111/j.1741-3737.2010.00769.x
   Cramer SC, 2019, JAMA NEUROL, V76, P1079, DOI 10.1001/jamaneurol.2019.1604
   Crutchley S, 2010, INT J TELEREHABILITA, V2, P23, DOI 10.5195/ijt.2010.6049
   Donaghy E, 2019, BRIT J GEN PRACT, V69, pE586, DOI 10.3399/bjgp19X704141
   Eckberg S, 2013, J OCC THER SCH EARLY, V6, P326, DOI 10.1080/19411243.2013.860765
   Hammersley V, 2019, BRIT J GEN PRACT, V69, pE595, DOI 10.3399/bjgp19X704573
   Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Howard IM, 2018, MUSCLE NERVE, V58, P475, DOI 10.1002/mus.26115
   Kloek CJJ, 2020, TELEMED E-HEALTH, V26, P1051, DOI 10.1089/tmj.2019.0143
   Knepley KD, 2020, TELEMED E-HEALTH, DOI 10.1089/tmj.2020.0019
   Koppenaal T, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891-020-3174-z
   Little LM, 2018, AM J OCCUP THER, V72, DOI 10.5014/ajot.2018.024786
   Lovo S, 2019, J MULTIDISCIP HEALTH, V12, P855, DOI 10.2147/JMDH.S208888
   Mani S, 2017, J TELEMED TELECARE, V23, P379, DOI 10.1177/1357633X16642369
   Molini-Avejonas DR, 2015, J TELEMED TELECARE, V21, P367, DOI 10.1177/1357633X15583215
   Nelson M, 2020, PHYSIOTHERAPY, V107, P19, DOI 10.1016/j.physio.2019.06.006
   Ogrinc Greg, 2016, BMJ Qual Saf, V25, P986, DOI 10.1136/bmjqs-2015-004411
   Polinski JM, 2016, J GEN INTERN MED, V31, P269, DOI 10.1007/s11606-015-3489-x
   Tanaka MJ, 2020, J BONE JOINT SURG AM, V102, DOI 10.2106/JBJS.20.00609
   Tenforde AS, 2020, PM&R, V12, P926, DOI 10.1002/pmrj.12422
   Tenforde AS, 2017, PM&R, V9, pS51, DOI 10.1016/j.pmrj.2017.02.013
   Thiyagarajan A, 2020, BJGP OPEN, V4
   Tucker JK, 2012, INT J TELEREHABILITA, V4, P61, DOI 10.5195/ijt.2012.6100
   Uscher-Pines L, 2014, HEALTH AFFAIR, V33, P258, DOI 10.1377/hlthaff.2013.0989
   Verduzco-Gutierrez M, 2020, PM&R, V12, P714, DOI 10.1002/pmrj.12380
   Wallisch A, 2019, INT J TELEREHABILITA, V11, P15, DOI 10.5195/ijt.2019.6274
   Ward EC, 2017, CURR OPIN OTOLARYNGO, V25, P169, DOI 10.1097/MOO.0000000000000357
NR 34
TC 1
Z9 1
U1 11
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0894-9115
EI 1537-7385
J9 AM J PHYS MED REHAB
JI Am. J. Phys. Med. Rehabil.
PD NOV
PY 2020
VL 99
IS 11
BP 977
EP 981
DI 10.1097/PHM.0000000000001571
PG 5
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA NX9HP
UT WOS:000576013100006
PM 32804713
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Lankarani, KB
AF Lankarani, Kamran B.
TI Dangerous interactions of gastrointestinal drugs with experimental
   treatments for COVID-19
SO EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Letter
C1 [Lankarani, Kamran B.] Shiraz Univ Med Sci, Inst Hlth, Ctr Hlth Policy Res, Shiraz, Iran.
RP Lankarani, KB (corresponding author), Shiraz Sch Med, Inst Hlth, Ctr Hlth Policy Res, Zand Blvd, Shiraz 7134845794, Iran.
EM lankaran@sums.ac.ir
CR Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Liverpool drug interactions group, INT EXP COVID 19 THE
NR 2
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0954-691X
EI 1473-5687
J9 EUR J GASTROEN HEPAT
JI Eur. J. Gastroenterol. Hepatol.
PD NOV
PY 2020
VL 32
IS 11
BP 1481
EP 1481
DI 10.1097/MEG.0000000000001778
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA NX3OG
UT WOS:000575621000014
PM 32453009
OA Bronze
DA 2021-01-01
ER

PT J
AU Filippi, AR
   Russi, E
   Magrini, SM
   Corvo, R
AF Filippi, Andrea Riccardo
   Russi, Elvio
   Magrini, Stefano Maria
   Corvo, Renzo
TI Letter from Italy: First practical indications for radiation therapy
   departments during COVID-19 outbreak
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Letter
C1 [Filippi, Andrea Riccardo] Fdn IRCCS Policlin San Matteo, Dept Radiat Oncol, Pavia, Italy.
   [Filippi, Andrea Riccardo] Univ Pavia, Pavia, Italy.
   [Russi, Elvio] S Croce & Carle Teaching Hosp, Dept Radiat Oncol, Cuneo, Italy.
   [Magrini, Stefano Maria] ASST Spedali Civili, Dept Radiat Oncol, Brescia, Italy.
   [Magrini, Stefano Maria] Brescia Univ, Brescia, Italy.
   [Corvo, Renzo] IRCCS Osped Policlin San Martino, Dept Radiat Oncol, Genoa, Italy.
   [Corvo, Renzo] Univ Genoa, Dept Hlth Sci, Genoa, Italy.
RP Filippi, AR (corresponding author), Fdn IRCCS Policlin San Matteo, Dept Radiat Oncol, Pavia, Italy.; Filippi, AR (corresponding author), Univ Pavia, Pavia, Italy.
EM a.filippi@smatteo.pv.it
RI Magrini, Stefano Maria/ABE-8820-2020
OI Magrini, Stefano Maria/0000-0002-4126-733X; Filippi, Andrea
   Riccardo/0000-0001-7159-7869
CR [Anonymous], 2020, RATIONAL USE PERONAL
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Spina S, 2020, LANCET, V395, pE49, DOI 10.1016/S0140-6736(20)30493-1
   The Royal College of Radiologists, TIM DEL RAD RAD GUID
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 5
TC 45
Z9 46
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD NOV 1
PY 2020
VL 107
IS 3
BP 597
EP 599
DI 10.1016/j.ijrobp.2020.03.007
PG 3
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA NX1MK
UT WOS:000575481000030
PM 32199941
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ma, QH
   Li, RF
   Pan, WQ
   Huang, WB
   Liu, B
   Xie, YQ
   Wang, ZL
   Li, CF
   Jiang, HM
   Huang, JC
   Shi, YX
   Dai, J
   Zheng, K
   Li, XB
   Hui, M
   Fu, L
   Yang, ZF
AF Ma, Qinhai
   Li, Runfeng
   Pan, Weiqi
   Huang, Wenbo
   Liu, Bin
   Xie, Yuqi
   Wang, Zhoulang
   Li, Chufang
   Jiang, Haiming
   Huang, Jicheng
   Shi, Yongxia
   Dai, Jun
   Zheng, Kui
   Li, Xiaobo
   Hui, Min
   Fu, Li
   Yang, Zifeng
TI Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities
   against novel coronavirus (SARS-CoV-2) and human coronavirus 229E
   (HCoV-229E) by suppressing the nuclear factor kappa B (NF-kappa B)
   signaling pathway
SO PHYTOMEDICINE
LA English
DT Article
DE Phillyrin (KD-1); SARS-CoV-2; Antiviral; Anti-inflammatory; NF-kappa B
ID RESPIRATORY SYNDROME CORONAVIRUS; INFLAMMATION; LIGNANS; MAPK
AB Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has extensively and rapidly spread in the world, causing an outbreak of acute infectious pneumonia. However, no specific antiviral drugs or vaccines can be used. Phillyrin (KD-1), a representative ingredient of Forsythia suspensa, possesses anti-inflammatory, anti-oxidant, and antiviral activities. However, little is known about the antiviral abilities and mechanism of KD-1 against SARS-CoV-2 and human coronavirus 229E (HCoV-229E).
   Purpose: The study was designed to investigate the antiviral and anti-inflammatory activities of KD-1 against the novel SARS-CoV-2 and HCoV-229E and its potential effect in regulating host immune response in vitro.
   Methods: The antiviral activities of KD-1 against SARS-CoV-2 and HCoV-229E were assessed in Vero E6 cells using cytopathic effect and plaque-reduction assay. Proinflammatory cytokine expression levels upon infection with SARS-CoV-2 and HCoV-229E infection in Huh-7 cells were measured by real-time quantitative PCR assays. Western blot assay was used to determine the protein expression of nuclear factor kappa B (NF-kappa B) p65, p-NF-kappa B p65, I kappa B alpha, and p-I kappa B alpha in Huh-7 cells, which are the key targets of the NF-kappa B pathway.
   Results: KD-1 could significantly inhibit SARS-CoV-2 and HCoV-229E replication in vitro. KD-1 could also markedly reduce the production of proinflammatory cytokines (TNF-alpha, IL-6, IL-1 MCP-1, and IP-10) at the mRNA levels. Moreover, KD-1 could significantly reduce the protein expression of p-NF-KB p65, NF-KB p65, and p-I kappa B alpha, while increasing the expression of I kappa B alpha in Huh-7 cells.
   Conclusions: KD-1 could significantly inhibit virus proliferation in vitro, the up-regulated expression of proinflammatory cytokines induced by SARS-CoV-2 and HCoV-229E by regulating the activity of the NF-kappa B signaling pathway. Our findings indicated that KD-1 protected against virus attack and can thus be used as a novel strategy for controlling the coronavirus disease 2019.
C1 [Ma, Qinhai; Li, Runfeng; Pan, Weiqi; Huang, Wenbo; Xie, Yuqi; Wang, Zhoulang; Li, Chufang; Jiang, Haiming; Yang, Zifeng] Guangzhou Med Univ, Natl Clin Res Ctr Resp Dis, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis,Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
   [Yang, Zifeng] Macau Univ Sci & Technol, Macau Inst Appl Res Med & Hlth, State Key Lab Qual Res Chinese Med, Taipa, Macau, Peoples R China.
   [Yang, Zifeng] KingMed Virol Diagnost & Translat Ctr, Guangzhou, Peoples R China.
   [Huang, Jicheng; Shi, Yongxia; Dai, Jun; Zheng, Kui; Li, Xiaobo] Guangzhou Customs, Technol Ctr, Guangzhou, Peoples R China.
   [Liu, Bin] Kunming Univ Sci & Technol Lib, Kunming, Yunnan, Peoples R China.
   [Hui, Min; Fu, Li] Jilin Yatai Chinese Med Dev Inst, Changchun, Jilin, Peoples R China.
RP Yang, ZF (corresponding author), Guangzhou Med Univ, Natl Clin Res Ctr Resp Dis, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis,Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.; Yang, ZF (corresponding author), Macau Univ Sci & Technol, Macau Inst Appl Res Med & Hlth, State Key Lab Qual Res Chinese Med, Taipa, Macau, Peoples R China.; Yang, ZF (corresponding author), KingMed Virol Diagnost & Translat Ctr, Guangzhou, Peoples R China.
EM jeffyah@163.com
FU China Postdoctoral Science FoundationChina Postdoctoral Science
   Foundation [2020T130028ZX]; Department of Education of Guangdong
   Provincial [2020KZDZX1159]; Science research project of the Guangdong
   Province [2020B111110001]; Macao Science and Technology Development Fund
   [0172/2019/A3]; National Key R&D Program of China [2020YFC0842400];
   Foshan Science and Technology Bureau [2020001000206]; China Evergrande
   Group; Jack Ma Foundation [2020-CMKYGG-02]; National Key Technology RD
   ProgramNational Key Technology R&D Program [2018YFC1311900]; Guangdong
   Science and Technology Foundation [2019B030316028]
FX This work was supported by China Postdoctoral Science Foundation
   (2020T130028ZX), Department of Education of Guangdong Provincial
   (2020KZDZX1159), Science research project of the Guangdong Province
   (Nos. 2020B111110001), Macao Science and Technology Development Fund
   (0172/2019/A3), National Key R&D Program of China (2020YFC0842400),
   Foshan Science and Technology Bureau (2020001000206), China Evergrande
   Group, Jack Ma Foundation (2020-CMKYGG-02), National Key Technology R&D
   Program (2018YFC1311900) and Guangdong Science and Technology Foundation
   (2019B030316028).
CR Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Carlos WG, 2020, AM J RESP CRIT CARE, V201, pP7, DOI 10.1164/rccm.2014P7
   CDC China, DISTR 2019 NCOV INF
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen XF, 2004, BIOMED CHROMATOGR, V18, P673, DOI 10.1002/bmc.373
   Clercq GLED, 2020, NAT REV DRUG DISCOV
   Coleman CM, 2016, J VIROL, V90, P8924, DOI 10.1128/JVI.01429-16
   Coon TA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115937
   Du Toit A, 2020, NAT REV MICROBIOL, V18, P123, DOI 10.1038/s41579-020-0332-0
   Fan J, 2001, AM J PHYSIOL-LUNG C, V281, pL1037
   Guan W.J., 2002, CLIN CHARACTERISTICS, V2006
   Gulcin I, 2006, EUR FOOD RES TECHNOL, V223, P759, DOI 10.1007/s00217-006-0265-5
   Guo H, 2007, RAPID COMMUN MASS SP, V21, P715, DOI 10.1002/rcm.2875
   Heimdal I, 2019, J INFECT DIS, V219, P1198, DOI 10.1093/infdis/jiy646
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lanza AMD, 2001, PLANTA MED, V67, P219, DOI 10.1055/s-2001-12004
   Lee DG, 2011, ARCH PHARM RES, V34, P2029, DOI 10.1007/s12272-011-1204-y
   Leong HN, 2006, ANN ACAD MED SINGAP, V35, P332
   Lu T, 2010, FOOD CHEM TOXICOL, V48, P764, DOI 10.1016/j.fct.2009.12.018
   MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M408
   Mitchell S, 2016, WIRES SYST BIOL MED, V8, P227, DOI 10.1002/wsbm.1331
   Nkengasong J, 2020, NAT MED, V26, P310, DOI 10.1038/s41591-020-0771-1
   Owusu M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099782
   Pan XL, 2014, INFLAMM RES, V63, P597, DOI 10.1007/s00011-014-0731-7
   Park KI, 2011, J ETHNOPHARMACOL, V133, P634, DOI 10.1016/j.jep.2010.10.057
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Russell C.D., 2020, LANCET N AM ED
   Santoro MG, 2003, EMBO J, V22, P2552, DOI 10.1093/emboj/cdg267
   WHO, 2020, NOV COR 2019NCOV SIT
   Xia S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4580
   Xu X, 2020, EUR J NUCL MED MOL I, V47, P1022, DOI 10.1007/s00259-020-04720-2
   Yao K.T., 2020, CHIN J EXP TRADIT ME, DOI [10.13422/j.cnki.syfjx.20201099, DOI 10.13422/J.CNKI.SYFJX.20201099]
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhong WT, 2013, FITOTERAPIA, V90, P132, DOI 10.1016/j.fitote.2013.06.003
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zumla A., 2020, LANCET, V22, P395
NR 38
TC 0
Z9 0
U1 10
U2 10
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944-7113
EI 1618-095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD NOV
PY 2020
VL 78
AR 153296
DI 10.1016/j.phymed.2020.153296
PG 9
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA NW7GZ
UT WOS:000575189000007
PM 32890913
OA Green Published
DA 2021-01-01
ER

PT J
AU Kimmel, SD
   Bazzi, AR
   Barocas, JA
AF Kimmel, Simeon D.
   Bazzi, Angela R.
   Barocas, Joshua A.
TI Integrating harm reduction and clinical care: Lessons from Covid-19
   respite and recuperation facilities
SO JOURNAL OF SUBSTANCE ABUSE TREATMENT
LA English
DT Article
DE Harm reduction; Covid-19; SARS-CoV-2; Respite and recuperation
   facilities; Homelessness
ID SERVICES; PEOPLE
AB In response to the novel coronavirus 2019 (Covid-19) pandemic, many people experiencing homelessness and substance use disorders entered respite and recuperation facilities for care and to isolate and prevent subsequent SARS-CoV-2 transmission. However, because drug use was officially prohibited in these facilities, we observed people who use substances leaving isolation temporarily or prematurely. The initial Covid-19 surge magnified the need for harm reduction access for those who use substances to ensure their safety and well-being and that of their local communities. In this commentary, we argue that expanding harm reduction access is crucial for subsequent waves of SARS-CoV-2 infection and also for patients who use substances and are hospitalized for other reasons.
C1 [Kimmel, Simeon D.] Boston Med Ctr, Dept Med, Sect Gen Internal Med, Boston, MA 02118 USA.
   [Kimmel, Simeon D.; Barocas, Joshua A.] Boston Med Ctr, Dept Med, Sect Infect Dis, Boston, MA 02118 USA.
   [Kimmel, Simeon D.; Barocas, Joshua A.] Boston Univ, Sch Med, Boston, MA 02215 USA.
   [Bazzi, Angela R.] Boston Univ, Sch Publ Hlth, Dept Community Hlth Sci, Boston, MA 02215 USA.
RP Kimmel, SD (corresponding author), Boston Med Ctr, Dept Med, Crosstown Ctr, 801 Massachusetts Ave,2nd Floor, Boston, MA 02118 USA.
EM simeon.kimmel@bmc.org
FU National Institute on Drug Abuse (NIDA)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Drug Abuse (NIDA) [5UM1DA049412-02]; NIDAUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)
   [K01DA051684]
FX SDK and JAB are supported by the National Institute on Drug Abuse (NIDA)
   (5UM1DA049412-02). ARB is supported by NIDA (K01DA043412). JAB is also
   supported by NIDA (K01DA051684).
CR Alter A., 2020, COVID 19 IMPACT US N
   [Anonymous], 2020, RISK MITIGATION CONT
   [Anonymous], 2020, COVID 19 PROVINCIAL
   Barocas JA, 2020, J ADDICT MED, V14, pE261, DOI 10.1097/ADM.0000000000000700
   Bearnot B, 2019, J SUBST ABUSE TREAT, V102, P16, DOI 10.1016/j.jsat.2019.04.008
   Biancarelli DL, 2019, DRUG ALCOHOL DEPEN, V198, P80, DOI 10.1016/j.drugalcdep.2019.01.037
   Chen YJ, 2020, DRUG ALCOHOL DEPEN, V213, DOI 10.1016/j.drugalcdep.2020.108009
   Dong KA, 2020, CAN MED ASSOC J, V192, pE476, DOI 10.1503/cmaj.191365
   Englander H, 2019, J GEN INTERN MED, V34, P2796, DOI 10.1007/s11606-019-05251-9
   Fernandes RM, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4210-2
   Gaeta JM, 2020, NEW ENGL J MED, V383, P170, DOI 10.1056/NEJMcpc2002421
   Glick SN, 2020, AIDS BEHAV, V24, P2466, DOI 10.1007/s10461-020-02886-2
   Harm Reduction Coalition, PRINC HARM RED
   Heller D, 2004, PUBLIC HEALTH REP, V119, P32, DOI 10.1177/003335490411900109
   McNeil R, 2014, SOC SCI MED, V105, P59, DOI 10.1016/j.socscimed.2014.01.010
   Mosites E, 2020, MMWR-MORBID MORTAL W, V69, P521, DOI 10.15585/mmwr.mm6917e1
   Potier C, 2014, DRUG ALCOHOL DEPEN, V145, P48, DOI 10.1016/j.drugalcdep.2014.10.012
   Ti LP, 2015, J HOSP MED, V10, P301, DOI 10.1002/jhm.2344
   Wood E, 2006, NEW ENGL J MED, V354, P2512, DOI 10.1056/NEJMc052939
NR 19
TC 1
Z9 1
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0740-5472
J9 J SUBST ABUSE TREAT
JI J. Subst. Abus. Treat.
PD NOV
PY 2020
VL 118
AR 108103
DI 10.1016/j.jsat.2020.108103
PG 3
WC Psychology, Clinical; Substance Abuse
SC Psychology; Substance Abuse
GA NW3MD
UT WOS:000574913300002
PM 32972644
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Zastepa, E
   Sun, JC
   Clune, J
   Mathew, N
AF Zastepa, Evelyn
   Sun, Jane C.
   Clune, Jennifer
   Mathew, Nickie
TI Adaptation of contingency management for stimulant use disorder during
   the COVID-19 pandemic
SO JOURNAL OF SUBSTANCE ABUSE TREATMENT
LA English
DT Article
DE Stimulant; Cocaine; Amphetamine; Contingency management; COVID-19
ID SUBSTANCE-USE DISORDERS; RANDOMIZED CONTROLLED-TRIAL; PROMOTE
   SMOKING-CESSATION; INTERVENTION; COCAINE; PREVALENCE; CHALLENGES;
   DEPENDENCE
AB The current coronavirus disease (COVID-19) pandemic has rapidly spread across the world. Individuals with stimulant use disorder are a vulnerable population, who are particularly at risk of negative outcomes during this pandemic due to several risk factors, including mental and physical comorbidities, weakened immune responses, high-risk behaviors, and barriers to healthcare access. Engaging patients with stimulant use disorder in regular treatment has become even more difficult during this pandemic, which has resulted in many cuts to addiction treatment programs. The most effective treatment options for stimulant use disorder are psychosocial interventions, which rely heavily on in-person interactions, posing an added challenge during physical distancing. In particular, contingency management (CM) is a behavioral therapy that utilizes tangible reinforcements to incentivize targeted behavior changes, and is an effective treatment intervention used for stimulant use disorder. This paper highlights the treatment challenges for individuals with stimulant use disorder and the importance of adapting CM programs during COVID-19. We present strategies for how CM can be adapted and its role expanded in a safe way during the COVID-19 pandemic to help prevent infection spread, stimulant use relapse, and worsened psychosocial consequences.
C1 [Zastepa, Evelyn; Clune, Jennifer; Mathew, Nickie] Univ British Columbia, Fac Med, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada.
   [Sun, Jane C.] British Columbia Mental Hlth & Subst Use Serv, Prov Hlth Serv Author, 4949 Heather St, Vancouver, BC V5Z 3L7, Canada.
   [Mathew, Nickie] Burnaby Ctr Mental Hlth & Addict, 3405 Willingdon Ave, Burnaby, BC V5G 3H4, Canada.
RP Zastepa, E (corresponding author), Univ British Columbia, Fac Med, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada.
EM evelyn.zastepa@alumni.ubc.ca; jane.sun1@phsa.ca; jclune@alumni.ubc.ca;
   nick.mathew@phsa.ca
CR [Anonymous], 2020, NY TIMES
   Balanza-Martinez V, 2020, ACTA PSYCHIAT SCAND, V141, P399, DOI 10.1111/acps.13177
   Bao YP, 2020, LANCET, V395, pE37, DOI 10.1016/S0140-6736(20)30309-3
   Carrico AW, 2020, AIDS BEHAV, V24, P3020, DOI 10.1007/s10461-020-02854-w
   Carrico AW, 2018, DRUG ALCOHOL DEPEN, V192, P8, DOI 10.1016/j.drugalcdep.2018.07.029
   Chan B, 2019, J GEN INTERN MED, V34, P2858, DOI 10.1007/s11606-019-05074-8
   Chatterjee SS, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102071
   City of Vancouver, 2020, OV DEATHS SPIK AM CO
   Dallery J, 2019, PERSPECT BEHAV SCI, V42, P445, DOI 10.1007/s40614-019-00214-1
   Dallery J, 2017, ADDICTION, V112, P875, DOI 10.1111/add.13715
   Dallery J, 2013, J APPL BEHAV ANAL, V46, P750, DOI 10.1002/jaba.89
   De Crescenzo F, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002715
   Farhoudian A, 2020, BASIC CLIN NEUROSCI, V11, P133, DOI 10.32598/bcn.11.covid19.1
   Farhoudian A, 2013, PSYCHIAT CLIN N AM, V36, P385, DOI 10.1016/j.psc.2013.05.003
   Getty CA, 2019, ADDICTION, V114, P1915, DOI 10.1111/add.14725
   Government of British Columbia, 2020, COVID 19 SUPP INC DI
   Henggeler SW, 2008, J CONSULT CLIN PSYCH, V76, P556, DOI 10.1037/0022-006X.76.4.556
   Higgins ST, 2000, J CONSULT CLIN PSYCH, V68, P64, DOI 10.1037/0022-006X.68.1.64
   Landovitz RJ, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofu114
   Levy MS, 2008, J PSYCHOACTIVE DRUGS, V40, P167, DOI 10.1080/02791072.2008.10400627
   Lussier JP, 2006, ADDICTION, V101, P192, DOI 10.1111/j.1360-0443.2006.01311.x
   Marsden J, 2020, ADDICTION, V115, P1007, DOI 10.1111/add.15080
   McDonell MG, 2013, AM J PSYCHIAT, V170, P94, DOI 10.1176/appi.ajp.2012.11121831
   McPherson S, 2018, BEHAV PHARMACOL, V29, P370, DOI 10.1097/FBP.0000000000000349
   McPherson SM, 2018, SUBST ABUSE REHABIL, V9, P43, DOI 10.2147/SAR.S138439
   Petry NM, 2018, J CONSULT CLIN PSYCH, V86, P799, DOI 10.1037/ccp0000330
   Petry NM, 2017, PSYCHOL ADDICT BEHAV, V31, P897, DOI 10.1037/adb0000287
   Prem K, 2020, LANCET PUBLIC HEALTH, V5, pE261, DOI 10.1016/S2468-2667(20)30073-6
   Rash CJ, 2017, J SUBST ABUSE TREAT, V72, P10, DOI 10.1016/j.jsat.2016.09.008
   Rawson RA, 2006, ADDICTION, V101, P267, DOI 10.1111/j.1360-0443.2006.01312.x
   Restrepo CS, 2007, RADIOGRAPHICS, V27, P941, DOI 10.1148/rg.274065144
   Roll JM, 2006, PSYCHOL REC, V56, P67, DOI 10.1007/BF03395538
   Schwartz BG, 2010, CIRCULATION, V122, P2558, DOI 10.1161/CIRCULATIONAHA.110.940569
   Sequeira A, 2020, COUNS PSYCHOL Q, DOI 10.1080/09515070.2020.1777940
   Sheidow AJ, 2012, PSYCHIATR REHABIL J, V35, P235, DOI 10.2975/35.3.2012.235.243
   Shoptaw S, 2005, DRUG ALCOHOL DEPEN, V78, P125, DOI 10.1016/j.drugalcdep.2004.10.004
   Shoptaw S, 2017, J SUBST ABUSE TREAT, V72, P19, DOI 10.1016/j.jsat.2016.09.004
   Sun YK, 2020, AM J ADDICTION, V29, P174, DOI 10.1111/ajad.13031
   Lima CKT, 2020, PSYCHIAT RES, V287, DOI 10.1016/j.psychres.2020.112915
   Toftdahl NG, 2016, SOC PSYCH PSYCH EPID, V51, P129, DOI 10.1007/s00127-015-1104-4
   Vocci FJ, 2009, CURR OPIN PSYCHIATR, V22, P263, DOI 10.1097/YCO.0b013e32832a3b44
   Volkow ND, 2020, ANN INTERN MED, V173, P61, DOI 10.7326/M20-1212
   Xiang YT, 2020, INT J BIOL SCI, V16, P1741, DOI 10.7150/ijbs.45072
   Yao H, 2020, LANCET PSYCHIAT, V7, pE21, DOI 10.1016/S2215-0366(20)30090-0
NR 44
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0740-5472
J9 J SUBST ABUSE TREAT
JI J. Subst. Abus. Treat.
PD NOV
PY 2020
VL 118
AR 108102
DI 10.1016/j.jsat.2020.108102
PG 3
WC Psychology, Clinical; Substance Abuse
SC Psychology; Substance Abuse
GA NW3MD
UT WOS:000574913300009
PM 32854983
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Aghababaeian, H
   Hamdanieh, L
   Ostadtaghizadeh, A
AF Aghababaeian, Hamidreza
   Hamdanieh, Lara
   Ostadtaghizadeh, Abbas
TI Alcohol intake in an attempt to fight COVID-19: A medical myth in Iran
SO ALCOHOL
LA English
DT Article
DE Alcohol poisoning; COVID-19; Iran; Methanol
AB The coronavirus disease 2019 (COVID-19) spread rapidly worldwide and led to the deaths of thousands of people. To date, there is not any vaccine or specific antiviral medicine that can prevent or treat this virus. This caused panic among people who try their best to prevent being infected. In Iran, methanol poisoning was reported and led to the death of hundreds of people in several provinces. The incident occurred after a rumor circulated in the country that drinking alcohol (ethanol) can cure or prevent being infected by COVID-19. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Aghababaeian, Hamidreza; Hamdanieh, Lara; Ostadtaghizadeh, Abbas] Univ Tehran Med Sci, Sch Publ Hlth, Dept Hlth Emergencies & Disasters, Tehran, Iran.
   [Aghababaeian, Hamidreza] Dezful Univ Med Sci, Dept Nursing & Emergency Med, Dezful, Iran.
RP Ostadtaghizadeh, A (corresponding author), Univ Tehran Med Sci, Sch Publ Hlth, Dept Hlth Emergencies & Disasters, Tehran, Iran.
EM ostadtaghizadeh@gmail.com
RI Aghababaeian, Hamidreza/D-7325-2017
OI Aghababaeian, Hamidreza/0000-0003-3339-5507; Hamdanieh,
   Lara/0000-0003-2603-3719; Ostadtaghizadeh, Abbas/0000-0001-5260-6221
CR Aghababaeian H, 2019, ALCOHOL ALCOHOLISM, V54, P128, DOI 10.1093/alcalc/agz005
   [Anonymous], 2020, WHO DIR GEN OP REM M
   [Anonymous], 2016, 95 DEATHS DUE ALC CO
   [Anonymous], 2020, MOR 10000 VICT COUNT
   [Anonymous], 2020, 100S DIE IR FALS BEL
   [Anonymous], 2020, ALC COVID 19 WHAT YO
   Centers for Disease Control and Prevention, 2020, COP STRESS
   Centers for Disease Control and Prevention, 2014, CERC SOC MED MOB MED
   Centers for Disease Control and Prevention, 2020, CLEAN DIS YOUR HOM
   Centers for Disease Control and Prevention, 2017, RESP RUM MIS
   Centers for Disease Control and Prevention, 2018, CRIS EM RISK COMM CE
   Citroner G., 2020, HEALTHLINE WHAT WE K
   Farahmandnia B, 2020, PREHOSP DISASTER MED, V35, P464, DOI 10.1017/S1049023X20000631
   Fars University of Medical Sciences, 2020, LAT STAT COR FARS
   Federal Emergency Management Agency, 2020, COR RUM CONTR
   Harvard Health Publishing, 2020, COVID 19 BASICS SYMP
   Iranian Legal Medicine Organization, 2020, FOR MED MED
   Iranian Legal Medicine Organization, 2020, REF MOR 700 DEATHS A
   IRB News Agency, 2020, POIS 727 PEOPL DUE A
   Javaonline, 2018, LAT DEATH TOLL ALC C
   Jones NM, 2017, P NATL ACAD SCI USA, V114, P11663, DOI 10.1073/pnas.1708518114
   Khabaronline News Agency, 2018, DEADL SHOCK STAT DEA
   Lankarani KB, 2014, LANCET, V384, P1927, DOI 10.1016/S0140-6736(14)62279-0
   WHO, 2020, Q A COR COVID 19
   World Health Organization, 2020, EM RISK COMM TRAIN M
   World Health Organization, 2020, DYN LIST RUM MAN MOD
   World Health Organization, 2014, METH POIS OUTBR
   World Health Organization, 2020, EM RESP VIR INCL COI
   World Health Organization, 2020, WHO COR DIS COVID 19
   World Health Organization, 2020, COR DIS COVID 19 ADV
NR 30
TC 0
Z9 0
U1 8
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0741-8329
EI 1873-6823
J9 ALCOHOL
JI Alcohol
PD NOV
PY 2020
VL 88
BP 29
EP 32
DI 10.1016/j.alcohol.2020.07.006
PG 4
WC Substance Abuse; Pharmacology & Pharmacy; Toxicology
SC Substance Abuse; Pharmacology & Pharmacy; Toxicology
GA NR3QW
UT WOS:000571479200003
PM 32693023
OA Green Published
DA 2021-01-01
ER

PT J
AU Zhuang, MW
   Cheng, Y
   Zhang, J
   Jiang, XM
   Wang, L
   Deng, J
   Wang, PH
AF Zhuang, Meng-Wei
   Cheng, Yun
   Zhang, Jing
   Jiang, Xue-Mei
   Wang, Li
   Deng, Jian
   Wang, Pei-Hui
TI Increasing host cellular receptor-angiotensin-converting enzyme 2
   expression by coronavirus may facilitate 2019-nCoV (or SARS-CoV-2)
   infection
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE 2019-nCoV; ACE2; COVID-19; IFN; ISG; SARS-CoV-2
AB The ongoing outbreak of a new coronavirus (2019-nCoV, or severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) has caused an epidemic of the acute respiratory syndrome known as coronavirus disease (COVID-19) in humans. SARS-CoV-2 rapidly spread to multiple regions of China and multiple other countries, posing a serious threat to public health. The spike (S) proteins of SARS-CoV-1 and SARS-CoV-2 may use the same host cellular receptor, angiotensin-converting enzyme 2 (ACE2), for entering host cells. The affinity between ACE2 and the SARS-CoV-2 S protein is much higher than that of ACE2 binding to the SARS-CoV S protein, explaining why SARS-CoV-2 seems to be more readily transmitted from human to human. Here, we report that ACE2 can be significantly upregulated after infection of various viruses, including SARS-CoV-1 and SARS-CoV-2, or by the stimulation with inflammatory cytokines such as interferons. We propose that SARS-CoV-2 may positively induce its cellular entry receptor, ACE2, to accelerate its replication and spread; high inflammatory cytokine levels increase ACE2 expression and act as high-risk factors for developing COVID-19, and the infection of other viruses may increase the risk of SARS-CoV-2 infection. Therefore, drugs targeting ACE2 may be developed for the future emerging infectious diseases caused by this cluster of coronaviruses.
C1 [Zhuang, Meng-Wei; Zhang, Jing; Wang, Pei-Hui] Shandong Univ, Cheeloo Coll Med, Adv Med Res Inst, Jinan 250012, Shandong, Peoples R China.
   [Cheng, Yun; Deng, Jian] Univ Hong Kong, Sch Biomed Sci, Pokfulam, Hong Kong, Peoples R China.
   [Jiang, Xue-Mei; Wang, Li] Shandong Univ, Cheeloo Coll Med, Jinan Infect Dis Hosp, Jinan, Peoples R China.
RP Wang, PH (corresponding author), Shandong Univ, Cheeloo Coll Med, Adv Med Res Inst, Jinan 250012, Shandong, Peoples R China.
EM pei-hui.wang@sdu.edu.cn
RI Wang, Pei-Hui/F-7682-2014
OI Wang, Pei-Hui/0000-0001-6853-2423
FU COVID-19 Emergency Tackling Research Project of Shandong University
   [2020XGB03] Funding Source: Medline
CR Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chu KH, 2005, KIDNEY INT, V67, P698, DOI 10.1111/j.1523-1755.2005.67130.x
   Glowacka I, 2010, J VIROL, V84, P1198, DOI 10.1128/JVI.01248-09
   Gralinski LE, 2018, MBIO, V9, DOI 10.1128/mBio.01753-18
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Proud D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040762
   Shapira SD, 2009, CELL, V139, P1255, DOI 10.1016/j.cell.2009.12.018
   Smith JC, 2020, DEV CELL
   Swindell WR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034594
   Totura AL, 2015, MBIO, V6, DOI 10.1128/mBio.00638-15
   Wang B, 2020, J MED VIROL, V92, P1684, DOI 10.1002/jmv.25946
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang PH, 2019, INT REV CEL MOL BIO, V345, P287, DOI 10.1016/bs.ircmb.2018.11.002
   Wang PH, 2018, EMBO REP, V19, DOI 10.15252/embr.201845737
   Wang PH, 2018, NUCLEIC ACIDS RES, V46, P4054, DOI 10.1093/nar/gky186
   Wei Lin, 2020, SINGLE CELL ANAL ACE
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Zhang YF, 2020, DIGEST DIS SCI, DOI 10.1007/s10620-020-06488-9
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
NR 26
TC 10
Z9 10
U1 15
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD NOV
PY 2020
VL 92
IS 11
BP 2693
EP 2701
DI 10.1002/jmv.26139
PG 9
WC Virology
SC Virology
GA NU0EN
UT WOS:000573313300094
PM 32497323
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Andrade-Campos, M
   Escuder-Azuara, B
   de Frutos, LL
   Serrano-Gonzalo, I
   Giraldo, P
AF Andrade-Campos, Marcio
   Escuder-Azuara, Beatriz
   Lopez de Frutos, Laura
   Serrano-Gonzalo, Irene
   Giraldo, Pilar
CA GEEDL
   FEETEG
   AEEFEG
TI Direct and indirect effects of the SARS-CoV-2 pandemic on Gaucher
   Disease patients in Spain: Time to reconsider home-based therapies?
SO BLOOD CELLS MOLECULES AND DISEASES
LA English
DT Article
DE COVID-19; SARS-CoV-2; Gaucher Disease; ERT; Home therapy
ID REGISTRY
AB Objective: An analysis of the SARS-CoV-2 pandemic impact in the Spanish Gaucher Disease (GD) community is presented here.
   Patients & methods: The Spanish GD foundation (FEETEF) surveyed 113 GD patients from March 30 to April 27; all patients provided a verbal consent.
   Results: 110 surveys were analyzed. The median age was 47 years old (y.o.), 31 patients were >= 60 y.o.; and 34% of patients reported comorbidities. 46% (51/110) of patients were treated by enzyme replacement therapy (ERT), 48 of them at hospitals; 45.1% (45/110) were on substrate reduction therapy (SRT) and 9% (10/110) receive no therapy. 25% (11/48) of ERT-hospital-based patients reported therapy interruptions, while SRT-patients did not report missing doses. No bone crises were reported. However, 50% (55/110) of patients reported being worried about their predisposition to a severe SARS-COV-2 infection and 29% (16/55) of them took anxiolytics or antidepressants for this. While 6 patients reported to have contact with an infected person, another two confirmed SARS-CoV-2 infections were reported in splenectomyzed patients, one of them (a 79-year-old diabetic) died.
   Conclusions: One quarter of the patients treated at hospitals reported dose interruptions. Home-based therapy may need to be considered in order to minimize the impact of the COVID-19 pandemic.
C1 [Andrade-Campos, Marcio] Hosp del Mar, Inst Hosp del Mar Invest Med, Barcelona, Spain.
   [Andrade-Campos, Marcio; Escuder-Azuara, Beatriz; Lopez de Frutos, Laura; Serrano-Gonzalo, Irene; Giraldo, Pilar] Fdn Espanola Estudio & Terapeut Enfermedad Gauche, Zaragoza, Spain.
   [Andrade-Campos, Marcio; Lopez de Frutos, Laura; Giraldo, Pilar] Soc Espanola Hematol & Hemoterapia, Grp Estudio Enfermedades Deposito Lisosomal, Zaragoza, Spain.
   [Lopez de Frutos, Laura; Serrano-Gonzalo, Irene] Fdn Inst Invest Sanitaria Aragon IIS Aragon, Grp Invest Enfermedades Metab & Hematol Raras GII, Zaragoza, Spain.
RP Giraldo, P (corresponding author), FEETEG, C Jose Ma Lacarra de Miguel 35,2 Izda, Zaragoza 50008, Spain.
EM giraldocastellano@gmail.com
OI Serrano Gonzalo, Irene/0000-0002-7507-9249; Lopez de Frutos,
   Laura/0000-0002-1369-6225
FU FundacionEspanola para el Estudio y Terapeutica de la Enfermedad de
   Gaucher y otras Lisosomales (FEETEG)
FX This work was funded by FundacionEspanola para el Estudio y Terapeutica
   de la Enfermedad de Gaucher y otras Lisosomales (FEETEG).
CR Andrade-Campos M, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-017-0627-z
   Bussink AP, 2006, INT REV CYTOL, V252, P71, DOI 10.1016/S0074-7696(06)52001-7
   Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2
   Giraldo P, 2000, HAEMATOLOGICA, V85, P792
   Giraldo P, 2011, BLOOD CELL MOL DIS, V46, P115, DOI 10.1016/j.bcmd.2010.09.005
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Ministry of Spanish Health, SUPP MIN SCI INN COO
   Mistry P, 2020, MOL GENET METAB, V130, P164, DOI 10.1016/j.ymgme.2020.05.002
   Mistry Pramod K., 2013, Critical Reviews in Oncogenesis, V18, P235
   Palmer K, 2020, AGING CLIN EXP RES, V32, P1189, DOI 10.1007/s40520-020-01601-4
   Sechi A, 2020, MOL GENET METAB, DOI 10.1016/
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 13
TC 0
Z9 0
U1 4
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1079-9796
EI 1096-0961
J9 BLOOD CELL MOL DIS
JI Blood Cells Mol. Dis.
PD NOV
PY 2020
VL 85
AR 102478
DI 10.1016/j.bcmd.2020.102478
PG 4
WC Hematology
SC Hematology
GA NQ6SQ
UT WOS:000571001800015
PM 32688219
OA Green Published
DA 2021-01-01
ER

PT J
AU Huggins, DJ
AF Huggins, David J.
TI Structural analysis of experimental drugs binding to the SARS-CoV-2
   target TMPRSS2
SO JOURNAL OF MOLECULAR GRAPHICS & MODELLING
LA English
DT Article
DE Molecular modelling; Serine protease; TMPRSS2; Homology modelling;
   SARS-CoV-2; Drug design
ID SYNTHETIC INHIBITORS; CRYSTAL-STRUCTURE; INFLUENZA-VIRUS; SPIKE PROTEIN;
   SERINE; UROKINASE; IDENTIFICATION; DETERMINANTS; DERIVATIVES; ACTIVATION
AB The emergence of SARS-CoV-2 has prompted a worldwide health emergency. There is an urgent need for therapeutics, both through the repurposing of approved drugs and the development of new treatments. In addition to the viral drug targets, a number of human drug targets have been suggested. In theory, targeting human proteins should provide an advantage over targeting viral proteins in terms of drug resistance, which is commonly a problem in treating RNA viruses. This paper focuses on the human protein TMPRSS2, which supports coronavirus life cycles by cleaving viral spike proteins. The three-dimensional structure of TMPRSS2 is not known and so we have generated models of the TMPRSS2 in the apo state as well as in complex with a peptide substrate and putative inhibitors to aid future work. Importantly, many related human proteases have 80% or higher identity with TMPRSS2 in the S1-S1' subsites, with plasminogen and urokinase-type plasminogen activator (uPA) having 95% identity. We highlight 376 approved, investigational or experimental drugs targeting S1A serine proteases that may also inhibit TMPRSS2. Whilst the presence of a relatively uncommon lysine residue in the S2/S3 subsites means that some serine protease inhibitors will not inhibit TMPRSS2, this residue is likely to provide a handle for selective targeting in a focused drug discovery project. We discuss how experimental drugs targeting related serine proteases might be repurposed as TMPRSS2 inhibitors to treat coronaviruses. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Huggins, David J.] Triinst Therapeut Discovery Inst, New York, NY 10021 USA.
   [Huggins, David J.] Cornell Univ, Dept Physiol & Biophys, Weill Cornell Med Coll, New York, NY USA.
RP Huggins, DJ (corresponding author), Triinst Therapeut Discovery Inst, New York, NY 10021 USA.
EM dhuggins@tritdi.org
OI Huggins, David/0000-0003-1579-2496
FU Tri-Institutional Therapeutics Discovery Institute (TDI), a 501(c) (3)
   organization; Takeda Pharmaceutical Company, TDI's parent institute
   (Memorial Sloan Kettering Cancer Center); Takeda Pharmaceutical Company,
   TDI's parent institute (Rockefeller University); Takeda Pharmaceutical
   Company, TDI's parent institute (Weill Cornell Medicine)
FX Acknowledgements go to Neil Rawlings for help with the MEROPS database
   and to Fraser Glickman, Patti Aha, Nigel Liverton, and Peter Meinke for
   careful reading of the manuscript. The author gratefully acknowledges
   the support to the project generously provided by the Tri-Institutional
   Therapeutics Discovery Institute (TDI), a 501(c) (3) organization. TDI
   receives financial support from Takeda Pharmaceutical Company, TDI's
   parent institutes (Memorial Sloan Kettering Cancer Center, The
   Rockefeller University andWeill Cornell Medicine) and from a generous
   contribution from Mr. Lewis Sanders and other philanthropic sources.
CR Afar DEH, 2001, CANCER RES, V61, P1686
   [Anonymous], 2020, BIORXIV
   Asselta R, 2020, ACE2 TMPRSS2 VARIANT
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bestle D., 2020, BIORXIV, DOI DOI 10.1101/2020.04.15.042085V1.ABSTRACT
   Bosch BJ, 2008, J VIROL, V82, P8887, DOI 10.1128/JVI.00415-08
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Frederickson M, 2008, J MED CHEM, V51, P183, DOI 10.1021/jm701359z
   FUJII S, 1981, BIOCHIM BIOPHYS ACTA, V661, P342, DOI 10.1016/0005-2744(81)90023-1
   Guvench O, 2002, J COMPUT CHEM, V23, P214, DOI 10.1002/jcc.1167
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00754-20
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Jaimes JA, 2020, J MOL BIOL, V432, P3309, DOI 10.1016/j.jmb.2020.04.009
   Kam YW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007870
   Katz BA, 2004, J MOL BIOL, V344, P527, DOI 10.1016/j.jmb.2004.09.032
   Katz BA, 2001, CHEM BIOL, V8, P1107, DOI 10.1016/S1074-5521(01)00084-9
   Katz BA, 2001, J MOL BIOL, V307, P1451, DOI 10.1006/jmbi.2001.4516
   Kawase M, 2012, J VIROL, V86, P6537, DOI 10.1128/JVI.00094-12
   Kim TS, 2006, MOL CELL BIOL, V26, P965, DOI 10.1128/MCB.26.3.965-975.2006
   Kleine-Weber H, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34859-w
   Kyrieleis OJP, 2007, FEBS J, V274, P2148, DOI 10.1111/j.1742-4658.2007.05756.x
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Lukassen S, 2020, EMBO J, DOI 10.15252/embj.20105114
   Maryanoff BE, 2004, J MED CHEM, V47, P769, DOI 10.1021/jm030493t
   Meyer D, 2013, BIOCHEM J, V452, P331, DOI 10.1042/BJ20130101
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Qi J, 2020, BIORXIV PREPRINT, DOI [10.1101/2020.04.16.045690, DOI 10.1101/2020.04.16.045690]
   Rawlings ND, 2018, NUCLEIC ACIDS RES, V46, pD624, DOI 10.1093/nar/gkx1134
   Riggs JR, 2006, BIOORG MED CHEM LETT, V16, P3197, DOI 10.1016/j.bmcl.2006.03.049
   Shen LW, 2017, BIOCHIMIE, V142, P1, DOI 10.1016/j.biochi.2017.07.016
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Simeonov P, 2012, PROTEINS, V80, P1907, DOI 10.1002/prot.24084
   Sperl S, 2000, P NATL ACAD SCI USA, V97, P5113, DOI 10.1073/pnas.97.10.5113
   Stopsack KH, 2020, CANCER DISCOV, V10, P779, DOI 10.1158/2159-8290.CD-20-0451
   Vukovic S., 2018, DRUG DISCOV TODAY
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   Wang Q, 2020, VIROL SIN, V35, P337, DOI 10.1007/s12250-020-00212-7
   Wendt MD, 2004, BIOORG MED CHEM LETT, V14, P3063, DOI 10.1016/j.bmcl.2004.04.030
   Wendt MD, 2004, J MED CHEM, V47, P303, DOI 10.1021/jm0300072
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Zakharova E, 2009, P NATL ACAD SCI USA, V106, P11034, DOI 10.1073/pnas.0902463106
   Zang R., 2020, BIORXIV, DOI DOI 10.1101/2020.04.21.054015V1.ABSTRACT
   Zang RC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc3582
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 48
TC 0
Z9 0
U1 13
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1093-3263
EI 1873-4243
J9 J MOL GRAPH MODEL
JI J. Mol. Graph.
PD NOV
PY 2020
VL 100
AR 107710
DI 10.1016/j.jmgm.2020.107710
PG 7
WC Biochemical Research Methods; Biochemistry & Molecular Biology; Computer
   Science, Interdisciplinary Applications; Crystallography; Mathematical &
   Computational Biology
SC Biochemistry & Molecular Biology; Computer Science; Crystallography;
   Mathematical & Computational Biology
GA NR0BN
UT WOS:000571229800006
PM 32829149
OA Green Published
DA 2021-01-01
ER

PT J
AU Khalifa, I
   Nawaz, A
   Sobhy, R
   Althwab, SA
   Barakat, H
AF Khalifa, Ibrahim
   Nawaz, Asad
   Sobhy, Remah
   Althwab, Sami A.
   Barakat, Hassan
TI Polyacylated anthocyanins constructively network with catalytic dyad
   residues of 3CL(pro) of 2019-nCoV than monomeric anthocyanins: A
   structural-relationship activity study with 10 anthocyanins using
   in-silico approaches
SO JOURNAL OF MOLECULAR GRAPHICS & MODELLING
LA English
DT Article
DE COVID-19; Anthocyanins; Protease; Molecular docking;
   Structural-relationship effects
ID BINDING; POLYPHENOLS; INHIBITION
AB Coronavirus epidemic 2019 (COVID-19), caused by novel coronavirus (2019-nCoV), is newly increasing worldwide and elevating global health concerns. Similar to SARS-CoV and MERS-CoV, the viral key 3-chymotrypsin-like cysteine protease enzyme (3CL(Pro)), which controls 2019-nCoV duplications and manages its life cycle, could be pointed as a drug discovery target. Herein, we theoretically studied the binding ability of 10 structurally different anthocyanins with the catalytic dyad residues of 3CL(pro) of 2019-nCoV using molecular docking modelling. The results revealed that the polyacylated anthocyanins, including phacelianin, gentiodelphin, cyanodelphin, and tecophilin, were found to authentically bind with the receptor binding site and catalytic dyad (Cys145 and His41) of 2019-nCoV-3CL(pro). Our analyses revealed that the top four hits might serve as potential anti-2019-nCoV leading molecules for further optimization and drug development process to combat COVID-19. This study unleashed that anthocyanins with specific structure could be used as effective anti-COVID-19 natural components. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Khalifa, Ibrahim; Barakat, Hassan] Benha Univ, Fac Agr, Food Technol Dept, Moshtohor 13736, Egypt.
   [Nawaz, Asad] Yangzhou Univ, Coll Agr, Jiangsu Key Lab Crop Genet & Physiol, Key Lab Plant Funct Genom,Minist Educ, Yangzhou 225009, Jiangsu, Peoples R China.
   [Sobhy, Remah] Huazhong Agr Univ, Coll Food Sci & Technol, Wuhan 430070, Peoples R China.
   [Sobhy, Remah] Benha Univ, Fac Agr, Dept Biochem, Moshtohor 13736, Egypt.
   [Althwab, Sami A.; Barakat, Hassan] Qassim Univ, Coll Agr & Vet Med, Food Sci & Human Nutr Dept, Buraydah, Saudi Arabia.
RP Khalifa, I (corresponding author), Benha Univ, Fac Agr, Food Technol Dept, Moshtohor 13736, Egypt.
EM ibrahiem.khalifa@fagr.bu.edu.eg; thaoab@qu.edu.sa; haa.mohamed@qu.edu.sa
OI Barakat, Hassan/0000-0002-8358-4835
CR Cao YC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101647
   Chen LL, 2006, BIOORGAN MED CHEM, V14, P8295, DOI 10.1016/j.bmc.2006.09.014
   Desai AG, 2008, CURR DRUG METAB, V9, P581, DOI 10.2174/138920008785821657
   Dutta K, 2018, J HAZARD MATER, V357, P187, DOI 10.1016/j.jhazmat.2018.05.024
   Gerardi C, 2016, J FUNCT FOODS, V27, P537, DOI 10.1016/j.jff.2016.09.024
   Hayashi K, 2003, FOOD SCI TECHNOL RES, V9, P242, DOI 10.3136/fstr.9.242
   Ji W, 2020, J MED VIROL, V22, P1
   Jia YY, 2019, FOOD BIOPROD PROCESS, V118, P67, DOI 10.1016/j.fbp.2019.08.018
   Jiang F, 2020, J GEN INTERN MED, V35, P1545, DOI 10.1007/s11606-020-05762-w
   Jing P, 2008, J AGR FOOD CHEM, V56, P9391, DOI 10.1021/jf8005917
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI 10.20944/preprints202003.0226.v1
   Khalifa I., 2020, EFFECTS 10 STRUCTURA
   Khalifa I, 2020, BIOORG CHEM, V96, DOI 10.1016/j.bioorg.2020.103615
   Khalifa I, 2019, INT J BIOL MACROMOL, V123, P10, DOI 10.1016/j.ijbiomac.2018.11.016
   Khalifa I, 2018, INT J BIOL MACROMOL, V119, P116, DOI 10.1016/j.ijbiomac.2018.07.117
   Khalifa I, 2018, J FUNCT FOODS, V40, P28, DOI 10.1016/j.jff.2017.10.041
   Khalifa I, 2016, J FOOD QUALITY, V39, P504, DOI 10.1111/jfq.12213
   Khan W, 2017, ADVAN LIFE SCI, V4, P113
   Khoo HE, 2017, FOOD NUTR RES, V61, P1, DOI 10.1080/16546628.2017.1361779
   Kim S., 2020, INSUFFICIENT SENSITI
   Lin BW, 2017, BRIT J PHARMACOL, V174, P1226, DOI 10.1111/bph.13627
   Macchiagodena M., 2020, INHIBITION MAIN PROT
   Moorthy V, 2020, B WORLD HEALTH ORGAN, V98, P150, DOI 10.2471/BLT.20.251561
   Pillaiyar T, 2020, DRUG DISCOV TODAY, V25, P668, DOI 10.1016/j.drudis.2020.01.015
   Pour PM, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01207
   Rut W., 2020, SUBSTRATE SPECIFICIT
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Swaminathan K, 2013, ANAL BIOANAL CHEM, V405, P6563, DOI 10.1007/s00216-013-7068-x
   Trouillas P, 2016, CHEM REV, V116, P4937, DOI 10.1021/acs.chemrev.5b00507
   Wang L, 2015, J AM CHEM SOC, V137, P2695, DOI 10.1021/ja512751q
   Xie YX, 2013, CURR DRUG METAB, V14, P414, DOI 10.2174/1389200211314040005
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Yi L, 2010, FEBS LETT, V584, P583, DOI 10.1016/j.febslet.2009.12.006
   Zhang L., 2020, PREPRINT
   Zhu W, 2018, J BIOMOL STRUCT DYN, V36, P2862, DOI 10.1080/07391102.2017.1369163
NR 36
TC 0
Z9 0
U1 10
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1093-3263
EI 1873-4243
J9 J MOL GRAPH MODEL
JI J. Mol. Graph.
PD NOV
PY 2020
VL 100
AR 107690
DI 10.1016/j.jmgm.2020.107690
PG 11
WC Biochemical Research Methods; Biochemistry & Molecular Biology; Computer
   Science, Interdisciplinary Applications; Crystallography; Mathematical &
   Computational Biology
SC Biochemistry & Molecular Biology; Computer Science; Crystallography;
   Mathematical & Computational Biology
GA NR0AR
UT WOS:000571227600001
PM 32745925
OA Green Published
DA 2021-01-01
ER

PT J
AU Kato, K
   Honma, T
   Fukuzawa, K
AF Kato, Koichiro
   Honma, Teruki
   Fukuzawa, Kaori
TI Intermolecular interaction among Remdesivir, RNA and RNA-dependent RNA
   polymerase of SARS-CoV-2 analyzed by fragment molecular orbital
   calculation
SO JOURNAL OF MOLECULAR GRAPHICS & MODELLING
LA English
DT Article
DE Coronaviruses; SARS-CoV-2; RNA dependent RNA polymerase; Remdesivir;
   Template-primer RNA; Interaction analysis; Fragment molecular orbital
   method
ID DNA; BINDING
AB COVID-19, a disease caused by a new strain of coronavirus (SARS-CoV-2) originating from Wuhan, China, has now spread around the world, triggering a global pandemic, leaving the public eagerly awaiting the development of a specific medicine and vaccine. In response, aggressive efforts are underway around the world to overcome COVID-19. In this study, referencing the data published on the Protein Data Bank (PDB ID: 7BV2) on April 22, we conducted a detailed analysis of the interaction between the complex structures of the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 and Remdesivir, an antiviral drug, from the quantum chemical perspective based on the fragment molecular orbital (FMO) method. In addition to the hydrogen bonding and intra-strand stacking between complementary strands as seen in normal base pairs, Remdesivir bound to the terminus of an primer-RNA strand was further stabilized by diagonal p-p stacking with the -1A' base of the complementary strand and an additional hydrogen bond with an intra-strand base, due to the effect of chemically modified functional group. Moreover, stable OH/p interaction is also formed with Thr687 of the RdRp. We quantitatively revealed the exhaustive interaction within the complex among Remdesivir, template-primer-RNA, RdRp and co-factors, and published the results in the FMODB database. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Kato, Koichiro] Kyushu Univ, Grad Sch Engn, Dept Appl Chem, Nishi Ku, 744 Motooka, Fukuoka 8190395, Japan.
   [Kato, Koichiro] Kyushu Univ, Ctr Mol Syst CMS, Nishi Ku, 744 Motooka, Fukuoka 8190395, Japan.
   [Honma, Teruki] RIKEN Ctr Biosyst Dynam Res, Tsurumi Ku, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.
   [Fukuzawa, Kaori] Hoshi Univ, Sch Pharm & Pharmaceut Sci, Dept Phys Chem, Shinagawa Ku, 2-4-41 Ebara, Tokyo 1428501, Japan.
   [Fukuzawa, Kaori] Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Aoba Ku, 6-6-11 Aoba, Sendai, Miyagi 9808579, Japan.
RP Fukuzawa, K (corresponding author), Hoshi Univ, Sch Pharm & Pharmaceut Sci, Dept Phys Chem, Shinagawa Ku, 2-4-41 Ebara, Tokyo 1428501, Japan.
EM kato.koichiro.957@m.kyushu-u.ac.jp; honma.teruki@riken.jp;
   k-fukuzawa@hoshi.ac.jp
OI Fukuzawa, Kaori/0000-0001-5357-8250; Kato, Koichiro/0000-0003-4392-8741
FU Platform Project for Supporting Drug Discovery and Life Science Research
   (Basis for Supporting Innovative Drug Discovery and Life Science
   Research (BINDS)) fromAMED [JP20am0101113]; HPCI project [hp200101]
FX The authors thank Dr. Daisuke Takaya, Dr. ChiduruWatanabe and Dr. Kikuko
   Kamisaka at RIKEN for data registration in the FMO database (FMODB). KF
   thank to Prof. Yuji Mochizuki (Rikkyo University) and Prof. Shigenori
   Tanaka (Kobe University) for discussion on FMO calculation of COVID-19.
   This research was partially supported by Platform Project for Supporting
   Drug Discovery and Life Science Research (Basis for Supporting
   Innovative Drug Discovery and Life Science Research (BINDS)) fromAMED
   under GrantNumber JP20am0101113. A part of this research was done in
   activities of the FMO drug design consortium (FMODD), and the results
   were obtained using Oakforest-PACS supercomputer system in the HPCI
   project (hp200101). The authors thank Crimson Interactive Pvt. Ltd.
   (Ulatus) for their assistance in manuscript translation.
CR [Anonymous], 2018, MOL OP ENV MOE
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   D.E. Shaw Research, 2020, MOL DYN SIM REL SARS
   Dong E., 2020, LANCET INFECT DIS, DOI [10.1016/S1473-3099(20)30120-30121., DOI 10.1016/S1473-3099(20)30120-1_MEDLINE]
   Fedorov DG, 2012, PHYS CHEM CHEM PHYS, V14, P7562, DOI 10.1039/c2cp23784a
   Fedorov DG, 2007, J COMPUT CHEM, V28, P222, DOI 10.1002/jcc.20496
   Fukuzawa K, 2015, COMPUT THEOR CHEM, V1054, P29, DOI 10.1016/j.comptc.2014.11.020
   Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Hatada R, 2020, J CHEM INF MODEL, V60, P3593, DOI 10.1021/acs.jcim.0c00283
   Heifetz A, 2018, METHODS MOL BIOL, V1705, P375, DOI 10.1007/978-1-4939-7465-8_19
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kitaura K, 1999, CHEM PHYS LETT, V313, P701, DOI 10.1016/S0009-2614(99)00874-X
   Koiwai K, 2020, J BIOL CHEM, V295, P7154, DOI 10.1074/jbc.RA119.011463
   Komeiji Y, 2018, B CHEM SOC JPN, V91, P1596, DOI 10.1246/bcsj.20180150
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Lim H., NAT RES, DOI [10.21203/rs.3.rs-17218/v1., DOI 10.21203/RS.3.RS-17218/V1]
   Liu S., EVALUATION 19 ANTIVI, DOI [10.1101/2020.04.29.067983, DOI 10.1101/2020.04.29.067983]
   Lu CC, 2020, J CHIN MED ASSOC, V83, P534, DOI 10.1097/JCMA.0000000000000318
   Lwasaki S, 2019, MOL CELL, V73, P738, DOI 10.1016/j.molcel.2018.11.026
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Mochizuki Y, 2004, THEOR CHEM ACC, V112, P442, DOI 10.1007/s00214-004-0602-3
   Mochizuki Y, 2004, CHEM PHYS LETT, V396, P473, DOI 10.1016/j.cplett.2004.08.082
   Nutho B, 2020, BIOCHEMISTRY-US, V59, P1769, DOI 10.1021/acs.biochem.0c00160
   Ohashi H., BIORXIV PREPRINT, DOI [10.1101/2020.04.14.039925, DOI 10.1101/2020.04.14.039925DOI]
   Rossberg A, 2019, CHEM COMMUN, V55, P2015, DOI 10.1039/c8cc09329f
   Sheng YL, 2018, COMPUT STRUCT BIOTEC, V16, P421, DOI 10.1016/j.csbj.2018.10.003
   Tanaka S, 2014, PHYS CHEM CHEM PHYS, V16, P10310, DOI 10.1039/c4cp00316k
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   te Velthuis AJW, 2014, CELL MOL LIFE SCI, V71, P4403, DOI 10.1007/s00018-014-1695-z
   Venkataraman S, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020076
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Watanabe C, 2019, CHEM-BIO INFORM J, V19, P5, DOI 10.1273/cbij.19.5
   Watanabe C, 2017, J CHEM INF MODEL, V57, P2996, DOI 10.1021/acs.jcim.7b00110
   Yamada H, 2017, COMPUT THEOR CHEM, V1101, P46, DOI 10.1016/j.comptc.2016.12.008
   Yamamoto N., 2020, BIORXIV, DOI [DOI 10.1101/2020.04.06.026476, 10.1101/ 2020.04.06.026476]
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Ziebuhr J, 2005, CURR TOP MICROBIOL, V287, P57, DOI 10.1007/3-540-26765-4_3
NR 41
TC 0
Z9 0
U1 11
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1093-3263
EI 1873-4243
J9 J MOL GRAPH MODEL
JI J. Mol. Graph.
PD NOV
PY 2020
VL 100
AR 107695
DI 10.1016/j.jmgm.2020.107695
PG 5
WC Biochemical Research Methods; Biochemistry & Molecular Biology; Computer
   Science, Interdisciplinary Applications; Crystallography; Mathematical &
   Computational Biology
SC Biochemistry & Molecular Biology; Computer Science; Crystallography;
   Mathematical & Computational Biology
GA NO9JZ
UT WOS:000569803400004
PM 32702590
OA Green Published
DA 2021-01-01
ER

PT J
AU Terali, K
   Baddal, B
   Gulcan, HO
AF Terali, Kerem
   Baddal, Buket
   Gulcan, Hayrettin Ozan
TI Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic:
   Insights from a molecular mechanics-assisted structure-based virtual
   screening experiment
SO JOURNAL OF MOLECULAR GRAPHICS & MODELLING
LA English
DT Article
DE SARS-CoV-2; COVID-19; ACE2; Drug repositioning; Entry inhibitor
ID ANGIOTENSIN-CONVERTING ENZYME; WEB SERVER; CORONAVIRUS; PROTEIN; HOMOLOG
AB Angiotensin-converting enzyme 2 (ACE2) is a membrane-bound zinc metallopeptidase that generates the vasodilatory peptide angiotensin 1-7 and thus performs a protective role in heart disease. It is considered an important therapeutic target in controlling the COVID-19 outbreak, since SARS-CoV-2 enters permissive cells via an ACE2-mediated mechanism. The present in silico study attempted to repurpose existing drugs for use as prospective viral-entry inhibitors targeting human ACE2. Initially, a clinically approved drug library of 7,173 ligands was screened against the receptor using molecular docking, followed by energy minimization and rescoring of docked ligands. Finally, potential binders were inspected to ensure molecules with different scaffolds were engaged in favorable contacts with both the metal cofactor and the critical residues lining the receptor's active site. The results of the calculations suggest that lividomycin, burixafor, quisinostat, fluprofylline, pemetrexed, spirofylline, edotecarin, and diniprofylline emerge as promising repositionable drug candidates for stabilizing the closed (substrate/inhibitor-bound) conformation of ACE2, thereby shifting the relative positions of the receptor's critical exterior residues recognized by SARS-CoV-2. This study is among the rare ones in the relevant scientific literature to search for potential ACE2 inhibitors. In practical terms, the drugs, unmodified as they are, may be introduced into the therapeutic armamentarium of the ongoing fight against COVID-19 now, or their scaffolds may serve as rich skeletons for designing novel ACE2 inhibitors in the near future. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Terali, Kerem] Near East Univ, Dept Med Biochem, Near East Blvd, CY-99138 Nicosia, Cyprus.
   [Terali, Kerem] Near East Univ, DESAM Inst, Bioinformat & Computat Biol Res Grp, CY-99138 Nicosia, Cyprus.
   [Baddal, Buket] Near East Univ, Dept Med Microbiol & Clin Microbiol, CY-99138 Nicosia, Cyprus.
   [Baddal, Buket] Near East Univ, DESAM Inst, Microbial Pathogenesis Res Grp, CY-99138 Nicosia, Cyprus.
   [Gulcan, Hayrettin Ozan] Eastern Mediterranean Univ, Dept Pharmaceut Chem, CY-99628 Gazimagusa, Cyprus.
RP Terali, K (corresponding author), Near East Univ, Dept Med Biochem, Near East Blvd, CY-99138 Nicosia, Cyprus.
EM kerem.terali@neu.edu.tr
RI Terali, Kerem/Q-3270-2016
OI Terali, Kerem/0000-0002-9964-6383; Gulcan, Hayrettin/0000-0002-9503-5841
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   [Anonymous], COR DIS COVID 19 SIT
   Berman H.M., 2000, NUCLEIC ACIDS RES, DOI [10.1093/nar/28.1.235, DOI 10.1093/NAR/28.1.235.WWW.RCSB.ORG]
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Fourcaud G, 1970, Therapeutique, V46, P307
   Guy JL, 2005, FEBS J, V272, P3512, DOI 10.1111/j.1742-4658.2005.04756.x
   Heurich A, 2014, J VIROL, V88, P1293, DOI 10.1128/JVI.02202-13
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huentelman MJ, 2004, HYPERTENSION, V44, P903, DOI 10.1161/01.HYP.0000146120.29648.36
   Hulswit RJG, 2016, ADV VIRUS RES, V96, P29, DOI 10.1016/bs.aivir.2016.08.004
   Jin L, 2017, MOL REPROD DEV, V84, P340, DOI 10.1002/mrd.22787
   Kawai K, 2012, EUR J MED CHEM, V51, P271, DOI 10.1016/j.ejmech.2012.02.028
   Korstanje C, 2000, INT J CLIN PRACT, P2
   Kuba K, 2006, CURR OPIN PHARMACOL, V6, P271, DOI 10.1016/j.coph.2006.03.001
   Labbe CM, 2017, NUCLEIC ACIDS RES, V45, pW350, DOI 10.1093/nar/gkx397
   Labbe CM, 2015, NUCLEIC ACIDS RES, V43, pW448, DOI 10.1093/nar/gkv306
   Lagarde N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184648
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Paul M, 2006, PHYSIOL REV, V86, P747, DOI 10.1152/physrev.00036.2005
   Pencheva T, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-438
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Putignano V, 2018, NUCLEIC ACIDS RES, V46, pD459, DOI 10.1093/nar/gkx989
   Rice GI, 2004, BIOCHEM J, V383, P45, DOI 10.1042/BJ20040634
   Rollins KD, 2005, CLIN THER, V27, P1343, DOI 10.1016/j.clinthera.2005.09.010
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Saif M Wasif, 2005, Clin Colorectal Cancer, V5, P27, DOI 10.3816/CCC.2005.n.014
   Salentin S, 2015, NUCLEIC ACIDS RES, V43, pW443, DOI 10.1093/nar/gkv315
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Towler P, 2004, J BIOL CHEM, V279, P17996, DOI 10.1074/jbc.M311191200
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang K, 2020, SARS COV 2 INVADES H, V3, P14, DOI DOI 10.1101/2020.03.14.988345
   WHO, 2020, DIR GEN OP REM MED B
   World Health Organization, SOL CLIN TRIAL COVID
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhang H, 2001, J BIOL CHEM, V276, P17132, DOI 10.1074/jbc.M006723200
   Zhang H, 2020, DIGESTIVE SYSTEM IS, DOI [10.1101/2020.01.30.927806, DOI 10.1101/2020.01.30.927806]
   Zhao YX, 2020, SCI CHINA CHEM, DOI 10.1007/s11426-020-9864-7
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 45
TC 0
Z9 0
U1 15
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1093-3263
EI 1873-4243
J9 J MOL GRAPH MODEL
JI J. Mol. Graph.
PD NOV
PY 2020
VL 100
AR 107697
DI 10.1016/j.jmgm.2020.107697
PG 10
WC Biochemical Research Methods; Biochemistry & Molecular Biology; Computer
   Science, Interdisciplinary Applications; Crystallography; Mathematical &
   Computational Biology
SC Biochemistry & Molecular Biology; Computer Science; Crystallography;
   Mathematical & Computational Biology
GA NO9JZ
UT WOS:000569803400003
PM 32739642
OA Green Published
DA 2021-01-01
ER

PT J
AU Gil-Badenes, J
   Valero, R
   Valenti, M
   Macau, E
   Bertran, MJ
   Claver, G
   Bioque, M
   Baeza, I
   Salvado, AB
   Mencia, ML
   Pacchiarotti, I
   Bernardo, M
   Vieta, E
AF Gil-Badenes, Joaquin
   Valero, Ricard
   Valenti, Marc
   Macau, Elisabet
   Jesus Bertran, Maria
   Claver, Gerard
   Bioque, Miquel
   Baeza, Inmaculada
   Bastidas Salvado, Anna
   Lombrana Mencia, Maria
   Pacchiarotti, Isabella
   Bernardo, Miquel
   Vieta, Eduard
TI Electroconvulsive therapy protocol adaptation during the COVID-19
   pandemic
SO JOURNAL OF AFFECTIVE DISORDERS
LA English
DT Article
DE Coronavirus; COVID-19; SARS-CoV-2; Electroconvulsive therapy; ECT;
   Protocol
ID MENTAL-HEALTH; SCHIZOPHRENIA; CARE
AB Background: During the COVID-19 pandemic, electroconvulsive therapy units have had to confront challenges such as the infectious hazard due to aerosol-generating ventilation, or the lack of staff and material resources. Our objective was to elaborate a protocol to make ECT during the COVID-19 pandemic a safer procedure for patients and professionals.
   Methods: A multidisciplinary workgroup (including mental health, anesthesia, preventive medicine, and occupational risk professionals) was formed in the Hospital Clinic de Barcelona, in March 2020. A core group conducted a review of the scientific literature and healthcare organizations' guidelines and wrote a protocol draft. Then, a discussion with the workgroup was made until consensus was reached. The protocol has been continuously updated. Discussions were made by group e-mailing and video conferencing.
   Results: The protocol includes the following main areas: (1) ECT unit's structural and functional considerations; (2) SARS-CoV-2 screening protocol; (3) ECT clinical practice adaptation (personal protective equipment, airway management, recovery room, and maintenance of the facilities); (4) management of COVID-19 cases; and (5) protocol assessment.
   Limitations: The literature review was not systematic; the consensus was not based on a structured methodology. For other ECT units, local advisories may not be valid, and resource shortages (such as anesthetist availability, or the lack of respirators and PCR tests) may impede or prevent their implementation.
   Conclusions: During the COVID-19 pandemic, ECT should continue to be advocated as an essential medical procedure. It is recommended that each ECT unit develop its own protocol. This proposal may be used as a reference.
C1 [Gil-Badenes, Joaquin; Valenti, Marc; Pacchiarotti, Isabella; Vieta, Eduard] Hosp Clin Barcelona, Bipolar & Depress Disorders Unit, Catalonia, Spain.
   [Gil-Badenes, Joaquin; Bioque, Miquel; Bernardo, Miquel] Hosp Clin Barcelona, Barcelona Clin Schizophrenia Unit, Catalonia, Spain.
   [Gil-Badenes, Joaquin; Valenti, Marc; Macau, Elisabet; Bioque, Miquel; Bastidas Salvado, Anna; Lombrana Mencia, Maria; Pacchiarotti, Isabella; Bernardo, Miquel; Vieta, Eduard] Hosp Clin Barcelona, Dept Psychiat & Psychol, Catalonia, Spain.
   [Baeza, Inmaculada] Hosp Clin Barcelona, Dept Child & Adolescent Psychiat & Psychol, Catalonia, Spain.
   [Gil-Badenes, Joaquin; Valenti, Marc; Macau, Elisabet; Bioque, Miquel; Baeza, Inmaculada; Bastidas Salvado, Anna; Lombrana Mencia, Maria; Pacchiarotti, Isabella; Bernardo, Miquel; Vieta, Eduard] Hosp Clin Barcelona, Inst Neurosci ICN, Catalonia, Spain.
   [Valero, Ricard] Hosp Clin Barcelona, Dept Anaesthesiol, Catalonia, Spain.
   [Jesus Bertran, Maria] Hosp Clin Barcelona, Prevent Med & Epidemiol Dept, Catalonia, Spain.
   [Jesus Bertran, Maria] Hosp Clin Barcelona, Clin Inst Med & Dermatol ICMiD, Catalonia, Spain.
   [Claver, Gerard] Hosp Clin Barcelona, Occupat Hlth Serv, Catalonia, Spain.
   [Gil-Badenes, Joaquin; Valero, Ricard; Valenti, Marc; Macau, Elisabet; Jesus Bertran, Maria; Claver, Gerard; Bioque, Miquel; Baeza, Inmaculada; Bastidas Salvado, Anna; Lombrana Mencia, Maria; Pacchiarotti, Isabella; Bernardo, Miquel; Vieta, Eduard] Hosp Clin Barcelona, 170 Villarroel St, Barcelona 08036, Catalonia, Spain.
   [Valero, Ricard; Valenti, Marc; Bioque, Miquel; Baeza, Inmaculada; Bastidas Salvado, Anna; Pacchiarotti, Isabella; Bernardo, Miquel; Vieta, Eduard] Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona 08036, Spain.
   [Valero, Ricard; Valenti, Marc; Bioque, Miquel; Baeza, Inmaculada; Pacchiarotti, Isabella; Bernardo, Miquel; Vieta, Eduard] Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid 28029, Spain.
   [Valero, Ricard; Valenti, Marc; Bioque, Miquel; Baeza, Inmaculada; Bastidas Salvado, Anna; Lombrana Mencia, Maria; Pacchiarotti, Isabella; Bernardo, Miquel; Vieta, Eduard] Univ Barcelona, Barcelona 08036, Catalonia, Spain.
RP Vieta, E (corresponding author), Hosp Clin Barcelona, 170 Villarroel St, Barcelona 08036, Catalonia, Spain.
EM evieta@clinic.cat
RI ; valero, ricard/G-1770-2015
OI Gil-Badenes, Joaquin/0000-0002-6235-0036; valero,
   ricard/0000-0001-7875-9496
FU Spanish Ministry of Science, InnovationSpanish Government
   [PI15/00283-PI18/00805]; Instituto Carlos IIIInstituto de Salud Carlos
   III; CIBERSAM; Comissionat per a Universitats i Recerca del DIUE de la
   Generalitat de Catalunya [SLT006/17/00357]; PERIS 2016-2020 (Departament
   de Salut) CERCA Programme/Generalitat de Catalunya [SLT006/17/00357];
   Instituto de Salud Carlos IIIInstituto de Salud Carlos III [INT19/00021]
FX We thank all medical and management authorities who worked at the
   Hospital Clinic de Barcelona to maintain the operation of the ECT unit
   during the COVID-19 crisis. We thank our patients and families for their
   understanding of the activity reduction and their cooperation in
   applying the protocol. We are most thankful to all government agencies,
   companies, nonprofit organizations, and individuals who donated personal
   protective equipment and extra funding to our hospital during the
   current crisis. EV thanks the support of the Spanish Ministry of
   Science, Innovation (PI15/00283-PI18/00805) and co-financed by the
   Instituto Carlos III integrated into the Plan Nacional de I+D+I
   (cofounded by European Regional Development Fund/European Social Fund)
   ``investing in your future''; CIBERSAM; and the Comissionat per a
   Universitats i Recerca del DIUE de la Generalitat de Catalunya to the
   Bipolar Disorders Group (2017 SGR 1365) and the project SLT006/17/00357,
   from PERIS 2016-2020 (Departament de Salut) CERCA Programme/Generalitat
   de Catalunya. IB thanks the support of Instituto de Salud Carlos III for
   the grant INT19/00021.
CR Aminian A, 2020, ANN SURG, V272, pE27, DOI 10.1097/SLA.0000000000003925
   Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   [Anonymous], 2020, WHO DIR GEN OP REM M
   Arango C, 2020, BIOL PSYCHIAT, V88, pE33, DOI 10.1016/j.biopsych.2020.04.003
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Bazyar J, 2020, PREHOSP DISASTER MED, V35, P305, DOI 10.1017/S1049023X20000291
   Bernardo M., 2018, SOC ESPANOLA PSIQUIA
   Bernardo M, 2015, REV PSIQUIATR SALUD, V8, P51, DOI 10.1016/j.rpsm.2015.01.002
   Blumberger DM, 2017, ACTA PSYCHIAT SCAND, V136, P583, DOI 10.1111/acps.12815
   Colbert S., 2020, J ECT, DOI [10.1097/YCT.0000000000000690, DOI 10.1097/YCT.0000000000000690]
   Cook TM, 2020, ANAESTHESIA, V75, P785, DOI 10.1111/anae.15054
   Druss BG, 2020, JAMA PSYCHIAT, V77, P891, DOI 10.1001/jamapsychiatry.2020.0894
   Espinoza Randall T, 2020, J ECT, DOI 10.1097/YCT.0000000000000689
   Fernandez-Candil J, 2020, REV PSIQUIATR SALUD, V13, P36, DOI 10.1016/j.rpsm.2018.05.002
   Flexman AM, 2020, J NEUROSURG ANESTH, V32, P202, DOI 10.1097/ANA.0000000000000691
   Garriga M, 2020, ACTA PSYCHIAT SCAND, V141, P479, DOI 10.1111/acps.13173
   Gunnell D, 2020, LANCET PSYCHIAT, V7, P468, DOI 10.1016/S2215-0366(20)30171-1
   JONES J, 1995, BRIT MED J, V311, P376, DOI 10.1136/bmj.311.7001.376
   Lally J, 2016, SCHIZOPHR RES, V171, P215, DOI 10.1016/j.schres.2016.01.024
   Levy-Rueff M, 2010, PSYCHIAT RES, V175, P280, DOI 10.1016/j.psychres.2008.10.012
   Mahase E, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1071
   Mizumoto K, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.10.2000180
   Momen NC, 2020, NEW ENGL J MED, V382, P1721, DOI 10.1056/NEJMoa1915784
   Nishiura H, 2020, INT J INFECT DIS, V94, P154, DOI 10.1016/j.ijid.2020.03.020
   Pfefferbaum B, 2020, NEW ENGL J MED, V383, P510, DOI 10.1056/NEJMp2008017
   Reger MA, 2020, JAMA PSYCHIAT, V77, P1093, DOI 10.1001/jamapsychiatry.2020.1060
   Samalin L, 2020, J AFFECT DISORDERS, V264, P318, DOI 10.1016/j.jad.2020.01.004
   SEDAR, 2020, REC MAN VIA AER PAC
   Sienaert P, 2020, AM J GERIAT PSYCHIAT, V28, P772, DOI 10.1016/j.jagp.2020.04.013
   Sub-direccio General de Vigilancia i Resposta a Emergencies de Salut Publica Generalitat de Catalunya, 2020, PROC ACT ENFR CAS IN
   Tor Phern Chern, 2020, J ECT, DOI 10.1097/YCT.0000000000000690
   Vieta E, 2020, REV PSIQUIATR SALUD, V13, P105, DOI 10.1016/j.rpsm.2020.04.004
   Wilder-Smith A, 2020, LANCET INFECT DIS, V20, pE102, DOI 10.1016/S1473-3099(20)30129-8
   Xiang Y., 2020, JAMA PSYCHIAT, DOI [10.1001/jamapsychiatry.2020.105, DOI 10.1001/JAMAPSYCHIATRY.2020.105]
   Xiang YT, 2020, INT J BIOL SCI, V16, P1741, DOI 10.7150/ijbs.45072
   Zheng W, 2020, J AFFECT DISORDERS, V269, P201, DOI 10.1016/j.jad.2020.03.041
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 37
TC 0
Z9 0
U1 26
U2 26
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0165-0327
EI 1573-2517
J9 J AFFECT DISORDERS
JI J. Affect. Disord.
PD NOV 1
PY 2020
VL 276
BP 241
EP 248
DI 10.1016/j.jad.2020.06.051
PG 8
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA NJ2MF
UT WOS:000565879800028
PM 32697705
OA Green Published
DA 2021-01-01
ER

PT J
AU Cameron, EE
   Joyce, KM
   Delaquis, CP
   Reynolds, K
   Protudjer, JLP
   Roos, LE
AF Cameron, Emily E.
   Joyce, Kayla M.
   Delaquis, Chantal P.
   Reynolds, Kristin
   Protudjer, Jennifer L. P.
   Roos, Leslie E.
TI Maternal psychological distress & mental health service use during the
   COVID-19 pandemic
SO JOURNAL OF AFFECTIVE DISORDERS
LA English
DT Article
DE Depression; Anxiety; Maternal; Mental health services; COVID-19
ID DIALECTICAL BEHAVIOR-THERAPY; MARITAL CONFLICT; CHILD OUTCOMES;
   DEPRESSION; ANXIETY; DISORDER; ASSOCIATIONS; STRESS; SCALE;
   PSYCHOPATHOLOGY
AB Background: Mental health problems are increasingly recognized as a significant and concerning secondary effect of the COVID-19 pandemic. Research on previous epidemics/pandemics suggest that families, particularly mothers, may be at increased risk, but this population has yet to be examined. The current study (1) described prevalence rates of maternal depressive and anxiety symptoms from an online convenience sample during the COVID-19 pandemic, (2) identified risk and protective factors for elevated symptoms, and (3) described current mental health service use and barriers.
   Methods: Participants (N = 641) were mothers of children age 0-8 years, including expectant mothers. Mothers completed an online survey assessing mental health, sociodemographic information, and COVID-19-related variables.
   Results: Clinically-relevant depression was indicated in 33.16%, 42.55%, and 43.37% of mothers of children age 0-18 months, 18 months to 4 years, and 5 to 8 years, respectively. Prevalence of anxiety was 36.27%, 32.62%, and 29.59% for mothers across age groups, respectively. Binary logistic regressions indicated significant associations between risk factors and depression/anxiety across child age groups.
   Limitations: Cross-sectional data was used to describe maternal mental health problems during COVID-19 limiting the ability to make inferences about the long-term impact of maternal depression and anxiety on family well-being.
   Conclusions: Maternal depression and anxiety appear to be elevated in the context of COVID-19 compared to previously reported population norms. Identified risk factors for depression and anxiety across different child age ranges can inform targeted early intervention strategies to prevent long-term impacts of the COVID-19 pandemic on family well-being and child development.
C1 [Cameron, Emily E.] Univ Calgary, Dept Psychol, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.
   [Cameron, Emily E.] Univ Manitoba, Dept Clin Hlth Psychol, Winnipeg, MB, Canada.
   [Joyce, Kayla M.; Delaquis, Chantal P.; Reynolds, Kristin; Roos, Leslie E.] Univ Manitoba, Dept Psychol, Winnipeg, MB, Canada.
   [Protudjer, Jennifer L. P.; Roos, Leslie E.] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB, Canada.
   [Protudjer, Jennifer L. P.; Roos, Leslie E.] Childrens Hosp, Res Inst Manitoba, Winnipeg, MB, Canada.
   [Protudjer, Jennifer L. P.] George & Fay Yee Ctr Healthcare Innovat, Winnipeg, MB, Canada.
   [Protudjer, Jennifer L. P.] Karolinska Inst, Inst Environm Med, Stockholm, Sweden.
   [Protudjer, Jennifer L. P.] Univ Manitoba, Dept Food & Human Nutr Sci, Winnipeg, MB, Canada.
RP Cameron, EE (corresponding author), Univ Calgary, Dept Psychol, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.
EM camerone@ucalgary.ca
OI Protudjer, Jennifer/0000-0002-3888-8688; Roos,
   Leslie/0000-0001-7083-4017
FU Children's Hospital Research Institute of Manitoba; University of
   Manitoba; Social Science and Humanities Research CouncilSocial Sciences
   and Humanities Research Council of Canada (SSHRC)
FX The funding sources mentioned in the Acknowledgements contributed to
   participant remuneration and resources necessary for study development.
   Start-up funds, Children's Hospital Research Institute of Manitoba,
   University of Manitoba, and Social Science and Humanities Research
   Council provided funding for student involvement.
CR American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   Barlow D.H., 2017, UNIFIED PROTOCOL TRA, DOI [10.1002/wps.20748, DOI 10.1002/WPS.20748]
   Braunack-Mayer A, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-344
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   BUSBY DM, 1995, J MARITAL FAM THER, V21, P289, DOI 10.1111/j.1752-0606.1995.tb00163.x
   Clavarino AM, 2010, J ATTEN DISORD, V13, P658, DOI 10.1177/1087054709347203
   Cluver L, 2020, LANCET, V395, pE64, DOI 10.1016/S0140-6736(20)30736-4
   COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782
   Dennis CL, 2017, BRIT J PSYCHIAT, V210, P315, DOI 10.1192/bjp.bp.116.187179
   Eaton W. W., 2004, USE PSYCHOL TESTING, P363, DOI DOI 10.4324/9781410610614
   Ekers D, 2008, PSYCHOL MED, V38, P611, DOI 10.1017/S0033291707001614
   El-Sheikh M, 2006, J FAM PSYCHOL, V20, P30, DOI 10.1037/0893-3200.20.1.30
   Essex MJ, 2003, J AM ACAD CHILD PSY, V42, P728, DOI 10.1097/01.CHI.0000046849.56865.1D
   Farchione TJ, 2012, BEHAV THER, V43, P666, DOI 10.1016/j.beth.2012.01.001
   Gelaye B, 2016, LANCET PSYCHIAT, V3, P973, DOI 10.1016/S2215-0366(16)30284-X
   Goodman SH, 2011, CLIN CHILD FAM PSYCH, V14, P1, DOI 10.1007/s10567-010-0080-1
   Gotlib IH, 2008, BIOL PSYCHIAT, V63, P847, DOI 10.1016/j.biopsych.2007.10.008
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Hawryluck L, 2004, EMERG INFECT DIS, V10, P1206, DOI 10.3201/eid1007.030703
   Hofmann SG, 2008, J CLIN PSYCHIAT, V69, P621, DOI 10.4088/jcp.v69n0415
   Holt S, 2008, CHILD ABUSE NEGLECT, V32, P797, DOI 10.1016/j.chiabu.2008.02.004
   Jeong H, 2016, EPIDEMIOL HEALTH, V38, DOI 10.4178/epih.e2016048
   Lau JTF, 2006, J INFECTION, V53, P114, DOI 10.1016/j.jinf.2005.10.019
   Lebel C., 2020, ELEVATED DEPRESSION, DOI [10.31234/osf.io/gdhkt, DOI 10.31234/OSF.IO/GDHKT]
   Leis JA, 2014, J ABNORM CHILD PSYCH, V42, P161, DOI 10.1007/s10802-013-9766-4
   Letourneau NL, 2013, J PEDIATR NURS, V28, P223, DOI 10.1016/j.pedn.2012.07.014
   LINEHAN MM, 1987, B MENNINGER CLIN, V51, P261
   Martin CG, 2017, COGN BEHAV PRACT, V24, P405, DOI 10.1016/j.cbpra.2016.08.002
   Martins C, 2000, J CHILD PSYCHOL PSYC, V41, P737, DOI 10.1111/1469-7610.00661
   Mihashi M, 2009, HEALTH PSYCHOL, V28, P91, DOI 10.1037/a0013674
   Nestler EJ, 2014, JAMA PSYCHIAT, V71, P454, DOI 10.1001/jamapsychiatry.2013.4291
   Patel V, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001448
   Perkins Suzanne C, 2013, Innov Clin Neurosci, V10, P10
   Pfefferbaum B, 2020, NEW ENGL J MED, V383, P510, DOI 10.1056/NEJMp2008017
   Public Safety Canada, 2009, NAT STRAT CRIT INFR
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Rahman A, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001442
   Ritschel LA, 2015, AM J PSYCHOTHER, V69, P111, DOI 10.1176/appi.psychotherapy.2015.69.2.111
   Sanchez-Villegas A, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-43
   SEXTON MB, 2016, J DEPRESS ANXIETY, V5, DOI DOI 10.4172/2167-1044
   Shonkoff JP, 2013, DEV PSYCHOPATHOL, V25, P1635, DOI 10.1017/S0954579413000813
   Somerville S, 2014, ARCH WOMEN MENT HLTH, V17, P443, DOI 10.1007/s00737-014-0425-8
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092
   Sprang G, 2013, DISASTER MED PUBLIC, V7, P105, DOI 10.1017/dmp.2013.22
   Statistics Canada, 2020, EMPL INS CLAIMS REC
   Vernon-Feagans L, 2012, EARLY CHILD RES Q, V27, P339, DOI 10.1016/j.ecresq.2011.11.001
   Vostanis P, 2006, SOC PSYCH PSYCH EPID, V41, P509, DOI 10.1007/s00127-006-0061-3
   Wachs TD, 2009, CHILD DEV PERSPECT, V3, P51, DOI 10.1111/j.1750-8606.2008.00077.x
   Williams C, 2016, INFANT MENT HEALTH J, V37, P259, DOI 10.1002/imhj.21564
   Wolford SN, 2019, AM J ORTHOPSYCHIAT, V89, P181, DOI 10.1037/ort0000365
   Woody CA, 2017, J AFFECT DISORDERS, V219, P86, DOI 10.1016/j.jad.2017.05.003
   World Health Organization, 2020, 1 WHO
   Yim IS, 2015, ANNU REV CLIN PSYCHO, V11, P99, DOI 10.1146/annurev-clinpsy-101414-020426
   Zalewski M, 2018, CURR OPIN PSYCHOL, V21, P122, DOI 10.1016/j.copsyc.2018.02.013
   ZIMET GD, 1988, J PERS ASSESS, V52, P30, DOI 10.1207/s15327752jpa5201_2
NR 55
TC 6
Z9 6
U1 24
U2 24
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0165-0327
EI 1573-2517
J9 J AFFECT DISORDERS
JI J. Affect. Disord.
PD NOV 1
PY 2020
VL 276
BP 765
EP 774
DI 10.1016/j.jad.2020.07.081
PG 10
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA NJ2MU
UT WOS:000565881500038
PM 32736186
OA Green Published
DA 2021-01-01
ER

PT J
AU Ray, I
AF Ray, Isha
TI Viewpoint - Handwashing and COVID-19: Simple, right there ... ?
SO WORLD DEVELOPMENT
LA English
DT Article
ID WATER; HEALTH
AB COVID-19 is a disease with no proven pharmaceutical intervention and no proven vaccine. In such circumstances, prevention is all we have. The role of handwashing in the prevention of communicable diseases has been known for over a century, yet it remains severely neglected as a public health investment, to be periodically re-discovered during pandemic-scale infections. Over 26% of the global population has no access to a handwashing station in the home; for many low-income countries this proportion rises to over 50%. In other instances, the water is unaffordable or the supply has been shut off on account of unpaid bills. But when there is no water in the home or yard, or no mechanism for delivering enough water, good hand-washing is extremely difficult. Well before COVID-19, global cost-benefit analyses of water and sanitation investments, with benefits measured in time-savings as well as health, showed significant net benefits in all sub-regions of the developing world. This Viewpoint paper argues that, in the current crisis and its aftermath, it is imperative for governments and donors to prioritize and generously fund affordable, reliable, and accessible water services in underserved regions of the world. More than ever before, this is a foundational investment for health, dignity and development. (c) 2020 Elsevier Ltd. All rights reserved.
C1 [Ray, Isha] Univ Calif Berkeley, Energy & Resources Grp, 310 Barrows Hall 3050, Berkeley, CA 94720 USA.
RP Ray, I (corresponding author), Univ Calif Berkeley, Energy & Resources Grp, 310 Barrows Hall 3050, Berkeley, CA 94720 USA.
EM isharay@berkeley.edu
CR Bakker K, 2014, ANNU REV ENV RESOUR, V39, P469, DOI 10.1146/annurev-environ-070312-132730
   Banerjee S., 2010, 5384 WPS WORLD BANK
   Bartram J, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000367
   Biswas D, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4316-6
   Brauer M, 2020, ENVIRON HEALTH PERSP, V128, DOI 10.1289/EHP7200
   CAIRNCROSS S, 1987, T ROY SOC TROP MED H, V81, P51, DOI 10.1016/0035-9203(87)90280-X
   Contzen N, 2015, SOC SCI MED, V124, P103, DOI 10.1016/j.socscimed.2014.11.006
   Ejemot-Nwadiaro RI, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004265.pub3
   Haffajee F., 2007, 13 MUN SERV PROJ
   Hsan K, 2019, J WATER SANIT HYG DE, V9, P794, DOI 10.2166/washdev.2019.038
   Hutton G, 2012, WHOHSEWSH1201
   Hutton G., 2016, COSTS M 2030 SUST DE
   Kumpel E, 2013, WATER RES, V47, P5176, DOI 10.1016/j.watres.2013.05.058
   Marmot M, 2020, LANCET, V395, P1413, DOI 10.1016/S0140-6736(20)30940-5
   Sabourin C., 2016, J LAW POLICY, V51, P305
   Scott B, 2007, HEALTH POLICY PLANN, V22, P225, DOI 10.1093/heapol/czm016
   Swain M, 2020, J PLAN EDUC RES, DOI 10.1177/0739456X20904431
   Thaler R. H, 2017, NUDGE IMPROVING DECI
   Thompson J., 2001, DRAWERS WATER 2
   Townsend J, 2017, TROP MED INT HEALTH, V22, P74, DOI 10.1111/tmi.12808
   von Schnitzler A, 2008, J S AFR STUD, V34, P899, DOI 10.1080/03057070802456821
   Vujcic J, 2015, J WATER SANIT HYG DE, V5, P574, DOI 10.2166/washdev.2015.009
   WHO/UNICEF, 2017, ANN REPORT
NR 23
TC 0
Z9 0
U1 21
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0305-750X
J9 WORLD DEV
JI World Dev.
PD NOV
PY 2020
VL 135
AR 105086
DI 10.1016/j.worlddev.2020.105086
PG 3
WC Development Studies; Economics
SC Development Studies; Business & Economics
GA NH5LR
UT WOS:000564711800026
PM 32834382
OA Green Published
DA 2021-01-01
ER

PT J
AU Lechner, WV
   Laurene, KR
   Patel, S
   Anderson, M
   Grega, C
   Kenne, DR
AF Lechner, William, V
   Laurene, Kimberly R.
   Patel, Sweta
   Anderson, Megan
   Grega, Chelsea
   Kenne, Deric R.
TI Changes in alcohol use as a function of psychological distress and
   social support following COVID-19 related University closings
SO ADDICTIVE BEHAVIORS
LA English
DT Article
DE COVID-19; Alcohol use; Depressive symptoms; Anxiety symptoms; Social
   support
ID GENERALIZED ANXIETY DISORDER; MENTAL-HEALTH; COLLEGE; DEPRESSION;
   STRESS; DRINKING; DRUGS; RISK
AB Amidst the coronavirus pandemic, universities across the country abruptly closed campuses and transitioned to remote learning. The effects of these unprecedented closures are unknown. The current study examined reported alcohol consumption during the week prior to and after campus closure at a public university in Northeast Ohio. Analysis of data from 1,958 students, who endorsed using alcohol in the past 30 days, demonstrates that alcohol consumption (amount and frequency) increased as time progressed. Those with more symptoms of depression and anxiety reported greater increases in alcohol consumption (assessed via retrospective timeline follow-back) compared to students with fewer symptoms. Furthermore, students with greater perceived social support reported less alcohol consumption. Together, these findings highlight the need for universities to offer services and programs to students that will minimize risk factors and maximize protective factors in order to reduce or prevent alcohol abuse during the coronavirus pandemic.
C1 [Lechner, William, V] Kent State Univ, Dept Psychol Sci, 232 Kent Hall, Kent, OH 44242 USA.
   [Laurene, Kimberly R.; Patel, Sweta; Anderson, Megan; Grega, Chelsea; Kenne, Deric R.] Kent State Univ, Coll Publ Hlth, Ctr Publ Policy & Hlth, Div Mental Hlth & Subst Use, Kent, OH 44242 USA.
RP Lechner, WV (corresponding author), Kent State Univ, Dept Psychol Sci, 232 Kent Hall, Kent, OH 44242 USA.
EM wlechner@kent.edu
CR Aldridge-Gerry AA, 2011, J STUD ALCOHOL DRUGS, V72, P125, DOI 10.15288/jsad.2011.72.125
   Bolton J, 2006, J NERV MENT DIS, V194, P818, DOI 10.1097/01.nmd.0000244481.63148.98
   Bott K, 2005, J STUD ALCOHOL, V66, P246, DOI 10.15288/jsa.2005.66.246
   Briere FN, 2014, COMPR PSYCHIAT, V55, P526, DOI 10.1016/j.comppsych.2013.10.007
   Burns L, 2002, DRUG ALCOHOL DEPEN, V68, P299, DOI 10.1016/S0376-8716(02)00220-X
   CDC, 2020, PREV COVID 19 CAS DA
   Chao RCL, 2011, J COUNS DEV, V89, P338, DOI 10.1002/j.1556-6678.2011.tb00098.x
   Clay JM, 2020, LANCET PUBLIC HEALTH, V5, pE259, DOI 10.1016/S2468-2667(20)30088-8
   Cole DA, 2017, COMPUT HUM BEHAV, V68, P456, DOI 10.1016/j.chb.2016.11.058
   Eysenbach G, 2014, J MED INTERNET RES, V16, P4, DOI 10.2196/jmir.3358
   Geisner IM, 2004, ADDICT BEHAV, V29, P843, DOI 10.1016/j.addbeh.2004.02.024
   Grant BF, 2005, PSYCHOL MED, V35, P1747, DOI 10.1017/S0033291705006069
   Hefner J, 2009, AM J ORTHOPSYCHIAT, V79, P491, DOI 10.1037/a0016918
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Menagi FS, 2008, J RELIG HEALTH, V47, P217, DOI 10.1007/s10943-008-9164-3
   Okoro CA, 2004, AM J PREV MED, V26, P230, DOI 10.1016/j.amepre.2003.10.022
   Paschall MJ, 2011, J STUD ALCOHOL DRUGS, V72, P642, DOI 10.15288/jsad.2011.72.642
   Pauley PM, 2009, COMMUN STUD, V60, P493, DOI 10.1080/10510970903260335
   Riper H, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1691
   Robinson J, 2009, J ANXIETY DISORD, V23, P38, DOI 10.1016/j.janxdis.2008.03.013
   Sobell LC, 1996, DRUG ALCOHOL DEPEN, V42, P49, DOI 10.1016/0376-8716(96)01263-X
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092
   Walsh K, 2014, COMPR PSYCHIAT, V55, P621, DOI 10.1016/j.comppsych.2013.11.016
   Walters ST, 2007, PREV SCI, V8, P83, DOI 10.1007/s11121-006-0059-9
   Wang CCDC, 2008, J COLL COUNS, V11, P101, DOI 10.1002/j.2161-1882.2008.tb00028.x
   ZIMET GD, 1988, J PERS ASSESS, V52, P30, DOI 10.1207/s15327752jpa5201_2
NR 27
TC 3
Z9 3
U1 152
U2 152
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4603
EI 1873-6327
J9 ADDICT BEHAV
JI Addict. Behav.
PD NOV
PY 2020
VL 110
AR 106527
DI 10.1016/j.addbeh.2020.106527
PG 4
WC Psychology, Clinical; Substance Abuse
SC Psychology; Substance Abuse
GA MW0NS
UT WOS:000556744900027
PM 32679435
OA Green Published
DA 2021-01-01
ER

PT J
AU Jin, MM
   Shi, NN
   Wang, M
   Shi, CZ
   Lu, SJ
   Chang, Q
   Sha, S
   Lin, Y
   Chen, YM
   Zhou, H
   Liang, KY
   Huang, XY
   Shi, YX
   Huang, G
AF Jin, Mingming
   Shi, Nannan
   Wang, Meng
   Shi, Chunzi
   Lu, Shengjie
   Chang, Qing
   Sha, Shuang
   Lin, Yun
   Chen, Yingmin
   Zhou, Hui
   Liang, Kaiyi
   Huang, Xuyuan
   Shi, Yuxin
   Huang, Gang
TI CD45: a critical regulator in immune cells to predict severe and
   non-severe COVID-19 patients
SO AGING-US
LA English
DT Article
DE coronavirus disease 2019 (COVID-19); severe acute respiratory syndrome
   coronavirus-2 (SARS-CoV-2); pneumonia; clinical characteristics;
   immunopathology
ID CORONAVIRUS
AB The ongoing outbreak of COVID-19 has been announced by the World Health Organization as a worldwide public health emergency. The aim of this study was to distinguish between severe and non-severe patients in early diagnosis. The results showed that the mortality of COVID-19 patients increased accompanied by age. Host factors CRP, IL-1 beta, hs-CRP, IL-8, and IL-6 levels in severe pneumonia patients were higher than in non-severe patients. CD3, CD8, and CD45 counts were decreased in COVID-19 patients. The results of this study suggest that the K-values of CD45 might be useful in distinguishing between severe and non-severe cases. The cut-off value for CD45 was -94.33. The K-values for CD45 in non-severe case were above the cut-off values, indicating a 100% prediction success rate for severe and non-severe cases following SARS-CoV-2 infection. The results confirmed that immune system dysfunction is a potential cause of mortality following COVID-19 infection, particularly for the elderly. CD45 deficiency dysfunction the naive and memory T lymphocytes which may affects the long-term effectiveness of COVID-19 vaccines. K-values of CD45 might be useful in distinguishing between severe and non-severe cases in the early infection. May be CD45 could increase the diagnostic sensitivity.
C1 [Jin, Mingming; Wang, Meng; Shi, Chunzi; Lu, Shengjie; Huang, Gang] Shanghai Univ Med & Hlth Sci, Shanghai Key Lab Mol Imaging, Shanghai 201318, Peoples R China.
   [Shi, Nannan; Shi, Yuxin] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Radiol, Shanghai 201508, Peoples R China.
   [Chang, Qing; Sha, Shuang; Chen, Yingmin; Zhou, Hui; Liang, Kaiyi; Huang, Xuyuan] Shanghai Univ Med & Hlth Sci, Jiading Cent Hosp, Key Lab Mol Imaging, Shanghai 201800, Peoples R China.
   [Lin, Yun] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Infect Dis, Shanghai 201508, Peoples R China.
RP Huang, G (corresponding author), Shanghai Univ Med & Hlth Sci, Shanghai Key Lab Mol Imaging, Shanghai 201318, Peoples R China.; Shi, YX (corresponding author), Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Radiol, Shanghai 201508, Peoples R China.; Huang, XY (corresponding author), Shanghai Univ Med & Hlth Sci, Jiading Cent Hosp, Key Lab Mol Imaging, Shanghai 201800, Peoples R China.
EM hxy12777@sumhs.edu.cn; shiyuxin@shphc.org.cn; huanggang@sumhs.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81830052, 81530053]; Construction project of
   Shanghai Key Laboratory of Molecular Imaging [18DZ2260400]; Shanghai
   Municipal Education Commission (Class II Plateau Disciplinary
   Construction Program of Medical Technology of SUMHS, 2018-2020)
FX This project was supported by the Key Program of National Natural
   Science Foundation of China (Grant No.81830052, 81530053), Construction
   project of Shanghai Key Laboratory of Molecular Imaging (18DZ2260400),
   Shanghai Municipal Education Commission (Class II Plateau Disciplinary
   Construction Program of Medical Technology of SUMHS, 2018-2020).
CR Akha AAS, 2018, J IMMUNOL METHODS, V463, P21, DOI 10.1016/j.jim.2018.08.005
   Altin JG, 1997, IMMUNOL CELL BIOL, V75, P430, DOI 10.1038/icb.1997.68
   Andersen AH, 2020, JOVE-J VIS EXP, V155
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Fisicaro P, 2018, CURR OPIN VIROL, V30, P1, DOI 10.1016/j.coviro.2018.01.003
   Gao XS, 2020, EUR J CLIN MICROBIOL, V39, P1611, DOI 10.1007/s10096-020-03880-1
   Hermiston ML, 2003, ANNU REV IMMUNOL, V21, P107, DOI 10.1146/annurev.immunol.21.120601.140946
   Khot Wasim Yunus, 2020, J Assoc Physicians India, V68, P67
   Kim ES, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e142
   Krummey SM, 2020, CELL REP, V30, P1282, DOI 10.1016/j.celrep.2020.01.016
   Lagunas-Rangel FA, 2020, J MED VIROL, V10, P1002
   Li MM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230295
   Liu BW, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102452
   Mahallawi WH, 2018, CYTOKINE, V104, P8, DOI 10.1016/j.cyto.2018.01.025
   Pan LG, 2020, INTENS CARE MED, V46, P573, DOI 10.1007/s00134-020-05964-0
   Pawelec G, 2020, IMMUN AGEING, V17, DOI 10.1186/s12979-020-00180-2
   Qian Z P, 2020, Zhonghua Gan Zang Bing Za Zhi, V28, P229, DOI 10.3760/cma.j.cn501113-20200229-00076
   Rheinlander A, 2018, IMMUNOL LETT, V196, P22, DOI 10.1016/j.imlet.2018.01.009
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Trifonova RT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02719
   Wang JK, 2020, IEEE T AUTOM SCI ENG, V17, P2063, DOI [10.1109/TASE.2020.2987397, 10.1109/TASE.2020.2976560, 10.1007/s11845-020-02218-2, 10.1007/978-981-13-8237-6_1]
   Wang L, 2020, MED MALADIES INFECT, V50, P332, DOI 10.1016/j.medmal.2020.03.007
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YL, 2020, ANN PALLIAT MED, V9, P428, DOI 10.21037/apm.2020.03.26
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zwald ML, 2020, MMWR-MORBID MORTAL W, V69, P419, DOI 10.15585/mmwr.mm6914e3
NR 31
TC 0
Z9 0
U1 1
U2 1
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD OCT 31
PY 2020
VL 12
IS 20
BP 19867
EP 19879
DI 10.18632/aging.103941
PG 13
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA OJ3AX
UT WOS:000583838700006
PM 33065551
OA Green Published
DA 2021-01-01
ER

PT J
AU Blanch-Rubio, J
   Soldevila-Domenech, N
   Tio, L
   Llorente-Onaindia, J
   Ciria-Recasens, M
   Polino, L
   Gurt, A
   de la Torre, R
   Maldonado, R
   Monfort, J
AF Blanch-Rubio, Josep
   Soldevila-Domenech, Natalia
   Tio, Laura
   Llorente-Onaindia, Jone
   Ciria-Recasens, Manuel
   Polino, Luciano
   Gurt, Alba
   de la Torre, Rafael
   Maldonado, Rafael
   Monfort, Jordi
CA Covidmar Study Grp
TI Influence of anti-osteoporosis treatments on the incidence of COVID-19
   in patients with non-inflammatory rheumatic conditions
SO AGING-US
LA English
DT Article
DE denosumab; zoledronate; calcium; vitamin D; anti-resorptive drugs;
   COVID-19
ID IMMUNE-RESPONSES; ZOLEDRONIC ACID; MORTALITY; PREGABALIN; MECHANISM;
   CALCIUM
AB Coronavirus disease 19 (COVID-19) is currently a global pandemic that affects patients with other pathologies. Here, we investigated the influence of treatments for osteoporosis and other non-inflammatory rheumatic conditions, such as osteoarthritis and fibromyalgia, on COVID-19 incidence. To this end, we conducted a cross-sectional study of 2,102 patients being treated at the Rheumatology Service of Hospital del Mar (Barcelona, Spain). In our cohort, COVID-19 cumulative incidence from March 1 to May 3, 2020 was compared to population estimates for the same city. We used Poisson regression models to determine the adjusted relative risk ratios for COVID-19 associated with different treatments and comorbidities. Denosumab, zoledronate and calcium were negatively associated with COVID-19 incidence. Some analgesics, particularly pregabalin and most of the studied antidepressants, were positively associated with COVID-19 incidence, whereas duloxetine presented a negative association. Oral bisphosphonates, vitamin D, thiazide diuretics, anti-hypertensive drugs and chronic nonsteroidal anti-inflammatory drugs had no effect on COVID-19 incidence in the studied population. Our results provide novel evidence to support the maintenance of the main anti-osteoporosis treatments in COVID-19 patients, which may be of particular relevance to elderly patients affected by the SARS-CoV-2 pandemic.
C1 [Blanch-Rubio, Josep; Ciria-Recasens, Manuel; Monfort, Jordi] Hosp del Mar, Rheumatol Serv, Barcelona 08003, Spain.
   [Blanch-Rubio, Josep; Tio, Laura; Llorente-Onaindia, Jone; Ciria-Recasens, Manuel; Polino, Luciano; Maldonado, Rafael; Monfort, Jordi] IMIM Hosp del Mar, PRBB, Med Res Inst, Barcelona 08003, Spain.
   [Soldevila-Domenech, Natalia; de la Torre, Rafael] IMIM Inst Hosp Mar Invest Med, PRBB, Neurosci Res Program, Integrat Pharmacol & Syst Neurosci Res Grp, Barcelona 08003, Spain.
   [Maldonado, Rafael] Univ Pompeu Fabra, Dept Expt & Hlth Sci, Lab Neuropharmacol, PRBB, Barcelona 08003, Spain.
   [Gurt, Alba] CAP Vila Olimp, Parc Sanitari Pere Virgili, Barcelona 08003, Spain.
   [de la Torre, Rafael] Inst Salud Carlos III ISCIII, Spanish Biomed Res Ctr Physiopathol Obes & Nutr C, Madrid 28029, Spain.
   [Soldevila-Domenech, Natalia; de la Torre, Rafael] Univ Pompeu Fabra, Dept Expt & Hlth Sci, PRBB, Barcelona 08003, Spain.
RP Maldonado, R (corresponding author), IMIM Hosp del Mar, PRBB, Med Res Inst, Barcelona 08003, Spain.; Maldonado, R (corresponding author), Univ Pompeu Fabra, Dept Expt & Hlth Sci, Lab Neuropharmacol, PRBB, Barcelona 08003, Spain.
EM rafael.maldonado@upf.edu
OI Soldevila-Domenech, Natalia/0000-0001-6024-8508; Ojeda Morillo, Fabiola
   Alejandra/0000-0002-6734-9288; Polino, Luciano/0000-0002-9586-1377
FU Hospital del Mar; Ministerio de Ciencia, Innovacion y Universidades
   [AEI-SAF2017-84060-R, DPI2016-80283-C2-2-R]; Ministerio de Sanidad,
   Servicios Sociales e Igualdad [RD16/0017/0020, PNSD-2017I068,
   PI18/00059]; Generalitat de CatalunyaGeneralitat de Catalunya
   [2017-SGR-669, ICREA-Academia 2015, 2017-SGR-138]; DIUE-AGAUR of the
   "Generalitat de Catalunya" [2019-DI-47]
FX This study was supported by Hospital del Mar. Authors funding includes
   "Ministerio de Ciencia, Innovacion y Universidades"
   (#AEI-SAF2017-84060-R FEDER to R.M., #DPI2016-80283-C2-2-R), "Ministerio
   de Sanidad, Servicios Sociales e Igualdad" (#RD16/0017/0020 &
   #PNSD-2017I068 to R.M., #PI18/00059 to TCS-M) and "Generalitat de
   Catalunya" (#2017-SGR-669 & #ICREA-Academia 2015 to R.M., #2017-SGR-138
   to R.D.L.T.). N.S.D. is recipient of predoctoral fellowship #2019-DI-47
   from the DIUE-AGAUR of the "Generalitat de Catalunya".
CR Abu-rish EY, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61006-1
   Agencia de Salut Publica de Barcelona, 2020, DAD DIAR INF PERC SA
   American College of Rheumatology COVID-19 Guidance Task Force, 2020, AM COLL SURG, P1
   Amrhein V, 2019, NATURE, V567, P305, DOI 10.1038/d41586-019-00857-9
   [Anonymous], 2020, COVID 19 DASHB CTR S
   [Anonymous], 2020, ASBMR WEBINAR PANEL
   [Anonymous], XGEV DEN
   Awwad ZM, 2020, CARDIOVASC TOXICOL, V20, P301, DOI 10.1007/s12012-019-09553-6
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Bergman J, 2019, OSTEOPOROSIS INT, V30, P1973, DOI 10.1007/s00198-019-05097-1
   Brufsky A, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02433-6
   Brunton LL., 2018, GOODMAN GILMANS PHAR, V13th ed
   Buschmann HH, 2007, Spain, Patent No. [EP 1 787 679 A1, 1787679]
   Cao ZH, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234764
   Cappellini F, 2020, CLIN CHEM LAB MED, V58, pE171, DOI 10.1515/cclm-2020-0611
   Cheng ML, 2014, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00329
   Chiu YG, 2017, EXPERT OPIN BIOL TH, V17, P119, DOI 10.1080/14712598.2017.1263614
   Colon-Emeric CS, 2010, J BONE MINER RES, V25, P91, DOI 10.1359/jbmr.090704
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Cremers S, 2019, BRIT J CLIN PHARMACO, V85, P1052, DOI 10.1111/bcp.13867
   El-Kurdi B, 2020, GASTROENTEROLOGY, V159, P1015, DOI 10.1053/j.gastro.2020.05.057
   Gianfrancesco M, 2020, ANN RHEUM DIS, V79, P859, DOI [10.1136/annrheumdis-2020-217871, 10.1136/annrheumdis-2020-218328, 10.1136/annrheumdis-2020-218713]
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Haberman R, 2020, NEW ENGL J MED, V383, P85, DOI 10.1056/NEJMc2009567
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kanis JA, 2019, CALCIFIED TISSUE INT, V104, P235, DOI 10.1007/s00223-018-00512-x
   Khan F, 2020, SYSTEMATIC REV ANAKI, DOI DOI 10.1101/2020.04.23.20076612V1?%253FCOLLECTION=1
   KOBAYASHISAKAMO.M, 2015, INTEGR MOL MED, V2, P384
   Landewe RBM, 2020, ANN RHEUM DIS, V79, P851, DOI [10.1136/annrheumdis-2020-216999, 10.1136/annrheumdis-2020-217877]
   Lee K, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-44
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Martino M, 2012, CURR NEUROPHARMACOL, V10, P97, DOI 10.2174/157015912800604542
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Michelena X, 2020, SEMIN ARTHRITIS RHEU, V50, P564, DOI 10.1016/j.semarthrit.2020.05.001
   Okamoto S, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.475
   Ortuno MJ, 2016, NAT MED, V22, P1170, DOI 10.1038/nm.4166
   PECK WA, 1993, AM J MED, V94, P646
   Poccia F, 2006, J INFECT DIS, V193, P1244, DOI 10.1086/502975
   Santos RAS, 2018, PHYSIOL REV, V98, P505, DOI 10.1152/physrev.00023.2016
   Taylor CP, 2007, EPILEPSY RES, V73, P137, DOI 10.1016/j.eplepsyres.2006.09.008
   Vaeth M, 2016, IMMUNITY, V44, P1350, DOI 10.1016/j.immuni.2016.04.013
   Wasserstein RL, 2019, AM STAT, V73, P1, DOI 10.1080/00031305.2019.1583913
   World Health Organization. World Health Organization, 2020, 32 WHO
   Yu EW, 2020, J BONE MINER RES, V35, P1009, DOI 10.1002/jbmr.4049
   Zhang X, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104927
NR 45
TC 0
Z9 0
U1 1
U2 1
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD OCT 31
PY 2020
VL 12
IS 20
BP 19923
EP 19937
DI 10.18632/aging.104117
PG 15
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA OJ3AX
UT WOS:000583838700010
PM 33080571
OA Green Published
DA 2021-01-01
ER

PT J
AU Kim, YS
   Lee, SY
   Yoon, JW
   Kim, D
   Yu, S
   Kim, JS
   Kim, JH
AF Kim, Ye Seul
   Lee, Soo Yong
   Yoon, Jung Won
   Kim, Dasol
   Yu, Sangbin
   Kim, Jeong Su
   Kim, Jae Ho
TI Cardiotoxicity induced by the combination therapy of chloroquine and
   azithromycin in human embryonic stem cell-derived cardiomyocytes
SO BMB REPORTS
LA English
DT Article
DE Cardiomyocytes; Cardiotoxicity; Chloroquine; COVID-19; Embryonic stem
   cells
ID SAFETY
AB Combination therapy using chloroquine (CQ) and azithromycin (AZM) has drawn great attention due to its potential anti-viral activity against SARS-CoV-2. However, clinical trials have revealed that the co-administration of CQ and AZM resulted in severe side effects, including cardiac arrhythmia, in patients with COVID-19. To elucidate the cardiotoxicity induced by CQ and AZM, we examined the effects of these drugs based on the electrophysiological properties of human embryonic stem cell-derived cardiomyocytes (hESC-CMs) using multi-electrode arrays. CQ treatment significantly increased the field potential duration, which corresponds to prolongation of the QT interval, and decreased the spike amplitude, spike slope, and conduction velocity of hESC-CMs. AZM had no significant effect on the field potentials of hESC-CMs. However, CQ in combination with AZM greatly increased the field potential duration and decreased the beat period and spike slope of hESC-CMs when compared with CQ monotherapy. In support of the clinical data suggesting the cardiovascular side effects of the combination therapy of CQ and AZM, our results suggest that AZM reinforces the cardiotoxicity induced by CQ in hESC-CMs.
C1 [Kim, Ye Seul; Yoon, Jung Won; Kim, Dasol; Yu, Sangbin; Kim, Jae Ho] Pusan Natl Univ, Sch Med, Dept Physiol, Yangsan 50612, South Korea.
   [Lee, Soo Yong; Kim, Jeong Su] Pusan Natl Univ, Sch Med, Dept Internal Med, Div Cardiol,Yangsan Hosp, Yangsan 50612, South Korea.
   [Lee, Soo Yong; Kim, Jeong Su] Pusan Natl Univ, Sch Med, Res Inst Convergence Biomed Sci & Technol, Yangsan Hosp, Yangsan 50612, South Korea.
RP Kim, JH (corresponding author), Pusan Natl Univ, Sch Med, Dept Physiol, Yangsan 50612, South Korea.; Kim, JS (corresponding author), Pusan Natl Univ, Sch Med, Dept Internal Med, Div Cardiol,Yangsan Hosp, Yangsan 50612, South Korea.; Kim, JS (corresponding author), Pusan Natl Univ, Sch Med, Res Inst Convergence Biomed Sci & Technol, Yangsan Hosp, Yangsan 50612, South Korea.
EM j25ngsukim@gmail.com; jhkimst@pusan.ac.kr
OI Reis, AlessanRSS/0000-0001-8486-7469
FU National Research Foundation of Korea (NRF) - Ministry of Education,
   Science, and TechnologyMinistry of Education, Science and Technology,
   Republic of KoreaNational Research Foundation of Korea
   [NRF-2015R1A5A2009656, NRF-2015M3A9C6030280, NRF-2017M3A9B 4051542]
FX This study was supported by research grants (NRF-2015R1A5A2009656,
   NRF-2015M3A9C6030280, and NRF-2017M3A9B 4051542) of the National
   Research Foundation of Korea (NRF) funded by the Ministry of Education,
   Science, and Technology.
CR Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Chatre C, 2018, DRUG SAFETY, V41, P919, DOI 10.1007/s40264-018-0689-4
   Cheng DKL, 1999, AM J PHYSIOL-HEART C, V277, pH351
   Chorin E, 2020, NAT MED, V26, P808, DOI 10.1038/s41591-020-0888-2
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Das S, 2020, CLIN DRUG INVEST, V40, P591, DOI 10.1007/s40261-020-00927-1
   Tran DH, 2019, J ANTIBIOT, V72, P759, DOI 10.1038/s41429-019-0204-x
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gintant G, 2016, NAT REV DRUG DISCOV, V15, P457, DOI 10.1038/nrd.2015.34
   Haeusler IL, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1188-2
   Inciardi RM, 2020, JAMA CARDIOL, V5, P819, DOI 10.1001/jamacardio.2020.1096
   Juurlink DN, 2020, CAN MED ASSOC J, V192, pE450, DOI 10.1503/cmaj.200528
   Juurlink DN, 2014, CAN MED ASSOC J, V186, P1127, DOI 10.1503/cmaj.140572
   Lian XJ, 2013, NAT PROTOC, V8, P162, DOI 10.1038/nprot.2012.150
   Lian XJ, 2012, P NATL ACAD SCI USA, V109, pE1848, DOI 10.1073/pnas.1200250109
   Min JY, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/649570
   Mitra Raman L, 2020, HeartRhythm Case Rep, V6, P244, DOI 10.1016/j.hrcr.2020.03.016
   Mubagwa K, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106057
   Ohe M, 2020, BIOSCI TRENDS, V14, P159, DOI 10.5582/bst.2020.03058
   Pillat MM, 2020, CYTOM PART A, V97, P872, DOI 10.1002/cyto.a.24190
   Ramireddy A, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.017144
   Rast G, 2015, J PHARMACOL TOX MET, V75, P91, DOI 10.1016/j.vascn.2015.04.005
   Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMoa1003833
   Sala S, 2020, EUR HEART J, V41, P1861, DOI 10.1093/eurheartj/ehaa286
   Satarker S, 2020, CURR PHARM REP, V6, P203
   Satsuka A, 2020, CURR PHARM BIOTECHNO, V21, P765, DOI 10.2174/1389201020666190628143345
   Savarino A, 2006, LANCET INFECT DIS, V6, P67, DOI 10.1016/S1473-3099(06)70361-9
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Scherrmann JM, 2020, AAPS J, V22, DOI 10.1208/s12248-020-00465-w
   Sharma A, 2018, NAT PROTOC, V13, P3018, DOI 10.1038/s41596-018-0076-8
   Sirenko O, 2013, J BIOMOL SCREEN, V18, P39, DOI 10.1177/1087057112457590
   Tavazzi G, 2020, EUR J HEART FAIL, V22, P911, DOI 10.1002/ejhf.1828
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tohyama S, 2013, CELL STEM CELL, V12, P127, DOI 10.1016/j.stem.2012.09.013
   Traebert M, 2004, EUR J PHARMACOL, V484, P41, DOI 10.1016/j.ejphar.2003.11.003
   Vicente J, 2019, CLIN PHARMACOL THER, V105, P943, DOI 10.1002/cpt.1303
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   White NJ, 2007, LANCET INFECT DIS, V7, P549, DOI 10.1016/S1473-3099(07)70187-1
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 40
TC 0
Z9 0
U1 1
U2 1
PU KOREAN SOCIETY BIOCHEMISTRY & MOLECULAR BIOLOGY
PI SEOUL
PA KOREA SCIENCE & TECHNOLOGY CENTER, # 801,  635-4 , YEOKSAM-DONG,
   KANGNAM-KU, SEOUL, 135-703, SOUTH KOREA
SN 1976-6696
EI 1976-670X
J9 BMB REP
JI BMB Rep.
PD OCT 31
PY 2020
VL 53
IS 10
BP 545
EP 550
DI 10.5483/BMBRep.2020.53.10.165
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA OP0AN
UT WOS:000587737700008
PM 32958120
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kocayigit, H
   Suner, KO
   Tomak, Y
   Demir, G
   Yaylaci, S
   Dheir, H
   Guclu, E
   Erdem, AF
AF Kocayigit, Havva
   Ozmen Suner, Kezban
   Tomak, Yakup
   Demir, Gurkan
   Yaylaci, Selcuk
   Dheir, Hamad
   Guclu, Ertugrul
   Erdem, Ali Fuat
TI Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir
   on clinical outcomes in critically Ill patients with COVID-19
SO JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
LA English
DT Article; Early Access
DE COV&#304; D&#8208; 19; favipiravir; lopinavir
ID GUIDELINES
AB What is known and objectives In November 2019, several patients were diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China. So far, there are no specific treatments with proven high efficacy in patients with SARS-CoV-2. Presently, several drugs, such as hydroxychloroquine, ribavirin, favipiravir (FVP), lopinavir/ritonavir (LPV/r), remdesivir and oseltamivir, have been suggested as effective treatments for SARS-CoV-2. The aim of this study was to describe the clinical experience with FPV and LPV/r in critically ill patients with COVID-19 at Sakarya University Education and Research Hospital.
   Methods The study included 107 consecutive patients who had a laboratory confirmation of COVID-19 and were admitted to the intensive care unit (ICU) between 19 March and 19 May 2020. Follow-up continued through 30 May 2020 when the last observed patients were discharged.
   Results and discussion Of the 107 patients, 65 received FPV (Group FPV) and 42 received LPV/r (Group LPV/r). The two groups were similar in terms of demographic data and clinical findings. 43 (66.2%) of the 65 patients in the FPV group and 23 (54.8%) of the 42 patients in the LPV/r group died (p = 0.237). The median ICU stay was 6.6 (IQR, 3-10) days in the FPV group and 9 (IQR, 6-16) days in the LPV/r group, which was a statistically significant difference (p = 0.010).
   What is new and conclusion The length of hospital stay was significantly lower in the FVP group compared to the LPV/r group among patients who were discharged from the ICU. Although the analysis was done with a limited number of patients and the observed difference in mortality rate is of some concern, FVP treatment may be more beneficial than LPV/r in terms of effective use in the ICU.
C1 [Kocayigit, Havva; Tomak, Yakup; Demir, Gurkan; Erdem, Ali Fuat] Sakarya Univ Educ & Res Hosp, Dept Anaesthesiol & Reanimat, TR-54100 Sakarya, Turkey.
   [Ozmen Suner, Kezban] Sakarya Univ Educ & Res Hosp, Dept Intens Care, Sakarya, Turkey.
   [Yaylaci, Selcuk] Sakarya Univ Educ & Res Hosp, Dept Internal Med, Sakarya, Turkey.
   [Dheir, Hamad] Sakarya Univ Educ & Res Hosp, Dept Nephrol, Sakarya, Turkey.
   [Guclu, Ertugrul] Sakarya Univ Educ & Res Hosp, Dept Infect Dis & Clin Microbiol, Sakarya, Turkey.
RP Kocayigit, H (corresponding author), Sakarya Univ Educ & Res Hosp, Dept Anaesthesiol & Reanimat, TR-54100 Sakarya, Turkey.
EM havvakocayigit@gmail.com
OI DEMIR, GURKAN/0000-0002-7193-5394; YAYLACI, SELCUK/0000-0002-6768-7973;
   dheir, hamad/0000-0002-3569-6269
CR [Anonymous], 2020, FAV LOP ARCT EARL AN
   BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Chen C, 2020, FAVIPIRAVIR VERSUS A
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Croxtall JD, 2010, DRUGS, V70, P1885, DOI 10.2165/11204950-000000000-00000
   Delang L, 2018, ANTIVIR RES, V153, P85, DOI 10.1016/j.antiviral.2018.03.003
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Khalili JS, 2020, J MED VIROL, V92, P740, DOI 10.1002/jmv.25798
   Khwaja A, 2012, NEPHRON CLIN PRACT, V120, pC179, DOI 10.1159/000339789
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Remdesivir, 2006, REMD DRUGS LACT DAT
   Shiraki K, 2020, PHARMACOL THERAPEUT, V209, DOI 10.1016/j.pharmthera.2020.107512
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wu Renyi, 2020, Curr Pharmacol Rep, P1, DOI 10.1007/s40495-020-00216-7
   Yousefi B, 2020, J CELL PHYSIOL, V235, P9133, DOI 10.1002/jcp.29785
   Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035
NR 19
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-4727
EI 1365-2710
J9 J CLIN PHARM THER
JI J. Clin. Pharm. Ther.
DI 10.1111/jcpt.13305
EA OCT 2020
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA ON9RF
UT WOS:000587027600001
PM 33128482
OA Bronze
DA 2021-01-01
ER

PT J
AU Chou, WYS
   Budenz, A
AF Chou, Wen-Ying Sylvia
   Budenz, Alexandra
TI Considering Emotion in COVID-19 Vaccine Communication: Addressing
   Vaccine Hesitancy and Fostering Vaccine Confidence
SO HEALTH COMMUNICATION
LA English
DT Article
ID FEAR; MISINFORMATION; METAANALYSIS; APPEALS
AB Long-term control of the COVID-19 pandemic hinges in part on the development and uptake of a preventive vaccine. In addition to a segment of population that refuses vaccines, the novelty of the disease and concerns over safety and efficacy of the vaccine have a sizable proportion of the U.S. indicating reluctance to getting vaccinated against COVID-19. Among various efforts to address vaccine hesitancy and foster vaccine confidence, evidence-based communication strategies are critical. There are opportunities to consider the role of emotion in communication efforts. In this commentary, we highlight several ways negative as well as positive emotions may be considered and leveraged. Examples include attending to negative emotions such as fear and anxiety, raising awareness of emotional manipulations by anti-vaccine disinformation efforts, and activating positive emotions such as altruism and hope as part of vaccine education endeavors.
C1 [Chou, Wen-Ying Sylvia] NCI, Div Canc Control & Populat Sci, Behav Res Program, Hlth Commun & Informat Res Branch, 9609 Med Ctr Dr,3E614, Bethesda, MD 20892 USA.
   [Budenz, Alexandra] NCI, Div Canc Control & Populat Sci, Behav Res Program, Tobacco Control Res Branch, Bethesda, MD 20892 USA.
RP Chou, WYS (corresponding author), NCI, Div Canc Control & Populat Sci, Behav Res Program, Hlth Commun & Informat Res Branch, 9609 Med Ctr Dr,3E614, Bethesda, MD 20892 USA.
EM chouws@mail.nih.gov
CR Associated Press-University of Chicago National Opinion Research Center, 2020, EXPECTATIONS COVID 1
   Banas JA, 2013, HUM COMMUN RES, V39, P184, DOI 10.1111/hcre.12000
   Bavel Jay J Van, 2020, Nat Hum Behav, V4, P460, DOI 10.1038/s41562-020-0884-z
   Bean SJ, 2011, VACCINE, V29, P1874, DOI 10.1016/j.vaccine.2011.01.003
   Betsch C, 2011, MED DECIS MAKING, V31, P742, DOI 10.1177/0272989X11400419
   Broniatowski DA, 2018, AM J PUBLIC HEALTH, V108, P1378, DOI 10.2105/AJPH.2018.304567
   Carey RN, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3227-2
   Cook J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175799
   Dillard JP, 2006, J COMM, V56, pS123
   Dube E, 2015, EXPERT REV VACCINES, V14, P99, DOI 10.1586/14760584.2015.964212
   Duhachek A, 2012, J MARKETING RES, V49, P928, DOI 10.1509/jmr.10.0244
   Eppright David R, 2002, Health Mark Q, V20, P51
   Ferrer RA, 2019, SOC PERSONAL PSYCHOL, V13, DOI 10.1111/spc3.12502
   Fisher Kimberly A, 2020, Ann Intern Med, V173, P964, DOI 10.7326/M20-3569
   Funk C., 2020, TRUST MEDICAL SCIENT
   Heffner J., 2020, EMOTIONAL RESPONSES, V170, DOI [10.31234/osf.io/qkxvb, DOI 10.31234/OSF.IO/QKXVB]
   Jamieson Kathleen Hall, 2020, HARVARD KENNEDY SCH, DOI [10.37016/mr-2020-012, DOI 10.37016/MR-2020-012, 10.37016/mr-2020-012.]
   JANIS IL, 1953, J ABNORM SOC PSYCH, V48, P78, DOI 10.1037/h0060732
   Jolley D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089177
   Jordan J., 2020, DONT GET IT DONT SPR, DOI [10.31234/osf.io/yuq7x, DOI 10.31234/OSF.IO/YUQ7X]
   Jungmann SM, 2020, J ANXIETY DISORD, V73, DOI 10.1016/j.janxdis.2020.102239
   Kaiser Family Foundation, 2020, KFF HLTH TRACKING PO
   Kata A, 2012, VACCINE, V30, P3778, DOI 10.1016/j.vaccine.2011.11.112
   Kata A, 2010, VACCINE, V28, P1709, DOI 10.1016/j.vaccine.2009.12.022
   Lang A, 2008, J BROADCAST ELECTRON, V52, P432, DOI 10.1080/08838150802205629
   Lerner JS, 2001, J PERS SOC PSYCHOL, V81, P146, DOI 10.1037//0022-3514.81.1.146
   Lewandowsky S, 2012, PSYCHOL SCI PUBL INT, V13, P106, DOI 10.1177/1529100612451018
   Lwin May Oo, 2020, JMIR Public Health Surveill, V6, pe19447, DOI 10.2196/19447
   MacFarlane D, 2020, SOC SCI MED, V259, DOI 10.1016/j.socscimed.2020.112790
   MCGUIRE WJ, 1961, J ABNORM SOC PSYCH, V62, P327, DOI 10.1037/h0042026
   Mitra T., 2016, P 10 INT C WEB SOC M
   Morgul E, 2020, INT J SOC PSYCHIATR, DOI 10.1177/0020764020941889
   Murphy-Hoefer R, 2010, J AM COLL HEALTH, V58, P373, DOI 10.1080/07448480903380276
   Ness AM, 2017, COMPUT HUM BEHAV, V72, P496, DOI 10.1016/j.chb.2017.02.061
   Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018
   Ojala M, 2012, ENVIRON EDUC RES, V18, P625, DOI 10.1080/13504622.2011.637157
   Perugini M, 2001, BRIT J SOC PSYCHOL, V40, P79, DOI 10.1348/014466601164704
   Qiu JY, 2020, GEN PSYCHIAT, V33, DOI 10.1136/gpsych-2020-100213
   Ruiz N., 2020, MANY BLACK ASIAN AME
   Sear RF, 2020, IEEE ACCESS, V8, P91886, DOI 10.1109/ACCESS.2020.2993967
   Seligman M., 1981, BEHAVIOR THERAPY DEP, P123
   Seligman M.E.P., 1975, HELPLESSNESS DEPRESS
   Suffolk University Political Research Center, 2020, SUPRC NAT POLL NAT P
   Tannenbaum MB, 2015, PSYCHOL BULL, V141, P1178, DOI 10.1037/a0039729
   Taylor S, 2020, FEM PSYCHOL, V30, P63, DOI 10.1177/0959353519864390
   The City University of New York School of Public Health, 2020, LACK KNOWL MAY STOP
   Thigpen C., 2020, MOST AM EXPECT COVID
   Tyson A, 2020, US PUBLIC NOW DIVIDE
   Tyson A, 2020, REPUBLICANS REMAIN F
   U.S. Department of Health and Human Services, 2020, FACT SHEET EXPLANING
   van der Linden S, 2017, GLOB CHALL, V1, DOI 10.1002/gch2.201600008
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Williams-Piehota P, 2004, J NUTR EDUC BEHAV, V36, P114, DOI 10.1016/S1499-4046(06)60146-2
   Witte K, 2000, HEALTH EDUC BEHAV, V27, P591, DOI 10.1177/109019810002700506
   World Health Organization, 2020, CORONAVIRUS DIS COVI
NR 55
TC 0
Z9 0
U1 13
U2 13
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1041-0236
EI 1532-7027
J9 HEALTH COMMUN
JI Health Commun.
PD DEC 5
PY 2020
VL 35
IS 14
BP 1718
EP 1722
DI 10.1080/10410236.2020.1838096
EA OCT 2020
PG 5
WC Communication; Health Policy & Services
SC Communication; Health Care Sciences & Services
GA OU6GS
UT WOS:000586076500001
PM 33124475
OA Bronze
DA 2021-01-01
ER

PT J
AU Teng, XB
   Shen, Y
   Han, MF
   Yang, G
   Zha, L
   Shi, JF
AF Teng, Xiao-bao
   Shen, Ya
   Han, Ming-feng
   Yang, Gang
   Zha, Lei
   Shi, Jing-feng
TI The value of high-flow nasal cannula oxygen therapy in treating novel
   coronavirus pneumonia
SO EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article; Early Access
DE coronavirus disease 2019; high nasal flow oxygen therapy; pneumonia
AB Objective This study aimed to investigate the value of high-flow nasal cannula (HNFC) oxygen therapy in treating patients with severe novel coronavirus pneumonia (COVID-19).
   Methods The clinical data of 22 patients with severe COVID-19 were collected. The heart rate (HR), respiratory rate (RR) and oxygenation index (PO2/FiO(2)) at 0, 6, 24 and 72 hours after treatment were compared between the HFNC oxygen therapy group and the conventional oxygen therapy (COT) group. In addition, the white blood cell (WBC) count, lymphocyte (L) count, C-reactive protein (CRP) and procalcitonin (PCT) were compared before and at 72 hours after oxygen therapy treatment.
   Results The differences at 0 hours between the two groups were not statistically significant. Compared with COT group,in the HFNC oxygen therapy group, HR, RR and PaO2/FiO(2) were better at 6 hours after treatment, PaO2/FiO(2) was better at 24 and 72 hours. After 72 hours, L and CRP had improved in the HFNC oxygen therapy group compared with the COT group, but the differences in WBC and PCT were not statistically significant. The length of stay in the intensive care unit (ICU) and the total length of hospitalization was shorter in the HFNC oxygen therapy group than in the COT group.
   Conclusion Compared with COT, early application of HFNC oxygen therapy in patients with severe COVID-19 can improve oxygenation and RR, and HFNC oxygen therapy can improve the infection indexes of patients and reduce the length of stay in the ICU of patients. Therefore, it has high clinical application value.
C1 [Teng, Xiao-bao; Shen, Ya; Han, Ming-feng; Shi, Jing-feng] 2 Peoples Hosp Fuyang City, Dept Resp & Crit Care Med, 1088 Yinghexi Rd, Fuyang 236000, Anhui, Peoples R China.
   [Yang, Gang; Zha, Lei] 2 Peoples Hosp Wuhu City, Dept Resp & Crit Care Med, Wuhu, Anhui, Peoples R China.
RP Han, MF (corresponding author), 2 Peoples Hosp Fuyang City, Dept Resp & Crit Care Med, 1088 Yinghexi Rd, Fuyang 236000, Anhui, Peoples R China.
EM hanmingf_eng@163.com
FU COVID-19 emergency science and technology project in Fuyang city
   [FK20202802]
FX The second batch of COVID-19 emergency science and technology project in
   Fuyang city (FK20202802).
CR Corley A, 2011, BRIT J ANAESTH, V107, P998, DOI 10.1093/bja/aer265
   Cuquemelle E, 2012, RESP CARE, V57, P1571, DOI 10.4187/respcare.01681
   Dysart K, 2009, RESP MED, V103, P1400, DOI 10.1016/j.rmed.2009.04.007
   Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326
   Frat JP, 2015, RESP CARE, V60, P170, DOI 10.4187/respcare.03075
   Frizzola M, 2011, PEDIATR PULM, V46, P67, DOI 10.1002/ppul.21326
   Groves Nicole, 2007, Aust Crit Care, V20, P126
   Jin FY, 2016, J IND ENG CHEM, V39, P153, DOI 10.1016/j.jiec.2016.05.018
   National Health Commission, DIAGN TREATM PROT CO
   Peters SG, 2013, RESP CARE, V58, P597, DOI 10.4187/respcare.01887
   Schwabbauer N, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-66
   Spence CJT, 2012, EXP FLUIDS, V52, P569, DOI 10.1007/s00348-011-1044-z
   Vargas F, 2015, RESP CARE, V60, P1369, DOI 10.4187/respcare.03814
   Wang R, 2017, CHINESE J TUBERCULOS, V2, P155
NR 14
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2972
EI 1365-2362
J9 EUR J CLIN INVEST
JI Eur. J. Clin. Invest.
AR e13435
DI 10.1111/eci.13435
EA OCT 2020
PG 6
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA OI4VZ
UT WOS:000583279500001
PM 33068293
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ramaswamy, A
   Nayak, L
   Moulik, NR
   Sengar, M
   Chinnaswamy, G
   Jobanputra, K
   Shah, MJ
   Kapoor, A
   Joshi, A
   Kumar, A
   Gokarn, A
   Bonda, A
   Parambil, BC
   Prasad, M
   Bagal, B
   Dhamne, C
   Narula, G
   Jain, H
   Ghosh, J
   Thorat, J
   Bajpai, J
   Menon, N
   Khattry, N
   Bhargava, P
   Punatar, S
   Gulia, S
   Banavali, S
   Gupta, S
   Srinivas, S
   Rath, S
   Vora, T
   Noronha, V
   Patil, VM
   Ostwal, V
   Prabhash, K
AF Ramaswamy, Anant
   Nayak, Lingaraj
   Roy Moulik, Nirmalya
   Sengar, Manju
   Chinnaswamy, Girish
   Jobanputra, Kunal
   Shah, Minit J.
   Kapoor, Akhil
   Joshi, Amit
   Kumar, Amit
   Gokarn, Anant
   Bonda, Avinash
   Cheriyalinkal Parambil, Badira
   Prasad, Maya
   Bagal, Bhausaheb
   Dhamne, Chetan
   Narula, Gaurav
   Jain, Hasmukh
   Ghosh, Jaya
   Thorat, Jayashree
   Bajpai, Jyoti
   Menon, Nandini
   Khattry, Navin
   Bhargava, Prabhat
   Punatar, Sachin
   Gulia, Seema
   Banavali, Shripad
   Gupta, Sudeep
   Srinivas, Sujay
   Rath, Sushmita
   Vora, Tushar
   Noronha, Vanita
   Patil, Vijay M.
   Ostwal, Vikas
   Prabhash, Kumar
TI COVID-19 in cancer patients on active systemic therapy - Outcomes from
   LMIC scenario with an emphasis on need for active treatment
SO CANCER MEDICINE
LA English
DT Article
ID MORTALITY
AB Background There is limited data on outcomes in cancer patients with coronavirus disease 2019 (COVID-19) from lower middle-income countries (LMICs).
   Patients and Methods This was an observational study, conducted between 12 April and 10 June 2020 at Tata Memorial centre, Mumbai, in cancer patients undergoing systemic therapy with laboratory confirmed COVID-19. The objectives were to evaluate cumulative 30-day all-cause mortality, COVID-19 attributable mortality, factors predicting mortality, and time to viral negativity after initial diagnosis.
   Results Of the 24 660 footfalls and 7043 patients evaluated, 230 patients on active systemic therapy with a median age of 42 (1-75) years were included. COVID-19 infection severity, as per WHO criteria, was mild, moderate, and severe in 195 (85%), 11 (5%), and 24 (11%) patients, respectively. Twenty-three patients (10%) expired during follow-up, with COVID-19 attributable mortality seen in 15 patients (6.5%). There were no mortalities in the pediatric cohort of 31 (14%) patients. Advanced stage cancer being treated with palliative intent vs others [30-day mortality 24%% vs 5%, odds ratio (OR) 5.6, 95% CI 2.28-13.78, P < .001], uncontrolled cancer status vs controlled cancer (30-day mortality37.5%% vs 4%%, OR 14, 95% CI 4.46-44.16, P < .001) and severe COVID-19 vs mild COVID-19 (30-day mortality 71% vs 3%, OR 92.29, 95% CI 26.43-322.21, P < .001) were significantly associated with mortality. The median time to SARS-CoV-2 RT-PCR negativity was 17 days [interquartile range (IQR)17-28) in the cohort.
   Conclusions The mortality rates in cancer patients with COVID-19 who are receiving systemic anti-cancer therapy in LMICSs are marginally higher than that reported in unselected COVID-19 cohorts with prolonged time to viral negativity in a substantial number of patients. The pediatric cancer patients tended to have favorable outcomes.
C1 [Ramaswamy, Anant; Nayak, Lingaraj; Roy Moulik, Nirmalya; Sengar, Manju; Chinnaswamy, Girish; Jobanputra, Kunal; Shah, Minit J.; Kapoor, Akhil; Joshi, Amit; Kumar, Amit; Gokarn, Anant; Bonda, Avinash; Cheriyalinkal Parambil, Badira; Prasad, Maya; Bagal, Bhausaheb; Dhamne, Chetan; Narula, Gaurav; Jain, Hasmukh; Ghosh, Jaya; Thorat, Jayashree; Bajpai, Jyoti; Menon, Nandini; Khattry, Navin; Bhargava, Prabhat; Punatar, Sachin; Gulia, Seema; Banavali, Shripad; Gupta, Sudeep; Srinivas, Sujay; Rath, Sushmita; Vora, Tushar; Noronha, Vanita; Patil, Vijay M.; Ostwal, Vikas; Prabhash, Kumar] Homi Bhabha Natl Inst HBNI, Tata Mem Hosp, Dept Med Oncol, Dr E Borges Rd, Mumbai 400012, Maharashtra, India.
RP Ostwal, V; Prabhash, K (corresponding author), Homi Bhabha Natl Inst HBNI, Tata Mem Hosp, Dept Med Oncol, Dr E Borges Rd, Mumbai 400012, Maharashtra, India.
EM dr.vikas.ostwal@gmail.com; kprabhash1@gmail.com
RI BHARGAVA, PRABHAT/ABC-9756-2020; Bajpai, Jyoti/ABG-6370-2020
OI BHARGAVA, PRABHAT/0000-0002-6440-2186; Bajpai,
   Jyoti/0000-0001-7657-3460; Kumar, Amit/0000-0001-5920-0048
CR [Anonymous], 2020, LAB TESTING 2019 NOV
   Boulad F, 2020, JAMA ONCOL
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Mehta V, 2020, CANCER DISCOV, V10, P935, DOI 10.1158/2159-8290.CD-20-0516
   Miyashita H, 2020, ANN ONCOL, V31, P1088, DOI 10.1016/j.annonc.2020.04.006
   Othus M, 2014, LEUKEMIA, V28, P289, DOI 10.1038/leu.2013.176
   Pramesh CS, 2020, INDIAN J CANCER, V57, P123, DOI 10.4103/ijc.IJC_250_20
   Pramesh CS, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2011595
NR 9
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2045-7634
J9 CANCER MED-US
JI Cancer Med.
PD DEC
PY 2020
VL 9
IS 23
BP 8747
EP 8753
DI 10.1002/cam4.3423
EA OCT 2020
PG 7
WC Oncology
SC Oncology
GA PB8MZ
UT WOS:000582978600001
PM 33128509
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kardes, S
   Kuzu, AS
   Pakhchanian, H
   Raiker, R
   Karagulle, M
AF Kardes, Sinan
   Kuzu, Ali Suat
   Pakhchanian, Haig
   Raiker, Rahul
   Karagulle, Mine
TI Population-level interest in anti-rheumatic drugs in the COVID-19 era:
   insights from Google Trends
SO CLINICAL RHEUMATOLOGY
LA English
DT Article; Early Access
DE Anakinra; Colchicine; Google search; Hydroxychloroquine; Internet;
   Tocilizumab
AB Introduction/objective The general public may utilize online information through search engines for implications and risks of some anti-rheumatic drugs. These drugs have been used in the management of coronavirus disease 2019 (COVID-19) and associated inflammatory sequelae or cytokine storm of infection. Therefore, the objective of this study was to investigate the population-level interest in anti-rheumatic drugs during the COVID-19 era, by analyzing changes in Google search frequency data.
   Method To obtain the relative search volume (RSV) of anti-rheumatic drugs, we queried Google Trends for 78 search terms representing non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, antigout agents, conventional disease-modifying anti-rheumatic drugs (DMARDs), immunosuppressants, biologics, and Janus kinase (JAK) inhibitors within the USA. Three 8-week periods in 2020 (March 15-May 9), (May 10-July 4), and (July 5-August 29) representing the initial- and short-term periods were compared to overlapping periods of the preceding 3 years (2017-2019).
   Results We found statistically significant increases in RSV for colchicine, hydroxychloroquine, tocilizumab (and its brand name-Actemra), and anakinra, and statistically significant decreases among brand names of immunosuppressive agents (i.e., mycophenolate mofetil, azathioprine, cyclophosphamide, tacrolimus, cyclosporine) during both the initial- and short-term COVID-19 periods as compared to overlapping periods of the preceding 3 years.
   Conclusion There were significant increases in RSV of colchicine, hydroxychloroquine, tocilizumab, and anakinra during both initial- and short-term COVID-19 periods when compared to overlapping periods of the preceding 3 years reflecting a heightened level of information-seeking on these drugs during the pandemic. Rheumatologists should address this increase in informational demand. Further research assessing medium- and long-term interest in anti-rheumatic drugs is required to increase our knowledge on this new pandemic.
C1 [Kardes, Sinan; Kuzu, Ali Suat; Karagulle, Mine] Istanbul Univ, Dept Med Ecol & Hydroclimatol, Istanbul Fac Med, TR-34093 Istanbul, Turkey.
   [Pakhchanian, Haig] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA.
   [Raiker, Rahul] West Virginia Univ, Sch Med, Morgantown, WV 26506 USA.
RP Kardes, S (corresponding author), Istanbul Univ, Dept Med Ecol & Hydroclimatol, Istanbul Fac Med, TR-34093 Istanbul, Turkey.
EM sinan.kardes@istanbul.edu.tr; alisuatkuzu@gmail.com;
   haig@gwmail.gwu.edu; rsr0010@mix.wvu.edu; mkgulle@istanbul.edu.tr
RI Kardes, Sinan/L-6731-2015; Karagulle, Mine/J-4418-2016
OI Kardes, Sinan/0000-0002-6311-8634; Karagulle, Mine/0000-0002-8060-970X
CR Akintayo RO, 2020, CLIN RHEUMATOL, DOI 10.1007/s10067-020-05355-2
   Bhambhvani HP, 2020, UROL PRACT, V7, P496, DOI 10.1097/UPJ.0000000000000179
   Bhimraj Adarsh, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa478
   Boseley S, RECOVERY TRIAL COVID
   Carbone C, NEW TRIAL TEST ANTII
   Benlidayi IC, 2020, RHEUMATOL INT, V40, P1707, DOI 10.1007/s00296-020-04635-z
   Dhanda AK, 2020, AESTHET PLAST SURG, V44, P1378, DOI 10.1007/s00266-020-01903-y
   Dominus S, COVID DRUG WARS PITT
   Eysenbach G, 2009, J MED INTERNET RES, V11, DOI 10.2196/jmir.1157
   Furer V, 2019, RMD OPEN, V5, DOI 10.1136/rmdopen-2019-001041
   Ginsberg J, 2009, NATURE, V457, P1012, DOI 10.1038/nature07634
   Grady D, PANDEMICS HIDDEN VIC
   Guzman AK, 2020, J AM ACAD DERMATOL, V83, P963, DOI 10.1016/j.jaad.2020.05.147
   Haslak F, 2020, RHEUMATOL INT, V40, P1423, DOI 10.1007/s00296-020-04645-x
   Hein A, GOUT MED EYED POSSIB
   Jella TK, 2020, J ARTHROPLASTY, V35, P2813, DOI 10.1016/j.arth.2020.05.051
   Kardes S, 2019, ARCH DERMATOL RES, V311, P461, DOI 10.1007/s00403-019-01921-0
   Kardes S, 2019, CLIN RHEUMATOL, V38, P769, DOI 10.1007/s10067-018-4345-2
   Kastritis E, 2020, RHEUMATOL INT, V40, P1353, DOI 10.1007/s00296-020-04629-x
   Ladani AP, 2020, CLIN RHEUMATOL, V39, P3245, DOI 10.1007/s10067-020-05387-8
   Landewe RBM, 2020, ANN RHEUM DIS, V79, P851, DOI [10.1136/annrheumdis-2020-216999, 10.1136/annrheumdis-2020-217877]
   Liu M, 2020, JAMA INTERN MED, V180, P1116, DOI 10.1001/jamainternmed.2020.1764
   Mandavilli A, CORONAVIRUS PATIENTS
   Martinez-Arroyo G, 2019, CLIN RHEUMATOL, V38, P869, DOI 10.1007/s10067-018-4364-z
   Mavragani A, 2019, JMIR PUBLIC HLTH SUR, V5, P59, DOI 10.2196/13439
   Mikuls TR, 2020, ARTHRITIS RHEUMATOL, V72, pE1, DOI 10.1002/art.41437
   Misra DP, 2020, RHEUMATOL INT, V40, P1741, DOI 10.1007/s00296-020-04694-2
   Misra DP, 2020, CLIN RHEUMATOL, V39, P2055, DOI 10.1007/s10067-020-05073-9
   Montero F, 2020, RHEUMATOL INT, V40, P1593, DOI 10.1007/s00296-020-04676-4
   Moore N, 2020, DRUG SAFETY, V43, P611, DOI 10.1007/s40264-020-00953-0
   National Institutes of Health, COR DIS 2019 COVID 1
   Olson DR, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003256
   Rivas K, TOCILIZUMAB DRUG SHO
   Schrezenmeier EV, 2020, CURR OPIN RHEUMATOL, V32, P449, DOI 10.1097/BOR.0000000000000731
   Seyahi E, 2020, RHEUMATOL INT, V40, P1229, DOI 10.1007/s00296-020-04626-0
   Teng Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0165085
   World Health Organization, US NONST ANT DRUGS N
   Yang SH, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005607
NR 38
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0770-3198
EI 1434-9949
J9 CLIN RHEUMATOL
JI Clin. Rheumatol.
DI 10.1007/s10067-020-05490-w
EA OCT 2020
PG 9
WC Rheumatology
SC Rheumatology
GA OI2XV
UT WOS:000583148900002
PM 33130946
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Rokach, A
   Boulazreg, S
AF Rokach, Ami
   Boulazreg, Samir
TI The COVID-19 era: How therapists can diminish burnout symptoms through
   self-care
SO CURRENT PSYCHOLOGY
LA English
DT Article; Early Access
DE Psychologist; Self-care; Burnout; Occupational hazards; Competence
   constellation; Mindfulness
ID WORK-FAMILY CONFLICT; MENTAL-HEALTH; PERSONAL THERAPY; MASSAGE THERAPY;
   NATIONAL-SURVEY; COMPARATIVE METAANALYSIS; CLINICAL PSYCHOLOGISTS;
   SUSTAINING BEHAVIORS; PSYCHOTHERAPY; DISTRESS
AB COVID-19 is a frightening, stress-inducing, and unchartered territory for all. It is suggested that stress, loneliness, and the emotional toll of the pandemic will result in increased numbers of those who will seek psychological intervention, need support, and guidance on how to cope with a time period that none of us were prepared for. Psychologists, in general, are trained in and know how to help others. They are less effective in taking care of themselves, so that they can be their best in helping others. The article, which aims to heighten clinicians' awareness of the need for self-care, especially now in the post-pandemic era, describes the demanding nature of psychotherapy and the initial resistance by therapists to engage in self-care, and outlines the consequences of neglecting to care for themselves. We covered the demanding nature of psychotherapy and its grinding trajectory, the loneliness and isolation felt by clinicians in private practice, the professional hazards faced by those caring for others, and the creative and insightful ways that mental health practitioners can care for themselves for the good of their clients, their families, and obviously, themselves.
C1 [Rokach, Ami] York Univ, Toronto, ON, Canada.
   [Boulazreg, Samir] Western Univ, London, ON, Canada.
RP Rokach, A (corresponding author), York Univ, Toronto, ON, Canada.
EM arokach@yorku.ca
CR American Psychological Association, 2017, ETH PRINC PSYCH COD
   American Psychological Association, 2006, ADV COLL ASS PROF PS
   American Psychological Association, 2010, TIPS SELF CAR
   Augustin S, 2017, HDB PRIVATE PRACTICE
   Barnett J. E., 2008, HDB CLIN PSYCHOL, V1, P857
   BARROW JC, 1987, PROF PSYCHOL-RES PR, V18, P66
   BERNARD JL, 1987, PROF PSYCHOL-RES PR, V18, P489, DOI 10.1037/0735-7028.18.5.489
   BIENEN M, 1990, PSYCHOTHER, V27, P607, DOI 10.1037/0033-3204.27.4.607
   Briggs DB, 2008, PSYCHOL REP, V103, P443, DOI 10.2466/PR0.103.2.443-454
   Burns E. M, 2018, THESIS
   Bush AD, 2015, SIMPLE SELF CARE THE
   Carr M. L., 2014, J THREAT ASSESSMENT, V1, DOI [10.1037/tam0000003, DOI 10.1037/TAM0000003]
   Chen WC, 2008, J OCCUP HEALTH, V50, P288, DOI 10.1539/joh.L7132
   Chiesa A, 2010, PSYCHOL MED, V40, P1239, DOI 10.1017/S0033291709991747
   Chodron P, 1994, START YOU ARE GUIDE
   CLARK MM, 1986, PROF PSYCHOL-RES PR, V17, P541, DOI 10.1037/0735-7028.17.6.541
   Coster JS, 1997, PROF PSYCHOL-RES PR, V28, P5, DOI 10.1037/0735-7028.28.1.5
   Crowley JD, 2012, PROF PSYCHOL-RES PR, V43, P65, DOI 10.1037/a0026212
   de Bloom J, 2009, J OCCUP HEALTH, V51, P13, DOI 10.1539/joh.K8004
   Del Castillo D. M, 2010, THESIS
   Devlin AS, 2009, J ENVIRON PSYCHOL, V29, P503, DOI 10.1016/j.jenvp.2009.08.008
   Di Martino V, 1992, CONDITIONS WORK DIGE, P11
   DOYLE BB, 1987, PSYCHIAT ANN, V17, P760, DOI 10.3928/0048-5713-19871101-10
   Dunn R, 2013, PSYCHOTHER RES, V23, P78, DOI 10.1080/10503307.2012.731713
   Efstathiou V, 2017, THESIS
   El-Ghoroury NH, 2012, TRAIN EDUC PROF PSYC, V6, P122, DOI 10.1037/a0028768
   Ellis A., 1984, PSYCHOTHERAPY PRIVAT, V2, P25
   Ellis A, 1977, HDB RATIONAL EMOTIVE
   Estacio RD, 2019, CURRENT PERSPECTIVES, V9, P115, DOI [10.18844/gjgc.v9i3.4343, DOI 10.18844/GJGC.V9I3.4343]
   Farber B, 1990, PSYCHOTHERAPY PRIVAT, V8, P35, DOI DOI 10.1300/J294V08N01_
   Farber B. A., 2005, J CLIN PSYCHOL SESSI, V61, P8
   FARBER BA, 1981, PROF PSYCHOL, V12, P621, DOI 10.1037/0735-7028.12.5.621
   Farber NK, 2000, PSYCHOTHERAPY, V37, P341, DOI 10.1037/0033-3204.37.4.341
   Fauth J, 2005, J COUNS PSYCHOL, V52, P443, DOI 10.1037/0022-0167.52.3.443
   Field TM, 1998, AM PSYCHOL, V53, P1270, DOI 10.1037/0003-066X.53.12.1270
   Figley CR, 2015, TREATING COMPASSION
   Freud S, 1933, COLLECTED PAPERS SIG, V3, P572
   Freudenberger H.J, 1990, PSYCHOTHERAPY PRIVAT, V8, P31, DOI DOI 10.1300/J29v08n01_06
   FREUDENBERGER HJ, 1990, PSYCHOTHER, V27, P340, DOI 10.1037/0033-3204.27.3.340
   FREUDENBERGER HJ, 1979, PSYCHOANAL REV, V66, P275
   FREUDENBERGER HJ, 1974, J SOC ISSUES, V30, P1, DOI 10.1111/j.1540-4560.1974.tb00689.x
   Freudenberger HJ, 1990, ENCY HDB PRIVATE PRA, P461
   Freudenberger HJ, 1980, BURN OUT BEAT HIGH C
   Geller S, 2017, PRACTICAL GUIDE CULT
   Gill IJ, 2012, TRAIN EDUC PROF PSYC, V6, P151, DOI 10.1037/a0029666
   Gold SH, 2015, CLIN PSYCHOL PSYCHOT, V22, P304, DOI 10.1002/cpp.1888
   Goldberg C, 1986, BEING PSYCHOTHERAPIS
   Golden V, 1998, PROF PSYCHOL-RES PR, V29, P135, DOI 10.1037/0735-7028.29.2.135
   Goldfried MR, 2001, THERAPISTS CHANGE
   Gottlieb MC, 2013, PROF PSYCHOL-RES PR, V44, P307, DOI 10.1037/a0033541
   GREENFELD D, 1985, Hillside Journal of Clinical Psychiatry, V7, P165
   Gundoan H, 2017, THESIS
   Guy J. D., 1993, PSYCHOTHERAPY PRIVAT, V12, P73, DOI DOI 10.1300/J294v12n02_05
   GUY JD, 1986, PSYCHOTHER, V23, P297, DOI 10.1037/h0085612
   GUY JD, 1989, PROF PSYCHOL-RES PR, V20, P48, DOI 10.1037/0735-7028.20.1.48
   GUY JD, 1986, PROF PSYCHOL-RES PR, V17, P509, DOI 10.1037/0735-7028.17.6.509
   GUY JD, 1992, PROF PSYCHOL-RES PR, V23, P421, DOI 10.1037/0735-7028.23.5.421
   GUY JD, 1986, PROF PSYCHOL-RES PR, V17, P111, DOI 10.1037/0735-7028.17.2.111
   Guy JD, 1987, PERSONAL LIFE PSYCHO
   Hatchard T, 2017, PSYCHOL NEUROSCI, V10, P41, DOI [10.1037/pne0000073, DOI 10.1037/PNE0000073]
   Hayes J. A., 2011, PSYCHOTHERAPY RELATI, P239, DOI DOI 10.1093/ACPROF:OSO/9780199737208.003.0012
   Hendin H, 2004, AM J PSYCHIAT, V161, P1442, DOI 10.1176/appi.ajp.161.8.1442
   Herzog B, 2012, LONELINESS LONGING C, P187
   Hill CE, 2003, PSYCHOTHER RES, V13, P475, DOI 10.1093/ptr/kpg040
   Hou WH, 2010, J CLIN PSYCHIAT, V71, P894, DOI 10.4088/JCP.09r05009blu
   Irwin MR, 2006, HEALTH PSYCHOL, V25, P3, DOI 10.1037/0278-6133.25.1.3
   Johnson WB, 2013, PROF PSYCHOL-RES PR, V44, P343, DOI 10.1037/a0033131
   Johnson WB, 2012, AM PSYCHOL, V67, P557, DOI 10.1037/a0027206
   Karaoglu N, 2015, J PAK MED ASSOC, V65, P183
   KASLOW F W, 1987, Journal of Psychotherapy and the Family, V3, P79
   Kazak AE, 2004, PROF PSYCHOL-RES PR, V35, P219, DOI 10.1037/0735-7028.35.3.219
   King P, 1983, IDENTITY PSYCHOANALY
   Knapp S., 2012, PENNSYLVANIA PSYCHOL, V76, P9
   Knapp S, 1993, PSYCHOTHERAPY B, V28, P46
   Koekkoek B, 2006, PSYCHIAT SERV, V57, P795, DOI 10.1176/appi.ps.57.6.795
   Kois L, 2016, TRAIN EDUC PROF PSYC, V10, P29, DOI 10.1037/tep0000100
   Korn L, 2014, FOOD IMPROVES MOOD B, P30
   Kottler J, 2017, ON BEING A THERAPIST
   Kottler J. A, 2011, THERAPISTS WORKBOOK
   Kottler JA, 2015, INTRO COUNSELING VOI
   Krasner MS, 2009, JAMA-J AM MED ASSOC, V302, P1284, DOI 10.1001/jama.2009.1384
   Kushnir T, 1997, CANCER NURS, V20, P414, DOI 10.1097/00002820-199712000-00005
   Lamb DH, 2003, PROF PSYCHOL-RES PR, V34, P102, DOI 10.1037/0735-7028.34.1.102
   Lamb Y. S, 2006, WASHINGTON POST
   Lasky R, 2005, PSYCHOTHERAPISTS OWN
   Leiter MP, 2005, ANXIETY STRESS COPIN, V18, P131, DOI 10.1080/10615800500082473
   Lent J., 2012, J MENTAL HLTH COUNSE, V34, P355, DOI DOI 10.17744/mehc.34.4.e3k8u2k552515166
   Levin LS, 1976, SELF CARE LAY INITIA, P10
   Levitt DH, 2005, J HUMANIST COUNS, V44, P46, DOI 10.1002/j.2164-490X.2005.tb00055.x
   Locker-Forman A, 2005, REAL MEETS PRETEND E
   Luck T. T, 2009, THESIS
   Luther L, 2017, PSYCHIATR REHABIL J, V40, P252, DOI 10.1037/prj0000234
   MacDonald HA, 2003, J OCCUP REHABIL, V13, P63, DOI 10.1023/A:1022563930482
   Macran S, 1999, J COUNS PSYCHOL, V46, P419, DOI 10.1037/0022-0167.46.4.419
   Macran S, 1998, BRIT J MED PSYCHOL, V71, P13, DOI 10.1111/j.2044-8341.1998.tb01364.x
   Maranzan KA, 2018, CAN PSYCHOL, V59, P361, DOI 10.1037/cap0000153
   Maroda KJ, 2010, PSYCHODYNAMIC TECHNI
   Maslach C., 2003, BURNOUT COST CARING
   Maslach C, 2008, J APPL PSYCHOL, V93, P498, DOI 10.1037/0021-9010.93.3.498
   Maslach C, 2016, WORLD PSYCHIATRY, V15, P103, DOI 10.1002/wps.20311
   McAdams III C. R., 2000, J MENTAL HLTH COUNSE, V22, P107, DOI DOI 10.1002/J.1556-6978.1999.TB01787.X
   Miller RD, 2019, ART PSYCHOTHER, V63, P94, DOI 10.1016/j.aip.2018.12.007
   Misch DA, 2000, AM J PSYCHOTHER, V54, P172
   Moyer CA, 2004, PSYCHOL BULL, V130, P3, DOI 10.1037/0033-2909.130.1.3
   Mullenbach M., 2016, RESILIENT PRACTITION
   Murphy BC, 2002, INTERVIEWING ACTION
   Nelson W, 2007, J MED ETHICS, V33, P136, DOI 10.1136/jme.2006.015966
   Neuhaus M, 2014, OBES REV, V15, P822, DOI 10.1111/obr.12201
   Nissen-Lie HA, 2013, J COUNS PSYCHOL, V60, P483, DOI 10.1037/a0033643
   Norcross J., 1992, CLIN PSYCHOL FORUM, V44, P29
   Norcross J.C., 2018, LEAVING IT OFFICE GU
   Norcross JC, 2005, AM PSYCHOL, V60, P840, DOI 10.1037/0003-066X.60.8.840
   NORCROSS JC, 1986, PSYCHOTHER, V23, P102, DOI 10.1037/h0085577
   Norcross JC, 2018, HDB PSYCHOTHERAPY IN
   Norcross JC, 2017, PSYCHOTHERAPY, V54, P66, DOI 10.1037/pst0000097
   Norris DM, 2003, PSYCHIAT SERV, V54, P517, DOI 10.1176/appi.ps.54.4.517
   Orlinsky DE, 2005, PSYCHOLOGISTS OWN PS
   Pearlman L. A., 1995, TRAUMA THERAPIST COU
   PERLMAN B, 1982, HUM RELAT, V35, P283, DOI 10.1177/001872678203500402
   Persi J, 1992, T ANAL J, V22, P144, DOI [10.1177/036215379202200304, DOI 10.1177/036215379202200304]
   Pieterse AL, 2013, COUNS PSYCHOL Q, V26, P190, DOI 10.1080/09515070.2013.793451
   Pope K. S, 2017, EXERCISES EFFECTS PS
   POPE KS, 1993, PROF PSYCHOL-RES PR, V24, P142, DOI 10.1037/0735-7028.24.2.142
   POPE KS, 1987, AM PSYCHOL, V42, P993, DOI 10.1037/0003-066X.42.11.993
   POPE KS, 1994, PROF PSYCHOL-RES PR, V25, P247, DOI 10.1037/0735-7028.25.3.247
   Pope KS, 2016, ETHICS PSYCHOTHERAPY
   Pope KS, 2005, SURVIVE THRIVE THERA
   Portoghese I, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.02105
   Reik T., 1948, LISTENING 3 EAR INNE
   Reuben A, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.6095
   Rokach A, 1984, ONT PSYCH ASS 37 ANN
   Rokach A., 2013, PSYCHOL EMOTIONS MOT
   Rokach A, 2019, PSYCHOL JOURNEY LONE
   Romero J, 2018, THESIS
   Rosenbaum R, 1999, ZEN HEART PSYCHOTHER
   Rupert PA, 2005, PROF PSYCHOL-RES PR, V36, P544, DOI 10.1037/0735-7028.36.5.544
   Rupert PA, 2007, PROF PSYCHOL-RES PR, V38, P88, DOI 10.1037/0735-7028.38.1.88
   Rupert PA, 2013, PROF PSYCHOL-RES PR, V44, P283, DOI 10.1037/a0034494
   Rupert PA, 2009, PROF PSYCHOL-RES PR, V40, P54, DOI 10.1037/a0012538
   Ryan A, 2012, PSYCHOTHER RES, V22, P289, DOI 10.1080/10503307.2011.650653
   Sander L., 2020, 5 PSYCHOL REASONS RE
   Schaufeli WB, 2009, CAREER DEV INT, V14, P204, DOI 10.1108/13620430910966406
   Schernhammer ES, 2004, AM J PSYCHIAT, V161, P2295, DOI 10.1176/appi.ajp.161.12.2295
   Schoenfeld LS, 2001, PROF PSYCHOL-RES PR, V32, P491
   Schutte N, 2000, J OCCUP ORGAN PSYCH, V73, P53, DOI 10.1348/096317900166877
   Schwartz R, 2004, LARGER SELF PSYCHOTH
   SEGALL A, 1989, SOC SCI MED, V29, P153, DOI 10.1016/0277-9536(89)90163-9
   Shen-Miller DS, 2011, TRAIN EDUC PROF PSYC, V5, P112, DOI 10.1037/a0023824
   Sherman MD, 1998, PROF PSYCHOL-RES PR, V29, P79, DOI 10.1037/0735-7028.29.1.79
   Simpson S, 2019, CLIN PSYCHOL PSYCHOT, V26, P35, DOI 10.1002/cpp.2328
   Skovholt T. M., 2004, MASTER THERAPISTS EX
   Skovholt TM, 2003, J CAREER DEV, V30, P1
   Skovholt TM., 2016, RESILIENT PRACTITION, V3nd edn
   Smith MT, 2002, AM J PSYCHIAT, V159, P5, DOI 10.1176/appi.ajp.159.1.5
   Smith PL, 2009, CLIN PSYCHOL-SCI PR, V16, P1, DOI 10.1111/j.1468-2850.2009.01137.x
   Soler-Gonzalez J, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.01475
   SPIEGEL PB, 1990, PSYCHOTHER, V27, P636, DOI 10.1037/0033-3204.27.4.636
   Stathopoulou G, 2006, CLIN PSYCHOL-SCI PR, V13, P179, DOI 10.1111/j.1468-2850.2006.00021.x
   Stevanovic P, 2004, PSYCHOTHERAPY, V41, P301, DOI 10.1037/0033-3204.41.3.301
   Sue DW, 2001, COUNS PSYCHOL, V29, P790, DOI 10.1177/0011000001296002
   Swift JK, 2012, J CONSULT CLIN PSYCH, V80, P547, DOI 10.1037/a0028226
   Szymanska K., 2002, COUNS PSYCHOL, V17, P22
   Tamura L. J, 1994, PSYCHOTHERAPY PRIVAT, V13, P1, DOI [10.1300/J294v13n02_01, DOI 10.1300/J294V13N02_01]
   Taylor K, 2008, NEW YORK SUN
   Thomas JT, 2005, PROF PSYCHOL-RES PR, V36, P426, DOI 10.1037/0735-7028.36.4.426
   Thompson Isabel A., 2014, J MENTAL HLTH COUNSE, V36, P58, DOI DOI 10.17744/MEHC.36.1.P61M73373M4617R3
   THORESON RW, 1989, PROF PSYCHOL-RES PR, V20, P153, DOI 10.1037/0735-7028.20.3.153
   Tryon G. S., 1983, CLIN PSYCHOL, V36, P45
   Turner JA, 2005, PROF PSYCHOL-RES PR, V36, P674, DOI 10.1037/0735-7028.36.6.674
   Vogel DL, 2007, J COUNS PSYCHOL, V54, P40, DOI 10.1037/0022-0167.54.1.40
   Vogel DL, 2006, J SOC CLIN PSYCHOL, V25, P305, DOI 10.1521/jscp.2006.25.3.305
   Walfish S, 2012, PSYCHOL REP, V110, P639, DOI 10.2466/02.07.17.PR0.110.2.639-644
   Walters M, 2018, THESIS
   Welch ID, 1998, PATH PSYCHOTHERAPY M
   Welfel E. R, 2015, ETHICS COUNSELING PS
   Westmacott R, 2017, CLIN PSYCHOL PSYCHOT, V24, P687, DOI 10.1002/cpp.2037
   Wilcox MM, 2020, COUNS PSYCHOL, V48, P466, DOI 10.1177/0011000020904709
   WILL OA, 1979, CONTEMP PSYCHOANAL, V15, P560
   Wise EH, 2012, PROF PSYCHOL-RES PR, V43, P487, DOI 10.1037/a0029446
   Zackson J, 2012, IMPACT PRIMARY MATER
   Zur O, 2009, PROF PSYCHOL-RES PR, V40, P22, DOI 10.1037/a0014745
NR 181
TC 0
Z9 0
U1 3
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1046-1310
EI 1936-4733
J9 CURR PSYCHOL
JI Curr. Psychol.
DI 10.1007/s12144-020-01149-6
EA OCT 2020
PG 18
WC Psychology, Multidisciplinary
SC Psychology
GA OI2EA
UT WOS:000583097300004
PM 33162724
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Moradi, S
   Masoumi, M
   Mohammadi, S
   Vafaeimanesh, J
   Mohseni, M
   Mahdavi, H
   Aryannejad, A
AF Moradi, Soroush
   Masoumi, Maryam
   Mohammadi, Somayeh
   Vafaeimanesh, Jamshid
   Mohseni, Mohaddeseh
   Mahdavi, Hossein
   Aryannejad, Armin
TI Prevalence of coronavirus disease 2019 in rheumatic patients and
   evaluation of the effect of disease-modifying anti-rheumatic drugs
SO INTERNAL AND EMERGENCY MEDICINE
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; Rheumatic diseases; DMARDs
ID COVID-19
AB One of the most controversial issues among rheumatologists is the best approach to managing a rheumatic patient (RP) with coronavirus disease 2019 (COVID-19). This study aims to evaluate the prevalence of COVID-19 in RPs compared to the general population and to relatively assess the potential role of RPs' treatment regimen against COVID-19. In a cross-sectional study, all RPs with an updated medical record between December 1, 2019, and February 29, 2020, at the rheumatology clinic of Shahid Beheshti Hospital, Qom, Iran were included (as the case group), and the prevalence of COVID-19 was compared to the paired control group-individuals without RDs, randomly selected from the Qom Health Network's database. Qom was the first city in Iran in which COVID-19 was identified and spread rapidly. Both groups were paired regarding sex, age, and underlying severe conditions. The prevalence of COVID-19 was lower in RPs than the control group (p = 0.028). Moreover, patients who were under treatment with disease-modifying anti-rheumatic drugs (DMARDs) and biologic agents seemed to possess a lower risk for COVID-19. Two RPs died from COVID-19, both of whom had granulomatosis and polyangiitis (GPA). The prevalence of COVID-19 in the RPs was lower than the control group, which could be associated with more adherence to the quarantine and social distancing rules by RPs and stricter routine follow-ups than the general population. Besides, taking DMARDs, such as leflunomide, might possess a protective effect against severe COVID-19, probably as a result of preventing cytokine storm.
C1 [Moradi, Soroush; Aryannejad, Armin] Univ Tehran Med Sci, Tehran, Iran.
   [Masoumi, Maryam; Mohammadi, Somayeh; Mohseni, Mohaddeseh] Qom Univ Med Sci & Hlth Serv, Clin Res & Dev Ctr, Qom, Iran.
   [Vafaeimanesh, Jamshid] Qom Univ Med Sci, Gastroenterol & Hepatol Dis Res Ctr, Qom, Iran.
   [Mahdavi, Hossein] Shahid Beheshti Univ Med Sci, Tehran, Iran.
RP Masoumi, M (corresponding author), Qom Univ Med Sci & Hlth Serv, Clin Res & Dev Ctr, Qom, Iran.
EM mmasoomi@muq.ac.ir
OI Mahdavi, Hossein/0000-0002-0969-2918; Masoumi,
   Maryam/0000-0003-2635-2656
FU Qom University of Medical Sciences and Health Services, Qom, Iran
FX This study was funded by Qom University of Medical Sciences and Health
   Services, Qom, Iran. The university had no role in any of the study
   steps.
CR Bashiri A, 2020, J MATERN-FETAL NEO M, DOI [10.1080/14767058.2020.1839877, 10.1080/09546634.2020.1742438]
   Diao K, 2020, PREC CLIN MED, V3, P9, DOI [10.1093/pcmedi/pbaa004, DOI 10.1093/PCMEDI/PBAA004]
   Ferro F, 2020, CLIN EXP RHEUMATOL, V38, P373
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kapoor KM, 2020, ROLE CHLOROQUINE HYD
   Kearney J, 2020, CHLOROQUINE POTENTIA
   Khan AM, 2006, SURG-J R COLL SURG E, V4, P45, DOI 10.1016/S1479-666X(06)80021-1
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Misra DP, 2020, CLIN RHEUMATOL, V39, P2055, DOI 10.1007/s10067-020-05073-9
   da Rosa GP, 2020, CLIN EXP RHEUMATOL, V38, P370
   Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
   von Elm E, 2007, ANN INTERN MED, V147, P573, DOI 10.7326/0003-4819-147-8-200710160-00010
   World Health Organization, 2020, COR DIS 2019 SIT REP
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
NR 15
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1828-0447
EI 1970-9366
J9 INTERN EMERG MED
JI Intern. Emerg. Med.
DI 10.1007/s11739-020-02535-5
EA OCT 2020
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA OI2TR
UT WOS:000583138100001
PM 33128696
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Du, PC
   Ding, N
   Li, JR
   Zhang, FJ
   Wang, Q
   Chen, ZH
   Song, C
   Han, K
   Xie, W
   Liu, JY
   Wang, LH
   Wei, LR
   Ma, SF
   Hua, MX
   Yu, FT
   Wang, L
   Wang, W
   An, K
   Chen, JJ
   Liu, HZ
   Gao, GJ
   Wang, S
   Huang, YY
   Wu, AR
   Wang, JB
   Liu, D
   Zeng, H
   Chen, C
AF Du, Pengcheng
   Ding, Nan
   Li, Jiarui
   Zhang, Fujie
   Wang, Qi
   Chen, Zhihai
   Song, Chuan
   Han, Kai
   Xie, Wen
   Liu, Jingyuan
   Wang, Linghang
   Wei, Lirong
   Ma, Shanfang
   Hua, Mingxi
   Yu, Fengting
   Wang, Lin
   Wang, Wei
   An, Kang
   Chen, Jianjun
   Liu, Haizhou
   Gao, Guiju
   Wang, Sa
   Huang, Yanyi
   Wu, Angela R.
   Wang, Jianbin
   Liu, Di
   Zeng, Hui
   Chen, Chen
TI Genomic surveillance of COVID-19 cases in Beijing
SO NATURE COMMUNICATIONS
LA English
DT Article
ID ALIGNMENT; SEARCH
AB The spread of SARS-CoV-2 in Beijing before May, 2020 resulted from transmission following both domestic and global importation of cases. Here we present genomic surveillance data on 102 imported cases, which account for 17.2% of the total cases in Beijing. Our data suggest that all of the cases in Beijing can be broadly classified into one of three groups: Wuhan exposure, local transmission and overseas imports. We classify all sequenced genomes into seven clusters based on representative high-frequency single nucleotide polymorphisms (SNPs). Genomic comparisons reveal higher genomic diversity in the imported group compared to both the Wuhan exposure and local transmission groups, indicating continuous genomic evolution during global transmission. The imported group show region-specific SNPs, while the intra-host single nucleotide variations present as random features, and show no significant differences among groups. Epidemiological data suggest that detection of cases at immigration with mandatory quarantine may be an effective way to prevent recurring outbreaks triggered by imported cases. Notably, we also identify a set of novel indels. Our data imply that SARS-CoV-2 genomes may have high mutational tolerance. In this study, Chen and colleagues present genomic sequences of 102 SARS-CoV-2 isolates collected in Beijing. They look closely at genomic variation between isolates that arose as a result of domestic and global transmission. Their data suggest that SARS-CoV-2 genomes have a high mutational tolerance, which may have potential implications for the development of vaccines.
C1 [Du, Pengcheng; Ding, Nan; Li, Jiarui; Zhang, Fujie; Wang, Qi; Chen, Zhihai; Song, Chuan; Han, Kai; Xie, Wen; Liu, Jingyuan; Wang, Linghang; Wei, Lirong; Ma, Shanfang; Hua, Mingxi; Yu, Fengting; Gao, Guiju; Wang, Sa; Zeng, Hui; Chen, Chen] Capital Med Univ, Beijing Ditan Hosp, Beijing 100015, Peoples R China.
   [Du, Pengcheng; Ding, Nan; Li, Jiarui; Song, Chuan; Han, Kai; Hua, Mingxi; Zeng, Hui; Chen, Chen] Beijing Key Lab Emerging Infect Dis, Beijing 100015, Peoples R China.
   [Wang, Lin; Wang, Wei] BGI Shenzhen, MGI, Shenzhen 518083, Peoples R China.
   [An, Kang] BGI Shenzhen, BGI Genom, Shenzhen 518083, Peoples R China.
   [Chen, Jianjun; Liu, Di] Chinese Acad Sci, CAS Key Lab Special Pathogens, Wuhan Inst Virol, Ctr Biosafety Mega Sci, Wuhan 430071, Peoples R China.
   [Chen, Jianjun; Liu, Haizhou; Liu, Di] Chinese Acad Sci, Wuhan Inst Virol, Natl Virus Resource Ctr, Wuhan 430071, Peoples R China.
   [Huang, Yanyi] Peking Univ, Biomed Pioneering Innovat Ctr BIOPIC, Beijing Adv Innovat Ctr Genom ICG, Coll Chem & Mol Engn,Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China.
   [Wu, Angela R.] Hong Kong Univ Sci & Technol, Div Life Sci, Hong Kong, Peoples R China.
   [Wu, Angela R.] Hong Kong Univ Sci & Technol, Dept Chem & Biol Engn, Hong Kong, Peoples R China.
   [Wang, Jianbin] Tsinghua Univ, Sch Life Sci, Tsinghua Peking Ctr Life Sci, Beijing Adv Innovat Ctr Struct Biol ICSB,Chinese, Beijing 100084, Peoples R China.
   [Liu, Di] Univ Chinese Acad Sci, Beijing 101409, Peoples R China.
RP Zeng, H; Chen, C (corresponding author), Capital Med Univ, Beijing Ditan Hosp, Beijing 100015, Peoples R China.; Zeng, H; Chen, C (corresponding author), Beijing Key Lab Emerging Infect Dis, Beijing 100015, Peoples R China.; Liu, D (corresponding author), Chinese Acad Sci, CAS Key Lab Special Pathogens, Wuhan Inst Virol, Ctr Biosafety Mega Sci, Wuhan 430071, Peoples R China.; Liu, D (corresponding author), Chinese Acad Sci, Wuhan Inst Virol, Natl Virus Resource Ctr, Wuhan 430071, Peoples R China.; Wang, JB (corresponding author), Tsinghua Univ, Sch Life Sci, Tsinghua Peking Ctr Life Sci, Beijing Adv Innovat Ctr Struct Biol ICSB,Chinese, Beijing 100084, Peoples R China.; Liu, D (corresponding author), Univ Chinese Acad Sci, Beijing 101409, Peoples R China.
EM jianbinwang@tsinghua.edu.cn; liud@im.ac.cn; zenghui@ccmu.edu.cn;
   chenchen1@ccmu.edu.cn
OI chen, chen/0000-0003-1765-8899; ding, nan/0000-0002-1045-1695
CR ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   [Anonymous], 2020, WHO CORONAVIRUS DIS
   Brown NP, 1998, BIOINFORMATICS, V14, P380, DOI 10.1093/bioinformatics/14.4.380
   Chen C, 2020, MINERVA FACILE STRAT, DOI DOI 10.1101/2020.04.25.060947V1
   Chen C, 2020, ANN INTERN MED, V172, P832, DOI 10.7326/M20-0991
   CHINESE SME, 2004, SCIENCE, V303, P1666, DOI DOI 10.1126/SCIENCE.1092002
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Di L, 2020, P NATL ACAD SCI USA, V117, P2886, DOI 10.1073/pnas.1919800117
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Heywood AE, 2020, LANCET INFECT DIS, V20, P1005, DOI 10.1016/S1473-3099(20)30633-2
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Kraemer MUG, 2020, SCIENCE, V368, P493, DOI 10.1126/science.abb4218
   Nguyen LT, 2015, MOL BIOL EVOL, V32, P268, DOI 10.1093/molbev/msu300
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Leung K, 2020, LANCET, V395, P1382, DOI 10.1016/S0140-6736(20)30746-7
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Lu J, 2020, CELL, V181, P997, DOI 10.1016/j.cell.2020.04.023
   Ni M, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.151, 10.1038/nmicrobiol.2016.151]
   Pan A, 2020, JAMA-J AM MED ASSOC, V323, P1915, DOI 10.1001/jama.2020.6130
   Rambaut Andrew, 2020, Nat Microbiol, V5, P1403, DOI 10.1038/s41564-020-0770-5
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494
   Su YCF, 2020, MBIO, V11, DOI 10.1128/mBio.01610-20
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   Tian HY, 2020, SCIENCE, V368, P638, DOI 10.1126/science.abb6105
   World Health Organization, 2020, 71 WHO
   Yu FT, 2020, CLIN INFECT DIS, V71, P793, DOI 10.1093/cid/ciaa345
   Yue TX, 2020, SCI BULL, V65, P1225, DOI 10.1016/j.scib.2020.04.016
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 31
TC 0
Z9 0
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD OCT 30
PY 2020
VL 11
IS 1
AR 5503
DI 10.1038/s41467-020-19345-0
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OP4PH
UT WOS:000588063600026
PM 33127911
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Santos, IKFD
   Costa, CHN
AF de Miranda Santos, Isabel Kinney Ferreira
   Costa, Carlos Henrique Nery
TI Impact of Hydroxychloroquine on Antibody Responses to the SARS-CoV-2
   Coronavirus
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE COVID-19; Sars-CoV-2; coronavirus; antibodies; hydroxychloroquine
ID VACCINE
C1 [de Miranda Santos, Isabel Kinney Ferreira] Univ Sao Paulo, Ribeirao Preto Sch Med, Sao Paulo, Brazil.
   [Costa, Carlos Henrique Nery] Univ Fed Piaui, Nathan Portela Inst Trop Med, Teresina, Brazil.
RP Santos, IKFD (corresponding author), Univ Sao Paulo, Ribeirao Preto Sch Med, Sao Paulo, Brazil.
EM imsantos@fmrp.usp.br
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2020/09093-5]
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) (Grant Number 2020/09093-5 to IM).
CR Beavis KG, 2020, J CLIN VIROL, V129, DOI 10.1016/j.jcv.2020.104468
   Endy TP, 2020, J INFECT DIS, V221, P927, DOI 10.1093/infdis/jiz558
   Fryauff DJ, 1998, J INFECT DIS, V177, P1762, DOI 10.1086/517441
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Huang Angkana T, 2020, medRxiv, DOI 10.1101/2020.04.14.20065771
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   PAPPAIOANOU M, 1986, NEW ENGL J MED, V314, P280, DOI 10.1056/NEJM198601303140504
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   World Health Organization, 2020, SCI BRIEF IMM PASSP, DOI [10.15557/PiMR.2020.0024, DOI 10.15557/PIMR.2020.0024]
NR 12
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD OCT 30
PY 2020
VL 11
AR 1739
DI 10.3389/fimmu.2020.01739
PG 2
WC Immunology
SC Immunology
GA OX5AM
UT WOS:000593577100001
PM 32849619
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Li, HY
   Wang, JW
   Xu, LW
   Zhao, XL
   Feng, JX
   Xu, YZ
AF Li, Hai-yan
   Wang, Jin-wei
   Xu, Li-wei
   Zhao, Xu-ling
   Feng, Jia-xi
   Xu, You-zu
TI Clinical analysis of 132 cases COVID-19 from Wuhan
SO MEDICINE
LA English
DT Article
DE clinical characteristics; coronavirus; COVID-19; Treatment
AB Numerous cases of pneumonia from a novel coronavirus (SARS-CoV-2) emerged in Wuhan, China during December 2019.
   We determined the correlations of patient parameters with disease severity in patients with COVID-19. A total of 132 patients from Wuhan Fourth Hospital who had COVID-19 from February 1 to February 29 in 2020 were retrospectively analyzed.
   Ninety patients had mild disease, 32 had severe disease, and 10 had critical disease. The severe/critical group was older (P < .05), had a higher proportion of males (P < .05), and had a greater mortality rate (0% vs 61.9%, P < .05). The main symptoms were fever (n = 112, 84.8%) and cough (n = 96, 72.7%). Patients were treated with antiviral agents (n = 94, 71.2%), antibiotics (n = 92, 69.7%), glucocorticoids (n = 46, 34.8%), intravenous immunoglobulin (n = 38, 27.3%), and/or traditional Chinese medicine (n = 40, 30.3%). Patients in the severe/critical group received mechanical ventilation (n = 22, 16.7%) or high-flow nasal can-nula oxygen therapy (n = 6, 4.5%). Chest computed tomography (CT) indicated bilateral pneumonia in all patients. Relative to the mild group, the severe/critical group had higher levels of leukocytes, C-reactive protein (CRP), procalcitonin (PCT), D-dimer, B-type natriuretic peptide (BNP), liver enzymes, and myocardial enzymes (P < .05), and decreased levels of lymphocytes and blood oxygen partial pressure (P < .05).
   The main clinical symptoms of patients from Wuhan who had COVID-19 were fever and cough. Patients with severe/critical disease were more likely to be male and elderly. Disease severity correlated with increased leukocytes, CRP, PCT, BNP, D-dimer, liver enzymes, and myocardial enzymes, and with decreased lymphocytes and blood oxygen partial pressure.
C1 [Li, Hai-yan; Zhao, Xu-ling; Feng, Jia-xi; Xu, You-zu] Shaoxing Univ, TaiZhou Hosp Zhejiang Prov, Dept Resp Med, Linhai 317000, Zhejiang, Peoples R China.
   [Wang, Jin-wei] Wenzhou Med Univ, Funct Inspect Sect, Taizhou Hosp Zhejiang Prov, Wenzhou, Zhejiang, Peoples R China.
   [Xu, Li-wei] Wenzhou Med Univ, Endocrine Dept, Taizhou Hosp Zhejiang Prov, Wenzhou, Zhejiang, Peoples R China.
RP Xu, YZ (corresponding author), Shaoxing Univ, TaiZhou Hosp Zhejiang Prov, Dept Resp Med, Linhai 317000, Zhejiang, Peoples R China.
EM xuyz@enzemed.com
FU Medjaden Academy & Research Foundation for Young Scientists
   [COVID-19-MJA20200324]
FX This project was supported by the Medjaden Academy & Research Foundation
   for Young Scientists (Grant No. COVID-19-MJA20200324).
CR Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE005, DOI [10.3760/cma.j.issn.1001-0939.2020.03.013, 10.3760/cma.j.issn.1001-0939.2020.0005]
   China NHCotpsRo, DIAGN TREATM PNEUM N
   Dong N, 2020, F1000RESEARCH, V9, P121, DOI [10.12688/f1000research.22357.1, DOI 10.12688/F1000RESEARCH.22357.1]
   Gao LQ, 2017, EXP THER MED, V13, P3479, DOI 10.3892/etm.2017.4417
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Guo LX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02752
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Korppi M, 2004, PEDIATR INT, V46, P545, DOI 10.1111/j.1442-200x.2004.01947.x
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Paraskevis D, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104212
   [温珂 Wen Ke], 2020, [中华传染病杂志, Chinese Journal of Infections Diseases], V38, P150
   WHO, 2020, CLIN MAN SEV AC RESP
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Wu VC, 2004, NEPHROL DIAL TRANSPL, V19, P3180, DOI 10.1093/ndt/gfh436
NR 16
TC 0
Z9 0
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD OCT 30
PY 2020
VL 99
IS 44
AR e22847
DI 10.1097/MD.0000000000022847
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA OP6HX
UT WOS:000588186500029
PM 33126325
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ghati, N
   Roy, A
   Bhatnagar, S
   Bhati, S
   Bhushan, S
   Mahendran, M
   Thakur, A
   Tiwari, P
   Dwivedi, T
   Mani, K
   Gupta, R
   Mohan, A
   Garg, R
   Saxena, A
   Guleria, R
   Deepti, S
AF Ghati, Nirmal
   Roy, Ambuj
   Bhatnagar, Sushma
   Bhati, Sumit
   Bhushan, Sudha
   Mahendran, Manjit
   Thakur, Abhishek
   Tiwari, Pawan
   Dwivedi, Tanima
   Mani, Kalaivani
   Gupta, Ritu
   Mohan, Anant
   Garg, Rakesh
   Saxena, Anita
   Guleria, Randeep
   Deepti, Siddharthan
TI Atorvastatin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2
   Infection: A structured summary of a study protocol for a randomised
   controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised control trial; Protocol; Statin; Aspirin; Mortality
AB Objectives: To assess the impact of adding statin (atorvastatin) and/or aspirin on clinical deterioration in patients infected with SARS-CoV-2 who require hospitalisation. The safety of these drugs in COVID-19 patients will also be evaluated.
   Trial design: This is a single-centre, prospective, four-arm parallel design, open-label, randomized control trial.
   Participants: The study will be conducted at National Cancer Institute (NCI), Jhajjar, Haryana, which is a part of All India Institute of Medical Sciences (AIIMS), New Delhi, and has been converted into a dedicated COVID-19 management centre since the outbreak of the pandemic. All RT-PCR confirmed cases of SARS-CoV-2 infection with age >= 40 years and < 75 years requiring hospital admission (patients with WHO clinical improvement ordinal score 3 to 5) will be included in the trial. Written informed consent will be taken for all recruited patients. Patients with a critical illness (WHO clinical improvement ordinal score > 5), documented significant liver disease/dysfunction (aspartate transaminase [AST] / alanine aminotransferase [ALT] > 240), myopathy and rhabdomyolysis (creatine phosphokinase [CPK] > 5x normal), allergy or intolerance to statins or aspirin, prior statin or aspirin use within 30 days, history of active gastrointestinal bleeding in past three months, coagulopathy, thrombocytopenia (platelet count < 100000/ dl), pregnancy, active breastfeeding, or inability to take oral or nasogastric medications will be excluded. Patients refusing to give written consent and taking drugs that are known to have a significant drug interaction with statin or aspirin [including cyclosporine, HIV protease inhibitors, hepatitis C protease inhibitor, telaprevir, fibric acid derivatives (gemfibrozil), niacin, azole antifungals (itraconazole, ketoconazole), clarithromycin and colchicine] will also be excluded from the trial.
   Intervention and comparator: In this study, the benefit and safety of atorvastatin (statin) and/or aspirin as adjuvant therapy will be compared with the control group receiving usual care for management of COVID-19. Atorvastatin will be prescribed as 40 mg oral tablets once daily for ten days or until discharge, whichever is earlier. The dose of aspirin will be 75 mg once daily for ten days or until discharge, whichever is earlier. All other therapies will be administered according to the institute's COVID-19 treatment protocol and the treating physician's clinical judgment.
   Main outcomes: All study participants will be prospectively followed up for ten days or until hospital discharge, whichever is longer for outcomes. The primary outcome will be clinical deterioration characterized by progression to WHO clinical improvement ordinal score >= 6 (i.e., endotracheal intubation, non-invasive mechanical ventilation, pressor agents, renal replacement therapy, ECMO requirement, and mortality). The secondary outcomes will be change in serum inflammatory markers (C-reactive protein and Interleukin-6), Troponin I, and creatine phosphokinase (CPK) from time zero to 5th day of study enrolment or 7th day after symptom onset, whichever is later. Other clinical outcomes that will be assessed include progression to Acute Respiratory Distress Syndrome (ARDS), shock, ICU admission, length of ICU admission, length of hospital admission, and in-hospital mortality. Adverse drug effects like myalgia, myopathy, rhabdomyolysis, hepatotoxicity, and bleeding will also be examined in the trial to assess the safety of the interventions.
   Randomisation: The study will use a four-arm parallel-group design. A computer-generated permuted block randomization with mixed block size will be used to randomize the participants in a 1:1:1:1 ratio to group A (atorvastatin with conventional therapy), group B (aspirin with conventional therapy), group C (aspirin + atorvastatin with conventional therapy), and group D (control; only conventional therapy).
   Blinding (masking): The study will be an open-label trial.
   Numbers to be randomised (sample size): As there is no existing study that has evaluated the role of aspirin and atorvastatin in COVID-19 patients, formal sample size calculation has not been done. Patients satisfying the inclusion and exclusion criteria will be recruited during six months of study period. Once the first 200 patients are included in each arm (i.e., total 800 patients), the final sample size calculation will be done on the basis of the interim analysis of the collected data. Trial Status: The institutional ethical committee has approved the study protocol (Protocol version 3.0 [June 2020]).
   Participant recruitment starting date: 28th July 2020
   Participant recruitment ending date: 27th January 2021
   Trial duration: 6 months
   Trial registration: The trial has been prospectively registered in Clinical Trial Registry - India (ICMR- NIMS): Reference no. CTRI/2020/07/026791 (registered on 25 July 2020)].
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Ghati, Nirmal; Roy, Ambuj; Bhati, Sumit; Bhushan, Sudha; Mahendran, Manjit; Thakur, Abhishek; Saxena, Anita; Deepti, Siddharthan] All India Inst Med Sci AIIMS, Dept Cardiol, New Delhi 110029, India.
   [Bhatnagar, Sushma; Garg, Rakesh] Rotary Canc Hosp, All India Inst Med Sci AIIMS, Dr BRA Inst, Dept Oncoanaesthesia, New Delhi, India.
   [Tiwari, Pawan; Mohan, Anant; Guleria, Randeep] All India Inst Med Sci AIIMS, Dept Pulm Med & Sleep Disorders, New Delhi, India.
   [Dwivedi, Tanima] All India Inst Med Sci AIIMS, Natl Canc Inst Jhajjar Haryana, Dept Lab Med, New Delhi, India.
   [Mani, Kalaivani] All India Inst Med Sci AIIMS, Dept Biostat, New Delhi, India.
   [Gupta, Ritu] Rotary Canc Hosp, Dr BRA Inst, All India Inst Med Sci AIIMS, Dept Lab Oncol, New Delhi, India.
RP Deepti, S (corresponding author), All India Inst Med Sci AIIMS, Dept Cardiol, New Delhi 110029, India.
EM deeptikailath@gmail.com
RI tiwari, pawan/ABI-3256-2020; ghati, nirmal/ABF-6015-2020
OI tiwari, pawan/0000-0002-5136-4221; ghati, nirmal/0000-0001-8744-2108
NR 0
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD OCT 30
PY 2020
VL 21
IS 1
AR 902
DI 10.1186/s13063-020-04840-y
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OR6EY
UT WOS:000589562800002
PM 33126910
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU El Hassab, MA
   Shoun, AA
   Al-Rashood, ST
   Al-Warhi, T
   Eldehna, WM
AF El Hassab, Mahmoud A.
   Shoun, Aly A.
   Al-Rashood, Sara T.
   Al-Warhi, Tarfah
   Eldehna, Wagdy M.
TI Identification of a New Potential SARS-COV-2 RNA-Dependent RNA
   Polymerase Inhibitor via Combining Fragment-Based Drug Design, Docking,
   Molecular Dynamics, and MM-PBSA Calculations
SO FRONTIERS IN CHEMISTRY
LA English
DT Article
DE COVID-19; polymerase inhibitors; fragment-based drug design; molecular
   dynamics; MM-PBSA calculations
ID CORONAVIRUS; ENZYME
AB The world has recently been struck by the SARS-Cov-2 pandemic, a situation that people have never before experienced. Infections are increasing without reaching a peak. The WHO has reported more than 25 million infections and nearly 857,766 confirmed deaths. Safety measures are insufficient and there are still no approved drugs for the COVID-19 disease. Thus, it is an urgent necessity to develop a specific inhibitor for COVID-19. One of the most attractive targets in the virus life cycle is the polymerase enzyme responsible for the replication of the virus genome. Here, we describe our Structure-Based Drug Design (SBDD) protocol for designing of a new potential inhibitor for SARS-COV-2 RNA-dependent RNA Polymerase. Firstly, the crystal structure of the enzyme was retrieved from the protein data bank PDB ID (7bv2). Then, Fragment-Based Drug Design (FBDD) strategy was implemented using Discovery Studio 2016. The five best generated fragments were linked together using suitable carbon linkers to yield compound MAW-22. Thereafter, the strength of the binds between compound MAW-22 and the SARS-COV-2 RNA-dependent RNA Polymerase was predicted by docking strategy using docking software. MAW-22 achieved a high docking score, even more so than the score achieved by Remdesivir, indicating very strong binding between MAW-22 and its target. Finally, three molecular dynamic simulation experiments were performed for 150 ns to validate our concept of design. The three experiments revealed that MAW-22 has a great potentiality to inhibit the SARS-COV-2 RNA-dependent RNA Polymerase compared to Remdesivir. Also, it is thought that this study has proven SBDD to be the most suitable avenue for future drug development for the COVID-19 infection.
C1 [El Hassab, Mahmoud A.] Badr Univ Cairo BUC, Sch Pharm, Dept Pharmaceut Chem, Cairo, Egypt.
   [Shoun, Aly A.] Damanhour Univ, Dept Microbiol & Immunol, Fac Pharm, Damanhour, Egypt.
   [Al-Rashood, Sara T.] King Saud Univ, Dept Pharmaceut Chem, Coll Pharm, Riyadh, Saudi Arabia.
   [Al-Warhi, Tarfah] Princess Nourah Bint Abdulrahman Univ, Dept Chem, Coll Sci, Riyadh, Saudi Arabia.
   [Eldehna, Wagdy M.] Kafrelsheikh Univ, Dept Pharmaceut Chem, Fac Pharm, Kafrelsheikh, Egypt.
RP El Hassab, MA (corresponding author), Badr Univ Cairo BUC, Sch Pharm, Dept Pharmaceut Chem, Cairo, Egypt.; Eldehna, WM (corresponding author), Kafrelsheikh Univ, Dept Pharmaceut Chem, Fac Pharm, Kafrelsheikh, Egypt.
EM mahmoud65582@pharm.tanta.edu.eg; wagdy2000@gmail.com
FU King Saud University, Riyadh, Saudi ArabiaKing Saud University
   [RSP-2020/103]; Deanship of Scientific Research at Princess Nourah Bint
   Abdulrahman University through the Fast-track Research Funding Program
FX The authors acknowledge financial support from the Researchers
   Supporting Project number (RSP-2020/103), King Saud University, Riyadh,
   Saudi Arabia. Also, this research was funded by the Deanship of
   Scientific Research at Princess Nourah Bint Abdulrahman University
   through the Fast-track Research Funding Program.
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Alamri MA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1782768
   Almeida JD, 1968, NATURE, V220, P650
   Armstrong GL, 2019, NEW ENGL J MED, V381, P2569, DOI 10.1056/NEJMsr1813907
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Bhardwaj VK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1766572
   Blum LC, 2009, J AM CHEM SOC, V131, P8732, DOI 10.1021/ja902302h
   BOHM HJ, 1992, J COMPUT AID MOL DES, V6, P61, DOI 10.1007/BF00124387
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Bose-Basu B, 2004, BIOCHEMISTRY-US, V43, P8911, DOI 10.1021/bi049641n
   CAFLISCH A, 1993, J MED CHEM, V36, P2142, DOI 10.1021/jm00067a013
   Carlos WG, 2020, AM J RESP CRIT CARE, V201, pP7, DOI 10.1164/rccm.2014P7
   Cavanagh D, 2007, VET RES, V38, P281, DOI 10.1051/vetres:2006055
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chan-Yeung M, 2003, RESPIROLOGY, V8, pS9, DOI 10.1046/j.1440-1843.2003.00518.x
   Chiu SW, 2009, J PHYS CHEM B, V113, P2748, DOI 10.1021/jp807056c
   Choudhury C, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1771424
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Dassault Systemes BIOVIA BIOVIA Workbook Release, 2016, BIOVIA PIP PIL
   de Kloe GE, 2009, DRUG DISCOV TODAY, V14, P630, DOI 10.1016/j.drudis.2009.03.009
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Drodal S., 2020, DRUG RESIST UPDATE, V53, P100719
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   El-Hasab MA, 2018, J BIOMOL STRUCT DYN, V36, P1713, DOI 10.1080/07391102.2017.1332689
   Evensen E., 1997, MCSS VERSION 2 1
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Griffiths SK, 2015, BJA EDUC, V15, P84, DOI 10.1093/bjaceaccp/mku013
   Kennedy WP, 2007, J MOL BIOL, V370, P256, DOI 10.1016/j.jmb.2007.03.041
   Kirsch P, 2019, MOLECULES, V24, DOI 10.3390/molecules24234309
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kumar A, 2012, CURR MED CHEM, V19, P5128, DOI 10.2174/092986712803530467
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Lamb YN, 2020, DRUGS, V80, P1355, DOI 10.1007/s40265-020-01378-w
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mehta N, 2020, AM J EMERG MED, V38, P1488, DOI [10.1016/j.ajem.2020.03.011, 10.1016/j.ajem.2020.04.035]
   Mortenson PN, 2011, J COMPUT AID MOL DES, V25, P663, DOI 10.1007/s10822-011-9435-z
   Nagarajan H, 2020, MUTAT RES-FUND MOL M, V819, DOI 10.1016/j.mrfmmm.2020.111687
   Naqvi AA, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165878
   Perlman S, 2020, NEW ENGL J MED, V382, P760, DOI 10.1056/NEJMe2001126
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Roughley SD, 2011, J MED CHEM, V54, P3989, DOI 10.1021/jm200350g
   She J, 2020, CLIN TRANSL MED, V9, DOI 10.1186/s40169-020-00271-z
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Tyrrell D. A., 2002, COLD WARS FIGHT COMM
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu GS, 2003, J COMPUT CHEM, V24, P1549, DOI 10.1002/jcc.10306
   Yin W., 2020, STRUCTURAL BASIS INH, DOI [DOI 10.1101/2020.04.08.032763, 10.1101/2020.04.08.032763]
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Ziebuhr J, 2005, CURR TOP MICROBIOL, V287, P57, DOI 10.1007/3-540-26765-4_3
NR 54
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-2646
J9 FRONT CHEM
JI Front. Chem.
PD OCT 30
PY 2020
VL 8
AR 584894
DI 10.3389/fchem.2020.584894
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA OQ4SR
UT WOS:000588775700001
PM 33195080
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Haun, BK
   Lai, CY
   Williams, CA
   Wong, TAS
   Lieberman, MM
   Pessaint, L
   Andersen, H
   Lehrer, AT
AF Haun, Brien K.
   Lai, Chih-Yun
   Williams, Caitlin A.
   Wong, Teri Ann S.
   Lieberman, Michael M.
   Pessaint, Laurent
   Andersen, Hanne
   Lehrer, Axel T.
TI CoVaccine HT (TM) Adjuvant Potentiates Robust Immune Responses to
   Recombinant SARS-CoV-2 Spike S1 Immunization
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE adjuvant; recombinant subunit; COVID-19; immunogenicity; rapid response;
   SARS-CoV-2
ID T-CELL RESPONSES; SARS CORONAVIRUS; VACCINE ADJUVANTS; MICE; INFECTION;
   IMMUNOGENICITY; ACTIVATION; DISEASE
AB The current COVID-19 pandemic has claimed hundreds of thousands of lives and its causative agent, SARS-CoV-2, has infected millions, globally. The highly contagious nature of this respiratory virus has spurred massive global efforts to develop vaccines at record speeds. In addition to enhanced immunogen delivery, adjuvants may greatly impact protective efficacy of a SARS-CoV-2 vaccine. To investigate adjuvant suitability, we formulated protein subunit vaccines consisting of the recombinant S1 domain of SARS-CoV-2 Spike protein alone or in combination with either CoVaccine HT (TM) or Alhydrogel. CoVaccine HT (TM) induced high titres of antigen-binding IgG after a single dose, facilitated affinity maturation and class switching to a greater extent than Alhydrogel and elicited potent cell-mediated immunity as well as virus neutralizing antibody titres. Data presented here suggests that adjuvantation with CoVaccine HT (TM) can rapidly induce a comprehensive and protective immune response to SARS-CoV-2.
C1 [Haun, Brien K.; Lai, Chih-Yun; Williams, Caitlin A.; Wong, Teri Ann S.; Lieberman, Michael M.; Lehrer, Axel T.] Univ Hawaii, John A Burns Sch Med, Dept Trop Med, Honolulu, HI 96822 USA.
   [Haun, Brien K.; Lehrer, Axel T.] Univ Hawaii, John A Burns Sch Med, Cell & Mol Biol Grad Program, Honolulu, HI 96822 USA.
   [Pessaint, Laurent; Andersen, Hanne] BIOQUAL Inc, Rockville, MD USA.
RP Lehrer, AT (corresponding author), Univ Hawaii, John A Burns Sch Med, Dept Trop Med, Honolulu, HI 96822 USA.; Lehrer, AT (corresponding author), Univ Hawaii, John A Burns Sch Med, Cell & Mol Biol Grad Program, Honolulu, HI 96822 USA.
EM lehrer@hawaii.edu
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI132323]; Centers of Biomedical Research Excellence, National
   Institute of General Medical Sciences [P30GM114737]
FX We would like to acknowledge partial funding for these studies from
   R01AI132323 (National Institute of Allergy and Infectious Diseases),
   from P30GM114737 (Centers of Biomedical Research Excellence, National
   Institute of General Medical Sciences) and institutional funds. The
   funders played no role in the conceptualization, design, data
   collection, analysis, decision to publish, or preparation of the
   manuscript.
CR Allison AC, 1999, METHODS, V19, P87, DOI 10.1006/meth.1999.0832
   Bisht H, 2005, VIROLOGY, V334, P160, DOI 10.1016/j.virol.2005.01.042
   Blom AG, 2004, VACCINE, V23, P743, DOI 10.1016/j.vaccine.2004.07.021
   CDC, 2020, WHAT IS ADJ WHY IS I
   Channappanavar R, 2014, J VIROL, V88, P11034, DOI 10.1128/JVI.01505-14
   Chen J, 2010, J VIROL, V84, P1289, DOI 10.1128/JVI.01281-09
   Garcon N, 2012, EXPERT REV VACCINES, V11, P349, DOI [10.1586/ERV.11.192, 10.1586/erv.11.192]
   GRAHAM BS, 1993, J IMMUNOL, V151, P2032
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Gupta T, 2020, INT IMMUNOPHARMACOL, V86, DOI 10.1016/j.intimp.2020.106717
   Hamid MMA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020547
   Harris JR, 2012, MICRON, V43, P192, DOI 10.1016/j.micron.2011.07.012
   Haun Brien K, 2020, bioRxiv, DOI 10.1101/2020.07.24.220715
   Haun BK, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007614
   HILGERS LAT, 1994, VACCINE, V12, P653, DOI 10.1016/0264-410X(94)90272-0
   Hilgers LAT, 2006, VACCINE, V24, pS81, DOI 10.1016/j.vaccine.2005.01.133
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Iwasaki A, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0321-6
   Jaume M, 2011, J VIROL, V85, P10582, DOI 10.1128/JVI.00671-11
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P545, DOI 10.1016/j.it.2020.04.008
   KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955
   Kumar M, 2014, VIRUSES-BASEL, V6, P2328, DOI 10.3390/v6062328
   Kusi KA, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-182
   Lehrer AT, 2018, VACCINE, V36, P3090, DOI 10.1016/j.vaccine.2017.01.068
   Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490
   Li HF, 2008, J IMMUNOL, V181, P17, DOI 10.4049/jimmunol.181.1.17
   Luo F, 2018, VIROL SIN, V33, P201, DOI 10.1007/s12250-018-0009-2
   Ma H, 2020, CELL MOL IMMUNOL, V17, P773, DOI 10.1038/s41423-020-0474-z
   Matsuoka Y, 2016, IMMUNOL LETT, V178, P61, DOI 10.1016/j.imlet.2016.07.016
   Medina LO, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02464
   Milken Institute, 2020, COVID 19 TREATM VACC
   Morefield GL, 2005, VACCINE, V23, P1588, DOI 10.1016/j.vaccine.2004.07.050
   Namekar M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045851
   Ng OW, 2016, VACCINE, V34, P2008, DOI 10.1016/j.vaccine.2016.02.063
   Nkolola JP, 2014, VACCINE, V32, P2109, DOI 10.1016/j.vaccine.2014.02.001
   Orr MT, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-018-0094-0
   Perrin-Cocon L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002260
   Ravichandran S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc3539
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Shah RR, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47885-z
   Snell LM, 2016, CELL REP, V16, P3286, DOI 10.1016/j.celrep.2016.08.065
   Stevens NE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068895
   Sun BQ, 2020, EMERG MICROBES INFEC, V9, P940, DOI 10.1080/22221751.2020.1762515
   Sun HF, 2003, VACCINE, V21, P849, DOI 10.1016/S0264-410X(02)00531-5
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   To A, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00576-17
   Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421
   Wang YX, 2020, J MED VIROL, V92, P568, DOI 10.1002/jmv.25748
   WHO, 2020, COR DIS COVID 19 WEE, P155
   Wong SJ, 2004, J CLIN MICROBIOL, V42, P65, DOI 10.1128/JCM.42.1.65-72.2004
   Yip M S, 2016, Hong Kong Med J, V22, P25
   Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10
NR 53
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD OCT 30
PY 2020
VL 11
AR 599587
DI 10.3389/fimmu.2020.599587
PG 10
WC Immunology
SC Immunology
GA OQ3FE
UT WOS:000588672300001
PM 33193454
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Nailescu, C
   Khalid, M
   Wilson, AC
   Amanat, F
   Arregui, S
   Canas, J
   Hooks, J
   Krammer, F
   Schwaderer, AL
   Hains, DS
AF Nailescu, Corina
   Khalid, Myda
   Wilson, Amy C.
   Amanat, Fatima
   Arregui, Samuel
   Canas, Jorge
   Hooks, Jenaya
   Krammer, Florian
   Schwaderer, Andrew L.
   Hains, David S.
TI Assessment of Seroconversion to SARS-CoV-2 in a Cohort of Pediatric
   Kidney Transplant Recipients
SO FRONTIERS IN PEDIATRICS
LA English
DT Article
DE SARS-CoV-2; COVID-19; pandemic; children; pediatric; kidney; transplant;
   seroconversion
ID INFECTION; CORONAVIRUS; CHILDREN
AB Background: The occurrence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the associated coronavirus disease 2019 (COVID-19) have profoundly affected adult kidney disease patients. In contrast, pediatric solid organ transplant recipients, including pediatric kidney transplant (KT) recipients, do not seem to be at particularly higher risk for SARS-CoV-2 infection or for severe COVID-19 disease. This patient population might be protected by certain mechanisms, such as the immunosuppressive medications with their anti-inflammatory properties or simply being well-versed in self-protection techniques. Assessing SARS-CoV-2 antibody serologies could potentially help understand why this patient population is apparently spared from severe SARS-CoV-2 clinical courses.
   Objective: To examine SARS-CoV-2 serologic status in a cohort of pediatric KT recipients.
   Methods: SARS-CoV-2 anti-spike IgG and IgM antibodies were measured by three different methods in pediatric KT recipients coming for routine clinic visits immediately post-confinement in May-June of 2020. The patients were considered seroconverted if SARS-CoV-2 antibodies were positive by 2/3 methods and weak positive/indeterminate if positive by 1/3.
   Results: Thirty-one patients were evaluated (about 1/3 of our institution's pediatric KT population). One patient seroconverted, while three were considered weak positive/indeterminate. None were symptomatic and none had nasopharyngeal PCR confirmed SARS-CoV-2 disease.
   Conclusions: Seroconversion to SARS-CoV-2 was rare in this population and likely reflects the social distancing practiced by these patients. The results will serve as a foundation for a future longitudinal study to evaluate the long-term emergence and persistence of antibodies in this population and may inform studies of response to a future vaccine.
C1 [Nailescu, Corina; Khalid, Myda; Wilson, Amy C.; Arregui, Samuel; Canas, Jorge; Hooks, Jenaya; Schwaderer, Andrew L.; Hains, David S.] Indiana Univ, Dept Pediat, Indianapolis, IN 46204 USA.
   [Amanat, Fatima; Krammer, Florian] Icahn Sch Med Mt Sinai, Dept Microbiol, Med Ctr, New York, NY 10029 USA.
RP Nailescu, C (corresponding author), Indiana Univ, Dept Pediat, Indianapolis, IN 46204 USA.
EM cnailesc@iu.edu
FU Indiana Clinical and Translational Sciences Institute; National
   Institute of Health, National Center for Advancing Translational
   Sciences, Clinical and Translational Science Award [UL1TR002529]; Lilly
   Endowment Inc.
FX This project was supported in part with support from the Indiana
   Clinical and Translational Sciences Institute funded, in part by Award
   Number UL1TR002529 from the National Institute of Health, National
   Center for Advancing Translational Sciences, Clinical and Translational
   Science Award. The content is solely the responsibility of the authors
   and does not necessarily represent the official views of the National
   Institutes of Health. We acknowledge the assistance of the Clinical
   Diagnostics Laboratory, Eli Lilly and Company, for providing serologic
   samples from individuals with PCR-positive SARS-CoV-2. The study was
   supported by the Lilly Endowment Inc. Physician Scientist Initiative to
   DH and AS. FK was supported by institutional seed funding.
CR Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9
   Bunyavanich S, 2020, JAMA-J AM MED ASSOC, V323, P2427, DOI 10.1001/jama.2020.8707
   CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019
   Downes Kevin J, 2020, J Pediatric Infect Dis Soc, V9, P551, DOI 10.1093/jpids/piaa095
   Fung Monica, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa863
   Fung M, 2020, AM J TRANSPLANT, V20, P3225, DOI 10.1111/ajt.16079
   Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310
   Hains DS, 2020, JAMA-J AM MED ASSOC, V323, P2424, DOI 10.1001/jama.2020.8438
   Hicks Jennifer, 2020, medRxiv, DOI 10.1101/2020.06.22.20137695
   Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490
   Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2
   Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1088, DOI 10.1111/apa.15270
   Marlais M, 2020, LANCET CHILD ADOLESC, V4, pE17, DOI 10.1016/S2352-4642(20)30145-0
   Mehta Nisha S, 2020, Clin Infect Dis, V71, P2469, DOI 10.1093/cid/ciaa556
   Menachemi N, 2020, MMWR-MORBID MORTAL W, V69, P960, DOI 10.15585/mmwr.mm6929e1
   Minotti C, 2020, J INFECTION, V81, pE61, DOI 10.1016/j.jinf.2020.04.026
   Nickbakhsh S, 2019, P NATL ACAD SCI USA, V116, P27142, DOI 10.1073/pnas.1911083116
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Sharfstein JM, 2020, JAMA-J AM MED ASSOC, V323, P1437, DOI 10.1001/jama.2020.3864
   Simon AK, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.3085
   Slota M, 2001, CRIT CARE MED, V29, P405, DOI 10.1097/00003246-200102000-00034
   Stadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100
   Xia ZP, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13349
NR 25
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-2360
J9 FRONT PEDIATR
JI Front. Pediatr.
PD OCT 30
PY 2020
VL 8
AR 601327
DI 10.3389/fped.2020.601327
PG 5
WC Pediatrics
SC Pediatrics
GA OQ3EN
UT WOS:000588670600001
PM 33194930
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Li, JZ
   Li, XC
   Jiang, J
   Xu, XX
   Wu, J
   Xu, YY
   Lin, X
   Hall, J
   Xu, HS
   Xu, JC
   Xu, XY
AF Li, Jinzhi
   Li, Xiuchuan
   Jiang, Jie
   Xu, Xuexue
   Wu, Jing
   Xu, Yuanyuan
   Lin, Xin
   Hall, John
   Xu, Huashan
   Xu, Jincheng
   Xu, Xiaoyue
TI The Effect of Cognitive Behavioral Therapy on Depression, Anxiety, and
   Stress in Patients With COVID-19: A Randomized Controlled Trial
SO FRONTIERS IN PSYCHIATRY
LA English
DT Article
DE cognitive behavioral therapy (CBT); COVID-19; DASS-21; psychological
   health; depression; anxiety; stress
ID PSYCHOLOGICAL DISTRESS; SCALES DASS-21; NORMATIVE DATA; BREAST-CANCER;
   IMMEDIATE; SURVIVORS; IMPACT; CORONAVIRUS; SYMPTOMS; OUTBREAK
AB Background: As a public health emergency of international concern, the COVID-19 outbreak has had a tremendous impact on patients' psychological health. However, studies on psychological interventions in patients with COVID-19 are relatively rare.
   Objectives: This study examined the effectiveness of Cognitive Behavioral Therapy (CBT) in relieving patients' psychological distress during the COVID-19 epidemic.
   Methods: Ninety-three eligible participants selected by cluster sampling were randomized to an intervention group (N = 47) and a control group (N = 46). Participants in the control group received routine treatment according to the Chinese Management Guidelines for COVID-19, while participants in the intervention group received routine treatment with additional CBT. The Chinese Version of Depression Anxiety and Stress Scale-21 (DASS-21) was used to evaluate depression, anxiety, and stress for all participants at baseline and post-intervention. Two-sided t-test, and proportion tests were used to examine the differences between the intervention and control group for each DASS-21 indicator. Univariate linear regression was used to examine the association between chronic disease status and change in each DASS-21 indicator after intervention. Two-way scatter plots were generated to show the association of the length of hospital stay and the changes of each DASS-21 indicator by intervention and control groups.
   Results: Significant decreases in means were found for scales of depression, anxiety, stress and total DASS-21 in both intervention (p < 0.001) and control group (p = 0.001), with participants in the intervention group having a bigger reduction in means. After the intervention, more participants in the intervention group had no depression or anxiety symptoms than in the control group, but no statistical differences were found (p > 0.05). Compared with participants with chronic disease, participants with no chronic disease had a significantly larger reduction of total DASS-21 scale (coefficient = -4.74, 95% CI: -9.31; -0.17).The length of hospital stay was significantly associated with a greater increase in anxiety scale in the intervention group (p = 0.005), whilst no significant association was found in the control group (p = 0.29).
   Conclusions: The patients with COVID-19 experienced high levels of anxiety, depression and stress. Our study result highlights the effectiveness of CBT in improving the psychological health among patients with COVID-19, also suggests that CBT should be focused on patients with chronic disease and those who have longer hospital stays. These results have important implications in clinical practice in improving psychological health in the context of COVID-19 pandemic.
C1 [Li, Jinzhi] Bengbu Med Coll, Dept Nursing, Bengbu, Peoples R China.
   [Li, Xiuchuan] Bengbu Med Coll, Affiliated Hosp 1, Dept Nursing, Bengbu, Peoples R China.
   [Jiang, Jie; Xu, Xuexue; Xu, Jincheng] Bengbu Med Coll, Affiliated Hosp 1, Dept Stomatol, Bengbu, Peoples R China.
   [Wu, Jing; Xu, Yuanyuan] Bengbu Med Coll, Affiliated Hosp 1, Dept Resp, Bengbu, Peoples R China.
   [Lin, Xin] Peoples Hosp Bengbu 3, Dept Intens Care Unit, Bengbu, Peoples R China.
   [Hall, John; Xu, Xiaoyue] Univ New South Wales, Sch Populat Hlth, Kensington, NSW, Australia.
   [Xu, Huashan] Bengbu Med Coll, Dept Psychiat, Bengbu, Peoples R China.
RP Xu, XY (corresponding author), Univ New South Wales, Sch Populat Hlth, Kensington, NSW, Australia.
EM luna.xu@unsw.edu.au
OI Xu, Xiaoyue/0000-0003-4787-6547
FU Department of scientific center of Bengbu Medical College
FX The study was funded by Department of scientific center of Bengbu
   Medical College.
CR [Anonymous], 2020, CHIN J EPIDEMIOL, V41, DOI [10.3760/cma.j.issn.0254-6450.2020.02.003, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003, DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003]
   Arico D, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.01162
   Beck A.T., 1979, COGNITIVE THERAPY DE
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   [蔡欢乐 Cai Huanle], 2020, [中国公共卫生, China Journal of Public Health], V36, P152
   Canadian Psychiatric Association, 2006, CAN J PSYCHIAT, V51, p9S
   Carpenter JK, 2018, DEPRESS ANXIETY, V35, P502, DOI 10.1002/da.22728
   Chan P, 2018, JMIR RES PROTOC, V7, DOI 10.2196/resprot.9902
   Chen YF, 2017, PERSPECT PSYCHIATR C, V53, P329, DOI 10.1111/ppc.12184
   Cheng JG, 2020, J NURS MANAGE, V20, P247, DOI DOI 10.3969/j.issn.1671-315x.2020.04.005
   Cheng L., 2020, ZHEJIANG MED J, V42, P315
   Cheng SKW, 2004, PSYCHOL MED, V34, P1187, DOI 10.1017/S0033291704002272
   Chinese Center for Disease Control and Prevention, 2020, EP UPD RISK ASS 2019
   Crawford JR, 2003, BRIT J CLIN PSYCHOL, V42, P111, DOI 10.1348/014466503321903544
   Doerfler Leonard A, 2004, J Cardiopulm Rehabil, V24, P414, DOI 10.1097/00008483-200411000-00009
   Faller H, 2017, PSYCHO-ONCOLOGY, V26, P1741, DOI 10.1002/pon.4358
   Fukui H, 2008, MED HYPOTHESES, V71, P765, DOI 10.1016/j.mehy.2008.06.019
   [龚栩 Gong Xu], 2010, [中国临床心理学杂志, Chinese Journal of Clinical Psychology], V18, P443
   Gromisch Elizabeth S, 2020, Int J MS Care, V22, P8, DOI 10.7224/1537-2073.2018-023
   Hartley S, 2016, ENCEPHALE, V42, P395, DOI 10.1016/j.encep.2016.08.013
   Henry JD, 2005, BRIT J CLIN PSYCHOL, V44, P227, DOI 10.1348/014466505X29657
   Hofmann SG, 2013, BEHAV THER, V44, P199, DOI 10.1016/j.beth.2009.01.007
   Hollon SD, 2006, ANNU REV PSYCHOL, V57, P285, DOI 10.1146/annurev.psych.57.102904.190044
   Huang LL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205243
   Huang Wei, 2004, Zhonghua Liu Xing Bing Xue Za Zhi, V25, P23
   Jerath R, 2006, MED HYPOTHESES, V67, P566, DOI 10.1016/j.mehy.2006.02.042
   Jovanovic V, 2014, PSIHOLOGIJA, V47, P93, DOI 10.2298/PSI1401093J
   [琚明亮 Ju Mingliang], 2020, [中国神经精神疾病杂志, Chinese Journal of Nervous and Mental Diseases], V46, P65
   Kennedy SH, 2016, CAN J PSYCHIAT, V61, P540, DOI 10.1177/0706743716659417
   Kong Y, 2020, PREVALENCE FACTORS A, DOI [10.1101/2020.03.24.20043075, DOI 10.1101/2020.03.24.20043075]
   Lancaster GA, 2004, J EVAL CLIN PRACT, V10, P307, DOI 10.1111/j..2002.384.doc.x
   Laurino RA, 2012, CLINICS, V67, P1291, DOI 10.6061/clinics/2012(11)12
   Lee AM, 2007, CAN J PSYCHIAT, V52, P233, DOI 10.1177/070674370705200405
   Li JH, 2019, CONTEMP NURSE, V55, P543, DOI 10.1080/10376178.2020.1729827
   Li W, 2020, J TONGJI U MED SCI, V42, P147, DOI [10.16118/j.1008-0392.2020.02.002, DOI 10.16118/J.1008-0392.2020.02.002]
   Liu TB, 2003, J CLIN PSYCHOL MED S, V13, P188
   LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U
   Lv JF, 2016, INT HEART J, V57, P167, DOI 10.1536/ihj.15-259
   Mahase E, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m408
   Mak IWC, 2009, GEN HOSP PSYCHIAT, V31, P318, DOI 10.1016/j.genhosppsych.2009.03.001
   Marthoenis M, 2019, ASIAN J PSYCHIATR, V43, P154, DOI 10.1016/j.ajp.2019.05.030
   Maunder R, 2003, CAN MED ASSOC J, V168, P1245
   McAlonan GM, 2007, CAN J PSYCHIAT, V52, P241, DOI 10.1177/070674370705200406
   National Health Commission of the People's Republic of China, 2020, CHIN MAN GUID COVID
   National Health Commission of the People's Republic of China, 2020, TECHN GUID COVID 19
   Norton PJ, 2007, ANXIETY STRESS COPIN, V20, P253, DOI 10.1080/10615800701309279
   Olason M, 2018, INT J BEHAV MED, V25, P55, DOI 10.1007/s12529-017-9690-z
   Park E, 2013, BURNS, V39, P1101, DOI 10.1016/j.burns.2013.01.006
   Pauwels EKJ, 2014, MED PRIN PRACT, V23, P403, DOI 10.1159/000364873
   Qi Y, 2020, J TROP MED, V20, P145
   Salimpoor VN, 2011, NAT NEUROSCI, V14, P257, DOI 10.1038/nn.2726
   Schure MB, 2019, J MED INTERNET RES, V21, DOI 10.2196/14754
   Shuhaida MHN, 2019, J TAIBAH UNIV MED SC, V14, P268, DOI 10.1016/j.jtumed.2019.03.002
   Streeter CC, 2012, MED HYPOTHESES, V78, P571, DOI 10.1016/j.mehy.2012.01.021
   Tang W, 2017, JMIR MENT HEALTH, V4, DOI 10.2196/mental.5283
   Taouk M, 2001, PSYCHOMETRIC PROPERT
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   [文艺 Wen Yi], 2012, [中国公共卫生, China Public Health], V28, P1436
   World Health Organisation, 2020, 140 WHO
   [吴荔荔 Wu Lili], 2020, [第二军医大学学报, Academic Journal of Second Military Medical University], V41, P186
   Xiang YT, 2019, LANCET PSYCHIAT, V2020, P228, DOI DOI 10.1016/S2215-0366(20)30046-8
   Xu M. C., 2020, NURSING RES CHINA, V34, P368, DOI DOI 10.12102/j.issn.1009-6493.2020.03.002
   Yang YL, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-956
   [张凤 Zhang Feng], 2020, [解放军护理杂志, Nursing Journal of Chinese People's Liberation Army], V37, P16
   Zhou P, 2020, CHIN J MULT ORG DIS, V19, P221, DOI [10.11915/j.issn.1671-5403.2020.03.050, DOI 10.11915/J.ISSN.1671-5403.2020.03.050]
   魏华, 2016, [中国心理卫生杂志, Chinese Mental Health Journal], V30, P270
NR 66
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD OCT 30
PY 2020
VL 11
AR 580827
DI 10.3389/fpsyt.2020.580827
PG 12
WC Psychiatry
SC Psychiatry
GA OQ3GT
UT WOS:000588676400001
PM 33192723
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lou, E
   Teoh, D
   Brown, K
   Blaes, A
   Holtan, SG
   Jewett, P
   Parsons, H
   Mburu, EW
   Thomaier, L
   Hui, JYC
   Nelson, HH
   Vogel, RI
AF Lou, Emil
   Teoh, Deanna
   Brown, Katherine
   Blaes, Anne
   Holtan, Shernan G.
   Jewett, Patricia
   Parsons, Helen
   Mburu, E. Waruiru
   Thomaier, Lauren
   Jane Yuet Ching Hui
   Nelson, Heather H.
   Vogel, Rachel, I
TI Perspectives of cancer patients and their health during the COVID-19
   pandemic
SO PLOS ONE
LA English
DT Article
AB Introduction
   The immunosuppressive nature of some cancers and many cancer-directed treatments may increase the risk of infection with and severe sequelae from Coronavirus Disease 2019 (COVID-19). The objective of this study was to compare concerns about COVID-19 among individuals undergoing cancer treatment to those with a history of cancer not currently receiving therapy and to those without a cancer history.
   Methods
   We conducted a cross-sectional anonymous online survey study of adults currently residing in the United States. Participants were recruited over a one-week period (April 3-11, 2020) using promoted advertisements on Facebook and Twitter. Groups were compared using chi-squared tests, Fisher's exact tests, and t-tests.
   Results
   543 respondents from 47 states provided information on their cancer history and were included in analyses. Participants receiving active treatment reported greater concern about infection from the SARS-CoV-2 coronavirus (p<0.001), higher levels of family distress caused by the COVID-19 pandemic (p = 0.004), and greater concern that the general public does not adequately understand the seriousness of COVID-19 (p = 0.04). Those with metastatic disease were more likely to indicate that COVID-19 had negatively affected their cancer care compared to patients with non-metastatic cancer (50.8% vs. 31.0%; p = 0.02). The most commonly reported treatment modifications included chemotherapy delays.
   Conclusions
   Patients undergoing active treatment for cancer were most concerned about the short-term effects of the COVID-19 pandemic on the logistics as well as potential efficacy of ongoing cancer treatment, longer term effects, and overarching societal concerns that the population at large is not as concerned about the public health implications of SARS-CoV-2 infection.
C1 [Lou, Emil; Blaes, Anne; Holtan, Shernan G.; Jewett, Patricia] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA.
   [Lou, Emil; Teoh, Deanna; Blaes, Anne; Holtan, Shernan G.; Parsons, Helen; Jane Yuet Ching Hui; Nelson, Heather H.; Vogel, Rachel, I] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA.
   [Teoh, Deanna; Brown, Katherine; Thomaier, Lauren; Vogel, Rachel, I] Univ Minnesota, Dept Obstet Gynecol & Womens Hlth, Minneapolis, MN USA.
   [Parsons, Helen] Univ Minnesota, Sch Publ Hlth, Div Hlth Policy & Management, Minneapolis, MN USA.
   [Mburu, E. Waruiru; Nelson, Heather H.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
   [Jane Yuet Ching Hui] Univ Minnesota, Dept Surg, Box 242 UMHC, Minneapolis, MN 55455 USA.
RP Lou, E (corresponding author), Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA.; Lou, E (corresponding author), Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA.
EM lou@umn.edu
OI Lou, Emil/0000-0002-1607-1386; Vogel, Rachel/0000-0003-0149-8464; Hui,
   Jane Yuet Ching/0000-0002-2628-0720
FU National Institutes of Health's National Center for Advancing
   Translational Sciences [UL1TR002494]; National Cancer Institute P30
   Cancer Center Support Grant [CA77598]
FX This research was supported in part by the National Institutes of
   Health's National Center for Advancing Translational Sciences, grant
   UL1TR002494 as well as the National Cancer Institute P30 Cancer Center
   Support Grant, grant CA77598. The content is solely the responsibility
   of the authors and does not necessarily represent the official views of
   the National Institutes of Health's National Center for Advancing
   Translational Sciences or the National Cancer Institute.
CR Al-Quteimat OM, 2020, AM J CLIN ONCOL-CANC, V43, P452, DOI 10.1097/COC.0000000000000712
   American Cancer Society, COVID 19 PAND IMP CA
   Centers for Disease Control and Prevention, COR DIS 2019 COVID 1
   Chabner BA, 2020, ONCOLOGIST, V25, P455, DOI 10.1634/theoncologist.2020-0313
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Kroenke K, 2009, J AFFECT DISORDERS, V114, P163, DOI 10.1016/j.jad.2008.06.026
   Marron JM, 2020, J CLIN ONCOL, V38, P2201, DOI 10.1200/JCO.20.00960
   Schattner E, 2015, FORBES MAGAZINE
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092
   UK Coronavirus Canc, 2020, LANCET ONCOL, V21, P622, DOI 10.1016/S1470-2045(20)30230-8
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 11
TC 1
Z9 1
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 30
PY 2020
VL 15
IS 10
AR e0241741
DI 10.1371/journal.pone.0241741
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OP8VN
UT WOS:000588368900043
PM 33125442
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Olagoke, AA
   Olagoke, OO
   Hughes, AM
AF Olagoke, Ayokunle A.
   Olagoke, Olakanmi O.
   Hughes, Ashley M.
TI Intention to Vaccinate Against the Novel 2019 Coronavirus Disease: The
   Role of Health Locus of Control and Religiosity
SO JOURNAL OF RELIGION & HEALTH
LA English
DT Article; Early Access
DE Religiosity; Health Locus of Control; COVID-19; Vaccination
AB The urgency to develop a vaccine against the 2019 coronavirus (COVID-19) has waxed stronger in speed, scale, and scope. However, wisdom dictates that we take a vantage position and start to examine the demographic predictors of COVID-19 vaccine hesitancy. The objective of this study was to examine the role of health locus of control (HLOC) in the relationship between religiosity and COVID-19 vaccination intention. In a cross-sectional survey (N = 501), we found a significantly negative association between religiosity and COVID-19 vaccination intention. This relationship was partially mediated by external HLOC. Collaborative efforts with religious institutions may influence COVID-19 vaccine uptake.
C1 [Olagoke, Ayokunle A.] Univ Illinois, Sch Publ Hlth, Div Community Hlth Sci, 1603 W Taylor, Chicago, IL 60612 USA.
   [Olagoke, Olakanmi O.] John H Stroger Jr Hosp Cook Cty, Dept Internal Med, Chicago, IL USA.
   [Hughes, Ashley M.] Univ Illinois, Coll Appl Hlth Sci, Dept Biomed & Hlth Informat Sci, Chicago, IL USA.
   [Hughes, Ashley M.] Edward Hines JR VA Med Ctr, Ctr Innovat Chron & Complex Healthcare, Hines, IL USA.
RP Olagoke, AA (corresponding author), Univ Illinois, Sch Publ Hlth, Div Community Hlth Sci, 1603 W Taylor, Chicago, IL 60612 USA.
EM aolago2@uic.edu
RI Olagoke, Ayo/AAZ-2484-2020
OI Olagoke, Ayokunle/0000-0003-0271-4069
FU Bill and Melinda Gates FoundationBill & Melinda Gates Foundation
FX Ayokunle Olagoke (MPH) founded Health Disseminate, a non-governmental
   organization on knowledge translation of public health research. She is
   a doctoral candidate at the Department of Community Health Sciences,
   School of Public Health, University of Illinois, Chicago. She is the
   founder and Minister in Charge of Friends Bible Study, an online
   non-denominational group with over 5000 total attendance since 2019
   (https://sites.google.com/site/icallufriendz/home?authuser=0).She has
   worked as a Media Consultant to the Johns Hopkins public health
   initiative in Africa, funded by Bill and Melinda Gates Foundation. Her
   current project is the development of a Scriptureembedded message to
   improve human papillomavirus vaccination among religious parents.
CR Aharon AA, 2018, HUM VACC IMMUNOTHER, V14, P1618, DOI 10.1080/21645515.2018.1471305
   Ali I, 2020, MED ANTHROPOL, V39, P376, DOI 10.1080/01459740.2020.1745481
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Bentzen J. S, 2020, CEPR DISCUSSION PAPE
   Bentzen JS, 2019, ECON J, V129, P2295, DOI 10.1093/ej/uez008
   Cacciatore MA, 2018, PUBLIC UNDERST SCI, V27, P11, DOI 10.1177/0963662516661090
   CDC, 2020, COR DIS 2019 COVID 1
   Cumming G, 2014, PSYCHOL SCI, V25, P7, DOI 10.1177/0956797613504966
   Dollinger S. J., 2001, INT J PSYCHOL RELIG, V11, P71, DOI [DOI 10.1207/S15327582IJPR1102_, DOI 10.1207/S15327582IJPR1102_01]
   Erdem G, 2016, J COMMUNITY PSYCHOL, V44, P464, DOI 10.1002/jcop.21782
   Harris A H, 1999, J Health Psychol, V4, P413, DOI 10.1177/135910539900400309
   Hayes AF, 2009, COMMUN MONOGR, V76, P408, DOI 10.1080/03637750903310360
   Holt Cheryl L, 2009, Urol Nurs, V29, P249
   Koenig HG, 2010, RELIGIONS, V1, P78, DOI 10.3390/rel1010078
   Koenig HG, 1997, AM J GERIAT PSYCHIAT, V5, P131
   Kouzy R, 2020, CUREUS, V12, DOI 10.7759/cureus.7255
   Le Daisy, 2018, JMIR Form Res, V2, pe5, DOI 10.2196/formative.8112
   Lee BY, 2020, FORBES
   Liao QY, 2011, INT J BEHAV MED, V18, P93, DOI 10.1007/s12529-010-9123-8
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Mahdi S, 2016, J RELIG HEALTH, V55, P403, DOI 10.1007/s10943-015-0154-y
   McPhetres J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207125
   Palan S, 2018, J BEHAV EXP FINANC, V17, P22, DOI 10.1016/j.jbef.2017.12.004
   Pargament K. I., 2001, PSYCHOL RELIG COPING
   Pashak TJ, 2020, J RELIG HEALTH, V59, P725, DOI 10.1007/s10943-018-0623-1
   Peer E, 2017, J EXP SOC PSYCHOL, V70, P153, DOI 10.1016/j.jesp.2017.01.006
   Pereira I., 2020, ABC NEWS
   Pulpit and Pen, 2020, CHAR PROPH SAYS COR
   Robins D., 2020, IS BILL GATES PREPAR
   Scheitle CP, 2018, PUBLIC UNDERST SCI, V27, P59, DOI 10.1177/0963662517718145
   Scheufele DA, 2009, NAT NANOTECHNOL, V4, P91, DOI [10.1038/nnano.2008.361, 10.1038/NNANO.2008.361]
   Singh L., 2020, ARXIV200313907
   Sjolander A, 2017, EPIDEMIOLOGY, V28, P540, DOI 10.1097/EDE.0000000000000649
   Sobel M.E., 1982, SOCIOL METHODOL, V13, P290, DOI DOI 10.2307/270723
   Thabane L, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-92
   Tix AP, 1998, J CONSULT CLIN PSYCH, V66, P411, DOI 10.1037/0022-006X.66.2.411
   Walker TY, 2017, MMWR-MORBID MORTAL W, V66, P874, DOI 10.15585/mmwr.mm6633a2
   WALLSTON KA, 1978, HEALTH EDUC QUART, V6, P160, DOI 10.1177/109019817800600107
   Wallston KA, 2005, J HEALTH PSYCHOL, V10, P623, DOI 10.1177/1359105305055304
   WHO, 2020, 84 WHO
   Wilder-Smith A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa020
   Wilson AR, 2016, BMC WOMENS HEALTH, V16, DOI 10.1186/s12905-016-0323-5
   Wormald B, 2015, RELIG LANDSCAPE STUD, P11
   Cuan-Baltazar JY, 2020, JMIR PUBLIC HLTH SUR, V6, P176, DOI 10.2196/18444
NR 44
TC 0
Z9 0
U1 3
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0022-4197
EI 1573-6571
J9 J RELIG HEALTH
JI J. Relig. Health
DI 10.1007/s10943-020-01090-9
EA OCT 2020
PG 16
WC Public, Environmental & Occupational Health; Religion
SC Public, Environmental & Occupational Health; Religion
GA ON9OQ
UT WOS:000587020900003
PM 33125543
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Heinz, FX
   Stiasny, K
AF Heinz, Franz X.
   Stiasny, Karin
TI Profile of SARS-CoV-2
SO WIENER KLINISCHE WOCHENSCHRIFT
LA English
DT Article
DE COVID-19; Coronavirus; Origin and evolution; Vaccines; Antivirals
ID CORONAVIRUS; SARS; EMERGENCE; ACE2; EPIDEMIOLOGY; PATHOGENESIS;
   PNEUMONIA; COVID-19; PROTECTS; IMMUNITY
AB The recent emergence of a new coronavirus (severe acute respiratory syndrome corona-virus-2, SARS-CoV-2) that is transmitted efficiently among humans and can result in serious disease and/or death has become a global threat to public health and economy. In this article, we describe some of the most important characteristics of this new virus (including gaps in our understanding) and provide a perspective of ongoing activities for developing virus-specific countermeasures, such as vaccines and antiviral drugs.
C1 [Heinz, Franz X.; Stiasny, Karin] Med Univ Vienna, Ctr Virol, Kinderspitalgasse 15, A-1090 Vienna, Austria.
RP Heinz, FX (corresponding author), Med Univ Vienna, Ctr Virol, Kinderspitalgasse 15, A-1090 Vienna, Austria.
EM franz.x.heinz@meduniwien.ac.at
FU Medical University of Vienna
FX Open access funding provided by Medical University of Vienna.
CR Abella BS, 2020, JAMA INTERN MED, DOI 10.1001/jamainternmed.2020.6319
   Akbar AN, 2020, SCIENCE, V369, P256, DOI 10.1126/science.abb0762
   Altmann DM, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd6160
   Alturki SO, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01880
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Arvin AM, 2020, NATURE, DOI 10.1038/s41586-020-2538-8
   Bottcher-Friebertshauser E, 2013, PATHOG DIS, V69, P87, DOI 10.1111/2049-632X.12053
   Boni MF, 2020, NAT MICROBIOL, V5, P1408, DOI 10.1038/s41564-020-0771-4
   Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9
   Bunders MJ, 2020, IMMUNITY, V53, P487, DOI 10.1016/j.immuni.2020.08.003
   Burton DR, 2020, CELL HOST MICROBE, V27, P695, DOI 10.1016/j.chom.2020.04.022
   Canete PF, 2020, CELL, V183, P13, DOI 10.1016/j.cell.2020.09.013
   Case JB, 2020, CELL HOST MICROBE, V28, P465, DOI 10.1016/j.chom.2020.07.018
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Cunha LL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01748
   Day T, 2020, CURR BIOL, V30, pR849, DOI 10.1016/j.cub.2020.06.031
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Dearlove B, 2020, P NATL ACAD SCI USA, V117, P23652, DOI 10.1073/pnas.2008281117
   Dong MZ, 2020, BIOMED PHARMACOTHER, V131, DOI 10.1016/j.biopha.2020.110678
   Edridge AWD, 2020, NAT MED, V26, P1691, DOI 10.1038/s41591-020-1083-1
   Fiolet Thibault, 2021, Clin Microbiol Infect, V27, P19, DOI 10.1016/j.cmi.2020.08.022
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Forni D, 2017, TRENDS MICROBIOL, V25, P35, DOI 10.1016/j.tim.2016.09.001
   Fu LF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18233-x
   Fulton CDM, 2020, BRAIN BEHAV IMMUN HL, V7, P100105, DOI 10.1016/j.bbih.2020.100105
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Graham RL, 2020, IMMUNITY, V52, P734, DOI 10.1016/j.immuni.2020.04.016
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Gross S, 2020, J MOL CELL CARDIOL, V144, P47, DOI 10.1016/j.yjmcc.2020.04.031
   Grubaugh ND, 2020, CELL, V182, P794, DOI 10.1016/j.cell.2020.06.040
   Hansen J, 2020, SCIENCE, V369, P1010, DOI 10.1126/science.abd0827
   Hassan AO, 2020, CELL, V183, P169, DOI 10.1016/j.cell.2020.08.026
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Iacob S, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01224
   Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483
   Jeyanathan M, 2020, NAT REV IMMUNOL, V20, P615, DOI 10.1038/s41577-020-00434-6
   Jin ZM, 2020, NAT STRUCT MOL BIOL, V27, P529, DOI 10.1038/s41594-020-0440-6
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Khbou MK, 2020, VET MED SCI, DOI 10.1002/vms3.359
   Klasse PJ, 2020, ELIFE, V9, DOI 10.7554/eLife.57877
   Konno Y, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108185
   Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lee WS, 2020, NAT MICROBIOL, V5, P1185, DOI 10.1038/s41564-020-00789-5
   Lei XB, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17665-9
   Liu DX, 2014, ANTIVIR RES, V109, P97, DOI 10.1016/j.antiviral.2014.06.013
   Liu P, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008421
   Liu STH, 2020, NAT MED, V26, P1708, DOI 10.1038/s41591-020-1088-9
   MacLean OA, 2020, VIRUS EVOL, V6, DOI 10.1093/ve/veaa034
   Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871
   McCreary EK, 2020, JAMA-J AM MED ASSOC, V324, P1041, DOI 10.1001/jama.2020.16337
   McKay PF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17409-9
   Memish ZA, 2020, LANCET, V395, P1063, DOI 10.1016/S0140-6736(19)33221-0
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Minskaia E, 2006, P NATL ACAD SCI USA, V103, P5108, DOI 10.1073/pnas.0508200103
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4
   Nathanson N, 2010, AM J EPIDEMIOL, V172, P1213, DOI 10.1093/aje/kwq320
   Pardo Joe, 2020, Drugs Context, V9, DOI 10.7573/dic.2020-4-14
   Peeples L, 2020, P NATL ACAD SCI USA, V117, P8218, DOI 10.1073/pnas.2005456117
   Poland GA, 2020, MAYO CLIN PROC, V95, P2172, DOI 10.1016/j.mayocp.2020.07.021
   Reusken CBEM, 2016, CURR OPIN VIROL, V16, P55, DOI 10.1016/j.coviro.2016.01.004
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Santos ID, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01818
   Scully EP, 2020, NAT REV IMMUNOL, V20, P442, DOI 10.1038/s41577-020-0348-8
   Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0
   Tang T, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104792
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   To Kelvin Kai-Wang, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1275
   Vardhana SA, 2020, J EXP MED, V217, DOI 10.1084/jem.20200678
   Walls AC, 2020, ELICITATION POTENT N
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wilder-Smith A, 2020, LANCET INFECT DIS, V20, pE102, DOI 10.1016/S1473-3099(20)30129-8
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wrobel AG, 2020, NAT STRUCT MOL BIOL, V27, P763, DOI 10.1038/s41594-020-0468-7
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Xia HJ, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108234
   Xiao KP, 2020, NATURE, V583, P286, DOI 10.1038/s41586-020-2313-x
   Xie XP, 2020, CELL HOST MICROBE, V27, P841, DOI 10.1016/j.chom.2020.04.004
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang JY, 2020, NATURE, V586, P572, DOI 10.1038/s41586-020-2599-8
   Yao HP, 2020, CELL, V183, P730, DOI 10.1016/j.cell.2020.09.018
   Young BE, 2020, LANCET, V396, P603, DOI 10.1016/S0140-6736(20)31757-8
   Yurkovetskiy L, 2020, CELL, V183, P739, DOI 10.1016/j.cell.2020.09.032
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zost SJ, 2020, NATURE, DOI 10.1038/s41586-020-2548-6
NR 94
TC 0
Z9 0
U1 4
U2 4
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0043-5325
EI 1613-7671
J9 WIEN KLIN WOCHENSCHR
JI Wien. Klin. Wochen.
PD NOV
PY 2020
VL 132
IS 21-22
SI SI
BP 635
EP 644
DI 10.1007/s00508-020-01763-1
EA OCT 2020
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA PD0SK
UT WOS:000585779900002
PM 33125580
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Oberemok, VV
   Laikova, KV
   Yurchenko, KA
   Fomochkina, II
   Kubyshkin, AV
AF Oberemok, Volodymyr V.
   Laikova, Kateryna V.
   Yurchenko, Kseniya A.
   Fomochkina, Irina I.
   Kubyshkin, Anatolii V.
TI SARS-CoV-2 will continue to circulate in the human population: no
   worries with state-of-the-art research and dependably useful results
SO INFLAMMATION RESEARCH
LA English
DT Letter; Early Access
ID COVID-19 PNEUMONIA; RADIATION-THERAPY
AB This short article provides additional justification for our understanding of the virus-host relationship in the population. Some new data are presented concerning viral structure/behavior and a critical assessment on the possibilities of using new approaches for the treatment of patients with COVID-19.
C1 [Oberemok, Volodymyr V.; Laikova, Kateryna V.; Yurchenko, Kseniya A.; Fomochkina, Irina I.; Kubyshkin, Anatolii V.] VI Vernadsky Crimean Fed Univ, Simferopol, Ukraine.
RP Kubyshkin, AV (corresponding author), VI Vernadsky Crimean Fed Univ, Simferopol, Ukraine.
EM Kubyshkin_av@mail.ru
RI Kubyshkin, Anatoliy/L-9262-2013
OI Kubyshkin, Anatoliy/0000-0002-1309-4005
FU Russian FederationRussian Federation [FZEG-20200060]
FX This work was supported by state program No FZEG-20200060 of the Russian
   Federation.
CR Bevelacqua JJ, 2020, INFLAMM RES, V69, P1159, DOI 10.1007/s00011-020-01405-2
   Iordanskiy S, 2015, VIROLOGY, V485, P1, DOI 10.1016/j.virol.2015.06.021
   Kefayat A, 2020, RADIOTHER ONCOL, V147, P224, DOI 10.1016/j.radonc.2020.04.026
   Kirsch DG, 2020, RADIOTHER ONCOL, V147, P217, DOI 10.1016/j.radonc.2020.04.060
   Kupferschmidt K, 2020, SCIENCE, V369, P238, DOI 10.1126/science.369.6501.238
   Oberemok VV, 2020, INFLAMM RES, V69, P801, DOI 10.1007/s00011-020-01377-3
   Oberemok VV, 2020, INFLAMM RES, V69, P635, DOI 10.1007/s00011-020-01352-y
   Ramirez-Fort MK, 2018, J CLIN VIROL, V98, P18, DOI 10.1016/j.jcv.2017.11.004
NR 8
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1023-3830
EI 1420-908X
J9 INFLAMM RES
JI Inflamm. Res.
DI 10.1007/s00011-020-01417-y
EA OCT 2020
PG 2
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA OK9XC
UT WOS:000584996400001
PM 33123787
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Vinals, C
   Mesa, A
   Roca, D
   Vidal, M
   Pueyo, I
   Conget, I
   Gimenez, M
AF Vinals, Clara
   Mesa, Alex
   Roca, Daria
   Vidal, Merce
   Pueyo, Irene
   Conget, Ignacio
   Gimenez, Marga
TI Management of glucose profile throughout strict COVID-19 lockdown by
   patients with type 1 diabetes prone to hypoglycaemia using
   sensor-augmented pump
SO ACTA DIABETOLOGICA
LA English
DT Article; Early Access
DE Type 1 diabetes; Hypoglycaemia; COVID-19 lockdown; sensor-augmented pump
ID GLYCEMIC CONTROL; ADULTS; THERAPY
AB Aims Spain has been one of the worst affected countries by the COVID-19 pandemic. A very strict lockdown at home was imposed with a tough restriction of mobility. We aimed to evaluate the impact of this exceptional scenario on glucose profile of patients with type 1 diabetes (T1D) prone to hypoglycaemia using sensor-augmented pump (SAP). Methods Patients with T1D prone to hypoglycaemia using SAP (640G Medtronic-Minimed (R)) for at least 6 months under the funding of a National Health Service were included in an observational, retrospective study. Data were collected in two periods: pre-lockdown (PL), February 23rd-March 7th and within lockdown (WL), April 1st to 14th 2020. The primary outcome was the difference in the proportion of time in target glucose range of 70-180 mg/dL (TIR). Additional glucometric data and total daily insulin were also analysed. Results Fifty-nine patients were included: 33 women, age 46.17 +/- 13.0 years and disease duration of 30.2 +/- 12.0 years. TIR 70-180 mg/dL (67.6 +/- 11.8 vs. 69.8 +/- 12.0%), time > 180 (28.1 +/- 13.6 vs. 25.5 +/- 13.1%), time > 250 (6.9 +/- 6.1 vs. 5.1 +/- 4.8) and estimated HbA(1c) (6.94 +/- 0.8 vs. 6.75 +/- 0.7%) significantly improved (PL vs. WL, respectively, p < 0.05). Time in hypoglycaemia, coefficient of variation, sensor usage and total daily insulin dose remained unchanged. Conclusions Lockdown conditions imposed by the COVID-19 pandemic may be managed successfully in terms of glycaemia control by population with DT1 prone to hypoglycaemia using SAP. The strict daily routine at home could probably explain the improvement in the time in glycemic target without increasing the time hypoglycaemia.
C1 [Vinals, Clara; Mesa, Alex; Roca, Daria; Vidal, Merce; Pueyo, Irene; Conget, Ignacio; Gimenez, Marga] Hosp Clin & Univ, Endocrinol & Nutr Dept, Diabet Unit, Villarroel 170, Barcelona 08036, Spain.
   [Conget, Ignacio; Gimenez, Marga] Ctr Invest Biomed Red Diabet & Enfermedades Metab, CIBERDEM, Madrid, Spain.
   [Conget, Ignacio; Gimenez, Marga] Inst Invest Biomed August Pi i Sunyer, IDIBAPS, Barcelona, Spain.
RP Vinals, C (corresponding author), Hosp Clin & Univ, Endocrinol & Nutr Dept, Diabet Unit, Villarroel 170, Barcelona 08036, Spain.
EM vinals@clinic.cat
OI Vinals, Clara/0000-0002-6888-0396
CR Abraham MB, 2018, DIABETES CARE, V41, P303, DOI 10.2337/dc17-1604
   American Diabetes Association 11, 2020, DIABETES CARE S1, V43, pS135, DOI [10.2337/dc20-S011, DOI 10.2337/DC20-S005]
   [Anonymous], 2020, BOEA20203692
   Battelino T, 2019, DIABETES CARE, V42, P1593, DOI 10.2337/dci19-0028
   Beato-Vibora PI, 2020, DIABETES TECHNOL THE, V22, P643, DOI 10.1089/dia.2020.0184.retract
   Bonora BM, 2020, DIABETES THER, V11, P1369, DOI 10.1007/s13300-020-00829-7
   Bosi E, 2019, LANCET DIABETES ENDO, V7, P462, DOI 10.1016/S2213-8587(19)30150-0
   Capaldo B, 2020, DIABETES CARE, V43, pE88, DOI 10.2337/dc20-1127
   Chu DK, 2020, LANCET, V395, P1973, DOI 10.1016/S0140-6736(20)31142-9
   Fernandez E, 2020, DIABETES RES CLIN PR, V166, DOI 10.1016/j.diabres.2020.108348
   Ghosal S, 2020, DIABETES METAB SYND, V14, P319, DOI 10.1016/j.dsx.2020.03.014
   Griggs S, 2019, DIABETES RES CLIN PR, V150, P17, DOI 10.1016/j.diabres.2019.02.012
   Hansen UM, 2019, DIABETES CARE, V42, P797, DOI 10.2337/dc18-1426
   Beato-Vibora PI, 2018, DIABETES TECHNOL THE, V20, P738, DOI 10.1089/dia.2018.0199
   Keesara S, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2005835
   Ly TT, 2013, JAMA-J AM MED ASSOC, V310, P1240, DOI 10.1001/jama.2013.277818
   Mesa A, 2020, DIABETES RES CLIN PR, V167, DOI 10.1016/j.diabres.2020.108354
   Norgaard Kirsten, 2020, J Diabetes Sci Technol, V14, P767, DOI 10.1177/1932296820929378
   Rodbard D, 2020, DIABETES TECHNOL THE, V22, P492, DOI 10.1089/dia.2019.0440
   Tornese G, 2020, DIABETES TECHNOL THE, V22, P462, DOI 10.1089/dia.2020.0169
NR 20
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 0940-5429
EI 1432-5233
J9 ACTA DIABETOL
JI Acta Diabetol.
DI 10.1007/s00592-020-01625-2
EA OCT 2020
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA OI0QD
UT WOS:000582990700001
PM 33125525
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Azam, F
   Taban, IM
   Eid, EEM
   Iqbal, M
   Alam, O
   Khan, S
   Mahmood, D
   Anwar, MJ
   Khalilullah, H
   Khan, MU
AF Azam, Faizul
   Taban, Ismail M.
   Eid, Eltayeb E. M.
   Iqbal, Muzaffar
   Alam, Ozair
   Khan, Shamshir
   Mahmood, Danish
   Anwar, Md Jamir
   Khalilullah, Habibullah
   Khan, M. U.
TI An in-silico analysis of ivermectin interaction with potential
   SARS-CoV-2 targets and host nuclear importin alpha
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Antiviral agents; SARS-CoV-2; ivermectin; docking; molecular dynamics
ID STRUCTURE-BASED DESIGN; MOLECULAR DOCKING; MM-GBSA; INHIBITORS;
   DYNAMICS; BINDING; IDENTIFICATION; LOCALIZATION; DERIVATIVES; PROTECTION
AB Ivermectin (IVM) is a broad-spectrum antiparasitic agent, having inhibitory potential against wide range of viral infections. It has also been found to hamper SARS-CoV-2 replication in vitro, and its precise mechanism of action against SARS-CoV-2 is yet to be understood. IVM is known to interact with host importin (IMP)alpha directly and averts interaction with IMP beta 1, leading to the prevention of nuclear localization signal (NLS) recognition. Therefore, the current study seeks to employ molecular docking, molecular mechanics generalized Born surface area (MM-GBSA) analysis and molecular dynamics simulation studies for decrypting the binding mode, key interacting residues as well as mechanistic insights on IVM interaction with 15 potential drug targets associated with COVID-19 as well as IMP alpha. Among all COVID-19 targets, the non-structural protein 9 (Nsp9) exhibited the strongest affinity to IVM showing -5.30 kcal/mol and -84.85 kcal/mol binding energies estimated by AutoDock Vina and MM-GBSA, respectively. However, moderate affinity was accounted for IMP alpha amounting -6.9 kcal/mol and -66.04 kcal/mol. Stability of the protein-ligand complexes of Nsp9-IVM and IMP alpha-IVM was ascertained by 100 ns trajectory of all-atom molecular dynamics simulation. Structural conformation of protein in complex with docked IVM exhibited stable root mean square deviation while root mean square fluctuations were also found to be consistent. In silico exploration of the potential targets and their interaction profile with IVM can assist experimental studies as well as designing of COVID-19 drugs.
   Communicated by Ramaswamy H. Sarma
C1 [Azam, Faizul; Eid, Eltayeb E. M.; Khalilullah, Habibullah; Khan, M. U.] Qassim Univ, Unaizah Coll Pharm, Dept Pharmaceut Chem & Pharmacognosy, Buraydah, Saudi Arabia.
   [Taban, Ismail M.] Cardiff Univ, Sch Biosci, Cardiff, Wales.
   [Taban, Ismail M.] Misurata Univ, Fac Pharm, Dept Pharmaceut Chem, Misurata, Libya.
   [Iqbal, Muzaffar] King Saud Univ, Coll Pharm, Dept Pharmaceut Chem, Riyadh, Saudi Arabia.
   [Alam, Ozair] Sch Pharmaceut Educ & Res, Dept Pharmaceut Chem, Med Chem & Mol Modelling Lab, New Delhi, India.
   [Khan, Shamshir] Buraydah Private Coll, Dent & Pharm Coll, Dept Pharmaceut Chem, Buraydah, Saudi Arabia.
   [Mahmood, Danish; Anwar, Md Jamir] Qassim Univ, Unaizah Coll Pharm, Dept Pharmacol & Toxicol, Buraydah, Saudi Arabia.
RP Azam, F (corresponding author), Qassim Univ, Unaizah Coll Pharm, Dept Pharmaceut Chem & Pharmacognosy, Buraydah, Saudi Arabia.
EM faizulazam@gmail.com
RI Azam, Faizul/G-9993-2013
OI Azam, Faizul/0000-0002-2927-8167
CR Ahmed Musa, 2016, Curr Drug Discov Technol, V13, P41
   Ahmed MA, 2012, J PHARM BIOALLIED SC, V4, P43, DOI 10.4103/0975-7406.92728
   [Anonymous], 2020, DESMOND MOL DYNAMICS
   Azam F, 2019, MOL SIMULAT, V45, P1563, DOI 10.1080/08927022.2019.1662003
   Azam F, 2018, J BIOMOL STRUCT DYN, V36, P2099, DOI 10.1080/07391102.2017.1338164
   Azam F, 2015, NETWORK-COMP NEURAL, V26, P97, DOI 10.3109/0954898X.2016.1146416
   Azam F, 2014, DRUG DES DEV THER, V8, P2045, DOI 10.2147/DDDT.S67778
   Azam F, 2012, MED CHEM, V8, P1057
   BORKOTOKY S, 2020, J BIOMOL STRUCT 0608, DOI DOI https://doi.org/10.1080/07391102.2020.1774419
   Bowers K. J., 2006, SC 06 P 2006 ACM IEE
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   CHANDEL V, 2020, J BIOMOL STRUCT 0824, DOI DOI https://doi.org/10.1080/07391102.2020.1811773
   DEOLIVEIRA OV, 2020, J BIOMOL STRUCT 0601, DOI DOI https://doi.org/10.1080/07391102.2020.1772885
   EID EEM, 2019, MOLECULES, V24, DOI DOI https://doi.org/10.3390/molecules24142554
   FAHMY NM, 2020, CHEM BIODIVERS, V17, DOI DOI https://doi.org/10.1002/cbdv.201900511
   Fraser JE, 2014, J INFECT DIS, V210, P1780, DOI 10.1093/infdis/jiu319
   Gaillard T, 2018, J CHEM INF MODEL, V58, P1697, DOI 10.1021/acs.jcim.8b00312
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Gotz V, 2016, SCI REP-UK, V6, DOI 10.1038/srep23138
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864
   HOOVER WG, 1985, PHYS REV A, V31, P1695, DOI 10.1103/PhysRevA.31.1695
   Hospital Adam, 2015, Adv Appl Bioinform Chem, V8, P37, DOI 10.2147/AABC.S70333
   HUMPHREYS DD, 1994, J PHYS CHEM-US, V98, P6885, DOI 10.1021/j100078a035
   Hussain MS, 2016, PHARM BIOL, V54, P628, DOI 10.3109/13880209.2015.1070877
   Jans DA, 2019, CURR OPIN CELL BIOL, V58, P50, DOI 10.1016/j.ceb.2019.01.001
   KHAN MT, 2020, J BIOMOL STRUCT 0527, DOI DOI https://doi.org/10.1080/07391102.2020.1769733
   Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625
   Kong Ren, 2020, Bioinformatics, V36, P5109, DOI 10.1093/bioinformatics/btaa645
   Kosyna FK, 2015, BIOL CHEM, V396, P1357, DOI 10.1515/hsz-2015-0171
   Littler DR, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101258
   Lundberg L, 2013, ANTIVIR RES, V100, P662, DOI 10.1016/j.antiviral.2013.10.004
   Luvira V, 2014, INT HEALTH, V6, P273, DOI 10.1093/inthealth/ihu058
   Lyne PD, 2006, J MED CHEM, V49, P4805, DOI 10.1021/jm060522a
   MAHANTA S, 2020, J BIOMOL STRUCT 0522, DOI DOI https://doi.org/10.1080/07391102.2020.1768902
   MARTYNA GJ, 1994, J CHEM PHYS, V101, P4177, DOI 10.1063/1.467468
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   OBOYLE NM, 2011, J CHEMINFORMATICS, V3, DOI DOI https://doi.org/10.1186/1758-2946-3-33
   Pumroy RA, 2015, BIOCHEM J, V466, P13, DOI 10.1042/BJ20141186
   ROMANO M, 2020, CELLS BASEL, V9, DOI DOI https://doi.org/10.3390/cells9051267
   Schenone M, 2013, NAT CHEM BIOL, V9, P232, DOI [10.1038/NCHEMBIO.1199, 10.1038/nchembio.1199]
   Sgobba M, 2012, EUR J MED CHEM, V58, P431, DOI 10.1016/j.ejmech.2012.10.024
   Shushni M. A. M., 2013, NATURAL PRODUCT COMM, V8
   SK MF, 2020, J BIOMOL STRUCT 0527, DOI DOI https://doi.org/10.1080/07391102.2020.1768149
   Snijder EJ, 2016, ADV VIRUS RES, V96, P59, DOI 10.1016/bs.aivir.2016.08.008
   Tay MYF, 2013, ANTIVIR RES, V99, P301, DOI 10.1016/j.antiviral.2013.06.002
   Tay MYF, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005886
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   VIHINEN M, 1987, PROTEIN ENG, V1, P477, DOI 10.1093/protein/1.6.477
   Vijayakumar B, 2014, PHARMACOGN MAG, V10, P639, DOI 10.4103/0973-1296.139809
   Wagstaff KM, 2012, BIOCHEM J, V443, P851, DOI 10.1042/BJ20120150
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Yamasmith E., 2018, HE 34 ANN M ROYAL CO
   Yang CW, 2020, BIOMED J, V43, P368, DOI 10.1016/j.bj.2020.05.003
   YANG SNY, 2019, CELLS BASEL, V8, DOI DOI https://doi.org/10.3390/cells8030281
   Yang SNY, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104760
   Zeng Z, 2018, J VIROL, V92, DOI 10.1128/JVI.00692-18
NR 58
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1841028
EA OCT 2020
PG 14
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OI7LK
UT WOS:000583455200001
PM 33131430
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Wiwanitkit, V
AF Wiwanitkit, Viroj
TI Plasma exchange therapy and COVID-19
SO THERAPEUTIC APHERESIS AND DIALYSIS
LA English
DT Letter; Early Access
C1 [Wiwanitkit, Viroj] Dr DY Patil Univ, Dept Community Med, Pune, Maharashtra, India.
RP Wiwanitkit, V (corresponding author), Dr DY Patil Univ, Dept Community Med, Pune, Maharashtra, India.
EM wviroj@yahoo.com
CR Hua TF, 2020, THER APHER DIAL, DOI 10.1111/1744-9987.13586
   Joob B, 2020, J AM ACAD DERMATOL, V82, pE177, DOI 10.1016/j.jaad.2020.03.036
   Wiwanitkit V, 2010, EXPERT REV ANTI-INFE, V8, P841, DOI [10.1586/eri.10.53, 10.1586/ERI.10.53]
NR 3
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1744-9979
EI 1744-9987
J9 THER APHER DIAL
JI Ther. Apher. Dial.
DI 10.1111/1744-9987.13596
EA OCT 2020
PG 1
WC Hematology; Urology & Nephrology
SC Hematology; Urology & Nephrology
GA OL0BM
UT WOS:000585008200001
PM 33040416
OA Green Published
DA 2021-01-01
ER

PT J
AU Oertel, M
   Elsayad, K
   Engenhart-Cabillic, R
   Reinartz, G
   Baues, C
   Schmidberger, H
   Vordermark, D
   Marnitz, S
   Lukas, P
   Ruebe, C
   Engert, A
   Lenz, G
   Eich, HT
AF Oertel, M.
   Elsayad, K.
   Engenhart-Cabillic, R.
   Reinartz, G.
   Baues, C.
   Schmidberger, H.
   Vordermark, D.
   Marnitz, S.
   Lukas, P.
   Ruebe, C.
   Engert, A.
   Lenz, G.
   Eich, H. T.
TI Radiation treatment of hemato-oncological patients in times of the
   COVID-19 pandemic Expert recommendations from the radiation oncology
   panels of the German Hodgkin Study Group and the German Lymphoma
   Alliance
SO STRAHLENTHERAPIE UND ONKOLOGIE
LA English
DT Article
DE COVID; SARS-CoV-2; recommendation; lymphoma; hematology
ID DOSE RADIOTHERAPY; THERAPY; PLASMACYTOMA; GUIDELINES
AB Purpose The coronavirus pandemic is affecting global health systems, endangering daily patient care. Hemato-oncological patients are particularly vulnerable to infection, requiring decisive recommendations on treatment and triage. The aim of this survey amongst experts on radiation therapy (RT) for lymphoma and leukemia is to delineate typical clinical scenarios and to provide counsel for high-quality care. Methods A multi-item questionnaire containing multiple-choice and free-text questions was developed in a peer-reviewed process and sent to members of the radiation oncology panels of the German Hodgkin Study Group and the German Lymphoma Alliance. Answers were assessed online and analyzed centrally. Results Omission of RT was only considered in a minority of cases if alternative treatment options were available. Hypofractionated regimens and reduced dosages may be used for indolent lymphoma and fractures due to multiple myeloma. Overall, there was a tendency to shorten RT rather than to postpone or omit it. Even in case of critical resource shortage, panelists agreed to start emergency RT for typical indications (intracranial pressure, spinal compression, superior vena cava syndrome) within 24-h. Possible criteria to consider for patient triage are the availability of (systemic) options, the underlying disease dynamic, and the treatment rationale (curative/palliative). Conclusion RT for hemato-oncological patients receives high-priority and should be maintained even in later stages of the pandemic. Hypofractionation and shortened treatment schedules are feasible options for well-defined constellations, but have to be discussed in the clinical context.
C1 [Oertel, M.; Elsayad, K.; Reinartz, G.; Eich, H. T.] Univ Hosp Muenster, Dept Radiat Oncol, Albert Schweitzer Campus 1 Bldg A1, D-48149 Munster, Germany.
   [Engenhart-Cabillic, R.] Univ Hosp Giessen Marburg, Dept Radiotherapy & Radiat Oncol, Marburg, Germany.
   [Baues, C.; Marnitz, S.] Univ Hosp Cologne, Dept Radiat Oncol, Cologne, Germany.
   [Baues, C.; Marnitz, S.] Univ Hosp Cologne, Cyberknife Ctr, Cologne, Germany.
   [Schmidberger, H.] Univ Hosp Mainz, Dept Radiotherapy & Radiat Oncol, Mainz, Germany.
   [Vordermark, D.] Univ Hosp Halle Saale, Dept Radiat Oncol, Halle, Saale, Germany.
   [Lukas, P.] Med Univ Innsbruck, Dept Radiooncol, Innsbruck, Austria.
   [Ruebe, C.] Saarland Univ Hosp, Dept Radiat Oncol, Homburg, Germany.
   [Engert, A.] Univ Hosp Cologne, Dept Internal Med 1, Ctr Integrated Oncol Aachen Bonn Cologne Dusseldo, Cologne, Germany.
   [Lenz, G.] Univ Hosp Muenster, Dept Med A, Hematol, Oncol, Munster, Germany.
RP Eich, HT (corresponding author), Univ Hosp Muenster, Dept Radiat Oncol, Albert Schweitzer Campus 1 Bldg A1, D-48149 Munster, Germany.
EM hans.eich@ukmuenster.de
FU Projekt DEAL
FX Open Access funding enabled and organized by Projekt DEAL.
CR [Anonymous], 2017, WHO CLASSIFICATION T
   Aries JA, 2020, BRIT J HAEMATOL, V190, pE64, DOI 10.1111/bjh.16852
   Choi YW, 2004, RADIOGRAPHICS, V24, P985, DOI 10.1148/rg.244035160
   Combs SE, 2020, RADIAT ONCOL, V15, DOI 10.1186/s13014-020-01527-1
   Deutsche Gesellschaft fur Radioonkologie (DEGRO), BER DTSCH STRAHL STE
   Deutsche Gesellschaft fur Radioonkologie (DEGRO), HYP BESTR REG ALT KO
   Deutsche Rontgengesellschaft, 2020, COVID 19 INF AG THOR
   Deutscher Ethikrat, 2020, SOL RESP COR CRIS AD
   Elsayad K, 2017, ONCOL RES TREAT, V40, P244, DOI 10.1159/000475634
   Formenti SC, 2013, JNCI-J NATL CANCER I, V105, P256, DOI 10.1093/jnci/djs629
   Fuchs M, 2019, J CLIN ONCOL, V37, P2835, DOI 10.1200/JCO.19.00964
   German society of radiation oncology (DEGRO), 2020, 2 STELL ARO DEGRO BE
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guckenberger M, 2020, RADIOTHER ONCOL, V146, P223, DOI 10.1016/j.radonc.2020.04.001
   Hoskin PJ, 2014, LANCET ONCOL, V15, P457, DOI 10.1016/S1470-2045(14)70036-1
   Konig L, 2018, STRAHLENTHER ONKOL, V194, P454, DOI 10.1007/s00066-018-1277-3
   Konig L, 2016, STRAHLENTHER ONKOL, V192, P414, DOI 10.1007/s00066-016-0962-3
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lowry L, 2011, RADIOTHER ONCOL, V100, P86, DOI 10.1016/j.radonc.2011.05.013
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Malard F, 2020, BONE MARROW TRANSPL, V55, P2180, DOI 10.1038/s41409-020-0931-4
   Mehta V, 2020, CANCER DISCOV, V10, P935, DOI 10.1158/2159-8290.CD-20-0516
   Miyashita H, 2020, ANN ONCOL, V31, P1088, DOI 10.1016/j.annonc.2020.04.006
   Nagar H, 2020, NAT REV CLIN ONCOL, DOI 10.1038/s41571-020-0375-1
   Oertel M, 2020, STRAHLENTHER ONKOL, V196, P126, DOI 10.1007/s00066-019-01541-7
   Oertel M, 2019, RADIAT ONCOL, V14, DOI 10.1186/s13014-019-1265-5
   Rades D, 2006, INT J RADIAT ONCOL, V64, P1452, DOI 10.1016/j.ijrobp.2005.10.018
   Radford J, 2015, NEW ENGL J MED, V372, P1598, DOI 10.1056/NEJMoa1408648
   Raemaekers JMM, 2014, J CLIN ONCOL, V32, P1188, DOI 10.1200/JCO.2013.51.9298
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Robert-Koch-Institut, 2020, INF HILF PERS EIN HO
   Ruckert M, 2018, STRAHLENTHER ONKOL, V194, P509, DOI 10.1007/s00066-018-1287-1
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, DOI 10.3332/ecancer.2020.1023
   Strojan P, 2002, INT J RADIAT ONCOL, V53, P692, DOI 10.1016/S0360-3016(02)02780-3
   Thomson DJ, 2020, INT J RADIAT ONCOL, V107, P618, DOI 10.1016/j.ijrobp.2020.04.016
   Tsang RW, 2018, INT J RADIAT ONCOL, V101, P794, DOI 10.1016/j.ijrobp.2018.05.009
   Wong JYC, 2018, INT J RADIAT ONCOL, V101, P521, DOI 10.1016/j.ijrobp.2018.04.071
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yahalom J, 2020, BLOOD, V135, P1829, DOI 10.1182/blood.2020006028
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zylka-Menhorn V, 2020, DTSCH ARZTEBL, V117, pA658
NR 43
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0179-7158
EI 1439-099X
J9 STRAHLENTHER ONKOL
JI Strahlenther. Onkol.
PD DEC
PY 2020
VL 196
IS 12
SI SI
BP 1096
EP 1102
DI 10.1007/s00066-020-01705-w
EA OCT 2020
PG 7
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA PB8LZ
UT WOS:000583015700001
PM 33125504
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Yan, FF
   Huang, FM
   Xu, J
   Yang, PH
   Qin, YH
   Lv, JJ
   Zhang, SG
   Ye, L
   Gong, M
   Liu, ZB
   Wei, J
   Xie, TX
   Xu, KF
   Gao, GF
   Wang, FS
   Cai, L
   Jiang, CY
AF Yan, Feifei
   Huang, Fengming
   Xu, Jun
   Yang, Penghui
   Qin, Yuhao
   Lv, Jingjun
   Zhang, Shaogeng
   Ye, Lu
   Gong, Ming
   Liu, Zhibo
   Wei, Jie
   Xie, Tuxiu
   Xu, Kai-Feng
   Gao, George F.
   Wang, Fu-Sheng
   Cai, Lin
   Jiang, Chengyu
TI Antihypertensive drugs are associated with reduced fatal outcomes and
   improved clinical characteristics in elderly COVID-19 patients
SO CELL DISCOVERY
LA English
DT Article
ID CONVERTING ENZYME-INHIBITORS; II RECEPTOR BLOCKERS; CORONAVIRUS
   OUTBREAK; ACE-INHIBITORS; GLOBAL HEALTH; ANGIOTENSIN; PNEUMONIA; UPDATE;
   RISK
AB The novel coronavirus (CoV) severe acute respiratory syndrome (SARS)-CoV-2 outbreak began at the end of 2019 in Wuhan, China, and has spread to over 200 countries. In this multicenter retrospective study, we identified 2190 adult patients admitted for laboratory-confirmed COVID-19 in three participating centers. Multivariate logistic regression was conducted in patients with comorbid hypertension to examine the potential association between clinical outcomes, disease severity, and clinical characteristics with the use of ACEI, ARB, calcium-channel blockers (CCB), beta-blockers (BB), and thiazide diuretics. The clinical outcome, dyspnea, and fatigue were significantly improved in patients, especially elderly patients who were older than 65 years, who took ARB drugs prior to hospitalization compared to patients who took no drugs. The reduction of disease severity of elderly COVID-19 patients was associated with CCB and ACEI users. Clinical indices, including CRP, lymphocyte count, procalcitonin D dimer, and hemoglobin, were significantly improved in elderly ARB users. In addition, the clinical outcomes were statistically significantly improved in patients who took antihypertension drugs ARB, BB, and CCB after statistical adjustment by all ages, gender, baseline of blood pressures, and coexisting medical conditions. Our data indicate that hypertension drugs ARB, ACEI, CCB, and BB might be beneficial for COVID-19 patients.
C1 [Yan, Feifei; Gong, Ming; Liu, Zhibo; Cai, Lin] Wuhan Univ, Dept Orthoped, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China.
   [Yan, Feifei] Leishenshan Hosp, Dept Med Qual Control, Wuhan 430000, Hubei, Peoples R China.
   [Huang, Fengming; Qin, Yuhao; Jiang, Chengyu] Chinese Acad Med Sci, Inst Basic Med Sci, Dept Biochem, Peking Union Med Coll,State Key Lab Med Mol Biol, Beijing 100005, Peoples R China.
   [Xu, Jun] Chinese Acad Med Sci, Emergency Dept, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China.
   [Yang, Penghui; Zhang, Shaogeng; Wang, Fu-Sheng] Fifth Med Ctr Chinese PLA Gen Hosp, Beijing 100039, Peoples R China.
   [Lv, Jingjun; Ye, Lu; Wei, Jie] Wuhan Univ, Emergency Dept, Renmin Hosp, Wuhan 430060, Hubei, Peoples R China.
   [Xie, Tuxiu] Wuhan Univ, Gen Med Dept, Guang Gu Div, Renmin Hosp, Wuhan 430200, Hubei, Peoples R China.
   [Xu, Kai-Feng] Chinese Acad Med Sci, Dept Pulm & Crit Care Med, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China.
   [Gao, George F.] Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing 100101, Peoples R China.
RP Cai, L (corresponding author), Wuhan Univ, Dept Orthoped, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China.; Jiang, CY (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Dept Biochem, Peking Union Med Coll,State Key Lab Med Mol Biol, Beijing 100005, Peoples R China.
EM orthopedics@whu.edu.cn; jiang@pumc.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81788101]; Chinese Academy of Medical
   Sciences Innovation Fund for Medical Sciences [2017-12M-1-009]; National
   Key Research and Development Plan of China [2020YFC0845500]
FX The authors would like to thank Prof. Linzhao Cheng of Johns Hopkins
   University and USTC for the fruitful discussions and editing of this
   paper. The authors would also like to thank Dr. Yingxia Liu, Lei Liu,
   and Hong Gao for providing clinical data of patients from ShenZhen Third
   people's hospital when this project started. These data were used in
   another project. This work was supported by the National Natural Science
   Foundation of China (81788101), the Chinese Academy of Medical Sciences
   Innovation Fund for Medical Sciences (2017-12M-1-009), and the National
   Key Research and Development Plan of China (2020YFC0845500).
CR Arai T, 1998, LANCET, V352, P1937, DOI 10.1016/S0140-6736(05)60437-0
   Bureau of Disease P C. N. National Center for Cardiovascular D, 2019, ZHONGHUA XIN XUE GUA, V48, P10
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen YC, 2020, DIABETES CARE, V43, P1399, DOI 10.2337/dc20-0660
   Dhakarwal P, 2014, RENAL FAILURE, V36, P963, DOI 10.3109/0886022X.2014.900425
   Feng Y, 2020, AM J RESP CRIT CARE, V201, P1380, DOI 10.1164/rccm.202002-0445OC
   Forrester SJ, 2018, PHYSIOL REV, V98, P1627, DOI 10.1152/physrev.00038.2017
   Fosbol EL, 2020, JAMA-J AM MED ASSOC, V324, P168, DOI 10.1001/jama.2020.11301
   Gao Y, 2020, J MED VIROL, V92, P791, DOI 10.1002/jmv.25770
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Han H, 2020, CLIN CHEM LAB MED, V58, P1116, DOI 10.1515/cclm-2020-0188
   Hu JH, 2020, J INFECTION, V81, P983, DOI 10.1016/j.jinf.2020.05.056
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang FM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4595
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Jung Sun-Young, 2020, Clin Infect Dis, V71, P2121, DOI 10.1093/cid/ciaa624
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lam KW, 2020, J INFECT DIS, V222, P1256, DOI 10.1093/infdis/jiaa447
   Li JY, 2020, JAMA CARDIOL, V5, P825, DOI 10.1001/jamacardio.2020.1624
   Lin YC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188975
   Liu Y, 2020, NATL SCI REV
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Marciniak C, 2009, AM J PHYS MED REHAB, V88, P30, DOI 10.1097/PHM.0b013e3181909b73
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Mehta N, 2020, JAMA CARDIOL, V5, P1020, DOI 10.1001/jamacardio.2020.1855
   Meng J, 2020, EMERG MICROBES INFEC, V9, P757, DOI 10.1080/22221751.2020.1746200
   Montastruc F, 2020, THERAPIE, V75, P381, DOI 10.1016/j.therap.2020.05.005
   Mortensen EM, 2012, CLIN INFECT DIS, V55, P1466, DOI 10.1093/cid/cis733
   Oussalah Abderrahim, 2020, Clin Infect Dis, V71, P2447, DOI 10.1093/cid/ciaa677
   Palmer SC, 2015, LANCET, V385, P2047, DOI 10.1016/S0140-6736(14)62459-4
   Patel AB, 2020, JAMA-J AM MED ASSOC, V323, P2386, DOI 10.1001/jama.2020.8946
   Peng Y D, 2020, Zhonghua Xin Xue Guan Bing Za Zhi, V48, P450, DOI 10.3760/cma.j.cn112148-20200220-00105
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Saavedra JM, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104832
   Sama IE, 2020, EUR HEART J, V41, P1810, DOI 10.1093/eurheartj/ehaa373
   Sekizawa K, 1998, LANCET, V352, P1069, DOI 10.1016/S0140-6736(05)60114-6
   Sun Y, 2015, PART FIBRE TOXICOL, V12, DOI 10.1186/s12989-015-0080-x
   Tan ND, 2020, GASTROENTEROLOGY, V159, P1170, DOI 10.1053/j.gastro.2020.05.034
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang HL, 2008, CELL RES, V18, P290, DOI 10.1038/cr.2008.15
   Williams B, 2018, EUR HEART J, V39, P3021, DOI 10.1093/eurheartj/ehy339
   World Health Organization, 2020, LAB TEST 2019 NOV CO
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yan YW, 2015, SCI CHINA LIFE SCI, V58, P208, DOI 10.1007/s11427-015-4814-7
   Zhang NR, 2020, J MED VIROL, V92, P408, DOI 10.1002/jmv.25674
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhou F, 2020, HYPERTENSION, V76, pE15, DOI 10.1161/HYPERTENSIONAHA.120.15622
   Zhou X, 2020, CLIN EXP HYPERTENS, DOI 10.1080/10641963.2020.1764018
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4594
NR 53
TC 0
Z9 0
U1 1
U2 1
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
EI 2056-5968
J9 CELL DISCOV
JI Cell Discov.
PD OCT 29
PY 2020
VL 6
IS 1
AR 77
DI 10.1038/s41421-020-00221-6
PG 10
WC Cell Biology
SC Cell Biology
GA OT0OK
UT WOS:000590553900002
PM 33298897
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Schmidt, M
   Hajage, D
   Demoule, A
   Pham, T
   Combes, A
   Dres, M
   Lebbah, S
   Kimmoun, A
   Mercat, A
   Beduneau, G
   Palmyre, J
   Prevost, M
   Asfar, P
   Beloncle, F
   Demiselle, J
   Pavot, A
   Monnet, X
   Richard, C
   Mayaux, J
   Beurton, A
   Descamps, R
   Joret, A
   Du Cheyron, D
   Pene, F
   Chiche, JD
   Jozwiak, M
   Jaubert, P
   Voiriot, G
   Fartoukh, M
   Teulier, M
   Blayau, C
   L'Her, E
   Aubron, C
   Bodenes, L
   Ferriere, N
   Auchabie, J
   Le Meur, A
   Pignal, S
   Mazzoni, T
   Quenot, JP
   Andreu, P
   Roudau, JB
   Labruyere, M
   Nseir, S
   Preau, S
   Poissy, J
   Mathieu, D
   Benhamida, S
   Paulet, R
   Roucaud, N
   Thyrault, M
   Daviet, F
   Hraiech, S
   Parzy, G
   Sylvestre, A
   Jochmans, S
   Bouilland, AL
   Monchi, M
   des Deserts, MD
   Mathais, Q
   Rager, G
   Pasquier, P
   Jean, R
   Amelie, S
   Charlotte, G
   Emmanuel, C
   Dellamonica, J
   Saccheri, C
   Lombardi, R
   Kouchit, Y
   Jacquier, S
   Mathonnet, A
   Nay, MA
   Runge, I
   Martino, F
   Flurin, L
   Rolle, A
   Carles, M
   Coudroy, R
   Thille, AW
   Frat, JP
   Rodriguez, M
   Beuret, P
   Tientcheu, A
   Vincent, A
   Michelin, F
   Melone, MA
   Gauzi, M
   Guilbert, A
   Kouadri, G
   Gissot, V
   Ehrmann, S
   Salmon-Gandonniere, C
   Elaroussi, D
   Delbove, A
   Fedun, Y
   Huntzinger, J
   Lebas, E
   Kisoka, G
   Gregoire, C
   Marchetta, S
   Lambermont, B
   Argaud, L
   Baudry, T
   Bertrand, PJ
   Dargent, A
   Guitton, C
   Chudeau, N
   Landais, M
   Darreau, C
   Ferre, A
   Gros, A
   Lacave, G
   Bruneel, F
   Neuville, M
   Devaquet, JM
   Tachon, G
   Gallot, R
   Chelha, R
   Galbois, A
   Jallot, A
   Lemoine, LC
   Kuteifan, K
   Pointurier, V
   Jandeaux, LM
   Mootien, J
   Damoisel, C
   Sztrymf, B
   Chommeloux, J
   Luyt, CE
   Schortgen, F
   Rusel, L
   Jung, CM
   Gobert, F
   Vimpere, D
   Lamhaut, L
   Sauneuf, B
   Charrier, L
   Calus, J
   Desmeules, I
   Painvin, B
   Tadie, JM
   Castelain, V
   Michard, B
   Herbrecht, JE
   Baldacini, M
   Weiss, N
   Demeret, S
   Marois, C
   Rohaut, B
   Moury, PH
   Savida, AC
   Couadau, E
   Serie, M
   Alexandru, N
   Bruel, C
   Fontaine, C
   Garrigou, S
   Mahler, JC
   Leclerc, M
   Ramakers, M
   Garcon, P
   Massou, N
   Van Vong, LP
   Sen, J
   Lucas, N
   Chemouni, F
   Stoclin, A
   Avenel, A
   Faure, H
   Gentilhomme, A
   Ricome, S
   Abraham, P
   Monard, C
   Textoris, J
   Rimmele, T
   Montini, F
   Lejour, G
   Lazard, T
   Etienney, I
   Kerroumi, Y
   Claire, D
   Coupez, BM
   Francois, T
   Hoffmann, C
   Donat, N
   Muller, V
   Martinez, T
   Jacquot, A
   Mattei, M
   Levy, B
   Ravan, R
   Dopeux, L
   Liteaudon, JM
   Roux, D
   Rey, B
   Anghel, R
   Schenesse, D
   Gevrey, V
   Castanera, J
   Petua, P
   Madeux, B
   Hartman, O
   Piagnerelli, M
   Joosten, A
   Noel, C
   Biston, P
   Noel, T
   Bouar, GLE
   Boukhanza, M
   Demarest, E
   Bajolet, MF
   Charrier, N
   Quenet, A
   Zylberfajn, C
   Dufour, N
   Megarbane, B
   Voicu, S
   Deye, N
   Malissin, I
   Legay, F
   Debarre, M
   Barbarot, N
   Fillatre, P
   Delord, B
   Laterrade, T
   Saghi, T
   Pujol, W
   Cungi, PJ
   Esnault, P
   Cardinale, M
   Ha, VHT
   Fleury, G
   Brou, MA
   Zafimahazo, D
   Tran-Van, D
   Avargues, P
   Carenco, L
   Robin, N
   Ouali, A
   Houdou, L
   Le Terrier, C
   Suh, N
   Primmaz, S
   Pugin, J
   Weiss, E
   Gauss, T
   Moyer, JD
   Paugam-Burtz, C
   La Combe, B
   Smonig, R
   Violleau, J
   Cailliez, P
   Chelly, J
   Marchalot, A
   Saladin, C
   Bigot, C
   Fayolle, PM
   Fatseas, J
   Ibrahim, A
   Resiere, D
   Hage, R
   Cholet, C
   Cantier, M
   Trouiller, P
   Montravers, P
   Lortat-Jacob, B
   Tanaka, S
   Tran-Dinh, A
   Duranteau, J
   Harrois, A
   Dubreuil, G
   Werner, M
   Godier, A
   Hamada, S
   Zlotnik, D
   Nougue, H
   Mekontso-Dessap, A
   Carteaux, G
   Razazi, K
   De Prost, N
   Mongardon, N
   Langeron, O
   Levesque, E
   Attias, A
   de Roquetaillade, C
   Chousterman, BG
   Mebazaa, A
   Gayat, E
   Garnier, M
   Pardo, E
   Satre-Buisson, L
   Gutton, C
   Yvin, E
   Marcault, C
   Azoulay, E
   Darmon, M
   Bonnet, N
   Ebstein, N
   Gaudry, S
   Cohen, Y
   Ait-Oufella, H
   Hariri, G
   Urbina, T
   Mazerand, S
   Heming, N
   Santi, F
   Moine, P
   Annane, D
   Bougle, A
   Omar, E
   Lancelot, A
   Begot, E
   Plantefeve, G
   Contou, D
   Mentec, H
   Pajot, O
   Faguer, S
   Cointault, O
   Lavayssiere, L
   Nogier, MB
   Jamme, M
   Pichereau, C
   Hayon, J
   Outin, H
   Depret, F
   Coutrot, M
   Chaussard, M
   Guillemet, L
   Goffin, P
   Thouny, R
   Guntz, J
   Jadot, L
   Persichini, R
   Jean-Michel, V
   Georges, H
   Caulier, T
   Pradel, G
   Hausermann, MH
   Nguyen-Valat, TH
   Boudinaud, M
   Vivier, E
   Rosseli, S
   Bourdin, G
   Pommier, C
   Vinclair, M
   Poignant, S
   Mons, S
   Bougouin, W
   Bruna, F
   Maestraggi, Q
   Roth, C
   Bitker, L
   Dhelft, F
   Bonnet-Chateau, J
   Filippelli, M
   Morichau-Beauchant, T
   Thierry, S
   Le Roy, C
   Saint Jouan, M
   Goncalves, B
   Mazeraud, A
   Daniel, M
   Sharshar, T
   Cadoz, C
   Gaci, R
   Gette, S
   Louis, G
   Sacleux, SC
   Ordan, MA
   Cravoisy, A
   Conrad, M
   Courte, G
   Gibot, S
   Benzidi, Y
   Casella, C
   Serpin, L
   Setti, JL
   Besse, MC
   Bourreau, A
   Pillot, JM
   Rivera, C
   Vinclair, C
   Robaux, MA
   Achino, C
   Delignette, MC
   Mazard, T
   Aubrun, F
   Bouchet, B
   Frerou, A
   Muller, L
   Quentin, C
   Degoul, S
   Stihle, X
   Sumian, C
   Bergero, N
   Lanaspre, B
   Quintard, H
   Maiziere, EM
   Egreteau, PY
   Leloup, G
   Berteau, F
   Cottrel, M
   Bouteloup, M
   Jeannot, M
   Blanc, Q
   Saison, J
   Geneau, I
   Grenot, R
   Ouchike, A
   Hazera, P
   Masse, AL
   Demiri, S
   Vezinet, C
   Baron, E
   Benchetrit, D
   Monsel, A
   Trebbia, G
   Schaack, E
   Lepecq, R
   Bobet, M
   Vinsonneau, C
   Dekeyser, T
   Delforge, Q
   Rahmani, I
   Vivet, B
   Paillot, J
   Hierle, L
   Chaignat, C
   Valette, S
   Her, B
   Brunet, J
   Page, M
   Boiste, F
   Collin, A
   Bavozet, F
   Garin, A
   Dlala, M
   Mhamdi, K
   Beilouny, B
   Lavalard, A
   Perez, S
   Veber, B
   Guitard, PG
   Gouin, P
   Lamacz, A
   Plouvier, F
   Delaborde, BP
   Kherchache, A
   Chaalal, A
   Ricard, JD
   Amouretti, M
   Freita-Ramos, S
   Roux, D
   Constantin, JM
   Assefi, M
   Lecore, M
   Selves, A
   Prevost, F
   Lamer, C
   Shi, RY
   Knani, L
   Pili-Floury, S
   Vettoretti, L
   Levy, M
   Marsac, L
   Dauger, S
   Guilmin-Crepon, S
   Putegnat, JB
   Bayle, F
   Perrou, M
   Thao, G
   Geri, G
   Charron, C
   Repesse, X
   Vieillard-Baron, A
   Guilbart, M
   Roger, PA
   Hinard, S
   Macq, PY
   Chaulier, K
   Goutte, S
   Chillet, P
   Pitta, A
   Darjent, B
   Bruneau, A
   Lasocki, S
   Leger, M
   Gergaud, S
   Lemarie, P
   Terzi, N
   Schwebel, C
   Dartevel, A
   Galerneau, LM
   Diehl, JL
   Hauw-Berlemont, C
   Peron, N
   Guerot, E
   Amoli, AM
   Benhamou, M
   Deyme, JP
   Andremont, O
   Lena, D
   Cady, J
   Causeret, A
   de la Chapelle, A
   Cracco, C
   Rouleau, S
   Schnell, D
   Lory, C
   Chapelle, T
   Bruckert, V
   Garcia, J
   Sahraoui, A
   Abbosh, N
   Bornstain, C
   Pernet, P
   Poirson, F
   Pasem, A
   Karoubi, P
   Poupinel, V
   Gauthier, C
   Bouniol, F
   Feuchere, P
   Bavozet, F
   Heron, A
   Carreira, S
   Emery, M
   Le Floch, A
   Giovannangeli, L
   Herzog, N
   Giacardi, C
   Baudic, T
   Thill, C
   Tubach, F
   Lesieur, O
   Noublanche, J
   Colin, G
   Lacherade, JC
   Bionz, G
   Maquigneau, N
   Sement, A
   Roca-Cerezo, I
   Pascal, M
   Sma, N
AF Schmidt, Matthieu
   Hajage, David
   Demoule, Alexandre
   Pham, Tai
   Combes, Alain
   Dres, Martin
   Lebbah, Said
   Kimmoun, Antoine
   Mercat, Alain
   Beduneau, Gaetan
   Palmyre, Jessica
   Prevost, Margot
   Asfar, Pierre
   Beloncle, Francois
   Demiselle, Julien
   Pavot, Arthur
   Monnet, Xavier
   Richard, Christian
   Mayaux, Julien
   Beurton, Alexandra
   Descamps, Richard
   Joret, Aurelie
   Du Cheyron, Damien
   Pene, Frederic
   Chiche, Jean-Daniel
   Jozwiak, Mathieu
   Jaubert, Paul
   Voiriot, Guillaume
   Fartoukh, Muriel
   Teulier, Marion
   Blayau, Clarisse
   L'Her, Erwen
   Aubron, Cecile
   Bodenes, Laetitia
   Ferriere, Nicolas
   Auchabie, Johann
   Le Meur, Anthony
   Pignal, Sylvain
   Mazzoni, Thierry
   Quenot, Jean-Pierre
   Andreu, Pascal
   Roudau, Jean-Baptiste
   Labruyere, Marie
   Nseir, Saad
   Preau, Sebastien
   Poissy, Julien
   Mathieu, Daniel
   Benhamida, Sarah
   Paulet, Remi
   Roucaud, Nicolas
   Thyrault, Martial
   Daviet, Florence
   Hraiech, Sami
   Parzy, Gabriel
   Sylvestre, Aude
   Jochmans, Sebastien
   Bouilland, Anne-Laure
   Monchi, Mehran
   Danguy des Deserts, Marc
   Mathais, Quentin
   Rager, Gwendoline
   Pasquier, Pierre
   Jean, Reignier
   Amelie, Seguin
   Charlotte, Garret
   Emmanuel, Canet
   Dellamonica, Jean
   Saccheri, Clement
   Lombardi, Romain
   Kouchit, Yanis
   Jacquier, Sophie
   Mathonnet, Armelle
   Nay, Mai-Ahn
   Runge, Isabelle
   Martino, Frederic
   Flurin, Laure
   Rolle, Amelie
   Carles, Michel
   Coudroy, Remi
   Thille, Arnaud W.
   Frat, Jean-Pierre
   Rodriguez, Maeva
   Beuret, Pascal
   Tientcheu, Audrey
   Vincent, Arthur
   Michelin, Florian
   Melone, Marie Anne
   Gauzi, Maxime
   Guilbert, Arnaud
   Kouadri, Geoffrey
   Gissot, Valerie
   Ehrmann, Stephan
   Salmon-Gandonniere, Charlotte
   Elaroussi, Djlali
   Delbove, Agathe
   Fedun, Yannick
   Huntzinger, Julien
   Lebas, Eddy
   Kisoka, Grace
   Gregoire, Celine
   Marchetta, Stella
   Lambermont, Bernard
   Argaud, Laurent
   Baudry, Thomas
   Bertrand, Pierre-Jean
   Dargent, Auguste
   Guitton, Christophe
   Chudeau, Nicolas
   Landais, Mickael
   Darreau, Cedric
   Ferre, Alexis
   Gros, Antoine
   Lacave, Guillaume
   Bruneel, Fabrice
   Neuville, Mathilde
   Devaquet, Jerome
   Tachon, Guillaume
   Gallot, Richard
   Chelha, Riad
   Galbois, Arnaud
   Jallot, Anne
   Lemoine, Ludivine Chalumeau
   Kuteifan, Khaldoun
   Pointurier, Valentin
   Jandeaux, Louise-Marie
   Mootien, Joy
   Damoisel, Charles
   Sztrymf, Benjamin
   Chommeloux, Juliette
   Luyt, Charles Edouard
   Schortgen, Frederique
   Rusel, Leon
   Jung, Camille
   Gobert, Florent
   Vimpere, Damien
   Lamhaut, Lionel
   Sauneuf, Bertrand
   Charrier, Liliane
   Calus, Julien
   Desmeules, Isabelle
   Painvin, Benoit
   Tadie, Jean-Marc
   Castelain, Vincent
   Michard, Baptiste
   Herbrecht, Jean-Etienne
   Baldacini, Mathieu
   Weiss, Nicolas
   Demeret, Sophie
   Marois, Clemence
   Rohaut, Benjamin
   Moury, Pierre-Henri
   Savida, Anne-Charlotte
   Couadau, Emmanuel
   Serie, Mathieu
   Alexandru, Nica
   Bruel, Cedric
   Fontaine, Candice
   Garrigou, Sonia
   Mahler, Juliette Courtiade
   Leclerc, Maxime
   Ramakers, Michel
   Garcon, Pierre
   Massou, Nicole
   Van Vong, Ly Phacs
   Sen, Juliane
   Lucas, Nolwenn
   Chemouni, Franck
   Stoclin, Annabelle
   Avenel, Alexandre
   Faure, Henri
   Gentilhomme, Angelie
   Ricome, Sylvie
   Abraham, Paul
   Monard, Celine
   Textoris, Julien
   Rimmele, Thomas
   Montini, Florent
   Lejour, Gabriel
   Lazard, Thierry
   Etienney, Isabelle
   Kerroumi, Younes
   Claire, Dupuis
   Coupez, Bereiziat Marine
   Francois, Thouy
   Hoffmann, Clemet
   Donat, Nicolas
   Muller, Violaine
   Martinez, Thibault
   Jacquot, Audrey
   Mattei, Matthieu
   Levy, Bruno
   Ravan, Ramin
   Dopeux, Loic
   Liteaudon, Jean-Mathias
   Roux, Delphine
   Rey, Brice
   Anghel, Radu
   Schenesse, Deborah
   Gevrey, Vincent
   Castanera, Jermy
   Petua, Philippe
   Madeux, Benjamin
   Hartman, Otto
   Piagnerelli, Michael
   Joosten, Anne
   Noel, Cinderella
   Biston, Patrick
   Noel, Thibaut
   Bouar, Gurvan L. E.
   Boukhanza, Messabi
   Demarest, Elsa
   Bajolet, Marie-France
   Charrier, Nathanael
   Quenet, Audrey
   Zylberfajn, Cecile
   Dufour, Nicolas
   Megarbane, Buno
   Voicu, Sqebastian
   Deye, Nicolas
   Malissin, Isabelle
   Legay, Francois
   Debarre, Matthieu
   Barbarot, Nicolas
   Fillatre, Pierre
   Delord, Bertrand
   Laterrade, Thomas
   Saghi, Tahar
   Pujol, Wilfried
   Cungi, Pierre Julien
   Esnault, Pierre
   Cardinale, Mickael
   Hong Tuan Ha, Vivien
   Fleury, Gregory
   Brou, Marie-Ange
   Zafimahazo, Daniel
   Tran-Van, David
   Avargues, Patrick
   Carenco, Lisa
   Robin, Nicolas
   Ouali, Alexandre
   Houdou, Lucie
   Le Terrier, Christophe
   Suh, Noemie
   Primmaz, Steve
   Pugin, Jerome
   Weiss, Emmanuel
   Gauss, Tobias
   Moyer, Jean-Denis
   Paugam-Burtz, Catherine
   La Combe, Beatrice
   Smonig, Rolland
   Violleau, Jade
   Cailliez, Pauline
   Chelly, Jonathan
   Marchalot, Antoine
   Saladin, Cecile
   Bigot, Christelle
   Fayolle, Pierre-Marie
   Fatseas, Jules
   Ibrahim, Amr
   Resiere, Dabor
   Hage, Rabih
   Cholet, Clementine
   Cantier, Marie
   Trouiller, Pierre
   Montravers, Philippe
   Lortat-Jacob, Brice
   Tanaka, Sebastien
   Tran-Dinh, Alexy
   Duranteau, Jacques
   Harrois, Anatole
   Dubreuil, Guillaume
   Werner, Marie
   Godier, Anne
   Hamada, Sophie
   Zlotnik, Diane
   Nougue, Helene
   Mekontso-Dessap, Armand
   Carteaux, Guillaume
   Razazi, Keyvan
   De Prost, Nicolas
   Mongardon, Nicolas
   Langeron, Olivier
   Levesque, Eric
   Attias, Arie
   de Roquetaillade, Charles
   Chousterman, Benjamin G.
   Mebazaa, Alexandre
   Gayat, Etienne
   Garnier, Marc
   Pardo, Emmanuel
   Satre-Buisson, Lea
   Gutton, Christophe
   Yvin, Elise
   Marcault, Clemence
   Azoulay, Elie
   Darmon, Michael
   Bonnet, Nicolas
   Ebstein, Nathan
   Gaudry, Stephane
   Cohen, Yves
   Ait-Oufella, Hafid
   Hariri, Geoffroy
   Urbina, Tomas
   Mazerand, Sandie
   Heming, Nicholas
   Santi, Francesca
   Moine, Pierre
   Annane, Djillali
   Bougle, Adrien
   Omar, Edris
   Lancelot, Aymeric
   Begot, Emmanuelle
   Plantefeve, Gaetan
   Contou, Damien
   Mentec, Herve
   Pajot, Olivier
   Faguer, Stanislas
   Cointault, Olivier
   Lavayssiere, Laurence
   Nogier, Marie-Beatrice
   Jamme, Matthieu
   Pichereau, Claire
   Hayon, Jan
   Outin, Herve
   Depret, Francois
   Coutrot, Maxime
   Chaussard, Maite
   Guillemet, Lucie
   Goffin, Pierre
   Thouny, Romain
   Guntz, Julien
   Jadot, Laurent
   Persichini, Romain
   Jean-Michel, Vanessa
   Georges, Hugues
   Caulier, Thomas
   Pradel, Gael
   Hausermann, Marie-Helene
   Nguyen-Valat, ThiMy Hue
   Boudinaud, Michel
   Vivier, Emmanuel
   Rosseli, Sylvene
   Bourdin, Gael
   Pommier, Christian
   Vinclair, Marc
   Poignant, Simon
   Mons, Sandrine
   Bougouin, Wulfran
   Bruna, Franklin
   Maestraggi, Quentin
   Roth, Christian
   Bitker, Laurent
   Dhelft, Francois
   Bonnet-Chateau, Justine
   Filippelli, Mathilde
   Morichau-Beauchant, Tristan
   Thierry, Stephane
   Le Roy, Charlotte
   Saint Jouan, Melanie
   Goncalves, Bruno
   Mazeraud, Aurelien
   Daniel, Matthieu
   Sharshar, Tarek
   Cadoz, Cyril
   Gaci, Rostane
   Gette, Sebastien
   Louis, Guillaune
   Sacleux, Sophe-Caroline
   Ordan, Marie-Amelie
   Cravoisy, Aurelie
   Conrad, Marie
   Courte, Guilhem
   Gibot, Sebastien
   Benzidi, Younes
   Casella, Claudia
   Serpin, Laurent
   Setti, Jean-Lou
   Besse, Marie-Catherine
   Bourreau, Anna
   Pillot, Jerome
   Rivera, Caroline
   Vinclair, Camille
   Robaux, Marie-Aline
   Achino, Chloe
   Delignette, Marie-Charlotte
   Mazard, Tessa
   Aubrun, Frederic
   Bouchet, Bruno
   Frerou, Aurelien
   Muller, Laura
   Quentin, Charlotte
   Degoul, Samuel
   Stihle, Xavier
   Sumian, Claude
   Bergero, Nicoletta
   Lanaspre, Bernard
   Quintard, Herve
   Maiziere, Eve Marie
   Egreteau, Pierre-Yves
   Leloup, Guillaume
   Berteau, Florin
   Cottrel, Marjolaine
   Bouteloup, Marie
   Jeannot, Matthieu
   Blanc, Quentin
   Saison, Julien
   Geneau, Isabelle
   Grenot, Romaric
   Ouchike, Abdel
   Hazera, Pascal
   Masse, Anne-Lyse
   Demiri, Suela
   Vezinet, Corinne
   Baron, Elodie
   Benchetrit, Deborah
   Monsel, Antoine
   Trebbia, Gregoire
   Schaack, Emmanuelle
   Lepecq, Raphael
   Bobet, Mathieu
   Vinsonneau, Christophe
   Dekeyser, Thibault
   Delforge, Quentin
   Rahmani, Imen
   Vivet, Berengere
   Paillot, Jonathan
   Hierle, Lucie
   Chaignat, Claire
   Valette, Sarah
   Her, Benoit
   Brunet, Jennifier
   Page, Mathieu
   Boiste, Fabienne
   Collin, Anthony
   Bavozet, Florent
   Garin, Aude
   Dlala, Mohamed
   Mhamdi, Kais
   Beilouny, Bassem
   Lavalard, Alexandra
   Perez, Severine
   Veber, Benoit
   Guitard, Pierre-Gildas
   Gouin, Philippe
   Lamacz, Anna
   Plouvier, Fabienne
   Delaborde, Bertrand P.
   Kherchache, Aissa
   Chaalal, Amina
   Ricard, Jean-Damien
   Amouretti, Marc
   Freita-Ramos, Santiago
   Roux, Damien
   Constantin, Jean-Michel
   Assefi, Mona
   Lecore, Marine
   Selves, Agathe
   Prevost, Florian
   Lamer, Christian
   Shi, Ruiying
   Knani, Lyes
   Pili-Floury, Sebastien
   Vettoretti, Lucie
   Levy, Michael
   Marsac, Lucile
   Dauger, Stephane
   Guilmin-Crepon, Sophie
   Putegnat, Jean-Baptiste
   Bayle, Frederique
   Perrou, Maya
   Thao, Ghyslaine
   Geri, Guillaume
   Charron, Cyril
   Repesse, Xavier
   Vieillard-Baron, Antoine
   Guilbart, Mathieu
   Roger, Pierre-Alexandre
   Hinard, Sebastien
   Macq, Pierre-Yves
   Chaulier, Kevin
   Goutte, Sylvie
   Chillet, Patrick
   Pitta, Anais
   Darjent, Barbara
   Bruneau, Amandine
   Lasocki, Sigismond
   Leger, Maxime
   Gergaud, Soizic
   Lemarie, Pierre
   Terzi, Nicolas
   Schwebel, Carole
   Dartevel, Anais
   Galerneau, Louis-Marie
   Diehl, Jean-Luc
   Hauw-Berlemont, Caroline
   Peron, Nicolas
   Guerot, Emmanuel
   Amoli, Abolfazl Mohebbi
   Benhamou, Michel
   Deyme, Jean-Pierre
   Andremont, Olivier
   Lena, Diane
   Cady, Julien
   Causeret, Arnaud
   de la Chapelle, Arnaud
   Cracco, Christophe
   Rouleau, Stephane
   Schnell, David
   Lory, Cecile
   Chapelle, Thibault
   Bruckert, Vincent
   Garcia, Julie
   Sahraoui, Abdlazize
   Abbosh, Nathalie
   Bornstain, Caroline
   Pernet, Pierre
   Poirson, Florent
   Pasem, Ahmed
   Karoubi, Philippe
   Poupinel, Virginie
   Gauthier, Caroline
   Bouniol, Francois
   Feuchere, Philippe
   Bavozet, Florent
   Heron, Anne
   Carreira, Serge
   Emery, Malo
   Le Floch, Anne
   Giovannangeli, Luana
   Herzog, Nicolas
   Giacardi, Christophe
   Baudic, Thibaut
   Thill, Chloe
   Tubach, Florence
   Lesieur, Olivier
   Noublanche, Julie
   Colin, Gwenhael
   Lacherade, Jean-Claude
   Bionz, Gauthier
   Maquigneau, Natacha
   Sement, Arnaud
   Roca-Cerezo, Isabel
   Pascal, Michel
   Sma, Nesrine
CA REVA Network Covid-ICU Invest
TI Clinical characteristics and day-90 outcomes of 4244 critically ill
   adults with COVID-19: a prospective cohort study
SO INTENSIVE CARE MEDICINE
LA English
DT Article; Early Access
DE Acute respiratory distress syndrome; Mechanical ventilation; COVID-19;
   Outcome; Mortality risk factor
ID RESPIRATORY-DISTRESS-SYNDROME; EPIDEMIOLOGY; SCORE; CARE
AB Purpose To describe acute respiratory distress syndrome (ARDS) severity, ventilation management, and the outcomes of ICU patients with laboratory-confirmed COVID-19 and to determine risk factors of 90-day mortality post-ICU admission. Methods COVID-ICU is a multi-center, prospective cohort study conducted in 138 hospitals in France, Belgium, and Switzerland. Demographic, clinical, respiratory support, adjunctive interventions, ICU length-of-stay, and survival data were collected. Results From February 25 to May 4, 2020, 4643 patients (median [IQR] age 63 [54-71] years and SAPS II 37 [28-50]) were admitted in ICU, with day-90 post-ICU admission status available for 4244. On ICU admission, standard oxygen therapy, high-flow oxygen, and non-invasive ventilation were applied to 29%, 19%, and 6% patients, respectively. 2635 (63%) patients were intubated during the first 24 h whereas overall 3376 (80%) received invasive mechanical ventilation (MV) at one point during their ICU stay. Median (IQR) positive end-expiratory and plateau pressures were 12 (10-14) cmH(2)O, and 24 (21-27) cmH(2)O, respectively. The mechanical power transmitted by the MV to the lung was 26.5 (18.6-34.9) J/min. Paralyzing agents and prone position were applied to 88% and 70% of patients intubated at Day-1, respectively. Pulmonary embolism and ventilator-associated pneumonia were diagnosed in 207 (9%) and 1209 (58%) of these patients. On day 90, 1298/4244 (31%) patients had died. Among patients who received invasive or non-invasive ventilation on the day of ICU admission, day-90 mortality increased with the severity of ARDS at ICU admission (30%, 34%, and 50% for mild, moderate, and severe ARDS, respectively) and decreased from 42 to 25% over the study period. Early independent predictors of 90-day mortality were older age, immunosuppression, severe obesity, diabetes, higher renal and cardiovascular SOFA score components, lower PaO2/FiO(2) ratio and a shorter time between first symptoms and ICU admission. Conclusion Among more than 4000 critically ill patients with COVID-19 admitted to our ICUs, 90-day mortality was 31% and decreased from 42 to 25% over the study period. Mortality was higher in older, diabetic, obese and severe ARDS patients.
C1 [Mercat, Alain; Asfar, Pierre; Beloncle, Francois; Demiselle, Julien] CHU Angers, Angers, France.
   [Pham, Tai; Pavot, Arthur; Monnet, Xavier; Richard, Christian] Hop Bicetre, AP HP, Le Kremlin Bicetre, France.
   [Schmidt, Matthieu; Hajage, David; Demoule, Alexandre; Combes, Alain; Dres, Martin; Lebbah, Said; Palmyre, Jessica; Mayaux, Julien; Beurton, Alexandra; Chommeloux, Juliette; Luyt, Charles Edouard; Weiss, Nicolas; Demeret, Sophie; Marois, Clemence; Rohaut, Benjamin; Bougle, Adrien; Omar, Edris; Lancelot, Aymeric; Begot, Emmanuelle; Masse, Anne-Lyse; Demiri, Suela; Vezinet, Corinne; Baron, Elodie; Benchetrit, Deborah; Monsel, Antoine; Constantin, Jean-Michel; Assefi, Mona; Lecore, Marine; Selves, Agathe; Tubach, Florence] Hop La Pitie Salpetriere, AP HP, Paris, France.
   [Descamps, Richard; Joret, Aurelie; Du Cheyron, Damien] CHU Caen Normandie, Hop Cote Nacre, Caen, France.
   [Pene, Frederic; Chiche, Jean-Daniel; Jozwiak, Mathieu; Jaubert, Paul] Hop Cochin, AP HP, Paris, France.
   [Voiriot, Guillaume; Fartoukh, Muriel; Teulier, Marion; Blayau, Clarisse] Hop Tenon, AP HP, Paris, France.
   [L'Her, Erwen; Aubron, Cecile; Bodenes, Laetitia; Ferriere, Nicolas] CHRU Brest La Cavale Blanche, Brest, France.
   [Auchabie, Johann; Le Meur, Anthony; Pignal, Sylvain; Mazzoni, Thierry] Ctr Hosp Cholet, Cholet, France.
   [Quenot, Jean-Pierre; Andreu, Pascal; Roudau, Jean-Baptiste; Labruyere, Marie] CHU Dijon Bourgogne, Dijon, France.
   [Nseir, Saad; Preau, Sebastien; Poissy, Julien; Mathieu, Daniel] CHU Lille, Hop Roger Salengero, Lille, France.
   [Benhamida, Sarah; Paulet, Remi; Roucaud, Nicolas; Thyrault, Martial] Grp Hosp Nord Essonne, Longjumeau, France.
   [Daviet, Florence; Hraiech, Sami; Parzy, Gabriel; Sylvestre, Aude] Hop Nord Marseille, AP HM, Marseille, France.
   [Jochmans, Sebastien; Bouilland, Anne-Laure; Monchi, Mehran] Hop Melun Senart, Melun, France.
   [Danguy des Deserts, Marc; Mathais, Quentin; Rager, Gwendoline; Pasquier, Pierre] Element Mil Reanimat SSA, Mulhouse, France.
   [Jean, Reignier; Amelie, Seguin; Charlotte, Garret; Emmanuel, Canet] CHU Nantes, Hop Hotel Dieu, Nantes, France.
   [Dellamonica, Jean; Saccheri, Clement; Lombardi, Romain; Kouchit, Yanis] CHU Nice, Hop Archet, Nice, France.
   [Jacquier, Sophie; Mathonnet, Armelle; Nay, Mai-Ahn; Runge, Isabelle] Ctr Hosp Orleans, Orleans, France.
   [Martino, Frederic; Flurin, Laure; Rolle, Amelie; Carles, Michel] CHU Guadeloupe, Pointe A Pitre, Guadeloupe, France.
   [Coudroy, Remi; Thille, Arnaud W.; Frat, Jean-Pierre; Rodriguez, Maeva] Hop Miletrie, Poitiers, France.
   [Beuret, Pascal; Tientcheu, Audrey; Vincent, Arthur; Michelin, Florian] Ctr Hosp Roanne, Roanne, France.
   [Melone, Marie Anne; Gauzi, Maxime; Guilbert, Arnaud; Kouadri, Geoffrey; Veber, Benoit; Guitard, Pierre-Gildas; Gouin, Philippe; Lamacz, Anna] CHU Rouen, Hop Charles Nicolle, Rouen, France.
   [Gissot, Valerie; Ehrmann, Stephan; Salmon-Gandonniere, Charlotte; Elaroussi, Djlali] CHRU Tours, Hop Bretonneau, Tours, France.
   [Delbove, Agathe; Fedun, Yannick; Huntzinger, Julien; Lebas, Eddy] Ctr Hosp Bretagne Atlantique, Vannes, France.
   [Kisoka, Grace; Gregoire, Celine; Marchetta, Stella; Lambermont, Bernard] CHU Liege, Liege, Belgium.
   [Argaud, Laurent; Baudry, Thomas; Bertrand, Pierre-Jean; Dargent, Auguste] Hop Edouard Herriot, Hosp Civils Lyon, Lyon, France.
   [Guitton, Christophe; Chudeau, Nicolas; Landais, Mickael; Darreau, Cedric] Ctr Hosp Mans, Le Mans, France.
   [Ferre, Alexis; Gros, Antoine; Lacave, Guillaume; Bruneel, Fabrice] Ctr Hosp Versailles, Le Chesnay, France.
   [Neuville, Mathilde; Devaquet, Jerome; Tachon, Guillaume; Gallot, Richard] Hop Foch, Suresnes, France.
   [Chelha, Riad; Galbois, Arnaud; Jallot, Anne; Lemoine, Ludivine Chalumeau] Hop Claude Galien, Quincy Sous Senart, France.
   [Kuteifan, Khaldoun; Pointurier, Valentin; Jandeaux, Louise-Marie; Mootien, Joy] GHR Mulhouse Sud Alsace, Mulhouse, France.
   [Damoisel, Charles; Sztrymf, Benjamin] Hop Antoine Beclere, AP HP, Clamart, France.
   [Schortgen, Frederique; Rusel, Leon; Jung, Camille] Hop Intercommunal Creteil, Creteil, France.
   [Gobert, Florent] Hop Neurol, Hosp Civils Lyon, Lyon, France.
   [Vimpere, Damien; Lamhaut, Lionel] Hop Necker Enfants Malad, AP HP, Paris, France.
   [Sauneuf, Bertrand; Charrier, Liliane; Calus, Julien; Desmeules, Isabelle] Hop Louis Pasteur, Ctr Hosp Publ Cotentin, Cherbourg En Cotentin, France.
   [Painvin, Benoit; Tadie, Jean-Marc] CHU Rennes, Hop Pontchaillou, Rennes, France.
   [Castelain, Vincent; Michard, Baptiste; Herbrecht, Jean-Etienne; Baldacini, Mathieu] CHU Strasbourg, Hop Hautepierre, Strasbourg, France.
   [Moury, Pierre-Henri; Savida, Anne-Charlotte; Couadau, Emmanuel; Serie, Mathieu] Ctr Hosp Terr Gaston Bourret, Noumea, France.
   [Alexandru, Nica] Ctr Hosp Compiegne Noyon, Compiegne, France.
   [Bruel, Cedric; Fontaine, Candice; Garrigou, Sonia; Mahler, Juliette Courtiade] Grp Hosp St Joseph, Paris, France.
   [Leclerc, Maxime; Ramakers, Michel] Ctr Hosp Mem St Lo, St Lo, France.
   [Garcon, Pierre; Massou, Nicole; Van Vong, Ly Phacs; Sen, Juliane] Grand Hop Est Francilien, Jossigny, France.
   [Lucas, Nolwenn; Chemouni, Franck; Stoclin, Annabelle] Gustave Roussy, Villejuif, France.
   [Avenel, Alexandre; Faure, Henri; Gentilhomme, Angelie; Ricome, Sylvie] Ctr Hosp Intercommunal Robert Ballanger, Aulnay Sous Bois, France.
   [Abraham, Paul; Monard, Celine; Textoris, Julien; Rimmele, Thomas] Hop Edouard Herriot, Hosp Civiles Lyon, Lyon, France.
   [Montini, Florent] Ctr Hosp Avignon, Avignon, France.
   [Lejour, Gabriel; Lazard, Thierry; Etienney, Isabelle; Kerroumi, Younes] Grp Hosp Diaconesses Croix St Simon, Paris, France.
   [Claire, Dupuis; Coupez, Bereiziat Marine; Francois, Thouy] CHU Clermont Ferrand, Hop Gabriel Montpied, Clermont Ferrand, France.
   [Hoffmann, Clemet; Donat, Nicolas; Muller, Violaine; Martinez, Thibault] Hop Instruct Armees Percy, Clamart, France.
   [Kimmoun, Antoine; Jacquot, Audrey; Mattei, Matthieu; Levy, Bruno] CHU Nancy, Hop Brabois, Vandoeuvre Les Nancy, France.
   [Ravan, Ramin; Dopeux, Loic; Liteaudon, Jean-Mathias; Roux, Delphine] Ctr Hosp Vichy, Vichy, France.
   [Rey, Brice; Anghel, Radu; Schenesse, Deborah; Gevrey, Vincent] Hop Pierre Beregovoy, Nevers, France.
   [Castanera, Jermy; Petua, Philippe; Madeux, Benjamin] Ctr Hosp Tarbes, Tarbes, France.
   [Hartman, Otto] Hop Louis Pasteur, Hop Civils Colmar, Colmar, France.
   [Piagnerelli, Michael; Joosten, Anne; Noel, Cinderella; Biston, Patrick] CHU Charleroi, Hop Marie Curie, Brussels, Belgium.
   [Noel, Thibaut] Ctr Hosp Verdun St Mihiel, St Mihiel, France.
   [Bouar, Gurvan L. E.; Boukhanza, Messabi; Demarest, Elsa; Bajolet, Marie-France] CH Eure Seine, Hop Evreux Vernon, Evreux, France.
   [Charrier, Nathanael; Quenet, Audrey; Zylberfajn, Cecile; Dufour, Nicolas] Hop Rene Dubos, Pontoise, France.
   [Megarbane, Buno; Voicu, Sqebastian; Deye, Nicolas; Malissin, Isabelle; de Roquetaillade, Charles; Chousterman, Benjamin G.; Mebazaa, Alexandre; Gayat, Etienne] Hop Lariboisiere, AP HP, Paris, France.
   [Legay, Francois; Debarre, Matthieu; Barbarot, Nicolas; Fillatre, Pierre] Ctr Hosp St Brieuc, St Brieuc, France.
   [Delord, Bertrand; Laterrade, Thomas; Saghi, Tahar; Pujol, Wilfried] Polyclin Bordeaux Nord Aquitaine, Bordeaux, France.
   [Cungi, Pierre Julien; Esnault, Pierre; Cardinale, Mickael] HIA St Anne, Toulon, France.
   [Hong Tuan Ha, Vivien; Fleury, Gregory; Brou, Marie-Ange; Zafimahazo, Daniel] Grand Hop Est Francilien, Meaux, Seine & Marne, France.
   [Tran-Van, David; Avargues, Patrick; Carenco, Lisa] HIA Robert Picque, Villenave Dornon, France.
   [Robin, Nicolas; Ouali, Alexandre; Houdou, Lucie] Ctr Hosp Fontainebleau, Fontainebleau, France.
   [Le Terrier, Christophe; Suh, Noemie; Primmaz, Steve; Pugin, Jerome] Hop Univ Geneve, Geneva, Switzerland.
   [Weiss, Emmanuel; Gauss, Tobias; Moyer, Jean-Denis; Paugam-Burtz, Catherine] Hop Beaujon, AP HP, Clichy, France.
   [La Combe, Beatrice; Smonig, Rolland; Violleau, Jade; Cailliez, Pauline] Grp Hosp Bretage Sud, Lorient, France.
   [Chelly, Jonathan] Ctr Hosp Intercommunal Toulon, La Seyne Sur Mer, France.
   [Marchalot, Antoine; Saladin, Cecile; Bigot, Christelle] Ctr Hosp Dieppe, Dieppe, France.
   [Fayolle, Pierre-Marie; Fatseas, Jules; Ibrahim, Amr; Resiere, Dabor] CHU Martinique, Fort De France, Martinique, France.
   [Hage, Rabih; Cholet, Clementine; Cantier, Marie; Trouiller, Pierre] Hop Fdn Adolphe Rothchild, Paris, France.
   [Montravers, Philippe; Lortat-Jacob, Brice; Tanaka, Sebastien; Tran-Dinh, Alexy] Bichat Claude Bernard, AP HP, Paris, France.
   [Duranteau, Jacques; Harrois, Anatole; Dubreuil, Guillaume; Werner, Marie] Hop Univ Paris Sud, AP HP, Le Kremlin Bicetre, France.
   [Godier, Anne; Hamada, Sophie; Zlotnik, Diane; Nougue, Helene; Diehl, Jean-Luc; Hauw-Berlemont, Caroline; Peron, Nicolas; Guerot, Emmanuel] Hop Europeen Georges Pompidou, AP HP, Paris, France.
   [Mekontso-Dessap, Armand; Carteaux, Guillaume; Razazi, Keyvan; De Prost, Nicolas] GHU Henri Mondor, AP HP, Creteil, France.
   [Mongardon, Nicolas; Langeron, Olivier; Levesque, Eric; Attias, Arie] Hop Univ Henri Mondor, AP HP, Creteil, France.
   [Garnier, Marc; Pardo, Emmanuel; Satre-Buisson, Lea; Gutton, Christophe; Ait-Oufella, Hafid; Hariri, Geoffroy; Urbina, Tomas; Mazerand, Sandie] Hop St Antoine, AP HP, Paris, France.
   [Yvin, Elise; Marcault, Clemence; Azoulay, Elie; Darmon, Michael; Depret, Francois; Coutrot, Maxime; Chaussard, Maite; Guillemet, Lucie] Hop St Louis, AP HP, Paris, France.
   [Bonnet, Nicolas; Ebstein, Nathan; Gaudry, Stephane; Cohen, Yves] Hop Avicennes, AP HP, Bobigny, France.
   [Heming, Nicholas; Santi, Francesca; Moine, Pierre; Annane, Djillali] Hop Raymond Pointcarre, AP HP, Garches, France.
   [Plantefeve, Gaetan; Contou, Damien; Mentec, Herve; Pajot, Olivier] Ctr Hosp Victor Dupouy, Argenteuil, France.
   [Faguer, Stanislas; Cointault, Olivier; Lavayssiere, Laurence; Nogier, Marie-Beatrice] CHU Toulouse, Hop Rangueil, Toulouse, France.
   [Jamme, Matthieu; Pichereau, Claire; Hayon, Jan; Outin, Herve] Ctr Hosp Poissy, Poissy, France.
   [Goffin, Pierre; Thouny, Romain; Guntz, Julien; Jadot, Laurent] CHC Groupe Sante, Clin MontLegia, Liege, Belgium.
   [Persichini, Romain] CHU St Denis, La Reunion, France.
   [Jean-Michel, Vanessa; Georges, Hugues; Caulier, Thomas] Ctr Hosp Tourcoing, Tourcoing, France.
   [Pradel, Gael; Hausermann, Marie-Helene; Nguyen-Valat, ThiMy Hue; Boudinaud, Michel] Ctr Hosp Henri Mondor Aurillac, Aurillac, France.
   [Vivier, Emmanuel; Rosseli, Sylvene; Bourdin, Gael; Pommier, Christian] Ctr Hosp St Joseph St Luc, Lyon, France.
   [Vinclair, Marc; Poignant, Simon; Mons, Sandrine] Ctr Hosp Polynesie Francaise, Polynesie, France.
   [Bougouin, Wulfran] Hop Prive Jacques Cartier, Ramsay Gen Sante, Massy, France.
   [Bruna, Franklin; Maestraggi, Quentin; Roth, Christian] Ctr Hosp Alpes Leman, Contamine Sur Arve, France.
   [Bitker, Laurent; Dhelft, Francois; Bonnet-Chateau, Justine; Filippelli, Mathilde; Achino, Chloe; Delignette, Marie-Charlotte; Mazard, Tessa; Aubrun, Frederic] Hop Croix Rousse, Hosp Civils Lyon, Lyon, France.
   [Morichau-Beauchant, Tristan; Thierry, Stephane; Le Roy, Charlotte; Saint Jouan, Melanie] Ctr Cardiol Nord, St Denis, France.
   [Goncalves, Bruno; Mazeraud, Aurelien; Daniel, Matthieu; Sharshar, Tarek] GHU Hop St Anne, Paris, France.
   [Cadoz, Cyril; Gaci, Rostane; Gette, Sebastien; Louis, Guillaune] CHR Metz Hop Mercy, Metz, France.
   [Sacleux, Sophe-Caroline; Ordan, Marie-Amelie] Hop Paul Brousse, AP HP, Villejuif, France.
   [Cravoisy, Aurelie; Conrad, Marie; Courte, Guilhem; Gibot, Sebastien] CHRU Nancy, Hop Cent, Nancy, France.
   [Benzidi, Younes; Casella, Claudia; Serpin, Laurent; Setti, Jean-Lou; Besse, Marie-Catherine; Bourreau, Anna] Ctr Hosp Ajaccio, Ajaccio, France.
   [Pillot, Jerome; Rivera, Caroline; Vinclair, Camille; Robaux, Marie-Aline] Ctr Hosp Bourges, Bourges, France.
   Ctr Hosp Cote Basque, Bayonne, France.
   [Bouchet, Bruno; Frerou, Aurelien; Muller, Laura; Quentin, Charlotte] CH St Malo, St Malo, France.
   [Degoul, Samuel] Ctr Hosp Mulhouse, Mulhouse, France.
   [Stihle, Xavier; Sumian, Claude; Bergero, Nicoletta; Lanaspre, Bernard] Ctr Hosp Briancon, Briancon, France.
   [Quintard, Herve; Maiziere, Eve Marie] CHU Nice, Hop Pasteur 2, Nice, France.
   [Egreteau, Pierre-Yves; Leloup, Guillaume; Berteau, Florin; Cottrel, Marjolaine] Ctr Hosp Pays Morlaix, Morlaix, France.
   [Bouteloup, Marie; Jeannot, Matthieu; Blanc, Quentin; Saison, Julien] Ctr Hosp Valence, Valence, France.
   [Geneau, Isabelle; Grenot, Romaric; Ouchike, Abdel; Hazera, Pascal] Ctr Hosp Niort, Niort, France.
   [Trebbia, Gregoire; Schaack, Emmanuelle; Lepecq, Raphael; Bobet, Mathieu] Clin Val dOr, St Cloud, France.
   [Vinsonneau, Christophe; Dekeyser, Thibault; Delforge, Quentin; Rahmani, Imen] Ctr Hosp Bethune, Bethune, France.
   [Vivet, Berengere; Paillot, Jonathan; Hierle, Lucie; Chaignat, Claire; Valette, Sarah] Grp Hosp Intercommunal Haute Saone, Vesoul, France.
   [Her, Benoit; Brunet, Jennifier] Clin St Martin, Caen, France.
   [Page, Mathieu; Boiste, Fabienne; Collin, Anthony] Ramsay Gen Sante, Clin Convert, Bourg En Bresse, France.
   [Bavozet, Florent; Garin, Aude; Dlala, Mohamed; Mhamdi, Kais] Hop Victor Jousselin, Dreux, France.
   [Beilouny, Bassem; Lavalard, Alexandra; Perez, Severine] Ctr Hosp Troye, Troye, France.
   [Plouvier, Fabienne; Delaborde, Bertrand P.; Kherchache, Aissa; Chaalal, Amina] Ctr Hosp Agen Nerac, Agen, Lot & Garonne, France.
   [Ricard, Jean-Damien; Amouretti, Marc; Freita-Ramos, Santiago; Roux, Damien] Hop Louis Mourier, AP HP, Colombes, France.
   [Prevost, Florian; Lamer, Christian; Shi, Ruiying; Knani, Lyes] Inst Mutualiste Montsouris, Paris, France.
   [Pili-Floury, Sebastien; Vettoretti, Lucie] CHU Besancon, Hop Jean Minjoz, Besancon, France.
   [Levy, Michael; Marsac, Lucile; Dauger, Stephane; Guilmin-Crepon, Sophie] Hop Univ Robert Debre, AP HP, Paris, France.
   [Putegnat, Jean-Baptiste; Bayle, Frederique; Perrou, Maya; Thao, Ghyslaine] Medipole Lyon Villeurbanne, Vileurbanne, France.
   [Geri, Guillaume; Charron, Cyril; Repesse, Xavier; Vieillard-Baron, Antoine] Ambroise Pare, AP HP, Boulogne, France.
   [Guilbart, Mathieu; Roger, Pierre-Alexandre; Hinard, Sebastien; Macq, Pierre-Yves] CHU Amiens Picardie, Amiens, France.
   [Chaulier, Kevin; Goutte, Sylvie] Hop Nord Ouest, Villefranche, France.
   [Chillet, Patrick; Pitta, Anais; Darjent, Barbara; Bruneau, Amandine] CH Chalons en Champagne, Chalons Sur Marne, France.
   [Lasocki, Sigismond; Leger, Maxime; Gergaud, Soizic; Lemarie, Pierre] CHU Angers, Angers, France.
   [Terzi, Nicolas; Schwebel, Carole; Dartevel, Anais; Galerneau, Louis-Marie] CHU Grenoble Alpes, Grenoble, France.
   [Amoli, Abolfazl Mohebbi; Benhamou, Michel; Deyme, Jean-Pierre; Andremont, Olivier] Hop Prive Antony, Antony, France.
   [Lena, Diane; Cady, Julien; Causeret, Arnaud; de la Chapelle, Arnaud] Inst Arnault Tzanck, St Laurent Du Var, France.
   [Cracco, Christophe; Rouleau, Stephane; Schnell, David] Ctr Hosp Angouleme, Angouleme, France.
   Ctr Hosp Cahors, Cahors, France.
   [Lory, Cecile] Ctr Hosp Carcassonne, Carcassonne, France.
   [Chapelle, Thibault; Bruckert, Vincent; Garcia, Julie; Sahraoui, Abdlazize] CHU Nice, Hop LArchet 2, Nice, France.
   [Abbosh, Nathalie; Bornstain, Caroline; Pernet, Pierre] Hop Prive Vert Galant, Tremblay En France, France.
   [Poirson, Florent; Pasem, Ahmed; Karoubi, Philippe] Ctr Hosp Rambouillet, Rambouillet, France.
   [Poupinel, Virginie; Gauthier, Caroline; Bouniol, Francois; Feuchere, Philippe] Hop Leman, Thonon Les Bains, France.
   [Bavozet, Florent; Heron, Anne] Ctr Hosp Victor Jousselin, Dreux, France.
   [Carreira, Serge; Emery, Malo; Le Floch, Anne; Giovannangeli, Luana] Hop Sainte Camille, Brie Sur Marne, France.
   [Herzog, Nicolas; Giacardi, Christophe; Baudic, Thibaut; Thill, Chloe] Hop Instruct Armees Clermont Tonnerre, Brest, France.
   [Lesieur, Olivier; Colin, Gwenhael] Grp Hosp Re Aunis, La Rochelle, France.
   [Colin, Gwenhael; Lacherade, Jean-Claude; Bionz, Gauthier; Maquigneau, Natacha] Ctr Hosp Dept Vendee, La Roche Sur Yon, France.
   [Sement, Arnaud; Roca-Cerezo, Isabel; Pascal, Michel; Sma, Nesrine] Ctr Hosp Intercommunal Mont Marsan & Pays Sources, Mont De Marsan, France.
RP Schmidt, M (corresponding author), CHU Angers, Angers, France.
EM matthieu.schmidt@aphp.fr
RI Castelain, Vincent/ABG-9778-2020; Leger, Maxime/AAO-4525-2020; Deserts,
   Marc Danguy des/AAE-3237-2019
OI Leger, Maxime/0000-0002-5447-6595; Deserts, Marc Danguy
   des/0000-0002-0185-9955; Louis, Guillaume/0000-0002-4208-8122; TERZI,
   Nicolas/0000-0003-4036-6245
FU Fondation AP-HP; Direction de la Recherche Clinique et du Developpement;
   French Ministry of Health; Air Liquide Healthcare; Assistance Publique
   Hopitaux de Paris (AP-HP)
FX This study was funded by the Fondation AP-HP and the Direction de la
   Recherche Clinique et du Developpement and the French Ministry of
   Health. The REVA network received a 75,000 (sic) research grant form Air
   Liquide Healthcare. Sponsor: The sponsor was Assistance Publique
   Hopitaux de Paris (AP-HP).
CR Alban A, 2020, INTENS CARE MED, V46, P1624, DOI 10.1007/s00134-020-06066-7
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Auld SC, 2020, CRIT CARE MED, V48, pE1382, DOI 10.1097/CCM.0000000000004687
   Azoulay E, 2020, INTENS CARE MED, V46, P1714, DOI 10.1007/s00134-020-06202-3
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Chait A, 2020, FRONT CARDIOVASC MED, V7, DOI 10.3389/fcvm.2020.00022
   Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2
   Gabarre P, 2020, INTENS CARE MED, V46, P1339, DOI 10.1007/s00134-020-06153-9
   Gattinoni L, 2016, INTENS CARE MED, V42, P1567, DOI 10.1007/s00134-016-4505-2
   Gattinoni L, 2020, INTENS CARE MED, V46, P1438, DOI 10.1007/s00134-020-06103-5
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Gong MN, 2010, THORAX, V65, P44, DOI 10.1136/thx.2009.117572
   GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515
   Grasselli Giacomo, 2020, Lancet Respir Med, V8, P1201, DOI 10.1016/S2213-2600(20)30370-2
   Grasselli G, 2020, JAMA INTERN MED, V180, P1345, DOI 10.1001/jamainternmed.2020.3539
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Green WD, 2017, ANN AM THORAC SOC, V14, pS406, DOI 10.1513/AnnalsATS.201706-447AW
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Juma S, 2016, CAN GERIATR J, V19, P34, DOI 10.5770/cgj.19.196
   LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957
   Liu ZM, 2020, J INFECTION, V81, P331, DOI 10.1016/j.jinf.2020.03.054
   McLaren L, 2007, EPIDEMIOL REV, V29, P29, DOI 10.1093/epirev/mxm001
   Millar JE, 2020, LANCET RESP MED, V8, P952, DOI 10.1016/S2213-2600(20)30368-4
   Poissy J, 2020, CIRCULATION, V142, P184, DOI 10.1161/CIRCULATIONAHA.120.047430
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Schmidt M, 2020, LANCET RESP MED, V8, P1121, DOI 10.1016/S2213-2600(20)30328-3
   Neto AS, 2018, INTENS CARE MED, V44, P1914, DOI 10.1007/s00134-018-5375-6
   Sinha P, 2019, AM J RESP CRIT CARE, V199, P333, DOI 10.1164/rccm.201804-0692OC
   STERNE JAC, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.b2393, DOI 10.1136/BMJ.B2393]
   Vincent JL, 2009, JAMA-J AM MED ASSOC, V302, P2323, DOI 10.1001/jama.2009.1754
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Xie JF, 2020, INTENS CARE MED, V46, P1863, DOI 10.1007/s00134-020-06211-2
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 37
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
DI 10.1007/s00134-020-06294-x
EA OCT 2020
PG 14
WC Critical Care Medicine
SC General & Internal Medicine
GA OT6CA
UT WOS:000590930900001
PM 33211135
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Boily-Larouche, G
   Carson, G
   Golding, J
   Depoortere, E
   de Almeida, JR
   Vaux, R
   Paparella, G
   Vitali, D
   Khursigara, D
   Madelaine, C
   Lay, AM
   Kerstiens, B
   Yazdanpanah, Y
   Kaushic, C
   Zaidi, A
   Saville, M
   Yeskey, D
   Gray, G
   Veloso, V
   Koopmans, M
   Fisman, D
   Crooks, K
   Camargo, K
AF Boily-Larouche, Genevieve
   Carson, Gail
   Golding, Josie
   Depoortere, Evelyn
   de Almeida, Joao Rangel
   Vaux, Richard
   Paparella, Giuseppe
   Vitali, Danielle
   Khursigara, Deborah
   Madelaine, Claire
   Lay, A. Morgan
   Kerstiens, Barbara
   Yazdanpanah, Yazdan
   Kaushic, Charu
   Zaidi, Anita
   Saville, Melanie
   Yeskey, Debra
   Gray, Glenda
   Veloso, Valdilea
   Koopmans, Marion
   Fisman, David
   Crooks, Kristy
   Camargo, Kenneth
CA Meeting Co-Chairs
   COVID-19 Res GloPID-R Synerg
TI Ending COVID-19: progress and gaps in research-highlights of the July
   2020 GloPID-R COVID-19 Research Synergies Meetings
SO BMC MEDICINE
LA English
DT Article
DE COVID-19; SARS-CoV-2; GloPID-R; COVID-19 vaccines; COVID-19
   therapeutics; SARS-CoV-2 transmission; Social sciences
C1 [Boily-Larouche, Genevieve] Canadian Inst Hlth Res, Inst Infect & Immun, Hamilton, ON, Canada.
   [Boily-Larouche, Genevieve] Univ Oxford, ISARIC, Oxford, England.
   Wellcome, London, England.
   European Commiss, Brussels, Belgium.
   GloPID R Secretariat, Merieux Fdn, Lyon, France.
   INSERM, Paris, France.
   [COVID-19 Res GloPID-R Synerg] Canadian Inst Hlth Res, Inst Populat & Publ Hlth, Toronto, ON, Canada.
   Bill & Melinda Gates Fdn, Seattle, WA USA.
   CEPI, Washington, DC USA.
   South African Med Res Council, Cape Town, South Africa.
   Fiocruz MS, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   Erasmus MC, Rotterdam, Netherlands.
   Univ Toronto, Toronto, ON, Canada.
   Charles Darwin Univ, Menzies Sch Hlth Res Casuarina, Darwin, NT, Australia.
   [Meeting Co-Chairs] Univ Estado Rio De Janeiro, Rio De Janeiro, Brazil.
RP Boily-Larouche, G (corresponding author), Canadian Inst Hlth Res, Inst Infect & Immun, Hamilton, ON, Canada.; Boily-Larouche, G (corresponding author), Univ Oxford, ISARIC, Oxford, England.
EM kaushic@mcmaster.ca
OI Paparella, Giuseppe/0000-0002-8119-9001
FU GloPID-R; Canadian Institutes of Health ResearchCanadian Institutes of
   Health Research (CIHR); Institute of Infection and ImmunityCanadian
   Institutes of Health Research (CIHR); Institute of Population and Public
   Health; Wellcome; European CommissionEuropean CommissionEuropean
   Commission Joint Research Centre; ISARIC; InsermInstitut National de la
   Sante et de la Recherche Medicale (Inserm)
FX GloPID-R provided the funding to support the Synergies Meetings with the
   in-kind contribution of the Canadian Institutes of Health Research,
   Institute of Infection and Immunity and Institute of Population and
   Public Health, Wellcome, European Commission, ISARIC and Inserm.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1741-7015
J9 BMC MED
JI BMC Med.
PD OCT 29
PY 2020
VL 18
IS 1
AR 342
DI 10.1186/s12916-020-01807-3
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA OP4BD
UT WOS:000588024700001
PM 33115460
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Chapman, B
   Swainston, J
   Grunfeld, EA
   Derakshan, N
AF Chapman, Bethany
   Swainston, Jessica
   Grunfeld, Elizabeth A.
   Derakshan, Nazanin
TI COVID-19 Outbreak Effects on Job Security and Emotional Functioning
   Amongst Women Living With Breast Cancer
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Article
DE breast cancer; COVID-19; anxiety; depression; cognition; employment; job
   security
ID QUALITY-OF-LIFE; COGNITIVE FUNCTION; ANXIETY SYMPTOMS; WORK LIMITATIONS;
   HOSPITAL ANXIETY; DEPRESSION; RUMINATION; SURVIVORS; EMPLOYMENT; THERAPY
AB The outbreak of Coronavirus disease 2019 (COVID-19) has negatively impacted global economies and employment. In the UK, it is predicted that approximately eight million jobs were furloughed as a result of the outbreak and the associated restriction of movement or shielding measures. This study aimed to investigate the impact of changes in employment status on cognitive and emotional health as well as perceptions of work. Furthermore, it examined the relationships between women's job security and anxiety, depression and cognitive function. Women living with breast cancer (N = 234) completed online questionnaires to measure their cognitive function, general emotional well-being, COVID-19 related emotional vulnerability (COVID-EMV), work ability and COVID-19 related perceptions of work. Our results revealed that threat to job security was predictive of depression and cognitive function in the entire sample Such that those with higher levels of perceived job security had lower depression and better cognitive function. Further, women who were furloughed or unable to continue work reported higher job insecurity compared to those who had worked throughout the pandemic. Greater rumination was also associated with worse anxiety and depression as well as poorer cognitive function. Finally, moderation analysis highlighted that women who had better cognitive functioning were less likely to experience anxiety when their job security was high. Given our findings, we suggest that employers provide women with accessible interventions to enhance cognitive and emotional resilience and thus help protect against the detrimental effects of job insecurity created by the COVID-19 outbreak.
C1 [Chapman, Bethany; Swainston, Jessica; Grunfeld, Elizabeth A.; Derakshan, Nazanin] Birkbeck Univ London, Dept Psychol Sci, London, England.
RP Chapman, B (corresponding author), Birkbeck Univ London, Dept Psychol Sci, London, England.
EM bchapm02@mail.bbk.ac.uk
FU Economic and Social Research CouncilEconomic & Social Research Council
   (ESRC) [ES/P000592/1]
FX The current study was funded by an Economic and Social Research Council
   grant awarded to BC (Grant Reference: ES/P000592/1)
   (https://esrc.ukri.org/).
CR Ahles TA, 2018, ANNU REV CLIN PSYCHO, V14, P425, DOI [10.1146/annurev-clinpsy-050817084903, 10.1146/annurev-clinpsy-050817-084903]
   Akel Reem, 2017, Asian Pac J Cancer Prev, V18, P2809
   Avis NE, 2015, CANCER EPIDEM BIOMAR, V24, P1789, DOI 10.1158/1055-9965.EPI-15-0327
   Beckwe M, 2014, PSYCHOL RES-PSYCH FO, V78, P651, DOI 10.1007/s00426-013-0517-5
   Bell T., 2020, GETTING BRITAIN WORK
   Blinder VS, 2012, J COMMUN HEALTH, V37, P763, DOI 10.1007/s10900-011-9509-9
   Blom V., 2015, EC IND DEMOCR, V39, P48, DOI [10.1177/0143831X1560911, DOI 10.1177/0143831X1560911]
   Boya FO, 2008, IND HEALTH, V46, P613, DOI 10.2486/indhealth.46.613
   Breast Cancer Now, 2020, FACTS STAT 2020
   Brown SL, 2020, CLIN PSYCHOL PSYCHOT, V27, P1, DOI 10.1002/cpp.2399
   Burgess C, 2005, BRIT MED J, V330, P702, DOI 10.1136/bmj.38343.670868.D3
   Calvio L, 2010, J OCCUP ENVIRON MED, V52, P219, DOI 10.1097/JOM.0b013e3181d0bef7
   Carreira H, 2018, JNCI-J NATL CANCER I, V110, P1311, DOI 10.1093/jnci/djy177
   Chapman B, 2019, HEALTH PSYCHOL OPEN, V6, DOI 10.1177/2055102919871661
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Cvetkovic J, 2016, PSYCHIAT RES, V240, P343, DOI 10.1016/j.psychres.2016.04.048
   Eichler Christian, 2015, Asian Pac J Cancer Prev, V16, P1063
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149
   Fu MR, 2015, J PERS MED, V5, P229, DOI 10.3390/jpm5030229
   Gaitanidis A, 2018, PSYCHO-ONCOLOGY, V27, P1450, DOI 10.1002/pon.4570
   Gallo WT, 2000, J GERONTOL B-PSYCHOL, V55, pS131, DOI 10.1093/geronb/55.3.S131
   Ganz PA, 2013, JNCI-J NATL CANCER I, V105, P791, DOI 10.1093/jnci/djt073
   Government UK, 2020, CORONAVIRUS COVID 19
   HOPWOOD P, 1991, BRIT J CANCER, V64, P349, DOI 10.1038/bjc.1991.304
   Janelsins MC, 2014, INT REV PSYCHIATR, V26, P102, DOI 10.3109/09540261.2013.864260
   Jansen CE, 2011, SUPPORT CARE CANCER, V19, P1647, DOI 10.1007/s00520-010-0997-4
   Johnsson A, 2010, EUR J CANCER CARE, V19, P317, DOI 10.1111/j.1365-2354.2008.01043.x
   Kaiser Jochen, 2019, Front Psychol, V10, P2584, DOI 10.3389/fpsyg.2019.02584
   Kawohl W, 2020, LANCET PSYCHIAT, V7, P389, DOI 10.1016/S2215-0366(20)30141-3
   Keim-Malpass J, 2016, PSYCHO-ONCOLOGY, V25, P873, DOI 10.1002/pon.3951
   Koppelmans V, 2012, J CLIN ONCOL, V30, P1080, DOI 10.1200/JCO.2011.37.0189
   Lerner D, 2003, MED CARE, V41, P649, DOI 10.1097/00005650-200305000-00012
   Lerner D, 2001, MED CARE, V39, P72, DOI 10.1097/00005650-200101000-00009
   Llosa JA, 2018, AN PSICOL-SPAIN, V34, P211, DOI 10.6018/analesps.34.2.281651
   Menning S, 2016, J PAIN SYMPTOM MANAG, V52, P560, DOI 10.1016/j.jpainsymman.2016.04.012
   MEYER TJ, 1990, BEHAV RES THER, V28, P487, DOI 10.1016/0005-7967(90)90135-6
   Nolen-Hoeksema S, 2000, J ABNORM PSYCHOL, V109, P504, DOI 10.1037/0021-843X.109.3.504
   Ochoa C, 2017, INT J CLIN HLTH PSYC, V17, P28, DOI 10.1016/j.ijchp.2016.09.002
   Osborne RH, 2004, QUAL LIFE RES, V13, P191, DOI 10.1023/B:QURE.0000015292.56268.e7
   Papanastasiou A, 2019, ONCOL LETT, V18, P507, DOI 10.3892/ol.2019.10361
   Qualtrics X. M., 2020, OTHER COVID 19 CRISI
   Rasmussen DM, 2008, PSYCHO-ONCOL, V17, P1232, DOI 10.1002/pon.1354
   Ren WW, 2019, PSYCHIAT RES, V271, P52, DOI 10.1016/j.psychres.2018.11.026
   Ryum T, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00924
   Schairer C, 2006, JNCI-J NATL CANCER I, V98, P1416, DOI 10.1093/jnci/djj377
   Spinhoven P, 2018, J AFFECT DISORDERS, V241, P216, DOI 10.1016/j.jad.2018.08.037
   Steiner JL, 2014, FAM SYST HEALTH, V32, P378, DOI 10.1037/fsh0000066
   Stolove CA, 2017, PSYCHIAT RES, V253, P79, DOI 10.1016/j.psychres.2017.03.036
   Swainston J, 2018, PSYCHO-ONCOLOGY, V27, P1780, DOI 10.1002/pon.4727
   Theofilou P, 2012, ONCOL REV, V6, P37, DOI 10.4081/oncol.2012.e5
   Timperi AW, 2013, PSYCHO-ONCOLOGY, V22, P1411, DOI 10.1002/pon.3157
   Treynor W, 2003, COGNITIVE THER RES, V27, P247, DOI 10.1023/A:1023910315561
   Vance DE, 2016, NURSING-RES REV, V6, P61, DOI 10.2147/NRR.S115625
   Vardy JL, 2019, BRAIN IMAGING BEHAV, V13, P15, DOI 10.1007/s11682-017-9728-5
   Von Ah D, 2018, J CANCER SURVIV, V12, P246, DOI 10.1007/s11764-017-0664-6
   Von Ah D, 2015, J PAIN SYMPTOM MANAG, V49, P697, DOI 10.1016/j.jpainsymman.2014.08.012
   Wagner LI, 2009, J SUPPORT ONCOL, V7, pW32
   ZHANG Y, 2016, BMJ OPEN, V6
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 60
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD OCT 29
PY 2020
VL 11
AR 582014
DI 10.3389/fpsyg.2020.582014
PG 13
WC Psychology, Multidisciplinary
SC Psychology
GA OP9EO
UT WOS:000588393300001
PM 33192902
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lon, JR
   Bai, YM
   Zhong, BX
   Cai, FQ
   Du, HL
AF Lon, Jerome Rumdon
   Bai, Yunmeng
   Zhong, Bingxu
   Cai, Fuqiang
   Du, Hongli
TI Prediction and evolution of B cell epitopes of surface protein in
   SARS-CoV-2
SO VIROLOGY JOURNAL
LA English
DT Article
DE SARS-CoV-2; Epitopes; Bioinformatics; Evolution
ID SEQUENCE
AB Background In order to obtain antibodies that recognize natural proteins, it is possible to predict the antigenic determinants of natural proteins, which are eventually embodied as polypeptides. The polypeptides can be coupled with corresponding vectors to stimulate the immune system to produce corresponding antibodies, which is also a simple and effective vaccine development method. The discovery of epitopes is helpful to the development of SARS-CoV-2 vaccine. Methods The analyses were related to epitopes on 3 proteins, including spike (S), envelope (E) and membrane (M) proteins, which are located on the lipid envelope of the SARS-CoV-2. Based on the NCBI Reference Sequence: NC_045512.2, the conformational and linear B cell epitopes of the surface protein were predicted separately by various prediction methods. Furthermore, the conservation of the epitopes, the adaptability and other evolutionary characteristics were also analyzed, the sequences of the whole genome of SARS-CoV-2 were obtained from the GISAID. Results 7 epitopes were predicted, including 6 linear epitopes and 1 conformational epitope. One of the linear and one of the conformational consist of identical sequence, but represent different forms of epitopes. It is worth mentioning that all 6 identified epitopes were conserved in nearly 3500 SARS-CoV-2 genomes, showing that it is helpful to obtain stable and long-acting epitopes under the condition of high frequency of amino acid mutation, which deserved further study at the experiment level. Conclusion The findings would facilitate the vaccine development, had the potential to be directly applied on the prevention in this disease, but also have the potential to prevent the possible threats caused by other types of coronavirus.
C1 [Lon, Jerome Rumdon; Bai, Yunmeng; Zhong, Bingxu; Cai, Fuqiang; Du, Hongli] South China Univ Technol, Sch Biol & Biol Engn, Guangzhou 510006, Peoples R China.
RP Du, HL (corresponding author), South China Univ Technol, Sch Biol & Biol Engn, Guangzhou 510006, Peoples R China.
EM hldu@scut.edu.cn
OI Lon, Jerome Rumdon/0000-0003-4714-6931
FU National Key R&D Program of China [2018YFC0910201]; Key R&D Program of
   Guangdong Province [2019B020226001]; Science and the Technology Planning
   Project of Guangzhou [201704020176]
FX This work was supported by the National Key R&D Program of China
   (2018YFC0910201), the Key R&D Program of Guangdong Province
   (2019B020226001), and the Science and the Technology Planning Project of
   Guangzhou (201704020176).
CR Ashkenazy H, 2016, NUCLEIC ACIDS RES, V44, pW344, DOI 10.1093/nar/gkw408
   Bai Yunmeng, 2020, Int J Infect Dis, V100, P164, DOI 10.1016/j.ijid.2020.08.066
   Baruah V, 2020, J MED VIROL, V92, P495, DOI 10.1002/jmv.25698
   Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310
   Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD464, DOI 10.1093/nar/gky1004
   Chen WT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049224
   Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004
   De Groot AS, 2002, IMMUNOL CELL BIOL, V80, P255, DOI 10.1046/j.1440-1711.2002.01092.x
   El-Manzalawy Yasser, 2010, Immunome Res, V6 Suppl 2, pS2, DOI 10.1186/1745-7580-6-S2-S2
   EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985
   Grifoni A, 2020, CELL HOST MICROBE
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Gupta R., 2004, PREDICTION N GLYCOSY
   Han QM, 2020, J INFECTION, V80, P373, DOI 10.1016/j.jinf.2020.02.010
   Herrera NG, 2020, BIORXIV
   JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181
   KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768
   Korber B, SPIKE MUTATION PIPEL
   Larsen Jens Erik Pontoppidan, 2006, Immunome Res, V2, P2, DOI 10.1186/1745-7580-2-2
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Lv HB, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107725
   Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514
   Rathore JS, 2020, PATHOG DIS, V78, DOI 10.1093/femspd/ftaa042
   Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078
   SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097
   Sun PP, 2013, COMPUT MATH METHOD M, DOI 10.1155/2013/943636
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Vashi Y, 2020, INFECT GENET EVOL, V84, DOI 10.1016/j.meegid.2020.104382
   Verdia-Baguena C, 2013, BBA-BIOMEMBRANES, V1828, P2026, DOI 10.1016/j.bbamem.2013.05.008
   WALKER JS, 1999, ST ADV MATH, P1
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   [王舒宁 Wang Shuning], 2012, [生物物理学报, Acta Biophysica Sinica], V28, P486
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Yang XD, 2009, REV MED VIROL, V19, P77, DOI 10.1002/rmv.602
   Ying L, 2020, J TRAVEL MED
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhou C, 2019, NUCLEIC ACIDS RES, V47, pW388, DOI 10.1093/nar/gkz413
NR 38
TC 0
Z9 0
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1743-422X
J9 VIROL J
JI Virol. J.
PD OCT 29
PY 2020
VL 17
IS 1
AR 165
DI 10.1186/s12985-020-01437-4
PG 9
WC Virology
SC Virology
GA OP4HN
UT WOS:000588042000001
PM 33121513
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Huang, ZL
   Guo, HL
   Lee, YM
   Ho, EC
   Ang, H
   Chow, A
AF Huang, Zhilian
   Guo, Huiling
   Lee, Yee-Mun
   Ho, Eu Chin
   Ang, Hou
   Chow, Angela
TI Performance of Digital Contact Tracing Tools for COVID-19 Response in
   Singapore: Cross-Sectional Study
SO JMIR MHEALTH AND UHEALTH
LA English
DT Article
DE infectious disease; real-time locating systems; electronic medical
   records; COVID-19; contact tracing; public health
AB Background: Effective contact tracing is labor intensive and time sensitive during the COVID-19 pandemic, but also essential in the absence of effective treatment and vaccines. Singapore launched the first Bluetooth-based contact tracing app-TraceTogether-in March 2020 to augment Singapore's contact tracing capabilities.
   Objective: This study aims to compare the performance of the contact tracing app-TraceTogether-with that of a wearable tag-based real-time locating system (RTLS) and to validate them against the electronic medical records at the National Centre for Infectious Diseases (NCID), the national referral center for COVID-19 screening.
   Methods: All patients and physicians in the NCID screening center were issued RTLS tags (CADI Scientific) for contact tracing. In total, 18 physicians were deployed to the NCID screening center from May 10 to May 20, 2020. The physicians activated the TraceTogether app (version 1.6; GovTech) on their smartphones during shifts and urged their patients to use the app. We compared patient contacts identified by TraceTogether and those identified by RTLS tags within the NCID vicinity during physicians' 10-day posting. We also validated both digital contact tracing tools by verifying the physician-patient contacts with the electronic medical records of 156 patients who attended the NCID screening center over a 24-hour time frame within the study period.
   Results: RTLS tags had a high sensitivity of 95.3% for detecting patient contacts identified either by the system or TraceTogether while TraceTogether had an overall sensitivity of 6.5% and performed significantly better on Android phones than iPhones (Android: 9.7%, iPhone: 2.7%; P<.001). When validated against the electronic medical records, RTLS tags had a sensitivity of 96.9% and specificity of 83.1%, while TraceTogether only detected 2 patient contacts with physicians who did not attend to them.
   Conclusions: TraceTogether had a much lower sensitivity than RTLS tags for identifying patient contacts in a clinical setting. Although the tag-based RTLS performed well for contact tracing in a clinical setting, its implementation in the community would be more challenging than TraceTogether. Given the uncertainty of the adoption and capabilities of contact tracing apps, policy makers should be cautioned against overreliance on such apps for contact tracing. Nonetheless, leveraging technology to augment conventional manual contact tracing is a necessary move for returning some normalcy to life during the long haul of the COVID-19 pandemic.
C1 [Huang, Zhilian; Guo, Huiling; Chow, Angela] Tan Tock Seng Hosp, Dept Clin Epidemiol, Off Clin Epidemiol Analyt & Knowledge, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
   [Lee, Yee-Mun] Tan Tock Seng Hosp, Dept Urol, Singapore, Singapore.
   [Lee, Yee-Mun; Chow, Angela] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore.
   [Ho, Eu Chin] Tan Tock Seng Hosp, Dept Ear Nose & Throat, Singapore, Singapore.
   [Ang, Hou] Tan Tock Seng Hosp, Dept Emergency Med, Singapore, Singapore.
RP Chow, A (corresponding author), Tan Tock Seng Hosp, Dept Clin Epidemiol, Off Clin Epidemiol Analyt & Knowledge, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
EM angela_chow@ttsh.com.sg
OI Ho, Eu Chin/0000-0002-4869-9493; Chow, Angela/0000-0002-4063-736X
CR Anglemyer A, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013699
   [Anonymous], 2017, CONT TRAC
   Baraniuk C, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1859
   Brack S, DECENTRALIZED CONTAC
   Chang YT, 2011, INT J MED INFORM, V80, P872, DOI 10.1016/j.ijmedinf.2011.09.006
   Cho H, 2020, CONTACT TRACING MOBI
   Chow Angela, 2020, Infect Control Hosp Epidemiol, P1, DOI 10.1017/ice.2020.419
   Cohen IG, 2020, JAMA-J AM MED ASSOC, V323, P2371, DOI 10.1001/jama.2020.8570
   Dubov A, 2020, AM J BIOETHICS, V20, pW7, DOI 10.1080/15265161.2020.1764136
   Ebrahimzadeh F, 2017, J PATIENT SAF, DOI [10.1097/PTS.0000000000000446, DOI 10.1097/PTS.0000000000000446]
   Ferretti L, 2020, SCIENCE, V368, P619, DOI 10.1126/science.abb6936
   Hellewell J, 2020, LANCET GLOB HEALTH, V8, pE488, DOI 10.1016/S2214-109X(20)30074-7
   Hellmich TR, 2017, AM J INFECT CONTROL, V45, P1308, DOI 10.1016/j.ajic.2017.08.014
   Ho HJ, 2020, J MED INTERNET RES, V22, DOI 10.2196/19437
   Kretzschmar ME, 2020, LANCET PUBLIC HEALTH, V5, pE452, DOI 10.1016/S2468-2667(20)30157-2
   Kucharski AJ, 2020, EFFECTIVENESS ISOLAT, DOI [10.1101/2020.04.23.20077024, DOI 10.1101/2020.04.23.20077024]
   Li J, 2020, SSRN J, DOI [10.2139/ssrn.3609516, DOI 10.2139/SSRN.3609516]
   Lowery-North DW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070854
   Mathews M, ATTITUDES USE SURVEI
   ONeill Patrick Howell, 2020, MIT TECHNOLOGY REV
   Osman M, 2020, J BEHAV EC POLICY, V4, P57
   Saurabh S, 2017, AFR HEALTH SCI, V17, P225, DOI 10.4314/ahs.v17i1.28
   Vaughan A, 2020, NEW SCI, V245, P9, DOI 10.1016/S0262-4079(20)30787-9
   Vilamovska AM, 2009, TECHNICAL REPORT
   Wise J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2294
   World Health Organization, CONT TRAC CONT COVID
   Xu SQ, 2020, LANCET, V395, P1321, DOI 10.1016/S0140-6736(20)30845-X
   Yazici HJ, 2014, INT J INFORM MANAGE, V34, P603, DOI 10.1016/j.ijinfomgt.2014.04.010
NR 28
TC 0
Z9 0
U1 2
U2 2
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 2291-5222
J9 JMIR MHEALTH UHEALTH
JI JMIR mHealth uHealth
PD OCT 29
PY 2020
VL 8
IS 10
AR e23148
DI 10.2196/23148
PG 9
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA OO5TA
UT WOS:000587439400001
PM 33006944
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Horigian, VE
   Schmidt, RD
   Feaster, DJ
AF Horigian, Viviana E.
   Schmidt, Renae D.
   Feaster, Daniel J.
TI Loneliness, Mental Health, and Substance Use among US Young Adults
   during COVID-19
SO JOURNAL OF PSYCHOACTIVE DRUGS
LA English
DT Article; Early Access
DE COVID-19; loneliness; anxiety; depression; alcohol use; drug use
ID DISORDERS; ANXIETY
AB As COVID-19 converges with loneliness and addiction epidemics in the US, both public health and mental health experts forecast dramatic increases in substance use and mental health conditions. This cross-sectional study evaluated relationships of loneliness with depression, anxiety, alcohol use, and drug use during COVID-19, and assessed perceived increases in these symptoms in young adults. Between April 22 and May 11, 2020, 1,008 participants ages 18-35 were recruited through social media to a one-time, online anonymous survey. Symptomatology was assessed using six scales. Perceived changes since COVID-19 were evaluated using 5-point Likert scales. Forty-nine percent of respondents reported loneliness scores above 50; 80% reported significant depressive symptoms; 61% reported moderate to severe anxiety; 30% disclosed harmful levels of drinking. While only 22% of the population reported using drugs, 38% reported severe drug use. Loneliness was associated with higher levels of mental health symptomatology. Participants reported significant increases across mental health and substance use symptoms since COVID-19. While direct impacts of COVID-19 could only be calculated with pre-pandemic assessments of these symptoms, estimates indicate elevated psychosocial symptomatology and suggest that symptoms could have worsened since the pandemic. Findings underscore the importance of prevention and intervention to address these public health problems.
C1 [Horigian, Viviana E.; Schmidt, Renae D.; Feaster, Daniel J.] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA.
RP Horigian, VE (corresponding author), 1120 NW 14th St, Miami, FL 33136 USA.
EM vhorigian@med.miami.edu
OI Schmidt, Renae/0000-0002-0390-0712
FU University of Miami Office of the Vice Provost for Research [UM
   2020-2228]
FX This work was supported by the University of Miami Office of the Vice
   Provost for Research under Grant #UM 2020-2228; University of Miami
   Office of the Vice Provost for Research [Grant #UM 2020-2228.].
CR AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P667, DOI 10.1109/TAC.1974.1100707
   Amsalem Doron, 2020, JAMA Psychiatry, DOI 10.1001/jamapsychiatry.2020.1730
   ANDRESEN EM, 1994, AM J PREV MED, V10, P77
   Auerbach J, 2020, AM J PUBLIC HEALTH, V110, P969, DOI 10.2105/AJPH.2020.305699
   Brody DJ, 2018, PREVALENCE DEPRESSIO
   Bruce LD, 2019, AM J HEALTH PROMOT, V33, P1123, DOI 10.1177/0890117119856551
   Cacioppo JT, 2018, LANCET, V391, P426, DOI 10.1016/S0140-6736(18)30142-9
   Campion J, 2020, LANCET PSYCHIAT, V7, P657, DOI 10.1016/S2215-0366(20)30240-6
   Cao WJ, 2020, PSYCHIAT RES, V287, DOI 10.1016/j.psychres.2020.112934
   Chang Jinghui, 2020, Nan Fang Yi Ke Da Xue Xue Bao, V40, P171, DOI 10.12122/j.issn.1673-4254.2020.02.06
   Cigna International, 2018, CIGN US LON IND
   Fegert JM, 2020, CHILD ADOL PSYCH MEN, V14, DOI 10.1186/s13034-020-00329-3
   Gabbatt A, 2020, GUARDIAN
   Galea S, 2020, JAMA INTERN MED, V180, P817, DOI 10.1001/jamainternmed.2020.1562
   Hawkley LC, 2010, ANN BEHAV MED, V40, P218, DOI 10.1007/s12160-010-9210-8
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Huckins JF, 2020, J MED INTERNET RES, V22, DOI 10.2196/20185
   Izaguirre-Torres D, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.109846
   Kessler RC, 2012, INT J METH PSYCH RES, V21, P169, DOI 10.1002/mpr.1359
   Killgore WDS, 2020, PSYCHIAT RES, V290, DOI 10.1016/j.psychres.2020.113117
   Lamis DA, 2014, SUICIDE LIFE-THREAT, V44, P629, DOI 10.1111/sltb.12095
   Lee RM, 2001, J COUNS PSYCHOL, V48, P310
   Luchetti M, 2020, AM PSYCHOL, V75, P897, DOI 10.1037/amp0000690
   MacKinnon D. P., 2008, INTRO STAT MEDIATION
   Murthy V., 2017, HARVARDBUSINESS REV
   Muthen . K., 2018, MPLUS COMPREHENSIVE
   Ornell F, 2020, PSYCHIAT RES, V289, DOI 10.1016/j.psychres.2020.113096
   Panchal N, 2020, IMPLICATIONS COVID 1
   Rehm J, 2020, DRUG ALCOHOL REV, V39, P301, DOI 10.1111/dar.13074
   RUSSELL D, 1980, J PERS SOC PSYCHOL, V39, P472, DOI 10.1037/0022-3514.39.3.472
   SAS, 2015, SAS IMLR 14 1 US GUI
   SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x
   Schulenberg J. E., 2019, MONITORING FUTURE NA, VII
   SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092
   Sutin AR, 2020, PSYCHIAT RES, V291, DOI 10.1016/j.psychres.2020.113295
   Volkow ND, 2020, ANN INTERN MED, V173, P61, DOI 10.7326/M20-1212
NR 37
TC 0
Z9 0
U1 4
U2 4
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0279-1072
EI 2159-9777
J9 J PSYCHOACTIVE DRUGS
JI J. Psychoact. Drugs
DI 10.1080/02791072.2020.1836435
EA OCT 2020
PG 9
WC Psychology, Clinical; Substance Abuse
SC Psychology; Substance Abuse
GA OK7CL
UT WOS:000584803700001
PM 33111650
OA Bronze
DA 2021-01-01
ER

EF